Inclusion NCT03931772 0 9 O
Criteria NCT03931772 10 18 O
: NCT03931772 19 20 O

- NCT03931772 24 25 O
18 NCT03931772 27 29 B-Eq-Comparison
years NCT03931772 30 35 I-Eq-Comparison
or NCT03931772 36 38 I-Eq-Comparison
older NCT03931772 39 44 I-Eq-Comparison

- NCT03931772 47 48 O
Able NCT03931772 50 54 O
to NCT03931772 55 57 O
read NCT03931772 58 62 O
and NCT03931772 63 66 O
understand NCT03931772 67 77 O
English NCT03931772 78 85 O

- NCT03931772 88 89 O
Desire NCT03931772 91 97 B-Assertion___Assertion-Type-Value:intention
to NCT03931772 98 100 I-Assertion___Assertion-Type-Value:intention
quit NCT03931772 101 105 B-Condition
smoking NCT03931772 106 113 I-Condition
( NCT03931772 114 115 O
specifically NCT03931772 116 128 O
, NCT03931772 129 130 O
report NCT03931772 131 137 O
a NCT03931772 138 139 O
motivation NCT03931772 140 150 B-Modifier
of NCT03931772 151 153 O
≥ NCT03931772 154 155 B-Eq-Comparison
5 NCT03931772 156 157 I-Eq-Comparison
out NCT03931772 158 161 I-Eq-Comparison
of NCT03931772 162 164 I-Eq-Comparison
10 NCT03931772 165 167 I-Eq-Comparison
to NCT03931772 168 170 O
quit NCT03931772 171 175 B-Condition|Observation
smoking NCT03931772 176 183 I-Condition|Observation
on NCT03931772 184 186 O
a NCT03931772 187 188 O
10 NCT03931772 189 191 O
- NCT03931772 192 193 O
point NCT03931772 194 199 O
Likert NCT03931772 200 206 O
- NCT03931772 207 208 O
type NCT03931772 209 213 O
scale NCT03931772 214 219 O
) NCT03931772 220 221 O

- NCT03931772 225 226 O
Having NCT03931772 228 234 O
access NCT03931772 235 241 O
to NCT03931772 242 244 O
wireless NCT03931772 245 253 O
internet NCT03931772 254 262 O
connection NCT03931772 263 273 O
or NCT03931772 274 276 O
mobile NCT03931772 277 283 O
data NCT03931772 284 288 O

- NCT03931772 291 292 O
Reporting NCT03931772 294 303 O
being NCT03931772 304 309 O
a NCT03931772 310 311 O
daily NCT03931772 312 317 B-Eq-Comparison
smoker NCT03931772 318 324 B-Condition
for NCT03931772 325 328 O
at NCT03931772 329 331 B-Eq-Comparison
least NCT03931772 332 337 I-Eq-Comparison
one NCT03931772 338 341 I-Eq-Comparison
year NCT03931772 342 346 I-Eq-Comparison
, NCT03931772 347 348 O
smoking NCT03931772 349 356 B-Condition|Observation
an NCT03931772 357 359 O
average NCT03931772 360 367 B-Eq-Comparison
≥ NCT03931772 368 369 I-Eq-Comparison
5 NCT03931772 370 371 I-Eq-Comparison
cigarettes NCT03931772 372 382 I-Eq-Comparison
per NCT03931772 383 386 I-Eq-Comparison
day NCT03931772 387 390 I-Eq-Comparison

Exclusion NCT03931772 391 400 O
Criteria NCT03931772 401 409 O
: NCT03931772 410 411 O

- NCT03931772 415 416 O
Meeting NCT03931772 418 425 O
criteria NCT03931772 426 434 O
for NCT03931772 435 438 O
drug NCT03931772 439 443 B-Condition
abuse NCT03931772 444 449 I-Condition
of NCT03931772 450 452 O
depressants NCT03931772 453 464 B-Drug
, NCT03931772 465 466 O
dissociative NCT03931772 467 479 B-Drug
anesthetics NCT03931772 480 491 I-Drug
, NCT03931772 492 493 O
hallucinogens NCT03931772 494 507 B-Drug
, NCT03931772 508 509 O
opioids NCT03931772 510 517 B-Drug
, NCT03931772 518 519 O
cocaine NCT03931772 520 527 B-Drug
, NCT03931772 528 529 O
or NCT03931772 530 532 O
amphetamine NCT03931772 533 544 B-Drug
within NCT03931772 545 551 B-Eq-Comparison
the NCT03931772 552 555 I-Eq-Comparison
last NCT03931772 556 560 I-Eq-Comparison
3 NCT03931772 561 562 I-Eq-Comparison
months NCT03931772 563 569 I-Eq-Comparison
. NCT03931772 569 570 O

- NCT03931772 574 575 O
Severe NCT03931772 577 583 O
psychiatric NCT03931772 584 595 B-Modifier
or NCT03931772 596 598 B-Or
structural NCT03931772 599 609 B-Modifier
brain NCT03931772 610 615 B-Condition
disease NCT03931772 616 623 I-Condition
( NCT03931772 624 625 O
i. NCT03931772 626 628 O
e. NCT03931772 629 631 O
psychosis NCT03931772 633 642 B-Condition
, NCT03931772 643 644 O
stroke NCT03931772 645 651 B-Condition
with NCT03931772 652 656 B-And
functional NCT03931772 657 667 B-Condition
impairment NCT03931772 668 678 I-Condition
, NCT03931772 679 680 O
dementia NCT03931772 681 689 B-Condition
) NCT03931772 690 691 O
or NCT03931772 692 694 B-Or
[ NCT03931772 695 696 O
current NCT03931772 697 704 B-Eq-Comparison
/ NCT03931772 705 706 B-Or
recent NCT03931772 707 713 B-Eq-Comparison
risk NCT03931772 714 718 B-Condition
to NCT03931772 719 721 I-Condition
self NCT03931772 722 726 I-Condition
. NCT03931772 726 727 O
Indicated NCT03931772 729 738 O
by NCT03931772 739 741 O
denial NCT03931772 742 748 O
of NCT03931772 749 751 O
question NCT03931772 752 760 O
pertaining NCT03931772 761 771 O
to NCT03931772 772 774 O
inpatient NCT03931772 775 784 B-Encounter
hospitalization NCT03931772 785 800 I-Encounter

- NCT03931772 803 804 O
Hearing NCT03931772 806 813 B-Condition
impairment NCT03931772 814 824 I-Condition
that NCT03931772 825 829 O
would NCT03931772 830 835 B-Assertion___Assertion-Type-Value:hypothetical
impede NCT03931772 836 842 O
ability NCT03931772 843 850 O
to NCT03931772 851 853 O
listen NCT03931772 854 860 O
the NCT03931772 861 864 O
auditory NCT03931772 865 873 B-Modifier
intervention NCT03931772 874 886 B-Study

- NCT03931772 889 890 O
Major NCT03931772 892 897 O
illnesses NCT03931772 898 907 B-Condition
impacting NCT03931772 908 917 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03931772 918 921 O
study NCT03931772 922 927 B-Study
results NCT03931772 928 935 O

- NCT03931772 938 939 O
Currently NCT03931772 941 950 B-Eq-Comparison
taking NCT03931772 951 957 I-Eq-Comparison
Wellbutrin NCT03931772 958 968 B-Drug
, NCT03931772 969 970 O
Chantix NCT03931772 971 978 B-Drug
, NCT03931772 979 980 O
or NCT03931772 981 983 B-Or
other NCT03931772 984 989 O
pharmacological NCT03931772 990 1005 O
smoking NCT03931772 1006 1013 B-Drug
cessation NCT03931772 1014 1023 I-Drug
aids NCT03931772 1024 1028 I-Drug
that NCT03931772 1029 1033 O
could NCT03931772 1034 1039 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03931772 1040 1048 O
results NCT03931772 1049 1056 O
of NCT03931772 1057 1059 O
the NCT03931772 1060 1063 O
study NCT03931772 1064 1069 B-Study

Inclusion NCT03931941 0 9 O
Criteria NCT03931941 10 18 O
: NCT03931941 19 20 O

1 NCT03931941 24 25 O
. NCT03931941 25 26 O
≥ NCT03931941 28 29 B-Eq-Comparison
18 NCT03931941 30 32 I-Eq-Comparison
years NCT03931941 33 38 I-Eq-Comparison
old NCT03931941 39 42 B-Age
. NCT03931941 42 43 O

2 NCT03931941 47 48 O
. NCT03931941 48 49 O
Medical NCT03931941 51 58 O
record NCT03931941 59 65 O
documentation NCT03931941 66 79 O
of NCT03931941 80 82 O
either NCT03931941 83 89 O
: NCT03931941 90 91 O
a NCT03931941 92 93 O
) NCT03931941 94 95 O
recurrent NCT03931941 96 105 B-Modifier
CDI NCT03931941 106 109 B-Condition
per NCT03931941 110 113 O
the NCT03931941 114 117 O
study NCT03931941 118 123 O
definition NCT03931941 124 134 O
, NCT03931941 135 136 O
that NCT03931941 137 141 O
includes NCT03931941 142 150 O
at NCT03931941 151 153 B-Eq-Comparison
least NCT03931941 154 159 I-Eq-Comparison
one NCT03931941 160 163 I-Eq-Comparison
recurrence NCT03931941 164 174 B-Coreference
after NCT03931941 175 180 B-Temporal-Connection___Temporal-Connection-Type-Value:after
a NCT03931941 181 182 O
primary NCT03931941 183 190 O
episode NCT03931941 191 198 B-Coreference
and NCT03931941 199 202 O
has NCT03931941 203 206 O
completed NCT03931941 207 216 O
at NCT03931941 217 219 B-Eq-Comparison
least NCT03931941 220 225 I-Eq-Comparison
one NCT03931941 226 229 I-Eq-Comparison
round NCT03931941 230 235 O
of NCT03931941 236 238 O
standard NCT03931941 239 247 O
- NCT03931941 248 249 O
of NCT03931941 250 252 O
- NCT03931941 253 254 O
care NCT03931941 255 259 O
oral NCT03931941 260 264 B-Procedure
antibiotic NCT03931941 265 275 I-Procedure
therapy NCT03931941 276 283 I-Procedure
, NCT03931941 284 285 O
b NCT03931941 286 287 O
) NCT03931941 288 289 O
or NCT03931941 290 292 B-Or
has NCT03931941 293 296 O
had NCT03931941 297 300 O
at NCT03931941 301 303 B-Eq-Comparison
least NCT03931941 304 309 I-Eq-Comparison
two NCT03931941 310 313 I-Eq-Comparison
episodes NCT03931941 314 322 O
of NCT03931941 323 325 O
severe NCT03931941 326 332 O
CDI NCT03931941 333 336 B-Condition
resulting NCT03931941 337 346 O
in NCT03931941 347 349 O
hospitalization NCT03931941 350 365 B-Encounter
. NCT03931941 365 366 O

3 NCT03931941 370 371 O
. NCT03931941 371 372 O
A NCT03931941 374 375 O
positive NCT03931941 376 384 O
stool NCT03931941 385 390 B-Observation
test NCT03931941 391 395 I-Observation
for NCT03931941 396 399 O
the NCT03931941 400 403 O
presence NCT03931941 404 412 O
of NCT03931941 413 415 O
toxigenic NCT03931941 416 425 B-Organism
C. NCT03931941 426 428 I-Organism|Organism
difficile NCT03931941 430 439 I-Organism|Organism
or NCT03931941 440 442 B-Or
C. NCT03931941 443 445 O
difficile NCT03931941 447 456 O
toxin NCT03931941 457 462 I-Organism
within NCT03931941 463 469 B-Eq-Comparison
30 NCT03931941 470 472 I-Eq-Comparison
days NCT03931941 473 477 I-Eq-Comparison
prior NCT03931941 478 483 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03931941 484 486 I-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03931941 487 489 O
on NCT03931941 490 492 O
the NCT03931941 493 496 O
date NCT03931941 497 501 O
of NCT03931941 502 504 O
enrollment NCT03931941 505 515 B-Study
. NCT03931941 515 516 O

4 NCT03931941 520 521 O
. NCT03931941 521 522 O
Is NCT03931941 524 526 O
currently NCT03931941 527 536 B-Eq-Comparison
taking NCT03931941 537 543 O
or NCT03931941 544 546 B-Or
was NCT03931941 547 550 O
just NCT03931941 551 555 B-Eq-Comparison
prescribed NCT03931941 556 566 O
antibiotics NCT03931941 567 578 B-Drug
to NCT03931941 579 581 O
control NCT03931941 582 589 O
CDI NCT03931941 590 593 B-Condition
related NCT03931941 594 601 O
diarrhea NCT03931941 602 610 B-Condition
at NCT03931941 611 613 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03931941 614 617 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03931941 618 622 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03931941 623 625 O
enrollment NCT03931941 626 636 B-Study
. NCT03931941 636 637 O

[ NCT03931941 640 641 O
Note NCT03931941 642 646 O
: NCT03931941 647 648 O
Subject NCT03931941 649 656 O
's NCT03931941 656 658 O
CDI NCT03931941 659 662 B-Condition
diarrhea NCT03931941 663 671 B-Condition
must NCT03931941 672 676 O
be NCT03931941 677 679 O
controlled NCT03931941 680 690 O
( NCT03931941 691 692 O
< NCT03931941 694 695 B-Eq-Comparison
3 NCT03931941 696 697 I-Eq-Comparison
unformed NCT03931941 698 706 I-Eq-Comparison
/ NCT03931941 707 708 I-Eq-Comparison
loose NCT03931941 709 714 I-Eq-Comparison
stools NCT03931941 715 721 I-Eq-Comparison
/ NCT03931941 722 723 O
day NCT03931941 724 727 I-Eq-Comparison
) NCT03931941 728 729 O
while NCT03931941 730 735 B-Temporal-Connection___Temporal-Connection-Type-Value:during

taking NCT03931941 736 742 B-Eq-Comparison
antibiotics NCT03931941 743 754 B-Drug
during NCT03931941 755 761 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03931941 762 771 B-Study
. NCT03931941 771 772 O
] NCT03931941 773 774 O

Exclusion NCT03931941 776 785 O
Criteria NCT03931941 786 794 O
: NCT03931941 795 796 O

1 NCT03931941 800 801 O
. NCT03931941 801 802 O
Has NCT03931941 804 807 O
continued NCT03931941 808 817 O
CDI NCT03931941 818 821 B-Condition
diarrhea NCT03931941 822 830 B-Condition
despite NCT03931941 831 838 O
being NCT03931941 839 844 O
on NCT03931941 845 847 O
a NCT03931941 848 849 O
course NCT03931941 850 856 O
of NCT03931941 857 859 O
antibiotics NCT03931941 860 871 B-Drug
prescribed NCT03931941 872 882 O
for NCT03931941 883 886 O
CDI NCT03931941 887 890 B-Condition
treatment NCT03931941 891 900 O
. NCT03931941 900 901 O

2 NCT03931941 905 906 O
. NCT03931941 906 907 O
Requires NCT03931941 909 917 B-Assertion___Assertion-Type-Value:hypothetical
systemic NCT03931941 918 926 O
antibiotic NCT03931941 927 937 B-Procedure
therapy NCT03931941 938 945 I-Procedure
for NCT03931941 946 949 O
a NCT03931941 950 951 O
condition NCT03931941 952 961 B-Condition
other NCT03931941 962 967 B-Exception
than NCT03931941 968 972 I-Exception
CDI NCT03931941 973 976 B-Condition
. NCT03931941 976 977 O

3 NCT03931941 981 982 O
. NCT03931941 982 983 O
Fecal NCT03931941 985 990 B-Procedure
microbiota NCT03931941 991 1001 I-Procedure
transplant NCT03931941 1002 1012 I-Procedure
( NCT03931941 1013 1014 O
FMT NCT03931941 1015 1018 B-Procedure|Procedure
) NCT03931941 1019 1020 O
within NCT03931941 1021 1027 B-And|Eq-Comparison
the NCT03931941 1028 1031 I-Eq-Comparison
past NCT03931941 1032 1036 I-Eq-Comparison
6 NCT03931941 1037 1038 I-Eq-Comparison
months NCT03931941 1039 1045 I-Eq-Comparison
. NCT03931941 1045 1046 O

4 NCT03931941 1050 1051 O
. NCT03931941 1051 1052 O
FMT NCT03931941 1054 1057 O
with NCT03931941 1058 1062 O
an NCT03931941 1063 1065 O
associated NCT03931941 1066 1076 O
serious NCT03931941 1077 1084 O
adverse NCT03931941 1085 1092 B-Observation
event NCT03931941 1093 1098 I-Observation
related NCT03931941 1099 1106 O
to NCT03931941 1107 1109 O
the NCT03931941 1110 1113 O
FMT NCT03931941 1114 1117 B-Procedure
product NCT03931941 1118 1125 O
or NCT03931941 1126 1128 B-Or
procedure NCT03931941 1129 1138 B-Procedure
. NCT03931941 1138 1139 O

5 NCT03931941 1143 1144 O
. NCT03931941 1144 1145 O
Bezlotoxumab NCT03931941 1147 1159 B-Drug
( NCT03931941 1160 1161 O
CDI NCT03931941 1162 1165 B-Condition
monoclonal NCT03931941 1166 1176 B-Drug
antibodies NCT03931941 1177 1187 I-Drug
) NCT03931941 1188 1189 O
if NCT03931941 1190 1192 O
received NCT03931941 1193 1201 B-Eq-Comparison
within NCT03931941 1202 1208 B-Eq-Comparison
the NCT03931941 1209 1212 I-Eq-Comparison
last NCT03931941 1213 1217 I-Eq-Comparison
year NCT03931941 1218 1222 I-Eq-Comparison
. NCT03931941 1222 1223 O

6 NCT03931941 1227 1228 O
. NCT03931941 1228 1229 O
CD4 NCT03931941 1231 1234 B-Observation
count NCT03931941 1235 1240 I-Observation
< NCT03931941 1241 1242 B-Eq-Comparison
200 NCT03931941 1243 1246 I-Eq-Comparison
/ NCT03931941 1247 1248 I-Eq-Comparison
mm3 NCT03931941 1249 1252 I-Eq-Comparison
during NCT03931941 1253 1259 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03931941 1260 1269 B-Study
. NCT03931941 1269 1270 O

7 NCT03931941 1274 1275 O
. NCT03931941 1275 1276 O
An NCT03931941 1278 1280 O
absolute NCT03931941 1281 1289 B-Observation
neutrophil NCT03931941 1290 1300 I-Observation
count NCT03931941 1301 1306 I-Observation
of NCT03931941 1307 1309 O
< NCT03931941 1310 1311 B-Eq-Comparison
1000 NCT03931941 1312 1316 I-Eq-Comparison
cells NCT03931941 1317 1322 O
/ NCT03931941 1323 1324 O
µL NCT03931941 1325 1327 O
during NCT03931941 1328 1334 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03931941 1335 1344 B-Study
. NCT03931941 1344 1345 O

8 NCT03931941 1349 1350 O
. NCT03931941 1350 1351 O
Pregnant NCT03931941 1353 1361 B-Condition
, NCT03931941 1362 1363 O
breastfeeding NCT03931941 1364 1377 B-Condition
, NCT03931941 1378 1379 O
or NCT03931941 1380 1382 B-Or
intends NCT03931941 1383 1390 B-Assertion___Assertion-Type-Value:intention
to NCT03931941 1391 1393 I-Assertion___Assertion-Type-Value:intention
become NCT03931941 1394 1400 O
pregnant NCT03931941 1401 1409 B-Condition
during NCT03931941 1410 1416 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03931941 1417 1422 B-Study
participation NCT03931941 1423 1436 O
. NCT03931941 1436 1437 O

Inclusion NCT03930108 0 9 O
Criteria NCT03930108 10 18 O
: NCT03930108 19 20 O

- NCT03930108 24 25 O
adult NCT03930108 27 32 O
patients NCT03930108 33 41 O
( NCT03930108 42 43 O
age NCT03930108 44 47 B-Age
18 NCT03930108 48 50 B-Eq-Comparison
and NCT03930108 51 54 I-Eq-Comparison
above NCT03930108 55 60 I-Eq-Comparison
) NCT03930108 61 62 O
who NCT03930108 63 66 O
admitted NCT03930108 67 75 B-Encounter
to NCT03930108 76 78 O
burn NCT03930108 79 83 O
unit NCT03930108 84 88 O
during NCT03930108 89 95 B-Temporal-Connection___Temporal-Connection-Type-Value:during
sampling NCT03930108 96 104 B-Study
period NCT03930108 105 111 O

Exclusion NCT03930108 112 121 O
Criteria NCT03930108 122 130 O
: NCT03930108 131 132 O

- NCT03930108 136 137 O
patients NCT03930108 139 147 O
discharged NCT03930108 148 158 B-Encounter
or NCT03930108 159 161 B-Or
deceased NCT03930108 162 170 B-Death
less NCT03930108 171 175 B-Eq-Comparison
than NCT03930108 176 180 I-Eq-Comparison
24 NCT03930108 181 183 I-Eq-Comparison
hours NCT03930108 184 189 I-Eq-Comparison
of NCT03930108 190 192 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03930108 193 202 B-Encounter

- NCT03930108 205 206 O
patients NCT03930108 208 216 O
referred NCT03930108 217 225 B-Encounter
to NCT03930108 226 228 O
other NCT03930108 229 234 B-Other
hospital NCT03930108 235 243 O
within NCT03930108 244 250 B-Eq-Comparison
30 NCT03930108 251 253 I-Eq-Comparison
days NCT03930108 254 258 I-Eq-Comparison
admission NCT03930108 259 268 B-Encounter

Inclusion NCT03930134 0 9 O
Criteria NCT03930134 10 18 O
: NCT03930134 19 20 O

- NCT03930134 24 25 O
singleton NCT03930134 27 36 B-Modifier
pregnancy NCT03930134 37 46 B-Condition

- NCT03930134 49 50 O
Cicatricial NCT03930134 52 63 B-Condition
uterus NCT03930134 64 70 I-Condition
with NCT03930134 71 75 B-And
contraindication NCT03930134 76 92 B-Contraindication
to NCT03930134 93 95 O
vaginal NCT03930134 96 103 B-Procedure
delivery NCT03930134 104 112 I-Procedure
( NCT03930134 113 114 O
uterus NCT03930134 115 121 B-Condition
bi NCT03930134 122 124 B-Modifier
or NCT03930134 125 127 B-Or
multi NCT03930134 128 133 B-Modifier
- NCT03930134 134 135 I-Modifier
cicatricial NCT03930134 136 147 I-Modifier
, NCT03930134 148 149 O
corporal NCT03930134 150 158 B-Condition
uterine NCT03930134 159 166 I-Condition
scar NCT03930134 167 171 I-Condition
, NCT03930134 172 173 O
intra NCT03930134 174 179 B-Procedure
- NCT03930134 180 181 I-Procedure
mural NCT03930134 182 187 I-Procedure
myomectomy NCT03930134 188 198 I-Procedure
, NCT03930134 199 200 O
dystocic NCT03930134 201 209 B-Condition
presentation NCT03930134 210 222 I-Condition
) NCT03930134 223 224 O

- NCT03930134 228 229 O
Fetal NCT03930134 231 236 B-Condition
macrosomia NCT03930134 237 247 I-Condition
with NCT03930134 248 252 B-And
a NCT03930134 253 254 O
weight NCT03930134 255 261 B-Observation
greater NCT03930134 262 269 B-Eq-Comparison
than NCT03930134 270 274 I-Eq-Comparison
4 NCT03930134 275 276 I-Eq-Comparison
Kg NCT03930134 277 279 O

- NCT03930134 282 283 O
Placenta NCT03930134 285 293 B-Condition
previa NCT03930134 294 300 I-Condition

Exclusion NCT03930134 301 310 O
Criteria NCT03930134 311 319 O
: NCT03930134 320 321 O

- NCT03930134 325 326 O
Patients NCT03930134 328 336 O
who NCT03930134 337 340 O
refuse NCT03930134 341 347 O
to NCT03930134 348 350 O
participate NCT03930134 351 362 O
in NCT03930134 363 365 O
the NCT03930134 366 369 O
study NCT03930134 370 375 B-Study

- NCT03930134 378 379 O
prenatally NCT03930134 381 391 O
diagnosed NCT03930134 392 401 O
fetal NCT03930134 402 407 B-Condition
pathology NCT03930134 408 417 I-Condition
( NCT03930134 418 419 O
intrauterine NCT03930134 420 432 B-Condition
growth NCT03930134 433 439 I-Condition
restriction NCT03930134 440 451 I-Condition
, NCT03930134 452 453 O
malformation NCT03930134 454 466 B-Condition
, NCT03930134 467 468 O
genetics NCT03930134 469 477 B-Condition
disorders NCT03930134 478 487 I-Condition
) NCT03930134 488 489 O

- NCT03930134 493 494 O
adherent NCT03930134 496 504 B-Condition
placenta NCT03930134 505 513 I-Condition
, NCT03930134 514 515 O
an NCT03930134 516 518 O
adnexal NCT03930134 519 526 B-Condition
mass NCT03930134 527 531 I-Condition
or NCT03930134 532 534 B-Or
a NCT03930134 535 536 O
myoma NCT03930134 537 542 B-Condition
at NCT03930134 543 545 I-Condition
the NCT03930134 546 549 I-Condition
lower NCT03930134 550 555 I-Condition
uterine NCT03930134 556 563 I-Condition
segment NCT03930134 564 571 I-Condition

- NCT03930134 574 575 O
Cesarean NCT03930134 577 585 B-Procedure
section NCT03930134 586 593 I-Procedure
in NCT03930134 594 596 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03930134 597 598 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
context NCT03930134 599 606 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
of NCT03930134 607 609 O
medical NCT03930134 610 617 B-Modifier
or NCT03930134 618 620 B-Or
obstetrical NCT03930134 621 632 B-Modifier
emergency NCT03930134 633 642 B-Observation

- NCT03930134 645 646 O
Caesarean NCT03930134 648 657 B-Procedure
section NCT03930134 658 665 I-Procedure
with NCT03930134 666 670 B-And
a NCT03930134 671 672 O
high NCT03930134 673 677 O
risk NCT03930134 678 682 B-Risk
of NCT03930134 683 685 O
bleeding NCT03930134 686 694 B-Condition

Inclusion NCT03932045 0 9 O
Criteria NCT03932045 10 18 O
: NCT03932045 19 20 O

1 NCT03932045 24 25 O
. NCT03932045 25 26 O
Individuals NCT03932045 28 39 O
who NCT03932045 40 43 O
desire NCT03932045 44 50 B-Assertion___Assertion-Type-Value:intention
an NCT03932045 51 53 O
improvement NCT03932045 54 65 O
in NCT03932045 66 68 O
the NCT03932045 69 72 O
appearance NCT03932045 73 83 B-Observation
of NCT03932045 84 86 I-Observation
the NCT03932045 87 90 I-Observation
nasolabial NCT03932045 91 101 I-Observation
fold NCT03932045 102 106 I-Observation
on NCT03932045 107 109 O
both NCT03932045 110 114 O
sides NCT03932045 115 120 O
of NCT03932045 121 123 O
the NCT03932045 124 127 O
face NCT03932045 128 132 O
and NCT03932045 133 136 B-And
who NCT03932045 137 140 O
have NCT03932045 141 145 O
a NCT03932045 146 147 O
score NCT03932045 148 153 B-Eq-Comparison
of NCT03932045 154 156 I-Eq-Comparison
3 NCT03932045 157 158 I-Eq-Comparison
or NCT03932045 159 161 I-Eq-Comparison
4 NCT03932045 162 163 I-Eq-Comparison
on NCT03932045 164 166 O
the NCT03932045 167 170 O
Wrinkle NCT03932045 171 178 B-Observation
Severity NCT03932045 179 187 I-Observation
Rating NCT03932045 188 194 I-Observation
Scale NCT03932045 195 200 I-Observation
( NCT03932045 201 202 O
WSRS NCT03932045 203 207 B-Observation
) NCT03932045 208 209 O

2 NCT03932045 213 214 O
. NCT03932045 214 215 O
Individuals NCT03932045 217 228 O
who NCT03932045 229 232 O
have NCT03932045 233 237 O
consented NCT03932045 238 247 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03932045 248 250 I-Assertion___Assertion-Type-Value:hypothetical
abstain NCT03932045 251 258 B-Negation
from NCT03932045 259 263 I-Negation
any NCT03932045 264 267 O
other NCT03932045 268 273 O
dermatological NCT03932045 274 288 B-Procedure
procedures NCT03932045 289 299 I-Procedure
or NCT03932045 300 302 B-Or
treatments NCT03932045 303 313 B-Procedure
, NCT03932045 314 315 O
including NCT03932045 316 325 O
treatments NCT03932045 326 336 O
for NCT03932045 337 340 O
wrinkle NCT03932045 341 348 B-Procedure
reduction NCT03932045 349 358 I-Procedure
in NCT03932045 359 361 O
the NCT03932045 362 365 O
facial NCT03932045 366 372 O
area NCT03932045 373 377 O
, NCT03932045 378 379 O
during NCT03932045 380 386 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03932045 387 390 O
duration NCT03932045 391 399 O
of NCT03932045 400 402 O
this NCT03932045 403 407 O
study NCT03932045 408 413 B-Study
. NCT03932045 413 414 O

Exclusion NCT03932045 416 425 O
Criteria NCT03932045 426 434 O
: NCT03932045 435 436 O

1 NCT03932045 440 441 O
. NCT03932045 441 442 O
Administered NCT03932045 444 456 B-Eq-Comparison
an NCT03932045 457 459 B-Drug
anticoagulant NCT03932045 460 473 O
( NCT03932045 474 475 O
with NCT03932045 476 480 O
the NCT03932045 481 484 O
exception NCT03932045 485 494 B-Exception
of NCT03932045 495 497 O
low NCT03932045 498 501 B-Eq-Comparison
dosage NCT03932045 502 508 O
aspirin NCT03932045 509 516 B-Drug
( NCT03932045 517 518 O
100 NCT03932045 519 522 B-Eq-Comparison
mg NCT03932045 523 525 O
, NCT03932045 526 527 O
up NCT03932045 528 530 I-Eq-Comparison
to NCT03932045 531 533 I-Eq-Comparison
300 NCT03932045 534 537 I-Eq-Comparison
mg NCT03932045 538 540 O
/ NCT03932045 541 542 I-Eq-Comparison
day NCT03932045 543 546 I-Eq-Comparison
) NCT03932045 547 548 O
) NCT03932045 550 551 O
within NCT03932045 552 558 B-Eq-Comparison
2 NCT03932045 559 560 I-Eq-Comparison
weeks NCT03932045 561 566 I-Eq-Comparison
of NCT03932045 567 569 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 570 573 O
date NCT03932045 574 578 O
of NCT03932045 579 581 O
the NCT03932045 582 585 O
screening NCT03932045 586 595 B-Study

2 NCT03932045 598 599 O
. NCT03932045 599 600 O
Administered NCT03932045 602 614 B-Eq-Comparison
Vitamin NCT03932045 615 622 B-Drug
E NCT03932045 623 624 I-Drug
or NCT03932045 625 627 B-Or
non NCT03932045 628 631 B-Drug
- NCT03932045 632 633 I-Drug
steroidal NCT03932045 634 643 I-Drug
anti NCT03932045 644 648 I-Drug
- NCT03932045 649 650 O
inflammatory NCT03932045 651 663 I-Drug
drugs NCT03932045 664 669 I-Drug
or NCT03932045 670 672 B-Or
Collagen NCT03932045 673 681 B-Drug
within NCT03932045 682 688 B-Eq-Comparison
1 NCT03932045 689 690 I-Eq-Comparison
week NCT03932045 691 695 I-Eq-Comparison
of NCT03932045 696 698 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 699 702 O
date NCT03932045 703 707 O
of NCT03932045 708 710 O
the NCT03932045 711 714 O
screening NCT03932045 715 724 B-Study
, NCT03932045 725 726 O
or NCT03932045 727 729 O
who NCT03932045 730 733 O
require NCT03932045 734 741 B-Assertion___Assertion-Type-Value:hypothetical
these NCT03932045 742 747 B-Coreference
during NCT03932045 748 754 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03932045 755 758 O
period NCT03932045 759 765 O
of NCT03932045 766 768 O
the NCT03932045 769 772 O
study NCT03932045 773 778 B-Study

3 NCT03932045 781 782 O
. NCT03932045 782 783 O
History NCT03932045 785 792 B-Eq-Comparison
of NCT03932045 793 795 O
bleeding NCT03932045 796 804 B-Condition
disorder NCT03932045 805 813 I-Condition
in NCT03932045 814 816 O
past NCT03932045 817 821 B-Eq-Comparison
or NCT03932045 822 824 B-Or
present NCT03932045 825 832 B-Eq-Comparison

4 NCT03932045 835 836 O
. NCT03932045 836 837 O
Received NCT03932045 839 847 B-Eq-Comparison
deep NCT03932045 848 852 B-Procedure
- NCT03932045 853 854 I-Procedure
peeling NCT03932045 855 862 I-Procedure
, NCT03932045 863 864 O
skin NCT03932045 865 869 B-Procedure
regeneration NCT03932045 870 882 I-Procedure
, NCT03932045 883 884 O
plastic NCT03932045 885 892 B-Procedure
surgery NCT03932045 893 900 I-Procedure
( NCT03932045 901 902 O
including NCT03932045 903 912 O
botulinum NCT03932045 913 922 B-Procedure
toxin NCT03932045 923 928 I-Procedure
injection NCT03932045 929 938 I-Procedure
) NCT03932045 939 940 O
, NCT03932045 942 943 O
wrinkle NCT03932045 944 951 B-Procedure
improvement NCT03932045 952 963 I-Procedure
or NCT03932045 964 966 B-Or
acne NCT03932045 967 971 B-Procedure
scar NCT03932045 972 976 I-Procedure
treatment NCT03932045 977 986 I-Procedure
in NCT03932045 987 989 O
the NCT03932045 990 993 O
facial NCT03932045 994 1000 O
area NCT03932045 1001 1005 O
within NCT03932045 1006 1012 B-Eq-Comparison
24 NCT03932045 1013 1015 I-Eq-Comparison
weeks NCT03932045 1016 1021 I-Eq-Comparison
of NCT03932045 1022 1024 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 1025 1028 O
date NCT03932045 1029 1033 O
of NCT03932045 1034 1036 O
the NCT03932045 1037 1040 O
screening NCT03932045 1041 1050 B-Study

5 NCT03932045 1053 1054 O
. NCT03932045 1054 1055 O
Administered NCT03932045 1057 1069 B-Eq-Comparison
an NCT03932045 1070 1072 O
hyaluronic NCT03932045 1073 1083 B-Drug
acid NCT03932045 1084 1088 I-Drug
filler NCT03932045 1089 1095 I-Drug
within NCT03932045 1096 1102 B-Eq-Comparison
24 NCT03932045 1103 1105 I-Eq-Comparison
weeks NCT03932045 1106 1111 I-Eq-Comparison
of NCT03932045 1112 1114 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 1115 1118 O
date NCT03932045 1119 1123 O
of NCT03932045 1124 1126 O
the NCT03932045 1127 1130 O
screening NCT03932045 1131 1140 B-Study


Inclusion NCT03934346 0 9 O
Criteria NCT03934346 10 18 O
: NCT03934346 19 20 O

- NCT03934346 24 25 O
Apparently NCT03934346 27 37 B-Assertion___Assertion-Type-Value:possible
healthy NCT03934346 38 45 B-Condition
men NCT03934346 46 49 O

- NCT03934346 52 53 O
Body NCT03934346 55 59 B-Observation
mass NCT03934346 60 64 I-Observation
index NCT03934346 65 70 I-Observation
between NCT03934346 71 78 B-Eq-Comparison
18 NCT03934346 79 81 I-Eq-Comparison
and NCT03934346 82 85 I-Eq-Comparison
30 NCT03934346 86 88 I-Eq-Comparison
kg NCT03934346 89 91 I-Eq-Comparison
/ NCT03934346 92 93 I-Eq-Comparison
m2 NCT03934346 94 96 I-Eq-Comparison

- NCT03934346 99 100 O
Willing NCT03934346 102 109 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03934346 110 112 I-Assertion___Assertion-Type-Value:hypothetical
eat NCT03934346 113 116 B-Observation
only NCT03934346 117 121 O
the NCT03934346 122 125 O
foods NCT03934346 126 131 O
provided NCT03934346 132 140 O
by NCT03934346 141 143 O
the NCT03934346 144 147 O
study NCT03934346 148 153 B-Study
for NCT03934346 154 157 O
a NCT03934346 158 159 O
2 NCT03934346 160 161 B-Eq-Comparison
week NCT03934346 162 166 I-Eq-Comparison
period NCT03934346 167 173 O

Exclusion NCT03934346 174 183 O
Criteria NCT03934346 184 192 O
: NCT03934346 193 194 O

- NCT03934346 198 199 O
Those NCT03934346 201 206 O
reporting NCT03934346 207 216 O
any NCT03934346 217 220 O
chronic NCT03934346 221 228 B-Modifier
or NCT03934346 229 231 B-Or
acute NCT03934346 232 237 O
diseases NCT03934346 238 246 B-Condition
, NCT03934346 247 248 O
food NCT03934346 249 253 O
allergies NCT03934346 254 263 B-Allergy
, NCT03934346 264 265 O
smoking NCT03934346 266 273 B-Modifier
or NCT03934346 274 276 B-Or
alcohol NCT03934346 277 284 B-Modifier
abuse NCT03934346 285 290 B-Condition

- NCT03934346 293 294 O
Use NCT03934346 296 299 B-Eq-Comparison
of NCT03934346 300 302 O
illicit NCT03934346 303 310 B-Drug
drugs NCT03934346 311 316 I-Drug
; NCT03934346 316 317 O
regular NCT03934346 318 325 O
consumption NCT03934346 326 337 O
of NCT03934346 338 340 O
medications NCT03934346 341 352 B-Drug
, NCT03934346 353 354 O
micronutrient NCT03934346 355 368 B-Drug
supplements NCT03934346 369 380 I-Drug
, NCT03934346 381 382 O
or NCT03934346 383 385 B-Or
both NCT03934346 386 390 B-Coreference

- NCT03934346 393 394 O
Vegetarians NCT03934346 396 407 B-Condition
, NCT03934346 408 409 O
or NCT03934346 410 412 B-Or
those NCT03934346 413 418 O
unable NCT03934346 419 425 B-Condition
to NCT03934346 426 428 I-Condition
eat NCT03934346 429 432 I-Condition
meat NCT03934346 433 437 I-Condition
, NCT03934346 438 439 O
are NCT03934346 440 443 O
also NCT03934346 444 448 O
excluded NCT03934346 449 457 O
since NCT03934346 458 463 O
the NCT03934346 464 467 O
foods NCT03934346 468 473 O
for NCT03934346 474 477 O
the NCT03934346 478 481 O
study NCT03934346 482 487 O
contain NCT03934346 488 495 O
meat NCT03934346 496 500 O

- NCT03934346 503 504 O
Unable NCT03934346 506 512 B-Negation
to NCT03934346 513 515 O
refrain NCT03934346 516 523 B-Negation
from NCT03934346 524 528 O
taking NCT03934346 529 535 B-Eq-Comparison
medications NCT03934346 536 547 B-Drug
during NCT03934346 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03934346 555 558 O
study NCT03934346 559 564 B-Study
period NCT03934346 565 571 O

Inclusion NCT03930849 0 9 O
Criteria NCT03930849 10 18 O
: NCT03930849 19 20 O

VA NCT03930849 22 24 O
Patient NCT03930849 25 32 O

- NCT03930849 35 36 O
Diagnosed NCT03930849 38 47 O
with NCT03930849 48 52 O
depression NCT03930849 53 63 B-Condition

- NCT03930849 66 67 O
Initiating NCT03930849 69 79 B-Eq-Comparison
or NCT03930849 80 82 B-Or
changing NCT03930849 83 91 O
to NCT03930849 92 94 O
a NCT03930849 95 96 O
new NCT03930849 97 100 O
antidepressant NCT03930849 101 115 B-Drug
medication NCT03930849 116 126 I-Drug

- NCT03930849 129 130 O
Cell NCT03930849 132 136 O
phone NCT03930849 137 142 O
with NCT03930849 143 147 O
text NCT03930849 148 152 O
messaging NCT03930849 153 162 O
capabilities NCT03930849 163 175 O

- NCT03930849 178 179 O
Registered NCT03930849 181 191 O
with NCT03930849 192 196 O
My NCT03930849 197 199 O
HealtheVet NCT03930849 200 210 O

- NCT03930849 213 214 O
Follow NCT03930849 216 222 B-Encounter
- NCT03930849 223 224 I-Encounter
up NCT03930849 225 227 I-Encounter
appointment NCT03930849 228 239 I-Encounter
with NCT03930849 240 244 O
their NCT03930849 245 250 O
provider NCT03930849 251 259 B-Provider
in NCT03930849 260 262 O
the NCT03930849 263 266 O
next NCT03930849 267 271 B-Eq-Comparison
12 NCT03930849 272 274 I-Eq-Comparison
weeks NCT03930849 275 280 I-Eq-Comparison

- NCT03930849 283 284 O
Internet NCT03930849 286 294 O
access NCT03930849 295 301 O

- NCT03930849 304 305 O
English NCT03930849 307 314 O
speaking NCT03930849 315 323 O
VA NCT03930849 324 326 O
Providers NCT03930849 327 336 B-Provider
: NCT03930849 337 338 O
provide NCT03930849 339 346 O
care NCT03930849 347 351 O
to NCT03930849 352 354 O
a NCT03930849 355 356 O
study NCT03930849 357 362 B-Study
participant NCT03930849 363 374 O

Exclusion NCT03930849 375 384 O
Criteria NCT03930849 385 393 O
: NCT03930849 394 395 O

- NCT03930849 399 400 O
Lack NCT03930849 402 406 O
of NCT03930849 407 409 O
cell NCT03930849 410 414 O
phone NCT03930849 415 420 O
access NCT03930849 421 427 O
/ NCT03930849 428 429 O
willingness NCT03930849 430 441 O
to NCT03930849 442 444 O
receive NCT03930849 445 452 O
text NCT03930849 453 457 O
messages NCT03930849 458 466 O

- NCT03930849 469 470 O
Diagnosis NCT03930849 472 481 O
of NCT03930849 482 484 O
cognitive NCT03930849 485 494 B-Condition
disorders NCT03930849 495 504 I-Condition
, NCT03930849 505 506 O
psychotic NCT03930849 507 516 B-Condition
disorders NCT03930849 517 526 I-Condition
, NCT03930849 527 528 O
bipolar NCT03930849 529 536 B-Condition
disorder NCT03930849 537 545 I-Condition
, NCT03930849 546 547 O
or NCT03930849 548 550 B-Or
active NCT03930849 551 557 B-Eq-Comparison
substance NCT03930849 558 567 B-Condition
abuse NCT03930849 568 573 I-Condition
. NCT03930849 573 574 O

Inclusion NCT03934385 0 9 O
Criteria NCT03934385 10 18 O
: NCT03934385 19 20 O

- NCT03934385 24 25 O
English NCT03934385 27 34 O
- NCT03934385 35 36 O
speaking NCT03934385 37 45 O

- NCT03934385 48 49 O
Elevated NCT03934385 51 59 O
score NCT03934385 60 65 O
on NCT03934385 66 68 O
Spider NCT03934385 69 75 B-Observation
Phobia NCT03934385 76 82 I-Observation
Questionnaire NCT03934385 83 96 I-Observation
( NCT03934385 97 98 O
SPQ NCT03934385 99 102 B-Observation
) NCT03934385 103 104 O

Exclusion NCT03934385 106 115 O
Criteria NCT03934385 116 124 O
: NCT03934385 125 126 O

- NCT03934385 130 131 O
Severe NCT03934385 133 139 O
allergies NCT03934385 140 149 B-Allergy
to NCT03934385 150 152 O
bees NCT03934385 153 157 O
/ NCT03934385 158 159 B-Or|Or
spiders NCT03934385 160 167 O
/ NCT03934385 168 169 O
insects NCT03934385 170 177 O

Inclusion NCT03934554 0 9 O
Criteria NCT03934554 10 18 O
: NCT03934554 19 20 O

- NCT03934554 24 25 O
Dialysis NCT03934554 27 35 B-Procedure
or NCT03934554 36 38 B-Or
non NCT03934554 39 42 B-Negation
- NCT03934554 43 44 O
dialysis NCT03934554 45 53 B-Procedure
patients NCT03934554 54 62 O
with NCT03934554 63 67 B-And
chronic NCT03934554 68 75 B-Condition
renal NCT03934554 76 81 I-Condition
insufficiency NCT03934554 82 95 I-Condition
with NCT03934554 96 100 B-And
a NCT03934554 101 102 O
GFR NCT03934554 103 106 B-Observation
< NCT03934554 107 108 B-Eq-Comparison
20 NCT03934554 109 111 I-Eq-Comparison
ml NCT03934554 112 114 O
/ NCT03934554 115 116 I-Eq-Comparison
min NCT03934554 117 120 I-Eq-Comparison
eligible NCT03934554 121 129 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03934554 130 133 O
transplant NCT03934554 134 144 B-Procedure

- NCT03934554 147 148 O
Patient NCT03934554 150 157 O
wishing NCT03934554 158 165 B-Assertion___Assertion-Type-Value:intention
to NCT03934554 166 168 I-Assertion___Assertion-Type-Value:intention
start NCT03934554 169 174 O
the NCT03934554 175 178 O
registration NCT03934554 179 191 O
process NCT03934554 192 199 O
at NCT03934554 200 202 O
the NCT03934554 203 206 O
transplant NCT03934554 207 217 B-Procedure

- NCT03934554 220 221 O
Patient NCT03934554 223 230 O
giving NCT03934554 231 237 O
consent NCT03934554 238 245 O
for NCT03934554 246 249 O
the NCT03934554 250 253 O
transmission NCT03934554 254 266 O
of NCT03934554 267 269 O
his NCT03934554 270 273 O
data NCT03934554 274 278 O
via NCT03934554 279 282 O
an NCT03934554 283 285 O
electronic NCT03934554 286 296 O
platform NCT03934554 297 305 O

Exclusion NCT03934554 306 315 O
Criteria NCT03934554 316 324 O
: NCT03934554 325 326 O

- NCT03934554 330 331 O
Patient NCT03934554 333 340 O
already NCT03934554 341 348 O
enrolled NCT03934554 349 357 O

- NCT03934554 360 361 O
Patient NCT03934554 363 370 O
having NCT03934554 371 377 B-Eq-Comparison
a NCT03934554 378 379 O
pathology NCT03934554 380 389 B-Condition
with NCT03934554 390 394 B-And
a NCT03934554 395 396 O
life NCT03934554 397 401 B-Observation
expectancy NCT03934554 402 412 I-Observation
of NCT03934554 413 415 O
less NCT03934554 416 420 B-Eq-Comparison
than NCT03934554 421 425 I-Eq-Comparison
two NCT03934554 426 429 I-Eq-Comparison
years NCT03934554 430 435 I-Eq-Comparison

- NCT03934554 438 439 O
Patient NCT03934554 441 448 O
with NCT03934554 449 453 O
serious NCT03934554 454 461 O
psychiatric NCT03934554 462 473 B-Condition
disorders NCT03934554 474 483 I-Condition
, NCT03934554 484 485 O
or NCT03934554 486 488 B-Or
dementia NCT03934554 489 497 B-Condition
. NCT03934554 497 498 O

Inclusion NCT03930901 0 9 O
Criteria NCT03930901 10 18 O
: NCT03930901 19 20 O

- NCT03930901 24 25 O
Grade NCT03930901 27 32 O
2 NCT03930901 33 34 O
- NCT03930901 35 36 O
6 NCT03930901 37 38 O

- NCT03930901 42 43 O
Orang NCT03930901 45 50 O
Asli NCT03930901 51 55 O
ethnicity NCT03930901 56 65 O

- NCT03930901 68 69 O
Schools NCT03930901 71 78 O
exclusively NCT03930901 79 90 O
for NCT03930901 91 94 O
Orang NCT03930901 95 100 O
Asli NCT03930901 101 105 O

Exclusion NCT03930901 106 115 O
Criteria NCT03930901 116 124 O
: NCT03930901 125 126 O

- NCT03930901 130 131 O
Grade NCT03930901 133 138 O
1 NCT03930901 139 140 O

- NCT03930901 144 145 O
Chronic NCT03930901 147 154 B-Modifier
sever NCT03930901 155 160 B-Condition
diseases NCT03930901 161 169 I-Condition

- NCT03930901 172 173 O
no NCT03930901 175 177 O
consent NCT03930901 178 185 O

- NCT03930901 188 189 O
schools NCT03930901 191 198 O
for NCT03930901 199 202 O
mixed NCT03930901 203 208 O
population NCT03930901 209 219 O
groups NCT03930901 220 226 O

Inclusion NCT03930524 0 9 O
Criteria NCT03930524 10 18 O
: NCT03930524 19 20 O

- NCT03930524 24 25 O
Incoming NCT03930524 27 35 O
college NCT03930524 36 43 O
students NCT03930524 44 52 O
aged NCT03930524 53 57 B-Age
18 NCT03930524 58 60 B-Eq-Comparison
- NCT03930524 61 62 I-Eq-Comparison
21 NCT03930524 63 65 O
at NCT03930524 66 68 O
the NCT03930524 69 72 O
University NCT03930524 73 83 O
of NCT03930524 84 86 O
Minnesota NCT03930524 87 96 O
will NCT03930524 97 101 O
be NCT03930524 102 104 O
eligible NCT03930524 105 113 O
and NCT03930524 114 117 O
randomly NCT03930524 118 126 O
selected NCT03930524 127 135 O
for NCT03930524 136 139 O
participation NCT03930524 140 153 O
. NCT03930524 153 154 O

Exclusion NCT03930524 156 165 O
Criteria NCT03930524 166 174 O
: NCT03930524 175 176 O

- NCT03930524 180 181 O
None NCT03930524 183 187 O

Inclusion NCT03931148 0 9 O
Criteria NCT03931148 10 18 O
: NCT03931148 19 20 O

- NCT03931148 24 25 O
French NCT03931148 27 33 O
speaker NCT03931148 34 41 O

- NCT03931148 44 45 O
Recent NCT03931148 47 53 B-Eq-Comparison
diagnosis NCT03931148 54 63 O
of NCT03931148 64 66 O
neurocognitive NCT03931148 67 81 B-Condition
disorder NCT03931148 82 90 I-Condition

- NCT03931148 93 94 O
Agreed NCT03931148 96 102 O
with NCT03931148 103 107 O
the NCT03931148 108 111 O
study NCT03931148 112 117 O

Exclusion NCT03931148 118 127 O
Criteria NCT03931148 128 136 O
: NCT03931148 137 138 O

- NCT03931148 142 143 O
Delirium NCT03931148 145 153 B-Condition

- NCT03931148 156 157 O
Major NCT03931148 159 164 O
depressive NCT03931148 165 175 B-Condition
symptoms NCT03931148 176 184 B-Assertion___Assertion-Type-Value:possible

- NCT03931148 187 188 O
MRI NCT03931148 190 193 B-Procedure
contraindication NCT03931148 194 210 B-Contraindication

Inclusion NCT03930121 0 9 O
Criteria NCT03930121 10 18 O
: NCT03930121 19 20 O

- NCT03930121 24 25 O
left NCT03930121 27 31 B-Modifier
- NCT03930121 32 33 I-Modifier
hemisphere NCT03930121 34 44 I-Modifier
cortical NCT03930121 45 53 I-Modifier
or NCT03930121 54 56 B-Or
subcortical NCT03930121 57 68 B-Modifier
stroke NCT03930121 69 75 B-Condition
with NCT03930121 76 80 B-And
first NCT03930121 81 86 B-Eq-Comparison
- NCT03930121 87 88 I-Eq-Comparison
ever NCT03930121 89 93 I-Eq-Comparison
aphasic NCT03930121 94 101 B-Condition
symptoms NCT03930121 102 110 B-Assertion___Assertion-Type-Value:possible

- NCT03930121 113 114 O
at NCT03930121 116 118 B-Eq-Comparison
least NCT03930121 119 124 I-Eq-Comparison
6 NCT03930121 125 126 I-Eq-Comparison
months NCT03930121 127 133 I-Eq-Comparison
post NCT03930121 134 138 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03930121 139 140 O
onset NCT03930121 141 146 B-Eq-Comparison
of NCT03930121 147 149 O
stroke NCT03930121 150 156 B-Condition
; NCT03930121 156 157 O

- NCT03930121 160 161 O
aphasia NCT03930121 163 170 B-Condition
, NCT03930121 171 172 O
as NCT03930121 173 175 O
determined NCT03930121 176 186 O
by NCT03930121 187 189 O
the NCT03930121 190 193 O
Aachen NCT03930121 194 200 B-Observation
Aphasia NCT03930121 201 208 I-Observation
Test NCT03930121 209 213 I-Observation
( NCT03930121 214 215 O
AAT NCT03930121 216 219 B-Observation
) NCT03930121 220 221 O
; NCT03930121 222 223 O

- NCT03930121 226 227 O
13 NCT03930121 229 231 B-Eq-Comparison
moderate NCT03930121 232 240 O
- NCT03930121 241 242 O
to NCT03930121 243 245 B-Or
- NCT03930121 246 247 O
severe NCT03930121 248 254 O
word NCT03930121 255 259 B-Condition
finding NCT03930121 260 267 I-Condition
difficulties NCT03930121 268 280 I-Condition
( NCT03930121 281 282 O
maximum NCT03930121 283 290 B-Eq-Comparison
of NCT03930121 291 293 I-Eq-Comparison
60 NCT03930121 294 296 I-Eq-Comparison
% NCT03930121 297 298 O
correct NCT03930121 299 306 O
items NCT03930121 307 312 O
on NCT03930121 313 315 O
a NCT03930121 316 317 O
computerized NCT03930121 318 330 B-Observation
naming NCT03930121 331 337 I-Observation
task NCT03930121 338 342 I-Observation
at NCT03930121 343 345 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03930121 346 354 B-Study
) NCT03930121 355 356 O
; NCT03930121 357 358 O

- NCT03930121 361 362 O
at NCT03930121 364 366 B-Eq-Comparison
least NCT03930121 367 372 I-Eq-Comparison
1 NCT03930121 373 374 I-Eq-Comparison
correct NCT03930121 375 382 I-Eq-Comparison
reaction NCT03930121 383 391 I-Eq-Comparison
on NCT03930121 392 394 O
the NCT03930121 395 398 O
first NCT03930121 399 404 O
part NCT03930121 405 409 O
of NCT03930121 410 412 O
the NCT03930121 413 416 O
AAT NCT03930121 417 420 B-Observation
subscale NCT03930121 421 429 I-Observation
Token NCT03930121 430 435 I-Observation
Test NCT03930121 436 440 I-Observation
( NCT03930121 441 442 O
ensuring NCT03930121 443 451 O
basic NCT03930121 452 457 O
comprehension NCT03930121 458 471 O
skills NCT03930121 472 478 O
) NCT03930121 479 480 O
; NCT03930121 481 482 O

- NCT03930121 485 486 O
at NCT03930121 488 490 B-Eq-Comparison
least NCT03930121 491 496 I-Eq-Comparison
1 NCT03930121 497 498 I-Eq-Comparison
point NCT03930121 499 504 I-Eq-Comparison
on NCT03930121 505 507 O
the NCT03930121 508 511 O
communicative NCT03930121 512 525 O
task NCT03930121 526 530 O
of NCT03930121 531 533 O
the NCT03930121 534 537 O
AAT NCT03930121 538 541 B-Observation
subscale NCT03930121 542 550 I-Observation
Spontaneous NCT03930121 551 562 I-Observation
Speech NCT03930121 563 569 I-Observation
( NCT03930121 570 571 O
ensuring NCT03930121 572 580 O
basic NCT03930121 581 586 O
communication NCT03930121 587 600 O
abilities NCT03930121 601 610 O
) NCT03930121 611 612 O
; NCT03930121 613 614 O

- NCT03930121 617 618 O
German NCT03930121 620 626 O
as NCT03930121 627 629 O
first NCT03930121 630 635 O
language NCT03930121 636 644 O
; NCT03930121 644 645 O

- NCT03930121 648 649 I-Condition
intact NCT03930121 651 657 B-Modifier
left NCT03930121 658 662 B-Condition
- NCT03930121 663 664 O
hemisphere NCT03930121 665 675 I-Condition
" NCT03930121 676 677 I-Condition
hand NCT03930121 677 681 O
knob NCT03930121 682 686 I-Condition
" NCT03930121 686 687 O
without NCT03930121 688 695 B-Negation
right NCT03930121 696 701 B-Modifier
prefrontal NCT03930121 702 712 B-Condition
lesions NCT03930121 713 720 I-Condition
for NCT03930121 721 724 B-Assertion___Assertion-Type-Value:hypothetical
placement NCT03930121 725 734 B-Procedure
of NCT03930121 735 737 I-Procedure
tDCS NCT03930121 738 742 I-Procedure
electrodes NCT03930121 743 753 I-Procedure
, NCT03930121 754 755 O
as NCT03930121 756 758 O
confirmed NCT03930121 759 768 O
by NCT03930121 769 771 O
magnetic NCT03930121 772 780 B-Procedure
resonance NCT03930121 781 790 I-Procedure
imaging NCT03930121 791 798 I-Procedure
or NCT03930121 799 801 B-Or
computer NCT03930121 802 810 B-Procedure
tomography NCT03930121 811 821 I-Procedure
scans NCT03930121 822 827 I-Procedure
. NCT03930121 827 828 O

Exclusion NCT03930121 830 839 O
Criteria NCT03930121 840 848 O
: NCT03930121 849 850 O

- NCT03930121 854 855 O
contraindications NCT03930121 857 874 B-Contraindication
for NCT03930121 875 878 O
tDCS NCT03930121 879 883 B-Procedure
( NCT03930121 884 885 O
e. NCT03930121 886 888 O
g. NCT03930121 889 891 O
, NCT03930121 892 893 O
cardiac NCT03930121 894 901 B-Condition
pacemaker NCT03930121 902 911 I-Condition
, NCT03930121 912 913 O
history NCT03930121 914 921 B-Eq-Comparison
of NCT03930121 922 924 O
seizures NCT03930121 925 933 B-Condition
, NCT03930121 934 935 O
implanted NCT03930121 936 945 B-Condition
metal NCT03930121 946 951 I-Condition
inside NCT03930121 952 958 I-Condition
the NCT03930121 959 962 I-Condition
head NCT03930121 963 967 I-Condition
) NCT03930121 968 969 O
; NCT03930121 970 971 O

- NCT03930121 974 975 O
more NCT03930121 977 981 B-Eq-Comparison
than NCT03930121 982 986 I-Eq-Comparison
one NCT03930121 987 990 I-Eq-Comparison
clinically NCT03930121 991 1001 B-Modifier
apparent NCT03930121 1002 1010 I-Modifier
stroke NCT03930121 1011 1017 B-Condition
with NCT03930121 1018 1022 B-And
aphasic NCT03930121 1023 1030 B-Condition
symptoms NCT03930121 1031 1039 B-Assertion___Assertion-Type-Value:possible
; NCT03930121 1039 1040 O

- NCT03930121 1043 1044 O
other NCT03930121 1046 1051 O
severe NCT03930121 1052 1058 O
neurological NCT03930121 1059 1071 B-Condition
diseases NCT03930121 1072 1080 I-Condition
( NCT03930121 1081 1082 O
e. NCT03930121 1083 1085 O
g. NCT03930121 1086 1088 O
, NCT03930121 1089 1090 O
epilepsy NCT03930121 1091 1099 B-Condition
, NCT03930121 1100 1101 O
brain NCT03930121 1102 1107 B-Condition
tumor NCT03930121 1108 1113 I-Condition
, NCT03930121 1114 1115 O
and NCT03930121 1116 1119 B-And
subdural NCT03930121 1120 1128 B-Condition
hematoma NCT03930121 1129 1137 I-Condition
) NCT03930121 1138 1139 O
; NCT03930121 1140 1141 O

- NCT03930121 1144 1145 O
history NCT03930121 1147 1154 B-Eq-Comparison
of NCT03930121 1155 1157 O
severe NCT03930121 1158 1164 O
alcohol NCT03930121 1165 1172 B-Modifier
or NCT03930121 1173 1175 B-Or
drug NCT03930121 1176 1180 B-Modifier
abuse NCT03930121 1181 1186 B-Condition
; NCT03930121 1186 1187 O

- NCT03930121 1190 1191 O
current NCT03930121 1193 1200 B-Eq-Comparison|Eq-Comparison
severe NCT03930121 1201 1207 O
depression NCT03930121 1208 1218 B-Condition
; NCT03930121 1218 1219 O

- NCT03930121 1222 1223 O
current NCT03930121 1225 1232 O
psychosis NCT03930121 1233 1242 B-Condition
or NCT03930121 1243 1245 B-Or
other NCT03930121 1246 1251 O
relevant NCT03930121 1252 1260 O
psychiatric NCT03930121 1261 1272 B-Condition
condition NCT03930121 1273 1282 I-Condition
; NCT03930121 1282 1283 O

- NCT03930121 1286 1287 O
very NCT03930121 1289 1293 O
severe NCT03930121 1294 1300 O
apraxia NCT03930121 1301 1308 B-Condition
of NCT03930121 1309 1311 I-Condition
speech NCT03930121 1312 1318 I-Condition
, NCT03930121 1319 1320 O
as NCT03930121 1321 1323 O
revealed NCT03930121 1324 1332 O
by NCT03930121 1333 1335 O
Hierarchical NCT03930121 1336 1348 B-Observation
Word NCT03930121 1349 1353 I-Observation
Lists NCT03930121 1354 1359 I-Observation
; NCT03930121 1359 1360 O

- NCT03930121 1363 1364 I-Condition
severe NCT03930121 1366 1372 O
non NCT03930121 1373 1376 B-Condition
- NCT03930121 1377 1378 O
verbal NCT03930121 1379 1385 I-Condition
cognitive NCT03930121 1386 1395 I-Condition
deficits NCT03930121 1396 1404 I-Condition
, NCT03930121 1405 1406 O
as NCT03930121 1407 1409 O
indicated NCT03930121 1410 1419 O
by NCT03930121 1420 1422 O
the NCT03930121 1423 1426 O
Corsi NCT03930121 1427 1432 B-Observation
Block NCT03930121 1433 1438 I-Observation
- NCT03930121 1439 1440 I-Observation
Tapping NCT03930121 1441 1448 I-Observation
Task NCT03930121 1449 1453 I-Observation
; NCT03930121 1453 1454 O

- NCT03930121 1457 1458 O
severe NCT03930121 1460 1466 O
uncontrolled NCT03930121 1467 1479 B-Modifier
medical NCT03930121 1480 1487 B-Condition
problems NCT03930121 1488 1496 I-Condition
; NCT03930121 1496 1497 O

- NCT03930121 1500 1501 O
severely NCT03930121 1503 1511 O
impaired NCT03930121 1512 1520 B-Condition
vision NCT03930121 1521 1527 B-Modifier
or NCT03930121 1528 1530 B-Or
hearing NCT03930121 1531 1538 B-Modifier
that NCT03930121 1539 1543 O
prevents NCT03930121 1544 1552 O
patients NCT03930121 1553 1561 O
from NCT03930121 1562 1566 O
engaging NCT03930121 1567 1575 O
in NCT03930121 1576 1578 O
intensive NCT03930121 1579 1588 O
SLT NCT03930121 1589 1592 O
; NCT03930121 1592 1593 O

- NCT03930121 1596 1597 O
changes NCT03930121 1599 1606 O
in NCT03930121 1607 1609 O
centrally NCT03930121 1610 1619 B-Drug
active NCT03930121 1620 1626 I-Drug
drugs NCT03930121 1627 1632 I-Drug
within NCT03930121 1633 1639 B-Eq-Comparison
2 NCT03930121 1640 1641 I-Eq-Comparison
weeks NCT03930121 1642 1647 I-Eq-Comparison
prior NCT03930121 1648 1653 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03930121 1654 1656 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03930121 1657 1662 B-Study
inclusion NCT03930121 1663 1672 O
. NCT03930121 1672 1673 O

Inclusion NCT03934151 0 9 O
Criteria NCT03934151 10 18 O
: NCT03934151 19 20 O

- NCT03934151 24 25 O
Patients NCT03934151 27 35 O
and NCT03934151 36 39 O
/ NCT03934151 40 41 O
or NCT03934151 42 44 O
legal NCT03934151 45 50 O
guardians NCT03934151 51 60 O
exhaustively NCT03934151 61 73 O
informed NCT03934151 74 82 O
by NCT03934151 83 85 O
the NCT03934151 86 89 O
investigator NCT03934151 90 102 O
, NCT03934151 103 104 O
and NCT03934151 105 108 O
who NCT03934151 109 112 O
have NCT03934151 113 117 O
voluntarily NCT03934151 118 129 O
provided NCT03934151 130 138 O
written NCT03934151 139 146 O
informed NCT03934151 147 155 O
consent NCT03934151 156 163 O
or NCT03934151 164 166 O
, NCT03934151 167 168 O
when NCT03934151 169 173 O
unable NCT03934151 174 180 O
to NCT03934151 181 183 O
read NCT03934151 184 188 O
and NCT03934151 189 192 O
/ NCT03934151 193 194 O
or NCT03934151 195 197 O
write NCT03934151 198 203 O
, NCT03934151 204 205 O
verbal NCT03934151 206 212 O
consent NCT03934151 213 220 O
put NCT03934151 221 224 O
into NCT03934151 225 229 O
writing NCT03934151 230 237 O
by NCT03934151 238 240 O
a NCT03934151 241 242 O
third NCT03934151 243 248 O
person NCT03934151 249 255 O

- NCT03934151 258 259 O
Patients NCT03934151 261 269 O
who NCT03934151 270 273 O
underwent NCT03934151 274 283 B-Eq-Comparison
elective NCT03934151 284 292 O
laparoscopic NCT03934151 293 305 B-Modifier
or NCT03934151 306 308 B-Or
video NCT03934151 309 314 B-Modifier
assisted NCT03934151 315 323 I-Modifier
right NCT03934151 324 329 B-Procedure
hemicolectomy NCT03934151 330 343 I-Procedure
at NCT03934151 344 346 O
U. NCT03934151 347 349 O
O. NCT03934151 350 352 O
General NCT03934151 354 361 B-Modifier
and NCT03934151 362 365 B-Or
Thoracic NCT03934151 366 374 B-Modifier
Surgery NCT03934151 375 382 B-Procedure
for NCT03934151 383 386 O
malignant NCT03934151 387 396 B-Modifier
or NCT03934151 397 399 B-Or
bening NCT03934151 400 406 B-Modifier
pathology NCT03934151 407 416 B-Condition
. NCT03934151 416 417 O

- NCT03934151 421 422 O
Patients NCT03934151 424 432 O
who NCT03934151 433 436 O
had NCT03934151 437 440 O
prior NCT03934151 441 446 B-Eq-Comparison
chemotherapy NCT03934151 447 459 B-Procedure
and NCT03934151 460 463 B-Or
radiotherapy NCT03934151 464 476 B-Procedure

Exclusion NCT03934151 477 486 O
Criteria NCT03934151 487 495 O
: NCT03934151 496 497 O

- NCT03934151 501 502 O
Patients NCT03934151 504 512 O
operated NCT03934151 513 521 B-Procedure
in NCT03934151 522 524 B-Temporal-Connection___Temporal-Connection-Type-Value:during
emergency NCT03934151 525 534 B-Encounter

- NCT03934151 537 538 O
Pregnant NCT03934151 540 548 B-Condition
women NCT03934151 549 554 O

- NCT03934151 557 558 O
Right NCT03934151 560 565 B-Procedure
laparotomic NCT03934151 566 577 I-Procedure
hemicolectomy NCT03934151 578 591 I-Procedure

- NCT03934151 594 595 O
BMI NCT03934151 597 600 B-Observation
> NCT03934151 601 602 B-Eq-Comparison
35 NCT03934151 603 605 I-Eq-Comparison

Inclusion NCT03932929 0 9 O
Criteria NCT03932929 10 18 O
: NCT03932929 19 20 O

- NCT03932929 24 25 O
over NCT03932929 27 31 B-Eq-Comparison
18 NCT03932929 32 34 I-Eq-Comparison
years NCT03932929 35 40 I-Eq-Comparison
old NCT03932929 41 44 B-Age

- NCT03932929 47 48 O
good NCT03932929 50 54 B-Condition
oral NCT03932929 55 59 I-Condition
hygiene NCT03932929 60 67 I-Condition

- NCT03932929 70 71 O
available NCT03932929 73 82 O
for NCT03932929 83 86 O
recall NCT03932929 87 93 O

- NCT03932929 96 97 O
at NCT03932929 99 101 B-Eq-Comparison
least NCT03932929 102 107 I-Eq-Comparison
20 NCT03932929 108 110 I-Eq-Comparison
teeth NCT03932929 111 116 B-Condition
under NCT03932929 117 122 I-Condition
occlusion NCT03932929 123 132 I-Condition

- NCT03932929 135 136 O
the NCT03932929 138 141 O
presence NCT03932929 142 150 O
of NCT03932929 151 153 O
at NCT03932929 154 156 B-Eq-Comparison
least NCT03932929 157 162 I-Eq-Comparison
three NCT03932929 163 168 I-Eq-Comparison
non NCT03932929 169 172 B-Negation
- NCT03932929 173 174 O
carious NCT03932929 175 182 B-Modifier
cervical NCT03932929 183 191 B-Condition
lesions NCT03932929 192 199 I-Condition

Exclusion NCT03932929 200 209 O
Criteria NCT03932929 210 218 O
: NCT03932929 219 220 O

- NCT03932929 224 225 O
poor NCT03932929 227 231 B-Condition
oral NCT03932929 232 236 I-Condition
hygiene NCT03932929 237 244 I-Condition

- NCT03932929 247 248 O
bruxism NCT03932929 250 257 B-Condition
habits NCT03932929 258 264 I-Condition

- NCT03932929 267 268 O
severe NCT03932929 270 276 O
or NCT03932929 277 279 B-Or
chronic NCT03932929 280 287 B-Modifier
periodontitis NCT03932929 288 301 B-Condition

- NCT03932929 304 305 O
If NCT03932929 307 309 O
the NCT03932929 310 313 O
teeth NCT03932929 314 319 O
selected NCT03932929 320 328 O
for NCT03932929 329 332 O
study NCT03932929 333 338 O
, NCT03932929 339 340 O
were NCT03932929 341 345 O
nonvital NCT03932929 346 354 O
, NCT03932929 355 356 O
or NCT03932929 357 359 O
had NCT03932929 360 363 O
any NCT03932929 364 367 O
restorations NCT03932929 368 380 O
on NCT03932929 381 383 O
other NCT03932929 384 389 O
surfaces NCT03932929 390 398 O
were NCT03932929 399 403 O
not NCT03932929 404 407 O
included NCT03932929 408 416 O
. NCT03932929 416 417 O

Inclusion NCT03931616 0 9 O
Criteria NCT03931616 10 18 O
: NCT03931616 19 20 O

1 NCT03931616 24 25 O
. NCT03931616 25 26 O
Suspected NCT03931616 28 37 B-Assertion___Assertion-Type-Value:possible
acute NCT03931616 38 43 O
stroke NCT03931616 44 50 B-Condition
according NCT03931616 51 60 O
to NCT03931616 61 63 O
the NCT03931616 64 67 O
dispatcher NCT03931616 68 78 O
stroke NCT03931616 79 85 O
identification NCT03931616 86 100 O
algorithm NCT03931616 101 110 O
during NCT03931616 111 117 O
STEMO NCT03931616 118 123 O
hours NCT03931616 124 129 O
( NCT03931616 130 131 O
7 NCT03931616 132 133 O
am NCT03931616 134 136 O
- NCT03931616 137 138 O
11 NCT03931616 139 141 O
pm NCT03931616 142 144 O
, NCT03931616 145 146 O
Monday NCT03931616 147 153 O
- NCT03931616 154 155 O
Sunday NCT03931616 156 162 O
) NCT03931616 163 164 O
and NCT03931616 165 168 O
within NCT03931616 169 175 O
the NCT03931616 176 179 O
STEMO NCT03931616 180 185 O
catchment NCT03931616 186 195 O
area NCT03931616 196 200 O
Inclusion NCT03931616 201 210 O
criteria NCT03931616 211 219 O
for NCT03931616 220 223 O
primary NCT03931616 224 231 O
study NCT03931616 232 237 O
population NCT03931616 238 248 O
: NCT03931616 249 250 O

2 NCT03931616 254 255 O
. NCT03931616 255 256 O
Final NCT03931616 258 263 O
diagnosis NCT03931616 264 273 O
of NCT03931616 274 276 O
ischemic NCT03931616 277 285 B-Condition
stroke NCT03931616 286 292 I-Condition
( NCT03931616 293 294 O
ICD NCT03931616 295 298 O
10 NCT03931616 299 301 O
: NCT03931616 302 303 O
I63 NCT03931616 304 307 O
) NCT03931616 308 309 O
or NCT03931616 310 312 B-Or
TIA NCT03931616 313 316 B-Condition
( NCT03931616 317 318 O
Transient NCT03931616 319 328 B-Condition
Ischemic NCT03931616 329 337 I-Condition
Attack NCT03931616 338 344 I-Condition
, NCT03931616 345 346 O
ICD NCT03931616 347 350 O
10 NCT03931616 351 353 O
: NCT03931616 354 355 O
G45 NCT03931616 356 359 B-Condition
except NCT03931616 360 366 B-Exception
G45.4 NCT03931616 367 372 O
) NCT03931616 373 374 O

3 NCT03931616 378 379 O
. NCT03931616 379 380 O
Confirmed NCT03931616 382 391 O
onset NCT03931616 392 397 B-Observation
- NCT03931616 398 399 I-Observation
to NCT03931616 400 402 I-Observation
- NCT03931616 403 404 O
alarm NCT03931616 405 410 I-Observation
time NCT03931616 411 415 I-Observation
≤ NCT03931616 416 417 B-Eq-Comparison
4 NCT03931616 418 419 I-Eq-Comparison
hours NCT03931616 420 425 I-Eq-Comparison
at NCT03931616 426 428 O
dispatch NCT03931616 429 437 O

4 NCT03931616 440 441 O
. NCT03931616 441 442 O
Pre NCT03931616 444 447 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03931616 448 449 O
stroke NCT03931616 450 456 B-Condition
modified NCT03931616 457 465 B-Observation
Rankin NCT03931616 466 472 I-Observation
scale NCT03931616 473 478 I-Observation
≤ NCT03931616 479 480 B-Eq-Comparison
3 NCT03931616 481 482 I-Eq-Comparison
( NCT03931616 483 484 O
being NCT03931616 485 490 O
able NCT03931616 491 495 B-Condition
to NCT03931616 496 498 I-Condition
ambulate NCT03931616 499 507 I-Condition
, NCT03931616 508 509 O
in NCT03931616 510 512 O
routine NCT03931616 513 520 O
clinical NCT03931616 521 529 O
care NCT03931616 530 534 O
, NCT03931616 535 536 O
patients NCT03931616 537 545 O
with NCT03931616 546 550 O
mRS NCT03931616 551 554 B-Observation
up NCT03931616 555 557 B-Eq-Comparison
to NCT03931616 558 560 I-Eq-Comparison
3 NCT03931616 561 562 I-Eq-Comparison
are NCT03931616 563 566 O
usually NCT03931616 567 574 O
deemed NCT03931616 575 581 O
suitable NCT03931616 582 590 O
for NCT03931616 591 594 O
tissue NCT03931616 595 601 O
plasminogen NCT03931616 602 613 O
activator NCT03931616 614 623 O
treatment NCT03931616 624 633 O
) NCT03931616 634 635 O

Exclusion NCT03931616 637 646 O
Criteria NCT03931616 647 655 O
: NCT03931616 656 657 O

1 NCT03931616 661 662 O
. NCT03931616 662 663 O
Remission NCT03931616 665 674 O
of NCT03931616 675 677 O
disabling NCT03931616 678 687 B-Condition
symptoms NCT03931616 688 696 B-Assertion___Assertion-Type-Value:possible
until NCT03931616 697 702 O
arrival NCT03931616 703 710 O
of NCT03931616 711 713 O
emergency NCT03931616 714 723 O
medical NCT03931616 724 731 O
service NCT03931616 732 739 O

2 NCT03931616 742 743 O
. NCT03931616 743 744 O
Malignant NCT03931616 746 755 B-Modifier
or NCT03931616 756 758 B-Or
other NCT03931616 759 764 B-Modifier
severe NCT03931616 765 771 O
primary NCT03931616 772 779 B-Condition
disease NCT03931616 780 787 I-Condition
with NCT03931616 788 792 B-And
life NCT03931616 793 797 B-Observation
expectancy NCT03931616 798 808 I-Observation
< NCT03931616 809 810 B-Eq-Comparison
1 NCT03931616 811 812 I-Eq-Comparison
year NCT03931616 813 817 I-Eq-Comparison
Additional NCT03931616 818 828 O
exclusion NCT03931616 829 838 O
criteria NCT03931616 839 847 O
for NCT03931616 848 851 O
primary NCT03931616 852 859 O
study NCT03931616 860 865 O
population NCT03931616 866 876 O
: NCT03931616 877 878 O

3 NCT03931616 882 883 O
. NCT03931616 883 884 O
Major NCT03931616 886 891 O
surgery NCT03931616 892 899 B-Procedure
within NCT03931616 900 906 B-Eq-Comparison
4 NCT03931616 907 908 I-Eq-Comparison
weeks NCT03931616 909 914 I-Eq-Comparison
before NCT03931616 915 921 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03931616 922 927 B-Study
inclusion NCT03931616 928 937 O

4 NCT03931616 940 941 O
. NCT03931616 941 942 O
Confirmed NCT03931616 944 953 O
stroke NCT03931616 954 960 B-Condition
within NCT03931616 961 967 B-Eq-Comparison
3 NCT03931616 968 969 I-Eq-Comparison
months NCT03931616 970 976 I-Eq-Comparison
before NCT03931616 977 983 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03931616 984 989 B-Study
inclusion NCT03931616 990 999 I-Study

5 NCT03931616 1002 1003 O
. NCT03931616 1003 1004 O
Absolute NCT03931616 1006 1014 O
contraindications NCT03931616 1015 1032 B-Contraindication
for NCT03931616 1033 1036 O
thrombolysis NCT03931616 1037 1049 B-Procedure
AND NCT03931616 1050 1053 B-And
thrombectomy NCT03931616 1054 1066 B-Procedure

Inclusion NCT03934008 0 9 O
Criteria NCT03934008 10 18 O
( NCT03934008 19 20 O
primary NCT03934008 21 28 O
outcome NCT03934008 29 36 O
) NCT03934008 37 38 O
: NCT03934008 40 41 O

- NCT03934008 45 46 O
Patients NCT03934008 48 56 O
0 NCT03934008 57 58 B-Eq-Comparison
- NCT03934008 59 60 I-Eq-Comparison
6 NCT03934008 61 62 I-Eq-Comparison
years NCT03934008 63 68 I-Eq-Comparison
of NCT03934008 69 71 O
age NCT03934008 72 75 B-Age

- NCT03934008 78 79 O
Seen NCT03934008 81 85 B-Encounter
in NCT03934008 86 88 O
the NCT03934008 89 92 O
Rocking NCT03934008 93 100 O
Horse NCT03934008 101 106 O
Community NCT03934008 107 116 O
Center NCT03934008 117 123 O
by NCT03934008 124 126 O
a NCT03934008 127 128 O
pediatric NCT03934008 129 138 B-Provider
provider NCT03934008 139 147 I-Provider
during NCT03934008 148 154 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03934008 155 158 O
baseline NCT03934008 159 167 B-Study
or NCT03934008 168 170 B-Or
study NCT03934008 171 176 B-Study
period NCT03934008 177 183 O

Inclusion NCT03934008 184 193 O
Criteria NCT03934008 194 202 O
( NCT03934008 203 204 O
secondary NCT03934008 205 214 O
parental NCT03934008 215 223 O
health NCT03934008 224 230 O
belief NCT03934008 231 237 O
outcomes NCT03934008 238 246 O
) NCT03934008 247 248 O
: NCT03934008 250 251 O

- NCT03934008 255 256 O
Parents NCT03934008 258 265 B-Family-Member___Family-Member-Type:parent
/ NCT03934008 266 267 O
caregivers NCT03934008 268 278 O
( NCT03934008 279 280 O
1 NCT03934008 281 282 O
) NCT03934008 283 284 O
≥ NCT03934008 285 286 B-Eq-Comparison
18 NCT03934008 287 289 I-Eq-Comparison
years NCT03934008 290 295 I-Eq-Comparison
old NCT03934008 296 299 B-Age

- NCT03934008 302 303 O
Read NCT03934008 305 309 O
English NCT03934008 310 317 O

- NCT03934008 320 321 O
Have NCT03934008 323 327 O
at NCT03934008 328 330 B-Eq-Comparison
least NCT03934008 331 336 I-Eq-Comparison
one NCT03934008 337 340 I-Eq-Comparison
child NCT03934008 341 346 O
≤ NCT03934008 347 348 B-Eq-Comparison
6 NCT03934008 349 350 I-Eq-Comparison
years NCT03934008 351 356 I-Eq-Comparison
of NCT03934008 357 359 O
age NCT03934008 360 363 B-Age

Inclusion NCT03934008 364 373 O
Criteria NCT03934008 374 382 O
( NCT03934008 383 384 O
secondary NCT03934008 385 394 O
provider NCT03934008 395 403 O
outcomes NCT03934008 404 412 O
) NCT03934008 413 414 O
: NCT03934008 416 417 O
All NCT03934008 418 421 O
providers NCT03934008 422 431 O
who NCT03934008 432 435 O
interact NCT03934008 436 444 O
with NCT03934008 445 449 O
pediatric NCT03934008 450 459 O

patients NCT03934008 460 468 O
in NCT03934008 469 471 O
the NCT03934008 472 475 O
Rocking NCT03934008 476 483 O
Horse NCT03934008 484 489 O
Community NCT03934008 490 499 O
Center NCT03934008 500 506 O
who NCT03934008 507 510 O

- NCT03934008 513 514 O
Complete NCT03934008 516 524 O
the NCT03934008 525 528 O
training NCT03934008 529 537 O
and NCT03934008 538 541 O

- NCT03934008 544 545 O
Implement NCT03934008 547 556 O
the NCT03934008 557 560 O
MOTIVE NCT03934008 561 567 O
tool NCT03934008 568 572 O
in NCT03934008 573 575 O
practice NCT03934008 576 584 O

Inclusion NCT03934034 0 9 O
Criteria NCT03934034 10 18 O
: NCT03934034 19 20 O

1 NCT03934034 24 25 O
. NCT03934034 25 26 O
Clinical NCT03934034 28 36 O
diagnosis NCT03934034 37 46 O
of NCT03934034 47 49 O
NTM NCT03934034 50 53 B-Condition
pulmonary NCT03934034 54 63 I-Condition
disease NCT03934034 64 71 I-Condition
. NCT03934034 71 72 O

2 NCT03934034 76 77 O
. NCT03934034 77 78 O
The NCT03934034 80 83 O
causative NCT03934034 84 93 B-Organism
agent NCT03934034 94 99 I-Organism
of NCT03934034 100 102 O
NTM NCT03934034 103 106 B-Condition
pulmonary NCT03934034 107 116 I-Condition
disease NCT03934034 117 124 I-Condition
includes NCT03934034 125 133 O
: NCT03934034 134 135 O
M. NCT03934034 136 138 B-Organism
avium NCT03934034 140 145 I-Organism
complex NCT03934034 146 153 I-Organism
, NCT03934034 154 155 O
or NCT03934034 156 158 B-Or
M. NCT03934034 159 161 B-Organism
abscessus NCT03934034 163 172 I-Organism
subspecies NCT03934034 173 183 I-Organism
abscessus NCT03934034 184 193 I-Organism
, NCT03934034 194 195 O
or NCT03934034 196 198 B-Or
M. NCT03934034 199 201 B-Organism
abscessus NCT03934034 203 212 I-Organism
subspecies NCT03934034 213 223 I-Organism
massiliense NCT03934034 224 235 I-Organism
, NCT03934034 236 237 O
or NCT03934034 238 240 B-Or
M. NCT03934034 241 243 B-Organism
kansasii NCT03934034 245 253 I-Organism
. NCT03934034 253 254 O

3 NCT03934034 258 259 O
. NCT03934034 259 260 O
Patients NCT03934034 262 270 O
who NCT03934034 271 274 O
starts NCT03934034 275 281 O
new NCT03934034 282 285 B-Eq-Comparison
treatment NCT03934034 286 295 B-Procedure
( NCT03934034 296 297 O
those NCT03934034 298 303 O
who NCT03934034 304 307 O
have NCT03934034 308 312 O
previous NCT03934034 313 321 B-Eq-Comparison
history NCT03934034 322 329 I-Eq-Comparison
of NCT03934034 330 332 O
treatment NCT03934034 333 342 B-Procedure
are NCT03934034 343 346 O
eligible NCT03934034 347 355 O
) NCT03934034 356 357 O

Exclusion NCT03934034 359 368 O
Criteria NCT03934034 369 377 O

1 NCT03934034 380 381 O
. NCT03934034 381 382 O
Patients NCT03934034 384 392 O
who NCT03934034 393 396 O
have NCT03934034 397 401 O
been NCT03934034 402 406 O
treated NCT03934034 407 414 B-Procedure
for NCT03934034 415 418 O
more NCT03934034 419 423 B-Eq-Comparison
than NCT03934034 424 428 I-Eq-Comparison
4 NCT03934034 429 430 I-Eq-Comparison
weeks NCT03934034 431 436 I-Eq-Comparison
. NCT03934034 436 437 O

2 NCT03934034 441 442 O
. NCT03934034 442 443 O
The NCT03934034 445 448 O
causative NCT03934034 449 458 B-Organism
agent NCT03934034 459 464 I-Organism
of NCT03934034 465 467 O
NTM NCT03934034 468 471 B-Condition
pulmonary NCT03934034 472 481 I-Condition
disease NCT03934034 482 489 I-Condition
is NCT03934034 490 492 O
none NCT03934034 493 497 B-Negation
of NCT03934034 498 500 I-Negation
M. NCT03934034 501 503 B-Organism|Organism
avium NCT03934034 505 510 I-Organism
complex NCT03934034 511 518 I-Organism
, NCT03934034 519 520 O
M. NCT03934034 521 523 O
abscessus NCT03934034 525 534 I-Organism
subspecies NCT03934034 535 545 I-Organism
abscessus NCT03934034 546 555 I-Organism
, NCT03934034 556 557 O
M. NCT03934034 558 560 B-Organism
abscessus NCT03934034 562 571 O
subspecies NCT03934034 572 582 I-Organism
massiliense NCT03934034 583 594 I-Organism
, NCT03934034 595 596 O
or NCT03934034 597 599 B-Or
M. NCT03934034 600 602 B-Organism
kansasii NCT03934034 604 612 I-Organism
. NCT03934034 612 613 O

Inclusion NCT03934593 0 9 O
Criteria NCT03934593 10 18 O
: NCT03934593 19 20 O

- NCT03934593 24 25 O
Church NCT03934593 27 33 O
eligibility NCT03934593 34 45 O
: NCT03934593 46 47 O
[ NCT03934593 48 49 O
Churches NCT03934593 50 58 O
must NCT03934593 59 63 O
be NCT03934593 64 66 O
predominantly NCT03934593 67 80 O
Hispanics NCT03934593 81 90 O
( NCT03934593 91 92 O
60 NCT03934593 93 95 O
% NCT03934593 96 97 O
) NCT03934593 98 99 O
with NCT03934593 100 104 O
at NCT03934593 105 107 B-Eq-Comparison
least NCT03934593 108 113 I-Eq-Comparison
20 NCT03934593 114 116 I-Eq-Comparison
adult NCT03934593 117 122 I-Eq-Comparison
congregants NCT03934593 123 134 O
with NCT03934593 135 139 B-And
T2D NCT03934593 140 143 B-Condition
willing NCT03934593 144 151 O
to NCT03934593 152 154 O
participate NCT03934593 155 166 O
in NCT03934593 167 169 O
the NCT03934593 170 173 O
study NCT03934593 174 179 O
. NCT03934593 179 180 O
The NCT03934593 182 185 O
rationale NCT03934593 186 195 O
for NCT03934593 196 199 O
20 NCT03934593 200 202 O
diabetic NCT03934593 203 211 O
voluntary NCT03934593 212 221 O
participants NCT03934593 222 234 O
per NCT03934593 235 238 O
church NCT03934593 239 245 O
is NCT03934593 246 248 O
based NCT03934593 249 254 O
on NCT03934593 255 257 O
the NCT03934593 258 261 O
Stanford NCT03934593 262 270 O
requirement NCT03934593 271 282 O
of NCT03934593 283 285 O

12 NCT03934593 291 293 O
- NCT03934593 294 295 O
16 NCT03934593 296 298 O
participants NCT03934593 299 311 O
allowed NCT03934593 312 319 O
per NCT03934593 320 323 O
support NCT03934593 324 331 O
group NCT03934593 332 337 O
and NCT03934593 338 341 O
with NCT03934593 342 346 O
an NCT03934593 347 349 O
anticipated NCT03934593 350 361 O
25 NCT03934593 362 364 O
% NCT03934593 365 366 O
attrition NCT03934593 367 376 O
. NCT03934593 376 377 O
] NCT03934593 378 379 O

- NCT03934593 383 384 O
Participants NCT03934593 386 398 O
' NCT03934593 398 399 O
eligibility NCT03934593 400 411 O
: NCT03934593 412 413 O
Participants NCT03934593 414 426 O
will NCT03934593 427 431 O
be NCT03934593 432 434 O
adults NCT03934593 435 441 O
age NCT03934593 442 445 B-Age
21 NCT03934593 446 448 B-Eq-Comparison
and NCT03934593 449 452 I-Eq-Comparison
above NCT03934593 453 458 I-Eq-Comparison
that NCT03934593 459 463 O
have NCT03934593 464 468 B-And
been NCT03934593 469 473 I-And
diagnosed NCT03934593 474 483 O
with NCT03934593 484 488 O
T2D. NCT03934593 489 493 B-Condition

Exclusion NCT03934593 495 504 O
Criteria NCT03934593 505 513 O
: NCT03934593 514 515 O

- NCT03934593 519 520 O
Children NCT03934593 522 530 O
, NCT03934593 531 532 O
adults NCT03934593 533 539 O
under NCT03934593 540 545 B-Eq-Comparison
21 NCT03934593 546 548 I-Eq-Comparison
years NCT03934593 549 554 I-Eq-Comparison
of NCT03934593 555 557 O
age NCT03934593 558 561 B-Age
, NCT03934593 562 563 O
and NCT03934593 564 567 B-And
pregnant NCT03934593 568 576 B-Condition
women NCT03934593 577 582 O

Inclusion NCT03934424 0 9 O
Criteria NCT03934424 10 18 O
: NCT03934424 19 20 O

- NCT03934424 24 25 O
Generally NCT03934424 27 36 O
healthy NCT03934424 37 44 B-Condition
individuals NCT03934424 45 56 O
aged NCT03934424 57 61 B-Age
from NCT03934424 62 66 O
18 NCT03934424 67 69 B-Eq-Comparison
to NCT03934424 70 72 I-Eq-Comparison
55 NCT03934424 73 75 I-Eq-Comparison
years NCT03934424 76 81 I-Eq-Comparison

- NCT03934424 84 85 O
BMI NCT03934424 87 90 B-Observation
25 NCT03934424 91 93 B-Eq-Comparison
- NCT03934424 94 95 I-Eq-Comparison
35 NCT03934424 96 98 I-Eq-Comparison
kg NCT03934424 99 101 I-Eq-Comparison
/ NCT03934424 102 103 I-Eq-Comparison
m2 NCT03934424 104 106 I-Eq-Comparison
will NCT03934424 107 111 O
be NCT03934424 112 114 O
recruited NCT03934424 115 124 O

Exclusion NCT03934424 125 134 O
Criteria NCT03934424 135 143 O
: NCT03934424 144 145 O

- NCT03934424 149 150 O
Being NCT03934424 152 157 B-Eq-Comparison
on NCT03934424 158 160 O
a NCT03934424 161 162 O
weight NCT03934424 163 169 B-Modifier
- NCT03934424 170 171 I-Modifier
loss NCT03934424 172 176 I-Modifier
or NCT03934424 177 179 B-Or
special NCT03934424 180 187 B-Modifier
diet NCT03934424 188 192 B-Procedure

- NCT03934424 195 196 O
Taking NCT03934424 198 204 B-Eq-Comparison
any NCT03934424 205 208 O
medications NCT03934424 209 220 B-Drug
or NCT03934424 221 223 B-Or
drugs NCT03934424 224 229 B-Drug
known NCT03934424 230 235 O
to NCT03934424 236 238 O
affect NCT03934424 239 245 O
appetite NCT03934424 246 254 B-Condition

- NCT03934424 257 258 O
Have NCT03934424 260 264 O
serious NCT03934424 265 272 O
claustrophobia NCT03934424 273 287 B-Condition
. NCT03934424 287 288 O

- NCT03934424 292 293 O
Individuals NCT03934424 295 306 O
with NCT03934424 307 311 O
mental NCT03934424 312 318 B-Condition
disorders NCT03934424 319 328 I-Condition
( NCT03934424 329 330 O
self NCT03934424 331 335 B-Assertion___Assertion-Type-Value:possible
- NCT03934424 336 337 I-Assertion___Assertion-Type-Value:possible
report NCT03934424 338 344 I-Assertion___Assertion-Type-Value:possible
) NCT03934424 345 346 O
will NCT03934424 347 351 O
be NCT03934424 352 354 O
excluded NCT03934424 355 363 B-Negation
. NCT03934424 363 364 O

- NCT03934424 368 369 O
Due NCT03934424 371 374 O
to NCT03934424 375 377 O
MRI NCT03934424 378 381 B-Procedure
, NCT03934424 382 383 O
any NCT03934424 384 387 O
individuals NCT03934424 388 399 O
with NCT03934424 400 404 O
metallic NCT03934424 405 413 B-Condition
objects NCT03934424 414 421 I-Condition
in NCT03934424 422 424 I-Condition
their NCT03934424 425 430 I-Condition
body NCT03934424 431 435 I-Condition
, NCT03934424 436 437 O
including NCT03934424 438 447 O
surgical NCT03934424 448 456 B-Condition
staples NCT03934424 457 464 I-Condition
left NCT03934424 465 469 I-Condition
in NCT03934424 470 472 I-Condition
the NCT03934424 473 476 I-Condition
body NCT03934424 477 481 I-Condition
following NCT03934424 482 491 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03934424 492 499 B-Procedure
, NCT03934424 500 501 O
middle NCT03934424 502 508 B-Condition
ear NCT03934424 509 512 I-Condition
prosthesis NCT03934424 513 523 I-Condition
, NCT03934424 524 525 O
permanent NCT03934424 526 535 B-Condition
eye NCT03934424 536 539 I-Condition
liner NCT03934424 540 545 I-Condition
, NCT03934424 546 547 O
metal NCT03934424 548 553 B-Condition
foreign NCT03934424 554 561 I-Condition
objects NCT03934424 562 569 I-Condition
lodged NCT03934424 570 576 I-Condition
inside NCT03934424 577 583 I-Condition
the NCT03934424 584 587 I-Condition
eye NCT03934424 588 591 I-Condition
, NCT03934424 592 593 O
heart NCT03934424 594 599 B-Condition
pacemakers NCT03934424 600 610 I-Condition
, NCT03934424 611 612 O
and NCT03934424 613 616 B-Or
/ NCT03934424 617 618 I-Or
or NCT03934424 619 621 B-Or|Or
pins NCT03934424 622 626 B-Condition
inside NCT03934424 627 633 I-Condition
the NCT03934424 634 637 O
knee NCT03934424 638 642 B-Modifier
or NCT03934424 643 645 B-Or
other NCT03934424 646 651 B-Modifier
joints NCT03934424 652 658 I-Modifier
or NCT03934424 659 661 B-Or
who NCT03934424 662 665 O
are NCT03934424 666 669 O
pregnant NCT03934424 670 678 B-Condition|Condition
or NCT03934424 679 681 O
could NCT03934424 682 687 B-Assertion___Assertion-Type-Value:possible
be NCT03934424 688 690 I-Assertion___Assertion-Type-Value:possible
pregnant NCT03934424 691 699 O
( NCT03934424 700 701 O
assessed NCT03934424 702 710 O
through NCT03934424 711 718 O
a NCT03934424 719 720 O
urine NCT03934424 721 726 B-Observation
pregnancy NCT03934424 727 736 I-Observation
test NCT03934424 737 741 I-Observation
for NCT03934424 742 745 O
women NCT03934424 746 751 O
) NCT03934424 752 753 O
will NCT03934424 754 758 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03934424 759 761 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03934424 762 770 B-Negation
from NCT03934424 771 775 O
this NCT03934424 776 780 O
study NCT03934424 781 786 B-Study
because NCT03934424 787 794 O
of NCT03934424 795 797 O
the NCT03934424 798 801 O
risk NCT03934424 802 806 B-Risk
associated NCT03934424 807 817 O
with NCT03934424 818 822 O
the NCT03934424 823 826 O
MRI NCT03934424 827 830 B-Procedure
scanner NCT03934424 831 838 O
. NCT03934424 838 839 O

Inclusion NCT03862404 0 9 O
Criteria NCT03862404 10 18 O
: NCT03862404 19 20 O

- NCT03862404 24 25 O
Male NCT03862404 27 31 O
and NCT03862404 32 35 B-Or
Female NCT03862404 36 42 O
, NCT03862404 43 44 O
between NCT03862404 45 52 B-Eq-Comparison
18 NCT03862404 53 55 I-Eq-Comparison
and NCT03862404 56 59 I-Eq-Comparison
80 NCT03862404 60 62 I-Eq-Comparison
years NCT03862404 63 68 I-Age|Eq-Comparison
, NCT03862404 69 70 O
ASA NCT03862404 71 74 B-Condition
1 NCT03862404 75 76 B-Eq-Comparison
- NCT03862404 77 78 I-Eq-Comparison
3 NCT03862404 79 80 O
, NCT03862404 81 82 O
Scheduled NCT03862404 83 92 B-Eq-Comparison
for NCT03862404 93 96 O
open NCT03862404 97 101 B-Modifier
thoracotomy NCT03862404 102 113 B-Procedure

Exclusion NCT03862404 114 123 O
Criteria NCT03862404 124 132 O
: NCT03862404 133 134 O

- NCT03862404 138 139 O
ASA NCT03862404 141 144 B-Condition
> NCT03862404 145 146 B-Eq-Comparison
3 NCT03862404 147 148 I-Eq-Comparison
, NCT03862404 149 150 O
morbid NCT03862404 151 157 B-Condition
obesity NCT03862404 158 165 I-Condition
BMI NCT03862404 166 169 B-Observation
> NCT03862404 170 171 B-Eq-Comparison
40 NCT03862404 172 174 I-Eq-Comparison
, NCT03862404 175 176 O
Previous NCT03862404 177 185 B-Eq-Comparison
cardiac NCT03862404 186 193 B-Modifier
or NCT03862404 194 196 B-Or
ipsilateral NCT03862404 197 208 B-Modifier
thoracic NCT03862404 209 217 B-Procedure
surgery NCT03862404 218 225 I-Procedure
, NCT03862404 226 227 O
Renal NCT03862404 228 233 B-Modifier
or NCT03862404 234 236 B-Or
hepatic NCT03862404 237 244 B-Modifier
failure NCT03862404 245 252 B-Condition
, NCT03862404 253 254 O
anemia NCT03862404 255 261 B-Condition
, NCT03862404 262 263 O
allergy NCT03862404 264 271 B-Allergy
to NCT03862404 272 274 O
local NCT03862404 275 280 B-Procedure
anesthetics NCT03862404 281 292 I-Procedure
, NCT03862404 293 294 O
contraindications NCT03862404 295 312 B-Contraindication
to NCT03862404 313 315 O
receive NCT03862404 316 323 O
regional NCT03862404 324 332 B-Procedure
anesthesia NCT03862404 333 343 I-Procedure
, NCT03862404 344 345 O
patient NCT03862404 346 353 O
refusal NCT03862404 354 361 O
, NCT03862404 362 363 O
reiteration NCT03862404 364 375 B-Observation
due NCT03862404 376 379 O
to NCT03862404 380 382 O
complication NCT03862404 383 395 B-Condition

Inclusion NCT03861858 0 9 O
Criteria NCT03861858 10 18 O
: NCT03861858 19 20 O

- NCT03861858 24 25 O
Age NCT03861858 27 30 B-Age
13 NCT03861858 31 33 B-Eq-Comparison
- NCT03861858 34 35 I-Eq-Comparison
17 NCT03861858 36 38 I-Eq-Comparison
years NCT03861858 39 44 I-Eq-Comparison
or NCT03861858 45 47 B-Or
18 NCT03861858 48 50 B-Eq-Comparison
- NCT03861858 51 52 I-Eq-Comparison
20 NCT03861858 53 55 O
if NCT03861858 56 58 O
still NCT03861858 59 64 O
living NCT03861858 65 71 O
at NCT03861858 72 74 O
home NCT03861858 75 79 O
with NCT03861858 80 84 O
parent NCT03861858 85 91 O
. NCT03861858 91 92 O

- NCT03861858 96 97 O
Agreement NCT03861858 99 108 O
of NCT03861858 109 111 O
at NCT03861858 112 114 B-Eq-Comparison
least NCT03861858 115 120 I-Eq-Comparison
one NCT03861858 121 124 I-Eq-Comparison
responsible NCT03861858 125 136 O
adult NCT03861858 137 142 O
parent NCT03861858 143 149 B-Family-Member___Family-Member-Type:parent
/ NCT03861858 150 151 O
caregiver NCT03861858 152 161 O
to NCT03861858 162 164 O
participate NCT03861858 165 176 O
in NCT03861858 177 179 O
treatment NCT03861858 180 189 B-Procedure
. NCT03861858 189 190 O

- NCT03861858 194 195 O
Agreement NCT03861858 197 206 O
to NCT03861858 207 209 O
take NCT03861858 210 214 O
part NCT03861858 215 219 O
in NCT03861858 220 222 O
assessments NCT03861858 223 234 O
, NCT03861858 235 236 O
videotaping NCT03861858 237 248 O
/ NCT03861858 249 250 O
audiotaping NCT03861858 251 262 O
and NCT03861858 263 266 O
coding NCT03861858 267 273 O
of NCT03861858 274 276 O
their NCT03861858 277 282 O
sessions NCT03861858 283 291 O
by NCT03861858 292 294 O
research NCT03861858 295 303 O
personnel NCT03861858 304 313 O
. NCT03861858 313 314 O

- NCT03861858 318 319 O
Agreement NCT03861858 321 330 O
to NCT03861858 331 333 O
pay NCT03861858 334 337 O
for NCT03861858 338 341 O
mental NCT03861858 342 348 O
health NCT03861858 349 355 O
services NCT03861858 356 364 O
at NCT03861858 365 367 O
the NCT03861858 368 371 O
DBT NCT03861858 372 375 O
- NCT03861858 376 377 O
RU NCT03861858 378 380 O
on NCT03861858 381 383 O
a NCT03861858 384 385 O
sliding NCT03861858 386 393 O
scale NCT03861858 394 399 O
, NCT03861858 400 401 O
and NCT03861858 402 405 O
to NCT03861858 406 408 O
participate NCT03861858 409 420 O
in NCT03861858 421 423 O
research NCT03861858 424 432 O
assessments NCT03861858 433 444 O
as NCT03861858 445 447 O
volunteers NCT03861858 448 458 O
. NCT03861858 458 459 O

- NCT03861858 463 464 O
Residence NCT03861858 466 475 O
within NCT03861858 476 482 O
commuting NCT03861858 483 492 B-Observation
distance NCT03861858 493 501 I-Observation
of NCT03861858 502 504 O
clinic NCT03861858 505 511 O
( NCT03861858 512 513 O
< NCT03861858 515 516 B-Eq-Comparison
45 NCT03861858 517 519 I-Eq-Comparison
minutes NCT03861858 520 527 I-Eq-Comparison
) NCT03861858 528 529 O
. NCT03861858 530 531 O

- NCT03861858 535 536 O
Agreement NCT03861858 538 547 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861858 548 550 O
discontinue NCT03861858 551 562 B-Negation
other NCT03861858 563 568 O
forms NCT03861858 569 574 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03861858 575 577 O
talk NCT03861858 578 582 B-Procedure
therapy NCT03861858 583 590 I-Procedure
for NCT03861858 591 594 O
duration NCT03861858 595 603 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03861858 604 606 O
DBT NCT03861858 607 610 B-Procedure
program NCT03861858 611 618 I-Procedure
( NCT03861858 619 620 O
does NCT03861858 621 625 B-Exception
not NCT03861858 626 629 I-Exception
refer NCT03861858 630 635 I-Exception
to NCT03861858 636 638 I-Exception
AA NCT03861858 639 641 B-Modifier
/ NCT03861858 642 643 B-Or
NA NCT03861858 644 646 B-Modifier
programs NCT03861858 647 655 B-Procedure
or NCT03861858 656 658 B-Or
psychotropic NCT03861858 659 671 B-Drug
medication NCT03861858 672 682 I-Drug
management NCT03861858 683 693 B-Procedure
) NCT03861858 694 695 O
. NCT03861858 696 697 O

- NCT03861858 701 702 O
Exhibits NCT03861858 704 712 O
dysregulation NCT03861858 713 726 B-Condition
within NCT03861858 727 733 B-Eq-Comparison
the NCT03861858 734 737 I-Eq-Comparison
past NCT03861858 738 742 I-Eq-Comparison
six NCT03861858 743 746 I-Eq-Comparison
months NCT03861858 747 753 I-Eq-Comparison
as NCT03861858 754 756 O
evidenced NCT03861858 757 766 O
by NCT03861858 767 769 O
1 NCT03861858 770 771 O
) NCT03861858 772 773 O
intentional NCT03861858 774 785 B-Modifier
self NCT03861858 786 790 B-Condition
- NCT03861858 791 792 I-Condition
injury NCT03861858 793 799 I-Condition
and NCT03861858 800 803 B-Or|Or
/ NCT03861858 804 805 I-Or|Or
or NCT03861858 806 808 I-Or|Or
suicide NCT03861858 809 816 B-Condition
attempt NCT03861858 817 824 I-Condition
and NCT03861858 825 828 O
/ NCT03861858 829 830 O
or NCT03861858 831 833 O
2 NCT03861858 834 835 O
) NCT03861858 836 837 O
substance NCT03861858 838 847 B-Condition
use NCT03861858 848 851 I-Condition
disorder NCT03861858 852 860 I-Condition
. NCT03861858 860 861 O

- NCT03861858 865 866 O
Meets NCT03861858 868 873 O
two NCT03861858 874 877 B-Eq-Comparison
additional NCT03861858 878 888 O
criteria NCT03861858 889 897 O
for NCT03861858 898 901 O
borderline NCT03861858 902 912 B-Condition
personality NCT03861858 913 924 I-Condition
disorder NCT03861858 925 933 I-Condition
( NCT03861858 934 935 O
BPD NCT03861858 936 939 B-Condition
) NCT03861858 940 941 O
. NCT03861858 942 943 O

Exclusion NCT03861858 945 954 O
Criteria NCT03861858 955 963 O
: NCT03861858 964 965 O

- NCT03861858 969 970 O
Clients NCT03861858 972 979 O
who NCT03861858 980 983 O
need NCT03861858 984 988 B-Assertion___Assertion-Type-Value:hypothetical
mental NCT03861858 989 995 B-Procedure
health NCT03861858 996 1002 I-Procedure
services NCT03861858 1003 1011 I-Procedure
not NCT03861858 1012 1015 B-Negation
available NCT03861858 1016 1025 O
at NCT03861858 1026 1028 O
the NCT03861858 1029 1032 O
DBT NCT03861858 1033 1036 O
- NCT03861858 1037 1038 O
RU NCT03861858 1039 1041 O
, NCT03861858 1042 1043 O
such NCT03861858 1044 1048 O
as NCT03861858 1049 1051 O
treatment NCT03861858 1052 1061 B-Procedure
for NCT03861858 1062 1065 O
schizophrenia NCT03861858 1066 1079 B-Condition
or NCT03861858 1080 1082 B-Or|Or
life NCT03861858 1083 1087 B-Death|Risk
- NCT03861858 1088 1089 I-Death|Risk
threatening NCT03861858 1090 1101 I-Death|Risk
anorexia NCT03861858 1102 1110 B-Condition
, NCT03861858 1111 1112 O
or NCT03861858 1113 1115 O
who NCT03861858 1116 1119 O
are NCT03861858 1120 1123 O
currently NCT03861858 1124 1133 B-Eq-Comparison
obtaining NCT03861858 1134 1143 O
optimum NCT03861858 1144 1151 O
professional NCT03861858 1152 1164 B-Procedure
treatment NCT03861858 1165 1174 I-Procedure
that NCT03861858 1175 1179 O
should NCT03861858 1180 1186 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03861858 1187 1190 B-Negation
be NCT03861858 1191 1193 O
ended NCT03861858 1194 1199 B-Negation
. NCT03861858 1199 1200 O

- NCT03861858 1204 1205 O
Non NCT03861858 1207 1210 B-Negation
- NCT03861858 1211 1212 O
English NCT03861858 1213 1220 O
speaking NCT03861858 1221 1229 O
. NCT03861858 1229 1230 O

- NCT03861858 1234 1235 O
IQ NCT03861858 1237 1239 B-Observation
< NCT03861858 1240 1241 B-Eq-Comparison
70 NCT03861858 1242 1244 I-Eq-Comparison
. NCT03861858 1244 1245 O

- NCT03861858 1249 1250 O
Unable NCT03861858 1252 1258 O
to NCT03861858 1259 1261 O
understand NCT03861858 1262 1272 O
research NCT03861858 1273 1281 O
consent NCT03861858 1282 1289 O
forms NCT03861858 1290 1295 O
. NCT03861858 1295 1296 O

- NCT03861858 1300 1301 I-Observation
Court NCT03861858 1303 1308 B-Observation
- NCT03861858 1309 1310 O
ordered NCT03861858 1311 1318 I-Observation
to NCT03861858 1319 1321 O
participate NCT03861858 1322 1333 O
in NCT03861858 1334 1336 O
treatment NCT03861858 1337 1346 B-Procedure
. NCT03861858 1346 1347 O

Inclusion NCT03869021 0 9 O
Criteria NCT03869021 10 18 O
: NCT03869021 19 20 O

1 NCT03869021 24 25 O
. NCT03869021 25 26 O
Patients NCT03869021 28 36 O
free NCT03869021 37 41 B-Negation
from NCT03869021 42 46 I-Negation
any NCT03869021 47 50 O
disease NCT03869021 51 58 B-Condition
affecting NCT03869021 59 68 B-Modifier
bone NCT03869021 69 73 I-Modifier
formation NCT03869021 74 83 I-Modifier
of NCT03869021 84 86 O
both NCT03869021 87 91 O
sexes NCT03869021 92 97 O
was NCT03869021 98 101 O
included NCT03869021 102 110 O
in NCT03869021 111 113 O
the NCT03869021 114 117 O
study NCT03869021 118 123 O
. NCT03869021 123 124 O

2 NCT03869021 128 129 O
. NCT03869021 129 130 O
Patients NCT03869021 132 140 O
younger NCT03869021 141 148 B-Eq-Comparison
than NCT03869021 149 153 I-Eq-Comparison
25 NCT03869021 154 156 I-Eq-Comparison
years NCT03869021 157 162 I-Eq-Comparison
old NCT03869021 163 166 B-Age
. NCT03869021 166 167 O

3 NCT03869021 171 172 O
. NCT03869021 172 173 O
Patients NCT03869021 175 183 O
included NCT03869021 184 192 O
in NCT03869021 193 195 O
the NCT03869021 196 199 O
study NCT03869021 200 205 O
were NCT03869021 206 210 O
hemifacial NCT03869021 211 221 B-Condition
microsomia NCT03869021 222 232 I-Condition

4 NCT03869021 235 236 O
. NCT03869021 236 237 O
Distraction NCT03869021 239 250 B-Observation
range NCT03869021 251 256 I-Observation
was NCT03869021 257 260 O
between NCT03869021 261 268 O
15 NCT03869021 269 271 B-Eq-Comparison
- NCT03869021 272 273 I-Eq-Comparison
20 NCT03869021 274 276 I-Eq-Comparison
mm NCT03869021 277 279 I-Eq-Comparison
. NCT03869021 279 280 O

Exclusion NCT03869021 282 291 O
Criteria NCT03869021 292 300 O
: NCT03869021 301 302 O

1 NCT03869021 306 307 O
. NCT03869021 307 308 O
The NCT03869021 310 313 O
presence NCT03869021 314 322 B-Eq-Comparison
of NCT03869021 323 325 O
uncontrolled NCT03869021 326 338 B-Modifier
systemic NCT03869021 339 347 I-Modifier
disease NCT03869021 348 355 B-Condition
. NCT03869021 355 356 O

2 NCT03869021 360 361 O
. NCT03869021 361 362 O
Previous NCT03869021 364 372 B-Eq-Comparison
radiotherapy NCT03869021 373 385 B-Procedure
on NCT03869021 386 388 O
head NCT03869021 389 393 B-Modifier
and NCT03869021 394 397 B-Or
neck NCT03869021 398 402 B-Modifier
region NCT03869021 403 409 I-Modifier
. NCT03869021 409 410 O

3 NCT03869021 414 415 O
. NCT03869021 415 416 O
Chemotherapy NCT03869021 418 430 B-Procedure
within NCT03869021 431 437 B-Eq-Comparison
the NCT03869021 438 441 I-Eq-Comparison
past NCT03869021 442 446 I-Eq-Comparison
12 NCT03869021 447 449 I-Eq-Comparison
- NCT03869021 450 451 I-Eq-Comparison
month NCT03869021 452 457 I-Eq-Comparison
period NCT03869021 458 464 O
. NCT03869021 464 465 O

4 NCT03869021 469 470 O
. NCT03869021 470 471 O
An NCT03869021 473 475 O
active NCT03869021 476 482 B-Eq-Comparison
infection NCT03869021 483 492 B-Condition
at NCT03869021 493 495 O
the NCT03869021 496 499 O
distraction NCT03869021 500 511 B-Modifier
site NCT03869021 512 516 I-Modifier
. NCT03869021 516 517 O

Inclusion NCT03864263 0 9 O
Criteria NCT03864263 10 18 O
: NCT03864263 19 20 O

- NCT03864263 24 25 O
The NCT03864263 27 30 O
father NCT03864263 31 37 B-Family-Member___Family-Member-Type:father
or NCT03864263 38 40 B-Or
( NCT03864263 41 42 I-Or
and NCT03864263 43 46 O
) NCT03864263 47 48 O
mother NCT03864263 49 55 B-Family-Member___Family-Member-Type:mother
is NCT03864263 56 58 O
HBV NCT03864263 59 62 B-Condition
- NCT03864263 63 64 I-Condition
infected NCT03864263 65 73 I-Condition
( NCT03864263 74 75 O
pre NCT03864263 76 79 B-Condition|Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864263 80 81 O
pregnancy NCT03864263 82 91 O
or NCT03864263 92 94 B-Or
present NCT03864263 95 102 B-Eq-Comparison
) NCT03864263 103 104 O
； NCT03864263 105 106 O

- NCT03864263 109 110 O
Children NCT03864263 112 120 B-Family-Member___Family-Member-Type:child
is NCT03864263 121 123 O
vaccinated NCT03864263 124 134 B-Immunization
with NCT03864263 135 139 O
hepatitis NCT03864263 140 149 O
B NCT03864263 150 151 O
vaccine NCT03864263 152 159 O
after NCT03864263 160 165 B-Temporal-Connection___Temporal-Connection-Type-Value:after
birth NCT03864263 166 171 B-Birth
; NCT03864263 171 172 O

Exclusion NCT03864263 173 182 O
Criteria NCT03864263 183 191 O
: NCT03864263 192 193 O

- NCT03864263 197 198 O
Children NCT03864263 200 208 B-Family-Member___Family-Member-Type:child
with NCT03864263 209 213 O
HBV NCT03864263 214 217 B-Condition
infection NCT03864263 218 227 I-Condition
; NCT03864263 227 228 O

- NCT03864263 231 232 O
Participants NCT03864263 234 246 O
agreed NCT03864263 247 253 O
to NCT03864263 254 256 O
undergo NCT03864263 257 264 O
clinical NCT03864263 265 273 O
follow NCT03864263 274 280 O
- NCT03864263 281 282 O
up NCT03864263 283 285 O
studies NCT03864263 286 293 O
. NCT03864263 293 294 O

Inclusion NCT03862612 0 9 O
Criteria NCT03862612 10 18 O
: NCT03862612 19 20 O

- NCT03862612 24 25 O
Male NCT03862612 27 31 O
and NCT03862612 32 35 B-Or
Female NCT03862612 36 42 O
participants NCT03862612 43 55 O
providing NCT03862612 56 65 O
written NCT03862612 66 73 O
informed NCT03862612 74 82 O
consent NCT03862612 83 90 O
, NCT03862612 91 92 O

- NCT03862612 96 97 O
ASA NCT03862612 99 102 B-Condition
grade NCT03862612 103 108 B-Eq-Comparison
1 NCT03862612 109 110 I-Eq-Comparison
- NCT03862612 111 112 I-Eq-Comparison
4 NCT03862612 113 114 I-Eq-Comparison
, NCT03862612 115 116 O

- NCT03862612 121 122 O
aged NCT03862612 124 128 B-Age
over NCT03862612 129 133 B-Eq-Comparison
18 NCT03862612 134 136 I-Eq-Comparison

- NCT03862612 140 141 O
undergoing NCT03862612 143 153 B-Eq-Comparison
a NCT03862612 154 155 O
VATS NCT03862612 156 160 B-Procedure
procedure NCT03862612 161 170 I-Procedure
under NCT03862612 171 176 O
General NCT03862612 177 184 B-Procedure
Anaesthesia NCT03862612 185 196 I-Procedure

Exclusion NCT03862612 197 206 O
Criteria NCT03862612 207 215 O
: NCT03862612 216 217 O

- NCT03862612 221 222 O
Absence NCT03862612 224 231 O
of NCT03862612 232 234 O
informed NCT03862612 235 243 O
written NCT03862612 244 251 O
consent NCT03862612 252 259 O
, NCT03862612 260 261 O

- NCT03862612 265 266 O
pre NCT03862612 268 271 B-Eq-Comparison
existing NCT03862612 272 280 I-Eq-Comparison
infection NCT03862612 281 290 B-Condition
at NCT03862612 291 293 O
block NCT03862612 294 299 B-Modifier
site NCT03862612 300 304 I-Modifier
, NCT03862612 305 306 O
- NCT03862612 308 309 O

- NCT03862612 313 314 O
severe NCT03862612 316 322 O
coagulopathy NCT03862612 323 335 B-Condition
, NCT03862612 336 337 O

- NCT03862612 341 342 O
allergy NCT03862612 344 351 B-Allergy
to NCT03862612 352 354 O
local NCT03862612 355 360 B-Procedure
anaesthesia NCT03862612 361 372 I-Procedure
, NCT03862612 373 374 O

- NCT03862612 378 379 O
pre NCT03862612 381 384 B-Eq-Comparison
existing NCT03862612 385 393 I-Eq-Comparison
neurological NCT03862612 394 406 B-Condition
deficit NCT03862612 407 414 I-Condition
, NCT03862612 415 416 O

- NCT03862612 420 421 O
previous NCT03862612 423 431 B-Eq-Comparison
history NCT03862612 432 439 I-Eq-Comparison
of NCT03862612 440 442 O
opiate NCT03862612 443 449 B-Condition
abuse NCT03862612 450 455 I-Condition
, NCT03862612 456 457 O

- NCT03862612 461 462 O
pre NCT03862612 464 467 B-Eq-Comparison
existing NCT03862612 468 476 I-Eq-Comparison
chronic NCT03862612 477 484 B-Modifier
pain NCT03862612 485 489 B-Condition
condition NCT03862612 490 499 I-Condition
, NCT03862612 500 501 O

- NCT03862612 505 506 I-Eq-Comparison
pre NCT03862612 508 511 B-Eq-Comparison
- NCT03862612 512 513 O
existing NCT03862612 514 522 I-Eq-Comparison
dementia NCT03862612 523 531 B-Condition
[ NCT03862612 532 533 O
because NCT03862612 534 541 O
of NCT03862612 542 544 O
need NCT03862612 545 549 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862612 550 552 I-Assertion___Assertion-Type-Value:hypothetical
co NCT03862612 553 555 O
- NCT03862612 556 557 I-Observation
operate NCT03862612 558 565 O
in NCT03862612 566 568 O
completing NCT03862612 569 579 O
QoR NCT03862612 580 583 B-Observation
- NCT03862612 584 585 O
15 NCT03862612 586 588 I-Observation
score NCT03862612 589 594 I-Observation
day NCT03862612 595 598 B-Eq-Comparison
after NCT03862612 599 604 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03862612 605 612 B-Procedure
] NCT03862612 613 614 O
. NCT03862612 615 616 O

Inclusion NCT03866460 0 9 O
Criteria NCT03866460 10 18 O
: NCT03866460 19 20 O

- NCT03866460 24 25 O
Signed NCT03866460 27 33 O
informed NCT03866460 34 42 O
consent NCT03866460 43 50 O
indicating NCT03866460 51 61 O
awareness NCT03866460 62 71 O
of NCT03866460 72 74 O
the NCT03866460 75 78 O
investigational NCT03866460 79 94 O
nature NCT03866460 95 101 O
of NCT03866460 102 104 O
the NCT03866460 105 108 O
protocol NCT03866460 109 117 O
. NCT03866460 117 118 O

- NCT03866460 122 123 O
Children NCT03866460 125 133 O
with NCT03866460 134 138 B-And
RB NCT03866460 139 141 B-Condition
aged NCT03866460 142 146 B-Age
3 NCT03866460 147 148 B-Eq-Comparison
months NCT03866460 149 155 I-Eq-Comparison
and NCT03866460 156 159 I-Eq-Comparison
older NCT03866460 160 165 I-Eq-Comparison
who NCT03866460 166 169 B-And
are NCT03866460 170 173 O
scheduled NCT03866460 174 183 B-Eq-Comparison
to NCT03866460 184 186 O
receive NCT03866460 187 194 O
their NCT03866460 195 200 O
first NCT03866460 201 206 B-Eq-Comparison
dose NCT03866460 207 211 O
of NCT03866460 212 214 O
IA NCT03866460 215 217 B-Drug
carboplatin NCT03866460 218 229 I-Drug
chemotherapy NCT03866460 230 242 B-Procedure
. NCT03866460 242 243 O

- NCT03866460 252 253 O
Retinoblastoma NCT03866460 255 269 B-Condition
is NCT03866460 270 272 O
rarely NCT03866460 273 279 O
seen NCT03866460 280 284 O
in NCT03866460 285 287 O
children NCT03866460 288 296 O
over NCT03866460 297 301 B-Eq-Comparison
8 NCT03866460 302 303 I-Eq-Comparison
years NCT03866460 304 309 I-Eq-Comparison
old NCT03866460 310 313 I-Eq-Comparison
, NCT03866460 314 315 O
however NCT03866460 316 323 O
we NCT03866460 324 326 O
will NCT03866460 327 331 O
not NCT03866460 332 335 O
include NCT03866460 336 343 O
an NCT03866460 344 346 O
upper NCT03866460 347 352 O
age NCT03866460 353 356 O
range NCT03866460 357 362 O
so NCT03866460 363 365 O
as NCT03866460 366 368 O
not NCT03866460 369 372 O
to NCT03866460 373 375 O
exclude NCT03866460 376 383 O
any NCT03866460 384 387 O
possible NCT03866460 388 396 O
participants NCT03866460 397 409 O

Exclusion NCT03866460 410 419 O
Criteria NCT03866460 420 428 O
: NCT03866460 429 430 O

- NCT03866460 434 435 O
Children NCT03866460 437 445 O
with NCT03866460 446 450 B-And
known NCT03866460 451 456 O
and NCT03866460 457 460 O
documented NCT03866460 461 471 O
preexisting NCT03866460 472 483 B-Eq-Comparison
hearing NCT03866460 484 491 B-Condition
loss NCT03866460 492 496 I-Condition
. NCT03866460 496 497 O

Inclusion NCT03863444 0 9 O
Criteria NCT03863444 10 18 O
: NCT03863444 19 20 O

- NCT03863444 24 25 O
( NCT03863444 27 28 O
1 NCT03863444 29 30 O
) NCT03863444 31 32 O
gestational NCT03863444 33 44 B-Observation
age NCT03863444 45 48 I-Observation
35 NCT03863444 49 51 B-Eq-Comparison
to NCT03863444 52 54 I-Eq-Comparison
39 NCT03863444 55 57 I-Eq-Comparison
weeks NCT03863444 58 63 I-Eq-Comparison

- NCT03863444 66 67 O
( NCT03863444 69 70 O
2 NCT03863444 71 72 O
) NCT03863444 73 74 O
adults NCT03863444 75 81 O

- NCT03863444 84 85 O
( NCT03863444 87 88 O
3 NCT03863444 89 90 O
) NCT03863444 91 92 O
primipara NCT03863444 93 102 B-Condition
and NCT03863444 103 106 B-And
their NCT03863444 107 112 O
spouses NCT03863444 113 120 B-Family-Member___Family-Member-Type:spouse

- NCT03863444 123 124 O
( NCT03863444 126 127 O
4 NCT03863444 128 129 O
) NCT03863444 130 131 O
having NCT03863444 132 138 B-Eq-Comparison
routine NCT03863444 139 146 O
prenatal NCT03863444 147 155 B-Modifier
visits NCT03863444 156 162 B-Encounter
and NCT03863444 163 166 B-And
plan NCT03863444 167 171 B-Assertion___Assertion-Type-Value:intention
to NCT03863444 172 174 O
have NCT03863444 175 179 O
the NCT03863444 180 183 O
birth NCT03863444 184 189 B-Birth
in NCT03863444 190 192 O
the NCT03863444 193 196 O
medical NCT03863444 197 204 O
center NCT03863444 205 211 O

- NCT03863444 214 215 O
( NCT03863444 217 218 O
5 NCT03863444 219 220 O
) NCT03863444 221 222 O
able NCT03863444 223 227 O
to NCT03863444 228 230 O
communicate NCT03863444 231 242 O
with NCT03863444 243 247 O
Mandarin NCT03863444 248 256 O
or NCT03863444 257 259 B-Or
Taiwanese NCT03863444 260 269 O

- NCT03863444 272 273 O
( NCT03863444 275 276 O
6 NCT03863444 277 278 O
) NCT03863444 279 280 O
willing NCT03863444 281 288 O
to NCT03863444 289 291 O
participate NCT03863444 292 303 O
in NCT03863444 304 306 O
this NCT03863444 307 311 O
study NCT03863444 312 317 O
and NCT03863444 318 321 O
give NCT03863444 322 326 O
written NCT03863444 327 334 O
inform NCT03863444 335 341 O
- NCT03863444 342 343 O
consent NCT03863444 344 351 O
forms NCT03863444 352 357 O

Exclusion NCT03863444 358 367 O
Criteria NCT03863444 368 376 O
: NCT03863444 377 378 O

- NCT03863444 382 383 O
( NCT03863444 385 386 O
1 NCT03863444 387 388 O
) NCT03863444 389 390 O
having NCT03863444 391 397 O
fetus NCT03863444 398 403 B-Condition
with NCT03863444 404 408 O
abnormality NCT03863444 409 420 O

- NCT03863444 423 424 O
( NCT03863444 426 427 O
2 NCT03863444 428 429 O
) NCT03863444 430 431 O
high NCT03863444 432 436 O
- NCT03863444 437 438 O
risk NCT03863444 439 443 B-Risk
pregnancy NCT03863444 444 453 B-Condition

- NCT03863444 456 457 I-Observation
( NCT03863444 459 460 O
3 NCT03863444 461 462 O
) NCT03863444 463 464 O
can NCT03863444 465 468 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03863444 468 471 O
room NCT03863444 472 476 B-Observation
- NCT03863444 477 478 O
in NCT03863444 479 481 I-Observation
due NCT03863444 482 485 O
to NCT03863444 486 488 O
newborn NCT03863444 489 496 B-Family-Member___Family-Member-Type:child
's NCT03863444 496 498 O
medical NCT03863444 499 506 B-Condition
conditions NCT03863444 507 517 I-Condition

Inclusion NCT03864471 0 9 O
Criteria NCT03864471 10 18 O
: NCT03864471 19 20 O

- NCT03864471 24 25 O
lived NCT03864471 27 32 O
in NCT03864471 33 35 O
the NCT03864471 36 39 O
community NCT03864471 40 49 O
at NCT03864471 50 52 B-Eq-Comparison
least NCT03864471 53 58 I-Eq-Comparison
three NCT03864471 59 64 I-Eq-Comparison
months NCT03864471 65 71 I-Eq-Comparison

- NCT03864471 74 75 O
over NCT03864471 77 81 B-Eq-Comparison
65 NCT03864471 82 84 I-Eq-Comparison
years NCT03864471 85 90 I-Eq-Comparison
old NCT03864471 91 94 B-Age

- NCT03864471 97 98 O
fluently NCT03864471 100 108 O
communicated NCT03864471 109 121 O
in NCT03864471 122 124 O
Mandarin NCT03864471 125 133 O
or NCT03864471 134 136 B-Or
Taiwanese NCT03864471 137 146 O

- NCT03864471 149 150 O
screened NCT03864471 152 160 O
by NCT03864471 161 163 O
the NCT03864471 164 167 O
High NCT03864471 168 172 B-Observation
- NCT03864471 173 174 I-Observation
need NCT03864471 175 179 I-Observation
Community NCT03864471 180 189 I-Observation
Older NCT03864471 190 195 I-Observation
Adults NCT03864471 196 202 I-Observation
Screening NCT03864471 203 212 I-Observation
Scale NCT03864471 213 218 I-Observation
( NCT03864471 219 220 O
HCOASS NCT03864471 221 227 B-Observation
) NCT03864471 228 229 O
as NCT03864471 230 232 O
high NCT03864471 233 237 B-Condition
- NCT03864471 238 239 I-Condition
need NCT03864471 240 244 I-Condition
older NCT03864471 245 250 O
adults NCT03864471 251 257 O

Exclusion NCT03864471 258 267 O
Criteria NCT03864471 268 276 O
: NCT03864471 277 278 O

- NCT03864471 282 283 O
diagnosed NCT03864471 285 294 O
as NCT03864471 295 297 O
dementia NCT03864471 298 306 B-Condition

Inclusion NCT03862014 0 9 O
Criteria NCT03862014 10 18 O
: NCT03862014 19 20 O

- NCT03862014 24 25 O
Patients NCT03862014 27 35 O
and NCT03862014 36 39 O
parents NCT03862014 40 47 B-Family-Member
of NCT03862014 48 50 O
the NCT03862014 51 54 O
patients NCT03862014 55 63 O
who NCT03862014 64 67 O
accept NCT03862014 68 74 O
to NCT03862014 75 77 O
participate NCT03862014 78 89 O
and NCT03862014 90 93 O
sign NCT03862014 94 98 O
the NCT03862014 99 102 O
informed NCT03862014 103 111 O
consent NCT03862014 112 119 O

- NCT03862014 122 123 O
Patients NCT03862014 125 133 O
whose NCT03862014 134 139 O
molar NCT03862014 140 145 B-Modifier
teeth NCT03862014 146 151 I-Modifier
are NCT03862014 152 155 O
diagnosed NCT03862014 156 165 O
as NCT03862014 166 168 O
molar NCT03862014 169 174 B-Condition
incisor NCT03862014 175 182 I-Condition
hypomineralization NCT03862014 183 201 I-Condition
by NCT03862014 202 204 O
EAPD NCT03862014 205 209 O

- NCT03862014 212 213 O
Teeth NCT03862014 215 220 B-Modifier
that NCT03862014 221 225 I-Modifier
are NCT03862014 226 229 O
fully NCT03862014 230 235 B-Condition
erupted NCT03862014 236 243 I-Condition

- NCT03862014 246 247 O
Patients NCT03862014 249 257 O
who NCT03862014 258 261 O
have NCT03862014 262 266 O
at NCT03862014 267 269 B-Eq-Comparison
least NCT03862014 270 275 I-Eq-Comparison
two NCT03862014 276 279 I-Eq-Comparison
permanent NCT03862014 280 289 B-Modifier
first NCT03862014 290 295 I-Modifier
molars NCT03862014 296 302 B-Condition
that NCT03862014 303 307 O
need NCT03862014 308 312 B-Assertion___Assertion-Type-Value:hypothetical
fissure NCT03862014 313 320 B-Procedure
sealant NCT03862014 321 328 I-Procedure

- NCT03862014 331 332 O
Teeth NCT03862014 334 339 B-Modifier
that NCT03862014 340 344 O
have NCT03862014 345 349 O
white NCT03862014 350 355 B-Modifier
- NCT03862014 356 357 I-Modifier
yellow NCT03862014 358 364 I-Modifier
- NCT03862014 365 366 I-Modifier
brown NCT03862014 367 372 I-Modifier
discoloration NCT03862014 373 386 B-Condition
that NCT03862014 387 391 O
indicate NCT03862014 392 400 O
high NCT03862014 401 405 O
- NCT03862014 406 407 O
caries NCT03862014 408 414 B-Condition
risk NCT03862014 415 419 B-Risk

Exclusion NCT03862014 420 429 O
Criteria NCT03862014 430 438 O
: NCT03862014 439 440 O

- NCT03862014 444 445 O
Teeth NCT03862014 447 452 B-Condition
that NCT03862014 453 457 O
are NCT03862014 458 461 O
previously NCT03862014 462 472 B-Eq-Comparison
restored NCT03862014 473 481 B-Procedure
or NCT03862014 482 484 B-Or
have NCT03862014 485 489 O
caries NCT03862014 490 496 B-Condition

- NCT03862014 499 500 O
Patients NCT03862014 502 510 O
who NCT03862014 511 514 O
have NCT03862014 515 519 O
orthodontic NCT03862014 520 531 B-Procedure
treatment NCT03862014 532 541 I-Procedure

- NCT03862014 544 545 O
Patients NCT03862014 547 555 O
who NCT03862014 556 559 O
are NCT03862014 560 563 O
not NCT03862014 564 567 B-Assertion___Assertion-Type-Value:hypothetical|Negation
cooperative NCT03862014 568 579 O
for NCT03862014 580 583 O
the NCT03862014 584 587 O
dental NCT03862014 588 594 B-Procedure
procedure NCT03862014 595 604 I-Procedure

- NCT03862014 607 608 O
Teeth NCT03862014 610 615 B-Modifier
that NCT03862014 616 620 O
have NCT03862014 621 625 O
dental NCT03862014 626 632 B-Condition
flourosis NCT03862014 633 642 I-Condition
or NCT03862014 643 645 B-Or
enamel NCT03862014 646 652 B-Condition
malformation NCT03862014 653 665 I-Condition
according NCT03862014 666 675 O
to NCT03862014 676 678 O
the NCT03862014 679 682 O
specific NCT03862014 683 691 O
syndromes NCT03862014 692 701 O

Inclusion NCT03869814 0 9 O
Criteria NCT03869814 10 18 O
: NCT03869814 19 20 O

1 NCT03869814 24 25 O
. NCT03869814 25 26 O
Age NCT03869814 28 31 B-Age
greater NCT03869814 32 39 B-Eq-Comparison
than NCT03869814 40 44 I-Eq-Comparison
or NCT03869814 45 47 I-Eq-Comparison
equal NCT03869814 48 53 I-Eq-Comparison
to NCT03869814 54 56 I-Eq-Comparison
21 NCT03869814 57 59 I-Eq-Comparison
years NCT03869814 60 65 I-Eq-Comparison
old NCT03869814 66 69 O

2 NCT03869814 72 73 O
. NCT03869814 73 74 O
Clinical NCT03869814 76 84 O
suspicion NCT03869814 85 94 B-Assertion___Assertion-Type-Value:possible
of NCT03869814 95 97 O
malignancy NCT03869814 98 108 B-Condition
based NCT03869814 109 114 O
on NCT03869814 115 117 O
signs NCT03869814 118 123 B-Assertion___Assertion-Type-Value:possible
, NCT03869814 124 125 O
symptoms NCT03869814 126 134 B-Assertion___Assertion-Type-Value:possible
, NCT03869814 135 136 O
imaging NCT03869814 137 144 B-Procedure
studies NCT03869814 145 152 I-Procedure
, NCT03869814 153 154 O
and NCT03869814 155 158 B-Or
/ NCT03869814 159 160 I-Or
or NCT03869814 161 163 I-Or
non NCT03869814 164 167 B-Negation
- NCT03869814 168 169 O
surgical NCT03869814 170 178 B-Modifier
biopsies NCT03869814 179 187 B-Procedure
of NCT03869814 188 190 O
any NCT03869814 191 194 O
of NCT03869814 195 197 O
the NCT03869814 198 201 O
following NCT03869814 202 211 O
cancer NCT03869814 212 218 B-Condition
types NCT03869814 219 224 O
: NCT03869814 225 226 O
bladder NCT03869814 227 234 B-Modifier
, NCT03869814 235 236 O
breast NCT03869814 237 243 B-Modifier
, NCT03869814 244 245 O
colorectal NCT03869814 246 256 B-Modifier
, NCT03869814 257 258 O
kidney NCT03869814 259 265 B-Modifier
, NCT03869814 266 267 O
liver NCT03869814 268 273 B-Modifier
, NCT03869814 274 275 O
lung NCT03869814 276 280 B-Modifier
, NCT03869814 281 282 O
pancreas NCT03869814 283 291 B-Modifier
or NCT03869814 292 294 B-Or
prostate NCT03869814 295 303 B-Modifier
. NCT03869814 303 304 O

3 NCT03869814 308 309 O
. NCT03869814 309 310 O
Candidate NCT03869814 312 321 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869814 322 325 I-Assertion___Assertion-Type-Value:hypothetical
subsequent NCT03869814 326 336 O
medical NCT03869814 337 344 B-Modifier
and NCT03869814 345 348 B-Or
/ NCT03869814 349 350 I-Or
or NCT03869814 351 353 I-Or
surgical NCT03869814 354 362 B-Modifier
work NCT03869814 363 367 B-Procedure
- NCT03869814 368 369 I-Modifier|Procedure
up NCT03869814 370 372 I-Procedure
to NCT03869814 373 375 O
complete NCT03869814 376 384 O
organ NCT03869814 385 390 B-Modifier
- NCT03869814 391 392 O
specific NCT03869814 393 401 I-Modifier
cancer NCT03869814 402 408 B-Condition
diagnosis NCT03869814 409 418 O
inclusive NCT03869814 419 428 O
of NCT03869814 429 431 O
pathologic NCT03869814 432 442 B-Procedure
staging NCT03869814 443 450 I-Procedure
as NCT03869814 451 453 O
specified NCT03869814 454 463 O
by NCT03869814 464 466 O
the NCT03869814 467 470 O
College NCT03869814 471 478 O
of NCT03869814 479 481 O
American NCT03869814 482 490 O
Pathology NCT03869814 491 500 O
( NCT03869814 501 502 O
CAP NCT03869814 503 506 O
) NCT03869814 507 508 O
. NCT03869814 509 510 O

4 NCT03869814 514 515 O
. NCT03869814 515 516 O
Provision NCT03869814 518 527 O
of NCT03869814 528 530 O
informed NCT03869814 531 539 O
consent NCT03869814 540 547 O
. NCT03869814 547 548 O

Exclusion NCT03869814 550 559 O
Criteria NCT03869814 560 568 O
: NCT03869814 569 570 O

1 NCT03869814 574 575 O
. NCT03869814 575 576 O
Age NCT03869814 578 581 B-Age
less NCT03869814 582 586 B-Eq-Comparison
than NCT03869814 587 591 I-Eq-Comparison
21 NCT03869814 592 594 I-Eq-Comparison
years NCT03869814 595 600 I-Eq-Comparison
old NCT03869814 601 604 O

2 NCT03869814 607 608 O
. NCT03869814 608 609 O
Any NCT03869814 611 614 O
prior NCT03869814 615 620 B-Eq-Comparison
cancer NCT03869814 621 627 B-Condition
diagnosis NCT03869814 628 637 O
, NCT03869814 638 639 O
without NCT03869814 640 647 B-And|Negation
or NCT03869814 648 650 B-Or
with NCT03869814 651 655 O
any NCT03869814 656 659 O
treatment NCT03869814 660 669 B-Procedure
( NCT03869814 670 671 O
e. NCT03869814 672 674 O
g. NCT03869814 675 677 O
, NCT03869814 678 679 O
medical NCT03869814 680 687 B-Modifier
, NCT03869814 688 689 O
surgical NCT03869814 690 698 B-Modifier
, NCT03869814 699 700 O
or NCT03869814 701 703 B-Or
radiation NCT03869814 704 713 B-Modifier
oncology NCT03869814 714 722 I-Modifier
) NCT03869814 723 724 O
within NCT03869814 725 731 B-Eq-Comparison
prior NCT03869814 732 737 I-Eq-Comparison
six NCT03869814 738 741 I-Eq-Comparison
months NCT03869814 742 748 I-Eq-Comparison
. NCT03869814 748 749 O

3 NCT03869814 753 754 O
. NCT03869814 754 755 O
Any NCT03869814 757 760 O
surgery NCT03869814 761 768 B-Procedure
, NCT03869814 769 770 O
i. NCT03869814 771 773 O
e. NCT03869814 774 776 O
, NCT03869814 777 778 O
invasive NCT03869814 779 787 B-Procedure
procedure NCT03869814 788 797 I-Procedure
performed NCT03869814 798 807 O
in NCT03869814 808 810 O
the NCT03869814 811 814 O
operating NCT03869814 815 824 O
room NCT03869814 825 829 O
with NCT03869814 830 834 B-Eq-Comparison
any NCT03869814 835 838 O
level NCT03869814 839 844 O
of NCT03869814 845 847 O
anesthesia NCT03869814 848 858 B-Procedure
, NCT03869814 859 860 O
within NCT03869814 861 867 O
prior NCT03869814 868 873 I-Eq-Comparison
month NCT03869814 874 879 I-Eq-Comparison
. NCT03869814 879 880 O

4 NCT03869814 884 885 O
. NCT03869814 885 886 O
Any NCT03869814 888 891 O
non NCT03869814 892 895 B-Negation
- NCT03869814 896 897 O
cancer NCT03869814 898 904 B-Condition
systemic NCT03869814 905 913 B-Procedure
therapy NCT03869814 914 921 I-Procedure
associated NCT03869814 922 932 O
with NCT03869814 933 937 O
molecularly NCT03869814 938 949 B-Modifier
targeted NCT03869814 950 958 I-Modifier
immune NCT03869814 959 965 B-Procedure
modulation NCT03869814 966 976 I-Procedure
, NCT03869814 977 978 O
e. NCT03869814 979 981 O
g. NCT03869814 982 984 O
, NCT03869814 985 986 O
monoclonal NCT03869814 987 997 B-Procedure
antibodies NCT03869814 998 1008 I-Procedure
. NCT03869814 1008 1009 O

5 NCT03869814 1013 1014 O
. NCT03869814 1014 1015 O
Any NCT03869814 1017 1020 O
concurrent NCT03869814 1021 1031 B-Modifier
or NCT03869814 1032 1034 B-Or
prior NCT03869814 1035 1040 B-Eq-Comparison
pregnancy NCT03869814 1041 1050 B-Condition
within NCT03869814 1051 1057 B-Eq-Comparison
previous NCT03869814 1058 1066 I-Eq-Comparison
twelve NCT03869814 1067 1073 I-Eq-Comparison
months NCT03869814 1074 1080 I-Eq-Comparison
. NCT03869814 1080 1081 O

6 NCT03869814 1085 1086 O
. NCT03869814 1086 1087 O
Any NCT03869814 1089 1092 O
history NCT03869814 1093 1100 B-Eq-Comparison|Eq-Comparison
of NCT03869814 1101 1103 O
organ NCT03869814 1104 1109 B-Procedure
tissue NCT03869814 1110 1116 I-Procedure
transplantation NCT03869814 1117 1132 I-Procedure

7 NCT03869814 1135 1136 O
. NCT03869814 1136 1137 O
Any NCT03869814 1139 1142 O
history NCT03869814 1143 1150 O
of NCT03869814 1151 1153 O
blood NCT03869814 1154 1159 B-Procedure
product NCT03869814 1160 1167 I-Procedure
transfusion NCT03869814 1168 1179 I-Procedure
within NCT03869814 1180 1186 B-Eq-Comparison|Eq-Comparison
prior NCT03869814 1187 1192 I-Eq-Comparison|Eq-Comparison
month NCT03869814 1193 1198 I-Eq-Comparison|Eq-Comparison
. NCT03869814 1198 1199 O

8 NCT03869814 1203 1204 O
. NCT03869814 1204 1205 O
Any NCT03869814 1207 1210 O
major NCT03869814 1211 1216 O
trauma NCT03869814 1217 1223 B-Condition
within NCT03869814 1224 1230 O
prior NCT03869814 1231 1236 O
six NCT03869814 1237 1240 I-Eq-Comparison
months NCT03869814 1241 1247 O
, NCT03869814 1248 1249 O
e. NCT03869814 1250 1252 O
g. NCT03869814 1253 1255 O
, NCT03869814 1256 1257 O
burn NCT03869814 1258 1262 B-Condition
injury NCT03869814 1263 1269 I-Condition|Condition
, NCT03869814 1270 1271 O
extremity NCT03869814 1272 1281 B-Condition
crush NCT03869814 1282 1287 I-Condition
injury NCT03869814 1288 1294 O
, NCT03869814 1295 1296 O
motor NCT03869814 1297 1302 B-Condition
vehicle NCT03869814 1303 1310 I-Condition
accident NCT03869814 1311 1319 I-Condition
, NCT03869814 1320 1321 O
etc NCT03869814 1322 1325 O
. NCT03869814 1325 1326 O

9 NCT03869814 1330 1331 O
. NCT03869814 1331 1332 O
Unable NCT03869814 1334 1340 O
to NCT03869814 1341 1343 O
provide NCT03869814 1344 1351 O
informed NCT03869814 1352 1360 O
consent NCT03869814 1361 1368 O
. NCT03869814 1368 1369 O

Inclusion NCT03865784 0 9 O
Criteria NCT03865784 10 18 O
: NCT03865784 19 20 O

- NCT03865784 24 25 O
Federated NCT03865784 27 36 B-Observation
boxers NCT03865784 37 43 I-Observation

- NCT03865784 46 47 O
Over NCT03865784 49 53 B-Eq-Comparison
18 NCT03865784 54 56 I-Eq-Comparison
years NCT03865784 57 62 I-Age|Eq-Comparison

- NCT03865784 65 66 O
Male NCT03865784 68 72 O

- NCT03865784 75 76 O
With NCT03865784 78 82 O
non NCT03865784 83 86 B-Negation
- NCT03865784 87 88 O
specific NCT03865784 89 97 B-Modifier
back NCT03865784 98 102 B-Condition
pain NCT03865784 103 107 I-Condition
that NCT03865784 108 112 O
does NCT03865784 113 117 O
not NCT03865784 118 121 O
incapacitate NCT03865784 122 134 O
them NCT03865784 135 139 O
for NCT03865784 140 143 O
the NCT03865784 144 147 O
realization NCT03865784 148 159 O
of NCT03865784 160 162 O
their NCT03865784 163 168 O
sport NCT03865784 169 174 O
or NCT03865784 175 177 O
work NCT03865784 178 182 O
activity NCT03865784 183 191 O
. NCT03865784 191 192 O

Exclusion NCT03865784 194 203 O
Criteria NCT03865784 204 212 O
: NCT03865784 213 214 O

- NCT03865784 218 219 O
Federated NCT03865784 221 230 B-Observation
boxers NCT03865784 231 237 I-Observation
with NCT03865784 238 242 B-And
lumbar NCT03865784 243 249 B-Modifier
injury NCT03865784 250 256 B-Condition
with NCT03865784 257 261 O
medical NCT03865784 262 269 O
diagnosis NCT03865784 270 279 O

- NCT03865784 282 283 O
Who NCT03865784 285 288 O
are NCT03865784 289 292 B-Eq-Comparison
or NCT03865784 293 295 B-Or
have NCT03865784 296 300 B-Eq-Comparison
been NCT03865784 301 305 I-Eq-Comparison
treated NCT03865784 306 313 B-Procedure
by NCT03865784 314 316 O
pharmacological NCT03865784 317 332 B-Procedure
or NCT03865784 333 335 B-Or
physiotherapy NCT03865784 336 349 B-Procedure
in NCT03865784 350 352 O
the NCT03865784 353 356 O
last NCT03865784 357 361 B-Eq-Comparison
6 NCT03865784 362 363 I-Eq-Comparison
months NCT03865784 364 370 I-Eq-Comparison

- NCT03865784 373 374 O
Presenting NCT03865784 376 386 O
allergies NCT03865784 387 396 B-Allergy
or NCT03865784 397 399 B-Or
alterations NCT03865784 400 411 B-Condition
of NCT03865784 412 414 O
the NCT03865784 415 418 O
skin NCT03865784 419 423 B-Modifier

- NCT03865784 426 427 O
Not NCT03865784 429 432 O
sign NCT03865784 433 437 O
the NCT03865784 438 441 O
informed NCT03865784 442 450 O
consent NCT03865784 451 458 O
document NCT03865784 459 467 O
. NCT03865784 467 468 O

Inclusion NCT03863652 0 9 O
Criteria NCT03863652 10 18 O
: NCT03863652 19 20 O

- NCT03863652 24 25 O
Patients NCT03863652 27 35 O
≥ NCT03863652 36 37 B-Eq-Comparison
18 NCT03863652 38 40 I-Eq-Comparison
years NCT03863652 41 46 I-Eq-Comparison
old NCT03863652 47 50 B-Age
requiring NCT03863652 51 60 B-Assertion___Assertion-Type-Value:hypothetical
PCI NCT03863652 61 64 B-Procedure

- NCT03863652 67 68 O
Patients NCT03863652 70 78 O
who NCT03863652 79 82 O
are NCT03863652 83 86 O
palpable NCT03863652 87 95 B-Condition
distal NCT03863652 96 102 I-Condition
radial NCT03863652 103 109 I-Condition
arter NCT03863652 110 115 I-Condition

- NCT03863652 118 119 O
The NCT03863652 121 124 O
decision NCT03863652 125 133 O
to NCT03863652 134 136 O
participate NCT03863652 137 148 O
voluntarily NCT03863652 149 160 O
in NCT03863652 161 163 O
this NCT03863652 164 168 O
study NCT03863652 169 174 O
and NCT03863652 175 178 O
the NCT03863652 179 182 O
written NCT03863652 183 190 O
consent NCT03863652 191 198 O
of NCT03863652 199 201 O
the NCT03863652 202 205 O
patient NCT03863652 206 213 O

Exclusion NCT03863652 214 223 O
Criteria NCT03863652 224 232 O
: NCT03863652 233 234 O

- NCT03863652 238 239 O
Patients NCT03863652 241 249 O
who NCT03863652 250 253 O
are NCT03863652 254 257 O
not NCT03863652 258 261 B-Negation
palpable NCT03863652 262 270 B-Condition
distal NCT03863652 271 277 I-Condition
radial NCT03863652 278 284 I-Condition
artery NCT03863652 285 291 I-Condition

- NCT03863652 294 295 O
Female NCT03863652 297 303 O
of NCT03863652 304 306 B-And
childbearing NCT03863652 307 319 B-Condition
potential NCT03863652 320 329 I-Condition
, NCT03863652 330 331 O
who NCT03863652 332 335 B-And
possibly NCT03863652 336 344 B-Assertion___Assertion-Type-Value:intention
plans NCT03863652 345 350 I-Assertion___Assertion-Type-Value:intention
to NCT03863652 351 353 O
become NCT03863652 354 360 O
pregnant NCT03863652 361 369 B-Condition
any NCT03863652 370 373 B-Eq-Comparison
time NCT03863652 374 378 I-Eq-Comparison
after NCT03863652 379 384 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03863652 385 395 O
into NCT03863652 396 400 O
this NCT03863652 401 405 O
study NCT03863652 406 411 B-Study
. NCT03863652 411 412 O

- NCT03863652 416 417 O
Patients NCT03863652 419 427 O
who NCT03863652 428 431 O
are NCT03863652 432 435 O
not NCT03863652 436 439 O
appropriate NCT03863652 440 451 O
for NCT03863652 452 455 O
this NCT03863652 456 460 O
study NCT03863652 461 466 O

Inclusion NCT03860415 0 9 O
Criteria NCT03860415 10 18 O
: NCT03860415 19 20 O

- NCT03860415 24 25 O
Chronic NCT03860415 27 34 B-Modifier
( NCT03860415 35 36 O
more NCT03860415 37 41 B-Eq-Comparison
than NCT03860415 42 46 I-Eq-Comparison
three NCT03860415 47 52 I-Eq-Comparison
months NCT03860415 53 59 I-Eq-Comparison
) NCT03860415 60 61 O
ESBL NCT03860415 62 66 B-Condition
colonization NCT03860415 67 79 I-Condition
of NCT03860415 80 82 O
the NCT03860415 83 86 O
same NCT03860415 87 91 O
strain NCT03860415 92 98 O
as NCT03860415 99 101 O
determined NCT03860415 102 112 O
by NCT03860415 113 115 O

- NCT03860415 118 119 O
species NCT03860415 121 128 B-Observation
, NCT03860415 129 130 O
phenotype NCT03860415 131 140 B-Condition
and NCT03860415 141 144 O
antibiogram NCT03860415 145 156 B-Procedure
. NCT03860415 156 157 O

- NCT03860415 161 162 O
Patients NCT03860415 164 172 O
must NCT03860415 173 177 O
be NCT03860415 178 180 O
able NCT03860415 181 185 O
to NCT03860415 186 188 O
swallow NCT03860415 189 196 O
sachets NCT03860415 197 204 O
. NCT03860415 204 205 O

- NCT03860415 209 210 O
Must NCT03860415 212 216 O
be NCT03860415 217 219 O
able NCT03860415 220 224 O
to NCT03860415 225 227 O
speak NCT03860415 228 233 O
and NCT03860415 234 237 O
understand NCT03860415 238 248 O
Swedish NCT03860415 249 256 O
. NCT03860415 256 257 O

- NCT03860415 261 262 O
Must NCT03860415 264 268 O
have NCT03860415 269 273 O
a NCT03860415 274 275 O
permanent NCT03860415 276 285 O
residence NCT03860415 286 295 O
in NCT03860415 296 298 O
Sweden NCT03860415 299 305 O
. NCT03860415 305 306 O

- NCT03860415 310 311 O
Must NCT03860415 313 317 O
be NCT03860415 318 320 O
able NCT03860415 321 325 O
to NCT03860415 326 328 O
sign NCT03860415 329 333 O
informed NCT03860415 334 342 O
consent NCT03860415 343 350 O
in NCT03860415 351 353 O
Swedish NCT03860415 354 361 O
. NCT03860415 361 362 O

Exclusion NCT03860415 364 373 O
Criteria NCT03860415 374 382 O
: NCT03860415 383 384 O

- NCT03860415 388 389 O
Immunosuppression NCT03860415 391 408 B-Procedure
( NCT03860415 409 410 O
i. NCT03860415 411 413 O
e. NCT03860415 414 416 O
chemotheraphy NCT03860415 418 431 B-Procedure
, NCT03860415 432 433 O
treatment NCT03860415 434 443 B-Procedure
with NCT03860415 444 448 I-Procedure
TNF NCT03860415 449 452 I-Procedure
- NCT03860415 453 454 I-Procedure
alpha NCT03860415 455 460 I-Procedure
- NCT03860415 461 462 O
inhibitors NCT03860415 463 473 I-Procedure
) NCT03860415 474 475 O
. NCT03860415 476 477 O

- NCT03860415 481 482 O
In NCT03860415 484 486 O
patient NCT03860415 487 494 O
care NCT03860415 495 499 O
. NCT03860415 499 500 O

- NCT03860415 504 505 O
immunodeficiency NCT03860415 507 523 B-Condition

- NCT03860415 526 527 O
psychiatric NCT03860415 529 540 B-Condition
disorder NCT03860415 541 549 I-Condition

- NCT03860415 552 553 O
alcohol NCT03860415 555 562 B-Modifier
or NCT03860415 563 565 B-Or
substance NCT03860415 566 575 B-Modifier
abuse NCT03860415 576 581 B-Condition

- NCT03860415 584 585 O
dementia NCT03860415 587 595 B-Condition

- NCT03860415 598 599 O
Invasive NCT03860415 601 609 B-Procedure
catheters NCT03860415 610 619 I-Procedure
. NCT03860415 619 620 O

Inclusion NCT03866070 0 9 O
Criteria NCT03866070 10 18 O
: NCT03866070 19 20 O

- NCT03866070 24 25 O
Female NCT03866070 27 33 O

- NCT03866070 36 37 O
Handball NCT03866070 39 47 B-Observation
players NCT03866070 48 55 I-Observation
federated NCT03866070 56 65 O
in NCT03866070 66 68 O
the NCT03866070 69 72 O
Madrid NCT03866070 73 79 O
Handball NCT03866070 80 88 O
Federation NCT03866070 89 99 O

- NCT03866070 102 103 O
With NCT03866070 105 109 O
an NCT03866070 110 112 O
age NCT03866070 113 116 B-Age
range NCT03866070 117 122 O
between NCT03866070 123 130 B-Eq-Comparison
18 NCT03866070 131 133 I-Eq-Comparison
and NCT03866070 134 137 I-Eq-Comparison
37 NCT03866070 138 140 I-Eq-Comparison
years NCT03866070 141 146 I-Eq-Comparison

- NCT03866070 149 150 O
More NCT03866070 152 156 B-Eq-Comparison
than NCT03866070 157 161 I-Eq-Comparison
2 NCT03866070 162 163 I-Eq-Comparison
years NCT03866070 164 169 I-Eq-Comparison
of NCT03866070 170 172 O
handball NCT03866070 173 181 B-Observation
sports NCT03866070 182 188 I-Observation

- NCT03866070 191 192 O
Currently NCT03866070 194 203 O
participate NCT03866070 204 215 O
in NCT03866070 216 218 O
amateur NCT03866070 219 226 O
competitions NCT03866070 227 239 O
of NCT03866070 240 242 O
First NCT03866070 243 248 O
National NCT03866070 249 257 O
Women NCT03866070 258 263 O
's NCT03866070 263 265 O
category NCT03866070 266 274 O
. NCT03866070 274 275 O

Exclusion NCT03866070 277 286 O
Criteria NCT03866070 287 295 O
: NCT03866070 296 297 O

- NCT03866070 301 302 O
Have NCT03866070 304 308 O
suffered NCT03866070 309 317 B-Eq-Comparison
a NCT03866070 318 319 O
shoulder NCT03866070 320 328 B-Modifier
injury NCT03866070 329 335 B-Condition
in NCT03866070 336 338 O
the NCT03866070 339 342 O
last NCT03866070 343 347 B-Eq-Comparison
six NCT03866070 348 351 I-Eq-Comparison
months NCT03866070 352 358 I-Eq-Comparison

- NCT03866070 361 362 O
Who NCT03866070 364 367 O
are NCT03866070 368 371 O
currently NCT03866070 372 381 B-Eq-Comparison
doing NCT03866070 382 387 O
some NCT03866070 388 392 O
physiotherapy NCT03866070 393 406 B-Procedure
treatment NCT03866070 407 416 I-Procedure

- NCT03866070 419 420 O
Who NCT03866070 422 425 O
fail NCT03866070 426 430 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866070 431 433 I-Assertion___Assertion-Type-Value:hypothetical|Negation
participate NCT03866070 434 445 O
in NCT03866070 446 448 O
the NCT03866070 449 452 O
established NCT03866070 453 464 O
intervention NCT03866070 465 477 B-Procedure
and NCT03866070 478 481 B-And
evaluation NCT03866070 482 492 B-Procedure
sessions NCT03866070 493 501 O

- NCT03866070 504 505 O
Refusing NCT03866070 507 515 O
to NCT03866070 516 518 O
sign NCT03866070 519 523 O
the NCT03866070 524 527 O
informed NCT03866070 528 536 O
consent NCT03866070 537 544 O
document NCT03866070 545 553 O
. NCT03866070 553 554 O

Inclusion NCT03863691 0 9 O
Criteria NCT03863691 10 18 O
: NCT03863691 19 20 O

- NCT03863691 24 25 O
Common NCT03863691 27 33 O
European NCT03863691 34 42 O
Framework NCT03863691 43 52 O
of NCT03863691 53 55 O
Reference NCT03863691 56 65 O
for NCT03863691 66 69 O
Languages NCT03863691 70 79 O
level NCT03863691 80 85 O
B2 NCT03863691 86 88 O
in NCT03863691 89 91 O
German NCT03863691 92 98 O
language NCT03863691 99 107 O
. NCT03863691 107 108 O

- NCT03863691 112 113 O
Consent NCT03863691 115 122 O
ability NCT03863691 123 130 O
for NCT03863691 131 134 O
all NCT03863691 135 138 O
relevant NCT03863691 139 147 O
aspects NCT03863691 148 155 O
of NCT03863691 156 158 O
the NCT03863691 159 162 O
experiment NCT03863691 163 173 O
. NCT03863691 173 174 O

Exclusion NCT03863691 176 185 O
Criteria NCT03863691 186 194 O
: NCT03863691 195 196 O

- NCT03863691 200 201 O
Amisulpride NCT03863691 203 214 B-Drug
allergy NCT03863691 215 222 B-Allergy
. NCT03863691 222 223 O

- NCT03863691 227 228 O
Allergy NCT03863691 230 237 B-Allergy
to NCT03863691 238 240 O
other NCT03863691 241 246 O
components NCT03863691 247 257 B-Drug
of NCT03863691 258 260 I-Drug
amisulpride NCT03863691 261 272 I-Drug
/ NCT03863691 273 274 B-Or
placebo NCT03863691 275 282 B-Drug
capsules NCT03863691 283 291 I-Drug
like NCT03863691 292 296 O
lactose NCT03863691 297 304 B-Drug
. NCT03863691 304 305 O

- NCT03863691 309 310 O
Daily NCT03863691 312 317 B-Eq-Comparison
intake NCT03863691 318 324 O
of NCT03863691 325 327 O
other NCT03863691 328 333 B-Other
medication NCT03863691 334 344 B-Drug
including NCT03863691 345 354 O
contraceptives NCT03863691 355 369 B-Drug
. NCT03863691 369 370 O

- NCT03863691 374 375 O
Tendency NCT03863691 377 385 B-Modifier
to NCT03863691 386 388 O
seizures NCT03863691 389 397 B-Condition
. NCT03863691 397 398 O

- NCT03863691 402 403 O
Diagnosis NCT03863691 405 414 O
of NCT03863691 415 417 O
cancer NCT03863691 418 424 B-Condition
especially NCT03863691 425 435 O
pheochromocytoma NCT03863691 436 452 B-Condition
, NCT03863691 453 454 O
prolactinoma NCT03863691 455 467 B-Condition
, NCT03863691 468 469 O
or NCT03863691 470 472 O
breast NCT03863691 473 479 B-Modifier
cancer NCT03863691 480 486 B-Condition
. NCT03863691 486 487 O

- NCT03863691 491 492 O
Kidney NCT03863691 494 500 B-Condition
dysfunction NCT03863691 501 512 I-Condition
: NCT03863691 513 514 O
creatinine NCT03863691 515 525 B-Observation
clearance NCT03863691 526 535 I-Observation
below NCT03863691 536 541 B-Eq-Comparison
10 NCT03863691 542 544 I-Eq-Comparison
ml NCT03863691 545 547 I-Eq-Comparison
per NCT03863691 548 551 I-Eq-Comparison
minute NCT03863691 552 558 I-Eq-Comparison
. NCT03863691 558 559 O

- NCT03863691 563 564 O
High NCT03863691 566 570 O
risk NCT03863691 571 575 B-Risk
for NCT03863691 576 579 O
stroke NCT03863691 580 586 B-Condition
or NCT03863691 587 589 B-Or
thrombosis NCT03863691 590 600 B-Condition
. NCT03863691 600 601 O

- NCT03863691 605 606 O
Known NCT03863691 608 613 O
prolongation NCT03863691 614 626 B-Condition
of NCT03863691 627 629 I-Condition
the NCT03863691 630 633 I-Condition
QT NCT03863691 634 636 I-Condition
interval NCT03863691 637 645 I-Condition
, NCT03863691 646 647 O

- NCT03863691 651 652 O
Any NCT03863691 654 657 O
substantial NCT03863691 658 669 O
medical NCT03863691 670 677 B-Condition
condition NCT03863691 678 687 I-Condition
that NCT03863691 688 692 O
is NCT03863691 693 695 O
capable NCT03863691 696 703 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863691 704 706 I-Assertion___Assertion-Type-Value:hypothetical
reducing NCT03863691 707 715 O
the NCT03863691 716 719 O
volunteers NCT03863691 720 730 O
ability NCT03863691 731 738 O
to NCT03863691 739 741 O
participate NCT03863691 742 753 O
at NCT03863691 754 756 O
the NCT03863691 757 760 O
study NCT03863691 761 766 B-Study
. NCT03863691 766 767 O

- NCT03863691 771 772 O
Suicidal NCT03863691 774 782 B-Condition
thoughts NCT03863691 783 791 I-Condition
or NCT03863691 792 794 B-Or
suicide NCT03863691 795 802 B-Condition
attempts NCT03863691 803 811 I-Condition
in NCT03863691 812 814 O
the NCT03863691 815 818 O
past NCT03863691 819 823 B-Eq-Comparison
or NCT03863691 824 826 B-Or
at NCT03863691 827 829 O
present NCT03863691 830 837 B-Eq-Comparison
. NCT03863691 837 838 O

- NCT03863691 842 843 O
Substantial NCT03863691 845 856 O
mental NCT03863691 857 863 B-Condition
disorders NCT03863691 864 873 I-Condition
especially NCT03863691 874 884 O
schizophrenia NCT03863691 885 898 B-Condition
, NCT03863691 899 900 O
bipolar NCT03863691 901 908 B-Condition
disorder NCT03863691 909 917 I-Condition
, NCT03863691 918 919 O
drug NCT03863691 920 924 B-Condition
abuse NCT03863691 925 930 I-Condition
, NCT03863691 931 932 O
or NCT03863691 933 935 B-Or
personality NCT03863691 936 947 B-Condition
disorders NCT03863691 948 957 I-Condition
. NCT03863691 957 958 O

- NCT03863691 962 963 O
Pregnancy NCT03863691 965 974 B-Condition
or NCT03863691 975 977 B-Or
breastfeeding NCT03863691 978 991 B-Condition
. NCT03863691 991 992 O

Inclusion NCT03861910 0 9 O
Criteria NCT03861910 10 18 O
: NCT03861910 19 20 O

- NCT03861910 24 25 O
age NCT03861910 27 30 B-Age
1 NCT03861910 31 32 B-Eq-Comparison
- NCT03861910 33 34 I-Eq-Comparison
12 NCT03861910 35 37 I-Eq-Comparison
months NCT03861910 38 44 I-Eq-Comparison

- NCT03861910 47 48 O
IgE NCT03861910 50 53 B-Modifier
- NCT03861910 54 55 I-Modifier
mediated NCT03861910 56 64 I-Modifier
CMA NCT03861910 65 68 B-Condition

Exclusion NCT03861910 69 78 O
Criteria NCT03861910 79 87 O
: NCT03861910 88 89 O

- NCT03861910 93 94 O
cow NCT03861910 96 99 B-Drug
's NCT03861910 99 101 O
milk NCT03861910 102 106 I-Drug
protein NCT03861910 107 114 I-Drug
- NCT03861910 115 116 O
induced NCT03861910 117 124 O
anaphylaxis NCT03861910 125 136 B-Condition
, NCT03861910 137 138 O

- NCT03861910 142 143 O
food NCT03861910 145 149 B-Drug
protein NCT03861910 150 157 I-Drug
induced NCT03861910 158 165 O
enterocolitis NCT03861910 166 179 B-Condition
syndrome NCT03861910 180 188 I-Condition
, NCT03861910 189 190 O

- NCT03861910 194 195 O
other NCT03861910 197 202 B-Other
food NCT03861910 203 207 O
allergies NCT03861910 208 217 B-Allergy
, NCT03861910 218 219 O

- NCT03861910 223 224 O
other NCT03861910 226 231 B-Other
allergic NCT03861910 232 240 B-Condition
diseases NCT03861910 241 249 I-Condition
, NCT03861910 250 251 O

- NCT03861910 255 256 I-Modifier
non NCT03861910 258 261 B-Negation
- NCT03861910 262 263 O
CMA NCT03861910 264 267 B-Modifier
- NCT03861910 268 269 O
related NCT03861910 270 277 I-Modifier
atopic NCT03861910 278 284 B-Condition
eczema NCT03861910 285 291 I-Condition
, NCT03861910 292 293 O

- NCT03861910 297 298 O
eosinophilic NCT03861910 300 312 B-Condition
disorders NCT03861910 313 322 I-Condition
of NCT03861910 323 325 O
the NCT03861910 326 329 O
gastrointestinal NCT03861910 330 346 B-Modifier
tract NCT03861910 347 352 I-Modifier
, NCT03861910 353 354 O

- NCT03861910 358 359 O
chronic NCT03861910 361 368 B-Modifier
systemic NCT03861910 369 377 I-Modifier
diseases NCT03861910 378 386 B-Condition
, NCT03861910 387 388 O

- NCT03861910 392 393 O
congenital NCT03861910 395 405 B-Modifier
cardiac NCT03861910 406 413 B-Condition
defects NCT03861910 414 421 I-Condition
, NCT03861910 422 423 O

- NCT03861910 427 428 O
active NCT03861910 430 436 B-Eq-Comparison
tuberculosis NCT03861910 437 449 B-Condition
, NCT03861910 450 451 O

- NCT03861910 455 456 O
autoimmune NCT03861910 458 468 B-Condition
diseases NCT03861910 469 477 I-Condition
, NCT03861910 478 479 O

- NCT03861910 483 484 O
immunodeficiency NCT03861910 486 502 B-Condition
, NCT03861910 503 504 O

- NCT03861910 508 509 O
chronic NCT03861910 511 518 B-Modifier
inflammatory NCT03861910 519 531 B-Condition
bowel NCT03861910 532 537 I-Condition
diseases NCT03861910 538 546 I-Condition|Condition
, NCT03861910 547 548 O

- NCT03861910 552 553 O
celiac NCT03861910 555 561 B-Condition
disease NCT03861910 562 569 O
, NCT03861910 570 571 O

- NCT03861910 575 576 O
cystic NCT03861910 578 584 B-Condition
fibrosis NCT03861910 585 593 I-Condition
, NCT03861910 594 595 O

- NCT03861910 599 600 O
metabolic NCT03861910 602 611 B-Condition
diseases NCT03861910 612 620 I-Condition
, NCT03861910 621 622 O

- NCT03861910 626 627 O
malignancy NCT03861910 629 639 B-Condition
, NCT03861910 640 641 O

- NCT03861910 645 646 O
chronic NCT03861910 648 655 B-Modifier
pulmonary NCT03861910 656 665 B-Condition
diseases NCT03861910 666 674 I-Condition
, NCT03861910 675 676 O

- NCT03861910 680 681 O
malformations NCT03861910 683 696 B-Condition
of NCT03861910 697 699 O
the NCT03861910 700 703 O
gastrointestinal NCT03861910 704 720 B-Modifier
and NCT03861910 721 724 B-Or
/ NCT03861910 725 726 I-Or
or NCT03861910 727 729 I-Or
respiratory NCT03861910 730 741 B-Modifier
tract NCT03861910 742 747 I-Modifier
, NCT03861910 748 749 O

- NCT03861910 753 754 O
administration NCT03861910 756 770 O
of NCT03861910 771 773 O
prebiotics NCT03861910 774 784 B-Drug
or NCT03861910 785 787 B-Or
probiotics NCT03861910 788 798 B-Drug
during NCT03861910 799 805 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861910 806 809 O
4 NCT03861910 810 811 B-Eq-Comparison
weeks NCT03861910 812 817 I-Eq-Comparison
before NCT03861910 818 824 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03861910 825 834 B-Study
. NCT03861910 834 835 O

Inclusion NCT03863860 0 9 O
Criteria NCT03863860 10 18 O
: NCT03863860 19 20 O

1 NCT03863860 24 25 O
. NCT03863860 25 26 O
Histologically NCT03863860 28 42 B-Procedure
diagnosed NCT03863860 43 52 O
high NCT03863860 53 57 O
- NCT03863860 58 59 O
grade NCT03863860 60 65 O
serous NCT03863860 66 72 B-Modifier
or NCT03863860 73 75 B-Or
endometrioid NCT03863860 76 88 B-Modifier
ovarian NCT03863860 89 96 I-Modifier
cancer NCT03863860 97 103 B-Condition
( NCT03863860 104 105 O
including NCT03863860 106 115 O
primary NCT03863860 116 123 B-Modifier
peritoneal NCT03863860 124 134 I-Modifier
and NCT03863860 135 138 B-Or
fallopian NCT03863860 139 148 B-Modifier
tube NCT03863860 149 153 I-Modifier
cancer NCT03863860 154 160 B-Condition
) NCT03863860 161 162 O

2 NCT03863860 166 167 O
. NCT03863860 167 168 O
Completion NCT03863860 170 180 O
of NCT03863860 181 183 O
≥ NCT03863860 184 185 B-Eq-Comparison
2 NCT03863860 186 187 I-Eq-Comparison
previous NCT03863860 188 196 B-Eq-Comparison
platinum NCT03863860 197 205 B-Procedure
- NCT03863860 206 207 I-Procedure
containing NCT03863860 208 218 I-Procedure
regimens NCT03863860 219 227 I-Procedure

3 NCT03863860 230 231 O
. NCT03863860 231 232 O
Complete NCT03863860 234 242 B-Condition
response NCT03863860 243 251 I-Condition
( NCT03863860 252 253 O
CR NCT03863860 254 256 B-Condition
) NCT03863860 257 258 O
or NCT03863860 259 261 B-Or
partial NCT03863860 262 269 B-Condition
response NCT03863860 270 278 I-Condition
( NCT03863860 279 280 O
PR NCT03863860 281 283 B-Condition
) NCT03863860 284 285 O
achieved NCT03863860 286 294 O
with NCT03863860 295 299 O
last NCT03863860 300 304 B-Eq-Comparison
platinum NCT03863860 305 313 B-Modifier
- NCT03863860 314 315 I-Modifier
based NCT03863860 316 321 I-Modifier
chemotherapy NCT03863860 322 334 B-Procedure
regimen NCT03863860 335 342 I-Procedure
as NCT03863860 343 345 O
determined NCT03863860 346 356 O
by NCT03863860 357 359 O
investigator NCT03863860 360 372 O

4 NCT03863860 375 376 O
. NCT03863860 376 377 O
Ability NCT03863860 379 386 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863860 387 389 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03863860 390 392 O
randomized NCT03863860 393 403 O
≤ NCT03863860 404 405 B-Eq-Comparison
8 NCT03863860 406 407 I-Eq-Comparison
weeks NCT03863860 408 413 I-Eq-Comparison
after NCT03863860 414 419 B-Temporal-Connection___Temporal-Connection-Type-Value:after
last NCT03863860 420 424 B-Eq-Comparison
dose NCT03863860 425 429 O
of NCT03863860 430 432 O
platinum NCT03863860 433 441 B-Procedure

Exclusion NCT03863860 442 451 O
Criteria NCT03863860 452 460 O
: NCT03863860 461 462 O

1 NCT03863860 466 467 O
. NCT03863860 467 468 O
Prior NCT03863860 470 475 B-Eq-Comparison
treatment NCT03863860 476 485 B-Procedure
with NCT03863860 486 490 O
a NCT03863860 491 492 O
poly NCT03863860 493 497 B-Drug
( NCT03863860 498 499 I-Drug
ADP NCT03863860 500 503 O
- NCT03863860 504 505 I-Drug
ribose NCT03863860 506 512 I-Drug
) NCT03863860 513 514 O
polymerase NCT03863860 515 525 O
( NCT03863860 526 527 O
PARP NCT03863860 528 532 B-Drug
) NCT03863860 533 534 O
inhibitor NCT03863860 535 544 B-Modifier

2 NCT03863860 547 548 O
. NCT03863860 548 549 O
Patients NCT03863860 551 559 O
who NCT03863860 560 563 O
have NCT03863860 564 568 O
received NCT03863860 569 577 O
other NCT03863860 578 583 B-Other
study NCT03863860 584 589 B-Study
drug NCT03863860 590 594 B-Drug
treatment NCT03863860 595 604 B-Procedure
within NCT03863860 605 611 B-Eq-Comparison
4 NCT03863860 612 613 I-Eq-Comparison
weeks NCT03863860 614 619 I-Eq-Comparison
prior NCT03863860 620 625 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863860 626 628 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863860 629 632 O
first NCT03863860 633 638 B-Eq-Comparison
administration NCT03863860 639 653 O
( NCT03863860 654 655 B-Eq-Comparison
< NCT03863860 657 658 I-Eq-Comparison
5 NCT03863860 659 660 I-Eq-Comparison
elimination NCT03863860 661 672 I-Eq-Comparison
half NCT03863860 673 677 I-Eq-Comparison
- NCT03863860 678 679 I-Eq-Comparison
lives NCT03863860 680 685 I-Eq-Comparison
of NCT03863860 686 688 O
the NCT03863860 689 692 O
study NCT03863860 693 698 B-Study
drug NCT03863860 699 703 B-Drug|Drug
molecular NCT03863860 704 713 B-Modifier
targeted NCT03863860 714 722 I-Modifier
anti NCT03863860 723 727 O
- NCT03863860 728 729 O
cancer NCT03863860 730 736 B-Condition
drugs NCT03863860 737 742 O
) NCT03863860 743 744 O
. NCT03863860 745 746 O

3 NCT03863860 750 751 O
. NCT03863860 751 752 O
Patients NCT03863860 754 762 O
with NCT03863860 763 767 O
clinical NCT03863860 768 776 O
symptoms NCT03863860 777 785 B-Assertion___Assertion-Type-Value:possible
of NCT03863860 786 788 O
cancer NCT03863860 789 795 B-Condition
ascites NCT03863860 796 803 I-Condition
, NCT03863860 804 805 O
pleural NCT03863860 806 813 B-Condition
effusion NCT03863860 814 822 I-Condition
, NCT03863860 823 824 O
who NCT03863860 825 828 B-And
need NCT03863860 829 833 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863860 834 836 O
drainage NCT03863860 837 845 I-Procedure|Procedure
, NCT03863860 846 847 O
or NCT03863860 848 850 B-Or
who NCT03863860 851 854 O
have NCT03863860 855 859 O
undergone NCT03863860 860 869 B-Eq-Comparison
ascites NCT03863860 870 877 B-Procedure
drainage NCT03863860 878 886 O
within NCT03863860 887 893 B-Eq-Comparison
2 NCT03863860 894 895 I-Eq-Comparison
months NCT03863860 896 902 I-Eq-Comparison
prior NCT03863860 903 908 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863860 909 911 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863860 912 915 O
first NCT03863860 916 921 B-Eq-Comparison
administration NCT03863860 922 936 B-Drug
. NCT03863860 936 937 O

Inclusion NCT03867409 0 9 O
Criteria NCT03867409 10 18 O
: NCT03867409 19 20 O

- NCT03867409 24 25 O
reside NCT03867409 27 33 O
within NCT03867409 34 40 O
the NCT03867409 41 44 O
United NCT03867409 45 51 O
States NCT03867409 52 58 O
but NCT03867409 59 62 B-Exception
outside NCT03867409 63 70 I-Exception
of NCT03867409 71 73 O
Florida NCT03867409 74 81 O

- NCT03867409 84 85 O
speak NCT03867409 87 92 O
English NCT03867409 93 100 O

- NCT03867409 103 104 O
are NCT03867409 106 109 O
of NCT03867409 110 112 O
either NCT03867409 113 119 O
black NCT03867409 120 125 O
or NCT03867409 126 128 B-Or
white NCT03867409 129 134 O
racial NCT03867409 135 141 O
background NCT03867409 142 152 O
. NCT03867409 152 153 O

- NCT03867409 157 158 O
are NCT03867409 160 163 O
out NCT03867409 164 167 O
- NCT03867409 168 169 O
of NCT03867409 170 172 O
- NCT03867409 173 174 O
guidelines NCT03867409 175 185 O
for NCT03867409 186 189 O
colorectal NCT03867409 190 200 B-Procedure
cancer NCT03867409 201 207 I-Procedure
screening NCT03867409 208 217 I-Procedure
( NCT03867409 218 219 O
> NCT03867409 221 222 B-Eq-Comparison
10 NCT03867409 223 225 I-Eq-Comparison
years NCT03867409 226 231 I-Eq-Comparison
for NCT03867409 232 235 O
colonoscopy NCT03867409 236 247 B-Procedure
, NCT03867409 248 249 O
> NCT03867409 250 251 B-Eq-Comparison
3 NCT03867409 252 253 I-Eq-Comparison
years NCT03867409 254 259 I-Eq-Comparison
for NCT03867409 260 263 O
Cologuard NCT03867409 264 273 B-Procedure
, NCT03867409 274 275 O
> NCT03867409 276 277 B-Eq-Comparison
1 NCT03867409 278 279 I-Eq-Comparison
year NCT03867409 280 284 I-Eq-Comparison
for NCT03867409 285 288 O
fecal NCT03867409 289 294 B-Procedure
immunochemical NCT03867409 295 309 I-Procedure
test NCT03867409 310 314 I-Procedure
) NCT03867409 315 316 O

Exclusion NCT03867409 318 327 O
Criteria NCT03867409 328 336 O
: NCT03867409 337 338 O

- NCT03867409 342 343 O
does NCT03867409 345 349 O
not NCT03867409 350 353 O
meet NCT03867409 354 358 O
the NCT03867409 359 362 O
above NCT03867409 363 368 O
criteria NCT03867409 369 377 O

Inclusion NCT03869424 0 9 O
Criteria NCT03869424 10 18 O
: NCT03869424 19 20 O

- NCT03869424 24 25 O
healthy NCT03869424 27 34 B-Condition
volunteers NCT03869424 35 45 O

- NCT03869424 48 49 O
fluent NCT03869424 51 57 O
in NCT03869424 58 60 O
German NCT03869424 61 67 O
language NCT03869424 68 76 O

Exclusion NCT03869424 77 86 O
Criteria NCT03869424 87 95 O
: NCT03869424 96 97 O

- NCT03869424 101 102 O
mental NCT03869424 104 110 B-Condition
disorders NCT03869424 111 120 I-Condition

- NCT03869424 123 124 O
allergic NCT03869424 126 134 B-Allergy
to NCT03869424 135 137 O
capsaicin NCT03869424 138 147 B-Drug

- NCT03869424 150 151 O
allergic NCT03869424 153 161 B-Allergy
to NCT03869424 162 164 O
sesame NCT03869424 165 171 B-Drug
oil NCT03869424 172 175 I-Drug

- NCT03869424 178 179 O
intake NCT03869424 181 187 O
of NCT03869424 188 190 O
psychopharmacological NCT03869424 191 212 B-Drug
drugs NCT03869424 213 218 I-Drug
in NCT03869424 219 221 O
the NCT03869424 222 225 O
last NCT03869424 226 230 B-Eq-Comparison
four NCT03869424 231 235 I-Eq-Comparison
weeks NCT03869424 236 241 I-Eq-Comparison

- NCT03869424 244 245 O
intake NCT03869424 247 253 O
of NCT03869424 254 256 O
illegal NCT03869424 257 264 B-Modifier
drugs NCT03869424 265 270 B-Drug
in NCT03869424 271 273 O
the NCT03869424 274 277 O
last NCT03869424 278 282 B-Eq-Comparison
two NCT03869424 283 286 I-Eq-Comparison
weeks NCT03869424 287 292 I-Eq-Comparison

- NCT03869424 295 296 O
consumption NCT03869424 298 309 O
of NCT03869424 310 312 O
alcohol NCT03869424 313 320 B-Drug
in NCT03869424 321 323 O
the NCT03869424 324 327 O
last NCT03869424 328 332 B-Eq-Comparison
twelve NCT03869424 333 339 I-Eq-Comparison
hours NCT03869424 340 345 I-Eq-Comparison

- NCT03869424 348 349 O
students NCT03869424 351 359 O
in NCT03869424 360 362 O
medicine NCT03869424 363 371 O
, NCT03869424 372 373 O
pharmacy NCT03869424 374 382 O
, NCT03869424 383 384 O
or NCT03869424 385 387 O
psychology NCT03869424 388 398 O

- NCT03869424 401 402 O
completed NCT03869424 404 413 O
studies NCT03869424 414 421 O
in NCT03869424 422 424 O
medicine NCT03869424 425 433 O
, NCT03869424 434 435 O
pharmacy NCT03869424 436 444 O
or NCT03869424 445 447 O
psychology NCT03869424 448 458 O

- NCT03869424 461 462 O
current NCT03869424 464 471 B-Eq-Comparison
pregnancy NCT03869424 472 481 B-Condition
or NCT03869424 482 484 B-Or
lactation NCT03869424 485 494 B-Condition

- NCT03869424 497 498 O
cardio NCT03869424 500 506 B-Condition
vascular NCT03869424 507 515 I-Condition
disease NCT03869424 516 523 I-Condition

- NCT03869424 526 527 O
kidney NCT03869424 529 535 B-Condition
disease NCT03869424 536 543 I-Condition

- NCT03869424 546 547 O
liver NCT03869424 549 554 B-Condition
disease NCT03869424 555 562 I-Condition

Inclusion NCT03861078 0 9 O
Criteria NCT03861078 10 18 O
- NCT03861078 19 20 O
- NCT03861078 22 23 O
Participants NCT03861078 24 36 O
must NCT03861078 37 41 O
be NCT03861078 42 44 O
: NCT03861078 45 46 O

- NCT03861078 50 51 O
Healthy NCT03861078 53 60 B-Condition
( NCT03861078 61 62 O
determined NCT03861078 63 73 O
by NCT03861078 74 76 O
self NCT03861078 77 81 O
- NCT03861078 82 83 O
report NCT03861078 84 90 O
) NCT03861078 91 92 O

- NCT03861078 96 97 O
Between NCT03861078 99 106 O
the NCT03861078 107 110 O
ages NCT03861078 111 115 B-Age
of NCT03861078 116 118 O
18 NCT03861078 119 121 B-Eq-Comparison
- NCT03861078 122 123 I-Eq-Comparison
55 NCT03861078 124 126 I-Eq-Comparison
years NCT03861078 127 132 I-Eq-Comparison
old NCT03861078 133 136 O

- NCT03861078 139 140 O
Current NCT03861078 142 149 B-Eq-Comparison
cigarette NCT03861078 150 159 B-Condition
smokers NCT03861078 160 167 I-Condition

- NCT03861078 170 171 O
Wiling NCT03861078 173 179 O
to NCT03861078 180 182 O
provide NCT03861078 183 190 O
informed NCT03861078 191 199 O
consent NCT03861078 200 207 O

- NCT03861078 210 211 O
Able NCT03861078 213 217 O
to NCT03861078 218 220 O
attend NCT03861078 221 227 O
the NCT03861078 228 231 O
lab NCT03861078 232 235 O
session NCT03861078 236 243 O
and NCT03861078 244 247 O
abstain NCT03861078 248 255 O
from NCT03861078 256 260 O
tobacco NCT03861078 261 268 O
/ NCT03861078 269 270 O
nicotine NCT03861078 271 279 O
products NCT03861078 280 288 O
as NCT03861078 289 291 O
required NCT03861078 292 300 O

- NCT03861078 303 304 O
Agree NCT03861078 306 311 O
to NCT03861078 312 314 O
use NCT03861078 315 318 O
designated NCT03861078 319 329 O
products NCT03861078 330 338 O
according NCT03861078 339 348 O
to NCT03861078 349 351 O
the NCT03861078 352 355 O
study NCT03861078 356 361 O
protocol NCT03861078 362 370 O

Exclusion NCT03861078 371 380 O
Criteria NCT03861078 381 389 O
: NCT03861078 390 391 O

- NCT03861078 395 396 O
Women NCT03861078 398 403 O
if NCT03861078 404 406 O
they NCT03861078 407 411 O
are NCT03861078 412 415 O
breast NCT03861078 416 422 B-Condition
- NCT03861078 423 424 I-Condition
feeding NCT03861078 425 432 I-Condition
or NCT03861078 433 435 B-Or
test NCT03861078 436 440 B-Observation
positive NCT03861078 441 449 O
for NCT03861078 450 453 O
pregnancy NCT03861078 454 463 B-Condition
( NCT03861078 464 465 O
by NCT03861078 466 468 O
urinalysis NCT03861078 469 479 B-Observation
) NCT03861078 480 481 O
at NCT03861078 482 484 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03861078 485 494 B-Study
. NCT03861078 494 495 O

- NCT03861078 499 500 O
Individuals NCT03861078 502 513 O
who NCT03861078 514 517 O
weigh NCT03861078 518 523 B-Observation
less NCT03861078 524 528 B-Eq-Comparison
than NCT03861078 529 533 I-Eq-Comparison
110 NCT03861078 534 537 I-Eq-Comparison
pounds NCT03861078 538 544 I-Eq-Comparison
. NCT03861078 544 545 O

Some NCT03861078 547 551 O
study NCT03861078 552 557 O
details NCT03861078 558 565 O
about NCT03861078 566 571 O
the NCT03861078 572 575 O
eligibility NCT03861078 576 587 O
criteria NCT03861078 588 596 O
are NCT03861078 597 600 O
purposely NCT03861078 601 610 O
omitted NCT03861078 611 618 O
at NCT03861078 619 621 O
this NCT03861078 622 626 O
time NCT03861078 627 631 O
to NCT03861078 632 634 O
preserve NCT03861078 635 643 O
scientific NCT03861078 644 654 O
integrity NCT03861078 655 664 O
. NCT03861078 664 665 O
Full NCT03861078 667 671 O
details NCT03861078 672 679 O
will NCT03861078 680 684 O
be NCT03861078 685 687 O
posted NCT03861078 688 694 O
at NCT03861078 695 697 O
the NCT03861078 698 701 O
conclusion NCT03861078 702 712 O
of NCT03861078 713 715 O
the NCT03861078 716 719 O
study NCT03861078 720 725 O
. NCT03861078 725 726 O


Inclusion NCT03860428 0 9 O
Criteria NCT03860428 10 18 O
: NCT03860428 19 20 O

- NCT03860428 24 25 O
Gestational NCT03860428 27 38 B-Observation
age NCT03860428 39 42 I-Observation
< NCT03860428 43 44 B-Eq-Comparison
32 NCT03860428 45 47 I-Eq-Comparison
weeks NCT03860428 48 53 I-Eq-Comparison

- NCT03860428 56 57 O
Birthweight NCT03860428 59 70 B-Observation
< NCT03860428 71 72 B-Eq-Comparison
1500 NCT03860428 73 77 I-Eq-Comparison
g NCT03860428 78 79 I-Eq-Comparison

- NCT03860428 82 83 O
Age NCT03860428 85 88 B-Age
less NCT03860428 89 93 B-Eq-Comparison
than NCT03860428 94 98 I-Eq-Comparison
72 NCT03860428 99 101 I-Eq-Comparison
hours NCT03860428 102 107 I-Eq-Comparison

- NCT03860428 110 111 O
PDA NCT03860428 113 116 B-Condition
diameter NCT03860428 117 125 B-Observation
> NCT03860428 126 127 B-Eq-Comparison
1.5 NCT03860428 128 131 I-Eq-Comparison
mm NCT03860428 132 134 I-Eq-Comparison

- NCT03860428 137 138 O
Signed NCT03860428 140 146 O
informed NCT03860428 147 155 O
consent NCT03860428 156 163 O
obtained NCT03860428 164 172 O
from NCT03860428 173 177 O
both NCT03860428 178 182 O
parents NCT03860428 183 190 O

Exclusion NCT03860428 191 200 O
Criteria NCT03860428 201 209 O
: NCT03860428 210 211 O

- NCT03860428 215 216 O
Birthweight NCT03860428 218 229 B-Observation
≥ NCT03860428 230 231 B-Eq-Comparison
1500 NCT03860428 232 236 I-Eq-Comparison
g NCT03860428 237 238 I-Eq-Comparison
and NCT03860428 239 242 B-Or
/ NCT03860428 243 244 I-Or
or NCT03860428 245 247 I-Or
gestation NCT03860428 248 257 B-Observation
age NCT03860428 258 261 I-Observation
≥ NCT03860428 262 263 B-Eq-Comparison
32 NCT03860428 264 266 I-Eq-Comparison
weeks NCT03860428 267 272 I-Eq-Comparison

- NCT03860428 275 276 O
Lack NCT03860428 278 282 O
of NCT03860428 283 285 O
informed NCT03860428 286 294 O
consent NCT03860428 295 302 O
of NCT03860428 303 305 O
the NCT03860428 306 309 O
parents NCT03860428 310 317 O

- NCT03860428 320 321 O
Congenital NCT03860428 323 333 B-Condition
heart NCT03860428 334 339 I-Condition
defect NCT03860428 340 346 I-Condition
, NCT03860428 347 348 O
other NCT03860428 349 354 B-Exception
than NCT03860428 355 359 I-Exception
PDA NCT03860428 360 363 B-Condition
and NCT03860428 364 367 B-Or
/ NCT03860428 368 369 I-Or
or NCT03860428 370 372 I-Or
patent NCT03860428 373 379 B-Condition
foramen NCT03860428 380 387 I-Condition
ovale NCT03860428 388 393 I-Condition
( NCT03860428 394 395 O
PFO NCT03860428 396 399 B-Condition
) NCT03860428 400 401 O

- NCT03860428 405 406 O
The NCT03860428 408 411 O
presence NCT03860428 412 420 O
of NCT03860428 421 423 O
a NCT03860428 424 425 O
clinically NCT03860428 426 436 O
apparent NCT03860428 437 445 O
hemorrhagic NCT03860428 446 457 B-Condition
syndrome NCT03860428 458 466 I-Condition

- NCT03860428 469 470 O
Any NCT03860428 472 475 O
intraventricular NCT03860428 476 492 B-Condition
hemorrhage NCT03860428 493 503 I-Condition
( NCT03860428 504 505 O
IVH NCT03860428 506 509 B-Condition
) NCT03860428 510 511 O
in NCT03860428 512 514 B-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03860428 515 518 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
first NCT03860428 519 524 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
48 NCT03860428 525 527 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
hours NCT03860428 528 533 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
or NCT03860428 534 536 B-Or
IVH NCT03860428 537 540 B-Condition
grade NCT03860428 541 546 B-Eq-Comparison
3 NCT03860428 547 548 I-Eq-Comparison
- NCT03860428 549 550 I-Eq-Comparison
4 NCT03860428 551 552 I-Eq-Comparison

- NCT03860428 556 557 O
A NCT03860428 559 560 O
platelet NCT03860428 561 569 B-Observation
count NCT03860428 570 575 I-Observation
of NCT03860428 576 578 O
< NCT03860428 579 580 B-Eq-Comparison
50 NCT03860428 581 583 I-Eq-Comparison
, NCT03860428 584 585 O
000 NCT03860428 586 589 O
/ NCT03860428 590 591 O
mm3 NCT03860428 592 595 O

- NCT03860428 598 599 O
A NCT03860428 601 602 O
serum NCT03860428 603 608 B-Observation
creatinine NCT03860428 609 619 I-Observation
concentration NCT03860428 620 633 I-Observation
of NCT03860428 634 636 O
> NCT03860428 637 638 B-Eq-Comparison
110 NCT03860428 639 642 I-Eq-Comparison
μmol NCT03860428 643 647 I-Eq-Comparison
/ NCT03860428 648 649 I-Eq-Comparison|Eq-Comparison
L NCT03860428 650 651 I-Eq-Comparison

- NCT03860428 654 655 O
Oliguria NCT03860428 657 665 B-Condition|Observation
< NCT03860428 666 667 B-Eq-Comparison
1 NCT03860428 668 669 I-Eq-Comparison
ml NCT03860428 670 672 I-Eq-Comparison
/ NCT03860428 673 674 I-Assertion___Assertion-Type-Value:possible|Eq-Comparison
kg NCT03860428 675 677 I-Eq-Comparison
/ NCT03860428 678 679 O
h NCT03860428 680 681 I-Eq-Comparison

- NCT03860428 684 685 O
Suspected NCT03860428 687 696 B-Assertion___Assertion-Type-Value:possible|Assertion___Assertion-Type-Value:possible
/ NCT03860428 697 698 I-Assertion___Assertion-Type-Value:possible
apparent NCT03860428 699 707 I-Assertion___Assertion-Type-Value:possible|Assertion___Assertion-Type-Value:possible
NEC NCT03860428 708 711 B-Condition

- NCT03860428 714 715 O
Suspected NCT03860428 717 726 O
/ NCT03860428 727 728 O
apparent NCT03860428 729 737 O
lung NCT03860428 738 742 B-Condition
hypoplasia NCT03860428 743 753 I-Condition

Inclusion NCT03865550 0 9 O
Criteria NCT03865550 10 18 O
: NCT03865550 19 20 O

- NCT03865550 24 25 O
18 NCT03865550 27 29 B-Eq-Comparison
- NCT03865550 30 31 I-Eq-Comparison
85 NCT03865550 32 34 I-Eq-Comparison
years NCT03865550 35 40 I-Eq-Comparison
of NCT03865550 41 43 O
age NCT03865550 44 47 B-Age

- NCT03865550 50 51 O
ASA NCT03865550 53 56 B-Condition
I NCT03865550 57 58 B-Eq-Comparison
- NCT03865550 59 60 I-Eq-Comparison
IV NCT03865550 61 63 I-Eq-Comparison

- NCT03865550 66 67 O
Undergoing NCT03865550 69 79 B-Eq-Comparison
primary NCT03865550 80 87 B-Modifier
unilateral NCT03865550 88 98 I-Modifier
elective NCT03865550 99 107 I-Modifier
total NCT03865550 108 113 B-Procedure
knee NCT03865550 114 118 I-Procedure
arthroplasty NCT03865550 119 131 I-Procedure
with NCT03865550 132 136 O
spinal NCT03865550 137 143 B-Procedure
anesthesia NCT03865550 144 154 I-Procedure

Exclusion NCT03865550 155 164 O
Criteria NCT03865550 165 173 O
: NCT03865550 174 175 O

- NCT03865550 179 180 O
BMI NCT03865550 182 185 B-Observation
over NCT03865550 186 190 B-Eq-Comparison
40 NCT03865550 191 193 I-Eq-Comparison
* NCT03865550 194 195 O

- NCT03865550 198 199 O
Contraindication NCT03865550 201 217 B-Contraindication
or NCT03865550 218 220 B-Or
allergy NCT03865550 221 228 B-Allergy
to NCT03865550 229 231 O
opioid NCT03865550 232 238 B-Drug
pain NCT03865550 239 243 I-Drug
medication NCT03865550 244 254 I-Drug
or NCT03865550 255 257 B-Or
ketamine NCT03865550 258 266 B-Drug
* NCT03865550 266 267 O

- NCT03865550 270 271 O
Daily NCT03865550 273 278 B-Eq-Comparison
opioid NCT03865550 279 285 B-Drug
use NCT03865550 286 289 O
for NCT03865550 290 293 O
pain NCT03865550 294 298 B-Condition
control NCT03865550 299 306 O
before NCT03865550 307 313 B-Temporal-Connection
surgery NCT03865550 314 321 B-Procedure
in NCT03865550 322 324 B-Eq-Comparison
excess NCT03865550 325 331 I-Eq-Comparison
of NCT03865550 332 334 I-Eq-Comparison
systemic NCT03865550 335 343 I-Eq-Comparison
morphine NCT03865550 344 352 I-Eq-Comparison
equivalent NCT03865550 353 363 I-Eq-Comparison
to NCT03865550 364 366 I-Eq-Comparison
10 NCT03865550 367 369 I-Eq-Comparison
mg NCT03865550 370 372 I-Eq-Comparison
* NCT03865550 372 373 O

- NCT03865550 376 377 O
Ejection NCT03865550 379 387 B-Observation
fraction NCT03865550 388 396 I-Observation
( NCT03865550 397 398 O
EF NCT03865550 399 401 B-Observation
) NCT03865550 402 403 O
less NCT03865550 404 408 B-Eq-Comparison
than NCT03865550 409 413 I-Eq-Comparison
30 NCT03865550 414 416 I-Eq-Comparison
% NCT03865550 417 418 O

- NCT03865550 421 422 O
Creatinine NCT03865550 424 434 B-Observation
clearance NCT03865550 435 444 I-Observation
less NCT03865550 445 449 B-Eq-Comparison
than NCT03865550 450 454 I-Eq-Comparison
30 NCT03865550 455 457 I-Eq-Comparison
mL NCT03865550 458 460 I-Eq-Comparison
/ NCT03865550 461 462 I-Eq-Comparison
min NCT03865550 463 466 I-Eq-Comparison
* NCT03865550 466 467 O

- NCT03865550 470 471 O
History NCT03865550 473 480 B-Eq-Comparison
of NCT03865550 481 483 O
chronic NCT03865550 484 491 B-Modifier
liver NCT03865550 492 497 B-Condition
failure NCT03865550 498 505 I-Condition

- NCT03865550 508 509 O
Desire NCT03865550 511 517 B-Assertion___Assertion-Type-Value:intention
for NCT03865550 518 521 I-Assertion___Assertion-Type-Value:intention
nerve NCT03865550 522 527 B-Procedure
block NCT03865550 528 533 I-Procedure
or NCT03865550 534 536 B-Or
general NCT03865550 537 544 B-Procedure
anesthesia NCT03865550 545 555 I-Procedure

- NCT03865550 558 559 O
Any NCT03865550 561 564 O
neurologic NCT03865550 565 575 B-Modifier
or NCT03865550 576 578 B-Or
psychiatric NCT03865550 579 590 B-Modifier
disorder NCT03865550 591 599 B-Condition
( NCT03865550 600 601 O
including NCT03865550 602 611 O
bipolar NCT03865550 612 619 B-Condition
disorder NCT03865550 620 628 I-Condition
, NCT03865550 629 630 O
post NCT03865550 631 635 B-Condition
traumatic NCT03865550 636 645 I-Condition
stress NCT03865550 646 652 I-Condition
disorder NCT03865550 653 661 I-Condition
, NCT03865550 662 663 O
schizophrenia NCT03865550 664 677 B-Condition
) NCT03865550 678 679 O

- NCT03865550 683 684 O
Prior NCT03865550 686 691 B-Eq-Comparison
surgery NCT03865550 692 699 B-Procedure
on NCT03865550 700 702 O
ipsilateral NCT03865550 703 714 B-Modifier
knee NCT03865550 715 719 I-Modifier
within NCT03865550 720 726 B-Eq-Comparison
the NCT03865550 727 730 I-Eq-Comparison
last NCT03865550 731 735 I-Eq-Comparison
6 NCT03865550 736 737 I-Eq-Comparison
months NCT03865550 738 744 I-Eq-Comparison

- NCT03865550 747 748 O
Alcohol NCT03865550 750 757 B-Condition
abuse NCT03865550 758 763 I-Condition

Inclusion NCT03869801 0 9 O
Criteria NCT03869801 10 18 O
: NCT03869801 19 20 O

- NCT03869801 24 25 O
Elective NCT03869801 27 35 B-Modifier
laparoscopic NCT03869801 36 48 B-Procedure
Cholecystectomy NCT03869801 49 64 I-Procedure
, NCT03869801 65 66 O
ASA NCT03869801 67 70 B-Condition
status NCT03869801 71 77 O
1 NCT03869801 78 79 B-Eq-Comparison
- NCT03869801 80 81 I-Eq-Comparison
2 NCT03869801 82 83 O

Exclusion NCT03869801 85 94 O
Criteria NCT03869801 95 103 O
: NCT03869801 104 105 O

- NCT03869801 109 110 O
Patient NCT03869801 112 119 O
refusal NCT03869801 120 127 O
Contraindications NCT03869801 128 145 B-Contraindication
to NCT03869801 146 148 O
regional NCT03869801 149 157 B-Procedure
anesthesia NCT03869801 158 168 I-Procedure
Known NCT03869801 169 174 O
allergy NCT03869801 175 182 B-Allergy
to NCT03869801 183 185 O
local NCT03869801 186 191 B-Drug
anesthetics NCT03869801 192 203 I-Drug
Bleeding NCT03869801 204 212 B-Condition
diathesis NCT03869801 213 222 B-Condition
Use NCT03869801 223 226 O
of NCT03869801 227 229 O
any NCT03869801 230 233 O
anti NCT03869801 234 238 B-Drug
- NCT03869801 239 240 I-Drug
coagulants NCT03869801 241 251 I-Drug
Inability NCT03869801 252 261 O
to NCT03869801 262 264 O
provide NCT03869801 265 272 O
informed NCT03869801 273 281 O
consent NCT03869801 282 289 O
Severe NCT03869801 290 296 O
kidney NCT03869801 297 303 B-Modifier
or NCT03869801 304 306 B-Or
liver NCT03869801 307 312 B-Modifier
disease NCT03869801 313 320 B-Condition
Inability NCT03869801 321 330 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869801 331 333 O
operate NCT03869801 334 341 B-Procedure
PCA NCT03869801 342 345 I-Procedure
system NCT03869801 346 352 O
Patient NCT03869801 353 360 O
with NCT03869801 361 365 O
psychiatric NCT03869801 366 377 B-Condition
disorders NCT03869801 378 387 I-Condition

Inclusion NCT03867838 0 9 O
Criteria NCT03867838 10 18 O
: NCT03867838 19 20 O

- NCT03867838 24 25 O
greater NCT03867838 27 34 B-Eq-Comparison
than NCT03867838 35 39 I-Eq-Comparison
6 NCT03867838 40 41 I-Eq-Comparison
months NCT03867838 42 48 I-Eq-Comparison
post NCT03867838 49 53 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03867838 54 55 O
stroke NCT03867838 56 62 B-Condition

- NCT03867838 65 66 O
passive NCT03867838 68 75 B-Condition|Observation
abduction NCT03867838 76 85 I-Condition|Observation
to NCT03867838 86 88 O
90 NCT03867838 89 91 B-Eq-Comparison
degrees NCT03867838 92 99 I-Eq-Comparison
at NCT03867838 100 102 O
shoulder NCT03867838 103 111 B-Modifier

- NCT03867838 114 115 O
reduced NCT03867838 117 124 O
active NCT03867838 125 131 B-Eq-Comparison
( NCT03867838 132 133 O
retro NCT03867838 134 139 B-Modifier
) NCT03867838 140 141 O
flexion NCT03867838 142 149 B-Condition
/ NCT03867838 150 151 B-Or
extension NCT03867838 152 161 B-Condition
at NCT03867838 162 164 O
shoulder NCT03867838 165 173 B-Modifier
when NCT03867838 174 178 O
abducted NCT03867838 179 187 B-Observation
to NCT03867838 188 190 O
90 NCT03867838 191 193 B-Eq-Comparison
degrees NCT03867838 194 201 I-Eq-Comparison

- NCT03867838 204 205 O
reduced NCT03867838 207 214 O
active NCT03867838 215 221 B-Eq-Comparison
flexion NCT03867838 222 229 B-Condition
/ NCT03867838 230 231 B-Or
extension NCT03867838 232 241 B-Condition
at NCT03867838 242 244 O
elbow NCT03867838 245 250 B-Modifier

Exclusion NCT03867838 251 260 O
Criteria NCT03867838 261 269 O
: NCT03867838 270 271 O

- NCT03867838 275 276 O
unable NCT03867838 278 284 O
to NCT03867838 285 287 O
give NCT03867838 288 292 O
informed NCT03867838 293 301 O
consent NCT03867838 302 309 O

- NCT03867838 312 313 O
unable NCT03867838 315 321 O
to NCT03867838 322 324 O
comprehend NCT03867838 325 335 O
and NCT03867838 336 339 O
follow NCT03867838 340 346 O
instructions NCT03867838 347 359 O

- NCT03867838 362 363 O
have NCT03867838 365 369 O
a NCT03867838 370 371 O
condition NCT03867838 372 381 B-Condition
( NCT03867838 382 383 O
other NCT03867838 384 389 B-Exception
than NCT03867838 390 394 I-Exception
stroke NCT03867838 395 401 B-Condition
) NCT03867838 402 403 O
affecting NCT03867838 404 413 O
sensorimotor NCT03867838 414 426 B-Condition
function NCT03867838 427 435 I-Condition

- NCT03867838 438 439 O
show NCT03867838 441 445 O
evidence NCT03867838 446 454 O
of NCT03867838 455 457 O
unilateral NCT03867838 458 468 B-Modifier
spatial NCT03867838 469 476 B-Condition
neglect NCT03867838 477 484 I-Condition

- NCT03867838 487 488 O
unable NCT03867838 490 496 B-Negation
to NCT03867838 497 499 O
sit NCT03867838 500 503 B-Condition
in NCT03867838 504 506 B-Modifier
a NCT03867838 507 508 I-Modifier
chair NCT03867838 509 514 I-Modifier
without NCT03867838 515 522 B-Negation
armrests NCT03867838 523 531 B-Modifier
for NCT03867838 532 535 O
2 NCT03867838 536 537 B-Eq-Comparison
hours NCT03867838 538 543 I-Eq-Comparison

Inclusion NCT03864302 0 9 O
Criteria NCT03864302 10 18 O
: NCT03864302 19 20 O

- NCT03864302 24 25 O
Doctors NCT03864302 27 34 B-Provider

- NCT03864302 37 38 O
Informed NCT03864302 40 48 O
written NCT03864302 49 56 O
consent NCT03864302 57 64 O
. NCT03864302 64 65 O

- NCT03864302 69 70 O
Four NCT03864302 72 76 B-Eq-Comparison
video NCT03864302 77 82 O
- NCT03864302 83 84 O
recordings NCT03864302 85 95 O
of NCT03864302 96 98 O
TURBs NCT03864302 99 104 B-Procedure
. NCT03864302 104 105 O

Exclusion NCT03864302 107 116 O
Criteria NCT03864302 117 125 O
: NCT03864302 126 127 O

- NCT03864302 131 132 O
Not NCT03864302 134 137 B-Negation
providing NCT03864302 138 147 O
four NCT03864302 148 152 B-Eq-Comparison
video NCT03864302 153 158 O
recordings NCT03864302 159 169 O
of NCT03864302 170 172 O
TURB NCT03864302 173 177 B-Procedure
procedures NCT03864302 178 188 I-Procedure

- NCT03864302 191 192 O
Simulation NCT03864302 194 204 B-Procedure
- NCT03864302 205 206 I-Procedure
based NCT03864302 207 212 I-Procedure
training NCT03864302 213 221 I-Procedure
course NCT03864302 222 228 O
in NCT03864302 229 231 O
TURB NCT03864302 232 236 B-Procedure
within NCT03864302 237 243 B-Eq-Comparison
6 NCT03864302 244 245 I-Eq-Comparison
months NCT03864302 246 252 I-Eq-Comparison

- NCT03864302 255 256 O
No NCT03864302 258 260 O
consent NCT03864302 261 268 O

Inclusion NCT03862001 0 9 O
Criteria NCT03862001 10 18 O
: NCT03862001 19 20 O

- NCT03862001 24 25 O
age NCT03862001 27 30 B-Age
55 NCT03862001 31 33 B-Eq-Comparison
- NCT03862001 34 35 I-Eq-Comparison
80 NCT03862001 36 38 O

- NCT03862001 42 43 O
smoked NCT03862001 45 51 B-Condition|Observation
at NCT03862001 52 54 B-Eq-Comparison
least NCT03862001 55 60 I-Eq-Comparison
30 NCT03862001 61 63 I-Eq-Comparison
pack NCT03862001 64 68 I-Eq-Comparison
- NCT03862001 69 70 I-Eq-Comparison
years NCT03862001 71 76 I-Eq-Comparison
in NCT03862001 77 79 I-Eq-Comparison
lifetime NCT03862001 80 88 I-Eq-Comparison

- NCT03862001 91 92 O
if NCT03862001 94 96 O
former NCT03862001 97 103 B-Eq-Comparison
smoker NCT03862001 104 110 B-Condition
, NCT03862001 111 112 O
quit NCT03862001 113 117 B-Negation
smoking NCT03862001 118 125 B-Condition
within NCT03862001 126 132 B-Eq-Comparison
the NCT03862001 133 136 I-Eq-Comparison
last NCT03862001 137 141 I-Eq-Comparison
15 NCT03862001 142 144 I-Eq-Comparison
years NCT03862001 145 150 I-Eq-Comparison

- NCT03862001 153 154 O
English NCT03862001 156 163 O
speaker NCT03862001 164 171 O

- NCT03862001 174 175 O
no NCT03862001 177 179 B-Negation
prior NCT03862001 180 185 B-Eq-Comparison
history NCT03862001 186 193 I-Eq-Comparison
of NCT03862001 194 196 O
lung NCT03862001 197 201 B-Modifier
cancer NCT03862001 202 208 B-Condition

- NCT03862001 211 212 O
did NCT03862001 214 217 O
not NCT03862001 218 221 B-Negation
have NCT03862001 222 226 O
a NCT03862001 227 228 O
lung NCT03862001 229 233 B-Modifier
cancer NCT03862001 234 240 B-Condition
screening NCT03862001 241 250 B-Procedure
test NCT03862001 251 255 I-Procedure
within NCT03862001 256 262 B-Eq-Comparison
the NCT03862001 263 266 I-Eq-Comparison
last NCT03862001 267 271 I-Eq-Comparison
year NCT03862001 272 276 I-Eq-Comparison

- NCT03862001 279 280 O
PCP NCT03862001 282 285 O
does NCT03862001 286 290 O
not NCT03862001 291 294 O
object NCT03862001 295 301 O
to NCT03862001 302 304 O
patient NCT03862001 305 312 O
's NCT03862001 312 314 O
participation NCT03862001 315 328 O

- NCT03862001 331 332 O
have NCT03862001 334 338 O
a NCT03862001 339 340 O
scheduled NCT03862001 341 350 B-Eq-Comparison
visit NCT03862001 351 356 B-Encounter
at NCT03862001 357 359 O
University NCT03862001 360 370 O
of NCT03862001 371 373 O
California NCT03862001 374 384 O
, NCT03862001 385 386 O
San NCT03862001 387 390 O
Francisco NCT03862001 391 400 O
( NCT03862001 401 402 O
UCSF NCT03862001 403 407 O
) NCT03862001 408 409 O
internal NCT03862001 410 418 O
medicine NCT03862001 419 427 O
clinics NCT03862001 428 435 O
. NCT03862001 435 436 O

Exclusion NCT03862001 438 447 O
Criteria NCT03862001 448 456 O
: NCT03862001 457 458 O

- NCT03862001 462 463 O
speaking NCT03862001 465 473 O
a NCT03862001 474 475 O
language NCT03862001 476 484 O
other NCT03862001 485 490 B-Negation
than NCT03862001 491 495 I-Negation
English NCT03862001 496 503 O

- NCT03862001 506 507 O
has NCT03862001 509 512 O
a NCT03862001 513 514 O
history NCT03862001 515 522 B-Eq-Comparison
of NCT03862001 523 525 O
lung NCT03862001 526 530 B-Modifier
cancer NCT03862001 531 537 B-Condition

- NCT03862001 540 541 O
had NCT03862001 543 546 B-Eq-Comparison
a NCT03862001 547 548 O
lung NCT03862001 549 553 B-Modifier
cancer NCT03862001 554 560 B-Condition
screening NCT03862001 561 570 B-Procedure
test NCT03862001 571 575 I-Procedure
within NCT03862001 576 582 B-Eq-Comparison
the NCT03862001 583 586 I-Eq-Comparison
last NCT03862001 587 591 I-Eq-Comparison
year NCT03862001 592 596 I-Eq-Comparison

- NCT03862001 599 600 O
PCP NCT03862001 602 605 O
objects NCT03862001 606 613 O
to NCT03862001 614 616 O
patient NCT03862001 617 624 O
's NCT03862001 624 626 O
participation NCT03862001 627 640 O
. NCT03862001 640 641 O

Inclusion NCT03861520 0 9 O
Criteria NCT03861520 10 18 O
: NCT03861520 19 20 O

1 NCT03861520 24 25 O
. NCT03861520 25 26 O
pregnant NCT03861520 28 36 B-Condition
woman NCT03861520 37 42 O
between NCT03861520 43 50 B-Eq-Comparison
( NCT03861520 51 52 I-Eq-Comparison
16 NCT03861520 53 55 O
- NCT03861520 56 57 I-Eq-Comparison
24 NCT03861520 58 60 I-Eq-Comparison
) NCT03861520 61 62 O
weeks NCT03861520 63 68 I-Eq-Comparison
of NCT03861520 69 71 O
gestation NCT03861520 72 81 B-Observation
. NCT03861520 81 82 O

2 NCT03861520 86 87 O
. NCT03861520 87 88 O
singelton NCT03861520 90 99 B-Modifier
pregnancy NCT03861520 100 109 B-Condition
. NCT03861520 109 110 O

Exclusion NCT03861520 112 121 O
Criteria NCT03861520 122 130 O
: NCT03861520 131 132 O

1 NCT03861520 136 137 O
. NCT03861520 137 138 O
Multiple NCT03861520 140 148 B-Eq-Comparison
pregnancies NCT03861520 149 160 B-Condition
. NCT03861520 160 161 O

2 NCT03861520 165 166 O
. NCT03861520 166 167 O
Mental NCT03861520 169 175 B-Condition
condition NCT03861520 176 185 I-Condition
rendering NCT03861520 186 195 O
the NCT03861520 196 199 O
patients NCT03861520 200 208 O
unable NCT03861520 209 215 B-Condition
to NCT03861520 216 218 I-Condition
understand NCT03861520 219 229 I-Condition
the NCT03861520 230 233 O
nature NCT03861520 234 240 O
and NCT03861520 241 244 O
scope NCT03861520 245 250 O
of NCT03861520 251 253 O
the NCT03861520 254 257 O
study NCT03861520 258 263 B-Study
. NCT03861520 263 264 O

Inclusion NCT03864289 0 9 O
Criteria NCT03864289 10 18 O
: NCT03864289 19 20 O

- NCT03864289 24 25 O
Children NCT03864289 27 35 O
with NCT03864289 36 40 B-And
ASD NCT03864289 41 44 B-Condition
or NCT03864289 45 47 B-Or
high NCT03864289 48 52 O
risk NCT03864289 53 57 B-Risk
for NCT03864289 58 61 O
autism NCT03864289 62 68 B-Condition
; NCT03864289 68 69 O

- NCT03864289 72 73 O
Han NCT03864289 75 78 O
ethic NCT03864289 79 84 O
; NCT03864289 84 85 O

- NCT03864289 88 89 O
Parents NCT03864289 91 98 B-Family-Member___Family-Member-Type:parent
were NCT03864289 99 103 O
at NCT03864289 104 106 B-Eq-Comparison
least NCT03864289 107 112 I-Eq-Comparison
middle NCT03864289 113 119 B-Observation
school NCT03864289 120 126 I-Observation
educated NCT03864289 127 135 I-Observation
, NCT03864289 136 137 O
and NCT03864289 138 141 B-And
agreed NCT03864289 142 148 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864289 149 151 I-Assertion___Assertion-Type-Value:hypothetical
do NCT03864289 152 154 O
at NCT03864289 155 157 B-Eq-Comparison
least NCT03864289 158 163 I-Eq-Comparison
20 NCT03864289 164 166 I-Eq-Comparison
hours NCT03864289 167 172 I-Eq-Comparison
per NCT03864289 173 176 I-Eq-Comparison
week NCT03864289 177 181 I-Eq-Comparison
of NCT03864289 182 184 O
planned NCT03864289 185 192 B-Eq-Comparison
practice NCT03864289 193 201 B-Observation
activities NCT03864289 202 212 I-Observation
with NCT03864289 213 217 O
the NCT03864289 218 221 O
child NCT03864289 222 227 O
in NCT03864289 228 230 O
daily NCT03864289 231 236 O
life NCT03864289 237 241 O
. NCT03864289 241 242 O

Exclusion NCT03864289 244 253 O
Criteria NCT03864289 254 262 O
: NCT03864289 263 264 O

- NCT03864289 268 269 O
Children NCT03864289 271 279 O
with NCT03864289 280 284 B-And
Syndromic NCT03864289 285 294 B-Modifier
ASD NCT03864289 295 298 B-Condition
caused NCT03864289 299 305 O
by NCT03864289 306 308 O
known NCT03864289 309 314 O
genetic NCT03864289 315 322 B-Condition
defects NCT03864289 323 330 I-Condition
or NCT03864289 331 333 B-Or
inherited NCT03864289 334 343 B-Modifier
metabolic NCT03864289 344 353 B-Condition
diseases NCT03864289 354 362 I-Condition
, NCT03864289 363 364 O
such NCT03864289 365 369 O
as NCT03864289 370 372 O
Rett NCT03864289 373 377 B-Condition
Syndrome NCT03864289 378 386 I-Condition
, NCT03864289 387 388 O
Fragile NCT03864289 389 396 B-Condition
X NCT03864289 397 398 I-Condition
Syndrome NCT03864289 399 407 I-Condition
, NCT03864289 408 409 O
Angelman NCT03864289 410 418 B-Condition
Syndrome NCT03864289 419 427 I-Condition
, NCT03864289 428 429 O
Prader NCT03864289 430 436 B-Condition
- NCT03864289 437 438 I-Condition
Willi NCT03864289 439 444 I-Condition
Syndrome NCT03864289 445 453 I-Condition
, NCT03864289 454 455 O
tuberous NCT03864289 456 464 B-Condition
sclerosis NCT03864289 465 474 I-Condition
; NCT03864289 474 475 O

- NCT03864289 478 479 O
Visual NCT03864289 481 487 B-Modifier
, NCT03864289 488 489 O
auditory NCT03864289 490 498 B-Modifier
and NCT03864289 499 502 B-Or
physical NCT03864289 503 511 B-Modifier
disabilities NCT03864289 512 524 B-Condition
; NCT03864289 524 525 O

- NCT03864289 528 529 O
Complication NCT03864289 531 543 O
with NCT03864289 544 548 O
other NCT03864289 549 554 B-Other
serious NCT03864289 555 562 O
chronic NCT03864289 563 570 B-Condition
diseases NCT03864289 571 579 I-Condition
, NCT03864289 580 581 O
such NCT03864289 582 586 O
as NCT03864289 587 589 O
liver NCT03864289 590 595 B-Modifier
and NCT03864289 596 599 B-Or
kidney NCT03864289 600 606 B-Modifier
failure NCT03864289 607 614 B-Condition
, NCT03864289 615 616 O
connective NCT03864289 617 627 B-Condition
tissue NCT03864289 628 634 I-Condition
diseases NCT03864289 635 643 I-Condition
, NCT03864289 644 645 O
tumors NCT03864289 646 652 B-Condition
. NCT03864289 652 653 O

Inclusion NCT03862820 0 9 O
Criteria NCT03862820 10 18 O
: NCT03862820 19 20 O

Pregnant NCT03862820 22 30 B-Condition
women NCT03862820 31 36 O
in NCT03862820 37 39 O
third NCT03862820 40 45 B-Condition
trimester NCT03862820 46 55 I-Condition
planned NCT03862820 56 63 B-Eq-Comparison
to NCT03862820 64 66 O
undergo NCT03862820 67 74 O
elective NCT03862820 75 83 B-Procedure
cesarean NCT03862820 84 92 I-Procedure
section NCT03862820 93 100 I-Procedure

Exclusion NCT03862820 101 110 O
Criteria NCT03862820 111 119 O
: NCT03862820 120 121 O

Primary NCT03862820 123 130 B-Modifier
elective NCT03862820 131 139 I-Modifier
cesarean NCT03862820 140 148 B-Procedure
section NCT03862820 149 156 I-Procedure
. NCT03862820 156 157 O

Inclusion NCT03864276 0 9 O
Criteria NCT03864276 10 18 O
: NCT03864276 19 20 O

- NCT03864276 24 25 O
patients NCT03864276 27 35 O
with NCT03864276 36 40 O
liver NCT03864276 41 46 B-Condition
cirrhosis NCT03864276 47 56 I-Condition
who NCT03864276 57 60 B-And
will NCT03864276 61 65 O
undergo NCT03864276 66 73 O
planned NCT03864276 74 81 B-Eq-Comparison
liver NCT03864276 82 87 B-Procedure
transplantation NCT03864276 88 103 I-Procedure

Exclusion NCT03864276 104 113 O
Criteria NCT03864276 114 122 O
: NCT03864276 123 124 O

- NCT03864276 128 129 O
1 NCT03864276 131 132 O
. NCT03864276 132 133 O
emergent NCT03864276 135 143 B-Modifier
liver NCT03864276 144 149 B-Procedure
transplantation NCT03864276 150 165 I-Procedure

- NCT03864276 168 169 O
2 NCT03864276 171 172 O
. NCT03864276 172 173 O
unstable NCT03864276 175 183 O
angina NCT03864276 184 190 B-Condition

- NCT03864276 193 194 O
3 NCT03864276 196 197 O
. NCT03864276 197 198 O
recent NCT03864276 200 206 B-Eq-Comparison
MI NCT03864276 207 209 B-Condition
( NCT03864276 210 211 O
Myocardial NCT03864276 212 222 B-Condition
Infarction NCT03864276 223 233 I-Condition
) NCT03864276 234 235 O

- NCT03864276 239 240 O
4 NCT03864276 242 243 O
. NCT03864276 243 244 O
uncontrolled NCT03864276 246 258 B-Modifier
hypertension NCT03864276 259 271 B-Condition
( NCT03864276 272 273 O
diastolic NCT03864276 274 283 B-Observation
BP NCT03864276 284 286 I-Observation
> NCT03864276 287 288 B-Eq-Comparison
110 NCT03864276 289 292 I-Eq-Comparison
mmHg NCT03864276 293 297 O
) NCT03864276 298 299 O

- NCT03864276 303 304 O
5 NCT03864276 306 307 O
. NCT03864276 307 308 O
implantable NCT03864276 310 321 B-Procedure
cardiac NCT03864276 322 329 I-Procedure
defibrillator NCT03864276 330 343 I-Procedure

- NCT03864276 346 347 O
6 NCT03864276 349 350 O
. NCT03864276 350 351 O
severe NCT03864276 353 359 O
obesity NCT03864276 360 367 B-Condition
( NCT03864276 368 369 O
BMI NCT03864276 370 373 B-Observation
> NCT03864276 374 375 B-Eq-Comparison
30 NCT03864276 376 378 I-Eq-Comparison
kg NCT03864276 379 381 O
/ NCT03864276 382 383 O
m2 NCT03864276 384 386 O
) NCT03864276 387 388 O

- NCT03864276 392 393 O
7 NCT03864276 395 396 O
. NCT03864276 396 397 O
allergy NCT03864276 399 406 B-Allergy
to NCT03864276 407 409 O
propofol NCT03864276 410 418 B-Drug

Inclusion NCT03864510 0 9 O
Criteria NCT03864510 10 18 O
: NCT03864510 19 20 O

- NCT03864510 24 25 O
Diabetes NCT03864510 27 35 B-Condition
type NCT03864510 36 40 B-Modifier
2 NCT03864510 41 42 I-Modifier

- NCT03864510 46 47 O
Age NCT03864510 49 52 B-Age
35 NCT03864510 53 55 B-Eq-Comparison
- NCT03864510 56 57 I-Eq-Comparison
75 NCT03864510 58 60 I-Eq-Comparison
year NCT03864510 61 65 I-Eq-Comparison

Exclusion NCT03864510 66 75 O
Criteria NCT03864510 76 84 O
: NCT03864510 85 86 O

- NCT03864510 90 91 O
Contraindication NCT03864510 93 109 B-Contraindication
to NCT03864510 110 112 O
MR NCT03864510 113 115 B-Procedure

- NCT03864510 118 119 O
Alcohol NCT03864510 121 128 B-Condition
dependance NCT03864510 129 139 I-Condition

- NCT03864510 142 143 O
Previously NCT03864510 145 155 B-Eq-Comparison
diagnosed NCT03864510 156 165 O
liver NCT03864510 166 171 B-Condition
cirrhosis NCT03864510 172 181 I-Condition

- NCT03864510 184 185 O
Previously NCT03864510 187 197 B-Eq-Comparison
known NCT03864510 198 203 O
liver NCT03864510 204 209 B-Condition
disease NCT03864510 210 217 I-Condition
( NCT03864510 218 219 O
other NCT03864510 220 225 B-Exception
than NCT03864510 226 230 I-Exception
fatty NCT03864510 231 236 B-Condition
liver NCT03864510 237 242 I-Condition
) NCT03864510 243 244 O

Inclusion NCT03861468 0 9 O
Criteria NCT03861468 10 18 O
: NCT03861468 19 20 O

- NCT03861468 24 25 O
Patients NCT03861468 27 35 O
aged NCT03861468 36 40 B-Age
from NCT03861468 41 45 O
18 NCT03861468 46 48 B-Eq-Comparison
to NCT03861468 49 51 I-Eq-Comparison
80 NCT03861468 52 54 I-Eq-Comparison
years NCT03861468 55 60 I-Eq-Comparison

- NCT03861468 63 64 O
Obese NCT03861468 66 71 B-Condition
( NCT03861468 72 73 O
BMI NCT03861468 74 77 B-Observation
≥ NCT03861468 78 79 B-Eq-Comparison
30 NCT03861468 80 82 I-Eq-Comparison
kg NCT03861468 83 85 O
/ NCT03861468 86 87 O
m² NCT03861468 88 90 O
) NCT03861468 91 92 O

- NCT03861468 96 97 O
Referred NCT03861468 99 107 B-Encounter
by NCT03861468 108 110 O
GPs NCT03861468 111 114 B-Provider
to NCT03861468 115 117 O
the NCT03861468 118 121 O
medical NCT03861468 122 129 O
analysis NCT03861468 130 138 O
laboratory NCT03861468 139 149 O
for NCT03861468 150 153 O
usual NCT03861468 154 159 O
biological NCT03861468 160 170 B-Observation
assessment NCT03861468 171 181 I-Observation

- NCT03861468 184 185 O
Patients NCT03861468 187 195 O
with NCT03861468 196 200 O
no NCT03861468 201 203 B-Negation
respiratory NCT03861468 204 215 B-Condition
follow NCT03861468 216 222 B-Encounter
- NCT03861468 223 224 I-Encounter
up NCT03861468 225 227 I-Encounter
already NCT03861468 228 235 B-Eq-Comparison
in NCT03861468 236 238 O
place NCT03861468 239 244 O

- NCT03861468 247 248 O
Bicarbonate NCT03861468 250 261 B-Observation
- NCT03861468 262 263 I-Observation
Concentration NCT03861468 264 277 I-Observation
≥ NCT03861468 278 279 B-Eq-Comparison
27 NCT03861468 280 282 I-Eq-Comparison
mmol NCT03861468 283 287 I-Eq-Comparison
/ NCT03861468 288 289 I-Eq-Comparison
L NCT03861468 290 291 I-Eq-Comparison

- NCT03861468 294 295 I-Observation
STOP NCT03861468 297 301 B-Observation
- NCT03861468 302 303 O
BANG NCT03861468 304 308 I-Observation
score NCT03861468 309 314 O
≥ NCT03861468 315 316 B-Eq-Comparison
3 NCT03861468 317 318 I-Eq-Comparison

Exclusion NCT03861468 320 329 O
Criteria NCT03861468 330 338 O
: NCT03861468 339 340 O

- NCT03861468 344 345 O
Acute NCT03861468 347 352 O
disease NCT03861468 353 360 B-Condition
or NCT03861468 361 363 B-Or
recently NCT03861468 364 372 B-Eq-Comparison
diagnosed NCT03861468 373 382 O
chronic NCT03861468 383 390 B-Modifier
disease NCT03861468 391 398 B-Condition
( NCT03861468 399 400 O
< NCT03861468 402 403 B-Eq-Comparison
2 NCT03861468 404 405 I-Eq-Comparison
months NCT03861468 406 412 I-Eq-Comparison
) NCT03861468 413 414 O

- NCT03861468 418 419 O
Hospitalization NCT03861468 421 436 B-Encounter
for NCT03861468 437 440 O
respiratory NCT03861468 441 452 B-Modifier
, NCT03861468 453 454 O
metabolic NCT03861468 455 464 B-Modifier
or NCT03861468 465 467 B-Or
cardiovascular NCT03861468 468 482 B-Modifier
event NCT03861468 483 488 B-Condition
( NCT03861468 489 490 O
< NCT03861468 492 493 B-Eq-Comparison
2 NCT03861468 494 495 I-Eq-Comparison
months NCT03861468 496 502 I-Eq-Comparison
) NCT03861468 503 504 O

- NCT03861468 508 509 O
Renal NCT03861468 511 516 B-Condition
insufficiency NCT03861468 517 530 I-Condition
stage NCT03861468 531 536 B-Eq-Comparison
4 NCT03861468 537 538 I-Eq-Comparison
or NCT03861468 539 541 I-Eq-Comparison|Or
5 NCT03861468 542 543 I-Eq-Comparison
, NCT03861468 544 545 O
or NCT03861468 546 548 B-Or
autoimmune NCT03861468 549 559 B-Condition
disease NCT03861468 560 567 I-Condition
, NCT03861468 568 569 O
or NCT03861468 570 572 B-Or
viral NCT03861468 573 578 B-Condition
hepatitis NCT03861468 579 588 I-Condition
, NCT03861468 589 590 O
or NCT03861468 591 593 O
cirrhosis NCT03861468 594 603 B-Condition

- NCT03861468 606 607 O
Pregnant NCT03861468 609 617 B-Condition
women NCT03861468 618 623 O

- NCT03861468 626 627 O
Patients NCT03861468 629 637 O
already NCT03861468 638 645 O
included NCT03861468 646 654 O
in NCT03861468 655 657 B-Study
an NCT03861468 658 660 O
interventional NCT03861468 661 675 O
study NCT03861468 676 681 B-Study|Study
( NCT03861468 682 683 O
end NCT03861468 684 687 O
of NCT03861468 688 690 O
the NCT03861468 691 694 O
study NCT03861468 695 700 O
< NCT03861468 701 702 B-Eq-Comparison
1 NCT03861468 703 704 I-Eq-Comparison
month NCT03861468 705 710 I-Eq-Comparison
) NCT03861468 711 712 O

Inclusion NCT03867019 0 9 O
Criteria NCT03867019 10 18 O
: NCT03867019 19 20 O

Subjects NCT03867019 22 30 O
with NCT03867019 31 35 O
BPPV NCT03867019 36 40 B-Condition
- NCT03867019 41 42 O
Patients NCT03867019 43 51 O
diagnosed NCT03867019 52 61 O
with NCT03867019 62 66 O
BPPV NCT03867019 67 71 B-Condition
, NCT03867019 72 73 O
who NCT03867019 74 77 O
meet NCT03867019 78 82 O
the NCT03867019 83 86 B-Criteria-Count
following NCT03867019 87 96 I-Criteria-Count
criteria NCT03867019 97 105 I-Criteria-Count
: NCT03867019 106 107 O

1 NCT03867019 111 112 O
. NCT03867019 112 113 O
Main NCT03867019 115 119 O
complain NCT03867019 120 128 O
of NCT03867019 129 131 O
spinning NCT03867019 132 140 B-Condition
sensation NCT03867019 141 150 I-Condition
( NCT03867019 151 152 O
Vertigo NCT03867019 153 160 B-Condition
) NCT03867019 161 162 O
when NCT03867019 163 167 O
changes NCT03867019 168 175 O
are NCT03867019 176 179 O
made NCT03867019 180 184 O
in NCT03867019 185 187 O
head NCT03867019 188 192 O
position NCT03867019 193 201 O
relative NCT03867019 202 210 O
to NCT03867019 211 213 O
gravity NCT03867019 214 221 O
( NCT03867019 222 223 O
such NCT03867019 224 228 O
as NCT03867019 229 231 O
when NCT03867019 232 236 O
moving NCT03867019 237 243 O
from NCT03867019 244 248 O
sitting NCT03867019 249 256 O
to NCT03867019 257 259 O
lying NCT03867019 260 265 O
down NCT03867019 266 270 O
or NCT03867019 271 273 O
rolling NCT03867019 274 281 O
in NCT03867019 282 284 O
bed NCT03867019 285 288 O
, NCT03867019 289 290 O
bending NCT03867019 291 298 O
over NCT03867019 299 303 O
etc NCT03867019 304 307 O
. NCT03867019 307 308 O
) NCT03867019 309 310 O

2 NCT03867019 314 315 O
. NCT03867019 315 316 O
Positive NCT03867019 318 326 O
Dix NCT03867019 327 330 B-Observation
- NCT03867019 331 332 I-Observation
Hallpike NCT03867019 333 341 I-Observation
/ NCT03867019 342 343 I-Observation
Supine NCT03867019 344 350 I-Observation
Roll NCT03867019 351 355 I-Observation
Test NCT03867019 356 360 I-Observation
, NCT03867019 361 362 O
confirmed NCT03867019 363 372 O
by NCT03867019 373 375 O
presence NCT03867019 376 384 O
of NCT03867019 385 387 O
nystagmus NCT03867019 388 397 B-Condition
. NCT03867019 397 398 O

Subjects NCT03867019 400 408 O
without NCT03867019 409 416 B-Negation
BPPV NCT03867019 417 421 B-Condition
( NCT03867019 422 423 O
Control NCT03867019 424 431 O
group NCT03867019 432 437 O
) NCT03867019 438 439 O
: NCT03867019 441 442 O

Subjects NCT03867019 444 452 O
who NCT03867019 453 456 O
do NCT03867019 457 459 O
not NCT03867019 460 463 B-Negation
suffer NCT03867019 464 470 O
from NCT03867019 471 475 O
dizziness NCT03867019 476 485 B-Condition
/ NCT03867019 486 487 O
spinning NCT03867019 488 496 B-Condition
sensation NCT03867019 497 506 I-Condition
( NCT03867019 507 508 O
Vertigo NCT03867019 509 516 B-Condition
) NCT03867019 517 518 O
. NCT03867019 519 520 O

Exclusion NCT03867019 522 531 O
Criteria NCT03867019 532 540 O
: NCT03867019 541 542 O

- NCT03867019 546 547 O
Suffering NCT03867019 549 558 O
from NCT03867019 559 563 O
pain NCT03867019 564 568 B-Condition
in NCT03867019 569 571 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867019 572 575 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03867019 576 579 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867019 580 582 I-Temporal-Connection___Temporal-Connection-Type-Value:during
assessment NCT03867019 583 593 B-Study
. NCT03867019 593 594 O

- NCT03867019 598 599 O
Postural NCT03867019 601 609 B-Modifier
Hypotension NCT03867019 610 621 B-Condition
. NCT03867019 621 622 O

- NCT03867019 626 627 O
Familial NCT03867019 629 637 B-Condition
Dysautonomia NCT03867019 638 650 I-Condition
. NCT03867019 650 651 O

- NCT03867019 655 656 O
Diabetic NCT03867019 658 666 B-Condition
Neuropathy NCT03867019 667 677 I-Condition
. NCT03867019 677 678 O

- NCT03867019 682 683 O
History NCT03867019 685 692 B-Eq-Comparison
of NCT03867019 693 695 O
Whiplash NCT03867019 696 704 B-Condition
or NCT03867019 705 707 B-Or
Traumatic NCT03867019 708 717 B-Condition
Brain NCT03867019 718 723 I-Condition
Injury NCT03867019 724 730 I-Condition
( NCT03867019 731 732 O
TBI NCT03867019 733 736 B-Condition
) NCT03867019 737 738 O
in NCT03867019 739 741 O
the NCT03867019 742 745 O
last NCT03867019 746 750 B-Eq-Comparison
year NCT03867019 751 755 I-Eq-Comparison
. NCT03867019 755 756 O

- NCT03867019 760 761 O
History NCT03867019 763 770 B-Eq-Comparison
of NCT03867019 771 773 O
Stroke NCT03867019 774 780 B-Condition
( NCT03867019 781 782 O
CVA NCT03867019 783 786 B-Condition
) NCT03867019 787 788 O
, NCT03867019 790 791 O
Multiple NCT03867019 792 800 B-Condition
Sclerosis NCT03867019 801 810 I-Condition
( NCT03867019 811 812 O
MS NCT03867019 813 815 B-Condition
) NCT03867019 816 817 O
or NCT03867019 818 820 B-Or
Central NCT03867019 821 828 B-Condition
Positional NCT03867019 829 839 I-Condition
Vertigo NCT03867019 840 847 I-Condition
. NCT03867019 847 848 O

- NCT03867019 852 853 O
Coronary NCT03867019 855 863 B-Condition
Heart NCT03867019 864 869 I-Condition|Condition
Disease NCT03867019 870 877 I-Condition
( NCT03867019 878 879 O
CHD NCT03867019 880 883 B-Condition
) NCT03867019 884 885 O
, NCT03867019 887 888 O
Cardiac NCT03867019 889 896 B-Condition|Condition
Heart NCT03867019 897 902 O
Failure NCT03867019 903 910 I-Condition
( NCT03867019 911 912 O
CHF NCT03867019 913 916 B-Condition
) NCT03867019 917 918 O
, NCT03867019 920 921 O
Cardiac NCT03867019 922 929 O
arrhythmias NCT03867019 930 941 I-Condition
, NCT03867019 942 943 O
Vertebrobasilar NCT03867019 944 959 B-Condition
Insufficiency NCT03867019 960 973 I-Condition
( NCT03867019 974 975 O
VBI NCT03867019 976 979 B-Condition
) NCT03867019 980 981 O
. NCT03867019 982 983 O

- NCT03867019 987 988 I-Drug
Under NCT03867019 990 995 O
treatment NCT03867019 996 1005 B-Procedure
of NCT03867019 1006 1008 O
Beta NCT03867019 1009 1013 B-Drug
- NCT03867019 1014 1015 O
Blockers NCT03867019 1016 1024 I-Drug
. NCT03867019 1024 1025 O

- NCT03867019 1029 1030 O
Anxiety NCT03867019 1032 1039 B-Condition
Disorders NCT03867019 1040 1049 I-Condition
. NCT03867019 1049 1050 O

- NCT03867019 1054 1055 O
Vestibular NCT03867019 1057 1067 B-Condition|Condition
Migraine NCT03867019 1068 1076 I-Condition
, NCT03867019 1077 1078 O
Vestibular NCT03867019 1079 1089 O
Neuritis NCT03867019 1090 1098 I-Condition
, NCT03867019 1099 1100 O
Menier NCT03867019 1101 1107 B-Condition
's NCT03867019 1107 1109 O
Disease NCT03867019 1110 1117 I-Condition
, NCT03867019 1118 1119 O
Perilymphatic NCT03867019 1120 1133 B-Condition
Fistula NCT03867019 1134 1141 I-Condition
, NCT03867019 1142 1143 O
Superior NCT03867019 1144 1152 B-Condition
Canal NCT03867019 1153 1158 I-Condition
Dehiscence NCT03867019 1159 1169 I-Condition
Syndrome NCT03867019 1170 1178 I-Condition
. NCT03867019 1178 1179 O

- NCT03867019 1183 1184 O
Medical NCT03867019 1186 1193 B-Condition
conditions NCT03867019 1194 1204 I-Condition
with NCT03867019 1205 1209 O
high NCT03867019 1210 1214 O
risk NCT03867019 1215 1219 B-Risk
of NCT03867019 1220 1222 O
subluxation NCT03867019 1223 1234 B-Condition
/ NCT03867019 1235 1236 B-Or
dislocation NCT03867019 1237 1248 B-Condition
of NCT03867019 1249 1251 O
the NCT03867019 1252 1255 O
Atlanto NCT03867019 1256 1263 B-Modifier
- NCT03867019 1264 1265 I-Modifier
axial NCT03867019 1266 1271 I-Modifier
joint NCT03867019 1272 1277 I-Modifier
. NCT03867019 1277 1278 O

- NCT03867019 1282 1283 O
Health NCT03867019 1285 1291 B-Provider
professionals NCT03867019 1292 1305 I-Provider
who NCT03867019 1306 1309 O
are NCT03867019 1310 1313 O
specialized NCT03867019 1314 1325 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867019 1326 1328 I-Assertion___Assertion-Type-Value:hypothetical
treat NCT03867019 1329 1334 B-Procedure
Vestibular NCT03867019 1335 1345 B-Condition|Provider
disorders NCT03867019 1346 1355 I-Condition
( NCT03867019 1356 1357 O
such NCT03867019 1358 1362 O
as NCT03867019 1363 1365 O
Vestibular NCT03867019 1366 1376 O
physiotherapists NCT03867019 1377 1393 I-Provider
) NCT03867019 1394 1395 O

Inclusion NCT03869008 0 9 O
Criteria NCT03869008 10 18 O
: NCT03869008 19 20 O

• NCT03869008 22 23 O
Clinical NCT03869008 24 32 O
Diagnosis NCT03869008 33 42 O
of NCT03869008 43 45 O
Primary NCT03869008 46 53 B-Condition
Raynaud NCT03869008 54 61 I-Condition
's NCT03869008 61 63 O
Phenomenon NCT03869008 64 74 I-Condition

Exclusion NCT03869008 75 84 O
Criteria NCT03869008 85 93 O
: NCT03869008 94 95 O

- NCT03869008 99 100 O
Less NCT03869008 102 106 B-Eq-Comparison
than NCT03869008 107 111 I-Eq-Comparison
18 NCT03869008 112 114 I-Eq-Comparison
years NCT03869008 115 120 I-Eq-Comparison
of NCT03869008 121 123 O
age NCT03869008 124 127 B-Age

- NCT03869008 130 131 O
Pregnant NCT03869008 133 141 B-Condition
women NCT03869008 142 147 O

- NCT03869008 150 151 O
Current NCT03869008 153 160 B-Eq-Comparison
smokers NCT03869008 161 168 B-Condition

- NCT03869008 171 172 O
Have NCT03869008 174 178 O
Digital NCT03869008 179 186 B-Modifier
ulcers NCT03869008 187 193 B-Condition

- NCT03869008 196 197 O
Diagnosed NCT03869008 199 208 O
Pulmonary NCT03869008 209 218 B-Condition
hypertension NCT03869008 219 231 I-Condition

- NCT03869008 234 235 O
Currently NCT03869008 237 246 B-Eq-Comparison
on NCT03869008 247 249 O
vasodilators NCT03869008 250 262 B-Drug
( NCT03869008 263 264 O
i. NCT03869008 265 267 O
e. NCT03869008 268 270 O
Phosphodiesterase NCT03869008 272 289 B-Drug
type NCT03869008 290 294 I-Drug
5 NCT03869008 295 296 I-Drug
inhibitors NCT03869008 297 307 I-Drug
, NCT03869008 308 309 O
prostacyclin NCT03869008 310 322 B-Drug
, NCT03869008 323 324 O
nitroglycerine NCT03869008 325 339 B-Drug
, NCT03869008 340 341 O
or NCT03869008 342 344 B-Or
other NCT03869008 345 350 B-Other
nitric NCT03869008 351 357 B-Drug
oxide NCT03869008 358 363 I-Drug
derivatives NCT03869008 364 375 I-Drug
) NCT03869008 376 377 O

- NCT03869008 381 382 O
Currently NCT03869008 384 393 B-Eq-Comparison
on NCT03869008 394 396 O
Calcium NCT03869008 397 404 B-Drug
Channel NCT03869008 405 412 I-Drug
Blockers NCT03869008 413 421 I-Drug

Inclusion NCT03860038 0 9 O
criteria NCT03860038 10 18 O
: NCT03860038 19 20 O

1 NCT03860038 24 25 O
. NCT03860038 25 26 O
Age NCT03860038 28 31 B-Age
≥ NCT03860038 32 33 B-Eq-Comparison
18 NCT03860038 34 36 I-Eq-Comparison
, NCT03860038 37 38 O
male NCT03860038 39 43 O
or NCT03860038 44 46 B-Or
female NCT03860038 47 53 O
; NCT03860038 53 54 O

2 NCT03860038 57 58 O
. NCT03860038 58 59 O
Subject NCT03860038 61 68 O
must NCT03860038 69 73 O
have NCT03860038 74 78 O
had NCT03860038 79 82 O
documented NCT03860038 83 93 O
MM NCT03860038 94 96 B-Condition
; NCT03860038 96 97 O

3 NCT03860038 100 101 O
. NCT03860038 101 102 O
At NCT03860038 104 106 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03860038 107 116 B-Study
phase NCT03860038 117 122 O
, NCT03860038 123 124 O
subject NCT03860038 125 132 O
must NCT03860038 133 137 O
have NCT03860038 138 142 O
measurable NCT03860038 143 153 B-Assertion___Assertion-Type-Value:hypothetical
disease NCT03860038 154 161 B-Condition
; NCT03860038 161 162 O

4 NCT03860038 165 166 O
. NCT03860038 166 167 O
Subject NCT03860038 169 176 O
is NCT03860038 177 179 O
in NCT03860038 180 182 O
a NCT03860038 183 184 O
state NCT03860038 185 190 O
of NCT03860038 191 193 O
progressive NCT03860038 194 205 B-Condition
disease NCT03860038 206 213 I-Condition
( NCT03860038 214 215 O
PD NCT03860038 216 218 B-Condition
) NCT03860038 219 220 O
; NCT03860038 221 222 O

5 NCT03860038 225 226 O
. NCT03860038 226 227 O
Subject NCT03860038 229 236 O
must NCT03860038 237 241 O
have NCT03860038 242 246 O
life NCT03860038 247 251 B-Observation
expectancy NCT03860038 252 262 I-Observation
of NCT03860038 263 265 O
no NCT03860038 266 268 B-Eq-Comparison
less NCT03860038 269 273 I-Eq-Comparison
than NCT03860038 274 278 I-Eq-Comparison
6 NCT03860038 279 280 I-Eq-Comparison
months NCT03860038 281 287 I-Eq-Comparison
; NCT03860038 287 288 O

6 NCT03860038 291 292 O
. NCT03860038 292 293 O
Subject NCT03860038 295 302 O
must NCT03860038 303 307 O
have NCT03860038 308 312 O
an NCT03860038 313 315 O
ECOG NCT03860038 316 320 B-Observation
( NCT03860038 321 322 O
Eastern NCT03860038 323 330 B-Observation
Cooperative NCT03860038 331 342 I-Observation
Oncology NCT03860038 343 351 I-Observation
Group NCT03860038 352 357 I-Observation
) NCT03860038 358 359 O
performance NCT03860038 360 371 O
status NCT03860038 372 378 O
score NCT03860038 379 384 O
of NCT03860038 385 387 O
0 NCT03860038 388 389 B-Eq-Comparison
~ NCT03860038 390 391 O
2 NCT03860038 392 393 O
; NCT03860038 394 395 O

Exclusion NCT03860038 396 405 O
criteria NCT03860038 406 414 O
: NCT03860038 415 416 O

1 NCT03860038 420 421 O
. NCT03860038 421 422 O
Subject NCT03860038 424 431 O
has NCT03860038 432 435 O
received NCT03860038 436 444 O
anti NCT03860038 445 449 B-Drug
- NCT03860038 450 451 I-Drug
CD38 NCT03860038 452 456 I-Drug
monoclonal NCT03860038 457 467 I-Drug
antibody NCT03860038 468 476 O
treatment NCT03860038 477 486 I-Drug
previously NCT03860038 487 497 B-Eq-Comparison
; NCT03860038 497 498 O

2 NCT03860038 501 502 O
. NCT03860038 502 503 O
Subject NCT03860038 505 512 O
has NCT03860038 513 516 O
received NCT03860038 517 525 O
CAR NCT03860038 526 529 B-Procedure
- NCT03860038 530 531 I-Procedure
T NCT03860038 532 533 I-Procedure
cell NCT03860038 534 538 I-Procedure
therapy NCT03860038 539 546 I-Procedure
previously NCT03860038 547 557 B-Eq-Comparison
; NCT03860038 557 558 O

3 NCT03860038 561 562 O
. NCT03860038 562 563 O
Subject NCT03860038 565 572 O
has NCT03860038 573 576 O
previously NCT03860038 577 587 B-Eq-Comparison
received NCT03860038 588 596 O
allogenic NCT03860038 597 606 B-Modifier
stem NCT03860038 607 611 B-Procedure
cell NCT03860038 612 616 I-Procedure
transplant NCT03860038 617 627 I-Procedure
, NCT03860038 628 629 O
or NCT03860038 630 632 B-Or
subject NCT03860038 633 640 O
has NCT03860038 641 644 O
received NCT03860038 645 653 O
autologous NCT03860038 654 664 B-Modifier
stem NCT03860038 665 669 B-Procedure
cell NCT03860038 670 674 I-Procedure
transplant NCT03860038 675 685 I-Procedure
within NCT03860038 686 692 B-Eq-Comparison
3 NCT03860038 693 694 I-Eq-Comparison
months NCT03860038 695 701 I-Eq-Comparison
before NCT03860038 702 708 B-Temporal-Connection___Temporal-Connection-Type-Value:before
administration NCT03860038 709 723 O
of NCT03860038 724 726 O
the NCT03860038 727 730 O
study NCT03860038 731 736 B-Study
agent NCT03860038 737 742 B-Drug
; NCT03860038 742 743 O

4 NCT03860038 746 747 O
. NCT03860038 747 748 O
Primary NCT03860038 750 757 B-Modifier
refractory NCT03860038 758 768 I-Modifier
multiple NCT03860038 769 777 I-Modifier
myeloma NCT03860038 778 785 B-Condition
( NCT03860038 786 787 O
subject NCT03860038 788 795 O
failed NCT03860038 796 802 O
to NCT03860038 803 805 O
generate NCT03860038 806 814 O
any NCT03860038 815 818 O
minimal NCT03860038 819 826 O
response NCT03860038 827 835 O
or NCT03860038 836 838 O
any NCT03860038 839 842 O
degree NCT03860038 843 849 O
of NCT03860038 850 852 O
response NCT03860038 853 861 O
to NCT03860038 862 864 O
any NCT03860038 865 868 O
therapy NCT03860038 869 876 B-Procedure
) NCT03860038 877 878 O
; NCT03860038 879 880 O

5 NCT03860038 883 884 O
. NCT03860038 884 885 O
Subject NCT03860038 887 894 O
has NCT03860038 895 898 O
received NCT03860038 899 907 O
anti NCT03860038 908 912 B-Procedure
- NCT03860038 913 914 I-Procedure
myeloma NCT03860038 915 922 I-Procedure
treatment NCT03860038 923 932 I-Procedure
( NCT03860038 933 934 O
radiotherapy NCT03860038 935 947 B-Procedure
is NCT03860038 948 950 O
excluded NCT03860038 951 959 B-Exception
) NCT03860038 960 961 O
within NCT03860038 962 968 B-Eq-Comparison
4 NCT03860038 969 970 I-Eq-Comparison
weeks NCT03860038 971 976 I-Eq-Comparison
or NCT03860038 977 979 B-Or
5 NCT03860038 980 981 B-Eq-Comparison
PK NCT03860038 982 984 I-Eq-Comparison
half NCT03860038 985 989 I-Eq-Comparison
- NCT03860038 990 991 I-Eq-Comparison
lives NCT03860038 992 997 I-Eq-Comparison
of NCT03860038 998 1000 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860038 1001 1004 O
treatment NCT03860038 1005 1014 B-Procedure
, NCT03860038 1015 1016 O
whichever NCT03860038 1017 1026 O
longer NCT03860038 1027 1033 O
, NCT03860038 1034 1035 O
before NCT03860038 1036 1042 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860038 1043 1046 O
first NCT03860038 1047 1052 B-Eq-Comparison
study NCT03860038 1053 1058 B-Study
agent NCT03860038 1059 1064 B-Drug
administration NCT03860038 1065 1079 O
. NCT03860038 1079 1080 O

Inclusion NCT03869593 0 9 O
Criteria NCT03869593 10 18 O
: NCT03869593 19 20 O

- NCT03869593 24 25 O
Patient NCT03869593 27 34 O
with NCT03869593 35 39 O
S. NCT03869593 40 42 B-Organism
aureus NCT03869593 44 50 I-Organism
or NCT03869593 51 53 B-Or
E. NCT03869593 54 56 B-Organism
coli NCT03869593 58 62 I-Organism
bacteriostatic NCT03869593 63 77 B-Condition
bacteremia NCT03869593 78 88 I-Condition
defined NCT03869593 89 96 O
by NCT03869593 97 99 O
at NCT03869593 100 102 B-Eq-Comparison
least NCT03869593 103 108 I-Eq-Comparison
one NCT03869593 109 112 I-Eq-Comparison
positive NCT03869593 113 121 O
blood NCT03869593 122 127 B-Observation
culture NCT03869593 128 135 I-Observation
bottle NCT03869593 136 142 O

- NCT03869593 145 146 O
Patient NCT03869593 148 155 O
requiring NCT03869593 156 165 O
a NCT03869593 166 167 O
blood NCT03869593 168 173 B-Observation
test NCT03869593 174 178 I-Observation
as NCT03869593 179 181 O
part NCT03869593 182 186 O
of NCT03869593 187 189 O
his NCT03869593 190 193 O
bacteremia NCT03869593 194 204 B-Condition

- NCT03869593 207 208 O
not NCT03869593 210 213 B-Negation
subject NCT03869593 214 221 O
to NCT03869593 222 224 O
a NCT03869593 225 226 O
judicial NCT03869593 227 235 B-Observation
protection NCT03869593 236 246 I-Observation
measure NCT03869593 247 254 O

- NCT03869593 257 258 O
Signature NCT03869593 260 269 O
of NCT03869593 270 272 O
the NCT03869593 273 276 O
non NCT03869593 277 280 O
- NCT03869593 281 282 O
opposition NCT03869593 283 293 O
of NCT03869593 294 296 O
consent NCT03869593 297 304 O
( NCT03869593 305 306 O
for NCT03869593 307 310 O
minor NCT03869593 311 316 O
patients NCT03869593 317 325 O
signed NCT03869593 326 332 O
by NCT03869593 333 335 O
one NCT03869593 336 339 O
of NCT03869593 340 342 O
the NCT03869593 343 346 O
parents NCT03869593 347 354 O
or NCT03869593 355 357 O
the NCT03869593 358 361 O
representative NCT03869593 362 376 O
of NCT03869593 377 379 O
the NCT03869593 380 383 O
parental NCT03869593 384 392 O
authority NCT03869593 393 402 O
) NCT03869593 403 404 O

- NCT03869593 408 409 O
Affiliation NCT03869593 411 422 O
to NCT03869593 423 425 O
social NCT03869593 426 432 O
security NCT03869593 433 441 O

Exclusion NCT03869593 442 451 O
Criteria NCT03869593 452 460 O
: NCT03869593 461 462 O

- NCT03869593 466 467 O
Immunocompromised NCT03869593 469 486 B-Condition
patient NCT03869593 487 494 O
defined NCT03869593 495 502 O
by NCT03869593 503 505 O
: NCT03869593 506 507 O

- NCT03869593 516 517 O
current NCT03869593 519 526 B-Eq-Comparison
immunosuppressive NCT03869593 527 544 B-Procedure
therapies NCT03869593 545 554 I-Procedure
: NCT03869593 555 556 O
corticosteroids NCT03869593 557 572 B-Drug
, NCT03869593 573 574 O
chemotherapy NCT03869593 575 587 B-Procedure
, NCT03869593 588 589 O
biotherapy NCT03869593 590 600 B-Procedure

- NCT03869593 608 609 O
solid NCT03869593 611 616 B-Procedure
organ NCT03869593 617 622 I-Procedure
transplant NCT03869593 623 633 I-Procedure
patient NCT03869593 634 641 O
or NCT03869593 642 644 B-Or
hematopoietic NCT03869593 645 658 B-Modifier
stem NCT03869593 659 663 B-Procedure
cell NCT03869593 664 668 I-Procedure
transplant NCT03869593 669 679 I-Procedure

- NCT03869593 687 688 O
chemotherapy NCT03869593 690 702 B-Procedure
- NCT03869593 703 704 O
induced NCT03869593 705 712 O
neutropenia NCT03869593 713 724 B-Condition

- NCT03869593 732 733 O
Congenital NCT03869593 735 745 B-Modifier
immune NCT03869593 746 752 B-Condition
deficiency NCT03869593 753 763 I-Condition

- NCT03869593 766 767 O
bacteremia NCT03869593 769 779 B-Condition
related NCT03869593 780 787 O
to NCT03869593 788 790 O
a NCT03869593 791 792 O
peripheral NCT03869593 793 803 B-Modifier
or NCT03869593 804 806 B-Or
central NCT03869593 807 814 B-Modifier
catheter NCT03869593 815 823 B-Procedure

- NCT03869593 826 827 O
Urinary NCT03869593 829 836 B-Condition
obstruction NCT03869593 837 848 I-Condition
not NCT03869593 849 852 B-Negation
lifted NCT03869593 853 859 B-Procedure
within NCT03869593 860 866 B-Eq-Comparison
the NCT03869593 867 870 I-Eq-Comparison
first NCT03869593 871 876 I-Eq-Comparison
24 NCT03869593 877 879 I-Eq-Comparison
hours NCT03869593 880 885 I-Eq-Comparison
of NCT03869593 886 888 O
management NCT03869593 889 899 O

- NCT03869593 902 903 I-Modifier
Intra NCT03869593 905 910 B-Modifier
- NCT03869593 911 912 O
abdominal NCT03869593 913 922 I-Modifier
infection NCT03869593 923 932 B-Condition
collected NCT03869593 933 942 O
undrained NCT03869593 943 952 B-Procedure
in NCT03869593 953 955 B-Eq-Comparison
the NCT03869593 956 959 I-Eq-Comparison
first NCT03869593 960 965 I-Eq-Comparison
24 NCT03869593 966 968 I-Eq-Comparison
hours NCT03869593 969 974 I-Eq-Comparison
of NCT03869593 975 977 O
management NCT03869593 978 988 O

- NCT03869593 991 992 O
primary NCT03869593 994 1001 B-Modifier
infectious NCT03869593 1002 1012 B-Condition
focus NCT03869593 1013 1018 O
represented NCT03869593 1019 1030 O
by NCT03869593 1031 1033 O
mechanically NCT03869593 1034 1046 B-Procedure
ventilated NCT03869593 1047 1057 I-Procedure
pneumonia NCT03869593 1058 1067 B-Condition

- NCT03869593 1070 1071 O
Pregnant NCT03869593 1073 1081 B-Condition
or NCT03869593 1082 1084 B-Or
lactating NCT03869593 1085 1094 B-Condition
woman NCT03869593 1095 1100 O

Inclusion NCT03866850 0 9 O
Criteria NCT03866850 10 18 O
: NCT03866850 19 20 O

- NCT03866850 24 25 O
Cochlear NCT03866850 27 35 B-Modifier
Nucleus NCT03866850 36 43 I-Modifier
cochlear NCT03866850 44 52 B-Procedure
implant NCT03866850 53 60 I-Procedure
users NCT03866850 61 66 O
or NCT03866850 67 69 B-Or
Advanced NCT03866850 70 78 B-Modifier
Bionics NCT03866850 79 86 I-Modifier
cochlear NCT03866850 87 95 B-Procedure
implant NCT03866850 96 103 I-Procedure
users NCT03866850 104 109 O

- NCT03866850 112 113 O
Native NCT03866850 115 121 O
speakers NCT03866850 122 130 O
of NCT03866850 131 133 O
English NCT03866850 134 141 O

- NCT03866850 144 145 O
Early NCT03866850 147 152 B-Modifier
onset NCT03866850 153 158 B-Eq-Comparison
of NCT03866850 159 161 O
deafness NCT03866850 162 170 B-Condition
( NCT03866850 171 172 O
< NCT03866850 174 175 B-Eq-Comparison
3 NCT03866850 176 177 I-Eq-Comparison
years NCT03866850 178 183 I-Eq-Comparison
of NCT03866850 184 186 O
age NCT03866850 187 190 B-Age
) NCT03866850 191 192 O
; NCT03866850 193 194 O
no NCT03866850 195 197 O
requirement NCT03866850 198 209 O
for NCT03866850 210 213 O
age NCT03866850 214 217 O
at NCT03866850 218 220 O
implantation NCT03866850 221 233 B-Procedure

- NCT03866850 236 237 O
Late NCT03866850 239 243 B-Modifier
onset NCT03866850 244 249 B-Eq-Comparison
of NCT03866850 250 252 O
deafness NCT03866850 253 261 B-Condition
( NCT03866850 262 263 O
> NCT03866850 265 266 B-Eq-Comparison
3 NCT03866850 267 268 I-Eq-Comparison
years NCT03866850 269 274 I-Eq-Comparison
of NCT03866850 275 277 O
age NCT03866850 278 281 B-Age
) NCT03866850 282 283 O
; NCT03866850 284 285 O
matched NCT03866850 286 293 O
in NCT03866850 294 296 O
duration NCT03866850 297 305 O
of NCT03866850 306 308 O
deafness NCT03866850 309 317 O
to NCT03866850 318 320 O
the NCT03866850 321 324 O
early NCT03866850 325 330 O
onset NCT03866850 331 336 O
group NCT03866850 337 342 O

- NCT03866850 345 346 O
Has NCT03866850 348 351 O
had NCT03866850 352 355 O
device NCT03866850 356 362 O
experience NCT03866850 363 373 O
for NCT03866850 374 377 O
at NCT03866850 378 380 O
least NCT03866850 381 386 O
one NCT03866850 387 390 O
year NCT03866850 391 395 O

- NCT03866850 398 399 O
Can NCT03866850 401 404 O
be NCT03866850 405 407 O
child NCT03866850 408 413 O
or NCT03866850 414 416 B-Or
adult NCT03866850 417 422 O
at NCT03866850 423 425 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866850 426 429 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866850 430 434 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866850 435 437 O
enrollment NCT03866850 438 448 B-Study

Exclusion NCT03866850 449 458 O
Criteria NCT03866850 459 467 O
: NCT03866850 468 469 O

- NCT03866850 473 474 O
None NCT03866850 476 480 O

Inclusion NCT03865381 0 9 O
Criteria NCT03865381 10 18 O
: NCT03865381 19 20 O

- NCT03865381 24 25 O
Male NCT03865381 27 31 O
and NCT03865381 32 35 B-Or
Female NCT03865381 36 42 O
; NCT03865381 42 43 O
18 NCT03865381 44 46 B-Eq-Comparison
years NCT03865381 47 52 I-Eq-Comparison
of NCT03865381 53 55 I-Eq-Comparison
age NCT03865381 56 59 I-Eq-Comparison
or NCT03865381 60 62 I-Eq-Comparison
older NCT03865381 63 68 I-Eq-Comparison

- NCT03865381 71 72 O
Confirmed NCT03865381 74 83 O
diagnosis NCT03865381 84 93 O
of NCT03865381 94 96 O
Type NCT03865381 97 101 B-Modifier
2 NCT03865381 102 103 I-Modifier
diabetes NCT03865381 104 112 B-Condition
mellitus NCT03865381 113 121 I-Condition

- NCT03865381 124 125 O
Willing NCT03865381 127 134 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865381 135 137 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03865381 138 141 O
CGM NCT03865381 142 145 B-Procedure
and NCT03865381 146 149 B-Or
BGM NCT03865381 150 153 B-Procedure

- NCT03865381 156 157 O
A1c NCT03865381 159 162 B-Observation
result NCT03865381 163 169 O
≥ NCT03865381 170 171 B-Eq-Comparison
8.0 NCT03865381 172 175 I-Eq-Comparison
% NCT03865381 176 177 O
and NCT03865381 178 181 B-And
≤ NCT03865381 182 183 B-Eq-Comparison
12.0 NCT03865381 184 188 I-Eq-Comparison
% NCT03865381 189 190 O

- NCT03865381 193 194 O
Receive NCT03865381 196 203 B-Eq-Comparison
their NCT03865381 204 209 O
diabetes NCT03865381 210 218 B-Condition
care NCT03865381 219 223 B-Procedure
from NCT03865381 224 228 O
Premier NCT03865381 229 236 O
Medical NCT03865381 237 244 O
Associates NCT03865381 245 255 O
or NCT03865381 256 258 B-Or
the NCT03865381 259 262 O
Palo NCT03865381 263 267 O
Alto NCT03865381 268 272 O
Medical NCT03865381 273 280 O
Foundation NCT03865381 281 291 O

- NCT03865381 294 295 O
Own NCT03865381 297 300 O
a NCT03865381 301 302 O
Smartphone NCT03865381 303 313 O
with NCT03865381 314 318 O
a NCT03865381 319 320 O
data NCT03865381 321 325 O
plan NCT03865381 326 330 O
and NCT03865381 331 334 O
be NCT03865381 335 337 O
the NCT03865381 338 341 O
primary NCT03865381 342 349 O
user NCT03865381 350 354 O
of NCT03865381 355 357 O
that NCT03865381 358 362 O
smartphone NCT03865381 363 373 O

- NCT03865381 376 377 O
Smartphone NCT03865381 379 389 O
must NCT03865381 390 394 O
use NCT03865381 395 398 O
a NCT03865381 399 400 O
supported NCT03865381 401 410 O
Android NCT03865381 411 418 O
OS NCT03865381 419 421 O
or NCT03865381 422 424 O
iOS NCT03865381 425 428 O

Exclusion NCT03865381 429 438 O
Criteria NCT03865381 439 447 O
: NCT03865381 448 449 O

- NCT03865381 453 454 O
Pregnant NCT03865381 456 464 B-Condition
or NCT03865381 465 467 B-Or
breastfeeding NCT03865381 468 481 B-Condition

- NCT03865381 484 485 O
Use NCT03865381 487 490 O
of NCT03865381 491 493 O
an NCT03865381 494 496 O
insulin NCT03865381 497 504 B-Procedure
pump NCT03865381 505 509 I-Procedure

- NCT03865381 512 513 O
Any NCT03865381 515 518 O
condition NCT03865381 519 528 B-Condition
or NCT03865381 529 531 B-Or
situation NCT03865381 532 541 B-Condition
that NCT03865381 542 546 O
the NCT03865381 547 550 O
Sponsor NCT03865381 551 558 O
or NCT03865381 559 561 O
Investigator NCT03865381 562 574 O
determines NCT03865381 575 585 O
as NCT03865381 586 588 O
inappropriate NCT03865381 589 602 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03865381 603 606 O
study NCT03865381 607 612 B-Study
inclusion NCT03865381 613 622 O

Inclusion NCT03867227 0 9 O
Criteria NCT03867227 10 18 O
: NCT03867227 19 20 O

- NCT03867227 24 25 O
Patient NCT03867227 27 34 O
with NCT03867227 35 39 O
paroxysmal NCT03867227 40 50 B-Modifier
/ NCT03867227 51 52 B-Or
persistent NCT03867227 53 63 B-Modifier
/ NCT03867227 64 65 B-Or
permanent NCT03867227 66 75 B-Modifier
atrial NCT03867227 76 82 B-Condition
fibrillation NCT03867227 83 95 I-Condition

- NCT03867227 98 99 O
CHA2DS2VASc NCT03867227 101 112 B-Observation
score NCT03867227 113 118 O
≥ NCT03867227 119 120 B-Eq-Comparison
2 NCT03867227 121 122 I-Eq-Comparison
for NCT03867227 123 126 O
male NCT03867227 127 131 O
and NCT03867227 132 135 B-And
≥ NCT03867227 136 137 B-Eq-Comparison
3 NCT03867227 138 139 I-Eq-Comparison
for NCT03867227 140 143 O
female NCT03867227 144 150 O

- NCT03867227 153 154 O
Without NCT03867227 156 163 B-Negation
contraindications NCT03867227 164 181 B-Contraindication
to NCT03867227 182 184 O
anticoagulation NCT03867227 185 200 B-Procedure
therapy NCT03867227 201 208 I-Procedure

Exclusion NCT03867227 209 218 O
Criteria NCT03867227 219 227 O
: NCT03867227 228 229 O

- NCT03867227 233 234 O
LAA NCT03867227 236 239 B-Modifier
thrombosis NCT03867227 240 250 B-Condition

- NCT03867227 253 254 O
mechanical NCT03867227 256 266 B-Procedure
prosthetic NCT03867227 267 277 I-Procedure
heart NCT03867227 278 283 I-Procedure
valve NCT03867227 284 289 I-Procedure

- NCT03867227 292 293 O
moderate NCT03867227 295 303 O
or NCT03867227 304 306 B-Or
severe NCT03867227 307 313 O
mitral NCT03867227 314 320 B-Condition
valve NCT03867227 321 326 I-Condition
stenosis NCT03867227 327 335 I-Condition

Inclusion NCT03861130 0 9 O
Criteria NCT03861130 10 18 O
: NCT03861130 19 20 O

- NCT03861130 24 25 O
Affected NCT03861130 27 35 O
children NCT03861130 36 44 O
will NCT03861130 45 49 O
be NCT03861130 50 52 O
recruited NCT03861130 53 62 O
if NCT03861130 63 65 O
the NCT03861130 66 69 O
treating NCT03861130 70 78 B-Procedure
clinician NCT03861130 79 88 B-Provider
has NCT03861130 89 92 O
made NCT03861130 93 97 O
a NCT03861130 98 99 O
diagnosis NCT03861130 100 109 O
of NCT03861130 110 112 O
possible NCT03861130 113 121 B-Assertion___Assertion-Type-Value:possible
Kawasaki NCT03861130 122 130 B-Condition
disease NCT03861130 131 138 I-Condition
( NCT03861130 139 140 O
even NCT03861130 141 145 O
if NCT03861130 146 148 O
they NCT03861130 149 153 O
do NCT03861130 154 156 O
not NCT03861130 157 160 O
fulfil NCT03861130 161 167 O
the NCT03861130 168 171 O
criteria NCT03861130 172 180 O
below NCT03861130 181 186 O
for NCT03861130 187 190 O
Kawasaki NCT03861130 191 199 B-Condition
disease NCT03861130 200 207 I-Condition
) NCT03861130 208 209 O
. NCT03861130 210 211 O

The NCT03861130 213 216 O
current NCT03861130 217 224 O
standard NCT03861130 225 233 O
diagnostic NCT03861130 234 244 O
criteria NCT03861130 245 253 O
for NCT03861130 254 257 O
KD NCT03861130 258 260 B-Condition
( NCT03861130 261 262 O
Circulation NCT03861130 263 274 O
2001 NCT03861130 275 279 O
103 NCT03861130 280 283 O
335 NCT03861130 284 287 O
- NCT03861130 288 289 O
336 NCT03861130 290 293 O
doi NCT03861130 294 297 O
: NCT03861130 298 299 O
10.1161 NCT03861130 300 307 O
/ NCT03861130 308 309 O
01 NCT03861130 310 312 O
. NCT03861130 312 313 O
CIR NCT03861130 314 317 O
103.2.335 NCT03861130 318 327 O
) NCT03861130 328 329 O
are NCT03861130 330 333 O
: NCT03861130 334 335 O

The NCT03861130 337 340 O
presence NCT03861130 341 349 O
of NCT03861130 350 352 O
fever NCT03861130 353 358 B-Condition
for NCT03861130 359 362 O
at NCT03861130 363 365 B-Eq-Comparison
least NCT03861130 366 371 I-Eq-Comparison
five NCT03861130 372 376 I-Eq-Comparison
days NCT03861130 377 381 I-Eq-Comparison
plus NCT03861130 382 386 B-And
four NCT03861130 387 391 B-Eq-Comparison
of NCT03861130 392 394 O
the NCT03861130 395 398 B-Criteria-Count
following NCT03861130 399 408 I-Criteria-Count
criteria NCT03861130 409 417 I-Criteria-Count
: NCT03861130 418 419 O

1 NCT03861130 423 424 O
. NCT03861130 424 425 O
Changes NCT03861130 427 434 O
in NCT03861130 435 437 O
the NCT03861130 438 441 O
peripheral NCT03861130 442 452 B-Condition
extremities NCT03861130 453 464 I-Condition
Acute NCT03861130 465 470 O
: NCT03861130 471 472 O
erythema NCT03861130 473 481 B-Condition
and NCT03861130 482 485 B-Or|Or
oedema NCT03861130 486 492 B-Condition
of NCT03861130 493 495 O
hands NCT03861130 496 501 B-Modifier
and NCT03861130 502 505 O
feet NCT03861130 506 510 B-Modifier
Convalescent NCT03861130 511 523 B-Modifier
: NCT03861130 524 525 O
membranous NCT03861130 526 536 B-Condition
desquamation NCT03861130 537 549 I-Condition
of NCT03861130 550 552 O
fingertips NCT03861130 553 563 B-Modifier

2 NCT03861130 566 567 O
. NCT03861130 567 568 O
Polymorphous NCT03861130 570 582 B-Condition
exanthema NCT03861130 583 592 I-Condition

3 NCT03861130 595 596 O
. NCT03861130 596 597 O
Bilateral NCT03861130 599 608 B-Modifier
painless NCT03861130 609 617 I-Modifier
bulbar NCT03861130 618 624 B-Condition
conjunctival NCT03861130 625 637 I-Condition
injection NCT03861130 638 647 I-Condition
without NCT03861130 648 655 B-Negation
exudate NCT03861130 656 663 B-Modifier

4 NCT03861130 666 667 O
. NCT03861130 667 668 O
Changes NCT03861130 670 677 O
in NCT03861130 678 680 O
lips NCT03861130 681 685 B-Modifier
and NCT03861130 686 689 B-Or
oral NCT03861130 690 694 B-Modifier
cavity NCT03861130 695 701 B-Condition
: NCT03861130 702 703 O
erythema NCT03861130 704 712 B-Condition
and NCT03861130 713 716 B-Or
cracking NCT03861130 717 725 B-Condition
of NCT03861130 726 728 I-Condition
lips NCT03861130 729 733 I-Condition
, NCT03861130 734 735 O
strawberry NCT03861130 736 746 B-Condition
tongue NCT03861130 747 753 I-Condition
, NCT03861130 754 755 O
diffuse NCT03861130 756 763 B-Condition
injection NCT03861130 764 773 I-Condition
of NCT03861130 774 776 O
oral NCT03861130 777 781 B-Modifier
and NCT03861130 782 785 B-Or
pharyngeal NCT03861130 786 796 B-Modifier
mucosae NCT03861130 797 804 I-Modifier

5 NCT03861130 807 808 O
. NCT03861130 808 809 O
Cervical NCT03861130 811 819 B-Condition
lymphadenopathy NCT03861130 820 835 I-Condition
( NCT03861130 836 837 O
> NCT03861130 839 840 B-Eq-Comparison
1.5 NCT03861130 841 844 I-Eq-Comparison
cm NCT03861130 845 847 O
diameter NCT03861130 848 856 B-Observation
) NCT03861130 857 858 O
, NCT03861130 860 861 O
usually NCT03861130 862 869 O
unilateral NCT03861130 870 880 O
Patients NCT03861130 881 889 O
meeting NCT03861130 890 897 O
not NCT03861130 898 901 O
all NCT03861130 902 905 O
of NCT03861130 906 908 O
these NCT03861130 909 914 O
criteria NCT03861130 915 923 O
may NCT03861130 924 927 O
meet NCT03861130 928 932 O
the NCT03861130 933 936 O
criteria NCT03861130 937 945 O
for NCT03861130 946 949 O
atypical NCT03861130 950 958 O
Kawasaki NCT03861130 959 967 B-Condition
disease NCT03861130 968 975 I-Condition
, NCT03861130 976 977 O
ie NCT03861130 978 980 O
. NCT03861130 980 981 O
if NCT03861130 983 985 O
they NCT03861130 986 990 O
have NCT03861130 991 995 O
fever NCT03861130 996 1001 B-Condition
and NCT03861130 1002 1005 B-And
two NCT03861130 1006 1009 O
or NCT03861130 1010 1012 O
three NCT03861130 1013 1018 O
of NCT03861130 1019 1021 O
the NCT03861130 1022 1025 O
above NCT03861130 1026 1031 O
criteria NCT03861130 1032 1040 O
and NCT03861130 1041 1044 O
elevation NCT03861130 1045 1054 O
of NCT03861130 1055 1057 O
CRP NCT03861130 1058 1061 B-Condition
or NCT03861130 1062 1064 B-Or
echocardiographic NCT03861130 1065 1082 B-Observation
evidence NCT03861130 1083 1091 I-Observation
of NCT03861130 1092 1094 O
coronary NCT03861130 1095 1103 B-Condition
artery NCT03861130 1104 1110 I-Condition
dilatation NCT03861130 1111 1121 I-Condition
. NCT03861130 1121 1122 O

Parents NCT03861130 1124 1131 B-Family-Member___Family-Member-Type:parent
of NCT03861130 1132 1134 O
affected NCT03861130 1135 1143 O
child NCT03861130 1144 1149 O
must NCT03861130 1150 1154 O
be NCT03861130 1155 1157 O
biological NCT03861130 1158 1168 O
parents NCT03861130 1169 1176 O
. NCT03861130 1176 1177 O

Exclusion NCT03861130 1179 1188 O
Criteria NCT03861130 1189 1197 O
: NCT03861130 1198 1199 O

- NCT03861130 1203 1204 O
children NCT03861130 1206 1214 B-Family-Member___Family-Member-Type:child
who NCT03861130 1215 1218 O
do NCT03861130 1219 1221 O
not NCT03861130 1222 1225 B-Negation
have NCT03861130 1226 1230 O
a NCT03861130 1231 1232 O
diagnosis NCT03861130 1233 1242 O
of NCT03861130 1243 1245 O
possible NCT03861130 1246 1254 B-Assertion___Assertion-Type-Value:possible
Kawasaki NCT03861130 1255 1263 B-Condition
disease NCT03861130 1264 1271 I-Condition


Inclusion NCT03865342 0 9 O
criteria NCT03865342 10 18 O
: NCT03865342 19 20 O

- NCT03865342 24 25 O
English NCT03865342 27 34 O
- NCT03865342 35 36 O
speaking NCT03865342 37 45 O

- NCT03865342 48 49 O
18 NCT03865342 51 53 B-Eq-Comparison
years NCT03865342 54 59 I-Eq-Comparison
of NCT03865342 60 62 I-Eq-Comparison
age NCT03865342 63 66 I-Eq-Comparison
and NCT03865342 67 70 I-Eq-Comparison
older NCT03865342 71 76 I-Eq-Comparison

- NCT03865342 79 80 O
Referral NCT03865342 82 90 B-Encounter
from NCT03865342 91 95 O
the NCT03865342 96 99 O
patient NCT03865342 100 107 O
's NCT03865342 107 109 O
physician NCT03865342 110 119 B-Provider

- NCT03865342 122 123 O
Hemoglobin NCT03865342 125 135 B-Observation
A1C NCT03865342 136 139 I-Observation
: NCT03865342 140 141 O
5.7 NCT03865342 142 145 B-Eq-Comparison
- NCT03865342 146 147 I-Eq-Comparison
6.4 NCT03865342 148 151 I-Eq-Comparison
within NCT03865342 152 158 B-Eq-Comparison
the NCT03865342 159 162 I-Eq-Comparison
3 NCT03865342 163 164 I-Eq-Comparison
months NCT03865342 165 171 I-Eq-Comparison
prior NCT03865342 172 177 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865342 178 180 O
enrollment NCT03865342 181 191 B-Study

- NCT03865342 194 195 O
Own NCT03865342 197 200 O
a NCT03865342 201 202 O
smartphone NCT03865342 203 213 O
( NCT03865342 214 215 O
Apple NCT03865342 216 221 O
or NCT03865342 222 224 O
Android NCT03865342 225 232 O
) NCT03865342 233 234 O

Exclusion NCT03865342 236 245 O
criteria NCT03865342 246 254 O
: NCT03865342 255 256 O

- NCT03865342 260 261 O
Recent NCT03865342 263 269 B-Eq-Comparison
weight NCT03865342 270 276 B-Condition|Observation
loss NCT03865342 277 281 I-Condition|Observation
( NCT03865342 282 283 O
by NCT03865342 284 286 O
patient NCT03865342 287 294 O
report NCT03865342 295 301 O
, NCT03865342 302 303 O
> NCT03865342 304 305 B-Eq-Comparison
5 NCT03865342 306 307 I-Eq-Comparison
lbs NCT03865342 308 311 I-Eq-Comparison
in NCT03865342 312 314 B-Eq-Comparison
the NCT03865342 315 318 I-Eq-Comparison
6 NCT03865342 319 320 I-Eq-Comparison
months NCT03865342 321 327 I-Eq-Comparison
preceding NCT03865342 328 337 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03865342 338 348 B-Study
visit NCT03865342 349 354 O
) NCT03865342 355 356 O

- NCT03865342 360 361 O
previous NCT03865342 363 371 B-Eq-Comparison
diagnosis NCT03865342 372 381 O
of NCT03865342 382 384 O
type NCT03865342 385 389 B-Modifier|Modifier
1 NCT03865342 390 391 I-Modifier
or NCT03865342 392 394 B-Or
type NCT03865342 395 399 O
2 NCT03865342 400 401 I-Modifier
diabetes NCT03865342 402 410 B-Condition

- NCT03865342 413 414 O
serious NCT03865342 416 423 O
or NCT03865342 424 426 B-Or
persistent NCT03865342 427 437 B-Modifier
mental NCT03865342 438 444 B-Condition
illnesses NCT03865342 445 454 I-Condition

- NCT03865342 457 458 O
more NCT03865342 460 464 B-Eq-Comparison
than NCT03865342 465 469 I-Eq-Comparison
72 NCT03865342 470 472 I-Eq-Comparison
hours NCT03865342 473 478 I-Eq-Comparison
of NCT03865342 479 481 O
hospitalization NCT03865342 482 497 B-Encounter
in NCT03865342 498 500 B-Eq-Comparison
the NCT03865342 501 504 I-Eq-Comparison
last NCT03865342 505 509 I-Eq-Comparison
30 NCT03865342 510 512 I-Eq-Comparison
days NCT03865342 513 517 I-Eq-Comparison

- NCT03865342 520 521 O
Enrollment NCT03865342 523 533 O
in NCT03865342 534 536 O
a NCT03865342 537 538 O
structured NCT03865342 539 549 O
weight NCT03865342 550 556 B-Procedure
- NCT03865342 557 558 I-Procedure
loss NCT03865342 559 563 I-Procedure
program NCT03865342 564 571 I-Procedure
currently NCT03865342 572 581 B-Eq-Comparison
or NCT03865342 582 584 B-Or
within NCT03865342 585 591 B-Eq-Comparison
the NCT03865342 592 595 I-Eq-Comparison
1 NCT03865342 596 597 I-Eq-Comparison
month NCT03865342 598 603 I-Eq-Comparison
preceding NCT03865342 604 613 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03865342 614 619 B-Study
enrollment NCT03865342 620 630 O

- NCT03865342 633 634 O
Pregnant NCT03865342 636 644 B-Condition

- NCT03865342 647 648 O
Currently NCT03865342 650 659 B-Eq-Comparison
nursing NCT03865342 660 667 B-Condition

- NCT03865342 670 671 O
Have NCT03865342 673 677 O
given NCT03865342 678 683 B-Condition
birth NCT03865342 684 689 I-Condition
within NCT03865342 690 696 B-Eq-Comparison
the NCT03865342 697 700 I-Eq-Comparison
past NCT03865342 701 705 I-Eq-Comparison
3 NCT03865342 706 707 I-Eq-Comparison
months NCT03865342 708 714 I-Eq-Comparison

- NCT03865342 717 718 O
Has NCT03865342 720 723 O
been NCT03865342 724 728 O
discouraged NCT03865342 729 740 B-Assertion___Assertion-Type-Value:hypothetical|Negation
by NCT03865342 741 743 O
a NCT03865342 744 745 O
physician NCT03865342 746 755 B-Provider
to NCT03865342 756 758 O
enroll NCT03865342 759 765 O
in NCT03865342 766 768 O
a NCT03865342 769 770 O
DPP NCT03865342 771 774 B-Procedure
program NCT03865342 775 782 I-Procedure

Inclusion NCT03863678 0 9 O
Criteria NCT03863678 10 18 O
: NCT03863678 19 20 O

- NCT03863678 24 25 O
First NCT03863678 27 32 B-Eq-Comparison
time NCT03863678 33 37 I-Eq-Comparison
stroke NCT03863678 38 44 B-Condition
, NCT03863678 45 46 O

- NCT03863678 50 51 O
Patients NCT03863678 53 61 O
who NCT03863678 62 65 O
has NCT03863678 66 69 O
spasticity NCT03863678 70 80 B-Condition
due NCT03863678 81 84 O
to NCT03863678 85 87 O
stroke NCT03863678 88 94 B-Condition
, NCT03863678 95 96 O

- NCT03863678 100 101 O
At NCT03863678 103 105 B-Eq-Comparison
least NCT03863678 106 111 I-Eq-Comparison
6 NCT03863678 112 113 I-Eq-Comparison
months NCT03863678 114 120 I-Eq-Comparison
after NCT03863678 121 126 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stroke NCT03863678 127 133 B-Condition
, NCT03863678 134 135 O

- NCT03863678 139 140 O
Individuals NCT03863678 142 153 O
between NCT03863678 154 161 B-Eq-Comparison
the NCT03863678 162 165 I-Eq-Comparison
ages NCT03863678 166 170 I-Age|Eq-Comparison
of NCT03863678 171 173 I-Eq-Comparison
18 NCT03863678 174 176 I-Eq-Comparison
- NCT03863678 177 178 I-Eq-Comparison
75 NCT03863678 179 181 I-Eq-Comparison
will NCT03863678 182 186 O
be NCT03863678 187 189 O
included NCT03863678 190 198 O
in NCT03863678 199 201 O
the NCT03863678 202 205 O
study NCT03863678 206 211 B-Study
. NCT03863678 211 212 O

Exclusion NCT03863678 214 223 O
Criteria NCT03863678 224 232 O
: NCT03863678 233 234 O

- NCT03863678 238 239 O
Any NCT03863678 241 244 O
contraindication NCT03863678 245 261 B-Contraindication
for NCT03863678 262 265 O
dry NCT03863678 266 269 B-Procedure
needling NCT03863678 270 278 I-Procedure
( NCT03863678 279 280 O
eg NCT03863678 281 283 O
, NCT03863678 284 285 O
anticoagulants NCT03863678 286 300 B-Drug
, NCT03863678 301 302 O
infections NCT03863678 303 313 B-Condition
, NCT03863678 314 315 O
bleeding NCT03863678 316 324 B-Condition
, NCT03863678 325 326 O
etc NCT03863678 327 330 O
. NCT03863678 330 331 O
) NCT03863678 332 333 O
, NCT03863678 335 336 O

- NCT03863678 340 341 O
Having NCT03863678 343 349 B-Eq-Comparison|Eq-Comparison
diabetes NCT03863678 350 358 B-Condition
, NCT03863678 359 360 O

- NCT03863678 364 365 O
Having NCT03863678 367 373 O
cardiovascular NCT03863678 374 388 B-Condition
diseases NCT03863678 389 397 I-Condition
, NCT03863678 398 399 O

- NCT03863678 403 404 O
Having NCT03863678 406 412 B-Eq-Comparison
any NCT03863678 413 416 O
other NCT03863678 417 422 B-Other
neurological NCT03863678 423 435 B-Condition
problems NCT03863678 436 444 I-Condition
, NCT03863678 445 446 O

- NCT03863678 450 451 O
Application NCT03863678 453 464 O
of NCT03863678 465 467 O
Botox NCT03863678 468 473 B-Procedure
within NCT03863678 474 480 B-Eq-Comparison
6 NCT03863678 481 482 I-Eq-Comparison
months NCT03863678 483 489 I-Eq-Comparison
prior NCT03863678 490 495 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863678 496 498 O
the NCT03863678 499 502 O
study NCT03863678 503 508 B-Study
, NCT03863678 509 510 O

- NCT03863678 514 515 O
Individuals NCT03863678 517 528 O
included NCT03863678 529 537 O
in NCT03863678 538 540 O
another NCT03863678 541 548 B-Other
treatment NCT03863678 549 558 B-Procedure
program NCT03863678 559 566 I-Procedure
will NCT03863678 567 571 O
not NCT03863678 572 575 B-Negation
be NCT03863678 576 578 O
included NCT03863678 579 587 O
in NCT03863678 588 590 O
the NCT03863678 591 594 O
study NCT03863678 595 600 B-Study
. NCT03863678 600 601 O

Inclusion NCT03867344 0 9 O
Criteria NCT03867344 10 18 O
: NCT03867344 19 20 O

- NCT03867344 24 25 O
Healthy NCT03867344 27 34 B-Condition
volunteers NCT03867344 35 45 O

- NCT03867344 48 49 O
Males NCT03867344 51 56 O
and NCT03867344 57 60 B-Or
Females NCT03867344 61 68 O
age NCT03867344 69 72 B-Age
18 NCT03867344 73 75 B-Eq-Comparison
to NCT03867344 76 78 I-Eq-Comparison
45 NCT03867344 79 81 I-Eq-Comparison
years NCT03867344 82 87 I-Eq-Comparison

- NCT03867344 90 91 O
BMI NCT03867344 93 96 B-Observation
18 NCT03867344 97 99 B-Eq-Comparison
- NCT03867344 100 101 I-Eq-Comparison
30 NCT03867344 102 104 I-Eq-Comparison
kg NCT03867344 105 107 I-Eq-Comparison
/ NCT03867344 108 109 I-Eq-Comparison
m2 NCT03867344 110 112 I-Eq-Comparison

Exclusion NCT03867344 113 122 O
Criteria NCT03867344 123 131 O
: NCT03867344 132 133 O

- NCT03867344 137 138 O
Pregnancy NCT03867344 140 149 B-Condition

- NCT03867344 152 153 O
Lactation NCT03867344 155 164 B-Condition

- NCT03867344 167 168 O
Menopause NCT03867344 170 179 B-Condition

- NCT03867344 182 183 O
Any NCT03867344 185 188 O
medical NCT03867344 189 196 B-Condition
condition NCT03867344 197 206 I-Condition

- NCT03867344 209 210 O
Current NCT03867344 212 219 B-Eq-Comparison
or NCT03867344 220 222 B-Or
prior NCT03867344 223 228 B-Eq-Comparison
alcohol NCT03867344 229 236 B-Modifier
or NCT03867344 237 239 B-Or
drug NCT03867344 240 244 B-Modifier
abuse NCT03867344 245 250 B-Condition

- NCT03867344 253 254 O
Active NCT03867344 256 262 B-Eq-Comparison
tobacco NCT03867344 263 270 B-Condition
use NCT03867344 271 274 I-Condition

- NCT03867344 277 278 O
Abnormal NCT03867344 280 288 O
ECG NCT03867344 289 292 B-Procedure

- NCT03867344 295 296 O
In NCT03867344 298 300 O
all NCT03867344 301 304 O
subjects NCT03867344 305 313 O
, NCT03867344 314 315 O
any NCT03867344 316 319 O
individuals NCT03867344 320 331 O
on NCT03867344 332 334 O
oral NCT03867344 335 339 B-Modifier
, NCT03867344 340 341 O
injected NCT03867344 342 350 B-Modifier
, NCT03867344 351 352 O
inhaled NCT03867344 353 360 B-Modifier
or NCT03867344 361 363 B-Or
topical NCT03867344 364 371 B-Modifier
corticosteroids NCT03867344 372 387 B-Drug
within NCT03867344 388 394 B-Eq-Comparison
the NCT03867344 395 398 I-Eq-Comparison
last NCT03867344 399 403 I-Eq-Comparison
year NCT03867344 404 408 I-Eq-Comparison
or NCT03867344 409 411 B-Or
oral NCT03867344 412 416 O
contraceptives NCT03867344 417 431 B-Drug
within NCT03867344 432 438 B-Eq-Comparison
the NCT03867344 439 442 I-Eq-Comparison
past NCT03867344 443 447 I-Eq-Comparison
3 NCT03867344 448 449 I-Eq-Comparison
months NCT03867344 450 456 I-Eq-Comparison
will NCT03867344 457 461 O
be NCT03867344 462 464 O
excluded NCT03867344 465 473 B-Negation
. NCT03867344 473 474 O

- NCT03867344 478 479 O
Use NCT03867344 481 484 O
of NCT03867344 485 487 O
medications NCT03867344 488 499 B-Drug

- NCT03867344 502 503 O
Serum NCT03867344 505 510 B-Observation
potassium NCT03867344 511 520 I-Observation
> NCT03867344 521 522 B-Eq-Comparison
5.0 NCT03867344 523 526 I-Eq-Comparison
mmol NCT03867344 527 531 I-Eq-Comparison
/ NCT03867344 532 533 I-Eq-Comparison
L NCT03867344 534 535 I-Eq-Comparison

- NCT03867344 538 539 O
Estimated NCT03867344 541 550 B-Observation
GFR NCT03867344 551 554 I-Observation
< NCT03867344 555 556 B-Eq-Comparison
60 NCT03867344 557 559 I-Eq-Comparison
mL NCT03867344 560 562 I-Eq-Comparison
/ NCT03867344 563 564 I-Eq-Comparison
min NCT03867344 565 568 I-Eq-Comparison
/ NCT03867344 569 570 O
1.73 NCT03867344 571 575 I-Eq-Comparison
m2 NCT03867344 576 578 I-Eq-Comparison

- NCT03867344 581 582 O
Hemoglobin NCT03867344 584 594 B-Observation
A1c NCT03867344 595 598 I-Observation
≥ NCT03867344 599 600 B-Eq-Comparison
6.5 NCT03867344 601 604 I-Eq-Comparison
% NCT03867344 605 606 O

- NCT03867344 609 610 O
LDL NCT03867344 612 615 B-Observation
> NCT03867344 616 617 B-Eq-Comparison
130 NCT03867344 618 621 I-Eq-Comparison
mg NCT03867344 622 624 I-Eq-Comparison
/ NCT03867344 625 626 I-Eq-Comparison
dL NCT03867344 627 629 I-Eq-Comparison|Eq-Comparison
; NCT03867344 629 630 O
Triglycerides NCT03867344 631 644 B-Observation
> NCT03867344 645 646 B-Eq-Comparison
150 NCT03867344 647 650 I-Eq-Comparison
mg NCT03867344 651 653 I-Eq-Comparison
/ NCT03867344 654 655 I-Eq-Comparison
dL NCT03867344 656 658 O

- NCT03867344 661 662 O
Patient NCT03867344 664 671 B-Observation
Health NCT03867344 672 678 I-Observation
Questionnaire NCT03867344 679 692 I-Observation
( NCT03867344 693 694 O
PHQ9 NCT03867344 695 699 B-Observation
) NCT03867344 700 701 O
for NCT03867344 702 705 O
depression NCT03867344 706 716 O
score NCT03867344 717 722 O
≥ NCT03867344 723 724 B-Eq-Comparison
15 NCT03867344 725 727 I-Eq-Comparison

- NCT03867344 731 732 I-Observation
GAD NCT03867344 734 737 B-Observation
- NCT03867344 738 739 O
73 NCT03867344 740 742 I-Observation
Questionnaire NCT03867344 743 756 I-Observation
for NCT03867344 757 760 O
anxiety NCT03867344 761 768 O
score NCT03867344 769 774 O
≥ NCT03867344 775 776 B-Eq-Comparison
10 NCT03867344 777 779 I-Eq-Comparison

- NCT03867344 783 784 O
Primary NCT03867344 786 793 B-Modifier
Care NCT03867344 794 798 I-Modifier
PTSD NCT03867344 799 803 B-Condition
Screen NCT03867344 804 810 B-Procedure
for NCT03867344 811 814 O
DSM NCT03867344 815 818 O
- NCT03867344 819 820 I-Observation
5 NCT03867344 821 822 O
for NCT03867344 823 826 O
post NCT03867344 827 831 B-Observation
- NCT03867344 832 833 O
traumatic NCT03867344 834 843 I-Observation
stress NCT03867344 844 850 I-Observation
disorder NCT03867344 851 859 I-Observation
score NCT03867344 860 865 I-Observation
≥ NCT03867344 866 867 B-Eq-Comparison|Eq-Comparison
10 NCT03867344 868 870 I-Eq-Comparison|Eq-Comparison

- NCT03867344 874 875 O
Blood NCT03867344 877 882 B-Observation
pressure NCT03867344 883 891 I-Observation|Observation
systolic NCT03867344 892 900 I-Observation
≥ NCT03867344 901 902 O
140 NCT03867344 903 906 I-Eq-Comparison
or NCT03867344 907 909 B-Or
< NCT03867344 910 911 B-Eq-Comparison
100 NCT03867344 912 915 O
mmHg NCT03867344 916 920 I-Eq-Comparison|Eq-Comparison
; NCT03867344 920 921 O
Blood NCT03867344 922 927 B-Observation
pressure NCT03867344 928 936 O
diastolic NCT03867344 937 946 I-Observation
> NCT03867344 947 948 B-Eq-Comparison
90 NCT03867344 949 951 I-Eq-Comparison
mmHg NCT03867344 952 956 O

- NCT03867344 959 960 O
Metal NCT03867344 962 967 B-Condition
in NCT03867344 968 970 I-Condition
the NCT03867344 971 974 I-Condition
body NCT03867344 975 979 I-Condition
including NCT03867344 980 989 O
: NCT03867344 990 991 O
cardiac NCT03867344 992 999 B-Procedure
pacemakers NCT03867344 1000 1010 I-Procedure
, NCT03867344 1011 1012 O
stents NCT03867344 1013 1019 B-Procedure
, NCT03867344 1020 1021 O
artificial NCT03867344 1022 1032 B-Procedure|Procedure
heart NCT03867344 1033 1038 I-Procedure
valves NCT03867344 1039 1045 I-Procedure
, NCT03867344 1046 1047 O
artificial NCT03867344 1048 1058 O
limbs NCT03867344 1059 1064 B-Modifier
or NCT03867344 1065 1067 B-Or
hands NCT03867344 1068 1073 B-Modifier
, NCT03867344 1074 1075 O
brain NCT03867344 1076 1081 B-Procedure
stimulator NCT03867344 1082 1092 I-Procedure
devices NCT03867344 1093 1100 I-Procedure
, NCT03867344 1101 1102 O
implanted NCT03867344 1103 1112 B-Procedure
drug NCT03867344 1113 1117 I-Procedure
pumps NCT03867344 1118 1123 I-Procedure
, NCT03867344 1124 1125 O
ear NCT03867344 1126 1129 B-Procedure
implants NCT03867344 1130 1138 I-Procedure|Procedure
, NCT03867344 1139 1140 O
eye NCT03867344 1141 1144 B-Modifier|Procedure
implants NCT03867344 1145 1153 O
or NCT03867344 1154 1156 B-Or
known NCT03867344 1157 1162 O
metal NCT03867344 1163 1168 B-Condition|Modifier
fragments NCT03867344 1169 1178 I-Condition
in NCT03867344 1179 1181 O
eyes NCT03867344 1182 1186 O
, NCT03867344 1187 1188 O
exposure NCT03867344 1189 1197 B-Condition
to NCT03867344 1198 1200 O
shrapnel NCT03867344 1201 1209 B-Modifier
or NCT03867344 1210 1212 B-Or
metal NCT03867344 1213 1218 I-Observation
filings NCT03867344 1219 1226 I-Modifier
( NCT03867344 1227 1228 O
wounded NCT03867344 1229 1236 B-Condition
in NCT03867344 1237 1239 I-Condition
military NCT03867344 1240 1248 I-Condition
combat NCT03867344 1249 1255 I-Condition
, NCT03867344 1256 1257 O
sheet NCT03867344 1258 1263 B-Observation
metal NCT03867344 1264 1269 B-Procedure
workers NCT03867344 1270 1277 I-Observation
, NCT03867344 1278 1279 O
welders NCT03867344 1280 1287 B-Observation
, NCT03867344 1288 1289 O
and NCT03867344 1290 1293 O
others NCT03867344 1294 1300 B-Other
) NCT03867344 1301 1302 O
, NCT03867344 1304 1305 O
other NCT03867344 1306 1311 O
metallic NCT03867344 1312 1320 O
surgical NCT03867344 1321 1329 I-Procedure
hardware NCT03867344 1330 1338 I-Procedure
in NCT03867344 1339 1341 I-Modifier
vital NCT03867344 1342 1347 B-Modifier
areas NCT03867344 1348 1353 I-Modifier
, NCT03867344 1354 1355 O
certain NCT03867344 1356 1363 O
tattoos NCT03867344 1364 1371 B-Condition
with NCT03867344 1372 1376 O
metallic NCT03867344 1377 1385 B-Modifier|Procedure
ink NCT03867344 1386 1389 O
, NCT03867344 1390 1391 O
certain NCT03867344 1392 1399 O
transdermal NCT03867344 1400 1411 B-Procedure
medication NCT03867344 1412 1422 I-Procedure
patches NCT03867344 1423 1430 I-Procedure
, NCT03867344 1431 1432 O
and NCT03867344 1433 1436 B-Or
metal NCT03867344 1437 1442 O
- NCT03867344 1443 1444 I-Procedure
containing NCT03867344 1445 1455 I-Procedure
IUDs NCT03867344 1456 1460 I-Procedure

Inclusion NCT03867422 0 9 O
Criteria NCT03867422 10 18 O
: NCT03867422 19 20 O

- NCT03867422 24 25 O
more NCT03867422 27 31 B-Eq-Comparison
or NCT03867422 32 34 I-Eq-Comparison
equal NCT03867422 35 40 I-Eq-Comparison
18 NCT03867422 41 43 I-Eq-Comparison
years NCT03867422 44 49 I-Eq-Comparison
- NCT03867422 50 51 O
old NCT03867422 52 55 B-Age
and NCT03867422 56 59 B-And
less NCT03867422 60 64 B-Eq-Comparison
or NCT03867422 65 67 I-Eq-Comparison
equal NCT03867422 68 73 I-Eq-Comparison
45 NCT03867422 74 76 I-Eq-Comparison
years NCT03867422 77 82 I-Eq-Comparison
- NCT03867422 83 84 O
old NCT03867422 85 88 B-Age

- NCT03867422 91 92 O
no NCT03867422 94 96 B-Negation
known NCT03867422 97 102 O
hearing NCT03867422 103 110 B-Condition
problem NCT03867422 111 118 I-Condition

Exclusion NCT03867422 119 128 O
Criteria NCT03867422 129 137 O
: NCT03867422 138 139 O

- NCT03867422 143 144 O
professional NCT03867422 146 158 B-Observation
musician NCT03867422 159 167 I-Observation

- NCT03867422 170 171 O
history NCT03867422 173 180 B-Eq-Comparison
of NCT03867422 181 183 O
neurologic NCT03867422 184 194 B-Modifier
, NCT03867422 195 196 O
psychiatric NCT03867422 197 208 B-Modifier
or NCT03867422 209 211 O
cadiologic NCT03867422 212 222 B-Modifier
disease NCT03867422 223 230 B-Condition

- NCT03867422 233 234 O
treatment NCT03867422 236 245 B-Procedure
which NCT03867422 246 251 O
could NCT03867422 252 257 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03867422 258 264 O
parameters NCT03867422 265 275 B-Observation
of NCT03867422 276 278 O
brain NCT03867422 279 284 B-Modifier
tissue NCT03867422 285 291 I-Modifier
pulsatility NCT03867422 292 303 I-Modifier
and NCT03867422 304 307 O
peripheral NCT03867422 308 318 B-Modifier
nervous NCT03867422 319 326 I-Modifier
system NCT03867422 327 333 I-Modifier

- NCT03867422 336 337 O
opposition NCT03867422 339 349 O
to NCT03867422 350 352 O
use NCT03867422 353 356 O
the NCT03867422 357 360 O
data NCT03867422 361 365 O

Inclusion NCT03861286 0 9 O
Criteria NCT03861286 10 18 O
: NCT03861286 19 20 O

1 NCT03861286 24 25 O
. NCT03861286 25 26 O
Patients NCT03861286 28 36 O
undergoing NCT03861286 37 47 B-Eq-Comparison
first NCT03861286 48 53 B-Eq-Comparison
time NCT03861286 54 58 I-Eq-Comparison
cardiopulmonary NCT03861286 59 74 B-Procedure
bypass NCT03861286 75 81 I-Procedure
surgery NCT03861286 82 89 I-Procedure
for NCT03861286 90 93 O
correction NCT03861286 94 104 O
of NCT03861286 105 107 O
atrial NCT03861286 108 114 B-Condition
septal NCT03861286 115 121 I-Condition
defects NCT03861286 122 129 I-Condition
or NCT03861286 130 132 B-Or
tissue NCT03861286 133 139 B-Procedure
mitral NCT03861286 140 146 I-Procedure
valve NCT03861286 147 152 I-Procedure
repair NCT03861286 153 159 I-Procedure

2 NCT03861286 162 163 O
. NCT03861286 163 164 O
Receiving NCT03861286 166 175 B-Eq-Comparison
intravenous NCT03861286 176 187 B-Modifier
Heparin NCT03861286 188 195 B-Drug
for NCT03861286 196 199 O
cardiopulmonary NCT03861286 200 215 B-Procedure
bypass NCT03861286 216 222 I-Procedure

Exclusion NCT03861286 223 232 O
Criteria NCT03861286 233 241 O
: NCT03861286 242 243 O

- NCT03861286 247 248 O
Concomitant NCT03861286 250 261 B-Modifier
Aortic NCT03861286 262 268 B-Condition
Stenosis NCT03861286 269 277 I-Condition
which NCT03861286 278 283 O
is NCT03861286 284 286 O
associated NCT03861286 287 297 O
with NCT03861286 298 302 O
an NCT03861286 303 305 O
acquired NCT03861286 306 314 B-Condition
von NCT03861286 315 318 I-Condition
Willebrand NCT03861286 319 329 I-Condition
Syndrome NCT03861286 330 338 I-Condition
( NCT03861286 339 340 O
aVWS NCT03861286 341 345 B-Condition
) NCT03861286 346 347 O

- NCT03861286 351 352 O
Patients NCT03861286 354 362 O
with NCT03861286 363 367 O
a NCT03861286 368 369 O
baseline NCT03861286 370 378 O
platelet NCT03861286 379 387 B-Observation
count NCT03861286 388 393 I-Observation
of NCT03861286 394 396 O
< NCT03861286 397 398 B-Eq-Comparison
100 NCT03861286 399 402 I-Eq-Comparison
x109 NCT03861286 403 407 O
/ NCT03861286 408 409 I-Eq-Comparison
L NCT03861286 410 411 I-Eq-Comparison

- NCT03861286 414 415 O
Patients NCT03861286 417 425 O
with NCT03861286 426 430 O
a NCT03861286 431 432 O
known NCT03861286 433 438 O
coagulation NCT03861286 439 450 B-Condition
factor NCT03861286 451 457 I-Condition
deficiency NCT03861286 458 468 I-Condition
or NCT03861286 469 471 B-Or
platelet NCT03861286 472 480 B-Condition
function NCT03861286 481 489 I-Condition
disorder NCT03861286 490 498 I-Condition

- NCT03861286 501 502 O
Patients NCT03861286 504 512 O
receiving NCT03861286 513 522 B-Eq-Comparison
heparin NCT03861286 523 530 B-Procedure
therapy NCT03861286 531 538 I-Procedure
prior NCT03861286 539 544 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861286 545 547 I-Temporal-Connection___Temporal-Connection-Type-Value:before
CPB NCT03861286 548 551 B-Procedure
within NCT03861286 552 558 B-Eq-Comparison
last NCT03861286 559 563 I-Eq-Comparison
7 NCT03861286 564 565 I-Eq-Comparison
days NCT03861286 566 570 I-Eq-Comparison

Inclusion NCT03864315 0 9 O
Criteria NCT03864315 10 18 O
: NCT03864315 19 20 O

1 NCT03864315 24 25 O
. NCT03864315 25 26 O
20 NCT03864315 28 30 B-Eq-Comparison
- NCT03864315 31 32 I-Eq-Comparison
75 NCT03864315 33 35 I-Eq-Comparison
years NCT03864315 36 41 I-Eq-Comparison
old NCT03864315 42 45 B-Age

2 NCT03864315 48 49 O
. NCT03864315 49 50 O
With NCT03864315 52 56 O
skin NCT03864315 57 61 B-Condition
type NCT03864315 62 66 I-Condition
Ⅲ NCT03864315 67 68 B-Eq-Comparison
or NCT03864315 69 71 I-Eq-Comparison
Ⅳ NCT03864315 72 73 I-Eq-Comparison

3 NCT03864315 76 77 O
. NCT03864315 77 78 O
With NCT03864315 80 84 O
Vitiligo NCT03864315 85 93 B-Condition

4 NCT03864315 96 97 O
. NCT03864315 97 98 O
Can NCT03864315 100 103 O
read NCT03864315 104 108 O
the NCT03864315 109 112 O
informed NCT03864315 113 121 O
consent NCT03864315 122 129 O
form NCT03864315 130 134 O

5 NCT03864315 137 138 O
. NCT03864315 138 139 O
Can NCT03864315 141 144 O
continue NCT03864315 145 153 O
the NCT03864315 154 157 O
original NCT03864315 158 166 O
treatments NCT03864315 167 177 O

Exclusion NCT03864315 178 187 O
Criteria NCT03864315 188 196 O
: NCT03864315 197 198 O

1 NCT03864315 202 203 O
. NCT03864315 203 204 O
With NCT03864315 206 210 O
segmental NCT03864315 211 220 B-Modifier
vitiligo NCT03864315 221 229 B-Condition
. NCT03864315 229 230 O

2 NCT03864315 234 235 O
. NCT03864315 235 236 O
Have NCT03864315 238 242 O
joined NCT03864315 243 249 O
other NCT03864315 250 255 B-Other
clinical NCT03864315 256 264 B-Study
trials NCT03864315 265 271 I-Study

Inclusion NCT03865745 0 9 O
Criteria NCT03865745 10 18 O
: NCT03865745 19 20 O

1 NCT03865745 24 25 O
. NCT03865745 25 26 O
Age NCT03865745 28 31 B-Age
of NCT03865745 32 34 O
40 NCT03865745 35 37 B-Eq-Comparison
~ NCT03865745 38 39 O
75 NCT03865745 40 42 O
men NCT03865745 43 46 O
and NCT03865745 47 50 B-Or
women NCT03865745 51 56 O

2 NCT03865745 59 60 O
. NCT03865745 60 61 O
Those NCT03865745 63 68 O
who NCT03865745 69 72 O
visited NCT03865745 73 80 B-Encounter
the NCT03865745 81 84 O
menopausal NCT03865745 85 95 O
clinic NCT03865745 96 102 O
with NCT03865745 103 107 B-And
complaints NCT03865745 108 118 O
of NCT03865745 119 121 O
climacteric NCT03865745 122 133 B-Condition
symptoms NCT03865745 134 142 B-Assertion___Assertion-Type-Value:possible
due NCT03865745 143 146 O
to NCT03865745 147 149 O
functional NCT03865745 150 160 O
deterioration NCT03865745 161 174 B-Condition
of NCT03865745 175 177 I-Condition
various NCT03865745 178 185 I-Condition
organs NCT03865745 186 192 I-Condition
such NCT03865745 193 197 O
as NCT03865745 198 200 O
fatigue NCT03865745 201 208 B-Condition
, NCT03865745 209 210 O
helplessness NCT03865745 211 223 B-Condition

3 NCT03865745 226 227 O
. NCT03865745 227 228 O
Those NCT03865745 230 235 O
who NCT03865745 236 239 O
have NCT03865745 240 244 O
agreed NCT03865745 245 251 O
to NCT03865745 252 254 O
voluntarily NCT03865745 255 266 O
decide NCT03865745 267 273 O
to NCT03865745 274 276 O
participate NCT03865745 277 288 O
and NCT03865745 289 292 O
observe NCT03865745 293 300 O
the NCT03865745 301 304 O
instructions NCT03865745 305 317 O
after NCT03865745 318 323 O
hearing NCT03865745 324 331 O
the NCT03865745 332 335 O
detailed NCT03865745 336 344 O
explanation NCT03865745 345 356 O
of NCT03865745 357 359 O
this NCT03865745 360 364 O
human NCT03865745 365 370 O
body NCT03865745 371 375 O
application NCT03865745 376 387 O
test NCT03865745 388 392 O

Exclusion NCT03865745 393 402 O
Criteria NCT03865745 403 411 O
: NCT03865745 412 413 O

1 NCT03865745 417 418 O
. NCT03865745 418 419 O
Those NCT03865745 421 426 O
who NCT03865745 427 430 O
have NCT03865745 431 435 O
suspected NCT03865745 436 445 B-Assertion___Assertion-Type-Value:possible
symptoms NCT03865745 446 454 I-Assertion___Assertion-Type-Value:possible
of NCT03865745 455 457 O
acute NCT03865745 458 463 O
disease NCT03865745 464 471 B-Condition
( NCT03865745 472 473 O
severe NCT03865745 474 480 O
infectious NCT03865745 481 491 B-Condition
disease NCT03865745 492 499 I-Condition
, NCT03865745 500 501 O
severe NCT03865745 502 508 O
trauma NCT03865745 509 515 B-Condition
, NCT03865745 516 517 O
severe NCT03865745 518 524 O
diarrhea NCT03865745 525 533 B-Condition
, NCT03865745 534 535 O
vomiting NCT03865745 536 544 B-Condition
, NCT03865745 545 546 O
etc NCT03865745 547 550 O
. NCT03865745 550 551 O
) NCT03865745 552 553 O

2 NCT03865745 557 558 O
. NCT03865745 558 559 O
Patients NCT03865745 561 569 O
with NCT03865745 570 574 O
a NCT03865745 575 576 O
history NCT03865745 577 584 B-Eq-Comparison
of NCT03865745 585 587 O
antibiotic NCT03865745 588 598 B-Drug
treatment NCT03865745 599 608 B-Procedure
for NCT03865745 609 612 O
more NCT03865745 613 617 B-Eq-Comparison
than NCT03865745 618 622 I-Eq-Comparison
1 NCT03865745 623 624 I-Eq-Comparison
month NCT03865745 625 630 I-Eq-Comparison
within NCT03865745 631 637 B-Eq-Comparison
the NCT03865745 638 641 I-Eq-Comparison
last NCT03865745 642 646 I-Eq-Comparison
6 NCT03865745 647 648 I-Eq-Comparison
months NCT03865745 649 655 I-Eq-Comparison

3 NCT03865745 663 664 O
. NCT03865745 664 665 O
Those NCT03865745 667 672 O
who NCT03865745 673 676 O
have NCT03865745 677 681 O
gastrointestinal NCT03865745 682 698 B-Condition
diseases NCT03865745 699 707 I-Condition
( NCT03865745 708 709 O
inflammatory NCT03865745 710 722 B-Condition
growth NCT03865745 723 729 I-Condition
disease NCT03865745 730 737 I-Condition
, NCT03865745 738 739 O
active NCT03865745 740 746 B-Condition
peptic NCT03865745 747 753 I-Condition
ulcer NCT03865745 754 759 I-Condition
, NCT03865745 760 761 O
etc NCT03865745 762 765 O
. NCT03865745 765 766 O
) NCT03865745 767 768 O
or NCT03865745 769 771 B-Or
gastrointestinal NCT03865745 772 788 B-Procedure
surgery NCT03865745 789 796 I-Procedure
( NCT03865745 797 798 O
except NCT03865745 799 805 B-Exception
for NCT03865745 806 809 O
simple NCT03865745 810 816 B-Modifier
appendectomy NCT03865745 817 829 B-Procedure
or NCT03865745 830 832 B-Or
hernia NCT03865745 833 839 B-Procedure
surgery NCT03865745 840 847 I-Procedure
) NCT03865745 848 849 O

4 NCT03865745 853 854 O
. NCT03865745 854 855 O
Those NCT03865745 857 862 O
taking NCT03865745 863 869 B-Eq-Comparison
health NCT03865745 870 876 B-Drug
functional NCT03865745 877 887 I-Drug
foods NCT03865745 888 893 I-Drug
, NCT03865745 894 895 O
lactic NCT03865745 896 902 B-Drug
acid NCT03865745 903 907 I-Drug
bacteria NCT03865745 908 916 I-Drug
, NCT03865745 917 918 O
and NCT03865745 919 922 B-Or
red NCT03865745 923 926 B-Drug
ginseng NCT03865745 927 934 I-Drug
extracts NCT03865745 935 943 I-Drug
for NCT03865745 944 947 O
the NCT03865745 948 951 O
past NCT03865745 952 956 B-Eq-Comparison
year NCT03865745 957 961 I-Eq-Comparison

5 NCT03865745 964 965 O
. NCT03865745 965 966 O
Those NCT03865745 968 973 O
who NCT03865745 974 977 O
are NCT03865745 978 981 O
currently NCT03865745 982 991 B-Eq-Comparison
participating NCT03865745 992 1005 O
in NCT03865745 1006 1008 O
other NCT03865745 1009 1014 B-Other
clinical NCT03865745 1015 1023 B-Study
studies NCT03865745 1024 1031 I-Study
or NCT03865745 1032 1034 B-Or|Or
human NCT03865745 1035 1040 B-Study
trials NCT03865745 1041 1047 I-Study
, NCT03865745 1048 1049 O
or NCT03865745 1050 1052 O
participating NCT03865745 1053 1066 O
in NCT03865745 1067 1069 O
clinical NCT03865745 1070 1078 B-Study
trials NCT03865745 1079 1085 I-Study
or NCT03865745 1086 1088 B-Or
human NCT03865745 1089 1094 B-Study
application NCT03865745 1095 1106 I-Study
tests NCT03865745 1107 1112 I-Study
within NCT03865745 1113 1119 B-Eq-Comparison
the NCT03865745 1120 1123 I-Eq-Comparison
past NCT03865745 1124 1128 I-Eq-Comparison
month NCT03865745 1129 1134 I-Eq-Comparison


Inclusion NCT03863730 0 9 O
Criteria NCT03863730 10 18 O
: NCT03863730 19 20 O

- NCT03863730 24 25 O
Prior NCT03863730 27 32 B-Eq-Comparison
or NCT03863730 33 35 B-Or
ongoing NCT03863730 36 43 B-Eq-Comparison
harmful NCT03863730 44 51 O
alcohol NCT03863730 52 59 B-Drug
intake NCT03863730 60 66 O
defined NCT03863730 67 74 O
as NCT03863730 75 77 O
an NCT03863730 78 80 O
average NCT03863730 81 88 O
of NCT03863730 89 91 O
≥ NCT03863730 92 93 B-Eq-Comparison
24 NCT03863730 94 96 I-Eq-Comparison
g NCT03863730 97 98 O
alcohol NCT03863730 99 106 I-Eq-Comparison
/ NCT03863730 107 108 I-Eq-Comparison
day NCT03863730 109 112 I-Eq-Comparison
for NCT03863730 113 116 O
women NCT03863730 117 122 O
and NCT03863730 123 126 O
≥ NCT03863730 127 128 B-Eq-Comparison
36 NCT03863730 129 131 I-Eq-Comparison
g NCT03863730 132 133 O
/ NCT03863730 134 135 I-Eq-Comparison
d NCT03863730 136 137 I-Eq-Comparison
for NCT03863730 138 141 O
men NCT03863730 142 145 O
for NCT03863730 146 149 O
≥ NCT03863730 150 151 B-Eq-Comparison
5 NCT03863730 152 153 I-Eq-Comparison
year NCT03863730 154 158 I-Eq-Comparison
. NCT03863730 158 159 O

- NCT03863730 168 169 O
Outpatients NCT03863730 171 182 B-Encounter
with NCT03863730 183 187 B-And
compensated NCT03863730 188 199 B-Modifier
advanced NCT03863730 200 208 I-Modifier
chronic NCT03863730 209 216 I-Modifier
alcohol NCT03863730 217 224 B-Drug
- NCT03863730 225 226 O
related NCT03863730 227 234 O
liver NCT03863730 235 240 B-Condition
disease NCT03863730 241 248 I-Condition
, NCT03863730 249 250 O
defined NCT03863730 251 258 O
as NCT03863730 259 261 O
stable NCT03863730 262 268 O
patients NCT03863730 269 277 O
with NCT03863730 278 282 O
: NCT03863730 283 284 O

1 NCT03863730 298 299 O
. NCT03863730 299 300 O
liver NCT03863730 302 307 B-Condition
stiffness NCT03863730 308 317 I-Condition
≥ NCT03863730 318 319 B-Eq-Comparison
15 NCT03863730 320 322 I-Eq-Comparison
kPa NCT03863730 323 326 B-Observation
and NCT03863730 327 330 B-And|Or
asymptomatic NCT03863730 331 343 B-Condition
and NCT03863730 344 347 O
/ NCT03863730 348 349 I-Or
or NCT03863730 350 352 I-Or

2 NCT03863730 365 366 O
. NCT03863730 366 367 O
New NCT03863730 369 372 B-Eq-Comparison
liver NCT03863730 373 378 B-Procedure
biopsy NCT03863730 379 385 I-Procedure
( NCT03863730 386 387 O
< NCT03863730 389 390 B-Eq-Comparison
6 NCT03863730 391 392 I-Eq-Comparison
months NCT03863730 393 399 O
) NCT03863730 400 401 O
with NCT03863730 402 406 B-And
at NCT03863730 407 409 B-Eq-Comparison
least NCT03863730 410 415 I-Eq-Comparison
F3 NCT03863730 416 418 I-Eq-Comparison
fibrosis NCT03863730 419 427 B-Condition
( NCT03863730 428 429 O
kleiner NCT03863730 430 437 B-Modifier
) NCT03863730 438 439 O
and NCT03863730 440 443 B-Or
/ NCT03863730 444 445 I-Or
or NCT03863730 446 448 I-Or

3 NCT03863730 461 462 O
. NCT03863730 462 463 O
Liver NCT03863730 465 470 B-Procedure
biopsy NCT03863730 471 477 I-Procedure
older NCT03863730 478 483 B-Eq-Comparison
that NCT03863730 484 488 I-Eq-Comparison
6 NCT03863730 489 490 I-Eq-Comparison
months NCT03863730 491 497 I-Eq-Comparison
with NCT03863730 498 502 B-And
liver NCT03863730 503 508 B-Condition
stiffness NCT03863730 509 518 I-Condition
≥ NCT03863730 519 520 B-Eq-Comparison
10 NCT03863730 521 523 I-Eq-Comparison
kPa NCT03863730 524 527 B-Observation

- NCT03863730 535 536 O
Understand NCT03863730 538 548 O
and NCT03863730 549 552 O
speak NCT03863730 553 558 O
Danish NCT03863730 559 565 O
written NCT03863730 566 573 O
and NCT03863730 574 577 O
orally NCT03863730 578 584 O

- NCT03863730 592 593 O
Informed NCT03863730 595 603 O
consent NCT03863730 604 611 O

Exclusion NCT03863730 612 621 O
Criteria NCT03863730 622 630 O
: NCT03863730 631 632 O

- NCT03863730 636 637 O
Hospitalised NCT03863730 639 651 B-Encounter

- NCT03863730 654 655 O
Moderete NCT03863730 657 665 O
or NCT03863730 666 668 B-Or
severe NCT03863730 669 675 O
Ascites NCT03863730 676 683 B-Condition
, NCT03863730 684 685 O
determined NCT03863730 686 696 O
from NCT03863730 697 701 O
imaging NCT03863730 702 709 B-Procedure
diagnostics NCT03863730 710 721 I-Procedure

- NCT03863730 724 725 O
High NCT03863730 727 731 O
- NCT03863730 732 733 O
risk NCT03863730 734 738 B-Risk
varices NCT03863730 739 746 B-Condition
needing NCT03863730 747 754 B-Assertion___Assertion-Type-Value:hypothetical
interventional NCT03863730 755 769 B-Procedure
treatment NCT03863730 770 779 I-Procedure
( NCT03863730 780 781 O
endoscopy NCT03863730 782 791 B-Procedure
, NCT03863730 792 793 O
TIPS NCT03863730 794 798 B-Procedure
) NCT03863730 799 800 O

- NCT03863730 804 805 I-Observation
Child NCT03863730 807 812 O
- NCT03863730 813 814 O
Pugh NCT03863730 815 819 O
C NCT03863730 820 821 O
score NCT03863730 822 827 O

- NCT03863730 830 831 O
MELD NCT03863730 833 837 B-Observation
- NCT03863730 838 839 O
Na NCT03863730 840 842 I-Observation
≥ NCT03863730 843 844 B-Eq-Comparison
15 NCT03863730 845 847 I-Eq-Comparison

- NCT03863730 851 852 O
Lactose NCT03863730 854 861 B-Condition
intolerance NCT03863730 862 873 I-Condition

- NCT03863730 876 877 O
Coeliac NCT03863730 879 886 B-Condition
disease NCT03863730 887 894 I-Condition

- NCT03863730 897 898 O
Irritable NCT03863730 900 909 B-Condition
bowel NCT03863730 910 915 I-Condition
syndrome NCT03863730 916 924 I-Condition
defined NCT03863730 925 932 O
by NCT03863730 933 935 O
ROME NCT03863730 936 940 O
III NCT03863730 941 944 O
criteria NCT03863730 945 953 O

- NCT03863730 956 957 O
Antibiotic NCT03863730 959 969 B-Drug
treatment NCT03863730 970 979 B-Procedure
the NCT03863730 980 983 O
prior NCT03863730 984 989 B-Eq-Comparison
3 NCT03863730 990 991 I-Eq-Comparison
months NCT03863730 992 998 I-Eq-Comparison

- NCT03863730 1001 1002 O
Treatment NCT03863730 1004 1013 B-Procedure
with NCT03863730 1014 1018 O
nutritional NCT03863730 1019 1030 B-Drug
drinks NCT03863730 1031 1037 I-Drug
, NCT03863730 1038 1039 O
probiotics NCT03863730 1040 1050 B-Drug
or NCT03863730 1051 1053 B-Or
prebiotics NCT03863730 1054 1064 B-Drug
within NCT03863730 1065 1071 B-Eq-Comparison
the NCT03863730 1072 1075 I-Eq-Comparison
last NCT03863730 1076 1080 I-Eq-Comparison
3 NCT03863730 1081 1082 I-Eq-Comparison
months NCT03863730 1083 1089 I-Eq-Comparison

- NCT03863730 1092 1093 O
The NCT03863730 1095 1098 O
investigator NCT03863730 1099 1111 O
judge NCT03863730 1112 1117 O
that NCT03863730 1118 1122 O
the NCT03863730 1123 1126 O
patient NCT03863730 1127 1134 O
would NCT03863730 1135 1140 O
not NCT03863730 1141 1144 O
be NCT03863730 1145 1147 O
compliant NCT03863730 1148 1157 O
with NCT03863730 1158 1162 O
trial NCT03863730 1163 1168 O
medicine NCT03863730 1169 1177 O

- NCT03863730 1180 1181 O
Pregnancy NCT03863730 1183 1192 B-Condition

- NCT03863730 1195 1196 O
Known NCT03863730 1198 1203 O
liver NCT03863730 1204 1209 B-Condition
disease NCT03863730 1210 1217 I-Condition
other NCT03863730 1218 1223 B-Exception
than NCT03863730 1224 1228 O
alcoholic NCT03863730 1229 1238 B-Condition
, NCT03863730 1239 1240 O
of NCT03863730 1241 1243 O
any NCT03863730 1244 1247 O
aetiology NCT03863730 1248 1257 O

- NCT03863730 1260 1261 O
Severe NCT03863730 1263 1269 O
malnutrition NCT03863730 1270 1282 B-Condition

- NCT03863730 1285 1286 I-Condition
Malignancy NCT03863730 1288 1298 B-Condition
- NCT03863730 1299 1300 O
except NCT03863730 1301 1307 B-Exception
spino NCT03863730 1308 1313 B-Condition
- NCT03863730 1314 1315 O
or NCT03863730 1316 1318 I-Condition
basocellular NCT03863730 1319 1331 I-Condition
skin NCT03863730 1332 1336 I-Condition
cancer NCT03863730 1337 1343 I-Condition
. NCT03863730 1343 1344 O
Patients NCT03863730 1346 1354 O
with NCT03863730 1355 1359 O
prior NCT03863730 1360 1365 B-Eq-Comparison
malignant NCT03863730 1366 1375 B-Condition
disease NCT03863730 1376 1383 I-Condition
are NCT03863730 1384 1387 O
allowed NCT03863730 1388 1395 O
if NCT03863730 1396 1398 O
cancer NCT03863730 1399 1405 B-Condition
- NCT03863730 1406 1407 O
free NCT03863730 1408 1412 B-Negation
for NCT03863730 1413 1416 O
at NCT03863730 1417 1419 B-Eq-Comparison
least NCT03863730 1420 1425 I-Eq-Comparison
one NCT03863730 1426 1429 I-Eq-Comparison
year NCT03863730 1430 1434 I-Eq-Comparison

- NCT03863730 1437 1438 O
Recent NCT03863730 1440 1446 B-Eq-Comparison
infectious NCT03863730 1447 1457 B-Modifier
gastroenteritis NCT03863730 1458 1473 B-Condition
( NCT03863730 1474 1475 O
for NCT03863730 1476 1479 O
the NCT03863730 1480 1483 O
last NCT03863730 1484 1488 B-Eq-Comparison
6 NCT03863730 1489 1490 I-Eq-Comparison
weeks NCT03863730 1491 1496 I-Eq-Comparison
) NCT03863730 1497 1498 O

Inclusion NCT03865355 0 9 O
Criteria NCT03865355 10 18 O
: NCT03865355 19 20 O

1 NCT03865355 24 25 O
. NCT03865355 25 26 O
All NCT03865355 28 31 O
patients NCT03865355 32 40 O
with NCT03865355 41 45 O
suspected NCT03865355 46 55 B-Assertion___Assertion-Type-Value:possible
newly NCT03865355 56 61 B-Eq-Comparison
diagnosed NCT03865355 62 71 O
glioma NCT03865355 72 78 B-Condition
( NCT03865355 79 80 O
grade NCT03865355 81 86 B-Eq-Comparison
I NCT03865355 87 88 I-Eq-Comparison
, NCT03865355 89 90 O
II NCT03865355 91 93 I-Eq-Comparison
, NCT03865355 94 95 O
III NCT03865355 96 99 I-Eq-Comparison
or NCT03865355 100 102 B-Or
glioblastoma NCT03865355 103 115 B-Condition
) NCT03865355 116 117 O
with NCT03865355 118 122 B-And
planned NCT03865355 123 130 B-Eq-Comparison
surgical NCT03865355 131 139 B-Procedure
intervention NCT03865355 140 152 I-Procedure
( NCT03865355 153 154 O
resection NCT03865355 155 164 B-Procedure
or NCT03865355 165 167 B-Or
biopsy NCT03865355 168 174 B-Procedure
) NCT03865355 175 176 O
. NCT03865355 177 178 O

2 NCT03865355 182 183 O
. NCT03865355 183 184 O
Patient NCT03865355 186 193 O
aged NCT03865355 194 198 B-Age
18 NCT03865355 199 201 B-Eq-Comparison
years NCT03865355 202 207 I-Eq-Comparison
or NCT03865355 208 210 I-Eq-Comparison
older NCT03865355 211 216 I-Eq-Comparison

3 NCT03865355 219 220 O
. NCT03865355 220 221 O
Patients NCT03865355 223 231 O
have NCT03865355 232 236 O
to NCT03865355 237 239 O
be NCT03865355 240 242 O
able NCT03865355 243 247 O
to NCT03865355 248 250 O
give NCT03865355 251 255 O
informed NCT03865355 256 264 O
consent NCT03865355 265 272 O

Exclusion NCT03865355 273 282 O
Criteria NCT03865355 283 291 O
: NCT03865355 292 293 O

1 NCT03865355 297 298 O
. NCT03865355 298 299 O
Prior NCT03865355 301 306 B-Eq-Comparison
Radiotherapy NCT03865355 307 319 B-Procedure
to NCT03865355 320 322 O
the NCT03865355 323 326 O
central NCT03865355 327 334 B-Modifier
nervous NCT03865355 335 342 I-Modifier
system NCT03865355 343 349 I-Modifier

2 NCT03865355 352 353 O
. NCT03865355 353 354 O
Prior NCT03865355 356 361 B-Eq-Comparison
Chemotherapy NCT03865355 362 374 B-Procedure
within NCT03865355 375 381 B-Eq-Comparison
the NCT03865355 382 385 I-Eq-Comparison
last NCT03865355 386 390 I-Eq-Comparison
5 NCT03865355 391 392 I-Eq-Comparison
years NCT03865355 393 398 I-Eq-Comparison

3 NCT03865355 401 402 O
. NCT03865355 402 403 O
Any NCT03865355 405 408 O
prior NCT03865355 409 414 B-Eq-Comparison
central NCT03865355 415 422 B-Modifier
nervous NCT03865355 423 430 I-Modifier
system NCT03865355 431 437 I-Modifier
malignancy NCT03865355 438 448 B-Condition

4 NCT03865355 451 452 O
. NCT03865355 452 453 O
Any NCT03865355 455 458 O
surgery NCT03865355 459 466 B-Procedure
during NCT03865355 467 473 B-Temporal-Connection___Temporal-Connection-Type-Value:during
last NCT03865355 474 478 B-Eq-Comparison
6 NCT03865355 479 480 I-Eq-Comparison
month NCT03865355 481 486 I-Eq-Comparison

Inclusion NCT03865433 0 9 O
Criteria NCT03865433 10 18 O
: NCT03865433 19 20 O

1 NCT03865433 24 25 O
. NCT03865433 25 26 O
are NCT03865433 28 31 O
aged NCT03865433 32 36 B-Age
13 NCT03865433 37 39 B-Eq-Comparison
- NCT03865433 40 41 I-Eq-Comparison
17 NCT03865433 42 44 I-Eq-Comparison
, NCT03865433 45 46 O
years NCT03865433 47 52 I-Eq-Comparison
and NCT03865433 53 56 B-And
a NCT03865433 57 58 O
high NCT03865433 59 63 O
school NCT03865433 64 70 O
student NCT03865433 71 78 O
- NCT03865433 79 80 O
athlete NCT03865433 81 88 O
who NCT03865433 89 92 O
attends NCT03865433 93 100 O
school NCT03865433 101 107 O
where NCT03865433 108 113 O
an NCT03865433 114 116 O
athletic NCT03865433 117 125 O
trainer NCT03865433 126 133 O
can NCT03865433 134 137 O
supervise NCT03865433 138 147 O
the NCT03865433 148 151 O
exercise NCT03865433 152 160 O
protocol NCT03865433 161 169 O
; NCT03865433 169 170 O

2 NCT03865433 173 174 O
. NCT03865433 174 175 O
have NCT03865433 177 181 O
sustained NCT03865433 182 191 O
a NCT03865433 192 193 O
concussion NCT03865433 194 204 B-Condition
within NCT03865433 205 211 B-Eq-Comparison
2 NCT03865433 212 213 I-Eq-Comparison
- NCT03865433 214 215 I-Eq-Comparison
7 NCT03865433 216 217 I-Eq-Comparison
days NCT03865433 218 222 I-Eq-Comparison
of NCT03865433 223 225 B-Temporal-Connection___Temporal-Connection-Type-Value:before
clinic NCT03865433 226 232 B-Encounter
presentation NCT03865433 233 245 I-Encounter
and NCT03865433 246 249 O
diagnosed NCT03865433 250 259 O
by NCT03865433 260 262 O
a NCT03865433 263 264 O
study NCT03865433 265 270 B-Study
physician NCT03865433 271 280 B-Provider
; NCT03865433 280 281 O

3 NCT03865433 284 285 O
. NCT03865433 285 286 O
demonstrate NCT03865433 288 299 O
symptom NCT03865433 300 307 O
exacerbation NCT03865433 308 320 O
during NCT03865433 321 327 O
a NCT03865433 328 329 O
graded NCT03865433 330 336 O
treadmill NCT03865433 337 346 O
exercise NCT03865433 347 355 O
test NCT03865433 356 360 O
and NCT03865433 361 364 O
can NCT03865433 365 368 O
not NCT03865433 368 371 O
complete NCT03865433 372 380 O
the NCT03865433 381 384 O
test NCT03865433 385 389 O
; NCT03865433 389 390 O

4 NCT03865433 393 394 O
. NCT03865433 394 395 O
are NCT03865433 397 400 O
currently NCT03865433 401 410 O
participating NCT03865433 411 424 O
in NCT03865433 425 427 O
a NCT03865433 428 429 O
school NCT03865433 430 436 O
or NCT03865433 437 439 O
club NCT03865433 440 444 O
sport NCT03865433 445 450 O
; NCT03865433 450 451 O

5 NCT03865433 454 455 O
. NCT03865433 455 456 O
are NCT03865433 458 461 O
English NCT03865433 462 469 O
speaking NCT03865433 470 478 O
and NCT03865433 479 482 O
capable NCT03865433 483 490 O
of NCT03865433 491 493 O
giving NCT03865433 494 500 O
assent NCT03865433 501 507 O

Exclusion NCT03865433 508 517 O
Criteria NCT03865433 518 526 O
: NCT03865433 527 528 O

1 NCT03865433 532 533 O
. NCT03865433 533 534 O
have NCT03865433 536 540 O
a NCT03865433 541 542 O
reported NCT03865433 543 551 O
history NCT03865433 552 559 B-Eq-Comparison
of NCT03865433 560 562 O
neurological NCT03865433 563 575 B-Condition
condition NCT03865433 576 585 I-Condition
or NCT03865433 586 588 B-Or
disorder NCT03865433 589 597 B-Condition
including NCT03865433 598 607 O
but NCT03865433 608 611 O
not NCT03865433 612 615 O
limited NCT03865433 616 623 O
to NCT03865433 624 626 O
brain NCT03865433 627 632 B-Procedure
surgery NCT03865433 633 640 I-Procedure
, NCT03865433 641 642 O
special NCT03865433 643 650 B-Procedure
education NCT03865433 651 660 I-Procedure
, NCT03865433 661 662 O
seizure NCT03865433 663 670 B-Condition
disorder NCT03865433 671 679 I-Condition
, NCT03865433 680 681 O
speech NCT03865433 682 688 B-Condition
pathology NCT03865433 689 698 I-Condition
, NCT03865433 699 700 O
previous NCT03865433 701 709 B-Eq-Comparison
diagnosis NCT03865433 710 719 O
of NCT03865433 720 722 O
Post NCT03865433 723 727 B-Condition
- NCT03865433 728 729 I-Condition
Concussion NCT03865433 730 740 I-Condition
Syndrome NCT03865433 741 749 I-Condition
( NCT03865433 750 751 O
PCS NCT03865433 752 755 B-Condition
) NCT03865433 756 757 O
, NCT03865433 759 760 O

2 NCT03865433 764 765 O
. NCT03865433 765 766 O
are NCT03865433 768 771 O
unwilling NCT03865433 772 781 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 782 784 O
exercise NCT03865433 785 793 B-Observation
, NCT03865433 794 795 O

3 NCT03865433 799 800 O
. NCT03865433 800 801 O
have NCT03865433 803 807 O
focal NCT03865433 808 813 B-Condition
neurologic NCT03865433 814 824 I-Condition
deficit NCT03865433 825 832 I-Condition
that NCT03865433 833 837 O
would NCT03865433 838 843 O
represent NCT03865433 844 853 O
risk NCT03865433 854 858 B-Risk
for NCT03865433 859 862 O
walking NCT03865433 863 870 B-Observation
/ NCT03865433 871 872 B-Or
running NCT03865433 873 880 B-Observation
on NCT03865433 881 883 O
treadmill NCT03865433 884 893 B-Modifier
, NCT03865433 894 895 O

4 NCT03865433 899 900 O
. NCT03865433 900 901 O
exhibit NCT03865433 903 910 O
an NCT03865433 911 913 O
inability NCT03865433 914 923 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 924 926 O
exercise NCT03865433 927 935 B-Observation
due NCT03865433 936 939 O
to NCT03865433 940 942 O
injury NCT03865433 943 949 B-Condition
, NCT03865433 950 951 O
known NCT03865433 952 957 O
heart NCT03865433 958 963 B-Condition
disease NCT03865433 964 971 I-Condition
, NCT03865433 972 973 O
or NCT03865433 974 976 B-Or
increased NCT03865433 977 986 O
cardiac NCT03865433 987 994 B-Condition
risk NCT03865433 995 999 B-Risk
, NCT03865433 1000 1001 O

5 NCT03865433 1005 1006 O
. NCT03865433 1006 1007 O
have NCT03865433 1009 1013 O
experienced NCT03865433 1014 1025 O
more NCT03865433 1026 1030 B-Eq-Comparison
than NCT03865433 1031 1035 I-Eq-Comparison
3 NCT03865433 1036 1037 I-Eq-Comparison
previous NCT03865433 1038 1046 B-Eq-Comparison
concussions NCT03865433 1047 1058 B-Condition
, NCT03865433 1059 1060 O

6 NCT03865433 1064 1065 O
. NCT03865433 1065 1066 O
have NCT03865433 1068 1072 O
suffered NCT03865433 1073 1081 B-Eq-Comparison
a NCT03865433 1082 1083 O
substantial NCT03865433 1084 1095 O
comorbidity NCT03865433 1096 1107 B-Condition
( NCT03865433 1108 1109 O
eg NCT03865433 1110 1112 O
, NCT03865433 1113 1114 O
cervical NCT03865433 1115 1123 B-Condition
injury NCT03865433 1124 1130 I-Condition
) NCT03865433 1131 1132 O
, NCT03865433 1134 1135 O

7 NCT03865433 1139 1140 O
. NCT03865433 1140 1141 O
currently NCT03865433 1143 1152 B-Eq-Comparison
taking NCT03865433 1153 1159 I-Eq-Comparison
β NCT03865433 1160 1161 B-Drug
- NCT03865433 1162 1163 I-Drug
blockers NCT03865433 1164 1172 I-Drug|Drug
, NCT03865433 1173 1174 O
calcium NCT03865433 1175 1182 B-Drug
channel NCT03865433 1183 1190 I-Drug
blockers NCT03865433 1191 1199 O
, NCT03865433 1200 1201 O
or NCT03865433 1202 1204 B-Or
prophylactic NCT03865433 1205 1217 B-Drug
headache NCT03865433 1218 1226 I-Drug
medications NCT03865433 1227 1238 I-Drug
( NCT03865433 1239 1240 O
e. NCT03865433 1241 1243 O
g. NCT03865433 1244 1246 O
, NCT03865433 1247 1248 O
amitriptyline NCT03865433 1249 1262 B-Drug
, NCT03865433 1263 1264 O
topiramate NCT03865433 1265 1275 B-Drug
) NCT03865433 1276 1277 O
, NCT03865433 1279 1280 O
or NCT03865433 1281 1283 B-Or

8 NCT03865433 1286 1287 O
. NCT03865433 1287 1288 O
have NCT03865433 1290 1294 O
a NCT03865433 1295 1296 O
resting NCT03865433 1297 1304 B-Modifier
blood NCT03865433 1305 1310 B-Observation
pressure NCT03865433 1311 1319 I-Observation
of NCT03865433 1320 1322 O
> NCT03865433 1323 1324 B-Eq-Comparison
140 NCT03865433 1325 1328 I-Eq-Comparison
/ NCT03865433 1329 1330 O
90 NCT03865433 1331 1333 O
. NCT03865433 1333 1334 O

9 NCT03865433 1338 1339 O
. NCT03865433 1339 1340 O
If NCT03865433 1342 1344 O
the NCT03865433 1345 1348 O
potential NCT03865433 1349 1358 O
participant NCT03865433 1359 1370 O
or NCT03865433 1371 1373 B-Or
parent NCT03865433 1374 1380 O
/ NCT03865433 1381 1382 O
guardian NCT03865433 1383 1391 O
is NCT03865433 1392 1394 O
unable NCT03865433 1395 1401 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 1402 1404 O
fully NCT03865433 1405 1410 O
understand NCT03865433 1411 1421 O
the NCT03865433 1422 1425 O
study NCT03865433 1426 1431 B-Study|Study
protocol NCT03865433 1432 1440 O
or NCT03865433 1441 1443 B-Or
study NCT03865433 1444 1449 O
risks NCT03865433 1450 1455 B-Risk
due NCT03865433 1456 1459 O
to NCT03865433 1460 1462 O
injury NCT03865433 1463 1469 B-Condition
or NCT03865433 1470 1472 O
developmental NCT03865433 1473 1486 B-Condition
delay NCT03865433 1487 1492 I-Condition
, NCT03865433 1493 1494 O
the NCT03865433 1495 1498 O
potential NCT03865433 1499 1508 O
participant NCT03865433 1509 1520 O
will NCT03865433 1521 1525 O
be NCT03865433 1526 1528 O
excluded NCT03865433 1529 1537 B-Negation
from NCT03865433 1538 1542 O
the NCT03865433 1543 1546 O
study NCT03865433 1547 1552 B-Study
. NCT03865433 1552 1553 O

Inclusion NCT03868670 0 9 O
Criteria NCT03868670 10 18 O
: NCT03868670 19 20 O

- NCT03868670 24 25 O
BMI NCT03868670 27 30 B-Observation
45 NCT03868670 31 33 B-Eq-Comparison
- NCT03868670 34 35 I-Eq-Comparison
60 NCT03868670 36 38 I-Eq-Comparison
kg NCT03868670 39 41 I-Eq-Comparison
/ NCT03868670 42 43 I-Eq-Comparison
m2 NCT03868670 44 46 I-Eq-Comparison

- NCT03868670 49 50 O
Failure NCT03868670 52 59 O
of NCT03868670 60 62 O
at NCT03868670 63 65 B-Eq-Comparison
least NCT03868670 66 71 I-Eq-Comparison
one NCT03868670 72 75 I-Eq-Comparison
weight NCT03868670 76 82 B-Drug
loss NCT03868670 83 87 I-Drug
medication NCT03868670 88 98 I-Drug

- NCT03868670 101 102 O
Previous NCT03868670 104 112 B-Eq-Comparison
Gastric NCT03868670 113 120 B-Procedure
Bypass NCT03868670 121 127 I-Procedure
Surgery NCT03868670 128 135 I-Procedure
lead NCT03868670 136 140 O
to NCT03868670 141 143 O
less NCT03868670 144 148 B-Eq-Comparison
than NCT03868670 149 153 I-Eq-Comparison
50 NCT03868670 154 156 I-Eq-Comparison
% NCT03868670 157 158 O
of NCT03868670 159 161 O
excess NCT03868670 162 168 B-Observation
weight NCT03868670 169 175 I-Observation
lost NCT03868670 176 180 O
by NCT03868670 181 183 O
2 NCT03868670 184 185 B-Eq-Comparison
years NCT03868670 186 191 I-Eq-Comparison
after NCT03868670 192 197 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03868670 198 205 B-Coreference

- NCT03868670 208 209 O
Significant NCT03868670 211 222 O
Loss NCT03868670 223 227 B-Condition
of NCT03868670 228 230 I-Condition
Control NCT03868670 231 238 I-Condition
over NCT03868670 239 243 O
eating NCT03868670 244 250 B-Modifier

- NCT03868670 253 254 O
Subject NCT03868670 256 263 O
is NCT03868670 264 266 O
able NCT03868670 267 271 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 272 274 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03868670 275 281 O
all NCT03868670 282 285 O
scheduled NCT03868670 286 295 B-Eq-Comparison
clinic NCT03868670 296 302 B-Encounter
appointments NCT03868670 303 315 I-Encounter
on NCT03868670 316 318 O
their NCT03868670 319 324 O
own NCT03868670 325 328 O
or NCT03868670 329 331 O
with NCT03868670 332 336 O
a NCT03868670 337 338 O
caregiver NCT03868670 339 348 O
. NCT03868670 348 349 O

- NCT03868670 353 354 O
Premenopausal NCT03868670 356 369 B-Condition
women NCT03868670 370 375 O
must NCT03868670 376 380 O
agree NCT03868670 381 386 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 387 389 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03868670 390 393 O
acceptable NCT03868670 394 404 O
methods NCT03868670 405 412 O
of NCT03868670 413 415 O
birth NCT03868670 416 421 B-Procedure
control NCT03868670 422 429 I-Procedure
. NCT03868670 429 430 O

- NCT03868670 434 435 O
Participants NCT03868670 437 449 O
provide NCT03868670 450 457 O
voluntary NCT03868670 458 467 O
, NCT03868670 468 469 O
decisionally NCT03868670 470 482 O
capable NCT03868670 483 490 O
, NCT03868670 491 492 O
and NCT03868670 493 496 O
appropriately NCT03868670 497 510 O
informed NCT03868670 511 519 O
consent NCT03868670 520 527 O
. NCT03868670 527 528 O

- NCT03868670 532 533 O
Subject NCT03868670 535 542 O
is NCT03868670 543 545 O
able NCT03868670 546 550 O
to NCT03868670 551 553 O
comply NCT03868670 554 560 O
w NCT03868670 561 562 O
/ NCT03868670 563 564 O
all NCT03868670 565 568 O
testing NCT03868670 569 576 O
and NCT03868670 577 580 O
follow NCT03868670 581 587 O
- NCT03868670 588 589 O
up NCT03868670 590 592 O
requirements NCT03868670 593 605 O
defined NCT03868670 606 613 O
by NCT03868670 614 616 O
the NCT03868670 617 620 O
study NCT03868670 621 626 O
protocol NCT03868670 627 635 O
. NCT03868670 635 636 O

- NCT03868670 640 641 O
Participant NCT03868670 643 654 O
has NCT03868670 655 658 O
no NCT03868670 659 661 B-Negation
immediate NCT03868670 662 671 O
plan NCT03868670 672 676 B-Assertion___Assertion-Type-Value:intention
for NCT03868670 677 680 O
relocation NCT03868670 681 691 B-Observation
beyond NCT03868670 692 698 B-Eq-Comparison
6 NCT03868670 699 700 I-Eq-Comparison
hours NCT03868670 701 706 I-Eq-Comparison
of NCT03868670 707 709 O
the NCT03868670 710 713 O
study NCT03868670 714 719 B-Study
site NCT03868670 720 724 O
. NCT03868670 724 725 O

- NCT03868670 729 730 O
Proficiency NCT03868670 732 743 O
with NCT03868670 744 748 O
the NCT03868670 749 752 O
English NCT03868670 753 760 O
language NCT03868670 761 769 O
. NCT03868670 769 770 O

Exclusion NCT03868670 772 781 O
Criteria NCT03868670 782 790 O
: NCT03868670 791 792 O

- NCT03868670 796 797 O
Subject NCT03868670 799 806 O
has NCT03868670 807 810 O
an NCT03868670 811 813 O
implanted NCT03868670 814 823 B-Procedure
medical NCT03868670 824 831 I-Procedure
device NCT03868670 832 838 I-Procedure
that NCT03868670 839 843 O
delivers NCT03868670 844 852 O
electrical NCT03868670 853 863 B-Procedure
energy NCT03868670 864 870 I-Procedure
to NCT03868670 871 873 O
the NCT03868670 874 877 O
brain NCT03868670 878 883 B-Modifier
. NCT03868670 883 884 O

- NCT03868670 888 889 O
Subject NCT03868670 891 898 O
has NCT03868670 899 902 O
an NCT03868670 903 905 O
implantable NCT03868670 906 917 B-Procedure
cardiac NCT03868670 918 925 I-Procedure
pacemaker NCT03868670 926 935 I-Procedure
, NCT03868670 936 937 O
defibrillator NCT03868670 938 951 B-Procedure
, NCT03868670 952 953 O
or NCT03868670 954 956 B-Or
neurostimulator NCT03868670 957 972 B-Procedure
. NCT03868670 972 973 O

- NCT03868670 977 978 O
Subject NCT03868670 980 987 O
is NCT03868670 988 990 O
likely NCT03868670 991 997 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 998 1000 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03868670 1001 1008 O
repeat NCT03868670 1009 1015 B-Modifier
MR NCT03868670 1016 1018 B-Procedure
imaging NCT03868670 1019 1026 I-Procedure
after NCT03868670 1027 1032 B-Temporal-Connection___Temporal-Connection-Type-Value:after
implant NCT03868670 1033 1040 B-Procedure
of NCT03868670 1041 1043 I-Procedure
the NCT03868670 1044 1047 I-Procedure
RNS NCT03868670 1048 1051 I-Procedure
Neurostimulator NCT03868670 1052 1067 B-Modifier
and NCT03868670 1068 1071 B-Or
Leads NCT03868670 1072 1077 B-Modifier
. NCT03868670 1077 1078 O

- NCT03868670 1082 1083 O
Subject NCT03868670 1085 1092 O
is NCT03868670 1093 1095 O
unable NCT03868670 1096 1102 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868670 1103 1105 O
fit NCT03868670 1106 1109 O
into NCT03868670 1110 1114 O
CT NCT03868670 1115 1117 B-Procedure
scanner NCT03868670 1118 1125 I-Procedure
( NCT03868670 1126 1127 O
500 NCT03868670 1128 1131 B-Eq-Comparison
lb NCT03868670 1132 1134 O
upper NCT03868670 1135 1140 I-Eq-Comparison
weight NCT03868670 1141 1147 B-Observation
limit NCT03868670 1148 1153 O
for NCT03868670 1154 1157 O
CT NCT03868670 1158 1160 B-Procedure
scanner NCT03868670 1161 1168 I-Procedure
) NCT03868670 1169 1170 O
. NCT03868670 1171 1172 O

- NCT03868670 1176 1177 O
Inability NCT03868670 1179 1188 O
to NCT03868670 1189 1191 O
provide NCT03868670 1192 1199 O
informed NCT03868670 1200 1208 O
consent NCT03868670 1209 1216 O
to NCT03868670 1217 1219 O
treatment NCT03868670 1220 1229 O
. NCT03868670 1229 1230 O

Inclusion NCT03865368 0 9 O
Criteria NCT03865368 10 18 O
: NCT03865368 19 20 O

- NCT03865368 24 25 O
Individuals NCT03865368 27 38 O
between NCT03865368 39 46 B-Eq-Comparison
age NCT03865368 47 50 I-Eq-Comparison
18 NCT03865368 51 53 I-Eq-Comparison
- NCT03865368 54 55 I-Eq-Comparison
65 NCT03865368 56 58 I-Eq-Comparison
with NCT03865368 59 63 B-And
Body NCT03865368 64 68 B-Observation
Mass NCT03865368 69 73 I-Observation
Index NCT03865368 74 79 I-Observation
( NCT03865368 80 81 O
BMI NCT03865368 82 85 B-Observation
) NCT03865368 86 87 O
of NCT03865368 88 90 O
> NCT03865368 91 92 B-Eq-Comparison
29.9 NCT03865368 93 97 I-Eq-Comparison
kg NCT03865368 98 100 I-Eq-Comparison
/ NCT03865368 101 102 I-Eq-Comparison
m2 NCT03865368 103 105 I-Eq-Comparison

Exclusion NCT03865368 106 115 O
Criteria NCT03865368 116 124 O
: NCT03865368 125 126 O

- NCT03865368 130 131 O
Unstable NCT03865368 133 141 O
hypertensive NCT03865368 142 154 B-Condition
patients NCT03865368 155 163 O

- NCT03865368 166 167 O
History NCT03865368 169 176 B-Eq-Comparison
of NCT03865368 177 179 O
cardiovascular NCT03865368 180 194 B-Modifier
, NCT03865368 195 196 O
neurologic NCT03865368 197 207 B-Modifier
, NCT03865368 208 209 O
or NCT03865368 210 212 B-Modifier|Or
orthopedic NCT03865368 213 223 O
diseases NCT03865368 224 232 B-Condition
, NCT03865368 233 234 O

- NCT03865368 238 239 O
Presence NCT03865368 241 249 O
of NCT03865368 250 252 O
knee NCT03865368 253 257 B-Procedure
prosthesis NCT03865368 258 268 I-Procedure
, NCT03865368 269 270 O
hip NCT03865368 271 274 B-Procedure
replacement NCT03865368 275 286 I-Procedure

- NCT03865368 289 290 O
Chronic NCT03865368 292 299 B-Modifier
inflammatory NCT03865368 300 312 B-Condition
disease NCT03865368 313 320 I-Condition
, NCT03865368 321 322 O

- NCT03865368 326 327 I-Procedure
Anti NCT03865368 329 333 B-Procedure
- NCT03865368 334 335 O
inflammatory NCT03865368 336 348 I-Procedure
treatment NCT03865368 349 358 I-Procedure

- NCT03865368 361 362 O
Cognitive NCT03865368 364 373 B-Condition
impairments NCT03865368 374 385 I-Condition

- NCT03865368 388 389 O
Pregnancy NCT03865368 391 400 B-Condition
. NCT03865368 400 401 O

Inclusion NCT03863080 0 9 O
Criteria NCT03863080 10 18 O
: NCT03863080 19 20 O

1 NCT03863080 24 25 O
. NCT03863080 25 26 O
Male NCT03863080 28 32 O
or NCT03863080 33 35 B-Or
female NCT03863080 36 42 O
≥ NCT03863080 43 44 B-Eq-Comparison
18 NCT03863080 45 47 I-Eq-Comparison
years NCT03863080 48 53 I-Eq-Comparison
of NCT03863080 54 56 O
age NCT03863080 57 60 B-Age
. NCT03863080 60 61 O

2 NCT03863080 65 66 O
. NCT03863080 66 67 O
Myasthenia NCT03863080 69 79 B-Condition
Gravis NCT03863080 80 86 I-Condition
Foundation NCT03863080 87 97 I-Condition
of NCT03863080 98 100 I-Condition
America NCT03863080 101 108 I-Condition
( NCT03863080 109 110 O
MGFA NCT03863080 111 115 B-Condition
) NCT03863080 116 117 O
Class NCT03863080 118 123 B-Eq-Comparison
II NCT03863080 124 126 I-Eq-Comparison
- NCT03863080 127 128 I-Eq-Comparison
IVa NCT03863080 129 132 I-Eq-Comparison
and NCT03863080 133 136 B-And
likely NCT03863080 137 143 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03863080 144 147 B-Negation
in NCT03863080 148 150 O
need NCT03863080 151 155 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863080 156 158 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03863080 159 160 O
respirator NCT03863080 161 171 B-Procedure
for NCT03863080 172 175 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863080 176 179 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03863080 180 188 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863080 189 191 O
the NCT03863080 192 195 O
study NCT03863080 196 201 B-Study
as NCT03863080 202 204 O
judged NCT03863080 205 211 O
by NCT03863080 212 214 O
the NCT03863080 215 218 O
Investigator NCT03863080 219 231 O
. NCT03863080 231 232 O

3 NCT03863080 236 237 O
. NCT03863080 237 238 O
QMG NCT03863080 240 243 B-Observation
score NCT03863080 244 249 O
≥ NCT03863080 250 251 B-Eq-Comparison
12 NCT03863080 252 254 I-Eq-Comparison
at NCT03863080 255 257 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03863080 258 267 B-Study
and NCT03863080 268 271 B-And
Baseline NCT03863080 272 280 B-Study
. NCT03863080 280 281 O

Other NCT03863080 283 288 O
, NCT03863080 289 290 O
more NCT03863080 291 295 O
specific NCT03863080 296 304 O
inclusion NCT03863080 305 314 O
criteria NCT03863080 315 323 O
are NCT03863080 324 327 O
defined NCT03863080 328 335 O
in NCT03863080 336 338 O
the NCT03863080 339 342 O
protocol NCT03863080 343 351 O
. NCT03863080 351 352 O

Exclusion NCT03863080 354 363 O
Criteria NCT03863080 364 372 O
: NCT03863080 373 374 O

1 NCT03863080 378 379 O
. NCT03863080 379 380 O
Use NCT03863080 382 385 O
of NCT03863080 386 388 O
rituximab NCT03863080 389 398 B-Drug
, NCT03863080 399 400 O
belimumab NCT03863080 401 410 B-Drug
, NCT03863080 411 412 O
eculizumab NCT03863080 413 423 B-Drug
or NCT03863080 424 426 B-Or
any NCT03863080 427 430 O
monoclonal NCT03863080 431 441 B-Drug
antibody NCT03863080 442 450 I-Drug
for NCT03863080 451 454 O
immunomodulation NCT03863080 455 471 B-Procedure
within NCT03863080 472 478 B-Eq-Comparison
6 NCT03863080 479 480 I-Eq-Comparison
months NCT03863080 481 487 I-Eq-Comparison
prior NCT03863080 488 493 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863080 494 496 O
first NCT03863080 497 502 B-Eq-Comparison
dosing NCT03863080 503 509 B-Procedure
. NCT03863080 509 510 O

2 NCT03863080 514 515 O
. NCT03863080 515 516 O
Immunoglobulins NCT03863080 518 533 B-Drug
given NCT03863080 534 539 O
by NCT03863080 540 542 O
SC NCT03863080 543 545 B-Modifier
, NCT03863080 546 547 O
IV NCT03863080 548 550 B-Modifier|Modifier
( NCT03863080 551 552 O
IVIG NCT03863080 553 557 O
) NCT03863080 558 559 O
, NCT03863080 561 562 O
or NCT03863080 563 565 B-Or|Or
intramuscular NCT03863080 566 579 B-Modifier
route NCT03863080 580 585 I-Modifier
, NCT03863080 586 587 O
or NCT03863080 588 590 O
plasmapheresis NCT03863080 591 605 B-Procedure|Procedure
/ NCT03863080 606 607 O
plasma NCT03863080 608 614 O
exchange NCT03863080 615 623 I-Procedure
( NCT03863080 624 625 O
PE NCT03863080 626 628 B-Procedure
) NCT03863080 629 630 O
within NCT03863080 631 637 B-Eq-Comparison
4 NCT03863080 638 639 I-Eq-Comparison
weeks NCT03863080 640 645 I-Eq-Comparison
before NCT03863080 646 652 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Screening NCT03863080 653 662 B-Study
. NCT03863080 662 663 O

3 NCT03863080 667 668 O
. NCT03863080 668 669 O
Thymectomy NCT03863080 671 681 B-Procedure
performed NCT03863080 682 691 O
< NCT03863080 692 693 B-Eq-Comparison
12 NCT03863080 694 696 I-Eq-Comparison
months NCT03863080 697 703 I-Eq-Comparison
prior NCT03863080 704 709 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863080 710 712 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03863080 713 722 B-Study
. NCT03863080 722 723 O

4 NCT03863080 727 728 O
. NCT03863080 728 729 O
Total NCT03863080 731 736 B-Observation
IgG NCT03863080 737 740 I-Observation
level NCT03863080 741 746 O
< NCT03863080 747 748 B-Eq-Comparison
6 NCT03863080 749 750 I-Eq-Comparison
g NCT03863080 751 752 I-Eq-Comparison
/ NCT03863080 753 754 I-Eq-Comparison
L NCT03863080 755 756 I-Eq-Comparison
( NCT03863080 757 758 O
at NCT03863080 759 761 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863080 762 771 B-Study
) NCT03863080 772 773 O
. NCT03863080 774 775 O

5 NCT03863080 779 780 O
. NCT03863080 780 781 O
Absolute NCT03863080 783 791 B-Observation
neutrophil NCT03863080 792 802 I-Observation
count NCT03863080 803 808 I-Observation
< NCT03863080 809 810 B-Eq-Comparison
1500 NCT03863080 811 815 I-Eq-Comparison
cells NCT03863080 816 821 I-Eq-Comparison
/ NCT03863080 822 823 I-Eq-Comparison
mm3 NCT03863080 824 827 I-Eq-Comparison
( NCT03863080 828 829 O
at NCT03863080 830 832 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863080 833 842 B-Study
) NCT03863080 843 844 O
. NCT03863080 845 846 O

Other NCT03863080 848 853 O
, NCT03863080 854 855 O
more NCT03863080 856 860 O
specific NCT03863080 861 869 O
exclusion NCT03863080 870 879 O
criteria NCT03863080 880 888 O
are NCT03863080 889 892 O
defined NCT03863080 893 900 O
in NCT03863080 901 903 O
the NCT03863080 904 907 O
protocol NCT03863080 908 916 O

Inclusion NCT03861442 0 9 O
Criteria NCT03861442 10 18 O
: NCT03861442 19 20 O

- NCT03861442 24 25 O
A NCT03861442 27 28 O
minimum NCT03861442 29 36 B-Eq-Comparison
of NCT03861442 37 39 I-Eq-Comparison
18 NCT03861442 40 42 I-Eq-Comparison
years NCT03861442 43 48 I-Eq-Comparison
old NCT03861442 49 52 B-Age

- NCT03861442 55 56 O
Experienced NCT03861442 58 69 O
user NCT03861442 70 74 O
( NCT03861442 75 76 O
≥ NCT03861442 78 79 B-Eq-Comparison
6 NCT03861442 80 81 I-Eq-Comparison
months NCT03861442 82 88 I-Eq-Comparison
) NCT03861442 89 90 O
of NCT03861442 91 93 O
a NCT03861442 94 95 O
MED NCT03861442 96 99 B-Procedure
- NCT03861442 100 101 I-Procedure
EL NCT03861442 102 104 I-Procedure
cochlear NCT03861442 105 113 I-Procedure
implant NCT03861442 114 121 I-Procedure
( NCT03861442 122 123 O
CI NCT03861442 124 126 B-Modifier
; NCT03861442 126 127 O
C40 NCT03861442 128 131 B-Modifier
+ NCT03861442 132 133 O
and NCT03861442 134 137 O
later NCT03861442 138 143 O
model NCT03861442 144 149 O
) NCT03861442 150 151 O

- NCT03861442 155 156 O
Experienced NCT03861442 158 169 O
user NCT03861442 170 174 O
of NCT03861442 175 177 O
a NCT03861442 178 179 O
MED NCT03861442 180 183 B-Procedure
- NCT03861442 184 185 I-Procedure
EL NCT03861442 186 188 I-Procedure
SONNET NCT03861442 189 195 I-Procedure
audio NCT03861442 196 201 I-Procedure
processor NCT03861442 202 211 I-Procedure
( NCT03861442 212 213 O
≥ NCT03861442 215 216 B-Eq-Comparison
6 NCT03861442 217 218 I-Eq-Comparison
months NCT03861442 219 225 I-Eq-Comparison
) NCT03861442 226 227 O

- NCT03861442 231 232 I-Modifier
Post NCT03861442 234 238 B-Modifier
- NCT03861442 239 240 O
lingual NCT03861442 241 248 I-Modifier
onset NCT03861442 249 254 B-Eq-Comparison
of NCT03861442 255 257 O
bilateral NCT03861442 258 267 B-Modifier
severe NCT03861442 268 274 B-Eq-Comparison
to NCT03861442 275 277 I-Eq-Comparison
profound NCT03861442 278 286 I-Eq-Comparison
sensory NCT03861442 287 294 B-Condition
- NCT03861442 295 296 I-Condition
neural NCT03861442 297 303 I-Condition
hearing NCT03861442 304 311 I-Condition
loss NCT03861442 312 316 I-Condition

- NCT03861442 319 320 O
Unilateral NCT03861442 322 332 B-Procedure
CI NCT03861442 333 335 I-Procedure
user NCT03861442 336 340 O

- NCT03861442 343 344 O
A NCT03861442 346 347 O
minimum NCT03861442 348 355 B-Eq-Comparison
of NCT03861442 356 358 I-Eq-Comparison
10 NCT03861442 359 361 I-Eq-Comparison
active NCT03861442 362 368 B-Eq-Comparison
electrodes NCT03861442 369 379 B-Procedure

- NCT03861442 382 383 O
A NCT03861442 385 386 O
minimum NCT03861442 387 394 B-Eq-Comparison
of NCT03861442 395 397 I-Eq-Comparison
40 NCT03861442 398 400 I-Eq-Comparison
% NCT03861442 401 402 O
speech NCT03861442 403 409 B-Modifier
recognition NCT03861442 410 421 I-Modifier
in NCT03861442 422 424 O
the NCT03861442 425 428 O
Freiburg NCT03861442 429 437 B-Observation
Monosyllables NCT03861442 438 451 I-Observation
test NCT03861442 452 456 I-Observation
in NCT03861442 457 459 O
quiet NCT03861442 460 465 B-Modifier
at NCT03861442 466 468 I-Modifier
65 NCT03861442 469 471 I-Modifier
dB NCT03861442 472 474 I-Modifier
sound NCT03861442 475 480 I-Modifier
pressure NCT03861442 481 489 I-Modifier
level NCT03861442 490 495 I-Modifier
( NCT03861442 496 497 O
SPL NCT03861442 498 501 B-Modifier
; NCT03861442 501 502 O
at NCT03861442 503 505 O
the NCT03861442 506 509 O
last NCT03861442 510 514 B-Eq-Comparison
time NCT03861442 515 519 I-Eq-Comparison
tested NCT03861442 520 526 O
) NCT03861442 527 528 O

- NCT03861442 532 533 O
Fluent NCT03861442 535 541 O
in NCT03861442 542 544 O
German NCT03861442 545 551 O
( NCT03861442 552 553 O
the NCT03861442 554 557 O
language NCT03861442 558 566 O
of NCT03861442 567 569 O
the NCT03861442 570 573 O
test NCT03861442 574 578 O
centre NCT03861442 579 585 O
) NCT03861442 586 587 O

- NCT03861442 591 592 O
Signed NCT03861442 594 600 O
and NCT03861442 601 604 O
dated NCT03861442 605 610 O
Informed NCT03861442 611 619 O
Consent NCT03861442 620 627 O
Form NCT03861442 628 632 O
before NCT03861442 633 639 O
the NCT03861442 640 643 O
start NCT03861442 644 649 O
of NCT03861442 650 652 O
any NCT03861442 653 656 O
study NCT03861442 657 662 O
- NCT03861442 663 664 O
specific NCT03861442 665 673 O
procedure NCT03861442 674 683 O
. NCT03861442 683 684 O

Exclusion NCT03861442 686 695 O
Criteria NCT03861442 696 704 O
: NCT03861442 705 706 O

- NCT03861442 710 711 O
Lack NCT03861442 713 717 O
of NCT03861442 718 720 O
compliance NCT03861442 721 731 O
with NCT03861442 732 736 O
any NCT03861442 737 740 O
inclusion NCT03861442 741 750 O
criteria NCT03861442 751 759 O

- NCT03861442 762 763 O
CI NCT03861442 765 767 B-Procedure
user NCT03861442 768 772 O
with NCT03861442 773 777 B-And
contralateral NCT03861442 778 791 B-Condition
hearing NCT03861442 792 799 I-Condition
equal NCT03861442 800 805 B-Eq-Comparison
to NCT03861442 806 808 I-Eq-Comparison
or NCT03861442 809 811 I-Eq-Comparison
better NCT03861442 812 818 I-Eq-Comparison
than NCT03861442 819 823 I-Eq-Comparison
60 NCT03861442 824 826 I-Eq-Comparison
dB NCT03861442 827 829 I-Eq-Comparison
( NCT03861442 830 831 O
PTA NCT03861442 832 835 B-Observation
measured NCT03861442 836 844 O
at NCT03861442 845 847 O
500 NCT03861442 848 851 B-Eq-Comparison
, NCT03861442 852 853 O
1000 NCT03861442 854 858 I-Eq-Comparison
, NCT03861442 859 860 O
and NCT03861442 861 864 I-Eq-Comparison
2000 NCT03861442 865 869 I-Eq-Comparison
Hz NCT03861442 870 872 O
) NCT03861442 873 874 O

- NCT03861442 881 882 I-Procedure
User NCT03861442 884 888 O
with NCT03861442 889 893 O
electric NCT03861442 894 902 B-Procedure
- NCT03861442 903 904 O
acoustic NCT03861442 905 913 I-Procedure
stimulation NCT03861442 914 925 I-Procedure
( NCT03861442 926 927 O
EAS NCT03861442 928 931 B-Procedure|Procedure
; NCT03861442 931 932 O
user NCT03861442 933 937 O
of NCT03861442 938 940 O
an NCT03861442 941 943 O
EAS NCT03861442 944 947 O
audio NCT03861442 948 953 I-Procedure
processor NCT03861442 954 963 I-Procedure
) NCT03861442 964 965 O

- NCT03861442 969 970 O
Implanted NCT03861442 972 981 B-Procedure|Procedure
with NCT03861442 982 986 O
C40 NCT03861442 987 990 B-Modifier|Modifier
X NCT03861442 991 992 O
and NCT03861442 993 996 B-Or
C40 NCT03861442 997 1000 O
C NCT03861442 1001 1002 O

- NCT03861442 1005 1006 O
Implanted NCT03861442 1008 1017 I-Modifier
with NCT03861442 1018 1022 O
an NCT03861442 1023 1025 O
Auditory NCT03861442 1026 1034 B-Modifier
Brainstem NCT03861442 1035 1044 I-Modifier
Implant NCT03861442 1045 1052 O
or NCT03861442 1053 1055 B-Or
Split NCT03861442 1056 1061 B-Modifier
electrode NCT03861442 1062 1071 I-Modifier
array NCT03861442 1072 1077 I-Modifier

- NCT03861442 1080 1081 O
Known NCT03861442 1083 1088 O
allergic NCT03861442 1089 1097 B-Allergy
reactions NCT03861442 1098 1107 O
to NCT03861442 1108 1110 O
components NCT03861442 1111 1121 O
of NCT03861442 1122 1124 O
the NCT03861442 1125 1128 O
investigational NCT03861442 1129 1144 B-Study
medical NCT03861442 1145 1152 B-Procedure
device NCT03861442 1153 1159 I-Procedure

- NCT03861442 1162 1163 O
Unstable NCT03861442 1165 1173 O
psychological NCT03861442 1174 1187 B-Condition
status NCT03861442 1188 1194 I-Condition

- NCT03861442 1197 1198 O
Anything NCT03861442 1200 1208 O
that NCT03861442 1209 1213 O
, NCT03861442 1214 1215 O
in NCT03861442 1216 1218 O
the NCT03861442 1219 1222 O
opinion NCT03861442 1223 1230 O
of NCT03861442 1231 1233 O
the NCT03861442 1234 1237 O
Investigator NCT03861442 1238 1250 O
, NCT03861442 1251 1252 O
would NCT03861442 1253 1258 B-Assertion___Assertion-Type-Value:hypothetical
place NCT03861442 1259 1264 O
the NCT03861442 1265 1268 O
subject NCT03861442 1269 1276 O
at NCT03861442 1277 1279 O
increased NCT03861442 1280 1289 O
risk NCT03861442 1290 1294 B-Risk
or NCT03861442 1295 1297 B-Or
preclude NCT03861442 1298 1306 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03861442 1307 1310 O
subject NCT03861442 1311 1318 O
's NCT03861442 1318 1320 O
full NCT03861442 1321 1325 O
compliance NCT03861442 1326 1336 O
with NCT03861442 1337 1341 O
or NCT03861442 1342 1344 O
completion NCT03861442 1345 1355 O
of NCT03861442 1356 1358 O
the NCT03861442 1359 1362 O
study NCT03861442 1363 1368 B-Study


Inclusion NCT03860012 0 9 O
Criteria NCT03860012 10 18 O
: NCT03860012 19 20 O

1 NCT03860012 24 25 O
. NCT03860012 25 26 O
inflammatory NCT03860012 28 40 B-Condition
bowel NCT03860012 41 46 I-Condition
disease NCT03860012 47 54 I-Condition

2 NCT03860012 57 58 O
. NCT03860012 58 59 O
on NCT03860012 61 63 B-Eq-Comparison
methotrexate NCT03860012 64 76 B-Drug
at NCT03860012 77 79 O
appropriate NCT03860012 80 91 O
dosing NCT03860012 92 98 O

3 NCT03860012 101 102 O
. NCT03860012 102 103 O
normal NCT03860012 105 111 O
folate NCT03860012 112 118 B-Observation
levels NCT03860012 119 125 I-Observation
at NCT03860012 126 128 O
onset NCT03860012 129 134 B-Eq-Comparison
of NCT03860012 135 137 O
study NCT03860012 138 143 B-Study

4 NCT03860012 146 147 O
. NCT03860012 147 148 O
treatment NCT03860012 150 159 B-Procedure
with NCT03860012 160 164 O
folic NCT03860012 165 170 B-Drug
acid NCT03860012 171 175 I-Drug

5 NCT03860012 178 179 O
. NCT03860012 179 180 O
ages NCT03860012 182 186 B-Age
2 NCT03860012 187 188 B-Eq-Comparison
- NCT03860012 189 190 I-Eq-Comparison
21 NCT03860012 191 193 I-Eq-Comparison
years NCT03860012 194 199 I-Eq-Comparison

Exclusion NCT03860012 200 209 O
Criteria NCT03860012 210 218 O
: NCT03860012 219 220 O

1 NCT03860012 224 225 O
. NCT03860012 225 226 O
abnormal NCT03860012 228 236 O
folate NCT03860012 237 243 B-Observation
levels NCT03860012 244 250 I-Observation

2 NCT03860012 253 254 O
. NCT03860012 254 255 O
age NCT03860012 257 260 B-Age
> NCT03860012 261 262 B-Eq-Comparison
21 NCT03860012 263 265 I-Eq-Comparison
or NCT03860012 266 268 B-Or
less NCT03860012 269 273 B-Eq-Comparison
than NCT03860012 274 278 I-Eq-Comparison
2 NCT03860012 279 280 I-Eq-Comparison

Inclusion NCT03866265 0 9 O
Criteria NCT03866265 10 18 O
: NCT03866265 19 20 O

- NCT03866265 24 25 O
The NCT03866265 27 30 O
selection NCT03866265 31 40 O
criteria NCT03866265 41 49 O
of NCT03866265 50 52 O
the NCT03866265 53 56 O
subjects NCT03866265 57 65 O
will NCT03866265 66 70 O
be NCT03866265 71 73 O
as NCT03866265 74 76 O
follows NCT03866265 77 84 O
: NCT03866265 85 86 O

1 NCT03866265 95 96 O
. NCT03866265 96 97 O
they NCT03866265 99 103 O
need NCT03866265 104 108 O
to NCT03866265 109 111 O
be NCT03866265 112 114 O
off NCT03866265 115 118 B-Negation
medication NCT03866265 119 129 B-Drug
and NCT03866265 130 133 B-And
off NCT03866265 134 137 B-Negation
intake NCT03866265 138 144 O
of NCT03866265 145 147 O
dietary NCT03866265 148 155 B-Drug
supplements NCT03866265 156 167 I-Drug

2 NCT03866265 175 176 O
. NCT03866265 176 177 O
they NCT03866265 179 183 O
need NCT03866265 184 188 O
to NCT03866265 189 191 O
have NCT03866265 192 196 O
no NCT03866265 197 199 B-Negation
blood NCT03866265 200 205 B-Condition
clotting NCT03866265 206 214 I-Condition
disorders NCT03866265 215 224 I-Condition
or NCT03866265 225 227 B-Or
dyslipidaemia NCT03866265 228 241 B-Condition
and NCT03866265 242 245 B-And

Exclusion NCT03866265 246 255 O
Criteria NCT03866265 256 264 O
: NCT03866265 265 266 O

Subjects NCT03866265 268 276 O
with NCT03866265 277 281 O
clotting NCT03866265 282 290 B-Condition
disorders NCT03866265 291 300 I-Condition
, NCT03866265 301 302 O
dyslipidemia NCT03866265 303 315 B-Condition
or NCT03866265 316 318 B-Or
being NCT03866265 319 324 O
on NCT03866265 325 327 B-Eq-Comparison
medication NCT03866265 328 338 B-Drug
( NCT03866265 339 340 O
i. NCT03866265 341 343 O
e. NCT03866265 344 346 O
statins NCT03866265 348 355 B-Drug
) NCT03866265 356 357 O
or NCT03866265 358 360 B-Or
other NCT03866265 361 366 B-Other
supplements NCT03866265 367 378 B-Drug
during NCT03866265 379 385 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866265 386 389 O
study NCT03866265 390 395 B-Study
will NCT03866265 396 400 O
be NCT03866265 401 403 O
excluded NCT03866265 404 412 B-Negation
. NCT03866265 412 413 O


Inclusion NCT03862573 0 9 O
Criteria NCT03862573 10 18 O
: NCT03862573 19 20 O

1 NCT03862573 24 25 O
. NCT03862573 25 26 O
Children NCT03862573 28 36 O
age NCT03862573 37 40 B-Age
4 NCT03862573 41 42 B-Eq-Comparison
to NCT03862573 43 45 I-Eq-Comparison
< NCT03862573 46 47 I-Eq-Comparison
17 NCT03862573 48 50 I-Eq-Comparison
years NCT03862573 51 56 I-Eq-Comparison

2 NCT03862573 59 60 O
. NCT03862573 60 61 O
Arriving NCT03862573 63 71 B-Encounter
to NCT03862573 72 74 O
the NCT03862573 75 78 O
UBC NCT03862573 79 82 O
dentistry NCT03862573 83 92 O
clinic NCT03862573 93 99 O
and NCT03862573 100 103 B-And
need NCT03862573 104 108 B-Assertion___Assertion-Type-Value:hypothetical
dental NCT03862573 109 115 B-Procedure
assessment NCT03862573 116 126 B-Modifier
/ NCT03862573 127 128 B-Or
procedures NCT03862573 129 139 B-Modifier

3 NCT03862573 142 143 O
. NCT03862573 143 144 O
Parents NCT03862573 146 153 O
will NCT03862573 154 158 O
sign NCT03862573 159 163 O
a NCT03862573 164 165 O
consent NCT03862573 166 173 O
form NCT03862573 174 178 O
and NCT03862573 179 182 O
children NCT03862573 183 191 O
will NCT03862573 192 196 O
sign NCT03862573 197 201 O
an NCT03862573 202 204 O
assent NCT03862573 205 211 O
form NCT03862573 212 216 O

Exclusion NCT03862573 217 226 O
Criteria NCT03862573 227 235 O
: NCT03862573 236 237 O

1 NCT03862573 241 242 O
. NCT03862573 242 243 O
Children NCT03862573 245 253 O
with NCT03862573 254 258 B-And
conditions NCT03862573 259 269 B-Condition
that NCT03862573 270 274 O
may NCT03862573 275 278 B-Assertion___Assertion-Type-Value:hypothetical
prohibit NCT03862573 279 287 B-Negation
participation NCT03862573 288 301 O
or NCT03862573 302 304 O
evaluation NCT03862573 305 315 O
of NCT03862573 316 318 O
the NCT03862573 319 322 O
procedure NCT03862573 323 332 B-Procedure
( NCT03862573 333 334 O
such NCT03862573 335 339 O
as NCT03862573 340 342 O
developmental NCT03862573 343 356 B-Condition
delay NCT03862573 357 362 I-Condition
, NCT03862573 363 364 O
autism NCT03862573 365 371 B-Condition
, NCT03862573 372 373 O
challenging NCT03862573 374 385 B-Condition
communication NCT03862573 386 399 I-Condition
) NCT03862573 400 401 O

2 NCT03862573 405 406 O
. NCT03862573 406 407 O
Facial NCT03862573 409 415 B-Condition
features NCT03862573 416 424 I-Condition
prohibiting NCT03862573 425 436 B-Assertion___Assertion-Type-Value:hypothetical|Negation
wearing NCT03862573 437 444 B-Observation
the NCT03862573 445 448 O
VR NCT03862573 449 451 B-Modifier
goggles NCT03862573 452 459 I-Modifier

3 NCT03862573 462 463 O
. NCT03862573 463 464 O
Children NCT03862573 466 474 O
needing NCT03862573 475 482 B-Assertion___Assertion-Type-Value:hypothetical
sedation NCT03862573 483 491 B-Procedure
that NCT03862573 492 496 O
includes NCT03862573 497 505 O
inhalation NCT03862573 506 516 B-Procedure
via NCT03862573 517 520 I-Procedure
a NCT03862573 521 522 I-Procedure
mask NCT03862573 523 527 I-Procedure
( NCT03862573 528 529 O
N2O NCT03862573 530 533 B-Procedure
) NCT03862573 534 535 O
or NCT03862573 536 538 B-Or
IV NCT03862573 539 541 B-Modifier
/ NCT03862573 542 543 B-Or
IM NCT03862573 544 546 B-Modifier
sedation NCT03862573 547 555 B-Procedure

Inclusion NCT03860402 0 9 O
Criteria NCT03860402 10 18 O
: NCT03860402 19 20 O

- NCT03860402 24 25 O
Among NCT03860402 27 32 O
the NCT03860402 33 36 O
pregnant NCT03860402 37 45 B-Condition
women NCT03860402 46 51 O
who NCT03860402 52 55 B-And
were NCT03860402 56 60 O
administered NCT03860402 61 73 B-Eq-Comparison
cesarean NCT03860402 74 82 B-Procedure
section NCT03860402 83 90 I-Procedure
in NCT03860402 91 93 O
this NCT03860402 94 98 O
study NCT03860402 99 104 B-Study
, NCT03860402 105 106 O
those NCT03860402 107 112 O
who NCT03860402 113 116 O
agreed NCT03860402 117 123 O
to NCT03860402 124 126 O
participate NCT03860402 127 138 O
in NCT03860402 139 141 O
this NCT03860402 142 146 O
study NCT03860402 147 152 O
. NCT03860402 152 153 O

Exclusion NCT03860402 155 164 O
Criteria NCT03860402 165 173 O
: NCT03860402 174 175 O

- NCT03860402 179 180 O
Fetal NCT03860402 182 187 B-Condition
distress NCT03860402 188 196 I-Condition
requiring NCT03860402 197 206 B-Assertion___Assertion-Type-Value:hypothetical
fast NCT03860402 207 211 B-Modifier
delivery NCT03860402 212 220 B-Procedure
. NCT03860402 220 221 O

- NCT03860402 225 226 O
Patients NCT03860402 228 236 O
with NCT03860402 237 241 O
hypersensitivity NCT03860402 242 258 B-Condition
, NCT03860402 259 260 O
allergic NCT03860402 261 269 B-Allergy
response NCT03860402 270 278 B-Condition
, NCT03860402 279 280 O
resistance NCT03860402 281 291 B-Condition
to NCT03860402 292 294 O
the NCT03860402 295 298 O
drugs NCT03860402 299 304 B-Drug
used NCT03860402 305 309 O
in NCT03860402 310 312 O
this NCT03860402 313 317 O
study NCT03860402 318 323 B-Study
( NCT03860402 324 325 O
fentanyl NCT03860402 326 334 B-Drug
, NCT03860402 335 336 O
ropivacaine NCT03860402 337 348 B-Drug
, NCT03860402 349 350 O
lidocaine NCT03860402 351 360 B-Drug
) NCT03860402 361 362 O
. NCT03860402 363 364 O

- NCT03860402 368 369 O
Patients NCT03860402 371 379 O
who NCT03860402 380 383 O
is NCT03860402 384 386 O
not NCT03860402 387 390 B-Negation
possible NCT03860402 391 399 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860402 400 403 O
regional NCT03860402 404 412 B-Procedure
anesthesia NCT03860402 413 423 I-Procedure

- NCT03860402 426 427 O
Patients NCT03860402 429 437 O
who NCT03860402 438 441 O
refused NCT03860402 442 449 O
to NCT03860402 450 452 O
participate NCT03860402 453 464 O
in NCT03860402 465 467 O
this NCT03860402 468 472 O
study NCT03860402 473 478 O
. NCT03860402 478 479 O

- NCT03860402 483 484 O
Patients NCT03860402 486 494 O
who NCT03860402 495 498 O
can NCT03860402 499 502 O
not NCT03860402 502 505 O
read NCT03860402 506 510 O
or NCT03860402 511 513 O
understand NCT03860402 514 524 O
the NCT03860402 525 528 O
agreement NCT03860402 529 538 O
. NCT03860402 538 539 O

- NCT03860402 543 544 O
Patients NCT03860402 546 554 O
whose NCT03860402 555 560 O
weight NCT03860402 561 567 B-Observation
is NCT03860402 568 570 O
less NCT03860402 571 575 B-Eq-Comparison
than NCT03860402 576 580 I-Eq-Comparison
50 NCT03860402 581 583 I-Eq-Comparison
kg NCT03860402 584 586 O
or NCT03860402 587 589 B-Or
exceeds NCT03860402 590 597 B-Eq-Comparison
100 NCT03860402 598 601 I-Eq-Comparison
kg NCT03860402 602 604 O
. NCT03860402 604 605 O

Inclusion NCT03861494 0 9 O
Criteria NCT03861494 10 18 O
: NCT03861494 19 20 O

- NCT03861494 24 25 O
patients NCT03861494 27 35 O
hospitalized NCT03861494 36 48 B-Encounter
with NCT03861494 49 53 B-And
primary NCT03861494 54 61 O
diagnosis NCT03861494 62 71 O
of NCT03861494 72 74 O
acute NCT03861494 75 80 O
or NCT03861494 81 83 B-Or
subacute NCT03861494 84 92 O
ischemic NCT03861494 93 101 B-Condition
cerebral NCT03861494 102 110 I-Condition
infarction NCT03861494 111 121 I-Condition

- NCT03861494 124 125 O
18 NCT03861494 127 129 B-Eq-Comparison
years NCT03861494 130 135 I-Eq-Comparison
of NCT03861494 136 138 I-Eq-Comparison
age NCT03861494 139 142 I-Eq-Comparison
or NCT03861494 143 145 I-Eq-Comparison
older NCT03861494 146 151 I-Eq-Comparison

- NCT03861494 154 155 O
English NCT03861494 157 164 O
speaking NCT03861494 165 173 O

- NCT03861494 176 177 O
admitted NCT03861494 179 187 B-Encounter
to NCT03861494 188 190 O
hospital NCT03861494 191 199 O
Sunday NCT03861494 200 206 B-Eq-Comparison
through NCT03861494 207 214 I-Eq-Comparison
Thursday NCT03861494 215 223 I-Eq-Comparison

- NCT03861494 226 227 O
patient NCT03861494 229 236 O
or NCT03861494 237 239 O
responsible NCT03861494 240 251 O
primary NCT03861494 252 259 O
caregiver NCT03861494 260 269 O
able NCT03861494 270 274 O
to NCT03861494 275 277 O
understand NCT03861494 278 288 O
and NCT03861494 289 292 O
provide NCT03861494 293 300 O
informed NCT03861494 301 309 O
consent NCT03861494 310 317 O

- NCT03861494 320 321 O
prognosis NCT03861494 323 332 B-Condition
for NCT03861494 333 336 I-Condition
survival NCT03861494 337 345 I-Condition
greater NCT03861494 346 353 B-Eq-Comparison
than NCT03861494 354 358 I-Eq-Comparison
6 NCT03861494 359 360 I-Eq-Comparison
months NCT03861494 361 367 I-Eq-Comparison

- NCT03861494 370 371 O
one NCT03861494 373 376 B-Eq-Comparison
or NCT03861494 377 379 I-Eq-Comparison
more NCT03861494 380 384 I-Eq-Comparison
vascular NCT03861494 385 393 B-Condition
risk NCT03861494 394 398 B-Risk
factors NCT03861494 399 406 I-Risk
( NCT03861494 407 408 O
HTN NCT03861494 409 412 B-Condition
, NCT03861494 413 414 O
DLP NCT03861494 415 418 B-Condition
, NCT03861494 419 420 O
current NCT03861494 421 428 B-Condition
smoker NCT03861494 429 435 I-Condition
, NCT03861494 436 437 O
DM NCT03861494 438 440 B-Condition
, NCT03861494 441 442 O
obesity NCT03861494 443 450 B-Condition
) NCT03861494 451 452 O

- NCT03861494 456 457 O
live NCT03861494 459 463 O
in NCT03861494 464 466 O
NWA NCT03861494 467 470 O
area NCT03861494 471 475 O
( NCT03861494 476 477 O
Benton NCT03861494 478 484 O
, NCT03861494 485 486 O
Boone NCT03861494 487 492 O
, NCT03861494 493 494 O
Carroll NCT03861494 495 502 O
, NCT03861494 503 504 O
Madison NCT03861494 505 512 O
, NCT03861494 513 514 O
and NCT03861494 515 518 O
Washington NCT03861494 519 529 O
counties NCT03861494 530 538 O
) NCT03861494 539 540 O
, NCT03861494 542 543 O

- NCT03861494 547 548 O
have NCT03861494 550 554 O
a NCT03861494 555 556 O
working NCT03861494 557 564 O
phone NCT03861494 565 570 O
. NCT03861494 570 571 O

Exclusion NCT03861494 573 582 O
Criteria NCT03861494 583 591 O
: NCT03861494 592 593 O

- NCT03861494 597 598 O
admitted NCT03861494 600 608 B-Encounter
with NCT03861494 609 613 B-And
transient NCT03861494 614 623 B-Condition
ischemic NCT03861494 624 632 I-Condition
attack NCT03861494 633 639 I-Condition

- NCT03861494 642 643 O
admitted NCT03861494 645 653 B-Encounter
with NCT03861494 654 658 B-And
an NCT03861494 659 661 O
intracerebral NCT03861494 662 675 B-Condition
hemorrhage NCT03861494 676 686 I-Condition

- NCT03861494 689 690 O
experience NCT03861494 692 702 O
an NCT03861494 703 705 O
in NCT03861494 706 708 O
- NCT03861494 709 710 O
hospital NCT03861494 711 719 O
ischemic NCT03861494 720 728 B-Condition
cerebral NCT03861494 729 737 I-Condition
infarction NCT03861494 738 748 I-Condition

- NCT03861494 751 752 O
hospital NCT03861494 754 762 O
to NCT03861494 763 765 O
hospital NCT03861494 766 774 O
transfer NCT03861494 775 783 B-Encounter
patients NCT03861494 784 792 O

- NCT03861494 795 796 O
nursing NCT03861494 798 805 O
home NCT03861494 806 810 O
as NCT03861494 811 813 O
primary NCT03861494 814 821 O
residence NCT03861494 822 831 O
before NCT03861494 832 838 B-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03861494 839 841 B-Or
after NCT03861494 842 847 B-Temporal-Connection___Temporal-Connection-Type-Value:after
discharge NCT03861494 848 857 B-Encounter

- NCT03861494 860 861 O
hospice NCT03861494 863 870 B-Condition

- NCT03861494 873 874 O
inability NCT03861494 876 885 B-Condition
to NCT03861494 886 888 I-Condition
comply NCT03861494 889 895 I-Condition
with NCT03861494 896 900 O
post NCT03861494 901 905 B-Temporal-Connection___Temporal-Connection-Type-Value:after
discharge NCT03861494 906 915 B-Encounter
follow NCT03861494 916 922 B-Encounter
up NCT03861494 923 925 I-Encounter

Inclusion NCT03861325 0 9 O
Criteria NCT03861325 10 18 O
: NCT03861325 19 20 O

- NCT03861325 24 25 O
The NCT03861325 27 30 O
patient NCT03861325 31 38 O
or NCT03861325 39 41 O
his NCT03861325 42 45 O
/ NCT03861325 46 47 O
her NCT03861325 48 51 O
representative NCT03861325 52 66 O
has NCT03861325 67 70 O
been NCT03861325 71 75 O
informed NCT03861325 76 84 O
about NCT03861325 85 90 O
the NCT03861325 91 94 O
implementation NCT03861325 95 109 O
of NCT03861325 110 112 O
the NCT03861325 113 116 O
study NCT03861325 117 122 O
, NCT03861325 123 124 O
its NCT03861325 125 128 O
objectives NCT03861325 129 139 O
, NCT03861325 140 141 O
its NCT03861325 142 145 O
constraints NCT03861325 146 157 O
, NCT03861325 158 159 O
the NCT03861325 160 163 O
rights NCT03861325 164 170 O
of NCT03861325 171 173 O
the NCT03861325 174 177 O
patient NCT03861325 178 185 O
and NCT03861325 186 189 O
must NCT03861325 190 194 O
have NCT03861325 195 199 O
received NCT03861325 200 208 O
the NCT03861325 209 212 O
newsletter NCT03861325 213 223 O
and NCT03861325 224 227 O
no NCT03861325 228 230 O
opposition NCT03861325 231 241 O
of NCT03861325 242 244 O
the NCT03861325 245 248 O
study NCT03861325 249 254 O
. NCT03861325 254 255 O

- NCT03861325 259 260 O
The NCT03861325 262 265 O
patient NCT03861325 266 273 O
must NCT03861325 274 278 O
be NCT03861325 279 281 O
an NCT03861325 282 284 O
affiliate NCT03861325 285 294 O
or NCT03861325 295 297 O
beneficiary NCT03861325 298 309 O
of NCT03861325 310 312 O
a NCT03861325 313 314 O
health NCT03861325 315 321 O
insurance NCT03861325 322 331 O
plan NCT03861325 332 336 O
. NCT03861325 336 337 O

- NCT03861325 341 342 O
The NCT03861325 344 347 O
patient NCT03861325 348 355 O
is NCT03861325 356 358 O
at NCT03861325 359 361 B-Eq-Comparison
least NCT03861325 362 367 I-Eq-Comparison
18 NCT03861325 368 370 I-Eq-Comparison
years NCT03861325 371 376 I-Eq-Comparison
old NCT03861325 377 380 B-Age
. NCT03861325 380 381 O

- NCT03861325 385 386 O
The NCT03861325 388 391 O
patient NCT03861325 392 399 O
has NCT03861325 400 403 O
septic NCT03861325 404 410 B-Condition
shock NCT03861325 411 416 I-Condition
as NCT03861325 417 419 O
defined NCT03861325 420 427 O
by NCT03861325 428 430 O
the NCT03861325 431 434 O
3 NCT03861325 435 436 O
rd NCT03861325 437 439 O
International NCT03861325 440 453 O
Conference NCT03861325 454 464 O
for NCT03861325 465 468 O
the NCT03861325 469 472 O
definition NCT03861325 473 483 O
of NCT03861325 484 486 O
sepsis NCT03861325 487 493 O
and NCT03861325 494 497 O
septic NCT03861325 498 504 O
shock NCT03861325 505 510 O

Exclusion NCT03861325 511 520 O
Criteria NCT03861325 521 529 O
: NCT03861325 530 531 O

- NCT03861325 535 536 O
The NCT03861325 538 541 O
patient NCT03861325 542 549 O
is NCT03861325 550 552 O
in NCT03861325 553 555 O
an NCT03861325 556 558 O
exclusion NCT03861325 559 568 O
period NCT03861325 569 575 O
determined NCT03861325 576 586 O
by NCT03861325 587 589 O
a NCT03861325 590 591 O
previous NCT03861325 592 600 O
study NCT03861325 601 606 O

- NCT03861325 609 610 O
The NCT03861325 612 615 O
patient NCT03861325 616 623 O
is NCT03861325 624 626 O
under NCT03861325 627 632 O
guardianship NCT03861325 633 645 O
, NCT03861325 646 647 O
under NCT03861325 648 653 O
guardianship NCT03861325 654 666 O
, NCT03861325 667 668 O
or NCT03861325 669 671 O
under NCT03861325 672 677 O
the NCT03861325 678 681 O
protection NCT03861325 682 692 O
of NCT03861325 693 695 O
justice NCT03861325 696 703 O

- NCT03861325 706 707 O
The NCT03861325 709 712 O
patient NCT03861325 713 720 O
has NCT03861325 721 724 O
already NCT03861325 725 732 O
participated NCT03861325 733 745 O
in NCT03861325 746 748 O
this NCT03861325 749 753 O
study NCT03861325 754 759 O

- NCT03861325 762 763 O
The NCT03861325 765 768 O
patient NCT03861325 769 776 O
or NCT03861325 777 779 O
his NCT03861325 780 783 O
/ NCT03861325 784 785 O
her NCT03861325 786 789 O
representative NCT03861325 790 804 O
refuses NCT03861325 805 812 O
to NCT03861325 813 815 O
participate NCT03861325 816 827 O
in NCT03861325 828 830 O
the NCT03861325 831 834 O
study NCT03861325 835 840 O

- NCT03861325 843 844 O
The NCT03861325 846 849 O
patient NCT03861325 850 857 O
is NCT03861325 858 860 O
pregnant NCT03861325 861 869 B-Condition
, NCT03861325 870 871 O
parturient NCT03861325 872 882 B-Condition
or NCT03861325 883 885 B-Or
is NCT03861325 886 888 O
breastfeeding NCT03861325 889 902 B-Condition

- NCT03861325 905 906 O
The NCT03861325 908 911 O
patient NCT03861325 912 919 O
is NCT03861325 920 922 O
a NCT03861325 923 924 O
minor NCT03861325 925 930 O

- NCT03861325 933 934 O
The NCT03861325 936 939 O
patient NCT03861325 940 947 O
is NCT03861325 948 950 O
in NCT03861325 951 953 O
therapeutic NCT03861325 954 965 B-Condition
limitation NCT03861325 966 976 I-Condition
or NCT03861325 977 979 B-Or
moribund NCT03861325 980 988 B-Condition

- NCT03861325 991 992 O
The NCT03861325 994 997 O
patient NCT03861325 998 1005 O
has NCT03861325 1006 1009 B-Eq-Comparison
undergone NCT03861325 1010 1019 I-Eq-Comparison
or NCT03861325 1020 1022 B-Or
is NCT03861325 1023 1025 B-Eq-Comparison
going NCT03861325 1026 1031 I-Eq-Comparison
to NCT03861325 1032 1034 I-Eq-Comparison
have NCT03861325 1035 1039 I-Eq-Comparison
scheduled NCT03861325 1040 1049 B-Modifier
or NCT03861325 1050 1052 B-Or
emergency NCT03861325 1053 1062 B-Encounter
digestive NCT03861325 1063 1072 B-Procedure
surgery NCT03861325 1073 1080 I-Procedure

- NCT03861325 1083 1084 O
The NCT03861325 1086 1089 O
patient NCT03861325 1090 1097 O
is NCT03861325 1098 1100 O
HIV NCT03861325 1101 1104 B-Condition
- NCT03861325 1105 1106 O
positive NCT03861325 1107 1115 O

- NCT03861325 1118 1119 O
The NCT03861325 1121 1124 O
patient NCT03861325 1125 1132 O
has NCT03861325 1133 1136 O
Child NCT03861325 1137 1142 B-Modifier
C NCT03861325 1143 1144 O
cirrhosis NCT03861325 1145 1154 B-Condition

- NCT03861325 1157 1158 O
The NCT03861325 1160 1163 O
patient NCT03861325 1164 1171 O
has NCT03861325 1172 1175 O
progressive NCT03861325 1176 1187 B-Modifier
digestive NCT03861325 1188 1197 B-Condition
neoplasia NCT03861325 1198 1207 I-Condition
, NCT03861325 1208 1209 O
digestive NCT03861325 1210 1219 B-Condition
lymphoma NCT03861325 1220 1228 I-Condition
, NCT03861325 1229 1230 O
chronic NCT03861325 1231 1238 B-Modifier
inflammatory NCT03861325 1239 1251 B-Condition
bowel NCT03861325 1252 1257 I-Condition
disease NCT03861325 1258 1265 I-Condition|Condition
( NCT03861325 1266 1267 O
Crohn NCT03861325 1268 1273 B-Condition
's NCT03861325 1273 1275 O
disease NCT03861325 1276 1283 O
. NCT03861325 1284 1285 O
. NCT03861325 1286 1287 O
. NCT03861325 1288 1289 O
) NCT03861325 1290 1291 O
. NCT03861325 1292 1293 O

Inclusion NCT03867032 0 9 O
Criteria NCT03867032 10 18 O
: NCT03867032 19 20 O

- NCT03867032 24 25 O
Native NCT03867032 27 33 O
speakers NCT03867032 34 42 O
of NCT03867032 43 45 O
English NCT03867032 46 53 O

- NCT03867032 56 57 O
Cochlear NCT03867032 59 67 B-Procedure
Nucleus NCT03867032 68 75 I-Procedure
cochlear NCT03867032 76 84 I-Procedure
implant NCT03867032 85 92 I-Procedure
users NCT03867032 93 98 O
or NCT03867032 99 101 B-Or
Advanced NCT03867032 102 110 B-Procedure
Bionics NCT03867032 111 118 I-Procedure
users NCT03867032 119 124 O

- NCT03867032 127 128 O
Postlingually NCT03867032 130 143 B-Modifier
deafened NCT03867032 144 152 B-Condition

- NCT03867032 155 156 O
Has NCT03867032 158 161 O
had NCT03867032 162 165 O
device NCT03867032 166 172 B-Procedure
experience NCT03867032 173 183 O
for NCT03867032 184 187 O
at NCT03867032 188 190 B-Eq-Comparison
least NCT03867032 191 196 I-Eq-Comparison
one NCT03867032 197 200 I-Eq-Comparison
year NCT03867032 201 205 I-Eq-Comparison

- NCT03867032 208 209 O
Can NCT03867032 211 214 O
be NCT03867032 215 217 O
child NCT03867032 218 223 O
or NCT03867032 224 226 B-Or
adult NCT03867032 227 232 O
at NCT03867032 233 235 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867032 236 239 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867032 240 244 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867032 245 247 O
enrollment NCT03867032 248 258 B-Study

Exclusion NCT03867032 259 268 O
Criteria NCT03867032 269 277 O
: NCT03867032 278 279 O

- NCT03867032 283 284 O
None NCT03867032 286 290 O

Inclusion NCT03862638 0 9 O
Criteria NCT03862638 10 18 O
: NCT03862638 19 20 O

- NCT03862638 24 25 O
Meeting NCT03862638 27 34 O
the NCT03862638 35 38 O
diagnostic NCT03862638 39 49 O
criteria NCT03862638 50 58 O
of NCT03862638 59 61 O
CTTH NCT03862638 62 66 B-Condition
in NCT03862638 67 69 O
the NCT03862638 70 73 O
international NCT03862638 74 87 O
classification NCT03862638 88 102 O
of NCT03862638 103 105 O
headache NCT03862638 106 114 O
disorders NCT03862638 115 124 O
, NCT03862638 125 126 O
3 NCT03862638 127 128 O
rd NCT03862638 129 131 O
edition NCT03862638 132 139 O
( NCT03862638 140 141 O
beta NCT03862638 142 146 O
version NCT03862638 147 154 O
) NCT03862638 155 156 O
( NCT03862638 157 158 O
ICHD NCT03862638 159 163 O
- NCT03862638 164 165 O
III NCT03862638 166 169 O
beta NCT03862638 170 174 O
) NCT03862638 175 176 O
; NCT03862638 177 178 O

- NCT03862638 181 182 I-Eq-Comparison
Aged NCT03862638 184 188 B-Age
18 NCT03862638 189 191 B-Eq-Comparison
- NCT03862638 192 193 O
55 NCT03862638 194 196 I-Eq-Comparison
years NCT03862638 197 202 I-Eq-Comparison
; NCT03862638 202 203 O

- NCT03862638 206 207 O
Having NCT03862638 209 215 O
the NCT03862638 216 219 O
ability NCT03862638 220 227 O
of NCT03862638 228 230 O
understanding NCT03862638 231 244 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03862638 245 248 B-And
completing NCT03862638 249 259 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03862638 260 263 O
headache NCT03862638 264 272 B-Observation
dairy NCT03862638 273 278 I-Observation
; NCT03862638 278 279 O

- NCT03862638 282 283 O
Provide NCT03862638 285 292 O
written NCT03862638 293 300 O
informed NCT03862638 301 309 O
consent NCT03862638 310 317 O
. NCT03862638 317 318 O

Exclusion NCT03862638 320 329 O
Criteria NCT03862638 330 338 O
: NCT03862638 339 340 O

- NCT03862638 344 345 O
No NCT03862638 347 349 B-Negation
headache NCT03862638 350 358 B-Condition
during NCT03862638 359 365 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862638 366 369 O
pervious NCT03862638 370 378 B-Eq-Comparison
3 NCT03862638 379 380 I-Eq-Comparison
months NCT03862638 381 387 I-Eq-Comparison
; NCT03862638 387 388 O

- NCT03862638 391 392 O
Taking NCT03862638 394 400 O
any NCT03862638 401 404 O
prophylactic NCT03862638 405 417 B-Drug
medication NCT03862638 418 428 I-Drug
during NCT03862638 429 435 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862638 436 439 O
previous NCT03862638 440 448 B-Eq-Comparison
one NCT03862638 449 452 I-Eq-Comparison
month NCT03862638 453 458 I-Eq-Comparison
; NCT03862638 458 459 O

- NCT03862638 462 463 O
Secondary NCT03862638 465 474 B-Modifier
headache NCT03862638 475 483 B-Condition
or NCT03862638 484 486 B-Or
any NCT03862638 487 490 O
systematic NCT03862638 491 501 B-Modifier
cause NCT03862638 502 507 B-Condition

- NCT03862638 510 511 O
Having NCT03862638 513 519 O
serious NCT03862638 520 527 O
conditions NCT03862638 528 538 B-Condition
of NCT03862638 539 541 O
the NCT03862638 542 545 O
heart NCT03862638 546 551 B-Modifier
, NCT03862638 552 553 O
liver NCT03862638 554 559 B-Modifier
, NCT03862638 560 561 O
kidney NCT03862638 562 568 B-Modifier
or NCT03862638 569 571 B-Modifier|Or
other NCT03862638 572 577 B-Other
organs NCT03862638 578 584 O
; NCT03862638 584 585 O

- NCT03862638 588 589 O
In NCT03862638 591 593 O
pregnancy NCT03862638 594 603 B-Condition
or NCT03862638 604 606 B-Or|Or
lactation NCT03862638 607 616 B-Condition
, NCT03862638 617 618 O
or NCT03862638 619 621 O
planning NCT03862638 622 630 B-Assertion___Assertion-Type-Value:intention
to NCT03862638 631 633 O
be NCT03862638 634 636 O
pregnant NCT03862638 637 645 B-Condition
in NCT03862638 646 648 O
6 NCT03862638 649 650 B-Eq-Comparison
months NCT03862638 651 657 I-Eq-Comparison
; NCT03862638 657 658 O

- NCT03862638 661 662 O
Drug NCT03862638 664 668 B-Modifier
and NCT03862638 669 672 B-Or
Substance NCT03862638 673 682 B-Modifier
abuse NCT03862638 683 688 B-Condition

- NCT03862638 691 692 O
Diagnosed NCT03862638 694 703 O
psychiatric NCT03862638 704 715 B-Condition
condition NCT03862638 716 725 I-Condition

- NCT03862638 728 729 O
Taking NCT03862638 731 737 B-Eq-Comparison
any NCT03862638 738 741 O
other NCT03862638 742 747 B-Other
complementary NCT03862638 748 761 B-Modifier
and NCT03862638 762 765 B-Or
alternative NCT03862638 766 777 B-Modifier
medicines NCT03862638 778 787 B-Drug

- NCT03862638 790 791 O
Practicing NCT03862638 793 803 O
yoga NCT03862638 804 808 B-Observation
of NCT03862638 809 811 O
any NCT03862638 812 815 O
kind NCT03862638 816 820 O
in NCT03862638 821 823 O
last NCT03862638 824 828 B-Eq-Comparison
three NCT03862638 829 834 I-Eq-Comparison
months NCT03862638 835 841 I-Eq-Comparison

Inclusion NCT03864705 0 9 O
Criteria NCT03864705 10 18 O
: NCT03864705 19 20 O

- NCT03864705 24 25 O
Type NCT03864705 27 31 B-Modifier
2 NCT03864705 32 33 I-Modifier
diabetes NCT03864705 34 42 B-Condition
mellitus NCT03864705 43 51 I-Condition
on NCT03864705 52 54 O
metformin NCT03864705 55 64 B-Drug
therapy NCT03864705 65 72 B-Procedure
for NCT03864705 73 76 O
at NCT03864705 77 79 B-Eq-Comparison
least NCT03864705 80 85 I-Eq-Comparison
3 NCT03864705 86 87 I-Eq-Comparison
months NCT03864705 88 94 I-Eq-Comparison

Exclusion NCT03864705 95 104 O
Criteria NCT03864705 105 113 O
: NCT03864705 114 115 O

- NCT03864705 118 119 O

Inclusion NCT03868891 0 9 O
Criteria NCT03868891 10 18 O
: NCT03868891 19 20 O

- NCT03868891 24 25 O
6 NCT03868891 27 28 B-Eq-Comparison
- NCT03868891 29 30 I-Eq-Comparison
17 NCT03868891 31 33 I-Eq-Comparison
years NCT03868891 34 39 I-Eq-Comparison
old NCT03868891 40 43 B-Age

- NCT03868891 46 47 O
Otherwise NCT03868891 49 58 O
healthy NCT03868891 59 66 B-Condition

- NCT03868891 69 70 O
Currently NCT03868891 72 81 B-Eq-Comparison
have NCT03868891 82 86 O
unilateral NCT03868891 87 97 B-Modifier
or NCT03868891 98 100 B-Or
bilateral NCT03868891 101 110 B-Modifier
ventilation NCT03868891 111 122 B-Procedure
tube NCT03868891 123 127 I-Procedure
( NCT03868891 128 129 O
s NCT03868891 130 131 O
) NCT03868891 132 133 O
( NCT03868891 134 135 O
VTs NCT03868891 136 139 B-Procedure
) NCT03868891 140 141 O
inserted NCT03868891 142 150 B-Modifier
for NCT03868891 151 154 O
otitis NCT03868891 155 161 B-Condition
media NCT03868891 162 167 I-Condition
with NCT03868891 168 172 I-Condition
effusion NCT03868891 173 181 I-Condition
( NCT03868891 182 183 O
OME NCT03868891 184 187 B-Condition
) NCT03868891 188 189 O
or NCT03868891 190 192 B-Or
tympanic NCT03868891 193 201 B-Procedure
membrane NCT03868891 202 210 I-Procedure
retraction NCT03868891 211 221 I-Procedure|Procedure
/ NCT03868891 222 223 B-Or
retraction NCT03868891 224 234 O
pocket NCT03868891 235 241 I-Procedure
( NCT03868891 242 243 O
TM NCT03868891 244 246 B-Condition|Procedure
- NCT03868891 247 248 I-Procedure
R NCT03868891 249 250 I-Procedure
/ NCT03868891 251 252 I-Procedure
RP NCT03868891 253 255 I-Procedure
) NCT03868891 256 257 O
or NCT03868891 258 260 B-Or
a NCT03868891 261 262 O
TM NCT03868891 263 265 O
perforation NCT03868891 266 277 I-Condition
after NCT03868891 278 283 B-Procedure|Temporal-Connection___Temporal-Connection-Type-Value:after
extrusion NCT03868891 284 293 B-Procedure
of NCT03868891 294 296 I-Procedure
a NCT03868891 297 298 O
VT NCT03868891 299 301 I-Procedure

- NCT03868891 304 305 O
History NCT03868891 307 314 B-Eq-Comparison
of NCT03868891 315 317 O
at NCT03868891 318 320 B-Eq-Comparison
least NCT03868891 321 326 I-Eq-Comparison
2 NCT03868891 327 328 I-Eq-Comparison
sets NCT03868891 329 333 I-Eq-Comparison
of NCT03868891 334 336 O
VT NCT03868891 337 339 B-Procedure
insertions NCT03868891 340 350 I-Procedure
in NCT03868891 351 353 O
the NCT03868891 354 357 O
past NCT03868891 358 362 B-Eq-Comparison

- NCT03868891 365 366 O
Eustachian NCT03868891 368 378 B-Observation
tube NCT03868891 379 383 I-Observation
( NCT03868891 384 385 O
ET NCT03868891 386 388 B-Observation|Observation
) NCT03868891 389 390 O
function NCT03868891 391 399 B-Modifier
( NCT03868891 400 401 O
ETF NCT03868891 402 405 O
) NCT03868891 406 407 O
tests NCT03868891 408 413 O
showing NCT03868891 414 421 O
an NCT03868891 422 424 O
active NCT03868891 425 431 B-Eq-Comparison
muscular NCT03868891 432 440 B-Modifier
pattern NCT03868891 441 448 I-Modifier
of NCT03868891 449 451 O
Eustachian NCT03868891 452 462 B-Condition
tube NCT03868891 463 467 I-Condition
dysfunction NCT03868891 468 479 I-Condition

- NCT03868891 482 483 O
Tubomanometry NCT03868891 485 498 B-Observation
test NCT03868891 499 503 I-Observation
results NCT03868891 504 511 O
showing NCT03868891 512 519 O
evidence NCT03868891 520 528 O
of NCT03868891 529 531 O
velopharyngeal NCT03868891 532 546 B-Condition
dysfunction NCT03868891 547 558 I-Condition
during NCT03868891 559 565 B-Temporal-Connection___Temporal-Connection-Type-Value:during
swallowing NCT03868891 566 576 B-Observation

- NCT03868891 579 580 O
Cleft NCT03868891 582 587 B-Condition
palate NCT03868891 588 594 I-Condition
( NCT03868891 595 596 O
CP NCT03868891 597 599 B-Condition
) NCT03868891 600 601 O
cohort NCT03868891 602 608 O
: NCT03868891 609 610 O
non NCT03868891 611 614 B-Negation
- NCT03868891 615 616 O
syndromic NCT03868891 617 626 B-Condition
; NCT03868891 626 627 O
prior NCT03868891 628 633 B-Eq-Comparison
Furlow NCT03868891 634 640 B-Procedure
palatoplasty NCT03868891 641 653 I-Procedure
without NCT03868891 654 661 B-Negation
complications NCT03868891 662 675 B-Condition
or NCT03868891 676 678 B-Or
need NCT03868891 679 683 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868891 684 687 I-Assertion___Assertion-Type-Value:hypothetical
revision NCT03868891 688 696 B-Procedure

- NCT03868891 699 700 O
Non NCT03868891 702 705 B-Negation
- NCT03868891 706 707 O
CP NCT03868891 708 710 B-Condition
cohort NCT03868891 711 717 O
: NCT03868891 718 719 O
have NCT03868891 720 724 O
had NCT03868891 725 728 O
prior NCT03868891 729 734 B-Eq-Comparison
adenoidectomy NCT03868891 735 748 B-Procedure

Exclusion NCT03868891 749 758 O
Criteria NCT03868891 759 767 O
: NCT03868891 768 769 O

- NCT03868891 773 774 O
Concurrent NCT03868891 776 786 B-Eq-Comparison
or NCT03868891 787 789 B-Or|Or
past NCT03868891 790 794 B-Eq-Comparison
diagnosis NCT03868891 795 804 O
of NCT03868891 805 807 O
cancer NCT03868891 808 814 B-Condition
or NCT03868891 815 817 O
history NCT03868891 818 825 B-Eq-Comparison
of NCT03868891 826 828 O
radiation NCT03868891 829 838 B-Procedure

- NCT03868891 841 842 O
Have NCT03868891 844 848 B-Eq-Comparison
or NCT03868891 849 851 B-Or
had NCT03868891 852 855 B-Eq-Comparison
vestibular NCT03868891 856 866 B-Condition
pathology NCT03868891 867 876 I-Condition
, NCT03868891 877 878 O
cranial NCT03868891 879 886 B-Modifier
base NCT03868891 887 891 I-Modifier
surgery NCT03868891 892 899 B-Procedure
or NCT03868891 900 902 B-Or
ossicular NCT03868891 903 912 B-Modifier
chain NCT03868891 913 918 B-Procedure
reconstruction NCT03868891 919 933 I-Procedure

- NCT03868891 936 937 O
Craniofacial NCT03868891 939 951 B-Condition
dysmorphology NCT03868891 952 965 I-Condition
( NCT03868891 966 967 O
other NCT03868891 968 973 B-Exception
than NCT03868891 974 978 I-Exception
non NCT03868891 979 982 B-Negation
- NCT03868891 983 984 O
syndromic NCT03868891 985 994 B-Modifier
CP NCT03868891 995 997 B-Condition|Condition
with NCT03868891 998 1002 B-And|Negation
or NCT03868891 1003 1005 B-Or
without NCT03868891 1006 1013 O
cleft NCT03868891 1014 1019 B-Condition
lip NCT03868891 1020 1023 I-Condition
in NCT03868891 1024 1026 O
the NCT03868891 1027 1030 O
CP NCT03868891 1031 1033 O
cohort NCT03868891 1034 1040 O
) NCT03868891 1041 1042 O
or NCT03868891 1043 1045 B-Or
other NCT03868891 1046 1051 B-Other
syndrome NCT03868891 1052 1060 B-Condition

- NCT03868891 1063 1064 O
A NCT03868891 1066 1067 O
non NCT03868891 1068 1071 B-Negation
- NCT03868891 1072 1073 O
patent NCT03868891 1074 1080 B-Modifier
nasal NCT03868891 1081 1086 B-Condition
cavity NCT03868891 1087 1093 I-Condition

- NCT03868891 1096 1097 O
Patulous NCT03868891 1099 1107 B-Condition
ET NCT03868891 1108 1110 I-Condition|Condition
or NCT03868891 1111 1113 B-Or|Or
pathologically NCT03868891 1114 1128 B-Condition
low NCT03868891 1129 1132 I-Condition
ET NCT03868891 1133 1135 O
opening NCT03868891 1136 1143 B-Modifier
or NCT03868891 1144 1146 O
closing NCT03868891 1147 1154 B-Modifier
pressures NCT03868891 1155 1164 I-Modifier

- NCT03868891 1167 1168 O
Pregnancy NCT03868891 1170 1179 B-Condition

- NCT03868891 1182 1183 O
Unable NCT03868891 1185 1191 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868891 1192 1194 B-Or
unwilling NCT03868891 1195 1204 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868891 1205 1207 O
perform NCT03868891 1208 1215 O
the NCT03868891 1216 1219 O
tests NCT03868891 1220 1225 B-Observation
and NCT03868891 1226 1229 B-Or
exercises NCT03868891 1230 1239 B-Observation
outlined NCT03868891 1240 1248 O
in NCT03868891 1249 1251 O
the NCT03868891 1252 1255 O
study NCT03868891 1256 1261 B-Study

Inclusion NCT03867552 0 9 O
Criteria NCT03867552 10 18 O
: NCT03867552 19 20 O

- NCT03867552 24 25 O
Woman NCT03867552 27 32 O
≥ NCT03867552 33 34 B-Eq-Comparison
18 NCT03867552 35 37 I-Eq-Comparison
years NCT03867552 38 43 I-Eq-Comparison
old NCT03867552 44 47 B-Age

- NCT03867552 50 51 O
undergoing NCT03867552 53 63 B-Eq-Comparison
laparoscopic NCT03867552 64 76 B-Procedure
surgery NCT03867552 77 84 I-Procedure
for NCT03867552 85 88 O
endometriosis NCT03867552 89 102 B-Condition
, NCT03867552 103 104 O
uterine NCT03867552 105 112 B-Condition
myoma NCT03867552 113 118 I-Condition
's NCT03867552 118 120 O
, NCT03867552 121 122 O
hysterectomy NCT03867552 123 135 B-Procedure
or NCT03867552 136 138 B-Or
colpopexy NCT03867552 139 148 B-Procedure
. NCT03867552 148 149 O

Exclusion NCT03867552 151 160 O
Criteria NCT03867552 161 169 O
: NCT03867552 170 171 O

- NCT03867552 175 176 O
Women NCT03867552 178 183 O
< NCT03867552 184 185 B-Eq-Comparison
18 NCT03867552 186 188 I-Eq-Comparison
years NCT03867552 189 194 I-Eq-Comparison
old NCT03867552 195 198 B-Age

- NCT03867552 201 202 O
Males NCT03867552 204 209 O

- NCT03867552 212 213 O
Pregnancy NCT03867552 215 224 B-Condition

- NCT03867552 227 228 O
Conditions NCT03867552 230 240 B-Condition
associated NCT03867552 241 251 O
with NCT03867552 252 256 O
chronic NCT03867552 257 264 B-Modifier
pain NCT03867552 265 269 B-Condition
, NCT03867552 270 271 O
such NCT03867552 272 276 O
as NCT03867552 277 279 O
peripheral NCT03867552 280 290 B-Condition
neuropathy NCT03867552 291 301 I-Condition
, NCT03867552 302 303 O
pathology NCT03867552 304 313 B-Condition
of NCT03867552 314 316 O
the NCT03867552 317 320 O
vertebral NCT03867552 321 330 B-Modifier
column NCT03867552 331 337 I-Modifier
and NCT03867552 338 341 B-Or
osteo NCT03867552 342 347 B-Condition
- NCT03867552 348 349 I-Condition
articular NCT03867552 350 359 I-Condition
disease NCT03867552 360 367 I-Condition
. NCT03867552 367 368 O

- NCT03867552 372 373 O
Conditions NCT03867552 375 385 B-Condition
causing NCT03867552 386 393 O
acute NCT03867552 394 399 O
pain NCT03867552 400 404 B-Condition
e. NCT03867552 405 407 O
g. NCT03867552 408 410 O
abdominal NCT03867552 412 421 B-Modifier
trauma NCT03867552 422 428 B-Condition

Inclusion NCT03868852 0 9 O
Criteria NCT03868852 10 18 O
: NCT03868852 19 20 O

- NCT03868852 24 25 O
Patients NCT03868852 27 35 O
must NCT03868852 36 40 O
be NCT03868852 41 43 O
≥ NCT03868852 44 45 B-Eq-Comparison
3 NCT03868852 46 47 I-Eq-Comparison
and NCT03868852 48 51 B-And
≤ NCT03868852 52 53 B-Eq-Comparison
18 NCT03868852 54 56 I-Eq-Comparison
years NCT03868852 57 62 I-Eq-Comparison
of NCT03868852 63 65 O
age NCT03868852 66 69 B-Age
. NCT03868852 69 70 O

- NCT03868852 74 75 O
The NCT03868852 77 80 O
predicted NCT03868852 81 90 B-Observation
survival NCT03868852 91 99 I-Observation
period NCT03868852 100 106 O
is NCT03868852 107 109 O
more NCT03868852 110 114 B-Eq-Comparison
than NCT03868852 115 119 I-Eq-Comparison
3 NCT03868852 120 121 I-Eq-Comparison
months NCT03868852 122 128 I-Eq-Comparison
. NCT03868852 128 129 O

- NCT03868852 133 134 O
According NCT03868852 136 145 O
to NCT03868852 146 148 O
RECIST NCT03868852 149 155 O
version NCT03868852 156 163 O
1.1 NCT03868852 164 167 O
, NCT03868852 168 169 O
there NCT03868852 170 175 O
is NCT03868852 176 178 O
at NCT03868852 179 181 B-Eq-Comparison
least NCT03868852 182 187 I-Eq-Comparison
one NCT03868852 188 191 I-Eq-Comparison
measurable NCT03868852 192 202 O
lesion NCT03868852 203 209 B-Condition
. NCT03868852 209 210 O

- NCT03868852 214 215 O
Post NCT03868852 217 221 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03868852 222 223 O
- NCT03868852 225 226 O
operative NCT03868852 227 236 B-Procedure
pathological NCT03868852 237 249 B-Condition
stage NCT03868852 250 255 I-Condition
was NCT03868852 256 259 O
group NCT03868852 260 265 B-Eq-Comparison
II NCT03868852 266 268 I-Eq-Comparison
- NCT03868852 269 270 I-Eq-Comparison
IV NCT03868852 271 273 I-Eq-Comparison
. NCT03868852 273 274 O

- NCT03868852 278 279 O
Patients NCT03868852 281 289 O
have NCT03868852 290 294 O
not NCT03868852 295 298 B-Negation
received NCT03868852 299 307 B-Eq-Comparison
radiotherapy NCT03868852 308 320 B-Procedure
before NCT03868852 321 327 B-Eq-Comparison
, NCT03868852 328 329 O
and NCT03868852 330 333 B-And
can NCT03868852 334 337 B-Assertion___Assertion-Type-Value:hypothetical
accept NCT03868852 338 344 I-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03868852 345 357 B-Procedure
and NCT03868852 358 361 B-Or
surgical NCT03868852 362 370 B-Procedure
treatment NCT03868852 371 380 I-Procedure
. NCT03868852 380 381 O

- NCT03868852 385 386 O
No NCT03868852 388 390 B-Negation
other NCT03868852 391 396 B-Other
anticancer NCT03868852 397 407 B-Procedure
therapy NCT03868852 408 415 I-Procedure
should NCT03868852 416 422 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03868852 423 425 I-Assertion___Assertion-Type-Value:hypothetical
used NCT03868852 426 430 O
during NCT03868852 431 437 B-Temporal-Connection___Temporal-Connection-Type-Value:during
radiotherapy NCT03868852 438 450 B-Procedure
. NCT03868852 450 451 O

- NCT03868852 455 456 O
The NCT03868852 458 461 O
main NCT03868852 462 466 B-Condition
organs NCT03868852 467 473 I-Condition
are NCT03868852 474 477 O
functioning NCT03868852 478 489 O
normally NCT03868852 490 498 O
, NCT03868852 499 500 O
which NCT03868852 501 506 O
meets NCT03868852 507 512 O
the NCT03868852 513 516 B-Criteria-Count
following NCT03868852 517 526 I-Criteria-Count
criteria NCT03868852 527 535 I-Criteria-Count
: NCT03868852 536 537 O

1 NCT03868852 546 547 O
. NCT03868852 547 548 O
Blood NCT03868852 550 555 B-Procedure
routine NCT03868852 556 563 I-Procedure
examination NCT03868852 564 575 I-Procedure
standards NCT03868852 576 585 O
should NCT03868852 586 592 O
be NCT03868852 593 595 O
met NCT03868852 596 599 O
: NCT03868852 600 601 O
( NCT03868852 602 603 O
no NCT03868852 604 606 B-Negation
blood NCT03868852 607 612 B-Procedure
transfusion NCT03868852 613 624 I-Procedure
within NCT03868852 625 631 B-Eq-Comparison
14 NCT03868852 632 634 I-Eq-Comparison
days NCT03868852 635 639 I-Eq-Comparison
) NCT03868852 640 641 O
A. NCT03868852 642 644 O
HB NCT03868852 646 648 B-Observation
> NCT03868852 649 650 B-Eq-Comparison|Eq-Comparison
90 NCT03868852 651 653 I-Eq-Comparison
g NCT03868852 654 655 I-Eq-Comparison
/ NCT03868852 656 657 I-Eq-Comparison|Eq-Comparison
L NCT03868852 658 659 I-Eq-Comparison|Eq-Comparison
; NCT03868852 659 660 O
B. NCT03868852 661 663 O
ANC NCT03868852 665 668 B-Observation
> NCT03868852 669 670 B-Eq-Comparison
1.5 NCT03868852 671 674 I-Eq-Comparison
* NCT03868852 675 676 I-Eq-Comparison|Eq-Comparison
109 NCT03868852 677 680 I-Eq-Comparison|Eq-Comparison
/ NCT03868852 681 682 I-Eq-Comparison
L NCT03868852 683 684 I-Eq-Comparison
; NCT03868852 684 685 O
C. NCT03868852 686 688 O
PLT NCT03868852 690 693 B-Observation
> NCT03868852 694 695 O
80 NCT03868852 696 698 I-Eq-Comparison
* NCT03868852 699 700 O
109 NCT03868852 701 704 O
/ NCT03868852 705 706 O
L NCT03868852 707 708 O

2 NCT03868852 716 717 O
. NCT03868852 717 718 O
Biochemical NCT03868852 720 731 B-Observation
tests NCT03868852 732 737 I-Observation
should NCT03868852 738 744 O
meet NCT03868852 745 749 O
the NCT03868852 750 753 B-Criteria-Count
following NCT03868852 754 763 I-Criteria-Count
criteria NCT03868852 764 772 I-Criteria-Count
: NCT03868852 773 774 O

A. NCT03868852 776 778 O
BIL NCT03868852 780 783 B-Observation
< NCT03868852 784 785 B-Eq-Comparison
1.25 NCT03868852 786 790 I-Eq-Comparison
times NCT03868852 791 796 I-Eq-Comparison
normal NCT03868852 797 803 I-Eq-Comparison
upper NCT03868852 804 809 I-Eq-Comparison
limit NCT03868852 810 815 I-Eq-Comparison
( NCT03868852 816 817 O
ULN NCT03868852 818 821 I-Eq-Comparison
) NCT03868852 822 823 O
; NCT03868852 824 825 O
B. NCT03868852 826 828 O
ALT NCT03868852 830 833 B-Observation
and NCT03868852 834 837 B-And
AST NCT03868852 838 841 B-Observation
< NCT03868852 842 843 B-Eq-Comparison|Eq-Comparison
2.5 NCT03868852 844 847 I-Eq-Comparison
ULN NCT03868852 848 851 I-Eq-Comparison
; NCT03868852 851 852 O
C. NCT03868852 853 855 O
Serum NCT03868852 857 862 B-Observation
Cr NCT03868852 863 865 I-Observation
< NCT03868852 866 867 O
1 NCT03868852 868 869 I-Eq-Comparison
ULN NCT03868852 870 873 O
, NCT03868852 874 875 O
endogenous NCT03868852 876 886 B-Observation
creatinine NCT03868852 887 897 I-Observation
clearance NCT03868852 898 907 I-Observation
> NCT03868852 908 909 B-Eq-Comparison
50 NCT03868852 910 912 I-Eq-Comparison
ml NCT03868852 913 915 I-Eq-Comparison
/ NCT03868852 916 917 I-Eq-Comparison
min NCT03868852 918 921 I-Eq-Comparison

- NCT03868852 924 925 O
Subjects NCT03868852 927 935 O
volunteered NCT03868852 936 947 O
to NCT03868852 948 950 O
participate NCT03868852 951 962 O
in NCT03868852 963 965 O
this NCT03868852 966 970 O
study NCT03868852 971 976 O
, NCT03868852 977 978 O
patients NCT03868852 979 987 O
or NCT03868852 988 990 O
legal NCT03868852 991 996 O
guardians NCT03868852 997 1006 O
signed NCT03868852 1007 1013 O
informed NCT03868852 1014 1022 O
consent NCT03868852 1023 1030 O
through NCT03868852 1031 1038 O
patient NCT03868852 1039 1046 O
consent NCT03868852 1047 1054 O
, NCT03868852 1055 1056 O
good NCT03868852 1057 1061 O
compliance NCT03868852 1062 1072 O
, NCT03868852 1073 1074 O
with NCT03868852 1075 1079 O
follow NCT03868852 1080 1086 O
- NCT03868852 1087 1088 O
up NCT03868852 1089 1091 O
. NCT03868852 1091 1092 O

- NCT03868852 1096 1097 O
Doctors NCT03868852 1099 1106 O
believe NCT03868852 1107 1114 O
that NCT03868852 1115 1119 O
treatment NCT03868852 1120 1129 O
can NCT03868852 1130 1133 O
benefit NCT03868852 1134 1141 O
patients NCT03868852 1142 1150 O
. NCT03868852 1150 1151 O


Inclusion NCT03869580 0 9 O
Criteria NCT03869580 10 18 O
: NCT03869580 19 20 O

- NCT03869580 24 25 O
Patients NCT03869580 27 35 O
with NCT03869580 36 40 O
a NCT03869580 41 42 O
double NCT03869580 43 49 B-Procedure
- NCT03869580 50 51 I-Procedure
J NCT03869580 52 53 I-Procedure
stent NCT03869580 54 59 I-Procedure
placement NCT03869580 60 69 B-Modifier
or NCT03869580 70 72 B-Or
change NCT03869580 73 79 B-Modifier
in NCT03869580 80 82 O
the NCT03869580 83 86 O
hospital NCT03869580 87 95 O

Exclusion NCT03869580 96 105 O
Criteria NCT03869580 106 114 O
: NCT03869580 115 116 O

- NCT03869580 120 121 O
renal NCT03869580 123 128 B-Modifier
transplants NCT03869580 129 140 B-Procedure
less NCT03869580 141 145 B-Eq-Comparison
than NCT03869580 146 150 I-Eq-Comparison
one NCT03869580 151 154 I-Eq-Comparison
year NCT03869580 155 159 I-Eq-Comparison
old NCT03869580 160 163 O

Inclusion NCT03867591 0 9 O
Criteria NCT03867591 10 18 O
: NCT03867591 19 20 O

- NCT03867591 24 25 O
Able NCT03867591 27 31 O
to NCT03867591 32 34 O
provide NCT03867591 35 42 O
written NCT03867591 43 50 O
informed NCT03867591 51 59 O
consent NCT03867591 60 67 O
in NCT03867591 68 70 O
English NCT03867591 71 78 O
. NCT03867591 78 79 O

- NCT03867591 83 84 O
Willing NCT03867591 86 93 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 94 96 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03867591 97 101 O
height NCT03867591 102 108 B-Observation
and NCT03867591 109 112 B-Or
weight NCT03867591 113 119 B-Observation
measured NCT03867591 120 128 O
and NCT03867591 129 132 O
provide NCT03867591 133 140 O
demographic NCT03867591 141 152 O
information NCT03867591 153 164 O
( NCT03867591 165 166 O
e. NCT03867591 167 169 O
g. NCT03867591 170 172 O
age NCT03867591 174 177 O
, NCT03867591 178 179 O
race NCT03867591 180 184 O
, NCT03867591 185 186 O
sex NCT03867591 187 190 O
) NCT03867591 191 192 O

- NCT03867591 196 197 O
Experience NCT03867591 199 209 O
heartburn NCT03867591 210 219 B-Condition
symptoms NCT03867591 220 228 B-Assertion___Assertion-Type-Value:possible
at NCT03867591 229 231 B-Eq-Comparison
least NCT03867591 232 237 I-Eq-Comparison
2 NCT03867591 238 239 I-Eq-Comparison
days NCT03867591 240 244 I-Eq-Comparison
a NCT03867591 245 246 I-Eq-Comparison
week NCT03867591 247 251 I-Eq-Comparison
during NCT03867591 252 258 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 259 262 O
past NCT03867591 263 267 B-Eq-Comparison
3 NCT03867591 268 269 I-Eq-Comparison
months NCT03867591 270 276 I-Eq-Comparison
. NCT03867591 276 277 O

- NCT03867591 281 282 O
Use NCT03867591 284 287 B-Eq-Comparison
OTC NCT03867591 288 291 B-Drug
product NCT03867591 292 299 I-Drug
( NCT03867591 300 301 O
s NCT03867591 302 303 O
) NCT03867591 304 305 O
, NCT03867591 307 308 O
supplements NCT03867591 309 320 B-Drug
, NCT03867591 321 322 O
or NCT03867591 323 325 B-Or
dietary NCT03867591 326 333 B-Drug
manipulation NCT03867591 334 346 I-Drug
to NCT03867591 347 349 O
relieve NCT03867591 350 357 O
heartburn NCT03867591 358 367 B-Condition
symptoms NCT03867591 368 376 B-Assertion___Assertion-Type-Value:possible
in NCT03867591 377 379 O
the NCT03867591 380 383 O
last NCT03867591 384 388 B-Eq-Comparison
3 NCT03867591 389 390 I-Eq-Comparison
months NCT03867591 391 397 I-Eq-Comparison
. NCT03867591 397 398 O

- NCT03867591 402 403 O
Willing NCT03867591 405 412 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 413 415 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03867591 416 420 O
the NCT03867591 421 424 O
study NCT03867591 425 430 B-Study
soy NCT03867591 431 434 B-Drug
supplement NCT03867591 435 445 I-Drug
before NCT03867591 446 452 B-Temporal-Connection___Temporal-Connection-Type-Value:before
resorting NCT03867591 453 462 O
to NCT03867591 463 465 O
OTC NCT03867591 466 469 B-Drug
product NCT03867591 470 477 I-Drug
( NCT03867591 478 479 O
s NCT03867591 480 481 O
) NCT03867591 482 483 O
to NCT03867591 484 486 O
control NCT03867591 487 494 O
heartburn NCT03867591 495 504 B-Condition
symptoms NCT03867591 505 513 B-Assertion___Assertion-Type-Value:possible
. NCT03867591 513 514 O

- NCT03867591 518 519 O
Willing NCT03867591 521 528 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 529 531 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03867591 532 540 O
questionnaires NCT03867591 541 555 B-Observation
, NCT03867591 556 557 O
records NCT03867591 558 565 B-Observation
, NCT03867591 566 567 O
and NCT03867591 568 571 B-Or
diaries NCT03867591 572 579 B-Observation
associated NCT03867591 580 590 O
with NCT03867591 591 595 O
the NCT03867591 596 599 O
study NCT03867591 600 605 B-Study
and NCT03867591 606 609 O
to NCT03867591 610 612 O
complete NCT03867591 613 621 O
all NCT03867591 622 625 O
clinical NCT03867591 626 634 B-Encounter
visits NCT03867591 635 641 I-Encounter
. NCT03867591 641 642 O

- NCT03867591 646 647 O
Willing NCT03867591 649 656 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 657 659 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03867591 660 667 O
information NCT03867591 668 679 O
about NCT03867591 680 685 O
dietary NCT03867591 686 693 B-Observation
intake NCT03867591 694 700 I-Observation
; NCT03867591 700 701 O
3 NCT03867591 702 703 B-Eq-Comparison
- NCT03867591 704 705 I-Eq-Comparison
day NCT03867591 706 709 I-Eq-Comparison
online NCT03867591 710 716 I-Eq-Comparison
24 NCT03867591 717 719 I-Eq-Comparison
- NCT03867591 720 721 O
hr NCT03867591 722 724 I-Eq-Comparison
recalls NCT03867591 725 732 B-Observation
during NCT03867591 733 739 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03867591 740 748 B-Study
, NCT03867591 749 750 O
intervention NCT03867591 751 763 B-Procedure
, NCT03867591 764 765 O
and NCT03867591 766 769 B-And
washout NCT03867591 770 777 B-Procedure
. NCT03867591 777 778 O

- NCT03867591 782 783 O
Willing NCT03867591 785 792 O
and NCT03867591 793 796 O
able NCT03867591 797 801 O
to NCT03867591 802 804 O
provide NCT03867591 805 812 O
a NCT03867591 813 814 O
valid NCT03867591 815 820 O
social NCT03867591 821 827 O
security NCT03867591 828 836 O
for NCT03867591 837 840 O
study NCT03867591 841 846 O
payment NCT03867591 847 854 O
purposes NCT03867591 855 863 O
. NCT03867591 863 864 O

Exclusion NCT03867591 866 875 O
Criteria NCT03867591 876 884 O
: NCT03867591 885 886 O

- NCT03867591 890 891 O
Do NCT03867591 893 895 O
not NCT03867591 896 899 O
meet NCT03867591 900 904 O
the NCT03867591 905 908 O
above NCT03867591 909 914 O
criteria NCT03867591 915 923 O
. NCT03867591 923 924 O

- NCT03867591 928 929 O
Soy NCT03867591 931 934 O
allergy NCT03867591 935 942 B-Allergy

- NCT03867591 945 946 O
Severe NCT03867591 948 954 O
heartburn NCT03867591 955 964 B-Condition
problem NCT03867591 965 972 I-Condition
( NCT03867591 973 974 O
can NCT03867591 975 978 O
not NCT03867591 978 981 O
be NCT03867591 982 984 O
ignored NCT03867591 985 992 O
and NCT03867591 993 996 O
often NCT03867591 997 1002 B-Assertion___Assertion-Type-Value:hypothetical
limits NCT03867591 1003 1009 O
your NCT03867591 1010 1014 O
concentration NCT03867591 1015 1028 B-Condition
on NCT03867591 1029 1031 O
daily NCT03867591 1032 1037 B-Eq-Comparison
activities NCT03867591 1038 1048 O
) NCT03867591 1049 1050 O
during NCT03867591 1051 1057 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 1058 1061 O
last NCT03867591 1062 1066 B-Eq-Comparison
week NCT03867591 1067 1071 I-Eq-Comparison

- NCT03867591 1074 1075 O
Diagnosed NCT03867591 1077 1086 B-Coreference
or NCT03867591 1087 1089 B-Or
currently NCT03867591 1090 1099 B-Eq-Comparison
being NCT03867591 1100 1105 I-Eq-Comparison
treated NCT03867591 1106 1113 B-Procedure
for NCT03867591 1114 1117 O
any NCT03867591 1118 1121 O
gastrointestinal NCT03867591 1122 1138 B-Condition
diseases NCT03867591 1139 1147 I-Condition
including NCT03867591 1148 1157 O
GERD NCT03867591 1158 1162 B-Condition
, NCT03867591 1163 1164 O
gastric NCT03867591 1165 1172 B-Condition
ulcers NCT03867591 1173 1179 I-Condition
, NCT03867591 1180 1181 O
Crohn NCT03867591 1182 1187 B-Condition
's NCT03867591 1187 1189 O
, NCT03867591 1190 1191 O
celiac NCT03867591 1192 1198 B-Condition
, NCT03867591 1199 1200 O
ulcerative NCT03867591 1201 1211 B-Condition
colitis NCT03867591 1212 1219 I-Condition
, NCT03867591 1220 1221 O
etc NCT03867591 1222 1225 O
. NCT03867591 1225 1226 O

- NCT03867591 1230 1231 I-Condition
Self NCT03867591 1233 1237 O
- NCT03867591 1238 1239 O
disclosed NCT03867591 1240 1249 O
as NCT03867591 1250 1252 O
pregnant NCT03867591 1253 1261 B-Condition
or NCT03867591 1262 1264 B-Or|Or
breast NCT03867591 1265 1271 B-Condition
- NCT03867591 1272 1273 O
feeding NCT03867591 1274 1281 I-Condition
or NCT03867591 1282 1284 O
planning NCT03867591 1285 1293 B-Assertion___Assertion-Type-Value:intention
on NCT03867591 1294 1296 O
becoming NCT03867591 1297 1305 O
pregnant NCT03867591 1306 1314 B-Condition
during NCT03867591 1315 1321 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 1322 1325 O
study NCT03867591 1326 1331 B-Study
duration NCT03867591 1332 1340 O
. NCT03867591 1340 1341 O

- NCT03867591 1345 1346 O
Currently NCT03867591 1348 1357 B-Eq-Comparison
participating NCT03867591 1358 1371 O
in NCT03867591 1372 1374 O
another NCT03867591 1375 1382 B-Other
clinical NCT03867591 1383 1391 O
study NCT03867591 1392 1397 B-Study
. NCT03867591 1397 1398 O

Inclusion NCT03863522 0 9 O
Criteria NCT03863522 10 18 O
: NCT03863522 19 20 O

- NCT03863522 24 25 O
Patient NCT03863522 27 34 O
must NCT03863522 35 39 O
be NCT03863522 40 42 O
female NCT03863522 43 49 O

- NCT03863522 52 53 O
Patient NCT03863522 55 62 O
must NCT03863522 63 67 O
be NCT03863522 68 70 O
18 NCT03863522 71 73 B-Eq-Comparison
years NCT03863522 74 79 I-Eq-Comparison
of NCT03863522 80 82 I-Eq-Comparison
age NCT03863522 83 86 I-Age|Eq-Comparison
or NCT03863522 87 89 I-Eq-Comparison
older NCT03863522 90 95 I-Eq-Comparison

- NCT03863522 98 99 O
Patient NCT03863522 101 108 O
has NCT03863522 109 112 O
been NCT03863522 113 117 O
recommended NCT03863522 118 129 O
for NCT03863522 130 133 O
ultrasound NCT03863522 134 144 B-Procedure
core NCT03863522 145 149 I-Procedure
needle NCT03863522 150 156 I-Procedure
biopsy NCT03863522 157 163 I-Procedure
of NCT03863522 164 166 O
a NCT03863522 167 168 O
suspicious NCT03863522 169 179 B-Assertion___Assertion-Type-Value:possible
breast NCT03863522 180 186 B-Condition
lesion NCT03863522 187 193 I-Condition

Exclusion NCT03863522 194 203 O
Criteria NCT03863522 204 212 O
: NCT03863522 213 214 O

- NCT03863522 218 219 O
Patients NCT03863522 221 229 O
may NCT03863522 230 233 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03863522 234 236 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03863522 237 245 B-Negation
for NCT03863522 246 249 O
any NCT03863522 250 253 O
condition NCT03863522 254 263 B-Condition
that NCT03863522 264 268 O
in NCT03863522 269 271 O
the NCT03863522 272 275 O
opinion NCT03863522 276 283 O
of NCT03863522 284 286 O
the NCT03863522 287 290 O
investigator NCT03863522 291 303 O
may NCT03863522 304 307 O
not NCT03863522 308 311 O
make NCT03863522 312 316 O
it NCT03863522 317 319 O
safe NCT03863522 320 324 O
to NCT03863522 325 327 O
take NCT03863522 328 332 O
part NCT03863522 333 337 O
( NCT03863522 338 339 O
e. NCT03863522 340 342 O
g. NCT03863522 343 345 O
certain NCT03863522 347 354 O
medicines NCT03863522 355 364 B-Drug
) NCT03863522 365 366 O
. NCT03863522 367 368 O

Inclusion NCT03868488 0 9 O
Criteria NCT03868488 10 18 O
: NCT03868488 19 20 O

- NCT03868488 24 25 O
The NCT03868488 27 30 O
scores NCT03868488 31 37 O
of NCT03868488 38 40 O
the NCT03868488 41 44 O
9 NCT03868488 45 46 O
items NCT03868488 47 52 O
of NCT03868488 53 55 O
The NCT03868488 56 59 O
Diagnostic NCT03868488 60 70 O
and NCT03868488 71 74 O
Statistical NCT03868488 75 86 O
Manual NCT03868488 87 93 O
of NCT03868488 94 96 O
Mental NCT03868488 97 103 O
Disorders NCT03868488 104 113 O
, NCT03868488 114 115 O
Fifth NCT03868488 116 121 O
Edition NCT03868488 122 129 O
( NCT03868488 130 131 O
DSM NCT03868488 132 135 O
- NCT03868488 136 137 O
5 NCT03868488 138 139 O
) NCT03868488 140 141 O
recommended NCT03868488 142 153 O
diagnosis NCT03868488 154 163 O
for NCT03868488 164 167 O
Internet NCT03868488 168 176 B-Condition
gaming NCT03868488 177 183 I-Condition
disorder NCT03868488 184 192 I-Condition
≥ NCT03868488 193 194 B-Eq-Comparison
5 NCT03868488 195 196 I-Eq-Comparison
. NCT03868488 196 197 O

- NCT03868488 201 202 O
Engagement NCT03868488 204 214 B-Observation
in NCT03868488 215 217 I-Observation
popular NCT03868488 218 225 I-Observation
Internet NCT03868488 226 234 I-Observation
games NCT03868488 235 240 I-Observation
( NCT03868488 241 242 O
e. NCT03868488 243 245 O
g. NCT03868488 246 248 O
Arena NCT03868488 250 255 O
of NCT03868488 256 258 O
Valor NCT03868488 259 264 O
, NCT03868488 265 266 O
League NCT03868488 267 273 O
of NCT03868488 274 276 O
Legends NCT03868488 277 284 O
and NCT03868488 285 288 O
Player NCT03868488 289 295 O
Unknown NCT03868488 296 303 O
's NCT03868488 303 305 O
Battle NCT03868488 306 312 O
Grounds NCT03868488 313 320 O
) NCT03868488 321 322 O
for NCT03868488 323 326 O
over NCT03868488 327 331 B-Eq-Comparison
20 NCT03868488 332 334 I-Eq-Comparison
hours NCT03868488 335 340 I-Eq-Comparison
per NCT03868488 341 344 I-Eq-Comparison
week NCT03868488 345 349 I-Eq-Comparison
for NCT03868488 350 353 O
a NCT03868488 354 355 O
minimum NCT03868488 356 363 B-Eq-Comparison
of NCT03868488 364 366 I-Eq-Comparison
12 NCT03868488 367 369 I-Eq-Comparison
months NCT03868488 370 376 I-Eq-Comparison
. NCT03868488 376 377 O

- NCT03868488 381 382 O
The NCT03868488 384 387 O
scores NCT03868488 388 394 O
of NCT03868488 395 397 O
the NCT03868488 398 401 O
Young NCT03868488 402 407 B-Observation
- NCT03868488 408 409 I-Observation
Internet NCT03868488 410 418 I-Observation
Addiction NCT03868488 419 428 I-Observation
Test NCT03868488 429 433 I-Observation
( NCT03868488 434 435 O
Y NCT03868488 436 437 B-Observation
- NCT03868488 438 439 I-Observation
IAT NCT03868488 440 443 I-Observation
) NCT03868488 444 445 O
≥ NCT03868488 446 447 B-Eq-Comparison
50 NCT03868488 448 450 I-Eq-Comparison

Exclusion NCT03868488 452 461 O
Criteria NCT03868488 462 470 O
: NCT03868488 471 472 O

- NCT03868488 476 477 O
Current NCT03868488 479 486 B-Eq-Comparison
or NCT03868488 487 489 B-Or
history NCT03868488 490 497 B-Eq-Comparison
of NCT03868488 498 500 O
use NCT03868488 501 504 O
of NCT03868488 505 507 O
illegal NCT03868488 508 515 B-Drug
substances NCT03868488 516 526 I-Drug
and NCT03868488 527 530 B-Or
gambling NCT03868488 531 539 B-Observation
; NCT03868488 539 540 O

- NCT03868488 543 544 O
Current NCT03868488 546 553 B-Eq-Comparison
or NCT03868488 554 556 B-Or
history NCT03868488 557 564 B-Eq-Comparison
of NCT03868488 565 567 O
psychiatric NCT03868488 568 579 B-Modifier
or NCT03868488 580 582 B-Or
neurological NCT03868488 583 595 B-Modifier
illness NCT03868488 596 603 B-Condition
; NCT03868488 603 604 O

- NCT03868488 607 608 O
Current NCT03868488 610 617 B-Eq-Comparison
use NCT03868488 618 621 O
of NCT03868488 622 624 O
psychotropic NCT03868488 625 637 B-Drug
medications NCT03868488 638 649 I-Drug
. NCT03868488 649 650 O


Inclusion NCT03866499 0 9 O
Criteria NCT03866499 10 18 O
: NCT03866499 19 20 O

- NCT03866499 24 25 O
Histologically NCT03866499 27 41 B-Procedure
or NCT03866499 42 44 B-Or
cytologically NCT03866499 45 58 B-Procedure
confirmed NCT03866499 59 68 O
non NCT03866499 69 72 B-Negation
- NCT03866499 73 74 O
small NCT03866499 75 80 B-Modifier
cell NCT03866499 81 85 I-Modifier
lung NCT03866499 86 90 I-Modifier
cancer NCT03866499 91 97 B-Condition
. NCT03866499 97 98 O

- NCT03866499 102 103 O
The NCT03866499 105 108 O
ECOG NCT03866499 109 113 B-Observation
score NCT03866499 114 119 O
of NCT03866499 120 122 O
performance NCT03866499 123 134 O
status NCT03866499 135 141 O
is NCT03866499 142 144 O
0 NCT03866499 145 146 B-Eq-Comparison
- NCT03866499 147 148 I-Eq-Comparison
1 NCT03866499 149 150 O
. NCT03866499 150 151 O

- NCT03866499 155 156 O
Locally NCT03866499 158 165 B-Modifier
advanced NCT03866499 166 174 I-Modifier
or NCT03866499 175 177 B-Or
recurrent NCT03866499 178 187 B-Modifier
metastatic NCT03866499 188 198 I-Modifier
NSCLC NCT03866499 199 204 B-Condition
that NCT03866499 205 209 O
has NCT03866499 210 213 O
never NCT03866499 214 219 B-Negation
received NCT03866499 220 228 B-Eq-Comparison
systemic NCT03866499 229 237 B-Procedure
treatment NCT03866499 238 247 I-Procedure
. NCT03866499 247 248 O

- NCT03866499 252 253 O
According NCT03866499 255 264 O
to NCT03866499 265 267 O
RECIST1.1 NCT03866499 268 277 O
criteria NCT03866499 278 286 O
, NCT03866499 287 288 O
there NCT03866499 289 294 O
is NCT03866499 295 297 O
at NCT03866499 298 300 B-Eq-Comparison
least NCT03866499 301 306 I-Eq-Comparison
1 NCT03866499 307 308 I-Eq-Comparison
measurable NCT03866499 309 319 O
lesion NCT03866499 320 326 B-Condition
that NCT03866499 327 331 O
has NCT03866499 332 335 O
not NCT03866499 336 339 B-Negation
been NCT03866499 340 344 O
previously NCT03866499 345 355 B-Eq-Comparison
irradiated NCT03866499 356 366 B-Procedure
. NCT03866499 366 367 O

- NCT03866499 371 372 O
Prior NCT03866499 374 379 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866499 380 382 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866499 383 393 B-Study
, NCT03866499 394 395 O
a NCT03866499 396 397 O
central NCT03866499 398 405 O
laboratory NCT03866499 406 416 B-Observation
testing NCT03866499 417 424 I-Observation
report NCT03866499 425 431 O
has NCT03866499 432 435 O
confirmed NCT03866499 436 445 O
that NCT03866499 446 450 O
the NCT03866499 451 454 O
tumor NCT03866499 455 460 B-Condition
has NCT03866499 461 464 O
one NCT03866499 465 468 B-Eq-Comparison
of NCT03866499 469 471 I-Eq-Comparison
two NCT03866499 472 475 I-Eq-Comparison
common NCT03866499 476 482 B-Condition
EGFR NCT03866499 483 487 I-Condition
mutations NCT03866499 488 497 I-Condition
positive NCT03866499 498 506 O
that NCT03866499 507 511 O
are NCT03866499 512 515 O
sensitive NCT03866499 516 525 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866499 526 528 I-Assertion___Assertion-Type-Value:hypothetical
EGFR NCT03866499 529 533 B-Procedure
- NCT03866499 534 535 I-Procedure
TKI NCT03866499 536 539 I-Procedure
therapy NCT03866499 540 547 I-Procedure
, NCT03866499 548 549 O
accompanied NCT03866499 550 561 O
with NCT03866499 562 566 B-And
or NCT03866499 567 569 B-Or
not NCT03866499 570 573 B-Negation
accompanied NCT03866499 574 585 O
with NCT03866499 586 590 O
other NCT03866499 591 596 B-Other
EGFR NCT03866499 597 601 B-Condition
mutation NCT03866499 602 610 I-Condition
, NCT03866499 611 612 O
with NCT03866499 613 617 O
the NCT03866499 618 621 O
exception NCT03866499 622 631 B-Exception
of NCT03866499 632 634 O
exon NCT03866499 635 639 B-Condition
20 NCT03866499 640 642 I-Condition
insertion NCT03866499 643 652 I-Condition
. NCT03866499 652 653 O

Exclusion NCT03866499 655 664 O
Criteria NCT03866499 665 673 O
: NCT03866499 674 675 O

- NCT03866499 679 680 O
Previously NCT03866499 682 692 B-Eq-Comparison
received NCT03866499 693 701 I-Eq-Comparison
systemic NCT03866499 702 710 B-Modifier
treatment NCT03866499 711 720 B-Procedure
for NCT03866499 721 724 O
locally NCT03866499 725 732 B-Modifier
advanced NCT03866499 733 741 I-Modifier
or NCT03866499 742 744 B-Or
recurrent NCT03866499 745 754 B-Modifier
metastatic NCT03866499 755 765 I-Modifier
cancer NCT03866499 766 772 B-Condition
. NCT03866499 772 773 O

- NCT03866499 777 778 O
Primary NCT03866499 780 787 B-Modifier
T790 NCT03866499 788 792 B-Condition
M NCT03866499 793 794 O
mutation NCT03866499 795 803 I-Condition
- NCT03866499 804 805 O
positive NCT03866499 806 814 O
patient NCT03866499 815 822 O
. NCT03866499 822 823 O

- NCT03866499 827 828 O
Previous NCT03866499 830 838 B-Eq-Comparison
interstitial NCT03866499 839 851 B-Condition
lung NCT03866499 852 856 I-Condition
disease NCT03866499 857 864 I-Condition
, NCT03866499 865 866 O
drug NCT03866499 867 871 B-Drug
- NCT03866499 872 873 O
induced NCT03866499 874 881 O
interstitial NCT03866499 882 894 B-Condition
lung NCT03866499 895 899 I-Condition
disease NCT03866499 900 907 I-Condition
, NCT03866499 908 909 O
radiation NCT03866499 910 919 B-Condition
pneumonia NCT03866499 920 929 I-Condition
requiring NCT03866499 930 939 B-Assertion___Assertion-Type-Value:hypothetical
hormonal NCT03866499 940 948 B-Procedure
therapy NCT03866499 949 956 I-Procedure
, NCT03866499 957 958 O
or NCT03866499 959 961 B-Or
any NCT03866499 962 965 O
clinically NCT03866499 966 976 O
proven NCT03866499 977 983 O
active NCT03866499 984 990 B-Eq-Comparison
interstitial NCT03866499 991 1003 B-Condition
lung NCT03866499 1004 1008 I-Condition
disease NCT03866499 1009 1016 I-Condition
. NCT03866499 1016 1017 O

- NCT03866499 1021 1022 O
Known NCT03866499 1024 1029 O
active NCT03866499 1030 1036 B-Eq-Comparison
infections NCT03866499 1037 1047 B-Condition
such NCT03866499 1048 1052 O
as NCT03866499 1053 1055 O
hepatitis NCT03866499 1056 1065 B-Condition|Condition
B NCT03866499 1066 1067 I-Condition
, NCT03866499 1068 1069 O
hepatitis NCT03866499 1070 1079 O
C NCT03866499 1080 1081 I-Condition
, NCT03866499 1082 1083 O
and NCT03866499 1084 1087 B-Or
human NCT03866499 1088 1093 B-Condition
immunodeficiency NCT03866499 1094 1110 I-Condition
virus NCT03866499 1111 1116 I-Condition
. NCT03866499 1116 1117 O

- NCT03866499 1121 1122 O
Local NCT03866499 1124 1129 B-Modifier
radiation NCT03866499 1130 1139 B-Procedure
therapy NCT03866499 1140 1147 I-Procedure
is NCT03866499 1148 1150 O
carried NCT03866499 1151 1158 B-Eq-Comparison
out NCT03866499 1159 1162 I-Eq-Comparison
within NCT03866499 1163 1169 B-Eq-Comparison
1 NCT03866499 1170 1171 I-Eq-Comparison
week NCT03866499 1172 1176 I-Eq-Comparison
; NCT03866499 1176 1177 O
more NCT03866499 1178 1182 B-Eq-Comparison
than NCT03866499 1183 1187 I-Eq-Comparison
30 NCT03866499 1188 1190 I-Eq-Comparison
% NCT03866499 1191 1192 O
bone NCT03866499 1193 1197 B-Procedure
marrow NCT03866499 1198 1204 I-Procedure
radiation NCT03866499 1205 1214 I-Procedure|Procedure
therapy NCT03866499 1215 1222 I-Procedure|Procedure
or NCT03866499 1223 1225 B-Or
extensive NCT03866499 1226 1235 O
radiation NCT03866499 1236 1245 O
therapy NCT03866499 1246 1253 O
is NCT03866499 1254 1256 O
performed NCT03866499 1257 1266 O
within NCT03866499 1267 1273 B-Eq-Comparison
4 NCT03866499 1274 1275 I-Eq-Comparison|Eq-Comparison
weeks NCT03866499 1276 1281 I-Eq-Comparison|Eq-Comparison
. NCT03866499 1281 1282 O

- NCT03866499 1286 1287 O
≤ NCT03866499 1289 1290 B-Eq-Comparison|Eq-Comparison
4 NCT03866499 1291 1292 O
weeks NCT03866499 1293 1298 I-Eq-Comparison
from NCT03866499 1299 1303 B-Temporal-Connection___Temporal-Connection-Type-Value:after|Temporal-Connection___Temporal-Connection-Type-Value:after
major NCT03866499 1304 1309 O
surgery NCT03866499 1310 1317 B-Procedure|Procedure
or NCT03866499 1318 1320 B-Or
≤ NCT03866499 1321 1322 O
2 NCT03866499 1323 1324 I-Eq-Comparison
weeks NCT03866499 1325 1330 O
from NCT03866499 1331 1335 O
minor NCT03866499 1336 1341 O
surgery NCT03866499 1342 1349 O
. NCT03866499 1349 1350 O

Inclusion NCT03866512 0 9 O
Criteria NCT03866512 10 18 O
: NCT03866512 19 20 O

- NCT03866512 24 25 O
Males NCT03866512 27 32 O
and NCT03866512 33 36 B-Or
females NCT03866512 37 44 O
18 NCT03866512 45 47 B-Eq-Comparison
- NCT03866512 48 49 I-Eq-Comparison
40 NCT03866512 50 52 I-Eq-Comparison
years NCT03866512 53 58 I-Eq-Comparison
of NCT03866512 59 61 O
age NCT03866512 62 65 B-Age

- NCT03866512 68 69 O
Body NCT03866512 71 75 B-Observation
mass NCT03866512 76 80 I-Observation
index NCT03866512 81 86 I-Observation
between NCT03866512 87 94 B-Eq-Comparison
18 NCT03866512 95 97 I-Eq-Comparison
and NCT03866512 98 101 I-Eq-Comparison
27 NCT03866512 102 104 I-Eq-Comparison

Exclusion NCT03866512 106 115 O
Criteria NCT03866512 116 124 O
: NCT03866512 125 126 O

- NCT03866512 130 131 O
Any NCT03866512 133 136 O
diagnosed NCT03866512 137 146 O
metabolic NCT03866512 147 156 B-Condition
impairment NCT03866512 157 167 I-Condition
( NCT03866512 168 169 O
e. NCT03866512 170 172 O
g. NCT03866512 173 175 O
type NCT03866512 177 181 B-Modifier
1 NCT03866512 182 183 I-Modifier
or NCT03866512 184 186 B-Or
2 NCT03866512 187 188 B-Modifier
diabetes NCT03866512 189 197 B-Condition
) NCT03866512 198 199 O

- NCT03866512 203 204 O
Any NCT03866512 206 209 O
diagnosed NCT03866512 210 219 O
cardiovascular NCT03866512 220 234 B-Condition
disease NCT03866512 235 242 I-Condition

- NCT03866512 245 246 O
Hypertension NCT03866512 248 260 B-Condition
( NCT03866512 261 262 O
≥ NCT03866512 264 265 B-Eq-Comparison
140 NCT03866512 266 269 I-Eq-Comparison
mmHg NCT03866512 270 274 I-Eq-Comparison
systolic NCT03866512 275 283 B-Observation
and NCT03866512 284 287 B-Or
/ NCT03866512 288 289 I-Or
or NCT03866512 290 292 I-Or
≥ NCT03866512 293 294 B-Eq-Comparison
90 NCT03866512 295 297 I-Eq-Comparison
mmHg NCT03866512 298 302 I-Eq-Comparison
diastolic NCT03866512 303 312 B-Observation
) NCT03866512 313 314 O

- NCT03866512 318 319 O
Chronic NCT03866512 321 328 B-Modifier
use NCT03866512 329 332 O
of NCT03866512 333 335 O
any NCT03866512 336 339 O
prescribed NCT03866512 340 350 B-Modifier
or NCT03866512 351 353 B-Or
over NCT03866512 354 358 B-Modifier
the NCT03866512 359 362 I-Modifier
counter NCT03866512 363 370 I-Modifier
pharmaceuticals NCT03866512 371 386 B-Drug
( NCT03866512 387 388 O
excluding NCT03866512 389 398 B-Exception
oral NCT03866512 399 403 B-Drug
contraceptives NCT03866512 404 418 I-Drug|Procedure
and NCT03866512 419 422 B-Or
contraceptive NCT03866512 423 436 O
devices NCT03866512 437 444 I-Procedure
) NCT03866512 445 446 O

- NCT03866512 450 451 O
Regular NCT03866512 453 460 B-Eq-Comparison
use NCT03866512 461 464 O
of NCT03866512 465 467 O
nutritional NCT03866512 468 479 B-Drug
supplements NCT03866512 480 491 I-Drug

- NCT03866512 494 495 O
Metallic NCT03866512 497 505 B-Procedure
implants NCT03866512 506 514 I-Procedure

- NCT03866512 517 518 O
A NCT03866512 520 521 O
personal NCT03866512 522 530 B-Family-Member___Family-Member-Type:patient
or NCT03866512 531 533 B-Or
family NCT03866512 534 540 B-Family-Member
history NCT03866512 541 548 I-Family-Member
of NCT03866512 549 551 O
thrombosis NCT03866512 552 562 B-Condition
, NCT03866512 563 564 O
epilepsy NCT03866512 565 573 B-Condition
, NCT03866512 574 575 O
seizures NCT03866512 576 584 B-Condition
or NCT03866512 585 587 B-Or
schizophrenia NCT03866512 588 601 B-Condition

- NCT03866512 604 605 O
Any NCT03866512 607 610 O
previous NCT03866512 611 619 B-Eq-Comparison
motor NCT03866512 620 625 B-Condition
disorders NCT03866512 626 635 I-Condition|Condition

- NCT03866512 638 639 O
Any NCT03866512 641 644 O
known NCT03866512 645 650 O
disorders NCT03866512 651 660 O
in NCT03866512 661 663 I-Condition
lipid NCT03866512 664 669 I-Condition
metabolism NCT03866512 670 680 I-Condition

- NCT03866512 683 684 O
Any NCT03866512 686 689 O
known NCT03866512 690 695 O
disorders NCT03866512 696 705 B-Condition
in NCT03866512 706 708 I-Condition
muscle NCT03866512 709 715 I-Condition
metabolism NCT03866512 716 726 I-Condition

- NCT03866512 729 730 O
Known NCT03866512 732 737 O
allergy NCT03866512 738 745 B-Allergy
for NCT03866512 746 749 O
Acipimox NCT03866512 750 758 B-Drug
, NCT03866512 759 760 O
beta NCT03866512 761 765 B-Drug
agonist NCT03866512 766 773 I-Drug
, NCT03866512 774 775 O
or NCT03866512 776 778 B-Or
other NCT03866512 779 784 B-Other
substances NCT03866512 785 795 B-Drug
in NCT03866512 796 798 I-Drug
the NCT03866512 799 802 I-Drug
tablets NCT03866512 803 810 I-Drug

- NCT03866512 813 814 O
Known NCT03866512 816 821 O
sensitivity NCT03866512 822 833 B-Condition
for NCT03866512 834 837 O
sympathomimetic NCT03866512 838 853 B-Drug
drugs NCT03866512 854 859 I-Drug

- NCT03866512 862 863 O
Known NCT03866512 865 870 O
hypokalaemia NCT03866512 871 883 B-Condition

- NCT03866512 886 887 O
Presence NCT03866512 889 897 B-Eq-Comparison
of NCT03866512 898 900 O
an NCT03866512 901 903 O
ulcer NCT03866512 904 909 B-Condition
in NCT03866512 910 912 O
the NCT03866512 913 916 O
stomach NCT03866512 917 924 B-Modifier
or NCT03866512 925 927 B-Or|Or
gut NCT03866512 928 931 B-Modifier
and NCT03866512 932 935 B-Or
/ NCT03866512 936 937 I-Or
or NCT03866512 938 940 O
strong NCT03866512 941 947 O
history NCT03866512 948 955 B-Eq-Comparison
of NCT03866512 956 958 O
indigestion NCT03866512 959 970 B-Condition

- NCT03866512 973 974 O
Known NCT03866512 976 981 O
severe NCT03866512 982 988 O
kidney NCT03866512 989 995 B-Condition
problems NCT03866512 996 1004 I-Condition

- NCT03866512 1007 1008 O
Pregnancy NCT03866512 1010 1019 B-Condition

- NCT03866512 1022 1023 O
Unable NCT03866512 1025 1031 O
to NCT03866512 1032 1034 O
give NCT03866512 1035 1039 O
consent NCT03866512 1040 1047 O

Inclusion NCT03867630 0 9 O
Criteria NCT03867630 10 18 O
: NCT03867630 19 20 O

- NCT03867630 24 25 O
20 NCT03867630 27 29 B-Eq-Comparison
to NCT03867630 30 32 I-Eq-Comparison
80 NCT03867630 33 35 I-Eq-Comparison
years NCT03867630 36 41 I-Eq-Comparison
old NCT03867630 42 45 B-Age

- NCT03867630 48 49 O
Patients NCT03867630 51 59 O
with NCT03867630 60 64 O
a NCT03867630 65 66 O
herniated NCT03867630 67 76 B-Condition
disc NCT03867630 77 81 I-Condition
, NCT03867630 82 83 O
spinal NCT03867630 84 90 B-Condition
stenosis NCT03867630 91 99 I-Condition

- NCT03867630 102 103 O
Patients NCT03867630 105 113 O
with NCT03867630 114 118 O
chronic NCT03867630 119 126 B-Modifier
low NCT03867630 127 130 I-Modifier
back NCT03867630 131 135 I-Modifier
pain NCT03867630 136 140 B-Condition
and NCT03867630 141 144 B-Or
lower NCT03867630 145 150 B-Modifier
extremity NCT03867630 151 160 I-Modifier
pain NCT03867630 161 165 B-Condition
who NCT03867630 166 169 B-And
did NCT03867630 170 173 O
not NCT03867630 174 177 O
respond NCT03867630 178 185 O
to NCT03867630 186 188 O
lumbar NCT03867630 189 195 B-Modifier
epidural NCT03867630 196 204 B-Procedure
steroid NCT03867630 205 212 I-Procedure
injections NCT03867630 213 223 I-Procedure

- NCT03867630 226 227 O
Patients NCT03867630 229 237 O
who NCT03867630 238 241 O
are NCT03867630 242 245 O
performed NCT03867630 246 255 B-Eq-Comparison
percutaneous NCT03867630 256 268 B-Procedure
epidural NCT03867630 269 277 I-Procedure
neuroplasty NCT03867630 278 289 I-Procedure
with NCT03867630 290 294 O
wire NCT03867630 295 299 B-Procedure
type NCT03867630 300 304 I-Procedure
catheter NCT03867630 305 313 I-Procedure
. NCT03867630 313 314 O

Exclusion NCT03867630 316 325 O
Criteria NCT03867630 326 334 O
: NCT03867630 335 336 O

- NCT03867630 340 341 O
Incomplete NCT03867630 343 353 O
medical NCT03867630 354 361 O
record NCT03867630 362 368 O

- NCT03867630 371 372 O
Contraindication NCT03867630 374 390 B-Contraindication
to NCT03867630 391 393 O
percutaneous NCT03867630 394 406 B-Procedure
epidural NCT03867630 407 415 I-Procedure
neuroplasty NCT03867630 416 427 I-Procedure

Inclusion NCT03861533 0 9 O
Criteria NCT03861533 10 18 O
: NCT03861533 19 20 O

1 NCT03861533 24 25 O
. NCT03861533 25 26 O
Adults NCT03861533 28 34 O
≥ NCT03861533 35 36 B-Eq-Comparison
18 NCT03861533 37 39 I-Eq-Comparison
years NCT03861533 40 45 I-Eq-Comparison
old NCT03861533 46 49 B-Age

2 NCT03861533 52 53 O
. NCT03861533 53 54 O
High NCT03861533 56 60 O
risk NCT03861533 61 65 B-Risk
for NCT03861533 66 69 O
cardiovascular NCT03861533 70 84 B-Condition
morbidity NCT03861533 85 94 I-Condition
and NCT03861533 95 98 B-Or
mortality NCT03861533 99 108 B-Death
such NCT03861533 109 113 O
as NCT03861533 114 116 O
prior NCT03861533 117 122 B-Eq-Comparison
history NCT03861533 123 130 I-Eq-Comparison
of NCT03861533 131 133 O
clinical NCT03861533 134 142 B-Modifier
cardiovascular NCT03861533 143 157 B-Condition
disease NCT03861533 158 165 I-Condition
and NCT03861533 166 169 B-Or
/ NCT03861533 170 171 I-Or
or NCT03861533 172 174 I-Or
history NCT03861533 175 182 B-Eq-Comparison
of NCT03861533 183 185 O
familial NCT03861533 186 194 B-Modifier
hypercholesterolemia NCT03861533 195 215 B-Condition

3 NCT03861533 218 219 O
. NCT03861533 219 220 O
LDL NCT03861533 222 225 B-Observation
- NCT03861533 226 227 I-Observation
C NCT03861533 228 229 I-Observation
within NCT03861533 230 236 B-Eq-Comparison
the NCT03861533 237 240 I-Eq-Comparison
past NCT03861533 241 245 I-Eq-Comparison
6 NCT03861533 246 247 I-Eq-Comparison
months NCT03861533 248 254 I-Eq-Comparison
above NCT03861533 255 260 B-Eq-Comparison
recommended NCT03861533 261 272 I-Eq-Comparison
level NCT03861533 273 278 I-Eq-Comparison
despite NCT03861533 279 286 B-And
maximal NCT03861533 287 294 B-Modifier
tolerated NCT03861533 295 304 I-Modifier
statin NCT03861533 305 311 B-Procedure
therapy NCT03861533 312 319 I-Procedure
± NCT03861533 320 321 O
ezetimibe NCT03861533 322 331 B-Drug
for NCT03861533 332 335 O
the NCT03861533 336 339 B-Eq-Comparison
past NCT03861533 340 344 I-Eq-Comparison
3 NCT03861533 345 346 I-Eq-Comparison
months NCT03861533 347 353 I-Eq-Comparison
. NCT03861533 353 354 O

Exclusion NCT03861533 356 365 O
Criteria NCT03861533 366 374 O
: NCT03861533 375 376 O

1 NCT03861533 380 381 O
. NCT03861533 381 382 O
Current NCT03861533 384 391 B-Eq-Comparison
treatment NCT03861533 392 401 B-Procedure
with NCT03861533 402 406 O
PCSK9 NCT03861533 407 412 B-Drug
inhibitor NCT03861533 413 422 I-Drug

2 NCT03861533 425 426 O
. NCT03861533 426 427 O
Current NCT03861533 429 436 B-Eq-Comparison
participation NCT03861533 437 450 O
in NCT03861533 451 453 O
investigational NCT03861533 454 469 O
study NCT03861533 470 475 B-Study

3 NCT03861533 478 479 O
. NCT03861533 479 480 O
Prior NCT03861533 482 487 O
participation NCT03861533 488 501 O
in NCT03861533 502 504 O
the NCT03861533 505 508 O
GOAL NCT03861533 509 513 O
program NCT03861533 514 521 O

Inclusion NCT03865966 0 9 O
Criteria NCT03865966 10 18 O
: NCT03865966 19 20 O

- NCT03865966 24 25 O
Patients NCT03865966 27 35 O
with NCT03865966 36 40 O
end NCT03865966 41 44 B-Modifier
- NCT03865966 45 46 I-Modifier
stage NCT03865966 47 52 I-Modifier
liver NCT03865966 53 58 B-Condition
disease NCT03865966 59 66 I-Condition
who NCT03865966 67 70 B-And
require NCT03865966 71 78 B-Assertion___Assertion-Type-Value:hypothetical
liver NCT03865966 79 84 B-Procedure
transplantation NCT03865966 85 100 I-Procedure

Exclusion NCT03865966 101 110 O
Criteria NCT03865966 111 119 O
: NCT03865966 120 121 O

- NCT03865966 125 126 O
Children NCT03865966 128 136 O
without NCT03865966 137 144 B-Negation
liver NCT03865966 145 150 B-Procedure
transplantation NCT03865966 151 166 I-Procedure
refer NCT03865966 167 172 O
to NCT03865966 173 175 O
children NCT03865966 176 184 O
; NCT03865966 184 185 O

- NCT03865966 188 189 O
Children NCT03865966 191 199 O
who NCT03865966 200 203 O
are NCT03865966 204 207 O
unwilling NCT03865966 208 217 O
to NCT03865966 218 220 O
participate NCT03865966 221 232 O
; NCT03865966 232 233 O

Inclusion NCT03864107 0 9 O
Criteria NCT03864107 10 18 O
: NCT03864107 19 20 O

- NCT03864107 24 25 O
Men NCT03864107 27 30 O
and NCT03864107 31 34 B-Or
women NCT03864107 35 40 O
aged NCT03864107 41 45 B-Age
18 NCT03864107 46 48 B-Eq-Comparison
- NCT03864107 49 50 I-Eq-Comparison
70 NCT03864107 51 53 I-Eq-Comparison
years NCT03864107 54 59 I-Eq-Comparison

- NCT03864107 62 63 O
BMI NCT03864107 65 68 B-Observation
18.5 NCT03864107 69 73 B-Eq-Comparison
- NCT03864107 74 75 I-Eq-Comparison
50 NCT03864107 76 78 I-Eq-Comparison
kg NCT03864107 79 81 I-Eq-Comparison
/ NCT03864107 82 83 I-Eq-Comparison
m2 NCT03864107 84 86 I-Eq-Comparison

- NCT03864107 89 90 O
Not NCT03864107 92 95 B-Negation
taking NCT03864107 96 102 B-Eq-Comparison
antibiotics NCT03864107 103 114 B-Drug
and NCT03864107 115 118 B-Or
antimicrobial NCT03864107 119 132 B-Drug
drugs NCT03864107 133 138 I-Drug
for NCT03864107 139 142 O
at NCT03864107 143 145 B-Eq-Comparison
least NCT03864107 146 151 I-Eq-Comparison
three NCT03864107 152 157 I-Eq-Comparison
months NCT03864107 158 164 I-Eq-Comparison

- NCT03864107 167 168 O
Both NCT03864107 170 174 O
physically NCT03864107 175 185 B-Observation
active NCT03864107 186 192 I-Observation
and NCT03864107 193 196 B-Or
sedentary NCT03864107 197 206 B-Observation
individuals NCT03864107 207 218 O
will NCT03864107 219 223 O
be NCT03864107 224 226 O
eligible NCT03864107 227 235 O
to NCT03864107 236 238 O
take NCT03864107 239 243 O
part NCT03864107 244 248 O
in NCT03864107 249 251 O
the NCT03864107 252 255 O
study NCT03864107 256 261 B-Study

- NCT03864107 264 265 O
Weight NCT03864107 267 273 B-Observation
stable NCT03864107 274 280 O
( NCT03864107 281 282 O
± NCT03864107 284 285 B-Eq-Comparison
5 NCT03864107 286 287 O
kg NCT03864107 288 290 O
) NCT03864107 291 292 O
for NCT03864107 293 296 O
at NCT03864107 297 299 B-Eq-Comparison
least NCT03864107 300 305 I-Eq-Comparison
6 NCT03864107 306 307 I-Eq-Comparison
months NCT03864107 308 314 I-Eq-Comparison

Excusion NCT03864107 315 323 O
Criteria NCT03864107 324 332 O
: NCT03864107 333 334 O

- NCT03864107 338 339 O
No NCT03864107 341 343 B-Negation
cardiometabolic NCT03864107 344 359 B-Condition
( NCT03864107 360 361 O
e. NCT03864107 362 364 O
g. NCT03864107 365 367 O
heart NCT03864107 369 374 B-Condition
disease NCT03864107 375 382 I-Condition
, NCT03864107 383 384 O
high NCT03864107 385 389 O
blood NCT03864107 390 395 B-Condition
pressure NCT03864107 396 404 I-Condition
) NCT03864107 405 406 O
or NCT03864107 407 409 B-Or
inflammatory NCT03864107 410 422 B-Modifier
illness NCT03864107 423 430 B-Condition

- NCT03864107 433 434 O
Smokers NCT03864107 436 443 B-Condition
( NCT03864107 444 445 O
including NCT03864107 446 455 O
the NCT03864107 456 459 O
use NCT03864107 460 463 O
of NCT03864107 464 466 O
vaporisers NCT03864107 467 477 B-Drug
and NCT03864107 478 481 B-Or
e NCT03864107 482 483 B-Drug
- NCT03864107 484 485 I-Drug
cigarettes NCT03864107 486 496 I-Drug
) NCT03864107 497 498 O

- NCT03864107 502 503 I-Drug
Taking NCT03864107 505 511 B-Eq-Comparison
anti NCT03864107 512 516 B-Drug
- NCT03864107 517 518 O
inflammatory NCT03864107 519 531 I-Drug
drugs NCT03864107 532 537 I-Drug
( NCT03864107 538 539 O
excluding NCT03864107 540 549 B-Exception
aspirin NCT03864107 550 557 B-Drug
) NCT03864107 558 559 O

Inclusion NCT03865225 0 9 O
Criteria NCT03865225 10 18 O
: NCT03865225 19 20 O

- NCT03865225 24 25 O
male NCT03865225 27 31 O
and NCT03865225 32 35 B-Or
female NCT03865225 36 42 O
subjects NCT03865225 43 51 O
aged NCT03865225 52 56 B-Age
between NCT03865225 57 64 B-Eq-Comparison
18 NCT03865225 65 67 I-Eq-Comparison
and NCT03865225 68 71 I-Eq-Comparison
90 NCT03865225 72 74 I-Eq-Comparison

- NCT03865225 78 79 O
written NCT03865225 81 88 O
and NCT03865225 89 92 O
oral NCT03865225 93 97 O
informed NCT03865225 98 106 O
consent NCT03865225 107 114 O

- NCT03865225 117 118 O
evidence NCT03865225 120 128 O
of NCT03865225 129 131 O
an NCT03865225 132 134 O
ischaemic NCT03865225 135 144 B-Condition
lesion NCT03865225 145 151 I-Condition
on NCT03865225 152 154 O
cranial NCT03865225 155 162 B-Procedure
computed NCT03865225 163 171 I-Procedure
tomography NCT03865225 172 182 I-Procedure
scan NCT03865225 183 187 I-Procedure
or NCT03865225 188 190 B-Or
magnetic NCT03865225 191 199 B-Procedure
resonance NCT03865225 200 209 I-Procedure
imaging NCT03865225 210 217 I-Procedure

Exclusion NCT03865225 218 227 O
Criteria NCT03865225 228 236 O
: NCT03865225 237 238 O

- NCT03865225 242 243 O
intake NCT03865225 245 251 O
of NCT03865225 252 254 O
any NCT03865225 255 258 O
tricyclic NCT03865225 259 268 B-Drug
antidepressant NCT03865225 269 283 I-Drug
within NCT03865225 284 290 B-Eq-Comparison
the NCT03865225 291 294 I-Eq-Comparison
last NCT03865225 295 299 I-Eq-Comparison
14 NCT03865225 300 302 I-Eq-Comparison
days NCT03865225 303 307 I-Eq-Comparison

- NCT03865225 310 311 O
atrial NCT03865225 313 319 B-Condition
fibrillation NCT03865225 320 332 I-Condition

- NCT03865225 335 336 O
prior NCT03865225 338 343 B-Eq-Comparison
diagnosed NCT03865225 344 353 O
autonomic NCT03865225 354 363 B-Condition
neuropathy NCT03865225 364 374 I-Condition

- NCT03865225 377 378 O
malignant NCT03865225 380 389 B-Condition
cerebral NCT03865225 390 398 I-Condition
infarct NCT03865225 399 406 I-Condition
or NCT03865225 407 409 B-Or
indication NCT03865225 410 420 B-Indication
for NCT03865225 421 424 O
treatment NCT03865225 425 434 B-Procedure
at NCT03865225 435 437 O
intensive NCT03865225 438 447 O
care NCT03865225 448 452 O
unit NCT03865225 453 457 O

- NCT03865225 460 461 O
aphasia NCT03865225 463 470 B-Condition
or NCT03865225 471 473 B-Or
cognitive NCT03865225 474 483 B-Condition
deficit NCT03865225 484 491 I-Condition
with NCT03865225 492 496 O
resulted NCT03865225 497 505 O
inability NCT03865225 506 515 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865225 516 518 O
participate NCT03865225 519 530 O
in NCT03865225 531 533 O
Heart NCT03865225 534 539 B-Modifier
rate NCT03865225 540 544 I-Modifier
variability NCT03865225 545 556 I-Modifier
- NCT03865225 557 558 O
biofeedback NCT03865225 559 570 B-Procedure
training NCT03865225 571 579 I-Procedure

- NCT03865225 582 583 O
respiratory NCT03865225 585 596 B-Condition
insufficiency NCT03865225 597 610 I-Condition

- NCT03865225 613 614 O
blindness NCT03865225 616 625 B-Condition
, NCT03865225 626 627 O
deafness NCT03865225 628 636 B-Condition
or NCT03865225 637 639 B-Or
other NCT03865225 640 645 B-Other
physical NCT03865225 646 654 B-Condition
limitations NCT03865225 655 666 I-Condition
with NCT03865225 667 671 O
resulted NCT03865225 672 680 O
inability NCT03865225 681 690 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865225 691 693 O
participate NCT03865225 694 705 O
in NCT03865225 706 708 O
heart NCT03865225 709 714 B-Modifier
rate NCT03865225 715 719 I-Modifier
variability NCT03865225 720 731 I-Modifier
- NCT03865225 732 733 O
biofeedback NCT03865225 734 745 B-Procedure
training NCT03865225 746 754 I-Procedure

Inclusion NCT03863873 0 9 O
Criteria NCT03863873 10 18 O
: NCT03863873 19 20 O

- NCT03863873 24 25 O
Patients NCT03863873 27 35 O
with NCT03863873 36 40 O
mild NCT03863873 41 45 B-Eq-Comparison
- NCT03863873 46 47 I-Eq-Comparison
to NCT03863873 48 50 I-Eq-Comparison
- NCT03863873 51 52 O
moderate NCT03863873 53 61 I-Eq-Comparison
idiopathic NCT03863873 62 72 B-Modifier
CTS NCT03863873 73 76 B-Condition
with NCT03863873 77 81 O
clinical NCT03863873 82 90 B-Condition
manifestations NCT03863873 91 105 I-Condition
failed NCT03863873 106 112 O
to NCT03863873 113 115 O
respond NCT03863873 116 123 O
to NCT03863873 124 126 O
conservative NCT03863873 127 139 B-Procedure
treatment NCT03863873 140 149 I-Procedure
( NCT03863873 150 151 O
such NCT03863873 152 156 O
as NCT03863873 157 159 O
splint NCT03863873 160 166 B-Procedure
, NCT03863873 167 168 O
medications NCT03863873 169 180 B-Drug
, NCT03863873 181 182 O
Physical NCT03863873 183 191 B-Procedure
therapy NCT03863873 192 199 I-Procedure
) NCT03863873 200 201 O
for NCT03863873 202 205 O
at NCT03863873 206 208 B-Eq-Comparison
least NCT03863873 209 214 I-Eq-Comparison
3 NCT03863873 215 216 I-Eq-Comparison
months NCT03863873 217 223 I-Eq-Comparison
and NCT03863873 224 227 B-And
they NCT03863873 228 232 O
were NCT03863873 233 237 O
diagnosed NCT03863873 238 247 O
by NCT03863873 248 250 O
electrophysiological NCT03863873 251 271 B-Procedure
study NCT03863873 272 277 I-Procedure
and NCT03863873 278 281 B-Or
musculoskeletal NCT03863873 282 297 B-Modifier
ultrasound NCT03863873 298 308 B-Procedure
. NCT03863873 308 309 O

Exclusion NCT03863873 311 320 O
Criteria NCT03863873 321 329 O
: NCT03863873 330 331 O

- NCT03863873 335 336 O
Diabetes NCT03863873 338 346 B-Condition

- NCT03863873 349 350 O
Hypothyroidism NCT03863873 352 366 B-Condition

- NCT03863873 369 370 O
Rheumatoid NCT03863873 372 382 B-Condition
arthritis NCT03863873 383 392 I-Condition

- NCT03863873 395 396 O
Previous NCT03863873 398 406 B-Eq-Comparison
carpal NCT03863873 407 413 B-Procedure
tunnel NCT03863873 414 420 I-Procedure
decompressive NCT03863873 421 434 I-Procedure
surgery NCT03863873 435 442 I-Procedure

- NCT03863873 445 446 O
Cervical NCT03863873 448 456 B-Condition
radiculopathy NCT03863873 457 470 I-Condition
, NCT03863873 471 472 O
polyneuropathy NCT03863873 473 487 B-Condition
, NCT03863873 488 489 O
brachial NCT03863873 490 498 B-Condition
plexopathy NCT03863873 499 509 I-Condition
, NCT03863873 510 511 O
traumatic NCT03863873 512 521 B-Condition
nerve NCT03863873 522 527 I-Condition
injury NCT03863873 528 534 I-Condition
, NCT03863873 535 536 O
thoracic NCT03863873 537 545 B-Condition
outlet NCT03863873 546 552 I-Condition
syndrome NCT03863873 553 561 I-Condition

- NCT03863873 564 565 O
Previous NCT03863873 567 575 B-Eq-Comparison
corticosteroid NCT03863873 576 590 B-Procedure
injection NCT03863873 591 600 I-Procedure
into NCT03863873 601 605 O
the NCT03863873 606 609 O
carpal NCT03863873 610 616 B-Modifier
tunnel NCT03863873 617 623 I-Modifier
in NCT03863873 624 626 O
the NCT03863873 627 630 O
preceding NCT03863873 631 640 B-Eq-Comparison
4 NCT03863873 641 642 I-Eq-Comparison
weeks NCT03863873 643 648 I-Eq-Comparison

- NCT03863873 651 652 O
Anemia NCT03863873 654 660 B-Condition
( NCT03863873 661 662 O
hemoglobin NCT03863873 663 673 B-Observation
< NCT03863873 674 675 B-Eq-Comparison
10 NCT03863873 676 678 I-Eq-Comparison
gm% NCT03863873 679 682 O
) NCT03863873 683 684 O

- NCT03863873 688 689 O
Coagulopathy NCT03863873 691 703 B-Condition

- NCT03863873 706 707 O
Pregnancy NCT03863873 709 718 B-Condition

Inclusion NCT03867396 0 9 O
Criteria NCT03867396 10 18 O
* NCT03867396 18 19 O
: NCT03867396 20 21 O

- NCT03867396 25 26 O
An NCT03867396 28 30 O
Advanced NCT03867396 31 39 B-Procedure
Bionics NCT03867396 40 47 I-Procedure
cochlear NCT03867396 48 56 I-Procedure
implant NCT03867396 57 64 I-Procedure
recipient NCT03867396 65 74 O
with NCT03867396 75 79 O
at NCT03867396 80 82 B-Eq-Comparison
least NCT03867396 83 88 I-Eq-Comparison
12 NCT03867396 89 91 I-Eq-Comparison
months NCT03867396 92 98 I-Eq-Comparison
of NCT03867396 99 101 O
listening NCT03867396 102 111 O
experience NCT03867396 112 122 O

- NCT03867396 125 126 O
Low NCT03867396 128 131 B-Observation
frequency NCT03867396 132 141 I-Observation
Pure NCT03867396 142 146 I-Observation
Tone NCT03867396 147 151 I-Observation
Audiometry NCT03867396 152 162 I-Observation
( NCT03867396 163 164 O
PTA NCT03867396 165 168 B-Observation
) NCT03867396 169 170 O

Exclusion NCT03867396 172 181 O
Criteria NCT03867396 182 190 O
* NCT03867396 190 191 O
: NCT03867396 192 193 O

- NCT03867396 197 198 O
Non NCT03867396 200 203 B-Negation
- NCT03867396 204 205 O
English NCT03867396 206 213 O
speakers NCT03867396 214 222 O

- NCT03867396 230 231 O
Additional NCT03867396 233 243 O
Inclusion NCT03867396 244 253 O
and NCT03867396 254 257 O
Exclusion NCT03867396 258 267 O
criteria NCT03867396 268 276 O
apply NCT03867396 277 282 O

Inclusion NCT03865797 0 9 O
Criteria NCT03865797 10 18 O
: NCT03865797 19 20 O

- NCT03865797 24 25 O
Rugby NCT03865797 27 32 B-Observation
players NCT03865797 33 40 I-Observation

- NCT03865797 43 44 O
Both NCT03865797 46 50 O
gender NCT03865797 51 57 O

- NCT03865797 60 61 O
From NCT03865797 63 67 B-Eq-Comparison
18 NCT03865797 68 70 I-Eq-Comparison
to NCT03865797 71 73 I-Eq-Comparison
40 NCT03865797 74 76 I-Eq-Comparison
years NCT03865797 77 82 I-Eq-Comparison
old NCT03865797 83 86 B-Age

- NCT03865797 89 90 O
Federated NCT03865797 92 101 O
. NCT03865797 101 102 O

Exclusion NCT03865797 104 113 O
Criteria NCT03865797 114 122 O
: NCT03865797 123 124 O

- NCT03865797 128 129 O
At NCT03865797 131 133 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865797 134 137 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865797 138 142 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865797 143 145 O
the NCT03865797 146 149 O
study NCT03865797 150 155 B-Study
, NCT03865797 156 157 O
they NCT03865797 158 162 O
present NCT03865797 163 170 O
an NCT03865797 171 173 O
injury NCT03865797 174 180 B-Condition
that NCT03865797 181 185 O
prevents NCT03865797 186 194 B-Assertion___Assertion-Type-Value:hypothetical|Negation
them NCT03865797 195 199 O
from NCT03865797 200 204 O
carrying NCT03865797 205 213 O
out NCT03865797 214 217 O
the NCT03865797 218 221 O
proposed NCT03865797 222 230 O
intervention NCT03865797 231 243 B-Procedure

- NCT03865797 246 247 O
Included NCT03865797 249 257 O
in NCT03865797 258 260 O
a NCT03865797 261 262 O
personal NCT03865797 263 271 B-Observation
training NCT03865797 272 280 I-Observation
regime NCT03865797 281 287 I-Observation

- NCT03865797 290 291 O
With NCT03865797 293 297 O
musculoskeletal NCT03865797 298 313 B-Modifier
injuries NCT03865797 314 322 B-Condition
in NCT03865797 323 325 O
the NCT03865797 326 329 O
ankle NCT03865797 330 335 B-Modifier
in NCT03865797 336 338 O
the NCT03865797 339 342 O
last NCT03865797 343 347 B-Eq-Comparison
3 NCT03865797 348 349 I-Eq-Comparison
months NCT03865797 350 356 I-Eq-Comparison

- NCT03865797 359 360 O
Not NCT03865797 362 365 O
sign NCT03865797 366 370 O
the NCT03865797 371 374 O
informed NCT03865797 375 383 O
consent NCT03865797 384 391 O
document NCT03865797 392 400 O
. NCT03865797 400 401 O

Inclusion NCT03863457 0 9 O
Criteria NCT03863457 10 18 O
: NCT03863457 19 20 O

- NCT03863457 24 25 O
Participants NCT03863457 27 39 O
will NCT03863457 40 44 O
be NCT03863457 45 47 O
≥ NCT03863457 48 49 B-Eq-Comparison
18 NCT03863457 50 52 I-Eq-Comparison
years NCT03863457 53 58 I-Eq-Comparison
of NCT03863457 59 61 O
age NCT03863457 62 65 B-Age

- NCT03863457 68 69 O
Known NCT03863457 71 76 B-Modifier
or NCT03863457 77 79 B-Or
suspected NCT03863457 80 89 B-Assertion___Assertion-Type-Value:possible
primary NCT03863457 90 97 B-Modifier
or NCT03863457 98 100 B-Or
metastatic NCT03863457 101 111 B-Modifier
breast NCT03863457 112 118 I-Modifier
cancer NCT03863457 119 125 B-Condition
. NCT03863457 125 126 O

- NCT03863457 130 131 O
At NCT03863457 133 135 B-Eq-Comparison
least NCT03863457 136 141 I-Eq-Comparison
one NCT03863457 142 145 I-Eq-Comparison
lesion NCT03863457 146 152 B-Condition|Observation
≥ NCT03863457 153 154 B-Eq-Comparison
1.5 NCT03863457 155 158 I-Eq-Comparison
cm NCT03863457 159 161 I-Eq-Comparison
that NCT03863457 162 166 O
is NCT03863457 167 169 O
seen NCT03863457 170 174 O
on NCT03863457 175 177 O
standard NCT03863457 178 186 B-Procedure
imaging NCT03863457 187 194 I-Procedure
( NCT03863457 195 196 O
e. NCT03863457 197 199 O
g. NCT03863457 200 202 O
CT NCT03863457 204 206 B-Procedure
, NCT03863457 207 208 O
MRI NCT03863457 209 212 B-Procedure
, NCT03863457 213 214 O
mammogram NCT03863457 215 224 B-Procedure
, NCT03863457 225 226 O
ultrasound NCT03863457 227 237 B-Procedure
, NCT03863457 238 239 O
FDG NCT03863457 240 243 B-Procedure
- NCT03863457 244 245 I-Procedure
PET NCT03863457 246 249 I-Procedure
/ NCT03863457 250 251 B-Or
CT NCT03863457 252 254 B-Procedure
) NCT03863457 255 256 O
. NCT03863457 257 258 O
Only NCT03863457 260 264 B-Eq-Comparison
one NCT03863457 265 268 I-Eq-Comparison
type NCT03863457 269 273 O
of NCT03863457 274 276 O
imaging NCT03863457 277 284 B-Procedure
is NCT03863457 285 287 O
required NCT03863457 288 296 O
to NCT03863457 297 299 O
show NCT03863457 300 304 O
a NCT03863457 305 306 O
lesion NCT03863457 307 313 B-Condition
. NCT03863457 313 314 O

- NCT03863457 318 319 O
Participants NCT03863457 321 333 O
must NCT03863457 334 338 O
be NCT03863457 339 341 O
informed NCT03863457 342 350 O
of NCT03863457 351 353 O
the NCT03863457 354 357 O
investigational NCT03863457 358 373 O
nature NCT03863457 374 380 O
of NCT03863457 381 383 O
this NCT03863457 384 388 O
study NCT03863457 389 394 O
and NCT03863457 395 398 O
be NCT03863457 399 401 O
willing NCT03863457 402 409 O
to NCT03863457 410 412 O
provide NCT03863457 413 420 O
written NCT03863457 421 428 O
informed NCT03863457 429 437 O
consent NCT03863457 438 445 O
and NCT03863457 446 449 O
participate NCT03863457 450 461 O
in NCT03863457 462 464 O
this NCT03863457 465 469 O
study NCT03863457 470 475 O
in NCT03863457 476 478 O
accordance NCT03863457 479 489 O
with NCT03863457 490 494 O
institutional NCT03863457 495 508 O
and NCT03863457 509 512 O
federal NCT03863457 513 520 O
guidelines NCT03863457 521 531 O
prior NCT03863457 532 537 O
to NCT03863457 538 540 O
study NCT03863457 541 546 O
- NCT03863457 547 548 O
specific NCT03863457 549 557 O
procedures NCT03863457 558 568 O
. NCT03863457 568 569 O

Exclusion NCT03863457 571 580 O
Criteria NCT03863457 581 589 O
: NCT03863457 590 591 O

- NCT03863457 595 596 O
Females NCT03863457 598 605 O
who NCT03863457 606 609 B-And
are NCT03863457 610 613 O
pregnant NCT03863457 614 622 B-Condition
or NCT03863457 623 625 B-Or
breast NCT03863457 626 632 B-Condition
feeding NCT03863457 633 640 I-Condition
at NCT03863457 641 643 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863457 644 647 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03863457 648 652 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863457 653 655 O
screening NCT03863457 656 665 B-Study
; NCT03863457 665 666 O
a NCT03863457 667 668 O
urine NCT03863457 669 674 B-Observation
pregnancy NCT03863457 675 684 I-Observation
test NCT03863457 685 689 I-Observation
will NCT03863457 690 694 O
be NCT03863457 695 697 O
performed NCT03863457 698 707 O
in NCT03863457 708 710 O
women NCT03863457 711 716 O
of NCT03863457 717 719 B-And
child NCT03863457 720 725 B-Condition
- NCT03863457 726 727 I-Condition
bearing NCT03863457 728 735 I-Condition
potential NCT03863457 736 745 I-Condition
at NCT03863457 746 748 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863457 749 758 B-Study
. NCT03863457 758 759 O

- NCT03863457 763 764 O
Inability NCT03863457 766 775 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863457 776 778 O
tolerate NCT03863457 779 787 O
imaging NCT03863457 788 795 B-Procedure
procedures NCT03863457 796 806 I-Procedure
in NCT03863457 807 809 O
the NCT03863457 810 813 O
opinion NCT03863457 814 821 O
of NCT03863457 822 824 O
an NCT03863457 825 827 O
investigator NCT03863457 828 840 O
or NCT03863457 841 843 O
treating NCT03863457 844 852 O
physician NCT03863457 853 862 O
. NCT03863457 862 863 O

- NCT03863457 867 868 O
Any NCT03863457 870 873 O
current NCT03863457 874 881 B-Eq-Comparison
medical NCT03863457 882 889 B-Condition
condition NCT03863457 890 899 I-Condition
, NCT03863457 900 901 O
illness NCT03863457 902 909 B-Condition
, NCT03863457 910 911 O
or NCT03863457 912 914 B-Or
disorder NCT03863457 915 923 B-Condition
, NCT03863457 924 925 O
as NCT03863457 926 928 O
assessed NCT03863457 929 937 O
by NCT03863457 938 940 O
medical NCT03863457 941 948 O
record NCT03863457 949 955 O
review NCT03863457 956 962 O
and NCT03863457 963 966 O
/ NCT03863457 967 968 O
or NCT03863457 969 971 O
self NCT03863457 972 976 O
- NCT03863457 977 978 O
reported NCT03863457 979 987 O
, NCT03863457 988 989 O
that NCT03863457 990 994 O
is NCT03863457 995 997 O
considered NCT03863457 998 1008 O
by NCT03863457 1009 1011 O
a NCT03863457 1012 1013 O
physician NCT03863457 1014 1023 O
investigator NCT03863457 1024 1036 O
to NCT03863457 1037 1039 O
be NCT03863457 1040 1042 O
a NCT03863457 1043 1044 O
condition NCT03863457 1045 1054 B-Condition
that NCT03863457 1055 1059 O
could NCT03863457 1060 1065 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03863457 1066 1076 O
participant NCT03863457 1077 1088 O
safety NCT03863457 1089 1095 O
or NCT03863457 1096 1098 O
successful NCT03863457 1099 1109 O
participation NCT03863457 1110 1123 O
in NCT03863457 1124 1126 O
the NCT03863457 1127 1130 O
study NCT03863457 1131 1136 B-Study
. NCT03863457 1136 1137 O

Inclusion NCT03860610 0 9 O
Criteria NCT03860610 10 18 O
: NCT03860610 19 20 O

- NCT03860610 24 25 O
Patients NCT03860610 27 35 O
with NCT03860610 36 40 O
an NCT03860610 41 43 O
unilateral NCT03860610 44 54 B-Modifier
THA NCT03860610 55 58 B-Procedure
or NCT03860610 59 61 B-Or
TKA NCT03860610 62 65 B-Procedure
, NCT03860610 66 67 O
which NCT03860610 68 73 O
they NCT03860610 74 78 O
received NCT03860610 79 87 B-Eq-Comparison
for NCT03860610 88 91 O
the NCT03860610 92 95 O
treatment NCT03860610 96 105 B-Procedure
of NCT03860610 106 108 O
osteoarthritis NCT03860610 109 123 B-Condition
( NCT03860610 124 125 O
Patient NCT03860610 126 133 O
groups NCT03860610 134 140 O
1 NCT03860610 141 142 O
+ NCT03860610 143 144 O
2 NCT03860610 145 146 O
) NCT03860610 147 148 O

- NCT03860610 152 153 O
Patients NCT03860610 155 163 O
diagnosed NCT03860610 164 173 O
with NCT03860610 174 178 O
unilateral NCT03860610 179 189 B-Modifier
OA NCT03860610 190 192 B-Condition
of NCT03860610 193 195 O
the NCT03860610 196 199 O
knee NCT03860610 200 204 B-Modifier
or NCT03860610 205 207 B-Or
hip NCT03860610 208 211 B-Modifier
planned NCT03860610 212 219 B-Eq-Comparison
for NCT03860610 220 223 O
a NCT03860610 224 225 O
treatment NCT03860610 226 235 B-Procedure
with NCT03860610 236 240 O
THA NCT03860610 241 244 B-Procedure
or NCT03860610 245 247 B-Or
TKA NCT03860610 248 251 B-Procedure
( NCT03860610 252 253 O
Patient NCT03860610 254 261 O
groups NCT03860610 262 268 O
3 NCT03860610 269 270 O
+ NCT03860610 271 272 O
4 NCT03860610 273 274 O
) NCT03860610 275 276 O

- NCT03860610 280 281 O
Age NCT03860610 283 286 B-Age
≥ NCT03860610 287 288 B-Eq-Comparison
30 NCT03860610 289 291 I-Eq-Comparison
years NCT03860610 292 297 I-Eq-Comparison
( NCT03860610 298 299 O
Healthy NCT03860610 300 307 B-Condition
control NCT03860610 308 315 O
group NCT03860610 316 321 O
) NCT03860610 322 323 O

Exclusion NCT03860610 325 334 O
Criteria NCT03860610 335 343 O
: NCT03860610 344 345 O

- NCT03860610 349 350 O
Body NCT03860610 352 356 B-Observation
mass NCT03860610 357 361 I-Observation
index NCT03860610 362 367 I-Observation
> NCT03860610 368 369 B-Eq-Comparison
35 NCT03860610 370 372 I-Eq-Comparison
kg NCT03860610 373 375 O
/ NCT03860610 376 377 O
m2 NCT03860610 378 380 O

- NCT03860610 383 384 O
Use NCT03860610 386 389 O
of NCT03860610 390 392 O
walking NCT03860610 393 400 B-Procedure
aids NCT03860610 401 405 I-Procedure

- NCT03860610 408 409 O
Neuromuscular NCT03860610 411 424 B-Condition
disorders NCT03860610 425 434 I-Condition
affecting NCT03860610 435 444 O
gait NCT03860610 445 449 B-Condition

- NCT03860610 452 453 O
Inability NCT03860610 455 464 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860610 465 467 O
follow NCT03860610 468 474 O
procedures NCT03860610 475 485 B-Procedure
due NCT03860610 486 489 O
to NCT03860610 490 492 O
psychological NCT03860610 493 506 B-Condition
disorders NCT03860610 507 516 I-Condition
or NCT03860610 517 519 B-Or
dementia NCT03860610 520 528 B-Condition

- NCT03860610 531 532 O
Diagnosed NCT03860610 534 543 O
hip NCT03860610 544 547 B-Modifier
or NCT03860610 548 550 O
knee NCT03860610 551 555 B-Modifier
OA NCT03860610 556 558 B-Condition
( NCT03860610 559 560 O
Healthy NCT03860610 561 568 B-Condition
control NCT03860610 569 576 O
group NCT03860610 577 582 O
) NCT03860610 583 584 O

- NCT03860610 588 589 O
Current NCT03860610 591 598 B-Eq-Comparison
pain NCT03860610 599 603 B-Condition
in NCT03860610 604 606 O
the NCT03860610 607 610 O
lower NCT03860610 611 616 B-Modifier|Modifier
extremities NCT03860610 617 628 I-Modifier
or NCT03860610 629 631 B-Or
lower NCT03860610 632 637 O
back NCT03860610 638 642 I-Modifier
( NCT03860610 643 644 O
Healthy NCT03860610 645 652 B-Condition
control NCT03860610 653 660 O
group NCT03860610 661 666 O
) NCT03860610 667 668 O

- NCT03860610 672 673 O
Rheumatoid NCT03860610 675 685 B-Condition
Arthritis NCT03860610 686 695 I-Condition
( NCT03860610 696 697 O
Healthy NCT03860610 698 705 B-Condition
control NCT03860610 706 713 O
group NCT03860610 714 719 O
) NCT03860610 720 721 O

- NCT03860610 725 726 O
Previous NCT03860610 728 736 B-Eq-Comparison
corrective NCT03860610 737 747 B-Procedure
osteotomy NCT03860610 748 757 I-Procedure
( NCT03860610 758 759 O
Healthy NCT03860610 760 767 B-Condition
control NCT03860610 768 775 O
group NCT03860610 776 781 O
) NCT03860610 782 783 O

- NCT03860610 787 788 O
Regular NCT03860610 790 797 O
intake NCT03860610 798 804 O
of NCT03860610 805 807 O
pain NCT03860610 808 812 B-Drug
medication NCT03860610 813 823 I-Drug
( NCT03860610 824 825 O
more NCT03860610 826 830 B-Eq-Comparison
than NCT03860610 831 835 I-Eq-Comparison
4 NCT03860610 836 837 I-Eq-Comparison
times NCT03860610 838 843 I-Eq-Comparison
per NCT03860610 844 847 I-Eq-Comparison
week NCT03860610 848 852 I-Eq-Comparison
) NCT03860610 853 854 O
( NCT03860610 855 856 O
Healthy NCT03860610 857 864 B-Condition
control NCT03860610 865 872 O
group NCT03860610 873 878 O
) NCT03860610 879 880 O

Inclusion NCT03863912 0 9 O
Criteria NCT03863912 10 18 O
: NCT03863912 19 20 O

- NCT03863912 24 25 O
planned NCT03863912 27 34 B-Eq-Comparison
6 NCT03863912 35 36 I-Eq-Comparison
cycles NCT03863912 37 43 I-Eq-Comparison
of NCT03863912 44 46 O
chemotherapy NCT03863912 47 59 B-Procedure
with NCT03863912 60 64 O
carboplatin NCT03863912 65 76 B-Drug
/ NCT03863912 77 78 B-Or
paclitaxel NCT03863912 79 89 B-Drug
or NCT03863912 90 92 B-Or
carboplatin NCT03863912 93 104 B-Drug
/ NCT03863912 105 106 B-Or
pegylated NCT03863912 107 116 B-Drug
liposomal NCT03863912 117 126 I-Drug
doxorubicin NCT03863912 127 138 I-Drug

- NCT03863912 141 142 O
Age NCT03863912 144 147 B-Age
> NCT03863912 148 149 B-Eq-Comparison
18 NCT03863912 150 152 I-Eq-Comparison
years NCT03863912 153 158 I-Eq-Comparison

Exclusion NCT03863912 159 168 O
Criteria NCT03863912 169 177 O
: NCT03863912 178 179 O

- NCT03863912 183 184 O
inadequate NCT03863912 186 196 B-Negation
knowledge NCT03863912 197 206 O
of NCT03863912 207 209 O
the NCT03863912 210 213 O
German NCT03863912 214 220 O
language NCT03863912 221 229 O

Inclusion NCT03861650 0 9 O
Criteria NCT03861650 10 18 O
: NCT03861650 19 20 O

1 NCT03861650 24 25 O
. NCT03861650 25 26 O
Patients NCT03861650 28 36 O
free NCT03861650 37 41 B-Negation
from NCT03861650 42 46 I-Negation
any NCT03861650 47 50 O
disease NCT03861650 51 58 B-Condition
affecting NCT03861650 59 68 O
bone NCT03861650 69 73 B-Condition
formation NCT03861650 74 83 I-Condition
of NCT03861650 84 86 O
both NCT03861650 87 91 O
sexes NCT03861650 92 97 O
was NCT03861650 98 101 O
included NCT03861650 102 110 O
in NCT03861650 111 113 O
the NCT03861650 114 117 O
study NCT03861650 118 123 O
. NCT03861650 123 124 O

2 NCT03861650 128 129 O
. NCT03861650 129 130 O
Patients NCT03861650 132 140 O
younger NCT03861650 141 148 B-Eq-Comparison
than NCT03861650 149 153 I-Eq-Comparison
25 NCT03861650 154 156 I-Eq-Comparison
years NCT03861650 157 162 I-Eq-Comparison
old NCT03861650 163 166 B-Age
. NCT03861650 166 167 O

3 NCT03861650 171 172 O
. NCT03861650 172 173 O
Patients NCT03861650 175 183 O
included NCT03861650 184 192 O
in NCT03861650 193 195 O
the NCT03861650 196 199 O
study NCT03861650 200 205 B-Study
were NCT03861650 206 210 O
post NCT03861650 211 215 B-Condition
traumatic NCT03861650 216 225 I-Condition
patients NCT03861650 226 234 O
, NCT03861650 235 236 O
hemifacial NCT03861650 237 247 B-Condition
microsomia NCT03861650 248 258 I-Condition
, NCT03861650 259 260 O
Treacher NCT03861650 261 269 B-Condition
Collins NCT03861650 270 277 I-Condition
and NCT03861650 278 281 B-Or
post NCT03861650 282 286 B-Condition
ankylotic NCT03861650 287 296 I-Condition
mandibular NCT03861650 297 307 I-Condition
deformity NCT03861650 308 317 I-Condition
. NCT03861650 317 318 O

4 NCT03861650 322 323 O
. NCT03861650 323 324 O
Distraction NCT03861650 326 337 B-Observation
range NCT03861650 338 343 I-Observation
was NCT03861650 344 347 O
between NCT03861650 348 355 B-Eq-Comparison
15 NCT03861650 356 358 I-Eq-Comparison
- NCT03861650 359 360 I-Eq-Comparison
20 NCT03861650 361 363 I-Eq-Comparison
mm NCT03861650 364 366 I-Eq-Comparison
. NCT03861650 366 367 O

Exclusion NCT03861650 369 378 O
Criteria NCT03861650 379 387 O
: NCT03861650 388 389 O

1 NCT03861650 393 394 O
. NCT03861650 394 395 O
The NCT03861650 397 400 O
presence NCT03861650 401 409 O
of NCT03861650 410 412 O
uncontrolled NCT03861650 413 425 B-Modifier
systemic NCT03861650 426 434 I-Modifier
disease NCT03861650 435 442 B-Condition
. NCT03861650 442 443 O

2 NCT03861650 447 448 O
. NCT03861650 448 449 O
Previous NCT03861650 451 459 B-Eq-Comparison
radiotherapy NCT03861650 460 472 B-Procedure
on NCT03861650 473 475 O
head NCT03861650 476 480 B-Modifier
and NCT03861650 481 484 B-Or
neck NCT03861650 485 489 B-Modifier
region NCT03861650 490 496 O
. NCT03861650 496 497 O

3 NCT03861650 501 502 O
. NCT03861650 502 503 O
Chemotherapy NCT03861650 505 517 B-Procedure
within NCT03861650 518 524 B-Eq-Comparison
the NCT03861650 525 528 I-Eq-Comparison
past NCT03861650 529 533 I-Eq-Comparison
12 NCT03861650 534 536 I-Eq-Comparison
- NCT03861650 537 538 I-Eq-Comparison
month NCT03861650 539 544 I-Eq-Comparison
period NCT03861650 545 551 O
. NCT03861650 551 552 O

4 NCT03861650 556 557 O
. NCT03861650 557 558 O
An NCT03861650 560 562 O
active NCT03861650 563 569 B-Eq-Comparison
infection NCT03861650 570 579 B-Condition
at NCT03861650 580 582 O
the NCT03861650 583 586 O
distraction NCT03861650 587 598 B-Modifier
site NCT03861650 599 603 I-Modifier
. NCT03861650 603 604 O

Inclusion NCT03862417 0 9 O
Criteria NCT03862417 10 18 O
: NCT03862417 19 20 O

- NCT03862417 24 25 O
Adults NCT03862417 27 33 O
over NCT03862417 34 38 B-Eq-Comparison
50 NCT03862417 39 41 I-Eq-Comparison
years NCT03862417 42 47 I-Eq-Comparison
old NCT03862417 48 51 B-Age
with NCT03862417 52 56 B-And
degenerative NCT03862417 57 69 B-Condition
scoliosis NCT03862417 70 79 I-Condition
( NCT03862417 80 81 O
n NCT03862417 82 83 O
= NCT03862417 84 85 O
20 NCT03862417 86 88 O
) NCT03862417 89 90 O
with NCT03862417 91 95 B-And
pain NCT03862417 96 100 B-Condition|Observation
( NCT03862417 101 102 O
> NCT03862417 104 105 B-Eq-Comparison
2 NCT03862417 106 107 I-Eq-Comparison
/ NCT03862417 108 109 O
10 NCT03862417 110 112 O
) NCT03862417 113 114 O
. NCT03862417 115 116 O
Other NCT03862417 118 123 O
inclusion NCT03862417 124 133 O
criteria NCT03862417 134 142 O
are NCT03862417 143 146 O
: NCT03862417 147 148 O
( NCT03862417 149 150 O
1 NCT03862417 151 152 O
) NCT03862417 153 154 O
curves NCT03862417 155 161 B-Observation
15 NCT03862417 162 164 B-Eq-Comparison
° NCT03862417 165 166 O
- NCT03862417 167 168 I-Eq-Comparison
45 NCT03862417 169 171 I-Eq-Comparison
° NCT03862417 172 173 O
. NCT03862417 173 174 O

Exclusion NCT03862417 176 185 O
Criteria NCT03862417 186 194 O
: NCT03862417 195 196 O

- NCT03862417 200 201 O
Curves NCT03862417 203 209 B-Observation
over NCT03862417 210 214 B-Eq-Comparison
50 NCT03862417 215 217 I-Eq-Comparison
° NCT03862417 218 219 O
are NCT03862417 220 223 O
surgical NCT03862417 224 232 B-Procedure
candidates NCT03862417 233 243 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03862417 244 245 O
and NCT03862417 246 249 O
will NCT03862417 250 254 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862417 255 257 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03862417 258 266 B-Negation
. NCT03862417 266 267 O
Patients NCT03862417 269 277 O
who NCT03862417 278 281 O
have NCT03862417 282 286 O
had NCT03862417 287 290 B-Eq-Comparison
cortisone NCT03862417 291 300 B-Drug
or NCT03862417 301 303 B-Or
anesthetic NCT03862417 304 314 B-Drug
injections NCT03862417 315 325 B-Procedure
within NCT03862417 326 332 B-Eq-Comparison
the NCT03862417 333 336 I-Eq-Comparison
last NCT03862417 337 341 I-Eq-Comparison
3 NCT03862417 342 343 I-Eq-Comparison
months NCT03862417 344 350 I-Eq-Comparison
, NCT03862417 351 352 O
surgery NCT03862417 353 360 B-Procedure
or NCT03862417 361 363 B-Or
presenting NCT03862417 364 374 O
contra NCT03862417 375 381 B-Contraindication
- NCT03862417 382 383 I-Contraindication
indications NCT03862417 384 395 I-Contraindication
to NCT03862417 396 398 O
exercises NCT03862417 399 408 B-Observation
( NCT03862417 409 410 O
fractures NCT03862417 411 420 B-Condition
, NCT03862417 421 422 O
cancer NCT03862417 423 429 B-Condition
, NCT03862417 430 431 O
severe NCT03862417 432 438 O
cardio NCT03862417 439 445 B-Condition
- NCT03862417 446 447 I-Condition
vascular NCT03862417 448 456 I-Condition
co NCT03862417 457 459 I-Condition
- NCT03862417 460 461 O
morbidities NCT03862417 462 473 I-Condition
, NCT03862417 474 475 O
or NCT03862417 476 478 B-Or
osteopenia NCT03862417 479 489 B-Condition
) NCT03862417 490 491 O
will NCT03862417 492 496 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862417 497 499 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03862417 500 508 B-Negation
. NCT03862417 508 509 O

Inclusion NCT03868930 0 9 O
Criteria NCT03868930 10 18 O
: NCT03868930 19 20 O

- NCT03868930 24 25 O
Post NCT03868930 27 31 B-Modifier
- NCT03868930 32 33 I-Modifier
9 NCT03868930 34 35 I-Modifier
/ NCT03868930 36 37 I-Modifier
11 NCT03868930 38 40 I-Modifier
Veterans NCT03868930 41 49 B-Observation
who NCT03868930 50 53 B-And
report NCT03868930 54 60 O
some NCT03868930 61 65 O
reintegration NCT03868930 66 79 B-Modifier
, NCT03868930 80 81 O
readjustment NCT03868930 82 94 B-Modifier
, NCT03868930 95 96 O
or NCT03868930 97 99 B-Or
anger NCT03868930 100 105 B-Modifier
difficulty NCT03868930 106 116 B-Condition

- NCT03868930 124 125 O
i. NCT03868930 127 129 O
e. NCT03868930 130 132 O
, NCT03868930 133 134 O
Veterans NCT03868930 135 143 B-Observation
who NCT03868930 144 147 B-And
report NCT03868930 148 154 O
" NCT03868930 155 156 O
some NCT03868930 156 160 B-Modifier
difficulty NCT03868930 161 171 I-Modifier
" NCT03868930 171 172 O
( NCT03868930 173 174 O
Likert NCT03868930 175 181 O
rating NCT03868930 182 188 O
) NCT03868930 189 190 O
on NCT03868930 191 193 I-Eq-Comparison
at NCT03868930 194 196 B-Eq-Comparison
least NCT03868930 197 202 I-Eq-Comparison
one NCT03868930 203 206 O
of NCT03868930 207 209 O
the NCT03868930 210 213 O
primary NCT03868930 214 221 B-Observation
measures NCT03868930 222 230 I-Observation
: NCT03868930 231 232 O
M2CQ NCT03868930 233 237 B-Observation
; NCT03868930 237 238 O
PDRI NCT03868930 239 243 B-Observation
; NCT03868930 243 244 O
STAXI NCT03868930 245 250 B-Observation
- NCT03868930 251 252 I-Eq-Comparison|Observation
2 NCT03868930 253 254 I-Observation

- NCT03868930 258 259 O
18 NCT03868930 261 263 B-Eq-Comparison
- NCT03868930 264 265 O
65 NCT03868930 266 268 I-Eq-Comparison
years NCT03868930 269 274 I-Eq-Comparison
old NCT03868930 275 278 B-Age
( NCT03868930 279 280 O
to NCT03868930 281 283 O
avoid NCT03868930 284 289 O
outcomes NCT03868930 290 298 O
being NCT03868930 299 304 O
affected NCT03868930 305 313 O
by NCT03868930 314 316 O
aging NCT03868930 317 322 O
) NCT03868930 323 324 O

- NCT03868930 328 329 O
English NCT03868930 331 338 O
- NCT03868930 339 340 O
speaking NCT03868930 341 349 O
( NCT03868930 350 351 O
sessions NCT03868930 352 360 O
will NCT03868930 361 365 O
be NCT03868930 366 368 O
conducted NCT03868930 369 378 O
in NCT03868930 379 381 O
English NCT03868930 382 389 O
) NCT03868930 390 391 O

- NCT03868930 395 396 O
Agreeing NCT03868930 398 406 O
to NCT03868930 407 409 O
participate NCT03868930 410 421 O

- NCT03868930 429 430 O
i. NCT03868930 432 434 O
e. NCT03868930 435 437 O
, NCT03868930 438 439 O
completion NCT03868930 440 450 O
of NCT03868930 451 453 O
ICF NCT03868930 454 457 B-Observation
/ NCT03868930 458 459 B-Or
HIPAA NCT03868930 460 465 B-Observation

Exclusion NCT03868930 466 475 O
Criteria NCT03868930 476 484 O
: NCT03868930 485 486 O

- NCT03868930 490 491 O
schizophreniform NCT03868930 493 509 B-Condition
disorder NCT03868930 510 518 I-Condition
/ NCT03868930 519 520 B-Or
active NCT03868930 521 527 B-Eq-Comparison
psychosis NCT03868930 528 537 B-Condition

- NCT03868930 540 541 O
bipolar NCT03868930 543 550 B-Condition
disorder NCT03868930 551 559 I-Condition

- NCT03868930 562 563 O
active NCT03868930 565 571 B-Eq-Comparison
suicidality NCT03868930 572 583 B-Condition
/ NCT03868930 584 585 B-Or
homicidality NCT03868930 586 598 B-Condition
requiring NCT03868930 599 608 B-Assertion___Assertion-Type-Value:hypothetical
crisis NCT03868930 609 615 B-Procedure
intervention NCT03868930 616 628 I-Procedure

- NCT03868930 631 632 O
other NCT03868930 634 639 B-Other
severe NCT03868930 640 646 O
psychiatric NCT03868930 647 658 B-Condition
disorders NCT03868930 659 668 I-Condition
prohibiting NCT03868930 669 680 B-Assertion___Assertion-Type-Value:hypothetical|Negation
appropriate NCT03868930 681 692 O
group NCT03868930 693 698 B-Procedure
participation NCT03868930 699 712 I-Procedure

- NCT03868930 715 716 O
neurological NCT03868930 718 730 B-Condition
diagnosis NCT03868930 731 740 O
prohibiting NCT03868930 741 752 B-Assertion___Assertion-Type-Value:hypothetical|Negation
appropriate NCT03868930 753 764 O
group NCT03868930 765 770 B-Procedure
participation NCT03868930 771 784 I-Procedure
( NCT03868930 785 786 O
excluding NCT03868930 787 796 B-Exception
TBI NCT03868930 797 800 B-Condition
) NCT03868930 801 802 O

- NCT03868930 806 807 O
current NCT03868930 809 816 B-Eq-Comparison|Eq-Comparison
substance NCT03868930 817 826 B-Condition
dependence NCT03868930 827 837 I-Condition

- NCT03868930 840 841 O
current NCT03868930 843 850 O
participation NCT03868930 851 864 O
in NCT03868930 865 867 O
any NCT03868930 868 871 O
other NCT03868930 872 877 B-Other
form NCT03868930 878 882 O
of NCT03868930 883 885 O
active NCT03868930 886 892 B-Eq-Comparison
behavioral NCT03868930 893 903 B-Procedure
therapy NCT03868930 904 911 I-Procedure|Temporal-Connection___Temporal-Connection-Type-Value:during
at NCT03868930 912 914 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868930 915 918 O
time NCT03868930 919 923 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03868930 924 926 O
enrollment NCT03868930 927 937 B-Study

- NCT03868930 945 946 O
e. NCT03868930 948 950 O
g. NCT03868930 951 953 O
, NCT03868930 954 955 O
Cognitive NCT03868930 956 965 B-Procedure
Processing NCT03868930 966 976 I-Procedure
Therapy NCT03868930 977 984 I-Procedure
, NCT03868930 985 986 O
cognitive NCT03868930 987 996 B-Procedure
rehabilitation NCT03868930 997 1011 I-Procedure
for NCT03868930 1012 1015 O
mTBI NCT03868930 1016 1020 B-Condition
, NCT03868930 1021 1022 O
or NCT03868930 1023 1025 B-Or
other NCT03868930 1026 1031 B-Other
psychotherapy NCT03868930 1032 1045 B-Procedure

Inclusion NCT03864887 0 9 O
Criteria NCT03864887 10 18 O
: NCT03864887 19 20 O

- NCT03864887 24 25 O
Patients NCT03864887 27 35 O
who NCT03864887 36 39 O
have NCT03864887 40 44 O
had NCT03864887 45 48 B-Eq-Comparison
brain NCT03864887 49 54 B-Condition
death NCT03864887 55 60 I-Condition
or NCT03864887 61 63 B-Or
serious NCT03864887 64 71 O
brain NCT03864887 72 77 B-Modifier
trauma NCT03864887 78 84 B-Condition
. NCT03864887 84 85 O

- NCT03864887 89 90 O
Healthy NCT03864887 92 99 B-Condition
people NCT03864887 100 106 O
who NCT03864887 107 110 B-And
are NCT03864887 111 114 O
interested NCT03864887 115 125 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03864887 126 128 I-Assertion___Assertion-Type-Value:hypothetical
optical NCT03864887 129 136 B-Procedure
assessment NCT03864887 137 147 I-Procedure
of NCT03864887 148 150 O
hemodynamic NCT03864887 151 162 B-Observation
parameters NCT03864887 163 173 I-Observation

Exclusion NCT03864887 174 183 O
Criteria NCT03864887 184 192 O
: NCT03864887 193 194 O

- NCT03864887 198 199 O
Patients NCT03864887 201 209 O
who NCT03864887 210 213 O
are NCT03864887 214 217 O
in NCT03864887 218 220 O
pregnancy NCT03864887 221 230 B-Condition
or NCT03864887 231 233 B-Or
have NCT03864887 234 238 O
plan NCT03864887 239 243 B-Assertion___Assertion-Type-Value:intention
to NCT03864887 244 246 I-Assertion___Assertion-Type-Value:intention
conception NCT03864887 247 257 B-Condition
. NCT03864887 257 258 O

- NCT03864887 262 263 O
Patients NCT03864887 265 273 O
who NCT03864887 274 277 O
have NCT03864887 278 282 O
vertebra NCT03864887 283 291 B-Procedure
surgery NCT03864887 292 299 I-Procedure
or NCT03864887 300 302 B-Or
have NCT03864887 303 307 O
plan NCT03864887 308 312 B-Assertion___Assertion-Type-Value:intention
of NCT03864887 313 315 I-Assertion___Assertion-Type-Value:intention
surgery NCT03864887 316 323 B-Procedure
. NCT03864887 323 324 O

- NCT03864887 328 329 O
Patients NCT03864887 331 339 O
who NCT03864887 340 343 O
are NCT03864887 344 347 O
inappropriate NCT03864887 348 361 O
to NCT03864887 362 364 O
join NCT03864887 365 369 O
this NCT03864887 370 374 O
trial NCT03864887 375 380 O
judged NCT03864887 381 387 O
by NCT03864887 388 390 O
the NCT03864887 391 394 O
radiologists NCT03864887 395 407 O
or NCT03864887 408 410 O
specialists NCT03864887 411 422 O
. NCT03864887 422 423 O

- NCT03864887 432 433 O
AIDS NCT03864887 435 439 B-Condition
, NCT03864887 440 441 O
Active NCT03864887 442 448 B-Eq-Comparison
Hepatitis NCT03864887 449 458 B-Condition
, NCT03864887 459 460 O
Tuberculosis NCT03864887 461 473 B-Condition
, NCT03864887 474 475 O
Syphilis NCT03864887 476 484 B-Condition

- NCT03864887 492 493 O
Patients NCT03864887 495 503 O
who NCT03864887 504 507 O
regularly NCT03864887 508 517 B-Eq-Comparison
take NCT03864887 518 522 I-Eq-Comparison
anticoagulants NCT03864887 523 537 B-Drug
, NCT03864887 538 539 O
antiplatelet NCT03864887 540 552 B-Drug
drugs NCT03864887 553 558 I-Drug

Inclusion NCT03860363 0 9 O
Criteria NCT03860363 10 18 O
: NCT03860363 19 20 O

- NCT03860363 24 25 O
Adult NCT03860363 27 32 O
( NCT03860363 33 34 O
age NCT03860363 35 38 B-Age
≥ NCT03860363 39 40 B-Eq-Comparison
18 NCT03860363 41 43 I-Eq-Comparison
) NCT03860363 44 45 O

- NCT03860363 49 50 O
Patient NCT03860363 52 59 O
undergoing NCT03860363 60 70 B-Eq-Comparison
non NCT03860363 71 74 B-Negation
- NCT03860363 75 76 O
emergent NCT03860363 77 85 B-Modifier
cardiac NCT03860363 86 93 B-Procedure
surgery NCT03860363 94 101 I-Procedure

- NCT03860363 104 105 O
Anticipated NCT03860363 107 118 B-Assertion___Assertion-Type-Value:possible
requirement NCT03860363 119 130 O
for NCT03860363 131 134 O
mediastinal NCT03860363 135 146 B-Procedure
chest NCT03860363 147 152 I-Procedure
tube NCT03860363 153 157 I-Procedure
drainage NCT03860363 158 166 I-Procedure

Exclusion NCT03860363 167 176 O
Criteria NCT03860363 177 185 O
: NCT03860363 186 187 O

- NCT03860363 191 192 O
Emergency NCT03860363 194 203 B-Modifier
surgery NCT03860363 204 211 B-Procedure

- NCT03860363 214 215 I-Modifier
Re NCT03860363 217 219 B-Modifier
- NCT03860363 220 221 O
do NCT03860363 222 224 I-Modifier
surgery NCT03860363 225 232 B-Procedure

- NCT03860363 235 236 O
Prior NCT03860363 238 243 B-Eq-Comparison
cardiac NCT03860363 244 251 B-Procedure
surgery NCT03860363 252 259 I-Procedure

- NCT03860363 262 263 O
Congenital NCT03860363 265 275 B-Modifier
cardiac NCT03860363 276 283 B-Condition
disease NCT03860363 284 291 I-Condition
or NCT03860363 292 294 B-Or
deformation NCT03860363 295 306 B-Condition

- NCT03860363 309 310 O
Transplant NCT03860363 312 322 B-Procedure
surgery NCT03860363 323 330 I-Procedure

- NCT03860363 333 334 O
Ventricular NCT03860363 336 347 B-Procedure
Assist NCT03860363 348 354 I-Procedure
Device NCT03860363 355 361 I-Procedure
Surgery NCT03860363 362 369 I-Procedure

- NCT03860363 372 373 O
Suspected NCT03860363 375 384 B-Assertion___Assertion-Type-Value:possible
pulmonary NCT03860363 385 394 B-Condition
air NCT03860363 395 398 I-Condition
leak NCT03860363 399 403 I-Condition

- NCT03860363 406 407 O
Atrial NCT03860363 409 415 B-Condition
fibrillation NCT03860363 416 428 I-Condition

- NCT03860363 431 432 O
In NCT03860363 434 436 O
the NCT03860363 437 440 O
opinion NCT03860363 441 448 O
of NCT03860363 449 451 O
the NCT03860363 452 455 O
investigator NCT03860363 456 468 O
the NCT03860363 469 472 O
patient NCT03860363 473 480 O
is NCT03860363 481 483 O
unsuitable NCT03860363 484 494 O
for NCT03860363 495 498 O
the NCT03860363 499 502 O
study NCT03860363 503 508 O
for NCT03860363 509 512 O
any NCT03860363 513 516 O
other NCT03860363 517 522 O
legitimate NCT03860363 523 533 O
reason NCT03860363 534 540 O
including NCT03860363 541 550 O
incarceration NCT03860363 551 564 O
, NCT03860363 565 566 O
pre NCT03860363 567 570 B-Eq-Comparison
- NCT03860363 571 572 I-Eq-Comparison
existing NCT03860363 573 581 I-Eq-Comparison
medical NCT03860363 582 589 B-Modifier
or NCT03860363 590 592 O
psychiatric NCT03860363 593 604 B-Modifier
condition NCT03860363 605 614 B-Condition
, NCT03860363 615 616 O
or NCT03860363 617 619 B-Or
interfering NCT03860363 620 631 O
medications NCT03860363 632 643 B-Drug

- NCT03860363 646 647 O
Known NCT03860363 649 654 O
previous NCT03860363 655 663 B-Eq-Comparison
or NCT03860363 664 666 B-Or
concurrent NCT03860363 667 677 B-Modifier
enrollment NCT03860363 678 688 O
in NCT03860363 689 691 O
a NCT03860363 692 693 O
clinical NCT03860363 694 702 B-Study
trial NCT03860363 703 708 I-Study
that NCT03860363 709 713 O
, NCT03860363 714 715 O
in NCT03860363 716 718 O
the NCT03860363 719 722 O
opinion NCT03860363 723 730 O
of NCT03860363 731 733 O
the NCT03860363 734 737 O
investigator NCT03860363 738 750 O
, NCT03860363 751 752 O
might NCT03860363 753 758 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860363 759 768 O
with NCT03860363 769 773 O
the NCT03860363 774 777 O
objectives NCT03860363 778 788 O
of NCT03860363 789 791 O
this NCT03860363 792 796 O
clinical NCT03860363 797 805 B-Study
trial NCT03860363 806 811 I-Study

- NCT03860363 814 815 O
Pregnancy NCT03860363 817 826 B-Condition

Inclusion NCT03862560 0 9 O
Criteria NCT03862560 10 18 O
: NCT03862560 19 20 O

- NCT03862560 24 25 O
Caucasian NCT03862560 27 36 O
, NCT03862560 37 38 O
Healthy NCT03862560 39 46 B-Condition
participant NCT03862560 47 58 O
, NCT03862560 59 60 O
from NCT03862560 61 65 O
12 NCT03862560 66 68 B-Eq-Comparison
to NCT03862560 69 71 I-Eq-Comparison
20 NCT03862560 72 74 I-Eq-Comparison
years NCT03862560 75 80 I-Eq-Comparison
old NCT03862560 81 84 B-Age
, NCT03862560 85 86 O
with NCT03862560 87 91 B-And
a NCT03862560 92 93 O
history NCT03862560 94 101 B-Eq-Comparison
of NCT03862560 102 104 O
training NCT03862560 105 113 B-Observation
at NCT03862560 114 116 B-Eq-Comparison
least NCT03862560 117 122 I-Eq-Comparison
3 NCT03862560 123 124 I-Eq-Comparison
years NCT03862560 125 130 I-Eq-Comparison
. NCT03862560 130 131 O

Exclusion NCT03862560 133 142 O
Criteria NCT03862560 143 151 O
: NCT03862560 152 153 O

- NCT03862560 157 158 O
Non NCT03862560 160 163 B-Negation
- NCT03862560 164 165 O
caucasian NCT03862560 166 175 O
, NCT03862560 176 177 O
injury NCT03862560 178 184 B-Condition
. NCT03862560 184 185 O

Inclusion NCT03868267 0 9 O
Criteria NCT03868267 10 18 O
: NCT03868267 19 20 O

- NCT03868267 24 25 O
adult NCT03868267 27 32 O
patients NCT03868267 33 41 O
( NCT03868267 42 43 O
≥ NCT03868267 45 46 B-Eq-Comparison
18 NCT03868267 47 49 I-Eq-Comparison
years NCT03868267 50 55 I-Eq-Comparison
of NCT03868267 56 58 O
age NCT03868267 59 62 B-Age
) NCT03868267 63 64 O
who NCT03868267 65 68 B-And
are NCT03868267 69 72 O
undergoing NCT03868267 73 83 B-Eq-Comparison
esophago NCT03868267 84 92 B-Procedure
- NCT03868267 93 94 I-Procedure
gastro NCT03868267 95 101 I-Procedure
duodenoscopy NCT03868267 102 114 I-Procedure
( NCT03868267 115 116 O
EGD NCT03868267 117 120 B-Procedure
) NCT03868267 121 122 O
for NCT03868267 123 126 O
any NCT03868267 127 130 O
reason NCT03868267 131 137 O
and NCT03868267 138 141 B-And
are NCT03868267 142 145 O
consenting NCT03868267 146 156 O
to NCT03868267 157 159 O
be NCT03868267 160 162 O
enrolled NCT03868267 163 171 O
in NCT03868267 172 174 O
the NCT03868267 175 178 O
study NCT03868267 179 184 B-Study
during NCT03868267 185 191 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868267 192 195 O
study NCT03868267 196 201 B-Study
period NCT03868267 202 208 O
. NCT03868267 208 209 O

Exclusion NCT03868267 211 220 O
Criteria NCT03868267 221 229 O
: NCT03868267 230 231 O

- NCT03868267 235 236 O
the NCT03868267 238 241 O
patients NCT03868267 242 250 O
who NCT03868267 251 254 O
can NCT03868267 255 258 B-Negation
not NCT03868267 258 261 O
speak NCT03868267 262 267 O
English NCT03868267 268 275 O
in NCT03868267 276 278 O
Canada NCT03868267 279 285 O
, NCT03868267 286 287 O
who NCT03868267 288 291 B-And
can NCT03868267 292 295 B-Negation
not NCT03868267 295 298 O
speak NCT03868267 299 304 O
Japanese NCT03868267 305 313 O
in NCT03868267 314 316 O
Japan NCT03868267 317 322 O
, NCT03868267 323 324 O
and NCT03868267 325 328 B-Or
can NCT03868267 329 332 B-Negation
not NCT03868267 332 335 O
speak NCT03868267 336 341 O
Persian NCT03868267 342 349 O
in NCT03868267 350 352 O
Iran NCT03868267 353 357 O
. NCT03868267 357 358 O

Inclusion NCT03866538 0 9 O
Criteria NCT03866538 10 18 O

- NCT03866538 21 22 O
Patients NCT03866538 24 32 O
will NCT03866538 33 37 O
be NCT03866538 38 40 O
recruited NCT03866538 41 50 O
from NCT03866538 51 55 O
the NCT03866538 56 59 O
Division NCT03866538 60 68 O
of NCT03866538 69 71 O
Gastroenterology NCT03866538 72 88 O
and NCT03866538 89 92 O
Hepatology NCT03866538 93 103 O
and NCT03866538 104 107 O
the NCT03866538 108 111 O
Mayo NCT03866538 112 116 O
Clinic NCT03866538 117 123 O
in NCT03866538 124 126 O
Rochester NCT03866538 127 136 O
, NCT03866538 137 138 O
MN NCT03866538 139 141 O
. NCT03866538 141 142 O

- NCT03866538 146 147 O
Adult NCT03866538 149 154 O
patients NCT03866538 155 163 O
with NCT03866538 164 168 B-And
immune NCT03866538 169 175 B-Condition
mediated NCT03866538 176 184 I-Condition
enteropathies NCT03866538 185 198 I-Condition
who NCT03866538 199 202 B-And
have NCT03866538 203 207 O
had NCT03866538 208 211 O
improvement NCT03866538 212 223 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03866538 224 226 I-Assertion___Assertion-Type-Value:hypothetical
symptoms NCT03866538 227 235 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03866538 236 239 B-Or
histology NCT03866538 240 249 B-Procedure
on NCT03866538 250 252 B-Eq-Comparison
oral NCT03866538 253 257 B-Procedure
budesonide NCT03866538 258 268 I-Procedure
therapy NCT03866538 269 276 I-Procedure
. NCT03866538 276 277 O

Exclusion NCT03866538 279 288 O
Criteria NCT03866538 289 297 O

- NCT03866538 300 301 O
Age NCT03866538 303 306 B-Age
< NCT03866538 307 308 B-Eq-Comparison
18 NCT03866538 309 311 I-Eq-Comparison
years NCT03866538 312 317 I-Eq-Comparison

- NCT03866538 320 321 O
Positive NCT03866538 323 331 O
stool NCT03866538 332 337 B-Observation
gluten NCT03866538 338 344 I-Observation
testing NCT03866538 345 352 I-Observation
in NCT03866538 353 355 O
patients NCT03866538 356 364 O
with NCT03866538 365 369 B-And
refractory NCT03866538 370 380 B-Condition
celiac NCT03866538 381 387 I-Condition
disease NCT03866538 388 395 I-Condition

- NCT03866538 398 399 O
Small NCT03866538 401 406 B-Condition
bowel NCT03866538 407 412 I-Condition
malignancy NCT03866538 413 423 I-Condition
or NCT03866538 424 426 B-Or
history NCT03866538 427 434 B-Eq-Comparison
of NCT03866538 435 437 O
small NCT03866538 438 443 B-Condition
bowel NCT03866538 444 449 I-Condition
malignancy NCT03866538 450 460 I-Condition

- NCT03866538 463 464 O
Refractory NCT03866538 466 476 B-Condition
celiac NCT03866538 477 483 I-Condition
disease NCT03866538 484 491 I-Condition
type NCT03866538 492 496 B-Modifier
2 NCT03866538 497 498 I-Modifier

- NCT03866538 502 503 O
Post NCT03866538 505 509 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03866538 510 511 O
transplant NCT03866538 512 522 B-Procedure
lymphoproliferative NCT03866538 523 542 B-Condition
disorder NCT03866538 543 551 I-Condition
associated NCT03866538 552 562 O
enteropathy NCT03866538 563 574 B-Condition

- NCT03866538 577 578 O
No NCT03866538 580 582 B-Negation
prior NCT03866538 583 588 B-Eq-Comparison
improvement NCT03866538 589 600 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03866538 601 603 I-Assertion___Assertion-Type-Value:hypothetical
symptoms NCT03866538 604 612 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03866538 613 616 B-Or
histology NCT03866538 617 626 B-Procedure
with NCT03866538 627 631 B-And
budesonide NCT03866538 632 642 B-Procedure
therapy NCT03866538 643 650 I-Procedure

- NCT03866538 653 654 O
Discontinuation NCT03866538 656 671 B-Negation
of NCT03866538 672 674 O
budesonide NCT03866538 675 685 B-Procedure
therapy NCT03866538 686 693 I-Procedure
prior NCT03866538 694 699 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866538 700 702 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866538 703 706 O
trial NCT03866538 707 712 B-Study

- NCT03866538 715 716 O
Other NCT03866538 718 723 B-Other
concurrent NCT03866538 724 734 B-Modifier
systemic NCT03866538 735 743 I-Modifier
corticosteroids NCT03866538 744 759 B-Drug

- NCT03866538 762 763 O
Other NCT03866538 765 770 B-Other
immune NCT03866538 771 777 B-Drug
mediating NCT03866538 778 787 I-Drug
medications NCT03866538 788 799 I-Drug
, NCT03866538 800 801 O
for NCT03866538 802 805 O
example NCT03866538 806 813 O
but NCT03866538 814 817 O
not NCT03866538 818 821 O
limited NCT03866538 822 829 O
to NCT03866538 830 832 O
azathioprine NCT03866538 833 845 B-Drug
, NCT03866538 846 847 O
6 NCT03866538 848 849 B-Drug
- NCT03866538 850 851 I-Drug
mercaptopurine NCT03866538 852 866 I-Drug
, NCT03866538 867 868 O
cyclosporine NCT03866538 869 881 B-Drug
, NCT03866538 882 883 O
methotrexate NCT03866538 884 896 B-Drug
, NCT03866538 897 898 O
anti NCT03866538 899 903 B-Drug
- NCT03866538 904 905 I-Drug
TNF NCT03866538 906 909 I-Drug
monoclonal NCT03866538 910 920 I-Drug
antibodies NCT03866538 921 931 I-Drug
, NCT03866538 932 933 O
alpha NCT03866538 934 939 B-Drug
- NCT03866538 940 941 I-Drug
4 NCT03866538 942 943 I-Drug
beta NCT03866538 944 948 I-Drug
- NCT03866538 949 950 O
7 NCT03866538 951 952 I-Drug
integrin NCT03866538 953 961 I-Drug
inhibiting NCT03866538 962 972 I-Drug
monoclonal NCT03866538 973 983 I-Drug
antibody NCT03866538 984 992 I-Drug
, NCT03866538 993 994 O
interleukin NCT03866538 995 1006 B-Drug
12 NCT03866538 1007 1009 I-Drug
/ NCT03866538 1010 1011 I-Drug
23 NCT03866538 1012 1014 I-Drug
inhibiting NCT03866538 1015 1025 I-Drug
monoclonal NCT03866538 1026 1036 I-Drug
antibody NCT03866538 1037 1045 I-Drug
, NCT03866538 1046 1047 O
JAK NCT03866538 1048 1051 B-Drug
inhibitors NCT03866538 1052 1062 I-Drug
. NCT03866538 1062 1063 O


Inclusion NCT03869151 0 9 O
Criteria NCT03869151 10 18 O
: NCT03869151 19 20 O

Patients NCT03869151 22 30 O
with NCT03869151 31 35 O
child NCT03869151 36 41 B-Modifier
A NCT03869151 42 43 I-Modifier
Hepatocellular NCT03869151 44 58 I-Modifier
carcinoma NCT03869151 59 68 B-Condition
. NCT03869151 68 69 O

Exclusion NCT03869151 71 80 O
Criteria NCT03869151 81 89 O
: NCT03869151 90 91 O

- NCT03869151 95 96 O
Patients NCT03869151 98 106 O
with NCT03869151 107 111 O
child NCT03869151 112 117 B-Modifier
C NCT03869151 118 119 I-Modifier
Hepatocellular NCT03869151 120 134 I-Modifier
carcinoma NCT03869151 135 144 B-Condition
. NCT03869151 144 145 O

- NCT03869151 149 150 O
Patients NCT03869151 152 160 O
with NCT03869151 161 165 O
heart NCT03869151 166 171 B-Condition
failure NCT03869151 172 179 I-Condition

Inclusion NCT03869970 0 9 O
Criteria NCT03869970 10 18 O
: NCT03869970 19 20 O

- NCT03869970 24 25 O
Diagnosis NCT03869970 27 36 O
of NCT03869970 37 39 O
mTBI NCT03869970 40 44 B-Condition
in NCT03869970 45 47 O
the NCT03869970 48 51 O
past NCT03869970 52 56 B-Eq-Comparison
48 NCT03869970 57 59 I-Eq-Comparison
hours NCT03869970 60 65 I-Eq-Comparison

Exclusion NCT03869970 66 75 O
Criteria NCT03869970 76 84 O
: NCT03869970 85 86 O

- NCT03869970 90 91 O
Patients NCT03869970 93 101 O
having NCT03869970 102 108 O
conditions NCT03869970 109 119 B-Condition
otherwise NCT03869970 120 129 O
which NCT03869970 130 135 O
limit NCT03869970 136 141 O
physical NCT03869970 142 150 B-Observation
activity NCT03869970 151 159 I-Observation
or NCT03869970 160 162 B-Or
neurocognitive NCT03869970 163 177 B-Modifier
assessment NCT03869970 178 188 B-Procedure

- NCT03869970 191 192 O
Do NCT03869970 194 196 O
not NCT03869970 197 200 O
have NCT03869970 201 205 O
a NCT03869970 206 207 O
smart NCT03869970 208 213 O
phone NCT03869970 214 219 O

- NCT03869970 222 223 O
History NCT03869970 225 232 B-Eq-Comparison
of NCT03869970 233 235 I-Eq-Comparison
past NCT03869970 236 240 I-Eq-Comparison
moderate NCT03869970 241 249 O
/ NCT03869970 250 251 B-Or
severe NCT03869970 252 258 O
TBI NCT03869970 259 262 B-Condition
, NCT03869970 263 264 O

- NCT03869970 268 269 O
Substance NCT03869970 271 280 B-Condition
abuse NCT03869970 281 286 I-Condition
, NCT03869970 287 288 O

- NCT03869970 292 293 O
Major NCT03869970 295 300 O
psychiatric NCT03869970 301 312 B-Condition
condition NCT03869970 313 322 I-Condition
, NCT03869970 323 324 O

- NCT03869970 328 329 O
Vestibular NCT03869970 331 341 B-Condition
disorder NCT03869970 342 350 I-Condition
, NCT03869970 351 352 O

- NCT03869970 356 357 O
Cardiac NCT03869970 359 366 B-Condition
condition NCT03869970 367 376 I-Condition
, NCT03869970 377 378 O

- NCT03869970 382 383 O
Unable NCT03869970 385 391 O
to NCT03869970 392 394 O
provide NCT03869970 395 402 O
consent NCT03869970 403 410 O
/ NCT03869970 411 412 O
assent NCT03869970 413 419 O

Inclusion NCT03865186 0 9 O
Criteria NCT03865186 10 18 O
: NCT03865186 19 20 O

- NCT03865186 24 25 O
Clinical NCT03865186 27 35 O
diagnosis NCT03865186 36 45 O
of NCT03865186 46 48 O
schizophrenia NCT03865186 49 62 B-Condition
according NCT03865186 63 72 O
to NCT03865186 73 75 O
DSM NCT03865186 76 79 O
- NCT03865186 80 81 O
IV NCT03865186 82 84 O

- NCT03865186 87 88 O
over NCT03865186 90 94 B-Eq-Comparison
the NCT03865186 95 98 I-Eq-Comparison
age NCT03865186 99 102 I-Eq-Comparison
of NCT03865186 103 105 I-Eq-Comparison
18 NCT03865186 106 108 I-Eq-Comparison

Exclusion NCT03865186 110 119 O
Criteria NCT03865186 120 128 O
: NCT03865186 129 130 O

- NCT03865186 134 135 O
having NCT03865186 137 143 B-Eq-Comparison
cominication NCT03865186 144 156 B-Condition
problems NCT03865186 157 165 I-Condition

- NCT03865186 168 169 O
having NCT03865186 171 177 B-Eq-Comparison
another NCT03865186 178 185 B-Other
psychiatric NCT03865186 186 197 B-Condition
disease NCT03865186 198 205 I-Condition

Inclusion NCT03865810 0 9 O
Criteria NCT03865810 10 18 O
: NCT03865810 19 20 O

- NCT03865810 24 25 O
All NCT03865810 27 30 O
patients NCT03865810 31 39 O
over NCT03865810 40 44 B-Eq-Comparison
18 NCT03865810 45 47 I-Eq-Comparison
years NCT03865810 48 53 I-Eq-Comparison
of NCT03865810 54 56 O
age NCT03865810 57 60 B-Age
undergoing NCT03865810 61 71 B-Eq-Comparison
gastric NCT03865810 72 79 B-Procedure
resection NCT03865810 80 89 I-Procedure
surgery NCT03865810 90 97 I-Procedure
due NCT03865810 98 101 O
to NCT03865810 102 104 O
cancer NCT03865810 105 111 B-Condition
within NCT03865810 112 118 B-And
or NCT03865810 119 121 B-Or
not NCT03865810 122 125 B-Negation
of NCT03865810 126 128 O
an NCT03865810 129 131 O
intensified NCT03865810 132 143 B-Modifier
recovery NCT03865810 144 152 B-Procedure
program NCT03865810 153 160 I-Procedure
( NCT03865810 161 162 O
ERAS NCT03865810 163 167 B-Procedure
) NCT03865810 168 169 O
with NCT03865810 170 174 O
any NCT03865810 175 178 O
level NCT03865810 179 184 O
of NCT03865810 185 187 O
compliance NCT03865810 188 198 O
with NCT03865810 199 203 O
the NCT03865810 204 207 O
protocol NCT03865810 208 216 O
( NCT03865810 217 218 O
from NCT03865810 219 223 O
0 NCT03865810 224 225 B-Eq-Comparison
- NCT03865810 226 227 I-Eq-Comparison
100 NCT03865810 228 231 I-Eq-Comparison
% NCT03865810 232 233 O
) NCT03865810 234 235 O
. NCT03865810 236 237 O

Exclusion NCT03865810 239 248 O
Criteria NCT03865810 249 257 O
: NCT03865810 258 259 O

- NCT03865810 263 264 O
Patients NCT03865810 266 274 O
undergoing NCT03865810 275 285 B-Eq-Comparison
emergency NCT03865810 286 295 B-Modifier
surgery NCT03865810 296 303 B-Procedure

- NCT03865810 311 312 O
Endoscopic NCT03865810 314 324 B-Procedure
procedures NCT03865810 325 335 I-Procedure

- NCT03865810 343 344 O
Non NCT03865810 346 349 B-Negation
- NCT03865810 350 351 O
oncological NCT03865810 352 363 B-Procedure
gastric NCT03865810 364 371 I-Procedure
surgery NCT03865810 372 379 I-Procedure

- NCT03865810 387 388 O
Patients NCT03865810 390 398 O
who NCT03865810 399 402 O
refuse NCT03865810 403 409 O
to NCT03865810 410 412 O
participate NCT03865810 413 424 O

Inclusion NCT03868449 0 9 O
Criteria NCT03868449 10 18 O
: NCT03868449 19 20 O

- NCT03868449 24 25 O
patients NCT03868449 27 35 O
with NCT03868449 36 40 O
common NCT03868449 41 47 B-Modifier
hand NCT03868449 48 52 I-Modifier
conditions NCT03868449 53 63 B-Condition

Exclusion NCT03868449 64 73 O
Criteria NCT03868449 74 82 O
: NCT03868449 83 84 O

- NCT03868449 87 88 O

Inclusion NCT03868878 0 9 O
Criteria NCT03868878 10 18 O
: NCT03868878 19 20 O

- NCT03868878 24 25 O
age NCT03868878 27 30 B-Age
greater NCT03868878 31 38 B-Eq-Comparison
than NCT03868878 39 43 I-Eq-Comparison
60 NCT03868878 44 46 I-Eq-Comparison
years NCT03868878 47 52 I-Eq-Comparison
; NCT03868878 52 53 O

- NCT03868878 56 57 O
is NCT03868878 59 61 O
not NCT03868878 62 65 B-Negation
engaged NCT03868878 66 73 O
in NCT03868878 74 76 O
physical NCT03868878 77 85 B-Observation
exercise NCT03868878 86 94 I-Observation
programs NCT03868878 95 103 O
for NCT03868878 104 107 O
at NCT03868878 108 110 B-Eq-Comparison
least NCT03868878 111 116 I-Eq-Comparison
one NCT03868878 117 120 I-Eq-Comparison
year NCT03868878 121 125 I-Eq-Comparison
; NCT03868878 125 126 O

- NCT03868878 129 130 O
do NCT03868878 132 134 O
not NCT03868878 135 138 B-Negation
present NCT03868878 139 146 O
severe NCT03868878 147 153 O
cardiovascular NCT03868878 154 168 B-Condition
disease NCT03868878 169 176 I-Condition
, NCT03868878 177 178 O
kidney NCT03868878 179 185 B-Condition
disease NCT03868878 186 193 I-Condition
, NCT03868878 194 195 O
liver NCT03868878 196 201 B-Condition
disease NCT03868878 202 209 I-Condition
or NCT03868878 210 212 B-Or
limiting NCT03868878 213 221 B-Modifier
cognitive NCT03868878 222 231 I-Modifier
or NCT03868878 232 234 B-Or
neuromuscular NCT03868878 235 248 B-Modifier
disease NCT03868878 249 256 B-Condition
and NCT03868878 257 260 B-And
; NCT03868878 260 261 O

- NCT03868878 264 265 O
does NCT03868878 267 271 O
not NCT03868878 272 275 B-Negation
present NCT03868878 276 283 O
visual NCT03868878 284 290 B-Modifier
or NCT03868878 291 293 B-Or
auditory NCT03868878 294 302 B-Modifier
inability NCT03868878 303 312 B-Condition
. NCT03868878 312 313 O

Exclusion NCT03868878 315 324 O
Criteria NCT03868878 325 333 O
: NCT03868878 334 335 O

- NCT03868878 339 340 O
failing NCT03868878 342 349 B-Negation
to NCT03868878 350 352 O
perform NCT03868878 353 360 O
any NCT03868878 361 364 O
of NCT03868878 365 367 O
the NCT03868878 368 371 O
evaluations NCT03868878 372 383 B-Study
suggested NCT03868878 384 393 O
during NCT03868878 394 400 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868878 401 404 O
intervention NCT03868878 405 417 B-Study
protocol NCT03868878 418 426 O
and NCT03868878 427 430 B-And
; NCT03868878 430 431 O

- NCT03868878 434 435 O
absence NCT03868878 437 444 B-Negation
in NCT03868878 445 447 O
five NCT03868878 448 452 B-Eq-Comparison
or NCT03868878 453 455 I-Eq-Comparison
more NCT03868878 456 460 I-Eq-Comparison
Capoeira NCT03868878 461 469 B-Procedure
training NCT03868878 470 478 I-Procedure
sessions NCT03868878 479 487 I-Procedure
. NCT03868878 487 488 O

Inclusion NCT03868111 0 9 O
Criteria NCT03868111 10 18 O
: NCT03868111 19 20 O

- NCT03868111 24 25 O
Patients NCT03868111 27 35 O
aged NCT03868111 36 40 B-Age
between NCT03868111 41 48 B-Eq-Comparison
19 NCT03868111 49 51 I-Eq-Comparison
and NCT03868111 52 55 I-Eq-Comparison
65 NCT03868111 56 58 I-Eq-Comparison
years NCT03868111 59 64 I-Eq-Comparison

- NCT03868111 67 68 O
Patients NCT03868111 70 78 O
with NCT03868111 79 83 O
American NCT03868111 84 92 B-Condition
Society NCT03868111 93 100 I-Condition
of NCT03868111 101 103 I-Condition
Anesthesiologists NCT03868111 104 121 I-Condition
physical NCT03868111 122 130 O
status NCT03868111 131 137 O
I NCT03868111 138 139 B-Eq-Comparison
or NCT03868111 140 142 I-Eq-Comparison
II NCT03868111 143 145 I-Eq-Comparison

- NCT03868111 148 149 O
Patients NCT03868111 151 159 O
scheduled NCT03868111 160 169 B-Eq-Comparison
for NCT03868111 170 173 O
elective NCT03868111 174 182 B-Modifier
laparoscopic NCT03868111 183 195 B-Procedure
cholecystectomy NCT03868111 196 211 I-Procedure
under NCT03868111 212 217 O
balanced NCT03868111 218 226 O
general NCT03868111 227 234 B-Procedure
anesthesia NCT03868111 235 245 I-Procedure
for NCT03868111 246 249 O
benign NCT03868111 250 256 B-Condition
cholecystic NCT03868111 257 268 I-Condition
diseases NCT03868111 269 277 I-Condition

- NCT03868111 280 281 O
Patients NCT03868111 283 291 O
obtaining NCT03868111 292 301 O
written NCT03868111 302 309 O
informed NCT03868111 310 318 O
consent NCT03868111 319 326 O

Exclusion NCT03868111 327 336 O
Criteria NCT03868111 337 345 O
: NCT03868111 346 347 O

- NCT03868111 351 352 O
Patients NCT03868111 354 362 O
with NCT03868111 363 367 O
asthma NCT03868111 368 374 B-Condition
or NCT03868111 375 377 B-Or
hypertension NCT03868111 378 390 B-Condition

- NCT03868111 393 394 O
Patients NCT03868111 396 404 O
with NCT03868111 405 409 O
an NCT03868111 410 412 O
inability NCT03868111 413 422 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868111 423 425 O
express NCT03868111 426 433 O
their NCT03868111 434 439 O
pain NCT03868111 440 444 B-Condition
accurately NCT03868111 445 455 O

- NCT03868111 458 459 O
Patients NCT03868111 461 469 O
with NCT03868111 470 474 O
an NCT03868111 475 477 O
inability NCT03868111 478 487 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 488 490 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03868111 491 501 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03868111 502 505 O
pain NCT03868111 506 510 B-Observation
scale NCT03868111 511 516 I-Observation

- NCT03868111 519 520 O
Patients NCT03868111 522 530 O
with NCT03868111 531 535 O
chronic NCT03868111 536 543 B-Modifier
abdominal NCT03868111 544 553 I-Modifier
pain NCT03868111 554 558 B-Condition
or NCT03868111 559 561 B-Or
chronic NCT03868111 562 569 B-Modifier
pain NCT03868111 570 574 B-Condition
syndrome NCT03868111 575 583 I-Condition

- NCT03868111 586 587 O
Patients NCT03868111 589 597 O
who NCT03868111 598 601 O
required NCT03868111 602 610 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 611 613 I-Assertion___Assertion-Type-Value:hypothetical
convert NCT03868111 614 621 O
to NCT03868111 622 624 O
laparotomy NCT03868111 625 635 B-Procedure
from NCT03868111 636 640 O
laparoscopic NCT03868111 641 653 B-Procedure
surgery NCT03868111 654 661 I-Procedure

- NCT03868111 664 665 O
Patients NCT03868111 667 675 O
who NCT03868111 676 679 O
required NCT03868111 680 688 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 689 691 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03868111 692 699 O
incidental NCT03868111 700 710 B-Modifier
lower NCT03868111 711 716 I-Modifier
abdominal NCT03868111 717 726 B-Procedure
procedures NCT03868111 727 737 I-Procedure
owing NCT03868111 738 743 O
to NCT03868111 744 746 O
adhesion NCT03868111 747 755 B-Condition
, NCT03868111 756 757 O
injury NCT03868111 758 764 B-Condition
, NCT03868111 765 766 O
or NCT03868111 767 769 B-Or
other NCT03868111 770 775 B-Other
incidental NCT03868111 776 786 B-Condition
findings NCT03868111 787 795 I-Condition
at NCT03868111 796 798 O
the NCT03868111 799 802 O
lower NCT03868111 803 808 B-Modifier
abdominal NCT03868111 809 818 I-Modifier
cavity NCT03868111 819 825 I-Modifier

- NCT03868111 828 829 O
Patients NCT03868111 831 839 O
with NCT03868111 840 844 O
a NCT03868111 845 846 O
history NCT03868111 847 854 B-Eq-Comparison
of NCT03868111 855 857 O
drug NCT03868111 858 862 B-Modifier
or NCT03868111 863 865 B-Or
alcohol NCT03868111 866 873 B-Modifier
abuse NCT03868111 874 879 B-Condition

- NCT03868111 882 883 O
Pregnant NCT03868111 885 893 B-Condition
women NCT03868111 894 899 O

Patient NCT03869541 0 7 O
participants NCT03869541 8 20 O
: NCT03869541 21 22 O

Inclusion NCT03869541 24 33 O
Criteria NCT03869541 34 42 O
: NCT03869541 43 44 O

- NCT03869541 48 49 O
Patients NCT03869541 51 59 O
admitted NCT03869541 60 68 B-Encounter
to NCT03869541 69 71 O
the NCT03869541 72 75 O
ICU NCT03869541 76 79 O
who NCT03869541 80 83 B-And
are NCT03869541 84 87 O
receiving NCT03869541 88 97 B-Eq-Comparison
vasoactive NCT03869541 98 108 B-Drug
drugs NCT03869541 109 114 I-Drug
. NCT03869541 114 115 O

- NCT03869541 119 120 O
Age NCT03869541 122 125 B-Age
greater NCT03869541 126 133 B-Eq-Comparison
than NCT03869541 134 138 I-Eq-Comparison
or NCT03869541 139 141 I-Eq-Comparison
equal NCT03869541 142 147 I-Eq-Comparison
to NCT03869541 148 150 I-Eq-Comparison
18 NCT03869541 151 153 I-Eq-Comparison
years NCT03869541 154 159 I-Eq-Comparison
old NCT03869541 160 163 O
. NCT03869541 163 164 O

- NCT03869541 168 169 O
Expected NCT03869541 171 179 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869541 180 182 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03869541 183 189 O
admitted NCT03869541 190 198 B-Encounter
to NCT03869541 199 201 O
the NCT03869541 202 205 O
ICU NCT03869541 206 209 O
for NCT03869541 210 213 O
at NCT03869541 214 216 B-Eq-Comparison
least NCT03869541 217 222 I-Eq-Comparison
24 NCT03869541 223 225 I-Eq-Comparison
hours NCT03869541 226 231 I-Eq-Comparison
post NCT03869541 232 236 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03869541 237 238 O
enrolment NCT03869541 239 248 B-Study
. NCT03869541 248 249 O

Exclusion NCT03869541 251 260 O
Criteria NCT03869541 261 269 O
: NCT03869541 270 271 O

- NCT03869541 275 276 O
Any NCT03869541 278 281 O
patient NCT03869541 282 289 O
who NCT03869541 290 293 O
is NCT03869541 294 296 O
expected NCT03869541 297 305 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869541 306 308 I-Assertion___Assertion-Type-Value:hypothetical
die NCT03869541 309 312 B-Death
imminently NCT03869541 313 323 B-Modifier
, NCT03869541 324 325 O
as NCT03869541 326 328 O
per NCT03869541 329 332 O
clinical NCT03869541 333 341 O
opinion NCT03869541 342 349 O
. NCT03869541 349 350 O

- NCT03869541 354 355 O
Any NCT03869541 357 360 O
patient NCT03869541 361 368 O
where NCT03869541 369 374 O
mobilization NCT03869541 375 387 B-Procedure
is NCT03869541 388 390 O
contraindicated NCT03869541 391 406 B-Contraindication
by NCT03869541 407 409 O
the NCT03869541 410 413 O
nature NCT03869541 414 420 O
of NCT03869541 421 423 O
their NCT03869541 424 429 O
existing NCT03869541 430 438 B-Eq-Comparison
injuries NCT03869541 439 447 B-Condition
. NCT03869541 447 448 O

- NCT03869541 452 453 O
Where NCT03869541 455 460 O
it NCT03869541 461 463 O
is NCT03869541 464 466 O
clear NCT03869541 467 472 O
from NCT03869541 473 477 O
the NCT03869541 478 481 O
medical NCT03869541 482 489 O
records NCT03869541 490 497 O
that NCT03869541 498 502 O
participants NCT03869541 503 515 O
are NCT03869541 516 519 O
prisoners NCT03869541 520 529 B-Observation
or NCT03869541 530 532 B-Or
offenders NCT03869541 533 542 O
on NCT03869541 543 545 B-Observation
probation NCT03869541 546 555 I-Observation
. NCT03869541 555 556 O

- NCT03869541 560 561 O
Patients NCT03869541 563 571 O
with NCT03869541 572 576 O
neuromuscular NCT03869541 577 590 B-Condition
disease NCT03869541 591 598 I-Condition
or NCT03869541 599 601 B-Or
acute NCT03869541 602 607 O
brain NCT03869541 608 613 B-Modifier
injury NCT03869541 614 620 B-Condition
or NCT03869541 621 623 B-Or
spinal NCT03869541 624 630 B-Modifier
cord NCT03869541 631 635 I-Modifier
injury NCT03869541 636 642 B-Condition
. NCT03869541 642 643 O

- NCT03869541 647 648 O
If NCT03869541 650 652 O
the NCT03869541 653 656 O
patient NCT03869541 657 664 O
and NCT03869541 665 668 O
/ NCT03869541 669 670 O
or NCT03869541 671 673 O
their NCT03869541 674 679 O
consultee NCT03869541 680 689 O
is NCT03869541 690 692 O
unable NCT03869541 693 699 B-Negation
to NCT03869541 700 702 O
speak NCT03869541 703 708 O
English NCT03869541 709 716 O
. NCT03869541 716 717 O

Clinicians NCT03869541 719 729 O
participating NCT03869541 730 743 O
in NCT03869541 744 746 O
a NCT03869541 747 748 O
survey NCT03869541 749 755 O
on NCT03869541 756 758 O
hypothetical NCT03869541 759 771 O
randomization NCT03869541 772 785 O
of NCT03869541 786 788 O
patient NCT03869541 789 796 O
participants NCT03869541 797 809 O
: NCT03869541 810 811 O

Inclusion NCT03869541 813 822 O
criteria NCT03869541 823 831 O
: NCT03869541 832 833 O

- NCT03869541 837 838 O
Clinicians NCT03869541 840 850 O
who NCT03869541 851 854 O
work NCT03869541 855 859 O
in NCT03869541 860 862 O
the NCT03869541 863 866 O
intensive NCT03869541 867 876 O
care NCT03869541 877 881 O
unit NCT03869541 882 886 O
where NCT03869541 887 892 O
a NCT03869541 893 894 O
patient NCT03869541 895 902 O
participant NCT03869541 903 914 O
has NCT03869541 915 918 B-Eq-Comparison
been NCT03869541 919 923 I-Eq-Comparison
admitted NCT03869541 924 932 B-Encounter
. NCT03869541 932 933 O

Exclusion NCT03869541 935 944 O
criteria NCT03869541 945 953 O
: NCT03869541 954 955 O

- NCT03869541 959 960 O
None NCT03869541 962 966 O
. NCT03869541 966 967 O

Clinician NCT03869541 969 978 O
participants NCT03869541 979 991 O
in NCT03869541 992 994 O
the NCT03869541 995 998 O
survey NCT03869541 999 1005 O
on NCT03869541 1006 1008 O
the NCT03869541 1009 1012 O
feasibility NCT03869541 1013 1024 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03869541 1025 1027 O
the NCT03869541 1028 1031 O
ICU NCT03869541 1032 1035 O
physical NCT03869541 1036 1044 B-Procedure
rehabilitation NCT03869541 1045 1059 I-Procedure
adverse NCT03869541 1060 1067 O
event NCT03869541 1068 1073 O
tool NCT03869541 1074 1078 O
: NCT03869541 1079 1080 O

Inclusion NCT03869541 1082 1091 O
criteria NCT03869541 1092 1100 O
: NCT03869541 1101 1102 O

- NCT03869541 1106 1107 O
An NCT03869541 1109 1111 O
ICU NCT03869541 1112 1115 O
clinician NCT03869541 1116 1125 O
at NCT03869541 1126 1128 O
the NCT03869541 1129 1132 O
research NCT03869541 1133 1141 O
site NCT03869541 1142 1146 O
. NCT03869541 1146 1147 O

- NCT03869541 1151 1152 O
Has NCT03869541 1154 1157 O
used NCT03869541 1158 1162 O
the NCT03869541 1163 1166 O
ICU NCT03869541 1167 1170 O
physical NCT03869541 1171 1179 B-Observation
rehabilitation NCT03869541 1180 1194 I-Observation
adverse NCT03869541 1195 1202 I-Observation
event NCT03869541 1203 1208 I-Observation
tool NCT03869541 1209 1213 I-Observation
as NCT03869541 1214 1216 O
part NCT03869541 1217 1221 O
of NCT03869541 1222 1224 O
this NCT03869541 1225 1229 O
research NCT03869541 1230 1238 O
study NCT03869541 1239 1244 B-Study
. NCT03869541 1244 1245 O

Exclusion NCT03869541 1247 1256 O
criteria NCT03869541 1257 1265 O
: NCT03869541 1266 1267 O

- NCT03869541 1271 1272 O
None NCT03869541 1274 1278 O
. NCT03869541 1278 1279 O


Inclusion NCT03868176 0 9 O
Criteria NCT03868176 10 18 O
: NCT03868176 19 20 O

- NCT03868176 24 25 O
Patient NCT03868176 27 34 O
with NCT03868176 35 39 O
germ NCT03868176 40 44 B-Modifier
cell NCT03868176 45 49 I-Modifier
tumor NCT03868176 50 55 B-Condition
. NCT03868176 55 56 O

- NCT03868176 60 61 O
Patient NCT03868176 63 70 O
with NCT03868176 71 75 O
a NCT03868176 76 77 O
mobile NCT03868176 78 84 O
phone NCT03868176 85 90 O
. NCT03868176 90 91 O

- NCT03868176 95 96 O
Patient NCT03868176 98 105 O
on NCT03868176 106 108 B-Eq-Comparison
surveillance NCT03868176 109 121 B-Procedure
. NCT03868176 121 122 O

Exclusion NCT03868176 124 133 O
Criteria NCT03868176 134 142 O
: NCT03868176 143 144 O

- NCT03868176 148 149 O
Testicular NCT03868176 151 161 B-Modifier
cancer NCT03868176 162 168 B-Condition
without NCT03868176 169 176 B-Negation
germ NCT03868176 177 181 B-Modifier
cell NCT03868176 182 186 I-Modifier
component NCT03868176 187 196 I-Modifier
. NCT03868176 196 197 O

- NCT03868176 201 202 O
Prior NCT03868176 204 209 B-Eq-Comparison
history NCT03868176 210 217 I-Eq-Comparison
of NCT03868176 218 220 O
other NCT03868176 221 226 B-Other
malignancy NCT03868176 227 237 B-Condition
except NCT03868176 238 244 B-Exception
for NCT03868176 245 248 O
: NCT03868176 249 250 O
cutaneous NCT03868176 251 260 B-Condition
cancers NCT03868176 261 268 I-Condition
excluding NCT03868176 269 278 B-Exception
melanoma NCT03868176 279 287 B-Condition
, NCT03868176 288 289 O
superficial NCT03868176 290 301 B-Modifier
bladder NCT03868176 302 309 I-Modifier
tumor NCT03868176 310 315 B-Condition
, NCT03868176 316 317 O
localized NCT03868176 318 327 B-Modifier
prostate NCT03868176 328 336 I-Modifier
cancer NCT03868176 337 343 B-Condition
with NCT03868176 344 348 B-And
undetectable NCT03868176 349 361 O
PSA NCT03868176 362 365 B-Observation
. NCT03868176 365 366 O

- NCT03868176 370 371 O
Cognitive NCT03868176 373 382 B-Condition
condition NCT03868176 383 392 I-Condition
that NCT03868176 393 397 O
would NCT03868176 398 403 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03868176 404 412 B-Negation
patient NCT03868176 413 420 O
's NCT03868176 420 422 O
understanding NCT03868176 423 436 O
and NCT03868176 437 440 O
completion NCT03868176 441 451 O
of NCT03868176 452 454 O
study NCT03868176 455 460 B-Study
procedures NCT03868176 461 471 B-Procedure
. NCT03868176 471 472 O

Inclusion NCT03864016 0 9 O
Criteria NCT03864016 10 18 O
: NCT03864016 19 20 O

- NCT03864016 24 25 O
Person NCT03864016 27 33 O
who NCT03864016 34 37 O
has NCT03864016 38 41 O
given NCT03864016 42 47 O
written NCT03864016 48 55 O
consent NCT03864016 56 63 O

- NCT03864016 66 67 O
Adult NCT03864016 69 74 O
patient NCT03864016 75 82 O

- NCT03864016 85 86 O
Patient NCT03864016 88 95 O
undergoing NCT03864016 96 106 B-Eq-Comparison
coronary NCT03864016 107 115 B-Procedure
artery NCT03864016 116 122 I-Procedure
bypass NCT03864016 123 129 I-Procedure
surgery NCT03864016 130 137 I-Procedure
with NCT03864016 138 142 O
CEC NCT03864016 143 146 B-Procedure
, NCT03864016 147 148 O
with NCT03864016 149 153 B-And
or NCT03864016 154 156 B-Or
without NCT03864016 157 164 B-Negation
valve NCT03864016 165 170 B-Procedure
surgery NCT03864016 171 178 I-Procedure
, NCT03864016 179 180 O
by NCT03864016 181 183 O
sternotomy NCT03864016 184 194 B-Procedure
. NCT03864016 194 195 O

- NCT03864016 199 200 O
ASA NCT03864016 202 205 B-Condition
< NCT03864016 206 207 B-Eq-Comparison
4 NCT03864016 208 209 I-Eq-Comparison
. NCT03864016 209 210 O

Exclusion NCT03864016 212 221 O
Criteria NCT03864016 222 230 O
: NCT03864016 231 232 O

- NCT03864016 236 237 O
Person NCT03864016 239 245 O
not NCT03864016 246 249 B-Negation
affiliated NCT03864016 250 260 O
to NCT03864016 261 263 O
the NCT03864016 264 267 O
national NCT03864016 268 276 O
health NCT03864016 277 283 O
insurance NCT03864016 284 293 O
system NCT03864016 294 300 O

- NCT03864016 303 304 O
Person NCT03864016 306 312 O
subject NCT03864016 313 320 O
to NCT03864016 321 323 O
legal NCT03864016 324 329 B-Observation
protection NCT03864016 330 340 I-Observation
( NCT03864016 341 342 O
curatorship NCT03864016 343 354 B-Observation
, NCT03864016 355 356 O
guardianship NCT03864016 357 369 B-Observation
) NCT03864016 370 371 O

- NCT03864016 375 376 O
Person NCT03864016 378 384 O
who NCT03864016 385 388 O
has NCT03864016 389 392 O
been NCT03864016 393 397 O
deemed NCT03864016 398 404 O
mentally NCT03864016 405 413 B-Condition
incompetent NCT03864016 414 425 I-Condition

- NCT03864016 428 429 O
Pregnant NCT03864016 431 439 B-Condition
, NCT03864016 440 441 O
parturient NCT03864016 442 452 B-Condition
or NCT03864016 453 455 B-Or
breastfeeding NCT03864016 456 469 B-Condition
woman NCT03864016 470 475 O

- NCT03864016 478 479 O
Adult NCT03864016 481 486 O
unable NCT03864016 487 493 O
or NCT03864016 494 496 O
unwilling NCT03864016 497 506 O
to NCT03864016 507 509 O
provide NCT03864016 510 517 O
consent NCT03864016 518 525 O

- NCT03864016 528 529 O
Patient NCT03864016 531 538 O
with NCT03864016 539 543 O
pre NCT03864016 544 547 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864016 548 549 O
- NCT03864016 551 552 O
operative NCT03864016 553 562 B-Procedure
cognitive NCT03864016 563 572 B-Condition
dysfunction NCT03864016 573 584 I-Condition
( NCT03864016 585 586 O
MMS NCT03864016 587 590 B-Observation
< NCT03864016 591 592 B-Eq-Comparison
13 NCT03864016 593 595 I-Eq-Comparison
) NCT03864016 596 597 O
( NCT03864016 598 599 O
APPENDIX NCT03864016 600 608 O
6 NCT03864016 609 610 O
) NCT03864016 611 612 O
, NCT03864016 614 615 O

- NCT03864016 619 620 O
Patient NCT03864016 622 629 O
with NCT03864016 630 634 O
morphine NCT03864016 635 643 B-Drug
intolerance NCT03864016 644 655 B-Condition
, NCT03864016 656 657 O

- NCT03864016 661 662 I-Modifier
Patient NCT03864016 664 671 O
on NCT03864016 672 674 B-Eq-Comparison
long NCT03864016 675 679 B-Modifier
- NCT03864016 680 681 O
term NCT03864016 682 686 I-Modifier
opioid NCT03864016 687 693 B-Drug
treatment NCT03864016 694 703 B-Procedure
, NCT03864016 704 705 O

- NCT03864016 709 710 O
Emergency NCT03864016 712 721 B-Modifier
surgery NCT03864016 722 729 B-Procedure
, NCT03864016 730 731 O

- NCT03864016 735 736 O
Eye NCT03864016 738 741 B-Condition
disease NCT03864016 742 749 I-Condition
, NCT03864016 750 751 O
corneal NCT03864016 752 759 B-Modifier
injury NCT03864016 760 766 B-Condition
, NCT03864016 767 768 O
or NCT03864016 769 771 B-Or
wearing NCT03864016 772 779 B-Modifier
contact NCT03864016 780 787 B-Procedure
lenses NCT03864016 788 794 I-Procedure
, NCT03864016 795 796 O
a NCT03864016 797 798 O
neurological NCT03864016 799 811 B-Condition
disease NCT03864016 812 819 I-Condition
that NCT03864016 820 824 O
can NCT03864016 825 828 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03864016 829 838 O
the NCT03864016 839 842 O
pupillary NCT03864016 843 852 B-Condition
reflex NCT03864016 853 859 I-Condition
, NCT03864016 860 861 O

- NCT03864016 865 866 O
Refusal NCT03864016 868 875 O
to NCT03864016 876 878 O
participate NCT03864016 879 890 O

Inclusion NCT03867279 0 9 O
Criteria NCT03867279 10 18 O
: NCT03867279 19 20 O

- NCT03867279 24 25 O
From NCT03867279 27 31 O
18 NCT03867279 32 34 B-Eq-Comparison
to NCT03867279 35 37 I-Eq-Comparison
24 NCT03867279 38 40 I-Eq-Comparison
years NCT03867279 41 46 I-Eq-Comparison
old NCT03867279 47 50 B-Age

- NCT03867279 53 54 O
Male NCT03867279 56 60 O

- NCT03867279 63 64 O
That NCT03867279 66 70 O
they NCT03867279 71 75 O
be NCT03867279 76 78 O
weight NCT03867279 79 85 B-Observation
lifters NCT03867279 86 93 I-Observation
with NCT03867279 94 98 O
at NCT03867279 99 101 B-Eq-Comparison
least NCT03867279 102 107 I-Eq-Comparison
one NCT03867279 108 111 I-Eq-Comparison
year NCT03867279 112 116 I-Eq-Comparison
of NCT03867279 117 119 O
experience NCT03867279 120 130 O

- NCT03867279 133 134 O
That NCT03867279 136 140 O
they NCT03867279 141 145 O
do NCT03867279 146 148 O
not NCT03867279 149 152 B-Negation
present NCT03867279 153 160 O
musculoskeletal NCT03867279 161 176 B-Modifier
injury NCT03867279 177 183 B-Condition
or NCT03867279 184 186 B-Or
pathology NCT03867279 187 196 B-Condition
in NCT03867279 197 199 O
the NCT03867279 200 203 O
three NCT03867279 204 209 B-Eq-Comparison
months NCT03867279 210 216 I-Eq-Comparison
prior NCT03867279 217 222 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867279 223 225 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867279 226 229 O
beginning NCT03867279 230 239 O
of NCT03867279 240 242 O
the NCT03867279 243 246 O
study NCT03867279 247 252 B-Study

Exclusion NCT03867279 253 262 O
Criteria NCT03867279 263 271 O
: NCT03867279 272 273 O

- NCT03867279 277 278 O
Can NCT03867279 280 283 O
not NCT03867279 284 287 B-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03867279 288 290 B-Encounter
present NCT03867279 291 298 I-Encounter
during NCT03867279 299 305 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867279 306 309 O
6 NCT03867279 310 311 B-Eq-Comparison
weeks NCT03867279 312 317 I-Eq-Comparison
of NCT03867279 318 320 O
the NCT03867279 321 324 O
intervention NCT03867279 325 337 B-Study
and NCT03867279 338 341 B-And
the NCT03867279 342 345 O
evaluations NCT03867279 346 357 B-Study
will NCT03867279 358 362 O
be NCT03867279 363 365 O
excluded NCT03867279 366 374 B-Negation

- NCT03867279 377 378 O
Under NCT03867279 380 385 B-Eq-Comparison
pharmacological NCT03867279 386 401 B-Procedure
treatment NCT03867279 402 411 I-Procedure

- NCT03867279 414 415 O
Who NCT03867279 417 420 O
are NCT03867279 421 424 O
performing NCT03867279 425 435 O
another NCT03867279 436 443 B-Other
physiotherapy NCT03867279 444 457 B-Procedure
study NCT03867279 458 463 B-Study

- NCT03867279 466 467 O
Not NCT03867279 469 472 O
sign NCT03867279 473 477 O
the NCT03867279 478 481 O
informed NCT03867279 482 490 O
consent NCT03867279 491 498 O
document NCT03867279 499 507 O
. NCT03867279 507 508 O

Inclusion NCT03864770 0 9 O
Criteria NCT03864770 10 18 O
: NCT03864770 19 20 O

1 NCT03864770 24 25 O
. NCT03864770 25 26 O
≥ NCT03864770 28 29 B-Eq-Comparison
20 NCT03864770 30 32 I-Eq-Comparison
y NCT03864770 33 34 I-Eq-Comparison
/ NCT03864770 35 36 I-Eq-Comparison
o NCT03864770 37 38 I-Age|Eq-Comparison
patients NCT03864770 39 47 O
with NCT03864770 48 52 O
NLCs NCT03864770 53 57 B-Condition
: NCT03864770 58 59 O
( NCT03864770 60 61 O
1 NCT03864770 62 63 O
) NCT03864770 64 65 O
4 NCT03864770 66 67 B-Eq-Comparison
times NCT03864770 68 73 I-Eq-Comparison
/ NCT03864770 74 75 I-Eq-Comparison
week NCT03864770 76 80 I-Eq-Comparison
, NCT03864770 81 82 O
last NCT03864770 83 87 B-Eq-Comparison
2 NCT03864770 88 89 I-Eq-Comparison
weeks NCT03864770 90 95 I-Eq-Comparison
; NCT03864770 95 96 O
( NCT03864770 97 98 O
2 NCT03864770 99 100 O
) NCT03864770 101 102 O
Occurred NCT03864770 103 111 O
in NCT03864770 112 114 O
nighttime NCT03864770 115 124 B-Modifier
or NCT03864770 125 127 B-Or
resting NCT03864770 128 135 B-Modifier
time NCT03864770 136 140 I-Modifier
of NCT03864770 141 143 I-Modifier
daytime NCT03864770 144 151 I-Modifier

2 NCT03864770 154 155 O
. NCT03864770 155 156 O
Patients NCT03864770 158 166 O
with NCT03864770 167 171 O
MTrPs NCT03864770 172 177 B-Condition
on NCT03864770 178 180 B-Eq-Comparison
gastrocnemius NCT03864770 181 194 B-Drug
( NCT03864770 195 196 O
According NCT03864770 197 206 O
to NCT03864770 207 209 O
the NCT03864770 210 213 O
diagnostic NCT03864770 214 224 O
criteria NCT03864770 225 233 O
proposed NCT03864770 234 242 O
by NCT03864770 243 245 O
Simons NCT03864770 246 252 B-Provider
& NCT03864770 253 254 I-Provider
Travell NCT03864770 255 262 I-Provider
) NCT03864770 263 264 O

Exclusion NCT03864770 266 275 O
Criteria NCT03864770 276 284 O
: NCT03864770 285 286 O

1 NCT03864770 290 291 O
. NCT03864770 291 292 O
( NCT03864770 294 295 O
1 NCT03864770 296 297 O
) NCT03864770 298 299 O
Taking NCT03864770 300 306 B-Eq-Comparison
medication NCT03864770 307 317 B-Drug
for NCT03864770 318 321 O
leg NCT03864770 322 325 B-Modifier
cramps NCT03864770 326 332 B-Condition
( NCT03864770 333 334 O
eg NCT03864770 335 337 O
. NCT03864770 337 338 O
Quinine NCT03864770 340 347 B-Drug
, NCT03864770 348 349 O
Magnesium NCT03864770 350 359 B-Drug
oxide NCT03864770 360 365 I-Drug
) NCT03864770 366 367 O
; NCT03864770 368 369 O
( NCT03864770 370 371 O
2 NCT03864770 372 373 O
) NCT03864770 374 375 O
Other NCT03864770 376 381 B-Other
drugs NCT03864770 382 387 B-Drug
that NCT03864770 388 392 O
affect NCT03864770 393 399 O
research NCT03864770 400 408 O
and NCT03864770 409 412 O
evaluation NCT03864770 413 423 B-Study
( NCT03864770 424 425 O
eg NCT03864770 426 428 O
. NCT03864770 428 429 O
diuretics NCT03864770 431 440 B-Drug
, NCT03864770 441 442 O
statins NCT03864770 443 450 B-Drug
, NCT03864770 451 452 O
calcium NCT03864770 453 460 B-Drug
channel NCT03864770 461 468 I-Drug
blockers NCT03864770 469 477 I-Drug
, NCT03864770 478 479 O
anticonvulsants NCT03864770 480 495 B-Drug
) NCT03864770 496 497 O

2 NCT03864770 501 502 O
. NCT03864770 502 503 O
Congenital NCT03864770 505 515 B-Condition
lower NCT03864770 516 521 I-Condition
limb NCT03864770 522 526 I-Condition|Modifier
musculoskeletal NCT03864770 527 542 I-Condition
diseases NCT03864770 543 551 I-Condition
, NCT03864770 552 553 O
Lower NCT03864770 554 559 B-Modifier
limb NCT03864770 560 564 O
or NCT03864770 565 567 B-Or|Or
spine NCT03864770 568 573 B-Modifier
surgery NCT03864770 574 581 B-Procedure

3 NCT03864770 584 585 O
. NCT03864770 585 586 O
Uncommunicated NCT03864770 588 602 B-Condition
or NCT03864770 603 605 O
cognitive NCT03864770 606 615 B-Condition
impaired NCT03864770 616 624 I-Condition

4 NCT03864770 627 628 O
. NCT03864770 628 629 O
Patients NCT03864770 631 639 O
refused NCT03864770 640 647 O
to NCT03864770 648 650 O
be NCT03864770 651 653 O
recruited NCT03864770 654 663 O

Inclusion NCT03868189 0 9 O
Criteria NCT03868189 10 18 O
: NCT03868189 19 20 O

- NCT03868189 24 25 O
Patient NCT03868189 27 34 O
requiring NCT03868189 35 44 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03868189 45 47 O
electroneuromyogram NCT03868189 48 67 B-Procedure
whose NCT03868189 68 73 O
indication NCT03868189 74 84 B-Indication
allows NCT03868189 85 91 O
the NCT03868189 92 95 O
application NCT03868189 96 107 O
of NCT03868189 108 110 O
a NCT03868189 111 112 O
standard NCT03868189 113 121 B-Modifier
protocol NCT03868189 122 130 I-Modifier
of NCT03868189 131 133 O
examination NCT03868189 134 145 B-Procedure
. NCT03868189 145 146 O

- NCT03868189 150 151 O
Patient NCT03868189 153 160 O
that NCT03868189 161 165 O
has NCT03868189 166 169 O
given NCT03868189 170 175 O
his NCT03868189 176 179 O
/ NCT03868189 180 181 O
her NCT03868189 182 185 O
free NCT03868189 186 190 O
and NCT03868189 191 194 O
informed NCT03868189 195 203 O
consent NCT03868189 204 211 O
. NCT03868189 211 212 O

- NCT03868189 216 217 O
Patient NCT03868189 219 226 O
that NCT03868189 227 231 O
signed NCT03868189 232 238 O
the NCT03868189 239 242 O
consent NCT03868189 243 250 O
form NCT03868189 251 255 O
. NCT03868189 255 256 O

- NCT03868189 260 261 O
Patient NCT03868189 263 270 O
with NCT03868189 271 275 O
an NCT03868189 276 278 O
health NCT03868189 279 285 O
insurance NCT03868189 286 295 O
plan NCT03868189 296 300 O
. NCT03868189 300 301 O

- NCT03868189 305 306 O
The NCT03868189 308 311 O
patient NCT03868189 312 319 O
is NCT03868189 320 322 O
at NCT03868189 323 325 B-Eq-Comparison
least NCT03868189 326 331 I-Eq-Comparison
18 NCT03868189 332 334 I-Eq-Comparison
years NCT03868189 335 340 I-Eq-Comparison
old NCT03868189 341 344 B-Age
( NCT03868189 345 346 O
≥ NCT03868189 348 349 O
) NCT03868189 351 352 O
. NCT03868189 353 354 O

- NCT03868189 358 359 O
he NCT03868189 361 363 O
patient NCT03868189 364 371 O
is NCT03868189 372 374 O
under NCT03868189 375 380 B-Eq-Comparison
80 NCT03868189 381 383 I-Eq-Comparison
years NCT03868189 384 389 I-Eq-Comparison
old NCT03868189 390 393 B-Age
( NCT03868189 394 395 O
≤ NCT03868189 397 398 O
) NCT03868189 400 401 O
. NCT03868189 402 403 O

Exclusion NCT03868189 405 414 O
Criteria NCT03868189 415 423 O
: NCT03868189 424 425 O

- NCT03868189 429 430 O
Patient NCT03868189 432 439 O
with NCT03868189 440 444 O
symptoms NCT03868189 445 453 B-Assertion___Assertion-Type-Value:possible
of NCT03868189 454 456 O
neuropathy NCT03868189 457 467 B-Condition
during NCT03868189 468 474 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868189 475 478 O
screening NCT03868189 479 488 B-Study
. NCT03868189 488 489 O

- NCT03868189 493 494 O
Patient NCT03868189 496 503 O
whose NCT03868189 504 509 O
Neurological NCT03868189 510 522 B-Observation
severity NCT03868189 523 531 I-Observation
score NCT03868189 532 537 I-Observation
( NCT03868189 538 539 O
NSS NCT03868189 540 543 B-Observation
) NCT03868189 544 545 O
score NCT03868189 546 551 O
is NCT03868189 552 554 O
≥ NCT03868189 555 556 B-Eq-Comparison
3 NCT03868189 557 558 I-Eq-Comparison
. NCT03868189 558 559 O

- NCT03868189 563 564 O
Patient NCT03868189 566 573 O
whose NCT03868189 574 579 O
neurological NCT03868189 580 592 B-Procedure
examination NCT03868189 593 604 I-Procedure
is NCT03868189 605 607 O
abnormal NCT03868189 608 616 O
and NCT03868189 617 620 B-Or
suggestive NCT03868189 621 631 B-Assertion___Assertion-Type-Value:possible
of NCT03868189 632 634 O
neuropathy NCT03868189 635 645 B-Condition
. NCT03868189 645 646 O

- NCT03868189 650 651 O
Patient NCT03868189 653 660 O
presenting NCT03868189 661 671 O
a NCT03868189 672 673 O
pathology NCT03868189 674 683 B-Condition
that NCT03868189 684 688 O
could NCT03868189 689 694 B-Assertion___Assertion-Type-Value:hypothetical
cause NCT03868189 695 700 O
neuropathy NCT03868189 701 711 B-Condition
( NCT03868189 712 713 O
e. NCT03868189 714 716 O
g. NCT03868189 717 719 O
diabetes NCT03868189 721 729 B-Condition
, NCT03868189 730 731 O
renal NCT03868189 732 737 B-Condition
failure NCT03868189 738 745 I-Condition
, NCT03868189 746 747 O
etc NCT03868189 748 751 O
. NCT03868189 751 752 O
) NCT03868189 753 754 O
. NCT03868189 755 756 O

- NCT03868189 760 761 O
Patient NCT03868189 763 770 O
already NCT03868189 771 778 O
participating NCT03868189 779 792 O
in NCT03868189 793 795 O
a NCT03868189 796 797 O
category NCT03868189 798 806 O
1 NCT03868189 807 808 O
research NCT03868189 809 817 O
study NCT03868189 818 823 O
( NCT03868189 824 825 O
Jardé NCT03868189 826 831 O
law NCT03868189 832 835 O
) NCT03868189 836 837 O
. NCT03868189 838 839 O

- NCT03868189 843 844 O
Patient NCT03868189 846 853 O
in NCT03868189 854 856 O
an NCT03868189 857 859 B-Other
exclusion NCT03868189 860 869 O
period NCT03868189 870 876 O
determined NCT03868189 877 887 O
by NCT03868189 888 890 O
another NCT03868189 891 898 O
study NCT03868189 899 904 B-Study
. NCT03868189 904 905 O

- NCT03868189 909 910 O
Patient NCT03868189 912 919 O
under NCT03868189 920 925 B-Observation
the NCT03868189 926 929 O
protection NCT03868189 930 940 B-Observation
of NCT03868189 941 943 I-Observation
justice NCT03868189 944 951 I-Observation
, NCT03868189 952 953 O
under NCT03868189 954 959 O
guardianship NCT03868189 960 972 I-Observation
or NCT03868189 973 975 B-Or
under NCT03868189 976 981 O
curatorship NCT03868189 982 993 B-Observation
. NCT03868189 993 994 O

- NCT03868189 998 999 O
Patient NCT03868189 1001 1008 O
refusing NCT03868189 1009 1017 O
to NCT03868189 1018 1020 O
sign NCT03868189 1021 1025 O
the NCT03868189 1026 1029 O
consent NCT03868189 1030 1037 O
form NCT03868189 1038 1042 O
. NCT03868189 1042 1043 O

- NCT03868189 1047 1048 O
Patient NCT03868189 1050 1057 O
for NCT03868189 1058 1061 O
which NCT03868189 1062 1067 O
it NCT03868189 1068 1070 O
is NCT03868189 1071 1073 O
impossible NCT03868189 1074 1084 O
to NCT03868189 1085 1087 O
provide NCT03868189 1088 1095 O
information NCT03868189 1096 1107 O
about NCT03868189 1108 1113 O
the NCT03868189 1114 1117 O
study NCT03868189 1118 1123 B-Study
. NCT03868189 1123 1124 O

- NCT03868189 1128 1129 O
Pregnant NCT03868189 1131 1139 B-Condition
patient NCT03868189 1140 1147 O
, NCT03868189 1148 1149 O
parturient NCT03868189 1150 1160 B-Condition
, NCT03868189 1161 1162 O
or NCT03868189 1163 1165 B-Or
breastfeeding NCT03868189 1166 1179 B-Condition
. NCT03868189 1179 1180 O

Inclusion NCT03867721 0 9 O
Criteria NCT03867721 10 18 O
: NCT03867721 19 20 O

- NCT03867721 24 25 O
All NCT03867721 27 30 O
individuals NCT03867721 31 42 O
affected NCT03867721 43 51 O
by NCT03867721 52 54 O
NMDs NCT03867721 55 59 B-Condition
attending NCT03867721 60 69 B-Encounter
our NCT03867721 70 73 O
Centre NCT03867721 74 80 O
for NCT03867721 81 84 O
Home NCT03867721 85 89 O
Mechanical NCT03867721 90 100 O
Ventilation NCT03867721 101 112 O
between NCT03867721 113 120 B-Eq-Comparison
January NCT03867721 121 128 I-Eq-Comparison
2015 NCT03867721 129 133 I-Eq-Comparison
and NCT03867721 134 137 I-Eq-Comparison
December NCT03867721 138 146 I-Eq-Comparison
2018 NCT03867721 147 151 I-Eq-Comparison
who NCT03867721 152 155 B-And
required NCT03867721 156 164 O
daytime NCT03867721 165 172 B-Modifier
MPV NCT03867721 173 176 B-Procedure
as NCT03867721 177 179 B-And
an NCT03867721 180 182 I-And
extension NCT03867721 183 192 I-And
of NCT03867721 193 195 I-And
nocturnal NCT03867721 196 205 B-Modifier
NIV NCT03867721 206 209 B-Procedure

Exclusion NCT03867721 210 219 O
Criteria NCT03867721 220 228 O
: NCT03867721 229 230 O

- NCT03867721 234 235 O
Patients NCT03867721 237 245 O
with NCT03867721 246 250 O
no NCT03867721 251 253 B-Negation
need NCT03867721 254 258 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867721 259 262 I-Assertion___Assertion-Type-Value:hypothetical
daytime NCT03867721 263 270 B-Modifier
ventilation NCT03867721 271 282 B-Procedure

- NCT03867721 285 286 O
patients NCT03867721 288 296 O
with NCT03867721 297 301 O
ineffective NCT03867721 302 313 B-Modifier
NIV NCT03867721 314 317 B-Procedure
during NCT03867721 318 324 B-Temporal-Connection___Temporal-Connection-Type-Value:during
sleep NCT03867721 325 330 B-Observation
as NCT03867721 331 333 O
assessed NCT03867721 334 342 O
by NCT03867721 343 345 O
the NCT03867721 346 349 O
measurement NCT03867721 350 361 O
of NCT03867721 362 364 O
TcCO2 NCT03867721 365 370 B-Observation
> NCT03867721 371 372 B-Eq-Comparison
49 NCT03867721 373 375 I-Eq-Comparison
mmHg NCT03867721 376 380 O
( NCT03867721 381 382 O
S NCT03867721 383 384 O
) NCT03867721 385 386 O

- NCT03867721 390 391 O
patients NCT03867721 393 401 O
with NCT03867721 402 406 O
uncontrollable NCT03867721 407 421 B-Modifier
oral NCT03867721 422 426 B-Condition
leaks NCT03867721 427 432 I-Condition
with NCT03867721 433 437 O
MPV NCT03867721 438 441 B-Procedure
or NCT03867721 442 444 B-Or
episode NCT03867721 445 452 O
of NCT03867721 453 455 O
acute NCT03867721 456 461 O
respiratory NCT03867721 462 473 B-Condition
infection NCT03867721 474 483 I-Condition
during NCT03867721 484 490 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867721 491 494 O
trials NCT03867721 495 501 B-Study

Inclusion NCT03860714 0 9 O
Criteria NCT03860714 10 18 O
: NCT03860714 19 20 O

- NCT03860714 24 25 O
Non NCT03860714 27 30 B-Negation
- NCT03860714 31 32 O
cardiac NCT03860714 33 40 B-Modifier
surgery NCT03860714 41 48 B-Procedure
patients NCT03860714 49 57 O
; NCT03860714 57 58 O

- NCT03860714 66 67 O
Age NCT03860714 69 72 B-Age
is NCT03860714 73 75 O
greater NCT03860714 76 83 B-Eq-Comparison
than NCT03860714 84 88 I-Eq-Comparison
or NCT03860714 89 91 I-Eq-Comparison
equal NCT03860714 92 97 I-Eq-Comparison
to NCT03860714 98 100 I-Eq-Comparison
60 NCT03860714 101 103 I-Eq-Comparison
years NCT03860714 104 109 I-Eq-Comparison
old NCT03860714 110 113 O
; NCT03860714 113 114 O
③ NCT03860714 115 116 O
Han NCT03860714 117 120 O
Nationality NCT03860714 121 132 O
, NCT03860714 133 134 O
mother NCT03860714 135 141 O
tongue NCT03860714 142 148 O
is NCT03860714 149 151 O
chinese NCT03860714 152 159 O
; NCT03860714 159 160 O
④ NCT03860714 161 162 O
The NCT03860714 163 166 O
MMSE NCT03860714 167 171 B-Observation
score NCT03860714 172 177 O
: NCT03860714 178 179 O
Illiteracy NCT03860714 180 190 O
is NCT03860714 191 193 O
greater NCT03860714 194 201 B-Eq-Comparison
than NCT03860714 202 206 I-Eq-Comparison
or NCT03860714 207 209 I-Eq-Comparison
equal NCT03860714 210 215 I-Eq-Comparison
to NCT03860714 216 218 I-Eq-Comparison
17 NCT03860714 219 221 I-Eq-Comparison
points NCT03860714 222 228 I-Eq-Comparison
, NCT03860714 229 230 O
primary NCT03860714 231 238 B-Observation
school NCT03860714 239 245 I-Observation
is NCT03860714 246 248 O
greater NCT03860714 249 256 B-Eq-Comparison
than NCT03860714 257 261 I-Eq-Comparison
or NCT03860714 262 264 I-Eq-Comparison
equal NCT03860714 265 270 I-Eq-Comparison
to NCT03860714 271 273 I-Eq-Comparison
20 NCT03860714 274 276 I-Eq-Comparison
points NCT03860714 277 283 I-Eq-Comparison
, NCT03860714 284 285 O
higher NCT03860714 286 292 B-Observation
secondary NCT03860714 293 302 I-Observation
school NCT03860714 303 309 I-Observation
is NCT03860714 310 312 O
more NCT03860714 313 317 B-Eq-Comparison
than NCT03860714 318 322 I-Eq-Comparison
24 NCT03860714 323 325 I-Eq-Comparison
points NCT03860714 326 332 I-Eq-Comparison
; NCT03860714 332 333 O
⑤The NCT03860714 334 338 O
people NCT03860714 339 345 O
signed NCT03860714 346 352 O
informed NCT03860714 353 361 O
consent NCT03860714 362 369 O
. NCT03860714 369 370 O

Exclusion NCT03860714 372 381 O
Criteria NCT03860714 382 390 O
: NCT03860714 391 392 O

- NCT03860714 396 397 O
The NCT03860714 399 402 O
diagnosis NCT03860714 403 412 O
of NCT03860714 413 415 O
pre NCT03860714 416 419 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03860714 420 421 O
- NCT03860714 423 424 O
operative NCT03860714 425 434 B-Procedure
delirium NCT03860714 435 443 B-Condition
； NCT03860714 443 444 O

- NCT03860714 452 453 O
The NCT03860714 455 458 O
diagnosis NCT03860714 459 468 O
Unstable NCT03860714 469 477 O
hypertension（Such NCT03860714 478 495 B-Condition
as NCT03860714 496 498 O
： NCT03860714 499 500 O
pheochromocytoma NCT03860714 501 517 B-Condition
or NCT03860714 518 520 B-Or
aortic NCT03860714 521 527 B-Condition
dissection NCT03860714 528 538 I-Condition
） NCT03860714 538 539 O
； NCT03860714 539 540 O
③ NCT03860714 541 542 O
Severe NCT03860714 543 549 O
chronic NCT03860714 550 557 B-Modifier
obstructive NCT03860714 558 569 B-Condition
pulmonary NCT03860714 570 579 I-Condition
disease NCT03860714 580 587 I-Condition
or NCT03860714 588 590 B-Or
congestive NCT03860714 591 601 B-Condition
heart NCT03860714 602 607 I-Condition
failure NCT03860714 608 615 I-Condition
； NCT03860714 615 616 O
④ NCT03860714 617 618 O
Severe NCT03860714 619 625 O
liver NCT03860714 626 631 B-Modifier
and NCT03860714 632 635 B-Or
kidney NCT03860714 636 642 B-Modifier
dysfunction NCT03860714 643 654 B-Condition
; NCT03860714 654 655 O

Inclusion NCT03865693 0 9 O
Criteria NCT03865693 10 18 O
: NCT03865693 19 20 O

- NCT03865693 24 25 O
Burn NCT03865693 27 31 B-Condition
patients NCT03865693 32 40 O

- NCT03865693 43 44 O
severe NCT03865693 46 52 O
neuropatic NCT03865693 53 63 B-Modifier
pain NCT03865693 64 68 B-Condition
rated NCT03865693 69 74 O
at NCT03865693 75 77 B-Eq-Comparison
least NCT03865693 78 83 I-Eq-Comparison
5 NCT03865693 84 85 I-Eq-Comparison
on NCT03865693 86 88 O
the NCT03865693 89 92 O
10 NCT03865693 93 95 B-Observation
- NCT03865693 96 97 I-Observation
point NCT03865693 98 103 I-Observation
numerical NCT03865693 104 113 I-Observation
rating NCT03865693 114 120 I-Observation
scale NCT03865693 121 126 I-Observation
( NCT03865693 127 128 O
NRS NCT03865693 129 132 B-Observation
) NCT03865693 133 134 O

Exclusion NCT03865693 136 145 O
Criteria NCT03865693 146 154 O
: NCT03865693 155 156 O

- NCT03865693 160 161 O
cardiac NCT03865693 163 170 B-Condition
arrest NCT03865693 171 177 I-Condition
history NCT03865693 178 185 B-Eq-Comparison

- NCT03865693 188 189 O
history NCT03865693 191 198 B-Eq-Comparison
of NCT03865693 199 201 O
neurologi NCT03865693 202 211 B-Condition
disease NCT03865693 212 219 I-Condition
or NCT03865693 220 222 B-Or
brain NCT03865693 223 228 B-Modifier
surgery NCT03865693 229 236 B-Procedure

- NCT03865693 239 240 O
unstable NCT03865693 242 250 O
heart NCT03865693 251 256 B-Condition
disease NCT03865693 257 264 I-Condition
or NCT03865693 265 267 B-Or
presence NCT03865693 268 276 O
of NCT03865693 277 279 O
a NCT03865693 280 281 O
cardiac NCT03865693 282 289 B-Procedure
pacemaker NCT03865693 290 299 I-Procedure

- NCT03865693 302 303 O
pain NCT03865693 305 309 B-Condition
resulting NCT03865693 310 319 O
from NCT03865693 320 324 O
other NCT03865693 325 330 B-Other
causes NCT03865693 331 337 B-Condition
like NCT03865693 338 342 O
as NCT03865693 343 345 O
neuromuscular NCT03865693 346 359 B-Condition
diseases NCT03865693 360 368 I-Condition

- NCT03865693 371 372 O
psychiatric NCT03865693 374 385 B-Condition
disorder NCT03865693 386 394 I-Condition

- NCT03865693 397 398 O
diabetes NCT03865693 400 408 B-Condition
mellitus NCT03865693 409 417 I-Condition

- NCT03865693 420 421 O
abnormal NCT03865693 423 431 O
renal NCT03865693 432 437 B-Condition
function NCT03865693 438 446 I-Condition

- NCT03865693 449 450 O
contraindication NCT03865693 452 468 B-Contraindication
for NCT03865693 469 472 O
MRI NCT03865693 473 476 B-Procedure
, NCT03865693 477 478 O
or NCT03865693 479 481 B-Or
pregnancy NCT03865693 482 491 B-Condition
. NCT03865693 491 492 O

Inclusion NCT03868956 0 9 O
Criteria NCT03868956 10 18 O
: NCT03868956 19 20 O

- NCT03868956 24 25 O
Age NCT03868956 27 30 B-Age
> NCT03868956 31 32 B-Eq-Comparison
= NCT03868956 34 35 I-Eq-Comparison
18 NCT03868956 36 38 I-Eq-Comparison
years NCT03868956 39 44 I-Eq-Comparison

- NCT03868956 47 48 O
Known NCT03868956 50 55 O
history NCT03868956 56 63 B-Eq-Comparison
of NCT03868956 64 66 O
objectively NCT03868956 67 78 O
documented NCT03868956 79 89 O
deep NCT03868956 90 94 B-Condition
vein NCT03868956 95 99 I-Condition
thrombosis NCT03868956 100 110 I-Condition
of NCT03868956 111 113 O
the NCT03868956 114 117 O
lower NCT03868956 118 123 B-Modifier
limb NCT03868956 124 128 I-Modifier
( NCT03868956 129 130 O
with NCT03868956 131 135 B-And
or NCT03868956 136 138 B-Or
without NCT03868956 139 146 B-Negation
pulmonary NCT03868956 147 156 B-Condition
embolism NCT03868956 157 165 I-Condition
) NCT03868956 166 167 O

- NCT03868956 171 172 I-Encounter
Out NCT03868956 174 177 B-Encounter
- NCT03868956 178 179 O
patients NCT03868956 180 188 I-Encounter
referred NCT03868956 189 197 O
for NCT03868956 198 201 O
clinically NCT03868956 202 212 O
suspected NCT03868956 213 222 B-Assertion___Assertion-Type-Value:possible
acute NCT03868956 223 228 O
recurrent NCT03868956 229 238 B-Modifier
ipsilateral NCT03868956 239 250 I-Modifier
DVT NCT03868956 251 254 B-Condition
of NCT03868956 255 257 O
the NCT03868956 258 261 O
lower NCT03868956 262 267 B-Modifier
limb NCT03868956 268 272 I-Modifier
i. NCT03868956 273 275 O
e. NCT03868956 276 278 O
the NCT03868956 280 283 O
occurrence NCT03868956 284 294 O
of NCT03868956 295 297 O
new NCT03868956 298 301 B-Eq-Comparison
symptoms NCT03868956 302 310 B-Assertion___Assertion-Type-Value:possible
and NCT03868956 311 314 B-And
signs NCT03868956 315 320 B-Assertion___Assertion-Type-Value:possible
of NCT03868956 321 323 O
DVT NCT03868956 324 327 B-Condition
or NCT03868956 328 330 B-Or
the NCT03868956 331 334 O
increase NCT03868956 335 343 O
of NCT03868956 344 346 O
symptoms NCT03868956 347 355 B-Assertion___Assertion-Type-Value:possible
and NCT03868956 356 359 B-And
signs NCT03868956 360 365 B-Assertion___Assertion-Type-Value:possible
in NCT03868956 366 368 O
patients NCT03868956 369 377 O
with NCT03868956 378 382 O
post NCT03868956 383 387 B-Condition
- NCT03868956 388 389 I-Condition
thrombotic NCT03868956 390 400 I-Condition
syndrome NCT03868956 401 409 I-Condition

- NCT03868956 412 413 O
Patients NCT03868956 415 423 O
covered NCT03868956 424 431 O
by NCT03868956 432 434 O
social NCT03868956 435 441 O
security NCT03868956 442 450 O
or NCT03868956 451 453 O
equivalent NCT03868956 454 464 O
regimen NCT03868956 465 472 O

- NCT03868956 475 476 O
Signed NCT03868956 478 484 O
and NCT03868956 485 488 O
dated NCT03868956 489 494 O
informed NCT03868956 495 503 O
consent NCT03868956 504 511 O

Exclusion NCT03868956 512 521 O
Criteria NCT03868956 522 530 O
: NCT03868956 531 532 O

- NCT03868956 536 537 O
Known NCT03868956 539 544 O
current NCT03868956 545 552 B-Eq-Comparison
pregnancy NCT03868956 553 562 B-Condition

- NCT03868956 565 566 O
Any NCT03868956 568 571 O
condition NCT03868956 572 581 B-Condition
, NCT03868956 582 583 O
which NCT03868956 584 589 O
, NCT03868956 590 591 O
in NCT03868956 592 594 O
the NCT03868956 595 598 O
opinion NCT03868956 599 606 O
of NCT03868956 607 609 O
the NCT03868956 610 613 O
investigator NCT03868956 614 626 O
may NCT03868956 627 630 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03868956 631 638 B-Negation
him NCT03868956 639 642 O
from NCT03868956 643 647 O
performing NCT03868956 648 658 O
the NCT03868956 659 662 O
colour NCT03868956 663 669 B-Procedure
doppler NCT03868956 670 677 I-Procedure
ultrasound NCT03868956 678 688 I-Procedure
test NCT03868956 689 693 I-Procedure
( NCT03868956 694 695 O
plaster NCT03868956 696 703 B-Condition
cast NCT03868956 704 708 I-Condition
, NCT03868956 709 710 O
inaccessible NCT03868956 711 723 B-Modifier
vein NCT03868956 724 728 B-Condition
segment NCT03868956 729 736 I-Condition
after NCT03868956 737 742 B-Temporal-Connection___Temporal-Connection-Type-Value:after
abdominal NCT03868956 743 752 B-Modifier
or NCT03868956 753 755 B-Or|Or
pelvic NCT03868956 756 762 B-Modifier
surgery NCT03868956 763 770 B-Procedure
, NCT03868956 771 772 O
or NCT03868956 773 775 O
other NCT03868956 776 781 B-Other
causes NCT03868956 782 788 B-Condition
that NCT03868956 789 793 O
may NCT03868956 794 797 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03868956 798 802 O
to NCT03868956 803 805 O
a NCT03868956 806 807 O
technically NCT03868956 808 819 O
inadequate NCT03868956 820 830 O
CDUS NCT03868956 831 835 O
) NCT03868956 836 837 O

- NCT03868956 841 842 O
Delay NCT03868956 844 849 O
from NCT03868956 850 854 O
onset NCT03868956 855 860 B-Eq-Comparison
of NCT03868956 861 863 O
symptoms NCT03868956 864 872 B-Coreference
to NCT03868956 873 875 B-Temporal-Connection___Temporal-Connection-Type-Value:after
inclusion NCT03868956 876 885 B-Study
of NCT03868956 886 888 O
more NCT03868956 889 893 B-Eq-Comparison
than NCT03868956 894 898 I-Eq-Comparison
10 NCT03868956 899 901 I-Eq-Comparison
days NCT03868956 902 906 I-Eq-Comparison

- NCT03868956 909 910 O
Therapeutic NCT03868956 912 923 B-Procedure
anticoagulation NCT03868956 924 939 I-Procedure
for NCT03868956 940 943 O
more NCT03868956 944 948 B-Eq-Comparison
than NCT03868956 949 953 I-Eq-Comparison
48 NCT03868956 954 956 I-Eq-Comparison
hours NCT03868956 957 962 I-Eq-Comparison
in NCT03868956 963 965 O
the NCT03868956 966 969 O
two NCT03868956 970 973 B-Eq-Comparison
days NCT03868956 974 978 I-Eq-Comparison
prior NCT03868956 979 984 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868956 985 987 I-Temporal-Connection___Temporal-Connection-Type-Value:before
consent NCT03868956 988 995 O

- NCT03868956 998 999 O
Prophylactic NCT03868956 1001 1013 B-Procedure
anticoagulation NCT03868956 1014 1029 I-Procedure
for NCT03868956 1030 1033 O
more NCT03868956 1034 1038 B-Eq-Comparison
than NCT03868956 1039 1043 I-Eq-Comparison
48 NCT03868956 1044 1046 I-Eq-Comparison
hours NCT03868956 1047 1052 I-Eq-Comparison
in NCT03868956 1053 1055 O
the NCT03868956 1056 1059 O
two NCT03868956 1060 1063 B-Eq-Comparison
days NCT03868956 1064 1068 I-Eq-Comparison
prior NCT03868956 1069 1074 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868956 1075 1077 I-Temporal-Connection___Temporal-Connection-Type-Value:before
consent NCT03868956 1078 1085 O

- NCT03868956 1088 1089 O
Clinical NCT03868956 1091 1099 O
symptoms NCT03868956 1100 1108 B-Assertion___Assertion-Type-Value:possible
of NCT03868956 1109 1111 O
pulmonary NCT03868956 1112 1121 B-Condition
embolism NCT03868956 1122 1130 I-Condition

- NCT03868956 1133 1134 O
Life NCT03868956 1136 1140 B-Observation
expectancy NCT03868956 1141 1151 I-Observation
less NCT03868956 1152 1156 B-Eq-Comparison
than NCT03868956 1157 1161 I-Eq-Comparison
3 NCT03868956 1162 1163 I-Eq-Comparison
months NCT03868956 1164 1170 I-Eq-Comparison

- NCT03868956 1173 1174 O
Patient NCT03868956 1176 1183 O
unable NCT03868956 1184 1190 O
to NCT03868956 1191 1193 O
adhere NCT03868956 1194 1200 O
to NCT03868956 1201 1203 O
protocol NCT03868956 1204 1212 O
or NCT03868956 1213 1215 O
follow NCT03868956 1216 1222 O
- NCT03868956 1223 1224 O
up NCT03868956 1225 1227 O
visits NCT03868956 1228 1234 O
and NCT03868956 1235 1238 O
contacts NCT03868956 1239 1247 O

- NCT03868956 1250 1251 O
Participants NCT03868956 1253 1265 O
under NCT03868956 1266 1271 O
legal NCT03868956 1272 1277 B-Observation
guardianship NCT03868956 1278 1290 I-Observation
or NCT03868956 1291 1293 B-Or
incapacitation NCT03868956 1294 1308 B-Condition

- NCT03868956 1311 1312 O
Patient NCT03868956 1314 1321 O
already NCT03868956 1322 1329 B-Eq-Comparison
enrolled NCT03868956 1330 1338 O
in NCT03868956 1339 1341 O
a NCT03868956 1342 1343 O
deep NCT03868956 1344 1348 B-Condition
vein NCT03868956 1349 1353 I-Condition
thrombosis NCT03868956 1354 1364 I-Condition
( NCT03868956 1365 1366 O
DVT NCT03868956 1367 1370 B-Condition
) NCT03868956 1371 1372 O
diagnostic NCT03868956 1373 1383 O
research NCT03868956 1384 1392 B-Study

Inclusion NCT03864822 0 9 O
Criteria NCT03864822 10 18 O
: NCT03864822 19 20 O

- NCT03864822 24 25 O
Otherwise NCT03864822 27 36 O
healthy NCT03864822 37 44 B-Condition
men NCT03864822 45 48 O
and NCT03864822 49 52 B-Or
women NCT03864822 53 58 O

- NCT03864822 61 62 O
Aged NCT03864822 64 68 B-Age
18 NCT03864822 69 71 B-Eq-Comparison
- NCT03864822 72 73 I-Eq-Comparison
60 NCT03864822 74 76 I-Eq-Comparison
years NCT03864822 77 82 I-Eq-Comparison

- NCT03864822 85 86 O
Continuous NCT03864822 88 98 B-Eq-Comparison
pain NCT03864822 99 103 B-Condition
( NCT03864822 104 105 O
> NCT03864822 107 108 B-Eq-Comparison
3 NCT03864822 109 110 I-Eq-Comparison
days NCT03864822 111 115 O
pain NCT03864822 116 120 I-Eq-Comparison
/ NCT03864822 121 122 I-Eq-Comparison
week NCT03864822 123 127 I-Eq-Comparison
) NCT03864822 128 129 O
episode NCT03864822 130 137 O
lasting NCT03864822 138 145 O
at NCT03864822 146 148 B-Eq-Comparison
least NCT03864822 149 154 I-Eq-Comparison
3 NCT03864822 155 156 I-Eq-Comparison
months NCT03864822 157 163 I-Eq-Comparison
, NCT03864822 164 165 O
sufficient NCT03864822 166 176 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864822 177 179 I-Assertion___Assertion-Type-Value:hypothetical
limit NCT03864822 180 185 O
daily NCT03864822 186 191 B-Eq-Comparison
activities NCT03864822 192 202 B-Observation

- NCT03864822 205 206 O
Pain NCT03864822 208 212 B-Condition
in NCT03864822 213 215 O
the NCT03864822 216 219 O
region NCT03864822 220 226 B-Modifier
posteriorly NCT03864822 227 238 I-Modifier
between NCT03864822 239 246 I-Modifier
the NCT03864822 247 250 I-Modifier
inferior NCT03864822 251 259 I-Modifier
border NCT03864822 260 266 I-Modifier
of NCT03864822 267 269 I-Modifier
the NCT03864822 270 273 I-Modifier
12 NCT03864822 274 276 I-Modifier
th NCT03864822 277 279 O
rib NCT03864822 280 283 I-Modifier
and NCT03864822 284 287 B-And
the NCT03864822 288 291 O
lower NCT03864822 292 297 B-Modifier
gluteal NCT03864822 298 305 I-Modifier
fold NCT03864822 306 310 I-Modifier
( NCT03864822 311 312 O
low NCT03864822 313 316 B-Modifier
back NCT03864822 317 321 I-Modifier
pain NCT03864822 322 326 B-Condition
) NCT03864822 327 328 O
at NCT03864822 329 331 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864822 332 335 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864822 336 340 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864822 341 343 O
recruitment NCT03864822 344 355 B-Study

- NCT03864822 358 359 O
Able NCT03864822 361 365 O
to NCT03864822 366 368 O
speak NCT03864822 369 374 O
, NCT03864822 375 376 O
read NCT03864822 377 381 O
and NCT03864822 382 385 O
understand NCT03864822 386 396 O
English NCT03864822 397 404 O

Exclusion NCT03864822 405 414 O
Criteria NCT03864822 415 423 O
: NCT03864822 424 425 O

- NCT03864822 429 430 O
Pregnancy NCT03864822 432 441 B-Condition

- NCT03864822 444 445 O
Low NCT03864822 447 450 B-Modifier
back NCT03864822 451 455 I-Modifier
pain NCT03864822 456 460 B-Condition
associated NCT03864822 461 471 O
with NCT03864822 472 476 O
menstruation NCT03864822 477 489 B-Condition

- NCT03864822 492 493 O
Currently NCT03864822 495 504 B-Eq-Comparison
seeking NCT03864822 505 512 B-Assertion___Assertion-Type-Value:intention
active NCT03864822 513 519 B-Eq-Comparison
treatment NCT03864822 520 529 B-Procedure
for NCT03864822 530 533 O
low NCT03864822 534 537 B-Modifier
back NCT03864822 538 542 I-Modifier
pain NCT03864822 543 547 B-Condition

- NCT03864822 550 551 O
Red NCT03864822 553 556 B-Condition
flags NCT03864822 557 562 I-Condition
symptoms NCT03864822 563 571 B-Assertion___Assertion-Type-Value:possible
( NCT03864822 572 573 O
i. NCT03864822 574 576 O
e. NCT03864822 577 579 O
fever NCT03864822 581 586 B-Condition
, NCT03864822 587 588 O
malaise NCT03864822 589 596 B-Condition
, NCT03864822 597 598 O
progressive NCT03864822 599 610 B-Modifier
neurologic NCT03864822 611 621 B-Condition
deficit NCT03864822 622 629 I-Condition
, NCT03864822 630 631 O
significant NCT03864822 632 643 O
trauma NCT03864822 644 650 B-Condition
, NCT03864822 651 652 O
prolonged NCT03864822 653 662 B-Modifier
corticosteroid NCT03864822 663 677 B-Drug
use NCT03864822 678 681 O
or NCT03864822 682 684 B-Or
osteoporosis NCT03864822 685 697 B-Condition
, NCT03864822 698 699 O
pain NCT03864822 700 704 B-Condition
worst NCT03864822 705 710 O
at NCT03864822 711 713 O
night NCT03864822 714 719 B-Modifier
, NCT03864822 720 721 O
urinary NCT03864822 722 729 B-Modifier
or NCT03864822 730 732 B-Or|Or
faecal NCT03864822 733 739 B-Modifier
incontinence NCT03864822 740 752 B-Condition
, NCT03864822 753 754 O
or NCT03864822 755 757 O
unintended NCT03864822 758 768 B-Modifier
weight NCT03864822 769 775 B-Condition
loss NCT03864822 776 780 I-Condition
) NCT03864822 781 782 O

- NCT03864822 786 787 O
Drug NCT03864822 789 793 B-Condition
addiction NCT03864822 794 803 I-Condition
defined NCT03864822 804 811 O
as NCT03864822 812 814 O
the NCT03864822 815 818 O
use NCT03864822 819 822 O
of NCT03864822 823 825 O
cannabis NCT03864822 826 834 B-Drug
, NCT03864822 835 836 O
opioids NCT03864822 837 844 B-Drug
or NCT03864822 845 847 B-Or|Or
other NCT03864822 848 853 B-Other
drugs NCT03864822 854 859 B-Drug

- NCT03864822 862 863 O
Current NCT03864822 865 872 B-Eq-Comparison
or NCT03864822 873 875 O
previous NCT03864822 876 884 B-Eq-Comparison
neurologic NCT03864822 885 895 B-Modifier
, NCT03864822 896 897 O
musculoskeletal NCT03864822 898 913 B-Modifier
, NCT03864822 914 915 O
mental NCT03864822 916 922 B-Modifier
, NCT03864822 923 924 O
or NCT03864822 925 927 B-Or
other NCT03864822 928 933 B-Other
illnesses NCT03864822 934 943 B-Condition
which NCT03864822 944 949 O
may NCT03864822 950 953 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864822 954 960 O
the NCT03864822 961 964 O
trial NCT03864822 965 970 B-Study

- NCT03864822 973 974 O
Current NCT03864822 976 983 B-Eq-Comparison
or NCT03864822 984 986 B-Or|Or
previous NCT03864822 987 995 B-Eq-Comparison
chronic NCT03864822 996 1003 B-Modifier
or NCT03864822 1004 1006 O
recurrent NCT03864822 1007 1016 B-Modifier
pain NCT03864822 1017 1021 B-Condition
condition NCT03864822 1022 1031 I-Condition
other NCT03864822 1032 1037 B-Exception
than NCT03864822 1038 1042 I-Exception
low NCT03864822 1043 1046 B-Modifier
back NCT03864822 1047 1051 I-Modifier
pain NCT03864822 1052 1056 B-Condition

- NCT03864822 1059 1060 O
Current NCT03864822 1062 1069 B-Eq-Comparison
regular NCT03864822 1070 1077 O
use NCT03864822 1078 1081 O
of NCT03864822 1082 1084 O
analgesic NCT03864822 1085 1094 B-Drug
medication NCT03864822 1095 1105 I-Drug|Drug
or NCT03864822 1106 1108 B-Or
other NCT03864822 1109 1114 B-Other
medication NCT03864822 1115 1125 O
which NCT03864822 1126 1131 O
may NCT03864822 1132 1135 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864822 1136 1142 O
the NCT03864822 1143 1146 O
trial NCT03864822 1147 1152 B-Study

- NCT03864822 1155 1156 O
Lack NCT03864822 1158 1162 O
of NCT03864822 1163 1165 O
ability NCT03864822 1166 1173 O
to NCT03864822 1174 1176 O
cooperate NCT03864822 1177 1186 O

Inclusion NCT03862274 0 9 O
Criteria NCT03862274 10 18 O
: NCT03862274 19 20 O

- NCT03862274 24 25 O
Patients NCT03862274 27 35 O
that NCT03862274 36 40 O
have NCT03862274 41 45 O
a NCT03862274 46 47 O
TPP1 NCT03862274 48 52 B-Modifier
enzyme NCT03862274 53 59 B-Condition
deficiency NCT03862274 60 70 I-Condition

- NCT03862274 73 74 O
Patients NCT03862274 76 84 O
have NCT03862274 85 89 O
confirmed NCT03862274 90 99 O
molecular NCT03862274 100 109 B-Procedure
diagnosis NCT03862274 110 119 O
of NCT03862274 120 122 O
pathogenic NCT03862274 123 133 B-Condition
variants NCT03862274 134 142 I-Condition
in NCT03862274 143 145 O
the NCT03862274 146 149 O
TPP1 NCT03862274 150 154 B-Modifier
gene NCT03862274 155 159 I-Modifier

- NCT03862274 162 163 O
Patients NCT03862274 165 173 O
that NCT03862274 174 178 O
are NCT03862274 179 182 O
enrolled NCT03862274 183 191 O
in NCT03862274 192 194 O
post NCT03862274 195 199 O
- NCT03862274 200 201 O
marketing NCT03862274 202 211 O
studies NCT03862274 212 219 O
will NCT03862274 220 224 O
be NCT03862274 225 227 O
allowed NCT03862274 228 235 O
to NCT03862274 236 238 O
enroll NCT03862274 239 245 O
into NCT03862274 246 250 O
the NCT03862274 251 254 O
current NCT03862274 255 262 O
study NCT03862274 263 268 O

Exclusion NCT03862274 269 278 O
Criteria NCT03862274 279 287 O
: NCT03862274 288 289 O

- NCT03862274 293 294 O
Patients NCT03862274 296 304 O
without NCT03862274 305 312 B-Negation
a NCT03862274 313 314 O
diagnosis NCT03862274 315 324 O
of NCT03862274 325 327 O
CLN2 NCT03862274 328 332 B-Condition
and NCT03862274 333 336 B-Or
deficiency NCT03862274 337 347 B-Condition
of NCT03862274 348 350 O
TPP1 NCT03862274 351 355 B-Modifier

- NCT03862274 358 359 O
Patients NCT03862274 361 369 O
that NCT03862274 370 374 O
are NCT03862274 375 378 O
currently NCT03862274 379 388 B-Eq-Comparison
enrolled NCT03862274 389 397 O
as NCT03862274 398 400 O
part NCT03862274 401 405 O
of NCT03862274 406 408 O
a NCT03862274 409 410 O
larger NCT03862274 411 417 O
multi NCT03862274 418 423 O
- NCT03862274 424 425 O
center NCT03862274 426 432 O
clinical NCT03862274 433 441 O
trial NCT03862274 442 447 B-Study

Inclusion NCT03860311 0 9 O
Criteria NCT03860311 10 18 O
: NCT03860311 19 20 O

- NCT03860311 24 25 O
Age NCT03860311 27 30 B-Age
8 NCT03860311 31 32 B-Eq-Comparison
yr NCT03860311 33 35 O
- NCT03860311 36 37 I-Eq-Comparison
18 NCT03860311 38 40 I-Eq-Comparison
yrs NCT03860311 41 44 O

- NCT03860311 47 48 O
Female NCT03860311 50 56 O

- NCT03860311 59 60 O
Likely NCT03860311 62 68 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860311 69 71 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03860311 72 76 O
order NCT03860311 77 82 O
placed NCT03860311 83 89 O
for NCT03860311 90 93 O
transabdominal NCT03860311 94 108 B-Procedure
pelvic NCT03860311 109 115 I-Procedure
ultrasound NCT03860311 116 126 I-Procedure
/ NCT03860311 127 128 B-Or
ovarian NCT03860311 129 136 B-Modifier
ultrasound NCT03860311 137 147 B-Procedure

- NCT03860311 150 151 O
No NCT03860311 153 155 B-Negation
history NCT03860311 156 163 B-Eq-Comparison
of NCT03860311 164 166 O
pelvic NCT03860311 167 173 B-Modifier
or NCT03860311 174 176 B-Or
bladder NCT03860311 177 184 B-Modifier
reconstructive NCT03860311 185 199 B-Procedure
surgery NCT03860311 200 207 I-Procedure

Exclusion NCT03860311 208 217 O
Criteria NCT03860311 218 226 O
: NCT03860311 227 228 O

- NCT03860311 232 233 O
Pregnancy NCT03860311 235 244 B-Condition
( NCT03860311 245 246 O
known NCT03860311 247 252 O
) NCT03860311 253 254 O

- NCT03860311 258 259 O
Critically NCT03860311 261 271 O
ill NCT03860311 272 275 B-Condition
patients NCT03860311 276 284 O

- NCT03860311 287 288 O
Patients NCT03860311 290 298 O
with NCT03860311 299 303 O
known NCT03860311 304 309 O
renal NCT03860311 310 315 B-Modifier
or NCT03860311 316 318 B-Or
genitourinary NCT03860311 319 332 B-Modifier
structural NCT03860311 333 343 I-Modifier
abnormalities NCT03860311 344 357 B-Condition
or NCT03860311 358 360 B-Or
prior NCT03860311 361 366 B-Eq-Comparison
pelvic NCT03860311 367 373 B-Modifier
/ NCT03860311 374 375 B-Or
genitourinary NCT03860311 376 389 B-Modifier
surgery NCT03860311 390 397 B-Procedure

- NCT03860311 400 401 O
Chronic NCT03860311 403 410 B-Modifier
renal NCT03860311 411 416 B-Condition
disease NCT03860311 417 424 I-Condition

- NCT03860311 427 428 O
Patients NCT03860311 430 438 O
presenting NCT03860311 439 449 O
outside NCT03860311 450 457 B-Negation
the NCT03860311 458 461 O
defined NCT03860311 462 469 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03860311 470 479 B-Procedure
windows NCT03860311 480 487 O

Inclusion NCT03868995 0 9 O
Criteria NCT03868995 10 18 O
: NCT03868995 19 20 O

1 NCT03868995 24 25 O
. NCT03868995 25 26 O
20 NCT03868995 28 30 B-Eq-Comparison
- NCT03868995 31 32 I-Eq-Comparison
70 NCT03868995 33 35 O
age NCT03868995 36 39 B-Age

2 NCT03868995 42 43 O
. NCT03868995 43 44 O
Chronic NCT03868995 46 53 B-Modifier
ankle NCT03868995 54 59 I-Modifier
sprain NCT03868995 60 66 B-Condition
more NCT03868995 67 71 B-Eq-Comparison
than NCT03868995 72 76 I-Eq-Comparison
3 NCT03868995 77 78 I-Eq-Comparison
months NCT03868995 79 85 O
with NCT03868995 86 90 B-And
chronic NCT03868995 91 98 B-Modifier
ankle NCT03868995 99 104 I-Modifier
pain NCT03868995 105 109 B-Condition
or NCT03868995 110 112 B-Or
instability NCT03868995 113 124 B-Modifier
sensation NCT03868995 125 134 B-Condition

3 NCT03868995 137 138 O
. NCT03868995 138 139 O
Ultrasound NCT03868995 141 151 B-Procedure
diagnosed NCT03868995 152 161 O
anterior NCT03868995 162 170 B-Modifier
talofibular NCT03868995 171 182 I-Modifier
ligament NCT03868995 183 191 B-Condition
sprain NCT03868995 192 198 I-Condition

Exclusion NCT03868995 199 208 O
Criteria NCT03868995 209 217 O
: NCT03868995 218 219 O

1 NCT03868995 223 224 O
. NCT03868995 224 225 O
Acute NCT03868995 227 232 O
ankle NCT03868995 233 238 B-Modifier
sprain NCT03868995 239 245 B-Condition
less NCT03868995 246 250 B-Eq-Comparison
than NCT03868995 251 255 I-Eq-Comparison
3 NCT03868995 256 257 I-Eq-Comparison
months NCT03868995 258 264 I-Eq-Comparison

2 NCT03868995 267 268 O
. NCT03868995 268 269 O
Lower NCT03868995 271 276 B-Modifier
limb NCT03868995 277 281 I-Modifier
fracture NCT03868995 282 290 B-Condition
history NCT03868995 291 298 B-Eq-Comparison

3 NCT03868995 301 302 O
. NCT03868995 302 303 O
Cognitive NCT03868995 305 314 B-Condition
impairment NCT03868995 315 325 I-Condition

4 NCT03868995 328 329 O
. NCT03868995 329 330 O
Other NCT03868995 332 337 B-Other
neurological NCT03868995 338 350 B-Modifier
or NCT03868995 351 353 B-Or
muscular NCT03868995 354 362 B-Modifier
disorders NCT03868995 363 372 B-Condition

5 NCT03868995 375 376 O
. NCT03868995 376 377 O
Sever NCT03868995 379 384 O
pain NCT03868995 385 389 B-Condition
could NCT03868995 390 395 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03868995 396 399 B-Negation
tolerate NCT03868995 400 408 B-Assertion___Assertion-Type-Value:hypothetical
examination NCT03868995 409 420 B-Procedure

Inclusion NCT03861741 0 9 O
Criteria NCT03861741 10 18 O
: NCT03861741 19 20 O

1 NCT03861741 24 25 O
. NCT03861741 25 26 O
NS NCT03861741 28 30 B-Condition
- NCT03861741 31 32 I-Condition
TAD NCT03861741 33 36 I-Condition
probands NCT03861741 37 45 O
operated NCT03861741 46 54 B-Procedure
on NCT03861741 55 57 O
( NCT03861741 58 59 O
n NCT03861741 60 61 O
= NCT03861741 62 63 O
16 NCT03861741 64 66 O
) NCT03861741 67 68 O
. NCT03861741 69 70 O

2 NCT03861741 74 75 O
. NCT03861741 75 76 O
FDR NCT03861741 78 81 B-Condition
and NCT03861741 82 85 B-Or
SDR NCT03861741 86 89 B-Condition
, NCT03861741 90 91 O
aged NCT03861741 92 96 B-Age
16 NCT03861741 97 99 B-Eq-Comparison
and NCT03861741 100 103 I-Eq-Comparison
above NCT03861741 104 109 I-Eq-Comparison
: NCT03861741 110 111 O

1 NCT03861741 120 121 O
. NCT03861741 121 122 O
At NCT03861741 124 126 B-Eq-Comparison
least NCT03861741 127 132 I-Eq-Comparison
two NCT03861741 133 136 I-Eq-Comparison
relatives NCT03861741 137 146 B-Family-Member
willing NCT03861741 147 154 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861741 155 157 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861741 158 169 O
in NCT03861741 170 172 O
the NCT03861741 173 176 O
screening NCT03861741 177 186 B-Study
programme NCT03861741 187 196 O
. NCT03861741 196 197 O

2 NCT03861741 206 207 O
. NCT03861741 207 208 O
Relatives NCT03861741 210 219 O
able NCT03861741 220 224 O
to NCT03861741 225 227 O
understand NCT03861741 228 238 O
English NCT03861741 239 246 O
. NCT03861741 246 247 O

Exclusion NCT03861741 249 258 O
Criteria NCT03861741 259 267 O
: NCT03861741 268 269 O

1 NCT03861741 273 274 O
. NCT03861741 274 275 O
Probands NCT03861741 277 285 O
with NCT03861741 286 290 O
syndromic NCT03861741 291 300 B-Condition
aortopathies NCT03861741 301 313 I-Condition
, NCT03861741 314 315 O
including NCT03861741 316 325 O
Marfan NCT03861741 326 332 B-Condition
Syndrome NCT03861741 333 341 I-Condition|Condition
, NCT03861741 342 343 O
Loeys NCT03861741 344 349 B-Condition
- NCT03861741 350 351 I-Condition|Condition
Dietz NCT03861741 352 357 I-Condition
Syndrome NCT03861741 358 366 I-Condition
, NCT03861741 367 368 O
Ehlers NCT03861741 369 375 B-Condition
- NCT03861741 376 377 I-Condition
Danlos NCT03861741 378 384 I-Condition
Syndrome NCT03861741 385 393 O
, NCT03861741 394 395 O
Shprintzen NCT03861741 396 406 B-Condition
- NCT03861741 407 408 I-Condition
Goldberg NCT03861741 409 417 I-Condition
syndrome NCT03861741 418 426 I-Condition
, NCT03861741 427 428 O
aneurysm NCT03861741 429 437 B-Condition
- NCT03861741 438 439 O
osteoarthritis NCT03861741 440 454 I-Condition
syndrome NCT03861741 455 463 I-Condition|Condition
, NCT03861741 464 465 O
arterial NCT03861741 466 474 B-Condition
tortuosity NCT03861741 475 485 I-Condition
syndrome NCT03861741 486 494 I-Condition
, NCT03861741 495 496 O
and NCT03861741 497 500 B-Or
cutis NCT03861741 501 506 B-Condition
laxa NCT03861741 507 511 I-Condition
syndrome NCT03861741 512 520 O
. NCT03861741 520 521 O

2 NCT03861741 525 526 O
. NCT03861741 526 527 O
Probands NCT03861741 529 537 O
with NCT03861741 538 542 O
aortic NCT03861741 543 549 B-Condition
lesions NCT03861741 550 557 I-Condition
associated NCT03861741 558 568 O
with NCT03861741 569 573 O
trauma NCT03861741 574 580 B-Condition
and NCT03861741 581 584 B-Or
infections NCT03861741 585 595 B-Condition
. NCT03861741 595 596 O

3 NCT03861741 600 601 O
. NCT03861741 601 602 O
Probands NCT03861741 604 612 O
/ NCT03861741 613 614 O
relatives NCT03861741 615 624 O
unable NCT03861741 625 631 O
to NCT03861741 632 634 O
give NCT03861741 635 639 O
informed NCT03861741 640 648 O
consent NCT03861741 649 656 O

Inclusion NCT03862248 0 9 O
Criteria NCT03862248 10 18 O
: NCT03862248 19 20 O

- NCT03862248 24 25 O
All NCT03862248 27 30 O
newly NCT03862248 31 36 O
registered NCT03862248 37 47 O
patients NCT03862248 48 56 O
with NCT03862248 57 61 O
smear NCT03862248 62 67 B-Modifier
- NCT03862248 68 69 O
positive NCT03862248 70 78 O
recurrent NCT03862248 79 88 B-Modifier
pulmonary NCT03862248 89 98 I-Modifier
TB NCT03862248 99 101 B-Condition

- NCT03862248 104 105 O
Adults NCT03862248 107 113 O
as NCT03862248 114 116 B-Or
well NCT03862248 117 121 I-Or
as NCT03862248 122 124 I-Or
children NCT03862248 125 133 O
( NCT03862248 134 135 O
no NCT03862248 136 138 O
age NCT03862248 139 142 O
limit NCT03862248 143 148 O
) NCT03862248 149 150 O

- NCT03862248 154 155 O
Able NCT03862248 157 161 O
and NCT03862248 162 165 O
willing NCT03862248 166 173 O
to NCT03862248 174 176 O
provide NCT03862248 177 184 O
written NCT03862248 185 192 O
informed NCT03862248 193 201 O
consent NCT03862248 202 209 O

Exclusion NCT03862248 210 219 O
Criteria NCT03862248 220 228 O
: NCT03862248 229 230 O

- NCT03862248 234 235 O
Patients NCT03862248 237 245 O
transferred NCT03862248 246 257 B-Encounter
to NCT03862248 258 260 O
a NCT03862248 261 262 O
health NCT03862248 263 269 O
facility NCT03862248 270 278 O
not NCT03862248 279 282 B-Negation
supported NCT03862248 283 292 B-Assertion___Assertion-Type-Value:hypothetical
by NCT03862248 293 295 I-Assertion___Assertion-Type-Value:hypothetical
Damien NCT03862248 296 302 O
Foundation NCT03862248 303 313 O
will NCT03862248 314 318 O
be NCT03862248 319 321 O
excluded NCT03862248 322 330 O
. NCT03862248 330 331 O
This NCT03862248 333 337 O
includes NCT03862248 338 346 O
patients NCT03862248 347 355 O
diagnosed NCT03862248 356 365 O
with NCT03862248 366 370 O
HIV NCT03862248 371 374 B-Condition
/ NCT03862248 375 376 B-Or
TB NCT03862248 377 379 B-Condition
- NCT03862248 380 381 O
coinfection NCT03862248 382 393 B-Condition
. NCT03862248 393 394 O

Inclusion NCT03862937 0 9 O
Criteria NCT03862937 10 18 O
: NCT03862937 19 20 O

- NCT03862937 24 25 O
Be NCT03862937 27 29 O
60 NCT03862937 30 32 B-Eq-Comparison
or NCT03862937 33 35 I-Eq-Comparison
older NCT03862937 36 41 I-Age|Eq-Comparison
, NCT03862937 42 43 O
and NCT03862937 44 47 O
in NCT03862937 48 50 O
the NCT03862937 51 54 O
case NCT03862937 55 59 O
of NCT03862937 60 62 O
women NCT03862937 63 68 O
, NCT03862937 69 70 O
they NCT03862937 71 75 O
must NCT03862937 76 80 O
be NCT03862937 81 83 O
postmenopausal NCT03862937 84 98 B-Condition
( NCT03862937 99 100 O
interruption NCT03862937 101 113 B-Negation
of NCT03862937 114 116 O
menstruation NCT03862937 117 129 B-Condition
for NCT03862937 130 133 O
more NCT03862937 134 138 B-Eq-Comparison
than NCT03862937 139 143 I-Eq-Comparison
one NCT03862937 144 147 I-Eq-Comparison
year NCT03862937 148 152 I-Eq-Comparison
) NCT03862937 153 154 O
. NCT03862937 155 156 O

- NCT03862937 160 161 O
Have NCT03862937 163 167 O
not NCT03862937 168 171 B-Negation
participated NCT03862937 172 184 O
in NCT03862937 185 187 O
any NCT03862937 188 191 O
systematic NCT03862937 192 202 B-Modifier
exercise NCT03862937 203 211 B-Procedure
program NCT03862937 212 219 I-Procedure
for NCT03862937 220 223 O
at NCT03862937 224 226 B-Eq-Comparison
least NCT03862937 227 232 I-Eq-Comparison
six NCT03862937 233 236 I-Eq-Comparison
months NCT03862937 237 243 I-Eq-Comparison
prior NCT03862937 244 249 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862937 250 252 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862937 253 256 O
start NCT03862937 257 262 O
of NCT03862937 263 265 O
this NCT03862937 266 270 O
project NCT03862937 271 278 B-Study
. NCT03862937 278 279 O

- NCT03862937 283 284 O
To NCT03862937 286 288 O
have NCT03862937 289 293 O
a NCT03862937 294 295 O
body NCT03862937 296 300 B-Observation
mass NCT03862937 301 305 I-Observation
index NCT03862937 306 311 I-Observation
( NCT03862937 312 313 O
BMI NCT03862937 314 317 B-Observation
) NCT03862937 318 319 O
between NCT03862937 320 327 B-Eq-Comparison
22 NCT03862937 328 330 I-Eq-Comparison
and NCT03862937 331 334 I-Eq-Comparison
30 NCT03862937 335 337 I-Eq-Comparison
kg NCT03862937 338 340 I-Eq-Comparison
/ NCT03862937 341 342 I-Eq-Comparison
m2 NCT03862937 343 345 I-Eq-Comparison
. NCT03862937 345 346 O

- NCT03862937 350 351 O
Are NCT03862937 353 356 O
not NCT03862937 357 360 B-Negation
cardiopathic NCT03862937 361 373 B-Condition
, NCT03862937 374 375 O
diabetic NCT03862937 376 384 B-Condition
or NCT03862937 385 387 B-Or
have NCT03862937 388 392 O
any NCT03862937 393 396 O
other NCT03862937 397 402 B-Other
metabolic NCT03862937 403 412 B-Condition
disease NCT03862937 413 420 I-Condition
. NCT03862937 420 421 O

- NCT03862937 425 426 O
Do NCT03862937 428 430 O
not NCT03862937 431 434 B-Negation
present NCT03862937 435 442 O
joint NCT03862937 443 448 B-Condition
problems NCT03862937 449 457 I-Condition
or NCT03862937 458 460 B-Or
any NCT03862937 461 464 O
other NCT03862937 465 470 B-Other
injury NCT03862937 471 477 B-Condition
that NCT03862937 478 482 O
prevents NCT03862937 483 491 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862937 492 495 O
proper NCT03862937 496 502 O
execution NCT03862937 503 512 O
of NCT03862937 513 515 O
the NCT03862937 516 519 O
exercises NCT03862937 520 529 B-Observation
of NCT03862937 530 532 O
the NCT03862937 533 536 O
training NCT03862937 537 545 B-Procedure
routine NCT03862937 546 553 I-Procedure
. NCT03862937 553 554 O

- NCT03862937 558 559 O
Non NCT03862937 561 564 B-Negation
- NCT03862937 565 566 O
smoker NCT03862937 567 573 B-Condition
or NCT03862937 574 576 B-Or
have NCT03862937 577 581 O
quit NCT03862937 582 586 B-Condition
smoking NCT03862937 587 594 I-Condition
for NCT03862937 595 598 O
at NCT03862937 599 601 B-Eq-Comparison
least NCT03862937 602 607 I-Eq-Comparison
five NCT03862937 608 612 I-Eq-Comparison
years NCT03862937 613 618 I-Eq-Comparison
ago NCT03862937 619 622 I-Eq-Comparison
. NCT03862937 622 623 O

- NCT03862937 627 628 O
Release NCT03862937 630 637 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03862937 638 640 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862937 641 644 O
doctor NCT03862937 645 651 O
( NCT03862937 652 653 O
medical NCT03862937 654 661 O
certificate NCT03862937 662 673 O
) NCT03862937 674 675 O
to NCT03862937 676 678 O
perform NCT03862937 679 686 O
the NCT03862937 687 690 O
physical NCT03862937 691 699 B-Observation
exercises NCT03862937 700 709 I-Observation
. NCT03862937 709 710 O

Exclusion NCT03862937 712 721 O
Criteria NCT03862937 722 730 O
: NCT03862937 731 732 O

- NCT03862937 736 737 O
Do NCT03862937 739 741 O
not NCT03862937 742 745 B-Negation
participate NCT03862937 746 757 O
in NCT03862937 758 760 O
at NCT03862937 761 763 B-Eq-Comparison
least NCT03862937 764 769 I-Eq-Comparison
20 NCT03862937 770 772 I-Eq-Comparison
training NCT03862937 773 781 B-Procedure
sessions NCT03862937 782 790 I-Procedure
or NCT03862937 791 793 B-Or
miss NCT03862937 794 798 B-Negation
more NCT03862937 799 803 B-Eq-Comparison
than NCT03862937 804 808 I-Eq-Comparison
three NCT03862937 809 814 I-Eq-Comparison
consecutive NCT03862937 815 826 I-Eq-Comparison
training NCT03862937 827 835 B-Procedure
sessions NCT03862937 836 844 I-Procedure
. NCT03862937 844 845 O

Inclusion NCT03869645 0 9 O
Criteria NCT03869645 10 18 O
: NCT03869645 19 20 O

- NCT03869645 24 25 O
Patients NCT03869645 27 35 O
who NCT03869645 36 39 O
are NCT03869645 40 43 O
> NCT03869645 44 45 B-Eq-Comparison
18 NCT03869645 46 48 I-Eq-Comparison
years NCT03869645 49 54 I-Eq-Comparison
of NCT03869645 55 57 O
age NCT03869645 58 61 B-Age

- NCT03869645 64 65 O
Patients NCT03869645 67 75 O
with NCT03869645 76 80 O
clinical NCT03869645 81 89 B-Assertion___Assertion-Type-Value:possible
signs NCT03869645 90 95 I-Assertion___Assertion-Type-Value:possible
, NCT03869645 96 97 O
symptoms NCT03869645 98 106 B-Assertion___Assertion-Type-Value:possible
and NCT03869645 107 110 B-And
presentation NCT03869645 111 123 B-Assertion___Assertion-Type-Value:possible
consistent NCT03869645 124 134 O
with NCT03869645 135 139 O
acute NCT03869645 140 145 O
thrombosis NCT03869645 146 156 B-Condition
; NCT03869645 156 157 O
onset NCT03869645 158 163 B-Eq-Comparison
of NCT03869645 164 166 O
symptoms NCT03869645 167 175 B-Coreference
< NCT03869645 176 177 B-Eq-Comparison
14 NCT03869645 178 180 I-Eq-Comparison
days NCT03869645 181 185 I-Eq-Comparison

- NCT03869645 188 189 O
Patients NCT03869645 191 199 O
cleared NCT03869645 200 207 B-Assertion___Assertion-Type-Value:hypothetical
medically NCT03869645 208 217 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03869645 218 221 I-Assertion___Assertion-Type-Value:hypothetical
invasive NCT03869645 222 230 B-Procedure
endovenous NCT03869645 231 241 I-Procedure
procedures NCT03869645 242 252 I-Procedure

Exclusion NCT03869645 253 262 O
Criteria NCT03869645 263 271 O
: NCT03869645 272 273 O

- NCT03869645 277 278 O
Patients NCT03869645 280 288 O
with NCT03869645 289 293 O
IVC NCT03869645 294 297 B-Procedure
filter NCT03869645 298 304 I-Procedure
in NCT03869645 305 307 O
area NCT03869645 308 312 B-Modifier
to NCT03869645 313 315 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03869645 316 318 I-Assertion___Assertion-Type-Value:hypothetical
treated NCT03869645 319 326 B-Procedure

- NCT03869645 329 330 O
Patients NCT03869645 332 340 O
who NCT03869645 341 344 O
are NCT03869645 345 348 O
< NCT03869645 349 350 B-Eq-Comparison
18 NCT03869645 351 353 I-Eq-Comparison
years NCT03869645 354 359 I-Eq-Comparison
of NCT03869645 360 362 O
age NCT03869645 363 366 B-Age
. NCT03869645 366 367 O

- NCT03869645 371 372 O
Known NCT03869645 374 379 O
anaphylactic NCT03869645 380 392 B-Condition
reaction NCT03869645 393 401 I-Condition
of NCT03869645 402 404 O
radiographic NCT03869645 405 417 B-Drug
contrast NCT03869645 418 426 I-Drug
agents NCT03869645 427 433 I-Drug
that NCT03869645 434 438 O
can NCT03869645 439 442 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03869645 442 445 O
be NCT03869645 446 448 O
pre NCT03869645 449 452 B-Procedure
- NCT03869645 453 454 I-Procedure
treated NCT03869645 455 462 I-Procedure

- NCT03869645 465 466 O
Imaging NCT03869645 468 475 B-Procedure
evidence NCT03869645 476 484 O
or NCT03869645 485 487 B-Or
other NCT03869645 488 493 B-Other
evidence NCT03869645 494 502 O
that NCT03869645 503 507 O
suggests NCT03869645 508 516 O
the NCT03869645 517 520 O
participant NCT03869645 521 532 O
is NCT03869645 533 535 O
not NCT03869645 536 539 B-Negation
appropriate NCT03869645 540 551 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869645 552 555 O
mechanical NCT03869645 556 566 B-Procedure
thrombectomy NCT03869645 567 579 I-Procedure
intervention NCT03869645 580 592 I-Procedure

- NCT03869645 595 596 O
Female NCT03869645 598 604 O
who NCT03869645 605 608 B-And
is NCT03869645 609 611 O
pregnant NCT03869645 612 620 B-Condition
or NCT03869645 621 623 B-Or
nursing NCT03869645 624 631 B-Condition

- NCT03869645 634 635 O
Concurrent NCT03869645 637 647 B-Modifier
participation NCT03869645 648 661 O
in NCT03869645 662 664 O
another NCT03869645 665 672 B-Other
investigational NCT03869645 673 688 B-Study
drug NCT03869645 689 693 B-Drug
or NCT03869645 694 696 B-Or
device NCT03869645 697 703 B-Procedure
treatment NCT03869645 704 713 I-Procedure
study NCT03869645 714 719 B-Study

Inclusion NCT03865043 0 9 O
criteria NCT03865043 10 18 O
: NCT03865043 19 20 O

- NCT03865043 24 25 O
Patients NCT03865043 27 35 O
undergoing NCT03865043 36 46 B-Eq-Comparison
a NCT03865043 47 48 O
TAVI NCT03865043 49 53 B-Procedure
at NCT03865043 54 56 O
Montpellier NCT03865043 57 68 O
University NCT03865043 69 79 O
Hospital NCT03865043 80 88 O

- NCT03865043 91 92 O
Since NCT03865043 94 99 B-Eq-Comparison
November NCT03865043 100 108 I-Eq-Comparison
2017 NCT03865043 109 113 I-Eq-Comparison

- NCT03865043 117 118 O
With NCT03865043 120 124 O
implantation NCT03865043 125 137 B-Procedure
of NCT03865043 138 140 O
a NCT03865043 141 142 O
COREVALVE NCT03865043 143 152 B-Modifier
or NCT03865043 153 155 B-Or
EDWARDS NCT03865043 156 163 B-Modifier

- NCT03865043 166 167 O
By NCT03865043 169 171 O
femoral NCT03865043 172 179 B-Procedure
approach NCT03865043 180 188 I-Procedure

Exclusion NCT03865043 189 198 O
criteria NCT03865043 199 207 O
: NCT03865043 208 209 O

- NCT03865043 213 214 O
Minor NCT03865043 216 221 O
patient NCT03865043 222 229 O

- NCT03865043 232 233 O
Patient NCT03865043 235 242 O
unable NCT03865043 243 249 O
to NCT03865043 250 252 O
give NCT03865043 253 257 O
consent NCT03865043 258 265 O
for NCT03865043 266 269 O
reasons NCT03865043 270 277 O
of NCT03865043 278 280 O
understanding NCT03865043 281 294 O
or NCT03865043 295 297 O
language NCT03865043 298 306 B-Condition
barrier NCT03865043 307 314 I-Condition

Inclusion NCT03865862 0 9 O
Criteria NCT03865862 10 18 O
: NCT03865862 19 20 O

- NCT03865862 24 25 O
Volleyball NCT03865862 27 37 B-Observation
players NCT03865862 38 45 I-Observation

- NCT03865862 48 49 O
Federated NCT03865862 51 60 O
that NCT03865862 61 65 O
at NCT03865862 66 68 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865862 69 72 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865862 73 77 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865862 78 80 O
the NCT03865862 81 84 O
study NCT03865862 85 90 B-Study
compete NCT03865862 91 98 O
in NCT03865862 99 101 O
clubs NCT03865862 102 107 O
of NCT03865862 108 110 O
the NCT03865862 111 114 O
Community NCT03865862 115 124 O
of NCT03865862 125 127 O
Madrid NCT03865862 128 134 O

- NCT03865862 137 138 O
Over NCT03865862 140 144 B-Eq-Comparison
18 NCT03865862 145 147 I-Eq-Comparison
years NCT03865862 148 153 I-Eq-Comparison
old NCT03865862 154 157 B-Age
. NCT03865862 157 158 O

Exclusion NCT03865862 160 169 O
Criteria NCT03865862 170 178 O
: NCT03865862 179 180 O

- NCT03865862 184 185 O
Present NCT03865862 187 194 O
a NCT03865862 195 196 O
medical NCT03865862 197 204 O
diagnosis NCT03865862 205 214 O
of NCT03865862 215 217 O
injury NCT03865862 218 224 B-Condition
or NCT03865862 225 227 B-Or
illness NCT03865862 228 235 B-Condition

- NCT03865862 238 239 O
Have NCT03865862 241 245 O
suffered NCT03865862 246 254 O
a NCT03865862 255 256 O
knee NCT03865862 257 261 B-Modifier
injury NCT03865862 262 268 B-Condition
in NCT03865862 269 271 O
the NCT03865862 272 275 O
6 NCT03865862 276 277 B-Eq-Comparison
months NCT03865862 278 284 I-Eq-Comparison
prior NCT03865862 285 290 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865862 291 293 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03865862 294 297 O
study NCT03865862 298 303 B-Study

- NCT03865862 306 307 O
Doing NCT03865862 309 314 O
some NCT03865862 315 319 O
pharmacological NCT03865862 320 335 B-Drug
or NCT03865862 336 338 B-Or
physiotherapy NCT03865862 339 352 B-Procedure
treatment NCT03865862 353 362 I-Procedure
external NCT03865862 363 371 B-Other
to NCT03865862 372 374 I-Other
the NCT03865862 375 378 O
study NCT03865862 379 384 B-Study

- NCT03865862 387 388 O
Not NCT03865862 390 393 O
signed NCT03865862 394 400 O
the NCT03865862 401 404 O
informed NCT03865862 405 413 O
consent NCT03865862 414 421 O
document NCT03865862 422 430 O
. NCT03865862 430 431 O

Inclusion NCT03862664 0 9 O
Criteria NCT03862664 10 18 O
: NCT03862664 19 20 O

- NCT03862664 24 25 O
Excellent NCT03862664 27 36 O
general NCT03862664 37 44 O
physical NCT03862664 45 53 B-Modifier
and NCT03862664 54 57 B-And
mental NCT03862664 58 64 B-Modifier
condition NCT03862664 65 74 B-Condition
, NCT03862664 75 76 O

- NCT03862664 80 81 O
Free NCT03862664 83 87 B-Negation
of NCT03862664 88 90 I-Negation
chronic NCT03862664 91 98 B-Modifier
disease NCT03862664 99 106 B-Condition
or NCT03862664 107 109 B-Or

- NCT03862664 112 113 O
Previous NCT03862664 115 123 B-Eq-Comparison
major NCT03862664 124 129 O
abdominal NCT03862664 130 139 B-Procedure
surgery NCT03862664 140 147 I-Procedure
, NCT03862664 148 149 O

- NCT03862664 153 154 O
Body NCT03862664 156 160 B-Observation
mass NCT03862664 161 165 I-Observation
index NCT03862664 166 171 I-Observation
( NCT03862664 172 173 O
BMI NCT03862664 174 177 B-Observation
) NCT03862664 178 179 O
< NCT03862664 180 181 B-Eq-Comparison
28 NCT03862664 182 184 I-Eq-Comparison
, NCT03862664 185 186 O

- NCT03862664 191 192 O
ABO NCT03862664 194 197 B-Observation
blood NCT03862664 198 203 I-Observation
group NCT03862664 204 209 O
identical NCT03862664 210 219 O
to NCT03862664 220 222 O
recipients NCT03862664 223 233 O
and NCT03862664 234 237 B-And

- NCT03862664 240 241 O
Negative NCT03862664 243 251 O
for NCT03862664 252 255 O
hepatitis NCT03862664 256 265 B-Condition
B NCT03862664 266 267 B-Modifier
, NCT03862664 268 269 O
C NCT03862664 270 271 B-Modifier
and NCT03862664 272 275 B-Or
human NCT03862664 276 281 B-Condition
immunodeficiency NCT03862664 282 298 I-Condition
viruses NCT03862664 299 306 I-Condition
( NCT03862664 307 308 O
HIV NCT03862664 309 312 B-Condition
) NCT03862664 313 314 O
. NCT03862664 315 316 O

Exclusion NCT03862664 318 327 O
Criteria NCT03862664 328 336 O
: NCT03862664 337 338 O

- NCT03862664 342 343 O
ASA NCT03862664 345 348 B-Condition
physical NCT03862664 349 357 O
status NCT03862664 358 364 O
> NCT03862664 365 366 B-Eq-Comparison|Eq-Comparison
II NCT03862664 367 369 I-Eq-Comparison
, NCT03862664 370 371 O

- NCT03862664 375 376 O
BMI NCT03862664 378 381 B-Observation
> NCT03862664 382 383 O
28 NCT03862664 384 386 I-Eq-Comparison
, NCT03862664 387 388 O

- NCT03862664 393 394 O
Psychiatric NCT03862664 396 407 B-Modifier
or NCT03862664 408 410 B-Or
mental NCT03862664 411 417 B-Modifier
retardation NCT03862664 418 429 B-Condition
, NCT03862664 430 431 O

- NCT03862664 435 436 O
pregnant NCT03862664 438 446 B-Condition
and NCT03862664 447 450 B-Or
nursing NCT03862664 451 458 B-Condition
women NCT03862664 459 464 O
or NCT03862664 465 467 B-Or

- NCT03862664 470 471 O
Patients NCT03862664 473 481 O
with NCT03862664 482 486 O
significant NCT03862664 487 498 O
laboratory NCT03862664 499 509 B-Observation
abnormalities NCT03862664 510 523 O

Inclusion NCT03867708 0 9 O
Criteria NCT03867708 10 18 O
: NCT03867708 19 20 O

- NCT03867708 24 25 O
Patients NCT03867708 27 35 O
with NCT03867708 36 40 O
suitable NCT03867708 41 49 O
indication NCT03867708 50 60 B-Indication
for NCT03867708 61 64 O
ASD NCT03867708 65 68 B-Condition
closure NCT03867708 69 76 B-Procedure
according NCT03867708 77 86 O
to NCT03867708 87 89 O
recent NCT03867708 90 96 O
guidelines NCT03867708 97 107 O
: NCT03867708 108 109 O

1 NCT03867708 118 119 O
. NCT03867708 119 120 O
Impaired NCT03867708 122 130 B-Condition
functional NCT03867708 131 141 I-Condition
capacity NCT03867708 142 150 I-Condition
. NCT03867708 150 151 O

2 NCT03867708 160 161 O
. NCT03867708 161 162 O
Right NCT03867708 164 169 B-Modifier
atrial NCT03867708 170 176 I-Modifier
and NCT03867708 177 180 B-Or
/ NCT03867708 181 182 I-Or
or NCT03867708 183 185 I-Or
RV NCT03867708 186 188 B-Modifier
enlargement NCT03867708 189 200 B-Condition
. NCT03867708 200 201 O

3 NCT03867708 210 211 O
. NCT03867708 211 212 O
Left NCT03867708 214 218 B-Modifier
- NCT03867708 219 220 I-Modifier
to NCT03867708 221 223 I-Modifier
- NCT03867708 224 225 O
right NCT03867708 226 231 I-Modifier
shunt NCT03867708 232 237 B-Condition
with NCT03867708 238 242 B-And
[ NCT03867708 243 244 O
Qp NCT03867708 245 247 B-Observation
: NCT03867708 248 249 O
Qs NCT03867708 250 252 I-Observation
] NCT03867708 253 254 O
≥ NCT03867708 255 256 B-Eq-Comparison
1.5 NCT03867708 257 260 I-Eq-Comparison
: NCT03867708 261 262 O
1 NCT03867708 263 264 O
. NCT03867708 264 265 O

4 NCT03867708 274 275 O
. NCT03867708 275 276 O
Paradoxical NCT03867708 278 289 B-Condition
embolism NCT03867708 290 298 I-Condition
. NCT03867708 298 299 O

- NCT03867708 303 304 O
Patients NCT03867708 306 314 O
with NCT03867708 315 319 O
isolated NCT03867708 320 328 B-Modifier
secundum NCT03867708 329 337 I-Modifier
ASD NCT03867708 338 341 B-Condition
with NCT03867708 342 346 B-And
sufficient NCT03867708 347 357 O
rims NCT03867708 358 362 B-Observation
suitable NCT03867708 363 371 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867708 372 375 I-Assertion___Assertion-Type-Value:hypothetical
device NCT03867708 376 382 B-Procedure
closure NCT03867708 383 390 I-Procedure
. NCT03867708 390 391 O

Exclusion NCT03867708 393 402 O
Criteria NCT03867708 403 411 O
: NCT03867708 412 413 O

- NCT03867708 417 418 O
Small NCT03867708 420 425 B-Modifier
ASD NCT03867708 426 429 B-Condition
with NCT03867708 430 434 B-And
Qp NCT03867708 435 437 B-Observation
/ NCT03867708 438 439 I-Observation
Qs NCT03867708 440 442 I-Observation
< NCT03867708 443 444 B-Eq-Comparison
1.5 NCT03867708 445 448 I-Eq-Comparison
: NCT03867708 449 450 O
1 NCT03867708 451 452 O
or NCT03867708 453 455 B-Or
no NCT03867708 456 458 B-Negation
signs NCT03867708 459 464 B-Assertion___Assertion-Type-Value:possible
of NCT03867708 465 467 O
RV NCT03867708 468 470 B-Condition
volume NCT03867708 471 477 I-Condition
overload NCT03867708 478 486 I-Condition

- NCT03867708 489 490 O
A NCT03867708 492 493 O
single NCT03867708 494 500 B-Eq-Comparison
defect NCT03867708 501 507 B-Condition|Observation
too NCT03867708 508 511 B-Modifier
large NCT03867708 512 517 I-Modifier
for NCT03867708 518 521 O
closure NCT03867708 522 529 B-Procedure
( NCT03867708 530 531 O
> NCT03867708 533 534 B-Eq-Comparison
38 NCT03867708 535 537 I-Eq-Comparison
mm NCT03867708 538 540 I-Eq-Comparison
) NCT03867708 541 542 O

- NCT03867708 546 547 O
Multiple NCT03867708 549 557 B-Eq-Comparison
ASDs NCT03867708 558 562 B-Condition
unsuitable NCT03867708 563 573 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03867708 574 577 O
percutaneous NCT03867708 578 590 B-Procedure
closure NCT03867708 591 598 I-Procedure
. NCT03867708 598 599 O

- NCT03867708 603 604 O
Anterior NCT03867708 606 614 B-Modifier
, NCT03867708 615 616 O
posterior NCT03867708 617 626 B-Modifier
, NCT03867708 627 628 O
superior NCT03867708 629 637 B-Modifier
, NCT03867708 638 639 O
or NCT03867708 640 642 B-Or
inferior NCT03867708 643 651 B-Modifier
rim NCT03867708 652 655 B-Observation
< NCT03867708 656 657 B-Eq-Comparison
5 NCT03867708 658 659 I-Eq-Comparison
mm NCT03867708 660 662 I-Eq-Comparison
. NCT03867708 662 663 O

- NCT03867708 667 668 O
Abnormal NCT03867708 670 678 O
pulmonary NCT03867708 679 688 B-Condition
venous NCT03867708 689 695 I-Condition
drainage NCT03867708 696 704 I-Condition
. NCT03867708 704 705 O

- NCT03867708 709 710 O
Associated NCT03867708 712 722 O
structural NCT03867708 723 733 B-Modifier
heart NCT03867708 734 739 B-Condition
disease NCT03867708 740 747 I-Condition
requiring NCT03867708 748 757 B-Assertion___Assertion-Type-Value:hypothetical
cardiac NCT03867708 758 765 B-Procedure
surgery NCT03867708 766 773 I-Procedure
. NCT03867708 773 774 O

- NCT03867708 778 779 O
ASD NCT03867708 781 784 B-Condition
with NCT03867708 785 789 B-And
severe NCT03867708 790 796 O
pulmonary NCT03867708 797 806 B-Condition
arterial NCT03867708 807 815 I-Condition
hypertension NCT03867708 816 828 I-Condition
and NCT03867708 829 832 B-And
bidirectional NCT03867708 833 846 B-Modifier
or NCT03867708 847 849 B-Or
right NCT03867708 850 855 B-Modifier
- NCT03867708 856 857 I-Modifier
to NCT03867708 858 860 I-Modifier
- NCT03867708 861 862 O
left NCT03867708 863 867 I-Modifier
shunting NCT03867708 868 876 B-Condition
. NCT03867708 876 877 O

- NCT03867708 881 882 O
Intracardiac NCT03867708 884 896 B-Condition
thrombi NCT03867708 897 904 I-Condition
diagnosed NCT03867708 905 914 O
by NCT03867708 915 917 O
echocardiography NCT03867708 918 934 B-Procedure
. NCT03867708 934 935 O

Inclusion NCT03860701 0 9 O
Criteria NCT03860701 10 18 O
: NCT03860701 19 20 O

- NCT03860701 24 25 O
Patients NCT03860701 27 35 O
with NCT03860701 36 40 O
NEC NCT03860701 41 44 B-Condition
( NCT03860701 45 46 O
stages NCT03860701 47 53 B-Eq-Comparison
I NCT03860701 54 55 I-Eq-Comparison
- NCT03860701 56 57 I-Eq-Comparison
III NCT03860701 58 61 I-Eq-Comparison
Bell NCT03860701 62 66 O
's NCT03860701 66 68 O
Classification NCT03860701 69 83 O
) NCT03860701 84 85 O

- NCT03860701 89 90 O
Weight NCT03860701 92 98 B-Observation
greater NCT03860701 99 106 B-Eq-Comparison
or NCT03860701 107 109 I-Eq-Comparison
equal NCT03860701 110 115 I-Eq-Comparison
to NCT03860701 116 118 I-Eq-Comparison
750 NCT03860701 119 122 I-Eq-Comparison
g. NCT03860701 123 125 I-Eq-Comparison

- NCT03860701 129 130 O
Gestational NCT03860701 132 143 B-Observation
age NCT03860701 144 147 I-Observation
< NCT03860701 148 149 B-Eq-Comparison
36 NCT03860701 150 152 I-Eq-Comparison
weeks NCT03860701 153 158 I-Eq-Comparison
. NCT03860701 158 159 O

- NCT03860701 163 164 O
Patients NCT03860701 166 174 O
whose NCT03860701 175 180 O
parents NCT03860701 181 188 O
consent NCT03860701 189 196 O
to NCT03860701 197 199 O
participate NCT03860701 200 211 O
in NCT03860701 212 214 O
the NCT03860701 215 218 O
study NCT03860701 219 224 O
. NCT03860701 224 225 O

Exclusion NCT03860701 227 236 O
Criteria NCT03860701 237 245 O
: NCT03860701 246 247 O

- NCT03860701 251 252 O
Patients NCT03860701 254 262 O
with NCT03860701 263 267 O
major NCT03860701 268 273 O
congenital NCT03860701 274 284 B-Condition
anomalies NCT03860701 285 294 I-Condition

- NCT03860701 297 298 O
No NCT03860701 300 302 B-Negation
antecedent NCT03860701 303 313 B-Condition
of NCT03860701 314 316 O
limb NCT03860701 317 321 B-Modifier
ischemia NCT03860701 322 330 B-Condition
/ NCT03860701 331 332 B-Or
limb NCT03860701 333 337 B-Modifier
thrombotic NCT03860701 338 348 B-Condition
events NCT03860701 349 355 I-Condition
. NCT03860701 355 356 O

- NCT03860701 360 361 O
No NCT03860701 363 365 B-Negation
antecedent NCT03860701 366 376 B-Condition
diagnosis NCT03860701 377 386 O
of NCT03860701 387 389 O
occlusive NCT03860701 390 399 B-Modifier
arterial NCT03860701 400 408 I-Modifier
or NCT03860701 409 411 B-Or
venous NCT03860701 412 418 B-Modifier
thrombosis NCT03860701 419 429 B-Condition

- NCT03860701 432 433 O
Hemodynamic NCT03860701 435 446 B-Condition
instability NCT03860701 447 458 O

Inclusion NCT03867734 0 9 O
Criteria NCT03867734 10 18 O
: NCT03867734 19 20 O

- NCT03867734 24 25 O
Persons NCT03867734 27 34 O
diagnosed NCT03867734 35 44 O
with NCT03867734 45 49 O
pharyngeal NCT03867734 50 60 B-Modifier
gonorrhea NCT03867734 61 70 B-Condition
or NCT03867734 71 73 B-Or
gonococcal NCT03867734 74 84 B-Modifier
urethritis NCT03867734 85 95 B-Condition
who NCT03867734 96 99 B-And
are NCT03867734 100 103 O
undergoing NCT03867734 104 114 B-Eq-Comparison
pharyngeal NCT03867734 115 125 B-Procedure
gonorrhea NCT03867734 126 135 I-Procedure
testing NCT03867734 136 143 I-Procedure
, NCT03867734 144 145 O
who NCT03867734 146 149 B-And
are NCT03867734 150 153 O
not NCT03867734 154 157 B-Negation
yet NCT03867734 158 161 O
treated NCT03867734 162 169 B-Procedure
. NCT03867734 169 170 O

Exclusion NCT03867734 172 181 O
Criteria NCT03867734 182 190 O
: NCT03867734 191 192 O

- NCT03867734 196 197 O
Age NCT03867734 199 202 B-Age
less NCT03867734 203 207 B-Eq-Comparison
than NCT03867734 208 212 I-Eq-Comparison
16 NCT03867734 213 215 I-Eq-Comparison
years NCT03867734 216 221 I-Eq-Comparison

- NCT03867734 224 225 O
Receipt NCT03867734 227 234 O
of NCT03867734 235 237 O
antibiotics NCT03867734 238 249 B-Drug
in NCT03867734 250 252 O
≤ NCT03867734 253 254 B-Eq-Comparison
30 NCT03867734 255 257 I-Eq-Comparison
days NCT03867734 258 262 I-Eq-Comparison

- NCT03867734 265 266 O
Known NCT03867734 268 273 O
allergy NCT03867734 274 281 B-Allergy
to NCT03867734 282 284 O
aztreonam NCT03867734 285 294 B-Drug

- NCT03867734 297 298 O
History NCT03867734 300 307 B-Eq-Comparison
of NCT03867734 308 310 O
renal NCT03867734 311 316 B-Condition
disease NCT03867734 317 324 I-Condition
( NCT03867734 325 326 O
including NCT03867734 327 336 O
diagnosis NCT03867734 337 346 O
of NCT03867734 347 349 O
solitary NCT03867734 350 358 B-Condition
kidney NCT03867734 359 365 I-Condition
, NCT03867734 366 367 O
chronic NCT03867734 368 375 B-Modifier
renal NCT03867734 376 381 B-Condition
insufficiency NCT03867734 382 395 I-Condition
, NCT03867734 396 397 O
renal NCT03867734 398 403 B-Condition
cell NCT03867734 404 408 I-Condition
carcinoma NCT03867734 409 418 I-Condition
etc NCT03867734 419 422 O
. NCT03867734 422 423 O
) NCT03867734 424 425 O

- NCT03867734 429 430 O
Concurrent NCT03867734 432 442 B-Modifier
infection NCT03867734 443 452 B-Condition
with NCT03867734 453 457 O
syphilis NCT03867734 458 466 B-Condition
or NCT03867734 467 469 B-Or
chlamydia NCT03867734 470 479 B-Condition

- NCT03867734 482 483 O
Pregnancy NCT03867734 485 494 B-Condition
and NCT03867734 495 498 B-Or
/ NCT03867734 499 500 I-Or
or NCT03867734 501 503 I-Or
nursing NCT03867734 504 511 B-Condition

- NCT03867734 514 515 O
Unable NCT03867734 517 523 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03867734 524 526 O
return NCT03867734 527 533 O
for NCT03867734 534 537 O
a NCT03867734 538 539 O
follow NCT03867734 540 546 B-Encounter
- NCT03867734 547 548 I-Encounter|Eq-Comparison
up NCT03867734 549 551 I-Encounter
visit NCT03867734 552 557 I-Encounter
4 NCT03867734 558 559 B-Eq-Comparison
- NCT03867734 560 561 I-Eq-Comparison
7 NCT03867734 562 563 I-Eq-Comparison
days NCT03867734 564 568 I-Eq-Comparison|Eq-Comparison
( NCT03867734 569 570 O
+ NCT03867734 572 573 B-Eq-Comparison
/ NCT03867734 575 576 I-Eq-Comparison
- NCT03867734 578 579 O
1 NCT03867734 580 581 I-Eq-Comparison
day NCT03867734 582 585 O
) NCT03867734 586 587 O
. NCT03867734 588 589 O

- NCT03867734 593 594 O
Study NCT03867734 596 601 O
team NCT03867734 602 606 O
's NCT03867734 606 608 O
discretion NCT03867734 609 619 O

Inclusion NCT03861806 0 9 O
Criteria NCT03861806 10 18 O
: NCT03861806 19 20 O

- NCT03861806 24 25 O
Unilateral NCT03861806 27 37 B-Modifier
ischemic NCT03861806 38 46 I-Modifier
stroke NCT03861806 47 53 B-Condition
with NCT03861806 54 58 B-And
residual NCT03861806 59 67 B-Modifier
arm NCT03861806 68 71 I-Modifier
weakness NCT03861806 72 80 B-Condition
( NCT03861806 81 82 O
Fugl NCT03861806 83 87 B-Observation
- NCT03861806 88 89 I-Observation
Meyer NCT03861806 90 95 I-Observation
Upper NCT03861806 96 101 I-Observation
Limb NCT03861806 102 106 I-Observation
< NCT03861806 107 108 B-Eq-Comparison
60 NCT03861806 109 111 I-Eq-Comparison
) NCT03861806 112 113 O
more NCT03861806 114 118 B-Eq-Comparison
than NCT03861806 119 123 I-Eq-Comparison
6 NCT03861806 124 125 I-Eq-Comparison
months NCT03861806 126 132 I-Eq-Comparison
prior NCT03861806 133 138 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861806 139 141 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03861806 142 152 B-Study
. NCT03861806 152 153 O

- NCT03861806 157 158 O
Ability NCT03861806 160 167 O
to NCT03861806 168 170 O
give NCT03861806 171 175 O
informed NCT03861806 176 184 O
consent NCT03861806 185 192 O
and NCT03861806 193 196 O
understand NCT03861806 197 207 O
the NCT03861806 208 211 O
tasks NCT03861806 212 217 O
involved NCT03861806 218 226 O
. NCT03861806 226 227 O

- NCT03861806 231 232 O
Age NCT03861806 234 237 B-Age
over NCT03861806 238 242 B-Eq-Comparison
18 NCT03861806 243 245 I-Eq-Comparison
years NCT03861806 246 251 I-Eq-Comparison
. NCT03861806 251 252 O

Exclusion NCT03861806 254 263 O
Criteria NCT03861806 264 272 O
: NCT03861806 273 274 O

- NCT03861806 278 279 O
Hemorrhagic NCT03861806 281 292 B-Modifier
Stroke NCT03861806 293 299 B-Condition

- NCT03861806 302 303 O
Contraindications NCT03861806 305 322 B-Contraindication
to NCT03861806 323 325 O
TMS NCT03861806 326 329 B-Drug
: NCT03861806 330 331 O
history NCT03861806 332 339 B-Eq-Comparison
of NCT03861806 340 342 O
seizure NCT03861806 343 350 B-Condition
/ NCT03861806 351 352 B-Or
epilepsy NCT03861806 353 361 B-Condition
, NCT03861806 362 363 O
pacemaker NCT03861806 364 373 B-Procedure
, NCT03861806 374 375 O
other NCT03861806 376 381 B-Other
neurological NCT03861806 382 394 B-Condition
disorders NCT03861806 395 404 I-Condition
, NCT03861806 405 406 O
brain NCT03861806 407 412 B-Procedure
surgery NCT03861806 413 420 I-Procedure
, NCT03861806 421 422 O
metal NCT03861806 423 428 B-Procedure
implant NCT03861806 429 436 B-Modifier
/ NCT03861806 437 438 B-Or
fragment NCT03861806 439 447 B-Modifier
in NCT03861806 448 450 O
the NCT03861806 451 454 O
head NCT03861806 455 459 B-Modifier
, NCT03861806 460 461 O
pregnancy NCT03861806 462 471 B-Condition

- NCT03861806 474 475 O
Taking NCT03861806 477 483 B-Eq-Comparison
medications NCT03861806 484 495 B-Drug
or NCT03861806 496 498 B-Or
substances NCT03861806 499 509 B-Drug
that NCT03861806 510 514 O
are NCT03861806 515 518 O
known NCT03861806 519 524 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861806 525 527 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861806 528 534 O
PAS NCT03861806 535 538 B-Modifier
- NCT03861806 539 540 I-Modifier
induced NCT03861806 541 548 I-Modifier
plasticity NCT03861806 549 559 B-Condition
within NCT03861806 560 566 B-Eq-Comparison
the NCT03861806 567 570 I-Eq-Comparison
past NCT03861806 571 575 I-Eq-Comparison
2 NCT03861806 576 577 I-Eq-Comparison
months NCT03861806 578 584 I-Eq-Comparison
: NCT03861806 585 586 O
selective NCT03861806 587 596 O
serotonin NCT03861806 597 606 B-Drug
reuptake NCT03861806 607 615 I-Drug
inhibitors NCT03861806 616 626 I-Drug
, NCT03861806 627 628 O
dopamine NCT03861806 629 637 B-Drug|Drug
, NCT03861806 638 639 O
dopamine NCT03861806 640 648 O
agonists NCT03861806 649 657 I-Drug
, NCT03861806 658 659 O
haloperidol NCT03861806 660 671 B-Drug
, NCT03861806 672 673 O
lithium NCT03861806 674 681 B-Drug
, NCT03861806 682 683 O
acetylcholinesterase NCT03861806 684 704 B-Drug
inhibitors NCT03861806 705 715 I-Drug
, NCT03861806 716 717 O
beta NCT03861806 718 722 B-Drug
- NCT03861806 723 724 I-Drug
blockers NCT03861806 725 733 I-Drug
, NCT03861806 734 735 O
nimodipine NCT03861806 736 746 B-Drug
, NCT03861806 747 748 O
levetiracetam NCT03861806 749 762 B-Drug
, NCT03861806 763 764 O
ethosuximide NCT03861806 765 777 B-Drug
, NCT03861806 778 779 O
benzodiazepines NCT03861806 780 795 B-Drug
, NCT03861806 796 797 O
baclofen NCT03861806 798 806 B-Drug
, NCT03861806 807 808 O
nicotine NCT03861806 809 817 B-Drug

- NCT03861806 820 821 O
Peripheral NCT03861806 823 833 B-Modifier
neuropathy NCT03861806 834 844 B-Condition
or NCT03861806 845 847 B-Or
history NCT03861806 848 855 B-Eq-Comparison
of NCT03861806 856 858 O
nerve NCT03861806 859 864 B-Modifier
injury NCT03861806 865 871 B-Condition
in NCT03861806 872 874 O
the NCT03861806 875 878 O
paretic NCT03861806 879 886 B-Modifier
upper NCT03861806 887 892 I-Modifier
limb NCT03861806 893 897 I-Modifier
. NCT03861806 897 898 O

- NCT03861806 902 903 O
Social NCT03861806 905 911 B-Modifier
and NCT03861806 912 915 B-Or
/ NCT03861806 916 917 I-Or
or NCT03861806 918 920 I-Or
personal NCT03861806 921 929 B-Modifier
circumstances NCT03861806 930 943 B-Condition
that NCT03861806 944 948 O
interfere NCT03861806 949 958 O
with NCT03861806 959 963 O
ability NCT03861806 964 971 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861806 972 974 I-Assertion___Assertion-Type-Value:hypothetical
return NCT03861806 975 981 O
for NCT03861806 982 985 O
all NCT03861806 986 989 O
study NCT03861806 990 995 B-Study
visits NCT03861806 996 1002 O
. NCT03861806 1002 1003 O

Inclusion NCT03863977 0 9 O
Criteria NCT03863977 10 18 O
: NCT03863977 19 20 O

- NCT03863977 24 25 O
Patients NCT03863977 27 35 O
' NCT03863977 35 36 O
age NCT03863977 37 40 B-Age
from NCT03863977 41 45 O
18 NCT03863977 46 48 B-Eq-Comparison
to NCT03863977 49 51 I-Eq-Comparison
60 NCT03863977 52 54 I-Eq-Comparison
years NCT03863977 55 60 I-Eq-Comparison
old NCT03863977 61 64 O
, NCT03863977 65 66 O

- NCT03863977 70 71 O
physical NCT03863977 73 81 O
status NCT03863977 82 88 O
ASA NCT03863977 89 92 B-Condition
I NCT03863977 93 94 B-Eq-Comparison
- NCT03863977 95 96 I-Eq-Comparison
II NCT03863977 97 99 O
( NCT03863977 100 101 O
by NCT03863977 102 104 O
the NCT03863977 105 108 O
American NCT03863977 109 117 B-Condition
Society NCT03863977 118 125 I-Condition
of NCT03863977 126 128 I-Condition
Anesthesiologists NCT03863977 129 146 I-Condition
) NCT03863977 147 148 O
, NCT03863977 150 151 O

- NCT03863977 155 156 O
Elective NCT03863977 158 166 B-Modifier
unilateral NCT03863977 167 177 I-Modifier
open NCT03863977 178 182 I-Modifier
inguinal NCT03863977 183 191 B-Procedure
hernia NCT03863977 192 198 I-Procedure
repair NCT03863977 199 205 I-Procedure
, NCT03863977 206 207 O

- NCT03863977 211 212 O
Under NCT03863977 214 219 O
spinal NCT03863977 220 226 B-Procedure
anesthesia NCT03863977 227 237 I-Procedure

Exclusion NCT03863977 238 247 O
Criteria NCT03863977 248 256 O
: NCT03863977 257 258 O

- NCT03863977 262 263 O
age NCT03863977 265 268 B-Age
< NCT03863977 269 270 B-Eq-Comparison
18 NCT03863977 271 273 I-Eq-Comparison
or NCT03863977 274 276 B-Or
> NCT03863977 277 278 B-Eq-Comparison
60 NCT03863977 279 281 I-Eq-Comparison
, NCT03863977 282 283 O

- NCT03863977 288 289 O
American NCT03863977 291 299 B-Condition
society NCT03863977 300 307 I-Condition
of NCT03863977 308 310 I-Condition
anesthesiologist NCT03863977 311 327 I-Condition
( NCT03863977 328 329 O
ASA NCT03863977 330 333 B-Condition
) NCT03863977 334 335 O
class NCT03863977 336 341 B-Eq-Comparison
III NCT03863977 342 345 I-Eq-Comparison|Eq-Comparison
- NCT03863977 346 347 I-Eq-Comparison
IV NCT03863977 348 350 I-Eq-Comparison
, NCT03863977 351 352 O

- NCT03863977 356 357 O
known NCT03863977 359 364 O
allergy NCT03863977 365 372 B-Allergy
to NCT03863977 373 375 O
amino NCT03863977 376 381 B-Drug
amide NCT03863977 382 387 I-Drug
local NCT03863977 388 393 I-Drug
anesthetics NCT03863977 394 405 I-Drug
, NCT03863977 406 407 O

- NCT03863977 411 412 O
skin NCT03863977 414 418 B-Modifier
infection NCT03863977 419 428 B-Condition
and NCT03863977 429 432 B-Or
diseases NCT03863977 433 441 B-Condition
at NCT03863977 442 444 O
site NCT03863977 445 449 B-Modifier
of NCT03863977 450 452 O
injection NCT03863977 453 462 B-Procedure
. NCT03863977 462 463 O

- NCT03863977 467 468 O
coagulation NCT03863977 470 481 B-Condition
disorders NCT03863977 482 491 I-Condition
, NCT03863977 492 493 O

- NCT03863977 497 498 O
patients NCT03863977 500 508 O
with NCT03863977 509 513 O
body NCT03863977 514 518 B-Observation
mass NCT03863977 519 523 I-Observation
index NCT03863977 524 529 I-Observation
( NCT03863977 530 531 O
BMI NCT03863977 532 535 B-Observation
) NCT03863977 536 537 O
> NCT03863977 538 539 B-Eq-Comparison
35 NCT03863977 540 542 I-Eq-Comparison
kg NCT03863977 543 545 I-Eq-Comparison
/ NCT03863977 546 547 I-Eq-Comparison
m2 NCT03863977 548 550 I-Eq-Comparison
, NCT03863977 551 552 O

- NCT03863977 557 558 O
scrotal NCT03863977 560 567 B-Modifier
hernias NCT03863977 568 575 B-Condition
, NCT03863977 576 577 O

For NCT03869255 0 3 O
community NCT03869255 4 13 O
patients NCT03869255 14 22 O
: NCT03869255 23 24 O

Inclusion NCT03869255 26 35 O
Criteria NCT03869255 36 44 O
: NCT03869255 45 46 O

- NCT03869255 50 51 O
the NCT03869255 53 56 O
selection NCT03869255 57 66 B-Assertion___Assertion-Type-Value:hypothetical
criteria NCT03869255 67 75 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03869255 76 79 O
blood NCT03869255 80 85 B-Observation
donation NCT03869255 86 94 I-Observation

- NCT03869255 97 98 O
age NCT03869255 100 103 B-Age
≥ NCT03869255 104 105 B-Eq-Comparison
18 NCT03869255 106 108 I-Eq-Comparison
years NCT03869255 109 114 I-Eq-Comparison
old NCT03869255 115 118 O

- NCT03869255 121 122 O
No NCT03869255 124 126 O
refusal NCT03869255 127 134 O
of NCT03869255 135 137 O
the NCT03869255 138 141 O
person NCT03869255 142 148 O

Exclusion NCT03869255 149 158 O
Criteria NCT03869255 159 167 O
: NCT03869255 168 169 O

- NCT03869255 173 174 O
None NCT03869255 176 180 O

For NCT03869255 181 184 O
hospitalized NCT03869255 185 197 B-Encounter
patients NCT03869255 198 206 O
: NCT03869255 207 208 O

Inclusion NCT03869255 210 219 O
Criteria NCT03869255 220 228 O
: NCT03869255 229 230 O

- NCT03869255 234 235 O
age NCT03869255 237 240 B-Age
≥ NCT03869255 241 242 B-Eq-Comparison
18 NCT03869255 243 245 I-Eq-Comparison
years NCT03869255 246 251 I-Eq-Comparison
old NCT03869255 252 255 O

- NCT03869255 258 259 O
hospitalization NCT03869255 261 276 B-Encounter
in NCT03869255 277 279 O
one NCT03869255 280 283 O
of NCT03869255 284 286 O
the NCT03869255 287 290 O
services NCT03869255 291 299 O
participating NCT03869255 300 313 O
in NCT03869255 314 316 O
the NCT03869255 317 320 O
study NCT03869255 321 326 B-Study

- NCT03869255 329 330 O
no NCT03869255 332 334 O
refusal NCT03869255 335 342 O
of NCT03869255 343 345 O
the NCT03869255 346 349 O
person NCT03869255 350 356 O

Exclusion NCT03869255 357 366 O
Criteria NCT03869255 367 375 O
: NCT03869255 376 377 O

- NCT03869255 381 382 O
None NCT03869255 384 388 O

Inclusion NCT03864003 0 9 O
Criteria NCT03864003 10 18 O
: NCT03864003 19 20 O

- NCT03864003 24 25 O
Bilateral NCT03864003 27 36 B-Modifier
hearing NCT03864003 37 44 B-Condition
loss NCT03864003 45 49 I-Condition
within NCT03864003 50 56 O
the NCT03864003 57 60 O
fitting NCT03864003 61 68 O
range NCT03864003 69 74 O
of NCT03864003 75 77 O
study NCT03864003 78 83 B-Study
hearing NCT03864003 84 91 B-Procedure
aids NCT03864003 92 96 I-Procedure

Exclusion NCT03864003 97 106 O
Criteria NCT03864003 107 115 O
: NCT03864003 116 117 O

- NCT03864003 121 122 O
Medically NCT03864003 124 133 O
unqualified NCT03864003 134 145 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864003 146 148 O
receive NCT03864003 149 156 O
hearing NCT03864003 157 164 B-Procedure
aids NCT03864003 165 169 I-Procedure

- NCT03864003 172 173 O
Current NCT03864003 175 182 B-Eq-Comparison
hearing NCT03864003 183 190 B-Procedure
aid NCT03864003 191 194 I-Procedure
user NCT03864003 195 199 O

- NCT03864003 202 203 O
Cognitively NCT03864003 205 216 B-Condition
impaired NCT03864003 217 225 I-Condition

Inclusion NCT03868163 0 9 O
Criteria NCT03868163 10 18 O
: NCT03868163 19 20 O

- NCT03868163 24 25 O
Treatment NCT03868163 27 36 B-Procedure
- NCT03868163 37 38 O
naïve NCT03868163 39 44 B-Negation
or NCT03868163 45 47 B-Or
- NCT03868163 48 49 O
pegIFN NCT03868163 50 56 B-Drug
( NCT03868163 57 58 O
or NCT03868163 59 61 B-Or
IFN NCT03868163 62 65 B-Drug
) NCT03868163 66 67 O
, NCT03868163 69 70 O
and NCT03868163 71 74 B-Or
/ NCT03868163 75 76 I-Or
or NCT03868163 77 79 I-Or
Ribavirin NCT03868163 80 89 B-Drug
( NCT03868163 90 91 O
RBV NCT03868163 92 95 B-Drug
) NCT03868163 96 97 O
and NCT03868163 98 101 B-Or
/ NCT03868163 102 103 I-Or
or NCT03868163 104 106 I-Or
sofosbuvir NCT03868163 107 117 B-Drug
( NCT03868163 118 119 O
PRS NCT03868163 120 123 B-Drug
) NCT03868163 124 125 O
experienced NCT03868163 126 137 B-Eq-Comparison
with NCT03868163 138 142 B-And
confirmed NCT03868163 143 152 O
CHC NCT03868163 153 156 B-Condition
, NCT03868163 157 158 O
genotypes NCT03868163 159 168 B-Modifier
1 NCT03868163 169 170 B-Modifier
, NCT03868163 171 172 O
2 NCT03868163 173 174 B-Modifier
, NCT03868163 175 176 O
3 NCT03868163 177 178 B-Modifier
, NCT03868163 179 180 O
4 NCT03868163 181 182 B-Modifier
, NCT03868163 183 184 O
5 NCT03868163 185 186 B-Modifier
, NCT03868163 187 188 O
or NCT03868163 189 191 B-Or|Or
6 NCT03868163 192 193 B-Modifier
, NCT03868163 194 195 O
with NCT03868163 196 200 B-And|Negation
or NCT03868163 201 203 O
without NCT03868163 204 211 O
compensated NCT03868163 212 223 B-Modifier
cirrhosis NCT03868163 224 233 B-Condition
, NCT03868163 234 235 O
receiving NCT03868163 236 245 B-Eq-Comparison
combination NCT03868163 246 257 B-Procedure
therapy NCT03868163 258 265 I-Procedure
with NCT03868163 266 270 O
the NCT03868163 271 274 O
all NCT03868163 275 278 O
oral NCT03868163 279 283 B-Drug
GLE NCT03868163 284 287 I-Drug
/ NCT03868163 288 289 B-Or
PIB NCT03868163 290 293 B-Drug
regimen NCT03868163 294 301 O
according NCT03868163 302 311 O
to NCT03868163 312 314 O
standard NCT03868163 315 323 O
of NCT03868163 324 326 O
care NCT03868163 327 331 O
, NCT03868163 332 333 O
international NCT03868163 334 347 O
guidelines NCT03868163 348 358 O
and NCT03868163 359 362 O
in NCT03868163 363 365 O
line NCT03868163 366 370 O
with NCT03868163 371 375 O
the NCT03868163 376 379 O
current NCT03868163 380 387 O
local NCT03868163 388 393 O
label NCT03868163 394 399 O
. NCT03868163 399 400 O

- NCT03868163 404 405 O
May NCT03868163 407 410 O
be NCT03868163 411 413 O
enrolled NCT03868163 414 422 O
up NCT03868163 423 425 B-Eq-Comparison
to NCT03868163 426 428 I-Eq-Comparison
4 NCT03868163 429 430 I-Eq-Comparison
weeks NCT03868163 431 436 I-Eq-Comparison
after NCT03868163 437 442 B-Temporal-Connection___Temporal-Connection-Type-Value:after
treatment NCT03868163 443 452 B-Procedure
initiation NCT03868163 453 463 B-Eq-Comparison
. NCT03868163 463 464 O

- NCT03868163 468 469 O
Patients NCT03868163 471 479 O
must NCT03868163 480 484 O
voluntarily NCT03868163 485 496 O
sign NCT03868163 497 501 O
and NCT03868163 502 505 O
date NCT03868163 506 510 O
Informed NCT03868163 511 519 O
Consent NCT03868163 520 527 O
Form NCT03868163 528 532 O
prior NCT03868163 533 538 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868163 539 541 O
inclusion NCT03868163 542 551 O
into NCT03868163 552 556 O
the NCT03868163 557 560 O
study NCT03868163 561 566 B-Study
. NCT03868163 566 567 O

- NCT03868163 571 572 O
Patient NCT03868163 574 581 O
must NCT03868163 582 586 O
not NCT03868163 587 590 B-Negation
be NCT03868163 591 593 O
participating NCT03868163 594 607 O
or NCT03868163 608 610 O
intending NCT03868163 611 620 O
to NCT03868163 621 623 O
participate NCT03868163 624 635 O
in NCT03868163 636 638 O
a NCT03868163 639 640 O
concurrent NCT03868163 641 651 O
interventional NCT03868163 652 666 O
therapeutic NCT03868163 667 678 B-Procedure
trial NCT03868163 679 684 B-Study
. NCT03868163 684 685 O

Exclusion NCT03868163 687 696 O
Criteria NCT03868163 697 705 O
: NCT03868163 706 707 O

- NCT03868163 711 712 O
None NCT03868163 714 718 O
. NCT03868163 718 719 O

Inclusion NCT03868605 0 9 O
Criteria NCT03868605 10 18 O
: NCT03868605 19 20 O

- NCT03868605 24 25 O
age NCT03868605 27 30 B-Age
≥ NCT03868605 31 32 B-Eq-Comparison
18 NCT03868605 33 35 I-Eq-Comparison
years NCT03868605 36 41 I-Eq-Comparison

- NCT03868605 44 45 O
colorectal NCT03868605 47 57 B-Modifier
lesions NCT03868605 58 65 B-Condition|Observation
of NCT03868605 66 68 O
10 NCT03868605 69 71 B-Eq-Comparison
- NCT03868605 72 73 I-Eq-Comparison
25 NCT03868605 74 76 I-Eq-Comparison
mm NCT03868605 77 79 I-Eq-Comparison
size NCT03868605 80 84 O
with NCT03868605 85 89 B-And
positive NCT03868605 90 98 O
non NCT03868605 99 102 B-Negation
- NCT03868605 103 104 O
lifting NCT03868605 105 112 B-Modifier
sign NCT03868605 113 117 B-Condition

- NCT03868605 120 121 O
signed NCT03868605 123 129 O
informed NCT03868605 130 138 O
consent NCT03868605 139 146 O
with NCT03868605 147 151 O
the NCT03868605 152 155 O
study NCT03868605 156 161 B-Study
and NCT03868605 162 165 O
with NCT03868605 166 170 O
colonoscopy NCT03868605 171 182 B-Procedure

Exclusion NCT03868605 183 192 O
Criteria NCT03868605 193 201 O
: NCT03868605 202 203 O

- NCT03868605 207 208 O
age NCT03868605 210 213 B-Age
< NCT03868605 214 215 B-Eq-Comparison
18 NCT03868605 216 218 I-Eq-Comparison
years NCT03868605 219 224 I-Eq-Comparison

- NCT03868605 227 228 O
lesions NCT03868605 230 237 B-Condition|Observation
> NCT03868605 238 239 B-Eq-Comparison
25 NCT03868605 240 242 I-Eq-Comparison
mm NCT03868605 243 245 I-Eq-Comparison

- NCT03868605 248 249 O
pedunculated NCT03868605 251 263 B-Condition
polyps NCT03868605 264 270 I-Condition

- NCT03868605 273 274 O
colorectal NCT03868605 276 286 B-Condition
stenosis NCT03868605 287 295 I-Condition

- NCT03868605 298 299 O
colonoscopy NCT03868605 301 312 B-Procedure
contraindication NCT03868605 313 329 B-Contraindication

- NCT03868605 332 333 O
severe NCT03868605 335 341 O
acute NCT03868605 342 347 O
inflammatory NCT03868605 348 360 B-Condition
bowel NCT03868605 361 366 I-Condition
disease NCT03868605 367 374 I-Condition

- NCT03868605 377 378 O
severe NCT03868605 380 386 O
comorbidities NCT03868605 387 400 B-Condition

- NCT03868605 403 404 O
patient NCT03868605 406 413 O
not NCT03868605 414 417 O
able NCT03868605 418 422 O
to NCT03868605 423 425 O
sign NCT03868605 426 430 O
the NCT03868605 431 434 O
informed NCT03868605 435 443 O
consent NCT03868605 444 451 O

Inclusion NCT03860259 0 9 O
Criteria NCT03860259 10 18 O
: NCT03860259 19 20 O

1 NCT03860259 24 25 O
. NCT03860259 25 26 O
Subject NCT03860259 28 35 O
is NCT03860259 36 38 O
greater NCT03860259 39 46 B-Eq-Comparison
than NCT03860259 47 51 I-Eq-Comparison
18 NCT03860259 52 54 I-Eq-Comparison
years NCT03860259 55 60 I-Eq-Comparison
of NCT03860259 61 63 O
age NCT03860259 64 67 B-Age

2 NCT03860259 70 71 O
. NCT03860259 71 72 O
Subject NCT03860259 74 81 O
is NCT03860259 82 84 O
willing NCT03860259 85 92 O
and NCT03860259 93 96 O
able NCT03860259 97 101 O
to NCT03860259 102 104 O
provide NCT03860259 105 112 O
informed NCT03860259 113 121 O
consent NCT03860259 122 129 O

3 NCT03860259 132 133 O
. NCT03860259 133 134 O
Subject NCT03860259 136 143 O
is NCT03860259 144 146 O
scheduled NCT03860259 147 156 B-Eq-Comparison
to NCT03860259 157 159 O
undergo NCT03860259 160 167 O
elective NCT03860259 168 176 B-Modifier
rotator NCT03860259 177 184 B-Procedure
cuff NCT03860259 185 189 I-Procedure
surgery NCT03860259 190 197 I-Procedure

4 NCT03860259 200 201 O
. NCT03860259 201 202 O
Subject NCT03860259 204 211 O
has NCT03860259 212 215 O
consented NCT03860259 216 225 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860259 226 228 I-Assertion___Assertion-Type-Value:hypothetical
an NCT03860259 229 231 O
interscalene NCT03860259 232 244 B-Procedure
block NCT03860259 245 250 I-Procedure

Exclusion NCT03860259 251 260 O
Criteria NCT03860259 261 269 O
: NCT03860259 270 271 O

1 NCT03860259 275 276 O
. NCT03860259 276 277 O
Opioid NCT03860259 279 285 B-Condition
dependence NCT03860259 286 296 I-Condition

2 NCT03860259 299 300 O
. NCT03860259 300 301 O
Any NCT03860259 303 306 O
subject NCT03860259 307 314 O
diagnosed NCT03860259 315 324 O
with NCT03860259 325 329 O
a NCT03860259 330 331 O
chronic NCT03860259 332 339 B-Modifier
pain NCT03860259 340 344 B-Condition
condition NCT03860259 345 354 I-Condition
which NCT03860259 355 360 O
daily NCT03860259 361 366 B-Eq-Comparison
opioid NCT03860259 367 373 B-Drug
use NCT03860259 374 377 O
is NCT03860259 378 380 O
needed NCT03860259 381 387 O

3 NCT03860259 390 391 O
. NCT03860259 391 392 O
Anatomical NCT03860259 394 404 B-Condition
malformation NCT03860259 405 417 I-Condition
, NCT03860259 418 419 O
which NCT03860259 420 425 O
in NCT03860259 426 428 O
the NCT03860259 429 432 O
investigator NCT03860259 433 445 O
's NCT03860259 445 447 O
opinion NCT03860259 448 455 O
may NCT03860259 456 459 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860259 460 469 O
with NCT03860259 470 474 O
the NCT03860259 475 478 O
placement NCT03860259 479 488 O
of NCT03860259 489 491 O
the NCT03860259 492 495 O
nerve NCT03860259 496 501 B-Procedure
block NCT03860259 502 507 I-Procedure

4 NCT03860259 510 511 O
. NCT03860259 511 512 O
Raynaud NCT03860259 514 521 B-Condition
's NCT03860259 521 523 O
disease NCT03860259 524 531 I-Condition
diagnosis NCT03860259 532 541 O

5 NCT03860259 544 545 O
. NCT03860259 545 546 O
Vasculopathy NCT03860259 548 560 B-Condition

6 NCT03860259 563 564 O
. NCT03860259 564 565 O
Patient NCT03860259 567 574 O
refusal NCT03860259 575 582 O

Inclusion NCT03869554 0 9 O
Criteria NCT03869554 10 18 O
: NCT03869554 19 20 O

- NCT03869554 24 25 O
Adult NCT03869554 27 32 O
patient NCT03869554 33 40 O
( NCT03869554 41 42 O
> NCT03869554 44 45 B-Eq-Comparison
18 NCT03869554 46 48 I-Eq-Comparison
years NCT03869554 49 54 I-Eq-Comparison
old NCT03869554 55 58 B-Age
) NCT03869554 59 60 O

- NCT03869554 64 65 O
Obtaining NCT03869554 67 76 O
consent NCT03869554 77 84 O
to NCT03869554 85 87 O
participate NCT03869554 88 99 O
in NCT03869554 100 102 O
the NCT03869554 103 106 O
study NCT03869554 107 112 O

- NCT03869554 115 116 O
Patients NCT03869554 118 126 O
whose NCT03869554 127 132 O
clinical NCT03869554 133 141 O
presentation NCT03869554 142 154 O
meets NCT03869554 155 160 O
at NCT03869554 161 163 B-Eq-Comparison
least NCT03869554 164 169 I-Eq-Comparison
one NCT03869554 170 173 I-Eq-Comparison
of NCT03869554 174 176 O
the NCT03869554 177 180 B-Criteria-Count
following NCT03869554 181 190 I-Criteria-Count
criteria NCT03869554 191 199 I-Criteria-Count
: NCT03869554 200 201 O

- NCT03869554 210 211 O
Undetermined NCT03869554 213 225 B-Modifier
nephropathy NCT03869554 226 237 B-Condition
despite NCT03869554 238 245 B-And
renal NCT03869554 246 251 B-Procedure
biopsy NCT03869554 252 258 I-Procedure
, NCT03869554 259 260 O

- NCT03869554 269 270 O
Nephroangiosclerosis NCT03869554 272 292 B-Condition
as NCT03869554 293 295 O
the NCT03869554 296 299 O
predominant NCT03869554 300 311 B-Modifier
lesion NCT03869554 312 318 B-Condition

- NCT03869554 326 327 O
Chronic NCT03869554 329 336 B-Modifier
tubulointerstitial NCT03869554 337 355 I-Modifier
nephropathy NCT03869554 356 367 B-Condition
, NCT03869554 368 369 O

- NCT03869554 378 379 O
Glomerulosclerosis NCT03869554 381 399 B-Condition
, NCT03869554 400 401 O

- NCT03869554 410 411 O
Segmental NCT03869554 413 422 B-Modifier
and NCT03869554 423 426 B-Or
focal NCT03869554 427 432 B-Modifier
hyalinosis NCT03869554 433 443 B-Condition
. NCT03869554 443 444 O

- NCT03869554 453 454 O
Optically NCT03869554 456 465 O
normal NCT03869554 466 472 O
kidney NCT03869554 473 479 B-Modifier
or NCT03869554 480 482 B-Or
seat NCT03869554 483 487 B-Modifier
of NCT03869554 488 490 I-Modifier
minimal NCT03869554 491 498 I-Modifier
lesions NCT03869554 499 506 B-Condition

Exclusion NCT03869554 507 516 O
Criteria NCT03869554 517 525 O
: NCT03869554 526 527 O

- NCT03869554 531 532 O
Patient NCT03869554 534 541 O
who NCT03869554 542 545 O
has NCT03869554 546 549 O
already NCT03869554 550 557 B-Eq-Comparison
been NCT03869554 558 562 O
screened NCT03869554 563 571 B-Procedure
for NCT03869554 572 575 O
Fabry NCT03869554 576 581 B-Condition
Disease NCT03869554 582 589 I-Condition

- NCT03869554 592 593 O
At NCT03869554 595 597 B-Eq-Comparison
least NCT03869554 598 603 I-Eq-Comparison
one NCT03869554 604 607 I-Eq-Comparison
of NCT03869554 608 610 O
the NCT03869554 611 614 B-Criteria-Count
following NCT03869554 615 624 I-Criteria-Count
criteria NCT03869554 625 633 I-Criteria-Count
: NCT03869554 634 635 O

- NCT03869554 644 645 O
Nephrotic NCT03869554 647 656 B-Condition
syndrome NCT03869554 657 665 I-Condition
and NCT03869554 666 669 B-Or
/ NCT03869554 670 671 I-Or
or NCT03869554 672 674 I-Or
Glomerular NCT03869554 675 685 B-Modifier
nephropathy NCT03869554 686 697 B-Condition

- NCT03869554 705 706 O
Histological NCT03869554 708 720 B-Procedure
diagnosis NCT03869554 721 730 O
of NCT03869554 731 733 O
certain NCT03869554 734 741 O
nephropathies NCT03869554 742 755 B-Condition
( NCT03869554 756 757 O
specific NCT03869554 758 766 O
kidney NCT03869554 767 773 B-Modifier
lesions NCT03869554 774 781 B-Condition
) NCT03869554 782 783 O

Inclusion NCT03865420 0 9 O
Criteria NCT03865420 10 18 O
: NCT03865420 19 20 O

- NCT03865420 24 25 O
Men NCT03865420 27 30 O
or NCT03865420 31 33 B-Or
women NCT03865420 34 39 O
of NCT03865420 40 42 O
any NCT03865420 43 46 O
race NCT03865420 47 51 O
or NCT03865420 52 54 O
ethnicity NCT03865420 55 64 O
aged NCT03865420 65 69 B-Age
18 NCT03865420 70 72 B-Eq-Comparison
or NCT03865420 73 75 I-Eq-Comparison
older NCT03865420 76 81 I-Eq-Comparison

- NCT03865420 84 85 O
No NCT03865420 87 89 B-Negation
symptoms NCT03865420 90 98 B-Assertion___Assertion-Type-Value:possible
of NCT03865420 99 101 O
ALS NCT03865420 102 105 B-Condition
or NCT03865420 106 108 B-Or
fronto NCT03865420 109 115 B-Modifier
- NCT03865420 116 117 I-Modifier
temporal NCT03865420 118 126 I-Modifier
dementia NCT03865420 127 135 B-Condition
at NCT03865420 136 138 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrollment NCT03865420 139 149 B-Study

- NCT03865420 152 153 O
Have NCT03865420 155 159 O
a NCT03865420 160 161 O
first NCT03865420 162 167 B-Family-Member
degree NCT03865420 168 174 I-Family-Member
relative NCT03865420 175 183 I-Family-Member
who NCT03865420 184 187 O
had NCT03865420 188 191 O
an NCT03865420 192 194 O
ALS NCT03865420 195 198 B-Condition
- NCT03865420 199 200 O
spectrum NCT03865420 201 209 O
diagnosis NCT03865420 210 219 O
with NCT03865420 220 224 B-And
a NCT03865420 225 226 O
confirmed NCT03865420 227 236 O
ALS NCT03865420 237 240 B-Condition
- NCT03865420 241 242 I-Condition
spectrum NCT03865420 243 251 I-Condition
gene NCT03865420 252 256 I-Condition
mutation NCT03865420 257 265 I-Condition
; NCT03865420 265 266 O
or NCT03865420 267 269 B-Or
already NCT03865420 270 277 B-Eq-Comparison
have NCT03865420 278 282 O
had NCT03865420 283 286 O
genetic NCT03865420 287 294 B-Procedure
testing NCT03865420 295 302 I-Procedure
and NCT03865420 303 306 B-And
have NCT03865420 307 311 O
tested NCT03865420 312 318 B-Observation
positive NCT03865420 319 327 O
for NCT03865420 328 331 O
an NCT03865420 332 334 O
ALS NCT03865420 335 338 B-Condition
- NCT03865420 339 340 I-Condition
spectrum NCT03865420 341 349 I-Condition
gene NCT03865420 350 354 I-Condition
mutation NCT03865420 355 363 I-Condition
. NCT03865420 363 364 O

- NCT03865420 368 369 O
Willing NCT03865420 371 378 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865420 379 381 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03865420 382 389 O
genetic NCT03865420 390 397 B-Procedure
testing NCT03865420 398 405 I-Procedure
with NCT03865420 406 410 O
option NCT03865420 411 417 O
of NCT03865420 418 420 O
whether NCT03865420 421 428 O
or NCT03865420 429 431 O
not NCT03865420 432 435 O
to NCT03865420 436 438 O
learn NCT03865420 439 444 O
results NCT03865420 445 452 O

- NCT03865420 455 456 O
Willing NCT03865420 458 465 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865420 466 468 I-Assertion___Assertion-Type-Value:hypothetical
travel NCT03865420 469 475 O
to NCT03865420 476 478 O
Columbia NCT03865420 479 487 O
University NCT03865420 488 498 O
Irving NCT03865420 499 505 O
Medical NCT03865420 506 513 O
Center NCT03865420 514 520 O
( NCT03865420 521 522 O
CUIMC NCT03865420 523 528 O
) NCT03865420 529 530 O
every NCT03865420 531 536 B-Eq-Comparison
6 NCT03865420 537 538 I-Eq-Comparison
- NCT03865420 539 540 I-Eq-Comparison
24 NCT03865420 541 543 I-Eq-Comparison
months NCT03865420 544 550 I-Eq-Comparison
for NCT03865420 551 554 O
study NCT03865420 555 560 B-Study
procedures NCT03865420 561 571 O

- NCT03865420 574 575 O
Capable NCT03865420 577 584 O
of NCT03865420 585 587 O
providing NCT03865420 588 597 O
informed NCT03865420 598 606 O
consent NCT03865420 607 614 O
and NCT03865420 615 618 O
following NCT03865420 619 628 O
study NCT03865420 629 634 O
procedures NCT03865420 635 645 O
, NCT03865420 646 647 O
or NCT03865420 648 650 O
has NCT03865420 651 654 O
a NCT03865420 655 656 O
legally NCT03865420 657 664 O
authorized NCT03865420 665 675 O
representative NCT03865420 676 690 O
who NCT03865420 691 694 O
is NCT03865420 695 697 O
able NCT03865420 698 702 O
to NCT03865420 703 705 O
consent NCT03865420 706 713 O
for NCT03865420 714 717 O
the NCT03865420 718 721 O
subject NCT03865420 722 729 O
. NCT03865420 729 730 O

Exclusion NCT03865420 732 741 O
Criteria NCT03865420 742 750 O
: NCT03865420 751 752 O

- NCT03865420 756 757 O
Known NCT03865420 759 764 O
HIV NCT03865420 765 768 B-Condition

- NCT03865420 771 772 O
Known NCT03865420 774 779 O
hepatitis NCT03865420 780 789 B-Condition
B NCT03865420 790 791 I-Condition

- NCT03865420 794 795 O
Known NCT03865420 797 802 O
hepatitis NCT03865420 803 812 B-Condition
C NCT03865420 813 814 I-Condition

Inclusion NCT03863938 0 9 O
Criteria NCT03863938 10 18 O
: NCT03863938 19 20 O

- NCT03863938 24 25 O
Healthy NCT03863938 27 34 B-Condition
adult NCT03863938 35 40 O
males NCT03863938 41 46 O
aged NCT03863938 47 51 B-Age
≥ NCT03863938 52 53 B-Eq-Comparison
19 NCT03863938 54 56 I-Eq-Comparison
years NCT03863938 57 62 I-Eq-Comparison
and NCT03863938 63 66 B-And
≤ NCT03863938 67 68 B-Eq-Comparison
50 NCT03863938 69 71 I-Eq-Comparison
years NCT03863938 72 77 I-Eq-Comparison

- NCT03863938 80 81 O
Body NCT03863938 83 87 B-Observation
weight NCT03863938 88 94 I-Observation
of NCT03863938 95 97 O
≥ NCT03863938 98 99 B-Eq-Comparison
55.0 NCT03863938 100 104 I-Eq-Comparison
kg NCT03863938 105 107 I-Eq-Comparison
and NCT03863938 108 111 B-And
≤ NCT03863938 112 113 B-Eq-Comparison
90.0 NCT03863938 114 118 I-Eq-Comparison
kg NCT03863938 119 121 I-Eq-Comparison
, NCT03863938 122 123 O
with NCT03863938 124 128 B-And
body NCT03863938 129 133 B-Observation
mass NCT03863938 134 138 I-Observation
index NCT03863938 139 144 I-Observation
( NCT03863938 145 146 O
BMI NCT03863938 147 150 B-Observation
) NCT03863938 151 152 O
of NCT03863938 153 155 O
≥ NCT03863938 156 157 B-Eq-Comparison
18.0 NCT03863938 158 162 I-Eq-Comparison
kg NCT03863938 163 165 I-Eq-Comparison
/ NCT03863938 166 167 I-Eq-Comparison
m2 NCT03863938 168 170 I-Eq-Comparison
and NCT03863938 171 174 B-And
≤ NCT03863938 175 176 B-Eq-Comparison
27.0 NCT03863938 177 181 I-Eq-Comparison
kg NCT03863938 182 184 I-Eq-Comparison
/ NCT03863938 185 186 I-Eq-Comparison
m2 NCT03863938 187 189 I-Eq-Comparison
at NCT03863938 190 192 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863938 193 196 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03863938 197 201 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863938 202 204 O
screening NCT03863938 205 214 B-Study

- NCT03863938 217 218 O
Helicobacter NCT03863938 220 232 B-Organism
pylori NCT03863938 233 239 I-Organism
negative NCT03863938 240 248 O

Exclusion NCT03863938 249 258 O
Criteria NCT03863938 259 267 O
: NCT03863938 268 269 O

- NCT03863938 273 274 O
Presence NCT03863938 276 284 B-Eq-Comparison
or NCT03863938 285 287 B-Or
history NCT03863938 288 295 B-Eq-Comparison
of NCT03863938 296 298 O
clinically NCT03863938 299 309 O
significant NCT03863938 310 321 O
diseases NCT03863938 322 330 B-Condition

- NCT03863938 333 334 O
Presence NCT03863938 336 344 B-Eq-Comparison
or NCT03863938 345 347 B-Or
history NCT03863938 348 355 B-Eq-Comparison
of NCT03863938 356 358 O
gastrointestinal NCT03863938 359 375 B-Condition
disorder NCT03863938 376 384 I-Condition
( NCT03863938 385 386 O
gastric NCT03863938 387 394 B-Condition
ulcer NCT03863938 395 400 I-Condition
, NCT03863938 401 402 O
GERD NCT03863938 403 407 B-Condition
, NCT03863938 408 409 O
Crohn NCT03863938 410 415 B-Condition
's NCT03863938 415 417 O
disease NCT03863938 418 425 I-Condition
, NCT03863938 426 427 O
etc NCT03863938 428 431 O
. NCT03863938 431 432 O
) NCT03863938 433 434 O

- NCT03863938 438 439 O
Hypersensitivity NCT03863938 441 457 B-Condition
to NCT03863938 458 460 O
drugs NCT03863938 461 466 B-Drug
containing NCT03863938 467 477 O
study NCT03863938 478 483 B-Study
drug NCT03863938 484 488 B-Drug
or NCT03863938 489 491 B-Or
proton NCT03863938 492 498 B-Drug
pump NCT03863938 499 503 I-Drug
inhibitor NCT03863938 504 513 I-Drug
and NCT03863938 514 517 B-Or
other NCT03863938 518 523 B-Other
drugs NCT03863938 524 529 B-Drug
( NCT03863938 530 531 O
aspirin NCT03863938 532 539 B-Drug
, NCT03863938 540 541 O
antibiotics NCT03863938 542 553 B-Drug
, NCT03863938 554 555 O
etc NCT03863938 556 559 O
. NCT03863938 559 560 O
) NCT03863938 561 562 O
or NCT03863938 563 565 B-Or
history NCT03863938 566 573 B-Eq-Comparison
of NCT03863938 574 576 O
clinically NCT03863938 577 587 O
significant NCT03863938 588 599 O
hypersensitivity NCT03863938 600 616 B-Condition

- NCT03863938 619 620 O
Serologic NCT03863938 622 631 B-Observation
test NCT03863938 632 636 I-Observation
positive NCT03863938 637 645 O

- NCT03863938 648 649 O
Abnormal NCT03863938 651 659 O
obstacle NCT03863938 660 668 O
to NCT03863938 669 671 O
insertion NCT03863938 672 681 B-Procedure
and NCT03863938 682 685 B-And
maintenance NCT03863938 686 697 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863938 698 700 O
pH NCT03863938 701 703 B-Procedure
meter NCT03863938 704 709 I-Procedure
catheter NCT03863938 710 718 I-Procedure

- NCT03863938 721 722 O
History NCT03863938 724 731 B-Eq-Comparison
of NCT03863938 732 734 O
drug NCT03863938 735 739 B-Condition
abuse NCT03863938 740 745 I-Condition

- NCT03863938 748 749 O
Excessive NCT03863938 751 760 O
caffeine NCT03863938 761 769 B-Drug
intake NCT03863938 770 776 O
or NCT03863938 777 779 B-Or
persistent NCT03863938 780 790 B-Modifier
alcohol NCT03863938 791 798 B-Drug
intake NCT03863938 799 805 O

- NCT03863938 808 809 O
Not NCT03863938 811 814 B-Negation
use NCT03863938 815 818 O
of NCT03863938 819 821 O
a NCT03863938 822 823 O
medically NCT03863938 824 833 O
acceptable NCT03863938 834 844 O
method NCT03863938 845 851 O
of NCT03863938 852 854 O
contraception NCT03863938 855 868 B-Procedure

Inclusion NCT03863509 0 9 O
Criteria NCT03863509 10 18 O
: NCT03863509 19 20 O

- NCT03863509 24 25 O
able NCT03863509 27 31 O
to NCT03863509 32 34 O
read NCT03863509 35 39 O
and NCT03863509 40 43 O
write NCT03863509 44 49 O
English NCT03863509 50 57 O

- NCT03863509 60 61 O
no NCT03863509 63 65 B-Negation
plans NCT03863509 66 71 B-Assertion___Assertion-Type-Value:intention
to NCT03863509 72 74 O
quit NCT03863509 75 79 B-Negation
smoking NCT03863509 80 87 B-Condition
and NCT03863509 88 91 B-Or
/ NCT03863509 92 93 I-Or
or NCT03863509 94 96 I-Or
e NCT03863509 97 98 B-Drug
- NCT03863509 99 100 I-Drug
cig NCT03863509 101 104 I-Drug
use NCT03863509 105 108 O
in NCT03863509 109 111 O
the NCT03863509 112 115 O
next NCT03863509 116 120 B-Eq-Comparison
month NCT03863509 121 126 I-Eq-Comparison

- NCT03863509 129 130 O
not NCT03863509 132 135 B-Negation
using NCT03863509 136 141 B-Eq-Comparison
cigars NCT03863509 142 148 B-Drug
/ NCT03863509 149 150 B-Or
smokeless NCT03863509 151 160 B-Drug
/ NCT03863509 161 162 B-Or
snus NCT03863509 163 167 B-Drug
tobacco NCT03863509 168 175 I-Drug
> NCT03863509 176 177 B-Eq-Comparison
/ NCT03863509 179 180 I-Eq-Comparison
= NCT03863509 182 183 I-Eq-Comparison
1 NCT03863509 184 185 I-Eq-Comparison
time NCT03863509 186 190 I-Eq-Comparison
per NCT03863509 191 194 I-Eq-Comparison
week NCT03863509 195 199 I-Eq-Comparison

- NCT03863509 202 203 O
having NCT03863509 205 211 O
a NCT03863509 212 213 O
stable NCT03863509 214 220 O
pattern NCT03863509 221 228 O
of NCT03863509 229 231 O
current NCT03863509 232 239 B-Eq-Comparison
product NCT03863509 240 247 B-Drug
use NCT03863509 248 251 I-Drug

- NCT03863509 254 255 O
able NCT03863509 257 261 B-Condition|Observation
to NCT03863509 262 264 I-Condition|Observation
walk NCT03863509 265 269 I-Condition|Observation
at NCT03863509 270 272 B-Eq-Comparison
least NCT03863509 273 278 I-Eq-Comparison
2 NCT03863509 279 280 I-Eq-Comparison
blocks NCT03863509 281 287 I-Eq-Comparison
without NCT03863509 288 295 B-Negation
assistance NCT03863509 296 306 B-Modifier
or NCT03863509 307 309 B-Or
stopping NCT03863509 310 318 B-Modifier

- NCT03863509 321 322 O
Specific NCT03863509 324 332 O
to NCT03863509 333 335 O
Exclusive NCT03863509 336 345 O
Smokers NCT03863509 346 353 B-Condition
: NCT03863509 354 355 O

- NCT03863509 364 365 O
smokes NCT03863509 367 373 B-Condition
daily NCT03863509 374 379 B-Eq-Comparison

- NCT03863509 387 388 O
> NCT03863509 390 391 O
/ NCT03863509 393 394 B-Eq-Comparison
= NCT03863509 396 397 I-Eq-Comparison
5 NCT03863509 398 399 I-Eq-Comparison
cigs NCT03863509 400 404 I-Drug|Eq-Comparison
/ NCT03863509 405 406 O
day NCT03863509 407 410 I-Eq-Comparison
for NCT03863509 411 414 O
last NCT03863509 415 419 B-Eq-Comparison
6 NCT03863509 420 421 I-Eq-Comparison
months NCT03863509 422 428 I-Eq-Comparison

- NCT03863509 436 437 I-Observation
< NCT03863509 439 440 B-Eq-Comparison
3 NCT03863509 441 442 I-Eq-Comparison
uses NCT03863509 443 447 O
E NCT03863509 448 449 B-Observation
- NCT03863509 450 451 O
cigs NCT03863509 452 456 I-Observation
in NCT03863509 457 459 O
lifetime NCT03863509 460 468 B-Eq-Comparison

- NCT03863509 476 477 O
> NCT03863509 479 480 B-Eq-Comparison
/ NCT03863509 482 483 I-Eq-Comparison
= NCT03863509 485 486 I-Eq-Comparison
5 NCT03863509 487 488 I-Eq-Comparison
ppm NCT03863509 489 492 I-Eq-Comparison
carbon NCT03863509 493 499 B-Observation
monoxide NCT03863509 500 508 I-Observation
( NCT03863509 509 510 O
CO NCT03863509 511 513 B-Observation
) NCT03863509 514 515 O

- NCT03863509 524 525 O
Cotinine NCT03863509 527 535 B-Observation
> NCT03863509 536 537 B-Eq-Comparison
100 NCT03863509 538 541 I-Eq-Comparison
ng NCT03863509 542 544 I-Eq-Comparison
/ NCT03863509 545 546 I-Eq-Comparison
ml NCT03863509 547 549 I-Eq-Comparison

- NCT03863509 552 553 O
Specific NCT03863509 555 563 O
to NCT03863509 564 566 O
Exclusive NCT03863509 567 576 B-Drug
E NCT03863509 577 578 O
- NCT03863509 579 580 I-Drug
cig NCT03863509 581 584 I-Drug
users NCT03863509 585 590 O
: NCT03863509 591 592 O

- NCT03863509 601 602 O
< NCT03863509 604 605 B-Eq-Comparison
/ NCT03863509 607 608 I-Eq-Comparison
= NCT03863509 610 611 I-Eq-Comparison
2 NCT03863509 612 613 I-Eq-Comparison
days NCT03863509 614 618 I-Eq-Comparison
per NCT03863509 619 622 I-Eq-Comparison
month NCT03863509 623 628 I-Eq-Comparison|Eq-Comparison
cigarette NCT03863509 629 638 B-Drug
use NCT03863509 639 642 O
for NCT03863509 643 646 O
last NCT03863509 647 651 B-Eq-Comparison
6 NCT03863509 652 653 I-Eq-Comparison
months NCT03863509 654 660 O

- NCT03863509 668 669 I-Drug
> NCT03863509 671 672 B-Eq-Comparison
/ NCT03863509 674 675 I-Eq-Comparison
= NCT03863509 677 678 I-Eq-Comparison
5 NCT03863509 679 680 I-Eq-Comparison
days NCT03863509 681 685 I-Eq-Comparison
per NCT03863509 686 689 I-Eq-Comparison
week NCT03863509 690 694 I-Eq-Comparison
E NCT03863509 695 696 B-Drug
- NCT03863509 697 698 O
cig NCT03863509 699 702 I-Drug
use NCT03863509 703 706 O
for NCT03863509 707 710 O
last NCT03863509 711 715 B-Eq-Comparison
3 NCT03863509 716 717 I-Eq-Comparison
months NCT03863509 718 724 I-Eq-Comparison

- NCT03863509 732 733 O
< NCT03863509 735 736 B-Eq-Comparison
/ NCT03863509 738 739 I-Eq-Comparison|Eq-Comparison
= NCT03863509 741 742 I-Eq-Comparison
4 NCT03863509 743 744 I-Eq-Comparison
ppm NCT03863509 745 748 I-Eq-Comparison
CO NCT03863509 749 751 B-Observation

- NCT03863509 759 760 O
Cotinine NCT03863509 762 770 B-Observation
> NCT03863509 771 772 B-Eq-Comparison|Eq-Comparison
100 NCT03863509 773 776 I-Eq-Comparison
ng NCT03863509 777 779 I-Eq-Comparison
/ NCT03863509 780 781 I-Eq-Comparison
ml NCT03863509 782 784 I-Eq-Comparison

- NCT03863509 787 788 O
Specific NCT03863509 790 798 O
to NCT03863509 799 801 O
Dual NCT03863509 802 806 O
users NCT03863509 807 812 O

- NCT03863509 820 821 O
> NCT03863509 823 824 B-Eq-Comparison
/ NCT03863509 826 827 I-Eq-Comparison
= NCT03863509 829 830 I-Eq-Comparison|Eq-Comparison
5 NCT03863509 831 832 I-Eq-Comparison|Eq-Comparison
cigs NCT03863509 833 837 I-Drug|Eq-Comparison
/ NCT03863509 838 839 O
day NCT03863509 840 843 I-Eq-Comparison|Eq-Comparison
for NCT03863509 844 847 O
last NCT03863509 848 852 B-Eq-Comparison|Eq-Comparison
6 NCT03863509 853 854 I-Eq-Comparison
months NCT03863509 855 861 I-Eq-Comparison|Eq-Comparison

- NCT03863509 869 870 I-Drug
> NCT03863509 872 873 B-Eq-Comparison
/ NCT03863509 875 876 I-Eq-Comparison
= NCT03863509 878 879 I-Eq-Comparison
5 NCT03863509 880 881 I-Eq-Comparison
days NCT03863509 882 886 O
per NCT03863509 887 890 I-Eq-Comparison
week NCT03863509 891 895 I-Eq-Comparison
E NCT03863509 896 897 B-Drug
- NCT03863509 898 899 O
cig NCT03863509 900 903 I-Drug
use NCT03863509 904 907 O
for NCT03863509 908 911 O
last NCT03863509 912 916 O
3 NCT03863509 917 918 I-Eq-Comparison
months NCT03863509 919 925 O

- NCT03863509 933 934 O
> NCT03863509 936 937 B-Eq-Comparison
/ NCT03863509 939 940 I-Eq-Comparison
= NCT03863509 942 943 O
5 NCT03863509 944 945 O
ppm NCT03863509 946 949 I-Eq-Comparison
CO NCT03863509 950 952 B-Observation

- NCT03863509 960 961 O
Continine NCT03863509 963 972 B-Observation
> NCT03863509 973 974 O
100 NCT03863509 975 978 I-Eq-Comparison|Eq-Comparison
ng NCT03863509 979 981 I-Eq-Comparison
/ NCT03863509 982 983 O
ml NCT03863509 984 986 I-Eq-Comparison

- NCT03863509 989 990 O
Specific NCT03863509 992 1000 O
to NCT03863509 1001 1003 O
Never NCT03863509 1004 1009 O
- NCT03863509 1010 1011 O
users NCT03863509 1012 1017 O

- NCT03863509 1025 1026 I-Drug
< NCT03863509 1028 1029 B-Eq-Comparison|Eq-Comparison
100 NCT03863509 1030 1033 O
cigarettes NCT03863509 1034 1044 B-Drug|Drug
in NCT03863509 1045 1047 O
a NCT03863509 1048 1049 O
lifetime NCT03863509 1050 1058 B-Eq-Comparison|Eq-Comparison
, NCT03863509 1059 1060 O
none NCT03863509 1061 1065 B-Eq-Comparison
for NCT03863509 1066 1069 O
> NCT03863509 1070 1071 B-Eq-Comparison
5 NCT03863509 1072 1073 I-Eq-Comparison
years NCT03863509 1074 1079 I-Eq-Comparison

- NCT03863509 1087 1088 O
< NCT03863509 1090 1091 B-Eq-Comparison|Eq-Comparison
3 NCT03863509 1092 1093 I-Eq-Comparison
E NCT03863509 1094 1095 B-Drug
- NCT03863509 1096 1097 O
cig NCT03863509 1098 1101 O
uses NCT03863509 1102 1106 O
in NCT03863509 1107 1109 O
a NCT03863509 1110 1111 O
lifetime NCT03863509 1112 1120 O

- NCT03863509 1128 1129 O
< NCT03863509 1131 1132 O
/ NCT03863509 1134 1135 I-Eq-Comparison|Eq-Comparison
= NCT03863509 1137 1138 I-Eq-Comparison
4 NCT03863509 1139 1140 I-Eq-Comparison
ppm NCT03863509 1141 1144 I-Eq-Comparison
CO NCT03863509 1145 1147 B-Observation

- NCT03863509 1155 1156 O
Continine NCT03863509 1158 1167 B-Observation
< NCT03863509 1168 1169 O
100 NCT03863509 1170 1173 I-Eq-Comparison
ng NCT03863509 1174 1176 I-Eq-Comparison
/ NCT03863509 1177 1178 O
ml NCT03863509 1179 1181 I-Eq-Comparison

Exclusion NCT03863509 1182 1191 O
Criteria NCT03863509 1192 1200 O
: NCT03863509 1201 1202 O

- NCT03863509 1206 1207 O
current NCT03863509 1209 1216 B-Eq-Comparison
use NCT03863509 1217 1220 O
of NCT03863509 1221 1223 O
a NCT03863509 1224 1225 O
smoking NCT03863509 1226 1233 B-Drug
cessation NCT03863509 1234 1243 I-Drug
medication NCT03863509 1244 1254 I-Drug

- NCT03863509 1257 1258 O
women NCT03863509 1260 1265 O
who NCT03863509 1266 1269 B-And|And
are NCT03863509 1270 1273 O
pregnant NCT03863509 1274 1282 B-Condition|Condition|Condition
or NCT03863509 1283 1285 B-Or
plan NCT03863509 1286 1290 B-Assertion___Assertion-Type-Value:intention
to NCT03863509 1291 1293 I-Assertion___Assertion-Type-Value:intention
get NCT03863509 1294 1297 O
pregnant NCT03863509 1298 1306 O
in NCT03863509 1307 1309 B-Observation
the NCT03863509 1310 1313 O
coming NCT03863509 1314 1320 B-Eq-Comparison
month NCT03863509 1321 1326 I-Eq-Comparison

- NCT03863509 1329 1330 O
women NCT03863509 1332 1337 O
who NCT03863509 1338 1341 O
might NCT03863509 1342 1347 B-Assertion___Assertion-Type-Value:possible
be NCT03863509 1348 1350 I-Assertion___Assertion-Type-Value:possible
pregnant NCT03863509 1351 1359 O

- NCT03863509 1362 1363 O
incarcerated NCT03863509 1365 1377 O
individuals NCT03863509 1378 1389 O

- NCT03863509 1392 1393 O
history NCT03863509 1395 1402 B-Eq-Comparison
of NCT03863509 1403 1405 O
sarcoidosis NCT03863509 1406 1417 B-Condition
in NCT03863509 1418 1420 B-Modifier
past NCT03863509 1421 1425 B-Eq-Comparison
5 NCT03863509 1426 1427 I-Eq-Comparison
years NCT03863509 1428 1433 I-Eq-Comparison
, NCT03863509 1434 1435 O
or NCT03863509 1436 1438 B-Or
active NCT03863509 1439 1445 B-Eq-Comparison
interstitial NCT03863509 1446 1458 O
lung NCT03863509 1459 1463 I-Modifier
/ NCT03863509 1464 1465 B-Or
pulmonary NCT03863509 1466 1475 B-Modifier
fibrosis NCT03863509 1476 1484 B-Condition

Inclusion NCT03860766 0 9 O
Criteria NCT03860766 10 18 O
: NCT03860766 19 20 O

- NCT03860766 24 25 O
Handball NCT03860766 27 35 B-Observation
players NCT03860766 36 43 I-Observation
; NCT03860766 43 44 O

- NCT03860766 47 48 O
Healthy NCT03860766 50 57 B-Condition
; NCT03860766 57 58 O

- NCT03860766 61 62 O
Participation NCT03860766 64 77 O
of NCT03860766 78 80 O
at NCT03860766 81 83 B-Eq-Comparison
least NCT03860766 84 89 I-Eq-Comparison
one NCT03860766 90 93 I-Eq-Comparison
official NCT03860766 94 102 B-Observation
match NCT03860766 103 108 I-Observation
in NCT03860766 109 111 O
the NCT03860766 112 115 O
last NCT03860766 116 120 B-Eq-Comparison
year NCT03860766 121 125 I-Eq-Comparison
and NCT03860766 126 129 B-And
attend NCT03860766 130 136 O
70 NCT03860766 137 139 B-Eq-Comparison
% NCT03860766 140 141 O
of NCT03860766 142 144 O
the NCT03860766 145 148 O
team NCT03860766 149 153 B-Observation
's NCT03860766 153 155 O
activities NCT03860766 156 166 I-Observation
during NCT03860766 167 173 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860766 174 177 O
current NCT03860766 178 185 B-Eq-Comparison
season NCT03860766 186 192 O
. NCT03860766 192 193 O

Exclusion NCT03860766 195 204 O
Criteria NCT03860766 205 213 O
: NCT03860766 214 215 O

- NCT03860766 219 220 O
musculoskeletal NCT03860766 222 237 B-Modifier
injury NCT03860766 238 244 B-Condition
in NCT03860766 245 247 O
the NCT03860766 248 251 O
last NCT03860766 252 256 B-Eq-Comparison
three NCT03860766 257 262 I-Eq-Comparison
months NCT03860766 263 269 I-Eq-Comparison
; NCT03860766 269 270 O

- NCT03860766 273 274 O
cardiovascular NCT03860766 276 290 B-Condition
diseases NCT03860766 291 299 I-Condition
; NCT03860766 299 300 O

- NCT03860766 303 304 O
use NCT03860766 306 309 O
of NCT03860766 310 312 O
anabolic NCT03860766 313 321 B-Modifier
, NCT03860766 322 323 O
anti NCT03860766 324 328 B-Modifier
- NCT03860766 329 330 I-Modifier
inflammatory NCT03860766 331 343 I-Modifier
and NCT03860766 344 347 B-Or
analgesic NCT03860766 348 357 B-Modifier
drugs NCT03860766 358 363 B-Drug
72 NCT03860766 364 366 B-Eq-Comparison
hours NCT03860766 367 372 I-Eq-Comparison
before NCT03860766 373 379 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860766 380 383 O
evaluations NCT03860766 384 395 B-Study
; NCT03860766 395 396 O

- NCT03860766 399 400 O
use NCT03860766 402 405 O
of NCT03860766 406 408 O
alcohol NCT03860766 409 416 B-Drug
and NCT03860766 417 420 B-Or
illicit NCT03860766 421 428 B-Drug
drugs NCT03860766 429 434 I-Drug
during NCT03860766 435 441 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860766 442 445 O
collection NCT03860766 446 456 B-Study
period NCT03860766 457 463 I-Study
; NCT03860766 463 464 O

Inclusion NCT03866317 0 9 O
Criteria NCT03866317 10 18 O
: NCT03866317 19 20 O

1 NCT03866317 24 25 O
. NCT03866317 25 26 O
Male NCT03866317 28 32 O
or NCT03866317 33 35 B-Or
female NCT03866317 36 42 O
subject NCT03866317 43 50 O
18 NCT03866317 51 53 B-Eq-Comparison
years NCT03866317 54 59 I-Eq-Comparison
of NCT03866317 60 62 I-Eq-Comparison
age NCT03866317 63 66 I-Age|Eq-Comparison
or NCT03866317 67 69 I-Eq-Comparison
older NCT03866317 70 75 I-Eq-Comparison

2 NCT03866317 78 79 O
. NCT03866317 79 80 O
Subjects NCT03866317 82 90 O
with NCT03866317 91 95 O
moderate NCT03866317 96 104 B-Eq-Comparison
to NCT03866317 105 107 I-Eq-Comparison
severe NCT03866317 108 114 I-Eq-Comparison
DLE NCT03866317 115 118 B-Condition
with NCT03866317 119 123 B-And
at NCT03866317 124 126 B-Eq-Comparison
least NCT03866317 127 132 I-Eq-Comparison
one NCT03866317 133 136 I-Eq-Comparison
active NCT03866317 137 143 B-Eq-Comparison
discoid NCT03866317 144 151 B-Modifier
target NCT03866317 152 158 I-Modifier
lesion NCT03866317 159 165 B-Condition|Observation
( NCT03866317 166 167 O
0.5 NCT03866317 168 171 B-Eq-Comparison
- NCT03866317 172 173 I-Eq-Comparison
1.0 NCT03866317 174 177 I-Eq-Comparison
cm2 NCT03866317 178 181 I-Eq-Comparison
) NCT03866317 182 183 O
, NCT03866317 185 186 O
with NCT03866317 187 191 B-And
CLASI NCT03866317 192 197 B-Observation
≥ NCT03866317 198 199 B-Eq-Comparison
5 NCT03866317 200 201 I-Eq-Comparison
. NCT03866317 201 202 O

3 NCT03866317 206 207 O
. NCT03866317 207 208 O
Willingness NCT03866317 210 221 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866317 222 224 O
subject NCT03866317 225 232 O
to NCT03866317 233 235 O
follow NCT03866317 236 242 O
all NCT03866317 243 246 O
study NCT03866317 247 252 B-Study
procedures NCT03866317 253 263 B-Procedure

4 NCT03866317 266 267 O
. NCT03866317 267 268 O
Willingness NCT03866317 270 281 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866317 282 284 I-Assertion___Assertion-Type-Value:hypothetical
avoid NCT03866317 285 290 B-Negation
excessive NCT03866317 291 300 O
exposure NCT03866317 301 309 O
of NCT03866317 310 312 O
diseased NCT03866317 313 321 B-Condition
areas NCT03866317 322 327 O
to NCT03866317 328 330 O
natural NCT03866317 331 338 B-Modifier
or NCT03866317 339 341 B-Or
artificial NCT03866317 342 352 B-Modifier
sunlight NCT03866317 353 361 I-Modifier

Exclusion NCT03866317 362 371 O
Criteria NCT03866317 372 380 O
: NCT03866317 381 382 O

1 NCT03866317 386 387 O
. NCT03866317 387 388 O
Pregnancy NCT03866317 390 399 B-Condition
or NCT03866317 400 402 B-Or
breast NCT03866317 403 409 B-Condition
feeding NCT03866317 410 417 I-Condition

2 NCT03866317 420 421 O
. NCT03866317 421 422 O
Any NCT03866317 424 427 O
condition NCT03866317 428 437 B-Condition
or NCT03866317 438 440 B-Or
therapy NCT03866317 441 448 B-Procedure
that NCT03866317 449 453 O
in NCT03866317 454 456 O
the NCT03866317 457 460 O
investigator NCT03866317 461 473 O
's NCT03866317 473 475 O
opinion NCT03866317 476 483 O
may NCT03866317 484 487 B-Assertion___Assertion-Type-Value:hypothetical
pose NCT03866317 488 492 O
a NCT03866317 493 494 O
risk NCT03866317 495 499 B-Risk
to NCT03866317 500 502 O
the NCT03866317 503 506 O
subject NCT03866317 507 514 O
or NCT03866317 515 517 B-Or
that NCT03866317 518 522 O
could NCT03866317 523 528 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03866317 529 538 O
with NCT03866317 539 543 O
any NCT03866317 544 547 O
evaluation NCT03866317 548 558 O
in NCT03866317 559 561 O
the NCT03866317 562 565 O
study NCT03866317 566 571 B-Study

3 NCT03866317 574 575 O
. NCT03866317 575 576 O
Systemic NCT03866317 578 586 B-Modifier
Lupus NCT03866317 587 592 B-Condition
Erythematosus NCT03866317 593 606 I-Condition
( NCT03866317 607 608 O
SLE NCT03866317 609 612 B-Condition
) NCT03866317 613 614 O
as NCT03866317 615 617 O
defined NCT03866317 618 625 O
by NCT03866317 626 628 O
ACR NCT03866317 629 632 O
criteria NCT03866317 633 641 O

4 NCT03866317 644 645 O
. NCT03866317 645 646 O
Known NCT03866317 648 653 O
hypersensitivity NCT03866317 654 670 B-Condition
to NCT03866317 671 673 O
any NCT03866317 674 677 O
of NCT03866317 678 680 O
the NCT03866317 681 684 O
constituents NCT03866317 685 697 B-Coreference
or NCT03866317 698 700 B-Or
excipients NCT03866317 701 711 B-Coreference
of NCT03866317 712 714 O
the NCT03866317 715 718 O
investigational NCT03866317 719 734 B-Study
product NCT03866317 735 742 B-Drug

5 NCT03866317 745 746 O
. NCT03866317 746 747 O
Use NCT03866317 749 752 B-Eq-Comparison
of NCT03866317 753 755 O
any NCT03866317 756 759 O
prescription NCT03866317 760 772 B-Modifier|Modifier
or NCT03866317 773 775 B-Or
non NCT03866317 776 779 B-Negation
- NCT03866317 780 781 O
prescription NCT03866317 782 794 O
medication NCT03866317 795 805 B-Drug
that NCT03866317 806 810 O
could NCT03866317 811 816 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03866317 817 826 O
with NCT03866317 827 831 O
efficacy NCT03866317 832 840 B-Procedure
evaluations NCT03866317 841 852 I-Procedure
in NCT03866317 853 855 O
the NCT03866317 856 859 O
study NCT03866317 860 865 B-Study

6 NCT03866317 868 869 O
. NCT03866317 869 870 O
Change NCT03866317 872 878 O
in NCT03866317 879 881 O
use NCT03866317 882 885 O
of NCT03866317 886 888 O
systemic NCT03866317 889 897 B-Modifier
DLE NCT03866317 898 901 B-Procedure
therapy NCT03866317 902 909 I-Procedure
, NCT03866317 910 911 O
e. NCT03866317 912 914 O
g. NCT03866317 915 917 O
systemic NCT03866317 919 927 B-Drug
corticosteroids NCT03866317 928 943 I-Drug
, NCT03866317 944 945 O
cyclosporine NCT03866317 946 958 B-Drug
A NCT03866317 959 960 I-Drug
, NCT03866317 961 962 O
azathioprine NCT03866317 963 975 B-Drug
, NCT03866317 976 977 O
mycophenolate NCT03866317 978 991 B-Drug
mofetil NCT03866317 992 999 I-Drug
, NCT03866317 1000 1001 O
in NCT03866317 1002 1004 O
the NCT03866317 1005 1008 O
past NCT03866317 1009 1013 B-Eq-Comparison
1 NCT03866317 1014 1015 I-Eq-Comparison
month NCT03866317 1016 1021 I-Eq-Comparison
. NCT03866317 1021 1022 O

7 NCT03866317 1026 1027 O
. NCT03866317 1027 1028 O
Use NCT03866317 1030 1033 B-Eq-Comparison
of NCT03866317 1034 1036 O
systemic NCT03866317 1037 1045 B-Modifier
pain NCT03866317 1046 1050 B-Condition
medications NCT03866317 1051 1062 B-Drug
, NCT03866317 1063 1064 O
e. NCT03866317 1065 1067 O
g. NCT03866317 1068 1070 O
oxycodone NCT03866317 1072 1081 B-Drug
in NCT03866317 1082 1084 O
the NCT03866317 1085 1088 O
past NCT03866317 1089 1093 B-Eq-Comparison
2 NCT03866317 1094 1095 I-Eq-Comparison
weeks NCT03866317 1096 1101 I-Eq-Comparison

8 NCT03866317 1104 1105 O
. NCT03866317 1105 1106 O
Participation NCT03866317 1108 1121 O
in NCT03866317 1122 1124 O
another NCT03866317 1125 1132 B-Other
clinical NCT03866317 1133 1141 O
research NCT03866317 1142 1150 O
study NCT03866317 1151 1156 B-Study
with NCT03866317 1157 1161 B-And|Eq-Comparison
an NCT03866317 1162 1164 O
investigational NCT03866317 1165 1180 B-Study
drug NCT03866317 1181 1185 B-Drug
within NCT03866317 1186 1192 O
4 NCT03866317 1193 1194 I-Eq-Comparison
weeks NCT03866317 1195 1200 I-Eq-Comparison
before NCT03866317 1201 1207 B-Temporal-Connection___Temporal-Connection-Type-Value:before
this NCT03866317 1208 1212 O
study NCT03866317 1213 1218 B-Study

9 NCT03866317 1221 1222 O
. NCT03866317 1222 1223 O
Use NCT03866317 1225 1228 B-Eq-Comparison
of NCT03866317 1229 1231 O
immune NCT03866317 1232 1238 B-Drug
- NCT03866317 1239 1240 I-Drug
suppressant NCT03866317 1241 1252 I-Drug
or NCT03866317 1253 1255 B-Or
other NCT03866317 1256 1261 B-Other
biological NCT03866317 1262 1272 B-Procedure
treatment NCT03866317 1273 1282 I-Procedure

10 NCT03866317 1284 1286 O
. NCT03866317 1286 1287 O
Starting NCT03866317 1289 1297 B-Eq-Comparison
antimalarial NCT03866317 1298 1310 B-Drug
medicine NCT03866317 1311 1319 I-Drug
after NCT03866317 1320 1325 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolling NCT03866317 1326 1335 O
in NCT03866317 1336 1338 O
the NCT03866317 1339 1342 O
study NCT03866317 1343 1348 B-Study
. NCT03866317 1348 1349 O
Subjects NCT03866317 1351 1359 O
who NCT03866317 1360 1363 O
are NCT03866317 1364 1367 O
already NCT03866317 1368 1375 B-Eq-Comparison
on NCT03866317 1376 1378 O
a NCT03866317 1379 1380 O
stable NCT03866317 1381 1387 O
dose NCT03866317 1388 1392 O
of NCT03866317 1393 1395 O
antimalarial NCT03866317 1396 1408 B-Drug
before NCT03866317 1409 1415 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866317 1416 1426 B-Study
, NCT03866317 1427 1428 O
may NCT03866317 1429 1432 O
continue NCT03866317 1433 1441 O
the NCT03866317 1442 1445 O
same NCT03866317 1446 1450 O
dose NCT03866317 1451 1455 O
. NCT03866317 1455 1456 O

11 NCT03866317 1459 1461 O
. NCT03866317 1461 1462 O
An NCT03866317 1464 1466 O
ongoing NCT03866317 1467 1474 B-Eq-Comparison
infection NCT03866317 1475 1484 B-Condition
. NCT03866317 1484 1485 O

Inclusion NCT03863535 0 9 O
Criteria NCT03863535 10 18 O
: NCT03863535 19 20 O

Type NCT03863535 22 26 B-Modifier
II NCT03863535 27 29 I-Modifier
diabetic NCT03863535 30 38 B-Condition
patients NCT03863535 39 47 O
, NCT03863535 48 49 O
18 NCT03863535 50 52 B-Eq-Comparison
years NCT03863535 53 58 I-Eq-Comparison
and NCT03863535 59 62 I-Eq-Comparison
older NCT03863535 63 68 I-Age|Eq-Comparison
, NCT03863535 69 70 O
were NCT03863535 71 75 O
included NCT03863535 76 84 O
if NCT03863535 85 87 O
the NCT03863535 88 91 O
participants NCT03863535 92 104 O
had NCT03863535 105 108 O
: NCT03863535 109 110 O

1 NCT03863535 114 115 O
. NCT03863535 115 116 O
severe NCT03863535 118 124 O
non NCT03863535 125 128 B-Negation
- NCT03863535 129 130 O
PDR NCT03863535 131 134 B-Condition
in NCT03863535 135 137 O
either NCT03863535 138 144 B-Modifier
eyes NCT03863535 145 149 I-Modifier
with NCT03863535 150 154 B-And|Negation
/ NCT03863535 155 156 B-Or
without NCT03863535 157 164 O
diabetic NCT03863535 165 173 B-Condition
macular NCT03863535 174 181 I-Condition
edema NCT03863535 182 187 I-Condition
; NCT03863535 187 188 O

2 NCT03863535 191 192 O
. NCT03863535 192 193 O
ETDRS NCT03863535 195 200 B-Modifier
letters NCT03863535 201 208 I-Modifier
- NCT03863535 209 210 I-Modifier
measured NCT03863535 211 219 I-Modifier
best NCT03863535 220 224 B-Observation
- NCT03863535 225 226 I-Observation
corrected NCT03863535 227 236 I-Observation
visual NCT03863535 237 243 I-Observation
acuity NCT03863535 244 250 I-Observation
( NCT03863535 251 252 O
BCVA NCT03863535 253 257 B-Observation
) NCT03863535 258 259 O
ranging NCT03863535 260 267 O
from NCT03863535 268 272 O
20 NCT03863535 273 275 B-Eq-Comparison
/ NCT03863535 276 277 I-Eq-Comparison
40 NCT03863535 278 280 I-Eq-Comparison
to NCT03863535 281 283 I-Eq-Comparison
20 NCT03863535 284 286 O
/ NCT03863535 287 288 O
320 NCT03863535 289 292 I-Eq-Comparison
Snellen NCT03863535 293 300 B-Modifier
equivalent NCT03863535 301 311 I-Modifier
; NCT03863535 311 312 O

3 NCT03863535 320 321 O
. NCT03863535 321 322 O
no NCT03863535 324 326 B-Negation
previous NCT03863535 327 335 B-Eq-Comparison
treatment NCT03863535 336 345 B-Procedure
( NCT03863535 346 347 O
of NCT03863535 348 350 O
any NCT03863535 351 354 O
type NCT03863535 355 359 O
) NCT03863535 360 361 O
in NCT03863535 362 364 O
either NCT03863535 365 371 B-Modifier
eye NCT03863535 372 375 I-Modifier
. NCT03863535 375 376 O

Exclusion NCT03863535 378 387 O
Criteria NCT03863535 388 396 O
: NCT03863535 397 398 O

1 NCT03863535 402 403 O
. NCT03863535 403 404 O
history NCT03863535 406 413 B-Eq-Comparison
of NCT03863535 414 416 I-Eq-Comparison
prior NCT03863535 417 422 I-Eq-Comparison
laser NCT03863535 423 428 B-Procedure
treatment NCT03863535 429 438 I-Procedure
or NCT03863535 439 441 B-Or
vitrectomy NCT03863535 442 452 B-Procedure
in NCT03863535 453 455 O
the NCT03863535 456 459 O
study NCT03863535 460 465 B-Study
eye NCT03863535 466 469 B-Modifier
; NCT03863535 469 470 O

2 NCT03863535 473 474 O
. NCT03863535 474 475 O
history NCT03863535 477 484 B-Eq-Comparison
of NCT03863535 485 487 O
thromboembolic NCT03863535 488 502 B-Condition
event NCT03863535 503 508 I-Condition
- NCT03863535 509 510 O
including NCT03863535 511 520 O
myocardial NCT03863535 521 531 B-Condition
infarction NCT03863535 532 542 I-Condition
or NCT03863535 543 545 B-Or
cerebral NCT03863535 546 554 B-Condition
vascular NCT03863535 555 563 I-Condition
accident NCT03863535 564 572 I-Condition
; NCT03863535 572 573 O

3 NCT03863535 576 577 O
. NCT03863535 577 578 O
major NCT03863535 580 585 O
surgery NCT03863535 586 593 B-Procedure
within NCT03863535 594 600 B-Eq-Comparison
the NCT03863535 601 604 I-Eq-Comparison
prior NCT03863535 605 610 I-Eq-Comparison
6 NCT03863535 611 612 I-Eq-Comparison
months NCT03863535 613 619 I-Eq-Comparison
or NCT03863535 620 622 B-Or
planned NCT03863535 623 630 B-Eq-Comparison
within NCT03863535 631 637 I-Eq-Comparison
the NCT03863535 638 641 I-Eq-Comparison
next NCT03863535 642 646 I-Eq-Comparison
28 NCT03863535 647 649 I-Eq-Comparison
days NCT03863535 650 654 I-Eq-Comparison
; NCT03863535 654 655 O

4 NCT03863535 658 659 O
. NCT03863535 659 660 O
history NCT03863535 662 669 B-Eq-Comparison
of NCT03863535 670 672 O
glaucoma NCT03863535 673 681 B-Condition
or NCT03863535 682 684 B-Or
ocular NCT03863535 685 691 B-Modifier
hypertension NCT03863535 692 704 B-Condition
; NCT03863535 704 705 O

5 NCT03863535 708 709 O
. NCT03863535 709 710 O
loss NCT03863535 712 716 B-Condition
of NCT03863535 717 719 I-Condition
vision NCT03863535 720 726 I-Condition
as NCT03863535 727 729 O
a NCT03863535 730 731 O
result NCT03863535 732 738 O
of NCT03863535 739 741 O
other NCT03863535 742 747 B-Other
causes NCT03863535 748 754 B-Condition
; NCT03863535 754 755 O

6 NCT03863535 758 759 O
. NCT03863535 759 760 O
history NCT03863535 762 769 B-Eq-Comparison
of NCT03863535 770 772 O
systemic NCT03863535 773 781 B-Modifier
corticosteroid NCT03863535 782 796 B-Procedure
therapy NCT03863535 797 804 I-Eq-Comparison|Procedure
within NCT03863535 805 811 B-Eq-Comparison
the NCT03863535 812 815 O
last NCT03863535 816 820 I-Eq-Comparison
3 NCT03863535 821 822 I-Eq-Comparison
months NCT03863535 823 829 I-Eq-Comparison
; NCT03863535 829 830 O

7 NCT03863535 833 834 O
. NCT03863535 834 835 O
severe NCT03863535 837 843 O
systemic NCT03863535 844 852 B-Modifier
disease NCT03863535 853 860 B-Condition
other NCT03863535 861 866 B-Exception
than NCT03863535 867 871 I-Exception
diabetes NCT03863535 872 880 B-Condition
mellitus NCT03863535 881 889 I-Condition
; NCT03863535 889 890 O

8 NCT03863535 893 894 O
. NCT03863535 894 895 O
known NCT03863535 897 902 O
coagulation NCT03863535 903 914 B-Condition
abnormalities NCT03863535 915 928 O
or NCT03863535 929 931 B-Or
current NCT03863535 932 939 B-Eq-Comparison
use NCT03863535 940 943 O
of NCT03863535 944 946 O
anticoagulative NCT03863535 947 962 B-Drug
medication NCT03863535 963 973 I-Drug
other NCT03863535 974 979 B-Exception
than NCT03863535 980 984 I-Exception
aspirin NCT03863535 985 992 B-Drug

9 NCT03863535 995 996 O
. NCT03863535 996 997 O
any NCT03863535 999 1002 O
condition NCT03863535 1003 1012 B-Condition
that NCT03863535 1013 1017 O
could NCT03863535 1018 1023 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03863535 1024 1030 O
followup NCT03863535 1031 1039 B-Encounter
or NCT03863535 1040 1042 B-Or
documentation NCT03863535 1043 1056 B-Observation
( NCT03863535 1057 1058 O
including NCT03863535 1059 1068 O
preretinal NCT03863535 1069 1079 B-Modifier
or NCT03863535 1080 1082 B-Or
vitreous NCT03863535 1083 1091 B-Modifier
hemorrhage NCT03863535 1092 1102 B-Condition
) NCT03863535 1103 1104 O
. NCT03863535 1105 1106 O


Inclusion NCT03868306 0 9 O
Criteria NCT03868306 10 18 O
: NCT03868306 19 20 O

- NCT03868306 24 25 O
All NCT03868306 27 30 O
patients NCT03868306 31 39 O
with NCT03868306 40 44 O
microcytic NCT03868306 45 55 B-Condition
hypochromic NCT03868306 56 67 I-Condition
anemia NCT03868306 68 74 I-Condition
( NCT03868306 75 76 O
according NCT03868306 77 86 O
to NCT03868306 87 89 O
WHO NCT03868306 90 93 O
, NCT03868306 94 95 O
MCV NCT03868306 96 99 B-Observation
less NCT03868306 100 104 B-Eq-Comparison
than NCT03868306 105 109 I-Eq-Comparison
80 NCT03868306 110 112 I-Eq-Comparison
fl NCT03868306 113 115 I-Eq-Comparison
and NCT03868306 116 119 B-And
HB NCT03868306 120 122 B-Observation
level NCT03868306 123 128 O
below NCT03868306 129 134 B-Eq-Comparison
the NCT03868306 135 138 I-Eq-Comparison
lower NCT03868306 139 144 I-Eq-Comparison
limit NCT03868306 145 150 I-Eq-Comparison
of NCT03868306 151 153 I-Eq-Comparison
normal NCT03868306 154 160 I-Eq-Comparison
value NCT03868306 161 166 I-Eq-Comparison
specified NCT03868306 167 176 O
by NCT03868306 177 179 O
age NCT03868306 180 183 O
and NCT03868306 184 187 O
gender NCT03868306 188 194 O
. NCT03868306 195 196 O

Exclusion NCT03868306 198 207 O
Criteria NCT03868306 208 216 O
: NCT03868306 217 218 O

- NCT03868306 222 223 O
Beta NCT03868306 225 229 B-Condition
thalassemia NCT03868306 230 241 I-Condition
major NCT03868306 242 247 I-Condition
patients NCT03868306 248 256 O
. NCT03868306 257 258 O

- NCT03868306 262 263 O
Chronic NCT03868306 265 272 B-Modifier
diseases NCT03868306 273 281 B-Condition
or NCT03868306 282 284 B-Or
infections NCT03868306 285 295 B-Condition
. NCT03868306 296 297 O

- NCT03868306 301 302 O
Lead NCT03868306 304 308 B-Condition
poisoning NCT03868306 309 318 I-Condition
. NCT03868306 319 320 O

- NCT03868306 324 325 O
Sideroblastic NCT03868306 327 340 B-Condition
anaemia NCT03868306 341 348 I-Condition
. NCT03868306 349 350 O

Inclusion NCT03867747 0 9 O
Criteria NCT03867747 10 18 O
: NCT03867747 19 20 O

- NCT03867747 24 25 O
Patients NCT03867747 27 35 O
with NCT03867747 36 40 O
structural NCT03867747 41 51 B-Modifier
heart NCT03867747 52 57 B-Condition
disease NCT03867747 58 65 I-Condition
and NCT03867747 66 69 B-Or
implantable NCT03867747 70 81 B-Procedure
cardioverter NCT03867747 82 94 I-Procedure
defibrillator NCT03867747 95 108 I-Procedure
( NCT03867747 109 110 O
ICD NCT03867747 111 114 B-Procedure
) NCT03867747 115 116 O

- NCT03867747 120 121 O
Age NCT03867747 123 126 B-Age
> NCT03867747 127 128 B-Eq-Comparison
18 NCT03867747 129 131 I-Eq-Comparison
years NCT03867747 132 137 I-Eq-Comparison

- NCT03867747 140 141 O
either NCT03867747 143 149 O

1 NCT03867747 157 158 O
. NCT03867747 158 159 O
Recurring NCT03867747 161 170 B-Modifier
symptomatic NCT03867747 171 182 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 183 194 B-Condition
ventricular NCT03867747 195 206 I-Condition
tachycardia NCT03867747 207 218 I-Condition
that NCT03867747 219 223 O
requires NCT03867747 224 232 B-Assertion___Assertion-Type-Value:hypothetical
ICD NCT03867747 233 236 B-Procedure
intervention NCT03867747 237 249 I-Procedure
( NCT03867747 250 251 O
e. NCT03867747 252 254 O
g. NCT03867747 255 257 O
shock NCT03867747 259 264 B-Modifier
or NCT03867747 265 267 B-Or
anti NCT03867747 268 272 B-Negation
- NCT03867747 273 274 O
tachycardia NCT03867747 275 286 B-Modifier
stimulation NCT03867747 287 298 B-Procedure
) NCT03867747 299 300 O
. NCT03867747 301 302 O
At NCT03867747 304 306 B-Eq-Comparison
least NCT03867747 307 312 I-Eq-Comparison
3 NCT03867747 313 314 I-Eq-Comparison
episodes NCT03867747 315 323 B-Coreference
within NCT03867747 324 330 B-Eq-Comparison
the NCT03867747 331 334 I-Eq-Comparison
3 NCT03867747 335 336 I-Eq-Comparison
months NCT03867747 337 343 I-Eq-Comparison
prior NCT03867747 344 349 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867747 350 352 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03867747 353 362 B-Study
or NCT03867747 363 365 B-Or

2 NCT03867747 373 374 O
. NCT03867747 374 375 O
induction NCT03867747 377 386 B-Procedure
of NCT03867747 387 389 O
symptomatic NCT03867747 390 401 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 402 413 B-Condition
ventricular NCT03867747 414 425 I-Condition
tachycardia NCT03867747 426 437 I-Condition
that NCT03867747 438 442 O
requires NCT03867747 443 451 B-Assertion___Assertion-Type-Value:hypothetical
ICD NCT03867747 452 455 B-Procedure
intervention NCT03867747 456 468 I-Procedure
( NCT03867747 469 470 O
e. NCT03867747 471 473 O
g. NCT03867747 474 476 O
shock NCT03867747 478 483 B-Modifier
or NCT03867747 484 486 B-Or
anti NCT03867747 487 491 B-Negation
- NCT03867747 492 493 O
tachycardia NCT03867747 494 505 B-Modifier
stimulation NCT03867747 506 517 B-Procedure
) NCT03867747 518 519 O
. NCT03867747 520 521 O
Induction NCT03867747 523 532 B-Procedure
triggered NCT03867747 533 542 O
by NCT03867747 543 545 O
ICD NCT03867747 546 549 B-Procedure
or NCT03867747 550 552 B-Or
during NCT03867747 553 559 B-Temporal-Connection___Temporal-Connection-Type-Value:during
electrophysiology NCT03867747 560 577 B-Procedure
studies NCT03867747 578 585 I-Procedure
( NCT03867747 586 587 O
EPS NCT03867747 588 591 B-Procedure
) NCT03867747 592 593 O
or NCT03867747 594 596 B-Or
both NCT03867747 597 601 B-Modifier
, NCT03867747 602 603 O
a NCT03867747 604 605 O
) NCT03867747 606 607 O
and NCT03867747 608 611 O
b NCT03867747 612 613 O
) NCT03867747 614 615 O

- NCT03867747 619 620 O
Refractory NCT03867747 622 632 B-Condition
to NCT03867747 633 635 O
antiarrhythmic NCT03867747 636 650 B-Procedure
combination NCT03867747 651 662 I-Procedure
therapy NCT03867747 663 670 I-Procedure

- NCT03867747 673 674 O
Beside NCT03867747 676 682 O
the NCT03867747 683 686 O
cardiac NCT03867747 687 694 B-Condition
conditions NCT03867747 695 705 I-Condition
: NCT03867747 706 707 O
No NCT03867747 708 710 B-Negation
competing NCT03867747 711 720 O
illness NCT03867747 721 728 B-Condition
that NCT03867747 729 733 O
would NCT03867747 734 739 B-Assertion___Assertion-Type-Value:hypothetical
additionally NCT03867747 740 752 O
limit NCT03867747 753 758 O
the NCT03867747 759 762 O
life NCT03867747 763 767 B-Observation
expectancy NCT03867747 768 778 I-Observation
to NCT03867747 779 781 O
less NCT03867747 782 786 B-Eq-Comparison
than NCT03867747 787 791 I-Eq-Comparison
6 NCT03867747 792 793 I-Eq-Comparison
months NCT03867747 794 800 I-Eq-Comparison

- NCT03867747 803 804 O
No NCT03867747 806 808 B-Negation
prior NCT03867747 809 814 B-Eq-Comparison
radiation NCT03867747 815 824 B-Procedure
therapy NCT03867747 825 832 I-Procedure
in NCT03867747 833 835 O
the NCT03867747 836 839 O
thorax NCT03867747 840 846 B-Modifier
area NCT03867747 847 851 I-Modifier

- NCT03867747 854 855 O
No NCT03867747 857 859 B-Negation
pregnancy NCT03867747 860 869 B-Condition
and NCT03867747 870 873 B-And
no NCT03867747 874 876 B-Negation
active NCT03867747 877 883 B-Eq-Comparison
breastfeeding NCT03867747 884 897 B-Condition

- NCT03867747 900 901 O
Ability NCT03867747 903 910 O
to NCT03867747 911 913 O
consent NCT03867747 914 921 O
and NCT03867747 922 925 O
consent NCT03867747 926 933 O
to NCT03867747 934 936 O
study NCT03867747 937 942 O
participation NCT03867747 943 956 O

Exclusion NCT03867747 957 966 O
Criteria NCT03867747 967 975 O
: NCT03867747 976 977 O

- NCT03867747 981 982 O
ICD NCT03867747 984 987 B-Condition|Procedure
electrode NCT03867747 988 997 I-Condition
malfunction NCT03867747 998 1009 I-Condition
of NCT03867747 1010 1012 O
ICD NCT03867747 1013 1016 O
readings NCT03867747 1017 1025 O
outside NCT03867747 1026 1033 O
reference NCT03867747 1034 1043 O
range NCT03867747 1044 1049 O

- NCT03867747 1052 1053 O
Lack NCT03867747 1055 1059 B-Negation
of NCT03867747 1060 1062 O
evidence NCT03867747 1063 1071 O
of NCT03867747 1072 1074 O
a NCT03867747 1075 1076 O
myocardial NCT03867747 1077 1087 B-Condition
scar NCT03867747 1088 1092 I-Condition
( NCT03867747 1093 1094 O
Computer NCT03867747 1095 1103 B-Procedure
tomography NCT03867747 1104 1114 I-Procedure|Procedure
or NCT03867747 1115 1117 B-Or
magnetic NCT03867747 1118 1126 B-Procedure
resonance NCT03867747 1127 1136 I-Procedure
tomography NCT03867747 1137 1147 O
for NCT03867747 1148 1151 O
MRI NCT03867747 1152 1155 B-Procedure
- NCT03867747 1156 1157 O
capable NCT03867747 1158 1165 O
ICD NCT03867747 1166 1169 B-Procedure
aggregates NCT03867747 1170 1180 I-Procedure
or NCT03867747 1181 1183 B-Or
electrophysiological NCT03867747 1184 1204 B-Observation
measurement NCT03867747 1205 1216 I-Observation
) NCT03867747 1217 1218 O

- NCT03867747 1222 1223 O
No NCT03867747 1225 1227 B-Negation
possible NCT03867747 1228 1236 B-Assertion___Assertion-Type-Value:hypothetical
induction NCT03867747 1237 1246 B-Procedure
of NCT03867747 1247 1249 O
symptomatic NCT03867747 1250 1261 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 1262 1273 B-Modifier
ventricular NCT03867747 1274 1285 B-Condition
tachycardia NCT03867747 1286 1297 I-Condition
non NCT03867747 1298 1301 B-Negation
- NCT03867747 1302 1303 O
persistent NCT03867747 1304 1314 B-Modifier|Modifier
or NCT03867747 1315 1317 B-Or
persistent NCT03867747 1318 1328 O
with NCT03867747 1329 1333 O
delivery NCT03867747 1334 1342 O
of NCT03867747 1343 1345 O
ICD NCT03867747 1346 1349 B-Procedure
therapies NCT03867747 1350 1359 I-Procedure
such NCT03867747 1360 1364 O
as NCT03867747 1365 1367 O
antitachycardic NCT03867747 1368 1383 B-Procedure
pacing NCT03867747 1384 1390 I-Procedure
or NCT03867747 1391 1393 B-Or
shock NCT03867747 1394 1399 B-Procedure

- NCT03867747 1402 1403 O
Contraindication NCT03867747 1405 1421 B-Contraindication
to NCT03867747 1422 1424 O
radiosurgery NCT03867747 1425 1437 B-Procedure
( NCT03867747 1438 1439 O
e. NCT03867747 1440 1442 O
g. NCT03867747 1443 1445 O
precise NCT03867747 1447 1454 O
target NCT03867747 1455 1461 B-Observation
volume NCT03867747 1462 1468 I-Observation
definition NCT03867747 1469 1479 I-Observation
not NCT03867747 1480 1483 B-Negation
possible NCT03867747 1484 1492 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03867747 1493 1496 O
to NCT03867747 1497 1499 O
image NCT03867747 1500 1505 B-Observation
artifacts NCT03867747 1506 1515 I-Observation
created NCT03867747 1516 1523 O
from NCT03867747 1524 1528 O
a NCT03867747 1529 1530 O
left NCT03867747 1531 1535 B-Procedure
ventricular NCT03867747 1536 1547 I-Procedure
assist NCT03867747 1548 1554 I-Procedure
device NCT03867747 1555 1561 I-Procedure
[ NCT03867747 1562 1563 O
LVAD NCT03867747 1564 1568 B-Procedure
] NCT03867747 1569 1570 O
) NCT03867747 1572 1573 O

- NCT03867747 1577 1578 O
Inability NCT03867747 1580 1589 O
to NCT03867747 1590 1592 O
consent NCT03867747 1593 1600 O
or NCT03867747 1601 1603 O
missing NCT03867747 1604 1611 O
or NCT03867747 1612 1614 O
withdrawn NCT03867747 1615 1624 O
consent NCT03867747 1625 1632 O

Inclusion NCT03865030 0 9 O
Criteria NCT03865030 10 18 O
: NCT03865030 19 20 O

- NCT03865030 24 25 O
Psoriatic NCT03865030 27 36 B-Condition
patients NCT03865030 37 45 O
that NCT03865030 46 50 O
are NCT03865030 51 54 O
treated NCT03865030 55 62 B-Procedure
in NCT03865030 63 65 O
our NCT03865030 66 69 O
institute NCT03865030 70 79 O
. NCT03865030 79 80 O

Exclusion NCT03865030 82 91 O
Criteria NCT03865030 92 100 O
: NCT03865030 101 102 O

- NCT03865030 106 107 O
Patients NCT03865030 109 117 O
suffering NCT03865030 118 127 O
from NCT03865030 128 132 O
cardiovascular NCT03865030 133 147 B-Condition
diseases NCT03865030 148 156 I-Condition
( NCT03865030 157 158 O
peripheral NCT03865030 159 169 B-Condition
vascular NCT03865030 170 178 I-Condition
disease NCT03865030 179 186 I-Condition
, NCT03865030 187 188 O
congestive NCT03865030 189 199 B-Condition
heart NCT03865030 200 205 I-Condition
failure NCT03865030 206 213 I-Condition
, NCT03865030 214 215 O
status NCT03865030 216 222 O
post NCT03865030 223 227 B-Temporal-Connection___Temporal-Connection-Type-Value:after
cerebrovascular NCT03865030 228 243 B-Condition
accident NCT03865030 244 252 I-Condition
) NCT03865030 253 254 O
. NCT03865030 255 256 O

- NCT03865030 260 261 O
Conditions NCT03865030 263 273 B-Condition
that NCT03865030 274 278 O
are NCT03865030 279 282 O
harmful NCT03865030 283 290 B-Condition
to NCT03865030 291 293 I-Condition
the NCT03865030 294 297 I-Condition
inner NCT03865030 298 303 I-Condition
ear NCT03865030 304 307 I-Condition
( NCT03865030 308 309 O
chronic NCT03865030 310 317 B-Modifier
renal NCT03865030 318 323 B-Condition
failure NCT03865030 324 331 I-Condition
, NCT03865030 332 333 O
history NCT03865030 334 341 B-Eq-Comparison
of NCT03865030 342 344 O
noise NCT03865030 345 350 B-Condition
exposure NCT03865030 351 359 I-Condition
, NCT03865030 360 361 O
usage NCT03865030 362 367 O
of NCT03865030 368 370 O
ototoxic NCT03865030 371 379 B-Drug
drugs NCT03865030 380 385 I-Drug
, NCT03865030 386 387 O
chronic NCT03865030 388 395 B-Modifier
otitis NCT03865030 396 402 B-Condition
media NCT03865030 403 408 I-Condition
, NCT03865030 409 410 O
ear NCT03865030 411 414 B-Procedure
surgery NCT03865030 415 422 I-Procedure
in NCT03865030 423 425 O
the NCT03865030 426 429 O
past NCT03865030 430 434 B-Eq-Comparison
, NCT03865030 435 436 O
significant NCT03865030 437 448 O
head NCT03865030 449 453 B-Modifier
trauma NCT03865030 454 460 B-Condition
in NCT03865030 461 463 O
the NCT03865030 464 467 O
past NCT03865030 468 472 B-Eq-Comparison
, NCT03865030 473 474 O
ear NCT03865030 475 478 B-Condition
drum NCT03865030 479 483 I-Condition
perforation NCT03865030 484 495 I-Condition
) NCT03865030 496 497 O
. NCT03865030 498 499 O

- NCT03865030 503 504 O
participant NCT03865030 506 517 O
that NCT03865030 518 522 O
complains NCT03865030 523 532 O
of NCT03865030 533 535 O
vertigo NCT03865030 536 543 B-Condition
/ NCT03865030 544 545 B-Or|Or
dizziness NCT03865030 546 555 B-Condition
/ NCT03865030 556 557 O
unsteadiness NCT03865030 558 570 B-Condition
. NCT03865030 570 571 O

- NCT03865030 575 576 O
Participant NCT03865030 578 589 O
who NCT03865030 590 593 O
is NCT03865030 594 596 O
/ NCT03865030 597 598 O
was NCT03865030 599 602 O
suffering NCT03865030 603 612 O
from NCT03865030 613 617 O
known NCT03865030 618 623 O
inner NCT03865030 624 629 B-Condition
ear NCT03865030 630 633 I-Condition
disease NCT03865030 634 641 I-Condition|Condition
: NCT03865030 642 643 O
meniere NCT03865030 644 651 B-Condition
disease NCT03865030 652 659 O
, NCT03865030 660 661 O
acoustic NCT03865030 662 670 B-Condition
neurinoma NCT03865030 671 680 I-Condition
, NCT03865030 681 682 O
vestibular NCT03865030 683 693 B-Condition
neuronitis NCT03865030 694 704 I-Condition
. NCT03865030 704 705 O

Inclusion NCT03868514 0 9 O
Criteria NCT03868514 10 18 O
: NCT03868514 19 20 O

Age NCT03868514 22 25 B-Age
[ NCT03868514 26 27 O
≥ NCT03868514 29 30 B-Eq-Comparison
18 NCT03868514 31 33 I-Eq-Comparison
] NCT03868514 34 35 O

Indications NCT03868514 37 48 B-Indication
of NCT03868514 49 51 O
breast NCT03868514 52 58 B-Procedure
reconstruction NCT03868514 59 73 I-Procedure
: NCT03868514 74 75 O
histologically NCT03868514 76 90 B-Procedure
confirmed NCT03868514 91 100 O
breast NCT03868514 101 107 B-Modifier
cancer NCT03868514 108 114 B-Condition
, NCT03868514 115 116 O
precancerous NCT03868514 117 129 B-Modifier
lesions NCT03868514 130 137 B-Condition
( NCT03868514 138 139 O
DCIS NCT03868514 140 144 B-Condition
, NCT03868514 145 146 O
LCIS NCT03868514 147 151 B-Condition
) NCT03868514 152 153 O
, NCT03868514 155 156 O
mutation NCT03868514 157 165 B-Condition
carrier NCT03868514 166 173 I-Condition
with NCT03868514 174 178 B-And
increased NCT03868514 179 188 O
breast NCT03868514 189 195 B-Modifier
cancer NCT03868514 196 202 B-Condition
risk NCT03868514 203 207 B-Risk
, NCT03868514 208 209 O
strong NCT03868514 210 216 O
family NCT03868514 217 223 B-Family-Member
history NCT03868514 224 231 I-Family-Member
( NCT03868514 232 233 O
lifetime NCT03868514 234 242 O
risk NCT03868514 243 247 B-Risk
> NCT03868514 248 249 B-Eq-Comparison
15 NCT03868514 250 252 I-Eq-Comparison
% NCT03868514 253 254 O
) NCT03868514 255 256 O

The NCT03868514 258 261 O
patient NCT03868514 262 269 O
is NCT03868514 270 272 O
capable NCT03868514 273 280 O
to NCT03868514 281 283 O
realise NCT03868514 284 291 O
the NCT03868514 292 295 O
nature NCT03868514 296 302 O
, NCT03868514 303 304 O
aims NCT03868514 305 309 O
and NCT03868514 310 313 O
possible NCT03868514 314 322 O
consequences NCT03868514 323 335 O
of NCT03868514 336 338 O
the NCT03868514 339 342 O
clinical NCT03868514 343 351 O
trial NCT03868514 352 357 O
( NCT03868514 358 359 O
MPG NCT03868514 360 363 O
§ NCT03868514 364 365 O
20.2.1 NCT03868514 365 371 O
) NCT03868514 372 373 O

Patient NCT03868514 375 382 O
information NCT03868514 383 394 O
has NCT03868514 395 398 O
been NCT03868514 399 403 O
provided NCT03868514 404 412 O
and NCT03868514 413 416 O
all NCT03868514 417 420 O
written NCT03868514 421 428 O
consents NCT03868514 429 437 O
of NCT03868514 438 440 O
the NCT03868514 441 444 O
patient NCT03868514 445 452 O
are NCT03868514 453 456 O
available NCT03868514 457 466 O

Exclusion NCT03868514 467 476 O
Criteria NCT03868514 477 485 O
: NCT03868514 486 487 O

Metastatic NCT03868514 489 499 B-Modifier
breast NCT03868514 500 506 I-Modifier
cancer NCT03868514 507 513 B-Condition

Patient NCT03868514 514 521 O
with NCT03868514 522 526 O
known NCT03868514 527 532 O
contraindications NCT03868514 533 550 B-Contraindication
against NCT03868514 551 558 O
mesh NCT03868514 559 563 B-Modifier
- NCT03868514 564 565 I-Modifier|Modifier
assisted NCT03868514 566 574 I-Modifier
or NCT03868514 575 577 B-Or
plastic NCT03868514 578 585 B-Modifier
- NCT03868514 586 587 O
reconstructive NCT03868514 588 602 I-Modifier
breast NCT03868514 603 609 B-Procedure
surgery NCT03868514 610 617 I-Procedure
according NCT03868514 618 627 O
to NCT03868514 628 630 O
the NCT03868514 631 634 O
instruction NCT03868514 635 646 O
for NCT03868514 647 650 O
use NCT03868514 651 654 O

Patient NCT03868514 655 662 O
is NCT03868514 663 665 O
kept NCT03868514 666 670 O
in NCT03868514 671 673 B-Observation
an NCT03868514 674 676 O
institution NCT03868514 677 688 O
under NCT03868514 689 694 I-Observation
judicial NCT03868514 695 703 I-Observation
or NCT03868514 704 706 O
official NCT03868514 707 715 O
orders NCT03868514 716 722 O
( NCT03868514 723 724 O
MPG NCT03868514 725 728 O
§ NCT03868514 729 730 O
20.3 NCT03868514 730 734 O
) NCT03868514 735 736 O

Participate NCT03868514 738 749 O
in NCT03868514 750 752 O
another NCT03868514 753 760 B-Other
operative NCT03868514 761 770 B-Procedure
clinical NCT03868514 771 779 B-Study
trial NCT03868514 780 785 I-Study
, NCT03868514 786 787 O
if NCT03868514 788 790 O
it NCT03868514 791 793 O
relates NCT03868514 794 801 O
to NCT03868514 802 804 O
the NCT03868514 805 808 O
area NCT03868514 809 813 O
of NCT03868514 814 816 O
reconstructive NCT03868514 817 831 B-Procedure
breast NCT03868514 832 838 I-Procedure
surgery NCT03868514 839 846 I-Procedure
and NCT03868514 847 850 B-Or
/ NCT03868514 851 852 I-Or
or NCT03868514 853 855 I-Or
influences NCT03868514 856 866 O
the NCT03868514 867 870 O
primary NCT03868514 871 878 O
endpoint NCT03868514 879 887 O
of NCT03868514 888 890 O
the NCT03868514 891 894 O
clinical NCT03868514 895 903 O
trial NCT03868514 904 909 B-Study


Inclusion NCT03863327 0 9 O
Criteria NCT03863327 10 18 O
: NCT03863327 19 20 O

- NCT03863327 24 25 O
Recorded NCT03863327 27 35 B-Eq-Comparison
EKG NCT03863327 36 39 B-Procedure
prior NCT03863327 40 45 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863327 46 48 I-Temporal-Connection___Temporal-Connection-Type-Value:before
cardiac NCT03863327 49 56 B-Procedure
catheterization NCT03863327 57 72 I-Procedure

Exclusion NCT03863327 73 82 O
Criteria NCT03863327 83 91 O
: NCT03863327 92 93 O

- NCT03863327 97 98 O
Absence NCT03863327 100 107 B-Negation
of NCT03863327 108 110 O
documented NCT03863327 111 121 O
EKG NCT03863327 122 125 B-Procedure
prior NCT03863327 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863327 132 134 I-Temporal-Connection___Temporal-Connection-Type-Value:before
cardiac NCT03863327 135 142 B-Procedure
catheterization NCT03863327 143 158 I-Procedure

Inclusion NCT03863496 0 9 O
Criteria NCT03863496 10 18 O
: NCT03863496 19 20 O

- NCT03863496 24 25 O
Signed NCT03863496 27 33 O
and NCT03863496 34 37 O
dated NCT03863496 38 43 O
informed NCT03863496 44 52 O
consent NCT03863496 53 60 O
for NCT03863496 61 64 O
participation NCT03863496 65 78 O
in NCT03863496 79 81 O
the NCT03863496 82 85 O
study NCT03863496 86 91 O
( NCT03863496 92 93 O
separate NCT03863496 94 102 O
informed NCT03863496 103 111 O
consents NCT03863496 112 120 O
for NCT03863496 121 124 O
child NCT03863496 125 130 B-Family-Member___Family-Member-Type:child
and NCT03863496 131 134 B-Or
parents NCT03863496 135 142 B-Family-Member___Family-Member-Type:parent
/ NCT03863496 143 144 O
caregivers NCT03863496 145 155 O
) NCT03863496 156 157 O
, NCT03863496 159 160 O
obtained NCT03863496 161 169 O
before NCT03863496 170 176 B-Temporal-Connection___Temporal-Connection-Type-Value:before
conducting NCT03863496 177 187 O
any NCT03863496 188 191 O
study NCT03863496 192 197 B-Study
procedures NCT03863496 198 208 B-Procedure

- NCT03863496 211 212 O
Verified NCT03863496 214 222 O
and NCT03863496 223 226 O
documented NCT03863496 227 237 O
diagnosis NCT03863496 238 247 O
( NCT03863496 248 249 O
neuromuscular NCT03863496 250 263 B-Condition
desease NCT03863496 264 271 I-Condition
, NCT03863496 272 273 O
NMD NCT03863496 274 277 B-Condition
) NCT03863496 278 279 O
with NCT03863496 280 284 O
the NCT03863496 285 288 O
results NCT03863496 289 296 O
of NCT03863496 297 299 O
neurologic NCT03863496 300 310 B-Procedure
examination NCT03863496 311 322 I-Procedure

- NCT03863496 325 326 O
Deformity NCT03863496 328 337 B-Condition
of NCT03863496 338 340 O
thoracic NCT03863496 341 349 B-Modifier
and NCT03863496 350 353 B-Or
/ NCT03863496 354 355 I-Or
or NCT03863496 356 358 I-Or
lumbar NCT03863496 359 365 B-Modifier
spine NCT03863496 366 371 I-Modifier
associated NCT03863496 372 382 O
with NCT03863496 383 387 O
NMD NCT03863496 388 391 B-Condition
, NCT03863496 392 393 O
which NCT03863496 394 399 O
requires NCT03863496 400 408 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03863496 409 417 B-Procedure
intervention NCT03863496 418 430 I-Procedure

Exclusion NCT03863496 431 440 O
Criteria NCT03863496 441 449 O
: NCT03863496 450 451 O

- NCT03863496 455 456 O
Patient NCT03863496 458 465 O
unwillingness NCT03863496 466 479 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03863496 480 482 B-Or
inability NCT03863496 483 492 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863496 493 495 O
follow NCT03863496 496 502 O
study NCT03863496 503 508 B-Study
procedures NCT03863496 509 519 B-Procedure

- NCT03863496 522 523 O
Absence NCT03863496 525 532 O
of NCT03863496 533 535 O
signed NCT03863496 536 542 O
and NCT03863496 543 546 O
dated NCT03863496 547 552 O
informed NCT03863496 553 561 O
consent NCT03863496 562 569 O
for NCT03863496 570 573 O
participation NCT03863496 574 587 O
in NCT03863496 588 590 O
the NCT03863496 591 594 O
study NCT03863496 595 600 O
( NCT03863496 601 602 O
as NCT03863496 603 605 O
for NCT03863496 606 609 O
child NCT03863496 610 615 B-Family-Member___Family-Member-Type:child
and NCT03863496 616 619 B-Or
for NCT03863496 620 623 O
parents NCT03863496 624 631 B-Family-Member___Family-Member-Type:parent
/ NCT03863496 632 633 O
caregivers NCT03863496 634 644 O
) NCT03863496 645 646 O

- NCT03863496 650 651 O
Patient NCT03863496 653 660 O
participation NCT03863496 661 674 O
in NCT03863496 675 677 O
another NCT03863496 678 685 B-Other
clinical NCT03863496 686 694 O
study NCT03863496 695 700 B-Study
, NCT03863496 701 702 O
which NCT03863496 703 708 O
can NCT03863496 709 712 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03863496 713 722 O
the NCT03863496 723 726 O
results NCT03863496 727 734 O
of NCT03863496 735 737 O
this NCT03863496 738 742 O
study NCT03863496 743 748 B-Study

- NCT03863496 751 752 O
Left NCT03863496 754 758 B-Observation
ventricle NCT03863496 759 768 I-Observation
ejection NCT03863496 769 777 I-Observation
fraction NCT03863496 778 786 I-Observation
less NCT03863496 787 791 B-Eq-Comparison
than NCT03863496 792 796 I-Eq-Comparison
40 NCT03863496 797 799 I-Eq-Comparison
% NCT03863496 800 801 O
by NCT03863496 802 804 O
echocardiography NCT03863496 805 821 B-Procedure

- NCT03863496 824 825 O
FEV NCT03863496 827 830 B-Observation
> NCT03863496 831 832 B-Eq-Comparison
20 NCT03863496 833 835 I-Eq-Comparison

- NCT03863496 839 840 O
Life NCT03863496 842 846 B-Observation
expectancy NCT03863496 847 857 I-Observation
< NCT03863496 858 859 B-Eq-Comparison
12 NCT03863496 860 862 I-Eq-Comparison
months NCT03863496 863 869 I-Eq-Comparison

- NCT03863496 872 873 O
Liver NCT03863496 875 880 B-Condition
insufficiency NCT03863496 881 894 I-Condition
: NCT03863496 895 896 O
ALT NCT03863496 897 900 B-Observation
, NCT03863496 901 902 O
AST NCT03863496 903 906 B-Observation
and NCT03863496 907 910 B-Or
total NCT03863496 911 916 B-Observation
bilirubin NCT03863496 917 926 I-Observation
twice NCT03863496 927 932 B-Eq-Comparison
higher NCT03863496 933 939 I-Eq-Comparison
than NCT03863496 940 944 I-Eq-Comparison
normal NCT03863496 945 951 I-Eq-Comparison

- NCT03863496 954 955 O
Kidney NCT03863496 957 963 B-Condition
insufficiency NCT03863496 964 977 I-Condition
( NCT03863496 978 979 O
creatinine NCT03863496 980 990 B-Observation
clearance NCT03863496 991 1000 I-Observation
< NCT03863496 1001 1002 B-Eq-Comparison
60 NCT03863496 1003 1005 I-Eq-Comparison
ml NCT03863496 1006 1008 I-Eq-Comparison
/ NCT03863496 1009 1010 I-Eq-Comparison
min NCT03863496 1011 1014 I-Eq-Comparison
) NCT03863496 1015 1016 O

- NCT03863496 1020 1021 O
Concomitant NCT03863496 1023 1034 B-Modifier
diseases NCT03863496 1035 1043 B-Condition
, NCT03863496 1044 1045 O
which NCT03863496 1046 1051 O
preclude NCT03863496 1052 1060 B-Assertion___Assertion-Type-Value:hypothetical|Negation
patient NCT03863496 1061 1068 O
participation NCT03863496 1069 1082 O
in NCT03863496 1083 1085 O
this NCT03863496 1086 1090 O
study NCT03863496 1091 1096 B-Study
according NCT03863496 1097 1106 O
to NCT03863496 1107 1109 O
doctor NCT03863496 1110 1116 O
's NCT03863496 1116 1118 O
opinion NCT03863496 1119 1126 O

Inclusion NCT03866707 0 9 O
Criteria NCT03866707 10 18 O
: NCT03866707 19 20 O

- NCT03866707 24 25 O
Childhood NCT03866707 27 36 O
cancer NCT03866707 37 43 B-Condition
survivors NCT03866707 44 53 O
age NCT03866707 54 57 B-Age
1 NCT03866707 58 59 B-Eq-Comparison
- NCT03866707 60 61 I-Eq-Comparison
18 NCT03866707 62 64 I-Eq-Comparison
years NCT03866707 65 70 I-Eq-Comparison
old NCT03866707 71 74 O
who NCT03866707 75 78 B-And
received NCT03866707 79 87 B-Eq-Comparison
intensive NCT03866707 88 97 O
treatment NCT03866707 98 107 B-Procedure
which NCT03866707 108 113 O
included NCT03866707 114 122 O
anthracycline NCT03866707 123 136 B-Drug
and NCT03866707 137 140 B-Or
/ NCT03866707 141 142 I-Or
or NCT03866707 143 145 I-Or
alkylating NCT03866707 146 156 B-Drug
agent NCT03866707 157 162 I-Drug
chemotherapy NCT03866707 163 175 B-Procedure
. NCT03866707 175 176 O

- NCT03866707 180 181 O
Diseases NCT03866707 183 191 B-Condition
which NCT03866707 192 197 O
will NCT03866707 198 202 O
be NCT03866707 203 205 O
eligible NCT03866707 206 214 O
include NCT03866707 215 222 O
, NCT03866707 223 224 O
high NCT03866707 225 229 O
risk NCT03866707 230 234 B-Risk
or NCT03866707 235 237 B-Or
very NCT03866707 238 242 O
high NCT03866707 243 247 O
risk NCT03866707 248 252 B-Risk
acute NCT03866707 253 258 O
lymphoblastic NCT03866707 259 272 B-Condition
leukemia NCT03866707 273 281 I-Condition
, NCT03866707 282 283 O
acute NCT03866707 284 289 O
myeloid NCT03866707 290 297 B-Condition
leukemia NCT03866707 298 306 I-Condition
, NCT03866707 307 308 O
Hodgkin NCT03866707 309 316 B-Condition
lymphoma NCT03866707 317 325 I-Condition
, NCT03866707 326 327 O
non NCT03866707 328 331 B-Negation
- NCT03866707 332 333 O
Hodgkin NCT03866707 334 341 B-Modifier
lymphoma NCT03866707 342 350 B-Condition
, NCT03866707 351 352 O
sarcomas NCT03866707 353 361 B-Condition
. NCT03866707 361 362 O

Healthy NCT03866707 364 371 B-Condition
controls NCT03866707 372 380 O
: NCT03866707 381 382 O

• NCT03866707 384 385 O
Healthy NCT03866707 386 393 B-Condition
controls NCT03866707 394 402 O
are NCT03866707 403 406 O
defined NCT03866707 407 414 O
as NCT03866707 415 417 O
children NCT03866707 418 426 O
ages NCT03866707 427 431 B-Age
1 NCT03866707 432 433 B-Eq-Comparison
- NCT03866707 434 435 I-Eq-Comparison
18 NCT03866707 436 438 I-Eq-Comparison
years NCT03866707 439 444 I-Eq-Comparison
old NCT03866707 445 448 O
who NCT03866707 449 452 B-And
are NCT03866707 453 456 O
free NCT03866707 457 461 B-Negation
from NCT03866707 462 466 I-Negation
diseases NCT03866707 467 475 B-Condition
or NCT03866707 476 478 B-Or
medical NCT03866707 479 486 B-Condition
conditions NCT03866707 487 497 I-Condition
that NCT03866707 498 502 O
might NCT03866707 503 508 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03866707 509 511 I-Assertion___Assertion-Type-Value:hypothetical
affected NCT03866707 512 520 O
by NCT03866707 521 523 O
or NCT03866707 524 526 B-Or
have NCT03866707 527 531 O
an NCT03866707 532 534 O
impact NCT03866707 535 541 O
on NCT03866707 542 544 O
this NCT03866707 545 549 O
research NCT03866707 550 558 O
study NCT03866707 559 564 B-Study
. NCT03866707 564 565 O
Healthy NCT03866707 567 574 B-Condition
controls NCT03866707 575 583 O
will NCT03866707 584 588 O
be NCT03866707 589 591 O
matched NCT03866707 592 599 O
with NCT03866707 600 604 O
patients NCT03866707 605 613 O
for NCT03866707 614 617 O
age NCT03866707 618 621 O
, NCT03866707 622 623 O
sex NCT03866707 624 627 O
, NCT03866707 628 629 O
ethnicity NCT03866707 630 639 O
, NCT03866707 640 641 O
geographic NCT03866707 642 652 O
region NCT03866707 653 659 O
, NCT03866707 660 661 O
and NCT03866707 662 665 O
tanner NCT03866707 666 672 O
stage NCT03866707 673 678 O
, NCT03866707 679 680 O
since NCT03866707 681 686 O
it NCT03866707 687 689 O
is NCT03866707 690 692 O
known NCT03866707 693 698 O
that NCT03866707 699 703 O
these NCT03866707 704 709 O
factors NCT03866707 710 717 O
can NCT03866707 718 721 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03866707 722 728 O
the NCT03866707 729 732 O
epigenetic NCT03866707 733 743 B-Observation
signature NCT03866707 744 753 I-Observation
of NCT03866707 754 756 O
an NCT03866707 757 759 O
individual NCT03866707 760 770 O
. NCT03866707 770 771 O
Controls NCT03866707 773 781 O
will NCT03866707 782 786 O
already NCT03866707 787 794 O
be NCT03866707 795 797 O
having NCT03866707 798 804 O
blood NCT03866707 805 810 B-Observation
drawn NCT03866707 811 816 O
as NCT03866707 817 819 O
part NCT03866707 820 824 O
of NCT03866707 825 827 O
their NCT03866707 828 833 O
routine NCT03866707 834 841 B-Procedure
care NCT03866707 842 846 I-Procedure
. NCT03866707 846 847 O

Exclusion NCT03866707 849 858 O
Criteria NCT03866707 859 867 O
: NCT03866707 868 869 O

Cancer NCT03866707 871 877 B-Condition
survivors NCT03866707 878 887 O
: NCT03866707 888 889 O

• NCT03866707 891 892 O
Patients NCT03866707 893 901 O
who NCT03866707 902 905 O
have NCT03866707 906 910 O
received NCT03866707 911 919 B-Eq-Comparison
a NCT03866707 920 921 O
bone NCT03866707 922 926 B-Procedure
marrow NCT03866707 927 933 I-Procedure
transplant NCT03866707 934 944 I-Procedure
will NCT03866707 945 949 O
not NCT03866707 950 953 B-Negation
be NCT03866707 954 956 O
eligible NCT03866707 957 965 O
. NCT03866707 965 966 O

Healthy NCT03866707 968 975 B-Condition
controls NCT03866707 976 984 O
: NCT03866707 985 986 O

• NCT03866707 988 989 O
Age NCT03866707 990 993 O
, NCT03866707 994 995 O
sex NCT03866707 996 999 O
, NCT03866707 1000 1001 O
ethnicity NCT03866707 1002 1011 O
, NCT03866707 1012 1013 O
geographic NCT03866707 1014 1024 O
region NCT03866707 1025 1031 O
, NCT03866707 1032 1033 O
and NCT03866707 1034 1037 O
tanner NCT03866707 1038 1044 O
stage NCT03866707 1045 1050 O
matched NCT03866707 1051 1058 O
controls NCT03866707 1059 1067 O
with NCT03866707 1068 1072 O
any NCT03866707 1073 1076 O
acute NCT03866707 1077 1082 O
or NCT03866707 1083 1085 B-Or
chronic NCT03866707 1086 1093 B-Modifier
disease NCT03866707 1094 1101 B-Condition
will NCT03866707 1102 1106 O
be NCT03866707 1107 1109 O
excluded NCT03866707 1110 1118 B-Negation
. NCT03866707 1118 1119 O


Inclusion NCT03860376 0 9 O
Criteria NCT03860376 10 18 O
: NCT03860376 19 20 O

- NCT03860376 24 25 O
Patients NCT03860376 27 35 O
aged NCT03860376 36 40 B-Age
21 NCT03860376 41 43 B-Eq-Comparison
years NCT03860376 44 49 I-Eq-Comparison
or NCT03860376 50 52 I-Eq-Comparison
younger NCT03860376 53 60 I-Eq-Comparison
at NCT03860376 61 63 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860376 64 67 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03860376 68 72 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860376 73 75 O
enrollment NCT03860376 76 86 B-Study
on NCT03860376 87 89 O
this NCT03860376 90 94 O
study NCT03860376 95 100 O
of NCT03860376 101 103 O
any NCT03860376 104 107 O
gender NCT03860376 108 114 O
, NCT03860376 115 116 O
race NCT03860376 117 121 O
or NCT03860376 122 124 O
ethnicity NCT03860376 125 134 O
. NCT03860376 134 135 O

- NCT03860376 144 145 O
Subjects NCT03860376 147 155 O
with NCT03860376 156 160 O
suspected NCT03860376 161 170 B-Assertion___Assertion-Type-Value:possible
or NCT03860376 171 173 B-Or
confirmed NCT03860376 174 183 B-Modifier
diagnosis NCT03860376 184 193 O
of NCT03860376 194 196 O
recurrent NCT03860376 197 206 B-Modifier
or NCT03860376 207 209 B-Or
refractory NCT03860376 210 220 B-Modifier
cancer NCT03860376 221 227 B-Condition

- NCT03860376 235 236 O
Subjects NCT03860376 238 246 O
who NCT03860376 247 250 O
are NCT03860376 251 254 O
scheduled NCT03860376 255 264 B-Eq-Comparison
for NCT03860376 265 268 O
or NCT03860376 269 271 B-Or
have NCT03860376 272 276 O
recently NCT03860376 277 285 B-Eq-Comparison
had NCT03860376 286 289 O
biopsy NCT03860376 290 296 B-Procedure
or NCT03860376 297 299 B-Or
tumor NCT03860376 300 305 B-Condition
excised NCT03860376 306 313 B-Procedure
( NCT03860376 314 315 O
solid NCT03860376 316 321 B-Modifier
tumors NCT03860376 322 328 B-Condition
) NCT03860376 329 330 O
or NCT03860376 331 333 B-Or
bone NCT03860376 334 338 B-Modifier
marrow NCT03860376 339 345 I-Modifier
aspirate NCT03860376 346 354 B-Procedure
( NCT03860376 355 356 O
blood NCT03860376 357 362 B-Modifier
cancers NCT03860376 363 370 B-Condition
) NCT03860376 371 372 O

- NCT03860376 381 382 O
Subjects NCT03860376 384 392 O
willing NCT03860376 393 400 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860376 401 403 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03860376 404 408 O
a NCT03860376 409 410 O
blood NCT03860376 411 416 B-Observation
draw NCT03860376 417 421 I-Observation
or NCT03860376 422 424 B-Or
buccal NCT03860376 425 431 B-Procedure
swab NCT03860376 432 436 I-Procedure
done NCT03860376 437 441 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860376 442 445 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03860376 446 449 O
purposes NCT03860376 450 458 O
of NCT03860376 459 461 O
genetic NCT03860376 462 469 B-Procedure
testing NCT03860376 470 477 I-Procedure

- NCT03860376 485 486 O
Subjects NCT03860376 488 496 O
or NCT03860376 497 499 O
their NCT03860376 500 505 O
parents NCT03860376 506 513 O
or NCT03860376 514 516 O
legal NCT03860376 517 522 O
guardians NCT03860376 523 532 O
willing NCT03860376 533 540 O
to NCT03860376 541 543 O
sign NCT03860376 544 548 O
informed NCT03860376 549 557 O
consent NCT03860376 558 565 O

- NCT03860376 573 574 O
Subjects NCT03860376 576 584 O
aged NCT03860376 585 589 B-Age
7 NCT03860376 590 591 B-Eq-Comparison
to NCT03860376 592 594 I-Eq-Comparison
17 NCT03860376 595 597 I-Eq-Comparison
willing NCT03860376 598 605 O
to NCT03860376 606 608 O
sign NCT03860376 609 613 O
assent NCT03860376 614 620 O

Exclusion NCT03860376 621 630 O
Criteria NCT03860376 631 639 O
: NCT03860376 640 641 O

- NCT03860376 645 646 O
Subjects NCT03860376 648 656 O
who NCT03860376 657 660 O
do NCT03860376 661 663 O
not NCT03860376 664 667 B-Negation
have NCT03860376 668 672 O
malignant NCT03860376 673 682 B-Condition
tissue NCT03860376 683 689 I-Condition
available NCT03860376 690 699 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03860376 700 703 B-Or
accessible NCT03860376 704 714 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03860376 717 718 O
The NCT03860376 720 723 O
amount NCT03860376 724 730 O
of NCT03860376 731 733 O
excised NCT03860376 734 741 B-Procedure
malignant NCT03860376 742 751 B-Condition
tissue NCT03860376 752 758 I-Condition
is NCT03860376 759 761 O
not NCT03860376 762 765 B-Negation
sufficient NCT03860376 766 776 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860376 777 780 O
the NCT03860376 781 784 O
ex NCT03860376 785 787 B-Modifier
vivo NCT03860376 788 792 I-Modifier
drug NCT03860376 793 797 B-Procedure
testing NCT03860376 798 805 I-Procedure
and NCT03860376 806 809 B-Or
/ NCT03860376 810 811 I-Or
or NCT03860376 812 814 I-Or
genetic NCT03860376 815 822 B-Procedure
profiling NCT03860376 823 832 I-Procedure
. NCT03860376 832 833 O

- NCT03860376 837 838 O
Patients NCT03860376 840 848 O
with NCT03860376 849 853 O
newly NCT03860376 854 859 B-Eq-Comparison
diagnosed NCT03860376 860 869 O
tumors NCT03860376 870 876 B-Condition|Condition
and NCT03860376 877 880 B-Or
tumors NCT03860376 881 887 O
that NCT03860376 888 892 O
have NCT03860376 893 897 O
high NCT03860376 898 902 O
( NCT03860376 903 904 O
> NCT03860376 906 907 B-Eq-Comparison
90 NCT03860376 908 910 I-Eq-Comparison
% NCT03860376 911 912 O
) NCT03860376 913 914 O
cure NCT03860376 915 919 B-Observation
rate NCT03860376 920 924 I-Observation
with NCT03860376 925 929 O
safe NCT03860376 930 934 B-Modifier
standard NCT03860376 935 943 B-Procedure
therapy NCT03860376 944 951 I-Procedure
. NCT03860376 951 952 O

Inclusion NCT03869346 0 9 O
Criteria NCT03869346 10 18 O
: NCT03869346 19 20 O

- NCT03869346 24 25 O
American NCT03869346 27 35 B-Condition
Society NCT03869346 36 43 I-Condition
of NCT03869346 44 46 I-Condition
Anesthesiologists NCT03869346 47 64 I-Condition
GradeⅠ NCT03869346 65 71 B-Eq-Comparison
－ NCT03869346 72 73 O
II NCT03869346 74 76 O
, NCT03869346 77 78 O
Patients NCT03869346 79 87 O
undergo NCT03869346 88 95 B-Eq-Comparison
elective NCT03869346 96 104 B-Modifier
surgery NCT03869346 105 112 B-Procedure
for NCT03869346 113 116 O
benign NCT03869346 117 123 B-Modifier
Reproductive NCT03869346 124 136 B-Condition
diseases NCT03869346 137 145 I-Condition
( NCT03869346 146 147 O
including NCT03869346 148 157 O
laparoscopic NCT03869346 158 170 B-Procedure
ovarian NCT03869346 171 178 I-Procedure
cyst NCT03869346 179 183 I-Procedure
removal NCT03869346 184 191 I-Procedure
, NCT03869346 192 193 O
laparoscopic NCT03869346 194 206 B-Procedure
tubal NCT03869346 207 212 I-Procedure
ligation NCT03869346 213 221 I-Procedure
, NCT03869346 222 223 O
laparoscopic NCT03869346 224 236 B-Procedure
tubal NCT03869346 237 242 I-Procedure
drainage NCT03869346 243 251 I-Procedure
, NCT03869346 252 253 O
laparoscopic NCT03869346 254 266 B-Procedure
salpingoplasty NCT03869346 267 281 I-Procedure
, NCT03869346 282 283 O
etc NCT03869346 284 287 O
. NCT03869346 287 288 O
) NCT03869346 289 290 O
or NCT03869346 291 293 B-Or
breast NCT03869346 294 300 B-Condition
disease NCT03869346 301 308 I-Condition
. NCT03869346 308 309 O

- NCT03869346 313 314 I-Eq-Comparison
Aged NCT03869346 316 320 B-Age
18 NCT03869346 321 323 B-Eq-Comparison
- NCT03869346 324 325 O
45 NCT03869346 326 328 I-Eq-Comparison
years NCT03869346 329 334 I-Eq-Comparison

- NCT03869346 337 338 O
Body NCT03869346 340 344 B-Observation
Mass NCT03869346 345 349 I-Observation
Index NCT03869346 350 355 I-Observation
18 NCT03869346 356 358 B-Eq-Comparison
- NCT03869346 359 360 I-Eq-Comparison
25 NCT03869346 361 363 I-Eq-Comparison
kg NCT03869346 364 366 O
/ NCT03869346 367 368 I-Eq-Comparison
m2 NCT03869346 369 371 I-Eq-Comparison
, NCT03869346 372 373 O
body NCT03869346 375 379 B-Observation
weight NCT03869346 380 386 I-Observation
40 NCT03869346 387 389 B-Eq-Comparison
- NCT03869346 390 391 I-Eq-Comparison
65 NCT03869346 392 394 I-Eq-Comparison
kilograms NCT03869346 395 404 I-Eq-Comparison

- NCT03869346 407 408 O
Agreed NCT03869346 410 416 O
to NCT03869346 417 419 O
participate NCT03869346 420 431 O
the NCT03869346 432 435 O
research NCT03869346 436 444 O

Exclusion NCT03869346 445 454 O
Criteria NCT03869346 455 463 O
: NCT03869346 464 465 O

- NCT03869346 469 470 O
Difficult NCT03869346 472 481 B-Condition
airway NCT03869346 482 488 I-Condition

- NCT03869346 491 492 O
upper NCT03869346 494 499 B-Condition
respiratory NCT03869346 500 511 I-Condition
tract NCT03869346 512 517 I-Condition
infection NCT03869346 518 527 I-Condition
within NCT03869346 528 534 B-Eq-Comparison
2 NCT03869346 535 536 I-Eq-Comparison
weeks NCT03869346 537 542 I-Eq-Comparison

- NCT03869346 545 546 O
history NCT03869346 548 555 B-Eq-Comparison
of NCT03869346 556 558 O
allergy NCT03869346 559 566 B-Allergy
or NCT03869346 567 569 B-Or
long NCT03869346 570 574 B-Modifier
- NCT03869346 575 576 I-Modifier
term NCT03869346 577 581 I-Modifier
use NCT03869346 582 585 O
of NCT03869346 586 588 O
propofol NCT03869346 589 597 B-Drug
and NCT03869346 598 601 B-Or
opioids NCT03869346 602 609 B-Drug

- NCT03869346 612 613 I-Observation
self NCT03869346 615 619 B-Observation
- NCT03869346 620 621 O
rating NCT03869346 622 628 I-Observation
anxiety NCT03869346 629 636 I-Observation
scale NCT03869346 637 642 I-Observation
before NCT03869346 643 649 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operation NCT03869346 650 659 B-Procedure
indicates NCT03869346 660 669 O
anxiety NCT03869346 670 677 B-Condition

- NCT03869346 680 681 O
pregnancy NCT03869346 683 692 B-Condition
or NCT03869346 693 695 B-Or
lactation NCT03869346 696 705 B-Condition
. NCT03869346 705 706 O

Inclusion NCT03860389 0 9 O
Criteria NCT03860389 10 18 O
: NCT03860389 19 20 O

- NCT03860389 24 25 O
Diagnosis NCT03860389 27 36 O
of NCT03860389 37 39 O
autism NCT03860389 40 46 B-Condition
spectrum NCT03860389 47 55 I-Condition
disorder NCT03860389 56 64 I-Condition

Exclusion NCT03860389 65 74 O
Criteria NCT03860389 75 83 O
: NCT03860389 84 85 O

- NCT03860389 89 90 O
Any NCT03860389 92 95 O
medical NCT03860389 96 103 B-Condition
condition NCT03860389 104 113 I-Condition
which NCT03860389 114 119 O
excludes NCT03860389 120 128 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03860389 129 132 O
child NCT03860389 133 138 B-Family-Member___Family-Member-Type:child
from NCT03860389 139 143 O
partaking NCT03860389 144 153 O
in NCT03860389 154 156 O
exercise NCT03860389 157 165 B-Observation

Inclusion NCT03868475 0 9 O
Criteria NCT03868475 10 18 O
: NCT03868475 19 20 O

- NCT03868475 24 25 O
Women NCT03868475 27 32 O
over NCT03868475 33 37 B-Eq-Comparison
age NCT03868475 38 41 I-Age|Eq-Comparison
18 NCT03868475 42 44 I-Eq-Comparison
with NCT03868475 45 49 B-And
a NCT03868475 50 51 O
core NCT03868475 52 56 B-Modifier
biopsy NCT03868475 57 63 B-Procedure
proven NCT03868475 64 70 O
borderline NCT03868475 71 81 B-Modifier
or NCT03868475 82 84 B-Or
high NCT03868475 85 89 O
- NCT03868475 90 91 O
risk NCT03868475 92 96 B-Risk
breast NCT03868475 97 103 B-Condition
lesion NCT03868475 104 110 I-Condition
that NCT03868475 111 115 O
requires NCT03868475 116 124 B-Assertion___Assertion-Type-Value:hypothetical
further NCT03868475 125 132 O
excision NCT03868475 133 141 B-Procedure
for NCT03868475 142 145 O
management NCT03868475 146 156 O
based NCT03868475 157 162 O
on NCT03868475 163 165 O
the NCT03868475 166 169 O
surgeon NCT03868475 170 177 B-Provider
's NCT03868475 177 179 O
assessment NCT03868475 180 190 O

- NCT03868475 193 194 O
Informed NCT03868475 196 204 O
consent NCT03868475 205 212 O
must NCT03868475 213 217 O
be NCT03868475 218 220 O
obtained NCT03868475 221 229 O
. NCT03868475 229 230 O

Exclusion NCT03868475 232 241 O
Criteria NCT03868475 242 250 O
: NCT03868475 251 252 O

- NCT03868475 256 257 O
Women NCT03868475 259 264 O
who NCT03868475 265 268 B-And
are NCT03868475 269 272 O
considered NCT03868475 273 283 O
high NCT03868475 284 288 O
- NCT03868475 289 290 O
risk NCT03868475 291 295 B-Risk
based NCT03868475 296 301 O
on NCT03868475 302 304 O
a NCT03868475 305 306 O
greater NCT03868475 307 314 B-Eq-Comparison
than NCT03868475 315 319 I-Eq-Comparison
25 NCT03868475 320 322 I-Eq-Comparison
% NCT03868475 323 324 O
lifetime NCT03868475 325 333 O
risk NCT03868475 334 338 B-Risk
of NCT03868475 339 341 O
breast NCT03868475 342 348 B-Modifier
cancer NCT03868475 349 355 B-Condition
as NCT03868475 356 358 O
per NCT03868475 359 362 O
the NCT03868475 363 366 O
IBIS NCT03868475 367 371 O
( NCT03868475 372 373 O
International NCT03868475 374 387 O
Breast NCT03868475 388 394 O
Cancer NCT03868475 395 401 O
Intervention NCT03868475 402 414 O
Study NCT03868475 415 420 O
) NCT03868475 421 422 O
Breast NCT03868475 423 429 B-Observation
Cancer NCT03868475 430 436 I-Observation
Risk NCT03868475 437 441 I-Observation
Evaluation NCT03868475 442 452 I-Observation
Tool NCT03868475 453 457 I-Observation

- NCT03868475 460 461 O
Pathology NCT03868475 463 472 B-Condition
that NCT03868475 473 477 O
is NCT03868475 478 480 O
felt NCT03868475 481 485 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868475 486 488 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868475 489 491 O
discordant NCT03868475 492 502 B-Modifier
with NCT03868475 503 507 O
imaging NCT03868475 508 515 B-Procedure

- NCT03868475 518 519 O
Extensive NCT03868475 521 530 O
calcifications NCT03868475 531 545 B-Condition|Observation
extending NCT03868475 546 555 O
more NCT03868475 556 560 B-Eq-Comparison
than NCT03868475 561 565 I-Eq-Comparison
20 NCT03868475 566 568 I-Eq-Comparison
mm NCT03868475 569 571 I-Eq-Comparison
and NCT03868475 572 575 B-Or
/ NCT03868475 576 577 I-Or
or NCT03868475 578 580 I-Or
masses NCT03868475 581 587 B-Condition|Observation
greater NCT03868475 588 595 B-Eq-Comparison
than NCT03868475 596 600 I-Eq-Comparison
30 NCT03868475 601 603 I-Eq-Comparison
mm NCT03868475 604 606 I-Eq-Comparison

- NCT03868475 609 610 O
The NCT03868475 612 615 O
following NCT03868475 616 625 O
lesions NCT03868475 626 633 B-Condition
will NCT03868475 634 638 O
be NCT03868475 639 641 O
excluded NCT03868475 642 650 B-Negation
based NCT03868475 651 656 O
on NCT03868475 657 659 O
their NCT03868475 660 665 O
increased NCT03868475 666 675 O
risk NCT03868475 676 680 B-Risk
of NCT03868475 681 683 O
upstaging NCT03868475 684 693 B-Condition
; NCT03868475 693 694 O
lesions NCT03868475 695 702 B-Condition
( NCT03868475 703 704 O
other NCT03868475 705 710 B-Exception
than NCT03868475 711 715 I-Exception
fibroadenomas NCT03868475 716 729 B-Condition
, NCT03868475 730 731 O
phyllodes NCT03868475 732 741 B-Condition
and NCT03868475 742 745 B-Or
papillomas NCT03868475 746 756 B-Condition
) NCT03868475 757 758 O
that NCT03868475 759 763 O
are NCT03868475 764 767 O
associated NCT03868475 768 778 O
with NCT03868475 779 783 O
a NCT03868475 784 785 O
palpable NCT03868475 786 794 B-Condition
mass NCT03868475 795 799 I-Condition
, NCT03868475 800 801 O
ADH NCT03868475 802 805 B-Condition
( NCT03868475 806 807 O
atypical NCT03868475 808 816 B-Condition
ductal NCT03868475 817 823 I-Condition
hyperplasia NCT03868475 824 835 I-Condition
) NCT03868475 836 837 O
with NCT03868475 838 842 B-And
high NCT03868475 843 847 O
- NCT03868475 848 849 O
risk NCT03868475 850 854 B-Risk
features NCT03868475 855 863 B-Condition
( NCT03868475 864 865 O
ADH NCT03868475 866 869 B-Condition
with NCT03868475 870 874 B-And
zonal NCT03868475 875 880 B-Condition
necrosis NCT03868475 881 889 I-Condition
, NCT03868475 890 891 O
significant NCT03868475 892 903 O
cytological NCT03868475 904 915 B-Condition
atypia NCT03868475 916 922 I-Condition
or NCT03868475 923 925 B-Or
more NCT03868475 926 930 B-Eq-Comparison
than NCT03868475 931 935 I-Eq-Comparison
2 NCT03868475 936 937 I-Eq-Comparison
foci NCT03868475 938 942 B-Condition
) NCT03868475 943 944 O
, NCT03868475 946 947 O
LCIS NCT03868475 948 952 B-Condition
( NCT03868475 953 954 O
lobular NCT03868475 955 962 B-Modifier
carcinoma NCT03868475 963 972 B-Condition
in NCT03868475 973 975 B-Modifier
situ NCT03868475 976 980 I-Modifier
) NCT03868475 981 982 O
with NCT03868475 983 987 B-And
high NCT03868475 988 992 O
- NCT03868475 993 994 O
risk NCT03868475 995 999 B-Risk
features NCT03868475 1000 1008 B-Condition
( NCT03868475 1009 1010 O
associated NCT03868475 1011 1021 O
with NCT03868475 1022 1026 O
ADH NCT03868475 1027 1030 B-Condition
, NCT03868475 1031 1032 O
pleomorphic NCT03868475 1033 1044 B-Condition
LCIS NCT03868475 1045 1049 I-Condition
, NCT03868475 1050 1051 O
zonal NCT03868475 1052 1057 B-Condition
necrosis NCT03868475 1058 1066 I-Condition
and NCT03868475 1067 1070 B-Or
> NCT03868475 1071 1072 B-Eq-Comparison
4 NCT03868475 1073 1074 I-Eq-Comparison
foci NCT03868475 1075 1079 B-Condition
) NCT03868475 1080 1081 O
or NCT03868475 1082 1084 B-Or
discordant NCT03868475 1085 1095 B-Modifier
with NCT03868475 1096 1100 O
imaging NCT03868475 1101 1108 B-Procedure
, NCT03868475 1109 1110 O
papilloma NCT03868475 1111 1120 B-Condition
with NCT03868475 1121 1125 O
atypia NCT03868475 1126 1132 B-Modifier
, NCT03868475 1133 1134 O
and NCT03868475 1135 1138 B-Or
spindle NCT03868475 1139 1146 B-Modifier
cell NCT03868475 1147 1151 I-Modifier
lesion NCT03868475 1152 1158 B-Condition
( NCT03868475 1159 1160 O
especially NCT03868475 1161 1171 O
if NCT03868475 1172 1174 O
there NCT03868475 1175 1180 O
is NCT03868475 1181 1183 O
atypia NCT03868475 1184 1190 B-Modifier
) NCT03868475 1191 1192 O
. NCT03868475 1193 1194 O

- NCT03868475 1198 1199 O
Lesions NCT03868475 1201 1208 B-Condition
that NCT03868475 1209 1213 O
are NCT03868475 1214 1217 O
suspicious NCT03868475 1218 1228 B-Assertion___Assertion-Type-Value:possible
for NCT03868475 1229 1232 O
borderline NCT03868475 1233 1243 B-Modifier
or NCT03868475 1244 1246 B-Or
malignant NCT03868475 1247 1256 B-Modifier
Phyllodes NCT03868475 1257 1266 B-Condition
, NCT03868475 1267 1268 O
DCIS NCT03868475 1269 1273 B-Condition
( NCT03868475 1274 1275 O
ductal NCT03868475 1276 1282 B-Condition
carcinoma NCT03868475 1283 1292 I-Condition|Condition
in NCT03868475 1293 1295 B-Modifier|Modifier
situ NCT03868475 1296 1300 I-Modifier
) NCT03868475 1301 1302 O
, NCT03868475 1304 1305 O
invasive NCT03868475 1306 1314 O
mammary NCT03868475 1315 1322 I-Modifier
carcinoma NCT03868475 1323 1332 B-Condition
, NCT03868475 1333 1334 O
or NCT03868475 1335 1337 B-Or
encapsulated NCT03868475 1338 1350 B-Modifier
papillary NCT03868475 1351 1360 I-Modifier
carcinoma NCT03868475 1361 1370 O

- NCT03868475 1373 1374 O
Any NCT03868475 1376 1379 O
lesion NCT03868475 1380 1386 B-Condition
that NCT03868475 1387 1391 O
either NCT03868475 1392 1398 O
the NCT03868475 1399 1402 O
radiologist NCT03868475 1403 1414 B-Provider
, NCT03868475 1415 1416 O
pathologist NCT03868475 1417 1428 B-Provider
or NCT03868475 1429 1431 B-Or|Or
surgeon NCT03868475 1432 1439 B-Provider
feels NCT03868475 1440 1445 O
is NCT03868475 1446 1448 O
not NCT03868475 1449 1452 B-Negation
amenable NCT03868475 1453 1461 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868475 1462 1464 O
VAPE NCT03868475 1465 1469 B-Procedure
or NCT03868475 1470 1472 O
surgical NCT03868475 1473 1481 B-Procedure
excision NCT03868475 1482 1490 I-Procedure

Inclusion NCT03867292 0 9 O
Criteria NCT03867292 10 18 O
: NCT03867292 19 20 O

- NCT03867292 24 25 O
Padel NCT03867292 27 32 B-Observation
players NCT03867292 33 40 I-Observation

- NCT03867292 43 44 O
With NCT03867292 46 50 O
federal NCT03867292 51 58 O
sheet NCT03867292 59 64 O

- NCT03867292 67 68 O
Male NCT03867292 70 74 O

- NCT03867292 77 78 O
Over NCT03867292 80 84 B-Eq-Comparison
18 NCT03867292 85 87 I-Eq-Comparison
years NCT03867292 88 93 I-Age|Eq-Comparison

- NCT03867292 96 97 O
Currently NCT03867292 99 108 O
participate NCT03867292 109 120 O
in NCT03867292 121 123 O
regional NCT03867292 124 132 O
and NCT03867292 133 136 O
/ NCT03867292 137 138 O
or NCT03867292 139 141 O
national NCT03867292 142 150 O
competitions NCT03867292 151 163 O

Exclusion NCT03867292 164 173 O
Criteria NCT03867292 174 182 O
: NCT03867292 183 184 O

- NCT03867292 188 189 O
Present NCT03867292 191 198 O
a NCT03867292 199 200 O
medical NCT03867292 201 208 O
diagnosis NCT03867292 209 218 O
of NCT03867292 219 221 O
musculoskeletal NCT03867292 222 237 B-Modifier
pathology NCT03867292 238 247 B-Condition

- NCT03867292 250 251 O
Not NCT03867292 253 256 O
signed NCT03867292 257 263 O
the NCT03867292 264 267 O
informed NCT03867292 268 276 O
consent NCT03867292 277 284 O
document NCT03867292 285 293 O
. NCT03867292 293 294 O

Inclusion NCT03865056 0 9 O
Criteria NCT03865056 10 18 O
: NCT03865056 19 20 O

1 NCT03865056 24 25 O
. NCT03865056 25 26 O
Hypoxemia NCT03865056 28 37 B-Condition
defined NCT03865056 38 45 O
by NCT03865056 46 48 O
a NCT03865056 49 50 O
ratio NCT03865056 51 56 O
of NCT03865056 57 59 O
the NCT03865056 60 63 O
partial NCT03865056 64 71 B-Observation
pressure NCT03865056 72 80 I-Observation
of NCT03865056 81 83 I-Observation
arterial NCT03865056 84 92 I-Observation
oxygen NCT03865056 93 99 I-Observation
to NCT03865056 100 102 I-Observation
the NCT03865056 103 106 I-Observation
fraction NCT03865056 107 115 I-Observation
of NCT03865056 116 118 I-Observation
inspired NCT03865056 119 127 I-Observation
oxygen NCT03865056 128 134 I-Observation
( NCT03865056 135 136 O
PaO2 NCT03865056 137 141 B-Observation
: NCT03865056 142 143 O
FiO2 NCT03865056 144 148 O
) NCT03865056 149 150 O
≤ NCT03865056 151 152 B-Eq-Comparison
300 NCT03865056 153 156 I-Eq-Comparison
while NCT03865056 157 162 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865056 163 166 O
patient NCT03865056 167 174 O
is NCT03865056 175 177 O
breathing NCT03865056 178 187 B-Observation
oxygen NCT03865056 188 194 I-Observation
through NCT03865056 195 202 O
NHF NCT03865056 203 206 B-Procedure
for NCT03865056 207 210 O
at NCT03865056 211 213 B-Eq-Comparison
least NCT03865056 214 219 I-Eq-Comparison
15 NCT03865056 220 222 I-Eq-Comparison
minutes NCT03865056 223 230 I-Eq-Comparison
; NCT03865056 230 231 O

2 NCT03865056 234 235 O
. NCT03865056 235 236 O
Respiratory NCT03865056 238 249 B-Observation
rate NCT03865056 250 254 I-Observation
> NCT03865056 255 256 B-Eq-Comparison
25 NCT03865056 257 259 I-Eq-Comparison
breaths NCT03865056 260 267 I-Eq-Comparison
/ NCT03865056 268 269 I-Eq-Comparison
minute NCT03865056 270 276 I-Eq-Comparison
; NCT03865056 276 277 O

3 NCT03865056 280 281 O
. NCT03865056 281 282 O
Partial NCT03865056 284 291 B-Observation
pressure NCT03865056 292 300 I-Observation
of NCT03865056 301 303 I-Observation
arterial NCT03865056 304 312 I-Observation
carbon NCT03865056 313 319 I-Observation
dioxide NCT03865056 320 327 I-Observation
( NCT03865056 328 329 O
PaCO2 NCT03865056 330 335 B-Observation
) NCT03865056 336 337 O
≤ NCT03865056 338 339 B-Eq-Comparison
45 NCT03865056 340 342 I-Eq-Comparison
mmHg NCT03865056 343 347 I-Eq-Comparison
; NCT03865056 347 348 O

4 NCT03865056 351 352 O
. NCT03865056 352 353 O
Absence NCT03865056 355 362 B-Negation
of NCT03865056 363 365 O
clinical NCT03865056 366 374 O
history NCT03865056 375 382 B-Eq-Comparison
of NCT03865056 383 385 O
underlying NCT03865056 386 396 O
chronic NCT03865056 397 404 B-Modifier
respiratory NCT03865056 405 416 B-Condition
failure NCT03865056 417 424 I-Condition
. NCT03865056 424 425 O

Exclusion NCT03865056 427 436 O
Criteria NCT03865056 437 445 O
: NCT03865056 446 447 O

1 NCT03865056 451 452 O
. NCT03865056 452 453 O
Lack NCT03865056 455 459 O
of NCT03865056 460 462 O
consent NCT03865056 463 470 O
; NCT03865056 470 471 O

2 NCT03865056 474 475 O
. NCT03865056 475 476 O
Age NCT03865056 478 481 B-Age
< NCT03865056 482 483 B-Eq-Comparison
18 NCT03865056 484 486 I-Eq-Comparison
years NCT03865056 487 492 I-Eq-Comparison
; NCT03865056 492 493 O

3 NCT03865056 496 497 O
. NCT03865056 497 498 O
Invasive NCT03865056 500 508 B-Modifier
mechanical NCT03865056 509 519 B-Procedure
ventilation NCT03865056 520 531 I-Procedure
for NCT03865056 532 535 O
> NCT03865056 536 537 B-Eq-Comparison
48 NCT03865056 538 540 I-Eq-Comparison
hours NCT03865056 541 546 I-Eq-Comparison
in NCT03865056 547 549 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865056 550 553 I-Temporal-Connection___Temporal-Connection-Type-Value:during
same NCT03865056 554 558 I-Temporal-Connection___Temporal-Connection-Type-Value:during
hospital NCT03865056 559 567 O
admission NCT03865056 568 577 B-Encounter

4 NCT03865056 580 581 O
. NCT03865056 581 582 O
Immediate NCT03865056 584 593 O
need NCT03865056 594 598 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865056 599 602 I-Assertion___Assertion-Type-Value:hypothetical
intubation NCT03865056 603 613 B-Procedure
; NCT03865056 613 614 O

5 NCT03865056 617 618 O
. NCT03865056 618 619 O
Previous NCT03865056 621 629 B-Eq-Comparison
inclusion NCT03865056 630 639 O
in NCT03865056 640 642 O
the NCT03865056 643 646 O
present NCT03865056 647 654 O
study NCT03865056 655 660 B-Study
; NCT03865056 660 661 O

6 NCT03865056 664 665 O
. NCT03865056 665 666 O
Systolic NCT03865056 668 676 B-Observation
arterial NCT03865056 677 685 I-Observation
pressure NCT03865056 686 694 I-Observation
< NCT03865056 695 696 B-Eq-Comparison
90 NCT03865056 697 699 I-Eq-Comparison
mmHg NCT03865056 700 704 I-Eq-Comparison
after NCT03865056 705 710 B-Temporal-Connection___Temporal-Connection-Type-Value:after
optimal NCT03865056 711 718 B-Modifier
fluid NCT03865056 719 724 B-Procedure
therapy NCT03865056 725 732 I-Procedure
; NCT03865056 732 733 O

7 NCT03865056 736 737 O
. NCT03865056 737 738 O
Cardiogenic NCT03865056 740 751 B-Condition
pulmonary NCT03865056 752 761 I-Condition
edema NCT03865056 762 767 I-Condition
; NCT03865056 767 768 O

8 NCT03865056 771 772 O
. NCT03865056 772 773 O
Glasgow NCT03865056 775 782 B-Observation
Coma NCT03865056 783 787 I-Observation
Scale NCT03865056 788 793 I-Observation
< NCT03865056 794 795 B-Eq-Comparison
12 NCT03865056 796 798 I-Eq-Comparison
; NCT03865056 799 800 O

9 NCT03865056 803 804 O
. NCT03865056 804 805 O
Imminent NCT03865056 807 815 B-Risk
death NCT03865056 816 821 B-Death
; NCT03865056 821 822 O

10 NCT03865056 824 826 O
. NCT03865056 826 827 O
Contraindications NCT03865056 829 846 B-Contraindication
to NCT03865056 847 849 O
noninvasive NCT03865056 850 861 B-Procedure
ventilation NCT03865056 862 873 I-Procedure
; NCT03865056 873 874 O

11 NCT03865056 876 878 O
. NCT03865056 878 879 O
Tracheostomy NCT03865056 881 893 B-Procedure
. NCT03865056 893 894 O

Inclusion NCT03868228 0 9 O
Criteria NCT03868228 10 18 O
: NCT03868228 19 20 O

1 NCT03868228 24 25 O
. NCT03868228 25 26 O
Patients NCT03868228 28 36 O
with NCT03868228 37 41 O
CPM NCT03868228 42 45 B-Condition
with NCT03868228 46 50 B-And
expected NCT03868228 51 59 B-Modifier
life NCT03868228 60 64 B-Observation
expectancy NCT03868228 65 75 I-Observation
of NCT03868228 76 78 O
> NCT03868228 79 80 B-Eq-Comparison
6 NCT03868228 81 82 I-Eq-Comparison
months NCT03868228 83 89 I-Eq-Comparison
. NCT03868228 89 90 O

2 NCT03868228 94 95 O
. NCT03868228 95 96 O
ECOG NCT03868228 98 102 B-Observation
Scale NCT03868228 103 108 I-Observation
of NCT03868228 109 111 I-Observation
Performance NCT03868228 112 123 I-Observation
Status NCT03868228 124 130 I-Observation
( NCT03868228 131 132 O
PS NCT03868228 133 135 B-Observation
) NCT03868228 136 137 O
scores NCT03868228 138 144 B-Eq-Comparison
0 NCT03868228 145 146 I-Eq-Comparison
or NCT03868228 147 149 I-Eq-Comparison
1 NCT03868228 150 151 I-Eq-Comparison
. NCT03868228 151 152 O

3 NCT03868228 156 157 O
. NCT03868228 157 158 O
15 NCT03868228 160 162 O
mile NCT03868228 163 167 O
catchment NCT03868228 168 177 O
area NCT03868228 178 182 O
to NCT03868228 183 185 B-Assertion___Assertion-Type-Value:hypothetical
facilitate NCT03868228 186 196 I-Assertion___Assertion-Type-Value:hypothetical
overseeing NCT03868228 197 207 O
systemic NCT03868228 208 216 B-Modifier
chemotherapy NCT03868228 217 229 B-Procedure
administration NCT03868228 230 244 O

4 NCT03868228 247 248 O
. NCT03868228 248 249 O
Concomitant NCT03868228 251 262 B-Modifier
systemic NCT03868228 263 271 I-Modifier
chemotherapy NCT03868228 272 284 B-Procedure
regimens NCT03868228 285 293 O
with NCT03868228 294 298 O
FOLFIRI NCT03868228 299 306 B-Drug
, NCT03868228 307 308 O
FOLFOX NCT03868228 309 315 B-Drug
, NCT03868228 316 317 O
Mitomycin NCT03868228 318 327 B-Drug
C NCT03868228 328 329 I-Drug
& NCT03868228 330 331 B-Or

Fluorouracil NCT03868228 337 349 B-Drug
, NCT03868228 350 351 O
Capecitabine NCT03868228 352 364 B-Drug
( NCT03868228 365 366 O
excluding NCT03868228 367 376 B-Exception
Lonsurf NCT03868228 377 384 B-Drug
) NCT03868228 385 386 O
or NCT03868228 387 389 B-Or
without NCT03868228 390 397 B-Negation
systemic NCT03868228 398 406 B-Modifier
chemotherapy NCT03868228 407 419 B-Procedure
if NCT03868228 420 422 O
no NCT03868228 423 425 B-Negation
systemic NCT03868228 426 434 B-Modifier
options NCT03868228 435 442 O
available NCT03868228 443 452 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868228 453 455 O
patient NCT03868228 456 463 O

5 NCT03868228 466 467 O
. NCT03868228 467 468 O
Neutrophil NCT03868228 470 480 B-Observation
count NCT03868228 481 486 I-Observation
on NCT03868228 487 489 B-Temporal-Connection___Temporal-Connection-Type-Value:during
or NCT03868228 490 492 B-Or
just NCT03868228 493 497 O
before NCT03868228 498 504 B-Temporal-Connection___Temporal-Connection-Type-Value:before
chemotherapy NCT03868228 505 517 B-Procedure
due NCT03868228 518 521 O
date NCT03868228 522 526 O
of NCT03868228 527 529 O
> NCT03868228 530 531 B-Eq-Comparison
1.5 NCT03868228 532 535 I-Eq-Comparison

Exclusion NCT03868228 537 546 O
Criteria NCT03868228 547 555 O
: NCT03868228 556 557 O

1 NCT03868228 561 562 O
. NCT03868228 562 563 O
Age NCT03868228 565 568 B-Age
< NCT03868228 569 570 B-Eq-Comparison
18 NCT03868228 571 573 I-Eq-Comparison

2 NCT03868228 577 578 O
. NCT03868228 578 579 O
MDT NCT03868228 581 584 B-Condition
decision NCT03868228 585 593 O
that NCT03868228 594 598 O
patient NCT03868228 599 606 O
not NCT03868228 607 610 B-Negation
suitable NCT03868228 611 619 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868228 620 623 O
PIPAC NCT03868228 624 629 B-Procedure

3 NCT03868228 632 633 O
. NCT03868228 633 634 O
Decision NCT03868228 636 644 O
by NCT03868228 645 647 O
Pre NCT03868228 648 651 B-Procedure
- NCT03868228 652 653 O
- NCT03868228 655 656 O
operative NCT03868228 657 666 O
Assessment NCT03868228 667 677 I-Procedure
Department NCT03868228 678 688 O
or NCT03868228 689 691 B-Or
Consultant NCT03868228 692 702 B-Modifier
Anaesthetist NCT03868228 703 715 B-Provider
that NCT03868228 716 720 O
patient NCT03868228 721 728 O
not NCT03868228 729 732 B-Negation
fit NCT03868228 733 736 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868228 737 740 I-Assertion___Assertion-Type-Value:hypothetical
general NCT03868228 741 748 B-Procedure
anaesthesia NCT03868228 749 760 I-Procedure
and NCT03868228 761 764 B-Or
/ NCT03868228 765 766 I-Or
or NCT03868228 767 769 I-Or
laparoscopy NCT03868228 770 781 B-Procedure

4 NCT03868228 784 785 O
. NCT03868228 785 786 O
Clinically NCT03868228 788 798 O
evident NCT03868228 799 806 B-Condition
gross NCT03868228 807 812 I-Condition
ascites NCT03868228 813 820 I-Condition

5 NCT03868228 823 824 O
. NCT03868228 824 825 O
Bowel NCT03868228 827 832 B-Condition
obstruction NCT03868228 833 844 I-Condition

6 NCT03868228 847 848 O
. NCT03868228 848 849 O
Bevacizumab NCT03868228 851 862 B-Drug
as NCT03868228 863 865 O
part NCT03868228 866 870 O
of NCT03868228 871 873 O
systemic NCT03868228 874 882 B-Modifier
chemotherapy NCT03868228 883 895 B-Procedure|Procedure
regime NCT03868228 896 902 O
- NCT03868228 903 904 O
time NCT03868228 905 909 O
from NCT03868228 910 914 O
chemotherapy NCT03868228 915 927 O
to NCT03868228 928 930 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03868228 931 938 B-Procedure
would NCT03868228 939 944 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03868228 945 947 I-Assertion___Assertion-Type-Value:hypothetical
too NCT03868228 948 951 O
long NCT03868228 952 956 O
for NCT03868228 957 960 O
PIPAC NCT03868228 961 966 B-Procedure
to NCT03868228 967 969 O
be NCT03868228 970 972 O
feasible NCT03868228 973 981 O

7 NCT03868228 984 985 O
. NCT03868228 985 986 O
Previous NCT03868228 988 996 B-Eq-Comparison
bone NCT03868228 997 1001 B-Condition
marrow NCT03868228 1002 1008 I-Condition
suppression NCT03868228 1009 1020 I-Condition
due NCT03868228 1021 1024 O
to NCT03868228 1025 1027 O
chemotherapy NCT03868228 1028 1040 B-Procedure
given NCT03868228 1041 1046 O
risk NCT03868228 1047 1051 B-Risk
of NCT03868228 1052 1054 O
post NCT03868228 1055 1059 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03868228 1060 1061 O
- NCT03868228 1063 1064 O
operative NCT03868228 1065 1074 B-Procedure
neutropenia NCT03868228 1075 1086 B-Condition

Key NCT03866577 0 3 O
Criteria NCT03866577 4 12 O
for NCT03866577 13 16 O
Healthy NCT03866577 17 24 B-Condition
Volunteers NCT03866577 25 35 O
: NCT03866577 36 37 O
Subject NCT03866577 38 45 O
must NCT03866577 46 50 O
be NCT03866577 51 53 O
between NCT03866577 54 61 B-Eq-Comparison
the NCT03866577 62 65 I-Eq-Comparison
ages NCT03866577 66 70 I-Age|Eq-Comparison
of NCT03866577 71 73 I-Eq-Comparison
18 NCT03866577 74 76 I-Eq-Comparison
and NCT03866577 77 80 I-Eq-Comparison
55 NCT03866577 81 83 I-Eq-Comparison
years NCT03866577 84 89 I-Eq-Comparison
; NCT03866577 89 90 O

healthy NCT03866577 91 98 B-Condition
as NCT03866577 99 101 O
indicated NCT03866577 102 111 O
by NCT03866577 112 114 O
medical NCT03866577 115 122 B-Procedure
history NCT03866577 123 130 I-Procedure
, NCT03866577 131 132 O
physical NCT03866577 133 141 B-Procedure
examination NCT03866577 142 153 I-Procedure
, NCT03866577 154 155 O
vital NCT03866577 156 161 B-Observation
signs NCT03866577 162 167 I-Observation
, NCT03866577 168 169 O
clinical NCT03866577 170 178 O
laboratory NCT03866577 179 189 B-Observation
tests NCT03866577 190 195 I-Observation
, NCT03866577 196 197 O
and NCT03866577 198 201 B-Or
12 NCT03866577 202 204 B-Procedure
- NCT03866577 205 206 I-Procedure
lead NCT03866577 207 211 I-Procedure
electrocardiogram NCT03866577 212 229 I-Procedure
, NCT03866577 230 231 O
and NCT03866577 232 235 B-And
all NCT03866577 236 239 O
abnormal NCT03866577 240 248 O
findings NCT03866577 249 257 B-Condition
are NCT03866577 258 261 O
assessed NCT03866577 262 270 O
as NCT03866577 271 273 O
not NCT03866577 274 277 B-Negation
clinically NCT03866577 278 288 O
significant NCT03866577 289 300 O
by NCT03866577 301 303 O
the NCT03866577 304 307 O
Investigator NCT03866577 308 320 O
; NCT03866577 320 321 O
not NCT03866577 322 325 B-Negation
pregnant NCT03866577 326 334 B-Condition
or NCT03866577 335 337 B-Or
breastfeeding NCT03866577 338 351 B-Condition
; NCT03866577 351 352 O
and NCT03866577 353 356 B-And
no NCT03866577 357 359 B-Negation
other NCT03866577 360 365 B-Other
clinically NCT03866577 366 376 O
relevant NCT03866577 377 385 O
abnormalities NCT03866577 386 399 B-Condition
currently NCT03866577 400 409 B-Eq-Comparison
or NCT03866577 410 412 B-Or
in NCT03866577 413 415 O
their NCT03866577 416 421 O
history NCT03866577 422 429 B-Eq-Comparison
that NCT03866577 430 434 O
the NCT03866577 435 438 O
Investigator NCT03866577 439 451 O
would NCT03866577 452 457 O
deem NCT03866577 458 462 O
them NCT03866577 463 467 O
ineligible NCT03866577 468 478 O
to NCT03866577 479 481 O
participate NCT03866577 482 493 O
. NCT03866577 493 494 O

Key NCT03866577 496 499 O
Criteria NCT03866577 500 508 O
for NCT03866577 509 512 O
Immune NCT03866577 513 519 B-Condition
Thrombocytopenic NCT03866577 520 536 I-Condition
Purpura NCT03866577 537 544 I-Condition
( NCT03866577 545 546 O
ITP NCT03866577 547 550 B-Condition
) NCT03866577 551 552 O
Patients NCT03866577 553 561 O
: NCT03866577 562 563 O
Patient NCT03866577 564 571 O
must NCT03866577 572 576 O
be NCT03866577 577 579 B-Eq-Comparison
between NCT03866577 580 587 O
the NCT03866577 588 591 I-Eq-Comparison
ages NCT03866577 592 596 I-Age|Eq-Comparison
of NCT03866577 597 599 I-Eq-Comparison
18 NCT03866577 600 602 I-Eq-Comparison
to NCT03866577 603 605 I-Eq-Comparison
64 NCT03866577 606 608 I-Eq-Comparison
years NCT03866577 609 614 I-Eq-Comparison
and NCT03866577 615 618 B-And
diagnosed NCT03866577 619 628 O
with NCT03866577 629 633 O
ITP NCT03866577 634 637 B-Condition
at NCT03866577 638 640 B-Eq-Comparison
least NCT03866577 641 646 I-Eq-Comparison
3 NCT03866577 647 648 I-Eq-Comparison
months NCT03866577 649 655 I-Eq-Comparison
prior NCT03866577 656 661 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866577 662 664 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03866577 665 674 B-Study
, NCT03866577 675 676 O
stable NCT03866577 677 683 O
maintenance NCT03866577 684 695 B-Procedure
therapy NCT03866577 696 703 I-Procedure
for NCT03866577 704 707 O
at NCT03866577 708 710 B-Eq-Comparison
least NCT03866577 711 716 I-Eq-Comparison
4 NCT03866577 717 718 I-Eq-Comparison
weeks NCT03866577 719 724 I-Eq-Comparison
prior NCT03866577 725 730 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866577 731 733 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866577 734 737 O
first NCT03866577 738 743 B-Eq-Comparison
study NCT03866577 744 749 B-Study
visit NCT03866577 750 755 O
, NCT03866577 756 757 O
not NCT03866577 758 761 B-Negation
pregnant NCT03866577 762 770 B-Condition
or NCT03866577 771 773 B-Or
breastfeeding NCT03866577 774 787 B-Condition
, NCT03866577 788 789 O
and NCT03866577 790 793 B-And
no NCT03866577 794 796 B-Negation
other NCT03866577 797 802 B-Other
clinically NCT03866577 803 813 O
relevant NCT03866577 814 822 O
abnormalities NCT03866577 823 836 B-Condition
currently NCT03866577 837 846 B-Eq-Comparison
or NCT03866577 847 849 B-Or
in NCT03866577 850 852 O
their NCT03866577 853 858 O
history NCT03866577 859 866 B-Eq-Comparison
that NCT03866577 867 871 O
the NCT03866577 872 875 O
Investigator NCT03866577 876 888 O
would NCT03866577 889 894 O
deem NCT03866577 895 899 O
them NCT03866577 900 904 O
ineligible NCT03866577 905 915 O
to NCT03866577 916 918 O
participate NCT03866577 919 930 O
. NCT03866577 930 931 O


Inclusion NCT03865095 0 9 O
Criteria NCT03865095 10 18 O
: NCT03865095 19 20 O

- NCT03865095 24 25 O
age NCT03865095 27 30 B-Age
≥ NCT03865095 31 32 B-Eq-Comparison
18 NCT03865095 33 35 I-Eq-Comparison
years NCT03865095 36 41 I-Eq-Comparison

- NCT03865095 44 45 O
mechanical NCT03865095 47 57 B-Procedure
ventilation NCT03865095 58 69 I-Procedure
expected NCT03865095 70 78 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865095 79 82 O
at NCT03865095 83 85 B-Eq-Comparison
least NCT03865095 86 91 I-Eq-Comparison
48 NCT03865095 92 94 I-Eq-Comparison
hours NCT03865095 95 100 I-Eq-Comparison

Exclusion NCT03865095 101 110 O
Criteria NCT03865095 111 119 O
: NCT03865095 120 121 O

- NCT03865095 125 126 O
Clinical NCT03865095 128 136 B-Observation
Frailty NCT03865095 137 144 I-Observation
Score NCT03865095 145 150 I-Observation
above NCT03865095 151 156 B-Eq-Comparison
7 NCT03865095 157 158 I-Eq-Comparison
prior NCT03865095 159 164 B-Eq-Comparison
admission NCT03865095 165 174 B-Encounter

- NCT03865095 177 178 O
neuromuscular NCT03865095 180 193 B-Condition
disease NCT03865095 194 201 I-Condition
in NCT03865095 202 204 O
previous NCT03865095 205 213 B-Eq-Comparison
medical NCT03865095 214 221 I-Eq-Comparison
history NCT03865095 222 229 I-Eq-Comparison

- NCT03865095 232 233 O
amputated NCT03865095 235 244 B-Condition
lower NCT03865095 245 250 B-Modifier
extremities NCT03865095 251 262 I-Modifier

- NCT03865095 265 266 O
trauma NCT03865095 268 274 B-Condition
of NCT03865095 275 277 O
lower NCT03865095 278 283 B-Modifier
extremities NCT03865095 284 295 I-Modifier
involving NCT03865095 296 305 I-Modifier
tights NCT03865095 306 312 I-Modifier

- NCT03865095 315 316 O
age NCT03865095 318 321 B-Age
under NCT03865095 322 327 B-Eq-Comparison
18 NCT03865095 328 330 I-Eq-Comparison
years NCT03865095 331 336 I-Eq-Comparison

- NCT03865095 339 340 O
inability NCT03865095 342 351 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865095 352 354 O
perform NCT03865095 355 362 O
ultrasound NCT03865095 363 373 B-Procedure
examination NCT03865095 374 385 I-Procedure

- NCT03865095 388 389 O
death NCT03865095 391 396 B-Death
or NCT03865095 397 399 B-Or
discharge NCT03865095 400 409 B-Encounter
prior NCT03865095 410 415 B-Temporal-Connection___Temporal-Connection-Type-Value:before
completion NCT03865095 416 426 O
of NCT03865095 427 429 O
protocol NCT03865095 430 438 B-Study

- NCT03865095 441 442 O
full NCT03865095 444 448 B-Procedure
verticalization NCT03865095 449 464 I-Procedure
prior NCT03865095 465 470 B-Temporal-Connection___Temporal-Connection-Type-Value:before
completion NCT03865095 471 481 O
of NCT03865095 482 484 O
protocol NCT03865095 485 493 B-Study

Inclusion NCT03867682 0 9 O
Criteria NCT03867682 10 18 O
: NCT03867682 19 20 O

1 NCT03867682 24 25 O
. NCT03867682 25 26 O
Refractory NCT03867682 28 38 B-Modifier
or NCT03867682 39 41 B-Or
relapsed NCT03867682 42 50 B-Modifier
AML NCT03867682 51 54 B-Condition
which NCT03867682 55 60 O
will NCT03867682 61 65 O
include NCT03867682 66 73 O
: NCT03867682 74 75 O

1 NCT03867682 84 85 O
. NCT03867682 85 86 O
Refractory NCT03867682 88 98 B-Condition
disease NCT03867682 99 106 I-Condition
will NCT03867682 107 111 O
be NCT03867682 112 114 O
defined NCT03867682 115 122 O
as NCT03867682 123 125 O
at NCT03867682 126 128 B-Eq-Comparison
least NCT03867682 129 134 I-Eq-Comparison
1 NCT03867682 135 136 I-Eq-Comparison
prior NCT03867682 137 142 B-Eq-Comparison
treatment NCT03867682 143 152 B-Procedure
with NCT03867682 153 157 B-And
no NCT03867682 158 160 B-Negation
remission NCT03867682 161 170 B-Condition
. NCT03867682 170 171 O

2 NCT03867682 180 181 O
. NCT03867682 181 182 O
Relapsed NCT03867682 184 192 B-Condition
disease NCT03867682 193 200 I-Condition
will NCT03867682 201 205 O
be NCT03867682 206 208 O
defined NCT03867682 209 216 O
as NCT03867682 217 219 O
5 NCT03867682 220 221 B-Eq-Comparison
% NCT03867682 222 223 O
or NCT03867682 224 226 I-Eq-Comparison
more NCT03867682 227 231 I-Eq-Comparison
blasts NCT03867682 232 238 B-Observation
in NCT03867682 239 241 I-Observation
bone NCT03867682 242 246 I-Observation
marrow NCT03867682 247 253 I-Observation
seen NCT03867682 254 258 O
after NCT03867682 259 264 B-Temporal-Connection___Temporal-Connection-Type-Value:after
remission NCT03867682 265 274 B-Condition
. NCT03867682 274 275 O

3 NCT03867682 284 285 O
. NCT03867682 285 286 O
Patients NCT03867682 288 296 O
with NCT03867682 297 301 O
AML NCT03867682 302 305 B-Condition
arising NCT03867682 306 313 O
from NCT03867682 314 318 O
myelodysplastic NCT03867682 319 334 B-Condition
syndromes NCT03867682 335 344 I-Condition
( NCT03867682 345 346 O
including NCT03867682 347 356 O
CMML NCT03867682 357 361 B-Condition
) NCT03867682 362 363 O
or NCT03867682 364 366 B-Or
myeloproliferative NCT03867682 367 385 B-Condition
neoplasms NCT03867682 386 395 I-Condition
( NCT03867682 396 397 O
secondary NCT03867682 398 407 B-Modifier
AML NCT03867682 408 411 B-Condition|Condition
, NCT03867682 412 413 O
ts NCT03867682 414 416 B-Condition
- NCT03867682 417 418 I-Condition
AML NCT03867682 419 422 O
) NCT03867682 423 424 O
are NCT03867682 425 428 O
also NCT03867682 429 433 O
eligible NCT03867682 434 442 O
. NCT03867682 442 443 O

2 NCT03867682 447 448 O
. NCT03867682 448 449 O
Circulating NCT03867682 451 462 B-Observation
blast NCT03867682 463 468 I-Observation
count NCT03867682 469 474 I-Observation
≤ NCT03867682 475 476 B-Eq-Comparison
200 NCT03867682 477 480 I-Eq-Comparison
/ NCT03867682 481 482 I-Eq-Comparison
μL NCT03867682 483 485 I-Eq-Comparison
within NCT03867682 486 492 B-Eq-Comparison
10 NCT03867682 493 495 I-Eq-Comparison
days NCT03867682 496 500 I-Eq-Comparison
prior NCT03867682 501 506 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867682 507 509 I-Temporal-Connection___Temporal-Connection-Type-Value:before
first NCT03867682 510 515 B-Eq-Comparison
cycle NCT03867682 516 521 O
of NCT03867682 522 524 O
treatment NCT03867682 525 534 B-Procedure
. NCT03867682 534 535 O
Hydroxyurea NCT03867682 537 548 B-Drug
should NCT03867682 549 555 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867682 556 558 I-Assertion___Assertion-Type-Value:hypothetical
used NCT03867682 559 563 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867682 564 566 O
keep NCT03867682 567 571 O
the NCT03867682 572 575 O
peripheral NCT03867682 576 586 B-Observation
blast NCT03867682 587 592 I-Observation
count NCT03867682 593 598 I-Observation
≤ NCT03867682 599 600 B-Eq-Comparison
200 NCT03867682 601 604 I-Eq-Comparison
/ NCT03867682 605 606 I-Eq-Comparison
μL NCT03867682 607 609 I-Eq-Comparison
until NCT03867682 610 615 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867682 616 619 O
first NCT03867682 620 625 B-Eq-Comparison
day NCT03867682 626 629 I-Eq-Comparison
of NCT03867682 630 632 O
protocol NCT03867682 633 641 O
treatment NCT03867682 642 651 B-Procedure
, NCT03867682 652 653 O
to NCT03867682 654 656 O
the NCT03867682 657 660 O
extent NCT03867682 661 667 O
that NCT03867682 668 672 O
this NCT03867682 673 677 O
is NCT03867682 678 680 O
possible NCT03867682 681 689 O

3 NCT03867682 692 693 O
. NCT03867682 693 694 O
ECOG NCT03867682 696 700 B-Observation
≤ NCT03867682 701 702 B-Eq-Comparison
2 NCT03867682 703 704 I-Eq-Comparison

4 NCT03867682 708 709 O
. NCT03867682 709 710 O
Estimated NCT03867682 712 721 B-Observation
creatinine NCT03867682 722 732 I-Observation
clearance NCT03867682 733 742 I-Observation
≥ NCT03867682 743 744 B-Eq-Comparison
50 NCT03867682 745 747 I-Eq-Comparison
mL NCT03867682 748 750 I-Eq-Comparison
/ NCT03867682 751 752 I-Eq-Comparison
min NCT03867682 753 756 I-Eq-Comparison

5 NCT03867682 759 760 O
. NCT03867682 760 761 O
AST NCT03867682 763 766 B-Observation
and NCT03867682 767 770 B-And
ALT NCT03867682 771 774 B-Observation
≤ NCT03867682 775 776 B-Eq-Comparison|Eq-Comparison
3.0 NCT03867682 777 780 I-Eq-Comparison|Eq-Comparison
x NCT03867682 781 782 I-Eq-Comparison|Eq-Comparison
ULN NCT03867682 783 786 I-Eq-Comparison|Eq-Comparison

6 NCT03867682 789 790 O
. NCT03867682 790 791 O
Bilirubin NCT03867682 793 802 B-Observation
≤ NCT03867682 803 804 O
3.0 NCT03867682 805 808 O
x NCT03867682 809 810 O
ULN NCT03867682 811 814 O

Exclusion NCT03867682 815 824 O
Criteria NCT03867682 825 833 O
: NCT03867682 834 835 O

1 NCT03867682 839 840 O
. NCT03867682 840 841 O
Active NCT03867682 843 849 B-Eq-Comparison
CNS NCT03867682 850 853 B-Modifier
Leukemia NCT03867682 854 862 B-Condition
. NCT03867682 862 863 O

2 NCT03867682 867 868 O
. NCT03867682 868 869 O
Known NCT03867682 871 876 O
HIV NCT03867682 877 880 B-Condition
infection NCT03867682 881 890 I-Condition
or NCT03867682 891 893 B-Or|Or
known NCT03867682 894 899 O
hepatitis NCT03867682 900 909 B-Modifier|Modifier
B NCT03867682 910 911 I-Modifier
or NCT03867682 912 914 O
hepatitis NCT03867682 915 924 O
C NCT03867682 925 926 I-Modifier
infection NCT03867682 927 936 B-Condition
( NCT03867682 937 938 O
with NCT03867682 939 943 O
a NCT03867682 944 945 O
detectable NCT03867682 946 956 O
viral NCT03867682 957 962 B-Observation
load NCT03867682 963 967 I-Observation
) NCT03867682 968 969 O
. NCT03867682 970 971 O

3 NCT03867682 975 976 O
. NCT03867682 976 977 O
Participant NCT03867682 979 990 O
has NCT03867682 991 994 O
received NCT03867682 995 1003 B-Eq-Comparison
strong NCT03867682 1004 1010 O
and NCT03867682 1011 1014 B-Or
/ NCT03867682 1015 1016 I-Or
or NCT03867682 1017 1019 I-Or
moderate NCT03867682 1020 1028 O
CYP3A NCT03867682 1029 1034 B-Drug
inducers NCT03867682 1035 1043 I-Drug
within NCT03867682 1044 1050 B-Eq-Comparison
7 NCT03867682 1051 1052 I-Eq-Comparison
days NCT03867682 1053 1057 I-Eq-Comparison
prior NCT03867682 1058 1063 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867682 1064 1066 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867682 1067 1070 O
initiation NCT03867682 1071 1081 B-Eq-Comparison
of NCT03867682 1082 1084 O
study NCT03867682 1085 1090 B-Study
treatment NCT03867682 1091 1100 B-Procedure
. NCT03867682 1100 1101 O

4 NCT03867682 1105 1106 O
. NCT03867682 1106 1107 O
Have NCT03867682 1109 1113 O
received NCT03867682 1114 1122 B-Eq-Comparison
prior NCT03867682 1123 1128 I-Eq-Comparison
radiation NCT03867682 1129 1138 B-Procedure
to NCT03867682 1139 1141 I-Modifier
maximally NCT03867682 1142 1151 B-Modifier
tolerated NCT03867682 1152 1161 O
levels NCT03867682 1162 1168 I-Modifier
to NCT03867682 1169 1171 O
any NCT03867682 1172 1175 O
critical NCT03867682 1176 1184 O
normal NCT03867682 1185 1191 O
organ NCT03867682 1192 1197 B-Modifier
. NCT03867682 1197 1198 O

5 NCT03867682 1202 1203 O
. NCT03867682 1203 1204 O
Clinically NCT03867682 1206 1216 O
significant NCT03867682 1217 1228 O
cardiac NCT03867682 1229 1236 B-Condition
disease NCT03867682 1237 1244 I-Condition
. NCT03867682 1244 1245 O

6 NCT03867682 1249 1250 O
. NCT03867682 1250 1251 O
Active NCT03867682 1253 1259 B-Eq-Comparison
, NCT03867682 1260 1261 O
uncontrolled NCT03867682 1262 1274 B-Modifier
serious NCT03867682 1275 1282 O
infection NCT03867682 1283 1292 B-Condition
. NCT03867682 1292 1293 O

7 NCT03867682 1297 1298 O
. NCT03867682 1298 1299 O
Have NCT03867682 1301 1305 O
other NCT03867682 1306 1311 B-Other
non NCT03867682 1312 1315 B-Negation
- NCT03867682 1316 1317 O
myeloid NCT03867682 1318 1325 B-Modifier
malignancy NCT03867682 1326 1336 B-Condition
within NCT03867682 1337 1343 B-Eq-Comparison
2 NCT03867682 1344 1345 I-Eq-Comparison
years NCT03867682 1346 1351 I-Eq-Comparison
of NCT03867682 1352 1354 B-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03867682 1355 1360 B-Study
( NCT03867682 1361 1362 O
with NCT03867682 1363 1367 O
exceptions NCT03867682 1368 1378 O
) NCT03867682 1379 1380 O
. NCT03867682 1381 1382 O

8 NCT03867682 1386 1387 O
. NCT03867682 1387 1388 O
Psychiatric NCT03867682 1390 1401 B-Condition
disorder NCT03867682 1402 1410 I-Condition
that NCT03867682 1411 1415 O
would NCT03867682 1416 1421 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03867682 1422 1430 B-Negation
study NCT03867682 1431 1436 B-Study
participation NCT03867682 1437 1450 O

9 NCT03867682 1453 1454 O
. NCT03867682 1454 1455 O
Previous NCT03867682 1457 1465 B-Eq-Comparison
solid NCT03867682 1466 1471 B-Modifier
organ NCT03867682 1472 1477 B-Procedure
transplant NCT03867682 1478 1488 I-Procedure
( NCT03867682 1489 1490 O
prior NCT03867682 1491 1496 B-Eq-Comparison
treatment NCT03867682 1497 1506 B-Procedure
with NCT03867682 1507 1511 O
SCT NCT03867682 1512 1515 B-Procedure
is NCT03867682 1516 1518 O
allowed NCT03867682 1519 1526 O
but NCT03867682 1527 1530 B-And
not NCT03867682 1531 1534 B-Negation
if NCT03867682 1535 1537 O
patient NCT03867682 1538 1545 O
has NCT03867682 1546 1549 O
GVHD NCT03867682 1550 1554 B-Condition|Procedure
or NCT03867682 1555 1557 B-Or
is NCT03867682 1558 1560 O
still NCT03867682 1561 1566 O
receiving NCT03867682 1567 1576 B-Eq-Comparison
immunosuppression NCT03867682 1577 1594 B-Procedure
/ NCT03867682 1595 1596 B-Or
GVHD NCT03867682 1597 1601 O
therapy NCT03867682 1602 1609 I-Procedure
) NCT03867682 1610 1611 O
. NCT03867682 1612 1613 O

Inclusion NCT03861754 0 9 O
Criteria NCT03861754 10 18 O
: NCT03861754 19 20 O

- NCT03861754 24 25 O
Body NCT03861754 27 31 B-Observation
mass NCT03861754 32 36 I-Observation
Index NCT03861754 37 42 I-Observation
> NCT03861754 43 44 B-Eq-Comparison
30 NCT03861754 45 47 I-Eq-Comparison

- NCT03861754 51 52 O
Age NCT03861754 54 57 B-Age
18 NCT03861754 58 60 B-Eq-Comparison
- NCT03861754 61 62 I-Eq-Comparison
64 NCT03861754 63 65 O

Exclusion NCT03861754 67 76 O
Criteria NCT03861754 77 85 O
: NCT03861754 86 87 O

- NCT03861754 91 92 O
Pregnancy NCT03861754 94 103 B-Condition

- NCT03861754 106 107 O
Health NCT03861754 109 115 B-Condition
reasons NCT03861754 116 123 I-Condition
preventing NCT03861754 124 134 B-Assertion___Assertion-Type-Value:hypothetical|Negation
exercise NCT03861754 135 143 B-Observation
and NCT03861754 144 147 B-Or
exercise NCT03861754 148 156 B-Procedure
test NCT03861754 157 161 I-Procedure

- NCT03861754 164 165 O
Medication NCT03861754 167 177 B-Drug
preventing NCT03861754 178 188 B-Assertion___Assertion-Type-Value:hypothetical|Negation
exercise NCT03861754 189 197 B-Observation
and NCT03861754 198 201 B-Or
exercise NCT03861754 202 210 B-Procedure
test NCT03861754 211 215 I-Procedure

- NCT03861754 218 219 O
Previously NCT03861754 221 231 B-Eq-Comparison
diagnosed NCT03861754 232 241 O
diabetes NCT03861754 242 250 B-Condition

Inclusion NCT03862261 0 9 O
Criteria NCT03862261 10 18 O
: NCT03862261 19 20 O

- NCT03862261 24 25 O
Children NCT03862261 27 35 O
< NCT03862261 36 37 B-Eq-Comparison
5 NCT03862261 38 39 I-Eq-Comparison
years NCT03862261 40 45 I-Eq-Comparison
old NCT03862261 46 49 B-Age
. NCT03862261 49 50 O

- NCT03862261 54 55 O
Presumptive NCT03862261 57 68 B-Assertion___Assertion-Type-Value:possible
pulmonary NCT03862261 69 78 B-Modifier
or NCT03862261 79 81 B-Or
extra NCT03862261 82 87 B-Modifier
- NCT03862261 88 89 I-Modifier
pulmonary NCT03862261 90 99 I-Modifier
TB NCT03862261 100 102 B-Condition
case NCT03862261 103 107 O
: NCT03862261 108 109 O
symptoms NCT03862261 110 118 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 119 121 B-Or
clinical NCT03862261 122 130 O
signs NCT03862261 131 136 B-Assertion___Assertion-Type-Value:possible
suggestive NCT03862261 137 147 B-Assertion___Assertion-Type-Value:possible
of NCT03862261 148 150 O
active NCT03862261 151 157 B-Eq-Comparison
TB NCT03862261 158 160 B-Condition
disease NCT03862261 161 168 I-Condition
. NCT03862261 168 169 O

- NCT03862261 173 174 O
Other NCT03862261 176 181 B-Other
infectious NCT03862261 182 192 B-Condition
diseases NCT03862261 193 201 I-Condition
are NCT03862261 202 205 O
not NCT03862261 206 209 B-Negation
suspected NCT03862261 210 219 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 220 222 B-Or
have NCT03862261 223 227 O
already NCT03862261 228 235 O
been NCT03862261 236 240 O
ruled NCT03862261 241 246 O
out NCT03862261 247 250 O
. NCT03862261 250 251 O

- NCT03862261 255 256 O
Commitment NCT03862261 258 268 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862261 269 271 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03862261 272 276 O
treatment NCT03862261 277 286 B-Procedure
in NCT03862261 287 289 O
the NCT03862261 290 293 O
clinic NCT03862261 294 300 O
of NCT03862261 301 303 O
enrolment NCT03862261 304 313 O
or NCT03862261 314 316 B-Or
another NCT03862261 317 324 O
INPUT NCT03862261 325 330 O
study NCT03862261 331 336 B-Study
site NCT03862261 337 341 O
. NCT03862261 341 342 O

- NCT03862261 346 347 O
Parental NCT03862261 349 357 B-Family-Member___Family-Member-Type:parent
/ NCT03862261 358 359 O
caregiver NCT03862261 360 369 O
consent NCT03862261 370 377 O
for NCT03862261 378 381 O
the NCT03862261 382 385 O
child NCT03862261 386 391 B-Family-Member___Family-Member-Type:child
to NCT03862261 392 394 O
participate NCT03862261 395 406 O
in NCT03862261 407 409 O
the NCT03862261 410 413 O
study NCT03862261 414 419 B-Study
. NCT03862261 419 420 O

Exclusion NCT03862261 422 431 O
Criteria NCT03862261 432 440 O
: NCT03862261 441 442 O

- NCT03862261 446 447 O
Children NCT03862261 449 457 O
who NCT03862261 458 461 B-And
are NCT03862261 462 465 O
TB NCT03862261 466 468 B-Condition
contacts NCT03862261 469 477 O
but NCT03862261 478 481 B-And
without NCT03862261 482 489 B-Negation
symptoms NCT03862261 490 498 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 499 501 B-Or
signs NCT03862261 502 507 B-Assertion___Assertion-Type-Value:possible
of NCT03862261 508 510 O
active NCT03862261 511 517 B-Eq-Comparison
TB NCT03862261 518 520 B-Condition

Inclusion NCT03861637 0 9 O
Criteria NCT03861637 10 18 O
: NCT03861637 19 20 O

- NCT03861637 24 25 O
Patients NCT03861637 27 35 O
who NCT03861637 36 39 O
fulfilled NCT03861637 40 49 O
the NCT03861637 50 53 O
following NCT03861637 54 63 O
criteria NCT03861637 64 72 O
were NCT03861637 73 77 O
included NCT03861637 78 86 O
in NCT03861637 87 89 O
the NCT03861637 90 93 O
study NCT03861637 94 99 O
: NCT03861637 100 101 O

- NCT03861637 105 106 O
Adult NCT03861637 108 113 O
renal NCT03861637 114 119 B-Procedure
transplant NCT03861637 120 130 I-Procedure
patients NCT03861637 131 139 O
( NCT03861637 140 141 O
≥ NCT03861637 143 144 B-Eq-Comparison
21 NCT03861637 145 147 I-Eq-Comparison
years NCT03861637 148 153 B-Age
) NCT03861637 154 155 O
, NCT03861637 157 158 O

- NCT03861637 162 163 O
Informed NCT03861637 165 173 O
consent NCT03861637 174 181 O
, NCT03861637 182 183 O

- NCT03861637 187 188 O
Stable NCT03861637 190 196 O
maintenance NCT03861637 197 208 O
subcutaneous NCT03861637 209 221 B-Modifier
ESA NCT03861637 222 225 B-Procedure
therapy NCT03861637 226 233 I-Procedure
with NCT03861637 234 238 O
constant NCT03861637 239 247 O
dose NCT03861637 248 252 O
interval NCT03861637 253 261 O
during NCT03861637 262 268 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861637 269 272 O
last NCT03861637 273 277 B-Eq-Comparison
2 NCT03861637 278 279 I-Eq-Comparison
months NCT03861637 280 286 I-Eq-Comparison
, NCT03861637 287 288 O

- NCT03861637 292 293 O
Haemoglobin NCT03861637 295 306 B-Observation
( NCT03861637 307 308 O
Hb NCT03861637 309 311 B-Observation
) NCT03861637 312 313 O
≥ NCT03861637 314 315 B-Eq-Comparison
10 NCT03861637 316 318 I-Eq-Comparison
mg NCT03861637 319 321 O
/ NCT03861637 322 323 I-Eq-Comparison
dL NCT03861637 324 326 I-Eq-Comparison
( NCT03861637 327 328 O
Hct NCT03861637 329 332 B-Observation
32 NCT03861637 333 335 B-Eq-Comparison
% NCT03861637 336 337 O
) NCT03861637 338 339 O
, NCT03861637 341 342 O

- NCT03861637 346 347 O
Transferrin NCT03861637 349 360 B-Observation
saturation NCT03861637 361 371 I-Observation
( NCT03861637 372 373 O
TSAT NCT03861637 374 378 B-Observation
) NCT03861637 379 380 O
≥ NCT03861637 381 382 B-Eq-Comparison
20 NCT03861637 383 385 I-Eq-Comparison
% NCT03861637 386 387 O
( NCT03861637 388 389 O
during NCT03861637 390 396 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861637 397 400 O
screening NCT03861637 401 410 B-Study
phase NCT03861637 411 416 O
) NCT03861637 417 418 O
, NCT03861637 420 421 O

- NCT03861637 425 426 O
and NCT03861637 428 431 B-And
serum NCT03861637 432 437 B-Observation
ferritin NCT03861637 438 446 I-Observation
≥ NCT03861637 447 448 B-Eq-Comparison
100 NCT03861637 449 452 I-Eq-Comparison
ng NCT03861637 453 455 I-Eq-Comparison
/ NCT03861637 456 457 I-Eq-Comparison
mL NCT03861637 458 460 I-Eq-Comparison

Exclusion NCT03861637 461 470 O
Criteria NCT03861637 471 479 O
: NCT03861637 480 481 O

We NCT03861637 483 485 O
excluded NCT03861637 486 494 O
patients NCT03861637 495 503 O
with NCT03861637 504 508 O
the NCT03861637 509 512 O
following NCT03861637 513 522 O
criteria NCT03861637 523 531 O
: NCT03861637 532 533 O

- NCT03861637 537 538 O
Acute NCT03861637 540 545 O
or NCT03861637 546 548 B-Or|Or
chronic NCT03861637 549 556 B-Modifier
bleeding NCT03861637 557 565 B-Condition
, NCT03861637 566 567 O
or NCT03861637 568 570 O
erythrocyte NCT03861637 571 582 B-Procedure
transfusion NCT03861637 583 594 I-Procedure
, NCT03861637 595 596 O
within NCT03861637 597 603 B-Eq-Comparison
the NCT03861637 604 607 I-Eq-Comparison
preceding NCT03861637 608 617 I-Eq-Comparison
8 NCT03861637 618 619 I-Eq-Comparison
weeks NCT03861637 620 625 I-Eq-Comparison
. NCT03861637 625 626 O
change NCT03861637 628 634 O
in NCT03861637 635 637 O
Hb NCT03861637 638 640 B-Observation
level NCT03861637 641 646 O
≥ NCT03861637 647 648 B-Eq-Comparison
2 NCT03861637 649 650 I-Eq-Comparison
g NCT03861637 651 652 I-Eq-Comparison
/ NCT03861637 653 654 I-Eq-Comparison
dL NCT03861637 655 657 I-Eq-Comparison
during NCT03861637 658 664 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03861637 665 674 B-Study
phase NCT03861637 675 680 O
, NCT03861637 681 682 O

- NCT03861637 686 687 O
Hemolytic NCT03861637 689 698 B-Condition
anemia NCT03861637 699 705 I-Condition
, NCT03861637 706 707 O

- NCT03861637 711 712 O
Recent NCT03861637 714 720 B-Eq-Comparison
infection NCT03861637 721 730 B-Condition
or NCT03861637 731 733 B-Or|Or
rejection NCT03861637 734 743 B-Condition
, NCT03861637 744 745 O

- NCT03861637 749 750 O
Diastolic NCT03861637 752 761 B-Observation
blood NCT03861637 762 767 I-Observation
pressure NCT03861637 768 776 I-Observation
> NCT03861637 777 778 O
100 NCT03861637 779 782 B-Eq-Comparison
mmHg NCT03861637 783 787 O
or NCT03861637 788 790 O
discontinuation NCT03861637 791 806 B-Negation
of NCT03861637 807 809 O
ESA NCT03861637 810 813 B-Procedure
due NCT03861637 814 817 O
to NCT03861637 818 820 I-Temporal-Connection___Temporal-Connection-Type-Value:before
hypertension NCT03861637 821 833 B-Condition
in NCT03861637 834 836 O
the NCT03861637 837 840 O
6 NCT03861637 841 842 B-Eq-Comparison
months NCT03861637 843 849 I-Eq-Comparison
prior NCT03861637 850 855 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861637 856 858 O
study NCT03861637 859 864 B-Study
, NCT03861637 865 866 O

- NCT03861637 870 871 O
Vitamin NCT03861637 873 880 B-Modifier
B12 NCT03861637 881 884 I-Modifier
or NCT03861637 885 887 B-Or|Or
folic NCT03861637 888 893 B-Modifier
acid NCT03861637 894 898 I-Modifier
deficiency NCT03861637 899 909 B-Condition
, NCT03861637 910 911 O

- NCT03861637 915 916 O
Uncontrolled NCT03861637 918 930 B-Modifier
or NCT03861637 931 933 B-Or
secondary NCT03861637 934 943 B-Modifier
hyperparathyroidism NCT03861637 944 963 B-Condition
, NCT03861637 964 965 O

- NCT03861637 969 970 I-Observation
Acute NCT03861637 972 977 O
or NCT03861637 978 980 I-Or
chronic NCT03861637 981 988 B-Modifier
systemic NCT03861637 989 997 B-Condition
inflammatory NCT03861637 998 1010 I-Condition
disease NCT03861637 1011 1018 I-Condition
and NCT03861637 1019 1022 B-Or
/ NCT03861637 1023 1024 I-Eq-Comparison|Or
or NCT03861637 1025 1027 O
C NCT03861637 1028 1029 B-Observation
- NCT03861637 1030 1031 O
reactive NCT03861637 1032 1040 I-Observation
protein NCT03861637 1041 1048 I-Observation
( NCT03861637 1049 1050 O
CRP NCT03861637 1051 1054 B-Observation
) NCT03861637 1055 1056 O
> NCT03861637 1057 1058 B-Eq-Comparison
30 NCT03861637 1059 1061 I-Eq-Comparison
mg NCT03861637 1062 1064 I-Eq-Comparison
/ NCT03861637 1065 1066 O
L NCT03861637 1067 1068 I-Eq-Comparison
, NCT03861637 1069 1070 O

- NCT03861637 1074 1075 O
Hemodialysis NCT03861637 1077 1089 B-Procedure
due NCT03861637 1090 1093 O
to NCT03861637 1094 1096 O
failure NCT03861637 1097 1104 B-Modifier
of NCT03861637 1105 1107 O
a NCT03861637 1108 1109 O
kidney NCT03861637 1110 1116 B-Procedure
transplant NCT03861637 1117 1127 I-Procedure
, NCT03861637 1128 1129 O

- NCT03861637 1133 1134 O
and NCT03861637 1136 1139 B-Or
malignancy NCT03861637 1140 1150 B-Condition


Inclusion NCT03864029 0 9 O
Criteria NCT03864029 10 18 O
: NCT03864029 19 20 O

- NCT03864029 24 25 O
Willing NCT03864029 27 34 O
and NCT03864029 35 38 O
able NCT03864029 39 43 O
to NCT03864029 44 46 O
provide NCT03864029 47 54 O
informed NCT03864029 55 63 O
consent NCT03864029 64 71 O
( NCT03864029 72 73 O
unless NCT03864029 74 80 O
exemption NCT03864029 81 90 O
of NCT03864029 91 93 O
obtaining NCT03864029 94 103 O
consent NCT03864029 104 111 O
is NCT03864029 112 114 O
obtained NCT03864029 115 123 O
as NCT03864029 124 126 O
per NCT03864029 127 130 O
local NCT03864029 131 136 O
regulation NCT03864029 137 147 O
) NCT03864029 148 149 O
. NCT03864029 150 151 O
Assent NCT03864029 153 159 O
( NCT03864029 160 161 O
if NCT03864029 162 164 O
required NCT03864029 165 173 O
defined NCT03864029 174 181 O
by NCT03864029 182 184 O
local NCT03864029 185 190 O
regulation NCT03864029 191 201 O
and NCT03864029 202 205 O
requirement NCT03864029 206 217 O
) NCT03864029 218 219 O
should NCT03864029 220 226 O
also NCT03864029 227 231 O
be NCT03864029 232 234 O
obtained NCT03864029 235 243 O
from NCT03864029 244 248 O
the NCT03864029 249 252 O
subject NCT03864029 253 260 O
and NCT03864029 261 264 O
the NCT03864029 265 268 O
legal NCT03864029 269 274 O
authorized NCT03864029 275 285 O
representative NCT03864029 286 300 O
. NCT03864029 300 301 O

- NCT03864029 305 306 O
Diagnosed NCT03864029 308 317 O
with NCT03864029 318 322 O
BH4 NCT03864029 323 326 B-Condition
deficiency NCT03864029 327 337 I-Condition
per NCT03864029 338 341 O
local NCT03864029 342 347 O
practice NCT03864029 348 356 O
. NCT03864029 356 357 O

- NCT03864029 361 362 O
KUVAN NCT03864029 364 369 B-Drug
® NCT03864029 369 370 O
was NCT03864029 371 374 O
taken NCT03864029 375 380 O
at NCT03864029 381 383 B-Eq-Comparison
least NCT03864029 384 389 I-Eq-Comparison
1 NCT03864029 390 391 I-Eq-Comparison
dose NCT03864029 392 396 I-Eq-Comparison
to NCT03864029 397 399 O
treat NCT03864029 400 405 O
HPA NCT03864029 406 409 B-Condition
caused NCT03864029 410 416 O
by NCT03864029 417 419 O
BH4 NCT03864029 420 423 B-Condition
deficiency NCT03864029 424 434 I-Condition
during NCT03864029 435 441 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864029 442 445 O
period NCT03864029 446 452 O
of NCT03864029 453 455 O
observation NCT03864029 456 467 B-Study
. NCT03864029 467 468 O

- NCT03864029 472 473 O
Baseline NCT03864029 475 483 O
Phe NCT03864029 484 487 B-Observation
concentration NCT03864029 488 501 I-Observation
≥ NCT03864029 502 503 B-Eq-Comparison
450 NCT03864029 504 507 I-Eq-Comparison
µmol NCT03864029 508 512 I-Eq-Comparison
/ NCT03864029 513 514 I-Eq-Comparison
L NCT03864029 515 516 I-Eq-Comparison

Exclusion NCT03864029 517 526 O
Criteria NCT03864029 527 535 O
: NCT03864029 536 537 O

- NCT03864029 541 542 O
Subject NCT03864029 544 551 O
diagnosed NCT03864029 552 561 O
to NCT03864029 562 564 O
have NCT03864029 565 569 O
Phenylketonuria NCT03864029 570 585 B-Condition
( NCT03864029 586 587 O
PKU NCT03864029 588 591 B-Condition
) NCT03864029 592 593 O

- NCT03864029 597 598 O
Has NCT03864029 600 603 O
any NCT03864029 604 607 O
condition NCT03864029 608 617 B-Condition
that NCT03864029 618 622 O
, NCT03864029 623 624 O
in NCT03864029 625 627 O
the NCT03864029 628 631 O
view NCT03864029 632 636 O
of NCT03864029 637 639 O
the NCT03864029 640 643 O
Investigator NCT03864029 644 656 O
, NCT03864029 657 658 O
the NCT03864029 659 662 O
medical NCT03864029 663 670 O
record NCT03864029 671 677 O
of NCT03864029 678 680 O
the NCT03864029 681 684 O
subject NCT03864029 685 692 O
in NCT03864029 693 695 O
the NCT03864029 696 699 O
duration NCT03864029 700 708 O
of NCT03864029 709 711 O
observation NCT03864029 712 723 O
is NCT03864029 724 726 O
not NCT03864029 727 730 B-Negation
reliable NCT03864029 731 739 O
, NCT03864029 740 741 O
or NCT03864029 742 744 O
not NCT03864029 745 748 O
accessible NCT03864029 749 759 O
. NCT03864029 759 760 O

Inclusion NCT03869294 0 9 O
Criteria NCT03869294 10 18 O
: NCT03869294 19 20 O

- NCT03869294 24 25 O
1 NCT03869294 27 28 O
. NCT03869294 28 29 O
Histologically NCT03869294 30 44 B-Procedure
confirmed NCT03869294 45 54 O
pancreatic NCT03869294 55 65 B-Condition
adenocarcinoma NCT03869294 66 80 I-Condition
2 NCT03869294 81 82 O
. NCT03869294 82 83 O
Locally NCT03869294 84 91 B-Modifier
advanced NCT03869294 92 100 I-Modifier
or NCT03869294 101 103 B-Or
metastatic NCT03869294 104 114 B-Modifier
PC NCT03869294 115 117 B-Condition
3 NCT03869294 118 119 O
. NCT03869294 119 120 O
Chemotherapy NCT03869294 121 133 B-Procedure
- NCT03869294 134 135 O
naïve NCT03869294 136 141 B-Negation
4 NCT03869294 142 143 O
. NCT03869294 143 144 O
ECOG NCT03869294 145 149 B-Observation
performance NCT03869294 150 161 I-Observation
status NCT03869294 162 168 I-Observation
of NCT03869294 169 171 O
0 NCT03869294 172 173 B-Eq-Comparison
or NCT03869294 174 176 I-Eq-Comparison
1 NCT03869294 177 178 I-Eq-Comparison
5 NCT03869294 179 180 O
. NCT03869294 180 181 O
An NCT03869294 183 185 O
adequate NCT03869294 186 194 O
bone NCT03869294 195 199 B-Modifier
marrow NCT03869294 200 206 I-Modifier
, NCT03869294 207 208 O
liver NCT03869294 209 214 B-Modifier
function NCT03869294 215 223 B-Condition
and NCT03869294 224 227 B-And
kidney NCT03869294 228 234 B-Modifier
function NCT03869294 235 243 B-Condition

Exclusion NCT03869294 244 253 O
Criteria NCT03869294 254 262 O
: NCT03869294 263 264 O

- NCT03869294 268 269 O
1 NCT03869294 271 272 O
. NCT03869294 272 273 O
Age NCT03869294 274 277 B-Age
≥ NCT03869294 278 279 B-Eq-Comparison
80 NCT03869294 280 282 I-Eq-Comparison
years NCT03869294 283 288 I-Eq-Comparison
2 NCT03869294 289 290 O
. NCT03869294 290 291 O
Brain NCT03869294 292 297 B-Modifier
metastasis NCT03869294 298 308 B-Condition
3 NCT03869294 309 310 O
. NCT03869294 310 311 O
With NCT03869294 312 316 O
other NCT03869294 317 322 B-Other
malignancies NCT03869294 323 335 B-Condition
4 NCT03869294 336 337 O
. NCT03869294 337 338 O
Chronic NCT03869294 339 346 B-Modifier
diarrhea NCT03869294 347 355 B-Condition
, NCT03869294 356 357 O
cardiac NCT03869294 358 365 B-Condition
disease NCT03869294 366 373 I-Condition
, NCT03869294 374 375 O
pregnancy NCT03869294 376 385 B-Condition
or NCT03869294 386 388 B-Or
breast NCT03869294 389 395 B-Condition
feeding NCT03869294 396 403 I-Condition

Inclusion NCT03863236 0 9 O
Criteria NCT03863236 10 18 O
: NCT03863236 19 20 O

- NCT03863236 24 25 O
18 NCT03863236 27 29 B-Eq-Comparison
years NCT03863236 30 35 I-Eq-Comparison
or NCT03863236 36 38 I-Eq-Comparison
older NCT03863236 39 44 I-Age|Eq-Comparison

- NCT03863236 47 48 O
Primary NCT03863236 50 57 B-Modifier
colon NCT03863236 58 63 I-Modifier
adenocarcinoma NCT03863236 64 78 B-Condition

- NCT03863236 81 82 O
Curative NCT03863236 84 92 B-Procedure
operation NCT03863236 93 102 I-Procedure
is NCT03863236 103 105 O
possible NCT03863236 106 114 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03863236 117 118 O
Patient NCT03863236 120 127 O
has NCT03863236 128 131 O
a NCT03863236 132 133 O
life NCT03863236 134 138 B-Observation
expectancy NCT03863236 139 149 I-Observation
of NCT03863236 150 152 O
at NCT03863236 153 155 B-Eq-Comparison
least NCT03863236 156 161 I-Eq-Comparison
12 NCT03863236 162 164 I-Eq-Comparison
months NCT03863236 165 171 I-Eq-Comparison

- NCT03863236 174 175 O
Patient NCT03863236 177 184 O
signs NCT03863236 185 190 O
the NCT03863236 191 194 O
informed NCT03863236 195 203 O
consent NCT03863236 204 211 O
and NCT03863236 212 215 O
agrees NCT03863236 216 222 O
to NCT03863236 223 225 O
attend NCT03863236 226 232 O
all NCT03863236 233 236 O
study NCT03863236 237 242 O
visits NCT03863236 243 249 O

Exclusion NCT03863236 250 259 O
Criteria NCT03863236 260 268 O
: NCT03863236 269 270 O

- NCT03863236 274 275 O
Recurrent NCT03863236 277 286 B-Modifier
colon NCT03863236 287 292 I-Modifier
adenocarcinoma NCT03863236 293 307 B-Condition

- NCT03863236 310 311 O
Metastatic NCT03863236 313 323 B-Condition
disease NCT03863236 324 331 I-Condition

- NCT03863236 334 335 O
Cancer NCT03863236 337 343 B-Condition
that NCT03863236 344 348 O
will NCT03863236 349 353 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03863236 354 361 I-Assertion___Assertion-Type-Value:hypothetical
multiorgan NCT03863236 362 372 B-Procedure
resection NCT03863236 373 382 I-Procedure

- NCT03863236 385 386 O
Pregnant NCT03863236 388 396 B-Condition
or NCT03863236 397 399 B-Or
suspected NCT03863236 400 409 B-Assertion___Assertion-Type-Value:possible
pregnancy NCT03863236 410 419 B-Condition

- NCT03863236 422 423 O
Patient NCT03863236 425 432 O
with NCT03863236 433 437 O
a NCT03863236 438 439 O
comorbid NCT03863236 440 448 B-Condition
illness NCT03863236 449 456 I-Condition
or NCT03863236 457 459 B-Or
condition NCT03863236 460 469 B-Condition
that NCT03863236 470 474 O
would NCT03863236 475 480 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03863236 481 489 B-Negation
the NCT03863236 490 493 O
use NCT03863236 494 497 O
of NCT03863236 498 500 O
surgery NCT03863236 501 508 B-Procedure
( NCT03863236 509 510 O
ASA NCT03863236 511 514 B-Condition
5 NCT03863236 515 516 B-Eq-Comparison
) NCT03863236 517 518 O
. NCT03863236 519 520 O

- NCT03863236 524 525 O
Patients NCT03863236 527 535 O
with NCT03863236 536 540 O
concurrent NCT03863236 541 551 B-Modifier
or NCT03863236 552 554 B-Or
previous NCT03863236 555 563 B-Eq-Comparison
malignant NCT03863236 564 573 B-Condition
tumors NCT03863236 574 580 I-Condition
within NCT03863236 581 587 B-Eq-Comparison
5 NCT03863236 588 589 I-Eq-Comparison
years NCT03863236 590 595 I-Eq-Comparison
before NCT03863236 596 602 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863236 603 606 O
study NCT03863236 607 612 B-Study
enrollment NCT03863236 613 623 O

- NCT03863236 626 627 O
Patient NCT03863236 629 636 O
undergoing NCT03863236 637 647 B-Eq-Comparison
emergency NCT03863236 648 657 B-Modifier
procedures NCT03863236 658 668 B-Procedure

- NCT03863236 671 672 O
Dialysis NCT03863236 674 682 B-Procedure

- NCT03863236 685 686 O
Liver NCT03863236 688 693 B-Condition
dysfunction NCT03863236 694 705 I-Condition
, NCT03863236 706 707 O
child NCT03863236 708 713 B-Condition
pugh NCT03863236 714 718 I-Condition
B NCT03863236 719 720 B-Eq-Comparison
or NCT03863236 721 723 I-Eq-Comparison
worse NCT03863236 724 729 I-Eq-Comparison

- NCT03863236 732 733 O
NRS NCT03863236 735 738 B-Observation
score NCT03863236 739 744 B-Eq-Comparison
< NCT03863236 745 746 I-Eq-Comparison
2 NCT03863236 747 748 I-Eq-Comparison
or NCT03863236 749 751 B-Or
> NCT03863236 752 753 B-Eq-Comparison
5 NCT03863236 754 755 I-Eq-Comparison

- NCT03863236 759 760 O
BMI NCT03863236 762 765 B-Observation
under NCT03863236 766 771 B-Eq-Comparison
18.5 NCT03863236 772 776 I-Eq-Comparison

- NCT03863236 780 781 O
Weight NCT03863236 783 789 B-Observation
loss NCT03863236 790 794 I-Observation
15 NCT03863236 795 797 B-Eq-Comparison
% NCT03863236 798 799 O
or NCT03863236 800 802 I-Eq-Comparison
more NCT03863236 803 807 I-Eq-Comparison
past NCT03863236 808 812 B-Eq-Comparison
6 NCT03863236 813 814 I-Eq-Comparison
months NCT03863236 815 821 I-Eq-Comparison

- NCT03863236 824 825 O
Serum NCT03863236 827 832 B-Observation
albumin NCT03863236 833 840 I-Observation
less NCT03863236 841 845 B-Eq-Comparison
than NCT03863236 846 850 I-Eq-Comparison
30 NCT03863236 851 853 I-Eq-Comparison
without NCT03863236 854 861 B-Negation
liver NCT03863236 862 867 B-Modifier
or NCT03863236 868 870 B-Or
renal NCT03863236 871 876 B-Modifier
dysfunction NCT03863236 877 888 B-Condition

- NCT03863236 891 892 O
Chronic NCT03863236 894 901 B-Condition
malnutrition NCT03863236 902 914 I-Condition
: NCT03863236 915 916 O
short NCT03863236 917 922 B-Condition
bowel NCT03863236 923 928 I-Condition
syndrome NCT03863236 929 937 I-Condition
, NCT03863236 938 939 O
previous NCT03863236 940 948 B-Eq-Comparison
gastrectomy NCT03863236 949 960 B-Condition
, NCT03863236 961 962 O
pancreatic NCT03863236 963 973 B-Condition
dysfunction NCT03863236 974 985 I-Condition

- NCT03863236 988 989 O
Language NCT03863236 991 999 B-Condition
barrier NCT03863236 1000 1007 I-Condition
or NCT03863236 1008 1010 O
other NCT03863236 1011 1016 O
reasons NCT03863236 1017 1024 O
why NCT03863236 1025 1028 O
informed NCT03863236 1029 1037 O
consent NCT03863236 1038 1045 O
is NCT03863236 1046 1048 O
not NCT03863236 1049 1052 O
possible NCT03863236 1053 1061 O

Inclusion NCT03865121 0 9 O
criteria NCT03865121 10 18 O
: NCT03865121 19 20 O

- NCT03865121 24 25 O
Subjects NCT03865121 27 35 O
over NCT03865121 36 40 B-Eq-Comparison
60 NCT03865121 41 43 I-Eq-Comparison
years NCT03865121 44 49 I-Eq-Comparison
of NCT03865121 50 52 O
age NCT03865121 53 56 B-Age
with NCT03865121 57 61 B-And
a NCT03865121 62 63 O
clinical NCT03865121 64 72 O
diagnosis NCT03865121 73 82 O
of NCT03865121 83 85 O
Parkinson NCT03865121 86 95 B-Condition
's NCT03865121 95 97 O
disease NCT03865121 98 105 I-Condition

- NCT03865121 108 109 O
Stages NCT03865121 111 117 O
of NCT03865121 118 120 O
the NCT03865121 121 124 B-Coreference
disease NCT03865121 125 132 I-Coreference
2 NCT03865121 133 134 B-Eq-Comparison
- NCT03865121 135 136 I-Eq-Comparison
3 NCT03865121 137 138 I-Eq-Comparison
of NCT03865121 139 141 O
Hoehn NCT03865121 142 147 B-Modifier
and NCT03865121 148 151 I-Modifier
Yahr NCT03865121 152 156 I-Modifier

- NCT03865121 159 160 O
Not NCT03865121 162 165 B-Negation
exposed NCT03865121 166 173 B-Condition
to NCT03865121 174 176 I-Condition
tobacco NCT03865121 177 184 O
during NCT03865121 185 191 B-Temporal-Connection___Temporal-Connection-Type-Value:during
any NCT03865121 192 195 B-Eq-Comparison
stage NCT03865121 196 201 I-Eq-Comparison
of NCT03865121 202 204 I-Eq-Comparison
their NCT03865121 205 210 I-Eq-Comparison
life NCT03865121 211 215 I-Eq-Comparison

- NCT03865121 218 219 O
No NCT03865121 221 223 B-Negation
history NCT03865121 224 231 B-Eq-Comparison
of NCT03865121 232 234 O
lung NCT03865121 235 239 B-Condition
diseases NCT03865121 240 248 I-Condition

- NCT03865121 251 252 O
No NCT03865121 254 256 B-Negation
laboratory NCT03865121 257 267 B-Observation
abnormalities NCT03865121 268 281 O

- NCT03865121 284 285 O
No NCT03865121 287 289 B-Negation
history NCT03865121 290 297 B-Eq-Comparison
of NCT03865121 298 300 O
adverse NCT03865121 301 308 B-Condition
reactions NCT03865121 309 318 I-Condition
to NCT03865121 319 321 O
nicotine NCT03865121 322 330 B-Drug

- NCT03865121 333 334 O
Able NCT03865121 336 340 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865121 341 343 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03865121 344 347 O
nicotine NCT03865121 348 356 B-Drug
nasal NCT03865121 357 362 I-Drug
spray NCT03865121 363 368 I-Drug

- NCT03865121 371 372 O
Residents NCT03865121 374 383 O
of NCT03865121 384 386 O
Mexico NCT03865121 387 393 O
City NCT03865121 394 398 O
able NCT03865121 399 403 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865121 404 406 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03865121 407 413 O
for NCT03865121 414 417 O
evaluations NCT03865121 418 429 B-Study

- NCT03865121 432 433 O
Under NCT03865121 435 440 B-Eq-Comparison
current NCT03865121 441 448 I-Eq-Comparison
treatment NCT03865121 449 458 B-Procedure
with NCT03865121 459 463 O
levodopa NCT03865121 464 472 B-Drug
at NCT03865121 473 475 O
a NCT03865121 476 477 O
stable NCT03865121 478 484 O
dose NCT03865121 485 489 O

- NCT03865121 492 493 O
Not NCT03865121 495 498 B-Negation
currently NCT03865121 499 508 B-Eq-Comparison
receiving NCT03865121 509 518 I-Eq-Comparison
a NCT03865121 519 520 O
monoamine NCT03865121 521 530 B-Drug
oxidase NCT03865121 531 538 I-Drug
inhibitor NCT03865121 539 548 I-Drug
treatment NCT03865121 549 558 B-Procedure

Exclusion NCT03865121 559 568 O
Criteria NCT03865121 569 577 O

- NCT03865121 580 581 O
Unable NCT03865121 583 589 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865121 590 592 O
complete NCT03865121 593 601 O
follow NCT03865121 602 608 B-Encounter
- NCT03865121 609 610 I-Encounter
up NCT03865121 611 613 I-Encounter
protocol NCT03865121 614 622 O

- NCT03865121 625 626 O
Drug NCT03865121 628 632 B-Drug
adverse NCT03865121 633 640 B-Condition
reaction NCT03865121 641 649 I-Condition

- NCT03865121 652 653 O
Death NCT03865121 655 660 B-Death

Inclusion NCT03867656 0 9 O
Criteria NCT03867656 10 18 O
: NCT03867656 19 20 O

- NCT03867656 24 25 O
Male NCT03867656 27 31 O

- NCT03867656 34 35 O
Age NCT03867656 37 40 B-Age
25 NCT03867656 41 43 B-Eq-Comparison
to NCT03867656 44 46 I-Eq-Comparison
65 NCT03867656 47 49 I-Eq-Comparison
years NCT03867656 50 55 I-Eq-Comparison
old NCT03867656 56 59 O
. NCT03867656 59 60 O

- NCT03867656 64 65 O
Type NCT03867656 67 71 B-Modifier
2 NCT03867656 72 73 I-Modifier
diabetes NCT03867656 74 82 B-Condition
. NCT03867656 82 83 O

- NCT03867656 87 88 O
In NCT03867656 90 92 O
Metformin NCT03867656 93 102 B-Drug
or NCT03867656 103 105 B-Or
sulfonylureas NCT03867656 106 119 B-Drug

Exclusion NCT03867656 120 129 O
Criteria NCT03867656 130 138 O
: NCT03867656 139 140 O

- NCT03867656 144 145 O
Treatment NCT03867656 147 156 B-Procedure
with NCT03867656 157 161 O
other NCT03867656 162 167 B-Other
antidiabetics NCT03867656 168 181 B-Drug

- NCT03867656 184 185 O
Osteopososis NCT03867656 187 199 B-Condition
or NCT03867656 200 202 B-Or
gastrointestinal NCT03867656 203 219 B-Modifier
disease NCT03867656 220 227 B-Condition

- NCT03867656 230 231 O
Smoking NCT03867656 233 240 B-Condition

- NCT03867656 243 244 O
Long NCT03867656 246 250 B-Modifier
term NCT03867656 251 255 I-Modifier
steroid NCT03867656 256 263 B-Drug
treatment NCT03867656 264 273 B-Procedure

- NCT03867656 276 277 O
Weight NCT03867656 279 285 B-Observation
change NCT03867656 286 292 O
more NCT03867656 293 297 B-Eq-Comparison
than NCT03867656 298 302 I-Eq-Comparison
3 NCT03867656 303 304 I-Eq-Comparison
kg NCT03867656 305 307 I-Eq-Comparison
within NCT03867656 308 314 B-Eq-Comparison
the NCT03867656 315 318 I-Eq-Comparison
last NCT03867656 319 323 I-Eq-Comparison
3 NCT03867656 324 325 I-Eq-Comparison
months NCT03867656 326 332 I-Eq-Comparison
. NCT03867656 332 333 O

- NCT03867656 337 338 O
Overweight NCT03867656 340 350 B-Condition
or NCT03867656 351 353 B-Or
intestinal NCT03867656 354 364 B-Modifier
surgery NCT03867656 365 372 B-Procedure

Inclusion NCT03863418 0 9 O
Criteria NCT03863418 10 18 O
: NCT03863418 19 20 O

- NCT03863418 24 25 O
Children NCT03863418 27 35 O
aged NCT03863418 36 40 B-Age
6 NCT03863418 41 42 B-Eq-Comparison
- NCT03863418 43 44 I-Eq-Comparison
36 NCT03863418 45 47 I-Eq-Comparison
months NCT03863418 48 54 I-Eq-Comparison

- NCT03863418 57 58 O
diagnosis NCT03863418 60 69 O
of NCT03863418 70 72 O
Atopic NCT03863418 73 79 B-Condition
Dermatitis NCT03863418 80 90 I-Condition
according NCT03863418 91 100 O
to NCT03863418 101 103 O
SCORAD NCT03863418 104 110 B-Observation
index NCT03863418 111 116 I-Observation

Exclusion NCT03863418 117 126 O
Criteria NCT03863418 127 135 O

- NCT03863418 138 139 O
Age NCT03863418 141 144 B-Age
< NCT03863418 145 146 B-Eq-Comparison
6 NCT03863418 147 148 I-Eq-Comparison
months NCT03863418 149 155 I-Eq-Comparison

- NCT03863418 158 159 O
age NCT03863418 161 164 B-Age
> NCT03863418 165 166 B-Eq-Comparison
36 NCT03863418 167 169 I-Eq-Comparison
months NCT03863418 170 176 I-Eq-Comparison
, NCT03863418 177 178 O

- NCT03863418 182 183 O
skin NCT03863418 185 189 B-Modifier
infections NCT03863418 190 200 B-Condition
, NCT03863418 201 202 O

- NCT03863418 206 207 O
ichthyosis NCT03863418 209 219 B-Condition
, NCT03863418 220 221 O

- NCT03863418 225 226 O
food NCT03863418 228 232 O
allergies NCT03863418 233 242 B-Allergy
, NCT03863418 243 244 O

- NCT03863418 248 249 O
other NCT03863418 251 256 B-Other
allergic NCT03863418 257 265 B-Condition
diseases NCT03863418 266 274 I-Condition
, NCT03863418 275 276 O

- NCT03863418 280 281 O
chronic NCT03863418 283 290 B-Modifier
systemic NCT03863418 291 299 I-Modifier
diseases NCT03863418 300 308 B-Condition
, NCT03863418 309 310 O

- NCT03863418 314 315 O
congenital NCT03863418 317 327 B-Condition
cardiac NCT03863418 328 335 I-Condition
defects NCT03863418 336 343 I-Condition
, NCT03863418 344 345 O

- NCT03863418 349 350 O
active NCT03863418 352 358 B-Eq-Comparison
tuberculosis NCT03863418 359 371 B-Condition
, NCT03863418 372 373 O

- NCT03863418 377 378 O
autoimmune NCT03863418 380 390 B-Condition
diseases NCT03863418 391 399 I-Condition
, NCT03863418 400 401 O

- NCT03863418 405 406 O
immunodeficiency NCT03863418 408 424 B-Condition
, NCT03863418 425 426 O

- NCT03863418 430 431 O
chronic NCT03863418 433 440 B-Modifier
inflammatory NCT03863418 441 453 B-Condition
bowel NCT03863418 454 459 I-Condition
diseases NCT03863418 460 468 I-Condition|Condition
, NCT03863418 469 470 O

- NCT03863418 474 475 O
celiac NCT03863418 477 483 B-Condition
disease NCT03863418 484 491 O
, NCT03863418 492 493 O

- NCT03863418 497 498 O
cystic NCT03863418 500 506 B-Condition
fibrosis NCT03863418 507 515 I-Condition
, NCT03863418 516 517 O

- NCT03863418 521 522 O
metabolic NCT03863418 524 533 B-Condition
diseases NCT03863418 534 542 I-Condition
, NCT03863418 543 544 O

- NCT03863418 548 549 O
malignancy NCT03863418 551 561 B-Condition
, NCT03863418 562 563 O

- NCT03863418 567 568 O
chronic NCT03863418 570 577 B-Modifier
pulmonary NCT03863418 578 587 B-Condition
diseases NCT03863418 588 596 I-Condition
, NCT03863418 597 598 O

- NCT03863418 602 603 O
malformations NCT03863418 605 618 B-Condition
of NCT03863418 619 621 O
the NCT03863418 622 625 O
gastrointestinal NCT03863418 626 642 B-Modifier
and NCT03863418 643 646 B-Or
/ NCT03863418 647 648 I-Or
or NCT03863418 649 651 I-Or
respiratory NCT03863418 652 663 B-Modifier
tract NCT03863418 664 669 I-Modifier
, NCT03863418 670 671 O

- NCT03863418 675 676 O
administration NCT03863418 678 692 O
of NCT03863418 693 695 O
prebiotics NCT03863418 696 706 B-Drug
/ NCT03863418 707 708 B-Or|Or|Or
probiotics NCT03863418 709 719 B-Drug
/ NCT03863418 720 721 O
symbiotic NCT03863418 722 731 B-Modifier
/ NCT03863418 732 733 O
systemic NCT03863418 734 742 B-Modifier
immunomodulators NCT03863418 743 759 B-Drug
during NCT03863418 760 766 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863418 767 770 O
4 NCT03863418 771 772 B-Eq-Comparison
weeks NCT03863418 773 778 I-Eq-Comparison
before NCT03863418 779 785 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03863418 786 795 B-Study
, NCT03863418 796 797 O

- NCT03863418 801 802 O
treatments NCT03863418 804 814 B-Procedure
with NCT03863418 815 819 O
topical NCT03863418 820 827 B-Drug
immunomodulators NCT03863418 828 844 I-Drug
( NCT03863418 845 846 O
Tacrolimus NCT03863418 847 857 B-Drug
or NCT03863418 858 860 B-Or
Pimecrolimus NCT03863418 861 873 B-Drug
) NCT03863418 874 875 O
over NCT03863418 876 880 B-Eq-Comparison
the NCT03863418 881 884 I-Eq-Comparison
three NCT03863418 885 890 I-Eq-Comparison
months NCT03863418 891 897 I-Eq-Comparison
prior NCT03863418 898 903 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863418 904 906 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03863418 907 916 B-Study
; NCT03863418 916 917 O

- NCT03863418 920 921 O
use NCT03863418 923 926 O
of NCT03863418 927 929 O
corticosteroids NCT03863418 930 945 B-Drug
or NCT03863418 946 948 B-Or|Or
calcineurin NCT03863418 949 960 B-Drug
antagonists NCT03863418 961 972 I-Drug
or NCT03863418 973 975 O
phototherapy NCT03863418 976 988 B-Procedure
in NCT03863418 989 991 O
the NCT03863418 992 995 O
previous NCT03863418 996 1004 B-Eq-Comparison
4 NCT03863418 1005 1006 I-Eq-Comparison
weeks NCT03863418 1007 1012 I-Eq-Comparison
, NCT03863418 1013 1014 O

- NCT03863418 1018 1019 O
use NCT03863418 1021 1024 O
of NCT03863418 1025 1027 O
systemic NCT03863418 1028 1036 B-Modifier
antibiotics NCT03863418 1037 1048 B-Drug
or NCT03863418 1049 1051 B-Or
anti NCT03863418 1052 1056 O
- NCT03863418 1057 1058 O
mycotic NCT03863418 1059 1066 B-Condition
drugs NCT03863418 1067 1072 B-Drug
during NCT03863418 1073 1079 B-Temporal-Connection___Temporal-Connection-Type-Value:during
4 NCT03863418 1080 1081 B-Eq-Comparison
weeks NCT03863418 1082 1087 I-Eq-Comparison
before NCT03863418 1088 1094 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03863418 1095 1100 B-Study
entry NCT03863418 1101 1106 O
; NCT03863418 1106 1107 O

- NCT03863418 1110 1111 O
investigator NCT03863418 1113 1125 O
's NCT03863418 1125 1127 O
uncertainty NCT03863418 1128 1139 O
about NCT03863418 1140 1145 O
the NCT03863418 1146 1149 O
willingness NCT03863418 1150 1161 O
or NCT03863418 1162 1164 O
ability NCT03863418 1165 1172 O
of NCT03863418 1173 1175 O
the NCT03863418 1176 1179 O
subject NCT03863418 1180 1187 O
to NCT03863418 1188 1190 O
comply NCT03863418 1191 1197 O
with NCT03863418 1198 1202 O
the NCT03863418 1203 1206 O
protocol NCT03863418 1207 1215 O
requirements NCT03863418 1216 1228 O
; NCT03863418 1228 1229 O

- NCT03863418 1232 1233 O
participation NCT03863418 1235 1248 O
in NCT03863418 1249 1251 B-Study
any NCT03863418 1252 1255 O
other NCT03863418 1256 1261 B-Other
studies NCT03863418 1262 1269 B-Study
involving NCT03863418 1270 1279 O
investigational NCT03863418 1280 1295 O
or NCT03863418 1296 1298 B-Or|Or
marketed NCT03863418 1299 1307 B-Modifier
products NCT03863418 1308 1316 B-Drug
concomitantly NCT03863418 1317 1330 B-Modifier
or NCT03863418 1331 1333 O
within NCT03863418 1334 1340 B-Eq-Comparison
two NCT03863418 1341 1344 I-Eq-Comparison
weeks NCT03863418 1345 1350 I-Eq-Comparison
prior NCT03863418 1351 1356 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863418 1357 1359 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03863418 1360 1365 O
into NCT03863418 1366 1370 O
the NCT03863418 1371 1374 O
study NCT03863418 1375 1380 B-Study
; NCT03863418 1380 1381 O

- NCT03863418 1384 1385 O
hypersensitivity NCT03863418 1387 1403 B-Condition
to NCT03863418 1404 1406 O
components NCT03863418 1407 1417 O
contained NCT03863418 1418 1427 O
in NCT03863418 1428 1430 O
study NCT03863418 1431 1436 B-Study
product NCT03863418 1437 1444 B-Drug
. NCT03863418 1444 1445 O

Inclusion NCT03867695 0 9 O
criteria NCT03867695 10 18 O
: NCT03867695 19 20 O

- NCT03867695 24 25 O
All NCT03867695 27 30 O
patients NCT03867695 31 39 O
undergoing NCT03867695 40 50 B-Eq-Comparison
lobectomy NCT03867695 51 60 B-Procedure
VATS NCT03867695 61 65 I-Procedure

- NCT03867695 68 69 O
Older NCT03867695 71 76 B-Age
> NCT03867695 77 78 B-Eq-Comparison
18 NCT03867695 79 81 I-Eq-Comparison
years NCT03867695 82 87 I-Eq-Comparison

- NCT03867695 90 91 O
Patients NCT03867695 93 101 O
who NCT03867695 102 105 O
meet NCT03867695 106 110 O
criteria NCT03867695 111 119 O
of NCT03867695 120 122 O
ASA NCT03867695 123 126 B-Condition
1 NCT03867695 127 128 B-Eq-Comparison
to NCT03867695 129 131 I-Eq-Comparison
3 NCT03867695 132 133 I-Eq-Comparison
class NCT03867695 134 139 I-Eq-Comparison

Exclusion NCT03867695 140 149 O
criteria NCT03867695 150 158 O
: NCT03867695 159 160 O

- NCT03867695 164 165 O
Patient NCT03867695 167 174 O
's NCT03867695 174 176 O
refusal NCT03867695 177 184 O
to NCT03867695 185 187 O
participate NCT03867695 188 199 O
in NCT03867695 200 202 O
the NCT03867695 203 206 O
study NCT03867695 207 212 O

- NCT03867695 215 216 O
Psychiatric NCT03867695 218 229 B-Condition
disorder NCT03867695 230 238 I-Condition
( NCT03867695 239 240 O
impossibility NCT03867695 241 254 O
to NCT03867695 255 257 O
collect NCT03867695 258 265 O
the NCT03867695 266 269 O
informed NCT03867695 270 278 O
consent NCT03867695 279 286 O
) NCT03867695 287 288 O

- NCT03867695 292 293 O
Patient NCT03867695 295 302 O
under NCT03867695 303 308 O
juridical NCT03867695 309 318 B-Observation
protection NCT03867695 319 329 I-Observation

- NCT03867695 332 333 O
On NCT03867695 335 337 O
going NCT03867695 338 343 O
an NCT03867695 344 346 O
other NCT03867695 347 352 B-Other
study NCT03867695 353 358 B-Study

- NCT03867695 361 362 O
Non NCT03867695 364 367 B-Negation
balanced NCT03867695 368 376 B-Modifier
epilepsy NCT03867695 377 385 B-Condition

- NCT03867695 388 389 O
3 NCT03867695 391 392 B-Eq-Comparison
grade NCT03867695 393 398 I-Eq-Comparison
auriculo NCT03867695 399 407 B-Modifier
- NCT03867695 408 409 I-Modifier
ventricular NCT03867695 410 421 I-Modifier
heart NCT03867695 422 427 B-Condition
block NCT03867695 428 433 I-Condition
without NCT03867695 434 441 B-Negation
pacing NCT03867695 442 448 B-Modifier

- NCT03867695 451 452 O
Severe NCT03867695 454 460 O
hepatocellular NCT03867695 461 475 B-Condition
insufficiency NCT03867695 476 489 I-Condition

- NCT03867695 492 493 O
Anti NCT03867695 495 499 B-Procedure
arrhythmic NCT03867695 500 510 I-Procedure
treatment NCT03867695 511 520 I-Procedure
: NCT03867695 521 522 O
class NCT03867695 523 528 B-Eq-Comparison
III NCT03867695 529 532 I-Eq-Comparison
of NCT03867695 533 535 O
the NCT03867695 536 539 O
Vaughan NCT03867695 540 547 B-Modifier
William NCT03867695 548 555 I-Modifier
's NCT03867695 555 557 O
classification NCT03867695 558 572 I-Modifier

- NCT03867695 575 576 O
Pregnant NCT03867695 578 586 B-Condition
patient NCT03867695 587 594 O
or NCT03867695 595 597 B-Or
/ NCT03867695 598 599 I-Or
and NCT03867695 600 603 I-Or
breastfeeding NCT03867695 604 617 B-Condition

- NCT03867695 620 621 O
History NCT03867695 623 630 B-Eq-Comparison
of NCT03867695 631 633 O
opioid NCT03867695 634 640 B-Condition
abuse NCT03867695 641 646 I-Condition

- NCT03867695 649 650 O
Allergy NCT03867695 652 659 B-Allergy
to NCT03867695 660 662 O
local NCT03867695 663 668 B-Drug
anesthetic NCT03867695 669 679 I-Drug
drug NCT03867695 680 684 I-Drug
or NCT03867695 685 687 B-Or
opioids NCT03867695 688 695 B-Drug

Inclusion NCT03860688 0 9 O
Criteria NCT03860688 10 18 O
: NCT03860688 19 20 O

- NCT03860688 24 25 O
Men NCT03860688 27 30 O
and NCT03860688 31 34 B-Or
women NCT03860688 35 40 O
, NCT03860688 41 42 O
aged NCT03860688 43 47 B-Age
18 NCT03860688 48 50 B-Eq-Comparison
to NCT03860688 51 53 I-Eq-Comparison
60 NCT03860688 54 56 I-Eq-Comparison
years NCT03860688 57 62 I-Eq-Comparison
. NCT03860688 62 63 O

- NCT03860688 67 68 O
Body NCT03860688 70 74 B-Observation
mass NCT03860688 75 79 I-Observation
index NCT03860688 80 85 I-Observation
20 NCT03860688 86 88 B-Eq-Comparison
to NCT03860688 89 91 I-Eq-Comparison
27 NCT03860688 92 94 I-Eq-Comparison
kg NCT03860688 95 97 I-Eq-Comparison
/ NCT03860688 98 99 I-Eq-Comparison
m2 NCT03860688 100 102 I-Eq-Comparison

Exclusion NCT03860688 103 112 O
Criteria NCT03860688 113 121 O
: NCT03860688 122 123 O

1 NCT03860688 127 128 O
. NCT03860688 128 129 O
Patients NCT03860688 131 139 O
with NCT03860688 140 144 O
active NCT03860688 145 151 B-Eq-Comparison
inflammatory NCT03860688 152 164 B-Condition
bowel NCT03860688 165 170 I-Condition
disease NCT03860688 171 178 I-Condition

2 NCT03860688 181 182 O
. NCT03860688 182 183 O
Patients NCT03860688 185 193 O
with NCT03860688 194 198 O
pre NCT03860688 199 202 B-Eq-Comparison
- NCT03860688 203 204 I-Eq-Comparison
existing NCT03860688 205 213 I-Eq-Comparison
Celiac NCT03860688 214 220 B-Condition
disease NCT03860688 221 228 I-Condition
, NCT03860688 229 230 O
exocrine NCT03860688 231 239 B-Condition
pancreatic NCT03860688 240 250 I-Condition
insufficiency NCT03860688 251 264 I-Condition
or NCT03860688 265 267 B-Or
small NCT03860688 268 273 B-Condition
bowel NCT03860688 274 279 I-Condition
malabsorption NCT03860688 280 293 I-Condition

3 NCT03860688 296 297 O
. NCT03860688 297 298 O
Patients NCT03860688 300 308 O
with NCT03860688 309 313 O
active NCT03860688 314 320 B-Eq-Comparison
bowel NCT03860688 321 326 B-Condition
malignancy NCT03860688 327 337 I-Condition

4 NCT03860688 340 341 O
. NCT03860688 341 342 O
Patients NCT03860688 344 352 O
with NCT03860688 353 357 O
diabetes NCT03860688 358 366 B-Condition
mellitus NCT03860688 367 375 I-Condition
or NCT03860688 376 378 B-Or
known NCT03860688 379 384 B-Modifier
/ NCT03860688 385 386 B-Or
suspected NCT03860688 387 396 B-Assertion___Assertion-Type-Value:possible
motility NCT03860688 397 405 B-Condition
disorders NCT03860688 406 415 I-Condition
of NCT03860688 416 418 O
the NCT03860688 419 422 O
gut NCT03860688 423 426 B-Modifier

5 NCT03860688 429 430 O
. NCT03860688 430 431 O
Patients NCT03860688 433 441 O
with NCT03860688 442 446 O
decompensated NCT03860688 447 460 B-Modifier
liver NCT03860688 461 466 B-Condition
disease NCT03860688 467 474 I-Condition

6 NCT03860688 477 478 O
. NCT03860688 478 479 O
Patients NCT03860688 481 489 O
on NCT03860688 490 492 B-Eq-Comparison
ezetimibe NCT03860688 493 502 B-Drug
or NCT03860688 503 505 B-Or
bile NCT03860688 506 510 B-Drug
acid NCT03860688 511 515 I-Drug
sequestrants NCT03860688 516 528 I-Drug

7 NCT03860688 531 532 O
. NCT03860688 532 533 O
Patients NCT03860688 535 543 O
who NCT03860688 544 547 O
are NCT03860688 548 551 B-Eq-Comparison
pregnant NCT03860688 552 560 B-Condition
or NCT03860688 561 563 B-Or
breastfeeding NCT03860688 564 577 B-Condition
. NCT03860688 577 578 O

8 NCT03860688 582 583 O
. NCT03860688 583 584 O
Patients NCT03860688 586 594 O
with NCT03860688 595 599 O
renal NCT03860688 600 605 B-Condition
disease NCT03860688 606 613 I-Condition
. NCT03860688 613 614 O

9 NCT03860688 618 619 O
. NCT03860688 619 620 O
Patients NCT03860688 622 630 O
on NCT03860688 631 633 B-Eq-Comparison
benzodiazepine NCT03860688 634 648 B-Drug
. NCT03860688 648 649 O

10 NCT03860688 652 654 O
. NCT03860688 654 655 O
Unstable NCT03860688 657 665 O
cardiac NCT03860688 666 673 B-Modifier
or NCT03860688 674 676 B-Or
respiratory NCT03860688 677 688 B-Modifier
disease NCT03860688 689 696 B-Condition

11 NCT03860688 698 700 O
. NCT03860688 700 701 O
Any NCT03860688 703 706 O
changes NCT03860688 707 714 O
to NCT03860688 715 717 O
medication NCT03860688 718 728 B-Drug
in NCT03860688 729 731 O
the NCT03860688 732 735 O
preceding NCT03860688 736 745 B-Eq-Comparison
month NCT03860688 746 751 I-Eq-Comparison

12 NCT03860688 753 755 O
. NCT03860688 755 756 O
Patients NCT03860688 758 766 O
with NCT03860688 767 771 O
hypersensitive NCT03860688 772 786 B-Condition
to NCT03860688 787 789 O
Revestive NCT03860688 790 799 B-Drug
or NCT03860688 800 802 B-Or|Or
any NCT03860688 803 806 O
ingredient NCT03860688 807 817 B-Coreference
, NCT03860688 818 819 O
active NCT03860688 820 826 B-Eq-Comparison
or NCT03860688 827 829 O
a NCT03860688 830 831 O
history NCT03860688 832 839 B-Eq-Comparison
of NCT03860688 840 842 O
the NCT03860688 843 846 I-Coreference|Eq-Comparison
drug NCT03860688 847 851 I-Coreference
within NCT03860688 852 858 B-Eq-Comparison
the NCT03860688 859 862 O
last NCT03860688 863 867 I-Eq-Comparison
5 NCT03860688 868 869 I-Eq-Comparison
years NCT03860688 870 875 I-Eq-Comparison

13 NCT03860688 877 879 O
. NCT03860688 879 880 O
Patients NCT03860688 882 890 O
with NCT03860688 891 895 O
GI NCT03860688 896 898 B-Condition|Modifier
malignancy NCT03860688 899 909 I-Condition
( NCT03860688 910 911 O
GI NCT03860688 912 914 O
tract NCT03860688 915 920 I-Modifier
, NCT03860688 921 922 O
hepatobiliary NCT03860688 923 936 B-Modifier
, NCT03860688 937 938 O
pancreatic NCT03860688 939 949 B-Modifier
) NCT03860688 950 951 O

Inclusion NCT03869684 0 9 O
Criteria NCT03869684 10 18 O
: NCT03869684 19 20 O

- NCT03869684 24 25 O
Must NCT03869684 27 31 O
agree NCT03869684 32 37 O
to NCT03869684 38 40 O
sign NCT03869684 41 45 O
informed NCT03869684 46 54 O
consent NCT03869684 55 62 O
form NCT03869684 63 67 O
, NCT03869684 68 69 O
and NCT03869684 70 73 O
to NCT03869684 74 76 O
comply NCT03869684 77 83 O
with NCT03869684 84 88 O
protocol NCT03869684 89 97 O
requirements NCT03869684 98 110 O
, NCT03869684 111 112 O
including NCT03869684 113 122 O
study NCT03869684 123 128 O
visits NCT03869684 129 135 O
. NCT03869684 135 136 O

- NCT03869684 140 141 O
Must NCT03869684 143 147 O
have NCT03869684 148 152 O
clear NCT03869684 153 158 B-Modifier
optic NCT03869684 159 164 B-Observation
media NCT03869684 165 170 I-Observation
in NCT03869684 171 173 O
the NCT03869684 174 177 O
study NCT03869684 178 183 B-Study
eye NCT03869684 184 187 B-Modifier
that NCT03869684 188 192 O
is NCT03869684 193 195 O
capable NCT03869684 196 203 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03869684 204 206 I-Assertion___Assertion-Type-Value:hypothetical
producing NCT03869684 207 216 O
high NCT03869684 217 221 B-Modifier
- NCT03869684 222 223 I-Modifier
quality NCT03869684 224 231 I-Modifier
fundus NCT03869684 232 238 B-Observation
images NCT03869684 239 245 I-Observation
. NCT03869684 245 246 O

Exclusion NCT03869684 248 257 O
Criteria NCT03869684 258 266 O
: NCT03869684 267 268 O

- NCT03869684 272 273 O
Has NCT03869684 275 278 O
active NCT03869684 279 285 B-Eq-Comparison
CNV NCT03869684 286 289 B-Condition
due NCT03869684 290 293 O
to NCT03869684 294 296 O
causes NCT03869684 297 303 B-Condition
other NCT03869684 304 309 B-Exception
than NCT03869684 310 314 I-Exception
AMD NCT03869684 315 318 B-Condition
in NCT03869684 319 321 O
the NCT03869684 322 325 O
study NCT03869684 326 331 B-Study
eye NCT03869684 332 335 B-Modifier
. NCT03869684 335 336 O

- NCT03869684 340 341 O
Has NCT03869684 343 346 O
retinal NCT03869684 347 354 B-Condition
vascular NCT03869684 355 363 I-Condition
disease NCT03869684 364 371 I-Condition
or NCT03869684 372 374 B-Or
retinal NCT03869684 375 382 B-Condition
degeneration NCT03869684 383 395 I-Condition
other NCT03869684 396 401 B-Exception
than NCT03869684 402 406 I-Exception
AMD NCT03869684 407 410 B-Condition
in NCT03869684 411 413 O
the NCT03869684 414 417 O
study NCT03869684 418 423 B-Study
eye NCT03869684 424 427 B-Modifier
. NCT03869684 427 428 O

- NCT03869684 432 433 O
Has NCT03869684 435 438 O
had NCT03869684 439 442 B-Eq-Comparison
intraocular NCT03869684 443 454 B-Procedure
surgery NCT03869684 455 462 I-Procedure
, NCT03869684 463 464 O
cataract NCT03869684 465 473 B-Procedure
surgery NCT03869684 474 481 I-Procedure
or NCT03869684 482 484 B-Or
LASIK NCT03869684 485 490 B-Procedure
surgery NCT03869684 491 498 I-Procedure
on NCT03869684 499 501 O
the NCT03869684 502 505 O
study NCT03869684 506 511 B-Study
eye NCT03869684 512 515 B-Modifier
within NCT03869684 516 522 B-Eq-Comparison
90 NCT03869684 523 525 I-Eq-Comparison
days NCT03869684 526 530 I-Eq-Comparison
prior NCT03869684 531 536 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 537 539 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 540 543 O
study NCT03869684 544 549 B-Study
. NCT03869684 549 550 O

- NCT03869684 559 560 O
Has NCT03869684 562 565 O
had NCT03869684 566 569 O
yttrium NCT03869684 570 577 B-Procedure
aluminum NCT03869684 578 586 I-Procedure
garnet NCT03869684 587 593 I-Procedure
( NCT03869684 594 595 O
YAG NCT03869684 596 599 B-Procedure
) NCT03869684 600 601 O
laser NCT03869684 602 607 B-Procedure
capsulotomy NCT03869684 608 619 I-Procedure
on NCT03869684 620 622 O
the NCT03869684 623 626 O
study NCT03869684 627 632 B-Study
eye NCT03869684 633 636 B-Modifier
within NCT03869684 637 643 B-Eq-Comparison
30 NCT03869684 644 646 I-Eq-Comparison
days NCT03869684 647 651 I-Eq-Comparison
prior NCT03869684 652 657 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 658 660 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 661 664 O
study NCT03869684 665 670 B-Study
. NCT03869684 670 671 O

- NCT03869684 675 676 O
Has NCT03869684 678 681 O
active NCT03869684 682 688 B-Eq-Comparison
inflammation NCT03869684 689 701 B-Condition
, NCT03869684 702 703 O
infection NCT03869684 704 713 B-Condition
, NCT03869684 714 715 O
or NCT03869684 716 718 B-Or
other NCT03869684 719 724 B-Other
severe NCT03869684 725 731 O
ocular NCT03869684 732 738 B-Condition
disease NCT03869684 739 746 I-Condition
in NCT03869684 747 749 O
either NCT03869684 750 756 B-Modifier
eye NCT03869684 757 760 I-Modifier
. NCT03869684 760 761 O

- NCT03869684 765 766 O
Has NCT03869684 768 771 O
aphakia NCT03869684 772 779 B-Condition
in NCT03869684 780 782 O
the NCT03869684 783 786 O
study NCT03869684 787 792 B-Study
eye NCT03869684 793 796 B-Modifier
. NCT03869684 796 797 O

- NCT03869684 801 802 O
Has NCT03869684 804 807 O
uncontrolled NCT03869684 808 820 B-Modifier
glaucoma NCT03869684 821 829 B-Condition
or NCT03869684 830 832 B-Or
a NCT03869684 833 834 O
history NCT03869684 835 842 B-Eq-Comparison
of NCT03869684 843 845 I-Eq-Comparison
previous NCT03869684 846 854 I-Eq-Comparison
glaucoma NCT03869684 855 863 B-Procedure
filter NCT03869684 864 870 I-Procedure
surgery NCT03869684 871 878 I-Procedure
in NCT03869684 879 881 O
either NCT03869684 882 888 B-Modifier
eye NCT03869684 889 892 I-Modifier
. NCT03869684 892 893 O

- NCT03869684 897 898 O
Is NCT03869684 900 902 O
a NCT03869684 903 904 O
contact NCT03869684 905 912 B-Procedure
lens NCT03869684 913 917 I-Procedure
wearer NCT03869684 918 924 O
and NCT03869684 925 928 B-And
is NCT03869684 929 931 O
unable NCT03869684 932 938 B-Negation
to NCT03869684 939 941 O
discontinue NCT03869684 942 953 B-Assertion___Assertion-Type-Value:hypothetical|Negation
their NCT03869684 954 959 O
use NCT03869684 960 963 O
in NCT03869684 964 966 O
both NCT03869684 967 971 B-Modifier
eyes NCT03869684 972 976 I-Modifier
for NCT03869684 977 980 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869684 981 984 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03869684 985 993 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03869684 994 996 O
the NCT03869684 997 1000 O
study NCT03869684 1001 1006 B-Study
. NCT03869684 1006 1007 O

- NCT03869684 1011 1012 O
Has NCT03869684 1014 1017 O
a NCT03869684 1018 1019 O
serious NCT03869684 1020 1027 O
allergy NCT03869684 1028 1035 B-Allergy
to NCT03869684 1036 1038 O
, NCT03869684 1039 1040 O
or NCT03869684 1041 1043 B-Or
experienced NCT03869684 1044 1055 O
a NCT03869684 1056 1057 O
prior NCT03869684 1058 1063 B-Eq-Comparison
significant NCT03869684 1064 1075 O
adverse NCT03869684 1076 1083 B-Condition
reaction NCT03869684 1084 1092 I-Condition
to NCT03869684 1093 1095 O
fluorescein NCT03869684 1096 1107 B-Procedure
angiography NCT03869684 1108 1119 I-Procedure
( NCT03869684 1120 1121 O
FA NCT03869684 1122 1124 B-Procedure
) NCT03869684 1125 1126 O
or NCT03869684 1127 1129 B-Or
indocyanine NCT03869684 1130 1141 B-Procedure
green NCT03869684 1142 1147 I-Procedure
angiography NCT03869684 1148 1159 I-Procedure
( NCT03869684 1160 1161 O
ICGA NCT03869684 1162 1166 B-Procedure
) NCT03869684 1167 1168 O
. NCT03869684 1169 1170 O

- NCT03869684 1174 1175 O
Has NCT03869684 1177 1180 O
participated NCT03869684 1181 1193 O
in NCT03869684 1194 1196 O
any NCT03869684 1197 1200 O
other NCT03869684 1201 1206 B-Other
clinical NCT03869684 1207 1215 B-Study
trial NCT03869684 1216 1221 I-Study
and NCT03869684 1222 1225 B-Or
/ NCT03869684 1226 1227 I-Or
or NCT03869684 1228 1230 I-Or
has NCT03869684 1231 1234 O
taken NCT03869684 1235 1240 O
any NCT03869684 1241 1244 O
investigational NCT03869684 1245 1260 B-Study
drug NCT03869684 1261 1265 B-Drug
or NCT03869684 1266 1268 B-Or
product NCT03869684 1269 1276 B-Drug
within NCT03869684 1277 1283 B-Eq-Comparison
90 NCT03869684 1284 1286 I-Eq-Comparison
days NCT03869684 1287 1291 I-Eq-Comparison
prior NCT03869684 1292 1297 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 1298 1300 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 1301 1304 O
study NCT03869684 1305 1310 B-Study
. NCT03869684 1310 1311 O

Other NCT03869684 1313 1318 O
protocol NCT03869684 1319 1327 O
- NCT03869684 1328 1329 O
defined NCT03869684 1330 1337 O
inclusion NCT03869684 1338 1347 O
/ NCT03869684 1348 1349 O
exclusion NCT03869684 1350 1359 O
criteria NCT03869684 1360 1368 O
could NCT03869684 1369 1374 O
apply NCT03869684 1375 1380 O
. NCT03869684 1380 1381 O


Inclusion NCT03865914 0 9 O
Criteria NCT03865914 10 18 O
: NCT03865914 19 20 O

- NCT03865914 24 25 O
Age NCT03865914 27 30 B-Age
≥ NCT03865914 31 32 B-Eq-Comparison
18 NCT03865914 33 35 I-Eq-Comparison
, NCT03865914 36 37 O
male NCT03865914 38 42 O
or NCT03865914 43 45 B-Or
female NCT03865914 46 52 O

- NCT03865914 55 56 O
Clinical NCT03865914 58 66 O
diagnosed NCT03865914 67 76 O
as NCT03865914 77 79 O
type NCT03865914 80 84 B-Modifier
2 NCT03865914 85 86 I-Modifier
diabetes NCT03865914 87 95 B-Condition
mellitus NCT03865914 96 104 I-Condition

- NCT03865914 107 108 O
The NCT03865914 110 113 O
presence NCT03865914 114 122 O
of NCT03865914 123 125 O
renal NCT03865914 126 131 B-Condition
impairment NCT03865914 132 142 I-Condition
including NCT03865914 143 152 O
: NCT03865914 153 154 O
microalbuminuria NCT03865914 155 171 B-Condition
or NCT03865914 172 174 B-Or
overt NCT03865914 175 180 B-Modifier
proteinuria NCT03865914 181 192 B-Condition
or NCT03865914 193 195 B-Or
renal NCT03865914 196 201 B-Modifier
insufficiency NCT03865914 202 215 B-Condition

- NCT03865914 218 219 O
The NCT03865914 221 224 O
renal NCT03865914 225 230 B-Modifier
biopsy NCT03865914 231 237 B-Procedure
was NCT03865914 238 241 O
performed NCT03865914 242 251 O
with NCT03865914 252 256 O
complete NCT03865914 257 265 O
renal NCT03865914 266 271 B-Condition
pathological NCT03865914 272 284 I-Condition
diagnosis NCT03865914 285 294 O

- NCT03865914 297 298 O
Obtaining NCT03865914 300 309 O
the NCT03865914 310 313 O
signed NCT03865914 314 320 O
informed NCT03865914 321 329 O
consent NCT03865914 330 337 O
from NCT03865914 338 342 O
patients NCT03865914 343 351 O

Exclusion NCT03865914 352 361 O
Criteria NCT03865914 362 370 O
: NCT03865914 371 372 O

- NCT03865914 376 377 O
The NCT03865914 379 382 O
history NCT03865914 383 390 B-Eq-Comparison
of NCT03865914 391 393 O
the NCT03865914 394 397 B-Coreference
disease NCT03865914 398 405 I-Coreference
was NCT03865914 406 409 O
not NCT03865914 410 413 B-Assertion___Assertion-Type-Value:hypothetical|Negation
complete NCT03865914 414 422 I-Assertion___Assertion-Type-Value:hypothetical|Negation

- NCT03865914 425 426 O
Clinical NCT03865914 428 436 O
diagnosed NCT03865914 437 446 O
as NCT03865914 447 449 O
other NCT03865914 450 455 B-Other
secondary NCT03865914 456 465 B-Modifier
renal NCT03865914 466 471 B-Condition
diseases NCT03865914 472 480 I-Condition

- NCT03865914 483 484 O
Patients NCT03865914 486 494 O
with NCT03865914 495 499 O
hereditary NCT03865914 500 510 B-Modifier
kidney NCT03865914 511 517 B-Condition
disease NCT03865914 518 525 I-Condition

- NCT03865914 528 529 O
Autoimmune NCT03865914 531 541 B-Condition
diseases NCT03865914 542 550 I-Condition

- NCT03865914 553 554 O
Patients NCT03865914 556 564 O
with NCT03865914 565 569 O
malignant NCT03865914 570 579 B-Condition
tumor NCT03865914 580 585 I-Condition
were NCT03865914 586 590 B-And
expected NCT03865914 591 599 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865914 600 602 I-Assertion___Assertion-Type-Value:hypothetical
survive NCT03865914 603 610 B-Death
less NCT03865914 611 615 B-Eq-Comparison
than NCT03865914 616 620 I-Eq-Comparison
6 NCT03865914 621 622 I-Eq-Comparison
months NCT03865914 623 629 I-Eq-Comparison

- NCT03865914 632 633 O
Pregnancy NCT03865914 635 644 B-Condition
and NCT03865914 645 648 B-Or
lactation NCT03865914 649 658 B-Condition

Inclusion NCT03863626 0 9 O
Criteria NCT03863626 10 18 O
: NCT03863626 19 20 O

- NCT03863626 24 25 O
Age NCT03863626 27 30 B-Age
more NCT03863626 31 35 B-Eq-Comparison
than NCT03863626 36 40 I-Eq-Comparison
18 NCT03863626 41 43 I-Eq-Comparison
years NCT03863626 44 49 I-Eq-Comparison
. NCT03863626 49 50 O

- NCT03863626 54 55 O
Chronic NCT03863626 57 64 B-Modifier
heart NCT03863626 65 70 B-Condition
failure NCT03863626 71 78 I-Condition
prior NCT03863626 79 84 B-Eq-Comparison
diagnosis NCT03863626 85 94 O
, NCT03863626 95 96 O
based NCT03863626 97 102 O
on NCT03863626 103 105 O
signs NCT03863626 106 111 B-Assertion___Assertion-Type-Value:possible
and NCT03863626 112 115 B-Or
or NCT03863626 116 118 I-Or
symptoms NCT03863626 119 127 B-Assertion___Assertion-Type-Value:possible
of NCT03863626 128 130 O
heart NCT03863626 131 136 B-Condition
failure NCT03863626 137 144 I-Condition
, NCT03863626 145 146 O
presenting NCT03863626 147 157 O
with NCT03863626 158 162 O
acute NCT03863626 163 168 O
decompensation NCT03863626 169 183 B-Condition
as NCT03863626 184 186 O
judged NCT03863626 187 193 O
by NCT03863626 194 196 O
the NCT03863626 197 200 O
physician NCT03863626 201 210 B-Provider
to NCT03863626 211 213 O
require NCT03863626 214 221 B-Assertion___Assertion-Type-Value:hypothetical
hospitalization NCT03863626 222 237 B-Encounter
for NCT03863626 238 241 O
IV NCT03863626 242 244 B-Drug
diuretics NCT03863626 245 254 I-Drug

Exclusion NCT03863626 255 264 O
Criteria NCT03863626 265 273 O
: NCT03863626 274 275 O

- NCT03863626 279 280 O
Refusal NCT03863626 282 289 O
to NCT03863626 290 292 O
participate NCT03863626 293 304 O
in NCT03863626 305 307 O
the NCT03863626 308 311 O
study NCT03863626 312 317 O
. NCT03863626 317 318 O

- NCT03863626 322 323 O
Allergy NCT03863626 325 332 B-Allergy
to NCT03863626 333 335 O
IV NCT03863626 336 338 B-Drug
frusemide NCT03863626 339 348 I-Drug
. NCT03863626 348 349 O

- NCT03863626 353 354 O
Severe NCT03863626 356 362 O
renal NCT03863626 363 368 B-Condition
impairment NCT03863626 369 379 I-Condition
defined NCT03863626 380 387 O
as NCT03863626 388 390 O
eGFR NCT03863626 391 395 B-Observation
< NCT03863626 396 397 B-Eq-Comparison
30 NCT03863626 398 400 I-Eq-Comparison
ml NCT03863626 401 403 I-Eq-Comparison
/ NCT03863626 404 405 I-Eq-Comparison
m. NCT03863626 406 408 O

- NCT03863626 412 413 O
Cardiogenic NCT03863626 415 426 B-Condition
shock NCT03863626 427 432 I-Condition
or NCT03863626 433 435 B-Or
hemodynamic NCT03863626 436 447 B-Condition
instability NCT03863626 448 459 O
judged NCT03863626 460 466 O
by NCT03863626 467 469 O
the NCT03863626 470 473 O
treating NCT03863626 474 482 O
physician NCT03863626 483 492 O
to NCT03863626 493 495 O
be NCT03863626 496 498 O
unsuitable NCT03863626 499 509 O
to NCT03863626 510 512 O
participate NCT03863626 513 524 O
. NCT03863626 524 525 O

Inclusion NCT03863197 0 9 O
Criteria NCT03863197 10 18 O
: NCT03863197 19 20 O

- NCT03863197 24 25 O
Confirmed NCT03863197 27 36 O
diagnosis NCT03863197 37 46 O
of NCT03863197 47 49 O
SCP NCT03863197 50 53 B-Condition

- NCT03863197 56 57 O
Aged NCT03863197 59 63 B-Age
5 NCT03863197 64 65 B-Eq-Comparison
- NCT03863197 66 67 I-Eq-Comparison
12 NCT03863197 68 70 I-Eq-Comparison
years NCT03863197 71 76 I-Eq-Comparison

- NCT03863197 79 80 O
GMFCS NCT03863197 82 87 B-Observation
levels NCT03863197 88 94 B-Eq-Comparison
I NCT03863197 95 96 I-Eq-Comparison
- NCT03863197 97 98 I-Eq-Comparison
III NCT03863197 99 102 I-Eq-Comparison
( NCT03863197 103 104 O
GMFCS NCT03863197 105 110 B-Observation
= NCT03863197 111 112 B-Eq-Comparison
Gross NCT03863197 113 118 B-Observation
Motor NCT03863197 119 124 I-Observation
Function NCT03863197 125 133 I-Observation
Classification NCT03863197 134 148 I-Observation
Score NCT03863197 149 154 I-Observation
, NCT03863197 155 156 O
expressing NCT03863197 157 167 O
the NCT03863197 168 171 O
overall NCT03863197 172 179 O
functional NCT03863197 180 190 B-Condition
level NCT03863197 191 196 I-Condition
of NCT03863197 197 199 I-Condition
impairment NCT03863197 200 210 I-Condition
) NCT03863197 211 212 O

- NCT03863197 216 217 O
Sufficient NCT03863197 219 229 B-Assertion___Assertion-Type-Value:hypothetical
cooperation NCT03863197 230 241 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03863197 242 244 O
comprehend NCT03863197 245 255 O
and NCT03863197 256 259 O
complete NCT03863197 260 268 O
the NCT03863197 269 272 O
test NCT03863197 273 277 B-Procedure
procedure NCT03863197 278 287 I-Procedure

Exclusion NCT03863197 288 297 O
Criteria NCT03863197 298 306 O
: NCT03863197 307 308 O

- NCT03863197 312 313 O
Non NCT03863197 315 318 B-Negation
- NCT03863197 319 320 O
ambulatory NCT03863197 321 331 B-Condition

- NCT03863197 334 335 O
Botulinum NCT03863197 337 346 B-Drug
toxin NCT03863197 347 352 I-Drug
A NCT03863197 353 354 I-Drug
injections NCT03863197 355 365 B-Procedure
six NCT03863197 366 369 B-Eq-Comparison
months NCT03863197 370 376 I-Eq-Comparison
prior NCT03863197 377 382 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863197 383 385 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03863197 386 396 B-Study

- NCT03863197 399 400 O
Lower NCT03863197 402 407 B-Modifier
limb NCT03863197 408 412 I-Modifier
surgery NCT03863197 413 420 B-Procedure
two NCT03863197 421 424 B-Eq-Comparison
years NCT03863197 425 430 I-Eq-Comparison
prior NCT03863197 431 436 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863197 437 439 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03863197 440 450 B-Study

- NCT03863197 453 454 O
Presence NCT03863197 456 464 O
of NCT03863197 465 467 O
ataxia NCT03863197 468 474 B-Condition
or NCT03863197 475 477 B-Or
dystonia NCT03863197 478 486 B-Condition

- NCT03863197 489 490 O
Cognitive NCT03863197 492 501 B-Condition
problems NCT03863197 502 510 I-Condition
that NCT03863197 511 515 O
impede NCT03863197 516 522 O
measurements NCT03863197 523 535 B-Observation

- NCT03863197 538 539 I-Condition
Severe NCT03863197 541 547 O
co NCT03863197 548 550 B-Condition
- NCT03863197 551 552 O
morbidities NCT03863197 553 564 I-Condition
( NCT03863197 565 566 O
severe NCT03863197 567 573 O
epilepsy NCT03863197 574 582 B-Condition
, NCT03863197 583 584 O
non NCT03863197 585 588 B-Modifier
- NCT03863197 589 590 I-Modifier
correctable NCT03863197 591 602 I-Modifier
visual NCT03863197 603 609 B-Condition
impairment NCT03863197 610 620 I-Condition
, NCT03863197 621 622 O
autism NCT03863197 623 629 B-Condition
spectrum NCT03863197 630 638 I-Condition
disorders NCT03863197 639 648 I-Condition
, NCT03863197 649 650 O
mental NCT03863197 651 657 B-Condition
problems NCT03863197 658 666 I-Condition
that NCT03863197 667 671 O
prevent NCT03863197 672 679 B-Assertion___Assertion-Type-Value:hypothetical|Negation
comprehensiveness NCT03863197 680 697 O
of NCT03863197 698 700 O
the NCT03863197 701 704 O
tasks NCT03863197 705 710 B-Procedure
) NCT03863197 711 712 O

Inclusion NCT03864809 0 9 O
Criteria NCT03864809 10 18 O
: NCT03864809 19 20 O

- NCT03864809 23 24 O
patients NCT03864809 25 33 O
with NCT03864809 34 38 O
Psoriasis NCT03864809 39 48 B-Condition
and NCT03864809 49 52 B-Or
Patients NCT03864809 53 61 O
with NCT03864809 62 66 O
A NCT03864809 67 68 O
topic NCT03864809 69 74 B-Condition
dermatitis NCT03864809 75 85 I-Condition

Exclusion NCT03864809 86 95 O
Criteria NCT03864809 96 104 O
: NCT03864809 105 106 O

- NCT03864809 110 111 O
All NCT03864809 113 116 O
patient NCT03864809 117 124 O
have NCT03864809 125 129 O
another NCT03864809 130 137 B-Other
dermatological NCT03864809 138 152 B-Condition
disease NCT03864809 153 160 I-Condition

Inclusion NCT03868969 0 9 O
Criteria NCT03868969 10 18 O
: NCT03868969 19 20 O

- NCT03868969 24 25 O
clinical NCT03868969 27 35 O
suspicion NCT03868969 36 45 B-Assertion___Assertion-Type-Value:possible
of NCT03868969 46 48 O
urinary NCT03868969 49 56 B-Condition
tract NCT03868969 57 62 I-Condition
infection NCT03868969 63 72 I-Condition
( NCT03868969 73 74 O
UTI NCT03868969 75 78 B-Condition
) NCT03868969 79 80 O
defined NCT03868969 81 88 O
by NCT03868969 89 91 O
the NCT03868969 92 95 O
presence NCT03868969 96 104 O
of NCT03868969 105 107 O
at NCT03868969 108 110 B-Eq-Comparison
least NCT03868969 111 116 I-Eq-Comparison
one NCT03868969 117 120 I-Eq-Comparison
of NCT03868969 121 123 B-Criteria-Count
these NCT03868969 124 129 I-Criteria-Count
signs NCT03868969 130 135 I-Criteria-Count
: NCT03868969 136 137 O
fever NCT03868969 138 143 B-Condition|Observation
> NCT03868969 144 145 B-Eq-Comparison
38 NCT03868969 146 148 I-Eq-Comparison
° NCT03868969 149 150 O
C NCT03868969 150 151 O
and NCT03868969 152 155 B-Or
/ NCT03868969 156 157 I-Or
or NCT03868969 158 160 I-Or
sus NCT03868969 161 164 B-Modifier
- NCT03868969 165 166 I-Modifier
pubic NCT03868969 167 172 I-Modifier
pain NCT03868969 173 177 B-Condition
and NCT03868969 178 181 B-Or
/ NCT03868969 182 183 I-Or
or NCT03868969 184 186 I-Or
dysuria NCT03868969 187 194 B-Condition
and NCT03868969 195 198 B-Or
/ NCT03868969 199 200 I-Or
or NCT03868969 201 203 I-Or
pollakiuria NCT03868969 204 215 B-Condition
and NCT03868969 216 219 B-Or
/ NCT03868969 220 221 I-Or
or NCT03868969 222 224 I-Or
urinary NCT03868969 225 232 B-Modifier
burns NCT03868969 233 238 B-Condition
and NCT03868969 239 242 B-Or
/ NCT03868969 243 244 I-Or
or NCT03868969 245 247 I-Or
macroscopic NCT03868969 248 259 B-Modifier
hematuria NCT03868969 260 269 B-Condition
and NCT03868969 270 273 B-Or
/ NCT03868969 274 275 I-Or
or NCT03868969 276 278 I-Or
acute NCT03868969 279 284 O
urinary NCT03868969 285 292 B-Condition
retention NCT03868969 293 302 I-Condition
and NCT03868969 303 306 B-Or
/ NCT03868969 307 308 I-Or
or NCT03868969 309 311 I-Or
pain NCT03868969 312 316 B-Condition
with NCT03868969 317 321 O
the NCT03868969 322 325 O
rectal NCT03868969 326 332 B-Procedure
examination NCT03868969 333 344 I-Procedure
and NCT03868969 345 348 B-Or
/ NCT03868969 349 350 I-Or
or NCT03868969 351 353 I-Or
confusion NCT03868969 354 363 B-Condition

- NCT03868969 366 367 O
And NCT03868969 369 372 B-And
urinary NCT03868969 373 380 B-Observation
analysis NCT03868969 381 389 I-Observation
with NCT03868969 390 394 O
leukocyturia NCT03868969 395 407 B-Condition|Observation
> NCT03868969 408 409 B-Eq-Comparison|Eq-Comparison
10 NCT03868969 410 412 I-Eq-Comparison|Eq-Comparison
/ NCT03868969 413 414 I-Eq-Comparison
mm3 NCT03868969 415 418 I-Eq-Comparison
, NCT03868969 419 420 O
bacteriuria NCT03868969 421 432 B-Condition|Observation
> NCT03868969 433 434 O
10 NCT03868969 435 437 O
^3 NCT03868969 438 440 O
CFU NCT03868969 441 444 I-Eq-Comparison
/ NCT03868969 445 446 I-Eq-Comparison
mL NCT03868969 447 449 I-Eq-Comparison
with NCT03868969 450 454 B-And
ESBL NCT03868969 455 459 B-Modifier
producing NCT03868969 460 469 I-Modifier
enterobacteriaceae NCT03868969 470 488 B-Condition
and NCT03868969 489 492 B-And
resistance NCT03868969 493 503 B-Condition
associated NCT03868969 504 514 O
with NCT03868969 515 519 O
fluoroquinolones NCT03868969 520 536 B-Drug
( NCT03868969 537 538 O
FQ NCT03868969 539 541 B-Drug
) NCT03868969 542 543 O
and NCT03868969 544 547 B-Or
cotrimoxazole NCT03868969 548 561 B-Drug
( NCT03868969 562 563 O
CTX NCT03868969 564 567 B-Drug
) NCT03868969 568 569 O
but NCT03868969 570 573 B-And
sensitive NCT03868969 574 583 B-Condition
to NCT03868969 584 586 O
fosfomycin NCT03868969 587 597 B-Drug
. NCT03868969 597 598 O

Exclusion NCT03868969 600 609 O
Criteria NCT03868969 610 618 O
: NCT03868969 619 620 O

- NCT03868969 624 625 O
allergy NCT03868969 627 634 B-Allergy
to NCT03868969 635 637 O
fosfomycin NCT03868969 638 648 B-Drug
and NCT03868969 649 652 B-Or
/ NCT03868969 653 654 I-Or
or NCT03868969 655 657 I-Or
trometamol NCT03868969 658 668 B-Drug

- NCT03868969 671 672 O
Presence NCT03868969 674 682 O
of NCT03868969 683 685 O
material NCT03868969 686 694 B-Condition
in NCT03868969 695 697 O
the NCT03868969 698 701 O
urinary NCT03868969 702 709 B-Modifier
tract NCT03868969 710 715 I-Modifier

- NCT03868969 718 719 O
Severe NCT03868969 721 727 O
immunosuppression NCT03868969 728 745 B-Condition

- NCT03868969 748 749 O
Chronic NCT03868969 751 758 B-Modifier
prostatitis NCT03868969 759 770 B-Condition

- NCT03868969 773 774 O
Prostate NCT03868969 776 784 B-Condition
abscess NCT03868969 785 792 I-Condition

- NCT03868969 795 796 O
Acute NCT03868969 798 803 O
pyelonephritis NCT03868969 804 818 B-Condition

- NCT03868969 821 822 O
Hemodynamic NCT03868969 824 835 B-Condition
instability NCT03868969 836 847 O

- NCT03868969 850 851 O
Chronic NCT03868969 853 860 B-Condition
renal NCT03868969 861 866 I-Condition
failure NCT03868969 867 874 I-Condition
( NCT03868969 875 876 O
clearance NCT03868969 877 886 B-Observation
< NCT03868969 887 888 B-Eq-Comparison
60 NCT03868969 889 891 I-Eq-Comparison
mL NCT03868969 892 894 I-Eq-Comparison
/ NCT03868969 895 896 I-Eq-Comparison
min NCT03868969 897 900 I-Eq-Comparison
) NCT03868969 901 902 O

- NCT03868969 906 907 O
Prior NCT03868969 909 914 B-Eq-Comparison
antibiotic NCT03868969 915 925 B-Drug|Procedure
therapy NCT03868969 926 933 I-Procedure
, NCT03868969 934 935 O
with NCT03868969 936 940 B-And
an NCT03868969 941 943 B-Observation
antibiotic NCT03868969 944 954 O
sensitive NCT03868969 955 964 B-Condition
on NCT03868969 965 967 O
the NCT03868969 968 971 O
antibiotic NCT03868969 972 982 O
susceptibility NCT03868969 983 997 I-Observation
test NCT03868969 998 1002 I-Observation
except NCT03868969 1003 1009 B-Exception
: NCT03868969 1010 1011 O
amoxicillin NCT03868969 1012 1023 B-Drug
- NCT03868969 1024 1025 B-Or
clavulanic NCT03868969 1026 1036 B-Drug
acid NCT03868969 1037 1041 I-Drug
, NCT03868969 1042 1043 O
cefixime NCT03868969 1044 1052 B-Drug
, NCT03868969 1053 1054 O
nitrofurantoin NCT03868969 1055 1069 B-Drug
. NCT03868969 1069 1070 O

- NCT03868969 1074 1075 O
Co NCT03868969 1077 1079 O
- NCT03868969 1080 1081 O
treatment NCT03868969 1082 1091 B-Procedure
with NCT03868969 1092 1096 O
metoclopramide NCT03868969 1097 1111 B-Drug

Inclusion NCT03864835 0 9 O
Criteria NCT03864835 10 18 O

•Enrollment NCT03864835 19 30 O
and NCT03864835 31 34 O
completion NCT03864835 35 45 O
of NCT03864835 46 48 O
IRB NCT03864835 49 52 O
study NCT03864835 53 58 O
# NCT03864835 59 60 O
00011797 NCT03864835 61 69 O

Exclusion NCT03864835 71 80 O
Criteria NCT03864835 81 89 O

- NCT03864835 92 93 O
Inability NCT03864835 95 104 O
to NCT03864835 105 107 O
provide NCT03864835 108 115 O
informed NCT03864835 116 124 O
consent NCT03864835 125 132 O

- NCT03864835 135 136 O
Institutionalized NCT03864835 138 155 B-Observation
/ NCT03864835 156 157 B-Or
prisoner NCT03864835 158 166 B-Observation

- NCT03864835 169 170 O
Non NCT03864835 172 175 B-Negation
- NCT03864835 176 177 O
English NCT03864835 178 185 O
- NCT03864835 186 187 O
speaking NCT03864835 188 196 O
patients NCT03864835 197 205 O
due NCT03864835 206 209 O
to NCT03864835 210 212 O
unavailability NCT03864835 213 227 O
of NCT03864835 228 230 O
translators NCT03864835 231 242 O
for NCT03864835 243 246 O
all NCT03864835 247 250 O
visits NCT03864835 251 257 O
/ NCT03864835 258 259 O
sessions NCT03864835 260 268 O

Inclusion NCT03866005 0 9 O
Criteria NCT03866005 10 18 O
: NCT03866005 19 20 O

- NCT03866005 24 25 O
Diagnosed NCT03866005 27 36 O
diabetes NCT03866005 37 45 B-Condition
mellitus NCT03866005 46 54 I-Condition
and NCT03866005 55 58 B-And
treatment NCT03866005 59 68 B-Procedure
- NCT03866005 69 70 O
naïve NCT03866005 71 76 B-Negation
CI NCT03866005 77 79 B-Condition
- NCT03866005 80 81 I-Condition
DME NCT03866005 82 85 I-Condition
requiring NCT03866005 86 95 B-Assertion___Assertion-Type-Value:hypothetical
anti NCT03866005 96 100 O
- NCT03866005 101 102 O
VEGF NCT03866005 103 107 B-Condition
therapy NCT03866005 108 115 B-Procedure
per NCT03866005 116 119 O
retinal NCT03866005 120 127 B-Provider
specialist NCT03866005 128 138 I-Provider
's NCT03866005 138 140 O
customary NCT03866005 141 150 O
treatment NCT03866005 151 160 B-Procedure
regimen NCT03866005 161 168 O
will NCT03866005 169 173 O
be NCT03866005 174 176 O
recruited NCT03866005 177 186 O
to NCT03866005 187 189 O
participate NCT03866005 190 201 O
in NCT03866005 202 204 O
the NCT03866005 205 208 O
study NCT03866005 209 214 B-Study
. NCT03866005 214 215 O
CI NCT03866005 217 219 B-Condition
- NCT03866005 220 221 I-Condition
DME NCT03866005 222 225 I-Condition
will NCT03866005 226 230 O
be NCT03866005 231 233 O
defined NCT03866005 234 241 O
as NCT03866005 242 244 O
a NCT03866005 245 246 O
central NCT03866005 247 254 B-Observation
subfield NCT03866005 255 263 I-Observation
thickness NCT03866005 264 273 I-Observation
( NCT03866005 274 275 O
CST NCT03866005 276 279 B-Observation
) NCT03866005 280 281 O
> NCT03866005 282 283 B-Eq-Comparison
300 NCT03866005 284 287 I-Eq-Comparison
microns NCT03866005 288 295 I-Eq-Comparison
on NCT03866005 296 298 O
spectral NCT03866005 299 307 B-Modifier
domain NCT03866005 308 314 I-Modifier
optical NCT03866005 315 322 B-Procedure
coherence NCT03866005 323 332 I-Procedure
tomography NCT03866005 333 343 I-Procedure
( NCT03866005 344 345 O
SD NCT03866005 346 348 B-Procedure
- NCT03866005 349 350 I-Procedure
OCT NCT03866005 351 354 I-Procedure
) NCT03866005 355 356 O
or NCT03866005 357 359 B-Or
CST NCT03866005 360 363 B-Observation
> NCT03866005 364 365 B-Eq-Comparison
250 NCT03866005 366 369 I-Eq-Comparison
microns NCT03866005 370 377 I-Eq-Comparison
with NCT03866005 378 382 B-And
definite NCT03866005 383 391 O
intra NCT03866005 392 397 B-Modifier
- NCT03866005 398 399 I-Modifier
retinal NCT03866005 400 407 I-Modifier
cystic NCT03866005 408 414 B-Condition
fluid NCT03866005 415 420 I-Condition
accumulation NCT03866005 421 433 I-Condition
. NCT03866005 433 434 O
Additional NCT03866005 436 446 O
inclusion NCT03866005 447 456 O
criteria NCT03866005 457 465 O
are NCT03866005 466 469 O
age NCT03866005 470 473 B-Age
> NCT03866005 474 475 B-Eq-Comparison
18 NCT03866005 476 478 I-Eq-Comparison
years NCT03866005 479 484 I-Eq-Comparison
, NCT03866005 485 486 O
and NCT03866005 487 490 O
ability NCT03866005 491 498 O
to NCT03866005 499 501 O
give NCT03866005 502 506 O
informed NCT03866005 507 515 O
consent NCT03866005 516 523 O
. NCT03866005 523 524 O

Exclusion NCT03866005 526 535 O
Criteria NCT03866005 536 544 O
: NCT03866005 545 546 O

- NCT03866005 550 551 O
Age NCT03866005 553 556 B-Age
< NCT03866005 557 558 B-Eq-Comparison
18 NCT03866005 559 561 I-Eq-Comparison
years NCT03866005 562 567 I-Eq-Comparison
, NCT03866005 568 569 O
inability NCT03866005 570 579 O
to NCT03866005 580 582 O
give NCT03866005 583 587 O
informed NCT03866005 588 596 O
consent NCT03866005 597 604 O
, NCT03866005 605 606 O
evidence NCT03866005 607 615 O
of NCT03866005 616 618 O
proliferative NCT03866005 619 632 B-Condition
diabetic NCT03866005 633 641 I-Condition
retinopathy NCT03866005 642 653 I-Condition
, NCT03866005 654 655 O
evidence NCT03866005 656 664 O
of NCT03866005 665 667 O
other NCT03866005 668 673 B-Other
serious NCT03866005 674 681 O
ocular NCT03866005 682 688 B-Condition
disease NCT03866005 689 696 I-Condition
( NCT03866005 697 698 O
age NCT03866005 699 702 B-Modifier
- NCT03866005 703 704 I-Modifier
related NCT03866005 705 712 I-Modifier
macular NCT03866005 713 720 B-Condition
degeneration NCT03866005 721 733 I-Condition
, NCT03866005 734 735 O
glaucoma NCT03866005 736 744 B-Condition
, NCT03866005 745 746 O
significant NCT03866005 747 758 O
media NCT03866005 759 764 B-Condition
opacity NCT03866005 765 772 I-Condition
) NCT03866005 773 774 O
, NCT03866005 776 777 O
history NCT03866005 778 785 B-Eq-Comparison
of NCT03866005 786 788 I-Eq-Comparison
previous NCT03866005 789 797 I-Eq-Comparison
intraocular NCT03866005 798 809 B-Procedure
surgery NCT03866005 810 817 I-Procedure
, NCT03866005 818 819 O
including NCT03866005 820 829 O
macular NCT03866005 830 837 B-Modifier
or NCT03866005 838 840 B-Or
panretinal NCT03866005 841 851 B-Modifier
photocoagulation NCT03866005 852 868 B-Procedure
( NCT03866005 869 870 O
except NCT03866005 871 877 B-Exception
uncomplicated NCT03866005 878 891 B-Modifier
cataract NCT03866005 892 900 I-Modifier
or NCT03866005 901 903 B-Or
keratorefractive NCT03866005 904 920 B-Modifier
surgery NCT03866005 921 928 B-Procedure
more NCT03866005 929 933 B-Eq-Comparison
than NCT03866005 934 938 I-Eq-Comparison
6 NCT03866005 939 940 I-Eq-Comparison
months NCT03866005 941 947 I-Eq-Comparison
prior NCT03866005 948 953 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866005 954 956 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866005 957 967 B-Study
) NCT03866005 968 969 O
, NCT03866005 971 972 O
pregnant NCT03866005 973 981 B-Condition
and NCT03866005 982 985 B-Or
nursing NCT03866005 986 993 B-Condition
women NCT03866005 994 999 O
, NCT03866005 1000 1001 O
known NCT03866005 1002 1007 O
sensitivity NCT03866005 1008 1019 B-Condition
to NCT03866005 1020 1022 O
any NCT03866005 1023 1026 O
of NCT03866005 1027 1029 O
the NCT03866005 1030 1033 O
supplement NCT03866005 1034 1044 B-Drug
ingredients NCT03866005 1045 1056 I-Drug
. NCT03866005 1056 1057 O

Inclusion NCT03868982 0 9 O
Criteria NCT03868982 10 18 O
: NCT03868982 19 20 O

- NCT03868982 24 25 O
Diagnosis NCT03868982 27 36 O
of NCT03868982 37 39 O
ARDS NCT03868982 40 44 B-Condition
by NCT03868982 45 47 O
Berlin NCT03868982 48 54 O
definition NCT03868982 55 65 O

- NCT03868982 68 69 O
P NCT03868982 71 72 B-Observation
/ NCT03868982 73 74 I-Observation
F NCT03868982 75 76 I-Observation
ratio NCT03868982 77 82 I-Observation
between NCT03868982 83 90 B-Eq-Comparison
100 NCT03868982 91 94 I-Eq-Comparison
- NCT03868982 95 96 I-Eq-Comparison
300 NCT03868982 97 100 I-Eq-Comparison

- NCT03868982 104 105 O
Completed NCT03868982 107 116 O
the NCT03868982 117 120 O
case NCT03868982 121 125 O
enrollement NCT03868982 126 137 B-Study
within NCT03868982 138 144 B-Eq-Comparison
48 NCT03868982 145 147 I-Eq-Comparison
hours NCT03868982 148 153 I-Eq-Comparison

Exclusion NCT03868982 154 163 O
Criteria NCT03868982 164 172 O
: NCT03868982 173 174 O

- NCT03868982 178 179 O
Less NCT03868982 181 185 B-Eq-Comparison
than NCT03868982 186 190 I-Eq-Comparison
18 NCT03868982 191 193 I-Eq-Comparison
years NCT03868982 194 199 I-Eq-Comparison
old NCT03868982 200 203 B-Age

- NCT03868982 206 207 O
Pregnancy NCT03868982 209 218 B-Condition

- NCT03868982 221 222 O
Participants NCT03868982 224 236 O
with NCT03868982 237 241 O
tracheostomy NCT03868982 242 254 B-Procedure

- NCT03868982 257 258 O
Unable NCT03868982 260 266 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868982 267 269 O
insert NCT03868982 270 276 O
the NCT03868982 277 280 O
NG NCT03868982 281 283 B-Procedure
- NCT03868982 284 285 I-Procedure
tube NCT03868982 286 290 I-Procedure

Inclusion NCT03865524 0 9 O
Criteria NCT03865524 10 18 O
: NCT03865524 19 20 O

- NCT03865524 24 25 O
Men NCT03865524 27 30 O
and NCT03865524 31 34 B-Or
women NCT03865524 35 40 O
over NCT03865524 41 45 B-Eq-Comparison
18 NCT03865524 46 48 I-Eq-Comparison
years NCT03865524 49 54 I-Eq-Comparison
old NCT03865524 55 58 B-Age
. NCT03865524 58 59 O

- NCT03865524 63 64 O
Written NCT03865524 66 73 O
informed NCT03865524 74 82 O
consent NCT03865524 83 90 O
according NCT03865524 91 100 O
to NCT03865524 101 103 O
ICH NCT03865524 104 107 O
/ NCT03865524 108 109 O
GCP NCT03865524 110 113 O
and NCT03865524 114 117 O
Spanish NCT03865524 118 125 O
legislation NCT03865524 126 137 O
, NCT03865524 138 139 O
obtained NCT03865524 140 148 O
before NCT03865524 149 155 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03865524 156 159 O
study NCT03865524 160 165 B-Study
procedure NCT03865524 166 175 O
. NCT03865524 175 176 O

- NCT03865524 180 181 O
Patient NCT03865524 183 190 O
with NCT03865524 191 195 O
a NCT03865524 196 197 O
BMI NCT03865524 198 201 B-Observation
equal NCT03865524 202 207 B-Eq-Comparison
to NCT03865524 208 210 I-Eq-Comparison
or NCT03865524 211 213 I-Eq-Comparison
greater NCT03865524 214 221 I-Eq-Comparison
than NCT03865524 222 226 I-Eq-Comparison
30 NCT03865524 227 229 I-Eq-Comparison
Kg NCT03865524 230 232 I-Eq-Comparison
/ NCT03865524 233 234 I-Eq-Comparison
m2 NCT03865524 235 237 I-Eq-Comparison

- NCT03865524 240 241 O
Patients NCT03865524 243 251 O
with NCT03865524 252 256 O
clinical NCT03865524 257 265 B-Modifier
and NCT03865524 266 269 B-Or
radiological NCT03865524 270 282 B-Procedure
criteria NCT03865524 283 291 O
of NCT03865524 292 294 O
knee NCT03865524 295 299 B-Modifier
osteoarthritis NCT03865524 300 314 B-Condition
. NCT03865524 314 315 O

- NCT03865524 319 320 O
Patients NCT03865524 322 330 O
with NCT03865524 331 335 O
indication NCT03865524 336 346 B-Indication
for NCT03865524 347 350 O
primary NCT03865524 351 358 B-Modifier
TKA NCT03865524 359 362 B-Condition
according NCT03865524 363 372 O
to NCT03865524 373 375 O
medical NCT03865524 376 383 O
criteria NCT03865524 384 392 O
. NCT03865524 392 393 O

Exclusion NCT03865524 395 404 O
Criteria NCT03865524 405 413 O
: NCT03865524 414 415 O

- NCT03865524 419 420 O
Pregnancy NCT03865524 422 431 B-Condition
or NCT03865524 432 434 B-Or
lactation NCT03865524 435 444 B-Condition
. NCT03865524 444 445 O

- NCT03865524 449 450 O
Inability NCT03865524 452 461 O
to NCT03865524 462 464 O
give NCT03865524 465 469 O
informed NCT03865524 470 478 O
consent NCT03865524 479 486 O
in NCT03865524 487 489 O
the NCT03865524 490 493 O
absence NCT03865524 494 501 O
of NCT03865524 502 504 O
a NCT03865524 505 506 O
legal NCT03865524 507 512 O
representative NCT03865524 513 527 O
. NCT03865524 527 528 O

- NCT03865524 532 533 O
Subjects NCT03865524 535 543 O
that NCT03865524 544 548 O
are NCT03865524 549 552 O
participating NCT03865524 553 566 B-Eq-Comparison
in NCT03865524 567 569 O
a NCT03865524 570 571 O
study NCT03865524 572 577 B-Study
with NCT03865524 578 582 O
medicines NCT03865524 583 592 B-Drug
or NCT03865524 593 595 B-Or
other NCT03865524 596 601 B-Other
medical NCT03865524 602 609 B-Procedure
devices NCT03865524 610 617 I-Procedure
. NCT03865524 617 618 O

- NCT03865524 622 623 O
Those NCT03865524 625 630 O
who NCT03865524 631 634 O
show NCT03865524 635 639 O
inability NCT03865524 640 649 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865524 650 652 O
follow NCT03865524 653 659 O
the NCT03865524 660 663 O
instructions NCT03865524 664 676 O
or NCT03865524 677 679 O
collaborate NCT03865524 680 691 O
during NCT03865524 692 698 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865524 699 702 O
development NCT03865524 703 714 O
of NCT03865524 715 717 O
the NCT03865524 718 721 O
study NCT03865524 722 727 B-Study
. NCT03865524 727 728 O

- NCT03865524 732 733 O
If NCT03865524 735 737 O
in NCT03865524 738 740 O
the NCT03865524 741 744 O
opinion NCT03865524 745 752 O
of NCT03865524 753 755 O
the NCT03865524 756 759 O
researcher NCT03865524 760 770 O
there NCT03865524 771 776 O
are NCT03865524 777 780 O
findings NCT03865524 781 789 O
in NCT03865524 790 792 O
the NCT03865524 793 796 O
physical NCT03865524 797 805 B-Procedure
examination NCT03865524 806 817 I-Procedure
, NCT03865524 818 819 O
abnormalities NCT03865524 820 833 B-Condition
in NCT03865524 834 836 O
the NCT03865524 837 840 O
results NCT03865524 841 848 O
of NCT03865524 849 851 O
the NCT03865524 852 855 O
clinical NCT03865524 856 864 O
analyzes NCT03865524 865 873 O
or NCT03865524 874 876 B-Or
other NCT03865524 877 882 O
medical NCT03865524 883 890 O
, NCT03865524 891 892 O
social NCT03865524 893 899 B-Modifier
or NCT03865524 900 902 B-Or
psychosocial NCT03865524 903 915 B-Modifier
factors NCT03865524 916 923 B-Condition
that NCT03865524 924 928 O
could NCT03865524 929 934 B-Assertion___Assertion-Type-Value:hypothetical
have NCT03865524 935 939 O
a NCT03865524 940 941 O
negative NCT03865524 942 950 O
influence NCT03865524 951 960 O

- NCT03865524 963 964 O
Having NCT03865524 966 972 O
had NCT03865524 973 976 O
a NCT03865524 977 978 O
previous NCT03865524 979 987 B-Eq-Comparison
surgical NCT03865524 988 996 B-Procedure
procedure NCT03865524 997 1006 I-Procedure
on NCT03865524 1007 1009 B-Modifier
or NCT03865524 1010 1012 B-Or
around NCT03865524 1013 1019 B-Modifier
the NCT03865524 1020 1023 I-Modifier
knee NCT03865524 1024 1028 I-Modifier
in NCT03865524 1029 1031 O
the NCT03865524 1032 1035 O
last NCT03865524 1036 1040 B-Eq-Comparison
12 NCT03865524 1041 1043 I-Eq-Comparison
months NCT03865524 1044 1050 I-Eq-Comparison
( NCT03865524 1051 1052 O
such NCT03865524 1053 1057 O
as NCT03865524 1058 1060 O
proximal NCT03865524 1061 1069 B-Procedure
tibial NCT03865524 1070 1076 I-Procedure
osteotomy NCT03865524 1077 1086 I-Procedure
, NCT03865524 1087 1088 O
femoral NCT03865524 1089 1096 B-Procedure
osteotomy NCT03865524 1097 1106 I-Procedure
, NCT03865524 1107 1108 O
open NCT03865524 1109 1113 B-Procedure
reduction NCT03865524 1114 1123 I-Procedure
and NCT03865524 1124 1127 B-Or
internal NCT03865524 1128 1136 B-Procedure
fixation NCT03865524 1137 1145 I-Procedure
for NCT03865524 1146 1149 O
a NCT03865524 1150 1151 O
fracture NCT03865524 1152 1160 B-Condition
, NCT03865524 1161 1162 O
patellectomy NCT03865524 1163 1175 B-Procedure
or NCT03865524 1176 1178 B-Or
patellar NCT03865524 1179 1187 B-Procedure
realignment NCT03865524 1188 1199 I-Procedure
) NCT03865524 1200 1201 O
. NCT03865524 1202 1203 O

- NCT03865524 1207 1208 O
Need NCT03865524 1210 1214 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03865524 1215 1216 O
simultaneous NCT03865524 1217 1229 B-Modifier
bilateral NCT03865524 1230 1239 I-Modifier
TKA NCT03865524 1240 1243 B-Procedure
. NCT03865524 1243 1244 O

- NCT03865524 1248 1249 O
Have NCT03865524 1251 1255 O
a NCT03865524 1256 1257 O
varus NCT03865524 1258 1263 B-Observation
angle NCT03865524 1264 1269 I-Observation
or NCT03865524 1270 1272 B-Or
valgus NCT03865524 1273 1279 B-Observation
≥ NCT03865524 1280 1281 B-Eq-Comparison
15 NCT03865524 1282 1284 I-Eq-Comparison
° NCT03865524 1285 1286 I-Eq-Comparison
. NCT03865524 1286 1287 O

- NCT03865524 1291 1292 O
Total NCT03865524 1294 1299 B-Procedure
revision NCT03865524 1300 1308 I-Procedure
knee NCT03865524 1309 1313 I-Procedure
arthroplasty NCT03865524 1314 1326 I-Procedure
. NCT03865524 1326 1327 O

Inclusion NCT03867864 0 9 O
Criteria NCT03867864 10 18 O
: NCT03867864 19 20 O

- NCT03867864 24 25 O
Registered NCT03867864 27 37 O
nurses NCT03867864 38 44 B-Provider
, NCT03867864 45 46 O
working NCT03867864 47 54 O
in NCT03867864 55 57 O
intensive NCT03867864 58 67 O
care NCT03867864 68 72 O
units NCT03867864 73 78 O
( NCT03867864 79 80 O
ICU NCT03867864 81 84 O
) NCT03867864 85 86 O
or NCT03867864 87 89 B-Or
department NCT03867864 90 100 O
of NCT03867864 101 103 O
emergency NCT03867864 104 113 O
( NCT03867864 114 115 O
ED NCT03867864 116 118 O
) NCT03867864 119 120 O
. NCT03867864 121 122 O

- NCT03867864 126 127 O
The NCT03867864 129 132 O
frequency NCT03867864 133 142 O
of NCT03867864 143 145 O
headaches NCT03867864 146 155 B-Condition
more NCT03867864 156 160 B-Eq-Comparison
than NCT03867864 161 165 I-Eq-Comparison
three NCT03867864 166 171 I-Eq-Comparison
times NCT03867864 172 177 I-Eq-Comparison
per NCT03867864 178 181 I-Eq-Comparison
month NCT03867864 182 187 I-Eq-Comparison
. NCT03867864 187 188 O

- NCT03867864 192 193 O
The NCT03867864 195 198 O
type NCT03867864 199 203 O
of NCT03867864 204 206 O
headache NCT03867864 207 215 B-Condition
is NCT03867864 216 218 O
migraine NCT03867864 219 227 B-Condition
or NCT03867864 228 230 B-Or
frequent NCT03867864 231 239 B-Modifier
episodic NCT03867864 240 248 I-Modifier
tension NCT03867864 249 256 I-Modifier
- NCT03867864 257 258 I-Modifier
type NCT03867864 259 263 I-Modifier
headache NCT03867864 264 272 B-Condition
, NCT03867864 273 274 O
which NCT03867864 275 280 O
is NCT03867864 281 283 O
defined NCT03867864 284 291 O
by NCT03867864 292 294 O
the NCT03867864 295 298 O
Headache NCT03867864 299 307 O
Classification NCT03867864 308 322 O
Committee NCT03867864 323 332 O
of NCT03867864 333 335 O
the NCT03867864 336 339 O
International NCT03867864 340 353 O
Headache NCT03867864 354 362 O
Society NCT03867864 363 370 O
. NCT03867864 370 371 O
If NCT03867864 373 375 O
the NCT03867864 376 379 O
symptoms NCT03867864 380 388 B-Assertion___Assertion-Type-Value:possible
of NCT03867864 389 391 O
a NCT03867864 392 393 O
headache NCT03867864 394 402 B-Condition
can NCT03867864 403 406 O
not NCT03867864 406 409 O
be NCT03867864 410 412 O
defined NCT03867864 413 420 O
, NCT03867864 421 422 O
the NCT03867864 423 426 O
investigator NCT03867864 427 439 O
will NCT03867864 440 444 B-Assertion___Assertion-Type-Value:hypothetical
refer NCT03867864 445 450 B-Encounter
the NCT03867864 451 454 O
potential NCT03867864 455 464 O
participant NCT03867864 465 476 O
to NCT03867864 477 479 O
a NCT03867864 480 481 O
neurologist NCT03867864 482 493 B-Provider
for NCT03867864 494 497 O
further NCT03867864 498 505 O
diagnosis NCT03867864 506 515 O
. NCT03867864 515 516 O

Exclusion NCT03867864 518 527 O
Criteria NCT03867864 528 536 O
: NCT03867864 537 538 O

- NCT03867864 542 543 O
Current NCT03867864 545 552 B-Eq-Comparison
user NCT03867864 553 557 O
of NCT03867864 558 560 O
other NCT03867864 561 566 B-Other
kinds NCT03867864 567 572 O
of NCT03867864 573 575 O
essential NCT03867864 576 585 B-Drug
oils NCT03867864 586 590 I-Drug
( NCT03867864 591 592 O
e. NCT03867864 593 595 O
g. NCT03867864 596 598 O
, NCT03867864 599 600 O
the NCT03867864 601 604 O
external NCT03867864 605 613 B-Modifier
application NCT03867864 614 625 I-Modifier
on NCT03867864 626 628 I-Modifier
skin NCT03867864 629 633 I-Modifier
, NCT03867864 634 635 O
sniffing NCT03867864 636 644 B-Modifier
) NCT03867864 645 646 O
, NCT03867864 648 649 O
and NCT03867864 650 653 B-And
do NCT03867864 654 656 O
not NCT03867864 657 660 B-Negation
willing NCT03867864 661 668 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867864 669 671 I-Assertion___Assertion-Type-Value:hypothetical
temporarily NCT03867864 672 683 O
suspend NCT03867864 684 691 B-Negation
for NCT03867864 692 695 O
nine NCT03867864 696 700 B-Eq-Comparison
weeks NCT03867864 701 706 I-Eq-Comparison
. NCT03867864 706 707 O

- NCT03867864 711 712 O
Having NCT03867864 714 720 O
sensitive NCT03867864 721 730 B-Condition
responses NCT03867864 731 740 I-Condition
to NCT03867864 741 743 O
the NCT03867864 744 747 O
essential NCT03867864 748 757 B-Drug
oil NCT03867864 758 761 I-Drug
. NCT03867864 761 762 O

- NCT03867864 766 767 O
Pregnancy NCT03867864 769 778 B-Condition
or NCT03867864 779 781 B-Or
preparing NCT03867864 782 791 B-Assertion___Assertion-Type-Value:intention
for NCT03867864 792 795 O
pregnancy NCT03867864 796 805 B-Condition
. NCT03867864 805 806 O

- NCT03867864 810 811 O
Breastfeeding NCT03867864 813 826 B-Condition
. NCT03867864 826 827 O

- NCT03867864 831 832 O
The NCT03867864 834 837 O
type NCT03867864 838 842 O
of NCT03867864 843 845 O
headache NCT03867864 846 854 B-Condition
was NCT03867864 855 858 O
neither NCT03867864 859 866 B-Negation
migraine NCT03867864 867 875 B-Condition
nor NCT03867864 876 879 B-Negation
frequent NCT03867864 880 888 B-Modifier
episodic NCT03867864 889 897 I-Modifier
tension NCT03867864 898 905 I-Modifier
- NCT03867864 906 907 I-Modifier
type NCT03867864 908 912 I-Modifier
headache NCT03867864 913 921 B-Condition
after NCT03867864 922 927 B-Temporal-Connection___Temporal-Connection-Type-Value:after
diagnosed NCT03867864 928 937 B-Coreference
by NCT03867864 938 940 O
the NCT03867864 941 944 O
neurologist NCT03867864 945 956 B-Provider
. NCT03867864 956 957 O

- NCT03867864 961 962 O
With NCT03867864 964 968 O
hepatic NCT03867864 969 976 B-Modifier
or NCT03867864 977 979 B-Or
renal NCT03867864 980 985 B-Modifier
diseases NCT03867864 986 994 B-Condition
. NCT03867864 994 995 O

- NCT03867864 999 1000 I-Modifier
taking NCT03867864 1002 1008 B-Eq-Comparison
medicine NCT03867864 1009 1017 B-Drug
for NCT03867864 1018 1021 O
long NCT03867864 1022 1026 B-Modifier
- NCT03867864 1027 1028 I-Drug
term NCT03867864 1029 1033 I-Modifier
( NCT03867864 1034 1035 O
such NCT03867864 1036 1040 O
as NCT03867864 1041 1043 O
Aspirin NCT03867864 1044 1051 B-Drug
, NCT03867864 1052 1053 O
anti NCT03867864 1054 1058 B-Drug
- NCT03867864 1059 1060 O
coagulant NCT03867864 1061 1070 I-Drug
, NCT03867864 1071 1072 O
medication NCT03867864 1073 1083 B-Drug
for NCT03867864 1084 1087 O
mental NCT03867864 1088 1094 B-Condition
disorders NCT03867864 1095 1104 I-Condition
, NCT03867864 1105 1106 O
contraceptives NCT03867864 1107 1121 B-Drug
, NCT03867864 1122 1123 O
etc NCT03867864 1124 1127 O
. NCT03867864 1127 1128 O
) NCT03867864 1129 1130 O
. NCT03867864 1131 1132 O

Inclusion NCT03865901 0 9 O
Criteria NCT03865901 10 18 O
: NCT03865901 19 20 O

1 NCT03865901 24 25 O
. NCT03865901 25 26 O
Women NCT03865901 28 33 O
18 NCT03865901 34 36 B-Eq-Comparison
years NCT03865901 37 42 I-Eq-Comparison
of NCT03865901 43 45 I-Eq-Comparison
age NCT03865901 46 49 I-Age|Eq-Comparison
or NCT03865901 50 52 I-Eq-Comparison
older NCT03865901 53 58 I-Eq-Comparison
at NCT03865901 59 61 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrollment NCT03865901 62 72 B-Study

2 NCT03865901 75 76 O
. NCT03865901 76 77 O
Has NCT03865901 79 82 O
an NCT03865901 83 85 O
established NCT03865901 86 97 O
viable NCT03865901 98 104 B-Modifier
singleton NCT03865901 105 114 I-Modifier
pregnancy NCT03865901 115 124 B-Condition

3 NCT03865901 127 128 O
. NCT03865901 128 129 O
Is NCT03865901 131 133 O
recommended NCT03865901 134 145 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865901 146 149 I-Assertion___Assertion-Type-Value:hypothetical
routine NCT03865901 150 157 O
GDM NCT03865901 158 161 B-Procedure
screening NCT03865901 162 171 I-Procedure
between NCT03865901 172 179 B-Eq-Comparison
24 NCT03865901 180 182 I-Eq-Comparison
- NCT03865901 183 184 I-Eq-Comparison
28 NCT03865901 185 187 I-Eq-Comparison
weeks NCT03865901 188 193 I-Eq-Comparison
gestation NCT03865901 194 203 B-Observation

4 NCT03865901 206 207 O
. NCT03865901 207 208 O
Has NCT03865901 210 213 O
confirmed NCT03865901 214 223 O
gestational NCT03865901 224 235 B-Observation
age NCT03865901 236 239 I-Observation
of NCT03865901 240 242 O
24 NCT03865901 243 245 B-Eq-Comparison
- NCT03865901 246 247 I-Eq-Comparison
28 NCT03865901 248 250 I-Eq-Comparison
weeks NCT03865901 251 256 I-Eq-Comparison
at NCT03865901 257 259 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865901 260 263 O
Screening NCT03865901 264 273 B-Study
Visit NCT03865901 274 279 O

5 NCT03865901 282 283 O
. NCT03865901 283 284 O
Is NCT03865901 286 288 O
willing NCT03865901 289 296 O
and NCT03865901 297 300 O
able NCT03865901 301 305 O
to NCT03865901 306 308 O
provide NCT03865901 309 316 O
documentation NCT03865901 317 330 O
of NCT03865901 331 333 O
informed NCT03865901 334 342 O
consent NCT03865901 343 350 O

Exclusion NCT03865901 351 360 O
Criteria NCT03865901 361 369 O
: NCT03865901 370 371 O

1 NCT03865901 375 376 O
. NCT03865901 376 377 O
Has NCT03865901 379 382 O
diabetes NCT03865901 383 391 B-Condition
before NCT03865901 392 398 B-Temporal-Connection___Temporal-Connection-Type-Value:before
pregnancy NCT03865901 399 408 B-Condition
or NCT03865901 409 411 B-Or
has NCT03865901 412 415 O
already NCT03865901 416 423 B-Eq-Comparison
been NCT03865901 424 428 O
diagnosed NCT03865901 429 438 O
with NCT03865901 439 443 O
GDM NCT03865901 444 447 B-Condition

2 NCT03865901 450 451 O
. NCT03865901 451 452 O
Has NCT03865901 454 457 O
contraindications NCT03865901 458 475 B-Contraindication
for NCT03865901 476 479 O
drinking NCT03865901 480 488 B-Modifier
oral NCT03865901 489 493 I-Modifier
glucose NCT03865901 494 501 B-Drug
solution NCT03865901 502 510 O
up NCT03865901 511 513 B-Eq-Comparison
to NCT03865901 514 516 I-Eq-Comparison
100 NCT03865901 517 520 I-Eq-Comparison
g NCT03865901 521 522 I-Eq-Comparison
of NCT03865901 523 525 I-Eq-Comparison
sugar NCT03865901 526 531 I-Eq-Comparison

3 NCT03865901 534 535 B-Eq-Comparison
. NCT03865901 535 536 O
Is NCT03865901 538 540 O
taking NCT03865901 541 547 B-Eq-Comparison
metformin NCT03865901 548 557 B-Drug
for NCT03865901 558 561 O
any NCT03865901 562 565 O
reason NCT03865901 566 572 O

4 NCT03865901 575 576 O
. NCT03865901 576 577 O
Has NCT03865901 579 582 O
any NCT03865901 583 586 O
concomitant NCT03865901 587 598 B-Modifier
illness NCT03865901 599 606 B-Condition
, NCT03865901 607 608 O
disease NCT03865901 609 616 B-Condition
or NCT03865901 617 619 B-Or
condition NCT03865901 620 629 B-Condition
that NCT03865901 630 634 O
, NCT03865901 635 636 O
in NCT03865901 637 639 O
the NCT03865901 640 643 O
clinical NCT03865901 644 652 O
judgment NCT03865901 653 661 O
of NCT03865901 662 664 O
the NCT03865901 665 668 O
investigator NCT03865901 669 681 O
, NCT03865901 682 683 O
is NCT03865901 684 686 O
likely NCT03865901 687 693 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865901 694 696 O
prevent NCT03865901 697 704 O
the NCT03865901 705 708 O
subject NCT03865901 709 716 O
from NCT03865901 717 721 O
complying NCT03865901 722 731 O
with NCT03865901 732 736 O
any NCT03865901 737 740 O
aspect NCT03865901 741 747 O
of NCT03865901 748 750 O
the NCT03865901 751 754 O
protocol NCT03865901 755 763 B-Study
, NCT03865901 764 765 O
or NCT03865901 766 768 B-Or
that NCT03865901 769 773 O
may NCT03865901 774 777 O
put NCT03865901 778 781 O
the NCT03865901 782 785 O
subject NCT03865901 786 793 O
at NCT03865901 794 796 O
unacceptable NCT03865901 797 809 O
risk NCT03865901 810 814 B-Risk

Inclusion NCT03860662 0 9 O
Criteria NCT03860662 10 18 O
: NCT03860662 19 20 O

- NCT03860662 24 25 O
Being NCT03860662 27 32 O
between NCT03860662 33 40 B-Eq-Comparison
the NCT03860662 41 44 I-Eq-Comparison
ages NCT03860662 45 49 I-Age|Eq-Comparison
of NCT03860662 50 52 I-Eq-Comparison
18 NCT03860662 53 55 I-Eq-Comparison
- NCT03860662 56 57 I-Eq-Comparison
60 NCT03860662 58 60 O

- NCT03860662 64 65 O
To NCT03860662 67 69 O
accept NCT03860662 70 76 O
voluntary NCT03860662 77 86 O
participation NCT03860662 87 100 O
in NCT03860662 101 103 O
the NCT03860662 104 107 O
study NCT03860662 108 113 O

- NCT03860662 116 117 O
Spastic NCT03860662 119 126 B-Condition
Hemiplegia NCT03860662 127 137 I-Condition
( NCT03860662 138 139 O
Modified NCT03860662 140 148 B-Observation
Ashworth NCT03860662 149 157 I-Observation
Scale NCT03860662 158 163 I-Observation
2 NCT03860662 164 165 B-Eq-Comparison
and NCT03860662 166 169 I-Eq-Comparison
above NCT03860662 170 175 I-Eq-Comparison
) NCT03860662 176 177 O

Exclusion NCT03860662 179 188 O
Criteria NCT03860662 189 197 O
: NCT03860662 198 199 O

- NCT03860662 203 204 O
Pregnant NCT03860662 206 214 B-Condition
women NCT03860662 215 220 O
, NCT03860662 221 222 O
breastfeeding NCT03860662 223 236 B-Condition
and NCT03860662 237 240 B-And
younger NCT03860662 241 248 B-Eq-Comparison
than NCT03860662 249 253 I-Eq-Comparison
18 NCT03860662 254 256 I-Eq-Comparison
years NCT03860662 257 262 I-Age|Eq-Comparison

- NCT03860662 265 266 O
To NCT03860662 268 270 O
have NCT03860662 271 275 O
medication NCT03860662 276 286 B-Drug
and NCT03860662 287 290 B-Or
substance NCT03860662 291 300 B-Condition
use NCT03860662 301 304 I-Condition
causing NCT03860662 305 312 O
neuropathy NCT03860662 313 323 B-Condition
in NCT03860662 324 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860662 327 330 O
history NCT03860662 331 338 B-Eq-Comparison
of NCT03860662 339 341 O
the NCT03860662 342 345 O
disease NCT03860662 346 353 B-Condition
and NCT03860662 354 357 B-Or
/ NCT03860662 358 359 I-Or
or NCT03860662 360 362 I-Or
neuropathy NCT03860662 363 373 B-Condition

- NCT03860662 376 377 O
Companies NCT03860662 379 388 O
that NCT03860662 389 393 O
have NCT03860662 394 398 O
received NCT03860662 399 407 B-Eq-Comparison
botulinum NCT03860662 408 417 B-Procedure
toxin NCT03860662 418 423 I-Procedure
injection NCT03860662 424 433 I-Procedure
therapy NCT03860662 434 441 I-Procedure
and NCT03860662 442 445 B-Or
/ NCT03860662 446 447 I-Or
or NCT03860662 448 450 I-Modifier|Or
oral NCT03860662 451 455 O
antispastic NCT03860662 456 467 B-Procedure
therapy NCT03860662 468 475 I-Procedure
within NCT03860662 476 482 B-Eq-Comparison
the NCT03860662 483 486 I-Eq-Comparison
last NCT03860662 487 491 I-Eq-Comparison
6 NCT03860662 492 493 I-Eq-Comparison
months NCT03860662 494 500 I-Eq-Comparison

- NCT03860662 503 504 O
Have NCT03860662 506 510 O
a NCT03860662 511 512 O
history NCT03860662 513 520 B-Eq-Comparison
of NCT03860662 521 523 O
allergies NCT03860662 524 533 B-Allergy
and NCT03860662 534 537 B-Or
hypersensitivity NCT03860662 538 554 B-Condition
to NCT03860662 555 557 O
usability NCT03860662 558 567 B-Modifier
drug NCT03860662 568 572 B-Drug

- NCT03860662 575 576 O
Injection NCT03860662 578 587 B-Procedure
treatment NCT03860662 588 597 I-Procedure
planned NCT03860662 598 605 B-Eq-Comparison
purification NCT03860662 606 618 B-Procedure
hematoma NCT03860662 619 627 I-Procedure
, NCT03860662 628 629 O
cleaning NCT03860662 630 638 B-Modifier
or NCT03860662 639 641 B-Or
skin NCT03860662 642 646 B-Modifier
lesion NCT03860662 647 653 B-Condition
to NCT03860662 654 656 O
be NCT03860662 657 659 O

Inclusion NCT03866213 0 9 O
Criteria NCT03866213 10 18 O
: NCT03866213 19 20 O

- NCT03866213 24 25 O
The NCT03866213 27 30 O
patient NCT03866213 31 38 O
is NCT03866213 39 41 O
currently NCT03866213 42 51 B-Eq-Comparison
being NCT03866213 52 57 O
treated NCT03866213 58 65 B-Procedure
at NCT03866213 66 68 O
Queen NCT03866213 69 74 O
Elizabeth NCT03866213 75 84 O
Central NCT03866213 85 92 O
Hospital NCT03866213 93 101 O
or NCT03866213 102 104 B-Or
Kamuzu NCT03866213 105 111 O
Central NCT03866213 112 119 O
Hospital NCT03866213 120 128 O
in NCT03866213 129 131 O
the NCT03866213 132 135 O
neonatal NCT03866213 136 144 O
ward NCT03866213 145 149 O
. NCT03866213 149 150 O

- NCT03866213 154 155 O
The NCT03866213 157 160 O
patient NCT03866213 161 168 O
is NCT03866213 169 171 O
less NCT03866213 172 176 B-Eq-Comparison
than NCT03866213 177 181 I-Eq-Comparison
28 NCT03866213 182 184 I-Eq-Comparison
days NCT03866213 185 189 I-Eq-Comparison
old NCT03866213 190 193 B-Age
( NCT03866213 194 195 O
neonate NCT03866213 196 203 O
) NCT03866213 204 205 O
. NCT03866213 206 207 O

- NCT03866213 211 212 O
The NCT03866213 214 217 O
patient NCT03866213 218 225 O
is NCT03866213 226 228 O
deemed NCT03866213 229 235 O
to NCT03866213 236 238 O
be NCT03866213 239 241 O
at NCT03866213 242 244 O
risk NCT03866213 245 249 B-Risk
for NCT03866213 250 253 O
jaundice NCT03866213 254 262 B-Condition
or NCT03866213 263 265 B-Or
the NCT03866213 266 269 O
patient NCT03866213 270 277 O
is NCT03866213 278 280 O
undergoing NCT03866213 281 291 B-Eq-Comparison
blue NCT03866213 292 296 B-Modifier
light NCT03866213 297 302 I-Modifier
phototherapy NCT03866213 303 315 B-Procedure
for NCT03866213 316 319 O
treatment NCT03866213 320 329 B-Procedure
of NCT03866213 330 332 O
jaundice NCT03866213 333 341 B-Condition
. NCT03866213 341 342 O

- NCT03866213 346 347 O
The NCT03866213 349 352 O
patient NCT03866213 353 360 O
's NCT03866213 360 362 O
parent NCT03866213 363 369 B-Family-Member___Family-Member-Type:parent
or NCT03866213 370 372 O
guardian NCT03866213 373 381 O
has NCT03866213 382 385 O
provided NCT03866213 386 394 O
informed NCT03866213 395 403 O
consent NCT03866213 404 411 O
for NCT03866213 412 415 O
their NCT03866213 416 421 O
child NCT03866213 422 427 B-Family-Member___Family-Member-Type:child
to NCT03866213 428 430 O
participate NCT03866213 431 442 O
. NCT03866213 442 443 O

Exclusion NCT03866213 445 454 O
Criteria NCT03866213 455 463 O
: NCT03866213 464 465 O

- NCT03866213 469 470 O
Parent NCT03866213 472 478 O
or NCT03866213 479 481 O
guardian NCT03866213 482 490 O
is NCT03866213 491 493 O
unable NCT03866213 494 500 O
or NCT03866213 501 503 O
unwilling NCT03866213 504 513 O
to NCT03866213 514 516 O
provide NCT03866213 517 524 O
informed NCT03866213 525 533 O
consent NCT03866213 534 541 O
. NCT03866213 541 542 O

- NCT03866213 546 547 O
The NCT03866213 549 552 O
patient NCT03866213 553 560 O
is NCT03866213 561 563 O
unable NCT03866213 564 570 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866213 571 573 O
receive NCT03866213 574 581 O
a NCT03866213 582 583 O
blood NCT03866213 584 589 B-Observation
draw NCT03866213 590 594 I-Observation
/ NCT03866213 595 596 B-Or
heel NCT03866213 597 601 B-Observation
stick NCT03866213 602 607 I-Observation
as NCT03866213 608 610 O
determined NCT03866213 611 621 O
by NCT03866213 622 624 O
their NCT03866213 625 630 O
clinician NCT03866213 631 640 O
. NCT03866213 640 641 O

Inclusion NCT03865732 0 9 O
Criteria NCT03865732 10 18 O
: NCT03865732 19 20 O

- NCT03865732 24 25 O
Molecular NCT03865732 27 36 B-Procedure
confirmation NCT03865732 37 49 O
of NCT03865732 50 52 O
a NCT03865732 53 54 O
pathogenic NCT03865732 55 65 B-Modifier
or NCT03865732 66 68 B-Or
likely NCT03865732 69 75 B-Assertion___Assertion-Type-Value:possible
pathogenic NCT03865732 76 86 B-Modifier
PCDH19 NCT03865732 87 93 B-Condition
variant NCT03865732 94 101 I-Condition

- NCT03865732 104 105 O
Failure NCT03865732 107 114 B-Negation
to NCT03865732 115 117 O
control NCT03865732 118 125 O
seizures NCT03865732 126 134 B-Condition
despite NCT03865732 135 142 B-And
2 NCT03865732 143 144 B-Eq-Comparison
or NCT03865732 145 147 I-Eq-Comparison
more NCT03865732 148 152 I-Eq-Comparison
anti NCT03865732 153 157 O
- NCT03865732 158 159 O
seizure NCT03865732 160 167 B-Condition
medications NCT03865732 168 179 B-Drug

- NCT03865732 182 183 O
12 NCT03865732 185 187 B-Eq-Comparison
seizures NCT03865732 188 196 B-Condition
over NCT03865732 197 201 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03865732 202 203 O
12 NCT03865732 204 206 B-Eq-Comparison
- NCT03865732 207 208 I-Eq-Comparison
week NCT03865732 209 213 I-Eq-Comparison
period NCT03865732 214 220 I-Eq-Comparison
of NCT03865732 221 223 O
primary NCT03865732 224 231 B-Condition
seizure NCT03865732 232 239 I-Condition
types NCT03865732 240 245 O
prior NCT03865732 246 251 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 252 254 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 255 264 B-Study

- NCT03865732 267 268 O
On NCT03865732 270 272 B-Eq-Comparison
a NCT03865732 273 274 O
stable NCT03865732 275 281 O
regimen NCT03865732 282 289 O
of NCT03865732 290 292 O
anti NCT03865732 293 297 O
- NCT03865732 298 299 O
seizure NCT03865732 300 307 B-Condition
treatments NCT03865732 308 318 B-Procedure
( NCT03865732 319 320 O
Vagus NCT03865732 321 326 B-Procedure
nerve NCT03865732 327 332 I-Procedure
stimulator NCT03865732 333 343 I-Procedure
, NCT03865732 344 345 O
ketogenic NCT03865732 346 355 B-Observation
diet NCT03865732 356 360 I-Observation
, NCT03865732 361 362 O
and NCT03865732 363 366 B-Or
modified NCT03865732 367 375 B-Modifier
Atkins NCT03865732 376 382 B-Observation
diet NCT03865732 383 387 I-Observation
should NCT03865732 388 394 O
be NCT03865732 395 397 O
unchanged NCT03865732 398 407 O
for NCT03865732 408 411 O
3 NCT03865732 412 413 B-Eq-Comparison
months NCT03865732 414 420 I-Eq-Comparison
prior NCT03865732 421 426 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 427 429 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 430 439 B-Study
) NCT03865732 440 441 O

Exclusion NCT03865732 443 452 O
Criteria NCT03865732 453 461 O
: NCT03865732 462 463 O

- NCT03865732 467 468 O
Previous NCT03865732 470 478 B-Eq-Comparison
exposure NCT03865732 479 487 O
to NCT03865732 488 490 O
ganaxolone NCT03865732 491 501 B-Drug

- NCT03865732 504 505 O
> NCT03865732 507 508 B-Eq-Comparison
8 NCT03865732 509 510 I-Eq-Comparison
consecutive NCT03865732 511 522 I-Eq-Comparison
weeks NCT03865732 523 528 I-Eq-Comparison
of NCT03865732 529 531 O
seizure NCT03865732 532 539 B-Condition
freedom NCT03865732 540 547 B-Negation
during NCT03865732 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865732 555 558 O
12 NCT03865732 559 561 B-Eq-Comparison
weeks NCT03865732 562 567 I-Eq-Comparison
prior NCT03865732 568 573 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 574 576 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 577 586 B-Study

- NCT03865732 589 590 O
Concurrent NCT03865732 592 602 B-Modifier
use NCT03865732 603 606 O
of NCT03865732 607 609 O
strong NCT03865732 610 616 B-Drug
inducers NCT03865732 617 625 I-Drug
or NCT03865732 626 628 B-Or
inhibitors NCT03865732 629 639 B-Drug
of NCT03865732 640 642 O
CYP3A4 NCT03865732 643 649 B-Modifier
/ NCT03865732 650 651 B-Or|Or
5 NCT03865732 652 653 B-Modifier
/ NCT03865732 654 655 O
7 NCT03865732 656 657 B-Modifier
is NCT03865732 658 660 O
not NCT03865732 661 664 B-Negation
permitted NCT03865732 665 674 O

- NCT03865732 677 678 O
Use NCT03865732 680 683 B-Eq-Comparison
of NCT03865732 684 686 O
tetrahydrocannabinol NCT03865732 687 707 B-Drug
( NCT03865732 708 709 O
THC NCT03865732 710 713 B-Drug
) NCT03865732 714 715 O
or NCT03865732 716 718 B-Or
non NCT03865732 719 722 B-Modifier
- NCT03865732 723 724 I-Modifier
approved NCT03865732 725 733 I-Modifier
cannabidiol NCT03865732 734 745 B-Drug
( NCT03865732 746 747 O
CBD NCT03865732 748 751 B-Drug
) NCT03865732 752 753 O
is NCT03865732 754 756 O
prohibited NCT03865732 757 767 B-Negation
during NCT03865732 768 774 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865732 775 778 O
double NCT03865732 779 785 B-Modifier
- NCT03865732 786 787 I-Modifier
blind NCT03865732 788 793 I-Modifier
phase NCT03865732 794 799 O

- NCT03865732 802 803 O
Exposure NCT03865732 805 813 O
to NCT03865732 814 816 O
any NCT03865732 817 820 O
other NCT03865732 821 826 B-Other
investigational NCT03865732 827 842 B-Study
drug NCT03865732 843 847 B-Drug
within NCT03865732 848 854 B-Eq-Comparison
30 NCT03865732 855 857 I-Eq-Comparison
days NCT03865732 858 862 I-Eq-Comparison
or NCT03865732 863 865 B-Or
fewer NCT03865732 866 871 B-Eq-Comparison
than NCT03865732 872 876 I-Eq-Comparison
5 NCT03865732 877 878 I-Eq-Comparison
half NCT03865732 879 883 I-Eq-Comparison
- NCT03865732 884 885 I-Eq-Comparison
lives NCT03865732 886 891 I-Eq-Comparison
prior NCT03865732 892 897 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 898 900 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 901 910 B-Study

Inclusion NCT03867643 0 9 O
Criteria NCT03867643 10 18 O
: NCT03867643 19 20 O

- NCT03867643 24 25 O
Children NCT03867643 27 35 O
who NCT03867643 36 39 O
are NCT03867643 40 43 O
6 NCT03867643 44 45 B-Eq-Comparison
- NCT03867643 46 47 I-Eq-Comparison
12 NCT03867643 48 50 I-Eq-Comparison
years NCT03867643 51 56 I-Eq-Comparison
old NCT03867643 57 60 B-Age
， NCT03867643 61 62 O
in NCT03867643 63 65 O
Chongqing NCT03867643 66 75 O

- NCT03867643 78 79 O
After NCT03867643 81 86 B-Temporal-Connection___Temporal-Connection-Type-Value:after
birth NCT03867643 87 92 B-Birth
, NCT03867643 93 94 O
three NCT03867643 95 100 B-Eq-Comparison
injections NCT03867643 101 111 B-Procedure
of NCT03867643 112 114 O
Hep NCT03867643 115 118 B-Drug
B NCT03867643 119 120 I-Drug
were NCT03867643 121 125 O
inoculated NCT03867643 126 136 O
in NCT03867643 137 139 O
time NCT03867643 140 144 O
according NCT03867643 145 154 O
to NCT03867643 155 157 O
the NCT03867643 158 161 O
procedure NCT03867643 162 171 O
of NCT03867643 172 174 O
0 NCT03867643 175 176 B-Eq-Comparison
, NCT03867643 177 178 O
1 NCT03867643 179 180 I-Eq-Comparison
and NCT03867643 181 184 I-Eq-Comparison
6 NCT03867643 185 186 I-Eq-Comparison
months（The NCT03867643 187 197 I-Eq-Comparison
vaccination NCT03867643 198 209 O
certificate NCT03867643 210 221 O
record NCT03867643 222 228 O
） NCT03867643 228 229 O

- NCT03867643 232 233 O
No NCT03867643 235 237 B-Negation
HBV NCT03867643 238 241 B-Immunization
booster NCT03867643 242 249 I-Immunization
vaccine NCT03867643 250 257 I-Immunization
given NCT03867643 258 263 O
since NCT03867643 264 269 B-Temporal-Connection___Temporal-Connection-Type-Value:after
primary NCT03867643 270 277 B-Modifier
HBV NCT03867643 278 281 B-Immunization
immunization NCT03867643 282 294 I-Immunization

- NCT03867643 297 298 O
Children NCT03867643 300 308 O
or NCT03867643 309 311 B-Or
guardian NCT03867643 312 320 B-Family-Member___Family-Member-Type:parent
knew NCT03867643 321 325 O
and NCT03867643 326 329 O
agreed NCT03867643 330 336 O
to NCT03867643 337 339 O
accept NCT03867643 340 346 O
the NCT03867643 347 350 O
study NCT03867643 351 356 B-Study

- NCT03867643 359 360 O
Follow NCT03867643 362 368 B-Encounter
- NCT03867643 369 370 I-Encounter
up NCT03867643 371 373 I-Encounter
study NCT03867643 374 379 B-Study
and NCT03867643 380 383 B-And
blood NCT03867643 384 389 B-Observation
collection NCT03867643 390 400 I-Observation
after NCT03867643 401 406 B-Temporal-Connection___Temporal-Connection-Type-Value:after
vaccination NCT03867643 407 418 B-Immunization
can NCT03867643 419 422 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867643 423 425 I-Assertion___Assertion-Type-Value:hypothetical
accepted NCT03867643 426 434 O

Exclusion NCT03867643 435 444 O
Criteria NCT03867643 445 453 O
: NCT03867643 454 455 O

- NCT03867643 459 460 O
Unwilling NCT03867643 462 471 O
or NCT03867643 472 474 O
impossible NCT03867643 475 485 O
to NCT03867643 486 488 O
participate NCT03867643 489 500 O
in NCT03867643 501 503 O
this NCT03867643 504 508 O
research NCT03867643 509 517 O
project NCT03867643 518 525 O
; NCT03867643 525 526 O

- NCT03867643 529 530 O
Have NCT03867643 532 536 O
a NCT03867643 537 538 O
history NCT03867643 539 546 B-Eq-Comparison
of NCT03867643 547 549 O
allergy NCT03867643 550 557 B-Allergy
or NCT03867643 558 560 B-Or
have NCT03867643 561 565 O
had NCT03867643 566 569 O
a NCT03867643 570 571 O
serious NCT03867643 572 579 O
vaccine NCT03867643 580 587 B-Immunization
reaction NCT03867643 588 596 B-Condition

- NCT03867643 599 600 O
Have NCT03867643 602 606 O
immune NCT03867643 607 613 B-Condition
impairment NCT03867643 614 624 I-Condition
diseases NCT03867643 625 633 I-Condition
and NCT03867643 634 637 B-Or
appear NCT03867643 638 644 B-Assertion___Assertion-Type-Value:possible
immune NCT03867643 645 651 B-Condition
impairment NCT03867643 652 662 I-Condition
; NCT03867643 662 663 O

- NCT03867643 666 667 O
Immunosuppressive NCT03867643 669 686 B-Procedure
treatment NCT03867643 687 696 I-Procedure
, NCT03867643 697 698 O
receive NCT03867643 699 706 O
any NCT03867643 707 710 O
injection NCT03867643 711 720 B-Modifier
or NCT03867643 721 723 B-Modifier|Or
oral NCT03867643 724 728 O
administration NCT03867643 729 743 I-Modifier
of NCT03867643 744 746 O
cortisone NCT03867643 747 756 B-Drug
or NCT03867643 757 759 B-Or
cancer NCT03867643 760 766 B-Condition
chemotherapy NCT03867643 767 779 B-Procedure
; NCT03867643 779 780 O

- NCT03867643 783 784 O
Any NCT03867643 786 789 O
kind NCT03867643 790 794 O
of NCT03867643 795 797 O
vaccine NCT03867643 798 805 B-Immunization
or NCT03867643 806 808 B-Or
any NCT03867643 809 812 O
kind NCT03867643 813 817 O
of NCT03867643 818 820 O
observation NCT03867643 821 832 B-Study
drug NCT03867643 833 837 B-Drug
has NCT03867643 838 841 O
been NCT03867643 842 846 O
vaccinated NCT03867643 847 857 B-Immunization
in NCT03867643 858 860 O
the NCT03867643 861 864 O
past NCT03867643 865 869 B-Eq-Comparison
four NCT03867643 870 874 I-Eq-Comparison
weeks NCT03867643 875 880 I-Eq-Comparison
; NCT03867643 880 881 O

- NCT03867643 884 885 O
Any NCT03867643 887 890 O
acute NCT03867643 891 896 O
disease NCT03867643 897 904 B-Condition
or NCT03867643 905 907 B-Or
other NCT03867643 908 913 B-Other
infection NCT03867643 914 923 B-Condition
requiring NCT03867643 924 933 O
antibiotic NCT03867643 934 944 B-Drug
or NCT03867643 945 947 B-Or
antiviral NCT03867643 948 957 B-Drug
treatment NCT03867643 958 967 B-Procedure
in NCT03867643 968 970 O
the NCT03867643 971 974 O
past NCT03867643 975 979 B-Eq-Comparison
four NCT03867643 980 984 I-Eq-Comparison
weeks NCT03867643 985 990 I-Eq-Comparison
; NCT03867643 990 991 O

- NCT03867643 994 995 O
Fever NCT03867643 997 1002 B-Condition
symptoms NCT03867643 1003 1011 B-Assertion___Assertion-Type-Value:possible
occurred NCT03867643 1012 1020 O
in NCT03867643 1021 1023 O
the NCT03867643 1024 1027 O
past NCT03867643 1028 1032 B-Eq-Comparison
week NCT03867643 1033 1037 I-Eq-Comparison
( NCT03867643 1038 1039 O
axillary NCT03867643 1040 1048 B-Modifier
temperature NCT03867643 1049 1060 B-Observation
≥ NCT03867643 1061 1062 B-Eq-Comparison
38 NCT03867643 1063 1065 I-Eq-Comparison
℃ NCT03867643 1066 1067 I-Eq-Comparison
) NCT03867643 1068 1069 O

- NCT03867643 1073 1074 O
Blood NCT03867643 1076 1081 B-Procedure
transfusion NCT03867643 1082 1093 I-Procedure
experience NCT03867643 1094 1104 O
; NCT03867643 1104 1105 O

- NCT03867643 1108 1109 O
Has NCT03867643 1111 1114 O
a NCT03867643 1115 1116 O
history NCT03867643 1117 1124 B-Eq-Comparison
of NCT03867643 1125 1127 O
more NCT03867643 1128 1132 O
serious NCT03867643 1133 1140 O
infectious NCT03867643 1141 1151 B-Condition
diseases NCT03867643 1152 1160 I-Condition
( NCT03867643 1161 1162 O
five NCT03867643 1163 1167 O
types NCT03867643 1168 1173 O
of NCT03867643 1174 1176 O
hepatitis NCT03867643 1177 1186 B-Condition
, NCT03867643 1187 1188 O
AIDS NCT03867643 1189 1193 B-Condition
, NCT03867643 1194 1195 O
syphilis NCT03867643 1196 1204 B-Condition
, NCT03867643 1205 1206 O
gonorrhea NCT03867643 1207 1216 B-Condition
, NCT03867643 1217 1218 O
etc NCT03867643 1219 1222 O
. NCT03867643 1222 1223 O
) NCT03867643 1225 1226 O
; NCT03867643 1227 1228 O

- NCT03867643 1231 1232 O
Hepatitis NCT03867643 1234 1243 B-Condition
B NCT03867643 1244 1245 I-Condition
infection NCT03867643 1246 1255 B-Modifier
or NCT03867643 1256 1258 B-Or
carriers NCT03867643 1259 1267 B-Modifier
( NCT03867643 1268 1269 O
lineal NCT03867643 1270 1276 O
relationship NCT03867643 1277 1289 O
) NCT03867643 1290 1291 O
; NCT03867643 1292 1293 O

- NCT03867643 1296 1297 O
Abnormal NCT03867643 1299 1307 O
physical NCT03867643 1308 1316 B-Procedure
examination NCT03867643 1317 1328 I-Procedure

Inclusion NCT03863431 0 9 O
Criteria NCT03863431 10 18 O
: NCT03863431 19 20 O

- NCT03863431 24 25 O
18 NCT03863431 27 29 B-Eq-Comparison
- NCT03863431 30 31 I-Eq-Comparison
40 NCT03863431 32 34 I-Eq-Comparison
years NCT03863431 35 40 I-Age|Eq-Comparison

- NCT03863431 43 44 O
BMI NCT03863431 46 49 B-Observation
= NCT03863431 50 51 B-Eq-Comparison
18.5 NCT03863431 52 56 I-Eq-Comparison
- NCT03863431 57 58 I-Eq-Comparison
29.9 NCT03863431 59 63 I-Eq-Comparison
kg NCT03863431 64 66 I-Eq-Comparison
/ NCT03863431 67 68 I-Eq-Comparison
m2 NCT03863431 69 71 I-Eq-Comparison

- NCT03863431 74 75 O
Male NCT03863431 77 81 O
or NCT03863431 82 84 B-Or
female NCT03863431 85 91 O

- NCT03863431 94 95 O
Physically NCT03863431 97 107 B-Observation
active NCT03863431 108 114 I-Observation
( NCT03863431 115 116 O
> NCT03863431 118 119 B-Eq-Comparison
3 NCT03863431 120 121 I-Eq-Comparison
x NCT03863431 122 123 O
30 NCT03863431 124 126 B-Eq-Comparison
min NCT03863431 127 130 I-Eq-Comparison
moderate NCT03863431 131 139 I-Eq-Comparison
exercise NCT03863431 140 148 I-Eq-Comparison
per NCT03863431 149 152 I-Eq-Comparison
week NCT03863431 153 157 I-Eq-Comparison
) NCT03863431 158 159 O

- NCT03863431 163 164 O
Non NCT03863431 166 169 B-Negation
- NCT03863431 170 171 O
smoker NCT03863431 172 178 B-Condition
( NCT03863431 179 180 O
including NCT03863431 181 190 O
the NCT03863431 191 194 O
use NCT03863431 195 198 O
of NCT03863431 199 201 O
vaporisers NCT03863431 202 212 B-Drug
and NCT03863431 213 216 B-Or
e NCT03863431 217 218 B-Drug
- NCT03863431 219 220 I-Drug
cigarettes NCT03863431 221 231 I-Drug
) NCT03863431 232 233 O

- NCT03863431 237 238 O
Healthy NCT03863431 240 247 B-Condition
( NCT03863431 248 249 O
determined NCT03863431 250 260 O
by NCT03863431 261 263 O
the NCT03863431 264 267 O
School NCT03863431 268 274 B-Observation
's NCT03863431 274 276 O
standard NCT03863431 277 285 I-Observation
health NCT03863431 286 292 I-Observation
questionnaire NCT03863431 293 306 I-Observation
) NCT03863431 307 308 O

- NCT03863431 312 313 O
No NCT03863431 315 317 B-Negation
cardiometabolic NCT03863431 318 333 B-Modifier
or NCT03863431 334 336 B-Or
inflammatory NCT03863431 337 349 B-Modifier
illness NCT03863431 350 357 B-Condition

Exclusion NCT03863431 358 367 O
Criteria NCT03863431 368 376 O
: NCT03863431 377 378 O

- NCT03863431 382 383 O
Outside NCT03863431 385 392 O
of NCT03863431 393 395 O
age NCT03863431 396 399 O
- NCT03863431 400 401 O
range NCT03863431 402 407 B-Eq-Comparison

- NCT03863431 410 411 O
Outside NCT03863431 413 420 B-Negation
BMI NCT03863431 421 424 B-Observation
range NCT03863431 425 430 O

- NCT03863431 433 434 O
Inactive NCT03863431 436 444 B-Observation
( NCT03863431 445 446 O
< NCT03863431 448 449 B-Eq-Comparison
3 NCT03863431 450 451 I-Eq-Comparison
x NCT03863431 452 453 O
30 NCT03863431 454 456 B-Eq-Comparison
min NCT03863431 457 460 I-Eq-Comparison
moderate NCT03863431 461 469 I-Eq-Comparison
exercise NCT03863431 470 478 I-Eq-Comparison
per NCT03863431 479 482 I-Eq-Comparison
week NCT03863431 483 487 I-Eq-Comparison
) NCT03863431 488 489 O

- NCT03863431 493 494 O
Smoker NCT03863431 496 502 B-Condition

- NCT03863431 505 506 O
Taking NCT03863431 508 514 B-Eq-Comparison
medication NCT03863431 515 525 B-Drug

- NCT03863431 528 529 O
History NCT03863431 531 538 B-Eq-Comparison
of NCT03863431 539 541 O
cardiometabolic NCT03863431 542 557 B-Modifier
or NCT03863431 558 560 B-Or
inflammatory NCT03863431 561 573 B-Modifier
illness NCT03863431 574 581 B-Condition

- NCT03863431 584 585 O
Vegetarian NCT03863431 587 597 B-Condition
/ NCT03863431 598 599 B-Or
vegan NCT03863431 600 605 B-Condition
( NCT03863431 606 607 O
as NCT03863431 608 610 O
the NCT03863431 611 614 O
high NCT03863431 615 619 O
- NCT03863431 620 621 O
fat NCT03863431 622 625 O
diet NCT03863431 626 630 O
is NCT03863431 631 633 O
based NCT03863431 634 639 O
on NCT03863431 640 642 O
animal NCT03863431 643 649 O
fats NCT03863431 650 654 O
) NCT03863431 655 656 O

- NCT03863431 660 661 O
Other NCT03863431 663 668 B-Other
dietary NCT03863431 669 676 B-Condition
restrictions NCT03863431 677 689 I-Condition
which NCT03863431 690 695 O
prevent NCT03863431 696 703 B-Negation
consumption NCT03863431 704 715 O
of NCT03863431 716 718 O
the NCT03863431 719 722 O
experimental NCT03863431 723 735 B-Procedure
diet NCT03863431 736 740 I-Procedure

- NCT03863431 743 744 O
Consumption NCT03863431 746 757 O
of NCT03863431 758 760 O
probiotics NCT03863431 761 771 B-Drug
within NCT03863431 772 778 B-Eq-Comparison
last NCT03863431 779 783 I-Eq-Comparison
3 NCT03863431 784 785 I-Eq-Comparison
months NCT03863431 786 792 I-Eq-Comparison
( NCT03863431 793 794 O
these NCT03863431 795 800 O
influence NCT03863431 801 810 O
the NCT03863431 811 814 O
gut NCT03863431 815 818 O
microbiota NCT03863431 819 829 O
) NCT03863431 830 831 O

- NCT03863431 835 836 O
Participation NCT03863431 838 851 O
in NCT03863431 852 854 O
another NCT03863431 855 862 B-Other
clinical NCT03863431 863 871 B-Study
trial NCT03863431 872 877 I-Study

- NCT03863431 880 881 O
Those NCT03863431 883 888 O
with NCT03863431 889 893 O
known NCT03863431 894 899 B-Modifier
or NCT03863431 900 902 B-Or
suspected NCT03863431 903 912 B-Assertion___Assertion-Type-Value:possible
food NCT03863431 913 917 B-Condition
intolerances NCT03863431 918 930 I-Condition
, NCT03863431 931 932 O
allergies NCT03863431 933 942 B-Allergy
or NCT03863431 943 945 B-Or
hypersensitivity NCT03863431 946 962 B-Condition

- NCT03863431 965 966 O
Women NCT03863431 968 973 O
who NCT03863431 974 977 B-And
are NCT03863431 978 981 O
known NCT03863431 982 987 O
to NCT03863431 988 990 I-Assertion___Assertion-Type-Value:intention
be NCT03863431 991 993 O
pregnant NCT03863431 994 1002 B-Condition|Condition
or NCT03863431 1003 1005 B-Or
who NCT03863431 1006 1009 O
are NCT03863431 1010 1013 O
intending NCT03863431 1014 1023 B-Assertion___Assertion-Type-Value:intention
to NCT03863431 1024 1026 O
become NCT03863431 1027 1033 O
pregnant NCT03863431 1034 1042 O
over NCT03863431 1043 1047 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863431 1048 1051 I-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03863431 1052 1058 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863431 1059 1061 O
the NCT03863431 1062 1065 O
study NCT03863431 1066 1071 B-Study

Inclusion NCT03865875 0 9 O
Criteria NCT03865875 10 18 O

- NCT03865875 21 22 O
Adults NCT03865875 24 30 O
age NCT03865875 31 34 B-Age
18 NCT03865875 35 37 B-Eq-Comparison
years NCT03865875 38 43 I-Eq-Comparison
or NCT03865875 44 46 I-Eq-Comparison
older NCT03865875 47 52 I-Eq-Comparison
. NCT03865875 52 53 O

- NCT03865875 57 58 O
Diagnosed NCT03865875 60 69 O
within NCT03865875 70 76 B-Eq-Comparison
8 NCT03865875 77 78 I-Eq-Comparison
weeks NCT03865875 79 84 I-Eq-Comparison
with NCT03865875 85 89 O
upfront NCT03865875 90 97 O
resectable NCT03865875 98 108 B-Modifier
, NCT03865875 109 110 O
borderline NCT03865875 111 121 B-Modifier
resectable NCT03865875 122 132 I-Modifier
, NCT03865875 133 134 O
or NCT03865875 135 137 B-Or
locally NCT03865875 138 145 B-Modifier
advanced NCT03865875 146 154 I-Modifier
unresectable NCT03865875 155 167 I-Modifier
PDAC NCT03865875 168 172 B-Condition
as NCT03865875 173 175 O
defined NCT03865875 176 183 O
by NCT03865875 184 186 O
the NCT03865875 187 190 O
National NCT03865875 191 199 O
Comprehensive NCT03865875 200 213 O
Cancer NCT03865875 214 220 O
Network NCT03865875 221 228 O
( NCT03865875 229 230 O
NCCN NCT03865875 231 235 O
) NCT03865875 236 237 O
. NCT03865875 238 239 O

- NCT03865875 243 244 O
Planning NCT03865875 246 254 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 255 257 O
undergo NCT03865875 258 265 O
TNT NCT03865875 266 269 B-Procedure
at NCT03865875 270 272 O
MGH NCT03865875 273 276 O
. NCT03865875 276 277 O

- NCT03865875 281 282 O
Planning NCT03865875 284 292 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 293 295 O
receive NCT03865875 296 303 O
modified NCT03865875 304 312 B-Modifier
FOLFIRINOX NCT03865875 313 323 B-Drug
for NCT03865875 324 327 O
neoadjuvant NCT03865875 328 339 B-Modifier
chemotherapy NCT03865875 340 352 B-Procedure
. NCT03865875 352 353 O

- NCT03865875 357 358 O
Planning NCT03865875 360 368 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 369 371 O
undergo NCT03865875 372 379 O
surgical NCT03865875 380 388 B-Procedure
resection NCT03865875 389 398 I-Procedure
of NCT03865875 399 401 O
PDAC NCT03865875 402 406 B-Condition
at NCT03865875 407 409 O
MGH NCT03865875 410 413 O
. NCT03865875 413 414 O

- NCT03865875 418 419 O
Verbal NCT03865875 421 427 O
fluency NCT03865875 428 435 O
in NCT03865875 436 438 O
English NCT03865875 439 446 O
. NCT03865875 446 447 O

Exclusion NCT03865875 449 458 O
Criteria NCT03865875 459 467 O

- NCT03865875 470 471 O
Metastatic NCT03865875 473 483 B-Condition
disease NCT03865875 484 491 I-Condition
. NCT03865875 491 492 O

- NCT03865875 496 497 O
Previous NCT03865875 499 507 B-Eq-Comparison
treatment NCT03865875 508 517 B-Procedure
for NCT03865875 518 521 O
pancreas NCT03865875 522 530 B-Modifier
adenocarcinoma NCT03865875 531 545 B-Condition
and NCT03865875 546 549 B-And
no NCT03865875 550 552 B-Negation
prior NCT03865875 553 558 B-Eq-Comparison
therapy NCT03865875 559 566 B-Procedure
for NCT03865875 567 570 O
any NCT03865875 571 574 O
cancer NCT03865875 575 581 B-Condition
within NCT03865875 582 588 B-Eq-Comparison
5 NCT03865875 589 590 I-Eq-Comparison
years NCT03865875 591 596 I-Eq-Comparison
. NCT03865875 596 597 O

- NCT03865875 601 602 O
Known NCT03865875 604 609 O
history NCT03865875 610 617 B-Eq-Comparison
of NCT03865875 618 620 O
cognitive NCT03865875 621 630 B-Modifier
or NCT03865875 631 633 B-Or
psychologic NCT03865875 634 645 B-Modifier
impairment NCT03865875 646 656 B-Condition
. NCT03865875 656 657 O

- NCT03865875 661 662 O
Known NCT03865875 664 669 O
history NCT03865875 670 677 B-Eq-Comparison
of NCT03865875 678 680 O
physical NCT03865875 681 689 B-Condition
impairment NCT03865875 690 700 I-Condition
such NCT03865875 701 705 O
as NCT03865875 706 708 O
immobility NCT03865875 709 719 B-Condition
, NCT03865875 720 721 O
use NCT03865875 722 725 O
of NCT03865875 726 728 O
walking NCT03865875 729 736 B-Procedure
aids NCT03865875 737 741 I-Procedure
, NCT03865875 742 743 O
or NCT03865875 744 746 B-Or
required NCT03865875 747 755 O
wheelchair NCT03865875 756 766 B-Procedure
use NCT03865875 767 770 I-Procedure
. NCT03865875 770 771 O

- NCT03865875 775 776 O
Known NCT03865875 778 783 O
history NCT03865875 784 791 B-Eq-Comparison
of NCT03865875 792 794 O
the NCT03865875 795 798 O
following NCT03865875 799 808 O
orthopedic NCT03865875 809 819 B-Condition
comorbidities NCT03865875 820 833 I-Condition
: NCT03865875 834 835 O
advanced NCT03865875 836 844 O
osteoarthritis NCT03865875 845 859 B-Condition
or NCT03865875 860 862 B-Or
rheumatoid NCT03865875 863 873 B-Modifier
arthritis NCT03865875 874 883 B-Condition
, NCT03865875 884 885 O
mobility NCT03865875 886 894 B-Modifier
- NCT03865875 895 896 I-Modifier
limiting NCT03865875 897 905 I-Modifier
amputations NCT03865875 906 917 B-Condition
, NCT03865875 918 919 O
orthopedic NCT03865875 920 930 B-Modifier|Or
injuries NCT03865875 931 939 B-Condition
, NCT03865875 940 941 O
or NCT03865875 942 944 O
widespread NCT03865875 945 955 O
chronic NCT03865875 956 963 B-Modifier
pain NCT03865875 964 968 B-Condition
( NCT03865875 969 970 O
e. NCT03865875 971 973 O
g. NCT03865875 974 976 O
fibromyalgia NCT03865875 978 990 B-Condition
) NCT03865875 991 992 O
. NCT03865875 993 994 O

- NCT03865875 998 999 O
Known NCT03865875 1001 1006 O
history NCT03865875 1007 1014 B-Eq-Comparison
of NCT03865875 1015 1017 O
the NCT03865875 1018 1021 O
following NCT03865875 1022 1031 O
pulmonary NCT03865875 1032 1041 B-Modifier
comorbidities NCT03865875 1042 1055 B-Condition
: NCT03865875 1056 1057 O
severe NCT03865875 1058 1064 O
chronic NCT03865875 1065 1072 B-Modifier
obstructive NCT03865875 1073 1084 B-Condition
pulmonary NCT03865875 1085 1094 I-Condition
disease NCT03865875 1095 1102 I-Condition
( NCT03865875 1103 1104 O
COPD NCT03865875 1105 1109 B-Condition
) NCT03865875 1110 1111 O
defined NCT03865875 1112 1119 O
as NCT03865875 1120 1122 O
FEV1 NCT03865875 1123 1127 B-Observation
≤ NCT03865875 1128 1129 B-Eq-Comparison
50 NCT03865875 1130 1132 I-Eq-Comparison
% NCT03865875 1133 1134 O
, NCT03865875 1135 1136 O
emphysema NCT03865875 1137 1146 B-Condition
, NCT03865875 1147 1148 O
interstitial NCT03865875 1149 1161 B-Condition
lung NCT03865875 1162 1166 I-Condition
disease NCT03865875 1167 1174 I-Condition
, NCT03865875 1175 1176 O
and NCT03865875 1177 1180 B-Or
/ NCT03865875 1181 1182 I-Or
or NCT03865875 1183 1185 I-Or
use NCT03865875 1186 1189 O
of NCT03865875 1190 1192 O
supplemental NCT03865875 1193 1205 B-Procedure
oxygen NCT03865875 1206 1212 I-Procedure
. NCT03865875 1212 1213 O

- NCT03865875 1217 1218 O
Known NCT03865875 1220 1225 O
history NCT03865875 1226 1233 B-Eq-Comparison
of NCT03865875 1234 1236 O
the NCT03865875 1237 1240 O
following NCT03865875 1241 1250 O
cardiovascular NCT03865875 1251 1265 B-Condition
comorbidities NCT03865875 1266 1279 I-Condition
: NCT03865875 1280 1281 O
uncontrolled NCT03865875 1282 1294 B-Modifier
hypertension NCT03865875 1295 1307 B-Condition
, NCT03865875 1308 1309 O
severe NCT03865875 1310 1316 O
congestive NCT03865875 1317 1327 B-Condition
heart NCT03865875 1328 1333 I-Condition
failure NCT03865875 1334 1341 I-Condition
( NCT03865875 1342 1343 O
NYHA NCT03865875 1344 1348 B-Condition
Class NCT03865875 1349 1354 B-Eq-Comparison
IV NCT03865875 1355 1357 I-Eq-Comparison
) NCT03865875 1358 1359 O
, NCT03865875 1361 1362 O
and NCT03865875 1363 1366 B-Or
/ NCT03865875 1367 1368 I-Or
or NCT03865875 1369 1371 I-Or
myocardial NCT03865875 1372 1382 B-Condition
infarction NCT03865875 1383 1393 I-Condition
within NCT03865875 1394 1400 B-Eq-Comparison
the NCT03865875 1401 1404 I-Eq-Comparison
last NCT03865875 1405 1409 I-Eq-Comparison
6 NCT03865875 1410 1411 I-Eq-Comparison
months NCT03865875 1412 1418 I-Eq-Comparison
. NCT03865875 1418 1419 O

- NCT03865875 1423 1424 O
Inability NCT03865875 1426 1435 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865875 1436 1438 O
tolerate NCT03865875 1439 1447 O
diet NCT03865875 1448 1452 B-Observation
through NCT03865875 1453 1460 O
routine NCT03865875 1461 1468 O
oral NCT03865875 1469 1473 B-Modifier|Or
routes NCT03865875 1474 1480 I-Modifier
and NCT03865875 1481 1484 B-Or
/ NCT03865875 1485 1486 I-Or
or NCT03865875 1487 1489 O
patients NCT03865875 1490 1498 O
with NCT03865875 1499 1503 O
strict NCT03865875 1504 1510 O
nutritional NCT03865875 1511 1522 B-Condition
restrictions NCT03865875 1523 1535 I-Condition
, NCT03865875 1536 1537 O
allergies NCT03865875 1538 1547 B-Allergy
, NCT03865875 1548 1549 O
and NCT03865875 1550 1553 B-Or
/ NCT03865875 1554 1555 I-Or
or NCT03865875 1556 1558 I-Or
dietary NCT03865875 1559 1566 B-Observation
preferences NCT03865875 1567 1578 I-Observation
. NCT03865875 1578 1579 O

Inclusion NCT03860064 0 9 O
Criteria NCT03860064 10 18 O
: NCT03860064 19 20 O

- NCT03860064 24 25 O
18 NCT03860064 27 29 B-Eq-Comparison
- NCT03860064 30 31 I-Eq-Comparison
35 NCT03860064 32 34 I-Eq-Comparison
- NCT03860064 35 36 O
year NCT03860064 37 41 I-Eq-Comparison
- NCT03860064 42 43 O
old NCT03860064 44 47 B-Age
women NCT03860064 48 53 O

- NCT03860064 56 57 O
BMI NCT03860064 59 62 B-Observation
: NCT03860064 63 64 O
> NCT03860064 65 66 B-Eq-Comparison
18 NCT03860064 67 69 I-Eq-Comparison
and NCT03860064 70 73 B-And
< NCT03860064 74 75 B-Eq-Comparison
30 NCT03860064 76 78 I-Eq-Comparison
kg NCT03860064 79 81 I-Eq-Comparison
/ NCT03860064 82 83 I-Eq-Comparison
m2 NCT03860064 84 86 I-Eq-Comparison

- NCT03860064 89 90 O
Normal NCT03860064 92 98 O
female NCT03860064 99 105 B-Modifier
karyotype NCT03860064 106 115 B-Condition

- NCT03860064 118 119 O
Normal NCT03860064 121 127 O
uterus NCT03860064 128 134 B-Condition
and NCT03860064 135 138 B-And
ovaries NCT03860064 139 146 B-Condition
at NCT03860064 147 149 B-Temporal-Connection___Temporal-Connection-Type-Value:during
transvaginal NCT03860064 150 162 B-Procedure
ultrasound NCT03860064 163 173 I-Procedure

Exclusion NCT03860064 174 183 O
Criteria NCT03860064 184 192 O
: NCT03860064 193 194 O

- NCT03860064 198 199 O
> NCT03860064 201 202 B-Eq-Comparison
35 NCT03860064 203 205 I-Eq-Comparison
years NCT03860064 206 211 I-Age|Eq-Comparison

- NCT03860064 214 215 O
PCO NCT03860064 217 220 B-Condition
syndrome NCT03860064 221 229 I-Condition
carriers NCT03860064 230 238 O

- NCT03860064 241 242 O
Null NCT03860064 244 248 B-Modifier
follicle NCT03860064 249 257 B-Condition
aspiration NCT03860064 258 268 I-Condition

- NCT03860064 271 272 O
History NCT03860064 274 281 B-Eq-Comparison
of NCT03860064 282 284 O
chemotherapy NCT03860064 285 297 B-Procedure
or NCT03860064 298 300 B-Or
radiotherapy NCT03860064 301 313 B-Procedure

Inclusion NCT03865108 0 9 O
Criteria NCT03865108 10 18 O
: NCT03865108 19 20 O

- NCT03865108 24 25 O
Singleton NCT03865108 27 36 B-Modifier
gestation NCT03865108 37 46 B-Condition
. NCT03865108 46 47 O

- NCT03865108 56 57 O
Twin NCT03865108 59 63 B-Modifier
gestation NCT03865108 64 73 B-Condition
reduced NCT03865108 74 81 O
to NCT03865108 82 84 O
singleton NCT03865108 85 94 B-Modifier
either NCT03865108 95 101 O
spontaneously NCT03865108 102 115 B-Modifier
or NCT03865108 116 118 B-Or
therapeutically NCT03865108 119 134 B-Procedure
, NCT03865108 135 136 O
is NCT03865108 137 139 O
not NCT03865108 140 143 B-Negation
eligible NCT03865108 144 152 O
unless NCT03865108 153 159 B-Exception
the NCT03865108 160 163 B-Coreference
reduction NCT03865108 164 173 I-Coreference
occurred NCT03865108 174 182 O
before NCT03865108 183 189 B-Temporal-Connection___Temporal-Connection-Type-Value:before
13 NCT03865108 190 192 B-Eq-Comparison
weeks NCT03865108 193 198 I-Eq-Comparison
6 NCT03865108 199 200 I-Eq-Comparison
days NCT03865108 201 205 I-Eq-Comparison
project NCT03865108 206 213 O
gestational NCT03865108 214 225 B-Observation
age NCT03865108 226 229 I-Observation
. NCT03865108 229 230 O

- NCT03865108 239 240 O
Higher NCT03865108 242 248 B-Modifier
order NCT03865108 249 254 I-Modifier
multifetal NCT03865108 255 265 I-Modifier
gestations NCT03865108 266 276 B-Condition
reduced NCT03865108 277 284 O
to NCT03865108 285 287 O
singletons NCT03865108 288 298 B-Modifier
are NCT03865108 299 302 O
not NCT03865108 303 306 B-Negation
eligible NCT03865108 307 315 O
. NCT03865108 315 316 O

- NCT03865108 320 321 O
Gestational NCT03865108 323 334 B-Observation
age NCT03865108 335 338 I-Observation
at NCT03865108 339 341 B-Temporal-Connection___Temporal-Connection-Type-Value:during
randomization NCT03865108 342 355 B-Study
between NCT03865108 356 363 B-Eq-Comparison
16 NCT03865108 364 366 I-Eq-Comparison
weeks NCT03865108 367 372 I-Eq-Comparison
0 NCT03865108 373 374 I-Eq-Comparison
days NCT03865108 375 379 I-Eq-Comparison
and NCT03865108 380 383 B-And
23 NCT03865108 384 386 B-Eq-Comparison
weeks NCT03865108 387 392 I-Eq-Comparison
6 NCT03865108 393 394 I-Eq-Comparison
days NCT03865108 395 399 I-Eq-Comparison
based NCT03865108 400 405 O
on NCT03865108 406 408 O
clinical NCT03865108 409 417 O
information NCT03865108 418 429 O
and NCT03865108 430 433 O
evaluation NCT03865108 434 444 O
of NCT03865108 445 447 O
the NCT03865108 448 451 O
earliest NCT03865108 452 460 B-Eq-Comparison
ultrasound NCT03865108 461 471 B-Procedure
as NCT03865108 472 474 O
described NCT03865108 475 484 O
in NCT03865108 485 487 O
Gestational NCT03865108 488 499 B-Observation
Age NCT03865108 500 503 I-Observation
. NCT03865108 503 504 O

- NCT03865108 508 509 O
Cervical NCT03865108 511 519 B-Observation
length NCT03865108 520 526 I-Observation
on NCT03865108 527 529 O
transvaginal NCT03865108 530 542 B-Procedure
examination NCT03865108 543 554 I-Procedure
of NCT03865108 555 557 O
less NCT03865108 558 562 B-Eq-Comparison
than NCT03865108 563 567 I-Eq-Comparison
or NCT03865108 568 570 I-Eq-Comparison
equal NCT03865108 571 576 I-Eq-Comparison
to NCT03865108 577 579 I-Eq-Comparison
20 NCT03865108 580 582 I-Eq-Comparison
mm NCT03865108 583 585 I-Eq-Comparison
within NCT03865108 586 592 B-Eq-Comparison
10 NCT03865108 593 595 I-Eq-Comparison
days NCT03865108 596 600 I-Eq-Comparison
prior NCT03865108 601 606 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865108 607 609 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03865108 610 623 O
by NCT03865108 624 626 O
a NCT03865108 627 628 O
study NCT03865108 629 634 B-Study
certified NCT03865108 635 644 O
sonographer NCT03865108 645 656 B-Provider
. NCT03865108 656 657 O
There NCT03865108 659 664 O
is NCT03865108 665 667 O
no NCT03865108 668 670 B-Negation
lower NCT03865108 671 676 O
cervical NCT03865108 677 685 B-Observation
length NCT03865108 686 692 I-Observation
threshold NCT03865108 693 702 O
. NCT03865108 702 703 O

Exclusion NCT03865108 705 714 O
Criteria NCT03865108 715 723 O
: NCT03865108 724 725 O

- NCT03865108 729 730 O
Women NCT03865108 732 737 O
who NCT03865108 738 741 B-And
are NCT03865108 742 745 O
ineligible NCT03865108 746 756 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865108 757 760 O
the NCT03865108 761 764 O
TOPS NCT03865108 765 769 O
trial NCT03865108 770 775 O
. NCT03865108 775 776 O

Inclusion NCT03865134 0 9 O
Criteria NCT03865134 10 18 O
: NCT03865134 19 20 O

- NCT03865134 24 25 O
Age NCT03865134 27 30 B-Age
range NCT03865134 31 36 O
between NCT03865134 37 44 B-Eq-Comparison
2 NCT03865134 45 46 I-Eq-Comparison
- NCT03865134 47 48 I-Eq-Comparison
6 NCT03865134 49 50 I-Eq-Comparison
years NCT03865134 51 56 I-Eq-Comparison
of NCT03865134 57 59 O
age NCT03865134 60 63 O

- NCT03865134 66 67 O
Gestational NCT03865134 69 80 B-Observation
age NCT03865134 81 84 I-Observation
range NCT03865134 85 90 O
26 NCT03865134 91 93 B-Eq-Comparison
- NCT03865134 94 95 I-Eq-Comparison
34 NCT03865134 96 98 O
. NCT03865134 98 99 O
be NCT03865134 101 103 B-Eq-Comparison
between NCT03865134 104 111 O
weeks NCT03865134 112 117 I-Eq-Comparison

- NCT03865134 120 121 O
To NCT03865134 123 125 O
be NCT03865134 126 128 O
diagnosed NCT03865134 129 138 O
with NCT03865134 139 143 O
retinopathy NCT03865134 144 155 B-Condition
of NCT03865134 156 158 I-Condition
prematurity NCT03865134 159 170 I-Condition

- NCT03865134 173 174 O
Neurological NCT03865134 176 188 B-Modifier
, NCT03865134 189 190 O
hereditary NCT03865134 191 201 B-Modifier
and NCT03865134 202 205 B-Or
not NCT03865134 206 209 B-Negation
having NCT03865134 210 216 O
metabolic NCT03865134 217 226 B-Modifier
disease NCT03865134 227 234 B-Condition

- NCT03865134 237 238 O
Compliance NCT03865134 240 250 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03865134 251 255 I-Assertion___Assertion-Type-Value:hypothetical
visual NCT03865134 256 262 B-Procedure
examinations NCT03865134 263 275 I-Procedure
and NCT03865134 276 279 B-Or
physiotherapy NCT03865134 280 293 B-Procedure
evaluations NCT03865134 294 305 I-Procedure

- NCT03865134 308 309 O
To NCT03865134 311 313 O
be NCT03865134 314 316 O
children NCT03865134 317 325 O
and NCT03865134 326 329 O
parents NCT03865134 330 337 O
who NCT03865134 338 341 O
agree NCT03865134 342 347 O
to NCT03865134 348 350 O
participate NCT03865134 351 362 O
in NCT03865134 363 365 O
the NCT03865134 366 369 O
study NCT03865134 370 375 O

Exclusion NCT03865134 376 385 O
Criteria NCT03865134 386 394 O
: NCT03865134 395 396 O

- NCT03865134 400 401 O
To NCT03865134 403 405 O
be NCT03865134 406 408 O
a NCT03865134 409 410 O
child NCT03865134 411 416 O
who NCT03865134 417 420 B-And
does NCT03865134 421 425 O
not NCT03865134 426 429 B-Negation
comply NCT03865134 430 436 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03865134 437 441 I-Assertion___Assertion-Type-Value:hypothetical
Optical NCT03865134 442 449 B-Procedure
Kohlerans NCT03865134 450 459 I-Procedure
Tomography NCT03865134 460 470 I-Procedure
( NCT03865134 471 472 O
OCT NCT03865134 473 476 B-Procedure
) NCT03865134 477 478 O

- NCT03865134 482 483 O
Not NCT03865134 485 488 B-Negation
participating NCT03865134 489 502 B-Eq-Comparison
in NCT03865134 503 505 O
one NCT03865134 506 509 B-Eq-Comparison
or NCT03865134 510 512 I-Eq-Comparison
more NCT03865134 513 517 I-Eq-Comparison
of NCT03865134 518 520 O
the NCT03865134 521 524 O
eye NCT03865134 525 528 B-Procedure
examination NCT03865134 529 540 I-Procedure
or NCT03865134 541 543 B-Or
physiotherapy NCT03865134 544 557 B-Procedure
assessments NCT03865134 558 569 I-Procedure

- NCT03865134 572 573 O
Being NCT03865134 575 580 O
children NCT03865134 581 589 O
and NCT03865134 590 593 B-Or
parents NCT03865134 594 601 B-Family-Member___Family-Member-Type:parent
who NCT03865134 602 605 O
do NCT03865134 606 608 O
not NCT03865134 609 612 B-Negation
agree NCT03865134 613 618 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865134 619 621 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03865134 622 633 O
in NCT03865134 634 636 O
the NCT03865134 637 640 O
study NCT03865134 641 646 B-Study

Inclusion NCT03863223 0 9 O
Criteria NCT03863223 10 18 O
: NCT03863223 19 20 O

1 NCT03863223 24 25 O
. NCT03863223 25 26 O
HER2 NCT03863223 28 32 B-Modifier
positive NCT03863223 33 41 O
recurrent NCT03863223 42 51 B-Modifier
or NCT03863223 52 54 B-Or
metastasis NCT03863223 55 65 B-Modifier
breast NCT03863223 66 72 I-Modifier
cancer NCT03863223 73 79 B-Condition
. NCT03863223 79 80 O

2 NCT03863223 84 85 O
. NCT03863223 85 86 O
Patients NCT03863223 88 96 O
with NCT03863223 97 101 O
measurable NCT03863223 102 112 B-Modifier
disease NCT03863223 113 120 B-Condition
are NCT03863223 121 124 O
eligible NCT03863223 125 133 O
. NCT03863223 133 134 O

3 NCT03863223 138 139 O
. NCT03863223 139 140 O
Eastern NCT03863223 142 149 B-Observation
Cooperative NCT03863223 150 161 I-Observation
Oncology NCT03863223 162 170 I-Observation
Group NCT03863223 171 176 I-Observation
( NCT03863223 177 178 O
ECOG NCT03863223 179 183 B-Observation
) NCT03863223 184 185 O
performance NCT03863223 186 197 O
status NCT03863223 198 204 O
0 NCT03863223 205 206 B-Eq-Comparison
or NCT03863223 207 209 I-Eq-Comparison
1 NCT03863223 210 211 I-Eq-Comparison
. NCT03863223 211 212 O

4 NCT03863223 216 217 O
. NCT03863223 217 218 O
Adequate NCT03863223 220 228 O
organ NCT03863223 229 234 B-Condition
function NCT03863223 235 243 I-Condition
. NCT03863223 243 244 O

5 NCT03863223 248 249 O
. NCT03863223 249 250 O
Signed NCT03863223 252 258 O
, NCT03863223 259 260 O
written NCT03863223 261 268 O
inform NCT03863223 269 275 O
consent NCT03863223 276 283 O
obtained NCT03863223 284 292 O
prior NCT03863223 293 298 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863223 299 301 I-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03863223 302 305 O
study NCT03863223 306 311 B-Study
procedure NCT03863223 312 321 O
. NCT03863223 321 322 O

Exclusion NCT03863223 324 333 O
Criteria NCT03863223 334 342 O
: NCT03863223 343 344 O

1 NCT03863223 348 349 O
. NCT03863223 349 350 O
History NCT03863223 352 359 B-Eq-Comparison
of NCT03863223 360 362 O
anti NCT03863223 363 367 O
- NCT03863223 368 369 O
cancer NCT03863223 370 376 B-Condition
therapy NCT03863223 377 384 B-Procedure
for NCT03863223 385 388 O
MBC（with NCT03863223 389 397 B-Condition
the NCT03863223 398 401 O
exception NCT03863223 402 411 B-Exception
of NCT03863223 412 414 O
one NCT03863223 415 418 B-Eq-Comparison
prior NCT03863223 419 424 B-Eq-Comparison
hormonal NCT03863223 425 433 B-Procedure
regimen NCT03863223 434 441 I-Procedure
for NCT03863223 442 445 O
MBC NCT03863223 446 449 B-Condition
） NCT03863223 449 450 O
. NCT03863223 450 451 O

2 NCT03863223 455 456 O
. NCT03863223 456 457 O
History NCT03863223 459 466 B-Eq-Comparison
of NCT03863223 467 469 O
HER NCT03863223 470 473 B-Modifier
tyrosine NCT03863223 474 482 B-Drug
kinase NCT03863223 483 489 I-Drug
inhibitors NCT03863223 490 500 I-Drug
or NCT03863223 501 503 B-Or
monoclonal NCT03863223 504 514 B-Drug
antibody NCT03863223 515 523 I-Drug
for NCT03863223 524 527 O
breast NCT03863223 528 534 B-Modifier
cancer NCT03863223 535 541 B-Condition
in NCT03863223 542 544 O
any NCT03863223 545 548 O
treatment NCT03863223 549 558 B-Procedure
setting NCT03863223 559 566 O
， NCT03863223 567 568 O
except NCT03863223 569 575 B-Exception
trastuzumab NCT03863223 576 587 B-Drug
used NCT03863223 588 592 O
in NCT03863223 593 595 O
the NCT03863223 596 599 O
neo NCT03863223 600 603 B-Modifier
- NCT03863223 604 605 I-Modifier
adjuvant NCT03863223 606 614 I-Modifier|Modifier
or NCT03863223 615 617 B-Or
adjuvant NCT03863223 618 626 O
setting NCT03863223 627 634 O
. NCT03863223 634 635 O

3 NCT03863223 639 640 O
. NCT03863223 640 641 O
Assessed NCT03863223 643 651 O
by NCT03863223 652 654 O
the NCT03863223 655 658 O
investigator NCT03863223 659 671 O
to NCT03863223 672 674 O
be NCT03863223 675 677 O
unable NCT03863223 678 684 B-Assertion___Assertion-Type-Value:hypothetical|Negation
receive NCT03863223 685 692 O
systemic NCT03863223 693 701 B-Modifier
chemotherapy NCT03863223 702 714 B-Procedure
. NCT03863223 714 715 O

4 NCT03863223 719 720 O
. NCT03863223 720 721 O
History NCT03863223 723 730 B-Eq-Comparison
of NCT03863223 731 733 O
other NCT03863223 734 739 B-Other
malignancy NCT03863223 740 750 B-Condition
within NCT03863223 751 757 B-Eq-Comparison
the NCT03863223 758 761 I-Eq-Comparison
last NCT03863223 762 766 I-Eq-Comparison
5 NCT03863223 767 768 I-Eq-Comparison
years NCT03863223 769 774 I-Eq-Comparison
， NCT03863223 775 776 O
except NCT03863223 777 783 B-Exception
for NCT03863223 784 787 O
carcinoma NCT03863223 788 797 B-Condition
in NCT03863223 798 800 O
situ NCT03863223 801 805 B-Modifier
of NCT03863223 806 808 I-Modifier
cervix NCT03863223 809 815 I-Modifier
， NCT03863223 816 817 O
basal NCT03863223 818 823 B-Modifier
cell NCT03863223 824 828 I-Modifier|Modifier
carcinoma NCT03863223 829 838 I-Condition|Modifier
or NCT03863223 839 841 B-Or
squamous NCT03863223 842 850 B-Modifier
cell NCT03863223 851 855 O
carcinoma NCT03863223 856 865 O
of NCT03863223 866 868 O
the NCT03863223 869 872 O
skin NCT03863223 873 877 B-Modifier
that NCT03863223 878 882 O
has NCT03863223 883 886 O
been NCT03863223 887 891 O
previously NCT03863223 892 902 B-Eq-Comparison
treated NCT03863223 903 910 B-Procedure
with NCT03863223 911 915 O
curative NCT03863223 916 924 B-Modifier
intent NCT03863223 925 931 I-Modifier
. NCT03863223 931 932 O

5 NCT03863223 936 937 O
. NCT03863223 937 938 O
Pregnant NCT03863223 940 948 B-Condition
or NCT03863223 949 951 B-Or|Or
lactating NCT03863223 952 961 B-Condition
women NCT03863223 962 967 O
， NCT03863223 968 969 O
or NCT03863223 970 972 O
for NCT03863223 973 976 O
women NCT03863223 977 982 O
of NCT03863223 983 985 O
childbearing NCT03863223 986 998 B-Condition
potential NCT03863223 999 1008 B-Assertion___Assertion-Type-Value:hypothetical
unwilling NCT03863223 1009 1018 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863223 1019 1021 I-Assertion___Assertion-Type-Value:hypothetical|Negation
use NCT03863223 1022 1025 O
a NCT03863223 1026 1027 O
highly NCT03863223 1028 1034 B-Modifier
- NCT03863223 1035 1036 I-Modifier
effective NCT03863223 1037 1046 I-Modifier
contraception NCT03863223 1047 1060 B-Procedure
during NCT03863223 1061 1067 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863223 1068 1070 O
the NCT03863223 1071 1074 O
study NCT03863223 1075 1080 B-Study
treatment NCT03863223 1081 1090 B-Procedure
and NCT03863223 1091 1094 B-And
for NCT03863223 1095 1098 O
at NCT03863223 1099 1101 B-Eq-Comparison
least NCT03863223 1102 1107 I-Eq-Comparison
7 NCT03863223 1108 1109 I-Eq-Comparison
months NCT03863223 1110 1116 I-Eq-Comparison
after NCT03863223 1117 1122 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03863223 1123 1126 O
last NCT03863223 1127 1131 B-Eq-Comparison
dose NCT03863223 1132 1136 O
of NCT03863223 1137 1139 O
study NCT03863223 1140 1145 B-Study
treatment NCT03863223 1146 1155 B-Procedure
. NCT03863223 1155 1156 O

Inclusion NCT03867045 0 9 O
Criteria NCT03867045 10 18 O
: NCT03867045 19 20 O

Patients NCT03867045 22 30 O
> NCT03867045 31 32 B-Eq-Comparison
18 NCT03867045 33 35 I-Eq-Comparison
years NCT03867045 36 41 I-Eq-Comparison
of NCT03867045 42 44 O
age NCT03867045 45 48 B-Age
Patients NCT03867045 49 57 O
planning NCT03867045 58 66 B-Assertion___Assertion-Type-Value:intention
to NCT03867045 67 69 O
start NCT03867045 70 75 B-Eq-Comparison
treatment NCT03867045 76 85 B-Procedure
with NCT03867045 86 90 O
cabozantinib NCT03867045 91 103 B-Procedure
therapy NCT03867045 104 111 I-Procedure
for NCT03867045 112 115 O
renal NCT03867045 116 121 B-Modifier
cancer NCT03867045 122 128 B-Condition
. NCT03867045 128 129 O

Technology NCT03867045 131 141 O
requirement NCT03867045 142 153 O
: NCT03867045 154 155 O
The NCT03867045 156 159 O
patient NCT03867045 160 167 O
will NCT03867045 168 172 O
need NCT03867045 173 177 O
to NCT03867045 178 180 O
have NCT03867045 181 185 O
home NCT03867045 186 190 O
wireless NCT03867045 191 199 O
internet NCT03867045 200 208 O
access NCT03867045 209 215 O
for NCT03867045 216 219 O
use NCT03867045 220 223 O
of NCT03867045 224 226 O
the NCT03867045 227 230 O
software NCT03867045 231 239 O
and NCT03867045 240 243 O
technology NCT03867045 244 254 O
in NCT03867045 255 257 O
this NCT03867045 258 262 O
study NCT03867045 263 268 O
. NCT03867045 268 269 O
The NCT03867045 271 274 O
patient NCT03867045 275 282 O
will NCT03867045 283 287 O
need NCT03867045 288 292 O
to NCT03867045 293 295 O
already NCT03867045 296 303 O
have NCT03867045 304 308 O
or NCT03867045 309 311 O
be NCT03867045 312 314 O
willing NCT03867045 315 322 O
to NCT03867045 323 325 O
set NCT03867045 326 329 O
up NCT03867045 330 332 O
a NCT03867045 333 334 O
Duke NCT03867045 335 339 O
MyChart NCT03867045 340 347 O
account NCT03867045 348 355 O
. NCT03867045 355 356 O

Exclusion NCT03867045 358 367 O
Criteria NCT03867045 368 376 O
: NCT03867045 377 378 O

Non NCT03867045 380 383 B-Negation
- NCT03867045 384 385 O
English NCT03867045 386 393 O
Speaking NCT03867045 394 402 O
. NCT03867045 402 403 O
Any NCT03867045 405 408 O
patient NCT03867045 409 416 O
who NCT03867045 417 420 O
is NCT03867045 421 423 O
not NCT03867045 424 427 O
able NCT03867045 428 432 O
to NCT03867045 433 435 O
comprehend NCT03867045 436 446 O
and NCT03867045 447 450 O
operate NCT03867045 451 458 O
the NCT03867045 459 462 O
technology NCT03867045 463 473 O
at NCT03867045 474 476 O
the NCT03867045 477 480 O
discretion NCT03867045 481 491 O
of NCT03867045 492 494 O
the NCT03867045 495 498 O
enrolling NCT03867045 499 508 O
provider NCT03867045 509 517 O
. NCT03867045 517 518 O


Inclusion NCT03869281 0 9 O
Criteria NCT03869281 10 18 O
( NCT03869281 19 20 O
PTA NCT03869281 21 24 O
group NCT03869281 25 30 O
) NCT03869281 31 32 O

- NCT03869281 36 37 O
T1D NCT03869281 39 42 B-Condition
patients NCT03869281 43 51 O
who NCT03869281 52 55 B-And
received NCT03869281 56 64 B-Eq-Comparison
their NCT03869281 65 70 O
first NCT03869281 71 76 B-Eq-Comparison
PTA NCT03869281 77 80 B-Procedure
, NCT03869281 81 82 O
or NCT03869281 83 85 B-Or
second NCT03869281 86 92 B-Eq-Comparison
PTA NCT03869281 93 96 B-Procedure
only NCT03869281 97 101 B-And
if NCT03869281 102 104 I-And
their NCT03869281 105 110 O
first NCT03869281 111 116 B-Eq-Comparison
graft NCT03869281 117 122 B-Procedure
was NCT03869281 123 126 O
explanted NCT03869281 127 136 O
within NCT03869281 137 143 B-Eq-Comparison
a NCT03869281 144 145 I-Eq-Comparison
week NCT03869281 146 150 I-Eq-Comparison
, NCT03869281 151 152 O
between NCT03869281 153 160 B-Eq-Comparison
2 NCT03869281 161 162 I-Eq-Comparison
January NCT03869281 163 170 I-Eq-Comparison
2005 NCT03869281 171 175 I-Eq-Comparison
and NCT03869281 176 179 I-Eq-Comparison
31 NCT03869281 180 182 I-Eq-Comparison
December NCT03869281 183 191 I-Eq-Comparison
2017 NCT03869281 192 196 I-Eq-Comparison

- NCT03869281 200 201 O
age NCT03869281 203 206 B-Age
≥ NCT03869281 207 208 B-Eq-Comparison
18 NCT03869281 209 211 I-Eq-Comparison
and NCT03869281 212 215 B-And
< NCT03869281 216 217 B-Eq-Comparison
65 NCT03869281 218 220 I-Eq-Comparison
years NCT03869281 221 226 I-Eq-Comparison

- NCT03869281 229 230 O
willingness NCT03869281 232 243 O
to NCT03869281 244 246 O
participate NCT03869281 247 258 O
in NCT03869281 259 261 O
this NCT03869281 262 266 O
observational NCT03869281 267 280 O
study NCT03869281 281 286 O

Inclusion NCT03869281 287 296 O
Criteria NCT03869281 297 305 O
( NCT03869281 306 307 O
control NCT03869281 308 315 O
group NCT03869281 316 321 O
) NCT03869281 322 323 O

- NCT03869281 327 328 O
Type NCT03869281 330 334 B-Modifier
1 NCT03869281 335 336 I-Modifier
diabetes NCT03869281 337 345 B-Condition

- NCT03869281 348 349 O
age NCT03869281 351 354 B-Age
≥ NCT03869281 355 356 B-Eq-Comparison
18 NCT03869281 357 359 I-Eq-Comparison
years NCT03869281 360 365 I-Eq-Comparison
and NCT03869281 366 369 B-And
< NCT03869281 370 371 B-Eq-Comparison
65 NCT03869281 372 374 I-Eq-Comparison
years NCT03869281 375 380 I-Eq-Comparison

- NCT03869281 383 384 O
willingness NCT03869281 386 397 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869281 398 400 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03869281 401 412 O
in NCT03869281 413 415 O
this NCT03869281 416 420 O
observational NCT03869281 421 434 O
study NCT03869281 435 440 B-Study

- NCT03869281 443 444 O
minimum NCT03869281 446 453 O
disease NCT03869281 454 461 B-Condition
duration NCT03869281 462 470 O
of NCT03869281 471 473 O
5 NCT03869281 474 475 B-Eq-Comparison
years NCT03869281 476 481 I-Eq-Comparison

- NCT03869281 484 485 O
brittle NCT03869281 487 494 B-Condition
diabetes NCT03869281 495 503 I-Condition
, NCT03869281 504 505 O
as NCT03869281 506 508 O
defined NCT03869281 509 516 O
by NCT03869281 517 519 O
the NCT03869281 520 523 O
occurrence NCT03869281 524 534 O
of NCT03869281 535 537 O
frequent NCT03869281 538 546 B-Modifier
acute NCT03869281 547 552 O
complications NCT03869281 553 566 B-Condition
( NCT03869281 567 568 O
ketoacidosis NCT03869281 569 581 B-Condition
or NCT03869281 582 584 B-Or
severe NCT03869281 585 591 O
hypoglycaemic NCT03869281 592 605 B-Condition
episodes NCT03869281 606 614 O
requiring NCT03869281 615 624 O
third NCT03869281 625 630 B-Procedure
- NCT03869281 631 632 I-Procedure
part NCT03869281 633 637 I-Procedure
assistance NCT03869281 638 648 I-Procedure
or NCT03869281 649 651 B-Or
unawareness NCT03869281 652 663 B-Condition
despite NCT03869281 664 671 B-And
well NCT03869281 672 676 O
- NCT03869281 677 678 O
conducted NCT03869281 679 688 O
intensive NCT03869281 689 698 O
insulin NCT03869281 699 706 B-Procedure
therapy NCT03869281 707 714 I-Procedure
) NCT03869281 715 716 O

- NCT03869281 720 721 O
presence NCT03869281 723 731 O
of NCT03869281 732 734 O
at NCT03869281 735 737 B-Eq-Comparison
least NCT03869281 738 743 I-Eq-Comparison
one NCT03869281 744 747 I-Eq-Comparison
diabetes NCT03869281 748 756 B-Condition
- NCT03869281 757 758 O
related NCT03869281 759 766 O
complication NCT03869281 767 779 B-Condition
( NCT03869281 780 781 O
either NCT03869281 782 788 O
neuropathy NCT03869281 789 799 B-Condition
, NCT03869281 800 801 O
retinopathy NCT03869281 802 813 B-Condition
, NCT03869281 814 815 O
subclinical NCT03869281 816 827 B-Modifier
nephropathy NCT03869281 828 839 B-Condition
) NCT03869281 840 841 O
. NCT03869281 842 843 O

Exclusion NCT03869281 845 854 O
Criteria NCT03869281 855 863 O
( NCT03869281 864 865 O
both NCT03869281 866 870 O
groups NCT03869281 871 877 O
) NCT03869281 878 879 O

- NCT03869281 883 884 O
conditions NCT03869281 886 896 B-Condition
other NCT03869281 897 902 B-Exception
than NCT03869281 903 907 I-Exception
T1D NCT03869281 908 911 B-Condition
known NCT03869281 912 917 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869281 918 920 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869281 921 927 O
bone NCT03869281 928 932 B-Condition
health NCT03869281 933 939 I-Condition
( NCT03869281 940 941 O
i. NCT03869281 942 944 O
e. NCT03869281 945 947 O
, NCT03869281 948 949 O
non NCT03869281 950 953 B-Negation
- NCT03869281 954 955 O
compensated NCT03869281 956 967 B-Modifier
hypothyroidism NCT03869281 968 982 B-Condition
, NCT03869281 983 984 O
hyperthyroidism NCT03869281 985 1000 B-Condition
, NCT03869281 1001 1002 O
hyperparathyroidism NCT03869281 1003 1022 B-Condition
, NCT03869281 1023 1024 O
inflammatory NCT03869281 1025 1037 B-Condition
bowel NCT03869281 1038 1043 I-Condition
disease NCT03869281 1044 1051 I-Condition
, NCT03869281 1052 1053 O
malignancy NCT03869281 1054 1064 B-Condition
, NCT03869281 1065 1066 O
rheumatoid NCT03869281 1067 1077 B-Condition
arthritis NCT03869281 1078 1087 I-Condition
, NCT03869281 1088 1089 O
hypogonadism NCT03869281 1090 1102 B-Condition
, NCT03869281 1103 1104 O
severe NCT03869281 1105 1111 O
chronic NCT03869281 1112 1119 B-Modifier
obstructive NCT03869281 1120 1131 B-Condition
pulmonary NCT03869281 1132 1141 I-Condition
disease NCT03869281 1142 1149 I-Condition
, NCT03869281 1150 1151 O
hepatic NCT03869281 1152 1159 B-Condition
insufficiency NCT03869281 1160 1173 I-Condition
, NCT03869281 1174 1175 O
alcohol NCT03869281 1176 1183 B-Observation
intake NCT03869281 1184 1190 I-Observation
≥ NCT03869281 1191 1192 B-Eq-Comparison
3 NCT03869281 1193 1194 I-Eq-Comparison
units NCT03869281 1195 1200 I-Eq-Comparison
/ NCT03869281 1201 1202 I-Eq-Comparison
day NCT03869281 1203 1206 I-Eq-Comparison
) NCT03869281 1207 1208 O
, NCT03869281 1210 1211 O

- NCT03869281 1215 1216 O
use NCT03869281 1218 1221 B-Eq-Comparison
of NCT03869281 1222 1224 O
drugs NCT03869281 1225 1230 B-Drug
that NCT03869281 1231 1235 O
can NCT03869281 1236 1239 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869281 1240 1246 O
bone NCT03869281 1247 1251 B-Condition
metabolism NCT03869281 1252 1262 I-Condition
( NCT03869281 1263 1264 O
e. NCT03869281 1265 1267 O
g. NCT03869281 1268 1270 O
, NCT03869281 1271 1272 O
bisphosphonates NCT03869281 1273 1288 B-Drug
, NCT03869281 1289 1290 O
anticonvulsants NCT03869281 1291 1306 B-Drug
, NCT03869281 1307 1308 O
hormone NCT03869281 1309 1316 B-Procedure
replacement NCT03869281 1317 1328 I-Procedure
therapy NCT03869281 1329 1336 I-Procedure
) NCT03869281 1337 1338 O
other NCT03869281 1339 1344 B-Exception
than NCT03869281 1345 1349 I-Exception
glucocorticoids NCT03869281 1350 1365 B-Drug
and NCT03869281 1366 1369 B-Or
immunosuppressants NCT03869281 1370 1388 B-Drug

- NCT03869281 1391 1392 O
recipients NCT03869281 1394 1404 O
of NCT03869281 1405 1407 O
simultaneous NCT03869281 1408 1420 B-Modifier
pancreas NCT03869281 1421 1429 B-Procedure
kidney NCT03869281 1430 1436 I-Procedure
transplantation NCT03869281 1437 1452 I-Procedure|Procedure
, NCT03869281 1453 1454 O
pancreatic NCT03869281 1455 1465 B-Procedure
islet NCT03869281 1466 1471 I-Procedure
transplantation NCT03869281 1472 1487 O
, NCT03869281 1488 1489 O
multiple NCT03869281 1490 1498 B-Modifier
PTAs NCT03869281 1499 1503 B-Procedure
, NCT03869281 1504 1505 O
other NCT03869281 1506 1511 B-Other
transplants NCT03869281 1512 1523 B-Procedure

- NCT03869281 1526 1527 O
BMI NCT03869281 1529 1532 B-Observation
< NCT03869281 1533 1534 B-Eq-Comparison
18.5 NCT03869281 1535 1539 I-Eq-Comparison
or NCT03869281 1540 1542 B-Or
≥ NCT03869281 1543 1544 B-Eq-Comparison
30 NCT03869281 1545 1547 I-Eq-Comparison
kg NCT03869281 1548 1550 I-Eq-Comparison
/ NCT03869281 1551 1552 I-Eq-Comparison
m2 NCT03869281 1553 1555 I-Eq-Comparison

Inclusion NCT03866824 0 9 O
Criteria NCT03866824 10 18 O
: NCT03866824 19 20 O

Men NCT03866824 22 25 O
and NCT03866824 26 29 B-Or
women NCT03866824 30 35 O
aged NCT03866824 36 40 B-Age
20 NCT03866824 41 43 B-Eq-Comparison
to NCT03866824 44 46 I-Eq-Comparison
80 NCT03866824 47 49 I-Eq-Comparison

- NCT03866824 53 54 O
MDD NCT03866824 56 59 B-Condition
diagnosis NCT03866824 60 69 O
objected NCT03866824 70 78 O
to NCT03866824 79 81 O
MRI NCT03866824 82 85 B-Procedure
( NCT03866824 86 87 O
grade NCT03866824 88 93 B-Eq-Comparison
II NCT03866824 94 96 I-Eq-Comparison
/ NCT03866824 97 98 I-Eq-Comparison
III NCT03866824 99 102 O
) NCT03866824 103 104 O

- NCT03866824 108 109 O
Joint NCT03866824 111 116 B-Modifier
pain NCT03866824 117 121 B-Condition
for NCT03866824 122 125 O
more NCT03866824 126 130 B-Eq-Comparison
than NCT03866824 131 135 I-Eq-Comparison
3 NCT03866824 136 137 I-Eq-Comparison
month NCT03866824 138 143 I-Eq-Comparison

- NCT03866824 146 147 O
Absence NCT03866824 149 156 B-Negation
of NCT03866824 157 159 O
bone NCT03866824 160 164 B-Modifier
lesion NCT03866824 165 171 B-Condition
or NCT03866824 172 174 B-Or
moderate NCT03866824 175 183 O
knee NCT03866824 184 188 B-Modifier
osteoarthritis NCT03866824 189 203 B-Condition
stage NCT03866824 204 209 B-Eq-Comparison
< NCT03866824 210 211 I-Eq-Comparison
2 NCT03866824 212 213 I-Eq-Comparison
on NCT03866824 214 216 O
the NCT03866824 217 220 O
Kellgren NCT03866824 221 229 B-Observation
Laurence NCT03866824 230 238 I-Observation
scale NCT03866824 239 244 I-Observation
( NCT03866824 245 246 O
objectified NCT03866824 247 258 O
on NCT03866824 259 261 O
radiography NCT03866824 262 273 B-Procedure
in NCT03866824 274 276 O
schuss NCT03866824 277 283 B-Modifier
) NCT03866824 284 285 O
in NCT03866824 286 288 O
the NCT03866824 289 292 O
6 NCT03866824 293 294 B-Eq-Comparison
months NCT03866824 295 301 I-Eq-Comparison
prior NCT03866824 302 307 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866824 308 310 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03866824 311 320 B-Study

- NCT03866824 323 324 O
Axial NCT03866824 326 331 B-Condition|Observation
deformity NCT03866824 332 341 I-Condition|Observation
of NCT03866824 342 344 O
the NCT03866824 345 348 O
lower NCT03866824 349 354 B-Modifier
limbs NCT03866824 355 360 I-Modifier
less NCT03866824 361 365 B-Eq-Comparison
than NCT03866824 366 370 I-Eq-Comparison
or NCT03866824 371 373 I-Eq-Comparison
equal NCT03866824 374 379 I-Eq-Comparison
to NCT03866824 380 382 I-Eq-Comparison
5 NCT03866824 383 384 I-Eq-Comparison
° NCT03866824 385 386 I-Eq-Comparison

- NCT03866824 389 390 O
Signed NCT03866824 392 398 O
consent NCT03866824 399 406 O
signed NCT03866824 407 413 O
by NCT03866824 414 416 O
the NCT03866824 417 420 O
patient NCT03866824 421 428 O

- NCT03866824 431 432 O
Ability NCT03866824 434 441 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866824 442 444 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03866824 445 452 O
procedures NCT03866824 453 463 B-Procedure
as NCT03866824 464 466 O
part NCT03866824 467 471 O
of NCT03866824 472 474 O
the NCT03866824 475 478 O
follow NCT03866824 479 485 B-Encounter
- NCT03866824 486 487 I-Encounter
up NCT03866824 488 490 I-Encounter
( NCT03866824 491 492 O
walk NCT03866824 493 497 B-Observation
50 NCT03866824 498 500 B-Eq-Comparison
steps NCT03866824 501 506 I-Eq-Comparison
on NCT03866824 507 509 O
a NCT03866824 510 511 O
flat NCT03866824 512 516 B-Modifier
surface NCT03866824 517 524 I-Modifier
and NCT03866824 525 528 B-Or
up NCT03866824 529 531 B-Modifier
/ NCT03866824 532 533 B-Or
down NCT03866824 534 538 B-Modifier
stairs NCT03866824 539 545 I-Modifier
) NCT03866824 546 547 O
. NCT03866824 548 549 O

- NCT03866824 553 554 O
Be NCT03866824 556 558 O
affiliated NCT03866824 559 569 O
to NCT03866824 570 572 O
a NCT03866824 573 574 O
health NCT03866824 575 581 O
insurance NCT03866824 582 591 O
scheme NCT03866824 592 598 O

Exclusion NCT03866824 599 608 O
Criteria NCT03866824 609 617 O
: NCT03866824 618 619 O

- NCT03866824 623 624 O
Axial NCT03866824 626 631 B-Condition|Observation
deformity NCT03866824 632 641 I-Condition|Observation
> NCT03866824 642 643 B-Eq-Comparison
5 NCT03866824 644 645 I-Eq-Comparison
° NCT03866824 646 647 I-Eq-Comparison

- NCT03866824 650 651 O
Ligament NCT03866824 653 661 B-Condition
instability NCT03866824 662 673 I-Condition

- NCT03866824 676 677 O
Major NCT03866824 679 684 O
injuries NCT03866824 685 693 B-Condition
or NCT03866824 694 696 B-Or
surgery NCT03866824 697 704 B-Procedure
of NCT03866824 705 707 O
the NCT03866824 708 711 O
target NCT03866824 712 718 B-Modifier
knee NCT03866824 719 723 I-Modifier
or NCT03866824 724 726 B-Or
lateral NCT03866824 727 734 B-Modifier
contralateral NCT03866824 735 748 I-Modifier
knee NCT03866824 749 753 I-Modifier
in NCT03866824 754 756 O
the NCT03866824 757 760 O
12 NCT03866824 761 763 B-Eq-Comparison
months NCT03866824 764 770 I-Eq-Comparison
preceding NCT03866824 771 780 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866824 781 784 O
inclusion NCT03866824 785 794 B-Study
visit NCT03866824 795 800 O

- NCT03866824 803 804 O
Ligament NCT03866824 806 814 B-Procedure
reconstruction NCT03866824 815 829 I-Procedure
in NCT03866824 830 832 O
the NCT03866824 833 836 O
12 NCT03866824 837 839 B-Eq-Comparison
months NCT03866824 840 846 I-Eq-Comparison
prior NCT03866824 847 852 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866824 853 855 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866824 856 859 O
inclusion NCT03866824 860 869 B-Study
visit NCT03866824 870 875 O

- NCT03866824 878 879 O
Need NCT03866824 881 885 O
a NCT03866824 886 887 O
cane NCT03866824 888 892 B-Modifier
or NCT03866824 893 895 B-Or
assistance NCT03866824 896 906 B-Modifier
to NCT03866824 907 909 O
move NCT03866824 910 914 B-Condition

- NCT03866824 917 918 O
BMI NCT03866824 920 923 B-Observation
> NCT03866824 924 925 B-Eq-Comparison
35 NCT03866824 926 928 I-Eq-Comparison

- NCT03866824 932 933 O
Thrombocytopenia NCT03866824 935 951 B-Condition|Observation
< NCT03866824 952 953 B-Eq-Comparison
150 NCT03866824 954 957 I-Eq-Comparison
G NCT03866824 958 959 I-Eq-Comparison
/ NCT03866824 960 961 I-Eq-Comparison
L NCT03866824 962 963 I-Eq-Comparison

- NCT03866824 966 967 O
Thrombocytosis NCT03866824 969 983 B-Condition|Observation
> NCT03866824 984 985 B-Eq-Comparison
450 NCT03866824 986 989 I-Eq-Comparison
G NCT03866824 990 991 I-Eq-Comparison
/ NCT03866824 992 993 I-Eq-Comparison
L NCT03866824 994 995 I-Eq-Comparison

Inclusion NCT03866603 0 9 O
Criteria NCT03866603 10 18 O
: NCT03866603 19 20 O

- NCT03866603 24 25 O
Informed NCT03866603 27 35 O
consent NCT03866603 36 43 O
is NCT03866603 44 46 O
obtained NCT03866603 47 55 O
from NCT03866603 56 60 O
the NCT03866603 61 64 O
participant NCT03866603 65 76 O
. NCT03866603 76 77 O

- NCT03866603 81 82 O
The NCT03866603 84 87 O
participant NCT03866603 88 99 O
is NCT03866603 100 102 O
clinically NCT03866603 103 113 O
diagnosed NCT03866603 114 123 O
with NCT03866603 124 128 O
Parkinson NCT03866603 129 138 B-Condition
's NCT03866603 138 140 O
disease NCT03866603 141 148 I-Condition
or NCT03866603 149 151 B-Or
the NCT03866603 152 155 O
individual NCT03866603 156 166 O
is NCT03866603 167 169 O
a NCT03866603 170 171 O
family NCT03866603 172 178 B-Family-Member
member NCT03866603 179 185 I-Family-Member
of NCT03866603 186 188 O
a NCT03866603 189 190 O
participant NCT03866603 191 202 O
with NCT03866603 203 207 O
LRRK2 NCT03866603 208 213 B-Modifier
parkinsonism NCT03866603 214 226 B-Condition
or NCT03866603 227 229 B-Or
is NCT03866603 230 232 O
a NCT03866603 233 234 O
member NCT03866603 235 241 O
of NCT03866603 242 244 O
a NCT03866603 245 246 O
high NCT03866603 247 251 O
risk NCT03866603 252 256 B-Risk
population NCT03866603 257 267 O
with NCT03866603 268 272 O
an NCT03866603 273 275 O
early NCT03866603 276 281 B-Modifier
PD NCT03866603 282 284 B-Condition
onset NCT03866603 285 290 B-Eq-Comparison
. NCT03866603 290 291 O

- NCT03866603 295 296 O
The NCT03866603 298 301 O
participant NCT03866603 302 313 O
is NCT03866603 314 316 O
equal NCT03866603 317 322 B-Eq-Comparison
to NCT03866603 323 325 I-Eq-Comparison
or NCT03866603 326 328 I-Eq-Comparison
older NCT03866603 329 334 I-Eq-Comparison
than NCT03866603 335 339 I-Eq-Comparison
18 NCT03866603 340 342 I-Eq-Comparison
years NCT03866603 343 348 I-Eq-Comparison
old NCT03866603 349 352 B-Age
. NCT03866603 352 353 O

Exclusion NCT03866603 355 364 O
Criteria NCT03866603 365 373 O
: NCT03866603 374 375 O

- NCT03866603 379 380 O
Inability NCT03866603 382 391 O
to NCT03866603 392 394 O
provide NCT03866603 395 402 O
informed NCT03866603 403 411 O
consent NCT03866603 412 419 O
. NCT03866603 419 420 O

- NCT03866603 424 425 O
The NCT03866603 427 430 O
participant NCT03866603 431 442 O
is NCT03866603 443 445 O
not NCT03866603 446 449 B-Negation
suffering NCT03866603 450 459 O
from NCT03866603 460 464 O
Parkinson NCT03866603 465 474 B-Condition
's NCT03866603 474 476 O
disease NCT03866603 477 484 I-Condition
or NCT03866603 485 487 B-Or
the NCT03866603 488 491 O
individual NCT03866603 492 502 O
is NCT03866603 503 505 O
not NCT03866603 506 509 B-Negation
a NCT03866603 510 511 O
family NCT03866603 512 518 B-Family-Member
member NCT03866603 519 525 I-Family-Member
of NCT03866603 526 528 O
a NCT03866603 529 530 O
participant NCT03866603 531 542 O
with NCT03866603 543 547 O
LRRK2 NCT03866603 548 553 B-Modifier
parkinsonism NCT03866603 554 566 B-Condition
or NCT03866603 567 569 B-Or
is NCT03866603 570 572 O
not NCT03866603 573 576 B-Negation
a NCT03866603 577 578 O
member NCT03866603 579 585 O
of NCT03866603 586 588 O
a NCT03866603 589 590 O
high NCT03866603 591 595 O
risk NCT03866603 596 600 B-Risk
population NCT03866603 601 611 O
. NCT03866603 611 612 O

- NCT03866603 616 617 O
The NCT03866603 619 622 O
participant NCT03866603 623 634 O
is NCT03866603 635 637 O
younger NCT03866603 638 645 B-Eq-Comparison
than NCT03866603 646 650 I-Eq-Comparison
18 NCT03866603 651 653 I-Eq-Comparison
years NCT03866603 654 659 I-Eq-Comparison
old NCT03866603 660 663 B-Age
. NCT03866603 663 664 O

- NCT03866603 668 669 O
Previously NCT03866603 671 681 B-Eq-Comparison
enrolled NCT03866603 682 690 O
in NCT03866603 691 693 O
the NCT03866603 694 697 O
study NCT03866603 698 703 B-Study
. NCT03866603 703 704 O

- NCT03866603 708 709 O
Participant NCT03866603 711 722 O
in NCT03866603 723 725 B-Observation
custody NCT03866603 726 733 I-Observation
. NCT03866603 733 734 O

Inclusion NCT03866941 0 9 O
Criteria NCT03866941 10 18 O
: NCT03866941 19 20 O

1 NCT03866941 24 25 O
. NCT03866941 25 26 O
All NCT03866941 28 31 O
the NCT03866941 32 35 O
cases NCT03866941 36 41 O
with NCT03866941 42 46 O
the NCT03866941 47 50 O
primary NCT03866941 51 58 O
diagnosis NCT03866941 59 68 O
of NCT03866941 69 71 O
acute NCT03866941 72 77 O
or NCT03866941 78 80 B-Or
chronic NCT03866941 81 88 B-Modifier
synthetic NCT03866941 89 98 B-Condition
cannabinoids NCT03866941 99 111 I-Condition
toxicity NCT03866941 112 120 I-Condition
will NCT03866941 121 125 O
be NCT03866941 126 128 O
included NCT03866941 129 137 O
in NCT03866941 138 140 O
the NCT03866941 141 144 O
study NCT03866941 145 150 B-Study
. NCT03866941 150 151 O

2 NCT03866941 155 156 O
. NCT03866941 156 157 O
Willing NCT03866941 159 166 O
and NCT03866941 167 170 O
able NCT03866941 171 175 O
to NCT03866941 176 178 O
comply NCT03866941 179 185 O
with NCT03866941 186 190 O
the NCT03866941 191 194 O
study NCT03866941 195 200 O
procedures NCT03866941 201 211 O
and NCT03866941 212 215 O
provide NCT03866941 216 223 O
written NCT03866941 224 231 O
informed NCT03866941 232 240 O
consent NCT03866941 241 248 O
to NCT03866941 249 251 O
participate NCT03866941 252 263 O
in NCT03866941 264 266 O
the NCT03866941 267 270 O
study NCT03866941 271 276 B-Study
. NCT03866941 276 277 O

Exclusion NCT03866941 279 288 O
Criteria NCT03866941 289 297 O
: NCT03866941 298 299 O

- NCT03866941 303 304 O
1 NCT03866941 306 307 O
- NCT03866941 308 309 O
Patients NCT03866941 310 318 O
with NCT03866941 319 323 O
a NCT03866941 324 325 O
history NCT03866941 326 333 B-Eq-Comparison
of NCT03866941 334 336 O
any NCT03866941 337 340 O
chronic NCT03866941 341 348 B-Modifier
disease NCT03866941 349 356 B-Condition
( NCT03866941 357 358 O
renal NCT03866941 359 364 B-Modifier
and NCT03866941 365 368 B-Or
hepatic NCT03866941 369 376 B-Modifier
) NCT03866941 377 378 O
. NCT03866941 379 380 O
2 NCT03866941 382 383 O
- NCT03866941 384 385 O
Patients NCT03866941 386 394 O
refuse NCT03866941 395 401 O
to NCT03866941 402 404 O
participate NCT03866941 405 416 O
in NCT03866941 417 419 O
the NCT03866941 420 423 O
study NCT03866941 424 429 O
. NCT03866941 429 430 O
3 NCT03866941 432 433 O
- NCT03866941 434 435 O
Abuse NCT03866941 436 441 B-Condition
to NCT03866941 442 444 O
other NCT03866941 445 450 B-Other
drugs NCT03866941 451 456 B-Drug
. NCT03866941 456 457 O

Inclusion NCT03864159 0 9 O
Criteria NCT03864159 10 18 O
: NCT03864159 19 20 O

- NCT03864159 24 25 O
Age NCT03864159 27 30 B-Age
between NCT03864159 31 38 B-Eq-Comparison
18 NCT03864159 39 41 I-Eq-Comparison
to NCT03864159 42 44 I-Eq-Comparison
25 NCT03864159 45 47 I-Eq-Comparison
years NCT03864159 48 53 I-Eq-Comparison

- NCT03864159 56 57 O
Amateur NCT03864159 59 66 B-Observation
basketball NCT03864159 67 77 I-Observation
players NCT03864159 78 85 I-Observation

- NCT03864159 88 89 O
Belong NCT03864159 91 97 O
to NCT03864159 98 100 O
the NCT03864159 101 104 O
Celeste NCT03864159 105 112 O
club NCT03864159 113 117 O

- NCT03864159 120 121 O
Not NCT03864159 123 126 B-Negation
having NCT03864159 127 133 O
any NCT03864159 134 137 O
injury NCT03864159 138 144 B-Condition
to NCT03864159 145 147 O
the NCT03864159 148 151 O
hamstring NCT03864159 152 161 B-Modifier
musculature NCT03864159 162 173 I-Modifier
at NCT03864159 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864159 177 180 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864159 181 185 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864159 186 188 O
the NCT03864159 189 192 O
study NCT03864159 193 198 B-Study

Exclusion NCT03864159 199 208 O
Criteria NCT03864159 209 217 O
: NCT03864159 218 219 O

- NCT03864159 223 224 O
At NCT03864159 226 228 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864159 229 232 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864159 233 237 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864159 238 240 O
the NCT03864159 241 244 O
study NCT03864159 245 250 B-Study
they NCT03864159 251 255 O
are NCT03864159 256 259 O
included NCT03864159 260 268 O
in NCT03864159 269 271 O
a NCT03864159 272 273 O
program NCT03864159 274 281 B-Procedure
of NCT03864159 282 284 I-Procedure
individualized NCT03864159 285 299 I-Procedure
strength NCT03864159 300 308 I-Procedure
training NCT03864159 309 317 I-Procedure
in NCT03864159 318 320 O
lower NCT03864159 321 326 B-Modifier
limbs NCT03864159 327 332 I-Modifier

- NCT03864159 335 336 O
Subjects NCT03864159 338 346 O
with NCT03864159 347 351 O
alterations NCT03864159 352 363 B-Condition
in NCT03864159 364 366 O
venous NCT03864159 367 373 B-Modifier
return NCT03864159 374 380 I-Modifier
or NCT03864159 381 383 B-Or
congenital NCT03864159 384 394 B-Modifier
coagulopathies NCT03864159 395 409 B-Condition

- NCT03864159 412 413 O
Subjects NCT03864159 415 423 O
who NCT03864159 424 427 O
present NCT03864159 428 435 O
hypermobility NCT03864159 436 449 B-Condition

- NCT03864159 452 453 O
Not NCT03864159 455 458 O
signed NCT03864159 459 465 O
the NCT03864159 466 469 O
informed NCT03864159 470 478 O
consent NCT03864159 479 486 O
document NCT03864159 487 495 O

Inclusion NCT03866772 0 9 O
Criteria NCT03866772 10 18 O
: NCT03866772 19 20 O

- NCT03866772 24 25 O
unfavourable NCT03866772 27 39 B-Condition
cervix NCT03866772 40 46 I-Condition
( NCT03866772 47 48 O
Bishop NCT03866772 49 55 B-Observation
score NCT03866772 56 61 I-Observation
≤ NCT03866772 62 63 B-Eq-Comparison
4 NCT03866772 64 65 I-Eq-Comparison
) NCT03866772 66 67 O
, NCT03866772 69 70 O

- NCT03866772 74 75 O
indication NCT03866772 77 87 B-Indication
for NCT03866772 88 91 O
induction NCT03866772 92 101 B-Procedure
of NCT03866772 102 104 I-Procedure
labor NCT03866772 105 110 I-Procedure
( NCT03866772 111 112 O
medical NCT03866772 113 120 B-Modifier
or NCT03866772 121 123 B-Or
obstetrical NCT03866772 124 135 B-Modifier
) NCT03866772 136 137 O
, NCT03866772 139 140 O

- NCT03866772 144 145 O
37 NCT03866772 147 149 B-Eq-Comparison
completed NCT03866772 150 159 O
gestational NCT03866772 160 171 B-Observation
weeks NCT03866772 172 177 O
, NCT03866772 178 179 O

- NCT03866772 183 184 O
vertex NCT03866772 186 192 B-Condition
presentation NCT03866772 193 205 I-Condition
, NCT03866772 206 207 O

- NCT03866772 211 212 O
singleton NCT03866772 214 223 B-Modifier
pregnancy NCT03866772 224 233 B-Condition

- NCT03866772 236 237 O
intact NCT03866772 239 245 B-Condition
membranes NCT03866772 246 255 I-Condition
. NCT03866772 255 256 O

Exclusion NCT03866772 258 267 O
Criteria NCT03866772 268 276 O
: NCT03866772 277 278 O

- NCT03866772 282 283 O
previous NCT03866772 285 293 B-Eq-Comparison
cesarean NCT03866772 294 302 B-Procedure
delivery NCT03866772 303 311 I-Procedure

- NCT03866772 314 315 O
previous NCT03866772 317 325 B-Eq-Comparison
uterine NCT03866772 326 333 B-Procedure
surgery NCT03866772 334 341 I-Procedure
( NCT03866772 342 343 O
eg NCT03866772 344 346 O
: NCT03866772 347 348 O
myomectomy NCT03866772 349 359 B-Procedure
) NCT03866772 360 361 O

- NCT03866772 365 366 O
noncephalic NCT03866772 368 379 B-Condition
presentation NCT03866772 380 392 I-Condition

- NCT03866772 395 396 O
multiple NCT03866772 398 406 B-Eq-Comparison
pregnancy NCT03866772 407 416 B-Condition|Condition

- NCT03866772 419 420 I-Condition
pre NCT03866772 422 425 O
- NCT03866772 426 427 O
eclampsia NCT03866772 428 437 I-Condition
with NCT03866772 438 442 O
severe NCT03866772 443 449 O
features NCT03866772 450 458 B-Modifier

- NCT03866772 461 462 O
oligohydramnios NCT03866772 464 479 B-Condition
( NCT03866772 480 481 O
Maximal NCT03866772 482 489 B-Observation
vertical NCT03866772 490 498 I-Observation
pocket NCT03866772 499 505 I-Observation
≤ NCT03866772 506 507 B-Eq-Comparison
2 NCT03866772 508 509 I-Eq-Comparison
) NCT03866772 510 511 O

- NCT03866772 515 516 O
estimated NCT03866772 518 527 B-Modifier
fetal NCT03866772 528 533 B-Family-Member___Family-Member-Type:child
weight NCT03866772 534 540 B-Observation
< NCT03866772 541 542 B-Eq-Comparison
10 NCT03866772 543 545 I-Eq-Comparison
% NCT03866772 546 547 O
percentile NCT03866772 548 558 I-Eq-Comparison

- NCT03866772 561 562 O
any NCT03866772 564 567 O
contraindication NCT03866772 568 584 B-Contraindication
to NCT03866772 585 587 O
Vaginal NCT03866772 588 595 B-Procedure
delivery NCT03866772 596 604 I-Procedure

Inclusion NCT03866564 0 9 O
Criteria NCT03866564 10 18 O
: NCT03866564 19 20 O

- NCT03866564 24 25 O
Age NCT03866564 27 30 B-Age
24 NCT03866564 31 33 B-Eq-Comparison
- NCT03866564 34 35 I-Eq-Comparison
55 NCT03866564 36 38 O

- NCT03866564 42 43 O
Former NCT03866564 45 51 B-Eq-Comparison
professional NCT03866564 52 64 B-Observation
football NCT03866564 65 73 I-Observation
play NCT03866564 74 78 I-Observation
from NCT03866564 79 83 O
1960 NCT03866564 84 88 B-Eq-Comparison
to NCT03866564 89 91 I-Eq-Comparison
present NCT03866564 92 99 I-Eq-Comparison
. NCT03866564 99 100 O

- NCT03866564 104 105 O
Prior NCT03866564 107 112 B-Eq-Comparison
completed NCT03866564 113 122 O
the NCT03866564 123 126 O
first NCT03866564 127 132 B-Eq-Comparison
Health NCT03866564 133 139 B-Observation
and NCT03866564 140 143 I-Observation
Wellness NCT03866564 144 152 I-Observation
Questionnaire NCT03866564 153 166 I-Observation
( NCT03866564 167 168 O
Q1 NCT03866564 169 171 B-Observation
) NCT03866564 172 173 O

- NCT03866564 177 178 O
" NCT03866564 180 181 O
Healthy NCT03866564 181 188 O
" NCT03866564 188 189 O
subjects NCT03866564 190 198 O
: NCT03866564 199 200 O
ability NCT03866564 201 208 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866564 209 211 I-Assertion___Assertion-Type-Value:hypothetical
give NCT03866564 212 216 O
informed NCT03866564 217 225 O
consent NCT03866564 226 233 O
, NCT03866564 234 235 O
comply NCT03866564 236 242 O
with NCT03866564 243 247 O
study NCT03866564 248 253 O
procedures NCT03866564 254 264 O
, NCT03866564 265 266 O
and NCT03866564 267 270 O
have NCT03866564 271 275 O
a NCT03866564 276 277 O
Telephone NCT03866564 278 287 B-Observation
- NCT03866564 288 289 I-Observation
Montreal NCT03866564 290 298 I-Observation
Cognitive NCT03866564 299 308 I-Observation
Assessment NCT03866564 309 319 I-Observation
( NCT03866564 320 321 O
T NCT03866564 322 323 B-Observation
- NCT03866564 324 325 I-Observation
MoCA NCT03866564 326 330 I-Observation
) NCT03866564 331 332 O
score NCT03866564 333 338 O
of NCT03866564 339 341 O
> NCT03866564 342 343 B-Eq-Comparison
20 NCT03866564 344 346 I-Eq-Comparison
. NCT03866564 346 347 O

- NCT03866564 351 352 O
" NCT03866564 354 355 O
Afflicted NCT03866564 355 364 O
" NCT03866564 364 365 O
participants NCT03866564 366 378 O
: NCT03866564 379 380 O
must NCT03866564 381 385 O
meet NCT03866564 386 390 O
criteria NCT03866564 391 399 O
for NCT03866564 400 403 O
at NCT03866564 404 406 B-Eq-Comparison
least NCT03866564 407 412 I-Eq-Comparison
one NCT03866564 413 416 I-Eq-Comparison
of NCT03866564 417 419 O
the NCT03866564 420 423 B-Criteria-Count
following NCT03866564 424 433 I-Criteria-Count
subjective NCT03866564 434 444 B-Condition
afflictions NCT03866564 445 456 I-Condition
based NCT03866564 457 462 O
on NCT03866564 463 465 O
Q1 NCT03866564 466 468 B-Observation
responses NCT03866564 469 478 O
: NCT03866564 479 480 O
1 NCT03866564 481 482 O
) NCT03866564 483 484 O
Cardiovascular NCT03866564 485 499 B-Condition
Dysfunction NCT03866564 500 511 I-Condition
, NCT03866564 512 513 O
2 NCT03866564 514 515 O
) NCT03866564 516 517 O
Neurocognitive NCT03866564 518 532 B-Condition
Disease NCT03866564 533 540 I-Condition
, NCT03866564 541 542 O
3 NCT03866564 543 544 O
) NCT03866564 545 546 O
Chronic NCT03866564 547 554 B-Modifier
Pain NCT03866564 555 559 B-Condition
, NCT03866564 560 561 O
and NCT03866564 562 565 O
/ NCT03866564 566 567 O
or NCT03866564 568 570 O
4 NCT03866564 571 572 O
) NCT03866564 573 574 O
Sleep NCT03866564 575 580 B-Condition
Apnea NCT03866564 581 586 I-Condition

- NCT03866564 589 590 O
" NCT03866564 592 593 O
Afflicted NCT03866564 593 602 O
" NCT03866564 602 603 O
participants NCT03866564 604 616 O
must NCT03866564 617 621 O
be NCT03866564 622 624 O
able NCT03866564 625 629 O
to NCT03866564 630 632 O
give NCT03866564 633 637 O
informed NCT03866564 638 646 O
consent NCT03866564 647 654 O
or NCT03866564 655 657 O
have NCT03866564 658 662 O
a NCT03866564 663 664 O
legal NCT03866564 665 670 O
guardian NCT03866564 671 679 O
present NCT03866564 680 687 O
to NCT03866564 688 690 O
provide NCT03866564 691 698 O
informed NCT03866564 699 707 O
consent NCT03866564 708 715 O
( NCT03866564 716 717 O
if NCT03866564 718 720 O
participants NCT03866564 721 733 O
demonstrate NCT03866564 734 745 O
on NCT03866564 746 748 O
T NCT03866564 749 750 B-Observation
- NCT03866564 751 752 I-Observation
MoCA NCT03866564 753 757 I-Observation
score NCT03866564 758 763 B-Eq-Comparison
< NCT03866564 764 765 I-Eq-Comparison
19 NCT03866564 766 768 I-Eq-Comparison
) NCT03866564 769 770 O
and NCT03866564 771 774 O
to NCT03866564 775 777 O
comply NCT03866564 778 784 O
with NCT03866564 785 789 O
study NCT03866564 790 795 O
procedures NCT03866564 796 806 O
. NCT03866564 806 807 O

Exclusion NCT03866564 809 818 O
Criteria NCT03866564 819 827 O
: NCT03866564 828 829 O

- NCT03866564 833 834 O
Prior NCT03866564 836 841 B-Eq-Comparison
metallic NCT03866564 842 850 B-Procedure
device NCT03866564 851 857 I-Procedure
implants NCT03866564 858 866 I-Procedure
such NCT03866564 867 871 O
as NCT03866564 872 874 O
cardiac NCT03866564 875 882 B-Procedure
pacemakers NCT03866564 883 893 I-Procedure
/ NCT03866564 894 895 B-Or
defibrillators NCT03866564 896 910 B-Procedure
or NCT03866564 911 913 B-Or
perfusion NCT03866564 914 923 B-Procedure
pumps NCT03866564 924 929 I-Procedure
that NCT03866564 930 934 O
can NCT03866564 935 938 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03866564 938 941 O
be NCT03866564 942 944 O
removed NCT03866564 945 952 B-Negation
. NCT03866564 952 953 O

- NCT03866564 957 958 O
Ferromagnetic NCT03866564 960 973 B-Procedure
implants NCT03866564 974 982 I-Procedure
or NCT03866564 983 985 B-Or
objects NCT03866564 986 993 B-Procedure
that NCT03866564 994 998 O
can NCT03866564 999 1002 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03866564 1002 1005 O
be NCT03866564 1006 1008 O
removed NCT03866564 1009 1016 B-Negation
such NCT03866564 1017 1021 O
as NCT03866564 1022 1024 O
aneurysm NCT03866564 1025 1033 B-Procedure
clips NCT03866564 1034 1039 I-Procedure|Procedure
, NCT03866564 1040 1041 O
surgical NCT03866564 1042 1050 B-Procedure
clips NCT03866564 1051 1056 O
, NCT03866564 1057 1058 O
prostheses NCT03866564 1059 1069 B-Procedure
, NCT03866564 1070 1071 O
artificial NCT03866564 1072 1082 B-Procedure
hearts NCT03866564 1083 1089 I-Procedure
, NCT03866564 1090 1091 O
valves NCT03866564 1092 1098 B-Procedure
with NCT03866564 1099 1103 O
steel NCT03866564 1104 1109 B-Modifier
parts NCT03866564 1110 1115 I-Modifier
, NCT03866564 1116 1117 O
metal NCT03866564 1118 1123 B-Condition
fragments NCT03866564 1124 1133 I-Condition
, NCT03866564 1134 1135 O
shrapnel NCT03866564 1136 1144 B-Condition
, NCT03866564 1145 1146 O
tattoos NCT03866564 1147 1154 B-Condition
near NCT03866564 1155 1159 B-Modifier
the NCT03866564 1160 1163 I-Modifier
eye NCT03866564 1164 1167 I-Modifier
, NCT03866564 1168 1169 O
or NCT03866564 1170 1172 B-Or|Or
steel NCT03866564 1173 1178 B-Procedure
implants NCT03866564 1179 1187 B-Modifier
or NCT03866564 1188 1190 O
jewelry NCT03866564 1191 1198 B-Modifier

- NCT03866564 1201 1202 O
Body NCT03866564 1204 1208 B-Observation
weight NCT03866564 1209 1215 I-Observation
> NCT03866564 1216 1217 B-Eq-Comparison
450 NCT03866564 1218 1221 I-Eq-Comparison
lbs NCT03866564 1222 1225 I-Eq-Comparison

- NCT03866564 1228 1229 O
Inability NCT03866564 1231 1240 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866564 1241 1243 O
complete NCT03866564 1244 1252 O
the NCT03866564 1253 1256 O
telephone NCT03866564 1257 1266 B-Procedure
screener NCT03866564 1267 1275 I-Procedure

- NCT03866564 1278 1279 I-Observation
Low NCT03866564 1281 1284 O
T NCT03866564 1285 1286 B-Observation
- NCT03866564 1287 1288 O
MoCA NCT03866564 1289 1293 I-Observation
score NCT03866564 1294 1299 O
( NCT03866564 1300 1301 O
< NCT03866564 1303 1304 B-Eq-Comparison
20 NCT03866564 1305 1307 I-Eq-Comparison
) NCT03866564 1308 1309 O
and NCT03866564 1310 1313 O
absence NCT03866564 1314 1321 O
of NCT03866564 1322 1324 O
an NCT03866564 1325 1327 O
available NCT03866564 1328 1337 O
legal NCT03866564 1338 1343 O
guardian NCT03866564 1344 1352 O
who NCT03866564 1353 1356 O
can NCT03866564 1357 1360 O
accompany NCT03866564 1361 1370 O
the NCT03866564 1371 1374 O
participant NCT03866564 1375 1386 O
through NCT03866564 1387 1394 O
all NCT03866564 1395 1398 O
phases NCT03866564 1399 1405 O
of NCT03866564 1406 1408 O
the NCT03866564 1409 1412 O
study NCT03866564 1413 1418 B-Study
. NCT03866564 1418 1419 O

- NCT03866564 1423 1424 O
Significant NCT03866564 1426 1437 O
behavioral NCT03866564 1438 1448 B-Modifier
or NCT03866564 1449 1451 B-Or
functional NCT03866564 1452 1462 B-Modifier
disability NCT03866564 1463 1473 B-Condition
due NCT03866564 1474 1477 O
to NCT03866564 1478 1480 O
cognitive NCT03866564 1481 1490 B-Condition
impairment NCT03866564 1491 1501 I-Condition

Inclusion NCT03869125 0 9 O
Criteria NCT03869125 10 18 O
: NCT03869125 19 20 O

- NCT03869125 24 25 O
Obstructive NCT03869125 27 38 B-Condition
sleep NCT03869125 39 44 I-Condition
apnoea NCT03869125 45 51 I-Condition
syndrome NCT03869125 52 60 I-Condition

Exclusion NCT03869125 61 70 O
Criteria NCT03869125 71 79 O
: NCT03869125 80 81 O

- NCT03869125 85 86 O
Non NCT03869125 88 91 B-Assertion___Assertion-Type-Value:hypothetical
- NCT03869125 92 93 I-Assertion___Assertion-Type-Value:hypothetical
compliance NCT03869125 94 104 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03869125 105 107 O
patients NCT03869125 108 116 O
with NCT03869125 117 121 O
blood NCT03869125 122 127 B-Procedure
pressure NCT03869125 128 136 I-Procedure
monitoring NCT03869125 137 147 I-Procedure

Inclusion NCT03864367 0 9 O
Criteria NCT03864367 10 18 O
: NCT03864367 19 20 O

- NCT03864367 24 25 O
55 NCT03864367 27 29 B-Eq-Comparison
and NCT03864367 30 33 I-Eq-Comparison
older NCT03864367 34 39 I-Age|Eq-Comparison

- NCT03864367 42 43 O
distal NCT03864367 45 51 B-Modifier
femur NCT03864367 52 57 I-Modifier
fracture NCT03864367 58 66 B-Condition

- NCT03864367 69 70 O
able NCT03864367 72 76 B-Condition
to NCT03864367 77 79 I-Condition
walk NCT03864367 80 84 I-Condition
prior NCT03864367 85 90 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864367 91 93 I-Temporal-Connection___Temporal-Connection-Type-Value:before
fracture NCT03864367 94 102 B-Condition

Exclusion NCT03864367 103 112 O
Criteria NCT03864367 113 121 O
: NCT03864367 122 123 O

- NCT03864367 127 128 O
patients NCT03864367 130 138 O
unable NCT03864367 139 145 B-Condition
to NCT03864367 146 148 I-Condition
walk NCT03864367 149 153 I-Condition
without NCT03864367 154 161 B-Negation
any NCT03864367 162 165 O
assistive NCT03864367 166 175 B-Procedure
devices NCT03864367 176 183 I-Procedure
post NCT03864367 184 188 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864367 189 190 O
injury NCT03864367 191 197 B-Condition

- NCT03864367 200 201 O
patients NCT03864367 203 211 O
too NCT03864367 212 215 B-Assertion___Assertion-Type-Value:hypothetical|Negation
medically NCT03864367 216 225 B-Condition
unstable NCT03864367 226 234 O
to NCT03864367 235 237 O
participate NCT03864367 238 249 O
in NCT03864367 250 252 O
physical NCT03864367 253 261 B-Procedure
therapy NCT03864367 262 269 I-Procedure

Inclusion NCT03863795 0 9 O
Criteria NCT03863795 10 18 O
: NCT03863795 19 20 O

- NCT03863795 24 25 O
United NCT03863795 27 33 O
States NCT03863795 34 40 O
( NCT03863795 41 42 O
US NCT03863795 43 45 O
) NCT03863795 46 47 O
adult NCT03863795 48 53 O
smokers NCT03863795 54 61 B-Condition
. NCT03863795 61 62 O

Smokers NCT03863795 64 71 B-Condition
recruited NCT03863795 72 81 O
through NCT03863795 82 89 O
Amazon NCT03863795 90 96 O
Mechanical NCT03863795 97 107 O
Turk NCT03863795 108 112 O

Inclusion NCT03866161 0 9 O
Criteria NCT03866161 10 18 O
: NCT03866161 19 20 O

- NCT03866161 24 25 O
Newly NCT03866161 27 32 B-Eq-Comparison
diagnosed NCT03866161 33 42 O
obstructive NCT03866161 43 54 B-Condition
sleep NCT03866161 55 60 I-Condition
apnea NCT03866161 61 66 I-Condition
indicated NCT03866161 67 76 B-Indication
for NCT03866161 77 80 O
positive NCT03866161 81 89 O
airway NCT03866161 90 96 B-Procedure
pressure NCT03866161 97 105 I-Procedure
therapy NCT03866161 106 113 I-Procedure
, NCT03866161 114 115 O
i. NCT03866161 116 118 O
e. NCT03866161 119 121 O
Apnea NCT03866161 123 128 B-Observation
- NCT03866161 129 130 I-Observation
Hypopnea NCT03866161 131 139 I-Observation
index NCT03866161 140 145 I-Observation
AHI NCT03866161 146 149 B-Observation
> NCT03866161 150 151 B-Eq-Comparison
15 NCT03866161 152 154 I-Eq-Comparison

Exclusion NCT03866161 156 165 O
Criteria NCT03866161 166 174 O
: NCT03866161 175 176 O

- NCT03866161 180 181 O
Psychiatric NCT03866161 183 194 B-Procedure
treatment NCT03866161 195 204 I-Procedure

- NCT03866161 207 208 O
Treatment NCT03866161 210 219 B-Procedure
with NCT03866161 220 224 O
psychoactive NCT03866161 225 237 B-Drug
drugs NCT03866161 238 243 I-Drug

Inclusion NCT03863743 0 9 O
Criteria NCT03863743 10 18 O
: NCT03863743 19 20 O

- NCT03863743 24 25 O
ASA NCT03863743 27 30 B-Condition
grade NCT03863743 31 36 B-Eq-Comparison
I NCT03863743 37 38 I-Eq-Comparison
- NCT03863743 39 40 I-Eq-Comparison
III NCT03863743 41 44 I-Eq-Comparison

- NCT03863743 47 48 O
BMI NCT03863743 50 53 B-Observation
under NCT03863743 54 59 B-Eq-Comparison
36 NCT03863743 60 62 I-Eq-Comparison
kg NCT03863743 63 65 I-Eq-Comparison
/ NCT03863743 66 67 I-Eq-Comparison
m^2 NCT03863743 68 71 I-Eq-Comparison

- NCT03863743 75 76 O
Scheduled NCT03863743 78 87 B-Eq-Comparison
surgery NCT03863743 88 95 B-Procedure
for NCT03863743 96 99 O
primary NCT03863743 100 107 B-Modifier
total NCT03863743 108 113 B-Modifier
hip NCT03863743 114 117 I-Modifier
or NCT03863743 118 120 B-Or
knee NCT03863743 121 125 B-Modifier
replacement NCT03863743 126 137 B-Procedure

- NCT03863743 140 141 O
Age NCT03863743 143 146 B-Age
18 NCT03863743 147 149 B-Eq-Comparison
+ NCT03863743 150 151 O
years NCT03863743 152 157 I-Eq-Comparison

Exclusion NCT03863743 158 167 O
Criteria NCT03863743 168 176 O
: NCT03863743 177 178 O

- NCT03863743 182 183 O
Contraindications NCT03863743 185 202 B-Contraindication
or NCT03863743 203 205 B-Or
failure NCT03863743 206 213 B-Modifier
of NCT03863743 214 216 O
neuraxial NCT03863743 217 226 B-Procedure
anesthesia NCT03863743 227 237 I-Procedure

- NCT03863743 240 241 O
Patients NCT03863743 243 251 O
must NCT03863743 252 256 O
not NCT03863743 257 260 B-Negation
be NCT03863743 261 263 O
outpatient NCT03863743 264 274 B-Encounter
total NCT03863743 275 280 B-Modifier
hip NCT03863743 281 284 I-Modifier
or NCT03863743 285 287 B-Or
knee NCT03863743 288 292 B-Modifier
procedure NCT03863743 293 302 B-Procedure

- NCT03863743 305 306 O
Known NCT03863743 308 313 O
intercurrent NCT03863743 314 326 B-Modifier
UTI NCT03863743 327 330 B-Condition
, NCT03863743 331 332 O
incontinence NCT03863743 333 345 B-Condition
, NCT03863743 346 347 O
or NCT03863743 348 350 B-Or
urinary NCT03863743 351 358 B-Condition
retention NCT03863743 359 368 I-Condition
not NCT03863743 369 372 B-Negation
addressed NCT03863743 373 382 O
by NCT03863743 383 385 O
pre NCT03863743 386 389 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863743 390 391 O
- NCT03863743 393 394 O
operative NCT03863743 395 404 B-Procedure
urologic NCT03863743 405 413 B-Procedure
consultation NCT03863743 414 426 B-Modifier
and NCT03863743 427 430 B-Or
correction NCT03863743 431 441 B-Modifier

- NCT03863743 444 445 O
Pregnancy NCT03863743 447 456 B-Condition

- NCT03863743 459 460 O
Current NCT03863743 462 469 B-Eq-Comparison
nicotine NCT03863743 470 478 B-Drug
, NCT03863743 479 480 O
alcohol NCT03863743 481 488 B-Modifier
or NCT03863743 489 491 B-Or
drug NCT03863743 492 496 B-Modifier
abusers NCT03863743 497 504 B-Condition

- NCT03863743 507 508 O
Pre NCT03863743 510 513 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863743 514 515 O
- NCT03863743 517 518 O
operative NCT03863743 519 528 B-Procedure
narcotic NCT03863743 529 537 B-Drug|Drug
use NCT03863743 538 541 O
( NCT03863743 542 543 O
any NCT03863743 544 547 O
narcotic NCT03863743 548 556 O
consumption NCT03863743 557 568 O
within NCT03863743 569 575 B-Eq-Comparison
3 NCT03863743 576 577 I-Eq-Comparison
days NCT03863743 578 582 I-Eq-Comparison
prior NCT03863743 583 588 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863743 589 591 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03863743 592 599 B-Procedure
) NCT03863743 600 601 O

- NCT03863743 605 606 O
Post NCT03863743 608 612 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03863743 613 614 O
operative NCT03863743 615 624 B-Procedure
parenteral NCT03863743 625 635 B-Modifier
narcotic NCT03863743 636 644 B-Drug
administration NCT03863743 645 659 O

- NCT03863743 662 663 O
Allergy NCT03863743 665 672 B-Allergy
or NCT03863743 673 675 B-Or
intolerance NCT03863743 676 687 B-Condition
to NCT03863743 688 690 O
liposomal NCT03863743 691 700 B-Drug
bupivacaine NCT03863743 701 712 B-Drug|Drug
, NCT03863743 713 714 O
bupivacaine NCT03863743 715 726 O
, NCT03863743 727 728 O
celecoxib NCT03863743 729 738 B-Drug
, NCT03863743 739 740 O
dexamethasone NCT03863743 741 754 B-Drug
and NCT03863743 755 758 B-Or
/ NCT03863743 759 760 I-Or
or NCT03863743 761 763 I-Or
pregabalin NCT03863743 764 774 B-Drug

Minimum NCT03862105 0 7 B-Eq-Comparison
Age NCT03862105 8 11 I-Eq-Comparison
: NCT03862105 12 13 O
18 NCT03862105 14 16 I-Eq-Comparison
Years NCT03862105 17 22 I-Eq-Comparison
Maximum NCT03862105 23 30 B-Eq-Comparison
Age NCT03862105 31 34 I-Eq-Comparison
: NCT03862105 35 36 O
99 NCT03862105 37 39 I-Eq-Comparison
Years NCT03862105 40 45 I-Eq-Comparison
Sex NCT03862105 46 49 O
: NCT03862105 50 51 O
All NCT03862105 52 55 O
Gender NCT03862105 56 62 O
Based NCT03862105 63 68 O
: NCT03862105 69 70 O
No NCT03862105 71 73 O

Criteria NCT03862105 74 82 O
: NCT03862105 83 84 O
Inclusion NCT03862105 85 94 O
Criteria NCT03862105 95 103 O
: NCT03862105 104 105 O

- NCT03862105 109 110 O
Male NCT03862105 112 116 O
or NCT03862105 117 119 B-Or
female NCT03862105 120 126 O
patients NCT03862105 127 135 O
with NCT03862105 136 140 B-And
invasive NCT03862105 141 149 B-Modifier
bladder NCT03862105 150 157 I-Modifier
cancer NCT03862105 158 164 B-Condition
scheduled NCT03862105 165 174 B-Eq-Comparison
for NCT03862105 175 178 O
radical NCT03862105 179 186 B-Procedure
cystectomy NCT03862105 187 197 I-Procedure
at NCT03862105 198 200 O
UNC NCT03862105 201 204 O
within NCT03862105 205 211 B-Eq-Comparison
the NCT03862105 212 215 I-Eq-Comparison
next NCT03862105 216 220 I-Eq-Comparison
30 NCT03862105 221 223 I-Eq-Comparison
days NCT03862105 224 228 I-Eq-Comparison

- NCT03862105 231 232 O
English NCT03862105 234 241 O
- NCT03862105 242 243 O
speaking NCT03862105 244 252 O

- NCT03862105 255 256 O
Ability NCT03862105 258 265 O
to NCT03862105 266 268 O
access NCT03862105 269 275 O
the NCT03862105 276 279 O
Internet NCT03862105 280 288 O
( NCT03862105 289 290 O
either NCT03862105 291 297 O
themselves NCT03862105 298 308 O
or NCT03862105 309 311 O
with NCT03862105 312 316 O
assistance NCT03862105 317 327 O
from NCT03862105 328 332 O
their NCT03862105 333 338 O
caregiver NCT03862105 339 348 O
) NCT03862105 349 350 O

- NCT03862105 354 355 O
Ability NCT03862105 357 364 O
to NCT03862105 365 367 O
read NCT03862105 368 372 O

- NCT03862105 375 376 O
Ability NCT03862105 378 385 O
to NCT03862105 386 388 O
provide NCT03862105 389 396 O
informed NCT03862105 397 405 O
consent NCT03862105 406 413 O
. NCT03862105 413 414 O

Exclusion NCT03862105 416 425 O
Criteria NCT03862105 426 434 O
: NCT03862105 435 436 O

- NCT03862105 440 441 O
Inability NCT03862105 443 452 O
to NCT03862105 453 455 O
read NCT03862105 456 460 O

- NCT03862105 463 464 O
Inability NCT03862105 466 475 O
to NCT03862105 476 478 O
provide NCT03862105 479 486 O
informed NCT03862105 487 495 O
consent NCT03862105 496 503 O

- NCT03862105 506 507 O
Severe NCT03862105 509 515 O
psychiatric NCT03862105 516 527 B-Condition
illness NCT03862105 528 535 I-Condition

- NCT03862105 538 539 O
Cystectomy NCT03862105 541 551 B-Procedure
surgery NCT03862105 552 559 I-Procedure
without NCT03862105 560 567 B-Negation
cancer NCT03862105 568 574 B-Condition
diagnosis NCT03862105 575 584 O

- NCT03862105 587 588 O
Non NCT03862105 590 593 B-Negation
- NCT03862105 594 595 O
English NCT03862105 596 603 O
speaking NCT03862105 604 612 O

Inclusion NCT03862677 0 9 O
Criteria NCT03862677 10 18 O
: NCT03862677 19 20 O

- NCT03862677 24 25 O
Patients NCT03862677 27 35 O
with NCT03862677 36 40 O
( NCT03862677 41 42 O
suspicion NCT03862677 43 52 B-Assertion___Assertion-Type-Value:possible
of NCT03862677 53 55 O
) NCT03862677 56 57 O
primary NCT03862677 58 65 B-Modifier
or NCT03862677 66 68 B-Or
recurrent NCT03862677 69 78 B-Modifier
EOC NCT03862677 79 82 B-Condition
with NCT03862677 83 87 B-And
an NCT03862677 88 90 O
indication NCT03862677 91 101 B-Indication
for NCT03862677 102 105 O
surgery NCT03862677 106 113 B-Procedure
, NCT03862677 114 115 O
chemotherapy NCT03862677 116 128 B-Procedure
and NCT03862677 129 132 B-Or
/ NCT03862677 133 134 I-Or
or NCT03862677 135 137 I-Or
immunotherapy NCT03862677 138 151 B-Procedure
. NCT03862677 151 152 O

- NCT03862677 156 157 O
Age NCT03862677 159 162 B-Age
≥ NCT03862677 163 164 B-Eq-Comparison
18 NCT03862677 165 167 I-Eq-Comparison
years NCT03862677 168 173 I-Eq-Comparison
. NCT03862677 173 174 O

- NCT03862677 178 179 O
WHO NCT03862677 181 184 B-Observation
performance NCT03862677 185 196 I-Observation
status NCT03862677 197 203 I-Observation
0 NCT03862677 204 205 B-Eq-Comparison
- NCT03862677 206 207 I-Eq-Comparison
2 NCT03862677 208 209 O
. NCT03862677 209 210 O

- NCT03862677 214 215 O
Accessible NCT03862677 217 227 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03862677 228 231 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03862677 232 241 B-Procedure
and NCT03862677 242 245 B-And
follow NCT03862677 246 252 B-Encounter
- NCT03862677 253 254 I-Encounter
up NCT03862677 255 257 I-Encounter
. NCT03862677 257 258 O

- NCT03862677 262 263 O
Written NCT03862677 265 272 O
informed NCT03862677 273 281 O
consent NCT03862677 282 289 O
. NCT03862677 289 290 O

Exclusion NCT03862677 292 301 O
Criteria NCT03862677 302 310 O
: NCT03862677 311 312 O

- NCT03862677 316 317 O
Other NCT03862677 319 324 B-Other
active NCT03862677 325 331 B-Eq-Comparison
malignancy NCT03862677 332 342 B-Condition
in NCT03862677 343 345 O
past NCT03862677 346 350 B-Eq-Comparison
5 NCT03862677 351 352 I-Eq-Comparison
years NCT03862677 353 358 I-Eq-Comparison
prior NCT03862677 359 364 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862677 365 367 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03862677 368 373 O
into NCT03862677 374 378 O
the NCT03862677 379 382 O
study NCT03862677 383 388 B-Study
, NCT03862677 389 390 O
except NCT03862677 391 397 B-Exception
for NCT03862677 398 401 O
treated NCT03862677 402 409 B-Procedure
non NCT03862677 410 413 B-Negation
- NCT03862677 414 415 O
melanoma NCT03862677 416 424 B-Modifier
skin NCT03862677 425 429 I-Modifier
cancer NCT03862677 430 436 B-Condition
. NCT03862677 436 437 O

- NCT03862677 441 442 O
Any NCT03862677 444 447 O
known NCT03862677 448 453 O
severe NCT03862677 454 460 O
infection NCT03862677 461 470 B-Condition
like NCT03862677 471 475 O
HIV NCT03862677 476 479 B-Condition
, NCT03862677 480 481 O
hepatitis NCT03862677 482 491 B-Condition
A NCT03862677 492 493 B-Modifier
, NCT03862677 494 495 O
B NCT03862677 496 497 B-Modifier
and NCT03862677 498 501 B-Or
C. NCT03862677 502 504 B-Modifier

- NCT03862677 508 509 O
Receiving NCT03862677 511 520 B-Eq-Comparison
immune NCT03862677 521 527 B-Procedure
suppressive NCT03862677 528 539 I-Procedure
treatment NCT03862677 540 549 I-Procedure
. NCT03862677 549 550 O

- NCT03862677 554 555 O
Medical NCT03862677 557 564 B-Modifier
or NCT03862677 565 567 B-Or
psychological NCT03862677 568 581 B-Modifier
condition NCT03862677 582 591 B-Condition
which NCT03862677 592 597 O
in NCT03862677 598 600 O
the NCT03862677 601 604 O
opinion NCT03862677 605 612 O
of NCT03862677 613 615 O
the NCT03862677 616 619 O
investigator NCT03862677 620 632 O
would NCT03862677 633 638 O
not NCT03862677 639 642 B-Assertion___Assertion-Type-Value:hypothetical|Negation
permit NCT03862677 643 649 O
the NCT03862677 650 653 O
patient NCT03862677 654 661 O
to NCT03862677 662 664 O
complete NCT03862677 665 673 O
the NCT03862677 674 677 O
study NCT03862677 678 683 B-Study
or NCT03862677 684 686 O
sign NCT03862677 687 691 O
meaningful NCT03862677 692 702 O
informed NCT03862677 703 711 O
consent NCT03862677 712 719 O
. NCT03862677 719 720 O

Inclusion NCT03860909 0 9 O
Criteria NCT03860909 10 18 O
: NCT03860909 19 20 O

- NCT03860909 24 25 O
Female NCT03860909 27 33 O
patients NCT03860909 34 42 O
who NCT03860909 43 46 B-And
have NCT03860909 47 51 O
symptoms NCT03860909 52 60 B-Assertion___Assertion-Type-Value:possible
consistent NCT03860909 61 71 O
with NCT03860909 72 76 O
endometriosis NCT03860909 77 90 B-Condition
such NCT03860909 91 95 O
as NCT03860909 96 98 O
pelvic NCT03860909 99 105 B-Modifier
pain NCT03860909 106 110 B-Condition
, NCT03860909 111 112 O
dysmenorrhea NCT03860909 113 125 B-Condition
, NCT03860909 126 127 O
deep NCT03860909 128 132 B-Condition
dyspareunia NCT03860909 133 144 I-Condition
, NCT03860909 145 146 O
and NCT03860909 147 150 B-Or
infertility NCT03860909 151 162 B-Condition

Exclusion NCT03860909 163 172 O
Criteria NCT03860909 173 181 O
: NCT03860909 182 183 O

- NCT03860909 187 188 O
The NCT03860909 190 193 O
common NCT03860909 194 200 O
contraindication NCT03860909 201 217 B-Contraindication
to NCT03860909 218 220 O
MRI NCT03860909 221 224 B-Procedure
, NCT03860909 225 226 O
peacemaker NCT03860909 227 237 B-Procedure
, NCT03860909 238 239 O
metallic NCT03860909 240 248 B-Condition
foreign NCT03860909 249 256 I-Condition
bodies NCT03860909 257 263 I-Condition
, NCT03860909 264 265 O
and NCT03860909 266 269 B-Or
claustrophobia NCT03860909 270 284 B-Condition

Inclusion NCT03869905 0 9 O
Criteria NCT03869905 10 18 O
: NCT03869905 19 20 O

- NCT03869905 24 25 O
Ulcerative NCT03869905 27 37 B-Condition
colitis NCT03869905 38 45 I-Condition
with NCT03869905 46 50 O
confirmed NCT03869905 51 60 O
diagnosis NCT03869905 61 70 O
by NCT03869905 71 73 O
histology NCT03869905 74 83 B-Procedure
and NCT03869905 84 87 B-Or
endoscopy NCT03869905 88 97 B-Procedure
AND NCT03869905 98 101 B-And
in NCT03869905 102 104 O
stable NCT03869905 105 111 O
remission NCT03869905 112 121 B-Condition
for NCT03869905 122 125 O
3 NCT03869905 126 127 B-Eq-Comparison
months NCT03869905 128 134 I-Eq-Comparison
or NCT03869905 135 137 I-Eq-Comparison
more NCT03869905 138 142 I-Eq-Comparison
without NCT03869905 143 150 B-Negation
therapy NCT03869905 151 158 B-Procedure
or NCT03869905 159 161 B-Or
with NCT03869905 162 166 B-And
a NCT03869905 167 168 O
maintenance NCT03869905 169 180 B-Procedure
therapy NCT03869905 181 188 I-Procedure
( NCT03869905 189 190 O
except NCT03869905 191 197 B-Exception
steroids NCT03869905 198 206 B-Drug
and NCT03869905 207 210 B-Or
antibiotics NCT03869905 211 222 B-Drug
for NCT03869905 223 226 O
3 NCT03869905 227 228 B-Eq-Comparison
months NCT03869905 229 235 I-Eq-Comparison
) NCT03869905 236 237 O

- NCT03869905 241 242 O
A NCT03869905 244 245 O
negative NCT03869905 246 254 O
pregnancy NCT03869905 255 264 B-Observation
test NCT03869905 265 269 I-Observation

Exclusion NCT03869905 270 279 O
Criteria NCT03869905 280 288 O
: NCT03869905 289 290 O

- NCT03869905 294 295 O
No NCT03869905 297 299 B-Negation
history NCT03869905 300 307 B-Eq-Comparison
or NCT03869905 308 310 O
diagnosis NCT03869905 311 320 O
of NCT03869905 321 323 O
any NCT03869905 324 327 O
of NCT03869905 328 330 O
the NCT03869905 331 334 O
following NCT03869905 335 344 O
conditions NCT03869905 345 355 B-Condition
: NCT03869905 356 357 O
Chron NCT03869905 358 363 B-Condition
's NCT03869905 363 365 O
disease NCT03869905 366 373 I-Condition
, NCT03869905 374 375 O
bleeding NCT03869905 376 384 B-Condition
disorders NCT03869905 385 394 I-Condition
, NCT03869905 395 396 O
gastrointestinal NCT03869905 397 413 B-Modifier
or NCT03869905 414 416 B-Or
colonic NCT03869905 417 424 B-Modifier
malignancy NCT03869905 425 435 B-Condition
, NCT03869905 436 437 O
Kidney NCT03869905 438 444 B-Condition
disease NCT03869905 445 452 I-Condition
, NCT03869905 453 454 O
including NCT03869905 455 464 O
kidney NCT03869905 465 471 B-Condition
" NCT03869905 472 473 I-Condition
stones NCT03869905 473 479 O
" NCT03869905 479 480 O
or NCT03869905 481 483 B-Or
hypercalcemia NCT03869905 484 497 B-Condition
, NCT03869905 498 499 O
Coagulopathy NCT03869905 500 512 B-Condition
/ NCT03869905 513 514 B-Or
hereditary NCT03869905 515 525 B-Modifier
hemorrhagic NCT03869905 526 537 B-Condition
disorders NCT03869905 538 547 I-Condition
/ NCT03869905 548 549 O
or NCT03869905 550 552 B-Or
receiving NCT03869905 553 562 B-Eq-Comparison
therapeutic NCT03869905 563 574 B-Procedure
doses NCT03869905 575 580 O
of NCT03869905 581 583 O
Coumadin NCT03869905 584 592 B-Drug
or NCT03869905 593 595 B-Or
heparin NCT03869905 596 603 B-Drug
. NCT03869905 603 604 O

- NCT03869905 608 609 O
Ingested NCT03869905 611 619 B-Eq-Comparison
certain NCT03869905 620 627 O
medications NCT03869905 628 639 B-Drug
( NCT03869905 640 641 O
Calcium NCT03869905 642 649 B-Drug
, NCT03869905 650 651 O
Vitamin NCT03869905 652 659 B-Drug
D NCT03869905 660 661 I-Drug
, NCT03869905 662 663 O
fiber NCT03869905 664 669 B-Drug
supplements NCT03869905 670 681 I-Drug
and NCT03869905 682 685 B-Or
Non NCT03869905 686 689 B-Drug
- NCT03869905 690 691 I-Drug
steroidal NCT03869905 692 701 I-Drug
anti NCT03869905 702 706 I-Drug
- NCT03869905 707 708 O
inflammatory NCT03869905 709 721 I-Drug
drugs NCT03869905 722 727 I-Drug
- NCT03869905 728 729 O
NSAIDs NCT03869905 730 736 B-Drug
) NCT03869905 737 738 O
within NCT03869905 739 745 B-Eq-Comparison
30 NCT03869905 746 748 I-Eq-Comparison
days NCT03869905 749 753 I-Eq-Comparison
of NCT03869905 754 756 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03869905 757 762 B-Study
start NCT03869905 763 768 B-Eq-Comparison
. NCT03869905 768 769 O

Inclusion NCT03862703 0 9 O
Criteria NCT03862703 10 18 O
: NCT03862703 19 20 O

1 NCT03862703 24 25 O
. NCT03862703 25 26 O
must NCT03862703 28 32 O
be NCT03862703 33 35 O
at NCT03862703 36 38 B-Eq-Comparison
least NCT03862703 39 44 I-Eq-Comparison
18 NCT03862703 45 47 I-Eq-Comparison
years NCT03862703 48 53 I-Eq-Comparison
old NCT03862703 54 57 B-Age
. NCT03862703 57 58 O

2 NCT03862703 62 63 O
. NCT03862703 63 64 O
fulfil NCT03862703 66 72 O
the NCT03862703 73 76 O
DSM NCT03862703 77 80 O
- NCT03862703 81 82 O
5 NCT03862703 83 84 O
PTSD NCT03862703 85 89 B-Condition
diagnosis NCT03862703 90 99 O
criteria NCT03862703 100 108 O
. NCT03862703 108 109 O

3 NCT03862703 113 114 O
. NCT03862703 114 115 O
be NCT03862703 117 119 O
referred NCT03862703 120 128 O
to NCT03862703 129 131 O
PTSD NCT03862703 132 136 B-Condition
care NCT03862703 137 141 B-Procedure
package NCT03862703 142 149 I-Procedure
treatment NCT03862703 150 159 I-Procedure
( NCT03862703 160 161 O
Danske NCT03862703 162 168 O
regioner NCT03862703 169 177 O
, NCT03862703 178 179 O
pakkeforløb NCT03862703 180 191 O
for NCT03862703 192 195 O
PTSD NCT03862703 196 200 O
, NCT03862703 201 202 O
2017 NCT03862703 203 207 O
) NCT03862703 208 209 O

4 NCT03862703 217 218 O
. NCT03862703 218 219 O
have NCT03862703 221 225 O
access NCT03862703 226 232 O
to NCT03862703 233 235 O
a NCT03862703 236 237 O
smartphone NCT03862703 238 248 O
with NCT03862703 249 253 O
iOS NCT03862703 254 257 O
( NCT03862703 258 259 O
version NCT03862703 260 267 O
10 NCT03862703 268 270 O
or NCT03862703 271 273 O
higher NCT03862703 274 280 O
) NCT03862703 281 282 O
or NCT03862703 283 285 O
Android NCT03862703 286 293 O
( NCT03862703 294 295 O
version NCT03862703 296 303 O
5.0.1 NCT03862703 304 309 O
. NCT03862703 309 310 O
or NCT03862703 312 314 O
higher NCT03862703 315 321 O
) NCT03862703 322 323 O

5 NCT03862703 327 328 O
. NCT03862703 328 329 O
provide NCT03862703 331 338 O
informed NCT03862703 339 347 O
consent NCT03862703 348 355 O
. NCT03862703 355 356 O

Exclusion NCT03862703 358 367 O
Criteria NCT03862703 368 376 O
: NCT03862703 377 378 O

1 NCT03862703 382 383 O
. NCT03862703 383 384 O
suicidal NCT03862703 386 394 B-Condition
risk NCT03862703 395 399 B-Risk

2 NCT03862703 402 403 O
. NCT03862703 403 404 O
ongoing NCT03862703 406 413 B-Eq-Comparison
episode NCT03862703 414 421 O
of NCT03862703 422 424 O
bipolar NCT03862703 425 432 B-Condition
disease NCT03862703 433 440 I-Condition
or NCT03862703 441 443 B-Or
psychotic NCT03862703 444 453 B-Condition
disorder NCT03862703 454 462 I-Condition

3 NCT03862703 465 466 O
. NCT03862703 466 467 O
current NCT03862703 469 476 B-Eq-Comparison
abuse NCT03862703 477 482 B-Condition
of NCT03862703 483 485 O
alcohol NCT03862703 486 493 B-Modifier
or NCT03862703 494 496 B-Or
drugs NCT03862703 497 502 B-Modifier

4 NCT03862703 505 506 O
. NCT03862703 506 507 O
inability NCT03862703 509 518 B-Negation
to NCT03862703 519 521 O
understand NCT03862703 522 532 O
and NCT03862703 533 536 O
/ NCT03862703 537 538 O
or NCT03862703 539 541 O
read NCT03862703 542 546 O
Danish NCT03862703 547 553 O

5 NCT03862703 556 557 O
. NCT03862703 557 558 O
concurrent NCT03862703 560 570 B-Modifier
psychiatric NCT03862703 571 582 I-Modifier
or NCT03862703 583 585 B-Or
psychological NCT03862703 586 599 B-Modifier
treatment NCT03862703 600 609 B-Procedure
of NCT03862703 610 612 I-Exception
PTSD NCT03862703 613 617 B-Condition
outside NCT03862703 618 625 B-Exception
of NCT03862703 626 628 O
MHS NCT03862703 629 632 B-Procedure
- NCT03862703 633 634 I-Procedure
CRD NCT03862703 635 638 I-Procedure
. NCT03862703 638 639 O


Inclusion NCT03863353 0 9 O
Criteria NCT03863353 10 18 O
: NCT03863353 19 20 O

- NCT03863353 24 25 O
Undergoing NCT03863353 27 37 B-Eq-Comparison
an NCT03863353 38 40 O
elective NCT03863353 41 49 B-Modifier
surgical NCT03863353 50 58 B-Procedure
procedure NCT03863353 59 68 I-Procedure
for NCT03863353 69 72 O
which NCT03863353 73 78 O
it NCT03863353 79 81 O
is NCT03863353 82 84 O
expected NCT03863353 85 93 B-Assertion___Assertion-Type-Value:hypothetical
they NCT03863353 94 98 I-Assertion___Assertion-Type-Value:hypothetical
will NCT03863353 99 103 O
receive NCT03863353 104 111 O
a NCT03863353 112 113 O
prescription NCT03863353 114 126 B-Modifier
pain NCT03863353 127 131 B-Condition
medicine NCT03863353 132 140 B-Drug
for NCT03863353 141 144 O
management NCT03863353 145 155 O
of NCT03863353 156 158 O
pain NCT03863353 159 163 B-Condition
during NCT03863353 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recovery NCT03863353 171 179 B-Observation
at NCT03863353 180 182 O
home NCT03863353 183 187 O
. NCT03863353 187 188 O

Exclusion NCT03863353 190 199 O
Criteria NCT03863353 200 208 O
: NCT03863353 209 210 O

- NCT03863353 214 215 O
Undergoing NCT03863353 217 227 B-Eq-Comparison
non NCT03863353 228 231 B-Negation
- NCT03863353 232 233 O
elective NCT03863353 234 242 B-Modifier
procedure NCT03863353 243 252 B-Procedure

- NCT03863353 255 256 O
Cognitive NCT03863353 258 267 B-Condition
impairment NCT03863353 268 278 I-Condition
precluding NCT03863353 279 289 B-Assertion___Assertion-Type-Value:hypothetical|Negation
self NCT03863353 290 294 O
- NCT03863353 295 296 O
reporting NCT03863353 297 306 O
of NCT03863353 307 309 O
pain NCT03863353 310 314 B-Condition

- NCT03863353 317 318 O
Hematologic NCT03863353 320 331 B-Modifier
/ NCT03863353 332 333 B-Or
oncologic NCT03863353 334 343 B-Modifier
condition NCT03863353 344 353 B-Condition

- NCT03863353 356 357 O
Liver NCT03863353 359 364 B-Modifier
of NCT03863353 365 367 I-Modifier
kidney NCT03863353 368 374 I-Modifier
conditions NCT03863353 375 385 B-Condition
precluding NCT03863353 386 396 B-Assertion___Assertion-Type-Value:hypothetical|Negation
usual NCT03863353 397 402 O
analgesic NCT03863353 403 412 B-Drug
prescription NCT03863353 413 425 I-Drug
patters NCT03863353 426 433 I-Drug
( NCT03863353 434 435 O
opioid NCT03863353 436 442 B-Drug
plus NCT03863353 443 447 B-And
a NCT03863353 448 449 O
non NCT03863353 450 453 O
- NCT03863353 454 455 O
opioid NCT03863353 456 462 B-Drug
) NCT03863353 463 464 O

- NCT03863353 468 469 O
Use NCT03863353 471 474 B-Eq-Comparison
of NCT03863353 475 477 O
opioids NCT03863353 478 485 B-Drug
for NCT03863353 486 489 O
prolonged NCT03863353 490 499 B-Modifier
pain NCT03863353 500 504 B-Condition
pre NCT03863353 505 508 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863353 509 510 O
- NCT03863353 512 513 O
operatively NCT03863353 514 525 B-Procedure
( NCT03863353 526 527 O
< NCT03863353 529 530 B-Eq-Comparison
2 NCT03863353 531 532 I-Eq-Comparison
weeks NCT03863353 533 538 I-Eq-Comparison
) NCT03863353 539 540 O

Inclusion NCT03860896 0 9 O
Criteria NCT03860896 10 18 O
: NCT03860896 19 20 O

- NCT03860896 24 25 O
Patients NCT03860896 27 35 O
aged NCT03860896 36 40 B-Age
18 NCT03860896 41 43 B-Eq-Comparison
- NCT03860896 44 45 I-Eq-Comparison
74 NCT03860896 46 48 O
, NCT03860896 49 50 O
receiving NCT03860896 51 60 B-Eq-Comparison
therapy NCT03860896 61 68 B-Procedure
for NCT03860896 69 72 O
active NCT03860896 73 79 B-Eq-Comparison
ulcerative NCT03860896 80 90 B-Condition
colitis NCT03860896 91 98 I-Condition
confirmed NCT03860896 99 108 O
by NCT03860896 109 111 O
Mayo NCT03860896 112 116 B-Observation
Score NCT03860896 117 122 I-Observation
assessment NCT03860896 123 133 I-Observation
, NCT03860896 134 135 O
and NCT03860896 136 139 B-And
evidence NCT03860896 140 148 O
of NCT03860896 149 151 O
colonic NCT03860896 152 159 B-Condition
inflammation NCT03860896 160 172 I-Condition
. NCT03860896 172 173 O

Exclusion NCT03860896 175 184 O
Criteria NCT03860896 185 193 O
: NCT03860896 194 195 O

- NCT03860896 199 200 O
Evidence NCT03860896 202 210 O
of NCT03860896 211 213 O
Crohn NCT03860896 214 219 B-Condition
's NCT03860896 219 221 O
disease NCT03860896 222 229 I-Condition
, NCT03860896 230 231 O
indeterminate NCT03860896 232 245 B-Condition
colitis NCT03860896 246 253 I-Condition
, NCT03860896 254 255 O
or NCT03860896 256 258 B-Or
presence NCT03860896 259 267 O
of NCT03860896 268 270 O
bacterial NCT03860896 271 280 B-Modifier
or NCT03860896 281 283 B-Or
parasitic NCT03860896 284 293 B-Modifier
infection NCT03860896 294 303 B-Condition
. NCT03860896 303 304 O

- NCT03860896 308 309 O
Patients NCT03860896 311 319 O
receiving NCT03860896 320 329 B-Eq-Comparison
biologic NCT03860896 330 338 B-Drug
agents NCT03860896 339 345 I-Drug
and NCT03860896 346 349 B-Or
experimental NCT03860896 350 362 B-Drug
agents NCT03860896 363 369 I-Drug
are NCT03860896 370 373 O
excluded NCT03860896 374 382 B-Negation
. NCT03860896 382 383 O

Inclusion NCT03862924 0 9 O
Criteria NCT03862924 10 18 O
: NCT03862924 19 20 O

- NCT03862924 24 25 O
diagnosed NCT03862924 27 36 O
with NCT03862924 37 41 O
and NCT03862924 42 45 O
engaged NCT03862924 46 53 O
in NCT03862924 54 56 O
care NCT03862924 57 61 O
for NCT03862924 62 65 O
HIV NCT03862924 66 69 B-Condition
( NCT03862924 70 71 O
defined NCT03862924 72 79 O
as NCT03862924 80 82 O
at NCT03862924 83 85 B-Eq-Comparison
least NCT03862924 86 91 I-Eq-Comparison
one NCT03862924 92 95 I-Eq-Comparison
HIV NCT03862924 96 99 O
clinic NCT03862924 100 106 O
medical NCT03862924 107 114 B-Encounter
appointment NCT03862924 115 126 I-Encounter
within NCT03862924 127 133 B-Eq-Comparison
the NCT03862924 134 137 I-Eq-Comparison
past NCT03862924 138 142 I-Eq-Comparison
six NCT03862924 143 146 I-Eq-Comparison
month NCT03862924 147 152 I-Eq-Comparison
period NCT03862924 153 159 I-Eq-Comparison
) NCT03862924 160 161 O

- NCT03862924 165 166 O
at NCT03862924 168 170 B-Eq-Comparison
least NCT03862924 171 176 I-Eq-Comparison
18 NCT03862924 177 179 I-Eq-Comparison
years NCT03862924 180 185 I-Eq-Comparison
of NCT03862924 186 188 O
age NCT03862924 189 192 B-Age

- NCT03862924 195 196 O
smoke NCT03862924 198 203 B-Condition|Observation
at NCT03862924 204 206 B-Eq-Comparison
least NCT03862924 207 212 I-Eq-Comparison
5 NCT03862924 213 214 I-Eq-Comparison
cigarettes NCT03862924 215 225 I-Eq-Comparison
per NCT03862924 226 229 I-Eq-Comparison
day NCT03862924 230 233 I-Eq-Comparison
for NCT03862924 234 237 O
longer NCT03862924 238 244 B-Eq-Comparison
than NCT03862924 245 249 I-Eq-Comparison
one NCT03862924 250 253 I-Eq-Comparison
year NCT03862924 254 258 I-Eq-Comparison

- NCT03862924 261 262 O
exhaled NCT03862924 264 271 B-Observation
carbon NCT03862924 272 278 I-Observation
monoxide NCT03862924 279 287 I-Observation
( NCT03862924 288 289 O
CO NCT03862924 290 292 B-Observation
) NCT03862924 293 294 O
level NCT03862924 295 300 O
greater NCT03862924 301 308 B-Eq-Comparison
than NCT03862924 309 313 I-Eq-Comparison
5 NCT03862924 314 315 I-Eq-Comparison
at NCT03862924 316 318 O
BL NCT03862924 319 321 B-Modifier

Exclusion NCT03862924 322 331 O
Criteria NCT03862924 332 340 O
: NCT03862924 341 342 O

- NCT03862924 346 347 O
intention NCT03862924 349 358 B-Assertion___Assertion-Type-Value:intention
to NCT03862924 359 361 I-Assertion___Assertion-Type-Value:intention
quit NCT03862924 362 366 B-Condition
smoking NCT03862924 367 374 I-Condition
in NCT03862924 375 377 O
the NCT03862924 378 381 O
next NCT03862924 382 386 B-Eq-Comparison
30 NCT03862924 387 389 I-Eq-Comparison
days NCT03862924 390 394 I-Eq-Comparison

- NCT03862924 397 398 O
currently NCT03862924 400 409 B-Eq-Comparison
using NCT03862924 410 415 I-Eq-Comparison
pharmacotherapy NCT03862924 416 431 B-Procedure
for NCT03862924 432 435 O
smoking NCT03862924 436 443 B-Procedure
cessation NCT03862924 444 453 I-Procedure

- NCT03862924 456 457 O
currently NCT03862924 459 468 B-Eq-Comparison
using NCT03862924 469 474 I-Eq-Comparison
electronic NCT03862924 475 485 B-Modifier
cigarettes NCT03862924 486 496 B-Drug
more NCT03862924 497 501 B-Eq-Comparison
than NCT03862924 502 506 I-Eq-Comparison
2 NCT03862924 507 508 I-Eq-Comparison
days NCT03862924 509 513 I-Eq-Comparison
/ NCT03862924 514 515 I-Eq-Comparison
week NCT03862924 516 520 I-Eq-Comparison

- NCT03862924 523 524 O
unstable NCT03862924 526 534 O
medical NCT03862924 535 542 B-Modifier
or NCT03862924 543 545 B-Or
psychiatric NCT03862924 546 557 B-Modifier
condition NCT03862924 558 567 B-Condition
( NCT03862924 568 569 O
defined NCT03862924 570 577 O
as NCT03862924 578 580 O
hospitalization NCT03862924 581 596 B-Encounter
) NCT03862924 597 598 O

- NCT03862924 602 603 O
medical NCT03862924 605 612 O
contraindications NCT03862924 613 630 B-Contraindication
to NCT03862924 631 633 O
nicotine NCT03862924 634 642 B-Drug
( NCT03862924 643 644 O
unstable NCT03862924 645 653 O
angina NCT03862924 654 660 B-Condition
, NCT03862924 661 662 O
uncontrolled NCT03862924 663 675 B-Modifier
hypertension NCT03862924 676 688 B-Condition
, NCT03862924 689 690 O
or NCT03862924 691 693 B-Or
recent NCT03862924 694 700 B-Eq-Comparison
cardiovascular NCT03862924 701 715 B-Condition
event NCT03862924 716 721 I-Condition
, NCT03862924 722 723 O
including NCT03862924 724 733 O
hospitalization NCT03862924 734 749 B-Encounter
) NCT03862924 750 751 O

- NCT03862924 755 756 O
psychotic NCT03862924 758 767 B-Condition
symptoms NCT03862924 768 776 B-Assertion___Assertion-Type-Value:possible

- NCT03862924 779 780 O
substance NCT03862924 782 791 B-Condition
use NCT03862924 792 795 I-Condition
disorder NCT03862924 796 804 I-Condition
other NCT03862924 805 810 B-Exception
than NCT03862924 811 815 I-Exception
nicotine NCT03862924 816 824 B-Condition
dependence NCT03862924 825 835 I-Condition

- NCT03862924 838 839 I-Eq-Comparison
past NCT03862924 841 845 B-Eq-Comparison
- NCT03862924 846 847 O
month NCT03862924 848 853 I-Eq-Comparison
suicidal NCT03862924 854 862 B-Condition
ideation NCT03862924 863 871 I-Condition
or NCT03862924 872 874 B-Or
past NCT03862924 875 879 B-Eq-Comparison
- NCT03862924 880 881 I-Eq-Comparison
year NCT03862924 882 886 I-Eq-Comparison
suicide NCT03862924 887 894 B-Condition
attempt NCT03862924 895 902 I-Condition

- NCT03862924 905 906 O
pregnant NCT03862924 908 916 B-Condition
or NCT03862924 917 919 B-Or
nursing NCT03862924 920 927 B-Condition
. NCT03862924 927 928 O

Inclusion NCT03861975 0 9 O
Criteria NCT03861975 10 18 O
: NCT03861975 19 20 O

- NCT03861975 24 25 O
Participants NCT03861975 27 39 O
must NCT03861975 40 44 O
have NCT03861975 45 49 O
histologically NCT03861975 50 64 B-Modifier
or NCT03861975 65 67 B-Or
cytologically NCT03861975 68 81 B-Procedure
confirmed NCT03861975 82 91 O
invasive NCT03861975 92 100 B-Modifier
or NCT03861975 101 103 B-Or
in NCT03861975 104 106 B-Modifier
- NCT03861975 107 108 I-Modifier
situ NCT03861975 109 113 I-Modifier
carcinoma NCT03861975 114 123 B-Condition
of NCT03861975 124 126 O
the NCT03861975 127 130 O
breast NCT03861975 131 137 B-Modifier
and NCT03861975 138 141 B-And
will NCT03861975 142 146 B-Eq-Comparison
undergo NCT03861975 147 154 I-Eq-Comparison
unilateral NCT03861975 155 165 B-Modifier
breast NCT03861975 166 172 I-Modifier
cancer NCT03861975 173 179 B-Condition
surgery NCT03861975 180 187 B-Procedure

- NCT03861975 190 191 O
Willingness NCT03861975 193 204 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 205 207 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03861975 208 216 O
SEI NCT03861975 217 220 B-Observation
- NCT03861975 221 222 I-Observation
BCLE NCT03861975 223 227 I-Observation
Questionnaire NCT03861975 228 241 I-Observation

- NCT03861975 244 245 O
Age NCT03861975 247 250 B-Age
> NCT03861975 251 252 B-Eq-Comparison
18 NCT03861975 253 255 I-Eq-Comparison
years NCT03861975 256 261 I-Eq-Comparison
. NCT03861975 261 262 O

- NCT03861975 266 267 O
Ability NCT03861975 269 276 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 277 279 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03861975 280 290 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03861975 291 294 B-And
the NCT03861975 295 298 O
willingness NCT03861975 299 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 311 313 O
verbally NCT03861975 314 322 O
consent NCT03861975 323 330 O
to NCT03861975 331 333 O
the NCT03861975 334 337 O
trial NCT03861975 338 343 B-Study

Exclusion NCT03861975 344 353 O
Criteria NCT03861975 354 362 O
: NCT03861975 363 364 O

- NCT03861975 368 369 O
History NCT03861975 371 378 B-Eq-Comparison
of NCT03861975 379 381 O
primary NCT03861975 382 389 B-Modifier
lymphedema NCT03861975 390 400 B-Condition
. NCT03861975 400 401 O

- NCT03861975 405 406 O
Any NCT03861975 408 411 O
patient NCT03861975 412 419 O
with NCT03861975 420 424 O
a NCT03861975 425 426 O
current NCT03861975 427 434 B-Eq-Comparison
case NCT03861975 435 439 O
of NCT03861975 440 442 O
cellulitis NCT03861975 443 453 B-Condition
. NCT03861975 453 454 O

- NCT03861975 458 459 O
Participants NCT03861975 461 473 O
with NCT03861975 474 478 O
known NCT03861975 479 484 O
brain NCT03861975 485 490 B-Modifier
metastases NCT03861975 491 501 B-Condition
should NCT03861975 502 508 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861975 509 511 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03861975 512 520 B-Negation
from NCT03861975 521 525 O
this NCT03861975 526 530 O
clinical NCT03861975 531 539 B-Study
trial NCT03861975 540 545 I-Study
because NCT03861975 546 553 O
of NCT03861975 554 556 O
their NCT03861975 557 562 O
poor NCT03861975 563 567 B-Condition
prognosis NCT03861975 568 577 I-Condition
and NCT03861975 578 581 B-And
because NCT03861975 582 589 O
they NCT03861975 590 594 O
often NCT03861975 595 600 B-Assertion___Assertion-Type-Value:hypothetical
develop NCT03861975 601 608 I-Assertion___Assertion-Type-Value:hypothetical
progressive NCT03861975 609 620 B-Modifier
neurologic NCT03861975 621 631 B-Condition
dysfunction NCT03861975 632 643 I-Condition
that NCT03861975 644 648 O
would NCT03861975 649 654 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03861975 655 663 O
the NCT03861975 664 667 O
evaluation NCT03861975 668 678 B-Procedure
of NCT03861975 679 681 O
neurologic NCT03861975 682 692 B-Modifier
and NCT03861975 693 696 B-Or
other NCT03861975 697 702 B-Other
adverse NCT03861975 703 710 B-Condition
events NCT03861975 711 717 I-Condition
. NCT03861975 717 718 O

- NCT03861975 722 723 O
Uncontrolled NCT03861975 725 737 B-Modifier
intercurrent NCT03861975 738 750 B-Condition
illness NCT03861975 751 758 I-Condition
including NCT03861975 759 768 O
, NCT03861975 769 770 O
but NCT03861975 771 774 O
not NCT03861975 775 778 O
limited NCT03861975 779 786 O
to NCT03861975 787 789 O
, NCT03861975 790 791 O
ongoing NCT03861975 792 799 B-Eq-Comparison
or NCT03861975 800 802 B-Or
active NCT03861975 803 809 B-Eq-Comparison
infection NCT03861975 810 819 B-Condition
, NCT03861975 820 821 O
symptomatic NCT03861975 822 833 B-Assertion___Assertion-Type-Value:possible
congestive NCT03861975 834 844 B-Condition
heart NCT03861975 845 850 I-Condition
failure NCT03861975 851 858 I-Condition
, NCT03861975 859 860 O
unstable NCT03861975 861 869 O
angina NCT03861975 870 876 B-Condition
pectoris NCT03861975 877 885 I-Condition
, NCT03861975 886 887 O
cardiac NCT03861975 888 895 B-Condition
arrhythmia NCT03861975 896 906 I-Condition
, NCT03861975 907 908 O
or NCT03861975 909 911 B-Or
psychiatric NCT03861975 912 923 B-Modifier
illness NCT03861975 924 931 B-Condition
/ NCT03861975 932 933 B-Or
social NCT03861975 934 940 B-Observation
situations NCT03861975 941 951 I-Observation
that NCT03861975 952 956 O
would NCT03861975 957 962 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03861975 963 968 O
compliance NCT03861975 969 979 O
with NCT03861975 980 984 O
study NCT03861975 985 990 B-Study
requirements NCT03861975 991 1003 O
. NCT03861975 1003 1004 O

- NCT03861975 1008 1009 O
Participants NCT03861975 1011 1023 O
unable NCT03861975 1024 1030 B-Negation
to NCT03861975 1031 1033 O
abduct NCT03861975 1034 1040 B-Condition
upper NCT03861975 1041 1046 B-Modifier
- NCT03861975 1047 1048 I-Modifier
extremity NCT03861975 1049 1058 I-Modifier
perpendicular NCT03861975 1059 1072 I-Modifier
to NCT03861975 1073 1075 I-Modifier
body NCT03861975 1076 1080 I-Modifier
or NCT03861975 1081 1083 B-Or
to NCT03861975 1084 1086 O
stand NCT03861975 1087 1092 B-Observation
comfortably NCT03861975 1093 1104 O
without NCT03861975 1105 1112 O
aid NCT03861975 1113 1116 O
for NCT03861975 1117 1120 O
several NCT03861975 1121 1128 B-Eq-Comparison
minutes NCT03861975 1129 1136 I-Eq-Comparison
, NCT03861975 1137 1138 O
both NCT03861975 1139 1143 B-Coreference
of NCT03861975 1144 1146 I-Coreference
which NCT03861975 1147 1152 I-Coreference
are NCT03861975 1153 1156 O
necessary NCT03861975 1157 1166 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 1167 1169 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03861975 1170 1177 O
a NCT03861975 1178 1179 O
LymphaTech NCT03861975 1180 1190 B-Procedure
Scan NCT03861975 1191 1195 I-Procedure

Inclusion NCT03861949 0 9 O
Criteria NCT03861949 10 18 O
: NCT03861949 19 20 O

- NCT03861949 24 25 O
adult NCT03861949 27 32 O
patients NCT03861949 33 41 O
of NCT03861949 42 44 O
ASA NCT03861949 45 48 B-Condition
physical NCT03861949 49 57 O
status NCT03861949 58 64 B-Eq-Comparison
I NCT03861949 65 66 I-Eq-Comparison
and NCT03861949 67 70 I-Eq-Comparison
II NCT03861949 71 73 I-Eq-Comparison
undergoing NCT03861949 74 84 B-Eq-Comparison
surgery NCT03861949 85 92 B-Procedure
under NCT03861949 93 98 O
general NCT03861949 99 106 B-Procedure
anaesthesia NCT03861949 107 118 I-Procedure

Exclusion NCT03861949 119 128 O
Criteria NCT03861949 129 137 O
: NCT03861949 138 139 O

- NCT03861949 143 144 O
anticipated NCT03861949 146 157 B-Assertion___Assertion-Type-Value:hypothetical
difficult NCT03861949 158 167 B-Modifier
mask NCT03861949 168 172 B-Procedure
ventilation NCT03861949 173 184 I-Procedure
/ NCT03861949 185 186 B-Or
intubation NCT03861949 187 197 B-Procedure

- NCT03861949 200 201 O
individuals NCT03861949 203 214 O
with NCT03861949 215 219 O
significant NCT03861949 220 231 O
cardiorespiratory NCT03861949 232 249 B-Modifier
or NCT03861949 250 252 B-Or
cerebrovascular NCT03861949 253 268 B-Modifier
disease NCT03861949 269 276 B-Condition

- NCT03861949 279 280 O
pregnant NCT03861949 282 290 B-Condition
ladies NCT03861949 291 297 O

- NCT03861949 300 301 O
patient NCT03861949 303 310 O
with NCT03861949 311 315 O
history NCT03861949 316 323 B-Eq-Comparison
of NCT03861949 324 326 O
epilepsy NCT03861949 327 335 B-Condition

- NCT03861949 338 339 O
body NCT03861949 341 345 B-Observation
mass NCT03861949 346 350 I-Observation
index NCT03861949 351 356 I-Observation
> NCT03861949 357 358 B-Eq-Comparison
25 NCT03861949 359 361 I-Eq-Comparison
kg NCT03861949 362 364 I-Eq-Comparison
/ NCT03861949 365 366 I-Eq-Comparison
m2 NCT03861949 367 369 I-Eq-Comparison

- NCT03861949 372 373 O
hemoglobin NCT03861949 375 385 B-Observation
< NCT03861949 386 387 B-Eq-Comparison
8 NCT03861949 388 389 I-Eq-Comparison
gm NCT03861949 390 392 I-Eq-Comparison
/ NCT03861949 393 394 I-Eq-Comparison
dL NCT03861949 395 397 I-Eq-Comparison

- NCT03861949 400 401 O
patients NCT03861949 403 411 O
who NCT03861949 412 415 O
were NCT03861949 416 420 B-Eq-Comparison
non NCT03861949 421 424 B-Negation
- NCT03861949 425 426 O
ambulant NCT03861949 427 435 B-Condition
for NCT03861949 436 439 O
> NCT03861949 440 441 B-Eq-Comparison
24 NCT03861949 442 444 I-Eq-Comparison
h NCT03861949 445 446 I-Eq-Comparison
, NCT03861949 447 448 O
having NCT03861949 449 455 B-And
SpO2 NCT03861949 456 460 B-Observation
< NCT03861949 461 462 B-Eq-Comparison
97 NCT03861949 463 465 I-Eq-Comparison
% NCT03861949 466 467 O
while NCT03861949 468 473 B-Temporal-Connection___Temporal-Connection-Type-Value:during
breathing NCT03861949 474 483 B-Observation
in NCT03861949 484 486 O
room NCT03861949 487 491 B-Modifier
air NCT03861949 492 495 I-Modifier

- NCT03861949 498 499 O
phobia NCT03861949 501 507 B-Condition
to NCT03861949 508 510 O
facemask NCT03861949 511 519 B-Modifier
. NCT03861949 519 520 O

Inclusion NCT03867929 0 9 O
Criteria NCT03867929 10 18 O
: NCT03867929 19 20 O

- NCT03867929 24 25 O
presence NCT03867929 27 35 B-Eq-Comparison
of NCT03867929 36 38 O
erectile NCT03867929 39 47 B-Condition
dysfunction NCT03867929 48 59 I-Condition

Exclusion NCT03867929 60 69 O
Criteria NCT03867929 70 78 O
: NCT03867929 79 80 O

- NCT03867929 84 85 O
Presence NCT03867929 87 95 B-Eq-Comparison
of NCT03867929 96 98 O
uncontrolled NCT03867929 99 111 B-Modifier
diabetes NCT03867929 112 120 B-Condition
mellitus NCT03867929 121 129 I-Condition
, NCT03867929 130 131 O

- NCT03867929 135 136 O
Presence NCT03867929 138 146 B-Eq-Comparison
of NCT03867929 147 149 O
uncontrolled NCT03867929 150 162 B-Modifier
hypertension NCT03867929 163 175 B-Condition
, NCT03867929 176 177 O

- NCT03867929 181 182 O
Presence NCT03867929 184 192 B-Eq-Comparison
of NCT03867929 193 195 O
uncontrolled NCT03867929 196 208 B-Modifier
lipid NCT03867929 209 214 B-Condition
metabolism NCT03867929 215 225 I-Condition
disorders NCT03867929 226 235 I-Condition
, NCT03867929 236 237 O

- NCT03867929 241 242 O
Presence NCT03867929 244 252 B-Eq-Comparison
of NCT03867929 253 255 O
neurological NCT03867929 256 268 B-Condition
diseases NCT03867929 269 277 I-Condition
, NCT03867929 278 279 O

- NCT03867929 283 284 O
Presence NCT03867929 286 294 B-Eq-Comparison
of NCT03867929 295 297 O
heamatological NCT03867929 298 312 B-Condition
diseases NCT03867929 313 321 I-Condition
, NCT03867929 322 323 O

- NCT03867929 327 328 O
Urinary NCT03867929 330 337 B-Condition
tract NCT03867929 338 343 I-Condition
infection NCT03867929 344 353 I-Condition
, NCT03867929 354 355 O

- NCT03867929 359 360 O
Diagnosis NCT03867929 362 371 O
of NCT03867929 372 374 O
any NCT03867929 375 378 O
malignencies NCT03867929 379 391 B-Condition
, NCT03867929 392 393 O

- NCT03867929 397 398 O
Chronic NCT03867929 400 407 B-Modifier
kidney NCT03867929 408 414 B-Condition
failure NCT03867929 415 422 I-Condition
, NCT03867929 423 424 O

- NCT03867929 428 429 O
Presence NCT03867929 431 439 B-Eq-Comparison
of NCT03867929 440 442 O
metabolic NCT03867929 443 452 B-Condition
syndrome NCT03867929 453 461 I-Condition
, NCT03867929 462 463 O

- NCT03867929 467 468 O
Presence NCT03867929 470 478 B-Eq-Comparison
of NCT03867929 479 481 O
psychiatric NCT03867929 482 493 B-Condition
diseases NCT03867929 494 502 I-Condition
and NCT03867929 503 506 B-Or
/ NCT03867929 507 508 I-Or
or NCT03867929 509 511 I-Or
medical NCT03867929 512 519 B-Procedure
treatment NCT03867929 520 529 I-Procedure
, NCT03867929 530 531 O

- NCT03867929 535 536 O
Smoking NCT03867929 538 545 B-Condition
, NCT03867929 546 547 O

- NCT03867929 551 552 O
History NCT03867929 554 561 B-Eq-Comparison
of NCT03867929 562 564 O
pelvic NCT03867929 565 571 B-Procedure
surgery NCT03867929 572 579 I-Procedure|Procedure
, NCT03867929 580 581 O
cardiac NCT03867929 582 589 B-Procedure
surgery NCT03867929 590 597 O
and NCT03867929 598 601 B-Or
pelvic NCT03867929 602 608 B-Modifier
radiotherapy NCT03867929 609 621 B-Procedure

Inclusion NCT03865680 0 9 O
Criteria NCT03865680 10 18 O
: NCT03865680 19 20 O

- NCT03865680 24 25 O
Healthy NCT03865680 27 34 B-Condition
children NCT03865680 35 43 O
with NCT03865680 44 48 B-And
no NCT03865680 49 51 B-Negation
systemic NCT03865680 52 60 B-Modifier
diseases NCT03865680 61 69 B-Condition
. NCT03865680 69 70 O

- NCT03865680 74 75 O
High NCT03865680 77 81 O
caries NCT03865680 82 88 B-Condition
risk NCT03865680 89 93 B-Risk
children NCT03865680 94 102 O
with NCT03865680 103 107 B-And
the NCT03865680 108 111 O
presence NCT03865680 112 120 O
of NCT03865680 121 123 O
at NCT03865680 124 126 B-Eq-Comparison
least NCT03865680 127 132 I-Eq-Comparison
one NCT03865680 133 136 I-Eq-Comparison
visible NCT03865680 137 144 B-Modifier
active NCT03865680 145 151 B-Eq-Comparison
WSL NCT03865680 152 155 B-Condition
in NCT03865680 156 158 O
primary NCT03865680 159 166 B-Modifier
teeth NCT03865680 167 172 I-Modifier
with NCT03865680 173 177 B-And
ICDAS NCT03865680 178 183 B-Observation
II NCT03865680 184 186 I-Observation
score NCT03865680 187 192 I-Observation
of NCT03865680 193 195 O
1 NCT03865680 196 197 B-Eq-Comparison
, NCT03865680 198 199 O
2 NCT03865680 200 201 O
or NCT03865680 202 204 I-Eq-Comparison
3 NCT03865680 205 206 I-Eq-Comparison

- NCT03865680 210 211 O
Completion NCT03865680 213 223 O
of NCT03865680 224 226 O
a NCT03865680 227 228 O
parental NCT03865680 229 237 O
consent NCT03865680 238 245 O
to NCT03865680 246 248 O
participate NCT03865680 249 260 O
in NCT03865680 261 263 O
the NCT03865680 264 267 O
study NCT03865680 268 273 O
. NCT03865680 273 274 O

Exclusion NCT03865680 276 285 O
Criteria NCT03865680 286 294 O
: NCT03865680 295 296 O

- NCT03865680 300 301 O
Selected NCT03865680 303 311 B-Modifier
tooth NCT03865680 312 317 I-Modifier
with NCT03865680 318 322 O
cavitated NCT03865680 323 332 B-Condition
lesion NCT03865680 333 339 I-Condition
. NCT03865680 339 340 O

- NCT03865680 344 345 O
Selected NCT03865680 347 355 B-Modifier
tooth NCT03865680 356 361 I-Modifier
with NCT03865680 362 366 O
enamel NCT03865680 367 373 B-Condition
defects NCT03865680 374 381 I-Condition
. NCT03865680 381 382 O

- NCT03865680 386 387 O
Participants NCT03865680 389 401 O
allergic NCT03865680 402 410 B-Allergy
to NCT03865680 411 413 O
milk NCT03865680 414 418 O
products NCT03865680 419 427 O
. NCT03865680 427 428 O

Inclusion NCT03869086 0 9 O
Criteria NCT03869086 10 18 O
: NCT03869086 19 20 O

- NCT03869086 24 25 O
BMI NCT03869086 27 30 B-Observation
> NCT03869086 31 32 B-Eq-Comparison
= NCT03869086 34 35 I-Eq-Comparison
25 NCT03869086 36 38 I-Eq-Comparison
kg NCT03869086 39 41 I-Eq-Comparison
/ NCT03869086 42 43 I-Eq-Comparison
m2 NCT03869086 44 46 I-Eq-Comparison

- NCT03869086 49 50 O
Adults NCT03869086 52 58 O
aged NCT03869086 59 63 B-Age
50 NCT03869086 64 66 B-Eq-Comparison
- NCT03869086 67 68 I-Eq-Comparison
80 NCT03869086 69 71 I-Eq-Comparison
years NCT03869086 72 77 I-Eq-Comparison
old NCT03869086 78 81 O

- NCT03869086 84 85 O
Successful NCT03869086 87 97 B-Modifier
biochemical NCT03869086 98 109 I-Modifier
, NCT03869086 110 111 O
haematological NCT03869086 112 126 B-Modifier
, NCT03869086 127 128 O
and NCT03869086 129 132 B-Or
urinalysis NCT03869086 133 143 B-Modifier
assessment NCT03869086 144 154 B-Procedure
at NCT03869086 155 157 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03869086 158 167 B-Study

Exclusion NCT03869086 168 177 O
Criteria NCT03869086 178 186 O
: NCT03869086 187 188 O

- NCT03869086 192 193 O
Current NCT03869086 195 202 B-Eq-Comparison
smokers NCT03869086 203 210 B-Condition
, NCT03869086 211 212 O
or NCT03869086 213 215 B-Or
ex NCT03869086 216 218 B-Eq-Comparison
- NCT03869086 219 220 O
smokers NCT03869086 221 228 B-Condition
ceasing NCT03869086 229 236 O
< NCT03869086 237 238 B-Eq-Comparison
6 NCT03869086 239 240 I-Eq-Comparison
months NCT03869086 241 247 I-Eq-Comparison
ago NCT03869086 248 251 I-Eq-Comparison

- NCT03869086 254 255 O
existing NCT03869086 257 265 B-Eq-Comparison
or NCT03869086 266 268 B-Or
significant NCT03869086 269 280 O
past NCT03869086 281 285 B-Eq-Comparison
medical NCT03869086 286 293 I-Eq-Comparison
history NCT03869086 294 301 I-Eq-Comparison
of NCT03869086 302 304 O
vascular NCT03869086 305 313 B-Condition
disease NCT03869086 314 321 I-Condition
or NCT03869086 322 324 B-Or
medical NCT03869086 325 332 O
conditions NCT03869086 333 343 B-Condition
likely NCT03869086 344 350 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 351 353 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869086 354 360 O
the NCT03869086 361 364 O
study NCT03869086 365 370 B-Study
measures NCT03869086 371 379 O

- NCT03869086 382 383 O
Fructose NCT03869086 385 393 B-Modifier
or NCT03869086 394 396 B-Or
lactose NCT03869086 397 404 B-Modifier
intolerant NCT03869086 405 415 B-Condition
subjects NCT03869086 416 424 O
or NCT03869086 425 427 B-Or
known NCT03869086 428 433 O
allergies NCT03869086 434 443 B-Allergy
to NCT03869086 444 446 O
intervention NCT03869086 447 459 B-Study
treatments NCT03869086 460 470 B-Procedure

- NCT03869086 473 474 O
Those NCT03869086 476 481 O
unprepared NCT03869086 482 492 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 493 495 I-Assertion___Assertion-Type-Value:hypothetical
adhere NCT03869086 496 502 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 503 505 O
dietary NCT03869086 506 513 B-Procedure
instructions NCT03869086 514 526 I-Procedure

- NCT03869086 529 530 O
Parallel NCT03869086 532 540 O
participation NCT03869086 541 554 O
in NCT03869086 555 557 O
another NCT03869086 558 565 B-Other
research NCT03869086 566 574 B-Study
project NCT03869086 575 582 O
involving NCT03869086 583 592 O
dietary NCT03869086 593 600 B-Procedure
intervention NCT03869086 601 613 I-Procedure
and NCT03869086 614 617 B-Or
/ NCT03869086 618 619 I-Or
or NCT03869086 620 622 I-Or
sampling NCT03869086 623 631 B-Procedure
of NCT03869086 632 634 O
biological NCT03869086 635 645 B-Modifier
fluids NCT03869086 646 652 I-Modifier
/ NCT03869086 653 654 B-Or
material NCT03869086 655 663 B-Modifier

- NCT03869086 666 667 O
Those NCT03869086 669 674 O
on NCT03869086 675 677 B-Eq-Comparison
therapeutic NCT03869086 678 689 B-Procedure
diets NCT03869086 690 695 I-Procedure
or NCT03869086 696 698 B-Or
having NCT03869086 699 705 O
experienced NCT03869086 706 717 B-Eq-Comparison
substantial NCT03869086 718 729 O
weight NCT03869086 730 736 B-Condition
loss NCT03869086 737 741 I-Condition
within NCT03869086 742 748 B-Eq-Comparison
2 NCT03869086 749 750 I-Eq-Comparison
months NCT03869086 751 757 I-Eq-Comparison
of NCT03869086 758 760 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03869086 761 770 B-Study
. NCT03869086 770 771 O

- NCT03869086 775 776 O
Those NCT03869086 778 783 O
taking NCT03869086 784 790 B-Eq-Comparison
flavonoid NCT03869086 791 800 B-Drug
, NCT03869086 801 802 O
nitrate NCT03869086 803 810 B-Drug
/ NCT03869086 811 812 B-Or
nitrite NCT03869086 813 820 B-Drug
containing NCT03869086 821 831 I-Drug
or NCT03869086 832 834 B-Or
fish NCT03869086 835 839 B-Modifier
oil NCT03869086 840 843 I-Modifier
containing NCT03869086 844 854 I-Modifier
supplements NCT03869086 855 866 B-Drug
( NCT03869086 867 868 O
and NCT03869086 869 872 B-And
unwilling NCT03869086 873 882 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 883 885 I-Assertion___Assertion-Type-Value:hypothetical
cease NCT03869086 886 891 B-Negation
intake NCT03869086 892 898 B-Coreference
during NCT03869086 899 905 B-Temporal-Connection___Temporal-Connection-Type-Value:during
, NCT03869086 906 907 O
and NCT03869086 908 911 B-And
1 NCT03869086 912 913 B-Eq-Comparison
month NCT03869086 914 919 I-Eq-Comparison
preceding NCT03869086 920 929 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869086 930 933 O
trial NCT03869086 934 939 B-Study
) NCT03869086 940 941 O
or NCT03869086 942 944 B-Or
unwilling NCT03869086 945 954 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 955 957 I-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03869086 958 966 O
existing NCT03869086 967 975 B-Eq-Comparison
intake NCT03869086 976 982 O
of NCT03869086 983 985 O
other NCT03869086 986 991 B-Other
supplements NCT03869086 992 1003 B-Drug
. NCT03869086 1003 1004 O

- NCT03869086 1008 1009 O
Prescribed NCT03869086 1011 1021 O
hypoglycaemic NCT03869086 1022 1035 B-Drug
, NCT03869086 1036 1037 O
anti NCT03869086 1038 1042 B-Drug
- NCT03869086 1043 1044 I-Drug
hypertensive NCT03869086 1045 1057 I-Drug
, NCT03869086 1058 1059 O
vasodilator NCT03869086 1060 1071 B-Drug
or NCT03869086 1072 1074 B-Or
hormone NCT03869086 1075 1082 B-Procedure
replacement NCT03869086 1083 1094 I-Procedure
therapy NCT03869086 1095 1102 I-Procedure
( NCT03869086 1103 1104 O
HRT NCT03869086 1105 1108 B-Procedure
) NCT03869086 1109 1110 O
medication NCT03869086 1111 1121 B-Drug
. NCT03869086 1121 1122 O

- NCT03869086 1126 1127 O
Unsatisfactory NCT03869086 1129 1143 O
biochemical NCT03869086 1144 1155 B-Modifier
, NCT03869086 1156 1157 O
haematological NCT03869086 1158 1172 B-Modifier
or NCT03869086 1173 1175 B-Or|Or
urinary NCT03869086 1176 1183 B-Modifier
results NCT03869086 1184 1191 B-Observation
or NCT03869086 1192 1194 O
measurements NCT03869086 1195 1207 B-Observation
considered NCT03869086 1208 1218 O
to NCT03869086 1219 1221 O
be NCT03869086 1222 1224 O
counter NCT03869086 1225 1232 O
indicative NCT03869086 1233 1243 O
for NCT03869086 1244 1247 O
the NCT03869086 1248 1251 O
study NCT03869086 1252 1257 B-Study

- NCT03869086 1260 1261 O
Undiagnosed NCT03869086 1263 1274 B-Modifier
hypertension NCT03869086 1275 1287 B-Condition|Observation
( NCT03869086 1288 1289 O
elicited NCT03869086 1290 1298 O
at NCT03869086 1299 1301 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03869086 1302 1311 B-Study
; NCT03869086 1311 1312 O
i. NCT03869086 1313 1315 O
e. NCT03869086 1316 1318 O
≥ NCT03869086 1320 1321 B-Eq-Comparison
180 NCT03869086 1322 1325 I-Eq-Comparison
/ NCT03869086 1326 1327 I-Eq-Comparison
110 NCT03869086 1328 1331 I-Eq-Comparison
mmHg NCT03869086 1332 1336 O
) NCT03869086 1337 1338 O
at NCT03869086 1339 1341 O
a NCT03869086 1342 1343 O
level NCT03869086 1344 1349 O
requiring NCT03869086 1350 1359 B-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03869086 1360 1369 O
referral NCT03869086 1370 1378 O
back NCT03869086 1379 1383 O
to NCT03869086 1384 1386 O
general NCT03869086 1387 1394 B-Provider
practitioner NCT03869086 1395 1407 I-Provider
for NCT03869086 1408 1411 O
follow NCT03869086 1412 1418 B-Encounter
- NCT03869086 1419 1420 I-Encounter
up NCT03869086 1421 1423 I-Encounter

Inclusion NCT03864549 0 9 O
Criteria NCT03864549 10 18 O
: NCT03864549 19 20 O

- NCT03864549 24 25 O
Pregnant NCT03864549 27 35 B-Condition
women NCT03864549 36 41 O
who NCT03864549 42 45 B-And
were NCT03864549 46 50 O
diagnosed NCT03864549 51 60 O
with NCT03864549 61 65 O
GDM NCT03864549 66 69 B-Condition
from NCT03864549 70 74 B-Temporal-Connection___Temporal-Connection-Type-Value:during
13 NCT03864549 75 77 B-Eq-Comparison
to NCT03864549 78 80 I-Eq-Comparison
32.6 NCT03864549 81 85 I-Eq-Comparison
gestational NCT03864549 86 97 B-Observation
weeks NCT03864549 98 103 O

- NCT03864549 106 107 O
18 NCT03864549 109 111 B-Eq-Comparison
years NCT03864549 112 117 I-Eq-Comparison
old NCT03864549 118 121 I-Eq-Comparison
and NCT03864549 122 125 I-Eq-Comparison
older NCT03864549 126 131 I-Age|Eq-Comparison

- NCT03864549 134 135 O
Singleton NCT03864549 137 146 B-Modifier
pregnancy NCT03864549 147 156 B-Condition

Exclusion NCT03864549 157 166 O
Criteria NCT03864549 167 175 O
: NCT03864549 176 177 O

- NCT03864549 181 182 O
Women NCT03864549 184 189 O
with NCT03864549 190 194 B-And
pre NCT03864549 195 198 B-Modifier
- NCT03864549 199 200 I-Modifier
gestational NCT03864549 201 212 I-Modifier
diabetes NCT03864549 213 221 B-Condition
mellitus NCT03864549 222 230 I-Condition

- NCT03864549 233 234 O
GDM NCT03864549 236 239 B-Condition
diagnosed NCT03864549 240 249 O
≥ NCT03864549 250 251 B-Eq-Comparison
33 NCT03864549 252 254 I-Eq-Comparison
gestational NCT03864549 255 266 B-Observation
weeks NCT03864549 267 272 O

- NCT03864549 275 276 O
Women NCT03864549 278 283 O
using NCT03864549 284 289 B-Eq-Comparison
prophylactic NCT03864549 290 302 B-Procedure
antimicrobial NCT03864549 303 316 I-Procedure
treatment NCT03864549 317 326 I-Procedure

- NCT03864549 329 330 O
Immunocompromised NCT03864549 332 349 B-Condition
women NCT03864549 350 355 O

- NCT03864549 358 359 O
Multiple NCT03864549 361 369 B-Eq-Comparison
pregnancy NCT03864549 370 379 B-Condition

- NCT03864549 382 383 O
Women NCT03864549 385 390 O
taking NCT03864549 391 397 B-Eq-Comparison
oral NCT03864549 398 402 B-Modifier
probiotic NCT03864549 403 412 B-Drug
products NCT03864549 413 421 I-Drug
who NCT03864549 422 425 B-And
refuse NCT03864549 426 432 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864549 433 435 I-Assertion___Assertion-Type-Value:hypothetical
stop NCT03864549 436 440 B-Negation
the NCT03864549 441 444 B-Coreference
consumption NCT03864549 445 456 I-Coreference
( NCT03864549 457 458 O
food NCT03864549 459 463 B-Modifier
- NCT03864549 464 465 I-Modifier
containing NCT03864549 466 476 I-Modifier
probiotics NCT03864549 477 487 B-Drug
is NCT03864549 488 490 B-Exception
not NCT03864549 491 494 I-Exception
considered NCT03864549 495 505 I-Exception
an NCT03864549 506 508 I-Exception
exclusion NCT03864549 509 518 I-Exception
criterion NCT03864549 519 528 I-Exception
) NCT03864549 529 530 O
. NCT03864549 531 532 O

Inclusion NCT03869723 0 9 O
Criteria NCT03869723 10 18 O
: NCT03869723 19 20 O

- NCT03869723 24 25 O
Patients NCT03869723 27 35 O
who NCT03869723 36 39 O
underwent NCT03869723 40 49 B-Eq-Comparison
fibula NCT03869723 50 56 B-Procedure
free NCT03869723 57 61 I-Procedure
flap NCT03869723 62 66 I-Procedure
for NCT03869723 67 70 O
mandibular NCT03869723 71 81 B-Procedure
reconstruction NCT03869723 82 96 I-Procedure

- NCT03869723 99 100 O
Patient NCT03869723 102 109 O
≥ NCT03869723 110 111 B-Eq-Comparison
18 NCT03869723 112 114 I-Eq-Comparison
years NCT03869723 115 120 I-Eq-Comparison
old NCT03869723 121 124 B-Age

- NCT03869723 127 128 O
patient NCT03869723 130 137 O
alive NCT03869723 138 143 B-Death|Negation
6 NCT03869723 144 145 B-Eq-Comparison
months NCT03869723 146 152 I-Eq-Comparison
after NCT03869723 153 158 B-Temporal-Connection___Temporal-Connection-Type-Value:after
completion NCT03869723 159 169 O
of NCT03869723 170 172 O
treatment NCT03869723 173 182 B-Procedure

Exclusion NCT03869723 183 192 O
Criteria NCT03869723 193 201 O
: NCT03869723 202 203 O

- NCT03869723 207 208 O
Patient NCT03869723 210 217 O
without NCT03869723 218 225 B-Negation
post NCT03869723 226 230 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03869723 231 232 O
- NCT03869723 234 235 O
operative NCT03869723 236 245 B-Procedure
scan NCT03869723 246 250 B-Procedure
evaluation NCT03869723 251 261 I-Procedure

- NCT03869723 264 265 O
Patient NCT03869723 267 274 O
with NCT03869723 275 279 O
a NCT03869723 280 281 O
chirurgical NCT03869723 282 293 B-Procedure
contraindication NCT03869723 294 310 B-Contraindication

- NCT03869723 313 314 O
Pregnant NCT03869723 316 324 B-Condition
or NCT03869723 325 327 B-Or
nursing NCT03869723 328 335 B-Condition
woman NCT03869723 336 341 O

- NCT03869723 344 345 O
Adult NCT03869723 347 352 O
requiring NCT03869723 353 362 B-Observation
protection NCT03869723 363 373 I-Observation
( NCT03869723 374 375 O
guardianship NCT03869723 376 388 B-Observation
, NCT03869723 389 390 O
supervision NCT03869723 391 402 B-Observation
) NCT03869723 403 404 O

Inclusion NCT03861182 0 9 O
Criteria NCT03861182 10 18 O
: NCT03861182 19 20 O

Adult NCT03861182 22 27 O
Healthy NCT03861182 28 35 B-Condition
Volunteers NCT03861182 36 46 O
: NCT03861182 47 48 O

- NCT03861182 51 52 O
Over NCT03861182 53 57 B-Eq-Comparison
18 NCT03861182 58 60 I-Eq-Comparison
years NCT03861182 61 66 I-Eq-Comparison
of NCT03861182 67 69 O
age NCT03861182 70 73 B-Age

Neonates NCT03861182 74 82 B-Condition
: NCT03861182 83 84 O

- NCT03861182 88 89 O
Aged NCT03861182 91 95 B-Age
between NCT03861182 96 103 B-Eq-Comparison
1 NCT03861182 104 105 I-Eq-Comparison
h NCT03861182 106 107 O
of NCT03861182 108 110 I-Eq-Comparison
life NCT03861182 111 115 I-Eq-Comparison
and NCT03861182 116 119 I-Eq-Comparison
28 NCT03861182 120 122 I-Eq-Comparison
days NCT03861182 123 127 I-Eq-Comparison
of NCT03861182 128 130 O
life NCT03861182 131 135 O

- NCT03861182 138 139 O
Born NCT03861182 141 145 B-Birth
beyond NCT03861182 146 152 B-Eq-Comparison
33 NCT03861182 153 155 I-Eq-Comparison
Week NCT03861182 156 160 I-Eq-Comparison
of NCT03861182 161 163 B-Temporal-Connection___Temporal-Connection-Type-Value:after
Amenorrhea NCT03861182 164 174 B-Condition
+ NCT03861182 175 176 B-Temporal-Connection___Temporal-Connection-Type-Value:after
1 NCT03861182 177 178 B-Eq-Comparison
day NCT03861182 179 182 O
and NCT03861182 183 186 B-And
2 NCT03861182 187 188 B-Eq-Comparison
kg NCT03861182 189 191 O
of NCT03861182 192 194 O
birth NCT03861182 195 200 B-Observation
weight NCT03861182 201 207 I-Observation

- NCT03861182 210 211 O
Hospitalized NCT03861182 213 225 B-Encounter
in NCT03861182 226 228 O
the NCT03861182 229 232 O
medical NCT03861182 233 240 O
- NCT03861182 241 242 O
surgical NCT03861182 243 251 O
centre NCT03861182 252 258 O
of NCT03861182 259 261 O
Pediatrics NCT03861182 262 272 O
of NCT03861182 273 275 O
the NCT03861182 276 279 O
hospital NCT03861182 280 288 O
of NCT03861182 289 291 O
Strasbourg NCT03861182 292 302 O

- NCT03861182 305 306 O
For NCT03861182 308 311 O
whom NCT03861182 312 316 O
a NCT03861182 317 318 O
blood NCT03861182 319 324 B-Observation
sample NCT03861182 325 331 I-Observation
was NCT03861182 332 335 O
prescribed NCT03861182 336 346 O
as NCT03861182 347 349 O
part NCT03861182 350 354 O
of NCT03861182 355 357 O
their NCT03861182 358 363 O
routine NCT03861182 364 371 O
care NCT03861182 372 376 O

Exclusion NCT03861182 377 386 O
Criteria NCT03861182 387 395 O
: NCT03861182 396 397 O

Adult NCT03861182 399 404 O
Healthy NCT03861182 405 412 B-Condition
Volunteers NCT03861182 413 423 O
: NCT03861182 424 425 O

- NCT03861182 429 430 O
Systemic NCT03861182 432 440 B-Modifier
inflammatory NCT03861182 441 453 B-Condition
disease NCT03861182 454 461 I-Condition

- NCT03861182 464 465 O
Transient NCT03861182 467 476 B-Condition
inflammatory NCT03861182 477 489 I-Condition
state NCT03861182 490 495 I-Condition

- NCT03861182 498 499 O
Any NCT03861182 501 504 O
drug NCT03861182 505 509 B-Drug
that NCT03861182 510 514 O
modifies NCT03861182 515 523 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03861182 524 527 O
coagulation NCT03861182 528 539 B-Condition
cascade NCT03861182 540 547 I-Condition
during NCT03861182 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861182 555 558 O
48 NCT03861182 559 561 B-Eq-Comparison
h NCT03861182 562 563 O
preceding NCT03861182 564 573 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861182 574 577 O
sampling NCT03861182 578 586 B-Study

Neonates NCT03861182 587 595 O
: NCT03861182 596 597 O

- NCT03861182 601 602 O
Risk NCT03861182 604 608 B-Risk
of NCT03861182 609 611 O
anemia NCT03861182 612 618 B-Condition|Observation
< NCT03861182 619 620 B-Eq-Comparison
7 NCT03861182 621 622 I-Eq-Comparison
g NCT03861182 623 624 O
/ NCT03861182 625 626 I-Eq-Comparison
DL NCT03861182 627 629 I-Eq-Comparison

- NCT03861182 632 633 O
Current NCT03861182 635 642 B-Eq-Comparison
anticoagulant NCT03861182 643 656 B-Drug
treatment NCT03861182 657 666 B-Procedure

Inclusion NCT03866148 0 9 O
Criteria NCT03866148 10 18 O
: NCT03866148 19 20 O

- NCT03866148 24 25 O
Patients NCT03866148 27 35 O
with NCT03866148 36 40 O
moderate NCT03866148 41 49 B-Eq-Comparison
to NCT03866148 50 52 I-Eq-Comparison
severe NCT03866148 53 59 I-Eq-Comparison
sleep NCT03866148 60 65 B-Condition
apnoea NCT03866148 66 72 I-Condition
who NCT03866148 73 76 B-And
require NCT03866148 77 84 B-Assertion___Assertion-Type-Value:hypothetical
CPAP NCT03866148 85 89 B-Procedure
as NCT03866148 90 92 O
standard NCT03866148 93 101 B-Procedure
care NCT03866148 102 106 I-Procedure
( NCT03866148 107 108 O
AHI NCT03866148 109 112 B-Observation
> NCT03866148 113 114 B-Eq-Comparison
15 NCT03866148 115 117 I-Eq-Comparison
) NCT03866148 118 119 O

- NCT03866148 123 124 O
Patients NCT03866148 126 134 O
between NCT03866148 135 142 B-Eq-Comparison
the NCT03866148 143 146 I-Eq-Comparison
age NCT03866148 147 150 I-Age|Eq-Comparison
of NCT03866148 151 153 I-Eq-Comparison
18 NCT03866148 154 156 I-Eq-Comparison
and NCT03866148 157 160 I-Eq-Comparison
75 NCT03866148 161 163 I-Eq-Comparison

Exclusion NCT03866148 165 174 O
Criteria NCT03866148 175 183 O
: NCT03866148 184 185 O

- NCT03866148 189 190 O
Patients NCT03866148 192 200 O
with NCT03866148 201 205 O
a NCT03866148 206 207 O
diagnosis NCT03866148 208 217 O
of NCT03866148 218 220 O
atrial NCT03866148 221 227 B-Condition
fibrillation NCT03866148 228 240 I-Condition
( NCT03866148 241 242 O
AF NCT03866148 243 245 B-Condition
) NCT03866148 246 247 O
, NCT03866148 249 250 O
atrial NCT03866148 251 257 B-Condition
flutter NCT03866148 258 265 I-Condition
and NCT03866148 266 269 B-Or
/ NCT03866148 270 271 I-Or
or NCT03866148 272 274 I-Or
ventricular NCT03866148 275 286 B-Condition
tachycardia NCT03866148 287 298 I-Condition
( NCT03866148 299 300 O
VT NCT03866148 301 303 B-Condition
) NCT03866148 304 305 O

- NCT03866148 309 310 O
Patients NCT03866148 312 320 O
with NCT03866148 321 325 O
an NCT03866148 326 328 O
ILR NCT03866148 329 332 B-Procedure
already NCT03866148 333 340 B-Eq-Comparison
in NCT03866148 341 343 B-Modifier
- NCT03866148 344 345 I-Modifier
situ NCT03866148 346 350 I-Modifier
or NCT03866148 351 353 B-Or
an NCT03866148 354 356 O
established NCT03866148 357 368 O
indication NCT03866148 369 379 B-Indication
for NCT03866148 380 383 O
ILR NCT03866148 384 387 B-Procedure

- NCT03866148 390 391 O
Patients NCT03866148 393 401 O
with NCT03866148 402 406 O
a NCT03866148 407 408 O
palliative NCT03866148 409 419 B-Condition
diagnosis NCT03866148 420 429 O
i. NCT03866148 430 432 O
e. NCT03866148 433 435 O
life NCT03866148 437 441 B-Observation
expectancy NCT03866148 442 452 I-Observation
less NCT03866148 453 457 B-Eq-Comparison
than NCT03866148 458 462 I-Eq-Comparison
3 NCT03866148 463 464 I-Eq-Comparison
years NCT03866148 465 470 I-Eq-Comparison

- NCT03866148 473 474 O
Patients NCT03866148 476 484 O
who NCT03866148 485 488 O
lack NCT03866148 489 493 B-Condition
capacity NCT03866148 494 502 I-Condition

Inclusion NCT03863756 0 9 O
Criteria NCT03863756 10 18 O
: NCT03863756 19 20 O

- NCT03863756 24 25 O
Patients NCT03863756 27 35 O
with NCT03863756 36 40 O
Spondyloarthritis NCT03863756 41 58 B-Condition
( NCT03863756 59 60 O
SpA NCT03863756 61 64 B-Condition
) NCT03863756 65 66 O
meeting NCT03863756 67 74 O
the NCT03863756 75 78 O
criteria NCT03863756 79 87 O
of NCT03863756 88 90 O
Amor NCT03863756 91 95 O
and NCT03863756 96 99 O
/ NCT03863756 100 101 O
or NCT03863756 102 104 O
Assessement NCT03863756 105 116 O
of NCT03863756 117 119 O
spondyloarthritis NCT03863756 120 137 O
International NCT03863756 138 151 O
Society NCT03863756 152 159 O
( NCT03863756 160 161 O
ASAS NCT03863756 162 166 O
) NCT03863756 167 168 O

- NCT03863756 172 173 O
Indication NCT03863756 175 185 B-Indication
of NCT03863756 186 188 O
standard NCT03863756 189 197 B-Procedure
radiography NCT03863756 198 209 I-Procedure
for NCT03863756 210 213 O
the NCT03863756 214 217 O
follow NCT03863756 218 224 B-Encounter
- NCT03863756 225 226 I-Encounter
up NCT03863756 227 229 I-Encounter
of NCT03863756 230 232 O
the NCT03863756 233 236 O
patients NCT03863756 237 245 O
. NCT03863756 245 246 O

Exclusion NCT03863756 248 257 O
Criteria NCT03863756 258 266 O
: NCT03863756 267 268 O

- NCT03863756 272 273 O
the NCT03863756 275 278 O
presence NCT03863756 279 287 O
of NCT03863756 288 290 O
a NCT03863756 291 292 O
contraindication NCT03863756 293 309 B-Contraindication
to NCT03863756 310 312 O
the NCT03863756 313 316 O
performance NCT03863756 317 328 O
of NCT03863756 329 331 O
conventional NCT03863756 332 344 B-Procedure
radiography NCT03863756 345 356 I-Procedure
( NCT03863756 357 358 O
CR NCT03863756 359 361 B-Procedure
) NCT03863756 362 363 O
or NCT03863756 364 366 B-Or
EOS NCT03863756 367 370 B-Procedure
imaging NCT03863756 371 378 I-Procedure

- NCT03863756 381 382 O
any NCT03863756 384 387 O
disease NCT03863756 388 395 B-Condition
affecting NCT03863756 396 405 O
cognition NCT03863756 406 415 B-Condition

- NCT03863756 418 419 O
Patients NCT03863756 421 429 O
who NCT03863756 430 433 O
have NCT03863756 434 438 O
had NCT03863756 439 442 B-Eq-Comparison
surgery NCT03863756 443 450 B-Procedure
on NCT03863756 451 453 O
the NCT03863756 454 457 O
spine NCT03863756 458 463 B-Modifier
and NCT03863756 464 467 B-Or
/ NCT03863756 468 469 I-Or
or NCT03863756 470 472 I-Or
hip NCT03863756 473 476 B-Modifier
. NCT03863756 476 477 O

Inclusion NCT03864991 0 9 O
Criteria NCT03864991 10 18 O
: NCT03864991 19 20 O

- NCT03864991 24 25 O
Patient NCT03864991 27 34 O
diagnosed NCT03864991 35 44 O
with NCT03864991 45 49 O
T1D NCT03864991 50 53 B-Condition
> NCT03864991 54 55 B-Eq-Comparison
6 NCT03864991 56 57 I-Eq-Comparison
months NCT03864991 58 64 I-Eq-Comparison

- NCT03864991 67 68 O
Patient NCT03864991 70 77 O
's NCT03864991 77 79 O
age NCT03864991 80 83 B-Age
≥ NCT03864991 84 85 B-Eq-Comparison
15 NCT03864991 86 88 I-Eq-Comparison
years NCT03864991 89 94 I-Eq-Comparison

- NCT03864991 97 98 O
Patient NCT03864991 100 107 O
or NCT03864991 108 110 O
any NCT03864991 111 114 O
one NCT03864991 115 118 O
of NCT03864991 119 121 O
the NCT03864991 122 125 O
family NCT03864991 126 132 B-Family-Member
member NCT03864991 133 139 I-Family-Member
like NCT03864991 140 144 O
father NCT03864991 145 151 B-Family-Member___Family-Member-Type:father
, NCT03864991 152 153 O
mother NCT03864991 154 160 B-Family-Member___Family-Member-Type:parent
or NCT03864991 161 163 B-Or
sibling NCT03864991 164 171 B-Family-Member___Family-Member-Type:sibling
using NCT03864991 172 177 B-Eq-Comparison
smart NCT03864991 178 183 O
phone NCT03864991 184 189 O
. NCT03864991 189 190 O

- NCT03864991 194 195 O
Patient NCT03864991 197 204 O
or NCT03864991 205 207 O
any NCT03864991 208 211 O
one NCT03864991 212 215 O
of NCT03864991 216 218 O
the NCT03864991 219 222 O
family NCT03864991 223 229 B-Family-Member
member NCT03864991 230 236 I-Family-Member
know NCT03864991 237 241 O
how NCT03864991 242 245 O
to NCT03864991 246 248 O
use NCT03864991 249 252 O
( NCT03864991 253 254 O
receive NCT03864991 255 262 O
calls NCT03864991 263 268 O
or NCT03864991 269 271 O
read NCT03864991 272 276 O
text NCT03864991 277 281 O
message NCT03864991 282 289 O
) NCT03864991 290 291 O
a NCT03864991 292 293 O
smart NCT03864991 294 299 O
phone NCT03864991 300 305 O
. NCT03864991 305 306 O

Exclusion NCT03864991 308 317 O
Criteria NCT03864991 318 326 O
: NCT03864991 327 328 O

- NCT03864991 332 333 O
Patient NCT03864991 335 342 O
on NCT03864991 343 345 B-Eq-Comparison
insulin NCT03864991 346 353 B-Drug
pump NCT03864991 354 358 B-Modifier

- NCT03864991 361 362 O
Pregnant NCT03864991 364 372 B-Condition
females NCT03864991 373 380 O
, NCT03864991 381 382 O

- NCT03864991 386 387 O
Patient NCT03864991 389 396 O
with NCT03864991 397 401 O
neurodevelopmental NCT03864991 402 420 B-Condition
delay NCT03864991 421 426 I-Condition
or NCT03864991 427 429 B-Or
thalassemia NCT03864991 430 441 B-Condition

- NCT03864991 444 445 O
Patient NCT03864991 447 454 O
currently NCT03864991 455 464 B-Eq-Comparison
using NCT03864991 465 470 O
any NCT03864991 471 474 O
kind NCT03864991 475 479 O
of NCT03864991 480 482 O
authentic NCT03864991 483 492 O
e NCT03864991 493 494 B-Procedure
- NCT03864991 495 496 I-Procedure
device NCT03864991 497 503 I-Procedure
for NCT03864991 504 507 O
step NCT03864991 508 512 B-Observation
count NCT03864991 513 518 I-Observation
or NCT03864991 519 521 B-Or
physical NCT03864991 522 530 B-Observation
activity NCT03864991 531 539 I-Observation
. NCT03864991 539 540 O

Inclusion NCT03867240 0 9 O
Criteria NCT03867240 10 18 O
: NCT03867240 19 20 O

- NCT03867240 24 25 O
Be NCT03867240 27 29 O
aged NCT03867240 30 34 B-Age
10 NCT03867240 35 37 B-Eq-Comparison
- NCT03867240 38 39 I-Eq-Comparison
18 NCT03867240 40 42 I-Eq-Comparison
years NCT03867240 43 48 I-Eq-Comparison
at NCT03867240 49 51 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867240 52 55 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867240 56 60 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867240 61 63 O
surgery NCT03867240 64 71 B-Procedure

- NCT03867240 74 75 O
Have NCT03867240 77 81 O
a NCT03867240 82 83 O
diagnosis NCT03867240 84 93 O
of NCT03867240 94 96 O
idiopathic NCT03867240 97 107 B-Condition
scoliosis NCT03867240 108 117 I-Condition
and NCT03867240 118 121 B-Or
/ NCT03867240 122 123 I-Or
or NCT03867240 124 126 I-Or
kyphosis NCT03867240 127 135 B-Condition

- NCT03867240 138 139 O
Be NCT03867240 141 143 O
undergoing NCT03867240 144 154 B-Eq-Comparison
elective NCT03867240 155 163 B-Modifier
posterior NCT03867240 164 173 B-Procedure
spinal NCT03867240 174 180 I-Procedure
fusion NCT03867240 181 187 I-Procedure

- NCT03867240 190 191 O
Have NCT03867240 193 197 O
only NCT03867240 198 202 O
mild NCT03867240 203 207 O
systemic NCT03867240 208 216 B-Condition
disease NCT03867240 217 224 I-Condition

Exclusion NCT03867240 225 234 O
Criteria NCT03867240 235 243 O
: NCT03867240 244 245 O

- NCT03867240 249 250 O
A NCT03867240 252 253 O
diagnosis NCT03867240 254 263 O
of NCT03867240 264 266 O
neuromuscular NCT03867240 267 280 B-Condition
scoliosis NCT03867240 281 290 I-Condition
and NCT03867240 291 294 B-Or
/ NCT03867240 295 296 I-Or
or NCT03867240 297 299 I-Or
kyphosis NCT03867240 300 308 B-Condition

- NCT03867240 311 312 O
A NCT03867240 314 315 O
diagnosis NCT03867240 316 325 O
of NCT03867240 326 328 O
chronic NCT03867240 329 336 B-Modifier
pain NCT03867240 337 341 B-Condition

- NCT03867240 344 345 O
Used NCT03867240 347 351 B-Eq-Comparison
opioids NCT03867240 352 359 B-Drug
in NCT03867240 360 362 O
the NCT03867240 363 366 O
past NCT03867240 367 371 B-Eq-Comparison
6 NCT03867240 372 373 I-Eq-Comparison
months NCT03867240 374 380 I-Eq-Comparison

- NCT03867240 383 384 O
Developmental NCT03867240 386 399 B-Condition
delay NCT03867240 400 405 I-Condition

- NCT03867240 408 409 O
Liver NCT03867240 411 416 B-Modifier
or NCT03867240 417 419 B-Or
kidney NCT03867240 420 426 B-Modifier
disease NCT03867240 427 434 B-Condition

- NCT03867240 437 438 O
Obstructive NCT03867240 440 451 B-Condition
sleep NCT03867240 452 457 I-Condition
apnea NCT03867240 458 463 I-Condition

- NCT03867240 466 467 O
Body NCT03867240 469 473 B-Observation
mass NCT03867240 474 478 I-Observation
index NCT03867240 479 484 I-Observation
> NCT03867240 485 486 B-Eq-Comparison
40 NCT03867240 487 489 I-Eq-Comparison

- NCT03867240 493 494 O
Be NCT03867240 496 498 O
pregnant NCT03867240 499 507 B-Condition
or NCT03867240 508 510 B-Or
breastfeeding NCT03867240 511 524 B-Condition

Inclusion NCT03867526 0 9 O
Criteria NCT03867526 10 18 O
: NCT03867526 19 20 O

- NCT03867526 24 25 O
Informed NCT03867526 27 35 O
consent NCT03867526 36 43 O
will NCT03867526 44 48 O
be NCT03867526 49 51 O
obtained NCT03867526 52 60 O
from NCT03867526 61 65 O
the NCT03867526 66 69 O
patient NCT03867526 70 77 O
or NCT03867526 78 80 O
the NCT03867526 81 84 O
parents NCT03867526 85 92 B-Family-Member___Family-Member-Type:parent
before NCT03867526 93 99 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03867526 100 103 O
study NCT03867526 104 109 B-Study
related NCT03867526 110 117 O
procedures NCT03867526 118 128 B-Procedure
. NCT03867526 128 129 O

- NCT03867526 133 134 O
Patients NCT03867526 136 144 O
of NCT03867526 145 147 O
both NCT03867526 148 152 O
genders NCT03867526 153 160 O
older NCT03867526 161 166 I-Eq-Comparison
than NCT03867526 167 171 I-Eq-Comparison
6 NCT03867526 172 173 I-Eq-Comparison
months NCT03867526 174 180 I-Eq-Comparison
and NCT03867526 181 184 B-And
younger NCT03867526 185 192 B-Eq-Comparison
than NCT03867526 193 197 I-Eq-Comparison
80 NCT03867526 198 200 I-Eq-Comparison
years NCT03867526 201 206 I-Eq-Comparison

- NCT03867526 209 210 O
The NCT03867526 212 215 O
patient NCT03867526 216 223 O
has NCT03867526 224 227 O
a NCT03867526 228 229 O
diagnosis NCT03867526 230 239 O
of NCT03867526 240 242 O
Wilson NCT03867526 243 249 B-Condition
dis NCT03867526 250 253 I-Condition
- NCT03867526 254 255 I-Condition
ease NCT03867526 256 260 I-Condition

Exclusion NCT03867526 261 270 O
Criteria NCT03867526 271 279 O
: NCT03867526 280 281 O

- NCT03867526 285 286 O
No NCT03867526 288 290 O
Informed NCT03867526 291 299 O
consent NCT03867526 300 307 O
from NCT03867526 308 312 O
the NCT03867526 313 316 O
patient NCT03867526 317 324 O
or NCT03867526 325 327 O
the NCT03867526 328 331 O
parents NCT03867526 332 339 B-Family-Member___Family-Member-Type:parent
before NCT03867526 340 346 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03867526 347 350 O
study NCT03867526 351 356 B-Study
related NCT03867526 357 364 O
procedures NCT03867526 365 375 B-Procedure

- NCT03867526 378 379 O
Patients NCT03867526 381 389 O
of NCT03867526 390 392 O
both NCT03867526 393 397 O
genders NCT03867526 398 405 O
younger NCT03867526 406 413 B-Eq-Comparison
than NCT03867526 414 418 I-Eq-Comparison
6 NCT03867526 419 420 I-Eq-Comparison
months NCT03867526 421 427 I-Eq-Comparison
and NCT03867526 428 431 B-And
older NCT03867526 432 437 I-Eq-Comparison
than NCT03867526 438 442 I-Eq-Comparison
80 NCT03867526 443 445 I-Eq-Comparison
years NCT03867526 446 451 I-Eq-Comparison

- NCT03867526 454 455 O
No NCT03867526 457 459 B-Negation
diagnosis NCT03867526 460 469 O
of NCT03867526 470 472 O
Wilson NCT03867526 473 479 B-Condition
disease NCT03867526 480 487 I-Condition

Inclusion NCT03868826 0 9 O
Criteria NCT03868826 10 18 O
: NCT03868826 19 20 O

- NCT03868826 24 25 O
Patients NCT03868826 27 35 O
eligible NCT03868826 36 44 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868826 45 48 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03868826 49 58 B-Procedure
of NCT03868826 59 61 O
hamstring NCT03868826 62 71 B-Condition
avulsion NCT03868826 72 80 I-Condition

Exclusion NCT03868826 81 90 O
Criteria NCT03868826 91 99 O
: NCT03868826 100 101 O

- NCT03868826 105 106 O
Conditions NCT03868826 108 118 B-Condition
that NCT03868826 119 123 O
contraindicate NCT03868826 124 138 B-Contraindication
muscle NCT03868826 139 145 B-Procedure
strength NCT03868826 146 154 I-Procedure
testing NCT03868826 155 162 I-Procedure
e. NCT03868826 163 165 O
g. NCT03868826 166 168 O
cancer NCT03868826 170 176 B-Condition
and NCT03868826 177 180 B-Or
neurological NCT03868826 181 193 B-Condition
conditions NCT03868826 194 204 I-Condition

- NCT03868826 207 208 O
Patients NCT03868826 210 218 O
that NCT03868826 219 223 O
do NCT03868826 224 226 O
not NCT03868826 227 230 B-Negation
speak NCT03868826 231 236 O
or NCT03868826 237 239 O
understand NCT03868826 240 250 O
Danish NCT03868826 251 257 O

Inclusion NCT03866837 0 9 O
Criteria NCT03866837 10 18 O
: NCT03866837 19 20 O

- NCT03866837 24 25 O
vaginal NCT03866837 27 34 B-Procedure
delivery NCT03866837 35 43 I-Procedure

- NCT03866837 46 47 O
an NCT03866837 49 51 O
infant NCT03866837 52 58 B-Family-Member___Family-Member-Type:child
age NCT03866837 59 62 I-Eq-Comparison
of NCT03866837 63 65 I-Eq-Comparison
6 NCT03866837 66 67 I-Eq-Comparison
months NCT03866837 68 74 I-Eq-Comparison
( NCT03866837 75 76 O
± NCT03866837 78 79 B-Eq-Comparison
3 NCT03866837 80 81 O
weeks NCT03866837 82 87 I-Eq-Comparison
) NCT03866837 88 89 O

- NCT03866837 93 94 O
mother NCT03866837 96 102 B-Family-Member___Family-Member-Type:mother
≥ NCT03866837 103 104 B-Eq-Comparison
15 NCT03866837 105 107 I-Eq-Comparison
years NCT03866837 108 113 I-Eq-Comparison
of NCT03866837 114 116 O
age NCT03866837 117 120 B-Age

- NCT03866837 123 124 O
infant NCT03866837 126 132 O
still NCT03866837 133 138 O
breastfeeding NCT03866837 139 152 B-Condition

- NCT03866837 155 156 O
anticipated NCT03866837 158 169 O
residence NCT03866837 170 179 O
in NCT03866837 180 182 O
the NCT03866837 183 186 O
area NCT03866837 187 191 O
for NCT03866837 192 195 O
the NCT03866837 196 199 O
study NCT03866837 200 205 B-Study
duration NCT03866837 206 214 O
. NCT03866837 214 215 O

Exclusion NCT03866837 217 226 O
Criteria NCT03866837 227 235 O
: NCT03866837 236 237 O

- NCT03866837 241 242 O
inability NCT03866837 244 253 O
to NCT03866837 254 256 O
provide NCT03866837 257 264 O
informed NCT03866837 265 273 O
consent NCT03866837 274 281 O

- NCT03866837 284 285 O
hemoglobin NCT03866837 287 297 B-Observation
< NCT03866837 298 299 B-Eq-Comparison
70 NCT03866837 300 302 I-Eq-Comparison
g NCT03866837 303 304 I-Eq-Comparison
/ NCT03866837 305 306 I-Eq-Comparison
L NCT03866837 307 308 I-Eq-Comparison

- NCT03866837 311 312 O
Z NCT03866837 314 315 B-Observation
scores NCT03866837 316 322 I-Observation
for NCT03866837 323 326 I-Observation
weight NCT03866837 327 333 I-Observation
- NCT03866837 334 335 I-Observation
for NCT03866837 336 339 O
- NCT03866837 340 341 O
age NCT03866837 342 345 I-Observation
( NCT03866837 346 347 O
WAZ NCT03866837 348 351 B-Observation
) NCT03866837 352 353 O
or NCT03866837 354 356 B-Or
weight NCT03866837 357 363 B-Observation
- NCT03866837 364 365 I-Observation
for NCT03866837 366 369 I-Observation
- NCT03866837 370 371 O
height NCT03866837 372 378 I-Observation
( NCT03866837 379 380 O
WHZ NCT03866837 381 384 B-Observation
) NCT03866837 385 386 O
< NCT03866837 387 388 B-Eq-Comparison
3 NCT03866837 389 390 I-Eq-Comparison
, NCT03866837 391 392 O

- NCT03866837 397 398 O
any NCT03866837 400 403 O
maternal NCT03866837 404 412 B-Family-Member___Family-Member-Type:mother
or NCT03866837 413 415 B-Or
infant NCT03866837 416 422 B-Family-Member___Family-Member-Type:child
chronic NCT03866837 423 430 B-Modifier
illness NCT03866837 431 438 B-Condition

- NCT03866837 441 442 O
administration NCT03866837 444 458 O
of NCT03866837 459 461 O
any NCT03866837 462 465 O
infant NCT03866837 466 472 B-Family-Member___Family-Member-Type:child
vitamin NCT03866837 473 480 B-Modifier
or NCT03866837 481 483 B-Or
mineral NCT03866837 484 491 B-Modifier
supplements NCT03866837 492 503 B-Drug
for NCT03866837 504 507 O
the NCT03866837 508 511 O
past NCT03866837 512 516 B-Eq-Comparison
2 NCT03866837 517 518 I-Eq-Comparison
months NCT03866837 519 525 I-Eq-Comparison

- NCT03866837 528 529 O
any NCT03866837 531 534 O
history NCT03866837 535 542 B-Eq-Comparison
of NCT03866837 543 545 O
infant NCT03866837 546 552 B-Family-Member___Family-Member-Type:child
antibiotic NCT03866837 553 563 B-Drug
treatment NCT03866837 564 573 B-Procedure
. NCT03866837 573 574 O

Inclusion NCT03864952 0 9 O
Criteria NCT03864952 10 18 O
: NCT03864952 19 20 O

- NCT03864952 24 25 O
three NCT03864952 27 32 B-Eq-Comparison
months NCT03864952 33 39 I-Eq-Comparison
before NCT03864952 40 46 I-Eq-Comparison
, NCT03864952 47 48 O
having NCT03864952 49 55 O
been NCT03864952 56 60 O
infected NCT03864952 61 69 B-Condition
with NCT03864952 70 74 O
a NCT03864952 75 76 O
documented NCT03864952 77 87 O
pathogen NCT03864952 88 96 B-Condition

- NCT03864952 99 100 O
this NCT03864952 102 106 B-Coreference
infection NCT03864952 107 116 I-Coreference
must NCT03864952 117 121 O
have NCT03864952 122 126 O
been NCT03864952 127 131 O
clinically NCT03864952 132 142 O
obvious NCT03864952 143 150 O

- NCT03864952 153 154 O
the NCT03864952 156 159 O
patient NCT03864952 160 167 O
must NCT03864952 168 172 O
have NCT03864952 173 177 O
dental NCT03864952 178 184 B-Condition
calculus NCT03864952 185 193 I-Condition

Exclusion NCT03864952 194 203 O
Criteria NCT03864952 204 212 O
: NCT03864952 213 214 O

- NCT03864952 218 219 O
to NCT03864952 221 223 O
be NCT03864952 224 226 O
under NCT03864952 227 232 B-Eq-Comparison
18 NCT03864952 233 235 I-Eq-Comparison
years NCT03864952 236 241 I-Eq-Comparison
old NCT03864952 242 245 B-Age

- NCT03864952 248 249 O
to NCT03864952 251 253 O
be NCT03864952 254 256 O
incapable NCT03864952 257 266 O
to NCT03864952 267 269 O
consenting NCT03864952 270 280 O

- NCT03864952 283 284 O
a NCT03864952 286 287 O
tartar NCT03864952 288 294 B-Procedure
removal NCT03864952 295 302 I-Procedure
since NCT03864952 303 308 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03864952 309 312 B-Coreference
infection NCT03864952 313 322 I-Coreference

Inclusion NCT03869047 0 9 O
Criteria NCT03869047 10 18 O
: NCT03869047 19 20 O

- NCT03869047 24 25 O
physical NCT03869047 27 35 O
status NCT03869047 36 42 O
American NCT03869047 43 51 B-Condition
Society NCT03869047 52 59 I-Condition
of NCT03869047 60 62 I-Condition
Anesthesiologist NCT03869047 63 79 I-Condition
( NCT03869047 80 81 O
ASA NCT03869047 82 85 B-Condition
) NCT03869047 86 87 O
I NCT03869047 88 89 B-Eq-Comparison
or NCT03869047 90 92 I-Eq-Comparison
II NCT03869047 93 95 I-Eq-Comparison

Exclusion NCT03869047 96 105 O
Criteria NCT03869047 106 114 O
: NCT03869047 115 116 O

- NCT03869047 120 121 O
Patients NCT03869047 123 131 O
refusal NCT03869047 132 139 O

- NCT03869047 142 143 O
A NCT03869047 145 146 O
body NCT03869047 147 151 B-Observation
mass NCT03869047 152 156 I-Observation
index NCT03869047 157 162 I-Observation
( NCT03869047 163 164 O
BMI NCT03869047 165 168 B-Observation
) NCT03869047 169 170 O
> NCT03869047 171 172 B-Eq-Comparison
30 NCT03869047 173 175 I-Eq-Comparison
kg NCT03869047 176 178 I-Eq-Comparison
/ NCT03869047 179 180 I-Eq-Comparison
m2 NCT03869047 181 183 I-Eq-Comparison

- NCT03869047 186 187 O
ASA NCT03869047 189 192 B-Condition
physical NCT03869047 193 201 O
status NCT03869047 202 208 O
> NCT03869047 209 210 B-Eq-Comparison
II NCT03869047 211 213 I-Eq-Comparison

- NCT03869047 216 217 O
major NCT03869047 219 224 O
illnesses NCT03869047 225 234 B-Condition
( NCT03869047 235 236 O
e. NCT03869047 237 239 O
g. NCT03869047 240 242 O
, NCT03869047 243 244 O
cardiac NCT03869047 245 252 B-Modifier
, NCT03869047 253 254 O
respiratory NCT03869047 255 266 B-Modifier
, NCT03869047 267 268 O
renal NCT03869047 269 274 B-Modifier
, NCT03869047 275 276 O
hepatic NCT03869047 277 284 B-Modifier
or NCT03869047 285 287 B-Or
neurological NCT03869047 288 300 B-Modifier
) NCT03869047 301 302 O

- NCT03869047 306 307 O
Coagulation NCT03869047 309 320 B-Condition
abnormalities NCT03869047 321 334 O

- NCT03869047 337 338 O
Infection NCT03869047 340 349 B-Condition
at NCT03869047 350 352 O
the NCT03869047 353 356 O
injection NCT03869047 357 366 B-Procedure
site NCT03869047 367 371 B-Modifier

- NCT03869047 374 375 O
Allergy NCT03869047 377 384 B-Allergy
or NCT03869047 385 387 B-Or
contraindications NCT03869047 388 405 B-Contraindication
to NCT03869047 406 408 O
the NCT03869047 409 412 O
drugs NCT03869047 413 418 B-Drug
used NCT03869047 419 423 O
in NCT03869047 424 426 O
the NCT03869047 427 430 O
study NCT03869047 431 436 B-Study

- NCT03869047 439 440 O
History NCT03869047 442 449 B-Eq-Comparison
of NCT03869047 450 452 O
drug NCT03869047 453 457 B-Condition
addiction NCT03869047 458 467 I-Condition
or NCT03869047 468 470 B-Or
alcohol NCT03869047 471 478 B-Condition
abuse NCT03869047 479 484 I-Condition

- NCT03869047 487 488 O
A NCT03869047 490 491 O
psychiatric NCT03869047 492 503 B-Condition
illness NCT03869047 504 511 I-Condition
, NCT03869047 512 513 O
or NCT03869047 514 516 B-Or
mental NCT03869047 517 523 B-Condition
retardation NCT03869047 524 535 I-Condition
interfering NCT03869047 536 547 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03869047 548 552 O
the NCT03869047 553 556 O
evaluation NCT03869047 557 567 O
of NCT03869047 568 570 O
pain NCT03869047 571 575 B-Observation
scores NCT03869047 576 582 I-Observation
or NCT03869047 583 585 B-Or
PCA NCT03869047 586 589 B-Procedure
programs NCT03869047 590 598 I-Procedure
. NCT03869047 599 600 O

Inclusion NCT03865641 0 9 O
Criteria NCT03865641 10 18 O
: NCT03865641 19 20 O

- NCT03865641 24 25 O
The NCT03865641 27 30 O
patients NCT03865641 31 39 O
' NCT03865641 39 40 O
burn NCT03865641 41 45 B-Condition
scars NCT03865641 46 51 I-Condition
had NCT03865641 52 55 O
re NCT03865641 56 58 B-Modifier
- NCT03865641 59 60 I-Modifier
epithelialized NCT03865641 61 75 I-Modifier
after NCT03865641 76 81 B-Temporal-Connection___Temporal-Connection-Type-Value:after
aseptic NCT03865641 82 89 B-Procedure
care NCT03865641 90 94 I-Procedure
or NCT03865641 95 97 B-Or
skin NCT03865641 98 102 B-Procedure
graft NCT03865641 103 108 I-Procedure
. NCT03865641 108 109 O
We NCT03865641 111 113 O
included NCT03865641 114 122 O
patients NCT03865641 123 131 O
aged NCT03865641 132 136 B-Age
≥ NCT03865641 137 138 B-Eq-Comparison
18 NCT03865641 139 141 I-Eq-Comparison
years NCT03865641 142 147 I-Eq-Comparison
with NCT03865641 148 152 B-And
a NCT03865641 153 154 O
deep NCT03865641 155 159 B-Modifier
partial NCT03865641 160 167 I-Modifier
- NCT03865641 168 169 I-Modifier
thickness NCT03865641 170 179 I-Modifier
( NCT03865641 180 181 O
second NCT03865641 182 188 B-Modifier
- NCT03865641 189 190 I-Modifier
degree NCT03865641 191 197 I-Modifier
) NCT03865641 198 199 O
burn NCT03865641 200 204 B-Condition
or NCT03865641 205 207 B-Or
a NCT03865641 208 209 O
full NCT03865641 210 214 B-Modifier
thickness NCT03865641 215 224 I-Modifier
( NCT03865641 225 226 O
third NCT03865641 227 232 B-Modifier
- NCT03865641 233 234 I-Modifier
degree NCT03865641 235 241 I-Modifier
) NCT03865641 242 243 O
burn NCT03865641 244 248 B-Condition
to NCT03865641 249 251 O
their NCT03865641 252 257 O
hands NCT03865641 258 263 B-Modifier
, NCT03865641 264 265 O
with NCT03865641 266 270 B-And
joint NCT03865641 271 276 B-Condition
contracture NCT03865641 277 288 I-Condition
( NCT03865641 289 290 O
hand NCT03865641 291 295 B-Modifier
and NCT03865641 296 299 B-Or
wrist NCT03865641 300 305 B-Modifier
) NCT03865641 306 307 O
, NCT03865641 309 310 O
having NCT03865641 311 317 B-And
been NCT03865641 318 322 I-And
transferred NCT03865641 323 334 B-Encounter
to NCT03865641 335 337 O
the NCT03865641 338 341 O
rehabilitation NCT03865641 342 356 O
department NCT03865641 357 367 O
after NCT03865641 368 373 B-Temporal-Connection___Temporal-Connection-Type-Value:after
acute NCT03865641 374 379 O
burn NCT03865641 380 384 B-Condition
treatment NCT03865641 385 394 B-Procedure
, NCT03865641 395 396 O
and NCT03865641 397 400 O
less NCT03865641 401 405 B-Eq-Comparison
than NCT03865641 406 410 I-Eq-Comparison
6 NCT03865641 411 412 I-Eq-Comparison
months NCT03865641 413 419 I-Eq-Comparison
since NCT03865641 420 425 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865641 426 429 O
onset NCT03865641 430 435 B-Eq-Comparison
of NCT03865641 436 438 O
the NCT03865641 439 442 O
burn NCT03865641 443 447 B-Modifier
injury NCT03865641 448 454 B-Condition
. NCT03865641 454 455 O

Exclusion NCT03865641 457 466 O
Criteria NCT03865641 467 475 O
: NCT03865641 476 477 O

- NCT03865641 481 482 I-Modifier
patients NCT03865641 484 492 O
who NCT03865641 493 496 O
had NCT03865641 497 500 O
fourth NCT03865641 501 507 B-Modifier
- NCT03865641 508 509 O
degree NCT03865641 510 516 I-Modifier
burns NCT03865641 517 522 B-Condition
( NCT03865641 523 524 O
involving NCT03865641 525 534 O
muscles NCT03865641 535 542 B-Modifier
, NCT03865641 543 544 O
tendons NCT03865641 545 552 B-Modifier
, NCT03865641 553 554 O
and NCT03865641 555 558 B-Or
bone NCT03865641 559 563 B-Modifier
injuries NCT03865641 564 572 B-Condition
) NCT03865641 573 574 O
, NCT03865641 576 577 O
musculoskeletal NCT03865641 578 593 B-Condition
diseases NCT03865641 594 602 I-Condition
( NCT03865641 603 604 O
fracture NCT03865641 605 613 B-Condition
, NCT03865641 614 615 O
amputation NCT03865641 616 626 B-Condition
, NCT03865641 627 628 O
rheumatoid NCT03865641 629 639 B-Condition
arthritis NCT03865641 640 649 I-Condition
, NCT03865641 650 651 O
and NCT03865641 652 655 B-Or
degenerative NCT03865641 656 668 B-Condition
joint NCT03865641 669 674 I-Condition
diseases NCT03865641 675 683 I-Condition
) NCT03865641 684 685 O
in NCT03865641 686 688 O
the NCT03865641 689 692 O
burned NCT03865641 693 699 B-Modifier
hand NCT03865641 700 704 I-Modifier
, NCT03865641 705 706 O
or NCT03865641 707 709 B-Or
neurological NCT03865641 710 722 B-Condition
diseases NCT03865641 723 731 I-Condition
( NCT03865641 732 733 O
such NCT03865641 734 738 O
as NCT03865641 739 741 O
peripheral NCT03865641 742 752 B-Condition
nerve NCT03865641 753 758 I-Condition
disorders NCT03865641 759 768 I-Condition
) NCT03865641 769 770 O
, NCT03865641 772 773 O
preexisting NCT03865641 774 785 B-Eq-Comparison
physical NCT03865641 786 794 B-Modifier
and NCT03865641 795 798 B-Or|Or
psychologic NCT03865641 799 810 B-Modifier
disability NCT03865641 811 821 B-Condition
( NCT03865641 822 823 O
severe NCT03865641 824 830 O
aphasia NCT03865641 831 838 B-Condition
and NCT03865641 839 842 O
cognitive NCT03865641 843 852 B-Condition
impairment NCT03865641 853 863 I-Condition
that NCT03865641 864 868 O
could NCT03865641 869 874 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03865641 875 884 O
the NCT03865641 885 888 O
intervention NCT03865641 889 901 B-Study
) NCT03865641 902 903 O
, NCT03865641 905 906 O
and NCT03865641 907 910 B-Or
severe NCT03865641 911 917 O
pain NCT03865641 918 922 B-Condition
impeding NCT03865641 923 931 O
hand NCT03865641 932 936 B-Procedure
rehabilitation NCT03865641 937 951 I-Procedure
. NCT03865641 951 952 O

Inclusion NCT03868371 0 9 O
Criteria NCT03868371 10 18 O
: NCT03868371 19 20 O

- NCT03868371 24 25 O
≥ NCT03868371 27 28 B-Eq-Comparison
18 NCT03868371 29 31 I-Eq-Comparison
years NCT03868371 32 37 I-Eq-Comparison
of NCT03868371 38 40 O
age NCT03868371 41 44 B-Age

- NCT03868371 47 48 O
Currently NCT03868371 50 59 B-Eq-Comparison
treated NCT03868371 60 67 B-Procedure
with NCT03868371 68 72 O
peritoneal NCT03868371 73 83 B-Procedure
dialysis NCT03868371 84 92 I-Procedure
( NCT03868371 93 94 O
APD NCT03868371 95 98 B-Procedure
or NCT03868371 99 101 B-Or
CAPD NCT03868371 102 106 B-Procedure
) NCT03868371 107 108 O

- NCT03868371 112 113 O
Serum NCT03868371 115 120 B-Observation
ionized NCT03868371 121 128 I-Observation
calcium NCT03868371 129 136 I-Observation
between NCT03868371 137 144 B-Eq-Comparison
1.10 NCT03868371 145 149 I-Eq-Comparison
and NCT03868371 150 153 I-Eq-Comparison
1.40 NCT03868371 154 158 I-Eq-Comparison
mmol NCT03868371 159 163 I-Eq-Comparison
/ NCT03868371 164 165 I-Eq-Comparison
L NCT03868371 166 167 I-Eq-Comparison
for NCT03868371 168 171 O
> NCT03868371 172 173 B-Eq-Comparison
3 NCT03868371 174 175 I-Eq-Comparison
months NCT03868371 176 182 I-Eq-Comparison

- NCT03868371 185 186 O
Plasma NCT03868371 188 194 B-Observation
phosphate NCT03868371 195 204 I-Observation
between NCT03868371 205 212 B-Eq-Comparison
0.7 NCT03868371 213 216 I-Eq-Comparison
and NCT03868371 217 220 I-Eq-Comparison
3.0 NCT03868371 221 224 I-Eq-Comparison
mmol NCT03868371 225 229 I-Eq-Comparison
/ NCT03868371 230 231 I-Eq-Comparison
L NCT03868371 232 233 I-Eq-Comparison
for NCT03868371 234 237 O
> NCT03868371 238 239 B-Eq-Comparison
3 NCT03868371 240 241 I-Eq-Comparison
months NCT03868371 242 248 I-Eq-Comparison

Exclusion NCT03868371 249 258 O
Criteria NCT03868371 259 267 O
: NCT03868371 268 269 O

- NCT03868371 273 274 O
Earlier NCT03868371 276 283 B-Eq-Comparison
parathyroidectomized NCT03868371 284 304 B-Condition

- NCT03868371 307 308 O
Other NCT03868371 310 315 B-Other
conditions NCT03868371 316 326 B-Condition
, NCT03868371 327 328 O
which NCT03868371 329 334 O
hinders NCT03868371 335 342 O
the NCT03868371 343 346 O
participation NCT03868371 347 360 O
in NCT03868371 361 363 O
the NCT03868371 364 367 O
trial NCT03868371 368 373 B-Study

Inclusion NCT03867903 0 9 O
Criteria NCT03867903 10 18 O
: NCT03867903 19 20 O

- NCT03867903 24 25 O
Study NCT03867903 27 32 O
participants NCT03867903 33 45 O
will NCT03867903 46 50 O
be NCT03867903 51 53 O
infants NCT03867903 54 61 B-Family-Member___Family-Member-Type:child
( NCT03867903 62 63 O
and NCT03867903 64 67 B-Or
their NCT03867903 68 73 O
parents NCT03867903 74 81 B-Family-Member___Family-Member-Type:parent
) NCT03867903 82 83 O
who NCT03867903 84 87 O
have NCT03867903 88 92 O
undergone NCT03867903 93 102 B-Eq-Comparison
cardiac NCT03867903 103 110 B-Procedure
surgery NCT03867903 111 118 I-Procedure
at NCT03867903 119 121 O
Children NCT03867903 122 130 O
's NCT03867903 130 132 O
Mercy NCT03867903 133 138 O
Kansas NCT03867903 139 145 O
City NCT03867903 146 150 O
in NCT03867903 151 153 O
the NCT03867903 154 157 O
first NCT03867903 158 163 B-Eq-Comparison
six NCT03867903 164 167 I-Eq-Comparison
weeks NCT03867903 168 173 I-Eq-Comparison
of NCT03867903 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:after
life NCT03867903 177 181 B-Birth
and NCT03867903 182 185 B-And
are NCT03867903 186 189 O
currently NCT03867903 190 199 B-Eq-Comparison
less NCT03867903 200 204 B-Eq-Comparison
than NCT03867903 205 209 I-Eq-Comparison
18 NCT03867903 210 212 I-Eq-Comparison
months NCT03867903 213 219 I-Eq-Comparison
of NCT03867903 220 222 O
age NCT03867903 223 226 B-Age
at NCT03867903 227 229 O
the NCT03867903 230 233 O
time NCT03867903 234 238 O
of NCT03867903 239 241 O
being NCT03867903 242 247 O
approached NCT03867903 248 258 O
for NCT03867903 259 262 O
participation NCT03867903 263 276 O
in NCT03867903 277 279 O
this NCT03867903 280 284 O
study NCT03867903 285 290 B-Study
. NCT03867903 290 291 O

Exclusion NCT03867903 293 302 O
Criteria NCT03867903 303 311 O
: NCT03867903 312 313 O

- NCT03867903 317 318 O
• NCT03867903 320 321 O
Families NCT03867903 322 330 O
without NCT03867903 331 338 O
access NCT03867903 339 345 O
to NCT03867903 346 348 O
a NCT03867903 349 350 O
personal NCT03867903 351 359 O
device NCT03867903 360 366 O
for NCT03867903 367 370 O
download NCT03867903 371 379 O
( NCT03867903 380 381 O
no NCT03867903 382 384 O
devices NCT03867903 385 392 O
will NCT03867903 393 397 O
be NCT03867903 398 400 O
provided NCT03867903 401 409 O
) NCT03867903 410 411 O

- NCT03867903 420 421 O
Children NCT03867903 423 431 B-Family-Member___Family-Member-Type:child
who NCT03867903 432 435 O
are NCT03867903 436 439 O
deceased NCT03867903 440 448 B-Death
prior NCT03867903 449 454 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867903 455 457 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867903 458 461 O
family NCT03867903 462 468 O
being NCT03867903 469 474 O
approached NCT03867903 475 485 O
for NCT03867903 486 489 O
study NCT03867903 490 495 B-Study
participation NCT03867903 496 509 O

- NCT03867903 517 518 O
Neonates NCT03867903 520 528 B-Family-Member___Family-Member-Type:child
that NCT03867903 529 533 O
are NCT03867903 534 537 O
considered NCT03867903 538 548 O
non NCT03867903 549 552 B-Condition
- NCT03867903 553 554 I-Condition
viable NCT03867903 555 561 I-Condition
, NCT03867903 562 563 O
or NCT03867903 564 566 B-Or
have NCT03867903 567 571 O
the NCT03867903 572 575 O
potential NCT03867903 576 585 B-Risk
to NCT03867903 586 588 O
be NCT03867903 589 591 O
non NCT03867903 592 595 B-Condition
- NCT03867903 596 597 I-Condition
viable NCT03867903 598 604 I-Condition

- NCT03867903 612 613 O
Spanish NCT03867903 615 622 O
- NCT03867903 623 624 O
only NCT03867903 625 629 O
speaking NCT03867903 630 638 O
families NCT03867903 639 647 O

Exclude NCT03867903 648 655 O
special NCT03867903 656 663 O
populations NCT03867903 664 675 O
: NCT03867903 676 677 O

• NCT03867903 679 680 O
Wards NCT03867903 681 686 B-Observation
of NCT03867903 687 689 I-Observation
the NCT03867903 690 693 I-Observation
state NCT03867903 694 699 I-Observation

Inclusion NCT03860922 0 9 O
Criteria NCT03860922 10 18 O
: NCT03860922 19 20 O

- NCT03860922 24 25 O
patients NCT03860922 27 35 O
in NCT03860922 36 38 O
different NCT03860922 39 48 O
age NCT03860922 49 52 O
groups NCT03860922 53 59 O
and NCT03860922 60 63 O
both NCT03860922 64 68 O
sex NCT03860922 69 72 O
referred NCT03860922 73 81 O
from NCT03860922 82 86 O
orthopedic NCT03860922 87 97 O
outpatient NCT03860922 98 108 B-Encounter
clinic NCT03860922 109 115 O
with NCT03860922 116 120 B-And
chronic NCT03860922 121 128 B-Modifier
ankle NCT03860922 129 134 I-Modifier
pain NCT03860922 135 139 B-Condition
and NCT03860922 140 143 B-And
suspected NCT03860922 144 153 B-Assertion___Assertion-Type-Value:possible
clinically NCT03860922 154 164 O
to NCT03860922 165 167 O
have NCT03860922 168 172 O
impingement NCT03860922 173 184 B-Condition
syndrome NCT03860922 185 193 I-Condition
. NCT03860922 193 194 O

Exclusion NCT03860922 196 205 O
Criteria NCT03860922 206 214 O
: NCT03860922 215 216 O

1 NCT03860922 220 221 O
. NCT03860922 221 222 O
Inflammatory NCT03860922 224 236 B-Condition
arthritis NCT03860922 237 246 I-Condition
of NCT03860922 247 249 O
ankle NCT03860922 250 255 B-Modifier
joint NCT03860922 256 261 I-Modifier
, NCT03860922 262 263 O
infection NCT03860922 264 273 B-Condition
in NCT03860922 274 276 O
ankle NCT03860922 277 282 B-Modifier
joint NCT03860922 283 288 I-Modifier
, NCT03860922 289 290 O
neoplasm NCT03860922 291 299 B-Modifier
around NCT03860922 300 306 B-Modifier
ankle NCT03860922 307 312 I-Modifier
joint NCT03860922 313 318 I-Modifier
. NCT03860922 318 319 O

2 NCT03860922 323 324 O
. NCT03860922 324 325 O
Patients NCT03860922 327 335 O
with NCT03860922 336 340 O
contraindications NCT03860922 341 358 B-Contraindication
for NCT03860922 359 362 O
MRI NCT03860922 363 366 B-Procedure
, NCT03860922 367 368 O
e. NCT03860922 369 371 O
g. NCT03860922 372 374 O
an NCT03860922 376 378 O
implanted NCT03860922 379 388 B-Procedure
magnetic NCT03860922 389 397 I-Procedure
device NCT03860922 398 404 I-Procedure
, NCT03860922 405 406 O
pacemakers NCT03860922 407 417 B-Procedure
or NCT03860922 418 420 B-Or
claustrophobia NCT03860922 421 435 B-Condition
. NCT03860922 435 436 O

Inclusion NCT03868774 0 9 O
Criteria NCT03868774 10 18 O
: NCT03868774 19 20 O

1 NCT03868774 24 25 O
. NCT03868774 25 26 O
Moderate NCT03868774 28 36 B-Eq-Comparison
- NCT03868774 37 38 I-Eq-Comparison
severe NCT03868774 39 45 I-Eq-Comparison
uni NCT03868774 46 49 B-Modifier
- NCT03868774 50 51 I-Modifier
and NCT03868774 52 55 B-Or
bipolar NCT03868774 56 63 B-Modifier
depression NCT03868774 64 74 B-Condition
according NCT03868774 75 84 O
to NCT03868774 85 87 O
the NCT03868774 88 91 O
International NCT03868774 92 105 O
Classification NCT03868774 106 120 O
of NCT03868774 121 123 O
Diseases NCT03868774 124 132 O
( NCT03868774 133 134 O
ICD NCT03868774 135 138 O
- NCT03868774 139 140 O
10 NCT03868774 141 143 O
) NCT03868774 144 145 O

2 NCT03868774 149 150 O
. NCT03868774 150 151 O
A NCT03868774 153 154 O
Hamilton NCT03868774 155 163 B-Observation
scale NCT03868774 164 169 I-Observation
score NCT03868774 170 175 O
( NCT03868774 176 177 O
HDS NCT03868774 178 181 B-Observation
- NCT03868774 182 183 I-Observation
17 NCT03868774 184 186 I-Observation
) NCT03868774 187 188 O
of NCT03868774 189 191 O
≥ NCT03868774 192 193 B-Eq-Comparison
18 NCT03868774 194 196 I-Eq-Comparison
and NCT03868774 197 200 B-Or
/ NCT03868774 201 202 I-Or
or NCT03868774 203 205 I-Or
a NCT03868774 206 207 O
sub NCT03868774 208 211 B-Observation
- NCT03868774 212 213 I-Observation
scale NCT03868774 214 219 I-Observation
( NCT03868774 220 221 O
HDSS NCT03868774 222 226 B-Observation
) NCT03868774 227 228 O
score NCT03868774 229 234 O
of NCT03868774 235 237 O
≥ NCT03868774 238 239 B-Eq-Comparison
9 NCT03868774 240 241 I-Eq-Comparison
within NCT03868774 242 248 B-Eq-Comparison
24 NCT03868774 249 251 I-Eq-Comparison
- NCT03868774 252 253 I-Eq-Comparison
48 NCT03868774 254 256 I-Eq-Comparison
hours NCT03868774 257 262 I-Eq-Comparison
before NCT03868774 263 269 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03868774 270 273 O
first NCT03868774 274 279 B-Eq-Comparison
treatment NCT03868774 280 289 B-Procedure

Exclusion NCT03868774 290 299 O
Criteria NCT03868774 300 308 O
: NCT03868774 309 310 O

1 NCT03868774 314 315 O
. NCT03868774 315 316 O
Organic NCT03868774 318 325 B-Modifier
brain NCT03868774 326 331 B-Condition
disease NCT03868774 332 339 I-Condition
. NCT03868774 339 340 O

2 NCT03868774 344 345 I-Eq-Comparison
. NCT03868774 345 346 O
Epileptic NCT03868774 348 357 B-Condition
seizure NCT03868774 358 365 I-Condition
< NCT03868774 366 367 B-Eq-Comparison
2 NCT03868774 368 369 O
years NCT03868774 370 375 I-Eq-Comparison

3 NCT03868774 378 379 O
. NCT03868774 379 380 O
Patients NCT03868774 382 390 O
with NCT03868774 391 395 O
implanted NCT03868774 396 405 B-Procedure
metal NCT03868774 406 411 I-Procedure
parts NCT03868774 412 417 I-Procedure
in NCT03868774 418 420 O
the NCT03868774 421 424 O
brain NCT03868774 425 430 B-Modifier
or NCT03868774 431 433 B-Or
chest NCT03868774 434 439 B-Modifier

4 NCT03868774 442 443 O
. NCT03868774 443 444 O
Patients NCT03868774 446 454 O
with NCT03868774 455 459 O
pacemaker NCT03868774 460 469 B-Procedure

5 NCT03868774 472 473 O
. NCT03868774 473 474 O
Medical NCT03868774 476 483 O
diseases NCT03868774 484 492 B-Condition
with NCT03868774 493 497 O
cerebral NCT03868774 498 506 B-Condition
impact NCT03868774 507 513 O

6 NCT03868774 516 517 O
. NCT03868774 517 518 O
Serious NCT03868774 520 527 O
suicidal NCT03868774 528 536 B-Condition
danger NCT03868774 537 543 B-Risk


Inclusion NCT03861988 0 9 O
Criteria NCT03861988 10 18 O
: NCT03861988 19 20 O

- NCT03861988 24 25 O
Patient NCT03861988 27 34 O
presenting NCT03861988 35 45 O
for NCT03861988 46 49 O
primary NCT03861988 50 57 B-Modifier
total NCT03861988 58 63 B-Procedure
joint NCT03861988 64 69 I-Procedure
arthroplasty NCT03861988 70 82 I-Procedure

- NCT03861988 85 86 O
Major NCT03861988 88 93 O
Depressive NCT03861988 94 104 B-Condition
Disorder NCT03861988 105 113 I-Condition

Exclusion NCT03861988 114 123 O
Criteria NCT03861988 124 132 O
: NCT03861988 133 134 O

- NCT03861988 138 139 O
Pregnant NCT03861988 141 149 B-Condition
of NCT03861988 150 152 O
breastfeeding NCT03861988 153 166 B-Condition
women NCT03861988 167 172 O

Inclusion NCT03864172 0 9 O
Criteria NCT03864172 10 18 O

- NCT03864172 21 22 O
Screened NCT03864172 24 32 O
to NCT03864172 33 35 O
be NCT03864172 36 38 O
generally NCT03864172 39 48 O
healthy NCT03864172 49 56 B-Condition
as NCT03864172 57 59 O
determined NCT03864172 60 70 O
by NCT03864172 71 73 O
standard NCT03864172 74 82 B-Procedure
medical NCT03864172 83 90 I-Procedure
assessment NCT03864172 91 101 I-Procedure
on NCT03864172 102 104 O
physical NCT03864172 105 113 B-Modifier
and NCT03864172 114 117 B-Or
mental NCT03864172 118 124 B-Modifier
health NCT03864172 125 131 I-Modifier

- NCT03864172 134 135 O
Tanner NCT03864172 137 143 B-Condition
stage NCT03864172 144 149 B-Eq-Comparison
2 NCT03864172 150 151 I-Eq-Comparison
based NCT03864172 152 157 O
on NCT03864172 158 160 O
breast NCT03864172 161 167 B-Condition
development NCT03864172 168 179 I-Condition
for NCT03864172 180 183 O
girls NCT03864172 184 189 O
, NCT03864172 190 191 O
and NCT03864172 192 195 B-Or
pubic NCT03864172 196 201 B-Condition
hair NCT03864172 202 206 I-Condition
in NCT03864172 207 209 O
boys NCT03864172 210 214 O
. NCT03864172 214 215 O
Girls NCT03864172 217 222 O
will NCT03864172 223 227 O
have NCT03864172 228 232 O
to NCT03864172 233 235 O
be NCT03864172 236 238 O
premenarcheal NCT03864172 239 252 B-Condition

- NCT03864172 255 256 O
Having NCT03864172 258 264 O
obtained NCT03864172 265 273 O
his NCT03864172 274 277 O
/ NCT03864172 278 279 O
her NCT03864172 280 283 O
informed NCT03864172 284 292 O
consent NCT03864172 293 300 O
and NCT03864172 301 304 O
parents NCT03864172 305 312 O
or NCT03864172 313 315 O
legal NCT03864172 316 321 O
guardians NCT03864172 322 331 O
consent NCT03864172 332 339 O

Exclusion NCT03864172 340 349 O
Criteria NCT03864172 350 358 O
: NCT03864172 359 360 O

- NCT03864172 364 365 O
History NCT03864172 367 374 B-Eq-Comparison
of NCT03864172 375 377 O
serious NCT03864172 378 385 O
medical NCT03864172 386 393 B-Condition
conditions NCT03864172 394 404 I-Condition
such NCT03864172 405 409 O
as NCT03864172 410 412 O
intestinal NCT03864172 413 423 B-Modifier
or NCT03864172 424 426 B-Or
severe NCT03864172 427 433 O
metabolic NCT03864172 434 443 B-Condition
diseases NCT03864172 444 452 I-Condition
, NCT03864172 453 454 O
disorders NCT03864172 455 464 B-Condition
such NCT03864172 465 469 O
as NCT03864172 470 472 O
diabetes NCT03864172 473 481 B-Condition
, NCT03864172 482 483 O
renal NCT03864172 484 489 B-Modifier
, NCT03864172 490 491 O
hepatic NCT03864172 492 499 B-Modifier
or NCT03864172 500 502 B-Or
pancreatic NCT03864172 503 513 B-Modifier
diseases NCT03864172 514 522 B-Condition
, NCT03864172 523 524 O
disorders NCT03864172 525 534 B-Condition
, NCT03864172 535 536 O
ulcer NCT03864172 537 542 B-Condition
, NCT03864172 543 544 O
hyperthyroidism NCT03864172 545 560 B-Condition
, NCT03864172 561 562 O
malignance NCT03864172 563 573 B-Condition
, NCT03864172 574 575 O
chronic NCT03864172 576 583 B-Modifier
malnutrition NCT03864172 584 596 B-Condition
, NCT03864172 597 598 O
anaemia NCT03864172 599 606 B-Condition

- NCT03864172 609 610 O
History NCT03864172 612 619 B-Eq-Comparison
or NCT03864172 620 622 B-Or
on NCT03864172 623 625 B-Eq-Comparison
therapy NCT03864172 626 633 B-Procedure
with NCT03864172 634 638 O
medication NCT03864172 639 649 B-Drug
known NCT03864172 650 655 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864172 656 658 I-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864172 659 668 O
with NCT03864172 669 673 O
bone NCT03864172 674 678 B-Condition
metabolism NCT03864172 679 689 I-Condition
such NCT03864172 690 694 O
as NCT03864172 695 697 O
steroids NCT03864172 698 706 B-Drug
, NCT03864172 707 708 O
hormones NCT03864172 709 717 B-Drug
, NCT03864172 718 719 O
diuretics NCT03864172 720 729 B-Drug
, NCT03864172 730 731 O
cortisone NCT03864172 732 741 B-Drug
or NCT03864172 742 744 B-Or
anti NCT03864172 745 749 O
- NCT03864172 750 751 O
seizure NCT03864172 752 759 B-Condition
medication NCT03864172 760 770 B-Drug

- NCT03864172 773 774 O
Taking NCT03864172 776 782 B-Eq-Comparison
regularly NCT03864172 783 792 O
any NCT03864172 793 796 O
nutritional NCT03864172 797 808 B-Drug
supplements NCT03864172 809 820 I-Drug
and NCT03864172 821 824 B-And
unwilling NCT03864172 825 834 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864172 835 837 O
stop NCT03864172 838 842 B-Negation
for NCT03864172 843 846 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864172 847 850 I-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03864172 851 856 B-Study

Inclusion NCT03864614 0 9 O
Criteria NCT03864614 10 18 O
: NCT03864614 19 20 O

1 NCT03864614 24 25 O
. NCT03864614 25 26 O
Subject NCT03864614 28 35 O
has NCT03864614 36 39 O
a NCT03864614 40 41 O
diagnosis NCT03864614 42 51 O
of NCT03864614 52 54 O
MDD NCT03864614 55 58 B-Condition
as NCT03864614 59 61 O
diagnosed NCT03864614 62 71 O
by NCT03864614 72 74 O
SCID NCT03864614 75 79 O
- NCT03864614 80 81 O
5 NCT03864614 82 83 O
- NCT03864614 84 85 O
CT NCT03864614 86 88 O
, NCT03864614 89 90 O
with NCT03864614 91 95 B-And
symptoms NCT03864614 96 104 B-Coreference
that NCT03864614 105 109 O
have NCT03864614 110 114 O
been NCT03864614 115 119 O
present NCT03864614 120 127 O
for NCT03864614 128 131 O
at NCT03864614 132 134 B-Eq-Comparison
least NCT03864614 135 140 I-Eq-Comparison
a NCT03864614 141 142 O
4 NCT03864614 143 144 I-Eq-Comparison
- NCT03864614 145 146 I-Eq-Comparison
week NCT03864614 147 151 I-Eq-Comparison
period NCT03864614 152 158 O
. NCT03864614 158 159 O

2 NCT03864614 163 164 O
. NCT03864614 164 165 O
Subject NCT03864614 167 174 O
is NCT03864614 175 177 O
in NCT03864614 178 180 O
good NCT03864614 181 185 B-Condition
physical NCT03864614 186 194 I-Condition
health NCT03864614 195 201 I-Condition
and NCT03864614 202 205 B-And
has NCT03864614 206 209 O
no NCT03864614 210 212 B-Negation
clinically NCT03864614 213 223 O
significant NCT03864614 224 235 O
findings NCT03864614 236 244 B-Condition
, NCT03864614 245 246 O
as NCT03864614 247 249 O
determined NCT03864614 250 260 O
by NCT03864614 261 263 O
the NCT03864614 264 267 O
Investigator NCT03864614 268 280 O
, NCT03864614 281 282 O
on NCT03864614 283 285 O
physical NCT03864614 286 294 B-Procedure
examination NCT03864614 295 306 I-Procedure
, NCT03864614 307 308 O
12 NCT03864614 309 311 B-Procedure
- NCT03864614 312 313 I-Procedure
lead NCT03864614 314 318 I-Procedure
ECG NCT03864614 319 322 I-Procedure
, NCT03864614 323 324 O
or NCT03864614 325 327 B-Or
clinical NCT03864614 328 336 O
laboratory NCT03864614 337 347 B-Observation
tests NCT03864614 348 353 I-Observation
. NCT03864614 353 354 O

Exclusion NCT03864614 356 365 O
Criteria NCT03864614 366 374 O
: NCT03864614 375 376 O

1 NCT03864614 380 381 O
. NCT03864614 381 382 O
Subject NCT03864614 384 391 O
has NCT03864614 392 395 O
attempted NCT03864614 396 405 B-Condition
suicide NCT03864614 406 413 I-Condition
associated NCT03864614 414 424 B-Temporal-Connection___Temporal-Connection-Type-Value:during
with NCT03864614 425 429 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864614 430 433 O
current NCT03864614 434 441 B-Eq-Comparison
episode NCT03864614 442 449 O
of NCT03864614 450 452 O
MDD NCT03864614 453 456 B-Condition
. NCT03864614 456 457 O

2 NCT03864614 461 462 O
. NCT03864614 462 463 O
Subject NCT03864614 465 472 O
has NCT03864614 473 476 O
a NCT03864614 477 478 O
medical NCT03864614 479 486 O
history NCT03864614 487 494 B-Eq-Comparison
of NCT03864614 495 497 O
bipolar NCT03864614 498 505 B-Condition
disorder NCT03864614 506 514 I-Condition
, NCT03864614 515 516 O
schizophrenia NCT03864614 517 530 B-Condition
, NCT03864614 531 532 O
and NCT03864614 533 536 B-Or
/ NCT03864614 537 538 I-Or
or NCT03864614 539 541 I-Or
schizoaffective NCT03864614 542 557 B-Condition
disorder NCT03864614 558 566 I-Condition
. NCT03864614 566 567 O

3 NCT03864614 571 572 O
. NCT03864614 572 573 O
Subject NCT03864614 575 582 O
has NCT03864614 583 586 O
had NCT03864614 587 590 B-Eq-Comparison
vagus NCT03864614 591 596 B-Procedure
nerve NCT03864614 597 602 I-Procedure
stimulation NCT03864614 603 614 I-Procedure
, NCT03864614 615 616 O
electroconvulsive NCT03864614 617 634 B-Procedure
therapy NCT03864614 635 642 I-Procedure
, NCT03864614 643 644 O
or NCT03864614 645 647 B-Or
has NCT03864614 648 651 O
taken NCT03864614 652 657 B-Eq-Comparison
ketamine NCT03864614 658 666 B-Drug
( NCT03864614 667 668 O
including NCT03864614 669 678 O
esketamine NCT03864614 679 689 B-Drug
) NCT03864614 690 691 O
within NCT03864614 692 698 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864614 699 702 I-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03864614 703 710 B-Eq-Comparison
major NCT03864614 711 716 O
depressive NCT03864614 717 727 B-Condition
episode NCT03864614 728 735 I-Condition
. NCT03864614 735 736 O

Inclusion NCT03861585 0 9 O
Criteria NCT03861585 10 18 O
: NCT03861585 19 20 O

- NCT03861585 24 25 O
Children NCT03861585 27 35 O
between NCT03861585 36 43 B-Eq-Comparison
7 NCT03861585 44 45 I-Eq-Comparison
and NCT03861585 46 49 I-Eq-Comparison
12 NCT03861585 50 52 I-Eq-Comparison
years NCT03861585 53 58 I-Eq-Comparison
old NCT03861585 59 62 B-Age
… NCT03861585 62 63 O
… NCT03861585 63 64 O
… NCT03861585 64 65 O
… NCT03861585 65 66 O
… NCT03861585 66 67 O
… NCT03861585 67 68 O
… NCT03861585 68 69 O
… NCT03861585 69 70 O
… NCT03861585 70 71 O
… NCT03861585 71 72 O
… NCT03861585 72 73 O
. NCT03861585 73 74 O

- NCT03861585 78 79 O
Normal NCT03861585 81 87 O
or NCT03861585 88 90 B-Or
corrected NCT03861585 91 100 B-Modifier
visual NCT03861585 101 107 B-Condition
acuity NCT03861585 108 114 I-Condition
… NCT03861585 115 116 O
… NCT03861585 116 117 O
… NCT03861585 117 118 O
… NCT03861585 118 119 O
… NCT03861585 119 120 O
… NCT03861585 120 121 O
… NCT03861585 121 122 O
… NCT03861585 122 123 O
… NCT03861585 123 124 O
… NCT03861585 124 125 O
… NCT03861585 125 126 O
… NCT03861585 126 127 O
. NCT03861585 127 128 O

- NCT03861585 132 133 O
ADHD NCT03861585 135 139 B-Condition
diagnostic NCT03861585 140 150 O
given NCT03861585 151 156 O
by NCT03861585 157 159 O
a NCT03861585 160 161 O
doctor NCT03861585 162 168 O
according NCT03861585 169 178 O
to NCT03861585 179 181 O
DSM NCT03861585 182 185 O
5 NCT03861585 186 187 O
criteria NCT03861585 188 196 O
( NCT03861585 197 198 O
Diagnostic NCT03861585 199 209 O
and NCT03861585 210 213 O
Statistical NCT03861585 214 225 O
Manual NCT03861585 226 232 O
of NCT03861585 233 235 O
Mental NCT03861585 236 242 O
Disorders NCT03861585 243 252 O
) NCT03861585 253 254 O

- NCT03861585 258 259 O
Free NCT03861585 261 265 B-Negation
from NCT03861585 266 270 I-Negation
drug NCT03861585 271 275 B-Drug
treatment NCT03861585 276 285 B-Procedure
until NCT03861585 286 291 B-Eq-Comparison
24 NCT03861585 292 294 I-Eq-Comparison
hours NCT03861585 295 300 I-Eq-Comparison
before NCT03861585 301 307 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861585 308 311 O
experiment NCT03861585 312 322 B-Study
session NCT03861585 323 330 O
… NCT03861585 330 331 O
… NCT03861585 331 332 O
… NCT03861585 332 333 O
… NCT03861585 333 334 O
… NCT03861585 334 335 O
… NCT03861585 335 336 O
… NCT03861585 336 337 O
… NCT03861585 337 338 O
… NCT03861585 338 339 O
. NCT03861585 339 340 O

- NCT03861585 344 345 O
Affiliation NCT03861585 347 358 O
to NCT03861585 359 361 O
a NCT03861585 362 363 O
social NCT03861585 364 370 O
security NCT03861585 371 379 O
system NCT03861585 380 386 O
… NCT03861585 386 387 O
… NCT03861585 387 388 O
… NCT03861585 388 389 O
… NCT03861585 389 390 O
… NCT03861585 390 391 O
… NCT03861585 391 392 O
… NCT03861585 392 393 O
… NCT03861585 393 394 O
. NCT03861585 394 395 O

- NCT03861585 399 400 O
Signature NCT03861585 402 411 O
of NCT03861585 412 414 O
the NCT03861585 415 418 O
authorization NCT03861585 419 432 O
documents NCT03861585 433 442 O
from NCT03861585 443 447 O
one NCT03861585 448 451 O
parent NCT03861585 452 458 O
or NCT03861585 459 461 O
the NCT03861585 462 465 O
holder NCT03861585 466 472 O
of NCT03861585 473 475 O
parental NCT03861585 476 484 O
authority NCT03861585 485 494 O

Exclusion NCT03861585 495 504 O
Criteria NCT03861585 505 513 O
: NCT03861585 514 515 O

- NCT03861585 518 519 O
History NCT03861585 520 527 B-Eq-Comparison
of NCT03861585 528 530 O
neurological NCT03861585 531 543 B-Condition
troubles NCT03861585 544 552 I-Condition
, NCT03861585 553 554 O
dysphasia NCT03861585 555 564 B-Condition
, NCT03861585 565 566 O
autistic NCT03861585 567 575 B-Condition
spectrum NCT03861585 576 584 I-Condition
disorder NCT03861585 585 593 I-Condition
, NCT03861585 594 595 O
intellectual NCT03861585 596 608 B-Condition
disabilities NCT03861585 609 621 I-Condition


Inclusion NCT03863392 0 9 O
Criteria NCT03863392 10 18 O
: NCT03863392 19 20 O

- NCT03863392 24 25 O
Primigravida NCT03863392 27 39 B-Condition
or NCT03863392 40 42 B-Or
Primipara NCT03863392 43 52 B-Condition

- NCT03863392 55 56 O
Pregnancy NCT03863392 58 67 B-Condition
between NCT03863392 68 75 B-Eq-Comparison
36 NCT03863392 76 78 I-Eq-Comparison
and NCT03863392 79 82 I-Eq-Comparison
42 NCT03863392 83 85 I-Eq-Comparison
weeks NCT03863392 86 91 I-Eq-Comparison
of NCT03863392 92 94 O
gestation NCT03863392 95 104 B-Observation
. NCT03863392 104 105 O

- NCT03863392 109 110 O
A NCT03863392 112 113 O
live NCT03863392 114 118 B-Modifier
singleton NCT03863392 119 128 B-Condition
fetus NCT03863392 129 134 I-Condition
in NCT03863392 135 137 O
cephalic NCT03863392 138 146 B-Modifier
presentation NCT03863392 147 159 I-Modifier
. NCT03863392 159 160 O

- NCT03863392 164 165 O
No NCT03863392 167 169 B-Negation
history NCT03863392 170 177 B-Eq-Comparison
of NCT03863392 178 180 O
uterine NCT03863392 181 188 B-Procedure
surgery NCT03863392 189 196 I-Procedure
. NCT03863392 196 197 O

- NCT03863392 201 202 O
Clinically NCT03863392 204 214 O
adequate NCT03863392 215 223 O
pelvis NCT03863392 224 230 B-Condition
. NCT03863392 230 231 O

- NCT03863392 235 236 O
Modified NCT03863392 238 246 B-Modifier
Bishop NCT03863392 247 253 B-Observation
's NCT03863392 253 255 O
score NCT03863392 256 261 I-Observation
< NCT03863392 262 263 B-Eq-Comparison
5 NCT03863392 264 265 I-Eq-Comparison
. NCT03863392 265 266 O

- NCT03863392 270 271 O
Reactive NCT03863392 273 281 O
Non NCT03863392 282 285 B-Procedure
stress NCT03863392 286 292 I-Procedure
test NCT03863392 293 297 I-Procedure
( NCT03863392 298 299 O
NST NCT03863392 300 303 B-Procedure
) NCT03863392 304 305 O
. NCT03863392 306 307 O

Exclusion NCT03863392 309 318 O
Criteria NCT03863392 319 327 O
: NCT03863392 328 329 O

- NCT03863392 333 334 O
•Known NCT03863392 336 342 O
hypersensitivity NCT03863392 343 359 B-Condition
or NCT03863392 360 362 B-Or
contraindications NCT03863392 363 380 B-Contraindication
to NCT03863392 381 383 O
oral NCT03863392 384 388 B-Modifier
misoprostol NCT03863392 389 400 B-Drug
( NCT03863392 401 402 O
uterine NCT03863392 403 410 B-Procedure
surgery NCT03863392 411 418 I-Procedure
) NCT03863392 419 420 O
. NCT03863392 421 422 O

- NCT03863392 431 432 O
Any NCT03863392 434 437 O
antenatal NCT03863392 438 447 B-Modifier
medical NCT03863392 448 455 O
complications NCT03863392 456 469 B-Condition
. NCT03863392 469 470 O

- NCT03863392 479 480 O
A NCT03863392 482 483 O
situation NCT03863392 484 493 B-Condition
requiring NCT03863392 494 503 B-Assertion___Assertion-Type-Value:hypothetical
LSCS NCT03863392 504 508 B-Procedure
( NCT03863392 509 510 O
Maternal NCT03863392 511 519 B-Modifier
or NCT03863392 520 522 B-Or
Fetal NCT03863392 523 528 B-Modifier
) NCT03863392 529 530 O
e. NCT03863392 531 533 O
g NCT03863392 534 535 O
: NCT03863392 536 537 O
fetal NCT03863392 538 543 B-Condition
distress NCT03863392 544 552 I-Condition

- NCT03863392 560 561 O
Non NCT03863392 563 566 O
- NCT03863392 567 568 O
reactive NCT03863392 569 577 O
NST NCT03863392 578 581 B-Procedure
. NCT03863392 581 582 O

- NCT03863392 591 592 O
Patient NCT03863392 594 601 O
's NCT03863392 601 603 O
refusal NCT03863392 604 611 O
to NCT03863392 612 614 O
give NCT03863392 615 619 O
consent NCT03863392 620 627 O

Inclusion NCT03860857 0 9 O
Criteria NCT03860857 10 18 O
: NCT03860857 19 20 O

1 NCT03860857 24 25 O
. NCT03860857 25 26 O
Between NCT03860857 28 35 B-Eq-Comparison
the NCT03860857 36 39 I-Eq-Comparison
ages NCT03860857 40 44 I-Age|Eq-Comparison
of NCT03860857 45 47 I-Eq-Comparison
60 NCT03860857 48 50 I-Eq-Comparison
and NCT03860857 51 54 I-Eq-Comparison
85 NCT03860857 55 57 I-Eq-Comparison
; NCT03860857 58 59 O

2 NCT03860857 62 63 O
. NCT03860857 63 64 O
Speaks NCT03860857 66 72 O
fluent NCT03860857 73 79 O
English NCT03860857 80 87 O
; NCT03860857 87 88 O

3 NCT03860857 91 92 O
. NCT03860857 92 93 O
Visual NCT03860857 95 101 B-Modifier
and NCT03860857 102 105 B-And
auditory NCT03860857 106 114 B-Modifier
acuity NCT03860857 115 121 B-Condition
adequate NCT03860857 122 130 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860857 131 134 I-Assertion___Assertion-Type-Value:hypothetical
neuropsychological NCT03860857 135 153 B-Modifier
and NCT03860857 154 157 B-And
computerized NCT03860857 158 170 B-Modifier
testing NCT03860857 171 178 B-Procedure
; NCT03860857 178 179 O

4 NCT03860857 182 183 O
. NCT03860857 183 184 O
Good NCT03860857 186 190 O
general NCT03860857 191 198 B-Condition
health NCT03860857 199 205 I-Condition
with NCT03860857 206 210 B-And
no NCT03860857 211 213 B-Negation
disease NCT03860857 214 221 B-Condition
( NCT03860857 222 223 O
s NCT03860857 224 225 O
) NCT03860857 226 227 O
expected NCT03860857 228 236 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860857 237 239 I-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860857 240 249 O
with NCT03860857 250 254 O
the NCT03860857 255 258 O
study NCT03860857 259 264 B-Study
; NCT03860857 264 265 O

5 NCT03860857 268 269 O
. NCT03860857 269 270 O
Willing NCT03860857 272 279 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03860857 280 283 B-And
able NCT03860857 284 288 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860857 289 291 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03860857 292 303 O
for NCT03860857 304 307 O
the NCT03860857 308 311 O
duration NCT03860857 312 320 O
of NCT03860857 321 323 O
the NCT03860857 324 327 O
study NCT03860857 328 333 B-Study
and NCT03860857 334 337 B-And
in NCT03860857 338 340 O
all NCT03860857 341 344 O
study NCT03860857 345 350 B-Study
procedures NCT03860857 351 361 B-Procedure
including NCT03860857 362 371 O
MRI NCT03860857 372 375 B-Procedure
and NCT03860857 376 379 B-Or
PET NCT03860857 380 383 B-Procedure
; NCT03860857 383 384 O

6 NCT03860857 387 388 O
. NCT03860857 388 389 O
Normal NCT03860857 391 397 O
cognition NCT03860857 398 407 B-Condition
defined NCT03860857 408 415 O
as NCT03860857 416 418 O
a NCT03860857 419 420 O
Clinical NCT03860857 421 429 B-Observation
Dementia NCT03860857 430 438 I-Observation
Rating NCT03860857 439 445 I-Observation
of NCT03860857 446 448 O
0 NCT03860857 449 450 B-Eq-Comparison
and NCT03860857 451 454 B-And
a NCT03860857 455 456 O
Mini NCT03860857 457 461 B-Observation
- NCT03860857 462 463 I-Observation
Mental NCT03860857 464 470 I-Observation
State NCT03860857 471 476 I-Observation
Examination NCT03860857 477 488 I-Observation
score NCT03860857 489 494 B-Eq-Comparison
of NCT03860857 495 497 I-Eq-Comparison
27 NCT03860857 498 500 I-Eq-Comparison
or NCT03860857 501 503 I-Eq-Comparison
higher NCT03860857 504 510 I-Eq-Comparison
. NCT03860857 510 511 O

Exclusion NCT03860857 513 522 O
Criteria NCT03860857 523 531 O
: NCT03860857 532 533 O

1 NCT03860857 537 538 O
. NCT03860857 538 539 O
Significant NCT03860857 541 552 O
co NCT03860857 553 555 B-Modifier
- NCT03860857 556 557 I-Modifier
morbid NCT03860857 558 564 I-Modifier
neurologic NCT03860857 565 575 B-Condition
disease NCT03860857 576 583 I-Condition
such NCT03860857 584 588 O
as NCT03860857 589 591 O
Parkinson NCT03860857 592 601 B-Condition
's NCT03860857 601 603 O
disease NCT03860857 604 611 I-Condition
, NCT03860857 612 613 O
multiple NCT03860857 614 622 B-Condition
sclerosis NCT03860857 623 632 I-Condition
, NCT03860857 633 634 O
brain NCT03860857 635 640 B-Condition
cyst NCT03860857 641 645 I-Condition
, NCT03860857 646 647 O
tumor NCT03860857 648 653 B-Condition
or NCT03860857 654 656 B-Or
aneurysm NCT03860857 657 665 B-Condition
; NCT03860857 665 666 O

2 NCT03860857 669 670 O
. NCT03860857 670 671 O
Major NCT03860857 673 678 O
health NCT03860857 679 685 B-Condition
conditions NCT03860857 686 696 I-Condition
such NCT03860857 697 701 O
as NCT03860857 702 704 O
uncontrolled NCT03860857 705 717 B-Modifier
diabetes NCT03860857 718 726 B-Condition
mellitus NCT03860857 727 735 I-Condition
, NCT03860857 736 737 O
uncontrolled NCT03860857 738 750 B-Modifier
hypertension NCT03860857 751 763 B-Condition
, NCT03860857 764 765 O
nutritional NCT03860857 766 777 B-Condition
deficiency NCT03860857 778 788 I-Condition
or NCT03860857 789 791 B-Or
uncontrolled NCT03860857 792 804 B-Modifier
thyroid NCT03860857 805 812 B-Condition
disease NCT03860857 813 820 I-Condition
; NCT03860857 820 821 O

3 NCT03860857 824 825 O
. NCT03860857 825 826 O
Significant NCT03860857 828 839 O
psychiatric NCT03860857 840 851 B-Condition
disorders NCT03860857 852 861 I-Condition
such NCT03860857 862 866 O
as NCT03860857 867 869 O
schizophrenia NCT03860857 870 883 B-Condition
, NCT03860857 884 885 O
bipolar NCT03860857 886 893 B-Condition
disorder NCT03860857 894 902 I-Condition|Condition
, NCT03860857 903 904 O
anxiety NCT03860857 905 912 B-Condition
disorder NCT03860857 913 921 I-Condition
, NCT03860857 922 923 O
major NCT03860857 924 929 O
depressive NCT03860857 930 940 B-Condition
disorder NCT03860857 941 949 O
, NCT03860857 950 951 O
or NCT03860857 952 954 B-Or
attention NCT03860857 955 964 B-Condition
- NCT03860857 965 966 I-Condition
deficit NCT03860857 967 974 I-Condition
hyperactivity NCT03860857 975 988 I-Condition
disorder NCT03860857 989 997 I-Condition
; NCT03860857 997 998 O

4 NCT03860857 1001 1002 O
. NCT03860857 1002 1003 O
ADRC NCT03860857 1005 1009 O
consensus NCT03860857 1010 1019 O
diagnosis NCT03860857 1020 1029 O
of NCT03860857 1030 1032 O
dementia NCT03860857 1033 1041 B-Condition
or NCT03860857 1042 1044 B-Or
mild NCT03860857 1045 1049 O
cognitive NCT03860857 1050 1059 B-Condition
impairment NCT03860857 1060 1070 I-Condition|Condition
; NCT03860857 1070 1071 O

5 NCT03860857 1074 1075 O
. NCT03860857 1075 1076 O
Cognitive NCT03860857 1078 1087 B-Condition
impairment NCT03860857 1088 1098 O
when NCT03860857 1099 1103 O
tested NCT03860857 1104 1110 O
at NCT03860857 1111 1113 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860857 1114 1122 B-Study
( NCT03860857 1123 1124 O
defined NCT03860857 1125 1132 O
as NCT03860857 1133 1135 O
a NCT03860857 1136 1137 O
score NCT03860857 1138 1143 O
on NCT03860857 1144 1146 O
any NCT03860857 1147 1150 O
neuropsychological NCT03860857 1151 1169 B-Observation
test NCT03860857 1170 1174 I-Observation
of NCT03860857 1175 1177 O
1.5 NCT03860857 1178 1181 B-Eq-Comparison
SDs NCT03860857 1182 1185 I-Eq-Comparison
or NCT03860857 1186 1188 I-Eq-Comparison
more NCT03860857 1189 1193 I-Eq-Comparison
outside NCT03860857 1194 1201 B-Modifier
the NCT03860857 1202 1205 I-Modifier
age NCT03860857 1206 1209 I-Modifier
norm NCT03860857 1210 1214 I-Modifier
) NCT03860857 1215 1216 O
; NCT03860857 1217 1218 O

6 NCT03860857 1221 1222 O
. NCT03860857 1222 1223 O
Alcohol NCT03860857 1225 1232 B-Modifier
or NCT03860857 1233 1235 B-Or|Or
substance NCT03860857 1236 1245 B-Modifier
abuse NCT03860857 1246 1251 B-Condition
or NCT03860857 1252 1254 O
dependence NCT03860857 1255 1265 B-Condition
within NCT03860857 1266 1272 B-Eq-Comparison
the NCT03860857 1273 1276 I-Eq-Comparison
past NCT03860857 1277 1281 I-Eq-Comparison
2 NCT03860857 1282 1283 I-Eq-Comparison
years NCT03860857 1284 1289 I-Eq-Comparison
( NCT03860857 1290 1291 O
DSM NCT03860857 1292 1295 O
- NCT03860857 1296 1297 O
IV NCT03860857 1298 1300 O
criteria NCT03860857 1301 1309 O
) NCT03860857 1310 1311 O
; NCT03860857 1312 1313 O

7 NCT03860857 1316 1317 O
. NCT03860857 1317 1318 O
MRI NCT03860857 1320 1323 B-Procedure
contraindications NCT03860857 1324 1341 B-Contraindication
, NCT03860857 1342 1343 O
e. NCT03860857 1344 1346 O
g. NCT03860857 1347 1349 O
pacemakers NCT03860857 1351 1361 B-Procedure
, NCT03860857 1362 1363 O
aneurysm NCT03860857 1364 1372 B-Procedure
clips NCT03860857 1373 1378 I-Procedure
, NCT03860857 1379 1380 O
artificial NCT03860857 1381 1391 B-Procedure
heart NCT03860857 1392 1397 I-Procedure
valves NCT03860857 1398 1404 I-Procedure
, NCT03860857 1405 1406 O
ear NCT03860857 1407 1410 B-Procedure
implants NCT03860857 1411 1419 I-Procedure
, NCT03860857 1420 1421 O
metal NCT03860857 1422 1427 B-Condition
fragments NCT03860857 1428 1437 I-Condition
or NCT03860857 1438 1440 B-Or|Or
foreign NCT03860857 1441 1448 B-Modifier
objects NCT03860857 1449 1456 B-Condition
in NCT03860857 1457 1459 O
the NCT03860857 1460 1463 O
eyes NCT03860857 1464 1468 B-Modifier
, NCT03860857 1469 1470 O
skin NCT03860857 1471 1475 B-Modifier
or NCT03860857 1476 1478 B-Or
body NCT03860857 1479 1483 B-Modifier
. NCT03860857 1483 1484 O
Females NCT03860857 1486 1493 O
who NCT03860857 1494 1497 B-And
are NCT03860857 1498 1501 O
pregnant NCT03860857 1502 1510 B-Condition|Condition
or NCT03860857 1511 1513 O
trying NCT03860857 1514 1520 B-Assertion___Assertion-Type-Value:intention
to NCT03860857 1521 1523 I-Assertion___Assertion-Type-Value:intention
get NCT03860857 1524 1527 O
pregnant NCT03860857 1528 1536 O
are NCT03860857 1537 1540 O
also NCT03860857 1541 1545 O
excluded NCT03860857 1546 1554 B-Negation
; NCT03860857 1554 1555 O

8 NCT03860857 1558 1559 O
. NCT03860857 1559 1560 O
PET NCT03860857 1562 1565 B-Procedure
contraindications NCT03860857 1566 1583 B-Contraindication
, NCT03860857 1584 1585 O
e. NCT03860857 1586 1588 O
g. NCT03860857 1589 1591 O
significant NCT03860857 1593 1604 O
prior NCT03860857 1605 1610 B-Eq-Comparison
radiation NCT03860857 1611 1620 B-Condition
exposure NCT03860857 1621 1629 I-Condition
and NCT03860857 1630 1633 B-Or
pregnancy NCT03860857 1634 1643 B-Condition
. NCT03860857 1643 1644 O

Inclusion NCT03861546 0 9 O
Criteria NCT03861546 10 18 O
: NCT03861546 19 20 O

1 NCT03861546 24 25 O
. NCT03861546 25 26 O
age NCT03861546 28 31 B-Age
> NCT03861546 32 33 B-Eq-Comparison
18 NCT03861546 34 36 I-Eq-Comparison
years NCT03861546 37 42 I-Eq-Comparison
; NCT03861546 42 43 O

2 NCT03861546 46 47 O
. NCT03861546 47 48 O
confirmed NCT03861546 50 59 O
diagnosis NCT03861546 60 69 O
of NCT03861546 70 72 O
prediabetes NCT03861546 73 84 B-Condition
or NCT03861546 85 87 B-Or
T2D NCT03861546 88 91 B-Condition
( NCT03861546 92 93 O
documented NCT03861546 94 104 O
A1c NCT03861546 105 108 B-Observation
of NCT03861546 109 111 O
≥ NCT03861546 112 113 B-Eq-Comparison
5.7 NCT03861546 114 117 I-Eq-Comparison
% NCT03861546 118 119 O
, NCT03861546 120 121 O
2 NCT03861546 122 123 B-Observation
- NCT03861546 124 125 I-Observation
hour NCT03861546 126 130 I-Observation
post NCT03861546 131 135 I-Observation
- NCT03861546 136 137 I-Observation
load NCT03861546 138 142 I-Observation
glucose NCT03861546 143 150 I-Observation
of NCT03861546 151 153 O
> NCT03861546 154 155 B-Eq-Comparison
140 NCT03861546 156 159 I-Eq-Comparison
, NCT03861546 160 161 O
or NCT03861546 162 164 B-Or
FBG NCT03861546 165 168 B-Observation
of NCT03861546 169 171 O
> NCT03861546 172 173 B-Eq-Comparison
100 NCT03861546 174 177 I-Eq-Comparison
) NCT03861546 178 179 O
; NCT03861546 180 181 O

3 NCT03861546 184 185 O
. NCT03861546 185 186 O
a NCT03861546 188 189 O
family NCT03861546 190 196 B-Family-Member___Family-Member-Type:parent
member NCT03861546 197 203 O
or NCT03861546 204 206 O
peer NCT03861546 207 211 O
willing NCT03861546 212 219 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861546 220 222 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861546 223 234 O
and NCT03861546 235 238 O
attend NCT03861546 239 245 O
all NCT03861546 246 249 O
sessions NCT03861546 250 258 B-Procedure
as NCT03861546 259 261 O
a NCT03861546 262 263 O
social NCT03861546 264 270 O
influencer NCT03861546 271 281 O
; NCT03861546 281 282 O

4 NCT03861546 285 286 O
. NCT03861546 286 287 O
proficiency NCT03861546 289 300 O
in NCT03861546 301 303 O
English NCT03861546 304 311 O
of NCT03861546 312 314 O
at NCT03861546 315 317 B-Eq-Comparison
least NCT03861546 318 323 I-Eq-Comparison
one NCT03861546 324 327 I-Eq-Comparison
member NCT03861546 328 334 O
of NCT03861546 335 337 O
each NCT03861546 338 342 O
dyad NCT03861546 343 347 O
, NCT03861546 348 349 O

5 NCT03861546 353 354 O
. NCT03861546 354 355 O
willingness NCT03861546 357 368 O
to NCT03861546 369 371 O
provide NCT03861546 372 379 O
written NCT03861546 380 387 O
consent NCT03861546 388 395 O
. NCT03861546 395 396 O

Exclusion NCT03861546 398 407 O
Criteria NCT03861546 408 416 O
: NCT03861546 417 418 O

1 NCT03861546 422 423 I-Modifier
. NCT03861546 423 424 O
type NCT03861546 426 430 B-Modifier
1 NCT03861546 431 432 O
diabetes NCT03861546 433 441 B-Condition|Condition
or NCT03861546 442 444 B-Or
diabetes NCT03861546 445 453 O
secondary NCT03861546 454 463 B-Modifier
to NCT03861546 464 466 O
other NCT03861546 467 472 B-Other
conditions NCT03861546 473 483 B-Condition
( NCT03861546 484 485 O
e. NCT03861546 486 488 O
g. NCT03861546 489 491 O
steroid NCT03861546 493 500 B-Drug
- NCT03861546 501 502 O
induced NCT03861546 503 510 B-Modifier
, NCT03861546 511 512 O
pancreatic NCT03861546 513 523 B-Modifier
insufficiency NCT03861546 524 537 B-Condition
, NCT03861546 538 539 O
or NCT03861546 540 542 B-Or
chemotherapy NCT03861546 543 555 B-Procedure
- NCT03861546 556 557 O
induced NCT03861546 558 565 B-Modifier
) NCT03861546 566 567 O
; NCT03861546 568 569 O

2 NCT03861546 572 573 O
. NCT03861546 573 574 O
malignancy NCT03861546 576 586 B-Condition
or NCT03861546 587 589 B-Or
life NCT03861546 590 594 B-Death|Observation|Risk
- NCT03861546 595 596 I-Death|Risk
threatening NCT03861546 597 608 I-Death|Risk
illness NCT03861546 609 616 B-Condition
with NCT03861546 617 621 B-And
life NCT03861546 622 626 O
expectancy NCT03861546 627 637 I-Observation
of NCT03861546 638 640 O
< NCT03861546 641 642 B-Eq-Comparison
5 NCT03861546 643 644 I-Eq-Comparison
years NCT03861546 645 650 I-Eq-Comparison
; NCT03861546 650 651 O

3 NCT03861546 654 655 O
. NCT03861546 655 656 O
end NCT03861546 658 661 B-Modifier
- NCT03861546 662 663 I-Modifier
stage NCT03861546 664 669 I-Modifier
disease NCT03861546 670 677 B-Condition
or NCT03861546 678 680 B-Or
serious NCT03861546 681 688 O
illness NCT03861546 689 696 B-Condition
that NCT03861546 697 701 O
prohibits NCT03861546 702 711 B-Assertion___Assertion-Type-Value:hypothetical|Negation
participation NCT03861546 712 725 B-Study
( NCT03861546 726 727 O
e. NCT03861546 728 730 O
g. NCT03861546 731 733 O
end NCT03861546 735 738 B-Modifier
- NCT03861546 739 740 I-Modifier
stage NCT03861546 741 746 I-Modifier
renal NCT03861546 747 752 B-Condition
disease NCT03861546 753 760 I-Condition
or NCT03861546 761 763 B-Or
class NCT03861546 764 769 B-Eq-Comparison
IV NCT03861546 770 772 I-Eq-Comparison
congestive NCT03861546 773 783 B-Condition
heart NCT03861546 784 789 I-Condition
failure NCT03861546 790 797 I-Condition
) NCT03861546 798 799 O
; NCT03861546 800 801 O

4 NCT03861546 804 805 O
. NCT03861546 805 806 O
inability NCT03861546 808 817 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861546 818 820 O
perform NCT03861546 821 828 O
unsupervised NCT03861546 829 841 B-Modifier
physical NCT03861546 842 850 B-Observation
activity NCT03861546 851 859 I-Observation
; NCT03861546 859 860 O

5 NCT03861546 863 864 O
. NCT03861546 864 865 O
pregnancy NCT03861546 867 876 B-Condition
; NCT03861546 876 877 O

6 NCT03861546 880 881 O
. NCT03861546 881 882 O
diagnosed NCT03861546 884 893 O
cognitive NCT03861546 894 903 B-Condition
deficits NCT03861546 904 912 I-Condition
or NCT03861546 913 915 B-Or|Or
limited NCT03861546 916 923 O
decision NCT03861546 924 932 B-Condition
- NCT03861546 933 934 I-Condition
making NCT03861546 935 941 I-Condition
capacity NCT03861546 942 950 I-Condition
; NCT03861546 950 951 O

7 NCT03861546 954 955 O
. NCT03861546 955 956 O
alcohol NCT03861546 958 965 B-Modifier
or NCT03861546 966 968 B-Or
substance NCT03861546 969 978 B-Modifier
abuse NCT03861546 979 984 B-Condition
; NCT03861546 984 985 O

8 NCT03861546 988 989 O
. NCT03861546 989 990 O
homelessness NCT03861546 992 1004 B-Condition
or NCT03861546 1005 1007 O
no NCT03861546 1008 1010 B-Negation
fixed NCT03861546 1011 1016 O
address NCT03861546 1017 1024 O
. NCT03861546 1024 1025 O

Inclusion NCT03863379 0 9 O
Criteria NCT03863379 10 18 O
: NCT03863379 19 20 O

Persons NCT03863379 22 29 O
with NCT03863379 30 34 O

- NCT03863379 37 38 O
stroke NCT03863379 40 46 B-Condition
/ NCT03863379 47 48 B-Or
cerebrovascular NCT03863379 49 64 B-Condition
disease NCT03863379 65 72 I-Condition

- NCT03863379 75 76 O
traumatic NCT03863379 78 87 B-Condition
brain NCT03863379 88 93 I-Condition
injury NCT03863379 94 100 I-Condition

- NCT03863379 103 104 O
multiple NCT03863379 106 114 B-Condition
sclerosis NCT03863379 115 124 I-Condition

- NCT03863379 127 128 O
spinal NCT03863379 130 136 B-Modifier
cord NCT03863379 137 141 I-Modifier
injuries NCT03863379 142 150 B-Condition
( NCT03863379 151 152 O
including NCT03863379 153 162 O
spinal NCT03863379 163 169 B-Modifier
cord NCT03863379 170 174 I-Modifier
lesions NCT03863379 175 182 B-Condition
i. NCT03863379 183 185 O
e. NCT03863379 186 188 O
myelopathies NCT03863379 190 202 B-Condition
etc NCT03863379 203 206 O
. NCT03863379 206 207 O
) NCT03863379 208 209 O

Exclusion NCT03863379 211 220 O
Criteria NCT03863379 221 229 O
: NCT03863379 230 231 O

Persons NCT03863379 233 240 O
with NCT03863379 241 245 O

- NCT03863379 248 249 O
heterotopic NCT03863379 251 262 B-Condition
ossifications NCT03863379 263 276 I-Condition
, NCT03863379 277 278 O

- NCT03863379 282 283 O
chronic NCT03863379 285 292 B-Modifier
administration NCT03863379 293 307 O
of NCT03863379 308 310 O
drugs NCT03863379 311 316 B-Drug
, NCT03863379 317 318 O
which NCT03863379 319 324 O
promote NCT03863379 325 332 O
fat NCT03863379 333 336 B-Condition
increase NCT03863379 337 345 O

- NCT03863379 348 349 O
chronic NCT03863379 351 358 B-Modifier
administration NCT03863379 359 373 O
of NCT03863379 374 376 O
drugs NCT03863379 377 382 B-Drug
, NCT03863379 383 384 O
which NCT03863379 385 390 O
promote NCT03863379 391 398 O
bone NCT03863379 399 403 B-Modifier
or NCT03863379 404 406 B-Or
muscle NCT03863379 407 413 B-Modifier
loss NCT03863379 414 418 B-Condition

- NCT03863379 421 422 I-Modifier
co NCT03863379 424 426 B-Modifier
- NCT03863379 427 428 O
existing NCT03863379 429 437 I-Modifier
other NCT03863379 438 443 B-Other
diseases NCT03863379 444 452 B-Condition
such NCT03863379 453 457 O
as NCT03863379 458 460 O
: NCT03863379 461 462 O
endocrinopathies NCT03863379 463 479 B-Condition
, NCT03863379 480 481 O
muscular NCT03863379 482 490 B-Condition
dystrophies NCT03863379 491 502 I-Condition
, NCT03863379 503 504 O
non NCT03863379 505 508 B-Negation
- NCT03863379 509 510 O
alcoholic NCT03863379 511 520 B-Modifier
fatty NCT03863379 521 526 B-Condition
liver NCT03863379 527 532 I-Condition
disease NCT03863379 533 540 I-Condition
. NCT03863379 540 541 O

Inclusion NCT03861208 0 9 O
Criteria NCT03861208 10 18 O
: NCT03861208 19 20 O

- NCT03861208 24 25 O
healthy NCT03861208 27 34 B-Condition
children NCT03861208 35 43 O

Exclusion NCT03861208 44 53 O
Criteria NCT03861208 54 62 O
: NCT03861208 63 64 O

- NCT03861208 68 69 O
no NCT03861208 71 73 B-Negation
food NCT03861208 74 78 O
allergies NCT03861208 79 88 B-Allergy

- NCT03861208 91 92 O
no NCT03861208 94 96 B-Negation
medications NCT03861208 97 108 B-Drug
that NCT03861208 109 113 O
affect NCT03861208 114 120 B-Assertion___Assertion-Type-Value:hypothetical
behavior NCT03861208 121 129 B-Condition
/ NCT03861208 130 131 B-Or
learning NCT03861208 132 140 B-Condition
/ NCT03861208 141 142 B-Or
appetite NCT03861208 143 151 B-Condition

Inclusion NCT03860116 0 9 O
Criteria NCT03860116 10 18 O
: NCT03860116 19 20 O

- NCT03860116 24 25 O
1 NCT03860116 27 28 O
. NCT03860116 28 29 O
diagnosed NCT03860116 31 40 O
as NCT03860116 41 43 O
HIV NCT03860116 44 47 B-Condition
positive NCT03860116 48 56 O
; NCT03860116 56 57 O

- NCT03860116 60 61 O
2 NCT03860116 63 64 O
. NCT03860116 64 65 O
initiate NCT03860116 67 75 B-Eq-Comparison
antiretroviral NCT03860116 76 90 B-Procedure
therapy NCT03860116 91 98 I-Procedure
on NCT03860116 99 101 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860116 102 105 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03860116 106 109 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860116 110 112 O
recruitment NCT03860116 113 124 B-Study
; NCT03860116 124 125 O

- NCT03860116 128 129 O
3 NCT03860116 131 132 O
. NCT03860116 132 133 O
was NCT03860116 135 138 O
infected NCT03860116 139 147 B-Condition
through NCT03860116 148 155 O
male NCT03860116 156 160 B-Modifier
same NCT03860116 161 165 B-Condition
- NCT03860116 166 167 I-Condition
sex NCT03860116 168 171 I-Condition
behavior NCT03860116 172 180 I-Condition
; NCT03860116 180 181 O

- NCT03860116 184 185 O
4 NCT03860116 187 188 O
. NCT03860116 188 189 O
has NCT03860116 191 194 O
access NCT03860116 195 201 O
to NCT03860116 202 204 O
internet NCT03860116 205 213 O
on NCT03860116 214 216 O
a NCT03860116 217 218 O
personal NCT03860116 219 227 O
mobile NCT03860116 228 234 O
phone NCT03860116 235 240 O
; NCT03860116 240 241 O

- NCT03860116 244 245 O
5 NCT03860116 247 248 O
. NCT03860116 248 249 O
has NCT03860116 251 254 O
a NCT03860116 255 256 O
Wechat NCT03860116 257 263 O
account NCT03860116 264 271 O
and NCT03860116 272 275 O
use NCT03860116 276 279 O
it NCT03860116 280 282 O
daily NCT03860116 283 288 O
; NCT03860116 288 289 O

- NCT03860116 292 293 O
6 NCT03860116 295 296 O
. NCT03860116 296 297 O
willing NCT03860116 299 306 O
to NCT03860116 307 309 O
provide NCT03860116 310 317 O
written NCT03860116 318 325 O
informed NCT03860116 326 334 O
consent NCT03860116 335 342 O
; NCT03860116 342 343 O

Exclusion NCT03860116 344 353 O
Criteria NCT03860116 354 362 O
: NCT03860116 363 364 O

- NCT03860116 368 369 O
1 NCT03860116 371 372 O
. NCT03860116 372 373 O
under NCT03860116 375 380 O
severe NCT03860116 381 387 O
physical NCT03860116 388 396 B-Modifier
or NCT03860116 397 399 B-Or
mental NCT03860116 400 406 B-Modifier
condition NCT03860116 407 416 B-Condition
which NCT03860116 417 422 O
precludes NCT03860116 423 432 B-Assertion___Assertion-Type-Value:hypothetical|Negation
study NCT03860116 433 438 B-Study
participation NCT03860116 439 452 O
; NCT03860116 452 453 O

- NCT03860116 456 457 O
2 NCT03860116 459 460 O
. NCT03860116 460 461 O
being NCT03860116 463 468 B-Eq-Comparison
an NCT03860116 469 471 O
inpatient NCT03860116 472 481 B-Encounter
of NCT03860116 482 484 O
the NCT03860116 485 488 O
hospital NCT03860116 489 497 O
; NCT03860116 497 498 O

Inclusion NCT03862846 0 9 O
Criteria NCT03862846 10 18 O
: NCT03862846 19 20 O

- NCT03862846 24 25 O
Subjects NCT03862846 27 35 O
must NCT03862846 36 40 O
give NCT03862846 41 45 O
written NCT03862846 46 53 O
, NCT03862846 54 55 O
signed NCT03862846 56 62 O
and NCT03862846 63 66 O
dated NCT03862846 67 72 O
informed NCT03862846 73 81 O
consent NCT03862846 82 89 O

- NCT03862846 92 93 O
Confirmed NCT03862846 95 104 O
diagnosis NCT03862846 105 114 O
of NCT03862846 115 117 O
PMM NCT03862846 118 121 B-Condition
according NCT03862846 122 131 O
to NCT03862846 132 134 O
the NCT03862846 135 138 O
2016 NCT03862846 139 143 O
Rome NCT03862846 144 148 O
Consensus NCT03862846 149 158 O
recommendations NCT03862846 159 174 O

- NCT03862846 177 178 O
Confirmed NCT03862846 180 189 O
mitochondrial NCT03862846 190 203 B-Condition
mutation NCT03862846 204 212 I-Condition
with NCT03862846 213 217 B-And
evidence NCT03862846 218 226 O
of NCT03862846 227 229 O
myopathy NCT03862846 230 238 B-Condition

- NCT03862846 241 242 O
Able NCT03862846 244 248 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862846 249 251 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03862846 252 258 O
on NCT03862846 259 261 O
stable NCT03862846 262 268 O
medication NCT03862846 269 279 B-Drug
throughout NCT03862846 280 290 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862846 291 294 O
study NCT03862846 295 300 B-Study

Exclusion NCT03862846 301 310 O
Criteria NCT03862846 311 319 O
: NCT03862846 320 321 O

- NCT03862846 325 326 O
Documented NCT03862846 328 338 O
evidence NCT03862846 339 347 O
of NCT03862846 348 350 O
ongoing NCT03862846 351 358 B-Eq-Comparison
rhabdomyolysis NCT03862846 359 373 B-Condition

- NCT03862846 376 377 O
Subjects NCT03862846 379 387 O
with NCT03862846 388 392 O
motor NCT03862846 393 398 B-Condition
abnormalities NCT03862846 399 412 I-Condition
other NCT03862846 413 418 B-Exception
than NCT03862846 419 423 I-Exception
related NCT03862846 424 431 O
to NCT03862846 432 434 O
mitochondrial NCT03862846 435 448 B-Condition
disease NCT03862846 449 456 I-Condition

- NCT03862846 459 460 O
Treatment NCT03862846 462 471 B-Procedure
with NCT03862846 472 476 O
an NCT03862846 477 479 O
investigational NCT03862846 480 495 B-Study
drug NCT03862846 496 500 B-Drug
within NCT03862846 501 507 B-Eq-Comparison
3 NCT03862846 508 509 I-Eq-Comparison
months NCT03862846 510 516 I-Eq-Comparison
prior NCT03862846 517 522 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862846 523 525 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03862846 526 529 B-Study
1 NCT03862846 530 531 O

- NCT03862846 535 536 O
Hospitalised NCT03862846 538 550 B-Encounter
within NCT03862846 551 557 B-Eq-Comparison
3 NCT03862846 558 559 I-Eq-Comparison
months NCT03862846 560 566 I-Eq-Comparison
prior NCT03862846 567 572 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862846 573 575 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03862846 576 585 B-Study
for NCT03862846 586 589 O
any NCT03862846 590 593 O
major NCT03862846 594 599 O
medical NCT03862846 600 607 B-Condition
condition NCT03862846 608 617 I-Condition

- NCT03862846 620 621 O
Pregnant NCT03862846 623 631 B-Condition
or NCT03862846 632 634 B-Or
nursing NCT03862846 635 642 B-Condition
females NCT03862846 643 650 O

Inclusion NCT03867916 0 9 O
Criteria NCT03867916 10 18 O
: NCT03867916 19 20 O

- NCT03867916 24 25 O
FOR NCT03867916 27 30 O
INTERVIEWS NCT03867916 31 41 O
AND NCT03867916 42 45 O
FOCUS NCT03867916 46 51 O
GROUPS NCT03867916 52 58 O
: NCT03867916 59 60 O
Cancer NCT03867916 61 67 B-Condition
patients NCT03867916 68 76 O
: NCT03867916 77 78 O
Self NCT03867916 79 83 O
- NCT03867916 84 85 O
identifies NCT03867916 86 96 O
as NCT03867916 97 99 O
Asian NCT03867916 100 105 O
American NCT03867916 106 114 O
, NCT03867916 115 116 O
lives NCT03867916 117 122 O
in NCT03867916 123 125 O
San NCT03867916 126 129 O
Francisco NCT03867916 130 139 O
, NCT03867916 140 141 O
speaks NCT03867916 142 148 O
English NCT03867916 149 156 O
, NCT03867916 157 158 O
Mandarin NCT03867916 159 167 O
, NCT03867916 168 169 O
Cantonese NCT03867916 170 179 O
, NCT03867916 180 181 O
or NCT03867916 182 184 B-Or
Vietnamese NCT03867916 185 195 O
, NCT03867916 196 197 O
has NCT03867916 198 201 O
a NCT03867916 202 203 O
history NCT03867916 204 211 B-Eq-Comparison
of NCT03867916 212 214 O
cancer NCT03867916 215 221 B-Condition
of NCT03867916 222 224 O
any NCT03867916 225 228 O
kind NCT03867916 229 233 O

- NCT03867916 236 237 O
FOR NCT03867916 239 242 O
INTERVIEWS NCT03867916 243 253 O
AND NCT03867916 254 257 O
FOCUS NCT03867916 258 263 O
GROUPS NCT03867916 264 270 O
: NCT03867916 271 272 O
Caregivers NCT03867916 273 283 O
: NCT03867916 284 285 O
any NCT03867916 286 289 O
person NCT03867916 290 296 O
who NCT03867916 297 300 O
has NCT03867916 301 304 O
provided NCT03867916 305 313 O
care NCT03867916 314 318 O
to NCT03867916 319 321 O
an NCT03867916 322 324 O
Asian NCT03867916 325 330 O
American NCT03867916 331 339 O
cancer NCT03867916 340 346 B-Condition
patient NCT03867916 347 354 O

- NCT03867916 357 358 O
FOR NCT03867916 360 363 O
INTERVIEWS NCT03867916 364 374 O
AND NCT03867916 375 378 O
FOCUS NCT03867916 379 384 O
GROUPS NCT03867916 385 391 O
: NCT03867916 392 393 O
Health NCT03867916 394 400 O
professionals NCT03867916 401 414 O
: NCT03867916 415 416 O
physicians NCT03867916 417 427 B-Provider
and NCT03867916 428 431 O
other NCT03867916 432 437 O
health NCT03867916 438 444 B-Provider
professionals NCT03867916 445 458 I-Provider
who NCT03867916 459 462 O
provide NCT03867916 463 470 O
care NCT03867916 471 475 O
to NCT03867916 476 478 O
Asian NCT03867916 479 484 O
American NCT03867916 485 493 O
patients NCT03867916 494 502 O
with NCT03867916 503 507 B-And
cancer NCT03867916 508 514 B-Condition

- NCT03867916 517 518 O
FOR NCT03867916 520 523 O
PILOT NCT03867916 524 529 O
AND NCT03867916 530 533 O
FULL NCT03867916 534 538 O
IMPLEMENTATION NCT03867916 539 553 O
: NCT03867916 554 555 O
Self NCT03867916 556 560 O
- NCT03867916 561 562 O
identifies NCT03867916 563 573 O
as NCT03867916 574 576 O
Asian NCT03867916 577 582 O
American NCT03867916 583 591 O
, NCT03867916 592 593 O
lives NCT03867916 594 599 O
in NCT03867916 600 602 O
San NCT03867916 603 606 O
Francisco NCT03867916 607 616 O
, NCT03867916 617 618 O
speaks NCT03867916 619 625 O
English NCT03867916 626 633 O
, NCT03867916 634 635 O
Mandarin NCT03867916 636 644 O
, NCT03867916 645 646 O
Cantonese NCT03867916 647 656 O
, NCT03867916 657 658 O
or NCT03867916 659 661 B-Or
Vietnamese NCT03867916 662 672 O
, NCT03867916 673 674 O
has NCT03867916 675 678 O
stage NCT03867916 679 684 B-Eq-Comparison
I NCT03867916 685 686 I-Eq-Comparison
- NCT03867916 687 688 I-Eq-Comparison
III NCT03867916 689 692 I-Eq-Comparison
colorectal NCT03867916 693 703 B-Modifier
, NCT03867916 704 705 O
lung NCT03867916 706 710 B-Modifier
, NCT03867916 711 712 O
or NCT03867916 713 715 B-Or
liver NCT03867916 716 721 B-Modifier
cancer NCT03867916 722 728 B-Condition
, NCT03867916 729 730 O
has NCT03867916 731 734 O
not NCT03867916 735 738 B-Negation
yet NCT03867916 739 742 O
undergone NCT03867916 743 752 B-Eq-Comparison
treatment NCT03867916 753 762 B-Procedure

- NCT03867916 765 766 O
FOR NCT03867916 768 771 O
PILOT NCT03867916 772 777 O
AND NCT03867916 778 781 O
FULL NCT03867916 782 786 O
IMPLEMENTATION NCT03867916 787 801 O
: NCT03867916 802 803 O
Is NCT03867916 804 806 O
willing NCT03867916 807 814 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867916 815 817 I-Assertion___Assertion-Type-Value:hypothetical
stay NCT03867916 818 822 O
in NCT03867916 823 825 O
the NCT03867916 826 829 O
study NCT03867916 830 835 B-Study
for NCT03867916 836 839 O
six NCT03867916 840 843 B-Eq-Comparison
months NCT03867916 844 850 I-Eq-Comparison

Exclusion NCT03867916 851 860 O
Criteria NCT03867916 861 869 O
: NCT03867916 870 871 O

- NCT03867916 875 876 O
Any NCT03867916 878 881 O
medical NCT03867916 882 889 B-Modifier
or NCT03867916 890 892 B-Or
psychological NCT03867916 893 906 B-Modifier
conditions NCT03867916 907 917 B-Condition
precluding NCT03867916 918 928 O
informed NCT03867916 929 937 O
consent NCT03867916 938 945 O

Inclusion NCT03864562 0 9 O
Criteria NCT03864562 10 18 O
: NCT03864562 19 20 O

- NCT03864562 24 25 O
White NCT03864562 27 32 O
European NCT03864562 33 41 O
or NCT03864562 42 44 B-Or
black NCT03864562 45 50 O
African NCT03864562 51 58 O
/ NCT03864562 59 60 B-Or
Caribbean NCT03864562 61 70 O
heritage NCT03864562 71 79 O

- NCT03864562 82 83 O
BMI NCT03864562 85 88 B-Observation
> NCT03864562 89 90 B-Eq-Comparison
18 NCT03864562 91 93 I-Eq-Comparison
kg NCT03864562 94 96 I-Eq-Comparison
/ NCT03864562 97 98 I-Eq-Comparison
m2 NCT03864562 99 101 I-Eq-Comparison

- NCT03864562 104 105 O
Ability NCT03864562 107 114 O
to NCT03864562 115 117 O
give NCT03864562 118 122 O
written NCT03864562 123 130 O
informed NCT03864562 131 139 O
consent NCT03864562 140 147 O

- NCT03864562 150 151 O
English NCT03864562 153 160 O
speaking NCT03864562 161 169 O

Exclusion NCT03864562 170 179 O
Criteria NCT03864562 180 188 O
: NCT03864562 189 190 O

- NCT03864562 194 195 O
Any NCT03864562 197 200 O
significant NCT03864562 201 212 O
medical NCT03864562 213 220 B-Condition
condition NCT03864562 221 230 I-Condition

- NCT03864562 233 234 O
Uncontrolled NCT03864562 236 248 B-Modifier
hypertension NCT03864562 249 261 B-Condition

- NCT03864562 264 265 O
Alcohol NCT03864562 267 274 B-Observation
consumption NCT03864562 275 286 I-Observation
> NCT03864562 287 288 O
14 NCT03864562 289 291 B-Eq-Comparison
units NCT03864562 292 297 I-Eq-Comparison
/ NCT03864562 298 299 I-Eq-Comparison
week NCT03864562 300 304 I-Eq-Comparison

- NCT03864562 307 308 O
Random NCT03864562 310 316 B-Modifier
blood NCT03864562 317 322 B-Observation
Glucose NCT03864562 323 330 I-Observation
concentration NCT03864562 331 344 I-Observation
above NCT03864562 345 350 B-Eq-Comparison
7.8 NCT03864562 351 354 I-Eq-Comparison
mmol NCT03864562 355 359 O
/ NCT03864562 360 361 I-Eq-Comparison
l NCT03864562 362 363 I-Eq-Comparison

- NCT03864562 366 367 O
Hemoglobin NCT03864562 369 379 B-Observation
A1c NCT03864562 380 383 I-Observation
( NCT03864562 384 385 O
HbA1c NCT03864562 386 391 B-Observation
) NCT03864562 392 393 O
> NCT03864562 394 395 B-Eq-Comparison
47 NCT03864562 396 398 B-Eq-Comparison
mmol NCT03864562 399 403 O
/ NCT03864562 404 405 I-Eq-Comparison
mol NCT03864562 406 409 I-Eq-Comparison
( NCT03864562 410 411 O
> NCT03864562 413 414 O
6.4 NCT03864562 415 418 I-Eq-Comparison
% NCT03864562 419 420 O
) NCT03864562 421 422 O

- NCT03864562 426 427 O
Use NCT03864562 429 432 B-Eq-Comparison
of NCT03864562 433 435 O
regular NCT03864562 436 443 O
medication NCT03864562 444 454 B-Drug
, NCT03864562 455 456 O
( NCT03864562 457 458 O
oral NCT03864562 459 463 B-Drug|Or
contraceptive NCT03864562 464 477 I-Drug
pill NCT03864562 478 482 I-Drug
or NCT03864562 483 485 O
antihypertensive NCT03864562 486 502 B-Drug
medication NCT03864562 503 513 I-Drug
are NCT03864562 514 517 O
acceptable NCT03864562 518 528 B-Exception
if NCT03864562 529 531 I-Exception
use NCT03864562 532 535 O
has NCT03864562 536 539 O
been NCT03864562 540 544 O
for NCT03864562 545 548 O
> NCT03864562 549 550 B-Eq-Comparison
6 NCT03864562 551 552 I-Eq-Comparison
months NCT03864562 553 559 I-Eq-Comparison
) NCT03864562 560 561 O

- NCT03864562 565 566 O
History NCT03864562 568 575 B-Eq-Comparison
of NCT03864562 576 578 O
Irritable NCT03864562 579 588 B-Condition
Bowel NCT03864562 589 594 I-Condition
Syndrome NCT03864562 595 603 I-Condition
, NCT03864562 604 605 O
food NCT03864562 606 610 B-Condition
intolerances NCT03864562 611 623 I-Condition
or NCT03864562 624 626 B-Or
any NCT03864562 627 630 O
gastrointestinal NCT03864562 631 647 B-Condition
disorders NCT03864562 648 657 I-Condition

- NCT03864562 660 661 O
Previous NCT03864562 663 671 B-Eq-Comparison
bariatric NCT03864562 672 681 B-Procedure
surgery NCT03864562 682 689 I-Procedure|Procedure
, NCT03864562 690 691 O
or NCT03864562 692 694 B-Or
gastrointestinal NCT03864562 695 711 B-Procedure
surgery NCT03864562 712 719 O
which NCT03864562 720 725 O
may NCT03864562 726 729 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864562 730 736 O
normal NCT03864562 737 743 O
function NCT03864562 744 752 B-Condition
( NCT03864562 753 754 O
e. NCT03864562 755 757 O
g. NCT03864562 758 760 O
bowel NCT03864562 762 767 B-Procedure
resection NCT03864562 768 777 I-Procedure
) NCT03864562 778 779 O

Inclusion NCT03868358 0 9 O
Criteria NCT03868358 10 18 O
: NCT03868358 19 20 O

- NCT03868358 24 25 O
Patients NCT03868358 27 35 O
met NCT03868358 36 39 O
diagnostic NCT03868358 40 50 O
criteria NCT03868358 51 59 O
for NCT03868358 60 63 O
schizophrenia NCT03868358 64 77 B-Condition
or NCT03868358 78 80 B-Or
schizoaffective NCT03868358 81 96 B-Condition
disorder NCT03868358 97 105 I-Condition
using NCT03868358 106 111 O
the NCT03868358 112 115 O
Structural NCT03868358 116 126 O
Clinical NCT03868358 127 135 O
Interview NCT03868358 136 145 O
for NCT03868358 146 149 O
Diagnostic NCT03868358 150 160 O
and NCT03868358 161 164 O
Statistical NCT03868358 165 176 O
Manual NCT03868358 177 183 O
Diploma NCT03868358 184 191 O
in NCT03868358 192 194 O
Social NCT03868358 195 201 O
Medicine NCT03868358 202 210 O
( NCT03868358 211 212 O
DSM NCT03868358 213 216 O
) NCT03868358 217 218 O
- NCT03868358 220 221 O
IV NCT03868358 222 224 O
( NCT03868358 225 226 O
SCID NCT03868358 227 231 O
, NCT03868358 232 233 O
Version NCT03868358 234 241 O
2.0 NCT03868358 242 245 O
) NCT03868358 246 247 O
. NCT03868358 248 249 O

- NCT03868358 253 254 O
Patients NCT03868358 256 264 O
remain NCT03868358 265 271 O
their NCT03868358 272 277 O
psychotropic NCT03868358 278 290 B-Drug
medication NCT03868358 291 301 I-Drug
at NCT03868358 302 304 O
steady NCT03868358 305 311 O
dosages NCT03868358 312 319 O
for NCT03868358 320 323 O
at NCT03868358 324 326 B-Eq-Comparison
least NCT03868358 327 332 I-Eq-Comparison
4 NCT03868358 333 334 I-Eq-Comparison
weeks NCT03868358 335 340 I-Eq-Comparison
prior NCT03868358 341 346 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868358 347 349 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03868358 350 355 B-Study
entry NCT03868358 356 361 O
and NCT03868358 362 365 B-And
for NCT03868358 366 369 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868358 370 373 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03868358 374 382 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03868358 383 385 O
the NCT03868358 386 389 O
trial NCT03868358 390 395 B-Study
. NCT03868358 395 396 O

- NCT03868358 400 401 O
Verbal NCT03868358 403 409 B-Observation
intelligence NCT03868358 410 422 I-Observation
quotient NCT03868358 423 431 I-Observation
> NCT03868358 432 433 B-Eq-Comparison
85 NCT03868358 434 436 I-Eq-Comparison
as NCT03868358 437 439 O
measured NCT03868358 440 448 O
by NCT03868358 449 451 O
using NCT03868358 452 457 O
a NCT03868358 458 459 O
Chinese NCT03868358 460 467 B-Modifier
version NCT03868358 468 475 I-Modifier
of NCT03868358 476 478 O
the NCT03868358 479 482 O
National NCT03868358 483 491 B-Observation
Adult NCT03868358 492 497 I-Observation
Reading NCT03868358 498 505 I-Observation
Test NCT03868358 506 510 I-Observation
. NCT03868358 510 511 O

Exclusion NCT03868358 513 522 O
Criteria NCT03868358 523 531 O
: NCT03868358 532 533 O

- NCT03868358 537 538 O
History NCT03868358 540 547 B-Eq-Comparison
of NCT03868358 548 550 O
significant NCT03868358 551 562 O
head NCT03868358 563 567 B-Modifier
trauma NCT03868358 568 574 B-Condition
or NCT03868358 575 577 B-Or
neurological NCT03868358 578 590 B-Condition
disorders NCT03868358 591 600 I-Condition

- NCT03868358 603 604 O
Alcohol NCT03868358 606 613 B-Modifier
or NCT03868358 614 616 B-Or
drug NCT03868358 617 621 B-Modifier
abuse NCT03868358 622 627 B-Condition
Focal NCT03868358 628 633 B-Condition
brain NCT03868358 634 639 I-Condition
lesions NCT03868358 640 647 I-Condition
on NCT03868358 648 650 O
T1 NCT03868358 651 653 B-Modifier
- NCT03868358 654 655 I-Modifier
or NCT03868358 656 658 B-Or
T2 NCT03868358 659 661 B-Modifier
- NCT03868358 662 663 I-Modifier
weighted NCT03868358 664 672 I-Modifier
fluid NCT03868358 673 678 B-Modifier
- NCT03868358 679 680 I-Modifier
attenuated NCT03868358 681 691 I-Modifier
inversion NCT03868358 692 701 I-Modifier
- NCT03868358 702 703 O
recovery NCT03868358 704 712 I-Modifier
magnetic NCT03868358 713 721 B-Procedure
resonance NCT03868358 722 731 I-Procedure
images NCT03868358 732 738 I-Procedure

- NCT03868358 741 742 O
a NCT03868358 744 745 O
prior NCT03868358 746 751 B-Eq-Comparison
history NCT03868358 752 759 I-Eq-Comparison
of NCT03868358 760 762 O
a NCT03868358 763 764 O
seizure NCT03868358 765 772 B-Condition
not NCT03868358 773 776 B-Negation
induced NCT03868358 777 784 O
by NCT03868358 785 787 O
drug NCT03868358 788 792 B-Condition
withdrawal NCT03868358 793 803 I-Condition
, NCT03868358 804 805 O
first NCT03868358 806 811 B-Modifier
degree NCT03868358 812 818 I-Modifier
relative NCT03868358 819 827 B-Family-Member
with NCT03868358 828 832 O
epilepsy NCT03868358 833 841 B-Condition
, NCT03868358 842 843 O
significant NCT03868358 844 855 O
neurological NCT03868358 856 868 B-Condition
illness NCT03868358 869 876 I-Condition
or NCT03868358 877 879 B-Or
head NCT03868358 880 884 B-Modifier
trauma NCT03868358 885 891 B-Condition
, NCT03868358 892 893 O
endocrine NCT03868358 894 903 B-Condition
disease NCT03868358 904 911 I-Condition|Condition
, NCT03868358 912 913 O
such NCT03868358 914 918 O
as NCT03868358 919 921 O
thyroid NCT03868358 922 929 B-Condition
disease NCT03868358 930 937 O
, NCT03868358 938 939 O
significant NCT03868358 940 951 O
unstable NCT03868358 952 960 O
medical NCT03868358 961 968 B-Condition
condition NCT03868358 969 978 I-Condition
, NCT03868358 979 980 O
recent NCT03868358 981 987 B-Eq-Comparison
aggression NCT03868358 988 998 B-Condition
or NCT03868358 999 1001 B-Or
other NCT03868358 1002 1007 B-Other
forms NCT03868358 1008 1013 O
of NCT03868358 1014 1016 O
behavioral NCT03868358 1017 1027 B-Condition
dyscontrol NCT03868358 1028 1038 I-Condition

- NCT03868358 1041 1042 I-Condition
left NCT03868358 1044 1048 B-Condition
- NCT03868358 1049 1050 O
handedness NCT03868358 1051 1061 I-Condition
, NCT03868358 1062 1063 O
pregnancy NCT03868358 1064 1073 B-Condition

- NCT03868358 1076 1077 O
estimated NCT03868358 1079 1088 B-Observation
intelligence NCT03868358 1089 1101 I-Observation
quotient NCT03868358 1102 1110 I-Observation
< NCT03868358 1111 1112 B-Eq-Comparison
80 NCT03868358 1113 1115 I-Eq-Comparison

- NCT03868358 1119 1120 O
current NCT03868358 1122 1129 B-Eq-Comparison
alcohol NCT03868358 1130 1137 B-Modifier
or NCT03868358 1138 1140 B-Or
drug NCT03868358 1141 1145 B-Modifier
abuse NCT03868358 1146 1151 B-Condition

- NCT03868358 1154 1155 O
inability NCT03868358 1157 1166 O
to NCT03868358 1167 1169 O
provide NCT03868358 1170 1177 O
informed NCT03868358 1178 1186 O
consent NCT03868358 1187 1194 O
. NCT03868358 1194 1195 O

- NCT03868358 1199 1200 O
Hamilton NCT03868358 1202 1210 B-Observation|Observation
Anxiety NCT03868358 1211 1218 I-Observation
Rating NCT03868358 1219 1225 I-Observation
Scale NCT03868358 1226 1231 I-Observation|Observation
or NCT03868358 1232 1234 B-Or
the NCT03868358 1235 1238 O
Hamilton NCT03868358 1239 1247 O
Depression NCT03868358 1248 1258 I-Observation
Rating NCT03868358 1259 1265 I-Observation
Scale NCT03868358 1266 1271 O
score NCT03868358 1272 1277 B-Eq-Comparison
> NCT03868358 1278 1279 I-Eq-Comparison
10 NCT03868358 1280 1282 I-Eq-Comparison

Inclusion NCT03861195 0 9 O
Criteria NCT03861195 10 18 O
: NCT03861195 19 20 O

- NCT03861195 24 25 O
age NCT03861195 27 30 B-Age
≥ NCT03861195 31 32 B-Eq-Comparison
18 NCT03861195 33 35 I-Eq-Comparison
years NCT03861195 36 41 I-Eq-Comparison

- NCT03861195 44 45 O
BMI NCT03861195 47 50 B-Observation
≤ NCT03861195 51 52 B-Eq-Comparison
40 NCT03861195 53 55 I-Eq-Comparison
kg NCT03861195 56 58 I-Eq-Comparison
/ NCT03861195 59 60 I-Eq-Comparison
m2 NCT03861195 61 63 I-Eq-Comparison

- NCT03861195 66 67 O
indication NCT03861195 69 79 B-Indication
for NCT03861195 80 83 O
hysterectomy NCT03861195 84 96 B-Procedure
for NCT03861195 97 100 O
benign NCT03861195 101 107 B-Condition
disease NCT03861195 108 115 I-Condition
or NCT03861195 116 118 B-Or
prophylactic NCT03861195 119 131 B-Procedure
surgery NCT03861195 132 139 I-Procedure
due NCT03861195 140 143 O
to NCT03861195 144 146 O
hereditary NCT03861195 147 157 B-Modifier
cancer NCT03861195 158 164 B-Condition

- NCT03861195 167 168 O
indication NCT03861195 170 180 B-Indication
for NCT03861195 181 184 O
radical NCT03861195 185 192 B-Procedure
hysterectomy NCT03861195 193 205 I-Procedure
and NCT03861195 206 209 B-Or
/ NCT03861195 210 211 I-Or
or NCT03861195 212 214 I-Or
pelvic NCT03861195 215 221 B-Modifier
- NCT03861195 222 223 I-Modifier
/ NCT03861195 225 226 B-Or
para NCT03861195 227 231 B-Modifier
- NCT03861195 232 233 O
aortic NCT03861195 234 240 I-Modifier
( NCT03861195 241 242 O
sentinel NCT03861195 243 251 B-Modifier
- NCT03861195 252 253 I-Modifier
node NCT03861195 254 258 I-Modifier
) NCT03861195 259 260 O
lymphadenectomy NCT03861195 261 276 B-Procedure
for NCT03861195 277 280 O
cervical NCT03861195 281 289 B-Modifier
cancer NCT03861195 290 296 B-Condition

- NCT03861195 299 300 O
indication NCT03861195 302 312 B-Indication
for NCT03861195 313 316 O
modified NCT03861195 317 325 B-Modifier
radical NCT03861195 326 333 I-Modifier
hysterectomy NCT03861195 334 346 B-Procedure
and NCT03861195 347 350 B-Or
/ NCT03861195 351 352 I-Or|Or
or NCT03861195 353 355 I-Or
pelvic NCT03861195 356 362 B-Modifier
- NCT03861195 363 364 I-Modifier
/ NCT03861195 366 367 O
para NCT03861195 368 372 B-Modifier
- NCT03861195 373 374 I-Modifier
aortic NCT03861195 375 381 I-Modifier
( NCT03861195 382 383 O
sentinel NCT03861195 384 392 B-Modifier
- NCT03861195 393 394 O
node NCT03861195 395 399 I-Modifier
) NCT03861195 400 401 O
lymphadenectomy NCT03861195 402 417 B-Procedure
for NCT03861195 418 421 O
endometrial NCT03861195 422 433 B-Modifier
cancer NCT03861195 434 440 B-Condition

- NCT03861195 443 444 O
size NCT03861195 446 450 B-Observation
of NCT03861195 451 453 O
uterus NCT03861195 454 460 B-Modifier
and NCT03861195 461 464 B-Or
vagina NCT03861195 465 471 B-Modifier
allows NCT03861195 472 478 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861195 479 482 I-Assertion___Assertion-Type-Value:hypothetical
retrieval NCT03861195 483 492 B-Procedure
by NCT03861195 493 495 O
the NCT03861195 496 499 O
vaginal NCT03861195 500 507 B-Modifier
route NCT03861195 508 513 I-Modifier
in NCT03861195 514 516 O
cancer NCT03861195 517 523 B-Condition
patients NCT03861195 524 532 O

- NCT03861195 535 536 O
written NCT03861195 538 545 O
informed NCT03861195 546 554 O
consent NCT03861195 555 562 O

Exclusion NCT03861195 563 572 O
Criteria NCT03861195 573 581 O
: NCT03861195 582 583 O

- NCT03861195 587 588 I-Modifier
known NCT03861195 590 595 O
extensive NCT03861195 596 605 O
intra NCT03861195 606 611 B-Modifier
- NCT03861195 612 613 O
abdominal NCT03861195 614 623 I-Modifier
adhesions NCT03861195 624 633 B-Condition

- NCT03861195 636 637 O
anaesthesiological NCT03861195 639 657 B-Modifier
contraindications NCT03861195 658 675 B-Contraindication
to NCT03861195 676 678 O
laparoscopy NCT03861195 679 690 B-Procedure

- NCT03861195 693 694 O
women NCT03861195 696 701 O
with NCT03861195 702 706 B-And
pacemaker NCT03861195 707 716 B-Procedure
or NCT03861195 717 719 B-Or
other NCT03861195 720 725 B-Other
implants NCT03861195 726 734 B-Procedure
where NCT03861195 735 740 B-And
electrosurgery NCT03861195 741 755 B-Procedure
is NCT03861195 756 758 O
to NCT03861195 759 761 B-Contraindication
be NCT03861195 762 764 I-Contraindication
avoided NCT03861195 765 772 I-Contraindication

- NCT03861195 775 776 O
women NCT03861195 778 783 O
with NCT03861195 784 788 B-And
known NCT03861195 789 794 O
defects NCT03861195 795 802 B-Condition
of NCT03861195 803 805 I-Condition
the NCT03861195 806 809 I-Condition
hemostasis NCT03861195 810 820 I-Condition

- NCT03861195 823 824 O
pregnancy NCT03861195 826 835 B-Condition

- NCT03861195 838 839 O
other NCT03861195 841 846 B-Other
internal NCT03861195 847 855 B-Modifier
or NCT03861195 856 858 B-Or
anatomical NCT03861195 859 869 B-Modifier
criteria NCT03861195 870 878 B-Condition
that NCT03861195 879 883 O
preclude NCT03861195 884 892 B-Assertion___Assertion-Type-Value:hypothetical|Negation
a NCT03861195 893 894 O
minimal NCT03861195 895 902 B-Procedure
invasive NCT03861195 903 911 I-Procedure
approach NCT03861195 912 920 I-Procedure

- NCT03861195 923 924 O
inability NCT03861195 926 935 O
to NCT03861195 936 938 O
understand NCT03861195 939 949 O
patient NCT03861195 950 957 O
information NCT03861195 958 969 O

Inclusion NCT03861156 0 9 O
Criteria NCT03861156 10 18 O
: NCT03861156 19 20 O

- NCT03861156 24 25 O
Aged NCT03861156 27 31 B-Age
at NCT03861156 32 34 B-Eq-Comparison
least NCT03861156 35 40 I-Eq-Comparison
18 NCT03861156 41 43 I-Eq-Comparison
years NCT03861156 44 49 I-Eq-Comparison
. NCT03861156 49 50 O

- NCT03861156 54 55 O
Histologically NCT03861156 57 71 B-Modifier
or NCT03861156 72 74 B-Or
cytologically NCT03861156 75 88 B-Procedure
proven NCT03861156 89 95 O
diagnosis NCT03861156 96 105 O
of NCT03861156 106 108 O
NSCLC NCT03861156 109 114 B-Condition
that NCT03861156 115 119 O
is NCT03861156 120 122 O
locally NCT03861156 123 130 B-Modifier
advanced NCT03861156 131 139 I-Modifier
or NCT03861156 140 142 B-Or
metastatic NCT03861156 143 153 B-Modifier
. NCT03861156 153 154 O

- NCT03861156 158 159 O
Radiological NCT03861156 161 173 B-Procedure
documentation NCT03861156 174 187 O
of NCT03861156 188 190 O
disease NCT03861156 191 198 B-Condition
progression NCT03861156 199 210 I-Condition
while NCT03861156 211 216 B-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03861156 217 219 O
a NCT03861156 220 221 O
previous NCT03861156 222 230 B-Eq-Comparison
continuous NCT03861156 231 241 B-Modifier
treatment NCT03861156 242 251 B-Procedure
with NCT03861156 252 256 O
an NCT03861156 257 259 O
first NCT03861156 260 265 B-Modifier
or NCT03861156 266 268 B-Or
second NCT03861156 269 275 B-Modifier
generation NCT03861156 276 286 I-Modifier
of NCT03861156 287 289 O
EGFR NCT03861156 290 294 B-Drug
TKI NCT03861156 295 298 I-Drug
e. NCT03861156 299 301 O
g. NCT03861156 302 304 O
gefitinib NCT03861156 306 315 B-Drug
or NCT03861156 316 318 B-Or
erlotinib NCT03861156 319 328 B-Drug
. NCT03861156 328 329 O

- NCT03861156 333 334 O
patients NCT03861156 336 344 O
must NCT03861156 345 349 O
also NCT03861156 350 354 O
have NCT03861156 355 359 O
confirmation NCT03861156 360 372 O
of NCT03861156 373 375 O
tumour NCT03861156 376 382 B-Condition
T790 NCT03861156 383 387 I-Condition
M NCT03861156 388 389 O
mutation NCT03861156 390 398 I-Condition
status NCT03861156 399 405 O
( NCT03861156 406 407 O
confirmed NCT03861156 408 417 O
positive NCT03861156 418 426 O
) NCT03861156 427 428 O
after NCT03861156 429 434 B-Temporal-Connection___Temporal-Connection-Type-Value:after
disease NCT03861156 435 442 B-Condition
progression NCT03861156 443 454 I-Condition
on NCT03861156 455 457 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 458 461 O
prior NCT03861156 462 467 B-Eq-Comparison
EGFR NCT03861156 468 472 B-Drug
TKI NCT03861156 473 476 I-Drug
. NCT03861156 476 477 O

- NCT03861156 481 482 O
Eastern NCT03861156 484 491 B-Observation
cooperative NCT03861156 492 503 I-Observation
oncology NCT03861156 504 512 I-Observation
group NCT03861156 513 518 I-Observation
performance NCT03861156 519 530 I-Observation
status NCT03861156 531 537 I-Observation
( NCT03861156 538 539 O
ECOG NCT03861156 540 544 B-Observation
PS NCT03861156 545 547 O
) NCT03861156 548 549 O
of NCT03861156 550 552 O
0 NCT03861156 553 554 B-Eq-Comparison
- NCT03861156 555 556 I-Eq-Comparison
1 NCT03861156 557 558 O
. NCT03861156 558 559 O

- NCT03861156 563 564 O
a NCT03861156 566 567 O
minimum NCT03861156 568 575 O
life NCT03861156 576 580 B-Observation
expectancy NCT03861156 581 591 I-Observation
of NCT03861156 592 594 O
12 NCT03861156 595 597 B-Eq-Comparison
weeks NCT03861156 598 603 I-Eq-Comparison
. NCT03861156 603 604 O

- NCT03861156 608 609 O
At NCT03861156 611 613 B-Eq-Comparison
least NCT03861156 614 619 I-Eq-Comparison
one NCT03861156 620 623 I-Eq-Comparison
lesion NCT03861156 624 630 B-Condition
, NCT03861156 631 632 O
not NCT03861156 633 636 B-Negation
previously NCT03861156 637 647 B-Eq-Comparison
irradiated NCT03861156 648 658 B-Procedure
during NCT03861156 659 665 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 666 669 O
study NCT03861156 670 675 B-Study
screening NCT03861156 676 685 O
period NCT03861156 686 692 O
, NCT03861156 693 694 O
that NCT03861156 695 699 B-And
can NCT03861156 700 703 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861156 704 706 I-Assertion___Assertion-Type-Value:hypothetical
accurately NCT03861156 707 717 O
measured NCT03861156 718 726 B-Observation
at NCT03861156 727 729 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03861156 730 738 B-Study
according NCT03861156 739 748 O
to NCT03861156 749 751 O
RECIST NCT03861156 752 758 O
1.1 NCT03861156 759 762 O
. NCT03861156 762 763 O

- NCT03861156 767 768 O
Agree NCT03861156 770 775 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861156 776 778 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03861156 779 782 O
routine NCT03861156 783 790 O
adequate NCT03861156 791 799 O
and NCT03861156 800 803 O
effective NCT03861156 804 813 O
contraceptive NCT03861156 814 827 B-Procedure
measures NCT03861156 828 836 O
during NCT03861156 837 843 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 844 847 O
entire NCT03861156 848 854 O
study NCT03861156 855 860 B-Study
period NCT03861156 861 867 O
and NCT03861156 868 871 B-And
within NCT03861156 872 878 B-Eq-Comparison
6 NCT03861156 879 880 I-Eq-Comparison
weeks NCT03861156 881 886 I-Eq-Comparison
after NCT03861156 887 892 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03861156 893 896 O
last NCT03861156 897 901 B-Eq-Comparison
dose NCT03861156 902 906 O
pre NCT03861156 907 910 B-Condition
- NCT03861156 911 912 I-Condition
menopausal NCT03861156 913 923 I-Condition
fertility NCT03861156 924 933 I-Condition
possible NCT03861156 934 942 O
; NCT03861156 942 943 O
Female NCT03861156 944 950 O
patients NCT03861156 951 959 O
need NCT03861156 960 964 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861156 965 967 I-Assertion___Assertion-Type-Value:hypothetical
exclude NCT03861156 968 975 B-Negation
pregnancy NCT03861156 976 985 B-Condition
( NCT03861156 986 987 O
ie NCT03861156 988 990 O
negative NCT03861156 991 999 O
pregnancy NCT03861156 1000 1009 B-Observation
test NCT03861156 1010 1014 I-Observation
) NCT03861156 1015 1016 O
and NCT03861156 1017 1020 B-Or
in NCT03861156 1021 1023 O
non NCT03861156 1024 1027 B-Negation
- NCT03861156 1028 1029 O
lactation NCT03861156 1030 1039 B-Condition
period NCT03861156 1040 1046 O
. NCT03861156 1046 1047 O

Exclusion NCT03861156 1049 1058 O
Criteria NCT03861156 1059 1067 O
: NCT03861156 1068 1069 O

- NCT03861156 1073 1074 O
Treatment NCT03861156 1076 1085 B-Procedure
with NCT03861156 1086 1090 O
a NCT03861156 1091 1092 O
first NCT03861156 1093 1098 B-Modifier
or NCT03861156 1099 1101 B-Or
second NCT03861156 1102 1108 B-Modifier
generation NCT03861156 1109 1119 I-Modifier
of NCT03861156 1120 1122 B-Temporal-Connection___Temporal-Connection-Type-Value:before
EGFR NCT03861156 1123 1127 B-Drug
- NCT03861156 1128 1129 I-Drug
TKI NCT03861156 1130 1133 I-Drug
within NCT03861156 1134 1140 B-Eq-Comparison
7 NCT03861156 1141 1142 I-Eq-Comparison
days NCT03861156 1143 1147 I-Eq-Comparison
of NCT03861156 1148 1150 O
study NCT03861156 1151 1156 B-Study
entry NCT03861156 1157 1162 O
; NCT03861156 1162 1163 O
previous NCT03861156 1164 1172 B-Eq-Comparison
treatment NCT03861156 1173 1182 B-Procedure
with NCT03861156 1183 1187 O
a NCT03861156 1188 1189 O
third NCT03861156 1190 1195 B-Modifier
generation NCT03861156 1196 1206 I-Modifier
of NCT03861156 1207 1209 O
EGFR NCT03861156 1210 1214 B-Drug
- NCT03861156 1215 1216 I-Drug
TKI NCT03861156 1217 1220 I-Drug
. NCT03861156 1220 1221 O

- NCT03861156 1225 1226 O
Unresolved NCT03861156 1228 1238 B-Eq-Comparison
toxicities NCT03861156 1239 1249 B-Condition
from NCT03861156 1250 1254 O
prior NCT03861156 1255 1260 B-Eq-Comparison
therapy NCT03861156 1261 1268 B-Procedure
. NCT03861156 1268 1269 O

- NCT03861156 1273 1274 O
Unstable NCT03861156 1276 1284 O
spinal NCT03861156 1285 1291 B-Condition
cord NCT03861156 1292 1296 I-Condition
compression NCT03861156 1297 1308 I-Condition
/ NCT03861156 1309 1310 B-Or|Or
brain NCT03861156 1311 1316 B-Modifier
metastases NCT03861156 1317 1327 B-Condition
. NCT03861156 1327 1328 O

- NCT03861156 1332 1333 O
Severe NCT03861156 1335 1341 O
/ NCT03861156 1342 1343 O
uncontrolled NCT03861156 1344 1356 B-Modifier
systemic NCT03861156 1357 1365 I-Modifier
diseases NCT03861156 1366 1374 B-Condition
, NCT03861156 1375 1376 O
including NCT03861156 1377 1386 O
uncontrolled NCT03861156 1387 1399 B-Modifier
hypertension NCT03861156 1400 1412 B-Condition
, NCT03861156 1413 1414 O
bleeding NCT03861156 1415 1423 B-Condition
diatheses NCT03861156 1424 1433 I-Condition
or NCT03861156 1434 1436 B-Or
infection NCT03861156 1437 1446 B-Condition
. NCT03861156 1446 1447 O

- NCT03861156 1451 1452 O
QTcF NCT03861156 1454 1458 B-Observation
> NCT03861156 1459 1460 B-Eq-Comparison
470 NCT03861156 1461 1464 I-Eq-Comparison
msec NCT03861156 1465 1469 I-Eq-Comparison
during NCT03861156 1470 1476 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 1477 1480 O
screening NCT03861156 1481 1490 B-Study
period NCT03861156 1491 1497 O
. NCT03861156 1497 1498 O

- NCT03861156 1502 1503 O
Severe NCT03861156 1505 1511 O
respiratory NCT03861156 1512 1523 B-Condition
diseases NCT03861156 1524 1532 I-Condition|Condition
such NCT03861156 1533 1537 O
as NCT03861156 1538 1540 B-Condition
interstitial NCT03861156 1541 1553 B-Condition
lung NCT03861156 1554 1558 I-Condition
disease NCT03861156 1559 1566 O
, NCT03861156 1567 1568 O
severe NCT03861156 1569 1575 O
asthma NCT03861156 1576 1582 O
, NCT03861156 1583 1584 O
pulmonary NCT03861156 1585 1594 B-Condition
embolism NCT03861156 1595 1603 I-Condition
, NCT03861156 1604 1605 O
etc NCT03861156 1606 1609 O
. NCT03861156 1609 1610 O

- NCT03861156 1614 1615 O
previous NCT03861156 1617 1625 B-Eq-Comparison
treatment NCT03861156 1626 1635 B-Procedure
with NCT03861156 1636 1640 O
2 NCT03861156 1641 1642 B-Eq-Comparison
or NCT03861156 1643 1645 I-Eq-Comparison|Or
more NCT03861156 1646 1650 I-Eq-Comparison
lines NCT03861156 1651 1656 O
of NCT03861156 1657 1659 O
Chemotherapy NCT03861156 1660 1672 B-Procedure
or NCT03861156 1673 1675 O
immunotherapy NCT03861156 1676 1689 B-Procedure
. NCT03861156 1689 1690 O

Inclusion NCT03861624 0 9 O
Criteria NCT03861624 10 18 O
: NCT03861624 19 20 O

1 NCT03861624 24 25 O
. NCT03861624 25 26 O
Skeletal NCT03861624 28 36 B-Condition
maturity NCT03861624 37 45 I-Condition

2 NCT03861624 48 49 O
. NCT03861624 49 50 O
AO NCT03861624 52 54 B-Eq-Comparison
/ NCT03861624 55 56 I-Eq-Comparison
OTA NCT03861624 57 60 I-Eq-Comparison
42 NCT03861624 61 63 I-Eq-Comparison
open NCT03861624 64 68 B-Modifier
tibia NCT03861624 69 74 I-Modifier
fractures NCT03861624 75 84 B-Condition

3 NCT03861624 87 88 O
. NCT03861624 88 89 O
Wound NCT03861624 91 96 B-Condition
primarily NCT03861624 97 106 B-Modifier
closeable NCT03861624 107 116 I-Modifier
( NCT03861624 117 118 O
no NCT03861624 119 121 B-Negation
flap NCT03861624 122 126 B-Modifier
or NCT03861624 127 129 B-Or
delay NCT03861624 130 135 B-Modifier
in NCT03861624 136 138 O
closure NCT03861624 139 146 B-Procedure
due NCT03861624 147 150 O
to NCT03861624 151 153 O
contamination NCT03861624 154 167 B-Condition
needed NCT03861624 168 174 O
) NCT03861624 175 176 O

4 NCT03861624 180 181 O
. NCT03861624 181 182 O
Palpable NCT03861624 184 192 B-Modifier
pedal NCT03861624 193 198 B-Observation
pulses NCT03861624 199 205 I-Observation
( NCT03861624 206 207 O
no NCT03861624 208 210 B-Negation
vascular NCT03861624 211 219 B-Condition
injury NCT03861624 220 226 I-Condition
sustained NCT03861624 227 236 O
) NCT03861624 237 238 O

5 NCT03861624 242 243 O
. NCT03861624 243 244 O
Presentation NCT03861624 246 258 O
within NCT03861624 259 265 B-Eq-Comparison
24 NCT03861624 266 268 I-Eq-Comparison
hours NCT03861624 269 274 I-Eq-Comparison
from NCT03861624 275 279 B-Temporal-Connection___Temporal-Connection-Type-Value:after
injury NCT03861624 280 286 B-Condition

Exclusion NCT03861624 287 296 O
Criteria NCT03861624 297 305 O
: NCT03861624 306 307 O

1 NCT03861624 311 312 O
. NCT03861624 312 313 O
Current NCT03861624 315 322 B-Eq-Comparison
injury NCT03861624 323 329 B-Condition
is NCT03861624 330 332 O
a NCT03861624 333 334 O
pathologic NCT03861624 335 345 B-Modifier
fracture NCT03861624 346 354 B-Condition

2 NCT03861624 357 358 O
. NCT03861624 358 359 O
Sustained NCT03861624 361 370 O
bilateral NCT03861624 371 380 B-Modifier
tibia NCT03861624 381 386 I-Modifier
fracture NCT03861624 387 395 B-Condition

3 NCT03861624 398 399 O
. NCT03861624 399 400 O
Sustained NCT03861624 402 411 O
comminuted NCT03861624 412 422 B-Modifier
femur NCT03861624 423 428 I-Modifier
fracture NCT03861624 429 437 B-Condition

4 NCT03861624 440 441 O
. NCT03861624 441 442 O
Sustained NCT03861624 444 453 O
severe NCT03861624 454 460 O
Traumatic NCT03861624 461 470 B-Condition
Brain NCT03861624 471 476 I-Condition
Injury NCT03861624 477 483 I-Condition
( NCT03861624 484 485 O
GCS NCT03861624 486 489 B-Observation
< NCT03861624 490 491 B-Eq-Comparison
12 NCT03861624 492 494 I-Eq-Comparison
) NCT03861624 495 496 O
* NCT03861624 497 498 O
* NCT03861624 498 499 O
* NCT03861624 499 500 O

5 NCT03861624 503 504 O
. NCT03861624 504 505 O
Sustained NCT03861624 507 516 O
severe NCT03861624 517 523 O
spinal NCT03861624 524 530 B-Modifier
cord NCT03861624 531 535 I-Modifier
injury NCT03861624 536 542 B-Condition
( NCT03861624 543 544 O
lower NCT03861624 545 550 B-Modifier
extremity NCT03861624 551 560 I-Modifier
paresis NCT03861624 561 568 B-Condition
/ NCT03861624 569 570 B-Or
paralysis NCT03861624 571 580 B-Condition
) NCT03861624 581 582 O

6 NCT03861624 586 587 O
. NCT03861624 587 588 O
Sustained NCT03861624 590 599 O
severe NCT03861624 600 606 O
burns NCT03861624 607 612 B-Condition
( NCT03861624 613 614 O
> NCT03861624 616 617 B-Eq-Comparison
10 NCT03861624 618 620 I-Eq-Comparison
% NCT03861624 621 622 O
total NCT03861624 623 628 B-Observation
body NCT03861624 629 633 I-Observation
surface NCT03861624 634 641 I-Observation
area NCT03861624 642 646 I-Observation
( NCT03861624 647 648 O
TBSA NCT03861624 649 653 B-Eq-Comparison|Observation|Observation
) NCT03861624 654 655 O
or NCT03861624 656 658 B-Or|Or
> NCT03861624 659 660 B-Eq-Comparison
5 NCT03861624 661 662 I-Eq-Comparison
% NCT03861624 663 664 O
TBSA NCT03861624 665 669 O
with NCT03861624 670 674 B-And
full NCT03861624 675 679 B-Modifier
thickness NCT03861624 680 689 I-Modifier
or NCT03861624 690 692 O
circumferential NCT03861624 693 708 B-Modifier
injury NCT03861624 709 715 B-Condition|Condition
) NCT03861624 716 717 O

7 NCT03861624 721 722 O
. NCT03861624 722 723 O
Prior NCT03861624 725 730 B-Eq-Comparison
ipsilateral NCT03861624 731 742 B-Modifier
leg NCT03861624 743 746 I-Modifier
injury NCT03861624 747 753 O
requiring NCT03861624 754 763 B-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03861624 764 771 B-Procedure

8 NCT03861624 774 775 O
. NCT03861624 775 776 O
Prior NCT03861624 778 783 B-Eq-Comparison
or NCT03861624 784 786 B-Or|Or
current NCT03861624 787 794 B-Eq-Comparison
lower NCT03861624 795 800 B-Modifier
limb NCT03861624 801 805 I-Modifier
deformity NCT03861624 806 815 B-Condition
or NCT03861624 816 818 O
abnormality NCT03861624 819 830 B-Condition

9 NCT03861624 833 834 O
. NCT03861624 834 835 O
Unable NCT03861624 837 843 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861624 844 846 O
complete NCT03861624 847 855 O
follow NCT03861624 856 862 B-Encounter
- NCT03861624 863 864 I-Encounter
up NCT03861624 865 867 I-Encounter
visits NCT03861624 868 874 I-Encounter

Inclusion NCT03863769 0 9 O
Criteria NCT03863769 10 18 O
: NCT03863769 19 20 O

- NCT03863769 24 25 O
Age NCT03863769 27 30 B-Age
greater NCT03863769 31 38 B-Eq-Comparison
than NCT03863769 39 43 I-Eq-Comparison
48 NCT03863769 44 46 I-Eq-Comparison
years NCT03863769 47 52 I-Eq-Comparison
old NCT03863769 53 56 O

- NCT03863769 59 60 O
Patient NCT03863769 62 69 O
has NCT03863769 70 73 O
leg NCT03863769 74 77 B-Modifier
or NCT03863769 78 80 B-Or
buttock NCT03863769 81 88 B-Modifier
pain NCT03863769 89 93 B-Condition
while NCT03863769 94 99 O
walking NCT03863769 100 107 B-Observation

- NCT03863769 110 111 O
Patient NCT03863769 113 120 O
feels NCT03863769 121 126 O
relief NCT03863769 127 133 O
of NCT03863769 134 136 O
symptoms NCT03863769 137 145 B-Coreference
with NCT03863769 146 150 O
bending NCT03863769 151 158 O
( NCT03863769 159 160 O
flexing NCT03863769 161 168 O
) NCT03863769 169 170 O
forward NCT03863769 171 178 O

- NCT03863769 181 182 O
Patient NCT03863769 184 191 O
feels NCT03863769 192 197 O
relief NCT03863769 198 204 O
when NCT03863769 205 209 O
using NCT03863769 210 215 O
a NCT03863769 216 217 O
shopping NCT03863769 218 226 O
cart NCT03863769 227 231 O
of NCT03863769 232 234 O
bicycle NCT03863769 235 242 O

- NCT03863769 245 246 O
Patient NCT03863769 248 255 O
has NCT03863769 256 259 O
motor NCT03863769 260 265 B-Modifier
or NCT03863769 266 268 B-Or
sensory NCT03863769 269 276 B-Modifier
disturbance NCT03863769 277 288 B-Condition
while NCT03863769 289 294 O
walking NCT03863769 295 302 B-Observation

- NCT03863769 305 306 O
Patient NCT03863769 308 315 O
has NCT03863769 316 319 O
normal NCT03863769 320 326 O
and NCT03863769 327 330 B-And
symmetrical NCT03863769 331 342 B-Modifier
foot NCT03863769 343 347 B-Observation
pulses NCT03863769 348 354 I-Observation

- NCT03863769 357 358 O
Patient NCT03863769 360 367 O
has NCT03863769 368 371 O
lower NCT03863769 372 377 B-Modifier
extremity NCT03863769 378 387 I-Modifier
weakness NCT03863769 388 396 B-Condition

- NCT03863769 399 400 O
Patient NCT03863769 402 409 O
has NCT03863769 410 413 O
low NCT03863769 414 417 B-Modifier
back NCT03863769 418 422 I-Modifier
pain NCT03863769 423 427 B-Condition

- NCT03863769 430 431 O
Duration NCT03863769 433 441 O
of NCT03863769 442 444 O
symptoms NCT03863769 445 453 B-Coreference
and NCT03863769 454 457 I-Coreference
signs NCT03863769 458 463 I-Coreference
for NCT03863769 464 467 O
more NCT03863769 468 472 B-Eq-Comparison
than NCT03863769 473 477 I-Eq-Comparison
1 NCT03863769 478 479 I-Eq-Comparison
month NCT03863769 480 485 I-Eq-Comparison

- NCT03863769 488 489 O
Able NCT03863769 491 495 B-Condition
to NCT03863769 496 498 I-Condition
stand NCT03863769 499 504 B-Modifier
and NCT03863769 505 508 B-And
walk NCT03863769 509 513 B-Modifier
without NCT03863769 514 521 B-Negation
assistive NCT03863769 522 531 B-Procedure
devices NCT03863769 532 539 I-Procedure
for NCT03863769 540 543 O
at NCT03863769 544 546 B-Eq-Comparison
least NCT03863769 547 552 I-Eq-Comparison
20 NCT03863769 553 555 I-Eq-Comparison
minutes NCT03863769 556 563 I-Eq-Comparison

- NCT03863769 566 567 O
Able NCT03863769 569 573 O
to NCT03863769 574 576 O
give NCT03863769 577 581 O
written NCT03863769 582 589 O
informed NCT03863769 590 598 O
consent NCT03863769 599 606 O
and NCT03863769 607 610 O
complete NCT03863769 611 619 O
interviews NCT03863769 620 630 O
and NCT03863769 631 634 O
questionnaires NCT03863769 635 649 O
in NCT03863769 650 652 O
English NCT03863769 653 660 O

Exclusion NCT03863769 661 670 O
Criteria NCT03863769 671 679 O
: NCT03863769 680 681 O

- NCT03863769 685 686 O
Complicated NCT03863769 688 699 O
spinal NCT03863769 700 706 B-Modifier
pain NCT03863769 707 711 B-Condition
due NCT03863769 712 715 O
to NCT03863769 716 718 O
fracture NCT03863769 719 727 B-Condition
, NCT03863769 728 729 O
tumor NCT03863769 730 735 B-Condition
, NCT03863769 736 737 O
infection NCT03863769 738 747 B-Condition
, NCT03863769 748 749 O
or NCT03863769 750 752 B-Or
severe NCT03863769 753 759 O
spondyloarthropathy NCT03863769 760 779 B-Condition

- NCT03863769 782 783 O
Has NCT03863769 785 788 O
other NCT03863769 789 794 B-Other
severe NCT03863769 795 801 O
co NCT03863769 802 804 B-Condition
- NCT03863769 805 806 I-Condition
morbidities NCT03863769 807 818 I-Condition
, NCT03863769 819 820 O
including NCT03863769 821 830 O
progressive NCT03863769 831 842 B-Modifier
neurological NCT03863769 843 855 B-Condition
deficit NCT03863769 856 863 I-Condition

- NCT03863769 866 867 O
Other NCT03863769 869 874 B-Other
serious NCT03863769 875 882 O
pathologies NCT03863769 883 894 B-Condition
of NCT03863769 895 897 O
the NCT03863769 898 901 O
locomotor NCT03863769 902 911 B-Modifier
system NCT03863769 912 918 I-Modifier

- NCT03863769 921 922 O
No NCT03863769 924 926 O
correspondence NCT03863769 927 941 O
availability NCT03863769 942 954 O
through NCT03863769 955 962 O
email NCT03863769 963 968 O

- NCT03863769 971 972 O
Inability NCT03863769 974 983 B-Negation
to NCT03863769 984 986 O
read NCT03863769 987 991 O
/ NCT03863769 992 993 O
comprehend NCT03863769 994 1004 O
English NCT03863769 1005 1012 O

- NCT03863769 1015 1016 O
Compensation NCT03863769 1018 1030 O
or NCT03863769 1031 1033 O
seeking NCT03863769 1034 1041 O
compensation NCT03863769 1042 1054 O
from NCT03863769 1055 1059 O
a NCT03863769 1060 1061 O
third NCT03863769 1062 1067 O
- NCT03863769 1068 1069 O
party NCT03863769 1070 1075 O
liability NCT03863769 1076 1085 O
or NCT03863769 1086 1088 O
workers NCT03863769 1089 1096 O
' NCT03863769 1096 1097 O
compensation NCT03863769 1098 1110 O

- NCT03863769 1113 1114 O
Previous NCT03863769 1116 1124 B-Eq-Comparison
spinal NCT03863769 1125 1131 B-Procedure
manipulation NCT03863769 1132 1144 I-Procedure
within NCT03863769 1145 1151 B-Eq-Comparison
the NCT03863769 1152 1155 I-Eq-Comparison
past NCT03863769 1156 1160 I-Eq-Comparison
month NCT03863769 1161 1166 I-Eq-Comparison

Inclusion NCT03866200 0 9 O
Criteria NCT03866200 10 18 O
: NCT03866200 19 20 O

- NCT03866200 24 25 O
The NCT03866200 27 30 O
diagnosis NCT03866200 31 40 O
of NCT03866200 41 43 O
pseudoachondroplasia NCT03866200 44 64 B-Condition
is NCT03866200 65 67 O
based NCT03866200 68 73 O
on NCT03866200 74 76 O
clinical NCT03866200 77 85 B-Procedure
assessment NCT03866200 86 96 I-Procedure
either NCT03866200 97 103 O
in NCT03866200 104 106 B-Modifier
person NCT03866200 107 113 I-Modifier
or NCT03866200 114 116 B-Or
by NCT03866200 117 119 O
photographic NCT03866200 120 132 B-Modifier
review NCT03866200 133 139 I-Modifier
by NCT03866200 140 142 O
skeletal NCT03866200 143 151 B-Provider
dysplasia NCT03866200 152 161 I-Provider
specialist NCT03866200 162 172 I-Provider
( NCT03866200 173 174 O
JTH NCT03866200 175 178 O
) NCT03866200 179 180 O
, NCT03866200 182 183 O

- NCT03866200 187 188 O
Healthy NCT03866200 190 197 B-Condition
beyond NCT03866200 198 204 B-Exception
pseudoachondroplasia NCT03866200 205 225 B-Condition
associated NCT03866200 226 236 O
complications NCT03866200 237 250 B-Condition
, NCT03866200 251 252 O

Exclusion NCT03866200 254 263 O
Criteria NCT03866200 264 272 O
: NCT03866200 273 274 O

- NCT03866200 278 279 O
Current NCT03866200 281 288 B-Eq-Comparison
use NCT03866200 289 292 O
of NCT03866200 293 295 O
resveratrol NCT03866200 296 307 B-Drug

- NCT03866200 310 311 O
Current NCT03866200 313 320 B-Eq-Comparison
use NCT03866200 321 324 O
of NCT03866200 325 327 O
blood NCT03866200 328 333 B-Drug
thinners NCT03866200 334 342 I-Drug
, NCT03866200 343 344 O
lovastatin NCT03866200 345 355 B-Drug
, NCT03866200 356 357 O
ketoconazole NCT03866200 358 370 B-Drug
, NCT03866200 371 372 O
itraconazole NCT03866200 373 385 B-Drug
, NCT03866200 386 387 O
fexofenadine NCT03866200 388 400 B-Drug
and NCT03866200 401 404 B-Or
triazolam NCT03866200 405 414 B-Drug
. NCT03866200 414 415 O

- NCT03866200 419 420 O
Other NCT03866200 422 427 B-Other
non NCT03866200 428 431 B-Negation
- NCT03866200 432 433 O
pseudoachondroplasia NCT03866200 434 454 B-Condition
related NCT03866200 455 462 O
health NCT03866200 463 469 B-Condition
conditions NCT03866200 470 480 I-Condition
, NCT03866200 481 482 O
e. NCT03866200 483 485 O
g. NCT03866200 486 488 O
cancers NCT03866200 490 497 B-Condition
. NCT03866200 497 498 O

- NCT03866200 502 503 O
Pregnancy NCT03866200 505 514 B-Condition
or NCT03866200 515 517 B-Or
breastfeeding NCT03866200 518 531 B-Condition
. NCT03866200 531 532 O
Women NCT03866200 534 539 O
must NCT03866200 540 544 O
use NCT03866200 545 548 O
adequate NCT03866200 549 557 O
contraception NCT03866200 558 571 B-Procedure
during NCT03866200 572 578 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866200 579 582 O
study NCT03866200 583 588 B-Study
. NCT03866200 588 589 O

- NCT03866200 593 594 O
Participation NCT03866200 596 609 O
in NCT03866200 610 612 O
another NCT03866200 613 620 B-Other
clinical NCT03866200 621 629 O
study NCT03866200 630 635 B-Study
and NCT03866200 636 639 B-Or
/ NCT03866200 640 641 I-Or
or NCT03866200 642 644 I-Or
using NCT03866200 645 650 B-Eq-Comparison
investigational NCT03866200 651 666 B-Drug
agents NCT03866200 667 673 I-Drug
. NCT03866200 673 674 O

- NCT03866200 678 679 I-Drug
Use NCT03866200 681 684 B-Eq-Comparison
of NCT03866200 685 687 O
Non NCT03866200 688 691 B-Drug
- NCT03866200 692 693 O
steroid NCT03866200 694 701 I-Drug
anti NCT03866200 702 706 I-Drug
- NCT03866200 707 708 O
inflammatory NCT03866200 709 721 I-Drug
( NCT03866200 722 723 O
NSAIDs NCT03866200 724 730 B-Drug
) NCT03866200 731 732 O
or NCT03866200 733 735 B-Or
aspirin NCT03866200 736 743 B-Drug
. NCT03866200 743 744 O

- NCT03866200 748 749 O
Current NCT03866200 751 758 B-Eq-Comparison
use NCT03866200 759 762 O
of NCT03866200 763 765 O
Alfentanil NCT03866200 766 776 B-Drug
, NCT03866200 777 778 O
Cyclosporine NCT03866200 779 791 B-Drug
, NCT03866200 792 793 O
Dihydroergotamine NCT03866200 794 811 B-Drug
, NCT03866200 812 813 O
Dofetilide NCT03866200 814 824 B-Drug
, NCT03866200 825 826 O
Ergotamine NCT03866200 827 837 B-Drug
, NCT03866200 838 839 O
Fentanyl NCT03866200 840 848 B-Drug
, NCT03866200 849 850 O
Flibanserin NCT03866200 851 862 B-Drug
, NCT03866200 863 864 O
Oxycodone NCT03866200 865 874 B-Drug
, NCT03866200 875 876 O
Pimavanserin NCT03866200 877 889 B-Drug
, NCT03866200 890 891 O
Pimozide NCT03866200 892 900 B-Drug
, NCT03866200 901 902 O
Quinidine NCT03866200 903 912 B-Drug
, NCT03866200 913 914 O
Saquinavir NCT03866200 915 925 B-Drug
, NCT03866200 926 927 O
Sirolimus NCT03866200 928 937 B-Drug
, NCT03866200 938 939 O
Tacrolimus NCT03866200 940 950 B-Drug
, NCT03866200 951 952 O
Temsirolimus NCT03866200 953 965 B-Drug
, NCT03866200 966 967 O
Theophylline NCT03866200 968 980 B-Drug
, NCT03866200 981 982 O
Tizanidine NCT03866200 983 993 B-Drug
, NCT03866200 994 995 O
Thioridazine NCT03866200 996 1008 B-Drug
, NCT03866200 1009 1010 O
Fosphenytoin NCT03866200 1011 1023 B-Drug
, NCT03866200 1024 1025 O
Phenytoin NCT03866200 1026 1035 B-Drug
or NCT03866200 1036 1038 B-Eq-Comparison|Or
Warfarin NCT03866200 1039 1047 B-Drug
. NCT03866200 1047 1048 O

- NCT03866200 1052 1053 O
Baseline NCT03866200 1055 1063 O
level NCT03866200 1064 1069 O
of NCT03866200 1070 1072 O
pain NCT03866200 1073 1077 B-Condition|Observation
of NCT03866200 1078 1080 O
2 NCT03866200 1081 1082 B-Eq-Comparison
or NCT03866200 1083 1085 O
higher NCT03866200 1086 1092 I-Eq-Comparison
on NCT03866200 1093 1095 O
10 NCT03866200 1096 1098 B-Modifier
point NCT03866200 1099 1104 I-Modifier
scale NCT03866200 1105 1110 I-Modifier
. NCT03866200 1110 1111 O

- NCT03866200 1115 1116 O
Platelet NCT03866200 1118 1126 B-Observation
count NCT03866200 1127 1132 I-Observation|Observation
below NCT03866200 1133 1138 B-Eq-Comparison
50 NCT03866200 1139 1141 I-Eq-Comparison
, NCT03866200 1142 1143 O
000 NCT03866200 1144 1147 O
per NCT03866200 1148 1151 I-Eq-Comparison
ul NCT03866200 1152 1154 I-Eq-Comparison
on NCT03866200 1155 1157 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03866200 1158 1166 B-Study
complete NCT03866200 1167 1175 B-Observation
blood NCT03866200 1176 1181 I-Observation
count NCT03866200 1182 1187 O
( NCT03866200 1188 1189 O
CBC NCT03866200 1190 1193 B-Observation
) NCT03866200 1194 1195 O
. NCT03866200 1196 1197 O

Inclusion NCT03862066 0 9 O
Criteria NCT03862066 10 18 O
: NCT03862066 19 20 O

- NCT03862066 24 25 O
Newly NCT03862066 27 32 B-Eq-Comparison
diagnosed NCT03862066 33 42 O
histologically NCT03862066 43 57 O
proven NCT03862066 58 64 O
locoregional NCT03862066 65 77 B-Modifier
oral NCT03862066 78 82 I-Modifier
squamous NCT03862066 83 91 I-Modifier
cell NCT03862066 92 96 I-Modifier
carcinoma NCT03862066 97 106 B-Condition
( NCT03862066 107 108 O
OSCC NCT03862066 109 113 B-Condition
) NCT03862066 114 115 O
without NCT03862066 116 123 B-Negation
evidence NCT03862066 124 132 O
of NCT03862066 133 135 O
distant NCT03862066 136 143 B-Modifier
metastases NCT03862066 144 154 B-Condition
. NCT03862066 154 155 O
OSCC NCT03862066 157 161 B-Condition
includes NCT03862066 162 170 O
the NCT03862066 171 174 O
subsites NCT03862066 175 183 B-Modifier
of NCT03862066 184 186 I-Modifier
oral NCT03862066 187 191 I-Modifier
tongue NCT03862066 192 198 I-Modifier
, NCT03862066 199 200 O
floor NCT03862066 201 206 B-Modifier
of NCT03862066 207 209 I-Modifier
mouth NCT03862066 210 215 I-Modifier
, NCT03862066 216 217 O
gingiva NCT03862066 218 225 B-Modifier
, NCT03862066 226 227 O
retromolar NCT03862066 228 238 B-Modifier
trigone NCT03862066 239 246 I-Modifier
and NCT03862066 247 250 B-Or
buccal NCT03862066 251 257 B-Modifier
mucosa NCT03862066 258 264 I-Modifier
OR NCT03862066 265 267 B-Or
Recurrent NCT03862066 268 277 B-Modifier
or NCT03862066 278 280 B-Or
persistent NCT03862066 281 291 B-Modifier
histologically NCT03862066 292 306 O
proven NCT03862066 307 313 O
locoregional NCT03862066 314 326 B-Modifier
OSCC NCT03862066 327 331 B-Condition
that NCT03862066 332 336 O
was NCT03862066 337 340 O
initially NCT03862066 341 350 B-Eq-Comparison
treated NCT03862066 351 358 B-Procedure
with NCT03862066 359 363 O
surgery NCT03862066 364 371 B-Procedure
alone NCT03862066 372 377 O
. NCT03862066 377 378 O

- NCT03862066 382 383 O
must NCT03862066 385 389 O
be NCT03862066 390 392 O
eligible NCT03862066 393 401 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03862066 402 405 I-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03862066 406 414 B-Procedure
resection NCT03862066 415 424 I-Procedure

- NCT03862066 427 428 O
greater NCT03862066 430 437 B-Eq-Comparison
than NCT03862066 438 442 I-Eq-Comparison
18 NCT03862066 443 445 I-Eq-Comparison
years NCT03862066 446 451 I-Eq-Comparison
of NCT03862066 452 454 O
age NCT03862066 455 458 B-Age

Exclusion NCT03862066 459 468 O
Criteria NCT03862066 469 477 O
: NCT03862066 478 479 O

- NCT03862066 483 484 O
prior NCT03862066 486 491 B-Eq-Comparison
immunotherapy NCT03862066 492 505 B-Procedure
or NCT03862066 506 508 B-Or
treatment NCT03862066 509 518 B-Procedure
with NCT03862066 519 523 O
another NCT03862066 524 531 B-Other
anti NCT03862066 532 536 B-Drug
PD NCT03862066 537 539 I-Drug
- NCT03862066 540 541 I-Drug
1 NCT03862066 542 543 I-Drug
agent NCT03862066 544 549 I-Drug
besides NCT03862066 550 557 B-Exception
nivolumab NCT03862066 558 567 B-Drug

- NCT03862066 570 571 O
prior NCT03862066 573 578 B-Eq-Comparison
chemotherapy NCT03862066 579 591 B-Procedure
including NCT03862066 592 601 O
cetuximab NCT03862066 602 611 B-Drug
or NCT03862066 612 614 B-Or
radiation NCT03862066 615 624 B-Procedure
therapy NCT03862066 625 632 I-Procedure

- NCT03862066 635 636 O
concomitant NCT03862066 638 649 B-Modifier
malignancies NCT03862066 650 662 B-Condition
except NCT03862066 663 669 B-Exception
cutaneous NCT03862066 670 679 B-Modifier
squamous NCT03862066 680 688 I-Modifier
cell NCT03862066 689 693 I-Modifier
carcinoma NCT03862066 694 703 B-Condition
or NCT03862066 704 706 B-Or
basal NCT03862066 707 712 B-Modifier
cell NCT03862066 713 717 I-Modifier
carcinoma NCT03862066 718 727 B-Condition

- NCT03862066 730 731 O
unresectable NCT03862066 733 745 B-Modifier
primary NCT03862066 746 753 I-Modifier
tumor NCT03862066 754 759 B-Condition
or NCT03862066 760 762 B-Or
regional NCT03862066 763 771 B-Condition
disease NCT03862066 772 779 I-Condition
or NCT03862066 780 782 B-Or
distant NCT03862066 783 790 B-Modifier
metastases NCT03862066 791 801 B-Condition


Inclusion NCT03860103 0 9 O
Criteria NCT03860103 10 18 O
: NCT03860103 19 20 O

- NCT03860103 24 25 O
Patient NCT03860103 27 34 O
who NCT03860103 35 38 O
accepted NCT03860103 39 47 O
to NCT03860103 48 50 O
participate NCT03860103 51 62 O
in NCT03860103 63 65 O
the NCT03860103 66 69 O
study NCT03860103 70 75 O

- NCT03860103 78 79 O
Woman NCT03860103 81 86 O
over NCT03860103 87 91 B-Eq-Comparison
18 NCT03860103 92 94 I-Eq-Comparison
years NCT03860103 95 100 I-Eq-Comparison
old NCT03860103 101 104 B-Age

- NCT03860103 107 108 O
Affiliated NCT03860103 110 120 O
to NCT03860103 121 123 O
a NCT03860103 124 125 O
social NCT03860103 126 132 O
security NCT03860103 133 141 O
scheme NCT03860103 142 148 O

- NCT03860103 151 152 O
Mono NCT03860103 154 158 B-Modifier
- NCT03860103 159 160 I-Modifier
fetal NCT03860103 161 166 I-Modifier
pregnancy NCT03860103 167 176 B-Condition

- NCT03860103 179 180 O
Patients NCT03860103 182 190 O
with NCT03860103 191 195 O
normal NCT03860103 196 202 O
pregnancy NCT03860103 203 212 B-Condition
between NCT03860103 213 220 B-Eq-Comparison
11 NCT03860103 221 223 I-Eq-Comparison
and NCT03860103 224 227 I-Eq-Comparison
42 NCT03860103 228 230 I-Eq-Comparison
weeks NCT03860103 231 236 I-Eq-Comparison
of NCT03860103 237 239 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03860103 240 250 B-Condition

- NCT03860103 253 254 O
Patients NCT03860103 256 264 O
hospitalized NCT03860103 265 277 B-Encounter
for NCT03860103 278 281 O
preeclampsia NCT03860103 282 294 B-Condition
and NCT03860103 295 298 B-Or
/ NCT03860103 299 300 I-Or
or NCT03860103 301 303 I-Or
intrauterine NCT03860103 304 316 B-Condition
growth NCT03860103 317 323 I-Condition
retardation NCT03860103 324 335 I-Condition
, NCT03860103 336 337 O
beyond NCT03860103 338 344 B-Eq-Comparison
20 NCT03860103 345 347 I-Eq-Comparison
weeks NCT03860103 348 353 I-Eq-Comparison
of NCT03860103 354 356 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03860103 357 367 B-Condition

Exclusion NCT03860103 368 377 O
Criteria NCT03860103 378 386 O
: NCT03860103 387 388 O

- NCT03860103 392 393 O
Minors NCT03860103 395 401 O
, NCT03860103 402 403 O
adults NCT03860103 404 410 O
under NCT03860103 411 416 B-Observation
guardianship NCT03860103 417 429 I-Observation
, NCT03860103 430 431 O
protected NCT03860103 432 441 B-Observation
persons NCT03860103 442 449 I-Observation

- NCT03860103 452 453 O
Not NCT03860103 455 458 O
affiliated NCT03860103 459 469 O
to NCT03860103 470 472 O
a NCT03860103 473 474 O
social NCT03860103 475 481 O
security NCT03860103 482 490 O
scheme NCT03860103 491 497 O

- NCT03860103 500 501 O
Multiple NCT03860103 503 511 B-Eq-Comparison
pregnancy NCT03860103 512 521 B-Condition

Inclusion NCT03861221 0 9 O
Criteria NCT03861221 10 18 O
: NCT03861221 19 20 O

- NCT03861221 24 25 O
Female NCT03861221 27 33 O
, NCT03861221 34 35 O
older NCT03861221 36 41 I-Eq-Comparison
than NCT03861221 42 46 I-Eq-Comparison
35 NCT03861221 47 49 I-Eq-Comparison
years NCT03861221 50 55 I-Eq-Comparison
. NCT03861221 55 56 O
Already NCT03861221 58 65 B-Eq-Comparison
have NCT03861221 66 70 O
mammography NCT03861221 71 82 B-Procedure
, NCT03861221 83 84 O
or NCT03861221 85 87 B-Or
other NCT03861221 88 93 B-Other
standard NCT03861221 94 102 B-Procedure
exams NCT03861221 103 108 I-Procedure
( NCT03861221 109 110 O
ultrasound NCT03861221 111 121 B-Procedure
, NCT03861221 122 123 O
MRI NCT03861221 124 127 B-Procedure
, NCT03861221 128 129 O
etc NCT03861221 130 133 O
) NCT03861221 134 135 O
. NCT03861221 136 137 O
Could NCT03861221 139 144 B-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861221 145 156 O
this NCT03861221 157 161 O
trial NCT03861221 162 167 B-Study
within NCT03861221 168 174 B-Eq-Comparison
2 NCT03861221 175 176 I-Eq-Comparison
weeks NCT03861221 177 182 I-Eq-Comparison
after NCT03861221 183 188 B-Temporal-Connection___Temporal-Connection-Type-Value:after
mammography NCT03861221 189 200 B-Procedure
. NCT03861221 200 201 O
Have NCT03861221 203 207 O
the NCT03861221 208 211 O
ability NCT03861221 212 219 O
of NCT03861221 220 222 O
consent NCT03861221 223 230 O
inform NCT03861221 231 237 O
. NCT03861221 237 238 O

Exclusion NCT03861221 240 249 O
Criteria NCT03861221 250 258 O
: NCT03861221 259 260 O

- NCT03861221 264 265 O
During NCT03861221 267 273 O
pregnancy NCT03861221 274 283 B-Condition
or NCT03861221 284 286 B-Or
lactation NCT03861221 287 296 B-Condition
period NCT03861221 297 303 O
. NCT03861221 303 304 O
Patients NCT03861221 306 314 O
that NCT03861221 315 319 O
may NCT03861221 320 323 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03861221 324 327 B-Negation
be NCT03861221 328 330 O
capable NCT03861221 331 338 B-Observation
of NCT03861221 339 341 I-Observation
prone NCT03861221 342 347 I-Observation
position NCT03861221 348 356 I-Observation
, NCT03861221 357 358 O
such NCT03861221 359 363 O
as NCT03861221 364 366 O
patients NCT03861221 367 375 O
with NCT03861221 376 380 O
scapulohumeral NCT03861221 381 395 B-Condition
periarthritis NCT03861221 396 409 I-Condition
, NCT03861221 410 411 O
cardiac NCT03861221 412 419 B-Procedure
pacemaker NCT03861221 420 429 I-Procedure
or NCT03861221 430 432 B-Or
have NCT03861221 433 437 O
recent NCT03861221 438 444 B-Eq-Comparison
cardiac NCT03861221 445 452 B-Procedure
surgery NCT03861221 453 460 I-Procedure
. NCT03861221 460 461 O

Lymphoma NCT03861221 463 471 B-Condition
patients NCT03861221 472 480 O
that NCT03861221 481 485 O
under NCT03861221 486 491 B-Eq-Comparison
therapy NCT03861221 492 499 B-Procedure
. NCT03861221 499 500 O
Severe NCT03861221 502 508 O
scoliosis NCT03861221 509 518 B-Condition
. NCT03861221 518 519 O

Inclusion NCT03867877 0 9 O
Criteria NCT03867877 10 18 O
: NCT03867877 19 20 O

- NCT03867877 24 25 O
Hoehn NCT03867877 27 32 B-Condition
& NCT03867877 33 34 I-Condition
Yahr NCT03867877 35 39 I-Condition
Classification NCT03867877 40 54 I-Condition
of NCT03867877 55 57 I-Condition
Disability NCT03867877 58 68 I-Condition
, NCT03867877 69 70 O
stage NCT03867877 71 76 B-Eq-Comparison
1 NCT03867877 77 78 I-Eq-Comparison
- NCT03867877 79 80 I-Eq-Comparison
3 NCT03867877 81 82 O

- NCT03867877 86 87 O
can NCT03867877 89 92 B-Condition|Observation
ambulate NCT03867877 93 101 I-Condition|Observation
with NCT03867877 102 106 B-And
or NCT03867877 107 109 B-Or
without NCT03867877 110 117 B-Negation
an NCT03867877 118 120 O
assistive NCT03867877 121 130 B-Procedure
device NCT03867877 131 137 I-Procedure
for NCT03867877 138 141 O
at NCT03867877 142 144 B-Eq-Comparison
least NCT03867877 145 150 I-Eq-Comparison
50 NCT03867877 151 153 I-Eq-Comparison
feet NCT03867877 154 158 I-Eq-Comparison

- NCT03867877 161 162 O
able NCT03867877 164 168 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867877 169 171 I-Assertion___Assertion-Type-Value:hypothetical
get NCT03867877 172 175 B-Observation
up NCT03867877 176 178 I-Observation
and NCT03867877 179 182 I-Observation
down NCT03867877 183 187 I-Observation
from NCT03867877 188 192 I-Observation
the NCT03867877 193 196 I-Observation
floor NCT03867877 197 202 I-Observation
with NCT03867877 203 207 O
minimal NCT03867877 208 215 B-Modifier
assistance NCT03867877 216 226 I-Modifier

- NCT03867877 229 230 O
has NCT03867877 232 235 O
a NCT03867877 236 237 O
score NCT03867877 238 243 O
of NCT03867877 244 246 O
24 NCT03867877 247 249 B-Eq-Comparison
or NCT03867877 250 252 I-Eq-Comparison
above NCT03867877 253 258 I-Eq-Comparison
on NCT03867877 259 261 O
the NCT03867877 262 265 O
Folstein NCT03867877 266 274 B-Observation
Mini NCT03867877 275 279 I-Observation
- NCT03867877 280 281 I-Observation
Mental NCT03867877 282 288 I-Observation
State NCT03867877 289 294 I-Observation
Exam NCT03867877 295 299 I-Observation

Exclusion NCT03867877 300 309 O
Criteria NCT03867877 310 318 O
: NCT03867877 319 320 O

- NCT03867877 324 325 O
Greater NCT03867877 327 334 B-Eq-Comparison
than NCT03867877 335 339 I-Eq-Comparison
Stage NCT03867877 340 345 I-Eq-Comparison
3 NCT03867877 346 347 I-Eq-Comparison
on NCT03867877 348 350 O
the NCT03867877 351 354 O
Hoehn NCT03867877 355 360 B-Condition
& NCT03867877 361 362 I-Condition
Yahr NCT03867877 363 367 I-Condition
Classification NCT03867877 368 382 I-Condition
of NCT03867877 383 385 I-Condition
Disability NCT03867877 386 396 I-Condition

- NCT03867877 399 400 O
decline NCT03867877 402 409 O
in NCT03867877 410 412 O
immune NCT03867877 413 419 B-Condition
function NCT03867877 420 428 I-Condition
such NCT03867877 429 433 O
as NCT03867877 434 436 O
pneumonia NCT03867877 437 446 B-Condition
or NCT03867877 447 449 B-Or
systemic NCT03867877 450 458 B-Modifier
infection NCT03867877 459 468 B-Condition

- NCT03867877 471 472 O
progressive NCT03867877 474 485 B-Condition
degenerative NCT03867877 486 498 I-Condition
disease NCT03867877 499 506 I-Condition
besides NCT03867877 507 514 B-Exception
PD NCT03867877 515 517 B-Condition

- NCT03867877 520 521 O
spinal NCT03867877 523 529 B-Procedure
fusion NCT03867877 530 536 I-Procedure
or NCT03867877 537 539 B-Or|Procedure
other NCT03867877 540 545 B-Other
orthopedic NCT03867877 546 556 O
surgery NCT03867877 557 564 I-Procedure
in NCT03867877 565 567 O
the NCT03867877 568 571 O
past NCT03867877 572 576 B-Eq-Comparison
six NCT03867877 577 580 I-Eq-Comparison
months NCT03867877 581 587 I-Eq-Comparison

- NCT03867877 590 591 O
mental NCT03867877 593 599 B-Condition
disease NCT03867877 600 607 I-Condition
/ NCT03867877 608 609 B-Or
psychosis NCT03867877 610 619 B-Condition
such NCT03867877 620 624 O
as NCT03867877 625 627 O
dementia NCT03867877 628 636 B-Condition

- NCT03867877 639 640 O
greater NCT03867877 642 649 B-Eq-Comparison
than NCT03867877 650 654 I-Eq-Comparison
minimal NCT03867877 655 662 B-Observation
assistance NCT03867877 663 673 I-Observation
required NCT03867877 674 682 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867877 683 686 O
gait NCT03867877 687 691 B-Modifier
and NCT03867877 692 695 B-And
transfers NCT03867877 696 705 B-Modifier

- NCT03867877 708 709 O
inability NCT03867877 711 720 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03867877 721 723 O
make NCT03867877 724 728 O
regular NCT03867877 729 736 O
time NCT03867877 737 741 O
commitments NCT03867877 742 753 O
to NCT03867877 754 756 O
the NCT03867877 757 760 O
scheduled NCT03867877 761 770 B-Eq-Comparison
training NCT03867877 771 779 B-Procedure
sessions NCT03867877 780 788 I-Procedure

- NCT03867877 791 792 O
participation NCT03867877 794 807 O
in NCT03867877 808 810 O
resistance NCT03867877 811 821 B-Observation
training NCT03867877 822 830 I-Observation
on NCT03867877 831 833 O
a NCT03867877 834 835 O
regular NCT03867877 836 843 O
basis NCT03867877 844 849 O
within NCT03867877 850 856 B-Eq-Comparison
the NCT03867877 857 860 I-Eq-Comparison
past NCT03867877 861 865 I-Eq-Comparison
six NCT03867877 866 869 I-Eq-Comparison
months NCT03867877 870 876 I-Eq-Comparison

- NCT03867877 879 880 O
inability NCT03867877 882 891 O
to NCT03867877 892 894 O
provide NCT03867877 895 902 O
consent NCT03867877 903 910 O

- NCT03867877 913 914 O
pregnancy NCT03867877 916 925 B-Condition

- NCT03867877 928 929 O
a NCT03867877 931 932 O
prisoner NCT03867877 933 941 B-Observation

Inclusion NCT03860467 0 9 O
Criteria NCT03860467 10 18 O
: NCT03860467 19 20 O

- NCT03860467 24 25 O
admitted NCT03860467 27 35 B-Encounter
to NCT03860467 36 38 O
the NCT03860467 39 42 O
ICU NCT03860467 43 46 O
at NCT03860467 47 49 O
the NCT03860467 50 53 O
University NCT03860467 54 64 O
Hospital NCT03860467 65 73 O
Basel NCT03860467 74 79 O

- NCT03860467 82 83 O
suffered NCT03860467 85 93 O
from NCT03860467 94 98 O
one NCT03860467 99 102 B-Eq-Comparison
or NCT03860467 103 105 I-Eq-Comparison
more NCT03860467 106 110 I-Eq-Comparison
epileptic NCT03860467 111 120 B-Condition
seizures NCT03860467 121 129 I-Condition
( NCT03860467 130 131 O
detected NCT03860467 132 140 O
clinically NCT03860467 141 151 B-Modifier
and NCT03860467 152 155 B-Or
/ NCT03860467 156 157 I-Or
or NCT03860467 158 160 I-Or
by NCT03860467 161 163 O
EEG NCT03860467 164 167 B-Procedure
) NCT03860467 168 169 O
during NCT03860467 170 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03860467 177 182 O
ICU NCT03860467 183 186 O
- NCT03860467 187 188 O
stay NCT03860467 189 193 B-Encounter

Exclusion NCT03860467 194 203 O
Criteria NCT03860467 204 212 O
: NCT03860467 213 214 O

- NCT03860467 218 219 O
patients NCT03860467 221 229 O
with NCT03860467 230 234 O
epileptic NCT03860467 235 244 B-Condition
seizures NCT03860467 245 253 I-Condition
transforming NCT03860467 254 266 O
into NCT03860467 267 271 O
Status NCT03860467 272 278 B-Condition
epilepticus NCT03860467 279 290 I-Condition
( NCT03860467 291 292 O
SE NCT03860467 293 295 B-Condition
) NCT03860467 296 297 O

Inclusion NCT03865251 0 9 O
Criteria NCT03865251 10 18 O
: NCT03865251 19 20 O

- NCT03865251 24 25 O
Undertake NCT03865251 27 36 B-Eq-Comparison
regular NCT03865251 37 44 B-Modifier
exercise NCT03865251 45 53 B-Observation
at NCT03865251 54 56 B-Eq-Comparison
least NCT03865251 57 62 I-Eq-Comparison
3 NCT03865251 63 64 I-Eq-Comparison
times NCT03865251 65 70 I-Eq-Comparison
a NCT03865251 71 72 I-Eq-Comparison
week NCT03865251 73 77 I-Eq-Comparison
with NCT03865251 78 82 O
accumulation NCT03865251 83 95 O
of NCT03865251 96 98 O
150 NCT03865251 99 102 B-Eq-Comparison
min NCT03865251 103 106 I-Eq-Comparison
per NCT03865251 107 110 I-Eq-Comparison
week NCT03865251 111 115 I-Eq-Comparison

- NCT03865251 118 119 O
Age NCT03865251 121 124 B-Age
between NCT03865251 125 132 B-Eq-Comparison
20 NCT03865251 133 135 I-Eq-Comparison
and NCT03865251 136 139 I-Eq-Comparison
30 NCT03865251 140 142 I-Eq-Comparison
years NCT03865251 143 148 I-Eq-Comparison
old NCT03865251 149 152 O

Exclusion NCT03865251 153 162 O
Criteria NCT03865251 163 171 O
: NCT03865251 172 173 O

- NCT03865251 177 178 O
History NCT03865251 180 187 B-Eq-Comparison
of NCT03865251 188 190 O
severe NCT03865251 191 197 O
neuromuscular NCT03865251 198 211 B-Modifier
injury NCT03865251 212 218 B-Condition

- NCT03865251 221 222 O
Current NCT03865251 224 231 B-Eq-Comparison
lower NCT03865251 232 237 B-Modifier
extremity NCT03865251 238 247 I-Modifier
injury NCT03865251 248 254 B-Condition

- NCT03865251 257 258 O
Current NCT03865251 260 267 B-Eq-Comparison
neurological NCT03865251 268 280 B-Condition
diseases NCT03865251 281 289 I-Condition

Inclusion NCT03865537 0 9 O
Criteria NCT03865537 10 18 O
: NCT03865537 19 20 O

- NCT03865537 24 25 O
Any NCT03865537 27 30 O
patient NCT03865537 31 38 O
≥ NCT03865537 39 40 B-Eq-Comparison
18 NCT03865537 41 43 I-Age|Eq-Comparison
who NCT03865537 44 47 B-And
presents NCT03865537 48 56 B-Eq-Comparison
for NCT03865537 57 60 I-Eq-Comparison
a NCT03865537 61 62 O
colonoscopy NCT03865537 63 74 B-Procedure
and NCT03865537 75 78 B-And
who NCT03865537 79 82 O
does NCT03865537 83 87 O
not NCT03865537 88 91 B-Negation
have NCT03865537 92 96 O
criteria NCT03865537 97 105 B-Condition
for NCT03865537 106 109 O
exclusion NCT03865537 110 119 B-Negation

- NCT03865537 122 123 O
Patients NCT03865537 125 133 O
with NCT03865537 134 138 O
a NCT03865537 139 140 O
≥ NCT03865537 141 142 B-Eq-Comparison
20 NCT03865537 143 145 I-Eq-Comparison
mm NCT03865537 146 148 O
non NCT03865537 149 152 B-Negation
- NCT03865537 153 154 O
pedunculated NCT03865537 155 167 B-Modifier
colorectal NCT03865537 168 178 B-Modifier
polyp NCT03865537 179 184 B-Condition|Observation

Exclusion NCT03865537 185 194 O
Criteria NCT03865537 195 203 O
: NCT03865537 204 205 O

- NCT03865537 209 210 O
Pedunculated NCT03865537 212 224 B-Modifier
polyps NCT03865537 225 231 B-Condition
( NCT03865537 232 233 O
as NCT03865537 234 236 O
defined NCT03865537 237 244 O
by NCT03865537 245 247 O
Paris NCT03865537 248 253 O
Classification NCT03865537 254 268 O
type NCT03865537 269 273 O
Ip NCT03865537 274 276 O
) NCT03865537 277 278 O

- NCT03865537 282 283 O
Suspected NCT03865537 285 294 B-Assertion___Assertion-Type-Value:possible
adenocarcinoma NCT03865537 295 309 B-Condition
with NCT03865537 310 314 O
deep NCT03865537 315 319 B-Modifier
submucosal NCT03865537 320 330 I-Modifier
invasion NCT03865537 331 339 I-Modifier

- NCT03865537 342 343 O
Patients NCT03865537 345 353 O
with NCT03865537 354 358 O
ulcerated NCT03865537 359 368 B-Modifier
depressed NCT03865537 369 378 I-Modifier
lesions NCT03865537 379 386 B-Condition
( NCT03865537 387 388 O
as NCT03865537 389 391 O
defined NCT03865537 392 399 O
by NCT03865537 400 402 O
Paris NCT03865537 403 408 O
Classification NCT03865537 409 423 O
type NCT03865537 424 428 O
III NCT03865537 429 432 O
) NCT03865537 433 434 O
or NCT03865537 435 437 B-Or
confirmed NCT03865537 438 447 O
adenocarcinoma NCT03865537 448 462 B-Condition

- NCT03865537 465 466 O
Patients NCT03865537 468 476 O
with NCT03865537 477 481 O
inflammatory NCT03865537 482 494 B-Condition
bowel NCT03865537 495 500 I-Condition
disease NCT03865537 501 508 I-Condition

- NCT03865537 511 512 O
Patients NCT03865537 514 522 O
who NCT03865537 523 526 O
are NCT03865537 527 530 O
receiving NCT03865537 531 540 B-Eq-Comparison
an NCT03865537 541 543 O
emergency NCT03865537 544 553 B-Modifier
colonoscopy NCT03865537 554 565 B-Procedure

- NCT03865537 568 569 O
Poor NCT03865537 571 575 B-Condition
general NCT03865537 576 583 I-Condition
health NCT03865537 584 590 I-Condition
( NCT03865537 591 592 O
ASA NCT03865537 593 596 B-Condition
class NCT03865537 597 602 O
> NCT03865537 603 604 B-Eq-Comparison
3 NCT03865537 605 606 I-Eq-Comparison
) NCT03865537 607 608 O

- NCT03865537 612 613 O
Patients NCT03865537 615 623 O
with NCT03865537 624 628 B-And
coagulopathy NCT03865537 629 641 B-Condition
with NCT03865537 642 646 O
an NCT03865537 647 649 O
elevated NCT03865537 650 658 O
INR NCT03865537 659 662 B-Observation
≥ NCT03865537 663 664 B-Eq-Comparison
1.5 NCT03865537 665 668 I-Eq-Comparison
, NCT03865537 669 670 O
or NCT03865537 671 673 B-Or
platelets NCT03865537 674 683 B-Observation
< NCT03865537 684 685 B-Eq-Comparison
50 NCT03865537 686 688 I-Eq-Comparison

- NCT03865537 692 693 O
Inadequate NCT03865537 695 705 B-Condition
bowel NCT03865537 706 711 I-Condition
preparation NCT03865537 712 723 I-Condition
( NCT03865537 724 725 O
Boston NCT03865537 726 732 B-Observation
Bowel NCT03865537 733 738 I-Observation
Prep NCT03865537 739 743 I-Observation
Scale NCT03865537 744 749 I-Observation
, NCT03865537 750 751 O
total NCT03865537 752 757 O
score NCT03865537 758 763 O
≤ NCT03865537 764 765 B-Eq-Comparison
2 NCT03865537 766 767 I-Eq-Comparison
) NCT03865537 768 769 O

- NCT03865537 773 774 O
Pregnancy NCT03865537 776 785 B-Condition


Inclusion NCT03868761 0 9 O
Criteria NCT03868761 10 18 O
: NCT03868761 19 20 O

1 NCT03868761 24 25 O
. NCT03868761 25 26 O
Males NCT03868761 28 33 O
& NCT03868761 34 35 B-Or
females NCT03868761 36 43 O
aged NCT03868761 44 48 B-Age
13 NCT03868761 49 51 B-Eq-Comparison
- NCT03868761 52 53 I-Eq-Comparison
17 NCT03868761 54 56 I-Eq-Comparison
years NCT03868761 57 62 I-Eq-Comparison
directly NCT03868761 63 71 O
impacted NCT03868761 72 80 O
by NCT03868761 81 83 O
the NCT03868761 84 87 O
2017 NCT03868761 88 92 O
wildfires NCT03868761 93 102 O
having NCT03868761 103 109 O
lost NCT03868761 110 114 B-Observation
their NCT03868761 115 120 I-Observation
home NCT03868761 121 125 I-Observation
or NCT03868761 126 128 B-Or
been NCT03868761 129 133 O
temporarily NCT03868761 134 145 B-Observation
displaced NCT03868761 146 155 I-Observation

2 NCT03868761 158 159 O
. NCT03868761 159 160 O
Screen NCT03868761 162 168 O
positive NCT03868761 169 177 O
for NCT03868761 178 181 O
PTSD NCT03868761 182 186 B-Condition
( NCT03868761 187 188 O
Child NCT03868761 189 194 B-Observation
Trauma NCT03868761 195 201 I-Observation
Screening NCT03868761 202 211 I-Observation
Questionnaire NCT03868761 212 225 I-Observation
= NCT03868761 226 227 B-Eq-Comparison
5 NCT03868761 228 229 I-Eq-Comparison
or NCT03868761 230 232 I-Eq-Comparison
higher NCT03868761 233 239 I-Eq-Comparison
) NCT03868761 240 241 O

3 NCT03868761 245 246 O
. NCT03868761 246 247 O
Have NCT03868761 249 253 O
regular NCT03868761 254 261 O
access NCT03868761 262 268 O
to NCT03868761 269 271 O
a NCT03868761 272 273 O
smart NCT03868761 274 279 O
phone NCT03868761 280 285 O
and NCT03868761 286 289 O
a NCT03868761 290 291 O
computer NCT03868761 292 300 O

4 NCT03868761 303 304 O
. NCT03868761 304 305 O
Have NCT03868761 307 311 O
a NCT03868761 312 313 O
personal NCT03868761 314 322 O
email NCT03868761 323 328 O
address NCT03868761 329 336 O

5 NCT03868761 339 340 O
. NCT03868761 340 341 O
Speak NCT03868761 343 348 O
and NCT03868761 349 352 O
read NCT03868761 353 357 O
English NCT03868761 358 365 O
fluently NCT03868761 366 374 O

6 NCT03868761 377 378 O
. NCT03868761 378 379 O
Have NCT03868761 381 385 O
parental NCT03868761 386 394 O
consent NCT03868761 395 402 O

Exclusion NCT03868761 403 412 O
Criteria NCT03868761 413 421 O
: NCT03868761 422 423 O

1 NCT03868761 427 428 O
. NCT03868761 428 429 O
A NCT03868761 431 432 O
positive NCT03868761 433 441 O
self NCT03868761 442 446 O
- NCT03868761 447 448 O
reported NCT03868761 449 457 O
history NCT03868761 458 465 B-Eq-Comparison
of NCT03868761 466 468 O
psychosis NCT03868761 469 478 B-Condition
, NCT03868761 479 480 O
bipolar NCT03868761 481 488 B-Condition
, NCT03868761 489 490 O
or NCT03868761 491 493 B-Or
schizophrenia NCT03868761 494 507 B-Condition

2 NCT03868761 510 511 O
. NCT03868761 511 512 O
Serious NCT03868761 514 521 O
self NCT03868761 522 526 O
- NCT03868761 527 528 O
reported NCT03868761 529 537 O
physical NCT03868761 538 546 B-Condition
health NCT03868761 547 553 I-Condition
concerns NCT03868761 554 562 I-Condition
necessitating NCT03868761 563 576 B-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03868761 577 584 B-Procedure
or NCT03868761 585 587 B-Or
with NCT03868761 588 592 O
prognosis NCT03868761 593 602 B-Observation
< NCT03868761 603 604 B-Eq-Comparison
6 NCT03868761 605 606 I-Eq-Comparison
months NCT03868761 607 613 I-Eq-Comparison

3 NCT03868761 621 622 O
. NCT03868761 622 623 O
A NCT03868761 625 626 O
positive NCT03868761 627 635 O
screen NCT03868761 636 642 O
for NCT03868761 643 646 O
a NCT03868761 647 648 O
current NCT03868761 649 656 B-Eq-Comparison
Substance NCT03868761 657 666 B-Condition
User NCT03868761 667 671 I-Condition
Disorder NCT03868761 672 680 I-Condition
( NCT03868761 681 682 O
CRAFFT NCT03868761 683 689 B-Observation
= NCT03868761 690 691 B-Eq-Comparison
2 NCT03868761 692 693 I-Eq-Comparison
or NCT03868761 694 696 I-Eq-Comparison
higher NCT03868761 697 703 I-Eq-Comparison
) NCT03868761 704 705 O

4 NCT03868761 709 710 O
. NCT03868761 710 711 O
Current NCT03868761 713 720 B-Eq-Comparison
self NCT03868761 721 725 O
- NCT03868761 726 727 O
reported NCT03868761 728 736 O
suicidal NCT03868761 737 745 B-Condition
ideation NCT03868761 746 754 I-Condition

5 NCT03868761 757 758 O
. NCT03868761 758 759 O
Self NCT03868761 761 765 O
- NCT03868761 766 767 O
reported NCT03868761 768 776 O
pregnancy NCT03868761 777 786 B-Condition

6 NCT03868761 789 790 O
. NCT03868761 790 791 O
Self NCT03868761 793 797 O
- NCT03868761 798 799 O
reported NCT03868761 800 808 O
less NCT03868761 809 813 B-Eq-Comparison
than NCT03868761 814 818 I-Eq-Comparison
four NCT03868761 819 823 I-Eq-Comparison
weeks NCT03868761 824 829 I-Eq-Comparison
of NCT03868761 830 832 O
stable NCT03868761 833 839 O
prescription NCT03868761 840 852 O
medication NCT03868761 853 863 B-Drug
for NCT03868761 864 867 O
anxiety NCT03868761 868 875 B-Condition
, NCT03868761 876 877 O
anti NCT03868761 878 882 B-Drug
- NCT03868761 883 884 I-Drug
depressant NCT03868761 885 895 I-Drug
, NCT03868761 896 897 O
and NCT03868761 898 901 B-Or
sleep NCT03868761 902 907 B-Condition
promoting NCT03868761 908 917 O
medications NCT03868761 918 929 B-Drug
prior NCT03868761 930 935 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868761 936 938 O
the NCT03868761 939 942 O
screening NCT03868761 943 952 B-Study
assessment NCT03868761 953 963 B-Procedure


Inclusion NCT03861962 0 9 O
Criteria NCT03861962 10 18 O
: NCT03861962 19 20 O

- NCT03861962 24 25 O
patients NCT03861962 27 35 O
( NCT03861962 36 37 O
adults NCT03861962 38 44 O
and NCT03861962 45 48 B-Or
children NCT03861962 49 57 O
) NCT03861962 58 59 O

- NCT03861962 63 64 O
patients NCT03861962 66 74 O
recipients NCT03861962 75 85 O
in NCT03861962 86 88 O
France NCT03861962 89 95 O
from NCT03861962 96 100 O
2008 NCT03861962 101 105 B-Eq-Comparison
to NCT03861962 106 108 I-Eq-Comparison
2015 NCT03861962 109 113 I-Eq-Comparison
of NCT03861962 114 116 O
a NCT03861962 117 118 O
first NCT03861962 119 124 B-Eq-Comparison
kidney NCT03861962 125 131 B-Modifier
transplant NCT03861962 132 142 B-Procedure
/ NCT03861962 143 144 B-Or
heart NCT03861962 145 150 B-Modifier
/ NCT03861962 151 152 B-Or
lung NCT03861962 153 157 B-Modifier
/ NCT03861962 158 159 B-Or
liver NCT03861962 160 165 B-Modifier
donor NCT03861962 166 171 I-Modifier
living NCT03861962 172 178 B-Death|Negation
or NCT03861962 179 181 B-Or
deceased NCT03861962 182 190 B-Death
, NCT03861962 191 192 O
non NCT03861962 193 196 B-Negation
- NCT03861962 197 198 O
immunized NCT03861962 199 208 B-Immunization
anti NCT03861962 209 213 O
- NCT03861962 214 215 O
HLA NCT03861962 216 219 B-Condition
before NCT03861962 220 226 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861962 227 230 O
transplant NCT03861962 231 241 B-Coreference|Procedure

- NCT03861962 244 245 O
patients NCT03861962 247 255 O
having NCT03861962 256 262 O
preserved NCT03861962 263 272 O
their NCT03861962 273 278 O
graft NCT03861962 279 284 B-Procedure
> NCT03861962 285 286 B-Eq-Comparison
2 NCT03861962 287 288 I-Eq-Comparison
years NCT03861962 289 294 I-Eq-Comparison

- NCT03861962 297 298 O
having NCT03861962 300 306 O
agreed NCT03861962 307 313 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861962 314 316 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03861962 317 320 O
use NCT03861962 321 324 O
for NCT03861962 325 328 O
research NCT03861962 329 337 O
purposes NCT03861962 338 346 O
in NCT03861962 347 349 O
transplantation NCT03861962 350 365 B-Procedure
of NCT03861962 366 368 O
the NCT03861962 369 372 O
remains NCT03861962 373 380 O
of NCT03861962 381 383 O
the NCT03861962 384 387 O
DNA NCT03861962 388 391 B-Observation
and NCT03861962 392 395 B-And
serum NCT03861962 396 401 B-Observation
samples NCT03861962 402 409 I-Observation
taken NCT03861962 410 415 O
as NCT03861962 416 418 O
part NCT03861962 419 423 O
of NCT03861962 424 426 O
the NCT03861962 427 430 O
care NCT03861962 431 435 O
of NCT03861962 436 438 O
which NCT03861962 439 444 O
the NCT03861962 445 448 O
remains NCT03861962 449 456 O
are NCT03861962 457 460 O
available NCT03861962 461 470 O

Exclusion NCT03861962 471 480 O
Criteria NCT03861962 481 489 O
: NCT03861962 490 491 O

- NCT03861962 495 496 O
no NCT03861962 498 500 O
inclusion NCT03861962 501 510 O
if NCT03861962 511 513 O
one NCT03861962 514 517 O
of NCT03861962 518 520 O
the NCT03861962 521 524 O
inclusion NCT03861962 525 534 O
criteria NCT03861962 535 543 O
is NCT03861962 544 546 O
not NCT03861962 547 550 O
met NCT03861962 551 554 O

Inclusion NCT03864198 0 9 O
Criteria NCT03864198 10 18 O
: NCT03864198 19 20 O

- NCT03864198 24 25 O
male NCT03864198 27 31 O
18 NCT03864198 32 34 B-Eq-Comparison
- NCT03864198 35 36 I-Eq-Comparison
50 NCT03864198 37 39 I-Eq-Comparison
years NCT03864198 40 45 I-Age|Eq-Comparison

- NCT03864198 48 49 O
oligozoospermia NCT03864198 51 66 B-Condition
: NCT03864198 67 68 O
< NCT03864198 69 70 B-Eq-Comparison
5 NCT03864198 71 72 I-Eq-Comparison
million NCT03864198 73 80 I-Eq-Comparison
spermatozoa NCT03864198 81 92 I-Eq-Comparison|Observation
/ NCT03864198 93 94 I-Eq-Comparison
mL NCT03864198 95 97 I-Eq-Comparison
; NCT03864198 97 98 O

- NCT03864198 101 102 O
asthenozoospermia NCT03864198 104 121 B-Condition
: NCT03864198 122 123 O
< NCT03864198 124 125 B-Eq-Comparison
32 NCT03864198 126 128 I-Eq-Comparison
% NCT03864198 129 130 O
progressive NCT03864198 131 142 B-Observation
motile NCT03864198 143 149 I-Observation
spermatozoa NCT03864198 150 161 I-Observation
; NCT03864198 161 162 O

- NCT03864198 165 166 O
teratozoospermia NCT03864198 168 184 B-Condition
: NCT03864198 185 186 O
< NCT03864198 187 188 B-Eq-Comparison
4 NCT03864198 189 190 I-Eq-Comparison
% NCT03864198 191 192 O
normal NCT03864198 193 199 O
forms NCT03864198 200 205 B-Observation
. NCT03864198 205 206 O

Exclusion NCT03864198 208 217 O
Criteria NCT03864198 218 226 O
: NCT03864198 227 228 O

- NCT03864198 232 233 O
azoospermia NCT03864198 235 246 B-Condition

- NCT03864198 249 250 O
smoke NCT03864198 252 257 B-Condition

- NCT03864198 260 261 O
use NCT03864198 263 266 B-Eq-Comparison
drugs NCT03864198 267 272 B-Drug

- NCT03864198 275 276 O
use NCT03864198 278 281 B-Eq-Comparison
drugs NCT03864198 282 287 B-Drug
with NCT03864198 288 292 B-And
proven NCT03864198 293 299 O
fertility NCT03864198 300 309 B-Condition
toxicity NCT03864198 310 318 I-Condition

- NCT03864198 321 322 O
exposition NCT03864198 324 334 O
to NCT03864198 335 337 O
any NCT03864198 338 341 O
environmental NCT03864198 342 355 B-Modifier
or NCT03864198 356 358 B-Or
occupational NCT03864198 359 371 B-Modifier
toxic NCT03864198 372 377 I-Modifier
substances NCT03864198 378 388 B-Drug

- NCT03864198 391 392 O
exposition NCT03864198 394 404 O
to NCT03864198 405 407 O
radiation NCT03864198 408 417 B-Procedure
or NCT03864198 418 420 B-Condition|Or
heat NCT03864198 421 425 B-Modifier

- NCT03864198 428 429 O
orchitis NCT03864198 431 439 O
secondary NCT03864198 440 449 B-Modifier
to NCT03864198 450 452 O
mumps NCT03864198 453 458 B-Condition

- NCT03864198 461 462 O
sexually NCT03864198 464 472 B-Condition
transmitted NCT03864198 473 484 I-Condition
diseases NCT03864198 485 493 I-Condition

- NCT03864198 496 497 O
history NCT03864198 499 506 B-Eq-Comparison
of NCT03864198 507 509 O
cryptorchidism NCT03864198 510 524 B-Condition

- NCT03864198 527 528 O
previous NCT03864198 530 538 B-Eq-Comparison
testicular NCT03864198 539 549 B-Procedure
torsion NCT03864198 550 557 I-Procedure

- NCT03864198 560 561 O
genitourinary NCT03864198 563 576 B-Condition
anomalies NCT03864198 577 586 I-Condition

- NCT03864198 589 590 O
alterations NCT03864198 592 603 B-Procedure
of NCT03864198 604 606 O
the NCT03864198 607 610 O
epididymis NCT03864198 611 621 B-Modifier
or NCT03864198 622 624 B-Or
deferens NCT03864198 625 633 B-Modifier

- NCT03864198 636 637 O
inguinal NCT03864198 639 647 B-Procedure
surgery NCT03864198 648 655 I-Procedure

Inclusion NCT03868631 0 9 O
Criteria NCT03868631 10 18 O
: NCT03868631 19 20 O

- NCT03868631 24 25 O
non NCT03868631 27 30 B-Negation
- NCT03868631 31 32 O
smoking NCT03868631 33 40 B-Condition

- NCT03868631 43 44 O
body NCT03868631 46 50 B-Observation
mass NCT03868631 51 55 I-Observation
index NCT03868631 56 61 I-Observation
( NCT03868631 62 63 O
BMI NCT03868631 64 67 B-Observation
) NCT03868631 68 69 O
18.5 NCT03868631 70 74 B-Eq-Comparison
- NCT03868631 75 76 I-Eq-Comparison
24.9 NCT03868631 77 81 I-Eq-Comparison

- NCT03868631 85 86 O
recreationally NCT03868631 88 102 B-Observation
active NCT03868631 103 109 B-Eq-Comparison

Exclusion NCT03868631 110 119 O
Criteria NCT03868631 120 128 O
: NCT03868631 129 130 O

- NCT03868631 134 135 O
participated NCT03868631 137 149 O
in NCT03868631 150 152 O
structured NCT03868631 153 163 B-Modifier
weight NCT03868631 164 170 B-Observation
training NCT03868631 171 179 I-Observation
during NCT03868631 180 186 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868631 187 190 O
previous NCT03868631 191 199 B-Eq-Comparison
12 NCT03868631 200 202 I-Eq-Comparison
month NCT03868631 203 208 I-Eq-Comparison

- NCT03868631 211 212 O
vegetarian NCT03868631 214 224 B-Condition
or NCT03868631 225 227 B-Or
vegan NCT03868631 228 233 B-Condition

- NCT03868631 236 237 O
presence NCT03868631 239 247 O
of NCT03868631 248 250 O
chronic NCT03868631 251 258 B-Modifier
disease NCT03868631 259 266 B-Condition

- NCT03868631 269 270 O
pregnant NCT03868631 272 280 B-Condition
, NCT03868631 281 282 O
postpartum NCT03868631 283 293 B-Condition
up NCT03868631 294 296 B-Eq-Comparison
to NCT03868631 297 299 I-Eq-Comparison
six NCT03868631 300 303 I-Eq-Comparison
months NCT03868631 304 310 I-Eq-Comparison
, NCT03868631 311 312 O
lactating NCT03868631 313 322 B-Condition
, NCT03868631 323 324 O
or NCT03868631 325 327 B-Or
intention NCT03868631 328 337 B-Assertion___Assertion-Type-Value:intention
to NCT03868631 338 340 I-Assertion___Assertion-Type-Value:intention
become NCT03868631 341 347 O
pregnant NCT03868631 348 356 B-Condition

- NCT03868631 359 360 O
allergy NCT03868631 362 369 B-Allergy
to NCT03868631 370 372 O
whey NCT03868631 373 377 O
or NCT03868631 378 380 B-Or
soy NCT03868631 381 384 O

- NCT03868631 387 388 O
changes NCT03868631 390 397 O
in NCT03868631 398 400 O
body NCT03868631 401 405 B-Observation
weight NCT03868631 406 412 I-Observation
more NCT03868631 413 417 B-Eq-Comparison
than NCT03868631 418 422 I-Eq-Comparison
10 NCT03868631 423 425 I-Eq-Comparison
pounds NCT03868631 426 432 I-Eq-Comparison
in NCT03868631 433 435 O
the NCT03868631 436 439 O
past NCT03868631 440 444 B-Eq-Comparison
three NCT03868631 445 450 I-Eq-Comparison
months NCT03868631 451 457 I-Eq-Comparison

Inclusion NCT03865329 0 9 O
Criteria NCT03865329 10 18 O

- NCT03865329 21 22 O
COPD NCT03865329 24 28 B-Condition
related NCT03865329 29 36 O
hospitalization NCT03865329 37 52 B-Encounter
and NCT03865329 53 56 B-And
eligible NCT03865329 57 65 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865329 66 69 O
PR NCT03865329 70 72 B-Procedure

- NCT03865329 75 76 O
Exclusion NCT03865329 78 87 O
Criteria NCT03865329 88 96 O

- NCT03865329 99 100 O
Inability NCT03865329 102 111 B-Condition
to NCT03865329 112 114 I-Condition
walk NCT03865329 115 119 I-Condition
( NCT03865329 120 121 O
orthopedic NCT03865329 122 132 B-Modifier
- NCT03865329 133 134 B-Or
neurologic NCT03865329 135 145 B-Modifier
problems NCT03865329 146 154 B-Condition
or NCT03865329 155 157 B-Or
confined NCT03865329 158 166 B-Condition
to NCT03865329 167 169 I-Condition
bed NCT03865329 170 173 I-Condition
) NCT03865329 174 175 O

Inclusion NCT03865498 0 9 O
Criteria NCT03865498 10 18 O
: NCT03865498 19 20 O

- NCT03865498 24 25 O
18 NCT03865498 27 29 B-Eq-Comparison
years NCT03865498 30 35 I-Eq-Comparison
of NCT03865498 36 38 I-Eq-Comparison
age NCT03865498 39 42 I-Age|Eq-Comparison
or NCT03865498 43 45 I-Eq-Comparison
older NCT03865498 46 51 I-Eq-Comparison

- NCT03865498 54 55 O
Black NCT03865498 57 62 O
or NCT03865498 63 65 B-Or
Hispanic NCT03865498 66 74 O
, NCT03865498 75 76 O
living NCT03865498 77 83 O
in NCT03865498 84 86 O
the NCT03865498 87 90 O
U. NCT03865498 91 93 O
S. NCT03865498 94 96 O
including NCT03865498 98 107 O
the NCT03865498 108 111 O
U. NCT03865498 112 114 O
S. NCT03865498 115 117 O
territories NCT03865498 119 130 O

- NCT03865498 133 134 O
a NCT03865498 136 137 O
dementia NCT03865498 138 146 B-Condition
caregiver NCT03865498 147 156 B-Family-Member___Family-Member-Type:parent
with NCT03865498 157 161 O
any NCT03865498 162 165 O
duration NCT03865498 166 174 O
, NCT03865498 175 176 O
able NCT03865498 177 181 O
to NCT03865498 182 184 O
speak NCT03865498 185 190 O
English NCT03865498 191 198 O
or NCT03865498 199 201 B-Or
Spanish NCT03865498 202 209 O
/ NCT03865498 210 211 O
bilingual NCT03865498 212 221 O

- NCT03865498 224 225 O
must NCT03865498 227 231 O
agree NCT03865498 232 237 O
to NCT03865498 238 240 O
terms NCT03865498 241 246 O
of NCT03865498 247 249 O
conditions NCT03865498 250 260 O
of NCT03865498 261 263 O
use NCT03865498 264 267 O
and NCT03865498 268 271 O
privacy NCT03865498 272 279 O
policy NCT03865498 280 286 O
and NCT03865498 287 290 O
rules NCT03865498 291 296 O
of NCT03865498 297 299 O
one NCT03865498 300 303 O
of NCT03865498 304 306 O
the NCT03865498 307 310 O
two NCT03865498 311 314 O
dementia NCT03865498 315 323 O
caregiver NCT03865498 324 333 O
network NCT03865498 334 341 O
( NCT03865498 342 343 O
Hispanic NCT03865498 344 352 O
@dcnh NCT03865498 353 358 O
, NCT03865498 359 360 O
Black NCT03865498 361 366 O
@dcnaab NCT03865498 367 374 O
) NCT03865498 375 376 O
, NCT03865498 378 379 O
the NCT03865498 380 383 O
Twitter NCT03865498 384 391 O
user NCT03865498 392 396 O
agreement NCT03865498 397 406 O
of NCT03865498 407 409 O
the NCT03865498 410 413 O
terms NCT03865498 414 419 O
of NCT03865498 420 422 O
service NCT03865498 423 430 O
, NCT03865498 431 432 O
Twitter NCT03865498 433 440 O
privacy NCT03865498 441 448 O
policy NCT03865498 449 455 O
and NCT03865498 456 459 O
Twitter NCT03865498 460 467 O
rules NCT03865498 468 473 O
including NCT03865498 474 483 O
intellectual NCT03865498 484 496 O
property NCT03865498 497 505 O
, NCT03865498 506 507 O
violence NCT03865498 508 516 B-Condition
, NCT03865498 517 518 O
misconduct NCT03865498 519 529 B-Condition
, NCT03865498 530 531 O
abuse NCT03865498 532 537 B-Condition
behavior NCT03865498 538 546 I-Condition
, NCT03865498 547 548 O
private NCT03865498 549 556 O
information NCT03865498 557 568 O
and NCT03865498 569 572 O
spam NCT03865498 573 577 O
and NCT03865498 578 581 O
security NCT03865498 582 590 O

- NCT03865498 593 594 O
use NCT03865498 596 599 O
a NCT03865498 600 601 O
smartphone NCT03865498 602 612 O
or NCT03865498 613 615 O
a NCT03865498 616 617 O
feature NCT03865498 618 625 O
phone NCT03865498 626 631 O
( NCT03865498 632 633 O
i. NCT03865498 634 636 O
e. NCT03865498 637 639 O
, NCT03865498 640 641 O
a NCT03865498 642 643 O
cell NCT03865498 644 648 O
phone NCT03865498 649 654 O
with NCT03865498 655 659 O
text NCT03865498 660 664 O
messaging NCT03865498 665 674 O
) NCT03865498 675 676 O

Exclusion NCT03865498 678 687 O
Criteria NCT03865498 688 696 O
: NCT03865498 697 698 O

- NCT03865498 702 703 O
do NCT03865498 705 707 O
not NCT03865498 708 711 O
have NCT03865498 712 716 O
de NCT03865498 717 719 O
- NCT03865498 720 721 O
identified NCT03865498 722 732 O
Twitter NCT03865498 733 740 O
account NCT03865498 741 748 O
, NCT03865498 749 750 O
children NCT03865498 751 759 O
, NCT03865498 760 761 O
not NCT03865498 762 765 B-Negation
a NCT03865498 766 767 O
dementia NCT03865498 768 776 B-Condition
family NCT03865498 777 783 B-Family-Member___Family-Member-Type:parent
caregiver NCT03865498 784 793 I-Family-Member___Family-Member-Type:parent

Inclusion NCT03860090 0 9 O
Criteria NCT03860090 10 18 O
: NCT03860090 19 20 O

- NCT03860090 24 25 O
Patients NCT03860090 27 35 O
with NCT03860090 36 40 O
a NCT03860090 41 42 O
endovenous NCT03860090 43 53 B-Procedure
pacemaker NCT03860090 54 63 I-Procedure
or NCT03860090 64 66 B-Or
defibrillator NCT03860090 67 80 B-Procedure
indication NCT03860090 81 91 B-Indication
. NCT03860090 91 92 O

Exclusion NCT03860090 94 103 O
Criteria NCT03860090 104 112 O
: NCT03860090 113 114 O

- NCT03860090 118 119 O
Pre NCT03860090 121 124 B-Eq-Comparison
- NCT03860090 125 126 I-Eq-Comparison
existing NCT03860090 127 135 I-Eq-Comparison
ipsilateral NCT03860090 136 147 B-Procedure
pacing NCT03860090 148 154 I-Procedure
electrode NCT03860090 155 164 I-Procedure
. NCT03860090 164 165 O

- NCT03860090 169 170 O
Previous NCT03860090 172 180 B-Eq-Comparison
ipsilateral NCT03860090 181 192 B-Condition
lymphadenectomy NCT03860090 193 208 I-Condition
. NCT03860090 208 209 O

- NCT03860090 213 214 O
Indication NCT03860090 216 226 B-Indication
of NCT03860090 227 229 O
cardiac NCT03860090 230 237 B-Procedure
resynchronization NCT03860090 238 255 I-Procedure
therapy NCT03860090 256 263 I-Procedure
. NCT03860090 263 264 O

For NCT03869671 0 3 O
all NCT03869671 4 7 O
phases NCT03869671 8 14 O
: NCT03869671 15 16 O

Inclusion NCT03869671 18 27 O
Criteria NCT03869671 28 36 O
: NCT03869671 37 38 O

- NCT03869671 42 43 O
An NCT03869671 45 47 O
adult NCT03869671 48 53 O
PWID NCT03869671 54 58 B-Condition

- NCT03869671 61 62 O
Self NCT03869671 64 68 O
report NCT03869671 69 75 O
of NCT03869671 76 78 O
any NCT03869671 79 82 O
high NCT03869671 83 87 O
risk NCT03869671 88 92 B-Risk
behaviors NCT03869671 93 102 I-Risk
for NCT03869671 103 106 O
HIV NCT03869671 107 110 B-Condition
( NCT03869671 111 112 O
past NCT03869671 113 117 B-Eq-Comparison
- NCT03869671 118 119 I-Eq-Comparison
month NCT03869671 120 125 I-Eq-Comparison
receptive NCT03869671 126 135 B-Modifier
syringe NCT03869671 136 143 B-Condition
sharing NCT03869671 144 151 I-Condition
, NCT03869671 152 153 O
transactional NCT03869671 154 167 B-Condition
sex NCT03869671 168 171 I-Condition
, NCT03869671 172 173 O
condomless NCT03869671 174 184 B-Modifier
sex NCT03869671 185 188 B-Condition
with NCT03869671 189 193 O
an NCT03869671 194 196 O
HIV NCT03869671 197 200 B-Modifier
- NCT03869671 201 202 I-Modifier
infected NCT03869671 203 211 I-Modifier
or NCT03869671 212 214 B-Or
unknown NCT03869671 215 222 B-Modifier
status NCT03869671 223 229 I-Modifier
partner NCT03869671 230 237 I-Modifier
) NCT03869671 238 239 O

Exclusion NCT03869671 241 250 O
Criteria NCT03869671 251 259 O
: NCT03869671 260 261 O

- NCT03869671 265 266 O
Unable NCT03869671 268 274 O
or NCT03869671 275 277 O
unwilling NCT03869671 278 287 O
to NCT03869671 288 290 O
provide NCT03869671 291 298 O
informed NCT03869671 299 307 O
consent NCT03869671 308 315 O

For NCT03869671 316 319 O
Phase NCT03869671 320 325 O
3 NCT03869671 326 327 O
( NCT03869671 328 329 O
the NCT03869671 330 333 O
RCT NCT03869671 334 337 O
pilot NCT03869671 338 343 O
) NCT03869671 344 345 O
: NCT03869671 347 348 O

Inclusion NCT03869671 350 359 O
Criteria NCT03869671 360 368 O
: NCT03869671 369 370 O

- NCT03869671 374 375 O
Clinically NCT03869671 377 387 O
eligible NCT03869671 388 396 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869671 397 400 I-Assertion___Assertion-Type-Value:hypothetical
PrEP NCT03869671 401 405 B-Procedure
( NCT03869671 406 407 O
confirmed NCT03869671 408 417 O
HIV NCT03869671 418 421 B-Condition
- NCT03869671 422 423 O
uninfected NCT03869671 424 434 B-Negation
status NCT03869671 435 441 O
, NCT03869671 442 443 O
adequate NCT03869671 444 452 O
renal NCT03869671 453 458 B-Observation
function NCT03869671 459 467 I-Observation
[ NCT03869671 468 469 O
estimated NCT03869671 470 479 B-Observation
creatinine NCT03869671 480 490 I-Observation
clearance NCT03869671 491 500 I-Observation
≥ NCT03869671 501 502 B-Eq-Comparison
60 NCT03869671 503 505 I-Eq-Comparison
ml NCT03869671 506 508 I-Eq-Comparison
/ NCT03869671 509 510 I-Eq-Comparison
min NCT03869671 511 514 I-Eq-Comparison
] NCT03869671 515 516 O
, NCT03869671 518 519 O
and NCT03869671 520 523 B-And
documented NCT03869671 524 534 O
hepatitis NCT03869671 535 544 B-Condition
B NCT03869671 545 546 I-Condition
virus NCT03869671 547 552 I-Condition
[ NCT03869671 553 554 O
HBV NCT03869671 555 558 B-Condition
] NCT03869671 559 560 O
status NCT03869671 561 567 O
) NCT03869671 568 569 O

Inclusion NCT03864341 0 9 O
Criteria NCT03864341 10 18 O
: NCT03864341 19 20 O

- NCT03864341 24 25 O
Be NCT03864341 27 29 O
a NCT03864341 30 31 O
patient NCT03864341 32 39 O
in NCT03864341 40 42 O
the NCT03864341 43 46 O
Bellevue NCT03864341 47 55 O
Hospital NCT03864341 56 64 O
Center NCT03864341 65 71 O
ED NCT03864341 72 74 O
. NCT03864341 74 75 O

- NCT03864341 79 80 O
Be NCT03864341 82 84 O
≥ NCT03864341 85 86 B-Eq-Comparison
18 NCT03864341 87 89 I-Eq-Comparison
years NCT03864341 90 95 I-Eq-Comparison
old NCT03864341 96 99 B-Age
. NCT03864341 99 100 O

- NCT03864341 104 105 O
Screen NCT03864341 107 113 O
positive NCT03864341 114 122 O
for NCT03864341 123 126 O
homelessness NCT03864341 127 139 B-Condition
risk NCT03864341 140 144 B-Risk
using NCT03864341 145 150 O
a NCT03864341 151 152 O
homelessness NCT03864341 153 165 B-Observation
risk NCT03864341 166 170 I-Observation
screening NCT03864341 171 180 I-Observation
tool NCT03864341 181 185 I-Observation
( NCT03864341 186 187 O
HRST NCT03864341 188 192 B-Observation
) NCT03864341 193 194 O
. NCT03864341 195 196 O

- NCT03864341 200 201 O
Screen NCT03864341 203 209 O
positive NCT03864341 210 218 O
for NCT03864341 219 222 O
unhealthy NCT03864341 223 232 O
alcohol NCT03864341 233 240 B-Modifier
or NCT03864341 241 243 B-Or
drug NCT03864341 244 248 B-Modifier
use NCT03864341 249 252 B-Condition
. NCT03864341 252 253 O

- NCT03864341 257 258 O
Able NCT03864341 260 264 O
to NCT03864341 265 267 O
provide NCT03864341 268 275 O
consent NCT03864341 276 283 O
. NCT03864341 283 284 O

Exclusion NCT03864341 286 295 O
Criteria NCT03864341 296 304 O
: NCT03864341 305 306 O

- NCT03864341 310 311 O
Medically NCT03864341 313 322 B-Modifier
( NCT03864341 323 324 O
e. NCT03864341 325 327 O
g. NCT03864341 328 330 O
, NCT03864341 331 332 O
critically NCT03864341 333 343 B-Condition
ill NCT03864341 344 347 I-Condition
) NCT03864341 348 349 O
or NCT03864341 350 352 B-Or
psychiatrically NCT03864341 353 368 B-Modifier
unstable NCT03864341 369 377 B-Condition
. NCT03864341 377 378 O

- NCT03864341 382 383 O
Unable NCT03864341 385 391 O
to NCT03864341 392 394 O
provide NCT03864341 395 402 O
informed NCT03864341 403 411 O
consent NCT03864341 412 419 O
for NCT03864341 420 423 O
other NCT03864341 424 429 O
reason NCT03864341 430 436 O
( NCT03864341 437 438 O
e. NCT03864341 439 441 O
g. NCT03864341 442 444 O
, NCT03864341 445 446 O
cognitive NCT03864341 447 456 B-Condition
deficit NCT03864341 457 464 I-Condition
, NCT03864341 465 466 O
profound NCT03864341 467 475 B-Condition
intoxication NCT03864341 476 488 I-Condition
) NCT03864341 489 490 O
. NCT03864341 491 492 O

- NCT03864341 496 497 O
Incarcerated NCT03864341 499 511 B-Observation
or NCT03864341 512 514 B-Or
in NCT03864341 515 517 O
police NCT03864341 518 524 B-Observation
custody NCT03864341 525 532 I-Observation
. NCT03864341 532 533 O

- NCT03864341 537 538 O
Unable NCT03864341 540 546 B-Negation
to NCT03864341 547 549 O
understand NCT03864341 550 560 O
and NCT03864341 561 564 O
speak NCT03864341 565 570 O
English NCT03864341 571 578 O
. NCT03864341 578 579 O

- NCT03864341 583 584 O
Lives NCT03864341 586 591 O
outside NCT03864341 592 599 B-Negation
NYC NCT03864341 600 603 O
and NCT03864341 604 607 B-Or
/ NCT03864341 608 609 I-Or
or NCT03864341 610 612 I-Or
can NCT03864341 613 616 B-Negation
not NCT03864341 616 619 O
give NCT03864341 620 624 O
a NCT03864341 625 626 O
NYC NCT03864341 627 630 O
ZIP NCT03864341 631 634 O
code NCT03864341 635 639 O
. NCT03864341 639 640 O

- NCT03864341 644 645 O
Already NCT03864341 647 654 O
homeless NCT03864341 655 663 B-Condition
( NCT03864341 664 665 O
residing NCT03864341 666 674 O
in NCT03864341 675 677 O
a NCT03864341 678 679 O
shelter NCT03864341 680 687 O
or NCT03864341 688 690 B-Or
on NCT03864341 691 693 O
the NCT03864341 694 697 O
streets NCT03864341 698 705 O
) NCT03864341 706 707 O
. NCT03864341 708 709 O

- NCT03864341 713 714 O
Does NCT03864341 716 720 O
not NCT03864341 721 724 O
have NCT03864341 725 729 O
a NCT03864341 730 731 O
telephone NCT03864341 732 741 O
where NCT03864341 742 747 O
can NCT03864341 748 751 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864341 752 754 I-Assertion___Assertion-Type-Value:hypothetical
reached NCT03864341 755 762 O
for NCT03864341 763 766 O
follow NCT03864341 767 773 B-Encounter
- NCT03864341 774 775 I-Encounter
up NCT03864341 776 778 I-Encounter
. NCT03864341 778 779 O

- NCT03864341 783 784 O
Has NCT03864341 786 789 O
already NCT03864341 790 797 B-Eq-Comparison
received NCT03864341 798 806 I-Eq-Comparison
specialized NCT03864341 807 818 O
peer NCT03864341 819 823 B-Modifier
navigator NCT03864341 824 833 I-Modifier
/ NCT03864341 834 835 B-Or
addiction NCT03864341 836 845 B-Modifier
social NCT03864341 846 852 B-Procedure
worker NCT03864341 853 859 I-Procedure
services NCT03864341 860 868 I-Procedure
during NCT03864341 869 875 B-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03864341 876 883 O
ED NCT03864341 884 886 B-Encounter
visit NCT03864341 887 892 I-Encounter
. NCT03864341 892 893 O

- NCT03864341 897 898 O
Has NCT03864341 900 903 O
already NCT03864341 904 911 B-Eq-Comparison
participated NCT03864341 912 924 I-Eq-Comparison
in NCT03864341 925 927 O
the NCT03864341 928 931 O
study NCT03864341 932 937 B-Study
. NCT03864341 937 938 O

Inclusion NCT03867890 0 9 O
Criteria NCT03867890 10 18 O
: NCT03867890 19 20 O

- NCT03867890 24 25 O
walk NCT03867890 27 31 B-Observation
or NCT03867890 32 34 B-Or
run NCT03867890 35 38 B-Observation
at NCT03867890 39 41 B-Eq-Comparison
least NCT03867890 42 47 I-Eq-Comparison
10 NCT03867890 48 50 I-Eq-Comparison
kilometres NCT03867890 51 61 I-Eq-Comparison
per NCT03867890 62 65 I-Eq-Comparison
week NCT03867890 66 70 I-Eq-Comparison

- NCT03867890 73 74 O
maintain NCT03867890 76 84 B-Observation
a NCT03867890 85 86 O
minimal NCT03867890 87 94 B-Eq-Comparison
distance NCT03867890 95 103 I-Eq-Comparison
of NCT03867890 104 106 I-Eq-Comparison
ten NCT03867890 107 110 I-Eq-Comparison
kilometres NCT03867890 111 121 I-Eq-Comparison
per NCT03867890 122 125 I-Eq-Comparison
week NCT03867890 126 130 I-Eq-Comparison
, NCT03867890 131 132 O
for NCT03867890 133 136 O
a NCT03867890 137 138 O
period NCT03867890 139 145 O
of NCT03867890 146 148 O
24 NCT03867890 149 151 B-Eq-Comparison
weeks NCT03867890 152 157 I-Eq-Comparison

- NCT03867890 160 161 O
wear NCT03867890 163 167 B-Observation
one NCT03867890 168 171 B-Eq-Comparison
and NCT03867890 172 175 B-And
the NCT03867890 176 179 O
same NCT03867890 180 184 B-Modifier
pair NCT03867890 185 189 I-Modifier
of NCT03867890 190 192 I-Modifier
shoes NCT03867890 193 198 I-Modifier
during NCT03867890 199 205 B-Temporal-Connection___Temporal-Connection-Type-Value:during
walking NCT03867890 206 213 B-Observation
/ NCT03867890 214 215 B-Or
running NCT03867890 216 223 B-Observation
activities NCT03867890 224 234 O
during NCT03867890 235 241 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03867890 242 246 O
period NCT03867890 247 253 O

Exclusion NCT03867890 254 263 O
Criteria NCT03867890 264 272 O
: NCT03867890 273 274 O

- NCT03867890 278 279 O
systemic NCT03867890 281 289 B-Condition
disease NCT03867890 290 297 I-Condition
, NCT03867890 298 299 O
cardiac NCT03867890 300 307 B-Condition
problems NCT03867890 308 316 I-Condition
or NCT03867890 317 319 B-Or
diabetes NCT03867890 320 328 B-Condition

- NCT03867890 331 332 O
complaints NCT03867890 334 344 B-Condition
at NCT03867890 345 347 O
the NCT03867890 348 351 O
lower NCT03867890 352 357 B-Modifier
extremities NCT03867890 358 369 I-Modifier
in NCT03867890 370 372 O
the NCT03867890 373 376 O
last NCT03867890 377 381 B-Eq-Comparison
two NCT03867890 382 385 I-Eq-Comparison
weeks NCT03867890 386 391 I-Eq-Comparison
, NCT03867890 392 393 O

- NCT03867890 397 398 O
surgery NCT03867890 400 407 B-Procedure
at NCT03867890 408 410 O
the NCT03867890 411 414 O
lower NCT03867890 415 420 B-Modifier
extremities NCT03867890 421 432 I-Modifier
in NCT03867890 433 435 O
the NCT03867890 436 439 O
last NCT03867890 440 444 B-Eq-Comparison
three NCT03867890 445 450 I-Eq-Comparison
years NCT03867890 451 456 I-Eq-Comparison

Inclusion NCT03860480 0 9 O
Criteria NCT03860480 10 18 O
: NCT03860480 19 20 O

• NCT03860480 22 23 O
Patients NCT03860480 24 32 O
> NCT03860480 33 34 B-Eq-Comparison
18 NCT03860480 35 37 I-Eq-Comparison
years NCT03860480 38 43 I-Eq-Comparison
old NCT03860480 44 47 B-Age
with NCT03860480 48 52 B-And
to NCT03860480 53 55 O
ASA NCT03860480 56 59 B-Condition
status NCT03860480 60 66 O
I NCT03860480 67 68 B-Eq-Comparison
- NCT03860480 69 70 I-Eq-Comparison
III NCT03860480 71 74 I-Eq-Comparison
, NCT03860480 75 76 O
undergoing NCT03860480 77 87 B-Eq-Comparison
VATS NCT03860480 88 92 B-Procedure
for NCT03860480 93 96 O
lobectomy NCT03860480 97 106 B-Procedure
or NCT03860480 107 109 B-Or
wedge NCT03860480 110 115 B-Procedure
. NCT03860480 115 116 O

Non NCT03860480 118 121 O
- NCT03860480 122 123 O
inclusion NCT03860480 124 133 O
Criteria NCT03860480 134 142 O
: NCT03860480 143 144 O

- NCT03860480 148 149 O
< NCT03860480 151 152 B-Eq-Comparison
18 NCT03860480 153 155 I-Eq-Comparison
years NCT03860480 156 161 I-Eq-Comparison
old NCT03860480 162 165 B-Age

- NCT03860480 168 169 O
BMI NCT03860480 171 174 B-Observation
> NCT03860480 175 176 B-Eq-Comparison
35 NCT03860480 177 179 I-Eq-Comparison

- NCT03860480 183 184 O
Chronic NCT03860480 186 193 B-Modifier
pain NCT03860480 194 198 B-Condition
history NCT03860480 199 206 B-Eq-Comparison
with NCT03860480 207 211 B-And
regular NCT03860480 212 219 O
opioid NCT03860480 220 226 B-Drug
and NCT03860480 227 230 B-Or
/ NCT03860480 231 232 I-Or
or NCT03860480 233 235 I-Or
gabapentinoids NCT03860480 236 250 B-Drug
use NCT03860480 251 254 O
during NCT03860480 255 261 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860480 262 265 O
2 NCT03860480 266 267 B-Eq-Comparison
weeks NCT03860480 268 273 I-Eq-Comparison
before NCT03860480 274 280 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03860480 281 288 B-Procedure

- NCT03860480 291 292 O
Regular NCT03860480 294 301 B-Eq-Comparison
marijuana NCT03860480 302 311 B-Drug
use NCT03860480 312 315 O

- NCT03860480 318 319 O
History NCT03860480 321 328 B-Eq-Comparison
of NCT03860480 329 331 O
thoracic NCT03860480 332 340 B-Procedure
surgery NCT03860480 341 348 I-Procedure
on NCT03860480 349 351 O
the NCT03860480 352 355 O
operated NCT03860480 356 364 B-Modifier
side NCT03860480 365 369 I-Modifier

- NCT03860480 372 373 O
Epidural NCT03860480 375 383 B-Procedure
analgesia NCT03860480 384 393 I-Procedure
preferred NCT03860480 394 403 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03860480 404 407 O
to NCT03860480 408 410 O
an NCT03860480 411 413 B-Assertion___Assertion-Type-Value:hypothetical
anticipated NCT03860480 414 425 O
high NCT03860480 426 430 O
risk NCT03860480 431 435 B-Risk
of NCT03860480 436 438 O
conversion NCT03860480 439 449 B-Modifier
to NCT03860480 450 452 O
thoracotomy NCT03860480 453 464 B-Procedure

- NCT03860480 467 468 O
Unable NCT03860480 470 476 B-Condition
to NCT03860480 477 479 I-Condition
communicate NCT03860480 480 491 I-Condition
with NCT03860480 492 496 O
the NCT03860480 497 500 O
investigators NCT03860480 501 514 O

- NCT03860480 517 518 O
Receiving NCT03860480 520 529 B-Eq-Comparison
anticoagulation NCT03860480 530 545 B-Procedure
or NCT03860480 546 548 B-Or
experiencing NCT03860480 549 561 B-Eq-Comparison
any NCT03860480 562 565 O
bleeding NCT03860480 566 574 B-Condition
disorder NCT03860480 575 583 I-Condition

- NCT03860480 586 587 O
Surgery NCT03860480 589 596 B-Procedure
for NCT03860480 597 600 O
empyema NCT03860480 601 608 B-Condition
and NCT03860480 609 612 B-Or
sympathectomy NCT03860480 613 626 B-Procedure

- NCT03860480 629 630 O
Known NCT03860480 632 637 O
allergy NCT03860480 638 645 B-Allergy
to NCT03860480 646 648 O
local NCT03860480 649 654 B-Procedure
anesthetics NCT03860480 655 666 I-Procedure
, NCT03860480 667 668 O
fentanyl NCT03860480 669 677 B-Drug
or NCT03860480 678 680 B-Or
hydromorphone NCT03860480 681 694 B-Drug

- NCT03860480 697 698 O
Active NCT03860480 700 706 B-Eq-Comparison
infection NCT03860480 707 716 B-Condition
at NCT03860480 717 719 O
injection NCT03860480 720 729 B-Modifier
sites NCT03860480 730 735 I-Modifier

- NCT03860480 738 739 O
Preexisting NCT03860480 741 752 B-Eq-Comparison
neurological NCT03860480 753 765 B-Condition
deficit NCT03860480 766 773 I-Condition
or NCT03860480 774 776 B-Or
psychiatric NCT03860480 777 788 B-Condition
illness NCT03860480 789 796 I-Condition

- NCT03860480 799 800 O
Severe NCT03860480 802 808 O
cardiovascular NCT03860480 809 823 B-Condition
disease NCT03860480 824 831 I-Condition

- NCT03860480 834 835 O
Liver NCT03860480 837 842 B-Condition
failure NCT03860480 843 850 I-Condition

- NCT03860480 853 854 O
Renal NCT03860480 856 861 B-Condition
failure NCT03860480 862 869 I-Condition
( NCT03860480 870 871 O
estimated NCT03860480 872 881 B-Observation
glomerular NCT03860480 882 892 I-Observation
filtration NCT03860480 893 903 I-Observation
rate NCT03860480 904 908 I-Observation
< NCT03860480 909 910 B-Eq-Comparison
15 NCT03860480 911 913 I-Eq-Comparison
mL NCT03860480 914 916 I-Eq-Comparison
/ NCT03860480 917 918 I-Eq-Comparison
min NCT03860480 919 922 I-Eq-Comparison
/ NCT03860480 923 924 O
1.73 NCT03860480 925 929 I-Eq-Comparison
m2 NCT03860480 930 932 I-Eq-Comparison
) NCT03860480 933 934 O

- NCT03860480 938 939 O
Pregnancy NCT03860480 941 950 B-Condition

Exclusion NCT03860480 951 960 O
Criteria NCT03860480 961 969 O
: NCT03860480 970 971 O

- NCT03860480 975 976 O
Peri NCT03860480 978 982 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03860480 983 984 O
- NCT03860480 986 987 O
operative NCT03860480 988 997 B-Procedure
conversion NCT03860480 998 1008 B-Modifier
to NCT03860480 1009 1011 O
thoracotomy NCT03860480 1012 1023 B-Procedure

- NCT03860480 1026 1027 I-Temporal-Connection___Temporal-Connection-Type-Value:during
Severe NCT03860480 1029 1035 O
intra NCT03860480 1036 1041 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03860480 1042 1043 O
or NCT03860480 1044 1046 B-Or
post NCT03860480 1047 1051 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03860480 1052 1053 O
- NCT03860480 1055 1056 O
operative NCT03860480 1057 1066 B-Procedure
bleeding NCT03860480 1067 1075 B-Condition

- NCT03860480 1078 1079 O
Patients NCT03860480 1081 1089 O
requiring NCT03860480 1090 1099 B-Assertion___Assertion-Type-Value:hypothetical
post NCT03860480 1100 1104 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03860480 1105 1106 O
- NCT03860480 1108 1109 O
operative NCT03860480 1110 1119 B-Procedure
mechanical NCT03860480 1120 1130 B-Procedure
ventilation NCT03860480 1131 1142 I-Procedure

- NCT03860480 1145 1146 O
Technical NCT03860480 1148 1157 O
inability NCT03860480 1158 1167 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860480 1168 1170 O
proceed NCT03860480 1171 1178 O
with NCT03860480 1179 1183 O
the NCT03860480 1184 1187 O
blocks NCT03860480 1188 1194 O

Inclusion NCT03868787 0 9 O
Criteria NCT03868787 10 18 O
: NCT03868787 19 20 O

1 NCT03868787 24 25 O
. NCT03868787 25 26 O
Women NCT03868787 28 33 O
≥ NCT03868787 34 35 B-Eq-Comparison
18 NCT03868787 36 38 I-Eq-Comparison
years NCT03868787 39 44 I-Eq-Comparison
of NCT03868787 45 47 O
age NCT03868787 48 51 B-Age

2 NCT03868787 54 55 O
. NCT03868787 55 56 O
Gestational NCT03868787 58 69 B-Observation
age NCT03868787 70 73 I-Observation
between NCT03868787 74 81 B-Eq-Comparison
14 NCT03868787 82 84 I-Eq-Comparison
weeks NCT03868787 85 90 I-Eq-Comparison
and NCT03868787 91 94 I-Eq-Comparison
23 NCT03868787 95 97 I-Eq-Comparison
weeks NCT03868787 98 103 I-Eq-Comparison
6 NCT03868787 104 105 I-Eq-Comparison
days NCT03868787 106 110 I-Eq-Comparison

3 NCT03868787 113 114 O
. NCT03868787 114 115 O
Willing NCT03868787 117 124 O
and NCT03868787 125 128 O
able NCT03868787 129 133 O
to NCT03868787 134 136 O
sign NCT03868787 137 141 O
an NCT03868787 142 144 O
informed NCT03868787 145 153 O
consent NCT03868787 154 161 O
in NCT03868787 162 164 O
English NCT03868787 165 172 O

4 NCT03868787 175 176 O
. NCT03868787 176 177 O
No NCT03868787 179 181 B-Negation
contraindications NCT03868787 182 199 B-Contraindication
to NCT03868787 200 202 O
TENS NCT03868787 203 207 B-Procedure

Exclusion NCT03868787 208 217 O
Criteria NCT03868787 218 226 O
: NCT03868787 227 228 O

1 NCT03868787 232 233 O
. NCT03868787 233 234 O
Incarceration NCT03868787 236 249 B-Observation

2 NCT03868787 252 253 O
. NCT03868787 253 254 O
Preterm NCT03868787 256 263 B-Condition
Premature NCT03868787 264 273 I-Condition
Rupture NCT03868787 274 281 I-Condition
of NCT03868787 282 284 O
Membranes NCT03868787 285 294 B-Modifier
or NCT03868787 295 297 B-Or
evidence NCT03868787 298 306 O
of NCT03868787 307 309 O
intra NCT03868787 310 315 B-Modifier
- NCT03868787 316 317 I-Modifier
amniotic NCT03868787 318 326 I-Modifier
infection NCT03868787 327 336 B-Condition

3 NCT03868787 339 340 O
. NCT03868787 340 341 O
Presence NCT03868787 343 351 O
of NCT03868787 352 354 O
implanted NCT03868787 355 364 B-Procedure
cardiac NCT03868787 365 372 I-Procedure
device NCT03868787 373 379 I-Procedure

4 NCT03868787 382 383 O
. NCT03868787 383 384 O
Lack NCT03868787 386 390 B-Negation
of NCT03868787 391 393 O
sensation NCT03868787 394 403 B-Condition
to NCT03868787 404 406 I-Condition
touch NCT03868787 407 412 O
on NCT03868787 413 415 O
area NCT03868787 416 420 B-Modifier
of NCT03868787 421 423 O
electrode NCT03868787 424 433 B-Procedure
placement NCT03868787 434 443 I-Procedure

5 NCT03868787 446 447 O
. NCT03868787 447 448 O
Prior NCT03868787 450 455 B-Eq-Comparison
TENS NCT03868787 456 460 B-Procedure
use NCT03868787 461 464 O

6 NCT03868787 467 468 O
. NCT03868787 468 469 O
Opioid NCT03868787 471 477 B-Condition
dependence NCT03868787 478 488 I-Condition

Inclusion NCT03860324 0 9 O
Criteria NCT03860324 10 18 O
: NCT03860324 19 20 O

- NCT03860324 24 25 O
Surgical NCT03860324 27 35 O
plan NCT03860324 36 40 B-Eq-Comparison
for NCT03860324 41 44 I-Eq-Comparison
total NCT03860324 45 50 B-Procedure
hip NCT03860324 51 54 I-Procedure
replacement NCT03860324 55 66 I-Procedure

- NCT03860324 69 70 O
Signing NCT03860324 72 79 O
of NCT03860324 80 82 O
consent NCT03860324 83 90 O
form NCT03860324 91 95 O
to NCT03860324 96 98 O
participate NCT03860324 99 110 O
in NCT03860324 111 113 O
the NCT03860324 114 117 O
study NCT03860324 118 123 O

Exclusion NCT03860324 124 133 O
Criteria NCT03860324 134 142 O
: NCT03860324 143 144 O

- NCT03860324 148 149 O
Patient NCT03860324 151 158 O
refusal NCT03860324 159 166 O

- NCT03860324 169 170 O
BMI NCT03860324 172 175 B-Observation
> NCT03860324 176 177 B-Eq-Comparison
40 NCT03860324 178 180 I-Eq-Comparison
kg NCT03860324 181 183 I-Eq-Comparison
/ NCT03860324 184 185 I-Eq-Comparison
m2 NCT03860324 186 188 I-Eq-Comparison

- NCT03860324 191 192 O
Surgical NCT03860324 194 202 O
plan NCT03860324 203 207 B-Eq-Comparison
for NCT03860324 208 211 I-Eq-Comparison
revision NCT03860324 212 220 B-Modifier
of NCT03860324 221 223 O
hip NCT03860324 224 227 B-Procedure
replacement NCT03860324 228 239 I-Procedure

- NCT03860324 242 243 O
Patient NCT03860324 245 252 O
unable NCT03860324 253 259 B-Negation
to NCT03860324 260 262 O
quantify NCT03860324 263 271 O
pain NCT03860324 272 276 B-Condition|Observation
level NCT03860324 277 282 O

- NCT03860324 285 286 O
Chronic NCT03860324 288 295 B-Modifier
kidney NCT03860324 296 302 B-Condition
disease NCT03860324 303 310 I-Condition
with NCT03860324 311 315 B-And
a NCT03860324 316 317 O
Glomerular NCT03860324 318 328 B-Observation
Filtration NCT03860324 329 339 I-Observation
Rate NCT03860324 340 344 I-Observation
< NCT03860324 345 346 B-Eq-Comparison
50 NCT03860324 347 349 I-Eq-Comparison
ml NCT03860324 350 352 O
/ NCT03860324 353 354 I-Eq-Comparison
min NCT03860324 355 358 I-Eq-Comparison

- NCT03860324 361 362 O
Previously NCT03860324 364 374 B-Eq-Comparison
medicated NCT03860324 375 384 B-Procedure
with NCT03860324 385 389 O
opioids NCT03860324 390 397 B-Drug

- NCT03860324 400 401 O
Patient NCT03860324 403 410 O
unable NCT03860324 411 417 B-Negation
to NCT03860324 418 420 O
perform NCT03860324 421 428 O
the NCT03860324 429 432 B-Coreference
surgery NCT03860324 433 440 I-Coreference|Procedure
with NCT03860324 441 445 O
spinal NCT03860324 446 452 B-Procedure
block NCT03860324 453 458 I-Procedure

- NCT03860324 461 462 O
Allergy NCT03860324 464 471 B-Allergy
to NCT03860324 472 474 O
local NCT03860324 475 480 B-Procedure
anesthetics NCT03860324 481 492 I-Procedure

- NCT03860324 495 496 O
Infection NCT03860324 498 507 B-Condition
in NCT03860324 508 510 O
the NCT03860324 511 514 O
site NCT03860324 515 519 B-Modifier
of NCT03860324 520 522 O
the NCT03860324 523 526 O
Erector NCT03860324 527 534 B-Modifier
Spinae NCT03860324 535 541 I-Modifier
Plane NCT03860324 542 547 I-Modifier
or NCT03860324 548 550 B-Or
Fascia NCT03860324 551 557 B-Modifier
Iliaca NCT03860324 558 564 I-Modifier
block NCT03860324 565 570 I-Modifier

- NCT03860324 573 574 O
Allergy NCT03860324 576 583 B-Allergy
or NCT03860324 584 586 B-Or
contraindication NCT03860324 587 603 B-Contraindication
to NCT03860324 604 606 O
the NCT03860324 607 610 O
use NCT03860324 611 614 O
of NCT03860324 615 617 O
morphine NCT03860324 618 626 B-Drug

Inclusion NCT03863639 0 9 O
Criteria NCT03863639 10 18 O
: NCT03863639 19 20 O
Severe NCT03863639 21 27 O
Pre NCT03863639 28 31 B-Condition
- NCT03863639 32 33 I-Condition
Eclampsia NCT03863639 34 43 I-Condition
defined NCT03863639 44 51 O
by NCT03863639 52 54 O

- NCT03863639 57 58 O
Symptoms NCT03863639 60 68 B-Assertion___Assertion-Type-Value:possible
of NCT03863639 69 71 O
central NCT03863639 72 79 B-Condition
nervous NCT03863639 80 87 I-Condition
system NCT03863639 88 94 I-Condition
dysfunction NCT03863639 95 106 I-Condition
( NCT03863639 107 108 O
New NCT03863639 109 112 B-Eq-Comparison
onset NCT03863639 113 118 I-Eq-Comparison
cerebral NCT03863639 119 127 B-Modifier
or NCT03863639 128 130 B-Or
visual NCT03863639 131 137 B-Modifier
disturbance NCT03863639 138 149 B-Condition
, NCT03863639 150 151 O
such NCT03863639 152 156 O
as NCT03863639 157 159 O
: NCT03863639 160 161 O
Photopsia NCT03863639 162 171 B-Condition
, NCT03863639 172 173 O
scotomata NCT03863639 174 183 B-Condition
, NCT03863639 184 185 O
cortical NCT03863639 186 194 B-Condition
blindness NCT03863639 195 204 I-Condition
, NCT03863639 205 206 O
retinal NCT03863639 207 214 B-Condition
vasospasm NCT03863639 215 224 I-Condition
) NCT03863639 225 226 O

- NCT03863639 230 231 O
Severe NCT03863639 233 239 O
headache NCT03863639 240 248 B-Condition
( NCT03863639 249 250 O
ie NCT03863639 251 253 O
, NCT03863639 254 255 O
incapacitating NCT03863639 256 270 B-Condition
, NCT03863639 271 272 O
" NCT03863639 273 274 O
the NCT03863639 274 277 O
worst NCT03863639 278 283 O
headache NCT03863639 284 292 B-Condition
I NCT03863639 293 294 O
've NCT03863639 294 297 O
ever NCT03863639 298 302 O
had NCT03863639 303 306 O
" NCT03863639 306 307 O
) NCT03863639 308 309 O
or NCT03863639 310 312 B-Or
headache NCT03863639 313 321 B-Condition
that NCT03863639 322 326 O
persists NCT03863639 327 335 B-Modifier
and NCT03863639 336 339 B-And
progresses NCT03863639 340 350 B-Modifier
despite NCT03863639 351 358 O
analgesic NCT03863639 359 368 B-Procedure
therapy NCT03863639 369 376 I-Procedure

- NCT03863639 379 380 O
Altered NCT03863639 382 389 B-Condition
mental NCT03863639 390 396 I-Condition
status NCT03863639 397 403 I-Condition

- NCT03863639 406 407 O
Hepatic NCT03863639 409 416 B-Condition
abnormality NCT03863639 417 428 O
( NCT03863639 429 430 O
Severe NCT03863639 431 437 O
persistent NCT03863639 438 448 B-Modifier
right NCT03863639 449 454 I-Modifier
upper NCT03863639 455 460 B-Modifier
quadrant NCT03863639 461 469 I-Modifier
or NCT03863639 470 472 B-Or
epigastric NCT03863639 473 483 B-Modifier
pain NCT03863639 484 488 B-Condition
unresponsive NCT03863639 489 501 O
to NCT03863639 502 504 O
medication NCT03863639 505 515 B-Drug
and NCT03863639 516 519 B-And
not NCT03863639 520 523 B-Negation
accounted NCT03863639 524 533 O
for NCT03863639 534 537 O
by NCT03863639 538 540 O
an NCT03863639 541 543 O
alternative NCT03863639 544 555 B-Other
diagnosis NCT03863639 556 565 B-Condition
or NCT03863639 566 568 B-Or
serum NCT03863639 569 574 B-Observation
transaminase NCT03863639 575 587 I-Observation
concentration NCT03863639 588 601 I-Observation
≥ NCT03863639 602 603 B-Eq-Comparison
twice NCT03863639 604 609 I-Eq-Comparison
normal NCT03863639 610 616 I-Eq-Comparison
, NCT03863639 617 618 O
or NCT03863639 619 621 O
both NCT03863639 622 626 O
) NCT03863639 627 628 O

- NCT03863639 632 633 O
Severe NCT03863639 635 641 O
blood NCT03863639 642 647 B-Observation
pressure NCT03863639 648 656 I-Observation
elevation NCT03863639 657 666 O
( NCT03863639 667 668 O
Systolic NCT03863639 669 677 B-Observation
blood NCT03863639 678 683 I-Observation
pressure NCT03863639 684 692 I-Observation
≥ NCT03863639 693 694 B-Eq-Comparison
160 NCT03863639 695 698 I-Eq-Comparison
mmHg NCT03863639 699 703 I-Eq-Comparison
or NCT03863639 704 706 B-Or
diastolic NCT03863639 707 716 B-Observation
blood NCT03863639 717 722 I-Observation
pressure NCT03863639 723 731 I-Observation
≥ NCT03863639 732 733 B-Eq-Comparison
110 NCT03863639 734 737 I-Eq-Comparison
mmHg NCT03863639 738 742 I-Eq-Comparison
on NCT03863639 743 745 O
two NCT03863639 746 749 B-Eq-Comparison
occasions NCT03863639 750 759 I-Eq-Comparison
at NCT03863639 760 762 B-Eq-Comparison
least NCT03863639 763 768 I-Eq-Comparison
four NCT03863639 769 773 I-Eq-Comparison
hours NCT03863639 774 779 I-Eq-Comparison
apart NCT03863639 780 785 I-Eq-Comparison
while NCT03863639 786 791 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863639 792 795 I-Temporal-Connection___Temporal-Connection-Type-Value:during
patient NCT03863639 796 803 I-Temporal-Connection___Temporal-Connection-Type-Value:during
is NCT03863639 804 806 I-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03863639 807 809 I-Temporal-Connection___Temporal-Connection-Type-Value:during
bedrest NCT03863639 810 817 B-Encounter
( NCT03863639 818 819 O
unless NCT03863639 820 826 B-Exception
the NCT03863639 827 830 O
patient NCT03863639 831 838 O
is NCT03863639 839 841 O
on NCT03863639 842 844 O
antihypertensive NCT03863639 845 861 B-Procedure
therapy NCT03863639 862 869 I-Procedure
) NCT03863639 870 871 O
) NCT03863639 873 874 O

- NCT03863639 878 879 O
Thrombocytopenia NCT03863639 881 897 B-Condition
( NCT03863639 898 899 O
< NCT03863639 901 902 B-Eq-Comparison
100 NCT03863639 903 906 I-Eq-Comparison
, NCT03863639 907 908 O
000 NCT03863639 909 912 O
platelets NCT03863639 913 922 I-Eq-Comparison|Observation
/ NCT03863639 923 924 I-Eq-Comparison
microL NCT03863639 925 931 I-Eq-Comparison
) NCT03863639 932 933 O

- NCT03863639 937 938 O
Renal NCT03863639 940 945 B-Condition
abnormality NCT03863639 946 957 O
( NCT03863639 958 959 O
Progressive NCT03863639 960 971 B-Condition
renal NCT03863639 972 977 I-Condition
insufficiency NCT03863639 978 991 I-Condition
( NCT03863639 992 993 O
serum NCT03863639 994 999 B-Observation
creatinine NCT03863639 1000 1010 I-Observation
> NCT03863639 1011 1012 B-Eq-Comparison
1.1 NCT03863639 1013 1016 I-Eq-Comparison
mg NCT03863639 1017 1019 I-Eq-Comparison
/ NCT03863639 1020 1021 I-Eq-Comparison
dL NCT03863639 1022 1024 I-Eq-Comparison
or NCT03863639 1025 1027 B-Or
doubling NCT03863639 1028 1036 B-Eq-Comparison
of NCT03863639 1037 1039 O
serum NCT03863639 1040 1045 B-Observation
creatinine NCT03863639 1046 1056 I-Observation
concentration NCT03863639 1057 1070 I-Observation
in NCT03863639 1071 1073 B-And
the NCT03863639 1074 1077 I-And
absence NCT03863639 1078 1085 B-Negation
of NCT03863639 1086 1088 O
other NCT03863639 1089 1094 B-Other
renal NCT03863639 1095 1100 B-Condition
disease NCT03863639 1101 1108 I-Condition
) NCT03863639 1109 1110 O
) NCT03863639 1112 1113 O

- NCT03863639 1117 1118 O
Pulmonary NCT03863639 1120 1129 B-Condition
edema NCT03863639 1130 1135 I-Condition

15 NCT03863639 1141 1143 O
English NCT03863639 1144 1151 O
- NCT03863639 1152 1153 O
speaking NCT03863639 1154 1162 O
pregnant NCT03863639 1163 1171 B-Condition
controls NCT03863639 1172 1180 O
with NCT03863639 1181 1185 B-And
uncomplicated NCT03863639 1186 1199 B-Modifier
pregnancy NCT03863639 1200 1209 B-Condition
matched NCT03863639 1210 1217 O
by NCT03863639 1218 1220 O
age NCT03863639 1221 1224 I-Observation
and NCT03863639 1225 1228 O
gestational NCT03863639 1229 1240 B-Observation
age NCT03863639 1241 1244 O
will NCT03863639 1245 1249 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03863639 1250 1252 I-Assertion___Assertion-Type-Value:hypothetical
enrolled NCT03863639 1253 1261 B-Study
from NCT03863639 1262 1266 O
the NCT03863639 1267 1270 O
antenatal NCT03863639 1271 1280 O
clinic NCT03863639 1281 1287 O
or NCT03863639 1288 1290 B-Or
the NCT03863639 1291 1294 O
labor NCT03863639 1295 1300 O
ward NCT03863639 1301 1305 O
. NCT03863639 1305 1306 O

Exclusion NCT03863639 1308 1317 O
Criteria NCT03863639 1318 1326 O
: NCT03863639 1327 1328 O

- NCT03863639 1332 1333 O
History NCT03863639 1335 1342 B-Eq-Comparison
of NCT03863639 1343 1345 O
symptomatic NCT03863639 1346 1357 B-Assertion___Assertion-Type-Value:possible
cerebrovascular NCT03863639 1358 1373 B-Condition
disease NCT03863639 1374 1381 I-Condition
with NCT03863639 1382 1386 B-And
substantial NCT03863639 1387 1398 O
residual NCT03863639 1399 1407 B-Condition
deficit NCT03863639 1408 1415 I-Condition

- NCT03863639 1418 1419 O
History NCT03863639 1421 1428 B-Eq-Comparison|Eq-Comparison
of NCT03863639 1429 1431 O
alcoholism NCT03863639 1432 1442 B-Condition

- NCT03863639 1445 1446 O
History NCT03863639 1448 1455 B-Eq-Comparison
of NCT03863639 1456 1458 O
psychiatric NCT03863639 1459 1470 B-Condition
illness NCT03863639 1471 1478 I-Condition

- NCT03863639 1481 1482 O
History NCT03863639 1484 1491 O
of NCT03863639 1492 1494 O
claustrophobia NCT03863639 1495 1509 B-Condition

- NCT03863639 1512 1513 O
Renal NCT03863639 1515 1520 B-Condition
failure NCT03863639 1521 1528 I-Condition
( NCT03863639 1529 1530 O
creatinine NCT03863639 1531 1541 B-Observation
> NCT03863639 1542 1543 B-Eq-Comparison
2.0 NCT03863639 1544 1547 I-Eq-Comparison
mg NCT03863639 1548 1550 I-Eq-Comparison
/ NCT03863639 1551 1552 I-Eq-Comparison
dl NCT03863639 1553 1555 I-Eq-Comparison
) NCT03863639 1556 1557 O

- NCT03863639 1561 1562 O
Patients NCT03863639 1564 1572 O
with NCT03863639 1573 1577 O
less NCT03863639 1578 1582 B-Eq-Comparison
than NCT03863639 1583 1587 I-Eq-Comparison
a NCT03863639 1588 1589 I-Eq-Comparison
7 NCT03863639 1590 1591 I-Eq-Comparison
th NCT03863639 1592 1594 O
grade NCT03863639 1595 1600 I-Eq-Comparison
education NCT03863639 1601 1610 B-Observation
or NCT03863639 1611 1613 B-Or
unable NCT03863639 1614 1620 B-Assertion___Assertion-Type-Value:hypothetical|Condition|Negation
to NCT03863639 1621 1623 I-Condition
read NCT03863639 1624 1628 I-Condition
and NCT03863639 1629 1632 O
thus NCT03863639 1633 1637 O
unable NCT03863639 1638 1644 O
complete NCT03863639 1645 1653 O
the NCT03863639 1654 1657 O
neuropsychological NCT03863639 1658 1676 B-Procedure
testing NCT03863639 1677 1684 I-Procedure

- NCT03863639 1687 1688 O
Patients NCT03863639 1690 1698 O
with NCT03863639 1699 1703 O
bodily NCT03863639 1704 1710 B-Procedure
implants NCT03863639 1711 1719 I-Procedure
unsafe NCT03863639 1720 1726 B-Contraindication
for NCT03863639 1727 1730 O
MRI NCT03863639 1731 1734 B-Procedure
use NCT03863639 1735 1738 O

Inclusion NCT03867305 0 9 O
Criteria NCT03867305 10 18 O
: NCT03867305 19 20 O

- NCT03867305 24 25 O
Patient NCT03867305 27 34 O
requiring NCT03867305 35 44 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03867305 45 46 O
first NCT03867305 47 52 B-Eq-Comparison
total NCT03867305 53 58 B-Procedure
knee NCT03867305 59 63 I-Procedure
prosthesis NCT03867305 64 74 I-Procedure
( NCT03867305 75 76 O
scheduled NCT03867305 77 86 B-Eq-Comparison
between NCT03867305 87 94 I-Eq-Comparison
Tuesday NCT03867305 95 102 I-Eq-Comparison
and NCT03867305 103 106 I-Eq-Comparison
Friday NCT03867305 107 113 I-Eq-Comparison
) NCT03867305 114 115 O
. NCT03867305 116 117 O

- NCT03867305 121 122 O
Patient NCT03867305 124 131 O
that NCT03867305 132 136 O
has NCT03867305 137 140 O
given NCT03867305 141 146 O
his NCT03867305 147 150 O
/ NCT03867305 151 152 O
her NCT03867305 153 156 O
free NCT03867305 157 161 O
and NCT03867305 162 165 O
informed NCT03867305 166 174 O
consent NCT03867305 175 182 O
and NCT03867305 183 186 O
signed NCT03867305 187 193 O
the NCT03867305 194 197 O
consent NCT03867305 198 205 O
form NCT03867305 206 210 O
. NCT03867305 210 211 O

- NCT03867305 215 216 O
The NCT03867305 218 221 O
patient NCT03867305 222 229 O
must NCT03867305 230 234 O
be NCT03867305 235 237 O
a NCT03867305 238 239 O
member NCT03867305 240 246 O
or NCT03867305 247 249 O
beneficiary NCT03867305 250 261 O
of NCT03867305 262 264 O
a NCT03867305 265 266 O
health NCT03867305 267 273 O
insurance NCT03867305 274 283 O
plan NCT03867305 284 288 O

- NCT03867305 291 292 O
The NCT03867305 294 297 O
patient NCT03867305 298 305 O
is NCT03867305 306 308 O
at NCT03867305 309 311 B-Eq-Comparison
least NCT03867305 312 317 I-Eq-Comparison
18 NCT03867305 318 320 I-Eq-Comparison
years NCT03867305 321 326 I-Eq-Comparison
old NCT03867305 327 330 B-Age
( NCT03867305 331 332 O
≥ NCT03867305 334 335 O
) NCT03867305 337 338 O
and NCT03867305 339 342 B-And
under NCT03867305 343 348 B-Eq-Comparison
90 NCT03867305 349 351 I-Eq-Comparison
years NCT03867305 352 357 I-Eq-Comparison
old NCT03867305 358 361 O
( NCT03867305 362 363 O
< NCT03867305 365 366 O
) NCT03867305 368 369 O
. NCT03867305 370 371 O

Exclusion NCT03867305 373 382 O
Criteria NCT03867305 383 391 O
: NCT03867305 392 393 O

- NCT03867305 397 398 O
The NCT03867305 400 403 O
subject NCT03867305 404 411 O
is NCT03867305 412 414 O
in NCT03867305 415 417 O
a NCT03867305 418 419 O
period NCT03867305 420 426 O
of NCT03867305 427 429 O
exclusion NCT03867305 430 439 O
determined NCT03867305 440 450 O
by NCT03867305 451 453 O
a NCT03867305 454 455 O
previous NCT03867305 456 464 B-Eq-Comparison
study NCT03867305 465 470 B-Study|Study
( NCT03867305 471 472 O
therapeutic NCT03867305 473 484 B-Procedure
study NCT03867305 485 490 O
) NCT03867305 491 492 O

- NCT03867305 496 497 O
The NCT03867305 499 502 O
subject NCT03867305 503 510 O
refuses NCT03867305 511 518 O
to NCT03867305 519 521 O
sign NCT03867305 522 526 O
the NCT03867305 527 530 O
consent NCT03867305 531 538 O

- NCT03867305 541 542 O
It NCT03867305 544 546 O
is NCT03867305 547 549 O
impossible NCT03867305 550 560 O
to NCT03867305 561 563 O
give NCT03867305 564 568 O
the NCT03867305 569 572 O
subject NCT03867305 573 580 O
informed NCT03867305 581 589 O
information NCT03867305 590 601 O

- NCT03867305 604 605 O
The NCT03867305 607 610 O
patient NCT03867305 611 618 O
is NCT03867305 619 621 O
under NCT03867305 622 627 B-Observation
safeguard NCT03867305 628 637 I-Observation
of NCT03867305 638 640 I-Observation
justice NCT03867305 641 648 I-Observation
or NCT03867305 649 651 B-Or
state NCT03867305 652 657 B-Observation
guardianship NCT03867305 658 670 I-Observation

- NCT03867305 673 674 O
The NCT03867305 676 679 O
patient NCT03867305 680 687 O
is NCT03867305 688 690 O
pregnant NCT03867305 691 699 B-Condition
or NCT03867305 700 702 B-Or
breastfeeding NCT03867305 703 716 B-Condition

- NCT03867305 719 720 O
The NCT03867305 722 725 O
patient NCT03867305 726 733 O
is NCT03867305 734 736 O
allergic NCT03867305 737 745 B-Allergy
to NCT03867305 746 748 O
latex NCT03867305 749 754 O
bandages NCT03867305 755 763 O
. NCT03867305 763 764 O

- NCT03867305 768 769 O
The NCT03867305 771 774 O
subject NCT03867305 775 782 O
has NCT03867305 783 786 O
contralateral NCT03867305 787 800 B-Condition
amputation NCT03867305 801 811 I-Condition
, NCT03867305 812 813 O
pressure NCT03867305 814 822 B-Condition
ulcers NCT03867305 823 829 I-Condition
, NCT03867305 830 831 O
severe NCT03867305 832 838 O
Obstructive NCT03867305 839 850 B-Condition
Arteriopathy NCT03867305 851 863 I-Condition
of NCT03867305 864 866 O
Lower NCT03867305 867 872 B-Modifier
Limbs NCT03867305 873 878 I-Modifier
, NCT03867305 879 880 O
lymphoedema NCT03867305 881 892 B-Modifier
or NCT03867305 893 895 B-Or
thromboembolic NCT03867305 896 910 B-Condition
event NCT03867305 911 916 I-Condition
of NCT03867305 917 919 O
the NCT03867305 920 923 O
lower NCT03867305 924 929 B-Modifier
limb NCT03867305 930 934 I-Modifier
( NCT03867305 935 936 O
ipsilateral NCT03867305 937 948 B-Modifier
and NCT03867305 949 952 B-Or
/ NCT03867305 953 954 I-Or|Or
or NCT03867305 955 957 I-Or
contralateral NCT03867305 958 971 B-Modifier
/ NCT03867305 972 973 O
superficial NCT03867305 974 985 B-Modifier
or NCT03867305 986 988 B-Or|Or
deep NCT03867305 989 993 B-Modifier
or NCT03867305 994 996 O
detected NCT03867305 997 1005 O
by NCT03867305 1006 1008 O
post NCT03867305 1009 1013 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03867305 1014 1015 O
- NCT03867305 1017 1018 O
operative NCT03867305 1019 1028 B-Procedure
Doppler NCT03867305 1029 1036 B-Procedure
) NCT03867305 1037 1038 O
. NCT03867305 1039 1040 O

- NCT03867305 1044 1045 O
The NCT03867305 1047 1050 O
subject NCT03867305 1051 1058 O
has NCT03867305 1059 1062 O
chronic NCT03867305 1063 1070 B-Modifier
or NCT03867305 1071 1073 B-Or|Or
active NCT03867305 1074 1080 B-Eq-Comparison
wounds NCT03867305 1081 1087 B-Condition
or NCT03867305 1088 1090 O
any NCT03867305 1091 1094 O
cause NCT03867305 1095 1100 B-Condition
that NCT03867305 1101 1105 O
hinders NCT03867305 1106 1113 B-Assertion___Assertion-Type-Value:hypothetical
normal NCT03867305 1114 1120 O
rehabilitation NCT03867305 1121 1135 B-Procedure
or NCT03867305 1136 1138 B-Or
the NCT03867305 1139 1142 O
application NCT03867305 1143 1154 O
of NCT03867305 1155 1157 O
a NCT03867305 1158 1159 O
bandage NCT03867305 1160 1167 B-Procedure
. NCT03867305 1167 1168 O

- NCT03867305 1172 1173 O
patient NCT03867305 1175 1182 O
with NCT03867305 1183 1187 O
a NCT03867305 1188 1189 O
stroke NCT03867305 1190 1196 B-Condition
/ NCT03867305 1197 1198 B-Or
Disabling NCT03867305 1199 1208 B-Modifier
Neurological NCT03867305 1209 1221 B-Condition
Pathology NCT03867305 1222 1231 I-Condition|Condition
, NCT03867305 1232 1233 O
Chronic NCT03867305 1234 1241 B-Modifier
Immunological NCT03867305 1242 1255 B-Condition
Pathology NCT03867305 1256 1265 O
/ NCT03867305 1266 1267 B-Or
Systemic NCT03867305 1268 1276 B-Modifier
Disease NCT03867305 1277 1284 B-Condition
. NCT03867305 1284 1285 O

- NCT03867305 1289 1290 O
patient NCT03867305 1292 1299 O
with NCT03867305 1300 1304 O
Hepatic NCT03867305 1305 1312 B-Condition
insufficiency NCT03867305 1313 1326 I-Condition|Condition
. NCT03867305 1326 1327 O

- NCT03867305 1331 1332 O
patient NCT03867305 1334 1341 O
with NCT03867305 1342 1346 O
Venous NCT03867305 1347 1353 B-Condition
insufficiency NCT03867305 1354 1367 O
( NCT03867305 1368 1369 O
stages NCT03867305 1370 1376 B-Eq-Comparison
3 NCT03867305 1377 1378 I-Eq-Comparison
and NCT03867305 1379 1382 I-Eq-Comparison
4 NCT03867305 1383 1384 I-Eq-Comparison
) NCT03867305 1385 1386 O
. NCT03867305 1387 1388 O

- NCT03867305 1392 1393 O
The NCT03867305 1395 1398 O
patient NCT03867305 1399 1406 O
is NCT03867305 1407 1409 O
on NCT03867305 1410 1412 B-Eq-Comparison
dialysis NCT03867305 1413 1421 B-Procedure
. NCT03867305 1421 1422 O

- NCT03867305 1426 1427 O
The NCT03867305 1429 1432 O
subject NCT03867305 1433 1440 O
has NCT03867305 1441 1444 O
cognitive NCT03867305 1445 1454 B-Modifier
or NCT03867305 1455 1457 B-Or
behavioral NCT03867305 1458 1468 B-Modifier
disorders NCT03867305 1469 1478 B-Condition
( NCT03867305 1479 1480 O
Parkinson NCT03867305 1481 1490 B-Condition
's NCT03867305 1490 1492 O
disease NCT03867305 1493 1500 I-Condition
, NCT03867305 1501 1502 O
cerebellar NCT03867305 1503 1513 B-Condition
syndrome NCT03867305 1514 1522 I-Condition
, NCT03867305 1523 1524 O
opposition NCT03867305 1525 1535 B-Condition
, NCT03867305 1536 1537 O
agitation NCT03867305 1538 1547 B-Condition
, NCT03867305 1548 1549 O
dementia NCT03867305 1550 1558 B-Condition
) NCT03867305 1559 1560 O
. NCT03867305 1561 1562 O

- NCT03867305 1566 1567 O
The NCT03867305 1569 1572 O
subject NCT03867305 1573 1580 O
has NCT03867305 1581 1584 O
a NCT03867305 1585 1586 O
history NCT03867305 1587 1594 B-Eq-Comparison
of NCT03867305 1595 1597 O
knee NCT03867305 1598 1602 B-Procedure
surgery NCT03867305 1603 1610 I-Procedure
. NCT03867305 1610 1611 O

Inclusion NCT03864354 0 9 O
Criteria NCT03864354 10 18 O
: NCT03864354 19 20 O

- NCT03864354 24 25 O
18 NCT03864354 27 29 B-Eq-Comparison
years NCT03864354 30 35 I-Eq-Comparison
of NCT03864354 36 38 I-Eq-Comparison
age NCT03864354 39 42 I-Age|Eq-Comparison
or NCT03864354 43 45 I-Eq-Comparison
older NCT03864354 46 51 I-Eq-Comparison

- NCT03864354 54 55 O
previously NCT03864354 57 67 B-Eq-Comparison
diagnosed NCT03864354 68 77 O
with NCT03864354 78 82 O
asthma NCT03864354 83 89 B-Condition

Exclusion NCT03864354 90 99 O
Criteria NCT03864354 100 108 O
: NCT03864354 109 110 O

- NCT03864354 114 115 O
Current NCT03864354 117 124 B-Eq-Comparison
smoker NCT03864354 125 131 B-Condition

- NCT03864354 134 135 O
Diagnosed NCT03864354 137 146 O
with NCT03864354 147 151 O
any NCT03864354 152 155 O
other NCT03864354 156 161 B-Other
respiratory NCT03864354 162 173 B-Condition
disease NCT03864354 174 181 I-Condition
besides NCT03864354 182 189 B-Exception
asthma NCT03864354 190 196 B-Condition

- NCT03864354 199 200 O
Receiving NCT03864354 202 211 B-Eq-Comparison
OMM NCT03864354 212 215 B-Drug
from NCT03864354 216 220 O
a NCT03864354 221 222 O
licensed NCT03864354 223 231 O
physician NCT03864354 232 241 B-Provider
, NCT03864354 242 243 O
chiropractic NCT03864354 244 256 B-Procedure
treatment NCT03864354 257 266 I-Procedure
, NCT03864354 267 268 O
or NCT03864354 269 271 B-Or
massage NCT03864354 272 279 B-Procedure
therapy NCT03864354 280 287 I-Procedure
for NCT03864354 288 291 O
30 NCT03864354 292 294 B-Eq-Comparison
days NCT03864354 295 299 I-Eq-Comparison
prior NCT03864354 300 305 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864354 306 308 I-Temporal-Connection___Temporal-Connection-Type-Value:before
and NCT03864354 309 312 B-Or
during NCT03864354 313 319 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864354 320 323 O
study NCT03864354 324 329 B-Study

Inclusion NCT03864432 0 9 O
Criteria NCT03864432 10 18 O
: NCT03864432 19 20 O

- NCT03864432 24 25 O
Healthy NCT03864432 27 34 B-Condition
male NCT03864432 35 39 O
and NCT03864432 40 43 B-Or
female NCT03864432 44 50 O
subjects NCT03864432 51 59 O
( NCT03864432 60 61 O
aged NCT03864432 62 66 B-Age
19 NCT03864432 67 69 B-Eq-Comparison
~ NCT03864432 70 71 O
45 NCT03864432 72 74 O
years NCT03864432 75 80 I-Eq-Comparison
at NCT03864432 81 83 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864432 84 87 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864432 88 92 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864432 93 95 O
screening NCT03864432 96 105 B-Study
) NCT03864432 106 107 O

- NCT03864432 111 112 O
Subjects NCT03864432 114 122 O
weighing NCT03864432 123 131 B-Observation
between NCT03864432 132 139 B-Eq-Comparison
50 NCT03864432 140 142 I-Eq-Comparison
kg NCT03864432 143 145 O
( NCT03864432 146 147 I-Eq-Comparison
inclusive NCT03864432 148 157 O
) NCT03864432 158 159 O
and NCT03864432 160 163 I-Eq-Comparison
90 NCT03864432 164 166 I-Eq-Comparison
kg NCT03864432 167 169 O
( NCT03864432 170 171 O
exclusive NCT03864432 172 181 O
) NCT03864432 182 183 O
, NCT03864432 185 186 O
and NCT03864432 187 190 B-And
having NCT03864432 191 197 O
a NCT03864432 198 199 O
body NCT03864432 200 204 B-Observation
mass NCT03864432 205 209 I-Observation
index NCT03864432 210 215 I-Observation
( NCT03864432 216 217 O
BMI NCT03864432 218 221 B-Observation
) NCT03864432 222 223 O
of NCT03864432 224 226 O
17.1 NCT03864432 227 231 B-Eq-Comparison
～ NCT03864432 232 233 O
25.8 NCT03864432 233 237 O
( NCT03864432 238 239 O
inclusive NCT03864432 240 249 O
of NCT03864432 250 252 O
limits NCT03864432 253 259 O
) NCT03864432 260 261 O
. NCT03864432 262 263 O

- NCT03864432 267 268 O
Subjects NCT03864432 270 278 O
with NCT03864432 279 283 O
a NCT03864432 284 285 O
fasting NCT03864432 286 293 B-Observation
plasma NCT03864432 294 300 I-Observation
glucose NCT03864432 301 308 I-Observation
( NCT03864432 309 310 O
FPG NCT03864432 311 314 B-Observation
) NCT03864432 315 316 O
of NCT03864432 317 319 O
70 NCT03864432 320 322 B-Eq-Comparison
～ NCT03864432 323 324 O
110 NCT03864432 324 327 O
mg NCT03864432 328 330 O
/ NCT03864432 331 332 I-Eq-Comparison
dL NCT03864432 333 335 I-Eq-Comparison
( NCT03864432 336 337 O
inclusive NCT03864432 338 347 O
of NCT03864432 348 350 O
limits NCT03864432 351 357 O
) NCT03864432 358 359 O
at NCT03864432 360 362 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864432 363 366 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864432 367 371 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864432 372 374 O
screening NCT03864432 375 384 B-Study

- NCT03864432 387 388 O
Subjects NCT03864432 390 398 O
who NCT03864432 399 402 O
are NCT03864432 403 406 O
willing NCT03864432 407 414 O
to NCT03864432 415 417 O
participate NCT03864432 418 429 O
in NCT03864432 430 432 O
the NCT03864432 433 436 O
entire NCT03864432 437 443 O
study NCT03864432 444 449 O
cycle NCT03864432 450 455 O
and NCT03864432 456 459 O
comply NCT03864432 460 466 O
with NCT03864432 467 471 O
the NCT03864432 472 475 O
study NCT03864432 476 481 O
protocol NCT03864432 482 490 O
( NCT03864432 491 492 O
including NCT03864432 493 502 O
contraception NCT03864432 503 516 O
) NCT03864432 517 518 O
. NCT03864432 519 520 O
Subjects NCT03864432 522 530 O
who NCT03864432 531 534 O
can NCT03864432 535 538 O
sign NCT03864432 539 543 O
the NCT03864432 544 547 O
written NCT03864432 548 555 O
Informed NCT03864432 556 564 O
Consent NCT03864432 565 572 O
Form NCT03864432 573 577 O
after NCT03864432 578 583 O
being NCT03864432 584 589 O
informed NCT03864432 590 598 O
of NCT03864432 599 601 O
the NCT03864432 602 605 O
study NCT03864432 606 611 O
procedures NCT03864432 612 622 O
. NCT03864432 622 623 O

Exclusion NCT03864432 625 634 O
Criteria NCT03864432 635 643 O
: NCT03864432 644 645 O

- NCT03864432 649 650 O
Those NCT03864432 652 657 O
with NCT03864432 658 662 O
a NCT03864432 663 664 O
history NCT03864432 665 672 B-Eq-Comparison
of NCT03864432 673 675 O
allergies NCT03864432 676 685 B-Allergy|Allergy
including NCT03864432 686 695 O
drug NCT03864432 696 700 B-Drug
allergies NCT03864432 701 710 O
( NCT03864432 711 712 O
aspirin NCT03864432 713 720 B-Drug
, NCT03864432 721 722 O
antibiotics NCT03864432 723 734 B-Drug
, NCT03864432 735 736 O
etc NCT03864432 737 740 O
. NCT03864432 740 741 O
) NCT03864432 742 743 O
, NCT03864432 745 746 O
or NCT03864432 747 749 B-Or
other NCT03864432 750 755 B-Other
clinically NCT03864432 756 766 O
significant NCT03864432 767 778 O
allergies NCT03864432 779 788 B-Allergy
. NCT03864432 788 789 O

- NCT03864432 793 794 O
Those NCT03864432 796 801 O
with NCT03864432 802 806 O
diseases NCT03864432 807 815 B-Condition
of NCT03864432 816 818 O
the NCT03864432 819 822 O
liver NCT03864432 823 828 B-Modifier
( NCT03864432 829 830 O
including NCT03864432 831 840 O
carriers NCT03864432 841 849 O
of NCT03864432 850 852 O
hepatitis NCT03864432 853 862 B-Condition
virus NCT03864432 863 868 I-Condition
) NCT03864432 869 870 O
, NCT03864432 872 873 O
kidney NCT03864432 874 880 B-Modifier
, NCT03864432 881 882 O
respiratory NCT03864432 883 894 B-Modifier
system NCT03864432 895 901 I-Modifier|Modifier|Modifier
, NCT03864432 902 903 O
endocrine NCT03864432 904 913 B-Modifier
system NCT03864432 914 920 I-Modifier
, NCT03864432 921 922 O
nervous NCT03864432 923 930 B-Modifier
system NCT03864432 931 937 O
or NCT03864432 938 940 B-Or
immune NCT03864432 941 947 B-Modifier
system NCT03864432 948 954 O
. NCT03864432 954 955 O
Those NCT03864432 957 962 O
with NCT03864432 963 967 O
a NCT03864432 968 969 O
medical NCT03864432 970 977 O
history NCT03864432 978 985 B-Eq-Comparison
of NCT03864432 986 988 O
hematology NCT03864432 989 999 B-Modifier
/ NCT03864432 1000 1001 B-Or
oncology NCT03864432 1002 1010 B-Modifier
, NCT03864432 1011 1012 O
psychiatry NCT03864432 1013 1023 B-Modifier
or NCT03864432 1024 1026 B-Or
cardiovascular NCT03864432 1027 1041 B-Modifier
diseases NCT03864432 1042 1050 B-Condition
. NCT03864432 1050 1051 O

- NCT03864432 1055 1056 O
Those NCT03864432 1058 1063 O
with NCT03864432 1064 1068 O
a NCT03864432 1069 1070 O
medical NCT03864432 1071 1078 O
history NCT03864432 1079 1086 B-Eq-Comparison
of NCT03864432 1087 1089 O
gastrointestinal NCT03864432 1090 1106 B-Condition
diseases NCT03864432 1107 1115 I-Condition|Condition
( NCT03864432 1116 1117 O
ulcers NCT03864432 1118 1124 B-Condition
, NCT03864432 1125 1126 O
Crohn NCT03864432 1127 1132 B-Condition
's NCT03864432 1132 1134 O
disease NCT03864432 1135 1142 O
, NCT03864432 1143 1144 O
etc NCT03864432 1145 1148 O
. NCT03864432 1148 1149 O
) NCT03864432 1150 1151 O
or NCT03864432 1152 1154 B-Or|Or
surgery NCT03864432 1155 1162 B-Procedure
( NCT03864432 1163 1164 O
excluding NCT03864432 1165 1174 B-Exception
simple NCT03864432 1175 1181 B-Modifier
appendectomy NCT03864432 1182 1194 B-Procedure
or NCT03864432 1195 1197 O
hernia NCT03864432 1198 1204 B-Procedure
repair NCT03864432 1205 1211 I-Procedure
) NCT03864432 1212 1213 O
, NCT03864432 1215 1216 O
and NCT03864432 1217 1220 O
these NCT03864432 1221 1226 O
situations NCT03864432 1227 1237 O
can NCT03864432 1238 1241 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864432 1242 1248 O
the NCT03864432 1249 1252 O
absorption NCT03864432 1253 1263 B-Condition
of NCT03864432 1264 1266 O
the NCT03864432 1267 1270 O
study NCT03864432 1271 1276 B-Study
drug NCT03864432 1277 1281 B-Drug
. NCT03864432 1281 1282 O

Inclusion NCT03868397 0 9 O
Criteria NCT03868397 10 18 O
: NCT03868397 19 20 O

- NCT03868397 24 25 O
older NCT03868397 27 32 I-Eq-Comparison
than NCT03868397 33 37 I-Eq-Comparison
18 NCT03868397 38 40 I-Eq-Comparison
years NCT03868397 41 46 I-Eq-Comparison

- NCT03868397 49 50 O
And NCT03868397 52 55 O
signed NCT03868397 56 62 O
informed NCT03868397 63 71 O
consent NCT03868397 72 79 O

- NCT03868397 82 83 O
And NCT03868397 85 88 O
planned NCT03868397 89 96 B-Eq-Comparison
either NCT03868397 97 103 O
a NCT03868397 104 105 O
) NCT03868397 106 107 O
liver NCT03868397 108 113 B-Procedure
transplantation NCT03868397 114 129 I-Procedure
as NCT03868397 130 132 O
a NCT03868397 133 134 O
recipient NCT03868397 135 144 B-Modifier
; NCT03868397 144 145 O
or NCT03868397 146 148 B-Or
b NCT03868397 149 150 O
) NCT03868397 151 152 O
liver NCT03868397 153 158 B-Procedure
transplantation NCT03868397 159 174 I-Procedure
as NCT03868397 175 177 O
a NCT03868397 178 179 O
donor NCT03868397 180 185 B-Modifier

Exclusion NCT03868397 186 195 O
Criteria NCT03868397 196 204 O
: NCT03868397 205 206 O

- NCT03868397 210 211 O
any NCT03868397 213 216 O
absolute NCT03868397 217 225 O
/ NCT03868397 226 227 O
relative NCT03868397 228 236 O
contraindication NCT03868397 237 253 B-Contraindication
of NCT03868397 254 256 O
contrast NCT03868397 257 265 B-Modifier
- NCT03868397 266 267 I-Modifier
enhanced NCT03868397 268 276 I-Modifier
MRI NCT03868397 277 280 B-Procedure

Inclusion NCT03869710 0 9 O
Criteria NCT03869710 10 18 O
: NCT03869710 19 20 O

- NCT03869710 24 25 O
Chronic NCT03869710 27 34 B-Modifier
neck NCT03869710 35 39 I-Modifier
pain NCT03869710 40 44 B-Condition

- NCT03869710 47 48 O
Chronic NCT03869710 50 57 B-Modifier
head NCT03869710 58 62 I-Modifier
pain NCT03869710 63 67 B-Condition

Exclusion NCT03869710 68 77 O
Criteria NCT03869710 78 86 O
: NCT03869710 87 88 O

- NCT03869710 92 93 O
previous NCT03869710 95 103 B-Eq-Comparison
surgery NCT03869710 104 111 B-Procedure
of NCT03869710 112 114 O
neck NCT03869710 115 119 B-Modifier
and NCT03869710 120 123 B-Or
head NCT03869710 124 128 B-Modifier

- NCT03869710 131 132 O
Body NCT03869710 134 138 B-Observation
Mass NCT03869710 139 143 I-Observation
Index NCT03869710 144 149 I-Observation
> NCT03869710 150 151 B-Eq-Comparison
39 NCT03869710 152 154 I-Eq-Comparison
, NCT03869710 155 156 O
99 NCT03869710 157 159 O

- NCT03869710 163 164 O
politrauma NCT03869710 166 176 B-Condition
patients NCT03869710 177 185 O

- NCT03869710 188 189 O
pregnancy NCT03869710 191 200 B-Condition

- NCT03869710 203 204 O
neck NCT03869710 206 210 B-Modifier
and NCT03869710 211 214 B-Or
head NCT03869710 215 219 B-Modifier
infections NCT03869710 220 230 B-Condition

Inclusion NCT03864744 0 9 O
Criteria NCT03864744 10 18 O
: NCT03864744 19 20 O

- NCT03864744 24 25 O
Subject NCT03864744 27 34 O
scheduled NCT03864744 35 44 B-Eq-Comparison
for NCT03864744 45 48 O
total NCT03864744 49 54 B-Procedure
pancreatectomy NCT03864744 55 69 I-Procedure
or NCT03864744 70 72 B-Or
pancreaticoduodenectomy NCT03864744 73 96 B-Procedure

- NCT03864744 99 100 O
Informed NCT03864744 102 110 O
consent NCT03864744 111 118 O
signed NCT03864744 119 125 O
prior NCT03864744 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864744 132 134 I-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03864744 135 138 O
study NCT03864744 139 144 B-Study
- NCT03864744 145 146 O
related NCT03864744 147 154 O
procedure NCT03864744 155 164 B-Procedure

Exclusion NCT03864744 165 174 O
Criteria NCT03864744 175 183 O
: NCT03864744 184 185 O

- NCT03864744 189 190 O
Known NCT03864744 192 197 O
liver NCT03864744 198 203 B-Condition
disease NCT03864744 204 211 I-Condition
before NCT03864744 212 218 B-Temporal-Connection___Temporal-Connection-Type-Value:before
total NCT03864744 219 224 B-Procedure
pancreatectomy NCT03864744 225 239 I-Procedure
or NCT03864744 240 242 B-Or
pancreaticoduodenectomy NCT03864744 243 266 B-Procedure
( NCT03864744 267 268 O
excluding NCT03864744 269 278 B-Exception
NAFLD NCT03864744 279 284 B-Condition
) NCT03864744 285 286 O

- NCT03864744 290 291 O
Severe NCT03864744 293 299 O
co NCT03864744 300 302 B-Condition
- NCT03864744 303 304 I-Condition
morbid NCT03864744 305 311 I-Condition
disease NCT03864744 312 319 I-Condition
( NCT03864744 320 321 O
besides NCT03864744 322 329 B-Exception
from NCT03864744 330 334 O
the NCT03864744 335 338 O
indication NCT03864744 339 349 B-Indication
for NCT03864744 350 353 O
the NCT03864744 354 357 O
pancreas NCT03864744 358 366 B-Procedure
surgery NCT03864744 367 374 I-Procedure
) NCT03864744 375 376 O

- NCT03864744 380 381 O
Pregnancy NCT03864744 383 392 B-Condition

- NCT03864744 395 396 O
Any NCT03864744 398 401 O
condition NCT03864744 402 411 B-Condition
that NCT03864744 412 416 O
the NCT03864744 417 420 O
investigator NCT03864744 421 433 O
feels NCT03864744 434 439 O
would NCT03864744 440 445 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864744 446 455 O
with NCT03864744 456 460 O
the NCT03864744 461 464 O
safety NCT03864744 465 471 O
of NCT03864744 472 474 O
the NCT03864744 475 478 O
trial NCT03864744 479 484 B-Study
participation NCT03864744 485 498 O
or NCT03864744 499 501 O
the NCT03864744 502 505 O
safety NCT03864744 506 512 O
of NCT03864744 513 515 O
the NCT03864744 516 519 O
subject NCT03864744 520 527 O

- NCT03864744 530 531 O
Metastatic NCT03864744 533 543 B-Condition
disease NCT03864744 544 551 I-Condition

Percutaneous NCT03864744 552 564 B-Modifier
liver NCT03864744 565 570 B-Procedure
biopsy NCT03864744 571 577 I-Procedure
exclusion NCT03864744 578 587 O
criteria NCT03864744 588 596 O
( NCT03864744 597 598 O
to NCT03864744 599 601 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864744 602 604 B-Assertion___Assertion-Type-Value:hypothetical|Temporal-Connection___Temporal-Connection-Type-Value:before
evaluated NCT03864744 605 614 B-Procedure
before NCT03864744 615 621 O
last NCT03864744 622 626 B-Eq-Comparison
visit NCT03864744 627 632 B-Encounter
) NCT03864744 633 634 O

- NCT03864744 638 639 O
MR NCT03864744 641 643 B-Procedure
spectroscopy NCT03864744 644 656 I-Procedure
demonstrating NCT03864744 657 670 O
lipid NCT03864744 671 676 B-Observation
content NCT03864744 677 684 I-Observation
< NCT03864744 685 686 B-Eq-Comparison
2 NCT03864744 687 688 I-Eq-Comparison
% NCT03864744 689 690 O

- NCT03864744 693 694 O
Haemoglobin NCT03864744 696 707 B-Observation
< NCT03864744 708 709 B-Eq-Comparison
6 NCT03864744 710 711 I-Eq-Comparison
mmol NCT03864744 712 716 I-Eq-Comparison
/ NCT03864744 717 718 I-Eq-Comparison
L NCT03864744 719 720 I-Eq-Comparison

- NCT03864744 723 724 O
INR NCT03864744 726 729 B-Observation
> NCT03864744 730 731 B-Eq-Comparison
1.5 NCT03864744 732 735 I-Eq-Comparison

- NCT03864744 739 740 O
Trombocytes NCT03864744 742 753 B-Observation
< NCT03864744 754 755 B-Eq-Comparison
40 NCT03864744 756 758 I-Eq-Comparison
× NCT03864744 759 760 I-Eq-Comparison
109 NCT03864744 761 764 I-Eq-Comparison
/ NCT03864744 765 766 I-Eq-Comparison
L NCT03864744 767 768 I-Eq-Comparison

- NCT03864744 771 772 O
Skin NCT03864744 774 778 B-Modifier
infection NCT03864744 779 788 B-Condition
in NCT03864744 789 791 O
area NCT03864744 792 796 B-Modifier
where NCT03864744 797 802 O
biopsy NCT03864744 803 809 B-Procedure
will NCT03864744 810 814 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864744 815 817 I-Assertion___Assertion-Type-Value:hypothetical
sampled NCT03864744 818 825 O

Inclusion NCT03868618 0 9 O
Criteria NCT03868618 10 18 O
: NCT03868618 19 20 O

- NCT03868618 24 25 O
Body NCT03868618 27 31 B-Observation
mass NCT03868618 32 36 I-Observation
index NCT03868618 37 42 I-Observation
( NCT03868618 43 44 O
BMI NCT03868618 45 48 B-Observation
) NCT03868618 49 50 O
limitations NCT03868618 51 62 B-Modifier

- NCT03868618 65 66 O
Likely NCT03868618 68 74 B-Assertion___Assertion-Type-Value:possible
suffer NCT03868618 75 81 O
from NCT03868618 82 86 O
moderate NCT03868618 87 95 B-Eq-Comparison
to NCT03868618 96 98 I-Eq-Comparison
severe NCT03868618 99 105 I-Eq-Comparison
OSA NCT03868618 106 109 B-Condition
based NCT03868618 110 115 O
on NCT03868618 116 118 O
history NCT03868618 119 126 B-Eq-Comparison
and NCT03868618 127 130 B-Or
physical NCT03868618 131 139 B-Procedure

- NCT03868618 142 143 O
Has NCT03868618 145 148 O
either NCT03868618 149 155 O
not NCT03868618 156 159 B-Negation
tolerated NCT03868618 160 169 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03868618 170 171 O
has NCT03868618 172 175 O
failed NCT03868618 176 182 O
or NCT03868618 183 185 O
refused NCT03868618 186 193 O
positive NCT03868618 194 202 B-Procedure
airway NCT03868618 203 209 I-Procedure
pressure NCT03868618 210 218 I-Procedure
( NCT03868618 219 220 O
PAP NCT03868618 221 224 B-Procedure
) NCT03868618 225 226 O
treatments NCT03868618 227 237 B-Procedure

- NCT03868618 240 241 O
Willing NCT03868618 243 250 O
and NCT03868618 251 254 O
capable NCT03868618 255 262 O
of NCT03868618 263 265 O
providing NCT03868618 266 275 O
informed NCT03868618 276 284 O
consent NCT03868618 285 292 O

Exclusion NCT03868618 293 302 O
Criteria NCT03868618 303 311 O
: NCT03868618 312 313 O

- NCT03868618 317 318 O
Inadequately NCT03868618 320 332 B-Modifier
treated NCT03868618 333 340 B-Procedure
sleep NCT03868618 341 346 B-Condition
disorders NCT03868618 347 356 I-Condition
other NCT03868618 357 362 B-Exception
than NCT03868618 363 367 I-Exception
OSA NCT03868618 368 371 B-Condition

- NCT03868618 374 375 O
Significant NCT03868618 377 388 O
co NCT03868618 389 391 B-Condition
- NCT03868618 392 393 I-Condition
morbidities NCT03868618 394 405 I-Condition
that NCT03868618 406 410 O
contraindicates NCT03868618 411 426 B-Contraindication
surgery NCT03868618 427 434 B-Procedure
or NCT03868618 435 437 B-Or
general NCT03868618 438 445 B-Procedure
anesthesia NCT03868618 446 456 I-Procedure

Inclusion NCT03866421 0 9 O
Criteria NCT03866421 10 18 O
( NCT03866421 19 20 O
kidney NCT03866421 21 27 B-Procedure
transplanted NCT03866421 28 40 I-Procedure
patients NCT03866421 41 49 O
) NCT03866421 50 51 O
: NCT03866421 53 54 O

- NCT03866421 58 59 O
Outpatient NCT03866421 61 71 B-Encounter
at NCT03866421 72 74 O
the NCT03866421 75 78 O
department NCT03866421 79 89 O
of NCT03866421 90 92 O
nephrology NCT03866421 93 103 O
at NCT03866421 104 106 O
either NCT03866421 107 113 O
Rigshospitalet NCT03866421 114 128 O
or NCT03866421 129 131 B-Or
Herlev NCT03866421 132 138 O
Hospital NCT03866421 139 147 O
scheduled NCT03866421 148 157 B-Eq-Comparison
for NCT03866421 158 161 O
a NCT03866421 162 163 O
kidney NCT03866421 164 170 B-Procedure
transplantation NCT03866421 171 186 I-Procedure
with NCT03866421 187 191 O
a NCT03866421 192 193 O
living NCT03866421 194 200 B-Observation
donor NCT03866421 201 206 I-Observation

- NCT03866421 209 210 O
Impaired NCT03866421 212 220 B-Condition
glucose NCT03866421 221 228 I-Condition
tolerance NCT03866421 229 238 I-Condition
: NCT03866421 239 240 O
fasting NCT03866421 241 248 B-Modifier
glucose NCT03866421 249 256 B-Observation
concentration NCT03866421 257 270 I-Observation
< NCT03866421 271 272 B-Eq-Comparison
7 NCT03866421 273 274 I-Eq-Comparison
, NCT03866421 275 276 O
0 NCT03866421 277 278 O
mmol NCT03866421 279 283 I-Eq-Comparison
/ NCT03866421 284 285 I-Eq-Comparison
l NCT03866421 286 287 I-Eq-Comparison
and NCT03866421 288 291 B-And
a NCT03866421 292 293 O
2 NCT03866421 294 295 B-Observation
- NCT03866421 296 297 I-Observation
hour NCT03866421 298 302 I-Observation
glucose NCT03866421 303 310 I-Observation
load NCT03866421 311 315 I-Observation
≥ NCT03866421 316 317 B-Eq-Comparison
7 NCT03866421 318 319 I-Eq-Comparison
, NCT03866421 320 321 O
8 NCT03866421 322 323 O
mmol NCT03866421 324 328 I-Eq-Comparison
/ NCT03866421 329 330 I-Eq-Comparison
l NCT03866421 331 332 I-Eq-Comparison|Eq-Comparison
and NCT03866421 333 336 B-And
< NCT03866421 337 338 B-Eq-Comparison
11 NCT03866421 339 341 I-Eq-Comparison
, NCT03866421 342 343 O
1 NCT03866421 344 345 O
mmol NCT03866421 346 350 I-Eq-Comparison
/ NCT03866421 351 352 I-Eq-Comparison
l NCT03866421 353 354 O
OR NCT03866421 355 357 B-Or
Impaired NCT03866421 358 366 B-Condition
fasting NCT03866421 367 374 I-Condition
glycaemia NCT03866421 375 384 I-Condition
: NCT03866421 385 386 O
Fasting NCT03866421 387 394 B-Modifier
blood NCT03866421 395 400 B-Observation
glucose NCT03866421 401 408 I-Observation
≥ NCT03866421 409 410 B-Eq-Comparison
6 NCT03866421 411 412 I-Eq-Comparison
, NCT03866421 413 414 O
1 NCT03866421 415 416 O
mmol NCT03866421 417 421 I-Eq-Comparison|Eq-Comparison
/ NCT03866421 422 423 I-Eq-Comparison|Eq-Comparison
l NCT03866421 424 425 I-Eq-Comparison|Eq-Comparison
and NCT03866421 426 429 B-And|And
< NCT03866421 430 431 B-Eq-Comparison
7 NCT03866421 432 433 I-Eq-Comparison
, NCT03866421 434 435 O
0 NCT03866421 436 437 O
mmol NCT03866421 438 442 O
/ NCT03866421 443 444 O
l NCT03866421 445 446 O
and NCT03866421 447 450 O
a NCT03866421 451 452 O
2 NCT03866421 453 454 B-Observation
- NCT03866421 455 456 I-Observation
hour NCT03866421 457 461 I-Observation
glucose NCT03866421 462 469 I-Observation
load NCT03866421 470 474 I-Eq-Comparison|Observation
< NCT03866421 475 476 B-Eq-Comparison
7 NCT03866421 477 478 I-Eq-Comparison
, NCT03866421 479 480 O
8 NCT03866421 481 482 O
mmol NCT03866421 483 487 I-Eq-Comparison
/ NCT03866421 488 489 I-Eq-Comparison
l NCT03866421 490 491 O
OR NCT03866421 492 494 B-Or
Normal NCT03866421 495 501 O
glucose NCT03866421 502 509 B-Condition|Observation
tolerance NCT03866421 510 519 I-Condition
: NCT03866421 520 521 O
fasting NCT03866421 522 529 B-Modifier
glucose NCT03866421 530 537 O
concentration NCT03866421 538 551 I-Observation
< NCT03866421 552 553 B-Eq-Comparison
6 NCT03866421 554 555 I-Eq-Comparison
, NCT03866421 556 557 O
1 NCT03866421 558 559 O
mmol NCT03866421 560 564 I-Eq-Comparison
/ NCT03866421 565 566 I-Eq-Comparison
l NCT03866421 567 568 I-Eq-Comparison
and NCT03866421 569 572 B-And
a NCT03866421 573 574 O
2 NCT03866421 575 576 B-Observation
- NCT03866421 577 578 I-Observation
hour NCT03866421 579 583 I-Observation
glucose NCT03866421 584 591 I-Observation
load NCT03866421 592 596 I-Eq-Comparison|Observation
< NCT03866421 597 598 B-Eq-Comparison
7 NCT03866421 599 600 I-Eq-Comparison
, NCT03866421 601 602 O
8 NCT03866421 603 604 O
mmol NCT03866421 605 609 I-Eq-Comparison
/ NCT03866421 610 611 I-Eq-Comparison
l. NCT03866421 612 614 O

Inclusion NCT03866421 616 625 O
criteria NCT03866421 626 634 O
( NCT03866421 635 636 O
control NCT03866421 637 644 O
group NCT03866421 645 650 O
) NCT03866421 651 652 O
: NCT03866421 654 655 O

- NCT03866421 659 660 O
Normal NCT03866421 662 668 O
kidney NCT03866421 669 675 B-Condition
function NCT03866421 676 684 I-Condition

- NCT03866421 687 688 O
Normal NCT03866421 690 696 O
glucose NCT03866421 697 704 B-Condition
tolerance NCT03866421 705 714 I-Condition

Exclusion NCT03866421 715 724 O
Criteria NCT03866421 725 733 O
: NCT03866421 734 735 O

- NCT03866421 739 740 O
End NCT03866421 742 745 B-Modifier
stage NCT03866421 746 751 I-Modifier
liver NCT03866421 752 757 B-Condition
disease NCT03866421 758 765 I-Condition
as NCT03866421 766 768 O
diagnosed NCT03866421 769 778 O
by NCT03866421 779 781 O
MELD NCT03866421 782 786 O
( NCT03866421 787 788 O
model NCT03866421 789 794 O
for NCT03866421 795 798 O
end NCT03866421 799 802 O
stage NCT03866421 803 808 O
liver NCT03866421 809 814 O
disease NCT03866421 815 822 O
) NCT03866421 823 824 O
criteria NCT03866421 825 833 O
OR NCT03866421 834 836 B-Or

- NCT03866421 839 840 O
At NCT03866421 842 844 O
the NCT03866421 845 848 O
waiting NCT03866421 849 856 B-Assertion___Assertion-Type-Value:hypothetical
list NCT03866421 857 861 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03866421 862 865 O
liver NCT03866421 866 871 B-Procedure
transplantation NCT03866421 872 887 I-Procedure
OR NCT03866421 888 890 B-Or

- NCT03866421 893 894 O
Daily NCT03866421 896 901 B-Eq-Comparison
alcohol NCT03866421 902 909 B-Observation
intake NCT03866421 910 916 I-Observation
above NCT03866421 917 922 B-Eq-Comparison
20 NCT03866421 923 925 I-Eq-Comparison
g NCT03866421 926 927 I-Eq-Comparison|Eq-Comparison
and NCT03866421 928 931 B-And|Or
30 NCT03866421 932 934 B-Eq-Comparison
g NCT03866421 935 936 O
for NCT03866421 937 940 O
women NCT03866421 941 946 O
and NCT03866421 947 950 O
men NCT03866421 951 954 O
respectively NCT03866421 955 967 O
OR NCT03866421 968 970 B-Or

- NCT03866421 973 974 O
Known NCT03866421 976 981 O
hepatitis NCT03866421 982 991 B-Condition
A NCT03866421 992 993 B-Modifier
, NCT03866421 994 995 O
B NCT03866421 996 997 B-Modifier
or NCT03866421 998 1000 B-Or|Or|Or
C NCT03866421 1001 1002 B-Modifier
or NCT03866421 1003 1005 O
hepatocellular NCT03866421 1006 1020 B-Modifier
carcinoma NCT03866421 1021 1030 B-Condition
or NCT03866421 1031 1033 O
other NCT03866421 1034 1039 B-Other
known NCT03866421 1040 1045 O
liver NCT03866421 1046 1051 B-Condition
disease NCT03866421 1052 1059 I-Condition
OR NCT03866421 1060 1062 B-Or|Or|Or

- NCT03866421 1065 1066 O
Pregnancy NCT03866421 1068 1077 B-Condition
OR NCT03866421 1078 1080 O

- NCT03866421 1083 1084 O
Weight NCT03866421 1086 1092 B-Observation
> NCT03866421 1093 1094 B-Eq-Comparison
130 NCT03866421 1095 1098 I-Eq-Comparison
kg NCT03866421 1099 1101 I-Eq-Comparison
OR NCT03866421 1102 1104 O

- NCT03866421 1107 1108 O
Implanted NCT03866421 1110 1119 B-Procedure
pacemaker NCT03866421 1120 1129 I-Procedure

Inclusion NCT03863821 0 9 O
Criteria NCT03863821 10 18 O
: NCT03863821 19 20 O

- NCT03863821 24 25 O
Mild NCT03863821 27 31 O
COPD NCT03863821 32 36 B-Condition
with NCT03863821 37 41 B-And
performed NCT03863821 42 51 O
pulmonary NCT03863821 52 61 B-Observation
function NCT03863821 62 70 I-Observation
test NCT03863821 71 75 I-Observation

Exclusion NCT03863821 76 85 O
Criteria NCT03863821 86 94 O
: NCT03863821 95 96 O

- NCT03863821 100 101 O
Left NCT03863821 103 107 B-Modifier
- NCT03863821 108 109 I-Modifier
side NCT03863821 110 114 I-Modifier
heart NCT03863821 115 120 B-Condition
failure NCT03863821 121 128 I-Condition

- NCT03863821 131 132 O
COPD NCT03863821 134 138 B-Condition
exacerbation NCT03863821 139 151 O
within NCT03863821 152 158 B-Eq-Comparison
3 NCT03863821 159 160 I-Eq-Comparison
month NCT03863821 161 166 I-Eq-Comparison

- NCT03863821 169 170 O
Diagnosed NCT03863821 172 181 O
neuromuscular NCT03863821 182 195 B-Condition
disease NCT03863821 196 203 I-Condition

- NCT03863821 206 207 O
Unable NCT03863821 209 215 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863821 216 218 O
perform NCT03863821 219 226 O
6 NCT03863821 227 228 B-Observation
- NCT03863821 229 230 I-Observation
MWT NCT03863821 231 234 I-Observation

Inclusion NCT03865277 0 9 O
Criteria NCT03865277 10 18 O
: NCT03865277 19 20 O

- NCT03865277 24 25 O
Age NCT03865277 27 30 B-Age
: NCT03865277 31 32 O
older NCT03865277 33 38 B-Eq-Comparison
than NCT03865277 39 43 I-Eq-Comparison
18 NCT03865277 44 46 I-Eq-Comparison
years NCT03865277 47 52 I-Eq-Comparison

- NCT03865277 55 56 O
WHO NCT03865277 58 61 O
( NCT03865277 62 63 O
ECOG NCT03865277 64 68 B-Observation
) NCT03865277 69 70 O
performance NCT03865277 71 82 O
status NCT03865277 83 89 O
0 NCT03865277 90 91 B-Eq-Comparison
- NCT03865277 92 93 I-Eq-Comparison
2 NCT03865277 94 95 O

- NCT03865277 99 100 O
Histological NCT03865277 102 114 O
proven NCT03865277 115 121 O
HNSCC NCT03865277 122 127 B-Condition

- NCT03865277 130 131 O
HPV NCT03865277 133 136 B-Condition
negative NCT03865277 137 145 O
tumors NCT03865277 146 152 B-Modifier
or NCT03865277 153 155 B-Or
HPV NCT03865277 156 159 B-Condition
positive NCT03865277 160 168 O
tumors NCT03865277 169 175 B-Modifier

- NCT03865277 178 179 O
Stage NCT03865277 181 186 B-Eq-Comparison
III NCT03865277 187 190 I-Eq-Comparison
, NCT03865277 191 192 O
IVA NCT03865277 193 196 B-Modifier
or NCT03865277 197 199 B-Or
IVB NCT03865277 200 203 B-Modifier
HNSCC NCT03865277 204 209 B-Condition
according NCT03865277 210 219 O
to NCT03865277 220 222 O
UICC NCT03865277 223 227 O
and NCT03865277 228 231 O
AJCC NCT03865277 232 236 O
guidelines NCT03865277 237 247 O

- NCT03865277 250 251 O
Tumor NCT03865277 253 258 B-Condition
classified NCT03865277 259 269 O
as NCT03865277 270 272 O
irresectable NCT03865277 273 285 B-Modifier
or NCT03865277 286 288 B-Or
patient NCT03865277 289 296 O
inoperable NCT03865277 297 307 B-Modifier
or NCT03865277 308 310 B-Or
patient NCT03865277 311 318 O
refused NCT03865277 319 326 B-Assertion___Assertion-Type-Value:hypothetical|Negation
surgery NCT03865277 327 334 B-Procedure

- NCT03865277 337 338 O
Tumor NCT03865277 340 345 B-Condition
extension NCT03865277 346 355 B-Modifier
and NCT03865277 356 359 B-And
localization NCT03865277 360 372 B-Modifier
suitable NCT03865277 373 381 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865277 382 385 I-Assertion___Assertion-Type-Value:hypothetical
radiochemotherapy NCT03865277 386 403 B-Procedure
with NCT03865277 404 408 O
curative NCT03865277 409 417 O
intent NCT03865277 418 424 O

- NCT03865277 427 428 O
Simultaneous NCT03865277 430 442 B-Modifier
standard NCT03865277 443 451 I-Modifier
chemotherapy NCT03865277 452 464 B-Procedure
with NCT03865277 465 469 O
cisplatin NCT03865277 470 479 B-Drug
applicable NCT03865277 480 490 B-Assertion___Assertion-Type-Value:hypothetical
( NCT03865277 491 492 O
no NCT03865277 493 495 B-Negation
contra NCT03865277 496 502 B-Contraindication
- NCT03865277 503 504 I-Contraindication
indications NCT03865277 505 516 I-Contraindication
) NCT03865277 517 518 O

- NCT03865277 522 523 O
Dental NCT03865277 525 531 B-Procedure
examination NCT03865277 532 543 B-Modifier
and NCT03865277 544 547 B-And
- NCT03865277 548 549 O
treatment NCT03865277 550 559 B-Modifier
before NCT03865277 560 566 B-Temporal-Connection___Temporal-Connection-Type-Value:before
start NCT03865277 567 572 B-Eq-Comparison
of NCT03865277 573 575 O
therapy NCT03865277 576 583 B-Procedure

- NCT03865277 586 587 O
For NCT03865277 589 592 O
women NCT03865277 593 598 O
with NCT03865277 599 603 B-And
childbearing NCT03865277 604 616 B-Condition
potential NCT03865277 617 626 I-Condition
and NCT03865277 627 630 B-Or
men NCT03865277 631 634 O
in NCT03865277 635 637 B-And
reproductive NCT03865277 638 650 B-Condition
ages NCT03865277 651 655 I-Condition
adequate NCT03865277 656 664 O
contraception NCT03865277 665 678 B-Procedure
. NCT03865277 678 679 O

- NCT03865277 683 684 O
Ability NCT03865277 686 693 O
of NCT03865277 694 696 O
subject NCT03865277 697 704 O
to NCT03865277 705 707 O
understand NCT03865277 708 718 O
character NCT03865277 719 728 O
and NCT03865277 729 732 O
individual NCT03865277 733 743 O
consequences NCT03865277 744 756 O
of NCT03865277 757 759 O
the NCT03865277 760 763 O
clinical NCT03865277 764 772 O
trial NCT03865277 773 778 O

- NCT03865277 781 782 O
Written NCT03865277 784 791 O
informed NCT03865277 792 800 O
consent NCT03865277 801 808 O
( NCT03865277 809 810 O
must NCT03865277 811 815 O
be NCT03865277 816 818 B-Temporal-Connection___Temporal-Connection-Type-Value:before
available NCT03865277 819 828 O
before NCT03865277 829 835 O
enrolment NCT03865277 836 845 O
in NCT03865277 846 848 O
the NCT03865277 849 852 O
trial NCT03865277 853 858 B-Study
) NCT03865277 859 860 O

Exclusion NCT03865277 862 871 O
Criteria NCT03865277 872 880 O
: NCT03865277 881 882 O

- NCT03865277 886 887 O
Refusal NCT03865277 889 896 O
of NCT03865277 897 899 O
the NCT03865277 900 903 O
patients NCT03865277 904 912 O
to NCT03865277 913 915 O
take NCT03865277 916 920 O
part NCT03865277 921 925 O
in NCT03865277 926 928 O
the NCT03865277 929 932 O
trial NCT03865277 933 938 O

- NCT03865277 941 942 O
Presence NCT03865277 944 952 B-Eq-Comparison
of NCT03865277 953 955 O
distant NCT03865277 956 963 B-Modifier
metastases NCT03865277 964 974 B-Condition
( NCT03865277 975 976 O
UICC NCT03865277 977 981 B-Condition
stage NCT03865277 982 987 B-Eq-Comparison
IVC NCT03865277 988 991 I-Eq-Comparison
) NCT03865277 992 993 O

- NCT03865277 997 998 O
Previous NCT03865277 1000 1008 B-Eq-Comparison
radiotherapy NCT03865277 1009 1021 B-Procedure
in NCT03865277 1022 1024 O
the NCT03865277 1025 1028 O
head NCT03865277 1029 1033 B-Modifier
and NCT03865277 1034 1037 B-Or
neck NCT03865277 1038 1042 B-Modifier
region NCT03865277 1043 1049 O

- NCT03865277 1052 1053 O
Second NCT03865277 1055 1061 B-Eq-Comparison
malignancy NCT03865277 1062 1072 B-Condition
that NCT03865277 1073 1077 O
is NCT03865277 1078 1080 O
likely NCT03865277 1081 1087 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865277 1088 1090 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03865277 1091 1098 O
treatment NCT03865277 1099 1108 B-Procedure
during NCT03865277 1109 1115 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865277 1116 1119 O
trial NCT03865277 1120 1125 B-Study
intervention NCT03865277 1126 1138 I-Study
or NCT03865277 1139 1141 B-Or
follow NCT03865277 1142 1148 B-Encounter
- NCT03865277 1149 1150 I-Encounter
up NCT03865277 1151 1153 I-Encounter
period NCT03865277 1154 1160 O
or NCT03865277 1161 1163 O
that NCT03865277 1164 1168 O
, NCT03865277 1169 1170 O
in NCT03865277 1171 1173 O
the NCT03865277 1174 1177 O
opinion NCT03865277 1178 1185 O
of NCT03865277 1186 1188 O
the NCT03865277 1189 1192 O
physician NCT03865277 1193 1202 O
, NCT03865277 1203 1204 O
has NCT03865277 1205 1208 O
a NCT03865277 1209 1210 O
considerable NCT03865277 1211 1223 O
risk NCT03865277 1224 1228 B-Risk
of NCT03865277 1229 1231 O
recurrence NCT03865277 1232 1242 B-Modifier
or NCT03865277 1243 1245 B-Or
metastases NCT03865277 1246 1256 B-Condition
within NCT03865277 1257 1263 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865277 1264 1267 O
follow NCT03865277 1268 1274 B-Encounter
- NCT03865277 1275 1276 I-Encounter
up NCT03865277 1277 1279 I-Encounter
period NCT03865277 1280 1286 O

- NCT03865277 1289 1290 O
Serious NCT03865277 1292 1299 O
disease NCT03865277 1300 1307 B-Condition
or NCT03865277 1308 1310 B-Or
medical NCT03865277 1311 1318 B-Condition
condition NCT03865277 1319 1328 I-Condition
with NCT03865277 1329 1333 B-And
life NCT03865277 1334 1338 B-Observation
expectancy NCT03865277 1339 1349 I-Observation
of NCT03865277 1350 1352 O
less NCT03865277 1353 1357 B-Eq-Comparison
than NCT03865277 1358 1362 I-Eq-Comparison
one NCT03865277 1363 1366 I-Eq-Comparison
year NCT03865277 1367 1371 I-Eq-Comparison

- NCT03865277 1374 1375 O
Participation NCT03865277 1377 1390 O
in NCT03865277 1391 1393 B-Study
competing NCT03865277 1394 1403 B-Other
interventional NCT03865277 1404 1418 O
trial NCT03865277 1419 1424 I-Study
on NCT03865277 1425 1427 O
cancer NCT03865277 1428 1434 B-Condition
treatment NCT03865277 1435 1444 B-Procedure

- NCT03865277 1447 1448 O
Patients NCT03865277 1450 1458 O
who NCT03865277 1459 1462 O
are NCT03865277 1463 1466 O
not NCT03865277 1467 1470 B-Contraindication
suitable NCT03865277 1471 1479 I-Contraindication
for NCT03865277 1480 1483 O
radiochemotherapy NCT03865277 1484 1501 B-Procedure

- NCT03865277 1504 1505 O
Pregnant NCT03865277 1507 1515 B-Condition
or NCT03865277 1516 1518 B-Or
lactating NCT03865277 1519 1528 B-Condition
women NCT03865277 1529 1534 O

- NCT03865277 1537 1538 O
Patients NCT03865277 1540 1548 O
not NCT03865277 1549 1552 B-Negation
able NCT03865277 1553 1557 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865277 1558 1560 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03865277 1561 1571 O
the NCT03865277 1572 1575 O
character NCT03865277 1576 1585 O
and NCT03865277 1586 1589 O
individual NCT03865277 1590 1600 O
consequences NCT03865277 1601 1613 B-Risk
of NCT03865277 1614 1616 O
the NCT03865277 1617 1620 O
trial NCT03865277 1621 1626 B-Study

- NCT03865277 1629 1630 O
Nasopharyngeal NCT03865277 1632 1646 B-Condition
Carcinomas NCT03865277 1647 1657 I-Condition

Inclusion NCT03866018 0 9 O
Criteria NCT03866018 10 18 O
: NCT03866018 19 20 O

- NCT03866018 24 25 O
Male NCT03866018 27 31 O
or NCT03866018 32 34 B-Or
Female NCT03866018 35 41 O
≥ NCT03866018 42 43 B-Eq-Comparison
60 NCT03866018 44 46 I-Eq-Comparison
years NCT03866018 47 52 I-Eq-Comparison
old NCT03866018 53 56 B-Age

- NCT03866018 59 60 O
MMSE NCT03866018 62 66 B-Observation
score NCT03866018 67 72 O
between NCT03866018 73 80 B-Eq-Comparison
4 NCT03866018 81 82 I-Eq-Comparison
and NCT03866018 83 86 I-Eq-Comparison
26 NCT03866018 87 89 I-Eq-Comparison
/ NCT03866018 90 91 I-Eq-Comparison
30 NCT03866018 92 94 I-Eq-Comparison

- NCT03866018 98 99 O
Diagnosis NCT03866018 101 110 O
of NCT03866018 111 113 O
minor NCT03866018 114 119 B-Eq-Comparison
to NCT03866018 120 122 I-Eq-Comparison
major NCT03866018 123 128 I-Eq-Comparison
NeuroCognitive NCT03866018 129 143 B-Condition
Disorder NCT03866018 144 152 I-Condition
of NCT03866018 153 155 O
the NCT03866018 156 159 O
Alzheimer NCT03866018 160 169 B-Condition
type NCT03866018 170 174 O
or NCT03866018 175 177 B-Or
multiple NCT03866018 178 186 B-Eq-Comparison
etiology NCT03866018 187 195 B-Condition
; NCT03866018 195 196 O

- NCT03866018 199 200 O
Subject NCT03866018 202 209 O
without NCT03866018 210 217 B-Negation
a NCT03866018 218 219 O
major NCT03866018 220 225 O
hearing NCT03866018 226 233 B-Modifier
or NCT03866018 234 236 B-Or
visual NCT03866018 237 243 B-Modifier
impairment NCT03866018 244 254 B-Condition
; NCT03866018 254 255 O

- NCT03866018 258 259 O
Subject NCT03866018 261 268 O
not NCT03866018 269 272 B-Negation
presenting NCT03866018 273 283 O
any NCT03866018 284 287 O
contraindications NCT03866018 288 305 B-Contraindication
to NCT03866018 306 308 O
the NCT03866018 309 312 O
practice NCT03866018 313 321 O
of NCT03866018 322 324 O
adapted NCT03866018 325 332 O
physical NCT03866018 333 341 B-Observation
activity NCT03866018 342 350 I-Observation
; NCT03866018 350 351 O

- NCT03866018 354 355 O
Subject NCT03866018 357 364 O
affiliated NCT03866018 365 375 O
to NCT03866018 376 378 O
Social NCT03866018 379 385 O
Security NCT03866018 386 394 O
System NCT03866018 395 401 O
; NCT03866018 401 402 O

- NCT03866018 405 406 O
Signing NCT03866018 408 415 O
informed NCT03866018 416 424 O
consent NCT03866018 425 432 O

Exclusion NCT03866018 433 442 O
Criteria NCT03866018 443 451 O
: NCT03866018 452 453 O

- NCT03866018 457 458 O
< NCT03866018 460 461 B-Eq-Comparison
60 NCT03866018 462 464 I-Eq-Comparison
years NCT03866018 465 470 I-Age|Eq-Comparison

- NCT03866018 473 474 O
Medical NCT03866018 476 483 O
indications NCT03866018 484 495 O
: NCT03866018 496 497 O
Recent NCT03866018 498 504 B-Eq-Comparison
or NCT03866018 505 507 B-Or
unstable NCT03866018 508 516 O
cardiovascular NCT03866018 517 531 B-Condition
events NCT03866018 532 538 I-Condition
: NCT03866018 539 540 O
ECG NCT03866018 541 544 B-Procedure
changes NCT03866018 545 552 O
, NCT03866018 553 554 O
unstable NCT03866018 555 563 O
angina NCT03866018 564 570 B-Condition
, NCT03866018 571 572 O
uncontrolled NCT03866018 573 585 B-Modifier
arrhythmia NCT03866018 586 596 B-Condition
, NCT03866018 597 598 O
3 NCT03866018 599 600 B-Modifier
rd NCT03866018 601 603 O
degree NCT03866018 604 610 I-Modifier
BAV NCT03866018 611 614 B-Condition
, NCT03866018 615 616 O
acute NCT03866018 617 622 O
heart NCT03866018 623 628 B-Condition
failure NCT03866018 629 636 I-Condition
. NCT03866018 636 637 O

- NCT03866018 641 642 O
MMSE NCT03866018 644 648 B-Observation
score NCT03866018 649 654 B-Eq-Comparison
< NCT03866018 655 656 I-Eq-Comparison
4 NCT03866018 657 658 I-Eq-Comparison

- NCT03866018 662 663 O
Subject NCT03866018 665 672 O
already NCT03866018 673 680 B-Eq-Comparison
engaged NCT03866018 681 688 O
in NCT03866018 689 691 O
appropriate NCT03866018 692 703 O
physical NCT03866018 704 712 B-Observation
activity NCT03866018 713 721 I-Observation

- NCT03866018 724 725 O
Subject NCT03866018 727 734 O
with NCT03866018 735 739 O
a NCT03866018 740 741 O
perceptual NCT03866018 742 752 B-Condition
disorder NCT03866018 753 761 I-Condition
( NCT03866018 762 763 O
AMD NCT03866018 764 767 B-Condition
, NCT03866018 768 769 O
deafness NCT03866018 770 778 B-Condition
. NCT03866018 778 779 O
. NCT03866018 780 781 O
. NCT03866018 782 783 O
) NCT03866018 784 785 O

- NCT03866018 789 790 O
Subject NCT03866018 792 799 O
with NCT03866018 800 804 O
a NCT03866018 805 806 O
motor NCT03866018 807 812 B-Condition
disability NCT03866018 813 823 I-Condition

- NCT03866018 826 827 O
Subject NCT03866018 829 836 O
under NCT03866018 837 842 B-Observation
guardianship NCT03866018 843 855 I-Observation
, NCT03866018 856 857 O
curatorship NCT03866018 858 869 B-Observation
or NCT03866018 870 872 B-Or
safeguard NCT03866018 873 882 B-Observation
of NCT03866018 883 885 I-Observation
justice NCT03866018 886 893 I-Observation

- NCT03866018 896 897 O
Persons NCT03866018 899 906 O
deprived NCT03866018 907 915 B-Observation
of NCT03866018 916 918 I-Observation
their NCT03866018 919 924 I-Observation
liberty NCT03866018 925 932 I-Observation
( NCT03866018 933 934 O
administrative NCT03866018 935 949 B-Modifier
or NCT03866018 950 952 B-Or
judicial NCT03866018 953 961 B-Modifier
) NCT03866018 962 963 O

Inclusion NCT03867474 0 9 O
Criteria NCT03867474 10 18 O
: NCT03867474 19 20 O

- NCT03867474 24 25 O
Inclusion NCT03867474 27 36 O
criteria NCT03867474 37 45 O
for NCT03867474 46 49 O
study NCT03867474 50 55 O
participants NCT03867474 56 68 O
include NCT03867474 69 76 O
: NCT03867474 77 78 O
( NCT03867474 79 80 O
1 NCT03867474 81 82 O
) NCT03867474 83 84 O
age NCT03867474 85 88 B-Age
≥ NCT03867474 89 90 B-Eq-Comparison
60 NCT03867474 91 93 I-Eq-Comparison
years NCT03867474 94 99 I-Eq-Comparison
; NCT03867474 99 100 O
( NCT03867474 101 102 O
2 NCT03867474 103 104 O
) NCT03867474 105 106 O
English NCT03867474 107 114 O
fluency NCT03867474 115 122 O
; NCT03867474 122 123 O
( NCT03867474 124 125 O
3 NCT03867474 126 127 O
) NCT03867474 128 129 O
living NCT03867474 130 136 B-Observation
independently NCT03867474 137 150 I-Observation
in NCT03867474 151 153 O
the NCT03867474 154 157 O
community NCT03867474 158 167 O
; NCT03867474 167 168 O
( NCT03867474 169 170 O
4 NCT03867474 171 172 O
) NCT03867474 173 174 O
self NCT03867474 175 179 O
- NCT03867474 180 181 O
reported NCT03867474 182 190 O
demographic NCT03867474 191 202 O
information NCT03867474 203 214 O
that NCT03867474 215 219 O
includes NCT03867474 220 228 O
either NCT03867474 229 235 O
the NCT03867474 236 239 O
label NCT03867474 240 245 O
of NCT03867474 246 248 O
SCD NCT03867474 249 252 B-Condition
or NCT03867474 253 255 B-Or
MCI NCT03867474 256 259 B-Condition

Exclusion NCT03867474 260 269 O
Criteria NCT03867474 270 278 O
: NCT03867474 279 280 O

- NCT03867474 284 285 O
( NCT03867474 287 288 O
1 NCT03867474 289 290 O
) NCT03867474 291 292 O
history NCT03867474 293 300 B-Eq-Comparison
of NCT03867474 301 303 I-Eq-Comparison
prior NCT03867474 304 309 I-Eq-Comparison
participation NCT03867474 310 323 O
in NCT03867474 324 326 O
any NCT03867474 327 330 O
MBSR NCT03867474 331 335 B-Modifier
or NCT03867474 336 338 B-Or
other NCT03867474 339 344 B-Other
mindfulness NCT03867474 345 356 B-Modifier
- NCT03867474 357 358 I-Modifier
based NCT03867474 359 364 I-Modifier
interventions NCT03867474 365 378 B-Procedure
, NCT03867474 379 380 O
or NCT03867474 381 383 B-Or
participation NCT03867474 384 397 O
in NCT03867474 398 400 O
regular NCT03867474 401 408 O
( NCT03867474 409 410 O
weekly NCT03867474 411 417 B-Eq-Comparison
) NCT03867474 418 419 O
mindfulness NCT03867474 420 431 B-Modifier
or NCT03867474 432 434 B-Or
yoga NCT03867474 435 439 B-Modifier
practice NCT03867474 440 448 B-Observation
; NCT03867474 448 449 O
( NCT03867474 450 451 O
2 NCT03867474 452 453 O
) NCT03867474 454 455 O
low NCT03867474 456 459 O
mood NCT03867474 460 464 B-Condition
as NCT03867474 465 467 O
indicated NCT03867474 468 477 O
by NCT03867474 478 480 O
a NCT03867474 481 482 O
5 NCT03867474 483 484 B-Eq-Comparison
or NCT03867474 485 487 I-Eq-Comparison
greater NCT03867474 488 495 I-Eq-Comparison
on NCT03867474 496 498 O
the NCT03867474 499 502 O
Geriatric NCT03867474 503 512 B-Observation
Depression NCT03867474 513 523 I-Observation
Scale NCT03867474 524 529 I-Observation
( NCT03867474 530 531 O
GDS NCT03867474 532 535 B-Observation
) NCT03867474 536 537 O
( NCT03867474 538 539 O
3 NCT03867474 540 541 O
) NCT03867474 542 543 O
alcoholism NCT03867474 544 554 B-Condition
and NCT03867474 555 558 B-Or
/ NCT03867474 559 560 I-Or
or NCT03867474 561 563 I-Or
other NCT03867474 564 569 B-Other
substance NCT03867474 570 579 B-Condition
abuse NCT03867474 580 585 I-Condition
defined NCT03867474 586 593 O
in NCT03867474 594 596 O
the NCT03867474 597 600 O
Diagnostic NCT03867474 601 611 O
and NCT03867474 612 615 O
Statistical NCT03867474 616 627 O
Manual NCT03867474 628 634 O
of NCT03867474 635 637 O
Mental NCT03867474 638 644 O
Disorders NCT03867474 645 654 O
, NCT03867474 655 656 O
Fifth NCT03867474 657 662 O
Edition NCT03867474 663 670 O
( NCT03867474 671 672 O
DSM NCT03867474 673 676 O
- NCT03867474 677 678 O
V NCT03867474 679 680 O
) NCT03867474 681 682 O
( NCT03867474 683 684 O
American NCT03867474 685 693 O
Psychiatric NCT03867474 694 705 O
Association NCT03867474 706 717 O
, NCT03867474 718 719 O
2013 NCT03867474 720 724 O
; NCT03867474 725 726 O
Kiefer NCT03867474 727 733 O
, NCT03867474 734 735 O
Israel NCT03867474 736 742 O
, NCT03867474 743 744 O
& NCT03867474 745 746 O
Martino NCT03867474 747 754 O
, NCT03867474 755 756 O
2016 NCT03867474 757 761 O
) NCT03867474 762 763 O
; NCT03867474 764 765 O
( NCT03867474 766 767 O
4 NCT03867474 768 769 O
) NCT03867474 770 771 O
Montreal NCT03867474 772 780 B-Observation
Cognitive NCT03867474 781 790 I-Observation
Assessment NCT03867474 791 801 I-Observation
( NCT03867474 802 803 I-Eq-Comparison
MoCA NCT03867474 804 808 B-Observation
) NCT03867474 809 810 O
of NCT03867474 811 813 O
23 NCT03867474 814 816 B-Eq-Comparison
( NCT03867474 817 818 O
+ NCT03867474 820 821 O
/ NCT03867474 823 824 I-Eq-Comparison
- NCT03867474 826 827 I-Eq-Comparison
4 NCT03867474 828 829 I-Eq-Comparison
) NCT03867474 830 831 O
( NCT03867474 832 833 O
Clarnette NCT03867474 834 843 O
, NCT03867474 844 845 O
O'Caoimh NCT03867474 846 854 O
, NCT03867474 855 856 O
Antony NCT03867474 857 863 O
, NCT03867474 864 865 O
Svendrovski NCT03867474 866 877 O
, NCT03867474 878 879 O
& NCT03867474 880 881 O
Molloy NCT03867474 882 888 O
, NCT03867474 889 890 O
2017 NCT03867474 891 895 O
; NCT03867474 896 897 O
O'Caoimh NCT03867474 898 906 O
, NCT03867474 907 908 O
Timmons NCT03867474 909 916 O
, NCT03867474 917 918 O
& NCT03867474 919 920 O
Molloy NCT03867474 921 927 O
, NCT03867474 928 929 O
2016 NCT03867474 930 934 O
) NCT03867474 935 936 O
or NCT03867474 937 939 O
under NCT03867474 940 945 O
; NCT03867474 945 946 O
and NCT03867474 947 950 O
( NCT03867474 951 952 O
5 NCT03867474 953 954 O
) NCT03867474 955 956 O
if NCT03867474 957 959 O
participating NCT03867474 960 973 O
in NCT03867474 974 976 O
other NCT03867474 977 982 O
concurrent NCT03867474 983 993 B-Modifier
group NCT03867474 994 999 B-Procedure
( NCT03867474 1000 1001 O
s NCT03867474 1002 1003 O
) NCT03867474 1004 1005 O
e. NCT03867474 1006 1008 O
g. NCT03867474 1009 1011 O
cognitive NCT03867474 1013 1022 B-Procedure
behavioural NCT03867474 1023 1034 I-Procedure
therapy NCT03867474 1035 1042 I-Procedure
( NCT03867474 1043 1044 O
CBT NCT03867474 1045 1048 B-Procedure
) NCT03867474 1049 1050 O
or NCT03867474 1051 1053 B-Or
memory NCT03867474 1054 1060 B-Procedure
training NCT03867474 1061 1069 I-Procedure
programs NCT03867474 1070 1078 I-Procedure
in NCT03867474 1079 1081 O
the NCT03867474 1082 1085 O
community NCT03867474 1086 1095 O
, NCT03867474 1096 1097 O
while NCT03867474 1098 1103 B-Temporal-Connection___Temporal-Connection-Type-Value:during
in NCT03867474 1104 1106 O
the NCT03867474 1107 1110 O
study NCT03867474 1111 1116 B-Study
. NCT03867474 1116 1117 O


Inclusion NCT03864380 0 9 O
Criteria NCT03864380 10 18 O
: NCT03864380 19 20 O

- NCT03864380 24 25 O
Person NCT03864380 27 33 O
registered NCT03864380 34 44 O
at NCT03864380 45 47 O
the NCT03864380 48 51 O
2019 NCT03864380 52 56 O
Paris NCT03864380 57 62 O
Marathon NCT03864380 63 71 O

Exclusion NCT03864380 72 81 O
Criteria NCT03864380 82 90 O
: NCT03864380 91 92 O

- NCT03864380 96 97 O
Ophthalmological NCT03864380 99 115 B-Condition
disorders NCT03864380 116 125 I-Condition
making NCT03864380 126 132 O
access NCT03864380 133 139 B-Observation
to NCT03864380 140 142 O
the NCT03864380 143 146 O
fundus NCT03864380 147 153 B-Modifier
impossible NCT03864380 154 164 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03864380 165 168 O
both NCT03864380 169 173 B-Modifier
eyes NCT03864380 174 178 I-Modifier

Inclusion NCT03860870 0 9 O
Criteria NCT03860870 10 18 O
: NCT03860870 19 20 O

- NCT03860870 24 25 O
Healthy NCT03860870 27 34 B-Condition

- NCT03860870 37 38 O
Male NCT03860870 40 44 O

- NCT03860870 47 48 O
18 NCT03860870 50 52 B-Eq-Comparison
- NCT03860870 53 54 I-Eq-Comparison
40 NCT03860870 55 57 I-Eq-Comparison
years NCT03860870 58 63 I-Eq-Comparison
of NCT03860870 64 66 O
age NCT03860870 67 70 B-Age

- NCT03860870 73 74 O
No NCT03860870 76 78 B-Negation
known NCT03860870 79 84 O
contraindications NCT03860870 85 102 B-Contraindication
for NCT03860870 103 106 O
anabolic NCT03860870 107 115 B-Drug
drugs NCT03860870 116 121 I-Drug
( NCT03860870 122 123 O
e. NCT03860870 124 126 O
g. NCT03860870 127 129 O
cancer NCT03860870 131 137 B-Condition
) NCT03860870 138 139 O

Exclusion NCT03860870 141 150 O
Criteria NCT03860870 151 159 O
: NCT03860870 160 161 O

- NCT03860870 165 166 O
Abnormal NCT03860870 168 176 O
ECG NCT03860870 177 180 B-Procedure

- NCT03860870 183 184 O
Steroid NCT03860870 186 193 B-Condition
abuse NCT03860870 194 199 I-Condition

- NCT03860870 202 203 O
Ongoing NCT03860870 205 212 B-Eq-Comparison
use NCT03860870 213 216 O
of NCT03860870 217 219 O
prescription NCT03860870 220 232 B-Drug
medication NCT03860870 233 243 I-Drug

- NCT03860870 246 247 O
heavy NCT03860870 249 254 O
resistance NCT03860870 255 265 B-Observation
training NCT03860870 266 274 I-Observation
more NCT03860870 275 279 B-Eq-Comparison
than NCT03860870 280 284 I-Eq-Comparison
2 NCT03860870 285 286 I-Eq-Comparison
times NCT03860870 287 292 I-Eq-Comparison
weekly NCT03860870 293 299 I-Eq-Comparison

- NCT03860870 302 303 O
Disease NCT03860870 305 312 B-Condition
deemed NCT03860870 313 319 O
by NCT03860870 320 322 O
the NCT03860870 323 326 O
MD NCT03860870 327 329 O
to NCT03860870 330 332 O
infer NCT03860870 333 338 O
a NCT03860870 339 340 O
risk NCT03860870 341 345 B-Risk
to NCT03860870 346 348 O
participate NCT03860870 349 360 O
in NCT03860870 361 363 O
the NCT03860870 364 367 O
trial NCT03860870 368 373 B-Study

Inclusion NCT03868592 0 9 O
Criteria NCT03868592 10 18 O
: NCT03868592 19 20 O

- NCT03868592 24 25 O
BMI NCT03868592 27 30 B-Observation
40 NCT03868592 31 33 B-Eq-Comparison
- NCT03868592 34 35 I-Eq-Comparison
50 NCT03868592 36 38 I-Eq-Comparison
kg NCT03868592 39 41 I-Eq-Comparison
/ NCT03868592 42 43 I-Eq-Comparison
m2 NCT03868592 44 46 I-Eq-Comparison
. NCT03868592 46 47 O

- NCT03868592 51 52 O
Mo NCT03868592 54 56 O
active NCT03868592 57 63 B-Eq-Comparison
physical NCT03868592 64 72 B-Condition
illness NCT03868592 73 80 I-Condition
that NCT03868592 81 85 O
would NCT03868592 86 91 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03868592 92 101 O
with NCT03868592 102 106 O
mobility NCT03868592 107 115 B-Condition
or NCT03868592 116 118 B-Or
weight NCT03868592 119 125 B-Condition
loss NCT03868592 126 130 I-Condition
after NCT03868592 131 136 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bariatric NCT03868592 137 146 B-Procedure
surgery NCT03868592 147 154 I-Procedure

Exclusion NCT03868592 155 164 O
Criteria NCT03868592 165 173 O
: NCT03868592 174 175 O

- NCT03868592 179 180 O
Type NCT03868592 182 186 B-Modifier
1 NCT03868592 187 188 I-Modifier
or NCT03868592 189 191 B-Or
Type NCT03868592 192 196 B-Modifier
2 NCT03868592 197 198 I-Modifier
Diabetes NCT03868592 199 207 B-Condition
diagnosis NCT03868592 208 217 O
or NCT03868592 218 220 B-Or
fasting NCT03868592 221 228 B-Modifier
plasma NCT03868592 229 235 B-Observation
glucose NCT03868592 236 243 I-Observation
≥ NCT03868592 244 245 B-Eq-Comparison
126 NCT03868592 246 249 I-Eq-Comparison
mg NCT03868592 250 252 I-Eq-Comparison
/ NCT03868592 253 254 I-Eq-Comparison
dL NCT03868592 255 257 I-Eq-Comparison

- NCT03868592 260 261 O
Active NCT03868592 263 269 B-Eq-Comparison
coronary NCT03868592 270 278 B-Condition
artery NCT03868592 279 285 I-Condition
disease NCT03868592 286 293 I-Condition

- NCT03868592 296 297 O
Participation NCT03868592 299 312 O
in NCT03868592 313 315 O
structured NCT03868592 316 326 B-Observation
exercise NCT03868592 327 335 I-Observation
( NCT03868592 336 337 O
> NCT03868592 339 340 B-Eq-Comparison
2 NCT03868592 341 342 I-Eq-Comparison
times NCT03868592 343 348 I-Eq-Comparison
per NCT03868592 349 352 I-Eq-Comparison
week NCT03868592 353 357 I-Eq-Comparison
for NCT03868592 358 361 O
30 NCT03868592 362 364 B-Eq-Comparison
minutes NCT03868592 365 372 I-Eq-Comparison
or NCT03868592 373 375 I-Eq-Comparison
longer NCT03868592 376 382 I-Eq-Comparison
) NCT03868592 383 384 O

- NCT03868592 388 389 O
Smoking NCT03868592 391 398 B-Condition

- NCT03868592 401 402 O
Medications NCT03868592 404 415 B-Drug
known NCT03868592 416 421 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868592 422 424 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03868592 425 431 O
adipose NCT03868592 432 439 B-Condition
tissue NCT03868592 440 446 I-Condition
metabolism NCT03868592 447 457 I-Condition
( NCT03868592 458 459 O
e. NCT03868592 460 462 O
g. NCT03868592 463 465 O
, NCT03868592 466 467 O
beta NCT03868592 468 472 B-Drug
blockers NCT03868592 473 481 I-Drug
, NCT03868592 482 483 O
corticosteroids NCT03868592 484 499 B-Drug
) NCT03868592 500 501 O

- NCT03868592 505 506 O
Renal NCT03868592 508 513 B-Condition
insufficiency NCT03868592 514 527 I-Condition
( NCT03868592 528 529 O
serum NCT03868592 530 535 B-Observation
creatinine NCT03868592 536 546 I-Observation
> NCT03868592 547 548 B-Eq-Comparison
1.5 NCT03868592 549 552 I-Eq-Comparison
mg NCT03868592 553 555 O
/ NCT03868592 556 557 I-Eq-Comparison
dl NCT03868592 558 560 I-Eq-Comparison
) NCT03868592 561 562 O

- NCT03868592 566 567 O
Chronic NCT03868592 569 576 B-Modifier
active NCT03868592 577 583 B-Eq-Comparison
liver NCT03868592 584 589 B-Condition
disease NCT03868592 590 597 I-Condition
( NCT03868592 598 599 O
Bilirubin NCT03868592 600 609 B-Observation
> NCT03868592 610 611 B-Eq-Comparison|Eq-Comparison
17 NCT03868592 612 614 I-Eq-Comparison
mmol NCT03868592 615 619 O
/ NCT03868592 620 621 I-Eq-Comparison|Eq-Comparison|Eq-Comparison
L NCT03868592 622 623 I-Eq-Comparison|Eq-Comparison|Eq-Comparison
, NCT03868592 624 625 O
AST NCT03868592 626 629 B-Observation
> NCT03868592 630 631 B-Eq-Comparison
144 NCT03868592 632 635 I-Eq-Comparison
IU NCT03868592 636 638 I-Eq-Comparison
/ NCT03868592 639 640 O
L NCT03868592 641 642 O
, NCT03868592 643 644 O
or NCT03868592 645 647 B-Or|Or
ALT NCT03868592 648 651 B-Observation
> NCT03868592 652 653 O
165 NCT03868592 654 657 I-Eq-Comparison
IU NCT03868592 658 660 O
/ NCT03868592 661 662 O
L NCT03868592 663 664 O
) NCT03868592 665 666 O

- NCT03868592 670 671 O
Pregnancy NCT03868592 673 682 B-Condition
or NCT03868592 683 685 O
breastfeeding NCT03868592 686 699 B-Condition
. NCT03868592 699 700 O

Inclusion NCT03866226 0 9 O
Criteria NCT03866226 10 18 O
: NCT03866226 19 20 O

1 NCT03866226 24 25 O
. NCT03866226 25 26 O
Signed NCT03866226 28 34 O
written NCT03866226 35 42 O
informed NCT03866226 43 51 O
consent NCT03866226 52 59 O

2 NCT03866226 62 63 O
. NCT03866226 63 64 O
Age NCT03866226 66 69 B-Age
18 NCT03866226 70 72 B-Eq-Comparison
- NCT03866226 73 74 I-Eq-Comparison
80 NCT03866226 75 77 I-Eq-Comparison
years NCT03866226 78 83 I-Eq-Comparison

3 NCT03866226 86 87 O
. NCT03866226 87 88 O
Capable NCT03866226 90 97 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866226 98 100 I-Assertion___Assertion-Type-Value:hypothetical
understanding NCT03866226 101 114 O
the NCT03866226 115 118 O
test NCT03866226 119 123 B-Procedure
and NCT03866226 124 127 B-And
cooperating NCT03866226 128 139 O
with NCT03866226 140 144 O
the NCT03866226 145 148 O
questionnaire NCT03866226 149 162 B-Observation
. NCT03866226 162 163 O

Exclusion NCT03866226 165 174 O
Criteria NCT03866226 175 183 O
: NCT03866226 184 185 O

1 NCT03866226 189 190 O
. NCT03866226 190 191 O
History NCT03866226 193 200 B-Eq-Comparison
of NCT03866226 201 203 O
psychosis NCT03866226 204 213 B-Condition
, NCT03866226 214 215 O
including NCT03866226 216 225 O
schizophrenia NCT03866226 226 239 B-Condition
, NCT03866226 240 241 O
bipolar NCT03866226 242 249 B-Condition
disorder NCT03866226 250 258 I-Condition
, NCT03866226 259 260 O
depression NCT03866226 261 271 B-Condition
, NCT03866226 272 273 O
anxiety NCT03866226 274 281 B-Condition
, NCT03866226 282 283 O
obsessive NCT03866226 284 293 B-Condition
- NCT03866226 294 295 I-Condition
compulsive NCT03866226 296 306 I-Condition
disorder NCT03866226 307 315 I-Condition
, NCT03866226 316 317 O
phobia NCT03866226 318 324 B-Condition
, NCT03866226 325 326 O
somatoform NCT03866226 327 337 B-Condition
disorder NCT03866226 338 346 I-Condition
, NCT03866226 347 348 O
stress NCT03866226 349 355 B-Condition
- NCT03866226 356 357 I-Condition
related NCT03866226 358 365 I-Condition
disorders NCT03866226 366 375 I-Condition

2 NCT03866226 378 379 O
. NCT03866226 379 380 O
History NCT03866226 382 389 B-Eq-Comparison
of NCT03866226 390 392 O
insomnia NCT03866226 393 401 B-Condition
, NCT03866226 402 403 O
currently NCT03866226 404 413 B-Eq-Comparison
with NCT03866226 414 418 O
medication NCT03866226 419 429 B-Drug

3 NCT03866226 432 433 O
. NCT03866226 433 434 O
History NCT03866226 436 443 B-Eq-Comparison
of NCT03866226 444 446 O
obstructive NCT03866226 447 458 B-Condition
sleep NCT03866226 459 464 I-Condition
apnea NCT03866226 465 470 I-Condition
( NCT03866226 471 472 O
OSA NCT03866226 473 476 B-Condition
) NCT03866226 477 478 O

4 NCT03866226 482 483 O
. NCT03866226 483 484 O
History NCT03866226 486 493 B-Eq-Comparison
of NCT03866226 494 496 O
other NCT03866226 497 502 B-Other
sleep NCT03866226 503 508 B-Condition
disorders NCT03866226 509 518 I-Condition
, NCT03866226 519 520 O
including NCT03866226 521 530 O
narcolepsy NCT03866226 531 541 B-Condition
/ NCT03866226 542 543 B-Or
hypersomnias NCT03866226 544 556 B-Condition
, NCT03866226 557 558 O
circadian NCT03866226 559 568 B-Condition
rhythm NCT03866226 569 575 I-Condition
sleep NCT03866226 576 581 I-Condition|Modifier
disorder NCT03866226 582 590 I-Condition
, NCT03866226 591 592 O
parasomnias NCT03866226 593 604 B-Condition
, NCT03866226 605 606 O
sleep NCT03866226 607 612 O
- NCT03866226 613 614 I-Modifier
related NCT03866226 615 622 I-Modifier
dyskinesia NCT03866226 623 633 B-Condition

5 NCT03866226 636 637 O
. NCT03866226 637 638 O
History NCT03866226 640 647 B-Eq-Comparison
of NCT03866226 648 650 O
heart NCT03866226 651 656 B-Condition|Condition
failure NCT03866226 657 664 I-Condition
, NCT03866226 665 666 O
that NCT03866226 667 671 O
is NCT03866226 672 674 O
New NCT03866226 675 678 B-Condition
York NCT03866226 679 683 I-Condition
heart NCT03866226 684 689 O
association NCT03866226 690 701 I-Condition
( NCT03866226 702 703 O
NYHA NCT03866226 704 708 B-Condition
) NCT03866226 709 710 O
Class NCT03866226 711 716 B-Eq-Comparison
Ⅲ NCT03866226 717 718 I-Eq-Comparison
- NCT03866226 719 720 I-Eq-Comparison
Ⅳ NCT03866226 721 722 I-Eq-Comparison

6 NCT03866226 725 726 O
. NCT03866226 726 727 O
History NCT03866226 729 736 B-Eq-Comparison
of NCT03866226 737 739 O
atrial NCT03866226 740 746 B-Condition|Modifier
fibrillation NCT03866226 747 759 I-Condition
and NCT03866226 760 763 B-Or
frequent NCT03866226 764 772 O
atrial NCT03866226 773 779 O
or NCT03866226 780 782 B-Or
ventricular NCT03866226 783 794 B-Modifier
extrasystoles NCT03866226 795 808 B-Condition

7 NCT03866226 811 812 O
. NCT03866226 812 813 O
Ongoing NCT03866226 815 822 B-Eq-Comparison
substance NCT03866226 823 832 B-Modifier
or NCT03866226 833 835 B-Or
alcohol NCT03866226 836 843 B-Modifier
abuse NCT03866226 844 849 B-Condition

8 NCT03866226 852 853 O
. NCT03866226 853 854 O
Currently NCT03866226 856 865 B-Eq-Comparison
receiving NCT03866226 866 875 I-Eq-Comparison
sedative NCT03866226 876 884 B-Drug
hypnotic NCT03866226 885 893 I-Drug
medication NCT03866226 894 904 I-Drug
within NCT03866226 905 911 B-Eq-Comparison
1 NCT03866226 912 913 I-Eq-Comparison
week NCT03866226 914 918 I-Eq-Comparison

9 NCT03866226 921 922 O
. NCT03866226 922 923 O
Pregnant NCT03866226 925 933 B-Condition
women NCT03866226 934 939 O

10 NCT03866226 941 943 O
. NCT03866226 943 944 O
Ongoing NCT03866226 946 953 B-Eq-Comparison
involvement NCT03866226 954 965 O
in NCT03866226 966 968 O
night NCT03866226 969 974 B-Observation
- NCT03866226 975 976 I-Eq-Comparison|Observation
shift NCT03866226 977 982 I-Observation
work NCT03866226 983 987 I-Observation
( NCT03866226 988 989 O
22 NCT03866226 990 992 B-Eq-Comparison
: NCT03866226 993 994 O
00 NCT03866226 995 997 O
- NCT03866226 998 999 O
6 NCT03866226 1000 1001 I-Eq-Comparison
: NCT03866226 1002 1003 O
00 NCT03866226 1004 1006 O
) NCT03866226 1007 1008 O
within NCT03866226 1009 1015 B-Eq-Comparison
1 NCT03866226 1016 1017 I-Eq-Comparison
week NCT03866226 1018 1022 I-Eq-Comparison

11 NCT03866226 1024 1026 O
. NCT03866226 1026 1027 O
Ongoing NCT03866226 1029 1036 O
need NCT03866226 1037 1041 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866226 1042 1044 I-Assertion___Assertion-Type-Value:hypothetical
care NCT03866226 1045 1049 B-Procedure
of NCT03866226 1050 1052 O
families NCT03866226 1053 1061 B-Family-Member
at NCT03866226 1062 1064 I-Family-Member
home NCT03866226 1065 1069 I-Family-Member
that NCT03866226 1070 1074 O
wake NCT03866226 1075 1079 B-Condition
during NCT03866226 1080 1086 I-Condition
the NCT03866226 1087 1090 I-Condition
night NCT03866226 1091 1096 I-Condition
within NCT03866226 1097 1103 B-Eq-Comparison
1 NCT03866226 1104 1105 I-Eq-Comparison
week NCT03866226 1106 1110 I-Eq-Comparison

12 NCT03866226 1112 1114 O
. NCT03866226 1114 1115 O
Incomprehensible NCT03866226 1117 1133 O
or NCT03866226 1134 1136 O
unwilling NCT03866226 1137 1146 O
to NCT03866226 1147 1149 O
fill NCT03866226 1150 1154 O
in NCT03866226 1155 1157 O
informed NCT03866226 1158 1166 O
consent NCT03866226 1167 1174 O
or NCT03866226 1175 1177 O
questionnaire NCT03866226 1178 1191 O

Inclusion NCT03868579 0 9 O
Criteria NCT03868579 10 18 O
: NCT03868579 19 20 O

- NCT03868579 24 25 O
Patients NCT03868579 27 35 O
who NCT03868579 36 39 O
will NCT03868579 40 44 B-Eq-Comparison
undergo NCT03868579 45 52 I-Eq-Comparison
pleuroscopy NCT03868579 53 64 B-Procedure
with NCT03868579 65 69 O
biopsy NCT03868579 70 76 B-Procedure

Exclusion NCT03868579 77 86 O
Criteria NCT03868579 87 95 O
: NCT03868579 96 97 O

- NCT03868579 101 102 O
Patients NCT03868579 104 112 O
with NCT03868579 113 117 O
known NCT03868579 118 123 O
malignant NCT03868579 124 133 B-Modifier
pleural NCT03868579 134 141 B-Condition
effusion NCT03868579 142 150 I-Condition

- NCT03868579 153 154 O
Inability NCT03868579 156 165 O
or NCT03868579 166 168 O
unwillingness NCT03868579 169 182 O
to NCT03868579 183 185 O
give NCT03868579 186 190 O
informed NCT03868579 191 199 O
consent NCT03868579 200 207 O

Resident NCT03861429 0 8 O
Inclusion NCT03861429 9 18 O
Criteria NCT03861429 19 27 O
: NCT03861429 28 29 O

- NCT03861429 33 34 O
Identified NCT03861429 36 46 O
as NCT03861429 47 49 O
having NCT03861429 50 56 O
Alzheimer NCT03861429 57 66 B-Condition
's NCT03861429 66 68 O
or NCT03861429 69 71 B-Or
related NCT03861429 72 79 O
dementia NCT03861429 80 88 B-Condition

- NCT03861429 91 92 O
Mild NCT03861429 94 98 B-Eq-Comparison
to NCT03861429 99 101 I-Eq-Comparison
moderate NCT03861429 102 110 I-Eq-Comparison
cognitive NCT03861429 111 120 B-Condition
impairment NCT03861429 121 131 I-Condition
( NCT03861429 132 133 O
BIMS NCT03861429 134 138 B-Observation
= NCT03861429 139 140 B-Eq-Comparison
8 NCT03861429 141 142 I-Eq-Comparison
- NCT03861429 143 144 I-Eq-Comparison
15 NCT03861429 145 147 O
, NCT03861429 148 149 O
( NCT03861429 150 151 O
MDS NCT03861429 152 155 O
C0500 NCT03861429 156 161 O
) NCT03861429 162 163 O
( NCT03861429 164 165 O
nursing NCT03861429 166 173 O
home NCT03861429 174 178 O
residents NCT03861429 179 188 O
only NCT03861429 189 193 O
) NCT03861429 194 195 O

- NCT03861429 199 200 O
Makes NCT03861429 202 207 B-Observation
Self NCT03861429 208 212 I-Observation
Understood NCT03861429 213 223 I-Observation
= NCT03861429 224 225 B-Eq-Comparison
< NCT03861429 226 227 I-Eq-Comparison
1 NCT03861429 228 229 I-Eq-Comparison
( NCT03861429 230 231 O
MDS NCT03861429 232 235 O
B0700 NCT03861429 236 241 O
) NCT03861429 242 243 O
/ NCT03861429 245 246 O
present NCT03861429 247 254 O
in NCT03861429 255 257 O
medical NCT03861429 258 265 O
record NCT03861429 266 272 O

- NCT03861429 275 276 O
Understood NCT03861429 278 288 B-Observation
By NCT03861429 289 291 I-Observation
Others NCT03861429 292 298 I-Observation
= NCT03861429 299 300 B-Eq-Comparison
< NCT03861429 301 302 I-Eq-Comparison
1 NCT03861429 303 304 I-Eq-Comparison
( NCT03861429 305 306 O
MDS NCT03861429 307 310 O
B0800 NCT03861429 311 316 O
) NCT03861429 317 318 O
/ NCT03861429 320 321 O
present NCT03861429 322 329 O
in NCT03861429 330 332 O
medical NCT03861429 333 340 O
record NCT03861429 341 347 O

- NCT03861429 350 351 O
Reside NCT03861429 353 359 B-Encounter
at NCT03861429 360 362 B-Eq-Comparison
the NCT03861429 363 366 O
facility NCT03861429 367 375 O
at NCT03861429 376 378 O
least NCT03861429 379 384 I-Eq-Comparison
2 NCT03861429 385 386 I-Eq-Comparison
weeks NCT03861429 387 392 I-Eq-Comparison
identified NCT03861429 393 403 O
as NCT03861429 404 406 O
a NCT03861429 407 408 O
long NCT03861429 409 413 B-Observation
- NCT03861429 414 415 I-Observation
term NCT03861429 416 420 I-Observation
resident NCT03861429 421 429 I-Observation

- NCT03861429 432 433 O
Age NCT03861429 435 438 B-Age
> NCT03861429 439 440 B-Eq-Comparison
65 NCT03861429 441 443 I-Eq-Comparison
years NCT03861429 444 449 I-Eq-Comparison

- NCT03861429 452 453 O
Speaks NCT03861429 455 461 O
English NCT03861429 462 469 O

Family NCT03861429 470 476 O
Inclusion NCT03861429 477 486 O
Criteria NCT03861429 487 495 O
: NCT03861429 496 497 O

- NCT03861429 501 502 O
Speaks NCT03861429 504 510 O
English NCT03861429 511 518 O

- NCT03861429 521 522 O
Willing NCT03861429 524 531 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03861429 532 535 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03861429 536 540 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 541 543 I-Assertion___Assertion-Type-Value:hypothetical
watch NCT03861429 544 549 O
the NCT03861429 550 553 O
videos NCT03861429 554 560 O

- NCT03861429 563 564 O
Willing NCT03861429 566 573 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 574 576 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03861429 577 585 O
short NCT03861429 586 591 B-Observation
surveys NCT03861429 592 599 I-Observation
. NCT03861429 599 600 O
Being NCT03861429 602 607 O
unable NCT03861429 608 614 O
to NCT03861429 615 617 O
attend NCT03861429 618 624 O
care NCT03861429 625 629 O
conference NCT03861429 630 640 O
to NCT03861429 641 643 O
view NCT03861429 644 648 O
the NCT03861429 649 652 O
video NCT03861429 653 658 O
( NCT03861429 659 660 O
e. NCT03861429 661 663 O
g. NCT03861429 664 666 O
due NCT03861429 668 671 O
to NCT03861429 672 674 O
distance NCT03861429 675 683 O
) NCT03861429 684 685 O
will NCT03861429 686 690 O
not NCT03861429 691 694 O
exclude NCT03861429 695 702 O
family NCT03861429 703 709 O
from NCT03861429 710 714 O
participating NCT03861429 715 728 O
. NCT03861429 728 729 O

Staff NCT03861429 731 736 O
Inclusion NCT03861429 737 746 O
Criteria NCT03861429 747 755 O
: NCT03861429 756 757 O

- NCT03861429 761 762 O
Speaks NCT03861429 764 770 O
English NCT03861429 771 778 O

- NCT03861429 781 782 O
Willing NCT03861429 784 791 B-Assertion___Assertion-Type-Value:hypothetical|Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 792 794 I-Assertion___Assertion-Type-Value:hypothetical|Assertion___Assertion-Type-Value:hypothetical
watch NCT03861429 795 800 O
the NCT03861429 801 804 O
videos NCT03861429 805 811 O

- NCT03861429 814 815 O
Willing NCT03861429 817 824 O
to NCT03861429 825 827 O
complete NCT03861429 828 836 O
short NCT03861429 837 842 O
surveys NCT03861429 843 850 O

Resident NCT03861429 851 859 O
Exclusion NCT03861429 860 869 O
Criteria NCT03861429 870 878 O
: NCT03861429 879 880 O

- NCT03861429 884 885 O
Limited NCT03861429 887 894 O
communication NCT03861429 895 908 B-Condition
capacity NCT03861429 909 917 I-Condition
( NCT03861429 918 919 O
e. NCT03861429 920 922 O
g. NCT03861429 923 925 O
aphasia NCT03861429 927 934 B-Condition
) NCT03861429 935 936 O

- NCT03861429 940 941 O
Comatose NCT03861429 943 951 B-Condition

- NCT03861429 954 955 O
Cognitively NCT03861429 957 968 B-Condition
intact NCT03861429 969 975 I-Condition

- NCT03861429 978 979 O
Severe NCT03861429 981 987 O
cognitive NCT03861429 988 997 B-Condition
impairment NCT03861429 998 1008 I-Condition

Inclusion NCT03867058 0 9 O
Criteria NCT03867058 10 18 O
: NCT03867058 19 20 O

- NCT03867058 24 25 O
Native NCT03867058 27 33 O
speakers NCT03867058 34 42 O
of NCT03867058 43 45 O
English NCT03867058 46 53 O

- NCT03867058 56 57 O
Cochlear NCT03867058 59 67 B-Procedure
Nucleus NCT03867058 68 75 I-Procedure
cochlear NCT03867058 76 84 I-Procedure
implant NCT03867058 85 92 I-Procedure
users NCT03867058 93 98 O
or NCT03867058 99 101 B-Or
Advanced NCT03867058 102 110 B-Procedure
Bionics NCT03867058 111 118 I-Procedure
users NCT03867058 119 124 O

- NCT03867058 127 128 O
Postlingually NCT03867058 130 143 B-Modifier
deafened NCT03867058 144 152 B-Condition

- NCT03867058 155 156 O
Has NCT03867058 158 161 O
had NCT03867058 162 165 O
device NCT03867058 166 172 B-Procedure
experience NCT03867058 173 183 O
for NCT03867058 184 187 O
at NCT03867058 188 190 B-Eq-Comparison
least NCT03867058 191 196 I-Eq-Comparison
one NCT03867058 197 200 I-Eq-Comparison
year NCT03867058 201 205 I-Eq-Comparison

- NCT03867058 208 209 O
Can NCT03867058 211 214 O
be NCT03867058 215 217 O
child NCT03867058 218 223 O
or NCT03867058 224 226 B-Or
adult NCT03867058 227 232 O
at NCT03867058 233 235 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867058 236 239 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867058 240 244 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867058 245 247 O
enrollment NCT03867058 248 258 B-Study

Exclusion NCT03867058 259 268 O
Criteria NCT03867058 269 277 O
: NCT03867058 278 279 O

- NCT03867058 283 284 O
None NCT03867058 286 290 O

Inclusion NCT03868800 0 9 O
Criteria NCT03868800 10 18 O
: NCT03868800 19 20 O

- NCT03868800 24 25 O
Estimated NCT03868800 27 36 B-Observation
glomerular NCT03868800 37 47 I-Observation
filtration NCT03868800 48 58 I-Observation
rate NCT03868800 59 63 I-Observation
below NCT03868800 64 69 B-Eq-Comparison
20 NCT03868800 70 72 I-Eq-Comparison
ml NCT03868800 73 75 I-Eq-Comparison
/ NCT03868800 76 77 I-Eq-Comparison
min NCT03868800 78 81 I-Eq-Comparison

- NCT03868800 84 85 O
A NCT03868800 87 88 O
clinical NCT03868800 89 97 O
judgement NCT03868800 98 107 O
made NCT03868800 108 112 O
by NCT03868800 113 115 O
the NCT03868800 116 119 O
contact NCT03868800 120 127 O
nurse NCT03868800 128 133 O
and NCT03868800 134 137 O
the NCT03868800 138 141 O
contact NCT03868800 142 149 O
physician NCT03868800 150 159 O

Exclusion NCT03868800 160 169 O
Criteria NCT03868800 170 178 O
: NCT03868800 179 180 O

- NCT03868800 184 185 O
Conservative NCT03868800 187 199 B-Procedure
care NCT03868800 200 204 I-Procedure

- NCT03868800 207 208 O
A NCT03868800 210 211 O
set NCT03868800 212 215 B-Eq-Comparison
date NCT03868800 216 220 I-Eq-Comparison
for NCT03868800 221 224 O
a NCT03868800 225 226 O
transplantation NCT03868800 227 242 B-Procedure
with NCT03868800 243 247 O
a NCT03868800 248 249 O
living NCT03868800 250 256 B-Modifier
donor NCT03868800 257 262 I-Modifier

- NCT03868800 265 266 O
Not NCT03868800 268 271 B-Negation
able NCT03868800 272 276 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868800 277 279 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868800 280 291 B-Study
due NCT03868800 292 295 O
to NCT03868800 296 298 O
cognitive NCT03868800 299 308 B-Condition
impairment NCT03868800 309 319 I-Condition

Inclusion NCT03866811 0 9 O
Criteria NCT03866811 10 18 O
: NCT03866811 19 20 O

- NCT03866811 24 25 O
female NCT03866811 27 33 O
emergency NCT03866811 34 43 B-Encounter
department NCT03866811 44 54 I-Encounter
patient NCT03866811 55 62 O

- NCT03866811 65 66 O
age NCT03866811 68 71 B-Age
14 NCT03866811 72 74 B-Eq-Comparison
- NCT03866811 75 76 I-Eq-Comparison
19 NCT03866811 77 79 I-Eq-Comparison
years NCT03866811 80 85 I-Eq-Comparison

- NCT03866811 88 89 O
sexually NCT03866811 91 99 B-Condition
active NCT03866811 100 106 I-Condition
with NCT03866811 107 111 B-Modifier
males NCT03866811 112 117 I-Modifier
in NCT03866811 118 120 O
the NCT03866811 121 124 O
past NCT03866811 125 129 B-Eq-Comparison
3 NCT03866811 130 131 I-Eq-Comparison
months NCT03866811 132 138 I-Eq-Comparison

Exclusion NCT03866811 139 148 O
Criteria NCT03866811 149 157 O
: NCT03866811 158 159 O

- NCT03866811 163 164 O
currently NCT03866811 166 175 B-Eq-Comparison
using NCT03866811 176 181 I-Eq-Comparison
any NCT03866811 182 185 O
effective NCT03866811 186 195 O
form NCT03866811 196 200 O
of NCT03866811 201 203 O
contraception NCT03866811 204 217 B-Procedure

- NCT03866811 220 221 O
do NCT03866811 223 225 O
not NCT03866811 226 229 O
own NCT03866811 230 233 O
a NCT03866811 234 235 O
mobile NCT03866811 236 242 O
phone NCT03866811 243 248 O
with NCT03866811 249 253 O
texting NCT03866811 254 261 O

- NCT03866811 264 265 O
are NCT03866811 267 270 B-Eq-Comparison
pregnant NCT03866811 271 279 B-Condition

- NCT03866811 282 283 O
are NCT03866811 285 288 B-Eq-Comparison
too NCT03866811 289 292 O
ill NCT03866811 293 296 B-Condition
for NCT03866811 297 300 O
participation NCT03866811 301 314 O
per NCT03866811 315 318 O
the NCT03866811 319 322 O
attending NCT03866811 323 332 B-Provider
physician NCT03866811 333 342 I-Provider

- NCT03866811 345 346 O
are NCT03866811 348 351 B-Eq-Comparison
cognitively NCT03866811 352 363 B-Condition
impaired NCT03866811 364 372 I-Condition

- NCT03866811 375 376 O
do NCT03866811 378 380 O
not NCT03866811 381 384 B-Negation
live NCT03866811 385 389 O
locally NCT03866811 390 397 O

- NCT03866811 400 401 O
do NCT03866811 403 405 O
not NCT03866811 406 409 B-Negation
speak NCT03866811 410 415 O
English NCT03866811 416 423 O

- NCT03866811 426 427 O
want NCT03866811 429 433 B-Assertion___Assertion-Type-Value:intention
to NCT03866811 434 436 I-Assertion___Assertion-Type-Value:intention
" NCT03866811 437 438 O
become NCT03866811 438 444 O
pregnant NCT03866811 445 453 B-Condition
in NCT03866811 454 456 O
the NCT03866811 457 460 O
next NCT03866811 461 465 B-Eq-Comparison
year NCT03866811 466 470 I-Eq-Comparison
" NCT03866811 470 471 O

Inclusion NCT03865459 0 9 O
Criteria NCT03865459 10 18 O
: NCT03865459 19 20 O

- NCT03865459 24 25 O
age NCT03865459 27 30 B-Age
> NCT03865459 31 32 B-Eq-Comparison
18 NCT03865459 33 35 I-Eq-Comparison
years NCT03865459 36 41 I-Eq-Comparison

- NCT03865459 44 45 O
female NCT03865459 47 53 O
gender NCT03865459 54 60 O

- NCT03865459 63 64 O
rigid NCT03865459 66 71 B-Modifier
cystoscopy NCT03865459 72 82 B-Procedure
for NCT03865459 83 86 O
the NCT03865459 87 90 O
first NCT03865459 91 96 B-Eq-Comparison
time NCT03865459 97 101 I-Eq-Comparison

Exclusion NCT03865459 102 111 O
Criteria NCT03865459 112 120 O
: NCT03865459 121 122 O

- NCT03865459 126 127 O
presence NCT03865459 129 137 O
of NCT03865459 138 140 O
any NCT03865459 141 144 O
contraindication NCT03865459 145 161 B-Contraindication
for NCT03865459 162 165 O
cystoscopy NCT03865459 166 176 B-Procedure
( NCT03865459 177 178 O
such NCT03865459 179 183 O
as NCT03865459 184 186 O
lidocaine NCT03865459 187 196 B-Drug
allergy NCT03865459 197 204 B-Allergy
, NCT03865459 205 206 O
urinary NCT03865459 207 214 B-Condition
tract NCT03865459 215 220 I-Condition
infection NCT03865459 221 230 I-Condition
, NCT03865459 231 232 O
and NCT03865459 233 236 B-Or
urethra NCT03865459 237 244 B-Modifier
- NCT03865459 245 246 O
related NCT03865459 247 254 O
anatomical NCT03865459 255 265 B-Condition
disorders NCT03865459 266 275 I-Condition
) NCT03865459 276 277 O

- NCT03865459 281 282 O
any NCT03865459 284 287 O
analgesic NCT03865459 288 297 B-Drug
used NCT03865459 298 302 O
24 NCT03865459 303 305 B-Eq-Comparison
hours NCT03865459 306 311 I-Eq-Comparison
before NCT03865459 312 318 B-Temporal-Connection___Temporal-Connection-Type-Value:before
cystoscopy NCT03865459 319 329 B-Procedure

- NCT03865459 332 333 O
manipulations NCT03865459 335 348 B-Procedure
such NCT03865459 349 353 O
as NCT03865459 354 356 O
Double NCT03865459 357 363 B-Procedure
- NCT03865459 364 365 I-Procedure
J NCT03865459 366 367 I-Procedure
stent NCT03865459 368 373 I-Procedure
placement NCT03865459 374 383 B-Modifier
or NCT03865459 384 386 B-Or
removal NCT03865459 387 394 B-Modifier
, NCT03865459 395 396 O
and NCT03865459 397 400 B-Or
/ NCT03865459 401 402 I-Or
or NCT03865459 403 405 I-Or
bladder NCT03865459 406 413 B-Modifier
biopsy NCT03865459 414 420 B-Procedure
. NCT03865459 420 421 O

Inclusion NCT03865303 0 9 O
Criteria NCT03865303 10 18 O

- NCT03865303 21 22 O
For NCT03865303 24 27 O
EMR NCT03865303 28 31 O
review NCT03865303 32 38 O
all NCT03865303 39 42 O
adults NCT03865303 43 49 O
admitted NCT03865303 50 58 B-Encounter
to NCT03865303 59 61 O
the NCT03865303 62 65 O
hospital NCT03865303 66 74 O
ages NCT03865303 75 79 B-Age
18 NCT03865303 80 82 B-Eq-Comparison
and NCT03865303 83 86 I-Eq-Comparison
older NCT03865303 87 92 I-Eq-Comparison
with NCT03865303 93 97 O
research NCT03865303 98 106 O
authorization NCT03865303 107 120 O

- NCT03865303 123 124 O
For NCT03865303 126 129 O
survey NCT03865303 130 136 O
- NCT03865303 137 138 O
clinicians NCT03865303 139 149 O
including NCT03865303 150 159 O
physicians NCT03865303 160 170 B-Provider
, NCT03865303 171 172 O
advanced NCT03865303 173 181 B-Provider
care NCT03865303 182 186 I-Provider
practitioners NCT03865303 187 200 I-Provider

- NCT03865303 203 204 O
For NCT03865303 206 209 O
focus NCT03865303 210 215 O
groups NCT03865303 216 222 O
and NCT03865303 223 226 O
interviews NCT03865303 227 237 O
- NCT03865303 238 239 O
clinicians NCT03865303 240 250 O
including NCT03865303 251 260 O
physicians NCT03865303 261 271 B-Provider
, NCT03865303 272 273 O
advanced NCT03865303 274 282 B-Provider
care NCT03865303 283 287 I-Provider
practitioners NCT03865303 288 301 I-Provider

Exclusion NCT03865303 302 311 O
Criteria NCT03865303 312 320 O

- NCT03865303 323 324 O
Age NCT03865303 326 329 B-Age
< NCT03865303 330 331 B-Eq-Comparison
18 NCT03865303 332 334 I-Eq-Comparison
years NCT03865303 335 340 I-Eq-Comparison
old NCT03865303 341 344 O

- NCT03865303 347 348 O
No NCT03865303 350 352 O
research NCT03865303 353 361 O
authorization NCT03865303 362 375 O

- NCT03865303 378 379 O
Refusal NCT03865303 381 388 O
to NCT03865303 389 391 O
give NCT03865303 392 396 O
consent NCT03865303 397 404 O

Inclusion NCT03867266 0 9 O
criteria NCT03867266 10 18 O
: NCT03867266 19 20 O

- NCT03867266 24 25 O
paroxysmal NCT03867266 27 37 B-Modifier
, NCT03867266 38 39 O
persistent NCT03867266 40 50 B-Modifier
and NCT03867266 51 54 B-Or
/ NCT03867266 55 56 I-Or
or NCT03867266 57 59 I-Or
long NCT03867266 60 64 B-Modifier
standing NCT03867266 65 73 I-Modifier
atrial NCT03867266 74 80 B-Condition
flutter NCT03867266 81 88 I-Condition
even NCT03867266 89 93 O
in NCT03867266 94 96 O
the NCT03867266 97 100 O
presence NCT03867266 101 109 O
of NCT03867266 110 112 O
structural NCT03867266 113 123 B-Modifier
heart NCT03867266 124 129 B-Condition
disease NCT03867266 130 137 I-Condition

- NCT03867266 140 141 O
Informed NCT03867266 143 151 O
consent NCT03867266 152 159 O
form NCT03867266 160 164 O

- NCT03867266 167 168 O
Age NCT03867266 170 173 B-Age
equal NCT03867266 174 179 B-Eq-Comparison
or NCT03867266 180 182 I-Eq-Comparison
above NCT03867266 183 188 I-Eq-Comparison
18 NCT03867266 189 191 I-Eq-Comparison
years NCT03867266 192 197 I-Eq-Comparison

- NCT03867266 200 201 O
Skilled NCT03867266 203 210 O
and NCT03867266 211 214 O
willing NCT03867266 215 222 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867266 223 225 I-Assertion___Assertion-Type-Value:hypothetical
comply NCT03867266 226 232 O
with NCT03867266 233 237 O
all NCT03867266 238 241 O
tests NCT03867266 242 247 B-Procedure
and NCT03867266 248 251 B-And
follow NCT03867266 252 258 B-Encounter
up NCT03867266 259 261 I-Encounter
requirements NCT03867266 262 274 O

- NCT03867266 277 278 O
Patients NCT03867266 280 288 O
that NCT03867266 289 293 O
, NCT03867266 294 295 O
in NCT03867266 296 298 O
the NCT03867266 299 302 O
context NCT03867266 303 310 O
of NCT03867266 311 313 O
ablation NCT03867266 314 322 B-Procedure
for NCT03867266 323 326 O
fibrillation NCT03867266 327 339 B-Condition
atrial NCT03867266 340 346 I-Condition
, NCT03867266 347 348 O
should NCT03867266 349 355 B-Assertion___Assertion-Type-Value:hypothetical
also NCT03867266 356 360 O
undergo NCT03867266 361 368 O
to NCT03867266 369 371 O
typical NCT03867266 372 379 B-Modifier
flutter NCT03867266 380 387 B-Procedure
ablation NCT03867266 388 396 I-Procedure
: NCT03867266 397 398 O
in NCT03867266 399 401 O
this NCT03867266 402 406 O
case NCT03867266 407 411 O
the NCT03867266 412 415 O
data NCT03867266 416 420 O
collected NCT03867266 421 430 O
will NCT03867266 431 435 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867266 436 438 I-Assertion___Assertion-Type-Value:hypothetical
those NCT03867266 439 444 O
related NCT03867266 445 452 O
to NCT03867266 453 455 O
typical NCT03867266 456 463 O
flutter NCT03867266 464 471 B-Procedure
ablation NCT03867266 472 480 I-Procedure
. NCT03867266 480 481 O

Exclusion NCT03867266 483 492 O
Criteria NCT03867266 493 501 O
: NCT03867266 502 503 O

- NCT03867266 507 508 O
Previous NCT03867266 510 518 B-Eq-Comparison
ablation NCT03867266 519 527 B-Procedure
for NCT03867266 528 531 O
atrial NCT03867266 532 538 B-Condition
flutter NCT03867266 539 546 I-Condition

- NCT03867266 549 550 O
Atrial NCT03867266 552 558 B-Condition
flutter NCT03867266 559 566 I-Condition
secondary NCT03867266 567 576 B-Modifier
to NCT03867266 577 579 O
electrolyte NCT03867266 580 591 B-Condition
imbalance NCT03867266 592 601 I-Condition
, NCT03867266 602 603 O
thyroid NCT03867266 604 611 B-Condition
disease NCT03867266 612 619 I-Condition
or NCT03867266 620 622 B-Or
to NCT03867266 623 625 O
a NCT03867266 626 627 O
reversible NCT03867266 628 638 B-Modifier
or NCT03867266 639 641 B-Or
non NCT03867266 642 645 B-Negation
- NCT03867266 646 647 O
cardiac NCT03867266 648 655 B-Modifier
cause NCT03867266 656 661 B-Condition

- NCT03867266 664 665 O
severe NCT03867266 667 673 O
anemia NCT03867266 674 680 B-Condition
, NCT03867266 681 682 O

- NCT03867266 686 687 O
sepsis NCT03867266 689 695 B-Condition
in NCT03867266 696 698 B-Eq-Comparison
progress NCT03867266 699 707 I-Eq-Comparison

- NCT03867266 710 711 O
Bypass NCT03867266 713 719 B-Procedure
procedure NCT03867266 720 729 I-Procedure
with NCT03867266 730 734 O
coronary NCT03867266 735 743 B-Modifier
arterial NCT03867266 744 752 I-Modifier
artery NCT03867266 753 759 I-Modifier
in NCT03867266 760 762 O
the NCT03867266 763 766 O
last NCT03867266 767 771 B-Eq-Comparison
three NCT03867266 772 777 I-Eq-Comparison
months NCT03867266 778 784 I-Eq-Comparison

- NCT03867266 787 788 O
Pending NCT03867266 790 797 B-Eq-Comparison
cardiac NCT03867266 798 805 B-Procedure
transplantation NCT03867266 806 821 I-Procedure
or NCT03867266 822 824 B-Or
other NCT03867266 825 830 B-Other
cardiac NCT03867266 831 838 B-Procedure
surgery NCT03867266 839 846 I-Procedure

- NCT03867266 849 850 O
Pregnant NCT03867266 852 860 B-Condition
or NCT03867266 861 863 B-Or
breastfeeding NCT03867266 864 877 B-Condition
women NCT03867266 878 883 O

- NCT03867266 886 887 O
Acute NCT03867266 889 894 O
disease NCT03867266 895 902 B-Condition
or NCT03867266 903 905 B-Or
active NCT03867266 906 912 B-Eq-Comparison
systemic NCT03867266 913 921 B-Modifier
infection NCT03867266 922 931 B-Condition
or NCT03867266 932 934 B-Or
sepsis NCT03867266 935 941 B-Condition

- NCT03867266 944 945 O
Documented NCT03867266 947 957 O
left NCT03867266 958 962 B-Modifier
atrial NCT03867266 963 969 B-Condition
thrombus NCT03867266 970 978 I-Condition

- NCT03867266 981 982 O
Unstable NCT03867266 984 992 O
angina NCT03867266 993 999 B-Condition

- NCT03867266 1002 1003 O
Uncontrolled NCT03867266 1005 1017 B-Modifier
heart NCT03867266 1018 1023 B-Condition
failure NCT03867266 1024 1031 I-Condition

- NCT03867266 1034 1035 O
Life NCT03867266 1037 1041 B-Observation
expectancy NCT03867266 1042 1052 I-Observation
of NCT03867266 1053 1055 O
less NCT03867266 1056 1060 B-Eq-Comparison
than NCT03867266 1061 1065 I-Eq-Comparison
12 NCT03867266 1066 1068 I-Eq-Comparison
months NCT03867266 1069 1075 I-Eq-Comparison

- NCT03867266 1078 1079 O
Registration NCT03867266 1081 1093 O
in NCT03867266 1094 1096 O
any NCT03867266 1097 1100 O
other NCT03867266 1101 1106 B-Other
study NCT03867266 1107 1112 B-Study
evaluating NCT03867266 1113 1123 O
another NCT03867266 1124 1131 B-Other
device NCT03867266 1132 1138 B-Procedure
or NCT03867266 1139 1141 B-Or
medication NCT03867266 1142 1152 B-Drug

- NCT03867266 1155 1156 O
Presence NCT03867266 1158 1166 O
of NCT03867266 1167 1169 O
intramural NCT03867266 1170 1180 B-Condition
thrombi NCT03867266 1181 1188 I-Condition
, NCT03867266 1189 1190 O
tumor NCT03867266 1191 1196 B-Condition
or NCT03867266 1197 1199 B-Or
other NCT03867266 1200 1205 B-Other
anomalies NCT03867266 1206 1215 B-Condition
that NCT03867266 1216 1220 O
preclude NCT03867266 1221 1229 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03867266 1230 1233 O
introduction NCT03867266 1234 1246 O
of NCT03867266 1247 1249 O
the NCT03867266 1250 1253 O
catheter NCT03867266 1254 1262 B-Procedure
into NCT03867266 1263 1267 O
the NCT03867266 1268 1271 O
vein NCT03867266 1272 1276 B-Modifier
system NCT03867266 1277 1283 I-Modifier

Inclusion NCT03867500 0 9 O
criteria NCT03867500 10 18 O
: NCT03867500 19 20 O

- NCT03867500 24 25 O
Women NCT03867500 27 32 O
and NCT03867500 33 36 B-Or
Men NCT03867500 37 40 O
( NCT03867500 41 42 O
Women NCT03867500 43 48 O
premenopausal NCT03867500 49 62 B-Condition
) NCT03867500 63 64 O

- NCT03867500 68 69 O
BMI NCT03867500 71 74 B-Observation
29 NCT03867500 75 77 B-Eq-Comparison
- NCT03867500 78 79 I-Eq-Comparison
37 NCT03867500 80 82 O

- NCT03867500 86 87 O
Weight NCT03867500 89 95 B-Observation
stable NCT03867500 96 102 O

- NCT03867500 105 106 O
Not NCT03867500 108 111 B-Negation
pregnant NCT03867500 112 120 B-Condition
/ NCT03867500 121 122 B-Or
nursing NCT03867500 123 130 B-Condition

Exclusion NCT03867500 131 140 O
criteria NCT03867500 141 149 O
: NCT03867500 150 151 O

- NCT03867500 155 156 O
Ischemic NCT03867500 158 166 B-Condition
heart NCT03867500 167 172 I-Condition
disease NCT03867500 173 180 I-Condition

- NCT03867500 183 184 O
Atherosclerotic NCT03867500 186 201 B-Condition
valvular NCT03867500 202 210 I-Condition
disease NCT03867500 211 218 I-Condition

- NCT03867500 221 222 O
Smokers NCT03867500 224 231 B-Condition|Observation
( NCT03867500 232 233 O
> NCT03867500 235 236 B-Eq-Comparison
20 NCT03867500 237 239 I-Eq-Comparison
cigarettes NCT03867500 240 250 I-Eq-Comparison
per NCT03867500 251 254 I-Eq-Comparison
week NCT03867500 255 259 I-Eq-Comparison
) NCT03867500 260 261 O

- NCT03867500 265 266 O
Bilateral NCT03867500 268 277 B-Modifier
oophorectomy NCT03867500 278 290 B-Procedure

- NCT03867500 293 294 O
Concomitant NCT03867500 296 307 B-Modifier
use NCT03867500 308 311 O
of NCT03867500 312 314 O
medications NCT03867500 315 326 B-Drug
that NCT03867500 327 331 O
can NCT03867500 332 335 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03867500 336 341 O
serum NCT03867500 342 347 B-Observation
lipid NCT03867500 348 353 I-Observation
profile NCT03867500 354 361 I-Observation
: NCT03867500 362 363 O

- NCT03867500 372 373 O
High NCT03867500 375 379 O
dose NCT03867500 380 384 O
fish NCT03867500 385 389 B-Drug
oil NCT03867500 390 393 I-Drug
( NCT03867500 394 395 O
> NCT03867500 397 398 B-Eq-Comparison
3 NCT03867500 399 400 I-Eq-Comparison
g NCT03867500 401 402 O
per NCT03867500 403 406 I-Eq-Comparison
day NCT03867500 407 410 I-Eq-Comparison
) NCT03867500 411 412 O
, NCT03867500 414 415 O

- NCT03867500 424 425 O
STATINS NCT03867500 427 434 B-Drug
( NCT03867500 435 436 O
if NCT03867500 437 439 O
yes NCT03867500 440 443 O
hold NCT03867500 444 448 B-Eq-Comparison
for NCT03867500 449 452 I-Eq-Comparison
6 NCT03867500 453 454 I-Eq-Comparison
weeks NCT03867500 455 460 I-Eq-Comparison
and NCT03867500 461 464 O
receive NCT03867500 465 472 O
PCP NCT03867500 473 476 B-Provider
's NCT03867500 476 478 O
approval NCT03867500 479 487 B-Observation
) NCT03867500 488 489 O
, NCT03867500 491 492 O

- NCT03867500 501 502 O
Niacin NCT03867500 504 510 B-Drug

- NCT03867500 518 519 O
Fibrates NCT03867500 521 529 B-Drug

- NCT03867500 537 538 O
thiazolidinediones NCT03867500 540 558 B-Drug

- NCT03867500 566 567 I-Drug
Beta NCT03867500 569 573 B-Drug
- NCT03867500 574 575 O
blockers NCT03867500 576 584 I-Drug

- NCT03867500 592 593 O
Atypical NCT03867500 595 603 B-Modifier
antipsychotics NCT03867500 604 618 B-Drug

- NCT03867500 621 622 O
Lidocaine NCT03867500 624 633 B-Drug
or NCT03867500 634 636 B-Or
Niacin NCT03867500 637 643 B-Drug
/ NCT03867500 644 645 B-Or
Niaspan NCT03867500 646 653 B-Drug
allergy NCT03867500 654 661 B-Allergy

- NCT03867500 664 665 O
Subjects NCT03867500 667 675 O
with NCT03867500 676 680 O
1.5 NCT03867500 681 684 B-Eq-Comparison
times NCT03867500 685 690 I-Eq-Comparison
upper NCT03867500 691 696 I-Eq-Comparison
limit NCT03867500 697 702 I-Eq-Comparison
of NCT03867500 703 705 I-Eq-Comparison
normal NCT03867500 706 712 I-Eq-Comparison
of NCT03867500 713 715 O
serum NCT03867500 716 721 B-Observation
creatinine NCT03867500 722 732 I-Observation
, NCT03867500 733 734 O
Alkaline NCT03867500 735 743 B-Observation
phosphatase NCT03867500 744 755 I-Observation
, NCT03867500 756 757 O
Aspartate NCT03867500 758 767 B-Observation
aminotransferase NCT03867500 768 784 I-Observation|Observation
( NCT03867500 785 786 O
AST NCT03867500 787 790 B-Observation
) NCT03867500 791 792 O
, NCT03867500 794 795 O
Alanine NCT03867500 796 803 B-Observation
aminotransferase NCT03867500 804 820 O
( NCT03867500 821 822 O
ALT NCT03867500 823 826 B-Observation
) NCT03867500 827 828 O
unless NCT03867500 829 835 B-Exception
participant NCT03867500 836 847 O
has NCT03867500 848 851 O
fatty NCT03867500 852 857 B-Condition
liver NCT03867500 858 863 I-Condition
disease NCT03867500 864 871 I-Condition
, NCT03867500 872 873 O
Total NCT03867500 874 879 B-Observation
bilirubin NCT03867500 880 889 I-Observation
( NCT03867500 890 891 O
unless NCT03867500 892 898 B-Exception
the NCT03867500 899 902 O
patient NCT03867500 903 910 O
has NCT03867500 911 914 O
documented NCT03867500 915 925 O
Gilbert NCT03867500 926 933 B-Condition
's NCT03867500 933 935 O
syndrome NCT03867500 936 944 I-Condition
) NCT03867500 945 946 O

Inclusion NCT03865316 0 9 O
Criteria NCT03865316 10 18 O
: NCT03865316 19 20 O

- NCT03865316 24 25 O
Patients NCT03865316 27 35 O
18 NCT03865316 36 38 B-Eq-Comparison
years NCT03865316 39 44 I-Eq-Comparison
old NCT03865316 45 48 I-Age|Eq-Comparison
and NCT03865316 49 52 I-Eq-Comparison
older NCT03865316 53 58 I-Eq-Comparison
at NCT03865316 59 61 O
the NCT03865316 62 65 O
time NCT03865316 66 70 O
of NCT03865316 71 73 O
consent NCT03865316 74 81 O
. NCT03865316 81 82 O

- NCT03865316 86 87 O
ASA NCT03865316 89 92 B-Condition
status NCT03865316 93 99 O
I NCT03865316 100 101 B-Eq-Comparison
, NCT03865316 102 103 O
II NCT03865316 104 106 I-Eq-Comparison
, NCT03865316 107 108 O
or NCT03865316 109 111 I-Eq-Comparison
III NCT03865316 112 115 O
. NCT03865316 115 116 O

- NCT03865316 120 121 O
English NCT03865316 123 130 O
- NCT03865316 131 132 O
speaking NCT03865316 133 141 O
subjects NCT03865316 142 150 O
. NCT03865316 150 151 O

- NCT03865316 155 156 O
Scheduled NCT03865316 158 167 B-Eq-Comparison
for NCT03865316 168 171 O
surgical NCT03865316 172 180 B-Modifier
and NCT03865316 181 184 B-Or
non NCT03865316 185 188 B-Negation
- NCT03865316 189 190 O
surgical NCT03865316 191 199 B-Modifier
procedures NCT03865316 200 210 B-Procedure
scheduled NCT03865316 211 220 B-Eq-Comparison
under NCT03865316 221 226 O
general NCT03865316 227 234 B-Procedure
anesthesia NCT03865316 235 245 I-Procedure
( NCT03865316 246 247 O
Common NCT03865316 248 254 B-Coreference
procedures NCT03865316 255 265 I-Coreference
include NCT03865316 266 273 O
but NCT03865316 274 277 O
are NCT03865316 278 281 O
not NCT03865316 282 285 O
restricted NCT03865316 286 296 O
to NCT03865316 297 299 B-Procedure
tonsillectomy NCT03865316 300 313 O
, NCT03865316 314 315 O
adenoidectomy NCT03865316 316 329 B-Procedure
, NCT03865316 330 331 O
urological NCT03865316 332 342 B-Procedure
procedures NCT03865316 343 353 I-Procedure
, NCT03865316 354 355 O
dental NCT03865316 356 362 B-Procedure
rehabilitation NCT03865316 363 377 I-Procedure
, NCT03865316 378 379 O
orthopedic NCT03865316 380 390 B-Procedure
procedures NCT03865316 391 401 I-Procedure
, NCT03865316 402 403 O
biopsies NCT03865316 404 412 B-Procedure
, NCT03865316 413 414 O
audiogram NCT03865316 415 424 B-Procedure
, NCT03865316 425 426 O
nuclear NCT03865316 427 434 B-Procedure
scans NCT03865316 435 440 I-Procedure
, NCT03865316 441 442 O
gastroscopy NCT03865316 443 454 B-Procedure
, NCT03865316 455 456 O
colonoscopy NCT03865316 457 468 B-Procedure
, NCT03865316 469 470 O
etc NCT03865316 471 474 O
. NCT03865316 474 475 O
) NCT03865316 476 477 O
. NCT03865316 478 479 O

Exclusion NCT03865316 481 490 O
Criteria NCT03865316 491 499 O
: NCT03865316 500 501 O

- NCT03865316 505 506 O
Any NCT03865316 508 511 O
deformities NCT03865316 512 523 B-Condition
or NCT03865316 524 526 B-Or
devices NCT03865316 527 534 B-Procedure
that NCT03865316 535 539 O
may NCT03865316 540 543 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03865316 544 551 B-Negation
application NCT03865316 552 563 O
of NCT03865316 564 566 O
EEG NCT03865316 567 570 B-Procedure
Sensor NCT03865316 571 577 I-Procedure
to NCT03865316 578 580 O
forehead NCT03865316 581 589 B-Modifier
with NCT03865316 590 594 O
a NCT03865316 595 596 O
proper NCT03865316 597 603 O
fit NCT03865316 604 607 O
. NCT03865316 607 608 O

- NCT03865316 612 613 O
Subjects NCT03865316 615 623 O
who NCT03865316 624 627 O
are NCT03865316 628 631 O
developmentally NCT03865316 632 647 B-Condition
delayed NCT03865316 648 655 I-Condition
. NCT03865316 655 656 O

- NCT03865316 660 661 O
Subjects NCT03865316 663 671 O
deemed NCT03865316 672 678 O
not NCT03865316 679 682 B-Assertion___Assertion-Type-Value:hypothetical|Negation
suitable NCT03865316 683 691 I-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03865316 692 695 O
study NCT03865316 696 701 B-Study
at NCT03865316 702 704 O
the NCT03865316 705 708 O
discretion NCT03865316 709 719 O
of NCT03865316 720 722 O
the NCT03865316 723 726 O
investigator NCT03865316 727 739 O
. NCT03865316 739 740 O

Inclusion NCT03863015 0 9 O
Criteria NCT03863015 10 18 O
: NCT03863015 19 20 O

Each NCT03863015 22 26 O
of NCT03863015 27 29 O
the NCT03863015 30 33 O
following NCT03863015 34 43 O
criteria NCT03863015 44 52 O
must NCT03863015 53 57 O
be NCT03863015 58 60 O
fulfilled NCT03863015 61 70 O
for NCT03863015 71 74 O
a NCT03863015 75 76 O
subject NCT03863015 77 84 O
to NCT03863015 85 87 O
be NCT03863015 88 90 O
eligible NCT03863015 91 99 O
: NCT03863015 100 101 O

1 NCT03863015 105 106 O
. NCT03863015 106 107 O
Age NCT03863015 109 112 B-Age
≥ NCT03863015 113 114 B-Eq-Comparison
18 NCT03863015 115 117 I-Eq-Comparison
years NCT03863015 118 123 I-Eq-Comparison

2 NCT03863015 126 127 O
. NCT03863015 127 128 O
OHCA NCT03863015 130 134 B-Condition
of NCT03863015 135 137 O
a NCT03863015 138 139 O
presumed NCT03863015 140 148 O
cardiac NCT03863015 149 156 B-Condition
cause NCT03863015 157 162 I-Condition

3 NCT03863015 165 166 O
. NCT03863015 166 167 O
Unconsciousness NCT03863015 169 184 B-Condition
upon NCT03863015 185 189 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 190 199 B-Encounter
, NCT03863015 200 201 O
i. NCT03863015 202 204 O
e. NCT03863015 205 207 O
a NCT03863015 209 210 O
GCS NCT03863015 211 214 B-Observation
< NCT03863015 215 216 B-Eq-Comparison
9 NCT03863015 217 218 I-Eq-Comparison

4 NCT03863015 222 223 O
. NCT03863015 223 224 O
Sustained NCT03863015 226 235 O
ROSC NCT03863015 236 240 B-Condition
for NCT03863015 241 244 O
more NCT03863015 245 249 B-Eq-Comparison
than NCT03863015 250 254 I-Eq-Comparison
20 NCT03863015 255 257 I-Eq-Comparison
minutes NCT03863015 258 265 I-Eq-Comparison

Exclusion NCT03863015 266 275 O
Criteria NCT03863015 276 284 O
: NCT03863015 285 286 O

None NCT03863015 288 292 O
of NCT03863015 293 295 O
the NCT03863015 296 299 O
following NCT03863015 300 309 O
criteria NCT03863015 310 318 O
must NCT03863015 319 323 O
be NCT03863015 324 326 O
fulfilled NCT03863015 327 336 O
for NCT03863015 337 340 O
a NCT03863015 341 342 O
subject NCT03863015 343 350 O
to NCT03863015 351 353 O
be NCT03863015 354 356 O
eligible NCT03863015 357 365 O
: NCT03863015 366 367 O

1 NCT03863015 371 372 O
. NCT03863015 372 373 O
Consciousness NCT03863015 375 388 B-Condition
upon NCT03863015 389 393 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 394 403 B-Encounter
, NCT03863015 404 405 O
i. NCT03863015 406 408 O
e. NCT03863015 409 411 O
a NCT03863015 413 414 O
GCS NCT03863015 415 418 B-Observation
≥ NCT03863015 419 420 B-Eq-Comparison
9 NCT03863015 421 422 I-Eq-Comparison

2 NCT03863015 426 427 O
. NCT03863015 427 428 O
Presumed NCT03863015 430 438 O
non NCT03863015 439 442 B-Negation
- NCT03863015 443 444 O
cardiac NCT03863015 445 452 B-Modifier
cause NCT03863015 453 458 O
of NCT03863015 459 461 O
arrest NCT03863015 462 468 B-Condition

3 NCT03863015 471 472 O
. NCT03863015 472 473 O
Unwitnessed NCT03863015 475 486 B-Condition
asystole NCT03863015 487 495 I-Condition

4 NCT03863015 498 499 O
. NCT03863015 499 500 O
Suspected NCT03863015 502 511 B-Assertion___Assertion-Type-Value:possible
or NCT03863015 512 514 B-Or
confirmed NCT03863015 515 524 B-Modifier
intracranial NCT03863015 525 537 B-Condition
bleeding NCT03863015 538 546 I-Condition
or NCT03863015 547 549 B-Or|Or
stroke NCT03863015 550 556 B-Condition

5 NCT03863015 559 560 O
. NCT03863015 560 561 O
Pregnancy NCT03863015 563 572 B-Condition
, NCT03863015 573 574 O
or NCT03863015 575 577 O
females NCT03863015 578 585 O
in NCT03863015 586 588 O
fertile NCT03863015 589 596 B-Condition
age NCT03863015 597 600 I-Condition
, NCT03863015 601 602 O
unless NCT03863015 603 609 B-Or
a NCT03863015 610 611 O
negative NCT03863015 612 620 O
serum NCT03863015 621 626 B-Observation
HCG NCT03863015 627 630 I-Observation
can NCT03863015 631 634 B-Assertion___Assertion-Type-Value:hypothetical
rule NCT03863015 635 639 I-Assertion___Assertion-Type-Value:hypothetical
out NCT03863015 640 643 I-Assertion___Assertion-Type-Value:hypothetical
pregnancy NCT03863015 644 653 B-Condition
within NCT03863015 654 660 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863015 661 664 O
inclusion NCT03863015 665 674 B-Study
window NCT03863015 675 681 I-Study
. NCT03863015 681 682 O

6 NCT03863015 686 687 O
. NCT03863015 687 688 O
Temperature NCT03863015 690 701 B-Observation
on NCT03863015 702 704 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 705 714 B-Encounter
< NCT03863015 715 716 B-Eq-Comparison
30 NCT03863015 717 719 I-Eq-Comparison
° NCT03863015 720 721 I-Eq-Comparison
C NCT03863015 721 722 O

7 NCT03863015 725 726 O
. NCT03863015 726 727 O
Persistent NCT03863015 729 739 B-Modifier
cardiogenic NCT03863015 740 751 B-Condition
shock NCT03863015 752 757 I-Condition
* NCT03863015 757 758 O
that NCT03863015 759 763 O
is NCT03863015 764 766 O
not NCT03863015 767 770 B-Negation
reversed NCT03863015 771 779 B-Modifier
within NCT03863015 780 786 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863015 787 790 O
inclusion NCT03863015 791 800 B-Study
window NCT03863015 801 807 I-Study

8 NCT03863015 810 811 O
. NCT03863015 811 812 O
Known NCT03863015 814 819 O
disease NCT03863015 820 827 B-Condition
making NCT03863015 828 834 O
180 NCT03863015 835 838 B-Eq-Comparison
day NCT03863015 839 842 I-Eq-Comparison
survival NCT03863015 843 851 B-Death|Risk
unlikely NCT03863015 852 860 I-Death|Risk

9 NCT03863015 863 864 O
. NCT03863015 864 865 O
Known NCT03863015 867 872 O
limitations NCT03863015 873 884 B-Assertion___Assertion-Type-Value:hypothetical|Negation
in NCT03863015 885 887 O
therapy NCT03863015 888 895 B-Procedure

10 NCT03863015 897 899 O
. NCT03863015 899 900 O
Known NCT03863015 902 907 O
pre NCT03863015 908 911 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863015 912 913 O
arrest NCT03863015 914 920 B-Condition
Cerebral NCT03863015 921 929 B-Observation
Performance NCT03863015 930 941 I-Observation
Category NCT03863015 942 950 I-Observation
of NCT03863015 951 953 O
3 NCT03863015 954 955 B-Eq-Comparison
to NCT03863015 956 958 I-Eq-Comparison
4 NCT03863015 959 960 I-Eq-Comparison

11 NCT03863015 963 965 O
. NCT03863015 965 966 O
> NCT03863015 968 969 B-Eq-Comparison
240 NCT03863015 970 973 I-Eq-Comparison
minutes NCT03863015 974 981 I-Eq-Comparison
from NCT03863015 982 986 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ROSC NCT03863015 987 991 B-Observation
to NCT03863015 992 994 O
randomization NCT03863015 995 1008 B-Study

Inclusion NCT03860246 0 9 O
Criteria NCT03860246 10 18 O
: NCT03860246 19 20 O

Nursing NCT03860246 22 29 O
home NCT03860246 30 34 O
residents NCT03860246 35 44 O
with NCT03860246 45 49 O
≥ NCT03860246 50 51 B-Eq-Comparison
2 NCT03860246 52 53 I-Eq-Comparison
of NCT03860246 54 56 O
the NCT03860246 57 60 B-Criteria-Count
following NCT03860246 61 70 I-Criteria-Count
risk NCT03860246 71 75 B-Risk
factors NCT03860246 76 83 I-Risk
for NCT03860246 84 87 O
atrial NCT03860246 88 94 B-Condition
fibrillation NCT03860246 95 107 I-Condition
: NCT03860246 108 109 O

- NCT03860246 113 114 O
age NCT03860246 116 119 B-Age
≥ NCT03860246 120 121 B-Eq-Comparison
75 NCT03860246 122 124 I-Eq-Comparison
years NCT03860246 125 130 I-Eq-Comparison

- NCT03860246 133 134 O
female NCT03860246 136 142 O
sex NCT03860246 143 146 O

- NCT03860246 149 150 O
obstructive NCT03860246 152 163 B-Condition
sleep NCT03860246 164 169 I-Condition
apnea NCT03860246 170 175 I-Condition

- NCT03860246 178 179 O
peripheral NCT03860246 181 191 B-Condition
vascular NCT03860246 192 200 I-Condition
disease NCT03860246 201 208 I-Condition

- NCT03860246 211 212 O
diabetes NCT03860246 214 222 B-Condition
mellitus NCT03860246 223 231 I-Condition

- NCT03860246 234 235 O
obesity NCT03860246 237 244 B-Condition
( NCT03860246 245 246 O
body NCT03860246 247 251 B-Observation
mass NCT03860246 252 256 I-Observation
index NCT03860246 257 262 I-Observation
[ NCT03860246 263 264 O
BMI NCT03860246 265 268 B-Observation
] NCT03860246 269 270 O
> NCT03860246 271 272 B-Eq-Comparison
30 NCT03860246 273 275 I-Eq-Comparison
kg NCT03860246 276 278 I-Eq-Comparison
/ NCT03860246 279 280 I-Eq-Comparison
m2 NCT03860246 281 283 I-Eq-Comparison
) NCT03860246 284 285 O

- NCT03860246 289 290 O
hypertension NCT03860246 292 304 B-Condition

- NCT03860246 307 308 O
congestive NCT03860246 310 320 B-Condition
heart NCT03860246 321 326 I-Condition
failure NCT03860246 327 334 I-Condition

Exclusion NCT03860246 335 344 O
Criteria NCT03860246 345 353 O
: NCT03860246 354 355 O

- NCT03860246 359 360 O
prior NCT03860246 362 367 B-Eq-Comparison
diagnosis NCT03860246 368 377 O
of NCT03860246 378 380 O
AF NCT03860246 381 383 B-Condition

- NCT03860246 386 387 O
continuous NCT03860246 389 399 B-Modifier
rhythm NCT03860246 400 406 B-Procedure
monitoring NCT03860246 407 417 I-Procedure
over NCT03860246 418 422 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860246 423 426 O
past NCT03860246 427 431 B-Eq-Comparison
year NCT03860246 432 436 I-Eq-Comparison

- NCT03860246 439 440 O
pacemaker NCT03860246 442 451 B-Procedure
or NCT03860246 452 454 B-Or
implantable NCT03860246 455 466 B-Procedure
cardioverter NCT03860246 467 479 I-Procedure
defibrillator NCT03860246 480 493 I-Procedure
in NCT03860246 494 496 B-Modifier
situ NCT03860246 497 501 I-Modifier

Inclusion NCT03861819 0 9 O
Criteria NCT03861819 10 18 O
: NCT03861819 19 20 O

- NCT03861819 24 25 O
Ages NCT03861819 27 31 B-Age
18 NCT03861819 32 34 B-Eq-Comparison
- NCT03861819 35 36 I-Eq-Comparison
59 NCT03861819 37 39 O

- NCT03861819 43 44 O
Histologically NCT03861819 46 60 O
confirmed NCT03861819 61 70 O
nonalcoholic NCT03861819 71 83 B-Condition
steatohepatitis NCT03861819 84 99 I-Condition
and NCT03861819 100 103 B-Or
fibrosis NCT03861819 104 112 B-Condition
( NCT03861819 113 114 O
stage NCT03861819 115 120 B-Eq-Comparison
1 NCT03861819 121 122 I-Eq-Comparison
- NCT03861819 123 124 I-Eq-Comparison
3 NCT03861819 125 126 I-Eq-Comparison
) NCT03861819 127 128 O
from NCT03861819 129 133 O
liver NCT03861819 134 139 B-Procedure
biopsy NCT03861819 140 146 I-Procedure

- NCT03861819 149 150 O
Able NCT03861819 152 156 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861819 157 159 I-Assertion___Assertion-Type-Value:hypothetical
row NCT03861819 160 163 O
on NCT03861819 164 166 O
an NCT03861819 167 169 O
indoor NCT03861819 170 176 B-Observation
rowing NCT03861819 177 183 I-Observation
apparatus NCT03861819 184 193 I-Observation

- NCT03861819 196 197 O
Not NCT03861819 199 202 B-Negation
participating NCT03861819 203 216 O
in NCT03861819 217 219 O
regular NCT03861819 220 227 O
physical NCT03861819 228 236 B-Observation
exercise NCT03861819 237 245 I-Observation
( NCT03861819 246 247 O
more NCT03861819 248 252 B-Eq-Comparison
than NCT03861819 253 257 I-Eq-Comparison
60 NCT03861819 258 260 I-Eq-Comparison
minutes NCT03861819 261 268 I-Eq-Comparison
of NCT03861819 269 271 O
moderate NCT03861819 272 280 O
intensity NCT03861819 281 290 O
or NCT03861819 291 293 B-Or
30 NCT03861819 294 296 B-Eq-Comparison
minutes NCT03861819 297 304 I-Eq-Comparison
of NCT03861819 305 307 O
vigorous NCT03861819 308 316 O
intensity NCT03861819 317 326 O
exercise NCT03861819 327 335 B-Observation
per NCT03861819 336 339 B-Eq-Comparison
week NCT03861819 340 344 I-Eq-Comparison
) NCT03861819 345 346 O

- NCT03861819 350 351 O
Not NCT03861819 353 356 B-Negation
actively NCT03861819 357 365 O
trying NCT03861819 366 372 B-Assertion___Assertion-Type-Value:intention
to NCT03861819 373 375 I-Assertion___Assertion-Type-Value:intention
lose NCT03861819 376 380 B-Condition
weight NCT03861819 381 387 I-Condition
through NCT03861819 388 395 O
a NCT03861819 396 397 O
dietary NCT03861819 398 405 B-Observation
approach NCT03861819 406 414 I-Observation

- NCT03861819 417 418 O
No NCT03861819 420 422 B-Negation
absolute NCT03861819 423 431 O
contra NCT03861819 432 438 B-Contraindication
- NCT03861819 439 440 I-Contraindication
indications NCT03861819 441 452 I-Contraindication
to NCT03861819 453 455 O
exercise NCT03861819 456 464 B-Observation
: NCT03861819 465 466 O
recent NCT03861819 467 473 B-Eq-Comparison
( NCT03861819 474 475 O
< NCT03861819 477 478 B-Eq-Comparison
6 NCT03861819 479 480 I-Eq-Comparison
months NCT03861819 481 487 I-Eq-Comparison
) NCT03861819 488 489 O
acute NCT03861819 490 495 O
cardiac NCT03861819 496 503 B-Condition
event NCT03861819 504 509 I-Condition
unstable NCT03861819 510 518 O
angina NCT03861819 519 525 B-Condition
, NCT03861819 526 527 O
uncontrolled NCT03861819 528 540 B-Modifier
dysrhythmias NCT03861819 541 553 B-Condition
causing NCT03861819 554 561 O
symptoms NCT03861819 562 570 B-Assertion___Assertion-Type-Value:possible
or NCT03861819 571 573 B-Or
hemodynamic NCT03861819 574 585 B-Modifier
compromise NCT03861819 586 596 B-Condition
, NCT03861819 597 598 O
symptomatic NCT03861819 599 610 B-Assertion___Assertion-Type-Value:possible
aortic NCT03861819 611 617 B-Condition
stenosis NCT03861819 618 626 I-Condition
, NCT03861819 627 628 O
uncontrolled NCT03861819 629 641 B-Modifier
symptomatic NCT03861819 642 653 B-Assertion___Assertion-Type-Value:possible
heart NCT03861819 654 659 B-Condition
failure NCT03861819 660 667 I-Condition
, NCT03861819 668 669 O
acute NCT03861819 670 675 O
pulmonary NCT03861819 676 685 B-Condition
embolus NCT03861819 686 693 I-Condition
, NCT03861819 694 695 O
acute NCT03861819 696 701 O
myocarditis NCT03861819 702 713 B-Condition
or NCT03861819 714 716 B-Or
pericarditis NCT03861819 717 729 B-Condition
, NCT03861819 730 731 O
suspected NCT03861819 732 741 B-Assertion___Assertion-Type-Value:possible
or NCT03861819 742 744 B-Or
known NCT03861819 745 750 O
dissecting NCT03861819 751 761 B-Condition
aneurism NCT03861819 762 770 I-Condition
and NCT03861819 771 774 B-Or
acute NCT03861819 775 780 O
systemic NCT03861819 781 789 B-Modifier
infection NCT03861819 790 799 B-Condition

- NCT03861819 802 803 O
No NCT03861819 805 807 B-Negation
other NCT03861819 808 813 B-Other
form NCT03861819 814 818 O
of NCT03861819 819 821 O
chronic NCT03861819 822 829 B-Modifier
liver NCT03861819 830 835 B-Condition
disease NCT03861819 836 843 I-Condition
( NCT03861819 844 845 O
as NCT03861819 846 848 O
confirmed NCT03861819 849 858 O
by NCT03861819 859 861 O
serology NCT03861819 862 870 B-Procedure
and NCT03861819 871 874 B-Or
histology NCT03861819 875 884 B-Procedure
) NCT03861819 885 886 O

- NCT03861819 890 891 O
No NCT03861819 893 895 B-Negation
liver NCT03861819 896 901 B-Condition
cirrhosis NCT03861819 902 911 I-Condition
( NCT03861819 912 913 O
stage NCT03861819 914 919 B-Eq-Comparison
4 NCT03861819 920 921 I-Eq-Comparison
fibrosis NCT03861819 922 930 B-Condition
on NCT03861819 931 933 O
liver NCT03861819 934 939 B-Procedure
biopsy NCT03861819 940 946 I-Procedure
) NCT03861819 947 948 O
or NCT03861819 949 951 B-Or
a NCT03861819 952 953 O
clinical NCT03861819 954 962 O
diagnosis NCT03861819 963 972 O
of NCT03861819 973 975 O
cirrhosis NCT03861819 976 985 B-Condition
as NCT03861819 986 988 O
ascertained NCT03861819 989 1000 O
by NCT03861819 1001 1003 O
a NCT03861819 1004 1005 O
hepatologist NCT03861819 1006 1018 B-Provider

- NCT03861819 1021 1022 O
No NCT03861819 1024 1026 B-Negation
coronary NCT03861819 1027 1035 B-Condition
artery NCT03861819 1036 1042 I-Condition
disease NCT03861819 1043 1050 I-Condition
or NCT03861819 1051 1053 B-Or
chronic NCT03861819 1054 1061 B-Modifier
obstructive NCT03861819 1062 1073 B-Condition
pulmonary NCT03861819 1074 1083 I-Condition
disease NCT03861819 1084 1091 I-Condition
. NCT03861819 1091 1092 O

- NCT03861819 1096 1097 O
No NCT03861819 1099 1101 B-Negation
diagnosis NCT03861819 1102 1111 O
of NCT03861819 1112 1114 O
malignancy NCT03861819 1115 1125 B-Condition
( NCT03861819 1126 1127 O
except NCT03861819 1128 1134 B-Exception
non NCT03861819 1135 1138 B-Negation
- NCT03861819 1139 1140 O
melanoma NCT03861819 1141 1149 B-Modifier
skin NCT03861819 1150 1154 B-Modifier
cancer NCT03861819 1155 1161 B-Condition
) NCT03861819 1162 1163 O

- NCT03861819 1167 1168 O
No NCT03861819 1170 1172 B-Negation
past NCT03861819 1173 1177 B-Eq-Comparison
or NCT03861819 1178 1180 B-Or
present NCT03861819 1181 1188 B-Eq-Comparison
history NCT03861819 1189 1196 I-Eq-Comparison
of NCT03861819 1197 1199 O
portal NCT03861819 1200 1206 B-Condition
hypertension NCT03861819 1207 1219 I-Condition
( NCT03861819 1220 1221 O
esophageal NCT03861819 1222 1232 B-Modifier
varices NCT03861819 1233 1240 B-Condition
, NCT03861819 1241 1242 O
ascites NCT03861819 1243 1250 B-Condition
, NCT03861819 1251 1252 O
hepatic NCT03861819 1253 1260 B-Condition
encephalopathy NCT03861819 1261 1275 I-Condition
) NCT03861819 1276 1277 O

- NCT03861819 1281 1282 O
No NCT03861819 1284 1286 B-Negation
use NCT03861819 1287 1290 O
of NCT03861819 1291 1293 O
immunosuppression NCT03861819 1294 1311 B-Drug
or NCT03861819 1312 1314 B-Or
chronic NCT03861819 1315 1322 B-Modifier
nonsteroidal NCT03861819 1323 1335 B-Drug
anti NCT03861819 1336 1340 I-Drug
- NCT03861819 1341 1342 I-Drug
inflammatory NCT03861819 1343 1355 I-Drug
medication NCT03861819 1356 1366 I-Drug

- NCT03861819 1369 1370 O
No NCT03861819 1372 1374 B-Eq-Comparison
more NCT03861819 1375 1379 I-Eq-Comparison
than NCT03861819 1380 1384 I-Eq-Comparison
14 NCT03861819 1385 1387 I-Eq-Comparison
drinks NCT03861819 1388 1394 I-Eq-Comparison|Eq-Comparison|Observation|Observation
per NCT03861819 1395 1398 I-Eq-Comparison
week NCT03861819 1399 1403 I-Eq-Comparison|Eq-Comparison
( NCT03861819 1404 1405 O
if NCT03861819 1406 1408 O
male NCT03861819 1409 1413 O
) NCT03861819 1414 1415 O
or NCT03861819 1416 1418 B-Or
7 NCT03861819 1419 1420 B-Eq-Comparison
drinks NCT03861819 1421 1427 O
a NCT03861819 1428 1429 I-Eq-Comparison
week NCT03861819 1430 1434 O
( NCT03861819 1435 1436 O
if NCT03861819 1437 1439 O
female NCT03861819 1440 1446 O
) NCT03861819 1447 1448 O
in NCT03861819 1449 1451 O
the NCT03861819 1452 1455 O
last NCT03861819 1456 1460 B-Eq-Comparison
2 NCT03861819 1461 1462 I-Eq-Comparison
years NCT03861819 1463 1468 I-Eq-Comparison

- NCT03861819 1471 1472 O
Cognitively NCT03861819 1474 1485 O
able NCT03861819 1486 1490 O
to NCT03861819 1491 1493 O
provide NCT03861819 1494 1501 O
consent NCT03861819 1502 1509 O

- NCT03861819 1512 1513 O
Able NCT03861819 1515 1519 O
to NCT03861819 1520 1522 O
read NCT03861819 1523 1527 O
, NCT03861819 1528 1529 O
write NCT03861819 1530 1535 O
, NCT03861819 1536 1537 O
and NCT03861819 1538 1541 O
understand NCT03861819 1542 1552 O
English NCT03861819 1553 1560 O

- NCT03861819 1563 1564 O
Transportation NCT03861819 1566 1580 O
to NCT03861819 1581 1583 O
the NCT03861819 1584 1587 O
exercise NCT03861819 1588 1596 O
and NCT03861819 1597 1600 O
testing NCT03861819 1601 1608 O
facility NCT03861819 1609 1617 O

Inclusion NCT03867071 0 9 O
Criteria NCT03867071 10 18 O
: NCT03867071 19 20 O

- NCT03867071 24 25 O
Patients NCT03867071 27 35 O
between NCT03867071 36 43 B-Eq-Comparison
18 NCT03867071 44 46 I-Eq-Comparison
to NCT03867071 47 49 I-Eq-Comparison
65 NCT03867071 50 52 I-Eq-Comparison
years NCT03867071 53 58 I-Eq-Comparison
old NCT03867071 59 62 B-Age

- NCT03867071 65 66 O
Patient NCT03867071 68 75 O
with NCT03867071 76 80 O
an NCT03867071 81 83 O
ASA NCT03867071 84 87 B-Condition
1 NCT03867071 88 89 B-Eq-Comparison
or NCT03867071 90 92 I-Eq-Comparison
2 NCT03867071 93 94 I-Eq-Comparison
( NCT03867071 95 96 O
ASA NCT03867071 97 100 O
1 NCT03867071 101 102 O
corresponding NCT03867071 103 116 O
to NCT03867071 117 119 O
a NCT03867071 120 121 O
patient NCT03867071 122 129 O
in NCT03867071 130 132 O
perfect NCT03867071 133 140 O
health NCT03867071 141 147 O
and NCT03867071 148 151 O
ASA NCT03867071 152 155 O
2 NCT03867071 156 157 O
to NCT03867071 158 160 O
a NCT03867071 161 162 O
patient NCT03867071 163 170 O
with NCT03867071 171 175 O
moderate NCT03867071 176 184 O
involvement NCT03867071 185 196 O
and NCT03867071 197 200 O
well NCT03867071 201 205 O
controlled NCT03867071 206 216 O
organ NCT03867071 217 222 O
function NCT03867071 223 231 O
) NCT03867071 232 233 O

- NCT03867071 237 238 O
patient NCT03867071 240 247 O
presenting NCT03867071 248 258 O
at NCT03867071 259 261 B-Eq-Comparison
least NCT03867071 262 267 I-Eq-Comparison
one NCT03867071 268 271 I-Eq-Comparison
of NCT03867071 272 274 O
the NCT03867071 275 278 B-Criteria-Count
following NCT03867071 279 288 I-Criteria-Count
fractures NCT03867071 289 298 B-Condition
: NCT03867071 299 300 O
Basin NCT03867071 301 306 B-Modifier
and NCT03867071 307 310 B-Or
/ NCT03867071 311 312 I-Or
or NCT03867071 313 315 I-Or
femur NCT03867071 316 321 B-Modifier
with NCT03867071 322 326 O
surgical NCT03867071 327 335 B-Procedure
indication NCT03867071 336 346 B-Indication
, NCT03867071 347 348 O
associated NCT03867071 349 359 O
or NCT03867071 360 362 O
not NCT03867071 363 366 O
with NCT03867071 367 371 O
other NCT03867071 372 377 B-Other
fractures NCT03867071 378 387 B-Condition
. NCT03867071 387 388 O

- NCT03867071 392 393 O
patient NCT03867071 395 402 O
with NCT03867071 403 407 O
hemoglobin NCT03867071 408 418 B-Observation
between NCT03867071 419 426 B-Eq-Comparison
9 NCT03867071 427 428 I-Eq-Comparison
and NCT03867071 429 432 I-Eq-Comparison
13 NCT03867071 433 435 I-Eq-Comparison
g NCT03867071 436 437 I-Eq-Comparison
/ NCT03867071 438 439 I-Eq-Comparison
dl NCT03867071 440 442 I-Eq-Comparison
at NCT03867071 443 445 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867071 446 449 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867071 450 454 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867071 455 457 O
admission NCT03867071 458 467 B-Encounter
on NCT03867071 468 470 O
trauma NCT03867071 471 477 O
department NCT03867071 478 488 O

Exclusion NCT03867071 489 498 O
Criteria NCT03867071 499 507 O
: NCT03867071 508 509 O

- NCT03867071 513 514 O
patient NCT03867071 516 523 O
with NCT03867071 524 528 O
contraindication NCT03867071 529 545 B-Contraindication
to NCT03867071 546 548 O
synthetic NCT03867071 549 558 B-Procedure
erythropoietin NCT03867071 559 573 I-Procedure

- NCT03867071 576 577 O
Patient NCT03867071 579 586 O
with NCT03867071 587 591 O
intravenous NCT03867071 592 603 B-Procedure
iron NCT03867071 604 608 I-Procedure
contraindication NCT03867071 609 625 B-Contraindication

- NCT03867071 628 629 O
pregnant NCT03867071 631 639 B-Condition
patient NCT03867071 640 647 O
or NCT03867071 648 650 B-Or
with NCT03867071 651 655 O
a NCT03867071 656 657 O
risk NCT03867071 658 662 B-Risk
of NCT03867071 663 665 O
pregnancy NCT03867071 666 675 B-Condition

- NCT03867071 678 679 O
patient NCT03867071 681 688 O
who NCT03867071 689 692 O
has NCT03867071 693 696 O
not NCT03867071 697 700 O
given NCT03867071 701 706 O
his NCT03867071 707 710 O
consent NCT03867071 711 718 O
or NCT03867071 719 721 O
does NCT03867071 722 726 O
not NCT03867071 727 730 O
understand NCT03867071 731 741 O
the NCT03867071 742 745 O
protocol NCT03867071 746 754 O

- NCT03867071 757 758 O
Patient NCT03867071 760 767 O
with NCT03867071 768 772 O
hemodynamic NCT03867071 773 784 B-Condition
instability NCT03867071 785 796 O

- NCT03867071 799 800 O
patient NCT03867071 802 809 O
participating NCT03867071 810 823 O
in NCT03867071 824 826 O
another NCT03867071 827 834 B-Other
research NCT03867071 835 843 B-Study
protocol NCT03867071 844 852 I-Study
for NCT03867071 853 856 O
less NCT03867071 857 861 B-Eq-Comparison
than NCT03867071 862 866 I-Eq-Comparison
3 NCT03867071 867 868 I-Eq-Comparison
months NCT03867071 869 875 I-Eq-Comparison
. NCT03867071 875 876 O


Inclusion NCT03862690 0 9 O
Criteria NCT03862690 10 18 O
: NCT03862690 19 20 O

- NCT03862690 24 25 O
Signed NCT03862690 27 33 O
consent NCT03862690 34 41 O
obtained NCT03862690 42 50 O
before NCT03862690 51 57 O
any NCT03862690 58 61 O
study NCT03862690 62 67 O
- NCT03862690 68 69 O
related NCT03862690 70 77 O
activities NCT03862690 78 88 O
( NCT03862690 89 90 O
study NCT03862690 91 96 O
- NCT03862690 97 98 O
related NCT03862690 99 106 O
activities NCT03862690 107 117 O
are NCT03862690 118 121 O
any NCT03862690 122 125 O
procedure NCT03862690 126 135 O
related NCT03862690 136 143 O
to NCT03862690 144 146 O
recording NCT03862690 147 156 O
of NCT03862690 157 159 O
data NCT03862690 160 164 O
according NCT03862690 165 174 O
to NCT03862690 175 177 O
the NCT03862690 178 181 O
protocol NCT03862690 182 190 O
) NCT03862690 191 192 O

- NCT03862690 196 197 O
The NCT03862690 199 202 O
decision NCT03862690 203 211 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862690 212 214 I-Assertion___Assertion-Type-Value:hypothetical
initiate NCT03862690 215 223 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03862690 224 233 B-Procedure
with NCT03862690 234 238 O
commercially NCT03862690 239 251 O
available NCT03862690 252 261 O
NovoMix NCT03862690 262 269 B-Drug
® NCT03862690 269 270 O
30 NCT03862690 271 273 I-Drug
has NCT03862690 274 277 O
been NCT03862690 278 282 O
made NCT03862690 283 287 O
by NCT03862690 288 290 O
the NCT03862690 291 294 O
patient NCT03862690 295 302 O
and NCT03862690 303 306 O
the NCT03862690 307 310 O
treating NCT03862690 311 319 O
physician NCT03862690 320 329 O
before NCT03862690 330 336 O
and NCT03862690 337 340 O
independently NCT03862690 341 354 O
from NCT03862690 355 359 O
the NCT03862690 360 363 O
decision NCT03862690 364 372 O
to NCT03862690 373 375 O
include NCT03862690 376 383 O
the NCT03862690 384 387 O
patient NCT03862690 388 395 O
in NCT03862690 396 398 O
this NCT03862690 399 403 O
study NCT03862690 404 409 O

- NCT03862690 412 413 O
Male NCT03862690 415 419 O
or NCT03862690 420 422 B-Or
female NCT03862690 423 429 O
, NCT03862690 430 431 O
greater NCT03862690 432 439 B-Eq-Comparison
than NCT03862690 440 444 I-Eq-Comparison
or NCT03862690 445 447 I-Eq-Comparison
equal NCT03862690 448 453 I-Eq-Comparison
to NCT03862690 454 456 I-Eq-Comparison
19 NCT03862690 457 459 I-Eq-Comparison
years NCT03862690 460 465 I-Age|Eq-Comparison
at NCT03862690 466 468 O
the NCT03862690 469 472 O
time NCT03862690 473 477 O
of NCT03862690 478 480 O
signing NCT03862690 481 488 O
informed NCT03862690 489 497 O
consent NCT03862690 498 505 O

- NCT03862690 508 509 O
Diagnosed NCT03862690 511 520 O
with NCT03862690 521 525 O
type NCT03862690 526 530 B-Modifier
2 NCT03862690 531 532 I-Modifier
diabetes NCT03862690 533 541 B-Condition
and NCT03862690 542 545 B-And
treated NCT03862690 546 553 B-Procedure
with NCT03862690 554 558 O
basal NCT03862690 559 564 B-Drug
insulin NCT03862690 565 572 I-Drug
plus NCT03862690 573 577 O
1 NCT03862690 578 579 B-Eq-Comparison
- NCT03862690 580 581 I-Eq-Comparison
3 NCT03862690 582 583 I-Eq-Comparison
bolus NCT03862690 584 589 I-Eq-Comparison
insulin NCT03862690 590 597 I-Eq-Comparison
injections NCT03862690 598 608 I-Eq-Comparison
per NCT03862690 609 612 I-Eq-Comparison
day NCT03862690 613 616 I-Eq-Comparison
for NCT03862690 617 620 O
at NCT03862690 621 623 B-Eq-Comparison
least NCT03862690 624 629 I-Eq-Comparison
24 NCT03862690 630 632 I-Eq-Comparison
weeks NCT03862690 633 638 I-Eq-Comparison
prior NCT03862690 639 644 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 645 647 I-Temporal-Connection___Temporal-Connection-Type-Value:before
informed NCT03862690 648 656 O
consent NCT03862690 657 664 O

- NCT03862690 667 668 O
Available NCT03862690 670 679 O
and NCT03862690 680 683 O
documented NCT03862690 684 694 O
HbA1c NCT03862690 695 700 B-Observation
value NCT03862690 701 706 O
less NCT03862690 707 711 B-Eq-Comparison
than NCT03862690 712 716 I-Eq-Comparison
or NCT03862690 717 719 I-Eq-Comparison
equal NCT03862690 720 725 I-Eq-Comparison
to NCT03862690 726 728 I-Eq-Comparison
12 NCT03862690 729 731 I-Eq-Comparison
weeks NCT03862690 732 737 I-Eq-Comparison
prior NCT03862690 738 743 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 744 746 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03862690 747 757 B-Eq-Comparison
of NCT03862690 758 760 O
NovoMix NCT03862690 761 768 B-Drug
® NCT03862690 768 769 O
30 NCT03862690 770 772 I-Drug
treatment NCT03862690 773 782 B-Procedure

Exclusion NCT03862690 783 792 O
Criteria NCT03862690 793 801 O
: NCT03862690 802 803 O

- NCT03862690 807 808 O
Previous NCT03862690 810 818 B-Eq-Comparison
participation NCT03862690 819 832 O
in NCT03862690 833 835 O
this NCT03862690 836 840 O
study NCT03862690 841 846 B-Study
. NCT03862690 846 847 O
Participation NCT03862690 849 862 O
is NCT03862690 863 865 O
defined NCT03862690 866 873 O
as NCT03862690 874 876 O
having NCT03862690 877 883 O
given NCT03862690 884 889 O
informed NCT03862690 890 898 O
consent NCT03862690 899 906 O
in NCT03862690 907 909 O
this NCT03862690 910 914 O
study NCT03862690 915 920 O

- NCT03862690 923 924 O
Mental NCT03862690 926 932 B-Condition
incapacity NCT03862690 933 943 I-Condition
, NCT03862690 944 945 O
unwillingness NCT03862690 946 959 B-Modifier
or NCT03862690 960 962 B-Or
language NCT03862690 963 971 B-Condition
barriers NCT03862690 972 980 I-Condition
precluding NCT03862690 981 991 O
adequate NCT03862690 992 1000 O
understanding NCT03862690 1001 1014 O
or NCT03862690 1015 1017 O
cooperation NCT03862690 1018 1029 O

- NCT03862690 1032 1033 O
Participation NCT03862690 1035 1048 O
in NCT03862690 1049 1051 O
any NCT03862690 1052 1055 O
clinical NCT03862690 1056 1064 B-Study
trial NCT03862690 1065 1070 I-Study
of NCT03862690 1071 1073 O
an NCT03862690 1074 1076 O
approved NCT03862690 1077 1085 O
or NCT03862690 1086 1088 B-Or
non NCT03862690 1089 1092 O
- NCT03862690 1093 1094 O
approved NCT03862690 1095 1103 O
investigational NCT03862690 1104 1119 B-Study
medicinal NCT03862690 1120 1129 B-Drug
product NCT03862690 1130 1137 I-Drug
within NCT03862690 1138 1144 B-Eq-Comparison
24 NCT03862690 1145 1147 I-Eq-Comparison
weeks NCT03862690 1148 1153 I-Eq-Comparison
prior NCT03862690 1154 1159 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 1160 1162 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03862690 1163 1173 B-Eq-Comparison
of NCT03862690 1174 1176 O
NovoMix NCT03862690 1177 1184 B-Drug
® NCT03862690 1184 1185 O
30 NCT03862690 1186 1188 I-Drug
treatment NCT03862690 1189 1198 B-Procedure
. NCT03862690 1198 1199 O
Clinical NCT03862690 1201 1209 O
trials NCT03862690 1210 1216 O
do NCT03862690 1217 1219 O
not NCT03862690 1220 1223 O
include NCT03862690 1224 1231 O
non NCT03862690 1232 1235 O
- NCT03862690 1236 1237 O
interventional NCT03862690 1238 1252 O
studies NCT03862690 1253 1260 O

- NCT03862690 1263 1264 O
Hypersensitivity NCT03862690 1266 1282 B-Condition
to NCT03862690 1283 1285 O
NovoMix NCT03862690 1286 1293 B-Drug
® NCT03862690 1293 1294 O
30 NCT03862690 1295 1297 I-Drug
or NCT03862690 1298 1300 B-Or
to NCT03862690 1301 1303 O
any NCT03862690 1304 1307 O
of NCT03862690 1308 1310 O
the NCT03862690 1311 1314 O
excipients NCT03862690 1315 1325 B-Coreference

- NCT03862690 1328 1329 O
Pregnancy NCT03862690 1331 1340 B-Condition
or NCT03862690 1341 1343 B-Or
intention NCT03862690 1344 1353 B-Assertion___Assertion-Type-Value:intention
of NCT03862690 1354 1356 O
becoming NCT03862690 1357 1365 O
pregnant NCT03862690 1366 1374 B-Condition

Inclusion NCT03865706 0 9 O
Criteria NCT03865706 10 18 O
: NCT03865706 19 20 O

1 NCT03865706 24 25 O
. NCT03865706 25 26 O
Hospitalized NCT03865706 28 40 B-Encounter
in NCT03865706 41 43 O
an NCT03865706 44 46 O
eligible NCT03865706 47 55 B-Assertion___Assertion-Type-Value:hypothetical
medical NCT03865706 56 63 O
ICU NCT03865706 64 67 O

2 NCT03865706 70 71 O
. NCT03865706 71 72 O
Age NCT03865706 74 77 B-Age
≥ NCT03865706 78 79 B-Eq-Comparison
18 NCT03865706 80 82 I-Eq-Comparison
years NCT03865706 83 88 I-Eq-Comparison
old NCT03865706 89 92 O
at NCT03865706 93 95 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865706 96 99 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865706 100 104 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865706 105 107 O
hospitalization NCT03865706 108 123 B-Encounter

3 NCT03865706 126 127 O
. NCT03865706 127 128 O
With NCT03865706 130 134 O
sepsis NCT03865706 135 141 B-Condition
as NCT03865706 142 144 O
defined NCT03865706 145 152 O
by NCT03865706 153 155 O
the NCT03865706 156 159 O
Sepsis NCT03865706 160 166 O
- NCT03865706 167 168 O
3 NCT03865706 169 170 O
( NCT03865706 171 172 O
2016 NCT03865706 173 177 O
) NCT03865706 178 179 O
consensus NCT03865706 180 189 O
as NCT03865706 190 192 O
a NCT03865706 193 194 O
known NCT03865706 195 200 B-Modifier
or NCT03865706 201 203 B-Or
suspected NCT03865706 204 213 B-Assertion___Assertion-Type-Value:possible
infection NCT03865706 214 223 B-Condition
with NCT03865706 224 228 B-And
a NCT03865706 229 230 O
SOFA NCT03865706 231 235 B-Observation
score NCT03865706 236 241 I-Observation
of NCT03865706 242 244 O
≥ NCT03865706 245 246 B-Eq-Comparison
2 NCT03865706 247 248 I-Eq-Comparison
points NCT03865706 249 255 I-Eq-Comparison
above NCT03865706 256 261 I-Eq-Comparison
baseline NCT03865706 262 270 I-Eq-Comparison

4 NCT03865706 273 274 O
. NCT03865706 274 275 O
Received NCT03865706 277 285 B-Eq-Comparison
broad NCT03865706 286 291 B-Modifier
- NCT03865706 292 293 I-Modifier
spectrum NCT03865706 294 302 I-Modifier
antibiotics NCT03865706 303 314 B-Drug
within NCT03865706 315 321 B-Eq-Comparison
the NCT03865706 322 325 I-Eq-Comparison
last NCT03865706 326 330 I-Eq-Comparison
24 NCT03865706 331 333 I-Eq-Comparison
hours NCT03865706 334 339 I-Eq-Comparison
or NCT03865706 340 342 B-Coreference|Or
ordered NCT03865706 343 350 O
and NCT03865706 351 354 O
pending NCT03865706 355 362 B-Assertion___Assertion-Type-Value:hypothetical
administration NCT03865706 363 377 I-Assertion___Assertion-Type-Value:hypothetical

5 NCT03865706 380 381 O
. NCT03865706 381 382 O
Able NCT03865706 384 388 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865706 389 391 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03865706 392 400 O
enrollment NCT03865706 401 411 B-Study
within NCT03865706 412 418 B-Eq-Comparison
4 NCT03865706 419 420 I-Eq-Comparison
hours NCT03865706 421 426 I-Eq-Comparison
of NCT03865706 427 429 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ICU NCT03865706 430 433 O
admission NCT03865706 434 443 B-Encounter
for NCT03865706 444 447 O
administration NCT03865706 448 462 O
of NCT03865706 463 465 O
the NCT03865706 466 469 O
intervention NCT03865706 470 482 B-Study
within NCT03865706 483 489 B-Eq-Comparison
6 NCT03865706 490 491 I-Eq-Comparison
hours NCT03865706 492 497 I-Eq-Comparison
of NCT03865706 498 500 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ICU NCT03865706 501 504 O
admission NCT03865706 505 514 B-Encounter

Exclusion NCT03865706 515 524 O
Criteria NCT03865706 525 533 O
: NCT03865706 534 535 O

1 NCT03865706 539 540 O
. NCT03865706 540 541 O
Inability NCT03865706 543 552 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865706 553 555 O
receive NCT03865706 556 563 O
oral NCT03865706 564 568 B-Modifier|Or
or NCT03865706 569 571 O
enteric NCT03865706 572 579 B-Modifier
fluids NCT03865706 580 586 B-Procedure

2 NCT03865706 589 590 O
. NCT03865706 590 591 O
Inulin NCT03865706 593 599 B-Drug
allergy NCT03865706 600 607 B-Allergy

3 NCT03865706 610 611 O
. NCT03865706 611 612 O
Hyponatremia NCT03865706 614 626 B-Condition
( NCT03865706 627 628 O
serum NCT03865706 629 634 B-Observation
sodium NCT03865706 635 641 I-Observation
≤ NCT03865706 642 643 B-Eq-Comparison
128 NCT03865706 644 647 I-Eq-Comparison
mEq NCT03865706 648 651 I-Eq-Comparison
/ NCT03865706 652 653 I-Eq-Comparison
L NCT03865706 654 655 I-Eq-Comparison
) NCT03865706 656 657 O

4 NCT03865706 661 662 O
. NCT03865706 662 663 O
Immunosuppression NCT03865706 665 682 B-Condition
, NCT03865706 683 684 O
defined NCT03865706 685 692 O
as NCT03865706 693 695 O
history NCT03865706 696 703 B-Eq-Comparison
of NCT03865706 704 706 O
solid NCT03865706 707 712 B-Procedure
organ NCT03865706 713 718 I-Or|Procedure
transplant NCT03865706 719 729 I-Procedure
or NCT03865706 730 732 O
as NCT03865706 733 735 O
receipt NCT03865706 736 743 B-Eq-Comparison
of NCT03865706 744 746 O
ablative NCT03865706 747 755 B-Procedure
chemotherapy NCT03865706 756 768 I-Procedure
, NCT03865706 769 770 O
steroids NCT03865706 771 779 B-Drug
at NCT03865706 780 782 O
the NCT03865706 783 786 O
equivalent NCT03865706 787 797 O
of NCT03865706 798 800 O
≥ NCT03865706 801 802 B-Eq-Comparison
5 NCT03865706 803 804 I-Eq-Comparison
mg NCT03865706 805 807 I-Eq-Comparison
/ NCT03865706 808 809 I-Eq-Comparison
day NCT03865706 810 813 I-Eq-Comparison
prednisone NCT03865706 814 824 B-Drug
, NCT03865706 825 826 O
antimetabolites NCT03865706 827 842 B-Drug|Drug
, NCT03865706 843 844 O
anti NCT03865706 845 849 O
- NCT03865706 850 851 I-Drug
TNFα NCT03865706 852 856 I-Drug
agents NCT03865706 857 863 I-Drug
, NCT03865706 864 865 O
calcineurin NCT03865706 866 877 B-Drug
inhibitors NCT03865706 878 888 I-Drug
, NCT03865706 889 890 O
or NCT03865706 891 893 B-Or
mycophenolate NCT03865706 894 907 B-Drug

5 NCT03865706 910 911 O
. NCT03865706 911 912 O
Surgery NCT03865706 914 921 B-Procedure
involving NCT03865706 922 931 O
the NCT03865706 932 935 O
intestinal NCT03865706 936 946 B-Modifier
lumen NCT03865706 947 952 I-Modifier
within NCT03865706 953 959 B-Eq-Comparison
30 NCT03865706 960 962 I-Eq-Comparison
days NCT03865706 963 967 I-Eq-Comparison
or NCT03865706 968 970 B-Or
known NCT03865706 971 976 O
intestinal NCT03865706 977 987 B-Condition
strictures NCT03865706 988 998 I-Condition

6 NCT03865706 1001 1002 O
. NCT03865706 1002 1003 O
Do NCT03865706 1005 1007 B-Observation|Observation
Not NCT03865706 1008 1011 I-Observation|Observation
Resuscitate NCT03865706 1012 1023 I-Observation
( NCT03865706 1024 1025 O
DNR NCT03865706 1026 1029 B-Observation
) NCT03865706 1030 1031 O
or NCT03865706 1032 1034 B-Or|Or
Do NCT03865706 1035 1037 O
Not NCT03865706 1038 1041 O
Intubate NCT03865706 1042 1050 I-Observation
( NCT03865706 1051 1052 O
DNI NCT03865706 1053 1056 B-Observation
) NCT03865706 1057 1058 O
status NCT03865706 1059 1065 O
, NCT03865706 1066 1067 O
or NCT03865706 1068 1070 O
" NCT03865706 1071 1072 O
no NCT03865706 1072 1074 B-Observation
escalation NCT03865706 1075 1085 I-Observation
of NCT03865706 1086 1088 I-Observation
care NCT03865706 1089 1093 I-Observation
" NCT03865706 1093 1094 O
orders NCT03865706 1095 1101 O

7 NCT03865706 1104 1105 O
. NCT03865706 1105 1106 O
Lack NCT03865706 1108 1112 O
capacity NCT03865706 1113 1121 O
for NCT03865706 1122 1125 O
consent NCT03865706 1126 1133 O
and NCT03865706 1134 1137 O
no NCT03865706 1138 1140 O
appropriate NCT03865706 1141 1152 O
Legally NCT03865706 1153 1160 O
Authorized NCT03865706 1161 1171 O
Representative NCT03865706 1172 1186 O
( NCT03865706 1187 1188 O
LAR NCT03865706 1189 1192 O
) NCT03865706 1193 1194 O


Inclusion NCT03863405 0 9 O
Criteria NCT03863405 10 18 O
: NCT03863405 19 20 O

- NCT03863405 24 25 O
Patients NCT03863405 27 35 O
older NCT03863405 36 41 I-Eq-Comparison
than NCT03863405 42 46 I-Eq-Comparison
18 NCT03863405 47 49 I-Eq-Comparison
years NCT03863405 50 55 I-Eq-Comparison
( NCT03863405 56 57 O
of NCT03863405 58 60 O
both NCT03863405 61 65 O
sexes NCT03863405 66 71 O
) NCT03863405 72 73 O
diagnosed NCT03863405 74 83 O
with NCT03863405 84 88 O
rheumatoid NCT03863405 89 99 B-Condition
arthritis NCT03863405 100 109 I-Condition
according NCT03863405 110 119 O
to NCT03863405 120 122 O
ACR NCT03863405 123 126 O
/ NCT03863405 127 128 O
EULAR NCT03863405 129 134 O
2010 NCT03863405 135 139 O
criteria NCT03863405 140 148 O
. NCT03863405 149 150 O

- NCT03863405 154 155 O
Patients NCT03863405 157 165 O
with NCT03863405 166 170 O
moderate NCT03863405 171 179 B-Eq-Comparison
to NCT03863405 180 182 I-Eq-Comparison
high NCT03863405 183 187 I-Eq-Comparison
disease NCT03863405 188 195 B-Condition
activity NCT03863405 196 204 I-Condition
( NCT03863405 205 206 O
DAS NCT03863405 207 210 B-Observation
- NCT03863405 211 212 I-Observation
28 NCT03863405 213 215 I-Observation
. NCT03863405 216 217 I-Observation
score NCT03863405 219 224 I-Observation
greater NCT03863405 225 232 B-Eq-Comparison
than NCT03863405 233 237 I-Eq-Comparison
3.2 NCT03863405 238 241 I-Eq-Comparison
) NCT03863405 242 243 O

- NCT03863405 247 248 O
Patients NCT03863405 250 258 O
received NCT03863405 259 267 B-Eq-Comparison
the NCT03863405 268 271 O
standard NCT03863405 272 280 B-Procedure
therapy NCT03863405 281 288 I-Procedure
( NCT03863405 289 290 O
i. NCT03863405 291 293 O
e. NCT03863405 294 296 O
one NCT03863405 298 301 B-Eq-Comparison
or NCT03863405 302 304 I-Eq-Comparison
more NCT03863405 305 309 I-Eq-Comparison
conventional NCT03863405 310 322 O
DMARDs NCT03863405 323 329 B-Drug
) NCT03863405 330 331 O
for NCT03863405 332 335 O
at NCT03863405 336 338 B-Eq-Comparison
least NCT03863405 339 344 I-Eq-Comparison
three NCT03863405 345 350 I-Eq-Comparison
months NCT03863405 351 357 I-Eq-Comparison
. NCT03863405 357 358 O

Exclusion NCT03863405 360 369 O
Criteria NCT03863405 370 378 O
: NCT03863405 379 380 O

- NCT03863405 384 385 O
Known NCT03863405 387 392 O
hypersensitivity NCT03863405 393 409 B-Condition
to NCT03863405 410 412 O
metformin NCT03863405 413 422 B-Drug
. NCT03863405 422 423 O

- NCT03863405 427 428 O
Patients NCT03863405 430 438 O
who NCT03863405 439 442 O
have NCT03863405 443 447 O
a NCT03863405 448 449 O
prior NCT03863405 450 455 B-Eq-Comparison
diagnosis NCT03863405 456 465 O
with NCT03863405 466 470 O
diabetes NCT03863405 471 479 B-Condition
mellitus NCT03863405 480 488 I-Condition
. NCT03863405 488 489 O

- NCT03863405 493 494 O
Patients NCT03863405 496 504 O
receive NCT03863405 505 512 B-Eq-Comparison
metformin NCT03863405 513 522 B-Drug
for NCT03863405 523 526 O
any NCT03863405 527 530 O
other NCT03863405 531 536 B-Other
indications NCT03863405 537 548 B-Indication
. NCT03863405 548 549 O

- NCT03863405 553 554 O
Patients NCT03863405 556 564 O
with NCT03863405 565 569 O
congestive NCT03863405 570 580 B-Condition
heart NCT03863405 581 586 I-Condition
failure NCT03863405 587 594 I-Condition
. NCT03863405 594 595 O

- NCT03863405 599 600 O
Patients NCT03863405 602 610 O
with NCT03863405 611 615 O
a NCT03863405 616 617 O
history NCT03863405 618 625 B-Eq-Comparison
of NCT03863405 626 628 O
myocardial NCT03863405 629 639 B-Condition
infarction NCT03863405 640 650 I-Condition
. NCT03863405 650 651 O

- NCT03863405 655 656 O
Patients NCT03863405 658 666 O
with NCT03863405 667 671 O
severe NCT03863405 672 678 O
anemia NCT03863405 679 685 B-Condition
. NCT03863405 685 686 O

- NCT03863405 690 691 O
Patients NCT03863405 693 701 O
with NCT03863405 702 706 O
active NCT03863405 707 713 B-Eq-Comparison
infections NCT03863405 714 724 B-Condition
or NCT03863405 725 727 B-Or
other NCT03863405 728 733 B-Other
inflammatory NCT03863405 734 746 B-Condition
diseases NCT03863405 747 755 I-Condition
. NCT03863405 755 756 O

- NCT03863405 760 761 O
Patients NCT03863405 763 771 O
receiving NCT03863405 772 781 B-Eq-Comparison
biological NCT03863405 782 792 B-Procedure
therapy NCT03863405 793 800 I-Procedure
. NCT03863405 800 801 O

- NCT03863405 805 806 O
Pregnancy NCT03863405 808 817 B-Condition
or NCT03863405 818 820 B-Or
lactation NCT03863405 821 830 B-Condition
. NCT03863405 830 831 O

- NCT03863405 835 836 O
Patients NCT03863405 838 846 O
with NCT03863405 847 851 O
impaired NCT03863405 852 860 B-Condition
liver NCT03863405 861 866 I-Condition
functions NCT03863405 867 876 I-Condition
. NCT03863405 876 877 O

- NCT03863405 881 882 O
Patients NCT03863405 884 892 O
with NCT03863405 893 897 O
impaired NCT03863405 898 906 B-Condition
kidney NCT03863405 907 913 I-Condition
functions NCT03863405 914 923 I-Condition
( NCT03863405 924 925 O
serum NCT03863405 926 931 B-Observation
creatinine NCT03863405 932 942 I-Observation
concentrations NCT03863405 943 957 I-Observation
≥ NCT03863405 958 959 B-Eq-Comparison|Eq-Comparison
1.5 NCT03863405 960 963 I-Eq-Comparison
and NCT03863405 964 967 B-Or|Or
≥ NCT03863405 968 969 O
1.4 NCT03863405 970 973 I-Eq-Comparison
mg NCT03863405 974 976 I-Eq-Comparison
/ NCT03863405 977 978 I-Eq-Comparison
dL NCT03863405 979 981 I-Eq-Comparison
in NCT03863405 982 984 O
males NCT03863405 985 990 O
and NCT03863405 991 994 O
females NCT03863405 995 1002 O
respectively NCT03863405 1003 1015 O
) NCT03863405 1016 1017 O
. NCT03863405 1018 1019 O

- NCT03863405 1023 1024 O
Patients NCT03863405 1026 1034 O
with NCT03863405 1035 1039 O
malignancies NCT03863405 1040 1052 B-Condition
. NCT03863405 1052 1053 O

Inclusion NCT03868020 0 9 O
Criteria NCT03868020 10 18 O
: NCT03868020 19 20 O

- NCT03868020 24 25 O
Adults NCT03868020 27 33 O
with NCT03868020 34 38 B-And
biopsy NCT03868020 39 45 B-Procedure
proven NCT03868020 46 52 O
metastatic NCT03868020 53 63 B-Modifier
cervical NCT03868020 64 72 I-Modifier
nodal NCT03868020 73 78 I-Modifier
squamous NCT03868020 79 87 I-Modifier
cell NCT03868020 88 92 I-Modifier
carcinoma NCT03868020 93 102 B-Condition

- NCT03868020 105 106 O
CT NCT03868020 108 110 B-Procedure
of NCT03868020 111 113 O
the NCT03868020 114 117 O
neck NCT03868020 118 122 B-Modifier
with NCT03868020 123 127 B-And
contrast NCT03868020 128 136 B-Modifier
that NCT03868020 137 141 O
does NCT03868020 142 146 O
not NCT03868020 147 150 B-Negation
confidently NCT03868020 151 162 O
identify NCT03868020 163 171 O
a NCT03868020 172 173 O
primary NCT03868020 174 181 B-Modifier
oropharyngeal NCT03868020 182 195 I-Modifier
site NCT03868020 196 200 I-Modifier
of NCT03868020 201 203 O
disease NCT03868020 204 211 B-Coreference

- NCT03868020 214 215 O
Planned NCT03868020 217 224 B-Eq-Comparison
standard NCT03868020 225 233 O
of NCT03868020 234 236 O
care NCT03868020 237 241 O
18 NCT03868020 242 244 B-Modifier
F NCT03868020 245 246 O
- NCT03868020 247 248 I-Modifier
FDG NCT03868020 249 252 I-Modifier
PET NCT03868020 253 256 B-Procedure
CT NCT03868020 257 259 I-Procedure
examination NCT03868020 260 271 I-Procedure

- NCT03868020 274 275 O
Planned NCT03868020 277 284 B-Eq-Comparison
standard NCT03868020 285 293 O
of NCT03868020 294 296 O
care NCT03868020 297 301 B-Procedure
exam NCT03868020 302 306 I-Procedure
under NCT03868020 307 312 O
anesthesia NCT03868020 313 323 B-Procedure
with NCT03868020 324 328 B-And
oropharyngeal NCT03868020 329 342 B-Procedure
surgical NCT03868020 343 351 I-Procedure
biopsy NCT03868020 352 358 I-Procedure

Exclusion NCT03868020 359 368 O
Criteria NCT03868020 369 377 O
: NCT03868020 378 379 O

- NCT03868020 383 384 O
Pregnant NCT03868020 386 394 B-Condition
women NCT03868020 395 400 O

- NCT03868020 403 404 O
Known NCT03868020 406 411 O
allergy NCT03868020 412 419 B-Allergy
to NCT03868020 420 422 O
FDG NCT03868020 423 426 B-Drug
, NCT03868020 427 428 O
fluciclovine NCT03868020 429 441 B-Drug
, NCT03868020 442 443 O
or NCT03868020 444 446 B-Or
iodine NCT03868020 447 453 B-Modifier
- NCT03868020 454 455 I-Modifier
based NCT03868020 456 461 I-Modifier
contrast NCT03868020 462 470 B-Drug
agents NCT03868020 471 477 I-Drug

- NCT03868020 480 481 O
Severe NCT03868020 483 489 O
renal NCT03868020 490 495 B-Condition
dysfunction NCT03868020 496 507 I-Condition
( NCT03868020 508 509 O
glomerular NCT03868020 510 520 B-Observation
filtrate NCT03868020 521 529 I-Observation
rate NCT03868020 530 534 I-Observation
[ NCT03868020 535 536 O
within NCT03868020 537 543 B-Eq-Comparison
30 NCT03868020 544 546 I-Eq-Comparison
days NCT03868020 547 551 I-Eq-Comparison
] NCT03868020 552 553 O
less NCT03868020 554 558 B-Eq-Comparison
than NCT03868020 559 563 I-Eq-Comparison
30 NCT03868020 564 566 I-Eq-Comparison
) NCT03868020 567 568 O

- NCT03868020 572 573 O
Inability NCT03868020 575 584 B-Condition
to NCT03868020 585 587 I-Condition
tolerate NCT03868020 588 596 O
lying NCT03868020 597 602 I-Condition
supine NCT03868020 603 609 I-Condition
, NCT03868020 610 611 O
relatively NCT03868020 612 622 B-Modifier
motionless NCT03868020 623 633 I-Modifier
for NCT03868020 634 637 O
up NCT03868020 638 640 B-Eq-Comparison
to NCT03868020 641 643 I-Eq-Comparison
1 NCT03868020 644 645 I-Eq-Comparison
hour NCT03868020 646 650 I-Eq-Comparison

Inclusion NCT03863613 0 9 O
Criteria NCT03863613 10 18 O
: NCT03863613 19 20 O

- NCT03863613 24 25 O
Women NCT03863613 27 32 O
with NCT03863613 33 37 B-And
a NCT03863613 38 39 O
twin NCT03863613 40 44 B-Modifier
pregnancy NCT03863613 45 54 B-Condition
( NCT03863613 55 56 O
mono NCT03863613 57 61 B-Modifier
- NCT03863613 62 63 I-Modifier
and NCT03863613 64 67 B-Or
di NCT03863613 68 70 B-Modifier
- NCT03863613 71 72 I-Modifier
chorionic NCT03863613 73 82 I-Modifier
) NCT03863613 83 84 O

- NCT03863613 88 89 O
16 NCT03863613 91 93 B-Eq-Comparison
0 NCT03863613 94 95 I-Eq-Comparison
/ NCT03863613 96 97 I-Eq-Comparison
7 NCT03863613 98 99 I-Eq-Comparison
to NCT03863613 100 102 I-Eq-Comparison
22 NCT03863613 103 105 I-Eq-Comparison
0 NCT03863613 106 107 O
/ NCT03863613 108 109 O
7 NCT03863613 110 111 O
weeks NCT03863613 112 117 I-Eq-Comparison
of NCT03863613 118 120 O
gestation NCT03863613 121 130 B-Observation

- NCT03863613 133 134 O
Maternal NCT03863613 136 144 O
age NCT03863613 145 148 B-Age
≥ NCT03863613 149 150 B-Eq-Comparison
18 NCT03863613 151 153 I-Eq-Comparison
yrs NCT03863613 154 157 I-Eq-Comparison

- NCT03863613 160 161 O
Cervical NCT03863613 163 171 B-Observation
length NCT03863613 172 178 I-Observation
≤ NCT03863613 179 180 B-Eq-Comparison
28 NCT03863613 181 183 I-Eq-Comparison
mm NCT03863613 184 186 I-Eq-Comparison

- NCT03863613 189 190 O
Informed NCT03863613 192 200 O
consent NCT03863613 201 208 O

- NCT03863613 211 212 O
Not NCT03863613 214 217 B-Negation
participating NCT03863613 218 231 O
in NCT03863613 232 234 O
another NCT03863613 235 242 B-Other
preterm NCT03863613 243 250 B-Modifier
birth NCT03863613 251 256 B-Birth
study NCT03863613 257 262 B-Study
at NCT03863613 263 265 O
the NCT03863613 266 269 O
same NCT03863613 270 274 O
time NCT03863613 275 279 O

Exclusion NCT03863613 280 289 O
Criteria NCT03863613 290 298 O
: NCT03863613 299 300 O

- NCT03863613 304 305 O
Uterine NCT03863613 307 314 B-Condition
anomalies NCT03863613 315 324 I-Condition

- NCT03863613 327 328 O
Cervical NCT03863613 330 338 B-Condition
dilation NCT03863613 339 347 I-Condition
with NCT03863613 348 352 B-And
visible NCT03863613 353 360 O
amniotic NCT03863613 361 369 B-Condition
membranes NCT03863613 370 379 I-Condition
or NCT03863613 380 382 B-Or
amniotic NCT03863613 383 391 B-Condition
membranes NCT03863613 392 401 I-Condition
prolapsed NCT03863613 402 411 I-Condition
into NCT03863613 412 416 B-Modifier
the NCT03863613 417 420 I-Modifier
vagina NCT03863613 421 427 I-Modifier

- NCT03863613 430 431 I-Modifier
Twin NCT03863613 433 437 B-Modifier
- NCT03863613 438 439 O
to NCT03863613 440 442 I-Modifier
- NCT03863613 443 444 O
twin NCT03863613 445 449 I-Modifier
transfusion NCT03863613 450 461 B-Condition
syndrome NCT03863613 462 470 I-Condition

- NCT03863613 473 474 O
Stillbirth NCT03863613 476 486 B-Condition
or NCT03863613 487 489 B-Or
major NCT03863613 490 495 O
congenital NCT03863613 496 506 B-Condition
abnormalities NCT03863613 507 520 I-Condition
in NCT03863613 521 523 O
any NCT03863613 524 527 O
of NCT03863613 528 530 O
the NCT03863613 531 534 O
fetus NCT03863613 535 540 B-Modifier

- NCT03863613 543 544 O
Severe NCT03863613 546 552 O
vaginal NCT03863613 553 560 B-Condition
discharge NCT03863613 561 570 I-Condition

- NCT03863613 573 574 O
Acute NCT03863613 576 581 O
vaginitis NCT03863613 582 591 B-Condition
or NCT03863613 592 594 B-Or
cervicitis NCT03863613 595 605 B-Condition

- NCT03863613 608 609 O
Vaginal NCT03863613 611 618 B-Modifier
bleeding NCT03863613 619 627 B-Condition

- NCT03863613 630 631 O
Placental NCT03863613 633 642 B-Condition
preavia NCT03863613 643 650 I-Condition|Condition

- NCT03863613 653 654 O
Vasa NCT03863613 656 660 B-Condition
preavia NCT03863613 661 668 O

- NCT03863613 671 672 O
Premature NCT03863613 674 683 B-Modifier
rupture NCT03863613 684 691 B-Condition
of NCT03863613 692 694 I-Condition
membranes NCT03863613 695 704 I-Condition

- NCT03863613 707 708 O
Premature NCT03863613 710 719 B-Modifier
labor NCT03863613 720 725 B-Condition
with NCT03863613 726 730 B-And|Negation
/ NCT03863613 731 732 B-Or
without NCT03863613 733 740 O
ruptured NCT03863613 741 749 B-Condition
membrane NCT03863613 750 758 I-Condition

- NCT03863613 761 762 O
Suspicion NCT03863613 764 773 B-Assertion___Assertion-Type-Value:possible
of NCT03863613 774 776 O
chorioamnionitis NCT03863613 777 793 B-Condition

- NCT03863613 796 797 O
Cerclage NCT03863613 799 807 B-Condition
in NCT03863613 808 810 I-Condition
place NCT03863613 811 816 I-Condition
or NCT03863613 817 819 B-Or
unable NCT03863613 820 826 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863613 827 829 O
undergo NCT03863613 830 837 O
cervical NCT03863613 838 846 B-Procedure
cerclage NCT03863613 847 855 B-Modifier
or NCT03863613 856 858 B-Or
pessary NCT03863613 859 866 B-Modifier

Inclusion NCT03867461 0 9 O
Criteria NCT03867461 10 18 O
: NCT03867461 19 20 O

- NCT03867461 24 25 O
Adults NCT03867461 27 33 O
determined NCT03867461 34 44 O
to NCT03867461 45 47 O
be NCT03867461 48 50 O
candidates NCT03867461 51 61 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867461 62 65 I-Assertion___Assertion-Type-Value:hypothetical
venous NCT03867461 66 72 B-Procedure
sinus NCT03867461 73 78 I-Procedure
stenting NCT03867461 79 87 I-Procedure

Inclusion NCT03866031 0 9 O
Criteria NCT03866031 10 18 O
: NCT03866031 19 20 O

1 NCT03866031 24 25 O
. NCT03866031 25 26 O
the NCT03866031 28 31 O
patient NCT03866031 32 39 O
should NCT03866031 40 46 O
be NCT03866031 47 49 O
completely NCT03866031 50 60 O
edentulous NCT03866031 61 71 B-Condition
for NCT03866031 72 75 O
at NCT03866031 76 78 B-Eq-Comparison
least NCT03866031 79 84 I-Eq-Comparison
6 NCT03866031 85 86 I-Eq-Comparison
months NCT03866031 87 93 I-Eq-Comparison
. NCT03866031 93 94 O

2 NCT03866031 98 99 O
. NCT03866031 99 100 O
first NCT03866031 102 107 O
class NCT03866031 108 113 O
jaw NCT03866031 114 117 O
relation NCT03866031 118 126 O
. NCT03866031 126 127 O

3 NCT03866031 131 132 O
. NCT03866031 132 133 O
adequate NCT03866031 135 143 O
bone NCT03866031 144 148 B-Condition|Observation
for NCT03866031 149 152 O
an NCT03866031 153 155 O
implant NCT03866031 156 163 B-Procedure
length NCT03866031 164 170 B-Modifier
of NCT03866031 171 173 O
at NCT03866031 174 176 B-Eq-Comparison
least NCT03866031 177 182 I-Eq-Comparison
10 NCT03866031 183 185 I-Eq-Comparison
mm NCT03866031 186 188 I-Eq-Comparison
and NCT03866031 189 192 B-And
diameter NCT03866031 193 201 B-Modifier
of NCT03866031 202 204 O
at NCT03866031 205 207 B-Eq-Comparison
least NCT03866031 208 213 I-Eq-Comparison
2.75 NCT03866031 214 218 I-Eq-Comparison
mm NCT03866031 219 221 I-Eq-Comparison
. NCT03866031 221 222 O

4 NCT03866031 226 227 O
. NCT03866031 227 228 O
the NCT03866031 230 233 O
patients NCT03866031 234 242 O
should NCT03866031 243 249 O
be NCT03866031 250 252 O
able NCT03866031 253 257 O
to NCT03866031 258 260 O
speak NCT03866031 261 266 O
and NCT03866031 267 270 O
write NCT03866031 271 276 O
in NCT03866031 277 279 O
arabic NCT03866031 280 286 O
. NCT03866031 286 287 O

Exclusion NCT03866031 289 298 O
Criteria NCT03866031 299 307 O
: NCT03866031 308 309 O

1 NCT03866031 311 312 O
) NCT03866031 313 314 O
patients NCT03866031 315 323 O
who NCT03866031 324 327 O
received NCT03866031 328 336 B-Eq-Comparison
radiotherapy NCT03866031 337 349 B-Procedure
to NCT03866031 350 352 O
the NCT03866031 353 356 O
head NCT03866031 357 361 B-Modifier
or NCT03866031 362 364 B-Or
neck NCT03866031 365 369 B-Modifier
region NCT03866031 370 376 O
for NCT03866031 377 380 O
tumors NCT03866031 381 387 B-Condition
. NCT03866031 387 388 O
( NCT03866031 390 391 O
2 NCT03866031 392 393 O
) NCT03866031 394 395 O
a NCT03866031 396 397 O
history NCT03866031 398 405 B-Eq-Comparison
of NCT03866031 406 408 O
chemotherapy NCT03866031 409 421 B-Procedure
. NCT03866031 421 422 O
( NCT03866031 424 425 O
3 NCT03866031 426 427 O
) NCT03866031 428 429 O
patients NCT03866031 430 438 O
on NCT03866031 439 441 B-Eq-Comparison
long NCT03866031 442 446 B-Modifier
- NCT03866031 447 448 I-Modifier
term NCT03866031 449 453 I-Modifier
steroids NCT03866031 454 462 B-Drug
, NCT03866031 463 464 O
or NCT03866031 465 467 B-Or
bisphosphonates NCT03866031 468 483 B-Drug
. NCT03866031 483 484 O
( NCT03866031 486 487 O
4 NCT03866031 488 489 O
) NCT03866031 490 491 O
heavy NCT03866031 492 497 O
smokers NCT03866031 498 505 B-Condition
. NCT03866031 505 506 O

( NCT03866031 509 510 O
5 NCT03866031 511 512 O
) NCT03866031 513 514 O
patients NCT03866031 515 523 O
with NCT03866031 524 528 O
physical NCT03866031 529 537 B-Modifier
and NCT03866031 538 541 B-Or
mental NCT03866031 542 548 B-Modifier
dis NCT03866031 549 552 B-Condition
- NCT03866031 553 554 I-Condition
abilities NCT03866031 555 564 I-Condition
that NCT03866031 565 569 O
interfere NCT03866031 570 579 O
with NCT03866031 580 584 O
the NCT03866031 585 588 O
maintenance NCT03866031 589 600 O
of NCT03866031 601 603 O
implants NCT03866031 604 612 B-Procedure
. NCT03866031 612 613 O

( NCT03866031 616 617 O
6 NCT03866031 618 619 O
) NCT03866031 620 621 O
uncontrolled NCT03866031 622 634 B-Modifier
systematic NCT03866031 635 645 I-Modifier
disease NCT03866031 646 653 B-Condition
that NCT03866031 654 658 O
could NCT03866031 659 664 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03866031 665 675 O
implant NCT03866031 676 683 B-Procedure
surgery NCT03866031 684 691 I-Procedure
. NCT03866031 691 692 O
( NCT03866031 694 695 O
7 NCT03866031 696 697 O
) NCT03866031 698 699 O
extreme NCT03866031 700 707 O
bruxism NCT03866031 708 715 B-Condition
. NCT03866031 715 716 O
( NCT03866031 718 719 O
8 NCT03866031 720 721 O
) NCT03866031 722 723 O
infectious NCT03866031 724 734 B-Condition
disease NCT03866031 735 742 I-Condition
. NCT03866031 742 743 O
( NCT03866031 745 746 O
9 NCT03866031 747 748 O
) NCT03866031 749 750 O
temporomandibular NCT03866031 751 768 B-Condition
joint NCT03866031 769 774 I-Condition
dysfunction NCT03866031 775 786 I-Condition
. NCT03866031 786 787 O


Inclusion NCT03860454 0 9 O
Criteria NCT03860454 10 18 O
: NCT03860454 19 20 O

- NCT03860454 24 25 O
LMNA NCT03860454 27 31 B-Condition
+ NCT03860454 32 33 O
cases NCT03860454 34 39 O
with NCT03860454 40 44 B-And
pathogenic NCT03860454 45 55 B-Condition
LMNA NCT03860454 56 60 I-Condition
mutations NCT03860454 61 70 I-Condition
for NCT03860454 71 74 O
LMNA NCT03860454 75 79 B-Condition
+ NCT03860454 80 81 O
and NCT03860454 82 85 B-Or
heart NCT03860454 86 91 B-Observation
myocardial NCT03860454 92 102 I-Observation
samples NCT03860454 103 110 I-Observation
from NCT03860454 111 115 O
the NCT03860454 116 119 O
explanted NCT03860454 120 129 B-Modifier
hearts NCT03860454 130 136 I-Modifier
of NCT03860454 137 139 O
LMNA NCT03860454 140 144 B-Condition
+ NCT03860454 145 146 O
patients NCT03860454 147 155 O
who NCT03860454 156 159 B-And
are NCT03860454 160 163 O
scheduled NCT03860454 164 173 B-Eq-Comparison
to NCT03860454 174 176 I-Eq-Comparison
undergo NCT03860454 177 184 I-Eq-Comparison
clinically NCT03860454 185 195 O
indicated NCT03860454 196 205 B-Indication
heart NCT03860454 206 211 B-Procedure
transplantation NCT03860454 212 227 I-Procedure
at NCT03860454 228 230 O
the NCT03860454 231 234 O
Papworth NCT03860454 235 243 O
Hospital NCT03860454 244 252 O
NHS NCT03860454 253 256 O
Trust NCT03860454 257 262 O
. NCT03860454 262 263 O

- NCT03860454 267 268 O
DCMWT NCT03860454 270 275 B-Condition
cases NCT03860454 276 281 O
: NCT03860454 282 283 O
patients NCT03860454 284 292 O
with NCT03860454 293 297 O
heart NCT03860454 298 303 B-Condition
muscle NCT03860454 304 310 I-Condition
failure NCT03860454 311 318 I-Condition
but NCT03860454 319 322 B-And
with NCT03860454 323 327 O
wild NCT03860454 328 332 B-Modifier
- NCT03860454 333 334 I-Modifier
type NCT03860454 335 339 I-Modifier
lamin NCT03860454 340 345 B-Condition
gene NCT03860454 346 350 I-Condition
. NCT03860454 350 351 O
Heart NCT03860454 353 358 B-Observation
myocardial NCT03860454 359 369 I-Observation
samples NCT03860454 370 377 I-Observation
from NCT03860454 378 382 O
the NCT03860454 383 386 O
explanted NCT03860454 387 396 B-Modifier
hearts NCT03860454 397 403 I-Modifier
of NCT03860454 404 406 O
DCMWT NCT03860454 407 412 B-Condition
patients NCT03860454 413 421 O
who NCT03860454 422 425 B-And
are NCT03860454 426 429 O
scheduled NCT03860454 430 439 B-Eq-Comparison
to NCT03860454 440 442 O
undergo NCT03860454 443 450 O
clinically NCT03860454 451 461 O
indicated NCT03860454 462 471 B-Indication
heart NCT03860454 472 477 B-Procedure
transplantation NCT03860454 478 493 I-Procedure
at NCT03860454 494 496 O
the NCT03860454 497 500 O
Papworth NCT03860454 501 509 O
Hospital NCT03860454 510 518 O
NHS NCT03860454 519 522 O
Trust NCT03860454 523 528 O
. NCT03860454 528 529 O

- NCT03860454 533 534 O
HV NCT03860454 536 538 O
( NCT03860454 539 540 O
controls NCT03860454 541 549 O
) NCT03860454 550 551 O
: NCT03860454 553 554 O
matched NCT03860454 555 562 O
to NCT03860454 563 565 O
cases NCT03860454 566 571 O
. NCT03860454 571 572 O

Exclusion NCT03860454 574 583 O
Criteria NCT03860454 584 592 O
: NCT03860454 593 594 O

- NCT03860454 598 599 I-Condition
Needle NCT03860454 601 607 B-Condition
- NCT03860454 608 609 O
phobia NCT03860454 610 616 I-Condition
that NCT03860454 617 621 O
would NCT03860454 622 627 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03860454 628 636 B-Negation
blood NCT03860454 637 642 B-Procedure
- NCT03860454 643 644 I-Procedure
letting NCT03860454 645 652 I-Procedure

- NCT03860454 655 656 O
Participants NCT03860454 658 670 O
unwilling NCT03860454 671 680 O
to NCT03860454 681 683 O
consent NCT03860454 684 691 O

- NCT03860454 694 695 O
Patients NCT03860454 697 705 O
that NCT03860454 706 710 O
have NCT03860454 711 715 O
a NCT03860454 716 717 O
conventional NCT03860454 718 730 O
contraindication NCT03860454 731 747 B-Contraindication
for NCT03860454 748 751 O
cardiac NCT03860454 752 759 B-Procedure
magnetic NCT03860454 760 768 I-Procedure
resonance NCT03860454 769 778 I-Procedure
imaging NCT03860454 779 786 I-Procedure
( NCT03860454 787 788 O
MRI NCT03860454 789 792 B-Procedure
) NCT03860454 793 794 O
. NCT03860454 795 796 O

- NCT03860454 800 801 O
Patients NCT03860454 803 811 O
that NCT03860454 812 816 O
have NCT03860454 817 821 O
had NCT03860454 822 825 O
a NCT03860454 826 827 O
blood NCT03860454 828 833 B-Procedure
transfusion NCT03860454 834 845 I-Procedure
within NCT03860454 846 852 B-Eq-Comparison
the NCT03860454 853 856 I-Eq-Comparison
last NCT03860454 857 861 I-Eq-Comparison
month NCT03860454 862 867 I-Eq-Comparison
and NCT03860454 868 871 B-Or
patients NCT03860454 872 880 O
having NCT03860454 881 887 B-Eq-Comparison
haemodialysis NCT03860454 888 901 B-Procedure
will NCT03860454 902 906 O
be NCT03860454 907 909 O
excluded NCT03860454 910 918 B-Negation
. NCT03860454 918 919 O

Inclusion NCT03869515 0 9 O
Criteria NCT03869515 10 18 O
: NCT03869515 19 20 O

- NCT03869515 24 25 O
The NCT03869515 27 30 O
chILD NCT03869515 31 36 B-Condition
syndrome NCT03869515 37 45 I-Condition
exists NCT03869515 46 52 O
when NCT03869515 53 57 O
a NCT03869515 58 59 O
child NCT03869515 60 65 B-Family-Member___Family-Member-Type:child
with NCT03869515 66 70 O
DLD NCT03869515 71 74 B-Condition
has NCT03869515 75 78 O
had NCT03869515 79 82 O
the NCT03869515 83 86 O
common NCT03869515 87 93 O
causes NCT03869515 94 100 B-Condition
of NCT03869515 101 103 O
DLD NCT03869515 104 107 B-Condition
excluded NCT03869515 108 116 B-Negation
as NCT03869515 117 119 O
the NCT03869515 120 123 O
primary NCT03869515 124 131 O
diagnosis NCT03869515 132 141 O
and NCT03869515 142 145 B-And
has NCT03869515 146 149 O
at NCT03869515 150 152 B-Eq-Comparison
least NCT03869515 153 158 I-Eq-Comparison
three NCT03869515 159 164 I-Eq-Comparison
of NCT03869515 165 167 B-Criteria-Count
the NCT03869515 168 171 I-Criteria-Count
following NCT03869515 172 181 I-Criteria-Count
four NCT03869515 182 186 B-Eq-Comparison
criteria NCT03869515 187 195 O
: NCT03869515 196 197 O
( NCT03869515 198 199 O
1 NCT03869515 200 201 O
) NCT03869515 202 203 O
respiratory NCT03869515 204 215 B-Condition
symptoms NCT03869515 216 224 B-Assertion___Assertion-Type-Value:possible
( NCT03869515 225 226 O
e. NCT03869515 227 229 O
g. NCT03869515 230 232 O
, NCT03869515 233 234 O
cough NCT03869515 235 240 B-Condition
, NCT03869515 241 242 O
rapid NCT03869515 243 248 B-Modifier
and NCT03869515 249 252 B-Or
/ NCT03869515 253 254 I-Or
or NCT03869515 255 257 I-Or
difficult NCT03869515 258 267 B-Modifier
breathing NCT03869515 268 277 B-Condition
, NCT03869515 278 279 O
or NCT03869515 280 282 B-Or
exercise NCT03869515 283 291 B-Condition
intolerance NCT03869515 292 303 I-Condition
) NCT03869515 304 305 O
; NCT03869515 306 307 O
( NCT03869515 308 309 O
2 NCT03869515 310 311 O
) NCT03869515 312 313 O
respiratory NCT03869515 314 325 B-Condition
signs NCT03869515 326 331 B-Assertion___Assertion-Type-Value:possible
( NCT03869515 332 333 O
e. NCT03869515 334 336 O
g. NCT03869515 337 339 O
, NCT03869515 340 341 O
resting NCT03869515 342 349 B-Condition
tachypnea NCT03869515 350 359 I-Condition
, NCT03869515 360 361 O
adventitious NCT03869515 362 374 B-Condition
sounds NCT03869515 375 381 I-Condition
, NCT03869515 382 383 O
retractions NCT03869515 384 395 B-Condition
, NCT03869515 396 397 O
digital NCT03869515 398 405 B-Condition
clubbing NCT03869515 406 414 I-Condition
, NCT03869515 415 416 O
failure NCT03869515 417 424 B-Condition
to NCT03869515 425 427 I-Condition
thrive NCT03869515 428 434 I-Condition
, NCT03869515 435 436 O
or NCT03869515 437 439 B-Or
respiratory NCT03869515 440 451 B-Condition
fail NCT03869515 452 456 I-Condition
- NCT03869515 457 458 I-Condition
ure NCT03869515 459 462 I-Condition
) NCT03869515 463 464 O
; NCT03869515 465 466 O
( NCT03869515 467 468 O
3 NCT03869515 469 470 O
) NCT03869515 471 472 O
hypoxemia NCT03869515 473 482 B-Condition
; NCT03869515 482 483 O
and NCT03869515 484 487 O
( NCT03869515 488 489 O
4 NCT03869515 490 491 O
) NCT03869515 492 493 O
diffuse NCT03869515 494 501 B-Condition
abnormalities NCT03869515 502 515 I-Condition
on NCT03869515 516 518 O
CXR NCT03869515 519 522 B-Procedure
or NCT03869515 523 525 B-Or
a NCT03869515 526 527 O
CT NCT03869515 528 530 B-Procedure
scan NCT03869515 531 535 I-Procedure
. NCT03869515 535 536 O

Exclusion NCT03869515 538 547 O
Criteria NCT03869515 548 556 O
: NCT03869515 557 558 O

- NCT03869515 562 563 O
These NCT03869515 565 570 O
include NCT03869515 571 578 O
cystic NCT03869515 579 585 B-Condition
fibrosis NCT03869515 586 594 I-Condition
, NCT03869515 595 596 O
congenital NCT03869515 597 607 B-Modifier
or NCT03869515 608 610 B-Or
acquired NCT03869515 611 619 B-Modifier
immunodeficiency NCT03869515 620 636 B-Condition
, NCT03869515 637 638 O
congenital NCT03869515 639 649 B-Condition
heart NCT03869515 650 655 I-Condition
disease NCT03869515 656 663 I-Condition
, NCT03869515 664 665 O
bronchopulmonary NCT03869515 666 682 B-Condition
dysplasia NCT03869515 683 692 I-Condition
, NCT03869515 693 694 O
pulmonary NCT03869515 695 704 B-Condition
infection NCT03869515 705 714 I-Condition
, NCT03869515 715 716 O
primary NCT03869515 717 724 B-Modifier
ciliary NCT03869515 725 732 I-Modifier
dyskinesia NCT03869515 733 743 B-Condition
presenting NCT03869515 744 754 O
with NCT03869515 755 759 O
newborn NCT03869515 760 767 B-Condition
respiratory NCT03869515 768 779 I-Condition
distress NCT03869515 780 788 I-Condition
and NCT03869515 789 792 B-Or
recurrent NCT03869515 793 802 B-Modifier
aspiration NCT03869515 803 813 B-Condition
. NCT03869515 813 814 O

Inclusion NCT03864757 0 9 O
Criteria NCT03864757 10 18 O
: NCT03864757 19 20 O

- NCT03864757 24 25 O
Male NCT03864757 27 31 O
and NCT03864757 32 35 B-Or
female NCT03864757 36 42 O
patients NCT03864757 43 51 O
between NCT03864757 52 59 B-Eq-Comparison
18 NCT03864757 60 62 I-Eq-Comparison
and NCT03864757 63 66 I-Eq-Comparison
80 NCT03864757 67 69 I-Eq-Comparison
years NCT03864757 70 75 I-Age|Eq-Comparison

- NCT03864757 78 79 O
Diagnosed NCT03864757 81 90 O
with NCT03864757 91 95 O
permanent NCT03864757 96 105 B-Modifier
UVFP NCT03864757 106 110 B-Condition
and NCT03864757 111 114 B-And
insufficient NCT03864757 115 127 B-Modifier
glottal NCT03864757 128 135 B-Condition
closure NCT03864757 136 143 I-Condition
and NCT03864757 144 147 B-And
planned NCT03864757 148 155 B-Eq-Comparison
type NCT03864757 156 160 B-Modifier
I NCT03864757 161 162 I-Modifier
thyroplasty NCT03864757 163 174 B-Procedure
with NCT03864757 175 179 O
conventional NCT03864757 180 192 B-Procedure
implant NCT03864757 193 200 I-Procedure

- NCT03864757 203 204 O
Ability NCT03864757 206 213 O
to NCT03864757 214 216 O
co NCT03864757 217 219 O
- NCT03864757 220 221 O
operate NCT03864757 222 229 O
with NCT03864757 230 234 O
the NCT03864757 235 238 O
investigator NCT03864757 239 251 O
and NCT03864757 252 255 O
to NCT03864757 256 258 O
comply NCT03864757 259 265 O
with NCT03864757 266 270 O
the NCT03864757 271 274 O
requirements NCT03864757 275 287 O
of NCT03864757 288 290 O
the NCT03864757 291 294 O
entire NCT03864757 295 301 O
study NCT03864757 302 307 O

Exclusion NCT03864757 308 317 O
Criteria NCT03864757 318 326 O
: NCT03864757 327 328 O

- NCT03864757 332 333 O
Any NCT03864757 335 338 O
other NCT03864757 339 344 B-Other
significant NCT03864757 345 356 O
disease NCT03864757 357 364 B-Condition
or NCT03864757 365 367 B-Or
disorder NCT03864757 368 376 B-Condition
which NCT03864757 377 382 O
, NCT03864757 383 384 O
in NCT03864757 385 387 O
the NCT03864757 388 391 O
opinion NCT03864757 392 399 O
of NCT03864757 400 402 O
the NCT03864757 403 406 O
investigator NCT03864757 407 419 O
, NCT03864757 420 421 O
may NCT03864757 422 425 B-Assertion___Assertion-Type-Value:hypothetical
either NCT03864757 426 432 O
put NCT03864757 433 436 O
the NCT03864757 437 440 O
participant NCT03864757 441 452 O
at NCT03864757 453 455 O
risk NCT03864757 456 460 B-Risk
because NCT03864757 461 468 O
of NCT03864757 469 471 O
participation NCT03864757 472 485 O
in NCT03864757 486 488 O
the NCT03864757 489 492 O
clinical NCT03864757 493 501 O
investigation NCT03864757 502 515 O
may NCT03864757 516 519 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03864757 520 529 O
the NCT03864757 530 533 O
result NCT03864757 534 540 O
of NCT03864757 541 543 O
the NCT03864757 544 547 O
clinical NCT03864757 548 556 O
investigation NCT03864757 557 570 O
, NCT03864757 571 572 O
or NCT03864757 573 575 O
the NCT03864757 576 579 O
participant NCT03864757 580 591 O
's NCT03864757 591 593 O
ability NCT03864757 594 601 O
to NCT03864757 602 604 O
participate NCT03864757 605 616 O
in NCT03864757 617 619 O
the NCT03864757 620 623 O
clinical NCT03864757 624 632 O
investigation NCT03864757 633 646 B-Study

- NCT03864757 649 650 O
Scheduled NCT03864757 652 661 B-Eq-Comparison
elective NCT03864757 662 670 B-Modifier
surgery NCT03864757 671 678 B-Procedure
or NCT03864757 679 681 B-Or
other NCT03864757 682 687 B-Other
procedures NCT03864757 688 698 B-Procedure
requiring NCT03864757 699 708 O
general NCT03864757 709 716 B-Procedure
anaesthesia NCT03864757 717 728 I-Procedure
during NCT03864757 729 735 B-Temporal-Connection___Temporal-Connection-Type-Value:during
clinical NCT03864757 736 744 O
investigation NCT03864757 745 758 B-Study

- NCT03864757 761 762 O
Had NCT03864757 764 767 O
medialization NCT03864757 768 781 B-Procedure
thyroplasty NCT03864757 782 793 I-Procedure
before NCT03864757 794 800 B-Eq-Comparison

- NCT03864757 803 804 O
Had NCT03864757 806 809 O
injection NCT03864757 810 819 B-Modifier
medialization NCT03864757 820 833 B-Procedure
laryngoplasty NCT03864757 834 847 I-Procedure
in NCT03864757 848 850 O
the NCT03864757 851 854 O
past NCT03864757 855 859 B-Eq-Comparison
two NCT03864757 860 863 I-Eq-Comparison
years NCT03864757 864 869 I-Eq-Comparison
. NCT03864757 869 870 O

- NCT03864757 874 875 O
Presence NCT03864757 877 885 O
of NCT03864757 886 888 O
structural NCT03864757 889 899 B-Modifier
vocal NCT03864757 900 905 I-Modifier
fold NCT03864757 906 910 I-Modifier
lesions NCT03864757 911 918 B-Condition
such NCT03864757 919 923 O
as NCT03864757 924 926 O
polyp NCT03864757 927 932 B-Condition
or NCT03864757 933 935 B-Or
nodules NCT03864757 936 943 B-Condition

- NCT03864757 946 947 O
Status NCT03864757 949 955 O
post NCT03864757 956 960 B-Temporal-Connection___Temporal-Connection-Type-Value:after
total NCT03864757 961 966 B-Procedure
cordectomy NCT03864757 967 977 I-Procedure

- NCT03864757 980 981 O
Previous NCT03864757 983 991 B-Eq-Comparison
laryngeal NCT03864757 992 1001 B-Procedure
framework NCT03864757 1002 1011 I-Procedure
surgery NCT03864757 1012 1019 I-Procedure
( NCT03864757 1020 1021 O
any NCT03864757 1022 1025 O
type NCT03864757 1026 1030 O
of NCT03864757 1031 1033 O
thyroplasty NCT03864757 1034 1045 B-Procedure
, NCT03864757 1046 1047 O
arytenoid NCT03864757 1048 1057 B-Procedure
adduction NCT03864757 1058 1067 I-Procedure
) NCT03864757 1068 1069 O

- NCT03864757 1073 1074 O
Significant NCT03864757 1076 1087 O
non NCT03864757 1088 1091 B-Negation
- NCT03864757 1092 1093 O
laryngeal NCT03864757 1094 1103 B-Modifier
speech NCT03864757 1104 1110 B-Modifier
abnormality NCT03864757 1111 1122 B-Condition
( NCT03864757 1123 1124 O
severe NCT03864757 1125 1131 O
dysarthria NCT03864757 1132 1142 B-Condition
determined NCT03864757 1143 1153 O
by NCT03864757 1154 1156 O
a NCT03864757 1157 1158 O
panel NCT03864757 1159 1164 O
of NCT03864757 1165 1167 O
trained NCT03864757 1168 1175 O
speech NCT03864757 1176 1182 B-Provider
therapists NCT03864757 1183 1193 I-Provider
) NCT03864757 1194 1195 O

- NCT03864757 1199 1200 O
Severe NCT03864757 1202 1208 O
coagulopathy NCT03864757 1209 1221 B-Condition

Inclusion NCT03862326 0 9 O
Criteria NCT03862326 10 18 O
: NCT03862326 19 20 O

Diaper NCT03862326 22 28 O
grant NCT03862326 29 34 O

- NCT03862326 37 38 O
Urinary NCT03862326 40 47 B-Condition
incontinency NCT03862326 48 60 I-Condition

- NCT03862326 64 65 O
Living NCT03862326 67 73 O
in NCT03862326 74 76 O
own NCT03862326 77 80 O
home NCT03862326 81 85 O
in NCT03862326 86 88 O
Aalborg NCT03862326 89 96 O
Municipality NCT03862326 97 109 O

Exclusion NCT03862326 110 119 O
Criteria NCT03862326 120 128 O
: NCT03862326 129 130 O

- NCT03862326 134 135 O
Dementia NCT03862326 137 145 O

- NCT03862326 149 150 O
Inability NCT03862326 152 161 O
to NCT03862326 162 164 O
transport NCT03862326 165 174 O
herself NCT03862326 175 182 O
to NCT03862326 183 185 O
the NCT03862326 186 189 O
training NCT03862326 190 198 O
facility NCT03862326 199 207 O

- NCT03862326 211 212 O
neurological NCT03862326 214 226 B-Condition
diseases NCT03862326 227 235 I-Condition

- NCT03862326 239 240 O
inability NCT03862326 242 251 B-Negation
to NCT03862326 252 254 O
understand NCT03862326 255 265 O
Danish NCT03862326 266 272 O
or NCT03862326 273 275 O
bring NCT03862326 276 281 O
a NCT03862326 282 283 O
translator NCT03862326 284 294 O


Inclusion NCT03863951 0 9 O
Criteria NCT03863951 10 18 O
: NCT03863951 19 20 O

- NCT03863951 24 25 O
diagnosed NCT03863951 27 36 O
with NCT03863951 37 41 O
the NCT03863951 42 45 O
first NCT03863951 46 51 B-Eq-Comparison
ever NCT03863951 52 56 I-Eq-Comparison
acute NCT03863951 57 62 O
ischemic NCT03863951 63 71 B-Modifier
stroke NCT03863951 72 78 B-Condition
occurring NCT03863951 79 88 O
within NCT03863951 89 95 B-Eq-Comparison
2 NCT03863951 96 97 I-Eq-Comparison
weeks NCT03863951 98 103 I-Eq-Comparison
and NCT03863951 104 107 O
were NCT03863951 108 112 O
confirmed NCT03863951 113 122 O
by NCT03863951 123 125 O
CT NCT03863951 126 128 B-Procedure
or NCT03863951 129 131 B-Or
MRI NCT03863951 132 135 B-Procedure
, NCT03863951 136 137 O

- NCT03863951 141 142 O
has NCT03863951 144 147 O
no NCT03863951 148 150 B-Negation
history NCT03863951 151 158 B-Eq-Comparison
of NCT03863951 159 161 O
depression NCT03863951 162 172 B-Condition
or NCT03863951 173 175 B-Or
use NCT03863951 176 179 O
of NCT03863951 180 182 O
antidepressants NCT03863951 183 198 B-Drug
or NCT03863951 199 201 B-Or
antipsychotics NCT03863951 202 216 B-Drug
, NCT03863951 217 218 O

- NCT03863951 222 223 O
were NCT03863951 225 229 O
competent NCT03863951 230 239 O
to NCT03863951 240 242 O
consent NCT03863951 243 250 O
to NCT03863951 251 253 O
take NCT03863951 254 258 O
part NCT03863951 259 263 O
in NCT03863951 264 266 O
this NCT03863951 267 271 O
research NCT03863951 272 280 O
. NCT03863951 280 281 O

Exclusion NCT03863951 283 292 O
Criteria NCT03863951 293 301 O
: NCT03863951 302 303 O

- NCT03863951 307 308 O
significant NCT03863951 310 321 O
acute NCT03863951 322 327 O
or NCT03863951 328 330 B-Or
severe NCT03863951 331 337 O
illness NCT03863951 338 345 B-Condition
such NCT03863951 346 350 O
as NCT03863951 351 353 O
infection NCT03863951 354 363 B-Condition
, NCT03863951 364 365 O
heart NCT03863951 366 371 B-Condition
failure NCT03863951 372 379 I-Condition
and NCT03863951 380 383 B-Or
tumor NCT03863951 384 389 B-Condition
, NCT03863951 390 391 O

- NCT03863951 395 396 O
previous NCT03863951 398 406 B-Eq-Comparison
diagnosis NCT03863951 407 416 O
of NCT03863951 417 419 O
depression NCT03863951 420 430 B-Condition
or NCT03863951 431 433 B-Or
other NCT03863951 434 439 B-Other
mental NCT03863951 440 446 B-Condition
disorder NCT03863951 447 455 I-Condition
or NCT03863951 456 458 B-Or
who NCT03863951 459 462 O
had NCT03863951 463 466 O
recently NCT03863951 467 475 B-Eq-Comparison
accepted NCT03863951 476 484 O
antidepressants NCT03863951 485 500 B-Drug
or NCT03863951 501 503 B-Or
antipsychotics NCT03863951 504 518 B-Drug
, NCT03863951 519 520 O

- NCT03863951 524 525 O
antibiotics NCT03863951 527 538 B-Drug
in NCT03863951 539 541 O
the NCT03863951 542 545 O
last NCT03863951 546 550 B-Eq-Comparison
two NCT03863951 551 554 I-Eq-Comparison
weeks NCT03863951 555 560 I-Eq-Comparison
, NCT03863951 561 562 O

- NCT03863951 566 567 O
severe NCT03863951 569 575 O
aphasia NCT03863951 576 583 B-Condition
or NCT03863951 584 586 B-Or
dysarthria NCT03863951 587 597 B-Condition
, NCT03863951 598 599 O
irritable NCT03863951 600 609 B-Condition
bowel NCT03863951 610 615 I-Condition
syndrome NCT03863951 616 624 I-Condition
, NCT03863951 625 626 O
asthma NCT03863951 627 633 B-Condition
, NCT03863951 634 635 O
and NCT03863951 636 639 B-Or
pregnant NCT03863951 640 648 B-Condition
or NCT03863951 649 651 B-Or
lactating NCT03863951 652 661 B-Condition
women NCT03863951 662 667 O
, NCT03863951 668 669 O

- NCT03863951 673 674 O
a NCT03863951 676 677 O
previous NCT03863951 678 686 B-Eq-Comparison
history NCT03863951 687 694 I-Eq-Comparison
of NCT03863951 695 697 O
neurological NCT03863951 698 710 B-Condition
illness NCT03863951 711 718 I-Condition
including NCT03863951 719 728 O
AD NCT03863951 729 731 B-Condition
and NCT03863951 732 735 B-Or
PD NCT03863951 736 738 B-Condition
， NCT03863951 739 740 O

- NCT03863951 744 745 O
Inflammatory NCT03863951 747 759 B-Condition
bowel NCT03863951 760 765 I-Condition
disease NCT03863951 766 773 I-Condition
， NCT03863951 774 775 O

Inclusion NCT03863548 0 9 O
Criteria NCT03863548 10 18 O
: NCT03863548 19 20 O

- NCT03863548 24 25 O
person NCT03863548 27 33 O
who NCT03863548 34 37 O
has NCT03863548 38 41 O
expressed NCT03863548 42 51 O
willingness NCT03863548 52 63 O
to NCT03863548 64 66 O
participate NCT03863548 67 78 O

- NCT03863548 81 82 O
person NCT03863548 84 90 O
over NCT03863548 91 95 B-Eq-Comparison
18 NCT03863548 96 98 I-Eq-Comparison
years NCT03863548 99 104 I-Eq-Comparison
of NCT03863548 105 107 O
age NCT03863548 108 111 B-Age

- NCT03863548 114 115 O
person NCT03863548 117 123 O
with NCT03863548 124 128 O
a NCT03863548 129 130 O
retinal NCT03863548 131 138 B-Condition
- NCT03863548 139 140 I-Condition
vitreous NCT03863548 141 149 I-Condition
condition NCT03863548 150 159 I-Condition
requiring NCT03863548 160 169 B-Assertion___Assertion-Type-Value:hypothetical
scheduled NCT03863548 170 179 B-Eq-Comparison
surgery NCT03863548 180 187 B-Procedure
( NCT03863548 188 189 O
epi NCT03863548 190 193 B-Procedure
- NCT03863548 194 195 I-Procedure
retinal NCT03863548 196 203 I-Procedure
membrane NCT03863548 204 212 I-Procedure
surgery NCT03863548 213 220 I-Procedure
, NCT03863548 221 222 O
vitreous NCT03863548 223 231 B-Procedure
traction NCT03863548 232 240 I-Procedure
surgery NCT03863548 241 248 I-Procedure
, NCT03863548 249 250 O
macular NCT03863548 251 258 B-Procedure
hole NCT03863548 259 263 I-Procedure
surgery NCT03863548 264 271 I-Procedure
) NCT03863548 272 273 O
. NCT03863548 274 275 O

Exclusion NCT03863548 277 286 O
Criteria NCT03863548 287 295 O
: NCT03863548 296 297 O

- NCT03863548 301 302 O
person NCT03863548 304 310 O
subject NCT03863548 311 318 O
to NCT03863548 319 321 O
legal NCT03863548 322 327 B-Observation
protection NCT03863548 328 338 I-Observation
( NCT03863548 339 340 O
curatorship NCT03863548 341 352 O
, NCT03863548 353 354 O
guardianship NCT03863548 355 367 O
) NCT03863548 368 369 O

- NCT03863548 373 374 O
person NCT03863548 376 382 O
deemed NCT03863548 383 389 O
mentally NCT03863548 390 398 B-Condition
incompetent NCT03863548 399 410 I-Condition

- NCT03863548 413 414 O
pregnant NCT03863548 416 424 B-Condition
, NCT03863548 425 426 O
parturient NCT03863548 427 437 B-Condition
or NCT03863548 438 440 B-Or
breastfeeding NCT03863548 441 454 B-Condition
woman NCT03863548 455 460 O

- NCT03863548 463 464 O
adult NCT03863548 466 471 O
unwilling NCT03863548 472 481 O
or NCT03863548 482 484 O
unable NCT03863548 485 491 O
to NCT03863548 492 494 O
consent NCT03863548 495 502 O

- NCT03863548 505 506 O
patient NCT03863548 508 515 O
who NCT03863548 516 519 O
has NCT03863548 520 523 O
already NCT03863548 524 531 B-Eq-Comparison
participated NCT03863548 532 544 I-Eq-Comparison
in NCT03863548 545 547 O
the NCT03863548 548 551 O
study NCT03863548 552 557 B-Study

- NCT03863548 560 561 O
person NCT03863548 563 569 O
with NCT03863548 570 574 O
a NCT03863548 575 576 O
physical NCT03863548 577 585 B-Modifier
or NCT03863548 586 588 B-Or
mental NCT03863548 589 595 B-Modifier
disability NCT03863548 596 606 B-Condition
that NCT03863548 607 611 O
does NCT03863548 612 616 O
not NCT03863548 617 620 B-Negation
allow NCT03863548 621 626 O
participation NCT03863548 627 640 O
. NCT03863548 640 641 O

- NCT03863548 645 646 O
a NCT03863548 648 649 O
person NCT03863548 650 656 O
who NCT03863548 657 660 O
has NCT03863548 661 664 O
participated NCT03863548 665 677 O
in NCT03863548 678 680 O
any NCT03863548 681 684 O
study NCT03863548 685 690 B-Study
of NCT03863548 691 693 O
an NCT03863548 694 696 O
experimental NCT03863548 697 709 O
medical NCT03863548 710 717 O
product NCT03863548 718 725 B-Drug
within NCT03863548 726 732 B-Eq-Comparison
the NCT03863548 733 736 I-Eq-Comparison
previous NCT03863548 737 745 I-Eq-Comparison
3 NCT03863548 746 747 I-Eq-Comparison
months NCT03863548 748 754 I-Eq-Comparison

- NCT03863548 757 758 O
person NCT03863548 760 766 O
who NCT03863548 767 770 O
experiences NCT03863548 771 782 O
any NCT03863548 783 786 O
of NCT03863548 787 789 O
the NCT03863548 790 793 B-Criteria-Count
following NCT03863548 794 803 I-Criteria-Count
during NCT03863548 804 810 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863548 811 814 O
ophthalmological NCT03863548 815 831 B-Procedure
examination NCT03863548 832 843 I-Procedure
: NCT03863548 844 845 O

- NCT03863548 854 855 O
severe NCT03863548 857 863 O
or NCT03863548 864 866 B-Or
proliferating NCT03863548 867 880 B-Modifier
diabetic NCT03863548 881 889 B-Condition
retinopathy NCT03863548 890 901 I-Condition

- NCT03863548 909 910 I-Modifier
intra NCT03863548 912 917 B-Modifier
- NCT03863548 918 919 O
vitreal NCT03863548 920 927 I-Modifier
hemorrhage NCT03863548 928 938 B-Condition

- NCT03863548 946 947 O
tractional NCT03863548 949 959 B-Condition
retinal NCT03863548 960 967 I-Condition
detachment NCT03863548 968 978 I-Condition

- NCT03863548 986 987 O
subretinal NCT03863548 989 999 B-Modifier
or NCT03863548 1000 1002 B-Or
retrohyaloidal NCT03863548 1003 1017 B-Modifier
hematoma NCT03863548 1018 1026 B-Condition
. NCT03863548 1026 1027 O

Inclusion NCT03866356 0 9 O
Criteria NCT03866356 10 18 O
: NCT03866356 19 20 O

- NCT03866356 24 25 O
The NCT03866356 27 30 O
inclusion NCT03866356 31 40 O
criteria NCT03866356 41 49 O
were NCT03866356 50 54 O
being NCT03866356 55 60 O
female NCT03866356 61 67 O
, NCT03866356 68 69 O
≥ NCT03866356 70 71 B-Eq-Comparison
18 NCT03866356 72 74 I-Eq-Comparison
years NCT03866356 75 80 I-Age|Eq-Comparison
, NCT03866356 81 82 O
having NCT03866356 83 89 B-And
an NCT03866356 90 92 O
initial NCT03866356 93 100 B-Eq-Comparison
diagnosis NCT03866356 101 110 O
of NCT03866356 111 113 O
SI NCT03866356 114 116 B-Condition
, NCT03866356 117 118 O
being NCT03866356 119 124 O
literate NCT03866356 125 133 B-Condition
, NCT03866356 134 135 O
having NCT03866356 136 142 O
no NCT03866356 143 145 B-Negation
sensory NCT03866356 146 153 B-Condition
disorder NCT03866356 154 162 I-Condition
affecting NCT03866356 163 172 O
communication NCT03866356 173 186 B-Condition
, NCT03866356 187 188 O
and NCT03866356 189 192 O
agreeing NCT03866356 193 201 O
to NCT03866356 202 204 O
participate NCT03866356 205 216 O
in NCT03866356 217 219 O
the NCT03866356 220 223 O
research NCT03866356 224 232 O

Exclusion NCT03866356 233 242 O
Criteria NCT03866356 243 251 O
: NCT03866356 252 253 O

- NCT03866356 257 258 O
The NCT03866356 260 263 O
exclusion NCT03866356 264 273 O
criteria NCT03866356 274 282 O
were NCT03866356 283 287 O
pregnancy NCT03866356 288 297 B-Condition
, NCT03866356 298 299 O
presence NCT03866356 300 308 O
of NCT03866356 309 311 O
a NCT03866356 312 313 O
urinary NCT03866356 314 321 B-Condition
tract NCT03866356 322 327 I-Condition
infection NCT03866356 328 337 I-Condition
and NCT03866356 338 341 B-Or
previous NCT03866356 342 350 B-Eq-Comparison
treatment NCT03866356 351 360 B-Procedure
for NCT03866356 361 364 O
SI NCT03866356 365 367 B-Condition
. NCT03866356 367 368 O
The NCT03866356 370 373 O
removal NCT03866356 374 381 O
criteria NCT03866356 382 390 O
were NCT03866356 391 395 O
patient NCT03866356 396 403 O
non NCT03866356 404 407 O
- NCT03866356 408 409 O
compliance NCT03866356 410 420 O
with NCT03866356 421 425 O
the NCT03866356 426 429 O
protocol NCT03866356 430 438 O
, NCT03866356 439 440 O
failure NCT03866356 441 448 O
in NCT03866356 449 451 O
contacting NCT03866356 452 462 O
the NCT03866356 463 466 O
patient NCT03866356 467 474 O
and NCT03866356 475 478 O
the NCT03866356 479 482 O
patient NCT03866356 483 490 O
's NCT03866356 490 492 O
wish NCT03866356 493 497 O
to NCT03866356 498 500 O
withdraw NCT03866356 501 509 O
from NCT03866356 510 514 O
the NCT03866356 515 518 O
study NCT03866356 519 524 O
. NCT03866356 524 525 O

Inclusion NCT03862118 0 9 O
Criteria NCT03862118 10 18 O
: NCT03862118 19 20 O

- NCT03862118 24 25 O
•Both NCT03862118 27 32 O
sexes NCT03862118 33 38 O
will NCT03862118 39 43 O
be NCT03862118 44 46 O
included NCT03862118 47 55 O
. NCT03862118 55 56 O

- NCT03862118 65 66 O
Age NCT03862118 68 71 B-Age
( NCT03862118 72 73 O
20 NCT03862118 74 76 B-Eq-Comparison
- NCT03862118 77 78 I-Eq-Comparison
50 NCT03862118 79 81 O
) NCT03862118 82 83 O

- NCT03862118 92 93 O
Patient NCT03862118 95 102 O
with NCT03862118 103 107 O
Fitzpatrick NCT03862118 108 119 B-Condition
skin NCT03862118 120 124 I-Condition
types NCT03862118 125 130 B-Eq-Comparison
III NCT03862118 131 134 I-Eq-Comparison
- NCT03862118 135 136 I-Eq-Comparison
IV NCT03862118 137 139 I-Eq-Comparison

Exclusion NCT03862118 140 149 O
Criteria NCT03862118 150 158 O
: NCT03862118 159 160 O

- NCT03862118 164 165 O
• NCT03862118 167 168 O
Patients NCT03862118 169 177 O
with NCT03862118 178 182 O
known NCT03862118 183 188 O
platelet NCT03862118 189 197 B-Condition
dysfunction NCT03862118 198 209 I-Condition
syndrome NCT03862118 210 218 I-Condition
, NCT03862118 219 220 O
critical NCT03862118 221 229 O
thrombocytopenia NCT03862118 230 246 B-Condition
( NCT03862118 247 248 O
< NCT03862118 250 251 B-Eq-Comparison
50 NCT03862118 252 254 I-Eq-Comparison
, NCT03862118 255 256 O
000 NCT03862118 257 260 O
/ NCT03862118 261 262 I-Eq-Comparison
ul NCT03862118 263 265 I-Eq-Comparison
) NCT03862118 266 267 O
, NCT03862118 269 270 O
any NCT03862118 271 274 O
hemodynamic NCT03862118 275 286 B-Condition
instability NCT03862118 287 298 I-Condition
. NCT03862118 298 299 O

- NCT03862118 308 309 O
Patients NCT03862118 311 319 O
with NCT03862118 320 324 O
chronic NCT03862118 325 332 B-Modifier
medical NCT03862118 333 340 B-Condition
illness NCT03862118 341 348 I-Condition
( NCT03862118 349 350 O
e. NCT03862118 351 353 O
g. NCT03862118 354 356 O
diabetes NCT03862118 358 366 B-Condition
, NCT03862118 367 368 O
chronic NCT03862118 369 376 B-Modifier
infections NCT03862118 377 387 B-Condition
, NCT03862118 388 389 O
and NCT03862118 390 393 B-Or
blood NCT03862118 394 399 B-Modifier
dyscrasias NCT03862118 400 410 B-Condition
) NCT03862118 411 412 O
. NCT03862118 413 414 O

- NCT03862118 423 424 O
Patients NCT03862118 426 434 O
with NCT03862118 435 439 O
local NCT03862118 440 445 B-Modifier
inflammatory NCT03862118 446 458 I-Modifier
skin NCT03862118 459 463 B-Condition
disorders NCT03862118 464 473 I-Condition
or NCT03862118 474 476 B-Or
active NCT03862118 477 483 B-Eq-Comparison
herpes NCT03862118 484 490 B-Condition
infection NCT03862118 491 500 I-Condition
at NCT03862118 501 503 O
the NCT03862118 504 507 O
site NCT03862118 508 512 B-Modifier
of NCT03862118 513 515 O
the NCT03862118 516 519 O
procedure NCT03862118 520 529 B-Procedure
. NCT03862118 529 530 O

- NCT03862118 539 540 O
Patients NCT03862118 542 550 O
on NCT03862118 551 553 B-Eq-Comparison
consistent NCT03862118 554 564 O
use NCT03862118 565 568 O
of NCT03862118 569 571 O
anti NCT03862118 572 576 B-Drug|Drug
- NCT03862118 577 578 I-Drug|Drug
coagulants NCT03862118 579 589 I-Drug
or NCT03862118 590 592 B-Or
non NCT03862118 593 596 B-Drug
- NCT03862118 597 598 O
steroidal NCT03862118 599 608 I-Drug
anti NCT03862118 609 613 O
- NCT03862118 614 615 O
inflammatory NCT03862118 616 628 I-Drug
drugs NCT03862118 629 634 I-Drug
( NCT03862118 635 636 O
NSAID NCT03862118 637 642 B-Drug
) NCT03862118 643 644 O
within NCT03862118 645 651 B-Eq-Comparison
48 NCT03862118 652 654 I-Eq-Comparison
hours NCT03862118 655 660 I-Eq-Comparison
of NCT03862118 661 663 B-Temporal-Connection___Temporal-Connection-Type-Value:before
procedure NCT03862118 664 673 B-Procedure
. NCT03862118 673 674 O

- NCT03862118 683 684 O
Haemoglobin NCT03862118 686 697 B-Observation
level NCT03862118 698 703 O
< NCT03862118 704 705 B-Eq-Comparison
10 NCT03862118 706 708 I-Eq-Comparison
g NCT03862118 709 710 I-Eq-Comparison
/ NCT03862118 711 712 I-Eq-Comparison
dl NCT03862118 713 715 I-Eq-Comparison
were NCT03862118 716 720 O
also NCT03862118 721 725 O
excluded NCT03862118 726 734 B-Negation
. NCT03862118 734 735 O

- NCT03862118 744 745 O
Patients NCT03862118 747 755 O
with NCT03862118 756 760 O
cancer NCT03862118 761 767 B-Condition
- NCT03862118 768 769 O
especially NCT03862118 770 780 O
hematopoietic NCT03862118 781 794 B-Modifier
or NCT03862118 795 797 B-Or
of NCT03862118 798 800 O
bone NCT03862118 801 805 B-Modifier
. NCT03862118 805 806 O

- NCT03862118 815 816 O
Pregnant NCT03862118 818 826 B-Condition
females NCT03862118 827 834 O
. NCT03862118 834 835 O

- NCT03862118 844 845 O
Patients NCT03862118 847 855 O
with NCT03862118 856 860 B-Eq-Comparison
corticosteroids NCT03862118 861 876 B-Drug
injection NCT03862118 877 886 O
at NCT03862118 887 889 O
treatment NCT03862118 890 899 B-Procedure
site NCT03862118 900 904 O
within NCT03862118 905 911 O
1 NCT03862118 912 913 I-Eq-Comparison
month NCT03862118 914 919 I-Eq-Comparison
or NCT03862118 920 922 B-Or
systemic NCT03862118 923 931 B-Modifier
use NCT03862118 932 935 O
of NCT03862118 936 938 O
corticosteroids NCT03862118 939 954 B-Drug
within NCT03862118 955 961 B-Eq-Comparison
2 NCT03862118 962 963 I-Eq-Comparison
weeks NCT03862118 964 969 I-Eq-Comparison
. NCT03862118 969 970 O

Inclusion NCT03861377 0 9 O
Criteria NCT03861377 10 18 O
: NCT03861377 19 20 O

- NCT03861377 24 25 O
Gynecological NCT03861377 27 40 B-Procedure
procedure NCT03861377 41 50 I-Procedure

- NCT03861377 53 54 O
Age NCT03861377 56 59 B-Age
18 NCT03861377 60 62 B-Eq-Comparison
- NCT03861377 63 64 I-Eq-Comparison
50 NCT03861377 65 67 I-Eq-Comparison
years NCT03861377 68 73 I-Eq-Comparison

- NCT03861377 76 77 O
General NCT03861377 79 86 B-Procedure
anesthesia NCT03861377 87 97 I-Procedure
planned NCT03861377 98 105 B-Eq-Comparison

- NCT03861377 108 109 O
Systolic NCT03861377 111 119 B-Observation
blood NCT03861377 120 125 I-Observation
pressure NCT03861377 126 134 I-Observation
< NCT03861377 135 136 B-Eq-Comparison
150 NCT03861377 137 140 I-Eq-Comparison
mmHg NCT03861377 141 145 I-Eq-Comparison
, NCT03861377 146 147 O
HR NCT03861377 148 150 B-Observation
< NCT03861377 151 152 B-Eq-Comparison
100 NCT03861377 153 156 I-Eq-Comparison
beats NCT03861377 157 162 I-Eq-Comparison
/ NCT03861377 163 164 I-Eq-Comparison
min NCT03861377 165 168 I-Eq-Comparison

Exclusion NCT03861377 169 178 O
Criteria NCT03861377 179 187 O
: NCT03861377 188 189 O

- NCT03861377 193 194 I-Eq-Comparison
Pre NCT03861377 196 199 B-Eq-Comparison
- NCT03861377 200 201 O
existing NCT03861377 202 210 I-Eq-Comparison
hypertension NCT03861377 211 223 B-Condition

- NCT03861377 226 227 O
Diabetes NCT03861377 229 237 B-Condition

- NCT03861377 240 241 O
Ischemic NCT03861377 243 251 B-Modifier
heart NCT03861377 252 257 B-Condition
disease NCT03861377 258 265 I-Condition
or NCT03861377 266 268 B-Or
cerebrovascular NCT03861377 269 284 B-Condition
disease NCT03861377 285 292 I-Condition

- NCT03861377 295 296 O
Heart NCT03861377 298 303 B-Condition
valve NCT03861377 304 309 I-Condition
disease NCT03861377 310 317 I-Condition

- NCT03861377 320 321 O
Verified NCT03861377 323 331 O
cardiac NCT03861377 332 339 B-Condition
arrhythmia NCT03861377 340 350 I-Condition
other NCT03861377 351 356 B-Exception
than NCT03861377 357 361 I-Exception
extrasystoles NCT03861377 362 375 B-Condition

- NCT03861377 378 379 O
Verified NCT03861377 381 389 O
anaemia NCT03861377 390 397 B-Condition
with NCT03861377 398 402 B-And
hemoglobin NCT03861377 403 413 B-Observation
level NCT03861377 414 419 O
below NCT03861377 420 425 B-Eq-Comparison
9.0 NCT03861377 426 429 I-Eq-Comparison
gr NCT03861377 430 432 I-Eq-Comparison
/ NCT03861377 433 434 I-Eq-Comparison
dl NCT03861377 435 437 I-Eq-Comparison
. NCT03861377 437 438 O

- NCT03861377 442 443 O
Kidney NCT03861377 445 451 B-Modifier
or NCT03861377 452 454 B-Or
hepatic NCT03861377 455 462 B-Modifier
disease NCT03861377 463 470 B-Condition

- NCT03861377 473 474 O
Hypersensitivity NCT03861377 476 492 B-Condition
for NCT03861377 493 496 O
propofol NCT03861377 497 505 B-Drug
, NCT03861377 506 507 O
soya NCT03861377 508 512 B-Modifier
, NCT03861377 513 514 O
eggs NCT03861377 515 519 B-Modifier
or NCT03861377 520 522 B-Or
peanuts NCT03861377 523 530 B-Modifier

- NCT03861377 533 534 O
Pregnancy NCT03861377 536 545 B-Condition

- NCT03861377 548 549 O
Poor NCT03861377 551 555 B-Condition
health NCT03861377 556 562 I-Condition
state NCT03861377 563 568 O

- NCT03861377 571 572 O
Illicit NCT03861377 574 581 B-Condition
substance NCT03861377 582 591 I-Condition
use NCT03861377 592 595 I-Condition

- NCT03861377 598 599 O
BMI NCT03861377 601 604 B-Observation
< NCT03861377 605 606 B-Eq-Comparison
20 NCT03861377 607 609 I-Eq-Comparison
or NCT03861377 610 612 B-Or
> NCT03861377 613 614 B-Eq-Comparison
35 NCT03861377 615 617 I-Eq-Comparison
kg NCT03861377 618 620 I-Eq-Comparison
/ NCT03861377 621 622 I-Eq-Comparison
m2 NCT03861377 623 625 I-Eq-Comparison

Inclusion NCT03869918 0 9 O
Criteria NCT03869918 10 18 O
: NCT03869918 19 20 O

1 NCT03869918 24 25 O
. NCT03869918 25 26 O
female NCT03869918 28 34 O

2 NCT03869918 37 38 O
. NCT03869918 38 39 O
age NCT03869918 41 44 B-Age
60 NCT03869918 45 47 B-Eq-Comparison
+ NCT03869918 48 49 O
years NCT03869918 50 55 I-Eq-Comparison

3 NCT03869918 58 59 O
. NCT03869918 59 60 O
community NCT03869918 62 71 O
dwelling NCT03869918 72 80 O

4 NCT03869918 83 84 O
. NCT03869918 84 85 O
Moderate NCT03869918 87 95 B-Eq-Comparison
to NCT03869918 96 98 I-Eq-Comparison
severe NCT03869918 99 105 I-Eq-Comparison
UUI NCT03869918 106 109 B-Condition
( NCT03869918 110 111 O
as NCT03869918 112 114 O
measured NCT03869918 115 123 O
by NCT03869918 124 126 O
International NCT03869918 127 140 B-Observation
Consultation NCT03869918 141 153 I-Observation
on NCT03869918 154 156 I-Observation
Incontinence NCT03869918 157 169 I-Observation
Questionnaire NCT03869918 170 183 I-Observation
Short NCT03869918 184 189 I-Observation
Form NCT03869918 190 194 I-Observation
) NCT03869918 195 196 O

5 NCT03869918 200 201 O
. NCT03869918 201 202 O
low NCT03869918 204 207 O
physical NCT03869918 208 216 B-Observation
activity NCT03869918 217 225 I-Observation
( NCT03869918 226 227 O
Physical NCT03869918 228 236 B-Observation
Activity NCT03869918 237 245 I-Observation
Staging NCT03869918 246 253 I-Observation
questionnaire NCT03869918 254 267 I-Observation
) NCT03869918 268 269 O

6 NCT03869918 273 274 O
. NCT03869918 274 275 O
cognitively NCT03869918 277 288 B-Condition
able NCT03869918 289 293 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869918 294 296 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03869918 297 305 O
the NCT03869918 306 309 O
study NCT03869918 310 315 B-Study
( NCT03869918 316 317 O
in NCT03869918 318 320 O
opinion NCT03869918 321 328 O
of NCT03869918 329 331 O
the NCT03869918 332 335 O
referring NCT03869918 336 345 O
provider NCT03869918 346 354 O
) NCT03869918 355 356 O
Women NCT03869918 357 362 O
currently NCT03869918 363 372 B-Eq-Comparison
on NCT03869918 373 375 O
anti NCT03869918 376 380 B-Drug
- NCT03869918 381 382 I-Drug
cholinergic NCT03869918 383 394 I-Drug
medication NCT03869918 395 405 I-Drug
for NCT03869918 406 409 O
urinary NCT03869918 410 417 B-Condition
incontinence NCT03869918 418 430 I-Condition
will NCT03869918 431 435 O
be NCT03869918 436 438 O
allowed NCT03869918 439 446 O
if NCT03869918 447 449 O
they NCT03869918 450 454 O
meet NCT03869918 455 459 O
the NCT03869918 460 463 O
above NCT03869918 464 469 O
criteria NCT03869918 470 478 O
. NCT03869918 478 479 O

Exclusion NCT03869918 481 490 O
Criteria NCT03869918 491 499 O
: NCT03869918 500 501 O

1 NCT03869918 505 506 O
. NCT03869918 506 507 O
cognitive NCT03869918 509 518 B-Condition
impairment NCT03869918 519 529 I-Condition
( NCT03869918 530 531 O
in NCT03869918 532 534 O
opinion NCT03869918 535 542 O
of NCT03869918 543 545 O
the NCT03869918 546 549 O
referring NCT03869918 550 559 O
provider NCT03869918 560 568 O
) NCT03869918 569 570 O

2 NCT03869918 574 575 O
. NCT03869918 575 576 O
unable NCT03869918 578 584 O
to NCT03869918 585 587 O
provide NCT03869918 588 595 O
informed NCT03869918 596 604 O
consent NCT03869918 605 612 O
or NCT03869918 613 615 O
communicate NCT03869918 616 627 O
in NCT03869918 628 630 O
English NCT03869918 631 638 O

3 NCT03869918 641 642 O
. NCT03869918 642 643 O
desire NCT03869918 645 651 B-Assertion___Assertion-Type-Value:intention
for NCT03869918 652 655 I-Assertion___Assertion-Type-Value:intention
surgical NCT03869918 656 664 B-Procedure
management NCT03869918 665 675 I-Procedure

4 NCT03869918 678 679 O
. NCT03869918 679 680 O
osteoporosis NCT03869918 682 694 B-Condition

5 NCT03869918 697 698 O
. NCT03869918 698 699 O
lack NCT03869918 701 705 O
of NCT03869918 706 708 O
medical NCT03869918 709 716 O
clearance NCT03869918 717 726 O
from NCT03869918 727 731 O
the NCT03869918 732 735 O
physician NCT03869918 736 745 B-Provider
. NCT03869918 745 746 O

Inclusion NCT03868384 0 9 O
Criteria NCT03868384 10 18 O
: NCT03868384 19 20 O

- NCT03868384 24 25 O
Patients NCT03868384 27 35 O
with NCT03868384 36 40 O
hypertension NCT03868384 41 53 B-Condition
and NCT03868384 54 57 B-And
taking NCT03868384 58 64 B-Eq-Comparison
antihypertensive NCT03868384 65 81 B-Drug
drugs NCT03868384 82 87 I-Drug
more NCT03868384 88 92 B-Eq-Comparison
than NCT03868384 93 97 I-Eq-Comparison
1 NCT03868384 98 99 I-Eq-Comparison
year NCT03868384 100 104 I-Eq-Comparison

Exclusion NCT03868384 105 114 O
Criteria NCT03868384 115 123 O
: NCT03868384 124 125 O

- NCT03868384 129 130 O
Secondary NCT03868384 132 141 B-Modifier
hypertension NCT03868384 142 154 B-Condition

- NCT03868384 157 158 O
Hypertensive NCT03868384 160 172 B-Condition
emergency NCT03868384 173 182 B-Encounter
and NCT03868384 183 186 B-Or
urgency NCT03868384 187 194 B-Encounter

- NCT03868384 197 198 O
Severe NCT03868384 200 206 O
heart NCT03868384 207 212 B-Condition
failure NCT03868384 213 220 I-Condition
( NCT03868384 221 222 O
NYHA NCT03868384 223 227 B-Condition
III NCT03868384 228 231 B-Eq-Comparison
and NCT03868384 232 235 I-Eq-Comparison
IV NCT03868384 236 238 I-Eq-Comparison
) NCT03868384 239 240 O

- NCT03868384 244 245 O
Angina NCT03868384 247 253 B-Condition
with NCT03868384 254 258 O
6 NCT03868384 259 260 B-Eq-Comparison
months NCT03868384 261 267 I-Eq-Comparison

- NCT03868384 270 271 O
Myocardial NCT03868384 273 283 B-Condition
infarction NCT03868384 284 294 I-Condition
within NCT03868384 295 301 B-Eq-Comparison
6 NCT03868384 302 303 I-Eq-Comparison
months NCT03868384 304 310 I-Eq-Comparison

- NCT03868384 313 314 O
Peripheral NCT03868384 316 326 B-Condition
artery NCT03868384 327 333 I-Condition
disease NCT03868384 334 341 I-Condition
within NCT03868384 342 348 B-Eq-Comparison
6 NCT03868384 349 350 I-Eq-Comparison
months NCT03868384 351 357 I-Eq-Comparison

- NCT03868384 360 361 O
Significant NCT03868384 363 374 O
arrhythmia NCT03868384 375 385 B-Condition
( NCT03868384 386 387 O
i. NCT03868384 388 390 O
e. NCT03868384 391 393 O
ventricular NCT03868384 395 406 B-Condition
tachycardia NCT03868384 407 418 I-Condition
and NCT03868384 419 422 B-Or
fibrillation NCT03868384 423 435 B-Condition
, NCT03868384 436 437 O
atrial NCT03868384 438 444 B-Condition
fibrillation NCT03868384 445 457 I-Condition
, NCT03868384 458 459 O
atrial NCT03868384 460 466 B-Condition
flutter NCT03868384 467 474 I-Condition
) NCT03868384 475 476 O

- NCT03868384 480 481 O
Pregnancy NCT03868384 483 492 B-Condition

- NCT03868384 495 496 O
Night NCT03868384 498 503 B-Observation
labor NCT03868384 504 509 I-Observation
, NCT03868384 510 511 O
shift NCT03868384 512 517 B-Observation
worker NCT03868384 518 524 I-Observation

- NCT03868384 527 528 O
Those NCT03868384 530 535 O
who NCT03868384 536 539 O
are NCT03868384 540 543 O
currently NCT03868384 544 553 B-Eq-Comparison
participating NCT03868384 554 567 O
in NCT03868384 568 570 O
other NCT03868384 571 576 B-Other
clinical NCT03868384 577 585 O
studies NCT03868384 586 593 B-Study

- NCT03868384 596 597 O
Those NCT03868384 599 604 O
who NCT03868384 605 608 O
have NCT03868384 609 613 O
taken NCT03868384 614 619 B-Eq-Comparison
other NCT03868384 620 625 B-Other
clinical NCT03868384 626 634 B-Study
trial NCT03868384 635 640 I-Study
drugs NCT03868384 641 646 B-Drug
within NCT03868384 647 653 B-Eq-Comparison
the NCT03868384 654 657 I-Eq-Comparison
past NCT03868384 658 662 I-Eq-Comparison
month NCT03868384 663 668 I-Eq-Comparison

- NCT03868384 671 672 O
According NCT03868384 674 683 O
to NCT03868384 684 686 O
the NCT03868384 687 690 O
opinion NCT03868384 691 698 O
of NCT03868384 699 701 O
the NCT03868384 702 705 O
researcher NCT03868384 706 716 O
, NCT03868384 717 718 O
those NCT03868384 719 724 O
who NCT03868384 725 728 O
have NCT03868384 729 733 I-Assertion___Assertion-Type-Value:possible
or NCT03868384 734 736 O
may NCT03868384 737 740 B-Assertion___Assertion-Type-Value:possible
have NCT03868384 741 745 O
a NCT03868384 746 747 O
disease NCT03868384 748 755 B-Condition
that NCT03868384 756 760 O
may NCT03868384 761 764 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03868384 765 774 O
with NCT03868384 775 779 O
the NCT03868384 780 783 O
completion NCT03868384 784 794 O
of NCT03868384 795 797 O
the NCT03868384 798 801 O
study NCT03868384 802 807 B-Study

- NCT03868384 810 811 O
History NCT03868384 813 820 B-Eq-Comparison
of NCT03868384 821 823 O
drug NCT03868384 824 828 B-Modifier
or NCT03868384 829 831 B-Or
alcohol NCT03868384 832 839 B-Modifier
dependence NCT03868384 840 850 B-Condition
within NCT03868384 851 857 B-Eq-Comparison
6 NCT03868384 858 859 I-Eq-Comparison
months NCT03868384 860 866 I-Eq-Comparison

Inclusion NCT03861559 0 9 O
Criteria NCT03861559 10 18 O
: NCT03861559 19 20 O

- NCT03861559 24 25 O
Has NCT03861559 27 30 O
a NCT03861559 31 32 O
2 NCT03861559 33 34 B-Eq-Comparison
- NCT03861559 35 36 I-Eq-Comparison
year NCT03861559 37 41 I-Eq-Comparison
history NCT03861559 42 49 I-Eq-Comparison
of NCT03861559 50 52 O
seasonal NCT03861559 53 61 O
allergic NCT03861559 62 70 B-Condition
rhinitis NCT03861559 71 79 I-Condition

- NCT03861559 82 83 O
Has NCT03861559 85 88 O
a NCT03861559 89 90 O
positive NCT03861559 91 99 O
skin NCT03861559 100 104 B-Observation
test NCT03861559 105 109 I-Observation
response NCT03861559 110 118 O
to NCT03861559 119 121 O
a NCT03861559 122 123 O
local NCT03861559 124 129 O
seasonal NCT03861559 130 138 O
allergen NCT03861559 139 147 B-Drug
( NCT03861559 148 149 O
current NCT03861559 150 157 B-Eq-Comparison
, NCT03861559 158 159 O
or NCT03861559 160 162 B-Or
performed NCT03861559 163 172 O
in NCT03861559 173 175 O
investigator NCT03861559 176 188 O
's NCT03861559 188 190 O
office NCT03861559 191 197 O
within NCT03861559 198 204 B-Eq-Comparison
the NCT03861559 205 208 I-Eq-Comparison
past NCT03861559 209 213 I-Eq-Comparison
year NCT03861559 214 218 I-Eq-Comparison
) NCT03861559 219 220 O

- NCT03861559 224 225 O
Is NCT03861559 227 229 O
in NCT03861559 230 232 O
good NCT03861559 233 237 B-Condition
health NCT03861559 238 244 I-Condition
and NCT03861559 245 248 B-And
free NCT03861559 249 253 B-Negation
of NCT03861559 254 256 I-Negation
any NCT03861559 257 260 O
unstable NCT03861559 261 269 O
, NCT03861559 270 271 O
clinically NCT03861559 272 282 O
- NCT03861559 283 284 O
significant NCT03861559 285 296 O
disease NCT03861559 297 304 B-Condition
, NCT03861559 305 306 O
other NCT03861559 307 312 B-Exception
than NCT03861559 313 317 I-Exception
allergic NCT03861559 318 326 B-Condition
rhinitis NCT03861559 327 335 I-Condition
, NCT03861559 336 337 O
that NCT03861559 338 342 O
would NCT03861559 343 348 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 349 358 O
with NCT03861559 359 363 O
the NCT03861559 364 367 O
study NCT03861559 368 373 B-Study
schedule NCT03861559 374 382 O
or NCT03861559 383 385 O
evaluation NCT03861559 386 396 O
of NCT03861559 397 399 O
seasonal NCT03861559 400 408 O
allergic NCT03861559 409 417 B-Condition
rhinitis NCT03861559 418 426 I-Condition

Exclusion NCT03861559 427 436 O
Criteria NCT03861559 437 445 O
: NCT03861559 446 447 O

- NCT03861559 451 452 O
Women NCT03861559 454 459 O
who NCT03861559 460 463 B-And
are NCT03861559 464 467 O
pregnant NCT03861559 468 476 B-Condition
or NCT03861559 477 479 B-Or
breastfeeding NCT03861559 480 493 B-Condition

- NCT03861559 496 497 O
Women NCT03861559 499 504 O
of NCT03861559 505 507 B-And
childbearing NCT03861559 508 520 B-Condition
potential NCT03861559 521 530 I-Condition
who NCT03861559 531 534 B-And
are NCT03861559 535 538 O
not NCT03861559 539 542 B-Negation
using NCT03861559 543 548 B-Eq-Comparison
an NCT03861559 549 551 O
acceptable NCT03861559 552 562 O
form NCT03861559 563 567 O
of NCT03861559 568 570 O
birth NCT03861559 571 576 B-Procedure
control NCT03861559 577 584 I-Procedure

- NCT03861559 587 588 O
Has NCT03861559 590 593 O
asthma NCT03861559 594 600 B-Condition
that NCT03861559 601 605 O
requires NCT03861559 606 614 B-Assertion___Assertion-Type-Value:hypothetical
therapy NCT03861559 615 622 B-Procedure
with NCT03861559 623 627 O
inhaled NCT03861559 628 635 B-Modifier
or NCT03861559 636 638 B-Or
systemic NCT03861559 639 647 B-Modifier
corticosteroids NCT03861559 648 663 B-Drug
, NCT03861559 664 665 O
cromolyn NCT03861559 666 674 B-Drug
, NCT03861559 675 676 O
or NCT03861559 677 679 B-Or
nedocromil NCT03861559 680 690 B-Drug

- NCT03861559 693 694 O
Has NCT03861559 696 699 O
significant NCT03861559 700 711 O
renal NCT03861559 712 717 B-Modifier
, NCT03861559 718 719 O
hepatic NCT03861559 720 727 B-Modifier
, NCT03861559 728 729 O
neurologic NCT03861559 730 740 B-Modifier
, NCT03861559 741 742 O
cardiovascular NCT03861559 743 757 B-Modifier
, NCT03861559 758 759 O
hematologic NCT03861559 760 771 B-Modifier
, NCT03861559 772 773 O
metabolic NCT03861559 774 783 B-Modifier
, NCT03861559 784 785 O
cerebrovascular NCT03861559 786 801 B-Modifier
, NCT03861559 802 803 O
respiratory NCT03861559 804 815 B-Modifier
, NCT03861559 816 817 O
gastrointestinal NCT03861559 818 834 B-Modifier
, NCT03861559 835 836 O
or NCT03861559 837 839 B-Or
other NCT03861559 840 845 B-Other
significant NCT03861559 846 857 O
medical NCT03861559 858 865 B-Condition
illness NCT03861559 866 873 I-Condition
or NCT03861559 874 876 B-Or
disorder NCT03861559 877 885 B-Condition
which NCT03861559 886 891 O
, NCT03861559 892 893 O
in NCT03861559 894 896 O
the NCT03861559 897 900 O
judgment NCT03861559 901 909 O
of NCT03861559 910 912 O
the NCT03861559 913 916 O
investigator NCT03861559 917 929 O
, NCT03861559 930 931 O
could NCT03861559 932 937 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 938 947 O
with NCT03861559 948 952 O
the NCT03861559 953 956 O
study NCT03861559 957 962 B-Study
, NCT03861559 963 964 O
or NCT03861559 965 967 B-Or
required NCT03861559 968 976 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03861559 977 986 B-Procedure
which NCT03861559 987 992 O
might NCT03861559 993 998 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 999 1008 O
with NCT03861559 1009 1013 O
the NCT03861559 1014 1017 O
study NCT03861559 1018 1023 B-Study

- NCT03861559 1026 1027 O
Is NCT03861559 1029 1031 O
on NCT03861559 1032 1034 B-Eq-Comparison
immunotherapy NCT03861559 1035 1048 B-Procedure
with NCT03861559 1049 1053 O
the NCT03861559 1054 1057 I-Procedure
exception NCT03861559 1058 1067 B-Exception
of NCT03861559 1068 1070 O
maintenance NCT03861559 1071 1082 B-Procedure
therapy NCT03861559 1083 1090 O

- NCT03861559 1093 1094 O
Has NCT03861559 1096 1099 O
a NCT03861559 1100 1101 O
clinically NCT03861559 1102 1112 O
significant NCT03861559 1113 1124 O
upper NCT03861559 1125 1130 B-Modifier
respiratory NCT03861559 1131 1142 I-Modifier
or NCT03861559 1143 1145 B-Or
sinus NCT03861559 1146 1151 B-Modifier
infection NCT03861559 1152 1161 B-Condition

- NCT03861559 1164 1165 O
Has NCT03861559 1167 1170 O
used NCT03861559 1171 1175 B-Eq-Comparison
an NCT03861559 1176 1178 O
investigational NCT03861559 1179 1194 B-Study
drug NCT03861559 1195 1199 B-Drug
within NCT03861559 1200 1206 B-Eq-Comparison
the NCT03861559 1207 1210 I-Eq-Comparison
previous NCT03861559 1211 1219 I-Eq-Comparison
30 NCT03861559 1220 1222 I-Eq-Comparison
days NCT03861559 1223 1227 I-Eq-Comparison

- NCT03861559 1230 1231 O
Has NCT03861559 1233 1236 O
nasal NCT03861559 1237 1242 B-Modifier
structural NCT03861559 1243 1253 I-Modifier
abnormalities NCT03861559 1254 1267 B-Condition
, NCT03861559 1268 1269 O
including NCT03861559 1270 1279 O
large NCT03861559 1280 1285 B-Modifier
nasal NCT03861559 1286 1291 B-Condition
polyps NCT03861559 1292 1298 I-Condition
and NCT03861559 1299 1302 B-Or
marked NCT03861559 1303 1309 O
septal NCT03861559 1310 1316 B-Condition
deviation NCT03861559 1317 1326 I-Condition
, NCT03861559 1327 1328 O
that NCT03861559 1329 1333 O
significantly NCT03861559 1334 1347 O
interfere NCT03861559 1348 1357 O
with NCT03861559 1358 1362 O
nasal NCT03861559 1363 1368 B-Condition
air NCT03861559 1369 1372 I-Condition
flow NCT03861559 1373 1377 I-Condition

- NCT03861559 1380 1381 O
Has NCT03861559 1383 1386 O
a NCT03861559 1387 1388 O
history NCT03861559 1389 1396 B-Eq-Comparison
of NCT03861559 1397 1399 O
multiple NCT03861559 1400 1408 B-Eq-Comparison
drug NCT03861559 1409 1413 B-Drug
allergies NCT03861559 1414 1423 B-Allergy
or NCT03861559 1424 1426 B-Or
an NCT03861559 1427 1429 B-Drug
allergy NCT03861559 1430 1437 B-Allergy
to NCT03861559 1438 1440 O
antihistamines NCT03861559 1441 1455 O
or NCT03861559 1456 1458 B-Or
corticoids NCT03861559 1459 1469 B-Drug

- NCT03861559 1472 1473 O
Has NCT03861559 1475 1478 O
dependence NCT03861559 1479 1489 O
upon NCT03861559 1490 1494 O
nasal NCT03861559 1495 1500 B-Modifier
, NCT03861559 1501 1502 O
oral NCT03861559 1503 1507 B-Modifier|Or|Or
or NCT03861559 1508 1510 O
ocular NCT03861559 1511 1517 B-Modifier
decongestants NCT03861559 1518 1531 B-Drug
, NCT03861559 1532 1533 O
or NCT03861559 1534 1536 O
nasal NCT03861559 1537 1542 B-Drug
topical NCT03861559 1543 1550 I-Drug
antihistamines NCT03861559 1551 1565 I-Drug
, NCT03861559 1566 1567 O
in NCT03861559 1568 1570 O
the NCT03861559 1571 1574 O
opinion NCT03861559 1575 1582 O
of NCT03861559 1583 1585 O
the NCT03861559 1586 1589 O
investigator NCT03861559 1590 1602 O

- NCT03861559 1605 1606 O
Has NCT03861559 1608 1611 O
rhinitis NCT03861559 1612 1620 B-Condition
medicamentosa NCT03861559 1621 1634 I-Condition

- NCT03861559 1637 1638 O
Is NCT03861559 1640 1642 O
using NCT03861559 1643 1648 B-Eq-Comparison
of NCT03861559 1649 1651 O
any NCT03861559 1652 1655 O
chronic NCT03861559 1656 1663 B-Modifier
medication NCT03861559 1664 1674 B-Drug
which NCT03861559 1675 1680 O
could NCT03861559 1681 1686 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861559 1687 1693 O
the NCT03861559 1694 1697 O
course NCT03861559 1698 1704 O
of NCT03861559 1705 1707 O
seasonal NCT03861559 1708 1716 O
allergic NCT03861559 1717 1725 B-Condition
rhinitis NCT03861559 1726 1734 I-Condition

Inclusion NCT03863366 0 9 O
Criteria NCT03863366 10 18 O
: NCT03863366 19 20 O

- NCT03863366 24 25 O
Male NCT03863366 27 31 O
or NCT03863366 32 34 B-Or
female NCT03863366 35 41 O

- NCT03863366 44 45 O
Aged NCT03863366 47 51 B-Age
18 NCT03863366 52 54 B-Eq-Comparison
- NCT03863366 55 56 I-Eq-Comparison
40 NCT03863366 57 59 I-Eq-Comparison
years NCT03863366 60 65 I-Eq-Comparison

- NCT03863366 68 69 O
Willing NCT03863366 71 78 O
and NCT03863366 79 82 O
able NCT03863366 83 87 O
to NCT03863366 88 90 O
give NCT03863366 91 95 O
informed NCT03863366 96 104 O
consent NCT03863366 105 112 O
for NCT03863366 113 116 O
participation NCT03863366 117 130 O
in NCT03863366 131 133 O
the NCT03863366 134 137 O
study NCT03863366 138 143 O

- NCT03863366 146 147 O
Sufficiently NCT03863366 149 161 O
fluent NCT03863366 162 168 O
English NCT03863366 169 176 O
to NCT03863366 177 179 O
understand NCT03863366 180 190 O
and NCT03863366 191 194 O
complete NCT03863366 195 203 O
the NCT03863366 204 207 O
task NCT03863366 208 212 O

Exclusion NCT03863366 213 222 O
Criteria NCT03863366 223 231 O
: NCT03863366 232 233 O

- NCT03863366 237 238 O
Current NCT03863366 240 247 B-Eq-Comparison
usage NCT03863366 248 253 O
of NCT03863366 254 256 O
psychoactive NCT03863366 257 269 B-Drug
medication NCT03863366 270 280 I-Drug
( NCT03863366 281 282 O
except NCT03863366 283 289 B-Exception
the NCT03863366 290 293 O
contraceptive NCT03863366 294 307 B-Drug
pill NCT03863366 308 312 I-Drug
, NCT03863366 313 314 O
the NCT03863366 315 318 O
Depo NCT03863366 319 323 B-Drug
- NCT03863366 324 325 I-Drug
Provera NCT03863366 326 333 I-Drug
injection NCT03863366 334 343 O
or NCT03863366 344 346 B-Or
the NCT03863366 347 350 O
progesterone NCT03863366 351 363 B-Procedure
implant NCT03863366 364 371 I-Procedure
) NCT03863366 372 373 O

- NCT03863366 377 378 O
Any NCT03863366 380 383 O
past NCT03863366 384 388 B-Eq-Comparison
or NCT03863366 389 391 B-Or
current NCT03863366 392 399 B-Eq-Comparison
Axis NCT03863366 400 404 B-Modifier
1 NCT03863366 405 406 I-Modifier
DSM NCT03863366 407 410 I-Modifier
- NCT03863366 411 412 I-Modifier
IV NCT03863366 413 415 I-Modifier
psychiatric NCT03863366 416 427 B-Condition
disorder NCT03863366 428 436 I-Condition

- NCT03863366 439 440 O
Significant NCT03863366 442 453 O
medical NCT03863366 454 461 B-Condition
condition NCT03863366 462 471 I-Condition

- NCT03863366 474 475 O
Current NCT03863366 477 484 B-Eq-Comparison
or NCT03863366 485 487 B-Or
past NCT03863366 488 492 B-Eq-Comparison
gastro NCT03863366 493 499 B-Modifier
- NCT03863366 500 501 I-Modifier
intestinal NCT03863366 502 512 I-Modifier
disorder NCT03863366 513 521 B-Condition
or NCT03863366 522 524 B-Or
irritable NCT03863366 525 534 B-Condition
bowel NCT03863366 535 540 I-Condition
syndrome NCT03863366 541 549 I-Condition

- NCT03863366 552 553 O
Current NCT03863366 555 562 B-Eq-Comparison
pregnancy NCT03863366 563 572 B-Condition
or NCT03863366 573 575 B-Or
breastfeeding NCT03863366 576 589 B-Condition

- NCT03863366 592 593 O
Known NCT03863366 595 600 O
lactate NCT03863366 601 608 B-Condition
deficiency NCT03863366 609 619 I-Condition
or NCT03863366 620 622 B-Or
any NCT03863366 623 626 O
other NCT03863366 627 632 B-Other
problem NCT03863366 633 640 B-Condition
absorbing NCT03863366 641 650 I-Condition
lactose NCT03863366 651 658 B-Modifier
, NCT03863366 659 660 O
galactose NCT03863366 661 670 B-Modifier
or NCT03863366 671 673 B-Or
glucose NCT03863366 674 681 B-Modifier

- NCT03863366 684 685 O
Current NCT03863366 687 694 B-Eq-Comparison
or NCT03863366 695 697 B-Or
past NCT03863366 698 702 B-Eq-Comparison
history NCT03863366 703 710 I-Eq-Comparison
of NCT03863366 711 713 O
drug NCT03863366 714 718 B-Modifier
or NCT03863366 719 721 B-Or
alcohol NCT03863366 722 729 B-Modifier
dependency NCT03863366 730 740 B-Condition

- NCT03863366 743 744 O
Participation NCT03863366 746 759 O
in NCT03863366 760 762 O
a NCT03863366 763 764 O
psychological NCT03863366 765 778 B-Modifier
or NCT03863366 779 781 B-Or
medical NCT03863366 782 789 B-Modifier
study NCT03863366 790 795 B-Study
involving NCT03863366 796 805 O
the NCT03863366 806 809 O
use NCT03863366 810 813 O
of NCT03863366 814 816 O
medication NCT03863366 817 827 B-Drug
within NCT03863366 828 834 B-Eq-Comparison
the NCT03863366 835 838 I-Eq-Comparison
last NCT03863366 839 843 I-Eq-Comparison
3 NCT03863366 844 845 I-Eq-Comparison
months NCT03863366 846 852 I-Eq-Comparison

- NCT03863366 855 856 O
Previous NCT03863366 858 866 B-Eq-Comparison
participation NCT03863366 867 880 O
in NCT03863366 881 883 O
a NCT03863366 884 885 O
study NCT03863366 886 891 B-Study
using NCT03863366 892 897 O
the NCT03863366 898 901 O
same NCT03863366 902 906 B-Modifier
, NCT03863366 907 908 O
or NCT03863366 909 911 B-Or
similar NCT03863366 912 919 B-Modifier
, NCT03863366 920 921 O
emotional NCT03863366 922 931 B-Procedure
processing NCT03863366 932 942 I-Procedure
tasks NCT03863366 943 948 I-Procedure

- NCT03863366 951 952 O
Smoker NCT03863366 954 960 B-Condition|Observation
> NCT03863366 961 962 B-Eq-Comparison
5 NCT03863366 963 964 I-Eq-Comparison
cigarettes NCT03863366 965 975 I-Eq-Comparison
per NCT03863366 976 979 I-Eq-Comparison
day NCT03863366 980 983 I-Eq-Comparison

- NCT03863366 986 987 O
Typically NCT03863366 989 998 O
drinks NCT03863366 999 1005 B-Observation
> NCT03863366 1006 1007 B-Eq-Comparison
6 NCT03863366 1008 1009 I-Eq-Comparison
caffeinated NCT03863366 1010 1021 I-Eq-Comparison
drinks NCT03863366 1022 1028 I-Eq-Comparison
per NCT03863366 1029 1032 I-Eq-Comparison
day NCT03863366 1033 1036 I-Eq-Comparison

Inclusion NCT03862534 0 9 O
Criteria NCT03862534 10 18 O
: NCT03862534 19 20 O

- NCT03862534 24 25 O
Age NCT03862534 27 30 B-Age
≥ NCT03862534 31 32 B-Eq-Comparison
18 NCT03862534 33 35 I-Eq-Comparison
years NCT03862534 36 41 I-Eq-Comparison

- NCT03862534 44 45 O
No NCT03862534 47 49 B-Negation
systemic NCT03862534 50 58 B-Modifier
diseases NCT03862534 59 67 B-Condition
or NCT03862534 68 70 B-Or
pregnancy NCT03862534 71 80 B-Condition
. NCT03862534 80 81 O

- NCT03862534 85 86 O
Self NCT03862534 88 92 O
- NCT03862534 93 94 O
reported NCT03862534 95 103 O
smoking NCT03862534 104 111 B-Condition|Observation
≤ NCT03862534 112 113 B-Eq-Comparison
10 NCT03862534 114 116 I-Eq-Comparison
cigarettes NCT03862534 117 127 I-Eq-Comparison
/ NCT03862534 128 129 I-Eq-Comparison
day NCT03862534 130 133 I-Eq-Comparison
. NCT03862534 133 134 O

- NCT03862534 138 139 I-Observation
Full NCT03862534 141 145 B-Observation
- NCT03862534 146 147 O
mouth NCT03862534 148 153 I-Observation
plaque NCT03862534 154 160 I-Observation
score NCT03862534 161 166 I-Observation
( NCT03862534 167 168 O
FMPS NCT03862534 169 173 B-Observation
) NCT03862534 174 175 O
and NCT03862534 176 179 B-And
full NCT03862534 180 184 B-Observation
- NCT03862534 185 186 I-Observation
mouth NCT03862534 187 192 I-Observation
bleeding NCT03862534 193 201 I-Observation
score NCT03862534 202 207 I-Observation
( NCT03862534 208 209 O
FMBS NCT03862534 210 214 B-Observation
) NCT03862534 215 216 O
≤ NCT03862534 217 218 B-Eq-Comparison
10 NCT03862534 219 221 I-Eq-Comparison
% NCT03862534 222 223 O
( NCT03862534 224 225 O
measured NCT03862534 226 234 O
at NCT03862534 235 237 O
four NCT03862534 238 242 B-Eq-Comparison
sites NCT03862534 243 248 I-Eq-Comparison
per NCT03862534 249 252 I-Eq-Comparison
tooth NCT03862534 253 258 I-Eq-Comparison
) NCT03862534 259 260 O
. NCT03862534 261 262 O

- NCT03862534 266 267 O
Presence NCT03862534 269 277 O
of NCT03862534 278 280 O
single NCT03862534 281 287 B-Eq-Comparison
RT1 NCT03862534 288 291 B-Modifier
buccal NCT03862534 292 298 I-Modifier
gingival NCT03862534 299 307 B-Condition|Observation
recessions NCT03862534 308 318 I-Condition|Observation
≥ NCT03862534 319 320 B-Eq-Comparison
2 NCT03862534 321 322 I-Eq-Comparison
mm NCT03862534 323 325 I-Eq-Comparison
of NCT03862534 326 328 O
depth NCT03862534 329 334 O
located NCT03862534 335 342 O
in NCT03862534 343 345 O
the NCT03862534 346 349 O
anterior NCT03862534 350 358 B-Modifier
area NCT03862534 359 363 I-Modifier
of NCT03862534 364 366 O
the NCT03862534 367 370 O
upper NCT03862534 371 376 B-Modifier
jaw NCT03862534 377 380 I-Modifier
( NCT03862534 381 382 O
central NCT03862534 383 390 B-Modifier
and NCT03862534 391 394 B-Or
lateral NCT03862534 395 402 B-Modifier
incisors NCT03862534 403 411 I-Modifier
, NCT03862534 412 413 O
canine NCT03862534 414 420 B-Modifier
, NCT03862534 421 422 O
first NCT03862534 423 428 B-Modifier
and NCT03862534 429 432 I-Modifier
second NCT03862534 433 439 I-Modifier
pre NCT03862534 440 443 I-Modifier
- NCT03862534 444 445 I-Modifier
molars NCT03862534 446 452 I-Modifier|Modifier
, NCT03862534 453 454 O
first NCT03862534 455 460 B-Modifier
molar NCT03862534 461 466 O
) NCT03862534 467 468 O
and NCT03862534 469 472 O
associated NCT03862534 473 483 O
with NCT03862534 484 488 O
aesthetic NCT03862534 489 498 B-Condition
complains NCT03862534 499 508 I-Condition
and NCT03862534 509 512 O
or NCT03862534 513 515 B-Or
dental NCT03862534 516 522 B-Condition
sensitivity NCT03862534 523 534 I-Condition
. NCT03862534 534 535 O

- NCT03862534 539 540 O
Presence NCT03862534 542 550 O
of NCT03862534 551 553 O
NCCL NCT03862534 554 558 B-Condition
associated NCT03862534 559 569 O
with NCT03862534 570 574 O
recession NCT03862534 575 584 B-Condition

- NCT03862534 587 588 O
No NCT03862534 590 592 B-Negation
history NCT03862534 593 600 B-Eq-Comparison
of NCT03862534 601 603 O
mucogingival NCT03862534 604 616 B-Modifier
or NCT03862534 617 619 B-Or
periodontal NCT03862534 620 631 B-Modifier
surgery NCT03862534 632 639 B-Procedure
at NCT03862534 640 642 O
experimental NCT03862534 643 655 B-Modifier
sites NCT03862534 656 661 I-Modifier
. NCT03862534 661 662 O

Exclusion NCT03862534 664 673 O
Criteria NCT03862534 674 682 O
: NCT03862534 683 684 O

- NCT03862534 688 689 O
Prosthetic NCT03862534 691 701 B-Condition
crown NCT03862534 702 707 I-Condition
at NCT03862534 708 710 O
experimental NCT03862534 711 723 B-Modifier
teeth NCT03862534 724 729 I-Modifier
. NCT03862534 729 730 O

- NCT03862534 734 735 O
Gingival NCT03862534 737 745 B-Condition
recessions NCT03862534 746 756 I-Condition
presenting NCT03862534 757 767 O
minimal NCT03862534 768 775 O
amount NCT03862534 776 782 O
( NCT03862534 783 784 O
< NCT03862534 786 787 B-Eq-Comparison
1 NCT03862534 788 789 I-Eq-Comparison
mm NCT03862534 790 792 O
) NCT03862534 793 794 O
of NCT03862534 795 797 O
apico NCT03862534 798 803 B-Condition|Observation
- NCT03862534 804 805 I-Condition|Observation
coronal NCT03862534 806 813 I-Condition|Observation
keratinized NCT03862534 814 825 I-Condition|Observation
tissue NCT03862534 826 832 I-Condition|Observation
( NCT03862534 833 834 O
KT NCT03862534 835 837 B-Condition
) NCT03862534 838 839 O
extension NCT03862534 840 849 O
apical NCT03862534 850 856 B-Modifier
to NCT03862534 857 859 I-Modifier
recession NCT03862534 860 869 I-Modifier
area NCT03862534 870 874 I-Modifier
. NCT03862534 874 875 O

Inclusion NCT03869307 0 9 O
Criteria NCT03869307 10 18 O
: NCT03869307 19 20 O

- NCT03869307 24 25 O
Men NCT03869307 27 30 O
and NCT03869307 31 34 B-Or
women NCT03869307 35 40 O
aged NCT03869307 41 45 B-Age
18 NCT03869307 46 48 B-Eq-Comparison
- NCT03869307 49 50 I-Eq-Comparison
65 NCT03869307 51 53 I-Eq-Comparison

- NCT03869307 57 58 O
Generalized NCT03869307 60 71 B-Modifier
HSD NCT03869307 72 75 B-Condition
( NCT03869307 76 77 O
G NCT03869307 78 79 B-Condition
- NCT03869307 80 81 I-Condition
HSD NCT03869307 82 85 I-Condition
) NCT03869307 86 87 O
defined NCT03869307 88 95 O
with NCT03869307 96 100 O
Beighton NCT03869307 101 109 B-Observation
score NCT03869307 110 115 I-Observation
cut NCT03869307 116 119 O
- NCT03869307 120 121 O
off NCT03869307 122 125 O
≥ NCT03869307 126 127 B-Eq-Comparison
5 NCT03869307 128 129 I-Eq-Comparison
for NCT03869307 130 133 O
women NCT03869307 134 139 O
up NCT03869307 140 142 B-Eq-Comparison
to NCT03869307 143 145 I-Eq-Comparison
the NCT03869307 146 149 I-Eq-Comparison
age NCT03869307 150 153 I-Age|Eq-Comparison
of NCT03869307 154 156 I-Eq-Comparison
50 NCT03869307 157 159 I-Eq-Comparison
years NCT03869307 160 165 I-Eq-Comparison
and NCT03869307 166 169 B-Or
≥ NCT03869307 170 171 B-Eq-Comparison
4 NCT03869307 172 173 I-Eq-Comparison
for NCT03869307 174 177 O
those NCT03869307 178 183 B-Coreference
above NCT03869307 184 189 B-Eq-Comparison
50 NCT03869307 190 192 I-Eq-Comparison
years NCT03869307 193 198 I-Age|Eq-Comparison
and NCT03869307 199 202 B-Or
all NCT03869307 203 206 O
men NCT03869307 207 210 O
, NCT03869307 211 212 O
or NCT03869307 213 215 B-Or
Historical NCT03869307 216 226 B-Modifier
HSD NCT03869307 227 230 B-Condition|Condition
( NCT03869307 231 232 O
H NCT03869307 233 234 O
- NCT03869307 235 236 I-Condition
HSD NCT03869307 237 240 O
) NCT03869307 241 242 O
if NCT03869307 243 245 O
the NCT03869307 246 249 O
Beighton NCT03869307 250 258 B-Observation
score NCT03869307 259 264 I-Observation
was NCT03869307 265 268 O
1 NCT03869307 269 270 B-Eq-Comparison
point NCT03869307 271 276 I-Eq-Comparison
below NCT03869307 277 282 I-Eq-Comparison
the NCT03869307 283 286 I-Eq-Comparison
age NCT03869307 287 290 I-Eq-Comparison
and NCT03869307 291 294 I-Eq-Comparison
sex NCT03869307 295 298 I-Eq-Comparison
- NCT03869307 299 300 I-Eq-Comparison
specific NCT03869307 301 309 I-Eq-Comparison
cut NCT03869307 310 313 I-Eq-Comparison
- NCT03869307 314 315 I-Observation
off NCT03869307 316 319 I-Eq-Comparison
AND NCT03869307 320 323 B-And
the NCT03869307 324 327 O
five NCT03869307 328 332 B-Observation
- NCT03869307 333 334 O
part NCT03869307 335 339 I-Observation
questionnaire NCT03869307 340 353 I-Observation
( NCT03869307 354 355 O
5 NCT03869307 356 357 B-Observation
PQ NCT03869307 358 360 O
) NCT03869307 361 362 O
was NCT03869307 363 366 O
positive NCT03869307 367 375 I-Eq-Comparison
( NCT03869307 376 377 O
= NCT03869307 379 380 O
at NCT03869307 381 383 B-Eq-Comparison
least NCT03869307 384 389 I-Eq-Comparison
two NCT03869307 390 393 I-Eq-Comparison
positive NCT03869307 394 402 O
items NCT03869307 403 408 I-Eq-Comparison
) NCT03869307 409 410 O
. NCT03869307 411 412 O

- NCT03869307 416 417 O
Present NCT03869307 419 426 O
with NCT03869307 427 431 O
one NCT03869307 432 435 B-Eq-Comparison
or NCT03869307 436 438 I-Eq-Comparison
more NCT03869307 439 443 I-Eq-Comparison
secondary NCT03869307 444 453 B-Modifier
symptomatic NCT03869307 454 465 B-Assertion___Assertion-Type-Value:possible
musculoskeletal NCT03869307 466 481 B-Condition
manifestations NCT03869307 482 496 I-Condition
, NCT03869307 497 498 O
defined NCT03869307 499 506 O
as NCT03869307 507 509 O
either NCT03869307 510 516 O

1 NCT03869307 524 525 O
. NCT03869307 525 526 O
musculoskeletal NCT03869307 528 543 B-Modifier
pain NCT03869307 544 548 B-Condition
in NCT03869307 549 551 O
minimum NCT03869307 552 559 B-Eq-Comparison
one NCT03869307 560 563 I-Eq-Comparison
shoulder NCT03869307 564 572 B-Modifier
for NCT03869307 573 576 O
at NCT03869307 577 579 B-Eq-Comparison
least NCT03869307 580 585 I-Eq-Comparison
three NCT03869307 586 591 I-Eq-Comparison
months NCT03869307 592 598 I-Eq-Comparison
and NCT03869307 599 602 B-Or
/ NCT03869307 603 604 I-Or
or NCT03869307 605 607 I-Or

2 NCT03869307 615 616 O
. NCT03869307 616 617 O
recurrent NCT03869307 619 628 B-Modifier
joint NCT03869307 629 634 I-Modifier|Modifier
dislocations NCT03869307 635 647 B-Condition
or NCT03869307 648 650 B-Or
joint NCT03869307 651 656 O
instability NCT03869307 657 668 B-Condition
without NCT03869307 669 676 B-Negation
a NCT03869307 677 678 O
reported NCT03869307 679 687 O
history NCT03869307 688 695 B-Eq-Comparison
of NCT03869307 696 698 O
trauma NCT03869307 699 705 B-Condition
defined NCT03869307 706 713 O
as NCT03869307 714 716 O
either NCT03869307 717 723 O
a NCT03869307 724 725 O
) NCT03869307 726 727 O
minimum NCT03869307 728 735 B-Eq-Comparison
three NCT03869307 736 741 I-Eq-Comparison
atraumatic NCT03869307 742 752 B-Modifier
dislocations NCT03869307 753 765 B-Condition
in NCT03869307 766 768 O
same NCT03869307 769 773 B-Modifier
shoulder NCT03869307 774 782 I-Modifier
, NCT03869307 783 784 O
b NCT03869307 785 786 O
) NCT03869307 787 788 O
minimum NCT03869307 789 796 B-Eq-Comparison
two NCT03869307 797 800 I-Eq-Comparison|Modifier
atraumatic NCT03869307 801 811 B-Modifier
dislocations NCT03869307 812 824 B-Condition
in NCT03869307 825 827 O
two NCT03869307 828 831 O
different NCT03869307 832 841 I-Modifier
joints NCT03869307 842 848 I-Modifier
( NCT03869307 849 850 O
minimum NCT03869307 851 858 B-Eq-Comparison
one NCT03869307 859 862 I-Eq-Comparison
in NCT03869307 863 865 O
the NCT03869307 866 869 O
shoulder NCT03869307 870 878 B-Modifier
) NCT03869307 879 880 O
occurring NCT03869307 881 890 O
at NCT03869307 891 893 O
different NCT03869307 894 903 O
times NCT03869307 904 909 O
, NCT03869307 910 911 O
or NCT03869307 912 914 B-Or
c NCT03869307 915 916 O
) NCT03869307 917 918 O
medical NCT03869307 919 926 O
confirmation NCT03869307 927 939 O
of NCT03869307 940 942 O
joint NCT03869307 943 948 I-Eq-Comparison|Modifier
instability NCT03869307 949 960 B-Condition
in NCT03869307 961 963 I-Modifier
minimum NCT03869307 964 971 B-Eq-Comparison|Eq-Comparison
two NCT03869307 972 975 I-Eq-Comparison
joints NCT03869307 976 982 O
( NCT03869307 983 984 O
minimum NCT03869307 985 992 O
one NCT03869307 993 996 B-Eq-Comparison|Modifier
in NCT03869307 997 999 O
the NCT03869307 1000 1003 I-Modifier
shoulder NCT03869307 1004 1012 I-Modifier
) NCT03869307 1013 1014 O
not NCT03869307 1015 1018 B-Negation
related NCT03869307 1019 1026 O
to NCT03869307 1027 1029 O
trauma NCT03869307 1030 1036 B-Condition
. NCT03869307 1036 1037 O

Exclusion NCT03869307 1039 1048 O
Criteria NCT03869307 1049 1057 O
: NCT03869307 1058 1059 O

- NCT03869307 1063 1064 O
Clinically NCT03869307 1066 1076 O
suspected NCT03869307 1077 1086 B-Assertion___Assertion-Type-Value:possible
referred NCT03869307 1087 1095 O
pain NCT03869307 1096 1100 B-Condition
from NCT03869307 1101 1105 O
the NCT03869307 1106 1109 O
cervical NCT03869307 1110 1118 B-Modifier
spine NCT03869307 1119 1124 I-Modifier

- NCT03869307 1127 1128 O
Systemic NCT03869307 1130 1138 B-Modifier
inflammatory NCT03869307 1139 1151 B-Condition
rheumatic NCT03869307 1152 1161 I-Condition
diseases NCT03869307 1162 1170 I-Condition|Condition

- NCT03869307 1173 1174 O
Connective NCT03869307 1176 1186 B-Condition
tissue NCT03869307 1187 1193 I-Condition
diseases NCT03869307 1194 1202 O
( NCT03869307 1203 1204 O
e. NCT03869307 1205 1207 O
g. NCT03869307 1208 1210 O
Marfans NCT03869307 1212 1219 B-Condition
, NCT03869307 1220 1221 O
Stickler NCT03869307 1222 1230 B-Condition
's NCT03869307 1230 1232 O
or NCT03869307 1233 1235 B-Or
Loeys NCT03869307 1236 1241 B-Condition
Dietz NCT03869307 1242 1247 I-Condition
syndromes NCT03869307 1248 1257 I-Condition
, NCT03869307 1258 1259 O
Ehlers NCT03869307 1260 1266 B-Condition
- NCT03869307 1267 1268 I-Condition
Danlos NCT03869307 1269 1275 I-Condition
Syndromes NCT03869307 1276 1285 I-Condition
except NCT03869307 1286 1292 B-Exception
hypermobile NCT03869307 1293 1304 B-Modifier
type NCT03869307 1305 1309 I-Modifier
) NCT03869307 1310 1311 O

- NCT03869307 1315 1316 O
Neurological NCT03869307 1318 1330 B-Condition
diseases NCT03869307 1331 1339 I-Condition

- NCT03869307 1342 1343 O
Pregnancy NCT03869307 1345 1354 B-Condition
or NCT03869307 1355 1357 B-Or|Or
childbirth NCT03869307 1358 1368 B-Condition
within NCT03869307 1369 1375 B-Eq-Comparison
the NCT03869307 1376 1379 I-Eq-Comparison
past NCT03869307 1380 1384 I-Eq-Comparison
year NCT03869307 1385 1389 I-Eq-Comparison
or NCT03869307 1390 1392 O
planning NCT03869307 1393 1401 B-Assertion___Assertion-Type-Value:intention
to NCT03869307 1402 1404 I-Assertion___Assertion-Type-Value:intention
get NCT03869307 1405 1408 O
pregnant NCT03869307 1409 1417 B-Condition
during NCT03869307 1418 1424 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869307 1425 1428 I-Eq-Comparison
study NCT03869307 1429 1434 B-Study
period NCT03869307 1435 1441 O

- NCT03869307 1444 1445 O
Shoulder NCT03869307 1447 1455 B-Modifier
surgery NCT03869307 1456 1463 B-Procedure
within NCT03869307 1464 1470 B-Eq-Comparison
the NCT03869307 1471 1474 O
past NCT03869307 1475 1479 I-Eq-Comparison
year NCT03869307 1480 1484 I-Eq-Comparison

- NCT03869307 1487 1488 O
Steroid NCT03869307 1490 1497 B-Procedure
injection NCT03869307 1498 1507 I-Procedure
in NCT03869307 1508 1510 O
the NCT03869307 1511 1514 O
affected NCT03869307 1515 1523 B-Modifier
shoulder NCT03869307 1524 1532 I-Modifier
within NCT03869307 1533 1539 B-Eq-Comparison
three NCT03869307 1540 1545 I-Eq-Comparison
months NCT03869307 1546 1552 I-Eq-Comparison

- NCT03869307 1555 1556 O
Inability NCT03869307 1558 1567 B-Negation
to NCT03869307 1568 1570 O
speak NCT03869307 1571 1576 O
and NCT03869307 1577 1580 O
understand NCT03869307 1581 1591 O
Danish NCT03869307 1592 1598 O
. NCT03869307 1598 1599 O

- NCT03869307 1603 1604 O
Unable NCT03869307 1606 1612 O
to NCT03869307 1613 1615 O
comply NCT03869307 1616 1622 O
with NCT03869307 1623 1627 O
protocol NCT03869307 1628 1636 O

Inclusion NCT03863158 0 9 O
Criteria NCT03863158 10 18 O
: NCT03863158 19 20 O

- NCT03863158 24 25 O
Patients NCT03863158 27 35 O
presenting NCT03863158 36 46 O
acute NCT03863158 47 52 O
myocardial NCT03863158 53 63 B-Condition
infarction NCT03863158 64 74 I-Condition
with NCT03863158 75 79 B-And
hemodynamic NCT03863158 80 91 B-Condition
stability NCT03863158 92 101 O
at NCT03863158 102 104 O
the NCT03863158 105 108 O
diagnosis NCT03863158 109 118 O

- NCT03863158 121 122 O
Patients NCT03863158 124 132 O
undergoing NCT03863158 133 143 B-Eq-Comparison
coronary NCT03863158 144 152 B-Procedure
artery NCT03863158 153 159 I-Procedure
bypass NCT03863158 160 166 I-Procedure
in NCT03863158 167 169 O
Dijon NCT03863158 170 175 O
University NCT03863158 176 186 O
hospital NCT03863158 187 195 O

Exclusion NCT03863158 196 205 O
Criteria NCT03863158 206 214 O
: NCT03863158 215 216 O

- NCT03863158 220 221 O
Patients NCT03863158 223 231 O
with NCT03863158 232 236 O
Acute NCT03863158 237 242 O
pulmonary NCT03863158 243 252 B-Condition
oedema NCT03863158 253 259 I-Condition

- NCT03863158 262 263 O
Patients NCT03863158 265 273 O
with NCT03863158 274 278 O
cardiorespiratory NCT03863158 279 296 B-Condition
arrest NCT03863158 297 303 I-Condition
before NCT03863158 304 310 B-Temporal-Connection___Temporal-Connection-Type-Value:before
coronary NCT03863158 311 319 B-Procedure
angiography NCT03863158 320 331 I-Procedure

- NCT03863158 334 335 O
hemodynamically NCT03863158 337 352 B-Condition
unstable NCT03863158 353 361 O
patient NCT03863158 362 369 O
at NCT03863158 370 372 O
diagnosis NCT03863158 373 382 O

- NCT03863158 385 386 O
patients NCT03863158 388 396 O
requiring NCT03863158 397 406 B-Assertion___Assertion-Type-Value:hypothetical
combined NCT03863158 407 415 B-Modifier
surgery NCT03863158 416 423 B-Procedure

- NCT03863158 426 427 O
patients NCT03863158 429 437 O
with NCT03863158 438 442 O
unstable NCT03863158 443 451 O
angina NCT03863158 452 458 B-Condition

Inclusion NCT03866746 0 9 O
Criteria NCT03866746 10 18 O
: NCT03866746 19 20 O

- NCT03866746 24 25 O
older NCT03866746 27 32 B-Eq-Comparison
than NCT03866746 33 37 I-Eq-Comparison
18 NCT03866746 38 40 I-Eq-Comparison
years NCT03866746 41 46 I-Eq-Comparison
old NCT03866746 47 50 B-Age

- NCT03866746 53 54 O
diagnosed NCT03866746 56 65 O
with NCT03866746 66 70 O
DME NCT03866746 71 74 B-Condition
with NCT03866746 75 79 B-And
central NCT03866746 80 87 B-Observation
macular NCT03866746 88 95 I-Observation
thickness NCT03866746 96 105 I-Observation
( NCT03866746 106 107 O
CMT NCT03866746 108 111 B-Observation
) NCT03866746 112 113 O
more NCT03866746 114 118 B-Eq-Comparison
than NCT03866746 119 123 I-Eq-Comparison
250 NCT03866746 124 127 I-Eq-Comparison
µm NCT03866746 128 130 I-Eq-Comparison
measured NCT03866746 131 139 O
by NCT03866746 140 142 O
OCT NCT03866746 143 146 B-Procedure

- NCT03866746 149 150 O
best NCT03866746 152 156 B-Observation
corrected NCT03866746 157 166 I-Observation
visual NCT03866746 167 173 I-Observation
acuity NCT03866746 174 180 I-Observation
( NCT03866746 181 182 O
BCVA NCT03866746 183 187 B-Observation
) NCT03866746 188 189 O
between NCT03866746 190 197 B-Eq-Comparison
20 NCT03866746 198 200 I-Eq-Comparison
/ NCT03866746 201 202 I-Eq-Comparison
400 NCT03866746 203 206 I-Eq-Comparison
and NCT03866746 207 210 I-Eq-Comparison
20 NCT03866746 211 213 I-Eq-Comparison
/ NCT03866746 214 215 I-Eq-Comparison
40 NCT03866746 216 218 O
. NCT03866746 218 219 O

Exclusion NCT03866746 221 230 O
Criteria NCT03866746 231 239 O
: NCT03866746 240 241 O

- NCT03866746 245 246 O
patients NCT03866746 248 256 O
with NCT03866746 257 261 O
intra NCT03866746 262 267 B-Modifier
- NCT03866746 268 269 I-Modifier
ocular NCT03866746 270 276 I-Modifier
surgery NCT03866746 277 284 B-Procedure
as NCT03866746 285 287 O
cataract NCT03866746 288 296 B-Procedure
surgery NCT03866746 297 304 I-Procedure
within NCT03866746 305 311 B-Eq-Comparison
6 NCT03866746 312 313 I-Eq-Comparison
months NCT03866746 314 320 I-Eq-Comparison

- NCT03866746 323 324 O
prior NCT03866746 326 331 B-Eq-Comparison
intravitreal NCT03866746 332 344 B-Procedure
injection NCT03866746 345 354 I-Procedure
of NCT03866746 355 357 O
any NCT03866746 358 361 O
drug NCT03866746 362 366 B-Drug
within NCT03866746 367 373 B-Eq-Comparison
the NCT03866746 374 377 I-Eq-Comparison
preceding NCT03866746 378 387 I-Eq-Comparison
6 NCT03866746 388 389 I-Eq-Comparison
months NCT03866746 390 396 I-Eq-Comparison

- NCT03866746 399 400 O
panretinal NCT03866746 402 412 B-Procedure
photocoagulation NCT03866746 413 429 I-Procedure
( NCT03866746 430 431 O
PRP NCT03866746 432 435 B-Procedure
) NCT03866746 436 437 O
within NCT03866746 438 444 B-Eq-Comparison
the NCT03866746 445 448 I-Eq-Comparison
former NCT03866746 449 455 I-Eq-Comparison
4 NCT03866746 456 457 I-Eq-Comparison
months NCT03866746 458 464 I-Eq-Comparison
. NCT03866746 464 465 O

- NCT03866746 469 470 O
Patients NCT03866746 472 480 O
with NCT03866746 481 485 O
previous NCT03866746 486 494 B-Eq-Comparison
macular NCT03866746 495 502 B-Procedure
laser NCT03866746 503 508 I-Procedure

- NCT03866746 511 512 O
patients NCT03866746 514 522 O
with NCT03866746 523 527 O
vitreo NCT03866746 528 534 B-Condition
- NCT03866746 535 536 I-Condition
macular NCT03866746 537 544 I-Condition
traction NCT03866746 545 553 I-Condition
( NCT03866746 554 555 O
VMT NCT03866746 556 559 B-Condition
) NCT03866746 560 561 O
syndrome NCT03866746 562 570 B-Modifier

- NCT03866746 573 574 O
severe NCT03866746 576 582 O
glaucoma NCT03866746 583 591 B-Condition

- NCT03866746 594 595 O
other NCT03866746 597 602 B-Other
retinal NCT03866746 603 610 B-Condition
vascular NCT03866746 611 619 I-Condition
diseases NCT03866746 620 628 I-Condition

- NCT03866746 631 632 O
conditions NCT03866746 634 644 B-Condition
that NCT03866746 645 649 O
impede NCT03866746 650 656 O
the NCT03866746 657 660 O
OCT NCT03866746 661 664 B-Procedure
interpretation NCT03866746 665 679 B-Modifier

Inclusion NCT03860337 0 9 O
Criteria NCT03860337 10 18 O
: NCT03860337 19 20 O

- NCT03860337 23 24 O

Exclusion NCT03860337 26 35 O
Criteria NCT03860337 36 44 O
: NCT03860337 45 46 O

- NCT03860337 50 51 O
pregnant NCT03860337 53 61 B-Condition
or NCT03860337 62 64 B-Or
lactating NCT03860337 65 74 B-Condition
. NCT03860337 74 75 O

Inclusion NCT03862508 0 9 O
Criteria NCT03862508 10 18 O
: NCT03862508 19 20 O

- NCT03862508 24 25 O
Height NCT03862508 27 33 B-Observation
jumpers NCT03862508 34 41 I-Observation

- NCT03862508 44 45 O
Age NCT03862508 47 50 B-Age
between NCT03862508 51 58 B-Eq-Comparison
18 NCT03862508 59 61 I-Eq-Comparison
and NCT03862508 62 65 I-Eq-Comparison
40 NCT03862508 66 68 I-Eq-Comparison
years NCT03862508 69 74 I-Eq-Comparison

- NCT03862508 77 78 O
Currently NCT03862508 80 89 O
participate NCT03862508 90 101 O
in NCT03862508 102 104 O
the NCT03862508 105 108 O
competitive NCT03862508 109 120 O
field NCT03862508 121 126 O

Exclusion NCT03862508 127 136 O
Criteria NCT03862508 137 145 O
: NCT03862508 146 147 O

- NCT03862508 151 152 O
Present NCT03862508 154 161 O
medical NCT03862508 162 169 O
diagnosis NCT03862508 170 179 O
of NCT03862508 180 182 O
musculoskeletal NCT03862508 183 198 B-Modifier
pathology NCT03862508 199 208 B-Condition

- NCT03862508 211 212 O
Who NCT03862508 214 217 O
have NCT03862508 218 222 O
not NCT03862508 223 226 B-Negation
had NCT03862508 227 230 O
musculoskeletal NCT03862508 231 246 B-Modifier
injuries NCT03862508 247 255 B-Condition
in NCT03862508 256 258 O
the NCT03862508 259 262 O
last NCT03862508 263 267 B-Eq-Comparison
month NCT03862508 268 273 I-Eq-Comparison

- NCT03862508 276 277 O
Not NCT03862508 279 282 O
signed NCT03862508 283 289 O
the NCT03862508 290 293 O
informed NCT03862508 294 302 O
consent NCT03862508 303 310 O
document NCT03862508 311 319 O
. NCT03862508 319 320 O

Inclusion NCT03860493 0 9 O
Criteria NCT03860493 10 18 O
: NCT03860493 19 20 O

1 NCT03860493 24 25 O
. NCT03860493 25 26 O
Patients NCT03860493 28 36 O
of NCT03860493 37 39 O
both NCT03860493 40 44 O
genders NCT03860493 45 52 O

2 NCT03860493 55 56 O
. NCT03860493 56 57 O
Minimum NCT03860493 59 66 O
age NCT03860493 67 70 B-Age
: NCT03860493 71 72 O
18 NCT03860493 73 75 B-Eq-Comparison
years NCT03860493 76 81 I-Eq-Comparison
old NCT03860493 82 85 O

3 NCT03860493 88 89 O
. NCT03860493 89 90 O
Spoken NCT03860493 92 98 O
and NCT03860493 99 102 O
written NCT03860493 103 110 O
command NCT03860493 111 118 O
of NCT03860493 119 121 O
the NCT03860493 122 125 O
language NCT03860493 126 134 O
spoken NCT03860493 135 141 O
in NCT03860493 142 144 O
the NCT03860493 145 148 O
country NCT03860493 149 156 O
's NCT03860493 156 158 O
center NCT03860493 159 165 O

4 NCT03860493 168 169 O
. NCT03860493 169 170 O
Ability NCT03860493 172 179 O
to NCT03860493 180 182 O
understand NCT03860493 183 193 O
and NCT03860493 194 197 O
follow NCT03860493 198 204 O
the NCT03860493 205 208 O
study NCT03860493 209 214 O
procedures NCT03860493 215 225 O
and NCT03860493 226 229 O
sign NCT03860493 230 234 O
the NCT03860493 235 238 O
informed NCT03860493 239 247 O
consent NCT03860493 248 255 O

5 NCT03860493 258 259 O
. NCT03860493 259 260 O
open NCT03860493 262 266 B-Modifier
surgical NCT03860493 267 275 B-Procedure
porcedures NCT03860493 276 286 I-Procedure

Exclusion NCT03860493 287 296 O
Criteria NCT03860493 297 305 O
: NCT03860493 306 307 O

1 NCT03860493 311 312 O
. NCT03860493 312 313 O
Known NCT03860493 315 320 O
allergies NCT03860493 321 330 B-Allergy
to NCT03860493 331 333 O
iodides NCT03860493 334 341 B-Drug

2 NCT03860493 344 345 O
. NCT03860493 345 346 O
Known NCT03860493 348 353 O
history NCT03860493 354 361 B-Eq-Comparison
of NCT03860493 362 364 O
coagulopathy NCT03860493 365 377 B-Condition

3 NCT03860493 380 381 O
. NCT03860493 381 382 O
Women NCT03860493 384 389 O
who NCT03860493 390 393 B-And
are NCT03860493 394 397 O
pregnant NCT03860493 398 406 B-Condition
or NCT03860493 407 409 B-Or
breastfeeding NCT03860493 410 423 B-Condition
, NCT03860493 424 425 O
or NCT03860493 426 428 B-Or
for NCT03860493 429 432 O
whom NCT03860493 433 437 O
possibility NCT03860493 438 449 B-Assertion___Assertion-Type-Value:possible
of NCT03860493 450 452 O
pregnancy NCT03860493 453 462 B-Condition
was NCT03860493 463 466 O
not NCT03860493 467 470 O
ruled NCT03860493 471 476 O
out NCT03860493 477 480 O

Inclusion NCT03863171 0 9 O
Criteria NCT03863171 10 18 O
: NCT03863171 19 20 O

- NCT03863171 24 25 O
Ocular NCT03863171 27 33 B-Condition
ischemia NCT03863171 34 42 I-Condition
syndrome NCT03863171 43 51 I-Condition
group NCT03863171 52 57 O
: NCT03863171 58 59 O
Patients NCT03863171 60 68 O
diagnosed NCT03863171 69 78 O
with NCT03863171 79 83 O
ocular NCT03863171 84 90 B-Condition
ischemia NCT03863171 91 99 I-Condition
syndrome NCT03863171 100 108 I-Condition
; NCT03863171 108 109 O

- NCT03863171 112 113 O
Age NCT03863171 115 118 B-Modifier
- NCT03863171 119 120 I-Modifier
related NCT03863171 121 128 I-Modifier
macular NCT03863171 129 136 B-Condition
degeneration NCT03863171 137 149 I-Condition
group NCT03863171 150 155 O
( NCT03863171 156 157 O
Control NCT03863171 158 165 O
group NCT03863171 166 171 O
) NCT03863171 172 173 O
: NCT03863171 175 176 O
Patients NCT03863171 177 185 O
diagnosed NCT03863171 186 195 O
with NCT03863171 196 200 O
age NCT03863171 201 204 B-Modifier
- NCT03863171 205 206 I-Modifier
related NCT03863171 207 214 I-Modifier
macular NCT03863171 215 222 B-Condition
degeneration NCT03863171 223 235 I-Condition
; NCT03863171 235 236 O

- NCT03863171 239 240 I-Eq-Comparison
Age NCT03863171 242 245 B-Age
: NCT03863171 246 247 O
50 NCT03863171 248 250 B-Eq-Comparison
- NCT03863171 251 252 O
80 NCT03863171 253 255 I-Eq-Comparison
years NCT03863171 256 261 I-Eq-Comparison
; NCT03863171 261 262 O

- NCT03863171 265 266 O
Sex NCT03863171 268 271 O
: NCT03863171 272 273 O
all NCT03863171 274 277 O
; NCT03863171 277 278 O

- NCT03863171 281 282 O
Patients NCT03863171 284 292 O
signed NCT03863171 293 299 O
written NCT03863171 300 307 O
informed NCT03863171 308 316 O
consent NCT03863171 317 324 O
. NCT03863171 324 325 O

Exclusion NCT03863171 327 336 O
Criteria NCT03863171 337 345 O
: NCT03863171 346 347 O

- NCT03863171 351 352 O
Fundus NCT03863171 354 360 B-Procedure
fluorescein NCT03863171 361 372 I-Procedure
angiography NCT03863171 373 384 I-Procedure
( NCT03863171 385 386 O
FFA NCT03863171 387 390 B-Procedure
) NCT03863171 391 392 O
clear NCT03863171 393 398 O
images NCT03863171 399 405 O
can NCT03863171 406 409 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03863171 409 412 O
be NCT03863171 413 415 I-Assertion___Assertion-Type-Value:hypothetical|Negation
obtained NCT03863171 416 424 I-Assertion___Assertion-Type-Value:hypothetical|Negation
due NCT03863171 425 428 O
to NCT03863171 429 431 O
refractive NCT03863171 432 442 B-Condition
media NCT03863171 443 448 I-Condition
problems NCT03863171 449 457 I-Condition
( NCT03863171 458 459 O
such NCT03863171 460 464 O
as NCT03863171 465 467 O
corneal NCT03863171 468 475 B-Condition
leukoplakia NCT03863171 476 487 I-Condition
, NCT03863171 488 489 O
severe NCT03863171 490 496 O
cataract NCT03863171 497 505 B-Condition
, NCT03863171 506 507 O
vitreous NCT03863171 508 516 B-Condition
hemorrhage NCT03863171 517 527 I-Condition
, NCT03863171 528 529 O
etc NCT03863171 530 533 O
. NCT03863171 533 534 O
) NCT03863171 535 536 O
; NCT03863171 537 538 O

- NCT03863171 541 542 O
Patients NCT03863171 544 552 O
with NCT03863171 553 557 O
contraindications NCT03863171 558 575 B-Contraindication
for NCT03863171 576 579 O
FFA NCT03863171 580 583 B-Procedure
; NCT03863171 583 584 O

- NCT03863171 587 588 O
Patients NCT03863171 590 598 O
was NCT03863171 599 602 O
unable NCT03863171 603 609 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863171 610 612 O
perform NCT03863171 613 620 O
magnetic NCT03863171 621 629 B-Procedure
resonance NCT03863171 630 639 I-Procedure
rmaging NCT03863171 640 647 I-Procedure
( NCT03863171 648 649 O
MRI NCT03863171 650 653 B-Procedure
) NCT03863171 654 655 O
test NCT03863171 656 660 O
; NCT03863171 660 661 O

- NCT03863171 664 665 O
Patients NCT03863171 667 675 O
with NCT03863171 676 680 O
history NCT03863171 681 688 B-Eq-Comparison
of NCT03863171 689 691 O
bleeding NCT03863171 692 700 B-Condition
and NCT03863171 701 704 B-Or
cerebral NCT03863171 705 713 B-Condition
infarction NCT03863171 714 724 I-Condition
; NCT03863171 724 725 O

- NCT03863171 728 729 O
Patients NCT03863171 731 739 O
with NCT03863171 740 744 B-Eq-Comparison
a NCT03863171 745 746 O
history NCT03863171 747 754 B-Eq-Comparison
of NCT03863171 755 757 O
surgery NCT03863171 758 765 B-Procedure
within NCT03863171 766 772 O
3 NCT03863171 773 774 I-Eq-Comparison
months NCT03863171 775 781 I-Eq-Comparison
; NCT03863171 781 782 O

- NCT03863171 785 786 O
Patients NCT03863171 788 796 O
who NCT03863171 797 800 O
had NCT03863171 801 804 O
participated NCT03863171 805 817 O
in NCT03863171 818 820 O
other NCT03863171 821 826 B-Other
clinical NCT03863171 827 835 B-Study
trials NCT03863171 836 842 I-Study
within NCT03863171 843 849 B-Eq-Comparison
3 NCT03863171 850 851 I-Eq-Comparison
months NCT03863171 852 858 I-Eq-Comparison
; NCT03863171 858 859 O

- NCT03863171 862 863 O
Patients NCT03863171 865 873 O
who NCT03863171 874 877 O
disagree NCT03863171 878 886 O
and NCT03863171 887 890 O
refuse NCT03863171 891 897 O
to NCT03863171 898 900 O
participate NCT03863171 901 912 O
in NCT03863171 913 915 O
the NCT03863171 916 919 O
trial NCT03863171 920 925 O
. NCT03863171 925 926 O

Inclusion NCT03862521 0 9 O
criteria NCT03862521 10 18 O

- NCT03862521 21 22 O
Prepubertal NCT03862521 24 35 B-Condition
children NCT03862521 36 44 O
2 NCT03862521 45 46 B-Eq-Comparison
to NCT03862521 47 49 I-Eq-Comparison
< NCT03862521 50 51 I-Eq-Comparison
12 NCT03862521 52 54 I-Eq-Comparison
years NCT03862521 55 60 I-Eq-Comparison
old NCT03862521 61 64 B-Age
( NCT03862521 65 66 O
i. NCT03862521 67 69 O
e. NCT03862521 70 72 O
, NCT03862521 73 74 O
before NCT03862521 75 81 O
12 NCT03862521 82 84 O
th NCT03862521 85 87 O
birthday NCT03862521 88 96 O
) NCT03862521 97 98 O

- NCT03862521 102 103 O
Type NCT03862521 105 109 B-Modifier
1 NCT03862521 110 111 I-Modifier
diabetes NCT03862521 112 120 B-Condition
for NCT03862521 121 124 O
at NCT03862521 125 127 B-Eq-Comparison
least NCT03862521 128 133 I-Eq-Comparison
6 NCT03862521 134 135 I-Eq-Comparison
months NCT03862521 136 142 I-Eq-Comparison

- NCT03862521 145 146 O
Patients NCT03862521 148 156 O
must NCT03862521 157 161 O
be NCT03862521 162 164 O
using NCT03862521 165 170 B-Eq-Comparison
insulin NCT03862521 171 178 B-Procedure
pump NCT03862521 179 183 I-Procedure
therapy NCT03862521 184 191 I-Procedure

- NCT03862521 194 195 O
Not NCT03862521 197 200 B-Negation
presently NCT03862521 201 210 B-Eq-Comparison
on NCT03862521 211 213 O
low NCT03862521 214 217 O
carbohydrate NCT03862521 218 230 B-Modifier
diet NCT03862521 231 235 B-Observation

Exclusion NCT03862521 236 245 O
criteria NCT03862521 246 254 O

- NCT03862521 257 258 O
On NCT03862521 260 262 B-Eq-Comparison
low NCT03862521 263 266 O
or NCT03862521 267 269 B-Or
very NCT03862521 270 274 O
low NCT03862521 275 278 O
carbohydrate NCT03862521 279 291 B-Modifier
diet NCT03862521 292 296 B-Observation

- NCT03862521 299 300 O
History NCT03862521 302 309 B-Eq-Comparison
of NCT03862521 310 312 O
endocrine NCT03862521 313 322 B-Modifier
or NCT03862521 323 325 B-Or
metabolic NCT03862521 326 335 B-Modifier
disorder NCT03862521 336 344 B-Condition
that NCT03862521 345 349 O
could NCT03862521 350 355 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03862521 356 362 O
counter NCT03862521 363 370 B-Condition
- NCT03862521 371 372 I-Condition
regulation NCT03862521 373 383 I-Condition
( NCT03862521 384 385 O
well NCT03862521 386 390 O
- NCT03862521 391 392 O
controlled NCT03862521 393 403 O
hypothyroidism NCT03862521 404 418 B-Condition
is NCT03862521 419 421 O
acceptable NCT03862521 422 432 O
if NCT03862521 433 435 O
on NCT03862521 436 438 B-Eq-Comparison
stable NCT03862521 439 445 O
dose NCT03862521 446 450 O
of NCT03862521 451 453 O
l NCT03862521 454 455 B-Drug
- NCT03862521 456 457 I-Drug
thyroxine NCT03862521 458 467 I-Drug
for NCT03862521 468 471 O
≥ NCT03862521 472 473 B-Eq-Comparison
3 NCT03862521 474 475 I-Eq-Comparison
months NCT03862521 476 482 I-Eq-Comparison
) NCT03862521 483 484 O

- NCT03862521 488 489 O
History NCT03862521 491 498 B-Eq-Comparison
of NCT03862521 499 501 O
metabolic NCT03862521 502 511 B-Condition
disorder NCT03862521 512 520 I-Condition
affection NCT03862521 521 530 O
lipid NCT03862521 531 536 B-Condition
metabolism NCT03862521 537 547 I-Condition

- NCT03862521 550 551 O
Severe NCT03862521 553 559 O
hypoglycemic NCT03862521 560 572 B-Condition
event NCT03862521 573 578 I-Condition
in NCT03862521 579 581 O
past NCT03862521 582 586 B-Eq-Comparison
3 NCT03862521 587 588 I-Eq-Comparison
months NCT03862521 589 595 I-Eq-Comparison

Inclusion NCT03862092 0 9 O
Criteria NCT03862092 10 18 O
: NCT03862092 19 20 O

- NCT03862092 24 25 O
Patients NCT03862092 27 35 O
aged NCT03862092 36 40 B-Age
≥ NCT03862092 41 42 B-Eq-Comparison
18 NCT03862092 43 45 I-Eq-Comparison
, NCT03862092 46 47 O
and NCT03862092 48 51 B-Or
< NCT03862092 52 53 B-Eq-Comparison
80 NCT03862092 54 56 I-Eq-Comparison
years NCT03862092 57 62 I-Eq-Comparison

- NCT03862092 65 66 I-Encounter
ER NCT03862092 68 70 B-Encounter
- NCT03862092 71 72 O
visit NCT03862092 73 78 I-Encounter
patients NCT03862092 79 87 O
with NCT03862092 88 92 B-And
acute NCT03862092 93 98 O
abdominal NCT03862092 99 108 B-Modifier
pain NCT03862092 109 113 B-Condition

- NCT03862092 121 122 O
NRS NCT03862092 124 127 B-Observation
≥ NCT03862092 128 129 B-Eq-Comparison
6 NCT03862092 130 131 I-Eq-Comparison

- NCT03862092 140 141 O
Unresponsive NCT03862092 143 155 B-Condition
to NCT03862092 156 158 O
gastrointestinal NCT03862092 159 175 B-Drug
motility NCT03862092 176 184 I-Drug
drug NCT03862092 185 189 I-Drug
, NCT03862092 190 191 O
antacid NCT03862092 192 199 B-Drug

Exclusion NCT03862092 200 209 O
Criteria NCT03862092 210 218 O
: NCT03862092 219 220 O

- NCT03862092 224 225 O
Unwilling NCT03862092 227 236 O
or NCT03862092 237 239 O
unable NCT03862092 240 246 O
to NCT03862092 247 249 O
give NCT03862092 250 254 O
informed NCT03862092 255 263 O
consent NCT03862092 264 271 O

- NCT03862092 274 275 O
Patients NCT03862092 277 285 O
who NCT03862092 286 289 O
take NCT03862092 290 294 B-Eq-Comparison
antiviral NCT03862092 295 304 B-Drug
agents NCT03862092 305 311 I-Drug
( NCT03862092 312 313 O
acyclovir NCT03862092 314 323 B-Drug
, NCT03862092 324 325 O
valacyclovir NCT03862092 326 338 B-Drug
, NCT03862092 339 340 O
famciclovir NCT03862092 341 352 B-Drug
, NCT03862092 353 354 O
ganciclovir NCT03862092 355 366 B-Drug
, NCT03862092 367 368 O
valganciclovir NCT03862092 369 383 B-Drug
, NCT03862092 384 385 O
foscarnet NCT03862092 386 395 B-Drug
. NCT03862092 395 396 O
. NCT03862092 397 398 O
. NCT03862092 399 400 O
) NCT03862092 401 402 O

- NCT03862092 406 407 O
Patients NCT03862092 409 417 O
complaining NCT03862092 418 429 O
abdominal NCT03862092 430 439 B-Modifier
pain NCT03862092 440 444 B-Condition
with NCT03862092 445 449 B-And
NRS NCT03862092 450 453 B-Observation
≤ NCT03862092 454 455 B-Eq-Comparison
5 NCT03862092 456 457 I-Eq-Comparison
or NCT03862092 458 460 B-Or
improved NCT03862092 461 469 O
symptom NCT03862092 470 477 B-Condition
by NCT03862092 478 480 O
gastrointestinal NCT03862092 481 497 B-Drug
motility NCT03862092 498 506 I-Drug
drug NCT03862092 507 511 I-Drug
, NCT03862092 512 513 O
antacid NCT03862092 514 521 B-Drug

Inclusion NCT03869879 0 9 O
Criteria NCT03869879 10 18 O
: NCT03869879 19 20 O

- NCT03869879 24 25 O
60 NCT03869879 27 29 B-Eq-Comparison
- NCT03869879 30 31 I-Eq-Comparison
89 NCT03869879 32 34 I-Eq-Comparison
years NCT03869879 35 40 I-Eq-Comparison
old NCT03869879 41 44 B-Age

- NCT03869879 47 48 O
gait NCT03869879 50 54 B-Condition
disturbances NCT03869879 55 67 I-Condition
requiring NCT03869879 68 77 B-Assertion___Assertion-Type-Value:hypothetical
physical NCT03869879 78 86 B-Procedure
therapy NCT03869879 87 94 I-Procedure

Exclusion NCT03869879 95 104 O
Criteria NCT03869879 105 113 O
: NCT03869879 114 115 O

- NCT03869879 119 120 O
unable NCT03869879 122 128 O
to NCT03869879 129 131 O
follow NCT03869879 132 138 O
instructions NCT03869879 139 151 O
( NCT03869879 152 153 O
up NCT03869879 154 156 O
to NCT03869879 157 159 O
the NCT03869879 160 163 O
practitioner NCT03869879 164 176 O
's NCT03869879 176 178 O
judgement NCT03869879 179 188 O
) NCT03869879 189 190 O

Inclusion NCT03862079 0 9 O
Criteria NCT03862079 10 18 O
: NCT03862079 19 20 O

- NCT03862079 24 25 O
Patients NCT03862079 27 35 O
who NCT03862079 36 39 O
are NCT03862079 40 43 O
day NCT03862079 44 47 B-Eq-Comparison
- NCT03862079 48 49 I-Eq-Comparison
10 NCT03862079 50 52 I-Eq-Comparison
pre NCT03862079 53 56 I-Eq-Comparison
- NCT03862079 57 58 I-Eq-Comparison
to NCT03862079 59 61 I-Eq-Comparison
day NCT03862079 62 65 I-Eq-Comparison
+ NCT03862079 66 67 I-Eq-Comparison
30 NCT03862079 68 70 O
post NCT03862079 71 75 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862079 76 77 O
allogeneic NCT03862079 78 88 B-Procedure
hematopoietic NCT03862079 89 102 I-Procedure
cell NCT03862079 103 107 I-Procedure
transplant NCT03862079 108 118 I-Procedure
( NCT03862079 119 120 O
AHCT NCT03862079 121 125 B-Procedure
) NCT03862079 126 127 O
from NCT03862079 128 132 O
any NCT03862079 133 136 O
donor NCT03862079 137 142 B-Modifier
or NCT03862079 143 145 B-Or
graft NCT03862079 146 151 B-Modifier
source NCT03862079 152 158 I-Modifier
and NCT03862079 159 162 B-And
for NCT03862079 163 166 O
any NCT03862079 167 170 O
conditioning NCT03862079 171 183 B-Procedure
regimen NCT03862079 184 191 I-Procedure

- NCT03862079 194 195 O
Patients NCT03862079 197 205 O
who NCT03862079 206 209 O
have NCT03862079 210 214 O
received NCT03862079 215 223 B-Eq-Comparison
treatment NCT03862079 224 233 B-Procedure
with NCT03862079 234 238 O
meropenem NCT03862079 239 248 B-Drug
or NCT03862079 249 251 B-Or
piperacillin NCT03862079 252 264 B-Drug
- NCT03862079 265 266 I-Drug
tazobactam NCT03862079 267 277 I-Drug
( NCT03862079 278 279 O
pip NCT03862079 280 283 B-Drug
- NCT03862079 284 285 I-Drug
tazo NCT03862079 286 290 I-Drug
) NCT03862079 291 292 O
intravenously NCT03862079 293 306 B-Modifier
( NCT03862079 307 308 O
IV NCT03862079 309 311 B-Modifier
) NCT03862079 312 313 O
( NCT03862079 314 315 O
of NCT03862079 316 318 O
at NCT03862079 319 321 B-Eq-Comparison
least NCT03862079 322 327 I-Eq-Comparison
24 NCT03862079 328 330 I-Eq-Comparison
hours NCT03862079 331 336 I-Eq-Comparison
duration NCT03862079 337 345 I-Eq-Comparison
) NCT03862079 346 347 O
in NCT03862079 348 350 O
past NCT03862079 351 355 B-Eq-Comparison
7 NCT03862079 356 357 I-Eq-Comparison
days NCT03862079 358 362 I-Eq-Comparison

- NCT03862079 365 366 O
Controlled NCT03862079 368 378 B-Modifier
infection NCT03862079 379 388 B-Condition
defined NCT03862079 389 396 O
as NCT03862079 397 399 O
hemodynamically NCT03862079 400 415 B-Condition
stable NCT03862079 416 422 O
and NCT03862079 423 426 B-And
not NCT03862079 427 430 B-Negation
requiring NCT03862079 431 440 B-Assertion___Assertion-Type-Value:hypothetical
supplemental NCT03862079 441 453 B-Observation|Procedure
oxygen NCT03862079 454 460 I-Observation|Procedure
of NCT03862079 461 463 O
more NCT03862079 464 468 B-Eq-Comparison
than NCT03862079 469 473 I-Eq-Comparison
2 NCT03862079 474 475 I-Eq-Comparison
liters NCT03862079 476 482 I-Eq-Comparison
via NCT03862079 483 486 I-Eq-Comparison
nasal NCT03862079 487 492 B-Modifier
cannula NCT03862079 493 500 I-Modifier

- NCT03862079 503 504 O
Patients NCT03862079 506 514 O
who NCT03862079 515 518 O
are NCT03862079 519 522 O
able NCT03862079 523 527 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862079 528 530 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03862079 531 535 O
oral NCT03862079 536 540 B-Drug
medications NCT03862079 541 552 I-Drug
in NCT03862079 553 555 O
suspension NCT03862079 556 566 B-Modifier
form NCT03862079 567 571 I-Modifier

- NCT03862079 574 575 O
Patients NCT03862079 577 585 O
who NCT03862079 586 589 O
are NCT03862079 590 593 O
able NCT03862079 594 598 O
to NCT03862079 599 601 O
provide NCT03862079 602 609 O
informed NCT03862079 610 618 O
consent NCT03862079 619 626 O
( NCT03862079 627 628 O
IC NCT03862079 629 631 O
) NCT03862079 632 633 O
and NCT03862079 634 637 O
comply NCT03862079 638 644 O
with NCT03862079 645 649 O
all NCT03862079 650 653 O
study NCT03862079 654 659 O
visits NCT03862079 660 666 O
and NCT03862079 667 670 O
procedures NCT03862079 671 681 O

Exclusion NCT03862079 682 691 O
Criteria NCT03862079 692 700 O
: NCT03862079 701 702 O

- NCT03862079 706 707 O
Patients NCT03862079 709 717 O
who NCT03862079 718 721 O
are NCT03862079 722 725 O
anticipated NCT03862079 726 737 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862079 738 740 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03862079 741 748 O
continued NCT03862079 749 758 O
broad NCT03862079 759 764 B-Modifier
spectrum NCT03862079 765 773 I-Modifier
antibiotics NCT03862079 774 785 B-Drug
with NCT03862079 786 790 B-And
meropenem NCT03862079 791 800 B-Drug
or NCT03862079 801 803 B-Or
pip NCT03862079 804 807 B-Drug
- NCT03862079 808 809 I-Drug
tazo NCT03862079 810 814 I-Drug
IV NCT03862079 815 817 B-Modifier
for NCT03862079 818 821 O
> NCT03862079 822 823 B-Eq-Comparison
96 NCT03862079 824 826 I-Eq-Comparison
hours NCT03862079 827 832 I-Eq-Comparison
post NCT03862079 833 837 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862079 838 839 O
engraftment NCT03862079 840 851 B-Procedure
such NCT03862079 852 856 O
as NCT03862079 857 859 O
for NCT03862079 860 863 O
known NCT03862079 864 869 O
, NCT03862079 870 871 O
documented NCT03862079 872 882 O
infections NCT03862079 883 893 B-Condition
necessitating NCT03862079 894 907 B-Assertion___Assertion-Type-Value:hypothetical
prolonged NCT03862079 908 917 O
treatment NCT03862079 918 927 B-Procedure

- NCT03862079 930 931 O
Patients NCT03862079 933 941 O
with NCT03862079 942 946 O
a NCT03862079 947 948 O
prior NCT03862079 949 954 B-Eq-Comparison
documented NCT03862079 955 965 O
infection NCT03862079 966 975 B-Condition
with NCT03862079 976 980 O
mycormycetes NCT03862079 981 993 B-Organism

- NCT03862079 996 997 O
Patients NCT03862079 999 1007 O
who NCT03862079 1008 1011 O
are NCT03862079 1012 1015 O
greater NCT03862079 1016 1023 B-Eq-Comparison
than NCT03862079 1024 1028 I-Eq-Comparison
2 NCT03862079 1029 1030 I-Eq-Comparison
days NCT03862079 1031 1035 I-Eq-Comparison
from NCT03862079 1036 1040 B-Temporal-Connection___Temporal-Connection-Type-Value:after
time NCT03862079 1041 1045 O
of NCT03862079 1046 1048 O
neutrophil NCT03862079 1049 1059 B-Procedure
engraftment NCT03862079 1060 1071 I-Procedure
post NCT03862079 1072 1076 B-Temporal-Connection___Temporal-Connection-Type-Value:after
AHCT NCT03862079 1077 1081 B-Procedure

- NCT03862079 1084 1085 O
Patients NCT03862079 1087 1095 O
with NCT03862079 1096 1100 O
active NCT03862079 1101 1107 B-Eq-Comparison
enteric NCT03862079 1108 1115 B-Modifier
infections NCT03862079 1116 1126 B-Condition

- NCT03862079 1129 1130 O
Patients NCT03862079 1132 1140 O
with NCT03862079 1141 1145 O
acute NCT03862079 1146 1151 O
GVHD NCT03862079 1152 1156 B-Condition
> NCT03862079 1157 1158 B-Eq-Comparison
= NCT03862079 1160 1161 I-Eq-Comparison
grade NCT03862079 1162 1167 I-Eq-Comparison
II NCT03862079 1168 1170 I-Eq-Comparison

- NCT03862079 1173 1174 O
Patients NCT03862079 1176 1184 O
unwilling NCT03862079 1185 1194 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03862079 1195 1197 B-Or
unable NCT03862079 1198 1204 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862079 1205 1207 O
undergo NCT03862079 1208 1215 O
the NCT03862079 1216 1219 O
FMT NCT03862079 1220 1223 B-Procedure
via NCT03862079 1224 1227 O
retention NCT03862079 1228 1237 B-Procedure
enema NCT03862079 1238 1243 I-Procedure
procedure NCT03862079 1244 1253 I-Procedure

- NCT03862079 1256 1257 O
Patients NCT03862079 1259 1267 O
who NCT03862079 1268 1271 O
have NCT03862079 1272 1276 O
received NCT03862079 1277 1285 B-Eq-Comparison
treatment NCT03862079 1286 1295 B-Procedure
with NCT03862079 1296 1300 B-Eq-Comparison
an NCT03862079 1301 1303 O
investigational NCT03862079 1304 1319 B-Study
agent NCT03862079 1320 1325 B-Drug
within NCT03862079 1326 1332 O
2 NCT03862079 1333 1334 I-Eq-Comparison
weeks NCT03862079 1335 1340 I-Eq-Comparison
of NCT03862079 1341 1343 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03862079 1344 1354 B-Study

- NCT03862079 1357 1358 O
Patients NCT03862079 1360 1368 O
unable NCT03862079 1369 1375 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862079 1376 1378 I-Assertion___Assertion-Type-Value:hypothetical|Negation
tolerate NCT03862079 1379 1387 O
oral NCT03862079 1388 1392 B-Procedure
decontamination NCT03862079 1393 1408 I-Procedure
regimen NCT03862079 1409 1416 O
of NCT03862079 1417 1419 O
pip NCT03862079 1420 1423 B-Drug
- NCT03862079 1424 1425 I-Drug
tazo NCT03862079 1426 1430 I-Drug
and NCT03862079 1431 1434 B-Or
nystatin NCT03862079 1435 1443 B-Drug
due NCT03862079 1444 1447 O
to NCT03862079 1448 1450 O
prior NCT03862079 1451 1456 B-Eq-Comparison
allergy NCT03862079 1457 1464 B-Allergy
or NCT03862079 1465 1467 B-Or
intolerance NCT03862079 1468 1479 B-Condition
of NCT03862079 1480 1482 O
these NCT03862079 1483 1488 B-Coreference
medications NCT03862079 1489 1500 I-Coreference

- NCT03862079 1503 1504 O
Patients NCT03862079 1506 1514 O
with NCT03862079 1515 1519 O
any NCT03862079 1520 1523 O
medical NCT03862079 1524 1531 B-Modifier
or NCT03862079 1532 1534 B-Or
psychological NCT03862079 1535 1548 B-Modifier
condition NCT03862079 1549 1558 B-Condition
that NCT03862079 1559 1563 O
, NCT03862079 1564 1565 O
in NCT03862079 1566 1568 O
the NCT03862079 1569 1572 O
opinion NCT03862079 1573 1580 O
of NCT03862079 1581 1583 O
the NCT03862079 1584 1587 O
investigator NCT03862079 1588 1600 O
, NCT03862079 1601 1602 O
might NCT03862079 1603 1608 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03862079 1609 1618 O
with NCT03862079 1619 1623 O
the NCT03862079 1624 1627 O
subject NCT03862079 1628 1635 O
's NCT03862079 1635 1637 O
participation NCT03862079 1638 1651 O
in NCT03862079 1652 1654 O
the NCT03862079 1655 1658 O
trial NCT03862079 1659 1664 B-Study
, NCT03862079 1665 1666 O
pose NCT03862079 1667 1671 O
any NCT03862079 1672 1675 O
additional NCT03862079 1676 1686 O
risk NCT03862079 1687 1691 B-Risk
for NCT03862079 1692 1695 O
the NCT03862079 1696 1699 O
subject NCT03862079 1700 1707 O
, NCT03862079 1708 1709 O
or NCT03862079 1710 1712 B-Or
confound NCT03862079 1713 1721 O
the NCT03862079 1722 1725 O
assessments NCT03862079 1726 1737 O
of NCT03862079 1738 1740 O
the NCT03862079 1741 1744 O
subject NCT03862079 1745 1752 O

Inclusion NCT03863561 0 9 O
Criteria NCT03863561 10 18 O
: NCT03863561 19 20 O

- NCT03863561 24 25 O
Diagnosis NCT03863561 27 36 O
of NCT03863561 37 39 O
type NCT03863561 40 44 B-Modifier
1 NCT03863561 45 46 I-Modifier
or NCT03863561 47 49 B-Or
type NCT03863561 50 54 B-Modifier
2 NCT03863561 55 56 I-Modifier
diabetes NCT03863561 57 65 B-Condition

- NCT03863561 68 69 O
Age NCT03863561 71 74 B-Age
≥ NCT03863561 75 76 B-Eq-Comparison
18 NCT03863561 77 79 I-Eq-Comparison
years NCT03863561 80 85 I-Eq-Comparison

- NCT03863561 88 89 O
Ability NCT03863561 91 98 O
to NCT03863561 99 101 O
read NCT03863561 102 106 O
English NCT03863561 107 114 O

- NCT03863561 117 118 O
Duration NCT03863561 120 128 O
of NCT03863561 129 131 O
diabetes NCT03863561 132 140 B-Condition
≥ NCT03863561 141 142 B-Eq-Comparison
6 NCT03863561 143 144 I-Eq-Comparison
months NCT03863561 145 151 I-Eq-Comparison
( NCT03863561 152 153 O
DSME NCT03863561 154 158 O
cohort NCT03863561 159 165 O
only NCT03863561 166 170 O
) NCT03863561 171 172 O

- NCT03863561 176 177 O
A1C NCT03863561 179 182 B-Observation
≥ NCT03863561 183 184 B-Eq-Comparison
8.0 NCT03863561 185 188 I-Eq-Comparison
% NCT03863561 189 190 O
( NCT03863561 191 192 O
DSME NCT03863561 193 197 O
cohort NCT03863561 198 204 O
only NCT03863561 205 209 O
) NCT03863561 210 211 O

Exclusion NCT03863561 213 222 O
Criteria NCT03863561 223 231 O
: NCT03863561 232 233 O

- NCT03863561 236 237 O

Inclusion NCT03862131 0 9 O
Criteria NCT03862131 10 18 O
: NCT03862131 19 20 O

- NCT03862131 24 25 O
Participant NCT03862131 27 38 O
in NCT03862131 39 41 O
the NCT03862131 42 45 O
SURVIVE NCT03862131 46 53 O
registry NCT03862131 54 62 O

- NCT03862131 65 66 O
Signed NCT03862131 68 74 O
informed NCT03862131 75 83 O
consent NCT03862131 84 91 O
form NCT03862131 92 96 O
for NCT03862131 97 100 O
PROACT NCT03862131 101 107 O

- NCT03862131 110 111 O
Histological NCT03862131 113 125 O
diagnosis NCT03862131 126 135 O
of NCT03862131 136 138 O
early NCT03862131 139 144 B-Modifier
or NCT03862131 145 147 B-Or
metastatic NCT03862131 148 158 B-Modifier
breast NCT03862131 159 165 I-Modifier
cancer NCT03862131 166 172 B-Condition
, NCT03862131 173 174 O
lymphoma NCT03862131 175 183 B-Condition
, NCT03862131 184 185 O
sarcoma NCT03862131 186 193 B-Condition
, NCT03862131 194 195 O
leukemia NCT03862131 196 204 B-Condition
, NCT03862131 205 206 O
myeloma NCT03862131 207 214 B-Condition
, NCT03862131 215 216 O
or NCT03862131 217 219 B-Or
lung NCT03862131 220 224 B-Modifier
cancer NCT03862131 225 231 B-Condition
( NCT03862131 232 233 O
patients NCT03862131 234 242 O
with NCT03862131 243 247 O
treated NCT03862131 248 255 B-Procedure
and NCT03862131 256 259 B-And
clinically NCT03862131 260 270 O
stable NCT03862131 271 277 O
brain NCT03862131 278 283 B-Modifier
metastasis NCT03862131 284 294 B-Condition
are NCT03862131 295 298 O
acceptable NCT03862131 299 309 O
) NCT03862131 310 311 O

- NCT03862131 315 316 O
Scheduled NCT03862131 318 327 B-Eq-Comparison
to NCT03862131 328 330 O
receive NCT03862131 331 338 O
anti NCT03862131 339 343 O
- NCT03862131 344 345 O
cancer NCT03862131 346 352 B-Condition
therapy NCT03862131 353 360 B-Procedure
( NCT03862131 361 362 O
radiation NCT03862131 363 372 B-Procedure
therapy NCT03862131 373 380 I-Procedure
is NCT03862131 381 383 O
permitted NCT03862131 384 393 O
) NCT03862131 394 395 O

Exclusion NCT03862131 397 406 O
Criteria NCT03862131 407 415 O
: NCT03862131 416 417 O

- NCT03862131 421 422 O
Contraindication NCT03862131 424 440 B-Contraindication
to NCT03862131 441 443 O
magnetic NCT03862131 444 452 B-Procedure
resonance NCT03862131 453 462 I-Procedure
imaging NCT03862131 463 470 I-Procedure
( NCT03862131 471 472 O
MRI NCT03862131 473 476 B-Procedure
) NCT03862131 477 478 O

- NCT03862131 482 483 O
Unable NCT03862131 485 491 O
to NCT03862131 492 494 O
comply NCT03862131 495 501 O
with NCT03862131 502 506 O
study NCT03862131 507 512 O
investigations NCT03862131 513 527 O
( NCT03862131 528 529 O
in NCT03862131 530 532 O
the NCT03862131 533 536 O
judgment NCT03862131 537 545 O
of NCT03862131 546 548 O
the NCT03862131 549 552 O
investigator NCT03862131 553 565 O
) NCT03862131 566 567 O

- NCT03862131 571 572 O
Life NCT03862131 574 578 B-Observation
expectancy NCT03862131 579 589 I-Observation
less NCT03862131 590 594 B-Eq-Comparison
than NCT03862131 595 599 I-Eq-Comparison
1 NCT03862131 600 601 I-Eq-Comparison
year NCT03862131 602 606 I-Eq-Comparison

Inclusion NCT03864965 0 9 O
Criteria NCT03864965 10 18 O
: NCT03864965 19 20 O

- NCT03864965 24 25 O
Patients NCT03864965 27 35 O
having NCT03864965 36 42 O
mild NCT03864965 43 47 O
cognitive NCT03864965 48 57 B-Condition
impairment NCT03864965 58 68 I-Condition
( NCT03864965 69 70 O
MCI NCT03864965 71 74 B-Condition
) NCT03864965 75 76 O
or NCT03864965 77 79 B-Or
very NCT03864965 80 84 O
mild NCT03864965 85 89 B-Eq-Comparison
to NCT03864965 90 92 I-Eq-Comparison
mild NCT03864965 93 97 I-Eq-Comparison
dementia NCT03864965 98 106 B-Condition
( NCT03864965 107 108 O
CDR NCT03864965 109 112 B-Observation
0.5 NCT03864965 113 116 B-Eq-Comparison
- NCT03864965 117 118 I-Eq-Comparison
1 NCT03864965 119 120 I-Eq-Comparison
) NCT03864965 121 122 O
. NCT03864965 123 124 O

Exclusion NCT03864965 126 135 O
Criteria NCT03864965 136 144 O
: NCT03864965 145 146 O

- NCT03864965 150 151 O
Patients NCT03864965 153 161 O
with NCT03864965 162 166 O
moderate NCT03864965 167 175 B-Eq-Comparison
to NCT03864965 176 178 I-Eq-Comparison
severe NCT03864965 179 185 I-Eq-Comparison
dementia NCT03864965 186 194 B-Condition
( NCT03864965 195 196 O
CDR NCT03864965 197 200 B-Observation
2 NCT03864965 201 202 B-Eq-Comparison
- NCT03864965 203 204 I-Eq-Comparison
3 NCT03864965 205 206 I-Eq-Comparison
) NCT03864965 207 208 O
. NCT03864965 209 210 O


Inclusion NCT03862482 0 9 O
Criteria NCT03862482 10 18 O
: NCT03862482 19 20 O

- NCT03862482 24 25 O
non NCT03862482 27 30 B-Negation
- NCT03862482 31 32 O
smoker NCT03862482 33 39 B-Condition

- NCT03862482 42 43 O
no NCT03862482 45 47 B-Negation
temporomandibular NCT03862482 48 65 B-Condition
joint NCT03862482 66 71 I-Condition
( NCT03862482 72 73 O
TMJ NCT03862482 74 77 B-Condition
) NCT03862482 78 79 O
disorder NCT03862482 80 88 B-Modifier
or NCT03862482 89 91 B-Or
facial NCT03862482 92 98 B-Modifier
pain NCT03862482 99 103 B-Condition

- NCT03862482 106 107 O
having NCT03862482 109 115 O
partcipated NCT03862482 116 127 O
in NCT03862482 128 130 O
the NCT03862482 131 134 O
original NCT03862482 135 143 O
study NCT03862482 144 149 B-Study
( NCT03862482 150 151 O
1993 NCT03862482 152 156 B-Eq-Comparison
- NCT03862482 157 158 I-Eq-Comparison
1996 NCT03862482 159 163 I-Eq-Comparison
) NCT03862482 164 165 O
at NCT03862482 166 168 O
which NCT03862482 169 174 O
time NCT03862482 175 179 O
the NCT03862482 180 183 O
mnimum NCT03862482 184 190 O
participate NCT03862482 191 202 O
age NCT03862482 203 206 B-Age
was NCT03862482 207 210 O
25 NCT03862482 211 213 B-Eq-Comparison
years NCT03862482 214 219 I-Eq-Comparison
and NCT03862482 220 223 B-And
the NCT03862482 224 227 O
maximum NCT03862482 228 235 B-Eq-Comparison
56 NCT03862482 236 238 I-Eq-Comparison
years NCT03862482 239 244 I-Eq-Comparison
. NCT03862482 244 245 O

Exclusion NCT03862482 247 256 O
Criteria NCT03862482 257 265 O
: NCT03862482 266 267 O

- NCT03862482 271 272 O
refusal NCT03862482 274 281 O
to NCT03862482 282 284 O
sign NCT03862482 285 289 O
informed NCT03862482 290 298 O
consent NCT03862482 299 306 O
documents NCT03862482 307 316 O
. NCT03862482 316 317 O

Inclusion NCT03862469 0 9 O
Criteria NCT03862469 10 18 O
: NCT03862469 19 20 O

- NCT03862469 24 25 O
Female NCT03862469 27 33 O

- NCT03862469 36 37 O
Aged NCT03862469 39 43 B-Age
18 NCT03862469 44 46 B-Eq-Comparison
- NCT03862469 47 48 I-Eq-Comparison
35 NCT03862469 49 51 I-Eq-Comparison
years NCT03862469 52 57 I-Eq-Comparison
, NCT03862469 58 59 O
established NCT03862469 60 71 O
by NCT03862469 72 74 O
visual NCT03862469 75 81 B-Procedure
inspection NCT03862469 82 92 I-Procedure
of NCT03862469 93 95 O
a NCT03862469 96 97 O
government NCT03862469 98 108 O
- NCT03862469 109 110 O
issued NCT03862469 111 117 O
ID NCT03862469 118 120 O

- NCT03862469 123 124 O
Average NCT03862469 126 133 O
menstrual NCT03862469 134 143 B-Observation
cycle NCT03862469 144 149 I-Observation
21 NCT03862469 150 152 B-Eq-Comparison
- NCT03862469 153 154 I-Eq-Comparison
35 NCT03862469 155 157 I-Eq-Comparison
days NCT03862469 158 162 I-Eq-Comparison

- NCT03862469 165 166 O
Access NCT03862469 168 174 O
to NCT03862469 175 177 O
smartphone NCT03862469 178 188 O
with NCT03862469 189 193 O
working NCT03862469 194 201 O
camera NCT03862469 202 208 O
for NCT03862469 209 212 O
daily NCT03862469 213 218 O
use NCT03862469 219 222 O
of NCT03862469 223 225 O
the NCT03862469 226 229 O
PreMom NCT03862469 230 236 O
application NCT03862469 237 248 O

Exclusion NCT03862469 249 258 O
Criteria NCT03862469 259 267 O
: NCT03862469 268 269 O

- NCT03862469 273 274 O
Lifetime NCT03862469 276 284 O
DSM NCT03862469 285 288 B-Condition
- NCT03862469 289 290 I-Condition
5 NCT03862469 291 292 I-Condition
Axis NCT03862469 293 297 I-Condition
1 NCT03862469 298 299 I-Condition
disorder NCT03862469 300 308 I-Condition
( NCT03862469 309 310 O
except NCT03862469 311 317 B-Exception
anxiety NCT03862469 318 325 B-Condition
and NCT03862469 326 329 B-Or
depression NCT03862469 330 340 B-Condition
) NCT03862469 341 342 O
, NCT03862469 344 345 O
as NCT03862469 346 348 O
documented NCT03862469 349 359 O
in NCT03862469 360 362 O
the NCT03862469 363 366 O
Mental NCT03862469 367 373 B-Procedure
Health NCT03862469 374 380 I-Procedure
Interview NCT03862469 381 390 I-Procedure

- NCT03862469 393 394 I-Condition
Current NCT03862469 396 403 B-Eq-Comparison
DSM NCT03862469 404 407 B-Condition
- NCT03862469 408 409 O
5 NCT03862469 410 411 I-Condition
Axis NCT03862469 412 416 I-Condition
depressive NCT03862469 417 427 I-Condition
or NCT03862469 428 430 B-Or
anxiety NCT03862469 431 438 B-Condition
disorder NCT03862469 439 447 I-Condition
, NCT03862469 448 449 O
as NCT03862469 450 452 O
documented NCT03862469 453 463 O
in NCT03862469 464 466 O
the NCT03862469 467 470 O
Mental NCT03862469 471 477 B-Procedure
Health NCT03862469 478 484 I-Procedure
Interview NCT03862469 485 494 I-Procedure

- NCT03862469 497 498 O
Positive NCT03862469 500 508 O
urine NCT03862469 509 514 B-Observation
drug NCT03862469 515 519 I-Observation
screen NCT03862469 520 526 I-Observation
test NCT03862469 527 531 I-Observation

- NCT03862469 534 535 O
Breath NCT03862469 537 543 B-Observation
alcohol NCT03862469 544 551 I-Observation
concentration NCT03862469 552 565 I-Observation
> NCT03862469 566 567 B-Eq-Comparison
0.00 NCT03862469 568 572 I-Eq-Comparison
% NCT03862469 573 574 O

- NCT03862469 577 578 O
Self NCT03862469 580 584 O
- NCT03862469 585 586 O
reported NCT03862469 587 595 O
smoker NCT03862469 596 602 B-Condition
or NCT03862469 603 605 B-Or
carbon NCT03862469 606 612 B-Observation
monoxide NCT03862469 613 621 I-Observation
concentration NCT03862469 622 635 I-Observation
≥ NCT03862469 636 637 B-Eq-Comparison
6 NCT03862469 638 639 I-Eq-Comparison
ppm NCT03862469 640 643 I-Eq-Comparison

- NCT03862469 646 647 O
Irregular NCT03862469 649 658 B-Condition
menstrual NCT03862469 659 668 I-Condition
cycle NCT03862469 669 674 I-Condition

- NCT03862469 677 678 O
Current NCT03862469 680 687 B-Eq-Comparison
pregnancy NCT03862469 688 697 B-Condition
( NCT03862469 698 699 O
urine NCT03862469 700 705 B-Observation
test NCT03862469 706 710 I-Observation
- NCT03862469 711 712 O
verified NCT03862469 713 721 O
) NCT03862469 722 723 O
or NCT03862469 724 726 B-Or|Or
lactation NCT03862469 727 736 B-Condition
, NCT03862469 737 738 O
or NCT03862469 739 741 O
a NCT03862469 742 743 O
plan NCT03862469 744 748 B-Assertion___Assertion-Type-Value:intention
to NCT03862469 749 751 I-Assertion___Assertion-Type-Value:intention
become NCT03862469 752 758 O
pregnant NCT03862469 759 767 B-Condition

- NCT03862469 770 771 O
Moderate NCT03862469 773 781 B-Eq-Comparison
or NCT03862469 782 784 I-Eq-Comparison
high NCT03862469 785 789 I-Eq-Comparison
suicide NCT03862469 790 797 B-Condition
risk NCT03862469 798 802 B-Risk

- NCT03862469 805 806 O
Shipley NCT03862469 808 815 B-Observation
IQ NCT03862469 816 818 I-Observation
( NCT03862469 819 820 O
vocabulary NCT03862469 821 831 B-Observation
standard NCT03862469 832 840 I-Observation
score NCT03862469 841 846 I-Observation
) NCT03862469 847 848 O
> NCT03862469 849 850 B-Eq-Comparison
80 NCT03862469 851 853 I-Eq-Comparison

- NCT03862469 857 858 O
Prescription NCT03862469 860 872 O
medications NCT03862469 873 884 B-Drug

Inclusion NCT03869528 0 9 O
Criteria NCT03869528 10 18 O
: NCT03869528 19 20 O

- NCT03869528 24 25 O
All NCT03869528 27 30 O
adults NCT03869528 31 37 O
≥ NCT03869528 38 39 B-Eq-Comparison
18 NCT03869528 40 42 I-Eq-Comparison
yrs NCT03869528 43 46 I-Eq-Comparison
of NCT03869528 47 49 O
age NCT03869528 50 53 B-Age
undergoing NCT03869528 54 64 B-Eq-Comparison
flexible NCT03869528 65 73 B-Modifier
bronchoscopy NCT03869528 74 86 B-Procedure

Exclusion NCT03869528 87 96 O
Criteria NCT03869528 97 105 O
: NCT03869528 106 107 O

- NCT03869528 111 112 O
Uncontrolled NCT03869528 114 126 B-Modifier
hypertension NCT03869528 127 139 B-Condition
Systolic NCT03869528 140 148 B-Observation
Blood NCT03869528 149 154 I-Observation
Pressure NCT03869528 155 163 I-Observation
> NCT03869528 164 165 B-Eq-Comparison
180 NCT03869528 166 169 I-Eq-Comparison
mm NCT03869528 170 172 I-Eq-Comparison
Hg NCT03869528 173 175 I-Eq-Comparison

- NCT03869528 178 179 O
Symptomatic NCT03869528 181 192 B-Assertion___Assertion-Type-Value:possible
coronary NCT03869528 193 201 B-Condition
artery NCT03869528 202 208 I-Condition
disease NCT03869528 209 216 I-Condition

- NCT03869528 219 220 O
Pregnancy NCT03869528 222 231 B-Condition

- NCT03869528 234 235 O
Not NCT03869528 237 240 O
giving NCT03869528 241 247 O
informed NCT03869528 248 256 O
consent NCT03869528 257 264 O
for NCT03869528 265 268 O
the NCT03869528 269 272 B-Coreference
procedure NCT03869528 273 282 I-Coreference

- NCT03869528 285 286 O
Hypoxemia NCT03869528 288 297 B-Condition
( NCT03869528 298 299 O
oxygen NCT03869528 300 306 B-Observation
saturation NCT03869528 307 317 I-Observation
[ NCT03869528 318 319 O
by NCT03869528 320 322 O
pulse NCT03869528 323 328 B-Procedure
oximetry NCT03869528 329 337 I-Procedure
] NCT03869528 338 339 O
< NCT03869528 340 341 B-Eq-Comparison
92 NCT03869528 342 344 I-Eq-Comparison
% NCT03869528 345 346 O
with NCT03869528 347 351 B-And
Fio2 NCT03869528 352 356 B-Observation
of NCT03869528 357 359 O
≥ NCT03869528 360 361 B-Eq-Comparison
0.3 NCT03869528 362 365 I-Eq-Comparison

- NCT03869528 369 370 O
Bronchoscopy NCT03869528 372 384 B-Procedure
performed NCT03869528 385 394 O
through NCT03869528 395 402 O
an NCT03869528 403 405 O
artificial NCT03869528 406 416 B-Procedure
airway NCT03869528 417 423 I-Procedure

Inclusion NCT03868150 0 9 O
Criteria NCT03868150 10 18 O
: NCT03868150 19 20 O

- NCT03868150 24 25 O
Patients NCT03868150 27 35 O
scheduled NCT03868150 36 45 B-Eq-Comparison
for NCT03868150 46 49 O
first NCT03868150 50 55 B-Eq-Comparison
- NCT03868150 56 57 I-Eq-Comparison
time NCT03868150 58 62 I-Eq-Comparison
non NCT03868150 63 66 B-Negation
- NCT03868150 67 68 O
emergent NCT03868150 69 77 B-Modifier
open NCT03868150 78 82 B-Procedure
- NCT03868150 83 84 I-Procedure
heart NCT03868150 85 90 I-Procedure
surgery NCT03868150 91 98 I-Procedure
for NCT03868150 99 102 O
coronary NCT03868150 103 111 B-Procedure
artery NCT03868150 112 118 I-Procedure
bypass NCT03868150 119 125 I-Procedure
graft NCT03868150 126 131 I-Procedure
( NCT03868150 132 133 O
CABG NCT03868150 134 138 B-Procedure
) NCT03868150 139 140 O
revascularization NCT03868150 141 158 B-Modifier
, NCT03868150 159 160 O
valvular NCT03868150 161 169 B-Procedure
repair NCT03868150 170 176 B-Modifier
or NCT03868150 177 179 B-Or
replacement NCT03868150 180 191 B-Modifier
, NCT03868150 192 193 O
combined NCT03868150 194 202 B-Modifier
CABG NCT03868150 203 207 B-Procedure
with NCT03868150 208 212 B-And
valve NCT03868150 213 218 B-Procedure
repair NCT03868150 219 225 B-Modifier
or NCT03868150 226 228 B-Or
replacement NCT03868150 229 240 B-Modifier
, NCT03868150 241 242 O
or NCT03868150 243 245 B-Or
valve NCT03868150 246 251 B-Procedure
sparing NCT03868150 252 259 I-Procedure
aortic NCT03868150 260 266 I-Procedure
root NCT03868150 267 271 I-Procedure
repair NCT03868150 272 278 I-Procedure

- NCT03868150 281 282 O
Normal NCT03868150 284 290 O
sinus NCT03868150 291 296 B-Condition
rhythm NCT03868150 297 303 I-Condition

- NCT03868150 306 307 O
No NCT03868150 309 311 B-Negation
documented NCT03868150 312 322 O
history NCT03868150 323 330 B-Eq-Comparison
of NCT03868150 331 333 O
atrial NCT03868150 334 340 B-Condition
fibrillation NCT03868150 341 353 I-Condition

Exclusion NCT03868150 354 363 O
Criteria NCT03868150 364 372 O
: NCT03868150 373 374 O

- NCT03868150 378 379 O
Prior NCT03868150 381 386 B-Eq-Comparison
surgical NCT03868150 387 395 B-Procedure
procedures NCT03868150 396 406 I-Procedure
involving NCT03868150 407 416 O
heart NCT03868150 417 422 B-Procedure
surgery NCT03868150 423 430 I-Procedure
and NCT03868150 431 434 B-Or
cardiopulmonary NCT03868150 435 450 B-Procedure
bypass NCT03868150 451 457 I-Procedure

- NCT03868150 460 461 O
Any NCT03868150 463 466 O
prior NCT03868150 467 472 B-Eq-Comparison
documented NCT03868150 473 483 O
history NCT03868150 484 491 B-Eq-Comparison
of NCT03868150 492 494 O
atrial NCT03868150 495 501 B-Condition
fibrillation NCT03868150 502 514 I-Condition
, NCT03868150 515 516 O
atrial NCT03868150 517 523 B-Condition
flutter NCT03868150 524 531 I-Condition
or NCT03868150 532 534 B-Or
atrial NCT03868150 535 541 B-Condition
tachycardia NCT03868150 542 553 I-Condition
lasting NCT03868150 554 561 O
longer NCT03868150 562 568 B-Eq-Comparison
than NCT03868150 569 573 I-Eq-Comparison
30 NCT03868150 574 576 I-Eq-Comparison
seconds NCT03868150 577 584 I-Eq-Comparison

- NCT03868150 587 588 O
Prior NCT03868150 590 595 B-Eq-Comparison
history NCT03868150 596 603 I-Eq-Comparison
of NCT03868150 604 606 O
Amiodarone NCT03868150 607 617 B-Drug
treatment NCT03868150 618 627 B-Procedure
for NCT03868150 628 631 O
the NCT03868150 632 635 O
management NCT03868150 636 646 O
of NCT03868150 647 649 O
supraventricular NCT03868150 650 666 B-Modifier
tachy NCT03868150 667 672 B-Condition
- NCT03868150 673 674 I-Condition
arrhythmias NCT03868150 675 686 I-Condition

- NCT03868150 689 690 O
Patients NCT03868150 692 700 O
requiring NCT03868150 701 710 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03868150 711 719 B-Procedure
treatment NCT03868150 720 729 I-Procedure
of NCT03868150 730 732 O
atrial NCT03868150 733 739 B-Condition
arrhythmias NCT03868150 740 751 I-Condition
such NCT03868150 752 756 O
as NCT03868150 757 759 O
pulmonary NCT03868150 760 769 B-Procedure
vein NCT03868150 770 774 I-Procedure
isolation NCT03868150 775 784 I-Procedure
or NCT03868150 785 787 B-Or
Maze NCT03868150 788 792 B-Procedure
procedure NCT03868150 793 802 I-Procedure
. NCT03868150 802 803 O

Inclusion NCT03867539 0 9 O
Criteria NCT03867539 10 18 O
: NCT03867539 19 20 O

- NCT03867539 24 25 O
carpal NCT03867539 27 33 B-Condition
tunnel NCT03867539 34 40 I-Condition
syndrome NCT03867539 41 49 I-Condition
diagnosed NCT03867539 50 59 O
either NCT03867539 60 66 O
by NCT03867539 67 69 O
physical NCT03867539 70 78 B-Procedure
exam NCT03867539 79 83 I-Procedure
or NCT03867539 84 86 B-Or
EMG NCT03867539 87 90 B-Procedure

- NCT03867539 93 94 O
age NCT03867539 96 99 B-Age
> NCT03867539 100 101 B-Eq-Comparison
18 NCT03867539 102 104 I-Eq-Comparison
. NCT03867539 104 105 O

Exclusion NCT03867539 107 116 O
Criteria NCT03867539 117 125 O
: NCT03867539 126 127 O

- NCT03867539 131 132 O
allergy NCT03867539 134 141 B-Allergy
to NCT03867539 142 144 O
bupivacaine NCT03867539 145 156 B-Drug

- NCT03867539 159 160 O
pre NCT03867539 162 165 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867539 166 167 O
- NCT03867539 169 170 O
operative NCT03867539 171 180 B-Procedure
opioid NCT03867539 181 187 B-Drug
usage NCT03867539 188 193 O
within NCT03867539 194 200 B-Eq-Comparison
the NCT03867539 201 204 I-Eq-Comparison
last NCT03867539 205 209 I-Eq-Comparison
six NCT03867539 210 213 I-Eq-Comparison
months NCT03867539 214 220 I-Eq-Comparison

- NCT03867539 223 224 O
patients NCT03867539 226 234 O
allergic NCT03867539 235 243 B-Allergy
to NCT03867539 244 246 O
Percocet NCT03867539 247 255 B-Drug
or NCT03867539 256 258 B-Or
acetaminophen NCT03867539 259 272 B-Drug

- NCT03867539 275 276 O
patients NCT03867539 278 286 O
taking NCT03867539 287 293 B-Eq-Comparison
tricyclic NCT03867539 294 303 B-Drug
antidepressants NCT03867539 304 319 I-Drug
( NCT03867539 320 321 O
interaction NCT03867539 322 333 O
with NCT03867539 334 338 O
bupivacaine NCT03867539 339 350 B-Drug
) NCT03867539 351 352 O

- NCT03867539 356 357 O
vulnerable NCT03867539 359 369 B-Observation
populations NCT03867539 370 381 I-Observation
( NCT03867539 382 383 O
prisoners NCT03867539 384 393 B-Observation
or NCT03867539 394 396 B-Or
pregnant NCT03867539 397 405 B-Condition
women NCT03867539 406 411 O
) NCT03867539 412 413 O

Inclusion NCT03862287 0 9 O
Criteria NCT03862287 10 18 O
: NCT03862287 19 20 O

- NCT03862287 24 25 O
ASA NCT03862287 27 30 B-Condition
I NCT03862287 31 32 B-Eq-Comparison
- NCT03862287 33 34 I-Eq-Comparison
III NCT03862287 35 38 I-Eq-Comparison
male NCT03862287 39 43 O
and NCT03862287 44 47 B-Or
female NCT03862287 48 54 O
patients NCT03862287 55 63 O
aged NCT03862287 64 68 B-Age
between NCT03862287 69 76 B-Eq-Comparison
18 NCT03862287 77 79 I-Eq-Comparison
to NCT03862287 80 82 I-Eq-Comparison
80 NCT03862287 83 85 I-Eq-Comparison
years NCT03862287 86 91 I-Eq-Comparison
old NCT03862287 92 95 O
, NCT03862287 96 97 O
who NCT03862287 98 101 B-And
will NCT03862287 102 106 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03862287 107 114 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03862287 115 121 B-Procedure
anesthesia NCT03862287 122 132 I-Procedure
for NCT03862287 133 136 O
surgeries NCT03862287 137 146 B-Procedure
lasting NCT03862287 147 154 O
less NCT03862287 155 159 B-Eq-Comparison
than NCT03862287 160 164 I-Eq-Comparison
one NCT03862287 165 168 I-Eq-Comparison
hour NCT03862287 169 173 I-Eq-Comparison
. NCT03862287 173 174 O

Exclusion NCT03862287 176 185 O
Criteria NCT03862287 186 194 O
: NCT03862287 195 196 O

- NCT03862287 200 201 O
Patients NCT03862287 203 211 O
younger NCT03862287 212 219 B-Eq-Comparison
than NCT03862287 220 224 I-Eq-Comparison
18 NCT03862287 225 227 I-Eq-Comparison
years NCT03862287 228 233 I-Eq-Comparison
old NCT03862287 234 237 B-Age
. NCT03862287 237 238 O

- NCT03862287 242 243 O
ASA NCT03862287 245 248 B-Condition
physical NCT03862287 249 257 O
status NCT03862287 258 264 O
> NCT03862287 265 266 B-Eq-Comparison
3 NCT03862287 267 268 I-Eq-Comparison
. NCT03862287 268 269 O

- NCT03862287 273 274 O
Immunosuppression NCT03862287 276 293 B-Condition
or NCT03862287 294 296 B-Or
high NCT03862287 297 301 O
risk NCT03862287 302 306 B-Risk
of NCT03862287 307 309 O
infection NCT03862287 310 319 B-Condition
. NCT03862287 319 320 O

- NCT03862287 324 325 O
Contraindications NCT03862287 327 344 B-Contraindication
to NCT03862287 345 347 O
receiving NCT03862287 348 357 O
spinal NCT03862287 358 364 B-Procedure
anesthesia NCT03862287 365 375 I-Procedure
( NCT03862287 376 377 O
e. NCT03862287 378 380 O
g. NCT03862287 381 383 O
coagulation NCT03862287 385 396 B-Condition
impairment NCT03862287 397 407 I-Condition
) NCT03862287 408 409 O
. NCT03862287 410 411 O

- NCT03862287 415 416 O
Patients NCT03862287 418 426 O
with NCT03862287 427 431 O
psychosis NCT03862287 432 441 B-Condition

- NCT03862287 444 445 O
Patients NCT03862287 447 455 O
with NCT03862287 456 460 O
preexisting NCT03862287 461 472 B-Eq-Comparison
back NCT03862287 473 477 B-Condition
pain NCT03862287 478 482 I-Condition
. NCT03862287 482 483 O

- NCT03862287 487 488 O
Patients NCT03862287 490 498 O
with NCT03862287 499 503 O
cognitive NCT03862287 504 513 B-Condition
impairment NCT03862287 514 524 I-Condition

- NCT03862287 527 528 O
Allergies NCT03862287 530 539 B-Allergy
to NCT03862287 540 542 O
local NCT03862287 543 548 B-Procedure
anesthetics NCT03862287 549 560 I-Procedure
, NCT03862287 561 562 O
analgesics NCT03862287 563 573 B-Drug
or NCT03862287 574 576 B-Or
any NCT03862287 577 580 O
medication NCT03862287 581 591 B-Drug
used NCT03862287 592 596 O
in NCT03862287 597 599 O
the NCT03862287 600 603 O
study NCT03862287 604 609 B-Study
. NCT03862287 609 610 O

- NCT03862287 614 615 O
Patients NCT03862287 617 625 O
with NCT03862287 626 630 O
chronic NCT03862287 631 638 B-Modifier
regular NCT03862287 639 646 B-Eq-Comparison
opioid NCT03862287 647 653 B-Drug
usage NCT03862287 654 659 O

- NCT03862287 662 663 O
Presence NCT03862287 665 673 O
of NCT03862287 674 676 O
preexisting NCT03862287 677 688 B-Eq-Comparison
neurological NCT03862287 689 701 B-Condition
symptoms NCT03862287 702 710 B-Assertion___Assertion-Type-Value:possible
. NCT03862287 710 711 O

Inclusion NCT03863600 0 9 O
Criteria NCT03863600 10 18 O
: NCT03863600 19 20 O

- NCT03863600 24 25 O
Residing NCT03863600 27 35 O
in NCT03863600 36 38 O
rural NCT03863600 39 44 O
village NCT03863600 45 52 O

- NCT03863600 55 56 O
Registered NCT03863600 58 68 O
for NCT03863600 69 72 O
pregnancy NCT03863600 73 82 B-Condition
care NCT03863600 83 87 B-Procedure
at NCT03863600 88 90 O
the NCT03863600 91 94 O
villages NCT03863600 95 103 O
governmental NCT03863600 104 116 O
clinic NCT03863600 117 123 O

- NCT03863600 126 127 O
With NCT03863600 129 133 O
singleton NCT03863600 134 143 B-Modifier
pregnancy NCT03863600 144 153 B-Condition

- NCT03863600 156 157 O
Gave NCT03863600 159 163 B-Eq-Comparison
birth NCT03863600 164 169 B-Birth
the NCT03863600 170 173 O
last NCT03863600 174 178 B-Eq-Comparison
one NCT03863600 179 182 I-Eq-Comparison
to NCT03863600 183 185 I-Eq-Comparison
six NCT03863600 186 189 I-Eq-Comparison
month NCT03863600 190 195 I-Eq-Comparison

Exclusion NCT03863600 196 205 O
Criteria NCT03863600 206 214 O
: NCT03863600 215 216 O

- NCT03863600 220 221 O
Residing NCT03863600 223 231 O
in NCT03863600 232 234 O
urban NCT03863600 235 240 O
areas NCT03863600 241 246 O

- NCT03863600 249 250 O
With NCT03863600 252 256 O
multiple NCT03863600 257 265 B-Eq-Comparison
pregnancy NCT03863600 266 275 B-Condition

- NCT03863600 278 279 O
Not NCT03863600 281 284 B-Negation
registered NCT03863600 285 295 O
for NCT03863600 296 299 O
antenatal NCT03863600 300 309 B-Procedure
care NCT03863600 310 314 I-Procedure
at NCT03863600 315 317 O
the NCT03863600 318 321 O
local NCT03863600 322 327 O
governmental NCT03863600 328 340 O
clinic NCT03863600 341 347 O

Inclusion NCT03868033 0 9 O
Criteria NCT03868033 10 18 O
: NCT03868033 19 20 O

1 NCT03868033 24 25 O
. NCT03868033 25 26 O
Postmenopausal NCT03868033 28 42 B-Condition
women NCT03868033 43 48 O

2 NCT03868033 51 52 O
. NCT03868033 52 53 O
Men NCT03868033 55 58 O
> NCT03868033 59 60 B-Eq-Comparison
50 NCT03868033 61 63 I-Eq-Comparison
- NCT03868033 64 65 I-Eq-Comparison
year NCT03868033 66 70 I-Eq-Comparison
- NCT03868033 71 72 O
old NCT03868033 73 76 B-Age

3 NCT03868033 79 80 O
. NCT03868033 80 81 O
After NCT03868033 83 88 B-Eq-Comparison
Denosumab NCT03868033 89 98 B-Drug
treatment NCT03868033 99 108 B-Procedure
≥ NCT03868033 109 110 B-Eq-Comparison
2 NCT03868033 111 112 I-Eq-Comparison
years NCT03868033 113 118 I-Eq-Comparison
due NCT03868033 119 122 O
to NCT03868033 123 125 O
osteoporosis NCT03868033 126 138 B-Condition

Exclusion NCT03868033 139 148 O
Criteria NCT03868033 149 157 O
: NCT03868033 158 159 O

1 NCT03868033 163 164 O
. NCT03868033 164 165 O
secondary NCT03868033 167 176 B-Modifier
osteoporosis NCT03868033 177 189 B-Condition

2 NCT03868033 192 193 O
. NCT03868033 193 194 O
metabolic NCT03868033 196 205 B-Condition
bone NCT03868033 206 210 I-Condition
disease NCT03868033 211 218 I-Condition

3 NCT03868033 221 222 O
. NCT03868033 222 223 O
cancer NCT03868033 225 231 B-Condition
history NCT03868033 232 239 B-Eq-Comparison

4 NCT03868033 242 243 O
. NCT03868033 243 244 O
continuous NCT03868033 246 256 B-Eq-Comparison
steroid NCT03868033 257 264 B-Procedure
therapy NCT03868033 265 272 I-Procedure

5 NCT03868033 275 276 O
. NCT03868033 276 277 O
hormone NCT03868033 279 286 B-Procedure
replacement NCT03868033 287 298 I-Procedure
therapy NCT03868033 299 306 I-Procedure

6 NCT03868033 309 310 O
. NCT03868033 310 311 O
ever NCT03868033 313 317 B-Eq-Comparison
used NCT03868033 318 322 O
any NCT03868033 323 326 O
other NCT03868033 327 332 B-Other
kind NCT03868033 333 337 O
of NCT03868033 338 340 O
anti NCT03868033 341 345 B-Procedure
- NCT03868033 346 347 I-Procedure
resorptive NCT03868033 348 358 I-Procedure
treatment NCT03868033 359 368 I-Procedure

6 NCT03868033 371 372 O
. NCT03868033 372 373 O
estimated NCT03868033 375 384 B-Observation
Glomerular NCT03868033 385 395 I-Observation
filtration NCT03868033 396 406 I-Observation
rate NCT03868033 407 411 I-Observation
< NCT03868033 412 413 B-Eq-Comparison
35 NCT03868033 414 416 I-Eq-Comparison
mL NCT03868033 417 419 I-Eq-Comparison
/ NCT03868033 420 421 I-Eq-Comparison
min NCT03868033 422 425 I-Eq-Comparison

7 NCT03868033 429 430 O
. NCT03868033 430 431 O
allergy NCT03868033 433 440 B-Allergy
to NCT03868033 441 443 O
Zoledronic NCT03868033 444 454 B-Drug
acid NCT03868033 455 459 I-Drug

8 NCT03868033 462 463 O
. NCT03868033 463 464 O
hypocalcaemia NCT03868033 466 479 B-Condition

9 NCT03868033 483 484 O
. NCT03868033 484 485 O
any NCT03868033 487 490 O
contraindications NCT03868033 491 508 B-Contraindication
to NCT03868033 509 511 O
use NCT03868033 512 515 O
Zoledronic NCT03868033 516 526 B-Drug
acid NCT03868033 527 531 I-Drug


Inclusion NCT03869463 0 9 O
Criteria NCT03869463 10 18 O
: NCT03869463 19 20 O

1 NCT03869463 24 25 O
. NCT03869463 25 26 O
Age NCT03869463 28 31 B-Age
18 NCT03869463 32 34 B-Eq-Comparison
- NCT03869463 35 36 I-Eq-Comparison
29 NCT03869463 37 39 O
. NCT03869463 39 40 O

2 NCT03869463 44 45 O
. NCT03869463 45 46 O
Current NCT03869463 48 55 B-Eq-Comparison
diagnosis NCT03869463 56 65 O
of NCT03869463 66 68 O
MDD NCT03869463 69 72 B-Condition
/ NCT03869463 73 74 B-Or
persistent NCT03869463 75 85 B-Modifier
depressive NCT03869463 86 96 B-Condition
disorder NCT03869463 97 105 I-Condition
or NCT03869463 106 108 B-Or
HDRS NCT03869463 109 113 B-Observation
greater NCT03869463 114 121 B-Eq-Comparison
than NCT03869463 122 126 I-Eq-Comparison
or NCT03869463 127 129 I-Eq-Comparison
equal NCT03869463 130 135 I-Eq-Comparison
to NCT03869463 136 138 I-Eq-Comparison
12 NCT03869463 139 141 I-Eq-Comparison
. NCT03869463 141 142 O
3 NCT03869463 144 145 O
. NCT03869463 145 146 O
Daily NCT03869463 148 153 O
access NCT03869463 154 160 O
to NCT03869463 161 163 O
smartphone NCT03869463 164 174 O
or NCT03869463 175 177 O
tablet NCT03869463 178 184 O
with NCT03869463 185 189 O
internet NCT03869463 190 198 O
connection NCT03869463 199 209 O
for NCT03869463 210 213 O
the NCT03869463 214 217 O
study NCT03869463 218 223 O
duration NCT03869463 224 232 O
. NCT03869463 232 233 O

4 NCT03869463 235 236 O
. NCT03869463 236 237 O
Willing NCT03869463 239 246 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03869463 247 250 B-And
able NCT03869463 251 255 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869463 256 258 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03869463 259 267 O
MRI NCT03869463 268 271 B-Procedure
, NCT03869463 272 273 O
mood NCT03869463 274 278 B-Modifier
, NCT03869463 279 280 O
and NCT03869463 281 284 B-Or
neuropsychological NCT03869463 285 303 B-Modifier
testing NCT03869463 304 311 B-Procedure
. NCT03869463 311 312 O
5 NCT03869463 314 315 O
. NCT03869463 315 316 O
IQ NCT03869463 318 320 B-Observation
> NCT03869463 321 322 B-Eq-Comparison
85 NCT03869463 323 325 I-Eq-Comparison
. NCT03869463 325 326 O

Exclusion NCT03869463 328 337 O
Criteria NCT03869463 338 346 O
: NCT03869463 347 348 O

1 NCT03869463 352 353 O
. NCT03869463 353 354 O
Lacks NCT03869463 356 361 O
English NCT03869463 362 369 O
- NCT03869463 370 371 O
speaking NCT03869463 372 380 O
ability NCT03869463 381 388 O
as NCT03869463 389 391 O
determined NCT03869463 392 402 O
by NCT03869463 403 405 O
self NCT03869463 406 410 O
- NCT03869463 411 412 O
report NCT03869463 413 419 O
and NCT03869463 420 423 O
clinical NCT03869463 424 432 O
evaluation NCT03869463 433 443 O
. NCT03869463 443 444 O

2 NCT03869463 448 449 O
. NCT03869463 449 450 O
Evidence NCT03869463 452 460 O
of NCT03869463 461 463 O
schizophrenia NCT03869463 464 477 B-Condition
, NCT03869463 478 479 O
schizoaffective NCT03869463 480 495 B-Condition
disorder NCT03869463 496 504 I-Condition
, NCT03869463 505 506 O
psychosis NCT03869463 507 516 B-Condition
, NCT03869463 517 518 O
bipolar NCT03869463 519 526 B-Condition
I NCT03869463 527 528 B-Eq-Comparison
and NCT03869463 529 532 I-Eq-Comparison
II NCT03869463 533 535 I-Eq-Comparison
disorder NCT03869463 536 544 B-Modifier
. NCT03869463 544 545 O

3 NCT03869463 549 550 O
. NCT03869463 550 551 O
Active NCT03869463 553 559 B-Eq-Comparison
suicidal NCT03869463 560 568 B-Condition
ideation NCT03869463 569 577 I-Condition
, NCT03869463 578 579 O
intent NCT03869463 580 586 B-Assertion___Assertion-Type-Value:intention
, NCT03869463 587 588 O
or NCT03869463 589 591 B-Or|Or
plan NCT03869463 592 596 B-Assertion___Assertion-Type-Value:intention
, NCT03869463 597 598 O
or NCT03869463 599 601 O
past NCT03869463 602 606 B-Eq-Comparison
attempt NCT03869463 607 614 B-Coreference
within NCT03869463 615 621 B-Eq-Comparison
1 NCT03869463 622 623 I-Eq-Comparison
year NCT03869463 624 628 I-Eq-Comparison
. NCT03869463 628 629 O

4 NCT03869463 633 634 O
. NCT03869463 634 635 O
Severe NCT03869463 637 643 O
depression NCT03869463 644 654 B-Condition
( NCT03869463 655 656 O
HDRS NCT03869463 657 661 B-Observation
> NCT03869463 662 663 B-Eq-Comparison
30 NCT03869463 664 666 I-Eq-Comparison
) NCT03869463 667 668 O
. NCT03869463 669 670 O

5 NCT03869463 674 675 O
. NCT03869463 675 676 O
Neurological NCT03869463 678 690 B-Condition
disorder NCT03869463 691 699 I-Condition
( NCT03869463 700 701 O
epilepsy NCT03869463 702 710 B-Condition
, NCT03869463 711 712 O
multiple NCT03869463 713 721 B-Condition
sclerosis NCT03869463 722 731 I-Condition
, NCT03869463 732 733 O
traumatic NCT03869463 734 743 B-Condition
brain NCT03869463 744 749 I-Condition
injury NCT03869463 750 756 I-Condition
, NCT03869463 757 758 O
clinical NCT03869463 759 767 B-Modifier
stroke NCT03869463 768 774 B-Condition
) NCT03869463 775 776 O
. NCT03869463 777 778 O

6 NCT03869463 782 783 O
. NCT03869463 783 784 O
Use NCT03869463 786 789 B-Eq-Comparison
of NCT03869463 790 792 O
medications NCT03869463 793 804 B-Drug
known NCT03869463 805 810 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869463 811 813 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03869463 814 818 I-Assertion___Assertion-Type-Value:hypothetical
negative NCT03869463 819 827 O
impact NCT03869463 828 834 O
on NCT03869463 835 837 O
cognition NCT03869463 838 847 B-Condition
( NCT03869463 848 849 O
benzodiazepines NCT03869463 850 865 B-Drug
and NCT03869463 866 869 B-Or
lorazepam NCT03869463 870 879 B-Drug
equivalents NCT03869463 880 891 O
> NCT03869463 892 893 B-Eq-Comparison
1 NCT03869463 894 895 I-Eq-Comparison
mg NCT03869463 896 898 O
daily NCT03869463 899 904 I-Eq-Comparison
, NCT03869463 905 906 O
narcotics NCT03869463 907 916 B-Drug
, NCT03869463 917 918 O
anticholinergics NCT03869463 919 935 B-Drug
) NCT03869463 936 937 O
. NCT03869463 938 939 O

7 NCT03869463 943 944 O
. NCT03869463 944 945 O
History NCT03869463 947 954 B-Eq-Comparison
of NCT03869463 955 957 O
alcohol NCT03869463 958 965 B-Modifier
or NCT03869463 966 968 B-Or|Or
drug NCT03869463 969 973 B-Modifier
abuse NCT03869463 974 979 B-Condition
or NCT03869463 980 982 O
dependence NCT03869463 983 993 B-Modifier
within NCT03869463 994 1000 B-Eq-Comparison
past NCT03869463 1001 1005 I-Eq-Comparison
year NCT03869463 1006 1010 I-Eq-Comparison
. NCT03869463 1010 1011 O

8 NCT03869463 1015 1016 O
. NCT03869463 1016 1017 O
Acute NCT03869463 1019 1024 O
, NCT03869463 1025 1026 O
severe NCT03869463 1027 1033 O
, NCT03869463 1034 1035 O
unstable NCT03869463 1036 1044 O
medical NCT03869463 1045 1052 B-Condition
illness NCT03869463 1053 1060 I-Condition|Condition
. NCT03869463 1060 1061 O
For NCT03869463 1063 1066 O
cancer NCT03869463 1067 1073 B-Condition
, NCT03869463 1074 1075 O
acutely NCT03869463 1076 1083 O
ill NCT03869463 1084 1087 O
patients NCT03869463 1088 1096 O
( NCT03869463 1097 1098 O
including NCT03869463 1099 1108 O
those NCT03869463 1109 1114 O
with NCT03869463 1115 1119 O
metastases NCT03869463 1120 1130 B-Condition
) NCT03869463 1131 1132 O
are NCT03869463 1133 1136 O
excluded NCT03869463 1137 1145 B-Negation
, NCT03869463 1146 1147 O
but NCT03869463 1148 1151 O
past NCT03869463 1152 1156 B-Eq-Comparison
history NCT03869463 1157 1164 I-Eq-Comparison
of NCT03869463 1165 1167 O
successfully NCT03869463 1168 1180 O
treated NCT03869463 1181 1188 B-Procedure
cancer NCT03869463 1189 1195 B-Condition
does NCT03869463 1196 1200 O
not NCT03869463 1201 1204 B-Negation
result NCT03869463 1205 1211 O
in NCT03869463 1212 1214 O
exclusion NCT03869463 1215 1224 B-Negation
. NCT03869463 1224 1225 O

9 NCT03869463 1229 1230 O
. NCT03869463 1230 1231 O
Regular NCT03869463 1233 1240 O
online NCT03869463 1241 1247 B-Modifier
brain NCT03869463 1248 1253 I-Modifier
training NCT03869463 1254 1262 B-Observation
or NCT03869463 1263 1265 B-Or
regular NCT03869463 1266 1273 O
player NCT03869463 1274 1280 O
of NCT03869463 1281 1283 O
non NCT03869463 1284 1287 B-Negation
- NCT03869463 1288 1289 O
fluency NCT03869463 1290 1297 B-Modifier
verbal NCT03869463 1298 1304 B-Observation
games NCT03869463 1305 1310 I-Observation
, NCT03869463 1311 1312 O
defined NCT03869463 1313 1320 O
as NCT03869463 1321 1323 O
doing NCT03869463 1324 1329 O
these NCT03869463 1330 1335 B-Coreference
procedures NCT03869463 1336 1346 I-Coreference
at NCT03869463 1347 1349 O
a NCT03869463 1350 1351 O
frequency NCT03869463 1352 1361 O
of NCT03869463 1362 1364 O
twice NCT03869463 1365 1370 B-Eq-Comparison
weekly NCT03869463 1371 1377 I-Eq-Comparison
or NCT03869463 1378 1380 I-Eq-Comparison
greater NCT03869463 1381 1388 I-Eq-Comparison
during NCT03869463 1389 1395 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869463 1396 1399 O
year NCT03869463 1400 1404 B-Eq-Comparison
prior NCT03869463 1405 1410 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869463 1411 1413 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03869463 1414 1423 B-Study
. NCT03869463 1423 1424 O

Inclusion NCT03861598 0 9 O
Criteria NCT03861598 10 18 O
: NCT03861598 19 20 O

- NCT03861598 24 25 O
Grade NCT03861598 27 32 B-Eq-Comparison
IV NCT03861598 33 35 I-Eq-Comparison
Glioblastoma NCT03861598 36 48 B-Condition
, NCT03861598 49 50 O
receiving NCT03861598 51 60 B-Eq-Comparison
chemotherapy NCT03861598 61 73 B-Procedure
with NCT03861598 74 78 O
or NCT03861598 79 81 B-Or
without NCT03861598 82 89 B-Negation
TTfields NCT03861598 90 98 B-Drug
. NCT03861598 98 99 O

- NCT03861598 103 104 O
Progressive NCT03861598 106 117 B-Modifier
or NCT03861598 118 120 B-Or
recurrent NCT03861598 121 130 B-Modifier
disease NCT03861598 131 138 B-Condition
requiring NCT03861598 139 148 B-Assertion___Assertion-Type-Value:hypothetical
second NCT03861598 149 155 B-Procedure
line NCT03861598 156 160 I-Procedure
treatment NCT03861598 161 170 I-Procedure

- NCT03861598 173 174 O
evidence NCT03861598 176 184 O
of NCT03861598 185 187 O
progression NCT03861598 188 199 B-Condition
of NCT03861598 200 202 I-Condition
disease NCT03861598 203 210 I-Condition
by NCT03861598 211 213 O
brain NCT03861598 214 219 B-Procedure
MRI NCT03861598 220 223 I-Procedure
and NCT03861598 224 227 B-And
are NCT03861598 228 231 O
planned NCT03861598 232 239 B-Eq-Comparison
to NCT03861598 240 242 O
receive NCT03861598 243 250 O
chemotherapy NCT03861598 251 263 B-Procedure

Exclusion NCT03861598 264 273 O
Criteria NCT03861598 274 282 O
: NCT03861598 283 284 O

- NCT03861598 288 289 O
Current NCT03861598 291 298 B-Eq-Comparison
use NCT03861598 299 302 O
of NCT03861598 303 305 O
another NCT03861598 306 313 B-Other
beta NCT03861598 314 318 B-Drug
blocker NCT03861598 319 326 I-Drug
that NCT03861598 327 331 O
can NCT03861598 332 335 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03861598 335 338 O
be NCT03861598 339 341 O
switched NCT03861598 342 350 O
to NCT03861598 351 353 O
carvedilol NCT03861598 354 364 B-Drug
at NCT03861598 365 367 O
the NCT03861598 368 371 O
onset NCT03861598 372 377 B-Eq-Comparison
of NCT03861598 378 380 O
the NCT03861598 381 384 O
trial NCT03861598 385 390 B-Study
. NCT03861598 390 391 O

- NCT03861598 395 396 O
Systolic NCT03861598 398 406 B-Observation
blood NCT03861598 407 412 I-Observation
pressure NCT03861598 413 421 I-Observation
< NCT03861598 422 423 B-Eq-Comparison
90 NCT03861598 424 426 I-Eq-Comparison
mmHg NCT03861598 427 431 I-Eq-Comparison
and NCT03861598 432 435 B-Or
/ NCT03861598 436 437 I-Or
or NCT03861598 438 440 I-Or
heart NCT03861598 441 446 B-Observation
rate NCT03861598 447 451 I-Observation
< NCT03861598 452 453 B-Eq-Comparison
60 NCT03861598 454 456 I-Eq-Comparison
bpm NCT03861598 457 460 I-Eq-Comparison
without NCT03861598 461 468 B-Negation
hypertensive NCT03861598 469 481 B-Condition
medications NCT03861598 482 493 B-Drug

- NCT03861598 496 497 O
Allergy NCT03861598 499 506 B-Allergy
to NCT03861598 507 509 O
beta NCT03861598 510 514 B-Drug
blockers NCT03861598 515 523 I-Drug

- NCT03861598 526 527 O
Severe NCT03861598 529 535 O
or NCT03861598 536 538 B-Or
uncontrolled NCT03861598 539 551 B-Modifier
asthma NCT03861598 552 558 B-Condition
or NCT03861598 559 561 B-Or
COPD NCT03861598 562 566 B-Condition
( NCT03861598 567 568 O
chronic NCT03861598 569 576 B-Condition
obstructive NCT03861598 577 588 I-Condition
pulmonary NCT03861598 589 598 I-Condition
disease NCT03861598 599 606 I-Condition
) NCT03861598 607 608 O

Inclusion NCT03861104 0 9 O
Criteria NCT03861104 10 18 O
: NCT03861104 19 20 O

- NCT03861104 24 25 O
patients NCT03861104 27 35 O
who NCT03861104 36 39 O
will NCT03861104 40 44 B-Eq-Comparison
undergo NCT03861104 45 52 I-Eq-Comparison
septoplasty NCT03861104 53 64 B-Procedure
/ NCT03861104 65 66 B-Or
septorhinoplasty NCT03861104 67 83 B-Procedure
procedures NCT03861104 84 94 I-Procedure

- NCT03861104 97 98 O
patients NCT03861104 100 108 O
who NCT03861104 109 112 O
will NCT03861104 113 117 B-Eq-Comparison
receive NCT03861104 118 125 I-Eq-Comparison
nasal NCT03861104 126 131 B-Procedure
packing NCT03861104 132 139 I-Procedure
at NCT03861104 140 142 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03861104 143 148 O
septoplasty NCT03861104 149 160 B-Procedure
septorhinoplasty NCT03861104 161 177 I-Procedure
procedures NCT03861104 178 188 I-Procedure

Exclusion NCT03861104 189 198 O
Criteria NCT03861104 199 207 O
: NCT03861104 208 209 O

- NCT03861104 213 214 O
patients NCT03861104 216 224 O
who NCT03861104 225 228 O
will NCT03861104 229 233 O
not NCT03861104 234 237 B-Negation
want NCT03861104 238 242 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861104 243 245 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861104 246 257 O
to NCT03861104 258 260 O
the NCT03861104 261 264 O
study NCT03861104 265 270 B-Study

- NCT03861104 273 274 O
revision NCT03861104 276 284 B-Modifier
surgeries NCT03861104 285 294 B-Procedure

- NCT03861104 297 298 O
if NCT03861104 300 302 O
the NCT03861104 303 306 O
patient NCT03861104 307 314 O
is NCT03861104 315 317 O
taking NCT03861104 318 324 B-Eq-Comparison
antidepressants NCT03861104 325 340 B-Drug
during NCT03861104 341 347 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861104 348 351 O
last NCT03861104 352 356 B-Eq-Comparison
6 NCT03861104 357 358 I-Eq-Comparison
months NCT03861104 359 365 I-Eq-Comparison

- NCT03861104 368 369 O
if NCT03861104 371 373 O
the NCT03861104 374 377 O
patient NCT03861104 378 385 O
has NCT03861104 386 389 O
a NCT03861104 390 391 O
history NCT03861104 392 399 B-Eq-Comparison
of NCT03861104 400 402 O
a NCT03861104 403 404 O
disease NCT03861104 405 412 B-Condition
that NCT03861104 413 417 O
can NCT03861104 418 421 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861104 422 428 O
anxiety NCT03861104 429 436 B-Condition
levels NCT03861104 437 443 O

- NCT03861104 446 447 O
if NCT03861104 449 451 O
patient NCT03861104 452 459 O
wants NCT03861104 460 465 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861104 466 468 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03861104 469 471 O
excluded NCT03861104 472 480 B-Negation
from NCT03861104 481 485 O
the NCT03861104 486 489 O
study NCT03861104 490 495 B-Study

Inclusion NCT03861676 0 9 O
Criteria NCT03861676 10 18 O
: NCT03861676 19 20 O

- NCT03861676 24 25 O
Adenocarcinoma NCT03861676 27 41 B-Condition
of NCT03861676 42 44 O
the NCT03861676 45 48 O
prostate NCT03861676 49 57 B-Modifier

- NCT03861676 60 61 O
Performance NCT03861676 63 74 B-Observation
Status NCT03861676 75 81 I-Observation
< NCT03861676 82 83 B-Eq-Comparison
2 NCT03861676 84 85 I-Eq-Comparison

- NCT03861676 89 90 O
Clinical NCT03861676 92 100 B-Coreference
stages NCT03861676 101 107 I-Coreference
( NCT03861676 108 109 O
not NCT03861676 110 113 B-Negation
radiographic NCT03861676 114 126 B-Modifier
stage NCT03861676 127 132 I-Modifier
) NCT03861676 133 134 O
T1c NCT03861676 135 138 B-Eq-Comparison
- NCT03861676 139 140 I-Eq-Comparison
T2a NCT03861676 141 144 I-Eq-Comparison
, NCT03861676 145 146 O
Nx NCT03861676 147 149 I-Eq-Comparison
or NCT03861676 150 152 B-Or
N0 NCT03861676 153 155 B-Eq-Comparison
, NCT03861676 156 157 O
Mx NCT03861676 158 160 I-Eq-Comparison
or NCT03861676 161 163 B-Or
M0 NCT03861676 164 166 B-Eq-Comparison

- NCT03861676 169 170 O
Gleason NCT03861676 172 179 B-Observation
6 NCT03861676 180 181 B-Eq-Comparison
- NCT03861676 182 183 I-Eq-Comparison
7 NCT03861676 184 185 I-Eq-Comparison
cancer NCT03861676 186 192 B-Condition

- NCT03861676 195 196 O
Prostate NCT03861676 198 206 B-Observation
volume NCT03861676 207 213 I-Observation
< NCT03861676 214 215 B-Eq-Comparison
60 NCT03861676 216 218 I-Eq-Comparison
cc NCT03861676 219 221 I-Eq-Comparison
( NCT03861676 222 223 O
if NCT03861676 224 226 O
MRI NCT03861676 227 230 B-Procedure
and NCT03861676 231 234 B-And
TRUS NCT03861676 235 239 B-Procedure
have NCT03861676 240 244 O
conflicting NCT03861676 245 256 O
values NCT03861676 257 263 O
, NCT03861676 264 265 O
then NCT03861676 266 270 O
MRI NCT03861676 271 274 B-Procedure
value NCT03861676 275 280 O
will NCT03861676 281 285 O
be NCT03861676 286 288 O
utilized NCT03861676 289 297 O
) NCT03861676 298 299 O

- NCT03861676 303 304 O
International NCT03861676 306 319 B-Observation
Prostate NCT03861676 320 328 I-Observation
symptom NCT03861676 329 336 I-Observation
score NCT03861676 337 342 I-Observation
( NCT03861676 343 344 O
IPSS NCT03861676 345 349 B-Observation
) NCT03861676 350 351 O
20 NCT03861676 352 354 B-Eq-Comparison
or NCT03861676 355 357 I-Eq-Comparison
less NCT03861676 358 362 I-Eq-Comparison

- NCT03861676 365 366 O
Ability NCT03861676 368 375 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861676 376 378 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03861676 379 386 O
DCF NCT03861676 387 390 B-Procedure
- NCT03861676 391 392 I-Procedure
Pyl NCT03861676 393 396 I-Procedure
PSMA NCT03861676 397 401 I-Procedure
PET NCT03861676 402 405 I-Procedure
as NCT03861676 406 408 O
part NCT03861676 409 413 O
of NCT03861676 414 416 O
pretreatment NCT03861676 417 429 B-Temporal-Connection___Temporal-Connection-Type-Value:before
staging NCT03861676 430 437 O

- NCT03861676 440 441 O
Signed NCT03861676 443 449 O
study NCT03861676 450 455 O
- NCT03861676 456 457 O
specific NCT03861676 458 466 O
consent NCT03861676 467 474 O
form NCT03861676 475 479 O
prior NCT03861676 480 485 O
to NCT03861676 486 488 O
registration NCT03861676 489 501 O

Exclusion NCT03861676 502 511 O
Criteria NCT03861676 512 520 O
: NCT03861676 521 522 O

- NCT03861676 526 527 O
Prior NCT03861676 529 534 B-Eq-Comparison
history NCT03861676 535 542 I-Eq-Comparison
of NCT03861676 543 545 O
pelvic NCT03861676 546 552 B-Modifier
radiation NCT03861676 553 562 B-Procedure
therapy NCT03861676 563 570 I-Procedure

- NCT03861676 573 574 O
Major NCT03861676 576 581 O
medical NCT03861676 582 589 B-Modifier
or NCT03861676 590 592 B-Or
psychiatric NCT03861676 593 604 B-Modifier
illness NCT03861676 605 612 B-Condition
which NCT03861676 613 618 O
, NCT03861676 619 620 O
in NCT03861676 621 623 O
the NCT03861676 624 627 O
investigator NCT03861676 628 640 O
's NCT03861676 640 642 O
opinion NCT03861676 643 650 O
, NCT03861676 651 652 O
would NCT03861676 653 658 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03861676 659 666 B-Negation
completion NCT03861676 667 677 O
of NCT03861676 678 680 O
treatment NCT03861676 681 690 B-Procedure|Procedure
and NCT03861676 691 694 B-And
would NCT03861676 695 700 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861676 701 710 O
with NCT03861676 711 715 O
follow NCT03861676 716 722 B-Encounter
up NCT03861676 723 725 I-Encounter
. NCT03861676 725 726 O

- NCT03861676 730 731 O
Implanted NCT03861676 733 742 B-Procedure
device NCT03861676 743 749 B-Modifier
or NCT03861676 750 752 B-Or
apparatus NCT03861676 753 762 B-Modifier
which NCT03861676 763 768 O
obstruct NCT03861676 769 777 B-Assertion___Assertion-Type-Value:hypothetical|Negation
visibility NCT03861676 778 788 O
of NCT03861676 789 791 O
the NCT03861676 792 795 O
implanted NCT03861676 796 805 B-Modifier
sources NCT03861676 806 813 I-Modifier
on NCT03861676 814 816 O
fluoroscopy NCT03861676 817 828 B-Procedure

- NCT03861676 831 832 O
Metallic NCT03861676 834 842 B-Procedure
implants NCT03861676 843 851 I-Procedure
, NCT03861676 852 853 O
claustrophobia NCT03861676 854 868 B-Condition
not NCT03861676 869 872 B-Negation
amenable NCT03861676 873 881 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861676 882 884 O
medication NCT03861676 885 895 B-Drug
, NCT03861676 896 897 O
or NCT03861676 898 900 B-Or
known NCT03861676 901 906 O
contraindications NCT03861676 907 924 B-Contraindication
to NCT03861676 925 927 O
undergoing NCT03861676 928 938 O
MR NCT03861676 939 941 B-Procedure
scanning NCT03861676 942 950 I-Procedure

- NCT03861676 953 954 O
History NCT03861676 956 963 B-Eq-Comparison
of NCT03861676 964 966 O
other NCT03861676 967 972 B-Other
malignancy NCT03861676 973 983 B-Condition
diagnosed NCT03861676 984 993 O
within NCT03861676 994 1000 B-Eq-Comparison
the NCT03861676 1001 1004 I-Eq-Comparison
past NCT03861676 1005 1009 I-Eq-Comparison
3 NCT03861676 1010 1011 I-Eq-Comparison
years NCT03861676 1012 1017 I-Eq-Comparison

Inclusion NCT03864068 0 9 O
Criteria NCT03864068 10 18 O
: NCT03864068 19 20 O

- NCT03864068 24 25 O
Women NCT03864068 27 32 O
with NCT03864068 33 37 B-And
chronic NCT03864068 38 45 B-Modifier
anovulation NCT03864068 46 57 B-Condition
or NCT03864068 58 60 B-Or
oligomenorrhea NCT03864068 61 75 B-Condition
defined NCT03864068 76 83 O
as NCT03864068 84 86 O
spontaneous NCT03864068 87 98 B-Condition
intermenstrual NCT03864068 99 113 I-Condition
periods NCT03864068 114 121 I-Condition
of NCT03864068 122 124 O
greater NCT03864068 125 132 B-Eq-Comparison
than NCT03864068 133 137 I-Eq-Comparison
or NCT03864068 138 140 I-Eq-Comparison
equal NCT03864068 141 146 I-Eq-Comparison
to NCT03864068 147 149 I-Eq-Comparison
45 NCT03864068 150 152 I-Eq-Comparison
days NCT03864068 153 157 I-Eq-Comparison
or NCT03864068 158 160 B-Or
a NCT03864068 161 162 O
total NCT03864068 163 168 O
of NCT03864068 169 171 O
less NCT03864068 172 176 B-Eq-Comparison
than NCT03864068 177 181 I-Eq-Comparison
or NCT03864068 182 184 I-Eq-Comparison
equal NCT03864068 185 190 I-Eq-Comparison
to NCT03864068 191 193 I-Eq-Comparison
8 NCT03864068 194 195 I-Eq-Comparison
menses NCT03864068 196 202 B-Observation
per NCT03864068 203 206 O
year NCT03864068 207 211 O
. NCT03864068 211 212 O

- NCT03864068 216 217 O
Women NCT03864068 219 224 O
with NCT03864068 225 229 B-And
Hyperandrogenism NCT03864068 230 246 B-Condition
defined NCT03864068 247 254 O
as NCT03864068 255 257 O
a NCT03864068 258 259 O
total NCT03864068 260 265 B-Observation
testosterone NCT03864068 266 278 I-Observation
greater NCT03864068 279 286 B-Eq-Comparison
than NCT03864068 287 291 I-Eq-Comparison
50 NCT03864068 292 294 I-Eq-Comparison
ng NCT03864068 295 297 I-Eq-Comparison
/ NCT03864068 298 299 I-Eq-Comparison
dL NCT03864068 300 302 I-Eq-Comparison
or NCT03864068 303 305 B-Or
a NCT03864068 306 307 O
free NCT03864068 308 312 B-Observation
androgen NCT03864068 313 321 I-Observation
index NCT03864068 322 327 I-Observation
greater NCT03864068 328 335 B-Eq-Comparison
than NCT03864068 336 340 I-Eq-Comparison
10 NCT03864068 341 343 I-Eq-Comparison
. NCT03864068 343 344 O

- NCT03864068 348 349 O
Women NCT03864068 351 356 O
with NCT03864068 357 361 B-And
Polycystic NCT03864068 362 372 B-Condition
Ovaries NCT03864068 373 380 I-Condition
on NCT03864068 381 383 O
Ultrasound NCT03864068 384 394 B-Procedure
defined NCT03864068 395 402 O
as NCT03864068 403 405 O
either NCT03864068 406 412 B-Eq-Comparison
12 NCT03864068 413 415 I-Eq-Comparison
or NCT03864068 416 418 I-Eq-Comparison
more NCT03864068 419 423 I-Eq-Comparison
follicles NCT03864068 424 433 B-Observation
measuring NCT03864068 434 443 I-Observation
2 NCT03864068 444 445 B-Eq-Comparison
- NCT03864068 446 447 I-Eq-Comparison
9 NCT03864068 448 449 I-Eq-Comparison
mm NCT03864068 450 452 I-Eq-Comparison
in NCT03864068 453 455 O
diameter NCT03864068 456 464 B-Modifier
or NCT03864068 465 467 B-Or
increased NCT03864068 468 477 O
ovarian NCT03864068 478 485 B-Observation
volume NCT03864068 486 492 I-Observation
greater NCT03864068 493 500 B-Eq-Comparison
than NCT03864068 501 505 I-Eq-Comparison
10 NCT03864068 506 508 I-Eq-Comparison
cm NCT03864068 509 511 I-Eq-Comparison
. NCT03864068 511 512 O

Exclusion NCT03864068 514 523 O
Criteria NCT03864068 524 532 O
: NCT03864068 533 534 O

- NCT03864068 538 539 O
Women NCT03864068 541 546 O
with NCT03864068 547 551 B-And
Hyperprolactinemia NCT03864068 552 570 B-Condition
defined NCT03864068 571 578 O
as NCT03864068 579 581 O
2 NCT03864068 582 583 B-Eq-Comparison
prolactin NCT03864068 584 593 B-Observation
levels NCT03864068 594 600 I-Observation
at NCT03864068 601 603 B-Eq-Comparison
least NCT03864068 604 609 I-Eq-Comparison
one NCT03864068 610 613 I-Eq-Comparison
week NCT03864068 614 618 I-Eq-Comparison
apart NCT03864068 619 624 O
greater NCT03864068 625 632 B-Eq-Comparison
than NCT03864068 633 637 I-Eq-Comparison
30 NCT03864068 638 640 I-Eq-Comparison
ng NCT03864068 641 643 I-Eq-Comparison
/ NCT03864068 644 645 I-Eq-Comparison
mL. NCT03864068 646 649 I-Eq-Comparison

- NCT03864068 653 654 O
Women NCT03864068 656 661 O
with NCT03864068 662 666 B-And
known NCT03864068 667 672 O
21 NCT03864068 673 675 B-Condition
- NCT03864068 676 677 I-Condition
hydroxylase NCT03864068 678 689 I-Condition
deficiency NCT03864068 690 700 I-Condition
or NCT03864068 701 703 B-Or
other NCT03864068 704 709 B-Other
enzyme NCT03864068 710 716 B-Condition
deficiency NCT03864068 717 727 I-Condition
leading NCT03864068 728 735 O
to NCT03864068 736 738 O
the NCT03864068 739 742 O
congenital NCT03864068 743 753 B-Condition
adrenal NCT03864068 754 761 I-Condition
hyperplasia NCT03864068 762 773 I-Condition
. NCT03864068 773 774 O

- NCT03864068 778 779 O
Women NCT03864068 781 786 O
with NCT03864068 787 791 B-And
elevated NCT03864068 792 800 O
FSH NCT03864068 801 804 B-Observation
levels NCT03864068 805 811 I-Observation
greater NCT03864068 812 819 B-Eq-Comparison
than NCT03864068 820 824 I-Eq-Comparison
10 NCT03864068 825 827 I-Eq-Comparison
mIU NCT03864068 828 831 I-Eq-Comparison
/ NCT03864068 832 833 I-Eq-Comparison
mL. NCT03864068 834 837 I-Eq-Comparison

- NCT03864068 841 842 O
Women NCT03864068 844 849 O
with NCT03864068 850 854 B-And
uncorrected NCT03864068 855 866 B-Modifier
thyroid NCT03864068 867 874 B-Condition
disease NCT03864068 875 882 I-Condition
as NCT03864068 883 885 O
per NCT03864068 886 889 O
ASRM NCT03864068 890 894 O
guidelines NCT03864068 895 905 O
for NCT03864068 906 909 O
nonpregnant NCT03864068 910 921 O
subjects NCT03864068 922 930 O
( NCT03864068 931 932 O
TSH NCT03864068 933 936 B-Observation
less NCT03864068 937 941 B-Eq-Comparison
than NCT03864068 942 946 I-Eq-Comparison
0.45 NCT03864068 947 951 I-Eq-Comparison
mIU NCT03864068 952 955 I-Eq-Comparison
/ NCT03864068 956 957 I-Eq-Comparison
mL NCT03864068 958 960 I-Eq-Comparison
or NCT03864068 961 963 B-Or
greater NCT03864068 964 971 B-Eq-Comparison
than NCT03864068 972 976 I-Eq-Comparison
4.5 NCT03864068 977 980 I-Eq-Comparison
MIU NCT03864068 981 984 I-Eq-Comparison
/ NCT03864068 985 986 I-Eq-Comparison
mL NCT03864068 987 989 I-Eq-Comparison
) NCT03864068 990 991 O
. NCT03864068 992 993 O

- NCT03864068 997 998 O
Women NCT03864068 1000 1005 O
with NCT03864068 1006 1010 B-And
a NCT03864068 1011 1012 O
suspected NCT03864068 1013 1022 B-Assertion___Assertion-Type-Value:possible
adrenal NCT03864068 1023 1030 B-Modifier
or NCT03864068 1031 1033 B-Or
ovarian NCT03864068 1034 1041 B-Modifier
tumor NCT03864068 1042 1047 B-Condition
secreting NCT03864068 1048 1057 B-Modifier
androgens NCT03864068 1058 1067 I-Modifier

- NCT03864068 1070 1071 O
Women NCT03864068 1073 1078 O
with NCT03864068 1079 1083 B-And
Cushing NCT03864068 1084 1091 B-Condition
's NCT03864068 1091 1093 O
syndrome NCT03864068 1094 1102 I-Condition

- NCT03864068 1105 1106 O
Women NCT03864068 1108 1113 O
on NCT03864068 1114 1116 B-Eq-Comparison
confounding NCT03864068 1117 1128 O
medications NCT03864068 1129 1140 B-Drug
which NCT03864068 1141 1146 O
affect NCT03864068 1147 1153 B-Assertion___Assertion-Type-Value:hypothetical
ovarian NCT03864068 1154 1161 B-Condition
function NCT03864068 1162 1170 I-Condition
including NCT03864068 1171 1180 O
metformin NCT03864068 1181 1190 B-Drug
, NCT03864068 1191 1192 O
hormonal NCT03864068 1193 1201 B-Drug
contraceptives NCT03864068 1202 1216 I-Drug
or NCT03864068 1217 1219 B-Or
other NCT03864068 1220 1225 B-Other
medications NCT03864068 1226 1237 B-Drug
for NCT03864068 1238 1241 O
type NCT03864068 1242 1246 B-Condition
2 NCT03864068 1247 1248 I-Condition
diabetes NCT03864068 1249 1257 I-Condition

- NCT03864068 1260 1261 O
Women NCT03864068 1263 1268 O
with NCT03864068 1269 1273 B-And
medical NCT03864068 1274 1281 B-Condition
conditions NCT03864068 1282 1292 I-Condition
that NCT03864068 1293 1297 O
are NCT03864068 1298 1301 O
contraindications NCT03864068 1302 1319 B-Contraindication
to NCT03864068 1320 1322 O
OTC NCT03864068 1323 1326 B-Drug
inositol NCT03864068 1327 1335 I-Drug
or NCT03864068 1336 1338 B-Or
previous NCT03864068 1339 1347 B-Eq-Comparison
allergic NCT03864068 1348 1356 B-Allergy
reactions NCT03864068 1357 1366 O
to NCT03864068 1367 1369 O
the NCT03864068 1370 1373 O
supplement NCT03864068 1374 1384 B-Drug
or NCT03864068 1385 1387 B-Or
to NCT03864068 1388 1390 O
the NCT03864068 1391 1394 O
placebo NCT03864068 1395 1402 B-Drug
maltodextrin NCT03864068 1403 1415 I-Drug
or NCT03864068 1416 1418 B-Or
inulin NCT03864068 1419 1425 B-Drug
. NCT03864068 1425 1426 O

Patient NCT03869216 0 7 O
Inclusion NCT03869216 8 17 O
Criteria NCT03869216 18 26 O
: NCT03869216 27 28 O

- NCT03869216 32 33 O
Receiving NCT03869216 35 44 B-Eq-Comparison
care NCT03869216 45 49 B-Procedure
at NCT03869216 50 52 O
the NCT03869216 53 56 O
clinical NCT03869216 57 65 O
sites NCT03869216 66 71 O

- NCT03869216 74 75 O
Identify NCT03869216 77 85 O
as NCT03869216 86 88 O
African NCT03869216 89 96 O
American NCT03869216 97 105 O
male NCT03869216 106 110 O

- NCT03869216 113 114 O
Ages NCT03869216 116 120 B-Age
40 NCT03869216 121 123 B-Eq-Comparison
- NCT03869216 124 125 I-Eq-Comparison
69 NCT03869216 126 128 I-Eq-Comparison
years NCT03869216 129 134 I-Eq-Comparison
old NCT03869216 135 138 O

- NCT03869216 141 142 O
Provider NCT03869216 144 152 O
- NCT03869216 153 154 O
estimated NCT03869216 155 164 O
life NCT03869216 165 169 B-Observation
expectancy NCT03869216 170 180 I-Observation
of NCT03869216 181 183 O
at NCT03869216 184 186 B-Eq-Comparison
least NCT03869216 187 192 I-Eq-Comparison
10 NCT03869216 193 195 I-Eq-Comparison
years NCT03869216 196 201 I-Eq-Comparison

Patient NCT03869216 202 209 O
Exclusion NCT03869216 210 219 O
Criteria NCT03869216 220 228 O
: NCT03869216 229 230 O

- NCT03869216 234 235 O
Personal NCT03869216 237 245 O
history NCT03869216 246 253 B-Eq-Comparison
of NCT03869216 254 256 O
prostate NCT03869216 257 265 B-Modifier
cancer NCT03869216 266 272 B-Condition
at NCT03869216 273 275 O
the NCT03869216 276 279 O
time NCT03869216 280 284 O
of NCT03869216 285 287 O
consent NCT03869216 288 295 O

- NCT03869216 298 299 O
Cognitive NCT03869216 301 310 B-Condition
impairment NCT03869216 311 321 I-Condition
that NCT03869216 322 326 O
would NCT03869216 327 332 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03869216 333 342 O
with NCT03869216 343 347 O
participation NCT03869216 348 361 O
in NCT03869216 362 364 O
the NCT03869216 365 368 O
study NCT03869216 369 374 B-Study

- NCT03869216 377 378 O
Unable NCT03869216 380 386 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869216 387 389 O
complete NCT03869216 390 398 O
any NCT03869216 399 402 O
aspect NCT03869216 403 409 O
of NCT03869216 410 412 O
the NCT03869216 413 416 O
intervention NCT03869216 417 429 B-Study
within NCT03869216 430 436 O
the NCT03869216 437 440 O
specified NCT03869216 441 450 O
time NCT03869216 451 455 O
limit NCT03869216 456 461 O

Inclusion NCT03861845 0 9 O
Criteria NCT03861845 10 18 O
: NCT03861845 19 20 O

- NCT03861845 24 25 O
18 NCT03861845 27 29 B-Eq-Comparison
years NCT03861845 30 35 I-Eq-Comparison
of NCT03861845 36 38 I-Eq-Comparison
age NCT03861845 39 42 I-Age|Eq-Comparison
or NCT03861845 43 45 I-Eq-Comparison
older NCT03861845 46 51 I-Eq-Comparison

- NCT03861845 54 55 O
speak NCT03861845 57 62 O
English NCT03861845 63 70 O

- NCT03861845 73 74 O
be NCT03861845 76 78 O
prescribed NCT03861845 79 89 O
to NCT03861845 90 92 O
take NCT03861845 93 97 O
two NCT03861845 98 101 B-Eq-Comparison
or NCT03861845 102 104 I-Eq-Comparison
more NCT03861845 105 109 I-Eq-Comparison
medications NCT03861845 110 121 B-Drug
per NCT03861845 122 125 O
day NCT03861845 126 129 B-Eq-Comparison
, NCT03861845 130 131 O
and NCT03861845 132 135 B-And
manage NCT03861845 136 142 B-Assertion___Assertion-Type-Value:hypothetical
their NCT03861845 143 148 I-Assertion___Assertion-Type-Value:hypothetical
own NCT03861845 149 152 O
medications NCT03861845 153 164 B-Drug
. NCT03861845 164 165 O

Exclusion NCT03861845 167 176 O
Criteria NCT03861845 177 185 O
: NCT03861845 186 187 O

- NCT03861845 191 192 O
have NCT03861845 194 198 O
a NCT03861845 199 200 O
significant NCT03861845 201 212 O
cognitive NCT03861845 213 222 B-Condition
impairment NCT03861845 223 233 I-Condition

- NCT03861845 236 237 O
unwilling NCT03861845 239 248 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861845 249 251 O
use NCT03861845 252 255 O
a NCT03861845 256 257 O
novel NCT03861845 258 263 B-Procedure
pillbox NCT03861845 264 271 I-Procedure

- NCT03861845 274 275 O
unable NCT03861845 277 283 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861845 284 286 O
meet NCT03861845 287 291 O
with NCT03861845 292 296 O
the NCT03861845 297 300 O
research NCT03861845 301 309 B-Study
team NCT03861845 310 314 I-Study

Inclusion NCT03860597 0 9 O
Criteria NCT03860597 10 18 O
: NCT03860597 19 20 O

- NCT03860597 24 25 O
diagnosis NCT03860597 27 36 O
of NCT03860597 37 39 O
schizophrenia NCT03860597 40 53 B-Condition
OR NCT03860597 54 56 B-Or
schizoaffective NCT03860597 57 72 B-Condition
- NCT03860597 73 74 I-Condition
depressed NCT03860597 75 84 I-Condition
OR NCT03860597 85 87 B-Or
healthy NCT03860597 88 95 B-Condition
subjects NCT03860597 96 104 O

- NCT03860597 107 108 O
ages NCT03860597 110 114 B-Age
18 NCT03860597 115 117 B-Eq-Comparison
- NCT03860597 118 119 I-Eq-Comparison
50 NCT03860597 120 122 I-Eq-Comparison
for NCT03860597 123 126 O
all NCT03860597 127 130 O
subjects NCT03860597 131 139 O

- NCT03860597 142 143 O
double NCT03860597 145 151 B-Modifier
barrier NCT03860597 152 159 I-Modifier
contraception NCT03860597 160 173 B-Procedure
for NCT03860597 174 177 O
all NCT03860597 178 181 O
subjects NCT03860597 182 190 O

- NCT03860597 193 194 O
not NCT03860597 196 199 B-Negation
pregnant NCT03860597 200 208 B-Condition
for NCT03860597 209 212 O
all NCT03860597 213 216 O
subjects NCT03860597 217 225 O

Exclusion NCT03860597 226 235 O
Criteria NCT03860597 236 244 O
: NCT03860597 245 246 O

- NCT03860597 250 251 I-Condition
DSM NCT03860597 253 256 B-Condition
- NCT03860597 257 258 O
IV NCT03860597 259 261 B-Condition|Eq-Comparison
Axis NCT03860597 262 266 I-Condition
I NCT03860597 267 268 O
or NCT03860597 269 271 I-Eq-Comparison
II NCT03860597 272 274 I-Eq-Comparison
Diagnosis NCT03860597 275 284 O
for NCT03860597 285 288 O
for NCT03860597 289 292 O
healthy NCT03860597 293 300 B-Condition
subjects NCT03860597 301 309 O

- NCT03860597 312 313 O
MEM NCT03860597 315 318 B-Condition
or NCT03860597 319 321 B-Or
amantadine NCT03860597 322 332 B-Drug
for NCT03860597 333 336 O
patients NCT03860597 337 345 O

- NCT03860597 348 349 O
current NCT03860597 351 358 B-Eq-Comparison
substance NCT03860597 359 368 B-Condition
abuse NCT03860597 369 374 I-Condition
for NCT03860597 375 378 O
all NCT03860597 379 382 O
subjects NCT03860597 383 391 O

- NCT03860597 394 395 O
current NCT03860597 397 404 B-Eq-Comparison
recreational NCT03860597 405 417 B-Condition
drug NCT03860597 418 422 I-Condition
use NCT03860597 423 426 I-Condition
for NCT03860597 427 430 O
all NCT03860597 431 434 O
subjects NCT03860597 435 443 O

- NCT03860597 446 447 O
history NCT03860597 449 456 B-Eq-Comparison
of NCT03860597 457 459 O
other NCT03860597 460 465 B-Other
significant NCT03860597 466 477 O
medical NCT03860597 478 485 B-Condition
illness NCT03860597 486 493 I-Condition
( NCT03860597 494 495 O
e. NCT03860597 496 498 O
g. NCT03860597 499 501 O
cancer NCT03860597 503 509 B-Condition
, NCT03860597 510 511 O
diabetes NCT03860597 512 520 B-Condition
, NCT03860597 521 522 O
heart NCT03860597 523 528 B-Condition
disease NCT03860597 529 536 I-Condition
, NCT03860597 537 538 O
HIV NCT03860597 539 542 B-Condition
, NCT03860597 543 544 O
seizures NCT03860597 545 553 B-Condition
) NCT03860597 554 555 O
for NCT03860597 556 559 O
all NCT03860597 560 563 O
subjects NCT03860597 564 572 O

- NCT03860597 575 576 O
open NCT03860597 578 582 B-Modifier
head NCT03860597 583 587 I-Modifier
injury NCT03860597 588 594 B-Condition
or NCT03860597 595 597 B-Or
closed NCT03860597 598 604 B-Modifier
head NCT03860597 605 609 I-Modifier
injury NCT03860597 610 616 B-Condition
with NCT03860597 617 621 B-And
loss NCT03860597 622 626 B-Condition
of NCT03860597 627 629 I-Condition
consciousness NCT03860597 630 643 I-Condition
> NCT03860597 644 645 B-Eq-Comparison
1 NCT03860597 646 647 I-Eq-Comparison
min NCT03860597 648 651 I-Eq-Comparison
for NCT03860597 652 655 O
all NCT03860597 656 659 O
subjects NCT03860597 660 668 O

- NCT03860597 671 672 O
hearing NCT03860597 674 681 B-Modifier
or NCT03860597 682 684 B-Or
visual NCT03860597 685 691 B-Modifier
impairment NCT03860597 692 702 B-Condition
for NCT03860597 703 706 O
all NCT03860597 707 710 O
subjects NCT03860597 711 719 O

- NCT03860597 722 723 O
pregnancy NCT03860597 725 734 B-Condition
for NCT03860597 735 738 O
all NCT03860597 739 742 O
subjects NCT03860597 743 751 O

- NCT03860597 754 755 O
dementia NCT03860597 757 765 B-Condition
for NCT03860597 766 769 O
all NCT03860597 770 773 O
subjects NCT03860597 774 782 O

- NCT03860597 785 786 O
mental NCT03860597 788 794 B-Condition
retardation NCT03860597 795 806 I-Condition
for NCT03860597 807 810 O
all NCT03860597 811 814 O
subjects NCT03860597 815 823 O

Inclusion NCT03861689 0 9 O
Criteria NCT03861689 10 18 O
: NCT03861689 19 20 O

- NCT03861689 24 25 O
Age NCT03861689 27 30 B-Age
≥ NCT03861689 31 32 B-Eq-Comparison
18 NCT03861689 33 35 I-Eq-Comparison
years NCT03861689 36 41 I-Eq-Comparison
old NCT03861689 42 45 O

- NCT03861689 48 49 O
Confirmed NCT03861689 51 60 O
diagnosis NCT03861689 61 70 O
of NCT03861689 71 73 O
perianal NCT03861689 74 82 B-Modifier
Crohn NCT03861689 83 88 B-Condition
's NCT03861689 88 90 O
disease NCT03861689 91 98 I-Condition

- NCT03861689 101 102 O
On NCT03861689 104 106 B-Eq-Comparison
biologics NCT03861689 107 116 B-Drug
or NCT03861689 117 119 B-Or
will NCT03861689 120 124 B-Eq-Comparison
start NCT03861689 125 130 I-Eq-Comparison
biologics NCT03861689 131 140 B-Drug

Exclusion NCT03861689 141 150 O
Criteria NCT03861689 151 159 O
: NCT03861689 160 161 O

- NCT03861689 165 166 O
Patients NCT03861689 168 176 O
who NCT03861689 177 180 O
have NCT03861689 181 185 O
perianal NCT03861689 186 194 B-Condition
fistula NCT03861689 195 202 I-Condition
due NCT03861689 203 206 O
to NCT03861689 207 209 O
causes NCT03861689 210 216 B-Condition
other NCT03861689 217 222 B-Exception
than NCT03861689 223 227 I-Exception
Crohn NCT03861689 228 233 B-Condition
's NCT03861689 233 235 O
disease NCT03861689 236 243 I-Condition

- NCT03861689 246 247 O
Fistulation NCT03861689 249 260 B-Condition
into NCT03861689 261 265 O
other NCT03861689 266 271 B-Other
organs NCT03861689 272 278 B-Modifier
, NCT03861689 279 280 O
including NCT03861689 281 290 O
bladder NCT03861689 291 298 B-Modifier
and NCT03861689 299 302 B-Or
intestine NCT03861689 303 312 B-Modifier

- NCT03861689 315 316 O
Patients NCT03861689 318 326 O
who NCT03861689 327 330 O
have NCT03861689 331 335 O
allergic NCT03861689 336 344 B-Allergy
reaction NCT03861689 345 353 B-Modifier
/ NCT03861689 354 355 B-Or
contraindications NCT03861689 356 373 B-Contraindication
to NCT03861689 374 376 O
anti NCT03861689 377 381 B-Drug
- NCT03861689 382 383 I-Drug
TNF NCT03861689 384 387 I-Drug

- NCT03861689 390 391 O
Patients NCT03861689 393 401 O
who NCT03861689 402 405 O
have NCT03861689 406 410 O
active NCT03861689 411 417 B-Eq-Comparison
cancer NCT03861689 418 424 B-Condition

- NCT03861689 427 428 O
Patients NCT03861689 430 438 O
who NCT03861689 439 442 O
have NCT03861689 443 447 O
contraindications NCT03861689 448 465 B-Contraindication
for NCT03861689 466 469 O
MRI NCT03861689 470 473 B-Procedure

- NCT03861689 476 477 O
Known NCT03861689 479 484 O
pregnancy NCT03861689 485 494 B-Condition

For NCT03861689 495 498 O
patients NCT03861689 499 507 O
who NCT03861689 508 511 O
refuse NCT03861689 512 518 O
to NCT03861689 519 521 O
participate NCT03861689 522 533 O
in NCT03861689 534 536 O
the NCT03861689 537 540 O
tight NCT03861689 541 546 O
monitoring NCT03861689 547 557 O
arm NCT03861689 558 561 O
, NCT03861689 562 563 O
they NCT03861689 564 568 O
will NCT03861689 569 573 O
be NCT03861689 574 576 O
consented NCT03861689 577 586 O
and NCT03861689 587 590 O
recruited NCT03861689 591 600 O
to NCT03861689 601 603 O
the NCT03861689 604 607 O
control NCT03861689 608 615 B-Procedure
arm NCT03861689 616 619 I-Procedure
for NCT03861689 620 623 O
comparison NCT03861689 624 634 O
. NCT03861689 634 635 O


Inclusion NCT03865160 0 9 O
Criteria NCT03865160 10 18 O
: NCT03865160 19 20 O

- NCT03865160 24 25 O
Children NCT03865160 27 35 O
aged NCT03865160 36 40 B-Age
6 NCT03865160 41 42 B-Eq-Comparison
- NCT03865160 43 44 I-Eq-Comparison
11 NCT03865160 45 47 I-Eq-Comparison
years NCT03865160 48 53 I-Eq-Comparison
with NCT03865160 54 58 B-And
- NCT03865160 59 60 B-Eq-Comparison
1 NCT03865160 61 62 I-Eq-Comparison
- NCT03865160 63 64 I-Eq-Comparison
to NCT03865160 65 67 I-Eq-Comparison
- NCT03865160 68 69 O
10 NCT03865160 70 72 I-Eq-Comparison
diopters NCT03865160 73 81 I-Eq-Comparison
( NCT03865160 82 83 O
D NCT03865160 84 85 O
) NCT03865160 86 87 O
myopia NCT03865160 88 94 B-Condition|Observation

Exclusion NCT03865160 95 104 O
Criteria NCT03865160 105 113 O
: NCT03865160 114 115 O

- NCT03865160 119 120 O
Any NCT03865160 122 125 O
organic NCT03865160 126 133 B-Condition
eye NCT03865160 134 137 I-Condition
disease NCT03865160 138 145 I-Condition
, NCT03865160 146 147 O
strabismus NCT03865160 148 158 B-Condition
, NCT03865160 159 160 O
astigmatism NCT03865160 161 172 B-Condition
and NCT03865160 173 176 B-Or
/ NCT03865160 177 178 I-Or
or NCT03865160 179 181 I-Or
anisometropia NCT03865160 182 195 B-Condition|Observation
> NCT03865160 196 197 B-Eq-Comparison
1.5 NCT03865160 198 201 I-Eq-Comparison
D NCT03865160 202 203 I-Eq-Comparison
, NCT03865160 204 205 O
prematurity NCT03865160 206 217 B-Condition
, NCT03865160 218 219 O
use NCT03865160 220 223 B-Eq-Comparison
of NCT03865160 224 226 O
mono NCT03865160 227 231 B-Modifier
- NCT03865160 232 233 I-Modifier
/ NCT03865160 234 235 B-Or
multifocal NCT03865160 236 246 B-Modifier
contact NCT03865160 247 254 B-Procedure
lenses NCT03865160 255 261 I-Procedure
, NCT03865160 262 263 O
pre NCT03865160 264 267 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03865160 268 269 O
treatment NCT03865160 270 279 B-Procedure
with NCT03865160 280 284 O
atropine NCT03865160 285 293 B-Drug

Inclusion NCT03861312 0 9 O
Criteria NCT03861312 10 18 O
: NCT03861312 19 20 O

- NCT03861312 24 25 O
The NCT03861312 27 30 O
inclusion NCT03861312 31 40 O
criteria NCT03861312 41 49 O
were NCT03861312 50 54 O
as NCT03861312 55 57 O
follows NCT03861312 58 65 O
: NCT03861312 66 67 O
a NCT03861312 68 69 O
) NCT03861312 70 71 O
men NCT03861312 72 75 O
and NCT03861312 76 79 B-Or
women NCT03861312 80 85 O
aged NCT03861312 86 90 B-Age
between NCT03861312 91 98 B-Eq-Comparison
18 NCT03861312 99 101 I-Eq-Comparison
- NCT03861312 102 103 I-Eq-Comparison
and NCT03861312 104 107 I-Eq-Comparison
65 NCT03861312 108 110 I-Eq-Comparison
- NCT03861312 111 112 O
years NCT03861312 113 118 I-Eq-Comparison
b NCT03861312 119 120 O
) NCT03861312 121 122 O
medical NCT03861312 123 130 O
diagnosis NCT03861312 131 140 O
of NCT03861312 141 143 O
Non NCT03861312 144 147 B-Modifier
- NCT03861312 148 149 I-Modifier
Specific NCT03861312 150 158 I-Modifier
Chronic NCT03861312 159 166 B-Modifier
Neck NCT03861312 167 171 I-Modifier
Pain NCT03861312 172 176 B-Condition
with NCT03861312 177 181 B-And
more NCT03861312 182 186 B-Eq-Comparison
than NCT03861312 187 191 I-Eq-Comparison
6 NCT03861312 192 193 I-Eq-Comparison
months NCT03861312 194 200 I-Eq-Comparison
of NCT03861312 201 203 O
evolution NCT03861312 204 213 O
of NCT03861312 214 216 O
neck NCT03861312 217 221 B-Modifier
pain NCT03861312 222 226 B-Condition
. NCT03861312 226 227 O

Exclusion NCT03861312 229 238 O
Criteria NCT03861312 239 247 O
: NCT03861312 248 249 O

- NCT03861312 253 254 O
Exclusion NCT03861312 256 265 O
criteria NCT03861312 266 274 O
included NCT03861312 275 283 O
the NCT03861312 284 287 O
following NCT03861312 288 297 O
: NCT03861312 298 299 O
a NCT03861312 300 301 O
) NCT03861312 302 303 O
patients NCT03861312 304 312 O
with NCT03861312 313 317 O
rheumatic NCT03861312 318 327 B-Condition
diseases NCT03861312 328 336 I-Condition
, NCT03861312 337 338 O
cervical NCT03861312 339 347 B-Condition
hernia NCT03861312 348 354 I-Condition
, NCT03861312 355 356 O
cervical NCT03861312 357 365 B-Condition
whiplash NCT03861312 366 374 I-Condition
syndrome NCT03861312 375 383 I-Condition
, NCT03861312 384 385 O
neck NCT03861312 386 390 B-Modifier
surgeries NCT03861312 391 400 B-Procedure
or NCT03861312 401 403 B-Or
history NCT03861312 404 411 B-Eq-Comparison
of NCT03861312 412 414 O
arthrodesis NCT03861312 415 426 B-Procedure
, NCT03861312 427 428 O
b NCT03861312 429 430 O
) NCT03861312 431 432 O
systemic NCT03861312 433 441 B-Modifier
diseases NCT03861312 442 450 B-Condition
, NCT03861312 451 452 O
c NCT03861312 453 454 O
) NCT03861312 455 456 O
vision NCT03861312 457 463 B-Modifier
, NCT03861312 464 465 O
hearing NCT03861312 466 473 B-Modifier
or NCT03861312 474 476 B-Or
vestibular NCT03861312 477 487 B-Modifier
problems NCT03861312 488 496 B-Condition
, NCT03861312 497 498 O
d NCT03861312 499 500 O
) NCT03861312 501 502 O
Severe NCT03861312 503 509 O
trauma NCT03861312 510 516 B-Condition
or NCT03861312 517 519 B-Or
traffic NCT03861312 520 527 B-Condition
accident NCT03861312 528 536 I-Condition
which NCT03861312 537 542 O
has NCT03861312 543 546 O
had NCT03861312 547 550 O
an NCT03861312 551 553 O
impact NCT03861312 554 560 O
on NCT03861312 561 563 O
the NCT03861312 564 567 O
cervical NCT03861312 568 576 B-Modifier
area NCT03861312 577 581 I-Modifier
. NCT03861312 581 582 O

Inclusion NCT03869996 0 9 O
Criteria NCT03869996 10 18 O
: NCT03869996 19 20 O

- NCT03869996 24 25 O
patients NCT03869996 27 35 O
affected NCT03869996 36 44 O
by NCT03869996 45 47 O
knee NCT03869996 48 52 B-Modifier
osteoarthritis NCT03869996 53 67 B-Condition
, NCT03869996 68 69 O
eligible NCT03869996 70 78 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869996 79 82 I-Assertion___Assertion-Type-Value:hypothetical
primary NCT03869996 83 90 B-Modifier
total NCT03869996 91 96 B-Procedure
knee NCT03869996 97 101 I-Procedure
arthroplasty NCT03869996 102 114 I-Procedure

- NCT03869996 117 118 O
BMI NCT03869996 120 123 B-Observation
< NCT03869996 124 125 B-Eq-Comparison
32 NCT03869996 126 128 I-Eq-Comparison

- NCT03869996 132 133 O
Time NCT03869996 135 139 B-Observation
up NCT03869996 140 142 I-Observation
ang NCT03869996 143 146 I-Observation
go NCT03869996 147 149 I-Observation
test NCT03869996 150 154 I-Observation
< NCT03869996 155 156 B-Eq-Comparison
/ NCT03869996 158 159 I-Eq-Comparison
= NCT03869996 161 162 I-Eq-Comparison
12 NCT03869996 163 165 I-Eq-Comparison
seconds NCT03869996 166 173 I-Eq-Comparison

- NCT03869996 176 177 O
American NCT03869996 179 187 B-Condition
Society NCT03869996 188 195 I-Condition
of NCT03869996 196 198 I-Condition
Anesthesiologists NCT03869996 199 216 I-Condition
physical NCT03869996 217 225 O
status NCT03869996 226 232 O
classification NCT03869996 233 247 O
system NCT03869996 248 254 O
( NCT03869996 255 256 O
ASA NCT03869996 257 260 B-Condition
) NCT03869996 261 262 O
< NCT03869996 263 264 B-Eq-Comparison
/ NCT03869996 266 267 I-Eq-Comparison
= NCT03869996 269 270 I-Eq-Comparison
2 NCT03869996 271 272 I-Eq-Comparison

- NCT03869996 276 277 O
pre NCT03869996 279 282 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03869996 283 284 O
- NCT03869996 286 287 O
operative NCT03869996 288 297 B-Procedure
hemoglobin NCT03869996 298 308 B-Observation
( NCT03869996 309 310 O
HB NCT03869996 311 313 B-Observation
) NCT03869996 314 315 O
> NCT03869996 316 317 B-Eq-Comparison
13 NCT03869996 318 320 I-Eq-Comparison
g NCT03869996 321 322 I-Eq-Comparison
/ NCT03869996 323 324 I-Eq-Comparison
dl NCT03869996 325 327 I-Eq-Comparison

- NCT03869996 330 331 O
patients NCT03869996 333 341 O
eligible NCT03869996 342 350 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869996 351 354 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03869996 355 361 B-Procedure
anesthesia NCT03869996 362 372 I-Procedure

- NCT03869996 375 376 O
presence NCT03869996 378 386 O
of NCT03869996 387 389 O
a NCT03869996 390 391 O
care NCT03869996 392 396 O
- NCT03869996 397 398 O
giver NCT03869996 399 404 O

Exclusion NCT03869996 405 414 O
Criteria NCT03869996 415 423 O
: NCT03869996 424 425 O

- NCT03869996 429 430 O
psychiatric NCT03869996 432 443 B-Condition
diseases NCT03869996 444 452 I-Condition

- NCT03869996 455 456 O
pre NCT03869996 458 461 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03869996 462 463 O
- NCT03869996 465 466 O
operative NCT03869996 467 476 B-Procedure
use NCT03869996 477 480 O
of NCT03869996 481 483 O
crutches NCT03869996 484 492 B-Procedure

- NCT03869996 495 496 O
ASA NCT03869996 498 501 B-Condition
> NCT03869996 502 503 B-Eq-Comparison
3 NCT03869996 504 505 I-Eq-Comparison

- NCT03869996 509 510 O
pre NCT03869996 512 515 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03869996 516 517 O
- NCT03869996 519 520 O
operative NCT03869996 521 530 B-Procedure
HB NCT03869996 531 533 B-Observation
< NCT03869996 534 535 B-Eq-Comparison
13 NCT03869996 536 538 I-Eq-Comparison
g NCT03869996 539 540 I-Eq-Comparison
/ NCT03869996 541 542 I-Eq-Comparison
dl NCT03869996 543 545 I-Eq-Comparison

Inclusion NCT03864874 0 9 O
Criteria NCT03864874 10 18 O
: NCT03864874 19 20 O

- NCT03864874 24 25 O
Patient NCT03864874 27 34 O
candidate NCT03864874 35 44 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864874 45 47 I-Assertion___Assertion-Type-Value:hypothetical
pulmonary NCT03864874 48 57 B-Procedure
metastasectomy NCT03864874 58 72 I-Procedure
with NCT03864874 73 77 O
curative NCT03864874 78 86 B-Modifier
intent NCT03864874 87 93 I-Modifier
by NCT03864874 94 96 O
mean NCT03864874 97 101 O
of NCT03864874 102 104 O
both NCT03864874 105 109 O
major NCT03864874 110 115 O
anatomical NCT03864874 116 126 B-Modifier
or NCT03864874 127 129 B-Or
limited NCT03864874 130 137 B-Modifier
resection NCT03864874 138 147 B-Procedure
; NCT03864874 147 148 O

- NCT03864874 151 152 O
Age NCT03864874 154 157 B-Age
> NCT03864874 158 159 B-Eq-Comparison
18 NCT03864874 160 162 I-Eq-Comparison
years NCT03864874 163 168 I-Eq-Comparison
. NCT03864874 168 169 O

Exclusion NCT03864874 171 180 O
Criteria NCT03864874 181 189 O
: NCT03864874 190 191 O

- NCT03864874 195 196 O
Patients NCT03864874 198 206 O
with NCT03864874 207 211 O
widespread NCT03864874 212 222 O
metastatic NCT03864874 223 233 B-Condition
disease NCT03864874 234 241 I-Condition
where NCT03864874 242 247 O
surgical NCT03864874 248 256 B-Procedure
resection NCT03864874 257 266 I-Procedure
is NCT03864874 267 269 B-Assertion___Assertion-Type-Value:hypothetical
performed NCT03864874 270 279 I-Assertion___Assertion-Type-Value:hypothetical
only NCT03864874 280 284 O
for NCT03864874 285 288 O
diagnostic NCT03864874 289 299 O
purposes NCT03864874 300 308 O
; NCT03864874 308 309 O

- NCT03864874 312 313 O
History NCT03864874 315 322 B-Eq-Comparison
of NCT03864874 323 325 I-Eq-Comparison
previous NCT03864874 326 334 I-Eq-Comparison
intrapleural NCT03864874 335 347 B-Procedure
talc NCT03864874 348 352 I-Procedure
injection NCT03864874 353 362 I-Procedure
; NCT03864874 362 363 O

- NCT03864874 366 367 O
Any NCT03864874 369 372 O
anatomical NCT03864874 373 383 B-Modifier
or NCT03864874 384 386 B-Or
pathological NCT03864874 387 399 B-Modifier
condition NCT03864874 400 409 B-Condition
( NCT03864874 410 411 O
eg NCT03864874 412 414 O
. NCT03864874 414 415 O
diffuse NCT03864874 417 424 B-Condition
adhesions NCT03864874 425 434 I-Condition
, NCT03864874 435 436 O
severe NCT03864874 437 443 O
emphysema NCT03864874 444 453 B-Condition
) NCT03864874 454 455 O
that NCT03864874 456 460 O
may NCT03864874 461 464 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864874 465 474 O
with NCT03864874 475 479 O
execution NCT03864874 480 489 O
of NCT03864874 490 492 O
ultrasonographic NCT03864874 493 509 B-Procedure
investigation NCT03864874 510 523 I-Procedure
; NCT03864874 523 524 O

- NCT03864874 527 528 O
Incomplete NCT03864874 530 540 B-Modifier
lung NCT03864874 541 545 B-Condition
exclusion NCT03864874 546 555 I-Condition
during NCT03864874 556 562 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgical NCT03864874 563 571 B-Procedure
procedure NCT03864874 572 581 I-Procedure
. NCT03864874 581 582 O

Inclusion NCT03869411 0 9 O
Criteria NCT03869411 10 18 O
: NCT03869411 19 20 O

- NCT03869411 24 25 O
Diabetes NCT03869411 27 35 O
group NCT03869411 36 41 O
: NCT03869411 42 43 O
1 NCT03869411 44 45 O
) NCT03869411 46 47 O
Age NCT03869411 48 51 B-Age
between NCT03869411 52 59 B-Eq-Comparison
30 NCT03869411 60 62 I-Eq-Comparison
- NCT03869411 63 64 I-Eq-Comparison
70 NCT03869411 65 67 I-Eq-Comparison
years NCT03869411 68 73 I-Eq-Comparison
of NCT03869411 74 76 O
old NCT03869411 77 80 O
, NCT03869411 81 82 O
2 NCT03869411 83 84 I-Modifier
) NCT03869411 85 86 O
type NCT03869411 87 91 B-Modifier
2 NCT03869411 92 93 O
diabetes NCT03869411 94 102 B-Condition
. NCT03869411 102 103 O

- NCT03869411 107 108 O
Healthy NCT03869411 110 117 B-Condition
control NCT03869411 118 125 O
group NCT03869411 126 131 O
: NCT03869411 132 133 O
1 NCT03869411 134 135 O
) NCT03869411 136 137 O
Age NCT03869411 138 141 B-Age
between NCT03869411 142 149 B-Eq-Comparison
30 NCT03869411 150 152 I-Eq-Comparison
- NCT03869411 153 154 I-Eq-Comparison
70 NCT03869411 155 157 I-Eq-Comparison
years NCT03869411 158 163 I-Eq-Comparison
of NCT03869411 164 166 O
old NCT03869411 167 170 O
, NCT03869411 171 172 O
2 NCT03869411 173 174 O
) NCT03869411 175 176 O
without NCT03869411 177 184 B-Negation
diabetes NCT03869411 185 193 B-Condition

Exclusion NCT03869411 194 203 O
Criteria NCT03869411 204 212 O
: NCT03869411 213 214 O

- NCT03869411 218 219 O
history NCT03869411 221 228 B-Eq-Comparison
of NCT03869411 229 231 O
moderate NCT03869411 232 240 B-Eq-Comparison
- NCT03869411 241 242 I-Eq-Comparison
severe NCT03869411 243 249 I-Eq-Comparison
somatic NCT03869411 250 257 B-Modifier
or NCT03869411 258 260 B-Or
autonomic NCT03869411 261 270 B-Modifier
neuropathy NCT03869411 271 281 B-Condition
, NCT03869411 282 283 O
cardiovascular NCT03869411 284 298 B-Condition
disease NCT03869411 299 306 I-Condition
, NCT03869411 307 308 O
preproliferative NCT03869411 309 325 B-Modifier
or NCT03869411 326 328 B-Or
proliferative NCT03869411 329 342 B-Modifier
retinopathy NCT03869411 343 354 B-Condition
, NCT03869411 355 356 O
and NCT03869411 357 360 B-Or
chronic NCT03869411 361 368 B-Modifier
renal NCT03869411 369 374 B-Condition
failure NCT03869411 375 382 I-Condition

- NCT03869411 385 386 O
unable NCT03869411 388 394 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869411 395 397 O
perform NCT03869411 398 405 O
the NCT03869411 406 409 O
programs NCT03869411 410 418 B-Procedure
or NCT03869411 419 421 B-Or
assessments NCT03869411 422 433 B-Procedure

- NCT03869411 436 437 O
other NCT03869411 439 444 B-Other
systematic NCT03869411 445 455 B-Modifier
diseases NCT03869411 456 464 B-Condition

1 NCT03866044 0 1 O
. NCT03866044 1 2 O
Parkinson NCT03866044 4 13 B-Condition
's NCT03866044 13 15 O
Disease NCT03866044 16 23 I-Condition
( NCT03866044 24 25 O
PD NCT03866044 26 28 B-Condition
) NCT03866044 29 30 O
group NCT03866044 31 36 O
Inclusion NCT03866044 37 46 O
criteria NCT03866044 47 55 O
: NCT03866044 56 57 O

- NCT03866044 66 67 O
Aged NCT03866044 69 73 B-Age
18 NCT03866044 74 76 B-Eq-Comparison
or NCT03866044 77 79 I-Eq-Comparison
more NCT03866044 80 84 I-Eq-Comparison
. NCT03866044 84 85 O

- NCT03866044 94 95 O
Clinically NCT03866044 97 107 O
established NCT03866044 108 119 B-Modifier
or NCT03866044 120 122 B-Or
probable NCT03866044 123 131 B-Assertion___Assertion-Type-Value:possible
PD NCT03866044 132 134 B-Condition
according NCT03866044 135 144 O
to NCT03866044 145 147 O
the NCT03866044 148 151 O
Movement NCT03866044 152 160 O
Disorder NCT03866044 161 169 O
Society NCT03866044 170 177 O
Clinical NCT03866044 178 186 O
Diagnostic NCT03866044 187 197 O
Criteria NCT03866044 198 206 O
for NCT03866044 207 210 O
Parkinson NCT03866044 211 220 O
's NCT03866044 220 222 O
Disease NCT03866044 223 230 O

- NCT03866044 238 239 O
Signed NCT03866044 241 247 O
informed NCT03866044 248 256 O
consent NCT03866044 257 264 O
Exclusion NCT03866044 265 274 O
criteria NCT03866044 275 283 O
: NCT03866044 284 285 O

- NCT03866044 294 295 O
Pregnancy NCT03866044 297 306 B-Condition
or NCT03866044 307 309 B-Or
breastfeeding NCT03866044 310 323 B-Condition

- NCT03866044 331 332 O
History NCT03866044 334 341 B-Eq-Comparison
of NCT03866044 342 344 O
other NCT03866044 345 350 B-Other
neurologic NCT03866044 351 361 B-Modifier
or NCT03866044 362 364 B-Or
psychiatric NCT03866044 365 376 B-Modifier
disease NCT03866044 377 384 B-Condition

- NCT03866044 392 393 O
Pacemaker NCT03866044 395 404 B-Procedure
or NCT03866044 405 407 B-Or
other NCT03866044 408 413 B-Other
implanted NCT03866044 414 423 B-Procedure
electronic NCT03866044 424 434 I-Procedure
devices NCT03866044 435 442 I-Procedure

- NCT03866044 450 451 O
Claustrophobia NCT03866044 453 467 B-Condition

2 NCT03866044 470 471 O
. NCT03866044 471 472 O
Healthy NCT03866044 474 481 B-Condition
participants NCT03866044 482 494 O
age NCT03866044 495 498 O
- NCT03866044 499 500 O
and NCT03866044 501 504 O
sex NCT03866044 505 508 O
- NCT03866044 509 510 O
matched NCT03866044 511 518 O
to NCT03866044 519 521 O
the NCT03866044 522 525 O
PD NCT03866044 526 528 B-Condition
group NCT03866044 529 534 O
: NCT03866044 535 536 O

Inclusion NCT03866044 538 547 O
criteria NCT03866044 548 556 O
: NCT03866044 557 558 O

- NCT03866044 562 563 O
Age NCT03866044 565 568 O
- NCT03866044 569 570 O
and NCT03866044 571 574 O
sex NCT03866044 575 578 O
- NCT03866044 579 580 O
matched NCT03866044 581 588 O
to NCT03866044 589 591 O
PD NCT03866044 592 594 B-Condition
group NCT03866044 595 600 O
( NCT03866044 601 602 O
aged NCT03866044 603 607 B-Age
18 NCT03866044 608 610 B-Eq-Comparison
or NCT03866044 611 613 I-Eq-Comparison
more NCT03866044 614 618 I-Eq-Comparison
) NCT03866044 619 620 O

- NCT03866044 624 625 O
Signed NCT03866044 627 633 O
informed NCT03866044 634 642 O
consent NCT03866044 643 650 O

Exclusion NCT03866044 651 660 O
criteria NCT03866044 661 669 O
: NCT03866044 670 671 O

- NCT03866044 675 676 O
Pregnancy NCT03866044 678 687 B-Condition
or NCT03866044 688 690 B-Or
breastfeeding NCT03866044 691 704 B-Condition

- NCT03866044 707 708 O
History NCT03866044 710 717 B-Eq-Comparison
of NCT03866044 718 720 O
neurologic NCT03866044 721 731 B-Modifier
or NCT03866044 732 734 B-Or
psychiatric NCT03866044 735 746 B-Modifier
disease NCT03866044 747 754 B-Condition

- NCT03866044 757 758 O
Pacemaker NCT03866044 760 769 B-Procedure
or NCT03866044 770 772 B-Or
other NCT03866044 773 778 B-Other
implanted NCT03866044 779 788 B-Procedure
electronic NCT03866044 789 799 I-Procedure
devices NCT03866044 800 807 I-Procedure

- NCT03866044 810 811 O
Claustrophobia NCT03866044 813 827 B-Condition

Inclusion NCT03864653 0 9 O
Criteria NCT03864653 10 18 O
: NCT03864653 19 20 O

- NCT03864653 24 25 O
Currently NCT03864653 27 36 B-Eq-Comparison
enrolled NCT03864653 37 45 O
within NCT03864653 46 52 O
the NCT03864653 53 56 O
" NCT03864653 57 58 O
Getting NCT03864653 58 65 O
Off NCT03864653 66 69 O
" NCT03864653 69 70 O
( NCT03864653 71 72 O
AKA NCT03864653 73 76 O
, NCT03864653 77 78 O
" NCT03864653 79 80 O
Friends NCT03864653 80 87 O
Getting NCT03864653 88 95 O
Off NCT03864653 96 99 O
" NCT03864653 99 100 O
) NCT03864653 101 102 O
outpatient NCT03864653 103 113 B-Encounter
methamphetamine NCT03864653 114 129 B-Drug
treatment NCT03864653 130 139 B-Procedure
program NCT03864653 140 147 I-Procedure
at NCT03864653 148 150 O
Friends NCT03864653 151 158 O
Community NCT03864653 159 168 O
Center NCT03864653 169 175 O
, NCT03864653 176 177 O
Los NCT03864653 178 181 O
Angeles NCT03864653 182 189 O
, NCT03864653 190 191 O
CA NCT03864653 192 194 O
, NCT03864653 195 196 O
USA NCT03864653 197 200 O
. NCT03864653 200 201 O

- NCT03864653 205 206 O
and NCT03864653 208 211 B-And
; NCT03864653 211 212 O
within NCT03864653 213 219 B-Eq-Comparison
two NCT03864653 220 223 I-Eq-Comparison
weeks NCT03864653 224 229 I-Eq-Comparison
of NCT03864653 230 232 B-Temporal-Connection___Temporal-Connection-Type-Value:before
initial NCT03864653 233 240 B-Eq-Comparison
enrollment NCT03864653 241 251 B-Study
into NCT03864653 252 256 O
the NCT03864653 257 260 O
" NCT03864653 261 262 O
Getting NCT03864653 262 269 O
Off NCT03864653 270 273 O
" NCT03864653 273 274 O
program NCT03864653 275 282 B-Procedure
. NCT03864653 282 283 O

Exclusion NCT03864653 285 294 O
Criteria NCT03864653 295 303 O
: NCT03864653 304 305 O

- NCT03864653 309 310 O
Not NCT03864653 312 315 B-Negation
currently NCT03864653 316 325 B-Eq-Comparison
enrolled NCT03864653 326 334 B-Study
within NCT03864653 335 341 O
the NCT03864653 342 345 O
" NCT03864653 346 347 O
Getting NCT03864653 347 354 O
Off NCT03864653 355 358 O
" NCT03864653 358 359 O
program NCT03864653 360 367 B-Procedure
. NCT03864653 367 368 O

- NCT03864653 372 373 O
or NCT03864653 375 377 B-Or
; NCT03864653 377 378 O
more NCT03864653 379 383 B-Eq-Comparison
than NCT03864653 384 388 I-Eq-Comparison
two NCT03864653 389 392 I-Eq-Comparison
weeks NCT03864653 393 398 I-Eq-Comparison
post NCT03864653 399 403 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864653 404 405 O
enrollment NCT03864653 406 416 B-Study
in NCT03864653 417 419 O
the NCT03864653 420 423 O
" NCT03864653 424 425 O
Getting NCT03864653 425 432 O
Off NCT03864653 433 436 O
" NCT03864653 436 437 O
program NCT03864653 438 445 B-Procedure
. NCT03864653 445 446 O

Inclusion NCT03861065 0 9 O
Criteria NCT03861065 10 18 O
: NCT03861065 19 20 O

- NCT03861065 24 25 O
Patients NCT03861065 27 35 O
with NCT03861065 36 40 O
high NCT03861065 41 45 O
risk NCT03861065 46 50 B-Risk
class NCT03861065 51 56 B-Eq-Comparison
II NCT03861065 57 59 I-Eq-Comparison
, NCT03861065 60 61 O
class NCT03861065 62 67 I-Eq-Comparison
III NCT03861065 68 71 I-Eq-Comparison
, NCT03861065 72 73 O
class NCT03861065 74 79 B-Eq-Comparison
IV NCT03861065 80 82 I-Eq-Comparison
abdominal NCT03861065 83 92 B-Modifier
wounds NCT03861065 93 99 B-Condition

- NCT03861065 102 103 O
Undergoing NCT03861065 105 115 B-Eq-Comparison
laparotomy NCT03861065 116 126 B-Procedure
for NCT03861065 127 130 O
gynecologic NCT03861065 131 142 B-Condition
related NCT03861065 143 150 I-Condition
disorders NCT03861065 151 160 I-Condition

- NCT03861065 163 164 O
Patients NCT03861065 166 174 O
undergoing NCT03861065 175 185 B-Eq-Comparison
laparotomy NCT03861065 186 196 B-Procedure
for NCT03861065 197 200 O
both NCT03861065 201 205 O
benign NCT03861065 206 212 B-Modifier
and NCT03861065 213 216 B-Or
malignant NCT03861065 217 226 B-Modifier
diagnoses NCT03861065 227 236 B-Condition
will NCT03861065 237 241 O
be NCT03861065 242 244 O
included NCT03861065 245 253 O
in NCT03861065 254 256 O
this NCT03861065 257 261 O
study NCT03861065 262 267 B-Study

Exclusion NCT03861065 268 277 O
Criteria NCT03861065 278 286 O
: NCT03861065 287 288 O

- NCT03861065 292 293 O
Pregnancy NCT03861065 295 304 B-Condition

- NCT03861065 307 308 O
Allergy NCT03861065 310 317 B-Allergy
to NCT03861065 318 320 O
triclosan NCT03861065 321 330 B-Drug

- NCT03861065 333 334 O
Patients NCT03861065 336 344 O
undergoing NCT03861065 345 355 B-Eq-Comparison
HIPEC NCT03861065 356 361 B-Procedure

Inclusion NCT03866291 0 9 O
Criteria NCT03866291 10 18 O
: NCT03866291 19 20 O

- NCT03866291 24 25 O
Travellers NCT03866291 27 37 B-Modifier
diarrhoea NCT03866291 38 47 B-Condition

- NCT03866291 50 51 O
foreign NCT03866291 53 60 O
traveller NCT03866291 61 70 O

Exclusion NCT03866291 71 80 O
Criteria NCT03866291 81 89 O
: NCT03866291 90 91 O

- NCT03866291 95 96 O
foreign NCT03866291 98 105 O
traveller NCT03866291 106 115 O
but NCT03866291 116 119 B-And
no NCT03866291 120 122 B-Negation
symptoms NCT03866291 123 131 B-Coreference

Inclusion NCT03867825 0 9 O
Criteria NCT03867825 10 18 O
: NCT03867825 19 20 O

- NCT03867825 24 25 O
Newborn NCT03867825 27 34 O
infants NCT03867825 35 42 O

Exclusion NCT03867825 43 52 O
Criteria NCT03867825 53 61 O
: NCT03867825 62 63 O

- NCT03867825 67 68 O
Infants NCT03867825 70 77 O
> NCT03867825 78 79 B-Eq-Comparison
1 NCT03867825 80 81 I-Eq-Comparison
month NCT03867825 82 87 I-Eq-Comparison
of NCT03867825 88 90 O
age NCT03867825 91 94 B-Age

Inclusion NCT03868280 0 9 O
Criteria NCT03868280 10 18 O
: NCT03868280 19 20 O

- NCT03868280 24 25 O
Mid NCT03868280 27 30 B-Modifier
shaft NCT03868280 31 36 I-Modifier
or NCT03868280 37 39 B-Or
subtrochanteric NCT03868280 40 55 B-Modifier
femur NCT03868280 56 61 I-Modifier
fracture NCT03868280 62 70 B-Condition
appropriate NCT03868280 71 82 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868280 83 86 O
antegrade NCT03868280 87 96 B-Procedure
fixation NCT03868280 97 105 I-Procedure

- NCT03868280 108 109 O
Surgeon NCT03868280 111 118 B-Provider
agreement NCT03868280 119 128 O
for NCT03868280 129 132 O
participation NCT03868280 133 146 O
in NCT03868280 147 149 O
study NCT03868280 150 155 B-Study

- NCT03868280 158 159 O
Ability NCT03868280 161 168 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868280 169 171 I-Assertion___Assertion-Type-Value:hypothetical
obtain NCT03868280 172 178 O
peri NCT03868280 179 183 B-Procedure
- NCT03868280 184 185 O
- NCT03868280 187 188 O
operative NCT03868280 189 198 O
imaging NCT03868280 199 206 I-Procedure
( NCT03868280 207 208 O
CT NCT03868280 209 211 B-Procedure
scans NCT03868280 212 217 I-Procedure
) NCT03868280 218 219 O

- NCT03868280 223 224 O
Provision NCT03868280 226 235 O
of NCT03868280 236 238 O
informed NCT03868280 239 247 O
consent NCT03868280 248 255 O

Exclusion NCT03868280 256 265 O
Criteria NCT03868280 266 274 O
: NCT03868280 275 276 O

- NCT03868280 280 281 O
Inability NCT03868280 283 292 O
to NCT03868280 293 295 O
provide NCT03868280 296 303 O
informed NCT03868280 304 312 O
consent NCT03868280 313 320 O
( NCT03868280 321 322 O
e. NCT03868280 323 325 O
g. NCT03868280 326 328 O
cognitive NCT03868280 330 339 B-Condition
disability NCT03868280 340 350 I-Condition
, NCT03868280 351 352 O
language NCT03868280 353 361 B-Condition
barrier NCT03868280 362 369 I-Condition
) NCT03868280 370 371 O

- NCT03868280 375 376 O
Bilateral NCT03868280 378 387 B-Modifier
Femoral NCT03868280 388 395 I-Modifier
Fractures NCT03868280 396 405 B-Condition

- NCT03868280 408 409 O
Inability NCT03868280 411 420 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868280 421 423 B-Or
lack NCT03868280 424 428 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03868280 429 431 I-Assertion___Assertion-Type-Value:hypothetical|Negation
willingness NCT03868280 432 443 I-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868280 444 446 O
attend NCT03868280 447 453 O
follow NCT03868280 454 460 B-Encounter
up NCT03868280 461 463 I-Encounter

- NCT03868280 466 467 O
Ipsilateral NCT03868280 469 480 B-Modifier
tibial NCT03868280 481 487 B-Condition
fracture NCT03868280 488 496 I-Condition

- NCT03868280 499 500 O
Ipsilateral NCT03868280 502 513 B-Modifier
femoral NCT03868280 514 521 I-Modifier
neck NCT03868280 522 526 I-Modifier
fracture NCT03868280 527 535 B-Condition

- NCT03868280 538 539 O
Ipsilateral NCT03868280 541 552 B-Modifier
acetabular NCT03868280 553 563 I-Modifier
fracture NCT03868280 564 572 B-Condition

- NCT03868280 575 576 O
Pregnant NCT03868280 578 586 B-Condition
or NCT03868280 587 589 B-Or
breastfeeding NCT03868280 590 603 B-Condition

- NCT03868280 606 607 O
Contraindications NCT03868280 609 626 B-Contraindication
to NCT03868280 627 629 O
CT NCT03868280 630 632 B-Procedure
imaging NCT03868280 633 640 I-Procedure
including NCT03868280 641 650 O
impaired NCT03868280 651 659 B-Condition
kidney NCT03868280 660 666 I-Condition
/ NCT03868280 667 668 B-Or
liver NCT03868280 669 674 B-Condition
function NCT03868280 675 683 I-Condition
, NCT03868280 684 685 O
or NCT03868280 686 688 B-Or
lack NCT03868280 689 693 O
of NCT03868280 694 696 O
timely NCT03868280 697 703 O
availability NCT03868280 704 716 O

- NCT03868280 719 720 O
Periprosthetic NCT03868280 722 736 B-Modifier
fracture NCT03868280 737 745 B-Condition

- NCT03868280 748 749 O
Pathologic NCT03868280 751 761 B-Modifier
fracture NCT03868280 762 770 B-Condition

- NCT03868280 773 774 O
Significant NCT03868280 776 787 O
delirium NCT03868280 788 796 B-Condition
or NCT03868280 797 799 B-Or
dementia NCT03868280 800 808 B-Condition

Inclusion NCT03860623 0 9 O
Criteria NCT03860623 10 18 O
: NCT03860623 19 20 O

- NCT03860623 24 25 O
BMI NCT03860623 27 30 B-Observation
30 NCT03860623 31 33 B-Eq-Comparison
- NCT03860623 34 35 I-Eq-Comparison
40 NCT03860623 36 38 I-Eq-Comparison
kg NCT03860623 39 41 I-Eq-Comparison
/ NCT03860623 42 43 I-Eq-Comparison
m2 NCT03860623 44 46 I-Eq-Comparison

- NCT03860623 49 50 O
BMI NCT03860623 52 55 B-Observation
18 NCT03860623 56 58 B-Eq-Comparison
- NCT03860623 59 60 I-Eq-Comparison
25 NCT03860623 61 63 I-Eq-Comparison
kg NCT03860623 64 66 I-Eq-Comparison
/ NCT03860623 67 68 I-Eq-Comparison
m2 NCT03860623 69 71 I-Eq-Comparison
; NCT03860623 71 72 O
those NCT03860623 73 78 O
with NCT03860623 79 83 O
BMI NCT03860623 84 87 B-Observation
up NCT03860623 88 90 B-Eq-Comparison
to NCT03860623 91 93 I-Eq-Comparison
28 NCT03860623 94 96 I-Eq-Comparison
kg NCT03860623 97 99 O
/ NCT03860623 100 101 I-Eq-Comparison
m2 NCT03860623 102 104 I-Eq-Comparison
will NCT03860623 105 109 O
be NCT03860623 110 112 O
included NCT03860623 113 121 O
if NCT03860623 122 124 O
waist NCT03860623 125 130 B-Observation
circumference NCT03860623 131 144 I-Observation
is NCT03860623 145 147 O
< NCT03860623 148 149 B-Eq-Comparison
96 NCT03860623 150 152 I-Eq-Comparison
cm NCT03860623 153 155 O
. NCT03860623 155 156 O

- NCT03860623 160 161 O
Males NCT03860623 163 168 O

- NCT03860623 171 172 I-Eq-Comparison
Aged NCT03860623 174 178 B-Age
18 NCT03860623 179 181 B-Eq-Comparison
- NCT03860623 182 183 O
60 NCT03860623 184 186 I-Eq-Comparison
yrs NCT03860623 187 190 O

Exclusion NCT03860623 191 200 O
Criteria NCT03860623 201 209 O
: NCT03860623 210 211 O

- NCT03860623 215 216 O
Acute NCT03860623 218 223 O
illness NCT03860623 224 231 B-Condition
in NCT03860623 232 234 O
the NCT03860623 235 238 O
preceding NCT03860623 239 248 B-Eq-Comparison
6 NCT03860623 249 250 I-Eq-Comparison
weeks NCT03860623 251 256 I-Eq-Comparison

- NCT03860623 259 260 O
Taking NCT03860623 262 268 B-Eq-Comparison
regular NCT03860623 269 276 O
medication NCT03860623 277 287 B-Drug

- NCT03860623 290 291 O
History NCT03860623 293 300 B-Eq-Comparison
of NCT03860623 301 303 O
deep NCT03860623 304 308 B-Condition
vein NCT03860623 309 313 I-Condition
thrombosis NCT03860623 314 324 I-Condition
or NCT03860623 325 327 B-Or
clotting NCT03860623 328 336 B-Condition
disorders NCT03860623 337 346 I-Condition

- NCT03860623 349 350 O
Hypertension NCT03860623 352 364 B-Condition

- NCT03860623 367 368 O
Diabetes NCT03860623 370 378 B-Condition

- NCT03860623 381 382 O
Any NCT03860623 384 387 O
clinically NCT03860623 388 398 O
significant NCT03860623 399 410 O
findings NCT03860623 411 419 B-Condition
at NCT03860623 420 422 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03860623 423 432 B-Study

- NCT03860623 435 436 O
History NCT03860623 438 445 B-Eq-Comparison
of NCT03860623 446 448 O
substance NCT03860623 449 458 B-Condition
abuse NCT03860623 459 464 I-Condition

- NCT03860623 467 468 O
Demonstrating NCT03860623 470 483 O
factors NCT03860623 484 491 B-Condition
precluding NCT03860623 492 502 B-Contraindication
safe NCT03860623 503 507 O
MRI NCT03860623 508 511 B-Procedure

- NCT03860623 514 515 O
History NCT03860623 517 524 B-Eq-Comparison
of NCT03860623 525 527 O
gastrointestinal NCT03860623 528 544 B-Condition
motility NCT03860623 545 553 I-Condition
disorders NCT03860623 554 563 I-Condition
( NCT03860623 564 565 O
e. NCT03860623 566 568 O
g. NCT03860623 569 571 O
gastroesophageal NCT03860623 573 589 B-Condition
reflux NCT03860623 590 596 I-Condition
disease NCT03860623 597 604 I-Condition
- NCT03860623 605 606 O
irritable NCT03860623 607 616 B-Condition
bowel NCT03860623 617 622 I-Condition
syndrome NCT03860623 623 631 I-Condition
, NCT03860623 632 633 O
gastroparesis NCT03860623 634 647 B-Condition
, NCT03860623 648 649 O
sphincter NCT03860623 650 659 B-Condition
of NCT03860623 660 662 I-Condition
Oddi NCT03860623 663 667 I-Condition
dysfunction NCT03860623 668 679 I-Condition
, NCT03860623 680 681 O
etc NCT03860623 682 685 O
. NCT03860623 685 686 O
) NCT03860623 687 688 O

- NCT03860623 692 693 O
Previous NCT03860623 695 703 B-Eq-Comparison
thoracic NCT03860623 704 712 B-Modifier
or NCT03860623 713 715 B-Or
abdominal NCT03860623 716 725 B-Modifier
surgery NCT03860623 726 733 B-Procedure
. NCT03860623 733 734 O

- NCT03860623 738 739 O
Those NCT03860623 741 746 O
who NCT03860623 747 750 O
report NCT03860623 751 757 O
having NCT03860623 758 764 O
≤ NCT03860623 765 766 B-Eq-Comparison
3 NCT03860623 767 768 I-Eq-Comparison
bowel NCT03860623 769 774 B-Observation
movements NCT03860623 775 784 I-Observation
/ NCT03860623 785 786 I-Eq-Comparison
week NCT03860623 787 791 O
or NCT03860623 792 794 B-Or
> NCT03860623 795 796 B-Eq-Comparison
2 NCT03860623 797 798 I-Eq-Comparison
/ NCT03860623 799 800 O
day NCT03860623 801 804 I-Eq-Comparison
. NCT03860623 804 805 O

Inclusion NCT03866252 0 9 O
Criteria NCT03866252 10 18 O
: NCT03866252 19 20 O

- NCT03866252 24 25 O
Major NCT03866252 27 32 O
Depressive NCT03866252 33 43 B-Condition
Disorder NCT03866252 44 52 I-Condition
according NCT03866252 53 62 O
to NCT03866252 63 65 O
Diagnostic NCT03866252 66 76 O
and NCT03866252 77 80 O
Statistical NCT03866252 81 92 O
Manual NCT03866252 93 99 O
of NCT03866252 100 102 O
Mental NCT03866252 103 109 O
Disorders NCT03866252 110 119 O
( NCT03866252 120 121 O
DSM NCT03866252 122 125 O
- NCT03866252 126 127 O
V NCT03866252 128 129 O
) NCT03866252 130 131 O

- NCT03866252 135 136 O
> NCT03866252 138 139 B-Eq-Comparison
25 NCT03866252 140 142 I-Eq-Comparison
years NCT03866252 143 148 I-Age|Eq-Comparison

- NCT03866252 151 152 O
Sufficient NCT03866252 154 164 O
understanding NCT03866252 165 178 O
of NCT03866252 179 181 O
the NCT03866252 182 185 O
German NCT03866252 186 192 O
language NCT03866252 193 201 O

Exclusion NCT03866252 202 211 O
Criteria NCT03866252 212 220 O
: NCT03866252 221 222 O

- NCT03866252 226 227 O
< NCT03866252 229 230 B-Eq-Comparison
25 NCT03866252 231 233 I-Eq-Comparison
years NCT03866252 234 239 I-Age|Eq-Comparison

- NCT03866252 242 243 O
Concomitant NCT03866252 245 256 O
diagnosis NCT03866252 257 266 O
of NCT03866252 267 269 O
past NCT03866252 270 274 B-Eq-Comparison
or NCT03866252 275 277 B-Or
present NCT03866252 278 285 B-Eq-Comparison
psychotic NCT03866252 286 295 B-Condition
disorder NCT03866252 296 304 I-Condition

- NCT03866252 307 308 O
Concomitant NCT03866252 310 321 O
diagnosis NCT03866252 322 331 O
of NCT03866252 332 334 O
past NCT03866252 335 339 B-Eq-Comparison
or NCT03866252 340 342 B-Or
present NCT03866252 343 350 B-Eq-Comparison
bipolar NCT03866252 351 358 B-Condition
disorder NCT03866252 359 367 I-Condition

- NCT03866252 370 371 O
First NCT03866252 373 378 B-Family-Member
degree NCT03866252 379 385 I-Family-Member
relative NCT03866252 386 394 I-Family-Member
with NCT03866252 395 399 O
a NCT03866252 400 401 O
psychotic NCT03866252 402 411 B-Condition
disorder NCT03866252 412 420 I-Condition

- NCT03866252 423 424 O
Unable NCT03866252 426 432 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03866252 433 435 B-Or
unwilling NCT03866252 436 445 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866252 446 448 O
discontinue NCT03866252 449 460 B-Negation
antidepressant NCT03866252 461 475 B-Drug
medication NCT03866252 476 486 I-Drug

- NCT03866252 489 490 O
Pregnancy NCT03866252 492 501 B-Condition
or NCT03866252 502 504 B-Or
breastfeeding NCT03866252 505 518 B-Condition

- NCT03866252 521 522 O
Known NCT03866252 524 529 O
hypersensitivity NCT03866252 530 546 B-Condition
to NCT03866252 547 549 O
LSD NCT03866252 550 553 B-Drug

- NCT03866252 556 557 O
Somatic NCT03866252 559 566 B-Condition
disorders NCT03866252 567 576 I-Condition
including NCT03866252 577 586 O
central NCT03866252 587 594 B-Condition
nervous NCT03866252 595 602 I-Condition
system NCT03866252 603 609 I-Condition
( NCT03866252 610 611 O
CNS NCT03866252 612 615 B-Condition
) NCT03866252 616 617 O
involvement NCT03866252 618 629 B-Modifier

- NCT03866252 632 633 O
Known NCT03866252 635 640 O
or NCT03866252 641 643 B-Or
suspected NCT03866252 644 653 B-Assertion___Assertion-Type-Value:possible
non NCT03866252 654 657 B-Negation
- NCT03866252 658 659 O
compliance NCT03866252 660 670 B-Modifier
, NCT03866252 671 672 O
drug NCT03866252 673 677 B-Modifier
or NCT03866252 678 680 B-Or
alcohol NCT03866252 681 688 B-Modifier
abuse NCT03866252 689 694 B-Condition

- NCT03866252 697 698 O
Metal NCT03866252 700 705 B-Procedure
implants NCT03866252 706 714 I-Procedure

- NCT03866252 717 718 O
Weight NCT03866252 720 726 B-Observation
< NCT03866252 727 728 B-Eq-Comparison
42 NCT03866252 729 731 I-Eq-Comparison
kg NCT03866252 732 734 I-Eq-Comparison

- NCT03866252 737 738 O
Suicide NCT03866252 740 747 B-Condition
risk NCT03866252 748 752 B-Risk
or NCT03866252 753 755 B-Or
very NCT03866252 756 760 O
likely NCT03866252 761 767 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866252 768 770 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03866252 771 778 O
psychiatric NCT03866252 779 790 B-Condition
hospitalisation NCT03866252 791 806 B-Encounter

Inclusion NCT03863470 0 9 O
Criteria NCT03863470 10 18 O
: NCT03863470 19 20 O

- NCT03863470 24 25 O
Age NCT03863470 27 30 B-Age
≥ NCT03863470 31 32 B-Eq-Comparison
18 NCT03863470 33 35 I-Eq-Comparison
years NCT03863470 36 41 I-Eq-Comparison
old NCT03863470 42 45 O
; NCT03863470 45 46 O
AND NCT03863470 47 50 B-And

- NCT03863470 53 54 O
Admission NCT03863470 56 65 B-Encounter
to NCT03863470 66 68 O
1 NCT03863470 69 70 O
of NCT03863470 71 73 O
12 NCT03863470 74 76 O
participating NCT03863470 77 90 O
ICUs NCT03863470 91 95 O
; NCT03863470 95 96 O
AND NCT03863470 97 100 B-And

- NCT03863470 103 104 O
Continuous NCT03863470 106 116 B-Modifier
mechanical NCT03863470 117 127 B-Procedure
ventilation NCT03863470 128 139 I-Procedure
for NCT03863470 140 143 O
≥ NCT03863470 144 145 B-Eq-Comparison
48 NCT03863470 146 148 I-Eq-Comparison
hours NCT03863470 149 154 I-Eq-Comparison
( NCT03863470 155 156 O
without NCT03863470 157 164 B-Modifier
interruption NCT03863470 165 177 I-Modifier
) NCT03863470 178 179 O
; NCT03863470 180 181 O
AND NCT03863470 182 185 B-And

- NCT03863470 188 189 O
Baseline NCT03863470 191 199 O
independent NCT03863470 200 211 B-Condition
ambulatory NCT03863470 212 222 I-Condition
status NCT03863470 223 229 O

Exclusion NCT03863470 230 239 O
Criteria NCT03863470 240 248 O
: NCT03863470 249 250 O

- NCT03863470 254 255 O
Admitting NCT03863470 257 266 O
diagnosis NCT03863470 267 276 O
of NCT03863470 277 279 O
any NCT03863470 280 283 O
of NCT03863470 284 286 O
the NCT03863470 287 290 B-Criteria-Count
following NCT03863470 291 300 I-Criteria-Count
conditions NCT03863470 301 311 I-Criteria-Count
: NCT03863470 312 313 O

- NCT03863470 322 323 O
Cardiopulmonary NCT03863470 325 340 B-Condition
arrest NCT03863470 341 347 I-Condition

- NCT03863470 355 356 O
Raised NCT03863470 358 364 O
intracranial NCT03863470 365 377 B-Condition
pressure NCT03863470 378 386 I-Condition

- NCT03863470 394 395 O
Acute NCT03863470 397 402 O
neurological NCT03863470 403 415 B-Modifier
admission NCT03863470 416 425 O
diagnosis NCT03863470 426 435 B-Condition

- NCT03863470 443 444 O
Subarachnoid NCT03863470 446 458 B-Condition
hemorrhage NCT03863470 459 469 I-Condition

- NCT03863470 477 478 O
Ischemic NCT03863470 480 488 B-Modifier
stroke NCT03863470 489 495 B-Condition

Inclusion NCT03862183 0 9 O
Criteria NCT03862183 10 18 O
: NCT03862183 19 20 O

1 NCT03862183 24 25 O
. NCT03862183 25 26 O
Outpatients NCT03862183 28 39 B-Encounter
from NCT03862183 40 44 O
departments NCT03862183 45 56 O
of NCT03862183 57 59 O
Cardiology NCT03862183 60 70 B-Provider
, NCT03862183 71 72 O
Endocrinology NCT03862183 73 86 B-Provider
, NCT03862183 87 88 O
Nephrology NCT03862183 89 99 B-Provider
, NCT03862183 100 101 O
Neurology NCT03862183 102 111 B-Provider
, NCT03862183 112 113 O
Geriatrics NCT03862183 114 124 B-Provider
or NCT03862183 125 127 B-Or
General NCT03862183 128 135 B-Provider
Internal NCT03862183 136 144 I-Provider
Medicine NCT03862183 145 153 I-Provider
. NCT03862183 153 154 O

2 NCT03862183 158 159 O
. NCT03862183 159 160 O
Diagnosed NCT03862183 162 171 O
as NCT03862183 172 174 O
hypertension NCT03862183 175 187 B-Condition
. NCT03862183 187 188 O
Diagnostic NCT03862183 190 200 O
criteria NCT03862183 201 209 O
: NCT03862183 210 211 O
1 NCT03862183 212 213 O
) NCT03862183 214 215 O
The NCT03862183 216 219 O
office NCT03862183 220 226 O
BP NCT03862183 227 229 B-Observation
measured NCT03862183 230 238 O
at NCT03862183 239 241 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862183 242 245 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03862183 246 249 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862183 250 252 O
visit NCT03862183 253 258 B-Encounter
and NCT03862183 259 262 O
at NCT03862183 263 265 B-Eq-Comparison
least NCT03862183 266 271 I-Eq-Comparison
one NCT03862183 272 275 I-Eq-Comparison
time NCT03862183 276 280 I-Eq-Comparison
before NCT03862183 281 287 B-Temporal-Connection___Temporal-Connection-Type-Value:before
that NCT03862183 288 292 O
day NCT03862183 293 296 O
were NCT03862183 297 301 O
above NCT03862183 302 307 B-Eq-Comparison
the NCT03862183 308 311 I-Eq-Comparison
cut NCT03862183 312 315 I-Eq-Comparison
- NCT03862183 316 317 I-Eq-Comparison
off NCT03862183 318 321 I-Eq-Comparison
values NCT03862183 322 328 I-Eq-Comparison
( NCT03862183 329 330 O
≥ NCT03862183 331 332 B-Eq-Comparison
140 NCT03862183 333 336 I-Eq-Comparison
mmHg NCT03862183 337 341 I-Eq-Comparison
SBP NCT03862183 342 345 I-Eq-Comparison|Observation
and NCT03862183 346 349 B-Or
/ NCT03862183 350 351 I-Or
or NCT03862183 352 354 I-Or
≥ NCT03862183 355 356 B-Eq-Comparison
90 NCT03862183 357 359 I-Eq-Comparison
mmHg NCT03862183 360 364 I-Eq-Comparison
DBP NCT03862183 365 368 I-Eq-Comparison|Observation
) NCT03862183 369 370 O
; NCT03862183 371 372 O
2 NCT03862183 373 374 O
) NCT03862183 375 376 O
for NCT03862183 377 380 O
patients NCT03862183 381 389 O
with NCT03862183 390 394 O
normal NCT03862183 395 401 O
BP NCT03862183 402 404 B-Observation
at NCT03862183 405 407 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862183 408 411 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03862183 412 415 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862183 416 418 O
visit NCT03862183 419 424 B-Encounter
, NCT03862183 425 426 O
they NCT03862183 427 431 O
should NCT03862183 432 438 O
have NCT03862183 439 443 O
already NCT03862183 444 451 O
been NCT03862183 452 456 O
given NCT03862183 457 462 B-Eq-Comparison
pre NCT03862183 463 466 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862183 467 468 O
treatment NCT03862183 469 478 B-Procedure
with NCT03862183 479 483 O
antihypertensive NCT03862183 484 500 B-Drug
drugs NCT03862183 501 506 I-Drug
≥ NCT03862183 507 508 B-Eq-Comparison
2 NCT03862183 509 510 I-Eq-Comparison
weeks NCT03862183 511 516 I-Eq-Comparison
. NCT03862183 516 517 O

3 NCT03862183 521 522 O
. NCT03862183 522 523 O
Voluntary NCT03862183 525 534 O
participation NCT03862183 535 548 O
. NCT03862183 548 549 O

Exclusion NCT03862183 551 560 O
Criteria NCT03862183 561 569 O
: NCT03862183 570 571 O

1 NCT03862183 575 576 O
. NCT03862183 576 577 O
Patients NCT03862183 579 587 O
aged NCT03862183 588 592 B-Age
< NCT03862183 593 594 B-Eq-Comparison
18 NCT03862183 595 597 I-Eq-Comparison
years NCT03862183 598 603 I-Eq-Comparison
old NCT03862183 604 607 O
. NCT03862183 607 608 O

2 NCT03862183 612 613 O
. NCT03862183 613 614 O
Patients NCT03862183 616 624 O
without NCT03862183 625 632 B-Negation
a NCT03862183 633 634 O
definite NCT03862183 635 643 O
diagnosis NCT03862183 644 653 O
of NCT03862183 654 656 O
hypertension（for NCT03862183 657 673 B-Condition
instance NCT03862183 674 682 O
, NCT03862183 683 684 O
if NCT03862183 685 687 O
the NCT03862183 688 691 O
patient NCT03862183 692 699 O
has NCT03862183 700 703 O
been NCT03862183 704 708 O
taking NCT03862183 709 715 B-Eq-Comparison
antihypertensive NCT03862183 716 732 B-Drug
drugs NCT03862183 733 738 I-Drug
irregularly NCT03862183 739 750 O
, NCT03862183 751 752 O
it NCT03862183 753 755 O
is NCT03862183 756 758 O
difficult NCT03862183 759 768 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862183 769 771 I-Assertion___Assertion-Type-Value:hypothetical
confirm NCT03862183 772 779 O
the NCT03862183 780 783 O
diagnosis NCT03862183 784 793 O
of NCT03862183 794 796 O
hypertension NCT03862183 797 809 B-Condition
） NCT03862183 809 810 O
. NCT03862183 810 811 O

3 NCT03862183 815 816 O
. NCT03862183 816 817 O
Patients NCT03862183 819 827 O
with NCT03862183 828 832 O
a NCT03862183 833 834 O
definite NCT03862183 835 843 O
diagnosis NCT03862183 844 853 O
of NCT03862183 854 856 O
secondary NCT03862183 857 866 B-Modifier
hypertension NCT03862183 867 879 B-Condition
. NCT03862183 879 880 O

4 NCT03862183 884 885 O
. NCT03862183 885 886 O
Patients NCT03862183 888 896 O
are NCT03862183 897 900 O
diagnosed NCT03862183 901 910 O
dyslipidemia NCT03862183 911 923 B-Condition
with NCT03862183 924 928 O
clear NCT03862183 929 934 O
cause NCT03862183 935 940 B-Condition
, NCT03862183 941 942 O
such NCT03862183 943 947 O
as NCT03862183 948 950 O
nephrotic NCT03862183 951 960 B-Condition
syndrome NCT03862183 961 969 I-Condition
, NCT03862183 970 971 O
severe NCT03862183 972 978 O
hypothyroidism NCT03862183 979 993 B-Condition
, NCT03862183 994 995 O
terminal NCT03862183 996 1004 B-Eq-Comparison
stage NCT03862183 1005 1010 I-Eq-Comparison
of NCT03862183 1011 1013 O
malignancy NCT03862183 1014 1024 B-Condition
, NCT03862183 1025 1026 O
etc NCT03862183 1027 1030 O
. NCT03862183 1030 1031 O

5 NCT03862183 1035 1036 O
. NCT03862183 1036 1037 O
Patients NCT03862183 1039 1047 O
are NCT03862183 1048 1051 O
diagnosed NCT03862183 1052 1061 O
end NCT03862183 1062 1065 B-Eq-Comparison
- NCT03862183 1066 1067 I-Eq-Comparison
stage NCT03862183 1068 1073 I-Eq-Comparison
renal NCT03862183 1074 1079 B-Condition
disease NCT03862183 1080 1087 I-Condition
, NCT03862183 1088 1089 O
hemodialysis NCT03862183 1090 1102 B-Procedure
, NCT03862183 1103 1104 O
and NCT03862183 1105 1108 B-Or
peritoneal NCT03862183 1109 1119 B-Procedure
dialysis NCT03862183 1120 1128 I-Procedure
patients NCT03862183 1129 1137 O
. NCT03862183 1137 1138 O

6 NCT03862183 1142 1143 O
. NCT03862183 1143 1144 O
Patients NCT03862183 1146 1154 O
diagnosed NCT03862183 1155 1164 O
with NCT03862183 1165 1169 O
mental NCT03862183 1170 1176 B-Condition
abnormalities NCT03862183 1177 1190 I-Condition
who NCT03862183 1191 1194 B-And
are NCT03862183 1195 1198 O
unable NCT03862183 1199 1205 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862183 1206 1208 O
complete NCT03862183 1209 1217 O
the NCT03862183 1218 1221 O
questionnaire NCT03862183 1222 1235 B-Observation
. NCT03862183 1235 1236 O

7 NCT03862183 1240 1241 O
. NCT03862183 1241 1242 O
Patients NCT03862183 1244 1252 O
have NCT03862183 1253 1257 O
once NCT03862183 1258 1262 O
participated NCT03862183 1263 1275 B-Eq-Comparison
in NCT03862183 1276 1278 O
this NCT03862183 1279 1283 O
research NCT03862183 1284 1292 B-Study
during NCT03862183 1293 1299 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03862183 1300 1304 O
study NCT03862183 1305 1310 B-Study
cycle（to NCT03862183 1311 1319 O
avoid NCT03862183 1320 1325 O
repeated NCT03862183 1326 1334 O
participation NCT03862183 1335 1348 O
） NCT03862183 1348 1349 O
. NCT03862183 1349 1350 O

Inclusion NCT03860025 0 9 O
Criteria NCT03860025 10 18 O
: NCT03860025 19 20 O

- NCT03860025 24 25 O
patients NCT03860025 27 35 O
with NCT03860025 36 40 O
one NCT03860025 41 44 B-Eq-Comparison
or NCT03860025 45 47 I-Eq-Comparison
more NCT03860025 48 52 I-Eq-Comparison
events NCT03860025 53 59 O
of NCT03860025 60 62 O
hip NCT03860025 63 66 B-Condition
dislocation NCT03860025 67 78 I-Condition
after NCT03860025 79 84 B-Temporal-Connection___Temporal-Connection-Type-Value:after
a NCT03860025 85 86 O
primary NCT03860025 87 94 B-Modifier
THA NCT03860025 95 98 B-Procedure

- NCT03860025 101 102 O
controls NCT03860025 104 112 O
with NCT03860025 113 117 O
a NCT03860025 118 119 O
primary NCT03860025 120 127 B-Modifier
THA NCT03860025 128 131 B-Procedure
without NCT03860025 132 139 B-Negation
events NCT03860025 140 146 O
of NCT03860025 147 149 O
hip NCT03860025 150 153 B-Condition
dislocation NCT03860025 154 165 I-Condition

Exclusion NCT03860025 166 175 O
Criteria NCT03860025 176 184 O
: NCT03860025 185 186 O

- NCT03860025 189 190 O

Inclusion NCT03863262 0 9 O
Criteria NCT03863262 10 18 O
: NCT03863262 19 20 O

- NCT03863262 24 25 O
Registered NCT03863262 27 37 O
patients NCT03863262 38 46 O
at NCT03863262 47 49 O
Eric NCT03863262 50 54 O
Williams NCT03863262 55 63 O
Medical NCT03863262 64 71 O
Sciences NCT03863262 72 80 O
Complex NCT03863262 81 88 O
in NCT03863262 89 91 O
any NCT03863262 92 95 O
of NCT03863262 96 98 O
the NCT03863262 99 102 O
cardiology NCT03863262 103 113 O
outpatient NCT03863262 114 124 O
clinics NCT03863262 125 132 O
. NCT03863262 132 133 O
This NCT03863262 135 139 O
was NCT03863262 140 143 O
confirmed NCT03863262 144 153 O
by NCT03863262 154 156 O
matching NCT03863262 157 165 O
patients NCT03863262 166 174 O
with NCT03863262 175 179 O
their NCT03863262 180 185 O
registration NCT03863262 186 198 O
numbers NCT03863262 199 206 O
on NCT03863262 207 209 O
the NCT03863262 210 213 O
cardiology NCT03863262 214 224 O
outpatient NCT03863262 225 235 O
clinic NCT03863262 236 242 O
appointment NCT03863262 243 254 O
listings NCT03863262 255 263 O
. NCT03863262 263 264 O
These NCT03863262 266 271 O
lists NCT03863262 272 277 O
are NCT03863262 278 281 O
made NCT03863262 282 286 O
prior NCT03863262 287 292 O
to NCT03863262 293 295 O
each NCT03863262 296 300 O
cardiology NCT03863262 301 311 O
clinic NCT03863262 312 318 O
that NCT03863262 319 323 O
is NCT03863262 324 326 O
scheduled NCT03863262 327 336 O
every NCT03863262 337 342 O
week NCT03863262 343 347 O
on NCT03863262 348 350 O
Mondays NCT03863262 351 358 O
, NCT03863262 359 360 O
Tuesdays NCT03863262 361 369 O
, NCT03863262 370 371 O
Wednesdays NCT03863262 372 382 O
, NCT03863262 383 384 O
Thursdays NCT03863262 385 394 O
and NCT03863262 395 398 O
Fridays NCT03863262 399 406 O
. NCT03863262 406 407 O

- NCT03863262 411 412 O
Patients NCT03863262 414 422 O
who NCT03863262 423 426 O
were NCT03863262 427 431 B-Eq-Comparison
18 NCT03863262 432 434 I-Eq-Comparison
years NCT03863262 435 440 I-Eq-Comparison
old NCT03863262 441 444 B-Age

Exclusion NCT03863262 445 454 O
Criteria NCT03863262 455 463 O
: NCT03863262 464 465 O

- NCT03863262 469 470 O
Patients NCT03863262 472 480 O
less NCT03863262 481 485 B-Eq-Comparison
than NCT03863262 486 490 I-Eq-Comparison
18 NCT03863262 491 493 I-Eq-Comparison
years NCT03863262 494 499 I-Eq-Comparison
old NCT03863262 500 503 B-Age

- NCT03863262 506 507 O
Those NCT03863262 509 514 O
who NCT03863262 515 518 O
did NCT03863262 519 522 O
not NCT03863262 523 526 O
give NCT03863262 527 531 O
informed NCT03863262 532 540 O
consent NCT03863262 541 548 O
to NCT03863262 549 551 O
participate NCT03863262 552 563 O
in NCT03863262 564 566 O
the NCT03863262 567 570 O
study NCT03863262 571 576 O

- NCT03863262 579 580 O
Patients NCT03863262 582 590 O
who NCT03863262 591 594 O
were NCT03863262 595 599 O
not NCT03863262 600 603 B-Negation
registered NCT03863262 604 614 O
patients NCT03863262 615 623 O
of NCT03863262 624 626 O
the NCT03863262 627 630 O
cardiology NCT03863262 631 641 O
outpatient NCT03863262 642 652 O
clinics NCT03863262 653 660 O
at NCT03863262 661 663 O
Eric NCT03863262 664 668 O
Williams NCT03863262 669 677 O
Medical NCT03863262 678 685 O
Sciences NCT03863262 686 694 O
Complex NCT03863262 695 702 O
along NCT03863262 703 708 O

- NCT03863262 711 712 O
Patients NCT03863262 714 722 O
who NCT03863262 723 726 O
were NCT03863262 727 731 O
acutely NCT03863262 732 739 O
unwell NCT03863262 740 746 B-Condition
requiring NCT03863262 747 756 B-Assertion___Assertion-Type-Value:hypothetical
hospital NCT03863262 757 765 O
admission NCT03863262 766 775 B-Encounter

Inclusion NCT03866681 0 9 O
Criteria NCT03866681 10 18 O
: NCT03866681 19 20 O

- NCT03866681 24 25 O
age NCT03866681 27 30 B-Age
18 NCT03866681 31 33 B-Eq-Comparison
- NCT03866681 34 35 I-Eq-Comparison
70 NCT03866681 36 38 I-Eq-Comparison
years NCT03866681 39 44 I-Eq-Comparison

- NCT03866681 47 48 O
diagnosed NCT03866681 50 59 O
with NCT03866681 60 64 O
PNH NCT03866681 65 68 B-Condition
and NCT03866681 69 72 B-And
no NCT03866681 73 75 B-Negation
thrombosis NCT03866681 76 86 B-Condition

- NCT03866681 89 90 O
ineffective NCT03866681 92 103 B-Modifier
, NCT03866681 104 105 O
relapsed NCT03866681 106 114 B-Modifier
or NCT03866681 115 117 B-Or
intolerant NCT03866681 118 128 B-Condition
to NCT03866681 129 131 O
conventional NCT03866681 132 144 B-Procedure
treatment NCT03866681 145 154 I-Procedure
( NCT03866681 155 156 O
eg NCT03866681 157 159 O
glucocorticoids NCT03866681 160 175 B-Drug
, NCT03866681 176 177 O
• NCT03866681 178 179 O
• NCT03866681 180 181 O
iron NCT03866681 182 186 B-Drug
, NCT03866681 187 188 O
folic NCT03866681 189 194 B-Drug
acid NCT03866681 195 199 I-Drug
, NCT03866681 200 201 O
androgen NCT03866681 202 210 B-Drug
, NCT03866681 211 212 O
etc NCT03866681 213 216 O
. NCT03866681 216 217 O
) NCT03866681 218 219 O

- NCT03866681 223 224 O
not NCT03866681 226 229 B-Negation
available NCT03866681 230 239 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03866681 240 243 O
hematopoietic NCT03866681 244 257 B-Procedure
stem NCT03866681 258 262 I-Procedure
cell NCT03866681 263 267 I-Procedure
transplantation NCT03866681 268 283 I-Procedure

- NCT03866681 286 287 O
ECOG NCT03866681 289 293 B-Observation
≤ NCT03866681 294 295 B-Eq-Comparison
2 NCT03866681 296 297 I-Eq-Comparison

- NCT03866681 301 302 O
agreed NCT03866681 304 310 O
to NCT03866681 311 313 O
sign NCT03866681 314 318 O
the NCT03866681 319 322 O
consent NCT03866681 323 330 O
forms NCT03866681 331 336 O

Exclusion NCT03866681 337 346 O
Criteria NCT03866681 347 355 O
: NCT03866681 356 357 O

- NCT03866681 361 362 O
severe NCT03866681 364 370 O
heart NCT03866681 371 376 B-Modifier
, NCT03866681 377 378 O
liver NCT03866681 379 384 B-Modifier
and NCT03866681 385 388 B-Or
kidney NCT03866681 389 395 B-Modifier
dysfunction NCT03866681 396 407 B-Condition

- NCT03866681 410 411 O
combined NCT03866681 413 421 O
with NCT03866681 422 426 O
thrombotic NCT03866681 427 437 B-Modifier
complications NCT03866681 438 451 B-Condition

- NCT03866681 454 455 O
people NCT03866681 457 463 O
who NCT03866681 464 467 O
are NCT03866681 468 471 O
pregnant NCT03866681 472 480 B-Condition
and NCT03866681 481 484 B-Or
breastfeeding NCT03866681 485 498 B-Condition

- NCT03866681 501 502 O
history NCT03866681 504 511 B-Eq-Comparison
of NCT03866681 512 514 O
other NCT03866681 515 520 B-Other
immunosuppressive NCT03866681 521 538 B-Drug
agents NCT03866681 539 545 I-Drug
in NCT03866681 546 548 O
recent NCT03866681 549 555 B-Eq-Comparison
3 NCT03866681 556 557 I-Eq-Comparison
months NCT03866681 558 564 I-Eq-Comparison

- NCT03866681 567 568 O
Patients NCT03866681 570 578 O
who NCT03866681 579 582 O
are NCT03866681 583 586 O
not NCT03866681 587 590 B-Negation
eligible NCT03866681 591 599 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866681 600 602 O
participate NCT03866681 603 614 O
in NCT03866681 615 617 O
this NCT03866681 618 622 O
trial NCT03866681 623 628 O
due NCT03866681 629 632 O
to NCT03866681 633 635 O
any NCT03866681 636 639 O
reason NCT03866681 640 646 O
based NCT03866681 647 652 O
• NCT03866681 653 654 O
• NCT03866681 655 656 O
• NCT03866681 657 658 O
on NCT03866681 659 661 O
the NCT03866681 662 665 O
consideration NCT03866681 666 679 O
of NCT03866681 680 682 O
investigator NCT03866681 683 695 O

Inclusion NCT03864900 0 9 O
Criteria NCT03864900 10 18 O
: NCT03864900 19 20 O

1 NCT03864900 24 25 O
. NCT03864900 25 26 O
≥ NCT03864900 28 29 B-Eq-Comparison
20 NCT03864900 30 32 I-Eq-Comparison
years NCT03864900 33 38 I-Eq-Comparison
of NCT03864900 39 41 O
age NCT03864900 42 45 B-Age

2 NCT03864900 48 49 O
. NCT03864900 49 50 O
fluent NCT03864900 52 58 O
in NCT03864900 59 61 O
Mandarin NCT03864900 62 70 O
or NCT03864900 71 73 B-Or
Taiwanese NCT03864900 74 83 O

3 NCT03864900 86 87 O
. NCT03864900 87 88 O
diagnosed NCT03864900 90 99 O
with NCT03864900 100 104 O
AF NCT03864900 105 107 B-Condition

4 NCT03864900 110 111 O
. NCT03864900 111 112 O
treated NCT03864900 114 121 B-Procedure
with NCT03864900 122 126 O
warfarin NCT03864900 127 135 B-Drug
or NCT03864900 136 138 B-Or
NOACs NCT03864900 139 144 B-Drug
for NCT03864900 145 148 O
anticoagulation NCT03864900 149 164 B-Procedure
. NCT03864900 164 165 O

Exclusion NCT03864900 167 176 O
Criteria NCT03864900 177 185 O
: NCT03864900 186 187 O

1 NCT03864900 191 192 O
. NCT03864900 192 193 O
diagnosed NCT03864900 195 204 O
with NCT03864900 205 209 O
psychological NCT03864900 210 223 B-Condition
diseases NCT03864900 224 232 I-Condition

2 NCT03864900 235 236 O
. NCT03864900 236 237 O
diagnosed NCT03864900 239 248 O
with NCT03864900 249 253 O
uncontrolled NCT03864900 254 266 B-Modifier
hypertension NCT03864900 267 279 B-Condition

3 NCT03864900 282 283 O
. NCT03864900 283 284 O
diagnosed NCT03864900 286 295 O
with NCT03864900 296 300 O
the NCT03864900 301 304 O
New NCT03864900 305 308 B-Condition
York NCT03864900 309 313 I-Condition
Heart NCT03864900 314 319 I-Condition
Association NCT03864900 320 331 I-Condition
( NCT03864900 332 333 O
NYHA NCT03864900 334 338 B-Condition
) NCT03864900 339 340 O
grade NCT03864900 341 346 B-Eq-Comparison
VI NCT03864900 347 349 I-Eq-Comparison
heart NCT03864900 350 355 B-Condition
failure NCT03864900 356 363 I-Condition

4 NCT03864900 366 367 O
. NCT03864900 367 368 O
implanted NCT03864900 370 379 O
with NCT03864900 380 384 O
a NCT03864900 385 386 O
cardiac NCT03864900 387 394 B-Procedure
pacemaker NCT03864900 395 404 I-Procedure

5 NCT03864900 407 408 O
. NCT03864900 408 409 O
had NCT03864900 411 414 O
a NCT03864900 415 416 O
cardiac NCT03864900 417 424 B-Procedure
surgery NCT03864900 425 432 I-Procedure
in NCT03864900 433 435 O
the NCT03864900 436 439 O
past NCT03864900 440 444 B-Eq-Comparison
three NCT03864900 445 450 I-Eq-Comparison
months NCT03864900 451 457 I-Eq-Comparison

6 NCT03864900 460 461 O
. NCT03864900 461 462 O
hospitalized NCT03864900 464 476 B-Encounter
for NCT03864900 477 480 O
AF NCT03864900 481 483 B-Condition
in NCT03864900 484 486 O
the NCT03864900 487 490 O
past NCT03864900 491 495 B-Eq-Comparison
three NCT03864900 496 501 I-Eq-Comparison
months NCT03864900 502 508 I-Eq-Comparison
. NCT03864900 508 509 O

Inclusion NCT03866642 0 9 O
Criteria NCT03866642 10 18 O
: NCT03866642 19 20 O

- NCT03866642 24 25 O
Ankle NCT03866642 27 32 B-Modifier
arthritis NCT03866642 33 42 B-Condition
treated NCT03866642 43 50 O
with NCT03866642 51 55 O
Cadence NCT03866642 56 63 B-Modifier
Total NCT03866642 64 69 B-Procedure
Ankle NCT03866642 70 75 I-Procedure
Replacement NCT03866642 76 87 I-Procedure
system NCT03866642 88 94 I-Procedure

Exclusion NCT03866642 95 104 O
Criteria NCT03866642 105 113 O
: NCT03866642 114 115 O

- NCT03866642 119 120 O
Under NCT03866642 122 127 B-Eq-Comparison
18 NCT03866642 128 130 I-Eq-Comparison
years NCT03866642 131 136 I-Eq-Comparison
of NCT03866642 137 139 O
age NCT03866642 140 143 B-Age

Inclusion NCT03860233 0 9 O
Criteria NCT03860233 10 18 O
: NCT03860233 19 20 O

- NCT03860233 24 25 O
Men NCT03860233 27 30 O
or NCT03860233 31 33 B-Or
women NCT03860233 34 39 O
18 NCT03860233 40 42 B-Eq-Comparison
years NCT03860233 43 48 I-Eq-Comparison
of NCT03860233 49 51 I-Eq-Comparison
age NCT03860233 52 55 I-Age|Eq-Comparison
or NCT03860233 56 58 I-Eq-Comparison
older NCT03860233 59 64 I-Eq-Comparison
. NCT03860233 64 65 O

Exclusion NCT03860233 67 76 O
Criteria NCT03860233 77 85 O
: NCT03860233 86 87 O

- NCT03860233 91 92 O
subjects NCT03860233 94 102 O
not NCT03860233 103 106 B-Negation
willing NCT03860233 107 114 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860233 115 117 I-Assertion___Assertion-Type-Value:hypothetical
or NCT03860233 118 120 B-Or
otherwise NCT03860233 121 130 O
unable NCT03860233 131 137 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860233 138 140 O
use NCT03860233 141 144 O
CPAP NCT03860233 145 149 B-Procedure
for NCT03860233 150 153 O
treatment NCT03860233 154 163 B-Procedure
of NCT03860233 164 166 O
OSA NCT03860233 167 170 B-Condition
. NCT03860233 170 171 O

- NCT03860233 175 176 O
Presence NCT03860233 178 186 O
of NCT03860233 187 189 O
other NCT03860233 190 195 B-Other
sleep NCT03860233 196 201 B-Condition
disorders NCT03860233 202 211 I-Condition

- NCT03860233 214 215 O
Pregnant NCT03860233 217 225 B-Condition
or NCT03860233 226 228 B-Or
breastfeeding NCT03860233 229 242 B-Condition
women NCT03860233 243 248 O

- NCT03860233 251 252 O
Women NCT03860233 254 259 O
of NCT03860233 260 262 B-And
child NCT03860233 263 268 B-Condition
- NCT03860233 269 270 I-Condition
bearing NCT03860233 271 278 I-Condition
age NCT03860233 279 282 I-Condition
( NCT03860233 283 284 O
WOCBA NCT03860233 285 290 B-Condition
) NCT03860233 291 292 O
not NCT03860233 293 296 B-Negation
willing NCT03860233 297 304 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03860233 305 307 B-Or
unable NCT03860233 308 314 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860233 315 317 O
use NCT03860233 318 321 O
an NCT03860233 322 324 O
accepted NCT03860233 325 333 O
method NCT03860233 334 340 B-Procedure
to NCT03860233 341 343 O
avoid NCT03860233 344 349 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03860233 350 359 B-Condition
for NCT03860233 360 363 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860233 364 367 I-Temporal-Connection___Temporal-Connection-Type-Value:during
entire NCT03860233 368 374 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03860233 375 383 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860233 384 386 O
the NCT03860233 387 390 O
study NCT03860233 391 396 B-Study

- NCT03860233 399 400 O
Prisoners NCT03860233 402 411 B-Observation
or NCT03860233 412 414 B-Or
subjects NCT03860233 415 423 O
who NCT03860233 424 427 O
are NCT03860233 428 431 O
involuntarily NCT03860233 432 445 B-Observation
incarcerated NCT03860233 446 458 I-Observation

- NCT03860233 461 462 O
Subjects NCT03860233 464 472 O
who NCT03860233 473 476 O
are NCT03860233 477 480 O
compulsorily NCT03860233 481 493 B-Observation
detain NCT03860233 494 500 I-Observation
or NCT03860233 501 503 B-Or
treatment NCT03860233 504 513 B-Procedure
of NCT03860233 514 516 O
either NCT03860233 517 523 O
a NCT03860233 524 525 O
psychiatric NCT03860233 526 537 B-Modifier
or NCT03860233 538 540 B-Or
physical NCT03860233 541 549 B-Modifier
( NCT03860233 550 551 O
i. NCT03860233 552 554 O
e. NCT03860233 555 557 O
infectious NCT03860233 559 569 B-Condition
disease NCT03860233 570 577 I-Condition
) NCT03860233 578 579 O
illness NCT03860233 580 587 B-Condition

- NCT03860233 590 591 O
Patients NCT03860233 593 601 O
unable NCT03860233 602 608 O
to NCT03860233 609 611 O
give NCT03860233 612 616 O
consent NCT03860233 617 624 O
because NCT03860233 625 632 O
of NCT03860233 633 635 O
a NCT03860233 636 637 O
language NCT03860233 638 646 B-Condition
barrier NCT03860233 647 654 I-Condition
, NCT03860233 655 656 O
or NCT03860233 657 659 O
other NCT03860233 660 665 O
reason NCT03860233 666 672 O
. NCT03860233 672 673 O

Inclusion NCT03864055 0 9 O
Criteria NCT03864055 10 18 O
: NCT03864055 19 20 O

- NCT03864055 24 25 O
age NCT03864055 27 30 B-Age
of NCT03864055 31 33 O
18 NCT03864055 34 36 B-Eq-Comparison
years NCT03864055 37 42 I-Eq-Comparison
or NCT03864055 43 45 I-Eq-Comparison
younger NCT03864055 46 53 I-Eq-Comparison

- NCT03864055 56 57 O
both NCT03864055 59 63 O
sexes NCT03864055 64 69 O
are NCT03864055 70 73 O
included NCT03864055 74 82 O

- NCT03864055 85 86 O
a NCT03864055 88 89 O
clinical NCT03864055 90 98 B-Modifier
or NCT03864055 99 101 B-Or
radiological NCT03864055 102 114 B-Procedure
finding NCT03864055 115 122 O
of NCT03864055 123 125 O
mastoiditis NCT03864055 126 137 B-Condition
in NCT03864055 138 140 O
the NCT03864055 141 144 O
patient NCT03864055 145 152 O
's NCT03864055 152 154 O
file NCT03864055 155 159 O

- NCT03864055 162 163 O
Documentation NCT03864055 165 178 O
of NCT03864055 179 181 O
CSVT NCT03864055 182 186 B-Condition
in NCT03864055 187 189 O
an NCT03864055 190 192 O
imaging NCT03864055 193 200 B-Procedure
study NCT03864055 201 206 I-Procedure
, NCT03864055 207 208 O
either NCT03864055 209 215 O
CT NCT03864055 216 218 B-Procedure
or NCT03864055 219 221 B-Or
MRI NCT03864055 222 225 B-Procedure
. NCT03864055 225 226 O

Patient NCT03864055 228 235 O
's NCT03864055 235 237 O
exclusion NCT03864055 238 247 O
criteria NCT03864055 248 256 O

- NCT03864055 259 260 O
age NCT03864055 262 265 B-Age
above NCT03864055 266 271 B-Eq-Comparison
18 NCT03864055 272 274 I-Eq-Comparison
years NCT03864055 275 280 I-Eq-Comparison

- NCT03864055 283 284 O
lack NCT03864055 286 290 B-Negation
of NCT03864055 291 293 I-Negation
a NCT03864055 294 295 O
clinical NCT03864055 296 304 B-Modifier
or NCT03864055 305 307 B-Or
radiological NCT03864055 308 320 B-Procedure
finding NCT03864055 321 328 O
of NCT03864055 329 331 O
mastoiditis NCT03864055 332 343 B-Condition
in NCT03864055 344 346 O
the NCT03864055 347 350 O
patient NCT03864055 351 358 O
's NCT03864055 358 360 O
file NCT03864055 361 365 O

- NCT03864055 368 369 O
Lack NCT03864055 371 375 B-Negation
of NCT03864055 376 378 O
documentation NCT03864055 379 392 O
of NCT03864055 393 395 O
CSVT NCT03864055 396 400 B-Condition
in NCT03864055 401 403 O
an NCT03864055 404 406 O
imaging NCT03864055 407 414 B-Procedure
study NCT03864055 415 420 I-Procedure
, NCT03864055 421 422 O
either NCT03864055 423 429 O
CT NCT03864055 430 432 B-Procedure
or NCT03864055 433 435 B-Or
MRI NCT03864055 436 439 B-Procedure
. NCT03864055 439 440 O

- NCT03864055 444 445 O
previous NCT03864055 447 455 B-Eq-Comparison
unprovoked NCT03864055 456 466 B-Modifier
venous NCT03864055 467 473 B-Condition
thromboembolism NCT03864055 474 489 I-Condition
event NCT03864055 490 495 O
. NCT03864055 495 496 O

Inclusion NCT03869203 0 9 O
Criteria NCT03869203 10 18 O
: NCT03869203 19 20 O

- NCT03869203 24 25 O
1 NCT03869203 27 28 O
. NCT03869203 28 29 O
elective NCT03869203 31 39 B-Modifier
total NCT03869203 40 45 B-Procedure
knee NCT03869203 46 50 I-Procedure
arthroplasty NCT03869203 51 63 I-Procedure
for NCT03869203 64 67 O
degenerative NCT03869203 68 80 B-Modifier
osteoarthritis NCT03869203 81 95 B-Condition

- NCT03869203 98 99 O
2 NCT03869203 101 102 O
. NCT03869203 102 103 O
elective NCT03869203 105 113 B-Modifier
total NCT03869203 114 119 B-Procedure
hip NCT03869203 120 123 I-Procedure
arthroplasty NCT03869203 124 136 I-Procedure
for NCT03869203 137 140 O
osteoarthritis NCT03869203 141 155 B-Condition
of NCT03869203 156 158 O
osteonecrosis NCT03869203 159 172 B-Condition
of NCT03869203 173 175 I-Condition
femoral NCT03869203 176 183 I-Condition
head NCT03869203 184 188 I-Condition

Exclusion NCT03869203 189 198 O
Criteria NCT03869203 199 207 O
: NCT03869203 208 209 O

- NCT03869203 213 214 O
1 NCT03869203 216 217 O
. NCT03869203 217 218 O
ASA NCT03869203 220 223 B-Condition
class NCT03869203 224 229 B-Eq-Comparison
> NCT03869203 230 231 I-Eq-Comparison
3 NCT03869203 232 233 I-Eq-Comparison

- NCT03869203 237 238 O
2 NCT03869203 240 241 O
. NCT03869203 241 242 O
severe NCT03869203 244 250 O
medical NCT03869203 251 258 B-Condition
comorbidities NCT03869203 259 272 I-Condition

- NCT03869203 275 276 O
3 NCT03869203 278 279 O
. NCT03869203 279 280 O
inflammatory NCT03869203 282 294 B-Condition
arthritis NCT03869203 295 304 I-Condition
including NCT03869203 305 314 O
rheumatoid NCT03869203 315 325 B-Condition
arthritis NCT03869203 326 335 I-Condition

- NCT03869203 338 339 O
4 NCT03869203 341 342 O
. NCT03869203 342 343 O
severe NCT03869203 345 351 O
instability NCT03869203 352 363 B-Condition
of NCT03869203 364 366 O
knee NCT03869203 367 371 B-Modifier
or NCT03869203 372 374 B-Or
hip NCT03869203 375 378 B-Modifier

- NCT03869203 381 382 O
5 NCT03869203 384 385 O
. NCT03869203 385 386 O
revision NCT03869203 388 396 B-Modifier
surgery NCT03869203 397 404 B-Procedure

Inclusion NCT03869502 0 9 O
Criteria NCT03869502 10 18 O
: NCT03869502 19 20 O

- NCT03869502 24 25 O
Age NCT03869502 27 30 B-Age
> NCT03869502 31 32 B-Eq-Comparison
18 NCT03869502 33 35 I-Eq-Comparison
years NCT03869502 36 41 I-Eq-Comparison

- NCT03869502 44 45 O
Diagnosis NCT03869502 47 56 O
of NCT03869502 57 59 O
BCR‐ABL NCT03869502 60 67 B-Condition
positive NCT03869502 68 76 O
CML NCT03869502 77 80 B-Modifier
blast NCT03869502 81 86 I-Modifier
crisis NCT03869502 87 93 I-Modifier
according NCT03869502 94 103 O
to NCT03869502 104 106 O
the NCT03869502 107 110 O
WHO NCT03869502 111 114 O
criteria NCT03869502 115 123 O
: NCT03869502 124 125 O

- NCT03869502 134 135 O
Blasts NCT03869502 137 143 B-Observation
20 NCT03869502 144 146 B-Eq-Comparison
% NCT03869502 147 148 O
or NCT03869502 149 151 I-Eq-Comparison
more NCT03869502 152 156 I-Eq-Comparison
of NCT03869502 157 159 O
peripheral NCT03869502 160 170 B-Modifier
blood NCT03869502 171 176 I-Modifier
white NCT03869502 177 182 I-Modifier
cells NCT03869502 183 188 I-Modifier
or NCT03869502 189 191 B-Or
bone NCT03869502 192 196 B-Modifier
marrow NCT03869502 197 203 I-Modifier
cells NCT03869502 204 209 I-Modifier
or NCT03869502 210 212 B-Or

- NCT03869502 220 221 O
Extramedullary NCT03869502 223 237 B-Modifier
blast NCT03869502 238 243 B-Condition
proliferation NCT03869502 244 257 I-Condition
or NCT03869502 258 260 B-Or

- NCT03869502 268 269 O
Large NCT03869502 271 276 B-Modifier
foci NCT03869502 277 281 I-Modifier
or NCT03869502 282 284 B-Or
clusters NCT03869502 285 293 B-Modifier
of NCT03869502 294 296 O
blasts NCT03869502 297 303 B-Condition
in NCT03869502 304 306 O
bone NCT03869502 307 311 B-Procedure
marrow NCT03869502 312 318 I-Procedure
biopsy NCT03869502 319 325 I-Procedure

Exclusion NCT03869502 326 335 O
Criteria NCT03869502 336 344 O
: NCT03869502 345 346 O

- NCT03869502 350 351 O
Lack NCT03869502 353 357 O
of NCT03869502 358 360 O
informed NCT03869502 361 369 O
consent NCT03869502 370 377 O

Inclusion NCT03862443 0 9 O
Criteria NCT03862443 10 18 O
for NCT03862443 19 22 O
Parent NCT03862443 23 29 O
/ NCT03862443 30 31 O
Caregiver NCT03862443 32 41 O
: NCT03862443 42 43 O

- NCT03862443 47 48 O
Provide NCT03862443 50 57 O
signed NCT03862443 58 64 O
and NCT03862443 65 68 O
dated NCT03862443 69 74 O
informed NCT03862443 75 83 O
consent NCT03862443 84 91 O
form NCT03862443 92 96 O
in NCT03862443 97 99 O
English NCT03862443 100 107 O
or NCT03862443 108 110 B-Or
Spanish NCT03862443 111 118 O
. NCT03862443 118 119 O

- NCT03862443 123 124 O
Agree NCT03862443 126 131 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862443 132 134 O
comply NCT03862443 135 141 O
with NCT03862443 142 146 O
all NCT03862443 147 150 O
study NCT03862443 151 156 B-Study
procedures NCT03862443 157 167 O
and NCT03862443 168 171 O
be NCT03862443 172 174 B-Assertion___Assertion-Type-Value:hypothetical
available NCT03862443 175 184 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03862443 185 188 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862443 189 192 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03862443 193 201 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862443 202 204 O
the NCT03862443 205 208 O
study NCT03862443 209 214 B-Study
visit NCT03862443 215 220 O
. NCT03862443 220 221 O

- NCT03862443 225 226 O
Male NCT03862443 228 232 O
or NCT03862443 233 235 B-Or
female NCT03862443 236 242 O
, NCT03862443 243 244 O
aged NCT03862443 245 249 B-Age
18 NCT03862443 250 252 B-Eq-Comparison
and NCT03862443 253 256 I-Eq-Comparison
older NCT03862443 257 262 I-Eq-Comparison
. NCT03862443 262 263 O

- NCT03862443 267 268 O
Speak NCT03862443 270 275 O
, NCT03862443 276 277 O
read NCT03862443 278 282 O
, NCT03862443 283 284 O
and NCT03862443 285 288 O
write NCT03862443 289 294 O
either NCT03862443 295 301 O
English NCT03862443 302 309 O
or NCT03862443 310 312 B-Or
Spanish NCT03862443 313 320 O
. NCT03862443 320 321 O

- NCT03862443 325 326 O
Be NCT03862443 328 330 O
a NCT03862443 331 332 O
parent NCT03862443 333 339 B-Family-Member___Family-Member-Type:parent
or NCT03862443 340 342 B-Or
caregiver NCT03862443 343 352 B-Family-Member___Family-Member-Type:parent
of NCT03862443 353 355 O
a NCT03862443 356 357 O
child NCT03862443 358 363 B-Family-Member___Family-Member-Type:child
at NCT03862443 364 366 B-Eq-Comparison
least NCT03862443 367 372 I-Eq-Comparison
6 NCT03862443 373 374 I-Eq-Comparison
months NCT03862443 375 381 I-Eq-Comparison
old NCT03862443 382 385 B-Age
but NCT03862443 386 389 B-And
less NCT03862443 390 394 B-Eq-Comparison
than NCT03862443 395 399 I-Eq-Comparison
3.5 NCT03862443 400 403 I-Eq-Comparison
years NCT03862443 404 409 I-Eq-Comparison
( NCT03862443 410 411 O
42 NCT03862443 412 414 B-Eq-Comparison
months NCT03862443 415 421 I-Eq-Comparison
) NCT03862443 422 423 O
, NCT03862443 425 426 O
with NCT03862443 427 431 B-And
at NCT03862443 432 434 B-Eq-Comparison
least NCT03862443 435 440 I-Eq-Comparison
2 NCT03862443 441 442 I-Eq-Comparison
fully NCT03862443 443 448 B-Modifier
erupted NCT03862443 449 456 I-Modifier
teeth NCT03862443 457 462 B-Condition
and NCT03862443 463 466 O
enrolled NCT03862443 467 475 O
in NCT03862443 476 478 O
, NCT03862443 479 480 O
or NCT03862443 481 483 O
waitlisted NCT03862443 484 494 O
for NCT03862443 495 498 O
, NCT03862443 499 500 O
one NCT03862443 501 504 O
of NCT03862443 505 507 O
the NCT03862443 508 511 O
three NCT03862443 512 517 O
participating NCT03862443 518 531 O
Los NCT03862443 532 535 O
Angeles NCT03862443 536 543 O
County NCT03862443 544 550 O
EHS NCT03862443 551 554 O
home NCT03862443 555 559 O
visit NCT03862443 560 565 O
programs NCT03862443 566 574 O
. NCT03862443 574 575 O

- NCT03862443 579 580 O
Not NCT03862443 582 585 B-Negation
be NCT03862443 586 588 O
planning NCT03862443 589 597 B-Assertion___Assertion-Type-Value:intention
to NCT03862443 598 600 I-Assertion___Assertion-Type-Value:intention
move NCT03862443 601 605 B-Observation
residence NCT03862443 606 615 O
for NCT03862443 616 619 O
the NCT03862443 620 623 O
next NCT03862443 624 628 B-Eq-Comparison
6 NCT03862443 629 630 I-Eq-Comparison
months NCT03862443 631 637 I-Eq-Comparison
outside NCT03862443 638 645 B-Negation
the NCT03862443 646 649 O
greater NCT03862443 650 657 O
Los NCT03862443 658 661 O
Angeles NCT03862443 662 669 O
area NCT03862443 670 674 O
. NCT03862443 674 675 O

- NCT03862443 679 680 O
Own NCT03862443 682 685 O
a NCT03862443 686 687 O
smartphone NCT03862443 688 698 O
with NCT03862443 699 703 O
the NCT03862443 704 707 O
Google NCT03862443 708 714 O
Play NCT03862443 715 719 O
or NCT03862443 720 722 O
iTunes NCT03862443 723 729 O
store NCT03862443 730 735 O
and NCT03862443 736 739 O
be NCT03862443 740 742 O
willing NCT03862443 743 750 O
to NCT03862443 751 753 O
download NCT03862443 754 762 O
the NCT03862443 763 766 O
smart NCT03862443 767 772 O
powered NCT03862443 773 780 O
TB NCT03862443 781 783 O
app NCT03862443 784 787 O

- NCT03862443 790 791 O
Be NCT03862443 793 795 O
willing NCT03862443 796 803 O
to NCT03862443 804 806 O
be NCT03862443 807 809 O
contacted NCT03862443 810 819 O
via NCT03862443 820 823 O
text NCT03862443 824 828 O
- NCT03862443 829 830 O
messaging NCT03862443 831 840 O
( NCT03862443 841 842 O
SMS NCT03862443 843 846 O
) NCT03862443 847 848 O
for NCT03862443 849 852 O
study NCT03862443 853 858 B-Study
related NCT03862443 859 866 O
notifications NCT03862443 867 880 O
, NCT03862443 881 882 O
such NCT03862443 883 887 O
as NCT03862443 888 890 O
incentives NCT03862443 891 901 O
earned NCT03862443 902 908 O
or NCT03862443 909 911 O
reminders NCT03862443 912 921 O
to NCT03862443 922 924 O
sync NCT03862443 925 929 O
the NCT03862443 930 933 O
TB NCT03862443 934 936 O

Exclusion NCT03862443 937 946 O
Criteria NCT03862443 947 955 O
: NCT03862443 956 957 O

- NCT03862443 961 962 O
Known NCT03862443 964 969 O
allergic NCT03862443 970 978 B-Allergy
reaction NCT03862443 979 987 O
to NCT03862443 988 990 O
components NCT03862443 991 1001 O
of NCT03862443 1002 1004 O
the NCT03862443 1005 1008 O
study NCT03862443 1009 1014 B-Study
product NCT03862443 1015 1022 B-Drug
( NCT03862443 1023 1024 O
s NCT03862443 1025 1026 O
) NCT03862443 1027 1028 O
. NCT03862443 1029 1030 O

- NCT03862443 1034 1035 O
Uncooperative NCT03862443 1037 1050 B-Condition
or NCT03862443 1051 1053 B-Or
behaviorally NCT03862443 1054 1066 B-Condition
unsuited NCT03862443 1067 1075 I-Condition
( NCT03862443 1076 1077 O
assessed NCT03862443 1078 1086 O
during NCT03862443 1087 1093 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03862443 1094 1095 O
TB NCT03862443 1096 1098 B-Procedure
prophylaxis NCT03862443 1099 1110 I-Procedure
at NCT03862443 1111 1113 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862443 1114 1117 O
initial NCT03862443 1118 1125 B-Eq-Comparison
baseline NCT03862443 1126 1134 B-Study
study NCT03862443 1135 1140 I-Study
visit NCT03862443 1141 1146 O
) NCT03862443 1147 1148 O
. NCT03862443 1149 1150 O

- NCT03862443 1154 1155 O
A NCT03862443 1157 1158 O
sibling NCT03862443 1159 1166 B-Family-Member___Family-Member-Type:sibling
of NCT03862443 1167 1169 O
a NCT03862443 1170 1171 O
child NCT03862443 1172 1177 B-Family-Member___Family-Member-Type:child
already NCT03862443 1178 1185 O
enrolled NCT03862443 1186 1194 O
in NCT03862443 1195 1197 O
the NCT03862443 1198 1201 O
study NCT03862443 1202 1207 B-Study
( NCT03862443 1208 1209 O
the NCT03862443 1210 1213 O
family NCT03862443 1214 1220 O
's NCT03862443 1220 1222 O
oldest NCT03862443 1223 1229 O
child NCT03862443 1230 1235 O
in NCT03862443 1236 1238 O
the NCT03862443 1239 1242 O
eligible NCT03862443 1243 1251 O
age NCT03862443 1252 1255 O
range NCT03862443 1256 1261 O
will NCT03862443 1262 1266 O
be NCT03862443 1267 1269 O
the NCT03862443 1270 1273 O
study NCT03862443 1274 1279 O
child NCT03862443 1280 1285 O
) NCT03862443 1286 1287 O
. NCT03862443 1288 1289 O

- NCT03862443 1293 1294 O
Enrolled NCT03862443 1296 1304 O
in NCT03862443 1305 1307 O
foster NCT03862443 1308 1314 B-Observation
care NCT03862443 1315 1319 I-Observation
. NCT03862443 1319 1320 O

- NCT03862443 1324 1325 O
Anything NCT03862443 1327 1335 B-Condition
else NCT03862443 1336 1340 I-Condition
that NCT03862443 1341 1345 O
would NCT03862443 1346 1351 B-Assertion___Assertion-Type-Value:hypothetical
place NCT03862443 1352 1357 O
him NCT03862443 1358 1361 O
/ NCT03862443 1362 1363 O
her NCT03862443 1364 1367 O
at NCT03862443 1368 1370 O
increased NCT03862443 1371 1380 O
health NCT03862443 1381 1387 O
risk NCT03862443 1388 1392 B-Risk
or NCT03862443 1393 1395 B-Or
preclude NCT03862443 1396 1404 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862443 1405 1408 O
individual NCT03862443 1409 1419 O
's NCT03862443 1419 1421 O
full NCT03862443 1422 1426 O
compliance NCT03862443 1427 1437 O
with NCT03862443 1438 1442 O
or NCT03862443 1443 1445 O
completion NCT03862443 1446 1456 O
of NCT03862443 1457 1459 O
the NCT03862443 1460 1463 O
study NCT03862443 1464 1469 B-Study
. NCT03862443 1469 1470 O

Inclusion NCT03868813 0 9 O
Criteria NCT03868813 10 18 O
: NCT03868813 19 20 O

Health NCT03868813 22 28 O
Coaches NCT03868813 29 36 O
Group NCT03868813 37 42 O
: NCT03868813 43 44 O

( NCT03868813 47 48 O
i NCT03868813 49 50 O
) NCT03868813 51 52 O
age NCT03868813 53 56 B-Age
between NCT03868813 57 64 B-Eq-Comparison
18 NCT03868813 65 67 I-Eq-Comparison
and NCT03868813 68 71 I-Eq-Comparison
80 NCT03868813 72 74 I-Eq-Comparison
years NCT03868813 75 80 I-Eq-Comparison
( NCT03868813 81 82 O
ii NCT03868813 83 85 O
) NCT03868813 86 87 O
fluent NCT03868813 88 94 O
in NCT03868813 95 97 O
English NCT03868813 98 105 O
( NCT03868813 106 107 O
iii NCT03868813 108 111 O
) NCT03868813 112 113 O
work NCT03868813 114 118 O
in NCT03868813 119 121 O
or NCT03868813 122 124 O
carry NCT03868813 125 130 O
expertise NCT03868813 131 140 O
in NCT03868813 141 143 O
physical NCT03868813 144 152 B-Observation
activity NCT03868813 153 161 I-Observation
, NCT03868813 162 163 O
nutrition NCT03868813 164 173 B-Condition
/ NCT03868813 174 175 B-Or
diet NCT03868813 176 180 B-Observation
or NCT03868813 181 183 B-Or
health NCT03868813 184 190 B-Condition
behavior NCT03868813 191 199 I-Condition
. NCT03868813 199 200 O

People NCT03868813 202 208 O
with NCT03868813 209 213 O
Diabetes NCT03868813 214 222 O
Group NCT03868813 223 228 O
( NCT03868813 229 230 O
Patient NCT03868813 231 238 O
/ NCT03868813 239 240 O
Caregiver NCT03868813 241 250 O
Dyads NCT03868813 251 256 O
) NCT03868813 257 258 O
: NCT03868813 260 261 O

( NCT03868813 264 265 O
i NCT03868813 266 267 O
) NCT03868813 268 269 O
age NCT03868813 270 273 B-Age
between NCT03868813 274 281 B-Eq-Comparison
18 NCT03868813 282 284 I-Eq-Comparison
and NCT03868813 285 288 I-Eq-Comparison
80 NCT03868813 289 291 I-Eq-Comparison
years NCT03868813 292 297 I-Eq-Comparison
( NCT03868813 298 299 O
ii NCT03868813 300 302 O
) NCT03868813 303 304 O
fluent NCT03868813 305 311 O
in NCT03868813 312 314 O
English NCT03868813 315 322 O
( NCT03868813 323 324 O
iii NCT03868813 325 328 O
) NCT03868813 329 330 O
have NCT03868813 331 335 O
Type NCT03868813 336 340 B-Modifier
- NCT03868813 341 342 I-Modifier
II NCT03868813 343 345 I-Modifier
diabetes NCT03868813 346 354 B-Condition
. NCT03868813 354 355 O

Exclusion NCT03868813 357 366 O
Criteria NCT03868813 367 375 O
: NCT03868813 376 377 O

None NCT03868813 379 383 O


Inclusion NCT03864224 0 9 O
Criteria NCT03864224 10 18 O
: NCT03864224 19 20 O

- NCT03864224 24 25 O
Patients NCT03864224 27 35 O
must NCT03864224 36 40 O
have NCT03864224 41 45 O
persistent NCT03864224 46 56 B-Modifier
low NCT03864224 57 60 I-Modifier
back NCT03864224 61 65 I-Modifier
pain NCT03864224 66 70 B-Condition
of NCT03864224 71 73 O
at NCT03864224 74 76 B-Eq-Comparison
least NCT03864224 77 82 I-Eq-Comparison
1 NCT03864224 83 84 I-Eq-Comparison
month NCT03864224 85 90 I-Eq-Comparison
's NCT03864224 90 92 O
duration NCT03864224 93 101 O
. NCT03864224 101 102 O

Exclusion NCT03864224 104 113 O
Criteria NCT03864224 114 122 O
: NCT03864224 123 124 O

- NCT03864224 128 129 O
Participating NCT03864224 131 144 O
currently NCT03864224 145 154 B-Eq-Comparison
in NCT03864224 155 157 O
a NCT03864224 158 159 O
supervised NCT03864224 160 170 O
exercise NCT03864224 171 179 B-Modifier
or NCT03864224 180 182 B-Or
rehabilitation NCT03864224 183 197 B-Modifier
program NCT03864224 198 205 B-Procedure
or NCT03864224 206 208 B-Or
enrolled NCT03864224 209 217 O
in NCT03864224 218 220 O
another NCT03864224 221 228 B-Other
interventional NCT03864224 229 243 O
clinical NCT03864224 244 252 B-Study
trial NCT03864224 253 258 I-Study
. NCT03864224 258 259 O

- NCT03864224 263 264 O
Patients NCT03864224 266 274 O
with NCT03864224 275 279 O
nerve NCT03864224 280 285 B-Condition
root NCT03864224 286 290 I-Condition
involvement NCT03864224 291 302 I-Condition
, NCT03864224 303 304 O
suspected NCT03864224 305 314 B-Assertion___Assertion-Type-Value:possible
serious NCT03864224 315 322 O
pathology NCT03864224 323 332 B-Condition
, NCT03864224 333 334 O
unstable NCT03864224 335 343 O
trauma NCT03864224 344 350 B-Condition
to NCT03864224 351 353 O
the NCT03864224 354 357 O
spine NCT03864224 358 363 B-Modifier
, NCT03864224 364 365 O
aspects NCT03864224 366 373 O
of NCT03864224 374 376 O
pregnancy NCT03864224 377 386 B-Condition
or NCT03864224 387 389 B-Or
other NCT03864224 390 395 B-Other
conditions NCT03864224 396 406 B-Condition
that NCT03864224 407 411 O
would NCT03864224 412 417 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03864224 418 425 B-Negation
participation NCT03864224 426 439 O
or NCT03864224 440 442 O
disallow NCT03864224 443 451 O
trial NCT03864224 452 457 B-Study
completion NCT03864224 458 468 O
within NCT03864224 469 475 O
the NCT03864224 476 479 O
prescribed NCT03864224 480 490 O
time NCT03864224 491 495 O
period NCT03864224 496 502 O
. NCT03864224 502 503 O

- NCT03864224 507 508 O
Persons NCT03864224 510 517 O
with NCT03864224 518 522 O
conditions NCT03864224 523 533 B-Condition
that NCT03864224 534 538 O
require NCT03864224 539 546 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03864224 547 548 O
specialist NCT03864224 549 559 B-Provider
consult NCT03864224 560 567 I-Provider
are NCT03864224 568 571 O
suspected NCT03864224 572 581 B-Assertion___Assertion-Type-Value:possible
of NCT03864224 582 584 O
needing NCT03864224 585 592 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03864224 593 594 O
specialist NCT03864224 595 605 B-Provider
consult NCT03864224 606 613 I-Provider
, NCT03864224 614 615 O
or NCT03864224 616 618 B-Or
have NCT03864224 619 623 O
conditions NCT03864224 624 634 B-Condition
that NCT03864224 635 639 O
would NCT03864224 640 645 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864224 646 648 O
aggravated NCT03864224 649 659 O
or NCT03864224 660 662 B-Or
worsened NCT03864224 663 671 O
if NCT03864224 672 674 O
treated NCT03864224 675 682 B-Procedure
by NCT03864224 683 685 O
the NCT03864224 686 689 O
interventions NCT03864224 690 703 B-Procedure
in NCT03864224 704 706 O
this NCT03864224 707 711 O
study NCT03864224 712 717 B-Study
. NCT03864224 717 718 O

Inclusion NCT03868436 0 9 O
Criteria NCT03868436 10 18 O
: NCT03868436 19 20 O

1 NCT03868436 24 25 O
. NCT03868436 25 26 O
Conscious NCT03868436 28 37 O
adult NCT03868436 38 43 O
patients NCT03868436 44 52 O
: NCT03868436 53 54 O
≥ NCT03868436 55 56 B-Eq-Comparison
18 NCT03868436 57 59 I-Eq-Comparison
years NCT03868436 60 65 I-Eq-Comparison
of NCT03868436 66 68 O
age NCT03868436 69 72 B-Age

2 NCT03868436 75 76 O
. NCT03868436 76 77 O
Moderate NCT03868436 79 87 B-Eq-Comparison
to NCT03868436 88 90 I-Eq-Comparison
severe NCT03868436 91 97 I-Eq-Comparison
pain NCT03868436 98 102 B-Condition
associated NCT03868436 103 113 O
with NCT03868436 114 118 O
trauma NCT03868436 119 125 B-Condition
( NCT03868436 126 127 O
NRS0 NCT03868436 128 132 B-Eq-Comparison|Observation
- NCT03868436 133 134 I-Eq-Comparison|Observation
10 NCT03868436 135 137 I-Eq-Comparison|Observation
≥ NCT03868436 138 139 I-Eq-Comparison
4 NCT03868436 140 141 I-Eq-Comparison
) NCT03868436 142 143 O
which NCT03868436 144 149 O
is NCT03868436 150 152 O
unlikely NCT03868436 153 161 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868436 162 164 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03868436 165 172 O
surgery NCT03868436 173 180 B-Procedure
/ NCT03868436 181 182 B-Or
hospitalization NCT03868436 183 198 B-Encounter
, NCT03868436 199 200 O
such NCT03868436 201 205 O
as NCT03868436 206 208 O

- NCT03868436 216 217 O
Musculoskeletal NCT03868436 219 234 B-Modifier
injuries NCT03868436 235 243 B-Condition
and NCT03868436 244 247 B-Or
physical NCT03868436 248 256 B-Modifier
wounds NCT03868436 257 263 B-Condition

- NCT03868436 271 272 O
Fractures NCT03868436 274 283 B-Condition

- NCT03868436 291 292 O
Lacerations NCT03868436 294 305 B-Condition

- NCT03868436 313 314 O
Burns NCT03868436 316 321 B-Condition

- NCT03868436 329 330 O
Dislocations NCT03868436 332 344 O

- NCT03868436 352 353 O
Contusions NCT03868436 355 365 B-Condition

- NCT03868436 373 374 O
Injury NCT03868436 376 382 B-Condition
due NCT03868436 383 386 O
to NCT03868436 387 389 O
foreign NCT03868436 390 397 B-Condition
bodies NCT03868436 398 404 I-Condition

3 NCT03868436 407 408 O
. NCT03868436 408 409 O
Patient NCT03868436 411 418 O
( NCT03868436 419 420 O
and NCT03868436 421 424 O
/ NCT03868436 425 426 O
or NCT03868436 427 429 O
patient NCT03868436 430 437 O
's NCT03868436 437 439 O
authorized NCT03868436 440 450 O
legal NCT03868436 451 456 O
representative NCT03868436 457 471 O
) NCT03868436 472 473 O
should NCT03868436 474 480 O
understand NCT03868436 481 491 O
the NCT03868436 492 495 O
nature NCT03868436 496 502 O
of NCT03868436 503 505 O
the NCT03868436 506 509 O
study NCT03868436 510 515 O
and NCT03868436 516 519 O
provide NCT03868436 520 527 O
written NCT03868436 528 535 O
informed NCT03868436 536 544 O
consent NCT03868436 545 552 O

4 NCT03868436 555 556 O
. NCT03868436 556 557 O
Patient NCT03868436 559 566 O
is NCT03868436 567 569 O
able NCT03868436 570 574 O
to NCT03868436 575 577 O
follow NCT03868436 578 584 O
all NCT03868436 585 588 O
study NCT03868436 589 594 O
requirements NCT03868436 595 607 O
and NCT03868436 608 611 O
procedures NCT03868436 612 622 O
and NCT03868436 623 626 O
complete NCT03868436 627 635 O
required NCT03868436 636 644 O
questionnaires NCT03868436 645 659 O

Exclusion NCT03868436 660 669 O
Criteria NCT03868436 670 678 O
: NCT03868436 679 680 O

1 NCT03868436 684 685 O
. NCT03868436 685 686 O
Multi NCT03868436 688 693 B-Condition
- NCT03868436 694 695 I-Condition
level NCT03868436 696 701 I-Condition
trauma NCT03868436 702 708 I-Condition

2 NCT03868436 711 712 O
. NCT03868436 712 713 O
Women NCT03868436 715 720 O
of NCT03868436 721 723 B-And
child NCT03868436 724 729 B-Condition
bearing NCT03868436 730 737 I-Condition
potential NCT03868436 738 747 I-Condition
who NCT03868436 748 751 B-And
are NCT03868436 752 755 O
pregnant NCT03868436 756 764 B-Condition
or NCT03868436 765 767 B-Or
peri NCT03868436 768 772 B-Condition
partum NCT03868436 773 779 I-Condition
, NCT03868436 780 781 O
including NCT03868436 782 791 O
labour NCT03868436 792 798 B-Condition

3 NCT03868436 801 802 O
. NCT03868436 802 803 O
An NCT03868436 805 807 O
altered NCT03868436 808 815 B-Condition
level NCT03868436 816 821 I-Condition
of NCT03868436 822 824 I-Condition
consciousness NCT03868436 825 838 I-Condition
, NCT03868436 839 840 O
due NCT03868436 841 844 O
to NCT03868436 845 847 O
any NCT03868436 848 851 O
cause NCT03868436 852 857 B-Condition
, NCT03868436 858 859 O
including NCT03868436 860 869 O
head NCT03868436 870 874 B-Modifier
injury NCT03868436 875 881 B-Condition
, NCT03868436 882 883 O
drugs NCT03868436 884 889 B-Drug
, NCT03868436 890 891 O
or NCT03868436 892 894 B-Or
alcohol NCT03868436 895 902 B-Drug

4 NCT03868436 905 906 O
. NCT03868436 906 907 O
Clinically NCT03868436 909 919 O
significant NCT03868436 920 931 O
renal NCT03868436 932 937 B-Condition
impairment NCT03868436 938 948 I-Condition

5 NCT03868436 951 952 O
. NCT03868436 952 953 O
A NCT03868436 955 956 O
history NCT03868436 957 964 B-Eq-Comparison
of NCT03868436 965 967 O
liver NCT03868436 968 973 B-Condition
dysfunction NCT03868436 974 985 I-Condition
after NCT03868436 986 991 B-Temporal-Connection___Temporal-Connection-Type-Value:after
previous NCT03868436 992 1000 B-Eq-Comparison
MEOF NCT03868436 1001 1005 B-Drug
use NCT03868436 1006 1009 O
or NCT03868436 1010 1012 B-Or
other NCT03868436 1013 1018 B-Other
halogenated NCT03868436 1019 1030 B-Drug
anesthetics NCT03868436 1031 1042 I-Drug

6 NCT03868436 1045 1046 O
. NCT03868436 1046 1047 O
Hypersensitivity NCT03868436 1049 1065 B-Condition
to NCT03868436 1066 1068 O
MEOF NCT03868436 1069 1073 B-Drug
or NCT03868436 1074 1076 B-Or
other NCT03868436 1077 1082 B-Other
halogenated NCT03868436 1083 1094 B-Drug
anesthetics NCT03868436 1095 1106 I-Drug
, NCT03868436 1107 1108 O
or NCT03868436 1109 1111 B-Or
to NCT03868436 1112 1114 O
butylated NCT03868436 1115 1124 B-Drug
hydroxytoluene NCT03868436 1125 1139 I-Drug

7 NCT03868436 1142 1143 O
. NCT03868436 1143 1144 O
Known NCT03868436 1146 1151 O
or NCT03868436 1152 1154 B-Or
genetically NCT03868436 1155 1166 B-Modifier
susceptible NCT03868436 1167 1178 I-Modifier
to NCT03868436 1179 1181 I-Modifier
malignant NCT03868436 1182 1191 I-Modifier
hyperthermia NCT03868436 1192 1204 B-Condition
or NCT03868436 1205 1207 B-Or
a NCT03868436 1208 1209 O
history NCT03868436 1210 1217 B-Eq-Comparison
of NCT03868436 1218 1220 O
severe NCT03868436 1221 1227 O
adverse NCT03868436 1228 1235 B-Condition
reactions NCT03868436 1236 1245 I-Condition
in NCT03868436 1246 1248 O
either NCT03868436 1249 1255 O
patient NCT03868436 1256 1263 B-Family-Member___Family-Member-Type:patient
or NCT03868436 1264 1266 B-Or
relatives NCT03868436 1267 1276 B-Family-Member

8 NCT03868436 1279 1280 O
. NCT03868436 1280 1281 O
Exacerbation NCT03868436 1283 1295 O
of NCT03868436 1296 1298 O
an NCT03868436 1299 1301 O
underlying NCT03868436 1302 1312 B-Condition
condition NCT03868436 1313 1322 I-Condition
( NCT03868436 1323 1324 O
i. NCT03868436 1325 1327 O
e. NCT03868436 1328 1330 O
, NCT03868436 1331 1332 O
chronic NCT03868436 1333 1340 B-Modifier
pain NCT03868436 1341 1345 B-Condition
) NCT03868436 1346 1347 O

9 NCT03868436 1351 1352 O
. NCT03868436 1352 1353 O
Clinically NCT03868436 1355 1365 O
evident NCT03868436 1366 1373 B-Modifier
or NCT03868436 1374 1376 B-Or
potential NCT03868436 1377 1386 B-Assertion___Assertion-Type-Value:hypothetical
hemodynamic NCT03868436 1387 1398 B-Condition
instability NCT03868436 1399 1410 O
as NCT03868436 1411 1413 O
per NCT03868436 1414 1417 O
the NCT03868436 1418 1421 O
opinion NCT03868436 1422 1429 O
of NCT03868436 1430 1432 O
the NCT03868436 1433 1436 O
investigator NCT03868436 1437 1449 O

10 NCT03868436 1451 1453 O
. NCT03868436 1453 1454 O
Clinically NCT03868436 1456 1466 O
evident NCT03868436 1467 1474 O
respiratory NCT03868436 1475 1486 B-Condition
impairment NCT03868436 1487 1497 I-Condition
as NCT03868436 1498 1500 O
per NCT03868436 1501 1504 O
the NCT03868436 1505 1508 O
opinion NCT03868436 1509 1516 O
of NCT03868436 1517 1519 O
the NCT03868436 1520 1523 O
investigator NCT03868436 1524 1536 O

11 NCT03868436 1538 1540 O
. NCT03868436 1540 1541 O
Prior NCT03868436 1543 1548 B-Eq-Comparison
treatment NCT03868436 1549 1558 B-Procedure
with NCT03868436 1559 1563 B-Eq-Comparison
PENTHROX NCT03868436 1564 1572 B-Drug
within NCT03868436 1573 1579 O
3 NCT03868436 1580 1581 I-Eq-Comparison
months NCT03868436 1582 1588 I-Eq-Comparison

Inclusion NCT03869112 0 9 O
Criteria NCT03869112 10 18 O
: NCT03869112 19 20 O

- NCT03869112 24 25 O
Participant NCT03869112 27 38 O
is NCT03869112 39 41 O
willing NCT03869112 42 49 O
and NCT03869112 50 53 O
able NCT03869112 54 58 O
to NCT03869112 59 61 O
give NCT03869112 62 66 O
informed NCT03869112 67 75 O
consent NCT03869112 76 83 O
for NCT03869112 84 87 O
participation NCT03869112 88 101 O
in NCT03869112 102 104 O
the NCT03869112 105 108 O
study NCT03869112 109 114 B-Study

- NCT03869112 117 118 O
Male NCT03869112 120 124 O
or NCT03869112 125 127 B-Or
Female NCT03869112 128 134 O
, NCT03869112 135 136 O
aged NCT03869112 137 141 B-Age
40 NCT03869112 142 144 B-Eq-Comparison
years NCT03869112 145 150 I-Eq-Comparison
to NCT03869112 151 153 I-Eq-Comparison
85 NCT03869112 154 156 I-Eq-Comparison
years NCT03869112 157 162 I-Eq-Comparison
. NCT03869112 162 163 O

- NCT03869112 167 168 O
Diagnosed NCT03869112 170 179 O
with NCT03869112 180 184 O
COPD NCT03869112 185 189 B-Condition

- NCT03869112 192 193 O
Able NCT03869112 195 199 O
( NCT03869112 200 201 O
in NCT03869112 202 204 O
the NCT03869112 205 208 O
Investigators NCT03869112 209 222 O
opinion NCT03869112 223 230 O
) NCT03869112 231 232 O
and NCT03869112 233 236 O
willing NCT03869112 237 244 O
to NCT03869112 245 247 O
comply NCT03869112 248 254 O
with NCT03869112 255 259 O
all NCT03869112 260 263 O
study NCT03869112 264 269 O
requirements NCT03869112 270 282 O
. NCT03869112 282 283 O

- NCT03869112 287 288 O
Participant NCT03869112 290 301 O
is NCT03869112 302 304 O
willing NCT03869112 305 312 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869112 313 315 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03869112 316 322 O
visits NCT03869112 323 329 B-Encounter
at NCT03869112 330 332 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03869112 333 341 B-Study
and NCT03869112 342 345 B-And
8 NCT03869112 346 347 B-Eq-Comparison
weeks NCT03869112 348 353 I-Eq-Comparison
( NCT03869112 354 355 O
sub NCT03869112 356 359 O
- NCT03869112 360 361 O
group NCT03869112 362 367 O
: NCT03869112 368 369 O
baseline NCT03869112 370 378 O
, NCT03869112 379 380 O
8 NCT03869112 381 382 O
weeks NCT03869112 383 388 O
) NCT03869112 389 390 O

- NCT03869112 398 399 O
Able NCT03869112 401 405 O
to NCT03869112 406 408 O
read NCT03869112 409 413 O
and NCT03869112 414 417 O
understand NCT03869112 418 428 O
English NCT03869112 429 436 O

Exclusion NCT03869112 437 446 O
Criteria NCT03869112 447 455 O
: NCT03869112 456 457 O

- NCT03869112 461 462 O
Age NCT03869112 464 467 B-Age
< NCT03869112 468 469 B-Eq-Comparison
40 NCT03869112 470 472 I-Eq-Comparison

- NCT03869112 476 477 O
Attended NCT03869112 479 487 O
a NCT03869112 488 489 O
pulmonary NCT03869112 490 499 B-Procedure
rehabilitation NCT03869112 500 514 I-Procedure
programme NCT03869112 515 524 O
or NCT03869112 525 527 B-Or
participating NCT03869112 528 541 O
in NCT03869112 542 544 O
a NCT03869112 545 546 O
physical NCT03869112 547 555 B-Procedure
activity NCT03869112 556 564 I-Procedure
intervention NCT03869112 565 577 I-Procedure
study NCT03869112 578 583 B-Study
in NCT03869112 584 586 O
current NCT03869112 587 594 B-Eq-Comparison
time NCT03869112 595 599 I-Eq-Comparison
or NCT03869112 600 602 B-Or
in NCT03869112 603 605 O
the NCT03869112 606 609 O
last NCT03869112 610 614 B-Eq-Comparison
6 NCT03869112 615 616 I-Eq-Comparison
months NCT03869112 617 623 I-Eq-Comparison
. NCT03869112 623 624 O

- NCT03869112 628 629 O
Any NCT03869112 631 634 O
other NCT03869112 635 640 B-Other
significant NCT03869112 641 652 O
diseases NCT03869112 653 661 B-Condition
or NCT03869112 662 664 B-Or
disorders NCT03869112 665 674 B-Condition
that NCT03869112 675 679 O
are NCT03869112 680 683 O
a NCT03869112 684 685 O
contraindication NCT03869112 686 702 B-Contraindication
to NCT03869112 703 705 O
be NCT03869112 706 708 O
enrolled NCT03869112 709 717 O
in NCT03869112 718 720 O
a NCT03869112 721 722 O
pulmonary NCT03869112 723 732 B-Procedure
rehabilitation NCT03869112 733 747 I-Procedure
programme NCT03869112 748 757 O
. NCT03869112 757 758 O


Inclusion NCT03861572 0 9 O
Criteria NCT03861572 10 18 O
: NCT03861572 19 20 O

- NCT03861572 24 25 O
Participants NCT03861572 27 39 O
will NCT03861572 40 44 O
be NCT03861572 45 47 O
male NCT03861572 48 52 O
and NCT03861572 53 56 B-Or
female NCT03861572 57 63 O
subjects NCT03861572 64 72 O
who NCT03861572 73 76 B-And
suffered NCT03861572 77 85 B-Eq-Comparison
total NCT03861572 86 91 B-Modifier
acute NCT03861572 92 97 O
Achilles NCT03861572 98 106 B-Condition
tendon NCT03861572 107 113 I-Condition
rupture NCT03861572 114 121 I-Condition
, NCT03861572 122 123 O
and NCT03861572 124 127 B-And
which NCT03861572 128 133 O
underwent NCT03861572 134 143 B-Eq-Comparison
surgical NCT03861572 144 152 B-Procedure
repair NCT03861572 153 159 I-Procedure
. NCT03861572 159 160 O
In NCT03861572 162 164 O
addition NCT03861572 165 173 O
, NCT03861572 174 175 O
to NCT03861572 176 178 O
participate NCT03861572 179 190 O
in NCT03861572 191 193 O
this NCT03861572 194 198 O
study NCT03861572 199 204 B-Study
all NCT03861572 205 208 O
volunteers NCT03861572 209 219 O
will NCT03861572 220 224 O
need NCT03861572 225 229 O
to NCT03861572 230 232 O
present NCT03861572 233 240 O
medical NCT03861572 241 248 O
and NCT03861572 249 252 O
/ NCT03861572 253 254 O
or NCT03861572 255 257 O
physiotherapeutic NCT03861572 258 275 O
release NCT03861572 276 283 O
for NCT03861572 284 287 O
physical NCT03861572 288 296 O
/ NCT03861572 297 298 O
sports NCT03861572 299 305 O
activities NCT03861572 306 316 O
practice NCT03861572 317 325 O
. NCT03861572 325 326 O

Exclusion NCT03861572 328 337 O
Criteria NCT03861572 338 346 O
: NCT03861572 347 348 O

- NCT03861572 352 353 O
Volunteers NCT03861572 355 365 O
that NCT03861572 366 370 O
did NCT03861572 371 374 O
not NCT03861572 375 378 B-Negation
have NCT03861572 379 383 O
Achilles NCT03861572 384 392 B-Procedure
tendon NCT03861572 393 399 I-Procedure
surgical NCT03861572 400 408 I-Procedure
reconstruction NCT03861572 409 423 I-Procedure
, NCT03861572 424 425 O
that NCT03861572 426 430 O
did NCT03861572 431 434 O
not NCT03861572 435 438 B-Negation
present NCT03861572 439 446 O
medical NCT03861572 447 454 B-Modifier
and NCT03861572 455 458 B-Or
/ NCT03861572 459 460 I-Or
or NCT03861572 461 463 I-Or
physiotherapeutic NCT03861572 464 481 B-Modifier
release NCT03861572 482 489 B-Observation
for NCT03861572 490 493 O
physical NCT03861572 494 502 B-Modifier
/ NCT03861572 503 504 B-Or
sports NCT03861572 505 511 B-Modifier
activities NCT03861572 512 522 I-Modifier
, NCT03861572 523 524 O
who NCT03861572 525 528 B-And
have NCT03861572 529 533 O
participated NCT03861572 534 546 O
in NCT03861572 547 549 O
strength NCT03861572 550 558 B-Procedure
training NCT03861572 559 567 I-Procedure
program NCT03861572 568 575 I-Procedure
for NCT03861572 576 579 O
the NCT03861572 580 583 O
plantar NCT03861572 584 591 B-Modifier
flexors NCT03861572 592 599 I-Modifier
in NCT03861572 600 602 O
the NCT03861572 603 606 O
last NCT03861572 607 611 B-Eq-Comparison
6 NCT03861572 612 613 I-Eq-Comparison
months NCT03861572 614 620 I-Eq-Comparison
, NCT03861572 621 622 O
patients NCT03861572 623 631 O
with NCT03861572 632 636 O
diabetic NCT03861572 637 645 B-Condition
diseases NCT03861572 646 654 I-Condition
, NCT03861572 655 656 O
as NCT03861572 657 659 B-And
well NCT03861572 660 664 I-And
as NCT03861572 665 667 O
those NCT03861572 668 673 O
with NCT03861572 674 678 O
difficulty NCT03861572 679 689 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03861572 690 693 O
understanding NCT03861572 694 707 O
and NCT03861572 708 711 O
/ NCT03861572 712 713 O
or NCT03861572 714 716 O
executing NCT03861572 717 726 O
the NCT03861572 727 730 O
test NCT03861572 731 735 B-Study
and NCT03861572 736 739 O
training NCT03861572 740 748 O
protocols NCT03861572 749 758 O
in NCT03861572 759 761 O
the NCT03861572 762 765 O
isokinetic NCT03861572 766 776 O
dynamometer NCT03861572 777 788 O
will NCT03861572 789 793 O
be NCT03861572 794 796 O
excluded NCT03861572 797 805 O
. NCT03861572 805 806 O

Inclusion NCT03864393 0 9 O
Criteria NCT03864393 10 18 O
: NCT03864393 19 20 O

- NCT03864393 24 25 O
18 NCT03864393 27 29 B-Eq-Comparison
years NCT03864393 30 35 I-Eq-Comparison
of NCT03864393 36 38 I-Eq-Comparison
age NCT03864393 39 42 I-Age|Eq-Comparison
or NCT03864393 43 45 I-Eq-Comparison
older NCT03864393 46 51 I-Eq-Comparison

- NCT03864393 54 55 O
diagnosis NCT03864393 57 66 O
of NCT03864393 67 69 O
idiopathic NCT03864393 70 80 B-Modifier
Parkinson NCT03864393 81 90 B-Condition
's NCT03864393 90 92 O
Disease NCT03864393 93 100 I-Condition
, NCT03864393 101 102 O
mild NCT03864393 103 107 B-Eq-Comparison
to NCT03864393 108 110 I-Eq-Comparison
moderate NCT03864393 111 119 I-Eq-Comparison
( NCT03864393 120 121 O
Hoehn NCT03864393 122 127 B-Observation
and NCT03864393 128 131 I-Observation
Yahr NCT03864393 132 136 I-Observation
score NCT03864393 137 142 I-Observation
less NCT03864393 143 147 B-Eq-Comparison
than NCT03864393 148 152 I-Eq-Comparison
or NCT03864393 153 155 I-Eq-Comparison
equal NCT03864393 156 161 I-Eq-Comparison
to NCT03864393 162 164 I-Eq-Comparison
3 NCT03864393 165 166 I-Eq-Comparison
) NCT03864393 167 168 O

- NCT03864393 172 173 O
speaks NCT03864393 175 181 O
English NCT03864393 182 189 O

- NCT03864393 192 193 O
able NCT03864393 195 199 B-Condition
to NCT03864393 200 202 I-Condition
ambulate NCT03864393 203 211 I-Condition
without NCT03864393 212 219 B-Negation
requiring NCT03864393 220 229 O
an NCT03864393 230 232 O
assistive NCT03864393 233 242 B-Procedure
device NCT03864393 243 249 I-Procedure

Exclusion NCT03864393 250 259 O
Criteria NCT03864393 260 268 O
: NCT03864393 269 270 O

- NCT03864393 274 275 O
neurological NCT03864393 277 289 B-Condition
disease NCT03864393 290 297 I-Condition
diagnosis NCT03864393 298 307 O
other NCT03864393 308 313 B-Exception
than NCT03864393 314 318 I-Exception
PD NCT03864393 319 321 B-Condition

- NCT03864393 324 325 O
uncontrolled NCT03864393 327 339 B-Modifier
cardiovascular NCT03864393 340 354 B-Modifier
, NCT03864393 355 356 O
pulmonary NCT03864393 357 366 B-Modifier
, NCT03864393 367 368 O
neurological NCT03864393 369 381 B-Modifier
, NCT03864393 382 383 O
or NCT03864393 384 386 B-Or
metabolic NCT03864393 387 396 B-Modifier
disease NCT03864393 397 404 B-Condition
which NCT03864393 405 410 O
may NCT03864393 411 414 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03864393 415 421 O
the NCT03864393 422 425 O
ability NCT03864393 426 433 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864393 434 436 I-Assertion___Assertion-Type-Value:hypothetical
exercise NCT03864393 437 445 B-Observation
or NCT03864393 446 448 B-Or
in NCT03864393 449 451 O
which NCT03864393 452 457 O
exercise NCT03864393 458 466 B-Observation
is NCT03864393 467 469 O
contraindicated NCT03864393 470 485 B-Contraindication

- NCT03864393 488 489 O
any NCT03864393 491 494 O
medications NCT03864393 495 506 B-Drug
, NCT03864393 507 508 O
such NCT03864393 509 513 O
as NCT03864393 514 516 O
beta NCT03864393 517 521 B-Drug
- NCT03864393 522 523 I-Drug
blockers NCT03864393 524 532 I-Drug
, NCT03864393 533 534 O
that NCT03864393 535 539 O
may NCT03864393 540 543 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03864393 544 549 O
HR NCT03864393 550 552 B-Observation
or NCT03864393 553 555 B-Or
metabolic NCT03864393 556 565 B-Observation
data NCT03864393 566 570 I-Observation

- NCT03864393 573 574 O
cognitive NCT03864393 576 585 B-Modifier
or NCT03864393 586 588 B-Or
psychiatric NCT03864393 589 600 B-Modifier
impairment NCT03864393 601 611 B-Condition
precluding NCT03864393 612 622 O
informed NCT03864393 623 631 O
consent NCT03864393 632 639 O
or NCT03864393 640 642 O
ability NCT03864393 643 650 O
to NCT03864393 651 653 O
following NCT03864393 654 663 O
instructions NCT03864393 664 676 O

- NCT03864393 679 680 I-Observation
mini NCT03864393 682 686 B-Observation
- NCT03864393 687 688 O
Mental NCT03864393 689 695 I-Observation
State NCT03864393 696 701 I-Observation
Examination NCT03864393 702 713 I-Observation
score NCT03864393 714 719 B-Eq-Comparison
< NCT03864393 720 721 I-Eq-Comparison
24 NCT03864393 722 724 I-Eq-Comparison

- NCT03864393 728 729 O
pregnancy NCT03864393 731 740 B-Condition

Inclusion NCT03866590 0 9 O
Criteria NCT03866590 10 18 O
: NCT03866590 19 20 O

- NCT03866590 24 25 O
Informed NCT03866590 27 35 O
consent NCT03866590 36 43 O
is NCT03866590 44 46 O
obtained NCT03866590 47 55 O
from NCT03866590 56 60 O
the NCT03866590 61 64 O
participant NCT03866590 65 76 O
or NCT03866590 77 79 O
its NCT03866590 80 83 O
legal NCT03866590 84 89 O
representatives NCT03866590 90 105 O

- NCT03866590 108 109 O
The NCT03866590 111 114 O
participant NCT03866590 115 126 O
is NCT03866590 127 129 O
older NCT03866590 130 135 B-Eq-Comparison
than NCT03866590 136 140 I-Eq-Comparison
14 NCT03866590 141 143 I-Eq-Comparison
years NCT03866590 144 149 I-Eq-Comparison
and NCT03866590 150 153 B-And
younger NCT03866590 154 161 B-Eq-Comparison
than NCT03866590 162 166 I-Eq-Comparison
25 NCT03866590 167 169 I-Eq-Comparison
years NCT03866590 170 175 I-Eq-Comparison
old NCT03866590 176 179 B-Age

- NCT03866590 182 183 O
The NCT03866590 185 188 O
patient NCT03866590 189 196 O
exhibits NCT03866590 197 205 O
chronic NCT03866590 206 213 B-Modifier
anaemia NCT03866590 214 221 B-Condition
or NCT03866590 222 224 B-Or
cholelithiasis NCT03866590 225 239 B-Condition
or NCT03866590 240 242 B-Or
cholecystitis NCT03866590 243 256 B-Condition
of NCT03866590 257 259 O
undetermined NCT03866590 260 272 B-Modifier
aetiology NCT03866590 273 282 I-Modifier
or NCT03866590 283 285 B-Or
The NCT03866590 286 289 O
patient NCT03866590 290 297 O
has NCT03866590 298 301 O
a NCT03866590 302 303 O
high NCT03866590 304 308 O
- NCT03866590 309 310 O
grade NCT03866590 311 316 O
PKD NCT03866590 317 320 B-Condition
suspicion NCT03866590 321 330 B-Assertion___Assertion-Type-Value:possible
due NCT03866590 331 334 O
to NCT03866590 335 337 O
any NCT03866590 338 341 O
clinical NCT03866590 342 350 O
item NCT03866590 351 355 O
or NCT03866590 356 358 B-Or
The NCT03866590 359 362 O
patient NCT03866590 363 370 O
is NCT03866590 371 373 O
diagnosed NCT03866590 374 383 O
biochemically NCT03866590 384 397 B-Procedure
and NCT03866590 398 401 B-Or
/ NCT03866590 402 403 I-Or
or NCT03866590 404 406 I-Or
genetically NCT03866590 407 418 B-Procedure
with NCT03866590 419 423 O
PKD NCT03866590 424 427 B-Condition

Exclusion NCT03866590 428 437 O
Criteria NCT03866590 438 446 O
: NCT03866590 447 448 O

- NCT03866590 452 453 O
Inability NCT03866590 455 464 O
to NCT03866590 465 467 O
provide NCT03866590 468 475 O
informed NCT03866590 476 484 O
consent NCT03866590 485 492 O

- NCT03866590 495 496 O
The NCT03866590 498 501 O
patient NCT03866590 502 509 O
does NCT03866590 510 514 O
not NCT03866590 515 518 B-Negation
suffer NCT03866590 519 525 O
from NCT03866590 526 530 O
chronic NCT03866590 531 538 B-Modifier
anaemia NCT03866590 539 546 B-Condition
or NCT03866590 547 549 B-Or
cholelithiasis NCT03866590 550 564 B-Condition
or NCT03866590 565 567 B-Or
cholecystitis NCT03866590 568 581 B-Condition

- NCT03866590 584 585 O
The NCT03866590 587 590 O
aetiology NCT03866590 591 600 O
of NCT03866590 601 603 O
chronic NCT03866590 604 611 B-Modifier
anaemia NCT03866590 612 619 B-Condition
or NCT03866590 620 622 B-Or
cholelithiasis NCT03866590 623 637 B-Condition
or NCT03866590 638 640 B-Or
cholecystitis NCT03866590 641 654 B-Condition
is NCT03866590 655 657 O
determined NCT03866590 658 668 O
and NCT03866590 669 672 O
is NCT03866590 673 675 O
not NCT03866590 676 679 B-Negation
due NCT03866590 680 683 O
to NCT03866590 684 686 O
PKD NCT03866590 687 690 B-Condition

- NCT03866590 693 694 O
The NCT03866590 696 699 O
participant NCT03866590 700 711 O
is NCT03866590 712 714 O
younger NCT03866590 715 722 B-Eq-Comparison
than NCT03866590 723 727 I-Eq-Comparison
14 NCT03866590 728 730 I-Eq-Comparison
years NCT03866590 731 736 I-Eq-Comparison
or NCT03866590 737 739 B-Or
older NCT03866590 740 745 B-Eq-Comparison
than NCT03866590 746 750 I-Eq-Comparison
25 NCT03866590 751 753 I-Eq-Comparison
years NCT03866590 754 759 I-Eq-Comparison
old NCT03866590 760 763 B-Age

- NCT03866590 766 767 O
Previously NCT03866590 769 779 B-Eq-Comparison
enrolled NCT03866590 780 788 O
in NCT03866590 789 791 O
the NCT03866590 792 795 O
study NCT03866590 796 801 B-Study

Inclusion NCT03869476 0 9 O
Criteria NCT03869476 10 18 O
: NCT03869476 19 20 O

- NCT03869476 24 25 O
Adult NCT03869476 27 32 O
( NCT03869476 33 34 O
18 NCT03869476 35 37 B-Eq-Comparison
years NCT03869476 38 43 I-Eq-Comparison
of NCT03869476 44 46 I-Eq-Comparison
age NCT03869476 47 50 I-Age|Eq-Comparison
or NCT03869476 51 53 I-Eq-Comparison
older NCT03869476 54 59 I-Eq-Comparison
) NCT03869476 60 61 O
with NCT03869476 62 66 B-And
the NCT03869476 67 70 O
diagnosis NCT03869476 71 80 O
of NCT03869476 81 83 O
essential NCT03869476 84 93 B-Modifier
thrombocytosis NCT03869476 94 108 B-Condition
, NCT03869476 109 110 O
prefibrotic NCT03869476 111 122 B-Condition
myelofibrosis NCT03869476 123 136 I-Condition
or NCT03869476 137 139 B-Or
overt NCT03869476 140 145 B-Modifier
myelofibrosis NCT03869476 146 159 B-Condition
according NCT03869476 160 169 O
to NCT03869476 170 172 O
WHO NCT03869476 173 176 O
2016 NCT03869476 177 181 O
criteria NCT03869476 182 190 O
; NCT03869476 190 191 O

- NCT03869476 194 195 O
Patient NCT03869476 197 204 O
who NCT03869476 205 208 O
has NCT03869476 209 212 O
not NCT03869476 213 216 B-Negation
received NCT03869476 217 225 B-Eq-Comparison
specific NCT03869476 226 234 O
treatment NCT03869476 235 244 B-Procedure
for NCT03869476 245 248 O
neoplasms NCT03869476 249 258 B-Condition
; NCT03869476 258 259 O

- NCT03869476 262 263 O
Patient NCT03869476 265 272 O
who NCT03869476 273 276 O
has NCT03869476 277 280 O
signed NCT03869476 281 287 O
the NCT03869476 288 291 O
consent NCT03869476 292 299 O
to NCT03869476 300 302 O
participate NCT03869476 303 314 O
in NCT03869476 315 317 O
the NCT03869476 318 321 O
study NCT03869476 322 327 B-Study
; NCT03869476 327 328 O

- NCT03869476 331 332 O
Patient NCT03869476 334 341 O
who NCT03869476 342 345 O
has NCT03869476 346 349 O
consented NCT03869476 350 359 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869476 360 362 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03869476 363 365 O
included NCT03869476 366 374 O
in NCT03869476 375 377 O
the NCT03869476 378 381 O
" NCT03869476 382 383 O
Malignant NCT03869476 383 392 O
Haemopathies NCT03869476 393 405 O
" NCT03869476 405 406 O
collection NCT03869476 407 417 O
at NCT03869476 418 420 O
the NCT03869476 421 424 O
University NCT03869476 425 435 O
Hospital NCT03869476 436 444 O
of NCT03869476 445 447 O
Angers NCT03869476 448 454 O
or NCT03869476 455 457 B-Or
Brest NCT03869476 458 463 O
and NCT03869476 464 467 O
for NCT03869476 468 471 O
whom NCT03869476 472 476 O
the NCT03869476 477 480 O
samples NCT03869476 481 488 O
necessary NCT03869476 489 498 O
for NCT03869476 499 502 O
the NCT03869476 503 506 O
study NCT03869476 507 512 B-Study
are NCT03869476 513 516 O
available NCT03869476 517 526 O
in NCT03869476 527 529 O
the NCT03869476 530 533 O
biocollection NCT03869476 534 547 O
. NCT03869476 547 548 O

Exclusion NCT03869476 550 559 O
Criteria NCT03869476 560 568 O
: NCT03869476 569 570 O

- NCT03869476 574 575 O
Patient NCT03869476 577 584 O
with NCT03869476 585 589 O
another NCT03869476 590 597 B-Other
hematologic NCT03869476 598 609 B-Condition
neoplasm NCT03869476 610 618 I-Condition
or NCT03869476 619 621 B-Or
progressive NCT03869476 622 633 B-Modifier
cancer NCT03869476 634 640 B-Condition
at NCT03869476 641 643 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869476 644 647 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03869476 648 652 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03869476 653 655 O
diagnosis NCT03869476 656 665 B-Coreference
; NCT03869476 665 666 O

- NCT03869476 669 670 O
Patient NCT03869476 672 679 O
with NCT03869476 680 684 O
a NCT03869476 685 686 O
diagnosis NCT03869476 687 696 O
of NCT03869476 697 699 O
secondary NCT03869476 700 709 B-Modifier
myelofibrosis NCT03869476 710 723 B-Condition
; NCT03869476 723 724 O

- NCT03869476 727 728 O
Pregnant NCT03869476 730 738 B-Condition
or NCT03869476 739 741 B-Or
breastfeeding NCT03869476 742 755 B-Condition
woman NCT03869476 756 761 O
; NCT03869476 761 762 O

- NCT03869476 765 766 O
Person NCT03869476 768 774 O
prived NCT03869476 775 781 B-Observation
of NCT03869476 782 784 I-Observation
liberty NCT03869476 785 792 I-Observation
by NCT03869476 793 795 O
judicial NCT03869476 796 804 O
or NCT03869476 805 807 O
administrative NCT03869476 808 822 O
decision NCT03869476 823 831 O
; NCT03869476 831 832 O

- NCT03869476 835 836 O
Person NCT03869476 838 844 O
subject NCT03869476 845 852 O
to NCT03869476 853 855 O
a NCT03869476 856 857 O
legal NCT03869476 858 863 B-Observation
protection NCT03869476 864 874 I-Observation
measure NCT03869476 875 882 I-Observation
; NCT03869476 882 883 O

Inclusion NCT03869489 0 9 O
Criteria NCT03869489 10 18 O
: NCT03869489 19 20 O

- NCT03869489 24 25 O
Normal NCT03869489 27 33 O
hearing NCT03869489 34 41 B-Condition
and NCT03869489 42 45 B-And
vision NCT03869489 46 52 B-Condition

Exclusion NCT03869489 53 62 O
Criteria NCT03869489 63 71 O
: NCT03869489 72 73 O

- NCT03869489 77 78 O
Left NCT03869489 80 84 B-Condition
- NCT03869489 85 86 I-Condition
handedness NCT03869489 87 97 I-Condition

- NCT03869489 100 101 O
History NCT03869489 103 110 B-Eq-Comparison
of NCT03869489 111 113 O
seizure NCT03869489 114 121 B-Condition
, NCT03869489 122 123 O
head NCT03869489 124 128 B-Modifier
injury NCT03869489 129 135 B-Condition
( NCT03869489 136 137 O
including NCT03869489 138 147 O
neurosurgery NCT03869489 148 160 B-Procedure
) NCT03869489 161 162 O
, NCT03869489 164 165 O
brain NCT03869489 166 171 B-Modifier
injury NCT03869489 172 178 B-Condition
, NCT03869489 179 180 O
diagnosis NCT03869489 181 190 O
or NCT03869489 191 193 B-Or
a NCT03869489 194 195 O
neurological NCT03869489 196 208 B-Modifier
or NCT03869489 209 211 B-Or
psychiatric NCT03869489 212 223 B-Modifier
disorder NCT03869489 224 232 B-Condition
, NCT03869489 233 234 O
metal NCT03869489 235 240 B-Condition
in NCT03869489 241 243 I-Condition
the NCT03869489 244 247 I-Condition
head NCT03869489 248 252 I-Condition
, NCT03869489 253 254 O
sensitive NCT03869489 255 264 B-Condition
scalp NCT03869489 265 270 I-Condition

- NCT03869489 273 274 O
History NCT03869489 276 283 B-Eq-Comparison
of NCT03869489 284 286 O
anxiolytic NCT03869489 287 297 B-Drug
and NCT03869489 298 301 B-Or
/ NCT03869489 302 303 I-Or
or NCT03869489 304 306 I-Or
antidepressant NCT03869489 307 321 B-Drug
medications NCT03869489 322 333 I-Drug

- NCT03869489 336 337 O
Participation NCT03869489 339 352 O
in NCT03869489 353 355 O
Experiment NCT03869489 356 366 B-Study
# NCT03869489 367 368 O
1 NCT03869489 368 369 O
or NCT03869489 370 372 B-Or
Experiment NCT03869489 373 383 B-Study
# NCT03869489 384 385 O
2 NCT03869489 385 386 O
of NCT03869489 387 389 O
the NCT03869489 390 393 O
larger NCT03869489 394 400 O
study NCT03869489 401 406 B-Study

Inclusion NCT03863210 0 9 O
Criteria NCT03863210 10 18 O
: NCT03863210 19 20 O

- NCT03863210 24 25 O
female NCT03863210 27 33 O
sex NCT03863210 34 37 O

- NCT03863210 40 41 O
age NCT03863210 43 46 B-Age
45 NCT03863210 47 49 B-Eq-Comparison
to NCT03863210 50 52 I-Eq-Comparison
60 NCT03863210 53 55 I-Eq-Comparison
years NCT03863210 56 61 I-Eq-Comparison

- NCT03863210 64 65 O
one NCT03863210 67 70 B-Eq-Comparison
or NCT03863210 71 73 I-Eq-Comparison
more NCT03863210 74 78 I-Eq-Comparison
CV NCT03863210 79 81 B-Condition
risk NCT03863210 82 86 B-Risk
factors NCT03863210 87 94 I-Risk
[ NCT03863210 95 96 O
overweight NCT03863210 97 107 B-Condition
or NCT03863210 108 110 B-Or
obesity NCT03863210 111 118 B-Condition
, NCT03863210 119 120 O
i. NCT03863210 121 123 O
e. NCT03863210 125 127 O
body NCT03863210 129 133 B-Observation
mass NCT03863210 134 138 I-Observation
index NCT03863210 139 144 I-Observation
( NCT03863210 145 146 O
BMI NCT03863210 147 150 B-Observation
) NCT03863210 151 152 O
≥ NCT03863210 153 154 B-Eq-Comparison
25 NCT03863210 155 157 I-Eq-Comparison
kg NCT03863210 158 160 I-Eq-Comparison
/ NCT03863210 161 162 I-Eq-Comparison|Or
m2 NCT03863210 163 165 I-Eq-Comparison
, NCT03863210 166 167 O
and NCT03863210 168 171 B-Or
/ NCT03863210 172 173 O
or NCT03863210 174 176 I-Or
central NCT03863210 177 184 B-Modifier
obesity NCT03863210 185 192 B-Condition
- NCT03863210 193 194 O
waist NCT03863210 195 200 B-Observation
circumference NCT03863210 201 214 I-Observation
≥ NCT03863210 215 216 B-Eq-Comparison
88 NCT03863210 217 219 I-Eq-Comparison
cm NCT03863210 220 222 I-Eq-Comparison
, NCT03863210 223 224 O
high NCT03863210 225 229 O
blood NCT03863210 230 235 B-Observation
pressure NCT03863210 236 244 I-Observation
( NCT03863210 245 246 O
systolic NCT03863210 247 255 B-Observation
blood NCT03863210 256 261 I-Observation
pressure NCT03863210 262 270 I-Observation
≥ NCT03863210 271 272 B-Eq-Comparison
140 NCT03863210 273 276 I-Eq-Comparison
mm NCT03863210 277 279 I-Eq-Comparison
Hg NCT03863210 280 282 I-Eq-Comparison
and NCT03863210 283 286 B-Or
/ NCT03863210 287 288 I-Or
or NCT03863210 289 291 I-Or
diastolic NCT03863210 292 301 B-Observation
blood NCT03863210 302 307 I-Observation
pressure NCT03863210 308 316 I-Observation
≥ NCT03863210 317 318 B-Eq-Comparison
90 NCT03863210 319 321 I-Eq-Comparison
mm NCT03863210 322 324 I-Eq-Comparison
Hg NCT03863210 325 327 I-Eq-Comparison
) NCT03863210 328 329 O
, NCT03863210 331 332 O
high NCT03863210 333 337 O
blood NCT03863210 338 343 B-Observation
cholesterol NCT03863210 344 355 I-Observation
( NCT03863210 356 357 O
≥ NCT03863210 359 360 B-Eq-Comparison
5.2 NCT03863210 361 364 I-Eq-Comparison
mmol NCT03863210 365 369 I-Eq-Comparison
/ NCT03863210 370 371 I-Eq-Comparison
L NCT03863210 372 373 I-Eq-Comparison
) NCT03863210 374 375 O
and NCT03863210 376 379 B-And
active NCT03863210 380 386 B-Eq-Comparison
smoking NCT03863210 387 394 B-Condition
] NCT03863210 395 396 O

- NCT03863210 400 401 O
participants NCT03863210 403 415 O
on NCT03863210 416 418 B-Eq-Comparison
antihypertensive NCT03863210 419 435 B-Procedure
therapy NCT03863210 436 443 I-Procedure
were NCT03863210 444 448 O
also NCT03863210 449 453 O
included NCT03863210 454 462 O
in NCT03863210 463 465 O
the NCT03863210 466 469 O
study NCT03863210 470 475 B-Study

Exclusion NCT03863210 476 485 O
Criteria NCT03863210 486 494 O
: NCT03863210 495 496 O

- NCT03863210 500 501 O
current NCT03863210 503 510 B-Eq-Comparison
cardiovascular NCT03863210 511 525 B-Condition
disease NCT03863210 526 533 I-Condition|Condition
( NCT03863210 534 535 O
CVD NCT03863210 536 539 B-Condition
) NCT03863210 540 541 O
( NCT03863210 542 543 O
ischemic NCT03863210 544 552 B-Condition
heart NCT03863210 553 558 I-Condition
disease NCT03863210 559 566 I-Condition
, NCT03863210 567 568 O
peripheral NCT03863210 569 579 B-Condition
artery NCT03863210 580 586 I-Condition
disease NCT03863210 587 594 I-Condition
, NCT03863210 595 596 O
and NCT03863210 597 600 B-Or
stroke NCT03863210 601 607 B-Condition
) NCT03863210 608 609 O

- NCT03863210 613 614 O
malignant NCT03863210 616 625 B-Condition
diseases NCT03863210 626 634 B-Condition

- NCT03863210 637 638 O
serious NCT03863210 640 647 O
systemic NCT03863210 648 656 B-Modifier
or NCT03863210 657 659 B-Or
mental NCT03863210 660 666 B-Modifier
diseases NCT03863210 667 675 O

Inclusion NCT03868345 0 9 O
Criteria NCT03868345 10 18 O
: NCT03868345 19 20 O

1 NCT03868345 24 25 O
. NCT03868345 25 26 O
male NCT03868345 28 32 O
or NCT03868345 33 35 B-Or
female NCT03868345 36 42 O
, NCT03868345 43 44 O
age NCT03868345 45 48 B-Age
21 NCT03868345 49 51 B-Eq-Comparison
or NCT03868345 52 54 I-Eq-Comparison
older NCT03868345 55 60 I-Eq-Comparison
, NCT03868345 61 62 O

2 NCT03868345 66 67 O
. NCT03868345 67 68 O
diagnosed NCT03868345 70 79 O
with NCT03868345 80 84 O
definite NCT03868345 85 93 B-Modifier
, NCT03868345 94 95 O
probable NCT03868345 96 104 B-Assertion___Assertion-Type-Value:possible
, NCT03868345 105 106 O
or NCT03868345 107 109 B-Or
possible NCT03868345 110 118 B-Assertion___Assertion-Type-Value:possible
ALS NCT03868345 119 122 B-Condition
according NCT03868345 123 132 O
to NCT03868345 133 135 O
the NCT03868345 136 139 O
modified NCT03868345 140 148 O
El NCT03868345 149 151 O
Escorial NCT03868345 152 160 O
Criteria NCT03868345 161 169 O
, NCT03868345 170 171 O

3 NCT03868345 175 176 O
. NCT03868345 176 177 O
a NCT03868345 179 180 O
score NCT03868345 181 186 B-Eq-Comparison
of NCT03868345 187 189 I-Eq-Comparison
2 NCT03868345 190 191 I-Eq-Comparison
or NCT03868345 192 194 I-Eq-Comparison
greater NCT03868345 195 202 I-Eq-Comparison
on NCT03868345 203 205 O
the NCT03868345 206 209 O
speech NCT03868345 210 216 B-Observation
question NCT03868345 217 225 I-Observation
of NCT03868345 226 228 I-Observation
the NCT03868345 229 232 I-Observation
ALSFRS NCT03868345 233 239 I-Observation
- NCT03868345 240 241 I-Observation
R NCT03868345 242 243 I-Observation
( NCT03868345 244 245 O
i. NCT03868345 246 248 O
e. NCT03868345 249 251 O
speech NCT03868345 253 259 B-Condition
is NCT03868345 260 262 O
intelligible NCT03868345 263 275 B-Modifier
with NCT03868345 276 280 O
occasional NCT03868345 281 291 B-Modifier
repetition NCT03868345 292 302 I-Modifier
) NCT03868345 303 304 O
, NCT03868345 306 307 O

4 NCT03868345 311 312 O
. NCT03868345 312 313 O
continuous NCT03868345 315 325 O
internet NCT03868345 326 334 O
access NCT03868345 335 341 O
at NCT03868345 342 344 O
home NCT03868345 345 349 O
, NCT03868345 350 351 O

5 NCT03868345 355 356 O
. NCT03868345 356 357 O
willingness NCT03868345 359 370 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03868345 371 374 I-Assertion___Assertion-Type-Value:hypothetical
medical NCT03868345 375 382 I-Assertion___Assertion-Type-Value:hypothetical
ability NCT03868345 383 390 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 391 393 O
comply NCT03868345 394 400 O
with NCT03868345 401 405 O
scheduled NCT03868345 406 415 B-Eq-Comparison
visits NCT03868345 416 422 B-Encounter
and NCT03868345 423 426 B-And
study NCT03868345 427 432 B-Study
procedures NCT03868345 433 443 B-Procedure
, NCT03868345 444 445 O

6 NCT03868345 449 450 O
. NCT03868345 450 451 O
ability NCT03868345 453 460 O
to NCT03868345 461 463 O
understand NCT03868345 464 474 O
the NCT03868345 475 478 O
purpose NCT03868345 479 486 O
and NCT03868345 487 490 O
risks NCT03868345 491 496 O
of NCT03868345 497 499 O
the NCT03868345 500 503 O
study NCT03868345 504 509 O
and NCT03868345 510 513 O
provide NCT03868345 514 521 O
signed NCT03868345 522 528 O
and NCT03868345 529 532 O
dated NCT03868345 533 538 O
informed NCT03868345 539 547 O
consent NCT03868345 548 555 O
and NCT03868345 556 559 O
authorization NCT03868345 560 573 O
to NCT03868345 574 576 O
use NCT03868345 577 580 O
protected NCT03868345 581 590 O
health NCT03868345 591 597 O
information NCT03868345 598 609 O
( NCT03868345 610 611 O
PHI NCT03868345 612 615 O
) NCT03868345 616 617 O
in NCT03868345 618 620 O
accordance NCT03868345 621 631 O
with NCT03868345 632 636 O
national NCT03868345 637 645 O
and NCT03868345 646 649 O
local NCT03868345 650 655 O
subject NCT03868345 656 663 O
privacy NCT03868345 664 671 O
regulations NCT03868345 672 683 O
, NCT03868345 684 685 O

7 NCT03868345 689 690 O
. NCT03868345 690 691 O
geographic NCT03868345 693 703 O
accessibility NCT03868345 704 717 O
to NCT03868345 718 720 O
study NCT03868345 721 726 O
site NCT03868345 727 731 O
, NCT03868345 732 733 O

8 NCT03868345 737 738 O
. NCT03868345 738 739 O
for NCT03868345 741 744 O
the NCT03868345 745 748 O
25 NCT03868345 749 751 O
participants NCT03868345 752 764 O
in NCT03868345 765 767 O
Group NCT03868345 768 773 O
1 NCT03868345 774 775 O
, NCT03868345 776 777 O
NO NCT03868345 778 780 B-Negation
noted NCT03868345 781 786 O
symptoms NCT03868345 787 795 B-Assertion___Assertion-Type-Value:possible
of NCT03868345 796 798 O
frontotemporal NCT03868345 799 813 B-Condition
cognitive NCT03868345 814 823 I-Condition
dysfunction NCT03868345 824 835 I-Condition
, NCT03868345 836 837 O
and NCT03868345 838 841 B-And

9 NCT03868345 844 845 O
. NCT03868345 845 846 O
for NCT03868345 848 851 O
the NCT03868345 852 855 O
25 NCT03868345 856 858 O
participants NCT03868345 859 871 O
in NCT03868345 872 874 O
Group NCT03868345 875 880 O
2 NCT03868345 881 882 O
, NCT03868345 883 884 O
MUST NCT03868345 885 889 O
have NCT03868345 890 894 O
cognitive NCT03868345 895 904 B-Condition
symptoms NCT03868345 905 913 B-Assertion___Assertion-Type-Value:possible
as NCT03868345 914 916 O
noted NCT03868345 917 922 O
either NCT03868345 923 929 O
by NCT03868345 930 932 O
themselves NCT03868345 933 943 O
or NCT03868345 944 946 O
a NCT03868345 947 948 O
caregiver NCT03868345 949 958 O
. NCT03868345 958 959 O

Exclusion NCT03868345 961 970 O
Criteria NCT03868345 971 979 O
: NCT03868345 980 981 O

1 NCT03868345 985 986 O
. NCT03868345 986 987 O
unwilling NCT03868345 989 998 O
or NCT03868345 999 1001 O
unable NCT03868345 1002 1008 O
to NCT03868345 1009 1011 O
comply NCT03868345 1012 1018 O
with NCT03868345 1019 1023 O
the NCT03868345 1024 1027 O
requirements NCT03868345 1028 1040 O
of NCT03868345 1041 1043 O
this NCT03868345 1044 1048 O
protocol NCT03868345 1049 1057 O
, NCT03868345 1058 1059 O
including NCT03868345 1060 1069 O
the NCT03868345 1070 1073 O
presence NCT03868345 1074 1082 O
of NCT03868345 1083 1085 O
any NCT03868345 1086 1089 O
condition NCT03868345 1090 1099 B-Condition
( NCT03868345 1100 1101 O
physical NCT03868345 1102 1110 B-Modifier
, NCT03868345 1111 1112 O
mental NCT03868345 1113 1119 B-Modifier
, NCT03868345 1120 1121 O
or NCT03868345 1122 1124 B-Or
social NCT03868345 1125 1131 B-Modifier
) NCT03868345 1132 1133 O
that NCT03868345 1134 1138 O
is NCT03868345 1139 1141 O
likely NCT03868345 1142 1148 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 1149 1151 O
affect NCT03868345 1152 1158 O
the NCT03868345 1159 1162 O
participant NCT03868345 1163 1174 O
's NCT03868345 1174 1176 O
ability NCT03868345 1177 1184 O
to NCT03868345 1185 1187 O
comply NCT03868345 1188 1194 O
with NCT03868345 1195 1199 O
the NCT03868345 1200 1203 O
protocol NCT03868345 1204 1212 O
, NCT03868345 1213 1214 O
and NCT03868345 1215 1218 O

2 NCT03868345 1221 1222 O
. NCT03868345 1222 1223 O
any NCT03868345 1225 1228 O
other NCT03868345 1229 1234 O
reasons NCT03868345 1235 1242 O
that NCT03868345 1243 1247 O
, NCT03868345 1248 1249 O
in NCT03868345 1250 1252 O
the NCT03868345 1253 1256 O
opinion NCT03868345 1257 1264 O
of NCT03868345 1265 1267 O
the NCT03868345 1268 1271 O
PI NCT03868345 1272 1274 O
, NCT03868345 1275 1276 O
cause NCT03868345 1277 1282 O
the NCT03868345 1283 1286 O
candidate NCT03868345 1287 1296 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 1297 1299 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868345 1300 1302 O
deemed NCT03868345 1303 1309 O
unsuitable NCT03868345 1310 1320 B-Negation
for NCT03868345 1321 1324 O
entry NCT03868345 1325 1330 O
into NCT03868345 1331 1335 O
the NCT03868345 1336 1339 O
study NCT03868345 1340 1345 B-Study
. NCT03868345 1345 1346 O

Inclusion NCT03862898 0 9 O
Criteria NCT03862898 10 18 O
: NCT03862898 19 20 O

- NCT03862898 24 25 O
patients NCT03862898 27 35 O
with NCT03862898 36 40 O
lumbar NCT03862898 41 47 B-Modifier
pain NCT03862898 48 52 B-Condition
present NCT03862898 53 60 O
for NCT03862898 61 64 O
more NCT03862898 65 69 B-Eq-Comparison
than NCT03862898 70 74 I-Eq-Comparison
12 NCT03862898 75 77 I-Eq-Comparison
weeks NCT03862898 78 83 I-Eq-Comparison
, NCT03862898 84 85 O

- NCT03862898 89 90 O
pain NCT03862898 92 96 B-Condition
during NCT03862898 97 103 B-Temporal-Connection___Temporal-Connection-Type-Value:during
changing NCT03862898 104 112 B-Observation
of NCT03862898 113 115 I-Observation
the NCT03862898 116 119 I-Observation
position NCT03862898 120 128 I-Observation
, NCT03862898 129 130 O

- NCT03862898 134 135 O
radicular NCT03862898 137 146 B-Modifier
pain NCT03862898 147 151 B-Condition
. NCT03862898 151 152 O

Exclusion NCT03862898 154 163 O
Criteria NCT03862898 164 172 O
: NCT03862898 173 174 O

- NCT03862898 178 179 O
Cauda NCT03862898 181 186 B-Condition
equina NCT03862898 187 193 I-Condition
syndrome NCT03862898 194 202 I-Condition
, NCT03862898 203 204 O

- NCT03862898 208 209 O
ankylosing NCT03862898 211 221 B-Condition
spondylitis NCT03862898 222 233 I-Condition
, NCT03862898 234 235 O

- NCT03862898 239 240 O
thoracic NCT03862898 242 250 B-Condition
deformities NCT03862898 251 262 I-Condition
( NCT03862898 263 264 O
pectus NCT03862898 265 271 B-Condition
carinatum NCT03862898 272 281 I-Condition
, NCT03862898 282 283 O
excavatum NCT03862898 284 293 B-Condition
) NCT03862898 294 295 O
, NCT03862898 297 298 O

- NCT03862898 302 303 O
spina NCT03862898 305 310 B-Condition
bifida NCT03862898 311 317 I-Condition
, NCT03862898 318 319 O

- NCT03862898 323 324 O
fractures NCT03862898 326 335 B-Condition
, NCT03862898 336 337 O

- NCT03862898 341 342 O
post NCT03862898 344 348 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862898 349 350 O
- NCT03862898 352 353 O
operative NCT03862898 354 363 B-Procedure
spinal NCT03862898 364 370 B-Condition
conditions NCT03862898 371 381 I-Condition
, NCT03862898 382 383 O

- NCT03862898 387 388 O
diabetes NCT03862898 390 398 B-Condition
, NCT03862898 399 400 O

- NCT03862898 404 405 O
inflammatory NCT03862898 407 419 B-Condition
processes NCT03862898 420 429 I-Condition
, NCT03862898 430 431 O

- NCT03862898 435 436 O
tumors NCT03862898 438 444 B-Condition
, NCT03862898 445 446 O

- NCT03862898 450 451 O
pregnancy NCT03862898 453 462 B-Condition
. NCT03862898 462 463 O

Inclusion NCT03869073 0 9 O
Criteria NCT03869073 10 18 O
: NCT03869073 19 20 O

- NCT03869073 24 25 O
Signed NCT03869073 27 33 O
informed NCT03869073 34 42 O
consent NCT03869073 43 50 O

- NCT03869073 53 54 O
At NCT03869073 56 58 B-Eq-Comparison
least NCT03869073 59 64 I-Eq-Comparison
19 NCT03869073 65 67 I-Eq-Comparison
years NCT03869073 68 73 I-Eq-Comparison
of NCT03869073 74 76 O
age NCT03869073 77 80 B-Age

- NCT03869073 83 84 O
Known NCT03869073 86 91 B-Modifier
or NCT03869073 92 94 B-Or
suspected NCT03869073 95 104 B-Assertion___Assertion-Type-Value:possible
infection NCT03869073 105 114 B-Condition

- NCT03869073 117 118 O
AND NCT03869073 120 123 B-And
one NCT03869073 124 127 B-Eq-Comparison
or NCT03869073 128 130 I-Eq-Comparison
more NCT03869073 131 135 I-Eq-Comparison
of NCT03869073 136 138 O
the NCT03869073 139 142 B-Criteria-Count
following NCT03869073 143 152 I-Criteria-Count
organ NCT03869073 153 158 B-Condition
dysfunctions NCT03869073 159 171 I-Condition
judged NCT03869073 172 178 O
due NCT03869073 179 182 O
to NCT03869073 183 185 O
sepsis NCT03869073 186 192 B-Condition
: NCT03869073 193 194 O

1 NCT03869073 203 204 O
. NCT03869073 204 205 O
Cardiovascular NCT03869073 207 221 B-Modifier
- NCT03869073 222 223 I-Modifier
refractory NCT03869073 224 234 I-Modifier
hypotension NCT03869073 235 246 B-Condition
( NCT03869073 247 248 O
a NCT03869073 249 250 O
systolic NCT03869073 251 259 B-Observation
blood NCT03869073 260 265 I-Observation
pressure NCT03869073 266 274 I-Observation
( NCT03869073 275 276 O
SBP NCT03869073 277 280 B-Observation
) NCT03869073 281 282 O
< NCT03869073 283 284 B-Eq-Comparison
90 NCT03869073 285 287 I-Eq-Comparison
mm NCT03869073 288 290 I-Eq-Comparison
Hg NCT03869073 291 293 I-Eq-Comparison
or NCT03869073 294 296 B-Or
mean NCT03869073 297 301 B-Observation
arterial NCT03869073 302 310 I-Observation
pressure NCT03869073 311 319 I-Observation
( NCT03869073 320 321 O
MAP NCT03869073 322 325 B-Observation
) NCT03869073 326 327 O
< NCT03869073 328 329 B-Eq-Comparison
60 NCT03869073 330 332 I-Eq-Comparison
mm NCT03869073 333 335 I-Eq-Comparison
Hg NCT03869073 336 338 I-Eq-Comparison
despite NCT03869073 339 346 B-And
an NCT03869073 347 349 O
IV NCT03869073 350 352 B-Observation
fluid NCT03869073 353 358 I-Observation
challenge NCT03869073 359 368 I-Observation
of NCT03869073 369 371 O
at NCT03869073 372 374 B-Eq-Comparison
least NCT03869073 375 380 I-Eq-Comparison
30 NCT03869073 381 383 I-Eq-Comparison
ml NCT03869073 384 386 I-Eq-Comparison
/ NCT03869073 387 388 I-Eq-Comparison
kg NCT03869073 389 391 I-Eq-Comparison
fluids NCT03869073 392 398 B-Modifier
) NCT03869073 399 400 O
, NCT03869073 402 403 O
or NCT03869073 404 406 B-Or
use NCT03869073 407 410 O
of NCT03869073 411 413 O
vasopressor NCT03869073 414 425 B-Procedure
( NCT03869073 426 427 O
s NCT03869073 428 429 O
) NCT03869073 430 431 O
to NCT03869073 432 434 B-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03869073 435 443 I-Assertion___Assertion-Type-Value:hypothetical
SAP NCT03869073 444 447 B-Observation
> NCT03869073 448 449 B-Eq-Comparison|Eq-Comparison
90 NCT03869073 450 452 I-Eq-Comparison
mm NCT03869073 453 455 I-Eq-Comparison|Eq-Comparison
Hg NCT03869073 456 458 I-Eq-Comparison|Eq-Comparison
or NCT03869073 459 461 B-Or|Or
MAP NCT03869073 462 465 B-Observation
> NCT03869073 466 467 O
60 NCT03869073 468 470 I-Eq-Comparison
mm NCT03869073 471 473 O
Hg NCT03869073 474 476 O
, NCT03869073 477 478 O
or NCT03869073 479 481 O
; NCT03869073 481 482 O

2 NCT03869073 490 491 O
. NCT03869073 491 492 O
Respiratory NCT03869073 494 505 B-Condition
: NCT03869073 506 507 O
PaO2 NCT03869073 508 512 B-Observation|Observation
/ NCT03869073 513 514 B-Or|Or
FiO2 NCT03869073 515 519 B-Observation|Observation
< NCT03869073 520 521 B-Eq-Comparison|Eq-Comparison
300 NCT03869073 522 525 I-Eq-Comparison
or NCT03869073 526 528 B-Or
PaO2 NCT03869073 529 533 O
/ NCT03869073 534 535 O
FiO2 NCT03869073 536 540 O
< NCT03869073 541 542 O
200 NCT03869073 543 546 I-Eq-Comparison
if NCT03869073 547 549 O
lung NCT03869073 550 554 B-Modifier
is NCT03869073 555 557 O
the NCT03869073 558 561 O
only NCT03869073 562 566 B-Modifier
organ NCT03869073 567 572 I-Modifier|Or
dysfunction NCT03869073 573 584 B-Condition
or NCT03869073 585 587 O
SaO2 NCT03869073 588 592 B-Observation
: NCT03869073 593 594 B-Or
FiO2 NCT03869073 595 599 B-Observation
150 NCT03869073 600 603 B-Eq-Comparison

Exclusion NCT03869073 605 614 O
Criteria NCT03869073 615 623 O
: NCT03869073 624 625 O

- NCT03869073 629 630 O
Known NCT03869073 632 637 O
pregnancy NCT03869073 638 647 B-Condition

- NCT03869073 650 651 O
Underlying NCT03869073 653 663 O
severe NCT03869073 664 670 O
congestive NCT03869073 671 681 B-Condition
heart NCT03869073 682 687 I-Condition
failure NCT03869073 688 695 I-Condition
( NCT03869073 696 697 O
New NCT03869073 698 701 B-Condition
York NCT03869073 702 706 I-Condition
Heart NCT03869073 707 712 I-Condition
Association NCT03869073 713 724 I-Condition
( NCT03869073 725 726 O
NYHA NCT03869073 727 731 B-Condition
) NCT03869073 732 733 O
IV NCT03869073 734 736 B-Eq-Comparison
) NCT03869073 737 738 O
, NCT03869073 740 741 O
severe NCT03869073 742 748 O
COPD NCT03869073 749 753 B-Condition
( NCT03869073 754 755 O
need NCT03869073 756 760 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869073 761 764 I-Assertion___Assertion-Type-Value:hypothetical
chronic NCT03869073 765 772 B-Procedure
oxygen NCT03869073 773 779 I-Procedure
or NCT03869073 780 782 B-Or
mechanical NCT03869073 783 793 B-Procedure
ventilation NCT03869073 794 805 I-Procedure
) NCT03869073 806 807 O
, NCT03869073 809 810 O
severe NCT03869073 811 817 O
liver NCT03869073 818 823 B-Condition
disease NCT03869073 824 831 I-Condition
( NCT03869073 832 833 O
Child NCT03869073 834 839 B-Condition|Eq-Comparison
- NCT03869073 840 841 I-Condition
Pugh NCT03869073 842 846 I-Condition
Class NCT03869073 847 852 B-Eq-Comparison
C NCT03869073 853 854 O
) NCT03869073 855 856 O
, NCT03869073 858 859 O
cancer NCT03869073 860 866 B-Condition
requiring NCT03869073 867 876 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03869073 877 889 B-Procedure
, NCT03869073 890 891 O
or NCT03869073 892 894 B-Or
transplantation NCT03869073 895 910 B-Procedure
( NCT03869073 911 912 O
bone NCT03869073 913 917 B-Modifier
marrow NCT03869073 918 924 I-Modifier
, NCT03869073 925 926 O
heart NCT03869073 927 932 B-Modifier
, NCT03869073 933 934 O
lung NCT03869073 935 939 B-Modifier
, NCT03869073 940 941 O
liver NCT03869073 942 947 B-Modifier
, NCT03869073 948 949 O
pancreas NCT03869073 950 958 B-Modifier
, NCT03869073 959 960 O
or NCT03869073 961 963 B-Or|Or
small NCT03869073 964 969 B-Modifier
bowel NCT03869073 970 975 I-Modifier
) NCT03869073 976 977 O
in NCT03869073 978 980 O
the NCT03869073 981 984 I-Eq-Comparison
past NCT03869073 985 989 B-Eq-Comparison
6 NCT03869073 990 991 I-Eq-Comparison|Eq-Comparison
months NCT03869073 992 998 I-Eq-Comparison|Eq-Comparison
or NCT03869073 999 1001 O
likely NCT03869073 1002 1008 B-Assertion___Assertion-Type-Value:possible
within NCT03869073 1009 1015 B-Eq-Comparison
the NCT03869073 1016 1019 O
next NCT03869073 1020 1024 I-Eq-Comparison
6 NCT03869073 1025 1026 O
months NCT03869073 1027 1033 O

- NCT03869073 1036 1037 O
Previous NCT03869073 1039 1047 B-Eq-Comparison
episode NCT03869073 1048 1055 O
of NCT03869073 1056 1058 O
sepsis NCT03869073 1059 1065 B-Condition
during NCT03869073 1066 1072 B-Temporal-Connection___Temporal-Connection-Type-Value:during
that NCT03869073 1073 1077 O
hospital NCT03869073 1078 1086 O
admission NCT03869073 1087 1096 B-Encounter

- NCT03869073 1099 1100 O
Absolute NCT03869073 1102 1110 B-Observation
Neutrophil NCT03869073 1111 1121 I-Observation
Count NCT03869073 1122 1127 I-Observation
< NCT03869073 1128 1129 B-Eq-Comparison|Eq-Comparison
500 NCT03869073 1130 1133 I-Eq-Comparison|Eq-Comparison
/ NCT03869073 1134 1135 I-Eq-Comparison|Eq-Comparison
mm³ NCT03869073 1136 1139 I-Eq-Comparison|Eq-Comparison

- NCT03869073 1142 1143 O
CD4 NCT03869073 1145 1148 B-Observation
count NCT03869073 1149 1154 I-Observation
< NCT03869073 1155 1156 O
50 NCT03869073 1157 1159 O
/ NCT03869073 1160 1161 O
mm³ NCT03869073 1162 1165 O

- NCT03869073 1168 1169 O
Treating NCT03869073 1171 1179 O
physician NCT03869073 1180 1189 O
deems NCT03869073 1190 1195 O
aggressive NCT03869073 1196 1206 O
care NCT03869073 1207 1211 B-Procedure|Procedure
unsuitable NCT03869073 1212 1222 B-Contraindication
( NCT03869073 1223 1224 O
i. NCT03869073 1225 1227 O
e. NCT03869073 1228 1230 O
no NCT03869073 1232 1234 B-Negation
commitment NCT03869073 1235 1245 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869073 1246 1248 I-Assertion___Assertion-Type-Value:hypothetical
active NCT03869073 1249 1255 B-Eq-Comparison
care NCT03869073 1256 1260 O
) NCT03869073 1261 1262 O

- NCT03869073 1266 1267 O
Participation NCT03869073 1269 1282 O
in NCT03869073 1283 1285 O
another NCT03869073 1286 1293 B-Other
interventional NCT03869073 1294 1308 O
drug NCT03869073 1309 1313 B-Drug|Drug
study NCT03869073 1314 1319 B-Study|Study
within NCT03869073 1320 1326 B-Eq-Comparison
previous NCT03869073 1327 1335 I-Eq-Comparison
1 NCT03869073 1336 1337 I-Eq-Comparison
month NCT03869073 1338 1343 I-Eq-Comparison

- NCT03869073 1346 1347 O
Allergic NCT03869073 1349 1357 B-Allergy
to NCT03869073 1358 1360 O
the NCT03869073 1361 1364 O
study NCT03869073 1365 1370 O
drug NCT03869073 1371 1375 O
or NCT03869073 1376 1378 B-Or
any NCT03869073 1379 1382 O
of NCT03869073 1383 1385 O
its NCT03869073 1386 1389 B-Coreference
components NCT03869073 1390 1400 I-Coreference

- NCT03869073 1403 1404 O
Lactation NCT03869073 1406 1415 B-Condition

- NCT03869073 1418 1419 O
Have NCT03869073 1421 1425 O
signed NCT03869073 1426 1432 B-Eq-Comparison
a NCT03869073 1433 1434 O
Do NCT03869073 1435 1437 B-Observation
No NCT03869073 1438 1440 I-Observation
Resuscitate NCT03869073 1441 1452 I-Observation
( NCT03869073 1453 1454 O
DNR NCT03869073 1455 1458 B-Observation
) NCT03869073 1459 1460 O
Form NCT03869073 1461 1465 O

Inclusion NCT03864796 0 9 O
Criteria NCT03864796 10 18 O
: NCT03864796 19 20 O

- NCT03864796 24 25 O
newly NCT03864796 27 32 B-Eq-Comparison
diagnosed NCT03864796 33 42 O
primary NCT03864796 43 50 B-Modifier
immune NCT03864796 51 57 I-Modifier
thrombocytopenic NCT03864796 58 74 B-Condition
patients NCT03864796 75 83 O

Exclusion NCT03864796 84 93 O
Criteria NCT03864796 94 102 O
: NCT03864796 103 104 O

- NCT03864796 108 109 O
We NCT03864796 111 113 O
will NCT03864796 114 118 O
exclude NCT03864796 119 126 B-Negation
patients NCT03864796 127 135 O
with NCT03864796 136 140 O
any NCT03864796 141 144 O
other NCT03864796 145 150 B-Other
possible NCT03864796 151 159 B-Assertion___Assertion-Type-Value:possible
cause NCT03864796 160 165 B-Condition
of NCT03864796 166 168 O
thrombocytopenia NCT03864796 169 185 B-Condition
either NCT03864796 186 192 O
immune NCT03864796 193 199 B-Modifier
or NCT03864796 200 202 B-Or
non NCT03864796 203 206 B-Negation
immune NCT03864796 207 213 B-Modifier
as NCT03864796 214 216 O
: NCT03864796 217 218 O

- NCT03864796 222 223 O
Patients NCT03864796 225 233 O
with NCT03864796 234 238 O
diabetes NCT03864796 239 247 B-Condition

- NCT03864796 250 251 O
HCV NCT03864796 253 256 B-Condition

- NCT03864796 259 260 O
other NCT03864796 262 267 B-Other
autoimmune NCT03864796 268 278 B-Condition
disease NCT03864796 279 286 I-Condition
( NCT03864796 287 288 O
as NCT03864796 289 291 O
SLE NCT03864796 292 295 B-Condition
or NCT03864796 296 298 B-Or
RA NCT03864796 299 301 B-Condition
) NCT03864796 302 303 O

- NCT03864796 307 308 O
Chronic NCT03864796 310 317 B-Modifier
Liver NCT03864796 318 323 I-Modifier
or NCT03864796 324 326 B-Or
kidney NCT03864796 327 333 B-Modifier
disease NCT03864796 334 341 B-Condition

Inclusion NCT03862495 0 9 O
Criteria NCT03862495 10 18 O
: NCT03862495 19 20 O

1 NCT03862495 24 25 O
. NCT03862495 25 26 O
pregnant NCT03862495 28 36 B-Condition
women NCT03862495 37 42 O
on NCT03862495 43 45 O
their NCT03862495 46 51 O
first NCT03862495 52 57 B-Eq-Comparison
visit NCT03862495 58 63 B-Encounter
to NCT03862495 64 66 O
the NCT03862495 67 70 O
hospital NCT03862495 71 79 O
( NCT03862495 80 81 O
regardless NCT03862495 82 92 O
of NCT03862495 93 95 O
gestational NCT03862495 96 107 B-Observation
age NCT03862495 108 111 I-Observation
) NCT03862495 112 113 O
; NCT03862495 114 115 O

2 NCT03862495 118 119 O
. NCT03862495 119 120 O
aged NCT03862495 122 126 B-Age
18 NCT03862495 127 129 B-Eq-Comparison
or NCT03862495 130 132 I-Eq-Comparison
above NCT03862495 133 138 I-Eq-Comparison
; NCT03862495 138 139 O

3 NCT03862495 142 143 O
. NCT03862495 143 144 O
agree NCT03862495 146 151 O
to NCT03862495 152 154 O
participate NCT03862495 155 166 O
and NCT03862495 167 170 O
sign NCT03862495 171 175 O
an NCT03862495 176 178 O
informed NCT03862495 179 187 O
consent NCT03862495 188 195 O
. NCT03862495 195 196 O

Exclusion NCT03862495 198 207 O
Criteria NCT03862495 208 216 O
: NCT03862495 217 218 O

1 NCT03862495 222 223 O
. NCT03862495 223 224 O
systemic NCT03862495 226 234 B-Modifier
or NCT03862495 235 237 B-Or
topical NCT03862495 238 245 B-Modifier
vaginal NCT03862495 246 253 I-Modifier
antibiotics NCT03862495 254 265 B-Drug
use NCT03862495 266 269 O
within NCT03862495 270 276 B-Eq-Comparison
2 NCT03862495 277 278 I-Eq-Comparison
weeks NCT03862495 279 284 I-Eq-Comparison
prior NCT03862495 285 290 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862495 291 293 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862495 294 297 O
first NCT03862495 298 303 B-Eq-Comparison
perinatal NCT03862495 304 313 B-Modifier
visit NCT03862495 314 319 B-Encounter
; NCT03862495 319 320 O

2 NCT03862495 323 324 O
. NCT03862495 324 325 O
comorbidities NCT03862495 327 340 B-Condition
that NCT03862495 341 345 O
are NCT03862495 346 349 O
known NCT03862495 350 355 O
to NCT03862495 356 358 O
be NCT03862495 359 361 O
related NCT03862495 362 369 O
to NCT03862495 370 372 O
adverse NCT03862495 373 380 B-Condition
pregnancy NCT03862495 381 390 I-Condition
outcomes NCT03862495 391 399 I-Condition
( NCT03862495 400 401 O
e. NCT03862495 402 404 O
g. NCT03862495 405 407 O
, NCT03862495 408 409 O
diabetes NCT03862495 410 418 B-Condition
and NCT03862495 419 422 B-Or
hypertension NCT03862495 423 435 B-Condition
) NCT03862495 436 437 O
; NCT03862495 438 439 O

3 NCT03862495 442 443 O
. NCT03862495 443 444 O
diagnosed NCT03862495 446 455 O
adverse NCT03862495 456 463 B-Condition
pregnancy NCT03862495 464 473 I-Condition
outcomes NCT03862495 474 482 I-Condition
at NCT03862495 483 485 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recruitment NCT03862495 486 497 B-Study
( NCT03862495 498 499 O
e. NCT03862495 500 502 O
g. NCT03862495 503 505 O
, NCT03862495 506 507 O
stillbirth NCT03862495 508 518 B-Condition
) NCT03862495 519 520 O
; NCT03862495 521 522 O
Women NCT03862495 523 528 O
with NCT03862495 529 533 B-And
a NCT03862495 534 535 O
previous NCT03862495 536 544 B-Eq-Comparison
history NCT03862495 545 552 I-Eq-Comparison
of NCT03862495 553 555 O
CT NCT03862495 556 558 B-Procedure
or NCT03862495 559 561 B-Or
NG NCT03862495 562 564 B-Procedure
and NCT03862495 565 568 B-Or
women NCT03862495 569 574 O
with NCT03862495 575 579 B-And
a NCT03862495 580 581 O
prior NCT03862495 582 587 B-Eq-Comparison
adverse NCT03862495 588 595 B-Condition
outcome NCT03862495 596 603 I-Condition
will NCT03862495 604 608 O
not NCT03862495 609 612 O
be NCT03862495 613 615 O
excluded NCT03862495 616 624 O
. NCT03862495 624 625 O
Instead NCT03862495 627 634 O
, NCT03862495 635 636 O
the NCT03862495 637 640 O
investigators NCT03862495 641 654 O
will NCT03862495 655 659 O
conduct NCT03862495 660 667 O
sub NCT03862495 668 671 O
- NCT03862495 672 673 O
analysis NCT03862495 674 682 O
and NCT03862495 683 686 O
check NCT03862495 687 692 O
whether NCT03862495 693 700 O
the NCT03862495 701 704 O
intervention NCT03862495 705 717 O
has NCT03862495 718 721 O
different NCT03862495 722 731 O
effects NCT03862495 732 739 O
on NCT03862495 740 742 O
different NCT03862495 743 752 O
groups NCT03862495 753 759 O
of NCT03862495 760 762 O
pregnant NCT03862495 763 771 O
women NCT03862495 772 777 O
. NCT03862495 777 778 O

Inclusion NCT03861611 0 9 O
Criteria NCT03861611 10 18 O
: NCT03861611 19 20 O

- NCT03861611 24 25 O
Men NCT03861611 27 30 O
or NCT03861611 31 33 B-Or
women NCT03861611 34 39 O
age NCT03861611 40 43 B-Age
18 NCT03861611 44 46 B-Eq-Comparison
- NCT03861611 47 48 I-Eq-Comparison
64 NCT03861611 49 51 O
. NCT03861611 51 52 O

- NCT03861611 56 57 O
Present NCT03861611 59 66 O
to NCT03861611 67 69 O
ED NCT03861611 70 72 B-Encounter
primary NCT03861611 73 80 O
for NCT03861611 81 84 O
management NCT03861611 85 95 O
of NCT03861611 96 98 O
Low NCT03861611 99 102 B-Condition
Back NCT03861611 103 107 I-Condition
Pain NCT03861611 108 112 I-Condition
( NCT03861611 113 114 O
LBP NCT03861611 115 118 B-Condition
) NCT03861611 119 120 O

- NCT03861611 124 125 O
Functionally NCT03861611 127 139 B-Modifier
impairing NCT03861611 140 149 I-Modifier
back NCT03861611 150 154 B-Condition
pain NCT03861611 155 159 I-Condition
: NCT03861611 160 161 O
A NCT03861611 162 163 O
baseline NCT03861611 164 172 O
score NCT03861611 173 178 O
of NCT03861611 179 181 O
greater NCT03861611 182 189 B-Eq-Comparison
than NCT03861611 190 194 I-Eq-Comparison
5 NCT03861611 195 196 I-Eq-Comparison
on NCT03861611 197 199 O
the NCT03861611 200 203 O
Roland NCT03861611 204 210 B-Observation
- NCT03861611 211 212 I-Observation
Morris NCT03861611 213 219 I-Observation
Disability NCT03861611 220 230 I-Observation
Questionnaire NCT03861611 231 244 I-Observation

- NCT03861611 247 248 O
Musculoskeletal NCT03861611 250 265 B-Condition
etiology NCT03861611 266 274 I-Condition
of NCT03861611 275 277 O
low NCT03861611 278 281 B-Modifier
back NCT03861611 282 286 I-Modifier
. NCT03861611 286 287 O

- NCT03861611 291 292 O
Non NCT03861611 294 297 B-Negation
- NCT03861611 298 299 O
radicular NCT03861611 300 309 B-Modifier
pain NCT03861611 310 314 B-Condition
. NCT03861611 314 315 O

- NCT03861611 319 320 O
Pain NCT03861611 322 326 B-Condition
duration NCT03861611 327 335 O
< NCT03861611 336 337 B-Eq-Comparison
2 NCT03861611 338 339 I-Eq-Comparison
weeks NCT03861611 340 345 I-Eq-Comparison
( NCT03861611 346 347 O
336 NCT03861611 348 351 B-Eq-Comparison
hours NCT03861611 352 357 I-Eq-Comparison
) NCT03861611 358 359 O
. NCT03861611 360 361 O

- NCT03861611 365 366 O
Non NCT03861611 368 371 B-Negation
- NCT03861611 372 373 O
traumatic NCT03861611 374 383 B-Modifier
LBP NCT03861611 384 387 B-Condition

- NCT03861611 390 391 O
Participant NCT03861611 393 404 O
is NCT03861611 405 407 O
to NCT03861611 408 410 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861611 411 413 I-Assertion___Assertion-Type-Value:hypothetical
discharged NCT03861611 414 424 B-Encounter
home NCT03861611 425 429 O
. NCT03861611 429 430 O

Exclusion NCT03861611 432 441 O
Criteria NCT03861611 442 450 O
: NCT03861611 451 452 O

- NCT03861611 456 457 O
Flank NCT03861611 459 464 B-Modifier
pain NCT03861611 465 469 B-Condition|Condition
, NCT03861611 470 471 O
that NCT03861611 472 476 O
is NCT03861611 477 479 O
pain NCT03861611 480 484 O
originating NCT03861611 485 496 O
from NCT03861611 497 501 O
tissues NCT03861611 502 509 B-Modifier
lateral NCT03861611 510 517 I-Modifier
to NCT03861611 518 520 I-Modifier
the NCT03861611 521 524 I-Modifier
paraspinal NCT03861611 525 535 I-Modifier
muscles NCT03861611 536 543 I-Modifier
. NCT03861611 543 544 O

- NCT03861611 548 549 I-Encounter
Not NCT03861611 551 554 B-Negation
available NCT03861611 555 564 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861611 565 568 O
follow NCT03861611 569 575 B-Encounter
- NCT03861611 576 577 O
up NCT03861611 578 580 I-Encounter

- NCT03861611 583 584 O
Pregnant NCT03861611 586 594 B-Condition

- NCT03861611 597 598 O
Chronic NCT03861611 600 607 B-Modifier
pain NCT03861611 608 612 B-Condition
syndrome NCT03861611 613 621 I-Condition

- NCT03861611 624 625 O
Allergic NCT03861611 627 635 B-Allergy
to NCT03861611 636 638 O
or NCT03861611 639 641 B-Or
intolerant NCT03861611 642 652 B-Condition
of NCT03861611 653 655 O
investigational NCT03861611 656 671 B-Study
medications NCT03861611 672 683 B-Drug

- NCT03861611 686 687 I-Contraindication
Contra NCT03861611 689 695 B-Contraindication
- NCT03861611 696 697 O
indications NCT03861611 698 709 I-Contraindication
to NCT03861611 710 712 O
investigational NCT03861611 713 728 B-Study
medications NCT03861611 729 740 B-Drug

Inclusion NCT03862456 0 9 O
Criteria NCT03862456 10 18 O
: NCT03862456 19 20 O

- NCT03862456 24 25 O
Diagnosis NCT03862456 27 36 O
of NCT03862456 37 39 O
periodontitis NCT03862456 40 53 B-Condition
( NCT03862456 54 55 O
stages NCT03862456 56 62 B-Eq-Comparison
III NCT03862456 63 66 I-Eq-Comparison
or NCT03862456 67 69 I-Eq-Comparison
IV NCT03862456 70 72 I-Eq-Comparison
) NCT03862456 73 74 O
that NCT03862456 75 79 O
may NCT03862456 80 83 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03862456 84 91 I-Assertion___Assertion-Type-Value:hypothetical
periodontal NCT03862456 92 103 B-Procedure
surgery NCT03862456 104 111 I-Procedure

- NCT03862456 114 115 O
Have NCT03862456 117 121 O
at NCT03862456 122 124 B-Eq-Comparison
least NCT03862456 125 130 I-Eq-Comparison
10 NCT03862456 131 133 I-Eq-Comparison
teeth NCT03862456 134 139 B-Condition
in NCT03862456 140 142 O
function NCT03862456 143 151 O
, NCT03862456 152 153 O
excluding NCT03862456 154 163 B-Exception
third NCT03862456 164 169 B-Modifier
molars NCT03862456 170 176 I-Modifier
. NCT03862456 176 177 O

- NCT03862456 181 182 O
Present NCT03862456 184 191 O
locations NCT03862456 192 201 O
with NCT03862456 202 206 O
probing NCT03862456 207 214 B-Observation
depth NCT03862456 215 220 I-Observation
( NCT03862456 221 222 O
PS NCT03862456 223 225 B-Observation
) NCT03862456 226 227 O
> NCT03862456 229 230 B-Eq-Comparison
6 NCT03862456 231 232 I-Eq-Comparison
mm NCT03862456 233 235 I-Eq-Comparison
in NCT03862456 236 238 O
at NCT03862456 239 241 B-Eq-Comparison
least NCT03862456 242 247 I-Eq-Comparison
30 NCT03862456 248 250 I-Eq-Comparison
% NCT03862456 251 252 O
of NCT03862456 253 255 O
the NCT03862456 256 259 O
teeth NCT03862456 260 265 B-Condition
. NCT03862456 265 266 O

- NCT03862456 270 271 O
Present NCT03862456 273 280 O
radiographic NCT03862456 281 293 B-Procedure
evidence NCT03862456 294 302 O
of NCT03862456 303 305 O
moderate NCT03862456 306 314 B-Eq-Comparison
- NCT03862456 315 316 I-Eq-Comparison
severe NCT03862456 317 323 I-Eq-Comparison
bone NCT03862456 324 328 B-Condition|Observation
loss NCT03862456 329 333 I-Condition|Observation
in NCT03862456 334 336 O
at NCT03862456 337 339 B-Eq-Comparison
least NCT03862456 340 345 I-Eq-Comparison
30 NCT03862456 346 348 I-Eq-Comparison
% NCT03862456 349 350 O
of NCT03862456 351 353 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862456 354 357 O
dentition NCT03862456 358 367 B-Procedure
. NCT03862456 367 368 O

- NCT03862456 372 373 O
Detection NCT03862456 375 384 O
of NCT03862456 385 387 O
P. NCT03862456 388 390 B-Organism
gingivalis NCT03862456 392 402 I-Organism
in NCT03862456 403 405 O
subgingival NCT03862456 406 417 B-Observation
samples NCT03862456 418 425 I-Observation
taken NCT03862456 426 431 B-Temporal-Connection___Temporal-Connection-Type-Value:during
at NCT03862456 432 434 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862456 435 438 O
screening NCT03862456 439 448 B-Study
visit NCT03862456 449 454 O
as NCT03862456 455 457 B-And
well NCT03862456 458 462 I-And
as NCT03862456 463 465 O
in NCT03862456 466 468 O
the NCT03862456 469 472 O
post NCT03862456 473 477 B-Modifier
- NCT03862456 478 479 I-Modifier
scaling NCT03862456 480 487 I-Modifier
and NCT03862456 488 491 B-Or
root NCT03862456 492 496 B-Modifier
planning NCT03862456 497 505 I-Modifier
visit NCT03862456 506 511 B-Encounter
and NCT03862456 512 515 O
processed NCT03862456 516 525 O
by NCT03862456 526 528 O
culture NCT03862456 529 536 O
. NCT03862456 536 537 O

- NCT03862456 541 542 O
Systemically NCT03862456 544 556 B-Modifier
healthy NCT03862456 557 564 B-Condition
patients NCT03862456 565 573 O
. NCT03862456 573 574 O

Exclusion NCT03862456 576 585 O
Criteria NCT03862456 586 594 O
: NCT03862456 595 596 O

- NCT03862456 600 601 O
Pregnant NCT03862456 603 611 B-Condition
or NCT03862456 612 614 B-Or
lactating NCT03862456 615 624 B-Condition
women NCT03862456 625 630 O
. NCT03862456 630 631 O

- NCT03862456 635 636 O
Presenting NCT03862456 638 648 O
systemic NCT03862456 649 657 B-Modifier
pathology NCT03862456 658 667 B-Condition
and NCT03862456 668 671 B-Or
/ NCT03862456 672 673 I-Or
or NCT03862456 674 676 I-Or
taking NCT03862456 677 683 B-Eq-Comparison
medication NCT03862456 684 694 B-Drug
that NCT03862456 695 699 O
may NCT03862456 700 703 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03862456 704 710 O
the NCT03862456 711 714 O
periodontal NCT03862456 715 726 B-Condition
situation NCT03862456 727 736 I-Condition
and NCT03862456 737 740 B-Or
/ NCT03862456 741 742 I-Or
or NCT03862456 743 745 I-Or
patients NCT03862456 746 754 O
requiring NCT03862456 755 764 B-Assertion___Assertion-Type-Value:hypothetical
antibiotic NCT03862456 765 775 B-Procedure
prophylaxis NCT03862456 776 787 I-Procedure
. NCT03862456 787 788 O

- NCT03862456 792 793 O
Have NCT03862456 795 799 O
received NCT03862456 800 808 B-Eq-Comparison
systemic NCT03862456 809 817 B-Modifier
antimicrobial NCT03862456 818 831 B-Procedure
treatment NCT03862456 832 841 I-Procedure
in NCT03862456 842 844 O
the NCT03862456 845 848 O
previous NCT03862456 849 857 B-Eq-Comparison
6 NCT03862456 858 859 I-Eq-Comparison
months NCT03862456 860 866 I-Eq-Comparison
. NCT03862456 866 867 O

- NCT03862456 871 872 O
Have NCT03862456 874 878 O
received NCT03862456 879 887 B-Eq-Comparison
periodontal NCT03862456 888 899 B-Procedure
treatment NCT03862456 900 909 I-Procedure
in NCT03862456 910 912 O
the NCT03862456 913 916 O
6 NCT03862456 917 918 B-Eq-Comparison
months NCT03862456 919 925 I-Eq-Comparison
prior NCT03862456 926 931 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862456 932 934 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862456 935 938 O
beginning NCT03862456 939 948 B-Eq-Comparison
of NCT03862456 949 951 O
the NCT03862456 952 955 O
study NCT03862456 956 961 B-Study
. NCT03862456 961 962 O

- NCT03862456 966 967 O
Patients NCT03862456 969 977 O
allergic NCT03862456 978 986 B-Allergy
to NCT03862456 987 989 O
metronidazole NCT03862456 990 1003 B-Drug
, NCT03862456 1004 1005 O
or NCT03862456 1006 1008 B-Or
to NCT03862456 1009 1011 O
any NCT03862456 1012 1015 O
of NCT03862456 1016 1018 O
the NCT03862456 1019 1022 O
components NCT03862456 1023 1033 O
of NCT03862456 1034 1036 O
commercial NCT03862456 1037 1047 B-Coreference
formulations NCT03862456 1048 1060 I-Coreference
thereof NCT03862456 1061 1068 I-Coreference
( NCT03862456 1069 1070 O
Flagyl NCT03862456 1071 1077 B-Drug
® NCT03862456 1077 1078 O
) NCT03862456 1079 1080 O
. NCT03862456 1081 1082 O

- NCT03862456 1086 1087 O
Patients NCT03862456 1089 1097 O
allergic NCT03862456 1098 1106 B-Allergy
to NCT03862456 1107 1109 O
azithromycin NCT03862456 1110 1122 B-Drug
, NCT03862456 1123 1124 O
or NCT03862456 1125 1127 B-Or
to NCT03862456 1128 1130 O
any NCT03862456 1131 1134 O
of NCT03862456 1135 1137 O
the NCT03862456 1138 1141 O
components NCT03862456 1142 1152 O
of NCT03862456 1153 1155 O
commercial NCT03862456 1156 1166 B-Coreference
formulations NCT03862456 1167 1179 I-Coreference
thereof NCT03862456 1180 1187 I-Coreference
( NCT03862456 1188 1189 O
Zithromax NCT03862456 1190 1199 B-Drug
® NCT03862456 1199 1200 O
) NCT03862456 1201 1202 O
. NCT03862456 1203 1204 O

- NCT03862456 1208 1209 O
Patients NCT03862456 1211 1219 O
who NCT03862456 1220 1223 O
refuse NCT03862456 1224 1230 O
to NCT03862456 1231 1233 O
sign NCT03862456 1234 1238 O
the NCT03862456 1239 1242 O
informed NCT03862456 1243 1251 O
consent NCT03862456 1252 1259 O
. NCT03862456 1259 1260 O

Inclusion NCT03867617 0 9 O
Criteria NCT03867617 10 18 O
: NCT03867617 19 20 O

- NCT03867617 24 25 O
Patient NCT03867617 27 34 O
has NCT03867617 35 38 O
provided NCT03867617 39 47 O
written NCT03867617 48 55 O
informed NCT03867617 56 64 O
consent NCT03867617 65 72 O
. NCT03867617 72 73 O

- NCT03867617 77 78 O
Patient NCT03867617 80 87 O
is NCT03867617 88 90 O
18 NCT03867617 91 93 B-Eq-Comparison
years NCT03867617 94 99 I-Eq-Comparison
or NCT03867617 100 102 I-Eq-Comparison
older NCT03867617 103 108 I-Age|Eq-Comparison
. NCT03867617 108 109 O

- NCT03867617 113 114 O
Patient NCT03867617 116 123 O
is NCT03867617 124 126 O
a NCT03867617 127 128 O
planned NCT03867617 129 136 B-Eq-Comparison
recipient NCT03867617 137 146 O
of NCT03867617 147 149 O
a NCT03867617 150 151 O
living NCT03867617 152 158 B-Modifier
donor NCT03867617 159 164 I-Modifier
kidney NCT03867617 165 171 B-Procedure
transplant NCT03867617 172 182 I-Procedure
. NCT03867617 182 183 O

- NCT03867617 187 188 O
Patient NCT03867617 190 197 O
is NCT03867617 198 200 O
a NCT03867617 201 202 O
planned NCT03867617 203 210 B-Eq-Comparison
recipient NCT03867617 211 220 O
of NCT03867617 221 223 O
an NCT03867617 224 226 O
ABO NCT03867617 227 230 B-Modifier
blood NCT03867617 231 236 I-Modifier
group NCT03867617 237 242 I-Modifier
- NCT03867617 243 244 I-Modifier
compatible NCT03867617 245 255 I-Modifier
kidney NCT03867617 256 262 B-Procedure
graft NCT03867617 263 268 I-Procedure
. NCT03867617 268 269 O

- NCT03867617 273 274 O
Patient NCT03867617 276 283 O
is NCT03867617 284 286 O
a NCT03867617 287 288 O
planned NCT03867617 289 296 B-Eq-Comparison
recipient NCT03867617 297 306 O
of NCT03867617 307 309 O
a NCT03867617 310 311 O
kidney NCT03867617 312 318 B-Procedure
graft NCT03867617 319 324 I-Procedure
from NCT03867617 325 329 O
a NCT03867617 330 331 O
donor NCT03867617 332 337 B-Modifier
that NCT03867617 338 342 O
is NCT03867617 343 345 O
not NCT03867617 346 349 B-Negation
HLA NCT03867617 350 353 B-Condition
( NCT03867617 354 355 O
human NCT03867617 356 361 B-Condition
leukocyte NCT03867617 362 371 I-Condition
antigen NCT03867617 372 379 I-Condition
) NCT03867617 380 381 O
- NCT03867617 383 384 O
identical NCT03867617 385 394 B-Modifier
. NCT03867617 394 395 O

- NCT03867617 399 400 O
Patient NCT03867617 402 409 O
is NCT03867617 410 412 O
negative NCT03867617 413 421 O
for NCT03867617 422 425 O
DSA NCT03867617 426 429 B-Condition
( NCT03867617 430 431 O
donor NCT03867617 432 437 B-Condition
- NCT03867617 438 439 I-Condition
specific NCT03867617 440 448 I-Condition
antibodies NCT03867617 449 459 I-Condition
) NCT03867617 460 461 O
. NCT03867617 462 463 O

- NCT03867617 467 468 O
WOCBP NCT03867617 470 475 B-Condition
( NCT03867617 476 477 O
women NCT03867617 478 483 O
of NCT03867617 484 486 B-And
child NCT03867617 487 492 B-Condition
- NCT03867617 493 494 I-Condition
bearing NCT03867617 495 502 I-Condition
potential NCT03867617 503 512 I-Condition
) NCT03867617 513 514 O
must NCT03867617 515 519 O
have NCT03867617 520 524 O
a NCT03867617 525 526 O
negative NCT03867617 527 535 O
pregnancy NCT03867617 536 545 B-Observation
test NCT03867617 546 550 I-Observation
at NCT03867617 551 553 B-Temporal-Connection___Temporal-Connection-Type-Value:during
inclusion NCT03867617 554 563 B-Study
. NCT03867617 563 564 O

- NCT03867617 568 569 O
WOCBP NCT03867617 571 576 B-Condition
must NCT03867617 577 581 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867617 582 584 I-Assertion___Assertion-Type-Value:hypothetical
using NCT03867617 585 590 B-Eq-Comparison
an NCT03867617 591 593 O
adequate NCT03867617 594 602 O
method NCT03867617 603 609 O
of NCT03867617 610 612 O
contraception NCT03867617 613 626 B-Procedure
to NCT03867617 627 629 O
avoid NCT03867617 630 635 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03867617 636 645 B-Condition
throughout NCT03867617 646 656 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867617 657 660 O
study NCT03867617 661 666 B-Study
and NCT03867617 667 670 B-And
for NCT03867617 671 674 O
up NCT03867617 675 677 B-Eq-Comparison
to NCT03867617 678 680 I-Eq-Comparison
12 NCT03867617 681 683 I-Eq-Comparison
weeks NCT03867617 684 689 I-Eq-Comparison
after NCT03867617 690 695 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03867617 696 699 O
study NCT03867617 700 705 B-Study
in NCT03867617 706 708 O
such NCT03867617 709 713 O
a NCT03867617 714 715 O
manner NCT03867617 716 722 O
that NCT03867617 723 727 O
the NCT03867617 728 731 O
risk NCT03867617 732 736 B-Risk
of NCT03867617 737 739 O
pregnancy NCT03867617 740 749 B-Condition
is NCT03867617 750 752 O
minimized NCT03867617 753 762 O
. NCT03867617 762 763 O

Exclusion NCT03867617 765 774 O
Criteria NCT03867617 775 783 O
: NCT03867617 784 785 O

- NCT03867617 789 790 O
Patient NCT03867617 792 799 O
is NCT03867617 800 802 O
EBV NCT03867617 803 806 B-Condition
( NCT03867617 807 808 O
epstein NCT03867617 809 816 B-Condition
barr NCT03867617 817 821 I-Condition
virus NCT03867617 822 827 I-Condition
) NCT03867617 828 829 O
- NCT03867617 831 832 O
negative NCT03867617 833 841 O
on NCT03867617 842 844 O
serology NCT03867617 845 853 B-Observation
. NCT03867617 853 854 O

- NCT03867617 858 859 O
Patient NCT03867617 861 868 O
is NCT03867617 869 871 O
HIV NCT03867617 872 875 B-Condition
- NCT03867617 876 877 O
positive NCT03867617 878 886 O
or NCT03867617 887 889 B-Or
suffering NCT03867617 890 899 B-Eq-Comparison
from NCT03867617 900 904 O
chronic NCT03867617 905 912 B-Modifier
viral NCT03867617 913 918 I-Modifier
hepatitis NCT03867617 919 928 B-Condition
. NCT03867617 928 929 O

- NCT03867617 933 934 O
Patient NCT03867617 936 943 O
is NCT03867617 944 946 O
CMV NCT03867617 947 950 B-Condition
( NCT03867617 951 952 O
cytomegalo NCT03867617 953 963 B-Condition
virus NCT03867617 964 969 I-Condition
) NCT03867617 970 971 O
- NCT03867617 973 974 O
negative NCT03867617 975 983 O
and NCT03867617 984 987 B-And
receiving NCT03867617 988 997 B-Eq-Comparison
a NCT03867617 998 999 O
kidney NCT03867617 1000 1006 B-Modifier
from NCT03867617 1007 1011 O
a NCT03867617 1012 1013 O
CMV NCT03867617 1014 1017 B-Condition
- NCT03867617 1018 1019 I-Observation
positive NCT03867617 1020 1028 O
donor NCT03867617 1029 1034 B-Modifier
. NCT03867617 1034 1035 O

- NCT03867617 1039 1040 O
Positive NCT03867617 1042 1050 O
T NCT03867617 1051 1052 B-Observation
- NCT03867617 1053 1054 O
cell NCT03867617 1055 1059 I-Observation
lymphocytotoxic NCT03867617 1060 1075 I-Observation
cross NCT03867617 1076 1081 I-Observation
match NCT03867617 1082 1087 I-Observation
. NCT03867617 1087 1088 O

- NCT03867617 1092 1093 O
Patient NCT03867617 1095 1102 O
with NCT03867617 1103 1107 O
prior NCT03867617 1108 1113 B-Eq-Comparison
kidney NCT03867617 1114 1120 B-Procedure
transplant NCT03867617 1121 1131 I-Procedure|Procedure
or NCT03867617 1132 1134 B-Or|Procedure
non NCT03867617 1135 1138 B-Negation
- NCT03867617 1139 1140 O
renal NCT03867617 1141 1146 B-Modifier
solid NCT03867617 1147 1152 B-Procedure
organ NCT03867617 1153 1158 O
transplant NCT03867617 1159 1169 O
. NCT03867617 1169 1170 O

- NCT03867617 1174 1175 O
Patient NCT03867617 1177 1184 O
has NCT03867617 1185 1188 O
a NCT03867617 1189 1190 O
known NCT03867617 1191 1196 O
contraindication NCT03867617 1197 1213 B-Contraindication
to NCT03867617 1214 1216 O
any NCT03867617 1217 1220 O
of NCT03867617 1221 1223 O
the NCT03867617 1224 1227 O
protocol NCT03867617 1228 1236 B-Study
- NCT03867617 1237 1238 I-Study
specified NCT03867617 1239 1248 I-Study
treatments NCT03867617 1249 1259 B-Procedure
. NCT03867617 1259 1260 O

- NCT03867617 1264 1265 O
Patient NCT03867617 1267 1274 O
had NCT03867617 1275 1278 O
been NCT03867617 1279 1283 O
diagnosed NCT03867617 1284 1293 O
with NCT03867617 1294 1298 B-Eq-Comparison
a NCT03867617 1299 1300 O
malignancy NCT03867617 1301 1311 B-Condition
within NCT03867617 1312 1318 O
5 NCT03867617 1319 1320 I-Eq-Comparison
years NCT03867617 1321 1326 I-Eq-Comparison
prior NCT03867617 1327 1332 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867617 1333 1335 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03867617 1336 1341 B-Study
entry NCT03867617 1342 1347 O
, NCT03867617 1348 1349 O
excluding NCT03867617 1350 1359 B-Exception
non NCT03867617 1360 1363 B-Negation
- NCT03867617 1364 1365 O
metastatic NCT03867617 1366 1376 B-Modifier
basal NCT03867617 1377 1382 I-Modifier
or NCT03867617 1383 1385 B-Or
squamous NCT03867617 1386 1394 B-Modifier
cell NCT03867617 1395 1399 I-Modifier
carcinoma NCT03867617 1400 1409 B-Condition
of NCT03867617 1410 1412 O
the NCT03867617 1413 1416 O
skin NCT03867617 1417 1421 B-Modifier
. NCT03867617 1421 1422 O

- NCT03867617 1426 1427 I-Condition
Female NCT03867617 1429 1435 O
patients NCT03867617 1436 1444 O
who NCT03867617 1445 1448 B-And
are NCT03867617 1449 1452 O
breast NCT03867617 1453 1459 B-Condition
- NCT03867617 1460 1461 O
feeding NCT03867617 1462 1469 I-Condition
. NCT03867617 1469 1470 O

- NCT03867617 1474 1475 O
Female NCT03867617 1477 1483 O
patients NCT03867617 1484 1492 O
with NCT03867617 1493 1497 B-And
a NCT03867617 1498 1499 O
positive NCT03867617 1500 1508 O
pregnancy NCT03867617 1509 1518 B-Observation
test NCT03867617 1519 1523 I-Observation
. NCT03867617 1523 1524 O

Inclusion NCT03869606 0 9 O
Criteria NCT03869606 10 18 O
: NCT03869606 19 20 O

- NCT03869606 24 25 O
Patients NCT03869606 27 35 O
11 NCT03869606 36 38 B-Eq-Comparison
to NCT03869606 39 41 I-Eq-Comparison
no NCT03869606 42 44 I-Eq-Comparison
older NCT03869606 45 50 I-Eq-Comparison
than NCT03869606 51 55 I-Eq-Comparison
17 NCT03869606 56 58 I-Eq-Comparison
years NCT03869606 59 64 I-Eq-Comparison
of NCT03869606 65 67 O
age NCT03869606 68 71 B-Age

Exclusion NCT03869606 72 81 O
Criteria NCT03869606 82 90 O
: NCT03869606 91 92 O

- NCT03869606 96 97 O
severed NCT03869606 99 106 O
developmental NCT03869606 107 120 B-Condition
delay NCT03869606 121 126 I-Condition
, NCT03869606 127 128 O

- NCT03869606 132 133 O
orthopedic NCT03869606 135 145 B-Procedure
patients NCT03869606 146 154 O
with NCT03869606 155 159 B-And
leg NCT03869606 160 163 B-Modifier
injuries NCT03869606 164 172 B-Condition

- NCT03869606 175 176 O
injury NCT03869606 178 184 B-Condition
that NCT03869606 185 189 O
would NCT03869606 190 195 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03869606 196 203 B-Negation
passive NCT03869606 204 211 B-Modifier
leg NCT03869606 212 215 I-Modifier
elevation NCT03869606 216 225 B-Procedure
. NCT03869606 225 226 O

- NCT03869606 230 231 O
severe NCT03869606 233 239 O
aortic NCT03869606 240 246 B-Condition
insufficiency NCT03869606 247 260 I-Condition
, NCT03869606 261 262 O

- NCT03869606 266 267 O
severe NCT03869606 269 275 O
anatomic NCT03869606 276 284 B-Condition
abnormalities NCT03869606 285 298 I-Condition
of NCT03869606 299 301 O
the NCT03869606 302 305 O
thoracic NCT03869606 306 314 B-Modifier
aorta NCT03869606 315 320 I-Modifier

- NCT03869606 323 324 O
patients NCT03869606 326 334 O
with NCT03869606 335 339 O
external NCT03869606 340 348 B-Procedure
cardiac NCT03869606 349 356 I-Procedure
pacemakers NCT03869606 357 367 I-Procedure
. NCT03869606 367 368 O
close NCT03869606 370 375 O

Inclusion NCT03861299 0 9 O
Criteria NCT03861299 10 18 O
: NCT03861299 19 20 O

1 NCT03861299 24 25 O
. NCT03861299 25 26 O
Age NCT03861299 28 31 B-Age
≥ NCT03861299 32 33 B-Eq-Comparison
18 NCT03861299 34 36 I-Eq-Comparison
years NCT03861299 37 42 I-Eq-Comparison
and NCT03861299 43 46 B-And
≤ NCT03861299 47 48 B-Eq-Comparison
90 NCT03861299 49 51 I-Eq-Comparison
years NCT03861299 52 57 I-Eq-Comparison

2 NCT03861299 60 61 O
. NCT03861299 61 62 O
Tumor NCT03861299 64 69 B-Condition
diagnosed NCT03861299 70 79 O
as NCT03861299 80 82 O
Glioblastoma NCT03861299 83 95 B-Modifier
Multiforme NCT03861299 96 106 I-Modifier
on NCT03861299 107 109 O
MRI NCT03861299 110 113 B-Procedure
with NCT03861299 114 118 O
distinct NCT03861299 119 127 B-Modifier
ring NCT03861299 128 132 I-Modifier
- NCT03861299 133 134 I-Modifier
like NCT03861299 135 139 I-Modifier
pattern NCT03861299 140 147 I-Modifier
of NCT03861299 148 150 O
contrast NCT03861299 151 159 B-Procedure
enhancement NCT03861299 160 171 I-Procedure
with NCT03861299 172 176 O
thick NCT03861299 177 182 B-Modifier
irregular NCT03861299 183 192 I-Modifier
walls NCT03861299 193 198 I-Modifier
and NCT03861299 199 202 B-And
a NCT03861299 203 204 O
core NCT03861299 205 209 B-Modifier
area NCT03861299 210 214 O
reduced NCT03861299 215 222 I-Modifier
signal NCT03861299 223 229 I-Modifier
suggestive NCT03861299 230 240 B-Assertion___Assertion-Type-Value:possible
of NCT03861299 241 243 O
tumour NCT03861299 244 250 B-Condition
necrosis NCT03861299 251 259 I-Condition
as NCT03861299 260 262 O
assessed NCT03861299 263 271 O
by NCT03861299 272 274 O
the NCT03861299 275 278 O
surgeon NCT03861299 279 286 B-Provider

3 NCT03861299 289 290 O
. NCT03861299 290 291 O
Tumors NCT03861299 293 299 B-Condition
situated NCT03861299 300 308 O
in NCT03861299 309 311 B-Modifier
or NCT03861299 312 314 I-Modifier
near NCT03861299 315 319 I-Modifier
eloquent NCT03861299 320 328 I-Modifier
areas NCT03861299 329 334 I-Modifier|Modifier
; NCT03861299 334 335 O
motor NCT03861299 336 341 B-Modifier
cortex NCT03861299 342 348 I-Modifier
, NCT03861299 349 350 O
sensory NCT03861299 351 358 B-Modifier
cortex NCT03861299 359 365 I-Modifier
, NCT03861299 366 367 O
subcortical NCT03861299 368 379 B-Modifier
pyramidal NCT03861299 380 389 I-Modifier
tract NCT03861299 390 395 I-Modifier
or NCT03861299 396 398 B-Or
speech NCT03861299 399 405 B-Modifier
areas NCT03861299 406 411 I-Modifier
as NCT03861299 412 414 O
indicated NCT03861299 415 424 O
on NCT03861299 425 427 O
MRI NCT03861299 428 431 B-Procedure
( NCT03861299 432 433 O
Sawaya NCT03861299 434 440 B-Condition
Grading NCT03861299 441 448 B-Eq-Comparison
II NCT03861299 449 451 I-Eq-Comparison
and NCT03861299 452 455 I-Eq-Comparison
II NCT03861299 456 458 O
) NCT03861299 459 460 O

4 NCT03861299 464 465 O
. NCT03861299 465 466 O
The NCT03861299 468 471 O
tumor NCT03861299 472 477 B-Condition
is NCT03861299 478 480 O
suitable NCT03861299 481 489 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861299 490 493 I-Assertion___Assertion-Type-Value:hypothetical
resection NCT03861299 494 503 B-Procedure
( NCT03861299 504 505 O
according NCT03861299 506 515 O
to NCT03861299 516 518 O
neurosurgeon NCT03861299 519 531 B-Provider
) NCT03861299 532 533 O

5 NCT03861299 537 538 O
. NCT03861299 538 539 O
Karnofsky NCT03861299 541 550 B-Observation
performance NCT03861299 551 562 I-Observation
scale NCT03861299 563 568 I-Observation
80 NCT03861299 569 571 B-Eq-Comparison
or NCT03861299 572 574 I-Eq-Comparison
more NCT03861299 575 579 I-Eq-Comparison

6 NCT03861299 582 583 O
. NCT03861299 583 584 O
Written NCT03861299 586 593 O
Informed NCT03861299 594 602 O
consent NCT03861299 603 610 O

Exclusion NCT03861299 611 620 O
Criteria NCT03861299 621 629 O
: NCT03861299 630 631 O

1 NCT03861299 635 636 O
. NCT03861299 636 637 O
Tumors NCT03861299 639 645 B-Condition
of NCT03861299 646 648 O
the NCT03861299 649 652 O
cerebellum NCT03861299 653 663 B-Modifier
, NCT03861299 664 665 O
brain NCT03861299 666 671 B-Modifier
stem NCT03861299 672 676 I-Modifier
or NCT03861299 677 679 B-Or
midline NCT03861299 680 687 B-Modifier

2 NCT03861299 690 691 O
. NCT03861299 691 692 O
Multifocal NCT03861299 694 704 B-Modifier
contrast NCT03861299 705 713 I-Modifier
enhancing NCT03861299 714 723 I-Modifier
lesions NCT03861299 724 731 B-Condition

3 NCT03861299 734 735 O
. NCT03861299 735 736 O
Substantial NCT03861299 738 749 O
non NCT03861299 750 753 B-Modifier
- NCT03861299 754 755 I-Modifier
contrast NCT03861299 756 764 I-Modifier
enhancing NCT03861299 765 774 I-Modifier
tumor NCT03861299 775 780 B-Condition
areas NCT03861299 781 786 O
suggesting NCT03861299 787 797 B-Assertion___Assertion-Type-Value:possible
low NCT03861299 798 801 O
grade NCT03861299 802 807 O
gliomas NCT03861299 808 815 B-Condition
with NCT03861299 816 820 O
malignant NCT03861299 821 830 B-Modifier
transformation NCT03861299 831 845 I-Modifier

4 NCT03861299 848 849 O
. NCT03861299 849 850 O
Medical NCT03861299 852 859 B-Condition
reasons NCT03861299 860 867 I-Condition
precluding NCT03861299 868 878 B-Assertion___Assertion-Type-Value:hypothetical|Negation
MRI NCT03861299 879 882 B-Procedure
( NCT03861299 883 884 O
eg NCT03861299 885 887 O
, NCT03861299 888 889 O
pacemaker NCT03861299 890 899 B-Procedure
) NCT03861299 900 901 O

5 NCT03861299 905 906 O
. NCT03861299 906 907 O
Inability NCT03861299 909 918 O
to NCT03861299 919 921 O
give NCT03861299 922 926 O
consent NCT03861299 927 934 O
because NCT03861299 935 942 O
of NCT03861299 943 945 O
or NCT03861299 946 948 O
language NCT03861299 949 957 B-Condition
barrier NCT03861299 958 965 I-Condition

6 NCT03861299 968 969 O
. NCT03861299 969 970 O
Psychiatric NCT03861299 972 983 B-Condition
history NCT03861299 984 991 B-Eq-Comparison

7 NCT03861299 994 995 O
. NCT03861299 995 996 O
Previous NCT03861299 998 1006 B-Eq-Comparison|Eq-Comparison
brain NCT03861299 1007 1012 B-Modifier
tumour NCT03861299 1013 1019 B-Condition
surgery NCT03861299 1020 1027 B-Procedure

8 NCT03861299 1030 1031 O
. NCT03861299 1031 1032 O
Previous NCT03861299 1034 1042 O
low NCT03861299 1043 1046 O
- NCT03861299 1047 1048 O
grade NCT03861299 1049 1054 O
glioma NCT03861299 1055 1061 B-Condition
. NCT03861299 1061 1062 O

9 NCT03861299 1066 1067 O
. NCT03861299 1067 1068 O
Second NCT03861299 1070 1076 B-Eq-Comparison
primary NCT03861299 1077 1084 B-Modifier
malignancy NCT03861299 1085 1095 B-Condition
within NCT03861299 1096 1102 B-Eq-Comparison
the NCT03861299 1103 1106 I-Eq-Comparison
past NCT03861299 1107 1111 I-Eq-Comparison
5 NCT03861299 1112 1113 I-Eq-Comparison
years NCT03861299 1114 1119 I-Eq-Comparison
with NCT03861299 1120 1124 O
the NCT03861299 1125 1128 O
exception NCT03861299 1129 1138 B-Exception
of NCT03861299 1139 1141 I-Exception
adequately NCT03861299 1142 1152 O
treated NCT03861299 1153 1160 B-Procedure
in NCT03861299 1161 1163 B-Modifier
situ NCT03861299 1164 1168 I-Modifier
carcinoma NCT03861299 1169 1178 B-Condition|Condition
of NCT03861299 1179 1181 O
any NCT03861299 1182 1185 B-Modifier
organ NCT03861299 1186 1191 I-Modifier|Or
or NCT03861299 1192 1194 O
basal NCT03861299 1195 1200 B-Modifier
cell NCT03861299 1201 1205 I-Modifier
carcinoma NCT03861299 1206 1215 O
of NCT03861299 1216 1218 O
the NCT03861299 1219 1222 O
skin NCT03861299 1223 1227 B-Modifier
. NCT03861299 1227 1228 O

10 NCT03861299 1231 1233 O
. NCT03861299 1233 1234 O
Severe NCT03861299 1236 1242 O
aphasia NCT03861299 1243 1250 B-Condition
or NCT03861299 1251 1253 B-Or
dysphasia NCT03861299 1254 1263 B-Condition

Inclusion NCT03864120 0 9 O
Criteria NCT03864120 10 18 O
: NCT03864120 19 20 O

1 NCT03864120 24 25 O
. NCT03864120 25 26 O
Age NCT03864120 28 31 B-Age
> NCT03864120 32 33 B-Eq-Comparison
18 NCT03864120 34 36 I-Eq-Comparison
years NCT03864120 37 42 I-Eq-Comparison

2 NCT03864120 45 46 O
. NCT03864120 46 47 O
on NCT03864120 49 51 B-Eq-Comparison
PD NCT03864120 52 54 B-Condition
treatment NCT03864120 55 64 B-Procedure
for NCT03864120 65 68 O
at NCT03864120 69 71 B-Eq-Comparison
least NCT03864120 72 77 I-Eq-Comparison
one NCT03864120 78 81 I-Eq-Comparison
month NCT03864120 82 87 I-Eq-Comparison

3 NCT03864120 90 91 O
. NCT03864120 91 92 O
signed NCT03864120 94 100 O
the NCT03864120 101 104 O
consent NCT03864120 105 112 O

Exclusion NCT03864120 113 122 O
Criteria NCT03864120 123 131 O
: NCT03864120 132 133 O

1 NCT03864120 137 138 O
. NCT03864120 138 139 O
Peritonitis NCT03864120 141 152 B-Condition
or NCT03864120 153 155 B-Or
recovery NCT03864120 156 164 B-Condition
from NCT03864120 165 169 O
peritonitis NCT03864120 170 181 B-Condition
for NCT03864120 182 185 O
less NCT03864120 186 190 B-Eq-Comparison
than NCT03864120 191 195 I-Eq-Comparison
one NCT03864120 196 199 I-Eq-Comparison
month NCT03864120 200 205 I-Eq-Comparison
. NCT03864120 205 206 O

2 NCT03864120 210 211 O
. NCT03864120 211 212 O
On NCT03864120 214 216 B-Eq-Comparison
any NCT03864120 217 220 O
intra NCT03864120 221 226 B-Modifier
peritoneal NCT03864120 227 237 B-Procedure
treatment NCT03864120 238 247 I-Procedure
apart NCT03864120 248 253 B-Exception
from NCT03864120 254 258 O
peritoneal NCT03864120 259 269 B-Procedure
dialysis NCT03864120 270 278 I-Procedure
. NCT03864120 278 279 O

3 NCT03864120 283 284 O
. NCT03864120 284 285 O
Evidence NCT03864120 287 295 O
of NCT03864120 296 298 O
decompensated NCT03864120 299 312 B-Modifier
liver NCT03864120 313 318 I-Modifier
cirrhosis NCT03864120 319 328 B-Condition
or NCT03864120 329 331 B-Or
heart NCT03864120 332 337 B-Condition
failure NCT03864120 338 345 I-Condition
. NCT03864120 345 346 O

4 NCT03864120 350 351 O
. NCT03864120 351 352 O
Evidence NCT03864120 354 362 O
of NCT03864120 363 365 O
extra NCT03864120 366 371 B-Modifier
peritoneal NCT03864120 372 382 B-Condition
leakage NCT03864120 383 390 I-Condition|Condition
, NCT03864120 391 392 O
eg NCT03864120 393 395 O
. NCT03864120 395 396 O
leakage NCT03864120 398 405 O
to NCT03864120 406 408 O
thoracic NCT03864120 409 417 B-Modifier
cavity NCT03864120 418 424 I-Modifier
, NCT03864120 425 426 O
post NCT03864120 427 431 B-Temporal-Connection___Temporal-Connection-Type-Value:after
peritoneal NCT03864120 432 442 B-Procedure
, NCT03864120 443 444 O
hernia NCT03864120 445 451 B-Condition
. NCT03864120 451 452 O

Inclusion NCT03864861 0 9 O
Criteria NCT03864861 10 18 O
: NCT03864861 19 20 O

- NCT03864861 24 25 O
All NCT03864861 27 30 O
adult NCT03864861 31 36 O
patients NCT03864861 37 45 O
( NCT03864861 46 47 O
aged NCT03864861 48 52 B-Age
≥ NCT03864861 53 54 B-Eq-Comparison
18 NCT03864861 55 57 I-Eq-Comparison
years NCT03864861 58 63 I-Eq-Comparison
) NCT03864861 64 65 O
undergoing NCT03864861 66 76 B-Eq-Comparison
elective NCT03864861 77 85 B-Modifier
bariatric NCT03864861 86 95 B-Procedure
surgery NCT03864861 96 103 I-Procedure
and NCT03864861 104 107 O
by NCT03864861 108 110 O
any NCT03864861 111 114 O
approach NCT03864861 115 123 O
( NCT03864861 124 125 O
Includes NCT03864861 126 134 O
surgery NCT03864861 135 142 B-Procedure
with NCT03864861 143 147 O
laparoscopic NCT03864861 148 160 B-Procedure
, NCT03864861 161 162 O
assisted NCT03864861 163 171 B-Modifier
laparoscopic NCT03864861 172 184 B-Procedure
approach NCT03864861 185 193 I-Procedure
or NCT03864861 194 196 B-Or
open NCT03864861 197 201 B-Procedure
approach NCT03864861 202 210 I-Procedure
) NCT03864861 211 212 O
in NCT03864861 213 215 O
a NCT03864861 216 217 O
participating NCT03864861 218 231 O
hospital NCT03864861 232 240 O
during NCT03864861 241 247 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864861 248 251 O
30 NCT03864861 252 254 B-Eq-Comparison
- NCT03864861 255 256 I-Eq-Comparison
day NCT03864861 257 260 I-Eq-Comparison
cohort NCT03864861 261 267 B-Study
period NCT03864861 268 274 O
with NCT03864861 275 279 B-And
a NCT03864861 280 281 O
planned NCT03864861 282 289 B-Eq-Comparison
overnight NCT03864861 290 299 B-Encounter
stay NCT03864861 300 304 I-Encounter
. NCT03864861 304 305 O

Exclusion NCT03864861 307 316 O
Criteria NCT03864861 317 325 O
: NCT03864861 326 327 O

- NCT03864861 331 332 O
Patients NCT03864861 334 342 O
undergoing NCT03864861 343 353 B-Eq-Comparison
emergency NCT03864861 354 363 B-Modifier
surgery NCT03864861 364 371 B-Procedure

- NCT03864861 379 380 O
Endoscopic NCT03864861 382 392 B-Procedure
procedures NCT03864861 393 403 I-Procedure

- NCT03864861 411 412 O
Patients NCT03864861 414 422 O
under NCT03864861 423 428 B-Eq-Comparison
18 NCT03864861 429 431 I-Eq-Comparison
years NCT03864861 432 437 I-Eq-Comparison
of NCT03864861 438 440 O
age NCT03864861 441 444 B-Age

- NCT03864861 452 453 O
Patients NCT03864861 455 463 O
with NCT03864861 464 468 O
previous NCT03864861 469 477 B-Eq-Comparison
bariatric NCT03864861 478 487 B-Procedure
surgery NCT03864861 488 495 I-Procedure
who NCT03864861 496 499 B-And
undergo NCT03864861 500 507 O
revision NCT03864861 508 516 B-Procedure
surgery NCT03864861 517 524 I-Procedure

- NCT03864861 532 533 O
Patients NCT03864861 535 543 O
who NCT03864861 544 547 O
refuse NCT03864861 548 554 O
to NCT03864861 555 557 O
participate NCT03864861 558 569 O

Inclusion NCT03868137 0 9 O
Criteria NCT03868137 10 18 O
: NCT03868137 19 20 O

- NCT03868137 24 25 O
Age NCT03868137 27 30 B-Age
≥ NCT03868137 31 32 B-Eq-Comparison
18 NCT03868137 33 35 I-Eq-Comparison

- NCT03868137 39 40 O
Female NCT03868137 42 48 O

- NCT03868137 51 52 O
Able NCT03868137 54 58 O
to NCT03868137 59 61 O
provide NCT03868137 62 69 O
informed NCT03868137 70 78 O
consent NCT03868137 79 86 O

- NCT03868137 89 90 O
English NCT03868137 92 99 O
speaking NCT03868137 100 108 O

- NCT03868137 111 112 O
Able NCT03868137 114 118 O
to NCT03868137 119 121 O
provide NCT03868137 122 129 O
telephone NCT03868137 130 139 O
and NCT03868137 140 143 O
address NCT03868137 144 151 O
contact NCT03868137 152 159 O
information NCT03868137 160 171 O

- NCT03868137 174 175 O
Able NCT03868137 177 181 O
and NCT03868137 182 185 O
willing NCT03868137 186 193 O
to NCT03868137 194 196 O
receive NCT03868137 197 204 O
HIPAA NCT03868137 205 210 O
compliant NCT03868137 211 220 O
telephone NCT03868137 221 230 O
texts NCT03868137 231 236 O
and NCT03868137 237 240 O
phone NCT03868137 241 246 O
messages NCT03868137 247 255 O

- NCT03868137 258 259 O
Stable NCT03868137 261 267 O
( NCT03868137 268 269 O
the NCT03868137 270 273 O
same NCT03868137 274 278 O
) NCT03868137 279 280 O
address NCT03868137 281 288 O
and NCT03868137 289 292 O
phone NCT03868137 293 298 O
number NCT03868137 299 305 O
within NCT03868137 306 312 B-Eq-Comparison
the NCT03868137 313 316 I-Eq-Comparison
last NCT03868137 317 321 I-Eq-Comparison
6 NCT03868137 322 323 I-Eq-Comparison
months NCT03868137 324 330 I-Eq-Comparison
. NCT03868137 330 331 O

Exclusion NCT03868137 333 342 O
Criteria NCT03868137 343 351 O
: NCT03868137 352 353 O

- NCT03868137 357 358 O
Contraindications NCT03868137 360 377 B-Contraindication
to NCT03868137 378 380 O
IUD NCT03868137 381 384 B-Procedure
insertion NCT03868137 385 394 I-Procedure
( NCT03868137 395 396 O
active NCT03868137 397 403 B-Eq-Comparison
pelvic NCT03868137 404 410 B-Modifier
infection NCT03868137 411 420 B-Condition
, NCT03868137 421 422 O
current NCT03868137 423 430 B-Eq-Comparison
pregnancy NCT03868137 431 440 B-Condition
) NCT03868137 441 442 O

- NCT03868137 446 447 O
Contraindications NCT03868137 449 466 B-Contraindication
to NCT03868137 467 469 O
NSAIDs NCT03868137 470 476 B-Drug
( NCT03868137 477 478 O
allergy NCT03868137 479 486 B-Allergy
, NCT03868137 487 488 O
history NCT03868137 489 496 B-Eq-Comparison
of NCT03868137 497 499 O
asthma NCT03868137 500 506 B-Condition
, NCT03868137 507 508 O
history NCT03868137 509 516 B-Eq-Comparison
of NCT03868137 517 519 O
aspirin NCT03868137 520 527 B-Drug
allergy NCT03868137 528 535 B-Allergy
, NCT03868137 536 537 O
history NCT03868137 538 545 B-Eq-Comparison
of NCT03868137 546 548 O
kidney NCT03868137 549 555 B-Condition
disease NCT03868137 556 563 I-Condition
, NCT03868137 564 565 O
history NCT03868137 566 573 B-Eq-Comparison
of NCT03868137 574 576 O
stomach NCT03868137 577 584 B-Modifier
ulcer NCT03868137 585 590 B-Condition
, NCT03868137 591 592 O
history NCT03868137 593 600 B-Eq-Comparison
of NCT03868137 601 603 O
active NCT03868137 604 610 B-Eq-Comparison
GI NCT03868137 611 613 B-Modifier
bleeding NCT03868137 614 622 B-Condition
, NCT03868137 623 624 O
history NCT03868137 625 632 B-Eq-Comparison
of NCT03868137 633 635 O
liver NCT03868137 636 641 B-Condition
disease NCT03868137 642 649 I-Condition
) NCT03868137 650 651 O

- NCT03868137 655 656 O
Not NCT03868137 658 661 B-Negation
undergoing NCT03868137 662 672 B-Eq-Comparison
any NCT03868137 673 676 O
other NCT03868137 677 682 B-Other
concurrent NCT03868137 683 693 B-Modifier
office NCT03868137 694 700 I-Modifier
procedures NCT03868137 701 711 B-Procedure

Inclusion NCT03865407 0 9 O
Criteria NCT03865407 10 18 O
: NCT03865407 19 20 O

- NCT03865407 24 25 O
Chronic NCT03865407 27 34 B-Modifier
Kidney NCT03865407 35 41 B-Condition
Disease NCT03865407 42 49 I-Condition
stage NCT03865407 50 55 B-Eq-Comparison
1 NCT03865407 56 57 I-Eq-Comparison
- NCT03865407 58 59 I-Eq-Comparison
5 NCT03865407 60 61 O

- NCT03865407 65 66 O
Hyperuricemic NCT03865407 68 81 B-Condition
( NCT03865407 82 83 O
UA NCT03865407 84 86 B-Observation
> NCT03865407 87 88 B-Eq-Comparison
= NCT03865407 90 91 I-Eq-Comparison
5.5 NCT03865407 92 95 I-Eq-Comparison
mg NCT03865407 96 98 I-Eq-Comparison
/ NCT03865407 99 100 I-Eq-Comparison
dL NCT03865407 101 103 I-Eq-Comparison
) NCT03865407 104 105 O

Exclusion NCT03865407 107 116 O
Criteria NCT03865407 117 125 O
: NCT03865407 126 127 O

- NCT03865407 131 132 O
Contraindication NCT03865407 134 150 B-Contraindication
to NCT03865407 151 153 O
Allopurinol NCT03865407 154 165 B-Drug

- NCT03865407 168 169 O
Elevated NCT03865407 171 179 O
baseline NCT03865407 180 188 O
liver NCT03865407 189 194 B-Observation
function NCT03865407 195 203 I-Observation
tests NCT03865407 204 209 I-Observation

- NCT03865407 212 213 O
Receiving NCT03865407 215 224 B-Eq-Comparison
acute NCT03865407 225 230 O
or NCT03865407 231 233 B-Or
chronic NCT03865407 234 241 B-Modifier
dialysis NCT03865407 242 250 B-Procedure

- NCT03865407 253 254 O
Primary NCT03865407 256 263 B-Modifier
metabolic NCT03865407 264 273 B-Condition
disorder NCT03865407 274 282 I-Condition

- NCT03865407 285 286 O
Sickle NCT03865407 288 294 B-Condition
cell NCT03865407 295 299 I-Condition
disease NCT03865407 300 307 I-Condition

- NCT03865407 310 311 O
Autosomal NCT03865407 313 322 B-Modifier
Dominant NCT03865407 323 331 I-Modifier
Polycystic NCT03865407 332 342 B-Condition
Kidney NCT03865407 343 349 I-Condition
Disease NCT03865407 350 357 I-Condition

- NCT03865407 360 361 O
Cystinosis NCT03865407 363 373 B-Condition

- NCT03865407 376 377 O
Bartter NCT03865407 379 386 B-Modifier
or NCT03865407 387 389 B-Or
Gitelman NCT03865407 390 398 B-Modifier
Disease NCT03865407 399 406 B-Condition

- NCT03865407 409 410 O
Pregnant NCT03865407 412 420 B-Condition
or NCT03865407 421 423 B-Or
nursing NCT03865407 424 431 B-Condition

Inclusion NCT03866668 0 9 O
Criteria NCT03866668 10 18 O
: NCT03866668 19 20 O

- NCT03866668 24 25 O
outpatients NCT03866668 27 38 B-Encounter
2 NCT03866668 39 40 B-Eq-Comparison
to NCT03866668 41 43 I-Eq-Comparison
6 NCT03866668 44 45 I-Eq-Comparison
years NCT03866668 46 51 I-Eq-Comparison
of NCT03866668 52 54 O
age NCT03866668 55 58 B-Age
; NCT03866668 58 59 O

- NCT03866668 62 63 O
males NCT03866668 65 70 O
and NCT03866668 71 74 B-Or
females NCT03866668 75 82 O
who NCT03866668 83 86 B-And
are NCT03866668 87 90 O
physically NCT03866668 91 101 O
healthy NCT03866668 102 109 B-Condition
; NCT03866668 109 110 O

- NCT03866668 113 114 O
diagnosis NCT03866668 116 125 O
of NCT03866668 126 128 O
autism NCT03866668 129 135 B-Condition
spectrum NCT03866668 136 144 I-Condition
disorder NCT03866668 145 153 I-Condition
based NCT03866668 154 159 O
on NCT03866668 160 162 O
clinical NCT03866668 163 171 O
evaluation NCT03866668 172 182 O
and NCT03866668 183 186 O
DSM NCT03866668 187 190 O
- NCT03866668 191 192 O
5 NCT03866668 193 194 O
criteria NCT03866668 195 203 O
, NCT03866668 204 205 O
and NCT03866668 206 209 O
confirmed NCT03866668 210 219 O
using NCT03866668 220 225 O
the NCT03866668 226 229 O
Autism NCT03866668 230 236 O
Diagnostic NCT03866668 237 247 O
Interview NCT03866668 248 257 O
- NCT03866668 258 259 O
Revised NCT03866668 260 267 O
, NCT03866668 268 269 O
and NCT03866668 270 273 O
the NCT03866668 274 277 O
Autism NCT03866668 278 284 O
Diagnostic NCT03866668 285 295 O
Observation NCT03866668 296 307 O
Schedule NCT03866668 308 316 O
; NCT03866668 316 317 O

- NCT03866668 320 321 O
care NCT03866668 323 327 B-Provider
provider NCT03866668 328 336 I-Provider
who NCT03866668 337 340 O
could NCT03866668 341 346 B-Assertion___Assertion-Type-Value:hypothetical
reliably NCT03866668 347 355 O
bring NCT03866668 356 361 O
subject NCT03866668 362 369 O
to NCT03866668 370 372 O
clinic NCT03866668 373 379 O
visits NCT03866668 380 386 B-Encounter
, NCT03866668 387 388 O
could NCT03866668 389 394 B-Assertion___Assertion-Type-Value:hypothetical
provide NCT03866668 395 402 O
trustworthy NCT03866668 403 414 O
ratings NCT03866668 415 422 O
, NCT03866668 423 424 O
and NCT03866668 425 428 O
interacted NCT03866668 429 439 O
with NCT03866668 440 444 O
subject NCT03866668 445 452 O
on NCT03866668 453 455 O
a NCT03866668 456 457 O
regular NCT03866668 458 465 O
basis NCT03866668 466 471 O
; NCT03866668 471 472 O

- NCT03866668 475 476 O
ability NCT03866668 478 485 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866668 486 488 I-Assertion___Assertion-Type-Value:hypothetical
subject NCT03866668 489 496 O
to NCT03866668 497 499 O
swallow NCT03866668 500 507 O
the NCT03866668 508 511 O
compound NCT03866668 512 520 B-Drug
; NCT03866668 520 521 O

- NCT03866668 524 525 O
stable NCT03866668 527 533 O
concomitant NCT03866668 534 545 B-Modifier
medications NCT03866668 546 557 B-Drug
for NCT03866668 558 561 O
at NCT03866668 562 564 B-Eq-Comparison
least NCT03866668 565 570 I-Eq-Comparison
2 NCT03866668 571 572 I-Eq-Comparison
weeks NCT03866668 573 578 I-Eq-Comparison|Eq-Comparison
( NCT03866668 579 580 O
4 NCT03866668 581 582 B-Eq-Comparison
weeks NCT03866668 583 588 O
if NCT03866668 589 591 O
patient NCT03866668 592 599 O
took NCT03866668 600 604 B-Eq-Comparison
fluoxetine NCT03866668 605 615 B-Drug
) NCT03866668 616 617 O
; NCT03866668 618 619 O

- NCT03866668 622 623 O
no NCT03866668 625 627 B-Negation
planned NCT03866668 628 635 B-Eq-Comparison
changes NCT03866668 636 643 O
in NCT03866668 644 646 O
psychosocial NCT03866668 647 659 B-Procedure
interventions NCT03866668 660 673 I-Procedure
during NCT03866668 674 680 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866668 681 684 O
open NCT03866668 685 689 B-Modifier
- NCT03866668 690 691 I-Modifier
label NCT03866668 692 697 I-Modifier
trial NCT03866668 698 703 B-Study
. NCT03866668 703 704 O

Exclusion NCT03866668 706 715 O
Criteria NCT03866668 716 724 O
: NCT03866668 725 726 O

- NCT03866668 730 731 O
DSM NCT03866668 733 736 O
- NCT03866668 737 738 O
5 NCT03866668 739 740 O
diagnosis NCT03866668 741 750 O
of NCT03866668 751 753 O
schizophrenia NCT03866668 754 767 B-Condition
, NCT03866668 768 769 O
schizoaffective NCT03866668 770 785 B-Condition
disorder NCT03866668 786 794 I-Condition
, NCT03866668 795 796 O
or NCT03866668 797 799 B-Or
psychotic NCT03866668 800 809 B-Condition
disorder NCT03866668 810 818 I-Condition
not NCT03866668 819 822 O
otherwise NCT03866668 823 832 O
specified NCT03866668 833 842 O
; NCT03866668 842 843 O

- NCT03866668 846 847 O
prior NCT03866668 849 854 B-Eq-Comparison
adequate NCT03866668 855 863 O
trial NCT03866668 864 869 B-Study
of NCT03866668 870 872 O
Esomeprazole NCT03866668 873 885 B-Drug
; NCT03866668 885 886 O

- NCT03866668 889 890 O
active NCT03866668 892 898 B-Eq-Comparison
medical NCT03866668 899 906 B-Condition
problems NCT03866668 907 915 I-Condition
such NCT03866668 916 920 O
as NCT03866668 921 923 O
unstable NCT03866668 924 932 O
seizures NCT03866668 933 941 B-Condition
, NCT03866668 942 943 O
or NCT03866668 944 946 B-Or
significant NCT03866668 947 958 O
physical NCT03866668 959 967 B-Condition
illness NCT03866668 968 975 I-Condition
( NCT03866668 976 977 O
e. NCT03866668 978 980 O
g. NCT03866668 981 983 O
, NCT03866668 984 985 O
serious NCT03866668 986 993 O
liver NCT03866668 994 999 B-Modifier
or NCT03866668 1000 1002 B-Or
renal NCT03866668 1003 1008 B-Modifier
pathology NCT03866668 1009 1018 B-Condition
) NCT03866668 1019 1020 O
. NCT03866668 1021 1022 O

Inclusion NCT03864731 0 9 O
Criteria NCT03864731 10 18 O
: NCT03864731 19 20 O

- NCT03864731 24 25 O
Unilateral NCT03864731 27 37 B-Modifier
and NCT03864731 38 41 B-Or
/ NCT03864731 42 43 I-Or
or NCT03864731 44 46 I-Or
bilateral NCT03864731 47 56 B-Modifier
conductive NCT03864731 57 67 B-Condition
hearing NCT03864731 68 75 I-Condition
loss NCT03864731 76 80 I-Condition
( NCT03864731 81 82 O
CHL NCT03864731 83 86 B-Condition
) NCT03864731 87 88 O

- NCT03864731 92 93 O
Conductive NCT03864731 95 105 B-Modifier
hearing NCT03864731 106 113 B-Condition|Observation
loss NCT03864731 114 118 I-Condition|Observation
> NCT03864731 119 120 B-Eq-Comparison
10 NCT03864731 121 123 I-Eq-Comparison
decibel NCT03864731 124 131 I-Eq-Comparison
on NCT03864731 132 134 O
average NCT03864731 135 142 O

- NCT03864731 145 146 O
Subjective NCT03864731 148 158 O
benefit NCT03864731 159 166 O
from NCT03864731 167 171 O
the NCT03864731 172 175 O
device NCT03864731 176 182 O

- NCT03864731 185 186 O
Subjects NCT03864731 188 196 O
aged NCT03864731 197 201 B-Age
13 NCT03864731 202 204 B-Eq-Comparison
years NCT03864731 205 210 I-Eq-Comparison
or NCT03864731 211 213 I-Eq-Comparison
older NCT03864731 214 219 I-Eq-Comparison

- NCT03864731 222 223 O
Capable NCT03864731 225 232 O
of NCT03864731 233 235 O
the NCT03864731 236 239 O
German NCT03864731 240 246 O
language NCT03864731 247 255 O

- NCT03864731 258 259 O
Willingness NCT03864731 261 272 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03864731 273 276 I-Assertion___Assertion-Type-Value:hypothetical
ability NCT03864731 277 284 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03864731 285 287 O
perform NCT03864731 288 295 O
all NCT03864731 296 299 O
tests NCT03864731 300 305 B-Observation
required NCT03864731 306 314 O
for NCT03864731 315 318 O
the NCT03864731 319 322 O
study NCT03864731 323 328 B-Study

- NCT03864731 331 332 O
Signed NCT03864731 334 340 O
, NCT03864731 341 342 O
and NCT03864731 343 346 O
dated NCT03864731 347 352 O
informed NCT03864731 353 361 O
consent NCT03864731 362 369 O
before NCT03864731 370 376 O
the NCT03864731 377 380 O
start NCT03864731 381 386 O
of NCT03864731 387 389 O
any NCT03864731 390 393 O
study NCT03864731 394 399 B-Study
specific NCT03864731 400 408 O
procedure NCT03864731 409 418 B-Procedure

Exclusion NCT03864731 419 428 O
Criteria NCT03864731 429 437 O
: NCT03864731 438 439 O

- NCT03864731 443 444 O
Pregnancy NCT03864731 446 455 B-Condition
or NCT03864731 456 458 B-Or
breastfeeding NCT03864731 459 472 B-Condition

- NCT03864731 475 476 O
Patient NCT03864731 478 485 O
uses NCT03864731 486 490 O
a NCT03864731 491 492 O
hearing NCT03864731 493 500 B-Condition
aid NCT03864731 501 504 I-Condition
or NCT03864731 505 507 B-Or
plans NCT03864731 508 513 B-Assertion___Assertion-Type-Value:intention
to NCT03864731 514 516 O
acquire NCT03864731 517 524 O
a NCT03864731 525 526 O
hearing NCT03864731 527 534 B-Condition
aid NCT03864731 535 538 I-Condition

- NCT03864731 541 542 O
Patient NCT03864731 544 551 O
is NCT03864731 552 554 O
intolerant NCT03864731 555 565 O
of NCT03864731 566 568 O
the NCT03864731 569 572 O
materials NCT03864731 573 582 O
as NCT03864731 583 585 O
described NCT03864731 586 595 O
by NCT03864731 596 598 O
Manufacturer NCT03864731 599 611 O

- NCT03864731 614 615 O
Patient NCT03864731 617 624 O
presents NCT03864731 625 633 O
with NCT03864731 634 638 O
a NCT03864731 639 640 O
skin NCT03864731 641 645 B-Modifier
or NCT03864731 646 648 B-Or
scalp NCT03864731 649 654 B-Modifier
condition NCT03864731 655 664 B-Condition
that NCT03864731 665 669 O
may NCT03864731 670 673 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03864731 674 682 B-Negation
the NCT03864731 683 686 O
attachment NCT03864731 687 697 B-Procedure
of NCT03864731 698 700 I-Procedure
the NCT03864731 701 704 I-Procedure
adhesive NCT03864731 705 713 I-Procedure
adapter NCT03864731 714 721 I-Procedure
. NCT03864731 721 722 O

- NCT03864731 726 727 O
Patient NCT03864731 729 736 O
can NCT03864731 737 740 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03864731 740 743 O
perform NCT03864731 744 751 O
the NCT03864731 752 755 O
audiological NCT03864731 756 768 B-Procedure
tests NCT03864731 769 774 I-Procedure
or NCT03864731 775 777 B-Or
is NCT03864731 778 780 O
unable NCT03864731 781 787 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864731 788 790 O
fill NCT03864731 791 795 O
out NCT03864731 796 799 O
the NCT03864731 800 803 O
questionnaires NCT03864731 804 818 B-Observation
. NCT03864731 818 819 O

- NCT03864731 823 824 O
Patient NCT03864731 826 833 O
presents NCT03864731 834 842 O
with NCT03864731 843 847 O
retrocochlear NCT03864731 848 861 B-Condition
, NCT03864731 862 863 O
or NCT03864731 864 866 B-Or
central NCT03864731 867 874 B-Modifier
auditory NCT03864731 875 883 B-Condition
disorder NCT03864731 884 892 I-Condition
. NCT03864731 892 893 O

- NCT03864731 897 898 O
any NCT03864731 900 903 O
physical NCT03864731 904 912 B-Modifier
, NCT03864731 913 914 O
psychological NCT03864731 915 928 B-Modifier
, NCT03864731 929 930 O
or NCT03864731 931 933 B-Or
emotional NCT03864731 934 943 B-Modifier
disorder NCT03864731 944 952 B-Condition
that NCT03864731 953 957 O
would NCT03864731 958 963 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864731 964 973 O
with NCT03864731 974 978 O
the NCT03864731 979 982 O
ability NCT03864731 983 990 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864731 991 993 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03864731 994 1001 O
on NCT03864731 1002 1004 O
test NCT03864731 1005 1009 B-Observation
and NCT03864731 1010 1013 B-Or
rehabilitation NCT03864731 1014 1028 B-Procedure
procedures NCT03864731 1029 1039 I-Procedure

Inclusion NCT03869567 0 9 O
Criteria NCT03869567 10 18 O
: NCT03869567 19 20 O

- NCT03869567 24 25 O
all NCT03869567 27 30 O
patients NCT03869567 31 39 O
with NCT03869567 40 44 O
cerebral NCT03869567 45 53 B-Condition
thrombectomy NCT03869567 54 66 I-Condition

- NCT03869567 69 70 O
Adults NCT03869567 72 78 O

- NCT03869567 81 82 O
Patients NCT03869567 84 92 O
able NCT03869567 93 97 O
to NCT03869567 98 100 O
express NCT03869567 101 108 O
consent NCT03869567 109 116 O

- NCT03869567 119 120 O
Signed NCT03869567 122 128 O
written NCT03869567 129 136 O
informed NCT03869567 137 145 O
consent NCT03869567 146 153 O
form NCT03869567 154 158 O

- NCT03869567 161 162 O
Covered NCT03869567 164 171 O
by NCT03869567 172 174 O
national NCT03869567 175 183 O
health NCT03869567 184 190 O
insurance NCT03869567 191 200 O

Exclusion NCT03869567 201 210 O
Criteria NCT03869567 211 219 O
: NCT03869567 220 221 O

- NCT03869567 225 226 O
minors NCT03869567 228 234 O

- NCT03869567 237 238 O
pregnancy NCT03869567 240 249 B-Condition
or NCT03869567 250 252 B-Or
beast NCT03869567 253 258 B-Condition
feeding NCT03869567 259 266 I-Condition

- NCT03869567 269 270 O
patient NCT03869567 272 279 O
deprived NCT03869567 280 288 B-Observation
of NCT03869567 289 291 I-Observation
liberty NCT03869567 292 299 I-Observation
by NCT03869567 300 302 O
administrative NCT03869567 303 317 O
or NCT03869567 318 320 O
judicial NCT03869567 321 329 O
decision NCT03869567 330 338 O
or NCT03869567 339 341 B-Or
placed NCT03869567 342 348 O
under NCT03869567 349 354 O
judicial NCT03869567 355 363 B-Observation
protection NCT03869567 364 374 I-Observation
( NCT03869567 375 376 O
guardianship NCT03869567 377 389 O
or NCT03869567 390 392 O
supervision NCT03869567 393 404 O
) NCT03869567 405 406 O

- NCT03869567 410 411 O
obstruction NCT03869567 413 424 O
to NCT03869567 425 427 O
participate NCT03869567 428 439 O

- NCT03869567 442 443 O
non NCT03869567 445 448 B-Negation
covered NCT03869567 449 456 O
by NCT03869567 457 459 O
national NCT03869567 460 468 O
health NCT03869567 469 475 O
insurance NCT03869567 476 485 O

Inclusion NCT03864094 0 9 O
Criteria NCT03864094 10 18 O
: NCT03864094 19 20 O

- NCT03864094 24 25 O
Healthy NCT03864094 27 34 B-Condition
women NCT03864094 35 40 O

- NCT03864094 43 44 O
Age NCT03864094 46 49 B-Age
18 NCT03864094 50 52 B-Eq-Comparison
- NCT03864094 53 54 I-Eq-Comparison
50 NCT03864094 55 57 I-Eq-Comparison
years NCT03864094 58 63 I-Eq-Comparison

- NCT03864094 66 67 O
Gynecological NCT03864094 69 82 B-Procedure
procedures NCT03864094 83 93 I-Procedure

- NCT03864094 96 97 O
General NCT03864094 99 106 B-Procedure
anesthesia NCT03864094 107 117 I-Procedure

Exclusion NCT03864094 118 127 O
Criteria NCT03864094 128 136 O
: NCT03864094 137 138 O

- NCT03864094 142 143 I-Eq-Comparison
Pre NCT03864094 145 148 B-Eq-Comparison
- NCT03864094 149 150 O
existing NCT03864094 151 159 I-Eq-Comparison
hypertension NCT03864094 160 172 B-Condition

- NCT03864094 175 176 O
Diabetes NCT03864094 178 186 B-Condition
for NCT03864094 187 190 O
several NCT03864094 191 198 B-Eq-Comparison
years NCT03864094 199 204 I-Eq-Comparison

- NCT03864094 207 208 O
Ischemic NCT03864094 210 218 B-Modifier
heart NCT03864094 219 224 B-Condition
disease NCT03864094 225 232 I-Condition

- NCT03864094 235 236 O
Cerebrovascular NCT03864094 238 253 B-Condition
disease NCT03864094 254 261 I-Condition

- NCT03864094 264 265 O
Heart NCT03864094 267 272 B-Condition
valve NCT03864094 273 278 I-Condition
disease NCT03864094 279 286 I-Condition

- NCT03864094 289 290 O
Verified NCT03864094 292 300 O
cardiac NCT03864094 301 308 B-Condition
arrhythmia NCT03864094 309 319 I-Condition

- NCT03864094 322 323 O
Anaemia NCT03864094 325 332 B-Condition

- NCT03864094 335 336 O
Kidney NCT03864094 338 344 B-Modifier
or NCT03864094 345 347 B-Or
hepatic NCT03864094 348 355 B-Modifier
disease NCT03864094 356 363 B-Condition

- NCT03864094 366 367 O
Hypersensitivity NCT03864094 369 385 B-Condition
for NCT03864094 386 389 O
soya NCT03864094 390 394 B-Modifier
, NCT03864094 395 396 O
eggs NCT03864094 397 401 B-Modifier
or NCT03864094 402 404 B-Or
peanuts NCT03864094 405 412 B-Modifier

- NCT03864094 415 416 O
Pregnancy NCT03864094 418 427 B-Condition

- NCT03864094 430 431 O
Poor NCT03864094 433 437 B-Condition
health NCT03864094 438 444 I-Condition
state NCT03864094 445 450 O

- NCT03864094 453 454 O
Illicit NCT03864094 456 463 B-Condition
substance NCT03864094 464 473 I-Condition
use NCT03864094 474 477 O

- NCT03864094 480 481 O
BMI NCT03864094 483 486 B-Observation
< NCT03864094 487 488 B-Eq-Comparison
20 NCT03864094 489 491 I-Eq-Comparison
or NCT03864094 492 494 B-Or
> NCT03864094 495 496 B-Eq-Comparison
35 NCT03864094 497 499 I-Eq-Comparison
kg NCT03864094 500 502 I-Eq-Comparison
/ NCT03864094 503 504 I-Eq-Comparison
m2 NCT03864094 505 507 I-Eq-Comparison

- NCT03864094 510 511 O
SBP NCT03864094 513 516 B-Observation
> NCT03864094 517 518 B-Eq-Comparison
150 NCT03864094 519 522 I-Eq-Comparison
mmHg NCT03864094 523 527 I-Eq-Comparison

- NCT03864094 530 531 O
HR NCT03864094 533 535 B-Observation
> NCT03864094 536 537 B-Eq-Comparison
100 NCT03864094 538 541 I-Eq-Comparison
beats NCT03864094 542 547 I-Eq-Comparison
/ NCT03864094 548 549 I-Eq-Comparison
min NCT03864094 550 553 I-Eq-Comparison

Inclusion NCT03867760 0 9 O
Criteria NCT03867760 10 18 O
: NCT03867760 19 20 O

- NCT03867760 24 25 O
self NCT03867760 27 31 O
- NCT03867760 32 33 O
reporting NCT03867760 34 43 O
moderate NCT03867760 44 52 B-Eq-Comparison
or NCT03867760 53 55 I-Eq-Comparison
higher NCT03867760 56 62 I-Eq-Comparison
pain NCT03867760 63 67 B-Condition
on NCT03867760 68 70 O
average NCT03867760 71 78 O
during NCT03867760 79 85 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867760 86 89 O
last NCT03867760 90 94 B-Eq-Comparison
week NCT03867760 95 99 I-Eq-Comparison
( NCT03867760 100 101 O
> NCT03867760 103 104 B-Eq-Comparison
3 NCT03867760 105 106 I-Eq-Comparison
on NCT03867760 107 109 O
a NCT03867760 110 111 O
0 NCT03867760 112 113 B-Modifier
- NCT03867760 114 115 I-Modifier
10 NCT03867760 116 118 I-Modifier
pain NCT03867760 119 123 B-Observation
intensity NCT03867760 124 133 I-Observation
numeric NCT03867760 134 141 I-Observation
scale NCT03867760 142 147 I-Observation
) NCT03867760 148 149 O

- NCT03867760 153 154 O
self NCT03867760 156 160 O
- NCT03867760 161 162 O
reporting NCT03867760 163 172 O
experiencing NCT03867760 173 185 O
pain NCT03867760 186 190 B-Condition
at NCT03867760 191 193 B-Eq-Comparison
least NCT03867760 194 199 I-Eq-Comparison
half NCT03867760 200 204 I-Eq-Comparison
of NCT03867760 205 207 I-Eq-Comparison
the NCT03867760 208 211 I-Eq-Comparison
days NCT03867760 212 216 I-Eq-Comparison
in NCT03867760 217 219 O
the NCT03867760 220 223 O
past NCT03867760 224 228 B-Eq-Comparison
4 NCT03867760 229 230 I-Eq-Comparison
weeks NCT03867760 231 236 I-Eq-Comparison

- NCT03867760 239 240 O
self NCT03867760 242 246 O
- NCT03867760 247 248 O
reporting NCT03867760 249 258 O
chronic NCT03867760 259 266 B-Modifier
pain NCT03867760 267 271 B-Condition
related NCT03867760 272 279 O
to NCT03867760 280 282 O
cancer NCT03867760 283 289 B-Condition
or NCT03867760 290 292 B-Or
its NCT03867760 293 296 B-Coreference
treatment NCT03867760 297 306 B-Procedure

- NCT03867760 309 310 O
completed NCT03867760 312 321 B-Eq-Comparison
active NCT03867760 322 328 B-Eq-Comparison
cancer NCT03867760 329 335 B-Condition
treatment NCT03867760 336 345 B-Procedure
other NCT03867760 346 351 B-Exception
than NCT03867760 352 356 I-Exception
maintenance NCT03867760 357 368 B-Procedure
therapy NCT03867760 369 376 I-Procedure

- NCT03867760 379 380 O
being NCT03867760 382 387 O
> NCT03867760 388 389 B-Eq-Comparison
18 NCT03867760 390 392 I-Eq-Comparison
years NCT03867760 393 398 I-Eq-Comparison
of NCT03867760 399 401 O
age NCT03867760 402 405 B-Age

- NCT03867760 408 409 O
functional NCT03867760 411 421 O
fluency NCT03867760 422 429 O
in NCT03867760 430 432 O
English NCT03867760 433 440 O

- NCT03867760 443 444 O
mentally NCT03867760 446 454 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03867760 455 458 I-Assertion___Assertion-Type-Value:hypothetical
physically NCT03867760 459 469 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03867760 470 474 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867760 475 477 O
participate NCT03867760 478 489 O
and NCT03867760 490 493 O
complete NCT03867760 494 502 O
surveys NCT03867760 503 510 B-Observation

Exclusion NCT03867760 511 520 O
Criteria NCT03867760 521 529 O
: NCT03867760 530 531 O

• NCT03867760 533 534 O
has NCT03867760 535 538 O
a NCT03867760 539 540 O
psychiatric NCT03867760 541 552 B-Condition
condition NCT03867760 553 562 I-Condition
or NCT03867760 563 565 B-Or
symptoms NCT03867760 566 574 B-Assertion___Assertion-Type-Value:possible
( NCT03867760 575 576 O
i. NCT03867760 577 579 O
e. NCT03867760 580 582 O
, NCT03867760 583 584 O
diagnosis NCT03867760 585 594 O
of NCT03867760 595 597 O
paranoid NCT03867760 598 606 B-Condition
schizophrenia NCT03867760 607 620 I-Condition
or NCT03867760 621 623 B-Or
active NCT03867760 624 630 B-Eq-Comparison
paranoid NCT03867760 631 639 B-Condition
delusional NCT03867760 640 650 I-Condition
thoughts NCT03867760 651 659 I-Condition
, NCT03867760 660 661 O
as NCT03867760 662 664 O
determined NCT03867760 665 675 O
via NCT03867760 676 679 O
a NCT03867760 680 681 O
telephone NCT03867760 682 691 B-Modifier
or NCT03867760 692 694 B-Or
in NCT03867760 695 697 B-Modifier
- NCT03867760 698 699 I-Modifier
person NCT03867760 700 706 I-Modifier
screening NCT03867760 707 716 B-Procedure
assessment NCT03867760 717 727 I-Procedure
) NCT03867760 728 729 O
that NCT03867760 730 734 O
would NCT03867760 735 740 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03867760 741 750 O
with NCT03867760 751 755 O
study NCT03867760 756 761 B-Study
participation NCT03867760 762 775 O
. NCT03867760 775 776 O

Exclusion NCT03867760 778 787 O
Criteria NCT03867760 788 796 O
for NCT03867760 797 800 O
Optional NCT03867760 801 809 O
EEG NCT03867760 810 813 O
Measurement NCT03867760 814 825 O
: NCT03867760 826 827 O

- NCT03867760 831 832 O
a NCT03867760 834 835 O
history NCT03867760 836 843 B-Eq-Comparison
of NCT03867760 844 846 O
seizure NCT03867760 847 854 B-Condition
condition NCT03867760 855 864 I-Condition
within NCT03867760 865 871 B-Eq-Comparison
the NCT03867760 872 875 I-Eq-Comparison
last NCT03867760 876 880 I-Eq-Comparison
year NCT03867760 881 885 I-Eq-Comparison

- NCT03867760 888 889 O
a NCT03867760 891 892 O
significant NCT03867760 893 904 O
brain NCT03867760 905 910 B-Modifier
injury NCT03867760 911 917 B-Condition
or NCT03867760 918 920 B-Or
skull NCT03867760 921 926 B-Modifier
defect NCT03867760 927 933 B-Condition

- NCT03867760 936 937 O
a NCT03867760 939 940 O
history NCT03867760 941 948 B-Eq-Comparison
of NCT03867760 949 951 O
brain NCT03867760 952 957 B-Modifier
cancer NCT03867760 958 964 B-Condition
. NCT03867760 964 965 O


Inclusion NCT03865836 0 9 O
Criteria NCT03865836 10 18 O
: NCT03865836 19 20 O

1 NCT03865836 24 25 O
. NCT03865836 25 26 O
Subject NCT03865836 28 35 O
must NCT03865836 36 40 O
have NCT03865836 41 45 O
a NCT03865836 46 47 O
diagnosis NCT03865836 48 57 O
of NCT03865836 58 60 O
LOPD NCT03865836 61 65 B-Condition
based NCT03865836 66 71 O
on NCT03865836 72 74 O
documentation NCT03865836 75 88 O
of NCT03865836 89 91 O
one NCT03865836 92 95 B-Eq-Comparison
of NCT03865836 96 98 O
the NCT03865836 99 102 B-Criteria-Count
following NCT03865836 103 112 I-Criteria-Count
: NCT03865836 113 114 O

1 NCT03865836 123 124 O
. NCT03865836 124 125 O
deficiency NCT03865836 127 137 B-Condition
of NCT03865836 138 140 O
GAA NCT03865836 141 144 B-Modifier
enzyme NCT03865836 145 151 I-Modifier

2 NCT03865836 159 160 O
. NCT03865836 160 161 O
GAA NCT03865836 163 166 B-Procedure
genotyping NCT03865836 167 177 I-Procedure

2 NCT03865836 180 181 O
. NCT03865836 181 182 O
Subject NCT03865836 184 191 O
must NCT03865836 192 196 O
provide NCT03865836 197 204 O
signed NCT03865836 205 211 O
informed NCT03865836 212 220 O
consent NCT03865836 221 228 O
prior NCT03865836 229 234 O
to NCT03865836 235 237 O
any NCT03865836 238 241 O
study NCT03865836 242 247 B-Study
- NCT03865836 248 249 O
related NCT03865836 250 257 O
procedures NCT03865836 258 268 B-Procedure
being NCT03865836 269 274 O
performed NCT03865836 275 284 O
. NCT03865836 284 285 O

Exclusion NCT03865836 287 296 O
Criteria NCT03865836 297 305 O
: NCT03865836 306 307 O

1 NCT03865836 311 312 O
. NCT03865836 312 313 O
Subject NCT03865836 315 322 O
is NCT03865836 323 325 O
eligible NCT03865836 326 334 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865836 335 338 I-Assertion___Assertion-Type-Value:hypothetical
enrollment NCT03865836 339 349 O
in NCT03865836 350 352 O
an NCT03865836 353 355 O
ongoing NCT03865836 356 363 B-Eq-Comparison
clinical NCT03865836 364 372 B-Study
trial NCT03865836 373 378 I-Study
using NCT03865836 379 384 O
ATB200 NCT03865836 385 391 B-Drug
/ NCT03865836 392 393 B-Or
AT2221 NCT03865836 394 400 B-Drug
. NCT03865836 400 401 O

2 NCT03865836 405 406 O
. NCT03865836 406 407 O
Subject NCT03865836 409 416 O
, NCT03865836 417 418 O
if NCT03865836 419 421 O
female NCT03865836 422 428 O
, NCT03865836 429 430 O
is NCT03865836 431 433 O
pregnant NCT03865836 434 442 B-Condition
or NCT03865836 443 445 B-Or
breastfeeding NCT03865836 446 459 B-Condition
at NCT03865836 460 462 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03865836 463 472 B-Study
. NCT03865836 472 473 O

3 NCT03865836 477 478 O
. NCT03865836 478 479 O
Subject NCT03865836 481 488 O
, NCT03865836 489 490 O
whether NCT03865836 491 498 O
male NCT03865836 499 503 O
or NCT03865836 504 506 B-Or
female NCT03865836 507 513 O
, NCT03865836 514 515 O
is NCT03865836 516 518 O
planning NCT03865836 519 527 B-Assertion___Assertion-Type-Value:intention
to NCT03865836 528 530 O
conceive NCT03865836 531 539 B-Condition
a NCT03865836 540 541 I-Condition
child NCT03865836 542 547 I-Condition
during NCT03865836 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865836 555 558 O
study NCT03865836 559 564 B-Study
. NCT03865836 564 565 O

Inclusion NCT03868241 0 9 O
Criteria NCT03868241 10 18 O
: NCT03868241 19 20 O

- NCT03868241 24 25 O
All NCT03868241 27 30 O
patients NCT03868241 31 39 O
admitted NCT03868241 40 48 B-Encounter
to NCT03868241 49 51 O
the NCT03868241 52 55 O
intensive NCT03868241 56 65 O
care NCT03868241 66 70 O
unit NCT03868241 71 75 O
which NCT03868241 76 81 O
will NCT03868241 82 86 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03868241 87 94 I-Assertion___Assertion-Type-Value:hypothetical
simultaneous NCT03868241 95 107 O
insertion NCT03868241 108 117 B-Procedure
of NCT03868241 118 120 I-Procedure
all NCT03868241 121 124 I-Procedure
three NCT03868241 125 130 I-Procedure
devices NCT03868241 131 138 I-Procedure
( NCT03868241 139 140 O
endotracheal NCT03868241 141 153 B-Procedure
tube NCT03868241 154 158 I-Procedure
, NCT03868241 159 160 O
central NCT03868241 161 168 B-Procedure
venous NCT03868241 169 175 I-Procedure
catheter NCT03868241 176 184 I-Procedure
and NCT03868241 185 188 B-Or
urinary NCT03868241 189 196 B-Procedure
catheter NCT03868241 197 205 I-Procedure
) NCT03868241 206 207 O
due NCT03868241 208 211 O
to NCT03868241 212 214 O
illness NCT03868241 215 222 B-Condition
severity NCT03868241 223 231 O
as NCT03868241 232 234 O
defined NCT03868241 235 242 O
by NCT03868241 243 245 O
the NCT03868241 246 249 O
attending NCT03868241 250 259 B-Provider
physician NCT03868241 260 269 I-Provider
. NCT03868241 269 270 O

Exclusion NCT03868241 272 281 O
Criteria NCT03868241 282 290 O
: NCT03868241 291 292 O

- NCT03868241 296 297 O
Patients NCT03868241 299 307 O
admitted NCT03868241 308 316 B-Encounter
to NCT03868241 317 319 O
the NCT03868241 320 323 O
intensive NCT03868241 324 333 O
care NCT03868241 334 338 O
unit NCT03868241 339 343 O
for NCT03868241 344 347 O
more NCT03868241 348 352 B-Eq-Comparison
than NCT03868241 353 357 I-Eq-Comparison
48 NCT03868241 358 360 I-Eq-Comparison
hours NCT03868241 361 366 I-Eq-Comparison
or NCT03868241 367 369 B-Or
admitted NCT03868241 370 378 B-Encounter
in NCT03868241 379 381 O
the NCT03868241 382 385 O
hospital NCT03868241 386 394 O
for NCT03868241 395 398 O
more NCT03868241 399 403 B-Eq-Comparison
than NCT03868241 404 408 I-Eq-Comparison
seven NCT03868241 409 414 I-Eq-Comparison
days NCT03868241 415 419 I-Eq-Comparison

- NCT03868241 422 423 O
Presence NCT03868241 425 433 O
of NCT03868241 434 436 O
any NCT03868241 437 440 O
of NCT03868241 441 443 O
the NCT03868241 444 447 O
invasive NCT03868241 448 456 B-Procedure
devices NCT03868241 457 464 I-Procedure
( NCT03868241 465 466 O
endotracheal NCT03868241 467 479 B-Procedure
tube NCT03868241 480 484 I-Procedure
, NCT03868241 485 486 O
central NCT03868241 487 494 B-Procedure
venous NCT03868241 495 501 I-Procedure
catheter NCT03868241 502 510 I-Procedure
or NCT03868241 511 513 B-Or
urinary NCT03868241 514 521 B-Procedure
catheters NCT03868241 522 531 I-Procedure
) NCT03868241 532 533 O
before NCT03868241 534 540 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03868241 541 554 B-Study
and NCT03868241 555 558 B-And
absence NCT03868241 559 566 B-Negation
of NCT03868241 567 569 O
the NCT03868241 570 573 O
intention NCT03868241 574 583 B-Assertion___Assertion-Type-Value:intention
to NCT03868241 584 586 O
exchange NCT03868241 587 595 O
the NCT03868241 596 599 O
devices NCT03868241 600 607 B-Coreference
; NCT03868241 607 608 O

- NCT03868241 611 612 O
Previous NCT03868241 614 622 B-Eq-Comparison
use NCT03868241 623 626 O
of NCT03868241 627 629 O
any NCT03868241 630 633 O
type NCT03868241 634 638 O
of NCT03868241 639 641 O
coated NCT03868241 642 648 B-Procedure
devices NCT03868241 649 656 I-Procedure
; NCT03868241 656 657 O

- NCT03868241 660 661 O
Age NCT03868241 663 666 B-Age
< NCT03868241 667 668 B-Eq-Comparison
18 NCT03868241 669 671 I-Eq-Comparison
years NCT03868241 672 677 I-Eq-Comparison
; NCT03868241 677 678 O

- NCT03868241 681 682 O
Known NCT03868241 684 689 O
pregnancy NCT03868241 690 699 B-Condition

- NCT03868241 702 703 O
Known NCT03868241 705 710 O
allergy NCT03868241 711 718 B-Allergy
to NCT03868241 719 721 O
gold NCT03868241 722 726 O
, NCT03868241 727 728 O
silver NCT03868241 729 735 O
and NCT03868241 736 739 B-Or
palladium NCT03868241 740 749 O
; NCT03868241 749 750 O

- NCT03868241 753 754 O
Suspected NCT03868241 756 765 B-Assertion___Assertion-Type-Value:possible
or NCT03868241 766 768 B-Or
confirmed NCT03868241 769 778 B-Modifier
brain NCT03868241 779 784 B-Modifier
death NCT03868241 785 790 B-Death
; NCT03868241 790 791 O

- NCT03868241 794 795 O
Previously NCT03868241 797 807 B-Eq-Comparison
enrolled NCT03868241 808 816 O
in NCT03868241 817 819 O
the NCT03868241 820 823 O
study NCT03868241 824 829 B-Study

Newly NCT03868241 830 835 O
added NCT03868241 836 841 O
exclusion NCT03868241 842 851 O
criteria NCT03868241 852 860 O
in NCT03868241 861 863 O
version NCT03868241 864 871 O
2.0 NCT03868241 872 875 O
: NCT03868241 876 877 O

- NCT03868241 881 882 O
Severe NCT03868241 884 890 O
chronic NCT03868241 891 898 B-Modifier
pulmonary NCT03868241 899 908 B-Condition
obstructive NCT03868241 909 920 I-Condition
disease NCT03868241 921 928 I-Condition
which NCT03868241 929 934 O
may NCT03868241 935 938 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03868241 939 944 O
catheter NCT03868241 945 953 B-Procedure
site NCT03868241 954 958 I-Procedure
selection NCT03868241 959 968 O

- NCT03868241 971 972 O
Previous NCT03868241 974 982 B-Eq-Comparison
irradiation NCT03868241 983 994 B-Procedure
and NCT03868241 995 998 B-Or
/ NCT03868241 999 1000 I-Or
or NCT03868241 1001 1003 I-Or
thrombosis NCT03868241 1004 1014 B-Condition
in NCT03868241 1015 1017 O
site NCT03868241 1018 1022 B-Modifier
selected NCT03868241 1023 1031 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868241 1032 1035 I-Assertion___Assertion-Type-Value:hypothetical
catheter NCT03868241 1036 1044 B-Procedure
insertion NCT03868241 1045 1054 I-Procedure

Inclusion NCT03863314 0 9 O
Criteria NCT03863314 10 18 O
: NCT03863314 19 20 O

- NCT03863314 24 25 O
Greater NCT03863314 27 34 B-Eq-Comparison
than NCT03863314 35 39 I-Eq-Comparison
18 NCT03863314 40 42 I-Eq-Comparison
years NCT03863314 43 48 I-Eq-Comparison
of NCT03863314 49 51 O
age NCT03863314 52 55 B-Age

- NCT03863314 58 59 O
Personnel NCT03863314 61 70 O
working NCT03863314 71 78 O
or NCT03863314 79 81 O
volunteering NCT03863314 82 94 O
at NCT03863314 95 97 O
Lucile NCT03863314 98 104 O
Packard NCT03863314 105 112 O
Children NCT03863314 113 121 O
's NCT03863314 121 123 O
Hospital NCT03863314 124 132 O
( NCT03863314 133 134 O
LPCH NCT03863314 135 139 O
) NCT03863314 140 141 O
or NCT03863314 142 144 B-Or
Stanford NCT03863314 145 153 O
Health NCT03863314 154 160 O
Care NCT03863314 161 165 O
( NCT03863314 166 167 O
SHC NCT03863314 168 171 O
) NCT03863314 172 173 O
facilities NCT03863314 174 184 O

Exclusion NCT03863314 185 194 O
Criteria NCT03863314 195 203 O
: NCT03863314 204 205 O

- NCT03863314 209 210 O
Patients NCT03863314 212 220 O
who NCT03863314 221 224 O
do NCT03863314 225 227 O
not NCT03863314 228 231 O
consent NCT03863314 232 239 O

- NCT03863314 242 243 O
Are NCT03863314 245 248 O
currently NCT03863314 249 258 B-Eq-Comparison
taking NCT03863314 259 265 I-Eq-Comparison
beta NCT03863314 266 270 B-Drug
blockers NCT03863314 271 279 I-Drug
or NCT03863314 280 282 B-Or
other NCT03863314 283 288 B-Other
chronotropic NCT03863314 289 301 B-Drug
heart NCT03863314 302 307 I-Drug
medication NCT03863314 308 318 I-Drug
( NCT03863314 319 320 O
s NCT03863314 321 322 O
) NCT03863314 323 324 O

- NCT03863314 328 329 O
Have NCT03863314 331 335 O
a NCT03863314 336 337 O
history NCT03863314 338 345 B-Eq-Comparison
of NCT03863314 346 348 O
severe NCT03863314 349 355 O
motion NCT03863314 356 362 B-Condition
sickness NCT03863314 363 371 I-Condition

- NCT03863314 374 375 O
Currently NCT03863314 377 386 B-Eq-Comparison
have NCT03863314 387 391 O
nausea NCT03863314 392 398 B-Condition

- NCT03863314 401 402 O
Currently NCT03863314 404 413 B-Eq-Comparison
experiencing NCT03863314 414 426 O
seizures NCT03863314 427 435 B-Condition

- NCT03863314 438 439 O
Are NCT03863314 441 444 O
clinically NCT03863314 445 455 O
unstable NCT03863314 456 464 O

Inclusion NCT03868527 0 9 O
Criteria NCT03868527 10 18 O
: NCT03868527 19 20 O

- NCT03868527 23 24 O
Patients NCT03868527 25 33 O
followed NCT03868527 34 42 B-Encounter
for NCT03868527 43 46 O
hematological NCT03868527 47 60 B-Condition
diseases NCT03868527 61 69 I-Condition
in NCT03868527 70 72 O
Lyon NCT03868527 73 77 O
Sud NCT03868527 78 81 O
Hospital NCT03868527 82 90 O

Exclusion NCT03868527 91 100 O
Criteria NCT03868527 101 109 O
: NCT03868527 110 111 O

- NCT03868527 114 115 O
Patients NCT03868527 116 124 O
who NCT03868527 125 128 O
does NCT03868527 129 133 B-Negation
n't NCT03868527 133 136 O
have NCT03868527 137 141 I-Negation
hematological NCT03868527 142 155 B-Condition
diseases NCT03868527 156 164 I-Condition

Inclusion NCT03865771 0 9 O
Criteria NCT03865771 10 18 O
: NCT03865771 19 20 O

Principal NCT03865771 22 31 O
: NCT03865771 32 33 O

- NCT03865771 37 38 O
normal NCT03865771 40 46 O
psychomotor NCT03865771 47 58 B-Condition
development NCT03865771 59 70 I-Condition

- NCT03865771 73 74 O
informed NCT03865771 76 84 O
consent NCT03865771 85 92 O
signed NCT03865771 93 99 O
by NCT03865771 100 102 O
both NCT03865771 103 107 O
parents NCT03865771 108 115 O
and NCT03865771 116 119 O
subject NCT03865771 120 127 O
if NCT03865771 128 130 O
able NCT03865771 131 135 O

- NCT03865771 138 139 O
affiliated NCT03865771 141 151 O
to NCT03865771 152 154 O
social NCT03865771 155 161 O
security NCT03865771 162 170 O
regimen NCT03865771 171 178 O

Specific NCT03865771 179 187 O

Patients NCT03865771 188 196 O
from NCT03865771 197 201 O
" NCT03865771 202 203 O
severe NCT03865771 203 209 O
" NCT03865771 209 210 O
and NCT03865771 211 214 O
" NCT03865771 215 216 O
benign NCT03865771 216 222 O
" NCT03865771 222 223 O
groups NCT03865771 224 230 O
: NCT03865771 231 232 O

- NCT03865771 236 237 O
focal NCT03865771 239 244 B-Modifier
age NCT03865771 245 248 I-Modifier
related NCT03865771 249 256 I-Modifier
epilepsy NCT03865771 257 265 B-Condition
: NCT03865771 266 267 O
BECTS NCT03865771 268 273 B-Condition
, NCT03865771 274 275 O
ABPE NCT03865771 276 280 B-Condition
, NCT03865771 281 282 O
ECSWS NCT03865771 283 288 B-Condition
( NCT03865771 289 290 O
ILAE NCT03865771 291 295 O
criteria NCT03865771 296 304 O
) NCT03865771 305 306 O

- NCT03865771 310 311 O
children NCT03865771 313 321 O
hospitalized NCT03865771 322 334 B-Encounter
for NCT03865771 335 338 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03865771 339 344 O
follow NCT03865771 345 351 B-Encounter
- NCT03865771 352 353 I-Encounter
up NCT03865771 354 356 I-Encounter

- NCT03865771 359 360 O
normal NCT03865771 362 368 O
neuroimaging NCT03865771 369 381 B-Procedure

Control NCT03865771 382 389 O
group NCT03865771 390 395 O

- NCT03865771 397 398 O
children NCT03865771 399 407 O
hospitalized NCT03865771 408 420 B-Encounter
for NCT03865771 421 424 O
a NCT03865771 425 426 O
non NCT03865771 427 430 B-Negation
neurologic NCT03865771 431 441 B-Condition
disease NCT03865771 442 449 I-Condition

Exclusion NCT03865771 450 459 O
Criteria NCT03865771 460 468 O
: NCT03865771 469 470 O

Principal NCT03865771 472 481 O
: NCT03865771 482 483 O

Psychiatric NCT03865771 485 496 B-Condition
trouble NCT03865771 497 504 I-Condition
( NCT03865771 505 506 O
DSM NCT03865771 507 510 O
V NCT03865771 511 512 O
) NCT03865771 513 514 O
Sensorial NCT03865771 515 524 B-Condition
trouble NCT03865771 525 532 I-Condition
without NCT03865771 533 540 B-Negation
correction NCT03865771 541 551 B-Modifier
Poor NCT03865771 552 556 B-Negation
command NCT03865771 557 564 I-Negation
of NCT03865771 565 567 O
French NCT03865771 568 574 O
language NCT03865771 575 583 O
Minor NCT03865771 584 589 O
under NCT03865771 590 595 O
care NCT03865771 596 600 O

Specific NCT03865771 601 609 O

Patients NCT03865771 610 618 O
from NCT03865771 619 623 O
" NCT03865771 624 625 O
severe NCT03865771 625 631 O
" NCT03865771 631 632 O
and NCT03865771 633 636 O
" NCT03865771 637 638 O
benign NCT03865771 638 644 O
" NCT03865771 644 645 O
groups NCT03865771 646 652 O
: NCT03865771 653 654 O

- NCT03865771 658 659 O
degenerative NCT03865771 661 673 B-Condition
disease NCT03865771 674 681 I-Condition

- NCT03865771 684 685 O
abnormal NCT03865771 687 695 O
neuroimaging NCT03865771 696 708 B-Procedure

- NCT03865771 711 712 O
mental NCT03865771 714 720 B-Condition
deficiency NCT03865771 721 731 I-Condition

Control NCT03865771 732 739 O
group NCT03865771 740 745 O

- NCT03865771 748 749 O
neurologic NCT03865771 751 761 B-Condition
trouble NCT03865771 762 769 I-Condition

- NCT03865771 772 773 O
abnormal NCT03865771 775 783 O
sleep NCT03865771 784 789 B-Procedure
EEG NCT03865771 790 793 I-Procedure

- NCT03865771 796 797 O
intellectual NCT03865771 799 811 B-Condition
deficiency NCT03865771 812 822 I-Condition


Inclusion NCT03862963 0 9 O
Criteria NCT03862963 10 18 O
: NCT03862963 19 20 O

- NCT03862963 24 25 O
Resident NCT03862963 27 35 O
of NCT03862963 36 38 O
the NCT03862963 39 42 O
Republic NCT03862963 43 51 O
of NCT03862963 52 54 O
Marshall NCT03862963 55 63 O
Islands NCT03862963 64 71 O

- NCT03862963 74 75 O
Aged NCT03862963 77 81 B-Age
18 NCT03862963 82 84 B-Eq-Comparison
- NCT03862963 85 86 I-Eq-Comparison
75 NCT03862963 87 89 I-Eq-Comparison
years NCT03862963 90 95 I-Eq-Comparison

- NCT03862963 98 99 O
HbA1c NCT03862963 101 106 B-Observation
≥ NCT03862963 107 108 B-Eq-Comparison
8.0 NCT03862963 109 112 I-Eq-Comparison
% NCT03862963 113 114 O
or NCT03862963 115 117 B-Or
diagnosed NCT03862963 118 127 O
with NCT03862963 128 132 O
T2D NCT03862963 133 136 B-Condition
and NCT03862963 137 140 B-And
taking NCT03862963 141 147 B-Eq-Comparison
diabetes NCT03862963 148 156 B-Condition
medication NCT03862963 157 167 B-Drug

- NCT03862963 170 171 O
Medical NCT03862963 173 180 O
clearance NCT03862963 181 190 O
to NCT03862963 191 193 O
participate NCT03862963 194 205 O
from NCT03862963 206 210 O
Diabetes NCT03862963 211 219 O
Wellness NCT03862963 220 228 O
Center NCT03862963 229 235 O
( NCT03862963 236 237 O
DWC NCT03862963 238 241 O
) NCT03862963 242 243 O
physicians NCT03862963 244 254 B-Provider
. NCT03862963 254 255 O

Exclusion NCT03862963 257 266 O
Criteria NCT03862963 267 275 O
: NCT03862963 276 277 O

- NCT03862963 281 282 O
Recent NCT03862963 284 290 B-Eq-Comparison
( NCT03862963 291 292 O
≤ NCT03862963 294 295 B-Eq-Comparison
3 NCT03862963 296 297 I-Eq-Comparison
months NCT03862963 298 304 I-Eq-Comparison
) NCT03862963 305 306 O
change NCT03862963 307 313 O
in NCT03862963 314 316 O
a NCT03862963 317 318 O
diabetes NCT03862963 319 327 B-Condition
- NCT03862963 328 329 O
related NCT03862963 330 337 O
medication NCT03862963 338 348 B-Drug
dosage NCT03862963 349 355 O

- NCT03862963 358 359 O
A NCT03862963 361 362 O
physical NCT03862963 363 371 B-Modifier
or NCT03862963 372 374 B-Or
medical NCT03862963 375 382 B-Modifier
condition NCT03862963 383 392 B-Condition
that NCT03862963 393 397 O
would NCT03862963 398 403 B-Assertion___Assertion-Type-Value:hypothetical
impede NCT03862963 404 410 O
participation NCT03862963 411 424 O
in NCT03862963 425 427 O
the NCT03862963 428 431 O
lifestyle NCT03862963 432 441 B-Procedure
intervention NCT03862963 442 454 I-Procedure
( NCT03862963 455 456 O
e. NCT03862963 457 459 O
g. NCT03862963 460 462 O
, NCT03862963 463 464 O
wheel NCT03862963 465 470 B-Condition
- NCT03862963 471 472 I-Condition
chair NCT03862963 473 478 I-Condition
bound NCT03862963 479 484 I-Condition
, NCT03862963 485 486 O
unstable NCT03862963 487 495 O
angina NCT03862963 496 502 B-Condition
) NCT03862963 503 504 O

- NCT03862963 508 509 O
Evidence NCT03862963 511 519 O
of NCT03862963 520 522 O
significant NCT03862963 523 534 O
coronary NCT03862963 535 543 B-Condition
heart NCT03862963 544 549 I-Condition
disease NCT03862963 550 557 I-Condition

- NCT03862963 560 561 O
Previous NCT03862963 563 571 B-Eq-Comparison
participation NCT03862963 572 585 O
in NCT03862963 586 588 O
an NCT03862963 589 591 O
intensive NCT03862963 592 601 O
lifestyle NCT03862963 602 611 B-Procedure
intervention NCT03862963 612 624 I-Procedure

Inclusion NCT03864484 0 9 O
Criteria NCT03864484 10 18 O
: NCT03864484 19 20 O

- NCT03864484 24 25 O
40 NCT03864484 27 29 B-Eq-Comparison
years NCT03864484 30 35 I-Eq-Comparison
and NCT03864484 36 39 I-Eq-Comparison
older NCT03864484 40 45 I-Age|Eq-Comparison

- NCT03864484 48 49 O
Males NCT03864484 51 56 O
and NCT03864484 57 60 B-Or
females NCT03864484 61 68 O

- NCT03864484 71 72 O
Center NCT03864484 74 80 B-Observation
for NCT03864484 81 84 I-Observation
Epidemiologic NCT03864484 85 98 I-Observation
Studies NCT03864484 99 106 I-Observation
Depression NCT03864484 107 117 I-Observation
Scale NCT03864484 118 123 I-Observation
score NCT03864484 124 129 B-Eq-Comparison
≥ NCT03864484 130 131 I-Eq-Comparison
16 NCT03864484 132 134 I-Eq-Comparison

- NCT03864484 138 139 O
Mini NCT03864484 141 145 B-Observation
Mental NCT03864484 146 152 I-Observation
State NCT03864484 153 158 I-Observation
Examination NCT03864484 159 170 I-Observation
score NCT03864484 171 176 I-Observation
≥ NCT03864484 177 178 B-Eq-Comparison
24 NCT03864484 179 181 I-Eq-Comparison

- NCT03864484 185 186 O
First NCT03864484 188 193 B-Eq-Comparison
stroke NCT03864484 194 200 B-Condition

- NCT03864484 203 204 O
Native NCT03864484 206 212 O
language NCT03864484 213 221 O
is NCT03864484 222 224 O
Japanese NCT03864484 225 233 O

- NCT03864484 236 237 O
Written NCT03864484 239 246 O
informed NCT03864484 247 255 O
consent NCT03864484 256 263 O
prior NCT03864484 264 269 O
to NCT03864484 270 272 O
participation NCT03864484 273 286 O

Exclusion NCT03864484 287 296 O
Criteria NCT03864484 297 305 O
: NCT03864484 306 307 O

- NCT03864484 311 312 O
Major NCT03864484 314 319 O
depressive NCT03864484 320 330 B-Condition
disorder NCT03864484 331 339 I-Condition
before NCT03864484 340 346 B-Temporal-Connection___Temporal-Connection-Type-Value:before
onset NCT03864484 347 352 B-Eq-Comparison
of NCT03864484 353 355 O
stroke NCT03864484 356 362 B-Condition

- NCT03864484 365 366 O
Bilateral NCT03864484 368 377 B-Modifier
hemiplegia NCT03864484 378 388 B-Condition

- NCT03864484 391 392 O
Vision NCT03864484 394 400 B-Modifier
or NCT03864484 401 403 B-Or
hearing NCT03864484 404 411 B-Modifier
deficits NCT03864484 412 420 B-Condition
that NCT03864484 421 425 O
negatively NCT03864484 426 436 O
impact NCT03864484 437 443 O
everyday NCT03864484 444 452 B-Observation
life NCT03864484 453 457 I-Observation

- NCT03864484 460 461 O
Severe NCT03864484 463 469 O
aphasia NCT03864484 470 477 B-Condition

- NCT03864484 480 481 O
Severe NCT03864484 483 489 O
unilateral NCT03864484 490 500 B-Modifier
spatial NCT03864484 501 508 B-Condition
neglect NCT03864484 509 516 I-Condition

- NCT03864484 519 520 O
Diagnosis NCT03864484 522 531 O
of NCT03864484 532 534 O
neurodegenerative NCT03864484 535 552 B-Condition
disease NCT03864484 553 560 I-Condition
such NCT03864484 561 565 O
as NCT03864484 566 568 O
Parkinson NCT03864484 569 578 B-Condition
's NCT03864484 578 580 O
disease NCT03864484 581 588 I-Condition
or NCT03864484 589 591 B-Or
multiple NCT03864484 592 600 B-Modifier
system NCT03864484 601 607 I-Modifier
atrophy NCT03864484 608 615 B-Condition

- NCT03864484 618 619 O
Current NCT03864484 621 628 B-Eq-Comparison
life NCT03864484 629 633 B-Death|Risk
- NCT03864484 634 635 I-Death|Risk
threatening NCT03864484 636 647 I-Death|Risk
severe NCT03864484 648 654 O
organ NCT03864484 655 660 B-Condition
failure NCT03864484 661 668 I-Condition
, NCT03864484 669 670 O
musculoskeletal NCT03864484 671 686 B-Condition
disorders NCT03864484 687 696 I-Condition
, NCT03864484 697 698 O
or NCT03864484 699 701 B-Or
cancer NCT03864484 702 708 B-Condition

Inclusion NCT03867370 0 9 O
Criteria NCT03867370 10 18 O
: NCT03867370 19 20 O

1 NCT03867370 24 25 O
. NCT03867370 25 26 O
Confirmed NCT03867370 28 37 O
by NCT03867370 38 40 O
histopathological NCT03867370 41 58 B-Procedure
or NCT03867370 59 61 B-Or
cytological NCT03867370 62 73 B-Procedure
examination NCT03867370 74 85 I-Procedure
; NCT03867370 85 86 O

2 NCT03867370 89 90 O
. NCT03867370 90 91 O
The NCT03867370 93 96 O
criteria NCT03867370 97 105 O
for NCT03867370 106 109 O
resectability NCT03867370 110 123 O
is NCT03867370 124 126 O
met NCT03867370 127 130 O

3 NCT03867370 133 134 O
. NCT03867370 134 135 O
Has NCT03867370 137 140 O
at NCT03867370 141 143 B-Eq-Comparison
least NCT03867370 144 149 I-Eq-Comparison
one NCT03867370 150 153 I-Eq-Comparison
evaluable NCT03867370 154 163 B-Modifier
lesion NCT03867370 164 170 B-Condition
according NCT03867370 171 180 O
to NCT03867370 181 183 O
the NCT03867370 184 187 O
RECIST NCT03867370 188 194 O
1.1 NCT03867370 195 198 O
standard NCT03867370 199 207 O
and NCT03867370 208 211 B-And
has NCT03867370 212 215 O
not NCT03867370 216 219 B-Negation
received NCT03867370 220 228 B-Eq-Comparison
local NCT03867370 229 234 B-Modifier
treatment NCT03867370 235 244 B-Procedure

Exclusion NCT03867370 245 254 O
Criteria NCT03867370 255 263 O
: NCT03867370 264 265 O

1 NCT03867370 269 270 O
. NCT03867370 270 271 O
Patients NCT03867370 273 281 O
who NCT03867370 282 285 O
previously NCT03867370 286 296 B-Eq-Comparison
received NCT03867370 297 305 I-Eq-Comparison
anti NCT03867370 306 310 B-Drug
- NCT03867370 311 312 I-Drug
programmed NCT03867370 313 323 I-Drug
death NCT03867370 324 329 I-Drug
receptor NCT03867370 330 338 I-Drug
- NCT03867370 339 340 I-Drug|Drug
1 NCT03867370 341 342 I-Drug|Drug
( NCT03867370 343 344 O
PD NCT03867370 345 347 B-Drug
- NCT03867370 348 349 O
1 NCT03867370 350 351 O
) NCT03867370 352 353 O
antibody NCT03867370 354 362 B-Drug|Modifier
, NCT03867370 363 364 O
anti NCT03867370 365 369 O
- NCT03867370 370 371 I-Drug
programmed NCT03867370 372 382 I-Drug
death NCT03867370 383 388 I-Drug
ligand NCT03867370 389 395 I-Drug
- NCT03867370 396 397 I-Drug|Drug
1 NCT03867370 398 399 I-Drug
( NCT03867370 400 401 O
PD NCT03867370 402 404 B-Drug
- NCT03867370 405 406 I-Drug
L1 NCT03867370 407 409 I-Drug
) NCT03867370 410 411 O
antibody NCT03867370 412 420 B-Drug|Modifier
, NCT03867370 421 422 O
anti NCT03867370 423 427 O
- NCT03867370 428 429 I-Drug
programmed NCT03867370 430 440 I-Drug
death NCT03867370 441 446 I-Drug
ligand NCT03867370 447 453 I-Drug
- NCT03867370 454 455 I-Drug
2 NCT03867370 456 457 I-Drug
( NCT03867370 458 459 O
PD NCT03867370 460 462 B-Drug
- NCT03867370 463 464 I-Drug
L2 NCT03867370 465 467 I-Drug
) NCT03867370 468 469 O
antibody NCT03867370 470 478 B-Drug|Modifier
or NCT03867370 479 481 B-Or
anti NCT03867370 482 486 O
- NCT03867370 487 488 I-Drug
cytotoxic NCT03867370 489 498 I-Drug
T NCT03867370 499 500 I-Drug
lymphocyte NCT03867370 501 511 I-Drug
- NCT03867370 512 513 I-Drug|Drug
associated NCT03867370 514 524 I-Drug
antigen NCT03867370 525 532 I-Drug
- NCT03867370 533 534 O
4 NCT03867370 535 536 I-Drug|Drug
( NCT03867370 537 538 O
CTLA NCT03867370 539 543 B-Drug
- NCT03867370 544 545 O
4 NCT03867370 546 547 O
) NCT03867370 548 549 O
antibodies NCT03867370 550 560 B-Modifier
, NCT03867370 561 562 O
including NCT03867370 563 572 O
those NCT03867370 573 578 O
who NCT03867370 579 582 O
have NCT03867370 583 587 O
participated NCT03867370 588 600 O
in NCT03867370 601 603 O
a NCT03867370 604 605 O
JS001 NCT03867370 606 611 O
clinical NCT03867370 612 620 O
study NCT03867370 621 626 B-Study
; NCT03867370 626 627 O

2 NCT03867370 630 631 O
. NCT03867370 631 632 O
Patients NCT03867370 634 642 O
who NCT03867370 643 646 O
previously NCT03867370 647 657 B-Eq-Comparison
received NCT03867370 658 666 I-Eq-Comparison
any NCT03867370 667 670 O
TACE NCT03867370 671 675 B-Procedure
, NCT03867370 676 677 O
radiofrequency NCT03867370 678 692 B-Procedure
ablation NCT03867370 693 701 I-Procedure
and NCT03867370 702 705 B-Or
other NCT03867370 706 711 B-Other
liver NCT03867370 712 717 B-Modifier
cancer NCT03867370 718 724 B-Condition
treatments NCT03867370 725 735 B-Procedure
; NCT03867370 735 736 O

3 NCT03867370 739 740 O
. NCT03867370 740 741 O
Patients NCT03867370 743 751 O
with NCT03867370 752 756 O
a NCT03867370 757 758 O
history NCT03867370 759 766 B-Eq-Comparison
of NCT03867370 767 769 O
gastroesophageal NCT03867370 770 786 B-Condition
varices NCT03867370 787 794 I-Condition
or NCT03867370 795 797 B-Or
active NCT03867370 798 804 B-Eq-Comparison
cardia NCT03867370 805 811 B-Condition
ulcers NCT03867370 812 818 I-Condition
associated NCT03867370 819 829 O
with NCT03867370 830 834 O
a NCT03867370 835 836 O
high NCT03867370 837 841 O
risk NCT03867370 842 846 B-Risk
of NCT03867370 847 849 O
bleeding NCT03867370 850 858 B-Condition
; NCT03867370 858 859 O

4 NCT03867370 862 863 O
. NCT03867370 863 864 O
Patients NCT03867370 866 874 O
who NCT03867370 875 878 O
have NCT03867370 879 883 O
upper NCT03867370 884 889 B-Modifier
gastrointestinal NCT03867370 890 906 I-Modifier
hemorrhage NCT03867370 907 917 B-Condition
within NCT03867370 918 924 B-Eq-Comparison
1 NCT03867370 925 926 I-Eq-Comparison
year NCT03867370 927 931 I-Eq-Comparison
; NCT03867370 931 932 O

5 NCT03867370 935 936 O
. NCT03867370 936 937 O
Patients NCT03867370 939 947 O
known NCT03867370 948 953 O
to NCT03867370 954 956 O
have NCT03867370 957 961 O
fibrous NCT03867370 962 969 B-Modifier
layer NCT03867370 970 975 I-Modifier
HCC NCT03867370 976 979 B-Condition|Condition
, NCT03867370 980 981 O
sarcomatoid NCT03867370 982 993 B-Modifier
HCC NCT03867370 994 997 B-Condition
or NCT03867370 998 1000 B-Or
mixed NCT03867370 1001 1006 B-Modifier
cholangiocarcinoma NCT03867370 1007 1025 B-Condition
and NCT03867370 1026 1029 B-And
HCC NCT03867370 1030 1033 O
; NCT03867370 1033 1034 O
Other NCT03867370 1035 1040 O
protocol NCT03867370 1041 1049 O
defined NCT03867370 1050 1057 O
inclusion NCT03867370 1058 1067 O
/ NCT03867370 1068 1069 O
exclusion NCT03867370 1070 1079 O
criteria NCT03867370 1080 1088 O
could NCT03867370 1089 1094 O
apply NCT03867370 1095 1100 O

Inclusion NCT03861715 0 9 O
Criteria NCT03861715 10 18 O
: NCT03861715 19 20 O

- NCT03861715 24 25 O
age NCT03861715 27 30 B-Age
20 NCT03861715 31 33 B-Eq-Comparison
- NCT03861715 34 35 I-Eq-Comparison
34 NCT03861715 36 38 I-Eq-Comparison
years NCT03861715 39 44 I-Eq-Comparison
; NCT03861715 44 45 O

- NCT03861715 48 49 O
body NCT03861715 51 55 B-Observation
mass NCT03861715 56 60 I-Observation
index NCT03861715 61 66 I-Observation
( NCT03861715 67 68 O
BMI NCT03861715 69 72 B-Observation
) NCT03861715 73 74 O
18 NCT03861715 75 77 B-Eq-Comparison
- NCT03861715 78 79 I-Eq-Comparison
29 NCT03861715 80 82 I-Eq-Comparison
kg NCT03861715 83 85 O
/ NCT03861715 86 87 I-Eq-Comparison
m2 NCT03861715 88 90 I-Eq-Comparison
; NCT03861715 90 91 O

- NCT03861715 94 95 O
regular NCT03861715 97 104 O
menstrual NCT03861715 105 114 B-Condition
cycle NCT03861715 115 120 I-Condition
of NCT03861715 121 123 O
26 NCT03861715 124 126 B-Eq-Comparison
- NCT03861715 127 128 I-Eq-Comparison
35 NCT03861715 129 131 O
days NCT03861715 132 136 O
, NCT03861715 137 138 O

- NCT03861715 142 143 O
AMH NCT03861715 145 148 B-Observation
levels NCT03861715 149 155 O
age NCT03861715 156 159 O
appropriate NCT03861715 160 171 O
( NCT03861715 172 173 O
≥ NCT03861715 175 176 B-Eq-Comparison
2.3 NCT03861715 177 180 I-Eq-Comparison
ng NCT03861715 181 183 I-Eq-Comparison
/ NCT03861715 184 185 I-Eq-Comparison
ml NCT03861715 186 188 I-Eq-Comparison
) NCT03861715 189 190 O

- NCT03861715 194 195 I-Modifier
early NCT03861715 197 202 B-Modifier
follicular NCT03861715 203 213 I-Modifier
- NCT03861715 214 215 O
phase NCT03861715 216 221 I-Modifier
serum NCT03861715 222 227 B-Observation
concentration NCT03861715 228 241 I-Observation
of NCT03861715 242 244 I-Observation
FSH NCT03861715 245 248 I-Observation
within NCT03861715 249 255 B-Eq-Comparison
normal NCT03861715 256 262 I-Eq-Comparison
limits NCT03861715 263 269 I-Eq-Comparison|Eq-Comparison
( NCT03861715 270 271 O
1 NCT03861715 272 273 B-Eq-Comparison
- NCT03861715 274 275 I-Eq-Comparison
12 NCT03861715 276 278 I-Eq-Comparison
IU NCT03861715 279 281 I-Eq-Comparison
/ NCT03861715 282 283 I-Eq-Comparison
l NCT03861715 284 285 O
) NCT03861715 286 287 O
. NCT03861715 288 289 O

Exclusion NCT03861715 291 300 O
Criteria NCT03861715 301 309 O
: NCT03861715 310 311 O

- NCT03861715 315 316 O
women NCT03861715 318 323 O
with NCT03861715 324 328 B-And
diabetes NCT03861715 329 337 B-Condition
and NCT03861715 338 341 B-Or
other NCT03861715 342 347 B-Other
metabolic NCT03861715 348 357 B-Condition
disease NCT03861715 358 365 I-Condition

- NCT03861715 368 369 O
women NCT03861715 371 376 O
with NCT03861715 377 381 B-And
hereditary NCT03861715 382 392 B-Modifier
genetic NCT03861715 393 400 B-Condition
diseases NCT03861715 401 409 I-Condition|Condition
; NCT03861715 409 410 O

- NCT03861715 413 414 O
women NCT03861715 416 421 O
with NCT03861715 422 426 B-And
heart NCT03861715 427 432 B-Condition|Condition
disease NCT03861715 433 440 O
, NCT03861715 441 442 O
QT NCT03861715 443 445 B-Condition
prolongation NCT03861715 446 458 I-Condition
, NCT03861715 459 460 O
heart NCT03861715 461 466 O
failure NCT03861715 467 474 I-Condition

- NCT03861715 477 478 O
elevated NCT03861715 480 488 O
liver NCT03861715 489 494 B-Condition|Condition
enzymes NCT03861715 495 502 I-Condition
, NCT03861715 503 504 O
liver NCT03861715 505 510 O
failure NCT03861715 511 518 I-Condition
, NCT03861715 519 520 O
hepatitis NCT03861715 521 530 B-Condition

- NCT03861715 533 534 O
women NCT03861715 536 541 O
with NCT03861715 542 546 B-And
inflammatory NCT03861715 547 559 B-Modifier
or NCT03861715 560 562 B-Or
autoimmune NCT03861715 563 573 B-Modifier
disease NCT03861715 574 581 B-Condition

- NCT03861715 584 585 O
abnormal NCT03861715 587 595 O
karyotype NCT03861715 596 605 B-Condition
; NCT03861715 605 606 O

- NCT03861715 609 610 O
endometriosis NCT03861715 612 625 B-Condition
stage NCT03861715 626 631 B-Eq-Comparison
III NCT03861715 632 635 I-Eq-Comparison
/ NCT03861715 636 637 I-Eq-Comparison
IV NCT03861715 638 640 I-Eq-Comparison
; NCT03861715 640 641 O

- NCT03861715 644 645 O
history NCT03861715 647 654 B-Eq-Comparison
of NCT03861715 655 657 O
recurrent NCT03861715 658 667 B-Condition
miscarriage NCT03861715 668 679 I-Condition
; NCT03861715 679 680 O

- NCT03861715 683 684 O
severe NCT03861715 686 692 O
OHSS NCT03861715 693 697 B-Condition
in NCT03861715 698 700 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03861715 701 702 O
previous NCT03861715 703 711 B-Eq-Comparison
stimulation NCT03861715 712 723 B-Procedure
cycle NCT03861715 724 729 I-Procedure
or NCT03861715 730 732 B-Or
any NCT03861715 733 736 O
contraindication NCT03861715 737 753 B-Contraindication
for NCT03861715 754 757 O
the NCT03861715 758 761 O
use NCT03861715 762 765 O
of NCT03861715 766 768 O
gonadotrophins NCT03861715 769 783 B-Drug
. NCT03861715 783 784 O

Inclusion NCT03866720 0 9 O
Criteria NCT03866720 10 18 O
: NCT03866720 19 20 O

- NCT03866720 24 25 O
Body NCT03866720 27 31 B-Observation
mass NCT03866720 32 36 I-Observation
index NCT03866720 37 42 I-Observation
18.5 NCT03866720 43 47 B-Eq-Comparison
- NCT03866720 48 49 I-Eq-Comparison
29.9 NCT03866720 50 54 I-Eq-Comparison
kg∙m NCT03866720 55 59 I-Eq-Comparison
- NCT03866720 60 61 I-Eq-Comparison
2 NCT03866720 62 63 I-Eq-Comparison

- NCT03866720 67 68 O
Age NCT03866720 70 73 B-Age
18 NCT03866720 74 76 B-Eq-Comparison
- NCT03866720 77 78 I-Eq-Comparison
65 NCT03866720 79 81 I-Eq-Comparison
years NCT03866720 82 87 I-Eq-Comparison

- NCT03866720 90 91 O
Able NCT03866720 93 97 O
and NCT03866720 98 101 O
willing NCT03866720 102 109 O
to NCT03866720 110 112 O
provide NCT03866720 113 120 O
informed NCT03866720 121 129 O
consent NCT03866720 130 137 O
and NCT03866720 138 141 O
safely NCT03866720 142 148 O
comply NCT03866720 149 155 O
with NCT03866720 156 160 O
study NCT03866720 161 166 B-Study
procedures NCT03866720 167 177 B-Procedure

- NCT03866720 180 181 O
Females NCT03866720 183 190 O
to NCT03866720 191 193 B-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03866720 194 202 I-Assertion___Assertion-Type-Value:hypothetical
record NCT03866720 203 209 O
of NCT03866720 210 212 O
regular NCT03866720 213 220 O
menstrual NCT03866720 221 230 B-Procedure
cycle NCT03866720 231 236 I-Procedure
phase NCT03866720 237 242 I-Procedure
or NCT03866720 243 245 B-Or
contraceptive NCT03866720 246 259 B-Procedure
use NCT03866720 260 263 O

- NCT03866720 266 267 O
No NCT03866720 269 271 B-Negation
anticipated NCT03866720 272 283 B-Assertion___Assertion-Type-Value:hypothetical
changes NCT03866720 284 291 O
in NCT03866720 292 294 O
diet NCT03866720 295 299 B-Observation
/ NCT03866720 300 301 B-Or
physical NCT03866720 302 310 B-Observation
activity NCT03866720 311 319 I-Observation
during NCT03866720 320 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866720 327 330 O
study NCT03866720 331 336 B-Study
( NCT03866720 337 338 O
e. NCT03866720 339 341 O
g. NCT03866720 342 344 O
holidays NCT03866720 346 354 O
or NCT03866720 355 357 O
diet NCT03866720 358 362 B-Observation
plans NCT03866720 363 368 B-Assertion___Assertion-Type-Value:intention
) NCT03866720 369 370 O

- NCT03866720 374 375 O
Inclusive NCT03866720 377 386 O
to NCT03866720 387 389 O
all NCT03866720 390 393 O
breakfast NCT03866720 394 403 O
habits NCT03866720 404 410 O
( NCT03866720 411 412 O
e. NCT03866720 413 415 O
g. NCT03866720 416 418 O
regular NCT03866720 420 427 O
skipper NCT03866720 428 435 O
/ NCT03866720 436 437 O
consumer NCT03866720 438 446 O
) NCT03866720 447 448 O

Exclusion NCT03866720 450 459 O
Criteria NCT03866720 460 468 O
: NCT03866720 469 470 O

- NCT03866720 474 475 O
Any NCT03866720 477 480 O
reported NCT03866720 481 489 O
condition NCT03866720 490 499 B-Condition
or NCT03866720 500 502 B-Or
behaviour NCT03866720 503 512 B-Condition
deemed NCT03866720 513 519 O
either NCT03866720 520 526 O
to NCT03866720 527 529 O
pose NCT03866720 530 534 O
undue NCT03866720 535 540 O
personal NCT03866720 541 549 O
risk NCT03866720 550 554 B-Risk
to NCT03866720 555 557 O
the NCT03866720 558 561 O
participant NCT03866720 562 573 O
or NCT03866720 574 576 B-Or
introduce NCT03866720 577 586 O
bias NCT03866720 587 591 O

- NCT03866720 594 595 O
Any NCT03866720 597 600 O
diagnosed NCT03866720 601 610 O
metabolic NCT03866720 611 620 B-Condition
disease NCT03866720 621 628 I-Condition
( NCT03866720 629 630 O
e. NCT03866720 631 633 O
g. NCT03866720 634 636 O
type NCT03866720 638 642 B-Modifier|Modifier
1 NCT03866720 643 644 I-Modifier
or NCT03866720 645 647 B-Or
type NCT03866720 648 652 O
2 NCT03866720 653 654 I-Modifier
diabetes NCT03866720 655 663 B-Condition
) NCT03866720 664 665 O

- NCT03866720 669 670 O
Any NCT03866720 672 675 O
reported NCT03866720 676 684 O
use NCT03866720 685 688 O
of NCT03866720 689 691 O
substances NCT03866720 692 702 B-Drug
which NCT03866720 703 708 O
may NCT03866720 709 712 B-Assertion___Assertion-Type-Value:hypothetical
pose NCT03866720 713 717 O
undue NCT03866720 718 723 O
personal NCT03866720 724 732 O
risk NCT03866720 733 737 B-Risk
to NCT03866720 738 740 O
the NCT03866720 741 744 O
participants NCT03866720 745 757 O
or NCT03866720 758 760 B-Or
introduce NCT03866720 761 770 O
bias NCT03866720 771 775 O
into NCT03866720 776 780 O
the NCT03866720 781 784 O
experiment NCT03866720 785 795 B-Study
( NCT03866720 796 797 O
e. NCT03866720 798 800 O
g. NCT03866720 801 803 O
smoking NCT03866720 805 812 B-Condition
/ NCT03866720 813 814 B-Or
substance NCT03866720 815 824 B-Condition
abuse NCT03866720 825 830 I-Condition
) NCT03866720 831 832 O

- NCT03866720 836 837 O
Lifestyle NCT03866720 839 848 O
not NCT03866720 849 852 B-Negation
conforming NCT03866720 853 863 O
to NCT03866720 864 866 O
standard NCT03866720 867 875 O
sleep NCT03866720 876 881 B-Condition
- NCT03866720 882 883 I-Condition
wake NCT03866720 884 888 I-Condition
cycle NCT03866720 889 894 I-Condition
( NCT03866720 895 896 O
e. NCT03866720 897 899 O
g. NCT03866720 900 902 O
shift NCT03866720 904 909 B-Observation
worker NCT03866720 910 916 I-Observation
) NCT03866720 917 918 O

- NCT03866720 922 923 O
Any NCT03866720 925 928 O
reported NCT03866720 929 937 O
recent NCT03866720 938 944 B-Eq-Comparison
( NCT03866720 945 946 O
< NCT03866720 948 949 B-Eq-Comparison
6 NCT03866720 950 951 I-Eq-Comparison
months NCT03866720 952 958 I-Eq-Comparison
) NCT03866720 959 960 O
change NCT03866720 961 967 O
in NCT03866720 968 970 O
body NCT03866720 971 975 B-Observation
mass NCT03866720 976 980 I-Observation
( NCT03866720 981 982 O
± NCT03866720 984 985 B-Eq-Comparison
3 NCT03866720 986 987 I-Eq-Comparison
% NCT03866720 988 989 O
) NCT03866720 990 991 O

Inclusion NCT03864692 0 9 O
Criteria NCT03864692 10 18 O
: NCT03864692 19 20 O

- NCT03864692 24 25 O
singleton NCT03864692 27 36 B-Modifier
parturient NCT03864692 37 47 B-Condition

- NCT03864692 50 51 O
planned NCT03864692 53 60 B-Eq-Comparison
for NCT03864692 61 64 O
elective NCT03864692 65 73 B-Modifier
LSCS NCT03864692 74 78 B-Procedure
under NCT03864692 79 84 O
spinal NCT03864692 85 91 B-Procedure
anesthesia NCT03864692 92 102 I-Procedure

Exclusion NCT03864692 103 112 O
Criteria NCT03864692 113 121 O
: NCT03864692 122 123 O

- NCT03864692 127 128 O
gestational NCT03864692 130 141 B-Observation
age NCT03864692 142 145 I-Observation
< NCT03864692 146 147 B-Eq-Comparison
36 NCT03864692 148 150 I-Eq-Comparison
weeks NCT03864692 151 156 I-Eq-Comparison

- NCT03864692 159 160 O
emergency NCT03864692 162 171 O
cases NCT03864692 172 177 O

- NCT03864692 180 181 O
placenta NCT03864692 183 191 B-Condition
previa NCT03864692 192 198 I-Condition
, NCT03864692 199 200 O
pre NCT03864692 201 204 B-Condition
- NCT03864692 205 206 I-Condition
eclampsia NCT03864692 207 216 I-Condition

- NCT03864692 219 220 O
BMI NCT03864692 222 225 B-Observation
> NCT03864692 226 227 B-Eq-Comparison
40 NCT03864692 228 230 I-Eq-Comparison

- NCT03864692 234 235 O
Reynauld NCT03864692 237 245 B-Condition
disease NCT03864692 246 253 I-Condition

- NCT03864692 256 257 O
patient NCT03864692 259 266 O
refusal NCT03864692 267 274 O

- NCT03864692 277 278 O
cardiovascular NCT03864692 280 294 B-Condition
disease NCT03864692 295 302 I-Condition

Inclusion NCT03868917 0 9 O
Criteria NCT03868917 10 18 O
: NCT03868917 19 20 O

- NCT03868917 24 25 O
Scheduled NCT03868917 27 36 B-Eq-Comparison
for NCT03868917 37 40 O
elective NCT03868917 41 49 B-Modifier
thoracotomy NCT03868917 50 61 B-Procedure

- NCT03868917 64 65 O
ASA NCT03868917 67 70 B-Condition
status NCT03868917 71 77 O
1 NCT03868917 78 79 B-Eq-Comparison
, NCT03868917 80 81 O
2 NCT03868917 82 83 O

Exclusion NCT03868917 85 94 O
Criteria NCT03868917 95 103 O
: NCT03868917 104 105 O

- NCT03868917 109 110 O
Inability NCT03868917 112 121 O
to NCT03868917 122 124 O
provide NCT03868917 125 132 O
adequate NCT03868917 133 141 O
informed NCT03868917 142 150 O
consent NCT03868917 151 158 O

- NCT03868917 161 162 O
Any NCT03868917 164 167 O
contraindication NCT03868917 168 184 B-Contraindication
to NCT03868917 185 187 O
the NCT03868917 188 191 O
placement NCT03868917 192 201 O
of NCT03868917 202 204 O
thoracic NCT03868917 205 213 B-Procedure
paravertebral NCT03868917 214 227 I-Procedure
catheters NCT03868917 228 237 I-Procedure

- NCT03868917 240 241 O
Unstable NCT03868917 243 251 O
vertebral NCT03868917 252 261 B-Modifier
and NCT03868917 262 265 B-Or
transverse NCT03868917 266 276 B-Modifier
process NCT03868917 277 284 I-Modifier
fractures NCT03868917 285 294 B-Condition

- NCT03868917 297 298 O
Any NCT03868917 300 303 O
chronic NCT03868917 304 311 B-Modifier
painful NCT03868917 312 319 B-Condition
conditions NCT03868917 320 330 I-Condition
or NCT03868917 331 333 B-Or
pre NCT03868917 334 337 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03868917 338 339 O
- NCT03868917 341 342 O
operative NCT03868917 343 352 B-Procedure
opioid NCT03868917 353 359 B-Drug
use NCT03868917 360 363 O
Any NCT03868917 364 367 O
chronic NCT03868917 368 375 B-Modifier
painful NCT03868917 376 383 B-Condition
conditions NCT03868917 384 394 I-Condition
or NCT03868917 395 397 B-Or
pre NCT03868917 398 401 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03868917 402 403 O
- NCT03868917 405 406 O
operative NCT03868917 407 416 B-Procedure
opioid NCT03868917 417 423 B-Drug
use NCT03868917 424 427 O

- NCT03868917 430 431 O
Coagulation NCT03868917 433 444 B-Condition
abnormalities NCT03868917 445 458 I-Condition
or NCT03868917 459 461 B-Or
expectation NCT03868917 462 473 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868917 474 476 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868917 477 479 O
on NCT03868917 480 482 B-Eq-Comparison
therapeutic NCT03868917 483 494 B-Drug
anticoagulants NCT03868917 495 509 I-Drug
post NCT03868917 510 514 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03868917 515 516 O
- NCT03868917 518 519 O
operatively NCT03868917 520 531 B-Procedure

- NCT03868917 534 535 O
Allergy NCT03868917 537 544 B-Allergy
to NCT03868917 545 547 O
any NCT03868917 548 551 O
of NCT03868917 552 554 O
the NCT03868917 555 558 O
drugs NCT03868917 559 564 B-Drug
/ NCT03868917 565 566 B-Or
agents NCT03868917 567 573 B-Drug
used NCT03868917 574 578 O
in NCT03868917 579 581 O
study NCT03868917 582 587 B-Study
protocol NCT03868917 588 596 O

- NCT03868917 599 600 O
Altered NCT03868917 602 609 B-Condition
mental NCT03868917 610 616 I-Condition
status NCT03868917 617 623 I-Condition
or NCT03868917 624 626 B-Or
emergency NCT03868917 627 636 B-Modifier
surgery NCT03868917 637 644 B-Procedure

- NCT03868917 647 648 O
Comorbid NCT03868917 650 658 B-Condition
conditions NCT03868917 659 669 I-Condition
such NCT03868917 670 674 O
as NCT03868917 675 677 O
sepsis NCT03868917 678 684 B-Condition
, NCT03868917 685 686 O
unstable NCT03868917 687 695 O
angina NCT03868917 696 702 B-Condition
, NCT03868917 703 704 O
congestive NCT03868917 705 715 B-Condition
heart NCT03868917 716 721 I-Condition
failure NCT03868917 722 729 I-Condition

Inclusion NCT03862547 0 9 O
Criteria NCT03862547 10 18 O
: NCT03862547 19 20 O

- NCT03862547 24 25 O
men NCT03862547 27 30 O
with NCT03862547 31 35 B-And
DE NCT03862547 36 38 B-Condition
and NCT03862547 39 42 B-And
metabolic NCT03862547 43 52 B-Condition
syndrome NCT03862547 53 61 I-Condition

Exclusion NCT03862547 62 71 O
Criteria NCT03862547 72 80 O
: NCT03862547 81 82 O

- NCT03862547 86 87 O
men NCT03862547 89 92 O
with NCT03862547 93 97 B-And
DE NCT03862547 98 100 B-Condition
without NCT03862547 101 108 B-Negation
metabolic NCT03862547 109 118 B-Condition
syndrome NCT03862547 119 127 I-Condition

Inclusion NCT03860350 0 9 O
Criteria NCT03860350 10 18 O
: NCT03860350 19 20 O

- NCT03860350 24 25 O
CAC NCT03860350 27 30 B-Observation
score NCT03860350 31 36 I-Observation
> NCT03860350 37 38 B-Eq-Comparison
10 NCT03860350 39 41 I-Eq-Comparison

- NCT03860350 45 46 O
Framingham NCT03860350 48 58 B-Observation
risk NCT03860350 59 63 I-Observation
score NCT03860350 64 69 I-Observation
( NCT03860350 70 71 O
10 NCT03860350 72 74 B-Eq-Comparison
% NCT03860350 75 76 I-Eq-Comparison
or NCT03860350 77 79 I-Eq-Comparison
above NCT03860350 80 85 I-Eq-Comparison
) NCT03860350 86 87 O

- NCT03860350 91 92 O
Subjects NCT03860350 94 102 O
are NCT03860350 103 106 O
required NCT03860350 107 115 O
to NCT03860350 116 118 O
be NCT03860350 119 121 O
on NCT03860350 122 124 O
stable NCT03860350 125 131 O
concomitant NCT03860350 132 143 B-Modifier
medications NCT03860350 144 155 B-Drug
for NCT03860350 156 159 O
at NCT03860350 160 162 B-Eq-Comparison
least NCT03860350 163 168 I-Eq-Comparison
12 NCT03860350 169 171 I-Eq-Comparison
weeks NCT03860350 172 177 I-Eq-Comparison
prior NCT03860350 178 183 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03860350 184 186 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03860350 187 200 B-Study

- NCT03860350 203 204 O
Subjects NCT03860350 206 214 O
with NCT03860350 215 219 O
diabetic NCT03860350 220 228 B-Condition
must NCT03860350 229 233 O
have NCT03860350 234 238 O
HbA1C NCT03860350 239 244 B-Observation
< NCT03860350 245 246 B-Eq-Comparison
8.0 NCT03860350 247 250 I-Eq-Comparison
, NCT03860350 251 252 O
and NCT03860350 253 256 B-And
stable NCT03860350 257 263 O
HbA1C NCT03860350 264 269 B-Observation
level NCT03860350 270 275 O
variation NCT03860350 276 285 B-Modifier
range NCT03860350 286 291 I-Modifier
within NCT03860350 292 298 B-Eq-Comparison
0.5 NCT03860350 299 302 I-Eq-Comparison
% NCT03860350 303 304 O
for NCT03860350 305 308 O
three NCT03860350 309 314 B-Eq-Comparison
months NCT03860350 315 321 I-Eq-Comparison
. NCT03860350 321 322 O

Exclusion NCT03860350 324 333 O
Criteria NCT03860350 334 342 O
: NCT03860350 343 344 O

- NCT03860350 348 349 O
Hypersensitivity NCT03860350 351 367 B-Condition
to NCT03860350 368 370 O
AGE NCT03860350 371 374 B-Procedure
therapy NCT03860350 375 382 I-Procedure
, NCT03860350 383 384 O

- NCT03860350 388 389 O
Unstable NCT03860350 391 399 O
medical NCT03860350 400 407 B-Modifier
, NCT03860350 408 409 O
psychiatric NCT03860350 410 421 B-Modifier
, NCT03860350 422 423 O
or NCT03860350 424 426 B-Or
substance NCT03860350 427 436 B-Modifier
abuse NCT03860350 437 442 I-Modifier
disorder NCT03860350 443 451 B-Condition
that NCT03860350 452 456 O
may NCT03860350 457 460 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860350 461 470 O
with NCT03860350 471 475 O
continuation NCT03860350 476 488 O
in NCT03860350 489 491 O
the NCT03860350 492 495 O
study NCT03860350 496 501 B-Study
, NCT03860350 502 503 O

- NCT03860350 507 508 O
Weight NCT03860350 510 516 B-Observation
≥ NCT03860350 517 518 B-Eq-Comparison
325 NCT03860350 519 522 I-Eq-Comparison
pounds NCT03860350 523 529 I-Eq-Comparison
, NCT03860350 530 531 O

- NCT03860350 535 536 O
Bleeding NCT03860350 538 546 B-Condition
disorder NCT03860350 547 555 I-Condition
, NCT03860350 556 557 O

- NCT03860350 561 562 O
History NCT03860350 564 571 B-Eq-Comparison
of NCT03860350 572 574 O
myocardial NCT03860350 575 585 B-Condition
infarction NCT03860350 586 596 I-Condition
, NCT03860350 597 598 O

- NCT03860350 602 603 I-Death|Risk
Stroke NCT03860350 605 611 B-Condition

- NCT03860350 614 615 O
Life NCT03860350 617 621 B-Death|Risk
- NCT03860350 622 623 O
threatening NCT03860350 624 635 I-Death|Risk
arrhythmia NCT03860350 636 646 B-Condition
within NCT03860350 647 653 B-Eq-Comparison
prior NCT03860350 654 659 I-Eq-Comparison
6 NCT03860350 660 661 I-Eq-Comparison
months NCT03860350 662 668 I-Eq-Comparison
, NCT03860350 669 670 O

- NCT03860350 674 675 O
Resting NCT03860350 677 684 B-Modifier
hypotension NCT03860350 685 696 B-Condition
( NCT03860350 697 698 O
systolic NCT03860350 699 707 B-Observation
< NCT03860350 708 709 B-Eq-Comparison
90 NCT03860350 710 712 I-Eq-Comparison
mmHg NCT03860350 713 717 I-Eq-Comparison
) NCT03860350 718 719 O
or NCT03860350 720 722 B-Or
hypertension NCT03860350 723 735 B-Condition
( NCT03860350 736 737 O
resting NCT03860350 738 745 B-Modifier
blood NCT03860350 746 751 B-Observation
pressure NCT03860350 752 760 I-Observation
> NCT03860350 761 762 B-Eq-Comparison
170 NCT03860350 763 766 I-Eq-Comparison
/ NCT03860350 767 768 I-Eq-Comparison
110 NCT03860350 769 772 I-Eq-Comparison
) NCT03860350 773 774 O

- NCT03860350 778 779 O
Heart NCT03860350 781 786 B-Condition
failure NCT03860350 787 794 I-Condition
NYHA NCT03860350 795 799 B-Condition
class NCT03860350 800 805 I-Condition
III NCT03860350 806 809 B-Eq-Comparison
or NCT03860350 810 812 I-Eq-Comparison
IV NCT03860350 813 815 I-Eq-Comparison
, NCT03860350 816 817 O

- NCT03860350 821 822 O
History NCT03860350 824 831 B-Eq-Comparison
of NCT03860350 832 834 O
malignancy NCT03860350 835 845 B-Condition
within NCT03860350 846 852 B-Eq-Comparison
the NCT03860350 853 856 I-Eq-Comparison
last NCT03860350 857 861 I-Eq-Comparison
5 NCT03860350 862 863 I-Eq-Comparison
years NCT03860350 864 869 I-Eq-Comparison
( NCT03860350 870 871 O
other NCT03860350 872 877 B-Exception
than NCT03860350 878 882 I-Exception
skin NCT03860350 883 887 B-Modifier
cancer NCT03860350 888 894 B-Condition|Condition
) NCT03860350 895 896 O
or NCT03860350 897 899 B-Or
evidence NCT03860350 900 908 O
of NCT03860350 909 911 O
active NCT03860350 912 918 B-Eq-Comparison
cancer NCT03860350 919 925 B-Procedure
which NCT03860350 926 931 O
would NCT03860350 932 937 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03860350 938 945 I-Assertion___Assertion-Type-Value:hypothetical
concomitant NCT03860350 946 957 B-Modifier
cancer NCT03860350 958 964 O
chemotherapy NCT03860350 965 977 I-Procedure

- NCT03860350 980 981 O
Serum NCT03860350 983 988 B-Observation
creatinine NCT03860350 989 999 I-Observation
> NCT03860350 1000 1001 B-Eq-Comparison|Eq-Comparison
1.4 NCT03860350 1002 1005 I-Eq-Comparison
mg NCT03860350 1006 1008 I-Eq-Comparison
/ NCT03860350 1009 1010 I-Eq-Comparison
dl NCT03860350 1011 1013 I-Eq-Comparison

- NCT03860350 1016 1017 O
Triglycerides NCT03860350 1019 1032 B-Observation
> NCT03860350 1033 1034 O
400 NCT03860350 1035 1038 I-Eq-Comparison
at NCT03860350 1039 1041 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860350 1042 1050 B-Study
visit NCT03860350 1051 1056 O

- NCT03860350 1059 1060 O
Diabetic NCT03860350 1062 1070 B-Condition
subjects NCT03860350 1071 1079 O
with NCT03860350 1080 1084 O
HbA1C NCT03860350 1085 1090 B-Observation
> NCT03860350 1091 1092 B-Eq-Comparison
8 NCT03860350 1093 1094 I-Eq-Comparison
% NCT03860350 1095 1096 I-Eq-Comparison
, NCT03860350 1097 1098 O

- NCT03860350 1102 1103 O
Drug NCT03860350 1105 1109 B-Modifier
or NCT03860350 1110 1112 B-Or
alcohol NCT03860350 1113 1120 B-Modifier
abuse NCT03860350 1121 1126 B-Condition

- NCT03860350 1129 1130 O
Conditions NCT03860350 1132 1142 B-Condition
interfering NCT03860350 1143 1154 O
with NCT03860350 1155 1159 O
accurate NCT03860350 1160 1168 O
assessment NCT03860350 1169 1179 O
of NCT03860350 1180 1182 O
coronary NCT03860350 1183 1191 B-Condition
calcification NCT03860350 1192 1205 I-Condition
( NCT03860350 1206 1207 O
metal NCT03860350 1208 1213 B-Condition
clips NCT03860350 1214 1219 I-Condition
, NCT03860350 1220 1221 O
bypass NCT03860350 1222 1228 B-Procedure
patients NCT03860350 1229 1237 O
, NCT03860350 1238 1239 O
intracoronary NCT03860350 1240 1253 B-Procedure
stents NCT03860350 1254 1260 I-Procedure
) NCT03860350 1261 1262 O
and NCT03860350 1263 1266 B-Or
drug NCT03860350 1267 1271 B-Condition
absorption NCT03860350 1272 1282 I-Condition
( NCT03860350 1283 1284 O
partial NCT03860350 1285 1292 B-Procedure
ileal NCT03860350 1293 1298 I-Procedure
bypass NCT03860350 1299 1305 I-Procedure
or NCT03860350 1306 1308 B-Or
malabsorption NCT03860350 1309 1322 B-Condition
syndrome NCT03860350 1323 1331 I-Condition
) NCT03860350 1332 1333 O
. NCT03860350 1334 1335 O

- NCT03860350 1339 1340 O
Current NCT03860350 1342 1349 B-Eq-Comparison
use NCT03860350 1350 1353 O
of NCT03860350 1354 1356 O
anticoagulants NCT03860350 1357 1371 B-Drug
( NCT03860350 1372 1373 O
except NCT03860350 1374 1380 B-Exception
for NCT03860350 1381 1384 I-Exception
antiplatelet NCT03860350 1385 1397 B-Drug
agents NCT03860350 1398 1404 I-Drug
) NCT03860350 1405 1406 O

- NCT03860350 1410 1411 O
Chronic NCT03860350 1413 1420 B-Modifier
renal NCT03860350 1421 1426 B-Condition
failure NCT03860350 1427 1434 I-Condition|Condition

- NCT03860350 1437 1438 O
Liver NCT03860350 1440 1445 B-Condition
failure NCT03860350 1446 1453 O

- NCT03860350 1456 1457 O
Hematological NCT03860350 1459 1472 B-Modifier
or NCT03860350 1473 1475 B-Or
biochemical NCT03860350 1476 1487 B-Modifier
values NCT03860350 1488 1494 B-Observation
at NCT03860350 1495 1497 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860350 1498 1506 B-Study
visit NCT03860350 1507 1512 O
outside NCT03860350 1513 1520 O
the NCT03860350 1521 1524 O
reference NCT03860350 1525 1534 O
ranges NCT03860350 1535 1541 O
considered NCT03860350 1542 1552 O
as NCT03860350 1553 1555 O
clinically NCT03860350 1556 1566 O
significant NCT03860350 1567 1578 O
. NCT03860350 1578 1579 O

Inclusion NCT03862235 0 9 O
Criteria NCT03862235 10 18 O
: NCT03862235 19 20 O

- NCT03862235 24 25 O
Anabolic NCT03862235 27 35 B-Drug
androgenic NCT03862235 36 46 I-Drug
steroids NCT03862235 47 55 I-Drug
users NCT03862235 56 61 O
and NCT03862235 62 65 B-Or
Anabolic NCT03862235 66 74 B-Drug
androgenic NCT03862235 75 85 I-Drug
steroids NCT03862235 86 94 I-Drug
nonusers NCT03862235 95 103 B-Negation
groups NCT03862235 104 110 O
had NCT03862235 111 114 O
been NCT03862235 115 119 O
involved NCT03862235 120 128 O
in NCT03862235 129 131 O
strength NCT03862235 132 140 B-Observation
training NCT03862235 141 149 I-Observation
for NCT03862235 150 153 O
at NCT03862235 154 156 B-Eq-Comparison
least NCT03862235 157 162 I-Eq-Comparison
2 NCT03862235 163 164 I-Eq-Comparison
years NCT03862235 165 170 I-Eq-Comparison
; NCT03862235 170 171 O

- NCT03862235 174 175 O
Anabolic NCT03862235 177 185 B-Drug
androgenic NCT03862235 186 196 I-Drug
steroids NCT03862235 197 205 I-Drug
users NCT03862235 206 211 O
should NCT03862235 212 218 O
be NCT03862235 219 221 O
self NCT03862235 222 226 O
- NCT03862235 227 228 O
administering NCT03862235 229 242 O
anabolic NCT03862235 243 251 B-Drug
androgenic NCT03862235 252 262 I-Drug
steroids NCT03862235 263 271 I-Drug
in NCT03862235 272 274 O
periodic NCT03862235 275 283 O
cycles NCT03862235 284 290 O
lasting NCT03862235 291 298 O
from NCT03862235 299 303 O
8 NCT03862235 304 305 B-Eq-Comparison
to NCT03862235 306 308 I-Eq-Comparison
12 NCT03862235 309 311 I-Eq-Comparison
weeks NCT03862235 312 317 I-Eq-Comparison
for NCT03862235 318 321 O
at NCT03862235 322 324 B-Eq-Comparison
least NCT03862235 325 330 I-Eq-Comparison
2 NCT03862235 331 332 I-Eq-Comparison
years NCT03862235 333 338 I-Eq-Comparison
with NCT03862235 339 343 O
2 NCT03862235 344 345 B-Eq-Comparison
- NCT03862235 346 347 I-Eq-Comparison
4 NCT03862235 348 349 I-Eq-Comparison
cycles NCT03862235 350 356 I-Eq-Comparison
per NCT03862235 357 360 I-Eq-Comparison
year NCT03862235 361 365 I-Eq-Comparison
; NCT03862235 365 366 O

- NCT03862235 369 370 O
All NCT03862235 372 375 O
anabolic NCT03862235 376 384 B-Drug
androgenic NCT03862235 385 395 I-Drug
steroids NCT03862235 396 404 I-Drug
users NCT03862235 405 410 O
were NCT03862235 411 415 O
on NCT03862235 416 418 O
a NCT03862235 419 420 O
cycle NCT03862235 421 426 O
over NCT03862235 427 431 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862235 432 435 I-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03862235 436 442 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862235 443 445 O
the NCT03862235 446 449 O
study NCT03862235 450 455 B-Study
; NCT03862235 455 456 O

- NCT03862235 459 460 O
Sedentary NCT03862235 462 471 O
control NCT03862235 472 479 O
group NCT03862235 480 485 O
: NCT03862235 486 487 O
sedentary NCT03862235 488 497 B-Condition
men NCT03862235 498 501 O
without NCT03862235 502 509 B-Negation
cardiovascular NCT03862235 510 524 B-Condition
disease NCT03862235 525 532 I-Condition
. NCT03862235 532 533 O

Exclusion NCT03862235 535 544 O
Criteria NCT03862235 545 553 O
: NCT03862235 554 555 O

- NCT03862235 559 560 O
Smoking NCT03862235 562 569 B-Condition
; NCT03862235 569 570 O

- NCT03862235 573 574 O
Alcohol NCT03862235 576 583 B-Observation
consumption NCT03862235 584 595 I-Observation
; NCT03862235 595 596 O

- NCT03862235 599 600 O
Use NCT03862235 602 605 O
of NCT03862235 606 608 O
diuretics NCT03862235 609 618 B-Drug
and NCT03862235 619 622 B-Or
/ NCT03862235 623 624 I-Or
or NCT03862235 625 627 I-Or
antihypertensive NCT03862235 628 644 B-Drug
medications NCT03862235 645 656 I-Drug
; NCT03862235 656 657 O

- NCT03862235 660 661 O
Liver NCT03862235 663 668 B-Modifier
and NCT03862235 669 672 B-Or
kidney NCT03862235 673 679 B-Modifier
disease NCT03862235 680 687 B-Condition

Inclusion NCT03862209 0 9 O
Criteria NCT03862209 10 18 O
: NCT03862209 19 20 O

Adults NCT03862209 22 28 O
( NCT03862209 29 30 O
ages NCT03862209 31 35 B-Age
18 NCT03862209 36 38 B-Eq-Comparison
- NCT03862209 39 40 I-Eq-Comparison
65 NCT03862209 41 43 O
) NCT03862209 44 45 O
, NCT03862209 47 48 O
current NCT03862209 49 56 O
service NCT03862209 57 64 O
users NCT03862209 65 70 O
, NCT03862209 71 72 O
with NCT03862209 73 77 B-And
severe NCT03862209 78 84 O
and NCT03862209 85 88 B-Or
enduring NCT03862209 89 97 B-Modifier
mental NCT03862209 98 104 B-Condition
ill NCT03862209 105 108 I-Condition
- NCT03862209 109 110 I-Condition
health NCT03862209 111 117 I-Condition
, NCT03862209 118 119 O
which NCT03862209 120 125 O
, NCT03862209 126 127 O
for NCT03862209 128 131 O
clinical NCT03862209 132 140 O
purposes NCT03862209 141 149 O
, NCT03862209 150 151 O
typically NCT03862209 152 161 O
relates NCT03862209 162 169 O
to NCT03862209 170 172 O
diagnostic NCT03862209 173 183 O
categories NCT03862209 184 194 O
of NCT03862209 195 197 O
bipolar NCT03862209 198 205 B-Condition
disorder NCT03862209 206 214 I-Condition
, NCT03862209 215 216 O
severe NCT03862209 217 223 O
depression NCT03862209 224 234 B-Condition
, NCT03862209 235 236 O
or NCT03862209 237 239 B-Or
schizophrenia NCT03862209 240 253 B-Condition
. NCT03862209 253 254 O
We NCT03862209 256 258 O
use NCT03862209 259 262 O
the NCT03862209 263 266 O
following NCT03862209 267 276 O
definition NCT03862209 277 287 O
for NCT03862209 288 291 O
SMI NCT03862209 292 295 B-Condition
: NCT03862209 296 297 O

- NCT03862209 301 302 O
Presence NCT03862209 304 312 O
of NCT03862209 313 315 O
a NCT03862209 316 317 O
psychiatric NCT03862209 318 329 B-Condition
disorder NCT03862209 330 338 I-Condition
that NCT03862209 339 343 O
requires NCT03862209 344 352 B-Assertion___Assertion-Type-Value:hypothetical
care NCT03862209 353 357 B-Procedure
and NCT03862209 358 361 B-And
treatment NCT03862209 362 371 B-Procedure
( NCT03862209 372 373 O
so NCT03862209 374 376 O
, NCT03862209 377 378 O
they NCT03862209 379 383 O
are NCT03862209 384 387 O
NOT NCT03862209 388 391 B-Negation
in NCT03862209 392 394 O
symptom NCT03862209 395 402 B-Modifier
remission NCT03862209 403 412 I-Modifier
) NCT03862209 413 414 O

- NCT03862209 418 419 O
Has NCT03862209 421 424 O
severe NCT03862209 425 431 O
limitations NCT03862209 432 443 B-Condition
in NCT03862209 444 446 O
social NCT03862209 447 453 B-Modifier
and NCT03862209 454 457 B-And
community NCT03862209 458 467 B-Modifier
functioning NCT03862209 468 479 I-Modifier
( NCT03862209 480 481 O
i. NCT03862209 482 484 O
e. NCT03862209 485 487 O
they NCT03862209 489 493 O
are NCT03862209 494 497 O
not NCT03862209 498 501 B-Negation
in NCT03862209 502 504 O
functional NCT03862209 505 515 B-Modifier
remission NCT03862209 516 525 I-Modifier
) NCT03862209 526 527 O

- NCT03862209 531 532 O
These NCT03862209 534 539 O
problems NCT03862209 540 548 B-Condition
are NCT03862209 549 552 O
not NCT03862209 553 556 B-Negation
transient NCT03862209 557 566 B-Modifier
( NCT03862209 567 568 O
e. NCT03862209 569 571 O
g. NCT03862209 572 574 O
temporary NCT03862209 576 585 B-Modifier
, NCT03862209 586 587 O
one NCT03862209 588 591 B-Modifier
- NCT03862209 592 593 I-Modifier
off NCT03862209 594 597 I-Modifier
) NCT03862209 598 599 O
in NCT03862209 600 602 O
nature NCT03862209 603 609 O
( NCT03862209 610 611 O
They NCT03862209 612 616 O
are NCT03862209 617 620 O
systematic NCT03862209 621 631 B-Modifier
and NCT03862209 632 635 B-And
long NCT03862209 636 640 B-Modifier
- NCT03862209 641 642 I-Modifier
term NCT03862209 643 647 I-Modifier
) NCT03862209 648 649 O

- NCT03862209 653 654 O
Coordinated NCT03862209 656 667 B-Procedure
care NCT03862209 668 672 I-Procedure|Provider
provided NCT03862209 673 681 O
by NCT03862209 682 684 O
care NCT03862209 685 689 O
networks NCT03862209 690 698 I-Provider
or NCT03862209 699 701 B-Or
teams NCT03862209 702 707 B-Provider
is NCT03862209 708 710 O
needed NCT03862209 711 717 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862209 718 720 I-Assertion___Assertion-Type-Value:hypothetical
implement NCT03862209 721 730 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862209 731 734 O
treatment NCT03862209 735 744 B-Procedure
plan NCT03862209 745 749 B-Eq-Comparison

Exclusion NCT03862209 750 759 O
Criteria NCT03862209 760 768 O
: NCT03862209 769 770 O

Exclusion NCT03862209 772 781 O
criteria NCT03862209 782 790 O
at NCT03862209 791 793 O
the NCT03862209 794 797 O
patient NCT03862209 798 805 O
level NCT03862209 806 811 O
includes NCT03862209 812 820 O
patients NCT03862209 821 829 O
who NCT03862209 830 833 O
do NCT03862209 834 836 O
not NCT03862209 837 840 O
consent NCT03862209 841 848 O
to NCT03862209 849 851 O
their NCT03862209 852 857 O
data NCT03862209 858 862 O
being NCT03862209 863 868 O
collected NCT03862209 869 878 O
who NCT03862209 879 882 O
are NCT03862209 883 886 O
part NCT03862209 887 891 O
of NCT03862209 892 894 O
the NCT03862209 895 898 O
intervention NCT03862209 899 911 O
or NCT03862209 912 914 O
control NCT03862209 915 922 O
conditions NCT03862209 923 933 O
, NCT03862209 934 935 O
those NCT03862209 936 941 O
who NCT03862209 942 945 O
are NCT03862209 946 949 O
under NCT03862209 950 955 B-Eq-Comparison
the NCT03862209 956 959 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:during
age NCT03862209 960 963 I-Eq-Comparison
of NCT03862209 964 966 I-Eq-Comparison
18 NCT03862209 967 969 I-Eq-Comparison
at NCT03862209 970 972 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862209 973 976 O
start NCT03862209 977 982 B-Eq-Comparison
of NCT03862209 983 985 O
the NCT03862209 986 989 O
study NCT03862209 990 995 B-Study
. NCT03862209 995 996 O


Inclusion NCT03862976 0 9 O
Criteria NCT03862976 10 18 O
: NCT03862976 19 20 O

- NCT03862976 24 25 O
Women NCT03862976 27 32 O
with NCT03862976 33 37 B-And
singleton NCT03862976 38 47 B-Modifier
gestation NCT03862976 48 57 B-Condition

- NCT03862976 60 61 O
18 NCT03862976 63 65 B-Eq-Comparison
years NCT03862976 66 71 I-Eq-Comparison
to NCT03862976 72 74 I-Eq-Comparison
50 NCT03862976 75 77 I-Eq-Comparison
years NCT03862976 78 83 I-Eq-Comparison

- NCT03862976 86 87 O
High NCT03862976 89 93 O
risk NCT03862976 94 98 B-Risk
pregnancies NCT03862976 99 110 B-Condition
: NCT03862976 111 112 O
DM NCT03862976 113 115 B-Condition
, NCT03862976 116 117 O
or NCT03862976 118 120 B-Or
GDM NCT03862976 121 124 B-Condition
, NCT03862976 125 126 O
or NCT03862976 127 129 B-Or
hypertension NCT03862976 130 142 B-Condition
, NCT03862976 143 144 O
or NCT03862976 145 147 B-Or
preeclampsia NCT03862976 148 160 B-Condition

Exclusion NCT03862976 161 170 O
Criteria NCT03862976 171 179 O
: NCT03862976 180 181 O

- NCT03862976 184 185 O
IUGR NCT03862976 186 190 B-Condition

Inclusion NCT03865758 0 9 O
Criteria NCT03865758 10 18 O
: NCT03865758 19 20 O

- NCT03865758 24 25 O
Probable NCT03865758 27 35 B-Assertion___Assertion-Type-Value:possible
dementia NCT03865758 36 44 B-Condition
indicated NCT03865758 45 54 O
by NCT03865758 55 57 O
prior NCT03865758 58 63 B-Eq-Comparison
diagnosis NCT03865758 64 73 B-Coreference
and NCT03865758 74 77 B-Or
/ NCT03865758 78 79 I-Or
or NCT03865758 80 82 I-Or
a NCT03865758 83 84 O
score NCT03865758 85 90 O
of NCT03865758 91 93 O
23 NCT03865758 94 96 B-Eq-Comparison
or NCT03865758 97 99 I-Eq-Comparison
less NCT03865758 100 104 I-Eq-Comparison
on NCT03865758 105 107 O
the NCT03865758 108 111 O
Brief NCT03865758 112 117 B-Observation
Alzheimer NCT03865758 118 127 I-Observation
Screen NCT03865758 128 134 I-Observation
. NCT03865758 134 135 O

Exclusion NCT03865758 137 146 O
Criteria NCT03865758 147 155 O
: NCT03865758 156 157 O

- NCT03865758 161 162 O
No NCT03865758 164 166 B-Negation
evidence NCT03865758 167 175 O
of NCT03865758 176 178 O
dementia NCT03865758 179 187 B-Condition

Inclusion NCT03862989 0 9 O
Criteria NCT03862989 10 18 O
: NCT03862989 19 20 O

- NCT03862989 24 25 O
post NCT03862989 27 31 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862989 32 33 O
myocardial NCT03862989 34 44 B-Condition
infarction NCT03862989 45 55 I-Condition
ventricular NCT03862989 56 67 B-Condition
tachycardia NCT03862989 68 79 I-Condition
diagnosis NCT03862989 80 89 O

- NCT03862989 92 93 O
scheduled NCT03862989 95 104 B-Eq-Comparison
to NCT03862989 105 107 I-Eq-Comparison
undergo NCT03862989 108 115 I-Eq-Comparison
radiofrequency NCT03862989 116 130 B-Procedure
catheter NCT03862989 131 139 I-Procedure
ablation NCT03862989 140 148 I-Procedure
as NCT03862989 149 151 O
either NCT03862989 152 158 O
emergency NCT03862989 159 168 B-Modifier
or NCT03862989 169 171 B-Or
elective NCT03862989 172 180 B-Modifier
case NCT03862989 181 185 O

Exclusion NCT03862989 186 195 O
Criteria NCT03862989 196 204 O
: NCT03862989 205 206 O

- NCT03862989 210 211 O
Unable NCT03862989 213 219 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 220 222 O
perform NCT03862989 223 230 O
pace NCT03862989 231 235 B-Procedure
mapping NCT03862989 236 243 I-Procedure
during NCT03862989 244 250 B-Temporal-Connection___Temporal-Connection-Type-Value:during
ablation NCT03862989 251 259 B-Procedure
procedure NCT03862989 260 269 I-Procedure

- NCT03862989 272 273 O
Unable NCT03862989 275 281 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 282 284 O
terminate NCT03862989 285 294 B-Condition
VT NCT03862989 295 297 I-Condition
thus NCT03862989 298 302 O
unable NCT03862989 303 309 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 310 312 O
provide NCT03862989 313 320 O
data NCT03862989 321 325 O
regarding NCT03862989 326 335 O
successful NCT03862989 336 346 O
ablation NCT03862989 347 355 B-Procedure
lesion NCT03862989 356 362 I-Procedure
sites NCT03862989 363 368 O

- NCT03862989 371 372 O
Intracardiac NCT03862989 374 386 B-Condition
thrombus NCT03862989 387 395 I-Condition

Inclusion NCT03868254 0 9 O
Criteria NCT03868254 10 18 O
: NCT03868254 19 20 O

- NCT03868254 24 25 O
Eye NCT03868254 27 30 B-Modifier
treated NCT03868254 31 38 B-Procedure
with NCT03868254 39 43 O
XEN NCT03868254 44 47 B-Modifier
45 NCT03868254 48 50 I-Modifier
Gel NCT03868254 51 54 B-Procedure
Stent NCT03868254 55 60 I-Procedure
for NCT03868254 61 64 O
primary NCT03868254 65 72 B-Modifier
open NCT03868254 73 77 I-Modifier
angle NCT03868254 78 83 I-Modifier
glaucoma NCT03868254 84 92 B-Condition
as NCT03868254 93 95 O
a NCT03868254 96 97 O
standalone NCT03868254 98 108 B-Coreference
procedure NCT03868254 109 118 I-Coreference
or NCT03868254 119 121 B-Or
in NCT03868254 122 124 B-Modifier
combination NCT03868254 125 136 I-Modifier
with NCT03868254 137 141 O
phacoemulsification NCT03868254 142 161 B-Procedure

- NCT03868254 164 165 O
XEN NCT03868254 167 170 B-Modifier
45 NCT03868254 171 173 I-Modifier
Gel NCT03868254 174 177 B-Procedure
Stent NCT03868254 178 183 I-Procedure
was NCT03868254 184 187 O
implanted NCT03868254 188 197 O
between NCT03868254 198 205 B-Eq-Comparison
1 NCT03868254 206 207 I-Eq-Comparison
January NCT03868254 208 215 I-Eq-Comparison
2014 NCT03868254 216 220 I-Eq-Comparison
and NCT03868254 221 224 I-Eq-Comparison
1 NCT03868254 225 226 I-Eq-Comparison
October NCT03868254 227 234 I-Eq-Comparison
2015 NCT03868254 235 239 I-Eq-Comparison

Exclusion NCT03868254 241 250 O
Criteria NCT03868254 251 259 O

- NCT03868254 262 263 O
None NCT03868254 265 269 O

Inclusion NCT03865823 0 9 O
Criteria NCT03865823 10 18 O
: NCT03865823 19 20 O

- NCT03865823 24 25 O
Patient NCT03865823 27 34 O
over NCT03865823 35 39 B-Eq-Comparison
the NCT03865823 40 43 I-Eq-Comparison
age NCT03865823 44 47 I-Age|Eq-Comparison
of NCT03865823 48 50 I-Eq-Comparison
18 NCT03865823 51 53 I-Eq-Comparison
, NCT03865823 54 55 O
patient NCT03865823 56 63 O
with NCT03865823 64 68 O
an NCT03865823 69 71 B-Modifier
anus NCT03865823 72 76 O
fistula NCT03865823 77 84 B-Condition
with NCT03865823 85 89 B-And
indication NCT03865823 90 100 B-Indication
for NCT03865823 101 104 O
surgical NCT03865823 105 113 B-Procedure
treatment NCT03865823 114 123 I-Procedure

Exclusion NCT03865823 124 133 O
Criteria NCT03865823 134 142 O
: NCT03865823 143 144 O

- NCT03865823 148 149 O
Cutaneous NCT03865823 151 160 B-Condition
Suppuration NCT03865823 161 172 I-Condition
, NCT03865823 173 174 O
without NCT03865823 175 182 B-Negation
fistula NCT03865823 183 190 B-Condition
( NCT03865823 191 192 O
e. NCT03865823 193 195 O
g. NCT03865823 196 198 O
, NCT03865823 199 200 O
Verneuil NCT03865823 201 209 B-Condition
disease NCT03865823 210 217 I-Condition
, NCT03865823 218 219 O
boil NCT03865823 220 224 B-Condition
) NCT03865823 225 226 O

Inclusion NCT03869957 0 9 O
Criteria NCT03869957 10 18 O
: NCT03869957 19 20 O

- NCT03869957 24 25 O
Patients NCT03869957 27 35 O
admitted NCT03869957 36 44 B-Encounter
in NCT03869957 45 47 O
the NCT03869957 48 51 O
non NCT03869957 52 55 B-Negation
- NCT03869957 56 57 O
critical NCT03869957 58 66 O
areas NCT03869957 67 72 O
of NCT03869957 73 75 O
the NCT03869957 76 79 O
Instituto NCT03869957 80 89 O
Nacional NCT03869957 90 98 O
de NCT03869957 99 101 O
Ciencias NCT03869957 102 110 O
Médicas NCT03869957 111 118 O
y NCT03869957 119 120 O
Nutrición NCT03869957 121 130 O
Salvador NCT03869957 131 139 O
Zubirán NCT03869957 140 147 O
( NCT03869957 148 149 O
INCMNSZ NCT03869957 150 157 O
) NCT03869957 158 159 O
with NCT03869957 160 164 B-And
a NCT03869957 165 166 O
nutritional NCT03869957 167 178 B-Condition
risk NCT03869957 179 183 B-Risk
between NCT03869957 184 191 B-Eq-Comparison
January NCT03869957 192 199 I-Eq-Comparison
2019 NCT03869957 200 204 I-Eq-Comparison
and NCT03869957 205 208 I-Eq-Comparison
July NCT03869957 209 213 I-Eq-Comparison
2020 NCT03869957 214 218 I-Eq-Comparison
will NCT03869957 219 223 O
be NCT03869957 224 226 O
considered NCT03869957 227 237 O
eligible NCT03869957 238 246 O
. NCT03869957 246 247 O

- NCT03869957 251 252 O
Patients NCT03869957 254 262 O
with NCT03869957 263 267 O
recent NCT03869957 268 274 B-Eq-Comparison
diagnosis NCT03869957 275 284 O
of NCT03869957 285 287 O
IF NCT03869957 288 290 B-Condition
type NCT03869957 291 295 B-Modifier
II NCT03869957 296 298 I-Modifier
( NCT03869957 299 300 O
an NCT03869957 301 303 O
evolution NCT03869957 304 313 O
> NCT03869957 314 315 B-Eq-Comparison
28 NCT03869957 316 318 I-Eq-Comparison
days NCT03869957 319 323 I-Eq-Comparison
) NCT03869957 324 325 O
originate NCT03869957 326 335 O
from NCT03869957 336 340 O
various NCT03869957 341 348 O
gastrointestinal NCT03869957 349 365 B-Modifier
or NCT03869957 366 368 B-Or
systemic NCT03869957 369 377 B-Modifier
diseases NCT03869957 378 386 B-Condition
( NCT03869957 387 388 O
short NCT03869957 389 394 B-Modifier
bowel NCT03869957 395 400 I-Modifier
, NCT03869957 401 402 O
intestinal NCT03869957 403 413 B-Modifier
fistula NCT03869957 414 421 I-Modifier
, NCT03869957 422 423 O
intestinal NCT03869957 424 434 B-Modifier
dysmotility NCT03869957 435 446 I-Modifier
, NCT03869957 447 448 O
mechanical NCT03869957 449 459 B-Modifier
obstruction NCT03869957 460 471 I-Modifier
, NCT03869957 472 473 O
and NCT03869957 474 477 B-Or
extensive NCT03869957 478 487 B-Modifier
small NCT03869957 488 493 I-Modifier
bowel NCT03869957 494 499 I-Modifier
mucosal NCT03869957 500 507 I-Modifier
disease NCT03869957 508 515 B-Condition
) NCT03869957 516 517 O
. NCT03869957 518 519 O

Exclusion NCT03869957 526 535 O
Criteria NCT03869957 536 544 O
: NCT03869957 545 546 O

- NCT03869957 550 551 O
Patients NCT03869957 553 561 O
with NCT03869957 562 566 O
contraindications NCT03869957 567 584 B-Contraindication
for NCT03869957 585 588 O
PN NCT03869957 589 591 B-Procedure

- NCT03869957 594 595 O
Patients NCT03869957 597 605 O
with NCT03869957 606 610 O
known NCT03869957 611 616 O
allergies NCT03869957 617 626 B-Allergy
to NCT03869957 627 629 O
the NCT03869957 630 633 O
components NCT03869957 634 644 O
of NCT03869957 645 647 O
the NCT03869957 648 651 O
PN NCT03869957 652 654 B-Procedure
formula NCT03869957 655 662 O

- NCT03869957 665 666 O
Severe NCT03869957 668 674 O
liver NCT03869957 675 680 B-Modifier
or NCT03869957 681 683 B-Or
renal NCT03869957 684 689 B-Modifier
insufficiency NCT03869957 690 703 B-Condition

- NCT03869957 706 707 O
Uncontrolled NCT03869957 709 721 O
diabetes NCT03869957 722 730 B-Condition
mellitus NCT03869957 731 739 I-Condition

- NCT03869957 742 743 O
Certain NCT03869957 745 752 O
acute NCT03869957 753 758 O
and NCT03869957 759 762 B-Or
life NCT03869957 763 767 B-Death|Risk
- NCT03869957 768 769 I-Death|Risk
threatening NCT03869957 770 781 I-Death|Risk
conditions NCT03869957 782 792 B-Condition

- NCT03869957 795 796 O
Immunological NCT03869957 798 811 B-Condition
diseases NCT03869957 812 820 I-Condition
( NCT03869957 821 822 O
such NCT03869957 823 827 O
as NCT03869957 828 830 O
autoimmune NCT03869957 831 841 B-Condition
diseases NCT03869957 842 850 I-Condition
, NCT03869957 851 852 O
human NCT03869957 853 858 B-Condition
immunodeficiency NCT03869957 859 875 I-Condition
virus NCT03869957 876 881 I-Condition
infection NCT03869957 882 891 I-Condition
, NCT03869957 892 893 O
cancer NCT03869957 894 900 B-Condition
, NCT03869957 901 902 O
etc NCT03869957 903 906 O
. NCT03869957 906 907 O
) NCT03869957 908 909 O

- NCT03869957 913 914 O
Those NCT03869957 916 921 O
that NCT03869957 922 926 O
take NCT03869957 927 931 B-Eq-Comparison
immunosuppressant NCT03869957 932 949 B-Drug
medications NCT03869957 950 961 I-Drug

- NCT03869957 964 965 O
Severe NCT03869957 967 973 O
hemorrhagic NCT03869957 974 985 B-Condition
disorders NCT03869957 986 995 I-Condition

- NCT03869957 998 999 O
Pregnant NCT03869957 1001 1009 B-Condition
or NCT03869957 1010 1012 B-Or
lactating NCT03869957 1013 1022 B-Condition


Inclusion NCT03863249 0 9 O
Criteria NCT03863249 10 18 O
: NCT03863249 19 20 O

1 NCT03863249 24 25 O
. NCT03863249 25 26 O
Subjects NCT03863249 28 36 O
of NCT03863249 37 39 O
40 NCT03863249 40 42 B-Eq-Comparison
- NCT03863249 43 44 I-Eq-Comparison
70 NCT03863249 45 47 I-Eq-Comparison
years NCT03863249 48 53 I-Age|Eq-Comparison
. NCT03863249 53 54 O

2 NCT03863249 58 59 O
. NCT03863249 59 60 O
No NCT03863249 62 64 B-Negation
smokers NCT03863249 65 72 B-Condition
or NCT03863249 73 75 B-Or
smokers NCT03863249 76 83 B-Condition|Observation
of NCT03863249 84 86 O
less NCT03863249 87 91 B-Eq-Comparison
than NCT03863249 92 96 I-Eq-Comparison
10 NCT03863249 97 99 I-Eq-Comparison
cigarettes NCT03863249 100 110 I-Eq-Comparison
a NCT03863249 111 112 I-Eq-Comparison
day NCT03863249 113 116 I-Eq-Comparison
. NCT03863249 116 117 O

3 NCT03863249 121 122 O
. NCT03863249 122 123 O
Patients NCT03863249 125 133 O
with NCT03863249 134 138 O
periodontitis NCT03863249 139 152 B-Condition
stages NCT03863249 153 159 B-Eq-Comparison
III NCT03863249 160 163 I-Eq-Comparison
and NCT03863249 164 167 I-Eq-Comparison
IV NCT03863249 168 170 I-Eq-Comparison
grades NCT03863249 171 177 B-Eq-Comparison
A NCT03863249 178 179 I-Eq-Comparison
- NCT03863249 180 181 I-Eq-Comparison
B. NCT03863249 182 184 I-Eq-Comparison

4 NCT03863249 188 189 O
. NCT03863249 189 190 O
Presence NCT03863249 192 200 O
of NCT03863249 201 203 O
20 NCT03863249 204 206 B-Eq-Comparison
natural NCT03863249 207 214 B-Modifier
teeth NCT03863249 215 220 B-Condition
, NCT03863249 221 222 O
including NCT03863249 223 232 O
at NCT03863249 233 235 B-Eq-Comparison
least NCT03863249 236 241 I-Eq-Comparison
three NCT03863249 242 247 I-Eq-Comparison
molar NCT03863249 248 253 B-Modifier
teeth NCT03863249 254 259 B-Condition
. NCT03863249 259 260 O

5 NCT03863249 264 265 O
. NCT03863249 265 266 O
Presence NCT03863249 268 276 O
of NCT03863249 277 279 O
at NCT03863249 280 282 B-Eq-Comparison
least NCT03863249 283 288 I-Eq-Comparison
4 NCT03863249 289 290 I-Eq-Comparison
sites NCT03863249 291 296 I-Eq-Comparison
with NCT03863249 297 301 O
at NCT03863249 302 304 B-Eq-Comparison
least NCT03863249 305 310 I-Eq-Comparison
6 NCT03863249 311 312 I-Eq-Comparison
mm NCT03863249 313 315 I-Eq-Comparison
probing NCT03863249 316 323 B-Observation
depth NCT03863249 324 329 I-Observation
. NCT03863249 329 330 O

6 NCT03863249 334 335 O
. NCT03863249 335 336 O
Good NCT03863249 338 342 O
general NCT03863249 343 350 B-Condition
health NCT03863249 351 357 I-Condition

Exclusion NCT03863249 358 367 O
Criteria NCT03863249 368 376 O
: NCT03863249 377 378 O

1 NCT03863249 382 383 O
. NCT03863249 383 384 O
Smokers NCT03863249 386 393 B-Condition|Observation
of NCT03863249 394 396 O
more NCT03863249 397 401 B-Eq-Comparison
than NCT03863249 402 406 I-Eq-Comparison
10 NCT03863249 407 409 I-Eq-Comparison
cigarettes NCT03863249 410 420 I-Eq-Comparison
a NCT03863249 421 422 I-Eq-Comparison
day NCT03863249 423 426 I-Eq-Comparison
. NCT03863249 426 427 O

2 NCT03863249 431 432 O
. NCT03863249 432 433 O
Patients NCT03863249 435 443 O
who NCT03863249 444 447 O
have NCT03863249 448 452 O
received NCT03863249 453 461 B-Eq-Comparison
periodontal NCT03863249 462 473 B-Procedure
treatment NCT03863249 474 483 I-Procedure
in NCT03863249 484 486 O
the NCT03863249 487 490 O
previous NCT03863249 491 499 B-Eq-Comparison
12 NCT03863249 500 502 I-Eq-Comparison
months NCT03863249 503 509 I-Eq-Comparison
. NCT03863249 509 510 O

3 NCT03863249 514 515 O
. NCT03863249 515 516 O
Patients NCT03863249 518 526 O
who NCT03863249 527 530 O
have NCT03863249 531 535 O
used NCT03863249 536 540 B-Eq-Comparison
antibiotics NCT03863249 541 552 B-Drug
in NCT03863249 553 555 O
the NCT03863249 556 559 O
last NCT03863249 560 564 B-Eq-Comparison
6 NCT03863249 565 566 I-Eq-Comparison
months NCT03863249 567 573 I-Eq-Comparison
. NCT03863249 573 574 O

4 NCT03863249 578 579 O
. NCT03863249 579 580 O
Routine NCT03863249 582 589 O
use NCT03863249 590 593 O
of NCT03863249 594 596 O
oral NCT03863249 597 601 B-Drug|Or
antiseptics NCT03863249 602 613 I-Drug
and NCT03863249 614 617 B-Or
/ NCT03863249 618 619 I-Or
or NCT03863249 620 622 O
during NCT03863249 623 629 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863249 630 633 O
previous NCT03863249 634 642 B-Eq-Comparison
3 NCT03863249 643 644 I-Eq-Comparison
months NCT03863249 645 651 I-Eq-Comparison
. NCT03863249 651 652 O

5 NCT03863249 656 657 O
. NCT03863249 657 658 O
Systemic NCT03863249 660 668 B-Modifier
conditions NCT03863249 669 679 B-Condition
that NCT03863249 680 684 O
required NCT03863249 685 693 O
antibiotic NCT03863249 694 704 B-Drug
premedication NCT03863249 705 718 I-Drug
. NCT03863249 718 719 O

6 NCT03863249 723 724 O
. NCT03863249 724 725 O
Women NCT03863249 727 732 O
pregnant NCT03863249 733 741 B-Condition
or NCT03863249 742 744 B-Or
nursing NCT03863249 745 752 B-Condition
. NCT03863249 752 753 O

7 NCT03863249 757 758 O
. NCT03863249 758 759 O
Medications NCT03863249 761 772 B-Drug
that NCT03863249 773 777 O
could NCT03863249 778 783 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03863249 784 793 O
the NCT03863249 794 797 I-Procedure
outcome NCT03863249 798 805 O
of NCT03863249 806 808 O
periodontal NCT03863249 809 820 B-Procedure
therapy NCT03863249 821 828 O
. NCT03863249 828 829 O

8 NCT03863249 833 834 O
. NCT03863249 834 835 O
Any NCT03863249 837 840 O
known NCT03863249 841 846 O
allergies NCT03863249 847 856 B-Allergy
to NCT03863249 857 859 O
the NCT03863249 860 863 O
test NCT03863249 864 868 B-Study
antimicrobial NCT03863249 869 882 B-Drug
agents NCT03863249 883 889 I-Drug
. NCT03863249 889 890 O

9 NCT03863249 894 895 O
. NCT03863249 895 896 O
Diabetics NCT03863249 898 907 B-Condition
. NCT03863249 907 908 O

Inclusion NCT03862625 0 9 O
Criteria NCT03862625 10 18 O
: NCT03862625 19 20 O

- NCT03862625 24 25 O
the NCT03862625 27 30 O
participant NCT03862625 31 42 O
6 NCT03862625 43 44 B-Eq-Comparison
to NCT03862625 45 47 I-Eq-Comparison
15 NCT03862625 48 50 I-Eq-Comparison
years NCT03862625 51 56 I-Eq-Comparison
of NCT03862625 57 59 O
age NCT03862625 60 63 B-Age
during NCT03862625 64 70 B-Temporal-Connection___Temporal-Connection-Type-Value:during
inclusion NCT03862625 71 80 B-Study

- NCT03862625 83 84 O
the NCT03862625 86 89 O
participant NCT03862625 90 101 O
is NCT03862625 102 104 O
diagnosed NCT03862625 105 114 O
as NCT03862625 115 117 O
cerebral NCT03862625 118 126 B-Condition
palsy NCT03862625 127 132 I-Condition
by NCT03862625 133 135 O
a NCT03862625 136 137 O
specialist NCT03862625 138 148 B-Provider

- NCT03862625 151 152 O
the NCT03862625 154 157 O
participant NCT03862625 158 169 O
's NCT03862625 169 171 O
Cobb NCT03862625 172 176 B-Observation
angle NCT03862625 177 182 I-Observation
is NCT03862625 183 185 O
between NCT03862625 186 193 B-Eq-Comparison
10 NCT03862625 194 196 I-Eq-Comparison
- NCT03862625 197 198 I-Eq-Comparison
40 NCT03862625 199 201 I-Eq-Comparison
degrees NCT03862625 202 209 I-Eq-Comparison
. NCT03862625 209 210 O
( NCT03862625 212 213 O
Cobb NCT03862625 214 218 B-Observation
angle NCT03862625 219 224 I-Observation
above NCT03862625 225 230 B-Eq-Comparison
40 NCT03862625 231 233 I-Eq-Comparison
degrees NCT03862625 234 241 I-Eq-Comparison
and NCT03862625 242 245 B-Or
patients NCT03862625 246 254 O
whose NCT03862625 255 260 O
parents NCT03862625 261 268 B-Family-Member___Family-Member-Type:parent
have NCT03862625 269 273 O
not NCT03862625 274 277 B-Negation
accepted NCT03862625 278 286 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03862625 287 290 O
operation NCT03862625 291 300 B-Procedure
) NCT03862625 301 302 O

- NCT03862625 306 307 O
There NCT03862625 309 314 O
is NCT03862625 315 317 O
no NCT03862625 318 320 B-Negation
history NCT03862625 321 328 B-Eq-Comparison
of NCT03862625 329 331 O
operation NCT03862625 332 341 B-Procedure
due NCT03862625 342 345 O
to NCT03862625 346 348 O
scoliosis NCT03862625 349 358 B-Condition
or NCT03862625 359 361 B-Or
the NCT03862625 362 365 O
decision NCT03862625 366 374 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03862625 375 377 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862625 378 381 O
operation NCT03862625 382 391 B-Procedure
has NCT03862625 392 395 O
not NCT03862625 396 399 B-Negation
been NCT03862625 400 404 O
accepted NCT03862625 405 413 B-Assertion___Assertion-Type-Value:hypothetical
by NCT03862625 414 416 O
the NCT03862625 417 420 O
patients NCT03862625 421 429 O
and NCT03862625 430 433 O
their NCT03862625 434 439 O
parents NCT03862625 440 447 B-Family-Member___Family-Member-Type:parent

- NCT03862625 450 451 O
the NCT03862625 453 456 O
participant NCT03862625 457 468 O
is NCT03862625 469 471 O
Gross NCT03862625 472 477 B-Observation
Motor NCT03862625 478 483 I-Observation
Function NCT03862625 484 492 I-Observation
Classification NCT03862625 493 507 I-Observation
System NCT03862625 508 514 I-Observation
Level NCT03862625 515 520 O
4 NCT03862625 521 522 B-Eq-Comparison
or NCT03862625 523 525 I-Eq-Comparison
5 NCT03862625 526 527 I-Eq-Comparison

- NCT03862625 531 532 O
Lack NCT03862625 534 538 B-Condition
of NCT03862625 539 541 I-Condition
contracture NCT03862625 542 553 I-Condition
to NCT03862625 554 556 O
prevent NCT03862625 557 564 B-Assertion___Assertion-Type-Value:hypothetical|Negation
sitting NCT03862625 565 572 B-Observation
in NCT03862625 573 575 O
the NCT03862625 576 579 O
lower NCT03862625 580 585 B-Modifier
extremity NCT03862625 586 595 I-Modifier

- NCT03862625 598 599 O
Parents NCT03862625 601 608 O
agree NCT03862625 609 614 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862625 615 617 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03862625 618 629 O
in NCT03862625 630 632 B-Modifier
the NCT03862625 633 636 O
intensive NCT03862625 637 646 O
therapy NCT03862625 647 654 B-Procedure
program NCT03862625 655 662 O
and NCT03862625 663 666 B-And
stop NCT03862625 667 671 B-Negation
the NCT03862625 672 675 B-Procedure
therapeutic NCT03862625 676 687 O
interventions NCT03862625 688 701 I-Procedure
for NCT03862625 702 705 O
scoliosis NCT03862625 706 715 B-Condition
and NCT03862625 716 719 B-Or
lower NCT03862625 720 725 B-Modifier
extremities NCT03862625 726 737 I-Modifier
during NCT03862625 738 744 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862625 745 748 O
3 NCT03862625 749 750 B-Eq-Comparison
- NCT03862625 751 752 I-Eq-Comparison
month NCT03862625 753 758 I-Eq-Comparison
follow NCT03862625 759 765 B-Encounter
- NCT03862625 766 767 I-Encounter
up NCT03862625 768 770 I-Encounter
period NCT03862625 771 777 O

Exclusion NCT03862625 778 787 O
Criteria NCT03862625 788 796 O
: NCT03862625 797 798 O

- NCT03862625 802 803 O
Having NCT03862625 805 811 O
a NCT03862625 812 813 O
history NCT03862625 814 821 B-Eq-Comparison
of NCT03862625 822 824 O
operation NCT03862625 825 834 B-Procedure
due NCT03862625 835 838 O
to NCT03862625 839 841 O
scoliosis NCT03862625 842 851 B-Condition

- NCT03862625 854 855 O
The NCT03862625 857 860 O
deformity NCT03862625 861 870 B-Condition
in NCT03862625 871 873 O
the NCT03862625 874 877 O
spine NCT03862625 878 883 B-Modifier
is NCT03862625 884 886 I-Modifier
rigid NCT03862625 887 892 I-Modifier

- NCT03862625 895 896 O
If NCT03862625 898 900 O
the NCT03862625 901 904 O
curvature NCT03862625 905 914 B-Observation
measured NCT03862625 915 923 O
in NCT03862625 924 926 O
the NCT03862625 927 930 O
spine NCT03862625 931 936 B-Modifier
is NCT03862625 937 939 O
less NCT03862625 940 944 B-Eq-Comparison
than NCT03862625 945 949 I-Eq-Comparison
10 NCT03862625 950 952 I-Eq-Comparison
degrees NCT03862625 953 960 I-Eq-Comparison
or NCT03862625 961 963 B-Or
more NCT03862625 964 968 B-Eq-Comparison
than NCT03862625 969 973 I-Eq-Comparison
40 NCT03862625 974 976 I-Eq-Comparison
degrees NCT03862625 977 984 I-Eq-Comparison
in NCT03862625 985 987 O
the NCT03862625 988 991 O
patients NCT03862625 992 1000 B-And
whose NCT03862625 1001 1006 I-And
operation NCT03862625 1007 1016 B-Procedure
decision NCT03862625 1017 1025 B-Assertion___Assertion-Type-Value:hypothetical
is NCT03862625 1026 1028 I-Assertion___Assertion-Type-Value:hypothetical
accepted NCT03862625 1029 1037 I-Assertion___Assertion-Type-Value:hypothetical
by NCT03862625 1038 1040 O
the NCT03862625 1041 1044 O
family NCT03862625 1045 1051 B-Family-Member

- NCT03862625 1054 1055 O
Having NCT03862625 1057 1063 O
a NCT03862625 1064 1065 O
seating NCT03862625 1066 1073 B-Condition
modification NCT03862625 1074 1086 I-Condition
applied NCT03862625 1087 1094 O
at NCT03862625 1095 1097 B-Eq-Comparison
least NCT03862625 1098 1103 I-Eq-Comparison
1 NCT03862625 1104 1105 I-Eq-Comparison
year NCT03862625 1106 1110 I-Eq-Comparison
before NCT03862625 1111 1117 B-Temporal-Connection___Temporal-Connection-Type-Value:before
being NCT03862625 1118 1123 O
included NCT03862625 1124 1132 O
in NCT03862625 1133 1135 O
the NCT03862625 1136 1139 O
study NCT03862625 1140 1145 B-Study

- NCT03862625 1148 1149 O
Having NCT03862625 1151 1157 O
a NCT03862625 1158 1159 O
spasticity NCT03862625 1160 1170 B-Condition
and NCT03862625 1171 1174 B-Or
contracture NCT03862625 1175 1186 B-Condition
to NCT03862625 1187 1189 O
prevent NCT03862625 1190 1197 B-Assertion___Assertion-Type-Value:hypothetical|Negation
sitting NCT03862625 1198 1205 B-Observation
in NCT03862625 1206 1208 O
the NCT03862625 1209 1212 O
hip NCT03862625 1213 1216 B-Modifier
and NCT03862625 1217 1220 B-And
knee NCT03862625 1221 1225 B-Modifier
joint NCT03862625 1226 1231 I-Modifier

- NCT03862625 1234 1235 O
Having NCT03862625 1237 1243 O
a NCT03862625 1244 1245 O
pressure NCT03862625 1246 1254 B-Condition
ulcer NCT03862625 1255 1260 I-Condition
to NCT03862625 1261 1263 O
prevent NCT03862625 1264 1271 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862625 1272 1275 O
patient NCT03862625 1276 1283 O
from NCT03862625 1284 1288 O
sitting NCT03862625 1289 1296 B-Observation

- NCT03862625 1299 1300 O
the NCT03862625 1302 1305 O
participant NCT03862625 1306 1317 O
has NCT03862625 1318 1321 O
comorbidity NCT03862625 1322 1333 B-Condition
that NCT03862625 1334 1338 O
is NCT03862625 1339 1341 O
not NCT03862625 1342 1345 B-Negation
related NCT03862625 1346 1353 O
about NCT03862625 1354 1359 O
cerebral NCT03862625 1360 1368 B-Condition
palsy NCT03862625 1369 1374 I-Condition

- NCT03862625 1377 1378 O
Having NCT03862625 1380 1386 O
epileptic NCT03862625 1387 1396 B-Condition
seizures NCT03862625 1397 1405 I-Condition
not NCT03862625 1406 1409 B-Negation
controlled NCT03862625 1410 1420 O

- NCT03862625 1423 1424 O
Having NCT03862625 1426 1432 O
bone NCT03862625 1433 1437 B-Procedure
operations NCT03862625 1438 1448 I-Procedure
for NCT03862625 1449 1452 O
hip NCT03862625 1453 1456 B-Modifier
joints NCT03862625 1457 1463 I-Modifier

Inclusion NCT03863275 0 9 O
Criteria NCT03863275 10 18 O
: NCT03863275 19 20 O

- NCT03863275 24 25 O
Boys NCT03863275 27 31 O
and NCT03863275 32 35 B-Or
girls NCT03863275 36 41 O
from NCT03863275 42 46 O
7 NCT03863275 47 48 B-Eq-Comparison
to NCT03863275 49 51 I-Eq-Comparison
12 NCT03863275 52 54 I-Eq-Comparison
years NCT03863275 55 60 I-Eq-Comparison
old NCT03863275 61 64 B-Age
with NCT03863275 65 69 B-And
class NCT03863275 70 75 B-Eq-Comparison
II NCT03863275 76 78 I-Eq-Comparison
skeletal NCT03863275 79 87 B-Condition
classification NCT03863275 88 102 I-Condition
attending NCT03863275 103 112 B-Encounter
a NCT03863275 113 114 O
consultation NCT03863275 115 127 O
in NCT03863275 128 130 O
the NCT03863275 131 134 O
dental NCT03863275 135 141 O
clinic NCT03863275 142 148 O
of NCT03863275 149 151 O
the NCT03863275 152 155 O
UNICIEO NCT03863275 156 163 O
foundation NCT03863275 164 174 O
, NCT03863275 175 176 O
to NCT03863275 177 179 B-Eq-Comparison
be NCT03863275 180 182 I-Eq-Comparison
fitted NCT03863275 183 189 O
with NCT03863275 190 194 O
myofunctional NCT03863275 195 208 B-Procedure
apparatus NCT03863275 209 218 I-Procedure
type NCT03863275 219 223 B-Modifier
Sn1 NCT03863275 224 227 I-Modifier

Exclusion NCT03863275 228 237 O
Criteria NCT03863275 238 246 O
: NCT03863275 247 248 O

- NCT03863275 252 253 O
Patients NCT03863275 255 263 O
who NCT03863275 264 267 O
have NCT03863275 268 272 O
had NCT03863275 273 276 O
previous NCT03863275 277 285 B-Eq-Comparison
orthopedic NCT03863275 286 296 B-Procedure
treatment NCT03863275 297 306 I-Procedure

- NCT03863275 309 310 O
Patients NCT03863275 312 320 O
with NCT03863275 321 325 O
signs NCT03863275 326 331 B-Assertion___Assertion-Type-Value:possible
of NCT03863275 332 334 O
condyle NCT03863275 335 342 B-Modifier
injuries NCT03863275 343 351 B-Condition

- NCT03863275 354 355 O
Patients NCT03863275 357 365 O
of NCT03863275 366 368 O
Pierre NCT03863275 369 375 B-Provider
Robin NCT03863275 376 381 I-Provider
or NCT03863275 382 384 B-Or
any NCT03863275 385 388 O
form NCT03863275 389 393 O
of NCT03863275 394 396 O
cleft NCT03863275 397 402 B-Condition

- NCT03863275 405 406 O
Patients NCT03863275 408 416 O
with NCT03863275 417 421 O
syndromes NCT03863275 422 431 B-Condition
that NCT03863275 432 436 O
associate NCT03863275 437 446 O
craniofacial NCT03863275 447 459 B-Condition
anomalies NCT03863275 460 469 I-Condition
and NCT03863275 470 473 B-Or
muscle NCT03863275 474 480 B-Condition
alterations NCT03863275 481 492 I-Condition
. NCT03863275 492 493 O

Inclusion NCT03861884 0 9 O
Criteria NCT03861884 10 18 O
: NCT03861884 19 20 O

1 NCT03861884 24 25 O
. NCT03861884 25 26 O
Ability NCT03861884 28 35 O
to NCT03861884 36 38 O
give NCT03861884 39 43 O
informed NCT03861884 44 52 O
consent NCT03861884 53 60 O
. NCT03861884 60 61 O

2 NCT03861884 65 66 O
. NCT03861884 66 67 O
Either NCT03861884 69 75 O
pathological NCT03861884 76 88 B-Procedure
, NCT03861884 89 90 O
genetic NCT03861884 91 98 B-Procedure
or NCT03861884 99 101 B-Or
imaging NCT03861884 102 109 B-Procedure
biomarker NCT03861884 110 119 O
evidence NCT03861884 120 128 O
to NCT03861884 129 131 O
suggest NCT03861884 132 139 O
Fronto NCT03861884 140 146 B-Condition
- NCT03861884 147 148 I-Condition
temporal NCT03861884 149 157 I-Condition
Lobar NCT03861884 158 163 I-Condition
Degeneration NCT03861884 164 176 I-Condition
, NCT03861884 177 178 O
Alzheimer NCT03861884 179 188 B-Condition
's NCT03861884 188 190 O
Disease NCT03861884 191 198 I-Condition
or NCT03861884 199 201 B-Or
Vascular NCT03861884 202 210 B-Modifier
Cognitive NCT03861884 211 220 B-Condition
Impairment NCT03861884 221 231 I-Condition
, NCT03861884 232 233 O
or NCT03861884 234 236 O
defined NCT03861884 237 244 O
clinical NCT03861884 245 253 O
diagnoses NCT03861884 254 263 O
. NCT03861884 263 264 O

Exclusion NCT03861884 266 275 O
Criteria NCT03861884 276 284 O
: NCT03861884 285 286 O

1 NCT03861884 290 291 O
. NCT03861884 291 292 O
Lack NCT03861884 294 298 B-Condition
of NCT03861884 299 301 I-Condition
mental NCT03861884 302 308 I-Condition
capacity NCT03861884 309 317 I-Condition
to NCT03861884 318 320 O
consent NCT03861884 321 328 O
to NCT03861884 329 331 O
study NCT03861884 332 337 O
involvement NCT03861884 338 349 O
. NCT03861884 349 350 O

2 NCT03861884 354 355 O
. NCT03861884 355 356 O
Not NCT03861884 358 361 B-Negation
speaking NCT03861884 362 370 O
English NCT03861884 371 378 O
before NCT03861884 379 385 B-Temporal-Connection___Temporal-Connection-Type-Value:before
age NCT03861884 386 389 B-Age
5 NCT03861884 390 391 B-Eq-Comparison
years NCT03861884 392 397 I-Eq-Comparison
. NCT03861884 397 398 O

3 NCT03861884 402 403 O
. NCT03861884 403 404 O
Learning NCT03861884 406 414 B-Condition
disability NCT03861884 415 425 I-Condition
. NCT03861884 425 426 O

4 NCT03861884 430 431 O
. NCT03861884 431 432 O
MRI NCT03861884 434 437 B-Procedure
contraindications NCT03861884 438 455 B-Contraindication

Inclusion NCT03866655 0 9 O
Criteria NCT03866655 10 18 O
: NCT03866655 19 20 O

- NCT03866655 24 25 O
female NCT03866655 27 33 O

- NCT03866655 36 37 O
adult NCT03866655 39 44 O
( NCT03866655 45 46 O
age NCT03866655 47 50 B-Age
18 NCT03866655 51 53 B-Eq-Comparison
years NCT03866655 54 59 I-Eq-Comparison
or NCT03866655 60 62 I-Eq-Comparison
over NCT03866655 63 67 I-Eq-Comparison
) NCT03866655 68 69 O

- NCT03866655 73 74 O
newly NCT03866655 76 81 B-Eq-Comparison
diagnosed NCT03866655 82 91 B-Coreference

- NCT03866655 94 95 O
early NCT03866655 97 102 B-Modifier
breast NCT03866655 103 109 I-Modifier
cancer NCT03866655 110 116 B-Condition

- NCT03866655 119 120 O
first NCT03866655 122 127 B-Eq-Comparison
primary NCT03866655 128 135 B-Modifier
cancer NCT03866655 136 142 B-Condition
diagnosis NCT03866655 143 152 O

- NCT03866655 155 156 O
under NCT03866655 158 163 B-Eq-Comparison
treatment NCT03866655 164 173 B-Procedure
at NCT03866655 174 176 O
one NCT03866655 177 180 O
of NCT03866655 181 183 O
the NCT03866655 184 187 O
participating NCT03866655 188 201 O
sites NCT03866655 202 207 O
. NCT03866655 207 208 O

Exclusion NCT03866655 210 219 O
Criteria NCT03866655 220 228 O
: NCT03866655 229 230 O

- NCT03866655 234 235 O
have NCT03866655 237 241 O
started NCT03866655 242 249 B-Eq-Comparison
anti NCT03866655 250 254 O
- NCT03866655 255 256 O
cancer NCT03866655 257 263 B-Condition
treatment NCT03866655 264 273 B-Procedure

- NCT03866655 276 277 O
private NCT03866655 279 286 O
patients NCT03866655 287 295 O

- NCT03866655 298 299 O
unable NCT03866655 301 307 B-Negation
to NCT03866655 308 310 O
read NCT03866655 311 315 O
or NCT03866655 316 318 O
write NCT03866655 319 324 O
in NCT03866655 325 327 O
English NCT03866655 328 335 O

- NCT03866655 338 339 O
significant NCT03866655 341 352 O
cognitive NCT03866655 353 362 B-Condition
impairment NCT03866655 363 373 I-Condition

- NCT03866655 376 377 O
poor NCT03866655 379 383 B-Condition
mental NCT03866655 384 390 I-Condition
health NCT03866655 391 397 I-Condition

- NCT03866655 400 401 O
do NCT03866655 403 405 O
not NCT03866655 406 409 O
have NCT03866655 410 414 O
access NCT03866655 415 421 O
to NCT03866655 422 424 O
the NCT03866655 425 428 O
internet NCT03866655 429 437 O

- NCT03866655 440 441 O
confirmed NCT03866655 443 452 O
metastatic NCT03866655 453 463 B-Condition
disease NCT03866655 464 471 I-Condition

Inclusion NCT03864718 0 9 O
Criteria NCT03864718 10 18 O
: NCT03864718 19 20 O

- NCT03864718 24 25 O
complex NCT03864718 27 34 B-Modifier
anal NCT03864718 35 39 B-Condition
fistula NCT03864718 40 47 I-Condition
according NCT03864718 48 57 O
to NCT03864718 58 60 O
Parks NCT03864718 61 66 O
classification NCT03864718 67 81 O

Exclusion NCT03864718 82 91 O
Criteria NCT03864718 92 100 O
: NCT03864718 101 102 O

- NCT03864718 106 107 O
Non NCT03864718 109 112 B-Negation
cryptoglandular NCT03864718 113 128 B-Condition
fistulas NCT03864718 129 137 I-Condition

- NCT03864718 140 141 O
acute NCT03864718 143 148 O
sepsis NCT03864718 149 155 B-Condition

- NCT03864718 158 159 O
inflammatory NCT03864718 161 173 B-Condition
bowel NCT03864718 174 179 I-Condition
diseases NCT03864718 180 188 I-Condition

- NCT03864718 191 192 O
simple NCT03864718 194 200 B-Condition
fistulas NCT03864718 201 209 I-Condition
( NCT03864718 210 211 O
defined NCT03864718 212 219 O
as NCT03864718 220 222 O
subcutaneous NCT03864718 223 235 B-Modifier
, NCT03864718 236 237 O
intersphincteric NCT03864718 238 254 B-Modifier
and NCT03864718 255 258 B-Or
low NCT03864718 259 262 B-Modifier
transsphincteric NCT03864718 263 279 I-Modifier
fistula NCT03864718 280 287 B-Condition
) NCT03864718 288 289 O

- NCT03864718 293 294 O
pregnant NCT03864718 296 304 B-Condition
patients NCT03864718 305 313 O

- NCT03864718 316 317 O
ASA NCT03864718 319 322 B-Condition
IV NCT03864718 323 325 B-Eq-Comparison

- NCT03864718 328 329 O
patients NCT03864718 331 339 B-Age
< NCT03864718 340 341 B-Eq-Comparison
18 NCT03864718 342 344 I-Eq-Comparison

- NCT03864718 348 349 O
immunocompromised NCT03864718 351 368 B-Condition

- NCT03864718 371 372 O
patients NCT03864718 374 382 O
who NCT03864718 383 386 O
refused NCT03864718 387 394 O
consent NCT03864718 395 402 O
. NCT03864718 402 403 O

Inclusion NCT03868644 0 9 O
Criteria NCT03868644 10 18 O
: NCT03868644 19 20 O

- NCT03868644 23 24 O
Youth NCT03868644 25 30 O
previously NCT03868644 31 41 B-Eq-Comparison
participated NCT03868644 42 54 O
in NCT03868644 55 57 O
an NCT03868644 58 60 O
earlier NCT03868644 61 68 O
study NCT03868644 69 74 B-Study
by NCT03868644 75 77 O
Duflo NCT03868644 78 83 O
, NCT03868644 84 85 O
Dupas NCT03868644 86 91 O
and NCT03868644 92 95 O
Kremer NCT03868644 96 102 O
in NCT03868644 103 105 O
328 NCT03868644 106 109 O
primary NCT03868644 110 117 O
schools NCT03868644 118 125 O
in NCT03868644 126 128 O
the NCT03868644 129 132 O
same NCT03868644 133 137 O
study NCT03868644 138 143 O
site NCT03868644 144 148 O
in NCT03868644 149 151 O
Western NCT03868644 152 159 O
Province NCT03868644 160 168 O
, NCT03868644 169 170 O
Kenya NCT03868644 171 176 O
who NCT03868644 177 180 O
consent NCT03868644 181 188 O
to NCT03868644 189 191 O

participate NCT03868644 192 203 O
. NCT03868644 203 204 O

Exclusion NCT03868644 206 215 O
Criteria NCT03868644 216 224 O
: NCT03868644 225 226 O

- NCT03868644 229 230 O
Youth NCT03868644 231 236 O
sampled NCT03868644 237 244 O
for NCT03868644 245 248 O
the NCT03868644 249 252 O
study NCT03868644 253 258 O
who NCT03868644 259 262 O
do NCT03868644 263 265 O
not NCT03868644 266 269 O
consent NCT03868644 270 277 O
to NCT03868644 278 280 O
participate NCT03868644 281 292 O
. NCT03868644 292 293 O

Inclusion NCT03863847 0 9 O
Criteria NCT03863847 10 18 O
: NCT03863847 19 20 O

- NCT03863847 24 25 O
Patients NCT03863847 27 35 O
suffering NCT03863847 36 45 O
from NCT03863847 46 50 O
chronic NCT03863847 51 58 B-Modifier
pain NCT03863847 59 63 B-Condition
due NCT03863847 64 67 O
to NCT03863847 68 70 O
tennis NCT03863847 71 77 B-Condition
elbow NCT03863847 78 83 I-Condition
for NCT03863847 84 87 O
at NCT03863847 88 90 B-Eq-Comparison
least NCT03863847 91 96 I-Eq-Comparison
3 NCT03863847 97 98 I-Eq-Comparison
months NCT03863847 99 105 I-Eq-Comparison

- NCT03863847 108 109 O
A NCT03863847 111 112 O
clinical NCT03863847 113 121 O
diagnosis NCT03863847 122 131 O
of NCT03863847 132 134 O
chronic NCT03863847 135 142 B-Modifier
lateral NCT03863847 143 150 B-Condition
epicondylalgia NCT03863847 151 165 I-Condition
, NCT03863847 166 167 O

- NCT03863847 171 172 O
Pain NCT03863847 174 178 B-Condition
associated NCT03863847 179 189 O
with NCT03863847 190 194 O
functional NCT03863847 195 205 B-Observation
activities NCT03863847 206 216 I-Observation
such NCT03863847 217 221 O
as NCT03863847 222 224 O
gripping NCT03863847 225 233 B-Observation
and NCT03863847 234 237 B-Or
pain NCT03863847 238 242 B-Condition
with NCT03863847 243 247 O
resisted NCT03863847 248 256 B-Observation
contraction NCT03863847 257 268 I-Observation
of NCT03863847 269 271 O
the NCT03863847 272 275 O
wrist NCT03863847 276 281 B-Modifier
extensors NCT03863847 282 291 I-Modifier
or NCT03863847 292 294 B-Or
extensor NCT03863847 295 303 B-Modifier
carpi NCT03863847 304 309 I-Modifier
radialis NCT03863847 310 318 B-Condition
brevis NCT03863847 319 325 I-Condition
, NCT03863847 326 327 O
or NCT03863847 328 330 B-Or
with NCT03863847 331 335 O
passive NCT03863847 336 343 B-Observation
stretching NCT03863847 344 354 I-Observation
of NCT03863847 355 357 O
the NCT03863847 358 361 O
wrist NCT03863847 362 367 B-Modifier
extensors NCT03863847 368 377 I-Modifier
. NCT03863847 377 378 O

Exclusion NCT03863847 380 389 O
Criteria NCT03863847 390 398 O
: NCT03863847 399 400 O

- NCT03863847 404 405 O
Clinical NCT03863847 407 415 O
diagnosis NCT03863847 416 425 O
of NCT03863847 426 428 O
chronic NCT03863847 429 436 B-Modifier
lateral NCT03863847 437 444 B-Condition
epicondylalgia NCT03863847 445 459 I-Condition
on NCT03863847 460 462 O
both NCT03863847 463 467 B-Modifier
sides NCT03863847 468 473 I-Modifier
, NCT03863847 474 475 O
cervicothoracic NCT03863847 476 491 B-Modifier
spinal NCT03863847 492 498 I-Modifier
pathology NCT03863847 499 508 B-Condition
, NCT03863847 509 510 O
other NCT03863847 511 516 B-Other
upper NCT03863847 517 522 B-Modifier
limb NCT03863847 523 527 I-Modifier
musculoskeletal NCT03863847 528 543 B-Condition
disorders NCT03863847 544 553 I-Condition
or NCT03863847 554 556 B-Or
neurological NCT03863847 557 569 B-Condition
disorders NCT03863847 570 579 I-Condition

- NCT03863847 582 583 O
Pregnancy NCT03863847 585 594 B-Condition

- NCT03863847 597 598 O
Drug NCT03863847 600 604 B-Condition
addiction NCT03863847 605 614 I-Condition
defined NCT03863847 615 622 O
as NCT03863847 623 625 O
the NCT03863847 626 629 O
use NCT03863847 630 633 O
of NCT03863847 634 636 O
cannabis NCT03863847 637 645 B-Drug
, NCT03863847 646 647 O
opioids NCT03863847 648 655 B-Drug
or NCT03863847 656 658 B-Or
other NCT03863847 659 664 B-Other
drugs NCT03863847 665 670 B-Drug

- NCT03863847 673 674 O
Previous NCT03863847 676 684 B-Eq-Comparison
or NCT03863847 685 687 B-Or
current NCT03863847 688 695 B-Eq-Comparison
neurologic NCT03863847 696 706 B-Modifier
, NCT03863847 707 708 O
musculoskeletal NCT03863847 709 724 B-Modifier
or NCT03863847 725 727 B-Or
mental NCT03863847 728 734 B-Modifier
illnesses NCT03863847 735 744 B-Condition
defined NCT03863847 745 752 O
as NCT03863847 753 755 O
an NCT03863847 756 758 O
on NCT03863847 759 761 B-Eq-Comparison
- NCT03863847 762 763 I-Eq-Comparison
going NCT03863847 764 769 I-Eq-Comparison
systemic NCT03863847 770 778 B-Modifier
condition NCT03863847 779 788 B-Condition

- NCT03863847 791 792 O
Lack NCT03863847 794 798 B-Negation
of NCT03863847 799 801 O
ability NCT03863847 802 809 B-Condition
to NCT03863847 810 812 I-Condition
cooperate NCT03863847 813 822 I-Condition

- NCT03863847 825 826 O
Current NCT03863847 828 835 B-Eq-Comparison
use NCT03863847 836 839 O
of NCT03863847 840 842 O
medications NCT03863847 843 854 B-Drug
that NCT03863847 855 859 O
may NCT03863847 860 863 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03863847 864 870 O
the NCT03863847 871 874 O
trial NCT03863847 875 880 B-Study
e. NCT03863847 881 883 O
g. NCT03863847 884 886 O
analgesics NCT03863847 888 898 B-Drug
, NCT03863847 899 900 O
anti NCT03863847 901 905 B-Drug
- NCT03863847 906 907 I-Drug
inflammatory NCT03863847 908 920 I-Drug
drugs NCT03863847 921 926 I-Drug

- NCT03863847 929 930 O
Consumption NCT03863847 932 943 O
of NCT03863847 944 946 O
alcohol NCT03863847 947 954 B-Drug
, NCT03863847 955 956 O
caffeine NCT03863847 957 965 B-Drug
, NCT03863847 966 967 O
nicotine NCT03863847 968 976 B-Drug
or NCT03863847 977 979 B-Or
painkillers NCT03863847 980 991 B-Drug
throughout NCT03863847 992 1002 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863847 1003 1006 O
study NCT03863847 1007 1012 B-Study
period NCT03863847 1013 1019 O

- NCT03863847 1022 1023 O
Past NCT03863847 1025 1029 B-Eq-Comparison
history NCT03863847 1030 1037 I-Eq-Comparison
of NCT03863847 1038 1040 O
chronic NCT03863847 1041 1048 B-Modifier
pain NCT03863847 1049 1053 B-Condition
, NCT03863847 1054 1055 O
neurological NCT03863847 1056 1068 B-Modifier
or NCT03863847 1069 1071 B-Or
psychiatric NCT03863847 1072 1083 B-Modifier
conditions NCT03863847 1084 1094 B-Condition

- NCT03863847 1097 1098 O
Participation NCT03863847 1100 1113 O
in NCT03863847 1114 1116 O
other NCT03863847 1117 1122 B-Other
pain NCT03863847 1123 1127 B-Condition
trials NCT03863847 1128 1134 B-Study
throughout NCT03863847 1135 1145 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863847 1146 1149 O
study NCT03863847 1150 1155 B-Study
period NCT03863847 1156 1162 O
and NCT03863847 1163 1166 B-Or
one NCT03863847 1167 1170 B-Eq-Comparison
month NCT03863847 1171 1176 I-Eq-Comparison
prior NCT03863847 1177 1182 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863847 1183 1185 I-Temporal-Connection___Temporal-Connection-Type-Value:before
participation NCT03863847 1186 1199 B-Study

- NCT03863847 1202 1203 O
Participation NCT03863847 1205 1218 O
in NCT03863847 1219 1221 O
more NCT03863847 1222 1226 B-Eq-Comparison
than NCT03863847 1227 1231 I-Eq-Comparison
two NCT03863847 1232 1235 I-Eq-Comparison
sessions NCT03863847 1236 1244 O
of NCT03863847 1245 1247 O
muscle NCT03863847 1248 1254 B-Observation
training NCT03863847 1255 1263 I-Observation
exercises NCT03863847 1264 1273 B-Eq-Comparison
per NCT03863847 1274 1277 I-Eq-Comparison
week NCT03863847 1278 1282 I-Eq-Comparison
involving NCT03863847 1283 1292 O
the NCT03863847 1293 1296 O
upper NCT03863847 1297 1302 B-Modifier
limb NCT03863847 1303 1307 I-Modifier
and NCT03863847 1308 1311 B-Or
/ NCT03863847 1312 1313 I-Or
or NCT03863847 1314 1316 I-Or
lower NCT03863847 1317 1322 B-Modifier
back NCT03863847 1323 1327 I-Modifier

- NCT03863847 1330 1331 O
Evidence NCT03863847 1333 1341 O
of NCT03863847 1342 1344 O
other NCT03863847 1345 1350 B-Other
sources NCT03863847 1351 1358 O
of NCT03863847 1359 1361 O
elbow NCT03863847 1362 1367 B-Modifier
pain NCT03863847 1368 1372 B-Condition
such NCT03863847 1373 1377 O
as NCT03863847 1378 1380 O
exacerbation NCT03863847 1381 1393 O
of NCT03863847 1394 1396 O
pain NCT03863847 1397 1401 B-Condition
with NCT03863847 1402 1406 O
neck NCT03863847 1407 1411 B-Observation
movement NCT03863847 1412 1420 I-Observation
or NCT03863847 1421 1423 B-Or
manual NCT03863847 1424 1430 B-Modifier
examination NCT03863847 1431 1442 B-Procedure

- NCT03863847 1445 1446 O
Sensory NCT03863847 1448 1455 B-Condition
disturbances NCT03863847 1456 1468 I-Condition

- NCT03863847 1471 1472 O
History NCT03863847 1474 1481 B-Eq-Comparison
of NCT03863847 1482 1484 O
fractures NCT03863847 1485 1494 B-Condition

- NCT03863847 1497 1498 O
Elbow NCT03863847 1500 1505 B-Procedure
surgery NCT03863847 1506 1513 I-Procedure

- NCT03863847 1516 1517 O
Contraindications NCT03863847 1519 1536 B-Contraindication
to NCT03863847 1537 1539 O
the NCT03863847 1540 1543 O
use NCT03863847 1544 1547 O
of NCT03863847 1548 1550 O
TMS NCT03863847 1551 1554 B-Procedure

Inclusion NCT03868735 0 9 O
Criteria NCT03868735 10 18 O
: NCT03868735 19 20 O

- NCT03868735 24 25 O
Orally NCT03868735 27 33 B-Modifier
intubated NCT03868735 34 43 B-Procedure
patient NCT03868735 44 51 O
with NCT03868735 52 56 O
endotracheal NCT03868735 57 69 B-Procedure
tube NCT03868735 70 74 I-Procedure

- NCT03868735 77 78 O
Mechanically NCT03868735 80 92 B-Procedure
ventilated NCT03868735 93 103 I-Procedure
less NCT03868735 104 108 B-Eq-Comparison
than NCT03868735 109 113 I-Eq-Comparison
24 NCT03868735 114 116 I-Eq-Comparison
hours NCT03868735 117 122 I-Eq-Comparison
prior NCT03868735 123 128 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868735 129 131 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03868735 132 142 B-Study

Exclusion NCT03868735 143 152 O
Criteria NCT03868735 153 161 O
: NCT03868735 162 163 O

- NCT03868735 167 168 O
Less NCT03868735 170 174 B-Eq-Comparison
than NCT03868735 175 179 I-Eq-Comparison
18 NCT03868735 180 182 I-Eq-Comparison
years NCT03868735 183 188 I-Eq-Comparison
old NCT03868735 189 192 B-Age

- NCT03868735 195 196 O
Tracheostomy NCT03868735 198 210 B-Procedure
tube NCT03868735 211 215 I-Procedure

- NCT03868735 218 219 O
Extracorporeal NCT03868735 221 235 B-Procedure
membrane NCT03868735 236 244 I-Procedure
oxygenation NCT03868735 245 256 I-Procedure

- NCT03868735 259 260 O
Transfer NCT03868735 262 270 B-Encounter
from NCT03868735 271 275 O
outside NCT03868735 276 283 B-Other
hospital NCT03868735 284 292 O
with NCT03868735 293 297 B-Temporal-Connection___Temporal-Connection-Type-Value:during
more NCT03868735 298 302 B-Eq-Comparison
than NCT03868735 303 307 I-Eq-Comparison
24 NCT03868735 308 310 I-Eq-Comparison
hours NCT03868735 311 316 I-Eq-Comparison
of NCT03868735 317 319 O
mechanical NCT03868735 320 330 B-Procedure
ventilation NCT03868735 331 342 I-Procedure

Inclusion NCT03869359 0 9 O
Criteria NCT03869359 10 18 O
: NCT03869359 19 20 O

- NCT03869359 24 25 O
Adult NCT03869359 27 32 O
patients NCT03869359 33 41 O
with NCT03869359 42 46 B-And
IBS NCT03869359 47 50 B-Condition
according NCT03869359 51 60 O
to NCT03869359 61 63 O
Rome NCT03869359 64 68 O
IV NCT03869359 69 71 O
criteria NCT03869359 72 80 O

Exclusion NCT03869359 81 90 O
Criteria NCT03869359 91 99 O
: NCT03869359 100 101 O

- NCT03869359 105 106 O
allergy NCT03869359 108 115 B-Allergy
or NCT03869359 116 118 B-Or
documented NCT03869359 119 129 O
intolerance NCT03869359 130 141 B-Condition
to NCT03869359 142 144 O
food NCT03869359 145 149 B-Modifier
, NCT03869359 150 151 O

- NCT03869359 155 156 O
severe NCT03869359 158 164 O
cardiovascular NCT03869359 165 179 B-Modifier
, NCT03869359 180 181 O
hepatic NCT03869359 182 189 B-Modifier
, NCT03869359 190 191 O
neurological NCT03869359 192 204 B-Modifier
or NCT03869359 205 207 B-Or
psychiatric NCT03869359 208 219 B-Modifier
disease NCT03869359 220 227 B-Condition

- NCT03869359 230 231 O
serious NCT03869359 233 240 O
gastrointestinal NCT03869359 241 257 B-Condition
disease NCT03869359 258 265 I-Condition
: NCT03869359 266 267 O
including NCT03869359 268 277 O
celiac NCT03869359 278 284 B-Condition
disease NCT03869359 285 292 I-Condition
and NCT03869359 293 296 B-Or
inflammatory NCT03869359 297 309 B-Condition
bowel NCT03869359 310 315 I-Condition
diseases NCT03869359 316 324 I-Condition
( NCT03869359 325 326 O
IBD NCT03869359 327 330 B-Condition
) NCT03869359 331 332 O
, NCT03869359 334 335 O

- NCT03869359 339 340 O
diabetes NCT03869359 342 350 B-Condition

- NCT03869359 353 354 O
bowel NCT03869359 356 361 B-Condition
dysfunction NCT03869359 362 373 I-Condition
related NCT03869359 374 381 O
to NCT03869359 382 384 O
previous NCT03869359 385 393 B-Eq-Comparison
surgery NCT03869359 394 401 B-Procedure

- NCT03869359 404 405 O
pregnant NCT03869359 407 415 B-Condition
or NCT03869359 416 418 B-Or
lactating NCT03869359 419 428 B-Condition
women NCT03869359 429 434 O

- NCT03869359 437 438 O
usage NCT03869359 440 445 O
of NCT03869359 446 448 O
antibiotics NCT03869359 449 460 B-Drug
within NCT03869359 461 467 B-Eq-Comparison
4 NCT03869359 468 469 I-Eq-Comparison
weeks NCT03869359 470 475 I-Eq-Comparison
before NCT03869359 476 482 B-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03869359 483 492 B-Study

- NCT03869359 495 496 O
strict NCT03869359 498 504 O
avoidance NCT03869359 505 514 O
of NCT03869359 515 517 O
foods NCT03869359 518 523 O

Inclusion NCT03864133 0 9 O
Criteria NCT03864133 10 18 O
: NCT03864133 19 20 O

- NCT03864133 24 25 O
Adults NCT03864133 27 33 O
age NCT03864133 34 37 B-Age
55 NCT03864133 38 40 B-Eq-Comparison
- NCT03864133 41 42 I-Eq-Comparison
90 NCT03864133 43 45 I-Eq-Comparison
years NCT03864133 46 51 I-Eq-Comparison
with NCT03864133 52 56 B-And
visual NCT03864133 57 63 B-Modifier
significant NCT03864133 64 75 O
cataracts NCT03864133 76 85 B-Condition
in NCT03864133 86 88 O
one NCT03864133 89 92 B-Modifier
or NCT03864133 93 95 B-Or
both NCT03864133 96 100 B-Modifier
eyes NCT03864133 101 105 I-Modifier
. NCT03864133 105 106 O

- NCT03864133 110 111 O
Healthy NCT03864133 113 120 B-Condition
individuals NCT03864133 121 132 O
able NCT03864133 133 137 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864133 138 140 I-Assertion___Assertion-Type-Value:hypothetical
tolerate NCT03864133 141 149 O
outpatient NCT03864133 150 160 B-Encounter
cataract NCT03864133 161 169 B-Procedure
surgery NCT03864133 170 177 I-Procedure
under NCT03864133 178 183 O
local NCT03864133 184 189 B-Procedure
anesthesia NCT03864133 190 200 I-Procedure
via NCT03864133 201 204 O
either NCT03864133 205 211 O
phacoemulsification NCT03864133 212 231 B-Procedure
and NCT03864133 232 235 B-Or
/ NCT03864133 236 237 I-Or
or NCT03864133 238 240 I-Or
femtosecond NCT03864133 241 252 B-Modifier
assisted NCT03864133 253 261 I-Modifier
cataract NCT03864133 262 270 B-Procedure
surgery NCT03864133 271 278 I-Procedure
. NCT03864133 278 279 O
Well NCT03864133 281 285 O
- NCT03864133 286 287 O
controlled NCT03864133 288 298 O
diabetes NCT03864133 299 307 B-Condition
, NCT03864133 308 309 O
hypertension NCT03864133 310 322 B-Condition
will NCT03864133 323 327 O
be NCT03864133 328 330 O
included NCT03864133 331 339 O
. NCT03864133 339 340 O

- NCT03864133 344 345 O
Females NCT03864133 347 354 O
of NCT03864133 355 357 O
childbearing NCT03864133 358 370 B-Condition
potential NCT03864133 371 380 B-Assertion___Assertion-Type-Value:hypothetical
must NCT03864133 381 385 O
agree NCT03864133 386 391 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864133 392 394 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03864133 395 398 O
a NCT03864133 399 400 O
reliable NCT03864133 401 409 O
method NCT03864133 410 416 O
of NCT03864133 417 419 O
birth NCT03864133 420 425 B-Procedure
control NCT03864133 426 433 I-Procedure
while NCT03864133 434 439 B-Temporal-Connection___Temporal-Connection-Type-Value:during
participating NCT03864133 440 453 O
in NCT03864133 454 456 O
this NCT03864133 457 461 O
study NCT03864133 462 467 B-Study
. NCT03864133 467 468 O
Reliable NCT03864133 470 478 O
methods NCT03864133 479 486 O
of NCT03864133 487 489 O
birth NCT03864133 490 495 B-Procedure
control NCT03864133 496 503 I-Procedure
are NCT03864133 504 507 O
: NCT03864133 508 509 O
abstinence NCT03864133 510 520 B-Condition
, NCT03864133 521 522 O
oral NCT03864133 523 527 B-Drug
contraceptives NCT03864133 528 542 I-Drug
, NCT03864133 543 544 O
intrauterine NCT03864133 545 557 B-Procedure
device NCT03864133 558 564 I-Procedure
( NCT03864133 565 566 O
IUD NCT03864133 567 570 B-Procedure
) NCT03864133 571 572 O
, NCT03864133 574 575 O
DepoProvera NCT03864133 576 587 B-Procedure
, NCT03864133 588 589 O
tubal NCT03864133 590 595 B-Procedure
ligation NCT03864133 596 604 I-Procedure
or NCT03864133 605 607 B-Or
vasectomy NCT03864133 608 617 B-Procedure
of NCT03864133 618 620 O
the NCT03864133 621 624 O
partner NCT03864133 625 632 O
( NCT03864133 633 634 O
with NCT03864133 635 639 B-And
confirmed NCT03864133 640 649 O
negative NCT03864133 650 658 O
sperm NCT03864133 659 664 B-Observation
counts NCT03864133 665 671 I-Observation
) NCT03864133 672 673 O
in NCT03864133 674 676 B-And
monogamous NCT03864133 677 687 B-Condition
relationship NCT03864133 688 700 I-Condition
( NCT03864133 701 702 O
same NCT03864133 703 707 O
partner NCT03864133 708 715 O
) NCT03864133 716 717 O
. NCT03864133 718 719 O
An NCT03864133 721 723 O
acceptable NCT03864133 724 734 O
, NCT03864133 735 736 O
although NCT03864133 737 745 O
less NCT03864133 746 750 O
reliable NCT03864133 751 759 O
, NCT03864133 760 761 O
method NCT03864133 762 768 O
involves NCT03864133 769 777 O
the NCT03864133 778 781 O
careful NCT03864133 782 789 O
use NCT03864133 790 793 O
of NCT03864133 794 796 O
condoms NCT03864133 797 804 B-Procedure
and NCT03864133 805 808 B-Or|Or
spermicidal NCT03864133 809 820 B-Procedure
foam NCT03864133 821 825 B-Modifier
or NCT03864133 826 828 B-Or|Or|Or
gel NCT03864133 829 832 B-Modifier
and NCT03864133 833 836 O
/ NCT03864133 837 838 I-Or
or NCT03864133 839 841 O
cervical NCT03864133 842 850 B-Procedure
cap NCT03864133 851 854 B-Modifier
or NCT03864133 855 857 O
sponge NCT03864133 858 864 B-Modifier
. NCT03864133 864 865 O
A NCT03864133 867 868 O
pregnancy NCT03864133 869 878 B-Observation
test NCT03864133 879 883 I-Observation
is NCT03864133 884 886 B-Assertion___Assertion-Type-Value:hypothetical
required NCT03864133 887 895 I-Assertion___Assertion-Type-Value:hypothetical
at NCT03864133 896 898 B-Eq-Comparison
least NCT03864133 899 904 I-Eq-Comparison
10 NCT03864133 905 907 I-Eq-Comparison
days NCT03864133 908 912 I-Eq-Comparison
from NCT03864133 913 917 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03864133 918 921 O
last NCT03864133 922 926 B-Eq-Comparison
normal NCT03864133 927 933 O
menstrual NCT03864133 934 943 B-Condition
period NCT03864133 944 950 I-Condition
, NCT03864133 951 952 O
if NCT03864133 953 955 O
the NCT03864133 956 959 O
patient NCT03864133 960 967 O
is NCT03864133 968 970 O
a NCT03864133 971 972 O
sexually NCT03864133 973 981 B-Condition
active NCT03864133 982 988 I-Condition
female NCT03864133 989 995 O
of NCT03864133 996 998 B-And
childbearing NCT03864133 999 1011 B-Condition
potential NCT03864133 1012 1021 I-Condition
. NCT03864133 1021 1022 O

Exclusion NCT03864133 1024 1033 O
Criteria NCT03864133 1034 1042 O
: NCT03864133 1043 1044 O

- NCT03864133 1048 1049 O
Allergy NCT03864133 1051 1058 B-Allergy
to NCT03864133 1059 1061 O
Phenylephrine NCT03864133 1062 1075 B-Drug
or NCT03864133 1076 1078 B-Or
NSAIDs NCT03864133 1079 1085 B-Drug
. NCT03864133 1085 1086 O

- NCT03864133 1090 1091 O
Inability NCT03864133 1093 1102 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864133 1103 1105 O
sit NCT03864133 1106 1109 B-Observation
steady NCT03864133 1110 1116 B-Modifier
and NCT03864133 1117 1120 B-And
upright NCT03864133 1121 1128 B-Modifier
for NCT03864133 1129 1132 O
the NCT03864133 1133 1136 O
Optical NCT03864133 1137 1144 B-Procedure
Coherence NCT03864133 1145 1154 I-Procedure
Tomography NCT03864133 1155 1165 I-Procedure
( NCT03864133 1166 1167 O
OCT NCT03864133 1168 1171 B-Procedure
) NCT03864133 1172 1173 O
. NCT03864133 1174 1175 O

- NCT03864133 1179 1180 O
Complications NCT03864133 1182 1195 B-Condition
during NCT03864133 1196 1202 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgery NCT03864133 1203 1210 B-Procedure
, NCT03864133 1211 1212 O
including NCT03864133 1213 1222 O
posterior NCT03864133 1223 1232 B-Modifier
capsular NCT03864133 1233 1241 B-Condition
rupture NCT03864133 1242 1249 I-Condition
, NCT03864133 1250 1251 O
vitreous NCT03864133 1252 1260 B-Condition
loss NCT03864133 1261 1265 I-Condition
, NCT03864133 1266 1267 O
zonular NCT03864133 1268 1275 B-Procedure
dialysis NCT03864133 1276 1284 I-Procedure
, NCT03864133 1285 1286 O
or NCT03864133 1287 1289 B-Or
iris NCT03864133 1290 1294 B-Modifier
trauma NCT03864133 1295 1301 B-Condition
. NCT03864133 1301 1302 O

- NCT03864133 1306 1307 O
Macular NCT03864133 1309 1316 B-Observation
thickness NCT03864133 1317 1326 I-Observation
above NCT03864133 1327 1332 B-Eq-Comparison
300 NCT03864133 1333 1336 I-Eq-Comparison
microns NCT03864133 1337 1344 I-Eq-Comparison
at NCT03864133 1345 1347 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03864133 1348 1356 B-Study

- NCT03864133 1359 1360 O
Currently NCT03864133 1362 1371 B-Eq-Comparison
taking NCT03864133 1372 1378 I-Eq-Comparison
a NCT03864133 1379 1380 O
prostaglandin NCT03864133 1381 1394 B-Drug
analogue NCT03864133 1395 1403 I-Drug

- NCT03864133 1406 1407 O
Presence NCT03864133 1409 1417 O
of NCT03864133 1418 1420 O
an NCT03864133 1421 1423 O
epiretinal NCT03864133 1424 1434 B-Condition
membrane NCT03864133 1435 1443 I-Condition
on NCT03864133 1444 1446 O
the NCT03864133 1447 1450 O
pre NCT03864133 1451 1454 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864133 1455 1456 O
- NCT03864133 1458 1459 O
operative NCT03864133 1460 1469 B-Procedure
OCT NCT03864133 1470 1473 B-Procedure
. NCT03864133 1473 1474 O

- NCT03864133 1478 1479 O
Retained NCT03864133 1481 1489 B-Modifier
lens NCT03864133 1490 1494 B-Condition
fragment NCT03864133 1495 1503 I-Condition
post NCT03864133 1504 1508 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864133 1509 1510 O
- NCT03864133 1512 1513 O
operatively NCT03864133 1514 1525 O
. NCT03864133 1525 1526 O

- NCT03864133 1530 1531 O
Inability NCT03864133 1533 1542 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864133 1543 1545 O
return NCT03864133 1546 1552 O
for NCT03864133 1553 1556 O
follow NCT03864133 1557 1563 O
appointments NCT03864133 1564 1576 B-Encounter

- NCT03864133 1579 1580 O
Female NCT03864133 1582 1588 O
patients NCT03864133 1589 1597 O
who NCT03864133 1598 1601 B-And
are NCT03864133 1602 1605 O
pregnant NCT03864133 1606 1614 B-Condition|Condition
, NCT03864133 1615 1616 O
lactating NCT03864133 1617 1626 B-Condition
or NCT03864133 1627 1629 B-Or
planning NCT03864133 1630 1638 B-Assertion___Assertion-Type-Value:intention
to NCT03864133 1639 1641 I-Assertion___Assertion-Type-Value:intention
become NCT03864133 1642 1648 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03864133 1649 1657 O
during NCT03864133 1658 1664 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864133 1665 1668 O
course NCT03864133 1669 1675 O
of NCT03864133 1676 1678 O
treatment NCT03864133 1679 1688 B-Procedure
. NCT03864133 1688 1689 O

Inclusion NCT03868709 0 9 O
Criteria NCT03868709 10 18 O
: NCT03868709 19 20 O

1 NCT03868709 24 25 O
. NCT03868709 25 26 O
Age NCT03868709 28 31 B-Age
of NCT03868709 32 34 O
50 NCT03868709 35 37 B-Eq-Comparison
years NCT03868709 38 43 I-Eq-Comparison
or NCT03868709 44 46 I-Eq-Comparison
over NCT03868709 47 51 I-Eq-Comparison
; NCT03868709 51 52 O

2 NCT03868709 55 56 O
. NCT03868709 56 57 O
Scheduled NCT03868709 59 68 B-Eq-Comparison
to NCT03868709 69 71 I-Eq-Comparison
undergo NCT03868709 72 79 I-Eq-Comparison
open NCT03868709 80 84 B-Modifier
or NCT03868709 85 87 B-Or
laparoscope NCT03868709 88 99 B-Modifier
assisted NCT03868709 100 108 I-Modifier
upper NCT03868709 109 114 B-Modifier
abdominal NCT03868709 115 124 I-Modifier
or NCT03868709 125 127 B-Or
intrathoracic NCT03868709 128 141 B-Modifier
surgery NCT03868709 142 149 B-Procedure
; NCT03868709 149 150 O

3 NCT03868709 153 154 O
. NCT03868709 154 155 O
The NCT03868709 157 160 O
expected NCT03868709 161 169 B-Assertion___Assertion-Type-Value:hypothetical
duration NCT03868709 170 178 O
of NCT03868709 179 181 O
surgery NCT03868709 182 189 B-Procedure
is NCT03868709 190 192 O
2 NCT03868709 193 194 B-Eq-Comparison
hours NCT03868709 195 200 I-Eq-Comparison
or NCT03868709 201 203 I-Eq-Comparison
longer NCT03868709 204 210 I-Eq-Comparison
; NCT03868709 210 211 O

4 NCT03868709 214 215 O
. NCT03868709 215 216 O
Identified NCT03868709 218 228 O
at NCT03868709 229 231 O
high NCT03868709 232 236 O
risk NCT03868709 237 241 B-Risk
of NCT03868709 242 244 O
PPCs NCT03868709 245 249 B-Condition
according NCT03868709 250 259 O
to NCT03868709 260 262 O
the NCT03868709 263 266 O
ARISCAT NCT03868709 267 274 B-Observation
risk NCT03868709 275 279 I-Observation
score NCT03868709 280 285 I-Observation
( NCT03868709 286 287 O
ARISCAT NCT03868709 288 295 B-Observation
predictive NCT03868709 296 306 I-Observation
score NCT03868709 307 312 B-Eq-Comparison|Observation
≥ NCT03868709 313 314 I-Eq-Comparison
45 NCT03868709 315 317 I-Eq-Comparison
) NCT03868709 318 319 O
. NCT03868709 320 321 O

Exclusion NCT03868709 323 332 O
Criteria NCT03868709 333 341 O
: NCT03868709 342 343 O

1 NCT03868709 347 348 O
. NCT03868709 348 349 O
American NCT03868709 351 359 B-Condition
Society NCT03868709 360 367 I-Condition
of NCT03868709 368 370 I-Condition
Anesthesiologists NCT03868709 371 388 I-Condition
( NCT03868709 389 390 O
ASA NCT03868709 391 394 B-Condition
) NCT03868709 395 396 O
physical NCT03868709 397 405 O
classification NCT03868709 406 420 B-Eq-Comparison
≥ NCT03868709 421 422 I-Eq-Comparison
IV NCT03868709 423 425 I-Eq-Comparison
or NCT03868709 426 428 B-Or
the NCT03868709 429 432 O
expected NCT03868709 433 441 B-Observation
survival NCT03868709 442 450 I-Observation
duration NCT03868709 451 459 O
≤ NCT03868709 460 461 B-Eq-Comparison
24 NCT03868709 462 464 I-Eq-Comparison
h NCT03868709 465 466 I-Eq-Comparison
; NCT03868709 466 467 O

2 NCT03868709 470 471 O
. NCT03868709 471 472 O
Pre NCT03868709 474 477 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03868709 478 479 O
- NCT03868709 481 482 O
operative NCT03868709 483 492 B-Procedure
history NCT03868709 493 500 B-Eq-Comparison
of NCT03868709 501 503 O
prostatic NCT03868709 504 513 B-Condition
hypertrophy NCT03868709 514 525 I-Condition
or NCT03868709 526 528 B-Or
glaucoma NCT03868709 529 537 B-Condition
; NCT03868709 537 538 O

3 NCT03868709 541 542 O
. NCT03868709 542 543 O
History NCT03868709 545 552 B-Eq-Comparison
of NCT03868709 553 555 O
myocardial NCT03868709 556 566 B-Condition
infarction NCT03868709 567 577 I-Condition
, NCT03868709 578 579 O
severe NCT03868709 580 586 O
heart NCT03868709 587 592 B-Condition
dysfunction NCT03868709 593 604 I-Condition
( NCT03868709 605 606 O
New NCT03868709 607 610 B-Condition
York NCT03868709 611 615 I-Condition
Heart NCT03868709 616 621 I-Condition
Association NCT03868709 622 633 I-Condition
functional NCT03868709 634 644 I-Condition
classification NCT03868709 645 659 B-Eq-Comparison
≥ NCT03868709 660 661 I-Eq-Comparison
3 NCT03868709 662 663 I-Eq-Comparison
) NCT03868709 664 665 O
or NCT03868709 666 668 B-Or
tachyarrhythmia NCT03868709 669 684 B-Condition
within NCT03868709 685 691 B-Eq-Comparison
one NCT03868709 692 695 I-Eq-Comparison
year NCT03868709 696 700 I-Eq-Comparison
; NCT03868709 700 701 O

4 NCT03868709 704 705 O
. NCT03868709 705 706 O
Inhalation NCT03868709 708 718 O
of NCT03868709 719 721 O
β2 NCT03868709 722 724 B-Drug
- NCT03868709 725 726 I-Drug|Drug
receptor NCT03868709 727 735 I-Drug|Drug
activator NCT03868709 736 745 I-Drug
, NCT03868709 746 747 O
M NCT03868709 748 749 B-Drug
- NCT03868709 750 751 O
receptor NCT03868709 752 760 O
blockers NCT03868709 761 769 I-Drug
and NCT03868709 770 773 B-Or
/ NCT03868709 774 775 I-Or
or NCT03868709 776 778 I-Or
glucocorticoids NCT03868709 779 794 B-Drug
within NCT03868709 795 801 B-Eq-Comparison
one NCT03868709 802 805 I-Eq-Comparison
month NCT03868709 806 811 I-Eq-Comparison
before NCT03868709 812 818 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03868709 819 826 B-Procedure
; NCT03868709 826 827 O

5 NCT03868709 830 831 O
. NCT03868709 831 832 O
Severe NCT03868709 834 840 O
renal NCT03868709 841 846 B-Condition|Procedure
dysfunction NCT03868709 847 858 I-Condition
( NCT03868709 859 860 O
requirement NCT03868709 861 872 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03868709 873 875 O
renal NCT03868709 876 881 O
replacement NCT03868709 882 893 I-Procedure
therapy NCT03868709 894 901 I-Procedure
) NCT03868709 902 903 O
or NCT03868709 904 906 B-Or
severe NCT03868709 907 913 O
hepatic NCT03868709 914 921 B-Condition
dysfunction NCT03868709 922 933 I-Condition
( NCT03868709 934 935 O
Child NCT03868709 936 941 B-Eq-Comparison|Observation
- NCT03868709 942 943 I-Observation
Pugh NCT03868709 944 948 I-Observation
grade NCT03868709 949 954 B-Eq-Comparison
C NCT03868709 955 956 O
) NCT03868709 957 958 O
; NCT03868709 959 960 O

6 NCT03868709 963 964 O
. NCT03868709 964 965 O
History NCT03868709 967 974 B-Eq-Comparison
of NCT03868709 975 977 O
acute NCT03868709 978 983 O
stroke NCT03868709 984 990 B-Condition
within NCT03868709 991 997 B-Eq-Comparison
three NCT03868709 998 1003 I-Eq-Comparison
months NCT03868709 1004 1010 I-Eq-Comparison
before NCT03868709 1011 1017 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03868709 1018 1025 B-Procedure
; NCT03868709 1025 1026 O

7 NCT03868709 1029 1030 O
. NCT03868709 1030 1031 O
Refuse NCT03868709 1033 1039 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868709 1040 1042 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868709 1043 1054 O
in NCT03868709 1055 1057 B-Procedure
the NCT03868709 1058 1061 I-Procedure
study NCT03868709 1062 1067 B-Study
or NCT03868709 1068 1070 B-Or
unable NCT03868709 1071 1077 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868709 1078 1080 O
cooperate NCT03868709 1081 1090 O
with NCT03868709 1091 1095 O
the NCT03868709 1096 1099 O
inhalation NCT03868709 1100 1110 O
therapy NCT03868709 1111 1118 O
; NCT03868709 1118 1119 O

8 NCT03868709 1122 1123 O
. NCT03868709 1123 1124 O
Participation NCT03868709 1126 1139 O
in NCT03868709 1140 1142 O
other NCT03868709 1143 1148 B-Other
clinical NCT03868709 1149 1157 B-Study
trial NCT03868709 1158 1163 I-Study
during NCT03868709 1164 1170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868709 1171 1174 I-Eq-Comparison
last NCT03868709 1175 1179 B-Eq-Comparison
month NCT03868709 1180 1185 I-Eq-Comparison
or NCT03868709 1186 1188 B-Or
within NCT03868709 1189 1195 B-Eq-Comparison
the NCT03868709 1196 1199 O
six NCT03868709 1200 1203 I-Eq-Comparison
half NCT03868709 1204 1208 I-Eq-Comparison
- NCT03868709 1209 1210 I-Eq-Comparison
life NCT03868709 1211 1215 I-Eq-Comparison
periods NCT03868709 1216 1223 B-Temporal-Connection___Temporal-Connection-Type-Value:before
of NCT03868709 1224 1226 O
the NCT03868709 1227 1230 O
study NCT03868709 1231 1236 B-Study
drug NCT03868709 1237 1241 B-Drug
used NCT03868709 1242 1246 B-Temporal-Connection___Temporal-Connection-Type-Value:during
in NCT03868709 1247 1249 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868709 1250 1253 O
last NCT03868709 1254 1258 B-Eq-Comparison
trial NCT03868709 1259 1264 B-Study
. NCT03868709 1264 1265 O

Inclusion NCT03860194 0 9 O
Criteria NCT03860194 10 18 O
: NCT03860194 19 20 O

- NCT03860194 24 25 O
Older NCT03860194 27 32 O
adults NCT03860194 33 39 O
( NCT03860194 40 41 O
≥ NCT03860194 43 44 B-Eq-Comparison
65 NCT03860194 45 47 I-Eq-Comparison
years NCT03860194 48 53 I-Age|Eq-Comparison
) NCT03860194 54 55 O

- NCT03860194 59 60 O
Subject NCT03860194 62 69 O
has NCT03860194 70 73 O
lower NCT03860194 74 79 B-Observation
appendicular NCT03860194 80 92 I-Observation
muscle NCT03860194 93 99 I-Observation
mass NCT03860194 100 104 I-Observation
index NCT03860194 105 110 I-Observation
( NCT03860194 111 112 O
AMMI NCT03860194 113 117 B-Observation
) NCT03860194 118 119 O
( NCT03860194 120 121 O
< NCT03860194 123 124 B-Eq-Comparison
7 NCT03860194 125 126 I-Eq-Comparison
kg NCT03860194 127 129 I-Eq-Comparison
/ NCT03860194 130 131 I-Eq-Comparison
m^2 NCT03860194 132 135 I-Eq-Comparison
in NCT03860194 136 138 O
men NCT03860194 139 142 O
; NCT03860194 142 143 O
< NCT03860194 144 145 B-Eq-Comparison
5.7 NCT03860194 146 149 I-Eq-Comparison
kg NCT03860194 150 152 I-Eq-Comparison
/ NCT03860194 153 154 I-Eq-Comparison
m^2 NCT03860194 155 158 I-Eq-Comparison
in NCT03860194 159 161 O
women NCT03860194 162 167 O
) NCT03860194 168 169 O
using NCT03860194 170 175 O
Bioelectrical NCT03860194 176 189 B-Procedure
impedance NCT03860194 190 199 I-Procedure
analysis NCT03860194 200 208 I-Procedure
( NCT03860194 209 210 O
BIA NCT03860194 211 214 O
, NCT03860194 215 216 O
TANITA NCT03860194 217 223 O
BC NCT03860194 224 226 O
- NCT03860194 227 228 O
418 NCT03860194 229 232 O
® NCT03860194 233 234 O
, NCT03860194 235 236 O
Tokyo NCT03860194 237 242 O
, NCT03860194 243 244 O
Japan NCT03860194 245 250 O
) NCT03860194 251 252 O

- NCT03860194 256 257 O
Subject NCT03860194 259 266 O
has NCT03860194 267 270 O
lower NCT03860194 271 276 B-Observation
handgrip NCT03860194 277 285 I-Observation
strength NCT03860194 286 294 I-Observation
( NCT03860194 295 296 O
< NCT03860194 298 299 B-Eq-Comparison|Eq-Comparison
26 NCT03860194 300 302 I-Eq-Comparison
kg NCT03860194 303 305 I-Eq-Comparison|Eq-Comparison
in NCT03860194 306 308 O
men NCT03860194 309 312 O
; NCT03860194 312 313 O
< NCT03860194 314 315 O
18 NCT03860194 316 318 I-Eq-Comparison
kg NCT03860194 319 321 O
in NCT03860194 322 324 O
women NCT03860194 325 330 O
) NCT03860194 331 332 O
using NCT03860194 333 338 O
dynamometer NCT03860194 339 350 B-Procedure
( NCT03860194 351 352 O
CAMRY NCT03860194 353 358 O
® NCT03860194 358 359 O
, NCT03860194 360 361 O
Zhongshan NCT03860194 362 371 O
, NCT03860194 372 373 O
Guangdong NCT03860194 374 383 O
) NCT03860194 384 385 O
or NCT03860194 386 388 B-Or
slowly NCT03860194 389 395 I-Eq-Comparison
gait NCT03860194 396 400 B-Observation
speed NCT03860194 401 406 I-Observation
( NCT03860194 407 408 O
< NCT03860194 410 411 B-Eq-Comparison
1 NCT03860194 412 413 I-Eq-Comparison
m NCT03860194 414 415 I-Eq-Comparison
/ NCT03860194 416 417 I-Eq-Comparison
s NCT03860194 418 419 O
) NCT03860194 420 421 O

Exclusion NCT03860194 423 432 O
Criteria NCT03860194 433 441 O
: NCT03860194 442 443 O

- NCT03860194 447 448 O
Subject NCT03860194 450 457 O
's NCT03860194 457 459 O
life NCT03860194 460 464 B-Observation
expectancy NCT03860194 465 475 I-Observation
was NCT03860194 476 479 O
shorter NCT03860194 480 487 B-Eq-Comparison
than NCT03860194 488 492 I-Eq-Comparison
6 NCT03860194 493 494 I-Eq-Comparison
months NCT03860194 495 501 I-Eq-Comparison

- NCT03860194 504 505 O
Nursing NCT03860194 507 514 O
home NCT03860194 515 519 O
resident NCT03860194 520 528 O

- NCT03860194 531 532 O
Subject NCT03860194 534 541 O
has NCT03860194 542 545 O
the NCT03860194 546 549 O
history NCT03860194 550 557 B-Eq-Comparison
of NCT03860194 558 560 O
kidney NCT03860194 561 567 B-Condition
failure NCT03860194 568 575 I-Condition

- NCT03860194 578 579 O
Subject NCT03860194 581 588 O
has NCT03860194 589 592 O
the NCT03860194 593 596 O
history NCT03860194 597 604 B-Eq-Comparison
of NCT03860194 605 607 O
liver NCT03860194 608 613 B-Condition
failure NCT03860194 614 621 I-Condition

- NCT03860194 624 625 O
Subject NCT03860194 627 634 O
has NCT03860194 635 638 O
the NCT03860194 639 642 O
history NCT03860194 643 650 B-Eq-Comparison
of NCT03860194 651 653 O
diabetes NCT03860194 654 662 B-Condition
mellitus NCT03860194 663 671 I-Condition

- NCT03860194 674 675 O
Subject NCT03860194 677 684 O
has NCT03860194 685 688 O
resistance NCT03860194 689 699 B-Observation
exercise NCT03860194 700 708 I-Observation
habit NCT03860194 709 714 O
. NCT03860194 714 715 O

Inclusion NCT03867604 0 9 O
Criteria NCT03867604 10 18 O
: NCT03867604 19 20 O

- NCT03867604 24 25 O
20 NCT03867604 27 29 B-Eq-Comparison
- NCT03867604 30 31 I-Eq-Comparison
70 NCT03867604 32 34 I-Eq-Comparison
years NCT03867604 35 40 I-Eq-Comparison
old NCT03867604 41 44 B-Age

- NCT03867604 47 48 O
diagnosed NCT03867604 50 59 O
as NCT03867604 60 62 O
a NCT03867604 63 64 O
myofascial NCT03867604 65 75 B-Condition
pain NCT03867604 76 80 I-Condition
syndrome NCT03867604 81 89 I-Condition
at NCT03867604 90 92 O
upper NCT03867604 93 98 B-Modifier
trapezium NCT03867604 99 108 I-Modifier
muscle NCT03867604 109 115 I-Modifier

- NCT03867604 118 119 O
trigger NCT03867604 121 128 B-Condition
point NCT03867604 129 134 I-Condition

- NCT03867604 137 138 O
taut NCT03867604 140 144 B-Condition
band NCT03867604 145 149 I-Condition

- NCT03867604 152 153 O
refer NCT03867604 155 160 O
pain NCT03867604 161 165 B-Condition
while NCT03867604 166 171 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taut NCT03867604 172 176 B-Condition
band NCT03867604 177 181 I-Condition
irritation NCT03867604 182 192 I-Condition

Exclusion NCT03867604 193 202 O
Criteria NCT03867604 203 211 O
: NCT03867604 212 213 O

- NCT03867604 217 218 O
Cognitive NCT03867604 220 229 B-Condition
impairment NCT03867604 230 240 I-Condition
. NCT03867604 240 241 O

- NCT03867604 245 246 O
Post NCT03867604 248 252 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operation NCT03867604 253 262 B-Procedure
at NCT03867604 263 265 O
neck NCT03867604 266 270 B-Modifier
and NCT03867604 271 274 B-Or
shoulder NCT03867604 275 283 B-Modifier
. NCT03867604 283 284 O

- NCT03867604 288 289 O
Nerve NCT03867604 291 296 B-Condition
compression NCT03867604 297 308 I-Condition
at NCT03867604 309 311 O
cervical NCT03867604 312 320 B-Modifier
region NCT03867604 321 327 I-Modifier
. NCT03867604 327 328 O

- NCT03867604 332 333 O
Could NCT03867604 335 340 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03867604 341 344 B-Negation
receive NCT03867604 345 352 O
injection NCT03867604 353 362 B-Procedure
therapy NCT03867604 363 370 I-Procedure
, NCT03867604 371 372 O
history NCT03867604 373 380 B-Eq-Comparison
of NCT03867604 381 383 O
fainting NCT03867604 384 392 B-Condition
during NCT03867604 393 399 B-Temporal-Connection___Temporal-Connection-Type-Value:during
needling NCT03867604 400 408 B-Procedure

Inclusion NCT03861507 0 9 O
Criteria NCT03861507 10 18 O
: NCT03861507 19 20 O

- NCT03861507 24 25 O
Male NCT03861507 27 31 O
, NCT03861507 32 33 O
aged NCT03861507 34 38 B-Age
18 NCT03861507 39 41 B-Eq-Comparison
years NCT03861507 42 47 I-Eq-Comparison
or NCT03861507 48 50 I-Eq-Comparison
older NCT03861507 51 56 I-Eq-Comparison

- NCT03861507 59 60 O
Willing NCT03861507 62 69 O
to NCT03861507 70 72 O
provide NCT03861507 73 80 O
written NCT03861507 81 88 O
consent NCT03861507 89 96 O

- NCT03861507 99 100 O
Pathologically NCT03861507 102 116 B-Procedure
confirmed NCT03861507 117 126 O
prostate NCT03861507 127 135 B-Modifier
cancer NCT03861507 136 142 B-Condition
on NCT03861507 143 145 O
previous NCT03861507 146 154 B-Eq-Comparison
biopsy NCT03861507 155 161 B-Procedure

- NCT03861507 164 165 O
Suitable NCT03861507 167 175 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861507 176 179 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03861507 180 183 O
consenting NCT03861507 184 194 O
to NCT03861507 195 197 O
high NCT03861507 198 202 B-Modifier
- NCT03861507 203 204 I-Modifier
dose NCT03861507 205 209 I-Modifier
- NCT03861507 210 211 I-Modifier
rate NCT03861507 212 216 I-Modifier
brachytherapy NCT03861507 217 230 B-Procedure
for NCT03861507 231 234 O
treatment NCT03861507 235 244 B-Procedure
as NCT03861507 245 247 O
standard NCT03861507 248 256 O
of NCT03861507 257 259 O
care NCT03861507 260 264 O
. NCT03861507 264 265 O

Exclusion NCT03861507 267 276 O
Criteria NCT03861507 277 285 O
: NCT03861507 286 287 O

- NCT03861507 291 292 O
• NCT03861507 294 295 O
Previous NCT03861507 296 304 B-Eq-Comparison
radiotherapy NCT03861507 305 317 B-Procedure
to NCT03861507 318 320 O
the NCT03861507 321 324 O
prostate NCT03861507 325 333 B-Condition

Inclusion NCT03860584 0 9 O
Criteria NCT03860584 10 18 O
: NCT03860584 19 20 O

- NCT03860584 24 25 O
Serum NCT03860584 27 32 B-Observation
Glucose NCT03860584 33 40 I-Observation
100 NCT03860584 41 44 B-Eq-Comparison
- NCT03860584 45 46 I-Eq-Comparison
126 NCT03860584 47 50 I-Eq-Comparison
mg NCT03860584 51 53 I-Eq-Comparison
/ NCT03860584 54 55 I-Eq-Comparison
dl NCT03860584 56 58 I-Eq-Comparison

- NCT03860584 61 62 O
Waist NCT03860584 64 69 B-Observation
C NCT03860584 70 71 I-Observation
> NCT03860584 72 73 B-Eq-Comparison
89 NCT03860584 74 76 I-Eq-Comparison
/ NCT03860584 77 78 I-Eq-Comparison
102 NCT03860584 79 82 I-Eq-Comparison
cm NCT03860584 83 85 I-Eq-Comparison
; NCT03860584 85 86 O
F NCT03860584 87 88 O
/ NCT03860584 89 90 B-Or
M NCT03860584 91 92 O

- NCT03860584 95 96 I-Observation
Serum NCT03860584 98 103 B-Observation
HDL NCT03860584 104 107 I-Observation
- NCT03860584 108 109 O
C NCT03860584 110 111 I-Observation
: NCT03860584 112 113 O
< NCT03860584 114 115 B-Eq-Comparison
50 NCT03860584 116 118 I-Eq-Comparison
/ NCT03860584 119 120 I-Eq-Comparison|Or
40 NCT03860584 121 123 I-Eq-Comparison
mg NCT03860584 124 126 I-Eq-Comparison
/ NCT03860584 127 128 O
dl NCT03860584 129 131 I-Eq-Comparison
; NCT03860584 131 132 O
F NCT03860584 133 134 O
/ NCT03860584 135 136 O
M NCT03860584 137 138 O

- NCT03860584 141 142 O
Serum NCT03860584 144 149 B-Observation
TG NCT03860584 150 152 I-Observation
: NCT03860584 153 154 O
> NCT03860584 155 156 B-Eq-Comparison|Eq-Comparison
150 NCT03860584 157 160 I-Eq-Comparison
mg NCT03860584 161 163 I-Eq-Comparison
/ NCT03860584 164 165 I-Eq-Comparison|Eq-Comparison
dl NCT03860584 166 168 I-Eq-Comparison

- NCT03860584 171 172 O
BP NCT03860584 174 176 B-Observation
> NCT03860584 177 178 O
130 NCT03860584 179 182 I-Eq-Comparison
/ NCT03860584 183 184 O
85 NCT03860584 185 187 I-Eq-Comparison
mmHg NCT03860584 188 192 I-Eq-Comparison

- NCT03860584 195 196 O
Serum NCT03860584 198 203 B-Observation
Endotoxin NCT03860584 204 213 I-Observation
> NCT03860584 214 215 B-Eq-Comparison
25 NCT03860584 216 218 I-Eq-Comparison
EU NCT03860584 219 221 I-Eq-Comparison
/ NCT03860584 222 223 I-Eq-Comparison
ml NCT03860584 224 226 I-Eq-Comparison

Exclusion NCT03860584 227 236 O
Criteria NCT03860584 237 245 O
: NCT03860584 246 247 O

- NCT03860584 251 252 O
Unstable NCT03860584 254 262 O
body NCT03860584 263 267 B-Observation
mass NCT03860584 268 272 I-Observation
( NCT03860584 273 274 O
± NCT03860584 276 277 B-Eq-Comparison
2 NCT03860584 278 279 O
kg NCT03860584 280 282 I-Eq-Comparison
over NCT03860584 283 287 O
prior NCT03860584 288 293 B-Eq-Comparison
3 NCT03860584 294 295 I-Eq-Comparison
- NCT03860584 296 297 I-Eq-Comparison
mo NCT03860584 298 300 I-Eq-Comparison
) NCT03860584 301 302 O

- NCT03860584 306 307 O
Vegetarian NCT03860584 309 319 B-Condition

- NCT03860584 322 323 O
Food NCT03860584 325 329 O
allergies NCT03860584 330 339 B-Allergy
or NCT03860584 340 342 B-Or
lactose NCT03860584 343 350 B-Condition
intolerance NCT03860584 351 362 I-Condition

- NCT03860584 365 366 O
User NCT03860584 368 372 B-Eq-Comparison
of NCT03860584 373 375 O
dietary NCT03860584 376 383 B-Drug
supplements NCT03860584 384 395 I-Drug
or NCT03860584 396 398 B-Or
probiotics NCT03860584 399 409 B-Drug
( NCT03860584 410 411 O
within NCT03860584 412 418 B-Eq-Comparison
past NCT03860584 419 423 I-Eq-Comparison
1 NCT03860584 424 425 I-Eq-Comparison
- NCT03860584 426 427 I-Eq-Comparison
mo NCT03860584 428 430 I-Eq-Comparison
) NCT03860584 431 432 O

- NCT03860584 436 437 O
Pregnancy NCT03860584 439 448 B-Condition
, NCT03860584 449 450 O
lactation NCT03860584 451 460 B-Condition
, NCT03860584 461 462 O
changes NCT03860584 463 470 O
in NCT03860584 471 473 O
birth NCT03860584 474 479 B-Procedure
control NCT03860584 480 487 I-Procedure
( NCT03860584 488 489 O
within NCT03860584 490 496 B-Eq-Comparison
6 NCT03860584 497 498 I-Eq-Comparison
- NCT03860584 499 500 O
mo NCT03860584 501 503 O
) NCT03860584 504 505 O

- NCT03860584 509 510 O
Any NCT03860584 512 515 O
gastrointestinal NCT03860584 516 532 B-Condition
disorders NCT03860584 533 542 I-Condition

- NCT03860584 545 546 O
Chronic NCT03860584 548 555 B-Modifier
diarrhea NCT03860584 556 564 B-Condition|Eq-Comparison

- NCT03860584 567 568 O
Smoker NCT03860584 570 576 B-Condition

- NCT03860584 579 580 O
Excess NCT03860584 582 588 O
alcohol NCT03860584 589 596 B-Observation
( NCT03860584 597 598 O
> NCT03860584 600 601 B-Eq-Comparison|Eq-Comparison
2 NCT03860584 602 603 I-Eq-Comparison
drinks NCT03860584 604 610 I-Eq-Comparison
/ NCT03860584 611 612 I-Eq-Comparison|Eq-Comparison
d NCT03860584 613 614 O
) NCT03860584 615 616 O

- NCT03860584 620 621 O
Excess NCT03860584 623 629 O
aerobic NCT03860584 630 637 B-Observation
exercise NCT03860584 638 646 I-Observation
( NCT03860584 647 648 O
> NCT03860584 650 651 O
5 NCT03860584 652 653 I-Eq-Comparison
h NCT03860584 654 655 I-Eq-Comparison
/ NCT03860584 656 657 O
wk NCT03860584 658 660 I-Eq-Comparison
) NCT03860584 661 662 O

- NCT03860584 666 667 I-Drug
Recent NCT03860584 669 675 B-Eq-Comparison
antibiotic NCT03860584 676 686 B-Drug|Drug
or NCT03860584 687 689 B-Or
anti NCT03860584 690 694 O
- NCT03860584 695 696 O
inflammatory NCT03860584 697 709 I-Drug
agent NCT03860584 710 715 I-Drug
use NCT03860584 716 719 O

- NCT03860584 722 723 O
BP NCT03860584 725 727 B-Observation
> NCT03860584 728 729 B-Eq-Comparison
140 NCT03860584 730 733 I-Eq-Comparison
/ NCT03860584 734 735 I-Eq-Comparison
90 NCT03860584 736 738 I-Eq-Comparison
mmHg NCT03860584 739 743 I-Eq-Comparison

Inclusion NCT03860220 0 9 O
Criteria NCT03860220 10 18 O
: NCT03860220 19 20 O

- NCT03860220 24 25 O
145 NCT03860220 27 30 B-Eq-Comparison
mmHg NCT03860220 31 35 I-Eq-Comparison
≤ NCT03860220 36 37 I-Eq-Comparison
msSBP NCT03860220 38 43 B-Observation
≤ NCT03860220 44 45 B-Eq-Comparison
190 NCT03860220 46 49 I-Eq-Comparison
mmHg NCT03860220 50 54 I-Eq-Comparison

- NCT03860220 57 58 O
Triglycerides NCT03860220 60 73 B-Observation
< NCT03860220 74 75 B-Eq-Comparison
500 NCT03860220 76 79 I-Eq-Comparison
mg NCT03860220 80 82 I-Eq-Comparison
/ NCT03860220 83 84 I-Eq-Comparison
dL NCT03860220 85 87 I-Eq-Comparison

- NCT03860220 90 91 O
LDL NCT03860220 93 96 B-Observation
- NCT03860220 97 98 I-Observation
C NCT03860220 99 100 I-Observation
≤ NCT03860220 101 102 B-Eq-Comparison
250 NCT03860220 103 106 I-Eq-Comparison
mg NCT03860220 107 109 I-Eq-Comparison
/ NCT03860220 110 111 I-Eq-Comparison
dL NCT03860220 112 114 I-Eq-Comparison

Exclusion NCT03860220 115 124 O
Criteria NCT03860220 125 133 O
: NCT03860220 134 135 O

- NCT03860220 139 140 O
sSBP NCT03860220 142 146 B-Observation
≥ NCT03860220 147 148 B-Eq-Comparison
20 NCT03860220 149 151 I-Eq-Comparison
mmHg NCT03860220 152 156 O
and NCT03860220 157 160 B-And
sDBP NCT03860220 161 165 B-Observation
≥ NCT03860220 166 167 B-Eq-Comparison
10 NCT03860220 168 170 I-Eq-Comparison
mmHg NCT03860220 171 175 O

- NCT03860220 178 179 O
symptomatic NCT03860220 181 192 B-Assertion___Assertion-Type-Value:possible
orthostatic NCT03860220 193 204 B-Modifier
hypotension NCT03860220 205 216 B-Condition
and NCT03860220 217 220 B-Or
secondary NCT03860220 221 230 B-Modifier
/ NCT03860220 231 232 B-Or
iatrogenic NCT03860220 233 243 B-Modifier
hypertension NCT03860220 244 256 B-Condition
and NCT03860220 257 260 B-Or
dyslipidemia NCT03860220 261 273 B-Condition

- NCT03860220 276 277 O
history NCT03860220 279 286 B-Eq-Comparison
of NCT03860220 287 289 O
moderate NCT03860220 290 298 B-Eq-Comparison
to NCT03860220 299 301 I-Eq-Comparison
severe NCT03860220 302 308 I-Eq-Comparison
cerebral NCT03860220 309 317 B-Condition
ischemia NCT03860220 318 326 I-Condition
, NCT03860220 327 328 O
cerebral NCT03860220 329 337 B-Condition
hemorrhage NCT03860220 338 348 I-Condition
, NCT03860220 349 350 O
transient NCT03860220 351 360 B-Condition
ischemic NCT03860220 361 369 I-Condition
attack NCT03860220 370 376 I-Condition
, NCT03860220 377 378 O
myocardial NCT03860220 379 389 B-Condition
infarction NCT03860220 390 400 I-Condition
, NCT03860220 401 402 O
or NCT03860220 403 405 B-Or
unstable NCT03860220 406 414 O
angina NCT03860220 415 421 B-Condition
in NCT03860220 422 424 O
the NCT03860220 425 428 O
past NCT03860220 429 433 B-Eq-Comparison
6 NCT03860220 434 435 I-Eq-Comparison
months NCT03860220 436 442 I-Eq-Comparison
; NCT03860220 442 443 O
severe NCT03860220 444 450 O
heart NCT03860220 451 456 B-Condition
failure NCT03860220 457 464 I-Condition
( NCT03860220 465 466 O
New NCT03860220 467 470 B-Condition
York NCT03860220 471 475 I-Condition
Heart NCT03860220 476 481 I-Condition
Association NCT03860220 482 493 I-Condition
functional NCT03860220 494 504 O
class NCT03860220 505 510 B-Eq-Comparison
III NCT03860220 511 514 I-Eq-Comparison
and NCT03860220 515 518 I-Eq-Comparison
IV NCT03860220 519 521 I-Eq-Comparison
) NCT03860220 522 523 O

- NCT03860220 527 528 O
hypersensitivity NCT03860220 530 546 B-Condition
to NCT03860220 547 549 O
telmisartan NCT03860220 550 561 B-Drug
or NCT03860220 562 564 B-Or
rosuvastatin NCT03860220 565 577 B-Drug

- NCT03860220 580 581 O
history NCT03860220 583 590 B-Eq-Comparison
of NCT03860220 591 593 O
angioedema NCT03860220 594 604 B-Condition
after NCT03860220 605 610 B-Temporal-Connection___Temporal-Connection-Type-Value:after
treatment NCT03860220 611 620 B-Procedure
with NCT03860220 621 625 O
angiotensin NCT03860220 626 637 B-Drug
- NCT03860220 638 639 I-Drug
converting NCT03860220 640 650 I-Drug
enzyme NCT03860220 651 657 I-Drug
inhibitors NCT03860220 658 668 I-Drug
or NCT03860220 669 671 B-Or
ARBs NCT03860220 672 676 B-Drug
; NCT03860220 676 677 O
creatinine NCT03860220 678 688 B-Observation
phosphokinase NCT03860220 689 702 I-Observation
levels NCT03860220 703 709 O
≥ NCT03860220 710 711 B-Eq-Comparison
3 NCT03860220 712 713 I-Eq-Comparison
times NCT03860220 714 719 I-Eq-Comparison
the NCT03860220 720 723 I-Eq-Comparison
upper NCT03860220 724 729 I-Eq-Comparison
limit NCT03860220 730 735 I-Eq-Comparison
of NCT03860220 736 738 I-Eq-Comparison
normal NCT03860220 739 745 I-Eq-Comparison

- NCT03860220 748 749 O
estimated NCT03860220 751 760 B-Observation
glomerular NCT03860220 761 771 I-Observation
filtration NCT03860220 772 782 I-Observation
rate NCT03860220 783 787 I-Observation
≤ NCT03860220 788 789 B-Eq-Comparison
30 NCT03860220 790 792 I-Eq-Comparison
mL NCT03860220 793 795 I-Eq-Comparison
/ NCT03860220 796 797 I-Eq-Comparison
min NCT03860220 798 801 I-Eq-Comparison
; NCT03860220 801 802 O
aspartate NCT03860220 803 812 B-Observation
aminotransferase NCT03860220 813 829 I-Observation
and NCT03860220 830 833 B-Or
alanine NCT03860220 834 841 B-Observation
aminotransferase NCT03860220 842 858 I-Observation
levels NCT03860220 859 865 O
≥ NCT03860220 866 867 B-Eq-Comparison
3 NCT03860220 868 869 I-Eq-Comparison
times NCT03860220 870 875 I-Eq-Comparison
the NCT03860220 876 879 I-Eq-Comparison
upper NCT03860220 880 885 I-Eq-Comparison
limit NCT03860220 886 891 I-Eq-Comparison
of NCT03860220 892 894 I-Eq-Comparison
normal NCT03860220 895 901 I-Eq-Comparison

- NCT03860220 904 905 O
potassium NCT03860220 907 916 B-Observation
levels NCT03860220 917 923 O
> NCT03860220 924 925 B-Eq-Comparison
5.5 NCT03860220 926 929 I-Eq-Comparison
mmol NCT03860220 930 934 I-Eq-Comparison
/ NCT03860220 935 936 I-Eq-Comparison
L NCT03860220 937 938 I-Eq-Comparison
; NCT03860220 938 939 O
or NCT03860220 940 942 B-Or
any NCT03860220 943 946 O
diseases NCT03860220 947 955 B-Condition
that NCT03860220 956 960 O
could NCT03860220 961 966 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03860220 967 973 O
the NCT03860220 974 977 O
results NCT03860220 978 985 O
of NCT03860220 986 988 O
the NCT03860220 989 992 O
study NCT03860220 993 998 B-Study
. NCT03860220 998 999 O

Inclusion NCT03866889 0 9 O
Criteria NCT03866889 10 18 O
: NCT03866889 19 20 O

- NCT03866889 24 25 O
Military NCT03866889 27 35 B-Observation
personnel NCT03866889 36 45 I-Observation
belonging NCT03866889 46 55 O
to NCT03866889 56 58 O
the NCT03866889 59 62 O
Military NCT03866889 63 71 B-Modifier
Emergency NCT03866889 72 81 I-Modifier
Unit NCT03866889 82 86 I-Modifier

- NCT03866889 89 90 O
male NCT03866889 92 96 O

- NCT03866889 99 100 O
With NCT03866889 102 106 O
an NCT03866889 107 109 O
age NCT03866889 110 113 B-Age
of NCT03866889 114 116 O
25 NCT03866889 117 119 B-Eq-Comparison
to NCT03866889 120 122 I-Eq-Comparison
45 NCT03866889 123 125 I-Eq-Comparison
years NCT03866889 126 131 I-Eq-Comparison

- NCT03866889 134 135 O
No NCT03866889 137 139 B-Negation
history NCT03866889 140 147 B-Eq-Comparison
of NCT03866889 148 150 O
musculoskeletal NCT03866889 151 166 B-Modifier
injury NCT03866889 167 173 B-Condition
in NCT03866889 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 177 180 O
3 NCT03866889 181 182 B-Eq-Comparison
months NCT03866889 183 189 I-Eq-Comparison
prior NCT03866889 190 195 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866889 196 198 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866889 199 202 O
study NCT03866889 203 208 B-Study

Exclusion NCT03866889 209 218 O
Criteria NCT03866889 219 227 O
: NCT03866889 228 229 O

- NCT03866889 233 234 O
Present NCT03866889 236 243 O
a NCT03866889 244 245 O
diagnosis NCT03866889 246 255 O
of NCT03866889 256 258 O
injury NCT03866889 259 265 B-Condition
in NCT03866889 266 268 O
the NCT03866889 269 272 O
period NCT03866889 273 279 O
prior NCT03866889 280 285 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866889 286 288 I-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03866889 289 291 B-Or
during NCT03866889 292 298 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 299 302 O
study NCT03866889 303 308 B-Study

- NCT03866889 311 312 O
Who NCT03866889 314 317 O
are NCT03866889 318 321 O
receiving NCT03866889 322 331 B-Eq-Comparison
a NCT03866889 332 333 O
physiotherapy NCT03866889 334 347 B-Procedure
intervention NCT03866889 348 360 I-Procedure
at NCT03866889 361 363 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 364 367 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866889 368 372 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866889 373 375 O
the NCT03866889 376 379 O
study NCT03866889 380 385 B-Study

- NCT03866889 388 389 O
Not NCT03866889 391 394 O
signed NCT03866889 395 401 O
the NCT03866889 402 405 O
informed NCT03866889 406 414 O
consent NCT03866889 415 422 O
document NCT03866889 423 431 O

Inclusion NCT03863067 0 9 O
Criteria NCT03863067 10 18 O
: NCT03863067 19 20 O

- NCT03863067 24 25 O
Patient NCT03863067 27 34 O
with NCT03863067 35 39 O
indication NCT03863067 40 50 B-Indication
for NCT03863067 51 54 O
epiduroscopy NCT03863067 55 67 B-Procedure
in NCT03863067 68 70 O
the NCT03863067 71 74 O
usual NCT03863067 75 80 O
clinical NCT03863067 81 89 O
practice NCT03863067 90 98 O

- NCT03863067 101 102 O
Neurogenic NCT03863067 104 114 B-Condition
claudication NCT03863067 115 127 I-Condition

- NCT03863067 130 131 O
Lumbar NCT03863067 133 139 B-Modifier
pain NCT03863067 140 144 B-Condition
for NCT03863067 145 148 O
more NCT03863067 149 153 B-Eq-Comparison
than NCT03863067 154 158 I-Eq-Comparison
6 NCT03863067 159 160 I-Eq-Comparison
months NCT03863067 161 167 I-Eq-Comparison

- NCT03863067 170 171 O
Numerical NCT03863067 173 182 B-Observation
rating NCT03863067 183 189 I-Observation
scale NCT03863067 190 195 I-Observation
> NCT03863067 196 197 B-Eq-Comparison
6 NCT03863067 198 199 I-Eq-Comparison

- NCT03863067 203 204 O
No NCT03863067 206 208 B-Negation
response NCT03863067 209 217 O
with NCT03863067 218 222 O
medical NCT03863067 223 230 O
treatment NCT03863067 231 240 B-Procedure

- NCT03863067 243 244 O
No NCT03863067 246 248 B-Negation
response NCT03863067 249 257 O
with NCT03863067 258 262 O
other NCT03863067 263 268 B-Other
interventional NCT03863067 269 283 O
treatment NCT03863067 284 293 B-Procedure
: NCT03863067 294 295 O
epidurolysis NCT03863067 296 308 B-Procedure

Exclusion NCT03863067 309 318 O
Criteria NCT03863067 319 327 O
: NCT03863067 328 329 O

- NCT03863067 333 334 O
Psychiatric NCT03863067 336 347 B-Condition
disorders NCT03863067 348 357 I-Condition

- NCT03863067 360 361 O
Opioid NCT03863067 363 369 B-Condition
addiction NCT03863067 370 379 I-Condition

- NCT03863067 382 383 O
Acute NCT03863067 385 390 O
organic NCT03863067 391 398 B-Condition
disease NCT03863067 399 406 I-Condition

- NCT03863067 409 410 O
Severe NCT03863067 412 418 O
chronic NCT03863067 419 426 B-Modifier
organic NCT03863067 427 434 B-Condition
disease NCT03863067 435 442 I-Condition

- NCT03863067 445 446 O
Vasculo NCT03863067 448 455 B-Condition
- NCT03863067 456 457 I-Condition
cerebral NCT03863067 458 466 I-Condition
disease NCT03863067 467 474 I-Condition

- NCT03863067 477 478 O
Coagulation NCT03863067 480 491 B-Condition
alterations NCT03863067 492 503 I-Condition

- NCT03863067 506 507 O
Ofthalmologic NCT03863067 509 522 B-Condition
disease NCT03863067 523 530 I-Condition

- NCT03863067 533 534 O
Allergic NCT03863067 536 544 B-Allergy

- NCT03863067 547 548 O
Infections NCT03863067 550 560 B-Condition

- NCT03863067 563 564 O
Impossibility NCT03863067 566 579 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863067 580 582 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03863067 583 593 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03863067 594 597 O
procedure NCT03863067 598 607 B-Procedure

key NCT03867201 0 3 O
inclusion NCT03867201 4 13 O
Criteria NCT03867201 14 22 O
: NCT03867201 23 24 O

1 NCT03867201 28 29 O
. NCT03867201 29 30 O
History NCT03867201 32 39 B-Eq-Comparison
of NCT03867201 40 42 O
at NCT03867201 43 45 B-Eq-Comparison
least NCT03867201 46 51 I-Eq-Comparison
5 NCT03867201 52 53 I-Eq-Comparison
attacks NCT03867201 54 61 O
of NCT03867201 62 64 O
migraine NCT03867201 65 73 B-Condition

2 NCT03867201 76 77 O
. NCT03867201 77 78 O
≥ NCT03867201 80 81 B-Eq-Comparison
15 NCT03867201 82 84 I-Eq-Comparison
headache NCT03867201 85 93 B-Condition
days NCT03867201 94 98 O
of NCT03867201 99 101 B-And
which NCT03867201 102 107 I-And
≥ NCT03867201 108 109 B-Eq-Comparison
8 NCT03867201 110 111 I-Eq-Comparison
headache NCT03867201 112 120 B-Condition
days NCT03867201 121 125 O
meet NCT03867201 126 130 O
criteria NCT03867201 131 139 O
as NCT03867201 140 142 O
migraine NCT03867201 143 151 B-Condition
days NCT03867201 152 156 B-Eq-Comparison
during NCT03867201 157 163 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867201 164 167 O
baseline NCT03867201 168 176 B-Study
period NCT03867201 177 183 O

3 NCT03867201 186 187 O
. NCT03867201 187 188 O
> NCT03867201 190 191 B-Eq-Comparison
= NCT03867201 193 194 I-Eq-Comparison
80 NCT03867201 195 197 I-Eq-Comparison
% NCT03867201 198 199 O
diary NCT03867201 200 205 B-Observation
compliance NCT03867201 206 216 I-Observation
during NCT03867201 217 223 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867201 224 227 O
baseline NCT03867201 228 236 B-Study
period NCT03867201 237 243 O

Key NCT03867201 244 247 O
exclusion NCT03867201 248 257 O
Criteria NCT03867201 258 266 O
: NCT03867201 267 268 O

1 NCT03867201 272 273 O
. NCT03867201 273 274 O
Older NCT03867201 276 281 B-Eq-Comparison
than NCT03867201 282 286 I-Eq-Comparison
50 NCT03867201 287 289 I-Eq-Comparison
years NCT03867201 290 295 I-Eq-Comparison
of NCT03867201 296 298 O
age NCT03867201 299 302 B-Age
at NCT03867201 303 305 B-Temporal-Connection___Temporal-Connection-Type-Value:during
migraine NCT03867201 306 314 B-Condition
onset NCT03867201 315 320 B-Eq-Comparison

2 NCT03867201 323 324 O
. NCT03867201 324 325 O
History NCT03867201 327 334 B-Eq-Comparison
of NCT03867201 335 337 O
cluster NCT03867201 338 345 B-Modifier
or NCT03867201 346 348 B-Or
hemiplegic NCT03867201 349 359 B-Modifier
headache NCT03867201 360 368 B-Condition

3 NCT03867201 371 372 O
. NCT03867201 372 373 O
Evidence NCT03867201 375 383 O
of NCT03867201 384 386 O
seizure NCT03867201 387 394 B-Condition
or NCT03867201 395 397 B-Or
major NCT03867201 398 403 O
psychiatric NCT03867201 404 415 B-Condition
disorder NCT03867201 416 424 I-Condition

4 NCT03867201 427 428 O
. NCT03867201 428 429 O
Cardiac NCT03867201 431 438 B-Modifier
or NCT03867201 439 441 B-Or
active NCT03867201 442 448 B-Eq-Comparison
hepatic NCT03867201 449 456 B-Condition
disease NCT03867201 457 464 I-Condition

5 NCT03867201 467 468 O
. NCT03867201 468 469 O
Pregnant NCT03867201 471 479 B-Condition
or NCT03867201 480 482 B-Or
nursing NCT03867201 483 490 B-Condition

Inclusion NCT03864913 0 9 O
Criteria NCT03864913 10 18 O
: NCT03864913 19 20 O

- NCT03864913 24 25 O
Testosterone NCT03864913 27 39 B-Condition
naive NCT03864913 40 45 I-Condition

- NCT03864913 48 49 O
Transgender NCT03864913 51 62 O
male NCT03864913 63 67 O

- NCT03864913 70 71 O
14 NCT03864913 73 75 B-Eq-Comparison
- NCT03864913 76 77 I-Eq-Comparison
19 NCT03864913 78 80 I-Eq-Comparison
years NCT03864913 81 86 I-Eq-Comparison
old NCT03864913 87 90 B-Age

Exclusion NCT03864913 91 100 O
Criteria NCT03864913 101 109 O
: NCT03864913 110 111 O

- NCT03864913 115 116 O
Transgender NCT03864913 118 129 O
males NCT03864913 130 135 O
who NCT03864913 136 139 B-And
have NCT03864913 140 144 O
received NCT03864913 145 153 B-Eq-Comparison
testosterone NCT03864913 154 166 B-Procedure
therapy NCT03864913 167 174 I-Procedure
in NCT03864913 175 177 O
the NCT03864913 178 181 O
past NCT03864913 182 186 B-Eq-Comparison

Inclusion NCT03868683 0 9 O
Criteria NCT03868683 10 18 O
: NCT03868683 19 20 O

- NCT03868683 24 25 O
Chinese NCT03868683 27 34 O
ethnicity NCT03868683 35 44 O

- NCT03868683 47 48 O
Age NCT03868683 50 53 B-Age
≥ NCT03868683 54 55 B-Eq-Comparison
21 NCT03868683 56 58 I-Eq-Comparison
and NCT03868683 59 62 B-And
≤ NCT03868683 63 64 B-Eq-Comparison
60 NCT03868683 65 67 I-Eq-Comparison
years NCT03868683 68 73 I-Eq-Comparison

- NCT03868683 76 77 O
Body NCT03868683 79 83 B-Observation
mass NCT03868683 84 88 I-Observation
index NCT03868683 89 94 I-Observation
between NCT03868683 95 102 B-Eq-Comparison
18.5 NCT03868683 103 107 I-Eq-Comparison
to NCT03868683 108 110 I-Eq-Comparison
25 NCT03868683 111 113 I-Eq-Comparison
kg NCT03868683 114 116 I-Eq-Comparison
/ NCT03868683 117 118 I-Eq-Comparison
m2 NCT03868683 119 121 I-Eq-Comparison

- NCT03868683 124 125 O
Normal NCT03868683 127 133 O
blood NCT03868683 134 139 B-Observation
pressure NCT03868683 140 148 I-Observation
< NCT03868683 149 150 B-Eq-Comparison
140 NCT03868683 151 154 I-Eq-Comparison
/ NCT03868683 155 156 I-Eq-Comparison
90 NCT03868683 157 159 I-Eq-Comparison
mmHg NCT03868683 160 164 I-Eq-Comparison

- NCT03868683 167 168 O
Fasting NCT03868683 170 177 B-Modifier
blood NCT03868683 178 183 B-Observation
glucose NCT03868683 184 191 I-Observation
< NCT03868683 192 193 B-Eq-Comparison
6.0 NCT03868683 194 197 I-Eq-Comparison
mmol NCT03868683 198 202 I-Eq-Comparison
/ NCT03868683 203 204 I-Eq-Comparison
L NCT03868683 205 206 I-Eq-Comparison

- NCT03868683 209 210 O
In NCT03868683 212 214 O
general NCT03868683 215 222 O
good NCT03868683 223 227 B-Condition
health NCT03868683 228 234 I-Condition

Exclusion NCT03868683 235 244 O
Criteria NCT03868683 245 253 O
: NCT03868683 254 255 O

- NCT03868683 259 260 O
Current NCT03868683 262 269 B-Eq-Comparison
Smoker NCT03868683 270 276 B-Condition

- NCT03868683 279 280 O
have NCT03868683 282 286 O
any NCT03868683 287 290 O
metabolic NCT03868683 291 300 B-Condition
diseases NCT03868683 301 309 I-Condition
( NCT03868683 310 311 O
such NCT03868683 312 316 O
as NCT03868683 317 319 O
diabetes NCT03868683 320 328 B-Condition
, NCT03868683 329 330 O
hypertension NCT03868683 331 343 B-Condition
etc NCT03868683 344 347 O
) NCT03868683 348 349 O

- NCT03868683 353 354 O
have NCT03868683 356 360 O
known NCT03868683 361 366 O
glucose NCT03868683 367 374 B-Condition
- NCT03868683 375 376 I-Condition
6 NCT03868683 377 378 I-Condition
- NCT03868683 379 380 O
phosphate NCT03868683 381 390 I-Condition
dehydrogenase NCT03868683 391 404 I-Condition
deficiency NCT03868683 405 415 I-Condition|Condition
( NCT03868683 416 417 O
G6PD NCT03868683 418 422 B-Condition
deficiency NCT03868683 423 433 O
) NCT03868683 434 435 O

- NCT03868683 439 440 O
having NCT03868683 442 448 O
medical NCT03868683 449 456 B-Condition
conditions NCT03868683 457 467 I-Condition
and NCT03868683 468 471 B-Or
/ NCT03868683 472 473 I-Or
or NCT03868683 474 476 I-Or
taking NCT03868683 477 483 B-Eq-Comparison
medications NCT03868683 484 495 B-Drug
known NCT03868683 496 501 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868683 502 504 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03868683 505 511 O
glycaemia NCT03868683 512 521 B-Condition
( NCT03868683 522 523 O
glucocorticoids NCT03868683 524 539 B-Drug
, NCT03868683 540 541 O
thyroid NCT03868683 542 549 B-Drug
hormones NCT03868683 550 558 I-Drug
, NCT03868683 559 560 O
thiazide NCT03868683 561 569 B-Drug
diuretics NCT03868683 570 579 I-Drug
) NCT03868683 580 581 O

- NCT03868683 585 586 O
have NCT03868683 588 592 O
intolerances NCT03868683 593 605 B-Condition
or NCT03868683 606 608 B-Or
allergies NCT03868683 609 618 B-Allergy
to NCT03868683 619 621 O
any NCT03868683 622 625 O
foods NCT03868683 626 631 O

- NCT03868683 634 635 O
partake NCT03868683 637 644 O
in NCT03868683 645 647 O
sports NCT03868683 648 654 B-Observation
at NCT03868683 655 657 O
the NCT03868683 658 661 O
competitive NCT03868683 662 673 B-Modifier
and NCT03868683 674 677 B-Or
/ NCT03868683 678 679 I-Or
or NCT03868683 680 682 I-Or
endurance NCT03868683 683 692 B-Modifier
levels NCT03868683 693 699 O

- NCT03868683 702 703 O
intentionally NCT03868683 705 718 O
restrict NCT03868683 719 727 B-Negation
food NCT03868683 728 732 B-Condition
intake NCT03868683 733 739 I-Condition

Inclusion NCT03866876 0 9 O
Criteria NCT03866876 10 18 O
: NCT03866876 19 20 O

- NCT03866876 24 25 O
All NCT03866876 27 30 O
birth NCT03866876 31 36 B-Birth
more NCT03866876 37 41 B-Eq-Comparison
than NCT03866876 42 46 I-Eq-Comparison
37 NCT03866876 47 49 I-Eq-Comparison
weeks NCT03866876 50 55 I-Eq-Comparison
of NCT03866876 56 58 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03866876 59 69 B-Condition
at NCT03866876 70 72 O
the NCT03866876 73 76 O
maternity NCT03866876 77 86 O
ward NCT03866876 87 91 O
of NCT03866876 92 94 O
the NCT03866876 95 98 O
hospital NCT03866876 99 107 O
Femme NCT03866876 108 113 O
- NCT03866876 114 115 O
Mère NCT03866876 116 120 O
- NCT03866876 121 122 O
Enfant NCT03866876 123 129 O

- NCT03866876 132 133 O
from NCT03866876 135 139 O
1 NCT03866876 140 141 B-Eq-Comparison
st NCT03866876 142 144 O
of NCT03866876 145 147 I-Eq-Comparison
january NCT03866876 148 155 I-Eq-Comparison
2000 NCT03866876 156 160 I-Eq-Comparison
to NCT03866876 161 163 I-Eq-Comparison
31 NCT03866876 164 166 I-Eq-Comparison
december NCT03866876 167 175 I-Eq-Comparison
2016 NCT03866876 176 180 I-Eq-Comparison

Exclusion NCT03866876 182 191 O
Criteria NCT03866876 192 200 O
: NCT03866876 201 202 O

- NCT03866876 206 207 O
Infants NCT03866876 209 216 O
born NCT03866876 217 221 B-Birth
out NCT03866876 222 225 B-Negation
of NCT03866876 226 228 I-Negation
the NCT03866876 229 232 O
hospital NCT03866876 233 241 O
and NCT03866876 242 245 B-And
secondarily NCT03866876 246 257 B-Encounter
hospitalized NCT03866876 258 270 I-Encounter
in NCT03866876 271 273 O
the NCT03866876 274 277 O
hospital NCT03866876 278 286 O
Femme NCT03866876 287 292 O
- NCT03866876 293 294 O
Mère NCT03866876 295 299 O
- NCT03866876 300 301 O
Enfant NCT03866876 302 308 O

- NCT03866876 311 312 O
Children NCT03866876 314 322 O
with NCT03866876 323 327 B-And
congenital NCT03866876 328 338 B-Condition
anomalies NCT03866876 339 348 I-Condition
or NCT03866876 349 351 B-Or
without NCT03866876 352 359 B-Negation
valid NCT03866876 360 365 O
arterial NCT03866876 366 374 B-Modifier
and NCT03866876 375 378 B-Or
venous NCT03866876 379 385 B-Modifier
umbilical NCT03866876 386 395 B-Observation
cord NCT03866876 396 400 I-Observation
samples NCT03866876 401 408 I-Observation

Inclusion NCT03866447 0 9 O
Criteria NCT03866447 10 18 O
: NCT03866447 19 20 O

1 NCT03866447 24 25 O
. NCT03866447 25 26 O
Patients NCT03866447 28 36 O
with NCT03866447 37 41 O
Acne NCT03866447 42 46 B-Condition
of NCT03866447 47 49 O
any NCT03866447 50 53 O
grade NCT03866447 54 59 O
. NCT03866447 59 60 O

2 NCT03866447 64 65 O
. NCT03866447 65 66 O
Patients NCT03866447 68 76 O
between NCT03866447 77 84 B-Eq-Comparison
18 NCT03866447 85 87 I-Eq-Comparison
and NCT03866447 88 91 I-Eq-Comparison
45 NCT03866447 92 94 I-Eq-Comparison
years NCT03866447 95 100 I-Eq-Comparison
old NCT03866447 101 104 B-Age
. NCT03866447 104 105 O

Exclusion NCT03866447 107 116 O
Criteria NCT03866447 117 125 O
: NCT03866447 126 127 O

1 NCT03866447 131 132 O
. NCT03866447 132 133 O
Patients NCT03866447 135 143 O
below NCT03866447 144 149 B-Eq-Comparison
18 NCT03866447 150 152 I-Eq-Comparison
and NCT03866447 153 156 B-Or
above NCT03866447 157 162 B-Eq-Comparison
45 NCT03866447 163 165 I-Eq-Comparison
years NCT03866447 166 171 B-Age
. NCT03866447 171 172 O

2 NCT03866447 176 177 O
. NCT03866447 177 178 O
Patients NCT03866447 180 188 O
with NCT03866447 189 193 O
any NCT03866447 194 197 O
concomitant NCT03866447 198 209 B-Modifier
Dermatologic NCT03866447 210 222 I-Modifier
or NCT03866447 223 225 B-Or
systemic NCT03866447 226 234 B-Modifier
illness NCT03866447 235 242 B-Condition

3 NCT03866447 245 246 O
. NCT03866447 246 247 O
Patients NCT03866447 249 257 O
on NCT03866447 258 260 O
any NCT03866447 261 264 O
topical NCT03866447 265 272 B-Modifier
or NCT03866447 273 275 B-Or
systemic NCT03866447 276 284 B-Modifier
medication NCT03866447 285 295 B-Drug
within NCT03866447 296 302 B-Eq-Comparison
4 NCT03866447 303 304 I-Eq-Comparison
weeks NCT03866447 305 310 I-Eq-Comparison
before NCT03866447 311 317 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866447 318 328 B-Study
. NCT03866447 328 329 O

4 NCT03866447 333 334 O
. NCT03866447 334 335 O
Pregnancy NCT03866447 337 346 B-Condition
. NCT03866447 346 347 O

Inclusion NCT03867981 0 9 O
Criteria NCT03867981 10 18 O
: NCT03867981 19 20 O

- NCT03867981 24 25 O
Age NCT03867981 27 30 B-Age
18 NCT03867981 31 33 B-Eq-Comparison
- NCT03867981 34 35 I-Eq-Comparison
70 NCT03867981 36 38 O

- NCT03867981 42 43 O
BMI NCT03867981 45 48 B-Observation
: NCT03867981 49 50 O
25 NCT03867981 51 53 B-Eq-Comparison
- NCT03867981 54 55 I-Eq-Comparison
45 NCT03867981 56 58 I-Eq-Comparison
kg NCT03867981 59 61 I-Eq-Comparison
/ NCT03867981 62 63 I-Eq-Comparison
m2 NCT03867981 64 66 I-Eq-Comparison

- NCT03867981 69 70 O
Regular NCT03867981 72 79 O
internet NCT03867981 80 88 O
access NCT03867981 89 95 O

Exclusion NCT03867981 96 105 O
Criteria NCT03867981 106 114 O
: NCT03867981 115 116 O

- NCT03867981 120 121 O
Currently NCT03867981 123 132 B-Eq-Comparison
pregnant NCT03867981 133 141 B-Condition
, NCT03867981 142 143 O
< NCT03867981 144 145 B-Eq-Comparison
6 NCT03867981 146 147 I-Eq-Comparison
months NCT03867981 148 154 I-Eq-Comparison
post NCT03867981 155 159 B-Condition
- NCT03867981 160 161 I-Condition
partum NCT03867981 162 168 I-Condition
, NCT03867981 169 170 O
nursing NCT03867981 171 178 B-Condition
, NCT03867981 179 180 O
or NCT03867981 181 183 B-Or
planning NCT03867981 184 192 B-Assertion___Assertion-Type-Value:intention
to NCT03867981 193 195 I-Assertion___Assertion-Type-Value:intention
become NCT03867981 196 202 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03867981 203 211 B-Condition
within NCT03867981 212 218 B-Eq-Comparison
the NCT03867981 219 222 I-Eq-Comparison
next NCT03867981 223 227 I-Eq-Comparison
12 NCT03867981 228 230 I-Eq-Comparison
months NCT03867981 231 237 I-Eq-Comparison
. NCT03867981 237 238 O

- NCT03867981 242 243 O
Current NCT03867981 245 252 B-Eq-Comparison
enrollment NCT03867981 253 263 O
in NCT03867981 264 266 O
a NCT03867981 267 268 O
commercial NCT03867981 269 279 B-Modifier
weight NCT03867981 280 286 B-Procedure
loss NCT03867981 287 291 I-Procedure
program NCT03867981 292 299 I-Procedure
or NCT03867981 300 302 B-Or
other NCT03867981 303 308 B-Other
weight NCT03867981 309 315 B-Procedure
loss NCT03867981 316 320 I-Procedure
research NCT03867981 321 329 O
study NCT03867981 330 335 B-Study

- NCT03867981 338 339 O
Currently NCT03867981 341 350 B-Eq-Comparison
taking NCT03867981 351 357 O
weight NCT03867981 358 364 B-Procedure
loss NCT03867981 365 369 I-Procedure
medications NCT03867981 370 381 B-Drug

- NCT03867981 384 385 O
Previously NCT03867981 387 397 B-Eq-Comparison
had NCT03867981 398 401 O
bariatric NCT03867981 402 411 B-Procedure
surgery NCT03867981 412 419 I-Procedure

- NCT03867981 422 423 O
Inability NCT03867981 425 434 B-Condition
to NCT03867981 435 437 I-Condition
walk NCT03867981 438 442 I-Condition
2 NCT03867981 443 444 B-Modifier
blocks NCT03867981 445 451 I-Modifier
without NCT03867981 452 459 I-Modifier
stopping NCT03867981 460 468 I-Modifier

- NCT03867981 471 472 O
Any NCT03867981 474 477 O
medical NCT03867981 478 485 B-Condition
condition NCT03867981 486 495 I-Condition
for NCT03867981 496 499 O
which NCT03867981 500 505 O
weight NCT03867981 506 512 B-Procedure
loss NCT03867981 513 517 I-Procedure
, NCT03867981 518 519 O
dietary NCT03867981 520 527 B-Procedure
restriction NCT03867981 528 539 I-Procedure
, NCT03867981 540 541 O
or NCT03867981 542 544 B-Or
physical NCT03867981 545 553 B-Observation
activity NCT03867981 554 562 I-Observation
is NCT03867981 563 565 O
contraindicated NCT03867981 566 581 B-Contraindication

Inclusion NCT03865628 0 9 O
Criteria NCT03865628 10 18 O
: NCT03865628 19 20 O

- NCT03865628 24 25 O
Singleton NCT03865628 27 36 B-Modifier
pregnancy NCT03865628 37 46 B-Condition

- NCT03865628 49 50 O
Estimation NCT03865628 52 62 O
of NCT03865628 63 65 O
the NCT03865628 66 69 O
fetal NCT03865628 70 75 B-Modifier
weight NCT03865628 76 82 B-Observation
less NCT03865628 83 87 B-Eq-Comparison
than NCT03865628 88 92 I-Eq-Comparison
estimation NCT03865628 93 103 I-Eq-Comparison
the NCT03865628 104 107 I-Eq-Comparison
10 NCT03865628 108 110 I-Eq-Comparison
th NCT03865628 111 113 O
percentile NCT03865628 114 124 I-Eq-Comparison

Exclusion NCT03865628 125 134 O
Criteria NCT03865628 135 143 O
: NCT03865628 144 145 O

- NCT03865628 149 150 O
Refusal NCT03865628 152 159 O
of NCT03865628 160 162 O
parents NCT03865628 163 170 O

- NCT03865628 173 174 O
Fetal NCT03865628 176 181 B-Modifier
and NCT03865628 182 185 B-Or
vascular NCT03865628 186 194 B-Modifier
malformations NCT03865628 195 208 B-Condition

- NCT03865628 211 212 O
Fetal NCT03865628 214 219 B-Condition
anemia NCT03865628 220 226 I-Condition

Inclusions NCT03864536 0 10 O
: NCT03864536 11 12 O

- NCT03864536 16 17 O
Must NCT03864536 19 23 O
be NCT03864536 24 26 O
African NCT03864536 27 34 O
American NCT03864536 35 43 O

- NCT03864536 46 47 O
Must NCT03864536 49 53 O
be NCT03864536 54 56 O
age NCT03864536 57 60 B-Age
50 NCT03864536 61 63 B-Eq-Comparison
to NCT03864536 64 66 I-Eq-Comparison
65 NCT03864536 67 69 I-Eq-Comparison

- NCT03864536 73 74 O
Must NCT03864536 76 80 O
have NCT03864536 81 85 O
a NCT03864536 86 87 O
working NCT03864536 88 95 O
cell NCT03864536 96 100 O
phone NCT03864536 101 106 O
with NCT03864536 107 111 O
unlimited NCT03864536 112 121 O
texting NCT03864536 122 129 O

- NCT03864536 132 133 O
Must NCT03864536 135 139 O
be NCT03864536 140 142 O
ambulatory NCT03864536 143 153 B-Condition

Exclusions NCT03864536 154 164 O
: NCT03864536 165 166 O

- NCT03864536 170 171 O
No NCT03864536 173 175 B-Negation
neurological NCT03864536 176 188 B-Modifier
( NCT03864536 189 190 O
including NCT03864536 191 200 O
dementia NCT03864536 201 209 B-Condition
diagnosis NCT03864536 210 219 O
) NCT03864536 220 221 O
or NCT03864536 222 224 B-Or
severe NCT03864536 225 231 O
psychiatric NCT03864536 232 243 B-Modifier
( NCT03864536 244 245 O
e. NCT03864536 246 248 O
g. NCT03864536 249 251 O
, NCT03864536 252 253 O
schizophrenia NCT03864536 254 267 B-Condition
or NCT03864536 268 270 B-Or
bipolar NCT03864536 271 278 B-Condition
disorder NCT03864536 279 287 I-Condition|Condition
) NCT03864536 288 289 O
disorders NCT03864536 290 299 O

- NCT03864536 302 303 O
No NCT03864536 305 307 B-Negation
insomnia NCT03864536 308 316 B-Condition

- NCT03864536 319 320 O
Telephone NCT03864536 322 331 B-Observation
Interview NCT03864536 332 341 I-Observation
for NCT03864536 342 345 I-Observation
Cognitive NCT03864536 346 355 I-Observation
Status NCT03864536 356 362 I-Observation
( NCT03864536 363 364 O
TICS NCT03864536 365 369 B-Observation
) NCT03864536 370 371 O
score NCT03864536 372 377 O
≤ NCT03864536 378 379 B-Eq-Comparison
20 NCT03864536 380 382 I-Eq-Comparison

Inclusion NCT03867942 0 9 O
Criteria NCT03867942 10 18 O
: NCT03867942 19 20 O

- NCT03867942 24 25 O
Age NCT03867942 27 30 B-Age
: NCT03867942 31 32 O
19 NCT03867942 33 35 B-Eq-Comparison
~ NCT03867942 36 37 O
45 NCT03867942 38 40 O

- NCT03867942 44 45 O
Body NCT03867942 47 51 B-Observation
weight NCT03867942 52 58 I-Observation
: NCT03867942 59 60 O
55 NCT03867942 61 63 B-Eq-Comparison
kg NCT03867942 64 66 O
or NCT03867942 67 69 I-Eq-Comparison
higher NCT03867942 70 76 I-Eq-Comparison
( NCT03867942 77 78 O
female NCT03867942 79 85 O
: NCT03867942 86 87 O
50 NCT03867942 88 90 B-Eq-Comparison
kg NCT03867942 91 93 O
or NCT03867942 94 96 I-Eq-Comparison
higher NCT03867942 97 103 I-Eq-Comparison
) NCT03867942 104 105 O
and NCT03867942 106 109 B-And
BMI NCT03867942 110 113 B-Observation
18 NCT03867942 114 116 B-Eq-Comparison
~ NCT03867942 117 118 O
27 NCT03867942 119 121 O
kg NCT03867942 122 124 O
/ NCT03867942 125 126 I-Eq-Comparison
m2 NCT03867942 127 129 I-Eq-Comparison

- NCT03867942 132 133 O
SBP NCT03867942 135 138 B-Observation
90 NCT03867942 139 141 B-Eq-Comparison
~ NCT03867942 142 143 O
150 NCT03867942 144 147 O
mmHg NCT03867942 148 152 O
, NCT03867942 153 154 O
DBP NCT03867942 155 158 B-Observation
60 NCT03867942 159 161 B-Eq-Comparison
- NCT03867942 162 163 I-Eq-Comparison
95 NCT03867942 164 166 O
mmHg NCT03867942 167 171 O

- NCT03867942 174 175 O
Fasting NCT03867942 177 184 B-Modifier
glucose NCT03867942 185 192 B-Observation
70 NCT03867942 193 195 B-Eq-Comparison
~ NCT03867942 196 197 O
120 NCT03867942 198 201 O
mg NCT03867942 202 204 O
/ NCT03867942 205 206 I-Eq-Comparison
dL NCT03867942 207 209 I-Eq-Comparison

- NCT03867942 212 213 O
Infertility NCT03867942 215 226 B-Condition

1 NCT03867942 234 235 O
. NCT03867942 235 236 O
Surgically NCT03867942 238 248 B-Modifier
infertile NCT03867942 249 258 B-Condition

2 NCT03867942 266 267 O
. NCT03867942 267 268 O
To NCT03867942 270 272 O
prevent NCT03867942 273 280 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03867942 281 290 B-Condition
, NCT03867942 291 292 O
participants NCT03867942 293 305 O
who NCT03867942 306 309 O
agreed NCT03867942 310 316 B-Assertion___Assertion-Type-Value:hypothetical
using NCT03867942 317 322 B-Eq-Comparison
2 NCT03867942 323 324 B-Eq-Comparison
or NCT03867942 325 327 I-Eq-Comparison
more NCT03867942 328 332 I-Eq-Comparison
contraceptive NCT03867942 333 346 B-Procedure
methods NCT03867942 347 354 I-Procedure|Procedure
. NCT03867942 354 355 O
Such NCT03867942 357 361 O
as NCT03867942 362 364 O

- NCT03867942 367 368 O
Barrier NCT03867942 370 377 B-Procedure
methods NCT03867942 378 385 O
: NCT03867942 386 387 O
Condom NCT03867942 388 394 B-Procedure
, NCT03867942 395 396 O
Diaphragm NCT03867942 397 406 B-Condition
, NCT03867942 407 408 O
Cervical NCT03867942 409 417 B-Procedure
cap NCT03867942 418 421 I-Procedure
( NCT03867942 422 423 O
Pessary NCT03867942 424 431 B-Procedure
) NCT03867942 432 433 O
, NCT03867942 435 436 O
Spermicide NCT03867942 437 447 B-Procedure

- NCT03867942 450 451 O
Hormonal NCT03867942 453 461 B-Procedure
methods NCT03867942 462 469 I-Procedure
: NCT03867942 470 471 O
Pills NCT03867942 472 477 B-Drug
, NCT03867942 478 479 O
Injection NCT03867942 480 489 B-Procedure
( NCT03867942 490 491 O
Depot NCT03867942 492 497 B-Modifier
) NCT03867942 498 499 O
, NCT03867942 501 502 O
Skin NCT03867942 503 507 B-Procedure
patch NCT03867942 508 513 I-Procedure
, NCT03867942 514 515 O
Hormonal NCT03867942 516 524 B-Procedure
implant NCT03867942 525 532 I-Procedure
( NCT03867942 533 534 O
Implanon NCT03867942 535 543 B-Modifier
) NCT03867942 544 545 O
, NCT03867942 547 548 O
Vaginal NCT03867942 549 556 B-Procedure
ring NCT03867942 557 561 I-Procedure

- NCT03867942 564 565 O
Intrauterine NCT03867942 567 579 B-Procedure
Devices NCT03867942 580 587 I-Procedure
( NCT03867942 588 589 O
IUDs NCT03867942 590 594 B-Procedure|Procedure|Procedure
) NCT03867942 595 596 O
: NCT03867942 598 599 O
Cooper NCT03867942 600 606 B-Modifier
IUD NCT03867942 607 610 O
( NCT03867942 611 612 O
Loop NCT03867942 613 617 B-Modifier
) NCT03867942 618 619 O
, NCT03867942 621 622 O
Hormonal NCT03867942 623 631 B-Modifier
IUD NCT03867942 632 635 O
( NCT03867942 636 637 O
Mirena NCT03867942 638 644 B-Modifier
) NCT03867942 645 646 O

- NCT03867942 650 651 O
Natural NCT03867942 653 660 B-Procedure
methods NCT03867942 661 668 I-Procedure
: NCT03867942 669 670 O
Basic NCT03867942 671 676 B-Modifier
body NCT03867942 677 681 B-Observation
temperature NCT03867942 682 693 I-Observation
, NCT03867942 694 695 O
Ovulation NCT03867942 696 705 B-Condition
period NCT03867942 706 712 I-Condition
, NCT03867942 713 714 O
Coitus NCT03867942 715 721 B-Procedure
interruptus NCT03867942 722 733 I-Procedure
, NCT03867942 734 735 O
Abstinent NCT03867942 736 745 B-Condition

- NCT03867942 748 749 O
People NCT03867942 751 757 O
who NCT03867942 758 761 O
perfectly NCT03867942 762 771 O
understood NCT03867942 772 782 O
clinical NCT03867942 783 791 O
trial NCT03867942 792 797 O
and NCT03867942 798 801 O
independently NCT03867942 802 815 O
decided NCT03867942 816 823 O
to NCT03867942 824 826 O
participate NCT03867942 827 838 O
in NCT03867942 839 841 O
clinical NCT03867942 842 850 O
trial NCT03867942 851 856 O
. NCT03867942 856 857 O

- NCT03867942 861 862 O
People NCT03867942 864 870 O
who NCT03867942 871 874 O
will NCT03867942 875 879 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867942 880 882 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03867942 883 887 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867942 888 890 O
collect NCT03867942 891 898 O
blood NCT03867942 899 904 B-Observation
sample NCT03867942 905 911 I-Observation
during NCT03867942 912 918 B-Temporal-Connection___Temporal-Connection-Type-Value:during
clinical NCT03867942 919 927 B-Study|Study
trial NCT03867942 928 933 I-Study|Study
period NCT03867942 934 940 O
. NCT03867942 940 941 O

- NCT03867942 945 946 O
People NCT03867942 948 954 O
who NCT03867942 955 958 O
are NCT03867942 959 962 O
suitable NCT03867942 963 971 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867942 972 974 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03867942 975 986 I-Assertion___Assertion-Type-Value:hypothetical
clinical NCT03867942 987 995 O
trial NCT03867942 996 1001 O
by NCT03867942 1002 1004 B-Modifier
physical NCT03867942 1005 1013 B-Procedure
examination NCT03867942 1014 1025 I-Procedure|Procedure
, NCT03867942 1026 1027 O
lab NCT03867942 1028 1031 B-Observation
test NCT03867942 1032 1036 I-Observation
and NCT03867942 1037 1040 B-And
medical NCT03867942 1041 1048 B-Procedure
examination NCT03867942 1049 1060 O
by NCT03867942 1061 1063 O
interview NCT03867942 1064 1073 I-Modifier
. NCT03867942 1073 1074 O

Exclusion NCT03867942 1076 1085 O
Criteria NCT03867942 1086 1094 O
: NCT03867942 1095 1096 O

- NCT03867942 1100 1101 O
Genetic NCT03867942 1103 1110 B-Condition
problems NCT03867942 1111 1119 I-Condition
such NCT03867942 1120 1124 O
as NCT03867942 1125 1127 O
galactose NCT03867942 1128 1137 I-Condition|Condition
intolerance NCT03867942 1138 1149 I-Condition
, NCT03867942 1150 1151 O
Lapp NCT03867942 1152 1156 B-Condition
lacatase NCT03867942 1157 1165 I-Condition
deficiency NCT03867942 1166 1176 I-Condition
, NCT03867942 1177 1178 O
glucose NCT03867942 1179 1186 B-Condition
- NCT03867942 1187 1188 I-Condition
galactose NCT03867942 1189 1198 O
malabsorption NCT03867942 1199 1212 I-Condition

- NCT03867942 1215 1216 O
Clinically NCT03867942 1218 1228 O
significant NCT03867942 1229 1240 O
disease NCT03867942 1241 1248 B-Condition
such NCT03867942 1249 1253 O
as NCT03867942 1254 1256 O
liver NCT03867942 1257 1262 B-Modifier
, NCT03867942 1263 1264 O
kidney NCT03867942 1265 1271 B-Modifier
, NCT03867942 1272 1273 O
digestive NCT03867942 1274 1283 B-Modifier
, NCT03867942 1284 1285 O
pulmonary NCT03867942 1286 1295 B-Modifier
, NCT03867942 1296 1297 O
endocrine NCT03867942 1298 1307 B-Modifier
system NCT03867942 1308 1314 I-Modifier
, NCT03867942 1315 1316 O
cardiovascular NCT03867942 1317 1331 B-Modifier
disease NCT03867942 1332 1339 I-Condition|Condition
etc NCT03867942 1340 1343 O
. NCT03867942 1343 1344 O

- NCT03867942 1348 1349 O
People NCT03867942 1351 1357 O
who NCT03867942 1358 1361 O
have NCT03867942 1362 1366 O
gastrointestinal NCT03867942 1367 1383 B-Condition
disease NCT03867942 1384 1391 O
or NCT03867942 1392 1394 B-Or
history NCT03867942 1395 1402 B-Eq-Comparison
of NCT03867942 1403 1405 O
surgery NCT03867942 1406 1413 B-Procedure
which NCT03867942 1414 1419 O
would NCT03867942 1420 1425 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03867942 1426 1432 O
absorption NCT03867942 1433 1443 B-Condition
of NCT03867942 1444 1446 O
drug NCT03867942 1447 1451 B-Drug|Drug
. NCT03867942 1451 1452 O

- NCT03867942 1456 1457 I-Condition
History NCT03867942 1459 1466 B-Eq-Comparison
of NCT03867942 1467 1469 O
clinically NCT03867942 1470 1480 O
significant NCT03867942 1481 1492 O
drug NCT03867942 1493 1497 B-Drug
induced NCT03867942 1498 1505 O
hyper NCT03867942 1506 1511 B-Condition
- NCT03867942 1512 1513 O
sensitive NCT03867942 1514 1523 I-Condition
reaction NCT03867942 1524 1532 I-Condition
or NCT03867942 1533 1535 B-Or
drug NCT03867942 1536 1540 O
related NCT03867942 1541 1548 O
muscular NCT03867942 1549 1557 B-Condition
disease NCT03867942 1558 1565 I-Condition

Inclusion NCT03865199 0 9 O
Criteria NCT03865199 10 18 O
: NCT03865199 19 20 O

- NCT03865199 24 25 O
Women NCT03865199 27 32 O
aged NCT03865199 33 37 B-Age
18 NCT03865199 38 40 B-Eq-Comparison
or NCT03865199 41 43 I-Eq-Comparison
older NCT03865199 44 49 I-Eq-Comparison
undergoing NCT03865199 50 60 B-Eq-Comparison
medical NCT03865199 61 68 B-Modifier
or NCT03865199 69 71 B-Or
surgical NCT03865199 72 80 B-Modifier
abortion NCT03865199 81 89 B-Procedure
at NCT03865199 90 92 O
Planned NCT03865199 93 100 O
Parenthood NCT03865199 101 111 O
of NCT03865199 112 114 O
Illinois NCT03865199 115 123 O
( NCT03865199 124 125 O
PPIL NCT03865199 126 130 O
) NCT03865199 131 132 O
will NCT03865199 133 137 O
be NCT03865199 138 140 O
eligible NCT03865199 141 149 O
for NCT03865199 150 153 O
inclusion NCT03865199 154 163 O
. NCT03865199 163 164 O
Inclusion NCT03865199 166 175 O
criteria NCT03865199 176 184 O
include NCT03865199 185 192 O
having NCT03865199 193 199 O
an NCT03865199 200 202 O
intrauterine NCT03865199 203 215 B-Modifier
pregnancy NCT03865199 216 225 B-Condition
, NCT03865199 226 227 O
having NCT03865199 228 234 O
a NCT03865199 235 236 O
smart NCT03865199 237 242 O
phone NCT03865199 243 248 O
to NCT03865199 249 251 O
be NCT03865199 252 254 O
able NCT03865199 255 259 O
to NCT03865199 260 262 O
follow NCT03865199 263 269 O
- NCT03865199 270 271 O
up NCT03865199 272 274 O
by NCT03865199 275 277 O
text NCT03865199 278 282 O
message NCT03865199 283 290 O
2 NCT03865199 291 292 B-Eq-Comparison
- NCT03865199 293 294 I-Eq-Comparison
4 NCT03865199 295 296 I-Eq-Comparison
weeks NCT03865199 297 302 I-Eq-Comparison
after NCT03865199 303 308 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865199 309 312 O
clinic NCT03865199 313 319 B-Encounter
appointment NCT03865199 320 331 I-Encounter
, NCT03865199 332 333 O
having NCT03865199 334 340 O
no NCT03865199 341 343 B-Negation
contraindications NCT03865199 344 361 B-Contraindication
to NCT03865199 362 364 O
an NCT03865199 365 367 O
outpatient NCT03865199 368 378 B-Encounter
medication NCT03865199 379 389 B-Modifier
or NCT03865199 390 392 B-Or
surgical NCT03865199 393 401 B-Modifier
abortion NCT03865199 402 410 B-Procedure
that NCT03865199 411 415 O
same NCT03865199 416 420 O
day NCT03865199 421 424 O
, NCT03865199 425 426 O
and NCT03865199 427 430 O
not NCT03865199 431 434 O
meeting NCT03865199 435 442 O
any NCT03865199 443 446 O
exclusion NCT03865199 447 456 O
criteria NCT03865199 457 465 O
. NCT03865199 465 466 O

Exclusion NCT03865199 468 477 O
Criteria NCT03865199 478 486 O
: NCT03865199 487 488 O

- NCT03865199 492 493 O
Exclusion NCT03865199 495 504 O
criteria NCT03865199 505 513 O
will NCT03865199 514 518 O
include NCT03865199 519 526 O
non NCT03865199 527 530 B-Negation
- NCT03865199 531 532 O
English NCT03865199 533 540 O
speaking NCT03865199 541 549 O
, NCT03865199 550 551 O
no NCT03865199 552 554 O
working NCT03865199 555 562 O
telephone NCT03865199 563 572 O
, NCT03865199 573 574 O
and NCT03865199 575 578 O
less NCT03865199 579 583 B-Eq-Comparison
than NCT03865199 584 588 I-Eq-Comparison
5 NCT03865199 589 590 I-Eq-Comparison
th NCT03865199 591 593 O
grade NCT03865199 594 599 I-Eq-Comparison
education NCT03865199 600 609 B-Observation
level NCT03865199 610 615 I-Observation
. NCT03865199 615 616 O

Inclusion NCT03860142 0 9 O
Criteria NCT03860142 10 18 O
: NCT03860142 19 20 O

- NCT03860142 24 25 O
Children NCT03860142 27 35 O
whose NCT03860142 36 41 B-And
age NCT03860142 42 45 B-Age
≥ NCT03860142 46 47 B-Eq-Comparison
24 NCT03860142 48 50 I-Eq-Comparison
months NCT03860142 51 57 I-Eq-Comparison
and NCT03860142 58 61 B-And
≤ NCT03860142 62 63 B-Eq-Comparison
36 NCT03860142 64 66 I-Eq-Comparison
months NCT03860142 67 73 I-Eq-Comparison

- NCT03860142 76 77 O
Full NCT03860142 79 83 B-Modifier
- NCT03860142 84 85 I-Modifier
term NCT03860142 86 90 I-Modifier
or NCT03860142 91 93 B-Or
prematurely NCT03860142 94 105 B-Modifier
born NCT03860142 106 110 B-Birth
( NCT03860142 111 112 O
< NCT03860142 114 115 B-Eq-Comparison
33 NCT03860142 116 118 I-Eq-Comparison
SA NCT03860142 119 121 B-Observation
) NCT03860142 122 123 O
at NCT03860142 124 126 O
Nice NCT03860142 127 131 O
University NCT03860142 132 142 O
Hospital NCT03860142 143 151 O

Exclusion NCT03860142 152 161 O
Criteria NCT03860142 162 170 O
: NCT03860142 171 172 O

- NCT03860142 176 177 O
Children NCT03860142 179 187 O
with NCT03860142 188 192 B-And
congenital NCT03860142 193 203 B-Condition
pathologies NCT03860142 204 215 I-Condition
( NCT03860142 216 217 O
with NCT03860142 218 222 O
malformations NCT03860142 223 236 B-Condition
in NCT03860142 237 239 O
the NCT03860142 240 243 O
oro NCT03860142 244 247 B-Modifier
- NCT03860142 248 249 I-Modifier
facial NCT03860142 250 256 I-Modifier
sphere NCT03860142 257 263 I-Modifier
) NCT03860142 264 265 O

- NCT03860142 269 270 O
Children NCT03860142 272 280 O
with NCT03860142 281 285 B-And
neurological NCT03860142 286 298 B-Modifier
and NCT03860142 299 302 B-Or
developmental NCT03860142 303 316 B-Modifier
pathologies NCT03860142 317 328 B-Condition
unrelated NCT03860142 329 338 B-Exception
to NCT03860142 339 341 I-Exception
prematurity NCT03860142 342 353 B-Condition

- NCT03860142 356 357 O
Children NCT03860142 359 367 O
with NCT03860142 368 372 B-And
ENT NCT03860142 373 376 B-Condition
deformities NCT03860142 377 388 I-Condition

- NCT03860142 391 392 O
Parental NCT03860142 394 402 B-Family-Member___Family-Member-Type:parent
langage NCT03860142 403 410 B-Condition
barrier NCT03860142 411 418 I-Condition

Inclusion NCT03862755 0 9 O
Criteria NCT03862755 10 18 O
: NCT03862755 19 20 O

- NCT03862755 24 25 O
Lung NCT03862755 27 31 B-Procedure
surgical NCT03862755 32 40 I-Procedure
patients NCT03862755 41 49 O
who NCT03862755 50 53 B-And
were NCT03862755 54 58 O
sent NCT03862755 59 63 B-Encounter
to NCT03862755 64 66 O
thoracic NCT03862755 67 75 B-Modifier
post NCT03862755 76 80 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862755 81 82 O
- NCT03862755 84 85 O
operative NCT03862755 86 95 B-Procedure
intensive NCT03862755 96 105 O
care NCT03862755 106 110 O
unit NCT03862755 111 115 O
( NCT03862755 116 117 O
ICU NCT03862755 118 121 O
) NCT03862755 122 123 O
ward NCT03862755 124 128 O
right NCT03862755 129 134 O
after NCT03862755 135 140 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03862755 141 148 B-Procedure
and NCT03862755 149 152 B-And
stayed NCT03862755 153 159 B-Encounter
in NCT03862755 160 162 O
ICU NCT03862755 163 166 O
for NCT03862755 167 170 O
at NCT03862755 171 173 B-Eq-Comparison
least NCT03862755 174 179 I-Eq-Comparison
24 NCT03862755 180 182 I-Eq-Comparison
hours NCT03862755 183 188 I-Eq-Comparison
. NCT03862755 188 189 O

Exclusion NCT03862755 191 200 O
Criteria NCT03862755 201 209 O
: NCT03862755 210 211 O

- NCT03862755 215 216 O
Cases NCT03862755 218 223 O
received NCT03862755 224 232 B-Eq-Comparison
inferior NCT03862755 233 241 B-Procedure
vena NCT03862755 242 246 I-Procedure
filter NCT03862755 247 253 I-Procedure
and NCT03862755 254 257 B-Or
anti NCT03862755 258 262 B-Procedure
- NCT03862755 263 264 I-Procedure
coagulation NCT03862755 265 276 I-Procedure
treatment NCT03862755 277 286 I-Procedure
history NCT03862755 287 294 B-Eq-Comparison
. NCT03862755 294 295 O

Inclusion NCT03862027 0 9 O
Criteria NCT03862027 10 18 O
: NCT03862027 19 20 O

- NCT03862027 24 25 O
Adult NCT03862027 27 32 O
patients NCT03862027 33 41 O
( NCT03862027 42 43 O
age NCT03862027 44 47 B-Age
> NCT03862027 48 49 B-Eq-Comparison
/ NCT03862027 51 52 I-Eq-Comparison
= NCT03862027 54 55 I-Eq-Comparison
18 NCT03862027 56 58 I-Eq-Comparison
) NCT03862027 59 60 O
admitted NCT03862027 61 69 B-Encounter
to NCT03862027 70 72 O
the NCT03862027 73 76 O
Neuro NCT03862027 77 82 O
ICU NCT03862027 83 86 O
of NCT03862027 87 89 O
UNC NCT03862027 90 93 O
Hospital NCT03862027 94 102 O
requiring NCT03862027 103 112 O
mechanical NCT03862027 113 123 B-Procedure
ventilation NCT03862027 124 135 I-Procedure
and NCT03862027 136 139 B-And
with NCT03862027 140 144 O
ICP NCT03862027 145 148 B-Procedure
monitoring NCT03862027 149 159 I-Procedure
in NCT03862027 160 162 O
place NCT03862027 163 168 O
. NCT03862027 168 169 O

Exclusion NCT03862027 171 180 O
Criteria NCT03862027 181 189 O
: NCT03862027 190 191 O

1 NCT03862027 195 196 O
. NCT03862027 196 197 O
Pneumothorax NCT03862027 199 211 B-Condition
or NCT03862027 212 214 B-Or
pneumomediastinum NCT03862027 215 232 B-Condition

2 NCT03862027 235 236 O
. NCT03862027 236 237 O
Life NCT03862027 239 243 B-Observation
expectancy NCT03862027 244 254 I-Observation
< NCT03862027 255 256 B-Eq-Comparison
24 NCT03862027 257 259 I-Eq-Comparison
hours NCT03862027 260 265 I-Eq-Comparison
or NCT03862027 266 268 B-Or
expected NCT03862027 269 277 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862027 278 280 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03862027 281 288 O
mechanical NCT03862027 289 299 B-Procedure
ventilation NCT03862027 300 311 I-Procedure
for NCT03862027 312 315 O
< NCT03862027 316 317 B-Eq-Comparison
24 NCT03862027 318 320 I-Eq-Comparison
hours NCT03862027 321 326 I-Eq-Comparison

3 NCT03862027 329 330 O
. NCT03862027 330 331 O
Condition NCT03862027 333 342 B-Condition
that NCT03862027 343 347 O
precludes NCT03862027 348 357 B-Assertion___Assertion-Type-Value:hypothetical|Negation
placement NCT03862027 358 367 O
of NCT03862027 368 370 O
an NCT03862027 371 373 O
esophageal NCT03862027 374 384 B-Procedure
balloon NCT03862027 385 392 I-Procedure
[ NCT03862027 393 394 O
esophageal NCT03862027 395 405 B-Modifier
or NCT03862027 406 408 B-Or
nasopharyngeal NCT03862027 409 423 B-Modifier
pathology NCT03862027 424 433 B-Condition
preventing NCT03862027 434 444 B-Assertion___Assertion-Type-Value:hypothetical|Negation
insertion NCT03862027 445 454 O
of NCT03862027 455 457 O
the NCT03862027 458 461 O
esophageal NCT03862027 462 472 B-Procedure
balloon NCT03862027 473 480 I-Procedure
catheter NCT03862027 481 489 I-Procedure
( NCT03862027 490 491 O
esophageal NCT03862027 492 502 B-Condition
ulcerations NCT03862027 503 514 I-Condition
, NCT03862027 515 516 O
tumors NCT03862027 517 523 B-Condition
, NCT03862027 524 525 O
diverticulitis NCT03862027 526 540 B-Condition
, NCT03862027 541 542 O
bleeding NCT03862027 543 551 B-Condition
varices NCT03862027 552 559 I-Condition
or NCT03862027 560 562 B-Or
in NCT03862027 563 565 O
patients NCT03862027 566 574 O
with NCT03862027 575 579 O
sinusitis NCT03862027 580 589 B-Condition
, NCT03862027 590 591 O
epistaxis NCT03862027 592 601 B-Condition
or NCT03862027 602 604 B-Or
recent NCT03862027 605 611 B-Eq-Comparison
nasopharyngeal NCT03862027 612 626 B-Procedure
surgery NCT03862027 627 634 I-Procedure
) NCT03862027 635 636 O
, NCT03862027 638 639 O
severe NCT03862027 640 646 O
thrombocytopenia NCT03862027 647 663 B-Condition
( NCT03862027 664 665 O
platelet NCT03862027 666 674 B-Observation
count NCT03862027 675 680 I-Observation
< NCT03862027 681 682 B-Eq-Comparison
30 NCT03862027 683 685 I-Eq-Comparison
) NCT03862027 686 687 O
or NCT03862027 688 690 B-Or|Or
coagulopathy NCT03862027 691 703 B-Condition
( NCT03862027 704 705 O
INR NCT03862027 706 709 B-Observation
> NCT03862027 710 711 B-Eq-Comparison
3 NCT03862027 712 713 I-Eq-Comparison
or NCT03862027 714 716 B-Drug
on NCT03862027 717 719 B-Eq-Comparison
oral NCT03862027 720 724 O
anticoagulants NCT03862027 725 739 I-Drug
) NCT03862027 740 741 O
. NCT03862027 742 743 O

4 NCT03862027 747 748 O
. NCT03862027 748 749 O
Pre NCT03862027 751 754 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 755 756 O
enrollment NCT03862027 757 767 B-Study
ICP NCT03862027 768 771 B-Observation
> NCT03862027 772 773 B-Eq-Comparison
20 NCT03862027 774 776 I-Eq-Comparison
mm NCT03862027 777 779 I-Eq-Comparison
Hg NCT03862027 780 782 I-Eq-Comparison|Eq-Comparison

5 NCT03862027 785 786 O
. NCT03862027 786 787 O
Pre NCT03862027 789 792 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 793 794 O
enrollment NCT03862027 795 805 B-Study
CPP NCT03862027 806 809 B-Observation
< NCT03862027 810 811 B-Eq-Comparison
60 NCT03862027 812 814 I-Eq-Comparison
mm NCT03862027 815 817 I-Eq-Comparison
Hg NCT03862027 818 820 O

6 NCT03862027 823 824 O
. NCT03862027 824 825 O
Planned NCT03862027 827 834 B-Eq-Comparison
change NCT03862027 835 841 O
in NCT03862027 842 844 O
the NCT03862027 845 848 O
external NCT03862027 849 857 B-Procedure
ventricular NCT03862027 858 869 I-Procedure
drain NCT03862027 870 875 I-Procedure
set NCT03862027 876 879 B-Modifier
point NCT03862027 880 885 I-Modifier
during NCT03862027 886 892 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862027 893 896 O
pre NCT03862027 897 900 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 901 902 O
intervention NCT03862027 903 915 B-Procedure|Procedure|Procedure
, NCT03862027 916 917 O
intervention NCT03862027 918 930 O
or NCT03862027 931 933 B-Or
post NCT03862027 934 938 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862027 939 940 O
intervention NCT03862027 941 953 O
periods NCT03862027 954 961 O

7 NCT03862027 964 965 O
. NCT03862027 965 966 O
Incarceration NCT03862027 968 981 B-Observation

8 NCT03862027 984 985 O
. NCT03862027 985 986 O
Variation NCT03862027 988 997 O
in NCT03862027 998 1000 B-Procedure
ICP NCT03862027 1001 1004 B-Observation
of NCT03862027 1005 1007 O
> NCT03862027 1008 1009 B-Eq-Comparison
2 NCT03862027 1010 1011 I-Eq-Comparison
cm NCT03862027 1012 1014 I-Eq-Comparison
H2O NCT03862027 1015 1018 I-Eq-Comparison
in NCT03862027 1019 1021 O
the NCT03862027 1022 1025 O
hour NCT03862027 1026 1030 B-Eq-Comparison
prior NCT03862027 1031 1036 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862027 1037 1039 I-Temporal-Connection___Temporal-Connection-Type-Value:before
intervention NCT03862027 1040 1052 O
. NCT03862027 1052 1053 O

Subjects NCT03860181 0 8 O
will NCT03860181 9 13 O
be NCT03860181 14 16 O
included NCT03860181 17 25 O
if NCT03860181 26 28 O
: NCT03860181 29 30 O

- NCT03860181 34 35 O
They NCT03860181 37 41 O
are NCT03860181 42 45 O
18 NCT03860181 46 48 B-Eq-Comparison
years NCT03860181 49 54 I-Eq-Comparison
or NCT03860181 55 57 I-Eq-Comparison
older NCT03860181 58 63 I-Age|Eq-Comparison
; NCT03860181 63 64 O

- NCT03860181 67 68 O
They NCT03860181 70 74 O
are NCT03860181 75 78 O
undergoing NCT03860181 79 89 B-Eq-Comparison
primary NCT03860181 90 97 B-Modifier
total NCT03860181 98 103 B-Procedure
shoulder NCT03860181 104 112 I-Procedure
arthroplasty NCT03860181 113 125 I-Procedure
by NCT03860181 126 128 O
the NCT03860181 129 132 O
principal NCT03860181 133 142 O
and NCT03860181 143 146 O
co NCT03860181 147 149 O
- NCT03860181 150 151 O
investigator NCT03860181 152 164 O
. NCT03860181 164 165 O

- NCT03860181 169 170 O
They NCT03860181 172 176 O
are NCT03860181 177 180 O
willing NCT03860181 181 188 O
and NCT03860181 189 192 O
have NCT03860181 193 197 O
the NCT03860181 198 201 O
capacity NCT03860181 202 210 O
to NCT03860181 211 213 O
provide NCT03860181 214 221 O
informed NCT03860181 222 230 O
consent NCT03860181 231 238 O
; NCT03860181 238 239 O

- NCT03860181 242 243 O
They NCT03860181 245 249 O
expect NCT03860181 250 256 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860181 257 259 I-Assertion___Assertion-Type-Value:hypothetical
continue NCT03860181 260 268 O
their NCT03860181 269 274 O
post NCT03860181 275 279 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03860181 280 281 O
- NCT03860181 283 284 O
operative NCT03860181 285 294 B-Procedure
follow NCT03860181 295 301 B-Encounter
up NCT03860181 302 304 I-Encounter
care NCT03860181 305 309 I-Encounter
with NCT03860181 310 314 O
their NCT03860181 315 320 O
operating NCT03860181 321 330 O
surgeons NCT03860181 331 339 O
at NCT03860181 340 342 O
Medical NCT03860181 343 350 O
University NCT03860181 351 361 O
of NCT03860181 362 364 O
South NCT03860181 365 370 O
Carolina NCT03860181 371 379 O
( NCT03860181 380 381 O
MUSC NCT03860181 382 386 O
) NCT03860181 387 388 O
. NCT03860181 389 390 O

Subjects NCT03860181 392 400 O
will NCT03860181 401 405 O
be NCT03860181 406 408 O
excluded NCT03860181 409 417 O
if NCT03860181 418 420 O
: NCT03860181 421 422 O

- NCT03860181 426 427 O
They NCT03860181 429 433 O
have NCT03860181 434 438 O
a NCT03860181 439 440 O
unique NCT03860181 441 447 O
, NCT03860181 448 449 O
identifying NCT03860181 450 461 O
tattoo NCT03860181 462 468 B-Condition
or NCT03860181 469 471 B-Or
skin NCT03860181 472 476 B-Condition
marking NCT03860181 477 484 I-Condition
within NCT03860181 485 491 B-Eq-Comparison
2 NCT03860181 492 493 I-Eq-Comparison
inches NCT03860181 494 500 I-Eq-Comparison
of NCT03860181 501 503 O
intended NCT03860181 504 512 B-Modifier
site NCT03860181 513 517 I-Modifier
of NCT03860181 518 520 O
surgical NCT03860181 521 529 B-Procedure
incision NCT03860181 530 538 I-Procedure

- NCT03860181 541 542 O
They NCT03860181 544 548 O
self NCT03860181 549 553 O
- NCT03860181 554 555 O
report NCT03860181 556 562 O
a NCT03860181 563 564 O
known NCT03860181 565 570 O
hypersensitivity NCT03860181 571 587 B-Condition
to NCT03860181 588 590 O
cyanoacrylate NCT03860181 591 604 B-Drug
, NCT03860181 605 606 O
formaldehyde NCT03860181 607 619 B-Drug
, NCT03860181 620 621 O
benzalkonium NCT03860181 622 634 B-Drug
chloride NCT03860181 635 643 I-Drug
, NCT03860181 644 645 O
or NCT03860181 646 648 B-Or
pressure NCT03860181 649 657 B-Condition
sensitive NCT03860181 658 667 I-Condition
adhesive NCT03860181 668 676 I-Condition
; NCT03860181 676 677 O

- NCT03860181 680 681 O
They NCT03860181 683 687 O
self NCT03860181 688 692 O
- NCT03860181 693 694 O
report NCT03860181 695 701 O
or NCT03860181 702 704 O
have NCT03860181 705 709 O
a NCT03860181 710 711 O
documented NCT03860181 712 722 O
prior NCT03860181 723 728 B-Eq-Comparison
ipsilateral NCT03860181 729 740 B-Modifier
shoulder NCT03860181 741 749 B-Procedure
arthroplasty NCT03860181 750 762 I-Procedure
or NCT03860181 763 765 B-Or
other NCT03860181 766 771 B-Other
open NCT03860181 772 776 B-Modifier
ispilateral NCT03860181 777 788 I-Modifier
shoulder NCT03860181 789 797 B-Procedure
surgery NCT03860181 798 805 I-Procedure
utilizing NCT03860181 806 815 O
the NCT03860181 816 819 O
delto NCT03860181 820 825 B-Modifier
- NCT03860181 826 827 I-Modifier
pectoral NCT03860181 828 836 I-Modifier
approach NCT03860181 837 845 I-Modifier
; NCT03860181 845 846 O

- NCT03860181 849 850 O
Their NCT03860181 852 857 O
medical NCT03860181 858 865 O
record NCT03860181 866 872 O
shows NCT03860181 873 878 O
that NCT03860181 879 883 O
they NCT03860181 884 888 O
are NCT03860181 889 892 O
HIV NCT03860181 893 896 B-Condition
positive NCT03860181 897 905 O
or NCT03860181 906 908 B-Or
otherwise NCT03860181 909 918 O
immunocompromised NCT03860181 919 936 B-Condition
; NCT03860181 936 937 O

- NCT03860181 940 941 O
Their NCT03860181 943 948 O
medical NCT03860181 949 956 O
record NCT03860181 957 963 O
shows NCT03860181 964 969 O
a NCT03860181 970 971 O
skin NCT03860181 972 976 B-Modifier
abnormality NCT03860181 977 988 B-Condition
or NCT03860181 989 991 B-Or
dermatological NCT03860181 992 1006 B-Condition
condition NCT03860181 1007 1016 I-Condition
which NCT03860181 1017 1022 O
affects NCT03860181 1023 1030 B-Assertion___Assertion-Type-Value:hypothetical
skin NCT03860181 1031 1035 B-Condition
healing NCT03860181 1036 1043 I-Condition
; NCT03860181 1043 1044 O

- NCT03860181 1047 1048 O
They NCT03860181 1050 1054 O
report NCT03860181 1055 1061 O
a NCT03860181 1062 1063 O
personal NCT03860181 1064 1072 B-Family-Member___Family-Member-Type:patient
or NCT03860181 1073 1075 B-Or
family NCT03860181 1076 1082 B-Family-Member
history NCT03860181 1083 1090 I-Family-Member
of NCT03860181 1091 1093 O
significant NCT03860181 1094 1105 O
keloid NCT03860181 1106 1112 B-Modifier
or NCT03860181 1113 1115 B-Or
significant NCT03860181 1116 1127 O
hypertrophic NCT03860181 1128 1140 B-Condition
scar NCT03860181 1141 1145 I-Condition
formations NCT03860181 1146 1156 I-Condition
, NCT03860181 1157 1158 O
or NCT03860181 1159 1161 B-Or
other NCT03860181 1162 1167 B-Other
problems NCT03860181 1168 1176 B-Condition
with NCT03860181 1177 1181 I-Condition
wound NCT03860181 1182 1187 I-Condition
healing NCT03860181 1188 1195 I-Condition
. NCT03860181 1195 1196 O

Inclusion NCT03867188 0 9 O
Criteria NCT03867188 10 18 O
: NCT03867188 19 20 O

- NCT03867188 24 25 O
Patients NCT03867188 27 35 O
with NCT03867188 36 40 O
a NCT03867188 41 42 O
soft NCT03867188 43 47 B-Modifier
tissue NCT03867188 48 54 I-Modifier
sarcoma NCT03867188 55 62 B-Condition
of NCT03867188 63 65 O
the NCT03867188 66 69 O
thigh NCT03867188 70 75 B-Modifier

- NCT03867188 78 79 O
Must NCT03867188 81 85 O
have NCT03867188 86 90 O
sufficient NCT03867188 91 101 O
health NCT03867188 102 108 B-Condition
to NCT03867188 109 111 B-Assertion___Assertion-Type-Value:hypothetical
withstand NCT03867188 112 121 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03867188 122 125 O
physical NCT03867188 126 134 O
demands NCT03867188 135 142 O
of NCT03867188 143 145 O
surgery NCT03867188 146 153 B-Procedure

- NCT03867188 156 157 O
≥ NCT03867188 159 160 B-Eq-Comparison
18 NCT03867188 161 163 I-Eq-Comparison
years NCT03867188 164 169 I-Eq-Comparison
old NCT03867188 170 173 I-Age|Eq-Comparison

- NCT03867188 176 177 O
ECOG NCT03867188 179 183 B-Observation
performance NCT03867188 184 195 I-Observation
status NCT03867188 196 202 I-Observation
of NCT03867188 203 205 O
≤ NCT03867188 206 207 B-Eq-Comparison
2 NCT03867188 208 209 I-Eq-Comparison

- NCT03867188 213 214 O
Ability NCT03867188 216 223 O
to NCT03867188 224 226 O
understand NCT03867188 227 237 O
and NCT03867188 238 241 O
the NCT03867188 242 245 O
willingness NCT03867188 246 257 O
to NCT03867188 258 260 O
sign NCT03867188 261 265 O
an NCT03867188 266 268 O
IRB NCT03867188 269 272 O
- NCT03867188 273 274 O
approved NCT03867188 275 283 O
informed NCT03867188 284 292 O
consent NCT03867188 293 300 O
document NCT03867188 301 309 O
( NCT03867188 310 311 O
either NCT03867188 312 318 O
directly NCT03867188 319 327 O
or NCT03867188 328 330 O
via NCT03867188 331 334 O
a NCT03867188 335 336 O
legally NCT03867188 337 344 O
authorized NCT03867188 345 355 O
representative NCT03867188 356 370 O
) NCT03867188 371 372 O

Exclusion NCT03867188 374 383 O
Criteria NCT03867188 384 392 O
: NCT03867188 393 394 O

- NCT03867188 398 399 O
History NCT03867188 401 408 B-Eq-Comparison
of NCT03867188 409 411 O
clinically NCT03867188 412 422 O
significant NCT03867188 423 434 O
medical NCT03867188 435 442 B-Condition
conditions NCT03867188 443 453 I-Condition
including NCT03867188 454 463 O
: NCT03867188 464 465 O
Cardiovascular NCT03867188 466 480 O
: NCT03867188 481 482 O
Atrial NCT03867188 483 489 B-Condition
Fibrillation NCT03867188 490 502 I-Condition
, NCT03867188 503 504 O
Ventricular NCT03867188 505 516 B-Condition
Fibrillation NCT03867188 517 529 I-Condition
, NCT03867188 530 531 O
Significant NCT03867188 532 543 O
Coronary NCT03867188 544 552 B-Condition
Artery NCT03867188 553 559 I-Condition
Disease NCT03867188 560 567 I-Condition
. NCT03867188 567 568 O
Hepatic NCT03867188 570 577 O
: NCT03867188 578 579 O
Viral NCT03867188 580 585 B-Modifier
or NCT03867188 586 588 B-Or
Autoimmune NCT03867188 589 599 B-Modifier
Hepatitis NCT03867188 600 609 B-Condition
, NCT03867188 610 611 O
Cirrhosis NCT03867188 612 621 B-Condition
of NCT03867188 622 624 O
the NCT03867188 625 628 O
Liver NCT03867188 629 634 B-Modifier|Modifier
, NCT03867188 635 636 O
Liver NCT03867188 637 642 O
Metabolism NCT03867188 643 653 B-Condition
Disorders NCT03867188 654 663 I-Condition
. NCT03867188 663 664 O
Renal NCT03867188 666 671 O
: NCT03867188 672 673 O
Any NCT03867188 674 677 O
form NCT03867188 678 682 O
of NCT03867188 683 685 O
renal NCT03867188 686 691 B-Condition
impairment NCT03867188 692 702 I-Condition
. NCT03867188 702 703 O
EXPAREL NCT03867188 705 712 B-Drug
® NCT03867188 712 713 O
is NCT03867188 714 716 O
cleared NCT03867188 717 724 O
by NCT03867188 725 727 O
the NCT03867188 728 731 O
kidneys NCT03867188 732 739 O
, NCT03867188 740 741 O
thus NCT03867188 742 746 O
any NCT03867188 747 750 O
form NCT03867188 751 755 O
of NCT03867188 756 758 O
renal NCT03867188 759 764 B-Condition
impairment NCT03867188 765 775 I-Condition
could NCT03867188 776 781 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03867188 782 786 O
to NCT03867188 787 789 O
an NCT03867188 790 792 O
adverse NCT03867188 793 800 B-Condition
reaction NCT03867188 801 809 I-Condition
. NCT03867188 809 810 O

- NCT03867188 814 815 O
Medical NCT03867188 817 824 B-Condition
condition NCT03867188 825 834 I-Condition
( NCT03867188 835 836 O
s NCT03867188 837 838 O
) NCT03867188 839 840 O
or NCT03867188 841 843 B-Or
concurrent NCT03867188 844 854 B-Modifier
surgery NCT03867188 855 862 B-Procedure
that NCT03867188 863 867 O
may NCT03867188 868 871 B-Assertion___Assertion-Type-Value:hypothetical
have NCT03867188 872 876 I-Assertion___Assertion-Type-Value:hypothetical
required NCT03867188 877 885 O
analgesic NCT03867188 886 895 B-Procedure
treatment NCT03867188 896 905 I-Procedure
in NCT03867188 906 908 O
the NCT03867188 909 912 O
post NCT03867188 913 917 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03867188 918 919 O
- NCT03867188 921 922 O
operative NCT03867188 923 932 B-Procedure
period NCT03867188 933 939 O
for NCT03867188 940 943 O
pain NCT03867188 944 948 B-Condition
that NCT03867188 949 953 O
was NCT03867188 954 957 O
not NCT03867188 958 961 B-Negation
strictly NCT03867188 962 970 O
related NCT03867188 971 978 O
to NCT03867188 979 981 O
the NCT03867188 982 985 O
study NCT03867188 986 991 B-Study
surgery NCT03867188 992 999 B-Procedure
. NCT03867188 999 1000 O

- NCT03867188 1004 1005 O
Any NCT03867188 1007 1010 O
clinically NCT03867188 1011 1021 O
significant NCT03867188 1022 1033 O
event NCT03867188 1034 1039 B-Observation
or NCT03867188 1040 1042 B-Or
condition NCT03867188 1043 1052 B-Condition
discovered NCT03867188 1053 1063 O
during NCT03867188 1064 1070 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgery NCT03867188 1071 1078 B-Procedure
that NCT03867188 1079 1083 O
may NCT03867188 1084 1087 O
have NCT03867188 1088 1092 O
complicated NCT03867188 1093 1104 O
the NCT03867188 1105 1108 O
patient NCT03867188 1109 1116 O
's NCT03867188 1116 1118 O
post NCT03867188 1119 1123 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgical NCT03867188 1124 1132 B-Procedure
course NCT03867188 1133 1139 O
such NCT03867188 1140 1144 O
as NCT03867188 1145 1147 O
vascular NCT03867188 1148 1156 B-Modifier
or NCT03867188 1157 1159 B-Or
nerve NCT03867188 1160 1165 B-Modifier
involvement NCT03867188 1166 1177 B-Condition
that NCT03867188 1178 1182 O
was NCT03867188 1183 1186 O
unknown NCT03867188 1187 1194 O
before NCT03867188 1195 1201 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03867188 1202 1209 B-Procedure
. NCT03867188 1209 1210 O

- NCT03867188 1214 1215 O
History NCT03867188 1217 1224 B-Eq-Comparison
of NCT03867188 1225 1227 O
allergic NCT03867188 1228 1236 B-Allergy
reactions NCT03867188 1237 1246 I-Allergy
attributed NCT03867188 1247 1257 O
to NCT03867188 1258 1260 O
compounds NCT03867188 1261 1270 O
of NCT03867188 1271 1273 O
similar NCT03867188 1274 1281 O
chemical NCT03867188 1282 1290 O
or NCT03867188 1291 1293 O
biologic NCT03867188 1294 1302 O
composition NCT03867188 1303 1314 O
to NCT03867188 1315 1317 O
liposomal NCT03867188 1318 1327 B-Drug
bupivacaine NCT03867188 1328 1339 I-Drug
. NCT03867188 1339 1340 O

- NCT03867188 1344 1345 O
Pregnant NCT03867188 1347 1355 B-Condition
women NCT03867188 1356 1361 O
are NCT03867188 1362 1365 O
excluded NCT03867188 1366 1374 B-Negation
from NCT03867188 1375 1379 O
this NCT03867188 1380 1384 O
study NCT03867188 1385 1390 B-Study
because NCT03867188 1391 1398 O
EXPAREL NCT03867188 1399 1406 B-Drug
has NCT03867188 1407 1410 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03867188 1411 1414 I-Assertion___Assertion-Type-Value:hypothetical
potential NCT03867188 1415 1424 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03867188 1425 1428 O
teratogenic NCT03867188 1429 1440 B-Modifier
or NCT03867188 1441 1443 B-Or
abortifacient NCT03867188 1444 1457 B-Modifier
effects NCT03867188 1458 1465 B-Condition
. NCT03867188 1465 1466 O
Because NCT03867188 1468 1475 O
there NCT03867188 1476 1481 O
is NCT03867188 1482 1484 O
an NCT03867188 1485 1487 O
unknown NCT03867188 1488 1495 O
but NCT03867188 1496 1499 O
potential NCT03867188 1500 1509 B-Assertion___Assertion-Type-Value:hypothetical
risk NCT03867188 1510 1514 B-Risk
for NCT03867188 1515 1518 O
adverse NCT03867188 1519 1526 B-Condition
events NCT03867188 1527 1533 I-Condition
in NCT03867188 1534 1536 B-Family-Member___Family-Member-Type:child
nursing NCT03867188 1537 1544 B-Condition
infants NCT03867188 1545 1552 O
secondary NCT03867188 1553 1562 O
to NCT03867188 1563 1565 O
treatment NCT03867188 1566 1575 B-Procedure
of NCT03867188 1576 1578 O
the NCT03867188 1579 1582 O
mother NCT03867188 1583 1589 B-Family-Member___Family-Member-Type:mother
with NCT03867188 1590 1594 O
EXPAREL NCT03867188 1595 1602 B-Drug
, NCT03867188 1603 1604 O
breastfeeding NCT03867188 1605 1618 B-Condition
should NCT03867188 1619 1625 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867188 1626 1628 I-Assertion___Assertion-Type-Value:hypothetical
discontinued NCT03867188 1629 1641 B-Negation
if NCT03867188 1642 1644 O
the NCT03867188 1645 1648 O
mother NCT03867188 1649 1655 B-Family-Member___Family-Member-Type:mother
is NCT03867188 1656 1658 O
treated NCT03867188 1659 1666 B-Procedure
with NCT03867188 1667 1671 O
EXPAREL NCT03867188 1672 1679 B-Drug
. NCT03867188 1679 1680 O

Inclusion NCT03865953 0 9 O
Criteria NCT03865953 10 18 O
: NCT03865953 19 20 O

1 NCT03865953 24 25 O
. NCT03865953 25 26 O
Clinical NCT03865953 28 36 O
diagnosis NCT03865953 37 46 O
of NCT03865953 47 49 O
post NCT03865953 50 54 B-Condition
herpetic NCT03865953 55 63 I-Condition
neuralgia NCT03865953 64 73 I-Condition
, NCT03865953 74 75 O
with NCT03865953 76 80 B-And
pain NCT03865953 81 85 B-Condition
persisting NCT03865953 86 96 O
for NCT03865953 97 100 O
at NCT03865953 101 103 B-Eq-Comparison
least NCT03865953 104 109 I-Eq-Comparison
3 NCT03865953 110 111 I-Eq-Comparison
months NCT03865953 112 118 I-Eq-Comparison
after NCT03865953 119 124 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865953 125 128 O
onset NCT03865953 129 134 B-Eq-Comparison
of NCT03865953 135 137 O
herpes NCT03865953 138 144 B-Condition
zoster NCT03865953 145 151 I-Condition
rash NCT03865953 152 156 I-Condition
OR NCT03865953 157 159 B-Or

2 NCT03865953 162 163 O
. NCT03865953 163 164 O
Clinical NCT03865953 166 174 O
diagnosis NCT03865953 175 184 O
of NCT03865953 185 187 O
distal NCT03865953 188 194 B-Modifier
painful NCT03865953 195 202 I-Modifier
polyneuropathy NCT03865953 203 217 B-Condition
due NCT03865953 218 221 O
to NCT03865953 222 224 O
Type NCT03865953 225 229 B-Modifier
I NCT03865953 230 231 I-Modifier
or NCT03865953 232 234 B-Or
Type NCT03865953 235 239 B-Modifier
II NCT03865953 240 242 I-Modifier
diabetes NCT03865953 243 251 B-Condition
mellitus NCT03865953 252 260 I-Condition
with NCT03865953 261 265 B-And
: NCT03865953 266 267 O

1 NCT03865953 276 277 O
. NCT03865953 277 278 O
symmetrical NCT03865953 280 291 B-Modifier
, NCT03865953 292 293 O
bilateral NCT03865953 294 303 B-Modifier
pain NCT03865953 304 308 B-Condition
in NCT03865953 309 311 O
the NCT03865953 312 315 O
lower NCT03865953 316 321 B-Modifier
extremities NCT03865953 322 333 I-Modifier
for NCT03865953 334 337 O
at NCT03865953 338 340 B-Eq-Comparison
least NCT03865953 341 346 I-Eq-Comparison
3 NCT03865953 347 348 I-Eq-Comparison
months NCT03865953 349 355 I-Eq-Comparison
and NCT03865953 356 359 B-And

2 NCT03865953 367 368 O
. NCT03865953 368 369 O
diabetes NCT03865953 371 379 B-Condition
under NCT03865953 380 385 O
control NCT03865953 386 393 O
for NCT03865953 394 397 O
at NCT03865953 398 400 B-Eq-Comparison
least NCT03865953 401 406 I-Eq-Comparison
3 NCT03865953 407 408 I-Eq-Comparison
months NCT03865953 409 415 I-Eq-Comparison
prior NCT03865953 416 421 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865953 422 424 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomisation NCT03865953 425 438 B-Study
, NCT03865953 439 440 O
as NCT03865953 441 443 O
indicated NCT03865953 444 453 O
by NCT03865953 454 456 O
a NCT03865953 457 458 O
glycated NCT03865953 459 467 B-Observation
haemoglobin NCT03865953 468 479 I-Observation
level NCT03865953 480 485 I-Observation
( NCT03865953 486 487 O
HbA1c NCT03865953 488 493 B-Observation
) NCT03865953 494 495 O
of NCT03865953 496 498 O
≤ NCT03865953 499 500 B-Eq-Comparison
11 NCT03865953 501 503 I-Eq-Comparison
% NCT03865953 504 505 O
( NCT03865953 506 507 O
97 NCT03865953 508 510 B-Eq-Comparison
mmol NCT03865953 511 515 I-Eq-Comparison
/ NCT03865953 516 517 I-Eq-Comparison
mol NCT03865953 518 521 I-Eq-Comparison
) NCT03865953 522 523 O
and NCT03865953 524 527 B-And
on NCT03865953 528 530 O
a NCT03865953 531 532 O
stable NCT03865953 533 539 O
dose NCT03865953 540 544 O
of NCT03865953 545 547 O
insulin NCT03865953 548 555 B-Drug
or NCT03865953 556 558 B-Modifier|Or
oral NCT03865953 559 563 O
diabetic NCT03865953 564 572 B-Condition
medication NCT03865953 573 583 B-Drug
for NCT03865953 584 587 O
3 NCT03865953 588 589 B-Eq-Comparison
months NCT03865953 590 596 I-Eq-Comparison
prior NCT03865953 597 602 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865953 603 605 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865953 606 615 B-Study
, NCT03865953 616 617 O
and NCT03865953 618 621 B-And

3 NCT03865953 629 630 O
. NCT03865953 630 631 O
no NCT03865953 633 635 B-Negation
change NCT03865953 636 642 O
in NCT03865953 643 645 O
diabetic NCT03865953 646 654 B-Condition
medication NCT03865953 655 665 B-Drug
planned NCT03865953 666 673 B-Eq-Comparison
for NCT03865953 674 677 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865953 678 681 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03865953 682 690 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865953 691 693 O
the NCT03865953 694 697 O
study NCT03865953 698 703 B-Study

3 NCT03865953 706 707 O
. NCT03865953 707 708 O
Positive NCT03865953 710 718 O
sensory NCT03865953 719 726 B-Condition
symptoms NCT03865953 727 735 I-Condition
( NCT03865953 736 737 O
mechanical NCT03865953 738 748 B-Modifier
or NCT03865953 749 751 B-Or
thermal NCT03865953 752 759 B-Modifier
) NCT03865953 760 761 O
associated NCT03865953 762 772 O
with NCT03865953 773 777 O
neuropathic NCT03865953 778 789 B-Modifier
pain NCT03865953 790 794 B-Condition
, NCT03865953 795 796 O
confirmed NCT03865953 797 806 O
by NCT03865953 807 809 O
: NCT03865953 810 811 O

1 NCT03865953 820 821 O
. NCT03865953 821 822 O
painDETECT NCT03865953 824 834 B-Observation
questionnaire NCT03865953 835 848 I-Observation
( NCT03865953 849 850 O
PD NCT03865953 851 853 B-Observation
- NCT03865953 854 855 I-Observation
Q NCT03865953 856 857 I-Observation
) NCT03865953 858 859 O
and NCT03865953 860 863 B-And

2 NCT03865953 871 872 O
. NCT03865953 872 873 O
Clinical NCT03865953 875 883 O
assessment NCT03865953 884 894 B-Procedure
, NCT03865953 895 896 O
showing NCT03865953 897 904 O
signs NCT03865953 905 910 B-Assertion___Assertion-Type-Value:possible
of NCT03865953 911 913 I-Assertion___Assertion-Type-Value:possible
neuropathic NCT03865953 914 925 B-Modifier
pain NCT03865953 926 930 B-Condition
in NCT03865953 931 933 B-And
either NCT03865953 934 940 O
a NCT03865953 941 942 O
dermatomal NCT03865953 943 953 B-Modifier
( NCT03865953 954 955 O
PHN NCT03865953 956 959 B-Condition
) NCT03865953 960 961 O
or NCT03865953 962 964 B-Or
distal NCT03865953 965 971 B-Modifier
symmetrical NCT03865953 972 983 B-Condition
distribution NCT03865953 984 996 I-Condition
( NCT03865953 997 998 O
DPN NCT03865953 999 1002 B-Condition
) NCT03865953 1003 1004 O

8 NCT03865953 1006 1007 O
. NCT03865953 1007 1008 O
An NCT03865953 1010 1012 O
average NCT03865953 1013 1020 O
daily NCT03865953 1021 1026 B-Eq-Comparison
pain NCT03865953 1027 1031 B-Observation
score NCT03865953 1032 1037 I-Observation
on NCT03865953 1038 1040 O
the NCT03865953 1041 1044 O
NPRS NCT03865953 1045 1049 B-Observation
of NCT03865953 1050 1052 O
at NCT03865953 1053 1055 B-Eq-Comparison
least NCT03865953 1056 1061 I-Eq-Comparison
4 NCT03865953 1062 1063 I-Eq-Comparison
and NCT03865953 1064 1067 B-And
no NCT03865953 1068 1070 B-Negation
more NCT03865953 1071 1075 B-Eq-Comparison
than NCT03865953 1076 1080 I-Eq-Comparison
8 NCT03865953 1081 1082 I-Eq-Comparison
in NCT03865953 1083 1085 O
the NCT03865953 1086 1089 O
last NCT03865953 1090 1094 O
five NCT03865953 1095 1099 O
diary NCT03865953 1100 1105 O
entries NCT03865953 1106 1113 O
before NCT03865953 1114 1120 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomisation NCT03865953 1121 1134 B-Study

Exclusion NCT03865953 1135 1144 O
Criteria NCT03865953 1145 1153 O
: NCT03865953 1154 1155 O

1 NCT03865953 1159 1160 O
. NCT03865953 1160 1161 O
Presence NCT03865953 1163 1171 O
of NCT03865953 1172 1174 O
moderate NCT03865953 1175 1183 B-Eq-Comparison
to NCT03865953 1184 1186 I-Eq-Comparison
severe NCT03865953 1187 1193 I-Eq-Comparison
pain NCT03865953 1194 1198 B-Condition
from NCT03865953 1199 1203 O
other NCT03865953 1204 1209 B-Other
causes NCT03865953 1210 1216 B-Condition
that NCT03865953 1217 1221 O
may NCT03865953 1222 1225 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03865953 1226 1234 O
assessment NCT03865953 1235 1245 B-Study
or NCT03865953 1246 1248 O
self NCT03865953 1249 1253 O
- NCT03865953 1254 1255 O
evaluation NCT03865953 1256 1266 O
of NCT03865953 1267 1269 O
NP NCT03865953 1270 1272 O
. NCT03865953 1272 1273 O

2 NCT03865953 1277 1278 O
. NCT03865953 1278 1279 O
Subjects NCT03865953 1281 1289 O
with NCT03865953 1290 1294 O
both NCT03865953 1295 1299 O
DPN NCT03865953 1300 1303 B-Condition
and NCT03865953 1304 1307 B-And
PHN NCT03865953 1308 1311 B-Condition


Inclusion NCT03869827 0 9 O
Criteria NCT03869827 10 18 O
: NCT03869827 19 20 O

- NCT03869827 24 25 O
All NCT03869827 27 30 O
birth NCT03869827 31 36 B-Birth
between NCT03869827 37 44 B-Eq-Comparison
24 NCT03869827 45 47 I-Eq-Comparison
+ NCT03869827 48 49 I-Eq-Comparison
0 NCT03869827 50 51 I-Eq-Comparison
weeks NCT03869827 52 57 I-Eq-Comparison
of NCT03869827 58 60 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 61 71 B-Condition
and NCT03869827 72 75 B-And
36 NCT03869827 76 78 B-Eq-Comparison
+ NCT03869827 79 80 I-Eq-Comparison
6 NCT03869827 81 82 I-Eq-Comparison
weeks NCT03869827 83 88 I-Eq-Comparison
of NCT03869827 89 91 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 92 102 B-Condition

- NCT03869827 105 106 O
with NCT03869827 108 112 O
isolated NCT03869827 113 121 B-Modifier
intrauterine NCT03869827 122 134 B-Condition
growth NCT03869827 135 141 I-Condition
restriction NCT03869827 142 153 I-Condition
at NCT03869827 154 156 O
the NCT03869827 157 160 O
maternity NCT03869827 161 170 O
ward NCT03869827 171 175 O
of NCT03869827 176 178 O
the NCT03869827 179 182 O
hospital NCT03869827 183 191 O
Femme NCT03869827 192 197 O
- NCT03869827 198 199 O
Mère NCT03869827 200 204 O
- NCT03869827 205 206 O
Enfant NCT03869827 207 213 O

- NCT03869827 216 217 O
from NCT03869827 219 223 O
1 NCT03869827 224 225 B-Eq-Comparison
st NCT03869827 226 228 O
of NCT03869827 229 231 I-Eq-Comparison
january NCT03869827 232 239 I-Eq-Comparison
2011 NCT03869827 240 244 I-Eq-Comparison
to NCT03869827 245 247 I-Eq-Comparison
31 NCT03869827 248 250 I-Eq-Comparison
december NCT03869827 251 259 I-Eq-Comparison
2016 NCT03869827 260 264 I-Eq-Comparison
. NCT03869827 264 265 O

Inclusion NCT03869827 267 276 O
Criteria NCT03869827 277 285 O
for NCT03869827 286 289 O
control NCT03869827 290 297 O
group NCT03869827 298 303 O
: NCT03869827 304 305 O

- NCT03869827 309 310 O
All NCT03869827 312 315 O
birth NCT03869827 316 321 B-Birth
between NCT03869827 322 329 B-Eq-Comparison
24 NCT03869827 330 332 I-Eq-Comparison
+ NCT03869827 333 334 I-Eq-Comparison
0 NCT03869827 335 336 I-Eq-Comparison
weeks NCT03869827 337 342 I-Eq-Comparison
of NCT03869827 343 345 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 346 356 B-Condition
and NCT03869827 357 360 B-And
36 NCT03869827 361 363 B-Eq-Comparison
+ NCT03869827 364 365 I-Eq-Comparison
6 NCT03869827 366 367 I-Eq-Comparison
weeks NCT03869827 368 373 I-Eq-Comparison
of NCT03869827 374 376 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 377 387 B-Condition

- NCT03869827 390 391 O
without NCT03869827 393 400 B-Negation
isolated NCT03869827 401 409 B-Modifier
intrauterine NCT03869827 410 422 B-Condition
growth NCT03869827 423 429 I-Condition
restriction NCT03869827 430 441 I-Condition
at NCT03869827 442 444 O
the NCT03869827 445 448 O
maternity NCT03869827 449 458 O
ward NCT03869827 459 463 O
of NCT03869827 464 466 O
the NCT03869827 467 470 O
hospital NCT03869827 471 479 O
Femme NCT03869827 480 485 O
- NCT03869827 486 487 O
Mère NCT03869827 488 492 O
- NCT03869827 493 494 O
Enfant NCT03869827 495 501 O

- NCT03869827 504 505 O
from NCT03869827 507 511 O
1 NCT03869827 512 513 B-Eq-Comparison
st NCT03869827 514 516 O
of NCT03869827 517 519 I-Eq-Comparison
january NCT03869827 520 527 I-Eq-Comparison
2011 NCT03869827 528 532 I-Eq-Comparison
to NCT03869827 533 535 I-Eq-Comparison
31 NCT03869827 536 538 I-Eq-Comparison
december NCT03869827 539 547 I-Eq-Comparison
2016 NCT03869827 548 552 I-Eq-Comparison
. NCT03869827 552 553 O

Exclusion NCT03869827 555 564 O
Criteria NCT03869827 565 573 O
: NCT03869827 574 575 O

- NCT03869827 579 580 O
Infants NCT03869827 582 589 O
born NCT03869827 590 594 B-Birth
out NCT03869827 595 598 B-Negation
of NCT03869827 599 601 I-Negation
the NCT03869827 602 605 O
hospital NCT03869827 606 614 O
and NCT03869827 615 618 B-And
secondarily NCT03869827 619 630 B-Encounter
hospitalized NCT03869827 631 643 I-Encounter
in NCT03869827 644 646 O
our NCT03869827 647 650 O
department NCT03869827 651 661 O

- NCT03869827 664 665 O
unaccompanied NCT03869827 667 680 B-Modifier
pregnancies NCT03869827 681 692 B-Condition

- NCT03869827 695 696 O
multiple NCT03869827 698 706 B-Eq-Comparison
pregnancies NCT03869827 707 718 B-Condition

- NCT03869827 721 722 O
children NCT03869827 724 732 O
with NCT03869827 733 737 B-And
malformations NCT03869827 738 751 B-Condition
or NCT03869827 752 754 B-Or
genetic NCT03869827 755 762 B-Condition
abnormalities NCT03869827 763 776 I-Condition
, NCT03869827 777 778 O

- NCT03869827 782 783 O
medical NCT03869827 785 792 B-Procedure
termination NCT03869827 793 804 I-Procedure
of NCT03869827 805 807 I-Procedure
pregnancy NCT03869827 808 817 I-Procedure

- NCT03869827 820 821 O
fetal NCT03869827 823 828 O
deaths NCT03869827 829 835 B-Death
in NCT03869827 836 838 B-Modifier
utero NCT03869827 839 844 I-Modifier

Inclusion NCT03866057 0 9 O
criteria NCT03866057 10 18 O
: NCT03866057 19 20 O

- NCT03866057 24 25 O
age NCT03866057 27 30 B-Age
18 NCT03866057 31 33 B-Eq-Comparison
- NCT03866057 34 35 I-Eq-Comparison
90 NCT03866057 36 38 O

- NCT03866057 42 43 O
acute NCT03866057 45 50 O
ischemic NCT03866057 51 59 B-Modifier
or NCT03866057 60 62 B-Or
hemorrhagic NCT03866057 63 74 B-Modifier
stroke NCT03866057 75 81 B-Condition
( NCT03866057 82 83 O
within NCT03866057 84 90 B-Eq-Comparison
30 NCT03866057 91 93 I-Eq-Comparison
days NCT03866057 94 98 I-Eq-Comparison
) NCT03866057 99 100 O

- NCT03866057 104 105 O
consent NCT03866057 107 114 O
to NCT03866057 115 117 O
participate NCT03866057 118 129 O
and NCT03866057 130 133 O
to NCT03866057 134 136 O
anonymous NCT03866057 137 146 O
processing NCT03866057 147 157 O
of NCT03866057 158 160 O
data NCT03866057 161 165 O
. NCT03866057 165 166 O

Additional NCT03866057 168 178 O
inclusion NCT03866057 179 188 O
criteria NCT03866057 189 197 O
for NCT03866057 198 201 O
Sub NCT03866057 202 205 O
- NCT03866057 206 207 O
project NCT03866057 208 215 O
Neurophysiological NCT03866057 216 234 O
Markers NCT03866057 235 242 O
: NCT03866057 243 244 O

- NCT03866057 247 248 O
signing NCT03866057 249 256 O
of NCT03866057 257 259 O
informed NCT03866057 260 268 O
consent NCT03866057 269 276 O
for NCT03866057 277 280 O
the NCT03866057 281 284 O
participation NCT03866057 285 298 O
in NCT03866057 299 301 O
the NCT03866057 302 305 O
sub NCT03866057 306 309 O
- NCT03866057 310 311 O
project NCT03866057 312 319 O
. NCT03866057 319 320 O

Additional NCT03866057 322 332 O
inclusion NCT03866057 333 342 O
criteria NCT03866057 343 351 O
for NCT03866057 352 355 O
Epigenetic NCT03866057 356 366 O
subproject NCT03866057 367 377 O
: NCT03866057 378 379 O

- NCT03866057 382 383 O
signing NCT03866057 384 391 O
of NCT03866057 392 394 O
informed NCT03866057 395 403 O
consent NCT03866057 404 411 O
for NCT03866057 412 415 O
participation NCT03866057 416 429 O
in NCT03866057 430 432 O
the NCT03866057 433 436 O
subproject NCT03866057 437 447 O
. NCT03866057 447 448 O

Exclusion NCT03866057 450 459 O
Criteria NCT03866057 460 468 O
: NCT03866057 469 470 O

- NCT03866057 473 474 O
Stroke NCT03866057 475 481 B-Condition
occurred NCT03866057 482 490 O
more NCT03866057 491 495 B-Eq-Comparison
than NCT03866057 496 500 I-Eq-Comparison
30 NCT03866057 501 503 I-Eq-Comparison
days NCT03866057 504 508 I-Eq-Comparison
after NCT03866057 509 514 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03866057 515 518 O
transfer NCT03866057 519 527 B-Encounter
to NCT03866057 528 530 O
intensive NCT03866057 531 540 O
rehabilitation NCT03866057 541 555 O

Additional NCT03866057 556 566 O
exclusion NCT03866057 567 576 O
criteria NCT03866057 577 585 O
for NCT03866057 586 589 O
Epigenetic NCT03866057 590 600 O
subproject NCT03866057 601 611 O
( NCT03866057 612 613 O
for NCT03866057 614 617 O
retrospective NCT03866057 618 631 O
analysis NCT03866057 632 640 O
) NCT03866057 641 642 O
: NCT03866057 644 645 O

- NCT03866057 649 650 O
history NCT03866057 652 659 B-Eq-Comparison
of NCT03866057 660 662 O
major NCT03866057 663 668 O
psychiatric NCT03866057 669 680 B-Condition
disorder NCT03866057 681 689 I-Condition
or NCT03866057 690 692 B-Or
recent NCT03866057 693 699 B-Eq-Comparison
exacerbation NCT03866057 700 712 B-Condition

- NCT03866057 715 716 O
global NCT03866057 718 724 B-Condition
aphasia NCT03866057 725 732 I-Condition

- NCT03866057 735 736 O
refusal NCT03866057 738 745 O
of NCT03866057 746 748 O
the NCT03866057 749 752 O
patient NCT03866057 753 760 O
to NCT03866057 761 763 O
participate NCT03866057 764 775 O
in NCT03866057 776 778 O
the NCT03866057 779 782 O
study NCT03866057 783 788 O
. NCT03866057 788 789 O

Inclusion NCT03864640 0 9 O
Criteria NCT03864640 10 18 O
: NCT03864640 19 20 O

- NCT03864640 24 25 O
Adult NCT03864640 27 32 O
patients NCT03864640 33 41 O
with NCT03864640 42 46 B-And
colorectal NCT03864640 47 57 B-Modifier
cancer NCT03864640 58 64 B-Condition
. NCT03864640 64 65 O

Exclusion NCT03864640 67 76 O
Criteria NCT03864640 77 85 O
: NCT03864640 86 87 O

- NCT03864640 91 92 O
Patients NCT03864640 94 102 O
reluctant NCT03864640 103 112 O
to NCT03864640 113 115 O
participate NCT03864640 116 127 O
in NCT03864640 128 130 O
the NCT03864640 131 134 O
study NCT03864640 135 140 O
. NCT03864640 140 141 O

Inclusion NCT03868046 0 9 O
Criteria NCT03868046 10 18 O
: NCT03868046 19 20 O

1 NCT03868046 24 25 O
. NCT03868046 25 26 O
Initiation NCT03868046 28 38 B-Eq-Comparison
of NCT03868046 39 41 O
treatment NCT03868046 42 51 B-Procedure
with NCT03868046 52 56 O
a NCT03868046 57 58 O
single NCT03868046 59 65 B-Eq-Comparison
ICI NCT03868046 66 69 B-Procedure
or NCT03868046 70 72 B-Or
a NCT03868046 73 74 O
combination NCT03868046 75 86 B-Eq-Comparison
of NCT03868046 87 89 O
ICIs NCT03868046 90 94 B-Procedure
. NCT03868046 94 95 O

2 NCT03868046 99 100 O
. NCT03868046 100 101 O
Acceptation NCT03868046 103 114 O
of NCT03868046 115 117 O
an NCT03868046 118 120 O
informed NCT03868046 121 129 O
consent NCT03868046 130 137 O
. NCT03868046 137 138 O

Exclusion NCT03868046 140 149 O
Criteria NCT03868046 150 158 O
: NCT03868046 159 160 O

1 NCT03868046 164 165 O
. NCT03868046 165 166 O
Life NCT03868046 168 172 B-Observation
expectancy NCT03868046 173 183 I-Observation
lower NCT03868046 184 189 B-Eq-Comparison
than NCT03868046 190 194 I-Eq-Comparison
3 NCT03868046 195 196 I-Eq-Comparison
months NCT03868046 197 203 I-Eq-Comparison
from NCT03868046 204 208 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03868046 209 212 O
initiation NCT03868046 213 223 B-Eq-Comparison
of NCT03868046 224 226 O
treatment NCT03868046 227 236 B-Procedure
with NCT03868046 237 241 O
ICIs NCT03868046 242 246 B-Procedure
. NCT03868046 246 247 O

2 NCT03868046 251 252 O
. NCT03868046 252 253 O
Proven NCT03868046 255 261 O
hypersensitivity NCT03868046 262 278 B-Condition
or NCT03868046 279 281 B-Or
previous NCT03868046 282 290 O
allergic NCT03868046 291 299 B-Allergy
anaphylactic NCT03868046 300 312 B-Condition
reaction NCT03868046 313 321 I-Condition
induced NCT03868046 322 329 O
by NCT03868046 330 332 O
a NCT03868046 333 334 O
specific NCT03868046 335 343 O
ICI NCT03868046 344 347 B-Procedure
. NCT03868046 347 348 O

3 NCT03868046 352 353 O
. NCT03868046 353 354 O
Active NCT03868046 356 362 B-Eq-Comparison
autoimmune NCT03868046 363 373 B-Condition
disease NCT03868046 374 381 I-Condition
with NCT03868046 382 386 O
severe NCT03868046 387 393 O
involvement NCT03868046 394 405 O
. NCT03868046 405 406 O

4 NCT03868046 410 411 O
. NCT03868046 411 412 O
Eastern NCT03868046 414 421 B-Observation
Cooperative NCT03868046 422 433 I-Observation
Oncology NCT03868046 434 442 I-Observation
Group NCT03868046 443 448 I-Observation
( NCT03868046 449 450 O
ECOG NCT03868046 451 455 B-Observation
) NCT03868046 456 457 O
performance NCT03868046 458 469 O
status NCT03868046 470 476 O
≥ NCT03868046 477 478 B-Eq-Comparison
3 NCT03868046 479 480 I-Eq-Comparison
. NCT03868046 480 481 O

5 NCT03868046 485 486 O
. NCT03868046 486 487 O
Ongoing NCT03868046 489 496 B-Eq-Comparison
immunosuppressive NCT03868046 497 514 B-Procedure
therapy NCT03868046 515 522 I-Procedure
: NCT03868046 523 524 O
prednisone NCT03868046 525 535 B-Drug
at NCT03868046 536 538 O
doses NCT03868046 539 544 O
> NCT03868046 545 546 B-Eq-Comparison
10 NCT03868046 547 549 I-Eq-Comparison
mg NCT03868046 550 552 I-Eq-Comparison
/ NCT03868046 553 554 I-Eq-Comparison
day NCT03868046 555 558 I-Eq-Comparison
or NCT03868046 559 561 O
equivalent NCT03868046 562 572 O
( NCT03868046 573 574 O
> NCT03868046 576 577 B-Eq-Comparison
1.5 NCT03868046 578 581 I-Eq-Comparison
mg NCT03868046 582 584 I-Eq-Comparison
/ NCT03868046 585 586 I-Eq-Comparison|Or
day NCT03868046 587 590 I-Eq-Comparison
of NCT03868046 591 593 O
dexamethasone NCT03868046 594 607 B-Drug
) NCT03868046 608 609 O
, NCT03868046 611 612 O
and NCT03868046 613 616 B-Or
/ NCT03868046 617 618 O
or NCT03868046 619 621 I-Or
any NCT03868046 622 625 O
dose NCT03868046 626 630 O
of NCT03868046 631 633 O
azathioprine NCT03868046 634 646 B-Drug
, NCT03868046 647 648 O
methotrexate NCT03868046 649 661 B-Drug
, NCT03868046 662 663 O
mycophenolate NCT03868046 664 677 B-Drug
, NCT03868046 678 679 O
cyclophosphamide NCT03868046 680 696 B-Drug
, NCT03868046 697 698 O
leflunomide NCT03868046 699 710 B-Drug
, NCT03868046 711 712 O
rituximab NCT03868046 713 722 B-Drug
, NCT03868046 723 724 O
anti NCT03868046 725 729 B-Drug
- NCT03868046 730 731 I-Drug
tumor NCT03868046 732 737 I-Drug
necrosis NCT03868046 738 746 I-Drug
factor NCT03868046 747 753 I-Drug
drugs NCT03868046 754 759 I-Drug
( NCT03868046 760 761 O
infliximab NCT03868046 762 772 B-Drug
, NCT03868046 773 774 O
etanercept NCT03868046 775 785 B-Drug
, NCT03868046 786 787 O
adalimumab NCT03868046 788 798 B-Drug
, NCT03868046 799 800 O
golimumab NCT03868046 801 810 B-Drug
) NCT03868046 811 812 O
, NCT03868046 814 815 O
belimumab NCT03868046 816 825 B-Drug
and NCT03868046 826 829 B-Or
abatacept NCT03868046 830 839 B-Drug
. NCT03868046 839 840 O

Inclusion NCT03865576 0 9 O
Criteria NCT03865576 10 18 O
: NCT03865576 19 20 O

- NCT03865576 24 25 O
ICU NCT03865576 27 30 B-Encounter
patients NCT03865576 31 39 O
suspected NCT03865576 40 49 B-Assertion___Assertion-Type-Value:possible
of NCT03865576 50 52 O
having NCT03865576 53 59 O
an NCT03865576 60 62 O
abnormality NCT03865576 63 74 O
of NCT03865576 75 77 O
ICP NCT03865576 78 81 B-Condition
undergoing NCT03865576 82 92 B-Eq-Comparison
monitoring NCT03865576 93 103 B-Procedure
with NCT03865576 104 108 O
commercially NCT03865576 109 121 O
- NCT03865576 122 123 O
available NCT03865576 124 133 O
, NCT03865576 134 135 O
FDA NCT03865576 136 139 O
- NCT03865576 140 141 O
approved NCT03865576 142 150 O
instrumentation NCT03865576 151 166 O
. NCT03865576 166 167 O

Exclusion NCT03865576 169 178 O
Criteria NCT03865576 179 187 O
: NCT03865576 188 189 O

History NCT03865576 191 198 B-Eq-Comparison
of NCT03865576 199 201 O
: NCT03865576 202 203 O

- NCT03865576 207 208 O
Glaucoma NCT03865576 210 218 B-Condition
or NCT03865576 219 221 B-Or
optic NCT03865576 222 227 B-Modifier
hypertension NCT03865576 228 240 B-Condition

- NCT03865576 243 244 O
Severe NCT03865576 246 252 O
orbital NCT03865576 253 260 B-Modifier|Or
or NCT03865576 261 263 O
ophthalmic NCT03865576 264 274 B-Modifier
injury NCT03865576 275 281 B-Condition

- NCT03865576 284 285 O
Orbital NCT03865576 287 294 B-Modifier
or NCT03865576 295 297 B-Or
intraocular NCT03865576 298 309 B-Modifier
surgery NCT03865576 310 317 B-Procedure
that NCT03865576 318 322 O
might NCT03865576 323 328 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03865576 329 338 O
with NCT03865576 339 343 O
orbital NCT03865576 344 351 B-Condition
compliance NCT03865576 352 362 I-Condition

- NCT03865576 365 366 O
Congenital NCT03865576 368 378 B-Condition
malformations NCT03865576 379 392 I-Condition
of NCT03865576 393 395 O
the NCT03865576 396 399 O
eye NCT03865576 400 403 B-Modifier
and NCT03865576 404 407 B-Or
/ NCT03865576 408 409 I-Or
or NCT03865576 410 412 B-Modifier|Or
orbit NCT03865576 413 418 O
that NCT03865576 419 423 O
might NCT03865576 424 429 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03865576 430 439 O
with NCT03865576 440 444 O
orbital NCT03865576 445 452 B-Condition
compliance NCT03865576 453 463 I-Condition
or NCT03865576 464 466 B-Condition|Or
orbital NCT03865576 467 474 O
vascular NCT03865576 475 483 I-Condition
anatomy NCT03865576 484 491 I-Condition

Inclusion NCT03861923 0 9 O
Criteria NCT03861923 10 18 O
: NCT03861923 19 20 O

- NCT03861923 24 25 O
Primary NCT03861923 27 34 O
complaint NCT03861923 35 44 O
of NCT03861923 45 47 O
shoulder NCT03861923 48 56 B-Modifier
pain NCT03861923 57 61 B-Condition
and NCT03861923 62 65 B-Or
stiffness NCT03861923 66 75 B-Condition

- NCT03861923 78 79 O
Gradual NCT03861923 81 88 O
onset NCT03861923 89 94 O
of NCT03861923 95 97 O
symptoms NCT03861923 98 106 O

- NCT03861923 109 110 O
Glenohumeral NCT03861923 112 124 B-Observation
passive NCT03861923 125 132 I-Observation
range NCT03861923 133 138 I-Observation
of NCT03861923 139 141 I-Observation
motion NCT03861923 142 148 I-Observation
limited NCT03861923 149 156 O
in NCT03861923 157 159 O
multiple NCT03861923 160 168 B-Modifier
directions NCT03861923 169 179 I-Modifier

- NCT03861923 182 183 O
Glenohumeral NCT03861923 185 197 B-Observation
passive NCT03861923 198 205 I-Observation
range NCT03861923 206 211 I-Observation
of NCT03861923 212 214 I-Observation
motion NCT03861923 215 221 I-Observation
decreases NCT03861923 222 231 O
as NCT03861923 232 234 O
the NCT03861923 235 238 O
humerus NCT03861923 239 246 B-Modifier
is NCT03861923 247 249 O
abducted NCT03861923 250 258 B-Observation
from NCT03861923 259 263 O
45 NCT03861923 264 266 B-Eq-Comparison
degrees NCT03861923 267 274 I-Eq-Comparison
to NCT03861923 275 277 I-Eq-Comparison
90 NCT03861923 278 280 I-Eq-Comparison
degrees NCT03861923 281 288 I-Eq-Comparison

- NCT03861923 291 292 O
Age NCT03861923 294 297 B-Age
18 NCT03861923 298 300 B-Eq-Comparison
to NCT03861923 301 303 I-Eq-Comparison
65 NCT03861923 304 306 I-Eq-Comparison
years NCT03861923 307 312 I-Eq-Comparison

- NCT03861923 315 316 O
Reports NCT03861923 318 325 O
pain NCT03861923 326 330 B-Condition
with NCT03861923 331 335 O
normal NCT03861923 336 342 B-Modifier
activity NCT03861923 343 351 I-Modifier
greater NCT03861923 352 359 B-Eq-Comparison
than NCT03861923 360 364 I-Eq-Comparison
or NCT03861923 365 367 I-Eq-Comparison
equal NCT03861923 368 373 I-Eq-Comparison
to NCT03861923 374 376 I-Eq-Comparison
2 NCT03861923 377 378 I-Eq-Comparison
/ NCT03861923 379 380 I-Eq-Comparison
10 NCT03861923 381 383 I-Eq-Comparison
on NCT03861923 384 386 O
the NCT03861923 387 390 O
numeric NCT03861923 391 398 O
pain NCT03861923 399 403 B-Observation
rating NCT03861923 404 410 I-Observation
scale NCT03861923 411 416 I-Observation

- NCT03861923 419 420 O
Read NCT03861923 422 426 O
and NCT03861923 427 430 O
speak NCT03861923 431 436 O
English NCT03861923 437 444 O

Exclusion NCT03861923 445 454 O
Criteria NCT03861923 455 463 O
: NCT03861923 464 465 O

- NCT03861923 469 470 O
Signs NCT03861923 472 477 B-Assertion___Assertion-Type-Value:possible
or NCT03861923 478 480 I-Assertion___Assertion-Type-Value:possible
symptoms NCT03861923 481 489 I-Assertion___Assertion-Type-Value:possible
of NCT03861923 490 492 O
cervical NCT03861923 493 501 B-Condition
radiculopathy NCT03861923 502 515 I-Condition
, NCT03861923 516 517 O
radiculitis NCT03861923 518 529 B-Condition
, NCT03861923 530 531 O
or NCT03861923 532 534 B-Or
referral NCT03861923 535 543 B-Condition
from NCT03861923 544 548 O
the NCT03861923 549 552 O
cervical NCT03861923 553 561 B-Modifier
spine NCT03861923 562 567 I-Modifier

- NCT03861923 570 571 O
Clinical NCT03861923 573 581 O
evidence NCT03861923 582 590 O
as NCT03861923 591 593 O
determined NCT03861923 594 604 O
in NCT03861923 605 607 O
the NCT03861923 608 611 O
examination NCT03861923 612 623 B-Procedure
of NCT03861923 624 626 O
an NCT03861923 627 629 O
alternative NCT03861923 630 641 B-Other
shoulder NCT03861923 642 650 B-Modifier
diagnosis NCT03861923 651 660 B-Condition

- NCT03861923 663 664 O
Normal NCT03861923 666 672 O
passive NCT03861923 673 680 B-Modifier
shoulder NCT03861923 681 689 I-Modifier
range NCT03861923 690 695 B-Observation
of NCT03861923 696 698 I-Observation
motion NCT03861923 699 705 I-Observation

- NCT03861923 708 709 O
Known NCT03861923 711 716 O
radiographic NCT03861923 717 729 B-Procedure
evidence NCT03861923 730 738 O
of NCT03861923 739 741 O
glenohumeral NCT03861923 742 754 B-Modifier
osteoarthritis NCT03861923 755 769 B-Condition

- NCT03861923 772 773 O
Known NCT03861923 775 780 O
neurologic NCT03861923 781 791 B-Condition
disease NCT03861923 792 799 I-Condition

- NCT03861923 802 803 O
Received NCT03861923 805 813 O
dry NCT03861923 814 817 B-Procedure
needling NCT03861923 818 826 I-Procedure
or NCT03861923 827 829 B-Or
acupuncture NCT03861923 830 841 B-Procedure
within NCT03861923 842 848 B-Eq-Comparison
the NCT03861923 849 852 I-Eq-Comparison
past NCT03861923 853 857 I-Eq-Comparison
6 NCT03861923 858 859 I-Eq-Comparison
months NCT03861923 860 866 I-Eq-Comparison

- NCT03861923 869 870 O
Fear NCT03861923 872 876 B-Condition
of NCT03861923 877 879 I-Condition
needling NCT03861923 880 888 I-Condition

- NCT03861923 891 892 O
Currently NCT03861923 894 903 B-Eq-Comparison
being NCT03861923 904 909 O
treated NCT03861923 910 917 B-Procedure
with NCT03861923 918 922 O
anticoagulant NCT03861923 923 936 B-Drug
medication NCT03861923 937 947 I-Drug

- NCT03861923 950 951 O
Shoulder NCT03861923 953 961 B-Observation
pain NCT03861923 962 966 I-Observation
and NCT03861923 967 970 I-Observation
disability NCT03861923 971 981 I-Observation
index NCT03861923 982 987 I-Observation
( NCT03861923 988 989 O
SPADI NCT03861923 990 995 B-Observation
) NCT03861923 996 997 O
score NCT03861923 998 1003 O
less NCT03861923 1004 1008 B-Eq-Comparison
than NCT03861923 1009 1013 I-Eq-Comparison
10 NCT03861923 1014 1016 I-Eq-Comparison
% NCT03861923 1017 1018 O
or NCT03861923 1019 1021 B-Or
greater NCT03861923 1022 1029 B-Eq-Comparison
than NCT03861923 1030 1034 I-Eq-Comparison
90 NCT03861923 1035 1037 I-Eq-Comparison
% NCT03861923 1038 1039 O

Inclusion NCT03865589 0 9 O
Criteria NCT03865589 10 18 O
: NCT03865589 19 20 O

- NCT03865589 24 25 O
Any NCT03865589 27 30 O
patient NCT03865589 31 38 O
undergoing NCT03865589 39 49 B-Eq-Comparison
a NCT03865589 50 51 O
myeloablative NCT03865589 52 65 B-Procedure
conditioning NCT03865589 66 78 I-Procedure
regimen NCT03865589 79 86 O
for NCT03865589 87 90 O
HCT NCT03865589 91 94 B-Condition
between NCT03865589 95 102 B-Eq-Comparison
4 NCT03865589 103 104 I-Eq-Comparison
/ NCT03865589 105 106 I-Eq-Comparison
1 NCT03865589 107 108 I-Eq-Comparison
/ NCT03865589 109 110 O
2019 NCT03865589 111 115 I-Eq-Comparison
and NCT03865589 116 119 I-Eq-Comparison
12 NCT03865589 120 122 I-Eq-Comparison
/ NCT03865589 123 124 I-Eq-Comparison
31 NCT03865589 125 127 I-Eq-Comparison
/ NCT03865589 128 129 O
2120 NCT03865589 130 134 I-Eq-Comparison
defined NCT03865589 135 142 O
as NCT03865589 143 145 O
one NCT03865589 146 149 B-Eq-Comparison
of NCT03865589 150 152 O
the NCT03865589 153 156 B-Criteria-Count
following NCT03865589 157 166 I-Criteria-Count
: NCT03865589 167 168 O

- NCT03865589 177 178 O
TBI NCT03865589 180 183 B-Observation
> NCT03865589 184 185 B-Eq-Comparison
= NCT03865589 187 188 I-Eq-Comparison
1200 NCT03865589 189 193 I-Eq-Comparison
cGy NCT03865589 194 197 I-Eq-Comparison
( NCT03865589 198 199 O
fractionated NCT03865589 200 212 B-Modifier
) NCT03865589 213 214 O

- NCT03865589 223 224 O
Cyclophosphamide NCT03865589 226 242 B-Drug
+ NCT03865589 243 244 B-And
TBI NCT03865589 245 248 B-Observation
( NCT03865589 249 250 O
> NCT03865589 252 253 B-Eq-Comparison
500 NCT03865589 254 257 I-Eq-Comparison
cGy NCT03865589 258 261 I-Eq-Comparison
( NCT03865589 262 263 O
single NCT03865589 264 270 B-Modifier
) NCT03865589 271 272 O
or NCT03865589 273 275 B-Or
> NCT03865589 276 277 B-Eq-Comparison
800 NCT03865589 278 281 I-Eq-Comparison
cGy NCT03865589 282 285 O
( NCT03865589 286 287 O
fractionated NCT03865589 288 300 B-Modifier
) NCT03865589 301 302 O
) NCT03865589 304 305 O

- NCT03865589 314 315 O
Cyclophosphamide NCT03865589 317 333 B-Drug
+ NCT03865589 334 335 B-And|And
Etoposide NCT03865589 336 345 B-Drug
+ NCT03865589 346 347 O
TBI NCT03865589 348 351 B-Observation
( NCT03865589 352 353 O
> NCT03865589 355 356 B-Eq-Comparison|Eq-Comparison
500 NCT03865589 357 360 I-Eq-Comparison
cGy NCT03865589 361 364 I-Eq-Comparison|Eq-Comparison
( NCT03865589 365 366 O
single NCT03865589 367 373 B-Modifier
) NCT03865589 374 375 O
or NCT03865589 376 378 B-Or
> NCT03865589 379 380 O
800 NCT03865589 381 384 I-Eq-Comparison
cGy NCT03865589 385 388 O
( NCT03865589 389 390 O
fractionated NCT03865589 391 403 B-Modifier
) NCT03865589 404 405 O
) NCT03865589 407 408 O

- NCT03865589 417 418 O
Cyclophosphamide NCT03865589 420 436 B-Drug
+ NCT03865589 437 438 B-And|And
Thiotepa NCT03865589 439 447 B-Drug
+ NCT03865589 448 449 O
TBI NCT03865589 450 453 B-Observation
( NCT03865589 454 455 O
> NCT03865589 457 458 B-Eq-Comparison|Eq-Comparison
500 NCT03865589 459 462 I-Eq-Comparison
cGy NCT03865589 463 466 I-Eq-Comparison|Eq-Comparison
( NCT03865589 467 468 O
single NCT03865589 469 475 B-Modifier
) NCT03865589 476 477 O
or NCT03865589 478 480 B-Or
> NCT03865589 481 482 O
800 NCT03865589 483 486 I-Eq-Comparison
cGy NCT03865589 487 490 O
( NCT03865589 491 492 O
fractionated NCT03865589 493 505 B-Modifier
) NCT03865589 506 507 O
) NCT03865589 509 510 O

- NCT03865589 519 520 O
Busulfan NCT03865589 522 530 B-Drug
( NCT03865589 531 532 O
Total NCT03865589 533 538 O
dose NCT03865589 539 543 O
> NCT03865589 544 545 B-Eq-Comparison|Eq-Comparison
7.2 NCT03865589 546 549 I-Eq-Comparison
mg NCT03865589 550 552 I-Eq-Comparison
/ NCT03865589 553 554 I-Eq-Comparison
kg NCT03865589 555 557 I-Eq-Comparison
IV NCT03865589 558 560 I-Eq-Comparison|Modifier
or NCT03865589 561 563 B-Modifier|Or
> NCT03865589 564 565 O
9.0 NCT03865589 566 569 I-Eq-Comparison
mg NCT03865589 570 572 O
/ NCT03865589 573 574 O
kg NCT03865589 575 577 O
orally NCT03865589 578 584 O
) NCT03865589 585 586 O
+ NCT03865589 587 588 B-And
Cyclophosphamide NCT03865589 589 605 B-Drug

- NCT03865589 613 614 O
Busulfan NCT03865589 616 624 B-Drug
( NCT03865589 625 626 O
Total NCT03865589 627 632 O
dose NCT03865589 633 637 O
> NCT03865589 638 639 B-Eq-Comparison|Eq-Comparison
7.2 NCT03865589 640 643 I-Eq-Comparison
mg NCT03865589 644 646 I-Eq-Comparison|Eq-Comparison
/ NCT03865589 647 648 I-Eq-Comparison|Eq-Comparison
kg NCT03865589 649 651 I-Eq-Comparison|Eq-Comparison
IV NCT03865589 652 654 B-Modifier
or NCT03865589 655 657 B-Modifier|Or
> NCT03865589 658 659 O
9.0 NCT03865589 660 663 I-Eq-Comparison
mg NCT03865589 664 666 O
/ NCT03865589 667 668 O
kg NCT03865589 669 671 O
orally NCT03865589 672 678 O
) NCT03865589 679 680 O
+ NCT03865589 681 682 B-And
Melphalan NCT03865589 683 692 B-Drug

- NCT03865589 700 701 O
Busulfan NCT03865589 703 711 B-Drug
( NCT03865589 712 713 O
Total NCT03865589 714 719 O
dose NCT03865589 720 724 O
> NCT03865589 725 726 B-Eq-Comparison|Eq-Comparison
7.2 NCT03865589 727 730 I-Eq-Comparison
mg NCT03865589 731 733 I-Eq-Comparison|Eq-Comparison
/ NCT03865589 734 735 I-Eq-Comparison|Eq-Comparison
kg NCT03865589 736 738 I-Eq-Comparison|Eq-Comparison
IV NCT03865589 739 741 B-Modifier
or NCT03865589 742 744 B-Modifier|Or
> NCT03865589 745 746 O
9.0 NCT03865589 747 750 I-Eq-Comparison
mg NCT03865589 751 753 O
/ NCT03865589 754 755 O
kg NCT03865589 756 758 O
orally NCT03865589 759 765 O
) NCT03865589 766 767 O
+ NCT03865589 768 769 B-And
Thiotepa NCT03865589 770 778 B-Drug

- NCT03865589 786 787 O
NOTE NCT03865589 789 793 O
: NCT03865589 794 795 O
Busulfan NCT03865589 796 804 B-Drug
cumulative NCT03865589 805 815 B-Observation
plasma NCT03865589 816 822 I-Observation
AUC NCT03865589 823 826 I-Observation
of NCT03865589 827 829 O
> NCT03865589 830 831 B-Eq-Comparison|Eq-Comparison
75 NCT03865589 832 834 I-Eq-Comparison
mg NCT03865589 835 837 I-Eq-Comparison
/ NCT03865589 838 839 I-Eq-Comparison
L NCT03865589 840 841 I-Eq-Comparison
per NCT03865589 842 845 I-Eq-Comparison|Eq-Comparison
hour NCT03865589 846 850 I-Eq-Comparison
or NCT03865589 851 853 B-Or
> NCT03865589 854 855 O
18270 NCT03865589 856 861 I-Eq-Comparison
microMolar NCT03865589 862 872 I-Eq-Comparison
per NCT03865589 873 876 O
minute NCT03865589 877 883 I-Eq-Comparison
could NCT03865589 884 889 O
be NCT03865589 890 892 O
used NCT03865589 893 897 O
in NCT03865589 898 900 O
the NCT03865589 901 904 O
preceding NCT03865589 905 914 O
criteria NCT03865589 915 923 O
in NCT03865589 924 926 O
lieu NCT03865589 927 931 O
of NCT03865589 932 934 O
the NCT03865589 935 938 O
mg NCT03865589 939 941 O
/ NCT03865589 942 943 O
kg NCT03865589 944 946 O
doses NCT03865589 947 952 O
. NCT03865589 952 953 O

OR NCT03865589 955 957 B-Or

2 NCT03865589 958 959 O
. NCT03865589 959 960 O
Any NCT03865589 962 965 O
patient NCT03865589 966 973 O
who NCT03865589 974 977 O
has NCT03865589 978 981 O
a NCT03865589 982 983 O
myeloablative NCT03865589 984 997 B-Procedure
conditioning NCT03865589 998 1010 I-Procedure
regimen NCT03865589 1011 1018 O
( NCT03865589 1019 1020 O
as NCT03865589 1021 1023 O
defined NCT03865589 1024 1031 O
by NCT03865589 1032 1034 O
the NCT03865589 1035 1038 O
local NCT03865589 1039 1044 O
HSCT NCT03865589 1045 1049 O
team NCT03865589 1050 1054 O
) NCT03865589 1055 1056 O
that NCT03865589 1057 1061 O
includes NCT03865589 1062 1070 O
sirolimus NCT03865589 1071 1080 B-Drug
and NCT03865589 1081 1084 B-Or
tacrolimus NCT03865589 1085 1095 B-Drug
for NCT03865589 1096 1099 O
GVHD NCT03865589 1100 1104 B-Condition
prophylaxis NCT03865589 1105 1116 B-Procedure
. NCT03865589 1116 1117 O

OR NCT03865589 1119 1121 B-Or

3 NCT03865589 1122 1123 O
. NCT03865589 1123 1124 O
Any NCT03865589 1126 1129 O
patient NCT03865589 1130 1137 O
who NCT03865589 1138 1141 O
is NCT03865589 1142 1144 O
high NCT03865589 1145 1149 O
risk NCT03865589 1150 1154 B-Risk
for NCT03865589 1155 1158 O
SOS NCT03865589 1159 1162 B-Condition
irrespective NCT03865589 1163 1175 O
of NCT03865589 1176 1178 O
conditioning NCT03865589 1179 1191 O
regimen NCT03865589 1192 1199 O
: NCT03865589 1200 1201 O

Neuroblastoma NCT03865589 1203 1216 B-Condition
, NCT03865589 1217 1218 O
HLH NCT03865589 1219 1222 B-Condition
, NCT03865589 1223 1224 O
Osteopetrosis NCT03865589 1225 1238 B-Condition
, NCT03865589 1239 1240 O
Thalassemia NCT03865589 1241 1252 B-Condition
, NCT03865589 1253 1254 O
treatment NCT03865589 1255 1264 B-Procedure
with NCT03865589 1265 1269 B-Eq-Comparison
inotuzumab NCT03865589 1270 1280 B-Drug
or NCT03865589 1281 1283 B-Or
gemtuzumab NCT03865589 1284 1294 B-Drug
within NCT03865589 1295 1301 B-Eq-Comparison
3 NCT03865589 1302 1303 I-Eq-Comparison
months NCT03865589 1304 1310 I-Eq-Comparison|Eq-Comparison
prior NCT03865589 1311 1316 B-Coreference|Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865589 1317 1319 I-Temporal-Connection___Temporal-Connection-Type-Value:before
HSCT NCT03865589 1320 1324 B-Procedure|Procedure
admission NCT03865589 1325 1334 B-Encounter
, NCT03865589 1335 1336 O
2 NCT03865589 1337 1338 B-Eq-Comparison
nd NCT03865589 1339 1341 O
HSCT NCT03865589 1342 1346 O
if NCT03865589 1347 1349 O
it NCT03865589 1350 1352 O
is NCT03865589 1353 1355 O
myeloablative NCT03865589 1356 1369 B-Modifier
and NCT03865589 1370 1373 O
within NCT03865589 1374 1380 O
6 NCT03865589 1381 1382 I-Eq-Comparison
months NCT03865589 1383 1389 O
of NCT03865589 1390 1392 B-Temporal-Connection___Temporal-Connection-Type-Value:before
prior NCT03865589 1393 1398 O
, NCT03865589 1399 1400 O
iron NCT03865589 1401 1405 B-Condition
overload NCT03865589 1406 1414 I-Condition
, NCT03865589 1415 1416 O
steatohepatitis NCT03865589 1417 1432 B-Condition
, NCT03865589 1433 1434 O
active NCT03865589 1435 1441 B-Eq-Comparison
inflammatory NCT03865589 1442 1454 B-Modifier
or NCT03865589 1455 1457 B-Or|Or
infection NCT03865589 1458 1467 B-Modifier
hepatitis NCT03865589 1468 1477 B-Condition
or NCT03865589 1478 1480 O
any NCT03865589 1481 1484 O
other NCT03865589 1485 1490 B-Other
condition NCT03865589 1491 1500 B-Condition
which NCT03865589 1501 1506 O
puts NCT03865589 1507 1511 O
the NCT03865589 1512 1515 O
patient NCT03865589 1516 1523 O
at NCT03865589 1524 1526 O
a NCT03865589 1527 1528 O
higher NCT03865589 1529 1535 O
risk NCT03865589 1536 1540 B-Risk
of NCT03865589 1541 1543 O
developing NCT03865589 1544 1554 O
SOS NCT03865589 1555 1558 B-Condition
. NCT03865589 1558 1559 O

Exclusion NCT03865589 1561 1570 O
Criteria NCT03865589 1571 1579 O
: NCT03865589 1580 1581 O

- NCT03865589 1585 1586 O
Any NCT03865589 1588 1591 O
patient NCT03865589 1592 1599 O
who NCT03865589 1600 1603 O
has NCT03865589 1604 1607 O
contraindication NCT03865589 1608 1624 B-Contraindication
to NCT03865589 1625 1627 I-Condition
US NCT03865589 1628 1630 B-Procedure
SWE NCT03865589 1631 1634 I-Procedure
( NCT03865589 1635 1636 O
e. NCT03865589 1637 1639 O
g. NCT03865589 1640 1642 O
unable NCT03865589 1644 1650 B-Condition
to NCT03865589 1651 1653 O
hold NCT03865589 1654 1658 I-Condition
still NCT03865589 1659 1664 I-Condition
) NCT03865589 1665 1666 O


Inclusion NCT03866902 0 9 O
criteria NCT03866902 10 18 O
for NCT03866902 19 22 O
mothers NCT03866902 23 30 B-Family-Member___Family-Member-Type:mother
will NCT03866902 31 35 O
be NCT03866902 36 38 O
: NCT03866902 39 40 O

- NCT03866902 44 45 O
age NCT03866902 47 50 B-Age
18 NCT03866902 51 53 B-Eq-Comparison
years NCT03866902 54 59 I-Eq-Comparison
or NCT03866902 60 62 I-Eq-Comparison
older NCT03866902 63 68 I-Eq-Comparison

- NCT03866902 71 72 O
self NCT03866902 74 78 O
- NCT03866902 79 80 O
identification NCT03866902 81 95 O
as NCT03866902 96 98 O
Hispanic NCT03866902 99 107 O

- NCT03866902 110 111 O
limited NCT03866902 113 120 B-Negation
English NCT03866902 121 128 O
proficiency NCT03866902 129 140 O
; NCT03866902 140 141 O
little NCT03866902 142 148 B-Negation
acculturation NCT03866902 149 162 B-Observation
, NCT03866902 163 164 O
as NCT03866902 165 167 O
measured NCT03866902 168 176 O
by NCT03866902 177 179 O
the NCT03866902 180 183 O
Short NCT03866902 184 189 B-Observation
Acculturation NCT03866902 190 203 I-Observation
Scale NCT03866902 204 209 I-Observation
for NCT03866902 210 213 I-Observation
Hispanics NCT03866902 214 223 I-Observation
with NCT03866902 224 228 O
a NCT03866902 229 230 O
score NCT03866902 231 236 O
from NCT03866902 237 241 O
1.00 NCT03866902 242 246 B-Eq-Comparison
to NCT03866902 247 249 I-Eq-Comparison
2.99 NCT03866902 250 254 I-Eq-Comparison

- NCT03866902 258 259 O
ability NCT03866902 261 268 O
to NCT03866902 269 271 O
understand NCT03866902 272 282 O
spoken NCT03866902 283 289 O
Spanish NCT03866902 290 297 O

- NCT03866902 300 301 O
a NCT03866902 303 304 O
BMI NCT03866902 305 308 B-Observation
> NCT03866902 309 310 B-Eq-Comparison
25 NCT03866902 311 313 I-Eq-Comparison
kg NCT03866902 314 316 O
/ NCT03866902 317 318 I-Eq-Comparison
m² NCT03866902 319 321 I-Eq-Comparison

- NCT03866902 324 325 O
residence NCT03866902 327 336 O
with NCT03866902 337 341 O
the NCT03866902 342 345 B-Family-Member___Family-Member-Type:child
child NCT03866902 346 351 I-Family-Member___Family-Member-Type:child

- NCT03866902 354 355 O
consent NCT03866902 357 364 O
to NCT03866902 365 367 O
join NCT03866902 368 372 O
the NCT03866902 373 376 O
study NCT03866902 377 382 O
and NCT03866902 383 386 O
consent NCT03866902 387 394 O
for NCT03866902 395 398 O
their NCT03866902 399 404 B-Family-Member___Family-Member-Type:child
child NCT03866902 405 410 I-Family-Member___Family-Member-Type:child
to NCT03866902 411 413 O
join NCT03866902 414 418 O
the NCT03866902 419 422 O
study NCT03866902 423 428 B-Study
. NCT03866902 428 429 O

Inclusion NCT03866902 431 440 O
criteria NCT03866902 441 449 O
for NCT03866902 450 453 O
children NCT03866902 454 462 B-Family-Member___Family-Member-Type:child
will NCT03866902 463 467 O
be NCT03866902 468 470 O
: NCT03866902 471 472 O

- NCT03866902 476 477 I-Eq-Comparison
age NCT03866902 479 482 B-Age
3 NCT03866902 483 484 B-Eq-Comparison
- NCT03866902 485 486 O
5 NCT03866902 487 488 I-Eq-Comparison
years NCT03866902 489 494 I-Eq-Comparison

- NCT03866902 497 498 O
ability NCT03866902 500 507 O
to NCT03866902 508 510 O
understand NCT03866902 511 521 O
spoken NCT03866902 522 528 O
Spanish NCT03866902 529 536 O

- NCT03866902 539 540 O
a NCT03866902 542 543 O
BMI NCT03866902 544 547 B-Observation
> NCT03866902 548 549 B-Eq-Comparison
25 NCT03866902 550 552 I-Eq-Comparison
th NCT03866902 553 555 O
percentile NCT03866902 556 566 I-Eq-Comparison
for NCT03866902 567 570 O
age NCT03866902 571 574 B-Modifier
and NCT03866902 575 578 I-Modifier
gender NCT03866902 579 585 I-Modifier

Exclusion NCT03866902 586 595 O
criteria NCT03866902 596 604 O
for NCT03866902 605 608 O
mothers NCT03866902 609 616 B-Family-Member___Family-Member-Type:mother
will NCT03866902 617 621 O
be NCT03866902 622 624 O
: NCT03866902 625 626 O

- NCT03866902 630 631 O
heart NCT03866902 633 638 B-Condition
murmur NCT03866902 639 645 I-Condition

- NCT03866902 648 649 O
congenital NCT03866902 651 661 B-Condition
heart NCT03866902 662 667 I-Condition
disease NCT03866902 668 675 I-Condition

- NCT03866902 678 679 O
family NCT03866902 681 687 B-Family-Member
history NCT03866902 688 695 I-Family-Member
of NCT03866902 696 698 O
sudden NCT03866902 699 705 B-Condition
death NCT03866902 706 711 I-Condition

- NCT03866902 714 715 O
difficulty NCT03866902 717 727 B-Negation
exercising NCT03866902 728 738 B-Observation

- NCT03866902 741 742 O
psychological NCT03866902 744 757 B-Condition
problems NCT03866902 758 766 I-Condition

Inclusion NCT03862807 0 9 O
Criteria NCT03862807 10 18 O
: NCT03862807 19 20 O

- NCT03862807 24 25 O
Received NCT03862807 27 35 B-Eq-Comparison
liver NCT03862807 36 41 B-Procedure
transplant NCT03862807 42 52 I-Procedure
for NCT03862807 53 56 O
treatment NCT03862807 57 66 B-Procedure
of NCT03862807 67 69 O
hATTR NCT03862807 70 75 B-Modifier
amyloidosis NCT03862807 76 87 B-Condition
≥ NCT03862807 88 89 B-Eq-Comparison
12 NCT03862807 90 92 I-Eq-Comparison
months NCT03862807 93 99 I-Eq-Comparison
before NCT03862807 100 106 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03862807 107 112 B-Study
start NCT03862807 113 118 B-Eq-Comparison

- NCT03862807 121 122 O
Has NCT03862807 124 127 O
increase NCT03862807 128 136 O
in NCT03862807 137 139 O
polyneuropathy NCT03862807 140 154 B-Condition
disability NCT03862807 155 165 I-Condition
( NCT03862807 166 167 O
PND NCT03862807 168 171 B-Condition
) NCT03862807 172 173 O
score NCT03862807 174 179 O
after NCT03862807 180 185 B-Temporal-Connection___Temporal-Connection-Type-Value:after
liver NCT03862807 186 191 B-Procedure
transplant NCT03862807 192 202 I-Procedure

- NCT03862807 205 206 O
Has NCT03862807 208 211 O
received NCT03862807 212 220 B-Eq-Comparison
stable NCT03862807 221 227 O
immunosuppressive NCT03862807 228 245 B-Procedure
regimen NCT03862807 246 253 I-Procedure
with NCT03862807 254 258 B-And
≤ NCT03862807 259 260 B-Eq-Comparison
10 NCT03862807 261 263 I-Eq-Comparison
mg NCT03862807 264 266 I-Eq-Comparison
/ NCT03862807 267 268 I-Eq-Comparison
day NCT03862807 269 272 I-Eq-Comparison
of NCT03862807 273 275 O
prednisone NCT03862807 276 286 B-Drug
for NCT03862807 287 290 O
at NCT03862807 291 293 B-Eq-Comparison
least NCT03862807 294 299 I-Eq-Comparison
3 NCT03862807 300 301 I-Eq-Comparison
months NCT03862807 302 308 I-Eq-Comparison
before NCT03862807 309 315 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03862807 316 321 B-Study
start NCT03862807 322 327 B-Eq-Comparison

- NCT03862807 330 331 O
Has NCT03862807 333 336 O
Karnofsky NCT03862807 337 346 B-Observation
Performance NCT03862807 347 358 I-Observation
Status NCT03862807 359 365 I-Observation
( NCT03862807 366 367 O
KPS NCT03862807 368 371 B-Observation
) NCT03862807 372 373 O
of NCT03862807 374 376 O
≥ NCT03862807 377 378 B-Eq-Comparison
70 NCT03862807 379 381 I-Eq-Comparison
% NCT03862807 382 383 O

- NCT03862807 386 387 O
Has NCT03862807 389 392 O
vitamin NCT03862807 393 400 B-Observation
A NCT03862807 401 402 I-Observation
level NCT03862807 403 408 I-Observation
greater NCT03862807 409 416 B-Eq-Comparison
than NCT03862807 417 421 I-Eq-Comparison
or NCT03862807 422 424 I-Eq-Comparison
equal NCT03862807 425 430 I-Eq-Comparison
to NCT03862807 431 433 I-Eq-Comparison
lower NCT03862807 434 439 I-Eq-Comparison
limit NCT03862807 440 445 I-Eq-Comparison
of NCT03862807 446 448 I-Eq-Comparison
normal NCT03862807 449 455 I-Eq-Comparison

Exclusion NCT03862807 456 465 O
Criteria NCT03862807 466 474 O
: NCT03862807 475 476 O

- NCT03862807 480 481 O
Has NCT03862807 483 486 O
previously NCT03862807 487 497 B-Eq-Comparison
received NCT03862807 498 506 I-Eq-Comparison
inotersen NCT03862807 507 516 B-Drug
or NCT03862807 517 519 B-Or
patisiran NCT03862807 520 529 B-Drug

- NCT03862807 532 533 O
Has NCT03862807 535 538 O
clinically NCT03862807 539 549 O
significant NCT03862807 550 561 O
liver NCT03862807 562 567 B-Observation
function NCT03862807 568 576 I-Observation
test NCT03862807 577 581 I-Observation
abnormalities NCT03862807 582 595 O

- NCT03862807 598 599 O
Has NCT03862807 601 604 O
known NCT03862807 605 610 O
portal NCT03862807 611 617 B-Condition
hypertension NCT03862807 618 630 I-Condition
with NCT03862807 631 635 B-And
ascites NCT03862807 636 643 B-Condition

- NCT03862807 646 647 O
Has NCT03862807 649 652 O
estimated NCT03862807 653 662 B-Observation
glomerular NCT03862807 663 673 I-Observation
filtration NCT03862807 674 684 I-Observation
rate NCT03862807 685 689 I-Observation
( NCT03862807 690 691 O
eGFR NCT03862807 692 696 B-Observation
) NCT03862807 697 698 O
≤ NCT03862807 699 700 B-Eq-Comparison
30 NCT03862807 701 703 I-Eq-Comparison
mL NCT03862807 704 706 I-Eq-Comparison
/ NCT03862807 707 708 I-Eq-Comparison
min NCT03862807 709 712 I-Eq-Comparison
/ NCT03862807 713 714 O
1.73 NCT03862807 715 719 I-Eq-Comparison
m^2 NCT03862807 720 723 I-Eq-Comparison

- NCT03862807 727 728 O
Has NCT03862807 730 733 O
known NCT03862807 734 739 O
leptomeningeal NCT03862807 740 754 B-Modifier
amyloidosis NCT03862807 755 766 B-Condition

- NCT03862807 769 770 O
Has NCT03862807 772 775 O
infection NCT03862807 776 785 B-Condition
with NCT03862807 786 790 B-And
hepatitis NCT03862807 791 800 B-Condition|Condition
B NCT03862807 801 802 I-Condition
, NCT03862807 803 804 O
hepatitis NCT03862807 805 814 O
C NCT03862807 815 816 I-Condition
or NCT03862807 817 819 B-Or
human NCT03862807 820 825 B-Condition
immunodeficiency NCT03862807 826 842 I-Condition
virus NCT03862807 843 848 I-Condition
( NCT03862807 849 850 O
HIV NCT03862807 851 854 B-Condition
) NCT03862807 855 856 O

- NCT03862807 860 861 O
Has NCT03862807 863 866 O
New NCT03862807 867 870 B-Condition
York NCT03862807 871 875 I-Condition
Heart NCT03862807 876 881 I-Condition
Association NCT03862807 882 893 I-Condition
heart NCT03862807 894 899 I-Condition
failure NCT03862807 900 907 I-Condition
classification NCT03862807 908 922 O
of NCT03862807 923 925 O
> NCT03862807 926 927 B-Eq-Comparison
2 NCT03862807 928 929 I-Eq-Comparison

- NCT03862807 933 934 O
Is NCT03862807 936 938 O
wheelchair NCT03862807 939 949 B-Condition
bound NCT03862807 950 955 I-Condition
or NCT03862807 956 958 B-Or
bedridden NCT03862807 959 968 B-Condition

- NCT03862807 971 972 O
Has NCT03862807 974 977 O
received NCT03862807 978 986 B-Eq-Comparison
organ NCT03862807 987 992 B-Procedure
transplants NCT03862807 993 1004 I-Procedure|Procedure
other NCT03862807 1005 1010 B-Exception
than NCT03862807 1011 1015 I-Exception
liver NCT03862807 1016 1021 B-Procedure
transplant NCT03862807 1022 1032 O

- NCT03862807 1035 1036 O
Will NCT03862807 1038 1042 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862807 1043 1045 I-Assertion___Assertion-Type-Value:hypothetical
using NCT03862807 1046 1051 O
an NCT03862807 1052 1054 O
other NCT03862807 1055 1060 B-Other
tetramer NCT03862807 1061 1069 B-Procedure
stabilizer NCT03862807 1070 1080 I-Procedure
during NCT03862807 1081 1087 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862807 1088 1091 O
study NCT03862807 1092 1097 B-Study

Inclusion NCT03860792 0 9 O
Criteria NCT03860792 10 18 O
: NCT03860792 19 20 O

- NCT03860792 24 25 O
Diagnosis NCT03860792 27 36 O
of NCT03860792 37 39 O
AD NCT03860792 40 42 B-Condition
by NCT03860792 43 45 O
current NCT03860792 46 53 O
McKhann NCT03860792 54 61 O
et NCT03860792 62 64 O
al NCT03860792 65 67 O
. NCT03860792 67 68 O
criteria NCT03860792 70 78 O

- NCT03860792 81 82 O
CDR NCT03860792 84 87 B-Observation
global NCT03860792 88 94 I-Observation
score NCT03860792 95 100 I-Observation
of NCT03860792 101 103 O
0.5 NCT03860792 104 107 B-Eq-Comparison
or NCT03860792 108 110 I-Eq-Comparison
1 NCT03860792 111 112 I-Eq-Comparison

- NCT03860792 116 117 O
Agreed NCT03860792 119 125 O
cooperation NCT03860792 126 137 O
from NCT03860792 138 142 O
an NCT03860792 143 145 O
appropriate NCT03860792 146 157 O
study NCT03860792 158 163 O
partner NCT03860792 164 171 O

- NCT03860792 174 175 O
Speaks NCT03860792 177 183 O
English NCT03860792 184 191 O
as NCT03860792 192 194 O
primary NCT03860792 195 202 O
language NCT03860792 203 211 O

- NCT03860792 214 215 O
Age NCT03860792 217 220 B-Age
50 NCT03860792 221 223 B-Eq-Comparison
to NCT03860792 224 226 I-Eq-Comparison
90 NCT03860792 227 229 I-Eq-Comparison

- NCT03860792 233 234 O
No NCT03860792 236 238 B-Negation
medication NCT03860792 239 249 B-Drug
changes NCT03860792 250 257 O
within NCT03860792 258 264 B-Eq-Comparison
the NCT03860792 265 268 I-Eq-Comparison
past NCT03860792 269 273 I-Eq-Comparison
30 NCT03860792 274 276 I-Eq-Comparison
days NCT03860792 277 281 I-Eq-Comparison

Exclusion NCT03860792 282 291 O
Criteria NCT03860792 292 300 O
: NCT03860792 301 302 O

- NCT03860792 306 307 O
Resides NCT03860792 309 316 O
in NCT03860792 317 319 O
a NCT03860792 320 321 O
nursing NCT03860792 322 329 O
home NCT03860792 330 334 O
or NCT03860792 335 337 B-Or
dementia NCT03860792 338 346 O
special NCT03860792 347 354 O
care NCT03860792 355 359 O
unit NCT03860792 360 364 O
, NCT03860792 365 366 O
or NCT03860792 367 369 B-Or
can NCT03860792 370 373 B-Negation
not NCT03860792 373 376 O
control NCT03860792 377 384 O
diet NCT03860792 385 389 B-Procedure

- NCT03860792 392 393 O
A NCT03860792 395 396 O
potentially NCT03860792 397 408 B-Assertion___Assertion-Type-Value:hypothetical
confounding NCT03860792 409 420 O
serious NCT03860792 421 428 O
medical NCT03860792 429 436 O
risk NCT03860792 437 441 B-Risk
including NCT03860792 442 451 O
insulin NCT03860792 452 459 B-Drug
- NCT03860792 460 461 O
requiring NCT03860792 462 471 B-Assertion___Assertion-Type-Value:hypothetical
diabetes NCT03860792 472 480 B-Condition
, NCT03860792 481 482 O
cancer NCT03860792 483 489 B-Condition
requiring NCT03860792 490 499 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03860792 500 512 B-Procedure
or NCT03860792 513 515 B-Or
radiation NCT03860792 516 525 B-Procedure
within NCT03860792 526 532 B-Eq-Comparison
the NCT03860792 533 536 I-Eq-Comparison
past NCT03860792 537 541 I-Eq-Comparison
5 NCT03860792 542 543 I-Eq-Comparison
years NCT03860792 544 549 I-Eq-Comparison
, NCT03860792 550 551 O
or NCT03860792 552 554 B-Or
a NCT03860792 555 556 O
recent NCT03860792 557 563 B-Eq-Comparison
cardiac NCT03860792 564 571 B-Condition
event NCT03860792 572 577 I-Condition
( NCT03860792 578 579 O
i. NCT03860792 580 582 O
e. NCT03860792 583 585 O
heart NCT03860792 587 592 B-Condition
attack NCT03860792 593 599 I-Condition
, NCT03860792 600 601 O
angioplasty NCT03860792 602 613 B-Procedure
, NCT03860792 614 615 O
etc NCT03860792 616 619 O
. NCT03860792 619 620 O
) NCT03860792 621 622 O

- NCT03860792 626 627 O
Participating NCT03860792 629 642 B-Eq-Comparison
in NCT03860792 643 645 O
another NCT03860792 646 653 B-Other
clinical NCT03860792 654 662 B-Study
trial NCT03860792 663 668 I-Study
or NCT03860792 669 671 B-Or
using NCT03860792 672 677 B-Eq-Comparison
an NCT03860792 678 680 O
investigational NCT03860792 681 696 B-Study
drug NCT03860792 697 701 B-Drug
or NCT03860792 702 704 B-Or
therapy NCT03860792 705 712 B-Procedure
within NCT03860792 713 719 B-Eq-Comparison
30 NCT03860792 720 722 I-Eq-Comparison
days NCT03860792 723 727 I-Eq-Comparison
of NCT03860792 728 730 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860792 731 734 O
Screening NCT03860792 735 744 B-Study
Visit NCT03860792 745 750 O

- NCT03860792 753 754 O
A NCT03860792 756 757 O
history NCT03860792 758 765 B-Eq-Comparison
of NCT03860792 766 768 O
renal NCT03860792 769 774 B-Condition
stones NCT03860792 775 781 I-Condition

Inclusion NCT03860779 0 9 O
Criteria NCT03860779 10 18 O
: NCT03860779 19 20 O

- NCT03860779 24 25 O
Age NCT03860779 27 30 B-Age
above NCT03860779 31 36 B-Eq-Comparison
18 NCT03860779 37 39 I-Eq-Comparison

- NCT03860779 43 44 O
ASA NCT03860779 46 49 B-Condition
classification NCT03860779 50 64 O
I NCT03860779 65 66 B-Eq-Comparison
to NCT03860779 67 69 I-Eq-Comparison
II NCT03860779 70 72 I-Eq-Comparison

- NCT03860779 75 76 O
Indication NCT03860779 78 88 B-Indication
for NCT03860779 89 92 O
colonoscopy NCT03860779 93 104 B-Procedure
with NCT03860779 105 109 O
propofol NCT03860779 110 118 B-Drug
sedation NCT03860779 119 127 B-Procedure

- NCT03860779 130 131 O
Written NCT03860779 133 140 O
informed NCT03860779 141 149 O
consent NCT03860779 150 157 O

Exclusion NCT03860779 158 167 O
Criteria NCT03860779 168 176 O
: NCT03860779 177 178 O

- NCT03860779 182 183 O
Pregnancy NCT03860779 185 194 B-Condition

Inclusion NCT03869749 0 9 O
Criteria NCT03869749 10 18 O
: NCT03869749 19 20 O

- NCT03869749 24 25 O
two NCT03869749 27 30 B-Eq-Comparison
parents NCT03869749 31 38 B-Family-Member___Family-Member-Type:parent
in NCT03869749 39 41 O
the NCT03869749 42 45 O
home NCT03869749 46 50 O

- NCT03869749 53 54 O
an NCT03869749 56 58 O
adolescent NCT03869749 59 69 O
who NCT03869749 70 73 B-And
is NCT03869749 74 76 O
between NCT03869749 77 84 B-Eq-Comparison
14 NCT03869749 85 87 I-Eq-Comparison
and NCT03869749 88 91 I-Eq-Comparison
18 NCT03869749 92 94 I-Eq-Comparison
years NCT03869749 95 100 I-Eq-Comparison
of NCT03869749 101 103 O
age NCT03869749 104 107 B-Age

- NCT03869749 110 111 O
marital NCT03869749 113 120 B-Observation
distress NCT03869749 121 129 I-Observation

- NCT03869749 132 133 O
youth NCT03869749 135 140 O
reports NCT03869749 141 148 O
of NCT03869749 149 151 O
stress NCT03869749 152 158 B-Condition
or NCT03869749 159 161 B-Or
anxiety NCT03869749 162 169 B-Condition

Exclusion NCT03869749 170 179 O
Criteria NCT03869749 180 188 O
: NCT03869749 189 190 O

- NCT03869749 194 195 O
two NCT03869749 197 200 B-Eq-Comparison
parents NCT03869749 201 208 B-Family-Member___Family-Member-Type:parent
in NCT03869749 209 211 O
the NCT03869749 212 215 O
home NCT03869749 216 220 O
, NCT03869749 221 222 O
but NCT03869749 223 226 B-And
they NCT03869749 227 231 O
are NCT03869749 232 235 O
pursuing NCT03869749 236 244 B-Assertion___Assertion-Type-Value:intention
legal NCT03869749 245 250 B-Observation
divorce NCT03869749 251 258 I-Observation
or NCT03869749 259 261 B-Or
separation NCT03869749 262 272 B-Observation

- NCT03869749 275 276 O
parents NCT03869749 278 285 B-Family-Member___Family-Member-Type:parent
are NCT03869749 286 289 O
not NCT03869749 290 293 B-Negation
willing NCT03869749 294 301 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869749 302 304 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03869749 305 312 O
marital NCT03869749 313 320 B-Modifier
education NCT03869749 321 330 B-Procedure
/ NCT03869749 331 332 B-Or
support NCT03869749 333 340 B-Procedure

- NCT03869749 343 344 O
adolescents NCT03869749 346 357 O
are NCT03869749 358 361 O
clinically NCT03869749 362 372 O
depressed NCT03869749 373 382 B-Condition
or NCT03869749 383 385 B-Or
report NCT03869749 386 392 O
suicidal NCT03869749 393 401 B-Condition
ideation NCT03869749 402 410 I-Condition
at NCT03869749 411 413 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03869749 414 422 B-Study

Inclusion NCT03865173 0 9 O
Criteria NCT03865173 10 18 O
: NCT03865173 19 20 O

- NCT03865173 24 25 O
Patient NCT03865173 27 34 O
being NCT03865173 35 40 O
over NCT03865173 41 45 B-Eq-Comparison
18 NCT03865173 46 48 I-Eq-Comparison
years NCT03865173 49 54 I-Eq-Comparison
of NCT03865173 55 57 O
age NCT03865173 58 61 B-Age
living NCT03865173 62 68 O
in NCT03865173 69 71 O
metropolitan NCT03865173 72 84 O
France NCT03865173 85 91 O
; NCT03865173 91 92 O

- NCT03865173 95 96 O
Patient NCT03865173 98 105 O
with NCT03865173 106 110 O
recent NCT03865173 111 117 B-Eq-Comparison
stroke NCT03865173 118 124 B-Condition
( NCT03865173 125 126 O
not NCT03865173 127 130 B-Negation
before NCT03865173 131 137 B-Eq-Comparison
2019 NCT03865173 138 142 I-Eq-Comparison
) NCT03865173 143 144 O
whose NCT03865173 145 150 O
diagnosis NCT03865173 151 160 O
confirmed NCT03865173 161 170 O
by NCT03865173 171 173 O
a NCT03865173 174 175 O
neuro NCT03865173 176 181 B-Provider
- NCT03865173 182 183 I-Provider
vascular NCT03865173 184 192 I-Provider
physician NCT03865173 193 202 I-Provider
; NCT03865173 202 203 O

- NCT03865173 206 207 O
Patient NCT03865173 209 216 O
managed NCT03865173 217 224 B-Procedure
for NCT03865173 225 228 O
stroke NCT03865173 229 235 B-Condition
in NCT03865173 236 238 O
one NCT03865173 239 242 O
of NCT03865173 243 245 O
the NCT03865173 246 249 O
13 NCT03865173 250 252 O
participating NCT03865173 253 266 O
hospitals NCT03865173 267 276 O
of NCT03865173 277 279 O
the NCT03865173 280 283 O
Aquitaine NCT03865173 284 293 O
region NCT03865173 294 300 O
; NCT03865173 300 301 O

- NCT03865173 304 305 O
Patient NCT03865173 307 314 O
giving NCT03865173 315 321 O
consent NCT03865173 322 329 O
to NCT03865173 330 332 O
participate NCT03865173 333 344 O
to NCT03865173 345 347 O
PAPASéPA NCT03865173 348 356 O
; NCT03865173 356 357 O

- NCT03865173 360 361 O
Patient NCT03865173 363 370 O
to NCT03865173 371 373 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03865173 374 376 I-Assertion___Assertion-Type-Value:hypothetical
alive NCT03865173 377 382 B-Observation
at NCT03865173 383 385 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865173 386 389 I-Temporal-Connection___Temporal-Connection-Type-Value:during
end NCT03865173 390 393 B-Eq-Comparison
of NCT03865173 394 396 O
the NCT03865173 397 400 O
acute NCT03865173 401 406 B-Modifier
management NCT03865173 407 417 I-Modifier
hospital NCT03865173 418 426 B-Encounter
stay NCT03865173 427 431 I-Encounter

Exclusion NCT03865173 432 441 O
Criteria NCT03865173 442 450 O
: NCT03865173 451 452 O

- NCT03865173 456 457 O
Patient NCT03865173 459 466 O
refuse NCT03865173 467 473 O
to NCT03865173 474 476 O
participate NCT03865173 477 488 O
to NCT03865173 489 491 O
PAPASéPA NCT03865173 492 500 O

- NCT03865173 503 504 O
Patient NCT03865173 506 513 O
died NCT03865173 514 518 B-Death
during NCT03865173 519 525 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865173 526 529 O
initial NCT03865173 530 537 B-Eq-Comparison
stay NCT03865173 538 542 B-Encounter

Inclusion NCT03868319 0 9 O
Criteria NCT03868319 10 18 O
: NCT03868319 19 20 O

- NCT03868319 24 25 O
scheduled NCT03868319 27 36 B-Eq-Comparison
for NCT03868319 37 40 O
elective NCT03868319 41 49 B-Modifier
RARC NCT03868319 50 54 B-Procedure

Exclusion NCT03868319 55 64 O
Criteria NCT03868319 65 73 O
: NCT03868319 74 75 O

- NCT03868319 79 80 O
history NCT03868319 82 89 B-Eq-Comparison
of NCT03868319 90 92 O
lung NCT03868319 93 97 B-Modifier
surgery NCT03868319 98 105 B-Procedure

- NCT03868319 108 109 O
patients NCT03868319 111 119 O
' NCT03868319 119 120 O
refusal NCT03868319 121 128 O
or NCT03868319 129 131 O
inability NCT03868319 132 141 O
to NCT03868319 142 144 O
give NCT03868319 145 149 O
informed NCT03868319 150 158 O
consent NCT03868319 159 166 O

Inclusion NCT03867994 0 9 O
Criteria NCT03867994 10 18 O
: NCT03867994 19 20 O

- NCT03867994 24 25 O
Patients NCT03867994 27 35 O
aged NCT03867994 36 40 B-Age
between NCT03867994 41 48 B-Eq-Comparison
18 NCT03867994 49 51 I-Eq-Comparison
and NCT03867994 52 55 I-Eq-Comparison
70 NCT03867994 56 58 I-Eq-Comparison
years NCT03867994 59 64 I-Eq-Comparison
. NCT03867994 64 65 O

- NCT03867994 69 70 O
Serum NCT03867994 72 77 B-Observation
creatinine NCT03867994 78 88 I-Observation
≤ NCT03867994 89 90 B-Eq-Comparison
1.5 NCT03867994 91 94 I-Eq-Comparison
mg NCT03867994 95 97 I-Eq-Comparison
/ NCT03867994 98 99 I-Eq-Comparison
dL. NCT03867994 100 103 I-Eq-Comparison

- NCT03867994 107 108 O
Using NCT03867994 110 115 B-Eq-Comparison
a NCT03867994 116 117 O
moderate NCT03867994 118 126 B-Eq-Comparison
dose NCT03867994 127 131 O
of NCT03867994 132 134 O
atorvastatin NCT03867994 135 147 B-Drug
( NCT03867994 148 149 O
40 NCT03867994 150 152 B-Eq-Comparison
mg NCT03867994 153 155 I-Eq-Comparison
or NCT03867994 156 158 B-Or
equivalent NCT03867994 159 169 O
dose NCT03867994 170 174 O
of NCT03867994 175 177 O
other NCT03867994 178 183 B-Other
statins NCT03867994 184 191 B-Drug
) NCT03867994 192 193 O
. NCT03867994 194 195 O

- NCT03867994 199 200 O
Moderate NCT03867994 202 210 B-Eq-Comparison
to NCT03867994 211 213 I-Eq-Comparison
high NCT03867994 214 218 I-Eq-Comparison
- NCT03867994 219 220 O
risk NCT03867994 221 225 B-Risk
for NCT03867994 226 229 O
CIN NCT03867994 230 233 B-Condition
. NCT03867994 233 234 O

Exclusion NCT03867994 236 245 O
Criteria NCT03867994 246 254 O
: NCT03867994 255 256 O

- NCT03867994 260 261 O
Patients NCT03867994 263 271 O
suffering NCT03867994 272 281 B-Eq-Comparison
from NCT03867994 282 286 O
ST NCT03867994 287 289 B-Modifier
- NCT03867994 290 291 I-Modifier
segment NCT03867994 292 299 I-Modifier
elevation NCT03867994 300 309 I-Modifier
myocardial NCT03867994 310 320 B-Condition
infarction NCT03867994 321 331 I-Condition
( NCT03867994 332 333 O
STEMI NCT03867994 334 339 B-Condition
) NCT03867994 340 341 O

- NCT03867994 345 346 O
Patients NCT03867994 348 356 O
need NCT03867994 357 361 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867994 362 365 I-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03867994 366 375 O
cardiac NCT03867994 376 383 B-Procedure
catheterization NCT03867994 384 399 I-Procedure

- NCT03867994 402 403 O
Elevated NCT03867994 405 413 O
liver NCT03867994 414 419 B-Condition
enzymes NCT03867994 420 427 I-Condition
( NCT03867994 428 429 O
Aspartate NCT03867994 430 439 B-Observation
aminotransferase NCT03867994 440 456 I-Observation
( NCT03867994 457 458 O
AST NCT03867994 459 462 B-Observation
) NCT03867994 463 464 O
and NCT03867994 465 468 B-Or
Alanine NCT03867994 469 476 B-Observation
aminotransferase NCT03867994 477 493 I-Observation
( NCT03867994 494 495 O
ALT NCT03867994 496 499 B-Observation
) NCT03867994 500 501 O
three NCT03867994 502 507 B-Eq-Comparison
times NCT03867994 508 513 I-Eq-Comparison
the NCT03867994 514 517 I-Eq-Comparison
upper NCT03867994 518 523 I-Eq-Comparison
limit NCT03867994 524 529 I-Eq-Comparison
of NCT03867994 530 532 I-Eq-Comparison
normal NCT03867994 533 539 I-Eq-Comparison
) NCT03867994 540 541 O
. NCT03867994 542 543 O

- NCT03867994 547 548 O
Active NCT03867994 550 556 B-Eq-Comparison
infection NCT03867994 557 566 B-Condition
. NCT03867994 566 567 O

- NCT03867994 571 572 O
Any NCT03867994 574 577 O
contraindication NCT03867994 578 594 B-Contraindication
to NCT03867994 595 597 O
carvedilol NCT03867994 598 608 B-Drug
, NCT03867994 609 610 O
or NCT03867994 611 613 B-Or
atorvastatin NCT03867994 614 626 B-Drug
. NCT03867994 626 627 O

- NCT03867994 631 632 O
Patients NCT03867994 634 642 O
on NCT03867994 643 645 B-Eq-Comparison
regular NCT03867994 646 653 O
use NCT03867994 654 657 O
of NCT03867994 658 660 O
vitamins NCT03867994 661 669 B-Drug
, NCT03867994 670 671 O
minerals NCT03867994 672 680 B-Drug
. NCT03867994 680 681 O

- NCT03867994 685 686 O
Using NCT03867994 688 693 B-Eq-Comparison
medication NCT03867994 694 704 B-Drug
with NCT03867994 705 709 O
antioxidant NCT03867994 710 721 B-Modifier
properties NCT03867994 722 732 I-Modifier
e. NCT03867994 733 735 O
g. NCT03867994 736 738 O
, NCT03867994 739 740 O
beta NCT03867994 741 745 B-Drug
- NCT03867994 746 747 I-Drug
carotene NCT03867994 748 756 I-Drug
, NCT03867994 757 758 O
vitamin NCT03867994 759 766 B-Drug|Drug
E NCT03867994 767 768 I-Drug
, NCT03867994 769 770 O
vitamin NCT03867994 771 778 O
C NCT03867994 779 780 I-Drug
, NCT03867994 781 782 O
selenium NCT03867994 783 791 B-Drug
, NCT03867994 792 793 O
theophylline NCT03867994 794 806 B-Drug
or NCT03867994 807 809 B-Or
N NCT03867994 810 811 B-Drug
- NCT03867994 812 813 I-Drug
acetyl NCT03867994 814 820 I-Drug
cysteine NCT03867994 821 829 I-Drug
7 NCT03867994 830 831 B-Eq-Comparison
days NCT03867994 832 836 I-Eq-Comparison
prior NCT03867994 837 842 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867994 843 845 I-Temporal-Connection___Temporal-Connection-Type-Value:before
CC NCT03867994 846 848 B-Procedure
. NCT03867994 848 849 O

- NCT03867994 853 854 O
Hemodynamically NCT03867994 856 871 B-Condition
unstable NCT03867994 872 880 O
patients NCT03867994 881 889 O
( NCT03867994 890 891 O
defined NCT03867994 892 899 O
as NCT03867994 900 902 O
abnormal NCT03867994 903 911 O
or NCT03867994 912 914 B-Or
unstable NCT03867994 915 923 O
blood NCT03867994 924 929 B-Observation|Observation
pressure NCT03867994 930 938 I-Observation|Observation
, NCT03867994 939 940 O
especially NCT03867994 941 951 O
hypotension NCT03867994 952 963 B-Condition
( NCT03867994 964 965 O
blood NCT03867994 966 971 O
pressure NCT03867994 972 980 O
less NCT03867994 981 985 B-Eq-Comparison
than NCT03867994 986 990 I-Eq-Comparison
90 NCT03867994 991 993 I-Eq-Comparison
/ NCT03867994 994 995 I-Eq-Comparison
60 NCT03867994 996 998 I-Eq-Comparison
mm NCT03867994 999 1001 I-Eq-Comparison
Hg NCT03867994 1002 1004 I-Eq-Comparison
) NCT03867994 1005 1006 O
. NCT03867994 1007 1008 O

- NCT03867994 1012 1013 O
Patients NCT03867994 1015 1023 O
who NCT03867994 1024 1027 O
required NCT03867994 1028 1036 B-Assertion___Assertion-Type-Value:hypothetical
dialysis NCT03867994 1037 1045 B-Procedure
. NCT03867994 1045 1046 O

- NCT03867994 1050 1051 O
Pregnancy NCT03867994 1053 1062 B-Condition
. NCT03867994 1062 1063 O

- NCT03867994 1067 1068 O
Using NCT03867994 1070 1075 O
of NCT03867994 1076 1078 O
carvedilol NCT03867994 1079 1089 B-Drug
in NCT03867994 1090 1092 O
the NCT03867994 1093 1096 O
past NCT03867994 1097 1101 B-Eq-Comparison
three NCT03867994 1102 1107 I-Eq-Comparison
months NCT03867994 1108 1114 I-Eq-Comparison
. NCT03867994 1114 1115 O

- NCT03867994 1119 1120 O
Using NCT03867994 1122 1127 O
a NCT03867994 1128 1129 O
nephrotoxic NCT03867994 1130 1141 B-Drug
agent NCT03867994 1142 1147 I-Drug|Procedure
in NCT03867994 1148 1150 O
the NCT03867994 1151 1154 O
past NCT03867994 1155 1159 B-Eq-Comparison|Eq-Comparison
48 NCT03867994 1160 1162 I-Eq-Comparison
hours NCT03867994 1163 1168 I-Eq-Comparison
or NCT03867994 1169 1171 B-Or
exposure NCT03867994 1172 1180 O
to NCT03867994 1181 1183 I-Temporal-Connection___Temporal-Connection-Type-Value:before
a NCT03867994 1184 1185 O
contrast NCT03867994 1186 1194 B-Procedure
agent NCT03867994 1195 1200 O
in NCT03867994 1201 1203 O
the NCT03867994 1204 1207 O
past NCT03867994 1208 1212 O
7 NCT03867994 1213 1214 I-Eq-Comparison
days NCT03867994 1215 1219 I-Eq-Comparison
prior NCT03867994 1220 1225 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867994 1226 1228 O
cardiac NCT03867994 1229 1236 B-Procedure
catheterization NCT03867994 1237 1252 I-Procedure
. NCT03867994 1252 1253 O

Inclusion NCT03869775 0 9 O
Criteria NCT03869775 10 18 O
: NCT03869775 19 20 O

- NCT03869775 24 25 O
the NCT03869775 27 30 O
patient NCT03869775 31 38 O
will NCT03869775 39 43 B-Eq-Comparison
be NCT03869775 44 46 I-Eq-Comparison
operated NCT03869775 47 55 B-Procedure
with NCT03869775 56 60 O
spinal NCT03869775 61 67 B-Procedure
anesthesia NCT03869775 68 78 I-Procedure

- NCT03869775 81 82 O
over NCT03869775 84 88 B-Eq-Comparison
18 NCT03869775 89 91 I-Eq-Comparison
years NCT03869775 92 97 I-Age|Eq-Comparison

- NCT03869775 100 101 O
no NCT03869775 103 105 B-Negation
additional NCT03869775 106 116 O
disease NCT03869775 117 124 B-Condition
and NCT03869775 125 128 O
only NCT03869775 129 133 B-Exception
DM NCT03869775 134 136 B-Condition

Exclusion NCT03869775 137 146 O
Criteria NCT03869775 147 155 O
: NCT03869775 156 157 O

- NCT03869775 161 162 O
patients NCT03869775 164 172 O
with NCT03869775 173 177 O
additional NCT03869775 178 188 O
disease NCT03869775 189 196 B-Condition

- NCT03869775 199 200 O
patients NCT03869775 202 210 O
under NCT03869775 211 216 B-Eq-Comparison
18 NCT03869775 217 219 I-Eq-Comparison
years NCT03869775 220 225 I-Eq-Comparison
of NCT03869775 226 228 O
age NCT03869775 229 232 B-Age

- NCT03869775 235 236 O
patients NCT03869775 238 246 O
contraindicated NCT03869775 247 262 B-Contraindication
in NCT03869775 263 265 O
spinal NCT03869775 266 272 B-Procedure
anesthesia NCT03869775 273 283 I-Procedure

Inclusion NCT03866863 0 9 O
Criteria NCT03866863 10 18 O
: NCT03866863 19 20 O

- NCT03866863 24 25 O
All NCT03866863 27 30 O
birth NCT03866863 31 36 B-Birth
more NCT03866863 37 41 B-Eq-Comparison
than NCT03866863 42 46 I-Eq-Comparison
24 NCT03866863 47 49 I-Eq-Comparison
+ NCT03866863 50 51 I-Eq-Comparison
0 NCT03866863 52 53 I-Eq-Comparison
weeks NCT03866863 54 59 I-Eq-Comparison
of NCT03866863 60 62 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03866863 63 73 B-Condition
at NCT03866863 74 76 O
the NCT03866863 77 80 O
maternity NCT03866863 81 90 O
ward NCT03866863 91 95 O
of NCT03866863 96 98 O
the NCT03866863 99 102 O
hospital NCT03866863 103 111 O
Femme NCT03866863 112 117 O
- NCT03866863 118 119 O
Mère NCT03866863 120 124 O
- NCT03866863 125 126 O
Enfant NCT03866863 127 133 O

- NCT03866863 136 137 O
from NCT03866863 139 143 O
1 NCT03866863 144 145 B-Eq-Comparison
st NCT03866863 146 148 O
of NCT03866863 149 151 I-Eq-Comparison
january NCT03866863 152 159 I-Eq-Comparison
2011 NCT03866863 160 164 I-Eq-Comparison
to NCT03866863 165 167 I-Eq-Comparison
31 NCT03866863 168 170 I-Eq-Comparison
december NCT03866863 171 179 I-Eq-Comparison
2017 NCT03866863 180 184 I-Eq-Comparison
. NCT03866863 184 185 O

Exclusion NCT03866863 187 196 O
Criteria NCT03866863 197 205 O
: NCT03866863 206 207 O

- NCT03866863 211 212 O
Infants NCT03866863 214 221 O
born NCT03866863 222 226 B-Birth
out NCT03866863 227 230 B-Negation
of NCT03866863 231 233 I-Negation
the NCT03866863 234 237 O
hospital NCT03866863 238 246 O
and NCT03866863 247 250 B-And
secondarily NCT03866863 251 262 B-Encounter
hospitalized NCT03866863 263 275 I-Encounter
in NCT03866863 276 278 O
the NCT03866863 279 282 O
hospital NCT03866863 283 291 O
Femme NCT03866863 292 297 O
- NCT03866863 298 299 O
Mère NCT03866863 300 304 O
- NCT03866863 305 306 O
Enfant NCT03866863 307 313 O
. NCT03866863 314 315 O

- NCT03866863 319 320 O
Multiple NCT03866863 322 330 B-Eq-Comparison
pregnancies NCT03866863 331 342 B-Condition
, NCT03866863 343 344 O

- NCT03866863 348 349 O
children NCT03866863 351 359 O
with NCT03866863 360 364 B-And
congenital NCT03866863 365 375 B-Condition
fetal NCT03866863 376 381 I-Condition
anomalies NCT03866863 382 391 I-Condition

- NCT03866863 394 395 O
pregnancies NCT03866863 397 408 B-Condition
without NCT03866863 409 416 B-Negation
first NCT03866863 417 422 B-Modifier
trimester NCT03866863 423 432 I-Modifier
ultrasound NCT03866863 433 443 B-Procedure
( NCT03866863 444 445 O
to NCT03866863 446 448 O
date NCT03866863 449 453 O
the NCT03866863 454 457 O
pregnancy NCT03866863 458 467 B-Condition
) NCT03866863 468 469 O

Inclusion NCT03868696 0 9 O
Criteria NCT03868696 10 18 O
: NCT03868696 19 20 O

- NCT03868696 24 25 O
Adults NCT03868696 27 33 O
with NCT03868696 34 38 B-And
Colles NCT03868696 39 45 B-Modifier
' NCT03868696 45 46 O
type NCT03868696 47 51 I-Modifier
fractures NCT03868696 52 61 B-Condition
of NCT03868696 62 64 O
the NCT03868696 65 68 O
distal NCT03868696 69 75 B-Modifier
radius NCT03868696 76 82 I-Modifier
undergoing NCT03868696 83 93 B-Eq-Comparison
fracture NCT03868696 94 102 B-Procedure
manipulation NCT03868696 103 115 I-Procedure
in NCT03868696 116 118 O
the NCT03868696 119 122 O
ED NCT03868696 123 125 O

- NCT03868696 128 129 O
UDiReCT NCT03868696 131 138 O
Trial NCT03868696 139 144 O
trained NCT03868696 145 152 O
staff NCT03868696 153 158 O
available NCT03868696 159 168 O

Exclusion NCT03868696 169 178 O
Criteria NCT03868696 179 187 O
: NCT03868696 188 189 O

- NCT03868696 193 194 O
Age NCT03868696 196 199 B-Age
under NCT03868696 200 205 B-Eq-Comparison
18 NCT03868696 206 208 I-Eq-Comparison

- NCT03868696 212 213 O
Volar NCT03868696 215 220 B-Modifier
displaced NCT03868696 221 230 I-Modifier
( NCT03868696 231 232 O
Smith NCT03868696 233 238 B-Modifier
's NCT03868696 238 240 O
) NCT03868696 241 242 O
type NCT03868696 243 247 O
fractures NCT03868696 248 257 B-Condition
( NCT03868696 258 259 O
well NCT03868696 260 264 O
established NCT03868696 265 276 O
as NCT03868696 277 279 O
being NCT03868696 280 285 O
unstable NCT03868696 286 294 O
and NCT03868696 295 298 B-And
requiring NCT03868696 299 308 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03868696 309 317 B-Procedure
treatment NCT03868696 318 327 I-Procedure
) NCT03868696 328 329 O

- NCT03868696 333 334 O
Unable NCT03868696 336 342 O
or NCT03868696 343 345 O
unwilling NCT03868696 346 355 O
to NCT03868696 356 358 O
give NCT03868696 359 363 O
informed NCT03868696 364 372 O
consent NCT03868696 373 380 O

- NCT03868696 383 384 O
Unable NCT03868696 386 392 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868696 393 395 I-Assertion___Assertion-Type-Value:hypothetical|Negation
unwilling NCT03868696 396 405 I-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868696 406 408 O
be NCT03868696 409 411 O
followed NCT03868696 412 420 B-Encounter
up NCT03868696 421 423 I-Encounter
( NCT03868696 424 425 O
e. NCT03868696 426 428 O
g. NCT03868696 429 431 O
orthopaedic NCT03868696 433 444 B-Provider
follow NCT03868696 445 451 B-Encounter
up NCT03868696 452 454 I-Encounter
in NCT03868696 455 457 O
another NCT03868696 458 465 B-Other
region NCT03868696 466 472 O
) NCT03868696 473 474 O

- NCT03868696 478 479 O
Major NCT03868696 481 486 O
trauma NCT03868696 487 493 B-Condition
with NCT03868696 494 498 B-And
other NCT03868696 499 504 B-Other
injuries NCT03868696 505 513 B-Condition
and NCT03868696 514 517 B-And
ISS NCT03868696 518 521 B-Observation
( NCT03868696 522 523 O
Injury NCT03868696 524 530 B-Observation
Severity NCT03868696 531 539 I-Observation
Score NCT03868696 540 545 I-Observation
) NCT03868696 546 547 O
> NCT03868696 548 549 B-Eq-Comparison
16 NCT03868696 550 552 I-Eq-Comparison

- NCT03868696 556 557 O
Urgent NCT03868696 559 565 B-Modifier
manipulation NCT03868696 566 578 B-Procedure
required NCT03868696 579 587 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03868696 588 591 O
to NCT03868696 592 594 O
neurovascular NCT03868696 595 608 B-Modifier
or NCT03868696 609 611 B-Or
skin NCT03868696 612 616 B-Modifier
compromise NCT03868696 617 627 B-Condition

- NCT03868696 630 631 O
Open NCT03868696 633 637 B-Modifier
fractures NCT03868696 638 647 B-Condition
or NCT03868696 648 650 B-Or
those NCT03868696 651 656 B-Coreference
with NCT03868696 657 661 O
associated NCT03868696 662 672 O
nerve NCT03868696 673 678 B-Modifier
or NCT03868696 679 681 B-Or
tendon NCT03868696 682 688 B-Modifier
involvement NCT03868696 689 700 I-Modifier
( NCT03868696 701 702 O
affect NCT03868696 703 709 O
functional NCT03868696 710 720 O
outcome NCT03868696 721 728 O
) NCT03868696 729 730 O

- NCT03868696 734 735 O
Prisoners NCT03868696 737 746 B-Observation

Inclusion NCT03867214 0 9 O
Criteria NCT03867214 10 18 O
: NCT03867214 19 20 O

- NCT03867214 24 25 O
Adult NCT03867214 27 32 O
patients NCT03867214 33 41 O
who NCT03867214 42 45 B-And
plan NCT03867214 46 50 B-Assertion___Assertion-Type-Value:intention
to NCT03867214 51 53 I-Assertion___Assertion-Type-Value:intention
undergo NCT03867214 54 61 O
simultaneous NCT03867214 62 74 B-Modifier
primary NCT03867214 75 82 I-Modifier
total NCT03867214 83 88 B-Procedure
knee NCT03867214 89 93 I-Procedure
arthroplasty NCT03867214 94 106 I-Procedure
on NCT03867214 107 109 O
bilateral NCT03867214 110 119 B-Modifier
knee NCT03867214 120 124 I-Modifier
joint NCT03867214 125 130 I-Modifier
with NCT03867214 131 135 B-And
a NCT03867214 136 137 O
diagnosis NCT03867214 138 147 O
of NCT03867214 148 150 O
osteoarthritis NCT03867214 151 165 B-Condition
or NCT03867214 166 168 B-Or
aseptic NCT03867214 169 176 B-Condition
bone NCT03867214 177 181 I-Condition
necrosis NCT03867214 182 190 I-Condition
, NCT03867214 191 192 O
but NCT03867214 193 196 B-And
not NCT03867214 197 200 B-Negation
of NCT03867214 201 203 O
rheumatoid NCT03867214 204 214 B-Condition
arthritis NCT03867214 215 224 I-Condition
; NCT03867214 224 225 O

- NCT03867214 228 229 O
All NCT03867214 231 234 O
patients NCT03867214 235 243 O
who NCT03867214 244 247 O
have NCT03867214 248 252 O
normal NCT03867214 253 259 O
pre NCT03867214 260 263 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867214 264 265 O
- NCT03867214 267 268 O
operative NCT03867214 269 278 B-Procedure
platelet NCT03867214 279 287 B-Observation
count NCT03867214 288 293 I-Observation
, NCT03867214 294 295 O
normal NCT03867214 296 302 O
prothrombin NCT03867214 303 314 B-Observation
time NCT03867214 315 319 I-Observation
, NCT03867214 320 321 O
normal NCT03867214 322 328 O
partial NCT03867214 329 336 B-Observation
thromboplastin NCT03867214 337 351 I-Observation
time NCT03867214 352 356 I-Observation
, NCT03867214 357 358 O
and NCT03867214 359 362 B-And
normal NCT03867214 363 369 O
international NCT03867214 370 383 B-Observation
normalized NCT03867214 384 394 I-Observation
ratio NCT03867214 395 400 I-Observation
; NCT03867214 400 401 O

- NCT03867214 404 405 O
The NCT03867214 407 410 O
use NCT03867214 411 414 O
of NCT03867214 415 417 O
only NCT03867214 418 422 O
balanced NCT03867214 423 431 B-Drug
electrolyte NCT03867214 432 443 I-Drug
solutions NCT03867214 444 453 I-Drug
and NCT03867214 454 457 B-Or
/ NCT03867214 458 459 I-Or
or NCT03867214 460 462 I-Or
albumin NCT03867214 463 470 B-Observation
for NCT03867214 471 474 O
plasma NCT03867214 475 481 B-Procedure
volume NCT03867214 482 488 I-Procedure
restitution NCT03867214 489 500 I-Procedure
. NCT03867214 500 501 O

Exclusion NCT03867214 503 512 O
Criteria NCT03867214 513 521 O
: NCT03867214 522 523 O

- NCT03867214 527 528 O
Allergy NCT03867214 530 537 B-Allergy
to NCT03867214 538 540 O
tranexamic NCT03867214 541 551 B-Drug
acid NCT03867214 552 556 I-Drug
; NCT03867214 556 557 O

- NCT03867214 560 561 O
Receiving NCT03867214 563 572 B-Eq-Comparison
warfarin NCT03867214 573 581 B-Drug
or NCT03867214 582 584 B-Or
heparin NCT03867214 585 592 B-Drug
; NCT03867214 592 593 O
had NCT03867214 594 597 O
a NCT03867214 598 599 O
history NCT03867214 600 607 B-Eq-Comparison
of NCT03867214 608 610 O
hemophilia NCT03867214 611 621 B-Condition
, NCT03867214 622 623 O
deep NCT03867214 624 628 B-Condition
venous NCT03867214 629 635 I-Condition
thrombosis NCT03867214 636 646 I-Condition
, NCT03867214 647 648 O
pulmonary NCT03867214 649 658 B-Condition
embolism NCT03867214 659 667 I-Condition
, NCT03867214 668 669 O
or NCT03867214 670 672 B-Or
renal NCT03867214 673 678 B-Condition
impairment NCT03867214 679 689 I-Condition
; NCT03867214 689 690 O
or NCT03867214 691 693 B-Or
were NCT03867214 694 698 B-Eq-Comparison
pregnant NCT03867214 699 707 B-Condition
; NCT03867214 707 708 O

- NCT03867214 711 712 O
Patients NCT03867214 714 722 O
with NCT03867214 723 727 O
any NCT03867214 728 731 O
cardiovascular NCT03867214 732 746 B-Condition
problems NCT03867214 747 755 I-Condition
( NCT03867214 756 757 O
such NCT03867214 758 762 O
as NCT03867214 763 765 O
myocardiac NCT03867214 766 776 B-Condition
infarction NCT03867214 777 787 I-Condition
history NCT03867214 788 795 B-Eq-Comparison
, NCT03867214 796 797 O
atrial NCT03867214 798 804 B-Condition
fibrillation NCT03867214 805 817 I-Condition
, NCT03867214 818 819 O
angina NCT03867214 820 826 B-Condition
) NCT03867214 827 828 O
; NCT03867214 829 830 O

- NCT03867214 833 834 O
Patients NCT03867214 836 844 O
with NCT03867214 845 849 O
thromboembolic NCT03867214 850 864 B-Condition
disorders NCT03867214 865 874 I-Condition
, NCT03867214 875 876 O
or NCT03867214 877 879 B-Or
those NCT03867214 880 885 O
exhibiting NCT03867214 886 896 O
a NCT03867214 897 898 O
deteriorating NCT03867214 899 912 O
general NCT03867214 913 920 B-Condition
condition NCT03867214 921 930 I-Condition
; NCT03867214 930 931 O

- NCT03867214 934 935 O
Pre NCT03867214 937 940 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867214 941 942 O
- NCT03867214 944 945 O
operative NCT03867214 946 955 B-Procedure
anemia NCT03867214 956 962 B-Condition
( NCT03867214 963 964 O
a NCT03867214 965 966 O
hemoglobin NCT03867214 967 977 B-Observation
value NCT03867214 978 983 O
of NCT03867214 984 986 O
< NCT03867214 987 988 B-Eq-Comparison|Eq-Comparison
11 NCT03867214 989 991 I-Eq-Comparison
g NCT03867214 992 993 I-Eq-Comparison|Eq-Comparison
/ NCT03867214 994 995 I-Eq-Comparison|Eq-Comparison
dL NCT03867214 996 998 I-Eq-Comparison|Eq-Comparison
in NCT03867214 999 1001 O
females NCT03867214 1002 1009 O
and NCT03867214 1010 1013 B-Or
< NCT03867214 1014 1015 O
12 NCT03867214 1016 1018 I-Eq-Comparison
g NCT03867214 1019 1020 O
/ NCT03867214 1021 1022 O
dL NCT03867214 1023 1025 O
in NCT03867214 1026 1028 O
males NCT03867214 1029 1034 O
) NCT03867214 1035 1036 O
, NCT03867214 1038 1039 O
refusal NCT03867214 1040 1047 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03867214 1048 1050 O
blood NCT03867214 1051 1056 B-Procedure
products NCT03867214 1057 1065 I-Procedure
; NCT03867214 1065 1066 O

- NCT03867214 1069 1070 O
Pre NCT03867214 1072 1075 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867214 1076 1077 O
- NCT03867214 1079 1080 O
operative NCT03867214 1081 1090 B-Procedure
use NCT03867214 1091 1094 O
of NCT03867214 1095 1097 O
anticoagulant NCT03867214 1098 1111 B-Procedure
therapy NCT03867214 1112 1119 I-Procedure
within NCT03867214 1120 1126 B-Eq-Comparison
five NCT03867214 1127 1131 I-Eq-Comparison
days NCT03867214 1132 1136 I-Eq-Comparison
before NCT03867214 1137 1143 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03867214 1144 1151 B-Procedure
, NCT03867214 1152 1153 O
fibrinolytic NCT03867214 1154 1166 B-Condition
disorders NCT03867214 1167 1176 I-Condition
requiring NCT03867214 1177 1186 B-Assertion___Assertion-Type-Value:hypothetical
intraoperative NCT03867214 1187 1201 O
antifibrinolytic NCT03867214 1202 1218 B-Procedure
treatment NCT03867214 1219 1228 I-Procedure
, NCT03867214 1229 1230 O
coagulopathy NCT03867214 1231 1243 B-Condition
( NCT03867214 1244 1245 O
as NCT03867214 1246 1248 O
identified NCT03867214 1249 1259 O
by NCT03867214 1260 1262 O
a NCT03867214 1263 1264 O
pre NCT03867214 1265 1268 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867214 1269 1270 O
- NCT03867214 1272 1273 O
operative NCT03867214 1274 1283 B-Procedure
platelet NCT03867214 1284 1292 B-Observation
count NCT03867214 1293 1298 I-Observation
of NCT03867214 1299 1301 O
< NCT03867214 1302 1303 B-Eq-Comparison
150 NCT03867214 1304 1307 I-Eq-Comparison
, NCT03867214 1308 1309 O
000 NCT03867214 1310 1313 O
/ NCT03867214 1314 1315 I-Eq-Comparison
mm3 NCT03867214 1316 1319 I-Eq-Comparison
, NCT03867214 1320 1321 O
an NCT03867214 1322 1324 O
international NCT03867214 1325 1338 B-Observation
normalized NCT03867214 1339 1349 I-Observation
ratio NCT03867214 1350 1355 I-Observation
of NCT03867214 1356 1358 O
> NCT03867214 1359 1360 B-Eq-Comparison|Eq-Comparison
1.4 NCT03867214 1361 1364 I-Eq-Comparison|Eq-Comparison
, NCT03867214 1365 1366 O
or NCT03867214 1367 1369 O
a NCT03867214 1370 1371 O
prolonged NCT03867214 1372 1381 O
partial NCT03867214 1382 1389 B-Observation
thromboplastin NCT03867214 1390 1404 I-Observation
time NCT03867214 1405 1409 I-Eq-Comparison|Observation
[ NCT03867214 1410 1411 O
> NCT03867214 1413 1414 O
1.4 NCT03867214 1415 1418 O
times NCT03867214 1419 1424 O
normal NCT03867214 1425 1431 I-Eq-Comparison
] NCT03867214 1432 1433 O
) NCT03867214 1435 1436 O
. NCT03867214 1437 1438 O

Inclusion NCT03862378 0 9 O
Criteria NCT03862378 10 18 O
: NCT03862378 19 20 O

- NCT03862378 24 25 O
Planned NCT03862378 27 34 B-Eq-Comparison
surgery NCT03862378 35 42 B-Procedure
for NCT03862378 43 46 O
gastric NCT03862378 47 54 B-Modifier
or NCT03862378 55 57 B-Or
colorectal NCT03862378 58 68 B-Modifier
cancer NCT03862378 69 75 B-Condition
with NCT03862378 76 80 O
primary NCT03862378 81 88 B-Modifier
anastomosis NCT03862378 89 100 B-Procedure
. NCT03862378 100 101 O

- NCT03862378 105 106 O
Inform NCT03862378 108 114 O
consent NCT03862378 115 122 O
signed NCT03862378 123 129 O
before NCT03862378 130 136 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03862378 137 144 B-Procedure
. NCT03862378 144 145 O

Exclusion NCT03862378 147 156 O
Criteria NCT03862378 157 165 O
: NCT03862378 166 167 O

- NCT03862378 171 172 O
No NCT03862378 174 176 B-Negation
drainage NCT03862378 177 185 B-Procedure
tube NCT03862378 186 190 I-Procedure
placed NCT03862378 191 197 O
. NCT03862378 197 198 O

Inclusion NCT03861117 0 9 O
Criteria NCT03861117 10 18 O
: NCT03861117 19 20 O

- NCT03861117 24 25 O
Patient NCT03861117 27 34 O
18 NCT03861117 35 37 B-Eq-Comparison
years NCT03861117 38 43 I-Eq-Comparison
old NCT03861117 44 47 I-Eq-Comparison
or NCT03861117 48 50 I-Eq-Comparison
more NCT03861117 51 55 I-Eq-Comparison

- NCT03861117 58 59 O
Intubated NCT03861117 61 70 B-Procedure
and NCT03861117 71 74 B-And
ventilated NCT03861117 75 85 B-Procedure
in NCT03861117 86 88 O
intensive NCT03861117 89 98 O
care NCT03861117 99 103 O
unit NCT03861117 104 108 O
for NCT03861117 109 112 O
more NCT03861117 113 117 B-Eq-Comparison
than NCT03861117 118 122 I-Eq-Comparison
24 NCT03861117 123 125 I-Eq-Comparison
hours NCT03861117 126 131 I-Eq-Comparison

- NCT03861117 134 135 O
Patient NCT03861117 137 144 O
ready NCT03861117 145 150 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861117 151 154 I-Assertion___Assertion-Type-Value:hypothetical
weaning NCT03861117 155 162 B-Procedure
evaluation NCT03861117 163 173 I-Procedure

- NCT03861117 176 177 O
Failure NCT03861117 179 186 O
of NCT03861117 187 189 O
a NCT03861117 190 191 O
first NCT03861117 192 197 B-Eq-Comparison
T NCT03861117 198 199 B-Modifier
- NCT03861117 200 201 I-Modifier
piece NCT03861117 202 207 I-Modifier
SBT NCT03861117 208 211 B-Procedure

Exclusion NCT03861117 212 221 O
Criteria NCT03861117 222 230 O
: NCT03861117 231 232 O

- NCT03861117 236 237 O
Chronic NCT03861117 239 246 B-Modifier
neuromuscular NCT03861117 247 260 B-Condition
disease NCT03861117 261 268 I-Condition

- NCT03861117 271 272 O
Guillain NCT03861117 274 282 B-Condition
- NCT03861117 283 284 I-Condition
Barré NCT03861117 285 290 I-Condition
Syndrome NCT03861117 291 299 I-Condition

- NCT03861117 302 303 O
Central NCT03861117 305 312 B-Condition
nervous NCT03861117 313 320 I-Condition
system NCT03861117 321 327 I-Condition
disease NCT03861117 328 335 I-Condition
with NCT03861117 336 340 B-And
consciousness NCT03861117 341 354 B-Condition
disorder NCT03861117 355 363 I-Condition

- NCT03861117 366 367 O
Tracheostomy NCT03861117 369 381 B-Procedure

- NCT03861117 384 385 O
Chronic NCT03861117 387 394 B-Modifier
disease NCT03861117 395 402 B-Condition
with NCT03861117 403 407 B-And
life NCT03861117 408 412 B-Observation
expectancy NCT03861117 413 423 I-Observation
less NCT03861117 424 428 B-Eq-Comparison
than NCT03861117 429 433 I-Eq-Comparison
1 NCT03861117 434 435 I-Eq-Comparison
year NCT03861117 436 440 I-Eq-Comparison

- NCT03861117 443 444 O
Pregnancy NCT03861117 446 455 B-Condition
, NCT03861117 456 457 O
breast NCT03861117 458 464 B-Condition
feeding NCT03861117 465 472 I-Condition

- NCT03861117 475 476 O
Withholding NCT03861117 478 489 B-Assertion___Assertion-Type-Value:hypothetical
life NCT03861117 490 494 B-Procedure
support NCT03861117 495 502 I-Procedure
regarding NCT03861117 503 512 O
a NCT03861117 513 514 O
reintubation NCT03861117 515 527 B-Procedure

- NCT03861117 530 531 O
Prisoner NCT03861117 533 541 B-Observation
or NCT03861117 542 544 B-Or
patient NCT03861117 545 552 O
interned NCT03861117 553 561 B-Encounter
in NCT03861117 562 564 O
psychiatric NCT03861117 565 576 O
hospital NCT03861117 577 585 O

- NCT03861117 588 589 O
Guardianship NCT03861117 591 603 B-Observation

- NCT03861117 606 607 O
Language NCT03861117 609 617 B-Condition
barrier NCT03861117 618 625 I-Condition

- NCT03861117 628 629 O
Lack NCT03861117 631 635 B-Negation
of NCT03861117 636 638 I-Negation
medical NCT03861117 639 646 O
insurance NCT03861117 647 656 O

- NCT03861117 659 660 O
Lack NCT03861117 662 666 O
of NCT03861117 667 669 O
the NCT03861117 670 673 O
patient NCT03861117 674 681 O
's NCT03861117 681 683 O
consent NCT03861117 684 691 O
( NCT03861117 692 693 O
or NCT03861117 694 696 O
of NCT03861117 697 699 O
the NCT03861117 700 703 O
next NCT03861117 704 708 O
of NCT03861117 709 711 O
kin NCT03861117 712 715 O
where NCT03861117 716 721 O
appropriate NCT03861117 722 733 O
) NCT03861117 734 735 O

- NCT03861117 739 740 O
Patient NCT03861117 742 749 O
under NCT03861117 750 755 O
an NCT03861117 756 758 O
exclusion NCT03861117 759 768 O
period NCT03861117 769 775 O
after NCT03861117 776 781 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03861117 782 792 O
in NCT03861117 793 795 O
another NCT03861117 796 803 B-Other
research NCT03861117 804 812 B-Study
study NCT03861117 813 818 I-Study

Inclusion NCT03866122 0 9 O
Criteria NCT03866122 10 18 O
: NCT03866122 19 20 O

- NCT03866122 24 25 O
The NCT03866122 27 30 O
subject NCT03866122 31 38 O
is NCT03866122 39 41 O
currently NCT03866122 42 51 B-Eq-Comparison
being NCT03866122 52 57 O
treated NCT03866122 58 65 B-Procedure
at NCT03866122 66 68 O
QECH NCT03866122 69 73 O
in NCT03866122 74 76 O
the NCT03866122 77 80 O
neonatal NCT03866122 81 89 B-Modifier
or NCT03866122 90 92 B-Or
KMC NCT03866122 93 96 B-Modifier
ward NCT03866122 97 101 O
. NCT03866122 101 102 O

- NCT03866122 106 107 O
Study NCT03866122 109 114 O
devices NCT03866122 115 122 O
are NCT03866122 123 126 O
available NCT03866122 127 136 O
for NCT03866122 137 140 O
use NCT03866122 141 144 O
. NCT03866122 144 145 O

- NCT03866122 149 150 O
The NCT03866122 152 155 O
subject NCT03866122 156 163 O
's NCT03866122 163 165 O
caregiver NCT03866122 166 175 B-Family-Member___Family-Member-Type:parent
has NCT03866122 176 179 O
provided NCT03866122 180 188 O
informed NCT03866122 189 197 O
consent NCT03866122 198 205 O
for NCT03866122 206 209 O
their NCT03866122 210 215 O
child NCT03866122 216 221 O
to NCT03866122 222 224 O
participate NCT03866122 225 236 O
. NCT03866122 236 237 O

Exclusion NCT03866122 239 248 O
Criteria NCT03866122 249 257 O
: NCT03866122 258 259 O

- NCT03866122 263 264 O
At NCT03866122 266 268 O
the NCT03866122 269 272 O
clinician NCT03866122 273 282 O
's NCT03866122 282 284 O
discretion NCT03866122 285 295 O
for NCT03866122 296 299 O
any NCT03866122 300 303 O
reason NCT03866122 304 310 O
including NCT03866122 311 320 O
, NCT03866122 321 322 O
but NCT03866122 323 326 O
not NCT03866122 327 330 O
limited NCT03866122 331 338 O
to NCT03866122 339 341 O
: NCT03866122 342 343 O

- NCT03866122 347 348 O
potential NCT03866122 350 359 B-Risk
for NCT03866122 360 363 O
skin NCT03866122 364 368 B-Modifier
irritation NCT03866122 369 379 B-Condition

- NCT03866122 382 383 O
Cough NCT03866122 385 390 B-Condition

- NCT03866122 393 394 O
other NCT03866122 396 401 B-Other
condition NCT03866122 402 411 B-Condition
that NCT03866122 412 416 O
may NCT03866122 417 420 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03866122 421 429 B-Negation
use NCT03866122 430 433 O
of NCT03866122 434 436 O
the NCT03866122 437 440 O
temperature NCT03866122 441 452 B-Procedure
belt NCT03866122 453 457 I-Procedure

- NCT03866122 460 461 O
concurrent NCT03866122 463 473 B-Modifier
treatments NCT03866122 474 484 B-Procedure
that NCT03866122 485 489 O
may NCT03866122 490 493 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03866122 494 501 O
increased NCT03866122 502 511 O
patient NCT03866122 512 519 B-Procedure
care NCT03866122 520 524 I-Procedure

Inclusion NCT03866096 0 9 O
Criteria NCT03866096 10 18 O
: NCT03866096 19 20 O

- NCT03866096 24 25 O
Volleyball NCT03866096 27 37 B-Observation
players NCT03866096 38 45 I-Observation

- NCT03866096 48 49 O
Female NCT03866096 51 57 O

- NCT03866096 60 61 O
From NCT03866096 63 67 O
18 NCT03866096 68 70 B-Eq-Comparison
to NCT03866096 71 73 I-Eq-Comparison
25 NCT03866096 74 76 I-Eq-Comparison
years NCT03866096 77 82 I-Age|Eq-Comparison

- NCT03866096 85 86 O
With NCT03866096 88 92 O
more NCT03866096 93 97 B-Eq-Comparison
than NCT03866096 98 102 I-Eq-Comparison
one NCT03866096 103 106 I-Eq-Comparison
year NCT03866096 107 111 I-Eq-Comparison
of NCT03866096 112 114 O
sports NCT03866096 115 121 B-Observation
practice NCT03866096 122 130 I-Observation

- NCT03866096 133 134 O
Currently NCT03866096 136 145 B-Eq-Comparison
participate NCT03866096 146 157 O
in NCT03866096 158 160 O
amateur NCT03866096 161 168 O
industry NCT03866096 169 177 O
competitions NCT03866096 178 190 O

Exclusion NCT03866096 191 200 O
Criteria NCT03866096 201 209 O
: NCT03866096 210 211 O

- NCT03866096 215 216 O
Present NCT03866096 218 225 O
a NCT03866096 226 227 O
medical NCT03866096 228 235 O
diagnosis NCT03866096 236 245 O
of NCT03866096 246 248 O
musculoskeletal NCT03866096 249 264 B-Modifier
injury NCT03866096 265 271 B-Condition
at NCT03866096 272 274 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866096 275 278 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866096 279 283 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866096 284 286 O
beginning NCT03866096 287 296 B-Eq-Comparison
the NCT03866096 297 300 O
study NCT03866096 301 306 B-Study

- NCT03866096 309 310 O
Receive NCT03866096 312 319 B-Eq-Comparison
a NCT03866096 320 321 O
physiotherapy NCT03866096 322 335 B-Procedure
treatment NCT03866096 336 345 I-Procedure
unrelated NCT03866096 346 355 B-Negation
to NCT03866096 356 358 O
the NCT03866096 359 362 O
study NCT03866096 363 368 B-Study

- NCT03866096 371 372 O
Have NCT03866096 374 378 O
suffered NCT03866096 379 387 B-Eq-Comparison
neurological NCT03866096 388 400 B-Condition
pathology NCT03866096 401 410 I-Condition
in NCT03866096 411 413 O
the NCT03866096 414 417 O
last NCT03866096 418 422 B-Eq-Comparison
6 NCT03866096 423 424 I-Eq-Comparison
months NCT03866096 425 431 I-Eq-Comparison

- NCT03866096 434 435 O
Have NCT03866096 437 441 O
some NCT03866096 442 446 O
type NCT03866096 447 451 O
of NCT03866096 452 454 O
auditory NCT03866096 455 463 B-Modifier
or NCT03866096 464 466 B-Or
vestibular NCT03866096 467 477 B-Modifier
disorder NCT03866096 478 486 B-Condition

- NCT03866096 489 490 O
Not NCT03866096 492 495 O
signed NCT03866096 496 502 O
the NCT03866096 503 506 O
informed NCT03866096 507 515 O
consent NCT03866096 516 523 O
. NCT03866096 523 524 O

Inclusion NCT03866733 0 9 O
Criteria NCT03866733 10 18 O
: NCT03866733 19 20 O

- NCT03866733 24 25 O
elective NCT03866733 27 35 B-Modifier
cardiac NCT03866733 36 43 B-Procedure
surgery NCT03866733 44 51 I-Procedure
. NCT03866733 51 52 O

- NCT03866733 56 57 O
age NCT03866733 59 62 B-Age
18 NCT03866733 63 65 B-Eq-Comparison
- NCT03866733 66 67 I-Eq-Comparison
65 NCT03866733 68 70 I-Eq-Comparison
years NCT03866733 71 76 I-Eq-Comparison
. NCT03866733 76 77 O

- NCT03866733 81 82 O
patients NCT03866733 84 92 O
with NCT03866733 93 97 O
median NCT03866733 98 104 B-Procedure
sternotomy NCT03866733 105 115 I-Procedure
. NCT03866733 115 116 O

- NCT03866733 120 121 O
body NCT03866733 123 127 B-Observation
mass NCT03866733 128 132 I-Observation
index NCT03866733 133 138 I-Observation
< NCT03866733 139 140 B-Eq-Comparison
30 NCT03866733 141 143 I-Eq-Comparison
kg NCT03866733 144 146 O
. NCT03866733 146 147 O
m2 NCT03866733 148 150 O
. NCT03866733 150 151 O

- NCT03866733 155 156 O
left NCT03866733 158 162 B-Observation
ventricular NCT03866733 163 174 I-Observation
ejection NCT03866733 175 183 I-Observation
fraction NCT03866733 184 192 I-Observation
> NCT03866733 193 194 B-Eq-Comparison
50 NCT03866733 195 197 I-Eq-Comparison
% NCT03866733 198 199 O
. NCT03866733 199 200 O

Exclusion NCT03866733 202 211 O
Criteria NCT03866733 212 220 O
: NCT03866733 221 222 O

- NCT03866733 226 227 O
signiﬁcant NCT03866733 229 239 O
aortic NCT03866733 240 246 B-Condition
stenosis NCT03866733 247 255 I-Condition
. NCT03866733 255 256 O

- NCT03866733 260 261 O
left NCT03866733 263 267 B-Modifier
main NCT03866733 268 272 I-Modifier
coronary NCT03866733 273 281 B-Condition
artery NCT03866733 282 288 I-Condition
disease NCT03866733 289 296 I-Condition
. NCT03866733 296 297 O

- NCT03866733 301 302 I-Drug
patient NCT03866733 304 311 O
on NCT03866733 312 314 B-Eq-Comparison
anti NCT03866733 315 319 B-Drug
- NCT03866733 320 321 O
coagulants0 NCT03866733 322 333 I-Drug

- NCT03866733 336 337 I-Eq-Comparison
pre NCT03866733 339 342 B-Eq-Comparison
- NCT03866733 343 344 O
existing NCT03866733 345 353 I-Eq-Comparison
respiratory NCT03866733 354 365 B-Modifier
, NCT03866733 366 367 O
neurological NCT03866733 368 380 B-Modifier
, NCT03866733 381 382 O
or NCT03866733 383 385 B-Or
renal NCT03866733 386 391 B-Modifier
disease NCT03866733 392 399 B-Condition
. NCT03866733 399 400 O

- NCT03866733 404 405 O
CSF NCT03866733 407 410 B-Procedure
or NCT03866733 411 413 B-Or
blood NCT03866733 414 419 B-Procedure
tap NCT03866733 420 423 I-Procedure
during NCT03866733 424 430 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866733 431 434 B-Coreference
procedure NCT03866733 435 444 I-Coreference
. NCT03866733 444 445 O

- NCT03866733 449 450 O
failure NCT03866733 452 459 B-Modifier
to NCT03866733 460 462 I-Modifier
thread NCT03866733 463 469 I-Modifier
the NCT03866733 470 473 O
catheter NCT03866733 474 482 B-Procedure
. NCT03866733 482 483 O

- NCT03866733 487 488 O
anomalies NCT03866733 490 499 B-Condition
of NCT03866733 500 502 O
vertebral NCT03866733 503 512 B-Modifier
column NCT03866733 513 519 I-Modifier
. NCT03866733 519 520 O

Inclusion NCT03869372 0 9 O
Criteria NCT03869372 10 18 O
: NCT03869372 19 20 O

- NCT03869372 24 25 O
Adults NCT03869372 27 33 O
between NCT03869372 34 41 B-Eq-Comparison
age NCT03869372 42 45 I-Eq-Comparison
18 NCT03869372 46 48 I-Eq-Comparison
and NCT03869372 49 52 I-Eq-Comparison
75 NCT03869372 53 55 I-Eq-Comparison

- NCT03869372 59 60 O
Participants NCT03869372 62 74 O
without NCT03869372 75 82 B-Negation
a NCT03869372 83 84 O
history NCT03869372 85 92 B-Eq-Comparison
of NCT03869372 93 95 O
gastrointestinal NCT03869372 96 112 B-Condition
disorders NCT03869372 113 122 I-Condition
( NCT03869372 123 124 O
control NCT03869372 125 132 O
group NCT03869372 133 138 O
) NCT03869372 139 140 O

- NCT03869372 144 145 O
Participants NCT03869372 147 159 O
with NCT03869372 160 164 O
functional NCT03869372 165 175 B-Modifier
dyspepsia NCT03869372 176 185 B-Condition
( NCT03869372 186 187 O
FD NCT03869372 188 190 O
group NCT03869372 191 196 O
) NCT03869372 197 198 O

- NCT03869372 202 203 O
Participants NCT03869372 205 217 O
with NCT03869372 218 222 O
moderate NCT03869372 223 231 B-Eq-Comparison
- NCT03869372 232 233 I-Eq-Comparison
to NCT03869372 234 236 I-Eq-Comparison
- NCT03869372 237 238 O
severe NCT03869372 239 245 I-Eq-Comparison
irritable NCT03869372 246 255 B-Condition
bowel NCT03869372 256 261 I-Condition
syndrome NCT03869372 262 270 I-Condition
( NCT03869372 271 272 O
defined NCT03869372 273 280 O
by NCT03869372 281 283 O
IBS NCT03869372 284 287 B-Observation
symptom NCT03869372 288 295 I-Observation
severity NCT03869372 296 304 I-Observation
scores NCT03869372 305 311 I-Observation
( NCT03869372 312 313 O
IBS NCT03869372 314 317 B-Observation
- NCT03869372 318 319 I-Observation
SSS NCT03869372 320 323 I-Observation
) NCT03869372 324 325 O
greater NCT03869372 326 333 B-Eq-Comparison
than NCT03869372 334 338 I-Eq-Comparison
250 NCT03869372 339 342 I-Eq-Comparison
) NCT03869372 343 344 O
( NCT03869372 345 346 O
IBS NCT03869372 347 350 O
group NCT03869372 351 356 O
) NCT03869372 357 358 O

Exclusion NCT03869372 360 369 O
Criteria NCT03869372 370 378 O
: NCT03869372 379 380 O

- NCT03869372 384 385 O
history NCT03869372 387 394 B-Eq-Comparison
of NCT03869372 395 397 O
myocardial NCT03869372 398 408 B-Condition
infarction NCT03869372 409 419 I-Condition
, NCT03869372 420 421 O
supplemental NCT03869372 422 434 B-Procedure
oxygen NCT03869372 435 441 I-Procedure
requirement NCT03869372 442 453 O
, NCT03869372 454 455 O
or NCT03869372 456 458 B-Or
diabetes NCT03869372 459 467 B-Condition

- NCT03869372 470 471 O
history NCT03869372 473 480 B-Eq-Comparison
of NCT03869372 481 483 O
chronic NCT03869372 484 491 B-Modifier
gastrointestinal NCT03869372 492 508 B-Condition
symptoms NCT03869372 509 517 B-Assertion___Assertion-Type-Value:possible
( NCT03869372 518 519 O
for NCT03869372 520 523 O
healthy NCT03869372 524 531 O
control NCT03869372 532 539 O
population NCT03869372 540 550 O
only NCT03869372 551 555 O
) NCT03869372 556 557 O

- NCT03869372 561 562 O
history NCT03869372 564 571 B-Eq-Comparison
of NCT03869372 572 574 O
gastric NCT03869372 575 582 B-Procedure
surgery NCT03869372 583 590 I-Procedure

- NCT03869372 593 594 O
psychosis NCT03869372 596 605 B-Condition
or NCT03869372 606 608 B-Or
altered NCT03869372 609 616 B-Condition
cognitive NCT03869372 617 626 I-Condition
status NCT03869372 627 633 I-Condition

- NCT03869372 636 637 O
history NCT03869372 639 646 B-Eq-Comparison
of NCT03869372 647 649 O
head NCT03869372 650 654 B-Modifier
injury NCT03869372 655 661 B-Condition|Condition
, NCT03869372 662 663 O
metal NCT03869372 664 669 B-Condition
in NCT03869372 670 672 O
the NCT03869372 673 676 I-Condition
skull NCT03869372 677 682 I-Condition
, NCT03869372 683 684 O
stroke NCT03869372 685 691 B-Condition
, NCT03869372 692 693 O
or NCT03869372 694 696 B-Or
a NCT03869372 697 698 O
history NCT03869372 699 706 B-Eq-Comparison
of NCT03869372 707 709 O
seizures NCT03869372 710 718 B-Condition

- NCT03869372 721 722 O
implantable NCT03869372 724 735 B-Procedure
devices NCT03869372 736 743 I-Procedure
, NCT03869372 744 745 O
such NCT03869372 746 750 O
as NCT03869372 751 753 O
a NCT03869372 754 755 O
pacemaker NCT03869372 756 765 B-Procedure
or NCT03869372 766 768 B-Or
nerve NCT03869372 769 774 B-Procedure
stimulator NCT03869372 775 785 I-Procedure

- NCT03869372 788 789 O
current NCT03869372 791 798 B-Eq-Comparison
use NCT03869372 799 802 O
of NCT03869372 803 805 O
the NCT03869372 806 809 O
following NCT03869372 810 819 O
medications NCT03869372 820 831 B-Drug
or NCT03869372 832 834 B-Or
use NCT03869372 835 838 O
of NCT03869372 839 841 O
substances NCT03869372 842 852 B-Drug
which NCT03869372 853 858 O
are NCT03869372 859 862 O
known NCT03869372 863 868 O
to NCT03869372 869 871 O
lower NCT03869372 872 877 O
the NCT03869372 878 881 O
seizure NCT03869372 882 889 B-Condition
threshold NCT03869372 890 899 B-Modifier
: NCT03869372 900 901 O
amitriptyline NCT03869372 902 915 B-Drug
( NCT03869372 916 917 O
Elavil NCT03869372 918 924 B-Drug
) NCT03869372 925 926 O
, NCT03869372 928 929 O
nortriptyline NCT03869372 930 943 B-Drug
( NCT03869372 944 945 O
Pamelor NCT03869372 946 953 B-Drug
) NCT03869372 954 955 O
, NCT03869372 957 958 O
imipramine NCT03869372 959 969 B-Drug
( NCT03869372 970 971 O
Tofranil NCT03869372 972 980 B-Drug
) NCT03869372 981 982 O
, NCT03869372 984 985 O
doxepin NCT03869372 986 993 B-Drug
( NCT03869372 994 995 O
Sinequan NCT03869372 996 1004 B-Drug
) NCT03869372 1005 1006 O
, NCT03869372 1008 1009 O
clozapine NCT03869372 1010 1019 B-Drug
( NCT03869372 1020 1021 O
Clozaril NCT03869372 1022 1030 B-Drug
) NCT03869372 1031 1032 O
, NCT03869372 1034 1035 O
chlorpromazine NCT03869372 1036 1050 B-Drug
( NCT03869372 1051 1052 O
Thorazine NCT03869372 1053 1062 B-Drug
) NCT03869372 1063 1064 O
, NCT03869372 1066 1067 O
amphetamines NCT03869372 1068 1080 B-Drug
or NCT03869372 1081 1083 B-Or
methamphetamine NCT03869372 1084 1099 B-Drug
, NCT03869372 1100 1101 O
Ecstasy NCT03869372 1102 1109 B-Drug
, NCT03869372 1110 1111 O
Ketamine NCT03869372 1112 1120 B-Drug
, NCT03869372 1121 1122 O
Angel NCT03869372 1123 1128 B-Drug
Dust NCT03869372 1129 1133 I-Drug
/ NCT03869372 1134 1135 B-Or
phencyclidine NCT03869372 1136 1149 B-Drug
( NCT03869372 1150 1151 O
PCP NCT03869372 1152 1155 B-Drug
) NCT03869372 1156 1157 O
, NCT03869372 1159 1160 O
cocaine NCT03869372 1161 1168 B-Drug
, NCT03869372 1169 1170 O
or NCT03869372 1171 1173 I-Eq-Comparison|Or
3 NCT03869372 1174 1175 B-Eq-Comparison
or NCT03869372 1176 1178 O
more NCT03869372 1179 1183 I-Eq-Comparison
alcoholic NCT03869372 1184 1193 B-Drug
drinks NCT03869372 1194 1200 I-Drug
per NCT03869372 1201 1204 O
day NCT03869372 1205 1208 O

- NCT03869372 1211 1212 O
pregnancy NCT03869372 1214 1223 B-Condition

Inclusion NCT03865979 0 9 O
Criteria NCT03865979 10 18 O
: NCT03865979 19 20 O

- NCT03865979 24 25 O
Subjects NCT03865979 27 35 O
with NCT03865979 36 40 O
stroke NCT03865979 41 47 B-Condition
symptoms NCT03865979 48 56 B-Assertion___Assertion-Type-Value:possible
who NCT03865979 57 60 B-And
undergo NCT03865979 61 68 O
CT NCT03865979 69 71 B-Procedure
brain NCT03865979 72 77 I-Procedure
imaging NCT03865979 78 85 I-Procedure
. NCT03865979 85 86 O

Exclusion NCT03865979 88 97 O
Criteria NCT03865979 98 106 O
: NCT03865979 107 108 O

- NCT03865979 112 113 O
Subjects NCT03865979 115 123 O
with NCT03865979 124 128 O
poor NCT03865979 129 133 B-Modifier
or NCT03865979 134 136 B-Or
incomplete NCT03865979 137 147 B-Modifier
CT NCT03865979 148 150 B-Procedure
brain NCT03865979 151 156 I-Procedure
imaging NCT03865979 157 164 I-Procedure
. NCT03865979 164 165 O

Inclusion NCT03864497 0 9 O
Criteria NCT03864497 10 18 O
: NCT03864497 19 20 O

• NCT03864497 22 23 O
Liver NCT03864497 24 29 B-Procedure
transplantation NCT03864497 30 45 I-Procedure
candidates NCT03864497 46 56 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03864497 57 61 O
one NCT03864497 62 65 O
or NCT03864497 66 68 O
more NCT03864497 69 73 O
of NCT03864497 74 76 O
the NCT03864497 77 80 O
following NCT03864497 81 90 O
: NCT03864497 91 92 O

- NCT03864497 96 97 O
inability NCT03864497 99 108 B-Negation
to NCT03864497 109 111 O
perform NCT03864497 112 119 O
> NCT03864497 120 121 B-Eq-Comparison
4 NCT03864497 122 123 I-Eq-Comparison
METs NCT03864497 124 128 B-Observation
by NCT03864497 129 131 O
history NCT03864497 132 139 B-Eq-Comparison

- NCT03864497 142 143 O
insulin NCT03864497 145 152 B-Modifier
- NCT03864497 153 154 I-Modifier
treated NCT03864497 155 162 I-Modifier
diabetes NCT03864497 163 171 B-Condition
mellitus NCT03864497 172 180 I-Condition

- NCT03864497 183 184 O
serum NCT03864497 186 191 B-Observation
creatinine NCT03864497 192 202 I-Observation
> NCT03864497 203 204 B-Eq-Comparison
152 NCT03864497 205 208 I-Eq-Comparison
μmol NCT03864497 209 213 O
/ NCT03864497 214 215 I-Eq-Comparison
l NCT03864497 216 217 I-Eq-Comparison

- NCT03864497 220 221 O
history NCT03864497 223 230 B-Eq-Comparison
of NCT03864497 231 233 O
MI NCT03864497 234 236 B-Condition
, NCT03864497 237 238 O
PCI NCT03864497 239 242 B-Procedure
or NCT03864497 243 245 B-Or
CABG NCT03864497 246 250 B-Procedure

- NCT03864497 253 254 O
stable NCT03864497 256 262 B-Condition
angina NCT03864497 263 269 I-Condition

- NCT03864497 272 273 O
cerebrovascular NCT03864497 275 290 B-Condition
disease NCT03864497 291 298 I-Condition

- NCT03864497 301 302 O
peripheral NCT03864497 304 314 B-Condition
vascular NCT03864497 315 323 I-Condition
disease NCT03864497 324 331 I-Condition

Exclusion NCT03864497 332 341 O
Criteria NCT03864497 342 350 O
: NCT03864497 351 352 O

- NCT03864497 356 357 O
Age NCT03864497 359 362 B-Age
< NCT03864497 363 364 B-Eq-Comparison
18 NCT03864497 365 367 I-Eq-Comparison
years NCT03864497 368 373 I-Eq-Comparison

- NCT03864497 376 377 O
Pregnancy NCT03864497 379 388 B-Condition

- NCT03864497 391 392 O
Contraindication NCT03864497 394 410 B-Contraindication
to NCT03864497 411 413 O
liver NCT03864497 414 419 B-Procedure
transplantation NCT03864497 420 435 I-Procedure

Inclusion NCT03865004 0 9 O
Criteria NCT03865004 10 18 O
: NCT03865004 19 20 O
Renal NCT03865004 21 26 B-Condition
colic NCT03865004 27 32 I-Condition
patients NCT03865004 33 41 O
- NCT03865004 42 43 O

Exclusion NCT03865004 45 54 O
Criteria NCT03865004 55 63 O
: NCT03865004 64 65 O
Not NCT03865004 66 69 B-Negation
renal NCT03865004 70 75 B-Condition
colic NCT03865004 76 81 I-Condition
patients NCT03865004 82 90 O

- NCT03865004 92 93 O

Inclusion NCT03860168 0 9 O
Criteria NCT03860168 10 18 O
for NCT03860168 19 22 O
Participating NCT03860168 23 36 O
Units NCT03860168 37 42 O
: NCT03860168 43 44 O

- NCT03860168 48 49 O
Participating NCT03860168 51 64 O
PICUs NCT03860168 65 70 O
must NCT03860168 71 75 O
be NCT03860168 76 78 O
a NCT03860168 79 80 O
separate NCT03860168 81 89 O
physical NCT03860168 90 98 O
space NCT03860168 99 104 O
dedicated NCT03860168 105 114 O
to NCT03860168 115 117 O
the NCT03860168 118 121 O
care NCT03860168 122 126 O
of NCT03860168 127 129 O
critically NCT03860168 130 140 B-Condition
ill NCT03860168 141 144 I-Condition
infants NCT03860168 145 152 O
and NCT03860168 153 156 B-Or
children NCT03860168 157 165 O
, NCT03860168 166 167 O
with NCT03860168 168 172 B-And
the NCT03860168 173 176 O
ability NCT03860168 177 184 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860168 185 187 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03860168 188 195 O
mechanical NCT03860168 196 206 B-Procedure
ventilation NCT03860168 207 218 I-Procedure
. NCT03860168 218 219 O

- NCT03860168 223 224 O
Not NCT03860168 226 229 O
implemented NCT03860168 230 241 O
a NCT03860168 242 243 O
PICU NCT03860168 244 248 O
mobility NCT03860168 249 257 O
protocol NCT03860168 258 266 O
and NCT03860168 267 270 O
would NCT03860168 271 276 O
commit NCT03860168 277 283 O
to NCT03860168 284 286 O
not NCT03860168 287 290 O
implementing NCT03860168 291 303 O
a NCT03860168 304 305 O
mobility NCT03860168 306 314 O
protocol NCT03860168 315 323 O
until NCT03860168 324 329 O
the NCT03860168 330 333 O
randomized NCT03860168 334 344 O
time NCT03860168 345 349 O
of NCT03860168 350 352 O
unit NCT03860168 353 357 O
implementation NCT03860168 358 372 O
. NCT03860168 372 373 O

Inclusion NCT03860168 375 384 O
Criteria NCT03860168 385 393 O
for NCT03860168 394 397 O
Patients NCT03860168 398 406 O
: NCT03860168 407 408 O

All NCT03860168 410 413 O
patients NCT03860168 414 422 O
admitted NCT03860168 423 431 B-Encounter
to NCT03860168 432 434 O
the NCT03860168 435 438 O
PICUs NCT03860168 439 444 O
regardless NCT03860168 445 455 O
of NCT03860168 456 458 O
length NCT03860168 459 465 O
of NCT03860168 466 468 O
stay NCT03860168 469 473 O
will NCT03860168 474 478 O
receive NCT03860168 479 486 O
the NCT03860168 487 490 O
unit NCT03860168 491 495 O
- NCT03860168 496 497 O
based NCT03860168 498 503 O
PICU NCT03860168 504 508 O
Up NCT03860168 509 511 O
! NCT03860168 511 512 O
intervention NCT03860168 513 525 B-Procedure
, NCT03860168 526 527 O
which NCT03860168 528 533 O
includes NCT03860168 534 542 O
criteria NCT03860168 543 551 O
for NCT03860168 552 555 O
no NCT03860168 556 558 B-Negation
mobilization NCT03860168 559 571 B-Procedure
based NCT03860168 572 577 O
on NCT03860168 578 580 O
specific NCT03860168 581 589 O
clinical NCT03860168 590 598 B-Condition
factors NCT03860168 599 606 I-Condition
( NCT03860168 607 608 O
i. NCT03860168 609 611 O
e. NCT03860168 612 614 O
open NCT03860168 616 620 B-Condition
chest NCT03860168 621 626 I-Condition
, NCT03860168 627 628 O
surgeon NCT03860168 629 636 B-Condition
request NCT03860168 637 644 I-Condition
) NCT03860168 645 646 O
.10 NCT03860168 647 650 O
For NCT03860168 651 654 O
inclusion NCT03860168 655 664 O
in NCT03860168 665 667 O
data NCT03860168 668 672 O
analysis NCT03860168 673 681 O
, NCT03860168 682 683 O

patients NCT03860168 685 693 O
will NCT03860168 694 698 O
be NCT03860168 699 701 O
eligible NCT03860168 702 710 O
if NCT03860168 711 713 O

- NCT03860168 716 717 O
Admitted NCT03860168 719 727 B-Encounter
to NCT03860168 728 730 O
the NCT03860168 731 734 O
participating NCT03860168 735 748 O
PICU NCT03860168 749 753 O
≥ NCT03860168 754 755 B-Eq-Comparison
3 NCT03860168 756 757 I-Eq-Comparison
days NCT03860168 758 762 I-Eq-Comparison
. NCT03860168 762 763 O

Exclusion NCT03860168 765 774 O
Criteria NCT03860168 775 783 O
for NCT03860168 784 787 O
Patients NCT03860168 788 796 O
: NCT03860168 797 798 O

- NCT03860168 802 803 O
Patients NCT03860168 805 813 O
with NCT03860168 814 818 O
an NCT03860168 819 821 O
active NCT03860168 822 828 B-Eq-Comparison
do NCT03860168 829 831 B-Observation
- NCT03860168 832 833 I-Observation
not NCT03860168 834 837 I-Observation
- NCT03860168 838 839 O
resuscitate NCT03860168 840 851 I-Observation
( NCT03860168 852 853 O
DNR NCT03860168 854 857 B-Observation
) NCT03860168 858 859 O
order NCT03860168 860 865 O
will NCT03860168 866 870 O
be NCT03860168 871 873 O
excluded NCT03860168 874 882 B-Negation
. NCT03860168 882 883 O


Inclusion NCT03869164 0 9 O
Criteria NCT03869164 10 18 O
: NCT03869164 19 20 O

1 NCT03869164 24 25 O
. NCT03869164 25 26 O
age NCT03869164 28 31 B-Age
older NCT03869164 32 37 B-Eq-Comparison
than NCT03869164 38 42 I-Eq-Comparison
60 NCT03869164 43 45 I-Eq-Comparison
years NCT03869164 46 51 I-Eq-Comparison
; NCT03869164 51 52 O

2 NCT03869164 55 56 O
. NCT03869164 56 57 O
moderate NCT03869164 59 67 B-Eq-Comparison
to NCT03869164 68 70 I-Eq-Comparison
severe NCT03869164 71 77 I-Eq-Comparison
or NCT03869164 78 80 B-Or
severe NCT03869164 81 87 O
mitral NCT03869164 88 94 B-Condition
regurgitation NCT03869164 95 108 I-Condition
; NCT03869164 108 109 O

3 NCT03869164 112 113 O
. NCT03869164 113 114 O
symptoms NCT03869164 116 124 B-Assertion___Assertion-Type-Value:possible
( NCT03869164 125 126 O
New NCT03869164 127 130 B-Condition
York NCT03869164 131 135 I-Condition
Heart NCT03869164 136 141 I-Condition
Association NCT03869164 142 153 I-Condition
[ NCT03869164 154 155 O
NYHA NCT03869164 156 160 B-Condition
] NCT03869164 161 162 O
cardiac NCT03869164 163 170 O
function NCT03869164 171 179 O
class NCT03869164 180 185 O
≥ NCT03869164 186 187 B-Eq-Comparison
2 NCT03869164 188 189 I-Eq-Comparison
) NCT03869164 190 191 O
related NCT03869164 192 199 O
to NCT03869164 200 202 O
MR NCT03869164 203 205 B-Condition
; NCT03869164 205 206 O

4 NCT03869164 209 210 O
. NCT03869164 210 211 O
the NCT03869164 213 216 O
primary NCT03869164 217 224 B-Modifier
regurgitant NCT03869164 225 236 I-Modifier
jet NCT03869164 237 240 I-Modifier
originated NCT03869164 241 251 I-Modifier
from NCT03869164 252 256 O
malcoaptation NCT03869164 257 270 B-Condition
of NCT03869164 271 273 O
the NCT03869164 274 277 O
A2 NCT03869164 278 280 B-Modifier
and NCT03869164 281 284 B-Or
P2 NCT03869164 285 287 B-Modifier
scallops NCT03869164 288 296 I-Modifier
of NCT03869164 297 299 I-Modifier
the NCT03869164 300 303 I-Modifier
mitral NCT03869164 304 310 I-Modifier
valve NCT03869164 311 316 I-Modifier
; NCT03869164 316 317 O

5 NCT03869164 320 321 O
. NCT03869164 321 322 O
high NCT03869164 324 328 O
risk NCT03869164 329 333 B-Risk
for NCT03869164 334 337 O
surgery NCT03869164 338 345 B-Procedure
according NCT03869164 346 355 O
the NCT03869164 356 359 O
MVARC NCT03869164 360 365 O
criteria NCT03869164 366 374 O
; NCT03869164 374 375 O

6 NCT03869164 378 379 O
. NCT03869164 379 380 O
providing NCT03869164 382 391 O
signed NCT03869164 392 398 O
informed NCT03869164 399 407 O
consent NCT03869164 408 415 O
. NCT03869164 415 416 O

Exclusion NCT03869164 418 427 O
Criteria NCT03869164 428 436 O
: NCT03869164 437 438 O

1 NCT03869164 442 443 O
. NCT03869164 443 444 O
acute NCT03869164 446 451 O
myocardial NCT03869164 452 462 B-Condition
infarction NCT03869164 463 473 I-Condition
in NCT03869164 474 476 O
the NCT03869164 477 480 O
prior NCT03869164 481 486 B-Eq-Comparison
4 NCT03869164 487 488 I-Eq-Comparison
weeks NCT03869164 489 494 I-Eq-Comparison
of NCT03869164 495 497 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869164 498 501 O
intended NCT03869164 502 510 O
treatment NCT03869164 511 520 B-Procedure
; NCT03869164 520 521 O

2 NCT03869164 524 525 O
. NCT03869164 525 526 O
any NCT03869164 528 531 O
interventional NCT03869164 532 546 B-Modifier
or NCT03869164 547 549 B-Or
surgical NCT03869164 550 558 B-Modifier
cardiac NCT03869164 559 566 B-Procedure
procedure NCT03869164 567 576 I-Procedure
performed NCT03869164 577 586 O
within NCT03869164 587 593 B-Eq-Comparison
30 NCT03869164 594 596 I-Eq-Comparison
days NCT03869164 597 601 I-Eq-Comparison
prior NCT03869164 602 607 I-Eq-Comparison
; NCT03869164 607 608 O

3 NCT03869164 611 612 O
. NCT03869164 612 613 O
the NCT03869164 615 618 O
need NCT03869164 619 623 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869164 624 627 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03869164 628 631 O
other NCT03869164 632 637 B-Other
cardiac NCT03869164 638 645 B-Procedure
surgery NCT03869164 646 653 I-Procedure
; NCT03869164 653 654 O

4 NCT03869164 657 658 O
. NCT03869164 658 659 O
echocardiographic NCT03869164 661 678 B-Procedure
evidence NCT03869164 679 687 O
of NCT03869164 688 690 O
intracardiac NCT03869164 691 703 B-Condition
mass NCT03869164 704 708 B-Modifier
, NCT03869164 709 710 O
thrombus NCT03869164 711 719 B-Modifier
, NCT03869164 720 721 O
or NCT03869164 722 724 B-Or
vegetation NCT03869164 725 735 B-Modifier
; NCT03869164 735 736 O

5 NCT03869164 739 740 O
. NCT03869164 740 741 O
life NCT03869164 743 747 B-Observation
expectancy NCT03869164 748 758 I-Observation
within NCT03869164 759 765 B-Eq-Comparison
12 NCT03869164 766 768 I-Eq-Comparison
months NCT03869164 769 775 I-Eq-Comparison
; NCT03869164 775 776 O

6 NCT03869164 779 780 O
. NCT03869164 780 781 O
moderate NCT03869164 783 791 O
or NCT03869164 792 794 B-Or
severe NCT03869164 795 801 O
aortic NCT03869164 802 808 B-Condition
stenosis NCT03869164 809 817 B-Modifier
or NCT03869164 818 820 B-Or
regurgitation NCT03869164 821 834 B-Modifier
; NCT03869164 834 835 O

7 NCT03869164 838 839 O
. NCT03869164 839 840 O
mitral NCT03869164 842 848 B-Observation
valve NCT03869164 849 854 I-Observation
orifice NCT03869164 855 862 I-Observation
area NCT03869164 863 867 I-Observation
< NCT03869164 868 869 B-Eq-Comparison
3.5 NCT03869164 870 873 I-Eq-Comparison
cm2 NCT03869164 874 877 I-Eq-Comparison
; NCT03869164 877 878 O

8 NCT03869164 881 882 O
. NCT03869164 882 883 O
untreated NCT03869164 885 894 B-Negation|Procedure
significant NCT03869164 895 906 O
coronary NCT03869164 907 915 B-Condition
stenosis NCT03869164 916 924 I-Condition
; NCT03869164 924 925 O

9 NCT03869164 928 929 O
. NCT03869164 929 930 O
history NCT03869164 932 939 B-Eq-Comparison
of NCT03869164 940 942 O
mitral NCT03869164 943 949 B-Condition
valvuloplasty NCT03869164 950 963 I-Condition
; NCT03869164 963 964 O

10 NCT03869164 966 968 O
. NCT03869164 968 969 O
Infective NCT03869164 971 980 B-Condition
endocarditis NCT03869164 981 993 I-Condition
and NCT03869164 994 997 B-Or
rheumatic NCT03869164 998 1007 B-Condition
heart NCT03869164 1008 1013 I-Condition
disease NCT03869164 1014 1021 I-Condition
; NCT03869164 1021 1022 O

11 NCT03869164 1024 1026 O
. NCT03869164 1026 1027 O
untreated NCT03869164 1029 1038 B-Negation|Procedure
cardiogenic NCT03869164 1039 1050 B-Condition
shock NCT03869164 1051 1056 I-Condition
, NCT03869164 1057 1058 O
acute NCT03869164 1059 1064 O
pulmonary NCT03869164 1065 1074 B-Condition
congestion NCT03869164 1075 1085 I-Condition
; NCT03869164 1085 1086 O

12 NCT03869164 1088 1090 O
. NCT03869164 1090 1091 O
unfavored NCT03869164 1093 1102 B-Modifier
mitral NCT03869164 1103 1109 B-Condition
valve NCT03869164 1110 1115 I-Condition
anatomy NCT03869164 1116 1123 I-Condition
that NCT03869164 1124 1128 O
may NCT03869164 1129 1132 O
preclude NCT03869164 1133 1141 B-Assertion___Assertion-Type-Value:hypothetical|Negation
device NCT03869164 1142 1148 B-Procedure
implantation NCT03869164 1149 1161 I-Procedure
including NCT03869164 1162 1171 O
: NCT03869164 1172 1173 O

calcification NCT03869164 1180 1193 B-Modifier
or NCT03869164 1194 1196 B-Or
significant NCT03869164 1197 1208 O
cleft NCT03869164 1209 1214 B-Condition
in NCT03869164 1215 1217 O
area NCT03869164 1218 1222 B-Modifier
of NCT03869164 1223 1225 I-Modifier
the NCT03869164 1226 1229 I-Modifier
A2 NCT03869164 1230 1232 I-Modifier
and NCT03869164 1233 1236 B-Or
/ NCT03869164 1237 1238 I-Or
or NCT03869164 1239 1241 I-Or
P2 NCT03869164 1242 1244 B-Modifier
scallops NCT03869164 1245 1253 I-Modifier
, NCT03869164 1254 1255 O
significant NCT03869164 1256 1267 O
regurgitation NCT03869164 1268 1281 B-Condition
beyond NCT03869164 1282 1288 B-Negation
A2 NCT03869164 1289 1291 B-Modifier
or NCT03869164 1292 1294 B-Or
P2 NCT03869164 1295 1297 B-Modifier
scallops NCT03869164 1298 1306 I-Modifier
and NCT03869164 1307 1310 B-Or
short NCT03869164 1311 1316 B-Observation
posterior NCT03869164 1317 1326 I-Observation
leaflet NCT03869164 1327 1334 I-Observation
( NCT03869164 1335 1336 O
< NCT03869164 1338 1339 B-Eq-Comparison
10 NCT03869164 1340 1342 I-Eq-Comparison
mm NCT03869164 1343 1345 O
) NCT03869164 1346 1347 O
. NCT03869164 1348 1349 O

13 NCT03869164 1352 1354 O
. NCT03869164 1354 1355 O
Other NCT03869164 1357 1362 B-Other
clinical NCT03869164 1363 1371 B-Study
trials NCT03869164 1372 1378 I-Study
that NCT03869164 1379 1383 O
the NCT03869164 1384 1387 O
subjects NCT03869164 1388 1396 O
participated NCT03869164 1397 1409 O
in NCT03869164 1410 1412 O
have NCT03869164 1413 1417 O
not NCT03869164 1418 1421 O
reached NCT03869164 1422 1429 O
the NCT03869164 1430 1433 O
end NCT03869164 1434 1437 O
point NCT03869164 1438 1443 O
. NCT03869164 1443 1444 O

Inclusion NCT03922828 0 9 O
Criteria NCT03922828 10 18 O
: NCT03922828 19 20 O

- NCT03922828 24 25 O
The NCT03922828 27 30 O
subject NCT03922828 31 38 O
must NCT03922828 39 43 O
meet NCT03922828 44 48 O
all NCT03922828 49 52 O
of NCT03922828 53 55 O
the NCT03922828 56 59 O
following NCT03922828 60 69 O
inclusion NCT03922828 70 79 O
criteria NCT03922828 80 88 O
to NCT03922828 89 91 O
participate NCT03922828 92 103 O
in NCT03922828 104 106 O
this NCT03922828 107 111 O
study NCT03922828 112 117 O
. NCT03922828 117 118 O

1 NCT03922828 127 128 O
. NCT03922828 128 129 O
Evidence NCT03922828 131 139 O
of NCT03922828 140 142 O
lung NCT03922828 143 147 B-Condition
nodule NCT03922828 148 154 I-Condition
on NCT03922828 155 157 O
chest NCT03922828 158 163 B-Procedure
radiograph NCT03922828 164 174 I-Procedure
or NCT03922828 175 177 B-Or
Computed NCT03922828 178 186 B-Procedure
Tomography NCT03922828 187 197 I-Procedure
regardless NCT03922828 198 208 O
of NCT03922828 209 211 O
underlying NCT03922828 212 222 O
aetiology NCT03922828 223 232 O

2 NCT03922828 240 241 O
. NCT03922828 241 242 O
Age NCT03922828 244 247 B-Age
> NCT03922828 248 249 B-Eq-Comparison
21 NCT03922828 250 252 I-Eq-Comparison
years NCT03922828 253 258 I-Eq-Comparison
old NCT03922828 259 262 O

3 NCT03922828 270 271 O
. NCT03922828 271 272 O
Ability NCT03922828 274 281 O
to NCT03922828 282 284 O
provide NCT03922828 285 292 O
informed NCT03922828 293 301 O
consent NCT03922828 302 309 O

Exclusion NCT03922828 310 319 O
Criteria NCT03922828 320 328 O
: NCT03922828 329 330 O

- NCT03922828 334 335 O
Subjects NCT03922828 337 345 O
who NCT03922828 346 349 O
no NCT03922828 350 352 B-Negation
radiographic NCT03922828 353 365 B-Procedure
evidence NCT03922828 366 374 O
of NCT03922828 375 377 O
lung NCT03922828 378 382 B-Condition
nodules NCT03922828 383 390 I-Condition
or NCT03922828 391 393 O
who NCT03922828 394 397 O
are NCT03922828 398 401 O
unwilling NCT03922828 402 411 O
/ NCT03922828 412 413 O
unable NCT03922828 414 420 O
to NCT03922828 421 423 O
provide NCT03922828 424 431 O
informed NCT03922828 432 440 O
consent NCT03922828 441 448 O

Inclusion NCT03926455 0 9 O
Criteria NCT03926455 10 18 O
: NCT03926455 19 20 O

- NCT03926455 24 25 O
Healthy NCT03926455 27 34 O
adult NCT03926455 35 40 O
men NCT03926455 41 44 O
or NCT03926455 45 47 B-Or
women NCT03926455 48 53 O
who NCT03926455 54 57 B-And
are NCT03926455 58 61 O
not NCT03926455 62 65 B-Negation
pregnant NCT03926455 66 74 B-Condition
or NCT03926455 75 77 O
planning NCT03926455 78 86 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926455 87 89 I-Assertion___Assertion-Type-Value:hypothetical
become NCT03926455 90 96 O
pregnant NCT03926455 97 105 B-Condition
during NCT03926455 106 112 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03926455 113 118 B-Study
duration NCT03926455 119 127 O
aged NCT03926455 128 132 B-Age
18 NCT03926455 133 135 B-Eq-Comparison
to NCT03926455 136 138 I-Eq-Comparison
55 NCT03926455 139 141 O
years NCT03926455 142 147 O
. NCT03926455 147 148 O

- NCT03926455 152 153 O
Clinical NCT03926455 155 163 O
laboratory NCT03926455 164 174 B-Observation
parameters NCT03926455 175 185 I-Observation
within NCT03926455 186 192 O
normal NCT03926455 193 199 O
laboratory NCT03926455 200 210 O
limits NCT03926455 211 217 O
or NCT03926455 218 220 O
not NCT03926455 221 224 O
found NCT03926455 225 230 O
to NCT03926455 231 233 O
be NCT03926455 234 236 O
clinically NCT03926455 237 247 O
significant NCT03926455 248 259 O
by NCT03926455 260 262 O
the NCT03926455 263 266 O
PI NCT03926455 267 269 O

Exclusion NCT03926455 270 279 O
Criteria NCT03926455 280 288 O
: NCT03926455 289 290 O

- NCT03926455 294 295 O
Relevant NCT03926455 297 305 O
history NCT03926455 306 313 B-Eq-Comparison
of NCT03926455 314 316 O
physical NCT03926455 317 325 B-Modifier
or NCT03926455 326 328 B-Or
psychiatric NCT03926455 329 340 B-Modifier
illness NCT03926455 341 348 B-Condition
or NCT03926455 349 351 B-Or
medical NCT03926455 352 359 B-Condition
disorder NCT03926455 360 368 I-Condition
that NCT03926455 369 373 O
required NCT03926455 374 382 O
treatment NCT03926455 383 392 B-Procedure
. NCT03926455 392 393 O

- NCT03926455 397 398 O
Known NCT03926455 400 405 O
or NCT03926455 406 408 O
suspected NCT03926455 409 418 O
hypersensitivity NCT03926455 419 435 B-Condition
to NCT03926455 436 438 O
investigational NCT03926455 439 454 B-Study
product NCT03926455 455 462 B-Drug

- NCT03926455 465 466 O
Immunocompromised NCT03926455 468 485 B-Condition
subjects NCT03926455 486 494 O

- NCT03926455 497 498 O
Previous NCT03926455 500 508 B-Eq-Comparison
Typhoid NCT03926455 509 516 B-Procedure
vaccination NCT03926455 517 528 I-Procedure
or NCT03926455 529 531 B-Or
elevated NCT03926455 532 540 O
anti NCT03926455 541 545 B-Observation
- NCT03926455 546 547 I-Observation
Vi NCT03926455 548 550 I-Observation
antibodies NCT03926455 551 561 I-Observation
at NCT03926455 562 564 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03926455 565 574 B-Study

- NCT03926455 577 578 O
Known NCT03926455 580 585 O
history NCT03926455 586 593 B-Eq-Comparison
of NCT03926455 594 596 O
Typhoid NCT03926455 597 604 B-Condition
infection NCT03926455 605 614 I-Condition
in NCT03926455 615 617 O
the NCT03926455 618 621 O
previous NCT03926455 622 630 B-Eq-Comparison
6 NCT03926455 631 632 I-Eq-Comparison
months NCT03926455 633 639 I-Eq-Comparison

- NCT03926455 642 643 O
Positive NCT03926455 645 653 O
HIV NCT03926455 654 657 B-Condition
, NCT03926455 658 659 O
HBsAg NCT03926455 660 665 B-Condition
, NCT03926455 666 667 O
or NCT03926455 668 670 B-Or
HCV NCT03926455 671 674 B-Condition
screen NCT03926455 675 681 O

- NCT03926455 684 685 O
Any NCT03926455 687 690 O
other NCT03926455 691 696 O
condition NCT03926455 697 706 B-Condition
or NCT03926455 707 709 B-Or
abnormality NCT03926455 710 721 B-Condition
that NCT03926455 722 726 O
, NCT03926455 727 728 O
in NCT03926455 729 731 O
the NCT03926455 732 735 O
opinion NCT03926455 736 743 O
of NCT03926455 744 746 O
the NCT03926455 747 750 O
Investigator NCT03926455 751 763 O
, NCT03926455 764 765 O
may NCT03926455 766 769 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03926455 770 780 O
the NCT03926455 781 784 O
safety NCT03926455 785 791 B-Observation
of NCT03926455 792 794 O
the NCT03926455 795 798 O
patients NCT03926455 799 807 O

Inclusion NCT03928444 0 9 O
Criteria NCT03928444 10 18 O
: NCT03928444 19 20 O

- NCT03928444 24 25 O
Clinically NCT03928444 27 37 O
diagnosed NCT03928444 38 47 O
facial NCT03928444 48 54 B-Condition
skin NCT03928444 55 59 I-Condition
aging NCT03928444 60 65 I-Condition
. NCT03928444 65 66 O

- NCT03928444 70 71 O
Glogau NCT03928444 73 79 B-Condition
photoaging NCT03928444 80 90 I-Condition
score NCT03928444 91 96 B-Eq-Comparison
II NCT03928444 97 99 I-Eq-Comparison
and NCT03928444 100 103 I-Eq-Comparison
III NCT03928444 104 107 I-Eq-Comparison
. NCT03928444 107 108 O

- NCT03928444 112 113 O
Body NCT03928444 115 119 B-Observation
mass NCT03928444 120 124 I-Observation
index NCT03928444 125 130 I-Observation
≥ NCT03928444 131 132 B-Eq-Comparison
20 NCT03928444 133 135 I-Eq-Comparison
with NCT03928444 136 140 B-And
adequate NCT03928444 141 149 O
abdominal NCT03928444 150 159 B-Modifier
or NCT03928444 160 162 B-Or
other NCT03928444 163 168 O
subcutaneous NCT03928444 169 181 B-Modifier
adipose NCT03928444 182 189 B-Observation
tissue NCT03928444 190 196 I-Observation
accessible NCT03928444 197 207 O
for NCT03928444 208 211 B-Assertion___Assertion-Type-Value:hypothetical
lipoaspiration NCT03928444 212 226 B-Procedure
. NCT03928444 226 227 O

Exclusion NCT03928444 229 238 O
Criteria NCT03928444 239 247 O
: NCT03928444 248 249 O

- NCT03928444 253 254 O
History NCT03928444 256 263 B-Eq-Comparison
of NCT03928444 264 266 O
keloid NCT03928444 267 273 B-Condition
formation NCT03928444 274 283 I-Condition
. NCT03928444 283 284 O

- NCT03928444 288 289 O
Any NCT03928444 291 294 O
coincidental NCT03928444 295 307 O
chronic NCT03928444 308 315 B-Modifier
illness NCT03928444 316 323 B-Condition
( NCT03928444 324 325 O
e. NCT03928444 326 328 O
g. NCT03928444 329 331 O
metabolic NCT03928444 333 342 B-Modifier
, NCT03928444 343 344 O
autoimmune NCT03928444 345 355 B-Modifier
or NCT03928444 356 358 B-Or
endocrinal NCT03928444 359 369 B-Modifier
) NCT03928444 370 371 O
or NCT03928444 372 374 B-Or
malignancy NCT03928444 375 385 B-Condition
. NCT03928444 385 386 O

- NCT03928444 390 391 O
Any NCT03928444 393 396 O
bleeding NCT03928444 397 405 B-Modifier
or NCT03928444 406 408 B-Or
coagulation NCT03928444 409 420 B-Modifier
disorder NCT03928444 421 429 B-Condition
or NCT03928444 430 432 B-Or
recent NCT03928444 433 439 B-Eq-Comparison
use NCT03928444 440 443 O
of NCT03928444 444 446 O
anticoagulant NCT03928444 447 460 B-Drug
therapy NCT03928444 461 468 I-Drug
. NCT03928444 468 469 O

- NCT03928444 473 474 O
Active NCT03928444 476 482 B-Eq-Comparison
infection NCT03928444 483 492 B-Condition
. NCT03928444 492 493 O

- NCT03928444 497 498 O
History NCT03928444 500 507 B-Eq-Comparison
of NCT03928444 508 510 I-Eq-Comparison
any NCT03928444 511 514 I-Eq-Comparison
previous NCT03928444 515 523 I-Eq-Comparison
aesthetic NCT03928444 524 533 B-Procedure
procedure NCT03928444 534 543 I-Procedure
on NCT03928444 544 546 O
the NCT03928444 547 550 I-Eq-Comparison
face NCT03928444 551 555 B-Modifier
within NCT03928444 556 562 B-Eq-Comparison
the NCT03928444 563 566 O
past NCT03928444 567 571 I-Eq-Comparison
6 NCT03928444 572 573 I-Eq-Comparison
months NCT03928444 574 580 I-Eq-Comparison
. NCT03928444 580 581 O

- NCT03928444 585 586 O
History NCT03928444 588 595 B-Eq-Comparison
of NCT03928444 596 598 O
intake NCT03928444 599 605 O
of NCT03928444 606 608 O
anti NCT03928444 609 613 B-Modifier
- NCT03928444 614 615 I-Modifier
aging NCT03928444 616 621 I-Modifier
systemic NCT03928444 622 630 I-Modifier
or NCT03928444 631 633 B-Or
topical NCT03928444 634 641 B-Modifier
medications NCT03928444 642 653 B-Drug
within NCT03928444 654 660 B-Eq-Comparison
the NCT03928444 661 664 I-Eq-Comparison
previous NCT03928444 665 673 I-Eq-Comparison
3 NCT03928444 674 675 I-Eq-Comparison
months NCT03928444 676 682 I-Eq-Comparison
. NCT03928444 682 683 O

Inclusion NCT03924518 0 9 O
Criteria NCT03924518 10 18 O
( NCT03924518 19 20 O
Only NCT03924518 21 25 O
patients NCT03924518 26 34 O
who NCT03924518 35 38 O
fully NCT03924518 39 44 O
meet NCT03924518 45 49 O
the NCT03924518 50 53 O
following NCT03924518 54 63 O
criteria NCT03924518 64 72 O
are NCT03924518 73 76 O
eligible NCT03924518 77 85 O
to NCT03924518 86 88 O

participate NCT03924518 89 100 O
in NCT03924518 101 103 O
the NCT03924518 104 107 O
trial NCT03924518 108 113 O
) NCT03924518 114 115 O
: NCT03924518 117 118 O

- NCT03924518 122 123 O
Meets NCT03924518 125 130 O
the NCT03924518 131 134 O
diagnostic NCT03924518 135 145 O
criteria NCT03924518 146 154 O
for NCT03924518 155 158 O
sepsis NCT03924518 159 165 B-Condition
- NCT03924518 166 167 O
3 NCT03924518 168 169 B-Eq-Comparison
developed NCT03924518 170 179 O
by NCT03924518 180 182 O
the NCT03924518 183 186 O
American NCT03924518 187 195 O
Society NCT03924518 196 203 O
of NCT03924518 204 206 O
Critical NCT03924518 207 215 O
Care NCT03924518 216 220 O
Medicine NCT03924518 221 229 O
( NCT03924518 230 231 O
SCCM NCT03924518 232 236 O
) NCT03924518 237 238 O
/ NCT03924518 240 241 O
European NCT03924518 242 250 O
Critical NCT03924518 251 259 O
Care NCT03924518 260 264 O
Medicine NCT03924518 265 273 O
Association NCT03924518 274 285 O
( NCT03924518 286 287 O
ESICM NCT03924518 288 293 O
) NCT03924518 294 295 O

- NCT03924518 299 300 O
Age NCT03924518 302 305 B-Age
≥ NCT03924518 306 307 B-Eq-Comparison
18 NCT03924518 308 310 I-Eq-Comparison
years NCT03924518 311 316 I-Eq-Comparison
old NCT03924518 317 320 O
and NCT03924518 321 324 B-And
age NCT03924518 325 328 B-Age
≤ NCT03924518 329 330 B-Eq-Comparison
80 NCT03924518 331 333 I-Eq-Comparison
years NCT03924518 334 339 O
old NCT03924518 340 343 O
. NCT03924518 343 344 O

- NCT03924518 348 349 O
Procalcitonin NCT03924518 351 364 B-Observation
≥ NCT03924518 365 366 B-Eq-Comparison
2 NCT03924518 367 368 I-Eq-Comparison
ng NCT03924518 369 371 O
/ NCT03924518 372 373 I-Eq-Comparison
ml NCT03924518 374 376 I-Eq-Comparison

Exclusion NCT03924518 377 386 O
Criteria NCT03924518 387 395 O
: NCT03924518 396 397 O

- NCT03924518 401 402 O
Age NCT03924518 404 407 B-Age
＜ NCT03924518 408 409 B-Eq-Comparison
18 NCT03924518 410 412 O
years NCT03924518 413 418 I-Eq-Comparison|Eq-Comparison
, NCT03924518 419 420 O
or NCT03924518 421 423 B-Or
age NCT03924518 424 427 B-Age
＞ NCT03924518 428 429 B-Eq-Comparison
80 NCT03924518 430 432 O
years NCT03924518 433 438 O
. NCT03924518 438 439 O

- NCT03924518 443 444 O
Pregnancy NCT03924518 446 455 B-Condition
or NCT03924518 456 458 B-Modifier|Or|Or
lactating NCT03924518 459 468 B-Condition

- NCT03924518 471 472 I-Modifier
A NCT03924518 474 475 O
solid NCT03924518 476 481 B-Modifier
- NCT03924518 482 483 O
organ NCT03924518 484 489 O
or NCT03924518 490 492 O
bone NCT03924518 493 497 B-Modifier
marrow NCT03924518 498 504 I-Modifier
transplant NCT03924518 505 515 B-Procedure
patients NCT03924518 516 524 O
. NCT03924518 524 525 O

- NCT03924518 529 530 O
Patients NCT03924518 532 540 O
with NCT03924518 541 545 B-Eq-Comparison
myocardial NCT03924518 546 556 B-Condition
infarction NCT03924518 557 567 I-Condition
within NCT03924518 568 574 O
the NCT03924518 575 578 I-Eq-Comparison
past NCT03924518 579 583 I-Eq-Comparison
3 NCT03924518 584 585 I-Eq-Comparison
months NCT03924518 586 592 I-Eq-Comparison
. NCT03924518 592 593 O

- NCT03924518 597 598 O
Advanced NCT03924518 600 608 B-Condition
pulmonary NCT03924518 609 618 I-Condition
fibrosis NCT03924518 619 627 I-Condition
. NCT03924518 628 629 O

- NCT03924518 633 634 O
Patients NCT03924518 636 644 O
with NCT03924518 645 649 O
cardiopulmonary NCT03924518 650 665 B-Condition
resuscitation NCT03924518 666 679 I-Condition
before NCT03924518 680 686 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924518 687 697 B-Study
. NCT03924518 697 698 O

- NCT03924518 702 703 O
HIV NCT03924518 705 708 B-Condition
- NCT03924518 709 710 I-Condition
positive NCT03924518 711 719 O
patients NCT03924518 720 728 O
. NCT03924518 728 729 O

- NCT03924518 733 734 O
granulocyte NCT03924518 736 747 B-Condition
- NCT03924518 748 749 O
deficient NCT03924518 750 759 I-Condition
patients NCT03924518 760 768 O
. NCT03924518 768 769 O

- NCT03924518 773 774 O
blood NCT03924518 776 781 B-Modifier
/ NCT03924518 782 783 B-Or
lymphatic NCT03924518 784 793 B-Modifier
system NCT03924518 794 800 I-Modifier
tumors NCT03924518 801 807 B-Condition
are NCT03924518 808 811 O
not NCT03924518 812 815 B-Negation
remission NCT03924518 816 825 B-Modifier
. NCT03924518 825 826 O

- NCT03924518 830 831 O
patients NCT03924518 833 841 O
with NCT03924518 842 846 O
limited NCT03924518 847 854 B-Observation
care NCT03924518 855 859 I-Observation
( NCT03924518 860 861 O
lack NCT03924518 862 866 B-Negation
of NCT03924518 867 869 I-Negation
commitment NCT03924518 870 880 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924518 881 883 I-Assertion___Assertion-Type-Value:hypothetical
full NCT03924518 884 888 O
， NCT03924518 889 890 O
aggressive NCT03924518 891 901 O
life NCT03924518 902 906 B-Procedure
support NCT03924518 907 914 I-Procedure
) NCT03924518 915 916 O
. NCT03924518 917 918 O

- NCT03924518 922 923 O
patients NCT03924518 925 933 O
with NCT03924518 934 938 O
long NCT03924518 939 943 O
- NCT03924518 944 945 O
term NCT03924518 946 950 O
use NCT03924518 951 954 O
of NCT03924518 955 957 O
immunosuppressive NCT03924518 958 975 B-Drug
drugs NCT03924518 976 981 I-Drug
or NCT03924518 982 984 B-Or
with NCT03924518 985 989 O
immunodeficiency NCT03924518 990 1006 B-Condition
. NCT03924518 1006 1007 O

- NCT03924518 1011 1012 O
patients NCT03924518 1014 1022 O
with NCT03924518 1023 1027 O
advanced NCT03924518 1028 1036 B-Condition
tumors NCT03924518 1037 1043 I-Condition
. NCT03924518 1043 1044 O

- NCT03924518 1048 1049 O
patients NCT03924518 1051 1059 O
combined NCT03924518 1060 1068 O
with NCT03924518 1069 1073 O
non NCT03924518 1074 1077 B-Negation
- NCT03924518 1078 1079 O
infectious NCT03924518 1080 1090 B-Condition
factors NCT03924518 1091 1098 I-Condition
leading NCT03924518 1099 1106 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924518 1107 1109 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03924518 1110 1113 O
death NCT03924518 1114 1119 B-Death
( NCT03924518 1120 1121 O
uncontrollable NCT03924518 1122 1136 B-Condition
major NCT03924518 1137 1142 I-Condition
bleeding NCT03924518 1143 1151 I-Condition
, NCT03924518 1152 1153 O
brain NCT03924518 1154 1159 B-Condition
hernia NCT03924518 1160 1166 B-Condition
, NCT03924518 1167 1168 O
etc NCT03924518 1169 1172 O
. NCT03924518 1172 1173 O
) NCT03924518 1174 1175 O
. NCT03924518 1176 1177 O

- NCT03924518 1181 1182 O
surgically NCT03924518 1184 1194 O
unresolved NCT03924518 1195 1205 B-Eq-Comparison
infection NCT03924518 1206 1215 B-Condition|Condition
sources NCT03924518 1216 1223 O
( NCT03924518 1224 1225 O
such NCT03924518 1226 1230 O
as NCT03924518 1231 1233 O
some NCT03924518 1234 1238 O
intraperitoneal NCT03924518 1239 1254 B-Condition
infection NCT03924518 1255 1264 O
etc NCT03924518 1265 1268 O
. NCT03924518 1268 1269 O
) NCT03924518 1270 1271 O

- NCT03924518 1275 1276 O
patients NCT03924518 1278 1286 O
allergic NCT03924518 1287 1295 B-Allergy
to NCT03924518 1296 1298 O
granisetron NCT03924518 1299 1310 O
. NCT03924518 1310 1311 O

- NCT03924518 1315 1316 O
patients NCT03924518 1318 1326 O
with NCT03924518 1327 1331 O
intestinal NCT03924518 1332 1342 B-Condition
obstruction NCT03924518 1343 1354 I-Condition
. NCT03924518 1354 1355 O

Inclusion NCT03926858 0 9 O
Criteria NCT03926858 10 18 O
: NCT03926858 19 20 O

- NCT03926858 24 25 O
18 NCT03926858 27 29 B-Eq-Comparison
years NCT03926858 30 35 I-Eq-Comparison
or NCT03926858 36 38 I-Eq-Comparison
older NCT03926858 39 44 I-Age|Eq-Comparison

- NCT03926858 47 48 O
Undergoing NCT03926858 50 60 B-Eq-Comparison
general NCT03926858 61 68 B-Modifier
or NCT03926858 69 71 B-Or
regional NCT03926858 72 80 B-Modifier
anesthesia NCT03926858 81 91 B-Procedure

- NCT03926858 94 95 O
Hospitalized NCT03926858 97 109 B-Encounter
for NCT03926858 110 113 O
at NCT03926858 114 116 B-Eq-Comparison
least NCT03926858 117 122 I-Eq-Comparison
24 NCT03926858 123 125 I-Eq-Comparison
hours NCT03926858 126 131 I-Eq-Comparison
after NCT03926858 132 137 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03926858 138 145 B-Procedure

- NCT03926858 148 149 O
Able NCT03926858 151 155 O
to NCT03926858 156 158 O
give NCT03926858 159 163 O
informed NCT03926858 164 172 O
consent NCT03926858 173 180 O

- NCT03926858 183 184 O
Able NCT03926858 186 190 O
to NCT03926858 191 193 O
read NCT03926858 194 198 O
and NCT03926858 199 202 O
write NCT03926858 203 208 O

Exclusion NCT03926858 209 218 O
Criteria NCT03926858 219 227 O
: NCT03926858 228 229 O

- NCT03926858 233 234 O
Existing NCT03926858 236 244 B-Eq-Comparison
diagnoses NCT03926858 245 254 O
of NCT03926858 255 257 O
psychiatric NCT03926858 258 269 B-Modifier
or NCT03926858 270 272 B-Or
neurologic NCT03926858 273 283 B-Modifier
pathology NCT03926858 284 293 B-Condition

- NCT03926858 296 297 O
A NCT03926858 299 300 O
history NCT03926858 301 308 B-Eq-Comparison
of NCT03926858 309 311 O
substance NCT03926858 312 321 B-Condition
abuse NCT03926858 322 327 I-Condition

- NCT03926858 330 331 O
Admitted NCT03926858 333 341 B-Encounter
to NCT03926858 342 344 O
ICU NCT03926858 345 348 O
after NCT03926858 349 354 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03926858 355 362 B-Procedure

Inclusion NCT03925389 0 9 O
Criteria NCT03925389 10 18 O
: NCT03925389 19 20 O

- NCT03925389 24 25 O
at NCT03925389 27 29 B-Eq-Comparison
least NCT03925389 30 35 I-Eq-Comparison
18 NCT03925389 36 38 I-Eq-Comparison
years NCT03925389 39 44 I-Eq-Comparison
old NCT03925389 45 48 B-Age

- NCT03925389 51 52 O
Patients NCT03925389 54 62 O
eligible NCT03925389 63 71 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925389 72 75 I-Assertion___Assertion-Type-Value:hypothetical
external NCT03925389 76 84 B-Procedure
septorhinoplasty NCT03925389 85 101 I-Procedure
: NCT03925389 102 103 O
patients NCT03925389 104 112 O
seen NCT03925389 113 117 O
in NCT03925389 118 120 O
consultation NCT03925389 121 133 O
because NCT03925389 134 141 O
of NCT03925389 142 144 O
nasal NCT03925389 145 150 B-Condition
obstruction NCT03925389 151 162 I-Condition
were NCT03925389 163 167 O
evaluated NCT03925389 168 177 B-Assertion___Assertion-Type-Value:possible
. NCT03925389 177 178 O
Patients NCT03925389 180 188 O
who NCT03925389 189 192 O
had NCT03925389 193 196 O
symptoms NCT03925389 197 205 B-Assertion___Assertion-Type-Value:possible
of NCT03925389 206 208 O
nasal NCT03925389 209 214 B-Condition
obstruction NCT03925389 215 226 I-Condition
for NCT03925389 227 230 O
at NCT03925389 231 233 B-Eq-Comparison
least NCT03925389 234 239 I-Eq-Comparison
1 NCT03925389 240 241 I-Eq-Comparison
year NCT03925389 242 246 I-Eq-Comparison
that NCT03925389 247 251 O
were NCT03925389 252 256 O
the NCT03925389 257 260 O
result NCT03925389 261 267 O
of NCT03925389 268 270 O
an NCT03925389 271 273 O
identifiable NCT03925389 274 286 O
anatomical NCT03925389 287 297 B-Condition
cause NCT03925389 298 303 I-Condition
such NCT03925389 304 308 O
as NCT03925389 309 311 O
septal NCT03925389 312 318 B-Condition
deviation NCT03925389 319 328 I-Condition
, NCT03925389 329 330 O
turbinate NCT03925389 331 340 B-Condition
hypertrophy NCT03925389 341 352 I-Condition
, NCT03925389 353 354 O
internal NCT03925389 355 363 B-Condition
valve NCT03925389 364 369 I-Condition
collapse NCT03925389 370 378 I-Condition
, NCT03925389 379 380 O
or NCT03925389 381 383 B-Or
external NCT03925389 384 392 B-Condition
valve NCT03925389 393 398 I-Condition
collapse NCT03925389 399 407 I-Condition
were NCT03925389 408 412 O
included NCT03925389 413 421 O
in NCT03925389 422 424 O
the NCT03925389 425 428 O
study NCT03925389 429 434 O
. NCT03925389 434 435 O

Exclusion NCT03925389 437 446 O
Criteria NCT03925389 447 455 O
: NCT03925389 456 457 O

- NCT03925389 461 462 O
< NCT03925389 464 465 B-Eq-Comparison
18 NCT03925389 466 468 I-Eq-Comparison
years NCT03925389 469 474 I-Age|Eq-Comparison

- NCT03925389 477 478 O
mental NCT03925389 480 486 B-Modifier
or NCT03925389 487 489 B-Or
physical NCT03925389 490 498 B-Modifier
incapacity NCT03925389 499 509 B-Condition
to NCT03925389 510 512 O
answer NCT03925389 513 519 O
the NCT03925389 520 523 O
questionnaires NCT03925389 524 538 O

- NCT03925389 541 542 O
nasal NCT03925389 544 549 B-Condition
fracture NCT03925389 550 558 I-Condition
or NCT03925389 559 561 B-Or
surgery NCT03925389 562 569 B-Procedure
in NCT03925389 570 572 O
the NCT03925389 573 576 O
past NCT03925389 577 581 B-Eq-Comparison
year NCT03925389 582 586 I-Eq-Comparison

- NCT03925389 589 590 O
nasal NCT03925389 592 597 B-Modifier
cocaine NCT03925389 598 605 B-Drug
use NCT03925389 606 609 O
in NCT03925389 610 612 O
the NCT03925389 613 616 O
past NCT03925389 617 621 B-Eq-Comparison
year NCT03925389 622 626 I-Eq-Comparison

Inclusion NCT03923920 0 9 O
Criteria NCT03923920 10 18 O
: NCT03923920 19 20 O

- NCT03923920 24 25 O
Age NCT03923920 27 30 B-Age
≥ NCT03923920 31 32 B-Eq-Comparison
50 NCT03923920 33 35 I-Eq-Comparison
years NCT03923920 36 41 I-Eq-Comparison

- NCT03923920 44 45 O
Undergoing NCT03923920 47 57 B-Eq-Comparison
surgical NCT03923920 58 66 B-Procedure
intervention NCT03923920 67 79 I-Procedure
for NCT03923920 80 83 O
non NCT03923920 84 87 B-Modifier
- NCT03923920 88 89 I-Modifier
congenital NCT03923920 90 100 I-Modifier
spinal NCT03923920 101 107 B-Condition
stenosis NCT03923920 108 116 I-Condition
and NCT03923920 117 120 B-Or
/ NCT03923920 121 122 I-Or
or NCT03923920 123 125 I-Or
spondyloarthropathy NCT03923920 126 145 B-Condition

- NCT03923920 148 149 O
Able NCT03923920 151 155 O
to NCT03923920 156 158 O
consent NCT03923920 159 166 O

Exclusion NCT03923920 167 176 O
Criteria NCT03923920 177 185 O
: NCT03923920 186 187 O

- NCT03923920 191 192 O
History NCT03923920 194 201 B-Eq-Comparison
of NCT03923920 202 204 O
congenital NCT03923920 205 215 B-Condition
spinal NCT03923920 216 222 I-Condition
stenosis NCT03923920 223 231 I-Condition
or NCT03923920 232 234 B-Or
congenital NCT03923920 235 245 B-Condition
spondyloarthropathy NCT03923920 246 265 I-Condition

Inclusion NCT03928691 0 9 O
criteria NCT03928691 10 18 O
: NCT03928691 19 20 O

pregnant NCT03928691 22 30 B-Condition
women NCT03928691 31 36 O
34 NCT03928691 37 39 B-Eq-Comparison
weeks NCT03928691 40 45 I-Eq-Comparison
or NCT03928691 46 48 I-Eq-Comparison
less NCT03928691 49 53 I-Eq-Comparison
admitted NCT03928691 54 62 B-Encounter
to NCT03928691 63 65 O
Women NCT03928691 66 71 O
's NCT03928691 71 73 O
Health NCT03928691 74 80 O
Hospital NCT03928691 81 89 O
with NCT03928691 90 94 O
a NCT03928691 95 96 O
diagnosis NCT03928691 97 106 O
of NCT03928691 107 109 O
: NCT03928691 110 111 O

- NCT03928691 115 116 O
sever NCT03928691 118 123 O
preeclampsia NCT03928691 124 136 B-Condition
. NCT03928691 136 137 O
It NCT03928691 139 141 O
is NCT03928691 142 144 O
defined NCT03928691 145 152 O
as NCT03928691 153 155 O
1 NCT03928691 156 157 O
- NCT03928691 158 159 O
blood NCT03928691 160 165 B-Observation
pressure NCT03928691 166 174 I-Observation
160 NCT03928691 175 178 B-Eq-Comparison
/ NCT03928691 179 180 I-Eq-Comparison
110 NCT03928691 181 184 I-Eq-Comparison
mmHg NCT03928691 185 189 I-Eq-Comparison
or NCT03928691 190 192 I-Eq-Comparison
more NCT03928691 193 197 I-Eq-Comparison
2 NCT03928691 198 199 O
- NCT03928691 200 201 O
proteinurea NCT03928691 202 213 B-Observation
( NCT03928691 214 215 O
+ NCT03928691 217 218 B-Eq-Comparison
3 NCT03928691 219 220 O
or NCT03928691 221 223 I-Eq-Comparison
more NCT03928691 224 228 I-Eq-Comparison
by NCT03928691 229 231 O
dipstick NCT03928691 232 240 O
) NCT03928691 241 242 O
3 NCT03928691 243 244 B-Condition
- NCT03928691 245 246 I-Condition
HELLP NCT03928691 247 252 I-Condition
syndrome NCT03928691 253 261 I-Condition

- NCT03928691 264 265 O
threatened NCT03928691 267 277 B-Assertion___Assertion-Type-Value:possible
preterm NCT03928691 278 285 B-Condition
labour NCT03928691 286 292 I-Condition
that NCT03928691 293 297 O
will NCT03928691 298 302 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03928691 303 310 O
Magnesium NCT03928691 311 320 B-Drug
Sulphate NCT03928691 321 329 I-Drug
either NCT03928691 330 336 O
for NCT03928691 337 340 O
tocolysis NCT03928691 341 350 O
or NCT03928691 351 353 O
neuroprotection NCT03928691 354 369 O
. NCT03928691 369 370 O

Exclusion NCT03928691 372 381 O
criteria NCT03928691 382 390 O
: NCT03928691 391 392 O

- NCT03928691 395 396 O
women NCT03928691 397 402 O
with NCT03928691 403 407 B-And
more NCT03928691 408 412 B-Eq-Comparison
than NCT03928691 413 417 I-Eq-Comparison
34 NCT03928691 418 420 I-Eq-Comparison
weeks NCT03928691 421 426 I-Eq-Comparison
gestation NCT03928691 427 436 B-Observation
and NCT03928691 437 440 B-And
with NCT03928691 441 445 O
any NCT03928691 446 449 O
contraindication NCT03928691 450 466 B-Contraindication
for NCT03928691 467 470 O
Magnesium NCT03928691 471 480 B-Drug
Sulphate NCT03928691 481 489 I-Drug
intake NCT03928691 490 496 O
like NCT03928691 497 501 O
severe NCT03928691 502 508 O
renal NCT03928691 509 514 B-Condition
impairment NCT03928691 515 525 I-Condition
or NCT03928691 526 528 B-Or
myasthenia NCT03928691 529 539 B-Condition
gravis NCT03928691 540 546 I-Condition
. NCT03928691 546 547 O


Inclusion NCT03922425 0 9 O
Criteria NCT03922425 10 18 O
: NCT03922425 19 20 O

- NCT03922425 24 25 O
Age NCT03922425 27 30 B-Age
18 NCT03922425 31 33 B-Eq-Comparison
- NCT03922425 34 35 I-Eq-Comparison
65 NCT03922425 36 38 O

- NCT03922425 42 43 O
Current NCT03922425 45 52 B-Eq-Comparison
service NCT03922425 53 60 B-Encounter
users NCT03922425 61 66 I-Encounter
, NCT03922425 67 68 O
with NCT03922425 69 73 B-And
severe NCT03922425 74 80 O
and NCT03922425 81 84 B-And
enduring NCT03922425 85 93 B-Modifier
mental NCT03922425 94 100 B-Condition
disorder NCT03922425 101 109 I-Condition
, NCT03922425 110 111 O

- NCT03922425 115 116 O
Severe NCT03922425 118 124 O
Mental NCT03922425 125 131 B-Condition
Illnesses NCT03922425 132 141 I-Condition
- NCT03922425 142 143 O
bipolar NCT03922425 144 151 B-Condition
disorder NCT03922425 152 160 I-Condition
, NCT03922425 161 162 O
severe NCT03922425 163 169 B-Condition
depression NCT03922425 170 180 I-Condition
, NCT03922425 181 182 O
or NCT03922425 183 185 B-Or
schizophrenia NCT03922425 186 199 B-Condition

Exclusion NCT03922425 200 209 O
Criteria NCT03922425 210 218 O
: NCT03922425 219 220 O

- NCT03922425 224 225 O
Patients NCT03922425 227 235 O
who NCT03922425 236 239 O
do NCT03922425 240 242 O
not NCT03922425 243 246 O
consent NCT03922425 247 254 O
to NCT03922425 255 257 O
their NCT03922425 258 263 O
data NCT03922425 264 268 O
being NCT03922425 269 274 O
collected NCT03922425 275 284 O

- NCT03922425 287 288 O
Patients NCT03922425 290 298 O
with NCT03922425 299 303 O
acute NCT03922425 304 309 O
somatic NCT03922425 310 317 B-Condition
disorders NCT03922425 318 327 I-Condition

- NCT03922425 330 331 O
Patients NCT03922425 333 341 O
who NCT03922425 342 345 O
are NCT03922425 346 349 O
under NCT03922425 350 355 B-Eq-Comparison
the NCT03922425 356 359 I-Eq-Comparison
age NCT03922425 360 363 I-Eq-Comparison
of NCT03922425 364 366 I-Eq-Comparison
18 NCT03922425 367 369 I-Eq-Comparison
at NCT03922425 370 372 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922425 373 376 O
start NCT03922425 377 382 O
of NCT03922425 383 385 O
the NCT03922425 386 389 O
study NCT03922425 390 395 B-Study
. NCT03922425 395 396 O

Inclusion NCT03921892 0 9 O
Criteria NCT03921892 10 18 O
: NCT03921892 19 20 O

- NCT03921892 24 25 O
age NCT03921892 27 30 B-Age
15 NCT03921892 31 33 B-Eq-Comparison
to NCT03921892 34 36 I-Eq-Comparison
21 NCT03921892 37 39 O
, NCT03921892 40 41 O

- NCT03921892 46 47 O
be NCT03921892 49 51 O
able NCT03921892 52 56 O
to NCT03921892 57 59 O
read NCT03921892 60 64 O
and NCT03921892 65 68 O
understand NCT03921892 69 79 O
English NCT03921892 80 87 O
( NCT03921892 88 89 O
as NCT03921892 90 92 O
determined NCT03921892 93 103 O
by NCT03921892 104 106 O
having NCT03921892 107 113 O
the NCT03921892 114 117 O
individual NCT03921892 118 128 O
read NCT03921892 129 133 O
a NCT03921892 134 135 O
brief NCT03921892 136 141 O
, NCT03921892 142 143 O
eighth NCT03921892 144 150 O
grade NCT03921892 151 156 O
reading NCT03921892 157 164 O
level NCT03921892 165 170 O
paragraph NCT03921892 171 180 O
) NCT03921892 181 182 O
, NCT03921892 184 185 O

- NCT03921892 189 190 O
able NCT03921892 192 196 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921892 197 199 I-Assertion___Assertion-Type-Value:hypothetical
begin NCT03921892 200 205 O
the NCT03921892 206 209 O
intervention NCT03921892 210 222 B-Study
within NCT03921892 223 229 B-Eq-Comparison
six NCT03921892 230 233 I-Eq-Comparison
weeks NCT03921892 234 239 I-Eq-Comparison
of NCT03921892 240 242 B-Temporal-Connection___Temporal-Connection-Type-Value:after
their NCT03921892 243 248 O
infant NCT03921892 249 255 B-Family-Member___Family-Member-Type:child
's NCT03921892 255 257 O
birth NCT03921892 258 263 B-Birth
, NCT03921892 264 265 O

- NCT03921892 269 270 O
be NCT03921892 272 274 O
able NCT03921892 275 279 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921892 280 282 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03921892 283 294 O
in NCT03921892 295 297 B-Study
an NCT03921892 298 300 O
intervention NCT03921892 301 313 O
over NCT03921892 314 318 B-Eq-Comparison
two NCT03921892 319 322 I-Eq-Comparison
weeks NCT03921892 323 328 I-Eq-Comparison
, NCT03921892 329 330 O
requiring NCT03921892 331 340 O
approximately NCT03921892 341 354 O
a NCT03921892 355 356 O
12 NCT03921892 357 359 O
- NCT03921892 360 361 O
hour NCT03921892 362 366 O
time NCT03921892 367 371 O
commitment NCT03921892 372 382 O
: NCT03921892 383 384 O
either NCT03921892 385 391 O
in NCT03921892 392 394 O
- NCT03921892 395 396 O
person NCT03921892 397 403 O
on NCT03921892 404 406 O
two NCT03921892 407 410 O
Saturdays NCT03921892 411 420 O
for NCT03921892 421 424 O
six NCT03921892 425 428 O
hours NCT03921892 429 434 O
each NCT03921892 435 439 O
, NCT03921892 440 441 O
or NCT03921892 442 444 O
a NCT03921892 445 446 O
self NCT03921892 447 451 O
- NCT03921892 452 453 O
paced NCT03921892 454 459 O
content NCT03921892 460 467 O
of NCT03921892 468 470 O
videos NCT03921892 471 477 O
and NCT03921892 478 481 O
resource NCT03921892 482 490 O
materials NCT03921892 491 500 O
over NCT03921892 501 505 O
two NCT03921892 506 509 O
weeks NCT03921892 510 515 O
, NCT03921892 516 517 O

- NCT03921892 521 522 O
own NCT03921892 524 527 O
or NCT03921892 528 530 O
have NCT03921892 531 535 O
access NCT03921892 536 542 O
to NCT03921892 543 545 O
a NCT03921892 546 547 O
device NCT03921892 548 554 O
with NCT03921892 555 559 O
internet NCT03921892 560 568 O
access NCT03921892 569 575 O
and NCT03921892 576 579 O

- NCT03921892 582 583 O
have NCT03921892 585 589 O
a NCT03921892 590 591 O
working NCT03921892 592 599 O
e NCT03921892 600 601 O
- NCT03921892 602 603 O
mail NCT03921892 604 608 O
address NCT03921892 609 616 O
. NCT03921892 616 617 O

Exclusion NCT03921892 619 628 O
Criteria NCT03921892 629 637 O
: NCT03921892 638 639 O

- NCT03921892 643 644 O
Any NCT03921892 646 649 O
condition NCT03921892 650 659 B-Condition
that NCT03921892 660 664 O
might NCT03921892 665 670 B-Assertion___Assertion-Type-Value:possible
prevent NCT03921892 671 678 B-Negation
the NCT03921892 679 682 O
father NCT03921892 683 689 B-Family-Member___Family-Member-Type:father
's NCT03921892 689 691 O
infant NCT03921892 692 698 B-Family-Member___Family-Member-Type:child
from NCT03921892 699 703 O
reaching NCT03921892 704 712 O
normal NCT03921892 713 719 O
developmental NCT03921892 720 733 B-Observation
milestones NCT03921892 734 744 I-Observation
will NCT03921892 745 749 O
participation NCT03921892 750 763 O
, NCT03921892 764 765 O
including NCT03921892 766 775 O
congenital NCT03921892 776 786 B-Condition
malformations NCT03921892 787 800 I-Condition
or NCT03921892 801 803 B-Or
prematurity NCT03921892 804 815 B-Condition
requiring NCT03921892 816 825 O
prolonged NCT03921892 826 835 O
/ NCT03921892 836 837 O
ongoing NCT03921892 838 845 B-Eq-Comparison
infant NCT03921892 846 852 B-Family-Member___Family-Member-Type:child
hospitalization NCT03921892 853 868 B-Encounter
. NCT03921892 868 869 O


Inclusion NCT03924726 0 9 O
Criteria NCT03924726 10 18 O
: NCT03924726 19 20 O

- NCT03924726 24 25 O
Aged NCT03924726 27 31 B-Age
18 NCT03924726 32 34 B-Eq-Comparison
years NCT03924726 35 40 I-Eq-Comparison
and NCT03924726 41 44 I-Eq-Comparison
above NCT03924726 45 50 I-Eq-Comparison
at NCT03924726 51 53 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924726 54 57 I-Temporal-Connection___Temporal-Connection-Type-Value:during
start NCT03924726 58 63 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03924726 64 66 O
the NCT03924726 67 70 O
treatment NCT03924726 71 80 B-Study
. NCT03924726 80 81 O

- NCT03924726 85 86 O
Molar NCT03924726 88 93 B-Condition
relationship NCT03924726 94 106 I-Condition
either NCT03924726 107 113 O
Class NCT03924726 114 119 B-Eq-Comparison
I NCT03924726 120 121 I-Eq-Comparison
, NCT03924726 122 123 O
< NCT03924726 124 125 B-Eq-Comparison
½ NCT03924726 126 127 I-Eq-Comparison
unit NCT03924726 128 132 I-Eq-Comparison
Class NCT03924726 133 138 I-Eq-Comparison
II NCT03924726 139 141 I-Eq-Comparison
or NCT03924726 142 144 B-Or
Class NCT03924726 145 150 B-Eq-Comparison
III NCT03924726 151 154 I-Eq-Comparison
. NCT03924726 154 155 O

- NCT03924726 159 160 O
Extraction NCT03924726 162 172 B-Procedure
of NCT03924726 173 175 I-Procedure
all NCT03924726 176 179 I-Procedure
four NCT03924726 180 184 I-Procedure
first NCT03924726 185 190 I-Procedure
premolar NCT03924726 191 199 I-Procedure
teeth NCT03924726 200 205 I-Procedure
as NCT03924726 206 208 O
part NCT03924726 209 213 O
of NCT03924726 214 216 O
orthodontic NCT03924726 217 228 B-Procedure
treatment NCT03924726 229 238 I-Procedure
. NCT03924726 238 239 O

- NCT03924726 243 244 O
Maximum NCT03924726 246 253 B-Procedure
anchorage NCT03924726 254 263 I-Procedure
required NCT03924726 264 272 O
using NCT03924726 273 278 O
mini NCT03924726 279 283 B-Procedure
- NCT03924726 284 285 I-Procedure
implant NCT03924726 286 293 I-Procedure
. NCT03924726 293 294 O

- NCT03924726 298 299 O
No NCT03924726 301 303 B-Negation
systemic NCT03924726 304 312 B-Condition
disease NCT03924726 313 320 I-Condition
. NCT03924726 320 321 O

- NCT03924726 325 326 O
Good NCT03924726 328 332 O
oral NCT03924726 333 337 O
hygiene NCT03924726 338 345 O
. NCT03924726 345 346 O

- NCT03924726 350 351 O
No NCT03924726 353 355 B-Negation
periodontal NCT03924726 356 367 B-Condition
disease NCT03924726 368 375 I-Condition
. NCT03924726 375 376 O

Exclusion NCT03924726 378 387 O
Criteria NCT03924726 388 396 O
: NCT03924726 397 398 O

- NCT03924726 402 403 O
Significant NCT03924726 405 416 O
vertical NCT03924726 417 425 B-Condition
skeletal NCT03924726 426 434 I-Condition
discrepancies NCT03924726 435 448 I-Condition
. NCT03924726 448 449 O

- NCT03924726 453 454 O
Systemic NCT03924726 456 464 B-Condition
diseases NCT03924726 465 473 I-Condition
requiring NCT03924726 474 483 B-Assertion___Assertion-Type-Value:hypothetical
long NCT03924726 484 488 O
- NCT03924726 489 490 O
term NCT03924726 491 495 O
antibiotic NCT03924726 496 506 B-Drug
use NCT03924726 507 510 O
, NCT03924726 511 512 O
phenytoin NCT03924726 513 522 B-Drug
, NCT03924726 523 524 O
cyclosporin NCT03924726 525 536 B-Drug
, NCT03924726 537 538 O
anti NCT03924726 539 543 B-Drug
- NCT03924726 544 545 I-Drug
inflammatory NCT03924726 546 558 I-Drug
drugs NCT03924726 559 564 I-Drug
, NCT03924726 565 566 O
bisphosphonates NCT03924726 567 582 B-Drug
, NCT03924726 583 584 O
systemic NCT03924726 585 593 B-Drug
corticosteroids NCT03924726 594 609 I-Drug
or NCT03924726 610 612 B-Or
calcium NCT03924726 613 620 B-Drug
channel NCT03924726 621 628 I-Drug
blockers NCT03924726 629 637 I-Drug
. NCT03924726 637 638 O

- NCT03924726 642 643 O
Poor NCT03924726 645 649 B-Condition
oral NCT03924726 650 654 I-Condition
hygiene NCT03924726 655 662 I-Condition
. NCT03924726 662 663 O

- NCT03924726 667 668 O
Active NCT03924726 670 676 B-Eq-Comparison
periodontal NCT03924726 677 688 B-Condition
disease NCT03924726 689 696 I-Condition
. NCT03924726 696 697 O


Inclusion NCT03923049 0 9 O
Criteria NCT03923049 10 18 O
: NCT03923049 19 20 O

1 NCT03923049 22 23 O
. NCT03923049 23 24 O
Subjects NCT03923049 25 33 O
older NCT03923049 34 39 B-Eq-Comparison
than NCT03923049 40 44 I-Eq-Comparison
18 NCT03923049 45 47 I-Eq-Comparison
years NCT03923049 48 53 I-Eq-Comparison
of NCT03923049 54 56 O
age NCT03923049 57 60 B-Age
with NCT03923049 61 65 B-And
high NCT03923049 66 70 O
suspicion NCT03923049 71 80 B-Assertion___Assertion-Type-Value:possible
of NCT03923049 81 83 O
cardiac NCT03923049 84 91 B-Condition
sarcoidosis NCT03923049 92 103 I-Condition
and NCT03923049 104 107 B-Or
/ NCT03923049 108 109 I-Or
or NCT03923049 110 112 I-Or

biopsy NCT03923049 113 119 B-Procedure
proven NCT03923049 120 126 O
extracardiac NCT03923049 127 139 B-Condition
sarcoidosis NCT03923049 140 151 I-Condition
and NCT03923049 152 155 B-Or
/ NCT03923049 156 157 I-Or
or NCT03923049 158 160 I-Or
positive NCT03923049 161 169 O
HRS NCT03923049 170 173 B-Condition
criteria NCT03923049 174 182 O
will NCT03923049 183 187 O
be NCT03923049 188 190 O
enrolled NCT03923049 191 199 O
. NCT03923049 199 200 O

Exclusion NCT03923049 202 211 O
Criteria NCT03923049 212 220 O
: NCT03923049 221 222 O

1 NCT03923049 226 227 O
. NCT03923049 227 228 O
Coronary NCT03923049 230 238 B-Condition
artery NCT03923049 239 245 I-Condition
disease NCT03923049 246 253 I-Condition

2 NCT03923049 256 257 O
. NCT03923049 257 258 O
Insulin NCT03923049 260 267 B-Modifier
dependent NCT03923049 268 277 I-Modifier
diabetes NCT03923049 278 286 B-Condition

3 NCT03923049 289 290 O
. NCT03923049 290 291 O
Claustrophobia NCT03923049 293 307 B-Condition

4 NCT03923049 310 311 O
. NCT03923049 311 312 O
Pregnancy NCT03923049 314 323 B-Condition
/ NCT03923049 324 325 B-Or
nursing NCT03923049 326 333 B-Condition

5 NCT03923049 336 337 O
. NCT03923049 337 338 O
Presence NCT03923049 340 348 O
of NCT03923049 349 351 O
pacemaker NCT03923049 352 361 B-Procedure
or NCT03923049 362 364 B-Or
automatic NCT03923049 365 374 B-Procedure
implantable NCT03923049 375 386 I-Procedure
cardioverter NCT03923049 387 399 I-Procedure
- NCT03923049 400 401 I-Procedure
defibrillator NCT03923049 402 415 I-Procedure

6 NCT03923049 418 419 O
. NCT03923049 419 420 O
Impaired NCT03923049 422 430 B-Condition
renal NCT03923049 431 436 I-Condition
function NCT03923049 437 445 I-Condition
( NCT03923049 446 447 O
estimated NCT03923049 448 457 B-Observation
glomerular NCT03923049 458 468 I-Observation
filtration NCT03923049 469 479 I-Observation
rate NCT03923049 480 484 I-Observation
< NCT03923049 485 486 B-Eq-Comparison
45 NCT03923049 487 489 I-Eq-Comparison
ml NCT03923049 490 492 I-Eq-Comparison
/ NCT03923049 493 494 I-Eq-Comparison
min NCT03923049 495 498 I-Eq-Comparison
/ NCT03923049 499 500 O
1.73 NCT03923049 501 505 I-Eq-Comparison
m2 NCT03923049 506 508 I-Eq-Comparison
) NCT03923049 509 510 O
will NCT03923049 511 515 O
be NCT03923049 516 518 O
excluded NCT03923049 519 527 O
. NCT03923049 527 528 O

7 NCT03923049 532 533 O
. NCT03923049 533 534 O
Inability NCT03923049 536 545 B-Negation
to NCT03923049 546 548 O
undergo NCT03923049 549 556 B-Assertion___Assertion-Type-Value:hypothetical
PET NCT03923049 557 560 B-Procedure
/ NCT03923049 561 562 B-Or
MRI NCT03923049 563 566 B-Procedure
due NCT03923049 567 570 O
to NCT03923049 571 573 O
any NCT03923049 574 577 O
other NCT03923049 578 583 O
condition NCT03923049 584 593 B-Condition
. NCT03923049 593 594 O

Inclusion NCT03920540 0 9 O
Criteria NCT03920540 10 18 O
: NCT03920540 19 20 O

- NCT03920540 24 25 O
Patients NCT03920540 27 35 O
diagnosed NCT03920540 36 45 O
with NCT03920540 46 50 O
Hunter NCT03920540 51 57 B-Condition
syndrome NCT03920540 58 66 I-Condition

- NCT03920540 69 70 O
Male NCT03920540 72 76 O
at NCT03920540 77 79 B-And
the NCT03920540 80 83 O
age NCT03920540 84 87 B-Age
of NCT03920540 88 90 O
≥ NCT03920540 91 92 B-Eq-Comparison
5 NCT03920540 93 94 I-Eq-Comparison

- NCT03920540 98 99 O
Adequate NCT03920540 101 109 O
abilities NCT03920540 110 119 O
( NCT03920540 120 121 O
including NCT03920540 122 131 O
6 NCT03920540 132 133 B-Observation
- NCT03920540 134 135 I-Observation
MWT NCT03920540 136 139 I-Observation
) NCT03920540 140 141 O
to NCT03920540 142 144 O
participate NCT03920540 145 156 O
in NCT03920540 157 159 O
this NCT03920540 160 164 O
study NCT03920540 165 170 O
in NCT03920540 171 173 O
the NCT03920540 174 177 O
opinion NCT03920540 178 185 O
of NCT03920540 186 188 O
the NCT03920540 189 192 O
investigator NCT03920540 193 205 O
. NCT03920540 205 206 O

- NCT03920540 210 211 O
Voluntarily NCT03920540 213 224 O
signed NCT03920540 225 231 O
written NCT03920540 232 239 O
informed NCT03920540 240 248 O
consent NCT03920540 249 256 O
to NCT03920540 257 259 O
participation NCT03920540 260 273 O
in NCT03920540 274 276 O
this NCT03920540 277 281 O
study NCT03920540 282 287 O

- NCT03920540 290 291 O
Consent NCT03920540 293 300 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920540 301 303 I-Assertion___Assertion-Type-Value:hypothetical
contraception NCT03920540 304 317 B-Procedure

Exclusion NCT03920540 318 327 O
Criteria NCT03920540 328 336 O
: NCT03920540 337 338 O

- NCT03920540 342 343 O
Prior NCT03920540 345 350 B-Eq-Comparison
treatment NCT03920540 351 360 B-Procedure
with NCT03920540 361 365 O
iduronate NCT03920540 366 375 B-Drug
- NCT03920540 376 377 I-Drug
2 NCT03920540 378 379 I-Drug
- NCT03920540 380 381 O
sulfatase NCT03920540 382 391 I-Drug
ERT NCT03920540 392 395 I-Drug

- NCT03920540 398 399 O
History NCT03920540 401 408 B-Eq-Comparison
of NCT03920540 409 411 O
bronchotomy NCT03920540 412 423 B-Procedure
, NCT03920540 424 425 O
bone NCT03920540 426 430 B-Procedure
marrow NCT03920540 431 437 I-Procedure
trasplanation NCT03920540 438 451 I-Procedure
, NCT03920540 452 453 O
or NCT03920540 454 456 B-Or
cord NCT03920540 457 461 B-Procedure
blood NCT03920540 462 467 I-Procedure
transplanation NCT03920540 468 482 I-Procedure
. NCT03920540 482 483 O

- NCT03920540 487 488 O
Known NCT03920540 490 495 O
hypersensitivity NCT03920540 496 512 B-Condition
reactions NCT03920540 513 522 O
to NCT03920540 523 525 O
any NCT03920540 526 529 O
of NCT03920540 530 532 O
the NCT03920540 533 536 O
components NCT03920540 537 547 O
of NCT03920540 548 550 O
the NCT03920540 551 554 O
invetigational NCT03920540 555 569 B-Study
product NCT03920540 570 577 B-Drug

- NCT03920540 580 581 O
Prior NCT03920540 583 588 B-Eq-Comparison
or NCT03920540 589 591 B-Or
planned NCT03920540 592 599 B-Eq-Comparison
administration NCT03920540 600 614 O
of NCT03920540 615 617 O
other NCT03920540 618 623 O
investigational NCT03920540 624 639 B-Study
products NCT03920540 640 648 B-Drug
within NCT03920540 649 655 B-Eq-Comparison
30 NCT03920540 656 658 I-Eq-Comparison
days NCT03920540 659 663 I-Eq-Comparison
before NCT03920540 664 670 B-Temporal-Connection___Temporal-Connection-Type-Value:before
treatment NCT03920540 671 680 B-Procedure
with NCT03920540 681 685 O
the NCT03920540 686 689 O
investigational NCT03920540 690 705 B-Study
product NCT03920540 706 713 B-Drug
in NCT03920540 714 716 O
this NCT03920540 717 721 O
study NCT03920540 722 727 O
or NCT03920540 728 730 O
duirng NCT03920540 731 737 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03920540 738 742 O
study NCT03920540 743 748 B-Study
. NCT03920540 748 749 O

- NCT03920540 753 754 O
Unable NCT03920540 756 762 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03920540 763 765 O
perform NCT03920540 766 773 O
6 NCT03920540 774 775 B-Observation
- NCT03920540 776 777 I-Observation
MWT NCT03920540 778 781 I-Observation
. NCT03920540 781 782 O

- NCT03920540 786 787 O
Female NCT03920540 789 795 O

Inclusion NCT03921138 0 9 O
Criteria NCT03921138 10 18 O
: NCT03921138 19 20 O

- NCT03921138 24 25 O
patients NCT03921138 27 35 O
who NCT03921138 36 39 O
underwent NCT03921138 40 49 B-Eq-Comparison
benign NCT03921138 50 56 B-Modifier
laparoscopic NCT03921138 57 69 B-Procedure
hysterectomy NCT03921138 70 82 I-Procedure
with NCT03921138 83 87 B-And
systematic NCT03921138 88 98 B-Procedure
salpingectomy NCT03921138 99 112 I-Procedure

Exclusion NCT03921138 113 122 O
Criteria NCT03921138 123 131 O
: NCT03921138 132 133 O

- NCT03921138 137 138 O
Hysterectomy NCT03921138 140 152 B-Procedure
in NCT03921138 153 155 O
a NCT03921138 156 157 O
context NCT03921138 158 165 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
of NCT03921138 166 168 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
gynecologic NCT03921138 169 180 B-Condition
cancer NCT03921138 181 187 I-Condition

- NCT03921138 190 191 O
Hysterectomy NCT03921138 193 205 B-Procedure
not NCT03921138 206 209 B-Negation
carried NCT03921138 210 217 O
out NCT03921138 218 221 O
using NCT03921138 222 227 O
laparoscopy NCT03921138 228 239 B-Procedure

- NCT03921138 242 243 O
Fimbriated NCT03921138 245 255 B-Condition
end NCT03921138 256 259 I-Condition
missing NCT03921138 260 267 B-Modifier
or NCT03921138 268 270 B-Or
damaged NCT03921138 271 278 B-Modifier
or NCT03921138 279 281 O
impossible NCT03921138 282 292 O
for NCT03921138 293 296 O
pathologist NCT03921138 297 308 O
to NCT03921138 309 311 O
analyze NCT03921138 312 319 O

Inclusion NCT03928652 0 9 O
Criteria NCT03928652 10 18 O
: NCT03928652 19 20 O

1 NCT03928652 24 25 O
. NCT03928652 25 26 O
Colon NCT03928652 28 33 B-Modifier
or NCT03928652 34 36 B-Or
rectal NCT03928652 37 43 B-Modifier
cancer NCT03928652 44 50 B-Condition
diagnosed NCT03928652 51 60 O
by NCT03928652 61 63 O
endoscopic NCT03928652 64 74 B-Procedure
biopsy NCT03928652 75 81 I-Procedure
histopathology NCT03928652 82 96 I-Procedure
; NCT03928652 96 97 O

2 NCT03928652 100 101 O
. NCT03928652 101 102 O
Complete NCT03928652 104 112 O
sample NCT03928652 113 119 B-Observation
information NCT03928652 120 131 O
, NCT03928652 132 133 O
including NCT03928652 134 143 O
sample NCT03928652 144 150 O
number NCT03928652 151 157 O
, NCT03928652 158 159 O
gender NCT03928652 160 166 O
, NCT03928652 167 168 O
age NCT03928652 169 172 O
and NCT03928652 173 176 O
clinical NCT03928652 177 185 O
molecular NCT03928652 186 195 O
diagnostic NCT03928652 196 206 O
information NCT03928652 207 218 O
, NCT03928652 219 220 O
etc NCT03928652 221 224 O
. NCT03928652 224 225 O
; NCT03928652 226 227 O

3 NCT03928652 230 231 O
. NCT03928652 231 232 O
Sufficient NCT03928652 234 244 O
surgical NCT03928652 245 253 B-Observation
tissue NCT03928652 254 260 I-Observation
samples NCT03928652 261 268 O
are NCT03928652 269 272 O
available NCT03928652 273 282 O
for NCT03928652 283 286 B-Assertion___Assertion-Type-Value:hypothetical
testing NCT03928652 287 294 B-Observation
; NCT03928652 294 295 O

4 NCT03928652 298 299 O
. NCT03928652 299 300 O
untreated NCT03928652 302 311 B-Modifier
colon NCT03928652 312 317 B-Modifier
or NCT03928652 318 320 B-Or
rectal NCT03928652 321 327 B-Modifier
cancer NCT03928652 328 334 B-Condition
patients NCT03928652 335 343 O
; NCT03928652 343 344 O

5 NCT03928652 347 348 O
. NCT03928652 348 349 O
Patient NCT03928652 351 358 O
able NCT03928652 359 363 O
to NCT03928652 364 366 O
understand NCT03928652 367 377 O
and NCT03928652 378 381 O
sign NCT03928652 382 386 O
written NCT03928652 387 394 O
informed NCT03928652 395 403 O
consent NCT03928652 404 411 O

6 NCT03928652 414 415 O
. NCT03928652 415 416 O
No NCT03928652 418 420 B-Negation
evidence NCT03928652 421 429 O
of NCT03928652 430 432 O
distant NCT03928652 433 440 B-Condition
metastasis NCT03928652 441 451 I-Condition
( NCT03928652 452 453 O
M0 NCT03928652 454 456 O
) NCT03928652 457 458 O

Exclusion NCT03928652 460 469 O
Criteria NCT03928652 470 478 O
: NCT03928652 479 480 O

1 NCT03928652 484 485 O
. NCT03928652 485 486 O
Previously NCT03928652 488 498 B-Eq-Comparison
treated NCT03928652 499 506 B-Procedure
CRC NCT03928652 507 510 B-Condition
, NCT03928652 511 512 O
including NCT03928652 513 522 O
cytotoxic NCT03928652 523 532 B-Drug
drug NCT03928652 533 537 I-Drug
therapy NCT03928652 538 545 I-Drug
, NCT03928652 546 547 O
targeted NCT03928652 548 556 B-Procedure
drug NCT03928652 557 561 I-Procedure
therapy NCT03928652 562 569 I-Procedure
, NCT03928652 570 571 O
etc NCT03928652 572 575 O
. NCT03928652 575 576 O
; NCT03928652 577 578 O

2 NCT03928652 581 582 O
. NCT03928652 582 583 O
Other NCT03928652 585 590 O
malignant NCT03928652 591 600 B-Condition
tumors NCT03928652 601 607 I-Condition
; NCT03928652 607 608 O

3 NCT03928652 611 612 O
. NCT03928652 612 613 O
Pregnant NCT03928652 615 623 B-Condition
women NCT03928652 624 629 O
; NCT03928652 629 630 O

4 NCT03928652 633 634 O
. NCT03928652 634 635 O
Hereditary NCT03928652 637 647 B-Family-Member
colorectal NCT03928652 648 658 B-Condition
cancer NCT03928652 659 665 I-Condition
linked NCT03928652 666 672 O
to NCT03928652 673 675 O
familial NCT03928652 676 684 B-Condition
colonic NCT03928652 685 692 I-Condition
polyposis NCT03928652 693 702 I-Condition
or NCT03928652 703 705 B-Or
Lynch NCT03928652 706 711 B-Condition
syndrome NCT03928652 712 720 I-Condition

Inclusion NCT03925376 0 9 O
Criteria NCT03925376 10 18 O
: NCT03925376 19 20 O

- NCT03925376 24 25 O
Patients NCT03925376 27 35 O
undergoing NCT03925376 36 46 B-Eq-Comparison
redo NCT03925376 47 51 O
cardiac NCT03925376 52 59 B-Procedure
surgery NCT03925376 60 67 I-Procedure

Exclusion NCT03925376 68 77 O
Criteria NCT03925376 78 86 O
: NCT03925376 87 88 O

- NCT03925376 92 93 O
Age NCT03925376 95 98 B-Age
< NCT03925376 99 100 B-Eq-Comparison
18 NCT03925376 101 103 I-Eq-Comparison
years NCT03925376 104 109 I-Eq-Comparison
; NCT03925376 109 110 O

- NCT03925376 113 114 O
Patients NCT03925376 116 124 O
with NCT03925376 125 129 O
a NCT03925376 130 131 O
DNR NCT03925376 132 135 B-Observation
order NCT03925376 136 141 I-Observation
or NCT03925376 142 144 B-Or
" NCT03925376 145 146 B-Observation
do NCT03925376 146 148 O
not NCT03925376 149 152 I-Observation
escalate NCT03925376 153 161 I-Observation
care NCT03925376 162 166 I-Observation
" NCT03925376 166 167 O
order NCT03925376 168 173 I-Observation
. NCT03925376 173 174 O

Inclusion NCT03923075 0 9 O
Criteria NCT03923075 10 18 O
: NCT03923075 19 20 O

- NCT03923075 24 25 O
children NCT03923075 27 35 O
underoing NCT03923075 36 45 B-Eq-Comparison
elective NCT03923075 46 54 O
surgery NCT03923075 55 62 B-Procedure
under NCT03923075 63 68 O
general NCT03923075 69 76 B-Procedure
anaesthsia NCT03923075 77 87 I-Procedure

- NCT03923075 90 91 O
age NCT03923075 93 96 B-Age
4 NCT03923075 97 98 B-Eq-Comparison
- NCT03923075 99 100 I-Eq-Comparison
12 NCT03923075 101 103 I-Eq-Comparison
years NCT03923075 104 109 I-Eq-Comparison
old NCT03923075 110 113 O

- NCT03923075 116 117 O
ASA NCT03923075 119 122 B-Condition
I NCT03923075 123 124 B-Eq-Comparison
- NCT03923075 125 126 I-Eq-Comparison
II NCT03923075 127 129 I-Eq-Comparison

Exclusion NCT03923075 130 139 O
Criteria NCT03923075 140 148 O
: NCT03923075 149 150 O

- NCT03923075 154 155 O
patient NCT03923075 157 164 O
or NCT03923075 165 167 O
parent NCT03923075 168 174 O
refusal NCT03923075 175 182 O

- NCT03923075 185 186 O
Mallampati NCT03923075 188 198 B-Observation
score NCT03923075 199 204 I-Observation
> NCT03923075 205 206 B-Eq-Comparison
3 NCT03923075 207 208 I-Eq-Comparison

- NCT03923075 212 213 O
BMI NCT03923075 215 218 B-Observation
> NCT03923075 219 220 B-Eq-Comparison
35 NCT03923075 221 223 I-Eq-Comparison

- NCT03923075 227 228 O
severe NCT03923075 230 236 O
systemic NCT03923075 237 245 B-Modifier
cardiac NCT03923075 246 253 B-Condition
disease NCT03923075 254 261 I-Condition

- NCT03923075 264 265 O
neuromuscular NCT03923075 267 280 B-Condition
disease NCT03923075 281 288 I-Condition

- NCT03923075 291 292 O
recent NCT03923075 294 300 B-Eq-Comparison
respiratory NCT03923075 301 312 B-Condition
infection NCT03923075 313 322 I-Condition

- NCT03923075 325 326 O
drug NCT03923075 328 332 B-Drug
allergy NCT03923075 333 340 B-Allergy

Inclusion NCT03929809 0 9 O
Criteria NCT03929809 10 18 O
: NCT03929809 19 20 O

1 NCT03929809 24 25 O
. NCT03929809 25 26 O
Participants NCT03929809 28 40 O
will NCT03929809 41 45 O
be NCT03929809 46 48 O
adults NCT03929809 49 55 O
who NCT03929809 56 59 B-And
utilize NCT03929809 60 67 O
English NCT03929809 68 75 O
as NCT03929809 76 78 O
their NCT03929809 79 84 O
primary NCT03929809 85 92 O
language NCT03929809 93 101 O
. NCT03929809 101 102 O

2 NCT03929809 106 107 O
. NCT03929809 107 108 O
Unilateral NCT03929809 110 120 O
severe NCT03929809 121 127 O
to NCT03929809 128 130 O
profound NCT03929809 131 139 B-Condition
sensorineural NCT03929809 140 153 I-Condition
hearing NCT03929809 154 161 I-Condition
loss NCT03929809 162 166 I-Condition
for NCT03929809 167 170 O
a NCT03929809 171 172 O
duration NCT03929809 173 181 O
of NCT03929809 182 184 O
at NCT03929809 185 187 B-Eq-Comparison
least NCT03929809 188 193 I-Eq-Comparison
6 NCT03929809 194 195 I-Eq-Comparison
months NCT03929809 196 202 I-Eq-Comparison
( NCT03929809 203 204 O
to NCT03929809 205 207 B-Assertion___Assertion-Type-Value:hypothetical
ensure NCT03929809 208 214 I-Assertion___Assertion-Type-Value:hypothetical
stability NCT03929809 215 224 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03929809 225 227 O
hearing NCT03929809 228 235 B-Condition
loss NCT03929809 236 240 I-Condition
) NCT03929809 241 242 O
, NCT03929809 244 245 O
but NCT03929809 246 249 O
no NCT03929809 250 252 B-Eq-Comparison|Negation
greater NCT03929809 253 260 I-Eq-Comparison
than NCT03929809 261 265 I-Eq-Comparison
10 NCT03929809 266 268 I-Eq-Comparison
years NCT03929809 269 274 I-Eq-Comparison
. NCT03929809 274 275 O

3 NCT03929809 279 280 O
. NCT03929809 280 281 O
Contralateral NCT03929809 283 296 B-Condition
ear NCT03929809 297 300 I-Condition
with NCT03929809 301 305 B-And
normal NCT03929809 306 312 O
, NCT03929809 313 314 O
or NCT03929809 315 317 B-Or
near NCT03929809 318 322 O
- NCT03929809 323 324 O
normal NCT03929809 325 331 O
, NCT03929809 332 333 O
hearing NCT03929809 334 341 B-Condition
. NCT03929809 341 342 O

4 NCT03929809 346 347 O
. NCT03929809 347 348 O
Poorer NCT03929809 350 356 B-Condition
ear NCT03929809 357 360 I-Condition|Modifier
( NCT03929809 361 362 O
ear NCT03929809 363 366 O
to NCT03929809 367 369 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929809 370 372 I-Assertion___Assertion-Type-Value:hypothetical
implanted NCT03929809 373 382 B-Procedure
) NCT03929809 383 384 O
: NCT03929809 386 387 O
severe NCT03929809 388 394 O
to NCT03929809 395 397 O
profound NCT03929809 398 406 B-Condition
sensorineural NCT03929809 407 420 I-Condition
hearing NCT03929809 421 428 I-Condition
loss NCT03929809 429 433 I-Condition
, NCT03929809 434 435 O
defined NCT03929809 436 443 O
as NCT03929809 444 446 O
pure NCT03929809 447 451 B-Observation
- NCT03929809 452 453 I-Observation
tone NCT03929809 454 458 I-Observation
thresholds NCT03929809 459 469 I-Observation
70 NCT03929809 470 472 B-Eq-Comparison
dB NCT03929809 473 475 I-Eq-Comparison
HL NCT03929809 476 478 I-Eq-Comparison
or NCT03929809 479 481 I-Eq-Comparison
greater NCT03929809 482 489 I-Eq-Comparison
for NCT03929809 490 493 O
the NCT03929809 494 497 O
frequencies NCT03929809 498 509 O
500 NCT03929809 510 513 O
, NCT03929809 514 515 O
1000 NCT03929809 516 520 O
, NCT03929809 521 522 O

2000 NCT03929809 530 534 O
, NCT03929809 535 536 O
3000 NCT03929809 537 541 O
, NCT03929809 542 543 O
and NCT03929809 544 547 O
4000 NCT03929809 548 552 O
Hz NCT03929809 553 555 O
with NCT03929809 556 560 B-And
monosyllabic NCT03929809 561 573 B-Condition
word NCT03929809 574 578 I-Condition
understanding NCT03929809 579 592 I-Condition
, NCT03929809 593 594 O
as NCT03929809 595 597 O
measured NCT03929809 598 606 O
using NCT03929809 607 612 B-Eq-Comparison
the NCT03929809 613 616 O
CNC NCT03929809 617 620 B-Observation
Word NCT03929809 621 625 I-Observation
Test NCT03929809 626 630 I-Observation
at NCT03929809 631 633 O
60 NCT03929809 634 636 B-Eq-Comparison
dBA NCT03929809 637 640 I-Eq-Comparison
under NCT03929809 641 646 O
earphones NCT03929809 647 656 O
, NCT03929809 657 658 O
less NCT03929809 659 663 B-Eq-Comparison
than NCT03929809 664 668 I-Eq-Comparison
or NCT03929809 669 671 I-Eq-Comparison
equal NCT03929809 672 677 I-Eq-Comparison
to NCT03929809 678 680 I-Eq-Comparison
20 NCT03929809 681 683 I-Eq-Comparison
% NCT03929809 684 685 O

5 NCT03929809 688 689 O
. NCT03929809 689 690 O
Better NCT03929809 692 698 B-Condition
ear NCT03929809 699 702 I-Condition|Condition
( NCT03929809 703 704 O
contralateral NCT03929809 705 718 B-Condition
ear NCT03929809 719 722 O
) NCT03929809 723 724 O
: NCT03929809 726 727 O
normal NCT03929809 728 734 O
or NCT03929809 735 737 B-Or
near NCT03929809 738 742 O
- NCT03929809 743 744 I-Observation
normal NCT03929809 745 751 O
hearing NCT03929809 752 759 B-Condition
defined NCT03929809 760 767 O
as NCT03929809 768 770 O
pure NCT03929809 771 775 B-Observation
- NCT03929809 776 777 O
tone NCT03929809 778 782 I-Observation
thresholds NCT03929809 783 793 I-Observation
no NCT03929809 794 796 B-Negation
poorer NCT03929809 797 803 B-Eq-Comparison
than NCT03929809 804 808 I-Eq-Comparison
30 NCT03929809 809 811 I-Eq-Comparison
dB NCT03929809 812 814 I-Eq-Comparison
HL NCT03929809 815 817 I-Eq-Comparison
at NCT03929809 818 820 O
250 NCT03929809 821 824 O
, NCT03929809 825 826 O
500 NCT03929809 827 830 O
, NCT03929809 831 832 O
1000 NCT03929809 833 837 O
, NCT03929809 838 839 O
2000 NCT03929809 840 844 O
, NCT03929809 845 846 O
and NCT03929809 847 850 B-And
3000 NCT03929809 851 855 O
Hz NCT03929809 856 858 O
and NCT03929809 859 862 O
no NCT03929809 863 865 B-Negation
poorer NCT03929809 866 872 B-Eq-Comparison
than NCT03929809 873 877 I-Eq-Comparison
40 NCT03929809 878 880 I-Eq-Comparison
dB NCT03929809 881 883 I-Eq-Comparison
HL NCT03929809 884 886 I-Eq-Comparison
at NCT03929809 887 889 O
4000 NCT03929809 890 894 O
Hz NCT03929809 895 897 O
with NCT03929809 898 902 B-And
monosyllabic NCT03929809 903 915 B-Condition
word NCT03929809 916 920 I-Condition
understanding NCT03929809 921 934 I-Condition
, NCT03929809 935 936 O
as NCT03929809 937 939 O
measured NCT03929809 940 948 O
using NCT03929809 949 954 B-Eq-Comparison
the NCT03929809 955 958 O
CNC NCT03929809 959 962 B-Observation
Word NCT03929809 963 967 I-Observation
Test NCT03929809 968 972 I-Observation
at NCT03929809 973 975 O
60 NCT03929809 976 978 B-Eq-Comparison
dBA NCT03929809 979 982 I-Eq-Comparison
under NCT03929809 983 988 O
earphones NCT03929809 989 998 O
, NCT03929809 999 1000 O
of NCT03929809 1001 1003 O
greater NCT03929809 1004 1011 B-Eq-Comparison
than NCT03929809 1012 1016 I-Eq-Comparison
or NCT03929809 1017 1019 I-Eq-Comparison
equal NCT03929809 1020 1025 I-Eq-Comparison
to NCT03929809 1026 1028 I-Eq-Comparison
85 NCT03929809 1029 1031 I-Eq-Comparison
% NCT03929809 1032 1033 O
. NCT03929809 1033 1034 O

6 NCT03929809 1038 1039 O
. NCT03929809 1039 1040 O
Willingness NCT03929809 1042 1053 O
to NCT03929809 1054 1056 O
comply NCT03929809 1057 1063 O
with NCT03929809 1064 1068 O
all NCT03929809 1069 1072 O
study NCT03929809 1073 1078 O
requirements NCT03929809 1079 1091 O
. NCT03929809 1091 1092 O

7 NCT03929809 1096 1097 O
. NCT03929809 1097 1098 O
Patent NCT03929809 1100 1106 B-Condition
cochlea NCT03929809 1107 1114 I-Condition|Condition
and NCT03929809 1115 1118 B-And
normal NCT03929809 1119 1125 O
cochlear NCT03929809 1126 1134 O
anatomy NCT03929809 1135 1142 I-Condition
. NCT03929809 1142 1143 O

Exclusion NCT03929809 1145 1154 O
Criteria NCT03929809 1155 1163 O
: NCT03929809 1164 1165 O

1 NCT03929809 1169 1170 O
. NCT03929809 1170 1171 O
Medical NCT03929809 1173 1180 B-Modifier
or NCT03929809 1181 1183 B-Or
psychological NCT03929809 1184 1197 B-Modifier
conditions NCT03929809 1198 1208 B-Condition
that NCT03929809 1209 1213 O
contraindicate NCT03929809 1214 1228 B-Contraindication
undergoing NCT03929809 1229 1239 B-Eq-Comparison
surgery NCT03929809 1240 1247 B-Procedure
. NCT03929809 1247 1248 O

2 NCT03929809 1252 1253 O
. NCT03929809 1253 1254 O
Ossification NCT03929809 1256 1268 B-Condition
or NCT03929809 1269 1271 B-Or
any NCT03929809 1272 1275 O
other NCT03929809 1276 1281 O
cochlear NCT03929809 1282 1290 B-Condition
anomaly NCT03929809 1291 1298 I-Condition
that NCT03929809 1299 1303 O
might NCT03929809 1304 1309 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03929809 1310 1317 B-Negation
complete NCT03929809 1318 1326 O
insertion NCT03929809 1327 1336 B-Procedure
of NCT03929809 1337 1339 I-Procedure
the NCT03929809 1340 1343 I-Procedure
electrode NCT03929809 1344 1353 I-Procedure
array NCT03929809 1354 1359 I-Procedure
. NCT03929809 1359 1360 O

3 NCT03929809 1364 1365 O
. NCT03929809 1365 1366 O
Unrealistic NCT03929809 1368 1379 O
expectations NCT03929809 1380 1392 B-Assertion___Assertion-Type-Value:hypothetical
on NCT03929809 1393 1395 O
the NCT03929809 1396 1399 O
part NCT03929809 1400 1404 O
of NCT03929809 1405 1407 O
the NCT03929809 1408 1411 O
candidate NCT03929809 1412 1421 O
and NCT03929809 1422 1425 O
/ NCT03929809 1426 1427 O
or NCT03929809 1428 1430 O
candidate NCT03929809 1431 1440 O
's NCT03929809 1440 1442 O
family NCT03929809 1443 1449 O
, NCT03929809 1450 1451 O
regarding NCT03929809 1452 1461 O
the NCT03929809 1462 1465 O
possible NCT03929809 1466 1474 O
benefits NCT03929809 1475 1483 O
, NCT03929809 1484 1485 O
risks NCT03929809 1486 1491 O
, NCT03929809 1492 1493 O
and NCT03929809 1494 1497 B-Or
limitations NCT03929809 1498 1509 O
that NCT03929809 1510 1514 O
are NCT03929809 1515 1518 O
inherent NCT03929809 1519 1527 O
to NCT03929809 1528 1530 O
the NCT03929809 1531 1534 O
surgical NCT03929809 1535 1543 B-Procedure
procedure NCT03929809 1544 1553 I-Procedure
( NCT03929809 1554 1555 O
s NCT03929809 1556 1557 O
) NCT03929809 1558 1559 O
and NCT03929809 1560 1563 O
prosthetic NCT03929809 1564 1574 B-Condition
devices NCT03929809 1575 1582 I-Condition
. NCT03929809 1582 1583 O

4 NCT03929809 1587 1588 O
. NCT03929809 1588 1589 O
Unwillingness NCT03929809 1591 1604 O
or NCT03929809 1605 1607 O
inability NCT03929809 1608 1617 O
of NCT03929809 1618 1620 O
the NCT03929809 1621 1624 O
candidate NCT03929809 1625 1634 O
to NCT03929809 1635 1637 O
comply NCT03929809 1638 1644 O
with NCT03929809 1645 1649 O
all NCT03929809 1650 1653 O
investigational NCT03929809 1654 1669 O
requirements NCT03929809 1670 1682 O
. NCT03929809 1682 1683 O

5 NCT03929809 1687 1688 O
. NCT03929809 1688 1689 O
Active NCT03929809 1691 1697 B-Eq-Comparison
middle NCT03929809 1698 1704 B-Modifier
ear NCT03929809 1705 1708 I-Modifier
infection NCT03929809 1709 1718 B-Condition
. NCT03929809 1718 1719 O

6 NCT03929809 1723 1724 O
. NCT03929809 1724 1725 O
Tinnitus NCT03929809 1727 1735 B-Condition
primary NCT03929809 1736 1743 O
motivation NCT03929809 1744 1754 O
for NCT03929809 1755 1758 O
implantation NCT03929809 1759 1771 B-Procedure
. NCT03929809 1771 1772 O

Inclusion NCT03924336 0 9 O
Criteria NCT03924336 10 18 O
: NCT03924336 19 20 O

- NCT03924336 24 25 O
Stage NCT03924336 27 32 B-Eq-Comparison
III NCT03924336 33 36 I-Eq-Comparison
periodontitis NCT03924336 37 50 B-Condition
patient NCT03924336 51 58 O
having NCT03924336 59 65 B-And
at NCT03924336 66 68 B-Eq-Comparison
least NCT03924336 69 74 I-Eq-Comparison
one NCT03924336 75 78 I-Eq-Comparison
tooth NCT03924336 79 84 I-Eq-Comparison
with NCT03924336 85 89 O
2 NCT03924336 90 91 B-Modifier
- NCT03924336 92 93 I-Modifier
wall NCT03924336 94 98 I-Modifier
, NCT03924336 99 100 O
3 NCT03924336 101 102 B-Modifier
- NCT03924336 103 104 I-Modifier
wall NCT03924336 105 109 I-Modifier
, NCT03924336 110 111 O
or NCT03924336 112 114 B-Or
combined NCT03924336 115 123 O
2 NCT03924336 124 125 B-Modifier
- NCT03924336 126 127 I-Modifier
to NCT03924336 128 130 I-Modifier
3 NCT03924336 131 132 I-Modifier
- NCT03924336 133 134 O
wall NCT03924336 135 139 I-Modifier
intraosseous NCT03924336 140 152 B-Observation
defect NCT03924336 153 159 I-Observation
≥ NCT03924336 160 161 B-Eq-Comparison
3 NCT03924336 162 163 I-Eq-Comparison
mm NCT03924336 164 166 I-Eq-Comparison
in NCT03924336 167 169 O
depth NCT03924336 170 175 O
( NCT03924336 176 177 O
assessed NCT03924336 178 186 O
by NCT03924336 187 189 O
bone NCT03924336 190 194 B-Procedure
sounding NCT03924336 195 203 I-Procedure
, NCT03924336 204 205 O
radiographic NCT03924336 206 218 B-Procedure
examination NCT03924336 219 230 I-Procedure
) NCT03924336 231 232 O
with NCT03924336 233 237 B-And
clinical NCT03924336 238 246 B-Observation
attachment NCT03924336 247 257 I-Observation
level NCT03924336 258 263 I-Observation
( NCT03924336 264 265 O
CAL NCT03924336 266 269 B-Observation
) NCT03924336 270 271 O
≥ NCT03924336 272 273 B-Eq-Comparison
5 NCT03924336 274 275 I-Eq-Comparison
mm NCT03924336 276 278 O
and NCT03924336 279 282 B-And
pocket NCT03924336 283 289 B-Observation
depth NCT03924336 290 295 I-Observation
( NCT03924336 296 297 O
PD NCT03924336 298 300 B-Observation
) NCT03924336 301 302 O
≥ NCT03924336 303 304 B-Eq-Comparison
6 NCT03924336 305 306 I-Eq-Comparison
mm NCT03924336 307 309 I-Eq-Comparison
. NCT03924336 309 310 O

- NCT03924336 314 315 O
Defect NCT03924336 317 323 B-Condition
not NCT03924336 324 327 B-Negation
extending NCT03924336 328 337 O
to NCT03924336 338 340 O
a NCT03924336 341 342 O
root NCT03924336 343 347 B-Modifier
furcation NCT03924336 348 357 I-Modifier
area NCT03924336 358 362 I-Modifier

- NCT03924336 365 366 O
Vital NCT03924336 368 373 O
teeth NCT03924336 374 379 O

- NCT03924336 382 383 O
Non NCT03924336 385 388 B-Negation|Negation
- NCT03924336 389 390 O
smokers NCT03924336 391 398 B-Condition
. NCT03924336 398 399 O

- NCT03924336 403 404 O
No NCT03924336 406 408 O
history NCT03924336 409 416 B-Eq-Comparison
of NCT03924336 417 419 O
intake NCT03924336 420 426 O
of NCT03924336 427 429 O
antibiotics NCT03924336 430 441 B-Drug
or NCT03924336 442 444 B-Or
other NCT03924336 445 450 O
medications NCT03924336 451 462 B-Drug
affecting NCT03924336 463 472 O
the NCT03924336 473 476 O
periodontium NCT03924336 477 489 B-Condition
in NCT03924336 490 492 O
the NCT03924336 493 496 O
previous NCT03924336 497 505 B-Eq-Comparison
6 NCT03924336 506 507 I-Eq-Comparison
months NCT03924336 508 514 I-Eq-Comparison
. NCT03924336 514 515 O

- NCT03924336 519 520 O
No NCT03924336 522 524 B-Negation
periodontal NCT03924336 525 536 B-Procedure
therapy NCT03924336 537 544 I-Procedure
carried NCT03924336 545 552 O
out NCT03924336 553 556 O
in NCT03924336 557 559 O
the NCT03924336 560 563 O
past NCT03924336 564 568 B-Eq-Comparison
6 NCT03924336 569 570 I-Eq-Comparison
months NCT03924336 571 577 I-Eq-Comparison
. NCT03924336 577 578 O

- NCT03924336 582 583 O
Able NCT03924336 585 589 O
to NCT03924336 590 592 O
sign NCT03924336 593 597 O
an NCT03924336 598 600 O
informed NCT03924336 601 609 O
consent NCT03924336 610 617 O
form NCT03924336 618 622 O
. NCT03924336 622 623 O

- NCT03924336 627 628 O
Patients NCT03924336 630 638 O
age NCT03924336 639 642 B-Age
between NCT03924336 643 650 B-Eq-Comparison
25 NCT03924336 651 653 I-Eq-Comparison
and NCT03924336 654 657 I-Eq-Comparison
50 NCT03924336 658 660 I-Eq-Comparison
years NCT03924336 661 666 I-Eq-Comparison
old NCT03924336 667 670 O
. NCT03924336 670 671 O

- NCT03924336 675 676 O
Patients NCT03924336 678 686 O
who NCT03924336 687 690 O
are NCT03924336 691 694 O
cooperative NCT03924336 695 706 O
, NCT03924336 707 708 O
motivated NCT03924336 709 718 O
, NCT03924336 719 720 O
and NCT03924336 721 724 O
hygiene NCT03924336 725 732 O
conscious NCT03924336 733 742 O
. NCT03924336 742 743 O

- NCT03924336 747 748 O
Systemically NCT03924336 750 762 O
free NCT03924336 763 767 O
according NCT03924336 768 777 O
to NCT03924336 778 780 O
Cornell NCT03924336 781 788 O
Medical NCT03924336 789 796 O
Index NCT03924336 797 802 O
( NCT03924336 803 804 O
Broadbent NCT03924336 805 814 O
, NCT03924336 815 816 O
1951 NCT03924336 817 821 O
) NCT03924336 822 823 O
. NCT03924336 824 825 O

Exclusion NCT03924336 827 836 O
Criteria NCT03924336 837 845 O
: NCT03924336 846 847 O

- NCT03924336 851 852 O
Pregnancy NCT03924336 854 863 B-Condition
or NCT03924336 864 866 B-Or
breast NCT03924336 867 873 B-Condition
feeding NCT03924336 874 881 I-Condition

- NCT03924336 884 885 O
The NCT03924336 887 890 O
presence NCT03924336 891 899 O
of NCT03924336 900 902 O
an NCT03924336 903 905 O
orthodontic NCT03924336 906 917 B-Condition
appliance NCT03924336 918 927 I-Condition

- NCT03924336 930 931 O
Teeth NCT03924336 933 938 B-Condition
mobility NCT03924336 939 947 I-Condition
greater NCT03924336 948 955 B-Eq-Comparison
than NCT03924336 956 960 I-Eq-Comparison
grade NCT03924336 961 966 I-Eq-Comparison
I NCT03924336 967 968 I-Eq-Comparison

Inclusion NCT03920150 0 9 O
Criteria NCT03920150 10 18 O
: NCT03920150 19 20 O

- NCT03920150 24 25 O
vitamin NCT03920150 27 34 B-Condition
D NCT03920150 35 36 I-Condition
deficiency NCT03920150 37 47 I-Condition
by NCT03920150 48 50 O
serum NCT03920150 51 56 B-Observation
level NCT03920150 57 62 I-Observation
< NCT03920150 63 64 B-Eq-Comparison
50 NCT03920150 65 67 I-Eq-Comparison
nmol NCT03920150 68 72 I-Eq-Comparison
/ NCT03920150 73 74 I-Eq-Comparison
l NCT03920150 75 76 I-Eq-Comparison

Exclusion NCT03920150 77 86 O
Criteria NCT03920150 87 95 O
: NCT03920150 96 97 O

- NCT03920150 101 102 O
hypercalcaemia NCT03920150 104 118 B-Condition

Inclusion NCT03922009 0 9 O
Criteria NCT03922009 10 18 O
: NCT03922009 19 20 O

1 NCT03922009 24 25 O
. NCT03922009 25 26 O
population NCT03922009 28 38 O
: NCT03922009 39 40 O
acceptance NCT03922009 41 51 O
of NCT03922009 52 54 O
lower NCT03922009 55 60 B-Condition
extremity NCT03922009 61 70 I-Condition
fractures NCT03922009 71 80 I-Condition
in NCT03922009 81 83 O
patients NCT03922009 84 92 O
with NCT03922009 93 97 B-And
spinal NCT03922009 98 104 B-Procedure
anesthesia NCT03922009 105 115 I-Procedure
. NCT03922009 115 116 O

2 NCT03922009 120 121 O
. NCT03922009 121 122 O
Anesthesia NCT03922009 124 134 B-Condition
classification NCT03922009 135 149 I-Condition
( NCT03922009 150 151 O
ASA NCT03922009 152 155 B-Condition
) NCT03922009 156 157 O
: NCT03922009 159 160 O
I NCT03922009 161 162 B-Eq-Comparison
- NCT03922009 163 164 I-Eq-Comparison
III NCT03922009 165 168 I-Eq-Comparison
. NCT03922009 168 169 O

3 NCT03922009 173 174 O
. NCT03922009 174 175 O
Age NCT03922009 177 180 B-Age
: NCT03922009 181 182 O
20 NCT03922009 183 185 B-Eq-Comparison
years NCT03922009 186 191 I-Eq-Comparison
old NCT03922009 192 195 I-Eq-Comparison
to NCT03922009 196 198 I-Eq-Comparison
70 NCT03922009 199 201 I-Eq-Comparison
years NCT03922009 202 207 O
of NCT03922009 208 210 O
age NCT03922009 211 214 O
. NCT03922009 214 215 O

Exclusion NCT03922009 217 226 O
Criteria NCT03922009 227 235 O
: NCT03922009 236 237 O

1 NCT03922009 241 242 O
. NCT03922009 242 243 O
Mental NCT03922009 245 251 B-Condition
illness NCT03922009 252 259 I-Condition
and NCT03922009 260 263 B-And
taking NCT03922009 264 270 B-Eq-Comparison
related NCT03922009 271 278 O
drugs NCT03922009 279 284 B-Drug
. NCT03922009 284 285 O

2 NCT03922009 289 290 O
. NCT03922009 290 291 O
Visually NCT03922009 293 301 B-Condition
impaired NCT03922009 302 310 I-Condition|Condition
and NCT03922009 311 314 B-And
hearing NCT03922009 315 322 B-Condition
impaired NCT03922009 323 331 O
. NCT03922009 331 332 O

3 NCT03922009 336 337 O
. NCT03922009 337 338 O
Being NCT03922009 340 345 O
unable NCT03922009 346 352 B-Condition
to NCT03922009 353 355 I-Condition
communicate NCT03922009 356 367 I-Condition
or NCT03922009 368 370 B-Or
illiterate NCT03922009 371 381 B-Condition
. NCT03922009 381 382 O

4 NCT03922009 386 387 O
. NCT03922009 387 388 O
The NCT03922009 390 393 O
condition NCT03922009 394 403 B-Condition
changes NCT03922009 404 411 O
or NCT03922009 412 414 B-Or
is NCT03922009 415 417 O
critical NCT03922009 418 426 O
, NCT03922009 427 428 O
and NCT03922009 429 432 B-And
the NCT03922009 433 436 O
intensive NCT03922009 437 446 O
care NCT03922009 447 451 O
unit NCT03922009 452 456 O
is NCT03922009 457 459 O
admitted NCT03922009 460 468 B-Encounter
after NCT03922009 469 474 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03922009 475 478 O
operation NCT03922009 479 488 B-Procedure
. NCT03922009 488 489 O

5 NCT03922009 493 494 O
. NCT03922009 494 495 O
Contact NCT03922009 497 504 O
isolation NCT03922009 505 514 O
. NCT03922009 514 515 O

6 NCT03922009 519 520 O
. NCT03922009 520 521 O
Trauma NCT03922009 523 529 B-Condition
of NCT03922009 530 532 O
the NCT03922009 533 536 O
head NCT03922009 537 541 B-Modifier|Modifier
and NCT03922009 542 545 B-And
wounds NCT03922009 546 552 B-Condition
on NCT03922009 553 555 O
the NCT03922009 556 559 O
head NCT03922009 560 564 O
. NCT03922009 564 565 O

7 NCT03922009 569 570 O
. NCT03922009 570 571 O
History NCT03922009 573 580 B-Eq-Comparison
of NCT03922009 581 583 O
motion NCT03922009 584 590 B-Condition
sickness NCT03922009 591 599 I-Condition
and NCT03922009 600 603 B-Or
vertigo NCT03922009 604 611 B-Condition
. NCT03922009 611 612 O

Inclusion NCT03925766 0 9 O
Criteria NCT03925766 10 18 O
: NCT03925766 19 20 O

- NCT03925766 24 25 O
Patient NCT03925766 27 34 O
with NCT03925766 35 39 O
altered NCT03925766 40 47 B-Modifier
Roux NCT03925766 48 52 B-Procedure
en NCT03925766 53 55 I-Procedure
Y NCT03925766 56 57 I-Procedure
Gastric NCT03925766 58 65 I-Procedure
Bypass NCT03925766 66 72 I-Procedure
anatomy NCT03925766 73 80 O

Exclusion NCT03925766 81 90 O
Criteria NCT03925766 91 99 O
: NCT03925766 100 101 O

- NCT03925766 105 106 O
Patients NCT03925766 108 116 O
without NCT03925766 117 124 B-Negation
Roux NCT03925766 125 129 B-Procedure
en NCT03925766 130 132 I-Procedure
Y NCT03925766 133 134 I-Procedure
Gastric NCT03925766 135 142 I-Procedure
Bypass NCT03925766 143 149 I-Procedure
anatomy NCT03925766 150 157 O

Inclusion NCT03923465 0 9 O
Criteria NCT03923465 10 18 O
: NCT03923465 19 20 O

- NCT03923465 24 25 O
Systemically NCT03923465 27 39 B-Modifier
healthy NCT03923465 40 47 B-Condition

- NCT03923465 50 51 O
Clinical NCT03923465 53 61 O
diagnosis NCT03923465 62 71 O
of NCT03923465 72 74 O
advanced NCT03923465 75 83 O
periodontitis NCT03923465 84 97 B-Condition

- NCT03923465 100 101 O
Having NCT03923465 103 109 O
one NCT03923465 110 113 B-Eq-Comparison
isolated NCT03923465 114 122 B-Condition
intrabony NCT03923465 123 132 I-Condition
defect NCT03923465 133 139 I-Condition
with NCT03923465 140 144 O
probing NCT03923465 145 152 B-Observation
depth NCT03923465 153 158 I-Observation
( NCT03923465 159 160 O
PD NCT03923465 161 163 B-Observation
) NCT03923465 164 165 O
≥ NCT03923465 166 167 B-Eq-Comparison
7 NCT03923465 168 169 I-Eq-Comparison
mm NCT03923465 170 172 I-Eq-Comparison
, NCT03923465 173 174 O
clinical NCT03923465 175 183 B-Observation
attachment NCT03923465 184 194 I-Observation
level NCT03923465 195 200 I-Observation
( NCT03923465 201 202 O
CAL NCT03923465 203 206 B-Observation
) NCT03923465 207 208 O
≥ NCT03923465 209 210 B-Eq-Comparison
8 NCT03923465 211 212 I-Eq-Comparison
mm NCT03923465 213 215 I-Eq-Comparison
and NCT03923465 216 219 B-And
at NCT03923465 220 222 B-Eq-Comparison
least NCT03923465 223 228 I-Eq-Comparison
4 NCT03923465 229 230 I-Eq-Comparison
mm NCT03923465 231 233 I-Eq-Comparison
intrabony NCT03923465 234 243 B-Observation
component NCT03923465 244 253 I-Observation
involving NCT03923465 254 263 O
predominantly NCT03923465 264 277 O
the NCT03923465 278 281 O
interproximal NCT03923465 282 295 O
area NCT03923465 296 300 O
of NCT03923465 301 303 O
the NCT03923465 304 307 O
affected NCT03923465 308 316 O
tooth NCT03923465 317 322 O
. NCT03923465 322 323 O

- NCT03923465 327 328 I-Observation
Full NCT03923465 330 334 B-Observation
- NCT03923465 335 336 O
mouth NCT03923465 337 342 I-Observation
plaque NCT03923465 343 349 I-Observation
score NCT03923465 350 355 I-Observation
( NCT03923465 356 357 O
FMPS NCT03923465 358 362 B-Observation
) NCT03923465 363 364 O
≤ NCT03923465 365 366 B-Eq-Comparison
20 NCT03923465 367 369 I-Eq-Comparison
% NCT03923465 370 371 O
. NCT03923465 371 372 O

- NCT03923465 376 377 I-Observation
Full NCT03923465 379 383 B-Observation
- NCT03923465 384 385 O
mouth NCT03923465 386 391 I-Observation
bleeding NCT03923465 392 400 I-Observation
score NCT03923465 401 406 I-Observation
( NCT03923465 407 408 O
FMBS NCT03923465 409 413 B-Observation
) NCT03923465 414 415 O
≤ NCT03923465 416 417 B-Eq-Comparison
20 NCT03923465 418 420 I-Eq-Comparison
% NCT03923465 421 422 O
. NCT03923465 422 423 O

Exclusion NCT03923465 425 434 O
Criteria NCT03923465 435 443 O
: NCT03923465 444 445 O

- NCT03923465 449 450 O
Smokers NCT03923465 452 459 O

- NCT03923465 462 463 O
Patients NCT03923465 465 473 O
with NCT03923465 474 478 O
known NCT03923465 479 484 O
systemic NCT03923465 485 493 B-Modifier
diseases NCT03923465 494 502 B-Condition
such NCT03923465 503 507 O
as NCT03923465 508 510 O
diabetes NCT03923465 511 519 B-Condition
and NCT03923465 520 523 B-And
cardiovascular NCT03923465 524 538 B-Condition
diseases NCT03923465 539 547 I-Condition
or NCT03923465 548 550 B-Or
using NCT03923465 551 556 B-Eq-Comparison
medications NCT03923465 557 568 B-Drug
that NCT03923465 569 573 O
affect NCT03923465 574 580 O
periodontal NCT03923465 581 592 B-Condition
tissues NCT03923465 593 600 I-Condition
, NCT03923465 601 602 O
pregnant NCT03923465 603 611 B-Condition
or NCT03923465 612 614 B-Or
lactating NCT03923465 615 624 B-Condition
women NCT03923465 625 630 O

- NCT03923465 633 634 I-Condition
One NCT03923465 636 639 B-Condition
- NCT03923465 640 641 O
wall NCT03923465 642 646 I-Condition
intrabony NCT03923465 647 656 I-Condition
defects NCT03923465 657 664 I-Condition

- NCT03923465 667 668 O
Defects NCT03923465 670 677 B-Condition
that NCT03923465 678 682 O
involve NCT03923465 683 690 O
buccal NCT03923465 691 697 B-Modifier
and NCT03923465 698 701 B-Or
lingual NCT03923465 702 709 B-Modifier
sites NCT03923465 710 715 I-Modifier

- NCT03923465 718 719 O
Presence NCT03923465 721 729 O
of NCT03923465 730 732 O
inadequate NCT03923465 733 743 O
endodontic NCT03923465 744 754 B-Procedure
treatment NCT03923465 755 764 I-Procedure
and NCT03923465 765 768 B-Or
/ NCT03923465 769 770 I-Or
or NCT03923465 771 773 I-Or
restoration NCT03923465 774 785 B-Procedure
in NCT03923465 786 788 I-Procedure
the NCT03923465 789 792 I-Procedure
relevant NCT03923465 793 801 I-Procedure
teeth NCT03923465 802 807 I-Procedure
. NCT03923465 807 808 O

Inclusion NCT03862352 0 9 O
Criteria NCT03862352 10 18 O
: NCT03862352 19 20 O

- NCT03862352 24 25 O
Any NCT03862352 27 30 O
coronary NCT03862352 31 39 B-Procedure
artery NCT03862352 40 46 I-Procedure
perforation NCT03862352 47 58 I-Procedure
during NCT03862352 59 65 B-Temporal-Connection___Temporal-Connection-Type-Value:during
percutaneous NCT03862352 66 78 B-Procedure
coronary NCT03862352 79 87 I-Procedure
intervention NCT03862352 88 100 I-Procedure

Exclusion NCT03862352 101 110 O
Criteria NCT03862352 111 119 O
: NCT03862352 120 121 O

- NCT03862352 125 126 O
Nil NCT03862352 128 131 O

Inclusion NCT03860545 0 9 O
Criteria NCT03860545 10 18 O
: NCT03860545 19 20 O

- NCT03860545 24 25 O
a NCT03860545 27 28 O
planned NCT03860545 29 36 B-Eq-Comparison
operation NCT03860545 37 46 O
of NCT03860545 47 49 O
coronary NCT03860545 50 58 B-Procedure
artery NCT03860545 59 65 I-Procedure
bypass NCT03860545 66 72 I-Procedure
grafting NCT03860545 73 81 I-Procedure
with NCT03860545 82 86 O
the NCT03860545 87 90 O
use NCT03860545 91 94 O
of NCT03860545 95 97 O
cardiopulmonary NCT03860545 98 113 B-Procedure
bypass NCT03860545 114 120 I-Procedure

Exclusion NCT03860545 121 130 O
Criteria NCT03860545 131 139 O
: NCT03860545 140 141 O

- NCT03860545 145 146 O
emergency NCT03860545 148 157 B-Encounter
operations NCT03860545 158 168 B-Procedure
or NCT03860545 169 171 B-Or
re NCT03860545 172 174 B-Procedure
- NCT03860545 175 176 I-Procedure
operations NCT03860545 177 187 I-Procedure
; NCT03860545 187 188 O

- NCT03860545 191 192 O
a NCT03860545 194 195 O
known NCT03860545 196 201 O
pathology NCT03860545 202 211 B-Condition
of NCT03860545 212 214 I-Condition
the NCT03860545 215 218 I-Condition
urinary NCT03860545 219 226 I-Condition
tract NCT03860545 227 232 I-Condition
or NCT03860545 233 235 B-Or
renal NCT03860545 236 241 B-Condition
failure NCT03860545 242 249 I-Condition
; NCT03860545 249 250 O

- NCT03860545 253 254 O
chronic NCT03860545 256 263 B-Modifier
use NCT03860545 264 267 O
of NCT03860545 268 270 O
the NCT03860545 271 274 O
following NCT03860545 275 284 O
medications NCT03860545 285 296 B-Drug
: NCT03860545 297 298 O
iron NCT03860545 299 303 B-Drug
, NCT03860545 304 305 O
non NCT03860545 306 309 B-Drug
- NCT03860545 310 311 I-Drug
steroidal NCT03860545 312 321 I-Drug
anti NCT03860545 322 326 I-Drug
- NCT03860545 327 328 I-Drug
inflammatory NCT03860545 329 341 I-Drug
drugs NCT03860545 342 347 I-Drug
( NCT03860545 348 349 O
NSAIDs NCT03860545 350 356 B-Drug
) NCT03860545 357 358 O
, NCT03860545 360 361 O
immunosuppression NCT03860545 362 379 B-Drug
, NCT03860545 380 381 O
or NCT03860545 382 384 O
steroids NCT03860545 385 393 B-Drug
in NCT03860545 394 396 O
the NCT03860545 397 400 O
pre NCT03860545 401 404 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03860545 405 406 O
- NCT03860545 408 409 O
operative NCT03860545 410 419 B-Procedure
period NCT03860545 420 426 O
; NCT03860545 426 427 O

- NCT03860545 430 431 O
polycythemia NCT03860545 433 445 B-Condition
, NCT03860545 446 447 O
porphyria NCT03860545 448 457 B-Condition
or NCT03860545 458 460 B-Or
pathological NCT03860545 461 473 B-Condition
hemoglobin NCT03860545 474 484 I-Condition
species NCT03860545 485 492 I-Condition
in NCT03860545 493 495 I-Condition
anamnesis NCT03860545 496 505 I-Condition
; NCT03860545 505 506 O

- NCT03860545 509 510 O
pre NCT03860545 512 515 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03860545 516 517 O
- NCT03860545 519 520 O
operative NCT03860545 521 530 B-Procedure
signs NCT03860545 531 536 B-Assertion___Assertion-Type-Value:possible
of NCT03860545 537 539 I-Assertion___Assertion-Type-Value:possible
hepatic NCT03860545 540 547 B-Condition
failure NCT03860545 548 555 I-Condition
; NCT03860545 555 556 O

- NCT03860545 559 560 O
active NCT03860545 562 568 B-Eq-Comparison
autoimmune NCT03860545 569 579 B-Modifier
or NCT03860545 580 582 B-Or
neoplastic NCT03860545 583 593 B-Modifier
diseases NCT03860545 594 602 B-Condition
, NCT03860545 603 604 O
active NCT03860545 605 611 B-Eq-Comparison
infection NCT03860545 612 621 B-Condition
; NCT03860545 621 622 O

- NCT03860545 625 626 O
anticipated NCT03860545 628 639 B-Assertion___Assertion-Type-Value:hypothetical
significant NCT03860545 640 651 O
bleeding NCT03860545 652 660 B-Condition
( NCT03860545 661 662 O
anti NCT03860545 663 667 B-Drug
- NCT03860545 668 669 I-Drug
platelet NCT03860545 670 678 I-Drug
agents NCT03860545 679 685 I-Drug
) NCT03860545 686 687 O
, NCT03860545 689 690 O
suggesting NCT03860545 691 701 B-Assertion___Assertion-Type-Value:possible
the NCT03860545 702 705 O
use NCT03860545 706 709 O
of NCT03860545 710 712 O
blood NCT03860545 713 718 B-Drug
- NCT03860545 719 720 I-Drug
derived NCT03860545 721 728 I-Drug
products NCT03860545 729 737 I-Drug
during NCT03860545 738 744 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860545 745 748 O
operation NCT03860545 749 758 B-Procedure
and NCT03860545 759 762 O
afterward NCT03860545 763 772 O

- NCT03860545 775 776 O
acute NCT03860545 778 783 B-Condition
myocardial NCT03860545 784 794 I-Condition
infarction NCT03860545 795 805 I-Condition
after NCT03860545 806 811 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operation NCT03860545 812 821 B-Procedure

Inclusion NCT03868657 0 9 O
Criteria NCT03868657 10 18 O
: NCT03868657 19 20 O

- NCT03868657 24 25 O
Healthy NCT03868657 27 34 O
men NCT03868657 35 38 O
and NCT03868657 39 42 B-Or
women NCT03868657 43 48 O

- NCT03868657 51 52 O
Age NCT03868657 54 57 B-Age
≥ NCT03868657 58 59 B-Eq-Comparison
20 NCT03868657 60 62 I-Eq-Comparison
and NCT03868657 63 66 I-Eq-Comparison
≤ NCT03868657 67 68 I-Eq-Comparison
40 NCT03868657 69 71 I-Eq-Comparison
years NCT03868657 72 77 I-Eq-Comparison

- NCT03868657 80 81 O
BMI NCT03868657 83 86 B-Observation
≥ NCT03868657 87 88 B-Eq-Comparison
18 NCT03868657 89 91 I-Eq-Comparison
, NCT03868657 92 93 O
5 NCT03868657 94 95 O
and NCT03868657 96 99 I-Eq-Comparison
≤ NCT03868657 100 101 I-Eq-Comparison
27 NCT03868657 102 104 I-Eq-Comparison
, NCT03868657 105 106 O
5 NCT03868657 107 108 O

Exclusion NCT03868657 110 119 O
Criteria NCT03868657 120 128 O
: NCT03868657 129 130 O

- NCT03868657 134 135 O
Chronic NCT03868657 137 144 B-Condition
diseases NCT03868657 145 153 I-Condition
( NCT03868657 154 155 O
cardiac NCT03868657 156 163 B-Modifier
, NCT03868657 164 165 O
metabolic NCT03868657 166 175 B-Modifier
, NCT03868657 176 177 O
liver NCT03868657 178 183 B-Modifier
) NCT03868657 184 185 O
including NCT03868657 186 195 O
a NCT03868657 196 197 O
family NCT03868657 198 204 B-Family-Member
history NCT03868657 205 212 I-Family-Member
of NCT03868657 213 215 O
congenital NCT03868657 216 226 B-Condition
Long NCT03868657 227 231 I-Condition
QT NCT03868657 232 234 I-Condition
syndrome NCT03868657 235 243 I-Condition
. NCT03868657 243 244 O

- NCT03868657 248 249 O
QTc NCT03868657 251 254 B-Observation
values NCT03868657 255 261 O
> NCT03868657 262 263 B-Eq-Comparison|Eq-Comparison
440 NCT03868657 264 267 I-Eq-Comparison
ms NCT03868657 268 270 I-Eq-Comparison|Eq-Comparison
( NCT03868657 271 272 O
men NCT03868657 273 276 O
) NCT03868657 277 278 O
and NCT03868657 279 282 B-And
> NCT03868657 283 284 O
450 NCT03868657 285 288 I-Eq-Comparison
ms NCT03868657 289 291 O
( NCT03868657 292 293 O
women NCT03868657 294 299 O
) NCT03868657 300 301 O

- NCT03868657 305 306 O
Clinical NCT03868657 308 316 B-Modifier
important NCT03868657 317 326 I-Modifier
and NCT03868657 327 330 B-Or
/ NCT03868657 331 332 I-Or
or NCT03868657 333 335 I-Or
symptomatic NCT03868657 336 347 B-Assertion___Assertion-Type-Value:possible
bradycardia NCT03868657 348 359 B-Condition

- NCT03868657 362 363 O
Regular NCT03868657 365 372 B-Eq-Comparison
medication NCT03868657 373 383 B-Drug
( NCT03868657 384 385 O
contraceptive NCT03868657 386 399 B-Drug
pills NCT03868657 400 405 I-Drug
allowed NCT03868657 406 413 B-Exception
) NCT03868657 414 415 O

- NCT03868657 419 420 O
Pregnancy NCT03868657 422 431 B-Condition
and NCT03868657 432 435 B-Or
breastfeeding NCT03868657 436 449 B-Condition

Inclusion NCT03862391 0 9 O
Criteria NCT03862391 10 18 O
: NCT03862391 19 20 O

- NCT03862391 24 25 O
ASA NCT03862391 27 30 B-Condition
physical NCT03862391 31 39 I-Condition
status NCT03862391 40 46 I-Condition
1 NCT03862391 47 48 B-Eq-Comparison
and NCT03862391 49 52 I-Eq-Comparison
2 NCT03862391 53 54 I-Eq-Comparison
, NCT03862391 55 56 O
underwent NCT03862391 57 66 B-Eq-Comparison
gynicological NCT03862391 67 80 B-Procedure
laparotomic NCT03862391 81 92 I-Procedure
surgery NCT03862391 93 100 I-Procedure
under NCT03862391 101 106 O
general NCT03862391 107 114 B-Procedure
anesthesia NCT03862391 115 125 I-Procedure
, NCT03862391 126 127 O
followed NCT03862391 128 136 B-Encounter|Temporal-Connection___Temporal-Connection-Type-Value:after
up NCT03862391 137 139 I-Encounter
in NCT03862391 140 142 O
PACU NCT03862391 143 147 O
( NCT03862391 148 149 O
post NCT03862391 150 154 O
- NCT03862391 155 156 O
- NCT03862391 158 159 O
operative NCT03862391 160 169 O
care NCT03862391 170 174 O
unit NCT03862391 175 179 O
) NCT03862391 180 181 O

Exclusion NCT03862391 183 192 O
Criteria NCT03862391 193 201 O
: NCT03862391 202 203 O

- NCT03862391 207 208 O
ASA NCT03862391 210 213 B-Condition
3 NCT03862391 214 215 B-Eq-Comparison
or NCT03862391 216 218 I-Eq-Comparison
4 NCT03862391 219 220 I-Eq-Comparison
, NCT03862391 221 222 O
mental NCT03862391 223 229 B-Condition
retardation NCT03862391 230 241 I-Condition
, NCT03862391 242 243 O
psychiatric NCT03862391 244 255 B-Condition
disease NCT03862391 256 263 I-Condition
, NCT03862391 264 265 O
history NCT03862391 266 273 B-Eq-Comparison
of NCT03862391 274 276 O
malignant NCT03862391 277 286 B-Condition
hyperthermia NCT03862391 287 299 I-Condition
in NCT03862391 300 302 O
patient NCT03862391 303 310 B-Family-Member___Family-Member-Type:patient
or NCT03862391 311 313 B-Or
her NCT03862391 314 317 O
family NCT03862391 318 324 B-Family-Member
, NCT03862391 325 326 O
neurological NCT03862391 327 339 B-Condition
disease NCT03862391 340 347 I-Condition
, NCT03862391 348 349 O
morbid NCT03862391 350 356 B-Condition
obesity NCT03862391 357 364 I-Condition
, NCT03862391 365 366 O
history NCT03862391 367 374 B-Eq-Comparison
of NCT03862391 375 377 O
asthma NCT03862391 378 384 B-Condition
and NCT03862391 385 388 B-And
follow NCT03862391 389 395 B-Encounter
- NCT03862391 396 397 I-Encounter
up NCT03862391 398 400 I-Encounter
in NCT03862391 401 403 O
the NCT03862391 404 407 O
intensive NCT03862391 408 417 O
care NCT03862391 418 422 O
unit NCT03862391 423 427 O
. NCT03862391 427 428 O

Inclusion NCT03863925 0 9 O
Criteria NCT03863925 10 18 O
: NCT03863925 19 20 O

- NCT03863925 24 25 O
Age NCT03863925 27 30 B-Age
between NCT03863925 31 38 B-Eq-Comparison
20 NCT03863925 39 41 I-Eq-Comparison
years NCT03863925 42 47 I-Eq-Comparison
old NCT03863925 48 51 I-Eq-Comparison
and NCT03863925 52 55 I-Eq-Comparison
65 NCT03863925 56 58 I-Eq-Comparison
years NCT03863925 59 64 I-Eq-Comparison
old NCT03863925 65 68 I-Eq-Comparison

- NCT03863925 71 72 O
Diagnosis NCT03863925 74 83 O
of NCT03863925 84 86 O
major NCT03863925 87 92 B-Modifier
depressive NCT03863925 93 103 B-Condition
disorder NCT03863925 104 112 I-Condition
, NCT03863925 113 114 O
bipolar NCT03863925 115 122 B-Condition
disorder NCT03863925 123 131 I-Condition
, NCT03863925 132 133 O
and NCT03863925 134 137 B-Or
schizophrenia NCT03863925 138 151 B-Condition
, NCT03863925 152 153 O
compatible NCT03863925 154 164 O
with NCT03863925 165 169 O
SCID NCT03863925 170 174 O
for NCT03863925 175 178 O
DSM NCT03863925 179 182 O
- NCT03863925 183 184 O
5 NCT03863925 185 186 O
, NCT03863925 187 188 O
with NCT03863925 189 193 B-And
clinical NCT03863925 194 202 O
necessity NCT03863925 203 212 B-Eq-Comparison
of NCT03863925 213 215 I-Eq-Comparison
ECT NCT03863925 216 219 B-Procedure
under NCT03863925 220 225 O
a NCT03863925 226 227 O
psychiatrist NCT03863925 228 240 O
's NCT03863925 240 242 O
evaluation NCT03863925 243 253 O
and NCT03863925 254 257 O
decision NCT03863925 258 266 O

- NCT03863925 269 270 O
Patients NCT03863925 272 280 O
with NCT03863925 281 285 O
adequate NCT03863925 286 294 B-Condition
visual NCT03863925 295 301 I-Condition
acuity NCT03863925 302 308 I-Condition
and NCT03863925 309 312 B-And
auditory NCT03863925 313 321 B-Condition
acuity NCT03863925 322 328 I-Condition
without NCT03863925 329 336 O
or NCT03863925 337 339 O
with NCT03863925 340 344 O
correction NCT03863925 345 355 O

- NCT03863925 358 359 O
Patients NCT03863925 361 369 O
or NCT03863925 370 372 O
patients NCT03863925 373 381 O
' NCT03863925 381 382 O
legal NCT03863925 383 388 O
representative NCT03863925 389 403 O
signing NCT03863925 404 411 O
up NCT03863925 412 414 O
the NCT03863925 415 418 O
informed NCT03863925 419 427 O
consent NCT03863925 428 435 O

Exclusion NCT03863925 436 445 O
Criteria NCT03863925 446 454 O
: NCT03863925 455 456 O

- NCT03863925 460 461 O
Patients NCT03863925 463 471 O
already NCT03863925 472 479 O
diagnosed NCT03863925 480 489 O
with NCT03863925 490 494 O
neurocognitive NCT03863925 495 509 B-Condition
disorder NCT03863925 510 518 I-Condition

- NCT03863925 521 522 O
Patients NCT03863925 524 532 O
with NCT03863925 533 537 O
contraindications NCT03863925 538 555 B-Contraindication
to NCT03863925 556 558 O
ECT NCT03863925 559 562 B-Procedure
, NCT03863925 563 564 O
including NCT03863925 565 574 O
myocardial NCT03863925 575 585 B-Condition
infarction NCT03863925 586 596 I-Condition
, NCT03863925 597 598 O
cerebrovascular NCT03863925 599 614 B-Condition
disease NCT03863925 615 622 I-Condition
, NCT03863925 623 624 O
elevated NCT03863925 625 633 B-Condition
intracranial NCT03863925 634 646 I-Condition
pressure NCT03863925 647 655 I-Condition
, NCT03863925 656 657 O
intracranial NCT03863925 658 670 B-Condition
angiomas NCT03863925 671 679 I-Condition
, NCT03863925 680 681 O
untreated NCT03863925 682 691 B-Modifier
bony NCT03863925 692 696 B-Condition
fractures NCT03863925 697 706 I-Condition
, NCT03863925 707 708 O
cervical NCT03863925 709 717 B-Condition
spine NCT03863925 718 723 I-Condition
injury NCT03863925 724 730 I-Condition
, NCT03863925 731 732 O
pheochromocytoma NCT03863925 733 749 B-Condition
, NCT03863925 750 751 O
heart NCT03863925 752 757 B-Condition
failure NCT03863925 758 765 I-Condition
, NCT03863925 766 767 O
sever NCT03863925 768 773 O
valvular NCT03863925 774 782 B-Condition
disease NCT03863925 783 790 I-Condition
, NCT03863925 791 792 O
deep NCT03863925 793 797 B-Condition
vein NCT03863925 798 802 I-Condition
thrombosis NCT03863925 803 813 I-Condition
, NCT03863925 814 815 O
etc NCT03863925 816 819 O
. NCT03863925 819 820 O

- NCT03863925 824 825 O
Patients NCT03863925 827 835 O
with NCT03863925 836 840 O
untreated NCT03863925 841 850 B-Negation|Procedure
substance NCT03863925 851 860 B-Condition
abuse NCT03863925 861 866 I-Condition
, NCT03863925 867 868 O
including NCT03863925 869 878 O
alcohol NCT03863925 879 886 B-Drug
and NCT03863925 887 890 B-Or
illegal NCT03863925 891 898 B-Drug
drugs NCT03863925 899 904 I-Drug

- NCT03863925 907 908 O
Patients NCT03863925 910 918 O
with NCT03863925 919 923 O
unspecified NCT03863925 924 935 B-Modifier
psychiatric NCT03863925 936 947 B-Condition
disorders NCT03863925 948 957 I-Condition

- NCT03863925 960 961 O
Patients NCT03863925 963 971 O
unable NCT03863925 972 978 O
to NCT03863925 979 981 O
cooperate NCT03863925 982 991 O

Inclusion NCT03860753 0 9 O
Criteria NCT03860753 10 18 O
: NCT03860753 19 20 O

- NCT03860753 24 25 O
treatment NCT03860753 27 36 B-Procedure
- NCT03860753 37 38 O
seeking NCT03860753 39 46 B-Assertion___Assertion-Type-Value:intention
individuals NCT03860753 47 58 O
diagnosed NCT03860753 59 68 O
with NCT03860753 69 73 O
AUD NCT03860753 74 77 B-Condition
diagnostic NCT03860753 78 88 O
statistical NCT03860753 89 100 O
manual NCT03860753 101 107 O
5 NCT03860753 108 109 O
( NCT03860753 110 111 O
DSM NCT03860753 112 115 O
- NCT03860753 116 117 O
5 NCT03860753 118 119 O
) NCT03860753 120 121 O

- NCT03860753 125 126 O
fluent NCT03860753 128 134 O
in NCT03860753 135 137 O
English NCT03860753 138 145 O

- NCT03860753 148 149 O
past NCT03860753 151 155 B-Eq-Comparison
month NCT03860753 156 161 I-Eq-Comparison
excessive NCT03860753 162 171 O
alcohol NCT03860753 172 179 B-Observation
use NCT03860753 180 183 I-Observation
( NCT03860753 184 185 O
> NCT03860753 187 188 B-Eq-Comparison
7 NCT03860753 189 190 I-Eq-Comparison
drinks NCT03860753 191 197 I-Eq-Comparison
/ NCT03860753 198 199 I-Eq-Comparison
week NCT03860753 200 204 I-Eq-Comparison
for NCT03860753 205 208 O
woman NCT03860753 209 214 O
, NCT03860753 215 216 O
> NCT03860753 217 218 B-Eq-Comparison
14 NCT03860753 219 221 I-Eq-Comparison
drinks NCT03860753 222 228 I-Eq-Comparison
/ NCT03860753 229 230 I-Eq-Comparison
week NCT03860753 231 235 I-Eq-Comparison
for NCT03860753 236 239 O
men NCT03860753 240 243 O
, NCT03860753 244 245 O
> NCT03860753 246 247 O
3 NCT03860753 248 249 B-Eq-Comparison
drinks NCT03860753 250 256 I-Eq-Comparison
/ NCT03860753 257 258 I-Eq-Comparison
occasion NCT03860753 259 267 I-Eq-Comparison
for NCT03860753 268 271 O
women NCT03860753 272 277 O
> NCT03860753 278 279 B-Eq-Comparison
4 NCT03860753 280 281 I-Eq-Comparison
drinks NCT03860753 282 288 I-Eq-Comparison
/ NCT03860753 289 290 I-Eq-Comparison
occasion NCT03860753 291 299 I-Eq-Comparison
for NCT03860753 300 303 O
men NCT03860753 304 307 O
) NCT03860753 308 309 O
14 NCT03860753 310 312 O

- NCT03860753 316 317 O
baseline NCT03860753 319 327 O
Hamilton NCT03860753 328 336 B-Observation
Anxiety NCT03860753 337 344 I-Observation|Observation
Rating NCT03860753 345 351 I-Observation
Scale NCT03860753 352 357 I-Observation
( NCT03860753 358 359 O
HAM NCT03860753 360 363 B-Observation
- NCT03860753 364 365 I-Observation
A NCT03860753 366 367 O
) NCT03860753 368 369 O
or NCT03860753 370 372 B-Or
Perceived NCT03860753 373 382 B-Observation
Stress NCT03860753 383 389 I-Observation
Scale NCT03860753 390 395 I-Observation
( NCT03860753 396 397 O
PSS NCT03860753 398 401 B-Observation
) NCT03860753 402 403 O
core NCT03860753 404 408 O
indicative NCT03860753 409 419 O
of NCT03860753 420 422 O
mild NCT03860753 423 427 O
to NCT03860753 428 430 B-Eq-Comparison|Or
moderate NCT03860753 431 439 O
anxiety NCT03860753 440 447 B-Condition
( NCT03860753 448 449 O
score NCT03860753 450 455 B-Eq-Comparison|Eq-Comparison
8 NCT03860753 456 457 I-Eq-Comparison
to NCT03860753 458 460 I-Eq-Comparison
23 NCT03860753 461 463 I-Eq-Comparison
) NCT03860753 464 465 O
or NCT03860753 466 468 B-Or
moderate NCT03860753 469 477 O
stress NCT03860753 478 484 B-Condition
( NCT03860753 485 486 O
score NCT03860753 487 492 O
14 NCT03860753 493 495 I-Eq-Comparison
to NCT03860753 496 498 O
26 NCT03860753 499 501 I-Eq-Comparison
) NCT03860753 502 503 O
, NCT03860753 505 506 O
respectively NCT03860753 507 519 O

- NCT03860753 522 523 O
increase NCT03860753 525 533 O
in NCT03860753 534 536 O
alcohol NCT03860753 537 544 B-Condition
craving NCT03860753 545 552 I-Condition
following NCT03860753 553 562 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03860753 563 566 O
baseline NCT03860753 567 575 B-Study
stress NCT03860753 576 582 O
reactivity NCT03860753 583 593 O
assessment NCT03860753 594 604 O
. NCT03860753 604 605 O

Exclusion NCT03860753 607 616 O
Criteria NCT03860753 617 625 O
: NCT03860753 626 627 O

- NCT03860753 631 632 O
Individuals NCT03860753 634 645 O
will NCT03860753 646 650 O
be NCT03860753 651 653 O
excluded NCT03860753 654 662 O
for NCT03860753 663 666 O
exhibiting NCT03860753 667 677 O
severe NCT03860753 678 684 O
scores NCT03860753 685 691 O
on NCT03860753 692 694 O
the NCT03860753 695 698 O
HAM NCT03860753 699 702 B-Observation
- NCT03860753 703 704 I-Condition|Observation
A NCT03860753 705 706 I-Observation
, NCT03860753 707 708 O
PSS NCT03860753 709 712 B-Observation
, NCT03860753 713 714 O
or NCT03860753 715 717 B-Or
post NCT03860753 718 722 B-Condition
- NCT03860753 723 724 I-Observation
traumatic NCT03860753 725 734 I-Condition
( NCT03860753 735 736 O
PTSD NCT03860753 737 741 B-Condition
) NCT03860753 742 743 O
checklist NCT03860753 744 753 B-Observation
( NCT03860753 754 755 O
PCL NCT03860753 756 759 B-Observation
- NCT03860753 760 761 O
5 NCT03860753 762 763 I-Observation
) NCT03860753 764 765 O
at NCT03860753 766 768 O
the NCT03860753 769 772 O
discretion NCT03860753 773 783 O
of NCT03860753 784 786 O
the NCT03860753 787 790 O
admitting NCT03860753 791 800 O
physician NCT03860753 801 810 O

- NCT03860753 813 814 O
physical NCT03860753 816 824 O
dependence NCT03860753 825 835 B-Condition
on NCT03860753 836 838 I-Condition
alcohol NCT03860753 839 846 I-Condition
Alcohol NCT03860753 847 854 B-Observation
Use NCT03860753 855 858 I-Observation
Disorders NCT03860753 859 868 I-Observation
Inventory NCT03860753 869 878 I-Observation
( NCT03860753 879 880 O
AUDIT NCT03860753 881 886 B-Observation
) NCT03860753 887 888 O
score NCT03860753 889 894 O
indicative NCT03860753 895 905 O
of NCT03860753 906 908 O
severe NCT03860753 909 915 O
alcohol NCT03860753 916 923 B-Condition
dependence NCT03860753 924 934 I-Condition
( NCT03860753 935 936 O
≥ NCT03860753 938 939 B-Eq-Comparison|Eq-Comparison
13 NCT03860753 940 942 I-Eq-Comparison
for NCT03860753 943 946 O
women NCT03860753 947 952 O
, NCT03860753 953 954 O
≥ NCT03860753 955 956 O
15 NCT03860753 957 959 I-Eq-Comparison
for NCT03860753 960 963 O
men NCT03860753 964 967 O
) NCT03860753 968 969 O

- NCT03860753 973 974 O
greater NCT03860753 976 983 B-Eq-Comparison
than NCT03860753 984 988 I-Eq-Comparison|Exception
mild NCT03860753 989 993 O
substance NCT03860753 994 1003 B-Condition
use NCT03860753 1004 1007 I-Condition
disorder NCT03860753 1008 1016 I-Condition
on NCT03860753 1017 1019 O
drugs NCT03860753 1020 1025 B-Drug
other NCT03860753 1026 1031 B-Exception
than NCT03860753 1032 1036 O
alcohol NCT03860753 1037 1044 B-Drug
, NCT03860753 1045 1046 O
nicotine NCT03860753 1047 1055 B-Drug
, NCT03860753 1056 1057 O
and NCT03860753 1058 1061 B-And
marijuana NCT03860753 1062 1071 B-Drug

- NCT03860753 1074 1075 O
contraindications NCT03860753 1077 1094 B-Contraindication
for NCT03860753 1095 1098 O
taking NCT03860753 1099 1105 B-Eq-Comparison
pioglitazone NCT03860753 1106 1118 B-Drug|Drug
; NCT03860753 1118 1119 O
medical NCT03860753 1120 1127 O
conditions NCT03860753 1128 1138 B-Condition
contraindicating NCT03860753 1139 1155 B-Contraindication
pioglitazone NCT03860753 1156 1168 O
pharmacotherapy NCT03860753 1169 1184 O
or NCT03860753 1185 1187 B-Or|Or
taking NCT03860753 1188 1194 B-Eq-Comparison
contraindicated NCT03860753 1195 1210 B-Contraindication
medications NCT03860753 1211 1222 B-Drug

- NCT03860753 1225 1226 O
be NCT03860753 1228 1230 O
pregnant NCT03860753 1231 1239 B-Condition|Condition
, NCT03860753 1240 1241 O
nursing NCT03860753 1242 1249 B-Condition
, NCT03860753 1250 1251 O
or NCT03860753 1252 1254 O
planning NCT03860753 1255 1263 B-Assertion___Assertion-Type-Value:intention
on NCT03860753 1264 1266 O
becoming NCT03860753 1267 1275 O
pregnant NCT03860753 1276 1284 O
during NCT03860753 1285 1291 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860753 1292 1295 O
course NCT03860753 1296 1302 O
of NCT03860753 1303 1305 O
the NCT03860753 1306 1309 O
study NCT03860753 1310 1315 B-Study

- NCT03860753 1318 1319 O
have NCT03860753 1321 1325 O
any NCT03860753 1326 1329 O
other NCT03860753 1330 1335 O
illness NCT03860753 1336 1343 B-Condition
, NCT03860753 1344 1345 O
condition NCT03860753 1346 1355 B-Condition
, NCT03860753 1356 1357 O
or NCT03860753 1358 1360 B-Or
use NCT03860753 1361 1364 O
of NCT03860753 1365 1367 O
medications NCT03860753 1368 1379 B-Drug
, NCT03860753 1380 1381 O
which NCT03860753 1382 1387 O
in NCT03860753 1388 1390 O
the NCT03860753 1391 1394 O
opinion NCT03860753 1395 1402 O
of NCT03860753 1403 1405 O
the NCT03860753 1406 1409 O
PI NCT03860753 1410 1412 O
and NCT03860753 1413 1416 B-Or
/ NCT03860753 1417 1418 I-Or
or NCT03860753 1419 1421 I-Or
admitting NCT03860753 1422 1431 O
physician NCT03860753 1432 1441 O
would NCT03860753 1442 1447 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03860753 1448 1456 B-Negation
safe NCT03860753 1457 1461 B-Modifier
and NCT03860753 1462 1465 O
/ NCT03860753 1466 1467 O
or NCT03860753 1468 1470 O
successful NCT03860753 1471 1481 B-Modifier
completion NCT03860753 1482 1492 O
of NCT03860753 1493 1495 O
the NCT03860753 1496 1499 O
study NCT03860753 1500 1505 B-Study
. NCT03860753 1505 1506 O


Inclusion NCT03867955 0 9 O
Criteria NCT03867955 10 18 O
: NCT03867955 19 20 O

- NCT03867955 24 25 O
Majors NCT03867955 27 33 O
patients NCT03867955 34 42 O

- NCT03867955 45 46 O
Score NCT03867955 48 53 O
American NCT03867955 54 62 B-Condition
Society NCT03867955 63 70 I-Condition
of NCT03867955 71 73 I-Condition
Anesthesiologists NCT03867955 74 91 I-Condition
( NCT03867955 92 93 O
ASA NCT03867955 94 97 B-Condition
) NCT03867955 98 99 O
1 NCT03867955 100 101 B-Eq-Comparison
or NCT03867955 102 104 I-Eq-Comparison
2 NCT03867955 105 106 I-Eq-Comparison

- NCT03867955 110 111 O
Managed NCT03867955 113 120 B-Encounter
in NCT03867955 121 123 O
the NCT03867955 124 127 O
operating NCT03867955 128 137 O
theater NCT03867955 138 145 O
of NCT03867955 146 148 O
the NCT03867955 149 152 O
University NCT03867955 153 163 O
Hospital NCT03867955 164 172 O
of NCT03867955 173 175 O
Saint NCT03867955 176 181 O
- NCT03867955 182 183 O
Etienne NCT03867955 184 191 O
for NCT03867955 192 195 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03867955 196 197 O
neurosurgical NCT03867955 198 211 B-Procedure
intervention NCT03867955 212 224 I-Procedure
. NCT03867955 224 225 O

Exclusion NCT03867955 227 236 O
Criteria NCT03867955 237 245 O
: NCT03867955 246 247 O

- NCT03867955 251 252 O
Single NCT03867955 254 260 B-Modifier
or NCT03867955 261 263 B-Or
bilateral NCT03867955 264 273 B-Modifier
eye NCT03867955 274 277 B-Procedure
surgery NCT03867955 278 285 I-Procedure
modifying NCT03867955 286 295 O
the NCT03867955 296 299 O
possibilities NCT03867955 300 313 O
of NCT03867955 314 316 O
variation NCT03867955 317 326 O
of NCT03867955 327 329 O
the NCT03867955 330 333 O
pupillary NCT03867955 334 343 O
diameter NCT03867955 344 352 O

- NCT03867955 355 356 O
Having NCT03867955 358 364 O
been NCT03867955 365 369 O
asleep NCT03867955 370 376 O
under NCT03867955 377 382 O
general NCT03867955 383 390 B-Procedure
anesthesia NCT03867955 391 401 I-Procedure
in NCT03867955 402 404 O
the NCT03867955 405 408 O
7 NCT03867955 409 410 B-Eq-Comparison
days NCT03867955 411 415 I-Eq-Comparison
prior NCT03867955 416 421 B-Temporal-Connection
to NCT03867955 422 424 I-Temporal-Connection
the NCT03867955 425 428 O
current NCT03867955 429 436 B-Eq-Comparison
surgery NCT03867955 437 444 B-Procedure

- NCT03867955 447 448 O
History NCT03867955 450 457 B-Eq-Comparison
of NCT03867955 458 460 O
Parkinson NCT03867955 461 470 B-Condition
's NCT03867955 470 472 O
disease NCT03867955 473 480 I-Condition
, NCT03867955 481 482 O
insulin NCT03867955 483 490 B-Modifier
- NCT03867955 491 492 I-Modifier
dependent NCT03867955 493 502 I-Modifier
or NCT03867955 503 505 B-Or
non NCT03867955 506 509 B-Modifier
- NCT03867955 510 511 I-Modifier
insulin NCT03867955 512 519 I-Modifier
- NCT03867955 520 521 O
dependent NCT03867955 522 531 I-Modifier
diabetes NCT03867955 532 540 B-Condition
at NCT03867955 541 543 O
a NCT03867955 544 545 O
dysautonomic NCT03867955 546 558 B-Modifier
stage NCT03867955 559 564 I-Modifier
or NCT03867955 565 567 B-Or
chronic NCT03867955 568 575 B-Modifier
alcoholism NCT03867955 576 586 B-Condition
at NCT03867955 587 589 O
a NCT03867955 590 591 O
dysautonomous NCT03867955 592 605 B-Modifier
stage NCT03867955 606 611 I-Modifier

Inclusion NCT03860974 0 9 O
Criteria NCT03860974 10 18 O
: NCT03860974 19 20 O

- NCT03860974 24 25 O
undergoing NCT03860974 27 37 B-Eq-Comparison
unilateral NCT03860974 38 48 B-Modifier
or NCT03860974 49 51 B-Or
bilateral NCT03860974 52 61 B-Modifier
breast NCT03860974 62 68 B-Procedure
surgery NCT03860974 69 76 I-Procedure
with NCT03860974 77 81 B-And
at NCT03860974 82 84 B-Eq-Comparison
least NCT03860974 85 90 I-Eq-Comparison
moderate NCT03860974 91 99 I-Eq-Comparison
post NCT03860974 100 104 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03860974 105 106 O
- NCT03860974 108 109 O
operative NCT03860974 110 119 B-Procedure
pain NCT03860974 120 124 B-Observation
anticipated NCT03860974 125 136 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03860974 139 140 O
analgesic NCT03860974 142 151 B-Drug
plan NCT03860974 152 156 B-Eq-Comparison
includes NCT03860974 157 165 O
a NCT03860974 166 167 O
single NCT03860974 168 174 B-Procedure
- NCT03860974 175 176 I-Procedure
injection NCT03860974 177 186 I-Procedure
peripheral NCT03860974 187 197 I-Procedure
nerve NCT03860974 198 203 I-Procedure
block NCT03860974 204 209 I-Procedure
( NCT03860974 210 211 O
s NCT03860974 212 213 O
) NCT03860974 214 215 O

- NCT03860974 219 220 O
age NCT03860974 222 225 B-Age
18 NCT03860974 226 228 B-Eq-Comparison
years NCT03860974 229 234 I-Eq-Comparison
or NCT03860974 235 237 I-Eq-Comparison
older NCT03860974 238 243 I-Eq-Comparison

Exclusion NCT03860974 244 253 O
Criteria NCT03860974 254 262 O
: NCT03860974 263 264 O

- NCT03860974 268 269 O
morbid NCT03860974 271 277 B-Condition
obesity NCT03860974 278 285 I-Condition
as NCT03860974 286 288 O
defined NCT03860974 289 296 O
by NCT03860974 297 299 O
a NCT03860974 300 301 O
body NCT03860974 302 306 B-Observation
mass NCT03860974 307 311 I-Observation
index NCT03860974 312 317 I-Observation
> NCT03860974 318 319 B-Eq-Comparison
40 NCT03860974 320 322 I-Eq-Comparison
( NCT03860974 323 324 O
BMI NCT03860974 325 328 O
= NCT03860974 329 330 O
weight NCT03860974 331 337 O
in NCT03860974 338 340 O
kg NCT03860974 341 343 O
/ NCT03860974 344 345 O
[ NCT03860974 346 347 O
height NCT03860974 348 354 O
in NCT03860974 355 357 O
meters NCT03860974 358 364 O
] NCT03860974 365 366 O
2 NCT03860974 367 368 O
) NCT03860974 369 370 O

- NCT03860974 374 375 O
renal NCT03860974 377 382 B-Condition
insufficiency NCT03860974 383 396 I-Condition
( NCT03860974 397 398 O
pre NCT03860974 399 402 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03860974 403 404 O
- NCT03860974 406 407 O
operative NCT03860974 408 417 B-Procedure
creatinine NCT03860974 418 428 B-Observation
> NCT03860974 429 430 B-Eq-Comparison
1.5 NCT03860974 431 434 I-Eq-Comparison
mg NCT03860974 435 437 O
/ NCT03860974 438 439 O
dL NCT03860974 440 442 O
) NCT03860974 443 444 O

- NCT03860974 448 449 O
chronic NCT03860974 451 458 B-Modifier
opioid NCT03860974 459 465 B-Drug
use NCT03860974 466 469 O
( NCT03860974 470 471 O
daily NCT03860974 472 477 B-Eq-Comparison
use NCT03860974 478 481 O
within NCT03860974 482 488 B-Eq-Comparison
the NCT03860974 489 492 I-Eq-Comparison
2 NCT03860974 493 494 I-Eq-Comparison
weeks NCT03860974 495 500 I-Eq-Comparison
prior NCT03860974 501 506 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03860974 507 509 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03860974 510 517 B-Procedure
and NCT03860974 518 521 O
duration NCT03860974 522 530 O
of NCT03860974 531 533 O
use NCT03860974 534 537 O
> NCT03860974 538 539 B-Eq-Comparison
4 NCT03860974 540 541 I-Eq-Comparison
weeks NCT03860974 542 547 I-Eq-Comparison
) NCT03860974 548 549 O

- NCT03860974 553 554 O
history NCT03860974 556 563 B-Eq-Comparison
of NCT03860974 564 566 O
opioid NCT03860974 567 573 B-Condition
abuse NCT03860974 574 579 I-Condition

- NCT03860974 582 583 O
any NCT03860974 585 588 O
comorbidity NCT03860974 589 600 B-Condition
which NCT03860974 601 606 O
results NCT03860974 607 614 O
in NCT03860974 615 617 O
moderate NCT03860974 618 626 O
or NCT03860974 627 629 B-Or
severe NCT03860974 630 636 O
functional NCT03860974 637 647 B-Condition
limitation NCT03860974 648 658 I-Condition
inability NCT03860974 659 668 I-Condition
to NCT03860974 669 671 I-Condition
communicate NCT03860974 672 683 I-Condition
with NCT03860974 684 688 O
the NCT03860974 689 692 O
investigators NCT03860974 693 706 O
or NCT03860974 707 709 O
hospital NCT03860974 710 718 O
staff NCT03860974 719 724 O

- NCT03860974 727 728 O
pregnancy NCT03860974 730 739 B-Condition

- NCT03860974 742 743 O
planned NCT03860974 745 752 B-Eq-Comparison
regional NCT03860974 753 761 B-Drug
analgesic NCT03860974 762 771 I-Drug
with NCT03860974 772 776 B-And
perineural NCT03860974 777 787 B-Procedure
catheter NCT03860974 788 796 I-Procedure
placement NCT03860974 797 806 I-Procedure

- NCT03860974 809 810 O
incarceration NCT03860974 812 825 B-Observation


Inclusion NCT03869788 0 9 O
Criteria NCT03869788 10 18 O
: NCT03869788 19 20 O

- NCT03869788 24 25 O
vague NCT03869788 27 32 B-Modifier
gastrointestinal NCT03869788 33 49 B-Condition
disturbances NCT03869788 50 62 I-Condition
. NCT03869788 62 63 O

- NCT03869788 67 68 O
intermittent NCT03869788 70 82 B-Modifier
eosinophilia NCT03869788 83 95 B-Condition
. NCT03869788 95 96 O

- NCT03869788 100 101 O
biliary NCT03869788 103 110 B-Condition
obstruction NCT03869788 111 122 I-Condition
. NCT03869788 122 123 O

- NCT03869788 127 128 O
biliary NCT03869788 130 137 B-Condition
colic NCT03869788 138 143 I-Condition
pain NCT03869788 144 148 I-Condition
. NCT03869788 148 149 O

- NCT03869788 153 154 O
intermittent NCT03869788 156 168 B-Modifier
jaundice NCT03869788 169 177 B-Condition
. NCT03869788 177 178 O

- NCT03869788 182 183 O
right NCT03869788 185 190 B-Condition
upper NCT03869788 191 196 I-Condition
- NCT03869788 197 198 I-Condition
quadrant NCT03869788 199 207 I-Condition
abdominal NCT03869788 208 217 I-Condition
tenderness NCT03869788 218 228 I-Condition
. NCT03869788 228 229 O

Exclusion NCT03869788 231 240 O
Criteria NCT03869788 241 249 O
: NCT03869788 250 251 O

- NCT03869788 255 256 O
no NCT03869788 258 260 O
exclusion NCT03869788 261 270 O
Criteria NCT03869788 271 279 O

Inclusion NCT03862742 0 9 O
Criteria NCT03862742 10 18 O
: NCT03862742 19 20 O

- NCT03862742 24 25 O
≥ NCT03862742 27 28 B-Eq-Comparison
18 NCT03862742 29 31 I-Eq-Comparison
years NCT03862742 32 37 I-Eq-Comparison
of NCT03862742 38 40 O
age NCT03862742 41 44 B-Age

- NCT03862742 47 48 O
Own NCT03862742 50 53 O
an NCT03862742 54 56 O
iOS NCT03862742 57 60 O
or NCT03862742 61 63 O
Android NCT03862742 64 71 O
device NCT03862742 72 78 O

Exclusion NCT03862742 79 88 O
Criteria NCT03862742 89 97 O
: NCT03862742 98 99 O

- NCT03862742 103 104 O
Inability NCT03862742 106 115 O
to NCT03862742 116 118 O
give NCT03862742 119 123 O
informed NCT03862742 124 132 O
consent NCT03862742 133 140 O

- NCT03862742 143 144 O
< NCT03862742 146 147 B-Eq-Comparison
18 NCT03862742 148 150 I-Eq-Comparison
years NCT03862742 151 156 I-Eq-Comparison
of NCT03862742 157 159 O
age NCT03862742 160 163 B-Age

- NCT03862742 166 167 O
Inability NCT03862742 169 178 B-Negation
to NCT03862742 179 181 I-Negation
understand NCT03862742 182 192 I-Negation
written NCT03862742 193 200 O
English NCT03862742 201 208 O
language NCT03862742 209 217 O

- NCT03862742 220 221 O
Hypertensive NCT03862742 223 235 B-Condition
urgency NCT03862742 236 243 B-Modifier
or NCT03862742 244 246 B-Or
emergency NCT03862742 247 256 B-Modifier
as NCT03862742 257 259 O
an NCT03862742 260 262 O
admission NCT03862742 263 272 O
diagnosis NCT03862742 273 282 O

Inclusion NCT03862781 0 9 O
Criteria NCT03862781 10 18 O
: NCT03862781 19 20 O

- NCT03862781 24 25 O
Eligible NCT03862781 27 35 O
patients NCT03862781 36 44 O
are NCT03862781 45 48 O
those NCT03862781 49 54 O
over NCT03862781 55 59 B-Eq-Comparison
18 NCT03862781 60 62 I-Eq-Comparison
years NCT03862781 63 68 I-Eq-Comparison
of NCT03862781 69 71 O
age NCT03862781 72 75 B-Age
who NCT03862781 76 79 B-And
are NCT03862781 80 83 O
regularly NCT03862781 84 93 O
scheduled NCT03862781 94 103 B-Eq-Comparison
to NCT03862781 104 106 O
undergo NCT03862781 107 114 O
a NCT03862781 115 116 O
right NCT03862781 117 122 B-Procedure
hemicolectomy NCT03862781 123 136 I-Procedure
via NCT03862781 137 140 O
a NCT03862781 141 142 O
minimally NCT03862781 143 152 B-Procedure
invasive NCT03862781 153 161 I-Procedure
approach NCT03862781 162 170 I-Procedure
( NCT03862781 171 172 O
robotic NCT03862781 173 180 B-Modifier
or NCT03862781 181 183 B-Or
laparoscopic NCT03862781 184 196 B-Modifier
) NCT03862781 197 198 O
with NCT03862781 199 203 B-And
the NCT03862781 204 207 O
creation NCT03862781 208 216 O
of NCT03862781 217 219 O
an NCT03862781 220 222 B-Procedure
anastomosis NCT03862781 223 234 O
. NCT03862781 234 235 O
Right NCT03862781 237 242 B-Procedure
colectomy NCT03862781 243 252 I-Procedure
will NCT03862781 253 257 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862781 258 260 I-Assertion___Assertion-Type-Value:hypothetical
defined NCT03862781 261 268 O
as NCT03862781 269 271 O
removal NCT03862781 272 279 B-Procedure
of NCT03862781 280 282 I-Procedure
the NCT03862781 283 286 I-Procedure
ascending NCT03862781 287 296 I-Procedure
colon NCT03862781 297 302 I-Procedure
, NCT03862781 303 304 O
ligation NCT03862781 305 313 B-Procedure
of NCT03862781 314 316 I-Procedure
the NCT03862781 317 320 I-Procedure
ileocolic NCT03862781 321 330 I-Procedure
artery NCT03862781 331 337 I-Procedure
and NCT03862781 338 341 I-Procedure
vein NCT03862781 342 346 I-Procedure
, NCT03862781 347 348 O
+ NCT03862781 349 350 O
/ NCT03862781 352 353 O
- NCT03862781 355 356 O
removal NCT03862781 357 364 B-Procedure
of NCT03862781 365 367 I-Procedure
the NCT03862781 368 371 I-Procedure
terminal NCT03862781 372 380 I-Procedure
ileum NCT03862781 381 386 I-Procedure
, NCT03862781 387 388 O
+ NCT03862781 389 390 O
/ NCT03862781 392 393 O
- NCT03862781 395 396 O
removal NCT03862781 397 404 B-Procedure
of NCT03862781 405 407 I-Procedure
the NCT03862781 408 411 I-Procedure
proximal NCT03862781 412 420 I-Procedure
transverse NCT03862781 421 431 I-Procedure
colon NCT03862781 432 437 I-Procedure
, NCT03862781 438 439 O
and NCT03862781 440 443 O
+ NCT03862781 444 445 O
/ NCT03862781 447 448 O
- NCT03862781 450 451 O
removal NCT03862781 452 459 B-Procedure
of NCT03862781 460 462 I-Procedure
the NCT03862781 463 466 I-Procedure
right NCT03862781 467 472 I-Procedure
branch NCT03862781 473 479 I-Procedure
of NCT03862781 480 482 O
the NCT03862781 483 486 O
middle NCT03862781 487 493 I-Procedure
colic NCT03862781 494 499 I-Procedure
artery NCT03862781 500 506 I-Procedure
and NCT03862781 507 510 I-Procedure
vein NCT03862781 511 515 I-Procedure
. NCT03862781 515 516 O

Exclusion NCT03862781 518 527 O
Criteria NCT03862781 528 536 O
: NCT03862781 537 538 O

- NCT03862781 542 543 O
Pregnant NCT03862781 545 553 B-Condition
women NCT03862781 554 559 O

- NCT03862781 562 563 O
Additional NCT03862781 565 575 O
colon NCT03862781 576 581 B-Procedure
resection NCT03862781 582 591 I-Procedure
is NCT03862781 592 594 O
planned NCT03862781 595 602 B-Eq-Comparison
( NCT03862781 603 604 O
i. NCT03862781 605 607 O
e. NCT03862781 608 610 O
left NCT03862781 612 616 B-Procedure
colectomy NCT03862781 617 626 I-Procedure
or NCT03862781 627 629 B-Or
proctectomy NCT03862781 630 641 B-Procedure
) NCT03862781 642 643 O

- NCT03862781 647 648 O
Vulnerable NCT03862781 650 660 B-Observation
populations NCT03862781 661 672 I-Observation
such NCT03862781 673 677 O
as NCT03862781 678 680 O
prisoners NCT03862781 681 690 B-Observation
or NCT03862781 691 693 O
adults NCT03862781 694 700 O
unable NCT03862781 701 707 O
to NCT03862781 708 710 O
give NCT03862781 711 715 O
consent NCT03862781 716 723 O

- NCT03862781 726 727 O
If NCT03862781 729 731 O
the NCT03862781 732 735 O
scheduled NCT03862781 736 745 O
surgery NCT03862781 746 753 B-Procedure
is NCT03862781 754 756 O
planned NCT03862781 757 764 B-Eq-Comparison
at NCT03862781 765 767 O
Butterworth NCT03862781 768 779 O
hospital NCT03862781 780 788 O
( NCT03862781 789 790 O
as NCT03862781 791 793 O
to NCT03862781 794 796 O
standardize NCT03862781 797 808 O
the NCT03862781 809 812 O
nursing NCT03862781 813 820 O
care NCT03862781 821 825 O
received NCT03862781 826 834 B-Eq-Comparison
post NCT03862781 835 839 O
- NCT03862781 840 841 O
- NCT03862781 843 844 O
operatively NCT03862781 845 856 O
) NCT03862781 857 858 O

- NCT03862781 862 863 O
Emergent NCT03862781 865 873 O
cases NCT03862781 874 879 O

Patients NCT03862781 880 888 O
will NCT03862781 889 893 O
be NCT03862781 894 896 O
excluded NCT03862781 897 905 O
from NCT03862781 906 910 O
the NCT03862781 911 914 O
study NCT03862781 915 920 O
intra NCT03862781 921 926 O
- NCT03862781 927 928 O
operatively NCT03862781 929 940 O
if NCT03862781 941 943 B-Assertion___Assertion-Type-Value:hypothetical
: NCT03862781 944 945 O

- NCT03862781 949 950 O
The NCT03862781 952 955 O
procedure NCT03862781 956 965 O
is NCT03862781 966 968 O
converted NCT03862781 969 978 O
to NCT03862781 979 981 O
an NCT03862781 982 984 O
open NCT03862781 985 989 B-Procedure
resection NCT03862781 990 999 I-Procedure

- NCT03862781 1002 1003 O
If NCT03862781 1005 1007 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03862781 1008 1009 O
loop NCT03862781 1010 1014 B-Procedure
ileostomy NCT03862781 1015 1024 I-Procedure
is NCT03862781 1025 1027 O
performed NCT03862781 1028 1037 O
in NCT03862781 1038 1040 B-And
addition NCT03862781 1041 1049 I-And
to NCT03862781 1050 1052 O
the NCT03862781 1053 1056 O
right NCT03862781 1057 1062 B-Procedure
colectomy NCT03862781 1063 1072 I-Procedure

Inclusion NCT03863886 0 9 O
Criteria NCT03863886 10 18 O
: NCT03863886 19 20 O

- NCT03863886 24 25 O
Adults NCT03863886 27 33 O
patients NCT03863886 34 42 O
≥ NCT03863886 43 44 B-Eq-Comparison
18 NCT03863886 45 47 I-Eq-Comparison
years NCT03863886 48 53 I-Eq-Comparison
of NCT03863886 54 56 O
age NCT03863886 57 60 B-Age
with NCT03863886 61 65 B-And
CD NCT03863886 66 68 B-Condition
with NCT03863886 69 73 B-And
at NCT03863886 74 76 O
least NCT03863886 77 82 O
colonic NCT03863886 83 90 B-Condition
involvement NCT03863886 91 102 I-Condition
, NCT03863886 103 104 O
UC NCT03863886 105 107 B-Condition
, NCT03863886 108 109 O
or NCT03863886 110 112 B-Or
non NCT03863886 113 116 B-Negation
- NCT03863886 117 118 O
IBD NCT03863886 119 122 B-Condition
controls NCT03863886 123 131 O
who NCT03863886 132 135 B-And
have NCT03863886 136 140 O
been NCT03863886 141 145 O
referred NCT03863886 146 154 B-Eq-Comparison
for NCT03863886 155 158 I-Eq-Comparison
colonoscopy NCT03863886 159 170 B-Procedure
for NCT03863886 171 174 O
clinical NCT03863886 175 183 O
reasons NCT03863886 184 191 O
. NCT03863886 191 192 O
The NCT03863886 194 197 O
clinical NCT03863886 198 206 B-Observation
reasons NCT03863886 207 214 I-Observation
may NCT03863886 215 218 O
include NCT03863886 219 226 O
colorectal NCT03863886 227 237 B-Procedure
cancer NCT03863886 238 244 I-Procedure
screening NCT03863886 245 254 I-Procedure
, NCT03863886 255 256 O
surveillance NCT03863886 257 269 B-Observation
, NCT03863886 270 271 O
diagnostic NCT03863886 272 282 O
for NCT03863886 283 286 O
CD NCT03863886 287 289 B-Condition
or NCT03863886 290 292 B-Or
UC NCT03863886 293 295 B-Condition
flare NCT03863886 296 301 O
, NCT03863886 302 303 O
or NCT03863886 304 306 B-Or
gastrointestinal NCT03863886 307 323 B-Condition
symptoms NCT03863886 324 332 B-Assertion___Assertion-Type-Value:possible
. NCT03863886 332 333 O

Exclusion NCT03863886 335 344 O
Criteria NCT03863886 345 353 O
: NCT03863886 354 355 O

- NCT03863886 359 360 O
Pregnant NCT03863886 362 370 B-Condition
patients NCT03863886 371 379 O
. NCT03863886 379 380 O

- NCT03863886 384 385 O
Patients NCT03863886 387 395 O
with NCT03863886 396 400 O
known NCT03863886 401 406 O
current NCT03863886 407 414 B-Eq-Comparison
colorectal NCT03863886 415 425 B-Modifier
cancer NCT03863886 426 432 B-Condition
, NCT03863886 433 434 O
infectious NCT03863886 435 445 B-Condition
colitis NCT03863886 446 453 I-Condition
, NCT03863886 454 455 O
diverticulitis NCT03863886 456 470 B-Condition
, NCT03863886 471 472 O
or NCT03863886 473 475 B-Or
microscopic NCT03863886 476 487 B-Condition
colitis NCT03863886 488 495 I-Condition
. NCT03863886 495 496 O

- NCT03863886 500 501 O
Patients NCT03863886 503 511 O
who NCT03863886 512 515 O
have NCT03863886 516 520 O
undergone NCT03863886 521 530 B-Eq-Comparison
surgery NCT03863886 531 538 B-Procedure
involving NCT03863886 539 548 O
the NCT03863886 549 552 O
cecum NCT03863886 553 558 B-Modifier
or NCT03863886 559 561 B-Or
rectum NCT03863886 562 568 B-Modifier
. NCT03863886 568 569 O

Inclusion NCT03866083 0 9 O
Criteria NCT03866083 10 18 O
: NCT03866083 19 20 O

- NCT03866083 23 24 O
Critically NCT03866083 25 35 O
ill NCT03866083 36 39 O
cirrhotics NCT03866083 40 50 B-Condition
with NCT03866083 51 55 B-And
early NCT03866083 56 61 B-Modifier
onset NCT03866083 62 67 I-Modifier
septic NCT03866083 68 74 B-Condition
shock NCT03866083 75 80 I-Condition
( NCT03866083 81 82 O
< NCT03866083 84 85 B-Eq-Comparison
24 NCT03866083 86 88 I-Eq-Comparison
hours NCT03866083 89 94 I-Eq-Comparison
) NCT03866083 95 96 O
with NCT03866083 97 101 B-And
norepinephrine NCT03866083 102 116 B-Drug

of NCT03866083 117 119 O
more NCT03866083 120 124 B-Eq-Comparison
than NCT03866083 125 129 I-Eq-Comparison
10 NCT03866083 130 132 I-Eq-Comparison
ug NCT03866083 133 135 O
/ NCT03866083 136 137 O
min NCT03866083 138 141 O
and NCT03866083 142 145 B-And
lactate NCT03866083 146 153 B-Observation
> NCT03866083 154 155 B-Eq-Comparison
4 NCT03866083 156 157 I-Eq-Comparison
mmol NCT03866083 158 162 I-Eq-Comparison
/ NCT03866083 163 164 I-Eq-Comparison
L. NCT03866083 165 167 I-Eq-Comparison

Exclusion NCT03866083 169 178 O
Criteria NCT03866083 179 187 O
: NCT03866083 188 189 O

- NCT03866083 193 194 O
Patients NCT03866083 196 204 O
with NCT03866083 205 209 O
age NCT03866083 210 213 B-Age
less NCT03866083 214 218 B-Eq-Comparison
than NCT03866083 219 223 I-Eq-Comparison
18 NCT03866083 224 226 I-Eq-Comparison
years NCT03866083 227 232 I-Eq-Comparison

- NCT03866083 235 236 O
Severe NCT03866083 238 244 O
known NCT03866083 245 250 O
cardiopulmonary NCT03866083 251 266 B-Condition
disease NCT03866083 267 274 I-Condition
( NCT03866083 275 276 O
structural NCT03866083 277 287 B-Modifier
or NCT03866083 288 290 B-Or
valvular NCT03866083 291 299 B-Modifier
heart NCT03866083 300 305 B-Condition
disease NCT03866083 306 313 I-Condition
, NCT03866083 314 315 O
coronary NCT03866083 316 324 B-Condition
artery NCT03866083 325 331 I-Condition
disease NCT03866083 332 339 I-Condition
, NCT03866083 340 341 O
COPD NCT03866083 342 346 B-Condition
) NCT03866083 347 348 O

- NCT03866083 352 353 O
Severe NCT03866083 355 361 O
coagulopathy NCT03866083 362 374 B-Condition
platelets NCT03866083 375 384 B-Observation
< NCT03866083 385 386 B-Eq-Comparison
20 NCT03866083 387 389 I-Eq-Comparison
, NCT03866083 390 391 O
000 NCT03866083 392 395 O
and NCT03866083 396 399 B-And
INR NCT03866083 400 403 B-Observation
> NCT03866083 404 405 B-Eq-Comparison
5 NCT03866083 406 407 I-Eq-Comparison

- NCT03866083 411 412 O
Active NCT03866083 414 420 B-Eq-Comparison
Bleed NCT03866083 421 426 B-Condition
( NCT03866083 427 428 O
Mucosal NCT03866083 429 436 B-Modifier
or NCT03866083 437 439 B-Or
variceal NCT03866083 440 448 B-Modifier
) NCT03866083 449 450 O

- NCT03866083 454 455 O
Pregnancy NCT03866083 457 466 B-Condition

- NCT03866083 469 470 O
Chronic NCT03866083 472 479 B-Modifier
kidney NCT03866083 480 486 B-Condition
disease NCT03866083 487 494 I-Condition

- NCT03866083 497 498 O
Extremely NCT03866083 500 509 O
moribund NCT03866083 510 518 B-Death|Risk
patients NCT03866083 519 527 O
with NCT03866083 528 532 B-And
an NCT03866083 533 535 O
expected NCT03866083 536 544 O
life NCT03866083 545 549 B-Observation
expectancy NCT03866083 550 560 I-Observation
of NCT03866083 561 563 O
less NCT03866083 564 568 B-Eq-Comparison
than NCT03866083 569 573 I-Eq-Comparison
24 NCT03866083 574 576 I-Eq-Comparison
hours NCT03866083 577 582 I-Eq-Comparison

- NCT03866083 585 586 O
Failure NCT03866083 588 595 O
to NCT03866083 596 598 O
give NCT03866083 599 603 O
informed NCT03866083 604 612 O
consent NCT03866083 613 620 O
from NCT03866083 621 625 O
family NCT03866083 626 632 O
members NCT03866083 633 640 O
. NCT03866083 640 641 O

- NCT03866083 645 646 O
Hemodynamic NCT03866083 648 659 B-Condition
instability NCT03866083 660 671 I-Condition
requiring NCT03866083 672 681 O
very NCT03866083 682 686 O
high NCT03866083 687 691 O
dose NCT03866083 692 696 O
of NCT03866083 697 699 O
vasopressors NCT03866083 700 712 B-Drug
, NCT03866083 713 714 O
late NCT03866083 715 719 B-Modifier
presentation NCT03866083 720 732 I-Modifier
or NCT03866083 733 735 B-Or
spontaneous NCT03866083 736 747 B-Modifier
reversal NCT03866083 748 756 I-Modifier
of NCT03866083 757 759 O
shock NCT03866083 760 765 B-Condition

- NCT03866083 768 769 O
Patient NCT03866083 771 778 O
enrolled NCT03866083 779 787 O
in NCT03866083 788 790 O
other NCT03866083 791 796 B-Other
clinical NCT03866083 797 805 B-Study
trials NCT03866083 806 812 I-Study

Inclusion NCT03868904 0 9 O
Criteria NCT03868904 10 18 O
: NCT03868904 19 20 O

- NCT03868904 24 25 O
Participant NCT03868904 27 38 O
in NCT03868904 39 41 O
TransMedics NCT03868904 42 53 O
OCS NCT03868904 54 57 O
Lung NCT03868904 58 62 O
System NCT03868904 63 69 O
INSPIRE NCT03868904 70 77 O
trial NCT03868904 78 83 B-Study

Exclusion NCT03868904 84 93 O
Criteria NCT03868904 94 102 O
: NCT03868904 103 104 O

- NCT03868904 108 109 O
None NCT03868904 111 115 O

Inclusion NCT03866915 0 9 O
Criteria NCT03866915 10 18 O
: NCT03866915 19 20 O

- NCT03866915 24 25 O
All NCT03866915 27 30 O
patients NCT03866915 31 39 O
older NCT03866915 40 45 I-Eq-Comparison
than NCT03866915 46 50 I-Eq-Comparison
18 NCT03866915 51 53 I-Eq-Comparison
years NCT03866915 54 59 I-Eq-Comparison
undergoing NCT03866915 60 70 B-Eq-Comparison
elective NCT03866915 71 79 O
surgery NCT03866915 80 87 B-Procedure
that NCT03866915 88 92 B-And
receive NCT03866915 93 100 O
a NCT03866915 101 102 O
pre NCT03866915 103 106 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03866915 107 108 O
- NCT03866915 110 111 O
operative NCT03866915 112 121 B-Coreference
visit NCT03866915 122 127 B-Encounter
by NCT03866915 128 130 O
anesthesiologists NCT03866915 131 148 B-Provider
. NCT03866915 148 149 O

Exclusion NCT03866915 151 160 O
Criteria NCT03866915 161 169 O
: NCT03866915 170 171 O

- NCT03866915 175 176 O
Patients NCT03866915 178 186 O
undergoing NCT03866915 187 197 B-Eq-Comparison
emergency NCT03866915 198 207 B-Procedure
surgery NCT03866915 208 215 I-Procedure

- NCT03866915 223 224 O
Patients NCT03866915 226 234 O
under NCT03866915 235 240 B-Eq-Comparison
18 NCT03866915 241 243 I-Eq-Comparison
years NCT03866915 244 249 I-Eq-Comparison
of NCT03866915 250 252 O
age NCT03866915 253 256 B-Age

- NCT03866915 264 265 O
Patients NCT03866915 267 275 O
who NCT03866915 276 279 O
refuse NCT03866915 280 286 O
to NCT03866915 287 289 O
participate NCT03866915 290 301 O

- NCT03866915 309 310 O
Patients NCT03866915 312 320 O
unable NCT03866915 321 327 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866915 328 330 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03866915 331 338 O
the NCT03866915 339 342 O
6 NCT03866915 343 344 B-Observation
MWT NCT03866915 345 348 O

- NCT03866915 356 357 O
Claudication NCT03866915 359 371 B-Condition
of NCT03866915 372 374 I-Condition
the NCT03866915 375 378 I-Condition
lower NCT03866915 379 384 I-Condition
extremities NCT03866915 385 396 I-Condition
and NCT03866915 397 400 B-And
inability NCT03866915 401 410 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866915 411 413 O
maintain NCT03866915 414 422 O
a NCT03866915 423 424 O
constant NCT03866915 425 433 O
pace NCT03866915 434 438 B-Observation
of NCT03866915 439 441 I-Observation
walking NCT03866915 442 449 I-Observation
on NCT03866915 450 452 O
level NCT03866915 453 458 B-Modifier
ground NCT03866915 459 465 I-Modifier

Inclusion NCT03869398 0 9 O
Criteria NCT03869398 10 18 O
: NCT03869398 19 20 O

- NCT03869398 24 25 O
All NCT03869398 27 30 O
patients NCT03869398 31 39 O
, NCT03869398 40 41 O
age NCT03869398 42 45 B-Age
> NCT03869398 46 47 B-Eq-Comparison
18 NCT03869398 48 50 I-Eq-Comparison
, NCT03869398 51 52 O
undergoing NCT03869398 53 63 B-Eq-Comparison
total NCT03869398 64 69 B-Procedure
thyroidectomy NCT03869398 70 83 I-Procedure
are NCT03869398 84 87 O
eligible NCT03869398 88 96 O
. NCT03869398 96 97 O

Exclusion NCT03869398 99 108 O
Criteria NCT03869398 109 117 O
: NCT03869398 118 119 O

- NCT03869398 123 124 O
partial NCT03869398 126 133 B-Procedure
thyroidectomy NCT03869398 134 147 I-Procedure
, NCT03869398 148 149 O
lobectomy NCT03869398 150 159 B-Procedure
, NCT03869398 160 161 O
or NCT03869398 162 164 B-Or
concurrent NCT03869398 165 175 B-Modifier
parathyroidectomy NCT03869398 176 193 B-Procedure
. NCT03869398 193 194 O

Inclusion NCT03867968 0 9 O
Criteria NCT03867968 10 18 O
: NCT03867968 19 20 O

- NCT03867968 24 25 O
Adult NCT03867968 27 32 O
18 NCT03867968 33 35 B-Eq-Comparison
years NCT03867968 36 41 I-Eq-Comparison
old NCT03867968 42 45 I-Eq-Comparison
or NCT03867968 46 48 I-Eq-Comparison
older NCT03867968 49 54 I-Eq-Comparison

- NCT03867968 57 58 O
Have NCT03867968 60 64 O
a NCT03867968 65 66 O
child NCT03867968 67 72 B-Family-Member___Family-Member-Type:child
age NCT03867968 73 76 B-Age
3 NCT03867968 77 78 B-Eq-Comparison
- NCT03867968 79 80 I-Eq-Comparison
18 NCT03867968 81 83 O
that NCT03867968 84 88 B-And
was NCT03867968 89 92 O
hospitalized NCT03867968 93 105 B-Encounter
overnight NCT03867968 106 115 O
with NCT03867968 116 120 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03867968 121 122 O
traumatic NCT03867968 123 132 B-Condition
brain NCT03867968 133 138 I-Condition
injury NCT03867968 139 145 I-Condition
( NCT03867968 146 147 O
TBI NCT03867968 148 151 B-Condition
) NCT03867968 152 153 O
. NCT03867968 154 155 O

- NCT03867968 159 160 O
Involved NCT03867968 162 170 O
in NCT03867968 171 173 O
the NCT03867968 174 177 O
care NCT03867968 178 182 O
and NCT03867968 183 186 O
support NCT03867968 187 194 O
of NCT03867968 195 197 O
the NCT03867968 198 201 O
child NCT03867968 202 207 B-Family-Member___Family-Member-Type:child
with NCT03867968 208 212 O
the NCT03867968 213 216 O
TBI NCT03867968 217 220 B-Condition
. NCT03867968 220 221 O

- NCT03867968 225 226 O
Live NCT03867968 228 232 O
in NCT03867968 233 235 O
the NCT03867968 236 239 O
same NCT03867968 240 244 O
household NCT03867968 245 254 O
as NCT03867968 255 257 O
child NCT03867968 258 263 B-Family-Member___Family-Member-Type:child
with NCT03867968 264 268 O
a NCT03867968 269 270 O
TBI NCT03867968 271 274 B-Condition
. NCT03867968 274 275 O

- NCT03867968 279 280 O
The NCT03867968 282 285 O
child NCT03867968 286 291 B-Family-Member___Family-Member-Type:child
with NCT03867968 292 296 O
the NCT03867968 297 300 O
TBI NCT03867968 301 304 B-Condition
is NCT03867968 305 307 O
able NCT03867968 308 312 O
to NCT03867968 313 315 O
follow NCT03867968 316 322 O
simple NCT03867968 323 329 O
instructions NCT03867968 330 342 O
such NCT03867968 343 347 O
as NCT03867968 348 350 O
" NCT03867968 351 352 O
please NCT03867968 352 358 O
eat NCT03867968 359 362 O
your NCT03867968 363 367 O
toast NCT03867968 368 373 O
. NCT03867968 373 374 O
" NCT03867968 375 376 O

Exclusion NCT03867968 377 386 O
Criteria NCT03867968 387 395 O
: NCT03867968 396 397 O

- NCT03867968 401 402 O
Does NCT03867968 404 408 O
not NCT03867968 409 412 B-Negation
speak NCT03867968 413 418 O
and NCT03867968 419 422 O
read NCT03867968 423 427 O
English NCT03867968 428 435 O
. NCT03867968 435 436 O

- NCT03867968 440 441 O
Does NCT03867968 443 447 O
not NCT03867968 448 451 O
have NCT03867968 452 456 O
high NCT03867968 457 461 O
speed NCT03867968 462 467 O
Internet NCT03867968 468 476 O
access NCT03867968 477 483 O
. NCT03867968 483 484 O

- NCT03867968 488 489 O
Not NCT03867968 491 494 B-Negation
US NCT03867968 495 497 O
resident NCT03867968 498 506 O

Inclusion NCT03866486 0 9 O
Criteria NCT03866486 10 18 O
: NCT03866486 19 20 O

- NCT03866486 24 25 O
1 NCT03866486 27 28 O
. NCT03866486 28 29 O
The NCT03866486 31 34 O
patients NCT03866486 35 43 O
who NCT03866486 44 47 O
enrolled NCT03866486 48 56 O
in NCT03866486 57 59 O
the NCT03866486 60 63 O
XPL NCT03866486 64 67 O
- NCT03866486 68 69 O
IVUS NCT03866486 70 74 O
study NCT03866486 75 80 B-Study
. NCT03866486 80 81 O

- NCT03866486 85 86 O
2 NCT03866486 88 89 O
. NCT03866486 89 90 O
Provision NCT03866486 92 101 O
of NCT03866486 102 104 O
informed NCT03866486 105 113 O
consent NCT03866486 114 121 O

Exclusion NCT03866486 122 131 O
Criteria NCT03866486 132 140 O
: NCT03866486 141 142 O

- NCT03866486 146 147 O
1 NCT03866486 149 150 O
. NCT03866486 150 151 O
This NCT03866486 153 157 O
observational NCT03866486 158 171 O
study NCT03866486 172 177 B-Study
does NCT03866486 178 182 O
not NCT03866486 183 186 O
have NCT03866486 187 191 O
any NCT03866486 192 195 O
specific NCT03866486 196 204 O
exclusion NCT03866486 205 214 O
criteria NCT03866486 215 223 O
. NCT03866486 223 224 O

Inclusion NCT03868332 0 9 O
Criteria NCT03868332 10 18 O
: NCT03868332 19 20 O

Patients NCT03868332 22 30 O
who NCT03868332 31 34 O
are NCT03868332 35 38 O
diagnosed NCT03868332 39 48 O
as NCT03868332 49 51 O
ulcerative NCT03868332 52 62 B-Condition
colitis NCT03868332 63 70 I-Condition
/ NCT03868332 71 72 B-Or
Crhon NCT03868332 73 78 B-Condition
s NCT03868332 79 80 I-Condition
disease NCT03868332 81 88 I-Condition
however NCT03868332 89 96 O
in NCT03868332 97 99 O
activity NCT03868332 100 108 B-Eq-Comparison
or NCT03868332 109 111 B-Or

in NCT03868332 112 114 B-Eq-Comparison
remission NCT03868332 115 124 I-Eq-Comparison
attending NCT03868332 125 134 B-Encounter
the NCT03868332 135 138 O
the NCT03868332 139 142 O
outpatient NCT03868332 143 153 O
clinics NCT03868332 154 161 O
and NCT03868332 162 165 B-Or
inpatient NCT03868332 166 175 B-Encounter
of NCT03868332 176 178 O
gastroenterology NCT03868332 179 195 O
units NCT03868332 196 201 O

of NCT03868332 202 204 O
Internal NCT03868332 205 213 O
medicine NCT03868332 214 222 O
department NCT03868332 223 233 O

Exclusion NCT03868332 234 243 O
Criteria NCT03868332 244 252 O
: NCT03868332 253 254 O

- NCT03868332 258 259 O
Previous NCT03868332 261 269 B-Eq-Comparison
history NCT03868332 270 277 I-Eq-Comparison
of NCT03868332 278 280 O
hypertension NCT03868332 281 293 B-Condition
, NCT03868332 294 295 O
diabetes NCT03868332 296 304 B-Condition
mellitus NCT03868332 305 313 I-Condition
, NCT03868332 314 315 O
Dyslipidemia NCT03868332 316 328 B-Condition

- NCT03868332 331 332 O
Previous NCT03868332 334 342 B-Eq-Comparison
history NCT03868332 343 350 I-Eq-Comparison
of NCT03868332 351 353 O
cardiovascular NCT03868332 354 368 B-Modifier
or NCT03868332 369 371 B-Or
cerebrovascular NCT03868332 372 387 B-Modifier
events NCT03868332 388 394 B-Condition

- NCT03868332 397 398 O
Autoimmune NCT03868332 400 410 B-Modifier
, NCT03868332 411 412 O
Neoplastic NCT03868332 413 423 B-Modifier
diseases NCT03868332 424 432 B-Condition

- NCT03868332 435 436 O
Thromboembolic NCT03868332 438 452 B-Condition
diseases NCT03868332 453 461 I-Condition

Inclusion NCT03867773 0 9 O
Criteria NCT03867773 10 18 O
: NCT03867773 19 20 O

- NCT03867773 24 25 O
Male NCT03867773 27 31 O
or NCT03867773 32 34 B-Or
female NCT03867773 35 41 O
; NCT03867773 41 42 O

- NCT03867773 45 46 O
body NCT03867773 48 52 B-Observation
mass NCT03867773 53 57 I-Observation
index NCT03867773 58 63 I-Observation
( NCT03867773 64 65 O
BMI NCT03867773 66 69 B-Observation
) NCT03867773 70 71 O
between NCT03867773 72 79 B-Eq-Comparison
30.0 NCT03867773 80 84 I-Eq-Comparison
and NCT03867773 85 88 I-Eq-Comparison
49.9 NCT03867773 89 93 I-Eq-Comparison
kg NCT03867773 94 96 I-Eq-Comparison
/ NCT03867773 97 98 I-Eq-Comparison
m2 NCT03867773 99 101 I-Eq-Comparison
; NCT03867773 101 102 O

- NCT03867773 105 106 O
age NCT03867773 108 111 B-Age
between NCT03867773 112 119 B-Eq-Comparison
18 NCT03867773 120 122 I-Eq-Comparison
and NCT03867773 123 126 I-Eq-Comparison
65 NCT03867773 127 129 I-Eq-Comparison
years NCT03867773 130 135 I-Eq-Comparison
; NCT03867773 135 136 O
sedentary NCT03867773 137 146 B-Observation
( NCT03867773 147 148 O
light NCT03867773 149 154 B-Observation
exercise NCT03867773 155 163 I-Observation
less NCT03867773 164 168 B-Eq-Comparison
than NCT03867773 169 173 I-Eq-Comparison
1 NCT03867773 174 175 I-Eq-Comparison
h NCT03867773 176 177 I-Eq-Comparison
per NCT03867773 178 181 I-Eq-Comparison
week NCT03867773 182 186 I-Eq-Comparison
) NCT03867773 187 188 O
or NCT03867773 189 191 B-Or
moderately NCT03867773 192 202 B-Observation
active NCT03867773 203 209 I-Observation
( NCT03867773 210 211 O
moderate NCT03867773 212 220 B-Observation
exercise NCT03867773 221 229 I-Observation
1 NCT03867773 230 231 B-Eq-Comparison
to NCT03867773 232 234 I-Eq-Comparison
2 NCT03867773 235 236 I-Eq-Comparison
h NCT03867773 237 238 I-Eq-Comparison
per NCT03867773 239 242 I-Eq-Comparison
week NCT03867773 243 247 I-Eq-Comparison
) NCT03867773 248 249 O
; NCT03867773 250 251 O

- NCT03867773 254 255 O
weight NCT03867773 257 263 B-Observation
stable NCT03867773 264 270 O
for NCT03867773 271 274 O
> NCT03867773 275 276 B-Eq-Comparison
3 NCT03867773 277 278 I-Eq-Comparison
months NCT03867773 279 285 I-Eq-Comparison
prior NCT03867773 286 291 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867773 292 294 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867773 295 298 O
beginning NCT03867773 299 308 O
of NCT03867773 309 311 O
the NCT03867773 312 315 O
study NCT03867773 316 321 B-Study
( NCT03867773 322 323 O
gain NCT03867773 324 328 B-Eq-Comparison
or NCT03867773 329 331 I-Eq-Comparison
loss NCT03867773 332 336 I-Eq-Comparison
< NCT03867773 337 338 I-Eq-Comparison
4 NCT03867773 339 340 I-Eq-Comparison
kg NCT03867773 341 343 I-Eq-Comparison
) NCT03867773 344 345 O
; NCT03867773 346 347 O

- NCT03867773 350 351 O
able NCT03867773 353 357 O
to NCT03867773 358 360 O
give NCT03867773 361 365 O
written NCT03867773 366 373 O
informed NCT03867773 374 382 O
consent NCT03867773 383 390 O

Exclusion NCT03867773 391 400 O
Criteria NCT03867773 401 409 O
: NCT03867773 410 411 O

- NCT03867773 415 416 O
Smoker NCT03867773 418 424 B-Condition
; NCT03867773 424 425 O
diabetic NCT03867773 426 434 B-Condition
; NCT03867773 434 435 O

- NCT03867773 438 439 O
history NCT03867773 441 448 B-Eq-Comparison
of NCT03867773 449 451 O
alcohol NCT03867773 452 459 B-Condition
dependance NCT03867773 460 470 I-Condition
( NCT03867773 471 472 O
score NCT03867773 473 478 B-Eq-Comparison
> NCT03867773 479 480 I-Eq-Comparison
20 NCT03867773 481 483 I-Eq-Comparison
from NCT03867773 484 488 O
Alcohol NCT03867773 489 496 B-Observation
and NCT03867773 497 500 I-Observation
Health NCT03867773 501 507 I-Observation
Questionnaire NCT03867773 508 521 I-Observation
8 NCT03867773 522 523 I-Observation
) NCT03867773 524 525 O
; NCT03867773 526 527 O

- NCT03867773 530 531 O
taking NCT03867773 533 539 B-Eq-Comparison
weight NCT03867773 540 546 B-Drug
loss NCT03867773 547 551 I-Drug
medications NCT03867773 552 563 I-Drug
; NCT03867773 563 564 O

- NCT03867773 567 568 O
taking NCT03867773 570 576 B-Eq-Comparison
medication NCT03867773 577 587 B-Drug
that NCT03867773 588 592 O
requires NCT03867773 593 601 O
eating NCT03867773 602 608 B-Observation
food NCT03867773 609 613 I-Observation
before NCT03867773 614 620 B-Temporal-Connection___Temporal-Connection-Type-Value:before
( NCT03867773 621 622 O
or NCT03867773 623 625 O
with NCT03867773 626 630 O
) NCT03867773 631 632 O
the NCT03867773 633 636 B-Coreference
medication NCT03867773 637 647 I-Coreference
; NCT03867773 647 648 O
history NCT03867773 649 656 B-Eq-Comparison
of NCT03867773 657 659 O
eating NCT03867773 660 666 B-Condition
disorders NCT03867773 667 676 I-Condition
; NCT03867773 676 677 O

- NCT03867773 680 681 O
night NCT03867773 683 688 O
- NCT03867773 689 690 O
shift NCT03867773 691 696 O
workers NCT03867773 697 704 O
; NCT03867773 704 705 O

- NCT03867773 708 709 O
perimenopausal NCT03867773 711 725 B-Condition
; NCT03867773 725 726 O

- NCT03867773 729 730 O
pregnant NCT03867773 732 740 B-Condition
women NCT03867773 741 746 O

Inclusion NCT03865602 0 9 O
Criteria NCT03865602 10 18 O
: NCT03865602 19 20 O

1 NCT03865602 24 25 O
. NCT03865602 25 26 O
Admitted NCT03865602 28 36 B-Encounter
from NCT03865602 37 41 O
the NCT03865602 42 45 O
emergency NCT03865602 46 55 O
department NCT03865602 56 66 O
to NCT03865602 67 69 B-Temporal-Connection___Temporal-Connection-Type-Value:after
inpatient NCT03865602 70 79 B-Encounter
or NCT03865602 80 82 B-Or
observation NCT03865602 83 94 B-Encounter
status NCT03865602 95 101 O
at NCT03865602 102 104 O
one NCT03865602 105 108 O
of NCT03865602 109 111 O
: NCT03865602 112 113 O

Carolinas NCT03865602 120 129 O
Medical NCT03865602 130 137 O
Center NCT03865602 138 144 O
, NCT03865602 145 146 O
Carolinas NCT03865602 147 156 O
Medical NCT03865602 157 164 O
Center NCT03865602 165 171 O
- NCT03865602 172 173 O
Mercy NCT03865602 174 179 O
, NCT03865602 180 181 O
or NCT03865602 182 184 B-Or
Atrium NCT03865602 185 191 O
Health NCT03865602 192 198 O
Northeast NCT03865602 199 208 O
; NCT03865602 208 209 O

2 NCT03865602 212 213 O
. NCT03865602 213 214 O
≥ NCT03865602 216 217 B-Eq-Comparison
18 NCT03865602 218 220 I-Eq-Comparison
years NCT03865602 221 226 I-Eq-Comparison
of NCT03865602 227 229 O
age NCT03865602 230 233 B-Age
upon NCT03865602 234 238 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03865602 239 248 B-Encounter
; NCT03865602 248 249 O

3 NCT03865602 252 253 O
. NCT03865602 253 254 O
oral NCT03865602 256 260 B-Modifier
/ NCT03865602 261 262 B-Or
parenteral NCT03865602 263 273 B-Modifier
antibiotic NCT03865602 274 284 B-Drug
or NCT03865602 285 287 B-Or
bacterial NCT03865602 288 297 B-Observation
culture NCT03865602 298 305 I-Observation
order NCT03865602 306 311 O
within NCT03865602 312 318 B-Eq-Comparison
24 NCT03865602 319 321 I-Eq-Comparison
hours NCT03865602 322 327 I-Eq-Comparison
of NCT03865602 328 330 B-Temporal-Connection___Temporal-Connection-Type-Value:after
emergency NCT03865602 331 340 B-Encounter
department NCT03865602 341 351 O
presentation NCT03865602 352 364 O
and NCT03865602 365 368 O

1 NCT03865602 376 377 O
. NCT03865602 377 378 O
culture NCT03865602 380 387 B-Observation
drawn NCT03865602 388 393 O
first NCT03865602 394 399 B-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03865602 400 401 O
antibiotics NCT03865602 402 413 B-Drug
ordered NCT03865602 414 421 O
within NCT03865602 422 428 B-Eq-Comparison
48 NCT03865602 429 431 I-Eq-Comparison
hours NCT03865602 432 437 I-Eq-Comparison
or NCT03865602 438 440 B-Or

2 NCT03865602 448 449 O
. NCT03865602 449 450 O
antibiotics NCT03865602 452 463 B-Drug
ordered NCT03865602 464 471 O
first NCT03865602 472 477 B-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03865602 478 479 O
culture NCT03865602 480 487 B-Observation
ordered NCT03865602 488 495 O
within NCT03865602 496 502 B-Eq-Comparison
48 NCT03865602 503 505 I-Eq-Comparison
hours NCT03865602 506 511 I-Eq-Comparison
( NCT03865602 512 513 O
adapted NCT03865602 514 521 O
from NCT03865602 522 526 O
criteria NCT03865602 527 535 O
applied NCT03865602 536 543 O
in NCT03865602 544 546 O
development NCT03865602 547 558 O
of NCT03865602 559 561 O
the NCT03865602 562 565 O
Third NCT03865602 566 571 O
International NCT03865602 572 585 O
Consensus NCT03865602 586 595 O
Definitions NCT03865602 596 607 O
for NCT03865602 608 611 O
Sepsis NCT03865602 612 618 O
and NCT03865602 619 622 O
Septic NCT03865602 623 629 O
Shock NCT03865602 630 635 O
) NCT03865602 636 637 O

4 NCT03865602 641 642 O
. NCT03865602 642 643 O
deemed NCT03865602 645 651 O
as NCT03865602 652 654 O
high NCT03865602 655 659 B-Modifier
- NCT03865602 660 661 I-Eq-Comparison
risk NCT03865602 662 666 B-Risk
for NCT03865602 667 670 O
30 NCT03865602 671 673 B-Eq-Comparison
- NCT03865602 674 675 O
day NCT03865602 676 679 I-Eq-Comparison
readmission NCT03865602 680 691 B-Encounter
( NCT03865602 692 693 O
i. NCT03865602 694 696 O
e. NCT03865602 697 699 O
, NCT03865602 700 701 O
≥ NCT03865602 702 703 B-Eq-Comparison
20 NCT03865602 704 706 I-Eq-Comparison
% NCT03865602 707 708 O
) NCT03865602 709 710 O
or NCT03865602 711 713 B-Or
30 NCT03865602 714 716 B-Eq-Comparison
- NCT03865602 717 718 I-Eq-Comparison
day NCT03865602 719 722 I-Eq-Comparison
mortality NCT03865602 723 732 B-Death
( NCT03865602 733 734 O
i. NCT03865602 735 737 O
e. NCT03865602 738 740 O
, NCT03865602 741 742 O
≥ NCT03865602 743 744 B-Eq-Comparison
10 NCT03865602 745 747 I-Eq-Comparison
% NCT03865602 748 749 O
) NCT03865602 750 751 O
using NCT03865602 752 757 B-Eq-Comparison
risk NCT03865602 758 762 B-Observation
- NCT03865602 763 764 I-Observation
scoring NCT03865602 765 772 I-Observation
models NCT03865602 773 779 I-Observation

5 NCT03865602 782 783 O
. NCT03865602 783 784 O
not NCT03865602 786 789 B-Negation
discharged NCT03865602 790 800 B-Encounter
at NCT03865602 801 803 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865602 804 807 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865602 808 812 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865602 813 815 I-Temporal-Connection___Temporal-Connection-Type-Value:during
patient NCT03865602 816 823 B-Study
list NCT03865602 824 828 I-Study
generation NCT03865602 829 839 I-Study

Exclusion NCT03865602 840 849 O
Criteria NCT03865602 850 858 O
: NCT03865602 859 860 O

1 NCT03865602 864 865 O
. NCT03865602 865 866 O
prior NCT03865602 868 873 B-Eq-Comparison
randomization NCT03865602 874 887 O
to NCT03865602 888 890 O
either NCT03865602 891 897 O
STAR NCT03865602 898 902 O
or NCT03865602 903 905 O
usual NCT03865602 906 911 O
care NCT03865602 912 916 O
study NCT03865602 917 922 O
arms NCT03865602 923 927 O
; NCT03865602 927 928 O

2 NCT03865602 931 932 O
. NCT03865602 932 933 O
not NCT03865602 935 938 B-Negation
a NCT03865602 939 940 O
North NCT03865602 941 946 O
Carolina NCT03865602 947 955 O
resident NCT03865602 956 964 O
or NCT03865602 965 967 B-Or
residence NCT03865602 968 977 B-Modifier
> NCT03865602 978 979 B-Eq-Comparison
2.5 NCT03865602 980 983 I-Eq-Comparison
- NCT03865602 984 985 I-Eq-Comparison
hour NCT03865602 986 990 I-Eq-Comparison
drive NCT03865602 991 996 B-Observation
time NCT03865602 997 1001 I-Observation
from NCT03865602 1002 1006 O
treating NCT03865602 1007 1015 O
hospital NCT03865602 1016 1024 O
; NCT03865602 1024 1025 O

3 NCT03865602 1028 1029 O
. NCT03865602 1029 1030 O
the NCT03865602 1032 1035 O
only NCT03865602 1036 1040 O
antibiotic NCT03865602 1041 1051 B-Drug
associated NCT03865602 1052 1062 O
with NCT03865602 1063 1067 O
patient NCT03865602 1068 1075 O
is NCT03865602 1076 1078 O
administered NCT03865602 1079 1091 B-Eq-Comparison
in NCT03865602 1092 1094 O
the NCT03865602 1095 1098 O
operating NCT03865602 1099 1108 O
room NCT03865602 1109 1113 O
as NCT03865602 1114 1116 O
this NCT03865602 1117 1121 O
likely NCT03865602 1122 1128 B-Assertion___Assertion-Type-Value:possible
represents NCT03865602 1129 1139 O
pre NCT03865602 1140 1143 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03865602 1144 1145 O
- NCT03865602 1147 1148 O
operative NCT03865602 1149 1158 B-Procedure
infection NCT03865602 1159 1168 B-Condition|Condition
prophylaxis NCT03865602 1169 1180 O
and NCT03865602 1181 1184 B-And
not NCT03865602 1185 1188 B-Negation
presumed NCT03865602 1189 1197 O
infection NCT03865602 1198 1207 O
; NCT03865602 1207 1208 O

4 NCT03865602 1211 1212 O
. NCT03865602 1212 1213 O
patients NCT03865602 1215 1223 O
transferred NCT03865602 1224 1235 B-Encounter
from NCT03865602 1236 1240 O
other NCT03865602 1241 1246 O
acute NCT03865602 1247 1252 O
care NCT03865602 1253 1257 O
hospitals NCT03865602 1258 1267 O
; NCT03865602 1267 1268 O

5 NCT03865602 1271 1272 O
. NCT03865602 1272 1273 O
patients NCT03865602 1275 1283 O
with NCT03865602 1284 1288 O
a NCT03865602 1289 1290 O
change NCT03865602 1291 1297 O
in NCT03865602 1298 1300 I-Observation
code NCT03865602 1301 1305 B-Observation
status NCT03865602 1306 1312 I-Observation
( NCT03865602 1313 1314 O
i. NCT03865602 1315 1317 O
e. NCT03865602 1318 1320 O
, NCT03865602 1321 1322 O
do NCT03865602 1323 1325 B-Observation|Observation
not NCT03865602 1326 1329 I-Observation|Observation
resuscitate NCT03865602 1330 1341 I-Observation
, NCT03865602 1342 1343 O
do NCT03865602 1344 1346 O
not NCT03865602 1347 1350 O
intubate NCT03865602 1351 1359 O
) NCT03865602 1360 1361 O
within NCT03865602 1362 1368 B-Eq-Comparison
24 NCT03865602 1369 1371 I-Eq-Comparison
hours NCT03865602 1372 1377 I-Eq-Comparison
after NCT03865602 1378 1383 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03865602 1384 1393 B-Encounter
due NCT03865602 1394 1397 O
to NCT03865602 1398 1400 O
the NCT03865602 1401 1404 O
general NCT03865602 1405 1412 O
assumption NCT03865602 1413 1423 O
of NCT03865602 1424 1426 O
increased NCT03865602 1427 1436 O
risk NCT03865602 1437 1441 O
of NCT03865602 1442 1444 O
exposure NCT03865602 1445 1453 O
to NCT03865602 1454 1456 O
less NCT03865602 1457 1461 O
aggressive NCT03865602 1462 1472 O
treatment NCT03865602 1473 1482 O
; NCT03865602 1482 1483 O

6 NCT03865602 1486 1487 O
. NCT03865602 1487 1488 O
patients NCT03865602 1490 1498 O
with NCT03865602 1499 1503 O
infection NCT03865602 1504 1513 B-Condition
ruled NCT03865602 1514 1519 B-Negation
out NCT03865602 1520 1523 I-Negation
during NCT03865602 1524 1530 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865602 1531 1534 O
index NCT03865602 1535 1540 O
hospitalization NCT03865602 1541 1556 B-Encounter
. NCT03865602 1556 1557 O


Inclusion NCT03864939 0 9 O
Criteria NCT03864939 10 18 O
: NCT03864939 19 20 O

- NCT03864939 24 25 O
patients NCT03864939 27 35 O
with NCT03864939 36 40 O
localized NCT03864939 41 50 B-Modifier
prostate NCT03864939 51 59 I-Modifier
cancer NCT03864939 60 66 B-Condition

- NCT03864939 69 70 O
indication NCT03864939 72 82 B-Indication
for NCT03864939 83 86 O
radical NCT03864939 87 94 B-Procedure
prostatectomy NCT03864939 95 108 I-Procedure

- NCT03864939 111 112 O
no NCT03864939 114 116 B-Negation
other NCT03864939 117 122 B-Other
treatment NCT03864939 123 132 B-Procedure
of NCT03864939 133 135 O
prostate NCT03864939 136 144 B-Modifier
cancer NCT03864939 145 151 B-Condition

- NCT03864939 154 155 O
availability NCT03864939 157 169 O
to NCT03864939 170 172 O
informed NCT03864939 173 181 O
consent NCT03864939 182 189 O

Exclusion NCT03864939 190 199 O
Criteria NCT03864939 200 208 O
: NCT03864939 209 210 O

- NCT03864939 214 215 O
pre NCT03864939 217 220 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864939 221 222 O
- NCT03864939 224 225 O
operative NCT03864939 226 235 B-Procedure
incontinence NCT03864939 236 248 B-Condition
( NCT03864939 249 250 O
24 NCT03864939 251 253 B-Observation
hrs NCT03864939 254 257 O
pad NCT03864939 258 261 I-Observation
- NCT03864939 262 263 I-Observation
test NCT03864939 264 268 I-Observation
) NCT03864939 269 270 O

- NCT03864939 274 275 O
pre NCT03864939 277 280 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864939 281 282 O
- NCT03864939 284 285 O
operative NCT03864939 286 295 B-Procedure
erectile NCT03864939 296 304 B-Condition
dysfunction NCT03864939 305 316 I-Condition
( NCT03864939 317 318 O
IIEF NCT03864939 319 323 B-Observation
- NCT03864939 324 325 O
5 NCT03864939 326 327 B-Eq-Comparison
< NCT03864939 328 329 I-Eq-Comparison
20 NCT03864939 330 332 I-Eq-Comparison
) NCT03864939 333 334 O

- NCT03864939 338 339 O
metastasized NCT03864939 341 353 B-Modifier
or NCT03864939 354 356 B-Or
locally NCT03864939 357 364 B-Modifier
advanced NCT03864939 365 373 I-Modifier
prostate NCT03864939 374 382 O
cancer NCT03864939 383 389 B-Condition
in NCT03864939 390 392 O
pre NCT03864939 393 396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864939 397 398 O
- NCT03864939 400 401 O
operative NCT03864939 402 411 B-Procedure
assessment NCT03864939 412 422 B-Observation

- NCT03864939 425 426 O
previous NCT03864939 428 436 B-Eq-Comparison
radiation NCT03864939 437 446 B-Procedure
of NCT03864939 447 449 O
pelvis NCT03864939 450 456 B-Modifier

- NCT03864939 459 460 O
previous NCT03864939 462 470 B-Eq-Comparison
prostate NCT03864939 471 479 B-Modifier
cancer NCT03864939 480 486 B-Condition
therapy NCT03864939 487 494 B-Procedure

- NCT03864939 497 498 O
psychiatric NCT03864939 500 511 B-Condition
disease NCT03864939 512 519 I-Condition

- NCT03864939 522 523 O
participation NCT03864939 525 538 O
at NCT03864939 539 541 O
another NCT03864939 542 549 B-Other
study NCT03864939 550 555 B-Study

Inclusion NCT03868865 0 9 O
Criteria NCT03868865 10 18 O
: NCT03868865 19 20 O

- NCT03868865 24 25 O
curative NCT03868865 27 35 B-Condition
malignancy NCT03868865 36 46 I-Condition
( NCT03868865 47 48 O
breast NCT03868865 49 55 B-Modifier
cancer NCT03868865 56 62 B-Condition
of NCT03868865 63 65 O
TNM NCT03868865 66 69 O
( NCT03868865 70 71 O
T NCT03868865 72 73 O
: NCT03868865 74 75 O
primary NCT03868865 76 83 O
tumor NCT03868865 84 89 O
, NCT03868865 90 91 O
N NCT03868865 92 93 O
: NCT03868865 94 95 O
regional NCT03868865 96 104 O
nodes NCT03868865 105 110 O
, NCT03868865 111 112 O
M NCT03868865 113 114 O
: NCT03868865 115 116 O
metastasis NCT03868865 117 127 O
) NCT03868865 128 129 O
staging NCT03868865 130 137 B-Eq-Comparison
I NCT03868865 138 139 I-Eq-Comparison
- NCT03868865 140 141 I-Eq-Comparison
III NCT03868865 142 145 I-Eq-Comparison
) NCT03868865 146 147 O

- NCT03868865 151 152 O
receiving NCT03868865 154 163 B-Eq-Comparison
chemotherapy NCT03868865 164 176 B-Procedure

- NCT03868865 179 180 O
at NCT03868865 182 184 B-Eq-Comparison
least NCT03868865 185 190 I-Eq-Comparison
18 NCT03868865 191 193 I-Eq-Comparison
years NCT03868865 194 199 I-Eq-Comparison
old NCT03868865 200 203 B-Age

- NCT03868865 206 207 O
written NCT03868865 209 216 O
informed NCT03868865 217 225 O
consent NCT03868865 226 233 O

- NCT03868865 236 237 O
willing NCT03868865 239 246 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03868865 247 250 B-And
physically NCT03868865 251 261 O
/ NCT03868865 262 263 O
mentally NCT03868865 264 272 O
able NCT03868865 273 277 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868865 278 280 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868865 281 292 O
in NCT03868865 293 295 O
a NCT03868865 296 297 O
six NCT03868865 298 301 B-Eq-Comparison
hours NCT03868865 302 307 I-Eq-Comparison
day NCT03868865 308 311 I-Eq-Comparison
care NCT03868865 312 316 B-Observation
clinic NCT03868865 317 323 I-Observation
program NCT03868865 324 331 I-Observation
eleven NCT03868865 332 338 B-Eq-Comparison
times NCT03868865 339 344 I-Eq-Comparison
during NCT03868865 345 351 B-Temporal-Connection___Temporal-Connection-Type-Value:during
chemotherapy NCT03868865 352 364 B-Procedure
. NCT03868865 364 365 O

Exclusion NCT03868865 367 376 O
Criteria NCT03868865 377 385 O
: NCT03868865 386 387 O

- NCT03868865 391 392 O
insufficient NCT03868865 394 406 B-Negation
knowledge NCT03868865 407 416 O
of NCT03868865 417 419 O
the NCT03868865 420 423 O
German NCT03868865 424 430 O
language NCT03868865 431 439 O

- NCT03868865 442 443 O
physical NCT03868865 445 453 B-Modifier
or NCT03868865 454 456 B-Or
mental NCT03868865 457 463 B-Modifier
disabilities NCT03868865 464 476 B-Condition
resulting NCT03868865 477 486 O
in NCT03868865 487 489 O
ineligibility NCT03868865 490 503 O
for NCT03868865 504 507 O
participation NCT03868865 508 521 O
in NCT03868865 522 524 O
the NCT03868865 525 528 O
program NCT03868865 529 536 O
or NCT03868865 537 539 O
filling NCT03868865 540 547 O
out NCT03868865 548 551 O
the NCT03868865 552 555 O
questionnaires NCT03868865 556 570 O
. NCT03868865 570 571 O


Inclusion NCT03867565 0 9 O
Criteria NCT03867565 10 18 O
: NCT03867565 19 20 O

- NCT03867565 24 25 O
Minor NCT03867565 27 32 B-Condition
burn NCT03867565 33 37 I-Condition
, NCT03867565 38 39 O
TBSA NCT03867565 40 44 B-Observation
< NCT03867565 45 46 B-Eq-Comparison
20 NCT03867565 47 49 I-Eq-Comparison
% NCT03867565 50 51 I-Eq-Comparison

- NCT03867565 54 55 O
Age NCT03867565 57 60 B-Age
≥ NCT03867565 61 62 B-Eq-Comparison
18 NCT03867565 63 65 I-Eq-Comparison
years NCT03867565 66 71 I-Eq-Comparison
old NCT03867565 72 75 O

- NCT03867565 78 79 O
Understands NCT03867565 81 92 O
Swedish NCT03867565 93 100 O
or NCT03867565 101 103 B-Or
English NCT03867565 104 111 O
verbally NCT03867565 112 120 O
and NCT03867565 121 124 O
in NCT03867565 125 127 O
writing NCT03867565 128 135 O

- NCT03867565 138 139 O
Mentally NCT03867565 141 149 B-Condition
adequate NCT03867565 150 158 I-Condition

- NCT03867565 161 162 O
Oral NCT03867565 164 168 O
and NCT03867565 169 172 O
written NCT03867565 173 180 O
informed NCT03867565 181 189 O
consent NCT03867565 190 197 O
. NCT03867565 197 198 O

Exclusion NCT03867565 200 209 O
Criteria NCT03867565 210 218 O
: NCT03867565 219 220 O

- NCT03867565 224 225 O
Patients NCT03867565 227 235 O
deemed NCT03867565 236 242 O
not NCT03867565 243 246 O
to NCT03867565 247 249 O
be NCT03867565 250 252 O
able NCT03867565 253 257 O
to NCT03867565 258 260 O
complete NCT03867565 261 269 O
study NCT03867565 270 275 O
protocol NCT03867565 276 284 O
. NCT03867565 284 285 O

- NCT03867565 289 290 O
TBSA NCT03867565 292 296 B-Observation
< NCT03867565 297 298 B-Eq-Comparison
2 NCT03867565 299 300 I-Eq-Comparison
% NCT03867565 301 302 I-Eq-Comparison
. NCT03867565 302 303 O

Inclusion NCT03868124 0 9 O
Criteria NCT03868124 10 18 O
: NCT03868124 19 20 O

- NCT03868124 24 25 O
Diagnosed NCT03868124 27 36 O
with NCT03868124 37 41 O
open NCT03868124 42 46 B-Modifier
- NCT03868124 47 48 I-Modifier
angle NCT03868124 49 54 I-Modifier
glaucoma NCT03868124 55 63 B-Condition
or NCT03868124 64 66 B-Or
ocular NCT03868124 67 73 B-Modifier
hypertension NCT03868124 74 86 B-Condition

- NCT03868124 89 90 O
C NCT03868124 92 93 B-Observation
/ NCT03868124 94 95 I-Observation
D NCT03868124 96 97 I-Observation
ratio NCT03868124 98 103 I-Observation
≤ NCT03868124 104 105 B-Eq-Comparison
0.8 NCT03868124 106 109 I-Eq-Comparison

- NCT03868124 113 114 O
Zero NCT03868124 116 120 B-Eq-Comparison
to NCT03868124 121 123 I-Eq-Comparison
two NCT03868124 124 127 I-Eq-Comparison
pre NCT03868124 128 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03868124 132 133 O
- NCT03868124 135 136 O
operative NCT03868124 137 146 B-Procedure
ocular NCT03868124 147 153 B-Drug
hypotensive NCT03868124 154 165 I-Drug
medications NCT03868124 166 177 I-Drug

Exclusion NCT03868124 178 187 O
Criteria NCT03868124 188 196 O
: NCT03868124 197 198 O

- NCT03868124 202 203 O
Active NCT03868124 205 211 B-Eq-Comparison
corneal NCT03868124 212 219 B-Condition
inflammation NCT03868124 220 232 I-Condition
or NCT03868124 233 235 B-Or
edema NCT03868124 236 241 B-Condition

- NCT03868124 244 245 O
Retinal NCT03868124 247 254 B-Condition
disorders NCT03868124 255 264 I-Condition
not NCT03868124 265 268 B-Exception
associated NCT03868124 269 279 O
with NCT03868124 280 284 O
glaucoma NCT03868124 285 293 B-Condition

Inclusion NCT03863717 0 9 O
Criteria NCT03863717 10 18 O
: NCT03863717 19 20 O

- NCT03863717 24 25 O
Diagnosis NCT03863717 27 36 O
of NCT03863717 37 39 O
COPD NCT03863717 40 44 B-Condition
confirmed NCT03863717 45 54 O
by NCT03863717 55 57 O
clinical NCT03863717 58 66 B-Observation
examination NCT03863717 67 78 I-Observation
and NCT03863717 79 82 B-And
a NCT03863717 83 84 O
pulmonary NCT03863717 85 94 B-Observation
function NCT03863717 95 103 I-Observation
test NCT03863717 104 108 I-Observation

- NCT03863717 111 112 O
Stable NCT03863717 114 120 O
clinical NCT03863717 121 129 B-Condition
condition NCT03863717 130 139 I-Condition
( NCT03863717 140 141 O
without NCT03863717 142 149 B-Negation
recent NCT03863717 150 156 B-Eq-Comparison
respiratory NCT03863717 157 168 B-Condition
system NCT03863717 169 175 I-Condition
infections NCT03863717 176 186 I-Condition
or NCT03863717 187 189 B-Or
any NCT03863717 190 193 O
exacerbation NCT03863717 194 206 O
of NCT03863717 207 209 O
the NCT03863717 210 213 B-Coreference
disease NCT03863717 214 221 I-Coreference
) NCT03863717 222 223 O

- NCT03863717 227 228 O
Patients NCT03863717 230 238 O
must NCT03863717 239 243 O
be NCT03863717 244 246 O
willing NCT03863717 247 254 O
to NCT03863717 255 257 O
re NCT03863717 258 260 O
evaluate NCT03863717 261 269 O
at NCT03863717 270 272 O
the NCT03863717 273 276 O
end NCT03863717 277 280 O
of NCT03863717 281 283 O
the NCT03863717 284 287 O
study NCT03863717 288 293 O

- NCT03863717 296 297 O
Patients NCT03863717 299 307 O
must NCT03863717 308 312 O
be NCT03863717 313 315 O
willing NCT03863717 316 323 O
to NCT03863717 324 326 O
give NCT03863717 327 331 O
written NCT03863717 332 339 O
consent NCT03863717 340 347 O
for NCT03863717 348 351 O
their NCT03863717 352 357 O
participation NCT03863717 358 371 O
in NCT03863717 372 374 O
the NCT03863717 375 378 O
study NCT03863717 379 384 O

Exclusion NCT03863717 385 394 O
Criteria NCT03863717 395 403 O
: NCT03863717 404 405 O

- NCT03863717 409 410 O
Age NCT03863717 412 415 B-Age
< NCT03863717 416 417 B-Eq-Comparison
18 NCT03863717 418 420 I-Eq-Comparison
years NCT03863717 421 426 I-Eq-Comparison
old NCT03863717 427 430 O

- NCT03863717 433 434 O
Unstable NCT03863717 436 444 O
cardiac NCT03863717 445 452 B-Condition
disease NCT03863717 453 460 I-Condition

- NCT03863717 463 464 O
Musculoskeletal NCT03863717 466 481 B-Modifier
and NCT03863717 482 485 B-Or
neurological NCT03863717 486 498 B-Modifier
diseases NCT03863717 499 507 B-Condition
that NCT03863717 508 512 O
could NCT03863717 513 518 O
affect NCT03863717 519 525 O
exercise NCT03863717 526 534 O
performance NCT03863717 535 546 O
or NCT03863717 547 549 O
preclude NCT03863717 550 558 O
exercise NCT03863717 559 567 O

- NCT03863717 570 571 O
Patients NCT03863717 573 581 O
of NCT03863717 582 584 O
COPD NCT03863717 585 589 B-Condition
final NCT03863717 590 595 B-Modifier
stage NCT03863717 596 601 I-Modifier
or NCT03863717 602 604 B-Or
other NCT03863717 605 610 O
serious NCT03863717 611 618 O
disease NCT03863717 619 626 B-Condition
final NCT03863717 627 632 B-Modifier
stage NCT03863717 633 638 I-Modifier

- NCT03863717 641 642 O
Significant NCT03863717 644 655 O
cognitive NCT03863717 656 665 B-Modifier
or NCT03863717 666 668 B-Or
psychiatric NCT03863717 669 680 B-Modifier
impairment NCT03863717 681 691 B-Condition
that NCT03863717 692 696 O
would NCT03863717 697 702 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03863717 703 707 O
to NCT03863717 708 710 O
an NCT03863717 711 713 O
inability NCT03863717 714 723 B-Condition
to NCT03863717 724 726 I-Condition
follow NCT03863717 727 733 I-Condition
simple NCT03863717 734 740 I-Condition
commands NCT03863717 741 749 I-Condition
in NCT03863717 750 752 O
a NCT03863717 753 754 O
group NCT03863717 755 760 O
setting NCT03863717 761 768 O

Inclusion NCT03866135 0 9 O
Criteria NCT03866135 10 18 O
: NCT03866135 19 20 O

- NCT03866135 24 25 O
Patients NCT03866135 27 35 O
diagnosed NCT03866135 36 45 O
as NCT03866135 46 48 O
AS NCT03866135 49 51 B-Condition
according NCT03866135 52 61 O
to NCT03866135 62 64 O
the NCT03866135 65 68 O
modified NCT03866135 69 77 O
New NCT03866135 78 81 O
York NCT03866135 82 86 O
diagnostic NCT03866135 87 97 O
criteria NCT03866135 98 106 O
were NCT03866135 107 111 O
included NCT03866135 112 120 O

Exclusion NCT03866135 121 130 O
Criteria NCT03866135 131 139 O
: NCT03866135 140 141 O

- NCT03866135 145 146 O
Patients NCT03866135 148 156 O
previously NCT03866135 157 167 B-Eq-Comparison
diagnosed NCT03866135 168 177 O
with NCT03866135 178 182 O
OP NCT03866135 183 185 B-Condition
, NCT03866135 186 187 O

- NCT03866135 191 192 O
Patients NCT03866135 194 202 O
previously NCT03866135 203 213 B-Eq-Comparison
treated NCT03866135 214 221 O
with NCT03866135 222 226 O
OP NCT03866135 227 229 B-Condition
, NCT03866135 230 231 O

- NCT03866135 235 236 O
Patients NCT03866135 238 246 O
with NCT03866135 247 251 B-Eq-Comparison
bone NCT03866135 252 256 B-Condition
fractures NCT03866135 257 266 I-Condition
previously NCT03866135 267 277 B-Eq-Comparison
associated NCT03866135 278 288 O
with NCT03866135 289 293 O
OP NCT03866135 294 296 B-Condition
, NCT03866135 297 298 O

- NCT03866135 302 303 O
Those NCT03866135 305 310 O
using NCT03866135 311 316 B-Eq-Comparison
drugs NCT03866135 317 322 B-Drug
that NCT03866135 323 327 O
affect NCT03866135 328 334 O
bone NCT03866135 335 339 B-Condition
metabolism NCT03866135 340 350 I-Condition
, NCT03866135 351 352 O
metabolic NCT03866135 353 362 B-Condition
bone NCT03866135 363 367 I-Condition
diseases NCT03866135 368 376 I-Condition
( NCT03866135 377 378 O
Paget NCT03866135 379 384 B-Condition
's NCT03866135 384 386 O
disease NCT03866135 387 394 I-Condition
, NCT03866135 395 396 O
osteomalacia NCT03866135 397 409 B-Condition
, NCT03866135 410 411 O
hyperparathyroidism NCT03866135 412 431 B-Condition
) NCT03866135 432 433 O
, NCT03866135 435 436 O

- NCT03866135 440 441 O
Diabetes NCT03866135 443 451 B-Condition
mellitus NCT03866135 452 460 I-Condition
, NCT03866135 461 462 O

- NCT03866135 466 467 O
Hypothyroidism NCT03866135 469 483 B-Condition
, NCT03866135 484 485 O
hyperthyroidism NCT03866135 486 501 B-Condition
, NCT03866135 502 503 O

- NCT03866135 507 508 O
Patients NCT03866135 510 518 O
with NCT03866135 519 523 O
kidney NCT03866135 524 530 B-Modifier
, NCT03866135 531 532 O
liver NCT03866135 533 538 B-Modifier
and NCT03866135 539 542 B-Or
intestinal NCT03866135 543 553 B-Modifier
diseases NCT03866135 554 562 B-Condition
, NCT03866135 563 564 O

- NCT03866135 568 569 O
Those NCT03866135 571 576 O
using NCT03866135 577 582 B-Eq-Comparison
corticosteroids NCT03866135 583 598 B-Drug


- NCT03921515 1 2 O
INCLUSION NCT03921515 4 13 O
CRITERIA NCT03921515 14 22 O
: NCT03921515 23 24 O

1 NCT03921515 33 34 O
. NCT03921515 34 35 O
Meets NCT03921515 37 42 O
one NCT03921515 43 46 O
of NCT03921515 47 49 O
the NCT03921515 50 53 O
following NCT03921515 54 63 O
: NCT03921515 64 65 O

1 NCT03921515 79 80 O
. NCT03921515 80 81 O
has NCT03921515 83 86 O
documentation NCT03921515 87 100 O
of NCT03921515 101 103 O
HIES NCT03921515 104 108 B-Condition
or NCT03921515 109 111 B-Or
CGD NCT03921515 112 115 B-Condition
( NCT03921515 116 117 O
patient NCT03921515 118 125 O
populations NCT03921515 126 137 O
) NCT03921515 138 139 O
; NCT03921515 140 141 O
or NCT03921515 142 144 B-Or

2 NCT03921515 157 158 O
. NCT03921515 158 159 O
does NCT03921515 161 165 O
not NCT03921515 166 169 B-Negation
have NCT03921515 170 174 O
clinically NCT03921515 175 185 O
apparent NCT03921515 186 194 O
evidence NCT03921515 195 203 O
of NCT03921515 204 206 O
an NCT03921515 207 209 O
immune NCT03921515 210 216 B-Condition
defect NCT03921515 217 223 I-Condition
or NCT03921515 224 226 B-Or
history NCT03921515 227 234 B-Eq-Comparison
of NCT03921515 235 237 O
invasive NCT03921515 238 246 B-Modifier
or NCT03921515 247 249 B-Or
recurrent NCT03921515 250 259 B-Modifier
S. NCT03921515 260 262 B-Organism
aureus NCT03921515 264 270 I-Organism
infections NCT03921515 271 281 B-Condition
( NCT03921515 282 283 O
healthy NCT03921515 284 291 B-Condition
volunteers NCT03921515 292 302 O
) NCT03921515 303 304 O
. NCT03921515 305 306 O

2 NCT03921515 315 316 O
. NCT03921515 316 317 O
Between NCT03921515 319 326 O
the NCT03921515 327 330 O
following NCT03921515 331 340 O
age NCT03921515 341 344 O
limits NCT03921515 345 351 O
( NCT03921515 352 353 O
inclusive NCT03921515 354 363 O
) NCT03921515 364 365 O
: NCT03921515 367 368 O

1 NCT03921515 382 383 O
. NCT03921515 383 384 O
18 NCT03921515 386 388 B-Eq-Comparison
and NCT03921515 389 392 I-Eq-Comparison
65 NCT03921515 393 395 I-Eq-Comparison
years NCT03921515 396 401 I-Eq-Comparison
old NCT03921515 402 405 B-Age
for NCT03921515 406 409 O
healthy NCT03921515 410 417 B-Condition
volunteers NCT03921515 418 428 O
; NCT03921515 428 429 O

2 NCT03921515 442 443 O
. NCT03921515 443 444 O
7 NCT03921515 446 447 B-Eq-Comparison
and NCT03921515 448 451 I-Eq-Comparison
65 NCT03921515 452 454 I-Eq-Comparison
years NCT03921515 455 460 I-Eq-Comparison
old NCT03921515 461 464 B-Age
for NCT03921515 465 468 O
patients NCT03921515 469 477 O
with NCT03921515 478 482 O
CGD NCT03921515 483 486 B-Condition
; NCT03921515 486 487 O

3 NCT03921515 500 501 O
. NCT03921515 501 502 O
18 NCT03921515 504 506 B-Eq-Comparison
and NCT03921515 507 510 I-Eq-Comparison
65 NCT03921515 511 513 I-Eq-Comparison
years NCT03921515 514 519 I-Eq-Comparison
old NCT03921515 520 523 B-Age
for NCT03921515 524 527 O
patients NCT03921515 528 536 O
with NCT03921515 537 541 O
HIES NCT03921515 542 546 B-Condition
. NCT03921515 546 547 O

3 NCT03921515 556 557 O
. NCT03921515 557 558 O
Willing NCT03921515 560 567 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921515 568 570 I-Assertion___Assertion-Type-Value:hypothetical
allow NCT03921515 571 576 B-Observation
storage NCT03921515 577 584 I-Observation
of NCT03921515 585 587 O
blood NCT03921515 588 593 B-Modifier
, NCT03921515 594 595 O
RNA NCT03921515 596 599 B-Modifier
, NCT03921515 600 601 O
bacterial NCT03921515 602 611 B-Modifier
and NCT03921515 612 615 B-Or|Or
fungal NCT03921515 616 622 B-Modifier
cultures NCT03921515 623 631 I-Modifier
, NCT03921515 632 633 O
and NCT03921515 634 637 O
other NCT03921515 638 643 O
tissue NCT03921515 644 650 B-Modifier
samples NCT03921515 651 658 I-Modifier
for NCT03921515 659 662 O
future NCT03921515 663 669 O
research NCT03921515 670 678 O
. NCT03921515 678 679 O

4 NCT03921515 688 689 O
. NCT03921515 689 690 O
Able NCT03921515 692 696 O
to NCT03921515 697 699 O
provide NCT03921515 700 707 O
informed NCT03921515 708 716 O
consent NCT03921515 717 724 O
. NCT03921515 724 725 O

EXCLUSION NCT03921515 727 736 O
CRITERIA NCT03921515 737 745 O
: NCT03921515 746 747 O

The NCT03921515 749 752 O
following NCT03921515 753 762 O
exclusion NCT03921515 763 772 O
criteria NCT03921515 773 781 O
apply NCT03921515 782 787 O
to NCT03921515 788 790 O
all NCT03921515 791 794 O
subjects NCT03921515 795 803 O
: NCT03921515 804 805 O

1 NCT03921515 809 810 O
. NCT03921515 810 811 O
For NCT03921515 813 816 O
individuals NCT03921515 817 828 O
undergoing NCT03921515 829 839 B-Eq-Comparison
blister NCT03921515 840 847 B-Modifier
or NCT03921515 848 850 B-Or
skin NCT03921515 851 855 B-Modifier
biopsy NCT03921515 856 862 B-Procedure
procedures NCT03921515 863 873 I-Procedure
, NCT03921515 874 875 O
history NCT03921515 876 883 B-Eq-Comparison
of NCT03921515 884 886 O
keloid NCT03921515 887 893 B-Condition
formation NCT03921515 894 903 I-Condition
. NCT03921515 903 904 O

2 NCT03921515 908 909 O
. NCT03921515 909 910 O
Current NCT03921515 912 919 B-Eq-Comparison
or NCT03921515 920 922 B-Or|Or
prior NCT03921515 923 928 B-Eq-Comparison
( NCT03921515 929 930 O
within NCT03921515 931 937 B-Eq-Comparison
3 NCT03921515 938 939 I-Eq-Comparison
months NCT03921515 940 946 I-Eq-Comparison
) NCT03921515 947 948 O
anticoagulant NCT03921515 949 962 B-Modifier|Modifier
or NCT03921515 963 965 O
anti NCT03921515 966 970 O
- NCT03921515 971 972 I-Drug|Modifier
platelet NCT03921515 973 981 I-Modifier
therapy NCT03921515 982 989 B-Procedure
( NCT03921515 990 991 O
other NCT03921515 992 997 B-Exception
than NCT03921515 998 1002 I-Exception
aspirin NCT03921515 1003 1010 B-Drug
or NCT03921515 1011 1013 B-Or
non NCT03921515 1014 1017 B-Drug
- NCT03921515 1018 1019 I-Drug
steroidal NCT03921515 1020 1029 I-Drug
anti NCT03921515 1030 1034 I-Drug
- NCT03921515 1035 1036 O
inflammatory NCT03921515 1037 1049 I-Drug
drugs NCT03921515 1050 1055 I-Drug
[ NCT03921515 1056 1057 O
NSAIDs NCT03921515 1058 1064 B-Drug
] NCT03921515 1065 1066 O
) NCT03921515 1068 1069 O
. NCT03921515 1070 1071 O

3 NCT03921515 1075 1076 I-Eq-Comparison
. NCT03921515 1076 1077 O
Current NCT03921515 1079 1086 B-Eq-Comparison
or NCT03921515 1087 1089 B-Or
prior NCT03921515 1090 1095 B-Eq-Comparison
( NCT03921515 1096 1097 O
within NCT03921515 1098 1104 B-Eq-Comparison
3 NCT03921515 1105 1106 O
months NCT03921515 1107 1113 I-Eq-Comparison
) NCT03921515 1114 1115 O
use NCT03921515 1116 1119 O
of NCT03921515 1120 1122 O
immunomodulatory NCT03921515 1123 1139 B-Drug
drugs NCT03921515 1140 1145 I-Drug
( NCT03921515 1146 1147 O
e. NCT03921515 1148 1150 O
g. NCT03921515 1151 1153 O
, NCT03921515 1154 1155 O
chemotherapy NCT03921515 1156 1168 B-Procedure
, NCT03921515 1169 1170 O
steroids NCT03921515 1171 1179 B-Drug
) NCT03921515 1180 1181 O
, NCT03921515 1183 1184 O
except NCT03921515 1185 1191 O
if NCT03921515 1192 1194 O
approved NCT03921515 1195 1203 O
by NCT03921515 1204 1206 O
the NCT03921515 1207 1210 O
principal NCT03921515 1211 1220 O
investigator NCT03921515 1221 1233 O
. NCT03921515 1233 1234 O

4 NCT03921515 1238 1239 O
. NCT03921515 1239 1240 O
Pregnancy NCT03921515 1242 1251 B-Condition
. NCT03921515 1251 1252 O

5 NCT03921515 1256 1257 O
. NCT03921515 1257 1258 O
Any NCT03921515 1260 1263 O
condition NCT03921515 1264 1273 B-Condition
that NCT03921515 1274 1278 O
, NCT03921515 1279 1280 O
in NCT03921515 1281 1283 O
the NCT03921515 1284 1287 O
opinion NCT03921515 1288 1295 O
of NCT03921515 1296 1298 O
the NCT03921515 1299 1302 O
investigator NCT03921515 1303 1315 O
, NCT03921515 1316 1317 O
contraindicates NCT03921515 1318 1333 B-Contraindication
participation NCT03921515 1334 1347 O
in NCT03921515 1348 1350 O
the NCT03921515 1351 1354 O
study NCT03921515 1355 1360 B-Study
. NCT03921515 1360 1361 O

Healthy NCT03924479 0 7 B-Observation
subjects NCT03924479 8 16 O
: NCT03924479 17 18 O
Adults NCT03924479 19 25 O
( NCT03924479 26 27 O
≥ NCT03924479 29 30 B-Eq-Comparison
21 NCT03924479 31 33 I-Eq-Comparison
years NCT03924479 34 39 I-Eq-Comparison
of NCT03924479 40 42 O
age NCT03924479 43 46 B-Age
) NCT03924479 47 48 O
in NCT03924479 49 51 O
the NCT03924479 52 55 O
absence NCT03924479 56 63 B-Negation
of NCT03924479 64 66 O
a NCT03924479 67 68 O
history NCT03924479 69 76 B-Condition
of NCT03924479 77 79 I-Condition
HFpEF NCT03924479 80 85 O
or NCT03924479 86 88 B-Or
HFrEF NCT03924479 89 94 B-Condition
, NCT03924479 95 96 O
pulmonary NCT03924479 97 106 B-Modifier
, NCT03924479 107 108 O
neurologic NCT03924479 109 119 B-Modifier
, NCT03924479 120 121 O
orthopedic NCT03924479 122 132 B-Modifier
, NCT03924479 133 134 O
or NCT03924479 135 137 B-Or
other NCT03924479 138 143 B-Modifier
diseases NCT03924479 144 152 B-Condition
affecting NCT03924479 153 162 I-Condition
the NCT03924479 163 166 I-Condition
neuromuscular NCT03924479 167 180 I-Condition
system NCT03924479 181 187 I-Condition
. NCT03924479 187 188 O

Controls NCT03924479 190 198 O
will NCT03924479 199 203 O
be NCT03924479 204 206 O
matched NCT03924479 207 214 O
for NCT03924479 215 218 O
age NCT03924479 219 222 O
and NCT03924479 223 226 O
sex NCT03924479 227 230 O
. NCT03924479 230 231 O

All NCT03924479 233 236 O
HFpEF NCT03924479 237 242 B-Condition
patients NCT03924479 243 251 O
will NCT03924479 252 256 O
be NCT03924479 257 259 O
managed NCT03924479 260 267 O
by NCT03924479 268 270 O
their NCT03924479 271 276 O
primary NCT03924479 277 284 O
care NCT03924479 285 289 O
physician NCT03924479 290 299 O
or NCT03924479 300 302 O
cardiologist NCT03924479 303 315 O
with NCT03924479 316 320 O
additional NCT03924479 321 331 O
review NCT03924479 332 338 O
and NCT03924479 339 342 O
oversight NCT03924479 343 352 O
by NCT03924479 353 355 O
Dr. NCT03924479 356 359 B-Provider
Borlaug NCT03924479 361 368 I-Provider
( NCT03924479 369 370 O
Co NCT03924479 371 373 O
- NCT03924479 374 375 O
Investigator NCT03924479 376 388 O
) NCT03924479 389 390 O
prior NCT03924479 391 396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924479 397 399 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924479 400 410 B-Study
to NCT03924479 411 413 O
ensure NCT03924479 414 420 O
adequacy NCT03924479 421 429 O
of NCT03924479 430 432 O
inclusion NCT03924479 433 442 O
and NCT03924479 443 446 O
exclusion NCT03924479 447 456 O
criteria NCT03924479 457 465 O
and NCT03924479 466 469 O
that NCT03924479 470 474 O
participation NCT03924479 475 488 O
in NCT03924479 489 491 O
exercise NCT03924479 492 500 O
testing NCT03924479 501 508 O
and NCT03924479 509 512 O
resistance NCT03924479 513 523 O
exercise NCT03924479 524 532 O
training NCT03924479 533 541 O
is NCT03924479 542 544 O
safe NCT03924479 545 549 O
. NCT03924479 549 550 O

Inclusion NCT03924479 552 561 O
Criteria NCT03924479 562 570 O
for NCT03924479 571 574 O
HFpEF NCT03924479 575 580 O
, NCT03924479 581 582 O
includes NCT03924479 583 591 O
: NCT03924479 592 593 O

- NCT03924479 597 598 O
Clinical NCT03924479 600 608 O
diagnosis NCT03924479 609 618 O
of NCT03924479 619 621 O
HFpEF NCT03924479 622 627 B-Condition
. NCT03924479 627 628 O

- NCT03924479 632 633 O
Patients NCT03924479 635 643 O
with NCT03924479 644 648 O
a NCT03924479 649 650 O
history NCT03924479 651 658 B-Eq-Comparison
stable NCT03924479 659 665 O
( NCT03924479 666 667 O
no NCT03924479 668 670 B-Negation
medication NCT03924479 671 681 B-Drug
changes NCT03924479 682 689 O
in NCT03924479 690 692 O
past NCT03924479 693 697 B-Eq-Comparison
6 NCT03924479 698 699 I-Eq-Comparison
weeks NCT03924479 700 705 I-Eq-Comparison
( NCT03924479 706 707 O
w NCT03924479 708 709 O
/ NCT03924479 710 711 O
duration NCT03924479 712 720 O
of NCT03924479 721 723 O
diagnosis NCT03924479 724 733 B-Coreference
> NCT03924479 734 735 B-Eq-Comparison
6 NCT03924479 736 737 I-Eq-Comparison
months NCT03924479 738 744 I-Eq-Comparison
) NCT03924479 745 746 O
. NCT03924479 747 748 O

- NCT03924479 752 753 O
New NCT03924479 755 758 B-Condition
York NCT03924479 759 763 I-Condition
Heart NCT03924479 764 769 I-Condition
Association NCT03924479 770 781 I-Condition
class NCT03924479 782 787 B-Eq-Comparison
I NCT03924479 788 789 I-Eq-Comparison
- NCT03924479 790 791 I-Eq-Comparison
III NCT03924479 792 795 I-Eq-Comparison
. NCT03924479 795 796 O

- NCT03924479 800 801 O
Current NCT03924479 803 810 B-Eq-Comparison
non NCT03924479 811 814 B-Negation
- NCT03924479 815 816 O
smokers NCT03924479 817 824 B-Condition
with NCT03924479 825 829 O
< NCT03924479 830 831 B-Eq-Comparison
15 NCT03924479 832 834 I-Eq-Comparison
pack NCT03924479 835 839 I-Eq-Comparison
year NCT03924479 840 844 I-Eq-Comparison
history NCT03924479 845 852 B-Eq-Comparison
. NCT03924479 852 853 O

- NCT03924479 857 858 O
Non NCT03924479 860 863 B-Negation
- NCT03924479 864 865 O
pregnant NCT03924479 866 874 B-Condition
women NCT03924479 875 880 O
, NCT03924479 881 882 O
and NCT03924479 883 886 B-And
individuals NCT03924479 887 898 O
who NCT03924479 899 902 O
are NCT03924479 903 906 O
able NCT03924479 907 911 B-Observation
to NCT03924479 912 914 I-Observation
exercise NCT03924479 915 923 I-Observation
( NCT03924479 924 925 O
i. NCT03924479 926 928 O
e. NCT03924479 929 931 O
without NCT03924479 933 940 B-Negation
orthopedic NCT03924479 941 951 B-Condition|Or
limitations NCT03924479 952 963 I-Condition
or NCT03924479 964 966 O
neuromuscular NCT03924479 967 980 B-Condition
disorders NCT03924479 981 990 I-Condition
) NCT03924479 991 992 O
. NCT03924479 993 994 O

Exclusion NCT03924479 996 1005 O
Criteria NCT03924479 1006 1014 O
for NCT03924479 1015 1018 O
all NCT03924479 1019 1022 O
subjects NCT03924479 1023 1031 O
, NCT03924479 1032 1033 O
includes NCT03924479 1034 1042 O
: NCT03924479 1043 1044 O

- NCT03924479 1048 1049 O
history NCT03924479 1051 1058 B-Eq-Comparison
of NCT03924479 1059 1061 O
dangerous NCT03924479 1062 1071 O
arrhythmias NCT03924479 1072 1083 B-Condition

- NCT03924479 1086 1087 O
body NCT03924479 1089 1093 B-Observation
mass NCT03924479 1094 1098 I-Observation
index NCT03924479 1099 1104 I-Observation
> NCT03924479 1105 1106 B-Eq-Comparison
35 NCT03924479 1107 1109 I-Eq-Comparison
kg NCT03924479 1110 1112 I-Eq-Comparison
/ NCT03924479 1113 1114 I-Eq-Comparison|Or
m2 NCT03924479 1115 1117 I-Eq-Comparison

- NCT03924479 1120 1121 O
current NCT03924479 1123 1130 B-Eq-Comparison
smokers NCT03924479 1131 1138 B-Condition
and NCT03924479 1139 1142 B-Or
/ NCT03924479 1143 1144 O
or NCT03924479 1145 1147 I-Or
smoking NCT03924479 1148 1155 B-Observation
history NCT03924479 1156 1163 I-Observation
> NCT03924479 1164 1165 B-Eq-Comparison
15 NCT03924479 1166 1168 I-Eq-Comparison
pack NCT03924479 1169 1173 I-Eq-Comparison
years NCT03924479 1174 1179 I-Eq-Comparison

- NCT03924479 1182 1183 O
pregnant NCT03924479 1185 1193 B-Condition
women NCT03924479 1194 1199 O

- NCT03924479 1202 1203 O
uremia NCT03924479 1205 1211 B-Condition
, NCT03924479 1212 1213 O
history NCT03924479 1214 1221 B-Eq-Comparison
of NCT03924479 1222 1224 O
allergy NCT03924479 1225 1232 B-Allergy
to NCT03924479 1233 1235 O
iodides NCT03924479 1236 1243 O

- NCT03924479 1246 1247 O
impaired NCT03924479 1249 1257 B-Condition
renal NCT03924479 1258 1263 I-Condition
function NCT03924479 1264 1272 I-Condition

- NCT03924479 1275 1276 O
creatinine NCT03924479 1278 1288 B-Observation
value NCT03924479 1289 1294 O
greater NCT03924479 1295 1302 B-Eq-Comparison
than NCT03924479 1303 1307 I-Eq-Comparison
or NCT03924479 1308 1310 I-Eq-Comparison
equal NCT03924479 1311 1316 I-Eq-Comparison
to NCT03924479 1317 1319 I-Eq-Comparison
1.3 NCT03924479 1320 1323 I-Eq-Comparison
mg NCT03924479 1324 1326 I-Eq-Comparison
/ NCT03924479 1327 1328 I-Eq-Comparison
dL NCT03924479 1329 1331 I-Eq-Comparison
( NCT03924479 1332 1333 O
via NCT03924479 1334 1337 O
clinical NCT03924479 1338 1346 O
record NCT03924479 1347 1353 O
within NCT03924479 1354 1360 B-Eq-Comparison
the NCT03924479 1361 1364 I-Eq-Comparison
past NCT03924479 1365 1369 I-Eq-Comparison
6 NCT03924479 1370 1371 I-Eq-Comparison
months NCT03924479 1372 1378 I-Eq-Comparison
) NCT03924479 1379 1380 O

- NCT03924479 1384 1385 O
diagnosis NCT03924479 1387 1396 O
of NCT03924479 1397 1399 O
liver NCT03924479 1400 1405 B-Condition
disease NCT03924479 1406 1413 I-Condition

- NCT03924479 1416 1417 O
individuals NCT03924479 1419 1430 O
who NCT03924479 1431 1434 O
are NCT03924479 1435 1438 O
not NCT03924479 1439 1442 B-Negation
able NCT03924479 1443 1447 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924479 1448 1450 I-Assertion___Assertion-Type-Value:hypothetical
engage NCT03924479 1451 1457 O
in NCT03924479 1458 1460 O
exercise NCT03924479 1461 1469 B-Observation


Inclusion NCT03926520 0 9 O
Criteria NCT03926520 10 18 O
: NCT03926520 19 20 O

1 NCT03926520 24 25 O
. NCT03926520 25 26 O
Diagnosis NCT03926520 28 37 O
of NCT03926520 38 40 O
Alzheimer NCT03926520 41 50 B-Condition
's NCT03926520 50 52 O
Dementia NCT03926520 53 61 I-Condition
according NCT03926520 62 71 O
to NCT03926520 72 74 O
NIA NCT03926520 75 78 O
- NCT03926520 79 80 O
AA NCT03926520 81 83 O
Criteria NCT03926520 84 92 O
for NCT03926520 93 96 O
dementia NCT03926520 97 105 O
[ NCT03926520 106 107 O
55 NCT03926520 108 110 O
] NCT03926520 111 112 O

2 NCT03926520 116 117 O
. NCT03926520 117 118 O
MMSE NCT03926520 120 124 B-Observation
< NCT03926520 125 126 B-Eq-Comparison
15 NCT03926520 127 129 I-Eq-Comparison

3 NCT03926520 133 134 O
. NCT03926520 134 135 O
Cohen NCT03926520 137 142 B-Observation
- NCT03926520 143 144 I-Observation
Mansfield NCT03926520 145 154 I-Observation
Agitation NCT03926520 155 164 I-Observation
Inventory NCT03926520 165 174 I-Observation
Short NCT03926520 175 180 I-Observation
Version NCT03926520 181 188 I-Observation
( NCT03926520 189 190 O
CMAI NCT03926520 191 195 B-Observation
) NCT03926520 196 197 O
score NCT03926520 198 203 O
of NCT03926520 204 206 O
≥ NCT03926520 207 208 B-Eq-Comparison
4 NCT03926520 209 210 I-Eq-Comparison
on NCT03926520 211 213 I-Eq-Comparison
at NCT03926520 214 216 B-Eq-Comparison
least NCT03926520 217 222 I-Eq-Comparison
one NCT03926520 223 226 O
item NCT03926520 227 231 I-Eq-Comparison
, NCT03926520 232 233 O
a NCT03926520 234 235 O
score NCT03926520 236 241 O
of NCT03926520 242 244 O
3 NCT03926520 245 246 B-Eq-Comparison
on NCT03926520 247 249 I-Eq-Comparison
at NCT03926520 250 252 I-Eq-Comparison
least NCT03926520 253 258 I-Eq-Comparison
two NCT03926520 259 262 I-Eq-Comparison
items NCT03926520 263 268 I-Eq-Comparison
, NCT03926520 269 270 O
or NCT03926520 271 273 B-Or
a NCT03926520 274 275 O
score NCT03926520 276 281 O
of NCT03926520 282 284 O
2 NCT03926520 285 286 B-Eq-Comparison
on NCT03926520 287 289 I-Eq-Comparison
at NCT03926520 290 292 I-Eq-Comparison
least NCT03926520 293 298 I-Eq-Comparison
three NCT03926520 299 304 I-Eq-Comparison
items NCT03926520 305 310 I-Eq-Comparison
. NCT03926520 310 311 O

4 NCT03926520 315 316 O
. NCT03926520 316 317 O
At NCT03926520 319 321 B-Eq-Comparison
least NCT03926520 322 327 I-Eq-Comparison
one NCT03926520 328 331 I-Eq-Comparison
failed NCT03926520 332 338 O
pharmacological NCT03926520 339 354 B-Drug
intervention NCT03926520 355 367 O
to NCT03926520 368 370 O
manage NCT03926520 371 377 O
behavioral NCT03926520 378 388 B-Condition
symptoms NCT03926520 389 397 B-Assertion___Assertion-Type-Value:possible

5 NCT03926520 400 401 O
. NCT03926520 401 402 O
Medically NCT03926520 404 413 B-Condition
stable NCT03926520 414 420 O
for NCT03926520 421 424 B-Assertion___Assertion-Type-Value:hypothetical
safe NCT03926520 425 429 O
administration NCT03926520 430 444 O
of NCT03926520 445 447 O
ECT NCT03926520 448 451 B-Procedure
verified NCT03926520 452 460 O
by NCT03926520 461 463 O
standard NCT03926520 464 472 B-Procedure
physical NCT03926520 473 481 I-Procedure
examination NCT03926520 482 493 I-Procedure
, NCT03926520 494 495 O
urinalysis NCT03926520 496 506 B-Observation
and NCT03926520 507 510 O
serum NCT03926520 511 516 B-Observation
chemistries NCT03926520 517 528 I-Observation

6 NCT03926520 531 532 O
. NCT03926520 532 533 O
Comprehension NCT03926520 535 548 O
of NCT03926520 549 551 O
English NCT03926520 552 559 O
language NCT03926520 560 568 O

7 NCT03926520 571 572 O
. NCT03926520 572 573 O
Authorized NCT03926520 575 585 O
legal NCT03926520 586 591 O
representative NCT03926520 592 606 O
able NCT03926520 607 611 O
and NCT03926520 612 615 O
willing NCT03926520 616 623 O
to NCT03926520 624 626 O
give NCT03926520 627 631 O
informed NCT03926520 632 640 O
consent NCT03926520 641 648 O

8 NCT03926520 651 652 O
. NCT03926520 652 653 O
Age NCT03926520 655 658 B-Age
55 NCT03926520 659 661 B-Eq-Comparison
- NCT03926520 662 663 I-Eq-Comparison
89 NCT03926520 664 666 I-Eq-Comparison
years NCT03926520 667 672 I-Eq-Comparison
old NCT03926520 673 676 O
( NCT03926520 677 678 O
inclusive NCT03926520 679 688 O
) NCT03926520 689 690 O

Exclusion NCT03926520 692 701 O
Criteria NCT03926520 702 710 O
: NCT03926520 711 712 O

1 NCT03926520 716 717 O
. NCT03926520 717 718 O
Current NCT03926520 720 727 B-Eq-Comparison
diagnosis NCT03926520 728 737 O
of NCT03926520 738 740 O
co NCT03926520 741 743 B-Condition
- NCT03926520 744 745 I-Condition
morbid NCT03926520 746 752 I-Condition
delirium NCT03926520 753 761 I-Condition
, NCT03926520 762 763 O
measured NCT03926520 764 772 O
by NCT03926520 773 775 O
the NCT03926520 776 779 O
Confusion NCT03926520 780 789 B-Observation
Assessment NCT03926520 790 800 I-Observation
Measure NCT03926520 801 808 I-Observation
( NCT03926520 809 810 O
CAM NCT03926520 811 814 B-Observation
) NCT03926520 815 816 O
and NCT03926520 817 820 O
by NCT03926520 821 823 O
clinical NCT03926520 824 832 O
diagnosis NCT03926520 833 842 O

2 NCT03926520 845 846 O
. NCT03926520 846 847 O
Diagnosis NCT03926520 849 858 O
of NCT03926520 859 861 O
Non NCT03926520 862 865 B-Negation
- NCT03926520 866 867 O
AD NCT03926520 868 870 B-Condition
Dementia NCT03926520 871 879 B-Condition

3 NCT03926520 882 883 O
. NCT03926520 883 884 O
Lifetime NCT03926520 886 894 B-Eq-Comparison
or NCT03926520 895 897 B-Or
current NCT03926520 898 905 B-Eq-Comparison
diagnosis NCT03926520 906 915 O
of NCT03926520 916 918 O
Schizophrenia NCT03926520 919 932 B-Condition
, NCT03926520 933 934 O
Bipolar NCT03926520 935 942 B-Condition
Disorder NCT03926520 943 951 I-Condition|Condition
or NCT03926520 952 954 B-Or
Schizoaffective NCT03926520 955 970 B-Condition
Disorder NCT03926520 971 979 O

4 NCT03926520 982 983 O
. NCT03926520 983 984 O
Current NCT03926520 986 993 B-Eq-Comparison
episode NCT03926520 994 1001 O
of NCT03926520 1002 1004 O
Major NCT03926520 1005 1010 B-Modifier
Depressive NCT03926520 1011 1021 B-Condition
Disorder NCT03926520 1022 1030 I-Condition
( NCT03926520 1031 1032 O
MDD NCT03926520 1033 1036 B-Condition
) NCT03926520 1037 1038 O

5 NCT03926520 1042 1043 O
. NCT03926520 1043 1044 O
Active NCT03926520 1046 1052 B-Eq-Comparison
substance NCT03926520 1053 1062 B-Condition
use NCT03926520 1063 1066 I-Condition
disorder NCT03926520 1067 1075 I-Condition
within NCT03926520 1076 1082 B-Eq-Comparison
past NCT03926520 1083 1087 I-Eq-Comparison
6 NCT03926520 1088 1089 I-Eq-Comparison
months NCT03926520 1090 1096 I-Eq-Comparison

6 NCT03926520 1099 1100 O
. NCT03926520 1100 1101 O
Treatment NCT03926520 1103 1112 B-Procedure
with NCT03926520 1113 1117 O
ECT NCT03926520 1118 1121 B-Procedure
or NCT03926520 1122 1124 B-Or
other NCT03926520 1125 1130 O
neurostimulation NCT03926520 1131 1147 B-Procedure
therapies NCT03926520 1148 1157 I-Procedure
( NCT03926520 1158 1159 O
e. NCT03926520 1160 1162 O
g. NCT03926520 1163 1165 O
, NCT03926520 1166 1167 O
TMS NCT03926520 1168 1171 B-Procedure
or NCT03926520 1172 1174 O
vagal NCT03926520 1175 1180 B-Procedure
nerve NCT03926520 1181 1186 I-Procedure
stimulation NCT03926520 1187 1198 I-Procedure
) NCT03926520 1199 1200 O
within NCT03926520 1201 1207 B-Eq-Comparison
the NCT03926520 1208 1211 I-Eq-Comparison
past NCT03926520 1212 1216 I-Eq-Comparison
3 NCT03926520 1217 1218 I-Eq-Comparison
months NCT03926520 1219 1225 I-Eq-Comparison

Inclusion NCT03924492 0 9 O
Criteria NCT03924492 10 18 O
: NCT03924492 19 20 O

1 NCT03924492 24 25 O
. NCT03924492 25 26 O
Subject NCT03924492 28 35 O
has NCT03924492 36 39 O
signed NCT03924492 40 46 O
an NCT03924492 47 49 O
informed NCT03924492 50 58 O
consent NCT03924492 59 66 O
form NCT03924492 67 71 O
prior NCT03924492 72 77 B-Eq-Comparison
to NCT03924492 78 80 O
any NCT03924492 81 84 O
study NCT03924492 85 90 O
- NCT03924492 91 92 O
specific NCT03924492 93 101 O
procedures NCT03924492 102 112 O
being NCT03924492 113 118 O
performed NCT03924492 119 128 O

2 NCT03924492 131 132 O
. NCT03924492 132 133 O
Subject NCT03924492 135 142 O
is NCT03924492 143 145 O
an NCT03924492 146 148 O
ambulatory NCT03924492 149 159 B-Condition
female NCT03924492 160 166 O
at NCT03924492 167 169 B-Eq-Comparison
least NCT03924492 170 175 I-Eq-Comparison
18 NCT03924492 176 178 I-Eq-Comparison
years NCT03924492 179 184 I-Eq-Comparison
of NCT03924492 185 187 O
age NCT03924492 188 191 B-Age

3 NCT03924492 194 195 O
. NCT03924492 195 196 O
Subject NCT03924492 198 205 O
agrees NCT03924492 206 212 O
to NCT03924492 213 215 O
adhere NCT03924492 216 222 O
to NCT03924492 223 225 O
the NCT03924492 226 229 O
study NCT03924492 230 235 O
requirements NCT03924492 236 248 O

4 NCT03924492 251 252 O
. NCT03924492 252 253 O
Subject NCT03924492 255 262 O
agrees NCT03924492 263 269 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03924492 270 273 O
to NCT03924492 274 276 O
be NCT03924492 277 279 O
the NCT03924492 280 283 O
primary NCT03924492 284 291 B-Observation
caregiver NCT03924492 292 301 I-Observation
of NCT03924492 302 304 O
any NCT03924492 305 308 O
dependents NCT03924492 309 319 O
during NCT03924492 320 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924492 327 330 O
infusion NCT03924492 331 339 B-Procedure

5 NCT03924492 342 343 O
. NCT03924492 343 344 O
Subject NCT03924492 346 353 O
must NCT03924492 354 358 O
have NCT03924492 359 363 O
a NCT03924492 364 365 O
negative NCT03924492 366 374 O
pregnancy NCT03924492 375 384 B-Observation
test NCT03924492 385 389 I-Observation
on NCT03924492 390 392 O
Day NCT03924492 393 396 O
1 NCT03924492 397 398 O
prior NCT03924492 399 404 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924492 405 407 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03924492 408 411 O
start NCT03924492 412 417 O
of NCT03924492 418 420 O
the NCT03924492 421 424 O
ZULRESSO NCT03924492 425 433 B-Procedure
infusion NCT03924492 434 442 I-Procedure

6 NCT03924492 445 446 O
. NCT03924492 446 447 O
Subject NCT03924492 449 456 O
has NCT03924492 457 460 O
a NCT03924492 461 462 O
current NCT03924492 463 470 B-Eq-Comparison
diagnosis NCT03924492 471 480 O
of NCT03924492 481 483 O
PPD NCT03924492 484 487 B-Condition
, NCT03924492 488 489 O
as NCT03924492 490 492 O
assessed NCT03924492 493 501 O
by NCT03924492 502 504 O
the NCT03924492 505 508 O
Investigator NCT03924492 509 521 O

Exclusion NCT03924492 522 531 O
Criteria NCT03924492 532 540 O
: NCT03924492 541 542 O

1 NCT03924492 546 547 O
. NCT03924492 547 548 O
Subject NCT03924492 550 557 O
has NCT03924492 558 561 O
end NCT03924492 562 565 B-Modifier
stage NCT03924492 566 571 I-Modifier
renal NCT03924492 572 577 B-Condition
disease NCT03924492 578 585 I-Condition

2 NCT03924492 588 589 O
. NCT03924492 589 590 O
Subject NCT03924492 592 599 O
has NCT03924492 600 603 O
a NCT03924492 604 605 O
known NCT03924492 606 611 O
allergy NCT03924492 612 619 B-Allergy
to NCT03924492 620 622 O
progesterone NCT03924492 623 635 B-Drug
or NCT03924492 636 638 B-Or
allopregnanolone NCT03924492 639 655 B-Drug

Inclusion NCT03925571 0 9 O
Criteria NCT03925571 10 18 O
: NCT03925571 19 20 O

- NCT03925571 24 25 O
Majors NCT03925571 27 33 O
aged NCT03925571 34 38 B-Age
between NCT03925571 39 46 B-Eq-Comparison
18 NCT03925571 47 49 I-Eq-Comparison
and NCT03925571 50 53 I-Eq-Comparison
55 NCT03925571 54 56 I-Eq-Comparison
years NCT03925571 57 62 I-Eq-Comparison
, NCT03925571 63 64 O
with NCT03925571 65 69 O
an NCT03925571 70 72 O
appropriate NCT03925571 73 84 O
hearing NCT03925571 85 92 O
and NCT03925571 93 96 O
able NCT03925571 97 101 O
to NCT03925571 102 104 O
use NCT03925571 105 108 O
Music NCT03925571 109 114 O
- NCT03925571 115 116 O
Care NCT03925571 117 121 O
© NCT03925571 121 122 O
( NCT03925571 123 124 O
selection NCT03925571 125 134 O
of NCT03925571 135 137 O
the NCT03925571 138 141 O
playlist NCT03925571 142 150 O
via NCT03925571 151 154 O
internet NCT03925571 155 163 O
access NCT03925571 164 170 O
) NCT03925571 171 172 O
, NCT03925571 174 175 O

- NCT03925571 179 180 O
Needing NCT03925571 182 189 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03925571 190 199 B-Procedure
in NCT03925571 200 202 O
odontology NCT03925571 203 213 B-Modifier
- NCT03925571 214 215 O
periodontal NCT03925571 216 227 B-Modifier
surgery NCT03925571 228 235 B-Procedure
( NCT03925571 236 237 O
coronary NCT03925571 238 246 B-Procedure
elongation NCT03925571 247 257 I-Procedure
or NCT03925571 258 260 B-Or
sanitation NCT03925571 261 271 B-Procedure
surgery NCT03925571 272 279 I-Procedure
or NCT03925571 280 282 B-Or
muco NCT03925571 283 287 B-Procedure
- NCT03925571 288 289 I-Procedure
gingival NCT03925571 290 298 I-Procedure
surgery NCT03925571 299 306 I-Procedure
) NCT03925571 307 308 O
or NCT03925571 309 311 B-Or
implantary NCT03925571 312 322 B-Procedure
surgery NCT03925571 323 330 I-Procedure
( NCT03925571 331 332 O
placement NCT03925571 333 342 B-Procedure
of NCT03925571 343 345 I-Procedure
an NCT03925571 346 348 I-Procedure
unit NCT03925571 349 353 I-Procedure
implant NCT03925571 354 361 B-Modifier|Modifier
or NCT03925571 362 364 B-Or
two NCT03925571 365 368 B-Modifier
implant NCT03925571 369 376 O
in NCT03925571 377 379 I-Modifier
the NCT03925571 380 383 I-Modifier
same NCT03925571 384 388 I-Modifier
localization NCT03925571 389 401 I-Modifier
) NCT03925571 402 403 O
, NCT03925571 405 406 O

- NCT03925571 410 411 O
Oral NCT03925571 413 417 O
and NCT03925571 418 421 O
dated NCT03925571 422 427 O
consent NCT03925571 428 435 O
, NCT03925571 436 437 O

- NCT03925571 441 442 O
Agreeing NCT03925571 444 452 O
to NCT03925571 453 455 O
be NCT03925571 456 458 O
contacted NCT03925571 459 468 O
via NCT03925571 469 472 O
phone NCT03925571 473 478 O
at NCT03925571 479 481 O
J NCT03925571 482 483 O
+ NCT03925571 484 485 O
1 NCT03925571 486 487 O
and NCT03925571 488 491 O
to NCT03925571 492 494 O
fill NCT03925571 495 499 O
follow NCT03925571 500 506 O
- NCT03925571 507 508 O
up NCT03925571 509 511 O
study NCT03925571 512 517 O
documents NCT03925571 518 527 O
, NCT03925571 528 529 O

- NCT03925571 533 534 O
Profiting NCT03925571 536 545 O
of NCT03925571 546 548 O
social NCT03925571 549 555 O
security NCT03925571 556 564 O
or NCT03925571 565 567 O
CMU NCT03925571 568 571 O
. NCT03925571 571 572 O

Exclusion NCT03925571 574 583 O
Criteria NCT03925571 584 592 O
: NCT03925571 593 594 O

- NCT03925571 598 599 O
Patients NCT03925571 601 609 O
with NCT03925571 610 614 O
a NCT03925571 615 616 O
long NCT03925571 617 621 O
- NCT03925571 622 623 O
term NCT03925571 624 628 O
taking NCT03925571 629 635 B-Eq-Comparison
of NCT03925571 636 638 O
anxiolytic NCT03925571 639 649 B-Drug
or NCT03925571 650 652 B-Or
analgesic NCT03925571 653 662 B-Drug
, NCT03925571 663 664 O

- NCT03925571 668 669 O
Regular NCT03925571 671 678 O
consumer NCT03925571 679 687 O
of NCT03925571 688 690 O
soft NCT03925571 691 695 B-Drug
drug NCT03925571 696 700 I-Drug|Drug
( NCT03925571 701 702 O
cannabis NCT03925571 703 711 B-Drug
) NCT03925571 712 713 O
or NCT03925571 714 716 B-Or
hard NCT03925571 717 721 B-Drug
drug NCT03925571 722 726 O
( NCT03925571 727 728 O
opioid NCT03925571 729 735 B-Drug
) NCT03925571 736 737 O
, NCT03925571 739 740 O

- NCT03925571 744 745 O
Patient NCT03925571 747 754 O
with NCT03925571 755 759 O
medical NCT03925571 760 767 O
history NCT03925571 768 775 B-Eq-Comparison
of NCT03925571 776 778 O
psychiatry NCT03925571 779 789 B-Procedure
( NCT03925571 790 791 O
mental NCT03925571 792 798 B-Condition
harm NCT03925571 799 803 I-Condition
) NCT03925571 804 805 O
, NCT03925571 807 808 O
hearing NCT03925571 809 816 B-Condition
problem NCT03925571 817 824 I-Condition
, NCT03925571 825 826 O
cognitive NCT03925571 827 836 B-Modifier
and NCT03925571 837 840 B-Or
behavioural NCT03925571 841 852 B-Modifier
impairment NCT03925571 853 863 B-Condition
( NCT03925571 864 865 O
claustrophobia NCT03925571 866 880 B-Condition
) NCT03925571 881 882 O
, NCT03925571 884 885 O
sensory NCT03925571 886 893 B-Condition
disabilities NCT03925571 894 906 I-Condition
, NCT03925571 907 908 O

- NCT03925571 912 913 O
Patient NCT03925571 915 922 O
with NCT03925571 923 927 O
problems NCT03925571 928 936 O
of NCT03925571 937 939 O
hemostasis NCT03925571 940 950 B-Procedure
, NCT03925571 951 952 O

- NCT03925571 956 957 O
Majors NCT03925571 959 965 O
under NCT03925571 966 971 O
trusteeship NCT03925571 972 983 O
or NCT03925571 984 986 B-Or
guardianship NCT03925571 987 999 O
, NCT03925571 1000 1001 O

- NCT03925571 1005 1006 O
Pregnant NCT03925571 1008 1016 B-Condition
women NCT03925571 1017 1022 O
or NCT03925571 1023 1025 O
lactating NCT03925571 1026 1035 B-Condition
, NCT03925571 1036 1037 O

- NCT03925571 1041 1042 O
Minors NCT03925571 1044 1050 O
, NCT03925571 1051 1052 O

- NCT03925571 1056 1057 O
Protected NCT03925571 1059 1068 B-Observation
person NCT03925571 1069 1075 I-Observation
, NCT03925571 1076 1077 O
deprived NCT03925571 1078 1086 O
of NCT03925571 1087 1089 O
freedom NCT03925571 1090 1097 O
or NCT03925571 1098 1100 O
under NCT03925571 1101 1106 O
justice NCT03925571 1107 1114 O
safeguard NCT03925571 1115 1124 O
, NCT03925571 1125 1126 O

- NCT03925571 1130 1131 O
Profiting NCT03925571 1133 1142 O
of NCT03925571 1143 1145 O
a NCT03925571 1146 1147 O
medical NCT03925571 1148 1155 O
help NCT03925571 1156 1160 O
from NCT03925571 1161 1165 O
government NCT03925571 1166 1176 O
( NCT03925571 1177 1178 O
AME NCT03925571 1179 1182 O
) NCT03925571 1183 1184 O
, NCT03925571 1186 1187 O

- NCT03925571 1191 1192 O
Not NCT03925571 1194 1197 O
contactable NCT03925571 1198 1209 O
after NCT03925571 1210 1215 O
care NCT03925571 1216 1220 O
, NCT03925571 1221 1222 O

- NCT03925571 1226 1227 O
Patient NCT03925571 1229 1236 O
with NCT03925571 1237 1241 O
hepatic NCT03925571 1242 1249 B-Condition
impairment NCT03925571 1250 1260 I-Condition
, NCT03925571 1261 1262 O

- NCT03925571 1266 1267 O
Patient NCT03925571 1269 1276 O
with NCT03925571 1277 1281 O
dry NCT03925571 1282 1285 B-Condition
mouth NCT03925571 1286 1291 I-Condition
, NCT03925571 1292 1293 O

- NCT03925571 1297 1298 O
Patient NCT03925571 1300 1307 O
relevant NCT03925571 1308 1316 O
a NCT03925571 1317 1318 O
suboptimal NCT03925571 1319 1329 B-Condition
hearing NCT03925571 1330 1337 I-Condition
incompatible NCT03925571 1338 1350 O
with NCT03925571 1351 1355 O
musicotherapy NCT03925571 1356 1369 O
or NCT03925571 1370 1372 O
inability NCT03925571 1373 1382 O
to NCT03925571 1383 1385 O
use NCT03925571 1386 1389 O
Music NCT03925571 1390 1395 O
- NCT03925571 1396 1397 O
care NCT03925571 1398 1402 O
® NCT03925571 1402 1403 O
. NCT03925571 1403 1404 O

Inclusion NCT03926078 0 9 O
criteria NCT03926078 10 18 O
: NCT03926078 19 20 O

- NCT03926078 24 25 O
All NCT03926078 27 30 O
patients NCT03926078 31 39 O
that NCT03926078 40 44 O
visit NCT03926078 45 50 B-Encounter
the NCT03926078 51 54 O
Zuyderland NCT03926078 55 65 O
Medical NCT03926078 66 73 O
Centre NCT03926078 74 80 O
outpatient NCT03926078 81 91 O
clinic NCT03926078 92 98 O
for NCT03926078 99 102 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
evaluation NCT03926078 103 113 B-Assertion___Assertion-Type-Value:possible
of NCT03926078 114 116 O
their NCT03926078 117 122 O
pectus NCT03926078 123 129 B-Condition
excavatum NCT03926078 130 139 I-Condition
. NCT03926078 139 140 O

- NCT03926078 144 145 O
No NCT03926078 147 149 O
age NCT03926078 150 153 O
restrictions NCT03926078 154 166 O
were NCT03926078 167 171 O
imposed NCT03926078 172 179 O
, NCT03926078 180 181 O
however NCT03926078 182 189 O
, NCT03926078 190 191 O
to NCT03926078 192 194 O
be NCT03926078 195 197 O
eligible NCT03926078 198 206 O
, NCT03926078 207 208 O
it NCT03926078 209 211 O
was NCT03926078 212 215 O
mandatory NCT03926078 216 225 O
to NCT03926078 226 228 O
be NCT03926078 229 231 O
able NCT03926078 232 236 O
to NCT03926078 237 239 O
stand NCT03926078 240 245 O
still NCT03926078 246 251 O
in NCT03926078 252 254 O
and NCT03926078 255 258 O
upright NCT03926078 259 266 O
position NCT03926078 267 275 O
for NCT03926078 276 279 O
60 NCT03926078 280 282 O
seconds NCT03926078 283 290 O
. NCT03926078 290 291 O

Exclusion NCT03926078 293 302 O
criteria NCT03926078 303 311 O
: NCT03926078 312 313 O

- NCT03926078 316 317 O
Patients NCT03926078 318 326 O
that NCT03926078 327 331 O
suffer NCT03926078 332 338 O
from NCT03926078 339 343 O
any NCT03926078 344 347 O
form NCT03926078 348 352 O
of NCT03926078 353 355 O
light NCT03926078 356 361 B-Condition
hypersensitivity NCT03926078 362 378 I-Condition
or NCT03926078 379 381 B-Or
epilepsy NCT03926078 382 390 B-Condition
were NCT03926078 391 395 O
not NCT03926078 396 399 O

considered NCT03926078 400 410 O
while NCT03926078 411 416 O
3 NCT03926078 417 418 O
D NCT03926078 419 420 O
optical NCT03926078 421 428 O
surface NCT03926078 429 436 O
images NCT03926078 437 443 O
were NCT03926078 444 448 O
acquired NCT03926078 449 457 O
with NCT03926078 458 462 O
the NCT03926078 463 466 O
use NCT03926078 467 470 O
of NCT03926078 471 473 O
structured NCT03926078 474 484 O
, NCT03926078 485 486 O

flashing NCT03926078 488 496 O
light NCT03926078 497 502 O
. NCT03926078 502 503 O

Inclusion NCT03923114 0 9 O
Criteria NCT03923114 10 18 O
: NCT03923114 19 20 O

Patients NCT03923114 22 30 O
with NCT03923114 31 35 O
treatment NCT03923114 36 45 B-Observation
response NCT03923114 46 54 I-Observation
: NCT03923114 55 56 O

- NCT03923114 60 61 O
Age NCT03923114 63 66 B-Age
≥ NCT03923114 67 68 B-Eq-Comparison
18 NCT03923114 69 71 I-Eq-Comparison
years NCT03923114 72 77 I-Eq-Comparison

- NCT03923114 80 81 O
Subject NCT03923114 83 90 O
is NCT03923114 91 93 O
diagnosed NCT03923114 94 103 O
with NCT03923114 104 108 O
type NCT03923114 109 113 B-Condition
2 NCT03923114 114 115 I-Condition
diabetes NCT03923114 116 124 I-Condition

- NCT03923114 127 128 O
Subject NCT03923114 130 137 O
showed NCT03923114 138 144 O
response NCT03923114 145 153 B-Observation
to NCT03923114 154 156 O
GLP NCT03923114 157 160 B-Procedure
- NCT03923114 161 162 I-Procedure
1 NCT03923114 163 164 I-Procedure
RA NCT03923114 165 167 O
treatment NCT03923114 168 177 I-Procedure

- NCT03923114 180 181 O
Ability NCT03923114 183 190 O
to NCT03923114 191 193 O
sign NCT03923114 194 198 O
informed NCT03923114 199 207 O
consent NCT03923114 208 215 O

Patients NCT03923114 216 224 O
without NCT03923114 225 232 B-Negation
treatment NCT03923114 233 242 B-Observation
response NCT03923114 243 251 I-Observation
: NCT03923114 252 253 O

- NCT03923114 257 258 O
Age NCT03923114 260 263 B-Age
≥ NCT03923114 264 265 B-Eq-Comparison
18 NCT03923114 266 268 I-Eq-Comparison
years NCT03923114 269 274 I-Eq-Comparison

- NCT03923114 277 278 O
Subject NCT03923114 280 287 O
is NCT03923114 288 290 O
diagnosed NCT03923114 291 300 O
with NCT03923114 301 305 O
type NCT03923114 306 310 B-Condition
2 NCT03923114 311 312 I-Condition
diabetes NCT03923114 313 321 I-Condition

- NCT03923114 324 325 O
Subject NCT03923114 327 334 O
showed NCT03923114 335 341 O
no NCT03923114 342 344 B-Negation
response NCT03923114 345 353 B-Observation
to NCT03923114 354 356 O
GLP NCT03923114 357 360 B-Procedure
- NCT03923114 361 362 I-Procedure
1 NCT03923114 363 364 I-Procedure
RA NCT03923114 365 367 O
treatment NCT03923114 368 377 I-Procedure

- NCT03923114 380 381 O
Ability NCT03923114 383 390 O
to NCT03923114 391 393 O
sign NCT03923114 394 398 O
informed NCT03923114 399 407 O
consent NCT03923114 408 415 O

Exclusion NCT03923114 416 425 O
Criteria NCT03923114 426 434 O
: NCT03923114 435 436 O

- NCT03923114 440 441 O
Liver NCT03923114 443 448 B-Condition
disease NCT03923114 449 456 I-Condition

- NCT03923114 459 460 O
Renal NCT03923114 462 467 B-Condition
disease NCT03923114 468 475 I-Condition

- NCT03923114 478 479 O
Pregnancy NCT03923114 481 490 B-Condition
or NCT03923114 491 493 B-Or
the NCT03923114 494 497 O
wish NCT03923114 498 502 B-Assertion___Assertion-Type-Value:intention
to NCT03923114 503 505 I-Assertion___Assertion-Type-Value:intention
become NCT03923114 506 512 O
pregnant NCT03923114 513 521 B-Condition
within NCT03923114 522 528 B-Eq-Comparison
6 NCT03923114 529 530 I-Eq-Comparison
months NCT03923114 531 537 I-Eq-Comparison
after NCT03923114 538 543 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03923114 544 547 O
study NCT03923114 548 553 B-Study

- NCT03923114 556 557 O
Breastfeeding NCT03923114 559 572 B-Condition

- NCT03923114 575 576 O
Age NCT03923114 578 581 B-Age
< NCT03923114 582 583 B-Eq-Comparison
18 NCT03923114 584 586 I-Eq-Comparison
years NCT03923114 587 592 I-Eq-Comparison

- NCT03923114 595 596 O
Pituitary NCT03923114 598 607 B-Condition
disorder NCT03923114 608 616 I-Condition

- NCT03923114 619 620 O
Inability NCT03923114 622 631 O
to NCT03923114 632 634 O
sign NCT03923114 635 639 O
informed NCT03923114 640 648 O
consent NCT03923114 649 656 O

- NCT03923114 659 660 O
Exclusion NCT03923114 662 671 O
criteria NCT03923114 672 680 O
for NCT03923114 681 684 O
MR NCT03923114 685 687 O
: NCT03923114 688 689 O

- NCT03923114 698 699 O
Fragments NCT03923114 701 710 B-Modifier
, NCT03923114 711 712 O
clips NCT03923114 713 718 B-Modifier
or NCT03923114 719 721 B-Or
devices NCT03923114 722 729 B-Modifier
in NCT03923114 730 732 O
brain NCT03923114 733 738 B-Condition
, NCT03923114 739 740 O
eyes NCT03923114 741 745 B-Modifier
, NCT03923114 746 747 O
spinal NCT03923114 748 754 B-Modifier
canal NCT03923114 755 760 I-Modifier

- NCT03923114 768 769 O
Implantable NCT03923114 771 782 B-Procedure
defibrillator NCT03923114 783 796 I-Procedure
or NCT03923114 797 799 B-Or
pacemaker NCT03923114 800 809 B-Procedure
( NCT03923114 810 811 O
wires NCT03923114 812 817 O
) NCT03923114 818 819 O

- NCT03923114 828 829 O
Mandibular NCT03923114 831 841 B-Procedure
magnetic NCT03923114 842 850 I-Procedure
implants NCT03923114 851 859 I-Procedure

- NCT03923114 867 868 O
Neurostimulator NCT03923114 870 885 B-Procedure
, NCT03923114 886 887 O
bladder NCT03923114 888 895 B-Procedure
stimulator NCT03923114 896 906 I-Procedure
, NCT03923114 907 908 O
non NCT03923114 909 912 B-Procedure
- NCT03923114 913 914 I-Procedure
removable NCT03923114 915 924 I-Procedure
insulin NCT03923114 925 932 I-Procedure
pump NCT03923114 933 937 I-Procedure

- NCT03923114 945 946 I-Procedure
Metal NCT03923114 948 953 B-Procedure
tissue NCT03923114 954 960 I-Procedure
- NCT03923114 961 962 O
expander NCT03923114 963 971 I-Procedure
in NCT03923114 972 974 I-Procedure
chest NCT03923114 975 980 I-Procedure

- NCT03923114 988 989 O
Cochlear NCT03923114 991 999 B-Procedure
implant NCT03923114 1000 1007 I-Procedure

- NCT03923114 1015 1016 O
Ossicular NCT03923114 1018 1027 B-Procedure
replacement NCT03923114 1028 1039 I-Procedure
prosthesis NCT03923114 1040 1050 I-Procedure

Inclusion NCT03921918 0 9 O
Criteria NCT03921918 10 18 O
: NCT03921918 19 20 O

1 NCT03921918 24 25 O
. NCT03921918 25 26 O
Subject NCT03921918 28 35 O
≥ NCT03921918 36 37 B-Eq-Comparison
18 NCT03921918 38 40 I-Eq-Comparison
years NCT03921918 41 46 I-Eq-Comparison
old NCT03921918 47 50 B-Age

2 NCT03921918 53 54 O
. NCT03921918 54 55 O
Infant NCT03921918 57 63 O
is NCT03921918 64 66 B-And
≥ NCT03921918 67 68 B-Eq-Comparison
1 NCT03921918 69 70 I-Eq-Comparison
and NCT03921918 71 74 B-And
≤ NCT03921918 75 76 B-Eq-Comparison
6 NCT03921918 77 78 I-Eq-Comparison
month NCT03921918 79 84 I-Eq-Comparison
old NCT03921918 85 88 B-Age

3 NCT03921918 91 92 O
. NCT03921918 92 93 O
Subject NCT03921918 95 102 O
and NCT03921918 103 106 O
baby NCT03921918 107 111 B-Family-Member___Family-Member-Type:child
are NCT03921918 112 115 O
healthy NCT03921918 116 123 B-Condition
according NCT03921918 124 133 O
to NCT03921918 134 136 O
self NCT03921918 137 141 O
- NCT03921918 142 143 O
declaration NCT03921918 144 155 O
in NCT03921918 156 158 O
the NCT03921918 159 162 O
" NCT03921918 163 164 O
Mother NCT03921918 164 170 B-Observation
and NCT03921918 171 174 I-Observation
infant NCT03921918 175 181 I-Observation
health NCT03921918 182 188 I-Observation
questionnaire NCT03921918 189 202 I-Observation
" NCT03921918 202 203 O

4 NCT03921918 206 207 O
. NCT03921918 207 208 O
Subject NCT03921918 210 217 O
is NCT03921918 218 220 O
predominantly NCT03921918 221 234 O
breastfeeding NCT03921918 235 248 B-Condition
( NCT03921918 249 250 O
80 NCT03921918 251 253 B-Eq-Comparison
% NCT03921918 254 255 O
of NCT03921918 256 258 I-Eq-Comparison
all NCT03921918 259 262 I-Eq-Comparison
feeds NCT03921918 263 268 I-Eq-Comparison
, NCT03921918 269 270 O
i. NCT03921918 271 273 O
e. NCT03921918 274 276 O
≤ NCT03921918 278 279 B-Eq-Comparison
150 NCT03921918 280 283 I-Eq-Comparison
ml NCT03921918 284 286 I-Eq-Comparison
formula NCT03921918 287 294 I-Eq-Comparison
/ NCT03921918 295 296 I-Eq-Comparison
day NCT03921918 297 300 I-Eq-Comparison
or NCT03921918 301 303 O
equal NCT03921918 304 309 O
representative NCT03921918 310 324 O
amount NCT03921918 325 331 O
of NCT03921918 332 334 O
solid NCT03921918 335 340 O
food NCT03921918 341 345 O
) NCT03921918 346 347 O

5 NCT03921918 351 352 O
. NCT03921918 352 353 O
The NCT03921918 355 358 O
subject NCT03921918 359 366 O
agrees NCT03921918 367 373 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 374 376 I-Assertion___Assertion-Type-Value:hypothetical
pump NCT03921918 377 381 B-Observation
or NCT03921918 382 384 B-Or
feed NCT03921918 385 389 B-Observation
the NCT03921918 390 393 O
last NCT03921918 394 398 B-Eq-Comparison
time NCT03921918 399 403 I-Eq-Comparison
a NCT03921918 404 405 O
minimum NCT03921918 406 413 B-Eq-Comparison
of NCT03921918 414 416 I-Eq-Comparison
2 NCT03921918 417 418 I-Eq-Comparison
hours NCT03921918 419 424 I-Eq-Comparison
( NCT03921918 425 426 O
hr NCT03921918 427 429 O
) NCT03921918 430 431 O
before NCT03921918 432 438 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921918 439 442 O
start NCT03921918 443 448 O
of NCT03921918 449 451 O
the NCT03921918 452 455 O
pumping NCT03921918 456 463 O
session NCT03921918 464 471 O
at NCT03921918 472 474 O
the NCT03921918 475 478 O
study NCT03921918 479 484 B-Study
site NCT03921918 485 489 O

6 NCT03921918 492 493 O
. NCT03921918 493 494 O
The NCT03921918 496 499 O
subject NCT03921918 500 507 O
agrees NCT03921918 508 514 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 515 517 I-Assertion___Assertion-Type-Value:hypothetical
photographs NCT03921918 518 529 B-Observation
/ NCT03921918 530 531 I-Observation
3 NCT03921918 532 533 I-Observation
D NCT03921918 534 535 I-Observation
scan NCT03921918 536 540 I-Observation
of NCT03921918 541 543 O
the NCT03921918 544 547 O
breast NCT03921918 548 554 B-Modifier
and NCT03921918 555 558 B-Or
upper NCT03921918 559 564 B-Modifier
body NCT03921918 565 569 I-Modifier
( NCT03921918 570 571 O
no NCT03921918 572 574 B-Exception
face NCT03921918 575 579 B-Modifier
) NCT03921918 580 581 O
, NCT03921918 583 584 O

7 NCT03921918 588 589 O
. NCT03921918 589 590 O
The NCT03921918 592 595 O
subject NCT03921918 596 603 O
agrees NCT03921918 604 610 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 611 613 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03921918 614 615 O
video NCT03921918 616 621 B-Observation
while NCT03921918 622 627 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pumping NCT03921918 628 635 B-Observation

8 NCT03921918 638 639 O
. NCT03921918 639 640 O
The NCT03921918 642 645 O
subject NCT03921918 646 653 O
signs NCT03921918 654 659 O
the NCT03921918 660 663 O
informed NCT03921918 664 672 O
consent NCT03921918 673 680 O
documentation NCT03921918 681 694 O

9 NCT03921918 697 698 O
. NCT03921918 698 699 O
Subject NCT03921918 701 708 O
agrees NCT03921918 709 715 B-Assertion___Assertion-Type-Value:hypothetical
that NCT03921918 716 720 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03921918 721 722 O
maximum NCT03921918 723 730 B-Eq-Comparison
of NCT03921918 731 733 I-Eq-Comparison
2 NCT03921918 734 735 I-Eq-Comparison
male NCT03921918 736 740 I-Eq-Comparison
team NCT03921918 741 745 I-Eq-Comparison
members NCT03921918 746 753 I-Eq-Comparison
can NCT03921918 754 757 O
be NCT03921918 758 760 O
present NCT03921918 761 768 B-Observation
in NCT03921918 769 771 I-Observation
the NCT03921918 772 775 I-Observation
room NCT03921918 776 780 I-Observation
to NCT03921918 781 783 O
conduct NCT03921918 784 791 O
the NCT03921918 792 795 O
usability NCT03921918 796 805 O
part NCT03921918 806 810 O
of NCT03921918 811 813 O
the NCT03921918 814 817 O
study NCT03921918 818 823 O

10 NCT03921918 825 827 O
. NCT03921918 827 828 O
The NCT03921918 830 833 O
mother NCT03921918 834 840 O
accepts NCT03921918 841 848 B-Assertion___Assertion-Type-Value:hypothetical
that NCT03921918 849 853 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03921918 854 857 O
pumped NCT03921918 858 864 O
milk NCT03921918 865 869 O
in NCT03921918 870 872 O
visit NCT03921918 873 878 O
2 NCT03921918 879 880 O
must NCT03921918 881 885 O
be NCT03921918 886 888 O
donated NCT03921918 889 896 O
to NCT03921918 897 899 O
the NCT03921918 900 903 O
study NCT03921918 904 909 O
i. NCT03921918 910 912 O
e. NCT03921918 913 915 O
can NCT03921918 917 920 O
not NCT03921918 920 923 O
be NCT03921918 924 926 O
fed NCT03921918 927 930 O
to NCT03921918 931 933 O
the NCT03921918 934 937 O
baby NCT03921918 938 942 O

Exclusion NCT03921918 943 952 O
Criteria NCT03921918 953 961 O
: NCT03921918 962 963 O

1 NCT03921918 967 968 O
. NCT03921918 968 969 O
The NCT03921918 971 974 O
subject NCT03921918 975 982 O
has NCT03921918 983 986 O
a NCT03921918 987 988 O
nipple NCT03921918 989 995 B-Observation
size NCT03921918 996 1000 I-Observation
≥ NCT03921918 1001 1002 B-Eq-Comparison
21 NCT03921918 1003 1005 I-Eq-Comparison
mm NCT03921918 1006 1008 I-Eq-Comparison

2 NCT03921918 1011 1012 O
. NCT03921918 1012 1013 O
Mastitis NCT03921918 1015 1023 B-Condition
( NCT03921918 1024 1025 O
any NCT03921918 1026 1029 B-Modifier
breast NCT03921918 1030 1036 I-Modifier
within NCT03921918 1037 1043 B-Eq-Comparison
two NCT03921918 1044 1047 I-Eq-Comparison
weeks NCT03921918 1048 1053 I-Eq-Comparison
prior NCT03921918 1054 1059 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921918 1060 1062 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03921918 1063 1072 B-Study
) NCT03921918 1073 1074 O

3 NCT03921918 1078 1079 O
. NCT03921918 1079 1080 O
Engorgement NCT03921918 1082 1093 B-Condition
( NCT03921918 1094 1095 O
any NCT03921918 1096 1099 B-Modifier
breast NCT03921918 1100 1106 I-Modifier
within NCT03921918 1107 1113 B-Eq-Comparison
two NCT03921918 1114 1117 I-Eq-Comparison
weeks NCT03921918 1118 1123 I-Eq-Comparison
prior NCT03921918 1124 1129 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921918 1130 1132 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03921918 1133 1142 B-Study
) NCT03921918 1143 1144 O
. NCT03921918 1145 1146 O

4 NCT03921918 1150 1151 O
. NCT03921918 1151 1152 O
Case NCT03921918 1154 1158 O
of NCT03921918 1159 1161 O
current NCT03921918 1162 1169 B-Eq-Comparison
infection NCT03921918 1170 1179 B-Condition
as NCT03921918 1180 1182 O
self NCT03921918 1183 1187 O
- NCT03921918 1188 1189 O
declared NCT03921918 1190 1198 O
in NCT03921918 1199 1201 I-Observation
the NCT03921918 1202 1205 O
Mother NCT03921918 1206 1212 B-Observation
and NCT03921918 1213 1216 I-Observation
infant NCT03921918 1217 1223 O
health NCT03921918 1224 1230 I-Observation
questionnaire NCT03921918 1231 1244 I-Observation

Inclusion NCT03923699 0 9 O
Criteria NCT03923699 10 18 O
: NCT03923699 19 20 O

- NCT03923699 24 25 O
All NCT03923699 27 30 O
patients NCT03923699 31 39 O
18 NCT03923699 40 42 B-Eq-Comparison
years NCT03923699 43 48 I-Eq-Comparison
or NCT03923699 49 51 I-Eq-Comparison
older NCT03923699 52 57 I-Age|Eq-Comparison
undergoing NCT03923699 58 68 B-Eq-Comparison
surgery NCT03923699 69 76 B-Procedure
at NCT03923699 77 79 O
Barnes NCT03923699 80 86 O
Jewish NCT03923699 87 93 O
Hospital NCT03923699 94 102 O
in NCT03923699 103 105 O
St. NCT03923699 106 109 O
Louis NCT03923699 111 116 O
, NCT03923699 117 118 O
MO NCT03923699 119 121 O

Exclusion NCT03923699 122 131 O
Criteria NCT03923699 132 140 O
: NCT03923699 141 142 O

- NCT03923699 145 146 O

Inclusion NCT03920384 0 9 O
Criteria NCT03920384 10 18 O
: NCT03920384 19 20 O

- NCT03920384 24 25 O
Are NCT03920384 27 30 O
aged NCT03920384 31 35 B-Age
16 NCT03920384 36 38 B-Eq-Comparison
or NCT03920384 39 41 I-Eq-Comparison
over NCT03920384 42 46 I-Eq-Comparison

- NCT03920384 49 50 O
Are NCT03920384 52 55 O
competent NCT03920384 56 65 O
and NCT03920384 66 69 O
willing NCT03920384 70 77 O
to NCT03920384 78 80 O
provide NCT03920384 81 88 O
written NCT03920384 89 96 O
, NCT03920384 97 98 O
informed NCT03920384 99 107 O
consent NCT03920384 108 115 O

- NCT03920384 118 119 O
Are NCT03920384 121 124 O
experiencing NCT03920384 125 137 B-Eq-Comparison
delusions NCT03920384 138 147 B-Condition
( NCT03920384 148 149 O
A NCT03920384 150 151 O
score NCT03920384 152 157 B-Eq-Comparison
of NCT03920384 158 160 I-Eq-Comparison
≥ NCT03920384 161 162 I-Eq-Comparison
3 NCT03920384 163 164 I-Eq-Comparison
on NCT03920384 165 167 O
PANSS NCT03920384 168 173 B-Observation
item NCT03920384 174 178 O
P1 NCT03920384 179 181 B-Modifier
, NCT03920384 182 183 O
P5 NCT03920384 184 186 B-Modifier
or NCT03920384 187 189 B-Or
P6 NCT03920384 190 192 B-Modifier
) NCT03920384 193 194 O

Exclusion NCT03920384 196 205 O
Criteria NCT03920384 206 214 O
: NCT03920384 215 216 O

- NCT03920384 220 221 O
Significant NCT03920384 223 234 O
developmental NCT03920384 235 248 B-Condition
disability NCT03920384 249 259 I-Condition

- NCT03920384 262 263 O
Currently NCT03920384 265 274 B-Eq-Comparison
receiving NCT03920384 275 284 I-Eq-Comparison
or NCT03920384 285 287 B-Or
have NCT03920384 288 292 O
received NCT03920384 293 301 B-Eq-Comparison
CBTp NCT03920384 302 306 B-Procedure
in NCT03920384 307 309 O
the NCT03920384 310 313 O
last NCT03920384 314 318 B-Eq-Comparison
6 NCT03920384 319 320 I-Eq-Comparison
months NCT03920384 321 327 I-Eq-Comparison

- NCT03920384 330 331 O
Significant NCT03920384 333 344 O
difficulty NCT03920384 345 355 B-Negation
with NCT03920384 356 360 O
the NCT03920384 361 364 O
English NCT03920384 365 372 O
language NCT03920384 373 381 O

Inclusion NCT03925363 0 9 O
Criteria NCT03925363 10 18 O
: NCT03925363 19 20 O

- NCT03925363 24 25 O
Previous NCT03925363 27 35 B-Eq-Comparison
participants NCT03925363 36 48 O
in NCT03925363 49 51 O
healthy NCT03925363 52 59 O
aging NCT03925363 60 65 O
initiative NCT03925363 66 76 O
. NCT03925363 76 77 O

Exclusion NCT03925363 79 88 O
Criteria NCT03925363 89 97 O
: NCT03925363 98 99 O

- NCT03925363 103 104 O
Not NCT03925363 106 109 B-Negation
able NCT03925363 110 114 B-Condition
to NCT03925363 115 117 I-Condition
walk NCT03925363 118 122 I-Condition
or NCT03925363 123 125 B-Or
previous NCT03925363 126 134 B-Eq-Comparison
medical NCT03925363 135 142 O
diagnoses NCT03925363 143 152 B-Condition
that NCT03925363 153 157 O
severely NCT03925363 158 166 O
limits NCT03925363 167 173 B-Negation
the NCT03925363 174 177 O
possibility NCT03925363 178 189 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925363 190 192 O
exercise NCT03925363 193 201 B-Observation
. NCT03925363 201 202 O

Inclusion NCT03926130 0 9 O
Criteria NCT03926130 10 18 O
: NCT03926130 19 20 O

- NCT03926130 24 25 O
Diagnosis NCT03926130 27 36 O
of NCT03926130 37 39 O
CD NCT03926130 40 42 B-Condition
for NCT03926130 43 46 O
at NCT03926130 47 49 B-Eq-Comparison
least NCT03926130 50 55 I-Eq-Comparison
3 NCT03926130 56 57 I-Eq-Comparison
months NCT03926130 58 64 I-Eq-Comparison
prior NCT03926130 65 70 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926130 71 73 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926130 74 82 B-Study

- NCT03926130 85 86 O
Confirmed NCT03926130 88 97 O
diagnosis NCT03926130 98 107 O
of NCT03926130 108 110 O
moderate NCT03926130 111 119 O
to NCT03926130 120 122 B-Or
severe NCT03926130 123 129 O
CD NCT03926130 130 132 B-Condition
as NCT03926130 133 135 O
assessed NCT03926130 136 144 O
by NCT03926130 145 147 O
SF NCT03926130 148 150 B-Observation
, NCT03926130 151 152 O
AP NCT03926130 153 155 B-Observation
score NCT03926130 156 161 I-Observation
, NCT03926130 162 163 O
and NCT03926130 164 167 B-Or
SES NCT03926130 168 171 B-Observation
- NCT03926130 172 173 I-Observation
CD NCT03926130 174 176 I-Observation

- NCT03926130 179 180 O
Demonstrated NCT03926130 182 194 O
intolerance NCT03926130 195 206 B-Condition
, NCT03926130 207 208 O
loss NCT03926130 209 213 B-Condition
of NCT03926130 214 216 I-Condition
response NCT03926130 217 225 I-Condition
or NCT03926130 226 228 B-Or
inadequate NCT03926130 229 239 B-Condition
response NCT03926130 240 248 I-Condition
to NCT03926130 249 251 O
conventional NCT03926130 252 264 B-Modifier
or NCT03926130 265 267 B-Or
to NCT03926130 268 270 O
biologic NCT03926130 271 279 B-Modifier
therapy NCT03926130 280 287 B-Procedure
for NCT03926130 288 291 O
CD NCT03926130 292 294 B-Condition

- NCT03926130 297 298 O
If NCT03926130 300 302 O
female NCT03926130 303 309 O
, NCT03926130 310 311 O
subject NCT03926130 312 319 O
must NCT03926130 320 324 O
meet NCT03926130 325 329 O
the NCT03926130 330 333 O
contraception NCT03926130 334 347 B-Procedure
recommendations NCT03926130 348 363 B-Assertion___Assertion-Type-Value:hypothetical

Exclusion NCT03926130 364 373 O
Criteria NCT03926130 374 382 O
: NCT03926130 383 384 O

- NCT03926130 388 389 O
Have NCT03926130 391 395 O
a NCT03926130 396 397 O
current NCT03926130 398 405 B-Eq-Comparison
diagnosis NCT03926130 406 415 O
of NCT03926130 416 418 O
ulcerative NCT03926130 419 429 B-Condition
colitis NCT03926130 430 437 I-Condition
, NCT03926130 438 439 O
inflammatory NCT03926130 440 452 B-Condition
bowel NCT03926130 453 458 I-Condition
disease NCT03926130 459 466 I-Condition
- NCT03926130 467 468 I-Condition
unclassified NCT03926130 469 481 I-Condition
( NCT03926130 482 483 O
IBD NCT03926130 484 487 B-Condition
- NCT03926130 488 489 I-Condition
U NCT03926130 490 491 I-Condition
) NCT03926130 492 493 O
( NCT03926130 494 495 O
formerly NCT03926130 496 504 O
known NCT03926130 505 510 O
as NCT03926130 511 513 O
indeterminate NCT03926130 514 527 B-Condition
colitis NCT03926130 528 535 I-Condition
) NCT03926130 536 537 O
, NCT03926130 539 540 O
abdominal NCT03926130 541 550 B-Modifier
or NCT03926130 551 553 B-Or|Or
perianal NCT03926130 554 562 B-Modifier
abscess NCT03926130 563 570 B-Condition
or NCT03926130 571 573 O
short NCT03926130 574 579 B-Condition
bowel NCT03926130 580 585 I-Condition
syndrome NCT03926130 586 594 I-Condition

- NCT03926130 597 598 O
Have NCT03926130 600 604 O
a NCT03926130 605 606 O
stoma NCT03926130 607 612 B-Procedure
or NCT03926130 613 615 B-Or
ostomy NCT03926130 616 622 B-Procedure

- NCT03926130 625 626 O
Have NCT03926130 628 632 O
had NCT03926130 633 636 O
a NCT03926130 637 638 O
bowel NCT03926130 639 644 B-Procedure
resection NCT03926130 645 654 I-Procedure
within NCT03926130 655 661 B-Eq-Comparison
6 NCT03926130 662 663 I-Eq-Comparison
months NCT03926130 664 670 I-Eq-Comparison
, NCT03926130 671 672 O
or NCT03926130 673 675 B-Or
any NCT03926130 676 679 O
kind NCT03926130 680 684 O
of NCT03926130 685 687 O
intra NCT03926130 688 693 B-Modifier
- NCT03926130 694 695 I-Modifier
abdominal NCT03926130 696 705 I-Modifier|Modifier
or NCT03926130 706 708 B-Or
extra NCT03926130 709 714 B-Modifier
abdominal NCT03926130 715 724 O
surgery NCT03926130 725 732 B-Procedure
within NCT03926130 733 739 B-Eq-Comparison
3 NCT03926130 740 741 I-Eq-Comparison
months NCT03926130 742 748 I-Eq-Comparison
of NCT03926130 749 751 B-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926130 752 760 B-Study

- NCT03926130 763 764 O
Have NCT03926130 766 770 O
ever NCT03926130 771 775 O
received NCT03926130 776 784 B-Eq-Comparison
any NCT03926130 785 788 O
monoclonal NCT03926130 789 799 B-Procedure
antibodies NCT03926130 800 810 I-Procedure
binding NCT03926130 811 818 I-Procedure
IL NCT03926130 819 821 I-Procedure
- NCT03926130 822 823 I-Procedure
23 NCT03926130 824 826 I-Procedure

Inclusion NCT03926871 0 9 O
Criteria NCT03926871 10 18 O
: NCT03926871 19 20 O

To NCT03926871 22 24 O
Novato NCT03926871 25 31 O
workers NCT03926871 32 39 O

- NCT03926871 42 43 O
1 NCT03926871 45 46 B-Eq-Comparison
to NCT03926871 47 49 I-Eq-Comparison
2 NCT03926871 50 51 I-Eq-Comparison
days NCT03926871 52 56 I-Eq-Comparison
in NCT03926871 57 59 O
the NCT03926871 60 63 O
company NCT03926871 64 71 O

- NCT03926871 74 75 O
Not NCT03926871 77 80 O
have NCT03926871 81 85 O
previous NCT03926871 86 94 B-Eq-Comparison
experience NCT03926871 95 105 O
in NCT03926871 106 108 O
a NCT03926871 109 110 O
frigorifico NCT03926871 111 122 O
, NCT03926871 123 124 O
or NCT03926871 125 127 O
butcher NCT03926871 128 135 O
's NCT03926871 135 137 O
shop NCT03926871 138 142 O

- NCT03926871 145 146 O
Not NCT03926871 148 151 O
have NCT03926871 152 156 O
prior NCT03926871 157 162 B-Eq-Comparison
knowledge NCT03926871 163 172 O
of NCT03926871 173 175 O
the NCT03926871 176 179 O
activity NCT03926871 180 188 O
. NCT03926871 188 189 O
To NCT03926871 191 193 O
experienced NCT03926871 194 205 O
workers NCT03926871 206 213 O

- NCT03926871 216 217 O
Work NCT03926871 219 223 O
on NCT03926871 224 226 O
the NCT03926871 227 230 O
task NCT03926871 231 235 O
for NCT03926871 236 239 O
more NCT03926871 240 244 O
than NCT03926871 245 249 O
six NCT03926871 250 253 O
months NCT03926871 254 260 O

- NCT03926871 263 264 O
Be NCT03926871 266 268 O
present NCT03926871 269 276 O
in NCT03926871 277 279 O
company NCT03926871 280 287 O
during NCT03926871 288 294 O
the NCT03926871 295 298 O
study NCT03926871 299 304 B-Study
period NCT03926871 305 311 O

Exclusion NCT03926871 312 321 O
Criteria NCT03926871 322 330 O
: NCT03926871 331 332 O

For NCT03926871 334 337 O
all NCT03926871 338 341 O
workers NCT03926871 342 349 O

- NCT03926871 352 353 O
Had NCT03926871 355 358 O
already NCT03926871 359 366 O
received NCT03926871 367 375 B-Eq-Comparison
ergonomic NCT03926871 376 385 O
training NCT03926871 386 394 O
( NCT03926871 395 396 O
general NCT03926871 397 404 O
guidelines NCT03926871 405 415 O
and NCT03926871 416 419 O
postural NCT03926871 420 428 O
adjustments NCT03926871 429 440 O
) NCT03926871 441 442 O

- NCT03926871 446 447 O
Pregnant NCT03926871 449 457 B-Condition
women NCT03926871 458 463 O

- NCT03926871 466 467 O
People NCT03926871 469 475 O
with NCT03926871 476 480 O
disabilities NCT03926871 481 493 B-Condition
. NCT03926871 493 494 O

Inclusion NCT03928860 0 9 O
Criteria NCT03928860 10 18 O
: NCT03928860 19 20 O

- NCT03928860 24 25 O
Patients NCT03928860 27 35 O
with NCT03928860 36 40 O
at NCT03928860 41 43 B-Eq-Comparison
least NCT03928860 44 49 I-Eq-Comparison
3 NCT03928860 50 51 I-Eq-Comparison
months NCT03928860 52 58 I-Eq-Comparison
of NCT03928860 59 61 O
clinical NCT03928860 62 70 O
onset NCT03928860 71 76 B-Eq-Comparison
of NCT03928860 77 79 O
peripheral NCT03928860 80 90 B-Condition
vascular NCT03928860 91 99 I-Condition
disease NCT03928860 100 107 I-Condition

- NCT03928860 110 111 O
Patients NCT03928860 113 121 O
with NCT03928860 122 126 O
ABI NCT03928860 127 130 B-Observation
between NCT03928860 131 138 O
0.4 NCT03928860 139 142 O
- NCT03928860 143 144 B-Eq-Comparison
1.4 NCT03928860 145 148 I-Eq-Comparison

- NCT03928860 152 153 O
Patients NCT03928860 155 163 O
up NCT03928860 164 166 B-Eq-Comparison
to NCT03928860 167 169 I-Eq-Comparison
Stage NCT03928860 170 175 I-Eq-Comparison
2 NCT03928860 176 177 I-Eq-Comparison
b NCT03928860 178 179 O
according NCT03928860 180 189 O
to NCT03928860 190 192 O
the NCT03928860 193 196 O
Fontaine NCT03928860 197 205 B-Condition
classification NCT03928860 206 220 I-Condition
system NCT03928860 221 227 I-Condition

Exclusion NCT03928860 228 237 O
Criteria NCT03928860 238 246 O
: NCT03928860 247 248 O

- NCT03928860 252 253 O
Patients NCT03928860 255 263 O
undergoing NCT03928860 264 274 B-Eq-Comparison
vascular NCT03928860 275 283 B-Modifier
or NCT03928860 284 286 B-Or
endovascular NCT03928860 287 299 B-Modifier
surgery NCT03928860 300 307 B-Procedure
in NCT03928860 308 310 O
the NCT03928860 311 314 O
last NCT03928860 315 319 B-Eq-Comparison
3 NCT03928860 320 321 I-Eq-Comparison
months NCT03928860 322 328 I-Eq-Comparison

- NCT03928860 331 332 O
Patients NCT03928860 334 342 O
with NCT03928860 343 347 O
unstable NCT03928860 348 356 B-Condition
angina NCT03928860 357 363 I-Condition

- NCT03928860 366 367 O
Patients NCT03928860 369 377 O
with NCT03928860 378 382 O
myocardial NCT03928860 383 393 B-Condition
infarction NCT03928860 394 404 I-Condition
( NCT03928860 405 406 O
MI NCT03928860 407 409 B-Condition
) NCT03928860 410 411 O

- NCT03928860 415 416 O
Patients NCT03928860 418 426 O
with NCT03928860 427 431 O
stroke NCT03928860 432 438 B-Condition

- NCT03928860 441 442 O
Patients NCT03928860 444 452 O
with NCT03928860 453 457 O
heart NCT03928860 458 463 B-Condition
failure NCT03928860 464 471 I-Condition

- NCT03928860 474 475 O
Patients NCT03928860 477 485 O
with NCT03928860 486 490 O
significant NCT03928860 491 502 O
liver NCT03928860 503 508 B-Modifier
or NCT03928860 509 511 B-Or
renal NCT03928860 512 517 B-Modifier
failure NCT03928860 518 525 B-Condition
( NCT03928860 526 527 O
ie NCT03928860 528 530 O
, NCT03928860 531 532 O
dialysis NCT03928860 533 541 B-Procedure
) NCT03928860 542 543 O

- NCT03928860 547 548 O
Acute NCT03928860 550 555 O
infectious NCT03928860 556 566 B-Condition
diseases NCT03928860 567 575 I-Condition

- NCT03928860 578 579 O
Patients NCT03928860 581 589 O
with NCT03928860 590 594 O
neoplasia NCT03928860 595 604 B-Condition

Inclusion NCT03921307 0 9 O
Criteria NCT03921307 10 18 O
: NCT03921307 19 20 O

- NCT03921307 24 25 O
Healthy NCT03921307 27 34 B-Condition
periodontal NCT03921307 35 46 I-Condition
tissue NCT03921307 47 53 I-Condition
Adequate NCT03921307 54 62 O
root NCT03921307 63 67 B-Procedure
canal NCT03921307 68 73 I-Procedure
treatment NCT03921307 74 83 I-Procedure

Exclusion NCT03921307 84 93 O
Criteria NCT03921307 94 102 O
: NCT03921307 103 104 O

- NCT03921307 108 109 O
Parafunctional NCT03921307 111 125 B-Condition
habits NCT03921307 126 132 I-Condition

Inclusion NCT03926468 0 9 O
Criteria NCT03926468 10 18 O
: NCT03926468 19 20 O

- NCT03926468 24 25 O
histologically NCT03926468 27 41 O
confirmed NCT03926468 42 51 O
head NCT03926468 52 56 B-Modifier
and NCT03926468 57 60 B-Or
neck NCT03926468 61 65 B-Modifier
squamous NCT03926468 66 74 B-Condition
cell NCT03926468 75 79 I-Condition
carcinoma NCT03926468 80 89 I-Condition
( NCT03926468 90 91 O
HNSCC NCT03926468 92 97 B-Condition
) NCT03926468 98 99 O

- NCT03926468 103 104 O
WHO NCT03926468 106 109 B-Observation
performance NCT03926468 110 121 I-Observation
status NCT03926468 122 128 I-Observation
0 NCT03926468 129 130 B-Eq-Comparison
- NCT03926468 131 132 I-Eq-Comparison
2 NCT03926468 133 134 O

- NCT03926468 138 139 O
clinical NCT03926468 141 149 O
stage NCT03926468 150 155 B-Eq-Comparison
III NCT03926468 156 159 I-Eq-Comparison
patients NCT03926468 160 168 O
with NCT03926468 169 173 O
bulky NCT03926468 174 179 B-Modifier
T3 NCT03926468 180 182 I-Modifier
primary NCT03926468 183 190 I-Modifier
+ NCT03926468 191 192 B-Or
/ NCT03926468 194 195 I-Or
- NCT03926468 197 198 I-Or
neck NCT03926468 199 203 B-Modifier
metastasis NCT03926468 204 214 B-Condition

- NCT03926468 217 218 O
all NCT03926468 220 223 O
stage NCT03926468 224 229 B-Eq-Comparison
IV NCT03926468 230 232 I-Eq-Comparison
patients NCT03926468 233 241 O

- NCT03926468 244 245 O
referral NCT03926468 247 255 O
to NCT03926468 256 258 O
definitive NCT03926468 259 269 O
radiotherapy NCT03926468 270 282 B-Procedure
or NCT03926468 283 285 B-Or
chemoradiotherapy NCT03926468 286 303 B-Procedure
or NCT03926468 304 306 B-Or
multimodality NCT03926468 307 320 B-Procedure
treatment NCT03926468 321 330 I-Procedure

Exclusion NCT03926468 331 340 O
Criteria NCT03926468 341 349 O
: NCT03926468 350 351 O

- NCT03926468 355 356 O
patients NCT03926468 358 366 O
who NCT03926468 367 370 O
are NCT03926468 371 374 O
not NCT03926468 375 378 O
able NCT03926468 379 383 O
to NCT03926468 384 386 O
sign NCT03926468 387 391 O
written NCT03926468 392 399 O
informed NCT03926468 400 408 O
consent NCT03926468 409 416 O

Inclusion NCT03923504 0 9 O
Criteria NCT03923504 10 18 O
: NCT03923504 19 20 O

- NCT03923504 24 25 O
Ability NCT03923504 27 34 O
to NCT03923504 35 37 O
read NCT03923504 38 42 O
and NCT03923504 43 46 O
understand NCT03923504 47 57 O
and NCT03923504 58 61 O
willing NCT03923504 62 69 O
to NCT03923504 70 72 O
sign NCT03923504 73 77 O
a NCT03923504 78 79 O
written NCT03923504 80 87 O
informed NCT03923504 88 96 O
consent NCT03923504 97 104 O
form NCT03923504 105 109 O
. NCT03923504 109 110 O

- NCT03923504 114 115 O
Diagnosis NCT03923504 117 126 O
of NCT03923504 127 129 O
stage NCT03923504 130 135 B-Eq-Comparison
I NCT03923504 136 137 I-Eq-Comparison
- NCT03923504 138 139 I-Eq-Comparison
IV NCT03923504 140 142 I-Eq-Comparison
non NCT03923504 143 146 B-Modifier
- NCT03923504 147 148 O
or NCT03923504 149 151 B-Or
Hodgkin NCT03923504 152 159 B-Modifier
lymphoma NCT03923504 160 168 B-Condition
and NCT03923504 169 172 B-And
expect NCT03923504 173 179 B-Assertion___Assertion-Type-Value:intention
to NCT03923504 180 182 I-Assertion___Assertion-Type-Value:intention
receive NCT03923504 183 190 O
an NCT03923504 191 193 B-Drug
anthracycline NCT03923504 194 207 O
based NCT03923504 208 213 O
chemotherapeutic NCT03923504 214 230 B-Drug
regimen NCT03923504 231 238 I-Drug
. NCT03923504 238 239 O

- NCT03923504 243 244 O
Capacity NCT03923504 246 254 B-Observation
to NCT03923504 255 257 I-Observation
walk NCT03923504 258 262 I-Observation
at NCT03923504 263 265 B-Eq-Comparison
least NCT03923504 266 271 I-Eq-Comparison
2 NCT03923504 272 273 I-Eq-Comparison
city NCT03923504 274 278 I-Eq-Comparison
blocks NCT03923504 279 285 I-Eq-Comparison
on NCT03923504 286 288 O
a NCT03923504 289 290 O
flat NCT03923504 291 295 O
surface NCT03923504 296 303 O

Exclusion NCT03923504 304 313 O
Criteria NCT03923504 314 322 O
: NCT03923504 323 324 O

- NCT03923504 328 329 O
Contraindications NCT03923504 331 348 B-Contraindication
for NCT03923504 349 352 O
MRI NCT03923504 353 356 B-Procedure

- NCT03923504 359 360 O
Contraindications NCT03923504 362 379 B-Contraindication
for NCT03923504 380 383 O
exercise NCT03923504 384 392 B-Observation
training NCT03923504 393 401 B-Modifier
or NCT03923504 402 404 B-Or
testing NCT03923504 405 412 B-Modifier

- NCT03923504 415 416 O
Active NCT03923504 418 424 B-Eq-Comparison
Pregnancy NCT03923504 425 434 B-Condition

- NCT03923504 437 438 O
Subjects NCT03923504 440 448 O
with NCT03923504 449 453 O
claustrophobia NCT03923504 454 468 B-Condition

- NCT03923504 471 472 O
Inability NCT03923504 474 483 O
to NCT03923504 484 486 O
provide NCT03923504 487 494 O
informed NCT03923504 495 503 O
consent NCT03923504 504 511 O

Inclusion NCT03924531 0 9 O
Criteria NCT03924531 10 18 O
: NCT03924531 19 20 O

- NCT03924531 24 25 O
over NCT03924531 27 31 B-Eq-Comparison
21 NCT03924531 32 34 I-Eq-Comparison
years NCT03924531 35 40 I-Eq-Comparison
of NCT03924531 41 43 O
age NCT03924531 44 47 B-Age

- NCT03924531 50 51 O
able NCT03924531 53 57 O
to NCT03924531 58 60 O
understand NCT03924531 61 71 O
and NCT03924531 72 75 O
speak NCT03924531 76 81 O
English NCT03924531 82 89 O

- NCT03924531 92 93 O
self NCT03924531 95 99 O
- NCT03924531 100 101 O
report NCT03924531 102 108 O
of NCT03924531 109 111 O
having NCT03924531 112 118 O
difficulty NCT03924531 119 129 B-Negation
with NCT03924531 130 134 O
a NCT03924531 135 136 O
healthy NCT03924531 137 144 B-Observation
diet NCT03924531 145 149 I-Observation
and NCT03924531 150 153 B-And
engaging NCT03924531 154 162 O
in NCT03924531 163 165 O
regular NCT03924531 166 173 B-Observation
physical NCT03924531 174 182 I-Observation
activity NCT03924531 183 191 I-Observation
. NCT03924531 191 192 O

Exclusion NCT03924531 194 203 O
Criteria NCT03924531 204 212 O
: NCT03924531 213 214 O

- NCT03924531 218 219 O
On NCT03924531 221 223 O
chemotherapy NCT03924531 224 236 B-Procedure
for NCT03924531 237 240 O
cancer NCT03924531 241 247 B-Procedure
treatment NCT03924531 248 257 I-Procedure

- NCT03924531 260 261 O
Current NCT03924531 263 270 B-Eq-Comparison
substance NCT03924531 271 280 B-Condition
abuse NCT03924531 281 286 I-Condition
disorder NCT03924531 287 295 I-Condition
( NCT03924531 296 297 O
i. NCT03924531 298 300 O
e. NCT03924531 301 303 O
, NCT03924531 304 305 O
drugs NCT03924531 306 311 B-Drug
, NCT03924531 312 313 O
alcohol NCT03924531 314 321 B-Drug
) NCT03924531 322 323 O
. NCT03924531 324 325 O

- NCT03924531 329 330 O
Current NCT03924531 332 339 B-Eq-Comparison
diagnoses NCT03924531 340 349 O
of NCT03924531 350 352 O
Post NCT03924531 353 357 B-Condition
- NCT03924531 358 359 I-Condition
traumatic NCT03924531 360 369 I-Condition
stress NCT03924531 370 376 I-Condition
disorders NCT03924531 377 386 I-Condition
, NCT03924531 387 388 O
severe NCT03924531 389 395 O
anxiety NCT03924531 396 403 B-Condition
, NCT03924531 404 405 O
or NCT03924531 406 408 B-Or
severe NCT03924531 409 415 O
depression NCT03924531 416 426 B-Condition
. NCT03924531 426 427 O

- NCT03924531 431 432 O
On NCT03924531 434 436 B-Eq-Comparison
hemodialysis NCT03924531 437 449 B-Procedure
. NCT03924531 449 450 O

- NCT03924531 454 455 O
Pregnant NCT03924531 457 465 B-Condition|Condition
. NCT03924531 465 466 O
( NCT03924531 468 469 O
Pregnant NCT03924531 470 478 O
women NCT03924531 479 484 O
may NCT03924531 485 488 B-Assertion___Assertion-Type-Value:hypothetical
develop NCT03924531 489 496 O
Preeclampsia NCT03924531 497 509 B-Condition
, NCT03924531 510 511 O
which NCT03924531 512 517 O
is NCT03924531 518 520 O
a NCT03924531 521 522 O
pregnancy NCT03924531 523 532 B-Condition
complication NCT03924531 533 545 I-Condition
characterized NCT03924531 546 559 O
by NCT03924531 560 562 O
high NCT03924531 563 567 B-Condition
blood NCT03924531 568 573 I-Condition
pressure NCT03924531 574 582 I-Condition
) NCT03924531 583 584 O

Inclusion NCT03922815 0 9 O
Criteria NCT03922815 10 18 O
: NCT03922815 19 20 O

- NCT03922815 24 25 O
written NCT03922815 27 34 O
consent NCT03922815 35 42 O
to NCT03922815 43 45 O
participate NCT03922815 46 57 O
in NCT03922815 58 60 O
the NCT03922815 61 64 O
study NCT03922815 65 70 O

- NCT03922815 73 74 O
written NCT03922815 76 83 O
consent NCT03922815 84 91 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922815 92 94 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03922815 95 102 B-Eq-Comparison
deep NCT03922815 103 107 B-Procedure
sedation NCT03922815 108 116 I-Procedure
for NCT03922815 117 120 O
colonoscopic NCT03922815 121 133 B-Procedure
procedure NCT03922815 134 143 I-Procedure

- NCT03922815 146 147 O
general NCT03922815 149 156 O
heath NCT03922815 157 162 O
condition NCT03922815 163 172 O
I NCT03922815 173 174 B-Eq-Comparison
- NCT03922815 175 176 I-Eq-Comparison
III NCT03922815 177 180 I-Eq-Comparison
of NCT03922815 181 183 O
American NCT03922815 184 192 B-Condition
Society NCT03922815 193 200 I-Condition
of NCT03922815 201 203 I-Condition
Anaesthesiology NCT03922815 204 219 I-Condition

Exclusion NCT03922815 220 229 O
Criteria NCT03922815 230 238 O
: NCT03922815 239 240 O

- NCT03922815 244 245 O
necessity NCT03922815 247 256 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03922815 257 259 O
administration NCT03922815 260 274 O
of NCT03922815 275 277 O
vasoactive NCT03922815 278 288 B-Drug
drugs NCT03922815 289 294 I-Drug
influencing NCT03922815 295 306 O
SPI NCT03922815 307 310 B-Procedure
monitoring NCT03922815 311 321 I-Procedure

- NCT03922815 324 325 O
pregnancy NCT03922815 327 336 B-Condition

- NCT03922815 339 340 O
anatomical NCT03922815 342 352 B-Condition
malformation NCT03922815 353 365 I-Condition
that NCT03922815 366 370 O
make NCT03922815 371 375 O
monitoring NCT03922815 376 386 B-Procedure
using NCT03922815 387 392 I-Procedure
SE NCT03922815 393 395 I-Procedure
sensor NCT03922815 396 402 I-Procedure
impossible NCT03922815 403 413 B-Assertion___Assertion-Type-Value:hypothetical|Negation

- NCT03922815 416 417 O
general NCT03922815 419 426 B-Condition
atherosclerosis NCT03922815 427 442 I-Condition
, NCT03922815 443 444 O
heart NCT03922815 445 450 B-Condition
rhythm NCT03922815 451 457 I-Condition
disturbances NCT03922815 458 470 I-Condition
impairing NCT03922815 471 480 B-Assertion___Assertion-Type-Value:hypothetical|Negation
SPI NCT03922815 481 484 B-Procedure
monitoring NCT03922815 485 495 I-Procedure

- NCT03922815 498 499 O
chronic NCT03922815 501 508 B-Modifier
medication NCT03922815 509 519 O
using NCT03922815 520 525 B-Eq-Comparison
opioid NCT03922815 526 532 B-Drug
drugs NCT03922815 533 538 I-Drug
leading NCT03922815 539 546 O
to NCT03922815 547 549 O
resistancy NCT03922815 550 560 B-Condition
to NCT03922815 561 563 I-Condition
opioids NCT03922815 564 571 I-Condition
. NCT03922815 571 572 O

Inclusion NCT03921931 0 9 O
Criteria NCT03921931 10 18 O
: NCT03921931 19 20 O

- NCT03921931 24 25 O
men NCT03921931 27 30 O
and NCT03921931 31 34 B-Or
women NCT03921931 35 40 O
aged NCT03921931 41 45 B-Age
over NCT03921931 46 50 B-Eq-Comparison
18 NCT03921931 51 53 I-Eq-Comparison
years NCT03921931 54 59 I-Eq-Comparison

- NCT03921931 62 63 O
signed NCT03921931 65 71 O
informed NCT03921931 72 80 O
consent NCT03921931 81 88 O
form NCT03921931 89 93 O

- NCT03921931 96 97 O
ametropia NCT03921931 99 108 B-Observation
below NCT03921931 109 114 B-Eq-Comparison
3 NCT03921931 115 116 I-Eq-Comparison
diopters NCT03921931 117 125 I-Eq-Comparison

- NCT03921931 128 129 O
ability NCT03921931 131 138 O
and NCT03921931 139 142 O
willingness NCT03921931 143 154 O
to NCT03921931 155 157 O
follow NCT03921931 158 164 O
instructions NCT03921931 165 177 O

for NCT03921931 178 181 O
healthy NCT03921931 182 189 B-Observation
volunteers NCT03921931 190 200 O
: NCT03921931 201 202 O

- NCT03921931 206 207 O
normal NCT03921931 209 215 O
ophthalmologic NCT03921931 216 230 B-Observation
findings NCT03921931 231 239 I-Observation

for NCT03921931 240 243 O
primary NCT03921931 244 251 B-Modifier
open NCT03921931 252 256 I-Modifier
angle NCT03921931 257 262 I-Modifier
glaucoma NCT03921931 263 271 B-Condition
patients NCT03921931 272 280 O
( NCT03921931 281 282 O
POAG NCT03921931 283 287 B-Condition
) NCT03921931 288 289 O
: NCT03921931 291 292 O

- NCT03921931 296 297 O
diagnosed NCT03921931 299 308 B-Condition
POAG NCT03921931 309 313 O

- NCT03921931 316 317 O
MD NCT03921931 319 321 B-Observation
< NCT03921931 322 323 B-Eq-Comparison
= NCT03921931 325 326 I-Eq-Comparison
10 NCT03921931 327 329 I-Eq-Comparison
dB NCT03921931 330 332 O

for NCT03921931 333 336 O
age NCT03921931 337 340 B-Modifier
- NCT03921931 341 342 I-Modifier
related NCT03921931 343 350 I-Modifier
macular NCT03921931 351 358 B-Condition
degeneration NCT03921931 359 371 I-Condition
( NCT03921931 372 373 O
AMD NCT03921931 374 377 B-Condition
) NCT03921931 378 379 O
: NCT03921931 381 382 O

- NCT03921931 386 387 O
diagnosed NCT03921931 389 398 O
dry NCT03921931 399 402 B-Modifier
AMD NCT03921931 403 406 B-Condition

- NCT03921931 409 410 O
diagnosed NCT03921931 412 421 O
stage NCT03921931 422 427 B-Eq-Comparison|Eq-Comparison
II NCT03921931 428 430 I-Eq-Comparison|Eq-Comparison
or NCT03921931 431 433 B-Or
stage NCT03921931 434 439 O
III NCT03921931 440 443 O
AMD NCT03921931 444 447 B-Condition

Exclusion NCT03921931 448 457 O
Criteria NCT03921931 458 466 O
: NCT03921931 467 468 O

- NCT03921931 472 473 O
Presence NCT03921931 475 483 O
of NCT03921931 484 486 O
any NCT03921931 487 490 O
abnormalities NCT03921931 491 504 B-Condition
preventing NCT03921931 505 515 B-Assertion___Assertion-Type-Value:hypothetical|Negation
reliable NCT03921931 516 524 O
measurements NCT03921931 525 537 B-Observation

- NCT03921931 540 541 O
Ocular NCT03921931 543 549 B-Condition
inflammation NCT03921931 550 562 I-Condition
and NCT03921931 563 566 B-Or
ocular NCT03921931 567 573 B-Condition
disease NCT03921931 574 581 I-Condition
interfering NCT03921931 582 593 O
with NCT03921931 594 598 O
the NCT03921931 599 602 O
study NCT03921931 603 608 O
aims NCT03921931 609 613 O

- NCT03921931 616 617 O
Use NCT03921931 619 622 O
of NCT03921931 623 625 O
photosensitizing NCT03921931 626 642 B-Drug
medication NCT03921931 643 653 I-Drug
( NCT03921931 654 655 O
phototoxic NCT03921931 656 666 B-Drug
drugs NCT03921931 667 672 I-Drug|Drug
, NCT03921931 673 674 O
photoallergic NCT03921931 675 688 B-Drug
drugs NCT03921931 689 694 O
) NCT03921931 695 696 O
in NCT03921931 697 699 O
the NCT03921931 700 703 O
3 NCT03921931 704 705 B-Eq-Comparison
months NCT03921931 706 712 I-Eq-Comparison
preceding NCT03921931 713 722 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921931 723 726 O
study NCT03921931 727 732 B-Study

- NCT03921931 735 736 O
Presence NCT03921931 738 746 O
of NCT03921931 747 749 O
any NCT03921931 750 753 O
condition NCT03921931 754 763 B-Condition
with NCT03921931 764 768 O
the NCT03921931 769 772 O
possibility NCT03921931 773 784 B-Assertion___Assertion-Type-Value:possible
of NCT03921931 785 787 I-Assertion___Assertion-Type-Value:possible
causing NCT03921931 788 795 O
photosensitivity NCT03921931 796 812 B-Condition
, NCT03921931 813 814 O
including NCT03921931 815 824 O
systemic NCT03921931 825 833 B-Condition
lupus NCT03921931 834 839 I-Condition
erythematosus NCT03921931 840 853 I-Condition
SLE NCT03921931 854 857 B-Condition
, NCT03921931 858 859 O
Porphyria NCT03921931 860 869 B-Condition
, NCT03921931 870 871 O
Vitiligo NCT03921931 872 880 B-Condition
, NCT03921931 881 882 O
Xeroderma NCT03921931 883 892 B-Condition
Pigmentosum NCT03921931 893 904 I-Condition
and NCT03921931 905 908 B-Or
Albinism NCT03921931 909 917 B-Condition

- NCT03921931 920 921 O
Presence NCT03921931 923 931 O
of NCT03921931 932 934 O
any NCT03921931 935 938 O
form NCT03921931 939 943 O
of NCT03921931 944 946 O
epilepsy NCT03921931 947 955 B-Condition

- NCT03921931 958 959 O
Ocular NCT03921931 961 967 B-Procedure
surgery NCT03921931 968 975 I-Procedure
in NCT03921931 976 978 O
the NCT03921931 979 982 O
3 NCT03921931 983 984 B-Eq-Comparison
months NCT03921931 985 991 I-Eq-Comparison
preceding NCT03921931 992 1001 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921931 1002 1005 O
study NCT03921931 1006 1011 B-Study

- NCT03921931 1014 1015 O
Pregnancy NCT03921931 1017 1026 B-Condition
, NCT03921931 1027 1028 O
planned NCT03921931 1029 1036 B-Assertion___Assertion-Type-Value:intention
pregnancy NCT03921931 1037 1046 B-Condition
or NCT03921931 1047 1049 B-Or
lactating NCT03921931 1050 1059 B-Condition

- NCT03921931 1062 1063 O
Any NCT03921931 1065 1068 O
medical NCT03921931 1069 1076 O
or NCT03921931 1077 1079 O
surgical NCT03921931 1080 1088 B-Procedure
history NCT03921931 1089 1096 B-Eq-Comparison
, NCT03921931 1097 1098 O
disorder NCT03921931 1099 1107 B-Condition
or NCT03921931 1108 1110 B-Or|Or
disease NCT03921931 1111 1118 B-Condition
such NCT03921931 1119 1123 O
as NCT03921931 1124 1126 O
acute NCT03921931 1127 1132 B-Modifier
or NCT03921931 1133 1135 B-Condition
chronic NCT03921931 1136 1143 B-Modifier
severe NCT03921931 1144 1150 O
organic NCT03921931 1151 1158 O
disease NCT03921931 1159 1166 I-Condition

Inclusion NCT03926910 0 9 O
Criteria NCT03926910 10 18 O
: NCT03926910 19 20 O

- NCT03926910 24 25 O
Over NCT03926910 27 31 B-Eq-Comparison
18 NCT03926910 32 34 I-Eq-Comparison
years NCT03926910 35 40 I-Eq-Comparison
old NCT03926910 41 44 B-Age
, NCT03926910 45 46 O

- NCT03926910 50 51 O
Programmed NCT03926910 53 63 B-Eq-Comparison
for NCT03926910 64 67 O
cardiac NCT03926910 68 75 B-Procedure
surgery NCT03926910 76 83 I-Procedure
with NCT03926910 84 88 B-And
the NCT03926910 89 92 O
need NCT03926910 93 97 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03926910 98 101 I-Assertion___Assertion-Type-Value:hypothetical
invasive NCT03926910 102 110 B-Procedure
hemodynamic NCT03926910 111 122 I-Procedure
monitoring NCT03926910 123 133 I-Procedure
( NCT03926910 134 135 O
pulmonary NCT03926910 136 145 B-Procedure
artery NCT03926910 146 152 I-Procedure
catheter NCT03926910 153 161 I-Procedure
) NCT03926910 162 163 O
according NCT03926910 164 173 O
to NCT03926910 174 176 O
the NCT03926910 177 180 O
recommendations NCT03926910 181 196 O
: NCT03926910 197 198 O

- NCT03926910 207 208 O
Euroscore NCT03926910 210 219 O
with NCT03926910 220 224 O
predicted NCT03926910 225 234 B-Observation
mortality NCT03926910 235 244 I-Observation
> NCT03926910 245 246 B-Eq-Comparison
10 NCT03926910 247 249 I-Eq-Comparison
% NCT03926910 250 251 O

- NCT03926910 259 260 O
Left NCT03926910 262 266 B-Observation
ventricular NCT03926910 267 278 I-Observation
ejection NCT03926910 279 287 I-Observation
fraction NCT03926910 288 296 I-Observation
( NCT03926910 297 298 O
LVEF NCT03926910 299 303 B-Observation
) NCT03926910 304 305 O
< NCT03926910 306 307 B-Eq-Comparison
40 NCT03926910 308 310 I-Eq-Comparison
% NCT03926910 311 312 O

- NCT03926910 320 321 O
Left NCT03926910 323 327 B-Observation
ventricular NCT03926910 328 339 I-Observation
ejection NCT03926910 340 348 I-Observation
fraction NCT03926910 349 357 I-Observation
( NCT03926910 358 359 O
LVEF NCT03926910 360 364 B-Observation
) NCT03926910 365 366 O
< NCT03926910 367 368 B-Eq-Comparison
50 NCT03926910 369 371 I-Eq-Comparison
% NCT03926910 372 373 O
for NCT03926910 374 377 B-And
mitral NCT03926910 378 384 B-Condition
insufficiency NCT03926910 385 398 I-Condition

- NCT03926910 406 407 O
pulmonary NCT03926910 409 418 B-Condition
artery NCT03926910 419 425 I-Condition
hypertension NCT03926910 426 438 I-Condition
( NCT03926910 439 440 O
PAH NCT03926910 441 444 B-Condition
) NCT03926910 445 446 O
> NCT03926910 448 449 B-Eq-Comparison
50 NCT03926910 450 452 I-Eq-Comparison
mmHg NCT03926910 453 457 I-Eq-Comparison

- NCT03926910 465 466 O
Tricuspid NCT03926910 468 477 B-Condition
insufficiency NCT03926910 478 491 I-Condition
> NCT03926910 492 493 B-Eq-Comparison
3.4 NCT03926910 494 497 I-Eq-Comparison
m NCT03926910 498 499 I-Eq-Comparison
/ NCT03926910 500 501 I-Eq-Comparison
s NCT03926910 502 503 I-Eq-Comparison

- NCT03926910 511 512 O
Tricuspid NCT03926910 514 523 B-Observation
annular NCT03926910 524 531 I-Observation
plane NCT03926910 532 537 I-Observation
systolic NCT03926910 538 546 I-Observation
excursion NCT03926910 547 556 I-Observation
( NCT03926910 557 558 O
TAPSE NCT03926910 559 564 B-Observation
) NCT03926910 565 566 O
< NCT03926910 567 568 B-Eq-Comparison
16 NCT03926910 569 571 I-Eq-Comparison
mm NCT03926910 572 574 I-Eq-Comparison

- NCT03926910 582 583 O
Dilatation NCT03926910 585 595 B-Condition
of NCT03926910 596 598 I-Condition
the NCT03926910 599 602 I-Condition
inferior NCT03926910 603 611 I-Condition
vena NCT03926910 612 616 I-Condition
cava NCT03926910 617 621 I-Condition
under NCT03926910 622 627 I-Condition
respiratory NCT03926910 628 639 I-Condition
collapse NCT03926910 640 648 I-Condition

- NCT03926910 651 652 O
Sinus NCT03926910 654 659 B-Condition
rhythm NCT03926910 660 666 I-Condition
in NCT03926910 667 669 O
immediate NCT03926910 670 679 O
post NCT03926910 680 684 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03926910 685 686 O
- NCT03926910 688 689 O
operative NCT03926910 690 699 B-Procedure
period NCT03926910 700 706 O
, NCT03926910 707 708 O

- NCT03926910 712 713 O
Sedated NCT03926910 715 722 B-Procedure
with NCT03926910 723 727 O
mechanical NCT03926910 728 738 B-Procedure
ventilation NCT03926910 739 750 I-Procedure
, NCT03926910 751 752 O

- NCT03926910 756 757 O
Having NCT03926910 759 765 O
given NCT03926910 766 771 O
their NCT03926910 772 777 O
written NCT03926910 778 785 O
participation NCT03926910 786 799 O
consent NCT03926910 800 807 O
in NCT03926910 808 810 O
accordance NCT03926910 811 821 O
with NCT03926910 822 826 O
the NCT03926910 827 830 O
regulations NCT03926910 831 842 O
, NCT03926910 843 844 O

- NCT03926910 848 849 O
Benefiting NCT03926910 851 861 O
from NCT03926910 862 866 O
a NCT03926910 867 868 O
social NCT03926910 869 875 O
security NCT03926910 876 884 O

Exclusion NCT03926910 885 894 O
Criteria NCT03926910 895 903 O
: NCT03926910 904 905 O

- NCT03926910 909 910 O
Pregnant NCT03926910 912 920 B-Condition
or NCT03926910 921 923 B-Or
lactating NCT03926910 924 933 B-Condition
women NCT03926910 934 939 O
, NCT03926910 940 941 O

- NCT03926910 945 946 O
Patient NCT03926910 948 955 O
under NCT03926910 956 961 B-Observation
guardianship NCT03926910 962 974 I-Observation
, NCT03926910 975 976 O
Under NCT03926910 977 982 O
curatorship NCT03926910 983 994 O
or NCT03926910 995 997 O
court NCT03926910 998 1003 O
of NCT03926910 1004 1006 O
justice NCT03926910 1007 1014 O
, NCT03926910 1015 1016 O

- NCT03926910 1020 1021 O
Discomfort NCT03926910 1023 1033 B-Condition
to NCT03926910 1034 1036 I-Condition
communication NCT03926910 1037 1050 I-Condition
or NCT03926910 1051 1053 B-Or
neuropsychic NCT03926910 1054 1066 B-Condition
disorders NCT03926910 1067 1076 I-Condition
, NCT03926910 1077 1078 O
Inability NCT03926910 1079 1088 B-Negation
to NCT03926910 1089 1091 O
understand NCT03926910 1092 1102 O
, NCT03926910 1103 1104 O
to NCT03926910 1105 1107 O
read NCT03926910 1108 1112 O
or NCT03926910 1113 1115 O
to NCT03926910 1116 1118 O
write NCT03926910 1119 1124 O
the NCT03926910 1125 1128 O
French NCT03926910 1129 1135 O
language NCT03926910 1136 1144 O
, NCT03926910 1145 1146 O

- NCT03926910 1150 1151 O
Patients NCT03926910 1153 1161 O
for NCT03926910 1162 1165 O
whom NCT03926910 1166 1170 O
a NCT03926910 1171 1172 O
fluids NCT03926910 1173 1179 B-Condition
overload NCT03926910 1180 1188 I-Condition
seems NCT03926910 1189 1194 B-Assertion___Assertion-Type-Value:hypothetical
obvious NCT03926910 1195 1202 O
to NCT03926910 1203 1205 O
the NCT03926910 1206 1209 O
intensivist NCT03926910 1210 1221 O
and NCT03926910 1222 1225 B-And
for NCT03926910 1226 1229 O
whom NCT03926910 1230 1234 O
a NCT03926910 1235 1236 O
crystalloids NCT03926910 1237 1249 B-Procedure
filling NCT03926910 1250 1257 I-Procedure
would NCT03926910 1258 1263 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03926910 1264 1266 I-Assertion___Assertion-Type-Value:hypothetical
contraindicated NCT03926910 1267 1282 B-Contraindication
, NCT03926910 1283 1284 O

- NCT03926910 1288 1289 O
Patients NCT03926910 1291 1299 O
for NCT03926910 1300 1303 O
whom NCT03926910 1304 1308 O
respiratory NCT03926910 1309 1320 O
changes NCT03926910 1321 1328 O
in NCT03926910 1329 1331 O
pulse NCT03926910 1332 1337 B-Observation
pressure NCT03926910 1338 1346 I-Observation
( NCT03926910 1347 1348 O
ΔPP NCT03926910 1349 1352 B-Observation
) NCT03926910 1353 1354 O
measurement NCT03926910 1355 1366 O
is NCT03926910 1367 1369 O
not NCT03926910 1370 1373 B-Negation
validated NCT03926910 1374 1383 B-Assertion___Assertion-Type-Value:hypothetical
: NCT03926910 1384 1385 O
patients NCT03926910 1386 1394 O
with NCT03926910 1395 1399 O
spontaneous NCT03926910 1400 1411 B-Condition
ventilation NCT03926910 1412 1423 I-Condition
, NCT03926910 1424 1425 O
atrial NCT03926910 1426 1432 B-Condition
fibrillation NCT03926910 1433 1445 I-Condition
, NCT03926910 1446 1447 O
non NCT03926910 1448 1451 B-Condition
- NCT03926910 1452 1453 I-Condition
sedated NCT03926910 1454 1461 I-Condition

Inclusion NCT03925558 0 9 O
Criteria NCT03925558 10 18 O
: NCT03925558 19 20 O

- NCT03925558 23 24 O
Full NCT03925558 25 29 O
term NCT03925558 30 34 O
healthy NCT03925558 35 42 B-Condition
infant NCT03925558 43 49 O
aged NCT03925558 50 54 B-Age
3 NCT03925558 55 56 B-Eq-Comparison
- NCT03925558 57 58 I-Eq-Comparison
95 NCT03925558 59 61 O
days NCT03925558 62 66 O

Exclusion NCT03925558 67 76 O
Criteria NCT03925558 77 85 O
: NCT03925558 86 87 O

- NCT03925558 91 92 O
Prematurity NCT03925558 94 105 B-Condition

- NCT03925558 108 109 O
Low NCT03925558 111 114 O
birth NCT03925558 115 120 B-Observation
weight NCT03925558 121 127 I-Observation

- NCT03925558 130 131 O
Congenital NCT03925558 133 143 B-Condition
anomalies NCT03925558 144 153 I-Condition

- NCT03925558 156 157 O
Chronic NCT03925558 159 166 B-Condition
disease NCT03925558 167 174 I-Condition

- NCT03925558 177 178 O
Failure NCT03925558 180 187 B-Condition
to NCT03925558 188 190 I-Condition
thrive NCT03925558 191 197 I-Condition

- NCT03925558 200 201 O
Allergy NCT03925558 203 210 B-Allergy
or NCT03925558 211 213 B-Or
atopic NCT03925558 214 220 B-Condition
disease NCT03925558 221 228 I-Condition

- NCT03925558 231 232 O
Recent NCT03925558 234 240 B-Eq-Comparison
exposure NCT03925558 241 249 O
to NCT03925558 250 252 O
antibiotics NCT03925558 253 264 B-Drug

Inclusion NCT03928054 0 9 O
Criteria NCT03928054 10 18 O
: NCT03928054 19 20 O

- NCT03928054 24 25 O
Patients NCT03928054 27 35 O
with NCT03928054 36 40 O
both NCT03928054 41 45 O
sexes NCT03928054 46 51 O
from NCT03928054 52 56 O
40 NCT03928054 57 59 B-Eq-Comparison
to NCT03928054 60 62 I-Eq-Comparison
80 NCT03928054 63 65 I-Eq-Comparison
years NCT03928054 66 71 I-Eq-Comparison
old NCT03928054 72 75 B-Age

- NCT03928054 78 79 O
who NCT03928054 81 84 O
underwent NCT03928054 85 94 B-Eq-Comparison
imaging NCT03928054 95 102 B-Procedure
examination NCT03928054 103 114 I-Procedure
evidencing NCT03928054 115 125 O
grade NCT03928054 126 131 B-Eq-Comparison
II NCT03928054 132 134 I-Eq-Comparison
or NCT03928054 135 137 I-Eq-Comparison
III NCT03928054 138 141 I-Eq-Comparison
knee NCT03928054 142 146 B-Condition
osteoarthritis NCT03928054 147 161 I-Condition
according NCT03928054 162 171 O
to NCT03928054 172 174 O
the NCT03928054 175 178 O
Kellgren NCT03928054 179 187 O
and NCT03928054 188 191 O
Lawrence NCT03928054 192 200 O
classification NCT03928054 201 215 O

- NCT03928054 218 219 O
who NCT03928054 221 224 O
were NCT03928054 225 229 O
referred NCT03928054 230 238 B-Encounter
to NCT03928054 239 241 O
the NCT03928054 242 245 O
physiotherapy NCT03928054 246 259 B-Provider
service NCT03928054 260 267 I-Provider
by NCT03928054 268 270 O
a NCT03928054 271 272 O
physician NCT03928054 273 282 O
. NCT03928054 282 283 O

Exclusion NCT03928054 285 294 O
Criteria NCT03928054 295 303 O
: NCT03928054 304 305 O

- NCT03928054 309 310 O
Patients NCT03928054 312 320 O
who NCT03928054 321 324 O
are NCT03928054 325 328 O
unable NCT03928054 329 335 B-Negation
to NCT03928054 336 338 O
walk NCT03928054 339 343 B-Condition

- NCT03928054 346 347 O
with NCT03928054 349 353 O
a NCT03928054 354 355 O
history NCT03928054 356 363 B-Eq-Comparison
of NCT03928054 364 366 O
cancer NCT03928054 367 373 B-Condition

- NCT03928054 376 377 O
associated NCT03928054 379 389 O
neurological NCT03928054 390 402 B-Condition
diseases NCT03928054 403 411 I-Condition

- NCT03928054 414 415 O
morbid NCT03928054 417 423 B-Condition
obesity NCT03928054 424 431 I-Condition

Inclusion NCT03923101 0 9 O
Criteria NCT03923101 10 18 O
: NCT03923101 19 20 O

- NCT03923101 24 25 O
All NCT03923101 27 30 O
Keratoconus NCT03923101 31 42 B-Condition
patients NCT03923101 43 51 O
presenting NCT03923101 52 62 B-Encounter
in NCT03923101 63 65 O
the NCT03923101 66 69 O
department NCT03923101 70 80 O
of NCT03923101 81 83 O
ophthalmology NCT03923101 84 97 O
, NCT03923101 98 99 O
Saarland NCT03923101 100 108 O
University NCT03923101 109 119 O
Medical NCT03923101 120 127 O
Center NCT03923101 128 134 O
, NCT03923101 135 136 O
Homburg NCT03923101 137 144 O
, NCT03923101 145 146 O
Saarland NCT03923101 147 155 O
, NCT03923101 156 157 O
Germany NCT03923101 158 165 O
. NCT03923101 165 166 O

Exclusion NCT03923101 168 177 O
Criteria NCT03923101 178 186 O
: NCT03923101 187 188 O

- NCT03923101 192 193 O
Patients NCT03923101 195 203 O
without NCT03923101 204 211 B-Negation
Keratoconus NCT03923101 212 223 B-Condition
. NCT03923101 223 224 O

Inclusion NCT03926247 0 9 O
Criteria NCT03926247 10 18 O
: NCT03926247 19 20 O

- NCT03926247 24 25 O
Mexican NCT03926247 27 34 O
immigrant NCT03926247 35 44 O

- NCT03926247 47 48 O
Residing NCT03926247 50 58 O
in NCT03926247 59 61 O
Bernalillo NCT03926247 62 72 O
County NCT03926247 73 79 O
, NCT03926247 80 81 O
New NCT03926247 82 85 O
Mexico NCT03926247 86 92 O

Exclusion NCT03926247 93 102 O
Criteria NCT03926247 103 111 O
: NCT03926247 112 113 O

- NCT03926247 117 118 O
Severe NCT03926247 120 126 O
cognitive NCT03926247 127 136 B-Condition
functioning NCT03926247 137 148 I-Condition
problems NCT03926247 149 157 I-Condition

- NCT03926247 160 161 O
Imminent NCT03926247 163 171 O
suicide NCT03926247 172 179 B-Condition
risk NCT03926247 180 184 B-Risk

- NCT03926247 187 188 O
Mental NCT03926247 190 196 B-Condition
illness NCT03926247 197 204 I-Condition
that NCT03926247 205 209 O
is NCT03926247 210 212 O
so NCT03926247 213 215 O
severe NCT03926247 216 222 O
as NCT03926247 223 225 O
to NCT03926247 226 228 O
impede NCT03926247 229 235 O
participation NCT03926247 236 249 O
in NCT03926247 250 252 O
a NCT03926247 253 254 O
group NCT03926247 255 260 O
and NCT03926247 261 264 O
that NCT03926247 265 269 O
warrants NCT03926247 270 278 B-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03926247 279 288 O
individual NCT03926247 289 299 O
treatment NCT03926247 300 309 B-Procedure

Inclusion NCT03921502 0 9 O
Criteria NCT03921502 10 18 O
: NCT03921502 19 20 O

- NCT03921502 24 25 O
Symptomatic NCT03921502 27 38 B-Condition
choledocholithiasis NCT03921502 39 58 I-Condition
( NCT03921502 59 60 O
choledocholithiasis NCT03921502 61 80 B-Condition
demonstrated NCT03921502 81 93 O
radiologically NCT03921502 94 108 B-Procedure
or NCT03921502 109 111 B-Or
highly NCT03921502 112 118 O
suspected NCT03921502 119 128 B-Assertion___Assertion-Type-Value:possible
by NCT03921502 129 131 O
clinical NCT03921502 132 140 O
data NCT03921502 141 145 O
( NCT03921502 146 147 O
acute NCT03921502 148 153 B-Condition
cholangitis NCT03921502 154 165 I-Condition
or NCT03921502 166 168 B-Or
obstructive NCT03921502 169 180 B-Condition
jaundice NCT03921502 181 189 I-Condition
) NCT03921502 190 191 O
, NCT03921502 193 194 O
analytical NCT03921502 195 205 O
and NCT03921502 206 209 O
imaging NCT03921502 210 217 O
according NCT03921502 218 227 O
to NCT03921502 228 230 O
the NCT03921502 231 234 O
criteria NCT03921502 235 243 O
of NCT03921502 244 246 O
high NCT03921502 247 251 O
probability NCT03921502 252 263 B-Assertion___Assertion-Type-Value:possible
of NCT03921502 264 266 O
choledocholithiasis NCT03921502 267 286 B-Condition
established NCT03921502 287 298 O
in NCT03921502 299 301 O
the NCT03921502 302 305 O
clinical NCT03921502 306 314 O
guidelines NCT03921502 315 325 O
( NCT03921502 326 327 O
ASGE NCT03921502 328 332 O
Guide NCT03921502 333 338 O
) NCT03921502 339 340 O
. NCT03921502 341 342 O

- NCT03921502 346 347 O
Discarded NCT03921502 349 358 B-Negation
for NCT03921502 359 362 O
surgical NCT03921502 363 371 B-Procedure
treatment NCT03921502 372 381 I-Procedure
due NCT03921502 382 385 O
to NCT03921502 386 388 O
age NCT03921502 389 392 B-Age
, NCT03921502 393 394 O
comorbidity NCT03921502 395 406 B-Condition
or NCT03921502 407 409 B-Or
refusal NCT03921502 410 417 B-Observation
of NCT03921502 418 420 O
the NCT03921502 421 424 O
patient NCT03921502 425 432 O
. NCT03921502 432 433 O

- NCT03921502 437 438 O
Age NCT03921502 440 443 B-Age
> NCT03921502 444 445 B-Eq-Comparison
75 NCT03921502 446 448 I-Eq-Comparison
years NCT03921502 449 454 I-Eq-Comparison

Exclusion NCT03921502 455 464 O
Criteria NCT03921502 465 473 O
: NCT03921502 474 475 O

- NCT03921502 479 480 O
Charlson NCT03921502 482 490 B-Observation
comorbidity NCT03921502 491 502 I-Observation
scale NCT03921502 503 508 I-Observation
adjusted NCT03921502 509 517 B-Modifier
to NCT03921502 518 520 I-Modifier
age NCT03921502 521 524 I-Modifier
< NCT03921502 525 526 B-Eq-Comparison
4 NCT03921502 527 528 I-Eq-Comparison
. NCT03921502 528 529 O

- NCT03921502 533 534 O
Prior NCT03921502 536 541 B-Eq-Comparison
ERCP NCT03921502 542 546 B-Procedure
. NCT03921502 546 547 O

- NCT03921502 551 552 O
Previous NCT03921502 554 562 B-Eq-Comparison
episodes NCT03921502 563 571 O
of NCT03921502 572 574 O
cholangitis NCT03921502 575 586 B-Condition
, NCT03921502 587 588 O
pancreatitis NCT03921502 589 601 B-Condition
or NCT03921502 602 604 B-Or
lithiasic NCT03921502 605 614 B-Condition
cholecystitis NCT03921502 615 628 I-Condition
. NCT03921502 628 629 O

- NCT03921502 633 634 O
Hepatobiliary NCT03921502 636 649 B-Procedure
surgery NCT03921502 650 657 I-Procedure
or NCT03921502 658 660 B-Or
previous NCT03921502 661 669 B-Eq-Comparison
superior NCT03921502 670 678 B-Condition
digestive NCT03921502 679 688 I-Condition
tract NCT03921502 689 694 I-Condition
. NCT03921502 694 695 O

- NCT03921502 699 700 O
Ascitis NCT03921502 702 709 O
. NCT03921502 709 710 O

- NCT03921502 714 715 O
Inability NCT03921502 717 726 B-Negation
to NCT03921502 727 729 B-Assertion___Assertion-Type-Value:hypothetical
tolerate NCT03921502 730 738 O
sedation NCT03921502 739 747 B-Procedure
of NCT03921502 748 750 I-Procedure
endoscopy NCT03921502 751 760 I-Procedure
, NCT03921502 761 762 O
perforation NCT03921502 763 774 B-Condition
of NCT03921502 775 777 I-Condition
the NCT03921502 778 781 I-Condition
digestive NCT03921502 782 791 I-Condition
tract NCT03921502 792 797 I-Condition
or NCT03921502 798 800 O
other NCT03921502 801 806 O
contraindication NCT03921502 807 823 B-Contraindication
to NCT03921502 824 826 O
endoscopy NCT03921502 827 836 B-Procedure
. NCT03921502 836 837 O

- NCT03921502 841 842 O
Coagulopathy NCT03921502 844 856 B-Condition
with NCT03921502 857 861 B-And
INR NCT03921502 862 865 B-Observation
( NCT03921502 866 867 O
international NCT03921502 868 881 B-Observation
normalized NCT03921502 882 892 I-Observation
ratio NCT03921502 893 898 I-Observation
) NCT03921502 899 900 O
> NCT03921502 901 902 B-Eq-Comparison
1.5 NCT03921502 903 906 I-Eq-Comparison
not NCT03921502 907 910 O
correctable NCT03921502 911 922 O
or NCT03921502 923 925 O
thrombocytopenia NCT03921502 926 942 B-Condition
< NCT03921502 943 944 B-Eq-Comparison
50000 NCT03921502 945 950 I-Eq-Comparison
/ NCT03921502 951 952 I-Eq-Comparison
mm3 NCT03921502 953 956 I-Eq-Comparison
not NCT03921502 957 960 O
correctable NCT03921502 961 972 O
. NCT03921502 972 973 O

- NCT03921502 977 978 O
Other NCT03921502 980 985 O
diagnoses NCT03921502 986 995 B-Condition
at NCT03921502 996 998 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03921502 999 1008 B-Encounter
( NCT03921502 1009 1010 O
acute NCT03921502 1011 1016 B-Condition|Condition
cholecystitis NCT03921502 1017 1030 I-Condition
, NCT03921502 1031 1032 O
acute NCT03921502 1033 1038 O
pancreatitis NCT03921502 1039 1051 I-Condition
, NCT03921502 1052 1053 O
biliopancreatic NCT03921502 1054 1069 B-Condition
neoplasia NCT03921502 1070 1079 I-Condition
) NCT03921502 1080 1081 O
. NCT03921502 1082 1083 O

- NCT03921502 1087 1088 O
Hemodynamic NCT03921502 1090 1101 B-Condition
instability NCT03921502 1102 1113 I-Condition
. NCT03921502 1113 1114 O

- NCT03921502 1118 1119 O
Urgent NCT03921502 1121 1127 B-Procedure
procedure NCT03921502 1128 1137 I-Procedure
performed NCT03921502 1138 1147 O
after NCT03921502 1148 1153 O
hours NCT03921502 1154 1159 O

- NCT03921502 1162 1163 O
No NCT03921502 1165 1167 O
availability NCT03921502 1168 1180 O
of NCT03921502 1181 1183 O
expert NCT03921502 1184 1190 O
material NCT03921502 1191 1199 O
/ NCT03921502 1200 1201 O
endoscopist NCT03921502 1202 1213 O
in NCT03921502 1214 1216 O
drainage NCT03921502 1217 1225 O
. NCT03921502 1225 1226 O

- NCT03921502 1230 1231 O
Anatomical NCT03921502 1233 1243 O
impossibility NCT03921502 1244 1257 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03921502 1258 1260 O
performing NCT03921502 1261 1271 O
biliary NCT03921502 1272 1279 B-Procedure
drainage NCT03921502 1280 1288 I-Procedure
( NCT03921502 1289 1290 O
absence NCT03921502 1291 1298 B-Negation
of NCT03921502 1299 1301 O
vesicular NCT03921502 1302 1311 B-Condition
distension NCT03921502 1312 1322 I-Condition
, NCT03921502 1323 1324 O
contact NCT03921502 1325 1332 B-Condition
between NCT03921502 1333 1340 O
gallbladder NCT03921502 1341 1352 B-Modifier
and NCT03921502 1353 1356 B-And
stomach NCT03921502 1357 1364 B-Modifier
or NCT03921502 1365 1367 B-Or
duodenum NCT03921502 1368 1376 B-Modifier
, NCT03921502 1377 1378 O
contact NCT03921502 1379 1386 B-Observation
area NCT03921502 1387 1391 I-Observation
< NCT03921502 1392 1393 B-Eq-Comparison
10 NCT03921502 1394 1396 I-Eq-Comparison
mm NCT03921502 1397 1399 I-Eq-Comparison
) NCT03921502 1400 1401 O
. NCT03921502 1402 1403 O

- NCT03921502 1407 1408 O
Baseline NCT03921502 1410 1418 O
ECOG NCT03921502 1419 1423 B-Observation
( NCT03921502 1424 1425 O
Easthern NCT03921502 1426 1434 B-Observation
Cooperative NCT03921502 1435 1446 I-Observation
Oncology NCT03921502 1447 1455 I-Observation
Group NCT03921502 1456 1461 I-Observation
) NCT03921502 1462 1463 O
> NCT03921502 1464 1465 B-Eq-Comparison
= NCT03921502 1466 1467 I-Eq-Comparison
4 NCT03921502 1468 1469 I-Eq-Comparison

- NCT03921502 1473 1474 O
Expectancy NCT03921502 1476 1486 B-Observation
of NCT03921502 1487 1489 I-Observation
survival NCT03921502 1490 1498 I-Observation
< NCT03921502 1499 1500 B-Eq-Comparison
6 NCT03921502 1501 1502 I-Eq-Comparison
months NCT03921502 1503 1509 I-Eq-Comparison
. NCT03921502 1509 1510 O

- NCT03921502 1514 1515 O
Refusal NCT03921502 1517 1524 O
to NCT03921502 1525 1527 O
participate NCT03921502 1528 1539 O
. NCT03921502 1539 1540 O

- NCT03921502 1544 1545 O
Distance NCT03921502 1547 1555 B-Observation
between NCT03921502 1556 1563 O
the NCT03921502 1564 1567 O
gallbladder NCT03921502 1568 1579 B-Modifier
and NCT03921502 1580 1583 B-And
upper NCT03921502 1584 1589 B-Modifier
digestive NCT03921502 1590 1599 I-Modifier
tract NCT03921502 1600 1605 I-Modifier
> NCT03921502 1606 1607 B-Eq-Comparison
1 NCT03921502 1608 1609 I-Eq-Comparison
cm NCT03921502 1610 1612 O
, NCT03921502 1613 1614 O
scleroatrophic NCT03921502 1615 1629 B-Condition
vesicle NCT03921502 1630 1637 I-Condition
, NCT03921502 1638 1639 O
lack NCT03921502 1640 1644 B-Negation
of NCT03921502 1645 1647 I-Negation
stable NCT03921502 1648 1654 B-Observation
acoustic NCT03921502 1655 1663 I-Observation
window NCT03921502 1664 1670 I-Observation
for NCT03921502 1671 1674 I-Observation
drainage NCT03921502 1675 1683 I-Observation

- NCT03921502 1686 1687 O
ERCP NCT03921502 1689 1693 B-Condition
failed NCT03921502 1694 1700 O
( NCT03921502 1701 1702 O
inhability NCT03921502 1703 1713 B-Negation
to NCT03921502 1714 1716 O
dain NCT03921502 1717 1721 B-Condition
common NCT03921502 1722 1728 I-Condition
bile NCT03921502 1729 1733 I-Condition
duct NCT03921502 1734 1738 I-Condition
) NCT03921502 1739 1740 O

Inclusion NCT03920813 0 9 O
Criteria NCT03920813 10 18 O
: NCT03920813 19 20 O

- NCT03920813 24 25 O
Patients NCT03920813 27 35 O
have NCT03920813 36 40 O
been NCT03920813 41 45 O
diagnosed NCT03920813 46 55 O
with NCT03920813 56 60 O
Acute NCT03920813 61 66 B-Condition
Lymphoblastic NCT03920813 67 80 I-Condition
Leukemia NCT03920813 81 89 I-Condition

- NCT03920813 92 93 O
Childhood NCT03920813 95 104 O
patients NCT03920813 105 113 O
who NCT03920813 114 117 B-And
were NCT03920813 118 122 O
undergoing NCT03920813 123 133 B-Eq-Comparison
chemotherapy NCT03920813 134 146 B-Procedure
or NCT03920813 147 149 B-Or
continuous NCT03920813 150 160 O
follow NCT03920813 161 167 B-Encounter
- NCT03920813 168 169 I-Encounter
up NCT03920813 170 172 I-Encounter
after NCT03920813 173 178 B-Temporal-Connection___Temporal-Connection-Type-Value:after
completion NCT03920813 179 189 O
of NCT03920813 190 192 O
chemotherapy NCT03920813 193 205 B-Procedure

- NCT03920813 208 209 O
Patients NCT03920813 211 219 O
received NCT03920813 220 228 B-Eq-Comparison
the NCT03920813 229 232 O
phase NCT03920813 233 238 O
of NCT03920813 239 241 O
maintenance NCT03920813 242 253 B-Procedure
therapy NCT03920813 254 261 I-Procedure
that NCT03920813 262 266 O
included NCT03920813 267 275 O
oral NCT03920813 276 280 B-Modifier
6 NCT03920813 281 282 B-Drug
- NCT03920813 283 284 I-Drug
MP NCT03920813 285 287 I-Drug
( NCT03920813 288 289 O
> NCT03920813 291 292 B-Eq-Comparison
4 NCT03920813 293 294 I-Eq-Comparison
weeks NCT03920813 295 300 I-Eq-Comparison
) NCT03920813 301 302 O
and NCT03920813 303 306 O
completion NCT03920813 307 317 O
of NCT03920813 318 320 O
≥ NCT03920813 321 322 B-Eq-Comparison
6 NCT03920813 323 324 I-Eq-Comparison
months NCT03920813 325 331 I-Eq-Comparison
according NCT03920813 332 341 O
to NCT03920813 342 344 O
the NCT03920813 345 348 O
CCLG NCT03920813 349 353 O
( NCT03920813 354 355 O
Chinese NCT03920813 356 363 O
Children NCT03920813 364 372 O
's NCT03920813 372 374 O
Leukemia NCT03920813 375 383 O
Group NCT03920813 384 389 O
) NCT03920813 390 391 O
protocol NCT03920813 392 400 O
- NCT03920813 401 402 O
ALL NCT03920813 403 406 O
2015 NCT03920813 407 411 O

Exclusion NCT03920813 413 422 O
Criteria NCT03920813 423 431 O
: NCT03920813 432 433 O

- NCT03920813 437 438 O
Patients NCT03920813 440 448 O
with NCT03920813 449 453 O
high NCT03920813 454 458 O
- NCT03920813 459 460 O
risk NCT03920813 461 465 B-Risk
ALL NCT03920813 466 469 B-Condition
( NCT03920813 470 471 O
presence NCT03920813 472 480 O
of NCT03920813 481 483 O
higher NCT03920813 484 490 B-Coreference
- NCT03920813 491 492 I-Coreference
risk NCT03920813 493 497 I-Coreference
features NCT03920813 498 506 I-Coreference
: NCT03920813 507 508 O
MRD NCT03920813 509 512 B-Observation
≥ NCT03920813 513 514 B-Eq-Comparison
1 NCT03920813 515 516 I-Eq-Comparison
% NCT03920813 517 518 O
at NCT03920813 519 521 O
46 NCT03920813 522 524 O
day NCT03920813 525 528 O
, NCT03920813 529 530 O
or NCT03920813 531 533 B-Or
age NCT03920813 534 537 B-Age
< NCT03920813 538 539 B-Eq-Comparison
6 NCT03920813 540 541 I-Eq-Comparison
month NCT03920813 542 547 I-Eq-Comparison
and NCT03920813 548 551 B-And
white NCT03920813 552 557 B-Observation
blood NCT03920813 558 563 I-Observation
cell NCT03920813 564 568 I-Observation
( NCT03920813 569 570 O
WBC NCT03920813 571 574 B-Observation
) NCT03920813 575 576 O
count NCT03920813 577 582 B-Eq-Comparison
≥ NCT03920813 583 584 I-Eq-Comparison
300 NCT03920813 585 588 I-Eq-Comparison
×109 NCT03920813 589 593 O
/ NCT03920813 594 595 I-Eq-Comparison
L NCT03920813 596 597 I-Eq-Comparison
with NCT03920813 598 602 O
translocations NCT03920813 603 617 O
t NCT03920813 618 619 O
( NCT03920813 620 621 O
9 NCT03920813 622 623 O
; NCT03920813 624 625 O
22 NCT03920813 625 627 O
) NCT03920813 628 629 O
( NCT03920813 630 631 O
q34 NCT03920813 632 635 O
; NCT03920813 636 637 O
q11 NCT03920813 637 640 O
) NCT03920813 641 642 O
[ NCT03920813 643 644 O
BCR NCT03920813 645 648 O
- NCT03920813 649 650 O
ABL NCT03920813 651 654 O
] NCT03920813 655 656 O
, NCT03920813 658 659 O
t NCT03920813 660 661 O
( NCT03920813 662 663 O
4 NCT03920813 664 665 O
; NCT03920813 666 667 O
11 NCT03920813 667 669 O
) NCT03920813 670 671 O
( NCT03920813 672 673 O
q21 NCT03920813 674 677 O
; NCT03920813 678 679 O
q23 NCT03920813 679 682 O
) NCT03920813 683 684 O
[ NCT03920813 685 686 O
AF4 NCT03920813 687 690 O
/ NCT03920813 691 692 O
MLL NCT03920813 693 696 O
] NCT03920813 697 698 O
, NCT03920813 700 701 O
t NCT03920813 702 703 O
( NCT03920813 704 705 O
1 NCT03920813 706 707 O
; NCT03920813 708 709 O
19 NCT03920813 709 711 O
) NCT03920813 712 713 O
( NCT03920813 714 715 O
q23 NCT03920813 716 719 O
; NCT03920813 720 721 O
p13 NCT03920813 721 724 O
) NCT03920813 725 726 O
[ NCT03920813 727 728 O
E2A NCT03920813 729 732 O
- NCT03920813 733 734 O
PBX1 NCT03920813 735 739 O
] NCT03920813 740 741 O
or NCT03920813 742 744 O
other NCT03920813 745 750 O
MLL NCT03920813 751 754 O
- NCT03920813 755 756 O
rearrangements NCT03920813 757 771 O
) NCT03920813 772 773 O
were NCT03920813 774 778 O
removed NCT03920813 779 786 O

Inclusion NCT03927417 0 9 O
Criteria NCT03927417 10 18 O
: NCT03927417 19 20 O

• NCT03927417 22 23 O
Couples NCT03927417 24 31 O
with NCT03927417 32 36 O
primary NCT03927417 37 44 B-Modifier
/ NCT03927417 45 46 B-Or
secondary NCT03927417 47 56 B-Modifier
infertility NCT03927417 57 68 B-Condition
who NCT03927417 69 72 B-And
are NCT03927417 73 76 O
planned NCT03927417 77 84 B-Eq-Comparison
to NCT03927417 85 87 I-Eq-Comparison
undergo NCT03927417 88 95 I-Eq-Comparison
IVF NCT03927417 96 99 B-Procedure
/ NCT03927417 100 101 B-Or
ICSI NCT03927417 102 106 B-Procedure

treatment NCT03927417 107 116 O
in NCT03927417 117 119 O
one NCT03927417 120 123 O
of NCT03927417 124 126 O
the NCT03927417 127 130 O
above NCT03927417 131 136 O
mentioned NCT03927417 137 146 O
centers NCT03927417 147 154 O
and NCT03927417 155 158 O
who NCT03927417 159 162 O
agree NCT03927417 163 168 O
to NCT03927417 169 171 O
take NCT03927417 172 176 O
part NCT03927417 177 181 O
in NCT03927417 182 184 O
this NCT03927417 185 189 O
study NCT03927417 190 195 O
. NCT03927417 195 196 O

Exclusion NCT03927417 198 207 O
Criteria NCT03927417 208 216 O
: NCT03927417 217 218 O

- NCT03927417 222 223 O
Couples NCT03927417 225 232 O
planned NCT03927417 233 240 B-Eq-Comparison
for NCT03927417 241 244 O
oocyte NCT03927417 245 251 B-Modifier
and NCT03927417 252 255 B-Or
sperm NCT03927417 256 261 B-Modifier
donation NCT03927417 262 270 B-Observation

- NCT03927417 273 274 O
Couples NCT03927417 276 283 O
in NCT03927417 284 286 O
whom NCT03927417 287 291 O
the NCT03927417 292 295 O
female NCT03927417 296 302 O
partner NCT03927417 303 310 O
has NCT03927417 311 314 O
a NCT03927417 315 316 O
history NCT03927417 317 324 B-Eq-Comparison
of NCT03927417 325 327 O
: NCT03927417 328 329 O

- NCT03927417 333 334 O
Chemotherapy NCT03927417 336 348 B-Procedure
or NCT03927417 349 351 B-Or
radiation NCT03927417 352 361 B-Procedure
which NCT03927417 362 367 O
impacts NCT03927417 368 375 O
the NCT03927417 376 379 O
ovarian NCT03927417 380 387 O
reserve NCT03927417 388 395 O

- NCT03927417 398 399 O
Surgery NCT03927417 401 408 B-Procedure
at NCT03927417 409 411 O
the NCT03927417 412 415 O
ovaries NCT03927417 416 423 B-Modifier
/ NCT03927417 424 425 B-Or
adnex NCT03927417 426 431 B-Modifier
region NCT03927417 432 438 I-Modifier

- NCT03927417 441 442 O
Tubal NCT03927417 444 449 B-Procedure
ligation NCT03927417 450 458 I-Procedure

- NCT03927417 461 462 O
Reversal NCT03927417 464 472 B-Procedure
of NCT03927417 473 475 I-Procedure
tubal NCT03927417 476 481 I-Procedure
ligation NCT03927417 482 490 I-Procedure

- NCT03927417 493 494 O
Endometriosis NCT03927417 496 509 B-Condition

- NCT03927417 512 513 O
Couples NCT03927417 515 522 O
in NCT03927417 523 525 O
whom NCT03927417 526 530 O
the NCT03927417 531 534 O
male NCT03927417 535 539 O
partner NCT03927417 540 547 O
has NCT03927417 548 551 O
a NCT03927417 552 553 O
history NCT03927417 554 561 B-Eq-Comparison
of NCT03927417 562 564 O
: NCT03927417 565 566 O

- NCT03927417 570 571 O
Chemotherapy NCT03927417 573 585 B-Procedure
/ NCT03927417 586 587 B-Or
Radiation NCT03927417 588 597 B-Procedure
which NCT03927417 598 603 O
impacts NCT03927417 604 611 O
the NCT03927417 612 615 O
semen NCT03927417 616 621 B-Condition
result NCT03927417 622 628 O

- NCT03927417 631 632 O
Surgery NCT03927417 634 641 B-Procedure
at NCT03927417 642 644 O
the NCT03927417 645 648 O
testicles NCT03927417 649 658 B-Modifier

- NCT03927417 661 662 O
Vasectomy NCT03927417 664 673 B-Procedure

- NCT03927417 676 677 O
Surgery NCT03927417 679 686 B-Procedure
for NCT03927417 687 690 I-Procedure
reversal NCT03927417 691 699 I-Procedure
of NCT03927417 700 702 I-Procedure
vasectomy NCT03927417 703 712 I-Procedure

Inclusion NCT03928730 0 9 O
Criteria NCT03928730 10 18 O
: NCT03928730 19 20 O

- NCT03928730 24 25 O
All NCT03928730 27 30 O
with NCT03928730 31 35 O
oral NCT03928730 36 40 B-Modifier
and NCT03928730 41 44 B-Or
/ NCT03928730 45 46 I-Or
or NCT03928730 47 49 I-Or
maxillofacial NCT03928730 50 63 B-Modifier
swelling NCT03928730 64 72 B-Condition
, NCT03928730 73 74 O

Exclusion NCT03928730 76 85 O
Criteria NCT03928730 86 94 O
: NCT03928730 95 96 O

- NCT03928730 100 101 O
Any NCT03928730 103 106 O
other NCT03928730 107 112 O
swellings NCT03928730 113 122 B-Condition
that NCT03928730 123 127 O
were NCT03928730 128 132 O
caused NCT03928730 133 139 O
by NCT03928730 140 142 O
trauma NCT03928730 143 149 B-Condition
and NCT03928730 150 153 B-Or
/ NCT03928730 154 155 I-Or
or NCT03928730 156 158 I-Or
fracture NCT03928730 159 167 B-Condition
, NCT03928730 168 169 O
extended NCT03928730 170 178 B-Modifier
below NCT03928730 179 184 I-Modifier
the NCT03928730 185 188 I-Modifier
neck NCT03928730 189 193 I-Modifier
or NCT03928730 194 196 B-Or
patient NCT03928730 197 204 O
reluctant NCT03928730 205 214 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928730 215 217 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03928730 218 225 B-Eq-Comparison
US NCT03928730 226 228 B-Procedure
were NCT03928730 229 233 O
excluded NCT03928730 234 242 B-Negation
from NCT03928730 243 247 O
the NCT03928730 248 251 O
study NCT03928730 252 257 B-Study
. NCT03928730 257 258 O

Inclusion NCT03929406 0 9 O
Criteria NCT03929406 10 18 O
: NCT03929406 19 20 O

- NCT03929406 24 25 O
Eligible NCT03929406 27 35 B-Assertion___Assertion-Type-Value:hypothetical
patients NCT03929406 36 44 O
for NCT03929406 45 48 O
deep NCT03929406 49 53 B-Procedure
brain NCT03929406 54 59 I-Procedure
stimulation NCT03929406 60 71 I-Procedure
surgery NCT03929406 72 79 I-Procedure

- NCT03929406 82 83 O
Patients NCT03929406 85 93 O
affiliated NCT03929406 94 104 O
to NCT03929406 105 107 O
social NCT03929406 108 114 O
security NCT03929406 115 123 O
or NCT03929406 124 126 O
benefiting NCT03929406 127 137 O
of NCT03929406 138 140 O
a NCT03929406 141 142 O
similar NCT03929406 143 150 O
insurance NCT03929406 151 160 O
scheme NCT03929406 161 167 O

- NCT03929406 170 171 O
Patients NCT03929406 173 181 O
having NCT03929406 182 188 O
signed NCT03929406 189 195 O
a NCT03929406 196 197 O
consent NCT03929406 198 205 O
to NCT03929406 206 208 O
participate NCT03929406 209 220 O
to NCT03929406 221 223 O
the NCT03929406 224 227 O
study NCT03929406 228 233 O

Exclusion NCT03929406 234 243 O
Criteria NCT03929406 244 252 O
: NCT03929406 253 254 O

- NCT03929406 258 259 O
Patient NCT03929406 261 268 O
not NCT03929406 269 272 B-Negation
eligible NCT03929406 273 281 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929406 282 285 O
deep NCT03929406 286 290 B-Procedure
brain NCT03929406 291 296 I-Procedure
stimulation NCT03929406 297 308 I-Procedure
surgery NCT03929406 309 316 I-Procedure

- NCT03929406 319 320 O
Pregnant NCT03929406 322 330 B-Condition
women NCT03929406 331 336 O
or NCT03929406 337 339 B-Or
nursing NCT03929406 340 347 B-Condition
mothers NCT03929406 348 355 O

- NCT03929406 358 359 O
Persons NCT03929406 361 368 O
deprived NCT03929406 369 377 B-Observation
of NCT03929406 378 380 I-Observation
liberty NCT03929406 381 388 I-Observation
by NCT03929406 389 391 O
judicial NCT03929406 392 400 O
or NCT03929406 401 403 O
administrative NCT03929406 404 418 O
decision NCT03929406 419 427 O

- NCT03929406 430 431 O
Persons NCT03929406 433 440 O
unable NCT03929406 441 447 O
to NCT03929406 448 450 O
express NCT03929406 451 458 O
their NCT03929406 459 464 O
consent NCT03929406 465 472 O
or NCT03929406 473 475 O
legally NCT03929406 476 483 B-Observation
protected NCT03929406 484 493 I-Observation

- NCT03929406 496 497 O
Persons NCT03929406 499 506 O
in NCT03929406 507 509 O
period NCT03929406 510 516 O
of NCT03929406 517 519 O
disqualification NCT03929406 520 536 O
for NCT03929406 537 540 O
another NCT03929406 541 548 B-Other
interventional NCT03929406 549 563 B-Study
research NCT03929406 564 572 O

Inclusion NCT03920436 0 9 O
Criteria NCT03920436 10 18 O
: NCT03920436 19 20 O

- NCT03920436 24 25 O
19 NCT03920436 27 29 B-Eq-Comparison
years NCT03920436 30 35 I-Eq-Comparison
and NCT03920436 36 39 I-Eq-Comparison
older NCT03920436 40 45 I-Eq-Comparison

Exclusion NCT03920436 46 55 O
Criteria NCT03920436 56 64 O
: NCT03920436 65 66 O

- NCT03920436 70 71 O
aspartate NCT03920436 73 82 B-Observation
aminotransferase NCT03920436 83 99 I-Observation
( NCT03920436 100 101 O
AST NCT03920436 102 105 B-Observation
) NCT03920436 106 107 O
or NCT03920436 108 110 B-Or
alanine NCT03920436 111 118 B-Observation
aminotransferase NCT03920436 119 135 I-Observation
( NCT03920436 136 137 O
ALT NCT03920436 138 141 B-Observation
) NCT03920436 142 143 O
more NCT03920436 144 148 B-Eq-Comparison
than NCT03920436 149 153 I-Eq-Comparison
twice NCT03920436 154 159 I-Eq-Comparison
the NCT03920436 160 163 I-Eq-Comparison
highest NCT03920436 164 171 I-Eq-Comparison
reference NCT03920436 172 181 I-Eq-Comparison
value NCT03920436 182 187 I-Eq-Comparison

- NCT03920436 190 191 O
serum NCT03920436 193 198 B-Observation
creatinine NCT03920436 199 209 I-Observation
≥ NCT03920436 210 211 B-Eq-Comparison
1.5 NCT03920436 212 215 I-Eq-Comparison
mg NCT03920436 216 218 I-Eq-Comparison
/ NCT03920436 219 220 I-Eq-Comparison
dL NCT03920436 221 223 I-Eq-Comparison
) NCT03920436 224 225 O

- NCT03920436 229 230 O
uncontrolled NCT03920436 232 244 B-Modifier
diabetes NCT03920436 245 253 B-Condition
mellitus NCT03920436 254 262 I-Condition
( NCT03920436 263 264 O
a NCT03920436 265 266 O
fasting NCT03920436 267 274 B-Observation
glucose NCT03920436 275 282 I-Observation
of NCT03920436 283 285 O
> NCT03920436 286 287 B-Eq-Comparison
160 NCT03920436 288 291 I-Eq-Comparison
mg NCT03920436 292 294 I-Eq-Comparison
/ NCT03920436 295 296 I-Eq-Comparison
dL NCT03920436 297 299 I-Eq-Comparison
) NCT03920436 300 301 O

- NCT03920436 305 306 O
uncontrolled NCT03920436 308 320 B-Modifier
hypertension NCT03920436 321 333 B-Condition
( NCT03920436 334 335 O
BP NCT03920436 336 338 B-Observation
> NCT03920436 339 340 B-Eq-Comparison
160 NCT03920436 341 344 I-Eq-Comparison
/ NCT03920436 345 346 O
100 NCT03920436 347 350 O
mmHg NCT03920436 351 355 O
) NCT03920436 356 357 O

- NCT03920436 361 362 O
severe NCT03920436 364 370 O
gastrointestinal NCT03920436 371 387 B-Condition
symptoms NCT03920436 388 396 B-Assertion___Assertion-Type-Value:possible

- NCT03920436 399 400 O
alcohol NCT03920436 402 409 B-Observation
abuser NCT03920436 410 416 I-Observation

- NCT03920436 419 420 O
pregnant NCT03920436 422 430 B-Condition
or NCT03920436 431 433 B-Or
lactating NCT03920436 434 443 B-Condition
women NCT03920436 444 449 O

- NCT03920436 452 453 O
allergic NCT03920436 455 463 B-Allergy
to NCT03920436 464 466 O
the NCT03920436 467 470 O
ingredient NCT03920436 471 481 B-Drug
involved NCT03920436 482 490 O

- NCT03920436 493 494 O
cardiocebrovascular NCT03920436 496 515 B-Condition
diseases NCT03920436 516 524 I-Condition
or NCT03920436 525 527 B-Or
any NCT03920436 528 531 O
cancer NCT03920436 532 538 B-Condition
during NCT03920436 539 545 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920436 546 549 O
six NCT03920436 550 553 B-Eq-Comparison
months NCT03920436 554 560 I-Eq-Comparison
prior NCT03920436 561 566 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920436 567 569 O
study NCT03920436 570 575 B-Study

- NCT03920436 578 579 O
smoker NCT03920436 581 587 B-Condition

Inclusion NCT03924687 0 9 O
Criteria NCT03924687 10 18 O
: NCT03924687 19 20 O

- NCT03924687 24 25 O
being NCT03924687 27 32 O
18 NCT03924687 33 35 B-Eq-Comparison
years NCT03924687 36 41 I-Eq-Comparison
of NCT03924687 42 44 I-Eq-Comparison
age NCT03924687 45 48 I-Eq-Comparison
or NCT03924687 49 51 I-Eq-Comparison
older NCT03924687 52 57 I-Eq-Comparison

- NCT03924687 60 61 O
having NCT03924687 63 69 O
suffered NCT03924687 70 78 O
from NCT03924687 79 83 O
daily NCT03924687 84 89 B-Eq-Comparison
pain NCT03924687 90 94 B-Condition
for NCT03924687 95 98 O
more NCT03924687 99 103 B-Eq-Comparison
than NCT03924687 104 108 I-Eq-Comparison
three NCT03924687 109 114 I-Eq-Comparison
months NCT03924687 115 121 I-Eq-Comparison

- NCT03924687 124 125 O
having NCT03924687 127 133 O
reading NCT03924687 134 141 O
and NCT03924687 142 145 O
writing NCT03924687 146 153 O
abilities NCT03924687 154 163 O
in NCT03924687 164 166 O
French NCT03924687 167 173 O
equivalent NCT03924687 174 184 O
or NCT03924687 185 187 O
superior NCT03924687 188 196 O
to NCT03924687 197 199 O
grade NCT03924687 200 205 O
8 NCT03924687 206 207 O

- NCT03924687 211 212 O
having NCT03924687 214 220 O
access NCT03924687 221 227 O
to NCT03924687 228 230 O
Internet NCT03924687 231 239 O
at NCT03924687 240 242 O
home NCT03924687 243 247 O
and NCT03924687 248 251 O
having NCT03924687 252 258 O
a NCT03924687 259 260 O
valid NCT03924687 261 266 O
e NCT03924687 267 268 O
- NCT03924687 269 270 O
mail NCT03924687 271 275 O
address NCT03924687 276 283 O

- NCT03924687 286 287 O
not NCT03924687 289 292 B-Negation
having NCT03924687 293 299 O
previously NCT03924687 300 310 B-Eq-Comparison
completed NCT03924687 311 320 O
an NCT03924687 321 323 O
ACT NCT03924687 324 327 B-Procedure
- NCT03924687 328 329 I-Procedure
type NCT03924687 330 334 I-Procedure
psychotherapy NCT03924687 335 348 I-Procedure
, NCT03924687 349 350 O
not NCT03924687 351 354 B-Negation
having NCT03924687 355 361 O
practiced NCT03924687 362 371 B-Observation
mindfulness NCT03924687 372 383 I-Observation
meditation NCT03924687 384 394 I-Observation
regularly NCT03924687 395 404 O
and NCT03924687 405 408 B-And
not NCT03924687 409 412 B-Negation
having NCT03924687 413 419 O
read NCT03924687 420 424 O
a NCT03924687 425 426 O
bibliotherapy NCT03924687 427 440 B-Procedure
on NCT03924687 441 443 I-Procedure
ACT NCT03924687 444 447 I-Procedure
for NCT03924687 448 451 O
pain NCT03924687 452 456 B-Condition

- NCT03924687 459 460 O
having NCT03924687 462 468 O
stable NCT03924687 469 475 O
medication NCT03924687 476 486 B-Drug
for NCT03924687 487 490 O
at NCT03924687 491 493 B-Eq-Comparison
least NCT03924687 494 499 I-Eq-Comparison
one NCT03924687 500 503 I-Eq-Comparison
month NCT03924687 504 509 I-Eq-Comparison
, NCT03924687 510 511 O
if NCT03924687 512 514 O
applicable NCT03924687 515 525 O
. NCT03924687 525 526 O

Exclusion NCT03924687 528 537 O
Criteria NCT03924687 538 546 O
: NCT03924687 547 548 O

- NCT03924687 551 552 O

Inclusion NCT03921099 0 9 O
Criteria NCT03921099 10 18 O
: NCT03921099 19 20 O

- NCT03921099 24 25 O
Adults NCT03921099 27 33 O
who NCT03921099 34 37 B-And
are NCT03921099 38 41 O
critically NCT03921099 42 52 O
ill NCT03921099 53 56 B-Condition
and NCT03921099 57 60 B-And
with NCT03921099 61 65 O
MRSA NCT03921099 66 70 B-Condition
infection NCT03921099 71 80 I-Condition
suspection NCT03921099 81 91 B-Assertion___Assertion-Type-Value:possible
. NCT03921099 91 92 O

Exclusion NCT03921099 94 103 O
Criteria NCT03921099 104 112 O
: NCT03921099 113 114 O

1 NCT03921099 118 119 O
. NCT03921099 119 120 O
Pregnancy NCT03921099 122 131 B-Condition
or NCT03921099 132 134 B-Or
breast NCT03921099 135 141 B-Condition
feeding NCT03921099 142 149 I-Condition
. NCT03921099 149 150 O

2 NCT03921099 154 155 O
. NCT03921099 155 156 O
Known NCT03921099 158 163 O
allergy NCT03921099 164 171 B-Allergy
to NCT03921099 172 174 O
either NCT03921099 175 181 O
vancomycin NCT03921099 182 192 B-Drug
or NCT03921099 193 195 B-Or
ascorbic NCT03921099 196 204 B-Drug
acid NCT03921099 205 209 I-Drug
. NCT03921099 209 210 O

3 NCT03921099 214 215 O
. NCT03921099 215 216 O
Base NCT03921099 218 222 O
line NCT03921099 223 227 O
serum NCT03921099 228 233 B-Observation
creatinine NCT03921099 234 244 I-Observation
≥ NCT03921099 245 246 B-Eq-Comparison
2 NCT03921099 247 248 I-Eq-Comparison
mg NCT03921099 249 251 O
/ NCT03921099 252 253 O
dl NCT03921099 254 256 O
. NCT03921099 256 257 O

4 NCT03921099 261 262 O
. NCT03921099 262 263 O
Patients NCT03921099 265 273 O
receiving NCT03921099 274 283 O
other NCT03921099 284 289 O
nephrotoxic NCT03921099 290 301 B-Drug
drug NCT03921099 302 306 I-Drug
( NCT03921099 307 308 O
e. NCT03921099 309 311 O
g. NCT03921099 312 314 O
, NCT03921099 315 316 O
aminoglycosides NCT03921099 317 332 B-Drug
, NCT03921099 333 334 O
amphotericin NCT03921099 335 347 B-Drug
B NCT03921099 348 349 I-Drug
, NCT03921099 350 351 O
cisplatin NCT03921099 352 361 B-Drug
or NCT03921099 362 364 B-Or
calcinurine NCT03921099 365 376 B-Drug
inhibitors NCT03921099 377 387 I-Drug
) NCT03921099 388 389 O
. NCT03921099 390 391 O

5 NCT03921099 395 396 O
. NCT03921099 396 397 O
Anticepated NCT03921099 399 410 B-Assertion___Assertion-Type-Value:hypothetical
administration NCT03921099 411 425 O
of NCT03921099 426 428 O
contrast NCT03921099 429 437 B-Drug
medium NCT03921099 438 444 I-Drug
within NCT03921099 445 451 B-Eq-Comparison
7 NCT03921099 452 453 I-Eq-Comparison
days NCT03921099 454 458 I-Eq-Comparison
. NCT03921099 458 459 O

6 NCT03921099 463 464 O
. NCT03921099 464 465 O
Patients NCT03921099 467 475 O
suffering NCT03921099 476 485 O
from NCT03921099 486 490 O
some NCT03921099 491 495 O
underlying NCT03921099 496 506 O
diseases NCT03921099 507 515 B-Condition
( NCT03921099 516 517 O
e. NCT03921099 518 520 O
g. NCT03921099 521 523 O
, NCT03921099 524 525 O
cancer NCT03921099 526 532 B-Condition
, NCT03921099 533 534 O
HIV NCT03921099 535 538 B-Condition
infection NCT03921099 539 548 I-Condition
, NCT03921099 549 550 O
systemic NCT03921099 551 559 B-Condition
lupus NCT03921099 560 565 I-Condition
erythematoses NCT03921099 566 579 I-Condition
, NCT03921099 580 581 O
or NCT03921099 582 584 B-Or
urinary NCT03921099 585 592 B-Condition
tract NCT03921099 593 598 I-Condition
stones NCT03921099 599 605 I-Condition
) NCT03921099 606 607 O
. NCT03921099 608 609 O

7 NCT03921099 613 614 O
. NCT03921099 614 615 O
Unlikelyhood NCT03921099 617 629 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03921099 630 632 O
receiving NCT03921099 633 642 O
the NCT03921099 643 646 O
study NCT03921099 647 652 O
medications NCT03921099 653 664 B-Drug
for NCT03921099 665 668 O
at NCT03921099 669 671 B-Eq-Comparison
least NCT03921099 672 677 I-Eq-Comparison
72 NCT03921099 678 680 I-Eq-Comparison
hours NCT03921099 681 686 I-Eq-Comparison

Inclusion NCT03925610 0 9 O
Criteria NCT03925610 10 18 O
: NCT03925610 19 20 O

- NCT03925610 24 25 O
Body NCT03925610 27 31 B-Observation
mass NCT03925610 32 36 I-Observation
index NCT03925610 37 42 I-Observation
( NCT03925610 43 44 O
BMI NCT03925610 45 48 B-Observation
) NCT03925610 49 50 O
equal NCT03925610 51 56 B-Eq-Comparison
or NCT03925610 57 59 I-Eq-Comparison
greater NCT03925610 60 67 I-Eq-Comparison
than NCT03925610 68 72 I-Eq-Comparison
35 NCT03925610 73 75 I-Eq-Comparison
kg NCT03925610 76 78 I-Eq-Comparison
/ NCT03925610 79 80 I-Eq-Comparison
m2 NCT03925610 81 83 I-Eq-Comparison
. NCT03925610 83 84 O

- NCT03925610 88 89 O
American NCT03925610 91 99 B-Condition
Society NCT03925610 100 107 I-Condition
of NCT03925610 108 110 I-Condition
Anesthesiologists NCT03925610 111 128 I-Condition
( NCT03925610 129 130 O
ASA NCT03925610 131 134 B-Condition
) NCT03925610 135 136 O
physical NCT03925610 137 145 O
status NCT03925610 146 152 B-Eq-Comparison
I NCT03925610 153 154 I-Eq-Comparison
- NCT03925610 155 156 I-Eq-Comparison
III NCT03925610 157 160 I-Eq-Comparison
patients NCT03925610 161 169 O
. NCT03925610 169 170 O

- NCT03925610 174 175 O
Scheduled NCT03925610 177 186 B-Eq-Comparison
to NCT03925610 187 189 I-Eq-Comparison
undergo NCT03925610 190 197 I-Eq-Comparison
laparoscopic NCT03925610 198 210 B-Procedure
roux NCT03925610 211 215 I-Procedure
- NCT03925610 216 217 I-Procedure
en NCT03925610 218 220 I-Procedure
- NCT03925610 221 222 O
Y NCT03925610 223 224 I-Procedure
gastric NCT03925610 225 232 I-Procedure
bypass NCT03925610 233 239 I-Procedure
or NCT03925610 240 242 B-Or
gastric NCT03925610 243 250 B-Procedure
sleeve NCT03925610 251 257 I-Procedure
placement NCT03925610 258 267 I-Procedure
surgery NCT03925610 268 275 I-Procedure
for NCT03925610 276 279 O
weight NCT03925610 280 286 B-Condition
loss NCT03925610 287 291 I-Condition
. NCT03925610 291 292 O

Exclusion NCT03925610 294 303 O
Criteria NCT03925610 304 312 O
: NCT03925610 313 314 O

- NCT03925610 318 319 O
Chronic NCT03925610 321 328 B-Condition
obstructive NCT03925610 329 340 I-Condition
pulmonary NCT03925610 341 350 I-Condition
disorder NCT03925610 351 359 I-Condition
( NCT03925610 360 361 O
COPD NCT03925610 362 366 B-Condition
) NCT03925610 367 368 O
. NCT03925610 369 370 O

- NCT03925610 374 375 O
Treatment NCT03925610 377 386 B-Procedure
with NCT03925610 387 391 O
continuous NCT03925610 392 402 B-Procedure
positive NCT03925610 403 411 I-Procedure
airway NCT03925610 412 418 I-Procedure
pressure NCT03925610 419 427 I-Procedure
( NCT03925610 428 429 O
CPAP NCT03925610 430 434 B-Procedure
) NCT03925610 435 436 O
in NCT03925610 437 439 O
the NCT03925610 440 443 O
past NCT03925610 444 448 B-Eq-Comparison
three NCT03925610 449 454 I-Eq-Comparison
months NCT03925610 455 461 I-Eq-Comparison
. NCT03925610 461 462 O

- NCT03925610 466 467 O
Severe NCT03925610 469 475 O
neurological NCT03925610 476 488 B-Modifier
, NCT03925610 489 490 O
cardiopulmonary NCT03925610 491 506 B-Modifier
, NCT03925610 507 508 O
psychiatric NCT03925610 509 520 B-Modifier
, NCT03925610 521 522 O
or NCT03925610 523 525 B-Or
untreated NCT03925610 526 535 B-Modifier
thyroid NCT03925610 536 543 B-Modifier
disorder NCT03925610 544 552 B-Condition
. NCT03925610 552 553 O

- NCT03925610 557 558 O
Chronic NCT03925610 560 567 B-Condition
pain NCT03925610 568 572 I-Condition
condition NCT03925610 573 582 I-Condition
that NCT03925610 583 587 O
was NCT03925610 588 591 O
being NCT03925610 592 597 B-Eq-Comparison
treated NCT03925610 598 605 O
with NCT03925610 606 610 O
opioids NCT03925610 611 618 B-Drug
. NCT03925610 618 619 O

- NCT03925610 623 624 O
Patients NCT03925610 626 634 O
with NCT03925610 635 639 O
a NCT03925610 640 641 O
hematocrit NCT03925610 642 652 B-Observation
lower NCT03925610 653 658 B-Eq-Comparison
than NCT03925610 659 663 I-Eq-Comparison
35 NCT03925610 664 666 I-Eq-Comparison
% NCT03925610 667 668 O
. NCT03925610 668 669 O

Inclusion NCT03921476 0 9 O
Criteria NCT03921476 10 18 O
: NCT03921476 19 20 O

Female NCT03921476 22 28 O
subjects NCT03921476 29 37 O
between NCT03921476 38 45 B-Eq-Comparison
18 NCT03921476 46 48 I-Eq-Comparison
and NCT03921476 49 52 I-Eq-Comparison
65 NCT03921476 53 55 I-Eq-Comparison
years NCT03921476 56 61 I-Eq-Comparison
of NCT03921476 62 64 O
age NCT03921476 65 68 B-Age
currently NCT03921476 69 78 B-Eq-Comparison
taking NCT03921476 79 85 B-Eq-Comparison
spironolactone NCT03921476 86 100 B-Drug
for NCT03921476 101 104 O
a NCT03921476 105 106 O
diagnosis NCT03921476 107 116 O
of NCT03921476 117 119 O
acne NCT03921476 120 124 B-Condition
vulgaris NCT03921476 125 133 I-Condition

OR NCT03921476 134 136 B-Or

Female NCT03921476 137 143 O
subjects NCT03921476 144 152 O
between NCT03921476 153 160 B-Eq-Comparison
18 NCT03921476 161 163 I-Eq-Comparison
and NCT03921476 164 167 I-Eq-Comparison
65 NCT03921476 168 170 I-Eq-Comparison
years NCT03921476 171 176 I-Eq-Comparison
of NCT03921476 177 179 O
age NCT03921476 180 183 B-Age
currently NCT03921476 184 193 B-Eq-Comparison
taking NCT03921476 194 200 B-Eq-Comparison
oral NCT03921476 201 205 B-Drug
antibiotics NCT03921476 206 217 I-Drug
for NCT03921476 218 221 O
a NCT03921476 222 223 O
diagnosis NCT03921476 224 233 O
of NCT03921476 234 236 O
acne NCT03921476 237 241 B-Condition
vulgaris NCT03921476 242 250 I-Condition

AND NCT03921476 251 254 B-And
Subjects NCT03921476 255 263 O
able NCT03921476 264 268 O
to NCT03921476 269 271 O
complete NCT03921476 272 280 O
an NCT03921476 281 283 O
online NCT03921476 284 290 O
survey NCT03921476 291 297 O
in NCT03921476 298 300 O
English NCT03921476 301 308 O

Exclusion NCT03921476 309 318 O
Criteria NCT03921476 319 327 O
: NCT03921476 328 329 O

Subjects NCT03921476 331 339 O
less NCT03921476 340 344 B-Eq-Comparison
than NCT03921476 345 349 I-Eq-Comparison
18 NCT03921476 350 352 I-Eq-Comparison
years NCT03921476 353 358 I-Eq-Comparison
of NCT03921476 359 361 O
age NCT03921476 362 365 B-Age
or NCT03921476 366 368 B-Or
older NCT03921476 369 374 B-Eq-Comparison
than NCT03921476 375 379 I-Eq-Comparison
65 NCT03921476 380 382 I-Eq-Comparison
years NCT03921476 383 388 I-Eq-Comparison
of NCT03921476 389 391 O
age NCT03921476 392 395 B-Age
Subjects NCT03921476 396 404 O
that NCT03921476 405 409 O
have NCT03921476 410 414 O
ever NCT03921476 415 419 O
been NCT03921476 420 424 O
diagnosed NCT03921476 425 434 O
with NCT03921476 435 439 O
any NCT03921476 440 443 O
mood NCT03921476 444 448 B-Condition
disorder NCT03921476 449 457 I-Condition
by NCT03921476 458 460 O
a NCT03921476 461 462 O
clinician NCT03921476 463 472 O
prior NCT03921476 473 478 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921476 479 481 O
starting NCT03921476 482 490 O
spironolactone NCT03921476 491 505 B-Drug
( NCT03921476 506 507 O
history NCT03921476 508 515 B-Eq-Comparison
of NCT03921476 516 518 O
mood NCT03921476 519 523 B-Condition
disorder NCT03921476 524 532 I-Condition
or NCT03921476 533 535 B-Or
current NCT03921476 536 543 B-Eq-Comparison
mood NCT03921476 544 548 B-Condition
disorder NCT03921476 549 557 I-Condition
) NCT03921476 558 559 O
Subjects NCT03921476 560 568 O
taking NCT03921476 569 575 B-Eq-Comparison
hormonal NCT03921476 576 584 B-Drug
contraception NCT03921476 585 598 I-Drug
( NCT03921476 599 600 O
including NCT03921476 601 610 O
but NCT03921476 611 614 O
not NCT03921476 615 618 O
limited NCT03921476 619 626 O
to NCT03921476 627 629 O
oral NCT03921476 630 634 B-Drug
contraceptive NCT03921476 635 648 I-Drug
pills NCT03921476 649 654 I-Drug
) NCT03921476 655 656 O
for NCT03921476 657 660 O
a NCT03921476 661 662 O
duration NCT03921476 663 671 O
of NCT03921476 672 674 O
less NCT03921476 675 679 B-Eq-Comparison
than NCT03921476 680 684 I-Eq-Comparison
6 NCT03921476 685 686 I-Eq-Comparison
months NCT03921476 687 693 I-Eq-Comparison
Subjects NCT03921476 694 702 O
that NCT03921476 703 707 O
have NCT03921476 708 712 O
ever NCT03921476 713 717 O
been NCT03921476 718 722 O
diagnosed NCT03921476 723 732 O
with NCT03921476 733 737 O
any NCT03921476 738 741 O
type NCT03921476 742 746 O
of NCT03921476 747 749 O
sexual NCT03921476 750 756 B-Condition
dysfunction NCT03921476 757 768 I-Condition
prior NCT03921476 769 774 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921476 775 777 O
starting NCT03921476 778 786 O
spironolactone NCT03921476 787 801 B-Drug
Subjects NCT03921476 802 810 O
not NCT03921476 811 814 B-Negation
able NCT03921476 815 819 O
to NCT03921476 820 822 O
complete NCT03921476 823 831 O
an NCT03921476 832 834 O
online NCT03921476 835 841 O
survey NCT03921476 842 848 O
in NCT03921476 849 851 O
English NCT03921476 852 859 O
Subjects NCT03921476 860 868 O
taking NCT03921476 869 875 B-Eq-Comparison
oral NCT03921476 876 880 B-Drug
isotretinoin NCT03921476 881 893 I-Drug
for NCT03921476 894 897 O
a NCT03921476 898 899 O
diagnosis NCT03921476 900 909 O
of NCT03921476 910 912 O
acne NCT03921476 913 917 B-Condition
Subjects NCT03921476 918 926 O
that NCT03921476 927 931 O
are NCT03921476 932 935 O
currently NCT03921476 936 945 B-Eq-Comparison
pregnant NCT03921476 946 954 B-Condition


Inclusion NCT03929770 0 9 O
Criteria NCT03929770 10 18 O
: NCT03929770 19 20 O

- NCT03929770 24 25 O
The NCT03929770 27 30 O
patients NCT03929770 31 39 O
who NCT03929770 40 43 O
need NCT03929770 44 48 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929770 49 51 I-Assertion___Assertion-Type-Value:hypothetical
Swan NCT03929770 52 56 B-Procedure
- NCT03929770 57 58 I-Procedure
Ganz NCT03929770 59 63 I-Procedure
catheterization NCT03929770 64 79 I-Procedure
for NCT03929770 80 83 O
heart NCT03929770 84 89 B-Procedure
surgeries NCT03929770 90 99 I-Procedure

Exclusion NCT03929770 100 109 O
Criteria NCT03929770 110 118 O
: NCT03929770 119 120 O

- NCT03929770 124 125 O
Who NCT03929770 127 130 O
does NCT03929770 131 135 O
n't NCT03929770 135 138 O
agree NCT03929770 139 144 O
to NCT03929770 145 147 O
enroll NCT03929770 148 154 O

- NCT03929770 157 158 O
Who NCT03929770 160 163 O
has NCT03929770 164 167 O
thrombus NCT03929770 168 176 B-Condition
in NCT03929770 177 179 I-Condition
the NCT03929770 180 183 I-Condition
heart NCT03929770 184 189 B-Modifier
or NCT03929770 190 192 B-Or
the NCT03929770 193 196 O
vena NCT03929770 197 201 B-Modifier
cavas NCT03929770 202 207 I-Modifier
. NCT03929770 207 208 O

Inclusion NCT03926325 0 9 O
Criteria NCT03926325 10 18 O
: NCT03926325 19 20 O

1 NCT03926325 24 25 O
. NCT03926325 25 26 O
OHCA NCT03926325 28 32 O
: NCT03926325 33 34 O
Every NCT03926325 35 40 O
patient NCT03926325 41 48 O
who NCT03926325 49 52 O
suffered NCT03926325 53 61 O
a NCT03926325 62 63 O
cardiac NCT03926325 64 71 B-Condition
arrest NCT03926325 72 78 I-Condition
that NCT03926325 79 83 O
occurred NCT03926325 84 92 O
in NCT03926325 93 95 O
any NCT03926325 96 99 O
location NCT03926325 100 108 O
other NCT03926325 109 114 B-Exception
than NCT03926325 115 119 I-Exception
a NCT03926325 120 121 O
hospital NCT03926325 122 130 O
, NCT03926325 131 132 O
and NCT03926325 133 136 B-And
was NCT03926325 137 140 O
attended NCT03926325 141 149 B-Encounter
and NCT03926325 150 153 O
/ NCT03926325 154 155 O
or NCT03926325 156 158 O
treated NCT03926325 159 166 O
by NCT03926325 167 169 O
an NCT03926325 170 172 O
EMS NCT03926325 173 176 B-Provider
. NCT03926325 176 177 O

2 NCT03926325 181 182 O
. NCT03926325 182 183 O
IHCA NCT03926325 185 189 O
: NCT03926325 190 191 O
Every NCT03926325 192 197 O
patient NCT03926325 198 205 O
who NCT03926325 206 209 O
suffered NCT03926325 210 218 O
a NCT03926325 219 220 O
cardiac NCT03926325 221 228 B-Condition
arrest NCT03926325 229 235 I-Condition
in NCT03926325 236 238 O
hospital NCT03926325 239 247 O
. NCT03926325 247 248 O

3 NCT03926325 252 253 O
. NCT03926325 253 254 O
the NCT03926325 256 259 O
representative NCT03926325 260 274 O
population NCT03926325 275 285 O
- NCT03926325 286 287 O
based NCT03926325 288 293 O
survey NCT03926325 294 300 O
: NCT03926325 301 302 O
Every NCT03926325 303 308 O
patient NCT03926325 309 316 O
who NCT03926325 317 320 O
suffered NCT03926325 321 329 O
a NCT03926325 330 331 O
cardiac NCT03926325 332 339 B-Condition
arrest NCT03926325 340 346 I-Condition
in NCT03926325 347 349 O
the NCT03926325 350 353 O
selected NCT03926325 354 362 O
cities NCT03926325 363 369 O
or NCT03926325 370 372 O
suburbs NCT03926325 373 380 O
. NCT03926325 380 381 O

Exclusion NCT03926325 383 392 O
Criteria NCT03926325 393 401 O
: NCT03926325 402 403 O

1 NCT03926325 407 408 O
. NCT03926325 408 409 O
OHCA NCT03926325 411 415 O
: NCT03926325 416 417 O
1 NCT03926325 418 419 O
) NCT03926325 420 421 O
The NCT03926325 422 425 O
out NCT03926325 426 429 B-Negation
- NCT03926325 430 431 I-Negation
of NCT03926325 432 434 I-Negation
- NCT03926325 435 436 O
hospital NCT03926325 437 445 O
cardiac NCT03926325 446 453 B-Condition
arrest NCT03926325 454 460 I-Condition
patients NCT03926325 461 469 O
who NCT03926325 470 473 O
were NCT03926325 474 478 O
taken NCT03926325 479 484 O
to NCT03926325 485 487 O
the NCT03926325 488 491 O
hospital NCT03926325 492 500 O
by NCT03926325 501 503 O
their NCT03926325 504 509 O
family NCT03926325 510 516 O
members NCT03926325 517 524 O
; NCT03926325 524 525 O
2 NCT03926325 526 527 O
) NCT03926325 528 529 O
Bystanders NCT03926325 530 540 O
suspected NCT03926325 541 550 B-Assertion___Assertion-Type-Value:possible
cardiac NCT03926325 551 558 B-Condition
arrest NCT03926325 559 565 I-Condition
, NCT03926325 566 567 O
but NCT03926325 568 571 O
the NCT03926325 572 575 O
ROSC NCT03926325 576 580 O
was NCT03926325 581 584 O
achieved NCT03926325 585 593 O
without NCT03926325 594 601 B-Negation
defibrillation NCT03926325 602 616 B-Procedure
or NCT03926325 617 619 B-Or
resuscitation NCT03926325 620 633 B-Procedure
by NCT03926325 634 636 O
EMS NCT03926325 637 640 B-Provider
. NCT03926325 640 641 O

2 NCT03926325 645 646 O
. NCT03926325 646 647 O
IHCA NCT03926325 649 653 O
: NCT03926325 654 655 O
The NCT03926325 656 659 O
patient NCT03926325 660 667 O
who NCT03926325 668 671 O
suffered NCT03926325 672 680 O
a NCT03926325 681 682 O
cardiac NCT03926325 683 690 B-Condition
arrest NCT03926325 691 697 I-Condition
that NCT03926325 698 702 O
occurred NCT03926325 703 711 O
out NCT03926325 712 715 B-Negation
- NCT03926325 716 717 I-Negation
of NCT03926325 718 720 I-Negation
- NCT03926325 721 722 O
hospital NCT03926325 723 731 O
and NCT03926325 732 735 O
then NCT03926325 736 740 B-Temporal-Connection___Temporal-Connection-Type-Value:before
transferred NCT03926325 741 752 B-Encounter
to NCT03926325 753 755 O
the NCT03926325 756 759 O
hospital NCT03926325 760 768 O
. NCT03926325 768 769 O

Inclusion NCT03924297 0 9 O
Criteria NCT03924297 10 18 O
: NCT03924297 19 20 O

- NCT03924297 24 25 O
Patients NCT03924297 27 35 O
who NCT03924297 36 39 O
have NCT03924297 40 44 O
seen NCT03924297 45 49 B-Encounter
the NCT03924297 50 53 O
study NCT03924297 54 59 O
PI NCT03924297 60 62 O
( NCT03924297 63 64 O
Remy NCT03924297 65 69 B-Provider
Coeytaux NCT03924297 70 78 I-Provider
, NCT03924297 79 80 O
MD NCT03924297 81 83 I-Provider
, NCT03924297 84 85 O
PhD NCT03924297 86 89 I-Provider
) NCT03924297 90 91 O
for NCT03924297 92 95 O
an NCT03924297 96 98 O
integrative NCT03924297 99 110 O
medicine NCT03924297 111 119 O
consultation NCT03924297 120 132 O
between NCT03924297 133 140 B-Eq-Comparison
September NCT03924297 141 150 I-Eq-Comparison
1 NCT03924297 151 152 I-Eq-Comparison
, NCT03924297 153 154 O
2018 NCT03924297 155 159 I-Eq-Comparison
and NCT03924297 160 163 I-Eq-Comparison
April NCT03924297 164 169 I-Eq-Comparison
30 NCT03924297 170 172 I-Eq-Comparison
, NCT03924297 173 174 O
2019 NCT03924297 175 179 I-Eq-Comparison
and NCT03924297 180 183 B-And
who NCT03924297 184 187 O
report NCT03924297 188 194 O
having NCT03924297 195 201 O
been NCT03924297 202 206 O
diagnoses NCT03924297 207 216 O
with NCT03924297 217 221 O
PTSD NCT03924297 222 226 B-Condition
or NCT03924297 227 229 B-Or
who NCT03924297 230 233 O
believe NCT03924297 234 241 O
they NCT03924297 242 246 O
may NCT03924297 247 250 B-Assertion___Assertion-Type-Value:possible
have NCT03924297 251 255 O
PTSD NCT03924297 256 260 B-Condition|Condition
or NCT03924297 261 263 B-Or
PTSD NCT03924297 264 268 O
- NCT03924297 269 270 O
related NCT03924297 271 278 O
symptoms NCT03924297 279 287 B-Assertion___Assertion-Type-Value:possible
are NCT03924297 288 291 O
eligible NCT03924297 292 300 O
to NCT03924297 301 303 O
participate NCT03924297 304 315 O
. NCT03924297 315 316 O

Exclusion NCT03924297 318 327 O
Criteria NCT03924297 328 336 O
: NCT03924297 337 338 O

- NCT03924297 342 343 O
No NCT03924297 345 347 O
exclusion NCT03924297 348 357 O
criteria NCT03924297 358 366 O

Inclusion NCT03926481 0 9 O
Criteria NCT03926481 10 18 O
: NCT03926481 19 20 O

- NCT03926481 24 25 O
English NCT03926481 27 34 O
Speaking NCT03926481 35 43 O

- NCT03926481 46 47 O
Age NCT03926481 49 52 B-Age
≥ NCT03926481 53 54 B-Eq-Comparison
65 NCT03926481 55 57 I-Eq-Comparison
years NCT03926481 58 63 I-Eq-Comparison

- NCT03926481 66 67 O
Body NCT03926481 69 73 O
Composition NCT03926481 74 85 O
Body NCT03926481 86 90 B-Observation
Fat NCT03926481 91 94 I-Observation
> NCT03926481 95 96 B-Eq-Comparison
25 NCT03926481 97 99 I-Eq-Comparison
% NCT03926481 100 101 O
for NCT03926481 102 105 O
Men NCT03926481 106 109 O

- NCT03926481 112 113 O
Body NCT03926481 115 119 O
Composition NCT03926481 120 131 O
Body NCT03926481 132 136 B-Observation
Fat NCT03926481 137 140 I-Observation
> NCT03926481 141 142 B-Eq-Comparison
30 NCT03926481 143 145 I-Eq-Comparison
% NCT03926481 146 147 O
for NCT03926481 148 151 O
Women NCT03926481 152 157 O

- NCT03926481 160 161 O
Participating NCT03926481 163 176 O
in NCT03926481 177 179 O
the NCT03926481 180 183 O
Dartmouth NCT03926481 184 193 O
Hitchcock NCT03926481 194 203 O
Weight NCT03926481 204 210 O
and NCT03926481 211 214 O
Wellness NCT03926481 215 223 O
Center NCT03926481 224 230 O
( NCT03926481 231 232 O
WWC NCT03926481 233 236 O
) NCT03926481 237 238 O
Healthy NCT03926481 239 246 O
Lifestyle NCT03926481 247 256 O
Program NCT03926481 257 264 O
( NCT03926481 265 266 O
HLP NCT03926481 267 270 O
) NCT03926481 271 272 O

- NCT03926481 276 277 O
Willing NCT03926481 279 286 O
and NCT03926481 287 290 O
able NCT03926481 291 295 O
to NCT03926481 296 298 O
give NCT03926481 299 303 O
informed NCT03926481 304 312 O
consent NCT03926481 313 320 O

Exclusion NCT03926481 321 330 O
Criteria NCT03926481 331 339 O
: NCT03926481 340 341 O

- NCT03926481 345 346 O
Unable NCT03926481 348 354 O
to NCT03926481 355 357 O
perform NCT03926481 358 365 O
measures NCT03926481 366 374 O

- NCT03926481 377 378 O
Individuals NCT03926481 380 391 O
unwilling NCT03926481 392 401 O
/ NCT03926481 402 403 O
unable NCT03926481 404 410 O
to NCT03926481 411 413 O
provide NCT03926481 414 421 O
consent NCT03926481 422 429 O

- NCT03926481 432 433 O
Severe NCT03926481 435 441 O
mental NCT03926481 442 448 B-Modifier
or NCT03926481 449 451 B-Or
life NCT03926481 452 456 B-Modifier
- NCT03926481 457 458 I-Modifier
threatening NCT03926481 459 470 I-Modifier
illness NCT03926481 471 478 B-Condition

- NCT03926481 481 482 O
History NCT03926481 484 491 B-Eq-Comparison
of NCT03926481 492 494 O
bariatric NCT03926481 495 504 B-Procedure
surgery NCT03926481 505 512 I-Procedure

Inclusion NCT03920033 0 9 O
Criteria NCT03920033 10 18 O
: NCT03920033 19 20 O

- NCT03920033 24 25 O
Pathologically NCT03920033 27 41 B-Procedure
confirmed NCT03920033 42 51 O
intermediate NCT03920033 52 64 O
- NCT03920033 65 66 O
or NCT03920033 67 69 B-Or
high NCT03920033 70 74 O
- NCT03920033 75 76 O
risk NCT03920033 77 81 B-Risk
prostate NCT03920033 82 90 B-Condition
cancer NCT03920033 91 97 I-Condition

- NCT03920033 100 101 O
Biochemical NCT03920033 103 114 O
recurrence NCT03920033 115 125 B-Coreference
after NCT03920033 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:after
radical NCT03920033 132 139 B-Procedure
prostatectomy NCT03920033 140 153 I-Procedure
( NCT03920033 154 155 O
Definition NCT03920033 156 166 O
: NCT03920033 167 168 O
Serial NCT03920033 169 175 O
elevation NCT03920033 176 185 O
of NCT03920033 186 188 O
PSA NCT03920033 189 192 B-Observation
over NCT03920033 193 197 B-Eq-Comparison
0.2 NCT03920033 198 201 I-Eq-Comparison
ng NCT03920033 202 204 I-Eq-Comparison
/ NCT03920033 205 206 I-Eq-Comparison
mL NCT03920033 207 209 I-Eq-Comparison
and NCT03920033 210 213 B-And
< NCT03920033 214 215 B-Eq-Comparison
= NCT03920033 217 218 I-Eq-Comparison
1.0 NCT03920033 219 222 I-Eq-Comparison
ng NCT03920033 223 225 I-Eq-Comparison
/ NCT03920033 226 227 I-Eq-Comparison
mL NCT03920033 228 230 I-Eq-Comparison
) NCT03920033 231 232 O

- NCT03920033 236 237 O
ECOG NCT03920033 239 243 B-Observation
performance NCT03920033 244 255 I-Observation
status NCT03920033 256 262 I-Observation
0 NCT03920033 263 264 B-Eq-Comparison
- NCT03920033 265 266 I-Eq-Comparison
1 NCT03920033 267 268 O

- NCT03920033 272 273 O
Appropriate NCT03920033 275 286 O
values NCT03920033 287 293 O
of NCT03920033 294 296 O
blood NCT03920033 297 302 O
tests NCT03920033 303 308 O
within NCT03920033 309 315 B-Eq-Comparison
6 NCT03920033 316 317 I-Eq-Comparison
months NCT03920033 318 324 I-Eq-Comparison
after NCT03920033 325 330 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 331 341 B-Study
Absolute NCT03920033 342 350 B-Observation
neutrophil NCT03920033 351 361 I-Observation
count NCT03920033 362 367 I-Observation
( NCT03920033 368 369 O
ANC NCT03920033 370 373 B-Observation
) NCT03920033 374 375 O
≥ NCT03920033 376 377 B-Eq-Comparison
1500 NCT03920033 378 382 I-Eq-Comparison
cells NCT03920033 383 388 O
/ NCT03920033 389 390 O
mm3 NCT03920033 391 394 O
Platelets NCT03920033 395 404 B-Observation
≥ NCT03920033 405 406 B-Eq-Comparison
50 NCT03920033 407 409 I-Eq-Comparison
, NCT03920033 410 411 O
000 NCT03920033 412 415 O
cells NCT03920033 416 421 O
/ NCT03920033 422 423 O
mm3 NCT03920033 424 427 O
Hemoglobin NCT03920033 428 438 B-Observation
≥ NCT03920033 439 440 B-Eq-Comparison
8.0 NCT03920033 441 444 I-Eq-Comparison
g NCT03920033 445 446 O
/ NCT03920033 447 448 O
dl NCT03920033 449 451 O

- NCT03920033 454 455 O
Appropriate NCT03920033 457 468 O
values NCT03920033 469 475 O
of NCT03920033 476 478 O
kidney NCT03920033 479 485 B-Observation
function NCT03920033 486 494 I-Observation
within NCT03920033 495 501 B-Eq-Comparison
6 NCT03920033 502 503 I-Eq-Comparison
months NCT03920033 504 510 I-Eq-Comparison
after NCT03920033 511 516 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 517 527 B-Study
Creatinine NCT03920033 528 538 B-Observation
< NCT03920033 539 540 B-Eq-Comparison
2.0 NCT03920033 541 544 I-Eq-Comparison
ng NCT03920033 545 547 I-Eq-Comparison
/ NCT03920033 548 549 I-Eq-Comparison
dL NCT03920033 550 552 I-Eq-Comparison

- NCT03920033 555 556 O
Appropriate NCT03920033 558 569 O
values NCT03920033 570 576 O
of NCT03920033 577 579 O
liver NCT03920033 580 585 B-Observation
function NCT03920033 586 594 I-Observation
within NCT03920033 595 601 B-Eq-Comparison
6 NCT03920033 602 603 I-Eq-Comparison
months NCT03920033 604 610 I-Eq-Comparison
after NCT03920033 611 616 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 617 627 B-Study
total NCT03920033 628 633 B-Observation
bilirubin NCT03920033 634 643 I-Observation
< NCT03920033 644 645 B-Eq-Comparison
1.5 NCT03920033 646 649 I-Eq-Comparison
X NCT03920033 650 651 I-Eq-Comparison
maximum NCT03920033 652 659 I-Eq-Comparison
normal NCT03920033 660 666 I-Eq-Comparison
value NCT03920033 667 672 I-Eq-Comparison
alanine NCT03920033 673 680 B-Observation
aminotransferase NCT03920033 681 697 I-Observation|Observation
or NCT03920033 698 700 B-Or
aspartate NCT03920033 701 710 B-Observation
aminotransferase NCT03920033 711 727 O
< NCT03920033 728 729 B-Eq-Comparison
2.5 NCT03920033 730 733 I-Eq-Comparison
X NCT03920033 734 735 I-Eq-Comparison
maximum NCT03920033 736 743 I-Eq-Comparison
normal NCT03920033 744 750 I-Eq-Comparison
value NCT03920033 751 756 I-Eq-Comparison

Exclusion NCT03920033 757 766 O
Criteria NCT03920033 767 775 O
: NCT03920033 776 777 O

- NCT03920033 781 782 O
Clinically NCT03920033 784 794 O
gross NCT03920033 795 800 B-Condition
recurrent NCT03920033 801 810 I-Condition
tumor NCT03920033 811 816 I-Condition

- NCT03920033 819 820 O
Presence NCT03920033 822 830 B-Eq-Comparison
of NCT03920033 831 833 O
distant NCT03920033 834 841 B-Modifier
metastasis NCT03920033 842 852 B-Condition

- NCT03920033 855 856 O
Presence NCT03920033 858 866 B-Eq-Comparison
of NCT03920033 867 869 O
pelvic NCT03920033 870 876 B-Modifier
LN NCT03920033 877 879 I-Modifier
metastasis NCT03920033 880 890 B-Condition

- NCT03920033 893 894 O
History NCT03920033 896 903 B-Eq-Comparison
of NCT03920033 904 906 O
pelvic NCT03920033 907 913 B-Modifier
irradiation NCT03920033 914 925 B-Procedure

- NCT03920033 928 929 O
History NCT03920033 931 938 B-Eq-Comparison
of NCT03920033 939 941 O
cryotherapy NCT03920033 942 953 B-Procedure
or NCT03920033 954 956 B-Or
brachytherapy NCT03920033 957 970 B-Procedure
for NCT03920033 971 974 O
prostate NCT03920033 975 983 B-Modifier
cancer NCT03920033 984 990 B-Condition|Condition

- NCT03920033 993 994 O
Double NCT03920033 996 1002 B-Eq-Comparison
primary NCT03920033 1003 1010 B-Modifier
cancer NCT03920033 1011 1017 B-Condition
other NCT03920033 1018 1023 B-Exception
than NCT03920033 1024 1028 I-Exception
skin NCT03920033 1029 1033 B-Modifier
/ NCT03920033 1034 1035 B-Or
thyroid NCT03920033 1036 1043 B-Modifier
cancer NCT03920033 1044 1050 O

- NCT03920033 1053 1054 O
Combined NCT03920033 1056 1064 O
serious NCT03920033 1065 1072 O
morbidity NCT03920033 1073 1082 B-Condition


Inclusion NCT03921463 0 9 O
Criteria NCT03921463 10 18 O
: NCT03921463 19 20 O

- NCT03921463 24 25 O
1 NCT03921463 27 28 O
) NCT03921463 29 30 O
Age NCT03921463 31 34 B-Age
: NCT03921463 35 36 O
20 NCT03921463 37 39 B-Eq-Comparison
~ NCT03921463 40 41 I-Eq-Comparison
35 NCT03921463 42 44 O
years NCT03921463 45 50 I-Eq-Comparison
old NCT03921463 51 54 O
; NCT03921463 54 55 O
2 NCT03921463 56 57 O
) NCT03921463 58 59 O
first NCT03921463 60 65 B-Eq-Comparison
parturients NCT03921463 66 77 B-Condition
registered NCT03921463 78 88 O
in NCT03921463 89 91 O
the NCT03921463 92 95 O
obstetrics NCT03921463 96 106 O
department NCT03921463 107 117 O
of NCT03921463 118 120 O
our NCT03921463 121 124 O
hospital NCT03921463 125 133 O
; NCT03921463 133 134 O
3 NCT03921463 135 136 O
) NCT03921463 137 138 O
no NCT03921463 139 141 B-Negation
medical NCT03921463 142 149 B-Condition
complications NCT03921463 150 163 I-Condition
before NCT03921463 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:before
pregnancy NCT03921463 171 180 B-Condition
, NCT03921463 181 182 O
no NCT03921463 183 185 B-Negation
UI NCT03921463 186 188 B-Condition
and NCT03921463 189 192 B-Or
POP NCT03921463 193 196 B-Condition
( NCT03921463 197 198 O
according NCT03921463 199 208 O
to NCT03921463 209 211 O
the NCT03921463 212 215 O
standard NCT03921463 216 224 B-Observation
of NCT03921463 225 227 I-Observation
POP NCT03921463 228 231 I-Observation
- NCT03921463 232 233 I-Observation
Q NCT03921463 234 235 I-Observation
stage NCT03921463 236 241 I-Observation
) NCT03921463 242 243 O
; NCT03921463 244 245 O
4 NCT03921463 246 247 O
) NCT03921463 248 249 O
no NCT03921463 250 252 B-Negation
obstetric NCT03921463 253 262 B-Condition
complications NCT03921463 263 276 I-Condition
; NCT03921463 276 277 O
5 NCT03921463 278 279 O
) NCT03921463 280 281 O
the NCT03921463 282 285 O
patients NCT03921463 286 294 O
agreed NCT03921463 295 301 O
to NCT03921463 302 304 O
conduct NCT03921463 305 312 O
the NCT03921463 313 316 O
study NCT03921463 317 322 O
and NCT03921463 323 326 O
signed NCT03921463 327 333 O
the NCT03921463 334 337 O
informed NCT03921463 338 346 O
consent NCT03921463 347 354 O
. NCT03921463 354 355 O

Exclusion NCT03921463 357 366 O
Criteria NCT03921463 367 375 O
: NCT03921463 376 377 O

- NCT03921463 381 382 O
1 NCT03921463 384 385 O
) NCT03921463 386 387 O
patients NCT03921463 388 396 O
with NCT03921463 397 401 O
uncontrolled NCT03921463 402 414 B-Modifier
epilepsy NCT03921463 415 423 B-Condition
, NCT03921463 424 425 O
central NCT03921463 426 433 B-Condition
nervous NCT03921463 434 441 I-Condition
system NCT03921463 442 448 I-Condition
diseases NCT03921463 449 457 I-Condition
or NCT03921463 458 460 B-Or
mental NCT03921463 461 467 B-Condition
disorders NCT03921463 468 477 I-Condition
, NCT03921463 478 479 O
whose NCT03921463 480 485 O
clinical NCT03921463 486 494 O
severity NCT03921463 495 503 O
shall NCT03921463 504 509 O
be NCT03921463 510 512 O
determined NCT03921463 513 523 O
by NCT03921463 524 526 O
the NCT03921463 527 530 O
researcher NCT03921463 531 541 O
to NCT03921463 542 544 O
affect NCT03921463 545 551 O
clinical NCT03921463 552 560 O
research NCT03921463 561 569 O
compliance NCT03921463 570 580 O
; NCT03921463 580 581 O
2 NCT03921463 582 583 O
) NCT03921463 584 585 O
follow NCT03921463 586 592 B-Encounter
up NCT03921463 593 595 I-Encounter
the NCT03921463 596 599 O
patients NCT03921463 600 608 O
with NCT03921463 609 613 B-Assertion___Assertion-Type-Value:hypothetical
difficulty NCT03921463 614 624 B-Negation
. NCT03921463 624 625 O

Inclusion NCT03923738 0 9 O
Criteria NCT03923738 10 18 O
: NCT03923738 19 20 O

- NCT03923738 24 25 O
Diagnosis NCT03923738 27 36 O
of NCT03923738 37 39 O
GCA NCT03923738 40 43 B-Condition
as NCT03923738 44 46 O
classified NCT03923738 47 57 O
according NCT03923738 58 67 O
to NCT03923738 68 70 O
protocol NCT03923738 71 79 O
- NCT03923738 80 81 O
specified NCT03923738 82 91 O
criteria NCT03923738 92 100 O
; NCT03923738 100 101 O

- NCT03923738 104 105 O
Participants NCT03923738 107 119 O
entering NCT03923738 120 128 B-Assertion___Assertion-Type-Value:hypothetical
Period NCT03923738 129 135 O
1 NCT03923738 136 137 O
must NCT03923738 138 142 O
be NCT03923738 143 145 O
receiving NCT03923738 146 155 B-Eq-Comparison
treatment NCT03923738 156 165 B-Procedure
with NCT03923738 166 170 O
TCZ NCT03923738 171 174 B-Drug
8 NCT03923738 175 176 B-Eq-Comparison
mg NCT03923738 177 179 I-Eq-Comparison
/ NCT03923738 180 181 I-Eq-Comparison
kg NCT03923738 182 184 I-Eq-Comparison
IV NCT03923738 185 187 I-Eq-Comparison
Q4W. NCT03923738 188 192 I-Eq-Comparison

Exclusion NCT03923738 194 203 O
Criteria NCT03923738 204 212 O
: NCT03923738 213 214 O

- NCT03923738 218 219 O
Treatment NCT03923738 221 230 B-Procedure
with NCT03923738 231 235 O
any NCT03923738 236 239 O
other NCT03923738 240 245 B-Other
investigational NCT03923738 246 261 B-Study
agent NCT03923738 262 267 B-Drug
besides NCT03923738 268 275 B-Exception
TCZ NCT03923738 276 279 B-Drug
within NCT03923738 280 286 B-Eq-Comparison
12 NCT03923738 287 289 I-Eq-Comparison
weeks NCT03923738 290 295 I-Eq-Comparison
( NCT03923738 296 297 O
or NCT03923738 298 300 B-Or
5 NCT03923738 301 302 B-Eq-Comparison
half NCT03923738 303 307 I-Eq-Comparison
- NCT03923738 308 309 I-Eq-Comparison
lives NCT03923738 310 315 I-Eq-Comparison
of NCT03923738 316 318 O
the NCT03923738 319 322 O
investigational NCT03923738 323 338 O
drug NCT03923738 339 343 O
, NCT03923738 344 345 O
whichever NCT03923738 346 355 O
is NCT03923738 356 358 O
longer NCT03923738 359 365 O
) NCT03923738 366 367 O
prior NCT03923738 368 373 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923738 374 376 O
screening NCT03923738 377 386 B-Study
; NCT03923738 386 387 O

- NCT03923738 390 391 O
Evidence NCT03923738 393 401 O
of NCT03923738 402 404 O
serious NCT03923738 405 412 O
uncontrolled NCT03923738 413 425 B-Modifier
disease NCT03923738 426 433 B-Condition
; NCT03923738 433 434 O

- NCT03923738 437 438 O
Known NCT03923738 440 445 O
active NCT03923738 446 452 B-Eq-Comparison
current NCT03923738 453 460 I-Eq-Comparison
or NCT03923738 461 463 B-Or
history NCT03923738 464 471 B-Eq-Comparison
of NCT03923738 472 474 I-Eq-Comparison
recurrent NCT03923738 475 484 O
bacterial NCT03923738 485 494 B-Modifier
, NCT03923738 495 496 O
viral NCT03923738 497 502 B-Modifier
, NCT03923738 503 504 O
fungal NCT03923738 505 511 B-Modifier
, NCT03923738 512 513 O
mycobacterial NCT03923738 514 527 B-Modifier
, NCT03923738 528 529 O
or NCT03923738 530 532 O
other NCT03923738 533 538 O
infections NCT03923738 539 549 B-Condition
; NCT03923738 549 550 O

- NCT03923738 553 554 O
Active NCT03923738 556 562 B-Eq-Comparison
TB NCT03923738 563 565 B-Condition
requiring NCT03923738 566 575 O
treatment NCT03923738 576 585 B-Drug
within NCT03923738 586 592 B-Eq-Comparison
the NCT03923738 593 596 I-Eq-Comparison
previous NCT03923738 597 605 I-Eq-Comparison
3 NCT03923738 606 607 I-Eq-Comparison
years NCT03923738 608 613 I-Eq-Comparison
. NCT03923738 613 614 O

Inclusion NCT03923062 0 9 O
Criteria NCT03923062 10 18 O
: NCT03923062 19 20 O

- NCT03923062 24 25 O
- NCT03923062 27 28 O
Subjects NCT03923062 29 37 O
presented NCT03923062 38 47 O
with NCT03923062 48 52 O
melasma NCT03923062 53 60 B-Condition
. NCT03923062 60 61 O

- NCT03923062 65 66 O
Age NCT03923062 68 71 B-Age
20 NCT03923062 72 74 B-Eq-Comparison
- NCT03923062 75 76 I-Eq-Comparison
40 NCT03923062 77 79 I-Eq-Comparison
years NCT03923062 80 85 I-Eq-Comparison
old NCT03923062 86 89 O
. NCT03923062 89 90 O

- NCT03923062 94 95 O
Melasma NCT03923062 97 104 B-Condition
persisting NCT03923062 105 115 O
for NCT03923062 116 119 O
more NCT03923062 120 124 B-Eq-Comparison
than NCT03923062 125 129 I-Eq-Comparison
6 NCT03923062 130 131 I-Eq-Comparison
months NCT03923062 132 138 I-Eq-Comparison
that NCT03923062 139 143 O
has NCT03923062 144 147 O
failed NCT03923062 148 154 O
to NCT03923062 155 157 O
respond NCT03923062 158 165 O
to NCT03923062 166 168 O
conventional NCT03923062 169 181 B-Procedure
treatment NCT03923062 182 191 I-Procedure
with NCT03923062 192 196 O
hydroquinone NCT03923062 197 209 B-Drug
or NCT03923062 210 212 B-Or
other NCT03923062 213 218 O
topical NCT03923062 219 226 B-Drug
lightening NCT03923062 227 237 I-Drug
agents NCT03923062 238 244 I-Drug
. NCT03923062 244 245 O

Exclusion NCT03923062 247 256 O
Criteria NCT03923062 257 265 O
: NCT03923062 266 267 O

- NCT03923062 271 272 O
- NCT03923062 274 275 O
History NCT03923062 276 283 B-Eq-Comparison
of NCT03923062 284 286 O
photosensitivity NCT03923062 287 303 B-Condition
, NCT03923062 304 305 O
keloids NCT03923062 306 313 B-Condition
, NCT03923062 314 315 O
hypertrophic NCT03923062 316 328 B-Condition
scarring NCT03923062 329 337 I-Condition
and NCT03923062 338 341 B-Or
post NCT03923062 342 346 B-Condition
- NCT03923062 347 348 I-Condition
inflammatory NCT03923062 349 361 I-Condition
hyperpigmentation NCT03923062 362 379 I-Condition
. NCT03923062 379 380 O

- NCT03923062 384 385 O
Pregnancy NCT03923062 387 396 B-Condition
and NCT03923062 397 400 B-Or
lactation NCT03923062 401 410 B-Condition
. NCT03923062 410 411 O

- NCT03923062 415 416 O
Subjects NCT03923062 418 426 O
with NCT03923062 427 431 O
local NCT03923062 432 437 B-Condition
inflammatory NCT03923062 438 450 I-Condition
skin NCT03923062 451 455 I-Condition
disorder NCT03923062 456 464 I-Condition
or NCT03923062 465 467 B-Or
active NCT03923062 468 474 B-Eq-Comparison
herpes NCT03923062 475 481 B-Condition
infection NCT03923062 482 491 I-Condition
at NCT03923062 492 494 O
the NCT03923062 495 498 O
site NCT03923062 499 503 B-Modifier
of NCT03923062 504 506 O
procedure NCT03923062 507 516 B-Procedure
. NCT03923062 516 517 O

- NCT03923062 521 522 O
Subjects NCT03923062 524 532 O
with NCT03923062 533 537 O
history NCT03923062 538 545 B-Eq-Comparison
of NCT03923062 546 548 O
medical NCT03923062 549 556 B-Condition
diseases NCT03923062 557 565 I-Condition
which NCT03923062 566 571 O
contraindicate NCT03923062 572 586 B-Contraindication
cryosurgery NCT03923062 587 598 B-Procedure
such NCT03923062 599 603 O
as NCT03923062 604 606 O
; NCT03923062 606 607 O
cold NCT03923062 608 612 B-Condition
intolerance NCT03923062 613 624 I-Condition
, NCT03923062 625 626 O
cold NCT03923062 627 631 B-Condition
urticaria NCT03923062 632 641 I-Condition
, NCT03923062 642 643 O
Raynaud`s NCT03923062 644 653 B-Condition
disease NCT03923062 654 661 I-Condition
and NCT03923062 662 665 B-And
history NCT03923062 666 673 B-Eq-Comparison
of NCT03923062 674 676 O
allergic NCT03923062 677 685 B-Allergy
reactions NCT03923062 686 695 O
to NCT03923062 696 698 O
cryosurgery NCT03923062 699 710 B-Procedure
. NCT03923062 710 711 O

Inclusion NCT03928080 0 9 O
Criteria NCT03928080 10 18 O
: NCT03928080 19 20 O

- NCT03928080 24 25 O
Aged NCT03928080 27 31 B-Age
18 NCT03928080 32 34 B-Eq-Comparison
and NCT03928080 35 38 I-Eq-Comparison
above NCT03928080 39 44 I-Eq-Comparison
. NCT03928080 44 45 O

- NCT03928080 49 50 O
Having NCT03928080 52 58 O
the NCT03928080 59 62 O
ability NCT03928080 63 70 O
to NCT03928080 71 73 O
learn NCT03928080 74 79 O
the NCT03928080 80 83 O
standard NCT03928080 84 92 O
toothbrushing NCT03928080 93 106 O
method NCT03928080 107 113 O
with NCT03928080 114 118 O
artificial NCT03928080 119 129 O
intelligence NCT03928080 130 142 O
powered NCT03928080 143 150 O
toothbrush NCT03928080 151 161 O
. NCT03928080 161 162 O

- NCT03928080 166 167 O
Ability NCT03928080 169 176 O
and NCT03928080 177 180 O
willingness NCT03928080 181 192 O
to NCT03928080 193 195 O
give NCT03928080 196 200 O
written NCT03928080 201 208 O
informed NCT03928080 209 217 O
consent NCT03928080 218 225 O
. NCT03928080 225 226 O

Exclusion NCT03928080 228 237 O
Criteria NCT03928080 238 246 O
: NCT03928080 247 248 O

- NCT03928080 252 253 O
Edentulous NCT03928080 255 265 B-Condition
mouth NCT03928080 266 271 I-Condition
. NCT03928080 271 272 O

- NCT03928080 276 277 O
Pregnant NCT03928080 279 287 B-Condition
females NCT03928080 288 295 O
. NCT03928080 295 296 O

- NCT03928080 300 301 O
Having NCT03928080 303 309 O
received NCT03928080 310 318 B-Eq-Comparison
professional NCT03928080 319 331 O
periodontal NCT03928080 332 343 B-Procedure
treatment NCT03928080 344 353 I-Procedure
( NCT03928080 354 355 O
other NCT03928080 356 361 B-Exception
than NCT03928080 362 366 I-Exception
supragingival NCT03928080 367 380 B-Procedure
cleaning NCT03928080 381 389 I-Procedure
) NCT03928080 390 391 O
within NCT03928080 392 398 B-Eq-Comparison
the NCT03928080 399 402 I-Eq-Comparison
previous NCT03928080 403 411 I-Eq-Comparison
12 NCT03928080 412 414 I-Eq-Comparison
months NCT03928080 415 421 I-Eq-Comparison
. NCT03928080 421 422 O

- NCT03928080 426 427 O
Having NCT03928080 429 435 O
received NCT03928080 436 444 B-Eq-Comparison
antibiotic NCT03928080 445 455 B-Drug
medication NCT03928080 456 466 I-Drug
within NCT03928080 467 473 B-Eq-Comparison
the NCT03928080 474 477 I-Eq-Comparison
previous NCT03928080 478 486 I-Eq-Comparison
3 NCT03928080 487 488 I-Eq-Comparison
months NCT03928080 489 495 I-Eq-Comparison
. NCT03928080 495 496 O

Inclusion NCT03920423 0 9 O
Criteria NCT03920423 10 18 O
: NCT03920423 19 20 O

- NCT03920423 24 25 O
requirement NCT03920423 27 38 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920423 39 41 I-Assertion___Assertion-Type-Value:hypothetical
radial NCT03920423 42 48 B-Procedure
arterial NCT03920423 49 57 I-Procedure
catheterization NCT03920423 58 73 I-Procedure
during NCT03920423 74 80 B-Temporal-Connection___Temporal-Connection-Type-Value:during
peri NCT03920423 81 85 O
- NCT03920423 86 87 O
- NCT03920423 89 90 O
operative NCT03920423 91 100 B-Procedure
period NCT03920423 101 107 O

- NCT03920423 110 111 O
within NCT03920423 113 119 O
cardiac NCT03920423 120 127 B-Condition
- NCT03920423 128 129 I-Condition
vascular NCT03920423 130 138 I-Condition
disease NCT03920423 139 146 I-Condition

- NCT03920423 149 150 O
written NCT03920423 152 159 O
consent NCT03920423 160 167 O

Exclusion NCT03920423 168 177 O
Criteria NCT03920423 178 186 O
: NCT03920423 187 188 O

- NCT03920423 192 193 O
contraindication NCT03920423 195 211 B-Contraindication
to NCT03920423 212 214 O
radial NCT03920423 215 221 B-Procedure
arterial NCT03920423 222 230 I-Procedure
catheterization NCT03920423 231 246 I-Procedure

- NCT03920423 249 250 O
abnormal NCT03920423 252 260 B-Condition
artery NCT03920423 261 267 I-Condition
evaluated NCT03920423 268 277 O
by NCT03920423 278 280 O
ultrasonography NCT03920423 281 296 B-Procedure

Inclusion NCT03923894 0 9 O
Criteria NCT03923894 10 18 O
: NCT03923894 19 20 O

- NCT03923894 24 25 O
Adult NCT03923894 27 32 O
men NCT03923894 33 36 O
and NCT03923894 37 40 B-Or
women NCT03923894 41 46 O
over NCT03923894 47 51 B-Eq-Comparison
50 NCT03923894 52 54 I-Eq-Comparison
years NCT03923894 55 60 I-Age|Eq-Comparison

- NCT03923894 63 64 O
After NCT03923894 66 71 O
fully NCT03923894 72 77 O
hearing NCT03923894 78 85 O
and NCT03923894 86 89 O
fully NCT03923894 90 95 O
understanding NCT03923894 96 109 O
this NCT03923894 110 114 O
clinical NCT03923894 115 123 O
trials NCT03923894 124 130 O
, NCT03923894 131 132 O
those NCT03923894 133 138 O
who NCT03923894 139 142 O
agree NCT03923894 143 148 O
to NCT03923894 149 151 O
voluntarily NCT03923894 152 163 O
decide NCT03923894 164 170 O
to NCT03923894 171 173 O
participate NCT03923894 174 185 O
and NCT03923894 186 189 O
to NCT03923894 190 192 O
comply NCT03923894 193 199 O
with NCT03923894 200 204 O
the NCT03923894 205 208 O
notice NCT03923894 209 215 O

Exclusion NCT03923894 216 225 O
Criteria NCT03923894 226 234 O
: NCT03923894 235 236 O

- NCT03923894 240 241 O
If NCT03923894 243 245 O
screening NCT03923894 246 255 B-Study
shows NCT03923894 256 261 B-Temporal-Connection___Temporal-Connection-Type-Value:during
that NCT03923894 262 266 O
the NCT03923894 267 270 O
white NCT03923894 271 276 B-Observation
blood NCT03923894 277 282 I-Observation
cell NCT03923894 283 287 I-Observation
( NCT03923894 288 289 O
WBC NCT03923894 290 293 B-Observation
) NCT03923894 294 295 O
is NCT03923894 296 298 O
less NCT03923894 299 303 B-Eq-Comparison
than NCT03923894 304 308 I-Eq-Comparison
3000 NCT03923894 309 313 I-Eq-Comparison
/ NCT03923894 314 315 I-Eq-Comparison
㎕ NCT03923894 316 317 I-Eq-Comparison
or NCT03923894 318 320 B-Or
more NCT03923894 321 325 B-Eq-Comparison
than NCT03923894 326 330 I-Eq-Comparison
8000 NCT03923894 331 335 I-Eq-Comparison
/ NCT03923894 336 337 I-Eq-Comparison
㎕ NCT03923894 338 339 I-Eq-Comparison

- NCT03923894 342 343 O
Those NCT03923894 345 350 O
who NCT03923894 351 354 O
received NCT03923894 355 363 B-Eq-Comparison
influenza NCT03923894 364 373 B-Immunization
vaccination NCT03923894 374 385 I-Immunization
within NCT03923894 386 392 B-Eq-Comparison
3 NCT03923894 393 394 I-Eq-Comparison
months NCT03923894 395 401 I-Eq-Comparison
before NCT03923894 402 408 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923894 409 412 O
screening NCT03923894 413 422 B-Study

- NCT03923894 425 426 O
Those NCT03923894 428 433 O
who NCT03923894 434 437 O
have NCT03923894 438 442 O
a NCT03923894 443 444 O
body NCT03923894 445 449 B-Observation
mass NCT03923894 450 454 I-Observation
index NCT03923894 455 460 I-Observation
( NCT03923894 461 462 O
BMI NCT03923894 463 466 B-Observation
) NCT03923894 467 468 O
of NCT03923894 469 471 O
less NCT03923894 472 476 B-Eq-Comparison
than NCT03923894 477 481 I-Eq-Comparison
18.5 NCT03923894 482 486 I-Eq-Comparison
kg NCT03923894 487 489 I-Eq-Comparison
/ NCT03923894 490 491 I-Eq-Comparison
m2 NCT03923894 492 494 I-Eq-Comparison
or NCT03923894 495 497 B-Or
greater NCT03923894 498 505 B-Eq-Comparison
than NCT03923894 506 510 I-Eq-Comparison
35 NCT03923894 511 513 I-Eq-Comparison
kg NCT03923894 514 516 I-Eq-Comparison
/ NCT03923894 517 518 I-Eq-Comparison
m2 NCT03923894 519 521 I-Eq-Comparison
at NCT03923894 522 524 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923894 525 528 O
screening NCT03923894 529 538 B-Study

- NCT03923894 541 542 O
Those NCT03923894 544 549 O
who NCT03923894 550 553 O
have NCT03923894 554 558 O
a NCT03923894 559 560 O
clinically NCT03923894 561 571 O
significant NCT03923894 572 583 O
acute NCT03923894 584 589 O
or NCT03923894 590 592 B-Or
chronic NCT03923894 593 600 B-Modifier
cardiovascular NCT03923894 601 615 B-Condition
system NCT03923894 616 622 I-Condition
, NCT03923894 623 624 O
endocrine NCT03923894 625 634 B-Condition
system NCT03923894 635 641 I-Condition|Condition
, NCT03923894 642 643 O
immune NCT03923894 644 650 B-Condition
system NCT03923894 651 657 O
, NCT03923894 658 659 O
respiratory NCT03923894 660 671 B-Condition
system NCT03923894 672 678 I-Condition
, NCT03923894 679 680 O
liver NCT03923894 681 686 B-Condition
biliary NCT03923894 687 694 I-Condition
system NCT03923894 695 701 I-Condition
, NCT03923894 702 703 O
kidney NCT03923894 704 710 B-Modifier
and NCT03923894 711 714 B-Or
urinary NCT03923894 715 722 B-Modifier
system NCT03923894 723 729 B-Condition
, NCT03923894 730 731 O
neuropsychiatry NCT03923894 732 747 B-Condition
, NCT03923894 748 749 O
musculoskeletal NCT03923894 750 765 B-Condition
system NCT03923894 766 772 I-Condition
, NCT03923894 773 774 O
inflammatory NCT03923894 775 787 B-Condition
and NCT03923894 788 791 B-Or
hematologic NCT03923894 792 803 B-Condition

- NCT03923894 806 807 O
Those NCT03923894 809 814 O
who NCT03923894 815 818 O
take NCT03923894 819 823 B-Eq-Comparison
a NCT03923894 824 825 O
medication NCT03923894 826 836 B-Drug
or NCT03923894 837 839 B-Or
health NCT03923894 840 846 B-Drug
function NCT03923894 847 855 I-Drug
food NCT03923894 856 860 I-Drug
that NCT03923894 861 865 O
affects NCT03923894 866 873 O
your NCT03923894 874 878 O
promotion NCT03923894 879 888 B-Condition
of NCT03923894 889 891 I-Condition
immunity NCT03923894 892 900 I-Condition
within NCT03923894 901 907 B-Eq-Comparison
1 NCT03923894 908 909 I-Eq-Comparison
month NCT03923894 910 915 I-Eq-Comparison
prior NCT03923894 916 921 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923894 922 924 O
the NCT03923894 925 928 O
screening NCT03923894 929 938 B-Study

- NCT03923894 941 942 O
Those NCT03923894 944 949 O
who NCT03923894 950 953 O
have NCT03923894 954 958 O
received NCT03923894 959 967 B-Eq-Comparison
antipsychotic NCT03923894 968 981 B-Drug
medication NCT03923894 982 992 I-Drug
within NCT03923894 993 999 B-Eq-Comparison
3 NCT03923894 1000 1001 I-Eq-Comparison
months NCT03923894 1002 1008 I-Eq-Comparison
before NCT03923894 1009 1015 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923894 1016 1025 B-Study

- NCT03923894 1028 1029 O
Those NCT03923894 1031 1036 O
who NCT03923894 1037 1040 O
alcoholic NCT03923894 1041 1050 B-Modifier
or NCT03923894 1051 1053 B-Or
drug NCT03923894 1054 1058 B-Modifier
abuse NCT03923894 1059 1064 B-Condition
suspected NCT03923894 1065 1074 B-Assertion___Assertion-Type-Value:possible

- NCT03923894 1077 1078 O
Those NCT03923894 1080 1085 O
who NCT03923894 1086 1089 O
participated NCT03923894 1090 1102 B-Observation
in NCT03923894 1103 1105 I-Observation
other NCT03923894 1106 1111 I-Observation
clinical NCT03923894 1112 1120 I-Observation
trials NCT03923894 1121 1127 I-Observation
within NCT03923894 1128 1134 B-Eq-Comparison
3 NCT03923894 1135 1136 I-Eq-Comparison
months NCT03923894 1137 1143 I-Eq-Comparison
before NCT03923894 1144 1150 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923894 1151 1160 B-Study

- NCT03923894 1163 1164 O
Laboratory NCT03923894 1166 1176 O
test NCT03923894 1177 1181 O
by NCT03923894 1182 1184 O
show NCT03923894 1185 1189 O
the NCT03923894 1190 1193 O
following NCT03923894 1194 1203 O
results NCT03923894 1204 1211 O

- NCT03923894 1219 1220 O
Aspartate NCT03923894 1222 1231 B-Observation
Transaminase NCT03923894 1232 1244 I-Observation
( NCT03923894 1245 1246 O
AST NCT03923894 1247 1250 B-Observation
) NCT03923894 1251 1252 O
, NCT03923894 1254 1255 O
Alanine NCT03923894 1256 1263 B-Observation
Transaminase NCT03923894 1264 1276 I-Observation
( NCT03923894 1277 1278 O
ALT NCT03923894 1279 1282 B-Observation
) NCT03923894 1283 1284 O
> NCT03923894 1285 1286 B-Eq-Comparison
Reference NCT03923894 1287 1296 I-Eq-Comparison
range NCT03923894 1297 1302 I-Eq-Comparison
3 NCT03923894 1303 1304 I-Eq-Comparison
times NCT03923894 1305 1310 I-Eq-Comparison
upper NCT03923894 1311 1316 I-Eq-Comparison
limit NCT03923894 1317 1322 I-Eq-Comparison

- NCT03923894 1330 1331 O
Serum NCT03923894 1333 1338 B-Observation
Creatinine NCT03923894 1339 1349 I-Observation
> NCT03923894 1350 1351 B-Eq-Comparison
2.0 NCT03923894 1352 1355 I-Eq-Comparison
mg NCT03923894 1356 1358 I-Eq-Comparison
/ NCT03923894 1359 1360 I-Eq-Comparison
dL NCT03923894 1361 1363 I-Eq-Comparison

- NCT03923894 1366 1367 O
Pregnancy NCT03923894 1369 1378 B-Condition
or NCT03923894 1379 1381 B-Or
breast NCT03923894 1382 1388 B-Condition
feeding NCT03923894 1389 1396 I-Condition

- NCT03923894 1399 1400 O
Those NCT03923894 1402 1407 O
who NCT03923894 1408 1411 O
does NCT03923894 1412 1416 B-Negation
n't NCT03923894 1416 1419 O
accept NCT03923894 1420 1426 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03923894 1427 1430 O
implementation NCT03923894 1431 1445 O
of NCT03923894 1446 1448 O
appropriate NCT03923894 1449 1460 O
contraception NCT03923894 1461 1474 B-Drug
of NCT03923894 1475 1477 O
a NCT03923894 1478 1479 O
childbearing NCT03923894 1480 1492 B-Condition
woman NCT03923894 1493 1498 O

- NCT03923894 1501 1502 O
Principal NCT03923894 1504 1513 O
Investigator NCT03923894 1514 1526 O
judged NCT03923894 1527 1533 O
inappropriate NCT03923894 1534 1547 O
for NCT03923894 1548 1551 O
participation NCT03923894 1552 1565 O
in NCT03923894 1566 1568 O
study NCT03923894 1569 1574 O
because NCT03923894 1575 1582 O
of NCT03923894 1583 1585 O
Laboratory NCT03923894 1586 1596 O
test NCT03923894 1597 1601 O
result NCT03923894 1602 1608 O
, NCT03923894 1609 1610 O
etc NCT03923894 1611 1614 O
. NCT03923894 1614 1615 O


Inclusion NCT03920345 0 9 O
Criteria NCT03920345 10 18 O
: NCT03920345 19 20 O

Subject NCT03920345 22 29 O
age NCT03920345 30 33 B-Age
18 NCT03920345 34 36 B-Eq-Comparison
- NCT03920345 37 38 I-Eq-Comparison
85 NCT03920345 39 41 I-Eq-Comparison
years NCT03920345 42 47 I-Eq-Comparison
; NCT03920345 47 48 O

- NCT03920345 51 52 O
SIJ NCT03920345 54 57 B-Condition
arthropathy NCT03920345 58 69 I-Condition
and NCT03920345 70 73 B-And
chronic NCT03920345 74 81 B-Condition
lower NCT03920345 82 87 I-Condition
back NCT03920345 88 92 I-Condition
pain NCT03920345 93 97 I-Condition
( NCT03920345 98 99 O
CLBP NCT03920345 100 104 B-Condition
) NCT03920345 105 106 O
; NCT03920345 107 108 O

- NCT03920345 111 112 O
Patient NCT03920345 114 121 O
to NCT03920345 122 124 O
undergo NCT03920345 125 132 B-Eq-Comparison
endoscopic NCT03920345 133 143 B-Procedure
electrothermic NCT03920345 144 158 I-Procedure
ablation NCT03920345 159 167 I-Procedure
of NCT03920345 168 170 B-And
spinal NCT03920345 171 177 B-Condition
levels NCT03920345 178 184 I-Condition
S1 NCT03920345 185 187 B-Eq-Comparison
- NCT03920345 188 189 I-Eq-Comparison
S3 NCT03920345 190 192 I-Eq-Comparison
. NCT03920345 192 193 O
The NCT03920345 195 198 O
L4 NCT03920345 199 201 B-Modifier
- NCT03920345 202 203 I-Modifier
L5 NCT03920345 204 206 I-Modifier|Modifier
and NCT03920345 207 210 B-Or
/ NCT03920345 211 212 I-Or
or NCT03920345 213 215 I-Or
L5 NCT03920345 216 218 O
- NCT03920345 219 220 I-Modifier
S1 NCT03920345 221 223 I-Modifier
facet NCT03920345 224 229 B-Procedure
joint NCT03920345 230 235 I-Procedure
can NCT03920345 236 239 O
be NCT03920345 240 242 O
included NCT03920345 243 251 O
in NCT03920345 252 254 O
the NCT03920345 255 258 O
ablation NCT03920345 259 267 B-Procedure
per NCT03920345 268 271 O
doctor NCT03920345 272 278 O
discretion NCT03920345 279 289 O
. NCT03920345 289 290 O

- NCT03920345 294 295 O
Correct NCT03920345 297 304 O
spinal NCT03920345 305 311 B-Condition
levels NCT03920345 312 318 I-Condition
( NCT03920345 319 320 O
ranging NCT03920345 321 328 O
L4 NCT03920345 329 331 B-Eq-Comparison
- NCT03920345 332 333 I-Eq-Comparison
S3 NCT03920345 334 336 I-Eq-Comparison
) NCT03920345 337 338 O
to NCT03920345 339 341 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03920345 342 344 I-Assertion___Assertion-Type-Value:hypothetical
treated NCT03920345 345 352 B-Procedure
have NCT03920345 353 357 O
been NCT03920345 358 362 O
confirmed NCT03920345 363 372 O
by NCT03920345 373 375 O
1 NCT03920345 376 377 O
) NCT03920345 378 379 O
diagnostic NCT03920345 380 390 B-Procedure
SIJ NCT03920345 391 394 I-Procedure
injection NCT03920345 395 404 I-Procedure
, NCT03920345 405 406 O
followed NCT03920345 407 415 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03920345 416 418 O
2 NCT03920345 419 420 O
) NCT03920345 421 422 O
diagnostic NCT03920345 423 433 B-Condition
Medial NCT03920345 434 440 B-Modifier
/ NCT03920345 441 442 B-Or
Lateral NCT03920345 443 450 B-Modifier
Branch NCT03920345 451 457 O
Block NCT03920345 458 463 O
at NCT03920345 464 466 O
the NCT03920345 467 470 O
applicable NCT03920345 471 481 O
levels NCT03920345 482 488 O
. NCT03920345 488 489 O

- NCT03920345 493 494 O
The NCT03920345 496 499 O
subject NCT03920345 500 507 O
is NCT03920345 508 510 O
likely NCT03920345 511 517 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920345 518 520 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03920345 521 527 B-Observation
standard NCT03920345 528 536 I-Observation
of NCT03920345 537 539 I-Observation
care NCT03920345 540 544 I-Observation
post NCT03920345 545 549 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03920345 550 551 O
- NCT03920345 553 554 O
operative NCT03920345 555 564 B-Procedure
follow NCT03920345 565 571 O
- NCT03920345 572 573 O
up NCT03920345 574 576 O
for NCT03920345 577 580 O
at NCT03920345 581 583 B-Eq-Comparison
least NCT03920345 584 589 I-Eq-Comparison
24 NCT03920345 590 592 I-Eq-Comparison
months NCT03920345 593 599 I-Eq-Comparison
. NCT03920345 599 600 O

Exclusion NCT03920345 602 611 O
Criteria NCT03920345 612 620 O
: NCT03920345 621 622 O

Patients NCT03920345 624 632 O
receiving NCT03920345 633 642 B-Eq-Comparison
additional NCT03920345 643 653 O
invasive NCT03920345 654 662 B-Procedure
back NCT03920345 663 667 I-Procedure
surgery NCT03920345 668 675 I-Procedure
after NCT03920345 676 681 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03920345 682 685 O
study NCT03920345 686 691 B-Study
treatment NCT03920345 692 701 O
. NCT03920345 701 702 O

- NCT03920345 706 707 O
Inability NCT03920345 709 718 B-Negation
to NCT03920345 719 721 B-Assertion___Assertion-Type-Value:hypothetical
complete NCT03920345 722 730 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03920345 731 737 O
- NCT03920345 738 739 O
up NCT03920345 740 742 O
visits NCT03920345 743 749 B-Encounter
or NCT03920345 750 752 O
required NCT03920345 753 761 O
questionnaires NCT03920345 762 776 O
. NCT03920345 776 777 O

- NCT03920345 781 782 O
Non NCT03920345 784 787 O
- NCT03920345 788 789 O
compliant NCT03920345 790 799 O
patients NCT03920345 800 808 O

- NCT03920345 811 812 O
Difficult NCT03920345 814 823 B-Modifier
or NCT03920345 824 826 B-Or
impossible NCT03920345 827 837 B-Modifier
communication NCT03920345 838 851 B-Condition
with NCT03920345 852 856 O
the NCT03920345 857 860 O
patient NCT03920345 861 868 O

- NCT03920345 871 872 O
Breastfeeding NCT03920345 874 887 B-Condition
, NCT03920345 888 889 O
pregnant NCT03920345 890 898 B-Condition
or NCT03920345 899 901 B-Or
patients NCT03920345 902 910 O
who NCT03920345 911 914 O
plan NCT03920345 915 919 B-Assertion___Assertion-Type-Value:intention
a NCT03920345 920 921 O
pregnancy NCT03920345 922 931 B-Condition
while NCT03920345 932 937 B-Temporal-Connection___Temporal-Connection-Type-Value:during
participating NCT03920345 938 951 O
in NCT03920345 952 954 O
the NCT03920345 955 958 O
study NCT03920345 959 964 B-Study

- NCT03920345 967 968 O
Systemic NCT03920345 970 978 B-Modifier
neurological NCT03920345 979 991 B-Condition
disorders NCT03920345 992 1001 I-Condition
with NCT03920345 1002 1006 B-And
mobility NCT03920345 1007 1015 B-Condition
limitations NCT03920345 1016 1027 I-Condition
( NCT03920345 1028 1029 O
e. NCT03920345 1030 1032 O
g. NCT03920345 1033 1035 O
advanced NCT03920345 1037 1045 O
Parkinson NCT03920345 1046 1055 B-Condition
's NCT03920345 1055 1057 O
disease NCT03920345 1058 1065 I-Condition
or NCT03920345 1066 1068 B-Or
multiple NCT03920345 1069 1077 B-Condition
sclerosis NCT03920345 1078 1087 I-Condition
) NCT03920345 1088 1089 O

- NCT03920345 1093 1094 O
Patients NCT03920345 1096 1104 O
with NCT03920345 1105 1109 O
incompatibilities NCT03920345 1110 1127 O
or NCT03920345 1128 1130 O
known NCT03920345 1131 1136 O
limitations NCT03920345 1137 1148 O
that NCT03920345 1149 1153 O
make NCT03920345 1154 1158 O
participation NCT03920345 1159 1172 O
impossible NCT03920345 1173 1183 O

- NCT03920345 1186 1187 O
Patients NCT03920345 1189 1197 O
after NCT03920345 1198 1203 O
stabilization NCT03920345 1204 1217 O
with NCT03920345 1218 1222 O
implants NCT03920345 1223 1231 B-Condition
on NCT03920345 1232 1234 O
thoracic NCT03920345 1235 1243 B-Modifier
or NCT03920345 1244 1246 B-Or
lumbar NCT03920345 1247 1253 B-Modifier
spine NCT03920345 1254 1259 I-Modifier
. NCT03920345 1259 1260 O

- NCT03920345 1264 1265 O
Inability NCT03920345 1267 1276 O
to NCT03920345 1277 1279 O
provide NCT03920345 1280 1287 O
informed NCT03920345 1288 1296 O
consent NCT03920345 1297 1304 O
without NCT03920345 1305 1312 O
a NCT03920345 1313 1314 O
legally NCT03920345 1315 1322 O
authorized NCT03920345 1323 1333 O
representative NCT03920345 1334 1348 O
. NCT03920345 1348 1349 O


Inclusion NCT03927833 0 9 O
Criteria NCT03927833 10 18 O
: NCT03927833 19 20 O

1 NCT03927833 24 25 O
. NCT03927833 25 26 O
Infants NCT03927833 28 35 B-Family-Member___Family-Member-Type:child
is NCT03927833 36 38 O
inborn NCT03927833 39 45 B-Condition

2 NCT03927833 48 49 O
. NCT03927833 49 50 O
Infant NCT03927833 52 58 B-Family-Member___Family-Member-Type:child
is NCT03927833 59 61 B-Observation
≤ NCT03927833 62 63 B-Eq-Comparison
750 NCT03927833 64 67 I-Eq-Comparison
grams NCT03927833 68 73 O
at NCT03927833 74 76 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03927833 77 82 B-Birth
and NCT03927833 83 86 B-Or
/ NCT03927833 87 88 I-Or
or NCT03927833 89 91 I-Or
< NCT03927833 92 93 B-Eq-Comparison
27 NCT03927833 94 96 I-Eq-Comparison
weeks NCT03927833 97 102 I-Eq-Comparison
gestation NCT03927833 103 112 B-Observation
at NCT03927833 113 115 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03927833 116 121 B-Birth
by NCT03927833 122 124 O
best NCT03927833 125 129 O
OB NCT03927833 130 132 O
estimate NCT03927833 133 141 O

3 NCT03927833 144 145 O
. NCT03927833 145 146 O
Infant NCT03927833 148 154 B-Family-Member___Family-Member-Type:child
is NCT03927833 155 157 O
12 NCT03927833 158 160 B-Eq-Comparison
- NCT03927833 161 162 I-Eq-Comparison
36 NCT03927833 163 165 I-Eq-Comparison
hours NCT03927833 166 171 I-Eq-Comparison
of NCT03927833 172 174 O
age NCT03927833 175 178 B-Age
. NCT03927833 178 179 O

Exclusion NCT03927833 181 190 O
Criteria NCT03927833 191 199 O
: NCT03927833 200 201 O

1 NCT03927833 205 206 O
. NCT03927833 206 207 O
Unable NCT03927833 209 215 O
to NCT03927833 216 218 O
enroll NCT03927833 219 225 B-Assertion___Assertion-Type-Value:hypothetical
infant NCT03927833 226 232 B-Family-Member___Family-Member-Type:child
by NCT03927833 233 235 B-Eq-Comparison
36 NCT03927833 236 238 I-Eq-Comparison
hours NCT03927833 239 244 I-Eq-Comparison
of NCT03927833 245 247 O
age NCT03927833 248 251 B-Age

2 NCT03927833 254 255 O
. NCT03927833 255 256 O
Previous NCT03927833 258 266 B-Eq-Comparison
phototherapy NCT03927833 267 279 B-Procedure

3 NCT03927833 282 283 O
. NCT03927833 283 284 O
Known NCT03927833 286 291 O
hemolytic NCT03927833 292 301 B-Condition
disease NCT03927833 302 309 I-Condition

4 NCT03927833 312 313 O
. NCT03927833 313 314 O
TSB NCT03927833 316 319 B-Observation
reported NCT03927833 320 328 O
as NCT03927833 329 331 O
> NCT03927833 332 333 B-Eq-Comparison
6.0 NCT03927833 334 337 I-Eq-Comparison
mg NCT03927833 338 340 I-Eq-Comparison
/ NCT03927833 341 342 I-Eq-Comparison
dL NCT03927833 343 345 I-Eq-Comparison
before NCT03927833 346 352 B-Temporal-Connection___Temporal-Connection-Type-Value:before
12 NCT03927833 353 355 B-Eq-Comparison
hours NCT03927833 356 361 I-Eq-Comparison
age NCT03927833 362 365 B-Age

5 NCT03927833 368 369 O
. NCT03927833 369 370 O
Major NCT03927833 372 377 B-Condition
anomaly NCT03927833 378 385 I-Condition

6 NCT03927833 388 389 O
. NCT03927833 389 390 O
Overt NCT03927833 392 397 B-Condition
nonbacterial NCT03927833 398 410 I-Condition
infection NCT03927833 411 420 I-Condition

7 NCT03927833 423 424 O
. NCT03927833 424 425 O
Infant NCT03927833 427 433 B-Family-Member___Family-Member-Type:child
is NCT03927833 434 436 O
likely NCT03927833 437 443 B-Risk
to NCT03927833 444 446 O
expire NCT03927833 447 453 B-Death
soon NCT03927833 454 458 O
: NCT03927833 459 460 O
Limiting NCT03927833 461 469 O
or NCT03927833 470 472 O
withdrawal NCT03927833 473 483 B-Negation
of NCT03927833 484 486 O
intensive NCT03927833 487 496 B-Encounter
care NCT03927833 497 501 I-Encounter
is NCT03927833 502 504 O
being NCT03927833 505 510 O
recommended NCT03927833 511 522 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927833 523 525 O
the NCT03927833 526 529 O
parents NCT03927833 530 537 O
, NCT03927833 538 539 O
the NCT03927833 540 543 O
parents NCT03927833 544 551 O
are NCT03927833 552 555 O
requesting NCT03927833 556 566 O
withdrawal NCT03927833 567 577 O
of NCT03927833 578 580 O
care NCT03927833 581 585 O
, NCT03927833 586 587 O
or NCT03927833 588 590 B-Or
the NCT03927833 591 594 O
pH NCT03927833 595 597 B-Observation
is NCT03927833 598 600 O
< NCT03927833 601 602 B-Eq-Comparison
6.80 NCT03927833 603 607 I-Eq-Comparison
or NCT03927833 608 610 O
persistent NCT03927833 611 621 B-Condition
bradycardia NCT03927833 622 633 I-Condition
with NCT03927833 634 638 B-And
hypoxemia NCT03927833 639 648 B-Condition
for NCT03927833 649 652 O
> NCT03927833 653 654 B-Eq-Comparison
2 NCT03927833 655 656 I-Eq-Comparison
h. NCT03927833 657 659 O

Inclusion NCT03929822 0 9 O
Criteria NCT03929822 10 18 O
: NCT03929822 19 20 O

- NCT03929822 24 25 O
Women NCT03929822 27 32 O
called NCT03929822 33 39 O
back NCT03929822 40 44 O
from NCT03929822 45 49 O
a NCT03929822 50 51 O
screening NCT03929822 52 61 B-Procedure
mammography NCT03929822 62 73 I-Procedure
by NCT03929822 74 76 O
either NCT03929822 77 83 O
FFDM NCT03929822 84 88 B-Procedure
or NCT03929822 89 91 B-Or
tomosynthesis NCT03929822 92 105 B-Procedure
with NCT03929822 106 110 B-And
soft NCT03929822 111 115 B-Condition
tissue NCT03929822 116 122 I-Condition
abnormalities NCT03929822 123 136 I-Condition
including NCT03929822 137 146 O
masses NCT03929822 147 153 B-Condition
, NCT03929822 154 155 O
asymmetries NCT03929822 156 167 B-Condition
, NCT03929822 168 169 O
focal NCT03929822 170 175 B-Condition
asymmetries NCT03929822 176 187 I-Condition
or NCT03929822 188 190 B-Or
architectural NCT03929822 191 204 B-Condition
distortion NCT03929822 205 215 I-Condition
with NCT03929822 216 220 B-Modifier
or NCT03929822 221 223 B-Or
without NCT03929822 224 231 B-Negation
calcifications NCT03929822 232 246 B-Condition
. NCT03929822 246 247 O
Patients NCT03929822 249 257 O
will NCT03929822 258 262 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929822 263 265 I-Assertion___Assertion-Type-Value:hypothetical
questioned NCT03929822 266 276 I-Assertion___Assertion-Type-Value:hypothetical
regarding NCT03929822 277 286 O
the NCT03929822 287 290 O
possibility NCT03929822 291 302 O
of NCT03929822 303 305 O
pregnancy NCT03929822 306 315 B-Condition
and NCT03929822 316 319 B-And
will NCT03929822 320 324 B-Assertion___Assertion-Type-Value:hypothetical
need NCT03929822 325 329 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03929822 330 331 O
negative NCT03929822 332 340 O
pregnancy NCT03929822 341 350 B-Observation
test NCT03929822 351 355 I-Observation
prior NCT03929822 356 361 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03929822 362 365 O
study NCT03929822 366 371 B-Study
intervention NCT03929822 372 384 O
. NCT03929822 384 385 O

Exclusion NCT03929822 387 396 O
Criteria NCT03929822 397 405 O
: NCT03929822 406 407 O

- NCT03929822 411 412 O
Age NCT03929822 414 417 B-Age
< NCT03929822 418 419 B-Eq-Comparison
30 NCT03929822 420 422 I-Eq-Comparison
years NCT03929822 423 428 I-Eq-Comparison
old NCT03929822 429 432 O

- NCT03929822 435 436 O
Screening NCT03929822 438 447 B-Procedure
mammography NCT03929822 448 459 I-Procedure
with NCT03929822 460 464 O
only NCT03929822 465 469 O
calcifications NCT03929822 470 484 B-Condition
abnormalities NCT03929822 485 498 I-Condition

- NCT03929822 501 502 O
Male NCT03929822 504 508 O
patients NCT03929822 509 517 O

- NCT03929822 520 521 O
Pregnant NCT03929822 523 531 B-Condition
or NCT03929822 532 534 B-Or
lactating NCT03929822 535 544 B-Condition
patients NCT03929822 545 553 O

- NCT03929822 556 557 O
Patients NCT03929822 559 567 O
with NCT03929822 568 572 O
any NCT03929822 573 576 O
allergy NCT03929822 577 584 B-Allergy
to NCT03929822 585 587 O
iodinated NCT03929822 588 597 O
contrast NCT03929822 598 606 O

- NCT03929822 609 610 O
Patients NCT03929822 612 620 O
with NCT03929822 621 625 O
eGFR NCT03929822 626 630 B-Observation
< NCT03929822 631 632 B-Eq-Comparison
45 NCT03929822 633 635 I-Eq-Comparison

- NCT03929822 639 640 O
Patients NCT03929822 642 650 O
that NCT03929822 651 655 O
may NCT03929822 656 659 B-Assertion___Assertion-Type-Value:possible
be NCT03929822 660 662 O
treated NCT03929822 663 670 B-Procedure
with NCT03929822 671 675 O
radioactive NCT03929822 676 687 B-Procedure
iodine NCT03929822 688 694 I-Procedure

Inclusion NCT03924453 0 9 O
Criteria NCT03924453 10 18 O
: NCT03924453 19 20 O

1 NCT03924453 24 25 O
. NCT03924453 25 26 O
Female NCT03924453 28 34 O
( NCT03924453 35 36 O
mandatory NCT03924453 37 46 O
) NCT03924453 47 48 O

2 NCT03924453 52 53 O
. NCT03924453 53 54 O
Not NCT03924453 56 59 B-Negation
currently NCT03924453 60 69 B-Eq-Comparison
pregnant NCT03924453 70 78 B-Condition
or NCT03924453 79 81 B-Or
nursing NCT03924453 82 89 B-Condition
( NCT03924453 90 91 O
mandatory NCT03924453 92 101 O
) NCT03924453 102 103 O

3 NCT03924453 107 108 O
. NCT03924453 108 109 O
Aged NCT03924453 111 115 B-Age
21 NCT03924453 116 118 B-Eq-Comparison
- NCT03924453 119 120 I-Eq-Comparison
45 NCT03924453 121 123 O
( NCT03924453 124 125 O
advanced NCT03924453 126 134 O
age NCT03924453 135 138 O
can NCT03924453 139 142 O
hinder NCT03924453 143 149 O
hormone NCT03924453 150 157 O
levels NCT03924453 158 164 O
) NCT03924453 165 166 O

4 NCT03924453 170 171 O
. NCT03924453 171 172 O
Not NCT03924453 174 177 B-Negation
be NCT03924453 178 180 O
diagnosed NCT03924453 181 190 O
as NCT03924453 191 193 O
sub NCT03924453 194 197 B-Condition
fertile NCT03924453 198 205 I-Condition
( NCT03924453 206 207 O
infertility NCT03924453 208 219 O
causes NCT03924453 220 226 O
inconsistent NCT03924453 227 239 O
hormone NCT03924453 240 247 O
levels NCT03924453 248 254 O
) NCT03924453 255 256 O

5 NCT03924453 260 261 O
. NCT03924453 261 262 O
Not NCT03924453 264 267 B-Negation
have NCT03924453 268 272 O
used NCT03924453 273 277 O
any NCT03924453 278 281 O
form NCT03924453 282 286 O
of NCT03924453 287 289 O
hormonal NCT03924453 290 298 B-Procedure
birth NCT03924453 299 304 I-Procedure
control NCT03924453 305 312 I-Procedure
in NCT03924453 313 315 O
the NCT03924453 316 319 B-Eq-Comparison
past NCT03924453 320 324 I-Eq-Comparison
2 NCT03924453 325 326 I-Eq-Comparison
months NCT03924453 327 333 I-Eq-Comparison
( NCT03924453 334 335 O
mandatory NCT03924453 336 345 O
) NCT03924453 346 347 O

6 NCT03924453 351 352 O
. NCT03924453 352 353 O
Currently NCT03924453 355 364 B-Eq-Comparison
trying NCT03924453 365 371 B-Assertion___Assertion-Type-Value:intention
to NCT03924453 372 374 I-Assertion___Assertion-Type-Value:intention
conceive NCT03924453 375 383 B-Condition
( NCT03924453 384 385 O
ideal NCT03924453 386 391 O
but NCT03924453 392 395 O
not NCT03924453 396 399 O
required NCT03924453 400 408 O
) NCT03924453 409 410 O

7 NCT03924453 414 415 O
. NCT03924453 415 416 O
Currently NCT03924453 418 427 B-Eq-Comparison
reside NCT03924453 428 434 O
in NCT03924453 435 437 O
the NCT03924453 438 441 O
US NCT03924453 442 444 O
( NCT03924453 445 446 O
mandatory NCT03924453 447 456 O
, NCT03924453 457 458 O
this NCT03924453 459 463 O
study NCT03924453 464 469 O
is NCT03924453 470 472 O
for NCT03924453 473 476 O
US NCT03924453 477 479 O
residents NCT03924453 480 489 O
only NCT03924453 490 494 O
) NCT03924453 495 496 O

Exclusion NCT03924453 498 507 O
Criteria NCT03924453 508 516 O
: NCT03924453 517 518 O

1 NCT03924453 522 523 O
. NCT03924453 523 524 O
Male NCT03924453 526 530 O

2 NCT03924453 533 534 O
. NCT03924453 534 535 O
Pregnant NCT03924453 537 545 B-Condition

3 NCT03924453 548 549 O
. NCT03924453 549 550 O
Nursing NCT03924453 552 559 B-Condition

Inclusion NCT03921112 0 9 O
Criteria NCT03921112 10 18 O
: NCT03921112 19 20 O

- NCT03921112 24 25 O
Mechanically NCT03921112 27 39 B-Procedure
ventilated NCT03921112 40 50 I-Procedure
patients NCT03921112 51 59 O

- NCT03921112 62 63 O
ASAI NCT03921112 65 69 B-Condition
, NCT03921112 70 71 O
ASAII NCT03921112 72 77 B-Condition
, NCT03921112 78 79 O
ASAIII NCT03921112 80 86 B-Condition

Exclusion NCT03921112 87 96 O
Criteria NCT03921112 97 105 O
: NCT03921112 106 107 O

- NCT03921112 111 112 O
Patients NCT03921112 114 122 O
or NCT03921112 123 125 O
gurdians NCT03921112 126 134 O
refuse NCT03921112 135 141 O

- NCT03921112 144 145 O
Patients NCT03921112 147 155 O
with NCT03921112 156 160 O
pneumthorax NCT03921112 161 172 B-Condition

- NCT03921112 175 176 O
Patients NCT03921112 178 186 O
with NCT03921112 187 191 O
pleural NCT03921112 192 199 B-Condition
effusion NCT03921112 200 208 I-Condition

- NCT03921112 211 212 O
Patients NCT03921112 214 222 O
with NCT03921112 223 227 O
surgical NCT03921112 228 236 B-Condition
emphysema NCT03921112 237 246 I-Condition

- NCT03921112 249 250 O
Glasco NCT03921112 252 258 B-Observation
coma NCT03921112 259 263 I-Observation
score NCT03921112 264 269 B-Eq-Comparison
more NCT03921112 270 274 I-Eq-Comparison
than NCT03921112 275 279 I-Eq-Comparison
8 NCT03921112 280 281 I-Eq-Comparison

- NCT03921112 285 286 O
Patients NCT03921112 288 296 O
on NCT03921112 297 299 B-Eq-Comparison
high NCT03921112 300 304 O
inotropic NCT03921112 305 314 B-Drug
support NCT03921112 315 322 I-Drug

- NCT03921112 325 326 O
patients NCT03921112 328 336 O
with NCT03921112 337 341 O
diaphragmatic NCT03921112 342 355 B-Condition
paralysis NCT03921112 356 365 I-Condition

Inclusion NCT03928678 0 9 O
Criteria NCT03928678 10 18 O
: NCT03928678 19 20 O

- NCT03928678 24 25 O
Age NCT03928678 27 30 B-Age
≤ NCT03928678 31 32 B-Eq-Comparison
60 NCT03928678 33 35 I-Eq-Comparison
years NCT03928678 36 41 I-Eq-Comparison
, NCT03928678 42 43 O

- NCT03928678 47 48 O
Good NCT03928678 50 54 O
nutrition NCT03928678 55 64 O
, NCT03928678 65 66 O

- NCT03928678 70 71 O
No NCT03928678 73 75 B-Negation
systemic NCT03928678 76 84 B-Condition
infection NCT03928678 85 94 I-Condition
and NCT03928678 95 98 B-And

- NCT03928678 101 102 O
Elective NCT03928678 104 112 O
laparoscopic NCT03928678 113 125 B-Procedure
surgery NCT03928678 126 133 I-Procedure

Exclusion NCT03928678 134 143 O
Criteria NCT03928678 144 152 O
: NCT03928678 153 154 O

- NCT03928678 158 159 O
Age NCT03928678 161 164 B-Age
> NCT03928678 165 166 B-Eq-Comparison
75 NCT03928678 167 169 I-Eq-Comparison
years NCT03928678 170 175 I-Eq-Comparison
, NCT03928678 176 177 O

- NCT03928678 181 182 O
Malnutrition NCT03928678 184 196 B-Condition
or NCT03928678 197 199 B-Condition|Or
an NCT03928678 200 202 O
organ NCT03928678 203 208 O
system NCT03928678 209 215 I-Condition
infection NCT03928678 216 225 I-Condition

- NCT03928678 228 229 O
Associated NCT03928678 231 241 O
with NCT03928678 242 246 O
obstruction NCT03928678 247 258 B-Condition
, NCT03928678 259 260 O
bleeding NCT03928678 261 269 B-Condition
, NCT03928678 270 271 O
emergency NCT03928678 272 281 B-Procedure
surgery NCT03928678 282 289 I-Procedure
or NCT03928678 290 292 B-Or
other NCT03928678 293 298 O
surgical NCT03928678 299 307 B-Procedure
intervention NCT03928678 308 320 I-Procedure

- NCT03928678 323 324 O
Tumor NCT03928678 326 331 B-Condition
with NCT03928678 332 336 I-Condition
extensive NCT03928678 337 346 I-Condition
metastasis NCT03928678 347 357 I-Condition

- NCT03928678 360 361 O
Prior NCT03928678 363 368 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928678 369 371 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03928678 372 379 B-Procedure
, NCT03928678 380 381 O
patient NCT03928678 382 389 O
was NCT03928678 390 393 O
fasting NCT03928678 394 401 B-Observation
, NCT03928678 402 403 O
underwent NCT03928678 404 413 B-Eq-Comparison
gastrointestinal NCT03928678 414 430 B-Procedure
decompression NCT03928678 431 444 I-Procedure
and NCT03928678 445 448 B-And
received NCT03928678 449 457 B-Eq-Comparison
nutritional NCT03928678 458 469 B-Procedure
support NCT03928678 470 477 I-Procedure

- NCT03928678 480 481 O
Previous NCT03928678 483 491 B-Eq-Comparison
history NCT03928678 492 499 I-Eq-Comparison
of NCT03928678 500 502 O
abdominal NCT03928678 503 512 B-Procedure
surgery NCT03928678 513 520 I-Procedure

- NCT03928678 523 524 O
Patient NCT03928678 526 533 O
have NCT03928678 534 538 O
previously NCT03928678 539 549 B-Eq-Comparison
undergone NCT03928678 550 559 I-Eq-Comparison
gastrostomy NCT03928678 560 571 B-Procedure

Inclusion NCT03921853 0 9 O
Criteria NCT03921853 10 18 O
: NCT03921853 19 20 O

Inclusion NCT03921853 22 31 O
Criteria NCT03921853 32 40 O
: NCT03921853 41 42 O

- NCT03921853 46 47 O
Older NCT03921853 49 54 B-Eq-Comparison
than NCT03921853 55 59 I-Eq-Comparison
18 NCT03921853 60 62 I-Eq-Comparison
and NCT03921853 63 66 O
younger NCT03921853 67 74 O
and NCT03921853 75 78 B-And
≤ NCT03921853 79 80 B-Eq-Comparison
65 NCT03921853 81 83 I-Eq-Comparison
years NCT03921853 84 89 I-Eq-Comparison
of NCT03921853 90 92 O
age NCT03921853 93 96 B-Age
. NCT03921853 96 97 O

- NCT03921853 101 102 O
With NCT03921853 104 108 O
risk NCT03921853 109 113 B-Risk
factors NCT03921853 114 121 O
to NCT03921853 122 124 O
Metabolic NCT03921853 125 134 B-Condition
syndrome NCT03921853 135 143 I-Condition

- NCT03921853 146 147 O
With NCT03921853 149 153 O
obesity NCT03921853 154 161 B-Condition
and NCT03921853 162 165 B-And
morbid NCT03921853 166 172 B-Condition
obesity NCT03921853 173 180 I-Condition
condition NCT03921853 181 190 O

- NCT03921853 193 194 O
Medical NCT03921853 196 203 O
authorization NCT03921853 204 217 O
by NCT03921853 218 220 O
a NCT03921853 221 222 O
physician NCT03921853 223 232 O
. NCT03921853 232 233 O

Exclusion NCT03921853 235 244 O
Criteria NCT03921853 245 253 O
: NCT03921853 254 255 O

- NCT03921853 259 260 O
Physical NCT03921853 262 270 B-Condition
limitations NCT03921853 271 282 I-Condition
( NCT03921853 283 284 O
e. NCT03921853 285 287 O
g. NCT03921853 288 290 O
, NCT03921853 291 292 O
restricting NCT03921853 293 304 B-Modifier
injuries NCT03921853 305 313 B-Condition
of NCT03921853 314 316 O
the NCT03921853 317 320 O
musculoskeletal NCT03921853 321 336 B-Modifier
system NCT03921853 337 343 I-Modifier
, NCT03921853 344 345 O
or NCT03921853 346 348 O
dependent NCT03921853 349 358 B-Observation
of NCT03921853 359 361 I-Observation
a NCT03921853 362 363 I-Observation
third NCT03921853 364 369 I-Observation
person NCT03921853 370 376 I-Observation
) NCT03921853 377 378 O
. NCT03921853 379 380 O

- NCT03921853 384 385 I-Condition
Exercise NCT03921853 387 395 B-Condition
- NCT03921853 396 397 O
related NCT03921853 398 405 I-Condition
dyspnoea NCT03921853 406 414 I-Condition
or NCT03921853 415 417 B-Or
respiratory NCT03921853 418 429 B-Condition
alterations NCT03921853 430 441 I-Condition
. NCT03921853 441 442 O

- NCT03921853 446 447 O
Chronic NCT03921853 449 456 B-Modifier
heart NCT03921853 457 462 B-Condition
disease NCT03921853 463 470 I-Condition
with NCT03921853 471 475 O
any NCT03921853 476 479 O
worsening NCT03921853 480 489 O
in NCT03921853 490 492 O
the NCT03921853 493 496 O
last NCT03921853 497 501 B-Eq-Comparison
month NCT03921853 502 507 I-Eq-Comparison
. NCT03921853 507 508 O

- NCT03921853 512 513 O
Adherence NCT03921853 515 524 B-Observation
rate NCT03921853 525 529 I-Observation
of NCT03921853 530 532 O
less NCT03921853 533 537 B-Eq-Comparison
than NCT03921853 538 542 I-Eq-Comparison
80 NCT03921853 543 545 I-Eq-Comparison
% NCT03921853 546 547 O
of NCT03921853 548 550 O
the NCT03921853 551 554 O
total NCT03921853 555 560 O
interventions NCT03921853 561 574 O
. NCT03921853 574 575 O

Inclusion NCT03923088 0 9 O
Criteria NCT03923088 10 18 O
: NCT03923088 19 20 O

- NCT03923088 24 25 O
Children NCT03923088 27 35 O
: NCT03923088 36 37 O
6 NCT03923088 38 39 B-Eq-Comparison
to NCT03923088 40 42 I-Eq-Comparison
9 NCT03923088 43 44 I-Eq-Comparison
years NCT03923088 45 50 I-Eq-Comparison
old NCT03923088 51 54 B-Age
children NCT03923088 55 63 O
. NCT03923088 63 64 O
Teeth NCT03923088 66 71 O
: NCT03923088 72 73 O
tooth NCT03923088 74 79 O
requiring NCT03923088 80 89 B-Assertion___Assertion-Type-Value:hypothetical
dental NCT03923088 90 96 B-Procedure
treatment NCT03923088 97 106 I-Procedure

Exclusion NCT03923088 107 116 O
Criteria NCT03923088 117 125 O
: NCT03923088 126 127 O

- NCT03923088 131 132 O
Children NCT03923088 134 142 O
having NCT03923088 143 149 B-And
allergy NCT03923088 150 157 B-Allergy
to NCT03923088 158 160 O
local NCT03923088 161 166 B-Procedure
anaesthesia NCT03923088 167 178 I-Procedure
or NCT03923088 179 181 B-Or
systemic NCT03923088 182 190 B-Modifier
problem NCT03923088 191 198 B-Condition
. NCT03923088 198 199 O
Refusal NCT03923088 201 208 O
of NCT03923088 209 211 O
participation NCT03923088 212 225 O
Mentally NCT03923088 226 234 B-Condition
ill NCT03923088 235 238 I-Condition
or NCT03923088 239 241 B-Or
mentally NCT03923088 242 250 B-Condition
retarded NCT03923088 251 259 I-Condition
children NCT03923088 260 268 O

Inclusion NCT03921489 0 9 O
Criteria NCT03921489 10 18 O
: NCT03921489 19 20 O

- NCT03921489 24 25 O
BME NCT03921489 27 30 B-Condition
diagnosed NCT03921489 31 40 O
on NCT03921489 41 43 O
MRI NCT03921489 44 47 B-Procedure

- NCT03921489 50 51 O
Pain NCT03921489 53 57 B-Condition
to NCT03921489 58 60 O
that NCT03921489 61 65 O
area NCT03921489 66 70 B-Modifier

- NCT03921489 73 74 O
Failed NCT03921489 76 82 O
3 NCT03921489 83 84 B-Eq-Comparison
months NCT03921489 85 91 I-Eq-Comparison
of NCT03921489 92 94 O
conservative NCT03921489 95 107 B-Procedure
treatment NCT03921489 108 117 I-Procedure

Exclusion NCT03921489 118 127 O
Criteria NCT03921489 128 136 O
: NCT03921489 137 138 O

- NCT03921489 142 143 O
Patient NCT03921489 145 152 O
< NCT03921489 153 154 B-Eq-Comparison
18 NCT03921489 155 157 I-Eq-Comparison
years NCT03921489 158 163 I-Eq-Comparison
of NCT03921489 164 166 O
age NCT03921489 167 170 B-Age

- NCT03921489 173 174 O
Presence NCT03921489 176 184 O
of NCT03921489 185 187 O
osteomyelitis NCT03921489 188 201 B-Condition
of NCT03921489 202 204 O
poor NCT03921489 205 209 O
surgical NCT03921489 210 218 O
candidates NCT03921489 219 229 O
due NCT03921489 230 233 O
to NCT03921489 234 236 O
comorbidities NCT03921489 237 250 B-Condition
such NCT03921489 251 255 O
as NCT03921489 256 258 O
diabetics NCT03921489 259 268 B-Condition
with NCT03921489 269 273 B-And
an NCT03921489 274 276 O
HbA1c NCT03921489 277 282 B-Observation
of NCT03921489 283 285 O
> NCT03921489 286 287 B-Eq-Comparison
8 NCT03921489 288 289 I-Eq-Comparison
% NCT03921489 290 291 O

- NCT03921489 294 295 O
Patient NCT03921489 297 304 O
with NCT03921489 305 309 O
previous NCT03921489 310 318 B-Eq-Comparison
foot NCT03921489 319 323 B-Modifier
and NCT03921489 324 327 B-Or
ankle NCT03921489 328 333 B-Modifier
surgeries NCT03921489 334 343 B-Procedure
that NCT03921489 344 348 O
may NCT03921489 349 352 O
interfere NCT03921489 353 362 O
with NCT03921489 363 367 O
future NCT03921489 368 374 O
outcomes NCT03921489 375 383 O

Inclusion NCT03926494 0 9 O
Criteria NCT03926494 10 18 O
: NCT03926494 19 20 O

- NCT03926494 24 25 O
All NCT03926494 27 30 O
comatose NCT03926494 31 39 B-Condition
patients NCT03926494 40 48 O
( NCT03926494 49 50 O
Glasgow NCT03926494 51 58 B-Observation
coma NCT03926494 59 63 I-Observation
score NCT03926494 64 69 I-Observation
< NCT03926494 70 71 B-Eq-Comparison
8 NCT03926494 72 73 I-Eq-Comparison
) NCT03926494 74 75 O
due NCT03926494 76 79 O
to NCT03926494 80 82 O
carbon NCT03926494 83 89 B-Condition
monoxide NCT03926494 90 98 I-Condition
poisoning NCT03926494 99 108 I-Condition
, NCT03926494 109 110 O
treated NCT03926494 111 118 O
by NCT03926494 119 121 O
hyperbaric NCT03926494 122 132 B-Procedure
oxygen NCT03926494 133 139 I-Procedure
therapy NCT03926494 140 147 I-Procedure
in NCT03926494 148 150 O
a NCT03926494 151 152 O
tertiary NCT03926494 153 161 O
hospital NCT03926494 162 170 O
in NCT03926494 171 173 O
Île NCT03926494 174 177 O
de NCT03926494 178 180 O
France NCT03926494 181 187 O
area NCT03926494 188 192 O
; NCT03926494 192 193 O

- NCT03926494 196 197 O
Aged NCT03926494 199 203 B-Age
≥ NCT03926494 204 205 B-Eq-Comparison
18 NCT03926494 206 208 I-Eq-Comparison
years NCT03926494 209 214 I-Eq-Comparison
; NCT03926494 214 215 O

- NCT03926494 218 219 O
Hospitalized NCT03926494 221 233 B-Encounter
in NCT03926494 234 236 O
hyperbaric NCT03926494 237 247 O
medicine NCT03926494 248 256 O
unity NCT03926494 257 262 O
of NCT03926494 263 265 O
Raymond NCT03926494 266 273 O
Poincaré NCT03926494 274 282 O
hospital NCT03926494 283 291 O
in NCT03926494 292 294 O
Garches NCT03926494 295 302 O
. NCT03926494 302 303 O

Exclusion NCT03926494 305 314 O
Criteria NCT03926494 315 323 O
: NCT03926494 324 325 O

- NCT03926494 329 330 O
Pregnant NCT03926494 332 340 B-Condition
woman NCT03926494 341 346 O
; NCT03926494 346 347 O

- NCT03926494 350 351 O
Patient NCT03926494 353 360 O
present NCT03926494 361 368 O
clinical NCT03926494 369 377 O
signes NCT03926494 378 384 B-Assertion___Assertion-Type-Value:possible
of NCT03926494 385 387 O
stroke NCT03926494 388 394 B-Condition
and NCT03926494 395 398 B-And
without NCT03926494 399 406 B-Negation
CO NCT03926494 407 409 B-Condition
detection NCT03926494 410 419 I-Condition
. NCT03926494 419 420 O

In NCT03926494 422 424 O
case NCT03926494 425 429 O
of NCT03926494 430 432 O
unusable NCT03926494 433 441 O
data NCT03926494 442 446 O
, NCT03926494 447 448 O
patient NCT03926494 449 456 O
will NCT03926494 457 461 O
be NCT03926494 462 464 O
excluded NCT03926494 465 473 O
from NCT03926494 474 478 O
study NCT03926494 479 484 O
. NCT03926494 484 485 O

Inclusion NCT03927638 0 9 O
Criteria NCT03927638 10 18 O
: NCT03927638 19 20 O

- NCT03927638 24 25 O
healthy NCT03927638 27 34 B-Condition
adult NCT03927638 35 40 O

Exclusion NCT03927638 41 50 O
Criteria NCT03927638 51 59 O
: NCT03927638 60 61 O

- NCT03927638 65 66 O
Have NCT03927638 68 72 O
a NCT03927638 73 74 O
history NCT03927638 75 82 B-Eq-Comparison
of NCT03927638 83 85 O
cancer NCT03927638 86 92 B-Condition
, NCT03927638 93 94 O
cardiac NCT03927638 95 102 B-Condition
issues NCT03927638 103 109 I-Condition
, NCT03927638 110 111 O
hypertension NCT03927638 112 124 B-Condition
, NCT03927638 125 126 O
pulmonary NCT03927638 127 136 B-Condition
disease NCT03927638 137 144 I-Condition
, NCT03927638 145 146 O
stroke NCT03927638 147 153 B-Condition
, NCT03927638 154 155 O
neurological NCT03927638 156 168 B-Modifier
or NCT03927638 169 171 B-Or
muscular NCT03927638 172 180 B-Modifier
dystrophy NCT03927638 181 190 B-Condition
, NCT03927638 191 192 O
uncontrolled NCT03927638 193 205 B-Modifier
diabetes NCT03927638 206 214 B-Condition
, NCT03927638 215 216 O
or NCT03927638 217 219 B-Or
any NCT03927638 220 223 O
life NCT03927638 224 228 B-Condition
threatening NCT03927638 229 240 I-Condition
chronic NCT03927638 241 248 I-Condition
conditions NCT03927638 249 259 I-Condition
. NCT03927638 259 260 O

- NCT03927638 264 265 O
Are NCT03927638 267 270 O
currently NCT03927638 271 280 B-Eq-Comparison
being NCT03927638 281 286 O
treated NCT03927638 287 294 B-Procedure
for NCT03927638 295 298 O
infectious NCT03927638 299 309 B-Condition
mononucleosis NCT03927638 310 323 I-Condition
, NCT03927638 324 325 O
hepatitis NCT03927638 326 335 B-Condition
, NCT03927638 336 337 O
pneumonia NCT03927638 338 347 B-Condition
, NCT03927638 348 349 O
or NCT03927638 350 352 B-Or
other NCT03927638 353 358 O
infectious NCT03927638 359 369 B-Condition
diseases NCT03927638 370 378 I-Condition
. NCT03927638 378 379 O

- NCT03927638 383 384 O
Are NCT03927638 386 389 O
unable NCT03927638 390 396 B-Negation
or NCT03927638 397 399 B-Or
unwilling NCT03927638 400 409 B-Negation
to NCT03927638 410 412 O
stand NCT03927638 413 418 B-Observation
in NCT03927638 419 421 I-Observation
one NCT03927638 422 425 I-Observation
position NCT03927638 426 434 I-Observation
continuously NCT03927638 435 447 O
for NCT03927638 448 451 O
15 NCT03927638 452 454 B-Eq-Comparison
- NCT03927638 455 456 I-Eq-Comparison
20 NCT03927638 457 459 I-Eq-Comparison
minutes NCT03927638 460 467 I-Eq-Comparison
at NCT03927638 468 470 O
a NCT03927638 471 472 O
time NCT03927638 473 477 O
. NCT03927638 477 478 O

- NCT03927638 482 483 O
Use NCT03927638 485 488 B-Eq-Comparison
nicotine NCT03927638 489 497 B-Drug
products NCT03927638 498 506 I-Drug
, NCT03927638 507 508 O
or NCT03927638 509 511 B-Or
non NCT03927638 512 515 B-Procedure
- NCT03927638 516 517 I-Procedure
contraceptive NCT03927638 518 531 I-Procedure
hormonal NCT03927638 532 540 I-Procedure
therapy NCT03927638 541 548 I-Procedure
( NCT03927638 549 550 O
birth NCT03927638 551 556 B-Procedure
control NCT03927638 557 564 I-Procedure
is NCT03927638 565 567 O
okay NCT03927638 568 572 B-Exception
) NCT03927638 573 574 O
. NCT03927638 575 576 O

- NCT03927638 580 581 O
Are NCT03927638 583 586 O
pregnant NCT03927638 587 595 B-Condition
or NCT03927638 596 598 B-Or
trying NCT03927638 599 605 B-Assertion___Assertion-Type-Value:intention
to NCT03927638 606 608 I-Assertion___Assertion-Type-Value:intention
become NCT03927638 609 615 O
pregnant NCT03927638 616 624 B-Condition
. NCT03927638 624 625 O

- NCT03927638 629 630 O
Are NCT03927638 632 635 O
not NCT03927638 636 639 B-Negation
between NCT03927638 640 647 B-Eq-Comparison
18 NCT03927638 648 650 I-Eq-Comparison
and NCT03927638 651 654 I-Eq-Comparison
50 NCT03927638 655 657 I-Eq-Comparison
years NCT03927638 658 663 I-Eq-Comparison
of NCT03927638 664 666 O
age NCT03927638 667 670 B-Age
. NCT03927638 670 671 O

Inclusion NCT03929198 0 9 O
Criteria NCT03929198 10 18 O
: NCT03929198 19 20 O

- NCT03929198 24 25 O
Dysfunctional NCT03929198 27 40 B-Condition
lipids NCT03929198 41 47 I-Condition
, NCT03929198 48 49 O
blood NCT03929198 50 55 B-Observation
pressure NCT03929198 56 64 I-Observation
and NCT03929198 65 68 B-And
glycemic NCT03929198 69 77 B-Condition
control NCT03929198 78 85 I-Condition
determined NCT03929198 86 96 O
at NCT03929198 97 99 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03929198 100 101 O
screening NCT03929198 102 111 B-Study
visit NCT03929198 112 117 O
: NCT03929198 118 119 O

- NCT03929198 128 129 O
Triglycerides NCT03929198 131 144 B-Observation
> NCT03929198 145 146 B-Eq-Comparison
150 NCT03929198 147 150 I-Eq-Comparison
mg NCT03929198 151 153 I-Eq-Comparison
/ NCT03929198 154 155 I-Eq-Comparison
dL NCT03929198 156 158 I-Eq-Comparison
OR NCT03929198 159 161 B-Or
HDL NCT03929198 162 165 B-Observation
< NCT03929198 166 167 B-Eq-Comparison
50 NCT03929198 168 170 I-Eq-Comparison
in NCT03929198 171 173 O
females NCT03929198 174 181 O
, NCT03929198 182 183 O
< NCT03929198 184 185 B-Eq-Comparison
40 NCT03929198 186 188 I-Eq-Comparison
mg NCT03929198 189 191 I-Eq-Comparison
/ NCT03929198 192 193 I-Eq-Comparison
dL NCT03929198 194 196 I-Eq-Comparison
in NCT03929198 197 199 O
males NCT03929198 200 205 O

- NCT03929198 213 214 O
Systolic NCT03929198 216 224 B-Observation
blood NCT03929198 225 230 I-Observation
pressure NCT03929198 231 239 I-Observation
≥ NCT03929198 240 241 B-Eq-Comparison
130 NCT03929198 242 245 I-Eq-Comparison
mmHg NCT03929198 246 250 I-Eq-Comparison
OR NCT03929198 251 253 B-Or
diastolic NCT03929198 254 263 B-Observation
blood NCT03929198 264 269 I-Observation
pressure NCT03929198 270 278 I-Observation
≥ NCT03929198 279 280 B-Eq-Comparison
80 NCT03929198 281 283 I-Eq-Comparison
mmHg NCT03929198 284 288 I-Eq-Comparison
( NCT03929198 289 290 O
or NCT03929198 291 293 B-Or
on NCT03929198 294 296 B-Eq-Comparison
hypertension NCT03929198 297 309 B-Condition
medication NCT03929198 310 320 B-Drug
) NCT03929198 321 322 O

- NCT03929198 331 332 O
HbA1c NCT03929198 334 339 B-Observation
≥ NCT03929198 340 341 B-Eq-Comparison
5.7 NCT03929198 342 345 I-Eq-Comparison
% NCT03929198 346 347 O
or NCT03929198 348 350 I-Eq-Comparison
higher NCT03929198 351 357 I-Eq-Comparison

- NCT03929198 360 361 O
No NCT03929198 363 365 B-Negation
diagnosis NCT03929198 366 375 O
or NCT03929198 376 378 O
treatment NCT03929198 379 388 B-Procedure
for NCT03929198 389 392 O
cancer NCT03929198 393 399 B-Condition
in NCT03929198 400 402 O
the NCT03929198 403 406 O
past NCT03929198 407 411 B-Eq-Comparison
year NCT03929198 412 416 I-Eq-Comparison

- NCT03929198 419 420 O
No NCT03929198 422 424 B-Negation
diagnosis NCT03929198 425 434 O
of NCT03929198 435 437 O
mild NCT03929198 438 442 B-Condition
cognitive NCT03929198 443 452 I-Condition
impairment NCT03929198 453 463 I-Condition
or NCT03929198 464 466 B-Or
dementia NCT03929198 467 475 B-Condition
in NCT03929198 476 478 O
the NCT03929198 479 482 O
past NCT03929198 483 487 B-Eq-Comparison
year NCT03929198 488 492 I-Eq-Comparison

- NCT03929198 495 496 O
Ability NCT03929198 498 505 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929198 506 508 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03929198 509 516 O
daily NCT03929198 517 522 B-Eq-Comparison
exercise NCT03929198 523 531 B-Observation
, NCT03929198 532 533 O
including NCT03929198 534 543 O
aerobic NCT03929198 544 551 B-Observation
activity NCT03929198 552 560 I-Observation
and NCT03929198 561 564 O
resistance NCT03929198 565 575 B-Observation
exercise NCT03929198 576 584 I-Observation

- NCT03929198 587 588 O
Non NCT03929198 590 593 B-Negation
- NCT03929198 594 595 O
smoker NCT03929198 596 602 B-Condition
in NCT03929198 603 605 O
the NCT03929198 606 609 O
past NCT03929198 610 614 B-Eq-Comparison
year NCT03929198 615 619 I-Eq-Comparison

Exclusion NCT03929198 620 629 O
Criteria NCT03929198 630 638 O
: NCT03929198 639 640 O

- NCT03929198 644 645 O
Positive NCT03929198 647 655 O
exercise NCT03929198 656 664 B-Observation
stress NCT03929198 665 671 I-Observation
test NCT03929198 672 676 I-Observation

Inclusion NCT03922230 0 9 O
Criteria NCT03922230 10 18 O
: NCT03922230 19 20 O

1 NCT03922230 24 25 O
. NCT03922230 25 26 O
Diagnosis NCT03922230 28 37 O
of NCT03922230 38 40 O
esophageal NCT03922230 41 51 B-Modifier
squamous NCT03922230 52 60 B-Condition
cell NCT03922230 61 65 I-Condition
carcinoma NCT03922230 66 75 I-Condition
by NCT03922230 76 78 O
pathological NCT03922230 79 91 B-Procedure
cytology NCT03922230 92 100 I-Procedure
and NCT03922230 101 104 B-And
histology NCT03922230 105 114 B-Procedure
. NCT03922230 114 115 O

2 NCT03922230 119 120 O
. NCT03922230 120 121 O
Clinically NCT03922230 123 133 O
judged NCT03922230 134 140 O
patients NCT03922230 141 149 O
with NCT03922230 150 154 O
p0 NCT03922230 155 157 B-Modifier
~ NCT03922230 158 159 B-Or
pIV NCT03922230 160 163 B-Modifier
initial NCT03922230 164 171 B-Eq-Comparison
treatment NCT03922230 172 181 B-Procedure
. NCT03922230 181 182 O
（ NCT03922230 183 184 O
1 NCT03922230 184 185 O
Variable NCT03922230 186 194 O
risk NCT03922230 195 199 B-Risk
factors NCT03922230 200 207 O
are NCT03922230 208 211 O
overeating NCT03922230 212 222 B-Condition
food NCT03922230 223 227 O
( NCT03922230 228 229 O
habits NCT03922230 230 236 O
) NCT03922230 237 238 O
and NCT03922230 239 242 O
family NCT03922230 243 249 B-Family-Member
history NCT03922230 250 257 I-Family-Member
. NCT03922230 257 258 O
2 NCT03922230 260 261 O
Among NCT03922230 262 267 O
all NCT03922230 268 271 O
the NCT03922230 272 275 O
patients NCT03922230 276 284 O
, NCT03922230 285 286 O
the NCT03922230 287 290 O
ratio NCT03922230 291 296 O
of NCT03922230 297 299 O
male NCT03922230 300 304 O
to NCT03922230 305 307 O
female NCT03922230 308 314 O
is NCT03922230 315 317 O
3 NCT03922230 318 319 O
: NCT03922230 320 321 O
1 NCT03922230 322 323 O
, NCT03922230 324 325 O
and NCT03922230 326 329 O
the NCT03922230 330 333 O
age NCT03922230 334 337 B-Age
is NCT03922230 338 340 O
between NCT03922230 341 348 B-Eq-Comparison
50 NCT03922230 349 351 I-Eq-Comparison
and NCT03922230 352 355 I-Eq-Comparison
70 NCT03922230 356 358 I-Eq-Comparison
years NCT03922230 359 364 I-Eq-Comparison
old NCT03922230 365 368 O
. NCT03922230 368 369 O
In NCT03922230 371 373 O
addition NCT03922230 374 382 O
to NCT03922230 383 385 O
eating NCT03922230 386 392 O
too NCT03922230 393 396 O
hot NCT03922230 397 400 O
food NCT03922230 401 405 O
, NCT03922230 406 407 O
other NCT03922230 408 413 O
eating NCT03922230 414 420 O
habits NCT03922230 421 427 O
( NCT03922230 428 429 O
such NCT03922230 430 434 O
as NCT03922230 435 437 O
eating NCT03922230 438 444 O
fresh NCT03922230 445 450 O
fruits NCT03922230 451 457 O
and NCT03922230 458 461 O
vegetables NCT03922230 462 472 O
, NCT03922230 473 474 O
eating NCT03922230 475 481 O
preserved NCT03922230 482 491 O
food NCT03922230 492 496 O
, NCT03922230 497 498 O
etc NCT03922230 499 502 O
. NCT03922230 502 503 O
) NCT03922230 504 505 O
are NCT03922230 506 509 O
consistent NCT03922230 510 520 O
, NCT03922230 521 522 O
other NCT03922230 523 528 O
factors NCT03922230 529 536 B-Condition
( NCT03922230 537 538 O
such NCT03922230 539 543 O
as NCT03922230 544 546 O
BMI NCT03922230 547 550 B-Observation
, NCT03922230 551 552 O
smoking NCT03922230 553 560 B-Condition
, NCT03922230 561 562 O
drinking NCT03922230 563 571 B-Condition
, NCT03922230 572 573 O
etc NCT03922230 574 577 O
. NCT03922230 577 578 O
) NCT03922230 579 580 O
as NCT03922230 581 583 O
much NCT03922230 584 588 O
as NCT03922230 589 591 O
possible NCT03922230 592 600 O
. NCT03922230 600 601 O
3 NCT03922230 603 604 O
In NCT03922230 605 607 O
order NCT03922230 608 613 O
to NCT03922230 614 616 O
rule NCT03922230 617 621 O
out NCT03922230 622 625 O
the NCT03922230 626 629 O
interference NCT03922230 630 642 O
of NCT03922230 643 645 O
other NCT03922230 646 651 O
diseases NCT03922230 652 660 O
, NCT03922230 661 662 O
each NCT03922230 663 667 O
sample NCT03922230 668 674 O
needs NCT03922230 675 680 O
to NCT03922230 681 683 O
be NCT03922230 684 686 O
determined NCT03922230 687 697 O
to NCT03922230 698 700 O
have NCT03922230 701 705 O
no NCT03922230 706 708 B-Negation
history NCT03922230 709 716 B-Eq-Comparison
of NCT03922230 717 719 O
other NCT03922230 720 725 O
diseases NCT03922230 726 734 B-Condition
( NCT03922230 735 736 O
such NCT03922230 737 741 O
as NCT03922230 742 744 O
neurodegenerative NCT03922230 745 762 B-Condition
diseases NCT03922230 763 771 I-Condition
, NCT03922230 772 773 O
leukemia NCT03922230 774 782 B-Condition
) NCT03922230 783 784 O
. NCT03922230 785 786 O
） NCT03922230 787 788 O

3 NCT03922230 791 792 O
. NCT03922230 792 793 O
The NCT03922230 795 798 O
normal NCT03922230 799 805 O
population NCT03922230 806 816 O
comes NCT03922230 817 822 O
from NCT03922230 823 827 O
the NCT03922230 828 831 O
healthy NCT03922230 832 839 O
population NCT03922230 840 850 O
of NCT03922230 851 853 O
Nanfang NCT03922230 854 861 O
Hospital NCT03922230 862 870 O
Health NCT03922230 871 877 O
Center NCT03922230 878 884 O
of NCT03922230 885 887 O
Southern NCT03922230 888 896 O
Medical NCT03922230 897 904 O
University NCT03922230 905 915 O
. NCT03922230 915 916 O

Exclusion NCT03922230 918 927 O
Criteria NCT03922230 928 936 O
: NCT03922230 937 938 O

1 NCT03922230 942 943 O
. NCT03922230 943 944 O
Pre NCT03922230 946 949 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03922230 950 951 O
- NCT03922230 953 954 O
operative NCT03922230 955 964 B-Procedure
patients NCT03922230 965 973 O
have NCT03922230 974 978 O
received NCT03922230 979 987 B-Eq-Comparison
relevant NCT03922230 988 996 O
treatment NCT03922230 997 1006 B-Procedure
, NCT03922230 1007 1008 O
such NCT03922230 1009 1013 O
as NCT03922230 1014 1016 O
radiotherapy NCT03922230 1017 1029 B-Procedure
and NCT03922230 1030 1033 O
chemotherapy NCT03922230 1034 1046 B-Procedure
; NCT03922230 1046 1047 O

2 NCT03922230 1050 1051 O
. NCT03922230 1051 1052 O
The NCT03922230 1054 1057 O
subject NCT03922230 1058 1065 O
has NCT03922230 1066 1069 O
other NCT03922230 1070 1075 O
diseases NCT03922230 1076 1084 B-Condition
, NCT03922230 1085 1086 O
such NCT03922230 1087 1091 O
as NCT03922230 1092 1094 O
tumors NCT03922230 1095 1101 B-Condition
in NCT03922230 1102 1104 O
other NCT03922230 1105 1110 O
parts NCT03922230 1111 1116 O
; NCT03922230 1116 1117 O

3 NCT03922230 1120 1121 O
. NCT03922230 1121 1122 O
Patients NCT03922230 1124 1132 O
do NCT03922230 1133 1135 O
not NCT03922230 1136 1139 B-Negation
meet NCT03922230 1140 1144 O
the NCT03922230 1145 1148 O
age NCT03922230 1149 1152 O
; NCT03922230 1152 1153 O

4 NCT03922230 1156 1157 O
. NCT03922230 1157 1158 O
There NCT03922230 1160 1165 O
is NCT03922230 1166 1168 O
no NCT03922230 1169 1171 O
guarantee NCT03922230 1172 1181 O
that NCT03922230 1182 1186 O
other NCT03922230 1187 1192 O
eating NCT03922230 1193 1199 O
habits NCT03922230 1200 1206 O
( NCT03922230 1207 1208 O
such NCT03922230 1209 1213 O
as NCT03922230 1214 1216 O
eating NCT03922230 1217 1223 O
fresh NCT03922230 1224 1229 O
fruits NCT03922230 1230 1236 O
and NCT03922230 1237 1240 O
vegetables NCT03922230 1241 1251 O
, NCT03922230 1252 1253 O
not NCT03922230 1254 1257 O
eating NCT03922230 1258 1264 O
preserved NCT03922230 1265 1274 O
foods NCT03922230 1275 1280 O
) NCT03922230 1281 1282 O
and NCT03922230 1283 1286 O
other NCT03922230 1287 1292 O
factors NCT03922230 1293 1300 B-Condition
( NCT03922230 1301 1302 O
such NCT03922230 1303 1307 O
as NCT03922230 1308 1310 O
BMI NCT03922230 1311 1314 B-Observation
, NCT03922230 1315 1316 O
smoking NCT03922230 1317 1324 B-Condition
, NCT03922230 1325 1326 O
drinking NCT03922230 1327 1335 B-Condition
, NCT03922230 1336 1337 O
etc NCT03922230 1338 1341 O
. NCT03922230 1341 1342 O
) NCT03922230 1343 1344 O
are NCT03922230 1345 1348 O
basically NCT03922230 1349 1358 O
the NCT03922230 1359 1362 O
same NCT03922230 1363 1367 O
. NCT03922230 1367 1368 O

Inclusion NCT03922542 0 9 O
Criteria NCT03922542 10 18 O
: NCT03922542 19 20 O

- NCT03922542 24 25 O
Documented NCT03922542 27 37 O
keratoconus NCT03922542 38 49 B-Condition
or NCT03922542 50 52 B-Or
ectasia NCT03922542 53 60 B-Condition
after NCT03922542 61 66 B-Temporal-Connection___Temporal-Connection-Type-Value:after
refractive NCT03922542 67 77 B-Procedure
surgery NCT03922542 78 85 I-Procedure

Exclusion NCT03922542 86 95 O
Criteria NCT03922542 96 104 O
: NCT03922542 105 106 O

- NCT03922542 110 111 O
Insufficient NCT03922542 113 125 B-Condition
corneal NCT03922542 126 133 I-Condition
thickness NCT03922542 134 143 I-Condition

- NCT03922542 146 147 O
Ocular NCT03922542 149 155 B-Condition
condition NCT03922542 156 165 I-Condition
that NCT03922542 166 170 O
may NCT03922542 171 174 B-Assertion___Assertion-Type-Value:possible
predispose NCT03922542 175 185 B-Risk
the NCT03922542 186 189 O
eye NCT03922542 190 193 B-Condition
to NCT03922542 194 196 I-Condition
complications NCT03922542 197 210 I-Condition

- NCT03922542 213 214 O
History NCT03922542 216 223 B-Eq-Comparison
of NCT03922542 224 226 O
chemical NCT03922542 227 235 B-Condition
injury NCT03922542 236 242 I-Condition
or NCT03922542 243 245 B-Or
delayed NCT03922542 246 253 B-Condition
epithelial NCT03922542 254 264 I-Condition
healing NCT03922542 265 272 I-Condition

- NCT03922542 275 276 O
Condition NCT03922542 278 287 B-Condition
that NCT03922542 288 292 O
would NCT03922542 293 298 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03922542 299 308 O
with NCT03922542 309 313 O
or NCT03922542 314 316 B-Or
prolong NCT03922542 317 324 O
epithelial NCT03922542 325 335 B-Condition
healing NCT03922542 336 343 I-Condition

- NCT03922542 346 347 O
Known NCT03922542 349 354 O
sensitivity NCT03922542 355 366 B-Condition
to NCT03922542 367 369 O
treatment NCT03922542 370 379 B-Procedure
medications NCT03922542 380 391 B-Drug

- NCT03922542 394 395 O
Pregnancy NCT03922542 397 406 B-Condition

Inclusion NCT03923660 0 9 O
Criteria NCT03923660 10 18 O
: NCT03923660 19 20 O

- NCT03923660 24 25 O
Severe NCT03923660 27 33 O
COPD NCT03923660 34 38 B-Condition
( NCT03923660 39 40 O
FEV1 NCT03923660 41 45 B-Observation
[ NCT03923660 46 47 O
forced NCT03923660 48 54 B-Observation
expiratory NCT03923660 55 65 I-Observation
volume NCT03923660 66 72 I-Observation
in NCT03923660 73 75 I-Observation
1 NCT03923660 76 77 I-Observation
second NCT03923660 78 84 I-Observation
] NCT03923660 85 86 O
/ NCT03923660 87 88 B-Or
FVC NCT03923660 89 92 B-Observation
[ NCT03923660 93 94 O
forced NCT03923660 95 101 B-Observation
vital NCT03923660 102 107 I-Observation
capacity NCT03923660 108 116 I-Observation
] NCT03923660 117 118 O
< NCT03923660 119 120 B-Eq-Comparison
70 NCT03923660 121 123 I-Eq-Comparison
% NCT03923660 124 125 O
et NCT03923660 126 128 O
FEV1 NCT03923660 129 133 B-Observation
< NCT03923660 134 135 B-Eq-Comparison
50 NCT03923660 136 138 I-Eq-Comparison
% NCT03923660 139 140 O
) NCT03923660 141 142 O

- NCT03923660 146 147 O
Informed NCT03923660 149 157 O
consent NCT03923660 158 165 O

- NCT03923660 168 169 O
Affiliation NCT03923660 171 182 O
to NCT03923660 183 185 O
a NCT03923660 186 187 O
social NCT03923660 188 194 O
security NCT03923660 195 203 O
scheme NCT03923660 204 210 O

Exclusion NCT03923660 211 220 O
Criteria NCT03923660 221 229 O
: NCT03923660 230 231 O

- NCT03923660 235 236 O
Effort NCT03923660 238 244 B-Procedure
oxygen NCT03923660 245 251 I-Procedure
therapy NCT03923660 252 259 I-Procedure

- NCT03923660 262 263 O
Cardiovascular NCT03923660 265 279 B-Modifier
, NCT03923660 280 281 O
neuromuscular NCT03923660 282 295 B-Modifier
or NCT03923660 296 298 B-Or
musculoskeletal NCT03923660 299 314 B-Modifier
disorders NCT03923660 315 324 B-Condition
that NCT03923660 325 329 O
can NCT03923660 330 333 O
provide NCT03923660 334 341 O
significant NCT03923660 342 353 O
dyspnea NCT03923660 354 361 B-Condition
or NCT03923660 362 364 B-Or
limit NCT03923660 365 370 O
exercise NCT03923660 371 379 B-Observation

- NCT03923660 382 383 O
Legal NCT03923660 385 390 B-Condition
incapacity NCT03923660 391 401 I-Condition

- NCT03923660 404 405 O
Low NCT03923660 407 410 O
or NCT03923660 411 413 B-Or
no NCT03923660 414 416 B-Negation
cooperation NCT03923660 417 428 B-Observation
anticipated NCT03923660 429 440 B-Assertion___Assertion-Type-Value:hypothetical

Inclusion NCT03928912 0 9 O
Criteria NCT03928912 10 18 O
: NCT03928912 19 20 O

- NCT03928912 24 25 O
The NCT03928912 27 30 O
tibial NCT03928912 31 37 B-Modifier
shaft NCT03928912 38 43 I-Modifier
fracture NCT03928912 44 52 B-Condition
was NCT03928912 53 56 O
caused NCT03928912 57 63 O
by NCT03928912 64 66 O
trauma NCT03928912 67 73 B-Condition
. NCT03928912 73 74 O

Exclusion NCT03928912 76 85 O
Criteria NCT03928912 86 94 O
: NCT03928912 95 96 O

- NCT03928912 100 101 O
The NCT03928912 103 106 O
tibial NCT03928912 107 113 B-Modifier
shaft NCT03928912 114 119 I-Modifier
fracture NCT03928912 120 128 B-Condition
was NCT03928912 129 132 O
caused NCT03928912 133 139 O
by NCT03928912 140 142 O
tumor NCT03928912 143 148 B-Condition
, NCT03928912 149 150 O
infection NCT03928912 151 160 B-Condition
and NCT03928912 161 164 O
other NCT03928912 165 170 O
reasons NCT03928912 171 178 O
. NCT03928912 178 179 O

Inclusion NCT03922581 0 9 O
Criteria NCT03922581 10 18 O
: NCT03922581 19 20 O

- NCT03922581 24 25 O
ability NCT03922581 27 34 O
to NCT03922581 35 37 O
provide NCT03922581 38 45 O
informed NCT03922581 46 54 O
consent NCT03922581 55 62 O

- NCT03922581 65 66 O
willingness NCT03922581 68 79 O
to NCT03922581 80 82 O
participate NCT03922581 83 94 O
in NCT03922581 95 97 O
study NCT03922581 98 103 O

- NCT03922581 106 107 O
self NCT03922581 109 113 O
- NCT03922581 114 115 O
identity NCT03922581 116 124 O
as NCT03922581 125 127 O
African NCT03922581 128 135 O
American NCT03922581 136 144 O

- NCT03922581 147 148 O
history NCT03922581 150 157 B-Eq-Comparison
of NCT03922581 158 160 O
childhood NCT03922581 161 170 O
and NCT03922581 171 174 B-Or
/ NCT03922581 175 176 I-Or
or NCT03922581 177 179 I-Or
adult NCT03922581 180 185 O
trauma NCT03922581 186 192 B-Condition
exposure NCT03922581 193 201 I-Condition
( NCT03922581 202 203 O
3 NCT03922581 204 205 B-Eq-Comparison
total NCT03922581 206 211 I-Eq-Comparison
criterion NCT03922581 212 221 I-Eq-Comparison
A NCT03922581 222 223 I-Eq-Comparison
traumas NCT03922581 224 231 I-Eq-Comparison
) NCT03922581 232 233 O

- NCT03922581 237 238 O
positive NCT03922581 240 248 O
PTSD NCT03922581 249 253 B-Condition
screen NCT03922581 254 260 O
( NCT03922581 261 262 O
PC NCT03922581 263 265 B-Observation
- NCT03922581 266 267 I-Observation
PTSD NCT03922581 268 272 I-Observation
≥ NCT03922581 273 274 B-Eq-Comparison
3 NCT03922581 275 276 I-Eq-Comparison
) NCT03922581 277 278 O

- NCT03922581 282 283 O
positive NCT03922581 285 293 O
MDD NCT03922581 294 297 B-Condition
screen NCT03922581 298 304 O
( NCT03922581 305 306 O
PHQ NCT03922581 307 310 B-Observation
- NCT03922581 311 312 I-Observation
9 NCT03922581 313 314 I-Observation
≥ NCT03922581 315 316 B-Eq-Comparison
5 NCT03922581 317 318 I-Eq-Comparison
) NCT03922581 319 320 O

Exclusion NCT03922581 322 331 O
Criteria NCT03922581 332 340 O
: NCT03922581 341 342 O

- NCT03922581 346 347 O
presence NCT03922581 349 357 O
of NCT03922581 358 360 O
intellectual NCT03922581 361 373 B-Condition
disability NCT03922581 374 384 I-Condition
, NCT03922581 385 386 O
bipolar NCT03922581 387 394 B-Condition
, NCT03922581 395 396 O
or NCT03922581 397 399 B-Or
psychotic NCT03922581 400 409 B-Condition
disorder NCT03922581 410 418 I-Condition

- NCT03922581 421 422 O
presence NCT03922581 424 432 O
of NCT03922581 433 435 O
current NCT03922581 436 443 B-Eq-Comparison
substance NCT03922581 444 453 B-Condition
use NCT03922581 454 457 I-Condition
disorder NCT03922581 458 466 I-Condition
( NCT03922581 467 468 O
past NCT03922581 469 473 B-Eq-Comparison
1 NCT03922581 474 475 I-Eq-Comparison
month NCT03922581 476 481 I-Eq-Comparison
; NCT03922581 481 482 O
see NCT03922581 483 486 O
cut NCT03922581 487 490 O
off NCT03922581 491 494 O
scores NCT03922581 495 501 O
in NCT03922581 502 504 O
psychological NCT03922581 505 518 O
measures NCT03922581 519 527 O
below NCT03922581 528 533 O
) NCT03922581 534 535 O

- NCT03922581 539 540 O
active NCT03922581 542 548 B-Eq-Comparison
suicidality NCT03922581 549 560 B-Condition

Inclusion NCT03920553 0 9 O
Criteria NCT03920553 10 18 O
: NCT03920553 19 20 O

- NCT03920553 24 25 O
No NCT03920553 27 29 B-Negation
systemic NCT03920553 30 38 B-Modifier
disease NCT03920553 39 46 B-Condition
, NCT03920553 47 48 O

- NCT03920553 52 53 O
the NCT03920553 55 58 O
presence NCT03920553 59 67 O
of NCT03920553 68 70 O
high NCT03920553 71 75 B-Condition
labial NCT03920553 76 82 I-Condition
frenulum NCT03920553 83 91 I-Condition
attachment NCT03920553 92 102 I-Condition
diagnosed NCT03920553 103 112 O
according NCT03920553 113 122 O
to NCT03920553 123 125 O
Mirko NCT03920553 126 131 O
et NCT03920553 132 134 O
al NCT03920553 135 137 O
. NCT03920553 137 138 O
, NCT03920553 139 140 O
- NCT03920553 141 142 O
periodontally NCT03920553 143 156 B-Observation
healthy NCT03920553 157 164 I-Observation
or NCT03920553 165 167 B-Or
a NCT03920553 168 169 O
requirement NCT03920553 170 181 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920553 182 185 I-Assertion___Assertion-Type-Value:hypothetical
periodontal NCT03920553 186 197 B-Procedure
treatment NCT03920553 198 207 I-Procedure
that NCT03920553 208 212 O
would NCT03920553 213 218 B-Assertion___Assertion-Type-Value:hypothetical
only NCT03920553 219 223 O
require NCT03920553 224 231 O
removing NCT03920553 232 240 B-Procedure
of NCT03920553 241 243 I-Procedure
dental NCT03920553 244 250 I-Procedure
plaque NCT03920553 251 257 I-Procedure
, NCT03920553 258 259 O

- NCT03920553 263 264 O
full NCT03920553 266 270 B-Observation
mouth NCT03920553 271 276 I-Observation
plaque NCT03920553 277 283 I-Observation
score NCT03920553 284 289 I-Observation
< NCT03920553 290 291 B-Eq-Comparison
15 NCT03920553 292 294 I-Eq-Comparison
% NCT03920553 295 296 O
, NCT03920553 297 298 O
probing NCT03920553 299 306 B-Observation
pocket NCT03920553 307 313 I-Observation
depth NCT03920553 314 319 I-Observation
< NCT03920553 320 321 B-Eq-Comparison
3 NCT03920553 322 323 I-Eq-Comparison
mm NCT03920553 324 326 O
in NCT03920553 327 329 O
all NCT03920553 330 333 O
teeth NCT03920553 334 339 O

- NCT03920553 342 343 O
no NCT03920553 345 347 B-Negation
history NCT03920553 348 355 B-Eq-Comparison
of NCT03920553 356 358 O
periodontal NCT03920553 359 370 B-Procedure
surgery NCT03920553 371 378 I-Procedure
. NCT03920553 378 379 O

Exclusion NCT03920553 381 390 O
Criteria NCT03920553 391 399 O
: NCT03920553 400 401 O

- NCT03920553 405 406 O
not NCT03920553 408 411 B-Negation
meet NCT03920553 412 416 O
the NCT03920553 417 420 O
optimal NCT03920553 421 428 O
level NCT03920553 429 434 O
of NCT03920553 435 437 O
oral NCT03920553 438 442 B-Observation
hygiene NCT03920553 443 450 I-Observation
, NCT03920553 451 452 O

- NCT03920553 456 457 O
had NCT03920553 459 462 O
any NCT03920553 463 466 O
condition NCT03920553 467 476 B-Condition
that NCT03920553 477 481 O
could NCT03920553 482 487 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920553 488 494 O
wound NCT03920553 495 500 B-Condition
healing NCT03920553 501 508 I-Condition
, NCT03920553 509 510 O

- NCT03920553 514 515 O
were NCT03920553 517 521 B-Eq-Comparison
pregnant NCT03920553 522 530 B-Condition
or NCT03920553 531 533 B-Or
lactating NCT03920553 534 543 B-Condition
, NCT03920553 544 545 O

- NCT03920553 549 550 O
were NCT03920553 552 556 B-Eq-Comparison
cigarette NCT03920553 557 566 B-Condition
smokers NCT03920553 567 574 I-Condition
or NCT03920553 575 577 B-Or
were NCT03920553 578 582 B-Eq-Comparison
takiing NCT03920553 583 590 I-Eq-Comparison
any NCT03920553 591 594 O
medication NCT03920553 595 605 B-Drug
that NCT03920553 606 610 O
might NCT03920553 611 616 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920553 617 623 O
the NCT03920553 624 627 O
outcome NCT03920553 628 635 O
of NCT03920553 636 638 O
the NCT03920553 639 642 O
study NCT03920553 643 648 B-Study
, NCT03920553 649 650 O

Inclusion NCT03926650 0 9 O
Criteria NCT03926650 10 18 O
: NCT03926650 19 20 O

- NCT03926650 24 25 O
surgery NCT03926650 27 34 B-Procedure
continues NCT03926650 35 44 O
more NCT03926650 45 49 B-Eq-Comparison
then NCT03926650 50 54 I-Eq-Comparison
1 NCT03926650 55 56 I-Eq-Comparison
hour NCT03926650 57 61 I-Eq-Comparison

- NCT03926650 64 65 O
between NCT03926650 67 74 B-Eq-Comparison
ages NCT03926650 75 79 I-Age|Eq-Comparison
18 NCT03926650 80 82 I-Eq-Comparison
- NCT03926650 83 84 I-Eq-Comparison
65 NCT03926650 85 87 I-Eq-Comparison

- NCT03926650 91 92 O
ASA NCT03926650 94 97 B-Condition
I NCT03926650 98 99 B-Eq-Comparison
, NCT03926650 100 101 O
II NCT03926650 102 104 O
and NCT03926650 105 108 I-Eq-Comparison
III NCT03926650 109 112 I-Eq-Comparison
patients NCT03926650 113 121 O

Exclusion NCT03926650 122 131 O
Criteria NCT03926650 132 140 O
: NCT03926650 141 142 O

- NCT03926650 146 147 O
The NCT03926650 149 152 O
patients NCT03926650 153 161 O
who NCT03926650 162 165 O
has NCT03926650 166 169 O
allergical NCT03926650 170 180 B-Allergy
reactions NCT03926650 181 190 O
of NCT03926650 191 193 O
the NCT03926650 194 197 O
drugs NCT03926650 198 203 B-Drug
used NCT03926650 204 208 O

- NCT03926650 211 212 O
neurological NCT03926650 214 226 B-Modifier
or NCT03926650 227 229 B-Or
neuromuscular NCT03926650 230 243 B-Modifier
diseases NCT03926650 244 252 B-Condition

- NCT03926650 255 256 O
the NCT03926650 258 261 O
patients NCT03926650 262 270 O
who NCT03926650 271 274 O
use NCT03926650 275 278 B-Eq-Comparison
drugs NCT03926650 279 284 B-Drug
effecting NCT03926650 285 294 O
the NCT03926650 295 298 O
neuromuscular NCT03926650 299 312 B-Condition
junction NCT03926650 313 321 I-Condition

- NCT03926650 324 325 O
pregnant NCT03926650 327 335 B-Condition
patients NCT03926650 336 344 O

- NCT03926650 347 348 O
electrolyte NCT03926650 350 361 B-Condition
disregulations NCT03926650 362 376 I-Condition

- NCT03926650 379 380 O
major NCT03926650 382 387 O
organ NCT03926650 388 393 B-Condition
failures NCT03926650 394 402 I-Condition
, NCT03926650 403 404 O
liver NCT03926650 405 410 B-Condition
failure NCT03926650 411 418 I-Condition
, NCT03926650 419 420 O
kidney NCT03926650 421 427 B-Condition
failure NCT03926650 428 435 I-Condition

- NCT03926650 438 439 O
obese NCT03926650 441 446 B-Condition
and NCT03926650 447 450 B-Or
cachectic NCT03926650 451 460 B-Condition
patients NCT03926650 461 469 O

Inclusion NCT03928899 0 9 O
Criteria NCT03928899 10 18 O
: NCT03928899 19 20 O

- NCT03928899 24 25 O
singleton NCT03928899 27 36 B-Condition
pregnant NCT03928899 37 45 I-Condition
women NCT03928899 46 51 O

- NCT03928899 54 55 O
in NCT03928899 57 59 O
vertex NCT03928899 60 66 B-Condition
presentation NCT03928899 67 79 I-Condition

- NCT03928899 82 83 O
GDM NCT03928899 85 88 B-Condition
that NCT03928899 89 93 O
is NCT03928899 94 96 O
controlled NCT03928899 97 107 O
with NCT03928899 108 112 O
only NCT03928899 113 117 O
diet NCT03928899 118 122 O
and NCT03928899 123 126 O
exercise NCT03928899 127 135 O

- NCT03928899 138 139 O
at NCT03928899 141 143 O
37 NCT03928899 144 146 B-Eq-Comparison
weeks NCT03928899 147 152 I-Eq-Comparison
0 NCT03928899 153 154 I-Eq-Comparison
days NCT03928899 155 159 I-Eq-Comparison
to NCT03928899 160 162 I-Eq-Comparison
37 NCT03928899 163 165 I-Eq-Comparison
weeks NCT03928899 166 171 I-Eq-Comparison
6 NCT03928899 172 173 I-Eq-Comparison
days NCT03928899 174 178 I-Eq-Comparison
of NCT03928899 179 181 O
gestation NCT03928899 182 191 B-Observation

- NCT03928899 194 195 O
more NCT03928899 197 201 B-Eq-Comparison
than NCT03928899 202 206 I-Eq-Comparison
18 NCT03928899 207 209 I-Eq-Comparison
years NCT03928899 210 215 I-Eq-Comparison
old NCT03928899 216 219 B-Age

- NCT03928899 222 223 O
have NCT03928899 225 229 O
no NCT03928899 230 232 B-Negation
other NCT03928899 233 238 B-Other
contraindications NCT03928899 239 256 B-Contraindication
to NCT03928899 257 259 O
vaginal NCT03928899 260 267 B-Procedure
delivery NCT03928899 268 276 I-Procedure
. NCT03928899 276 277 O

Exclusion NCT03928899 279 288 O
Criteria NCT03928899 289 297 O
: NCT03928899 298 299 O

- NCT03928899 303 304 O
prior NCT03928899 306 311 B-Eq-Comparison
caesarean NCT03928899 312 321 B-Procedure
section NCT03928899 322 329 I-Procedure
or NCT03928899 330 332 B-Or
myomectomy NCT03928899 333 343 B-Procedure

- NCT03928899 346 347 O
any NCT03928899 349 352 O
known NCT03928899 353 358 O
contraindications NCT03928899 359 376 B-Contraindication
to NCT03928899 377 379 O
vaginal NCT03928899 380 387 B-Procedure
delivery NCT03928899 388 396 I-Procedure

- NCT03928899 399 400 O
uncertain NCT03928899 402 411 B-Negation
gestational NCT03928899 412 423 B-Observation
age NCT03928899 424 427 I-Observation

- NCT03928899 430 431 O
non NCT03928899 433 436 B-Condition
reassuring NCT03928899 437 447 I-Condition
foetal NCT03928899 448 454 I-Condition
wellbeing NCT03928899 455 464 I-Condition
necessitating NCT03928899 465 478 B-Assertion___Assertion-Type-Value:hypothetical
delivery NCT03928899 479 487 B-Procedure

- NCT03928899 490 491 O
maternal NCT03928899 493 501 B-Family-Member___Family-Member-Type:mother
pregnancy NCT03928899 502 511 B-Condition
- NCT03928899 512 513 I-Condition
related NCT03928899 514 521 I-Condition
disease NCT03928899 522 529 I-Condition
necessitating NCT03928899 530 543 O
delivery NCT03928899 544 552 B-Procedure
( NCT03928899 553 554 O
any NCT03928899 555 558 O
hypertensive NCT03928899 559 571 B-Condition
disorder NCT03928899 572 580 I-Condition
, NCT03928899 581 582 O
cardiac NCT03928899 583 590 B-Condition
disease NCT03928899 591 598 I-Condition
, NCT03928899 599 600 O
renal NCT03928899 601 606 B-Condition
insufficiency NCT03928899 607 620 I-Condition
、 NCT03928899 621 622 O
immune NCT03928899 623 629 B-Condition
diseases NCT03928899 630 638 I-Condition
, NCT03928899 639 640 O
et NCT03928899 641 643 O
al NCT03928899 644 646 O
. NCT03928899 646 647 O
) NCT03928899 648 649 O

- NCT03928899 653 654 O
placenta NCT03928899 656 664 B-Condition
previa NCT03928899 665 671 B-Modifier
, NCT03928899 672 673 O
accreta NCT03928899 674 681 B-Modifier
, NCT03928899 682 683 O
vasa NCT03928899 684 688 B-Modifier
previa NCT03928899 689 695 I-Modifier

- NCT03928899 698 699 O
known NCT03928899 701 706 O
foetal NCT03928899 707 713 B-Condition
anomaly NCT03928899 714 721 I-Condition

- NCT03928899 724 725 O
negative NCT03928899 727 735 B-Negation
reproductive NCT03928899 736 748 B-Condition
history NCT03928899 749 756 I-Condition

- NCT03928899 759 760 O
ruptured NCT03928899 762 770 B-Condition
membranes NCT03928899 771 780 I-Condition
or NCT03928899 781 783 B-Or
known NCT03928899 784 789 O
oligohydramnios NCT03928899 790 805 B-Condition
( NCT03928899 806 807 O
defined NCT03928899 808 815 O
as NCT03928899 816 818 O
AFI NCT03928899 819 822 B-Observation
< NCT03928899 823 824 B-Eq-Comparison|Eq-Comparison
5 NCT03928899 825 826 I-Eq-Comparison
or NCT03928899 827 829 B-Or
MVP NCT03928899 830 833 B-Observation
< NCT03928899 834 835 O
2 NCT03928899 836 837 I-Eq-Comparison
) NCT03928899 838 839 O
before NCT03928899 840 846 B-Temporal-Connection___Temporal-Connection-Type-Value:before

37 NCT03928899 852 854 B-Eq-Comparison
weeks NCT03928899 855 860 O
6 NCT03928899 861 862 I-Eq-Comparison
days NCT03928899 863 867 I-Eq-Comparison
of NCT03928899 868 870 O
gestation NCT03928899 871 880 B-Observation

- NCT03928899 883 884 O
fetal NCT03928899 886 891 B-Condition
growth NCT03928899 892 898 I-Condition
restriction NCT03928899 899 910 I-Condition
, NCT03928899 911 912 O
defined NCT03928899 913 920 O
as NCT03928899 921 923 O
EFW NCT03928899 924 927 B-Observation
< NCT03928899 928 929 B-Eq-Comparison
10 NCT03928899 930 932 I-Eq-Comparison
th NCT03928899 933 935 O
percentile NCT03928899 936 946 I-Eq-Comparison

- NCT03928899 949 950 O
known NCT03928899 952 957 O
HIV NCT03928899 958 961 B-Condition
positivity NCT03928899 962 972 O
because NCT03928899 973 980 O
of NCT03928899 981 983 O
modified NCT03928899 984 992 O
delivery NCT03928899 993 1001 O
plan NCT03928899 1002 1006 O

- NCT03928899 1009 1010 O
signs NCT03928899 1012 1017 B-Assertion___Assertion-Type-Value:possible
of NCT03928899 1018 1020 O
labor NCT03928899 1021 1026 B-Condition
( NCT03928899 1027 1028 O
regular NCT03928899 1029 1036 B-Condition
painful NCT03928899 1037 1044 I-Condition
contractions NCT03928899 1045 1057 I-Condition
with NCT03928899 1058 1062 B-And
cervical NCT03928899 1063 1071 B-Condition
change NCT03928899 1072 1078 I-Condition
) NCT03928899 1079 1080 O
before NCT03928899 1081 1087 B-Temporal-Connection___Temporal-Connection-Type-Value:before
37 NCT03928899 1088 1090 B-Eq-Comparison
weeks NCT03928899 1091 1096 O
6 NCT03928899 1097 1098 I-Eq-Comparison
days NCT03928899 1099 1103 I-Eq-Comparison
of NCT03928899 1104 1106 O
gestation NCT03928899 1107 1116 B-Observation
. NCT03928899 1116 1117 O

Inclusion NCT03923933 0 9 O
Criteria NCT03923933 10 18 O
: NCT03923933 19 20 O

- NCT03923933 24 25 O
glomerular NCT03923933 27 37 B-Observation
filtration NCT03923933 38 48 I-Observation
rate NCT03923933 49 53 I-Observation
less NCT03923933 54 58 B-Eq-Comparison
than NCT03923933 59 63 I-Eq-Comparison
30 NCT03923933 64 66 I-Eq-Comparison
ml NCT03923933 67 69 I-Eq-Comparison
/ NCT03923933 70 71 I-Eq-Comparison
min NCT03923933 72 75 I-Eq-Comparison
/ NCT03923933 76 77 O
1.73 NCT03923933 78 82 I-Eq-Comparison
m NCT03923933 83 84 O

- NCT03923933 87 88 O
Without NCT03923933 90 97 B-Negation
replacement NCT03923933 98 109 B-Procedure
therapy NCT03923933 110 117 I-Procedure
( NCT03923933 118 119 O
dialysis NCT03923933 120 128 B-Procedure
or NCT03923933 129 131 B-Or
hemodialysis NCT03923933 132 144 B-Procedure
) NCT03923933 145 146 O

- NCT03923933 150 151 O
Volume NCT03923933 153 159 B-Condition
overload NCT03923933 160 168 I-Condition

- NCT03923933 171 172 O
At NCT03923933 174 176 B-Eq-Comparison
least NCT03923933 177 182 I-Eq-Comparison
100 NCT03923933 183 186 I-Eq-Comparison
ml NCT03923933 187 189 I-Eq-Comparison
per NCT03923933 190 193 I-Eq-Comparison
day NCT03923933 194 197 I-Eq-Comparison
of NCT03923933 198 200 O
residual NCT03923933 201 209 B-Observation
diuresis NCT03923933 210 218 I-Observation

- NCT03923933 221 222 O
Use NCT03923933 224 227 O
of NCT03923933 228 230 O
a NCT03923933 231 232 O
loop NCT03923933 233 237 B-Drug
diuretic NCT03923933 238 246 I-Drug
for NCT03923933 247 250 O
at NCT03923933 251 253 B-Eq-Comparison
least NCT03923933 254 259 I-Eq-Comparison
one NCT03923933 260 263 I-Eq-Comparison
month NCT03923933 264 269 I-Eq-Comparison

Exclusion NCT03923933 270 279 O
Criteria NCT03923933 280 288 O
: NCT03923933 289 290 O

- NCT03923933 294 295 O
Allergies NCT03923933 297 306 B-Allergy
known NCT03923933 307 312 O
to NCT03923933 313 315 O
diuretics NCT03923933 316 325 B-Drug

- NCT03923933 328 329 O
Patients NCT03923933 331 339 O
with NCT03923933 340 344 O
severe NCT03923933 345 351 O
infections NCT03923933 352 362 B-Condition

- NCT03923933 365 366 O
Patients NCT03923933 368 376 O
with NCT03923933 377 381 O
hemodynamic NCT03923933 382 393 B-Condition
instability NCT03923933 394 405 I-Condition

- NCT03923933 408 409 O
Amputees NCT03923933 411 419 B-Condition

- NCT03923933 422 423 O
Patients NCT03923933 425 433 O
with NCT03923933 434 438 O
cognitive NCT03923933 439 448 B-Condition
impairment NCT03923933 449 459 I-Condition

- NCT03923933 462 463 O
Patients NCT03923933 465 473 O
with NCT03923933 474 478 O
acute NCT03923933 479 484 O
renal NCT03923933 485 490 B-Condition
failure NCT03923933 491 498 I-Condition

- NCT03923933 501 502 O
Patients NCT03923933 504 512 O
with NCT03923933 513 517 O
graft NCT03923933 518 523 B-Condition
loss NCT03923933 524 528 I-Condition

Inclusion NCT03922620 0 9 O
Criteria NCT03922620 10 18 O
: NCT03922620 19 20 O

1 NCT03922620 24 25 O
. NCT03922620 25 26 O
Patients NCT03922620 28 36 O
18 NCT03922620 37 39 B-Eq-Comparison
years NCT03922620 40 45 I-Eq-Comparison
of NCT03922620 46 48 I-Eq-Comparison
age NCT03922620 49 52 I-Eq-Comparison
or NCT03922620 53 55 I-Eq-Comparison
older NCT03922620 56 61 I-Eq-Comparison

2 NCT03922620 64 65 O
. NCT03922620 65 66 O
Patients NCT03922620 68 76 O
undergoing NCT03922620 77 87 B-Eq-Comparison
elective NCT03922620 88 96 O
primary NCT03922620 97 104 B-Modifier
ankle NCT03922620 105 110 I-Modifier
or NCT03922620 111 113 B-Or
hindfoot NCT03922620 114 122 B-Modifier
surgery NCT03922620 123 130 B-Procedure
( NCT03922620 131 132 O
ankle NCT03922620 133 138 B-Procedure
arthrodesis NCT03922620 139 150 I-Procedure
, NCT03922620 151 152 O
subtalar NCT03922620 153 161 B-Procedure
arthrodesis NCT03922620 162 173 I-Procedure
, NCT03922620 174 175 O
triple NCT03922620 176 182 B-Procedure
arthrodesis NCT03922620 183 194 I-Procedure
, NCT03922620 195 196 O
total NCT03922620 197 202 B-Procedure
ankle NCT03922620 203 208 I-Procedure
arthroplasty NCT03922620 209 221 I-Procedure
, NCT03922620 222 223 O
peroneal NCT03922620 224 232 B-Procedure
tendon NCT03922620 233 239 I-Procedure
debridement NCT03922620 240 251 B-Modifier
/ NCT03922620 252 253 B-Or
transfer NCT03922620 254 262 B-Modifier
, NCT03922620 263 264 O
Cavus NCT03922620 265 270 B-Procedure
Reconstruction NCT03922620 271 285 I-Procedure
, NCT03922620 286 287 O
Medial NCT03922620 288 294 B-Procedure
Displacement NCT03922620 295 307 I-Procedure
Calcaneal NCT03922620 308 317 I-Procedure
Osteotomy NCT03922620 318 327 I-Procedure
, NCT03922620 328 329 O
Dwyer NCT03922620 330 335 B-Procedure
Osteotomy NCT03922620 336 345 I-Procedure
) NCT03922620 346 347 O

Exclusion NCT03922620 349 358 O
Criteria NCT03922620 359 367 O
: NCT03922620 368 369 O

1 NCT03922620 373 374 O
. NCT03922620 374 375 O
Patients NCT03922620 377 385 O
who NCT03922620 386 389 O
are NCT03922620 390 393 O
undergoing NCT03922620 394 404 B-Eq-Comparison
revision NCT03922620 405 413 B-Procedure
surgical NCT03922620 414 422 I-Procedure
procedure NCT03922620 423 432 I-Procedure

2 NCT03922620 435 436 O
. NCT03922620 436 437 O
Patients NCT03922620 439 447 O
who NCT03922620 448 451 O
have NCT03922620 452 456 O
taken NCT03922620 457 462 O
opioid NCT03922620 463 469 B-Drug
pain NCT03922620 470 474 I-Drug
medications NCT03922620 475 486 I-Drug
in NCT03922620 487 489 O
the NCT03922620 490 493 O
past NCT03922620 494 498 B-Eq-Comparison
3 NCT03922620 499 500 I-Eq-Comparison
months NCT03922620 501 507 I-Eq-Comparison
prior NCT03922620 508 513 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922620 514 516 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgical NCT03922620 517 525 B-Procedure
procedure NCT03922620 526 535 I-Procedure

3 NCT03922620 538 539 O
. NCT03922620 539 540 O
Patients NCT03922620 542 550 O
who NCT03922620 551 554 O
have NCT03922620 555 559 O
allergies NCT03922620 560 569 B-Allergy
to NCT03922620 570 572 O
any NCT03922620 573 576 O
of NCT03922620 577 579 O
the NCT03922620 580 583 O
medications NCT03922620 584 595 B-Drug
or NCT03922620 596 598 O
components NCT03922620 599 609 O
of NCT03922620 610 612 O
medications NCT03922620 613 624 O
investigated NCT03922620 625 637 O
in NCT03922620 638 640 O
the NCT03922620 641 644 O
study NCT03922620 645 650 B-Study

4 NCT03922620 653 654 O
. NCT03922620 654 655 O
Patients NCT03922620 657 665 O
currently NCT03922620 666 675 B-Eq-Comparison
incarcerated NCT03922620 676 688 B-Observation

5 NCT03922620 691 692 O
. NCT03922620 692 693 O
Patients NCT03922620 695 703 O
who NCT03922620 704 707 O
can NCT03922620 708 711 B-Negation
not NCT03922620 711 714 O
read NCT03922620 715 719 O
and NCT03922620 720 723 O
speak NCT03922620 724 729 O
English NCT03922620 730 737 O

Inclusion NCT03922152 0 9 O
Criteria NCT03922152 10 18 O
: NCT03922152 19 20 O

- NCT03922152 24 25 O
histologically NCT03922152 27 41 O
proven NCT03922152 42 48 O
advanced NCT03922152 49 57 O
esophageal NCT03922152 58 68 B-Modifier
cancer NCT03922152 69 75 B-Condition

- NCT03922152 78 79 O
excluded NCT03922152 81 89 B-Negation
from NCT03922152 90 94 O
curative NCT03922152 95 103 B-Procedure
therapy NCT03922152 104 111 I-Procedure
because NCT03922152 112 119 O
of NCT03922152 120 122 O
disease NCT03922152 123 130 B-Coreference
stage NCT03922152 131 136 I-Coreference
and NCT03922152 137 140 B-Or
/ NCT03922152 141 142 I-Or
or NCT03922152 143 145 I-Or
presence NCT03922152 146 154 O
of NCT03922152 155 157 O
multiple NCT03922152 158 166 B-Eq-Comparison
comorbidities NCT03922152 167 180 B-Condition
and NCT03922152 181 184 B-Or
/ NCT03922152 185 186 I-Or
or NCT03922152 187 189 I-Or
poor NCT03922152 190 194 B-Condition
performance NCT03922152 195 206 I-Condition
status NCT03922152 207 213 I-Condition

- NCT03922152 216 217 O
age NCT03922152 219 222 B-Age
> NCT03922152 223 224 B-Eq-Comparison
18 NCT03922152 225 227 I-Eq-Comparison
years NCT03922152 228 233 I-Eq-Comparison

- NCT03922152 236 237 O
Eastern NCT03922152 239 246 B-Condition
Cooperative NCT03922152 247 258 I-Condition
Oncology NCT03922152 259 267 I-Condition
Group NCT03922152 268 273 I-Condition
( NCT03922152 274 275 O
ECOG NCT03922152 276 280 B-Condition
) NCT03922152 281 282 O
< NCT03922152 283 284 B-Eq-Comparison
3 NCT03922152 285 286 I-Eq-Comparison

Exclusion NCT03922152 288 297 O
Criteria NCT03922152 298 306 O
: NCT03922152 307 308 O

- NCT03922152 312 313 O
prior NCT03922152 315 320 B-Eq-Comparison
radiotherapy NCT03922152 321 333 B-Procedure
to NCT03922152 334 336 O
the NCT03922152 337 340 O
same NCT03922152 341 345 B-Modifier
region NCT03922152 346 352 I-Modifier

Inclusion NCT03929991 0 9 O
Criteria NCT03929991 10 18 O
: NCT03929991 19 20 O

- NCT03929991 24 25 O
All NCT03929991 27 30 O
pregnant NCT03929991 31 39 B-Condition
women NCT03929991 40 45 O
undergoing NCT03929991 46 56 B-Eq-Comparison
a NCT03929991 57 58 O
C NCT03929991 59 60 B-Procedure
/ NCT03929991 61 62 I-Procedure
S NCT03929991 63 64 I-Procedure
in NCT03929991 65 67 O
on NCT03929991 68 70 O
the NCT03929991 71 74 O
hospitals NCT03929991 75 84 O
during NCT03929991 85 91 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929991 92 95 O
study NCT03929991 96 101 B-Study
period NCT03929991 102 108 O
will NCT03929991 109 113 O
be NCT03929991 114 116 O
eligible NCT03929991 117 125 O
to NCT03929991 126 128 O
participate NCT03929991 129 140 O
in NCT03929991 141 143 O
this NCT03929991 144 148 O
study NCT03929991 149 154 O
. NCT03929991 154 155 O

Exclusion NCT03929991 157 166 O
Criteria NCT03929991 167 175 O
: NCT03929991 176 177 O

The NCT03929991 179 182 O
following NCT03929991 183 192 O
conditions NCT03929991 193 203 O
will NCT03929991 204 208 O
not NCT03929991 209 212 O
be NCT03929991 213 215 O
considered NCT03929991 216 226 O
as NCT03929991 227 229 O
outcome NCT03929991 230 237 O
, NCT03929991 238 239 O
unless NCT03929991 240 246 O
they NCT03929991 247 251 O
present NCT03929991 252 259 O
with NCT03929991 260 264 O

systemic NCT03929991 265 273 B-Modifier
repercussion NCT03929991 274 286 B-Condition
due NCT03929991 287 290 O
to NCT03929991 291 293 O
infection NCT03929991 294 303 B-Condition
. NCT03929991 303 304 O
For NCT03929991 306 309 O
example NCT03929991 310 317 O
: NCT03929991 318 319 O

- NCT03929991 323 324 O
Vaginosis NCT03929991 326 335 B-Condition
, NCT03929991 336 337 O
candidiasis NCT03929991 338 349 B-Condition

- NCT03929991 352 353 O
Lower NCT03929991 355 360 B-Modifier
tract NCT03929991 361 366 I-Modifier
urinary NCT03929991 367 374 I-Modifier
infection NCT03929991 375 384 B-Condition

- NCT03929991 387 388 O
Fungal NCT03929991 390 396 B-Modifier
infections NCT03929991 397 407 B-Condition
of NCT03929991 408 410 O
the NCT03929991 411 414 O
skin NCT03929991 415 419 B-Modifier
( NCT03929991 420 421 O
athlete NCT03929991 422 429 B-Condition
's NCT03929991 429 431 O
foot NCT03929991 432 436 I-Condition
, NCT03929991 437 438 O
jockitch NCT03929991 439 447 B-Condition
, NCT03929991 448 449 O
ringworm NCT03929991 450 458 B-Condition
, NCT03929991 459 460 O
and NCT03929991 461 464 O
yeast NCT03929991 465 470 B-Condition
infections NCT03929991 471 481 I-Condition
) NCT03929991 482 483 O

- NCT03929991 487 488 O
Otitis NCT03929991 490 496 B-Condition

- NCT03929991 499 500 O
Pharyngitis NCT03929991 502 513 B-Condition

- NCT03929991 516 517 O
Herpes NCT03929991 519 525 B-Condition|Condition
simplex NCT03929991 526 533 I-Condition
, NCT03929991 534 535 O
Herpes NCT03929991 536 542 O
Zoster NCT03929991 543 549 I-Condition
( NCT03929991 550 551 O
Shingles NCT03929991 552 560 B-Condition
) NCT03929991 561 562 O

- NCT03929991 566 567 O
Uncomplicated NCT03929991 569 582 B-Modifier
chronic NCT03929991 583 590 B-Condition
infection NCT03929991 591 600 I-Condition

- NCT03929991 603 604 O
Sexually NCT03929991 606 614 B-Condition
transmitted NCT03929991 615 626 I-Condition
infections NCT03929991 627 637 I-Condition
( NCT03929991 638 639 O
Gonorrhoea NCT03929991 640 650 B-Condition
, NCT03929991 651 652 O
Syphilis NCT03929991 653 661 B-Condition
, NCT03929991 662 663 O
Trichomonas NCT03929991 664 675 B-Condition
, NCT03929991 676 677 O
Chlamydia NCT03929991 678 687 B-Condition
, NCT03929991 688 689 O
Hepatitis NCT03929991 690 699 B-Condition
, NCT03929991 700 701 O
HIV NCT03929991 702 705 B-Condition
) NCT03929991 706 707 O

- NCT03929991 711 712 O
Tuberculosis NCT03929991 714 726 B-Condition

- NCT03929991 729 730 O
Bacterial NCT03929991 732 741 B-Condition
colonization NCT03929991 742 754 I-Condition
( NCT03929991 755 756 O
presence NCT03929991 757 765 O
of NCT03929991 766 768 O
microorganisms NCT03929991 769 783 B-Organism
without NCT03929991 784 791 B-Negation
clinical NCT03929991 792 800 B-Condition
signs NCT03929991 801 806 I-Condition
/ NCT03929991 807 808 I-Condition
symptoms NCT03929991 809 817 I-Condition
) NCT03929991 818 819 O

- NCT03929991 823 824 O
Known NCT03929991 826 831 O
vaginal NCT03929991 832 839 B-Modifier
, NCT03929991 840 841 O
urethral NCT03929991 842 850 B-Modifier
and NCT03929991 851 854 B-Or
/ NCT03929991 855 856 I-Or
or NCT03929991 857 859 I-Or
rectal NCT03929991 860 866 B-Modifier
GBS NCT03929991 867 870 B-Condition
colonization NCT03929991 871 883 I-Condition

- NCT03929991 886 887 O
Asymptomatic NCT03929991 889 901 B-Condition
bacteriuria NCT03929991 902 913 I-Condition

- NCT03929991 916 917 O
Known NCT03929991 919 924 O
oropharyngeal NCT03929991 925 938 B-Condition
colonization NCT03929991 939 951 I-Condition

- NCT03929991 954 955 I-Modifier
Non NCT03929991 957 960 B-Modifier
- NCT03929991 961 962 O
infectious NCT03929991 963 973 I-Modifier
hypothermia NCT03929991 974 985 B-Condition
/ NCT03929991 986 987 B-Or
hyperthermia NCT03929991 988 1000 B-Condition
( NCT03929991 1001 1002 O
e. NCT03929991 1003 1005 O
g. NCT03929991 1006 1008 O
related NCT03929991 1010 1017 O
to NCT03929991 1018 1020 O
epidural NCT03929991 1021 1029 B-Procedure
, NCT03929991 1030 1031 O
thyroid NCT03929991 1032 1039 B-Condition
storm NCT03929991 1040 1045 I-Condition
, NCT03929991 1046 1047 O
prostaglandin NCT03929991 1048 1061 B-Drug
administration NCT03929991 1062 1076 O
) NCT03929991 1077 1078 O
during NCT03929991 1079 1085 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospital NCT03929991 1086 1094 B-Encounter
stay NCT03929991 1095 1099 I-Encounter

Inclusion NCT03928457 0 9 O
Criteria NCT03928457 10 18 O
: NCT03928457 19 20 O

- NCT03928457 24 25 O
preterm NCT03928457 27 34 B-Condition
neonates NCT03928457 35 43 O
born NCT03928457 44 48 B-Birth
at NCT03928457 49 51 B-Temporal-Connection___Temporal-Connection-Type-Value:during
26 NCT03928457 52 54 B-Eq-Comparison
to NCT03928457 55 57 I-Eq-Comparison
34 NCT03928457 58 60 I-Eq-Comparison
weeks NCT03928457 61 66 I-Eq-Comparison
of NCT03928457 67 69 O
gestational NCT03928457 70 81 B-Observation
age NCT03928457 82 85 I-Observation

- NCT03928457 88 89 O
signed NCT03928457 91 97 O
written NCT03928457 98 105 O
informed NCT03928457 106 114 O
consent NCT03928457 115 122 O
form NCT03928457 123 127 O

Exclusion NCT03928457 128 137 O
Criteria NCT03928457 138 146 O
: NCT03928457 147 148 O

- NCT03928457 152 153 O
infants NCT03928457 155 162 O
infected NCT03928457 163 171 B-Condition

- NCT03928457 174 175 O
infants NCT03928457 177 184 O
suffering NCT03928457 185 194 O
from NCT03928457 195 199 O
neurological NCT03928457 200 212 B-Condition
disorders NCT03928457 213 222 I-Condition

- NCT03928457 225 226 O
serious NCT03928457 228 235 O
heart NCT03928457 236 241 B-Modifier
, NCT03928457 242 243 O
respiratory NCT03928457 244 255 B-Modifier
, NCT03928457 256 257 O
digestive NCT03928457 258 267 B-Modifier
or NCT03928457 268 270 B-Or
metabolic NCT03928457 271 280 B-Modifier
diseases NCT03928457 281 289 B-Condition

- NCT03928457 292 293 O
infants NCT03928457 295 302 O
born NCT03928457 303 307 B-Birth
from NCT03928457 308 312 O
mothers NCT03928457 313 320 B-Family-Member___Family-Member-Type:mother
aged NCT03928457 321 325 B-Age
less NCT03928457 326 330 B-Eq-Comparison
than NCT03928457 331 335 I-Eq-Comparison
18 NCT03928457 336 338 I-Eq-Comparison
years NCT03928457 339 344 I-Eq-Comparison
old NCT03928457 345 348 O
or NCT03928457 349 351 B-Or
deprived NCT03928457 352 360 B-Observation
of NCT03928457 361 363 I-Observation
their NCT03928457 364 369 I-Observation
parental NCT03928457 370 378 I-Observation
rights NCT03928457 379 385 I-Observation

- NCT03928457 388 389 O
non NCT03928457 391 394 B-Negation
covered NCT03928457 395 402 O
by NCT03928457 403 405 O
national NCT03928457 406 414 O
health NCT03928457 415 421 O
insurance NCT03928457 422 431 O

Inclusion NCT03922191 0 9 O
Criteria NCT03922191 10 18 O
: NCT03922191 19 20 O

- NCT03922191 24 25 O
post NCT03922191 27 31 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03922191 32 33 O
cardiac NCT03922191 34 41 B-Procedure
surgery NCT03922191 42 49 I-Procedure
mediastinitis NCT03922191 50 63 B-Condition

- NCT03922191 66 67 O
patients NCT03922191 69 77 O
of NCT03922191 78 80 O
the NCT03922191 81 84 O
CHU NCT03922191 85 88 O
Brugmann NCT03922191 89 97 O
( NCT03922191 98 99 O
adults NCT03922191 100 106 O
) NCT03922191 107 108 O
and NCT03922191 109 112 O
HUDERF NCT03922191 113 119 O
( NCT03922191 120 121 O
pediatric NCT03922191 122 131 O
) NCT03922191 132 133 O
Hospitals NCT03922191 134 143 O

Exclusion NCT03922191 144 153 O
Criteria NCT03922191 154 162 O
: NCT03922191 163 164 O

- NCT03922191 167 168 O
none NCT03922191 169 173 O

Inclusion NCT03929952 0 9 O
Criteria NCT03929952 10 18 O
: NCT03929952 19 20 O

- NCT03929952 24 25 O
Patient NCT03929952 27 34 O
with NCT03929952 35 39 O
a NCT03929952 40 41 O
wifi NCT03929952 42 46 O
connexion NCT03929952 47 56 O
at NCT03929952 57 59 O
home NCT03929952 60 64 O

- NCT03929952 67 68 O
Patient NCT03929952 70 77 O
with NCT03929952 78 82 O
the NCT03929952 83 86 O
ability NCT03929952 87 94 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929952 95 97 I-Assertion___Assertion-Type-Value:hypothetical
modulate NCT03929952 98 106 B-Observation
the NCT03929952 107 110 I-Observation
height NCT03929952 111 117 I-Observation
of NCT03929952 118 120 I-Observation
the NCT03929952 121 124 I-Observation
candle NCT03929952 125 131 I-Observation
by NCT03929952 132 134 O
thinking NCT03929952 135 143 O
in NCT03929952 144 146 O
the NCT03929952 147 150 O
alpha NCT03929952 151 156 B-Observation
synchrony NCT03929952 157 166 I-Observation
test NCT03929952 167 171 I-Observation
. NCT03929952 171 172 O

- NCT03929952 176 177 O
Patient NCT03929952 179 186 O
with NCT03929952 187 191 O
chronic NCT03929952 192 199 B-Condition
low NCT03929952 200 203 I-Condition
back NCT03929952 204 208 I-Condition
pain NCT03929952 209 213 I-Condition
for NCT03929952 214 217 O
more NCT03929952 218 222 B-Eq-Comparison
than NCT03929952 223 227 I-Eq-Comparison
six NCT03929952 228 231 I-Eq-Comparison
months NCT03929952 232 238 I-Eq-Comparison
with NCT03929952 239 243 B-And
a NCT03929952 244 245 O
visual NCT03929952 246 252 B-Observation
analogue NCT03929952 253 261 I-Observation
pain NCT03929952 262 266 I-Observation
scale NCT03929952 267 272 I-Observation
greater NCT03929952 273 280 B-Eq-Comparison
than NCT03929952 281 285 I-Eq-Comparison
5 NCT03929952 286 287 I-Eq-Comparison
impacting NCT03929952 288 297 O
activities NCT03929952 298 308 O
of NCT03929952 309 311 O
daily NCT03929952 312 317 O
living NCT03929952 318 324 O
, NCT03929952 325 326 O
hobbies NCT03929952 327 334 O
and NCT03929952 335 338 O
work NCT03929952 339 343 O

- NCT03929952 346 347 O
Patient NCT03929952 349 356 O
having NCT03929952 357 363 O
given NCT03929952 364 369 O
free NCT03929952 370 374 O
and NCT03929952 375 378 O
informed NCT03929952 379 387 O
consent NCT03929952 388 395 O
and NCT03929952 396 399 O
signed NCT03929952 400 406 O
consent NCT03929952 407 414 O
. NCT03929952 414 415 O

- NCT03929952 419 420 O
Affected NCT03929952 422 430 O
patient NCT03929952 431 438 O
or NCT03929952 439 441 O
beneficiary NCT03929952 442 453 O
of NCT03929952 454 456 O
a NCT03929952 457 458 O
health NCT03929952 459 465 O
insurance NCT03929952 466 475 O
plan NCT03929952 476 480 O
. NCT03929952 480 481 O

- NCT03929952 485 486 O
Patient NCT03929952 488 495 O
who NCT03929952 496 499 O
is NCT03929952 500 502 O
at NCT03929952 503 505 B-Eq-Comparison
least NCT03929952 506 511 I-Eq-Comparison
18 NCT03929952 512 514 I-Eq-Comparison
years NCT03929952 515 520 I-Eq-Comparison
old NCT03929952 521 524 B-Age
( NCT03929952 525 526 O
≥ NCT03929952 528 529 O
) NCT03929952 531 532 O
and NCT03929952 533 536 B-And
younger NCT03929952 537 544 B-Eq-Comparison
than NCT03929952 545 549 I-Eq-Comparison
75 NCT03929952 550 552 I-Eq-Comparison
years NCT03929952 553 558 I-Eq-Comparison
old NCT03929952 559 562 B-Age
( NCT03929952 563 564 O
< NCT03929952 566 567 O
) NCT03929952 569 570 O
. NCT03929952 571 572 O

Exclusion NCT03929952 574 583 O
Criteria NCT03929952 584 592 O
: NCT03929952 593 594 O

- NCT03929952 598 599 O
Pregnant NCT03929952 601 609 B-Condition
or NCT03929952 610 612 B-Or
breastfeeding NCT03929952 613 626 B-Condition
patient NCT03929952 627 634 O

- NCT03929952 637 638 O
Patient NCT03929952 640 647 O
with NCT03929952 648 652 O
a NCT03929952 653 654 O
contraindication NCT03929952 655 671 B-Contraindication
to NCT03929952 672 674 O
performing NCT03929952 675 685 O
a NCT03929952 686 687 O
fMRI NCT03929952 688 692 B-Procedure
scan NCT03929952 693 697 I-Procedure
: NCT03929952 698 699 O
ferromagnetic NCT03929952 700 713 B-Procedure
implant NCT03929952 714 721 I-Procedure
in NCT03929952 722 724 O
the NCT03929952 725 728 O
body NCT03929952 729 733 O
, NCT03929952 734 735 O
piercing NCT03929952 736 744 B-Condition
, NCT03929952 745 746 O
claustrophobia NCT03929952 747 761 B-Condition
, NCT03929952 762 763 O
unable NCT03929952 764 770 B-Condition
to NCT03929952 771 773 I-Condition
remain NCT03929952 774 780 I-Condition
in NCT03929952 781 783 I-Condition
the NCT03929952 784 787 I-Condition
scanner NCT03929952 788 795 I-Condition
stationary NCT03929952 796 806 I-Condition
for NCT03929952 807 810 O
40 NCT03929952 811 813 B-Eq-Comparison
minutes NCT03929952 814 821 I-Eq-Comparison

- NCT03929952 824 825 O
Patient NCT03929952 827 834 O
already NCT03929952 835 842 O
included NCT03929952 843 851 O
in NCT03929952 852 854 O
another NCT03929952 855 862 O
study NCT03929952 863 868 O

- NCT03929952 871 872 O
Patient NCT03929952 874 881 O
in NCT03929952 882 884 O
a NCT03929952 885 886 O
exclusion NCT03929952 887 896 O
period NCT03929952 897 903 O
determined NCT03929952 904 914 O
by NCT03929952 915 917 O
a NCT03929952 918 919 O
previous NCT03929952 920 928 B-Eq-Comparison
study NCT03929952 929 934 B-Study

- NCT03929952 937 938 O
The NCT03929952 940 943 O
subject NCT03929952 944 951 O
is NCT03929952 952 954 O
under NCT03929952 955 960 O
the NCT03929952 961 964 O
protection NCT03929952 965 975 B-Observation
of NCT03929952 976 978 I-Observation
justice NCT03929952 979 986 I-Observation
, NCT03929952 987 988 O
guardianship NCT03929952 989 1001 O
or NCT03929952 1002 1004 O
curatorship NCT03929952 1005 1016 O
. NCT03929952 1016 1017 O

- NCT03929952 1021 1022 O
The NCT03929952 1024 1027 O
subject NCT03929952 1028 1035 O
refuses NCT03929952 1036 1043 O
to NCT03929952 1044 1046 O
sign NCT03929952 1047 1051 O
the NCT03929952 1052 1055 O
consent NCT03929952 1056 1063 O
. NCT03929952 1063 1064 O

- NCT03929952 1068 1069 O
It NCT03929952 1071 1073 O
is NCT03929952 1074 1076 O
not NCT03929952 1077 1080 O
possible NCT03929952 1081 1089 O
to NCT03929952 1090 1092 O
give NCT03929952 1093 1097 O
the NCT03929952 1098 1101 O
subject NCT03929952 1102 1109 O
informed NCT03929952 1110 1118 O
information NCT03929952 1119 1130 O
. NCT03929952 1130 1131 O

Inclusion NCT03920787 0 9 O
Criteria NCT03920787 10 18 O
: NCT03920787 19 20 O

- NCT03920787 24 25 O
8 NCT03920787 27 28 B-Eq-Comparison
- NCT03920787 29 30 I-Eq-Comparison
18 NCT03920787 31 33 I-Eq-Comparison
years NCT03920787 34 39 I-Eq-Comparison
old NCT03920787 40 43 B-Age

- NCT03920787 46 47 O
overweight NCT03920787 49 59 B-Condition
or NCT03920787 60 62 B-Or
obesity NCT03920787 63 70 B-Condition

- NCT03920787 73 74 O
basal NCT03920787 76 81 B-Drug
insulin NCT03920787 82 89 I-Drug
≥ NCT03920787 90 91 B-Eq-Comparison
20 NCT03920787 92 94 I-Eq-Comparison
uU NCT03920787 95 97 I-Eq-Comparison
/ NCT03920787 98 99 I-Eq-Comparison
ml NCT03920787 100 102 I-Eq-Comparison

Exclusion NCT03920787 103 112 O
Criteria NCT03920787 113 121 O
: NCT03920787 122 123 O

- NCT03920787 127 128 O
pubertal NCT03920787 130 138 B-Condition
delay NCT03920787 139 144 I-Condition

- NCT03920787 147 148 O
hypogonadism NCT03920787 150 162 B-Condition

- NCT03920787 165 166 O
hypothyroidism NCT03920787 168 182 B-Condition
or NCT03920787 183 185 B-Or
hyperthyroidism NCT03920787 186 201 B-Condition

- NCT03920787 204 205 O
obesity NCT03920787 207 214 B-Condition
- NCT03920787 215 216 O
related NCT03920787 217 224 O
genetic NCT03920787 225 232 B-Condition
diseases NCT03920787 233 241 I-Condition

Inclusion NCT03923517 0 9 O
Criteria NCT03923517 10 18 O
: NCT03923517 19 20 O

- NCT03923517 24 25 O
informal NCT03923517 27 35 O
carer NCT03923517 36 41 O
of NCT03923517 42 44 O
a NCT03923517 45 46 O
person NCT03923517 47 53 O
with NCT03923517 54 58 O
YOD NCT03923517 59 62 B-Condition
who NCT03923517 63 66 O
has NCT03923517 67 70 O
been NCT03923517 71 75 O
diagnosed NCT03923517 76 85 O
with NCT03923517 86 90 O
either NCT03923517 91 97 O
Frontal NCT03923517 98 105 B-Condition
Temporal NCT03923517 106 114 I-Condition
Dementia NCT03923517 115 123 I-Condition
( NCT03923517 124 125 O
FTD NCT03923517 126 129 B-Condition
) NCT03923517 130 131 O
or NCT03923517 132 134 B-Or
Alzheimer NCT03923517 135 144 B-Condition
's NCT03923517 144 146 O
Disease NCT03923517 147 154 I-Condition
( NCT03923517 155 156 O
AD NCT03923517 157 159 B-Condition
) NCT03923517 160 161 O
12 NCT03923517 162 164 B-Eq-Comparison
months NCT03923517 165 171 I-Eq-Comparison
ago NCT03923517 172 175 I-Eq-Comparison
or NCT03923517 176 178 I-Eq-Comparison
less NCT03923517 179 183 I-Eq-Comparison
; NCT03923517 183 184 O

- NCT03923517 187 188 O
the NCT03923517 190 193 O
carer NCT03923517 194 199 O
has NCT03923517 200 203 O
face NCT03923517 204 208 B-Observation
- NCT03923517 209 210 I-Observation
to NCT03923517 211 213 I-Observation
- NCT03923517 214 215 O
face NCT03923517 216 220 I-Observation
contact NCT03923517 221 228 I-Observation
with NCT03923517 229 233 O
the NCT03923517 234 237 O
person NCT03923517 238 244 O
with NCT03923517 245 249 O
YOD NCT03923517 250 253 B-Condition
at NCT03923517 254 256 B-Eq-Comparison
least NCT03923517 257 262 I-Eq-Comparison
twice NCT03923517 263 268 I-Eq-Comparison
a NCT03923517 269 270 I-Eq-Comparison
weak NCT03923517 271 275 I-Eq-Comparison
; NCT03923517 275 276 O

- NCT03923517 279 280 O
the NCT03923517 282 285 O
carer NCT03923517 286 291 O
has NCT03923517 292 295 O
a NCT03923517 296 297 O
working NCT03923517 298 305 O
computer NCT03923517 306 314 O
and NCT03923517 315 318 O
internet NCT03923517 319 327 O
access NCT03923517 328 334 O
in NCT03923517 335 337 O
his NCT03923517 338 341 O
home NCT03923517 342 346 O
; NCT03923517 346 347 O

- NCT03923517 350 351 O
the NCT03923517 353 356 O
carer NCT03923517 357 362 O
is NCT03923517 363 365 O
available NCT03923517 366 375 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923517 376 379 O
the NCT03923517 380 383 O
intervention NCT03923517 384 396 B-Study
duration NCT03923517 397 405 O
of NCT03923517 406 408 O
approximately NCT03923517 409 422 O
eight NCT03923517 423 428 B-Eq-Comparison
weeks NCT03923517 429 434 I-Eq-Comparison
; NCT03923517 434 435 O

- NCT03923517 438 439 O
the NCT03923517 441 444 O
carer NCT03923517 445 450 O
is NCT03923517 451 453 O
fluent NCT03923517 454 460 O
in NCT03923517 461 463 O
German NCT03923517 464 470 O
; NCT03923517 470 471 O

- NCT03923517 474 475 O
signed NCT03923517 477 483 O
consent NCT03923517 484 491 O
form NCT03923517 492 496 O
. NCT03923517 496 497 O

Exclusion NCT03923517 499 508 O
Criteria NCT03923517 509 517 O
: NCT03923517 518 519 O

- NCT03923517 523 524 O
the NCT03923517 526 529 O
carer NCT03923517 530 535 O
has NCT03923517 536 539 O
face NCT03923517 540 544 B-Observation
- NCT03923517 545 546 I-Observation
to NCT03923517 547 549 I-Observation
- NCT03923517 550 551 O
face NCT03923517 552 556 O
contact NCT03923517 557 564 I-Observation
with NCT03923517 565 569 O
the NCT03923517 570 573 O
person NCT03923517 574 580 O
with NCT03923517 581 585 O
YOD NCT03923517 586 589 B-Condition
less NCT03923517 590 594 B-Eq-Comparison
than NCT03923517 595 599 I-Eq-Comparison
twice NCT03923517 600 605 I-Eq-Comparison
a NCT03923517 606 607 I-Eq-Comparison
week NCT03923517 608 612 I-Eq-Comparison
; NCT03923517 612 613 O

- NCT03923517 616 617 O
the NCT03923517 619 622 O
person NCT03923517 623 629 O
with NCT03923517 630 634 O
YOD NCT03923517 635 638 B-Condition
the NCT03923517 639 642 O
carer NCT03923517 643 648 O
is NCT03923517 649 651 O
caring NCT03923517 652 658 O
for NCT03923517 659 662 O
has NCT03923517 663 666 O
a NCT03923517 667 668 O
different NCT03923517 669 678 B-Other
dementia NCT03923517 679 687 B-Condition
cause NCT03923517 688 693 B-Condition
other NCT03923517 694 699 B-Exception
than NCT03923517 700 704 I-Exception
FTD NCT03923517 705 708 B-Condition
or NCT03923517 709 711 B-Or|Or
AD NCT03923517 712 714 B-Condition
or NCT03923517 715 717 O
the NCT03923517 718 721 O
diagnosis NCT03923517 722 731 B-Coreference
is NCT03923517 732 734 O
older NCT03923517 735 740 B-Eq-Comparison
than NCT03923517 741 745 I-Eq-Comparison
12 NCT03923517 746 748 I-Eq-Comparison
months NCT03923517 749 755 I-Eq-Comparison
; NCT03923517 755 756 O

- NCT03923517 759 760 O
the NCT03923517 762 765 O
carer NCT03923517 766 771 O
does NCT03923517 772 776 O
not NCT03923517 777 780 O
have NCT03923517 781 785 O
a NCT03923517 786 787 O
working NCT03923517 788 795 O
computer NCT03923517 796 804 O
and NCT03923517 805 808 O
internet NCT03923517 809 817 O
access NCT03923517 818 824 O
at NCT03923517 825 827 O
home NCT03923517 828 832 O
or NCT03923517 833 835 O
is NCT03923517 836 838 O
not NCT03923517 839 842 O
confident NCT03923517 843 852 O
to NCT03923517 853 855 O
use NCT03923517 856 859 O
them NCT03923517 860 864 O
; NCT03923517 864 865 O

- NCT03923517 868 869 O
the NCT03923517 871 874 O
carer NCT03923517 875 880 O
is NCT03923517 881 883 O
not NCT03923517 884 887 B-Negation
available NCT03923517 888 897 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923517 898 901 O
the NCT03923517 902 905 O
approximately NCT03923517 906 919 O
eight NCT03923517 920 925 B-Eq-Comparison
week NCT03923517 926 930 I-Eq-Comparison
intervention NCT03923517 931 943 B-Study
duration NCT03923517 944 952 O
; NCT03923517 952 953 O

- NCT03923517 956 957 O
the NCT03923517 959 962 O
carer NCT03923517 963 968 O
is NCT03923517 969 971 O
not NCT03923517 972 975 B-Negation
fluent NCT03923517 976 982 O
in NCT03923517 983 985 O
German NCT03923517 986 992 O
; NCT03923517 992 993 O

- NCT03923517 996 997 O
the NCT03923517 999 1002 O
carer NCT03923517 1003 1008 O
has NCT03923517 1009 1012 O
a NCT03923517 1013 1014 O
significant NCT03923517 1015 1026 O
health NCT03923517 1027 1033 B-Condition
problem NCT03923517 1034 1041 I-Condition
or NCT03923517 1042 1044 B-Or
disability NCT03923517 1045 1055 B-Condition
, NCT03923517 1056 1057 O
which NCT03923517 1058 1063 O
precludes NCT03923517 1064 1073 O
him NCT03923517 1074 1077 O
/ NCT03923517 1078 1079 O
her NCT03923517 1080 1083 O
from NCT03923517 1084 1088 O
participating NCT03923517 1089 1102 O
in NCT03923517 1103 1105 O
the NCT03923517 1106 1109 O
study NCT03923517 1110 1115 O
; NCT03923517 1115 1116 O

- NCT03923517 1119 1120 O
no NCT03923517 1122 1124 O
signed NCT03923517 1125 1131 O
informed NCT03923517 1132 1140 O
consent NCT03923517 1141 1148 O
. NCT03923517 1148 1149 O

Inclusion NCT03928873 0 9 O
Criteria NCT03928873 10 18 O
: NCT03928873 19 20 O

1 NCT03928873 24 25 O
. NCT03928873 25 26 O
Older NCT03928873 28 33 B-Eq-Comparison
than NCT03928873 34 38 I-Eq-Comparison
20 NCT03928873 39 41 I-Eq-Comparison
years NCT03928873 42 47 I-Eq-Comparison
of NCT03928873 48 50 O
age NCT03928873 51 54 B-Age

2 NCT03928873 57 58 O
. NCT03928873 58 59 O
Grade NCT03928873 61 66 B-Eq-Comparison
2 NCT03928873 67 68 I-Eq-Comparison
~ NCT03928873 69 70 O
3 NCT03928873 71 72 O
trigger NCT03928873 73 80 B-Condition
finger NCT03928873 81 87 I-Condition
based NCT03928873 88 93 O
on NCT03928873 94 96 O
the NCT03928873 97 100 O
Quinnell NCT03928873 101 109 O
classification NCT03928873 110 124 O

Exclusion NCT03928873 125 134 O
Criteria NCT03928873 135 143 O
: NCT03928873 144 145 O

1 NCT03928873 149 150 O
. NCT03928873 150 151 O
Previous NCT03928873 153 161 B-Eq-Comparison
treatment NCT03928873 162 171 B-Procedure
by NCT03928873 172 174 O
physical NCT03928873 175 183 B-Procedure
therapy NCT03928873 184 191 I-Procedure
, NCT03928873 192 193 O
local NCT03928873 194 199 B-Procedure
corticosteroid NCT03928873 200 214 I-Procedure
injection NCT03928873 215 224 I-Procedure
, NCT03928873 225 226 O
or NCT03928873 227 229 B-Or
surgical NCT03928873 230 238 O
release NCT03928873 239 246 O
for NCT03928873 247 250 O
trigger NCT03928873 251 258 B-Condition
finger NCT03928873 259 265 I-Condition
before NCT03928873 266 272 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928873 273 276 O
study NCT03928873 277 282 B-Study

2 NCT03928873 285 286 O
. NCT03928873 286 287 O
The NCT03928873 289 292 O
presence NCT03928873 293 301 O
of NCT03928873 302 304 O
a NCT03928873 305 306 O
musculoskeletal NCT03928873 307 322 B-Condition
disease NCT03928873 323 330 I-Condition
or NCT03928873 331 333 B-Or
previous NCT03928873 334 342 B-Eq-Comparison
nerve NCT03928873 343 348 B-Condition
injuries NCT03928873 349 357 I-Condition
at NCT03928873 358 360 O
the NCT03928873 361 364 O
upper NCT03928873 365 370 B-Modifier
extremities NCT03928873 371 382 I-Modifier

3 NCT03928873 385 386 O
. NCT03928873 386 387 O
Multiple NCT03928873 389 397 B-Condition
trigger NCT03928873 398 405 I-Condition
finger NCT03928873 406 412 I-Condition
; NCT03928873 412 413 O
local NCT03928873 414 419 B-Condition
infection NCT03928873 420 429 I-Condition
; NCT03928873 429 430 O
malignancy NCT03928873 431 441 B-Condition
; NCT03928873 441 442 O
inflammatory NCT03928873 443 455 B-Condition
arthritis NCT03928873 456 465 I-Condition
; NCT03928873 465 466 O
cardiac NCT03928873 467 474 B-Condition
arrhythmia NCT03928873 475 485 I-Condition
or NCT03928873 486 488 B-Or
cardiac NCT03928873 489 496 B-Procedure
pacemaker NCT03928873 497 506 I-Procedure
; NCT03928873 506 507 O
and NCT03928873 508 511 B-Or
pregnancy NCT03928873 512 521 B-Condition
. NCT03928873 521 522 O

Inclusion NCT03922386 0 9 O
Criteria NCT03922386 10 18 O
: NCT03922386 19 20 O

1 NCT03922386 24 25 O
. NCT03922386 25 26 O
Any NCT03922386 28 31 O
subject NCT03922386 32 39 O
newly NCT03922386 40 45 O
implanted NCT03922386 46 55 O
according NCT03922386 56 65 O
to NCT03922386 66 68 O
the NCT03922386 69 72 O
most NCT03922386 73 77 O
recent NCT03922386 78 84 O
guidelines NCT03922386 85 95 O
from NCT03922386 96 100 O
the NCT03922386 101 104 O
European NCT03922386 105 113 O
Society NCT03922386 114 121 O
of NCT03922386 122 124 O
Cardiology NCT03922386 125 135 O
( NCT03922386 136 137 O
ESC NCT03922386 138 141 O
) NCT03922386 142 143 O
for NCT03922386 144 147 O
less NCT03922386 148 152 B-Eq-Comparison
than10 NCT03922386 153 159 I-Eq-Comparison
days NCT03922386 160 164 I-Eq-Comparison
with NCT03922386 165 169 O
: NCT03922386 170 171 O

- NCT03922386 180 181 O
a NCT03922386 183 184 O
Single NCT03922386 185 191 B-Modifier
Chamber NCT03922386 192 199 I-Modifier
( NCT03922386 200 201 O
SR NCT03922386 202 204 B-Modifier
) NCT03922386 205 206 O
or NCT03922386 207 209 B-Or
a NCT03922386 210 211 O
Dual NCT03922386 212 216 B-Modifier
Chamber NCT03922386 217 224 I-Modifier
( NCT03922386 225 226 O
DR NCT03922386 227 229 B-Modifier
) NCT03922386 230 231 O
pacemaker NCT03922386 232 241 B-Procedure
from NCT03922386 242 246 O
Microport NCT03922386 247 256 O
CRM NCT03922386 257 260 O
S. NCT03922386 261 263 O
r. NCT03922386 264 266 O
l. NCT03922386 267 269 O

- NCT03922386 278 279 O
any NCT03922386 281 284 O
right NCT03922386 285 290 B-Modifier
atrial NCT03922386 291 297 I-Modifier
and NCT03922386 298 301 B-Or
/ NCT03922386 302 303 I-Or
or NCT03922386 304 306 I-Or
right NCT03922386 307 312 B-Modifier
ventricular NCT03922386 313 324 I-Modifier
XFINE NCT03922386 325 330 B-Procedure
lead NCT03922386 331 335 I-Procedure

2 NCT03922386 338 339 O
. NCT03922386 339 340 O
Have NCT03922386 342 346 O
reviewed NCT03922386 347 355 O
, NCT03922386 356 357 O
signed NCT03922386 358 364 O
and NCT03922386 365 368 O
dated NCT03922386 369 374 O
the NCT03922386 375 378 O
informed NCT03922386 379 387 O
consent NCT03922386 388 395 O

Exclusion NCT03922386 396 405 O
Criteria NCT03922386 406 414 O
: NCT03922386 415 416 O

1 NCT03922386 420 421 O
. NCT03922386 421 422 O
Included NCT03922386 424 432 O
in NCT03922386 433 435 O
another NCT03922386 436 443 B-Other
clinical NCT03922386 444 452 O
study NCT03922386 453 458 B-Study
that NCT03922386 459 463 O
could NCT03922386 464 469 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03922386 470 478 O
the NCT03922386 479 482 O
results NCT03922386 483 490 O
of NCT03922386 491 493 O
this NCT03922386 494 498 O
study NCT03922386 499 504 B-Study
such NCT03922386 505 509 O
as NCT03922386 510 512 O
studies NCT03922386 513 520 B-Study
involving NCT03922386 521 530 O
intra NCT03922386 531 536 B-Procedure
- NCT03922386 537 538 I-Procedure
cardiac NCT03922386 539 546 I-Procedure
device NCT03922386 547 553 I-Procedure

2 NCT03922386 556 557 O
. NCT03922386 557 558 O
Contraindication NCT03922386 560 576 B-Contraindication
to NCT03922386 577 579 O
a NCT03922386 580 581 O
maximum NCT03922386 582 589 B-Eq-Comparison
single NCT03922386 590 596 I-Eq-Comparison
dose NCT03922386 597 601 I-Eq-Comparison
of NCT03922386 602 604 I-Eq-Comparison
310 NCT03922386 605 608 I-Eq-Comparison
µg NCT03922386 609 611 I-Eq-Comparison
Dexamethasone NCT03922386 612 625 B-Drug
Sodium NCT03922386 626 632 I-Drug
Phosphate NCT03922386 633 642 I-Drug
( NCT03922386 643 644 O
DSP NCT03922386 645 648 B-Drug
) NCT03922386 649 650 O

3 NCT03922386 654 655 O
. NCT03922386 655 656 O
Tricuspid NCT03922386 658 667 B-Condition
valvular NCT03922386 668 676 I-Condition
disease NCT03922386 677 684 I-Condition
or NCT03922386 685 687 B-Or
tricuspid NCT03922386 688 697 B-Procedure
replacement NCT03922386 698 709 I-Procedure
heart NCT03922386 710 715 I-Procedure
valve NCT03922386 716 721 I-Procedure
( NCT03922386 722 723 O
mechanical NCT03922386 724 734 B-Modifier
or NCT03922386 735 737 B-Or
tissue NCT03922386 738 744 B-Modifier
) NCT03922386 745 746 O
only NCT03922386 747 751 O
for NCT03922386 752 755 O
subject NCT03922386 756 763 O
with NCT03922386 764 768 O
DR NCT03922386 769 771 B-Procedure
pacemaker NCT03922386 772 781 I-Procedure

4 NCT03922386 784 785 O
. NCT03922386 785 786 O
Active NCT03922386 788 794 B-Eq-Comparison
myocarditis NCT03922386 795 806 B-Condition
, NCT03922386 807 808 O
pocket NCT03922386 809 815 B-Modifier
and NCT03922386 816 819 B-Or
/ NCT03922386 820 821 I-Or
or NCT03922386 822 824 I-Or
lead NCT03922386 825 829 B-Modifier
infection NCT03922386 830 839 B-Condition

5 NCT03922386 842 843 O
. NCT03922386 843 844 O
Age NCT03922386 846 849 B-Age
less NCT03922386 850 854 B-Eq-Comparison
than NCT03922386 855 859 I-Eq-Comparison
18 NCT03922386 860 862 I-Eq-Comparison
years NCT03922386 863 868 I-Eq-Comparison
old NCT03922386 869 872 O
or NCT03922386 873 875 O
under NCT03922386 876 881 O
guardianship NCT03922386 882 894 O
or NCT03922386 895 897 O
kept NCT03922386 898 902 O
in NCT03922386 903 905 O
detention NCT03922386 906 915 O

6 NCT03922386 918 919 O
. NCT03922386 919 920 O
Life NCT03922386 922 926 B-Observation
expectancy NCT03922386 927 937 I-Observation
less NCT03922386 938 942 B-Eq-Comparison
than NCT03922386 943 947 I-Eq-Comparison
1 NCT03922386 948 949 I-Eq-Comparison
year NCT03922386 950 954 I-Eq-Comparison

7 NCT03922386 957 958 O
. NCT03922386 958 959 O
Known NCT03922386 961 966 O
pregnancy NCT03922386 967 976 B-Condition
, NCT03922386 977 978 O
women NCT03922386 979 984 O
breastfeeding NCT03922386 985 998 B-Condition
or NCT03922386 999 1001 B-Or
in NCT03922386 1002 1004 O
childbearing NCT03922386 1005 1017 O
age NCT03922386 1018 1021 O
without NCT03922386 1022 1029 B-Negation
an NCT03922386 1030 1032 O
adequate NCT03922386 1033 1041 O
contraceptive NCT03922386 1042 1055 B-Procedure
method NCT03922386 1056 1062 I-Procedure

8 NCT03922386 1065 1066 O
. NCT03922386 1066 1067 O
Be NCT03922386 1069 1071 O
unavailable NCT03922386 1072 1083 O
for NCT03922386 1084 1087 O
the NCT03922386 1088 1091 O
scheduled NCT03922386 1092 1101 O
follow NCT03922386 1102 1108 O
- NCT03922386 1109 1110 O
up NCT03922386 1111 1113 O
associated NCT03922386 1114 1124 O
with NCT03922386 1125 1129 O
this NCT03922386 1130 1134 O
clinical NCT03922386 1135 1143 O
study NCT03922386 1144 1149 O
or NCT03922386 1150 1152 O
refusal NCT03922386 1153 1160 O
to NCT03922386 1161 1163 O
cooperate NCT03922386 1164 1173 O

Inclusion NCT03925402 0 9 O
Criteria NCT03925402 10 18 O
: NCT03925402 19 20 O

- NCT03925402 24 25 O
Adults NCT03925402 27 33 O
, NCT03925402 34 35 O
either NCT03925402 36 42 O
sex NCT03925402 43 46 O
, NCT03925402 47 48 O
ages NCT03925402 49 53 B-Age
18 NCT03925402 54 56 B-Eq-Comparison
years NCT03925402 57 62 I-Eq-Comparison
or NCT03925402 63 65 I-Eq-Comparison
above NCT03925402 66 71 I-Eq-Comparison

- NCT03925402 74 75 O
Patients NCT03925402 77 85 O
with NCT03925402 86 90 O
3 NCT03925402 91 92 B-Condition
GCRE NCT03925402 93 97 O
bacteremia NCT03925402 98 108 I-Condition

- NCT03925402 111 112 O
Patients NCT03925402 114 122 O
admitted NCT03925402 123 131 B-Encounter
to NCT03925402 132 134 O
any NCT03925402 135 138 O
of NCT03925402 139 141 O
the NCT03925402 142 145 O
study NCT03925402 146 151 O
sites NCT03925402 152 157 O

Exclusion NCT03925402 158 167 O
Criteria NCT03925402 168 176 O
: NCT03925402 177 178 O

- NCT03925402 182 183 O
Discontinuation NCT03925402 185 200 O
of NCT03925402 201 203 O
antibiotic NCT03925402 204 214 B-Drug
due NCT03925402 215 218 O
to NCT03925402 219 221 O
transition NCT03925402 222 232 B-Encounter
to NCT03925402 233 235 O
hospice NCT03925402 236 243 O
care NCT03925402 244 248 O

- NCT03925402 251 252 O
Polymicrobial NCT03925402 254 267 B-Condition
bacteremia NCT03925402 268 278 I-Condition

- NCT03925402 281 282 O
Empirical NCT03925402 284 293 B-Drug
antibiotic NCT03925402 294 304 I-Drug
after NCT03925402 305 310 B-Temporal-Connection___Temporal-Connection-Type-Value:after
24 NCT03925402 311 313 B-Eq-Comparison
hours NCT03925402 314 319 I-Eq-Comparison
of NCT03925402 320 322 I-Eq-Comparison
first NCT03925402 323 328 I-Eq-Comparison
evidence NCT03925402 329 337 O
of NCT03925402 338 340 O
bacteremia NCT03925402 341 351 B-Condition

Inclusion NCT03928132 0 9 O
Criteria NCT03928132 10 18 O
: NCT03928132 19 20 O

- NCT03928132 24 25 O
French NCT03928132 27 33 O
- NCT03928132 34 35 O
speaking NCT03928132 36 44 O
health NCT03928132 45 51 O
professionals NCT03928132 52 65 O
( NCT03928132 66 67 O
in NCT03928132 68 70 O
practice NCT03928132 71 79 O
and NCT03928132 80 83 O
in NCT03928132 84 86 O
training NCT03928132 87 95 O
) NCT03928132 96 97 O
. NCT03928132 98 99 O

Inclusion NCT03921658 0 9 O
Criteria NCT03921658 10 18 O
: NCT03921658 19 20 O

- NCT03921658 24 25 O
Age NCT03921658 27 30 B-Age
≥ NCT03921658 31 32 B-Eq-Comparison
18 NCT03921658 33 35 I-Eq-Comparison

- NCT03921658 39 40 O
Ability NCT03921658 42 49 O
to NCT03921658 50 52 O
read NCT03921658 53 57 O
and NCT03921658 58 61 O
write NCT03921658 62 67 O
in NCT03921658 68 70 O
English NCT03921658 71 78 O

- NCT03921658 81 82 O
women NCT03921658 84 89 O
with NCT03921658 90 94 B-And
newly NCT03921658 95 100 B-Eq-Comparison
diagnosed NCT03921658 101 110 O
with NCT03921658 111 115 O
ovarian NCT03921658 116 123 B-Modifier
, NCT03921658 124 125 O
primary NCT03921658 126 133 B-Modifier
peritoneal NCT03921658 134 144 I-Modifier
, NCT03921658 145 146 O
or NCT03921658 147 149 B-Or
fallopian NCT03921658 150 159 B-Modifier
tube NCT03921658 160 164 I-Modifier
cancer NCT03921658 165 171 B-Condition

- NCT03921658 174 175 O
Treatment NCT03921658 177 186 B-Procedure
plan NCT03921658 187 191 B-Assertion___Assertion-Type-Value:hypothetical
includes NCT03921658 192 200 O
chemotherapy NCT03921658 201 213 B-Procedure

- NCT03921658 216 217 O
Able NCT03921658 219 223 O
to NCT03921658 224 226 O
provide NCT03921658 227 234 O
written NCT03921658 235 242 O
voluntary NCT03921658 243 252 O
consent NCT03921658 253 260 O
before NCT03921658 261 267 O
performance NCT03921658 268 279 O
of NCT03921658 280 282 O
any NCT03921658 283 286 O
study NCT03921658 287 292 O
related NCT03921658 293 300 O
procedure NCT03921658 301 310 O
. NCT03921658 310 311 O

- NCT03921658 315 316 O
Cohort NCT03921658 318 324 O
1 NCT03921658 325 326 O
only NCT03921658 327 331 O
: NCT03921658 332 333 O
within NCT03921658 334 340 B-Eq-Comparison
2 NCT03921658 341 342 I-Eq-Comparison
years NCT03921658 343 348 I-Eq-Comparison
of NCT03921658 349 351 O
completing NCT03921658 352 362 O
initial NCT03921658 363 370 B-Eq-Comparison
chemotherapy NCT03921658 371 383 B-Procedure
treatment NCT03921658 384 393 I-Procedure

- NCT03921658 396 397 O
Cohort NCT03921658 399 405 O
2 NCT03921658 406 407 O
only NCT03921658 408 412 O
: NCT03921658 413 414 O
prior NCT03921658 415 420 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921658 421 423 O
starting NCT03921658 424 432 O
chemotherapy NCT03921658 433 445 B-Procedure

Exclusion NCT03921658 446 455 O
Criteria NCT03921658 456 464 O
: NCT03921658 465 466 O

- NCT03921658 470 471 O
Inability NCT03921658 473 482 O
to NCT03921658 483 485 O
provide NCT03921658 486 493 O
informed NCT03921658 494 502 O
written NCT03921658 503 510 O
consent NCT03921658 511 518 O

- NCT03921658 521 522 O
Previous NCT03921658 524 532 B-Eq-Comparison
exposure NCT03921658 533 541 O
to NCT03921658 542 544 O
chemotherapy NCT03921658 545 557 B-Procedure

- NCT03921658 560 561 O
Life NCT03921658 563 567 B-Observation
expectancy NCT03921658 568 578 I-Observation
< NCT03921658 579 580 B-Eq-Comparison
3 NCT03921658 581 582 I-Eq-Comparison
months NCT03921658 583 589 I-Eq-Comparison
or NCT03921658 590 592 B-Or
in NCT03921658 593 595 O
hospice NCT03921658 596 603 B-Observation
care NCT03921658 604 608 I-Observation
or NCT03921658 609 611 B-Or
nursing NCT03921658 612 619 B-Observation
home NCT03921658 620 624 I-Observation

Inclusion NCT03929562 0 9 O
Criteria NCT03929562 10 18 O
: NCT03929562 19 20 O

- NCT03929562 24 25 O
Referred NCT03929562 27 35 B-Encounter
for NCT03929562 36 39 O
elective NCT03929562 40 48 O
or NCT03929562 49 51 O
semi NCT03929562 52 56 O
- NCT03929562 57 58 O
elective NCT03929562 59 67 O
surgery NCT03929562 68 75 B-Procedure
or NCT03929562 76 78 B-Or
pre NCT03929562 79 82 B-Observation
- NCT03929562 83 84 I-Observation
- NCT03929562 86 87 O
operative NCT03929562 88 97 I-Observation
assessment NCT03929562 98 108 I-Observation
in NCT03929562 109 111 O
the NCT03929562 112 115 O
next NCT03929562 116 120 B-Eq-Comparison
120 NCT03929562 121 124 I-Eq-Comparison
days NCT03929562 125 129 I-Eq-Comparison

- NCT03929562 132 133 O
Meet NCT03929562 135 139 O
criteria NCT03929562 140 148 O
for NCT03929562 149 152 O
" NCT03929562 153 154 O
risky NCT03929562 154 159 B-Condition
drinking NCT03929562 160 168 I-Condition
" NCT03929562 168 169 O
as NCT03929562 170 172 O
defined NCT03929562 173 180 O
by NCT03929562 181 183 O
study NCT03929562 184 189 O
staff NCT03929562 190 195 O

Exclusion NCT03929562 196 205 O
Criteria NCT03929562 206 214 O
: NCT03929562 215 216 O

- NCT03929562 220 221 O
Displays NCT03929562 223 231 O
or NCT03929562 232 234 O
shows NCT03929562 235 240 O
evidence NCT03929562 241 249 O
of NCT03929562 250 252 O
psychotic NCT03929562 253 262 B-Condition
symptoms NCT03929562 263 271 B-Assertion___Assertion-Type-Value:possible

- NCT03929562 274 275 O
Undergoing NCT03929562 277 287 B-Eq-Comparison
surgeries NCT03929562 288 297 B-Procedure
that NCT03929562 298 302 O
commonly NCT03929562 303 311 O
require NCT03929562 312 319 O
local NCT03929562 320 325 B-Procedure
anesthesia NCT03929562 326 336 I-Procedure
only NCT03929562 337 341 O


Inclusion NCT03920397 0 9 O
Criteria NCT03920397 10 18 O
: NCT03920397 19 20 O

- NCT03920397 24 25 O
Diagnosis NCT03920397 27 36 O
of NCT03920397 37 39 O
Type NCT03920397 40 44 B-Condition
1 NCT03920397 45 46 I-Condition
Diabetes NCT03920397 47 55 I-Condition
according NCT03920397 56 65 O
to NCT03920397 66 68 O
the NCT03920397 69 72 O
American NCT03920397 73 81 O
Diabetes NCT03920397 82 90 O
Association NCT03920397 91 102 O
criteria NCT03920397 103 111 O
for NCT03920397 112 115 O
a NCT03920397 116 117 O
period NCT03920397 118 124 O
less NCT03920397 125 129 B-Eq-Comparison
than NCT03920397 130 134 I-Eq-Comparison
four NCT03920397 135 139 I-Eq-Comparison
months NCT03920397 140 146 I-Eq-Comparison
. NCT03920397 146 147 O

- NCT03920397 151 152 O
Pancreatic NCT03920397 154 164 B-Condition
Autoimmunity NCT03920397 165 177 I-Condition
( NCT03920397 178 179 O
positive NCT03920397 180 188 O
anti NCT03920397 189 193 B-Condition
- NCT03920397 194 195 I-Condition
glutamic NCT03920397 196 204 I-Condition
acid NCT03920397 205 209 I-Condition
decarboxylase NCT03920397 210 223 I-Condition
[ NCT03920397 224 225 O
GAD NCT03920397 226 229 B-Condition
] NCT03920397 230 231 O
; NCT03920397 232 233 O
and NCT03920397 234 237 B-Or
/ NCT03920397 238 239 I-Or
or NCT03920397 240 242 I-Or
Islet NCT03920397 243 248 B-Condition
antigen NCT03920397 249 256 I-Condition|Condition
2 NCT03920397 257 258 I-Condition
[ NCT03920397 259 260 O
anti NCT03920397 261 265 O
- NCT03920397 266 267 I-Condition
IA2 NCT03920397 268 271 I-Condition
] NCT03920397 272 273 O
) NCT03920397 275 276 O
. NCT03920397 277 278 O

Exclusion NCT03920397 280 289 O
Criteria NCT03920397 290 298 O
: NCT03920397 299 300 O

- NCT03920397 304 305 O
Clinical NCT03920397 307 315 O
evidence NCT03920397 316 324 O
of NCT03920397 325 327 O
malignancy NCT03920397 328 338 B-Condition
or NCT03920397 339 341 O
prior NCT03920397 342 347 B-Eq-Comparison
history NCT03920397 348 355 I-Eq-Comparison
. NCT03920397 355 356 O

- NCT03920397 360 361 O
Pregnancy NCT03920397 363 372 B-Condition
or NCT03920397 373 375 B-Or
desire NCT03920397 376 382 B-Assertion___Assertion-Type-Value:intention
to NCT03920397 383 385 I-Assertion___Assertion-Type-Value:intention
become NCT03920397 386 392 O
pregnant NCT03920397 393 401 B-Condition
within NCT03920397 402 408 B-Eq-Comparison
12 NCT03920397 409 411 I-Eq-Comparison
months NCT03920397 412 418 I-Eq-Comparison
of NCT03920397 419 421 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03920397 422 425 O
study NCT03920397 426 431 B-Study
. NCT03920397 431 432 O

- NCT03920397 436 437 O
Breastfeeding NCT03920397 439 452 B-Condition
. NCT03920397 453 454 O

- NCT03920397 458 459 O
HIV NCT03920397 461 464 B-Condition
( NCT03920397 465 466 O
+ NCT03920397 468 469 O
) NCT03920397 471 472 O
, NCT03920397 474 475 O
Hepatitis NCT03920397 476 485 B-Condition|Condition
B NCT03920397 486 487 I-Condition
( NCT03920397 488 489 O
+ NCT03920397 491 492 O
) NCT03920397 494 495 O
, NCT03920397 497 498 O
Hepatitis NCT03920397 499 508 O
C NCT03920397 509 510 I-Condition
( NCT03920397 511 512 O
+ NCT03920397 514 515 O
) NCT03920397 517 518 O
. NCT03920397 519 520 O

- NCT03920397 524 525 O
Diabetic NCT03920397 527 535 B-Condition
ketoacidosis NCT03920397 536 548 I-Condition
at NCT03920397 549 551 O
diagnosis NCT03920397 552 561 O
. NCT03920397 561 562 O

- NCT03920397 566 567 O
Glomerular NCT03920397 569 579 B-Observation
filtration NCT03920397 580 590 I-Observation
rate NCT03920397 591 595 I-Observation
less NCT03920397 596 600 B-Eq-Comparison
than NCT03920397 601 605 I-Eq-Comparison
60 NCT03920397 606 608 I-Eq-Comparison
ml NCT03920397 609 611 O
/ NCT03920397 612 613 O
min NCT03920397 614 617 O
. NCT03920397 617 618 O

- NCT03920397 622 623 O
Use NCT03920397 625 628 B-Eq-Comparison
of NCT03920397 629 631 O
immunosuppressors NCT03920397 632 649 B-Drug
or NCT03920397 650 652 B-Or
glucocorticoids NCT03920397 653 668 B-Drug
. NCT03920397 668 669 O

Inclusion NCT03922594 0 9 O
Criteria NCT03922594 10 18 O
: NCT03922594 19 20 O

- NCT03922594 24 25 O
All NCT03922594 27 30 O
infants NCT03922594 31 38 O
or NCT03922594 39 41 B-Or
fetuses NCT03922594 42 49 O
with NCT03922594 50 54 B-And
microcephaly NCT03922594 55 67 B-Condition
, NCT03922594 68 69 O
( NCT03922594 70 71 O
defined NCT03922594 72 79 O
as NCT03922594 80 82 O
head NCT03922594 83 87 B-Observation
circumference NCT03922594 88 101 I-Observation
≤ NCT03922594 102 103 B-Eq-Comparison
- NCT03922594 105 106 I-Eq-Comparison
3 NCT03922594 107 108 I-Eq-Comparison
SD NCT03922594 109 111 O
according NCT03922594 112 121 O
to NCT03922594 122 124 O
INTERGROWTH NCT03922594 125 136 O
standards NCT03922594 137 146 O
for NCT03922594 147 150 O
gestational NCT03922594 151 162 O
age NCT03922594 163 166 O
and NCT03922594 167 170 O
sex NCT03922594 171 174 O
, NCT03922594 175 176 O
detected NCT03922594 177 185 O
during NCT03922594 186 192 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922594 193 196 O
mother NCT03922594 197 203 B-Family-Member___Family-Member-Type:mother
's NCT03922594 203 205 O
pregnancy NCT03922594 206 215 B-Condition
, NCT03922594 216 217 O
or NCT03922594 218 220 B-Or
at NCT03922594 221 223 O
the NCT03922594 224 227 O
end NCT03922594 228 231 O
of NCT03922594 232 234 O
the NCT03922594 235 238 O
mother NCT03922594 239 245 B-Family-Member___Family-Member-Type:mother
's NCT03922594 245 247 O
pregnancy NCT03922594 248 257 B-Condition
at NCT03922594 258 260 O
one NCT03922594 261 264 O
of NCT03922594 265 267 O
the NCT03922594 268 271 O
participating NCT03922594 272 285 O
maternities NCT03922594 286 297 O
) NCT03922594 298 299 O

- NCT03922594 303 304 O
and NCT03922594 306 309 O
with NCT03922594 310 314 O
abnormal NCT03922594 315 323 O
ultrasound NCT03922594 324 334 B-Procedure
and NCT03922594 335 338 B-Or
/ NCT03922594 339 340 I-Or
or NCT03922594 341 343 I-Or
clinical NCT03922594 344 352 B-Observation
examination NCT03922594 353 364 I-Observation
findings NCT03922594 365 373 I-Observation
for NCT03922594 374 377 O
newborns NCT03922594 378 386 O
. NCT03922594 386 387 O

Exclusion NCT03922594 389 398 O
Criteria NCT03922594 399 407 O
: NCT03922594 408 409 O

- NCT03922594 413 414 O
Infants NCT03922594 416 423 O
/ NCT03922594 424 425 O
fetuses NCT03922594 426 433 O
with NCT03922594 434 438 B-And
microcephaly NCT03922594 439 451 B-Condition
whose NCT03922594 452 457 O
mothers NCT03922594 458 465 B-Family-Member___Family-Member-Type:mother
are NCT03922594 466 469 O
under NCT03922594 470 475 B-Eq-Comparison
the NCT03922594 476 479 I-Eq-Comparison
age NCT03922594 480 483 I-Eq-Comparison
of NCT03922594 484 486 I-Eq-Comparison
18 NCT03922594 487 489 I-Eq-Comparison
years NCT03922594 490 495 I-Eq-Comparison
, NCT03922594 496 497 O

- NCT03922594 501 502 O
or NCT03922594 504 506 O
inability NCT03922594 507 516 O
or NCT03922594 517 519 O
refusal NCT03922594 520 527 O
of NCT03922594 528 530 O
mothers NCT03922594 531 538 O
/ NCT03922594 539 540 O
guardians NCT03922594 541 550 O
to NCT03922594 551 553 O
give NCT03922594 554 558 O
informed NCT03922594 559 567 O
consent NCT03922594 568 575 O
. NCT03922594 575 576 O

Inclusion NCT03921710 0 9 O
criteria NCT03921710 10 18 O
: NCT03921710 19 20 O

- NCT03921710 24 25 O
< NCT03921710 27 28 B-Eq-Comparison
38 NCT03921710 29 31 I-Eq-Comparison
years NCT03921710 32 37 I-Age|Eq-Comparison

- NCT03921710 40 41 O
PCOS NCT03921710 43 47 B-Condition
patients NCT03921710 48 56 O
with NCT03921710 57 61 B-And
polycystic NCT03921710 62 72 B-Condition
ovarian NCT03921710 73 80 I-Condition
morphology NCT03921710 81 91 I-Condition
: NCT03921710 92 93 O
at NCT03921710 94 96 B-Eq-Comparison
least NCT03921710 97 102 I-Eq-Comparison
25 NCT03921710 103 105 I-Eq-Comparison
follicles NCT03921710 106 115 I-Eq-Comparison|Observation
( NCT03921710 116 117 O
2 NCT03921710 118 119 O
- NCT03921710 120 121 B-Eq-Comparison
9 NCT03921710 122 123 I-Eq-Comparison
mm NCT03921710 124 126 I-Eq-Comparison
) NCT03921710 127 128 O
throughout NCT03921710 129 139 O
the NCT03921710 140 143 O
whole NCT03921710 144 149 O
ovary NCT03921710 150 155 O
and NCT03921710 156 159 O
/ NCT03921710 160 161 O
or NCT03921710 162 164 O
increased NCT03921710 165 174 O
ovarian NCT03921710 175 182 B-Observation
volume NCT03921710 183 189 I-Observation
( NCT03921710 190 191 O
> NCT03921710 193 194 B-Eq-Comparison
10 NCT03921710 195 197 I-Eq-Comparison
ml NCT03921710 198 200 O
) NCT03921710 201 202 O
( NCT03921710 203 204 O
it NCT03921710 205 207 O
is NCT03921710 208 210 O
sufficient NCT03921710 211 221 O
that NCT03921710 222 226 O
1 NCT03921710 227 228 O
ovary NCT03921710 229 234 O
fits NCT03921710 235 239 O
these NCT03921710 240 245 O
criteria NCT03921710 246 254 O
) NCT03921710 255 256 O

- NCT03921710 260 261 O
No NCT03921710 263 265 B-Negation
major NCT03921710 266 271 B-Modifier
uterine NCT03921710 272 279 B-Modifier
or NCT03921710 280 282 B-Or
ovarian NCT03921710 283 290 B-Modifier
abnormalities NCT03921710 291 304 B-Condition

Exclusion NCT03921710 305 314 O
criteria NCT03921710 315 323 O
: NCT03921710 324 325 O

- NCT03921710 329 330 O
High NCT03921710 332 336 O
( NCT03921710 337 338 O
> NCT03921710 340 341 B-Eq-Comparison
grade NCT03921710 342 347 I-Eq-Comparison
2 NCT03921710 348 349 I-Eq-Comparison
) NCT03921710 350 351 O
grade NCT03921710 352 357 O
endometriosis NCT03921710 358 371 B-Condition

- NCT03921710 374 375 O
Cases NCT03921710 377 382 O
with NCT03921710 383 387 O
extremely NCT03921710 388 397 O
poor NCT03921710 398 402 B-Condition
sperm NCT03921710 403 408 I-Condition
( NCT03921710 409 410 O
OAT NCT03921710 411 414 B-Condition
) NCT03921710 415 416 O
such NCT03921710 417 421 O
as NCT03921710 422 424 O
azoospermia NCT03921710 425 436 B-Condition
or NCT03921710 437 439 B-Or
cryptozoospermia NCT03921710 440 456 B-Condition

Inclusion NCT03920618 0 9 O
Criteria NCT03920618 10 18 O
: NCT03920618 19 20 O

1 NCT03920618 24 25 O
. NCT03920618 25 26 O
Positive NCT03920618 28 36 O
hepatitis NCT03920618 37 46 B-Observation
b NCT03920618 47 48 I-Observation
surface NCT03920618 49 56 I-Observation
antigen NCT03920618 57 64 I-Observation
or NCT03920618 65 67 B-Or
hepatitis NCT03920618 68 77 B-Observation
b NCT03920618 78 79 I-Observation
virus NCT03920618 80 85 I-Observation
DNA NCT03920618 86 89 I-Observation
> NCT03920618 90 91 B-Eq-Comparison
0.5 NCT03920618 92 95 I-Eq-Comparison
year NCT03920618 96 100 I-Eq-Comparison
; NCT03920618 100 101 O

2 NCT03920618 104 105 O
. NCT03920618 105 106 O
Age NCT03920618 108 111 B-Age
from NCT03920618 112 116 O
18 NCT03920618 117 119 B-Eq-Comparison
to NCT03920618 120 122 I-Eq-Comparison
55 NCT03920618 123 125 I-Eq-Comparison
years NCT03920618 126 131 I-Eq-Comparison
old NCT03920618 132 135 O
; NCT03920618 135 136 O

3 NCT03920618 139 140 O
. NCT03920618 140 141 O
Serum NCT03920618 143 148 B-Observation
total NCT03920618 149 154 I-Observation
bilirubin NCT03920618 155 164 I-Observation
level NCT03920618 165 170 I-Observation
> NCT03920618 171 172 B-Eq-Comparison
10 NCT03920618 173 175 I-Eq-Comparison
times NCT03920618 176 181 I-Eq-Comparison
upper NCT03920618 182 187 I-Eq-Comparison
limit NCT03920618 188 193 I-Eq-Comparison
of NCT03920618 194 196 I-Eq-Comparison
normal NCT03920618 197 203 I-Eq-Comparison
; NCT03920618 203 204 O

4 NCT03920618 207 208 O
. NCT03920618 208 209 O
Prothrombin NCT03920618 211 222 B-Observation
time NCT03920618 223 227 I-Observation
activity NCT03920618 228 236 I-Observation
< NCT03920618 237 238 B-Eq-Comparison
40 NCT03920618 239 241 I-Eq-Comparison
% NCT03920618 242 243 O
or NCT03920618 244 246 B-Or
prothrombin NCT03920618 247 258 B-Observation
time NCT03920618 259 263 I-Observation
international NCT03920618 264 277 I-Observation
ratio NCT03920618 278 283 I-Observation
> NCT03920618 284 285 B-Eq-Comparison
1.5 NCT03920618 286 289 I-Eq-Comparison
； NCT03920618 290 291 O

5 NCT03920618 294 295 O
. NCT03920618 295 296 O
Do NCT03920618 298 300 O
not NCT03920618 301 304 B-Negation
receive NCT03920618 305 312 O
nucleotide NCT03920618 313 323 B-Modifier
/ NCT03920618 324 325 B-Or
nucleoside NCT03920618 326 336 B-Modifier
analogues NCT03920618 337 346 B-Procedure
treatment NCT03920618 347 356 I-Procedure
in NCT03920618 357 359 O
the NCT03920618 360 363 O
past NCT03920618 364 368 B-Eq-Comparison
half NCT03920618 369 373 I-Eq-Comparison
year NCT03920618 374 378 I-Eq-Comparison
. NCT03920618 378 379 O

Exclusion NCT03920618 381 390 O
Criteria NCT03920618 391 399 O
: NCT03920618 400 401 O

1 NCT03920618 405 406 O
. NCT03920618 406 407 O
Other NCT03920618 409 414 B-Other
active NCT03920618 415 421 B-Eq-Comparison
liver NCT03920618 422 427 B-Condition
diseases NCT03920618 428 436 I-Condition
; NCT03920618 436 437 O

2 NCT03920618 440 441 O
. NCT03920618 441 442 O
Hepatocellular NCT03920618 444 458 B-Condition
carcinoma NCT03920618 459 468 I-Condition
or NCT03920618 469 471 B-Or
other NCT03920618 472 477 B-Other
malignancy NCT03920618 478 488 B-Condition
; NCT03920618 488 489 O

3 NCT03920618 492 493 O
. NCT03920618 493 494 O
Pregnancy NCT03920618 496 505 B-Condition
or NCT03920618 506 508 B-Or
lactation NCT03920618 509 518 B-Condition
; NCT03920618 518 519 O

4 NCT03920618 522 523 O
. NCT03920618 523 524 O
Human NCT03920618 526 531 B-Condition
immunodeficiency NCT03920618 532 548 I-Condition
virus NCT03920618 549 554 I-Condition
infection NCT03920618 555 564 I-Condition
or NCT03920618 565 567 B-Or
congenital NCT03920618 568 578 B-Condition
immune NCT03920618 579 585 I-Condition
deficiency NCT03920618 586 596 I-Condition
diseases NCT03920618 597 605 I-Condition
; NCT03920618 605 606 O

5 NCT03920618 609 610 O
. NCT03920618 610 611 O
Severe NCT03920618 613 619 O
diabetes NCT03920618 620 628 B-Condition
, NCT03920618 629 630 O
autoimmune NCT03920618 631 641 B-Condition
diseases NCT03920618 642 650 I-Condition
; NCT03920618 650 651 O

6 NCT03920618 654 655 O
. NCT03920618 655 656 O
Other NCT03920618 658 663 B-Other
important NCT03920618 664 673 O
organ NCT03920618 674 679 B-Condition
dysfunctions NCT03920618 680 692 I-Condition
; NCT03920618 692 693 O

7 NCT03920618 696 697 O
. NCT03920618 697 698 O
Using NCT03920618 700 705 B-Eq-Comparison
glucocorticoid NCT03920618 706 720 B-Drug
; NCT03920618 720 721 O

8 NCT03920618 724 725 O
. NCT03920618 725 726 O
Patients NCT03920618 728 736 O
can NCT03920618 737 740 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03920618 741 744 B-Negation
follow NCT03920618 745 751 B-Encounter
- NCT03920618 752 753 I-Encounter
up NCT03920618 754 756 I-Encounter
; NCT03920618 756 757 O

9 NCT03920618 760 761 O
. NCT03920618 761 762 O
Investigator NCT03920618 764 776 O
considering NCT03920618 777 788 O
inappropriate NCT03920618 789 802 O
. NCT03920618 802 803 O

Inclusion NCT03928522 0 9 O
Criteria NCT03928522 10 18 O
: NCT03928522 19 20 O

- NCT03928522 24 25 O
Age NCT03928522 27 30 B-Age
over NCT03928522 31 35 B-Eq-Comparison
18 NCT03928522 36 38 I-Eq-Comparison

- NCT03928522 42 43 O
Total NCT03928522 45 50 B-Procedure
knee NCT03928522 51 55 I-Procedure
arthroplasty NCT03928522 56 68 I-Procedure
for NCT03928522 69 72 O
primary NCT03928522 73 80 B-Modifier
osteoarthritis NCT03928522 81 95 B-Condition
performed NCT03928522 96 105 O
by NCT03928522 106 108 O
Dr. NCT03928522 109 112 B-Provider
Rick NCT03928522 114 118 I-Provider
Wright NCT03928522 119 125 I-Provider
. NCT03928522 125 126 O

- NCT03928522 130 131 O
Primary NCT03928522 133 140 O
diagnosis NCT03928522 141 150 O
of NCT03928522 151 153 O
knee NCT03928522 154 158 B-Modifier
osteoarthritis NCT03928522 159 173 B-Condition

- NCT03928522 181 182 O
Exclusion NCT03928522 184 193 O
Criteria NCT03928522 194 202 O
: NCT03928522 203 204 O

- NCT03928522 208 209 O
Diminished NCT03928522 211 221 B-Condition
mental NCT03928522 222 228 I-Condition
capacity NCT03928522 229 237 I-Condition

- NCT03928522 240 241 O
Vancomycin NCT03928522 243 253 B-Drug
allergy NCT03928522 254 261 B-Allergy

- NCT03928522 264 265 O
Tobramycin NCT03928522 267 277 B-Drug
allergy NCT03928522 278 285 B-Allergy

- NCT03928522 288 289 O
Patient NCT03928522 291 298 O
history NCT03928522 299 306 B-Eq-Comparison
requiring NCT03928522 307 316 O
IV NCT03928522 317 319 O
administration NCT03928522 320 334 O
of NCT03928522 335 337 O
vancomycin NCT03928522 338 348 B-Drug
or NCT03928522 349 351 B-Or
tobramycin NCT03928522 352 362 B-Drug
peri NCT03928522 363 367 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03928522 368 369 O
- NCT03928522 371 372 O
operatively NCT03928522 373 384 B-Procedure

- NCT03928522 387 388 O
Chronic NCT03928522 390 397 B-Modifier
kidney NCT03928522 398 404 B-Condition
disease NCT03928522 405 412 I-Condition
stage NCT03928522 413 418 B-Eq-Comparison
III NCT03928522 419 422 I-Eq-Comparison
and NCT03928522 423 426 I-Eq-Comparison
stage NCT03928522 427 432 O
IV NCT03928522 433 435 I-Eq-Comparison

Inclusion NCT03929614 0 9 O
Criteria NCT03929614 10 18 O
: NCT03929614 19 20 O

- NCT03929614 24 25 O
AIS NCT03929614 27 30 B-Condition
. NCT03929614 30 31 O

- NCT03929614 35 36 O
10 NCT03929614 38 40 B-Eq-Comparison
- NCT03929614 41 42 I-Eq-Comparison
16 NCT03929614 43 45 I-Eq-Comparison
years NCT03929614 46 51 I-Eq-Comparison
old NCT03929614 52 55 B-Age
, NCT03929614 56 57 O
with NCT03929614 58 62 B-And
brace NCT03929614 63 68 B-Procedure
treatment NCT03929614 69 78 I-Procedure
. NCT03929614 78 79 O

- NCT03929614 83 84 O
Ability NCT03929614 86 93 O
to NCT03929614 94 96 O
read NCT03929614 97 101 O
and NCT03929614 102 105 O
understand NCT03929614 106 116 O
English NCT03929614 117 124 O
or NCT03929614 125 127 B-Or
French NCT03929614 128 134 O
. NCT03929614 134 135 O

- NCT03929614 139 140 O
Physical NCT03929614 142 150 O
and NCT03929614 151 154 O
mental NCT03929614 155 161 O
ability NCT03929614 162 169 O
to NCT03929614 170 172 O
adhere NCT03929614 173 179 O
to NCT03929614 180 182 O
bracing NCT03929614 183 190 O
protocol NCT03929614 191 199 O
. NCT03929614 199 200 O

Exclusion NCT03929614 202 211 O
Criteria NCT03929614 212 220 O
: NCT03929614 221 222 O

- NCT03929614 226 227 O
Diagnosis NCT03929614 229 238 O
of NCT03929614 239 241 O
other NCT03929614 242 247 B-Other
musculoskeletal NCT03929614 248 263 B-Modifier
or NCT03929614 264 266 B-Or
developmental NCT03929614 267 280 B-Modifier
illness NCT03929614 281 288 B-Condition
that NCT03929614 289 293 O
might NCT03929614 294 299 B-Assertion___Assertion-Type-Value:possible
be NCT03929614 300 302 I-Assertion___Assertion-Type-Value:possible
responsible NCT03929614 303 314 O
for NCT03929614 315 318 O
the NCT03929614 319 322 O
spinal NCT03929614 323 329 B-Condition
curvature NCT03929614 330 339 I-Condition
. NCT03929614 339 340 O

- NCT03929614 344 345 O
Patients NCT03929614 347 355 O
with NCT03929614 356 360 O
symptom NCT03929614 361 368 B-Assertion___Assertion-Type-Value:possible
of NCT03929614 369 371 O
a NCT03929614 372 373 O
neurological NCT03929614 374 386 B-Condition
disorder NCT03929614 387 395 I-Condition
. NCT03929614 395 396 O

- NCT03929614 400 401 O
Patients NCT03929614 403 411 O
with NCT03929614 412 416 O
any NCT03929614 417 420 O
other NCT03929614 421 426 O
disorder NCT03929614 427 435 B-Condition
of NCT03929614 436 438 I-Condition
the NCT03929614 439 442 I-Condition
musculoskeletal NCT03929614 443 458 I-Condition
system NCT03929614 459 465 I-Condition
affecting NCT03929614 466 475 O
the NCT03929614 476 479 O
lower NCT03929614 480 485 B-Modifier
limbs NCT03929614 486 491 I-Modifier
, NCT03929614 492 493 O

Inclusion NCT03926533 0 9 O
Criteria NCT03926533 10 18 O
: NCT03926533 19 20 O

- NCT03926533 24 25 O
index NCT03926533 27 32 O
ICU NCT03926533 33 36 B-Encounter
stay NCT03926533 37 41 I-Encounter
with NCT03926533 42 46 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03926533 47 48 O
diagnosis NCT03926533 49 58 O
of NCT03926533 59 61 O
sepsis NCT03926533 62 68 B-Condition
or NCT03926533 69 71 B-Or
acute NCT03926533 72 77 O
respiratory NCT03926533 78 89 B-Condition
distress NCT03926533 90 98 I-Condition
syndrome NCT03926533 99 107 I-Condition
projected NCT03926533 108 117 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926533 118 120 O
be NCT03926533 121 123 O
discharged NCT03926533 124 134 B-Encounter
alive NCT03926533 135 140 B-Condition
as NCT03926533 141 143 O
these NCT03926533 144 149 O
patients NCT03926533 150 158 O
are NCT03926533 159 162 O
at NCT03926533 163 165 O
the NCT03926533 166 169 O
highest NCT03926533 170 177 O
risk NCT03926533 178 182 B-Risk
for NCT03926533 183 186 O
developing NCT03926533 187 197 O
PICS NCT03926533 198 202 B-Condition

Exclusion NCT03926533 203 212 O
Criteria NCT03926533 213 221 O
: NCT03926533 222 223 O

1 NCT03926533 227 228 O
. NCT03926533 228 229 O
no NCT03926533 231 233 O
access NCT03926533 234 240 O
to NCT03926533 241 243 O
computer NCT03926533 244 252 O
, NCT03926533 253 254 O
electronic NCT03926533 255 265 O
device NCT03926533 266 272 O
( NCT03926533 273 274 O
e. NCT03926533 275 277 O
g. NCT03926533 278 280 O
, NCT03926533 281 282 O
tablet NCT03926533 283 289 O
, NCT03926533 290 291 O
smartphone NCT03926533 292 302 O
) NCT03926533 303 304 O
, NCT03926533 306 307 O
and NCT03926533 308 311 O
/ NCT03926533 312 313 O
or NCT03926533 314 316 O
internet NCT03926533 317 325 O
connection NCT03926533 326 336 O
for NCT03926533 337 340 O
virtual NCT03926533 341 348 O
clinic NCT03926533 349 355 O
visit NCT03926533 356 361 O
, NCT03926533 362 363 O

2 NCT03926533 367 368 O
. NCT03926533 368 369 O
primary NCT03926533 371 378 B-Encounter
care NCT03926533 379 383 I-Encounter
received NCT03926533 384 392 B-Eq-Comparison
outside NCT03926533 393 400 B-Other
of NCT03926533 401 403 O
VUMC NCT03926533 404 408 O
network NCT03926533 409 416 O
, NCT03926533 417 418 O

3 NCT03926533 422 423 O
. NCT03926533 423 424 O
hospice NCT03926533 426 433 O
care NCT03926533 434 438 O
at NCT03926533 439 441 O
discharge NCT03926533 442 451 B-Encounter
, NCT03926533 452 453 O

4 NCT03926533 457 458 O
. NCT03926533 458 459 O
substance NCT03926533 461 470 B-Condition
abuse NCT03926533 471 476 I-Condition
or NCT03926533 477 479 B-Or
psychiatric NCT03926533 480 491 B-Condition
disorder NCT03926533 492 500 I-Condition
that NCT03926533 501 505 O
prevents NCT03926533 506 514 B-Negation
independent NCT03926533 515 526 B-Condition
living NCT03926533 527 533 I-Condition
, NCT03926533 534 535 O

5 NCT03926533 539 540 O
. NCT03926533 540 541 O
blind NCT03926533 543 548 B-Condition
, NCT03926533 549 550 O
deaf NCT03926533 551 555 B-Condition
, NCT03926533 556 557 O
unable NCT03926533 558 564 B-Negation
to NCT03926533 565 567 O
speak NCT03926533 568 573 O
English NCT03926533 574 581 O
, NCT03926533 582 583 O
or NCT03926533 584 586 O

6 NCT03926533 589 590 O
. NCT03926533 590 591 O
severe NCT03926533 593 599 B-Condition
dementia NCT03926533 600 608 I-Condition
prior NCT03926533 609 614 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926533 615 617 I-Temporal-Connection___Temporal-Connection-Type-Value:before
index NCT03926533 618 623 O
hospitalization NCT03926533 624 639 B-Encounter

Inclusion NCT03928496 0 9 O
Criteria NCT03928496 10 18 O
: NCT03928496 19 20 O

- NCT03928496 24 25 O
male NCT03928496 27 31 O
or NCT03928496 32 34 B-Or
female NCT03928496 35 41 O

- NCT03928496 44 45 O
age NCT03928496 47 50 B-Age
18 NCT03928496 51 53 B-Eq-Comparison
- NCT03928496 54 55 I-Eq-Comparison
65 NCT03928496 56 58 O

- NCT03928496 62 63 O
meets NCT03928496 65 70 O
International NCT03928496 71 84 B-Condition
Classification NCT03928496 85 99 I-Condition
Headache NCT03928496 100 108 I-Condition
Disorders NCT03928496 109 118 I-Condition
II NCT03928496 119 121 B-Eq-Comparison
( NCT03928496 122 123 O
ICHD NCT03928496 124 128 B-Condition
- NCT03928496 129 130 O
II NCT03928496 131 133 B-Eq-Comparison
) NCT03928496 134 135 O
criteria NCT03928496 136 144 O
for NCT03928496 145 148 O
post NCT03928496 149 153 B-Condition
- NCT03928496 154 155 I-Condition
traumatic NCT03928496 156 165 I-Condition
headache NCT03928496 166 174 I-Condition

- NCT03928496 177 178 O
average NCT03928496 180 187 O
pain NCT03928496 188 192 B-Observation
score NCT03928496 193 198 I-Observation
of NCT03928496 199 201 O
greater NCT03928496 202 209 B-Eq-Comparison
than NCT03928496 210 214 I-Eq-Comparison
4 NCT03928496 215 216 I-Eq-Comparison
/ NCT03928496 217 218 I-Eq-Comparison
10 NCT03928496 219 221 I-Eq-Comparison
in NCT03928496 222 224 O
severity NCT03928496 225 233 O
on NCT03928496 234 236 O
the NCT03928496 237 240 O
numerical NCT03928496 241 250 O
rating NCT03928496 251 257 O
system NCT03928496 258 264 O

- NCT03928496 267 268 O
Rancho NCT03928496 270 276 B-Observation
Los NCT03928496 277 280 I-Observation
Amigos NCT03928496 281 287 I-Observation
cognitive NCT03928496 288 297 I-Observation
scale NCT03928496 298 303 I-Observation
score NCT03928496 304 309 I-Observation
greater NCT03928496 310 317 B-Eq-Comparison
than NCT03928496 318 322 I-Eq-Comparison
seven NCT03928496 323 328 I-Eq-Comparison
. NCT03928496 328 329 O

Exclusion NCT03928496 331 340 O
Criteria NCT03928496 341 349 O
: NCT03928496 350 351 O

- NCT03928496 355 356 O
Uncontrolled NCT03928496 358 370 B-Modifier
medical NCT03928496 371 378 B-Condition
condition NCT03928496 379 388 I-Condition
other NCT03928496 389 394 B-Exception
than NCT03928496 395 399 I-Exception
PTH NCT03928496 400 403 B-Condition

- NCT03928496 406 407 O
Severe NCT03928496 409 415 O
additional NCT03928496 416 426 O
chronic NCT03928496 427 434 B-Modifier
pain NCT03928496 435 439 B-Condition
complaint NCT03928496 440 449 O
which NCT03928496 450 455 O
could NCT03928496 456 461 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03928496 462 465 B-Negation
be NCT03928496 466 468 O
distinguished NCT03928496 469 482 O
from NCT03928496 483 487 O
headache NCT03928496 488 496 B-Modifier
pain NCT03928496 497 501 B-Condition

- NCT03928496 504 505 O
pregnancy NCT03928496 507 516 B-Condition
, NCT03928496 517 518 O
breast NCT03928496 519 525 B-Condition
feeding NCT03928496 526 533 I-Condition
, NCT03928496 534 535 O

- NCT03928496 539 540 O
prior NCT03928496 542 547 B-Eq-Comparison
treatment NCT03928496 548 557 B-Procedure
with NCT03928496 558 562 O
botulinum NCT03928496 563 572 B-Drug
toxin NCT03928496 573 578 I-Drug
within NCT03928496 579 585 B-Eq-Comparison
one NCT03928496 586 589 I-Eq-Comparison
year NCT03928496 590 594 I-Eq-Comparison
of NCT03928496 595 597 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928496 598 608 B-Study

- NCT03928496 611 612 O
current NCT03928496 614 621 B-Eq-Comparison
substance NCT03928496 622 631 B-Condition
abuse NCT03928496 632 637 I-Condition
/ NCT03928496 638 639 B-Or
dependence NCT03928496 640 650 B-Condition

- NCT03928496 653 654 O
medical NCT03928496 656 663 B-Condition
condition NCT03928496 664 673 I-Condition
that NCT03928496 674 678 O
would NCT03928496 679 684 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03928496 685 693 O
risk NCT03928496 694 698 B-Risk
of NCT03928496 699 701 O
neuromuscular NCT03928496 702 715 B-Condition
junction NCT03928496 716 724 I-Condition
blockade NCT03928496 725 733 I-Condition
with NCT03928496 734 738 O
botulinum NCT03928496 739 748 B-Drug
toxin NCT03928496 749 754 I-Drug
( NCT03928496 755 756 O
myasthenia NCT03928496 757 767 B-Condition
gravis NCT03928496 768 774 I-Condition
, NCT03928496 775 776 O
Eaton NCT03928496 777 782 B-Condition
Lambert NCT03928496 783 790 I-Condition
, NCT03928496 791 792 O
amyotrophic NCT03928496 793 804 B-Condition
lateral NCT03928496 805 812 I-Condition
sclerosis NCT03928496 813 822 I-Condition
) NCT03928496 823 824 O

- NCT03928496 828 829 O
poorly NCT03928496 831 837 O
controlled NCT03928496 838 848 O
psychiatric NCT03928496 849 860 O

- NCT03928496 863 864 O
initiation NCT03928496 866 876 O
of NCT03928496 877 879 O
a NCT03928496 880 881 O
new NCT03928496 882 885 B-Eq-Comparison
anti NCT03928496 886 890 B-Drug|Drug
- NCT03928496 891 892 I-Drug|Drug
depressant NCT03928496 893 903 I-Drug
or NCT03928496 904 906 B-Or
anti NCT03928496 907 911 O
- NCT03928496 912 913 O
seizure NCT03928496 914 921 I-Drug
medication NCT03928496 922 932 I-Drug
within NCT03928496 933 939 B-Eq-Comparison
three NCT03928496 940 945 I-Eq-Comparison
months NCT03928496 946 952 I-Eq-Comparison
of NCT03928496 953 955 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolling NCT03928496 956 965 O
in NCT03928496 966 968 O
study NCT03928496 969 974 B-Study

- NCT03928496 977 978 O
ongoing NCT03928496 980 987 B-Eq-Comparison
disability NCT03928496 988 998 B-Condition
or NCT03928496 999 1001 O
litigation NCT03928496 1002 1012 O
claim NCT03928496 1013 1018 O
. NCT03928496 1018 1019 O

Inclusion NCT03925818 0 9 O
Criteria NCT03925818 10 18 O
: NCT03925818 19 20 O

- NCT03925818 23 24 O
Positive NCT03925818 25 33 O
for NCT03925818 34 37 O
H. NCT03925818 38 40 B-Organism
pylori NCT03925818 42 48 I-Organism
infection NCT03925818 49 58 B-Condition

Exclusion NCT03925818 59 68 O
Criteria NCT03925818 69 77 O
: NCT03925818 78 79 O

- NCT03925818 83 84 O
Presence NCT03925818 86 94 O
of NCT03925818 95 97 O
malignancy NCT03925818 98 108 B-Condition

- NCT03925818 111 112 O
Pregnancy NCT03925818 114 123 B-Condition
or NCT03925818 124 126 B-Or
lactation NCT03925818 127 136 B-Condition

- NCT03925818 139 140 O
Clinically NCT03925818 142 152 O
significant NCT03925818 153 164 O
diseases NCT03925818 165 173 B-Condition

- NCT03925818 176 177 O
History NCT03925818 179 186 B-Eq-Comparison
of NCT03925818 187 189 O
drug NCT03925818 190 194 B-Modifier
or NCT03925818 195 197 B-Or
alcohol NCT03925818 198 205 B-Modifier
abuse NCT03925818 206 211 B-Condition

- NCT03925818 214 215 O
Allergy NCT03925818 217 224 B-Allergy
to NCT03925818 225 227 O
pantoprazole NCT03925818 228 240 B-Drug
or NCT03925818 241 243 B-Or
to NCT03925818 244 246 O
any NCT03925818 247 250 O
component NCT03925818 251 260 B-Drug
of NCT03925818 261 263 O
regimens NCT03925818 264 272 O
used NCT03925818 273 277 O
in NCT03925818 278 280 O
the NCT03925818 281 284 O
study NCT03925818 285 290 B-Study

- NCT03925818 293 294 O
Use NCT03925818 296 299 O
of NCT03925818 300 302 O
anti NCT03925818 303 307 B-Drug
- NCT03925818 308 309 I-Drug
secretory NCT03925818 310 319 I-Drug
drugs NCT03925818 320 325 I-Drug
, NCT03925818 326 327 O
antibiotics NCT03925818 328 339 B-Drug
or NCT03925818 340 342 B-Or
probiotics NCT03925818 343 353 B-Drug
4 NCT03925818 354 355 B-Eq-Comparison
weeks NCT03925818 356 361 I-Eq-Comparison
preceding NCT03925818 362 371 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03925818 372 375 O
enrollment NCT03925818 376 386 B-Study
. NCT03925818 386 387 O

Inclusion NCT03929978 0 9 O
Criteria NCT03929978 10 18 O
: NCT03929978 19 20 O

- NCT03929978 24 25 O
Inclusion NCT03929978 27 36 O
criteria NCT03929978 37 45 O
and NCT03929978 46 49 O
justification NCT03929978 50 63 O
hereof NCT03929978 64 70 O
: NCT03929978 71 72 O

1 NCT03929978 81 82 O
. NCT03929978 82 83 O
Have NCT03929978 85 89 O
a NCT03929978 90 91 O
colostomy NCT03929978 92 101 B-Procedure
, NCT03929978 102 103 O
ileostomy NCT03929978 104 113 B-Procedure
( NCT03929978 114 115 O
jejunostomy NCT03929978 116 127 B-Procedure
) NCT03929978 128 129 O
, NCT03929978 131 132 O
loop NCT03929978 133 137 B-Procedure
stoma NCT03929978 138 143 I-Procedure
, NCT03929978 144 145 O
or NCT03929978 146 148 O
two NCT03929978 149 152 B-Eq-Comparison
stomas NCT03929978 153 159 B-Procedure
placed NCT03929978 160 166 O
closely NCT03929978 167 174 O
together NCT03929978 175 183 O

2 NCT03929978 191 192 O
. NCT03929978 192 193 O
Have NCT03929978 195 199 O
given NCT03929978 200 205 O
written NCT03929978 206 213 O
informed NCT03929978 214 222 O
consent NCT03929978 223 230 O
( NCT03929978 231 232 O
the NCT03929978 233 236 O
legal NCT03929978 237 242 O
authorized NCT03929978 243 253 O
representative NCT03929978 254 268 O
of NCT03929978 269 271 O
the NCT03929978 272 275 O
subject NCT03929978 276 283 O
) NCT03929978 284 285 O

Exclusion NCT03929978 287 296 O
Criteria NCT03929978 297 305 O
: NCT03929978 306 307 O

- NCT03929978 311 312 O
The NCT03929978 314 317 O
subjects NCT03929978 318 326 O
are NCT03929978 327 330 O
not NCT03929978 331 334 O
allowed NCT03929978 335 342 O
to NCT03929978 343 345 O
participate NCT03929978 346 357 O
in NCT03929978 358 360 O
case NCT03929978 361 365 O
they NCT03929978 366 370 O
: NCT03929978 371 372 O

Are NCT03929978 374 377 O
currently NCT03929978 378 387 B-Eq-Comparison
suffering NCT03929978 388 397 O
from NCT03929978 398 402 O
peristomal NCT03929978 403 413 B-Condition
skin NCT03929978 414 418 I-Condition
problems NCT03929978 419 427 I-Condition
i. NCT03929978 428 430 O
e. NCT03929978 431 433 O
bleeding NCT03929978 435 443 B-Condition
and NCT03929978 444 447 B-Or
/ NCT03929978 448 449 I-Or
or NCT03929978 450 452 I-Or
broken NCT03929978 453 459 B-Condition
skin NCT03929978 460 464 I-Condition

( NCT03929978 466 467 O
assessed NCT03929978 468 476 O
by NCT03929978 477 479 O
the NCT03929978 480 483 O
investigator NCT03929978 484 496 O
) NCT03929978 497 498 O

Inclusion NCT03924284 0 9 O
Criteria NCT03924284 10 18 O
: NCT03924284 19 20 O

- NCT03924284 24 25 O
Nasopharyngeal NCT03924284 27 41 B-Observation
or NCT03924284 42 44 B-Or
saliva NCT03924284 45 51 B-Observation
specimens NCT03924284 52 61 O
of NCT03924284 62 64 O
patients NCT03924284 65 73 O
in NCT03924284 74 76 O
Queen NCT03924284 77 82 O
Mary NCT03924284 83 87 O
Hospital NCT03924284 88 96 O
of NCT03924284 97 99 O
Hong NCT03924284 100 104 O
Kong NCT03924284 105 109 O

- NCT03924284 112 113 O
Tested NCT03924284 115 121 O
for NCT03924284 122 125 O
influenza NCT03924284 126 135 B-Observation
A NCT03924284 136 137 I-Observation
virus NCT03924284 138 143 I-Observation
using NCT03924284 144 149 O
a NCT03924284 150 151 O
commercially NCT03924284 152 164 O
available NCT03924284 165 174 O
assay NCT03924284 175 180 O
or NCT03924284 181 183 O
by NCT03924284 184 186 O
the NCT03924284 187 190 O
Public NCT03924284 191 197 O
Health NCT03924284 198 204 O
Laboratory NCT03924284 205 215 O
Services NCT03924284 216 224 O
Branch NCT03924284 225 231 O
in NCT03924284 232 234 O
Hong NCT03924284 235 239 O
Kong NCT03924284 240 244 O

Exclusion NCT03924284 245 254 O
Criteria NCT03924284 255 263 O
: NCT03924284 264 265 O

- NCT03924284 269 270 O
Insufficient NCT03924284 272 284 O
specimen NCT03924284 285 293 O
volume NCT03924284 294 300 O

Inclusion NCT03922178 0 9 O
Criteria NCT03922178 10 18 O
: NCT03922178 19 20 O

- NCT03922178 24 25 O
Patient NCT03922178 27 34 O
of NCT03922178 35 37 O
the NCT03922178 38 41 O
CHU NCT03922178 42 45 O
Brugmann NCT03922178 46 54 O
Hospital NCT03922178 55 63 O
receiving NCT03922178 64 73 B-Eq-Comparison
elective NCT03922178 74 82 B-Modifier
coronary NCT03922178 83 91 B-Procedure
surgery NCT03922178 92 99 I-Procedure
. NCT03922178 99 100 O

- NCT03922178 104 105 O
Patient NCT03922178 107 114 O
in NCT03922178 115 117 O
sinusal NCT03922178 118 125 B-Condition
rhythm NCT03922178 126 132 I-Condition
before NCT03922178 133 139 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03922178 140 143 O
operation NCT03922178 144 153 B-Coreference
and NCT03922178 154 157 O
during NCT03922178 158 164 O
the NCT03922178 165 168 O
collection NCT03922178 169 179 O
of NCT03922178 180 182 O
hemodynamic NCT03922178 183 194 O
data NCT03922178 195 199 O
. NCT03922178 199 200 O

- NCT03922178 204 205 O
Patients NCT03922178 207 215 O
with NCT03922178 216 220 O
conserved NCT03922178 221 230 B-Condition
left NCT03922178 231 235 I-Condition
ventricular NCT03922178 236 247 I-Condition
function NCT03922178 248 256 I-Condition
( NCT03922178 257 258 O
based NCT03922178 259 264 O
on NCT03922178 265 267 O
left NCT03922178 268 272 B-Observation
ventricular NCT03922178 273 284 I-Observation
ejection NCT03922178 285 293 I-Observation
fraction NCT03922178 294 302 I-Observation
assessed NCT03922178 303 311 O
by NCT03922178 312 314 O
pre NCT03922178 315 318 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03922178 319 320 O
- NCT03922178 322 323 O
operative NCT03922178 324 333 B-Procedure
echocardiography NCT03922178 334 350 B-Procedure
and NCT03922178 351 354 O
superior NCT03922178 355 363 B-Eq-Comparison
to NCT03922178 364 366 I-Eq-Comparison
50 NCT03922178 367 369 I-Eq-Comparison
% NCT03922178 370 371 O
) NCT03922178 372 373 O

Exclusion NCT03922178 375 384 O
Criteria NCT03922178 385 393 O
: NCT03922178 394 395 O

- NCT03922178 399 400 O
Hypertrophic NCT03922178 402 414 B-Condition
cardiomyopathy NCT03922178 415 429 I-Condition
( NCT03922178 430 431 O
diastolic NCT03922178 432 441 B-Observation
septal NCT03922178 442 448 I-Observation
thickness NCT03922178 449 458 I-Observation
> NCT03922178 459 460 B-Eq-Comparison
15 NCT03922178 461 463 I-Eq-Comparison
mm NCT03922178 464 466 I-Eq-Comparison
) NCT03922178 467 468 O

- NCT03922178 472 473 O
Heart NCT03922178 475 480 B-Condition
failure NCT03922178 481 488 I-Condition
with NCT03922178 489 493 B-And
left NCT03922178 494 498 B-Observation
ventricular NCT03922178 499 510 I-Observation
ejection NCT03922178 511 519 I-Observation
fraction NCT03922178 520 528 I-Observation
< NCT03922178 529 530 B-Eq-Comparison
50 NCT03922178 531 533 I-Eq-Comparison
% NCT03922178 534 535 O

- NCT03922178 538 539 O
Presence NCT03922178 541 549 O
of NCT03922178 550 552 O
cardiac NCT03922178 553 560 B-Condition
valvulopathy NCT03922178 561 573 I-Condition
, NCT03922178 574 575 O
concerning NCT03922178 576 586 O
both NCT03922178 587 591 O
right NCT03922178 592 597 B-Modifier
and NCT03922178 598 601 B-And
left NCT03922178 602 606 B-Modifier
atrio NCT03922178 607 612 B-Modifier
- NCT03922178 613 614 I-Modifier
ventricular NCT03922178 615 626 I-Modifier
and NCT03922178 627 630 B-And
ventriculo NCT03922178 631 641 B-Modifier
- NCT03922178 642 643 I-Modifier
arterial NCT03922178 644 652 I-Modifier
valves NCT03922178 653 659 I-Modifier

- NCT03922178 662 663 O
Presence NCT03922178 665 673 O
of NCT03922178 674 676 O
valvular NCT03922178 677 685 B-Procedure
prosthesis NCT03922178 686 696 I-Procedure

- NCT03922178 699 700 O
Congenital NCT03922178 702 712 B-Condition
heart NCT03922178 713 718 I-Condition
disease NCT03922178 719 726 I-Condition

- NCT03922178 729 730 O
Pregnancy NCT03922178 732 741 B-Condition

- NCT03922178 744 745 O
Participation NCT03922178 747 760 O
to NCT03922178 761 763 O
another NCT03922178 764 771 B-Other
clinical NCT03922178 772 780 O
study NCT03922178 781 786 B-Study

Inclusion NCT03927014 0 9 O
Criteria NCT03927014 10 18 O
: NCT03927014 19 20 O

- NCT03927014 24 25 O
preeclampsia NCT03927014 27 39 B-Condition

- NCT03927014 42 43 O
healthy NCT03927014 45 52 B-Condition
pregnancy NCT03927014 53 62 B-Condition

Exclusion NCT03927014 63 72 O
Criteria NCT03927014 73 81 O
: NCT03927014 82 83 O

- NCT03927014 87 88 O
pregnant NCT03927014 90 98 B-Condition
women NCT03927014 99 104 O
with NCT03927014 105 109 O
any NCT03927014 110 113 O
systemic NCT03927014 114 122 B-Modifier
condition NCT03927014 123 132 B-Condition
( NCT03927014 133 134 O
such NCT03927014 135 139 O
as NCT03927014 140 142 O
chronic NCT03927014 143 150 B-Condition
hypertension NCT03927014 151 163 I-Condition
, NCT03927014 164 165 O
diabetes NCT03927014 166 174 B-Condition
mellitus NCT03927014 175 183 I-Condition
, NCT03927014 184 185 O
thyroid NCT03927014 186 193 B-Condition
diseases NCT03927014 194 202 I-Condition
, NCT03927014 203 204 O
liver NCT03927014 205 210 B-Modifier
and NCT03927014 211 214 B-Or
kidney NCT03927014 215 221 B-Modifier
diseases NCT03927014 222 230 B-Condition
) NCT03927014 231 232 O

- NCT03927014 236 237 O
women NCT03927014 239 244 O
with NCT03927014 245 249 B-And
a NCT03927014 250 251 O
history NCT03927014 252 259 B-Eq-Comparison
of NCT03927014 260 262 O
drug NCT03927014 263 267 B-Condition
use NCT03927014 268 271 I-Condition
throughout NCT03927014 272 282 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03927014 283 292 B-Condition

- NCT03927014 295 296 O
history NCT03927014 298 305 B-Eq-Comparison
of NCT03927014 306 308 O
medication NCT03927014 309 319 B-Drug
for NCT03927014 320 323 O
PE NCT03927014 324 326 B-Condition
treatment NCT03927014 327 336 O
at NCT03927014 337 339 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927014 340 343 O
time NCT03927014 344 348 O
of NCT03927014 349 351 O
first NCT03927014 352 357 B-Eq-Comparison
admission NCT03927014 358 367 B-Encounter

- NCT03927014 370 371 O
patients NCT03927014 373 381 O
who NCT03927014 382 385 O
had NCT03927014 386 389 O
fetal NCT03927014 390 395 B-Condition
congenital NCT03927014 396 406 I-Condition
abnormalities NCT03927014 407 420 I-Condition
or NCT03927014 421 423 B-Or
genetic NCT03927014 424 431 B-Condition
syndromes NCT03927014 432 441 I-Condition

- NCT03927014 444 445 O
multiple NCT03927014 447 455 B-Condition
gestation NCT03927014 456 465 I-Condition

- NCT03927014 468 469 O
active NCT03927014 471 477 B-Eq-Comparison
labor NCT03927014 478 483 B-Condition

Inclusion NCT03920592 0 9 O
Criteria NCT03920592 10 18 O
: NCT03920592 19 20 O

- NCT03920592 24 25 O
All NCT03920592 27 30 O
pupils NCT03920592 31 37 O
assisting NCT03920592 38 47 O
5 NCT03920592 48 49 O
th NCT03920592 50 52 O
and NCT03920592 53 56 O
6 NCT03920592 57 58 O
th NCT03920592 59 61 O
grade NCT03920592 62 67 O
of NCT03920592 68 70 O
primary NCT03920592 71 78 O
school NCT03920592 79 85 O
( NCT03920592 86 87 O
Spain NCT03920592 88 93 O
education NCT03920592 94 103 O
system NCT03920592 104 110 O
) NCT03920592 111 112 O
of NCT03920592 113 115 O
the NCT03920592 116 119 O
" NCT03920592 120 121 O
Escola NCT03920592 121 127 O
Parc NCT03920592 128 132 O
del NCT03920592 133 136 O
Guinardó NCT03920592 137 145 O
" NCT03920592 145 146 O
school NCT03920592 147 153 O

- NCT03920592 156 157 O
Pupils NCT03920592 159 165 O
who NCT03920592 166 169 O
s NCT03920592 169 170 O
parents NCT03920592 171 178 B-Family-Member___Family-Member-Type:parent
have NCT03920592 179 183 O
read NCT03920592 184 188 O
, NCT03920592 189 190 O
understand NCT03920592 191 201 O
and NCT03920592 202 205 O
approved NCT03920592 206 214 O
the NCT03920592 215 218 O
informed NCT03920592 219 227 O
consent NCT03920592 228 235 O
of NCT03920592 236 238 O
the NCT03920592 239 242 O
study NCT03920592 243 248 O
. NCT03920592 248 249 O

Exclusion NCT03920592 251 260 O
Criteria NCT03920592 261 269 O
: NCT03920592 270 271 O

- NCT03920592 275 276 O
Pupils NCT03920592 278 284 O
whose NCT03920592 285 290 O
parents NCT03920592 291 298 B-Family-Member___Family-Member-Type:parent
have NCT03920592 299 303 O
not NCT03920592 304 307 O
approved NCT03920592 308 316 O
their NCT03920592 317 322 O
inclusion NCT03920592 323 332 O
in NCT03920592 333 335 O
the NCT03920592 336 339 O
study NCT03920592 340 345 O
. NCT03920592 345 346 O

Inclusion NCT03921840 0 9 O
Criteria NCT03921840 10 18 O
: NCT03921840 19 20 O

- NCT03921840 24 25 O
Intact NCT03921840 27 33 B-Condition
cognition NCT03921840 34 43 I-Condition

- NCT03921840 46 47 O
Poor NCT03921840 49 53 B-Condition
sleep NCT03921840 54 59 I-Condition
quality NCT03921840 60 67 I-Condition

- NCT03921840 70 71 O
Self NCT03921840 73 77 O
- NCT03921840 78 79 O
reported NCT03921840 80 88 O
presence NCT03921840 89 97 O
of NCT03921840 98 100 O
pain NCT03921840 101 105 B-Condition

- NCT03921840 108 109 O
Capacity NCT03921840 111 119 O
for NCT03921840 120 123 O
mild NCT03921840 124 128 O
to NCT03921840 129 131 B-Or
moderate NCT03921840 132 140 O
physical NCT03921840 141 149 B-Observation
activity NCT03921840 150 158 I-Observation
. NCT03921840 158 159 O

Exclusion NCT03921840 161 170 O
Criteria NCT03921840 171 179 O
: NCT03921840 180 181 O

- NCT03921840 185 186 O
Non NCT03921840 188 191 B-Negation
- NCT03921840 192 193 O
ambulatory NCT03921840 194 204 B-Condition
or NCT03921840 205 207 B-Or
have NCT03921840 208 212 O
severely NCT03921840 213 221 O
impaired NCT03921840 222 230 B-Condition
mobility NCT03921840 231 239 I-Condition
, NCT03921840 240 241 O

- NCT03921840 245 246 O
Visual NCT03921840 248 254 B-Modifier
or NCT03921840 255 257 B-Or
hearing NCT03921840 258 265 B-Modifier
impairment NCT03921840 266 276 B-Condition
that NCT03921840 277 281 O
interfered NCT03921840 282 292 O
with NCT03921840 293 297 O
assessments NCT03921840 298 309 O
, NCT03921840 310 311 O
and NCT03921840 312 315 O

- NCT03921840 318 319 O
An NCT03921840 321 323 O
acute NCT03921840 324 329 O
or NCT03921840 330 332 B-Or
a NCT03921840 333 334 O
terminal NCT03921840 335 343 B-Modifier
illness NCT03921840 344 351 B-Condition

- NCT03921840 354 355 O
Neuropathic NCT03921840 357 368 B-Modifier
pain NCT03921840 369 373 B-Condition

Inclusion NCT03929549 0 9 O
Criteria NCT03929549 10 18 O
: NCT03929549 19 20 O

- NCT03929549 24 25 O
Moderate NCT03929549 27 35 O
to NCT03929549 36 38 B-Or
severe NCT03929549 39 45 O
OSA NCT03929549 46 49 B-Condition
( NCT03929549 50 51 O
AHI NCT03929549 52 55 B-Observation
> NCT03929549 56 57 B-Eq-Comparison
15 NCT03929549 58 60 I-Eq-Comparison
) NCT03929549 61 62 O

- NCT03929549 66 67 O
Age NCT03929549 69 72 B-Age
18 NCT03929549 73 75 B-Eq-Comparison
years NCT03929549 76 81 I-Eq-Comparison
or NCT03929549 82 84 I-Eq-Comparison
older NCT03929549 85 90 I-Eq-Comparison

- NCT03929549 93 94 O
BMI NCT03929549 96 99 B-Observation
< NCT03929549 100 101 B-Eq-Comparison
40 NCT03929549 102 104 I-Eq-Comparison
, NCT03929549 105 106 O

- NCT03929549 111 112 O
Baseline NCT03929549 114 122 O
polysomnogram NCT03929549 123 136 B-Procedure
completed NCT03929549 137 146 O
within NCT03929549 147 153 B-Eq-Comparison
the NCT03929549 154 157 I-Eq-Comparison
last NCT03929549 158 162 I-Eq-Comparison
12 NCT03929549 163 165 I-Eq-Comparison
months NCT03929549 166 172 I-Eq-Comparison
with NCT03929549 173 177 B-And
no NCT03929549 178 180 O
significant NCT03929549 181 192 O
weight NCT03929549 193 199 B-Observation
changes NCT03929549 200 207 O
( NCT03929549 208 209 O
< NCT03929549 211 212 B-Eq-Comparison
10 NCT03929549 213 215 I-Eq-Comparison
lbs NCT03929549 216 219 I-Eq-Comparison
. NCT03929549 219 220 O
weight NCT03929549 222 228 O
fluctuation NCT03929549 229 240 O
) NCT03929549 241 242 O
. NCT03929549 243 244 O

- NCT03929549 248 249 O
The NCT03929549 251 254 O
baseline NCT03929549 255 263 O
sleep NCT03929549 264 269 O
study NCT03929549 270 275 O
must NCT03929549 276 280 O
be NCT03929549 281 283 O
diagnostic NCT03929549 284 294 O
with NCT03929549 295 299 O
adequate NCT03929549 300 308 O
sample NCT03929549 309 315 O

Exclusion NCT03929549 316 325 O
Criteria NCT03929549 326 334 O
: NCT03929549 335 336 O

- NCT03929549 340 341 O
BMI NCT03929549 343 346 B-Observation
≥ NCT03929549 347 348 B-Eq-Comparison
40 NCT03929549 349 351 I-Eq-Comparison

- NCT03929549 355 356 O
pregnancy NCT03929549 358 367 B-Condition

- NCT03929549 370 371 O
Central NCT03929549 373 380 B-Condition
sleep NCT03929549 381 386 I-Condition
apnea NCT03929549 387 392 I-Condition
( NCT03929549 393 394 O
CSA NCT03929549 395 398 B-Condition
) NCT03929549 399 400 O
- NCT03929549 401 402 O
5 NCT03929549 403 404 B-Eq-Comparison
or NCT03929549 405 407 I-Eq-Comparison
more NCT03929549 408 412 I-Eq-Comparison
central NCT03929549 413 420 B-Eq-Comparison|Observation
apneas NCT03929549 421 427 I-Eq-Comparison|Observation
per NCT03929549 428 431 I-Eq-Comparison
hour NCT03929549 432 436 I-Eq-Comparison

- NCT03929549 439 440 O
Psychoactive NCT03929549 442 454 B-Drug
medications NCT03929549 455 466 I-Drug
that NCT03929549 467 471 O
influence NCT03929549 472 481 O
sleep NCT03929549 482 487 B-Condition

- NCT03929549 490 491 O
Chronic NCT03929549 493 500 B-Modifier
opioid NCT03929549 501 507 B-Drug
use NCT03929549 508 511 O

- NCT03929549 514 515 O
Other NCT03929549 517 522 B-Other
sleep NCT03929549 523 528 B-Condition
disorders NCT03929549 529 538 I-Condition

- NCT03929549 541 542 O
Active NCT03929549 544 550 B-Eq-Comparison
temporomandibular NCT03929549 551 568 B-Modifier
joint NCT03929549 569 574 I-Modifier
( NCT03929549 575 576 O
TMJ NCT03929549 577 580 B-Modifier
) NCT03929549 581 582 O
Disorders NCT03929549 583 592 B-Condition

- NCT03929549 595 596 O
Fibromyalgia NCT03929549 598 610 B-Condition
with NCT03929549 611 615 B-And
significant NCT03929549 616 627 O
facial NCT03929549 628 634 B-Modifier
pain NCT03929549 635 639 B-Condition

- NCT03929549 642 643 O
Inability NCT03929549 645 654 B-Negation
to NCT03929549 655 657 O
protrude NCT03929549 658 666 B-Observation
the NCT03929549 667 670 I-Observation
mandible NCT03929549 671 679 I-Observation
beyond NCT03929549 680 686 B-Eq-Comparison
5 NCT03929549 687 688 I-Eq-Comparison
mm NCT03929549 689 691 I-Eq-Comparison

- NCT03929549 694 695 I-Encounter
Inability NCT03929549 697 706 B-Negation
to NCT03929549 707 709 O
follow NCT03929549 710 716 B-Encounter
- NCT03929549 717 718 O
up NCT03929549 719 721 I-Encounter
after NCT03929549 722 727 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03929549 728 735 B-Procedure

- NCT03929549 738 739 O
Uncontrolled NCT03929549 741 753 B-Modifier
psychiatric NCT03929549 754 765 B-Condition
disorders NCT03929549 766 775 I-Condition|Condition

- NCT03929549 778 779 O
Dental NCT03929549 781 787 B-Condition
disorders NCT03929549 788 797 O
including NCT03929549 798 807 O
loose NCT03929549 808 813 B-Condition
teeth NCT03929549 814 819 I-Condition
and NCT03929549 820 823 B-Or
periodontal NCT03929549 824 835 B-Condition
disease NCT03929549 836 843 I-Condition

Inclusion NCT03920579 0 9 O
Criteria NCT03920579 10 18 O
: NCT03920579 19 20 O

1 NCT03920579 24 25 O
. NCT03920579 25 26 O
Healthy NCT03920579 28 35 B-Condition
volunteers NCT03920579 36 46 O
aged NCT03920579 47 51 B-Age
between NCT03920579 52 59 B-Eq-Comparison
≥ NCT03920579 60 61 I-Eq-Comparison
20 NCT03920579 62 64 I-Eq-Comparison
and NCT03920579 65 68 I-Eq-Comparison
≤ NCT03920579 69 70 I-Eq-Comparison
45 NCT03920579 71 73 I-Eq-Comparison
years NCT03920579 74 79 I-Eq-Comparison
old NCT03920579 80 83 O

2 NCT03920579 86 87 O
. NCT03920579 87 88 O
Weight NCT03920579 90 96 B-Observation
≥ NCT03920579 97 98 B-Eq-Comparison
50 NCT03920579 99 101 I-Eq-Comparison
kg NCT03920579 102 104 I-Eq-Comparison
, NCT03920579 105 106 O
with NCT03920579 107 111 O
calculated NCT03920579 112 122 O
body NCT03920579 123 127 B-Observation
mass NCT03920579 128 132 I-Observation
index NCT03920579 133 138 I-Observation
( NCT03920579 139 140 O
BMI NCT03920579 141 144 B-Observation
) NCT03920579 145 146 O
of NCT03920579 147 149 O
≥ NCT03920579 150 151 B-Eq-Comparison
18.5 NCT03920579 152 156 I-Eq-Comparison
and NCT03920579 157 160 B-And
≤ NCT03920579 161 162 B-Eq-Comparison
27.0 NCT03920579 163 167 I-Eq-Comparison
kg NCT03920579 168 170 I-Eq-Comparison
/ NCT03920579 171 172 I-Eq-Comparison
m2 NCT03920579 173 175 I-Eq-Comparison

3 NCT03920579 178 179 O
. NCT03920579 179 180 O
Those NCT03920579 182 187 O
who NCT03920579 188 191 O
have NCT03920579 192 196 O
no NCT03920579 197 199 B-Negation
congenital NCT03920579 200 210 B-Condition
chronic NCT03920579 211 218 I-Condition
disease NCT03920579 219 226 I-Condition
or NCT03920579 227 229 B-Or
chronic NCT03920579 230 237 B-Condition
disease NCT03920579 238 245 I-Condition
requiring NCT03920579 246 255 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03920579 256 265 B-Procedure
and NCT03920579 266 269 B-And
who NCT03920579 270 273 O
have NCT03920579 274 278 O
no NCT03920579 279 281 B-Negation
pathological NCT03920579 282 294 B-Condition
symptoms NCT03920579 295 303 B-Assertion___Assertion-Type-Value:possible
or NCT03920579 304 306 B-Or
findings NCT03920579 307 315 B-Modifier

4 NCT03920579 318 319 O
. NCT03920579 319 320 O
Those NCT03920579 322 327 O
who NCT03920579 328 331 O
are NCT03920579 332 335 O
judged NCT03920579 336 342 O
to NCT03920579 343 345 O
be NCT03920579 346 348 O
eligible NCT03920579 349 357 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920579 358 361 O
clinical NCT03920579 362 370 O
trials NCT03920579 371 377 O
based NCT03920579 378 383 O
on NCT03920579 384 386 O
laboratory NCT03920579 387 397 B-Observation
and NCT03920579 398 401 B-And
ECG NCT03920579 402 405 B-Observation
results NCT03920579 406 413 O
during NCT03920579 414 420 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920579 421 430 B-Study
tests NCT03920579 431 436 O

5 NCT03920579 439 440 O
. NCT03920579 440 441 O
Those NCT03920579 443 448 O
who NCT03920579 449 452 O
voluntarily NCT03920579 453 464 O
decide NCT03920579 465 471 O
to NCT03920579 472 474 O
participate NCT03920579 475 486 O
and NCT03920579 487 490 O
agree NCT03920579 491 496 O
to NCT03920579 497 499 O
comply NCT03920579 500 506 O
with NCT03920579 507 511 O
the NCT03920579 512 515 O
cautions NCT03920579 516 524 O
after NCT03920579 525 530 O
hearing NCT03920579 531 538 O
and NCT03920579 539 542 O
fully NCT03920579 543 548 O
understanding NCT03920579 549 562 O
the NCT03920579 563 566 O
detailed NCT03920579 567 575 O
description NCT03920579 576 587 O
of NCT03920579 588 590 O
this NCT03920579 591 595 O
clinical NCT03920579 596 604 O
trial NCT03920579 605 610 O

Exclusion NCT03920579 611 620 O
Criteria NCT03920579 621 629 O
: NCT03920579 630 631 O

1 NCT03920579 635 636 O
. NCT03920579 636 637 O
History NCT03920579 639 646 B-Eq-Comparison
of NCT03920579 647 649 O
presence NCT03920579 650 658 O
of NCT03920579 659 661 O
hepatobiliary NCT03920579 662 675 B-Modifier
, NCT03920579 676 677 O
renal NCT03920579 678 683 B-Modifier
, NCT03920579 684 685 O
cardiovascular NCT03920579 686 700 B-Modifier
, NCT03920579 701 702 O
endocrine NCT03920579 703 712 B-Modifier
, NCT03920579 713 714 O
respiratory NCT03920579 715 726 B-Modifier
, NCT03920579 727 728 O
gastrointestinal NCT03920579 729 745 B-Modifier
, NCT03920579 746 747 O
hematological NCT03920579 748 761 B-Modifier
, NCT03920579 762 763 O
neurologic NCT03920579 764 774 B-Modifier
, NCT03920579 775 776 O
psychiatric NCT03920579 777 788 B-Modifier
or NCT03920579 789 791 B-Or
musculoskeletal NCT03920579 792 807 B-Modifier
disorders NCT03920579 808 817 B-Condition
affecting NCT03920579 818 827 B-Assertion___Assertion-Type-Value:hypothetical
absorption NCT03920579 828 838 B-Modifier
, NCT03920579 839 840 O
distribution NCT03920579 841 853 B-Modifier
, NCT03920579 854 855 O
metabolism NCT03920579 856 866 B-Modifier
and NCT03920579 867 870 O
excretion NCT03920579 871 880 B-Modifier
of NCT03920579 881 883 O
the NCT03920579 884 887 O
drug NCT03920579 888 892 B-Drug

2 NCT03920579 895 896 O
. NCT03920579 896 897 O
Genetic NCT03920579 899 906 B-Condition
problems NCT03920579 907 915 I-Condition
such NCT03920579 916 920 O
as NCT03920579 921 923 O
galactose NCT03920579 924 933 B-Condition
intolerance NCT03920579 934 945 I-Condition
, NCT03920579 946 947 O
Lapp NCT03920579 948 952 B-Condition
lactose NCT03920579 953 960 I-Condition
deficiency NCT03920579 961 971 I-Condition
or NCT03920579 972 974 B-Or
glucose NCT03920579 975 982 B-Condition
- NCT03920579 983 984 I-Condition
galactose NCT03920579 985 994 I-Condition
malabsorption NCT03920579 995 1008 I-Condition

3 NCT03920579 1011 1012 O
. NCT03920579 1012 1013 O
Those NCT03920579 1015 1020 O
who NCT03920579 1021 1024 O
are NCT03920579 1025 1028 O
deemed NCT03920579 1029 1035 O
unfit NCT03920579 1036 1041 O
by NCT03920579 1042 1044 O
the NCT03920579 1045 1048 O
investigators NCT03920579 1049 1062 O
to NCT03920579 1063 1065 O
participate NCT03920579 1066 1077 O
in NCT03920579 1078 1080 O
the NCT03920579 1081 1084 O
clinical NCT03920579 1085 1093 O
trial NCT03920579 1094 1099 O
for NCT03920579 1100 1103 O
other NCT03920579 1104 1109 O
reasons NCT03920579 1110 1117 O
including NCT03920579 1118 1127 O
the NCT03920579 1128 1131 O
results NCT03920579 1132 1139 O
of NCT03920579 1140 1142 O
laboratory NCT03920579 1143 1153 O
tests NCT03920579 1154 1159 O

Inclusion NCT03929575 0 9 O
Criteria NCT03929575 10 18 O
: NCT03929575 19 20 O

- NCT03929575 24 25 O
Body NCT03929575 27 31 B-Observation
Mass NCT03929575 32 36 I-Observation
Index NCT03929575 37 42 I-Observation
between NCT03929575 43 50 B-Eq-Comparison
18.5 NCT03929575 51 55 I-Eq-Comparison
and NCT03929575 56 59 I-Eq-Comparison
35 NCT03929575 60 62 I-Eq-Comparison
kg NCT03929575 63 65 I-Eq-Comparison
/ NCT03929575 66 67 I-Eq-Comparison
m^2 NCT03929575 68 71 I-Eq-Comparison

- NCT03929575 75 76 O
Non NCT03929575 78 81 B-Negation
- NCT03929575 82 83 O
smoking NCT03929575 84 91 B-Condition
( NCT03929575 92 93 O
assessed NCT03929575 94 102 O
by NCT03929575 103 105 O
Health NCT03929575 106 112 B-Observation
History NCT03929575 113 120 I-Observation
Questionnaire NCT03929575 121 134 I-Observation
) NCT03929575 135 136 O

- NCT03929575 140 141 O
English NCT03929575 143 150 O
- NCT03929575 151 152 O
speaking NCT03929575 153 161 O

- NCT03929575 164 165 O
Regular NCT03929575 167 174 O
participation NCT03929575 175 188 O
in NCT03929575 189 191 O
physical NCT03929575 192 200 B-Observation
activity NCT03929575 201 209 I-Observation
( NCT03929575 210 211 O
> NCT03929575 213 214 B-Eq-Comparison
4 NCT03929575 215 216 I-Eq-Comparison
hours NCT03929575 217 222 I-Eq-Comparison
per NCT03929575 223 226 I-Eq-Comparison
week NCT03929575 227 231 I-Eq-Comparison
) NCT03929575 232 233 O

Exclusion NCT03929575 235 244 O
Criteria NCT03929575 245 253 O
: NCT03929575 254 255 O

- NCT03929575 259 260 O
Medical NCT03929575 262 269 O
conditions NCT03929575 270 280 B-Condition
that NCT03929575 281 285 O
prohibit NCT03929575 286 294 B-Negation
physical NCT03929575 295 303 B-Observation
activity NCT03929575 304 312 I-Observation
( NCT03929575 313 314 O
assessed NCT03929575 315 323 O
by NCT03929575 324 326 O
Health NCT03929575 327 333 B-Observation
History NCT03929575 334 341 I-Observation
Questionnaire NCT03929575 342 355 I-Observation
) NCT03929575 356 357 O

- NCT03929575 361 362 O
Pregnant NCT03929575 364 372 B-Condition
women NCT03929575 373 378 O
or NCT03929575 379 381 B-Or
women NCT03929575 382 387 O
expecting NCT03929575 388 397 B-Assertion___Assertion-Type-Value:intention
/ NCT03929575 398 399 B-Or
trying NCT03929575 400 406 B-Assertion___Assertion-Type-Value:intention
to NCT03929575 407 409 O
become NCT03929575 410 416 O
pregnant NCT03929575 417 425 B-Condition

- NCT03929575 428 429 O
BMI NCT03929575 431 434 B-Observation
greater NCT03929575 435 442 B-Eq-Comparison
than NCT03929575 443 447 I-Eq-Comparison
or NCT03929575 448 450 I-Eq-Comparison
equal NCT03929575 451 456 I-Eq-Comparison
to NCT03929575 457 459 I-Eq-Comparison
35 NCT03929575 460 462 I-Eq-Comparison
kg NCT03929575 463 465 I-Eq-Comparison
/ NCT03929575 466 467 I-Eq-Comparison
m^2 NCT03929575 468 471 I-Eq-Comparison

- NCT03929575 475 476 O
Current NCT03929575 478 485 B-Eq-Comparison
smoker NCT03929575 486 492 B-Condition
( NCT03929575 493 494 O
assessed NCT03929575 495 503 O
by NCT03929575 504 506 O
Health NCT03929575 507 513 B-Observation
History NCT03929575 514 521 I-Observation
Questionnaire NCT03929575 522 535 I-Observation
) NCT03929575 536 537 O

Inclusion NCT03928119 0 9 O
Criteria NCT03928119 10 18 O
: NCT03928119 19 20 O

- NCT03928119 24 25 O
ST NCT03928119 27 29 B-Condition
- NCT03928119 30 31 I-Condition
Segment NCT03928119 32 39 I-Condition
Elevation NCT03928119 40 49 I-Condition
Myocardial NCT03928119 50 60 I-Condition
Infarction NCT03928119 61 71 I-Condition
patients NCT03928119 72 80 O
within NCT03928119 81 87 B-Eq-Comparison
30 NCT03928119 88 90 I-Eq-Comparison
days NCT03928119 91 95 I-Eq-Comparison
since NCT03928119 96 101 B-Temporal-Connection___Temporal-Connection-Type-Value:after
symptoms NCT03928119 102 110 B-Assertion___Assertion-Type-Value:possible
onset NCT03928119 111 116 B-Eq-Comparison

Exclusion NCT03928119 117 126 O
Criteria NCT03928119 127 135 O
: NCT03928119 136 137 O

- NCT03928119 141 142 O
None NCT03928119 144 148 O

Inclusion NCT03923361 0 9 O
Criteria NCT03923361 10 18 O
: NCT03923361 19 20 O

- NCT03923361 24 25 O
Age NCT03923361 27 30 B-Age
18 NCT03923361 31 33 B-Eq-Comparison
- NCT03923361 34 35 I-Eq-Comparison
55 NCT03923361 36 38 O

- NCT03923361 42 43 O
Diagnosis NCT03923361 45 54 O
of NCT03923361 55 57 O
major NCT03923361 58 63 B-Modifier
depressive NCT03923361 64 74 B-Condition
disorder NCT03923361 75 83 I-Condition
or NCT03923361 84 86 B-Or
bipolar NCT03923361 87 94 B-Condition
disorder NCT03923361 95 103 I-Condition

- NCT03923361 106 107 O
Current NCT03923361 109 116 B-Eq-Comparison
moderate NCT03923361 117 125 O
- NCT03923361 126 127 O
to NCT03923361 128 130 B-Or
- NCT03923361 131 132 O
severe NCT03923361 133 139 O
depressive NCT03923361 140 150 B-Condition
episode NCT03923361 151 158 I-Condition

- NCT03923361 161 162 O
Episode NCT03923361 164 171 B-Coreference
duration NCT03923361 172 180 O
more NCT03923361 181 185 B-Eq-Comparison
than NCT03923361 186 190 I-Eq-Comparison
2 NCT03923361 191 192 I-Eq-Comparison
months NCT03923361 193 199 I-Eq-Comparison
and NCT03923361 200 203 B-And
less NCT03923361 204 208 B-Eq-Comparison
than NCT03923361 209 213 I-Eq-Comparison
5 NCT03923361 214 215 I-Eq-Comparison
years NCT03923361 216 221 I-Eq-Comparison

- NCT03923361 224 225 O
Failure NCT03923361 227 234 O
of NCT03923361 235 237 O
at NCT03923361 238 240 B-Eq-Comparison
least NCT03923361 241 246 I-Eq-Comparison
2 NCT03923361 247 248 I-Eq-Comparison
adequate NCT03923361 249 257 O
antidepressant NCT03923361 258 272 B-Drug
medication NCT03923361 273 283 I-Drug
trials NCT03923361 284 290 O
within NCT03923361 291 297 B-Eq-Comparison
the NCT03923361 298 301 I-Eq-Comparison
past NCT03923361 302 306 I-Eq-Comparison
2 NCT03923361 307 308 I-Eq-Comparison
years NCT03923361 309 314 I-Eq-Comparison

- NCT03923361 317 318 O
Body NCT03923361 320 324 B-Observation
mass NCT03923361 325 329 I-Observation
index NCT03923361 330 335 I-Observation
< NCT03923361 336 337 B-Eq-Comparison
40 NCT03923361 338 340 I-Eq-Comparison

- NCT03923361 344 345 I-Observation
16 NCT03923361 347 349 B-Observation
- NCT03923361 350 351 O
item NCT03923361 352 356 I-Observation
Quick NCT03923361 357 362 I-Observation
Inventory NCT03923361 363 372 I-Observation
of NCT03923361 373 375 I-Observation
Depressive NCT03923361 376 386 I-Observation
Symptomatology NCT03923361 387 401 I-Observation
, NCT03923361 402 403 O
self NCT03923361 404 408 O
- NCT03923361 409 410 O
rated NCT03923361 411 416 O
> NCT03923361 417 418 B-Eq-Comparison
10 NCT03923361 419 421 I-Eq-Comparison

Exclusion NCT03923361 423 432 O
Criteria NCT03923361 433 441 O
: NCT03923361 442 443 O

- NCT03923361 447 448 O
Contraindication NCT03923361 450 466 B-Contraindication
to NCT03923361 467 469 O
propofol NCT03923361 470 478 B-Drug
or NCT03923361 479 481 B-Or
midazolam NCT03923361 482 491 B-Drug

- NCT03923361 494 495 O
Daily NCT03923361 497 502 B-Eq-Comparison
use NCT03923361 503 506 O
of NCT03923361 507 509 O
benzodiazepine NCT03923361 510 524 B-Drug
, NCT03923361 525 526 O
opioid NCT03923361 527 533 B-Drug
, NCT03923361 534 535 O
ACE NCT03923361 536 539 B-Drug
inhibitor NCT03923361 540 549 I-Drug
, NCT03923361 550 551 O
or NCT03923361 552 554 B-Or
ARB NCT03923361 555 558 B-Drug
medication NCT03923361 559 569 I-Drug

- NCT03923361 572 573 O
Symptomatic NCT03923361 575 586 B-Assertion___Assertion-Type-Value:possible
coronary NCT03923361 587 595 B-Condition
artery NCT03923361 596 602 I-Condition
disease NCT03923361 603 610 I-Condition
or NCT03923361 611 613 B-Or
heart NCT03923361 614 619 B-Condition
failure NCT03923361 620 627 I-Condition

- NCT03923361 630 631 O
Poorly NCT03923361 633 639 B-Modifier
controlled NCT03923361 640 650 I-Modifier
hypertension NCT03923361 651 663 B-Condition
or NCT03923361 664 666 B-Or
diabetes NCT03923361 667 675 B-Condition

- NCT03923361 678 679 O
Abnormal NCT03923361 681 689 O
kidney NCT03923361 690 696 B-Modifier
or NCT03923361 697 699 B-Or
liver NCT03923361 700 705 B-Modifier
function NCT03923361 706 714 B-Condition

- NCT03923361 717 718 O
Pregnant NCT03923361 720 728 B-Condition
or NCT03923361 729 731 B-Or
breast NCT03923361 732 738 B-Condition
feeding NCT03923361 739 746 I-Condition

- NCT03923361 749 750 O
Traumatic NCT03923361 752 761 B-Condition
brain NCT03923361 762 767 I-Condition
injury NCT03923361 768 774 I-Condition
or NCT03923361 775 777 B-Or
significant NCT03923361 778 789 O
neurologic NCT03923361 790 800 B-Condition
signs NCT03923361 801 806 B-Assertion___Assertion-Type-Value:possible
( NCT03923361 807 808 O
past NCT03923361 809 813 B-Eq-Comparison
year NCT03923361 814 818 I-Eq-Comparison
) NCT03923361 819 820 O

- NCT03923361 824 825 O
Substance NCT03923361 827 836 B-Condition
use NCT03923361 837 840 I-Condition
disorder NCT03923361 841 849 I-Condition
( NCT03923361 850 851 O
past NCT03923361 852 856 B-Eq-Comparison
year NCT03923361 857 861 I-Eq-Comparison
) NCT03923361 862 863 O

- NCT03923361 867 868 O
Obsessive NCT03923361 870 879 B-Condition
compulsive NCT03923361 880 890 I-Condition
disorder NCT03923361 891 899 I-Condition
( NCT03923361 900 901 O
current NCT03923361 902 909 B-Eq-Comparison
) NCT03923361 910 911 O

- NCT03923361 915 916 I-Condition
Post NCT03923361 918 922 B-Condition
- NCT03923361 923 924 O
traumatic NCT03923361 925 934 I-Condition
stress NCT03923361 935 941 I-Condition
disorder NCT03923361 942 950 I-Condition
( NCT03923361 951 952 O
current NCT03923361 953 960 B-Eq-Comparison
) NCT03923361 961 962 O

- NCT03923361 966 967 I-Condition
Schizophrenia NCT03923361 969 982 B-Condition
- NCT03923361 983 984 O
spectrum NCT03923361 985 993 I-Condition
disorder NCT03923361 994 1002 I-Condition
( NCT03923361 1003 1004 O
lifetime NCT03923361 1005 1013 O
) NCT03923361 1014 1015 O

- NCT03923361 1019 1020 O
Neurocognitive NCT03923361 1022 1036 B-Condition
disorder NCT03923361 1037 1045 I-Condition|Condition
( NCT03923361 1046 1047 O
current NCT03923361 1048 1055 B-Eq-Comparison|Eq-Comparison
) NCT03923361 1056 1057 O

- NCT03923361 1061 1062 O
Personality NCT03923361 1064 1075 B-Condition
disorder NCT03923361 1076 1084 O
as NCT03923361 1085 1087 O
a NCT03923361 1088 1089 O
current NCT03923361 1090 1097 O
focus NCT03923361 1098 1103 O
of NCT03923361 1104 1106 O
treatment NCT03923361 1107 1116 B-Procedure

- NCT03923361 1119 1120 O
ECT NCT03923361 1122 1125 B-Procedure
within NCT03923361 1126 1132 B-Eq-Comparison
the NCT03923361 1133 1136 I-Eq-Comparison
past NCT03923361 1137 1141 I-Eq-Comparison
3 NCT03923361 1142 1143 I-Eq-Comparison
months NCT03923361 1144 1150 I-Eq-Comparison

- NCT03923361 1153 1154 O
Inappropriate NCT03923361 1156 1169 B-Contraindication
for NCT03923361 1170 1173 O
ECT NCT03923361 1174 1177 B-Procedure|Procedure
, NCT03923361 1178 1179 O
or NCT03923361 1180 1182 B-Or
poor NCT03923361 1183 1187 O
response NCT03923361 1188 1196 O
to NCT03923361 1197 1199 O
ECT NCT03923361 1200 1203 O
within NCT03923361 1204 1210 B-Eq-Comparison
the NCT03923361 1211 1214 I-Eq-Comparison
past NCT03923361 1215 1219 I-Eq-Comparison
5 NCT03923361 1220 1221 I-Eq-Comparison
years NCT03923361 1222 1227 I-Eq-Comparison

- NCT03923361 1230 1231 O
Incompetent NCT03923361 1233 1244 O
to NCT03923361 1245 1247 O
provide NCT03923361 1248 1255 O
consent NCT03923361 1256 1263 O

Inclusion NCT03923413 0 9 O
Criteria NCT03923413 10 18 O
: NCT03923413 19 20 O

- NCT03923413 24 25 O
Inclusion NCT03923413 27 36 O
Criteria NCT03923413 37 45 O
: NCT03923413 46 47 O
chronic NCT03923413 48 55 B-Condition
heart NCT03923413 56 61 I-Condition
failure NCT03923413 62 69 I-Condition
INTERMASC NCT03923413 70 79 B-Observation
5 NCT03923413 80 81 B-Eq-Comparison
- NCT03923413 82 83 I-Eq-Comparison
7 NCT03923413 84 85 O
or NCT03923413 86 88 B-Or

- NCT03923413 91 92 O
Patients NCT03923413 94 102 O
on NCT03923413 103 105 B-Eq-Comparison
LVAD NCT03923413 106 110 B-Procedure
support NCT03923413 111 118 I-Procedure

Exclusion NCT03923413 119 128 O
Criteria NCT03923413 129 137 O
: NCT03923413 138 139 O

- NCT03923413 143 144 O
current NCT03923413 146 153 B-Eq-Comparison
thrombembolic NCT03923413 154 167 B-Modifier
or NCT03923413 168 170 B-Or
bleeding NCT03923413 171 179 B-Modifier
event NCT03923413 180 185 B-Condition

Inclusion NCT03927885 0 9 O
Criteria NCT03927885 10 18 O
: NCT03927885 19 20 O

- NCT03927885 24 25 O
Patient NCT03927885 27 34 O
with NCT03927885 35 39 O
a NCT03927885 40 41 O
diagnosis NCT03927885 42 51 O
of NCT03927885 52 54 O
advanced NCT03927885 55 63 O
cancer NCT03927885 64 70 B-Condition
( NCT03927885 71 72 O
metastatic NCT03927885 73 83 B-Modifier
or NCT03927885 84 86 B-Or
recurrent NCT03927885 87 96 B-Modifier
incurable NCT03927885 97 106 I-Modifier
solid NCT03927885 107 112 B-Condition
tumors NCT03927885 113 119 I-Condition
) NCT03927885 120 121 O

- NCT03927885 125 126 O
Presence NCT03927885 128 136 O
of NCT03927885 137 139 O
fatigue NCT03927885 140 147 B-Condition
of NCT03927885 148 150 O
> NCT03927885 151 152 B-Eq-Comparison
= NCT03927885 154 155 I-Eq-Comparison
4 NCT03927885 156 157 I-Eq-Comparison
/ NCT03927885 158 159 I-Eq-Comparison
10 NCT03927885 160 162 I-Eq-Comparison
on NCT03927885 163 165 O
Edmonton NCT03927885 166 174 B-Observation
Symptom NCT03927885 175 182 I-Observation
Assessment NCT03927885 183 193 I-Observation
System NCT03927885 194 200 I-Observation
( NCT03927885 201 202 O
ESAS NCT03927885 203 207 B-Observation
) NCT03927885 208 209 O
Fatigue NCT03927885 210 217 O
item NCT03927885 218 222 O
( NCT03927885 223 224 O
0 NCT03927885 225 226 O
- NCT03927885 227 228 O
10 NCT03927885 229 231 O
severity NCT03927885 232 240 O
scale NCT03927885 241 246 O
) NCT03927885 247 248 O

- NCT03927885 252 253 O
Patient NCT03927885 255 262 O
should NCT03927885 263 269 O
describe NCT03927885 270 278 O
fatigue NCT03927885 279 286 B-Condition
as NCT03927885 287 289 O
being NCT03927885 290 295 O
present NCT03927885 296 303 O
for NCT03927885 304 307 O
a NCT03927885 308 309 O
minimum NCT03927885 310 317 B-Eq-Comparison
of NCT03927885 318 320 I-Eq-Comparison
2 NCT03927885 321 322 I-Eq-Comparison
weeks NCT03927885 323 328 I-Eq-Comparison
prior NCT03927885 329 334 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927885 335 337 O
screening NCT03927885 338 347 B-Study

- NCT03927885 350 351 O
Uncontrolled NCT03927885 353 365 B-Modifier
pain NCT03927885 366 370 B-Condition
; NCT03927885 370 371 O
patient NCT03927885 372 379 O
is NCT03927885 380 382 O
on NCT03927885 383 385 B-Eq-Comparison
opioids NCT03927885 386 393 B-Drug
for NCT03927885 394 397 O
the NCT03927885 398 401 O
treatment NCT03927885 402 411 B-Procedure
of NCT03927885 412 414 O
cancer NCT03927885 415 421 B-Condition
pain NCT03927885 422 426 B-Condition
, NCT03927885 427 428 O
he NCT03927885 429 431 O
/ NCT03927885 432 433 O
she NCT03927885 434 437 O
must NCT03927885 438 442 O
have NCT03927885 443 447 O
had NCT03927885 448 451 O
no NCT03927885 452 454 B-Negation
major NCT03927885 455 460 O
dose NCT03927885 461 465 O
change NCT03927885 466 472 O
( NCT03927885 473 474 O
> NCT03927885 476 477 B-Eq-Comparison
25 NCT03927885 478 480 I-Eq-Comparison
% NCT03927885 481 482 O
) NCT03927885 483 484 O
for NCT03927885 485 488 O
at NCT03927885 489 491 B-Eq-Comparison
least NCT03927885 492 497 I-Eq-Comparison
48 NCT03927885 498 500 I-Eq-Comparison
hours NCT03927885 501 506 I-Eq-Comparison
prior NCT03927885 507 512 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927885 513 515 O
study NCT03927885 516 521 B-Study
entry NCT03927885 522 527 O
. NCT03927885 527 528 O
Change NCT03927885 530 536 O
in NCT03927885 537 539 O
opioid NCT03927885 540 546 B-Drug
dose NCT03927885 547 551 O
after NCT03927885 552 557 B-Temporal-Connection___Temporal-Connection-Type-Value:after
study NCT03927885 558 563 B-Study
entry NCT03927885 564 569 O
is NCT03927885 570 572 O
allowed NCT03927885 573 580 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03927885 583 584 O
Patient NCT03927885 586 593 O
must NCT03927885 594 598 O
be NCT03927885 599 601 O
willing NCT03927885 602 609 O
to NCT03927885 610 612 O
engage NCT03927885 613 619 O
in NCT03927885 620 622 O
telephone NCT03927885 623 632 O
follow NCT03927885 633 639 O
up NCT03927885 640 642 O
with NCT03927885 643 647 O
research NCT03927885 648 656 O
staff NCT03927885 657 662 O

- NCT03927885 665 666 O
Patient NCT03927885 668 675 O
must NCT03927885 676 680 O
have NCT03927885 681 685 O
telephone NCT03927885 686 695 O
access NCT03927885 696 702 O
to NCT03927885 703 705 O
be NCT03927885 706 708 O
contacted NCT03927885 709 718 O
by NCT03927885 719 721 O
the NCT03927885 722 725 O
research NCT03927885 726 734 O
staff NCT03927885 735 740 O

- NCT03927885 743 744 O
Hemoglobin NCT03927885 746 756 B-Observation
level NCT03927885 757 762 O
of NCT03927885 763 765 O
> NCT03927885 766 767 B-Eq-Comparison
= NCT03927885 769 770 I-Eq-Comparison
9 NCT03927885 771 772 I-Eq-Comparison
g NCT03927885 773 774 I-Eq-Comparison
/ NCT03927885 775 776 I-Eq-Comparison
dL. NCT03927885 777 780 I-Eq-Comparison
Patient NCT03927885 782 789 O
may NCT03927885 790 793 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03927885 794 801 O
packed NCT03927885 802 808 B-Procedure
red NCT03927885 809 812 I-Procedure
blood NCT03927885 813 818 I-Procedure
cell NCT03927885 819 823 I-Procedure
( NCT03927885 824 825 O
PRBC NCT03927885 826 830 B-Procedure
) NCT03927885 831 832 O
transfusion NCT03927885 833 844 B-Modifier
so NCT03927885 845 847 B-Assertion___Assertion-Type-Value:hypothetical
as NCT03927885 848 850 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927885 851 853 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03927885 854 858 O
hemoglobin NCT03927885 859 869 B-Observation
level NCT03927885 870 875 O
of NCT03927885 876 878 O
> NCT03927885 879 880 B-Eq-Comparison
= NCT03927885 882 883 I-Eq-Comparison
9 NCT03927885 884 885 I-Eq-Comparison
g NCT03927885 886 887 I-Eq-Comparison
/ NCT03927885 888 889 I-Eq-Comparison
dL NCT03927885 890 892 I-Eq-Comparison
so NCT03927885 893 895 O
at NCT03927885 896 898 O
participate NCT03927885 899 910 O
in NCT03927885 911 913 O
the NCT03927885 914 917 O
study NCT03927885 918 923 B-Study

Exclusion NCT03927885 924 933 O
Criteria NCT03927885 934 942 O
: NCT03927885 943 944 O

- NCT03927885 948 949 O
Surgery NCT03927885 951 958 B-Procedure
, NCT03927885 959 960 O
or NCT03927885 961 963 B-Or
pain NCT03927885 964 968 B-Procedure
relieving NCT03927885 969 978 I-Procedure
procedures NCT03927885 979 989 I-Procedure
within NCT03927885 990 996 B-Eq-Comparison
2 NCT03927885 997 998 I-Eq-Comparison
weeks NCT03927885 999 1004 I-Eq-Comparison
of NCT03927885 1005 1007 B-Temporal-Connection___Temporal-Connection-Type-Value:after
entry NCT03927885 1008 1013 O
into NCT03927885 1014 1018 O
the NCT03927885 1019 1022 O
study NCT03927885 1023 1028 B-Study|Study
or NCT03927885 1029 1031 B-Or
during NCT03927885 1032 1038 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927885 1039 1042 O
study NCT03927885 1043 1048 O
period NCT03927885 1049 1055 O

- NCT03927885 1058 1059 O
Patients NCT03927885 1061 1069 O
with NCT03927885 1070 1074 O
history NCT03927885 1075 1082 B-Eq-Comparison
of NCT03927885 1083 1085 O
substance NCT03927885 1086 1095 B-Condition
abuse NCT03927885 1096 1101 I-Condition
( NCT03927885 1102 1103 O
Cut NCT03927885 1104 1107 B-Observation
down NCT03927885 1108 1112 I-Observation
, NCT03927885 1113 1114 O
Annoyed NCT03927885 1115 1122 I-Observation
, NCT03927885 1123 1124 O
Guilty NCT03927885 1125 1131 I-Observation
, NCT03927885 1132 1133 O
Eye NCT03927885 1134 1137 I-Observation
opener NCT03927885 1138 1144 I-Observation
[ NCT03927885 1145 1146 O
CAGE NCT03927885 1147 1151 B-Observation
] NCT03927885 1152 1153 O
> NCT03927885 1154 1155 B-Eq-Comparison
= NCT03927885 1157 1158 I-Eq-Comparison
2 NCT03927885 1159 1160 I-Eq-Comparison
+ NCT03927885 1161 1162 O
) NCT03927885 1164 1165 O
, NCT03927885 1167 1168 O
cognitively NCT03927885 1169 1180 B-Condition
impaired NCT03927885 1181 1189 I-Condition
( NCT03927885 1190 1191 O
MD NCT03927885 1192 1194 B-Condition|Condition
Anderson NCT03927885 1195 1203 I-Condition
Symptom NCT03927885 1204 1211 I-Condition
[ NCT03927885 1212 1213 O
MDAS NCT03927885 1214 1218 O
] NCT03927885 1219 1220 O
> NCT03927885 1221 1222 B-Eq-Comparison
7 NCT03927885 1223 1224 I-Eq-Comparison
) NCT03927885 1225 1226 O

Inclusion NCT03927846 0 9 O
Criteria NCT03927846 10 18 O
: NCT03927846 19 20 O
- NCT03927846 21 22 O

1 NCT03927846 26 27 O
. NCT03927846 27 28 O
patients NCT03927846 30 38 O
at NCT03927846 39 41 O
the NCT03927846 42 45 O
primary NCT03927846 46 53 O
care NCT03927846 54 58 O
or NCT03927846 59 61 B-Or
rheumatology NCT03927846 62 74 O
clinic NCT03927846 75 81 O
with NCT03927846 82 86 B-And
daily NCT03927846 87 92 B-Eq-Comparison
pain NCT03927846 93 97 B-Condition
for NCT03927846 98 101 O
6 NCT03927846 102 103 B-Eq-Comparison
months NCT03927846 104 110 I-Eq-Comparison
or NCT03927846 111 113 I-Eq-Comparison
longer NCT03927846 114 120 I-Eq-Comparison
affecting NCT03927846 121 130 O
the NCT03927846 131 134 O
low NCT03927846 135 138 B-Modifier
back NCT03927846 139 143 I-Modifier
, NCT03927846 144 145 O
neck NCT03927846 146 150 B-Modifier
, NCT03927846 151 152 O
hip NCT03927846 153 156 B-Modifier
, NCT03927846 157 158 O
knee NCT03927846 159 163 B-Modifier
or NCT03927846 164 166 B-Or
widespread NCT03927846 167 177 B-Condition
pain NCT03927846 178 182 I-Condition
; NCT03927846 182 183 O

2 NCT03927846 186 187 O
. NCT03927846 187 188 O
at NCT03927846 190 192 B-Eq-Comparison
least NCT03927846 193 198 I-Eq-Comparison
moderate NCT03927846 199 207 I-Eq-Comparison
in NCT03927846 208 210 O
average NCT03927846 211 218 O
pain NCT03927846 219 223 B-Condition
severity NCT03927846 224 232 O
, NCT03927846 233 234 O
defined NCT03927846 235 242 O
as NCT03927846 243 245 O
a NCT03927846 246 247 O
weekly NCT03927846 248 254 O
average NCT03927846 255 262 O
pain NCT03927846 263 267 B-Observation
severity NCT03927846 268 276 I-Observation
score NCT03927846 277 282 I-Observation
of NCT03927846 283 285 O
5 NCT03927846 286 287 B-Eq-Comparison
or NCT03927846 288 290 I-Eq-Comparison
greater NCT03927846 291 298 I-Eq-Comparison
24 NCT03927846 299 301 O
; NCT03927846 302 303 O

3 NCT03927846 306 307 O
. NCT03927846 307 308 O
at NCT03927846 310 312 B-Eq-Comparison
least NCT03927846 313 318 I-Eq-Comparison
18 NCT03927846 319 321 I-Eq-Comparison
years NCT03927846 322 327 I-Eq-Comparison
of NCT03927846 328 330 O
age NCT03927846 331 334 B-Age
; NCT03927846 334 335 O

4 NCT03927846 338 339 O
. NCT03927846 339 340 O
reliable NCT03927846 342 350 O
phone NCT03927846 351 356 O
( NCT03927846 357 358 O
landline NCT03927846 359 367 O
or NCT03927846 368 370 O
cell NCT03927846 371 375 O
) NCT03927846 376 377 O
, NCT03927846 379 380 O
and NCT03927846 381 384 O

5 NCT03927846 387 388 O
. NCT03927846 388 389 O
have NCT03927846 391 395 O
home NCT03927846 396 400 O
computer NCT03927846 401 409 O
with NCT03927846 410 414 O
reliable NCT03927846 415 423 O
internet NCT03927846 424 432 O
access NCT03927846 433 439 O
. NCT03927846 439 440 O

Exclusion NCT03927846 442 451 O
Criteria NCT03927846 452 460 O
: NCT03927846 461 462 O

1 NCT03927846 466 467 O
. NCT03927846 467 468 O
planned NCT03927846 470 477 B-Eq-Comparison
elective NCT03927846 478 486 O
surgery NCT03927846 487 494 B-Procedure
during NCT03927846 495 501 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927846 502 505 O
study NCT03927846 506 511 B-Study
period NCT03927846 512 518 O
; NCT03927846 518 519 O

2 NCT03927846 522 523 O
. NCT03927846 523 524 O
very NCT03927846 526 530 O
severe NCT03927846 531 537 O
symptoms NCT03927846 538 546 B-Assertion___Assertion-Type-Value:possible
of NCT03927846 547 549 O
depression NCT03927846 550 560 B-Condition
( NCT03927846 561 562 O
i. NCT03927846 563 565 O
e. NCT03927846 566 568 O
, NCT03927846 569 570 O
PHQ8 NCT03927846 571 575 B-Observation
score NCT03927846 576 581 O
of NCT03927846 582 584 O
≥ NCT03927846 585 586 B-Eq-Comparison
20 NCT03927846 587 589 I-Eq-Comparison
) NCT03927846 590 591 O
; NCT03927846 592 593 O

3 NCT03927846 596 597 O
. NCT03927846 597 598 O
ongoing NCT03927846 600 607 O
unresolved NCT03927846 608 618 O
disability NCT03927846 619 629 O
claims NCT03927846 630 636 O
; NCT03927846 636 637 O

4 NCT03927846 640 641 O
. NCT03927846 641 642 O
inflammatory NCT03927846 644 656 B-Condition
arthritis NCT03927846 657 666 I-Condition
( NCT03927846 667 668 O
e. NCT03927846 669 671 O
g. NCT03927846 672 674 O
, NCT03927846 675 676 O
lupus NCT03927846 677 682 B-Condition
, NCT03927846 683 684 O
rheumatoid NCT03927846 685 695 B-Condition
arthritis NCT03927846 696 705 I-Condition
, NCT03927846 706 707 O
ankylosing NCT03927846 708 718 B-Condition
spondylitis NCT03927846 719 730 I-Condition
, NCT03927846 731 732 O
etc NCT03927846 733 736 O
. NCT03927846 736 737 O
) NCT03927846 738 739 O
; NCT03927846 740 741 O

5 NCT03927846 744 745 O
. NCT03927846 745 746 O
cancer NCT03927846 748 754 B-Condition
- NCT03927846 755 756 O
related NCT03927846 757 764 O
musculoskeletal NCT03927846 765 780 B-Modifier
pain NCT03927846 781 785 B-Condition
; NCT03927846 785 786 O

6 NCT03927846 789 790 O
. NCT03927846 790 791 O
history NCT03927846 793 800 B-Eq-Comparison
of NCT03927846 801 803 O
bipolar NCT03927846 804 811 B-Condition
disorder NCT03927846 812 820 I-Condition
or NCT03927846 821 823 B-Or
schizophrenia NCT03927846 824 837 B-Condition
; NCT03927846 837 838 O
and NCT03927846 839 842 O

7 NCT03927846 845 846 O
. NCT03927846 846 847 O
takes NCT03927846 849 854 B-Eq-Comparison
daily NCT03927846 855 860 B-Eq-Comparison
opioid NCT03927846 861 867 B-Drug
for NCT03927846 868 871 O
more NCT03927846 872 876 B-Eq-Comparison
than NCT03927846 877 881 I-Eq-Comparison
one NCT03927846 882 885 I-Eq-Comparison
year NCT03927846 886 890 I-Eq-Comparison
. NCT03927846 890 891 O

Inclusion NCT03920683 0 9 O
Criteria NCT03920683 10 18 O
: NCT03920683 19 20 O

- NCT03920683 24 25 O
Age NCT03920683 27 30 B-Age
≥ NCT03920683 31 32 B-Eq-Comparison
18 NCT03920683 33 35 I-Eq-Comparison
ans NCT03920683 36 39 O

- NCT03920683 42 43 O
Diabetes NCT03920683 45 53 B-Condition
mellitus NCT03920683 54 62 I-Condition
( NCT03920683 63 64 O
type NCT03920683 65 69 B-Eq-Comparison
1 NCT03920683 70 71 I-Eq-Comparison
or NCT03920683 72 74 I-Eq-Comparison
2 NCT03920683 75 76 I-Eq-Comparison
) NCT03920683 77 78 O

- NCT03920683 82 83 O
Patients NCT03920683 85 93 O
addressed NCT03920683 94 103 O
to NCT03920683 104 106 O
a NCT03920683 107 108 O
one NCT03920683 109 112 B-Eq-Comparison
- NCT03920683 113 114 I-Eq-Comparison
day NCT03920683 115 118 I-Eq-Comparison
hospitalization NCT03920683 119 134 B-Encounter
to NCT03920683 135 137 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
assess NCT03920683 138 144 O
cardiovascular NCT03920683 145 159 B-Condition
comorbidities NCT03920683 160 173 I-Condition
, NCT03920683 174 175 O
between NCT03920683 176 183 B-Eq-Comparison
January NCT03920683 184 191 I-Eq-Comparison
2014 NCT03920683 192 196 I-Eq-Comparison
and NCT03920683 197 200 I-Eq-Comparison
May NCT03920683 201 204 I-Eq-Comparison
2017 NCT03920683 205 209 I-Eq-Comparison
, NCT03920683 210 211 O
in NCT03920683 212 214 O
the NCT03920683 215 218 O
diabetes NCT03920683 219 227 O
department NCT03920683 228 238 O
, NCT03920683 239 240 O
in NCT03920683 241 243 O
the NCT03920683 244 247 O
Pitié NCT03920683 248 253 O
- NCT03920683 254 255 O
Salpêtrière NCT03920683 256 267 O
hospital NCT03920683 268 276 O

- NCT03920683 279 280 O
Coronary NCT03920683 282 290 B-Observation
artery NCT03920683 291 297 I-Observation
calcium NCT03920683 298 305 I-Observation
score NCT03920683 306 311 I-Observation
available NCT03920683 312 321 O

- NCT03920683 324 325 I-Observation
Toe NCT03920683 327 330 B-Observation
- NCT03920683 331 332 O
brachial NCT03920683 333 341 I-Observation
index NCT03920683 342 347 I-Observation
available NCT03920683 348 357 O

Exclusion NCT03920683 358 367 O
Criteria NCT03920683 368 376 O
: NCT03920683 377 378 O

- NCT03920683 382 383 O
History NCT03920683 385 392 B-Eq-Comparison
of NCT03920683 393 395 O
coronary NCT03920683 396 404 B-Condition
artery NCT03920683 405 411 I-Condition
disease NCT03920683 412 419 I-Condition

- NCT03920683 422 423 O
History NCT03920683 425 432 B-Eq-Comparison
of NCT03920683 433 435 O
Raynaud NCT03920683 436 443 B-Condition
's NCT03920683 443 445 O
syndrome NCT03920683 446 454 I-Condition

- NCT03920683 457 458 O
Opposition NCT03920683 460 470 O
of NCT03920683 471 473 O
the NCT03920683 474 477 O
patient NCT03920683 478 485 O

Inclusion NCT03929328 0 9 O
Criteria NCT03929328 10 18 O
: NCT03929328 19 20 O

- NCT03929328 24 25 O
Adult NCT03929328 27 32 O
patients NCT03929328 33 41 O
aged NCT03929328 42 46 B-Age
18 NCT03929328 47 49 B-Eq-Comparison
years NCT03929328 50 55 I-Eq-Comparison
or NCT03929328 56 58 I-Eq-Comparison
more NCT03929328 59 63 I-Eq-Comparison
, NCT03929328 64 65 O
both NCT03929328 66 70 O
gender NCT03929328 71 77 O

- NCT03929328 80 81 O
Receiving NCT03929328 83 92 B-Eq-Comparison
endotracheal NCT03929328 93 105 B-Modifier
intubation NCT03929328 106 116 B-Procedure
and NCT03929328 117 120 B-And
mechanical NCT03929328 121 131 B-Modifier
ventilation NCT03929328 132 143 B-Procedure
for NCT03929328 144 147 O
more NCT03929328 148 152 B-Eq-Comparison
than NCT03929328 153 157 I-Eq-Comparison
12 NCT03929328 158 160 I-Eq-Comparison
hours NCT03929328 161 166 I-Eq-Comparison

- NCT03929328 169 170 O
Recovery NCT03929328 172 180 O
from NCT03929328 181 185 O
the NCT03929328 186 189 O
precipitating NCT03929328 190 203 O
illness NCT03929328 204 211 B-Condition

- NCT03929328 214 215 O
Weaning NCT03929328 217 224 O
readiness NCT03929328 225 234 O
according NCT03929328 235 244 O
to NCT03929328 245 247 O
the NCT03929328 248 251 O
following NCT03929328 252 261 O
criteria NCT03929328 262 270 O
: NCT03929328 271 272 O

1 NCT03929328 281 282 O
. NCT03929328 282 283 O
Respiratory NCT03929328 285 296 O
criteria NCT03929328 297 305 O
: NCT03929328 306 307 O

1 NCT03929328 321 322 O
. NCT03929328 322 323 O
PaO2 NCT03929328 325 329 B-Observation
: NCT03929328 330 331 O
FIO2 NCT03929328 332 336 O
> NCT03929328 337 338 B-Eq-Comparison
150 NCT03929328 339 342 I-Eq-Comparison
with NCT03929328 343 347 B-And
FIO2 NCT03929328 348 352 B-Observation
≤ NCT03929328 353 354 B-Eq-Comparison
0.4 NCT03929328 355 358 I-Eq-Comparison
, NCT03929328 359 360 O
PEEP NCT03929328 361 365 B-Observation
< NCT03929328 366 367 B-Eq-Comparison
8 NCT03929328 368 369 I-Eq-Comparison
cm NCT03929328 370 372 I-Eq-Comparison
H2O NCT03929328 373 376 I-Eq-Comparison

2 NCT03929328 389 390 O
. NCT03929328 390 391 O
Arterial NCT03929328 393 401 B-Observation
pH NCT03929328 402 404 I-Observation
> NCT03929328 405 406 B-Eq-Comparison
7.35 NCT03929328 407 411 I-Eq-Comparison

3 NCT03929328 425 426 O
. NCT03929328 426 427 O
Rapid NCT03929328 429 434 B-Observation
shallow NCT03929328 435 442 I-Observation
breathing NCT03929328 443 452 I-Observation
index NCT03929328 453 458 I-Observation
( NCT03929328 459 460 O
RSBI NCT03929328 461 465 B-Observation
) NCT03929328 466 467 O
< NCT03929328 468 469 B-Eq-Comparison
105 NCT03929328 470 473 I-Eq-Comparison

4 NCT03929328 487 488 O
. NCT03929328 488 489 O
Maximum NCT03929328 491 498 B-Observation
inspiratory NCT03929328 499 510 I-Observation
pressure NCT03929328 511 519 I-Observation
( NCT03929328 520 521 O
MIP NCT03929328 522 525 B-Observation
) NCT03929328 526 527 O
< NCT03929328 528 529 B-Eq-Comparison
- NCT03929328 530 531 I-Eq-Comparison
20 NCT03929328 532 534 I-Eq-Comparison
cm NCT03929328 535 537 I-Eq-Comparison
H20 NCT03929328 538 541 I-Eq-Comparison

2 NCT03929328 550 551 O
. NCT03929328 551 552 O
Clinical NCT03929328 554 562 O
criteria NCT03929328 563 571 O
: NCT03929328 572 573 O

1 NCT03929328 587 588 O
. NCT03929328 588 589 O
Absence NCT03929328 591 598 B-Negation
of NCT03929328 599 601 O
electrocardiographic NCT03929328 602 622 B-Procedure
signs NCT03929328 623 628 B-Assertion___Assertion-Type-Value:possible
of NCT03929328 629 631 O
myocardial NCT03929328 632 642 B-Condition
ischemia NCT03929328 643 651 I-Condition

2 NCT03929328 664 665 O
. NCT03929328 665 666 O
No NCT03929328 668 670 B-Negation
vasoactive NCT03929328 671 681 B-Drug
drugs NCT03929328 682 687 I-Drug
, NCT03929328 688 689 O
or NCT03929328 690 692 B-Or
vital NCT03929328 693 698 B-Observation
signs NCT03929328 699 704 I-Observation
are NCT03929328 705 708 O
stable NCT03929328 709 715 O
with NCT03929328 716 720 B-And
using NCT03929328 721 726 B-Eq-Comparison
vasoactive NCT03929328 727 737 B-Drug
drugs NCT03929328 738 743 I-Drug

3 NCT03929328 756 757 O
. NCT03929328 757 758 O
Heart NCT03929328 760 765 B-Observation
rate NCT03929328 766 770 I-Observation
< NCT03929328 771 772 B-Eq-Comparison
140 NCT03929328 773 776 I-Eq-Comparison
/ NCT03929328 777 778 O
min NCT03929328 779 782 O
, NCT03929328 783 784 O

4 NCT03929328 798 799 O
. NCT03929328 799 800 O
Hemoglobin NCT03929328 802 812 B-Observation
> NCT03929328 813 814 B-Eq-Comparison
8 NCT03929328 815 816 I-Eq-Comparison
g NCT03929328 817 818 I-Eq-Comparison
/ NCT03929328 819 820 I-Eq-Comparison
dL NCT03929328 821 823 I-Eq-Comparison

5 NCT03929328 836 837 O
. NCT03929328 837 838 O
Temperature NCT03929328 840 851 B-Observation
< NCT03929328 852 853 B-Eq-Comparison
38 NCT03929328 854 856 I-Eq-Comparison
° NCT03929328 857 858 O
C NCT03929328 858 859 O

6 NCT03929328 872 873 O
. NCT03929328 873 874 O
No NCT03929328 876 878 B-Negation
need NCT03929328 879 883 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929328 884 887 O
sedatives NCT03929328 888 897 B-Drug|Drug
, NCT03929328 898 899 O
or NCT03929328 900 902 B-Or
mental NCT03929328 903 909 B-Condition
status NCT03929328 910 916 I-Condition
are NCT03929328 917 920 O
stable NCT03929328 921 927 O
with NCT03929328 928 932 B-And
sedatives NCT03929328 933 942 O

7 NCT03929328 955 956 O
. NCT03929328 956 957 O
Presence NCT03929328 959 967 O
of NCT03929328 968 970 O
respiratory NCT03929328 971 982 B-Condition
stimulus NCT03929328 983 991 I-Condition
, NCT03929328 992 993 O
and NCT03929328 994 997 B-And
appropriate NCT03929328 998 1009 O
spontaneous NCT03929328 1010 1021 B-Condition
cough NCT03929328 1022 1027 I-Condition

8 NCT03929328 1040 1041 O
. NCT03929328 1041 1042 O
Absence NCT03929328 1044 1051 B-Negation
of NCT03929328 1052 1054 O
excessive NCT03929328 1055 1064 O
tracheobronchial NCT03929328 1065 1081 B-Condition
secretions NCT03929328 1082 1092 I-Condition

Exclusion NCT03929328 1093 1102 O
Criteria NCT03929328 1103 1111 O
: NCT03929328 1112 1113 O

- NCT03929328 1117 1118 I-Procedure
Tracheostomy NCT03929328 1120 1132 B-Procedure
status NCT03929328 1133 1139 O

- NCT03929328 1142 1143 O
Decision NCT03929328 1145 1153 O
to NCT03929328 1154 1156 O
stop NCT03929328 1157 1161 B-Negation
life NCT03929328 1162 1166 B-Procedure
- NCT03929328 1167 1168 O
supportive NCT03929328 1169 1179 I-Procedure
therapies NCT03929328 1180 1189 I-Procedure
before NCT03929328 1190 1196 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03929328 1197 1207 B-Study

Inclusion NCT03922269 0 9 O
Criteria NCT03922269 10 18 O
: NCT03922269 19 20 O

- NCT03922269 24 25 O
Participant NCT03922269 27 38 O
self NCT03922269 39 43 O
- NCT03922269 44 45 O
identifies NCT03922269 46 56 O
as NCT03922269 57 59 O
transgender NCT03922269 60 71 O
and NCT03922269 72 75 B-Or
/ NCT03922269 76 77 I-Or
or NCT03922269 78 80 I-Or
has NCT03922269 81 84 O
a NCT03922269 85 86 O
current NCT03922269 87 94 B-Eq-Comparison
gender NCT03922269 95 101 B-Condition
identity NCT03922269 102 110 I-Condition
which NCT03922269 111 116 O
differs NCT03922269 117 124 B-Negation
from NCT03922269 125 129 O
gender NCT03922269 130 136 O
assigned NCT03922269 137 145 O
at NCT03922269 146 148 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03922269 149 154 B-Birth
( NCT03922269 155 156 O
includes NCT03922269 157 165 O
all NCT03922269 166 169 O
gender NCT03922269 170 176 O
diverse NCT03922269 177 184 O
people NCT03922269 185 191 O
) NCT03922269 192 193 O

- NCT03922269 197 198 O
Age NCT03922269 200 203 B-Age
> NCT03922269 204 205 B-Eq-Comparison
18 NCT03922269 206 208 I-Eq-Comparison
years NCT03922269 209 214 I-Eq-Comparison

- NCT03922269 217 218 O
HIV NCT03922269 220 223 B-Condition
infection NCT03922269 224 233 I-Condition
diagnosis NCT03922269 234 243 O
at NCT03922269 244 246 O
any NCT03922269 247 250 O
time NCT03922269 251 255 O
before NCT03922269 256 262 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03922269 263 268 B-Study
consent NCT03922269 269 276 O

- NCT03922269 279 280 O
Having NCT03922269 282 288 O
been NCT03922269 289 293 O
prescribed NCT03922269 294 304 O
antiretroviral NCT03922269 305 319 B-Procedure
therapy NCT03922269 320 327 I-Procedure
at NCT03922269 328 330 O
any NCT03922269 331 334 O
time NCT03922269 335 339 O
( NCT03922269 340 341 O
including NCT03922269 342 351 O
people NCT03922269 352 358 O
for NCT03922269 359 362 O
who NCT03922269 363 366 O
antiretroviral NCT03922269 367 381 B-Procedure
therapy NCT03922269 382 389 I-Procedure
initiation NCT03922269 390 400 O
is NCT03922269 401 403 O
planned NCT03922269 404 411 B-Eq-Comparison
after NCT03922269 412 417 B-Temporal-Connection___Temporal-Connection-Type-Value:after
study NCT03922269 418 423 B-Study
enrolment NCT03922269 424 433 O
) NCT03922269 434 435 O

- NCT03922269 439 440 O
Willing NCT03922269 442 449 O
to NCT03922269 450 452 O
sign NCT03922269 453 457 O
an NCT03922269 458 460 O
informed NCT03922269 461 469 O
consent NCT03922269 470 477 O
and NCT03922269 478 481 O
take NCT03922269 482 486 O
part NCT03922269 487 491 O
in NCT03922269 492 494 O
the NCT03922269 495 498 O
study NCT03922269 499 504 O

Exclusion NCT03922269 505 514 O
Criteria NCT03922269 515 523 O
: NCT03922269 524 525 O

- NCT03922269 529 530 O
Age NCT03922269 532 535 B-Age
< NCT03922269 536 537 B-Eq-Comparison
18 NCT03922269 538 540 I-Eq-Comparison
years NCT03922269 541 546 I-Eq-Comparison

- NCT03922269 549 550 O
Unable NCT03922269 552 558 O
to NCT03922269 559 561 O
take NCT03922269 562 566 O
part NCT03922269 567 571 O
in NCT03922269 572 574 O
the NCT03922269 575 578 O
study NCT03922269 579 584 O
according NCT03922269 585 594 O
to NCT03922269 595 597 O
the NCT03922269 598 601 O
Investigator NCT03922269 602 614 O
opinion NCT03922269 615 622 O
( NCT03922269 623 624 O
example NCT03922269 625 632 O
: NCT03922269 633 634 O
unable NCT03922269 635 641 O
to NCT03922269 642 644 O
understand NCT03922269 645 655 O
the NCT03922269 656 659 O
study NCT03922269 660 665 O
information NCT03922269 666 677 O
leaflet NCT03922269 678 685 O
, NCT03922269 686 687 O
unable NCT03922269 688 694 O
to NCT03922269 695 697 O
provide NCT03922269 698 705 O
written NCT03922269 706 713 O
consent NCT03922269 714 721 O
, NCT03922269 722 723 O
etc NCT03922269 724 727 O
. NCT03922269 727 728 O
) NCT03922269 729 730 O

Inclusion NCT03925506 0 9 O
Criteria NCT03925506 10 18 O
: NCT03925506 19 20 O

- NCT03925506 24 25 O
Inpatient NCT03925506 27 36 B-Encounter
≥ NCT03925506 37 38 B-Eq-Comparison
18 NCT03925506 39 41 I-Eq-Comparison
y. NCT03925506 42 44 I-Eq-Comparison
o. NCT03925506 45 47 B-Age
who NCT03925506 49 52 B-And
are NCT03925506 53 56 O
scheduled NCT03925506 57 66 B-Eq-Comparison
elective NCT03925506 67 75 O
colonoscopy NCT03925506 76 87 B-Procedure
during NCT03925506 88 94 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03925506 95 110 B-Coreference
irrespective NCT03925506 111 123 O
of NCT03925506 124 126 O
the NCT03925506 127 130 O
indication NCT03925506 131 141 O
. NCT03925506 141 142 O

Exclusion NCT03925506 144 153 O
Criteria NCT03925506 154 162 O
: NCT03925506 163 164 O

- NCT03925506 168 169 O
Urgent NCT03925506 171 177 B-Modifier
colonoscopy NCT03925506 178 189 B-Procedure

- NCT03925506 192 193 O
Patients NCT03925506 195 203 O
who NCT03925506 204 207 O
are NCT03925506 208 211 O
not NCT03925506 212 215 B-Negation
hospitalized NCT03925506 216 228 B-Encounter
when NCT03925506 229 233 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taking NCT03925506 234 240 B-Eq-Comparison
bowel NCT03925506 241 246 B-Procedure
preparation NCT03925506 247 258 I-Procedure
or NCT03925506 259 261 B-Or
when NCT03925506 262 266 O
undergoing NCT03925506 267 277 B-Eq-Comparison
colonoscopy NCT03925506 278 289 B-Procedure

Inclusion NCT03927339 0 9 O
Criteria NCT03927339 10 18 O
: NCT03927339 19 20 O

- NCT03927339 24 25 O
: NCT03927339 27 28 O
knee NCT03927339 29 33 B-Modifier
OA NCT03927339 34 36 B-Condition
with NCT03927339 37 41 B-And
obesity NCT03927339 42 49 B-Condition
; NCT03927339 49 50 O
sedentary NCT03927339 51 60 B-Condition
with NCT03927339 61 65 B-And
no NCT03927339 66 68 B-Negation
previous NCT03927339 69 77 B-Eq-Comparison
education NCT03927339 78 87 B-Observation
; NCT03927339 88 89 O
ability NCT03927339 90 97 O
to NCT03927339 98 100 O
understand NCT03927339 101 111 O
and NCT03927339 112 115 O
follow NCT03927339 116 122 O
commands NCT03927339 123 131 O
; NCT03927339 131 132 O
and NCT03927339 133 136 O
ability NCT03927339 137 144 B-Condition
to NCT03927339 145 147 I-Condition
walk NCT03927339 148 152 I-Condition
independently NCT03927339 153 166 O
. NCT03927339 166 167 O

Exclusion NCT03927339 169 178 O
Criteria NCT03927339 179 187 O
: NCT03927339 188 189 O

- NCT03927339 193 194 O
Medical NCT03927339 196 203 B-Condition
conditions NCT03927339 204 214 I-Condition
contraindicating NCT03927339 215 231 B-Contraindication
moderate NCT03927339 232 240 O
aerobic NCT03927339 241 248 B-Observation
exercising NCT03927339 249 259 I-Observation
( NCT03927339 260 261 O
as NCT03927339 262 264 O
determined NCT03927339 265 275 O
through NCT03927339 276 283 O
prescreening NCT03927339 284 296 O
questions NCT03927339 297 306 O
, NCT03927339 307 308 O
i. NCT03927339 309 311 O
e. NCT03927339 312 314 O
, NCT03927339 315 316 O
cardiac NCT03927339 317 324 B-Modifier
or NCT03927339 325 327 B-Or
coronary NCT03927339 328 336 B-Modifier
artery NCT03927339 337 343 B-Condition
disease NCT03927339 344 351 I-Condition
as NCT03927339 352 354 O
ischemic NCT03927339 355 363 B-Condition
cardiomyopathy NCT03927339 364 378 I-Condition
, NCT03927339 379 380 O
chronic NCT03927339 381 388 B-Condition
lung NCT03927339 389 393 I-Condition
disease NCT03927339 394 401 I-Condition
, NCT03927339 402 403 O
asthma NCT03927339 404 410 B-Condition
, NCT03927339 411 412 O
uncontrolled NCT03927339 413 425 B-Modifier
hypertension NCT03927339 426 438 B-Condition
) NCT03927339 439 440 O
, NCT03927339 442 443 O
inability NCT03927339 444 453 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927339 454 456 O
exercise NCT03927339 457 465 B-Observation
via NCT03927339 466 469 I-Observation
treadmill NCT03927339 470 479 I-Observation
( NCT03927339 480 481 O
i. NCT03927339 482 484 O
e. NCT03927339 485 487 O
no NCT03927339 489 491 B-Negation
neuromuscular NCT03927339 492 505 B-Modifier
or NCT03927339 506 508 B-Or
lower NCT03927339 509 514 B-Modifier
extremity NCT03927339 515 524 I-Modifier
conditions NCT03927339 525 535 B-Condition
or NCT03927339 536 538 B-Or
any NCT03927339 539 542 O
other NCT03927339 543 548 O
medical NCT03927339 549 556 O
contraindication NCT03927339 557 573 B-Contraindication
that NCT03927339 574 578 O
could NCT03927339 579 584 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03927339 585 592 B-Negation
them NCT03927339 593 597 O
from NCT03927339 598 602 O
floor NCT03927339 603 608 B-Observation
walking NCT03927339 609 616 I-Observation
as NCT03927339 617 619 O
upset NCT03927339 620 625 O
affecting NCT03927339 626 635 O
movement NCT03927339 636 644 B-Condition
of NCT03927339 645 647 O
the NCT03927339 648 651 O
pelvic NCT03927339 652 658 B-Modifier
arch NCT03927339 659 663 I-Modifier
or NCT03927339 664 666 B-Or
pace NCT03927339 667 671 B-Modifier
, NCT03927339 672 673 O
story NCT03927339 674 679 O
of NCT03927339 680 682 O
previous NCT03927339 683 691 B-Eq-Comparison
hip NCT03927339 692 695 B-Modifier
or NCT03927339 696 698 B-Or
knee NCT03927339 699 703 B-Modifier
operating NCT03927339 704 713 B-Procedure
room NCT03927339 714 718 O
, NCT03927339 719 720 O
periarticular NCT03927339 721 734 B-Modifier
fractures NCT03927339 735 744 B-Condition
, NCT03927339 745 746 O
or NCT03927339 747 749 O
lower NCT03927339 750 755 B-Modifier
limb NCT03927339 756 760 I-Modifier
injuries NCT03927339 761 769 B-Condition
) NCT03927339 770 771 O
. NCT03927339 772 773 O
History NCT03927339 774 781 B-Eq-Comparison
of NCT03927339 782 784 O
recent NCT03927339 785 791 B-Eq-Comparison
reefer NCT03927339 792 798 B-Condition
transmission NCT03927339 799 811 I-Condition
or NCT03927339 812 814 B-Or
acute NCT03927339 815 820 O
joint NCT03927339 821 826 B-Condition
lighting NCT03927339 827 835 I-Condition
. NCT03927339 836 837 O
History NCT03927339 838 845 B-Eq-Comparison
of NCT03927339 846 848 O
recent NCT03927339 849 855 B-Eq-Comparison
joint NCT03927339 856 861 B-Procedure
injection NCT03927339 862 871 I-Procedure
( NCT03927339 872 873 O
steroid NCT03927339 874 881 B-Drug
, NCT03927339 882 883 O
hyaluronic NCT03927339 884 894 B-Drug
acid NCT03927339 895 899 I-Drug
, NCT03927339 900 901 O
etc NCT03927339 902 905 O
. NCT03927339 905 906 O
) NCT03927339 907 908 O
within NCT03927339 909 915 B-Eq-Comparison
6 NCT03927339 916 917 I-Eq-Comparison
calendar NCT03927339 918 926 I-Eq-Comparison
week NCT03927339 927 931 I-Eq-Comparison
of NCT03927339 932 934 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927339 935 940 B-Study
. NCT03927339 940 941 O
Ingestion NCT03927339 943 952 O
of NCT03927339 953 955 O
antioxidant NCT03927339 956 967 B-Drug
supplementation NCT03927339 968 983 I-Drug
and NCT03927339 984 987 B-Or
the NCT03927339 988 991 O
use NCT03927339 992 995 O
of NCT03927339 996 998 O
psychotropic NCT03927339 999 1011 B-Drug
agents NCT03927339 1012 1018 I-Drug
. NCT03927339 1018 1019 O

Inclusion NCT03924817 0 9 O
Criteria NCT03924817 10 18 O
: NCT03924817 19 20 O

- NCT03924817 24 25 O
Prescription NCT03924817 27 39 O
of NCT03924817 40 42 O
a NCT03924817 43 44 O
Narval NCT03924817 45 51 B-Procedure
CC NCT03924817 52 54 I-Procedure
mandibular NCT03924817 55 65 I-Procedure
advancement NCT03924817 66 77 I-Procedure
device NCT03924817 78 84 I-Procedure

- NCT03924817 87 88 O
Age NCT03924817 90 93 B-Age
≥ NCT03924817 94 95 B-Eq-Comparison
18 NCT03924817 96 98 I-Eq-Comparison
years NCT03924817 99 104 I-Eq-Comparison

- NCT03924817 107 108 O
Ability NCT03924817 110 117 O
to NCT03924817 118 120 O
understand NCT03924817 121 131 O
the NCT03924817 132 135 O
study NCT03924817 136 141 O
information NCT03924817 142 153 O
and NCT03924817 154 157 O
information NCT03924817 158 169 O
on NCT03924817 170 172 O
usage NCT03924817 173 178 O
of NCT03924817 179 181 O
personal NCT03924817 182 190 O
data NCT03924817 191 195 O

- NCT03924817 198 199 O
Signed NCT03924817 201 207 O
and NCT03924817 208 211 O
dated NCT03924817 212 217 O
informed NCT03924817 218 226 O
consent NCT03924817 227 234 O

Exclusion NCT03924817 235 244 O
Criteria NCT03924817 245 253 O
: NCT03924817 254 255 O

- NCT03924817 259 260 O
Patients NCT03924817 262 270 O
with NCT03924817 271 275 O
central NCT03924817 276 283 B-Condition
sleep NCT03924817 284 289 I-Condition
apnea NCT03924817 290 295 I-Condition
( NCT03924817 296 297 O
central NCT03924817 298 305 B-Observation
AI NCT03924817 306 308 I-Observation
> NCT03924817 309 310 B-Eq-Comparison
5 NCT03924817 311 312 I-Eq-Comparison
/ NCT03924817 313 314 I-Eq-Comparison
hour NCT03924817 315 319 I-Eq-Comparison
) NCT03924817 320 321 O

- NCT03924817 325 326 O
Patients NCT03924817 328 336 O
with NCT03924817 337 341 O
loose NCT03924817 342 347 B-Condition
teeth NCT03924817 348 353 I-Condition
and NCT03924817 354 357 B-Or
severe NCT03924817 358 364 O
parodontitis NCT03924817 365 377 B-Condition

- NCT03924817 380 381 O
Patients NCT03924817 383 391 O
with NCT03924817 392 396 O
completely NCT03924817 397 407 O
missing NCT03924817 408 415 B-Condition
teeth NCT03924817 416 421 I-Condition
or NCT03924817 422 424 B-Or
removable NCT03924817 425 434 B-Procedure
tooth NCT03924817 435 440 I-Procedure
replacement NCT03924817 441 452 I-Procedure
, NCT03924817 453 454 O
or NCT03924817 455 457 O
with NCT03924817 458 462 O
a NCT03924817 463 464 O
teeth NCT03924817 465 470 B-Condition
health NCT03924817 471 477 I-Condition
insufficient NCT03924817 478 490 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924817 491 493 O
retain NCT03924817 494 500 O
an NCT03924817 501 503 O
MAD NCT03924817 504 507 B-Procedure
Patients NCT03924817 508 516 O
with NCT03924817 517 521 O
missing NCT03924817 522 529 B-Condition
molars NCT03924817 530 536 I-Condition
Patients NCT03924817 537 545 O
with NCT03924817 546 550 O
maximum NCT03924817 551 558 B-Observation
protrusion NCT03924817 559 569 I-Observation
of NCT03924817 570 572 O
less NCT03924817 573 577 B-Eq-Comparison
than NCT03924817 578 582 I-Eq-Comparison
5 NCT03924817 583 584 I-Eq-Comparison
mm NCT03924817 585 587 O

Inclusion NCT03928977 0 9 O
Criteria NCT03928977 10 18 O
: NCT03928977 19 20 O

- NCT03928977 24 25 O
Patient NCT03928977 27 34 O
admitted NCT03928977 35 43 O
in NCT03928977 44 46 O
for NCT03928977 47 50 O
a NCT03928977 51 52 O
transient NCT03928977 53 62 B-Condition
neurologic NCT03928977 63 73 I-Condition
deficit NCT03928977 74 81 I-Condition
and NCT03928977 82 85 B-And
suspicion NCT03928977 86 95 B-Assertion___Assertion-Type-Value:possible
of NCT03928977 96 98 O
TIA NCT03928977 99 102 B-Condition
of NCT03928977 103 105 O
carotid NCT03928977 106 113 B-Modifier
circulation NCT03928977 114 125 I-Modifier

- NCT03928977 128 129 O
Prescription NCT03928977 131 143 O
for NCT03928977 144 147 O
conventionnal NCT03928977 148 161 O
MRI NCT03928977 162 165 B-Procedure

Exclusion NCT03928977 166 175 O
Criteria NCT03928977 176 184 O
: NCT03928977 185 186 O

- NCT03928977 190 191 O
Contraindication NCT03928977 193 209 B-Contraindication
to NCT03928977 210 212 O
MRI NCT03928977 213 216 B-Procedure

- NCT03928977 219 220 O
Previous NCT03928977 222 230 B-Eq-Comparison
neurological NCT03928977 231 243 B-Condition
disease NCT03928977 244 251 I-Condition
( NCT03928977 252 253 O
with NCT03928977 254 258 B-And
lesions NCT03928977 259 266 B-Condition
) NCT03928977 267 268 O

- NCT03928977 272 273 O
Severe NCT03928977 275 281 O
psychiatric NCT03928977 282 293 B-Condition
disease NCT03928977 294 301 I-Condition

Inclusion NCT03922282 0 9 O
Criteria NCT03922282 10 18 O
: NCT03922282 19 20 O

- NCT03922282 24 25 O
Subject NCT03922282 27 34 O
who NCT03922282 35 38 O
will NCT03922282 39 43 B-Eq-Comparison
have NCT03922282 44 48 I-Eq-Comparison
thyroid NCT03922282 49 56 B-Procedure
surgery NCT03922282 57 64 I-Procedure

Exclusion NCT03922282 65 74 O
Criteria NCT03922282 75 83 O
: NCT03922282 84 85 O

- NCT03922282 89 90 O
Subject NCT03922282 92 99 O
who NCT03922282 100 103 O
underwent NCT03922282 104 113 B-Eq-Comparison
thyroid NCT03922282 114 121 B-Procedure
surgery NCT03922282 122 129 I-Procedure

- NCT03922282 132 133 O
Subject NCT03922282 135 142 O
who NCT03922282 143 146 O
underwent NCT03922282 147 156 B-Eq-Comparison
any NCT03922282 157 160 O
radiotherapy NCT03922282 161 173 B-Procedure
on NCT03922282 174 176 O
neck NCT03922282 177 181 B-Modifier

- NCT03922282 184 185 O
Subject NCT03922282 187 194 O
who NCT03922282 195 198 O
need NCT03922282 199 203 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922282 204 206 O
neck NCT03922282 207 211 B-Modifier
dissection NCT03922282 212 222 B-Procedure

- NCT03922282 225 226 O
Subject NCT03922282 228 235 O
under NCT03922282 236 241 B-Eq-Comparison
18 NCT03922282 242 244 I-Eq-Comparison
years NCT03922282 245 250 I-Age|Eq-Comparison
or NCT03922282 251 253 B-Or
over NCT03922282 254 258 B-Eq-Comparison
70 NCT03922282 259 261 I-Eq-Comparison
years NCT03922282 262 267 I-Eq-Comparison

- NCT03922282 270 271 O
Bad NCT03922282 273 276 B-Condition
general NCT03922282 277 284 I-Condition
condition NCT03922282 285 294 I-Condition

- NCT03922282 297 298 O
High NCT03922282 300 304 O
American NCT03922282 305 313 B-Condition
Society NCT03922282 314 321 I-Condition
of NCT03922282 322 324 I-Condition
Anesthesiologists NCT03922282 325 342 I-Condition
( NCT03922282 343 344 O
ASA NCT03922282 345 348 B-Condition
) NCT03922282 349 350 O
score NCT03922282 351 356 O
( NCT03922282 357 358 O
over NCT03922282 359 363 B-Eq-Comparison
3 NCT03922282 364 365 I-Eq-Comparison
) NCT03922282 366 367 O

- NCT03922282 371 372 O
Breast NCT03922282 374 380 B-Condition
feeder NCT03922282 381 387 I-Condition
or NCT03922282 388 390 B-Or
pregnancy NCT03922282 391 400 B-Condition

- NCT03922282 403 404 O
Subject NCT03922282 406 413 O
who NCT03922282 414 417 O
disagree NCT03922282 418 426 O
to NCT03922282 427 429 O
do NCT03922282 430 432 O
this NCT03922282 433 437 O
trial NCT03922282 438 443 O

Inclusion NCT03929705 0 9 O
Criteria NCT03929705 10 18 O
: NCT03929705 19 20 O
Cohort NCT03929705 21 27 O
1 NCT03929705 28 29 O
a NCT03929705 30 31 O
and NCT03929705 32 35 O
1 NCT03929705 36 37 O
b NCT03929705 38 39 O

- NCT03929705 42 43 O
• NCT03929705 45 46 O
Must NCT03929705 47 51 O
be NCT03929705 52 54 O
at NCT03929705 55 57 B-Eq-Comparison
least NCT03929705 58 63 I-Eq-Comparison
18 NCT03929705 64 66 I-Eq-Comparison
years NCT03929705 67 72 I-Eq-Comparison
of NCT03929705 73 75 O
age NCT03929705 76 79 B-Age

- NCT03929705 87 88 O
Must NCT03929705 90 94 O
be NCT03929705 95 97 O
able NCT03929705 98 102 O
to NCT03929705 103 105 O
provide NCT03929705 106 113 O
informed NCT03929705 114 122 O
consent NCT03929705 123 130 O

- NCT03929705 138 139 O
Must NCT03929705 141 145 O
be NCT03929705 146 148 O
able NCT03929705 149 153 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929705 154 156 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929705 157 164 O
a NCT03929705 165 166 O
minimum NCT03929705 167 174 B-Eq-Comparison
of NCT03929705 175 177 I-Eq-Comparison
10 NCT03929705 178 180 I-Eq-Comparison
mL NCT03929705 181 183 I-Eq-Comparison
of NCT03929705 184 186 O
whole NCT03929705 187 192 B-Observation
blood NCT03929705 193 198 I-Observation
at NCT03929705 199 201 B-Temporal-Connection___Temporal-Connection-Type-Value:during
each NCT03929705 202 206 O
visit NCT03929705 207 212 B-Encounter
( NCT03929705 213 214 O
16 NCT03929705 215 217 B-Eq-Comparison
mL NCT03929705 218 220 O
for NCT03929705 221 224 O
immunocompromised NCT03929705 225 242 B-Condition
i. NCT03929705 243 245 O
e. NCT03929705 246 248 O
HIV NCT03929705 250 253 B-Condition
+ NCT03929705 254 255 O
) NCT03929705 257 258 O

- NCT03929705 267 268 O
Must NCT03929705 270 274 O
be NCT03929705 275 277 O
T NCT03929705 278 279 B-Observation
- NCT03929705 280 281 I-Observation
SPOT NCT03929705 282 286 I-Observation
. NCT03929705 286 287 O
TB NCT03929705 288 290 O
positive NCT03929705 291 299 O

- NCT03929705 307 308 O
First NCT03929705 310 315 B-Eq-Comparison
visit NCT03929705 316 321 B-Encounter
suspect NCT03929705 322 329 B-Assertion___Assertion-Type-Value:possible
TB NCT03929705 330 332 B-Condition
subjects NCT03929705 333 341 O
with NCT03929705 342 346 B-And
no NCT03929705 347 349 B-Negation
prior NCT03929705 350 355 B-Eq-Comparison
history NCT03929705 356 363 I-Eq-Comparison
of NCT03929705 364 366 O
TB NCT03929705 367 369 B-Condition
diagnosis NCT03929705 370 379 O
Inclusion NCT03929705 380 389 O
Criteria NCT03929705 390 398 O
: NCT03929705 399 400 O
Cohort NCT03929705 401 407 O
2 NCT03929705 408 409 O
a NCT03929705 410 411 O
and NCT03929705 412 415 O
2 NCT03929705 416 417 O
b NCT03929705 418 419 O

- NCT03929705 427 428 O
Must NCT03929705 430 434 O
be NCT03929705 435 437 O
at NCT03929705 438 440 B-Eq-Comparison
least NCT03929705 441 446 I-Eq-Comparison
18 NCT03929705 447 449 I-Eq-Comparison
years NCT03929705 450 455 I-Eq-Comparison
of NCT03929705 456 458 O
age NCT03929705 459 462 B-Age

- NCT03929705 470 471 O
Must NCT03929705 473 477 O
be NCT03929705 478 480 O
able NCT03929705 481 485 O
to NCT03929705 486 488 O
provide NCT03929705 489 496 O
informed NCT03929705 497 505 O
consent NCT03929705 506 513 O

- NCT03929705 521 522 O
Must NCT03929705 524 528 O
be NCT03929705 529 531 O
able NCT03929705 532 536 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929705 537 539 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929705 540 547 O
a NCT03929705 548 549 O
minimum NCT03929705 550 557 B-Eq-Comparison
of NCT03929705 558 560 I-Eq-Comparison
10 NCT03929705 561 563 I-Eq-Comparison
mL NCT03929705 564 566 I-Eq-Comparison
of NCT03929705 567 569 O
whole NCT03929705 570 575 B-Observation
blood NCT03929705 576 581 I-Observation
at NCT03929705 582 584 B-Temporal-Connection___Temporal-Connection-Type-Value:during
each NCT03929705 585 589 O
visit NCT03929705 590 595 B-Encounter
( NCT03929705 596 597 O
16 NCT03929705 598 600 B-Eq-Comparison
mL NCT03929705 601 603 O
for NCT03929705 604 607 O
immunocompromised NCT03929705 608 625 B-Condition
i. NCT03929705 626 628 O
e. NCT03929705 629 631 O
HIV NCT03929705 633 636 B-Condition
+ NCT03929705 637 638 O
) NCT03929705 640 641 O

- NCT03929705 650 651 I-Condition
Must NCT03929705 653 657 O
be NCT03929705 658 660 O
T NCT03929705 661 662 B-Condition
- NCT03929705 663 664 O
SPOT NCT03929705 665 669 I-Condition
. NCT03929705 669 670 O
TB NCT03929705 671 673 O
positive NCT03929705 674 682 O

- NCT03929705 690 691 O
No NCT03929705 693 695 B-Negation
prior NCT03929705 696 701 B-Eq-Comparison
history NCT03929705 702 709 I-Eq-Comparison
of NCT03929705 710 712 O
TB NCT03929705 713 715 B-Condition
diagnosis NCT03929705 716 725 O

Exclusion NCT03929705 726 735 O
Criteria NCT03929705 736 744 O
: NCT03929705 745 746 O
Cohort NCT03929705 747 753 O
1 NCT03929705 754 755 O
a NCT03929705 756 757 O
and NCT03929705 758 761 O
1 NCT03929705 762 763 O
b NCT03929705 764 765 O

- NCT03929705 768 769 I-Observation
• NCT03929705 771 772 O
Negative NCT03929705 773 781 O
in NCT03929705 782 784 O
the NCT03929705 785 788 O
T NCT03929705 789 790 B-Observation
- NCT03929705 791 792 O
SPOT NCT03929705 793 797 I-Observation
. NCT03929705 797 798 O
TB NCT03929705 799 801 O
test NCT03929705 802 806 I-Observation

- NCT03929705 814 815 I-Eq-Comparison
Previous NCT03929705 817 825 B-Eq-Comparison
or NCT03929705 826 828 B-Or
pre NCT03929705 829 832 B-Eq-Comparison
- NCT03929705 833 834 O
existing NCT03929705 835 843 I-Eq-Comparison
confirmed NCT03929705 844 853 O
TB NCT03929705 854 856 B-Condition|Condition
diagnosis NCT03929705 857 866 O

- NCT03929705 874 875 O
On NCT03929705 877 879 B-Eq-Comparison
anti NCT03929705 880 884 O
- NCT03929705 885 886 O
TB NCT03929705 887 889 O
treatment NCT03929705 890 899 B-Procedure
for NCT03929705 900 903 O
more NCT03929705 904 908 B-Eq-Comparison
than NCT03929705 909 913 I-Eq-Comparison
1 NCT03929705 914 915 I-Eq-Comparison
week NCT03929705 916 920 I-Eq-Comparison
* NCT03929705 920 921 O

- NCT03929705 929 930 O
Not NCT03929705 932 935 O
meeting NCT03929705 936 943 O
inclusion NCT03929705 944 953 O
criteria NCT03929705 954 962 O
Exclusion NCT03929705 963 972 O
Criteria NCT03929705 973 981 O
: NCT03929705 982 983 O
Cohort NCT03929705 984 990 O
2 NCT03929705 991 992 O
a NCT03929705 993 994 O
and NCT03929705 995 998 O
2 NCT03929705 999 1000 O
b NCT03929705 1001 1002 O

- NCT03929705 1010 1011 I-Observation
Negative NCT03929705 1013 1021 O
T NCT03929705 1022 1023 B-Observation
- NCT03929705 1024 1025 I-Eq-Comparison
SPOT NCT03929705 1026 1030 I-Observation
. NCT03929705 1030 1031 O
TB NCT03929705 1032 1034 O
test NCT03929705 1035 1039 I-Observation

- NCT03929705 1047 1048 O
Previous NCT03929705 1050 1058 B-Eq-Comparison
or NCT03929705 1059 1061 B-Or
pre NCT03929705 1062 1065 B-Eq-Comparison
- NCT03929705 1066 1067 O
existing NCT03929705 1068 1076 I-Eq-Comparison
confirmed NCT03929705 1077 1086 O
TB NCT03929705 1087 1089 B-Condition|Condition
diagnosis NCT03929705 1090 1099 O

- NCT03929705 1107 1108 O
On NCT03929705 1110 1112 B-Eq-Comparison
anti NCT03929705 1113 1117 O
- NCT03929705 1118 1119 O
TB NCT03929705 1120 1122 B-Condition
treatment NCT03929705 1123 1132 B-Procedure

- NCT03929705 1140 1141 O
Symptoms NCT03929705 1143 1151 B-Assertion___Assertion-Type-Value:possible
of NCT03929705 1152 1154 O
active NCT03929705 1155 1161 B-Eq-Comparison
TB NCT03929705 1162 1164 O

- NCT03929705 1172 1173 O
Not NCT03929705 1175 1178 O
meeting NCT03929705 1179 1186 O
inclusion NCT03929705 1187 1196 O
criteria NCT03929705 1197 1205 O

Inclusion NCT03927066 0 9 O
Criteria NCT03927066 10 18 O
: NCT03927066 19 20 O

- NCT03927066 24 25 O
Non NCT03927066 27 30 B-Negation
- NCT03927066 31 32 O
obese NCT03927066 33 38 B-Condition
( NCT03927066 39 40 O
BMI NCT03927066 41 44 B-Observation
< NCT03927066 45 46 B-Eq-Comparison
30 NCT03927066 47 49 I-Eq-Comparison
) NCT03927066 50 51 O

- NCT03927066 55 56 O
Non NCT03927066 58 61 O
- NCT03927066 62 63 O
smokers NCT03927066 64 71 O

- NCT03927066 74 75 O
Free NCT03927066 77 81 B-Negation
of NCT03927066 82 84 I-Negation
any NCT03927066 85 88 O
systemic NCT03927066 89 97 B-Modifier
diseases NCT03927066 98 106 B-Condition
including NCT03927066 107 116 O
hypertension NCT03927066 117 129 B-Condition
, NCT03927066 130 131 O
diabetes NCT03927066 132 140 B-Condition
, NCT03927066 141 142 O
coronary NCT03927066 143 151 B-Condition
artery NCT03927066 152 158 I-Condition
disease NCT03927066 159 166 I-Condition
, NCT03927066 167 168 O
neurologic NCT03927066 169 179 B-Condition
disease NCT03927066 180 187 I-Condition
, NCT03927066 188 189 O
or NCT03927066 190 192 B-Or
any NCT03927066 193 196 O
other NCT03927066 197 202 B-Other
major NCT03927066 203 208 O
medical NCT03927066 209 216 B-Condition
co NCT03927066 217 219 I-Condition
- NCT03927066 220 221 I-Condition
morbidity NCT03927066 222 231 I-Condition

- NCT03927066 234 235 O
Women NCT03927066 237 242 O
will NCT03927066 243 247 B-Eq-Comparison
be NCT03927066 248 250 I-Eq-Comparison
either NCT03927066 251 257 O
surgically NCT03927066 258 268 B-Procedure
sterilized NCT03927066 269 279 I-Procedure
or NCT03927066 280 282 B-Or
non NCT03927066 283 286 B-Negation
- NCT03927066 287 288 O
pregnant NCT03927066 289 297 B-Condition
as NCT03927066 298 300 O
determined NCT03927066 301 311 O
by NCT03927066 312 314 O
a NCT03927066 315 316 O
urine NCT03927066 317 322 B-Observation
pregnancy NCT03927066 323 332 I-Observation
test NCT03927066 333 337 I-Observation

Inclusion NCT03925103 0 9 O
Criteria NCT03925103 10 18 O
: NCT03925103 19 20 O

- NCT03925103 24 25 O
Clinical NCT03925103 27 35 O
NSCLC NCT03925103 36 41 O
early NCT03925103 42 47 O
stage NCT03925103 48 53 O
( NCT03925103 54 55 O
stage NCT03925103 56 61 O
I NCT03925103 62 63 O
- NCT03925103 64 65 O
II NCT03925103 66 68 O
) NCT03925103 69 70 O
. NCT03925103 71 72 O

- NCT03925103 76 77 O
Both NCT03925103 79 83 O
forced NCT03925103 84 90 B-Observation
expiratory NCT03925103 91 101 I-Observation
volume NCT03925103 102 108 I-Observation
in NCT03925103 109 111 I-Observation
one NCT03925103 112 115 I-Observation
second NCT03925103 116 122 I-Observation
( NCT03925103 123 124 O
FEV1 NCT03925103 125 129 B-Observation
) NCT03925103 130 131 O
and NCT03925103 132 135 B-And
diffusion NCT03925103 136 145 B-Observation
capacity NCT03925103 146 154 I-Observation
of NCT03925103 155 157 I-Observation
carbon NCT03925103 158 164 I-Observation
monoxide NCT03925103 165 173 I-Observation
( NCT03925103 174 175 O
DLCO NCT03925103 176 180 B-Observation
) NCT03925103 181 182 O
> NCT03925103 184 185 B-Eq-Comparison
60 NCT03925103 186 188 I-Eq-Comparison
% NCT03925103 189 190 O

- NCT03925103 193 194 O
Both NCT03925103 196 200 O
predicted NCT03925103 201 210 B-Modifier
post NCT03925103 211 215 I-Modifier
- NCT03925103 216 217 O
- NCT03925103 219 220 O
operative NCT03925103 221 230 O
( NCT03925103 231 232 O
PPO NCT03925103 233 236 B-Modifier|Modifier
) NCT03925103 237 238 O
FEV1 NCT03925103 239 243 B-Observation
and NCT03925103 244 247 B-And
PPO NCT03925103 248 251 O
DLCO NCT03925103 252 256 B-Observation
> NCT03925103 257 258 B-Eq-Comparison
35 NCT03925103 259 261 I-Eq-Comparison
% NCT03925103 262 263 O

- NCT03925103 266 267 O
American NCT03925103 269 277 B-Condition
Society NCT03925103 278 285 I-Condition
of NCT03925103 286 288 I-Condition
Anesthesia NCT03925103 289 299 I-Condition
( NCT03925103 300 301 O
ASA NCT03925103 302 305 B-Condition
) NCT03925103 306 307 O
score NCT03925103 308 313 B-Eq-Comparison
< NCT03925103 314 315 I-Eq-Comparison
= NCT03925103 317 318 I-Eq-Comparison
2 NCT03925103 319 320 I-Eq-Comparison

- NCT03925103 324 325 O
Body NCT03925103 327 331 B-Observation
mass NCT03925103 332 336 I-Observation
index NCT03925103 337 342 I-Observation
( NCT03925103 343 344 O
BMI NCT03925103 345 348 B-Observation
) NCT03925103 349 350 O
> NCT03925103 351 352 B-Eq-Comparison
18 NCT03925103 353 355 I-Eq-Comparison
< NCT03925103 356 357 B-Eq-Comparison
28 NCT03925103 358 360 I-Eq-Comparison

Exclusion NCT03925103 362 371 O
Criteria NCT03925103 372 380 O
: NCT03925103 381 382 O

- NCT03925103 386 387 O
Clinical NCT03925103 389 397 O
NSCLC NCT03925103 398 403 B-Condition
stage NCT03925103 404 409 B-Eq-Comparison
> NCT03925103 410 411 I-Eq-Comparison
II NCT03925103 412 414 I-Eq-Comparison

- NCT03925103 417 418 O
History NCT03925103 420 427 B-Eq-Comparison
of NCT03925103 428 430 O
Neoadjuvant NCT03925103 431 442 B-Procedure
chemotherapy NCT03925103 443 455 I-Procedure
or NCT03925103 456 458 B-Or
radiotherapy NCT03925103 459 471 B-Procedure

- NCT03925103 474 475 O
Radiologic NCT03925103 477 487 B-Procedure
evidence NCT03925103 488 496 O
of NCT03925103 497 499 O
extensive NCT03925103 500 509 O
pleural NCT03925103 510 517 B-Condition
adhesions NCT03925103 518 527 I-Condition
. NCT03925103 527 528 O

- NCT03925103 532 533 O
Age NCT03925103 535 538 B-Age
< NCT03925103 539 540 B-Eq-Comparison
18 NCT03925103 541 543 I-Eq-Comparison
or NCT03925103 544 546 B-Or
> NCT03925103 547 548 B-Eq-Comparison
80 NCT03925103 549 551 I-Eq-Comparison
years NCT03925103 552 557 I-Eq-Comparison
. NCT03925103 557 558 O

- NCT03925103 562 563 O
Patients NCT03925103 565 573 O
with NCT03925103 574 578 O
previous NCT03925103 579 587 B-Eq-Comparison
pleurodesis NCT03925103 588 599 B-Procedure
or NCT03925103 600 602 B-Or
thoracotomy NCT03925103 603 614 B-Procedure
in NCT03925103 615 617 O
the NCT03925103 618 621 O
affected NCT03925103 622 630 B-Modifier
hemithorax NCT03925103 631 641 I-Modifier
. NCT03925103 641 642 O

- NCT03925103 646 647 O
Patients NCT03925103 649 657 O
who NCT03925103 658 661 O
will NCT03925103 662 666 B-Eq-Comparison
undergo NCT03925103 667 674 I-Eq-Comparison
surgical NCT03925103 675 683 B-Procedure
lung NCT03925103 684 688 I-Procedure
resection NCT03925103 689 698 I-Procedure
other NCT03925103 699 704 B-Exception
than NCT03925103 705 709 I-Exception
lobectomy NCT03925103 710 719 B-Procedure
. NCT03925103 719 720 O

- NCT03925103 724 725 O
Patients NCT03925103 727 735 O
with NCT03925103 736 740 O
severe NCT03925103 741 747 O
comorbidity NCT03925103 748 759 B-Condition
contraindicating NCT03925103 760 776 B-Contraindication
lobectomy NCT03925103 777 786 B-Procedure
. NCT03925103 786 787 O

- NCT03925103 791 792 O
Patients NCT03925103 794 802 O
refusal NCT03925103 803 810 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03925103 811 813 B-Or
noncompliance NCT03925103 814 827 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925103 828 830 O
general NCT03925103 831 838 B-Procedure
surgery NCT03925103 839 846 I-Procedure
and NCT03925103 847 850 B-Or
one NCT03925103 851 854 B-Modifier
- NCT03925103 855 856 I-Modifier
lung NCT03925103 857 861 I-Modifier
ventilation NCT03925103 862 873 B-Procedure
. NCT03925103 873 874 O

Inclusion NCT03924037 0 9 O
Criteria NCT03924037 10 18 O
: NCT03924037 19 20 O

- NCT03924037 24 25 O
American NCT03924037 27 35 O
Indian NCT03924037 36 42 O
youth NCT03924037 43 48 O
aged NCT03924037 49 53 B-Age
13 NCT03924037 54 56 B-Eq-Comparison
- NCT03924037 57 58 I-Eq-Comparison
24 NCT03924037 59 61 I-Eq-Comparison
years NCT03924037 62 67 I-Eq-Comparison
old NCT03924037 68 71 O
who NCT03924037 72 75 O
are NCT03924037 76 79 O
San NCT03924037 80 83 O
Felipe NCT03924037 84 90 O
tribal NCT03924037 91 97 O
members NCT03924037 98 105 O
living NCT03924037 106 112 O
in NCT03924037 113 115 O
the NCT03924037 116 119 O
Pueblo NCT03924037 120 126 O

- NCT03924037 129 130 O
Endorse NCT03924037 132 139 O
suicidal NCT03924037 140 148 B-Condition
ideation NCT03924037 149 157 B-Modifier
or NCT03924037 158 160 B-Or
behaviors NCT03924037 161 170 B-Modifier
on NCT03924037 171 173 O
a NCT03924037 174 175 O
universal NCT03924037 176 185 B-Procedure
screen NCT03924037 186 192 I-Procedure
by NCT03924037 193 195 O
their NCT03924037 196 201 O
primary NCT03924037 202 209 B-Provider
care NCT03924037 210 214 I-Provider
provider NCT03924037 215 223 I-Provider
. NCT03924037 223 224 O

Exclusion NCT03924037 226 235 O
Criteria NCT03924037 236 244 O
: NCT03924037 245 246 O

- NCT03924037 250 251 O
Younger NCT03924037 253 260 B-Eq-Comparison
than NCT03924037 261 265 I-Eq-Comparison
age NCT03924037 266 269 I-Eq-Comparison
of NCT03924037 270 272 I-Eq-Comparison
13 NCT03924037 273 275 I-Eq-Comparison
years NCT03924037 276 281 I-Eq-Comparison
old NCT03924037 282 285 O
or NCT03924037 286 288 B-Or

- NCT03924037 291 292 O
Older NCT03924037 294 299 B-Eq-Comparison
than NCT03924037 300 304 I-Eq-Comparison
the NCT03924037 305 308 I-Eq-Comparison
age NCT03924037 309 312 I-Eq-Comparison
of NCT03924037 313 315 I-Eq-Comparison
24 NCT03924037 316 318 I-Eq-Comparison
, NCT03924037 319 320 O

- NCT03924037 325 326 O
Not NCT03924037 328 331 B-Negation
American NCT03924037 332 340 O
Indian NCT03924037 341 347 O
, NCT03924037 348 349 O

- NCT03924037 353 354 O
Youth NCT03924037 356 361 O
who NCT03924037 362 365 B-And
do NCT03924037 366 368 O
not NCT03924037 369 372 B-Negation
receive NCT03924037 373 380 O
health NCT03924037 381 387 B-Encounter
services NCT03924037 388 396 I-Encounter
at NCT03924037 397 399 O
either NCT03924037 400 406 O
of NCT03924037 407 409 O
the NCT03924037 410 413 O
IHS NCT03924037 414 417 O
clinics NCT03924037 418 425 O
at NCT03924037 426 428 O
the NCT03924037 429 432 O
Pueblo NCT03924037 433 439 O
of NCT03924037 440 442 O
San NCT03924037 443 446 O
Felipe NCT03924037 447 453 O
, NCT03924037 454 455 O

- NCT03924037 459 460 O
Youth NCT03924037 462 467 O
who NCT03924037 468 471 B-And
screen NCT03924037 472 478 O
negative NCT03924037 479 487 O
for NCT03924037 488 491 O
suicidal NCT03924037 492 500 B-Condition
ideation NCT03924037 501 509 B-Modifier
and NCT03924037 510 513 B-Or
/ NCT03924037 514 515 I-Or
or NCT03924037 516 518 I-Or
behavior NCT03924037 519 527 B-Modifier
, NCT03924037 528 529 O

- NCT03924037 533 534 O
Refuse NCT03924037 536 542 O
to NCT03924037 543 545 O
participate NCT03924037 546 557 O
in NCT03924037 558 560 O
the NCT03924037 561 564 O
study NCT03924037 565 570 O
, NCT03924037 571 572 O
and NCT03924037 573 576 O
/ NCT03924037 577 578 O
or NCT03924037 579 581 O

- NCT03924037 584 585 O
Cognitively NCT03924037 587 598 B-Condition
unable NCT03924037 599 605 I-Condition
to NCT03924037 606 608 O
provide NCT03924037 609 616 O
informed NCT03924037 617 625 O
consent NCT03924037 626 633 O
as NCT03924037 634 636 O
demonstrated NCT03924037 637 649 O
by NCT03924037 650 652 O
a NCT03924037 653 654 O
brief NCT03924037 655 660 O
cognitive NCT03924037 661 670 B-Procedure
screen NCT03924037 671 677 I-Procedure
prior NCT03924037 678 683 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924037 684 686 O
completion NCT03924037 687 697 O
of NCT03924037 698 700 O
the NCT03924037 701 704 O
baseline NCT03924037 705 713 B-Study
interview NCT03924037 714 723 O
. NCT03924037 723 724 O

Inclusion NCT03922334 0 9 O
Criteria NCT03922334 10 18 O
: NCT03922334 19 20 O

- NCT03922334 24 25 O
Pregnant NCT03922334 27 35 B-Condition
( NCT03922334 36 37 O
any NCT03922334 38 41 O
plurality NCT03922334 42 51 O
) NCT03922334 52 53 O
delivering NCT03922334 54 64 B-Eq-Comparison
at NCT03922334 65 67 B-Eq-Comparison
or NCT03922334 68 70 I-Eq-Comparison
after NCT03922334 71 76 I-Eq-Comparison
20 NCT03922334 77 79 I-Eq-Comparison
weeks NCT03922334 80 85 I-Eq-Comparison
of NCT03922334 86 88 O
gestation NCT03922334 89 98 B-Observation
OR NCT03922334 99 101 B-Or
postpartum NCT03922334 102 112 B-Condition
( NCT03922334 113 114 O
during NCT03922334 115 121 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03922334 122 137 B-Encounter
) NCT03922334 138 139 O
, NCT03922334 141 142 O
regardless NCT03922334 143 153 O
of NCT03922334 154 156 O
perinatal NCT03922334 157 166 O
outcome NCT03922334 167 174 O

- NCT03922334 177 178 O
16 NCT03922334 180 182 B-Eq-Comparison
years NCT03922334 183 188 I-Eq-Comparison
or NCT03922334 189 191 I-Eq-Comparison
older NCT03922334 192 197 I-Age|Eq-Comparison

- NCT03922334 200 201 O
Low NCT03922334 203 206 O
- NCT03922334 207 208 O
income NCT03922334 209 215 O
socioeconomic NCT03922334 216 229 O
status NCT03922334 230 236 O
( NCT03922334 237 238 O
publicly NCT03922334 239 247 O
funded NCT03922334 248 254 O
prenatal NCT03922334 255 263 O
care NCT03922334 264 268 O
) NCT03922334 269 270 O

- NCT03922334 274 275 O
Ability NCT03922334 277 284 O
to NCT03922334 285 287 O
speak NCT03922334 288 293 O
and NCT03922334 294 297 O
read NCT03922334 298 302 O
English NCT03922334 303 310 O
or NCT03922334 311 313 B-Or
Spanish NCT03922334 314 321 O

- NCT03922334 324 325 O
Established NCT03922334 327 338 O
patient NCT03922334 339 346 O
at NCT03922334 347 349 O
the NCT03922334 350 353 O
Northwestern NCT03922334 354 366 O
Medicine NCT03922334 367 375 O
Prentice NCT03922334 376 384 O
Ambulatory NCT03922334 385 395 O
Care NCT03922334 396 400 O
clinical NCT03922334 401 409 O
site NCT03922334 410 414 O
( NCT03922334 415 416 O
at NCT03922334 417 419 B-Eq-Comparison
least NCT03922334 420 425 I-Eq-Comparison
one NCT03922334 426 429 I-Eq-Comparison
antenatal NCT03922334 430 439 O
clinical NCT03922334 440 448 O
visit NCT03922334 449 454 B-Encounter
) NCT03922334 455 456 O
. NCT03922334 457 458 O

Exclusion NCT03922334 460 469 O
Criteria NCT03922334 470 478 O
: NCT03922334 479 480 O

- NCT03922334 484 485 O
Intent NCT03922334 487 493 B-Assertion___Assertion-Type-Value:intention
to NCT03922334 494 496 O
transfer NCT03922334 497 505 B-Encounter
care NCT03922334 506 510 I-Encounter
to NCT03922334 511 513 O
an NCT03922334 514 516 O
outside NCT03922334 517 524 B-Other
institution NCT03922334 525 536 O

- NCT03922334 539 540 O
HIV NCT03922334 542 545 B-Condition
( NCT03922334 546 547 O
as NCT03922334 548 550 O
these NCT03922334 551 556 O
patients NCT03922334 557 565 O
already NCT03922334 566 573 O
receive NCT03922334 574 581 O
intensive NCT03922334 582 591 O
social NCT03922334 592 598 O
support NCT03922334 599 606 O
and NCT03922334 607 610 O
navigation NCT03922334 611 621 O
- NCT03922334 622 623 O
like NCT03922334 624 628 O
services NCT03922334 629 637 O
at NCT03922334 638 640 O
this NCT03922334 641 645 O
institution NCT03922334 646 657 O
) NCT03922334 658 659 O

Inclusion NCT03923764 0 9 O
Criteria NCT03923764 10 18 O
: NCT03923764 19 20 O

- NCT03923764 24 25 O
Diagnosed NCT03923764 27 36 O
with NCT03923764 37 41 O
COPD NCT03923764 42 46 B-Condition

- NCT03923764 49 50 O
Participating NCT03923764 52 65 O
in NCT03923764 66 68 O
ongoing NCT03923764 69 76 B-Eq-Comparison
lung NCT03923764 77 81 B-Procedure
rehabilitating NCT03923764 82 96 I-Procedure
programme NCT03923764 97 106 O
at NCT03923764 107 109 O
Hvidovre NCT03923764 110 118 O
and NCT03923764 119 122 B-Or
Bispebjerg NCT03923764 123 133 O
Hospital NCT03923764 134 142 O

- NCT03923764 145 146 O
over NCT03923764 148 152 B-Eq-Comparison
18 NCT03923764 153 155 I-Eq-Comparison
years NCT03923764 156 161 I-Age|Eq-Comparison

Exclusion NCT03923764 162 171 O
Criteria NCT03923764 172 180 O
: NCT03923764 181 182 O

- NCT03923764 186 187 O
Plasma NCT03923764 189 195 B-Observation
creatinin NCT03923764 196 205 I-Observation
over NCT03923764 206 210 B-Eq-Comparison
200 NCT03923764 211 214 I-Eq-Comparison
mikrog NCT03923764 215 221 I-Eq-Comparison
/ NCT03923764 222 223 I-Eq-Comparison
l NCT03923764 224 225 I-Eq-Comparison

- NCT03923764 228 229 O
dementia NCT03923764 231 239 B-Condition

- NCT03923764 242 243 O
unable NCT03923764 245 251 B-Negation
to NCT03923764 252 254 O
read NCT03923764 255 259 O
or NCT03923764 260 262 O
speak NCT03923764 263 268 O
danish NCT03923764 269 275 O

Inclusion NCT03925467 0 9 O
Criteria NCT03925467 10 18 O
: NCT03925467 19 20 O

Patients NCT03925467 22 30 O
meet NCT03925467 31 35 O
at NCT03925467 36 38 B-Eq-Comparison
least NCT03925467 39 44 I-Eq-Comparison
three NCT03925467 45 50 I-Eq-Comparison
out NCT03925467 51 54 B-Criteria-Count
of NCT03925467 55 57 I-Criteria-Count
the NCT03925467 58 61 I-Criteria-Count
following NCT03925467 62 71 I-Criteria-Count
six NCT03925467 72 75 B-Eq-Comparison
conditions NCT03925467 76 86 O
: NCT03925467 87 88 O

- NCT03925467 92 93 O
Any NCT03925467 95 98 O
gender NCT03925467 99 105 O
aged NCT03925467 106 110 B-Age
50 NCT03925467 111 113 B-Eq-Comparison
years NCT03925467 114 119 I-Eq-Comparison
or NCT03925467 120 122 I-Eq-Comparison
above NCT03925467 123 128 I-Eq-Comparison
; NCT03925467 128 129 O

- NCT03925467 132 133 O
Have NCT03925467 135 139 O
less NCT03925467 140 144 B-Eq-Comparison
than NCT03925467 145 149 I-Eq-Comparison
30 NCT03925467 150 152 I-Eq-Comparison
mins NCT03925467 153 157 I-Eq-Comparison
of NCT03925467 158 160 O
morning NCT03925467 161 168 B-Observation
stiffness NCT03925467 169 178 I-Observation
; NCT03925467 178 179 O

- NCT03925467 182 183 O
Crepitus NCT03925467 185 193 B-Condition
on NCT03925467 194 196 I-Condition
active NCT03925467 197 203 I-Condition
motion NCT03925467 204 210 I-Condition
; NCT03925467 210 211 O

- NCT03925467 214 215 O
Bony NCT03925467 217 221 B-Condition
tenderness NCT03925467 222 232 I-Condition
; NCT03925467 232 233 O

- NCT03925467 236 237 O
Bony NCT03925467 239 243 B-Condition
enlargement NCT03925467 244 255 I-Condition
; NCT03925467 255 256 O

- NCT03925467 259 260 O
No NCT03925467 262 264 B-Negation
palpable NCT03925467 265 273 B-Condition
warmth NCT03925467 274 280 I-Condition
. NCT03925467 280 281 O

Exclusion NCT03925467 283 292 O
Criteria NCT03925467 293 301 O
: NCT03925467 302 303 O

- NCT03925467 307 308 O
Subjects NCT03925467 310 318 O
who NCT03925467 319 322 O
are NCT03925467 323 326 O
unable NCT03925467 327 333 B-Condition
to NCT03925467 334 336 I-Condition
walk NCT03925467 337 341 I-Condition
. NCT03925467 341 342 O

- NCT03925467 346 347 O
Malignancy NCT03925467 349 359 B-Condition
, NCT03925467 360 361 O

- NCT03925467 365 366 O
Any NCT03925467 368 371 O
acute NCT03925467 372 377 O
medical NCT03925467 378 385 B-Condition
condition NCT03925467 386 395 I-Condition
, NCT03925467 396 397 O

- NCT03925467 401 402 O
Poorly NCT03925467 404 410 B-Modifier
controlled NCT03925467 411 421 I-Modifier
diabetes NCT03925467 422 430 B-Condition
or NCT03925467 431 433 B-Or
hypertension NCT03925467 434 446 B-Condition
, NCT03925467 447 448 O

- NCT03925467 452 453 O
A NCT03925467 455 456 O
motor NCT03925467 457 462 B-Modifier
or NCT03925467 463 465 B-Or
sensory NCT03925467 466 473 B-Modifier
nerve NCT03925467 474 479 B-Condition
defect NCT03925467 480 486 I-Condition
, NCT03925467 487 488 O

- NCT03925467 492 493 O
Blood NCT03925467 495 500 O
clotting NCT03925467 501 509 O
disease NCT03925467 510 517 O
, NCT03925467 518 519 O

- NCT03925467 523 524 O
Mental NCT03925467 526 532 B-Condition
illness NCT03925467 533 540 I-Condition
, NCT03925467 541 542 O

- NCT03925467 546 547 O
Dementia NCT03925467 549 557 B-Condition
, NCT03925467 558 559 O

- NCT03925467 563 564 O
Mental NCT03925467 566 572 B-Condition
retardation NCT03925467 573 584 I-Condition
or NCT03925467 585 587 O
other NCT03925467 588 593 O
abnormal NCT03925467 594 602 O
person NCT03925467 603 609 O
on NCT03925467 610 612 O
the NCT03925467 613 616 O
organic NCT03925467 617 624 O
mind NCT03925467 625 629 O
. NCT03925467 629 630 O

- NCT03925467 634 635 I-Modifier
Subjects NCT03925467 637 645 O
with NCT03925467 646 650 O
intra NCT03925467 651 656 B-Modifier
- NCT03925467 657 658 O
articular NCT03925467 659 668 I-Modifier
solid NCT03925467 669 674 I-Modifier
or NCT03925467 675 677 B-Or
hyaluronic NCT03925467 678 688 B-Modifier
acid NCT03925467 689 693 I-Modifier
injection NCT03925467 694 703 B-Procedure
in NCT03925467 704 706 O
the NCT03925467 707 710 O
past NCT03925467 711 715 B-Eq-Comparison
3 NCT03925467 716 717 I-Eq-Comparison
months NCT03925467 718 724 I-Eq-Comparison
. NCT03925467 724 725 O

- NCT03925467 729 730 O
Knee NCT03925467 732 736 B-Modifier|Modifier
surgery NCT03925467 737 744 B-Procedure
, NCT03925467 745 746 O

- NCT03925467 750 751 O
Knee NCT03925467 753 757 O
trauma NCT03925467 758 764 B-Condition
, NCT03925467 765 766 O

- NCT03925467 770 771 O
Congenital NCT03925467 773 783 B-Modifier
knee NCT03925467 784 788 I-Modifier|Modifier
deformation NCT03925467 789 800 B-Condition
, NCT03925467 801 802 O

- NCT03925467 806 807 O
Severe NCT03925467 809 815 O
knee NCT03925467 816 820 O
varus NCT03925467 821 826 B-Condition
or NCT03925467 827 829 B-Or
valgus NCT03925467 830 836 B-Condition
deformation NCT03925467 837 848 I-Condition
, NCT03925467 849 850 O

- NCT03925467 854 855 O
Endocrine NCT03925467 857 866 B-Modifier
, NCT03925467 867 868 O
metabolic NCT03925467 869 878 B-Modifier
, NCT03925467 879 880 O
infectious NCT03925467 881 891 B-Modifier
, NCT03925467 892 893 O
inflammatory NCT03925467 894 906 B-Modifier
, NCT03925467 907 908 O
secondary NCT03925467 909 918 B-Modifier
degenerative NCT03925467 919 931 I-Modifier
knee NCT03925467 932 936 I-Modifier
arthritis NCT03925467 937 946 B-Condition
caused NCT03925467 947 953 O
by NCT03925467 954 956 O
problems NCT03925467 957 965 O
with NCT03925467 966 970 O
rheumatic NCT03925467 971 980 B-Condition
immune NCT03925467 981 987 I-Condition
diseases NCT03925467 988 996 I-Condition
. NCT03925467 996 997 O

- NCT03925467 1001 1002 O
Subjects NCT03925467 1004 1012 O
who NCT03925467 1013 1016 O
are NCT03925467 1017 1020 O
hypersensitive NCT03925467 1021 1035 B-Condition
to NCT03925467 1036 1038 O
needles NCT03925467 1039 1046 B-Modifier
. NCT03925467 1046 1047 O

- NCT03925467 1051 1052 O
Subjects NCT03925467 1054 1062 O
who NCT03925467 1063 1066 O
are NCT03925467 1067 1070 O
unwilling NCT03925467 1071 1080 O
to NCT03925467 1081 1083 O
cooperate NCT03925467 1084 1093 O
or NCT03925467 1094 1096 O
sign NCT03925467 1097 1101 O
the NCT03925467 1102 1105 O
subject NCT03925467 1106 1113 O
consent NCT03925467 1114 1121 O
. NCT03925467 1121 1122 O

Inclusion NCT03924180 0 9 O
Criteria NCT03924180 10 18 O
: NCT03924180 19 20 O

- NCT03924180 24 25 O
Phenylketonuric NCT03924180 27 42 B-Condition
patient NCT03924180 43 50 O
diagnosed NCT03924180 51 60 O
in NCT03924180 61 63 O
neonatal NCT03924180 64 72 B-Procedure
screening NCT03924180 73 82 I-Procedure

- NCT03924180 85 86 O
Patient NCT03924180 88 95 O
with NCT03924180 96 100 O
Phenylalaninemia NCT03924180 101 117 B-Observation
≥ NCT03924180 118 119 B-Eq-Comparison
900 NCT03924180 120 123 I-Eq-Comparison
μmol NCT03924180 124 128 O
/ NCT03924180 129 130 I-Eq-Comparison
L NCT03924180 131 132 I-Eq-Comparison
on NCT03924180 133 135 O
blotter NCT03924180 136 143 O
made NCT03924180 144 148 O
during NCT03924180 149 155 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 156 159 O
screening NCT03924180 160 169 B-Study
period NCT03924180 170 176 O
( NCT03924180 177 178 O
or NCT03924180 179 181 B-Or
average NCT03924180 182 189 O
blotting NCT03924180 190 198 B-Coreference|Observation
results NCT03924180 199 206 I-Coreference|Observation
≥ NCT03924180 207 208 B-Eq-Comparison
900 NCT03924180 209 212 I-Eq-Comparison
μmol NCT03924180 213 217 I-Eq-Comparison
/ NCT03924180 218 219 I-Eq-Comparison
L NCT03924180 220 221 I-Eq-Comparison
if NCT03924180 222 224 O
several NCT03924180 225 232 B-Eq-Comparison
blots NCT03924180 233 238 O
made NCT03924180 239 243 O
during NCT03924180 244 250 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 251 254 O
screening NCT03924180 255 264 B-Study
period NCT03924180 265 271 O
) NCT03924180 272 273 O

- NCT03924180 277 278 O
Untreated NCT03924180 280 289 O
patient NCT03924180 290 297 O
: NCT03924180 298 299 O
not NCT03924180 300 303 B-Negation
taking NCT03924180 304 310 B-Eq-Comparison
any NCT03924180 311 314 O
amino NCT03924180 315 320 B-Drug
acid NCT03924180 321 325 I-Drug
supplement NCT03924180 326 336 I-Drug
for NCT03924180 337 340 O
his NCT03924180 341 344 O
PKU NCT03924180 345 348 B-Condition
, NCT03924180 349 350 O
regardless NCT03924180 351 361 O
of NCT03924180 362 364 O
diet NCT03924180 365 369 O

Exclusion NCT03924180 370 379 O
Criteria NCT03924180 380 388 O
: NCT03924180 389 390 O

- NCT03924180 394 395 O
Protected NCT03924180 397 406 O
patient NCT03924180 407 414 O
: NCT03924180 415 416 O
court NCT03924180 417 422 B-Condition
bail NCT03924180 423 427 I-Condition
, NCT03924180 428 429 O
curatorship NCT03924180 430 441 B-Condition
, NCT03924180 442 443 O
guardianship NCT03924180 444 456 B-Condition

- NCT03924180 459 460 O
Patient NCT03924180 462 469 O
with NCT03924180 470 474 O
concomitant NCT03924180 475 486 B-Condition
diseases NCT03924180 487 495 I-Condition
/ NCT03924180 496 497 B-Or
conditions NCT03924180 498 508 B-Condition
that NCT03924180 509 513 O
may NCT03924180 514 517 B-Assertion___Assertion-Type-Value:possible
compromise NCT03924180 518 528 O
the NCT03924180 529 532 O
study NCT03924180 533 538 B-Study
, NCT03924180 539 540 O
at NCT03924180 541 543 O
the NCT03924180 544 547 O
discretion NCT03924180 548 558 O
of NCT03924180 559 561 O
the NCT03924180 562 565 O
investigator NCT03924180 566 578 O

- NCT03924180 581 582 O
Participated NCT03924180 584 596 O
in NCT03924180 597 599 O
a NCT03924180 600 601 O
clinical NCT03924180 602 610 B-Study
trial NCT03924180 611 616 I-Study|Study
or NCT03924180 617 619 B-Or
trial NCT03924180 620 625 O
to NCT03924180 626 628 O
evaluate NCT03924180 629 637 O
PKU NCT03924180 638 641 B-Condition
foods NCT03924180 642 647 O
or NCT03924180 648 650 B-Or
treatments NCT03924180 651 661 B-Procedure
in NCT03924180 662 664 O
the NCT03924180 665 668 O
last NCT03924180 669 673 B-Eq-Comparison
7 NCT03924180 674 675 I-Eq-Comparison
days NCT03924180 676 680 I-Eq-Comparison
prior NCT03924180 681 686 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924180 687 689 O
inclusion NCT03924180 690 699 B-Study
or NCT03924180 700 702 B-Or
planned NCT03924180 703 710 B-Eq-Comparison
during NCT03924180 711 717 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 718 721 O
next NCT03924180 722 726 B-Eq-Comparison
6 NCT03924180 727 728 I-Eq-Comparison
months NCT03924180 729 735 I-Eq-Comparison

- NCT03924180 738 739 O
Participation NCT03924180 741 754 O
in NCT03924180 755 757 O
an NCT03924180 758 760 O
interventional NCT03924180 761 775 O
study NCT03924180 776 781 B-Study
with NCT03924180 782 786 O
health NCT03924180 787 793 B-Drug
products NCT03924180 794 802 I-Drug
during NCT03924180 803 809 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 810 813 O
next NCT03924180 814 818 B-Eq-Comparison
6 NCT03924180 819 820 I-Eq-Comparison
months NCT03924180 821 827 I-Eq-Comparison

- NCT03924180 830 831 O
Pregnancy NCT03924180 833 842 B-Condition
project NCT03924180 843 850 O
within NCT03924180 851 857 B-Eq-Comparison
6 NCT03924180 858 859 I-Eq-Comparison
months NCT03924180 860 866 I-Eq-Comparison
, NCT03924180 867 868 O
pre NCT03924180 869 872 B-Condition
- NCT03924180 873 874 I-Condition
conception NCT03924180 875 885 I-Condition
diet NCT03924180 886 890 I-Condition
, NCT03924180 891 892 O
pregnancy NCT03924180 893 902 B-Condition
or NCT03924180 903 905 B-Or
breastfeeding NCT03924180 906 919 B-Condition

- NCT03924180 922 923 O
Refusal NCT03924180 925 932 O
to NCT03924180 933 935 O
consume NCT03924180 936 943 O
only NCT03924180 944 948 O
validated NCT03924180 949 958 O
complements NCT03924180 959 970 O
for NCT03924180 971 974 O
the NCT03924180 975 978 O
protocol NCT03924180 979 987 O

- NCT03924180 990 991 O
Phenylketonuria NCT03924180 993 1008 B-Condition
undergoing NCT03924180 1009 1019 B-Eq-Comparison
treatment NCT03924180 1020 1029 B-Procedure
with NCT03924180 1030 1034 O
BH4 NCT03924180 1035 1038 B-Drug

- NCT03924180 1041 1042 O
Allergy NCT03924180 1044 1051 B-Allergy
to NCT03924180 1052 1054 O
the NCT03924180 1055 1058 O
product NCT03924180 1059 1066 B-Drug
under NCT03924180 1067 1072 O
study NCT03924180 1073 1078 B-Study

Inclusion NCT03921749 0 9 O
Criteria NCT03921749 10 18 O
: NCT03921749 19 20 O

- NCT03921749 24 25 O
people NCT03921749 27 33 O
aged NCT03921749 34 38 B-Age
45 NCT03921749 39 41 B-Eq-Comparison
years NCT03921749 42 47 I-Eq-Comparison
or NCT03921749 48 50 I-Eq-Comparison
more NCT03921749 51 55 I-Eq-Comparison

- NCT03921749 58 59 O
subjects NCT03921749 61 69 O
diagnosed NCT03921749 70 79 O
with NCT03921749 80 84 O
knee NCT03921749 85 89 B-Modifier
OA NCT03921749 90 92 B-Condition
according NCT03921749 93 102 O
to NCT03921749 103 105 O
the NCT03921749 106 109 O
clinical NCT03921749 110 118 O
criteria NCT03921749 119 127 O
of NCT03921749 128 130 O
the NCT03921749 131 134 O
American NCT03921749 135 143 O
College NCT03921749 144 151 O
of NCT03921749 152 154 O
Rheumatology NCT03921749 155 167 O

- NCT03921749 170 171 O
subjects NCT03921749 173 181 O
diagnosed NCT03921749 182 191 O
with NCT03921749 192 196 O
grade NCT03921749 197 202 B-Eq-Comparison
II NCT03921749 203 205 I-Eq-Comparison
or NCT03921749 206 208 I-Eq-Comparison
III NCT03921749 209 212 I-Eq-Comparison
OA NCT03921749 213 215 B-Condition
during NCT03921749 216 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
radiologicalexamination NCT03921749 223 246 B-Procedure
as NCT03921749 247 249 O
defined NCT03921749 250 257 O
by NCT03921749 258 260 O
the NCT03921749 261 264 O
radiological NCT03921749 265 277 O
classification NCT03921749 278 292 O
of NCT03921749 293 295 O
Kellgren NCT03921749 296 304 O
and NCT03921749 305 308 O
Lawrence NCT03921749 309 317 O
( NCT03921749 318 319 O
K NCT03921749 320 321 O
- NCT03921749 322 323 O
L NCT03921749 324 325 O
) NCT03921749 326 327 O
scale NCT03921749 328 333 O
for NCT03921749 334 337 O
knee NCT03921749 338 342 O
OA NCT03921749 343 345 O

- NCT03921749 348 349 O
subjects NCT03921749 351 359 O
with NCT03921749 360 364 O
tenderness NCT03921749 365 375 B-Condition
in NCT03921749 376 378 O
the NCT03921749 379 382 O
medial NCT03921749 383 389 B-Modifier
tibial NCT03921749 390 396 I-Modifier
plateau NCT03921749 397 404 I-Modifier
area NCT03921749 405 409 I-Modifier

- NCT03921749 412 413 O
subjects NCT03921749 415 423 O
who NCT03921749 424 427 O
had NCT03921749 428 431 O
pain NCT03921749 432 436 B-Condition
on NCT03921749 437 439 B-Modifier
one NCT03921749 440 443 O
side NCT03921749 444 448 I-Modifier
of NCT03921749 449 451 I-Modifier
the NCT03921749 452 455 I-Modifier
knee NCT03921749 456 460 I-Modifier
. NCT03921749 460 461 O

Exclusion NCT03921749 463 472 O
Criteria NCT03921749 473 481 O
: NCT03921749 482 483 O

- NCT03921749 487 488 O
patients NCT03921749 490 498 O
with NCT03921749 499 503 O
a NCT03921749 504 505 O
history NCT03921749 506 513 B-Eq-Comparison
of NCT03921749 514 516 O
spinal NCT03921749 517 523 B-Condition
stenosis NCT03921749 524 532 I-Condition
, NCT03921749 533 534 O
evidence NCT03921749 535 543 O
of NCT03921749 544 546 O
neurologic NCT03921749 547 557 B-Condition
disease NCT03921749 558 565 I-Condition
by NCT03921749 566 568 O
history NCT03921749 569 576 B-Eq-Comparison
or NCT03921749 577 579 O
physical NCT03921749 580 588 B-Procedure
examination NCT03921749 589 600 I-Procedure
, NCT03921749 601 602 O
or NCT03921749 603 605 B-Or
secondary NCT03921749 606 615 O
causes NCT03921749 616 622 O
of NCT03921749 623 625 O
arthritis NCT03921749 626 635 B-Condition
( NCT03921749 636 637 O
inflammatory NCT03921749 638 650 B-Modifier
or NCT03921749 651 653 B-Or
metabolic NCT03921749 654 663 B-Modifier
) NCT03921749 664 665 O

- NCT03921749 669 670 O
those NCT03921749 672 677 O
who NCT03921749 678 681 O
had NCT03921749 682 685 O
a NCT03921749 686 687 O
surgical NCT03921749 688 696 B-Procedure
intervention NCT03921749 697 709 I-Procedure
or NCT03921749 710 712 B-Or
intra NCT03921749 713 718 B-Procedure
- NCT03921749 719 720 I-Procedure
articular NCT03921749 721 730 I-Procedure
injection NCT03921749 731 740 I-Procedure
in NCT03921749 741 743 O
the NCT03921749 744 747 O
affected NCT03921749 748 756 B-Modifier
knee NCT03921749 757 761 I-Modifier
in NCT03921749 762 764 O
the NCT03921749 765 768 O
previous NCT03921749 769 777 B-Eq-Comparison
6 NCT03921749 778 779 I-Eq-Comparison
months NCT03921749 780 786 I-Eq-Comparison

- NCT03921749 789 790 O
any NCT03921749 792 795 O
contraindication NCT03921749 796 812 B-Contraindication
to NCT03921749 813 815 O
extracorporeal NCT03921749 816 830 B-Procedure
shock NCT03921749 831 836 I-Procedure
wave NCT03921749 837 841 I-Procedure
( NCT03921749 842 843 O
pregnancy NCT03921749 844 853 B-Condition
, NCT03921749 854 855 O
cancer NCT03921749 856 862 B-Condition
, NCT03921749 863 864 O
coagulation NCT03921749 865 876 B-Condition
disorders NCT03921749 877 886 I-Condition
, NCT03921749 887 888 O
inflammatory NCT03921749 889 901 B-Condition
disease NCT03921749 902 909 I-Condition
, NCT03921749 910 911 O
pacemakers NCT03921749 912 922 B-Procedure
, NCT03921749 923 924 O
or NCT03921749 925 927 O
other NCT03921749 928 933 B-Other
electronic NCT03921749 934 944 B-Procedure
implants NCT03921749 945 953 I-Procedure
) NCT03921749 954 955 O
. NCT03921749 956 957 O

Inclusion NCT03926026 0 9 O
Criteria NCT03926026 10 18 O
: NCT03926026 19 20 O

- NCT03926026 24 25 O
history NCT03926026 27 34 B-Eq-Comparison
of NCT03926026 35 37 O
blepharitis NCT03926026 38 49 B-Condition
and NCT03926026 50 53 B-And
meet NCT03926026 54 58 O
qualifying NCT03926026 59 69 O
criteria NCT03926026 70 78 O
for NCT03926026 79 82 O
an NCT03926026 83 85 O
acute NCT03926026 86 91 O
exacerbation NCT03926026 92 104 O
of NCT03926026 105 107 O
blepharitis NCT03926026 108 119 B-Condition
in NCT03926026 120 122 O
both NCT03926026 123 127 B-Modifier
eyes NCT03926026 128 132 I-Modifier
at NCT03926026 133 135 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03926026 136 145 B-Study
and NCT03926026 146 149 B-And
Baseline NCT03926026 150 158 B-Study
/ NCT03926026 159 160 O
Day NCT03926026 161 164 O
1 NCT03926026 165 166 O
Visits NCT03926026 167 173 O

- NCT03926026 176 177 O
have NCT03926026 179 183 O
a NCT03926026 184 185 O
qualifying NCT03926026 186 196 O
best NCT03926026 197 201 B-Condition
- NCT03926026 202 203 I-Condition
corrected NCT03926026 204 213 I-Condition
visual NCT03926026 214 220 I-Condition
acuity NCT03926026 221 227 I-Condition

Exclusion NCT03926026 228 237 O
Criteria NCT03926026 238 246 O
: NCT03926026 247 248 O

- NCT03926026 252 253 O
abnormality NCT03926026 255 266 B-Condition
of NCT03926026 267 269 O
the NCT03926026 270 273 O
eyelids NCT03926026 274 281 B-Modifier
or NCT03926026 282 284 B-Or
lashes NCT03926026 285 291 B-Modifier
( NCT03926026 292 293 O
other NCT03926026 294 299 B-Exception
than NCT03926026 300 304 I-Exception
blepharitis NCT03926026 305 316 B-Condition
) NCT03926026 317 318 O
, NCT03926026 320 321 O
or NCT03926026 322 324 O
previous NCT03926026 325 333 B-Eq-Comparison
eyelid NCT03926026 334 340 B-Modifier
surgery NCT03926026 341 348 B-Procedure

- NCT03926026 351 352 O
IOP NCT03926026 354 357 B-Observation
> NCT03926026 358 359 B-Eq-Comparison
21 NCT03926026 360 362 I-Eq-Comparison
mmHg NCT03926026 363 367 I-Eq-Comparison
at NCT03926026 368 370 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03926026 371 380 B-Study
or NCT03926026 381 383 B-Or
Baseline NCT03926026 384 392 B-Study
/ NCT03926026 393 394 O
Day NCT03926026 395 398 O
1 NCT03926026 399 400 O
Visits NCT03926026 401 407 O

- NCT03926026 410 411 O
use NCT03926026 413 416 O
of NCT03926026 417 419 O
steroids NCT03926026 420 428 B-Drug
in NCT03926026 429 431 O
the NCT03926026 432 435 O
past NCT03926026 436 440 B-Eq-Comparison
30 NCT03926026 441 443 I-Eq-Comparison
days NCT03926026 444 448 I-Eq-Comparison
or NCT03926026 449 451 B-Or
retinoids NCT03926026 452 461 B-Drug
in NCT03926026 462 464 O
the NCT03926026 465 468 O
past NCT03926026 469 473 B-Eq-Comparison
12 NCT03926026 474 476 I-Eq-Comparison
months NCT03926026 477 483 I-Eq-Comparison

- NCT03926026 486 487 O
uncontrolled NCT03926026 489 501 B-Modifier
systemic NCT03926026 502 510 B-Condition
disease NCT03926026 511 518 I-Condition

Inclusion NCT03929315 0 9 O
Criteria NCT03929315 10 18 O
: NCT03929315 19 20 O

- NCT03929315 24 25 O
Pediatric NCT03929315 27 36 O
residents NCT03929315 37 46 O
and NCT03929315 47 50 O
fellows NCT03929315 51 58 O
from NCT03929315 59 63 O
the NCT03929315 64 67 O
Hospital NCT03929315 68 76 O
for NCT03929315 77 80 O
Sick NCT03929315 81 85 O
Children NCT03929315 86 94 O
, NCT03929315 95 96 O
Toronto NCT03929315 97 104 O

Exclusion NCT03929315 105 114 O
Criteria NCT03929315 115 123 O
: NCT03929315 124 125 O

- NCT03929315 129 130 O
Refusal NCT03929315 132 139 O
to NCT03929315 140 142 O
participate NCT03929315 143 154 O
in NCT03929315 155 157 O
study NCT03929315 158 163 O

- NCT03929315 166 167 O
Previous NCT03929315 169 177 B-Eq-Comparison
experience NCT03929315 178 188 O
with NCT03929315 189 193 O
at NCT03929315 194 196 O
most NCT03929315 197 201 O
two NCT03929315 202 205 O
OLV NCT03929315 206 209 O
in NCT03929315 210 212 O
children NCT03929315 213 221 O

- NCT03929315 224 225 O
Previous NCT03929315 227 235 B-Eq-Comparison
experience NCT03929315 236 246 O
with NCT03929315 247 251 O
at NCT03929315 252 254 O
most NCT03929315 255 259 O
two NCT03929315 260 263 O
OLV NCT03929315 264 267 O
in NCT03929315 268 270 O
manikins NCT03929315 271 279 O

Inclusion NCT03920319 0 9 O
Criteria NCT03920319 10 18 O
: NCT03920319 19 20 O

- NCT03920319 24 25 O
Treatment NCT03920319 27 36 B-Procedure
- NCT03920319 37 38 O
seeking NCT03920319 39 46 B-Assertion___Assertion-Type-Value:intention
cigarette NCT03920319 47 56 B-Condition
smoker NCT03920319 57 63 I-Condition

- NCT03920319 66 67 O
Meet NCT03920319 69 73 O
DSM NCT03920319 74 77 O
- NCT03920319 78 79 O
IV NCT03920319 80 82 O
criteria NCT03920319 83 91 O
for NCT03920319 92 95 O
nicotine NCT03920319 96 104 B-Condition
dependence NCT03920319 105 115 I-Condition

- NCT03920319 118 119 O
Negative NCT03920319 121 129 O
result NCT03920319 130 136 O
on NCT03920319 137 139 O
urine NCT03920319 140 145 B-Observation
test NCT03920319 146 150 I-Observation
for NCT03920319 151 154 I-Observation
drug NCT03920319 155 159 I-Observation
use NCT03920319 160 163 I-Observation
during NCT03920319 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920319 171 180 B-Study

Exclusion NCT03920319 181 190 O
Criteria NCT03920319 191 199 O
: NCT03920319 200 201 O

- NCT03920319 205 206 O
History NCT03920319 208 215 B-Eq-Comparison
of NCT03920319 216 218 O
any NCT03920319 219 222 O
Axis NCT03920319 223 227 B-Eq-Comparison
I NCT03920319 228 229 I-Eq-Comparison
psychiatric NCT03920319 230 241 B-Condition
diagnosis NCT03920319 242 251 I-Condition
other NCT03920319 252 257 B-Exception
than NCT03920319 258 262 I-Exception
nicotine NCT03920319 263 271 B-Condition
dependence NCT03920319 272 282 I-Condition

- NCT03920319 285 286 O
Medical NCT03920319 288 295 B-Condition
conditions NCT03920319 296 306 I-Condition
that NCT03920319 307 311 O
might NCT03920319 312 317 B-Assertion___Assertion-Type-Value:possible
affect NCT03920319 318 324 O
brain NCT03920319 325 330 B-Condition
function NCT03920319 331 339 I-Condition

- NCT03920319 342 343 O
Current NCT03920319 345 352 B-Eq-Comparison
use NCT03920319 353 356 O
of NCT03920319 357 359 O
medications NCT03920319 360 371 B-Drug
that NCT03920319 372 376 O
could NCT03920319 377 382 B-Assertion___Assertion-Type-Value:possible
alter NCT03920319 383 388 O
brain NCT03920319 389 394 B-Condition
function NCT03920319 395 403 I-Condition

- NCT03920319 406 407 O
Pregnancy NCT03920319 409 418 B-Condition

- NCT03920319 421 422 O
Current NCT03920319 424 431 B-Eq-Comparison
illicit NCT03920319 432 439 B-Condition
drug NCT03920319 440 444 I-Condition
use NCT03920319 445 448 I-Condition
other NCT03920319 449 454 B-Exception
than NCT03920319 455 459 I-Exception
occasional NCT03920319 460 470 O
use NCT03920319 471 474 O
of NCT03920319 475 477 O
marijuana NCT03920319 478 487 B-Condition

Inclution NCT03921775 0 9 O
Criteria NCT03921775 10 18 O
: NCT03921775 19 20 O

1 NCT03921775 24 25 O
. NCT03921775 25 26 O
18 NCT03921775 28 30 B-Eq-Comparison
~ NCT03921775 31 32 O
60 NCT03921775 33 35 O
years NCT03921775 36 41 I-Age|Eq-Comparison
, NCT03921775 42 43 O
female NCT03921775 44 50 O
or NCT03921775 51 53 B-Or
male NCT03921775 54 58 O

2 NCT03921775 61 62 O
. NCT03921775 62 63 O
Patients NCT03921775 65 73 O
scheduled NCT03921775 74 83 B-Eq-Comparison
for NCT03921775 84 87 O
an NCT03921775 88 90 O
elective NCT03921775 91 99 B-Procedure
surgical NCT03921775 100 108 I-Procedure
procedure NCT03921775 109 118 I-Procedure
( NCT03921775 119 120 O
mechanical NCT03921775 121 131 B-Procedure
ventilation NCT03921775 132 143 I-Procedure
via NCT03921775 144 147 O
endotracheal NCT03921775 148 160 B-Procedure
tube NCT03921775 161 165 I-Procedure
) NCT03921775 166 167 O

3 NCT03921775 171 172 O
. NCT03921775 172 173 O
BMI NCT03921775 175 178 B-Observation
: NCT03921775 179 180 O
18 NCT03921775 181 183 B-Eq-Comparison
~ NCT03921775 184 185 O
30 NCT03921775 186 188 O
kg NCT03921775 189 191 I-Eq-Comparison
/ NCT03921775 192 193 I-Eq-Comparison
m2 NCT03921775 194 196 I-Eq-Comparison

4 NCT03921775 199 200 O
. NCT03921775 200 201 O
Patients NCT03921775 203 211 O
understand NCT03921775 212 222 O
clearly NCT03921775 223 230 O
and NCT03921775 231 234 O
participate NCT03921775 235 246 O
in NCT03921775 247 249 O
the NCT03921775 250 253 O
study NCT03921775 254 259 O
voluntarily NCT03921775 260 271 O
, NCT03921775 272 273 O
and NCT03921775 274 277 O
sign NCT03921775 278 282 O
the NCT03921775 283 286 O
informed NCT03921775 287 295 O
consent NCT03921775 296 303 O

Exclusion NCT03921775 304 313 O
criteria NCT03921775 314 322 O
: NCT03921775 323 324 O

1 NCT03921775 328 329 O
. NCT03921775 329 330 O
Patients NCT03921775 332 340 O
scheduled NCT03921775 341 350 B-Eq-Comparison
for NCT03921775 351 354 O
emergency NCT03921775 355 364 B-Procedure
surgery NCT03921775 365 372 I-Procedure

2 NCT03921775 375 376 O
. NCT03921775 376 377 O
Patients NCT03921775 379 387 O
with NCT03921775 388 392 O
a NCT03921775 393 394 O
history NCT03921775 395 402 B-Eq-Comparison
of NCT03921775 403 405 O
drug NCT03921775 406 410 B-Condition
abuse NCT03921775 411 416 I-Condition|Condition
and NCT03921775 417 420 B-Or
/ NCT03921775 421 422 I-Or
or NCT03921775 423 425 I-Or
alcohol NCT03921775 426 433 B-Condition
abuse NCT03921775 434 439 O
2 NCT03921775 440 441 B-Eq-Comparison
years NCT03921775 442 447 I-Eq-Comparison
prior NCT03921775 448 453 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921775 454 456 O
the NCT03921775 457 460 O
screening NCT03921775 461 470 B-Study
period NCT03921775 471 477 O

3 NCT03921775 480 481 O
. NCT03921775 481 482 O
One NCT03921775 484 487 O
or NCT03921775 488 490 O
more NCT03921775 491 495 O
of NCT03921775 496 498 O
the NCT03921775 499 502 O
laboratory NCT03921775 503 513 B-Observation
findings NCT03921775 514 522 I-Observation
fall NCT03921775 523 527 O
out NCT03921775 528 531 O
of NCT03921775 532 534 O
the NCT03921775 535 538 O
limitations NCT03921775 539 550 O
for NCT03921775 551 554 O
this NCT03921775 555 559 O
study NCT03921775 560 565 O
( NCT03921775 566 567 O
platelet NCT03921775 568 576 B-Observation
, NCT03921775 577 578 O
hemoglobin NCT03921775 579 589 B-Observation
, NCT03921775 590 591 O
aspartate NCT03921775 592 601 B-Observation
aminotransferase NCT03921775 602 618 I-Observation
, NCT03921775 619 620 O
etc NCT03921775 621 624 O
. NCT03921775 624 625 O
) NCT03921775 626 627 O

4 NCT03921775 631 632 O
. NCT03921775 632 633 O
Pregnant NCT03921775 635 643 B-Condition
women NCT03921775 644 649 O
or NCT03921775 650 652 B-Or
those NCT03921775 653 658 O
in NCT03921775 659 661 O
lactation NCT03921775 662 671 B-Condition
period NCT03921775 672 678 O

5 NCT03921775 681 682 O
. NCT03921775 682 683 O
Allergic NCT03921775 685 693 B-Allergy
to NCT03921775 694 696 O
drugs NCT03921775 697 702 B-Drug
used NCT03921775 703 707 O
in NCT03921775 708 710 O
the NCT03921775 711 714 O
study NCT03921775 715 720 B-Study

6 NCT03921775 723 724 O
. NCT03921775 724 725 O
Patients NCT03921775 727 735 O
with NCT03921775 736 740 O
respiratory NCT03921775 741 752 B-Condition
management NCT03921775 753 763 I-Condition
difficulties NCT03921775 764 776 I-Condition
( NCT03921775 777 778 O
Modified NCT03921775 779 787 B-Condition
Mallampati NCT03921775 788 798 I-Condition
grade NCT03921775 799 804 B-Eq-Comparison
IV NCT03921775 805 807 I-Eq-Comparison
) NCT03921775 808 809 O

7 NCT03921775 813 814 O
. NCT03921775 814 815 O
Patients NCT03921775 817 825 O
have NCT03921775 826 830 O
participated NCT03921775 831 843 O
in NCT03921775 844 846 O
other NCT03921775 847 852 B-Other
clinical NCT03921775 853 861 B-Study
trial NCT03921775 862 867 I-Study
within NCT03921775 868 874 B-Eq-Comparison
the NCT03921775 875 878 I-Eq-Comparison
3 NCT03921775 879 880 I-Eq-Comparison
months NCT03921775 881 887 I-Eq-Comparison
prior NCT03921775 888 893 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921775 894 896 O
randomization NCT03921775 897 910 B-Study

8 NCT03921775 913 914 O
. NCT03921775 914 915 O
Any NCT03921775 917 920 O
patient NCT03921775 921 928 O
judged NCT03921775 929 935 O
by NCT03921775 936 938 O
the NCT03921775 939 942 O
Principal NCT03921775 943 952 O
Investigator NCT03921775 953 965 O
( NCT03921775 966 967 O
PI NCT03921775 968 970 O
) NCT03921775 971 972 O
or NCT03921775 973 975 O
Sub NCT03921775 976 979 O
- NCT03921775 980 981 O
Investigator NCT03921775 982 994 O
to NCT03921775 995 997 O
be NCT03921775 998 1000 O
inappropriate NCT03921775 1001 1014 O
for NCT03921775 1015 1018 O
the NCT03921775 1019 1022 O
subject NCT03921775 1023 1030 O
for NCT03921775 1031 1034 O
any NCT03921775 1035 1038 O
other NCT03921775 1039 1044 O
reason NCT03921775 1045 1051 O

Inclusion NCT03925922 0 9 O
Criteria NCT03925922 10 18 O
: NCT03925922 19 20 O

- NCT03925922 24 25 O
Nulliparous NCT03925922 27 38 B-Modifier
singleton NCT03925922 39 48 I-Modifier
pregnancy NCT03925922 49 58 B-Condition

- NCT03925922 61 62 O
gestational NCT03925922 64 75 B-Observation
age NCT03925922 76 79 I-Observation
between NCT03925922 80 87 B-Eq-Comparison
37 NCT03925922 88 90 I-Eq-Comparison
week NCT03925922 91 95 O
and NCT03925922 96 99 I-Eq-Comparison
42 NCT03925922 100 102 I-Eq-Comparison
weeks NCT03925922 103 108 I-Eq-Comparison

- NCT03925922 111 112 O
Cephalic NCT03925922 114 122 B-Condition
presentation NCT03925922 123 135 I-Condition

- NCT03925922 138 139 O
Bishop NCT03925922 141 147 B-Observation
score NCT03925922 148 153 I-Observation
of NCT03925922 154 156 O
5 NCT03925922 157 158 B-Eq-Comparison
or NCT03925922 159 161 I-Eq-Comparison
less NCT03925922 162 166 I-Eq-Comparison

- NCT03925922 169 170 O
No NCT03925922 172 174 B-Negation
clinical NCT03925922 175 183 O
evidence NCT03925922 184 192 O
of NCT03925922 193 195 O
regular NCT03925922 196 203 B-Condition
contraction NCT03925922 204 215 I-Condition

Exclusion NCT03925922 216 225 O
Criteria NCT03925922 226 234 O
: NCT03925922 235 236 O

- NCT03925922 240 241 O
Rupture NCT03925922 243 250 B-Condition
of NCT03925922 251 253 I-Condition
membrane NCT03925922 254 262 I-Condition

- NCT03925922 265 266 O
Vaginal NCT03925922 268 275 B-Condition
bleeding NCT03925922 276 284 I-Condition

- NCT03925922 287 288 O
Any NCT03925922 290 293 O
contraindication NCT03925922 294 310 B-Contraindication
to NCT03925922 311 313 O
vaginal NCT03925922 314 321 B-Modifier
delivery NCT03925922 322 330 B-Procedure

Inclusion NCT03920696 0 9 O
Criteria NCT03920696 10 18 O
: NCT03920696 19 20 O

- NCT03920696 24 25 O
Age NCT03920696 27 30 B-Age
≥ NCT03920696 31 32 B-Eq-Comparison
18 NCT03920696 33 35 I-Eq-Comparison
years NCT03920696 36 41 I-Eq-Comparison

- NCT03920696 44 45 O
Patients NCT03920696 47 55 O
with NCT03920696 56 60 O
Pityriasis NCT03920696 61 71 B-Condition
Lichenoides NCT03920696 72 83 I-Condition
selected NCT03920696 84 92 O
from NCT03920696 93 97 O
histological NCT03920696 98 110 O
coding NCT03920696 111 117 O
OT0431 NCT03920696 118 124 O
, NCT03920696 125 126 O
seen NCT03920696 127 131 B-Encounter
at NCT03920696 132 134 O
Henri NCT03920696 135 140 O
Mondor NCT03920696 141 147 O
and NCT03920696 148 151 O
with NCT03920696 152 156 O
a NCT03920696 157 158 O
diagnosis NCT03920696 159 168 O
verified NCT03920696 169 177 O
from NCT03920696 178 182 O
medical NCT03920696 183 190 O
records NCT03920696 191 198 O
. NCT03920696 198 199 O

Exclusion NCT03920696 201 210 O
Criteria NCT03920696 211 219 O
: NCT03920696 220 221 O

- NCT03920696 225 226 O
Histological NCT03920696 228 240 O
coding NCT03920696 241 247 O
error NCT03920696 248 253 O

- NCT03920696 256 257 O
Histological NCT03920696 259 271 O
records NCT03920696 272 279 O
of NCT03920696 280 282 O
patients NCT03920696 283 291 O
in NCT03920696 292 294 O
care NCT03920696 295 299 B-Encounter
outside NCT03920696 300 307 B-Other
Henri NCT03920696 308 313 O
Mondor NCT03920696 314 320 O
( NCT03920696 321 322 O
cases NCT03920696 323 328 O
referred NCT03920696 329 337 O
for NCT03920696 338 341 O
histological NCT03920696 342 354 O
expertise NCT03920696 355 364 O
only NCT03920696 365 369 O
but NCT03920696 370 373 O
not NCT03920696 374 377 O
seen NCT03920696 378 382 O
clinically NCT03920696 383 393 O
) NCT03920696 394 395 O

- NCT03920696 399 400 O
Clinical NCT03920696 402 410 B-Condition
lesions NCT03920696 411 418 I-Condition
incompatible NCT03920696 419 431 B-Negation
with NCT03920696 432 436 O
Pityriasis NCT03920696 437 447 B-Condition
Lichenoides NCT03920696 448 459 I-Condition
according NCT03920696 460 469 O
to NCT03920696 470 472 O
classically NCT03920696 473 484 O
published NCT03920696 485 494 O
semiological NCT03920696 495 507 O
data NCT03920696 508 512 O

- NCT03920696 515 516 O
Missing NCT03920696 518 525 O
or NCT03920696 526 528 O
insufficient NCT03920696 529 541 O
medical NCT03920696 542 549 O
records NCT03920696 550 557 O
for NCT03920696 558 561 O
data NCT03920696 562 566 O
exploitation NCT03920696 567 579 O

For NCT03924427 0 3 O
more NCT03924427 4 8 O
information NCT03924427 9 20 O
regarding NCT03924427 21 30 O
Bristol NCT03924427 31 38 O
- NCT03924427 39 40 O
Myers NCT03924427 41 46 O
Squibb NCT03924427 47 53 O
Clinical NCT03924427 54 62 O
Trial NCT03924427 63 68 O
participation NCT03924427 69 82 O
, NCT03924427 83 84 O
please NCT03924427 85 91 O

visit NCT03924427 92 97 O
www NCT03924427 98 101 O
. NCT03924427 101 102 O
BMSStudyConnect NCT03924427 103 118 O
. NCT03924427 118 119 O
com NCT03924427 120 123 O

Inclusion NCT03924427 124 133 O
Criteria NCT03924427 134 142 O
: NCT03924427 143 144 O

a. NCT03924427 146 148 O
For NCT03924427 150 153 O
participants NCT03924427 154 166 O
with NCT03924427 167 171 O
plaque NCT03924427 172 178 B-Condition
psoriasis NCT03924427 179 188 I-Condition
: NCT03924427 189 190 O
i. NCT03924427 191 193 O
Stable NCT03924427 195 201 O
plaque NCT03924427 202 208 B-Condition
psoriasis NCT03924427 209 218 I-Condition
for NCT03924427 219 222 O
at NCT03924427 223 225 B-Eq-Comparison
least NCT03924427 226 231 I-Eq-Comparison
6 NCT03924427 232 233 I-Eq-Comparison
months NCT03924427 234 240 I-Eq-Comparison

ii NCT03924427 241 243 O
. NCT03924427 243 244 O
Moderate NCT03924427 246 254 B-Eq-Comparison
to NCT03924427 255 257 I-Eq-Comparison
severe NCT03924427 258 264 I-Eq-Comparison
disease NCT03924427 265 272 B-Condition|Coreference
iii NCT03924427 273 276 O
. NCT03924427 276 277 O
Candidate NCT03924427 279 288 B-Indication
for NCT03924427 289 292 O
phototherapy NCT03924427 293 305 B-Procedure
or NCT03924427 306 308 B-Or
systemic NCT03924427 309 317 B-Procedure
therapy NCT03924427 318 325 I-Procedure
b. NCT03924427 326 328 O

Additional NCT03924427 330 340 O
protocol NCT03924427 341 349 O
- NCT03924427 350 351 O
specified NCT03924427 352 361 O
inclusion NCT03924427 362 371 O
criteria NCT03924427 372 380 O
apply NCT03924427 381 386 O
for NCT03924427 387 390 O
subjects NCT03924427 391 399 O
with NCT03924427 400 404 O
psoriatic NCT03924427 405 414 B-Condition
arthritis NCT03924427 415 424 I-Condition
, NCT03924427 425 426 O
erythrodermic NCT03924427 427 440 B-Condition
psoriasis NCT03924427 441 450 I-Condition
, NCT03924427 451 452 O
or NCT03924427 453 455 B-Or
generalized NCT03924427 456 467 B-Condition
pustular NCT03924427 468 476 I-Condition
psoriasis NCT03924427 477 486 I-Condition

Exclusion NCT03924427 487 496 O
Criteria NCT03924427 497 505 O
: NCT03924427 506 507 O

1 NCT03924427 511 512 O
. NCT03924427 512 513 O
Guttate NCT03924427 515 522 B-Modifier
, NCT03924427 523 524 O
inverse NCT03924427 525 532 B-Modifier
, NCT03924427 533 534 O
or NCT03924427 535 537 B-Or
drug NCT03924427 538 542 B-Modifier
- NCT03924427 543 544 I-Modifier
induced NCT03924427 545 552 I-Modifier
psoriasis NCT03924427 553 562 B-Condition
at NCT03924427 563 565 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03924427 566 575 B-Study
or NCT03924427 576 578 B-Or
Baseline NCT03924427 579 587 B-Study

2 NCT03924427 590 591 O
. NCT03924427 591 592 O
History NCT03924427 594 601 B-Eq-Comparison
of NCT03924427 602 604 O
recent NCT03924427 605 611 B-Eq-Comparison
infection NCT03924427 612 621 B-Condition

3 NCT03924427 624 625 O
. NCT03924427 625 626 O
Prior NCT03924427 628 633 B-Eq-Comparison
exposure NCT03924427 634 642 O
to NCT03924427 643 645 O
BMS NCT03924427 646 649 B-Drug
- NCT03924427 650 651 I-Drug
986165 NCT03924427 652 658 I-Drug
Other NCT03924427 659 664 O
protocol NCT03924427 665 673 O
defined NCT03924427 674 681 O
inclusion NCT03924427 682 691 O
/ NCT03924427 692 693 O
exclusion NCT03924427 694 703 O
criteria NCT03924427 704 712 O
could NCT03924427 713 718 O
apply NCT03924427 719 724 O


Inclusion NCT03925077 0 9 O
Criteria NCT03925077 10 18 O
: NCT03925077 19 20 O

1 NCT03925077 24 25 O
. NCT03925077 25 26 O
demonstrate NCT03925077 28 39 O
readiness NCT03925077 40 49 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925077 50 52 O
physical NCT03925077 53 61 B-Observation
activity NCT03925077 62 70 I-Observation
by NCT03925077 71 73 O
completing NCT03925077 74 84 O
the NCT03925077 85 88 O
online NCT03925077 89 95 O
Physical NCT03925077 96 104 B-Observation
Activity NCT03925077 105 113 I-Observation
Readiness NCT03925077 114 123 I-Observation
Questionnaire NCT03925077 124 137 I-Observation
( NCT03925077 138 139 O
PAR NCT03925077 140 143 B-Observation
- NCT03925077 144 145 I-Observation
Q NCT03925077 146 147 I-Observation
) NCT03925077 148 149 O
; NCT03925077 150 151 O

2 NCT03925077 154 155 O
. NCT03925077 155 156 O
have NCT03925077 158 162 O
a NCT03925077 163 164 O
SCI NCT03925077 165 168 B-Condition
resulting NCT03925077 169 178 O
in NCT03925077 179 181 B-Modifier
incomplete NCT03925077 182 192 O
or NCT03925077 193 195 B-Or
complete NCT03925077 196 204 B-Modifier
( NCT03925077 205 206 O
C5 NCT03925077 207 209 B-Eq-Comparison
and NCT03925077 210 213 I-Eq-Comparison
below NCT03925077 214 219 I-Eq-Comparison
) NCT03925077 220 221 O
paraplegia NCT03925077 222 232 B-Condition
or NCT03925077 233 235 B-Or
tetraplegia NCT03925077 236 247 B-Condition
; NCT03925077 247 248 O

3 NCT03925077 251 252 O
. NCT03925077 252 253 O
have NCT03925077 255 259 O
broadband NCT03925077 260 269 O
internet NCT03925077 270 278 O
access NCT03925077 279 285 O
; NCT03925077 285 286 O

4 NCT03925077 289 290 O
. NCT03925077 290 291 O
between NCT03925077 293 300 O
the NCT03925077 301 304 O
ages NCT03925077 305 309 B-Age
of NCT03925077 310 312 O
18 NCT03925077 313 315 B-Eq-Comparison
to NCT03925077 316 318 I-Eq-Comparison
65 NCT03925077 319 321 I-Eq-Comparison
years NCT03925077 322 327 I-Eq-Comparison
; NCT03925077 327 328 O

5 NCT03925077 331 332 O
. NCT03925077 332 333 O
have NCT03925077 335 339 O
the NCT03925077 340 343 O
ability NCT03925077 344 351 O
to NCT03925077 352 354 O
converse NCT03925077 355 363 O
and NCT03925077 364 367 O
read NCT03925077 368 372 O
English NCT03925077 373 380 O
. NCT03925077 380 381 O

Exclusion NCT03925077 383 392 O
Criteria NCT03925077 393 401 O
: NCT03925077 402 403 O

1 NCT03925077 407 408 O
. NCT03925077 408 409 O
significant NCT03925077 411 422 O
visual NCT03925077 423 429 B-Condition
impairment NCT03925077 430 440 I-Condition
that NCT03925077 441 445 O
prevents NCT03925077 446 454 B-Assertion___Assertion-Type-Value:hypothetical|Negation
seeing NCT03925077 455 461 O
a NCT03925077 462 463 O
computer NCT03925077 464 472 O
screen NCT03925077 473 479 O
to NCT03925077 480 482 O
follow NCT03925077 483 489 O
a NCT03925077 490 491 O
home NCT03925077 492 496 B-Procedure
exercise NCT03925077 497 505 I-Procedure
program NCT03925077 506 513 I-Procedure
; NCT03925077 513 514 O

2 NCT03925077 517 518 O
. NCT03925077 518 519 O
active NCT03925077 521 527 B-Eq-Comparison
pressure NCT03925077 528 536 B-Condition
ulcer NCT03925077 537 542 I-Condition
; NCT03925077 542 543 O

3 NCT03925077 546 547 O
. NCT03925077 547 548 O
any NCT03925077 550 553 O
contraindications NCT03925077 554 571 B-Contraindication
to NCT03925077 572 574 O
exercise NCT03925077 575 583 B-Observation
based NCT03925077 584 589 O
on NCT03925077 590 592 O
the NCT03925077 593 596 O
American NCT03925077 597 605 O
College NCT03925077 606 613 O
of NCT03925077 614 616 O
Sports NCT03925077 617 623 O
Medicine NCT03925077 624 632 O
guidelines NCT03925077 633 643 O
; NCT03925077 643 644 O

4 NCT03925077 647 648 O
. NCT03925077 648 649 O
significant NCT03925077 651 662 O
hearing NCT03925077 663 670 B-Condition
impairment NCT03925077 671 681 I-Condition
impeding NCT03925077 682 690 B-Assertion___Assertion-Type-Value:hypothetical|Negation
ability NCT03925077 691 698 B-Condition
to NCT03925077 699 701 I-Condition
hear NCT03925077 702 706 I-Condition
music NCT03925077 707 712 O
to NCT03925077 713 715 O
engage NCT03925077 716 722 B-Observation
in NCT03925077 723 725 I-Observation
exercise NCT03925077 726 734 I-Observation
. NCT03925077 734 735 O

Inclusion NCT03925038 0 9 O
Criteria NCT03925038 10 18 O
: NCT03925038 19 20 O

- NCT03925038 24 25 O
Patients NCT03925038 27 35 O
ages NCT03925038 36 40 B-Age
12 NCT03925038 41 43 B-Eq-Comparison
- NCT03925038 44 45 I-Eq-Comparison
100 NCT03925038 46 49 I-Eq-Comparison
years NCT03925038 50 55 I-Eq-Comparison

- NCT03925038 58 59 O
With NCT03925038 61 65 O
any NCT03925038 66 69 O
diagnosis NCT03925038 70 79 O
of NCT03925038 80 82 O
a NCT03925038 83 84 O
mood NCT03925038 85 89 B-Modifier
or NCT03925038 90 92 B-Or
anxiety NCT03925038 93 100 B-Modifier
disorder NCT03925038 101 109 B-Condition

- NCT03925038 112 113 O
Already NCT03925038 115 122 O
established NCT03925038 123 134 O
and NCT03925038 135 138 O
receiving NCT03925038 139 148 B-Eq-Comparison
care NCT03925038 149 153 B-Encounter
in NCT03925038 154 156 O
community NCT03925038 157 166 O
psychiatry NCT03925038 167 177 B-Provider
at NCT03925038 178 180 O
the NCT03925038 181 184 O
Johns NCT03925038 185 190 O
Hopkins NCT03925038 191 198 O
Bayview NCT03925038 199 206 O
Medical NCT03925038 207 214 O
Center NCT03925038 215 221 O
or NCT03925038 222 224 B-Or
at NCT03925038 225 227 O
Johns NCT03925038 228 233 O
Hopkins NCT03925038 234 241 O
Hospital NCT03925038 242 250 O
. NCT03925038 250 251 O

Exclusion NCT03925038 253 262 O
Criteria NCT03925038 263 271 O
: NCT03925038 272 273 O

- NCT03925038 277 278 O
Non NCT03925038 280 283 B-Negation
- NCT03925038 284 285 O
English NCT03925038 286 293 O
speaking NCT03925038 294 302 O

Inclusion NCT03924440 0 9 O
Criteria NCT03924440 10 18 O
: NCT03924440 19 20 O

1 NCT03924440 24 25 O
. NCT03924440 25 26 O
Female NCT03924440 28 34 O
( NCT03924440 35 36 O
mandatory NCT03924440 37 46 O
) NCT03924440 47 48 O

2 NCT03924440 52 53 O
. NCT03924440 53 54 O
Not NCT03924440 56 59 B-Negation
currently NCT03924440 60 69 B-Eq-Comparison
pregnant NCT03924440 70 78 B-Condition
or NCT03924440 79 81 B-Or
nursing NCT03924440 82 89 B-Condition
( NCT03924440 90 91 O
pregnancy NCT03924440 92 101 B-Condition
affects NCT03924440 102 109 B-Assertion___Assertion-Type-Value:hypothetical
PdG NCT03924440 110 113 B-Observation
levels NCT03924440 114 120 I-Observation
) NCT03924440 121 122 O

3 NCT03924440 126 127 O
. NCT03924440 127 128 O
Aged NCT03924440 130 134 B-Age
18 NCT03924440 135 137 B-Eq-Comparison
- NCT03924440 138 139 I-Eq-Comparison
34 NCT03924440 140 142 O
( NCT03924440 143 144 O
advanced NCT03924440 145 153 O
age NCT03924440 154 157 O
can NCT03924440 158 161 B-Assertion___Assertion-Type-Value:hypothetical
hinder NCT03924440 162 168 O
PdG NCT03924440 169 172 B-Observation
levels NCT03924440 173 179 I-Observation
) NCT03924440 180 181 O

4 NCT03924440 185 186 O
. NCT03924440 186 187 O
Cycle NCT03924440 189 194 B-Observation
length NCT03924440 195 201 I-Observation
of NCT03924440 202 204 O
26 NCT03924440 205 207 B-Eq-Comparison
- NCT03924440 208 209 I-Eq-Comparison
39 NCT03924440 210 212 I-Eq-Comparison
days NCT03924440 213 217 I-Eq-Comparison
( NCT03924440 218 219 O
long NCT03924440 220 224 B-Modifier
or NCT03924440 225 227 B-Or
short NCT03924440 228 233 B-Modifier
cycles NCT03924440 234 240 B-Observation
have NCT03924440 241 245 B-Assertion___Assertion-Type-Value:hypothetical
inconsistent NCT03924440 246 258 O
PdG NCT03924440 259 262 B-Observation
levels NCT03924440 263 269 I-Observation
) NCT03924440 270 271 O

5 NCT03924440 275 276 O
. NCT03924440 276 277 O
Currently NCT03924440 279 288 B-Eq-Comparison
use NCT03924440 289 292 O
other NCT03924440 293 298 O
fertility NCT03924440 299 308 B-Procedure
monitoring NCT03924440 309 319 I-Procedure
tools NCT03924440 320 325 I-Procedure
( NCT03924440 326 327 O
this NCT03924440 328 332 O
allows NCT03924440 333 339 O
us NCT03924440 340 342 O
to NCT03924440 343 345 O
compare NCT03924440 346 353 O
Proov NCT03924440 354 359 O
- NCT03924440 360 361 O
Ovulation NCT03924440 362 371 O
Double NCT03924440 372 378 O
Check NCT03924440 379 384 O
test NCT03924440 385 389 O
results NCT03924440 390 397 O
with NCT03924440 398 402 O
other NCT03924440 403 408 O
fertility NCT03924440 409 418 O
tracking NCT03924440 419 427 O
methods NCT03924440 428 435 O
) NCT03924440 436 437 O

Exclusion NCT03924440 439 448 O
Criteria NCT03924440 449 457 O
: NCT03924440 458 459 O

1 NCT03924440 463 464 O
. NCT03924440 464 465 O
Male NCT03924440 467 471 O

2 NCT03924440 474 475 O
. NCT03924440 475 476 O
Pregnant NCT03924440 478 486 B-Condition

3 NCT03924440 489 490 O
. NCT03924440 490 491 O
Nursing NCT03924440 493 500 B-Condition


Inclusion NCT03922958 0 9 O
Criteria NCT03922958 10 18 O
: NCT03922958 19 20 O

- NCT03922958 24 25 O
All NCT03922958 27 30 O
adults NCT03922958 31 37 O
undergoing NCT03922958 38 48 B-Eq-Comparison
cardiac NCT03922958 49 56 B-Procedure
surgery NCT03922958 57 64 I-Procedure
with NCT03922958 65 69 O
CPB NCT03922958 70 73 B-Procedure
will NCT03922958 74 78 O
be NCT03922958 79 81 O
considered NCT03922958 82 92 O
for NCT03922958 93 96 O
enrollment NCT03922958 97 107 O
. NCT03922958 107 108 O

Exclusion NCT03922958 110 119 O
Criteria NCT03922958 120 128 O
: NCT03922958 129 130 O

- NCT03922958 134 135 O
Factors NCT03922958 137 144 B-Condition
that NCT03922958 145 149 O
affect NCT03922958 150 156 O
immune NCT03922958 157 163 B-Condition
function NCT03922958 164 172 I-Condition
or NCT03922958 173 175 B-Or
AKI NCT03922958 176 179 B-Condition
assessment NCT03922958 180 190 O
are NCT03922958 191 194 O
the NCT03922958 195 198 O
basis NCT03922958 199 204 O
for NCT03922958 205 208 O
exclusion NCT03922958 209 218 O
criteria NCT03922958 219 227 O
: NCT03922958 228 229 O

- NCT03922958 238 239 O
Concurrent NCT03922958 241 251 O
disease NCT03922958 252 259 B-Condition
associated NCT03922958 260 270 O
with NCT03922958 271 275 O
immunosuppression NCT03922958 276 293 B-Condition
including NCT03922958 294 303 O
malignancy NCT03922958 304 314 B-Condition
, NCT03922958 315 316 O
chronic NCT03922958 317 324 B-Condition
infection NCT03922958 325 334 I-Condition
( NCT03922958 335 336 O
e. NCT03922958 337 339 O
g. NCT03922958 340 342 O
, NCT03922958 343 344 O
HIV NCT03922958 345 348 B-Condition
, NCT03922958 349 350 O
Hepatitis NCT03922958 351 360 B-Condition
C NCT03922958 361 362 I-Condition
) NCT03922958 363 364 O
, NCT03922958 366 367 O
organ NCT03922958 368 373 B-Procedure
transplant NCT03922958 374 384 I-Procedure
and NCT03922958 385 388 B-Or
immunosuppressant NCT03922958 389 406 B-Drug
medications NCT03922958 407 418 I-Drug

- NCT03922958 426 427 O
Documented NCT03922958 429 439 O
acute NCT03922958 440 445 B-Condition
infection NCT03922958 446 455 I-Condition
with NCT03922958 456 460 O
the NCT03922958 461 464 B-Eq-Comparison
past NCT03922958 465 469 I-Eq-Comparison
1 NCT03922958 470 471 I-Eq-Comparison
month NCT03922958 472 477 I-Eq-Comparison
( NCT03922958 478 479 O
e. NCT03922958 480 482 O
g. NCT03922958 483 485 O
, NCT03922958 486 487 O
pneumonia NCT03922958 488 497 B-Condition
, NCT03922958 498 499 O
urinary NCT03922958 500 507 B-Condition
tract NCT03922958 508 513 I-Condition
infection NCT03922958 514 523 I-Condition
) NCT03922958 524 525 O

- NCT03922958 534 535 O
Prednisone NCT03922958 537 547 B-Drug
or NCT03922958 548 550 B-Or
other NCT03922958 551 556 O
steroid NCT03922958 557 564 B-Drug
use NCT03922958 565 568 O
currently NCT03922958 569 578 B-Eq-Comparison
or NCT03922958 579 581 B-Or
within NCT03922958 582 588 B-Eq-Comparison
the NCT03922958 589 592 I-Eq-Comparison
past NCT03922958 593 597 I-Eq-Comparison
one NCT03922958 598 601 I-Eq-Comparison
month NCT03922958 602 607 I-Eq-Comparison

- NCT03922958 615 616 O
AKI NCT03922958 618 621 B-Condition
at NCT03922958 622 624 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922958 625 628 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03922958 629 633 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03922958 634 636 O
surgery NCT03922958 637 644 B-Procedure

- NCT03922958 652 653 O
ESRD NCT03922958 655 659 B-Condition
requiring NCT03922958 660 669 B-Assertion___Assertion-Type-Value:hypothetical
renal NCT03922958 670 675 B-Procedure
replacement NCT03922958 676 687 I-Procedure
therapy NCT03922958 688 695 I-Procedure

- NCT03922958 703 704 O
Estimated NCT03922958 706 715 O
GFR NCT03922958 716 719 B-Observation
< NCT03922958 720 721 B-Eq-Comparison
45 NCT03922958 722 724 I-Eq-Comparison
mL NCT03922958 725 727 I-Eq-Comparison
/ NCT03922958 728 729 I-Eq-Comparison
min NCT03922958 730 733 I-Eq-Comparison
( NCT03922958 734 735 O
as NCT03922958 736 738 O
judged NCT03922958 739 745 O
by NCT03922958 746 748 O
the NCT03922958 749 752 O
Chronic NCT03922958 753 760 O
Kidney NCT03922958 761 767 O
Disease NCT03922958 768 775 O
Epidemiology NCT03922958 776 788 O
Collaboration NCT03922958 789 802 O
( NCT03922958 803 804 O
CKD NCT03922958 805 808 O
- NCT03922958 809 810 O
EPI NCT03922958 811 814 O
) NCT03922958 815 816 O
equation NCT03922958 817 825 O

Inclusion NCT03927820 0 9 O
Criteria NCT03927820 10 18 O
: NCT03927820 19 20 O

- NCT03927820 24 25 O
Adult NCT03927820 27 32 O
patient NCT03927820 33 40 O
admitted NCT03927820 41 49 B-Encounter
to NCT03927820 50 52 O
Vanderbilt NCT03927820 53 63 O
University NCT03927820 64 74 O
Medical NCT03927820 75 82 O
Center NCT03927820 83 89 O
( NCT03927820 90 91 O
VUMC NCT03927820 92 96 O
) NCT03927820 97 98 O
( NCT03927820 99 100 O
excluding NCT03927820 101 110 B-Exception
surgery NCT03927820 111 118 B-Provider
services NCT03927820 119 127 I-Provider
) NCT03927820 128 129 O

- NCT03927820 133 134 O
on NCT03927820 136 138 B-Eq-Comparison
a NCT03927820 139 140 O
long NCT03927820 141 145 B-Drug
acting NCT03927820 146 152 I-Drug
inhaler NCT03927820 153 160 I-Drug
or NCT03927820 161 163 B-Or
prescribed NCT03927820 164 174 O
a NCT03927820 175 176 O
long NCT03927820 177 181 B-Drug
acting NCT03927820 182 188 I-Drug
inhaler NCT03927820 189 196 I-Drug
during NCT03927820 197 203 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03927820 204 213 B-Encounter
. NCT03927820 213 214 O

Exclusion NCT03927820 216 225 O
Criteria NCT03927820 226 234 O
: NCT03927820 235 236 O

- NCT03927820 240 241 O
Diagnosis NCT03927820 243 252 O
of NCT03927820 253 255 O
cystic NCT03927820 256 262 B-Condition
fibrosis NCT03927820 263 271 I-Condition

- NCT03927820 274 275 O
Diagnosis NCT03927820 277 286 O
of NCT03927820 287 289 O
graft NCT03927820 290 295 B-Condition
versus NCT03927820 296 302 I-Condition
host NCT03927820 303 307 I-Condition
disease NCT03927820 308 315 I-Condition
( NCT03927820 316 317 O
GVHD NCT03927820 318 322 B-Condition
) NCT03927820 323 324 O

- NCT03927820 328 329 O
no NCT03927820 331 333 B-Negation
medication NCT03927820 334 344 O
insurance NCT03927820 345 354 O

- NCT03927820 357 358 O
discharge NCT03927820 360 369 B-Encounter
to NCT03927820 370 372 O
any NCT03927820 373 376 O
post NCT03927820 377 381 O
- NCT03927820 382 383 O
acute NCT03927820 384 389 O
care NCT03927820 390 394 O
facility NCT03927820 395 403 O
or NCT03927820 404 406 B-Or
inpatient NCT03927820 407 416 O
hospice NCT03927820 417 424 O

- NCT03927820 427 428 O
death NCT03927820 430 435 B-Death
during NCT03927820 436 442 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03927820 443 458 B-Encounter

Cystic NCT03921060 0 6 B-Condition
Fibrosis NCT03921060 7 15 I-Condition
Main NCT03921060 16 20 O
Study NCT03921060 21 26 O
Inclusion NCT03921060 27 36 O
Criteria NCT03921060 37 45 O
: NCT03921060 46 47 O

- NCT03921060 51 52 O
Must NCT03921060 54 58 O
have NCT03921060 59 63 O
CF NCT03921060 64 66 B-Condition
diagnosis NCT03921060 67 76 O
confirmed NCT03921060 77 86 O
by NCT03921060 87 89 O
sweat NCT03921060 90 95 B-Observation
test NCT03921060 96 100 I-Observation
or NCT03921060 101 103 B-Or
genotype NCT03921060 104 112 B-Procedure
analysis NCT03921060 113 121 I-Procedure

- NCT03921060 124 125 O
Subjects NCT03921060 127 135 O
( NCT03921060 136 137 O
and NCT03921060 138 141 O
parents NCT03921060 142 149 O
/ NCT03921060 150 151 O
legal NCT03921060 152 157 O
guardians NCT03921060 158 167 O
as NCT03921060 168 170 O
applicable NCT03921060 171 181 O
) NCT03921060 182 183 O
must NCT03921060 184 188 O
have NCT03921060 189 193 O
the NCT03921060 194 197 O
ability NCT03921060 198 205 O
to NCT03921060 206 208 O
read NCT03921060 209 213 O
and NCT03921060 214 217 O
write NCT03921060 218 223 O
in NCT03921060 224 226 O
English NCT03921060 227 234 O

Sub NCT03921060 235 238 O
- NCT03921060 239 240 O
study NCT03921060 241 246 O
Exclusion NCT03921060 247 256 O
Criteria NCT03921060 257 265 O
: NCT03921060 266 267 O

- NCT03921060 271 272 O
No NCT03921060 274 276 B-Negation
CF NCT03921060 277 279 B-Condition
diagnosis NCT03921060 280 289 O

- NCT03921060 292 293 O
Men NCT03921060 295 298 O
or NCT03921060 299 301 B-Or
women NCT03921060 302 307 O
without NCT03921060 308 315 B-Negation
osteoporosis NCT03921060 316 328 B-Condition

- NCT03921060 331 332 O
Less NCT03921060 334 338 B-Eq-Comparison
than NCT03921060 339 343 I-Eq-Comparison
18 NCT03921060 344 346 I-Eq-Comparison
years NCT03921060 347 352 I-Eq-Comparison
of NCT03921060 353 355 O
age NCT03921060 356 359 B-Age

- NCT03921060 362 363 O
Unwilling NCT03921060 365 374 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921060 375 377 O
return NCT03921060 378 384 O
annually NCT03921060 385 393 O
for NCT03921060 394 397 O
study NCT03921060 398 403 B-Study
visits NCT03921060 404 410 O
for NCT03921060 411 414 O
up NCT03921060 415 417 B-Eq-Comparison
to NCT03921060 418 420 I-Eq-Comparison
5 NCT03921060 421 422 I-Eq-Comparison
years NCT03921060 423 428 I-Eq-Comparison

- NCT03921060 431 432 O
Unwilling NCT03921060 434 443 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03921060 444 447 B-Or
/ NCT03921060 448 449 I-Or
or NCT03921060 450 452 I-Or
medically NCT03921060 453 462 O
unable NCT03921060 463 469 B-Negation
to NCT03921060 470 472 O
take NCT03921060 473 477 O
denosumab NCT03921060 478 487 B-Drug

Inclusion NCT03928093 0 9 O
Criteria NCT03928093 10 18 O
: NCT03928093 19 20 O

- NCT03928093 24 25 O
Age NCT03928093 27 30 B-Age
: NCT03928093 31 32 O
> NCT03928093 33 34 B-Eq-Comparison
8 NCT03928093 35 36 I-Eq-Comparison
- NCT03928093 37 38 I-Eq-Comparison
40 NCT03928093 39 41 I-Eq-Comparison
years NCT03928093 42 47 I-Eq-Comparison
( NCT03928093 48 49 O
we NCT03928093 50 52 O
selected NCT03928093 53 61 O
this NCT03928093 62 66 O
range NCT03928093 67 72 O
due NCT03928093 73 76 O
to NCT03928093 77 79 O
lack NCT03928093 80 84 O
of NCT03928093 85 87 O
data NCT03928093 88 92 O
in NCT03928093 93 95 O
younger NCT03928093 96 103 O
population NCT03928093 104 114 O
and NCT03928093 115 118 O
the NCT03928093 119 122 O
difficulty NCT03928093 123 133 O
in NCT03928093 134 136 O
getting NCT03928093 137 144 O
patient NCT03928093 145 152 O
reported NCT03928093 153 161 O
outcomes NCT03928093 162 170 O
in NCT03928093 171 173 O
younger NCT03928093 174 181 O
patients NCT03928093 182 190 O
) NCT03928093 191 192 O

- NCT03928093 196 197 O
Diagnosis NCT03928093 199 208 O
of NCT03928093 209 211 O
RDEB NCT03928093 212 216 B-Condition
( NCT03928093 217 218 O
by NCT03928093 219 221 O
a NCT03928093 222 223 O
dermatologist NCT03928093 224 237 B-Provider
and NCT03928093 238 241 B-Or
/ NCT03928093 242 243 I-Or
or NCT03928093 244 246 I-Or
EB NCT03928093 247 249 B-Provider
specialist NCT03928093 250 260 I-Provider
and NCT03928093 261 264 B-Or
/ NCT03928093 265 266 I-Or
or NCT03928093 267 269 I-Or
genetic NCT03928093 270 277 B-Procedure
confirmation NCT03928093 278 290 I-Procedure
) NCT03928093 291 292 O

- NCT03928093 296 297 O
Evidence NCT03928093 299 307 O
of NCT03928093 308 310 O
neuropathy NCT03928093 311 321 B-Condition
defined NCT03928093 322 329 O
by NCT03928093 330 332 O
: NCT03928093 333 334 O
thermal NCT03928093 335 342 B-Condition
sensory NCT03928093 343 350 I-Condition
loss NCT03928093 351 355 I-Condition
( NCT03928093 356 357 O
determined NCT03928093 358 368 O
by NCT03928093 369 371 O
a NCT03928093 372 373 O
thermal NCT03928093 374 381 B-Procedure
roller NCT03928093 382 388 I-Procedure
, NCT03928093 389 390 O
ROLLTEMP2 NCT03928093 391 400 O
, NCT03928093 401 402 O
Sometic NCT03928093 403 410 O
, NCT03928093 411 412 O
Sweden NCT03928093 413 419 O
) NCT03928093 420 421 O
14 NCT03928093 422 424 O
and NCT03928093 425 428 O
> NCT03928093 429 430 B-Eq-Comparison
4 NCT03928093 431 432 I-Eq-Comparison
/ NCT03928093 433 434 I-Eq-Comparison
10 NCT03928093 435 437 I-Eq-Comparison
score NCT03928093 438 443 O
using NCT03928093 444 449 B-Eq-Comparison
a NCT03928093 450 451 O
screening NCT03928093 452 461 O
tool NCT03928093 462 466 O
for NCT03928093 467 470 O
neuropathic NCT03928093 471 482 B-Observation
pain NCT03928093 483 487 I-Observation
, NCT03928093 488 489 O
the NCT03928093 490 493 O
DN4 NCT03928093 494 497 O
questionnaire NCT03928093 498 511 O
15 NCT03928093 512 514 O

- NCT03928093 518 519 O
Pain NCT03928093 521 525 B-Observation
intensity NCT03928093 526 535 I-Observation
of NCT03928093 536 538 O
> NCT03928093 539 540 B-Eq-Comparison
4 NCT03928093 541 542 I-Eq-Comparison
/ NCT03928093 543 544 O
10 NCT03928093 545 547 O
on NCT03928093 548 550 O
a NCT03928093 551 552 O
0 NCT03928093 553 554 O
- NCT03928093 555 556 O
10 NCT03928093 557 559 O
VAS NCT03928093 560 563 O
scale NCT03928093 564 569 O
measured NCT03928093 570 578 O
daily NCT03928093 579 584 B-Eq-Comparison
( NCT03928093 585 586 O
reduced NCT03928093 587 594 O
frequency NCT03928093 595 604 O
is NCT03928093 605 607 O
also NCT03928093 608 612 O
acceptable NCT03928093 613 623 O
) NCT03928093 624 625 O
at NCT03928093 626 628 O
night NCT03928093 629 634 O
over NCT03928093 635 639 B-Eq-Comparison
2 NCT03928093 640 641 I-Eq-Comparison
weeks NCT03928093 642 647 I-Eq-Comparison

- NCT03928093 650 651 O
Itch NCT03928093 653 657 B-Observation
intensity NCT03928093 658 667 I-Observation
of NCT03928093 668 670 O
> NCT03928093 671 672 B-Eq-Comparison
4 NCT03928093 673 674 I-Eq-Comparison
/ NCT03928093 675 676 O
10 NCT03928093 677 679 O
on NCT03928093 680 682 O
a NCT03928093 683 684 O
0 NCT03928093 685 686 O
- NCT03928093 687 688 O
10 NCT03928093 689 691 O
VAS NCT03928093 692 695 O
scale NCT03928093 696 701 O
measures NCT03928093 702 710 O
daily NCT03928093 711 716 B-Eq-Comparison
( NCT03928093 717 718 O
reduced NCT03928093 719 726 O
frequency NCT03928093 727 736 O
is NCT03928093 737 739 O
also NCT03928093 740 744 O
acceptable NCT03928093 745 755 O
) NCT03928093 756 757 O
at NCT03928093 758 760 O
night NCT03928093 761 766 O
over NCT03928093 767 771 B-Eq-Comparison
2 NCT03928093 772 773 I-Eq-Comparison
weeks NCT03928093 774 779 I-Eq-Comparison

- NCT03928093 782 783 O
Consent NCT03928093 785 792 O
to NCT03928093 793 795 O
follow NCT03928093 796 802 O
with NCT03928093 803 807 O
study NCT03928093 808 813 O
procedures NCT03928093 814 824 O

Exclusion NCT03928093 825 834 O
Criteria NCT03928093 835 843 O
: NCT03928093 844 845 O

- NCT03928093 849 850 O
Intolerance NCT03928093 852 863 B-Condition
and NCT03928093 864 867 B-Or
/ NCT03928093 868 869 I-Or
or NCT03928093 870 872 B-Or|Or
allergy NCT03928093 873 880 B-Allergy
to NCT03928093 881 883 O
Pregabalin NCT03928093 884 894 B-Drug
or NCT03928093 895 897 O
gabapentin NCT03928093 898 908 B-Drug

- NCT03928093 911 912 O
Lactose NCT03928093 914 921 B-Condition
intolerance NCT03928093 922 933 I-Condition
( NCT03928093 934 935 O
placebo NCT03928093 936 943 O
capsules NCT03928093 944 952 O
contain NCT03928093 953 960 O
lactose NCT03928093 961 968 O
) NCT03928093 969 970 O

- NCT03928093 974 975 O
Pregabalin NCT03928093 977 987 B-Drug
use NCT03928093 988 991 O
within NCT03928093 992 998 B-Eq-Comparison
2 NCT03928093 999 1000 I-Eq-Comparison
weeks NCT03928093 1001 1006 I-Eq-Comparison
before NCT03928093 1007 1013 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928093 1014 1019 B-Study
enrolment NCT03928093 1020 1029 O

- NCT03928093 1032 1033 O
Ongoing NCT03928093 1035 1042 B-Eq-Comparison
treatment NCT03928093 1043 1052 B-Procedure
with NCT03928093 1053 1057 O
gabapentin NCT03928093 1058 1068 B-Drug
, NCT03928093 1069 1070 O
amitriptyline NCT03928093 1071 1084 B-Drug
, NCT03928093 1085 1086 O
duloxetine NCT03928093 1087 1097 B-Drug
, NCT03928093 1098 1099 O
nortriptyline NCT03928093 1100 1113 B-Drug
, NCT03928093 1114 1115 O
other NCT03928093 1116 1121 B-Other
tricyclics NCT03928093 1122 1132 B-Drug
or NCT03928093 1133 1135 B-Or
SNRIs NCT03928093 1136 1141 B-Drug

- NCT03928093 1144 1145 O
Medical NCT03928093 1147 1154 B-Condition
conditions NCT03928093 1155 1165 I-Condition
that NCT03928093 1166 1170 O
would NCT03928093 1171 1176 O
be NCT03928093 1177 1179 O
considered NCT03928093 1180 1190 O
as NCT03928093 1191 1193 O
contraindications NCT03928093 1194 1211 B-Contraindication
for NCT03928093 1212 1215 O
pregabalin NCT03928093 1216 1226 B-Drug
treatment NCT03928093 1227 1236 O
( NCT03928093 1237 1238 O
ischemic NCT03928093 1239 1247 B-Condition
heart NCT03928093 1248 1253 I-Condition
disease NCT03928093 1254 1261 I-Condition
, NCT03928093 1262 1263 O
cardiac NCT03928093 1264 1271 B-Condition
dysrhythmia NCT03928093 1272 1283 I-Condition
, NCT03928093 1284 1285 O
glaucoma NCT03928093 1286 1294 B-Condition
, NCT03928093 1295 1296 O
history NCT03928093 1297 1304 B-Eq-Comparison
of NCT03928093 1305 1307 O
urinary NCT03928093 1308 1315 B-Condition
retention NCT03928093 1316 1325 I-Condition
) NCT03928093 1326 1327 O

- NCT03928093 1331 1332 O
Pregnancy NCT03928093 1334 1343 B-Condition

- NCT03928093 1346 1347 O
History NCT03928093 1349 1356 B-Eq-Comparison
of NCT03928093 1357 1359 O
use NCT03928093 1360 1363 O
of NCT03928093 1364 1366 O
restrictive NCT03928093 1367 1378 B-Condition
substances NCT03928093 1379 1389 I-Condition
or NCT03928093 1390 1392 B-Or
alcohol NCT03928093 1393 1400 B-Condition
abuse NCT03928093 1401 1406 I-Condition

- NCT03928093 1409 1410 O
Allergy NCT03928093 1412 1419 B-Allergy
to NCT03928093 1420 1422 O
gelatin NCT03928093 1423 1430 O

Inclusion NCT03922347 0 9 O
Criteria NCT03922347 10 18 O
: NCT03922347 19 20 O

- NCT03922347 24 25 O
Inclusion NCT03922347 27 36 O
criteria NCT03922347 37 45 O
were NCT03922347 46 50 O
living NCT03922347 51 57 O
in NCT03922347 58 60 O
one NCT03922347 61 64 O
of NCT03922347 65 67 O
the NCT03922347 68 71 O
non NCT03922347 72 75 O
- NCT03922347 76 77 O
institutionalized NCT03922347 78 95 O
urban NCT03922347 96 101 O
or NCT03922347 102 104 B-Or
rural NCT03922347 105 110 O
residential NCT03922347 111 122 O
areas NCT03922347 123 128 O
in NCT03922347 129 131 O
one NCT03922347 132 135 O
of NCT03922347 136 138 O
the NCT03922347 139 142 O
survey NCT03922347 143 149 O
area NCT03922347 150 154 O
, NCT03922347 155 156 O
being NCT03922347 157 162 O
resident NCT03922347 163 171 O
in NCT03922347 172 174 O
the NCT03922347 175 178 O
same NCT03922347 179 183 O
address NCT03922347 184 191 B-Observation
for NCT03922347 192 195 O
at NCT03922347 196 198 B-Eq-Comparison
least NCT03922347 199 204 I-Eq-Comparison
6 NCT03922347 205 206 I-Eq-Comparison
months NCT03922347 207 213 I-Eq-Comparison
during NCT03922347 214 220 O
the NCT03922347 221 224 O
year NCT03922347 225 229 O
before NCT03922347 230 236 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03922347 237 240 O
enrolment NCT03922347 241 250 B-Study
, NCT03922347 251 252 O
age NCT03922347 253 256 B-Age
50 NCT03922347 257 259 B-Eq-Comparison
and NCT03922347 260 263 I-Eq-Comparison
over NCT03922347 264 268 I-Eq-Comparison
and NCT03922347 269 272 B-And
Iranian NCT03922347 273 280 O
nationality NCT03922347 281 292 O
. NCT03922347 292 293 O

Inclusion NCT03920020 0 9 O
Criteria NCT03920020 10 18 O
: NCT03920020 19 20 O

- NCT03920020 24 25 O
Diagnosis NCT03920020 27 36 O
of NCT03920020 37 39 O
primary NCT03920020 40 47 B-Modifier
knee NCT03920020 48 52 I-Modifier
osteoarthritis NCT03920020 53 67 B-Condition
according NCT03920020 68 77 O
to NCT03920020 78 80 O
American NCT03920020 81 89 O
College NCT03920020 90 97 O
of NCT03920020 98 100 O
Radiology NCT03920020 101 110 O

- NCT03920020 113 114 O
Being NCT03920020 116 121 O
radiographically NCT03920020 122 138 B-Condition
K NCT03920020 139 140 B-Eq-Comparison
- NCT03920020 141 142 I-Eq-Comparison
L NCT03920020 143 144 I-Eq-Comparison
grade NCT03920020 145 150 I-Eq-Comparison
2 NCT03920020 151 152 I-Eq-Comparison
- NCT03920020 153 154 I-Eq-Comparison
3 NCT03920020 155 156 I-Eq-Comparison

- NCT03920020 160 161 O
Presence NCT03920020 163 171 O
of NCT03920020 172 174 O
symptoms NCT03920020 175 183 B-Assertion___Assertion-Type-Value:possible|Coreference
for NCT03920020 184 187 O
at NCT03920020 188 190 B-Eq-Comparison
least NCT03920020 191 196 I-Eq-Comparison
3 NCT03920020 197 198 I-Eq-Comparison
months NCT03920020 199 205 I-Eq-Comparison

- NCT03920020 208 209 O
Patients NCT03920020 211 219 O
who NCT03920020 220 223 O
have NCT03920020 224 228 O
been NCT03920020 229 233 O
planned NCT03920020 234 241 B-Eq-Comparison
a NCT03920020 242 243 O
conventional NCT03920020 244 256 O
physiotherapy NCT03920020 257 270 B-Procedure
programme NCT03920020 271 280 O
because NCT03920020 281 288 O
of NCT03920020 289 291 O
knee NCT03920020 292 296 B-Modifier
osteoarthritis NCT03920020 297 311 B-Condition

- NCT03920020 314 315 O
Presence NCT03920020 317 325 O
of NCT03920020 326 328 O
functional NCT03920020 329 339 O
capacity NCT03920020 340 348 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920020 349 352 I-Assertion___Assertion-Type-Value:hypothetical
outpatient NCT03920020 353 363 B-Procedure
physical NCT03920020 364 372 I-Procedure
therapy NCT03920020 373 380 I-Procedure

Exclusion NCT03920020 381 390 O
Criteria NCT03920020 391 399 O
: NCT03920020 400 401 O

- NCT03920020 405 406 O
Patients NCT03920020 408 416 O
with NCT03920020 417 421 O
seconder NCT03920020 422 430 B-Modifier
knee NCT03920020 431 435 I-Modifier
osteoarthritis NCT03920020 436 450 B-Condition

- NCT03920020 453 454 O
History NCT03920020 456 463 B-Eq-Comparison
of NCT03920020 464 466 O
lower NCT03920020 467 472 O
extremity NCT03920020 473 482 B-Modifier
or NCT03920020 483 485 B-Or
spine NCT03920020 486 491 B-Modifier
surgery NCT03920020 492 499 B-Procedure

- NCT03920020 502 503 O
History NCT03920020 505 512 B-Eq-Comparison
of NCT03920020 513 515 O
intraarticular NCT03920020 516 530 B-Procedure
injection NCT03920020 531 540 I-Procedure
in NCT03920020 541 543 O
last NCT03920020 544 548 B-Eq-Comparison
1 NCT03920020 549 550 I-Eq-Comparison
month NCT03920020 551 556 I-Eq-Comparison

- NCT03920020 559 560 O
Patients NCT03920020 562 570 O
with NCT03920020 571 575 O
neurological NCT03920020 576 588 B-Condition
disease NCT03920020 589 596 I-Condition
that NCT03920020 597 601 O
will NCT03920020 602 606 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920020 607 613 O
muscle NCT03920020 614 620 B-Condition
strength NCT03920020 621 629 I-Condition
, NCT03920020 630 631 O
balance NCT03920020 632 639 B-Condition
and NCT03920020 640 643 B-Or
coordination NCT03920020 644 656 B-Condition

Inclusion NCT03925831 0 9 O
Criteria NCT03925831 10 18 O
: NCT03925831 19 20 O

Individuals NCT03925831 22 33 O
died NCT03925831 34 38 B-Death
from NCT03925831 39 43 O
cancer NCT03925831 44 50 B-Condition
between NCT03925831 51 58 B-Eq-Comparison
2008 NCT03925831 59 63 I-Eq-Comparison
and NCT03925831 64 67 I-Eq-Comparison
2017 NCT03925831 68 72 I-Eq-Comparison
. NCT03925831 72 73 O

Exclusion NCT03925831 75 84 O
Criteria NCT03925831 85 93 O
: NCT03925831 94 95 O

- NCT03925831 98 99 O

Inclusion NCT03928938 0 9 O
Criteria NCT03928938 10 18 O
: NCT03928938 19 20 O

1 NCT03928938 24 25 O
. NCT03928938 25 26 O
Signed NCT03928938 28 34 O
informed NCT03928938 35 43 O
consent NCT03928938 44 51 O

2 NCT03928938 54 55 O
. NCT03928938 55 56 O
Advanced NCT03928938 58 66 O
cancers NCT03928938 67 74 B-Condition

3 NCT03928938 77 78 O
. NCT03928938 78 79 O
Immune NCT03928938 81 87 B-Procedure
checkpoint NCT03928938 88 98 I-Procedure
inhibitor NCT03928938 99 108 I-Procedure
therapy NCT03928938 109 116 I-Procedure
initiated NCT03928938 117 126 O
within NCT03928938 127 133 B-Eq-Comparison
+ NCT03928938 134 135 I-Eq-Comparison
/ NCT03928938 137 138 I-Eq-Comparison
- NCT03928938 140 141 I-Eq-Comparison
2 NCT03928938 142 143 I-Eq-Comparison
wks NCT03928938 144 147 O

4 NCT03928938 150 151 O
. NCT03928938 151 152 O
Age NCT03928938 154 157 B-Age
> NCT03928938 158 159 B-Eq-Comparison
18 NCT03928938 160 162 I-Eq-Comparison
y NCT03928938 163 164 O

5 NCT03928938 167 168 O
. NCT03928938 168 169 O
ECOG NCT03928938 171 175 B-Observation
0 NCT03928938 176 177 B-Eq-Comparison
- NCT03928938 178 179 I-Eq-Comparison
3 NCT03928938 180 181 O

6 NCT03928938 185 186 O
. NCT03928938 186 187 O
Patient NCT03928938 189 196 O
compliant NCT03928938 197 206 O
with NCT03928938 207 211 O
the NCT03928938 212 215 O
study NCT03928938 216 221 O
procedures NCT03928938 222 232 O

Exclusion NCT03928938 233 242 O
Criteria NCT03928938 243 251 O
: NCT03928938 252 253 O

1 NCT03928938 257 258 O
. NCT03928938 258 259 O
Immune NCT03928938 261 267 B-Procedure
checkpoint NCT03928938 268 278 I-Procedure
inhibitor NCT03928938 279 288 I-Procedure
therapy NCT03928938 289 296 I-Procedure
initiated NCT03928938 297 306 O
> NCT03928938 307 308 B-Eq-Comparison
2 NCT03928938 309 310 I-Eq-Comparison
wks NCT03928938 311 314 O
ago NCT03928938 315 318 B-Temporal-Connection___Temporal-Connection-Type-Value:before

2 NCT03928938 321 322 O
. NCT03928938 322 323 O
General NCT03928938 325 332 B-Condition
vulnerability NCT03928938 333 346 I-Condition
affecting NCT03928938 347 356 O
the NCT03928938 357 360 O
participation NCT03928938 361 374 O
in NCT03928938 375 377 O
the NCT03928938 378 381 O
trial NCT03928938 382 387 B-Study

3 NCT03928938 390 391 O
. NCT03928938 391 392 O
No NCT03928938 394 396 O
internet NCT03928938 397 405 O
access NCT03928938 406 412 O

Inclusion NCT03925207 0 9 O
Criteria NCT03925207 10 18 O
: NCT03925207 19 20 O

- NCT03925207 24 25 O
Patients NCT03925207 27 35 O
were NCT03925207 36 40 O
included NCT03925207 41 49 O
if NCT03925207 50 52 O
they NCT03925207 53 57 O
underwent NCT03925207 58 67 B-Eq-Comparison
orbital NCT03925207 68 75 B-Procedure
ball NCT03925207 76 80 I-Procedure
implants NCT03925207 81 89 I-Procedure
after NCT03925207 90 95 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enucleation NCT03925207 96 107 B-Procedure
surgery NCT03925207 108 115 I-Procedure
by NCT03925207 116 118 O
one NCT03925207 119 122 O
ophthalmologist NCT03925207 123 138 B-Provider
surgeon NCT03925207 139 146 I-Provider
specializing NCT03925207 147 159 O
in NCT03925207 160 162 O
oculoplastic NCT03925207 163 175 B-Modifier
and NCT03925207 176 179 B-And
orbital NCT03925207 180 187 B-Modifier
surgery NCT03925207 188 195 I-Modifier
at NCT03925207 196 198 O
our NCT03925207 199 202 O
centre NCT03925207 203 209 O
. NCT03925207 209 210 O

Exclusion NCT03925207 212 221 O
Criteria NCT03925207 222 230 O
: NCT03925207 231 232 O

- NCT03925207 236 237 O
Patients NCT03925207 239 247 O
were NCT03925207 248 252 O
excluded NCT03925207 253 261 B-Negation
if NCT03925207 262 264 O
they NCT03925207 265 269 O
underwent NCT03925207 270 279 B-Eq-Comparison
other NCT03925207 280 285 B-Other
concurrent NCT03925207 286 296 O
surgical NCT03925207 297 305 B-Procedure
procedures NCT03925207 306 316 I-Procedure
, NCT03925207 317 318 O
or NCT03925207 319 321 B-Or
were NCT03925207 322 326 O
under NCT03925207 327 332 B-Eq-Comparison
18 NCT03925207 333 335 I-Eq-Comparison
yr NCT03925207 336 338 I-Eq-Comparison
of NCT03925207 339 341 O
age NCT03925207 342 345 B-Age
. NCT03925207 345 346 O

Inclusion NCT03922568 0 9 O
Criteria NCT03922568 10 18 O
: NCT03922568 19 20 O

- NCT03922568 24 25 O
Full NCT03922568 27 31 B-Modifier
Term NCT03922568 32 36 I-Modifier
Delivery NCT03922568 37 45 B-Condition

- NCT03922568 48 49 O
ICSI NCT03922568 51 55 B-Procedure
cases NCT03922568 56 61 O
using NCT03922568 62 67 B-Eq-Comparison
DGC NCT03922568 68 71 B-Procedure
for NCT03922568 72 75 I-Procedure
sperm NCT03922568 76 81 I-Procedure
selection NCT03922568 82 91 I-Procedure

- NCT03922568 94 95 O
ICSI NCT03922568 97 101 B-Procedure
cases NCT03922568 102 107 O
using NCT03922568 108 113 B-Eq-Comparison
MACS NCT03922568 114 118 B-Procedure
for NCT03922568 119 122 I-Procedure
sperm NCT03922568 123 128 I-Procedure
selection NCT03922568 129 138 I-Procedure

- NCT03922568 141 142 O
ICSI NCT03922568 144 148 B-Procedure
cases NCT03922568 149 154 O
using NCT03922568 155 160 B-Eq-Comparison
PICSI NCT03922568 161 166 B-Procedure
dishes NCT03922568 167 173 I-Procedure
for NCT03922568 174 177 I-Procedure
sperm NCT03922568 178 183 I-Procedure
selection NCT03922568 184 193 I-Procedure

- NCT03922568 196 197 O
Fresh NCT03922568 199 204 B-Procedure
blastocyst NCT03922568 205 215 I-Procedure
stage NCT03922568 216 221 I-Procedure
embryo NCT03922568 222 228 I-Procedure
transfer NCT03922568 229 237 I-Procedure
at NCT03922568 238 240 O

- NCT03922568 243 244 O
Fresh NCT03922568 246 251 B-Condition
ejaculate NCT03922568 252 261 I-Condition

Exclusion NCT03922568 262 271 O
Criteria NCT03922568 272 280 O
: NCT03922568 281 282 O

- NCT03922568 286 287 O
Frozen NCT03922568 289 295 B-Procedure
sperm NCT03922568 296 301 I-Procedure

- NCT03922568 304 305 O
Frozen NCT03922568 307 313 B-Procedure
Embryo NCT03922568 314 320 I-Procedure
transfer NCT03922568 321 329 I-Procedure

- NCT03922568 332 333 O
Fresh NCT03922568 335 340 B-Procedure
cleavage NCT03922568 341 349 I-Procedure
stage NCT03922568 350 355 I-Procedure
embryo NCT03922568 356 362 I-Procedure
transfer NCT03922568 363 371 I-Procedure

- NCT03922568 374 375 O
Vanishing NCT03922568 377 386 B-Condition
Twin NCT03922568 387 391 I-Condition
Syndrome NCT03922568 392 400 I-Condition

- NCT03922568 403 404 O
Fetal NCT03922568 406 411 B-Procedure
Reduction NCT03922568 412 421 I-Procedure

- NCT03922568 424 425 O
Preimlantation NCT03922568 427 441 O
genetically NCT03922568 442 453 B-Procedure
screened NCT03922568 454 462 I-Procedure
embryo NCT03922568 463 469 I-Procedure
transfer NCT03922568 470 478 I-Procedure

Inclusion NCT03927404 0 9 O
Criteria NCT03927404 10 18 O
: NCT03927404 19 20 O

- NCT03927404 24 25 O
1 NCT03927404 27 28 O
. NCT03927404 28 29 O
Ages NCT03927404 31 35 B-Age
of NCT03927404 36 38 O
18 NCT03927404 39 41 B-Eq-Comparison
and NCT03927404 42 45 I-Eq-Comparison
above NCT03927404 46 51 I-Eq-Comparison

- NCT03927404 54 55 O
2 NCT03927404 57 58 O
. NCT03927404 58 59 O
Unilateral NCT03927404 61 71 B-Modifier
transtibial NCT03927404 72 83 I-Modifier
or NCT03927404 84 86 B-Or
transfemoral NCT03927404 87 99 B-Modifier
amputee NCT03927404 100 107 B-Condition

- NCT03927404 110 111 O
3 NCT03927404 113 114 O
. NCT03927404 114 115 O
Ambulate NCT03927404 117 125 B-Condition
at NCT03927404 126 128 O
a NCT03927404 129 130 O
K2 NCT03927404 131 133 B-Eq-Comparison
level NCT03927404 134 139 I-Eq-Comparison
or NCT03927404 140 142 I-Eq-Comparison
higher NCT03927404 143 149 I-Eq-Comparison

- NCT03927404 152 153 O
4 NCT03927404 155 156 O
. NCT03927404 156 157 O
At NCT03927404 158 160 B-Eq-Comparison
least NCT03927404 161 166 I-Eq-Comparison
3 NCT03927404 167 168 I-Eq-Comparison
months NCT03927404 169 175 I-Eq-Comparison
post NCT03927404 176 180 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927404 181 182 O
amputation NCT03927404 183 193 B-Procedure
per NCT03927404 194 197 O
physician NCT03927404 198 207 O
discretion NCT03927404 208 218 O

- NCT03927404 221 222 O
5 NCT03927404 224 225 O
. NCT03927404 225 226 O
Residual NCT03927404 227 235 B-Observation
limb NCT03927404 236 240 I-Observation
length NCT03927404 241 247 I-Observation
greater NCT03927404 248 255 B-Eq-Comparison
than NCT03927404 256 260 I-Eq-Comparison
6.5 NCT03927404 261 264 I-Eq-Comparison
inches NCT03927404 265 271 I-Eq-Comparison
in NCT03927404 272 274 O
length NCT03927404 275 281 O

- NCT03927404 284 285 O
6 NCT03927404 287 288 O
. NCT03927404 288 289 O
Able NCT03927404 290 294 O
to NCT03927404 295 297 O
follow NCT03927404 298 304 O
directions NCT03927404 305 315 O
and NCT03927404 316 319 O
give NCT03927404 320 324 O
informed NCT03927404 325 333 O
consent NCT03927404 334 341 O
on NCT03927404 342 344 O
their NCT03927404 345 350 O
own NCT03927404 351 354 O

- NCT03927404 357 358 O
7 NCT03927404 360 361 O
. NCT03927404 361 362 O
Must NCT03927404 363 367 O
be NCT03927404 368 370 O
able NCT03927404 371 375 B-Condition
to NCT03927404 376 378 I-Condition
ambulate NCT03927404 379 387 I-Condition
without NCT03927404 388 395 O
assistance NCT03927404 396 406 O

Exclusion NCT03927404 407 416 O
Criteria NCT03927404 417 425 O
: NCT03927404 426 427 O

- NCT03927404 431 432 O
1 NCT03927404 434 435 O
. NCT03927404 435 436 O
Conditions NCT03927404 438 448 B-Condition
that NCT03927404 449 453 O
prevent NCT03927404 454 461 B-Assertion___Assertion-Type-Value:hypothetical|Negation
wearing NCT03927404 462 469 B-Condition
a NCT03927404 470 471 I-Condition
prosthetic NCT03927404 472 482 I-Condition
socket NCT03927404 483 489 I-Condition

- NCT03927404 492 493 O
2 NCT03927404 495 496 O
. NCT03927404 496 497 O
Cognitive NCT03927404 499 508 B-Condition
deficits NCT03927404 509 517 I-Condition
or NCT03927404 518 520 B-Or
mental NCT03927404 521 527 B-Condition
health NCT03927404 528 534 I-Condition
problems NCT03927404 535 543 I-Condition
that NCT03927404 544 548 O
would NCT03927404 549 554 O
limit NCT03927404 555 560 O
ability NCT03927404 561 568 O
to NCT03927404 569 571 O
consent NCT03927404 572 579 O
and NCT03927404 580 583 O
participate NCT03927404 584 595 O
fully NCT03927404 596 601 O
in NCT03927404 602 604 O
the NCT03927404 605 608 O
study NCT03927404 609 614 O
protocol NCT03927404 615 623 O

- NCT03927404 626 627 O
3 NCT03927404 629 630 O
. NCT03927404 630 631 O
Women NCT03927404 632 637 O
who NCT03927404 638 641 B-And
are NCT03927404 642 645 O
pregnant NCT03927404 646 654 B-Condition
or NCT03927404 655 657 B-Or
who NCT03927404 658 661 O
plan NCT03927404 662 666 B-Assertion___Assertion-Type-Value:intention
to NCT03927404 667 669 I-Assertion___Assertion-Type-Value:intention
become NCT03927404 670 676 O
pregnant NCT03927404 677 685 B-Condition
in NCT03927404 686 688 O
the NCT03927404 689 692 O
near NCT03927404 693 697 B-Eq-Comparison
future NCT03927404 698 704 I-Eq-Comparison

Inclusion NCT03929367 0 9 O
Criteria NCT03929367 10 18 O
: NCT03929367 19 20 O

- NCT03929367 24 25 O
Male NCT03929367 27 31 O
or NCT03929367 32 34 B-Or
female NCT03929367 35 41 O
> NCT03929367 42 43 B-Eq-Comparison
18 NCT03929367 44 46 I-Eq-Comparison
and NCT03929367 47 50 B-And
< NCT03929367 51 52 B-Eq-Comparison
60 NCT03929367 53 55 I-Eq-Comparison
years NCT03929367 56 61 I-Eq-Comparison
of NCT03929367 62 64 O
age NCT03929367 65 68 B-Age
, NCT03929367 69 70 O
Body NCT03929367 71 75 B-Observation
Mass NCT03929367 76 80 I-Observation
Index NCT03929367 81 86 I-Observation
( NCT03929367 87 88 O
BMI NCT03929367 89 92 B-Observation
) NCT03929367 93 94 O
< NCT03929367 95 96 B-Eq-Comparison
40 NCT03929367 97 99 I-Eq-Comparison
. NCT03929367 99 100 O

- NCT03929367 104 105 O
Generally NCT03929367 107 116 O
in NCT03929367 117 119 O
good NCT03929367 120 124 B-Condition
health NCT03929367 125 131 I-Condition
as NCT03929367 132 134 O
determined NCT03929367 135 145 O
by NCT03929367 146 148 O
the NCT03929367 149 152 O
Principal NCT03929367 153 162 O
Investigator NCT03929367 163 175 O
based NCT03929367 176 181 O
on NCT03929367 182 184 O
prior NCT03929367 185 190 O
medical NCT03929367 191 198 O
history NCT03929367 199 206 O
, NCT03929367 207 208 O
American NCT03929367 209 217 B-Condition
Society NCT03929367 218 225 I-Condition
of NCT03929367 226 228 I-Condition
Anesthesiologists NCT03929367 229 246 I-Condition
physical NCT03929367 247 255 O
status NCT03929367 256 262 B-Eq-Comparison
I NCT03929367 263 264 I-Eq-Comparison
or NCT03929367 265 267 I-Eq-Comparison
II NCT03929367 268 270 I-Eq-Comparison

- NCT03929367 273 274 O
Normal NCT03929367 276 282 O
blood NCT03929367 283 288 B-Observation
pressure NCT03929367 289 297 I-Observation
( NCT03929367 298 299 O
systolic NCT03929367 300 308 B-Observation
90 NCT03929367 309 311 B-Eq-Comparison
- NCT03929367 312 313 I-Eq-Comparison
140 NCT03929367 314 317 I-Eq-Comparison
mmHg NCT03929367 318 322 I-Eq-Comparison
; NCT03929367 322 323 O
diastolic NCT03929367 324 333 B-Observation
50 NCT03929367 334 336 B-Eq-Comparison
- NCT03929367 337 338 I-Eq-Comparison
90 NCT03929367 339 341 I-Eq-Comparison
mmHg NCT03929367 342 346 I-Eq-Comparison
) NCT03929367 347 348 O
resting NCT03929367 349 356 B-Observation
heart NCT03929367 357 362 I-Observation
rate NCT03929367 363 367 I-Observation

45 NCT03929367 373 375 B-Eq-Comparison
- NCT03929367 376 377 I-Eq-Comparison
100 NCT03929367 378 381 I-Eq-Comparison
beats NCT03929367 382 387 I-Eq-Comparison
per NCT03929367 388 391 I-Eq-Comparison
minute NCT03929367 392 398 I-Eq-Comparison
) NCT03929367 399 400 O
without NCT03929367 401 408 B-Negation
medication NCT03929367 409 419 B-Drug

- NCT03929367 422 423 O
Female NCT03929367 425 431 O
subjects NCT03929367 432 440 O
of NCT03929367 441 443 O
child NCT03929367 444 449 B-Condition
- NCT03929367 450 451 I-Condition
bearing NCT03929367 452 459 I-Condition
potential NCT03929367 460 469 I-Condition
and NCT03929367 470 473 B-And
those NCT03929367 474 479 O
< NCT03929367 480 481 B-Eq-Comparison
1 NCT03929367 482 483 I-Eq-Comparison
year NCT03929367 484 488 I-Eq-Comparison
post NCT03929367 489 493 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929367 494 495 O
menopausal NCT03929367 496 506 B-Condition
, NCT03929367 507 508 O
must NCT03929367 509 513 O
be NCT03929367 514 516 O
practicing NCT03929367 517 527 B-Eq-Comparison
highly NCT03929367 528 534 O
effective NCT03929367 535 544 O
methods NCT03929367 545 552 O
of NCT03929367 553 555 O
birth NCT03929367 556 561 B-Procedure
control NCT03929367 562 569 I-Procedure
such NCT03929367 570 574 O
as NCT03929367 575 577 O
hormonal NCT03929367 578 586 B-Procedure
methods NCT03929367 587 594 I-Procedure

Exclusion NCT03929367 595 604 O
Criteria NCT03929367 605 613 O
: NCT03929367 614 615 O

- NCT03929367 619 620 O
Hypersensitivity NCT03929367 622 638 B-Condition
, NCT03929367 639 640 O
allergy NCT03929367 641 648 B-Allergy
, NCT03929367 649 650 O
or NCT03929367 651 653 B-Or
significant NCT03929367 654 665 O
reaction NCT03929367 666 674 B-Condition
to NCT03929367 675 677 O
any NCT03929367 678 681 O
ingredient NCT03929367 682 692 O
of NCT03929367 693 695 O
Pitocin NCT03929367 696 703 B-Drug
® NCT03929367 703 704 O

- NCT03929367 707 708 O
Any NCT03929367 710 713 O
disease NCT03929367 714 721 B-Condition
, NCT03929367 722 723 O
diagnosis NCT03929367 724 733 B-Condition
, NCT03929367 734 735 O
or NCT03929367 736 738 B-Or|Or
condition NCT03929367 739 748 B-Condition
( NCT03929367 749 750 O
medical NCT03929367 751 758 B-Modifier
or NCT03929367 759 761 O
surgical NCT03929367 762 770 B-Modifier
) NCT03929367 771 772 O
that NCT03929367 773 777 O
, NCT03929367 778 779 O
in NCT03929367 780 782 O
the NCT03929367 783 786 O
opinion NCT03929367 787 794 O
of NCT03929367 795 797 O
the NCT03929367 798 801 O
Principal NCT03929367 802 811 O
Investigator NCT03929367 812 824 O
, NCT03929367 825 826 O
would NCT03929367 827 832 O
place NCT03929367 833 838 O
the NCT03929367 839 842 O
subject NCT03929367 843 850 O
at NCT03929367 851 853 O
increased NCT03929367 854 863 O
risk NCT03929367 864 868 B-Risk
( NCT03929367 869 870 O
active NCT03929367 871 877 B-Eq-Comparison
gynecologic NCT03929367 878 889 B-Condition
disease NCT03929367 890 897 I-Condition
in NCT03929367 898 900 O
which NCT03929367 901 906 O
increased NCT03929367 907 916 O
tone NCT03929367 917 921 O
would NCT03929367 922 927 O
be NCT03929367 928 930 O
detrimental NCT03929367 931 942 O
e. NCT03929367 943 945 O
g. NCT03929367 946 948 O
, NCT03929367 949 950 O
uterine NCT03929367 951 958 B-Condition
fibroids NCT03929367 959 967 I-Condition
with NCT03929367 968 972 B-And
ongoing NCT03929367 973 980 O
bleeding NCT03929367 981 989 B-Condition
) NCT03929367 990 991 O
, NCT03929367 993 994 O
compromise NCT03929367 995 1005 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03929367 1006 1009 O
subject NCT03929367 1010 1017 O
's NCT03929367 1017 1019 O
compliance NCT03929367 1020 1030 O
with NCT03929367 1031 1035 O
study NCT03929367 1036 1041 B-Study
procedures NCT03929367 1042 1052 O
, NCT03929367 1053 1054 O
or NCT03929367 1055 1057 O
compromise NCT03929367 1058 1068 O
the NCT03929367 1069 1072 O
quality NCT03929367 1073 1080 O
of NCT03929367 1081 1083 O
the NCT03929367 1084 1087 O
data NCT03929367 1088 1092 O

- NCT03929367 1095 1096 O
Women NCT03929367 1098 1103 O
who NCT03929367 1104 1107 B-And
are NCT03929367 1108 1111 O
pregnant NCT03929367 1112 1120 B-Condition
( NCT03929367 1121 1122 O
positive NCT03929367 1123 1131 O
result NCT03929367 1132 1138 O
for NCT03929367 1139 1142 O
serum NCT03929367 1143 1148 B-Observation
pregnancy NCT03929367 1149 1158 I-Observation
test NCT03929367 1159 1163 I-Observation
at NCT03929367 1164 1166 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929367 1167 1176 B-Study
visit NCT03929367 1177 1182 O
) NCT03929367 1183 1184 O
, NCT03929367 1186 1187 O
women NCT03929367 1188 1193 O
who NCT03929367 1194 1197 B-And
are NCT03929367 1198 1201 I-And
currently NCT03929367 1202 1211 B-Eq-Comparison
nursing NCT03929367 1212 1219 B-Condition
or NCT03929367 1220 1222 B-Or
lactating NCT03929367 1223 1232 B-Condition
, NCT03929367 1233 1234 O
women NCT03929367 1235 1240 O
that NCT03929367 1241 1245 B-And
have NCT03929367 1246 1250 B-Eq-Comparison
been NCT03929367 1251 1255 I-Eq-Comparison
pregnant NCT03929367 1256 1264 B-Condition
within NCT03929367 1265 1271 B-Eq-Comparison
2 NCT03929367 1272 1273 I-Eq-Comparison
years NCT03929367 1274 1279 I-Eq-Comparison

- NCT03929367 1282 1283 O
Subjects NCT03929367 1285 1293 O
with NCT03929367 1294 1298 O
neuropathy NCT03929367 1299 1309 B-Condition
, NCT03929367 1310 1311 O
chronic NCT03929367 1312 1319 B-Modifier
pain NCT03929367 1320 1324 B-Condition
, NCT03929367 1325 1326 O
diabetes NCT03929367 1327 1335 B-Condition
mellitus NCT03929367 1336 1344 I-Condition
, NCT03929367 1345 1346 O
or NCT03929367 1347 1349 B-Or|Or
taking NCT03929367 1350 1356 B-Eq-Comparison
benzodiazepines NCT03929367 1357 1372 B-Drug
or NCT03929367 1373 1375 O
pain NCT03929367 1376 1380 B-Drug
medications NCT03929367 1381 1392 I-Drug
on NCT03929367 1393 1395 O
a NCT03929367 1396 1397 O
daily NCT03929367 1398 1403 B-Eq-Comparison
basis NCT03929367 1404 1409 O
. NCT03929367 1409 1410 O

Inclusion NCT03922971 0 9 O
Criteria NCT03922971 10 18 O
: NCT03922971 19 20 O

- NCT03922971 24 25 O
Facilities NCT03922971 27 37 O
that NCT03922971 38 42 O
bill NCT03922971 43 47 O
to NCT03922971 48 50 O
fee NCT03922971 51 54 O
for NCT03922971 55 58 O
service NCT03922971 59 66 O
Medicare NCT03922971 67 75 O
for NCT03922971 76 79 O
gastrointestinal NCT03922971 80 96 B-Procedure
endoscopy NCT03922971 97 106 I-Procedure

Exclusion NCT03922971 107 116 O
Criteria NCT03922971 117 125 O
: NCT03922971 126 127 O

- NCT03922971 130 131 O

Inclusion NCT03920800 0 9 O
Criteria NCT03920800 10 18 O
: NCT03920800 19 20 O

- NCT03920800 24 25 O
Patients NCT03920800 27 35 O
followed NCT03920800 36 44 B-Encounter
within NCT03920800 45 51 O
the NCT03920800 52 55 O
CHU NCT03920800 56 59 O
Brugmann NCT03920800 60 68 O
Hospital NCT03920800 69 77 O
( NCT03920800 78 79 O
no NCT03920800 80 82 B-Negation
private NCT03920800 83 90 O
practices NCT03920800 91 100 O
) NCT03920800 101 102 O
. NCT03920800 103 104 O

- NCT03920800 108 109 O
HSIL NCT03920800 111 115 B-Condition
lesions NCT03920800 116 123 I-Condition
confirmed NCT03920800 124 133 O
by NCT03920800 134 136 O
anatomopathologic NCT03920800 137 154 O
analysis NCT03920800 155 163 O
on NCT03920800 164 166 O
cervical NCT03920800 167 175 B-Procedure
biopsies NCT03920800 176 184 I-Procedure
or NCT03920800 185 187 B-Or
cone NCT03920800 188 192 B-Observation
specimen NCT03920800 193 201 I-Observation
without NCT03920800 202 209 B-Negation
evidence NCT03920800 210 218 O
of NCT03920800 219 221 O
invasive NCT03920800 222 230 B-Condition
lesions NCT03920800 231 238 I-Condition

Exclusion NCT03920800 239 248 O
Criteria NCT03920800 249 257 O
: NCT03920800 258 259 O

- NCT03920800 263 264 O
Invasive NCT03920800 266 274 B-Condition
lesions NCT03920800 275 282 I-Condition

Inclusion NCT03927612 0 9 O
Criteria NCT03927612 10 18 O
: NCT03927612 19 20 O

- NCT03927612 24 25 O
Aged NCT03927612 27 31 B-Age
9 NCT03927612 32 33 B-Eq-Comparison
- NCT03927612 34 35 I-Eq-Comparison
12 NCT03927612 36 38 O

- NCT03927612 42 43 O
English NCT03927612 45 52 O
- NCT03927612 53 54 O
speaking NCT03927612 55 63 O

- NCT03927612 66 67 O
Meet NCT03927612 69 73 O
DSM NCT03927612 74 77 O
- NCT03927612 78 79 O
5 NCT03927612 80 81 O
criteria NCT03927612 82 90 O
for NCT03927612 91 94 O
oppositional NCT03927612 95 107 B-Condition
defiant NCT03927612 108 115 I-Condition
disorder NCT03927612 116 124 I-Condition
( NCT03927612 125 126 O
ODD NCT03927612 127 130 B-Condition
) NCT03927612 131 132 O
, NCT03927612 134 135 O
conduct NCT03927612 136 143 B-Condition
disorder NCT03927612 144 152 I-Condition
( NCT03927612 153 154 O
CD NCT03927612 155 157 B-Condition
) NCT03927612 158 159 O
, NCT03927612 161 162 O
or NCT03927612 163 165 B-Or
Other NCT03927612 166 171 B-Other
Specified NCT03927612 172 181 B-Modifier
or NCT03927612 182 184 B-Or
Unspecified NCT03927612 185 196 B-Modifier
Disruptive NCT03927612 197 207 I-Modifier
, NCT03927612 208 209 O
Impulse NCT03927612 210 217 B-Modifier
- NCT03927612 218 219 I-Modifier
Control NCT03927612 220 227 I-Modifier
, NCT03927612 228 229 O
and NCT03927612 230 233 B-Or
Conduct NCT03927612 234 241 B-Modifier
Disorder NCT03927612 242 250 B-Condition

- NCT03927612 253 254 O
Right NCT03927612 256 261 O
- NCT03927612 262 263 O
handed NCT03927612 264 270 O

- NCT03927612 273 274 I-Observation
Estimated NCT03927612 276 285 O
full NCT03927612 286 290 B-Observation
- NCT03927612 291 292 O
scale NCT03927612 293 298 I-Observation
IQ NCT03927612 299 301 I-Observation
greater NCT03927612 302 309 B-Eq-Comparison
than NCT03927612 310 314 I-Eq-Comparison
75 NCT03927612 315 317 I-Eq-Comparison

Exclusion NCT03927612 319 328 O
Criteria NCT03927612 329 337 O
: NCT03927612 338 339 O

- NCT03927612 343 344 O
Bipolar NCT03927612 346 353 B-Condition
disorder NCT03927612 354 362 I-Condition|Condition
, NCT03927612 363 364 O
any NCT03927612 365 368 O
disorder NCT03927612 369 377 O
involving NCT03927612 378 387 O
psychosis NCT03927612 388 397 B-Condition
, NCT03927612 398 399 O
pervasive NCT03927612 400 409 B-Condition
developmental NCT03927612 410 423 I-Condition
disorders NCT03927612 424 433 I-Condition
, NCT03927612 434 435 O
current NCT03927612 436 443 B-Eq-Comparison
or NCT03927612 444 446 B-Or
past NCT03927612 447 451 B-Eq-Comparison
substance NCT03927612 452 461 B-Condition
use NCT03927612 462 465 I-Condition
disorder NCT03927612 466 474 I-Condition
, NCT03927612 475 476 O
or NCT03927612 477 479 B-Or
current NCT03927612 480 487 B-Eq-Comparison
major NCT03927612 488 493 O
depressive NCT03927612 494 504 B-Condition
disorder NCT03927612 505 513 I-Condition

- NCT03927612 516 517 O
History NCT03927612 519 526 B-Eq-Comparison
of NCT03927612 527 529 O
neurological NCT03927612 530 542 B-Condition
problems NCT03927612 543 551 I-Condition
( NCT03927612 552 553 O
e. NCT03927612 554 556 O
g. NCT03927612 557 559 O
, NCT03927612 560 561 O
epilepsy NCT03927612 562 570 B-Condition
, NCT03927612 571 572 O
traumatic NCT03927612 573 582 B-Condition
brain NCT03927612 583 588 I-Condition
injury NCT03927612 589 595 I-Condition
) NCT03927612 596 597 O

- NCT03927612 601 602 O
Contraindications NCT03927612 604 621 B-Contraindication
for NCT03927612 622 625 O
MRI NCT03927612 626 629 B-Procedure

Inclusion NCT03929159 0 9 O
Criteria NCT03929159 10 18 O
: NCT03929159 19 20 O

- NCT03929159 24 25 O
Electively NCT03929159 27 37 O
scheduled NCT03929159 38 47 B-Eq-Comparison
for NCT03929159 48 51 O
surgical NCT03929159 52 60 B-Procedure
operation NCT03929159 61 70 I-Procedure
that NCT03929159 71 75 O
require NCT03929159 76 83 O
general NCT03929159 84 91 B-Procedure
anesthesia NCT03929159 92 102 I-Procedure
and NCT03929159 103 106 B-And
expected NCT03929159 107 115 B-Assertion___Assertion-Type-Value:hypothetical
duration NCT03929159 116 124 O
of NCT03929159 125 127 O
hospitalization NCT03929159 128 143 B-Encounter
of NCT03929159 144 146 O
longer NCT03929159 147 153 B-Eq-Comparison
than NCT03929159 154 158 I-Eq-Comparison
one NCT03929159 159 162 I-Eq-Comparison
day NCT03929159 163 166 I-Eq-Comparison
( NCT03929159 167 168 O
for NCT03929159 169 172 O
patients NCT03929159 173 181 O
in NCT03929159 182 184 O
Peri NCT03929159 185 189 B-Procedure
- NCT03929159 190 191 O
- NCT03929159 193 194 O
operative NCT03929159 195 204 O
Evaluation NCT03929159 205 215 I-Procedure
& NCT03929159 216 217 I-Procedure
Management NCT03929159 218 228 I-Procedure
[ NCT03929159 229 230 O
POEM NCT03929159 231 235 B-Procedure
] NCT03929159 236 237 O
) NCT03929159 239 240 O
or NCT03929159 241 243 B-Or
high NCT03929159 244 248 O
clinical NCT03929159 249 257 O
suspicion NCT03929159 258 267 B-Assertion___Assertion-Type-Value:possible
of NCT03929159 268 270 O
sepsis NCT03929159 271 277 B-Condition
by NCT03929159 278 280 O
the NCT03929159 281 284 O
emergency NCT03929159 285 294 B-Provider
physician NCT03929159 295 304 I-Provider
( NCT03929159 305 306 O
for NCT03929159 307 310 O
patients NCT03929159 311 319 O
in NCT03929159 320 322 O
emergency NCT03929159 323 332 B-Encounter
center NCT03929159 333 339 I-Encounter
) NCT03929159 340 341 O

- NCT03929159 345 346 O
Ability NCT03929159 348 355 O
to NCT03929159 356 358 O
give NCT03929159 359 363 O
informed NCT03929159 364 372 O
consent NCT03929159 373 380 O
. NCT03929159 380 381 O
If NCT03929159 383 385 O
the NCT03929159 386 389 O
patient NCT03929159 390 397 O
is NCT03929159 398 400 O
incapacitated NCT03929159 401 414 O
and NCT03929159 415 418 O
unable NCT03929159 419 425 O
to NCT03929159 426 428 O
give NCT03929159 429 433 O
informed NCT03929159 434 442 O
consent NCT03929159 443 450 O
, NCT03929159 451 452 O
the NCT03929159 453 456 O
next NCT03929159 457 461 O
- NCT03929159 462 463 O
of NCT03929159 464 466 O
- NCT03929159 467 468 O
kin NCT03929159 469 472 O
or NCT03929159 473 475 O
a NCT03929159 476 477 O
person NCT03929159 478 484 O
who NCT03929159 485 488 O
has NCT03929159 489 492 O
the NCT03929159 493 496 O
power NCT03929159 497 502 O
of NCT03929159 503 505 O
attorney NCT03929159 506 514 O
must NCT03929159 515 519 O
be NCT03929159 520 522 O
present NCT03929159 523 530 O
for NCT03929159 531 534 O
informed NCT03929159 535 543 O
consent NCT03929159 544 551 O
. NCT03929159 551 552 O

- NCT03929159 556 557 O
For NCT03929159 559 562 O
patients NCT03929159 563 571 O
in NCT03929159 572 574 O
the NCT03929159 575 578 O
emergency NCT03929159 579 588 B-Encounter
center NCT03929159 589 595 I-Encounter
only NCT03929159 596 600 O
, NCT03929159 601 602 O
two NCT03929159 603 606 B-Eq-Comparison
or NCT03929159 607 609 I-Eq-Comparison
more NCT03929159 610 614 I-Eq-Comparison
of NCT03929159 615 617 O
the NCT03929159 618 621 B-Criteria-Count
following NCT03929159 622 631 I-Criteria-Count
SIRS NCT03929159 632 636 B-Condition
criteria NCT03929159 637 645 O
: NCT03929159 646 647 O

- NCT03929159 656 657 O
Leukocytes NCT03929159 659 669 B-Observation
> NCT03929159 670 671 B-Eq-Comparison
12 NCT03929159 672 674 I-Eq-Comparison
, NCT03929159 675 676 O
000 NCT03929159 677 680 O
/ NCT03929159 681 682 I-Eq-Comparison|Eq-Comparison
mm^3 NCT03929159 683 687 I-Eq-Comparison|Eq-Comparison
or NCT03929159 688 690 B-Or|Or
< NCT03929159 691 692 B-Eq-Comparison
4 NCT03929159 693 694 I-Eq-Comparison
, NCT03929159 695 696 O
000 NCT03929159 697 700 O
/ NCT03929159 701 702 O
mm^3 NCT03929159 703 707 O
or NCT03929159 708 710 O
> NCT03929159 711 712 B-Eq-Comparison
10 NCT03929159 713 715 I-Eq-Comparison
% NCT03929159 716 717 O
immature NCT03929159 718 726 B-Observation
( NCT03929159 727 728 I-Observation
band NCT03929159 729 733 O
) NCT03929159 734 735 O
forms NCT03929159 736 741 I-Observation
, NCT03929159 742 743 O
provided NCT03929159 744 752 O
that NCT03929159 753 757 O
no NCT03929159 758 760 B-Negation
filgrastim NCT03929159 761 771 B-Drug
or NCT03929159 772 774 B-Or
pegfilgrastim NCT03929159 775 788 B-Drug
was NCT03929159 789 792 O
administered NCT03929159 793 805 B-Eq-Comparison
within NCT03929159 806 812 B-Eq-Comparison
30 NCT03929159 813 815 I-Eq-Comparison
days NCT03929159 816 820 I-Eq-Comparison
and NCT03929159 821 824 B-And
no NCT03929159 825 827 B-Negation
leukemia NCT03929159 828 836 B-Condition

- NCT03929159 844 845 O
Heart NCT03929159 847 852 B-Observation
rate NCT03929159 853 857 I-Observation
> NCT03929159 858 859 B-Eq-Comparison
90 NCT03929159 860 862 I-Eq-Comparison
beats NCT03929159 863 868 I-Eq-Comparison
/ NCT03929159 869 870 I-Eq-Comparison
minute NCT03929159 871 877 I-Eq-Comparison
( NCT03929159 878 879 O
min NCT03929159 880 883 O
) NCT03929159 884 885 O

- NCT03929159 894 895 O
Respiratory NCT03929159 897 908 B-Observation
rate NCT03929159 909 913 I-Observation
> NCT03929159 914 915 B-Eq-Comparison
20 NCT03929159 916 918 I-Eq-Comparison
breaths NCT03929159 919 926 I-Eq-Comparison
/ NCT03929159 927 928 I-Eq-Comparison
min NCT03929159 929 932 I-Eq-Comparison
or NCT03929159 933 935 O
partial NCT03929159 936 943 B-Observation
pressure NCT03929159 944 952 I-Observation
of NCT03929159 953 955 I-Observation
carbon NCT03929159 956 962 I-Observation
dioxide NCT03929159 963 970 I-Observation
( NCT03929159 971 972 O
CO2 NCT03929159 973 976 B-Observation
) NCT03929159 977 978 O
< NCT03929159 979 980 B-Eq-Comparison
32 NCT03929159 981 983 I-Eq-Comparison
mmHg NCT03929159 984 988 I-Eq-Comparison

- NCT03929159 996 997 O
Oral NCT03929159 999 1003 B-Modifier
temperature NCT03929159 1004 1015 B-Observation
> NCT03929159 1016 1017 B-Eq-Comparison
38 NCT03929159 1018 1020 I-Eq-Comparison
degrees NCT03929159 1021 1028 I-Eq-Comparison|Eq-Comparison
Celsius NCT03929159 1029 1036 I-Eq-Comparison|Eq-Comparison
( NCT03929159 1037 1038 O
C NCT03929159 1039 1040 O
) NCT03929159 1041 1042 O
or NCT03929159 1043 1045 B-Or|Or
< NCT03929159 1046 1047 B-Eq-Comparison
36 NCT03929159 1048 1050 I-Eq-Comparison
degrees NCT03929159 1051 1058 I-Eq-Comparison
C NCT03929159 1059 1060 I-Eq-Comparison
or NCT03929159 1061 1063 B-Or
axillary NCT03929159 1064 1072 B-Modifier
temperature NCT03929159 1073 1084 B-Observation
> NCT03929159 1085 1086 B-Eq-Comparison
37 NCT03929159 1087 1089 I-Eq-Comparison
degrees NCT03929159 1090 1097 I-Eq-Comparison
C NCT03929159 1098 1099 I-Eq-Comparison
or NCT03929159 1100 1102 O
< NCT03929159 1103 1104 B-Eq-Comparison
35 NCT03929159 1105 1107 I-Eq-Comparison
degrees NCT03929159 1108 1115 O
C NCT03929159 1116 1117 O

Exclusion NCT03929159 1118 1127 O
Criteria NCT03929159 1128 1136 O
: NCT03929159 1137 1138 O

- NCT03929159 1142 1143 O
Inability NCT03929159 1145 1154 O
to NCT03929159 1155 1157 O
give NCT03929159 1158 1162 O
informed NCT03929159 1163 1171 O
consent NCT03929159 1172 1179 O
or NCT03929159 1180 1182 O
a NCT03929159 1183 1184 O
person NCT03929159 1185 1191 O
who NCT03929159 1192 1195 O
has NCT03929159 1196 1199 O
power NCT03929159 1200 1205 O
of NCT03929159 1206 1208 O
attorney NCT03929159 1209 1217 O
for NCT03929159 1218 1221 O
medical NCT03929159 1222 1229 O
decision NCT03929159 1230 1238 O
is NCT03929159 1239 1241 O
not NCT03929159 1242 1245 O
available NCT03929159 1246 1255 O

- NCT03929159 1258 1259 O
Being NCT03929159 1261 1266 B-Eq-Comparison
moribund NCT03929159 1267 1275 B-Condition
( NCT03929159 1276 1277 O
for NCT03929159 1278 1281 O
patients NCT03929159 1282 1290 O
in NCT03929159 1291 1293 O
emergency NCT03929159 1294 1303 B-Encounter
center NCT03929159 1304 1310 I-Encounter
) NCT03929159 1311 1312 O
or NCT03929159 1313 1315 O
cancellation NCT03929159 1316 1328 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03929159 1329 1331 O
surgery NCT03929159 1332 1339 B-Procedure
( NCT03929159 1340 1341 O
for NCT03929159 1342 1345 O
patients NCT03929159 1346 1354 O
in NCT03929159 1355 1357 O
POEM NCT03929159 1358 1362 B-Procedure
) NCT03929159 1363 1364 O

- NCT03929159 1368 1369 O
Active NCT03929159 1371 1377 B-Eq-Comparison
" NCT03929159 1378 1379 O
Do NCT03929159 1379 1381 B-Observation|Observation
Not NCT03929159 1382 1385 I-Observation|Observation
Resuscitate NCT03929159 1386 1397 I-Observation
" NCT03929159 1397 1398 O
or NCT03929159 1399 1401 B-Or
" NCT03929159 1402 1403 O
Do NCT03929159 1403 1405 O
Not NCT03929159 1406 1409 O
Intubate NCT03929159 1410 1418 I-Observation
" NCT03929159 1418 1419 O
order NCT03929159 1420 1425 O


Inclusion NCT03928535 0 9 O
Criteria NCT03928535 10 18 O
: NCT03928535 19 20 O

- NCT03928535 24 25 O
Clinical NCT03928535 27 35 O
diagnosis NCT03928535 36 45 O
of NCT03928535 46 48 O
AECOPD NCT03928535 49 55 B-Condition

- NCT03928535 58 59 O
Extubation NCT03928535 61 71 B-Procedure
must NCT03928535 72 76 O
be NCT03928535 77 79 O
performed NCT03928535 80 89 O
after NCT03928535 90 95 B-Temporal-Connection___Temporal-Connection-Type-Value:after
48 NCT03928535 96 98 B-Eq-Comparison
hours NCT03928535 99 104 I-Eq-Comparison
of NCT03928535 105 107 O
invasive NCT03928535 108 116 B-Modifier
ventilation NCT03928535 117 128 B-Procedure

- NCT03928535 131 132 O
Must NCT03928535 134 138 O
be NCT03928535 139 141 O
treated NCT03928535 142 149 O
sequentially NCT03928535 150 162 O
with NCT03928535 163 167 O
HFNC NCT03928535 168 172 B-Procedure
or NCT03928535 173 175 B-Or
NIV NCT03928535 176 179 B-Procedure
after NCT03928535 180 185 B-Temporal-Connection___Temporal-Connection-Type-Value:after
extubation NCT03928535 186 196 B-Procedure

- NCT03928535 199 200 O
PaCO2 NCT03928535 202 207 B-Observation
≥ NCT03928535 208 209 B-Eq-Comparison
50 NCT03928535 210 212 I-Eq-Comparison
mmHg NCT03928535 213 217 O
when NCT03928535 218 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
extubation NCT03928535 223 233 B-Procedure

- NCT03928535 236 237 O
Positive NCT03928535 239 247 B-Observation
End NCT03928535 248 251 I-Observation
Expiratory NCT03928535 252 262 I-Observation
Pressure NCT03928535 263 271 I-Observation
( NCT03928535 272 273 O
PEEP NCT03928535 274 278 B-Observation
) NCT03928535 279 280 O
≤ NCT03928535 281 282 B-Eq-Comparison
8 NCT03928535 283 284 I-Eq-Comparison
cmH2O NCT03928535 285 290 O
( NCT03928535 291 292 O
1 NCT03928535 293 294 O
cmH2O NCT03928535 295 300 O
= NCT03928535 301 302 O
0.098 NCT03928535 303 308 O
kPa NCT03928535 309 312 O
) NCT03928535 313 314 O
when NCT03928535 315 319 B-Temporal-Connection___Temporal-Connection-Type-Value:during
extubation NCT03928535 320 330 B-Procedure

Exclusion NCT03928535 331 340 O
Criteria NCT03928535 341 349 O
: NCT03928535 350 351 O

- NCT03928535 355 356 I-Observation
Do NCT03928535 358 360 B-Observation
- NCT03928535 361 362 O
not NCT03928535 363 366 I-Observation
- NCT03928535 367 368 O
intubate NCT03928535 369 377 I-Observation

- NCT03928535 380 381 O
Tracheostomies NCT03928535 383 397 B-Procedure

- NCT03928535 400 401 O
Accidental NCT03928535 403 413 B-Modifier
extubation NCT03928535 414 424 B-Procedure

- NCT03928535 427 428 O
Self NCT03928535 430 434 B-Modifier
- NCT03928535 435 436 O
extubation NCT03928535 437 447 B-Procedure

Inclusion NCT03925987 0 9 O
Criteria NCT03925987 10 18 O
: NCT03925987 19 20 O

1 NCT03925987 24 25 O
. NCT03925987 25 26 O
DSM NCT03925987 28 31 O
- NCT03925987 32 33 O
V NCT03925987 34 35 O
diagnosis NCT03925987 36 45 O
of NCT03925987 46 48 O
an NCT03925987 49 51 O
Anxiety NCT03925987 52 59 B-Condition
disorder NCT03925987 60 68 I-Condition
( NCT03925987 69 70 O
Generalized NCT03925987 71 82 B-Condition
Anxiety NCT03925987 83 90 I-Condition
Disorder NCT03925987 91 99 I-Condition
, NCT03925987 100 101 O
Social NCT03925987 102 108 B-Condition
Anxiety NCT03925987 109 116 I-Condition
Disorder NCT03925987 117 125 I-Condition
, NCT03925987 126 127 O
Panic NCT03925987 128 133 B-Condition
Disorder NCT03925987 134 142 I-Condition
, NCT03925987 143 144 O
Agoraphobia NCT03925987 145 156 B-Condition
) NCT03925987 157 158 O

2 NCT03925987 162 163 O
. NCT03925987 163 164 O
Anxiety NCT03925987 166 173 B-Observation
Sensitivity NCT03925987 174 185 I-Observation
Index NCT03925987 186 191 I-Observation
( NCT03925987 192 193 O
ASI NCT03925987 194 197 B-Observation
- NCT03925987 198 199 I-Observation
3 NCT03925987 200 201 I-Observation
) NCT03925987 202 203 O
total NCT03925987 204 209 B-Eq-Comparison
score NCT03925987 210 215 I-Eq-Comparison
> NCT03925987 216 217 I-Eq-Comparison
29 NCT03925987 218 220 I-Eq-Comparison

3 NCT03925987 224 225 O
. NCT03925987 225 226 O
Overall NCT03925987 228 235 B-Observation
Anxiety NCT03925987 236 243 I-Observation
Severity NCT03925987 244 252 I-Observation
and NCT03925987 253 256 I-Observation
Impairment NCT03925987 257 267 I-Observation
Scale NCT03925987 268 273 I-Observation
( NCT03925987 274 275 O
OASIS NCT03925987 276 281 B-Observation
) NCT03925987 282 283 O
score NCT03925987 284 289 B-Eq-Comparison
> NCT03925987 290 291 I-Eq-Comparison
8 NCT03925987 292 293 I-Eq-Comparison

4 NCT03925987 297 298 O
. NCT03925987 298 299 O
Between NCT03925987 301 308 B-Eq-Comparison
18 NCT03925987 309 311 I-Eq-Comparison
- NCT03925987 312 313 I-Eq-Comparison
55 NCT03925987 314 316 I-Eq-Comparison
years NCT03925987 317 322 I-Eq-Comparison
of NCT03925987 323 325 O
age NCT03925987 326 329 B-Age

5 NCT03925987 332 333 O
. NCT03925987 333 334 O
Subject NCT03925987 336 343 O
must NCT03925987 344 348 O
be NCT03925987 349 351 O
" NCT03925987 352 353 O
treatment NCT03925987 353 362 B-Procedure
- NCT03925987 363 364 O
seeking NCT03925987 365 372 B-Assertion___Assertion-Type-Value:intention
" NCT03925987 372 373 O
and NCT03925987 374 377 B-And
willing NCT03925987 378 385 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925987 386 388 I-Assertion___Assertion-Type-Value:hypothetical
enroll NCT03925987 389 395 O
in NCT03925987 396 398 O
the NCT03925987 399 402 O
10 NCT03925987 403 405 B-Eq-Comparison
- NCT03925987 406 407 I-Eq-Comparison
week NCT03925987 408 412 I-Eq-Comparison
group NCT03925987 413 418 O
- NCT03925987 419 420 O
based NCT03925987 421 426 O
Exposure NCT03925987 427 435 B-Procedure
Therapy NCT03925987 436 443 I-Procedure

Exclusion NCT03925987 444 453 O
Criteria NCT03925987 454 462 O
: NCT03925987 463 464 O

1 NCT03925987 468 469 O
. NCT03925987 469 470 O
Comorbid NCT03925987 472 480 O
Bipolar NCT03925987 481 488 B-Condition
Disorder NCT03925987 489 497 I-Condition
, NCT03925987 498 499 O
Schizophrenia NCT03925987 500 513 B-Condition
, NCT03925987 514 515 O
Anorexia NCT03925987 516 524 B-Condition
or NCT03925987 525 527 B-Or|Or
Bulimia NCT03925987 528 535 B-Condition
Nervosa NCT03925987 536 543 I-Condition
, NCT03925987 544 545 O
or NCT03925987 546 548 O
Obsessive NCT03925987 549 558 B-Condition
- NCT03925987 559 560 I-Condition
Compulsive NCT03925987 561 571 I-Condition
Disorder NCT03925987 572 580 I-Condition|Condition

2 NCT03925987 583 584 O
. NCT03925987 584 585 O
Current NCT03925987 587 594 B-Eq-Comparison
Substance NCT03925987 595 604 B-Condition
Use NCT03925987 605 608 I-Condition
Disorder NCT03925987 609 617 O
> NCT03925987 618 619 B-Eq-Comparison
moderate NCT03925987 620 628 I-Eq-Comparison
( NCT03925987 629 630 O
within NCT03925987 631 637 B-Eq-Comparison
the NCT03925987 638 641 I-Eq-Comparison
past NCT03925987 642 646 I-Eq-Comparison
6 NCT03925987 647 648 I-Eq-Comparison
months NCT03925987 649 655 I-Eq-Comparison
) NCT03925987 656 657 O

3 NCT03925987 661 662 O
. NCT03925987 662 663 O
Currently NCT03925987 665 674 B-Eq-Comparison
taking NCT03925987 675 681 I-Eq-Comparison
a NCT03925987 682 683 O
psychotropic NCT03925987 684 696 B-Drug
medication NCT03925987 697 707 I-Drug

4 NCT03925987 710 711 O
. NCT03925987 711 712 O
Currently NCT03925987 714 723 B-Eq-Comparison
receiving NCT03925987 724 733 I-Eq-Comparison
psychotherapy NCT03925987 734 747 B-Procedure
/ NCT03925987 748 749 B-Or
counseling NCT03925987 750 760 B-Procedure
for NCT03925987 761 764 O
anxiety NCT03925987 765 772 B-Condition

5 NCT03925987 775 776 O
. NCT03925987 776 777 O
Currently NCT03925987 779 788 B-Eq-Comparison
being NCT03925987 789 794 O
treated NCT03925987 795 802 O
as NCT03925987 803 805 O
an NCT03925987 806 808 O
inpatient NCT03925987 809 818 B-Encounter

6 NCT03925987 821 822 O
. NCT03925987 822 823 O
Active NCT03925987 825 831 B-Eq-Comparison
suicidal NCT03925987 832 840 B-Condition
ideation NCT03925987 841 849 I-Condition
with NCT03925987 850 854 O
intent NCT03925987 855 861 B-Modifier
or NCT03925987 862 864 B-Or
plan NCT03925987 865 869 B-Modifier

7 NCT03925987 872 873 O
. NCT03925987 873 874 O
History NCT03925987 876 883 B-Eq-Comparison
of NCT03925987 884 886 O
neurological NCT03925987 887 899 B-Modifier
, NCT03925987 900 901 O
cardiovascular NCT03925987 902 916 B-Modifier
or NCT03925987 917 919 B-Or
respiratory NCT03925987 920 931 B-Modifier
problems NCT03925987 932 940 B-Condition
( NCT03925987 941 942 O
e. NCT03925987 943 945 O
g. NCT03925987 946 948 O
, NCT03925987 949 950 O
asthma NCT03925987 951 957 B-Condition
, NCT03925987 958 959 O
severe NCT03925987 960 966 O
brain NCT03925987 967 972 B-Modifier
injury NCT03925987 973 979 B-Condition
) NCT03925987 980 981 O

Inclusion NCT03928509 0 9 O
criteria NCT03928509 10 18 O
: NCT03928509 19 20 O

- NCT03928509 24 25 O
Participants NCT03928509 27 39 O
will NCT03928509 40 44 O
have NCT03928509 45 49 O
been NCT03928509 50 54 O
previously NCT03928509 55 65 B-Eq-Comparison
joined NCT03928509 66 72 O
for NCT03928509 73 76 O
a NCT03928509 77 78 O
public NCT03928509 79 85 O
health NCT03928509 86 92 O
survey NCT03928509 93 99 O
and NCT03928509 100 103 O
have NCT03928509 104 108 O
agreed NCT03928509 109 115 O
to NCT03928509 116 118 O
be NCT03928509 119 121 O
contacted NCT03928509 122 131 O
again NCT03928509 132 137 O
for NCT03928509 138 141 O
this NCT03928509 142 146 O
study NCT03928509 147 152 B-Study
; NCT03928509 153 154 O

- NCT03928509 157 158 O
Age NCT03928509 160 163 B-Age
: NCT03928509 164 165 O
18 NCT03928509 166 168 B-Eq-Comparison
years NCT03928509 169 174 I-Eq-Comparison
or NCT03928509 175 177 I-Eq-Comparison
over NCT03928509 178 182 I-Eq-Comparison
. NCT03928509 182 183 O

- NCT03928509 187 188 O
Place NCT03928509 190 195 O
of NCT03928509 196 198 O
residence NCT03928509 199 208 O
: NCT03928509 209 210 O
Sherbrooke NCT03928509 211 221 O
, NCT03928509 222 223 O
Moncton NCT03928509 224 231 O
or NCT03928509 232 234 B-Or
Saguenay NCT03928509 235 243 O
- NCT03928509 244 245 O
Lac NCT03928509 246 249 O
- NCT03928509 250 251 O
St NCT03928509 252 254 O
- NCT03928509 255 256 O
Jean NCT03928509 257 261 O
. NCT03928509 261 262 O

Inclusion NCT03924778 0 9 O
Criteria NCT03924778 10 18 O
: NCT03924778 19 20 O

- NCT03924778 24 25 O
female NCT03924778 27 33 O

- NCT03924778 36 37 O
non NCT03924778 39 42 B-Negation
- NCT03924778 43 44 O
Hispanic NCT03924778 45 53 O
, NCT03924778 54 55 O
black NCT03924778 56 61 O
or NCT03924778 62 64 B-Or
white NCT03924778 65 70 O

- NCT03924778 73 74 O
age NCT03924778 76 79 B-Age
19 NCT03924778 80 82 B-Eq-Comparison
- NCT03924778 83 84 I-Eq-Comparison
65 NCT03924778 85 87 I-Eq-Comparison
years NCT03924778 88 93 I-Eq-Comparison

- NCT03924778 96 97 O
BMI NCT03924778 99 102 B-Observation
> NCT03924778 103 104 B-Eq-Comparison
= NCT03924778 106 107 I-Eq-Comparison
30 NCT03924778 108 110 I-Eq-Comparison
kg NCT03924778 111 113 I-Eq-Comparison
/ NCT03924778 114 115 I-Eq-Comparison
m^2 NCT03924778 116 119 I-Eq-Comparison

- NCT03924778 123 124 O
able NCT03924778 126 130 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924778 131 133 I-Assertion___Assertion-Type-Value:hypothetical
visit NCT03924778 134 139 B-Encounter
Bionutrition NCT03924778 140 152 O
Unit NCT03924778 153 157 O
daily NCT03924778 158 163 B-Eq-Comparison

Exclusion NCT03924778 164 173 O
Criteria NCT03924778 174 182 O
: NCT03924778 183 184 O

- NCT03924778 188 189 O
gastrointestinal NCT03924778 191 207 B-Modifier
( NCT03924778 208 209 O
GI NCT03924778 210 212 B-Condition
) NCT03924778 213 214 O
conditions NCT03924778 215 225 B-Condition
i. NCT03924778 226 228 O
e. NCT03924778 229 231 O
, NCT03924778 232 233 O
irritable NCT03924778 234 243 B-Condition
bowel NCT03924778 244 249 I-Condition
, NCT03924778 250 251 O
diverticulitis NCT03924778 252 266 B-Condition
, NCT03924778 267 268 O
peptic NCT03924778 269 275 B-Condition
ulcers NCT03924778 276 282 I-Condition
, NCT03924778 283 284 O
Crohn NCT03924778 285 290 B-Condition
's NCT03924778 290 292 O
, NCT03924778 293 294 O
GI NCT03924778 295 297 B-Modifier
cancers NCT03924778 298 305 B-Condition
, NCT03924778 306 307 O
and NCT03924778 308 311 B-Or
adenatomous NCT03924778 312 323 B-Condition
polyps NCT03924778 324 330 I-Condition

- NCT03924778 333 334 O
antibiotic NCT03924778 336 346 B-Drug
or NCT03924778 347 349 B-Or
probiotic NCT03924778 350 359 B-Drug
use NCT03924778 360 363 O
in NCT03924778 364 366 O
the NCT03924778 367 370 O
previous NCT03924778 371 379 B-Eq-Comparison
90 NCT03924778 380 382 I-Eq-Comparison
days NCT03924778 383 387 I-Eq-Comparison

- NCT03924778 390 391 O
tobacco NCT03924778 393 400 B-Condition
use NCT03924778 401 404 I-Condition

- NCT03924778 407 408 O
heavy NCT03924778 410 415 O
alcohol NCT03924778 416 423 B-Condition
consumption NCT03924778 424 435 I-Condition

- NCT03924778 438 439 O
major NCT03924778 441 446 B-Modifier
medical NCT03924778 447 454 B-Condition
conditions NCT03924778 455 465 I-Condition
( NCT03924778 466 467 O
e. NCT03924778 468 470 O
g. NCT03924778 471 473 O
, NCT03924778 474 475 O
renal NCT03924778 476 481 B-Condition
disease NCT03924778 482 489 I-Condition
, NCT03924778 490 491 O
diabetes NCT03924778 492 500 B-Condition
, NCT03924778 501 502 O
cancer NCT03924778 503 509 B-Condition
) NCT03924778 510 511 O

Inclusion NCT03922321 0 9 O
Criteria NCT03922321 10 18 O
: NCT03922321 19 20 O

1 NCT03922321 24 25 O
. NCT03922321 25 26 O
Male NCT03922321 28 32 O
or NCT03922321 33 35 B-Or
female NCT03922321 36 42 O
≥ NCT03922321 43 44 B-Eq-Comparison
18 NCT03922321 45 47 I-Eq-Comparison
years NCT03922321 48 53 I-Eq-Comparison
of NCT03922321 54 56 O
age NCT03922321 57 60 B-Age
. NCT03922321 60 61 O

2 NCT03922321 65 66 O
. NCT03922321 66 67 O
Clinical NCT03922321 69 77 O
diagnosis NCT03922321 78 87 O
of NCT03922321 88 90 O
Graves NCT03922321 91 97 B-Condition
' NCT03922321 97 98 O
disease NCT03922321 99 106 I-Condition
with NCT03922321 107 111 B-And
hyperthyroidism NCT03922321 112 127 B-Condition
associated NCT03922321 128 138 O
with NCT03922321 139 143 O
active NCT03922321 144 150 B-Eq-Comparison
, NCT03922321 151 152 O
moderate NCT03922321 153 161 O
to NCT03922321 162 164 B-Or
severe NCT03922321 165 171 O
GO NCT03922321 172 174 B-Condition
with NCT03922321 175 179 O
a NCT03922321 180 181 O
Clinical NCT03922321 182 190 B-Observation
Activity NCT03922321 191 199 I-Observation
Score NCT03922321 200 205 I-Observation
( NCT03922321 206 207 O
CAS NCT03922321 208 211 B-Observation
) NCT03922321 212 213 O
≥ NCT03922321 214 215 B-Eq-Comparison
4 NCT03922321 216 217 I-Eq-Comparison
for NCT03922321 218 221 O
the NCT03922321 222 225 O
most NCT03922321 226 230 O
severely NCT03922321 231 239 O
affected NCT03922321 240 248 B-Modifier
eye NCT03922321 249 252 I-Modifier
at NCT03922321 253 255 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 256 265 B-Study
( NCT03922321 266 267 O
on NCT03922321 268 270 O
the NCT03922321 271 274 O
7 NCT03922321 275 276 O
- NCT03922321 277 278 O
item NCT03922321 279 283 O
scale NCT03922321 284 289 O
) NCT03922321 290 291 O
and NCT03922321 292 295 B-And
Baseline NCT03922321 296 304 B-Study
( NCT03922321 305 306 O
on NCT03922321 307 309 O
the NCT03922321 310 313 O
10 NCT03922321 314 316 O
- NCT03922321 317 318 O
item NCT03922321 319 323 O
scale NCT03922321 324 329 O
) NCT03922321 330 331 O
. NCT03922321 332 333 O

3 NCT03922321 337 338 O
. NCT03922321 338 339 O
Onset NCT03922321 341 346 B-Eq-Comparison
of NCT03922321 347 349 O
active NCT03922321 350 356 B-Eq-Comparison
GO NCT03922321 357 359 B-Condition
within NCT03922321 360 366 B-Eq-Comparison
9 NCT03922321 367 368 I-Eq-Comparison
months NCT03922321 369 375 I-Eq-Comparison
of NCT03922321 376 378 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03922321 379 388 B-Study
. NCT03922321 388 389 O

4 NCT03922321 393 394 O
. NCT03922321 394 395 O
Moderate NCT03922321 397 405 O
- NCT03922321 406 407 O
to NCT03922321 408 410 B-Or
- NCT03922321 411 412 O
severe NCT03922321 413 419 O
active NCT03922321 420 426 B-Eq-Comparison
GO NCT03922321 427 429 B-Condition
( NCT03922321 430 431 O
not NCT03922321 432 435 B-Negation
sight NCT03922321 436 441 B-Condition
- NCT03922321 442 443 I-Condition
threatening NCT03922321 444 455 I-Condition
but NCT03922321 456 459 B-And
has NCT03922321 460 463 O
an NCT03922321 464 466 O
appreciable NCT03922321 467 478 O
impact NCT03922321 479 485 O
on NCT03922321 486 488 O
daily NCT03922321 489 494 B-Observation
life NCT03922321 495 499 I-Observation
) NCT03922321 500 501 O
, NCT03922321 503 504 O
usually NCT03922321 505 512 O
associated NCT03922321 513 523 O
with NCT03922321 524 528 O
one NCT03922321 529 532 O
or NCT03922321 533 535 O
more NCT03922321 536 540 O
of NCT03922321 541 543 O
the NCT03922321 544 547 O
following NCT03922321 548 557 B-Condition
: NCT03922321 558 559 O
lid NCT03922321 560 563 B-Observation
retraction NCT03922321 564 574 I-Observation
≥ NCT03922321 575 576 B-Eq-Comparison
2 NCT03922321 577 578 I-Eq-Comparison
mm NCT03922321 579 581 I-Eq-Comparison
, NCT03922321 582 583 O
moderate NCT03922321 584 592 O
or NCT03922321 593 595 B-Or
severe NCT03922321 596 602 O
soft NCT03922321 603 607 B-Condition
tissue NCT03922321 608 614 I-Condition
involvement NCT03922321 615 626 I-Condition
, NCT03922321 627 628 O
proptosis NCT03922321 629 638 B-Observation
≥ NCT03922321 639 640 B-Eq-Comparison
3 NCT03922321 641 642 I-Eq-Comparison
mm NCT03922321 643 645 I-Eq-Comparison
above NCT03922321 646 651 I-Eq-Comparison
normal NCT03922321 652 658 I-Eq-Comparison
for NCT03922321 659 662 O
race NCT03922321 663 667 O
and NCT03922321 668 671 B-Or
gender NCT03922321 672 678 O
, NCT03922321 679 680 O
and NCT03922321 681 684 O
/ NCT03922321 685 686 I-Or
or NCT03922321 687 689 B-Or|Or
inconstant NCT03922321 690 700 B-Modifier
or NCT03922321 701 703 O
constant NCT03922321 704 712 B-Modifier
diplopia NCT03922321 713 721 B-Condition
. NCT03922321 721 722 O

5 NCT03922321 726 727 O
. NCT03922321 727 728 O
Other NCT03922321 730 735 O
, NCT03922321 736 737 O
more NCT03922321 738 742 O
specific NCT03922321 743 751 O
inclusion NCT03922321 752 761 O
criteria NCT03922321 762 770 O
are NCT03922321 771 774 O
defined NCT03922321 775 782 O
in NCT03922321 783 785 O
the NCT03922321 786 789 O
protocol NCT03922321 790 798 O

Exclusion NCT03922321 799 808 O
Criteria NCT03922321 809 817 O
: NCT03922321 818 819 O

1 NCT03922321 823 824 O
. NCT03922321 824 825 O
Use NCT03922321 827 830 O
of NCT03922321 831 833 O
any NCT03922321 834 837 O
steroid NCT03922321 838 845 B-Drug
( NCT03922321 846 847 O
intravenous NCT03922321 848 859 B-Modifier
[ NCT03922321 860 861 O
IV NCT03922321 862 864 B-Modifier
] NCT03922321 865 866 O
or NCT03922321 867 869 B-Modifier|Or
oral NCT03922321 870 874 O
) NCT03922321 875 876 O
with NCT03922321 877 881 O
a NCT03922321 882 883 O
cumulative NCT03922321 884 894 O
dose NCT03922321 895 899 O
equivalent NCT03922321 900 910 O
to NCT03922321 911 913 O
≥ NCT03922321 914 915 B-Eq-Comparison
1 NCT03922321 916 917 I-Eq-Comparison
g NCT03922321 918 919 I-Eq-Comparison
of NCT03922321 920 922 O
methylprednisolone NCT03922321 923 941 B-Drug
for NCT03922321 942 945 O
the NCT03922321 946 949 O
treatment NCT03922321 950 959 O
of NCT03922321 960 962 O
GO NCT03922321 963 965 B-Condition
within NCT03922321 966 972 B-Eq-Comparison
3 NCT03922321 973 974 I-Eq-Comparison
weeks NCT03922321 975 980 I-Eq-Comparison
prior NCT03922321 981 986 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922321 987 989 B-Drug
Screening NCT03922321 990 999 B-Study
. NCT03922321 999 1000 O

2 NCT03922321 1004 1005 O
. NCT03922321 1005 1006 O
Use NCT03922321 1008 1011 O
of NCT03922321 1012 1014 O
rituximab NCT03922321 1015 1024 B-Drug
, NCT03922321 1025 1026 O
tocilizumab NCT03922321 1027 1038 O
, NCT03922321 1039 1040 O
or NCT03922321 1041 1043 B-Or
any NCT03922321 1044 1047 O
monoclonal NCT03922321 1048 1058 B-Drug
antibody NCT03922321 1059 1067 I-Drug
for NCT03922321 1068 1071 O
immunomodulation NCT03922321 1072 1088 B-Condition
within NCT03922321 1089 1095 B-Eq-Comparison
the NCT03922321 1096 1099 I-Eq-Comparison
past NCT03922321 1100 1104 I-Eq-Comparison
9 NCT03922321 1105 1106 I-Eq-Comparison
months NCT03922321 1107 1113 I-Eq-Comparison
prior NCT03922321 1114 1119 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922321 1120 1122 O
Baseline NCT03922321 1123 1131 B-Study
. NCT03922321 1131 1132 O

3 NCT03922321 1136 1137 O
. NCT03922321 1137 1138 O
Total NCT03922321 1140 1145 B-Observation
IgG NCT03922321 1146 1149 I-Observation
level NCT03922321 1150 1155 I-Observation
< NCT03922321 1156 1157 B-Eq-Comparison|Eq-Comparison
6 NCT03922321 1158 1159 I-Eq-Comparison
g NCT03922321 1160 1161 O
/ NCT03922321 1162 1163 I-Eq-Comparison
L NCT03922321 1164 1165 I-Eq-Comparison
at NCT03922321 1166 1168 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1169 1178 B-Study
. NCT03922321 1178 1179 O

4 NCT03922321 1183 1184 O
. NCT03922321 1184 1185 O
Absolute NCT03922321 1187 1195 B-Observation
neutrophil NCT03922321 1196 1206 I-Observation
count NCT03922321 1207 1212 I-Observation
< NCT03922321 1213 1214 O
1500 NCT03922321 1215 1219 I-Eq-Comparison
cells NCT03922321 1220 1225 I-Eq-Comparison
/ NCT03922321 1226 1227 I-Eq-Comparison
mm3 NCT03922321 1228 1231 I-Eq-Comparison
at NCT03922321 1232 1234 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1235 1244 B-Study
. NCT03922321 1244 1245 O

5 NCT03922321 1249 1250 O
. NCT03922321 1250 1251 O
Participants NCT03922321 1253 1265 O
with NCT03922321 1266 1270 O
decreased NCT03922321 1271 1280 O
best NCT03922321 1281 1285 B-Condition
corrected NCT03922321 1286 1295 I-Condition
visual NCT03922321 1296 1302 I-Condition
acuity NCT03922321 1303 1309 I-Condition
due NCT03922321 1310 1313 O
to NCT03922321 1314 1316 O
optic NCT03922321 1317 1322 B-Condition
neuropathy NCT03922321 1323 1333 I-Condition
as NCT03922321 1334 1336 O
defined NCT03922321 1337 1344 O
by NCT03922321 1345 1347 O
a NCT03922321 1348 1349 O
decrease NCT03922321 1350 1358 B-Observation
in NCT03922321 1359 1361 I-Observation
vision NCT03922321 1362 1368 I-Observation
of NCT03922321 1369 1371 O
2 NCT03922321 1372 1373 B-Eq-Comparison
lines NCT03922321 1374 1379 I-Eq-Comparison
on NCT03922321 1380 1382 O
the NCT03922321 1383 1386 O
Snellen NCT03922321 1387 1394 O
chart NCT03922321 1395 1400 O
, NCT03922321 1401 1402 O
new NCT03922321 1403 1406 B-Eq-Comparison
visual NCT03922321 1407 1413 B-Condition
field NCT03922321 1414 1419 I-Condition
defect NCT03922321 1420 1426 I-Condition|Condition
, NCT03922321 1427 1428 O
or NCT03922321 1429 1431 B-Or
color NCT03922321 1432 1437 B-Condition
defect NCT03922321 1438 1444 O
secondary NCT03922321 1445 1454 O
to NCT03922321 1455 1457 O
optic NCT03922321 1458 1463 B-Condition
nerve NCT03922321 1464 1469 I-Condition
involvement NCT03922321 1470 1481 B-Modifier
within NCT03922321 1482 1488 B-Eq-Comparison
the NCT03922321 1489 1492 I-Eq-Comparison
last NCT03922321 1493 1497 I-Eq-Comparison
6 NCT03922321 1498 1499 I-Eq-Comparison
months NCT03922321 1500 1506 I-Eq-Comparison
at NCT03922321 1507 1509 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1510 1519 B-Study
. NCT03922321 1519 1520 O

6 NCT03922321 1524 1525 O
. NCT03922321 1525 1526 O
Previous NCT03922321 1528 1536 B-Eq-Comparison
orbital NCT03922321 1537 1544 B-Or|Procedure
irradiation NCT03922321 1545 1556 I-Procedure
or NCT03922321 1557 1559 O
surgery NCT03922321 1560 1567 B-Procedure
for NCT03922321 1568 1571 O
GO NCT03922321 1572 1574 B-Condition
. NCT03922321 1574 1575 O

7 NCT03922321 1579 1580 O
. NCT03922321 1580 1581 O
Other NCT03922321 1583 1588 O
, NCT03922321 1589 1590 O
more NCT03922321 1591 1595 O
specific NCT03922321 1596 1604 O
exclusion NCT03922321 1605 1614 O
criteria NCT03922321 1615 1623 O
are NCT03922321 1624 1627 O
defined NCT03922321 1628 1635 O
in NCT03922321 1636 1638 O
the NCT03922321 1639 1642 O
protocol NCT03922321 1643 1651 O

Inclusion NCT03926806 0 9 O
Criteria NCT03926806 10 18 O
: NCT03926806 19 20 O

- NCT03926806 24 25 O
BMI NCT03926806 27 30 B-Observation
27 NCT03926806 31 33 B-Eq-Comparison
- NCT03926806 34 35 I-Eq-Comparison
36 NCT03926806 36 38 O

- NCT03926806 42 43 O
HbA1C NCT03926806 45 50 B-Observation
< NCT03926806 51 52 B-Eq-Comparison
8.5 NCT03926806 53 56 I-Eq-Comparison
% NCT03926806 57 58 O

- NCT03926806 61 62 O
Constant NCT03926806 64 72 O
body NCT03926806 73 77 B-Observation
weight NCT03926806 78 84 I-Observation
and NCT03926806 85 88 B-And
dietary NCT03926806 89 96 B-Observation
habits NCT03926806 97 103 I-Observation
for NCT03926806 104 107 O
the NCT03926806 108 111 O
last NCT03926806 112 116 B-Eq-Comparison
3 NCT03926806 117 118 I-Eq-Comparison
months NCT03926806 119 125 I-Eq-Comparison

- NCT03926806 128 129 O
Stable NCT03926806 131 137 O
dose NCT03926806 138 142 O
of NCT03926806 143 145 O
oral NCT03926806 146 150 B-Drug
medication NCT03926806 151 161 I-Drug
for NCT03926806 162 165 O
at NCT03926806 166 168 B-Eq-Comparison
least NCT03926806 169 174 I-Eq-Comparison
3 NCT03926806 175 176 I-Eq-Comparison
months NCT03926806 177 183 I-Eq-Comparison

- NCT03926806 186 187 O
Diagnosed NCT03926806 189 198 O
with NCT03926806 199 203 O
T2DM NCT03926806 204 208 B-Condition
for NCT03926806 209 212 O
more NCT03926806 213 217 B-Eq-Comparison
than NCT03926806 218 222 I-Eq-Comparison
1 NCT03926806 223 224 I-Eq-Comparison
year NCT03926806 225 229 I-Eq-Comparison

Exclusion NCT03926806 230 239 O
Criteria NCT03926806 240 248 O
: NCT03926806 249 250 O

- NCT03926806 254 255 O
History NCT03926806 257 264 B-Eq-Comparison
of NCT03926806 265 267 O
cardiovascular NCT03926806 268 282 B-Modifier
, NCT03926806 283 284 O
gastrointestinal NCT03926806 285 301 B-Modifier
, NCT03926806 302 303 O
renal NCT03926806 304 309 B-Modifier
and NCT03926806 310 313 B-And
endocrinological NCT03926806 314 330 B-Modifier
diseases NCT03926806 331 339 B-Condition

- NCT03926806 342 343 O
Treatment NCT03926806 345 354 O
for NCT03926806 355 358 O
weight NCT03926806 359 365 B-Condition
reduction NCT03926806 366 375 I-Condition

- NCT03926806 378 379 O
Lactose NCT03926806 381 388 B-Condition
intolerance NCT03926806 389 400 I-Condition

- NCT03926806 403 404 O
Allergies NCT03926806 406 415 B-Allergy
to NCT03926806 416 418 B-Procedure
milk NCT03926806 419 423 O
and NCT03926806 424 427 B-Or
dairy NCT03926806 428 433 O
products NCT03926806 434 442 O

- NCT03926806 445 446 O
Alcohol NCT03926806 448 455 B-Observation
consumption NCT03926806 456 467 I-Observation
( NCT03926806 468 469 O
> NCT03926806 471 472 B-Eq-Comparison
2 NCT03926806 473 474 I-Eq-Comparison
drinks NCT03926806 475 481 I-Eq-Comparison
per NCT03926806 482 485 I-Eq-Comparison
day NCT03926806 486 489 I-Eq-Comparison
) NCT03926806 490 491 O

- NCT03926806 495 496 O
Intake NCT03926806 498 504 O
of NCT03926806 505 507 O
supplements NCT03926806 508 519 B-Drug

- NCT03926806 522 523 O
Receiving NCT03926806 525 534 B-Eq-Comparison
insulin NCT03926806 535 542 B-Drug

Inclusion NCT03921827 0 9 O
Criteria NCT03921827 10 18 O
: NCT03921827 19 20 O

1 NCT03921827 24 25 O
. NCT03921827 25 26 O
Patients NCT03921827 28 36 O
with NCT03921827 37 41 O
recent NCT03921827 42 48 B-Eq-Comparison
stroke NCT03921827 49 55 B-Condition
/ NCT03921827 56 57 B-Or
TIA NCT03921827 58 61 B-Condition
and NCT03921827 62 65 O
severe NCT03921827 66 72 O
stenosis NCT03921827 73 81 B-Condition
of NCT03921827 82 84 I-Condition
intracranial NCT03921827 85 97 I-Condition
ICA NCT03921827 98 101 B-Modifier
or NCT03921827 102 104 B-Or
MCA NCT03921827 105 108 B-Modifier
and NCT03921827 109 112 B-And
impaired NCT03921827 113 121 B-Condition
CVR NCT03921827 122 125 I-Condition
within NCT03921827 126 132 B-Eq-Comparison
previous NCT03921827 133 141 I-Eq-Comparison
three NCT03921827 142 147 I-Eq-Comparison
months NCT03921827 148 154 I-Eq-Comparison
but NCT03921827 155 158 B-And
not NCT03921827 159 162 B-Negation
before NCT03921827 163 169 B-Temporal-Connection___Temporal-Connection-Type-Value:before
3 NCT03921827 170 171 B-Eq-Comparison
weeks NCT03921827 172 177 I-Eq-Comparison
after NCT03921827 178 183 B-Temporal-Connection___Temporal-Connection-Type-Value:after
acute NCT03921827 184 189 O
stroke NCT03921827 190 196 B-Condition
. NCT03921827 196 197 O
This NCT03921827 199 203 O
is NCT03921827 204 206 O
to NCT03921827 207 209 O
differentiate NCT03921827 210 223 O
between NCT03921827 224 231 O
patients NCT03921827 232 240 O
with NCT03921827 241 245 O
a NCT03921827 246 247 O
long NCT03921827 248 252 B-Condition
- NCT03921827 253 254 I-Condition
standing NCT03921827 255 263 I-Condition
fixed NCT03921827 264 269 I-Condition
- NCT03921827 270 271 I-Condition
stenosis NCT03921827 272 280 I-Condition
from NCT03921827 281 285 O
patients NCT03921827 286 294 O
with NCT03921827 295 299 O
partially NCT03921827 300 309 B-Condition
recanalized NCT03921827 310 321 I-Condition
intracranial NCT03921827 322 334 I-Condition
artery NCT03921827 335 341 I-Condition
( NCT03921827 342 343 O
masquerading NCT03921827 344 356 O
as NCT03921827 357 359 O
severe NCT03921827 360 366 O
stenosis NCT03921827 367 375 B-Condition
) NCT03921827 376 377 O
. NCT03921827 378 379 O

2 NCT03921827 383 384 O
. NCT03921827 384 385 O
Age NCT03921827 387 390 B-Age
> NCT03921827 391 392 B-Eq-Comparison
21 NCT03921827 393 395 I-Eq-Comparison
years NCT03921827 396 401 I-Eq-Comparison

Exclusion NCT03921827 402 411 O
Criteria NCT03921827 412 420 O
: NCT03921827 421 422 O

1 NCT03921827 426 427 O
. NCT03921827 427 428 O
Patients NCT03921827 430 438 O
with NCT03921827 439 443 O
atrial NCT03921827 444 450 B-Condition
fibrillation NCT03921827 451 463 I-Condition
/ NCT03921827 464 465 B-Or
arrhythmias NCT03921827 466 477 B-Condition
. NCT03921827 477 478 O

2 NCT03921827 482 483 I-Eq-Comparison
. NCT03921827 483 484 O
Within NCT03921827 486 492 B-Eq-Comparison
2 NCT03921827 493 494 O
weeks NCT03921827 495 500 I-Eq-Comparison
of NCT03921827 501 503 O
cardiac NCT03921827 504 511 B-Procedure
catheterization NCT03921827 512 527 I-Procedure
or NCT03921827 528 530 B-Or
arterial NCT03921827 531 539 B-Procedure
puncture NCT03921827 540 548 I-Modifier|Procedure
at NCT03921827 549 551 O
femoral NCT03921827 552 559 B-Modifier
puncture NCT03921827 560 568 O
site NCT03921827 569 573 I-Modifier
. NCT03921827 573 574 O

3 NCT03921827 578 579 O
. NCT03921827 579 580 O
Decompensated NCT03921827 582 595 B-Modifier
heart NCT03921827 596 601 B-Condition
failure NCT03921827 602 609 I-Condition
, NCT03921827 610 611 O
usually NCT03921827 612 619 O
class NCT03921827 620 625 O
3 NCT03921827 626 627 B-Eq-Comparison
or NCT03921827 628 630 I-Eq-Comparison
4 NCT03921827 631 632 I-Eq-Comparison

4 NCT03921827 636 637 O
. NCT03921827 637 638 O
LV NCT03921827 640 642 B-Observation
EF NCT03921827 643 645 I-Observation
< NCT03921827 646 647 B-Eq-Comparison
30 NCT03921827 648 650 I-Eq-Comparison
% NCT03921827 651 652 O

5 NCT03921827 655 656 O
. NCT03921827 656 657 O
Moderate NCT03921827 659 667 O
or NCT03921827 668 670 B-Or
severe NCT03921827 671 677 O
AR NCT03921827 678 680 B-Condition

6 NCT03921827 683 684 O
. NCT03921827 684 685 O
Persistent NCT03921827 687 697 O
and NCT03921827 698 701 B-Or
uncontrolled NCT03921827 702 714 B-Modifier
hypertension NCT03921827 715 727 B-Condition
( NCT03921827 728 729 O
BP NCT03921827 730 732 B-Observation
persistently NCT03921827 733 745 O
> NCT03921827 746 747 B-Eq-Comparison
160 NCT03921827 748 751 I-Eq-Comparison
/ NCT03921827 752 753 I-Eq-Comparison
100 NCT03921827 754 757 I-Eq-Comparison
mmHg NCT03921827 758 762 I-Eq-Comparison
) NCT03921827 763 764 O

7 NCT03921827 768 769 O
. NCT03921827 769 770 O
Bleeding NCT03921827 772 780 B-Condition
diathesis NCT03921827 781 790 I-Condition

8 NCT03921827 793 794 O
. NCT03921827 794 795 O
Active NCT03921827 797 803 B-Eq-Comparison
thrombophlebitis NCT03921827 804 820 B-Condition
/ NCT03921827 821 822 B-Or
venous NCT03921827 823 829 B-Condition
disease NCT03921827 830 837 I-Condition
of NCT03921827 838 840 O
lower NCT03921827 841 846 B-Modifier|Modifier
limbs NCT03921827 847 852 I-Modifier

9 NCT03921827 855 856 O
. NCT03921827 856 857 O
Severe NCT03921827 859 865 O
lower NCT03921827 866 871 O
extremity NCT03921827 872 881 I-Modifier
vaso NCT03921827 882 886 B-Condition
- NCT03921827 887 888 I-Condition
occlusive NCT03921827 889 898 I-Condition
disease NCT03921827 899 906 I-Condition

10 NCT03921827 908 910 O
. NCT03921827 910 911 O
Presence NCT03921827 913 921 O
of NCT03921827 922 924 O
a NCT03921827 925 926 O
documented NCT03921827 927 937 O
aortic NCT03921827 938 944 B-Condition
aneurysm NCT03921827 945 953 I-Condition
/ NCT03921827 954 955 B-Or
dissection NCT03921827 956 966 B-Procedure
requiring NCT03921827 967 976 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03921827 977 985 B-Procedure
repair NCT03921827 986 992 I-Procedure

11 NCT03921827 994 996 O
. NCT03921827 996 997 O
Pregnancy NCT03921827 999 1008 B-Condition

Inclusion NCT03920293 0 9 O
Criteria NCT03920293 10 18 O
: NCT03920293 19 20 O

1 NCT03920293 24 25 O
. NCT03920293 25 26 O
Diagnosed NCT03920293 28 37 O
with NCT03920293 38 42 O
Myasthenia NCT03920293 43 53 B-Condition
Gravis NCT03920293 54 60 I-Condition
at NCT03920293 61 63 B-Eq-Comparison
least NCT03920293 64 69 I-Eq-Comparison
6 NCT03920293 70 71 I-Eq-Comparison
months NCT03920293 72 78 I-Eq-Comparison
( NCT03920293 79 80 O
180 NCT03920293 81 84 B-Eq-Comparison
days NCT03920293 85 89 I-Eq-Comparison
) NCT03920293 90 91 O
prior NCT03920293 92 97 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 98 100 O
the NCT03920293 101 104 O
date NCT03920293 105 109 O
of NCT03920293 110 112 O
the NCT03920293 113 116 O
Screening NCT03920293 117 126 B-Study
Visit NCT03920293 127 132 O
as NCT03920293 133 135 O
confirmed NCT03920293 136 145 O
by NCT03920293 146 148 O
specific NCT03920293 149 157 O
criteria NCT03920293 158 166 O
. NCT03920293 166 167 O

2 NCT03920293 171 172 O
. NCT03920293 172 173 O
Myasthenia NCT03920293 175 185 B-Condition
Gravis NCT03920293 186 192 I-Condition
Foundation NCT03920293 193 203 I-Condition
of NCT03920293 204 206 I-Condition
America NCT03920293 207 214 I-Condition
Clinical NCT03920293 215 223 I-Condition
Classification NCT03920293 224 238 I-Condition
Class NCT03920293 239 244 B-Eq-Comparison
II NCT03920293 245 247 I-Eq-Comparison
to NCT03920293 248 250 I-Eq-Comparison
IV NCT03920293 251 253 I-Eq-Comparison
at NCT03920293 254 256 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920293 257 266 B-Study
. NCT03920293 266 267 O

3 NCT03920293 271 272 O
. NCT03920293 272 273 O
MG NCT03920293 275 277 B-Observation
- NCT03920293 278 279 I-Observation
ADL NCT03920293 280 283 I-Observation
profile NCT03920293 284 291 O
must NCT03920293 292 296 O
be NCT03920293 297 299 O
≥ NCT03920293 300 301 B-Eq-Comparison
6 NCT03920293 302 303 I-Eq-Comparison
at NCT03920293 304 306 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920293 307 316 B-Study
and NCT03920293 317 320 O
randomization NCT03920293 321 334 O
( NCT03920293 335 336 O
Day NCT03920293 337 340 O
1 NCT03920293 341 342 O
) NCT03920293 343 344 O
. NCT03920293 345 346 O

4 NCT03920293 350 351 O
. NCT03920293 351 352 O
Vaccinated NCT03920293 354 364 B-Immunization
against NCT03920293 365 372 O
meningococcal NCT03920293 373 386 B-Condition
infections NCT03920293 387 397 I-Condition
within NCT03920293 398 404 B-Eq-Comparison
3 NCT03920293 405 406 I-Eq-Comparison
years NCT03920293 407 412 I-Eq-Comparison
prior NCT03920293 413 418 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 419 421 I-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03920293 422 423 O
or NCT03920293 424 426 B-Or
at NCT03920293 427 429 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920293 430 433 O
time NCT03920293 434 438 O
of NCT03920293 439 441 O
, NCT03920293 442 443 O
initiating NCT03920293 444 454 O
study NCT03920293 455 460 B-Study
drug NCT03920293 461 465 B-Drug
to NCT03920293 466 468 O
reduce NCT03920293 469 475 O
the NCT03920293 476 479 O
risk NCT03920293 480 484 B-Risk
of NCT03920293 485 487 O
meningococcal NCT03920293 488 501 B-Modifier
infection NCT03920293 502 511 B-Condition
( NCT03920293 512 513 O
N NCT03920293 514 515 B-Organism
meningitidis NCT03920293 516 528 I-Organism
) NCT03920293 529 530 O
. NCT03920293 531 532 O

Exclusion NCT03920293 534 543 O
Criteria NCT03920293 544 552 O
: NCT03920293 553 554 O

Medical NCT03920293 556 563 B-Condition
Conditions NCT03920293 564 574 I-Condition

1 NCT03920293 577 578 O
. NCT03920293 578 579 O
Any NCT03920293 581 584 O
active NCT03920293 585 591 B-Eq-Comparison
or NCT03920293 592 594 B-Or
untreated NCT03920293 595 604 B-Modifier
thymoma NCT03920293 605 612 B-Condition
. NCT03920293 612 613 O
History NCT03920293 615 622 B-Eq-Comparison
of NCT03920293 623 625 O
thymic NCT03920293 626 632 B-Condition|Condition
carcinoma NCT03920293 633 642 I-Condition
or NCT03920293 643 645 B-Or
thymic NCT03920293 646 652 O
malignancy NCT03920293 653 663 I-Condition
unless NCT03920293 664 670 B-Exception
deemed NCT03920293 671 677 O
cured NCT03920293 678 683 O
by NCT03920293 684 686 O
adequate NCT03920293 687 695 O
treatment NCT03920293 696 705 B-Procedure
with NCT03920293 706 710 B-And
no NCT03920293 711 713 B-Negation
evidence NCT03920293 714 722 O
of NCT03920293 723 725 O
recurrence NCT03920293 726 736 B-Coreference
for NCT03920293 737 740 O
≥ NCT03920293 741 742 B-Eq-Comparison
5 NCT03920293 743 744 I-Eq-Comparison
years NCT03920293 745 750 I-Eq-Comparison
before NCT03920293 751 757 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03920293 758 767 B-Study
. NCT03920293 767 768 O

2 NCT03920293 772 773 O
. NCT03920293 773 774 O
History NCT03920293 776 783 B-Eq-Comparison
of NCT03920293 784 786 O
thymectomy NCT03920293 787 797 B-Procedure
within NCT03920293 798 804 B-Eq-Comparison
the NCT03920293 805 808 I-Eq-Comparison
12 NCT03920293 809 811 I-Eq-Comparison
months NCT03920293 812 818 I-Eq-Comparison
prior NCT03920293 819 824 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 825 827 O
screening NCT03920293 828 837 B-Study
. NCT03920293 837 838 O

3 NCT03920293 842 843 O
. NCT03920293 843 844 O
History NCT03920293 846 853 B-Eq-Comparison
of NCT03920293 854 856 O
N NCT03920293 857 858 B-Organism
meningitidis NCT03920293 859 871 I-Organism
infection NCT03920293 872 881 B-Condition
. NCT03920293 881 882 O

4 NCT03920293 886 887 O
. NCT03920293 887 888 O
Use NCT03920293 890 893 O
of NCT03920293 894 896 O
the NCT03920293 897 900 O
following NCT03920293 901 910 O
within NCT03920293 911 917 O
the NCT03920293 918 921 O
time NCT03920293 922 926 O
period NCT03920293 927 933 O
specified NCT03920293 934 943 O
below NCT03920293 944 949 O
: NCT03920293 950 951 O

- NCT03920293 960 961 O
IV NCT03920293 963 965 B-Drug
immunoglobulin NCT03920293 966 980 I-Drug
within NCT03920293 981 987 B-Eq-Comparison
4 NCT03920293 988 989 I-Eq-Comparison
weeks NCT03920293 990 995 I-Eq-Comparison
of NCT03920293 996 998 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03920293 999 1012 B-Study

- NCT03920293 1020 1021 O
Use NCT03920293 1023 1026 O
of NCT03920293 1027 1029 B-Temporal-Connection___Temporal-Connection-Type-Value:before
plasma NCT03920293 1030 1036 B-Procedure
exchange NCT03920293 1037 1045 I-Procedure
within NCT03920293 1046 1052 B-Eq-Comparison
4 NCT03920293 1053 1054 I-Eq-Comparison
weeks NCT03920293 1055 1060 I-Eq-Comparison
of NCT03920293 1061 1063 O
randomization NCT03920293 1064 1077 B-Study

- NCT03920293 1085 1086 O
Use NCT03920293 1088 1091 O
of NCT03920293 1092 1094 B-Temporal-Connection___Temporal-Connection-Type-Value:before
rituximab NCT03920293 1095 1104 B-Drug
within NCT03920293 1105 1111 B-Eq-Comparison
6 NCT03920293 1112 1113 I-Eq-Comparison
months NCT03920293 1114 1120 I-Eq-Comparison
of NCT03920293 1121 1123 O
screening NCT03920293 1124 1133 B-Study

5 NCT03920293 1136 1137 O
. NCT03920293 1137 1138 O
Participants NCT03920293 1140 1152 O
who NCT03920293 1153 1156 O
have NCT03920293 1157 1161 O
received NCT03920293 1162 1170 O
previous NCT03920293 1171 1179 B-Eq-Comparison
treatment NCT03920293 1180 1189 B-Procedure
with NCT03920293 1190 1194 O
complement NCT03920293 1195 1205 B-Drug
inhibitors NCT03920293 1206 1216 I-Drug
( NCT03920293 1217 1218 O
for NCT03920293 1219 1222 O
example NCT03920293 1223 1230 O
, NCT03920293 1231 1232 O
eculizumab NCT03920293 1233 1243 B-Drug
) NCT03920293 1244 1245 O
. NCT03920293 1246 1247 O

Inclusion NCT03928340 0 9 O
Criteria NCT03928340 10 18 O
: NCT03928340 19 20 O

- NCT03928340 24 25 O
Diabetic NCT03928340 27 35 B-Condition
pregnant NCT03928340 36 44 B-Condition
patients NCT03928340 45 53 O
with NCT03928340 54 58 B-And
type NCT03928340 59 63 B-Condition
one NCT03928340 64 67 I-Condition
diabetes NCT03928340 68 76 I-Condition
and NCT03928340 77 80 B-And
no NCT03928340 81 83 B-Negation
other NCT03928340 84 89 B-Other
chronic NCT03928340 90 97 B-Modifier
disorders NCT03928340 98 107 B-Condition

- NCT03928340 110 111 O
Patients NCT03928340 113 121 O
on NCT03928340 122 124 B-Eq-Comparison
insulin NCT03928340 125 132 B-Drug
in NCT03928340 133 135 O
the NCT03928340 136 139 O
3 NCT03928340 140 141 B-Eq-Comparison
rd NCT03928340 142 144 O
trimester NCT03928340 145 154 I-Eq-Comparison
of NCT03928340 155 157 O
pregnancy NCT03928340 158 167 B-Condition
( NCT03928340 168 169 O
on NCT03928340 170 172 B-Eq-Comparison
insulin NCT03928340 173 180 B-Drug
therapy NCT03928340 181 188 I-Drug
since NCT03928340 189 194 B-Temporal-Connection___Temporal-Connection-Type-Value:after
start NCT03928340 195 200 B-Eq-Comparison
of NCT03928340 201 203 O
gestation NCT03928340 204 213 B-Condition
) NCT03928340 214 215 O

- NCT03928340 219 220 O
Patients NCT03928340 222 230 O
pregnant NCT03928340 231 239 B-Condition
in NCT03928340 240 242 O
single NCT03928340 243 249 B-Modifier
living NCT03928340 250 256 I-Modifier
fetus NCT03928340 257 262 B-Family-Member___Family-Member-Type:child
with NCT03928340 263 267 O
no NCT03928340 268 270 B-Negation
apparent NCT03928340 271 279 B-Assertion___Assertion-Type-Value:possible
congenital NCT03928340 280 290 B-Condition
anomalies NCT03928340 291 300 I-Condition

- NCT03928340 303 304 O
Haemoglobin NCT03928340 306 317 B-Observation
A NCT03928340 318 319 I-Observation
1 NCT03928340 320 321 I-Observation
C NCT03928340 322 323 I-Observation
( NCT03928340 324 325 O
HbA1c NCT03928340 326 331 B-Observation
) NCT03928340 332 333 O
level NCT03928340 334 339 O
between NCT03928340 340 347 B-Eq-Comparison
7 NCT03928340 348 349 I-Eq-Comparison
% NCT03928340 350 351 O
to NCT03928340 352 354 I-Eq-Comparison
11 NCT03928340 355 357 I-Eq-Comparison
% NCT03928340 358 359 O

- NCT03928340 362 363 O
All NCT03928340 365 368 O
patients NCT03928340 369 377 O
have NCT03928340 378 382 O
done NCT03928340 383 387 B-Eq-Comparison
a NCT03928340 388 389 O
dating NCT03928340 390 396 O
ultrasound NCT03928340 397 407 B-Procedure
to NCT03928340 408 410 O
confirm NCT03928340 411 418 O
gestational NCT03928340 419 430 B-Observation
age NCT03928340 431 434 I-Observation
, NCT03928340 435 436 O
viability NCT03928340 437 446 O
and NCT03928340 447 450 B-And
rule NCT03928340 451 455 B-Assertion___Assertion-Type-Value:hypothetical
out NCT03928340 456 459 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03928340 460 463 O
abnormality NCT03928340 464 475 B-Condition

Exclusion NCT03928340 476 485 O
Criteria NCT03928340 486 494 O
: NCT03928340 495 496 O

- NCT03928340 500 501 O
Patients NCT03928340 503 511 O
with NCT03928340 512 516 O
type NCT03928340 517 521 B-Modifier
2 NCT03928340 522 523 I-Modifier
or NCT03928340 524 526 B-Or
gestational NCT03928340 527 538 B-Modifier
diabetes NCT03928340 539 547 B-Condition

- NCT03928340 550 551 O
Patients NCT03928340 553 561 O
with NCT03928340 562 566 O
intolerance NCT03928340 567 578 B-Condition
or NCT03928340 579 581 B-Or
hypersensitivity NCT03928340 582 598 B-Condition
to NCT03928340 599 601 O
metformin NCT03928340 602 611 B-Drug

- NCT03928340 614 615 O
Patients NCT03928340 617 625 O
with NCT03928340 626 630 O
congestive NCT03928340 631 641 B-Condition
heart NCT03928340 642 647 I-Condition
failure NCT03928340 648 655 I-Condition
or NCT03928340 656 658 B-Or
a NCT03928340 659 660 O
history NCT03928340 661 668 B-Eq-Comparison
of NCT03928340 669 671 O
congestive NCT03928340 672 682 B-Condition
heart NCT03928340 683 688 I-Condition
failure NCT03928340 689 696 I-Condition

- NCT03928340 699 700 O
Patients NCT03928340 702 710 O
with NCT03928340 711 715 O
renal NCT03928340 716 721 B-Condition
insufficiency NCT03928340 722 735 I-Condition

- NCT03928340 738 739 O
Patients NCT03928340 741 749 O
having NCT03928340 750 756 O
current NCT03928340 757 764 B-Eq-Comparison
significant NCT03928340 765 776 O
gastrointestinal NCT03928340 777 793 B-Condition
problems NCT03928340 794 802 I-Condition
such NCT03928340 803 807 O
as NCT03928340 808 810 O
severe NCT03928340 811 817 O
vomiting NCT03928340 818 826 B-Condition
requiring NCT03928340 827 836 B-Assertion___Assertion-Type-Value:hypothetical
intravenous NCT03928340 837 848 B-Drug
fluids NCT03928340 849 855 I-Drug
or NCT03928340 856 858 B-Or
hospitalization NCT03928340 859 874 B-Encounter

- NCT03928340 877 878 O
Presence NCT03928340 880 888 O
of NCT03928340 889 891 O
acute NCT03928340 892 897 O
or NCT03928340 898 900 O
chronic NCT03928340 901 908 B-Modifier
metabolic NCT03928340 909 918 B-Condition
acidosis NCT03928340 919 927 I-Condition
, NCT03928340 928 929 O
including NCT03928340 930 939 O
diabetic NCT03928340 940 948 B-Condition
ketoacidosis NCT03928340 949 961 I-Condition
, NCT03928340 962 963 O
a NCT03928340 964 965 O
history NCT03928340 966 973 B-Eq-Comparison
of NCT03928340 974 976 O
diabetic NCT03928340 977 985 B-Condition
ketoacidosis NCT03928340 986 998 I-Condition
or NCT03928340 999 1001 B-Or
history NCT03928340 1002 1009 B-Eq-Comparison
of NCT03928340 1010 1012 O
lactic NCT03928340 1013 1019 B-Condition
acidosis NCT03928340 1020 1028 I-Condition

- NCT03928340 1031 1032 O
Patients NCT03928340 1034 1042 O
with NCT03928340 1043 1047 O
liver NCT03928340 1048 1053 B-Modifier
impairment NCT03928340 1054 1064 B-Condition

- NCT03928340 1067 1068 O
Patients NCT03928340 1070 1078 O
with NCT03928340 1079 1083 O
known NCT03928340 1084 1089 O
higher NCT03928340 1090 1096 B-Modifier
order NCT03928340 1097 1102 I-Modifier
pregnancies NCT03928340 1103 1114 B-Condition
( NCT03928340 1115 1116 O
twins NCT03928340 1117 1122 B-Modifier
, NCT03928340 1123 1124 O
triplets NCT03928340 1125 1133 B-Modifier
, NCT03928340 1134 1135 O
etc NCT03928340 1136 1139 O
. NCT03928340 1139 1140 O
) NCT03928340 1141 1142 O

- NCT03928340 1146 1147 O
Patients NCT03928340 1149 1157 O
having NCT03928340 1158 1164 O
a NCT03928340 1165 1166 O
known NCT03928340 1167 1172 O
potentially NCT03928340 1173 1184 B-Assertion___Assertion-Type-Value:hypothetical
fetal NCT03928340 1185 1190 B-Condition
lethal NCT03928340 1191 1197 I-Condition
anomaly NCT03928340 1198 1205 I-Condition

Inclusion NCT03925116 0 9 O
Criteria NCT03925116 10 18 O

- NCT03925116 21 22 O
Women NCT03925116 24 29 O
at NCT03925116 30 32 O
risk NCT03925116 33 37 B-Risk
for NCT03925116 38 41 O
pregnancy NCT03925116 42 51 B-Condition

- NCT03925116 54 55 O
Women NCT03925116 57 62 O
able NCT03925116 63 67 O
to NCT03925116 68 70 O
read NCT03925116 71 75 O
and NCT03925116 76 79 O
write NCT03925116 80 85 O
in NCT03925116 86 88 O
English NCT03925116 89 96 O

Exclusion NCT03925116 97 106 O
Criteria NCT03925116 107 115 O

- NCT03925116 118 119 O
Women NCT03925116 121 126 O
who NCT03925116 127 130 B-And
have NCT03925116 131 135 O
undergone NCT03925116 136 145 B-Eq-Comparison
permanent NCT03925116 146 155 B-Procedure
sterilization NCT03925116 156 169 I-Procedure

- NCT03925116 172 173 O
Women NCT03925116 175 180 O
not NCT03925116 181 184 B-Negation
sexually NCT03925116 185 193 B-Condition
active NCT03925116 194 200 I-Condition
with NCT03925116 201 205 B-And
a NCT03925116 206 207 O
male NCT03925116 208 212 O
partner NCT03925116 213 220 B-Other

- NCT03925116 223 224 O
Women NCT03925116 226 231 O
who NCT03925116 232 235 B-And
intend NCT03925116 236 242 B-Assertion___Assertion-Type-Value:intention
to NCT03925116 243 245 I-Assertion___Assertion-Type-Value:intention
become NCT03925116 246 252 O
pregnant NCT03925116 253 261 B-Condition
in NCT03925116 262 264 O
the NCT03925116 265 268 O
next NCT03925116 269 273 B-Eq-Comparison
12 NCT03925116 274 276 I-Eq-Comparison
months NCT03925116 277 283 I-Eq-Comparison

Inclusion NCT03926351 0 9 O
Criteria NCT03926351 10 18 O
: NCT03926351 19 20 O

- NCT03926351 24 25 O
Age NCT03926351 27 30 B-Age
> NCT03926351 31 32 B-Eq-Comparison
50 NCT03926351 33 35 I-Eq-Comparison
years NCT03926351 36 41 I-Eq-Comparison

- NCT03926351 44 45 O
SCD NCT03926351 47 50 B-Condition
or NCT03926351 51 53 B-Or
MCI NCT03926351 54 57 B-Condition

- NCT03926351 60 61 O
No NCT03926351 63 65 B-Negation
evidence NCT03926351 66 74 O
of NCT03926351 75 77 O
neurodegeneration NCT03926351 78 95 B-Condition
( NCT03926351 96 97 O
i. NCT03926351 98 100 O
e. NCT03926351 101 103 O
CSF NCT03926351 105 108 B-Observation
phospho NCT03926351 109 116 I-Observation
and NCT03926351 117 120 B-Or
total NCT03926351 121 126 B-Observation
tau NCT03926351 127 130 I-Observation
- NCT03926351 131 132 I-Observation
levels NCT03926351 133 139 I-Observation
below NCT03926351 140 145 B-Eq-Comparison
cut NCT03926351 146 149 I-Eq-Comparison
- NCT03926351 150 151 I-Eq-Comparison
off NCT03926351 152 155 I-Eq-Comparison
) NCT03926351 156 157 O

- NCT03926351 161 162 O
Scandinavian NCT03926351 164 176 O
mother NCT03926351 177 183 O
tongue NCT03926351 184 190 O

- NCT03926351 193 194 O
Completed NCT03926351 196 205 O
2 NCT03926351 206 207 B-Eq-Comparison
- NCT03926351 208 209 I-Encounter|Eq-Comparison
year NCT03926351 210 214 I-Eq-Comparison
follow NCT03926351 215 221 B-Encounter
- NCT03926351 222 223 O
up NCT03926351 224 226 I-Encounter
in NCT03926351 227 229 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926351 230 233 O
DDI NCT03926351 234 237 B-Other
- NCT03926351 238 239 O
study NCT03926351 240 245 B-Study

- NCT03926351 248 249 O
Stable NCT03926351 251 257 O
medication NCT03926351 258 268 B-Drug
for NCT03926351 269 272 O
at NCT03926351 273 275 B-Eq-Comparison
least NCT03926351 276 281 I-Eq-Comparison
3 NCT03926351 282 283 I-Eq-Comparison
months NCT03926351 284 290 I-Eq-Comparison
prior NCT03926351 291 296 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926351 297 299 O
baseline NCT03926351 300 308 B-Study
exam NCT03926351 309 313 O

Exclusion NCT03926351 314 323 O
Criteria NCT03926351 324 332 O
: NCT03926351 333 334 O

- NCT03926351 338 339 O
Dementia NCT03926351 341 349 B-Condition
( NCT03926351 350 351 O
defined NCT03926351 352 359 O
as NCT03926351 360 362 O
MMSE NCT03926351 363 367 B-Observation
< NCT03926351 368 369 B-Eq-Comparison
26 NCT03926351 370 372 I-Eq-Comparison
and NCT03926351 373 376 B-Or
/ NCT03926351 377 378 I-Eq-Comparison|Or
or NCT03926351 379 381 I-Or
CDR NCT03926351 382 385 B-Observation
> NCT03926351 386 387 B-Eq-Comparison
/ NCT03926351 389 390 O
= NCT03926351 392 393 I-Eq-Comparison
1 NCT03926351 394 395 I-Eq-Comparison
) NCT03926351 396 397 O
) NCT03926351 399 400 O

- NCT03926351 404 405 O
Other NCT03926351 407 412 B-Other
dementia NCT03926351 413 421 B-Condition
giving NCT03926351 422 428 O
disease NCT03926351 429 436 O
than NCT03926351 437 441 B-Exception
AD NCT03926351 442 444 B-Condition

- NCT03926351 447 448 O
Other NCT03926351 450 455 B-Other
brain NCT03926351 456 461 B-Condition
disease NCT03926351 462 469 I-Condition

- NCT03926351 472 473 O
Significant NCT03926351 475 486 O
depression NCT03926351 487 497 B-Condition

- NCT03926351 500 501 O
Unstable NCT03926351 503 511 O
coronary NCT03926351 512 520 B-Condition
heart NCT03926351 521 526 I-Condition|Condition
disease NCT03926351 527 534 I-Condition
or NCT03926351 535 537 B-Or
heart NCT03926351 538 543 O
failure NCT03926351 544 551 I-Condition
in NCT03926351 552 554 O
need NCT03926351 555 559 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03926351 560 562 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03926351 563 572 B-Procedure

- NCT03926351 575 576 O
Systemic NCT03926351 578 586 B-Modifier
inflammatory NCT03926351 587 599 B-Condition
diseases NCT03926351 600 608 I-Condition|Condition

- NCT03926351 611 612 O
Somatic NCT03926351 614 621 B-Condition
disease NCT03926351 622 629 O
that NCT03926351 630 634 O
might NCT03926351 635 640 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03926351 641 647 O
cognitive NCT03926351 648 657 B-Condition
function NCT03926351 658 666 I-Condition
adversely NCT03926351 667 676 O

- NCT03926351 679 680 O
Usage NCT03926351 682 687 B-Eq-Comparison
of NCT03926351 688 690 O
anticoagulants NCT03926351 691 705 B-Drug

- NCT03926351 708 709 I-Procedure
Prior NCT03926351 711 716 B-Eq-Comparison
radiation NCT03926351 717 726 B-Procedure
- NCT03926351 727 728 O
or NCT03926351 729 731 B-Or
chemo NCT03926351 732 737 B-Procedure
- NCT03926351 738 739 O
therapy NCT03926351 740 747 I-Procedure
possibly NCT03926351 748 756 B-Assertion___Assertion-Type-Value:hypothetical
affecting NCT03926351 757 766 O
CNS NCT03926351 767 770 B-Condition

- NCT03926351 773 774 O
Relevant NCT03926351 776 784 O
cancer NCT03926351 785 791 B-Condition
or NCT03926351 792 794 O
other NCT03926351 795 800 B-Other
serious NCT03926351 801 808 O
disease NCT03926351 809 816 B-Condition
with NCT03926351 817 821 B-And
expected NCT03926351 822 830 B-Observation
survival NCT03926351 831 839 I-Observation
< NCT03926351 840 841 B-Eq-Comparison
5 NCT03926351 842 843 I-Eq-Comparison
years NCT03926351 844 849 I-Eq-Comparison

- NCT03926351 852 853 O
Fish NCT03926351 855 859 B-Drug
meal NCT03926351 860 864 I-Drug
intake NCT03926351 865 871 O
more NCT03926351 872 876 B-Eq-Comparison
than NCT03926351 877 881 I-Eq-Comparison
2 NCT03926351 882 883 I-Eq-Comparison
times NCT03926351 884 889 I-Eq-Comparison
a NCT03926351 890 891 I-Eq-Comparison
week NCT03926351 892 896 I-Eq-Comparison

- NCT03926351 899 900 I-Drug
Regularly NCT03926351 902 911 B-Eq-Comparison
intake NCT03926351 912 918 O
of NCT03926351 919 921 O
Omega NCT03926351 922 927 B-Drug
- NCT03926351 928 929 O
3 NCT03926351 930 931 I-Drug|Eq-Comparison
supplements NCT03926351 932 943 I-Drug
over NCT03926351 944 948 O
the NCT03926351 949 952 O
last NCT03926351 953 957 B-Eq-Comparison
3 NCT03926351 958 959 O
months NCT03926351 960 966 I-Eq-Comparison

Inclusion NCT03927729 0 9 O
Criteria NCT03927729 10 18 O
: NCT03927729 19 20 O

- NCT03927729 24 25 O
Conscious NCT03927729 27 36 B-Condition
patient NCT03927729 37 44 O

- NCT03927729 47 48 O
Age NCT03927729 50 53 B-Age
≥ NCT03927729 54 55 B-Eq-Comparison
18 NCT03927729 56 58 I-Eq-Comparison
years NCT03927729 59 64 I-Eq-Comparison

- NCT03927729 67 68 O
Acute NCT03927729 70 75 O
pain NCT03927729 76 80 B-Condition
of NCT03927729 81 83 O
monotraumatic NCT03927729 84 97 B-Modifier
origin NCT03927729 98 104 I-Modifier

- NCT03927729 107 108 O
Pain NCT03927729 110 114 B-Observation
> NCT03927729 115 116 B-Eq-Comparison
4 NCT03927729 117 118 I-Eq-Comparison
on NCT03927729 119 121 O
a NCT03927729 122 123 O
visual NCT03927729 124 130 O
numerical NCT03927729 131 140 O
scale NCT03927729 141 146 O

Exclusion NCT03927729 147 156 O
Criteria NCT03927729 157 165 O
: NCT03927729 166 167 O

- NCT03927729 171 172 O
State NCT03927729 174 179 B-Condition
of NCT03927729 180 182 I-Condition
shock NCT03927729 183 188 I-Condition
with NCT03927729 189 193 B-And
unstable NCT03927729 194 202 O
hemodynamics NCT03927729 203 215 B-Condition
( NCT03927729 216 217 O
PA NCT03927729 218 220 B-Observation
< NCT03927729 221 222 B-Eq-Comparison
90 NCT03927729 223 225 I-Eq-Comparison
/ NCT03927729 226 227 O
60 NCT03927729 228 230 O
) NCT03927729 231 232 O

- NCT03927729 236 237 O
Suspected NCT03927729 239 248 B-Assertion___Assertion-Type-Value:possible
or NCT03927729 249 251 O
proven NCT03927729 252 258 O
trauma NCT03927729 259 265 B-Condition
to NCT03927729 266 268 O
the NCT03927729 269 272 O
chest NCT03927729 273 278 B-Modifier
, NCT03927729 279 280 O
abdomen NCT03927729 281 288 B-Modifier
or NCT03927729 289 291 B-Or
pelvis NCT03927729 292 298 B-Modifier

- NCT03927729 301 302 O
Serious NCT03927729 304 311 O
head NCT03927729 312 316 O
trauma NCT03927729 317 323 O

- NCT03927729 326 327 O
Consciousness NCT03927729 329 342 B-Condition
disorder NCT03927729 343 351 I-Condition
with NCT03927729 352 356 B-And
Glasgow NCT03927729 357 364 B-Observation
score NCT03927729 365 370 I-Observation
< NCT03927729 371 372 B-Eq-Comparison
15 NCT03927729 373 375 I-Eq-Comparison

- NCT03927729 379 380 O
Patient NCT03927729 382 389 O
who NCT03927729 390 393 O
has NCT03927729 394 397 O
already NCT03927729 398 405 O
received NCT03927729 406 414 B-Eq-Comparison
analgesics NCT03927729 415 425 B-Drug
( NCT03927729 426 427 O
with NCT03927729 428 432 O
the NCT03927729 433 436 O
exception NCT03927729 437 446 B-Exception
of NCT03927729 447 449 O
paracetamol NCT03927729 450 461 B-Drug
) NCT03927729 462 463 O

- NCT03927729 467 468 O
Patient NCT03927729 470 477 O
receiving NCT03927729 478 487 B-Eq-Comparison
an NCT03927729 488 490 O
intravenous NCT03927729 491 502 B-Modifier
approach NCT03927729 503 511 O
for NCT03927729 512 515 O
analgesia NCT03927729 516 525 B-Drug

- NCT03927729 528 529 O
Renal NCT03927729 531 536 B-Modifier
or NCT03927729 537 539 B-Or
hepatic NCT03927729 540 547 B-Modifier
disorders NCT03927729 548 557 B-Condition
known NCT03927729 558 563 O

- NCT03927729 566 567 O
Hypersensitivity NCT03927729 569 585 B-Condition
to NCT03927729 586 588 O
fluoridated NCT03927729 589 600 B-Modifier
anesthetics NCT03927729 601 612 I-Modifier
or NCT03927729 613 615 O
history NCT03927729 616 623 B-Eq-Comparison
of NCT03927729 624 626 O
malignant NCT03927729 627 636 B-Condition
hyperthermia NCT03927729 637 649 I-Condition
in NCT03927729 650 652 O
the NCT03927729 653 656 O
patient NCT03927729 657 664 B-Family-Member___Family-Member-Type:patient
or NCT03927729 665 667 B-Or
family NCT03927729 668 674 B-Family-Member

- NCT03927729 677 678 O
Pregnant NCT03927729 680 688 B-Condition
or NCT03927729 689 691 B-Or
nursing NCT03927729 692 699 B-Condition
woman NCT03927729 700 705 O

- NCT03927729 708 709 O
Patient NCT03927729 711 718 O
under NCT03927729 719 724 O
judicial NCT03927729 725 733 B-Observation
protection NCT03927729 734 744 I-Observation

- NCT03927729 747 748 O
Non NCT03927729 750 753 B-Condition
communicating NCT03927729 754 767 I-Condition
patient NCT03927729 768 775 O
or NCT03927729 776 778 B-Or
with NCT03927729 779 783 O
difficulties NCT03927729 784 796 B-Condition
of NCT03927729 797 799 I-Condition
understanding NCT03927729 800 813 I-Condition

Exclusion NCT03927729 814 823 O
Criteria NCT03927729 824 832 O
: NCT03927729 833 834 O

- NCT03927729 838 839 O
Intravenous NCT03927729 841 852 B-Modifier
injection NCT03927729 853 862 I-Modifier
for NCT03927729 863 866 O
analgesia NCT03927729 867 876 B-Drug

Inclusion NCT03920046 0 9 O
Criteria NCT03920046 10 18 O
: NCT03920046 19 20 O

- NCT03920046 24 25 O
ASA NCT03920046 27 30 B-Condition
( NCT03920046 31 32 O
American NCT03920046 33 41 B-Condition
Society NCT03920046 42 49 I-Condition
of NCT03920046 50 52 I-Condition
Anesthesiologists NCT03920046 53 70 I-Condition
) NCT03920046 71 72 O
I NCT03920046 73 74 B-Eq-Comparison
- NCT03920046 75 76 I-Eq-Comparison
ASA NCT03920046 77 80 I-Eq-Comparison
II NCT03920046 81 83 I-Eq-Comparison
patients NCT03920046 84 92 O

- NCT03920046 95 96 O
Aged NCT03920046 98 102 B-Age
1 NCT03920046 103 104 B-Eq-Comparison
- NCT03920046 105 106 I-Eq-Comparison
18 NCT03920046 107 109 I-Eq-Comparison
Year NCT03920046 110 114 I-Eq-Comparison
old NCT03920046 115 118 O
patients NCT03920046 119 127 O

Exclusion NCT03920046 128 137 O
Criteria NCT03920046 138 146 O
: NCT03920046 147 148 O

- NCT03920046 152 153 O
Smoker NCT03920046 155 161 B-Condition
patients NCT03920046 162 170 O

Inclusion NCT03920085 0 9 O
Criteria NCT03920085 10 18 O
: NCT03920085 19 20 O

- NCT03920085 24 25 O
Participants NCT03920085 27 39 O
must NCT03920085 40 44 O
be NCT03920085 45 47 O
enrolled NCT03920085 48 56 O
in NCT03920085 57 59 O
LifeScan NCT03920085 60 68 O
Patient NCT03920085 69 76 O
Registry NCT03920085 77 85 O
. NCT03920085 85 86 O

- NCT03920085 90 91 O
Participants NCT03920085 93 105 O
must NCT03920085 106 110 O
have NCT03920085 111 115 O
read NCT03920085 116 120 O
the NCT03920085 121 124 O
Information NCT03920085 125 136 O
sheet NCT03920085 137 142 O
and NCT03920085 143 146 O
signed NCT03920085 147 153 O
an NCT03920085 154 156 O
informedconsent NCT03920085 157 172 O
form NCT03920085 173 177 O
> NCT03920085 178 179 O
prior NCT03920085 180 185 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920085 186 188 O
study NCT03920085 189 194 B-Study
participation NCT03920085 195 208 O
. NCT03920085 208 209 O

- NCT03920085 213 214 O
Participants NCT03920085 216 228 O
must NCT03920085 229 233 O
be NCT03920085 234 236 O
16 NCT03920085 237 239 B-Eq-Comparison
years NCT03920085 240 245 I-Eq-Comparison
or NCT03920085 246 248 I-Eq-Comparison
older NCT03920085 249 254 I-Age|Eq-Comparison
. NCT03920085 254 255 O

- NCT03920085 259 260 O
Participants NCT03920085 262 274 O
must NCT03920085 275 279 O
be NCT03920085 280 282 O
diagnosed NCT03920085 283 292 O
with NCT03920085 293 297 O
Diabetes NCT03920085 298 306 B-Condition

Exclusion NCT03920085 307 316 O
Criteria NCT03920085 317 325 O
: NCT03920085 326 327 O

> NCT03920085 330 331 O
Participants NCT03920085 332 344 O
not NCT03920085 345 348 O
enrolled NCT03920085 349 357 O
in NCT03920085 358 360 O
the NCT03920085 361 364 O
LifeScan NCT03920085 365 373 O
Patient NCT03920085 374 381 O
Registry NCT03920085 382 390 O

Inclusion NCT03928223 0 9 O
Criteria NCT03928223 10 18 O
: NCT03928223 19 20 O

- NCT03928223 24 25 O
Dermatology NCT03928223 27 38 B-Provider
in NCT03928223 39 41 B-Encounter
- NCT03928223 42 43 O
and NCT03928223 44 47 B-Or
outpatients NCT03928223 48 59 B-Encounter
with NCT03928223 60 64 B-And
itch NCT03928223 65 69 B-Condition

Exclusion NCT03928223 70 79 O
Criteria NCT03928223 80 88 O
: NCT03928223 89 90 O

- NCT03928223 94 95 O
color NCT03928223 97 102 B-Condition
blindness NCT03928223 103 112 I-Condition

- NCT03928223 115 116 O
lack NCT03928223 118 122 O
of NCT03928223 123 125 O
time NCT03928223 126 130 O

- NCT03928223 133 134 O
lack NCT03928223 136 140 O
of NCT03928223 141 143 O
German NCT03928223 144 150 O
language NCT03928223 151 159 O
. NCT03928223 159 160 O

Inclusion NCT03924141 0 9 O
Criteria NCT03924141 10 18 O
: NCT03924141 19 20 O

- NCT03924141 24 25 O
Third NCT03924141 27 32 O
year NCT03924141 33 37 O
nursing NCT03924141 38 45 O
student NCT03924141 46 53 O

Exclusion NCT03924141 54 63 O
Criteria NCT03924141 64 72 O
: NCT03924141 73 74 O

- NCT03924141 78 79 O
Has NCT03924141 81 84 O
to NCT03924141 85 87 O
talk NCT03924141 88 92 O
and NCT03924141 93 96 O
understand NCT03924141 97 107 O
Norwegian NCT03924141 108 117 O

Inclusion NCT03922256 0 9 O

- NCT03922256 12 13 O
Age NCT03922256 15 18 B-Age
> NCT03922256 19 20 B-Eq-Comparison
18 NCT03922256 21 23 I-Eq-Comparison
years NCT03922256 24 29 I-Eq-Comparison
; NCT03922256 29 30 O

- NCT03922256 33 34 O
Unilateral NCT03922256 36 46 B-Modifier
fracture NCT03922256 47 55 B-Condition
of NCT03922256 56 58 O
distal NCT03922256 59 65 B-Modifier
radius NCT03922256 66 72 I-Modifier
without NCT03922256 73 80 I-Modifier
misalignment NCT03922256 81 93 I-Modifier
( NCT03922256 94 95 O
dorsal NCT03922256 96 102 B-Observation
angulation NCT03922256 103 113 I-Observation
< NCT03922256 114 115 B-Eq-Comparison
10 NCT03922256 116 118 I-Eq-Comparison
° NCT03922256 119 120 O
, NCT03922256 121 122 O
axial NCT03922256 123 128 B-Observation
radial NCT03922256 129 135 I-Observation
shortening NCT03922256 136 146 I-Observation
< NCT03922256 147 148 B-Eq-Comparison
5 NCT03922256 149 150 I-Eq-Comparison
mm NCT03922256 151 153 O
) NCT03922256 154 155 O
, NCT03922256 157 158 O
< NCT03922256 159 160 B-Eq-Comparison
2 NCT03922256 161 162 I-Eq-Comparison
mm NCT03922256 163 165 O
intraarticular NCT03922256 166 180 B-Observation
stepoff NCT03922256 181 188 I-Observation
; NCT03922256 188 189 O

- NCT03922256 192 193 O
Independent NCT03922256 195 206 B-Condition
in NCT03922256 207 209 O
activities NCT03922256 210 220 O
of NCT03922256 221 223 O
daily NCT03922256 224 229 O
living NCT03922256 230 236 O
; NCT03922256 236 237 O

- NCT03922256 240 241 O
Capable NCT03922256 243 250 O
and NCT03922256 251 254 O
willing NCT03922256 255 262 O
of NCT03922256 263 265 O
signing NCT03922256 266 273 O
informed NCT03922256 274 282 O
consent NCT03922256 283 290 O
. NCT03922256 290 291 O

Exclusion NCT03922256 293 302 O

- NCT03922256 305 306 O
Children NCT03922256 308 316 O
under NCT03922256 317 322 B-Eq-Comparison
the NCT03922256 323 326 I-Eq-Comparison
age NCT03922256 327 330 I-Eq-Comparison
of NCT03922256 331 333 I-Eq-Comparison
18 NCT03922256 334 336 I-Eq-Comparison
; NCT03922256 337 338 O

- NCT03922256 341 342 O
Fracture NCT03922256 344 352 B-Condition
of NCT03922256 353 355 O
the NCT03922256 356 359 O
contralateral NCT03922256 360 373 B-Modifier
arm NCT03922256 374 377 I-Modifier
; NCT03922256 377 378 O

- NCT03922256 381 382 O
Other NCT03922256 384 389 O
fractures NCT03922256 390 399 B-Condition
of NCT03922256 400 402 O
the NCT03922256 403 406 O
ipsilateral NCT03922256 407 418 B-Modifier
arm NCT03922256 419 422 I-Modifier
; NCT03922256 422 423 O

- NCT03922256 426 427 O
Open NCT03922256 429 433 B-Modifier
fractures NCT03922256 434 443 B-Condition
; NCT03922256 443 444 O

- NCT03922256 447 448 O
Fractures NCT03922256 450 459 B-Condition
that NCT03922256 460 464 O
require NCT03922256 465 472 B-Assertion___Assertion-Type-Value:hypothetical
reduction NCT03922256 473 482 B-Procedure
. NCT03922256 482 483 O

Inclusion NCT03929471 0 9 O
Criteria NCT03929471 10 18 O
: NCT03929471 19 20 O

- NCT03929471 24 25 O
Adult NCT03929471 27 32 O
( NCT03929471 33 34 O
> NCT03929471 36 37 B-Eq-Comparison
18 NCT03929471 38 40 I-Eq-Comparison
years NCT03929471 41 46 I-Eq-Comparison
old NCT03929471 47 50 B-Age
) NCT03929471 51 52 O
outpatients NCT03929471 53 64 B-Encounter
on NCT03929471 65 67 B-Eq-Comparison
3 NCT03929471 68 69 B-Eq-Comparison
- NCT03929471 70 71 I-Eq-Comparison
4 NCT03929471 72 73 I-Eq-Comparison
times NCT03929471 74 79 I-Eq-Comparison
per NCT03929471 80 83 I-Eq-Comparison
week NCT03929471 84 88 I-Eq-Comparison
HD NCT03929471 89 91 B-Procedure
sessions NCT03929471 92 100 O
for NCT03929471 101 104 O
at NCT03929471 105 107 B-Eq-Comparison
least NCT03929471 108 113 I-Eq-Comparison
6 NCT03929471 114 115 I-Eq-Comparison
weeks NCT03929471 116 121 I-Eq-Comparison
with NCT03929471 122 126 B-And
a NCT03929471 127 128 O
life NCT03929471 129 133 B-Observation
expectancy NCT03929471 134 144 I-Observation
> NCT03929471 145 146 B-Eq-Comparison
6 NCT03929471 147 148 I-Eq-Comparison
months NCT03929471 149 155 I-Eq-Comparison
. NCT03929471 155 156 O

- NCT03929471 160 161 O
Fluid NCT03929471 163 168 B-Observation
overload NCT03929471 169 177 I-Observation
≥ NCT03929471 178 179 B-Eq-Comparison
1.1 NCT03929471 180 183 I-Eq-Comparison
L. NCT03929471 184 186 O

- NCT03929471 190 191 O
Medically NCT03929471 193 202 B-Condition
stable NCT03929471 203 209 O
patient NCT03929471 210 217 O
. NCT03929471 217 218 O

- NCT03929471 222 223 O
Minimum NCT03929471 225 232 B-Eq-Comparison
of NCT03929471 233 235 I-Eq-Comparison
3 NCT03929471 236 237 I-Eq-Comparison
hours NCT03929471 238 243 I-Eq-Comparison
of NCT03929471 244 246 O
dialysis NCT03929471 247 255 B-Procedure
per NCT03929471 256 259 O
session NCT03929471 260 267 B-Coreference
. NCT03929471 267 268 O

Exclusion NCT03929471 270 279 O
Criteria NCT03929471 280 288 O
: NCT03929471 289 290 O

- NCT03929471 294 295 O
Pregnancy NCT03929471 297 306 B-Condition
or NCT03929471 307 309 B-Or
lactation NCT03929471 310 319 B-Condition
. NCT03929471 319 320 O

- NCT03929471 324 325 O
Declined NCT03929471 327 335 O
informed NCT03929471 336 344 O
consent NCT03929471 345 352 O
. NCT03929471 352 353 O

- NCT03929471 362 363 O
Patients NCT03929471 365 373 O
with NCT03929471 374 378 O
cognitive NCT03929471 379 388 B-Condition
dysfunction NCT03929471 389 400 I-Condition
. NCT03929471 400 401 O

- NCT03929471 410 411 I-Modifier
Severe NCT03929471 413 419 O
life NCT03929471 420 424 B-Modifier
- NCT03929471 425 426 O
limiting NCT03929471 427 435 I-Modifier
Comorbidities NCT03929471 436 449 B-Condition
( NCT03929471 450 451 O
malignant NCT03929471 452 461 B-Condition
tumour NCT03929471 462 468 I-Condition
, NCT03929471 469 470 O
tuberculosis NCT03929471 471 483 B-Condition
, NCT03929471 484 485 O
. NCT03929471 486 487 O
. NCT03929471 488 489 O
. NCT03929471 490 491 O
. NCT03929471 492 493 O
) NCT03929471 494 495 O

- NCT03929471 504 505 O
Surgery NCT03929471 507 514 B-Procedure
within NCT03929471 515 521 B-Eq-Comparison
six NCT03929471 522 525 I-Eq-Comparison
weeks NCT03929471 526 531 I-Eq-Comparison
of NCT03929471 532 534 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03929471 535 538 O
study NCT03929471 539 544 B-Study
. NCT03929471 544 545 O

- NCT03929471 554 555 O
Nocturnal NCT03929471 557 566 B-Modifier
dialysis NCT03929471 567 575 B-Procedure
patients NCT03929471 576 584 O
. NCT03929471 584 585 O

- NCT03929471 594 595 O
Patients NCT03929471 597 605 O
expected NCT03929471 606 614 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929471 615 617 O
receive NCT03929471 618 625 O
a NCT03929471 626 627 O
transplant NCT03929471 628 638 B-Procedure
or NCT03929471 639 641 B-Or
move NCT03929471 642 646 B-Observation
to NCT03929471 647 649 O
another NCT03929471 650 657 B-Other
center NCT03929471 658 664 O
within NCT03929471 665 671 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929471 672 675 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03929471 676 684 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03929471 685 687 O
the NCT03929471 688 691 O
study NCT03929471 692 697 B-Study
. NCT03929471 697 698 O

- NCT03929471 707 708 O
Patients NCT03929471 710 718 O
with NCT03929471 719 723 O
arteriovenous NCT03929471 724 737 B-Condition
fistula NCT03929471 738 745 I-Condition
issues NCT03929471 746 752 O
. NCT03929471 752 753 O

Inclusion NCT03922295 0 9 O
Criteria NCT03922295 10 18 O
: NCT03922295 19 20 O

- NCT03922295 24 25 O
Patients NCT03922295 27 35 O
with NCT03922295 36 40 O
chronic NCT03922295 41 48 B-Condition
suppurative NCT03922295 49 60 I-Condition
otitis NCT03922295 61 67 I-Condition
media NCT03922295 68 73 I-Condition
with NCT03922295 74 78 B-And
total NCT03922295 79 84 B-Modifier
or NCT03922295 85 87 B-Or
subtotal NCT03922295 88 96 B-Modifier
tympanic NCT03922295 97 105 B-Condition
membrane NCT03922295 106 114 I-Condition
perforation NCT03922295 115 126 I-Condition
with NCT03922295 127 131 B-And
limited NCT03922295 132 139 B-Condition
anterior NCT03922295 140 148 I-Condition
remnant NCT03922295 149 156 I-Condition
. NCT03922295 156 157 O

- NCT03922295 161 162 O
dry NCT03922295 164 167 B-Condition
perforation NCT03922295 168 179 I-Condition
for NCT03922295 180 183 O
at NCT03922295 184 186 B-Eq-Comparison
least NCT03922295 187 192 I-Eq-Comparison
3 NCT03922295 193 194 I-Eq-Comparison
months NCT03922295 195 201 I-Eq-Comparison
. NCT03922295 201 202 O

Exclusion NCT03922295 204 213 O
Criteria NCT03922295 214 222 O
: NCT03922295 223 224 O

- NCT03922295 228 229 O
Recurrent NCT03922295 231 240 B-Condition
perforation NCT03922295 241 252 I-Condition
after NCT03922295 253 258 B-Temporal-Connection___Temporal-Connection-Type-Value:during
previous NCT03922295 259 267 B-Eq-Comparison
myringoplasty NCT03922295 268 281 B-Procedure
. NCT03922295 281 282 O

- NCT03922295 286 287 O
Ossicular NCT03922295 289 298 B-Procedure
disruption NCT03922295 299 309 B-Modifier
or NCT03922295 310 312 B-Or
fixation NCT03922295 313 321 B-Modifier
. NCT03922295 321 322 O

- NCT03922295 326 327 O
immune NCT03922295 329 335 B-Condition
- NCT03922295 336 337 I-Condition
compromised NCT03922295 338 349 I-Condition
patients NCT03922295 350 358 O
including NCT03922295 359 368 O
uncontrolled NCT03922295 369 381 B-Modifier
diabetics NCT03922295 382 391 B-Condition
, NCT03922295 392 393 O
chronic NCT03922295 394 401 B-Modifier
liver NCT03922295 402 407 I-Modifier
and NCT03922295 408 411 B-Or
kidney NCT03922295 412 418 B-Modifier
diseases NCT03922295 419 427 B-Condition
. NCT03922295 427 428 O

Inclusion NCT03921944 0 9 O
Criteria NCT03921944 10 18 O
: NCT03921944 19 20 O

- NCT03921944 24 25 O
age NCT03921944 27 30 B-Age
> NCT03921944 31 32 B-Eq-Comparison
45 NCT03921944 33 35 I-Eq-Comparison
yrs NCT03921944 36 39 O

- NCT03921944 42 43 O
primary NCT03921944 45 52 B-Modifier
diagnosis NCT03921944 53 62 O
of NCT03921944 63 65 O
osteoarthritis NCT03921944 66 80 B-Condition
of NCT03921944 81 83 O
the NCT03921944 84 87 O
shoulder NCT03921944 88 96 B-Modifier

- NCT03921944 99 100 O
total NCT03921944 102 107 B-Procedure
shoulder NCT03921944 108 116 I-Procedure
replacement NCT03921944 117 128 I-Procedure
performed NCT03921944 129 138 O
by NCT03921944 139 141 O
Dr. NCT03921944 142 145 B-Provider
Armstrong NCT03921944 147 156 I-Provider

- NCT03921944 159 160 O
administered NCT03921944 162 174 B-Eq-Comparison
a NCT03921944 175 176 O
local NCT03921944 177 182 B-Procedure
anesthetic NCT03921944 183 193 I-Procedure
mixture NCT03921944 194 201 O
and NCT03921944 202 205 B-And
not NCT03921944 206 209 B-Negation
regional NCT03921944 210 218 B-Procedure
anesthesia NCT03921944 219 229 I-Procedure

- NCT03921944 232 233 O
all NCT03921944 235 238 O
genders NCT03921944 239 246 O

- NCT03921944 249 250 O
Fluent NCT03921944 252 258 O
in NCT03921944 259 261 O
written NCT03921944 262 269 O
and NCT03921944 270 273 O
spoken NCT03921944 274 280 O
English NCT03921944 281 288 O

- NCT03921944 291 292 O
Patients NCT03921944 294 302 O
capable NCT03921944 303 310 O
of NCT03921944 311 313 O
giving NCT03921944 314 320 O
informed NCT03921944 321 329 O
consent NCT03921944 330 337 O

Exclusion NCT03921944 338 347 O
Criteria NCT03921944 348 356 O
: NCT03921944 357 358 O

- NCT03921944 362 363 O
Known NCT03921944 365 370 O
contraindications NCT03921944 371 388 B-Contraindication
to NCT03921944 389 391 O
CT NCT03921944 392 394 B-Procedure
/ NCT03921944 395 396 B-Or
EMG NCT03921944 397 400 B-Procedure

- NCT03921944 403 404 O
Inability NCT03921944 406 415 O
to NCT03921944 416 418 O
provide NCT03921944 419 426 O
informed NCT03921944 427 435 O
consent NCT03921944 436 443 O

- NCT03921944 446 447 O
History NCT03921944 449 456 B-Eq-Comparison
of NCT03921944 457 459 O
recent NCT03921944 460 466 B-Eq-Comparison
trauma NCT03921944 467 473 B-Condition
to NCT03921944 474 476 O
the NCT03921944 477 480 O
shoulder NCT03921944 481 489 B-Modifier

- NCT03921944 492 493 O
Atypical NCT03921944 495 503 B-Modifier
shoulder NCT03921944 504 512 I-Modifier
pain NCT03921944 513 517 B-Condition

- NCT03921944 520 521 O
Other NCT03921944 523 528 O
suspected NCT03921944 529 538 B-Assertion___Assertion-Type-Value:possible
shoulder NCT03921944 539 547 B-Modifier
pathology NCT03921944 548 557 B-Condition
( NCT03921944 558 559 O
i. NCT03921944 560 562 O
e. NCT03921944 563 565 O
tumor NCT03921944 567 572 B-Condition
, NCT03921944 573 574 O
infection NCT03921944 575 584 B-Condition
) NCT03921944 585 586 O

- NCT03921944 590 591 O
Pregnancy NCT03921944 593 602 B-Condition

- NCT03921944 605 606 O
Bilateral NCT03921944 608 617 B-Modifier
total NCT03921944 618 623 B-Procedure
shoulder NCT03921944 624 632 I-Procedure
arthroplasty NCT03921944 633 645 I-Procedure

Inclusion NCT03921788 0 9 O
Criteria NCT03921788 10 18 O
: NCT03921788 19 20 O

- NCT03921788 24 25 O
The NCT03921788 27 30 O
reproductive NCT03921788 31 43 B-Observation
age NCT03921788 44 47 I-Observation
of NCT03921788 48 50 O
the NCT03921788 51 54 O
woman NCT03921788 55 60 O

- NCT03921788 63 64 O
Blood NCT03921788 66 71 B-Condition
reflux NCT03921788 72 78 I-Condition
in NCT03921788 79 81 O
the NCT03921788 82 85 O
parametric NCT03921788 86 96 B-Modifier
, NCT03921788 97 98 O
uterine NCT03921788 99 106 B-Modifier
, NCT03921788 107 108 O
gonadal NCT03921788 109 116 B-Modifier
veins NCT03921788 117 122 I-Modifier

- NCT03921788 125 126 O
The NCT03921788 128 131 O
absence NCT03921788 132 139 B-Negation
of NCT03921788 140 142 O
any NCT03921788 143 146 O
concomitant NCT03921788 147 158 O
pathology NCT03921788 159 168 B-Condition
, NCT03921788 169 170 O
accompanied NCT03921788 171 182 B-And
by NCT03921788 183 185 O
chronic NCT03921788 186 193 B-Modifier
pelvic NCT03921788 194 200 B-Condition
pain NCT03921788 201 205 I-Condition

Exclusion NCT03921788 206 215 O
Criteria NCT03921788 216 224 O
: NCT03921788 225 226 O

- NCT03921788 230 231 O
The NCT03921788 233 236 O
absence NCT03921788 237 244 B-Negation
of NCT03921788 245 247 O
blood NCT03921788 248 253 B-Condition
reflux NCT03921788 254 260 I-Condition
in NCT03921788 261 263 O
in NCT03921788 264 266 O
the NCT03921788 267 270 O
parametric NCT03921788 271 281 B-Modifier
, NCT03921788 282 283 O
uterine NCT03921788 284 291 B-Modifier
, NCT03921788 292 293 O
gonadal NCT03921788 294 301 B-Modifier
veins NCT03921788 302 307 I-Modifier

- NCT03921788 310 311 O
The NCT03921788 313 316 O
presence NCT03921788 317 325 O
of NCT03921788 326 328 O
diseases NCT03921788 329 337 B-Condition
, NCT03921788 338 339 O
the NCT03921788 340 343 O
clinical NCT03921788 344 352 O
course NCT03921788 353 359 O
of NCT03921788 360 362 O
which NCT03921788 363 368 O
suggests NCT03921788 369 377 B-Assertion___Assertion-Type-Value:possible
the NCT03921788 378 381 O
presence NCT03921788 382 390 O
of NCT03921788 391 393 O
chronic NCT03921788 394 401 B-Modifier
pelvic NCT03921788 402 408 B-Condition
pain NCT03921788 409 413 I-Condition
and NCT03921788 414 417 B-And
other NCT03921788 418 423 O
varieties NCT03921788 424 433 O
of NCT03921788 434 436 O
chronic NCT03921788 437 444 B-Modifier
pain NCT03921788 445 449 B-Condition
, NCT03921788 450 451 O
including NCT03921788 452 461 O
migraine NCT03921788 462 470 B-Condition

- NCT03921788 473 474 O
Pregnancy NCT03921788 476 485 B-Condition

Inclusion NCT03929263 0 9 O
Criteria NCT03929263 10 18 O
: NCT03929263 19 20 O

- NCT03929263 24 25 O
Eligible NCT03929263 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929263 36 39 O
fMRI NCT03929263 40 44 B-Procedure

- NCT03929263 47 48 O
Sufficient NCT03929263 50 60 O
English NCT03929263 61 68 O
fluency NCT03929263 69 76 O
to NCT03929263 77 79 O
complete NCT03929263 80 88 O
tasks NCT03929263 89 94 O

- NCT03929263 97 98 O
BMI NCT03929263 100 103 B-Observation
≦ NCT03929263 104 105 B-Eq-Comparison
40.0 NCT03929263 106 110 I-Eq-Comparison

- NCT03929263 114 115 O
Right NCT03929263 117 122 B-Condition
- NCT03929263 123 124 I-Condition
handed NCT03929263 125 131 I-Condition

- NCT03929263 134 135 O
Biological NCT03929263 137 147 B-Modifier
female NCT03929263 148 154 O

- NCT03929263 157 158 I-Observation
Co NCT03929263 160 162 B-Observation
- NCT03929263 163 164 O
residing NCT03929263 165 173 I-Observation
at NCT03929263 174 176 B-Eq-Comparison
least NCT03929263 177 182 I-Eq-Comparison
4 NCT03929263 183 184 I-Eq-Comparison
days NCT03929263 185 189 I-Eq-Comparison
/ NCT03929263 190 191 I-Eq-Comparison
week NCT03929263 192 196 I-Eq-Comparison

- NCT03929263 199 200 O
Adult NCT03929263 202 207 O
participants NCT03929263 208 220 O
: NCT03929263 221 222 O
Biological NCT03929263 223 233 O
mother NCT03929263 234 240 B-Family-Member___Family-Member-Type:mother
of NCT03929263 241 243 O
adolescent NCT03929263 244 254 O
participant NCT03929263 255 266 O

- NCT03929263 269 270 O
Adult NCT03929263 272 277 O
participants NCT03929263 278 290 O
: NCT03929263 291 292 O
Primary NCT03929263 293 300 B-Family-Member___Family-Member-Type:parent
caregiver NCT03929263 301 310 I-Family-Member___Family-Member-Type:parent
> NCT03929263 311 312 B-Eq-Comparison
50 NCT03929263 313 315 I-Eq-Comparison
% NCT03929263 316 317 O
of NCT03929263 318 320 O
child NCT03929263 321 326 B-Family-Member___Family-Member-Type:child
's NCT03929263 326 328 O
lifespan NCT03929263 329 337 B-Observation

- NCT03929263 340 341 O
Adult NCT03929263 343 348 O
participants NCT03929263 349 361 O
: NCT03929263 362 363 O
BMI NCT03929263 364 367 B-Observation
≧ NCT03929263 368 369 B-Eq-Comparison
18.0 NCT03929263 370 374 I-Eq-Comparison

- NCT03929263 378 379 O
Adolescent NCT03929263 381 391 O
participants NCT03929263 392 404 O
: NCT03929263 405 406 O
Age NCT03929263 407 410 B-Age
13 NCT03929263 411 413 B-Eq-Comparison
- NCT03929263 414 415 I-Eq-Comparison
17 NCT03929263 416 418 I-Eq-Comparison
years NCT03929263 419 424 I-Eq-Comparison

- NCT03929263 427 428 O
Adolescent NCT03929263 430 440 O
participants NCT03929263 441 453 O
: NCT03929263 454 455 O
BMI NCT03929263 456 459 B-Observation
≧ NCT03929263 460 461 B-Eq-Comparison
16.0 NCT03929263 462 466 I-Eq-Comparison

Exclusion NCT03929263 468 477 O
Criteria NCT03929263 478 486 O
: NCT03929263 487 488 O

- NCT03929263 492 493 O
Current NCT03929263 495 502 B-Eq-Comparison
psychiatric NCT03929263 503 514 B-Condition
diagnosis NCT03929263 515 524 I-Condition

- NCT03929263 527 528 O
Medications NCT03929263 530 541 B-Drug
influencing NCT03929263 542 553 O
fMRI NCT03929263 554 558 B-Procedure

- NCT03929263 561 562 O
Medical NCT03929263 564 571 B-Condition
conditions NCT03929263 572 582 I-Condition
influencing NCT03929263 583 594 O
fMRI NCT03929263 595 599 B-Procedure

- NCT03929263 602 603 O
Alcohol NCT03929263 605 612 B-Drug
or NCT03929263 613 615 B-Or
psychoactive NCT03929263 616 628 B-Drug
drug NCT03929263 629 633 I-Drug
on NCT03929263 634 636 B-Temporal-Connection___Temporal-Connection-Type-Value:during
scan NCT03929263 637 641 B-Study
day NCT03929263 642 645 O

- NCT03929263 648 649 O
Adolescent NCT03929263 651 661 O
participants NCT03929263 662 674 O
: NCT03929263 675 676 O
Neurodevelopmental NCT03929263 677 695 B-Condition
delay NCT03929263 696 701 I-Condition

- NCT03929263 704 705 O
Adolescent NCT03929263 707 717 O
participants NCT03929263 718 730 O
: NCT03929263 731 732 O
History NCT03929263 733 740 B-Eq-Comparison
of NCT03929263 741 743 O
mood NCT03929263 744 748 B-Modifier
or NCT03929263 749 751 B-Or
psychotic NCT03929263 752 761 B-Modifier
disorder NCT03929263 762 770 B-Condition

- NCT03929263 773 774 O
Adolescent NCT03929263 776 786 O
participants NCT03929263 787 799 O
: NCT03929263 800 801 O
History NCT03929263 802 809 B-Eq-Comparison
of NCT03929263 810 812 O
obsessive NCT03929263 813 822 B-Condition
- NCT03929263 823 824 I-Condition
compulsive NCT03929263 825 835 I-Condition
disorder NCT03929263 836 844 I-Condition
( NCT03929263 845 846 O
OCD NCT03929263 847 850 B-Condition
) NCT03929263 851 852 O
or NCT03929263 853 855 B-Or
attention NCT03929263 856 865 B-Condition
- NCT03929263 866 867 I-Condition
deficit NCT03929263 868 875 I-Condition
/ NCT03929263 876 877 I-Condition
hyperactivity NCT03929263 878 891 I-Condition
disorder NCT03929263 892 900 I-Condition
( NCT03929263 901 902 O
ADHD NCT03929263 903 907 B-Condition
) NCT03929263 908 909 O

Inclusion NCT03924960 0 9 O
Criteria NCT03924960 10 18 O
: NCT03924960 19 20 O

- NCT03924960 24 25 O
Subjects NCT03924960 27 35 O
diagnosed NCT03924960 36 45 O
according NCT03924960 46 55 O
to NCT03924960 56 58 O
the NCT03924960 59 62 O
American NCT03924960 63 71 O
College NCT03924960 72 79 O
of NCT03924960 80 82 O
Rheumatology NCT03924960 83 95 O
2016 NCT03924960 96 100 O
diagnostic NCT03924960 101 111 O
criteria NCT03924960 112 120 O
for NCT03924960 121 124 O
fibromyalgia NCT03924960 125 137 B-Condition
. NCT03924960 137 138 O

Exclusion NCT03924960 140 149 O
Criteria NCT03924960 150 158 O
: NCT03924960 159 160 O

- NCT03924960 164 165 O
History NCT03924960 167 174 B-Eq-Comparison
of NCT03924960 175 177 O
comorbid NCT03924960 178 186 B-Condition
inflammatory NCT03924960 187 199 I-Condition
rheumatic NCT03924960 200 209 I-Condition
/ NCT03924960 210 211 B-Or
connective NCT03924960 212 222 B-Condition
tissue NCT03924960 223 229 I-Condition
diseases NCT03924960 230 238 I-Condition

- NCT03924960 241 242 O
History NCT03924960 244 251 B-Eq-Comparison
of NCT03924960 252 254 O
cardiovascular NCT03924960 255 269 B-Modifier
or NCT03924960 270 272 B-Or
musculoskeletal NCT03924960 273 288 B-Modifier
problems NCT03924960 289 297 B-Condition
that NCT03924960 298 302 O
could NCT03924960 303 308 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03924960 309 316 B-Negation
them NCT03924960 317 321 O
to NCT03924960 322 324 O
participate NCT03924960 325 336 O
in NCT03924960 337 339 O
an NCT03924960 340 342 O
exercise NCT03924960 343 351 B-Procedure
program NCT03924960 352 359 I-Procedure
. NCT03924960 359 360 O

Inclusion NCT03928431 0 9 O
Criteria NCT03928431 10 18 O
: NCT03928431 19 20 O

- NCT03928431 24 25 O
Infants NCT03928431 27 34 B-Family-Member___Family-Member-Type:child
of NCT03928431 35 37 O
healthy NCT03928431 38 45 B-Condition
mothers NCT03928431 46 53 B-Family-Member___Family-Member-Type:mother
with NCT03928431 54 58 B-And
uncomplicated NCT03928431 59 72 B-Modifier
pregnancies NCT03928431 73 84 B-Condition
at NCT03928431 85 87 O
term NCT03928431 88 92 O
, NCT03928431 93 94 O
mothers NCT03928431 95 102 B-Family-Member___Family-Member-Type:mother
of NCT03928431 103 105 O
any NCT03928431 106 109 O
ethnic NCT03928431 110 116 O
or NCT03928431 117 119 O
social NCT03928431 120 126 O
background NCT03928431 127 137 O
that NCT03928431 138 142 O
can NCT03928431 143 146 O
speak NCT03928431 147 152 O
, NCT03928431 153 154 O
read NCT03928431 155 159 O
, NCT03928431 160 161 O
and NCT03928431 162 165 O
understand NCT03928431 166 176 O
Swedish NCT03928431 177 184 O
to NCT03928431 185 187 O
the NCT03928431 188 191 O
extent NCT03928431 192 198 O
that NCT03928431 199 203 O
they NCT03928431 204 208 O
can NCT03928431 209 212 O
consent NCT03928431 213 220 O
in NCT03928431 221 223 O
Swedish NCT03928431 224 231 O
. NCT03928431 231 232 O
An NCT03928431 234 236 O
additional NCT03928431 237 247 O
inclusion NCT03928431 248 257 O
criterion NCT03928431 258 267 O
for NCT03928431 268 271 O
mothers NCT03928431 272 279 O
in NCT03928431 280 282 O
the NCT03928431 283 286 O
CS NCT03928431 287 289 O
groups NCT03928431 290 296 O
is NCT03928431 297 299 O
vaginal NCT03928431 300 307 B-Observation
pH NCT03928431 308 310 I-Observation
≤ NCT03928431 311 312 B-Eq-Comparison
4 NCT03928431 313 314 I-Eq-Comparison
at NCT03928431 315 317 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928431 318 321 O
time NCT03928431 322 326 O
of NCT03928431 327 329 O
birth NCT03928431 330 335 B-Birth
. NCT03928431 335 336 O

Exclusion NCT03928431 338 347 O
Criteria NCT03928431 348 356 O
: NCT03928431 357 358 O

- NCT03928431 362 363 O
Infants NCT03928431 365 372 B-Family-Member___Family-Member-Type:child
of NCT03928431 373 375 O
mothers NCT03928431 376 383 B-Family-Member___Family-Member-Type:mother
with NCT03928431 384 388 O
pre NCT03928431 389 392 B-Condition
- NCT03928431 393 394 I-Condition
eclampsia NCT03928431 395 404 I-Condition
or NCT03928431 405 407 B-Or
complicated NCT03928431 408 419 B-Modifier
pregnancies NCT03928431 420 431 B-Condition
, NCT03928431 432 433 O
mothers NCT03928431 434 441 B-Family-Member___Family-Member-Type:mother
< NCT03928431 442 443 B-Eq-Comparison
18 NCT03928431 444 446 I-Eq-Comparison
years NCT03928431 447 452 I-Eq-Comparison|Eq-Comparison
or NCT03928431 453 455 B-Or
> NCT03928431 456 457 B-Eq-Comparison
40 NCT03928431 458 460 I-Eq-Comparison
years NCT03928431 461 466 O
of NCT03928431 467 469 O
age NCT03928431 470 473 B-Age
, NCT03928431 474 475 O
genital NCT03928431 476 483 B-Condition
herpes NCT03928431 484 490 I-Condition
simplex NCT03928431 491 498 I-Condition
, NCT03928431 499 500 O
genital NCT03928431 501 508 B-Condition
warts NCT03928431 509 514 I-Condition
, NCT03928431 515 516 O
HIV NCT03928431 517 520 B-Condition
, NCT03928431 521 522 O
Hepatitis NCT03928431 523 532 B-Condition
B NCT03928431 533 534 I-Condition
or NCT03928431 535 537 B-Or
complications NCT03928431 538 551 B-Condition
during NCT03928431 552 558 B-Temporal-Connection___Temporal-Connection-Type-Value:during
delivery NCT03928431 559 567 B-Condition
, NCT03928431 568 569 O
infants NCT03928431 570 577 B-Family-Member___Family-Member-Type:child
delivered NCT03928431 578 587 O
prior NCT03928431 588 593 B-Eq-Comparison
to NCT03928431 594 596 I-Eq-Comparison
37 NCT03928431 597 599 I-Eq-Comparison
weeks NCT03928431 600 605 I-Eq-Comparison
of NCT03928431 606 608 O
gestation NCT03928431 609 618 B-Observation
. NCT03928431 618 619 O
Additional NCT03928431 621 631 O
exclusion NCT03928431 632 641 O
criteria NCT03928431 642 650 O
for NCT03928431 651 654 O
mothers NCT03928431 655 662 O
in NCT03928431 663 665 O
the NCT03928431 666 669 O
CS NCT03928431 670 672 O
group NCT03928431 673 678 O
: NCT03928431 679 680 O
Mothers NCT03928431 681 688 B-Family-Member___Family-Member-Type:mother
positive NCT03928431 689 697 O
to NCT03928431 698 700 O
Group NCT03928431 701 706 B-Condition
B NCT03928431 707 708 I-Condition
Streptococcus NCT03928431 709 722 I-Condition|Condition
, NCT03928431 723 724 O
Group NCT03928431 725 730 B-Condition
A NCT03928431 731 732 I-Condition
Streptococcus NCT03928431 733 746 O
, NCT03928431 747 748 O
bacterial NCT03928431 749 758 B-Condition
vaginosis NCT03928431 759 768 I-Condition
, NCT03928431 769 770 O
vaginal NCT03928431 771 778 B-Observation
pH NCT03928431 779 781 I-Observation
> NCT03928431 782 783 B-Eq-Comparison
4 NCT03928431 784 785 I-Eq-Comparison
at NCT03928431 786 788 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928431 789 792 O
time NCT03928431 793 797 O
of NCT03928431 798 800 O
birth NCT03928431 801 806 B-Birth
. NCT03928431 806 807 O
Mothers NCT03928431 809 816 B-Family-Member___Family-Member-Type:mother
with NCT03928431 817 821 O
fecal NCT03928431 822 827 O
samples NCT03928431 828 835 B-Observation
positive NCT03928431 836 844 O
for NCT03928431 845 848 O
Salmonella NCT03928431 849 859 B-Organism
, NCT03928431 860 861 O
Shigella NCT03928431 862 870 B-Organism
, NCT03928431 871 872 O
Campylobacter NCT03928431 873 886 B-Organism
or NCT03928431 887 889 B-Or
Yersinia NCT03928431 890 898 B-Organism
. NCT03928431 898 899 O

Inclusion NCT03925129 0 9 O
Criteria NCT03925129 10 18 O
: NCT03925129 19 20 O

- NCT03925129 24 25 O
Patients NCT03925129 27 35 O
seeking NCT03925129 36 43 B-Assertion___Assertion-Type-Value:intention
medication NCT03925129 44 54 B-Drug
abortion NCT03925129 55 63 B-Procedure
with NCT03925129 64 68 O
a NCT03925129 69 70 O
definite NCT03925129 71 79 B-Modifier
, NCT03925129 80 81 O
singleton NCT03925129 82 91 B-Modifier
, NCT03925129 92 93 O
intrauterine NCT03925129 94 106 B-Modifier
pregnancy NCT03925129 107 116 B-Condition
( NCT03925129 117 118 O
IUP NCT03925129 119 122 B-Condition
) NCT03925129 123 124 O
< NCT03925129 125 126 B-Eq-Comparison
70 NCT03925129 127 129 I-Eq-Comparison
days NCT03925129 130 134 I-Eq-Comparison
' NCT03925129 134 135 O
gestation NCT03925129 136 145 B-Observation
on NCT03925129 146 148 O
ultrasound NCT03925129 149 159 B-Procedure

- NCT03925129 162 163 O
Rapid NCT03925129 165 170 B-Observation
Estimate NCT03925129 171 179 I-Observation
of NCT03925129 180 182 I-Observation
Adult NCT03925129 183 188 I-Observation
Literacy NCT03925129 189 197 I-Observation
in NCT03925129 198 200 I-Observation
Medicine NCT03925129 201 209 I-Observation
- NCT03925129 210 211 I-Observation
Short NCT03925129 212 217 I-Observation
Form NCT03925129 218 222 I-Observation
( NCT03925129 223 224 O
REALM NCT03925129 225 230 B-Observation
- NCT03925129 231 232 I-Observation
SF NCT03925129 233 235 I-Observation
) NCT03925129 236 237 O
22 NCT03925129 238 240 O
score NCT03925129 241 246 B-Eq-Comparison
> NCT03925129 247 248 I-Eq-Comparison
4 NCT03925129 249 250 I-Eq-Comparison

- NCT03925129 254 255 O
Age NCT03925129 257 260 B-Age
equal NCT03925129 261 266 B-Eq-Comparison
to NCT03925129 267 269 I-Eq-Comparison
or NCT03925129 270 272 I-Eq-Comparison
greater NCT03925129 273 280 I-Eq-Comparison
than NCT03925129 281 285 I-Eq-Comparison
18 NCT03925129 286 288 I-Eq-Comparison
years NCT03925129 289 294 I-Eq-Comparison

- NCT03925129 297 298 O
Provide NCT03925129 300 307 O
informed NCT03925129 308 316 O
consent NCT03925129 317 324 O
to NCT03925129 325 327 O
participate NCT03925129 328 339 O

- NCT03925129 342 343 O
Willing NCT03925129 345 352 O
to NCT03925129 353 355 O
adhere NCT03925129 356 362 O
to NCT03925129 363 365 O
study NCT03925129 366 371 O
procedures NCT03925129 372 382 O
, NCT03925129 383 384 O
including NCT03925129 385 394 O
access NCT03925129 395 401 O
to NCT03925129 402 404 O
a NCT03925129 405 406 O
smart NCT03925129 407 412 O
phone NCT03925129 413 418 O
, NCT03925129 419 420 O
ability NCT03925129 421 428 O
to NCT03925129 429 431 O
receive NCT03925129 432 439 O
text NCT03925129 440 444 O
messages NCT03925129 445 453 O
and NCT03925129 454 457 O
answer NCT03925129 458 464 O
online NCT03925129 465 471 O
surveys NCT03925129 472 479 O
on NCT03925129 480 482 O
smart NCT03925129 483 488 O
phone NCT03925129 489 494 O

Exclusion NCT03925129 495 504 O
Criteria NCT03925129 505 513 O
: NCT03925129 514 515 O

- NCT03925129 519 520 O
Contraindication NCT03925129 522 538 B-Contraindication
to NCT03925129 539 541 O
medication NCT03925129 542 552 B-Drug
abortion NCT03925129 553 561 B-Procedure

- NCT03925129 564 565 O
Allergy NCT03925129 567 574 B-Allergy
to NCT03925129 575 577 O
mifepristone NCT03925129 578 590 B-Drug
or NCT03925129 591 593 B-Or
misoprostol NCT03925129 594 605 B-Drug

- NCT03925129 608 609 O
Contraindication NCT03925129 611 627 B-Contraindication
or NCT03925129 628 630 B-Or
allergy NCT03925129 631 638 B-Allergy
to NCT03925129 639 641 O
ibuprofen NCT03925129 642 651 B-Drug

- NCT03925129 654 655 O
History NCT03925129 657 664 B-Eq-Comparison
of NCT03925129 665 667 O
cardiac NCT03925129 668 675 B-Condition
arrhythmia NCT03925129 676 686 I-Condition

- NCT03925129 689 690 O
Presence NCT03925129 692 700 O
of NCT03925129 701 703 O
an NCT03925129 704 706 O
implantable NCT03925129 707 718 B-Procedure
device NCT03925129 719 725 I-Procedure
with NCT03925129 726 730 O
electrical NCT03925129 731 741 B-Modifier
discharge NCT03925129 742 751 I-Modifier
, NCT03925129 752 753 O
i. NCT03925129 754 756 O
e. NCT03925129 757 759 O
cardiac NCT03925129 761 768 B-Procedure
pacemaker NCT03925129 769 778 I-Procedure

- NCT03925129 781 782 O
History NCT03925129 784 791 B-Eq-Comparison
of NCT03925129 792 794 O
chronic NCT03925129 795 802 B-Modifier
pain NCT03925129 803 807 B-Condition
disorder NCT03925129 808 816 I-Condition

- NCT03925129 819 820 O
Any NCT03925129 822 825 O
opioid NCT03925129 826 832 B-Drug
use NCT03925129 833 836 O
during NCT03925129 837 843 B-Temporal-Connection___Temporal-Connection-Type-Value:during
previous NCT03925129 844 852 B-Eq-Comparison
30 NCT03925129 853 855 I-Eq-Comparison
days NCT03925129 856 860 I-Eq-Comparison

- NCT03925129 863 864 O
Current NCT03925129 866 873 B-Eq-Comparison
or NCT03925129 874 876 B-Or
prior NCT03925129 877 882 B-Eq-Comparison
use NCT03925129 883 886 O
of NCT03925129 887 889 O
TENS NCT03925129 890 894 B-Procedure

- NCT03925129 897 898 O
BMI NCT03925129 900 903 B-Observation
> NCT03925129 904 905 B-Eq-Comparison
30 NCT03925129 906 908 I-Eq-Comparison

Inclusion NCT03925883 0 9 O
Criteria NCT03925883 10 18 O
: NCT03925883 19 20 O

- NCT03925883 24 25 O
Positive NCT03925883 27 35 O
FIT NCT03925883 36 39 B-Observation
test NCT03925883 40 44 I-Observation

Exclusion NCT03925883 45 54 O
Criteria NCT03925883 55 63 O
: NCT03925883 64 65 O

- NCT03925883 69 70 O
Prior NCT03925883 72 77 B-Eq-Comparison
colorectal NCT03925883 78 88 B-Modifier
cancer NCT03925883 89 95 B-Condition

- NCT03925883 98 99 O
Dialysis NCT03925883 101 109 B-Procedure
patient NCT03925883 110 117 O

Inclusion NCT03920904 0 9 O
Criteria NCT03920904 10 18 O
: NCT03920904 19 20 O

- NCT03920904 24 25 O
ASA NCT03920904 27 30 B-Condition
l NCT03920904 31 32 B-Eq-Comparison
- NCT03920904 33 34 I-Eq-Comparison
lll NCT03920904 35 38 I-Eq-Comparison

- NCT03920904 41 42 O
Undergoing NCT03920904 44 54 B-Eq-Comparison
sternotomy NCT03920904 55 65 B-Procedure
for NCT03920904 66 69 O
cardiac NCT03920904 70 77 B-Procedure
surgery NCT03920904 78 85 I-Procedure
under NCT03920904 86 91 O
a NCT03920904 92 93 O
PIFB NCT03920904 94 98 B-Procedure
and NCT03920904 99 102 B-And
general NCT03920904 103 110 B-Procedure
anesthesia NCT03920904 111 121 I-Procedure

Exclusion NCT03920904 122 131 O
Criteria NCT03920904 132 140 O
: NCT03920904 141 142 O

- NCT03920904 146 147 O
Patient NCT03920904 149 156 O
's NCT03920904 156 158 O
refusal NCT03920904 159 166 O
or NCT03920904 167 169 O
inability NCT03920904 170 179 O
to NCT03920904 180 182 O
consent NCT03920904 183 190 O

- NCT03920904 193 194 O
Allergy NCT03920904 196 203 B-Allergy
, NCT03920904 204 205 O
hypersensibility NCT03920904 206 222 B-Condition
or NCT03920904 223 225 B-Or
resistance NCT03920904 226 236 B-Condition
to NCT03920904 237 239 O
local NCT03920904 240 245 B-Procedure
anesthetic NCT03920904 246 256 I-Procedure

- NCT03920904 259 260 O
Contraindication NCT03920904 262 278 B-Contraindication
to NCT03920904 279 281 O
regional NCT03920904 282 290 B-Procedure
anesthesia NCT03920904 291 301 I-Procedure
: NCT03920904 302 303 O
infection NCT03920904 304 313 B-Condition
in NCT03920904 314 316 O
the NCT03920904 317 320 O
designated NCT03920904 321 331 O
area NCT03920904 332 336 O
, NCT03920904 337 338 O
severe NCT03920904 339 345 O
congenital NCT03920904 346 356 B-Modifier
coagulopathy NCT03920904 357 369 B-Condition
or NCT03920904 370 372 O
inadequate NCT03920904 373 383 B-Negation
hemostasis NCT03920904 384 394 B-Procedure
before NCT03920904 395 401 B-Temporal-Connection___Temporal-Connection-Type-Value:before
PIFB NCT03920904 402 406 B-Procedure

- NCT03920904 409 410 O
Severe NCT03920904 412 418 O
hepatic NCT03920904 419 426 B-Modifier
( NCT03920904 427 428 O
Child NCT03920904 429 434 O
B NCT03920904 435 436 B-Modifier
and NCT03920904 437 440 B-Or
C NCT03920904 441 442 B-Modifier
) NCT03920904 443 444 O
or NCT03920904 445 447 B-Or
renal NCT03920904 448 453 B-Modifier
insufficiency NCT03920904 454 467 B-Condition
( NCT03920904 468 469 O
GFR NCT03920904 470 473 B-Eq-Comparison|Observation
< NCT03920904 474 475 I-Eq-Comparison
30 NCT03920904 476 478 I-Eq-Comparison
mL NCT03920904 479 481 I-Eq-Comparison
/ NCT03920904 482 483 I-Eq-Comparison
min NCT03920904 484 487 I-Eq-Comparison
) NCT03920904 488 489 O

Inclusion NCT03922685 0 9 O
Criteria NCT03922685 10 18 O
: NCT03922685 19 20 O

- NCT03922685 24 25 O
postmenopausal NCT03922685 27 41 B-Condition

- NCT03922685 44 45 O
normal NCT03922685 47 53 O
blood NCT03922685 54 59 B-Observation
glucose NCT03922685 60 67 I-Observation

- NCT03922685 70 71 O
no NCT03922685 73 75 B-Negation
cholesterol NCT03922685 76 87 B-Condition
medication NCT03922685 88 98 B-Drug

- NCT03922685 101 102 O
age NCT03922685 104 107 B-Age
between NCT03922685 108 115 B-Eq-Comparison
50 NCT03922685 116 118 I-Eq-Comparison
an NCT03922685 119 121 I-Eq-Comparison
65 NCT03922685 122 124 I-Eq-Comparison
years NCT03922685 125 130 I-Eq-Comparison

- NCT03922685 133 134 O
overweight NCT03922685 136 146 B-Condition
but NCT03922685 147 150 B-And
not NCT03922685 151 154 B-Negation
obese NCT03922685 155 160 B-Condition

- NCT03922685 163 164 O
BMI NCT03922685 166 169 B-Observation
between NCT03922685 170 177 B-Eq-Comparison
25 NCT03922685 178 180 I-Eq-Comparison
and NCT03922685 181 184 I-Eq-Comparison
30 NCT03922685 185 187 I-Eq-Comparison
kg NCT03922685 188 190 I-Eq-Comparison
/ NCT03922685 191 192 I-Eq-Comparison
m2 NCT03922685 193 195 I-Eq-Comparison

- NCT03922685 198 199 O
weight NCT03922685 201 207 B-Observation
- NCT03922685 208 209 O
stable NCT03922685 210 216 O
during NCT03922685 217 223 B-Temporal-Connection___Temporal-Connection-Type-Value:during
past NCT03922685 224 228 B-Eq-Comparison
6 NCT03922685 229 230 I-Eq-Comparison
months NCT03922685 231 237 I-Eq-Comparison

- NCT03922685 240 241 O
exercise NCT03922685 243 251 B-Observation
less NCT03922685 252 256 B-Eq-Comparison
than NCT03922685 257 261 I-Eq-Comparison
20 NCT03922685 262 264 I-Eq-Comparison
minutes NCT03922685 265 272 I-Eq-Comparison
three NCT03922685 273 278 B-Eq-Comparison
times NCT03922685 279 284 I-Eq-Comparison
a NCT03922685 285 286 I-Eq-Comparison
week NCT03922685 287 291 I-Eq-Comparison

Exclusion NCT03922685 292 301 O
Criteria NCT03922685 302 310 O
: NCT03922685 311 312 O

- NCT03922685 316 317 O
metabolic NCT03922685 319 328 B-Condition
disease NCT03922685 329 336 I-Condition
other NCT03922685 337 342 B-Exception
than NCT03922685 343 347 I-Exception
hormonally NCT03922685 348 358 B-Modifier
- NCT03922685 359 360 I-Modifier
corrected NCT03922685 361 370 I-Modifier
hypothyroidism NCT03922685 371 385 B-Condition

- NCT03922685 388 389 I-Condition
musculo NCT03922685 391 398 B-Condition
- NCT03922685 399 400 O
skeletal NCT03922685 401 409 I-Condition
disability NCT03922685 410 420 I-Condition
that NCT03922685 421 425 O
would NCT03922685 426 431 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03922685 432 440 B-Negation
exercise NCT03922685 441 449 B-Observation

- NCT03922685 452 453 O
smoker NCT03922685 455 461 B-Condition

- NCT03922685 464 465 O
do NCT03922685 467 469 O
not NCT03922685 470 473 O
meet NCT03922685 474 478 O
inclusion NCT03922685 479 488 O
criteria NCT03922685 489 497 O

Inclusion NCT03921398 0 9 O
Criteria NCT03921398 10 18 O
( NCT03921398 19 20 O
ESRD NCT03921398 21 25 B-Condition
group NCT03921398 26 31 O
) NCT03921398 32 33 O
: NCT03921398 35 36 O

- NCT03921398 40 41 O
Age NCT03921398 43 46 B-Age
≥ NCT03921398 47 48 B-Eq-Comparison
18 NCT03921398 49 51 I-Eq-Comparison
years NCT03921398 52 57 I-Eq-Comparison
, NCT03921398 58 59 O

- NCT03921398 63 64 O
History NCT03921398 66 73 B-Eq-Comparison
of NCT03921398 74 76 O
biopsy NCT03921398 77 83 O
- NCT03921398 84 85 O
proven NCT03921398 86 92 O
lupus NCT03921398 93 98 B-Condition
nephritis NCT03921398 99 108 I-Condition

- NCT03921398 111 112 O
All NCT03921398 114 117 O
classes NCT03921398 118 125 O
of NCT03921398 126 128 O
lupus NCT03921398 129 134 B-Condition
nephritis NCT03921398 135 144 I-Condition

- NCT03921398 147 148 O
Written NCT03921398 150 157 O
informed NCT03921398 158 166 O
consent NCT03921398 167 174 O

- NCT03921398 177 178 O
Affiliation NCT03921398 180 191 O
to NCT03921398 192 194 O
a NCT03921398 195 196 O
social NCT03921398 197 203 O
security NCT03921398 204 212 O
regime NCT03921398 213 219 O

Exclusion NCT03921398 220 229 O
Criteria NCT03921398 230 238 O
( NCT03921398 239 240 O
ESRD NCT03921398 241 245 B-Condition
group NCT03921398 246 251 O
) NCT03921398 252 253 O
: NCT03921398 255 256 O

- NCT03921398 260 261 I-Eq-Comparison
Past NCT03921398 263 267 B-Eq-Comparison
- NCT03921398 268 269 O
history NCT03921398 270 277 I-Eq-Comparison
of NCT03921398 278 280 O
kidney NCT03921398 281 287 B-Modifier
transplantation NCT03921398 288 303 B-Procedure

- NCT03921398 306 307 O
Active NCT03921398 309 315 B-Eq-Comparison
infection NCT03921398 316 325 B-Condition

- NCT03921398 328 329 O
Active NCT03921398 331 337 B-Eq-Comparison
allergy NCT03921398 338 345 B-Allergy
( NCT03921398 346 347 O
such NCT03921398 348 352 O
as NCT03921398 353 355 O
hay NCT03921398 356 359 B-Condition
fever NCT03921398 360 365 I-Condition
) NCT03921398 366 367 O

- NCT03921398 371 372 O
Pregnant NCT03921398 374 382 B-Condition
or NCT03921398 383 385 B-Or
breastfeeding NCT03921398 386 399 B-Condition
women NCT03921398 400 405 O

- NCT03921398 408 409 O
Protected NCT03921398 411 420 O
adults NCT03921398 421 427 O
( NCT03921398 428 429 O
individuals NCT03921398 430 441 O
under NCT03921398 442 447 B-Observation
guardianship NCT03921398 448 460 I-Observation
by NCT03921398 461 463 O
court NCT03921398 464 469 O
order NCT03921398 470 475 O
) NCT03921398 476 477 O

Inclusion NCT03921398 479 488 O
criteria NCT03921398 489 497 O
( NCT03921398 498 499 O
non NCT03921398 500 503 B-Negation
ESRD NCT03921398 504 508 B-Condition
group NCT03921398 509 514 O
) NCT03921398 515 516 O
: NCT03921398 518 519 O

- NCT03921398 523 524 O
Age NCT03921398 526 529 B-Age
≥ NCT03921398 530 531 B-Eq-Comparison
18 NCT03921398 532 534 I-Eq-Comparison
years NCT03921398 535 540 I-Eq-Comparison
, NCT03921398 541 542 O

- NCT03921398 546 547 O
Biopsy NCT03921398 549 555 B-Procedure
proven NCT03921398 556 562 O
ACTIVE NCT03921398 563 569 B-Eq-Comparison
lupus NCT03921398 570 575 B-Condition
nephritis NCT03921398 576 585 I-Condition

- NCT03921398 588 589 O
First NCT03921398 591 596 B-Eq-Comparison
event NCT03921398 597 602 O
of NCT03921398 603 605 O
lupus NCT03921398 606 611 B-Condition
nephritis NCT03921398 612 621 I-Condition

- NCT03921398 624 625 O
No NCT03921398 627 629 B-Negation
immunosuppressive NCT03921398 630 647 B-Procedure
therapy NCT03921398 648 655 I-Procedure
( NCT03921398 656 657 O
including NCT03921398 658 667 O
corticosteroids NCT03921398 668 683 B-Drug
) NCT03921398 684 685 O

- NCT03921398 689 690 O
Written NCT03921398 692 699 O
informed NCT03921398 700 708 O
consent NCT03921398 709 716 O

- NCT03921398 719 720 O
Affiliation NCT03921398 722 733 O
to NCT03921398 734 736 O
a NCT03921398 737 738 O
social NCT03921398 739 745 O
security NCT03921398 746 754 O
regime NCT03921398 755 761 O

Exclusion NCT03921398 762 771 O
criteria NCT03921398 772 780 O
( NCT03921398 781 782 O
non NCT03921398 783 786 B-Negation
ESRD NCT03921398 787 791 B-Condition
group NCT03921398 792 797 O
) NCT03921398 798 799 O
: NCT03921398 800 801 O

- NCT03921398 805 806 O
Immunosuppressive NCT03921398 808 825 B-Procedure
treatment NCT03921398 826 835 I-Procedure

- NCT03921398 838 839 O
Relapse NCT03921398 841 848 B-Condition
of NCT03921398 849 851 O
lupus NCT03921398 852 857 B-Condition
nephritis NCT03921398 858 867 I-Condition
under NCT03921398 868 873 B-Temporal-Connection___Temporal-Connection-Type-Value:during
treatment NCT03921398 874 883 B-Procedure

- NCT03921398 886 887 O
Pregnant NCT03921398 889 897 B-Condition
or NCT03921398 898 900 B-Or
breastfeeding NCT03921398 901 914 B-Condition
women NCT03921398 915 920 O

- NCT03921398 923 924 O
Protected NCT03921398 926 935 B-Observation
adults NCT03921398 936 942 O
( NCT03921398 943 944 O
individuals NCT03921398 945 956 O
under NCT03921398 957 962 B-Observation
guardianship NCT03921398 963 975 I-Observation
by NCT03921398 976 978 O
court NCT03921398 979 984 O
order NCT03921398 985 990 O
) NCT03921398 991 992 O

Inclusion NCT03927924 0 9 O
Criteria NCT03927924 10 18 O
: NCT03927924 19 20 O

- NCT03927924 24 25 O
Visible NCT03927924 27 34 B-Condition
index NCT03927924 35 40 I-Condition
lesion NCT03927924 41 47 I-Condition
( NCT03927924 48 49 O
s NCT03927924 50 51 O
) NCT03927924 52 53 O
on NCT03927924 54 56 O
MRI NCT03927924 57 60 B-Procedure

- NCT03927924 63 64 O
Index NCT03927924 66 71 B-Observation
lesion NCT03927924 72 78 I-Observation
( NCT03927924 79 80 O
s NCT03927924 81 82 O
) NCT03927924 83 84 O
greater NCT03927924 85 92 B-Eq-Comparison
than NCT03927924 93 97 I-Eq-Comparison
0.5 NCT03927924 98 101 I-Eq-Comparison
cm3 NCT03927924 102 105 I-Eq-Comparison

- NCT03927924 108 109 O
Found NCT03927924 111 116 O
to NCT03927924 117 119 O
have NCT03927924 120 124 O
localized NCT03927924 125 134 B-Modifier
low NCT03927924 135 138 O
- NCT03927924 139 140 O
risk NCT03927924 141 145 B-Risk
or NCT03927924 146 148 B-Or
intermediate NCT03927924 149 161 O
- NCT03927924 162 163 O
risk NCT03927924 164 168 B-Risk
prostate NCT03927924 169 177 B-Condition
cancer NCT03927924 178 184 I-Condition
after NCT03927924 185 190 B-Temporal-Connection___Temporal-Connection-Type-Value:after
MRI NCT03927924 191 194 B-Procedure
- NCT03927924 195 196 I-Procedure
USG NCT03927924 197 200 I-Procedure
fusion NCT03927924 201 207 I-Procedure
targeted NCT03927924 208 216 I-Procedure
biopsy NCT03927924 217 223 I-Procedure
and NCT03927924 224 227 B-Or
saturation NCT03927924 228 238 B-Procedure
biopsy NCT03927924 239 245 I-Procedure
: NCT03927924 246 247 O

1 NCT03927924 256 257 O
. NCT03927924 257 258 O
Clinical NCT03927924 260 268 O
tumour NCT03927924 269 275 B-Condition
stage NCT03927924 276 281 B-Eq-Comparison
T2 NCT03927924 282 284 I-Eq-Comparison
, NCT03927924 285 286 O
or NCT03927924 287 289 B-Or

2 NCT03927924 297 298 O
. NCT03927924 298 299 O
Gleason NCT03927924 301 308 B-Observation
score NCT03927924 309 314 I-Observation
7 NCT03927924 315 316 B-Eq-Comparison
, NCT03927924 317 318 O
or NCT03927924 319 321 B-Or

3 NCT03927924 329 330 O
. NCT03927924 330 331 O
PSA NCT03927924 333 336 B-Observation
20 NCT03927924 337 339 B-Eq-Comparison
ng NCT03927924 340 342 I-Eq-Comparison
/ NCT03927924 343 344 I-Eq-Comparison
ml NCT03927924 345 347 I-Eq-Comparison

Exclusion NCT03927924 348 357 O
Criteria NCT03927924 358 366 O
: NCT03927924 367 368 O

- NCT03927924 372 373 O
Prostate NCT03927924 375 383 B-Observation
size NCT03927924 384 388 I-Observation
larger NCT03927924 389 395 B-Eq-Comparison
than NCT03927924 396 400 I-Eq-Comparison
50 NCT03927924 401 403 I-Eq-Comparison
ml NCT03927924 404 406 I-Eq-Comparison

- NCT03927924 409 410 O
Patients NCT03927924 412 420 O
unfit NCT03927924 421 426 B-Contraindication
for NCT03927924 427 430 O
contrast NCT03927924 431 439 B-Procedure
MRI NCT03927924 440 443 I-Procedure
exam NCT03927924 444 448 O

- NCT03927924 451 452 O
Patients NCT03927924 454 462 O
with NCT03927924 463 467 O
previous NCT03927924 468 476 B-Eq-Comparison
treatment NCT03927924 477 486 B-Procedure
of NCT03927924 487 489 O
prostate NCT03927924 490 498 B-Modifier
cancer NCT03927924 499 505 B-Condition

- NCT03927924 508 509 O
Patients NCT03927924 511 519 O
with NCT03927924 520 524 O
previous NCT03927924 525 533 B-Eq-Comparison
surgery NCT03927924 534 541 B-Procedure
on NCT03927924 542 544 O
the NCT03927924 545 548 O
prostate NCT03927924 549 557 B-Modifier

- NCT03927924 560 561 O
Patients NCT03927924 563 571 O
with NCT03927924 572 576 O
active NCT03927924 577 583 B-Eq-Comparison
urinary NCT03927924 584 591 B-Modifier
tract NCT03927924 592 597 I-Modifier
infection NCT03927924 598 607 B-Condition

- NCT03927924 610 611 O
Patients NCT03927924 613 621 O
with NCT03927924 622 626 O
bladder NCT03927924 627 634 B-Condition
pathology NCT03927924 635 644 I-Condition
including NCT03927924 645 654 O
bladder NCT03927924 655 662 B-Condition|Modifier
stone NCT03927924 663 668 I-Condition
and NCT03927924 669 672 B-Or
bladder NCT03927924 673 680 O
cancer NCT03927924 681 687 B-Condition

- NCT03927924 690 691 O
Patients NCT03927924 693 701 O
with NCT03927924 702 706 O
urethral NCT03927924 707 715 B-Condition
stricture NCT03927924 716 725 I-Condition

- NCT03927924 728 729 O
Patients NCT03927924 731 739 O
with NCT03927924 740 744 O
neurogenic NCT03927924 745 755 B-Condition
bladder NCT03927924 756 763 I-Condition
and NCT03927924 764 767 B-Or
/ NCT03927924 768 769 I-Or
or NCT03927924 770 772 I-Or
sphincter NCT03927924 773 782 B-Condition
abnormalities NCT03927924 783 796 I-Condition

- NCT03927924 799 800 O
Fail NCT03927924 802 806 O
to NCT03927924 807 809 O
give NCT03927924 810 814 O
informed NCT03927924 815 823 O
consent NCT03927924 824 831 O

Inclusion NCT03928418 0 9 O
Criteria NCT03928418 10 18 O
: NCT03928418 19 20 O

- NCT03928418 24 25 O
Age NCT03928418 27 30 B-Age
18 NCT03928418 31 33 B-Eq-Comparison
years NCT03928418 34 39 I-Eq-Comparison
and NCT03928418 40 43 I-Eq-Comparison
older NCT03928418 44 49 I-Eq-Comparison
; NCT03928418 49 50 O

- NCT03928418 53 54 O
HIV NCT03928418 56 59 B-Condition
positive NCT03928418 60 68 O
; NCT03928418 68 69 O

- NCT03928418 72 73 O
On NCT03928418 75 77 B-Eq-Comparison
ART NCT03928418 78 81 B-Procedure
for NCT03928418 82 85 O
at NCT03928418 86 88 B-Eq-Comparison
least NCT03928418 89 94 I-Eq-Comparison
six NCT03928418 95 98 I-Eq-Comparison
months NCT03928418 99 105 I-Eq-Comparison
; NCT03928418 105 106 O

- NCT03928418 109 110 O
Reported NCT03928418 112 120 O
alcohol NCT03928418 121 128 B-Drug
use NCT03928418 129 132 O
in NCT03928418 133 135 O
the NCT03928418 136 139 O
prior NCT03928418 140 145 B-Eq-Comparison
year NCT03928418 146 150 I-Eq-Comparison
at NCT03928418 151 153 O
clinic NCT03928418 154 160 O
entry NCT03928418 161 166 O
; NCT03928418 166 167 O

- NCT03928418 170 171 O
Fluency NCT03928418 173 180 O
in NCT03928418 181 183 O
Runyakole NCT03928418 184 193 O
; NCT03928418 193 194 O

- NCT03928418 197 198 O
Living NCT03928418 200 206 O
within NCT03928418 207 213 B-Eq-Comparison
two NCT03928418 214 217 I-Eq-Comparison
hours NCT03928418 218 223 I-Eq-Comparison
travel NCT03928418 224 230 B-Observation
time NCT03928418 231 235 I-Observation
from NCT03928418 236 240 O
the NCT03928418 241 244 O
clinic NCT03928418 245 251 O
; NCT03928418 251 252 O

- NCT03928418 255 256 O
Owning NCT03928418 258 264 O
or NCT03928418 265 267 O
having NCT03928418 268 274 O
daily NCT03928418 275 280 O
access NCT03928418 281 287 O
to NCT03928418 288 290 O
a NCT03928418 291 292 O
cell NCT03928418 293 297 O
phone NCT03928418 298 303 O
; NCT03928418 303 304 O

- NCT03928418 307 308 O
Screening NCT03928418 310 319 O
positive NCT03928418 320 328 O
on NCT03928418 329 331 O
the NCT03928418 332 335 O
AUDIT NCT03928418 336 341 B-Observation
- NCT03928418 342 343 I-Observation
C NCT03928418 344 345 I-Observation

Exclusion NCT03928418 346 355 O
Criteria NCT03928418 356 364 O
: NCT03928418 365 366 O

- NCT03928418 370 371 O
Plans NCT03928418 373 378 B-Assertion___Assertion-Type-Value:intention
to NCT03928418 379 381 O
move NCT03928418 382 386 B-Observation
out NCT03928418 387 390 I-Observation
of NCT03928418 391 393 O
the NCT03928418 394 397 O
catchment NCT03928418 398 407 O
area NCT03928418 408 412 O
within NCT03928418 413 419 B-Eq-Comparison
6 NCT03928418 420 421 I-Eq-Comparison
months NCT03928418 422 428 I-Eq-Comparison
; NCT03928418 428 429 O

- NCT03928418 432 433 O
Unable NCT03928418 435 441 O
to NCT03928418 442 444 O
provide NCT03928418 445 452 O
informed NCT03928418 453 461 O
consent NCT03928418 462 469 O
. NCT03928418 469 470 O

- NCT03928418 474 475 O
Participation NCT03928418 477 490 O
in NCT03928418 491 493 O
another NCT03928418 494 501 B-Other
research NCT03928418 502 510 O
study NCT03928418 511 516 B-Study
. NCT03928418 516 517 O

Inclusion NCT03924544 0 9 O
Criteria NCT03924544 10 18 O
: NCT03924544 19 20 O

- NCT03924544 24 25 O
Primary NCT03924544 27 34 B-Modifier
Open NCT03924544 35 39 I-Modifier
Angle NCT03924544 40 45 I-Modifier
Glaucoma NCT03924544 46 54 B-Condition

Exclusion NCT03924544 55 64 O
Criteria NCT03924544 65 73 O
: NCT03924544 74 75 O

- NCT03924544 79 80 O
Secondary NCT03924544 82 91 B-Modifier
Glaucoma NCT03924544 92 100 B-Condition
, NCT03924544 101 102 O
Closed NCT03924544 103 109 B-Modifier
angle NCT03924544 110 115 I-Modifier
glaucoma NCT03924544 116 124 B-Condition

Inclusion NCT03924791 0 9 O
Criteria NCT03924791 10 18 O
: NCT03924791 19 20 O

- NCT03924791 24 25 O
Diagnosed NCT03924791 27 36 O
with NCT03924791 37 41 O
sciatica NCT03924791 42 50 B-Condition
by NCT03924791 51 53 O
GP NCT03924791 54 56 B-Provider

- NCT03924791 59 60 O
NRS NCT03924791 62 65 B-Observation
leg NCT03924791 66 69 I-Observation
pain NCT03924791 70 74 I-Observation
of NCT03924791 75 77 O
6 NCT03924791 78 79 B-Eq-Comparison
or NCT03924791 80 82 I-Eq-Comparison
more NCT03924791 83 87 I-Eq-Comparison
on NCT03924791 88 90 O
a NCT03924791 91 92 O
10 NCT03924791 93 95 O
- NCT03924791 96 97 O
point NCT03924791 98 103 O
NRS NCT03924791 104 107 O
scale NCT03924791 108 113 O

- NCT03924791 116 117 O
Minimum NCT03924791 119 126 O
duration NCT03924791 127 135 O
of NCT03924791 136 138 O
symptoms NCT03924791 139 147 B-Assertion___Assertion-Type-Value:possible|Coreference
of NCT03924791 148 150 O
3 NCT03924791 151 152 B-Eq-Comparison
weeks NCT03924791 153 158 I-Eq-Comparison
and NCT03924791 159 162 O
maximum NCT03924791 163 170 B-Eq-Comparison
duration NCT03924791 171 179 I-Eq-Comparison
of NCT03924791 180 182 I-Eq-Comparison
8 NCT03924791 183 184 I-Eq-Comparison
weeks NCT03924791 185 190 I-Eq-Comparison

Exclusion NCT03924791 191 200 O
Criteria NCT03924791 201 209 O
: NCT03924791 210 211 O

- NCT03924791 215 216 O
Age NCT03924791 218 221 B-Age
under NCT03924791 222 227 B-Eq-Comparison
18 NCT03924791 228 230 I-Eq-Comparison
years NCT03924791 231 236 I-Eq-Comparison

- NCT03924791 239 240 O
Condition NCT03924791 242 251 B-Condition
preventing NCT03924791 252 262 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924791 263 265 O
receive NCT03924791 266 273 O
transforaminal NCT03924791 274 288 B-Modifier
epidural NCT03924791 289 297 B-Procedure
injection NCT03924791 298 307 I-Procedure

- NCT03924791 310 311 O
Severe NCT03924791 313 319 O
scoliosis NCT03924791 320 329 B-Condition

- NCT03924791 332 333 O
Transforaminal NCT03924791 335 349 B-Modifier
epidural NCT03924791 350 358 B-Procedure
injection NCT03924791 359 368 I-Procedure
received NCT03924791 369 377 B-Eq-Comparison
in NCT03924791 378 380 I-Eq-Comparison
6 NCT03924791 381 382 I-Eq-Comparison
months NCT03924791 383 389 I-Eq-Comparison
before NCT03924791 390 396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03924791 397 410 B-Study
date NCT03924791 411 415 O

- NCT03924791 418 419 O
Surgery NCT03924791 421 428 B-Procedure
for NCT03924791 429 432 O
sciatica NCT03924791 433 441 B-Condition
at NCT03924791 442 444 O
the NCT03924791 445 448 O
same NCT03924791 449 453 B-Modifier
level NCT03924791 454 459 I-Modifier

- NCT03924791 462 463 O
Surgery NCT03924791 465 472 B-Procedure
for NCT03924791 473 476 O
sciatica NCT03924791 477 485 B-Condition
at NCT03924791 486 488 O
another NCT03924791 489 496 B-Modifier
level NCT03924791 497 502 I-Modifier
within NCT03924791 503 509 B-Eq-Comparison
one NCT03924791 510 513 I-Eq-Comparison
year NCT03924791 514 518 I-Eq-Comparison
before NCT03924791 519 525 B-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03924791 526 535 B-Study

- NCT03924791 538 539 O
Pregnancy NCT03924791 541 550 B-Condition

Inclusion NCT03929289 0 9 O
Criteria NCT03929289 10 18 O
: NCT03929289 19 20 O

- NCT03929289 24 25 O
Male NCT03929289 27 31 O
or NCT03929289 32 34 B-Or
female NCT03929289 35 41 O

- NCT03929289 44 45 O
Aged NCT03929289 47 51 B-Age
18 NCT03929289 52 54 B-Eq-Comparison
to NCT03929289 55 57 I-Eq-Comparison
35 NCT03929289 58 60 I-Eq-Comparison
years NCT03929289 61 66 I-Eq-Comparison
old NCT03929289 67 70 O

- NCT03929289 73 74 O
Signed NCT03929289 76 82 O
written NCT03929289 83 90 O
informed NCT03929289 91 99 O
consent NCT03929289 100 107 O

- NCT03929289 110 111 O
Insurance NCT03929289 113 122 O
coverage NCT03929289 123 131 O

Exclusion NCT03929289 132 141 O
Criteria NCT03929289 142 150 O
: NCT03929289 151 152 O

- NCT03929289 156 157 O
Neurological NCT03929289 159 171 B-Modifier
or NCT03929289 172 174 B-Or
psychiatric NCT03929289 175 186 B-Modifier
or NCT03929289 187 189 B-Or
ophthalmological NCT03929289 190 206 B-Modifier
disorder NCT03929289 207 215 B-Condition

- NCT03929289 218 219 O
Non NCT03929289 221 224 B-Negation
- NCT03929289 225 226 O
stabilized NCT03929289 227 237 O
medical NCT03929289 238 245 B-Condition
condition NCT03929289 246 255 I-Condition

- NCT03929289 258 259 O
Ongoing NCT03929289 261 268 B-Eq-Comparison
treatment NCT03929289 269 278 B-Procedure
with NCT03929289 279 283 O
drugs NCT03929289 284 289 B-Drug
that NCT03929289 290 294 O
affect NCT03929289 295 301 O
the NCT03929289 302 305 O
central NCT03929289 306 313 B-Condition
nervous NCT03929289 314 321 I-Condition
system NCT03929289 322 328 I-Condition

- NCT03929289 336 337 O
Uncorrected NCT03929289 339 350 B-Modifier
visual NCT03929289 351 357 B-Condition
inadequacy NCT03929289 358 368 I-Condition

- NCT03929289 376 377 O
No NCT03929289 379 381 B-Negation
fluency NCT03929289 382 389 O
in NCT03929289 390 392 O
French NCT03929289 393 399 O
reading NCT03929289 400 407 O

- NCT03929289 415 416 O
Pregnant NCT03929289 418 426 B-Condition
and NCT03929289 427 430 B-Or
/ NCT03929289 431 432 I-Or
or NCT03929289 433 435 I-Or
breastfeeding NCT03929289 436 449 B-Condition
woman NCT03929289 450 455 O
, NCT03929289 456 457 O
this NCT03929289 458 462 O
exclusion NCT03929289 463 472 O
criterion NCT03929289 473 482 O
will NCT03929289 483 487 O
be NCT03929289 488 490 O
sought NCT03929289 491 497 O
by NCT03929289 498 500 O
questioning NCT03929289 501 512 O
the NCT03929289 513 516 O
subject NCT03929289 517 524 O

- NCT03929289 532 533 O
Subject NCT03929289 535 542 O
commonly NCT03929289 543 551 O
in NCT03929289 552 554 O
care NCT03929289 555 559 O
in NCT03929289 560 562 O
a NCT03929289 563 564 O
health NCT03929289 565 571 O
or NCT03929289 572 574 O
social NCT03929289 575 581 O
facility NCT03929289 582 590 O
for NCT03929289 591 594 O
purposes NCT03929289 595 603 O
other NCT03929289 604 609 O
than NCT03929289 610 614 O
that NCT03929289 615 619 O
of NCT03929289 620 622 O
research NCT03929289 623 631 O

- NCT03929289 639 640 O
Subject NCT03929289 642 649 O
under NCT03929289 650 655 B-Observation
guardianship NCT03929289 656 668 I-Observation

- NCT03929289 676 677 O
Subject NCT03929289 679 686 O
deprived NCT03929289 687 695 B-Observation
of NCT03929289 696 698 I-Observation
liberty NCT03929289 699 706 I-Observation
by NCT03929289 707 709 O
a NCT03929289 710 711 O
judicial NCT03929289 712 720 O
or NCT03929289 721 723 O
administrative NCT03929289 724 738 O
decision NCT03929289 739 747 O

- NCT03929289 755 756 O
Incompatibility NCT03929289 758 773 B-Contraindication
with NCT03929289 774 778 O
the NCT03929289 779 782 O
Magnetic NCT03929289 783 791 B-Procedure
Resonance NCT03929289 792 801 I-Procedure
Imaging NCT03929289 802 809 I-Procedure
( NCT03929289 810 811 O
MRI NCT03929289 812 815 B-Procedure
) NCT03929289 816 817 O
examination NCT03929289 818 829 O
determined NCT03929289 830 840 O
by NCT03929289 841 843 O
answering NCT03929289 844 853 O
the NCT03929289 854 857 O
following NCT03929289 858 867 O
questions NCT03929289 868 877 O
: NCT03929289 878 879 O

- NCT03929289 883 884 O
Carrier NCT03929289 886 893 O
of NCT03929289 894 896 O
a NCT03929289 897 898 O
neurological NCT03929289 899 911 B-Procedure
stimulator NCT03929289 912 922 I-Procedure
, NCT03929289 923 924 O
cardiac NCT03929289 925 932 B-Condition
( NCT03929289 933 934 O
battery NCT03929289 935 942 B-Modifier
) NCT03929289 943 944 O
or NCT03929289 945 947 B-Or
defibrillator NCT03929289 948 961 B-Procedure

- NCT03929289 964 965 O
Carrier NCT03929289 967 974 O
of NCT03929289 975 977 O
a NCT03929289 978 979 O
cardiac NCT03929289 980 987 B-Modifier
prosthesis NCT03929289 988 998 B-Procedure
( NCT03929289 999 1000 O
valve NCT03929289 1001 1006 B-Procedure
, NCT03929289 1007 1008 O
stent NCT03929289 1009 1014 B-Procedure
. NCT03929289 1015 1016 O
. NCT03929289 1017 1018 O
. NCT03929289 1019 1020 O
) NCT03929289 1021 1022 O
or NCT03929289 1023 1025 B-Or
vascular NCT03929289 1026 1034 B-Modifier

- NCT03929289 1037 1038 O
Holder NCT03929289 1040 1046 O
of NCT03929289 1047 1049 O
intracranial NCT03929289 1050 1062 B-Procedure
clips NCT03929289 1063 1068 B-Modifier
or NCT03929289 1069 1071 B-Or
clamps NCT03929289 1072 1078 B-Modifier
( NCT03929289 1079 1080 O
staples NCT03929289 1081 1088 B-Procedure
) NCT03929289 1089 1090 O

- NCT03929289 1094 1095 O
Carrier NCT03929289 1097 1104 O
of NCT03929289 1105 1107 O
a NCT03929289 1108 1109 O
cerebrospinal NCT03929289 1110 1123 B-Procedure
fluid NCT03929289 1124 1129 I-Procedure
bypass NCT03929289 1130 1136 I-Procedure

- NCT03929289 1139 1140 O
Presence NCT03929289 1142 1150 O
of NCT03929289 1151 1153 O
metal NCT03929289 1154 1159 B-Procedure
chips NCT03929289 1160 1165 I-Procedure
in NCT03929289 1166 1168 B-Modifier
the NCT03929289 1169 1172 I-Modifier
eyes NCT03929289 1173 1177 I-Modifier

- NCT03929289 1180 1181 O
Metal NCT03929289 1183 1188 B-Procedure
prosthesis NCT03929289 1189 1199 I-Procedure
carrier NCT03929289 1200 1207 O
( NCT03929289 1208 1209 O
teeth NCT03929289 1210 1215 B-Modifier
, NCT03929289 1216 1217 O
knees NCT03929289 1218 1223 B-Modifier
) NCT03929289 1224 1225 O

- NCT03929289 1229 1230 O
Pump NCT03929289 1232 1236 B-Procedure
carrier NCT03929289 1237 1244 I-Procedure
or NCT03929289 1245 1247 B-Or
infusion NCT03929289 1248 1256 B-Procedure
system NCT03929289 1257 1263 I-Procedure

- NCT03929289 1266 1267 O
Presence NCT03929289 1269 1277 O
of NCT03929289 1278 1280 O
metal NCT03929289 1281 1286 B-Procedure
tattoo NCT03929289 1287 1293 I-Procedure
near NCT03929289 1294 1298 B-Modifier
the NCT03929289 1299 1302 I-Modifier
head NCT03929289 1303 1307 I-Modifier

- NCT03929289 1310 1311 O
Presence NCT03929289 1313 1321 O
of NCT03929289 1322 1324 O
permanent NCT03929289 1325 1334 B-Procedure
makeup NCT03929289 1335 1341 I-Procedure

- NCT03929289 1344 1345 O
Claustrophobia NCT03929289 1347 1361 B-Condition
or NCT03929289 1362 1364 B-Or
respiratory NCT03929289 1365 1376 B-Condition
disorders NCT03929289 1377 1386 I-Condition

Inclusion NCT03928197 0 9 O
Criteria NCT03928197 10 18 O
: NCT03928197 19 20 O

- NCT03928197 24 25 O
Age NCT03928197 27 30 B-Age
between NCT03928197 31 38 B-Eq-Comparison
25 NCT03928197 39 41 I-Eq-Comparison
years NCT03928197 42 47 I-Eq-Comparison
and NCT03928197 48 51 I-Eq-Comparison
60 NCT03928197 52 54 I-Eq-Comparison
years NCT03928197 55 60 I-Eq-Comparison

- NCT03928197 63 64 O
For NCT03928197 66 69 O
the NCT03928197 70 73 O
volunteers NCT03928197 74 84 O
with NCT03928197 85 89 O
venous NCT03928197 90 96 B-Condition
insuffiency NCT03928197 97 108 I-Condition
: NCT03928197 109 110 O
clearly NCT03928197 111 118 B-Modifier
visual NCT03928197 119 125 I-Modifier
venous NCT03928197 126 132 B-Condition
insufficiency NCT03928197 133 146 I-Condition
( NCT03928197 147 148 O
CEAP NCT03928197 149 153 B-Condition
1 NCT03928197 154 155 B-Eq-Comparison
and NCT03928197 156 159 I-Eq-Comparison
2 NCT03928197 160 161 I-Eq-Comparison
) NCT03928197 162 163 O

- NCT03928197 167 168 O
BMI NCT03928197 170 173 B-Observation
between NCT03928197 174 181 B-Eq-Comparison
24 NCT03928197 182 184 I-Eq-Comparison
and NCT03928197 185 188 I-Eq-Comparison
30 NCT03928197 189 191 I-Eq-Comparison

Exclusion NCT03928197 193 202 O
Criteria NCT03928197 203 211 O
: NCT03928197 212 213 O

- NCT03928197 217 218 O
Volunteers NCT03928197 220 230 O
using NCT03928197 231 236 B-Eq-Comparison
medication NCT03928197 237 247 B-Drug
( NCT03928197 248 249 O
exception NCT03928197 250 259 B-Exception
for NCT03928197 260 263 O
contraception NCT03928197 264 277 B-Drug
) NCT03928197 278 279 O

- NCT03928197 283 284 O
Volunteers NCT03928197 286 296 O
having NCT03928197 297 303 B-Eq-Comparison
comorbidities NCT03928197 304 317 B-Condition

- NCT03928197 320 321 O
Pregnant NCT03928197 323 331 B-Condition
women NCT03928197 332 337 O

- NCT03928197 340 341 O
Women NCT03928197 343 348 O
who NCT03928197 349 352 B-And
menstruate NCT03928197 353 363 B-Condition
on NCT03928197 364 366 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928197 367 370 O
test NCT03928197 371 375 B-Study
date NCT03928197 376 380 I-Study

- NCT03928197 383 384 O
Volunteers NCT03928197 386 396 O
with NCT03928197 397 401 O
an NCT03928197 402 404 O
implanted NCT03928197 405 414 B-Procedure
elektronical NCT03928197 415 427 I-Procedure
device NCT03928197 428 434 I-Procedure
( NCT03928197 435 436 O
IPG NCT03928197 437 440 B-Procedure
, NCT03928197 441 442 O
Pacemaker NCT03928197 443 452 B-Procedure
) NCT03928197 453 454 O


Inclusion NCT03922451 0 9 O
Criteria NCT03922451 10 18 O
: NCT03922451 19 20 O

- NCT03922451 24 25 O
supported NCT03922451 27 36 B-Eq-Comparison
on NCT03922451 37 39 O
ECMO NCT03922451 40 44 B-Procedure

- NCT03922451 47 48 O
receive NCT03922451 50 57 B-Eq-Comparison
piperacillin NCT03922451 58 70 B-Drug
- NCT03922451 71 72 I-Drug
tazobactam NCT03922451 73 83 I-Drug
or NCT03922451 84 86 B-Or
cefazolin NCT03922451 87 96 B-Drug
as NCT03922451 97 99 O
part NCT03922451 100 104 O
of NCT03922451 105 107 O
routine NCT03922451 108 115 B-Procedure
care NCT03922451 116 120 I-Procedure
or NCT03922451 121 123 B-Or
infection NCT03922451 124 133 B-Procedure
management NCT03922451 134 144 I-Procedure

Exclusion NCT03922451 145 154 O
Criteria NCT03922451 155 163 O
: NCT03922451 164 165 O

- NCT03922451 169 170 O
> NCT03922451 172 173 B-Eq-Comparison
= NCT03922451 175 176 I-Eq-Comparison
18 NCT03922451 177 179 I-Eq-Comparison
years NCT03922451 180 185 I-Age|Eq-Comparison

- NCT03922451 188 189 O
No NCT03922451 191 193 O
Consent NCT03922451 194 201 O
provided NCT03922451 202 210 O

Key NCT03926637 0 3 O
Inclusion NCT03926637 4 13 O
Criteria NCT03926637 14 22 O
: NCT03926637 23 24 O

- NCT03926637 28 29 O
Ability NCT03926637 31 38 O
to NCT03926637 39 41 O
understand NCT03926637 42 52 O
the NCT03926637 53 56 O
purpose NCT03926637 57 64 O
and NCT03926637 65 68 O
risks NCT03926637 69 74 O
of NCT03926637 75 77 O
the NCT03926637 78 81 O
study NCT03926637 82 87 O
and NCT03926637 88 91 O
provide NCT03926637 92 99 O
signed NCT03926637 100 106 O
and NCT03926637 107 110 O
dated NCT03926637 111 116 O
informed NCT03926637 117 125 O
consent NCT03926637 126 133 O
and NCT03926637 134 137 O
authorization NCT03926637 138 151 O
to NCT03926637 152 154 O
use NCT03926637 155 158 O
confidential NCT03926637 159 171 O
health NCT03926637 172 178 O
information NCT03926637 179 190 O
in NCT03926637 191 193 O
accordance NCT03926637 194 204 O
with NCT03926637 205 209 O
applicable NCT03926637 210 220 O
participant NCT03926637 221 232 O
privacy NCT03926637 233 240 O
regulations NCT03926637 241 252 O

- NCT03926637 255 256 O
Diagnosis NCT03926637 258 267 O
of NCT03926637 268 270 O
MS NCT03926637 271 273 B-Condition
, NCT03926637 274 275 O
including NCT03926637 276 285 O
Clinically NCT03926637 286 296 B-Condition
Isolated NCT03926637 297 305 I-Condition
Syndrome NCT03926637 306 314 I-Condition

- NCT03926637 317 318 O
Ability NCT03926637 320 327 O
to NCT03926637 328 330 O
understand NCT03926637 331 341 O
the NCT03926637 342 345 O
audio NCT03926637 346 351 O
and NCT03926637 352 355 O
visual NCT03926637 356 362 O
instructions NCT03926637 363 375 O
for NCT03926637 376 379 O
the NCT03926637 380 383 O
test NCT03926637 384 388 O
modules NCT03926637 389 396 O

- NCT03926637 399 400 O
Visual NCT03926637 402 408 B-Condition
function NCT03926637 409 417 I-Condition
, NCT03926637 418 419 O
based NCT03926637 420 425 O
on NCT03926637 426 428 O
the NCT03926637 429 432 O
investigator NCT03926637 433 445 O
's NCT03926637 445 447 O
clinical NCT03926637 448 456 O
judgement NCT03926637 457 466 O
that NCT03926637 467 471 O
does NCT03926637 472 476 O
not NCT03926637 477 480 B-Negation
preclude NCT03926637 481 489 O
an NCT03926637 490 492 O
ability NCT03926637 493 500 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926637 501 503 I-Assertion___Assertion-Type-Value:hypothetical
interact NCT03926637 504 512 O
with NCT03926637 513 517 O
the NCT03926637 518 521 O
Multiple NCT03926637 522 530 B-Observation
Sclerosis NCT03926637 531 540 I-Observation
Performance NCT03926637 541 552 I-Observation
Test NCT03926637 553 557 I-Observation
( NCT03926637 558 559 O
MSPT NCT03926637 560 564 B-Observation
) NCT03926637 565 566 O
. NCT03926637 567 568 O

Key NCT03926637 570 573 O
Exclusion NCT03926637 574 583 O
Criteria NCT03926637 584 592 O
: NCT03926637 593 594 O

- NCT03926637 598 599 O
Unable NCT03926637 601 607 O
or NCT03926637 608 610 O
unwilling NCT03926637 611 620 O
to NCT03926637 621 623 O
provide NCT03926637 624 631 O
informed NCT03926637 632 640 O
consent NCT03926637 641 648 O

- NCT03926637 651 652 O
Participants NCT03926637 654 666 O
younger NCT03926637 667 674 B-Eq-Comparison
than NCT03926637 675 679 I-Eq-Comparison
18 NCT03926637 680 682 I-Eq-Comparison
years NCT03926637 683 688 I-Eq-Comparison
of NCT03926637 689 691 O
age NCT03926637 692 695 B-Age
, NCT03926637 696 697 O
unless NCT03926637 698 704 O
their NCT03926637 705 710 O
parent NCT03926637 711 717 O
or NCT03926637 718 720 O
legal NCT03926637 721 726 O
guardian NCT03926637 727 735 O
provides NCT03926637 736 744 O
the NCT03926637 745 748 O
required NCT03926637 749 757 O
signed NCT03926637 758 764 O
and NCT03926637 765 768 O
dated NCT03926637 769 774 O
informed NCT03926637 775 783 O
consent NCT03926637 784 791 O
and NCT03926637 792 795 O
authorization NCT03926637 796 809 O
to NCT03926637 810 812 O
use NCT03926637 813 816 O
confidential NCT03926637 817 829 O
health NCT03926637 830 836 O
information NCT03926637 837 848 O
and NCT03926637 849 852 O
the NCT03926637 853 856 O
participant NCT03926637 857 868 O
provides NCT03926637 869 877 O
assent NCT03926637 878 884 O
in NCT03926637 885 887 O
accordance NCT03926637 888 898 O
with NCT03926637 899 903 O
national NCT03926637 904 912 O
and NCT03926637 913 916 O
local NCT03926637 917 922 O
subject NCT03926637 923 930 O
privacy NCT03926637 931 938 O
regulations NCT03926637 939 950 O

NOTE NCT03926637 951 955 O
: NCT03926637 956 957 O
Other NCT03926637 958 963 O
protocol NCT03926637 964 972 O
defined NCT03926637 973 980 O
Inclusion NCT03926637 981 990 O
/ NCT03926637 991 992 O
Exclusion NCT03926637 993 1002 O
criteria NCT03926637 1003 1011 O
may NCT03926637 1012 1015 O
apply NCT03926637 1016 1021 O
. NCT03926637 1021 1022 O

Inclusion NCT03929510 0 9 O
Criteria NCT03929510 10 18 O
: NCT03929510 19 20 O

- NCT03929510 24 25 O
Male NCT03929510 27 31 O
participants NCT03929510 32 44 O
who NCT03929510 45 48 B-And
are NCT03929510 49 52 O
healthy NCT03929510 53 60 B-Condition
as NCT03929510 61 63 O
determined NCT03929510 64 74 O
by NCT03929510 75 77 O
medical NCT03929510 78 85 B-Procedure
evaluation NCT03929510 86 96 I-Procedure
including NCT03929510 97 106 O
a NCT03929510 107 108 O
detailed NCT03929510 109 117 O
medical NCT03929510 118 125 O
history NCT03929510 126 133 O
, NCT03929510 134 135 O
full NCT03929510 136 140 B-Modifier
physical NCT03929510 141 149 B-Procedure
examination NCT03929510 150 161 I-Procedure
, NCT03929510 162 163 O
including NCT03929510 164 173 O
blood NCT03929510 174 179 B-Observation
pressure NCT03929510 180 188 I-Observation
( NCT03929510 189 190 O
BP NCT03929510 191 193 B-Observation
) NCT03929510 194 195 O
and NCT03929510 196 199 B-And
pulse NCT03929510 200 205 B-Observation
rate NCT03929510 206 210 I-Observation
( NCT03929510 211 212 O
PR NCT03929510 213 215 B-Observation
) NCT03929510 216 217 O
measurement NCT03929510 218 229 O
, NCT03929510 230 231 O
12 NCT03929510 232 234 B-Procedure
lead NCT03929510 235 239 I-Procedure
ECG NCT03929510 240 243 I-Procedure
, NCT03929510 244 245 O
and NCT03929510 246 249 O
clinical NCT03929510 250 258 O
laboratory NCT03929510 259 269 B-Observation
tests NCT03929510 270 275 I-Observation
. NCT03929510 275 276 O

- NCT03929510 280 281 O
Body NCT03929510 283 287 B-Observation
mass NCT03929510 288 292 I-Observation
index NCT03929510 293 298 I-Observation
( NCT03929510 299 300 O
BMI NCT03929510 301 304 B-Observation
) NCT03929510 305 306 O
of NCT03929510 307 309 O
17.5 NCT03929510 310 314 B-Eq-Comparison
to NCT03929510 315 317 I-Eq-Comparison
30.5 NCT03929510 318 322 I-Eq-Comparison
kg NCT03929510 323 325 I-Eq-Comparison
/ NCT03929510 326 327 I-Eq-Comparison
m2 NCT03929510 328 330 I-Eq-Comparison
; NCT03929510 330 331 O
and NCT03929510 332 335 O
a NCT03929510 336 337 O
total NCT03929510 338 343 O
body NCT03929510 344 348 B-Observation
weight NCT03929510 349 355 I-Observation
> NCT03929510 356 357 B-Eq-Comparison
50 NCT03929510 358 360 I-Eq-Comparison
kg NCT03929510 361 363 I-Eq-Comparison
( NCT03929510 364 365 O
110 NCT03929510 366 369 B-Eq-Comparison
lb NCT03929510 370 372 I-Eq-Comparison
) NCT03929510 373 374 O
. NCT03929510 375 376 O

Exclusion NCT03929510 378 387 O
Criteria NCT03929510 388 396 O
: NCT03929510 397 398 O

- NCT03929510 402 403 O
Known NCT03929510 405 410 O
immunodeficiency NCT03929510 411 427 B-Condition
disorder NCT03929510 428 436 I-Condition
, NCT03929510 437 438 O
including NCT03929510 439 448 O
positive NCT03929510 449 457 O
serology NCT03929510 458 466 O
for NCT03929510 467 470 O
human NCT03929510 471 476 B-Condition
immunodeficiency NCT03929510 477 493 I-Condition
virus NCT03929510 494 499 I-Condition
( NCT03929510 500 501 O
HIV NCT03929510 502 505 B-Condition
) NCT03929510 506 507 O
at NCT03929510 508 510 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929510 511 520 B-Study
, NCT03929510 521 522 O
or NCT03929510 523 525 B-Or
a NCT03929510 526 527 O
first NCT03929510 528 533 B-Modifier
degree NCT03929510 534 540 I-Modifier
relative NCT03929510 541 549 B-Family-Member
with NCT03929510 550 554 O
a NCT03929510 555 556 O
hereditary NCT03929510 557 567 B-Modifier
immunodeficiency NCT03929510 568 584 B-Condition
. NCT03929510 584 585 O

- NCT03929510 589 590 O
Infection NCT03929510 592 601 B-Condition
with NCT03929510 602 606 I-Condition
hepatitis NCT03929510 607 616 I-Condition|Condition
B NCT03929510 617 618 I-Condition
or NCT03929510 619 621 B-Or
hepatitis NCT03929510 622 631 O
C NCT03929510 632 633 I-Condition
viruses NCT03929510 634 641 I-Condition
. NCT03929510 641 642 O

- NCT03929510 646 647 O
Participants NCT03929510 649 661 O
with NCT03929510 662 666 O
selected NCT03929510 667 675 O
acute NCT03929510 676 681 O
or NCT03929510 682 684 B-Or
chronic NCT03929510 685 692 B-Condition
infections NCT03929510 693 703 I-Condition|Condition
or NCT03929510 704 706 O
infection NCT03929510 707 716 O
history NCT03929510 717 724 B-Eq-Comparison
. NCT03929510 724 725 O

- NCT03929510 729 730 O
Participants NCT03929510 732 744 O
have NCT03929510 745 749 O
a NCT03929510 750 751 O
known NCT03929510 752 757 O
present NCT03929510 758 765 B-Eq-Comparison
or NCT03929510 766 768 B-Or
a NCT03929510 769 770 O
history NCT03929510 771 778 B-Eq-Comparison
of NCT03929510 779 781 O
malignancy NCT03929510 782 792 B-Condition
other NCT03929510 793 798 B-Exception
than NCT03929510 799 803 I-Exception
a NCT03929510 804 805 O
successfully NCT03929510 806 818 O
treated NCT03929510 819 826 B-Procedure
or NCT03929510 827 829 B-Or
excised NCT03929510 830 837 B-Procedure
non NCT03929510 838 841 B-Modifier
metastatic NCT03929510 842 852 I-Modifier
basal NCT03929510 853 858 I-Modifier
cell NCT03929510 859 863 I-Modifier|Modifier
or NCT03929510 864 866 B-Or
squamous NCT03929510 867 875 B-Modifier
cell NCT03929510 876 880 O
cancer NCT03929510 881 887 B-Condition
of NCT03929510 888 890 O
the NCT03929510 891 894 O
skin NCT03929510 895 899 B-Modifier
. NCT03929510 899 900 O

- NCT03929510 904 905 O
History NCT03929510 907 914 B-Eq-Comparison
of NCT03929510 915 917 O
alcohol NCT03929510 918 925 B-Condition
abuse NCT03929510 926 931 I-Condition
or NCT03929510 932 934 B-Or|Or
binge NCT03929510 935 940 B-Condition
drinking NCT03929510 941 949 I-Condition
and NCT03929510 950 953 B-Or
/ NCT03929510 954 955 I-Or
or NCT03929510 956 958 B-Or
any NCT03929510 959 962 O
other NCT03929510 963 968 B-Other
illicit NCT03929510 969 976 B-Condition
drug NCT03929510 977 981 I-Condition
use NCT03929510 982 985 I-Condition
or NCT03929510 986 988 O
dependence NCT03929510 989 999 B-Condition
within NCT03929510 1000 1006 B-Eq-Comparison
6 NCT03929510 1007 1008 I-Eq-Comparison
months NCT03929510 1009 1015 I-Eq-Comparison
of NCT03929510 1016 1018 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Screening NCT03929510 1019 1028 B-Study
. NCT03929510 1028 1029 O

- NCT03929510 1033 1034 O
Use NCT03929510 1036 1039 O
of NCT03929510 1040 1042 O
tobacco NCT03929510 1043 1050 B-Drug
/ NCT03929510 1051 1052 B-Or
nicotine NCT03929510 1053 1061 B-Drug
containing NCT03929510 1062 1072 O
products NCT03929510 1073 1081 O
within NCT03929510 1082 1088 B-Eq-Comparison
3 NCT03929510 1089 1090 I-Eq-Comparison
months NCT03929510 1091 1097 I-Eq-Comparison
prior NCT03929510 1098 1103 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929510 1104 1106 O
dosing NCT03929510 1107 1113 O
or NCT03929510 1114 1116 O
positive NCT03929510 1117 1125 O
urine NCT03929510 1126 1131 B-Observation
cotinine NCT03929510 1132 1140 I-Observation
test NCT03929510 1141 1145 I-Observation
. NCT03929510 1145 1146 O

Inclusion NCT03924752 0 9 O
Criteria NCT03924752 10 18 O
: NCT03924752 19 20 O

- NCT03924752 24 25 O
Between NCT03924752 27 34 B-Eq-Comparison
18 NCT03924752 35 37 I-Eq-Comparison
- NCT03924752 38 39 I-Eq-Comparison
85 NCT03924752 40 42 I-Eq-Comparison
years NCT03924752 43 48 I-Eq-Comparison
of NCT03924752 49 51 O
age NCT03924752 52 55 B-Age

- NCT03924752 58 59 O
Subjects NCT03924752 61 69 O
should NCT03924752 70 76 O
be NCT03924752 77 79 O
capable NCT03924752 80 87 B-Condition
of NCT03924752 88 90 I-Condition
walking NCT03924752 91 98 B-Modifier
, NCT03924752 99 100 O
ascending NCT03924752 101 110 B-Modifier
/ NCT03924752 111 112 I-Modifier
descending NCT03924752 113 123 I-Modifier
stairs NCT03924752 124 130 I-Modifier
and NCT03924752 131 134 O
ramps NCT03924752 135 140 O
with NCT03924752 141 145 B-And
full NCT03924752 146 150 B-Condition
capability NCT03924752 151 161 I-Condition
in NCT03924752 162 164 I-Condition
lower NCT03924752 165 170 I-Condition
extremity NCT03924752 171 180 I-Condition
passive NCT03924752 181 188 I-Condition
range NCT03924752 189 194 I-Condition
of NCT03924752 195 197 I-Condition
motion NCT03924752 198 204 I-Condition
( NCT03924752 205 206 O
knee NCT03924752 207 211 B-Observation
flexion NCT03924752 212 219 I-Observation
contracture NCT03924752 220 231 I-Observation
of NCT03924752 232 234 O
> NCT03924752 235 236 B-Eq-Comparison
10 NCT03924752 237 239 I-Eq-Comparison
degrees NCT03924752 240 247 I-Eq-Comparison
, NCT03924752 248 249 O
knee NCT03924752 250 254 B-Observation
flexion NCT03924752 255 262 I-Observation
ROM NCT03924752 263 266 I-Observation
< NCT03924752 267 268 B-Eq-Comparison
90 NCT03924752 269 271 I-Eq-Comparison
degrees NCT03924752 272 279 I-Eq-Comparison
, NCT03924752 280 281 O
hip NCT03924752 282 285 B-Observation
flexion NCT03924752 286 293 I-Observation
contracture NCT03924752 294 305 I-Observation
< NCT03924752 306 307 B-Eq-Comparison
25 NCT03924752 308 310 I-Eq-Comparison
degrees NCT03924752 311 318 I-Eq-Comparison
, NCT03924752 319 320 O
and NCT03924752 321 324 B-And
ankle NCT03924752 325 330 B-Observation
plantar NCT03924752 331 338 I-Observation
flexion NCT03924752 339 346 I-Observation
contracture NCT03924752 347 358 I-Observation
of NCT03924752 359 361 O
> NCT03924752 362 363 B-Eq-Comparison
15 NCT03924752 364 366 I-Eq-Comparison
degrees NCT03924752 367 374 I-Eq-Comparison
) NCT03924752 375 376 O
. NCT03924752 377 378 O

- NCT03924752 382 383 O
Subjects NCT03924752 385 393 O
must NCT03924752 394 398 O
be NCT03924752 399 401 O
able NCT03924752 402 406 B-Condition
to NCT03924752 407 409 I-Condition
walk NCT03924752 410 414 I-Condition
for NCT03924752 415 418 O
at NCT03924752 419 421 B-Eq-Comparison
least NCT03924752 422 427 I-Eq-Comparison
5 NCT03924752 428 429 I-Eq-Comparison
minutes NCT03924752 430 437 I-Eq-Comparison
and NCT03924752 438 441 B-And
willing NCT03924752 442 449 O
and NCT03924752 450 453 O
able NCT03924752 454 458 B-Condition
to NCT03924752 459 461 I-Condition
participate NCT03924752 462 473 I-Condition
over NCT03924752 474 478 O
a NCT03924752 479 480 O
1 NCT03924752 481 482 B-Eq-Comparison
- NCT03924752 483 484 I-Eq-Comparison
6 NCT03924752 485 486 I-Eq-Comparison
hours NCT03924752 487 492 I-Eq-Comparison
experiment NCT03924752 493 503 O
with NCT03924752 504 508 O
breaks NCT03924752 509 515 O
and NCT03924752 516 519 O
rest NCT03924752 520 524 O
enforced NCT03924752 525 533 O
regularly NCT03924752 534 543 O
and NCT03924752 544 547 O
as NCT03924752 548 550 O
needed NCT03924752 551 557 O
. NCT03924752 557 558 O

- NCT03924752 562 563 O
Subjects NCT03924752 565 573 O
must NCT03924752 574 578 O
be NCT03924752 579 581 O
able NCT03924752 582 586 B-Condition
to NCT03924752 587 589 I-Condition|Condition
transfer NCT03924752 590 598 I-Condition
( NCT03924752 599 600 O
sit NCT03924752 601 604 B-Condition
- NCT03924752 605 606 I-Condition|Condition
to NCT03924752 607 609 I-Condition
- NCT03924752 610 611 I-Condition
stand NCT03924752 612 617 I-Condition|Condition
and NCT03924752 618 621 B-And
stand NCT03924752 622 627 O
- NCT03924752 628 629 O
to NCT03924752 630 632 O
- NCT03924752 633 634 O
sit NCT03924752 635 638 I-Condition
) NCT03924752 639 640 O
with NCT03924752 641 645 O
no NCT03924752 646 648 O
external NCT03924752 649 657 O
support NCT03924752 658 665 O
( NCT03924752 666 667 O
arm NCT03924752 668 671 O
rests NCT03924752 672 677 O
OK NCT03924752 678 680 O
) NCT03924752 681 682 O
and NCT03924752 683 686 O
to NCT03924752 687 689 O
ambulate NCT03924752 690 698 B-Condition
over NCT03924752 699 703 B-Modifier
small NCT03924752 704 709 I-Modifier
slopes NCT03924752 710 716 I-Modifier
( NCT03924752 717 718 O
3 NCT03924752 719 720 B-Eq-Comparison
degrees NCT03924752 721 728 I-Eq-Comparison
) NCT03924752 729 730 O
and NCT03924752 731 734 B-And
a NCT03924752 735 736 O
few NCT03924752 737 740 O
steps NCT03924752 741 746 B-Eq-Comparison|Modifier
( NCT03924752 747 748 O
6 NCT03924752 749 750 B-Eq-Comparison
steps NCT03924752 751 756 O
) NCT03924752 757 758 O
. NCT03924752 759 760 O

Exclusion NCT03924752 762 771 O
Criteria NCT03924752 772 780 O
: NCT03924752 781 782 O

- NCT03924752 786 787 O
History NCT03924752 789 796 B-Eq-Comparison
of NCT03924752 797 799 O
neurological NCT03924752 800 812 B-Condition
injury NCT03924752 813 819 I-Condition
, NCT03924752 820 821 O
gait NCT03924752 822 826 B-Condition
pathology NCT03924752 827 836 I-Condition
, NCT03924752 837 838 O
or NCT03924752 839 841 B-Or
cardiovascular NCT03924752 842 856 B-Condition
condition NCT03924752 857 866 I-Condition
that NCT03924752 867 871 O
would NCT03924752 872 877 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03924752 878 883 O
your NCT03924752 884 888 O
ability NCT03924752 889 896 B-Condition
to NCT03924752 897 899 I-Condition
ambulate NCT03924752 900 908 I-Condition
for NCT03924752 909 912 O
multiple NCT03924752 913 921 B-Eq-Comparison
hours NCT03924752 922 927 I-Eq-Comparison
. NCT03924752 927 928 O

Inclusion NCT03929276 0 9 O
Criteria NCT03929276 10 18 O
: NCT03929276 19 20 O

- NCT03929276 24 25 O
Subjects NCT03929276 27 35 O
with NCT03929276 36 40 O
adhesive NCT03929276 41 49 B-Condition
capsulitis NCT03929276 50 60 I-Condition
diagnosis NCT03929276 61 70 O
by NCT03929276 71 73 O
physical NCT03929276 74 82 B-Procedure
examination NCT03929276 83 94 I-Procedure
( NCT03929276 95 96 O
Compared NCT03929276 97 105 O
with NCT03929276 106 110 O
intact NCT03929276 111 117 O
side NCT03929276 118 122 O
, NCT03929276 123 124 O
there NCT03929276 125 130 O
is NCT03929276 131 133 O
more NCT03929276 134 138 B-Eq-Comparison
than NCT03929276 139 143 I-Eq-Comparison
25 NCT03929276 144 146 I-Eq-Comparison
% NCT03929276 147 148 O
limitation NCT03929276 149 159 O
in NCT03929276 160 162 O
at NCT03929276 163 165 B-Eq-Comparison
least NCT03929276 166 171 I-Eq-Comparison
two NCT03929276 172 175 I-Eq-Comparison
directions NCT03929276 176 186 I-Eq-Comparison
of NCT03929276 187 189 O
shoulder NCT03929276 190 198 B-Observation
range NCT03929276 199 204 I-Observation
of NCT03929276 205 207 I-Observation
motion NCT03929276 208 214 I-Observation
) NCT03929276 215 216 O

- NCT03929276 220 221 O
Subjects NCT03929276 223 231 O
have NCT03929276 232 236 O
complaints NCT03929276 237 247 B-Condition
for NCT03929276 248 251 O
at NCT03929276 252 254 B-Eq-Comparison
least NCT03929276 255 260 I-Eq-Comparison
1 NCT03929276 261 262 I-Eq-Comparison
month NCT03929276 263 268 I-Eq-Comparison

- NCT03929276 271 272 O
No NCT03929276 274 276 B-Negation
pregnancy NCT03929276 277 286 B-Condition
/ NCT03929276 287 288 B-Or
breastfeeding NCT03929276 289 302 B-Condition

Exclusion NCT03929276 303 312 O
Criteria NCT03929276 313 321 O
: NCT03929276 322 323 O

- NCT03929276 327 328 O
History NCT03929276 330 337 B-Eq-Comparison
of NCT03929276 338 340 O
bilateral NCT03929276 341 350 B-Modifier
adhesive NCT03929276 351 359 B-Condition
capsulitis NCT03929276 360 370 I-Condition

- NCT03929276 373 374 O
History NCT03929276 376 383 B-Eq-Comparison
of NCT03929276 384 386 O
shoulder NCT03929276 387 395 B-Modifier
trauma NCT03929276 396 402 B-Condition
, NCT03929276 403 404 O
fracture NCT03929276 405 413 B-Condition
, NCT03929276 414 415 O
shoulder NCT03929276 416 424 B-Procedure
shoulder NCT03929276 425 433 O
surgery NCT03929276 434 441 I-Procedure
, NCT03929276 442 443 O
calcific NCT03929276 444 452 B-Condition
tendinopathy NCT03929276 453 465 I-Condition
, NCT03929276 466 467 O
glenohumeral NCT03929276 468 480 B-Condition
osteoarthritis NCT03929276 481 495 I-Condition
, NCT03929276 496 497 O
inflammatory NCT03929276 498 510 B-Condition
rheumatic NCT03929276 511 520 I-Condition
diseases NCT03929276 521 529 I-Condition
, NCT03929276 530 531 O
tumor NCT03929276 532 537 B-Condition
, NCT03929276 538 539 O
infection NCT03929276 540 549 B-Condition

- NCT03929276 552 553 O
History NCT03929276 555 562 B-Eq-Comparison
of NCT03929276 563 565 O
corticosteroid NCT03929276 566 580 B-Drug
injection NCT03929276 581 590 O
in NCT03929276 591 593 O
the NCT03929276 594 597 O
shoulder NCT03929276 598 606 B-Modifier
during NCT03929276 607 613 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929276 614 617 O
last NCT03929276 618 622 B-Eq-Comparison
3 NCT03929276 623 624 I-Eq-Comparison
months NCT03929276 625 631 I-Eq-Comparison

- NCT03929276 634 635 O
History NCT03929276 637 644 B-Eq-Comparison
of NCT03929276 645 647 O
recent NCT03929276 648 654 B-Eq-Comparison
lung NCT03929276 655 659 B-Modifier
, NCT03929276 660 661 O
breast NCT03929276 662 668 B-Modifier
or NCT03929276 669 671 B-Or
bypass NCT03929276 672 678 B-Modifier
surgery NCT03929276 679 686 B-Procedure

- NCT03929276 689 690 O
History NCT03929276 692 699 B-Eq-Comparison
of NCT03929276 700 702 O
cervical NCT03929276 703 711 B-Condition
radiculopathy NCT03929276 712 725 I-Condition
/ NCT03929276 726 727 B-Or
brachial NCT03929276 728 736 B-Condition
plexus NCT03929276 737 743 I-Condition
lesion NCT03929276 744 750 I-Condition

- NCT03929276 753 754 O
History NCT03929276 756 763 B-Eq-Comparison
of NCT03929276 764 766 O
neuromuscular NCT03929276 767 780 B-Condition
disease NCT03929276 781 788 I-Condition

- NCT03929276 791 792 O
History NCT03929276 794 801 B-Eq-Comparison
of NCT03929276 802 804 O
physical NCT03929276 805 813 B-Procedure
therapy NCT03929276 814 821 I-Procedure
program NCT03929276 822 829 O
for NCT03929276 830 833 O
the NCT03929276 834 837 O
same NCT03929276 838 842 B-Modifier
shoulder NCT03929276 843 851 I-Modifier
in NCT03929276 852 854 O
the NCT03929276 855 858 O
last NCT03929276 859 863 B-Eq-Comparison
6 NCT03929276 864 865 I-Eq-Comparison
months NCT03929276 866 872 I-Eq-Comparison

Inclusion NCT03921164 0 9 O
Criteria NCT03921164 10 18 O
: NCT03921164 19 20 O

- NCT03921164 24 25 O
Patients NCT03921164 27 35 O
> NCT03921164 36 37 B-Eq-Comparison
18 NCT03921164 38 40 I-Eq-Comparison
years NCT03921164 41 46 I-Age|Eq-Comparison
, NCT03921164 47 48 O
scheduled NCT03921164 49 58 B-Eq-Comparison
for NCT03921164 59 62 O
an NCT03921164 63 65 O
elective NCT03921164 66 74 B-Procedure
interventional NCT03921164 75 89 B-Procedure
neuroradiology NCT03921164 90 104 I-Procedure
procedure NCT03921164 105 114 I-Procedure
under NCT03921164 115 120 O
general NCT03921164 121 128 B-Procedure
anesthesia NCT03921164 129 139 I-Procedure
requiring NCT03921164 140 149 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03921164 150 151 O
continuous NCT03921164 152 162 O
monitoring NCT03921164 163 173 O
of NCT03921164 174 176 O
mean NCT03921164 177 181 B-Observation
arterial NCT03921164 182 190 I-Observation
pressure NCT03921164 191 199 I-Observation
and NCT03921164 200 203 B-And
cardiac NCT03921164 204 211 B-Observation
output NCT03921164 212 218 I-Observation
. NCT03921164 218 219 O

Exclusion NCT03921164 221 230 O
Criteria NCT03921164 231 239 O
: NCT03921164 240 241 O

- NCT03921164 245 246 O
age NCT03921164 248 251 B-Age
< NCT03921164 252 253 B-Eq-Comparison
18 NCT03921164 254 256 I-Eq-Comparison
years NCT03921164 257 262 I-Eq-Comparison

- NCT03921164 265 266 O
Patient NCT03921164 268 275 O
who NCT03921164 276 279 O
has NCT03921164 280 283 O
not NCT03921164 284 287 O
signed NCT03921164 288 294 O
the NCT03921164 295 298 O
consent NCT03921164 299 306 O

- NCT03921164 309 310 O
Pregnant NCT03921164 312 320 B-Condition
woman NCT03921164 321 326 O

- NCT03921164 329 330 O
Patient NCT03921164 332 339 O
under NCT03921164 340 345 O
judicial NCT03921164 346 354 B-Observation
protection NCT03921164 355 365 I-Observation

- NCT03921164 368 369 O
Patient NCT03921164 371 378 O
without NCT03921164 379 386 O
affiliation NCT03921164 387 398 O
to NCT03921164 399 401 O
a NCT03921164 402 403 O
social NCT03921164 404 410 O
security NCT03921164 411 419 O
scheme NCT03921164 420 426 O

Inclusion NCT03928626 0 9 O
Criteria NCT03928626 10 18 O
: NCT03928626 19 20 O

1 NCT03928626 24 25 O
. NCT03928626 25 26 O
Adults NCT03928626 28 34 O
ages NCT03928626 35 39 B-Age
18 NCT03928626 40 42 B-Eq-Comparison
- NCT03928626 43 44 I-Eq-Comparison
25 NCT03928626 45 47 O

2 NCT03928626 51 52 O
. NCT03928626 52 53 O
Capability NCT03928626 55 65 O
of NCT03928626 66 68 O
performing NCT03928626 69 79 O
the NCT03928626 80 83 O
experimental NCT03928626 84 96 O
tasks NCT03928626 97 102 O
( NCT03928626 103 104 O
e. NCT03928626 105 107 O
g. NCT03928626 108 110 O
, NCT03928626 111 112 O
can NCT03928626 113 116 O
read NCT03928626 117 121 O
, NCT03928626 122 123 O
able NCT03928626 124 128 O
to NCT03928626 129 131 O
use NCT03928626 132 135 O
computers NCT03928626 136 145 O
) NCT03928626 146 147 O

3 NCT03928626 151 152 O
. NCT03928626 152 153 O
Native NCT03928626 155 161 O
or NCT03928626 162 164 O
fluent NCT03928626 165 171 O
speaker NCT03928626 172 179 O
of NCT03928626 180 182 O
English NCT03928626 183 190 O

4 NCT03928626 193 194 O
. NCT03928626 194 195 O
Provides NCT03928626 197 205 O
informed NCT03928626 206 214 O
consent NCT03928626 215 222 O

5 NCT03928626 225 226 O
. NCT03928626 226 227 O
Normal NCT03928626 229 235 O
or NCT03928626 236 238 B-Or
corrected NCT03928626 239 248 O
- NCT03928626 249 250 O
to NCT03928626 251 253 O
- NCT03928626 254 255 O
normal NCT03928626 256 262 O
vision NCT03928626 263 269 B-Condition

6 NCT03928626 272 273 O
. NCT03928626 273 274 O
Willing NCT03928626 276 283 O
to NCT03928626 284 286 O
commit NCT03928626 287 293 O
to NCT03928626 294 296 O
the NCT03928626 297 300 O
full NCT03928626 301 305 O
length NCT03928626 306 312 O
of NCT03928626 313 315 O
the NCT03928626 316 319 O
protocol NCT03928626 320 328 O

7 NCT03928626 331 332 O
. NCT03928626 332 333 O
Heavy NCT03928626 335 340 B-Condition
drinking NCT03928626 341 349 I-Condition|Condition
or NCT03928626 350 352 B-Or
binge NCT03928626 353 358 B-Condition
- NCT03928626 359 360 I-Condition
drinking NCT03928626 361 369 O

Exclusion NCT03928626 370 379 O
Criteria NCT03928626 380 388 O
. NCT03928626 388 389 O

1 NCT03928626 393 394 O
. NCT03928626 394 395 O
Present NCT03928626 397 404 B-Eq-Comparison
DSM NCT03928626 405 408 B-Condition
disorders NCT03928626 409 418 I-Condition
, NCT03928626 419 420 O
apart NCT03928626 421 426 B-Exception
from NCT03928626 427 431 I-Exception
alcohol NCT03928626 432 439 B-Condition
use NCT03928626 440 443 I-Condition
disorders NCT03928626 444 453 I-Condition

2 NCT03928626 456 457 O
. NCT03928626 457 458 O
Reports NCT03928626 460 467 O
of NCT03928626 468 470 O
neurological NCT03928626 471 483 B-Modifier
or NCT03928626 484 486 B-Or
systemic NCT03928626 487 495 B-Modifier
disorders NCT03928626 496 505 B-Condition
that NCT03928626 506 510 O
can NCT03928626 511 514 B-Assertion___Assertion-Type-Value:hypothetical
cause NCT03928626 515 520 O
cognitive NCT03928626 521 530 B-Condition
impairment NCT03928626 531 541 I-Condition

3 NCT03928626 544 545 O
. NCT03928626 545 546 O
Minor NCT03928626 548 553 O
cognitive NCT03928626 554 563 B-Condition
impairment NCT03928626 564 574 I-Condition
evidenced NCT03928626 575 584 O
by NCT03928626 585 587 O
an NCT03928626 588 590 O
inability NCT03928626 591 600 B-Condition
to NCT03928626 601 603 I-Condition
correctly NCT03928626 604 613 I-Condition
understand NCT03928626 614 624 I-Condition
study NCT03928626 625 630 B-Study
information NCT03928626 631 642 O

4 NCT03928626 645 646 O
. NCT03928626 646 647 O
Reports NCT03928626 649 656 O
entirely NCT03928626 657 665 O
no NCT03928626 666 668 B-Negation
interest NCT03928626 669 677 B-Assertion___Assertion-Type-Value:intention
in NCT03928626 678 680 O
reducing NCT03928626 681 689 O
the NCT03928626 690 693 O
amount NCT03928626 694 700 O
of NCT03928626 701 703 O
drinking NCT03928626 704 712 B-Condition
( NCT03928626 713 714 O
Alcohol NCT03928626 715 722 B-Observation
Contemplation NCT03928626 723 736 I-Observation
Ladder NCT03928626 737 743 I-Observation
score NCT03928626 744 749 I-Observation
of NCT03928626 750 752 O
9 NCT03928626 753 754 B-Eq-Comparison
or NCT03928626 755 757 I-Eq-Comparison
10 NCT03928626 758 760 I-Eq-Comparison
) NCT03928626 761 762 O
. NCT03928626 763 764 O

Inclusion NCT03926780 0 9 O
Criteria NCT03926780 10 18 O
: NCT03926780 19 20 O

- NCT03926780 24 25 O
Evidence NCT03926780 27 35 O
of NCT03926780 36 38 O
LV NCT03926780 39 41 B-Condition
thrombus NCT03926780 42 50 I-Condition
as NCT03926780 51 53 O
assessed NCT03926780 54 62 O
by NCT03926780 63 65 O
trans NCT03926780 66 71 B-Procedure
- NCT03926780 72 73 I-Procedure
thoracic NCT03926780 74 82 I-Procedure
echocardiography NCT03926780 83 99 I-Procedure
( NCT03926780 100 101 O
TTE NCT03926780 102 105 B-Procedure
) NCT03926780 106 107 O
. NCT03926780 108 109 O

Exclusion NCT03926780 111 120 O
Criteria NCT03926780 121 129 O
: NCT03926780 130 131 O

- NCT03926780 135 136 O
Creatinine NCT03926780 138 148 B-Observation
clearance NCT03926780 149 158 I-Observation
less NCT03926780 159 163 B-Eq-Comparison
than NCT03926780 164 168 I-Eq-Comparison
50 NCT03926780 169 171 I-Eq-Comparison
ml NCT03926780 172 174 I-Eq-Comparison
/ NCT03926780 175 176 I-Eq-Comparison
min NCT03926780 177 180 I-Eq-Comparison
. NCT03926780 180 181 O

Inclusion NCT03922243 0 9 O
Criteria NCT03922243 10 18 O
: NCT03922243 19 20 O

- NCT03922243 24 25 O
Dental NCT03922243 27 33 B-Procedure
treatment NCT03922243 34 43 I-Procedure
performed NCT03922243 44 53 O
in NCT03922243 54 56 O
the NCT03922243 57 60 O
time NCT03922243 61 65 O
frame NCT03922243 66 71 O

Exclusion NCT03922243 72 81 O
Criteria NCT03922243 82 90 O
: NCT03922243 91 92 O

- NCT03922243 96 97 O
Dental NCT03922243 99 105 B-Procedure
treatment NCT03922243 106 115 I-Procedure
not NCT03922243 116 119 B-Negation
performed NCT03922243 120 129 O

Inclusion NCT03920332 0 9 O
Criteria NCT03920332 10 18 O
: NCT03920332 19 20 O

- NCT03920332 24 25 O
Inherited NCT03920332 27 36 B-Condition
fibrinogen NCT03920332 37 47 I-Condition
disorders NCT03920332 48 57 I-Condition
( NCT03920332 58 59 O
hypofibrinogenemia NCT03920332 60 78 B-Condition
, NCT03920332 79 80 O
dysfibrinogenemia NCT03920332 81 98 B-Condition
, NCT03920332 99 100 O
hypodysfibrinogenemia NCT03920332 101 122 B-Condition
) NCT03920332 123 124 O

- NCT03920332 128 129 O
At NCT03920332 131 133 B-Eq-Comparison
lest NCT03920332 134 138 I-Eq-Comparison
one NCT03920332 139 142 I-Eq-Comparison
past NCT03920332 143 147 I-Eq-Comparison
pregnancy NCT03920332 148 157 B-Condition

- NCT03920332 160 161 O
Adult NCT03920332 163 168 O

Exclusion NCT03920332 169 178 O
Criteria NCT03920332 179 187 O
: NCT03920332 188 189 O

- NCT03920332 193 194 O
No NCT03920332 196 198 B-Negation
past NCT03920332 199 203 B-Eq-Comparison
pregnancy NCT03920332 204 213 B-Condition

- NCT03920332 216 217 O
Not NCT03920332 219 222 B-Negation
confirmed NCT03920332 223 232 O
fibrinogen NCT03920332 233 243 B-Condition
disorder NCT03920332 244 252 I-Condition

Inclusion NCT03929458 0 9 O
Criteria NCT03929458 10 18 O
: NCT03929458 19 20 O

- NCT03929458 24 25 O
Both NCT03929458 27 31 O
sexes NCT03929458 32 37 O
aged NCT03929458 38 42 B-Age
between NCT03929458 43 50 O
20 NCT03929458 51 53 B-Eq-Comparison
- NCT03929458 54 55 I-Eq-Comparison
90 NCT03929458 56 58 I-Eq-Comparison
years NCT03929458 59 64 I-Eq-Comparison
. NCT03929458 64 65 O

- NCT03929458 69 70 O
Received NCT03929458 72 80 B-Eq-Comparison
stable NCT03929458 81 87 O
hemodialysis NCT03929458 88 100 B-Procedure
at NCT03929458 101 103 B-Eq-Comparison
least NCT03929458 104 109 I-Eq-Comparison
3 NCT03929458 110 111 I-Eq-Comparison
months NCT03929458 112 118 I-Eq-Comparison
. NCT03929458 118 119 O

- NCT03929458 123 124 O
Written NCT03929458 126 133 O
informed NCT03929458 134 142 O
consent NCT03929458 143 150 O
. NCT03929458 150 151 O

Exclusion NCT03929458 153 162 O
Criteria NCT03929458 163 171 O
: NCT03929458 172 173 O

- NCT03929458 177 178 O
patients NCT03929458 180 188 O
with NCT03929458 189 193 O
severe NCT03929458 194 200 O
infections NCT03929458 201 211 B-Condition
, NCT03929458 212 213 O
severe NCT03929458 214 220 O
heart NCT03929458 221 226 B-Condition
disease NCT03929458 227 234 I-Condition
and NCT03929458 235 238 B-Or
liver NCT03929458 239 244 B-Condition
disease NCT03929458 245 252 I-Condition
, NCT03929458 253 254 O
malignancy NCT03929458 255 265 B-Condition
, NCT03929458 266 267 O
autoimmune NCT03929458 268 278 B-Condition
disorders NCT03929458 279 288 I-Condition
, NCT03929458 289 290 O
severe NCT03929458 291 297 B-Condition
malnutrition NCT03929458 298 310 I-Condition
, NCT03929458 311 312 O
or NCT03929458 313 315 O
clinical NCT03929458 316 324 O
conditions NCT03929458 325 335 B-Condition
requiring NCT03929458 336 345 B-Assertion___Assertion-Type-Value:hypothetical
oral NCT03929458 346 350 B-Drug
nutrition NCT03929458 351 360 I-Drug
supplements NCT03929458 361 372 I-Drug
; NCT03929458 372 373 O

- NCT03929458 376 377 O
Inability NCT03929458 379 388 O
to NCT03929458 389 391 O
follow NCT03929458 392 398 O
protocol NCT03929458 399 407 O
. NCT03929458 407 408 O

- NCT03929458 412 413 O
Pregnancy NCT03929458 415 424 B-Condition
or NCT03929458 425 427 B-Or
wishing NCT03929458 428 435 B-Assertion___Assertion-Type-Value:intention
/ NCT03929458 436 437 B-Or
trying NCT03929458 438 444 B-Assertion___Assertion-Type-Value:intention
to NCT03929458 445 447 O
get NCT03929458 448 451 O
pregnant NCT03929458 452 460 B-Condition

Inclusion NCT03921762 0 9 O
Criteria NCT03921762 10 18 O
: NCT03921762 19 20 O

- NCT03921762 24 25 O
> NCT03921762 27 28 B-Eq-Comparison
50 NCT03921762 29 31 I-Eq-Comparison
years NCT03921762 32 37 I-Eq-Comparison
old NCT03921762 38 41 B-Age

- NCT03921762 44 45 O
Bilateral NCT03921762 47 56 B-Modifier
age NCT03921762 57 60 I-Modifier
- NCT03921762 61 62 I-Modifier
related NCT03921762 63 70 I-Modifier
cataract NCT03921762 71 79 B-Condition

- NCT03921762 82 83 O
Qualify NCT03921762 85 92 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03921762 93 96 I-Assertion___Assertion-Type-Value:hypothetical
bilateral NCT03921762 97 106 B-Procedure
implantation NCT03921762 107 119 I-Procedure
within NCT03921762 120 126 B-Eq-Comparison
1 NCT03921762 127 128 I-Eq-Comparison
month NCT03921762 129 134 I-Eq-Comparison

- NCT03921762 137 138 O
No NCT03921762 140 142 B-Negation
previous NCT03921762 143 151 B-Eq-Comparison
refractive NCT03921762 152 162 B-Modifier
or NCT03921762 163 165 B-Or
ocular NCT03921762 166 172 B-Modifier
surgery NCT03921762 173 180 B-Procedure

- NCT03921762 183 184 O
Available NCT03921762 186 195 O
IOL NCT03921762 196 199 B-Observation
dioptre NCT03921762 200 207 I-Observation
range NCT03921762 208 213 I-Observation
: NCT03921762 214 215 O
18 NCT03921762 216 218 B-Eq-Comparison
to NCT03921762 219 221 I-Eq-Comparison
27 NCT03921762 222 224 I-Eq-Comparison
D NCT03921762 225 226 O

- NCT03921762 229 230 O
Expected NCT03921762 232 240 B-Assertion___Assertion-Type-Value:hypothetical
post NCT03921762 241 245 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03921762 246 247 O
- NCT03921762 249 250 O
operative NCT03921762 251 260 B-Procedure
astigmatism NCT03921762 261 272 B-Observation
≤ NCT03921762 273 274 B-Eq-Comparison
0.75 NCT03921762 275 279 I-Eq-Comparison
D NCT03921762 280 281 O

Exclusion NCT03921762 282 291 O
Criteria NCT03921762 292 300 O
: NCT03921762 301 302 O

- NCT03921762 306 307 O
Pupil NCT03921762 309 314 B-Observation
> NCT03921762 315 316 B-Eq-Comparison
4 NCT03921762 317 318 I-Eq-Comparison
mm NCT03921762 319 321 I-Eq-Comparison

- NCT03921762 324 325 O
Occupation NCT03921762 327 337 O
requiring NCT03921762 338 347 O
night NCT03921762 348 353 O
- NCT03921762 354 355 O
time NCT03921762 356 360 O
driving NCT03921762 361 368 O
or NCT03921762 369 371 O
any NCT03921762 372 375 O
occupation NCT03921762 376 386 O
incompatible NCT03921762 387 399 O
with NCT03921762 400 404 O
multifocality NCT03921762 405 418 O

- NCT03921762 421 422 O
Acute NCT03921762 424 429 O
or NCT03921762 430 432 B-Or
chronic NCT03921762 433 440 B-Modifier
disease NCT03921762 441 448 B-Condition
or NCT03921762 449 451 B-Or
illness NCT03921762 452 459 B-Condition
that NCT03921762 460 464 O
would NCT03921762 465 470 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03921762 471 479 O
risk NCT03921762 480 484 B-Risk
or NCT03921762 485 487 B-Or
confound NCT03921762 488 496 O
study NCT03921762 497 502 B-Study
results NCT03921762 503 510 O
[ NCT03921762 511 512 O
e. NCT03921762 513 515 O
g. NCT03921762 516 518 O
diabetes NCT03921762 520 528 B-Condition
mellitus NCT03921762 529 537 I-Condition
( NCT03921762 538 539 O
with NCT03921762 540 544 B-And
retinopathy NCT03921762 545 556 B-Condition
) NCT03921762 557 558 O
, NCT03921762 560 561 O
immunocompromised NCT03921762 562 579 B-Condition
, NCT03921762 580 581 O
glaucoma NCT03921762 582 590 B-Condition
, NCT03921762 591 592 O
epiretinal NCT03921762 593 603 B-Condition
membrane NCT03921762 604 612 I-Condition
, NCT03921762 613 614 O
cornea NCT03921762 615 621 B-Condition
guttata NCT03921762 622 629 I-Condition
, NCT03921762 630 631 O
etc NCT03921762 632 635 O
… NCT03921762 635 636 O
. NCT03921762 636 637 O
] NCT03921762 638 639 O
found NCT03921762 640 645 O
to NCT03921762 646 648 O
be NCT03921762 649 651 O
relevant NCT03921762 652 660 O
by NCT03921762 661 663 O
the NCT03921762 664 667 O
investigators NCT03921762 668 681 O

- NCT03921762 684 685 O
Amblyopia NCT03921762 687 696 B-Condition
, NCT03921762 697 698 O
strabismus NCT03921762 699 709 B-Condition

- NCT03921762 712 713 O
Extremely NCT03921762 715 724 O
shallow NCT03921762 725 732 B-Condition
anterior NCT03921762 733 741 I-Condition
chamber NCT03921762 742 749 I-Condition

- NCT03921762 752 753 O
Capsule NCT03921762 755 762 B-Modifier
or NCT03921762 763 765 B-Or
zonular NCT03921762 766 773 B-Modifier
abnormalities NCT03921762 774 787 B-Condition
that NCT03921762 788 792 O
may NCT03921762 793 796 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03921762 797 803 O
post NCT03921762 804 808 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03921762 809 810 O
- NCT03921762 812 813 O
operative NCT03921762 814 823 B-Procedure
centration NCT03921762 824 834 B-Modifier
or NCT03921762 835 837 B-Or
tilt NCT03921762 838 842 B-Modifier
of NCT03921762 843 845 O
the NCT03921762 846 849 O
lens NCT03921762 850 854 B-Condition
( NCT03921762 855 856 O
e. NCT03921762 857 859 O
g. NCT03921762 860 862 O
pseudoexfoliation NCT03921762 864 881 B-Condition
syndrome NCT03921762 882 890 I-Condition|Condition
, NCT03921762 891 892 O
uveitis NCT03921762 893 900 B-Condition
, NCT03921762 901 902 O
Marfan NCT03921762 903 909 B-Condition
's NCT03921762 909 911 O
syndrome NCT03921762 912 920 O
) NCT03921762 921 922 O

- NCT03921762 926 927 I-Condition
Pupil NCT03921762 929 934 B-Condition
abnormalities NCT03921762 935 948 I-Condition
( NCT03921762 949 950 O
non NCT03921762 951 954 B-Condition
- NCT03921762 955 956 O
reactive NCT03921762 957 965 I-Condition
, NCT03921762 966 967 O
tonic NCT03921762 968 973 B-Condition
pupils NCT03921762 974 980 I-Condition|Condition|Condition
, NCT03921762 981 982 O
abnormally NCT03921762 983 993 B-Condition
shaped NCT03921762 994 1000 I-Condition
pupils NCT03921762 1001 1007 O
or NCT03921762 1008 1010 B-Or
pupils NCT03921762 1011 1017 O
that NCT03921762 1018 1022 I-Condition
do NCT03921762 1023 1025 I-Condition
not NCT03921762 1026 1029 I-Condition
dilate NCT03921762 1030 1036 I-Condition
under NCT03921762 1037 1042 B-Modifier
mesopic NCT03921762 1043 1050 I-Modifier
/ NCT03921762 1051 1052 I-Modifier
scotopic NCT03921762 1053 1061 I-Modifier
conditions NCT03921762 1062 1072 I-Modifier
) NCT03921762 1073 1074 O

- NCT03921762 1078 1079 O
Instability NCT03921762 1081 1092 O
to NCT03921762 1093 1095 O
place NCT03921762 1096 1101 B-Procedure
the NCT03921762 1102 1105 I-Procedure
intraocular NCT03921762 1106 1117 I-Procedure
lens NCT03921762 1118 1122 I-Procedure
safely NCT03921762 1123 1129 O
at NCT03921762 1130 1132 O
the NCT03921762 1133 1136 O
location NCT03921762 1137 1145 O
planned NCT03921762 1146 1153 O

- NCT03921762 1156 1157 O
Pregnancy NCT03921762 1159 1168 B-Condition
( NCT03921762 1169 1170 O
pregnancy NCT03921762 1171 1180 B-Observation|Temporal-Connection___Temporal-Connection-Type-Value:before
test NCT03921762 1181 1185 I-Observation
will NCT03921762 1186 1190 B-Eq-Comparison
be NCT03921762 1191 1193 I-Eq-Comparison
taken NCT03921762 1194 1199 O
pre NCT03921762 1200 1203 O
- NCT03921762 1204 1205 O
- NCT03921762 1207 1208 O
operatively NCT03921762 1209 1220 B-Procedure
in NCT03921762 1221 1223 O
women NCT03921762 1224 1229 O
of NCT03921762 1230 1232 B-And
reproductive NCT03921762 1233 1245 B-Condition
age NCT03921762 1246 1249 I-Condition
) NCT03921762 1250 1251 O

Inclusion NCT03925909 0 9 O
Criteria NCT03925909 10 18 O
: NCT03925909 19 20 O

- NCT03925909 24 25 O
30 NCT03925909 27 29 B-Eq-Comparison
- NCT03925909 30 31 I-Eq-Comparison
60 NCT03925909 32 34 I-Eq-Comparison
years NCT03925909 35 40 I-Age|Eq-Comparison

- NCT03925909 43 44 O
Increased NCT03925909 46 55 O
fasting NCT03925909 56 63 B-Observation
blood NCT03925909 64 69 I-Observation
glucose NCT03925909 70 77 I-Observation
from NCT03925909 78 82 O
6.1 NCT03925909 83 86 B-Eq-Comparison
to NCT03925909 87 89 I-Eq-Comparison
7.0 NCT03925909 90 93 I-Eq-Comparison
mmol NCT03925909 94 98 I-Eq-Comparison
/ NCT03925909 99 100 I-Eq-Comparison
L NCT03925909 101 102 I-Eq-Comparison
or NCT03925909 103 105 B-Or
, NCT03925909 106 107 O

- NCT03925909 111 112 O
Decreased NCT03925909 114 123 O
glucose NCT03925909 124 131 B-Observation
tolerance NCT03925909 132 141 I-Observation
of NCT03925909 142 144 O
7 NCT03925909 145 146 B-Eq-Comparison
, NCT03925909 147 148 I-Eq-Comparison
8 NCT03925909 149 150 I-Eq-Comparison
to NCT03925909 151 153 I-Eq-Comparison
11.1 NCT03925909 154 158 I-Eq-Comparison
mmol NCT03925909 159 163 I-Eq-Comparison
/ NCT03925909 164 165 I-Eq-Comparison
L NCT03925909 166 167 I-Eq-Comparison
or NCT03925909 168 170 B-Or
, NCT03925909 171 172 O

- NCT03925909 176 177 O
Glycated NCT03925909 179 187 B-Modifier
hemoglobin NCT03925909 188 198 B-Observation
with NCT03925909 199 203 O
values NCT03925909 204 210 O
between NCT03925909 211 218 B-Eq-Comparison
5.7 NCT03925909 219 222 I-Eq-Comparison
and NCT03925909 223 226 I-Eq-Comparison
6.4 NCT03925909 227 230 I-Eq-Comparison
% NCT03925909 231 232 O

Exclusion NCT03925909 233 242 O
Criteria NCT03925909 243 251 O
: NCT03925909 252 253 O

- NCT03925909 257 258 O
Use NCT03925909 260 263 B-Eq-Comparison
hypoglycemic NCT03925909 264 276 B-Drug
, NCT03925909 277 278 O
hypolipidemic NCT03925909 279 292 B-Drug
drugs NCT03925909 293 298 O
, NCT03925909 299 300 O

- NCT03925909 304 305 O
Use NCT03925909 307 310 B-Eq-Comparison
dietary NCT03925909 311 318 B-Drug
supplements NCT03925909 319 330 I-Drug
( NCT03925909 331 332 O
vitamins NCT03925909 333 341 B-Drug
, NCT03925909 342 343 O
minerals NCT03925909 344 352 B-Drug
, NCT03925909 353 354 O
bioflavonoids NCT03925909 355 368 B-Drug
, NCT03925909 369 370 O
prebiotics NCT03925909 371 381 B-Drug
, NCT03925909 382 383 O
probiotics NCT03925909 384 394 B-Drug
or NCT03925909 395 397 O
other NCT03925909 398 403 B-Other
bioactive NCT03925909 404 413 B-Drug
compounds NCT03925909 414 423 I-Drug
) NCT03925909 424 425 O
, NCT03925909 427 428 O

- NCT03925909 432 433 O
Exercise NCT03925909 435 443 B-Condition
intensely NCT03925909 444 453 O
( NCT03925909 454 455 O
more NCT03925909 456 460 B-Eq-Comparison
than NCT03925909 461 465 I-Eq-Comparison
10 NCT03925909 466 468 I-Eq-Comparison
hours NCT03925909 469 474 I-Eq-Comparison
per NCT03925909 475 478 I-Eq-Comparison
week NCT03925909 479 483 I-Eq-Comparison
) NCT03925909 484 485 O

- NCT03925909 489 490 O
History NCT03925909 492 499 B-Eq-Comparison
of NCT03925909 500 502 O
cardiovascular NCT03925909 503 517 B-Condition
diseases NCT03925909 518 526 I-Condition
, NCT03925909 527 528 O
diabetes NCT03925909 529 537 B-Condition
mellitus NCT03925909 538 546 I-Condition
, NCT03925909 547 548 O
liver NCT03925909 549 554 B-Modifier
and NCT03925909 555 558 B-Or
kidney NCT03925909 559 565 B-Modifier
disease NCT03925909 566 573 B-Condition
. NCT03925909 573 574 O

Inclusion NCT03928587 0 9 O
Criteria NCT03928587 10 18 O
: NCT03928587 19 20 O

1 NCT03928587 24 25 O
. NCT03928587 25 26 O
Healthy NCT03928587 28 35 B-Condition
children NCT03928587 36 44 O
with NCT03928587 45 49 B-And
absence NCT03928587 50 57 B-Negation
of NCT03928587 58 60 I-Negation
severe NCT03928587 61 67 O
chronic NCT03928587 68 75 B-Modifier
disease NCT03928587 76 83 B-Condition

2 NCT03928587 86 87 O
. NCT03928587 87 88 O
Age NCT03928587 90 93 B-Age
5 NCT03928587 94 95 B-Eq-Comparison
- NCT03928587 96 97 I-Eq-Comparison
8 NCT03928587 98 99 I-Eq-Comparison
years NCT03928587 100 105 I-Eq-Comparison
, NCT03928587 106 107 O
both NCT03928587 108 112 O
inclusive NCT03928587 113 122 O
, NCT03928587 123 124 O
at NCT03928587 125 127 O
inclusion NCT03928587 128 137 O

3 NCT03928587 140 141 O
. NCT03928587 141 142 O
Ability NCT03928587 144 151 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928587 152 154 I-Assertion___Assertion-Type-Value:hypothetical
cooperate NCT03928587 155 164 O
at NCT03928587 165 167 O
dental NCT03928587 168 174 B-Procedure
examination NCT03928587 175 186 I-Procedure

4 NCT03928587 189 190 O
. NCT03928587 190 191 O
Ability NCT03928587 193 200 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928587 201 203 I-Assertion___Assertion-Type-Value:hypothetical
cooperate NCT03928587 204 213 O
to NCT03928587 214 216 O
a NCT03928587 217 218 O
daily NCT03928587 219 224 B-Eq-Comparison
intake NCT03928587 225 231 O
of NCT03928587 232 234 O
a NCT03928587 235 236 O
lozenge NCT03928587 237 244 B-Drug

5 NCT03928587 247 248 O
. NCT03928587 248 249 O
Parents NCT03928587 251 258 O
/ NCT03928587 259 260 O
legal NCT03928587 261 266 O
guarding NCT03928587 267 275 O
provided NCT03928587 276 284 O
voluntary NCT03928587 285 294 O
written NCT03928587 295 302 O
informed NCT03928587 303 311 O
consent NCT03928587 312 319 O

Exclusion NCT03928587 320 329 O
Criteria NCT03928587 330 338 O
: NCT03928587 339 340 O

1 NCT03928587 344 345 O
. NCT03928587 345 346 O
Children NCT03928587 348 356 O
with NCT03928587 357 361 B-And
severe NCT03928587 362 368 O
medical NCT03928587 369 376 B-Condition
conditions NCT03928587 377 387 I-Condition

2 NCT03928587 390 391 O
. NCT03928587 391 392 O
Mentally NCT03928587 394 402 B-Modifier
or NCT03928587 403 405 B-Or
physically NCT03928587 406 416 B-Modifier
disabled NCT03928587 417 425 B-Condition
children NCT03928587 426 434 O

3 NCT03928587 437 438 O
. NCT03928587 438 439 O
Children NCT03928587 441 449 O
of NCT03928587 450 452 O
parents NCT03928587 453 460 B-Family-Member___Family-Member-Type:parent
with NCT03928587 461 465 O
language NCT03928587 466 474 O
barriers NCT03928587 475 483 O
and NCT03928587 484 487 O
not NCT03928587 488 491 O
able NCT03928587 492 496 O
to NCT03928587 497 499 O
give NCT03928587 500 504 O
written NCT03928587 505 512 O
informed NCT03928587 513 521 O
consent NCT03928587 522 529 O

Inclusion NCT03923439 0 9 O
Criteria NCT03923439 10 18 O
: NCT03923439 19 20 O

- NCT03923439 24 25 O
Patients NCT03923439 27 35 O
older NCT03923439 36 41 B-Eq-Comparison
than NCT03923439 42 46 I-Eq-Comparison
18 NCT03923439 47 49 I-Eq-Comparison
years NCT03923439 50 55 I-Eq-Comparison
old NCT03923439 56 59 B-Age

- NCT03923439 62 63 O
Cerebral NCT03923439 65 73 B-Condition
infarct NCT03923439 74 81 I-Condition
within NCT03923439 82 88 O
the NCT03923439 89 92 O
anterior NCT03923439 93 101 B-Modifier
circulation NCT03923439 102 113 I-Modifier
due NCT03923439 114 117 O
to NCT03923439 118 120 O
occlusion NCT03923439 121 130 B-Condition
of NCT03923439 131 133 I-Condition
intracranial NCT03923439 134 146 I-Condition
carotid NCT03923439 147 154 I-Condition
artery NCT03923439 155 161 I-Condition
or NCT03923439 162 164 O
proximal NCT03923439 165 173 B-Modifier
( NCT03923439 174 175 O
M1 NCT03923439 176 178 B-Eq-Comparison
) NCT03923439 179 180 O
MCA NCT03923439 181 184 B-Condition
. NCT03923439 184 185 O

- NCT03923439 189 190 O
With NCT03923439 192 196 O
acute NCT03923439 197 202 O
MRI NCT03923439 203 206 B-Procedure
performed NCT03923439 207 216 O
within NCT03923439 217 223 B-Eq-Comparison
the NCT03923439 224 227 I-Eq-Comparison
first NCT03923439 228 233 I-Eq-Comparison
24 NCT03923439 234 236 I-Eq-Comparison
h NCT03923439 237 238 O
and NCT03923439 239 242 B-And
showing NCT03923439 243 250 O
significant NCT03923439 251 262 O
penumbra NCT03923439 263 271 B-Condition
defined NCT03923439 272 279 O
as NCT03923439 280 282 O
ratio NCT03923439 283 288 B-Observation
between NCT03923439 289 296 I-Observation
the NCT03923439 297 300 I-Observation
volumes NCT03923439 301 308 I-Observation
of NCT03923439 309 311 O
critically NCT03923439 312 322 O
hypoperfused NCT03923439 323 335 B-Modifier
tissue NCT03923439 336 342 I-Modifier
( NCT03923439 343 344 O
defined NCT03923439 345 352 O
by NCT03923439 353 355 O
Tmax NCT03923439 356 360 B-Observation
> NCT03923439 361 362 B-Eq-Comparison
6 NCT03923439 363 364 I-Eq-Comparison
s NCT03923439 365 366 O
) NCT03923439 367 368 O
and NCT03923439 369 372 B-And
the NCT03923439 373 376 O
ischemic NCT03923439 377 385 B-Modifier
core NCT03923439 386 390 I-Modifier
( NCT03923439 391 392 O
defined NCT03923439 393 400 O
by NCT03923439 401 403 O
ADC NCT03923439 404 407 B-Observation
< NCT03923439 408 409 B-Eq-Comparison
600 NCT03923439 410 413 I-Eq-Comparison|Eq-Comparison
× NCT03923439 414 415 O
10 NCT03923439 416 418 B-Eq-Comparison
- NCT03923439 419 420 I-Eq-Comparison
6 NCT03923439 421 422 O
mm2 NCT03923439 423 426 I-Eq-Comparison
/ NCT03923439 427 428 I-Eq-Comparison
s NCT03923439 429 430 I-Eq-Comparison
) NCT03923439 431 432 O
of NCT03923439 433 435 O
1.8 NCT03923439 436 439 B-Eq-Comparison
or NCT03923439 440 442 I-Eq-Comparison
more NCT03923439 443 447 I-Eq-Comparison
, NCT03923439 448 449 O
with NCT03923439 450 454 O
an NCT03923439 455 457 O
absolute NCT03923439 458 466 B-Observation
difference NCT03923439 467 477 I-Observation
of NCT03923439 478 480 O
15 NCT03923439 481 483 B-Eq-Comparison
mL NCT03923439 484 486 I-Eq-Comparison
or NCT03923439 487 489 I-Eq-Comparison
more NCT03923439 490 494 I-Eq-Comparison
and NCT03923439 495 498 B-And
ischemic NCT03923439 499 507 B-Observation
core NCT03923439 508 512 I-Observation
volume NCT03923439 513 519 I-Observation
of NCT03923439 520 522 O
less NCT03923439 523 527 B-Eq-Comparison
than NCT03923439 528 532 I-Eq-Comparison
70 NCT03923439 533 535 I-Eq-Comparison
mL. NCT03923439 536 539 I-Eq-Comparison

- NCT03923439 543 544 O
Successful NCT03923439 546 556 O
recanalization NCT03923439 557 571 B-Procedure
( NCT03923439 572 573 O
TICI NCT03923439 574 578 B-Condition
2 NCT03923439 579 580 B-Eq-Comparison
b NCT03923439 581 582 O
- NCT03923439 583 584 I-Eq-Comparison
3 NCT03923439 585 586 I-Eq-Comparison
) NCT03923439 587 588 O
by NCT03923439 589 591 O
thrombectomy NCT03923439 592 604 B-Procedure
alone NCT03923439 605 610 B-Modifier
or NCT03923439 611 613 B-Or
in NCT03923439 614 616 O
combination NCT03923439 617 628 O
with NCT03923439 629 633 B-Eq-Comparison
IV NCT03923439 634 636 B-Modifier
thrombolysis NCT03923439 637 649 B-Procedure
( NCT03923439 650 651 O
if NCT03923439 652 654 O
within NCT03923439 655 661 O
the NCT03923439 662 665 I-Eq-Comparison
first NCT03923439 666 671 I-Eq-Comparison
4.5 NCT03923439 672 675 I-Eq-Comparison
h NCT03923439 676 677 O
) NCT03923439 678 679 O
. NCT03923439 680 681 O

- NCT03923439 685 686 O
Patient NCT03923439 688 695 O
/ NCT03923439 696 697 O
Legally NCT03923439 698 705 O
Authorized NCT03923439 706 716 O
Representative NCT03923439 717 731 O
has NCT03923439 732 735 O
signed NCT03923439 736 742 O
the NCT03923439 743 746 O
Informed NCT03923439 747 755 O
Consent NCT03923439 756 763 O
form NCT03923439 764 768 O
. NCT03923439 768 769 O

Exclusion NCT03923439 771 780 O
Criteria NCT03923439 781 789 O
: NCT03923439 790 791 O

- NCT03923439 795 796 O
History NCT03923439 798 805 B-Eq-Comparison
of NCT03923439 806 808 O
symptomatic NCT03923439 809 820 B-Assertion___Assertion-Type-Value:possible
cerebral NCT03923439 821 829 B-Condition
infarct NCT03923439 830 837 I-Condition
with NCT03923439 838 842 B-And
functional NCT03923439 843 853 B-Condition
deficit NCT03923439 854 861 I-Condition
( NCT03923439 862 863 O
pre NCT03923439 864 867 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03923439 868 869 O
stroke NCT03923439 870 876 B-Condition
modified NCT03923439 877 885 B-Observation
Rankin NCT03923439 886 892 I-Observation
Scale NCT03923439 893 898 I-Observation
score NCT03923439 899 904 B-Eq-Comparison
≥ NCT03923439 905 906 I-Eq-Comparison
1 NCT03923439 907 908 I-Eq-Comparison
) NCT03923439 909 910 O
to NCT03923439 911 913 B-Assertion___Assertion-Type-Value:hypothetical
measure NCT03923439 914 921 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03923439 922 925 O
impact NCT03923439 926 932 O
of NCT03923439 933 935 O
the NCT03923439 936 939 O
infarct NCT03923439 940 947 B-Condition
and NCT03923439 948 951 B-And
selective NCT03923439 952 961 B-Condition
neuronal NCT03923439 962 970 I-Condition
loss NCT03923439 971 975 I-Condition
on NCT03923439 976 978 O
long NCT03923439 979 983 O
- NCT03923439 984 985 O
term NCT03923439 986 990 O
outcome NCT03923439 991 998 O
without NCT03923439 999 1006 O
being NCT03923439 1007 1012 O
biased NCT03923439 1013 1019 O
by NCT03923439 1020 1022 O
pre NCT03923439 1023 1026 O
- NCT03923439 1027 1028 O
existing NCT03923439 1029 1037 O
deficits NCT03923439 1038 1046 O
. NCT03923439 1046 1047 O

- NCT03923439 1051 1052 O
History NCT03923439 1054 1061 B-Eq-Comparison
of NCT03923439 1062 1064 O
severe NCT03923439 1065 1071 O
cognitive NCT03923439 1072 1081 B-Condition
impairment NCT03923439 1082 1092 I-Condition
( NCT03923439 1093 1094 O
dementia NCT03923439 1095 1103 B-Condition
) NCT03923439 1104 1105 O
or NCT03923439 1106 1108 O
DSMIV NCT03923439 1109 1114 B-Eq-Comparison
axis NCT03923439 1115 1119 I-Eq-Comparison
1 NCT03923439 1120 1121 I-Eq-Comparison
psychiatric NCT03923439 1122 1133 B-Condition
disorders NCT03923439 1134 1143 I-Condition
that NCT03923439 1144 1148 O
would NCT03923439 1149 1154 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03923439 1155 1163 O
the NCT03923439 1164 1167 O
neurological NCT03923439 1168 1180 B-Procedure
evaluations NCT03923439 1181 1192 I-Procedure
. NCT03923439 1192 1193 O

- NCT03923439 1197 1198 I-Condition
Pregnant NCT03923439 1200 1208 B-Condition
or NCT03923439 1209 1211 B-Or
breast NCT03923439 1212 1218 B-Condition
- NCT03923439 1219 1220 O
feeding NCT03923439 1221 1228 I-Condition
women NCT03923439 1229 1234 O
. NCT03923439 1234 1235 O

- NCT03923439 1239 1240 O
Contraindications NCT03923439 1242 1259 B-Contraindication
to NCT03923439 1260 1262 O
MRI NCT03923439 1263 1266 B-Procedure
. NCT03923439 1266 1267 O

Inclusion NCT03925844 0 9 O
Criteria NCT03925844 10 18 O
: NCT03925844 19 20 O

- NCT03925844 24 25 O
population NCT03925844 27 37 O
aged NCT03925844 38 42 B-Age
55 NCT03925844 43 45 B-Eq-Comparison
to NCT03925844 46 48 I-Eq-Comparison
74 NCT03925844 49 51 I-Eq-Comparison
years NCT03925844 52 57 I-Eq-Comparison
from NCT03925844 58 62 O
NEDICES NCT03925844 63 70 O
2 NCT03925844 71 72 O
study NCT03925844 73 78 B-Study

- NCT03925844 81 82 O
to NCT03925844 84 86 O
have NCT03925844 87 91 O
signed NCT03925844 92 98 O
informed NCT03925844 99 107 O
consent NCT03925844 108 115 O

- NCT03925844 118 119 O
to NCT03925844 121 123 O
have NCT03925844 124 128 O
done NCT03925844 129 133 B-Eq-Comparison
the NCT03925844 134 137 O
neuropsicological NCT03925844 138 155 B-Procedure
assessment NCT03925844 156 166 I-Procedure

Exclusion NCT03925844 167 176 O
Criteria NCT03925844 177 185 O
: NCT03925844 186 187 O

- NCT03925844 191 192 O
to NCT03925844 194 196 O
have NCT03925844 197 201 O
a NCT03925844 202 203 O
dementia NCT03925844 204 212 B-Condition
diagnosis NCT03925844 213 222 O
at NCT03925844 223 225 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03925844 226 234 B-Study
. NCT03925844 234 235 O

Inclusion NCT03928145 0 9 O
Criteria NCT03928145 10 18 O
: NCT03928145 19 20 O

- NCT03928145 24 25 O
Adults NCT03928145 27 33 O
( NCT03928145 34 35 O
age NCT03928145 36 39 B-Age
30 NCT03928145 40 42 B-Eq-Comparison
to NCT03928145 43 45 I-Eq-Comparison
75 NCT03928145 46 48 I-Eq-Comparison
years NCT03928145 49 54 I-Eq-Comparison
) NCT03928145 55 56 O
. NCT03928145 57 58 O

- NCT03928145 62 63 O
Diagnosis NCT03928145 65 74 O
of NCT03928145 75 77 O
primary NCT03928145 78 85 B-Condition
hypertension NCT03928145 86 98 I-Condition
based NCT03928145 99 104 O
on NCT03928145 105 107 O
ABPM NCT03928145 108 112 B-Procedure
( NCT03928145 113 114 O
mean NCT03928145 115 119 B-Eq-Comparison
24 NCT03928145 120 122 I-Eq-Comparison
- NCT03928145 123 124 I-Eq-Comparison
h NCT03928145 125 126 I-Eq-Comparison
systolic NCT03928145 127 135 B-Observation
BP NCT03928145 136 138 I-Observation
≥ NCT03928145 139 140 B-Eq-Comparison
130 NCT03928145 141 144 I-Eq-Comparison
mmHg NCT03928145 145 149 I-Eq-Comparison
or NCT03928145 150 152 B-Or
mean NCT03928145 153 157 B-Eq-Comparison
24 NCT03928145 158 160 I-Eq-Comparison
- NCT03928145 161 162 I-Eq-Comparison
h NCT03928145 163 164 I-Eq-Comparison
diastolic NCT03928145 165 174 B-Observation
BP NCT03928145 175 177 I-Observation
≥ NCT03928145 178 179 B-Eq-Comparison
80 NCT03928145 180 182 I-Eq-Comparison
mmHg NCT03928145 183 187 I-Eq-Comparison
) NCT03928145 188 189 O
. NCT03928145 190 191 O

- NCT03928145 195 196 O
No NCT03928145 198 200 B-Negation
current NCT03928145 201 208 B-Eq-Comparison
use NCT03928145 209 212 O
of NCT03928145 213 215 O
antihypertensive NCT03928145 216 232 B-Drug
medication NCT03928145 233 243 I-Drug
. NCT03928145 243 244 O

Exclusion NCT03928145 246 255 O
Criteria NCT03928145 256 264 O
: NCT03928145 265 266 O

- NCT03928145 270 271 O
Low NCT03928145 273 276 O
life NCT03928145 277 281 B-Observation
expectancy NCT03928145 282 292 I-Observation
. NCT03928145 292 293 O

- NCT03928145 297 298 O
Other NCT03928145 300 305 B-Other
indications NCT03928145 306 317 B-Indication
for NCT03928145 318 321 O
the NCT03928145 322 325 O
use NCT03928145 326 329 O
of NCT03928145 330 332 O
diuretics NCT03928145 333 342 B-Drug
. NCT03928145 342 343 O

- NCT03928145 347 348 O
Intolerance NCT03928145 350 361 B-Condition
or NCT03928145 362 364 B-Or
contraindications NCT03928145 365 382 B-Contraindication
to NCT03928145 383 385 O
the NCT03928145 386 389 O
study NCT03928145 390 395 B-Study
drugs NCT03928145 396 401 B-Drug
. NCT03928145 401 402 O

- NCT03928145 406 407 O
Cardiovascular NCT03928145 409 423 B-Condition
disease NCT03928145 424 431 I-Condition
( NCT03928145 432 433 O
heart NCT03928145 434 439 B-Condition
failure NCT03928145 440 447 I-Condition
, NCT03928145 448 449 O
myocardial NCT03928145 450 460 B-Condition
infarction NCT03928145 461 471 I-Condition
or NCT03928145 472 474 B-Or
stroke NCT03928145 475 481 B-Condition
) NCT03928145 482 483 O
. NCT03928145 484 485 O

- NCT03928145 489 490 O
Secondary NCT03928145 492 501 B-Modifier
hypertension NCT03928145 502 514 B-Condition
. NCT03928145 514 515 O

- NCT03928145 519 520 O
Chronic NCT03928145 522 529 B-Modifier
kidney NCT03928145 530 536 I-Modifier
disease NCT03928145 537 544 B-Condition
and NCT03928145 545 548 B-Or
/ NCT03928145 549 550 I-Or
or NCT03928145 551 553 I-Or
abnormal NCT03928145 554 562 O
renal NCT03928145 563 568 B-Modifier
function NCT03928145 569 577 B-Condition
( NCT03928145 578 579 O
creatinine NCT03928145 580 590 B-Observation
> NCT03928145 591 592 B-Eq-Comparison
1.5 NCT03928145 593 596 I-Eq-Comparison
mg NCT03928145 597 599 I-Eq-Comparison
/ NCT03928145 600 601 I-Eq-Comparison
dL NCT03928145 602 604 I-Eq-Comparison
) NCT03928145 605 606 O
. NCT03928145 607 608 O

- NCT03928145 612 613 O
Hyperkalemia NCT03928145 615 627 B-Condition
( NCT03928145 628 629 O
serum NCT03928145 630 635 B-Observation
potassium NCT03928145 636 645 I-Observation
> NCT03928145 646 647 B-Eq-Comparison
5.5 NCT03928145 648 651 I-Eq-Comparison
mEq NCT03928145 652 655 I-Eq-Comparison
/ NCT03928145 656 657 I-Eq-Comparison
L NCT03928145 658 659 I-Eq-Comparison
) NCT03928145 660 661 O
. NCT03928145 662 663 O

- NCT03928145 667 668 O
Gout NCT03928145 670 674 B-Condition
. NCT03928145 674 675 O

- NCT03928145 679 680 O
Previous NCT03928145 682 690 B-Eq-Comparison
antihypertensive NCT03928145 691 707 B-Drug
treatment NCT03928145 708 717 B-Procedure
with NCT03928145 718 722 O
more NCT03928145 723 727 B-Eq-Comparison
than NCT03928145 728 732 I-Eq-Comparison
one NCT03928145 733 736 I-Eq-Comparison
drug NCT03928145 737 741 B-Drug
. NCT03928145 741 742 O

- NCT03928145 746 747 O
Systolic NCT03928145 749 757 B-Observation
blood NCT03928145 758 763 I-Observation|Observation
pressure NCT03928145 764 772 I-Observation|Observation
≥ NCT03928145 773 774 B-Eq-Comparison|Eq-Comparison
160 NCT03928145 775 778 I-Eq-Comparison
mmHg NCT03928145 779 783 I-Eq-Comparison|Eq-Comparison
or NCT03928145 784 786 B-Or
diastolic NCT03928145 787 796 B-Observation
blood NCT03928145 797 802 O
pressure NCT03928145 803 811 O
≥ NCT03928145 812 813 O
100 NCT03928145 814 817 I-Eq-Comparison
mmHg NCT03928145 818 822 O
measured NCT03928145 823 831 O
through NCT03928145 832 839 O
office NCT03928145 840 846 O
blood NCT03928145 847 852 O
pressure NCT03928145 853 861 O
. NCT03928145 861 862 O

- NCT03928145 866 867 O
Pregnancy NCT03928145 869 878 B-Condition
or NCT03928145 879 881 B-Or
prospective NCT03928145 882 893 B-Assertion___Assertion-Type-Value:intention
pregnancy NCT03928145 894 903 B-Condition
during NCT03928145 904 910 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928145 911 914 O
study NCT03928145 915 920 B-Study
. NCT03928145 920 921 O

- NCT03928145 925 926 O
Lactating NCT03928145 928 937 B-Condition
women NCT03928145 938 943 O
. NCT03928145 943 944 O

Inclusion NCT03922737 0 9 O
Criteria NCT03922737 10 18 O
: NCT03922737 19 20 O

1 NCT03922737 22 23 O
. NCT03922737 23 24 O
Subjects NCT03922737 26 34 O
over NCT03922737 35 39 B-Eq-Comparison
18 NCT03922737 40 42 I-Eq-Comparison
and NCT03922737 43 46 B-And
under NCT03922737 47 52 B-Eq-Comparison
75 NCT03922737 53 55 I-Eq-Comparison
years NCT03922737 56 61 I-Eq-Comparison
of NCT03922737 62 64 O
age NCT03922737 65 68 B-Age
undergoing NCT03922737 69 79 B-Eq-Comparison
elective NCT03922737 80 88 O
primary NCT03922737 89 96 B-Modifier
orthopaedic NCT03922737 97 108 B-Procedure
surgery NCT03922737 109 116 I-Procedure
at NCT03922737 117 119 O
Thomas NCT03922737 120 126 O
Jefferson NCT03922737 127 136 O
University NCT03922737 137 147 O
Hospital NCT03922737 148 156 O
, NCT03922737 157 158 O
Rothman NCT03922737 159 166 O
Orthopaedic NCT03922737 167 178 O
Specialty NCT03922737 179 188 O
Hospital NCT03922737 189 197 O
or NCT03922737 198 200 B-Or
Methodist NCT03922737 201 210 O
Hospital NCT03922737 211 219 O
who NCT03922737 220 223 O
have NCT03922737 224 228 O
the NCT03922737 229 232 O
capability NCT03922737 233 243 O
to NCT03922737 244 246 O
utilize NCT03922737 247 254 O
a NCT03922737 255 256 O
telecommunications NCT03922737 257 275 O
platform NCT03922737 276 284 O
( NCT03922737 285 286 O
computer NCT03922737 287 295 O
, NCT03922737 296 297 O
tablet NCT03922737 298 304 O
or NCT03922737 305 307 O
similar NCT03922737 308 315 O
device NCT03922737 316 322 O
at NCT03922737 323 325 O
home NCT03922737 326 330 O
with NCT03922737 331 335 O
a NCT03922737 336 337 O
webcam NCT03922737 338 344 O
, NCT03922737 345 346 O
microphone NCT03922737 347 357 O
and NCT03922737 358 361 O
access NCT03922737 362 368 O
to NCT03922737 369 371 O
high NCT03922737 372 376 O
- NCT03922737 377 378 O
speed NCT03922737 379 384 O
internet NCT03922737 385 393 O
) NCT03922737 394 395 O
. NCT03922737 396 397 O

Exclusion NCT03922737 399 408 O
Criteria NCT03922737 409 417 O
: NCT03922737 418 419 O

1 NCT03922737 423 424 O
. NCT03922737 424 425 O
Subjects NCT03922737 427 435 O
who NCT03922737 436 439 O
are NCT03922737 440 443 O
unable NCT03922737 444 450 O
to NCT03922737 451 453 O
access NCT03922737 454 460 O
the NCT03922737 461 464 O
telemedicine NCT03922737 465 477 O
platform NCT03922737 478 486 O
or NCT03922737 487 489 O
who NCT03922737 490 493 O
are NCT03922737 494 497 O
uncomfortable NCT03922737 498 511 O
with NCT03922737 512 516 O
following NCT03922737 517 526 O
up NCT03922737 527 529 O
in NCT03922737 530 532 O
this NCT03922737 533 537 O
fashion NCT03922737 538 545 O

2 NCT03922737 548 549 O
. NCT03922737 549 550 O
Subjects NCT03922737 552 560 O
who NCT03922737 561 564 O
are NCT03922737 565 568 O
unable NCT03922737 569 575 O
or NCT03922737 576 578 O
unwilling NCT03922737 579 588 O
to NCT03922737 589 591 O
provide NCT03922737 592 599 O
post NCT03922737 600 604 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03922737 605 606 O
- NCT03922737 608 609 O
operative NCT03922737 610 619 B-Procedure
radiographs NCT03922737 620 631 O
electronically NCT03922737 632 646 O
or NCT03922737 647 649 O
who NCT03922737 650 653 O
are NCT03922737 654 657 O
unable NCT03922737 658 664 O
or NCT03922737 665 667 O
unwilling NCT03922737 668 677 O
to NCT03922737 678 680 O
obtain NCT03922737 681 687 O
them NCT03922737 688 692 O

3 NCT03922737 695 696 O
. NCT03922737 696 697 O
Subjects NCT03922737 699 707 O
with NCT03922737 708 712 O
workman NCT03922737 713 720 O
's NCT03922737 720 722 O
compensation NCT03922737 723 735 O
or NCT03922737 736 738 O
automotive NCT03922737 739 749 O
claims NCT03922737 750 756 O
or NCT03922737 757 759 O
other NCT03922737 760 765 O
ongoing NCT03922737 766 773 O
litigation NCT03922737 774 784 O

4 NCT03922737 787 788 O
. NCT03922737 788 789 O
Subjects NCT03922737 791 799 O
that NCT03922737 800 804 O
are NCT03922737 805 808 O
unable NCT03922737 809 815 O
or NCT03922737 816 818 O
unwilling NCT03922737 819 828 O
to NCT03922737 829 831 O
consent NCT03922737 832 839 O
for NCT03922737 840 843 O
enrollment NCT03922737 844 854 O

5 NCT03922737 857 858 O
. NCT03922737 858 859 O
Patients NCT03922737 861 869 O
under NCT03922737 870 875 B-Eq-Comparison
the NCT03922737 876 879 I-Eq-Comparison
age NCT03922737 880 883 I-Age|Eq-Comparison
of NCT03922737 884 886 I-Eq-Comparison
18 NCT03922737 887 889 I-Eq-Comparison
years NCT03922737 890 895 I-Eq-Comparison

6 NCT03922737 898 899 O
. NCT03922737 899 900 O
Pregnant NCT03922737 902 910 B-Condition
or NCT03922737 911 913 B-Or
breastfeeding NCT03922737 914 927 B-Condition
women NCT03922737 928 933 O

7 NCT03922737 936 937 O
. NCT03922737 937 938 O
Patients NCT03922737 940 948 O
undergoing NCT03922737 949 959 B-Eq-Comparison
surgery NCT03922737 960 967 B-Procedure
for NCT03922737 968 971 O
tumor NCT03922737 972 977 B-Condition
, NCT03922737 978 979 O
trauma NCT03922737 980 986 B-Condition
or NCT03922737 987 989 B-Or
infection NCT03922737 990 999 B-Condition
or NCT03922737 1000 1002 O
who NCT03922737 1003 1006 O
require NCT03922737 1007 1014 O
revision NCT03922737 1015 1023 O
or NCT03922737 1024 1026 O
staged NCT03922737 1027 1033 O
procedures NCT03922737 1034 1044 O

8 NCT03922737 1047 1048 O
. NCT03922737 1048 1049 O
Patients NCT03922737 1051 1059 O
without NCT03922737 1060 1067 B-Negation
English NCT03922737 1068 1075 O
- NCT03922737 1076 1077 O
language NCT03922737 1078 1086 O
proficiency NCT03922737 1087 1098 O

9 NCT03922737 1101 1102 O
. NCT03922737 1102 1103 O
Patients NCT03922737 1105 1113 O
with NCT03922737 1114 1118 O
unforeseen NCT03922737 1119 1129 B-Assertion___Assertion-Type-Value:hypothetical
intra NCT03922737 1130 1135 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03922737 1136 1137 O
operative NCT03922737 1138 1147 B-Procedure|Procedure
or NCT03922737 1148 1150 B-Or
peri NCT03922737 1151 1155 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03922737 1156 1157 O
- NCT03922737 1159 1160 O
operative NCT03922737 1161 1170 O
complications NCT03922737 1171 1184 B-Condition


Inclusion NCT03925064 0 9 O
Criteria NCT03925064 10 18 O
: NCT03925064 19 20 O

- NCT03925064 24 25 O
18 NCT03925064 27 29 B-Eq-Comparison
- NCT03925064 30 31 I-Eq-Comparison
40 NCT03925064 32 34 I-Eq-Comparison
years NCT03925064 35 40 I-Eq-Comparison
old NCT03925064 41 44 B-Age
pregnant NCT03925064 45 53 B-Condition
women NCT03925064 54 59 O

Exclusion NCT03925064 60 69 O
Criteria NCT03925064 70 78 O
: NCT03925064 79 80 O

- NCT03925064 84 85 O
fetal NCT03925064 87 92 B-Condition
cardiac NCT03925064 93 100 I-Condition
anomalies NCT03925064 101 110 I-Condition

- NCT03925064 113 114 O
multiple NCT03925064 116 124 B-Condition
gestations NCT03925064 125 135 I-Condition

Inclusion NCT03921216 0 9 O
Criteria NCT03921216 10 18 O
: NCT03921216 19 20 O

Diabetic NCT03921216 22 30 B-Condition
nephropathy NCT03921216 31 42 I-Condition
, NCT03921216 43 44 O
because NCT03921216 45 52 O
of NCT03921216 53 55 O
type NCT03921216 56 60 B-Condition
2 NCT03921216 61 62 I-Condition
diabetes NCT03921216 63 71 I-Condition
, NCT03921216 72 73 O
undergoing NCT03921216 74 84 B-Eq-Comparison
hemodialysis NCT03921216 85 97 B-Procedure
and NCT03921216 98 101 B-And
subjects NCT03921216 102 110 O
with NCT03921216 111 115 O
chronic NCT03921216 116 123 B-Modifier
kidney NCT03921216 124 130 B-Condition
disease NCT03921216 131 138 I-Condition
of NCT03921216 139 141 O
other NCT03921216 142 147 B-Other
causes NCT03921216 148 154 B-Condition
undergoing NCT03921216 155 165 B-Eq-Comparison
hemodialysis NCT03921216 166 178 B-Procedure
. NCT03921216 178 179 O

Exclusion NCT03921216 181 190 O
Criteria NCT03921216 191 199 O
: NCT03921216 200 201 O

- NCT03921216 205 206 O
Active NCT03921216 208 214 B-Eq-Comparison
infection NCT03921216 215 224 B-Condition
that NCT03921216 225 229 O
increases NCT03921216 230 239 O
the NCT03921216 240 243 O
risk NCT03921216 244 248 B-Risk
of NCT03921216 249 251 O
secondary NCT03921216 252 261 B-Condition
infection NCT03921216 262 271 I-Condition
in NCT03921216 272 274 O
the NCT03921216 275 278 O
skin NCT03921216 279 283 B-Modifier
where NCT03921216 284 289 B-And
the NCT03921216 290 293 O
vesicles NCT03921216 294 302 B-Condition
containing NCT03921216 303 313 I-Condition
interstitial NCT03921216 314 326 I-Condition
fluid NCT03921216 327 332 I-Condition
have NCT03921216 333 337 O
been NCT03921216 338 342 O
emptied NCT03921216 343 350 B-Modifier
of NCT03921216 351 353 I-Modifier
interstitial NCT03921216 354 366 I-Modifier
fluid NCT03921216 367 372 I-Modifier
with NCT03921216 373 377 O
a NCT03921216 378 379 O
fine NCT03921216 380 384 B-Procedure
needle NCT03921216 385 391 I-Procedure
and NCT03921216 392 395 B-And
the NCT03921216 396 399 O
bladder NCT03921216 400 407 B-Condition
roof NCT03921216 408 412 I-Condition
is NCT03921216 413 415 O
intact NCT03921216 416 422 B-Modifier
. NCT03921216 422 423 O

- NCT03921216 427 428 O
Treatment NCT03921216 430 439 B-Procedure
with NCT03921216 440 444 O
Warfarin NCT03921216 445 453 B-Drug
due NCT03921216 454 457 O
to NCT03921216 458 460 O
increased NCT03921216 461 470 O
risk NCT03921216 471 475 B-Risk
of NCT03921216 476 478 O
Calciphylaxis NCT03921216 479 492 B-Condition
( NCT03921216 493 494 O
calcific NCT03921216 495 503 B-Condition
uremic NCT03921216 504 510 I-Condition
arteriolopathy NCT03921216 511 525 I-Condition
, NCT03921216 526 527 O
CUA NCT03921216 528 531 B-Condition
) NCT03921216 532 533 O


Inclusion NCT03924622 0 9 O
Criteria NCT03924622 10 18 O
: NCT03924622 19 20 O

- NCT03924622 24 25 O
Men NCT03924622 27 30 O
and NCT03924622 31 34 B-Or
women NCT03924622 35 40 O

- NCT03924622 43 44 O
Age NCT03924622 46 49 B-Age
18 NCT03924622 50 52 B-Eq-Comparison
to NCT03924622 53 55 I-Eq-Comparison
55 NCT03924622 56 58 I-Eq-Comparison

- NCT03924622 62 63 O
Meet NCT03924622 65 69 O
the NCT03924622 70 73 O
physical NCT03924622 74 82 O
standards NCT03924622 83 92 O
for NCT03924622 93 96 O
military NCT03924622 97 105 O
personnel NCT03924622 106 115 O

- NCT03924622 118 119 O
Weigh NCT03924622 121 126 B-Observation
less NCT03924622 127 131 B-Eq-Comparison
than NCT03924622 132 136 I-Eq-Comparison
250 NCT03924622 137 140 I-Eq-Comparison
pounds NCT03924622 141 147 I-Eq-Comparison

- NCT03924622 150 151 O
Be NCT03924622 153 155 O
able NCT03924622 156 160 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924622 161 163 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03924622 164 170 O
in NCT03924622 171 173 O
the NCT03924622 174 177 O
study NCT03924622 178 183 B-Study
position NCT03924622 184 192 B-Observation
for NCT03924622 193 196 O
the NCT03924622 197 200 O
duration NCT03924622 201 209 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03924622 210 212 O
the NCT03924622 213 216 O
study NCT03924622 217 222 B-Study
. NCT03924622 222 223 O

Exclusion NCT03924622 225 234 O
Criteria NCT03924622 235 243 O

- NCT03924622 246 247 O
Previous NCT03924622 249 257 B-Eq-Comparison
injuries NCT03924622 258 266 B-Condition
to NCT03924622 267 269 O
sacrum NCT03924622 270 276 B-Modifier
/ NCT03924622 277 278 B-Or
buttocks NCT03924622 279 287 B-Modifier
with NCT03924622 288 292 B-Modifier
scarring NCT03924622 293 301 I-Modifier

- NCT03924622 304 305 O
History NCT03924622 307 314 B-Eq-Comparison
of NCT03924622 315 317 O
pressure NCT03924622 318 326 B-Modifier
injuries NCT03924622 327 335 B-Condition

- NCT03924622 338 339 O
Cardiovascular NCT03924622 341 355 B-Condition
disease NCT03924622 356 363 I-Condition

- NCT03924622 366 367 O
Neurological NCT03924622 369 381 B-Condition
disease NCT03924622 382 389 I-Condition
that NCT03924622 390 394 O
would NCT03924622 395 400 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03924622 401 407 O
vascular NCT03924622 408 416 B-Modifier
response NCT03924622 417 425 B-Condition

- NCT03924622 428 429 O
Diabetes NCT03924622 431 439 B-Condition

- NCT03924622 442 443 O
History NCT03924622 445 452 B-Eq-Comparison
of NCT03924622 453 455 O
malignancy NCT03924622 456 466 B-Condition

- NCT03924622 469 470 O
Current NCT03924622 472 479 B-Eq-Comparison
skin NCT03924622 480 484 B-Condition
condition NCT03924622 485 494 I-Condition
( NCT03924622 495 496 O
e. NCT03924622 497 499 O
g. NCT03924622 500 502 O
, NCT03924622 503 504 O
eczema NCT03924622 505 511 B-Condition
or NCT03924622 512 514 B-Or
psoriasis NCT03924622 515 524 B-Condition
) NCT03924622 525 526 O

- NCT03924622 530 531 O
Current NCT03924622 533 540 B-Eq-Comparison
neck NCT03924622 541 545 B-Modifier
/ NCT03924622 546 547 B-Or
back NCT03924622 548 552 B-Modifier
pain NCT03924622 553 557 B-Condition
or NCT03924622 558 560 B-Or
history NCT03924622 561 568 B-Eq-Comparison
of NCT03924622 569 571 O
chronic NCT03924622 572 579 B-Modifier
neck NCT03924622 580 584 B-Modifier
/ NCT03924622 585 586 B-Or
back NCT03924622 587 591 B-Modifier
pain NCT03924622 592 596 B-Condition

- NCT03924622 599 600 O
Known NCT03924622 602 607 O
vertebral NCT03924622 608 617 B-Modifier
/ NCT03924622 618 619 B-Or
spinal NCT03924622 620 626 B-Modifier
cord NCT03924622 627 631 I-Modifier
disease NCT03924622 632 639 B-Condition
/ NCT03924622 640 641 B-Or
injury NCT03924622 642 648 B-Condition
( NCT03924622 649 650 O
scoliosis NCT03924622 651 660 B-Condition
, NCT03924622 661 662 O
kyphosis NCT03924622 663 671 B-Condition
, NCT03924622 672 673 O
or NCT03924622 674 676 B-Or
lordosis NCT03924622 677 685 B-Condition
) NCT03924622 686 687 O

- NCT03924622 691 692 I-Modifier
Self NCT03924622 694 698 B-Modifier
- NCT03924622 699 700 O
reported NCT03924622 701 709 I-Modifier
pregnancy NCT03924622 710 719 B-Condition

- NCT03924622 722 723 O
Concern NCT03924622 725 732 O
about NCT03924622 733 738 O
ability NCT03924622 739 746 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924622 747 749 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03924622 750 756 B-Observation
in NCT03924622 757 759 O
the NCT03924622 760 763 O
vacuum NCT03924622 764 770 B-Modifier
spine NCT03924622 771 776 I-Modifier
board NCT03924622 777 782 I-Modifier
for NCT03924622 783 786 O
120 NCT03924622 787 790 B-Eq-Comparison
minutes NCT03924622 791 798 I-Eq-Comparison

Inclusion NCT03925272 0 9 O
Criteria NCT03925272 10 18 O
: NCT03925272 19 20 O

- NCT03925272 24 25 O
unprotected NCT03925272 27 38 B-Modifier
adults NCT03925272 39 45 O
with NCT03925272 46 50 O
social NCT03925272 51 57 O
security NCT03925272 58 66 O
who NCT03925272 67 70 O
have NCT03925272 71 75 O
attested NCT03925272 76 84 O
their NCT03925272 85 90 O
consent NCT03925272 91 98 O
after NCT03925272 99 104 O
receiving NCT03925272 105 114 O
any NCT03925272 115 118 O
relevant NCT03925272 119 127 O
information NCT03925272 128 139 O
about NCT03925272 140 145 O
the NCT03925272 146 149 O
study NCT03925272 150 155 O

- NCT03925272 158 159 O
subjects NCT03925272 161 169 O
whose NCT03925272 170 175 O
ethno NCT03925272 176 181 O
- NCT03925272 182 183 O
geographical NCT03925272 184 196 O
origin NCT03925272 197 203 O
of NCT03925272 204 206 O
both NCT03925272 207 211 O
parents NCT03925272 212 219 B-Family-Member___Family-Member-Type:parent
is NCT03925272 220 222 O
known NCT03925272 223 228 O

- NCT03925272 231 232 O
subjects NCT03925272 234 242 O
for NCT03925272 243 246 O
whom NCT03925272 247 251 O
data NCT03925272 252 256 O
on NCT03925272 257 259 O
principal NCT03925272 260 269 B-Modifier
vaccinations NCT03925272 270 282 B-Immunization
( NCT03925272 283 284 O
diphtheria NCT03925272 285 295 B-Condition
, NCT03925272 296 297 O
tetanus NCT03925272 298 305 B-Condition
, NCT03925272 306 307 O
poliomyelitis NCT03925272 308 321 B-Condition
, NCT03925272 322 323 O
hepatitis NCT03925272 324 333 B-Condition
B NCT03925272 334 335 I-Condition
, NCT03925272 336 337 O
possibly NCT03925272 338 346 B-Assertion___Assertion-Type-Value:hypothetical
tuberculosis NCT03925272 347 359 B-Condition
) NCT03925272 360 361 O
are NCT03925272 362 365 O
documented NCT03925272 366 376 O

- NCT03925272 379 380 O
subjects NCT03925272 382 390 O
who NCT03925272 391 394 O
consented NCT03925272 395 404 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925272 405 407 I-Assertion___Assertion-Type-Value:hypothetical
carry NCT03925272 408 413 O
out NCT03925272 414 417 O
serological NCT03925272 418 429 B-Observation
tests NCT03925272 430 435 I-Observation
HIV NCT03925272 436 439 B-Condition
, NCT03925272 440 441 O
HCV NCT03925272 442 445 B-Condition
, NCT03925272 446 447 O
HBV NCT03925272 448 451 B-Condition

Exclusion NCT03925272 452 461 O
Criteria NCT03925272 462 470 O
: NCT03925272 471 472 O

- NCT03925272 476 477 O
Any NCT03925272 479 482 O
conditions NCT03925272 483 493 B-Condition
that NCT03925272 494 498 O
would NCT03925272 499 504 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03925272 505 508 B-Negation
allow NCT03925272 509 514 O
participation NCT03925272 515 528 O
in NCT03925272 529 531 O
the NCT03925272 532 535 O
present NCT03925272 536 543 O
study NCT03925272 544 549 B-Study
, NCT03925272 550 551 O
on NCT03925272 552 554 O
the NCT03925272 555 558 O
opinion NCT03925272 559 566 O
of NCT03925272 567 569 O
the NCT03925272 570 573 O
investigator NCT03925272 574 586 O
( NCT03925272 587 588 O
documenting NCT03925272 589 600 O
) NCT03925272 601 602 O
, NCT03925272 604 605 O
ie NCT03925272 606 608 O
any NCT03925272 609 612 O
acute NCT03925272 613 618 O
or NCT03925272 619 621 B-Or
chronic NCT03925272 622 629 B-Modifier
pathology NCT03925272 630 639 B-Condition
that NCT03925272 640 644 O
may NCT03925272 645 648 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03925272 649 658 O
with NCT03925272 659 663 O
the NCT03925272 664 667 O
immune NCT03925272 668 674 B-Condition
system NCT03925272 675 681 I-Condition
, NCT03925272 682 683 O
such NCT03925272 684 688 O
as NCT03925272 689 691 O
progressive NCT03925272 692 703 B-Modifier
or NCT03925272 704 706 B-Or
chronic NCT03925272 707 714 B-Modifier
pathology NCT03925272 715 724 B-Condition
severe NCT03925272 725 731 O
or NCT03925272 732 734 B-Or
uncontrolled NCT03925272 735 747 B-Modifier
by NCT03925272 748 750 O
current NCT03925272 751 758 B-Eq-Comparison
treatments NCT03925272 759 769 B-Procedure
or NCT03925272 770 772 B-Or
a NCT03925272 773 774 O
pathology NCT03925272 775 784 B-Condition
requiring NCT03925272 785 794 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03925272 795 798 O
administration NCT03925272 799 813 O
of NCT03925272 814 816 O
immune NCT03925272 817 823 B-Drug
impact NCT03925272 824 830 I-Drug
drugs NCT03925272 831 836 I-Drug
: NCT03925272 837 838 O
long NCT03925272 839 843 B-Modifier
- NCT03925272 844 845 I-Drug|Modifier
term NCT03925272 846 850 I-Modifier
anti NCT03925272 851 855 B-Drug
- NCT03925272 856 857 O
inflammatory NCT03925272 858 870 I-Drug
, NCT03925272 871 872 O
immunosuppressive NCT03925272 873 890 B-Drug
, NCT03925272 891 892 O
etc NCT03925272 893 896 O

- NCT03925272 899 900 O
Pregnant NCT03925272 902 910 B-Condition
or NCT03925272 911 913 B-Or
lactating NCT03925272 914 923 B-Condition
women NCT03925272 924 929 O

- NCT03925272 932 933 O
For NCT03925272 935 938 O
the NCT03925272 939 942 O
realization NCT03925272 943 954 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03925272 955 957 I-Assertion___Assertion-Type-Value:hypothetical
skin NCT03925272 958 962 B-Modifier
biopsies NCT03925272 963 971 B-Procedure
: NCT03925272 972 973 O
allergy NCT03925272 974 981 B-Allergy
to NCT03925272 982 984 O
local NCT03925272 985 990 B-Drug
anesthetics NCT03925272 991 1002 I-Drug
, NCT03925272 1003 1004 O
cardiac NCT03925272 1005 1012 B-Condition
valvulopathy NCT03925272 1013 1025 I-Condition

- NCT03925272 1028 1029 O
For NCT03925272 1031 1034 O
the NCT03925272 1035 1038 O
realization NCT03925272 1039 1050 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03925272 1051 1053 I-Assertion___Assertion-Type-Value:hypothetical
Tubertest NCT03925272 1054 1063 B-Observation
: NCT03925272 1064 1065 O
Subject NCT03925272 1066 1073 O
presenting NCT03925272 1074 1084 O
a NCT03925272 1085 1086 O
contraindication NCT03925272 1087 1103 B-Contraindication
to NCT03925272 1104 1106 O
tuberculin NCT03925272 1107 1117 B-Drug

Inclusion NCT03928756 0 9 O
Criteria NCT03928756 10 18 O
: NCT03928756 19 20 O

1 NCT03928756 24 25 O
. NCT03928756 25 26 O
Have NCT03928756 28 32 O
an NCT03928756 33 35 O
iPhone NCT03928756 36 42 O
smartphone NCT03928756 43 53 O
on NCT03928756 54 56 O
which NCT03928756 57 62 O
the NCT03928756 63 66 O
app NCT03928756 67 70 O
can NCT03928756 71 74 O
be NCT03928756 75 77 O
downloaded NCT03928756 78 88 O

2 NCT03928756 91 92 O
. NCT03928756 92 93 O
Self NCT03928756 95 99 O
- NCT03928756 100 101 O
reported NCT03928756 102 110 O
past NCT03928756 111 115 B-Eq-Comparison
- NCT03928756 116 117 I-Eq-Comparison
month NCT03928756 118 123 I-Eq-Comparison
binge NCT03928756 124 129 B-Condition
drinking NCT03928756 130 138 I-Condition
( NCT03928756 139 140 O
4 NCT03928756 141 142 B-Eq-Comparison
/ NCT03928756 143 144 I-Eq-Comparison
5 NCT03928756 145 146 I-Eq-Comparison
or NCT03928756 147 149 I-Eq-Comparison
more NCT03928756 150 154 I-Eq-Comparison
drinks NCT03928756 155 161 B-Observation
on NCT03928756 162 164 B-Eq-Comparison
one NCT03928756 165 168 O
occasion NCT03928756 169 177 I-Eq-Comparison
, NCT03928756 178 179 O
tailored NCT03928756 180 188 O
by NCT03928756 189 191 O
sex NCT03928756 192 195 B-Condition
) NCT03928756 196 197 O
OR NCT03928756 198 200 B-Or
any NCT03928756 201 204 O
past NCT03928756 205 209 B-Eq-Comparison
- NCT03928756 210 211 I-Eq-Comparison
month NCT03928756 212 217 I-Eq-Comparison
marijuana NCT03928756 218 227 B-Condition
use NCT03928756 228 231 I-Condition
without NCT03928756 232 239 B-Negation
a NCT03928756 240 241 O
medical NCT03928756 242 249 B-Observation
marijuana NCT03928756 250 259 I-Observation
card NCT03928756 260 264 I-Observation

3 NCT03928756 267 268 O
. NCT03928756 268 269 O
Meet NCT03928756 271 275 O
study NCT03928756 276 281 O
verification NCT03928756 282 294 O
criteria NCT03928756 295 303 O
( NCT03928756 304 305 O
i. NCT03928756 306 308 O
e. NCT03928756 309 311 O
, NCT03928756 312 313 O
use NCT03928756 314 317 O
of NCT03928756 318 320 O
CAPTCHA NCT03928756 321 328 O
, NCT03928756 329 330 O
IP NCT03928756 331 333 O
address NCT03928756 334 341 O
checks NCT03928756 342 348 O
, NCT03928756 349 350 O
social NCT03928756 351 357 O
media NCT03928756 358 363 O
checks NCT03928756 364 370 O
) NCT03928756 371 372 O
. NCT03928756 373 374 O

Exclusion NCT03928756 376 385 O
Criteria NCT03928756 386 394 O
: NCT03928756 395 396 O

1 NCT03928756 398 399 O
. NCT03928756 399 400 O
Unable NCT03928756 402 408 B-Negation
to NCT03928756 409 411 O
understand NCT03928756 412 422 O
English NCT03928756 423 430 O

Inclusion NCT03928795 0 9 O
Criteria NCT03928795 10 18 O
: NCT03928795 19 20 O

- NCT03928795 24 25 O
Monofetal NCT03928795 27 36 B-Modifier
pregnancy NCT03928795 37 46 B-Condition

- NCT03928795 49 50 O
Age NCT03928795 52 55 B-Age
over NCT03928795 56 60 B-Eq-Comparison
18 NCT03928795 61 63 I-Eq-Comparison
years NCT03928795 64 69 I-Eq-Comparison
old NCT03928795 70 73 O

- NCT03928795 76 77 O
Term NCT03928795 79 83 B-Condition
Pregnancy NCT03928795 84 93 I-Condition
≥ NCT03928795 94 95 B-Eq-Comparison
37 NCT03928795 96 98 I-Eq-Comparison
SA NCT03928795 99 101 O

- NCT03928795 104 105 O
Indication NCT03928795 107 117 B-Indication
for NCT03928795 118 121 O
Elective NCT03928795 122 130 B-Modifier
caesarean NCT03928795 131 140 B-Procedure
section NCT03928795 141 148 I-Procedure

Exclusion NCT03928795 149 158 O
Criteria NCT03928795 159 167 O
: NCT03928795 168 169 O

- NCT03928795 173 174 O
- NCT03928795 176 177 O
Fetal NCT03928795 178 183 B-Modifier
pathology NCT03928795 184 193 B-Condition
known NCT03928795 194 199 O
prenatally NCT03928795 200 210 O
like NCT03928795 211 215 O
intrauterine NCT03928795 216 228 B-Modifier
severe NCT03928795 229 235 O
growth NCT03928795 236 242 B-Condition
retardation NCT03928795 243 254 I-Condition
with NCT03928795 255 259 B-And
Doppler NCT03928795 260 267 B-Condition
abnormalities NCT03928795 268 281 O
, NCT03928795 282 283 O
fetal NCT03928795 284 289 B-Modifier
malformation NCT03928795 290 302 B-Condition
or NCT03928795 303 305 B-Or
a NCT03928795 306 307 O
known NCT03928795 308 313 O
fetal NCT03928795 314 319 B-Modifier
genetic NCT03928795 320 327 B-Condition
defect NCT03928795 328 334 I-Condition
. NCT03928795 334 335 O

- NCT03928795 339 340 O
Anomaly NCT03928795 342 349 B-Condition
of NCT03928795 350 352 O
placental NCT03928795 353 362 B-Modifier
adhesion NCT03928795 363 371 I-Modifier
. NCT03928795 371 372 O

- NCT03928795 376 377 O
Caesarean NCT03928795 379 388 B-Procedure
in NCT03928795 389 391 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03928795 392 393 I-Temporal-Connection___Temporal-Connection-Type-Value:during
context NCT03928795 394 401 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928795 402 404 O
medical NCT03928795 405 412 B-Modifier
or NCT03928795 413 415 B-Or
obstetric NCT03928795 416 425 B-Modifier
emergency NCT03928795 426 435 B-Observation
. NCT03928795 435 436 O

- NCT03928795 440 441 O
Caesarean NCT03928795 443 452 B-Procedure
section NCT03928795 453 460 I-Procedure
performed NCT03928795 461 470 O
under NCT03928795 471 476 O
general NCT03928795 477 484 B-Procedure
anesthesia NCT03928795 485 495 I-Procedure
following NCT03928795 496 505 B-Temporal-Connection___Temporal-Connection-Type-Value:after
failure NCT03928795 506 513 O
of NCT03928795 514 516 O
locoregional NCT03928795 517 529 B-Modifier
anesthesia NCT03928795 530 540 B-Procedure
. NCT03928795 540 541 O

- NCT03928795 545 546 O
Refusal NCT03928795 548 555 O
of NCT03928795 556 558 O
the NCT03928795 559 562 O
woman NCT03928795 563 568 O
to NCT03928795 569 571 O
participate NCT03928795 572 583 O
in NCT03928795 584 586 O
the NCT03928795 587 590 O
study NCT03928795 591 596 B-Study
. NCT03928795 596 597 O

- NCT03928795 601 602 O
Impossibility NCT03928795 604 617 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03928795 618 620 B-Or
failure NCT03928795 621 628 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03928795 629 631 O
study NCT03928795 632 637 O
the NCT03928795 638 641 O
neonatal NCT03928795 642 650 B-Modifier
acid NCT03928795 651 655 B-Observation
- NCT03928795 656 657 I-Observation
base NCT03928795 658 662 I-Observation
balance NCT03928795 663 670 I-Observation
on NCT03928795 671 673 O
the NCT03928795 674 677 O
umbilical NCT03928795 678 687 B-Modifier
cord NCT03928795 688 692 I-Modifier
. NCT03928795 692 693 O

Inclusion NCT03924024 0 9 O
Criteria NCT03924024 10 18 O
: NCT03924024 19 20 O

- NCT03924024 24 25 O
Male NCT03924024 27 31 O
or NCT03924024 32 34 B-Or
female NCT03924024 35 41 O
, NCT03924024 42 43 O
18 NCT03924024 44 46 B-Eq-Comparison
to NCT03924024 47 49 I-Eq-Comparison
65 NCT03924024 50 52 I-Eq-Comparison
years NCT03924024 53 58 I-Eq-Comparison
of NCT03924024 59 61 O
age NCT03924024 62 65 B-Age
. NCT03924024 65 66 O

- NCT03924024 70 71 O
Able NCT03924024 73 77 O
to NCT03924024 78 80 O
provide NCT03924024 81 88 O
informed NCT03924024 89 97 O
consent NCT03924024 98 105 O
. NCT03924024 105 106 O

- NCT03924024 110 111 O
Present NCT03924024 113 120 B-Encounter
to NCT03924024 121 123 O
Stanford NCT03924024 124 132 O
Emergency NCT03924024 133 142 O
Department NCT03924024 143 153 O
as NCT03924024 154 156 O
a NCT03924024 157 158 O
trauma NCT03924024 159 165 B-Condition
with NCT03924024 166 170 B-And
a NCT03924024 171 172 O
major NCT03924024 173 178 B-Modifier
operative NCT03924024 179 188 I-Modifier
lower NCT03924024 189 194 I-Modifier
extremity NCT03924024 195 204 I-Modifier
injury NCT03924024 205 211 B-Condition

- NCT03924024 214 215 O
Glasgow NCT03924024 217 224 B-Observation
coma NCT03924024 225 229 I-Observation
scale NCT03924024 230 235 I-Observation
of NCT03924024 236 238 O
15 NCT03924024 239 241 B-Eq-Comparison
within NCT03924024 242 248 B-Eq-Comparison
24 NCT03924024 249 251 I-Eq-Comparison
hours NCT03924024 252 257 I-Eq-Comparison
after NCT03924024 258 263 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924024 264 273 B-Encounter
or NCT03924024 274 276 B-Or
extubation NCT03924024 277 287 B-Procedure

- NCT03924024 290 291 O
Negative NCT03924024 293 301 O
urinary NCT03924024 302 309 B-Observation
toxicology NCT03924024 310 320 I-Observation
screen NCT03924024 321 327 B-Modifier
for NCT03924024 328 331 I-Modifier
illicit NCT03924024 332 339 I-Modifier
substances NCT03924024 340 350 I-Modifier
; NCT03924024 350 351 O

- NCT03924024 354 355 O
Negative NCT03924024 357 365 O
pregnancy NCT03924024 366 375 B-Condition
test NCT03924024 376 380 O
if NCT03924024 381 383 O
female NCT03924024 384 390 O
and NCT03924024 391 394 B-And
less NCT03924024 395 399 B-Eq-Comparison
then NCT03924024 400 404 I-Eq-Comparison
60 NCT03924024 405 407 I-Eq-Comparison
y NCT03924024 408 409 I-Eq-Comparison
/ NCT03924024 410 411 I-Eq-Comparison
o NCT03924024 412 413 I-Age|Eq-Comparison
; NCT03924024 413 414 O

- NCT03924024 417 418 O
No NCT03924024 420 422 B-Negation
suspicion NCT03924024 423 432 B-Assertion___Assertion-Type-Value:possible
for NCT03924024 433 436 O
a NCT03924024 437 438 O
head NCT03924024 439 443 B-Modifier
injury NCT03924024 444 450 B-Condition
and NCT03924024 451 454 B-Or
/ NCT03924024 455 456 I-Or
or NCT03924024 457 459 I-Or
negative NCT03924024 460 468 O
head NCT03924024 469 473 B-Modifier
CT NCT03924024 474 476 B-Procedure
scan NCT03924024 477 481 I-Procedure
for NCT03924024 482 485 O
intracranial NCT03924024 486 498 B-Condition
hemorrhage NCT03924024 499 509 I-Condition
or NCT03924024 510 512 B-Or
injury NCT03924024 513 519 B-Condition
based NCT03924024 520 525 O
on NCT03924024 526 528 O
standard NCT03924024 529 537 O
of NCT03924024 538 540 O
care NCT03924024 541 545 O

- NCT03924024 548 549 O
No NCT03924024 551 553 B-Negation
history NCT03924024 554 561 B-Eq-Comparison
of NCT03924024 562 564 O
seizure NCT03924024 565 572 B-Condition
disorder NCT03924024 573 581 I-Condition
or NCT03924024 582 584 B-Or
other NCT03924024 585 590 B-Other
neurological NCT03924024 591 603 B-Condition
disorders NCT03924024 604 613 I-Condition
. NCT03924024 613 614 O

- NCT03924024 618 619 O
All NCT03924024 621 624 O
patients NCT03924024 625 633 O
included NCT03924024 634 642 O
must NCT03924024 643 647 O
screen NCT03924024 648 654 O
positive NCT03924024 655 663 O
for NCT03924024 664 667 O
PHQ NCT03924024 668 671 B-Observation
- NCT03924024 672 673 I-Observation
9 NCT03924024 674 675 I-Observation
score NCT03924024 676 681 B-Eq-Comparison
> NCT03924024 682 683 I-Eq-Comparison
4 NCT03924024 684 685 I-Eq-Comparison
( NCT03924024 686 687 O
positive NCT03924024 688 696 O
symptoms NCT03924024 697 705 B-Assertion___Assertion-Type-Value:possible
of NCT03924024 706 708 O
depression NCT03924024 709 719 B-Condition
) NCT03924024 720 721 O
and NCT03924024 722 725 B-And
CES NCT03924024 726 729 B-Observation
- NCT03924024 730 731 I-Observation
T NCT03924024 732 733 I-Observation
score NCT03924024 734 739 B-Eq-Comparison
< NCT03924024 740 741 I-Eq-Comparison
36 NCT03924024 742 744 I-Eq-Comparison
( NCT03924024 745 746 O
poor NCT03924024 747 751 B-Condition
coping NCT03924024 752 758 I-Condition
self NCT03924024 759 763 I-Condition
- NCT03924024 764 765 I-Condition
efficacy NCT03924024 766 774 I-Condition
) NCT03924024 775 776 O
. NCT03924024 777 778 O

Exclusion NCT03924024 780 789 O
Criteria NCT03924024 790 798 O
: NCT03924024 799 800 O

- NCT03924024 804 805 O
Incarceration NCT03924024 807 820 B-Observation
, NCT03924024 821 822 O

- NCT03924024 826 827 O
Pregnant NCT03924024 829 837 B-Condition
females NCT03924024 838 845 O
, NCT03924024 846 847 O

- NCT03924024 851 852 O
Prior NCT03924024 854 859 B-Eq-Comparison
psychotic NCT03924024 860 869 B-Condition
disorder NCT03924024 870 878 I-Condition
, NCT03924024 879 880 O

- NCT03924024 884 885 I-Drug
Current NCT03924024 887 894 B-Eq-Comparison
use NCT03924024 895 898 I-Eq-Comparison
of NCT03924024 899 901 O
anti NCT03924024 902 906 B-Drug|Drug
- NCT03924024 907 908 I-Drug
depressant NCT03924024 909 919 I-Drug
or NCT03924024 920 922 B-Or
anti NCT03924024 923 927 O
- NCT03924024 928 929 O
psychotic NCT03924024 930 939 I-Drug
medications NCT03924024 940 951 I-Drug
, NCT03924024 952 953 O

- NCT03924024 957 958 O
Prior NCT03924024 960 965 B-Eq-Comparison
- NCT03924024 966 967 O
admission NCT03924024 968 977 B-Encounter
opioid NCT03924024 978 984 B-Condition
use NCT03924024 985 988 I-Condition
within NCT03924024 989 995 B-Eq-Comparison
30 NCT03924024 996 998 I-Eq-Comparison
days NCT03924024 999 1003 I-Eq-Comparison
( NCT03924024 1004 1005 O
patients NCT03924024 1006 1014 O
will NCT03924024 1015 1019 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924024 1020 1022 I-Assertion___Assertion-Type-Value:hypothetical
screened NCT03924024 1023 1031 O
for NCT03924024 1032 1035 O
recent NCT03924024 1036 1042 B-Eq-Comparison
prescription NCT03924024 1043 1055 O
opioid NCT03924024 1056 1062 B-Drug
use NCT03924024 1063 1066 O
using NCT03924024 1067 1072 O
the NCT03924024 1073 1076 O
CURES NCT03924024 1077 1082 B-Observation
report NCT03924024 1083 1089 O
) NCT03924024 1090 1091 O
, NCT03924024 1093 1094 O

- NCT03924024 1098 1099 O
Heavy NCT03924024 1101 1106 O
alcohol NCT03924024 1107 1114 B-Condition
use NCT03924024 1115 1118 I-Condition
, NCT03924024 1119 1120 O

- NCT03924024 1124 1125 O
Lesional NCT03924024 1127 1135 B-Modifier
neurological NCT03924024 1136 1148 B-Condition
disorder NCT03924024 1149 1157 I-Condition
or NCT03924024 1158 1160 B-Or|Or
brain NCT03924024 1161 1166 B-Modifier
implant NCT03924024 1167 1174 B-Procedure
or NCT03924024 1175 1177 O
intracranial NCT03924024 1178 1190 B-Condition
ferromagnetic NCT03924024 1191 1204 I-Condition
material NCT03924024 1205 1213 I-Condition
, NCT03924024 1214 1215 O

- NCT03924024 1219 1220 O
Seizure NCT03924024 1222 1229 B-Condition
disorder NCT03924024 1230 1238 I-Condition

Inclusion NCT03926169 0 9 O
Criteria NCT03926169 10 18 O
: NCT03926169 19 20 O

- NCT03926169 24 25 O
Participant NCT03926169 27 38 O
with NCT03926169 39 43 O
moderate NCT03926169 44 52 B-Eq-Comparison
to NCT03926169 53 55 I-Eq-Comparison
severe NCT03926169 56 62 I-Eq-Comparison
Hidradenitis NCT03926169 63 75 B-Condition
Suppurativa NCT03926169 76 87 I-Condition
( NCT03926169 88 89 O
HS NCT03926169 90 92 B-Condition
) NCT03926169 93 94 O
for NCT03926169 95 98 O
at NCT03926169 99 101 B-Eq-Comparison
least NCT03926169 102 107 I-Eq-Comparison
one NCT03926169 108 111 I-Eq-Comparison
year NCT03926169 112 116 I-Eq-Comparison
prior NCT03926169 117 122 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 123 125 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Baseline NCT03926169 126 134 B-Study
visit NCT03926169 135 140 O
. NCT03926169 140 141 O

- NCT03926169 145 146 O
HS NCT03926169 148 150 B-Condition
lesions NCT03926169 151 158 I-Condition
present NCT03926169 159 166 O
in NCT03926169 167 169 O
at NCT03926169 170 172 B-Eq-Comparison
least NCT03926169 173 178 I-Eq-Comparison
two NCT03926169 179 182 I-Eq-Comparison
distinct NCT03926169 183 191 I-Eq-Comparison
anatomical NCT03926169 192 202 I-Eq-Comparison
areas NCT03926169 203 208 I-Eq-Comparison
. NCT03926169 208 209 O

- NCT03926169 213 214 O
Draining NCT03926169 216 224 B-Observation
fistula NCT03926169 225 232 I-Observation
count NCT03926169 233 238 I-Observation
of NCT03926169 239 241 O
< NCT03926169 242 243 B-Eq-Comparison
= NCT03926169 245 246 I-Eq-Comparison
20 NCT03926169 247 249 I-Eq-Comparison
at NCT03926169 250 252 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Baseline NCT03926169 253 261 B-Study
visit NCT03926169 262 267 O
. NCT03926169 267 268 O

- NCT03926169 272 273 O
Total NCT03926169 275 280 O
abscesses NCT03926169 281 290 B-Observation
and NCT03926169 291 294 I-Observation
nodule NCT03926169 295 301 I-Observation
count NCT03926169 302 307 I-Observation|Observation
( NCT03926169 308 309 O
AN NCT03926169 310 312 B-Observation
count NCT03926169 313 318 O
) NCT03926169 319 320 O
of NCT03926169 321 323 O
> NCT03926169 324 325 B-Eq-Comparison
= NCT03926169 327 328 I-Eq-Comparison
5 NCT03926169 329 330 I-Eq-Comparison
at NCT03926169 331 333 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Baseline NCT03926169 334 342 B-Study
visit NCT03926169 343 348 O
. NCT03926169 348 349 O

- NCT03926169 353 354 O
Participants NCT03926169 356 368 O
are NCT03926169 369 372 O
required NCT03926169 373 381 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926169 382 384 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03926169 385 388 O
a NCT03926169 389 390 O
daily NCT03926169 391 396 B-Eq-Comparison
antiseptic NCT03926169 397 407 B-Procedure
wash NCT03926169 408 412 I-Procedure
on NCT03926169 413 415 O
their NCT03926169 416 421 O
HS NCT03926169 422 424 B-Condition
lesions NCT03926169 425 432 I-Condition
. NCT03926169 433 434 O

- NCT03926169 438 439 O
Participant NCT03926169 441 452 O
must NCT03926169 453 457 O
have NCT03926169 458 462 O
a NCT03926169 463 464 O
history NCT03926169 465 472 B-Eq-Comparison
of NCT03926169 473 475 O
inadequate NCT03926169 476 486 B-Condition
response NCT03926169 487 495 I-Condition
or NCT03926169 496 498 B-Or
intolerance NCT03926169 499 510 B-Condition
to NCT03926169 511 513 O
an NCT03926169 514 516 O
adequate NCT03926169 517 525 O
trial NCT03926169 526 531 O
of NCT03926169 532 534 O
oral NCT03926169 535 539 B-Drug
antibiotics NCT03926169 540 551 I-Drug
for NCT03926169 552 555 O
treatment NCT03926169 556 565 B-Procedure
of NCT03926169 566 568 O
HS NCT03926169 569 571 B-Condition
. NCT03926169 571 572 O

Exclusion NCT03926169 574 583 O
Criteria NCT03926169 584 592 O
: NCT03926169 593 594 O

- NCT03926169 598 599 O
Participant NCT03926169 601 612 O
has NCT03926169 613 616 O
a NCT03926169 617 618 O
history NCT03926169 619 626 B-Eq-Comparison
of NCT03926169 627 629 O
active NCT03926169 630 636 B-Eq-Comparison
skin NCT03926169 637 641 B-Condition
disease NCT03926169 642 649 I-Condition
other NCT03926169 650 655 B-Exception
than NCT03926169 656 660 I-Exception
HS NCT03926169 661 663 B-Condition
that NCT03926169 664 668 O
could NCT03926169 669 674 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03926169 675 684 O
with NCT03926169 685 689 O
the NCT03926169 690 693 O
assessment NCT03926169 694 704 B-Procedure
of NCT03926169 705 707 O
HS NCT03926169 708 710 B-Condition
. NCT03926169 710 711 O

- NCT03926169 715 716 O
Participant NCT03926169 718 729 O
has NCT03926169 730 733 O
active NCT03926169 734 740 B-Eq-Comparison
tuberculosis NCT03926169 741 753 B-Condition
( NCT03926169 754 755 O
TB NCT03926169 756 758 B-Condition
) NCT03926169 759 760 O
or NCT03926169 761 763 B-Or
concurrent NCT03926169 764 774 O
treatment NCT03926169 775 784 B-Procedure
for NCT03926169 785 788 O
latent NCT03926169 789 795 B-Modifier
TB NCT03926169 796 798 B-Condition
or NCT03926169 799 801 B-Or
evidence NCT03926169 802 810 O
of NCT03926169 811 813 O
hepatitis NCT03926169 814 823 B-Condition
B NCT03926169 824 825 I-Condition
virus NCT03926169 826 831 I-Condition
( NCT03926169 832 833 O
HBV NCT03926169 834 837 B-Condition
) NCT03926169 838 839 O
or NCT03926169 840 842 B-Or
hepatitis NCT03926169 843 852 B-Condition
C NCT03926169 853 854 I-Condition
virus NCT03926169 855 860 I-Condition
( NCT03926169 861 862 O
HCV NCT03926169 863 866 B-Condition
) NCT03926169 867 868 O
or NCT03926169 869 871 B-Or
human NCT03926169 872 877 B-Condition
immuno NCT03926169 878 884 I-Condition
deficiency NCT03926169 885 895 I-Condition
virus NCT03926169 896 901 I-Condition
( NCT03926169 902 903 O
HIV NCT03926169 904 907 B-Condition
) NCT03926169 908 909 O
infection NCT03926169 910 919 B-Condition
. NCT03926169 919 920 O

- NCT03926169 924 925 O
Participant NCT03926169 927 938 O
has NCT03926169 939 942 O
prior NCT03926169 943 948 B-Eq-Comparison
exposure NCT03926169 949 957 O
to NCT03926169 958 960 O
anti NCT03926169 961 965 O
- NCT03926169 966 967 I-Condition|Condition
interleukin NCT03926169 968 979 B-Condition
- NCT03926169 980 981 O
1 NCT03926169 982 983 I-Condition|Condition
( NCT03926169 984 985 O
anti NCT03926169 986 990 O
- NCT03926169 991 992 O
IL NCT03926169 993 995 B-Condition
- NCT03926169 996 997 O
1 NCT03926169 998 999 O
) NCT03926169 1000 1001 O
treatment NCT03926169 1002 1011 B-Procedure
within NCT03926169 1012 1018 B-Eq-Comparison
3 NCT03926169 1019 1020 I-Eq-Comparison
months NCT03926169 1021 1027 I-Eq-Comparison
or NCT03926169 1028 1030 B-Or
5 NCT03926169 1031 1032 B-Eq-Comparison
half NCT03926169 1033 1037 I-Eq-Comparison
- NCT03926169 1038 1039 I-Eq-Comparison
lives NCT03926169 1040 1045 I-Eq-Comparison
, NCT03926169 1046 1047 O
whichever NCT03926169 1048 1057 O
is NCT03926169 1058 1060 O
longer NCT03926169 1061 1067 O
, NCT03926169 1068 1069 O
prior NCT03926169 1070 1075 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1076 1078 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926169 1079 1087 B-Study
. NCT03926169 1087 1088 O

- NCT03926169 1092 1093 O
Participant NCT03926169 1095 1106 O
has NCT03926169 1107 1110 O
received NCT03926169 1111 1119 B-Eq-Comparison
prescription NCT03926169 1120 1132 O
topical NCT03926169 1133 1140 B-Drug|Drug
therapies NCT03926169 1141 1150 I-Drug
( NCT03926169 1151 1152 O
including NCT03926169 1153 1162 O
topical NCT03926169 1163 1170 I-Temporal-Connection___Temporal-Connection-Type-Value:before
antibiotics NCT03926169 1171 1182 I-Drug
) NCT03926169 1183 1184 O
within NCT03926169 1185 1191 B-Eq-Comparison
14 NCT03926169 1192 1194 I-Eq-Comparison
days NCT03926169 1195 1199 I-Eq-Comparison
prior NCT03926169 1200 1205 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1206 1208 O
the NCT03926169 1209 1212 O
Baseline NCT03926169 1213 1221 B-Study
visit NCT03926169 1222 1227 O
. NCT03926169 1227 1228 O

- NCT03926169 1232 1233 I-Procedure
Participant NCT03926169 1235 1246 O
has NCT03926169 1247 1250 O
received NCT03926169 1251 1259 B-Eq-Comparison
systemic NCT03926169 1260 1268 B-Modifier
non NCT03926169 1269 1272 B-Procedure
- NCT03926169 1273 1274 O
biologic NCT03926169 1275 1283 I-Procedure
therapies NCT03926169 1284 1293 I-Procedure
that NCT03926169 1294 1298 O
can NCT03926169 1299 1302 O
also NCT03926169 1303 1307 O
be NCT03926169 1308 1310 O
used NCT03926169 1311 1315 O
to NCT03926169 1316 1318 I-Temporal-Connection___Temporal-Connection-Type-Value:before
treat NCT03926169 1319 1324 O
HS NCT03926169 1325 1327 B-Condition
within NCT03926169 1328 1334 B-Eq-Comparison
4 NCT03926169 1335 1336 I-Eq-Comparison
weeks NCT03926169 1337 1342 I-Eq-Comparison
prior NCT03926169 1343 1348 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1349 1351 O
the NCT03926169 1352 1355 O
Baseline NCT03926169 1356 1364 B-Study
visit NCT03926169 1365 1370 O
. NCT03926169 1370 1371 O

- NCT03926169 1375 1376 O
Participant NCT03926169 1378 1389 O
has NCT03926169 1390 1393 O
received NCT03926169 1394 1402 B-Eq-Comparison
any NCT03926169 1403 1406 O
systemic NCT03926169 1407 1415 B-Modifier
( NCT03926169 1416 1417 O
including NCT03926169 1418 1427 O
oral NCT03926169 1428 1432 B-Modifier
) NCT03926169 1433 1434 O
antibiotic NCT03926169 1435 1445 B-Drug
treatment NCT03926169 1446 1455 B-Procedure
within NCT03926169 1456 1462 B-Eq-Comparison
4 NCT03926169 1463 1464 I-Eq-Comparison
weeks NCT03926169 1465 1470 I-Eq-Comparison
prior NCT03926169 1471 1476 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1477 1479 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926169 1480 1483 O
Baseline NCT03926169 1484 1492 B-Study
visit NCT03926169 1493 1498 O
. NCT03926169 1498 1499 O

Inclusion NCT03921606 0 9 O
Criteria NCT03921606 10 18 O
: NCT03921606 19 20 O

- NCT03921606 24 25 O
aged NCT03921606 27 31 B-Age
18 NCT03921606 32 34 B-Eq-Comparison
years NCT03921606 35 40 I-Eq-Comparison
or NCT03921606 41 43 I-Eq-Comparison
above NCT03921606 44 49 I-Eq-Comparison
, NCT03921606 50 51 O

- NCT03921606 55 56 O
able NCT03921606 58 62 O
to NCT03921606 63 65 O
speak NCT03921606 66 71 O
Cantonese NCT03921606 72 81 O
and NCT03921606 82 85 B-Or
read NCT03921606 86 90 O
Chinese NCT03921606 91 98 O

- NCT03921606 101 102 O
do NCT03921606 104 106 O
not NCT03921606 107 110 B-Negation
intend NCT03921606 111 117 B-Assertion___Assertion-Type-Value:intention
to NCT03921606 118 120 I-Assertion___Assertion-Type-Value:intention
quit NCT03921606 121 125 B-Condition
smoking NCT03921606 126 133 I-Condition
( NCT03921606 134 135 O
pre NCT03921606 136 139 B-Condition
- NCT03921606 140 141 I-Condition
contemplation NCT03921606 142 155 I-Condition
stage NCT03921606 156 161 I-Condition
) NCT03921606 162 163 O
, NCT03921606 165 166 O
but NCT03921606 167 170 B-And
are NCT03921606 171 174 O
willing NCT03921606 175 182 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921606 183 185 I-Assertion___Assertion-Type-Value:hypothetical
promote NCT03921606 186 193 O
their NCT03921606 194 199 O
health NCT03921606 200 206 B-Condition

- NCT03921606 209 210 O
use NCT03921606 212 215 O
a NCT03921606 216 217 O
smartphone NCT03921606 218 228 O
and NCT03921606 229 232 O
can NCT03921606 233 236 O
use NCT03921606 237 240 O
an NCT03921606 241 243 O
instant NCT03921606 244 251 O
messaging NCT03921606 252 261 O
tool NCT03921606 262 266 O
( NCT03921606 267 268 O
e. NCT03921606 269 271 O
g. NCT03921606 272 274 O
, NCT03921606 275 276 O
WhatsApp NCT03921606 277 285 O
/ NCT03921606 286 287 O
WeChat NCT03921606 288 294 O
) NCT03921606 295 296 O

- NCT03921606 300 301 O
willing NCT03921606 303 310 O
to NCT03921606 311 313 O
receive NCT03921606 314 321 O
health NCT03921606 322 328 O
promotion NCT03921606 329 338 O
advice NCT03921606 339 345 O
and NCT03921606 346 349 O
interact NCT03921606 350 358 O
with NCT03921606 359 363 O
our NCT03921606 364 367 O
interventionist NCT03921606 368 383 O
via NCT03921606 384 387 O
WhatsApp NCT03921606 388 396 O
/ NCT03921606 397 398 O
WeChat NCT03921606 399 405 O
on NCT03921606 406 408 O
a NCT03921606 409 410 O
smartphone NCT03921606 411 421 O
throughout NCT03921606 422 432 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921606 433 436 O
study NCT03921606 437 442 B-Study
period NCT03921606 443 449 O

Exclusion NCT03921606 450 459 O
Criteria NCT03921606 460 468 O
: NCT03921606 469 470 O

- NCT03921606 474 475 O
inability NCT03921606 477 486 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921606 487 489 O
give NCT03921606 490 494 O
informed NCT03921606 495 503 O
consent NCT03921606 504 511 O
or NCT03921606 512 514 O
participate NCT03921606 515 526 O
in NCT03921606 527 529 B-Procedure
our NCT03921606 530 533 O
intervention NCT03921606 534 546 O
due NCT03921606 547 550 O
to NCT03921606 551 553 O
impaired NCT03921606 554 562 B-Condition
mental NCT03921606 563 569 I-Condition
status NCT03921606 570 576 I-Condition
, NCT03921606 577 578 O
cognitive NCT03921606 579 588 B-Condition
impairment NCT03921606 589 599 I-Condition
or NCT03921606 600 602 O
communication NCT03921606 603 616 B-Condition
barriers NCT03921606 617 625 I-Condition

- NCT03921606 628 629 O
participate NCT03921606 631 642 O
in NCT03921606 643 645 O
another NCT03921606 646 653 B-Other
smoking NCT03921606 654 661 B-Procedure
cessation NCT03921606 662 671 I-Procedure
programme NCT03921606 672 681 O
or NCT03921606 682 684 O
service NCT03921606 685 692 O

Inclusion NCT03924232 0 9 O
Criteria NCT03924232 10 18 O
: NCT03924232 19 20 O

- NCT03924232 24 25 O
All NCT03924232 27 30 O
patients NCT03924232 31 39 O
aged NCT03924232 40 44 B-Age
18 NCT03924232 45 47 B-Eq-Comparison
or NCT03924232 48 50 I-Eq-Comparison
older NCT03924232 51 56 I-Eq-Comparison
and NCT03924232 57 60 B-And
with NCT03924232 61 65 O
a NCT03924232 66 67 O
recent NCT03924232 68 74 B-Eq-Comparison
( NCT03924232 75 76 O
< NCT03924232 78 79 B-Eq-Comparison
48 NCT03924232 80 82 I-Eq-Comparison
h NCT03924232 83 84 O
) NCT03924232 85 86 O
ICU NCT03924232 87 90 B-Encounter
entry NCT03924232 91 96 I-Encounter
requiring NCT03924232 97 106 O
mechanical NCT03924232 107 117 B-Procedure
ventilation NCT03924232 118 129 I-Procedure
for NCT03924232 130 133 O
at NCT03924232 134 136 B-Eq-Comparison
least NCT03924232 137 142 I-Eq-Comparison
3 NCT03924232 143 144 I-Eq-Comparison
days NCT03924232 145 149 I-Eq-Comparison
will NCT03924232 150 154 O
be NCT03924232 155 157 O
considered NCT03924232 158 168 O
for NCT03924232 169 172 O
enrolment NCT03924232 173 182 O

Exclusion NCT03924232 183 192 O
Criteria NCT03924232 193 201 O
: NCT03924232 202 203 O

- NCT03924232 207 208 O
not NCT03924232 210 213 B-Negation
intubated NCT03924232 214 223 B-Procedure
patients NCT03924232 224 232 O

- NCT03924232 235 236 O
patients NCT03924232 238 246 O
with NCT03924232 247 251 O
an NCT03924232 252 254 O
ICU NCT03924232 255 258 B-Encounter
prevision NCT03924232 259 268 I-Encounter
of NCT03924232 269 271 I-Encounter
stay NCT03924232 272 276 I-Encounter
less NCT03924232 277 281 B-Eq-Comparison
than NCT03924232 282 286 I-Eq-Comparison
3 NCT03924232 287 288 I-Eq-Comparison
days NCT03924232 289 293 I-Eq-Comparison

Inclusion NCT03925662 0 9 O
Criteria NCT03925662 10 18 O
: NCT03925662 19 20 O

- NCT03925662 24 25 O
Colorectal NCT03925662 27 37 B-Modifier
cancer NCT03925662 38 44 B-Condition
stage NCT03925662 45 50 B-Eq-Comparison
4 NCT03925662 51 52 I-Eq-Comparison
. NCT03925662 52 53 O

Exclusion NCT03925662 55 64 O
Criteria NCT03925662 65 73 O
: NCT03925662 74 75 O

- NCT03925662 79 80 O
Agranulocytosis NCT03925662 82 97 B-Condition

- NCT03925662 100 101 O
Pregnancy NCT03925662 103 112 B-Condition

- NCT03925662 115 116 O
Allergy NCT03925662 118 125 B-Allergy
to NCT03925662 126 128 O
mebendazole NCT03925662 129 140 B-Drug
. NCT03925662 140 141 O

Inclusion NCT03924583 0 9 O
Criteria NCT03924583 10 18 O
: NCT03924583 19 20 O

- NCT03924583 24 25 O
central NCT03924583 27 34 B-Procedure
venous NCT03924583 35 41 I-Procedure
catheter NCT03924583 42 50 I-Procedure
more NCT03924583 51 55 B-Eq-Comparison
than NCT03924583 56 60 I-Eq-Comparison
48 NCT03924583 61 63 I-Eq-Comparison
hours NCT03924583 64 69 I-Eq-Comparison
in NCT03924583 70 72 B-Modifier
situ NCT03924583 73 77 I-Modifier

- NCT03924583 80 81 O
consent NCT03924583 83 90 O
of NCT03924583 91 93 O
a NCT03924583 94 95 O
patient NCT03924583 96 103 O

Exclusion NCT03924583 104 113 O
Criteria NCT03924583 114 122 O
: NCT03924583 123 124 O

- NCT03924583 128 129 O
technical NCT03924583 131 140 B-Assertion___Assertion-Type-Value:hypothetical
difficulties NCT03924583 141 153 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03924583 154 156 O
ultrasound NCT03924583 157 167 B-Procedure
machine NCT03924583 168 175 I-Procedure

- NCT03924583 178 179 O
unfavorable NCT03924583 181 192 O
local NCT03924583 193 198 O
findings NCT03924583 199 207 B-Condition
- NCT03924583 208 209 O
inflammation NCT03924583 210 222 B-Condition
of NCT03924583 223 225 I-Condition
skin NCT03924583 226 230 I-Condition
, NCT03924583 231 232 O
excoriation NCT03924583 233 244 B-Condition
etc NCT03924583 245 248 O
. NCT03924583 248 249 O

Inclusion NCT03925688 0 9 O
Criteria NCT03925688 10 18 O
: NCT03925688 19 20 O

- NCT03925688 24 25 O
Have NCT03925688 27 31 O
a NCT03925688 32 33 O
previous NCT03925688 34 42 B-Eq-Comparison
history NCT03925688 43 50 I-Eq-Comparison
of NCT03925688 51 53 O
elbow NCT03925688 54 59 B-Modifier
joint NCT03925688 60 65 I-Modifier
fracture NCT03925688 66 74 B-Condition
or NCT03925688 75 77 B-Or
dislocation NCT03925688 78 89 B-Condition
that NCT03925688 90 94 O
conform NCT03925688 95 102 O
to NCT03925688 103 105 O
its NCT03925688 106 109 O
manifestations NCT03925688 110 124 O
and NCT03925688 125 128 O
signs NCT03925688 129 134 O
. NCT03925688 134 135 O
And NCT03925688 137 140 O
it NCT03925688 141 143 O
is NCT03925688 144 146 O
diagnosed NCT03925688 147 156 B-Coreference
by NCT03925688 157 159 O
X NCT03925688 160 161 B-Procedure
- NCT03925688 162 163 I-Procedure
ray NCT03925688 164 167 I-Procedure
test NCT03925688 168 172 I-Procedure
. NCT03925688 172 173 O
HO NCT03925688 175 177 O
must NCT03925688 178 182 O
accord NCT03925688 183 189 O
with NCT03925688 190 194 O
the NCT03925688 195 198 O
relative NCT03925688 199 207 O
diagnostic NCT03925688 208 218 O
criteria5 NCT03925688 219 228 O
and NCT03925688 229 232 O
have NCT03925688 233 237 O
imaging NCT03925688 238 245 B-Procedure
evidences NCT03925688 246 255 O
of NCT03925688 256 258 O
heterotopic NCT03925688 259 270 B-Condition
ossification NCT03925688 271 283 I-Condition
. NCT03925688 283 284 O

- NCT03925688 288 289 O
Have NCT03925688 291 295 O
complete NCT03925688 296 304 O
clinical NCT03925688 305 313 O
and NCT03925688 314 317 O
imaging NCT03925688 318 325 B-Procedure
dates NCT03925688 326 331 O
. NCT03925688 331 332 O

- NCT03925688 336 337 O
The NCT03925688 339 342 O
age NCT03925688 343 346 B-Age
＞ NCT03925688 347 348 B-Eq-Comparison
18 NCT03925688 349 351 O
and NCT03925688 352 355 O
no NCT03925688 356 358 O
gender NCT03925688 359 365 O
limitation NCT03925688 366 376 O
. NCT03925688 376 377 O

- NCT03925688 381 382 O
The NCT03925688 384 387 O
patient NCT03925688 388 395 O
is NCT03925688 396 398 O
being NCT03925688 399 404 O
a NCT03925688 405 406 O
relatively NCT03925688 407 417 O
stable NCT03925688 418 424 O
physical NCT03925688 425 433 B-Modifier
and NCT03925688 434 437 B-And
mental NCT03925688 438 444 B-Modifier
state NCT03925688 445 450 B-Condition
without NCT03925688 451 458 B-Negation
acute NCT03925688 459 464 O
injection NCT03925688 465 474 B-Procedure
or NCT03925688 475 477 B-Or
diseases NCT03925688 478 486 B-Condition
. NCT03925688 486 487 O

Exclusion NCT03925688 489 498 O
Criteria NCT03925688 499 507 O
: NCT03925688 508 509 O

- NCT03925688 513 514 O
Have NCT03925688 516 520 O
a NCT03925688 521 522 O
history NCT03925688 523 530 B-Eq-Comparison
of NCT03925688 531 533 O
diabetes NCT03925688 534 542 B-Condition
mellitus NCT03925688 543 551 I-Condition
or NCT03925688 552 554 B-Or
impaired NCT03925688 555 563 B-Condition
blood NCT03925688 564 569 I-Condition
glucose NCT03925688 570 577 I-Condition
, NCT03925688 578 579 O
metabolic NCT03925688 580 589 B-Condition
syndrome NCT03925688 590 598 I-Condition
and NCT03925688 599 602 B-Or
gout NCT03925688 603 607 B-Condition
or NCT03925688 608 610 B-Or
renal NCT03925688 611 616 B-Modifier
dysfunction NCT03925688 617 628 B-Condition
( NCT03925688 629 630 O
creatinine NCT03925688 631 641 B-Observation
≥ NCT03925688 642 643 B-Eq-Comparison
1.5 NCT03925688 644 647 I-Eq-Comparison
mg NCT03925688 648 650 I-Eq-Comparison
/ NCT03925688 651 652 I-Eq-Comparison
dL NCT03925688 653 655 I-Eq-Comparison
) NCT03925688 656 657 O
that NCT03925688 658 662 O
apparently NCT03925688 663 673 B-Assertion___Assertion-Type-Value:possible
influence NCT03925688 674 683 O
glucose NCT03925688 684 691 B-Modifier
, NCT03925688 692 693 O
lipid NCT03925688 694 699 B-Modifier
and NCT03925688 700 703 B-Or
protein NCT03925688 704 711 B-Modifier
metabolic NCT03925688 712 721 B-Condition
of NCT03925688 722 724 O
the NCT03925688 725 728 O
body NCT03925688 729 733 B-Modifier
. NCT03925688 733 734 O

- NCT03925688 738 739 O
Have NCT03925688 741 745 O
a NCT03925688 746 747 O
history NCT03925688 748 755 B-Eq-Comparison
of NCT03925688 756 758 O
taking NCT03925688 759 765 O
drugs NCT03925688 766 771 B-Drug
that NCT03925688 772 776 O
can NCT03925688 777 780 O
influence NCT03925688 781 790 O
uric NCT03925688 791 795 B-Condition
acid NCT03925688 796 800 I-Condition
metabolic NCT03925688 801 810 I-Condition
including NCT03925688 811 820 O
gout NCT03925688 821 825 B-Condition
suppressant NCT03925688 826 837 B-Drug
, NCT03925688 838 839 O
diuretic NCT03925688 840 848 B-Drug
, NCT03925688 849 850 O
small NCT03925688 851 856 O
- NCT03925688 857 858 O
dose NCT03925688 859 863 I-Eq-Comparison
aspirin NCT03925688 864 871 B-Drug
( NCT03925688 872 873 O
75 NCT03925688 874 876 B-Eq-Comparison
~ NCT03925688 877 878 O
300 NCT03925688 879 882 O
mg NCT03925688 883 885 O
/ NCT03925688 886 887 I-Eq-Comparison|Eq-Comparison
d NCT03925688 888 889 I-Eq-Comparison
) NCT03925688 890 891 O
or NCT03925688 892 894 B-Or
large NCT03925688 895 900 O
- NCT03925688 901 902 O
dose NCT03925688 903 907 O
aspirin NCT03925688 908 915 B-Drug
( NCT03925688 916 917 O
＞ NCT03925688 919 920 B-Eq-Comparison
3 NCT03925688 921 922 O
g NCT03925688 923 924 O
/ NCT03925688 925 926 O
d NCT03925688 927 928 O
) NCT03925688 929 930 O
, NCT03925688 932 933 O
anti NCT03925688 934 938 O
- NCT03925688 939 940 O
tuberculosis NCT03925688 941 953 B-Condition
drugs NCT03925688 954 959 B-Drug
, NCT03925688 960 961 O
immunosuppressor NCT03925688 962 978 B-Drug
, NCT03925688 979 980 O
nicotinic NCT03925688 981 990 B-Drug
acid NCT03925688 991 995 I-Drug
and NCT03925688 996 999 O
anti NCT03925688 1000 1004 O
- NCT03925688 1005 1006 O
tumor NCT03925688 1007 1012 B-Condition
drugs NCT03925688 1013 1018 B-Drug
such NCT03925688 1019 1023 O
as NCT03925688 1024 1026 O
cyclophosphamide NCT03925688 1027 1043 B-Drug
and NCT03925688 1044 1047 O
so NCT03925688 1048 1050 O
on NCT03925688 1051 1053 O
. NCT03925688 1053 1054 O

Inclusion NCT03924596 0 9 O
Criteria NCT03924596 10 18 O
: NCT03924596 19 20 O

- NCT03924596 24 25 O
Participants NCT03924596 27 39 O
with NCT03924596 40 44 O
renal NCT03924596 45 50 B-Observation
stones NCT03924596 51 57 I-Observation
equal NCT03924596 58 63 B-Eq-Comparison
or NCT03924596 64 66 I-Eq-Comparison
less NCT03924596 67 71 I-Eq-Comparison
than NCT03924596 72 76 I-Eq-Comparison
10 NCT03924596 77 79 I-Eq-Comparison
mm NCT03924596 80 82 O
in NCT03924596 83 85 O
size NCT03924596 86 90 O

Exclusion NCT03924596 91 100 O
Criteria NCT03924596 101 109 O
: NCT03924596 110 111 O

- NCT03924596 115 116 O
Participants NCT03924596 118 130 O
with NCT03924596 131 135 O
renal NCT03924596 136 141 B-Condition
pathology NCT03924596 142 151 I-Condition
( NCT03924596 152 153 O
Renal NCT03924596 154 159 B-Modifier
anomalies NCT03924596 160 169 B-Condition
, NCT03924596 170 171 O
multiple NCT03924596 172 180 B-Modifier
renal NCT03924596 181 186 I-Modifier
cysts NCT03924596 187 192 B-Condition
, NCT03924596 193 194 O
renal NCT03924596 195 200 B-Modifier
tumors NCT03924596 201 207 B-Condition
) NCT03924596 208 209 O

- NCT03924596 213 214 O
Participants NCT03924596 216 228 O
with NCT03924596 229 233 O
comorbidities NCT03924596 234 247 B-Condition
( NCT03924596 248 249 O
DM NCT03924596 250 252 B-Condition
, NCT03924596 253 254 O
CKD NCT03924596 255 258 B-Condition
) NCT03924596 259 260 O

Key NCT03921411 0 3 O
Inclusion NCT03921411 4 13 O
Criteria NCT03921411 14 22 O

- NCT03921411 25 26 O
Male NCT03921411 28 32 O
or NCT03921411 33 35 B-Or
female NCT03921411 36 42 O
subjects NCT03921411 43 51 O
≥ NCT03921411 52 53 B-Eq-Comparison
12 NCT03921411 54 56 I-Eq-Comparison
to NCT03921411 57 59 I-Eq-Comparison
< NCT03921411 60 61 I-Eq-Comparison
18 NCT03921411 62 64 I-Eq-Comparison
years NCT03921411 65 70 I-Eq-Comparison
of NCT03921411 71 73 O
age NCT03921411 74 77 B-Age

- NCT03921411 80 81 O
Chronic NCT03921411 83 90 B-Modifier
AD NCT03921411 91 93 B-Condition
that NCT03921411 94 98 O
has NCT03921411 99 102 O
been NCT03921411 103 107 O
documented NCT03921411 108 118 O
for NCT03921411 119 122 O
at NCT03921411 123 125 B-Eq-Comparison
least NCT03921411 126 131 I-Eq-Comparison
2 NCT03921411 132 133 I-Eq-Comparison
years NCT03921411 134 139 I-Eq-Comparison

- NCT03921411 142 143 O
Eczema NCT03921411 145 151 B-Observation
Area NCT03921411 152 156 I-Observation
and NCT03921411 157 160 I-Observation
Severity NCT03921411 161 169 I-Observation
Index NCT03921411 170 175 I-Observation
( NCT03921411 176 177 O
EASI NCT03921411 178 182 B-Observation
) NCT03921411 183 184 O
score NCT03921411 185 190 O
≥ NCT03921411 191 192 B-Eq-Comparison
16 NCT03921411 193 195 I-Eq-Comparison

- NCT03921411 199 200 O
IGA NCT03921411 202 205 B-Observation
score NCT03921411 206 211 O
≥ NCT03921411 212 213 B-Eq-Comparison
3 NCT03921411 214 215 I-Eq-Comparison

- NCT03921411 219 220 O
AD NCT03921411 222 224 B-Observation
involvement NCT03921411 225 236 I-Observation
≥ NCT03921411 237 238 B-Eq-Comparison
10 NCT03921411 239 241 I-Eq-Comparison
% NCT03921411 242 243 O
of NCT03921411 244 246 I-Eq-Comparison
Body NCT03921411 247 251 I-Eq-Comparison
Surface NCT03921411 252 259 I-Eq-Comparison
Area NCT03921411 260 264 I-Eq-Comparison
( NCT03921411 265 266 O
BSA NCT03921411 267 270 O
) NCT03921411 271 272 O

- NCT03921411 276 277 O
Documented NCT03921411 279 289 O
recent NCT03921411 290 296 B-Eq-Comparison
history NCT03921411 297 304 B-Eq-Comparison
of NCT03921411 305 307 O
inadequate NCT03921411 308 318 O
response NCT03921411 319 327 O
to NCT03921411 328 330 B-Drug
topical NCT03921411 331 338 O
medications NCT03921411 339 350 I-Drug

- NCT03921411 353 354 O
Women NCT03921411 356 361 O
of NCT03921411 362 364 O
childbearing NCT03921411 365 377 B-Condition
potential NCT03921411 378 387 B-Assertion___Assertion-Type-Value:hypothetical
must NCT03921411 388 392 O
agree NCT03921411 393 398 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921411 399 401 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03921411 402 404 O
strictly NCT03921411 405 413 O
abstinent NCT03921411 414 423 B-Condition
or NCT03921411 424 426 B-Or
to NCT03921411 427 429 O
use NCT03921411 430 433 O
an NCT03921411 434 436 O
effective NCT03921411 437 446 O
and NCT03921411 447 450 O
approved NCT03921411 451 459 O
method NCT03921411 460 466 O
of NCT03921411 467 469 O
contraception NCT03921411 470 483 B-Procedure
throughout NCT03921411 484 494 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921411 495 498 O
study NCT03921411 499 504 B-Study
and NCT03921411 505 508 B-And
for NCT03921411 509 512 O
12 NCT03921411 513 515 B-Eq-Comparison
weeks NCT03921411 516 521 I-Eq-Comparison
after NCT03921411 522 527 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03921411 528 531 O
last NCT03921411 532 536 B-Eq-Comparison
study NCT03921411 537 542 B-Study
drug NCT03921411 543 547 B-Procedure
injection NCT03921411 548 557 I-Procedure
. NCT03921411 557 558 O

Key NCT03921411 560 563 O
Exclusion NCT03921411 564 573 O
Criteria NCT03921411 574 582 O

- NCT03921411 585 586 O
Body NCT03921411 588 592 B-Observation
weight NCT03921411 593 599 I-Observation
< NCT03921411 600 601 B-Eq-Comparison
30 NCT03921411 602 604 I-Eq-Comparison
kg NCT03921411 605 607 I-Eq-Comparison

- NCT03921411 610 611 O
Cutaneous NCT03921411 613 622 B-Modifier
infection NCT03921411 623 632 B-Condition
within NCT03921411 633 639 B-Eq-Comparison
1 NCT03921411 640 641 I-Eq-Comparison
week NCT03921411 642 646 I-Eq-Comparison
or NCT03921411 647 649 B-Or
any NCT03921411 650 653 O
infection NCT03921411 654 663 B-Condition
requiring NCT03921411 664 673 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03921411 674 683 B-Procedure
with NCT03921411 684 688 O
oral NCT03921411 689 693 B-Modifier|Or
or NCT03921411 694 696 O
parenteral NCT03921411 697 707 B-Modifier
antibiotics NCT03921411 708 719 B-Procedure
, NCT03921411 720 721 O
antivirals NCT03921411 722 732 B-Drug
, NCT03921411 733 734 O
antiparasitics NCT03921411 735 749 B-Drug
, NCT03921411 750 751 O
or NCT03921411 752 754 B-Or
antifungals NCT03921411 755 766 B-Drug
within NCT03921411 767 773 B-Eq-Comparison
1 NCT03921411 774 775 I-Eq-Comparison
week NCT03921411 776 780 I-Eq-Comparison

- NCT03921411 783 784 O
History NCT03921411 786 793 B-Eq-Comparison
of NCT03921411 794 796 O
hypersensitivity NCT03921411 797 813 B-Condition
( NCT03921411 814 815 O
including NCT03921411 816 825 O
anaphylaxis NCT03921411 826 837 B-Condition
) NCT03921411 838 839 O
to NCT03921411 840 842 O
an NCT03921411 843 845 O
immunoglobulin NCT03921411 846 860 B-Drug
product NCT03921411 861 868 I-Drug
( NCT03921411 869 870 O
plasma NCT03921411 871 877 B-Modifier
- NCT03921411 878 879 I-Modifier
derived NCT03921411 880 887 I-Modifier
or NCT03921411 888 890 B-Or
recombinant NCT03921411 891 902 B-Modifier
, NCT03921411 903 904 O
eg NCT03921411 905 907 O
, NCT03921411 908 909 O
monoclonal NCT03921411 910 920 B-Drug
antibody NCT03921411 921 929 I-Drug
) NCT03921411 930 931 O

- NCT03921411 935 936 O
Any NCT03921411 938 941 O
clinically NCT03921411 942 952 O
significant NCT03921411 953 964 O
issue NCT03921411 965 970 B-Condition
, NCT03921411 971 972 O
based NCT03921411 973 978 O
investigator NCT03921411 979 991 O
judgement NCT03921411 992 1001 O

Inclusion NCT03924804 0 9 O
Criteria NCT03924804 10 18 O
: NCT03924804 19 20 O

- NCT03924804 24 25 O
1 NCT03924804 27 28 O
. NCT03924804 28 29 O
ethnic NCT03924804 31 37 O
Chinese NCT03924804 38 45 O
; NCT03924804 45 46 O

- NCT03924804 49 50 O
2 NCT03924804 52 53 O
. NCT03924804 53 54 O
age NCT03924804 56 59 B-Age
, NCT03924804 60 61 O
18 NCT03924804 62 64 B-Eq-Comparison
to NCT03924804 65 67 I-Eq-Comparison
65 NCT03924804 68 70 I-Eq-Comparison
years NCT03924804 71 76 I-Eq-Comparison
old NCT03924804 77 80 O
; NCT03924804 80 81 O

- NCT03924804 84 85 O
3 NCT03924804 87 88 O
. NCT03924804 88 89 O
American NCT03924804 91 99 B-Condition
Society NCT03924804 100 107 I-Condition
of NCT03924804 108 110 I-Condition
Anaesthesiologists NCT03924804 111 129 I-Condition
( NCT03924804 130 131 O
ASA NCT03924804 132 135 B-Condition
) NCT03924804 136 137 O
physical NCT03924804 138 146 O
status NCT03924804 147 153 O
I NCT03924804 154 155 B-Eq-Comparison
or NCT03924804 156 158 I-Eq-Comparison
II NCT03924804 159 161 I-Eq-Comparison
; NCT03924804 161 162 O

- NCT03924804 165 166 O
4 NCT03924804 168 169 O
. NCT03924804 169 170 O
Daytime NCT03924804 172 179 O
patients NCT03924804 180 188 O
scheduled NCT03924804 189 198 B-Eq-Comparison
for NCT03924804 199 202 O
general NCT03924804 203 210 B-Procedure
anesthesia NCT03924804 211 221 I-Procedure

Exclusion NCT03924804 222 231 O
Criteria NCT03924804 232 240 O
: NCT03924804 241 242 O

- NCT03924804 246 247 O
Patients NCT03924804 249 257 O
unwilling NCT03924804 258 267 O
to NCT03924804 268 270 O
cooperate NCT03924804 271 280 O
with NCT03924804 281 285 O
the NCT03924804 286 289 O
experiment NCT03924804 290 300 O

- NCT03924804 303 304 O
Body NCT03924804 306 310 B-Observation
mass NCT03924804 311 315 I-Observation
index NCT03924804 316 321 I-Observation
exceeding NCT03924804 322 331 B-Eq-Comparison
30 NCT03924804 332 334 I-Eq-Comparison
kg NCT03924804 335 337 I-Eq-Comparison
/ NCT03924804 338 339 I-Eq-Comparison
m2 NCT03924804 340 342 I-Eq-Comparison
; NCT03924804 342 343 O

- NCT03924804 346 347 O
Patients NCT03924804 349 357 O
with NCT03924804 358 362 O
a NCT03924804 363 364 O
history NCT03924804 365 372 B-Eq-Comparison
of NCT03924804 373 375 O
heart NCT03924804 376 381 B-Modifier
, NCT03924804 382 383 O
liver NCT03924804 384 389 B-Modifier
and NCT03924804 390 393 B-Or
Renal NCT03924804 394 399 B-Modifier
failure NCT03924804 400 407 B-Condition
, NCT03924804 408 409 O
hypertension NCT03924804 410 422 B-Condition
, NCT03924804 423 424 O
diabetes NCT03924804 425 433 B-Condition
mellitus NCT03924804 434 442 I-Condition
or NCT03924804 443 445 B-Or
arteriosclerosis NCT03924804 446 462 B-Condition
; NCT03924804 462 463 O
and NCT03924804 464 467 B-Or
any NCT03924804 468 471 O
allergy NCT03924804 472 479 B-Allergy
to NCT03924804 480 482 O
drugs NCT03924804 483 488 B-Drug
used NCT03924804 489 493 O
in NCT03924804 494 496 O
the NCT03924804 497 500 O
study NCT03924804 501 506 B-Study
. NCT03924804 506 507 O

- NCT03924804 511 512 O
Patients NCT03924804 514 522 O
with NCT03924804 523 527 O
the NCT03924804 528 531 O
urinary NCT03924804 532 539 B-Condition
diseases NCT03924804 540 548 I-Condition
, NCT03924804 549 550 O
such NCT03924804 551 555 O
as NCT03924804 556 558 O
kidney NCT03924804 559 565 B-Condition
, NCT03924804 566 567 O
ureteral NCT03924804 568 576 B-Condition
calculi NCT03924804 577 584 I-Condition
and NCT03924804 585 588 B-Or
tumors NCT03924804 589 595 B-Condition
, NCT03924804 596 597 O
prostatic NCT03924804 598 607 B-Condition
hypertrophy NCT03924804 608 619 I-Condition
. NCT03924804 619 620 O

Inclusion NCT03926975 0 9 O
Criteria NCT03926975 10 18 O
: NCT03926975 19 20 O

- NCT03926975 24 25 O
young NCT03926975 27 32 O
, NCT03926975 33 34 O
normal NCT03926975 35 41 O
individuals NCT03926975 42 53 O

Exclusion NCT03926975 54 63 O
Criteria NCT03926975 64 72 O
: NCT03926975 73 74 O

- NCT03926975 78 79 O
IOP NCT03926975 81 84 B-Observation
> NCT03926975 85 86 B-Eq-Comparison
20 NCT03926975 87 89 I-Eq-Comparison
mm NCT03926975 90 92 O
in NCT03926975 93 95 O
either NCT03926975 96 102 B-Modifier
eye NCT03926975 103 106 I-Modifier
, NCT03926975 107 108 O
and NCT03926975 109 112 O
h NCT03926975 113 114 B-Eq-Comparison
/ NCT03926975 115 116 I-Eq-Comparison
o NCT03926975 117 118 I-Eq-Comparison
ocular NCT03926975 119 125 B-Condition
hypertension NCT03926975 126 138 I-Condition
, NCT03926975 139 140 O
glaucoma NCT03926975 141 149 B-Condition
, NCT03926975 150 151 O
or NCT03926975 152 154 B-Or
ocular NCT03926975 155 161 B-Modifier
surgery NCT03926975 162 169 B-Procedure
that NCT03926975 170 174 O
can NCT03926975 175 178 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03926975 179 185 O
IOP NCT03926975 186 189 B-Observation
. NCT03926975 189 190 O

- NCT03926975 194 195 O
h NCT03926975 197 198 B-Eq-Comparison
/ NCT03926975 199 200 I-Eq-Comparison
o NCT03926975 201 202 I-Eq-Comparison
scleral NCT03926975 203 210 B-Condition
lens NCT03926975 211 215 I-Condition
wear NCT03926975 216 220 O
or NCT03926975 221 223 B-Or
current NCT03926975 224 231 B-Eq-Comparison
scleral NCT03926975 232 239 B-Condition
lens NCT03926975 240 244 I-Condition
wear NCT03926975 245 249 O

Inclusion NCT03925298 0 9 O
Criteria NCT03925298 10 18 O
: NCT03925298 19 20 O

- NCT03925298 24 25 O
Participants NCT03925298 27 39 O
were NCT03925298 40 44 O
eligible NCT03925298 45 53 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925298 54 57 I-Assertion___Assertion-Type-Value:hypothetical
inclusion NCT03925298 58 67 O
in NCT03925298 68 70 O
the NCT03925298 71 74 O
study NCT03925298 75 80 B-Study
if NCT03925298 81 83 O
they NCT03925298 84 88 O
had NCT03925298 89 92 O
evidence NCT03925298 93 101 O
suggesting NCT03925298 102 112 B-Assertion___Assertion-Type-Value:possible
acute NCT03925298 113 118 O
ischemic NCT03925298 119 127 B-Condition
stroke NCT03925298 128 134 I-Condition
that NCT03925298 135 139 O
lasted NCT03925298 140 146 O
for NCT03925298 147 150 O
≤ NCT03925298 151 152 B-Eq-Comparison
4.5 NCT03925298 153 156 I-Eq-Comparison
hours NCT03925298 157 162 I-Eq-Comparison
. NCT03925298 163 164 O

- NCT03925298 168 169 O
Those NCT03925298 171 176 O
Participants NCT03925298 177 189 O
were NCT03925298 190 194 O
treated NCT03925298 195 202 B-Procedure
with NCT03925298 203 207 O
intravenous NCT03925298 208 219 B-Modifier
thrombolytic NCT03925298 220 232 B-Procedure
therapy NCT03925298 233 240 I-Procedure
( NCT03925298 241 242 O
( NCT03925298 244 245 O
recombinant NCT03925298 246 257 B-Drug
tissue NCT03925298 258 264 I-Drug
plasminogen NCT03925298 265 276 I-Drug
activator NCT03925298 277 286 I-Drug
( NCT03925298 287 288 O
rt NCT03925298 289 291 B-Drug
- NCT03925298 292 293 I-Drug
PA NCT03925298 294 296 I-Drug
) NCT03925298 297 298 O
) NCT03925298 300 301 O
. NCT03925298 302 303 O

Exclusion NCT03925298 305 314 O
Criteria NCT03925298 315 323 O
: NCT03925298 324 325 O

- NCT03925298 329 330 O
Those NCT03925298 332 337 O
who NCT03925298 338 341 O
had NCT03925298 342 345 B-Eq-Comparison
hemorrhagic NCT03925298 346 357 B-Condition
stroke NCT03925298 358 364 I-Condition

- NCT03925298 367 368 O
participants NCT03925298 370 382 O
presented NCT03925298 383 392 O
with NCT03925298 393 397 O
acute NCT03925298 398 403 B-Condition
myocardial NCT03925298 404 414 I-Condition
infarction NCT03925298 415 425 I-Condition
, NCT03925298 426 427 O
cerebrovascular NCT03925298 428 443 B-Condition
stroke NCT03925298 444 450 I-Condition
in NCT03925298 451 453 O
the NCT03925298 454 457 O
previous NCT03925298 458 466 B-Eq-Comparison
three NCT03925298 467 472 I-Eq-Comparison
months NCT03925298 473 479 I-Eq-Comparison
. NCT03925298 479 480 O

- NCT03925298 484 485 O
serious NCT03925298 487 494 O
head NCT03925298 495 499 B-Modifier
trauma NCT03925298 500 506 B-Condition
in NCT03925298 507 509 O
the NCT03925298 510 513 O
previous NCT03925298 514 522 B-Eq-Comparison
three NCT03925298 523 528 I-Eq-Comparison
months NCT03925298 529 535 I-Eq-Comparison
. NCT03925298 535 536 O

- NCT03925298 540 541 O
urinary NCT03925298 543 550 B-Modifier
tract NCT03925298 551 556 I-Modifier
, NCT03925298 557 558 O
lung NCT03925298 559 563 B-Modifier
, NCT03925298 564 565 O
or NCT03925298 566 568 B-Or
gastrointestinal NCT03925298 569 585 B-Modifier
hemorrhage NCT03925298 586 596 B-Condition
within NCT03925298 597 603 B-Eq-Comparison
the NCT03925298 604 607 I-Eq-Comparison
three NCT03925298 608 613 I-Eq-Comparison
weeks NCT03925298 614 619 I-Eq-Comparison
. NCT03925298 619 620 O

- NCT03925298 624 625 O
serious NCT03925298 627 634 O
trauma NCT03925298 635 641 B-Condition
or NCT03925298 642 644 B-Or
major NCT03925298 645 650 B-Modifier
surgery NCT03925298 651 658 B-Procedure
within NCT03925298 659 665 B-Eq-Comparison
the NCT03925298 666 669 I-Eq-Comparison
previous NCT03925298 670 678 I-Eq-Comparison
two NCT03925298 679 682 I-Eq-Comparison
weeks NCT03925298 683 688 I-Eq-Comparison
. NCT03925298 688 689 O

- NCT03925298 693 694 O
lumbar NCT03925298 696 702 B-Modifier
or NCT03925298 703 705 B-Or
arterial NCT03925298 706 714 B-Modifier
puncture NCT03925298 715 723 B-Condition
at NCT03925298 724 726 O
a NCT03925298 727 728 O
non NCT03925298 729 732 B-Modifier
- NCT03925298 733 734 I-Modifier
compressible NCT03925298 735 747 I-Modifier
site NCT03925298 748 752 I-Modifier
within NCT03925298 753 759 B-Eq-Comparison
one NCT03925298 760 763 I-Eq-Comparison
week NCT03925298 764 768 I-Eq-Comparison
. NCT03925298 768 769 O

- NCT03925298 773 774 O
those NCT03925298 776 781 O
received NCT03925298 782 790 B-Eq-Comparison
heparin NCT03925298 791 798 B-Drug
within NCT03925298 799 805 B-Eq-Comparison
48 NCT03925298 806 808 I-Eq-Comparison
hours NCT03925298 809 814 I-Eq-Comparison
, NCT03925298 815 816 O
resulting NCT03925298 817 826 O
in NCT03925298 827 829 O
an NCT03925298 830 832 O
activated NCT03925298 833 842 B-Observation
partial NCT03925298 843 850 I-Observation
thromboplastin NCT03925298 851 865 I-Observation
time NCT03925298 866 870 I-Observation
greater NCT03925298 871 878 B-Eq-Comparison
than NCT03925298 879 883 I-Eq-Comparison
the NCT03925298 884 887 I-Eq-Comparison
upper NCT03925298 888 893 I-Eq-Comparison
limit NCT03925298 894 899 I-Eq-Comparison
of NCT03925298 900 902 I-Eq-Comparison
normal NCT03925298 903 909 I-Eq-Comparison
. NCT03925298 909 910 O

- NCT03925298 914 915 O
systolic NCT03925298 917 925 B-Observation
pressure NCT03925298 926 934 I-Observation
> NCT03925298 935 936 B-Eq-Comparison
185 NCT03925298 937 940 I-Eq-Comparison
mmHg NCT03925298 941 945 I-Eq-Comparison
or NCT03925298 946 948 B-Or
diastolic NCT03925298 949 958 B-Observation
pressure NCT03925298 959 967 I-Observation
> NCT03925298 968 969 B-Eq-Comparison
110 NCT03925298 970 973 I-Eq-Comparison
mmHg NCT03925298 974 978 I-Eq-Comparison
. NCT03925298 978 979 O

- NCT03925298 983 984 O
blood NCT03925298 986 991 B-Observation
glucose NCT03925298 992 999 I-Observation
< NCT03925298 1000 1001 B-Eq-Comparison
50 NCT03925298 1002 1004 I-Eq-Comparison
or NCT03925298 1005 1007 B-Or
> NCT03925298 1008 1009 B-Eq-Comparison
400 NCT03925298 1010 1013 I-Eq-Comparison
mg NCT03925298 1014 1016 I-Eq-Comparison
/ NCT03925298 1017 1018 I-Eq-Comparison
dL. NCT03925298 1019 1022 I-Eq-Comparison

- NCT03925298 1026 1027 O
current NCT03925298 1029 1036 B-Eq-Comparison
use NCT03925298 1037 1040 I-Eq-Comparison
of NCT03925298 1041 1043 O
anticoagulants NCT03925298 1044 1058 B-Drug
with NCT03925298 1059 1063 B-And
an NCT03925298 1064 1066 O
International NCT03925298 1067 1080 B-Observation
Normalized NCT03925298 1081 1091 I-Observation
Ratio NCT03925298 1092 1097 I-Observation
> NCT03925298 1098 1099 B-Eq-Comparison|Eq-Comparison
1.7 NCT03925298 1100 1103 I-Eq-Comparison
or NCT03925298 1104 1106 B-Or
prothrombin NCT03925298 1107 1118 B-Observation
time NCT03925298 1119 1123 I-Observation
> NCT03925298 1124 1125 O
15 NCT03925298 1126 1128 I-Eq-Comparison
sec NCT03925298 1129 1132 I-Eq-Comparison
; NCT03925298 1132 1133 O
platelet NCT03925298 1134 1142 B-Observation
count NCT03925298 1143 1148 I-Observation
< NCT03925298 1149 1150 B-Eq-Comparison
100 NCT03925298 1151 1154 I-Eq-Comparison
, NCT03925298 1155 1156 O
000 NCT03925298 1157 1160 O
/ NCT03925298 1161 1162 I-Eq-Comparison
mm3 NCT03925298 1163 1166 I-Eq-Comparison
. NCT03925298 1166 1167 O

- NCT03925298 1171 1172 O
pregnancy NCT03925298 1174 1183 B-Condition
; NCT03925298 1183 1184 O
serious NCT03925298 1185 1192 O
heart NCT03925298 1193 1198 B-Modifier
, NCT03925298 1199 1200 O
lung NCT03925298 1201 1205 B-Modifier
, NCT03925298 1206 1207 O
kidney NCT03925298 1208 1214 B-Modifier
or NCT03925298 1215 1217 B-Modifier|Or
other NCT03925298 1218 1223 B-Other
organ NCT03925298 1224 1229 O
dysfunction NCT03925298 1230 1241 B-Condition
. NCT03925298 1241 1242 O

- NCT03925298 1246 1247 I-Drug
allergy NCT03925298 1249 1256 B-Allergy
to NCT03925298 1257 1259 O
active NCT03925298 1260 1266 O
ingredients NCT03925298 1267 1278 O
of NCT03925298 1279 1281 O
rt NCT03925298 1282 1284 B-Drug
- NCT03925298 1285 1286 O
PA NCT03925298 1287 1289 I-Drug
; NCT03925298 1289 1290 O
patients NCT03925298 1291 1299 O
with NCT03925298 1300 1304 O
> NCT03925298 1305 1306 B-Eq-Comparison
4.5 NCT03925298 1307 1310 I-Eq-Comparison
hours NCT03925298 1311 1316 I-Eq-Comparison
from NCT03925298 1317 1321 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03925298 1322 1325 O
last NCT03925298 1326 1330 B-Eq-Comparison
time NCT03925298 1331 1335 I-Eq-Comparison
known NCT03925298 1336 1341 O
to NCT03925298 1342 1344 O
be NCT03925298 1345 1347 O
asymptomatic NCT03925298 1348 1360 B-Condition
. NCT03925298 1360 1361 O

- NCT03925298 1365 1366 O
those NCT03925298 1368 1373 O
in NCT03925298 1374 1376 O
whom NCT03925298 1377 1381 O
troponin NCT03925298 1382 1390 B-Observation
was NCT03925298 1391 1394 O
not NCT03925298 1395 1398 B-Negation
measured NCT03925298 1399 1407 O
at NCT03925298 1408 1410 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03925298 1411 1420 B-Encounter
were NCT03925298 1421 1425 O
excluded NCT03925298 1426 1434 B-Negation
from NCT03925298 1435 1439 O
the NCT03925298 1440 1443 O
study NCT03925298 1444 1449 B-Study

Inclusion NCT03928964 0 9 O
criteria NCT03928964 10 18 O
: NCT03928964 19 20 O

1 NCT03928964 24 25 O
. NCT03928964 25 26 O
Patients NCT03928964 28 36 O
with NCT03928964 37 41 O
locally NCT03928964 42 49 B-Modifier
advanced NCT03928964 50 58 I-Modifier
or NCT03928964 59 61 B-Or
metastatic NCT03928964 62 72 B-Modifier
renal NCT03928964 73 78 I-Modifier
cell NCT03928964 79 83 I-Modifier
carcinoma NCT03928964 84 93 B-Condition

2 NCT03928964 96 97 O
. NCT03928964 97 98 O
Whose NCT03928964 100 105 O
first NCT03928964 106 111 B-Procedure
- NCT03928964 112 113 I-Procedure
line NCT03928964 114 118 I-Procedure
treatment NCT03928964 119 128 I-Procedure
included NCT03928964 129 137 O
at NCT03928964 138 140 B-Eq-Comparison
least NCT03928964 141 146 I-Eq-Comparison
one NCT03928964 147 150 I-Eq-Comparison
anti NCT03928964 151 155 B-Drug
- NCT03928964 156 157 I-Drug
angiogenic NCT03928964 158 168 I-Drug
agent NCT03928964 169 174 I-Drug
( NCT03928964 175 176 O
tyrosine NCT03928964 177 185 B-Drug
kinase NCT03928964 186 192 I-Drug
inhibitor NCT03928964 193 202 I-Drug
or NCT03928964 203 205 O
monoclonal NCT03928964 206 216 B-Drug
antibodies NCT03928964 217 227 I-Drug
) NCT03928964 228 229 O
and NCT03928964 230 233 B-Or
/ NCT03928964 234 235 I-Or
or NCT03928964 236 238 I-Or
an NCT03928964 239 241 O
mTOR NCT03928964 242 246 B-Drug
inhibitor NCT03928964 247 256 I-Drug
; NCT03928964 256 257 O

3 NCT03928964 260 261 O
. NCT03928964 261 262 O
Whatever NCT03928964 264 272 O
was NCT03928964 273 276 O
the NCT03928964 277 280 O
overall NCT03928964 281 288 O
ECOG NCT03928964 289 293 B-Observation
- NCT03928964 294 295 I-Observation
PS NCT03928964 296 298 I-Observation
score NCT03928964 299 304 O
( NCT03928964 305 306 O
Eastern NCT03928964 307 314 B-Observation
Cooperative NCT03928964 315 326 I-Observation
Oncology NCT03928964 327 335 I-Observation
Group NCT03928964 336 341 I-Observation
Performance NCT03928964 342 353 I-Observation
Status NCT03928964 354 360 I-Observation
) NCT03928964 361 362 O
at NCT03928964 363 365 B-Temporal-Connection___Temporal-Connection-Type-Value:during
treatment NCT03928964 366 375 B-Procedure
initiation NCT03928964 376 386 B-Eq-Comparison
time NCT03928964 387 391 O

4 NCT03928964 394 395 O
. NCT03928964 395 396 O
With NCT03928964 398 402 O
first NCT03928964 403 408 B-Procedure
- NCT03928964 409 410 I-Procedure
line NCT03928964 411 415 I-Procedure
treatment NCT03928964 416 425 I-Procedure
carried NCT03928964 426 433 B-Eq-Comparison
out NCT03928964 434 437 I-Eq-Comparison
between NCT03928964 438 445 B-Eq-Comparison
2007 NCT03928964 446 450 I-Eq-Comparison
and NCT03928964 451 454 I-Eq-Comparison
June NCT03928964 455 459 I-Eq-Comparison
2016 NCT03928964 460 464 I-Eq-Comparison
. NCT03928964 464 465 O

Exclusion NCT03928964 467 476 O
criteria NCT03928964 477 485 O
: NCT03928964 486 487 O

1 NCT03928964 491 492 O
. NCT03928964 492 493 O
Patient NCT03928964 495 502 O
previously NCT03928964 503 513 B-Eq-Comparison
treated NCT03928964 514 521 B-Procedure
with NCT03928964 522 526 O
only NCT03928964 527 531 O
one NCT03928964 532 535 B-Eq-Comparison
cytokine NCT03928964 536 544 B-Drug
( NCT03928964 545 546 O
Interferon NCT03928964 547 557 B-Drug
α2 NCT03928964 558 560 I-Drug
a NCT03928964 561 562 O
, NCT03928964 563 564 O
high NCT03928964 565 569 O
- NCT03928964 570 571 I-Drug
dose NCT03928964 572 576 O
interleukin NCT03928964 577 588 B-Drug
- NCT03928964 589 590 O
2 NCT03928964 591 592 I-Drug
) NCT03928964 593 594 O

2 NCT03928964 598 599 O
. NCT03928964 599 600 O
Refusal NCT03928964 602 609 O
of NCT03928964 610 612 O
processing NCT03928964 613 623 O
of NCT03928964 624 626 O
personal NCT03928964 627 635 O
data NCT03928964 636 640 O

Inclusion NCT03926949 0 9 O
Criteria NCT03926949 10 18 O
: NCT03926949 19 20 O

1 NCT03926949 24 25 O
. NCT03926949 25 26 O
Patients NCT03926949 28 36 O
18 NCT03926949 37 39 B-Eq-Comparison
years NCT03926949 40 45 I-Eq-Comparison
of NCT03926949 46 48 I-Eq-Comparison
age NCT03926949 49 52 I-Eq-Comparison
or NCT03926949 53 55 I-Eq-Comparison
older NCT03926949 56 61 I-Eq-Comparison

2 NCT03926949 64 65 O
. NCT03926949 65 66 O
Patients NCT03926949 68 76 O
screened NCT03926949 77 85 O
at NCT03926949 86 88 O
risk NCT03926949 89 93 B-Risk
of NCT03926949 94 96 O
malnutrition NCT03926949 97 109 B-Condition
by NCT03926949 110 112 O
Canadian NCT03926949 113 121 B-Observation
Nutrition NCT03926949 122 131 I-Observation
Screening NCT03926949 132 141 I-Observation
Tool NCT03926949 142 146 I-Observation
( NCT03926949 147 148 O
CNST NCT03926949 149 153 B-Observation
) NCT03926949 154 155 O
and NCT03926949 156 159 B-And
identified NCT03926949 160 170 O
as NCT03926949 171 173 O
malnourished NCT03926949 174 186 B-Condition
by NCT03926949 187 189 O
subjective NCT03926949 190 200 B-Procedure
global NCT03926949 201 207 I-Procedure
assessment NCT03926949 208 218 I-Procedure
( NCT03926949 219 220 O
SGA NCT03926949 221 224 B-Procedure
) NCT03926949 225 226 O
B NCT03926949 227 228 B-Modifier
or NCT03926949 229 231 B-Or
C NCT03926949 232 233 B-Modifier

Exclusion NCT03926949 234 243 O
Criteria NCT03926949 244 252 O
: NCT03926949 253 254 O

1 NCT03926949 258 259 O
. NCT03926949 259 260 O
Patients NCT03926949 262 270 O
undergoing NCT03926949 271 281 B-Eq-Comparison
minor NCT03926949 282 287 B-Modifier
or NCT03926949 288 290 B-Or
laparoscopic NCT03926949 291 303 B-Modifier
surgery NCT03926949 304 311 B-Procedure

2 NCT03926949 314 315 O
. NCT03926949 315 316 O
Pregnancy NCT03926949 318 327 B-Condition

3 NCT03926949 330 331 O
. NCT03926949 331 332 O
Patients NCT03926949 334 342 O
with NCT03926949 343 347 O
severe NCT03926949 348 354 O
systemic NCT03926949 355 363 B-Modifier
diseases NCT03926949 364 372 B-Condition
defined NCT03926949 373 380 O
by NCT03926949 381 383 O
American NCT03926949 384 392 B-Condition
Society NCT03926949 393 400 I-Condition
of NCT03926949 401 403 I-Condition
Anesthesiologists NCT03926949 404 421 I-Condition
( NCT03926949 422 423 O
ASA NCT03926949 424 427 B-Condition
) NCT03926949 428 429 O
classification NCT03926949 430 444 B-Eq-Comparison
III NCT03926949 445 448 I-Eq-Comparison
to NCT03926949 449 451 I-Eq-Comparison
V NCT03926949 452 453 I-Eq-Comparison

4 NCT03926949 456 457 O
. NCT03926949 457 458 O
Patients NCT03926949 460 468 O
with NCT03926949 469 473 O
diabetes NCT03926949 474 482 B-Condition
mellitus NCT03926949 483 491 I-Condition

5 NCT03926949 494 495 O
. NCT03926949 495 496 O
Patients NCT03926949 498 506 O
with NCT03926949 507 511 O
planned NCT03926949 512 519 B-Eq-Comparison
palliative NCT03926949 520 530 B-Procedure
treatment NCT03926949 531 540 I-Procedure

Inclusion NCT03921983 0 9 O
Criteria NCT03921983 10 18 O
: NCT03921983 19 20 O

- NCT03921983 24 25 O
COPD NCT03921983 27 31 B-Condition
diagnostic NCT03921983 32 42 O

- NCT03921983 45 46 O
Both NCT03921983 48 52 O
sex NCT03921983 53 56 O

- NCT03921983 59 60 O
18 NCT03921983 62 64 B-Eq-Comparison
< NCT03921983 65 66 I-Eq-Comparison
Age NCT03921983 67 70 B-Age
< NCT03921983 71 72 B-Eq-Comparison
80 NCT03921983 73 75 I-Eq-Comparison
years NCT03921983 76 81 I-Eq-Comparison
old NCT03921983 82 85 O

- NCT03921983 88 89 O
LTOT NCT03921983 91 95 B-Condition
- NCT03921983 96 97 O
group NCT03921983 98 103 O
: NCT03921983 104 105 O
PaO2 NCT03921983 106 110 B-Observation
≥ NCT03921983 111 112 B-Eq-Comparison
65 NCT03921983 113 115 I-Eq-Comparison
mmHg NCT03921983 116 120 I-Eq-Comparison
and NCT03921983 121 124 B-And
SaO2 NCT03921983 125 129 B-Observation
≥ NCT03921983 130 131 B-Eq-Comparison
92 NCT03921983 132 134 I-Eq-Comparison
% NCT03921983 135 136 O

- NCT03921983 139 140 O
LTOT NCT03921983 142 146 B-Condition
+ NCT03921983 147 148 O
group NCT03921983 149 154 O
: NCT03921983 155 156 O
long NCT03921983 157 161 B-Modifier
term NCT03921983 162 166 I-Modifier
oxygenotherapy NCT03921983 167 181 B-Procedure
prescribed NCT03921983 182 192 O
for NCT03921983 193 196 O
more NCT03921983 197 201 B-Eq-Comparison
than NCT03921983 202 206 I-Eq-Comparison
3 NCT03921983 207 208 I-Eq-Comparison
months NCT03921983 209 215 I-Eq-Comparison
, NCT03921983 216 217 O
with NCT03921983 218 222 O
daily NCT03921983 223 228 B-Eq-Comparison
use NCT03921983 229 232 I-Eq-Comparison
between NCT03921983 233 240 I-Eq-Comparison
12 NCT03921983 241 243 I-Eq-Comparison
and NCT03921983 244 247 I-Eq-Comparison
15 NCT03921983 248 250 I-Eq-Comparison
hours NCT03921983 251 256 I-Eq-Comparison
. NCT03921983 256 257 O

Patients NCT03921983 259 267 O
in NCT03921983 268 270 O
both NCT03921983 271 275 O
groups NCT03921983 276 282 O
will NCT03921983 283 287 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03921983 288 290 I-Assertion___Assertion-Type-Value:hypothetical
matched NCT03921983 291 298 O
for NCT03921983 299 302 O
age NCT03921983 303 306 B-Age
( NCT03921983 307 308 O
± NCT03921983 310 311 B-Eq-Comparison
5 NCT03921983 312 313 I-Eq-Comparison
years NCT03921983 314 319 I-Eq-Comparison
) NCT03921983 320 321 O
, NCT03921983 323 324 O
sex NCT03921983 325 328 O
and NCT03921983 329 332 B-And
physical NCT03921983 333 341 B-Observation
activity NCT03921983 342 350 I-Observation

estimated NCT03921983 351 360 O
by NCT03921983 361 363 O
GPAQ NCT03921983 364 368 B-Observation
questionnaire NCT03921983 369 382 I-Observation
( NCT03921983 383 384 O
± NCT03921983 386 387 B-Eq-Comparison
15 NCT03921983 388 390 I-Eq-Comparison
% NCT03921983 391 392 O
Mets NCT03921983 393 397 I-Eq-Comparison
. NCT03921983 397 398 O
min NCT03921983 399 402 O
/ NCT03921983 403 404 I-Eq-Comparison
week NCT03921983 405 409 I-Eq-Comparison
) NCT03921983 410 411 O
. NCT03921983 412 413 O

Exclusion NCT03921983 415 424 O
Criteria NCT03921983 425 433 O
: NCT03921983 434 435 O

- NCT03921983 439 440 O
Recent NCT03921983 442 448 B-Eq-Comparison
cardiorespiratory NCT03921983 449 466 B-Condition
exacerbation NCT03921983 467 479 I-Condition
( NCT03921983 480 481 O
< NCT03921983 483 484 B-Eq-Comparison
6 NCT03921983 485 486 I-Eq-Comparison
weeks NCT03921983 487 492 I-Eq-Comparison
) NCT03921983 493 494 O
. NCT03921983 495 496 O

- NCT03921983 500 501 O
Pulmonary NCT03921983 503 512 B-Procedure
rehabilitation NCT03921983 513 527 I-Procedure
program NCT03921983 528 535 O
during NCT03921983 536 542 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921983 543 546 O
last NCT03921983 547 551 B-Eq-Comparison
2 NCT03921983 552 553 I-Eq-Comparison
months NCT03921983 554 560 I-Eq-Comparison

- NCT03921983 563 564 O
Continuous NCT03921983 566 576 B-Eq-Comparison
LTOT NCT03921983 577 581 B-Procedure
( NCT03921983 582 583 O
24 NCT03921983 584 586 B-Eq-Comparison
hours NCT03921983 587 592 I-Eq-Comparison
) NCT03921983 593 594 O
or NCT03921983 595 597 B-Or
deambulation NCT03921983 598 610 B-Modifier
O2 NCT03921983 611 613 B-Procedure
therapy NCT03921983 614 621 I-Procedure
alone NCT03921983 622 627 O

- NCT03921983 630 631 O
Anticoagulant NCT03921983 633 646 O
drugs NCT03921983 647 652 O

- NCT03921983 655 656 O
Hematocrit NCT03921983 658 668 B-Observation
outside NCT03921983 669 676 O
the NCT03921983 677 680 O
normal NCT03921983 681 687 O
range NCT03921983 688 693 O
( NCT03921983 694 695 O
35 NCT03921983 696 698 B-Eq-Comparison
- NCT03921983 699 700 I-Eq-Comparison
50 NCT03921983 701 703 I-Eq-Comparison
% NCT03921983 704 705 O
) NCT03921983 706 707 O

Inclusion NCT03922087 0 9 O
Criteria NCT03922087 10 18 O
: NCT03922087 19 20 O

- NCT03922087 24 25 O
Pregnant NCT03922087 27 35 B-Condition
women NCT03922087 36 41 O
who NCT03922087 42 45 B-And
have NCT03922087 46 50 O
plan NCT03922087 51 55 B-Assertion___Assertion-Type-Value:intention
to NCT03922087 56 58 I-Assertion___Assertion-Type-Value:intention
delivery NCT03922087 59 67 B-Condition
and NCT03922087 68 71 O
participate NCT03922087 72 83 O
in NCT03922087 84 86 O
child NCT03922087 87 92 O
care NCT03922087 93 97 O
in NCT03922087 98 100 O
Huizhou NCT03922087 101 108 O
hospital NCT03922087 109 117 O
; NCT03922087 117 118 O

- NCT03922087 121 122 O
Pregnant NCT03922087 124 132 B-Condition
women NCT03922087 133 138 O
who NCT03922087 139 142 B-And
have NCT03922087 143 147 O
resided NCT03922087 148 155 B-Observation
in NCT03922087 156 158 O
Huizhou NCT03922087 159 166 O
for NCT03922087 167 170 O
at NCT03922087 171 173 B-Eq-Comparison
least NCT03922087 174 179 I-Eq-Comparison
3 NCT03922087 180 181 I-Eq-Comparison
years NCT03922087 182 187 I-Eq-Comparison
; NCT03922087 187 188 O

- NCT03922087 191 192 O
Pregnant NCT03922087 194 202 B-Condition
women NCT03922087 203 208 O
who NCT03922087 209 212 B-And
are NCT03922087 213 216 O
consent NCT03922087 217 224 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03922087 225 228 I-Assertion___Assertion-Type-Value:hypothetical
specimens NCT03922087 229 238 O
and NCT03922087 239 242 O
data NCT03922087 243 247 O
collection NCT03922087 248 258 O
and NCT03922087 259 262 O
follow NCT03922087 263 269 B-Encounter
- NCT03922087 270 271 I-Encounter
ups NCT03922087 272 275 I-Encounter
for NCT03922087 276 279 O
both NCT03922087 280 284 O
mother NCT03922087 285 291 B-Family-Member___Family-Member-Type:mother
and NCT03922087 292 295 B-And
infant NCT03922087 296 302 B-Family-Member___Family-Member-Type:child
. NCT03922087 302 303 O

Exclusion NCT03922087 305 314 O
Criteria NCT03922087 315 323 O
: NCT03922087 324 325 O

- NCT03922087 329 330 O
Pregnant NCT03922087 332 340 B-Condition
women NCT03922087 341 346 O
who NCT03922087 347 350 B-And
are NCT03922087 351 354 O
with NCT03922087 355 359 O
gestational NCT03922087 360 371 B-Observation
age NCT03922087 372 375 I-Observation
more NCT03922087 376 380 B-Eq-Comparison
than NCT03922087 381 385 I-Eq-Comparison
24 NCT03922087 386 388 I-Eq-Comparison
weeks NCT03922087 389 394 I-Eq-Comparison
; NCT03922087 395 396 O

- NCT03922087 399 400 O
Pregnant NCT03922087 402 410 B-Condition
women NCT03922087 411 416 O
who NCT03922087 417 420 O
refuse NCT03922087 421 427 O
to NCT03922087 428 430 O
participate NCT03922087 431 442 O
or NCT03922087 443 445 O
be NCT03922087 446 448 O
unwilling NCT03922087 449 458 O
to NCT03922087 459 461 O
sign NCT03922087 462 466 O
informed NCT03922087 467 475 O
consent NCT03922087 476 483 O
; NCT03922087 483 484 O

- NCT03922087 487 488 O
Pregnant NCT03922087 490 498 B-Condition
women NCT03922087 499 504 O
who NCT03922087 505 508 B-And
are NCT03922087 509 512 O
mentally NCT03922087 513 521 B-Condition
incapacitated NCT03922087 522 535 I-Condition
and NCT03922087 536 539 O
need NCT03922087 540 544 O
guardians NCT03922087 545 554 O
. NCT03922087 554 555 O

Inclusion NCT03923400 0 9 O
Criteria NCT03923400 10 18 O
: NCT03923400 19 20 O

- NCT03923400 24 25 O
Any NCT03923400 27 30 O
kind NCT03923400 31 35 O
of NCT03923400 36 38 O
primary NCT03923400 39 46 B-Modifier
mesenchymal NCT03923400 47 58 B-Condition
tumor NCT03923400 59 64 I-Condition
of NCT03923400 65 67 O
the NCT03923400 68 71 O
gastrointestinal NCT03923400 72 88 B-Modifier
tract NCT03923400 89 94 I-Modifier
with NCT03923400 95 99 O
a NCT03923400 100 101 O
histomorphological NCT03923400 102 120 B-Modifier
and NCT03923400 121 124 B-Or
immunohistochemical NCT03923400 125 144 B-Modifier
( NCT03923400 145 146 O
CD117 NCT03923400 147 152 B-Condition
( NCT03923400 153 154 O
+ NCT03923400 156 157 O
) NCT03923400 159 160 O
and NCT03923400 161 164 B-Or
/ NCT03923400 165 166 I-Or
or NCT03923400 167 169 I-Or
DOG1 NCT03923400 170 174 B-Condition
( NCT03923400 175 176 O
+ NCT03923400 178 179 O
) NCT03923400 181 182 O
) NCT03923400 184 185 O
profile NCT03923400 186 193 B-Condition
consistent NCT03923400 194 204 O
with NCT03923400 205 209 O
GIST NCT03923400 210 214 B-Condition
. NCT03923400 214 215 O

Exclusion NCT03923400 217 226 O
Criteria NCT03923400 227 235 O
: NCT03923400 236 237 O

- NCT03923400 240 241 O

Inclusion NCT03921203 0 9 O
Criteria NCT03921203 10 18 O
: NCT03921203 19 20 O

- NCT03921203 24 25 O
Over NCT03921203 27 31 B-Eq-Comparison
18 NCT03921203 32 34 I-Eq-Comparison
years NCT03921203 35 40 I-Age|Eq-Comparison
. NCT03921203 40 41 O

- NCT03921203 45 46 O
For NCT03921203 48 51 O
the NCT03921203 52 55 O
T2D NCT03921203 56 59 B-Condition
study NCT03921203 60 65 O
group NCT03921203 66 71 O
: NCT03921203 72 73 O
Diagnosed NCT03921203 74 83 O
with NCT03921203 84 88 O
type NCT03921203 89 93 B-Condition
2 NCT03921203 94 95 I-Condition
diabetes NCT03921203 96 104 I-Condition
. NCT03921203 104 105 O

Exclusion NCT03921203 107 116 O
Criteria NCT03921203 117 125 O
: NCT03921203 126 127 O

For NCT03921203 129 132 O
subjects NCT03921203 133 141 O
with NCT03921203 142 146 O
type NCT03921203 147 151 B-Condition
2 NCT03921203 152 153 I-Condition
diabetes NCT03921203 154 162 I-Condition
: NCT03921203 163 164 O

- NCT03921203 168 169 O
Systemic NCT03921203 171 179 B-Modifier
inflammatory NCT03921203 180 192 B-Condition
disease NCT03921203 193 200 I-Condition
that NCT03921203 201 205 O
requires NCT03921203 206 214 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 215 221 B-Eq-Comparison
treatment NCT03921203 222 231 B-Procedure

- NCT03921203 234 235 O
Thyroid NCT03921203 237 244 B-Condition
disease NCT03921203 245 252 I-Condition
that NCT03921203 253 257 O
requires NCT03921203 258 266 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 267 273 B-Eq-Comparison
treatment NCT03921203 274 283 B-Procedure

- NCT03921203 286 287 O
Skin NCT03921203 289 293 B-Condition
disease NCT03921203 294 301 I-Condition
that NCT03921203 302 306 O
requires NCT03921203 307 315 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 316 322 B-Eq-Comparison
treatment NCT03921203 323 332 B-Procedure
and NCT03921203 333 336 B-And
causes NCT03921203 337 343 O
significant NCT03921203 344 355 O
changes NCT03921203 356 363 B-Condition
in NCT03921203 364 366 I-Condition
the NCT03921203 367 370 I-Condition
area NCT03921203 371 375 I-Condition
of NCT03921203 376 378 I-Condition
the NCT03921203 379 382 O
skin NCT03921203 383 387 I-Condition
that NCT03921203 388 392 O
is NCT03921203 393 395 O
to NCT03921203 396 398 O
be NCT03921203 399 401 O
investigated NCT03921203 402 414 O

- NCT03921203 417 418 O
Treatment NCT03921203 420 429 B-Procedure
with NCT03921203 430 434 O
oral NCT03921203 435 439 B-Drug
glucocorticoids NCT03921203 440 455 I-Drug

- NCT03921203 458 459 O
Levels NCT03921203 461 467 O
of NCT03921203 468 470 O
SR NCT03921203 471 473 B-Observation
, NCT03921203 474 475 O
TSH NCT03921203 476 479 B-Observation
, NCT03921203 480 481 O
T4 NCT03921203 482 484 B-Observation
or NCT03921203 485 487 B-Or
Hemoglobin NCT03921203 488 498 B-Observation
in NCT03921203 499 501 O
the NCT03921203 502 505 O
blood NCT03921203 506 511 O
pronouncedly NCT03921203 512 524 O
outside NCT03921203 525 532 O
the NCT03921203 533 536 O
reference NCT03921203 537 546 O
range NCT03921203 547 552 O

- NCT03921203 555 556 O
Pregnancy NCT03921203 558 567 B-Condition

For NCT03921203 568 571 O
healthy NCT03921203 572 579 O
controls NCT03921203 580 588 O
: NCT03921203 589 590 O

- NCT03921203 594 595 O
Registered NCT03921203 597 607 O
disease NCT03921203 608 615 B-Condition
in NCT03921203 616 618 O
the NCT03921203 619 622 O
health NCT03921203 623 629 O
declaration NCT03921203 630 641 O
that NCT03921203 642 646 O
requires NCT03921203 647 655 B-Assertion___Assertion-Type-Value:hypothetical
continuous NCT03921203 656 666 B-Eq-Comparison
systemic NCT03921203 667 675 B-Modifier
treatment NCT03921203 676 685 B-Procedure
. NCT03921203 685 686 O
Exception NCT03921203 688 697 B-Exception
to NCT03921203 698 700 O
the NCT03921203 701 704 O
above NCT03921203 705 710 O
: NCT03921203 711 712 O
well NCT03921203 713 717 O
controlled NCT03921203 718 728 B-Modifier
hypertension NCT03921203 729 741 B-Condition
in NCT03921203 742 744 O
which NCT03921203 745 750 O
case NCT03921203 751 755 O
the NCT03921203 756 759 O
subject NCT03921203 760 767 O
should NCT03921203 768 774 O
not NCT03921203 775 778 B-Negation
have NCT03921203 779 783 O
treatment NCT03921203 784 793 B-Procedure
with NCT03921203 794 798 O
more NCT03921203 799 803 B-Eq-Comparison
than NCT03921203 804 808 I-Eq-Comparison
one NCT03921203 809 812 I-Eq-Comparison
antihypertensive NCT03921203 813 829 B-Drug
drug NCT03921203 830 834 I-Coreference|Drug
, NCT03921203 835 836 O
the NCT03921203 837 840 O
drug NCT03921203 841 845 O
must NCT03921203 846 850 O
not NCT03921203 851 854 B-Negation
be NCT03921203 855 857 O
an NCT03921203 858 860 O
alpha NCT03921203 861 866 B-Drug
- NCT03921203 867 868 I-Drug|Drug
blocker NCT03921203 869 876 I-Drug|Drug
or NCT03921203 877 879 B-Or|Or
beta NCT03921203 880 884 B-Drug
- NCT03921203 885 886 O
blocker NCT03921203 887 894 O
or NCT03921203 895 897 O
thiazide NCT03921203 898 906 B-Drug
diuretic NCT03921203 907 915 I-Drug

- NCT03921203 918 919 O
Skin NCT03921203 921 925 B-Condition
disease NCT03921203 926 933 I-Condition
that NCT03921203 934 938 O
requires NCT03921203 939 947 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 948 954 B-Eq-Comparison
treatment NCT03921203 955 964 B-Procedure
and NCT03921203 965 968 B-And
causes NCT03921203 969 975 O
significant NCT03921203 976 987 O
changes NCT03921203 988 995 B-Condition
in NCT03921203 996 998 I-Condition
the NCT03921203 999 1002 I-Condition
area NCT03921203 1003 1007 I-Condition
of NCT03921203 1008 1010 I-Condition
the NCT03921203 1011 1014 O
skin NCT03921203 1015 1019 I-Condition
that NCT03921203 1020 1024 O
is NCT03921203 1025 1027 O
to NCT03921203 1028 1030 O
be NCT03921203 1031 1033 O
investigated NCT03921203 1034 1046 O

- NCT03921203 1049 1050 O
Blood NCT03921203 1052 1057 B-Observation
pressure NCT03921203 1058 1066 I-Observation
pronouncedly NCT03921203 1067 1079 O
above NCT03921203 1080 1085 B-Eq-Comparison
140 NCT03921203 1086 1089 I-Eq-Comparison
/ NCT03921203 1090 1091 I-Eq-Comparison
90 NCT03921203 1092 1094 I-Eq-Comparison

- NCT03921203 1098 1099 O
Blood NCT03921203 1101 1106 B-Observation
test NCT03921203 1107 1111 I-Observation
results NCT03921203 1112 1119 O
pronouncedly NCT03921203 1120 1132 O
outside NCT03921203 1133 1140 O
the NCT03921203 1141 1144 O
reference NCT03921203 1145 1154 O
range NCT03921203 1155 1160 O

- NCT03921203 1163 1164 O
Pregnancy NCT03921203 1166 1175 B-Condition

Inclusion NCT03929887 0 9 O
Criteria NCT03929887 10 18 O
: NCT03929887 19 20 O

- NCT03929887 24 25 O
Diagnosis NCT03929887 27 36 O
of NCT03929887 37 39 O
glomerulonephritis NCT03929887 40 58 B-Condition
( NCT03929887 59 60 O
MCD NCT03929887 61 64 B-Condition
, NCT03929887 65 66 O
FSGS NCT03929887 67 71 B-Condition
, NCT03929887 72 73 O
MN NCT03929887 74 76 B-Condition
, NCT03929887 77 78 O
IgAN NCT03929887 79 83 B-Condition
, NCT03929887 84 85 O
RPGN NCT03929887 86 90 B-Condition
, NCT03929887 91 92 O
lupus NCT03929887 93 98 B-Condition
nephritis NCT03929887 99 108 I-Condition
and NCT03929887 109 112 O
etc NCT03929887 113 116 O
. NCT03929887 116 117 O
) NCT03929887 118 119 O
on NCT03929887 120 122 O
first NCT03929887 123 128 B-Eq-Comparison
diagnostic NCT03929887 129 139 O
kidney NCT03929887 140 146 B-Modifier
biopsy NCT03929887 147 153 B-Procedure
, NCT03929887 154 155 O
as NCT03929887 156 158 O
per NCT03929887 159 162 O
specified NCT03929887 163 172 O
pathology NCT03929887 173 182 O
definitions NCT03929887 183 194 O

- NCT03929887 197 198 O
First NCT03929887 200 205 B-Eq-Comparison
diagnostic NCT03929887 206 216 O
kidney NCT03929887 217 223 B-Modifier
biopsy NCT03929887 224 230 B-Procedure
since NCT03929887 231 236 B-Eq-Comparison
2010 NCT03929887 237 241 I-Eq-Comparison

- NCT03929887 245 246 O
Willingness NCT03929887 248 259 O
to NCT03929887 260 262 O
comply NCT03929887 263 269 O
with NCT03929887 270 274 O
study NCT03929887 275 280 O
requirements NCT03929887 281 293 O
, NCT03929887 294 295 O
including NCT03929887 296 305 O
intention NCT03929887 306 315 O
to NCT03929887 316 318 O
fully NCT03929887 319 324 O
participate NCT03929887 325 336 O
in NCT03929887 337 339 O
protocol NCT03929887 340 348 O
- NCT03929887 349 350 O
specified NCT03929887 351 360 O
follow NCT03929887 361 367 O
- NCT03929887 368 369 O
up NCT03929887 370 372 O
at NCT03929887 373 375 O
a NCT03929887 376 377 O
clinical NCT03929887 378 386 O
study NCT03929887 387 392 O
site NCT03929887 393 397 O

- NCT03929887 400 401 O
Informed NCT03929887 403 411 O
consent NCT03929887 412 419 O
and NCT03929887 420 423 O
, NCT03929887 424 425 O
where NCT03929887 426 431 O
age NCT03929887 432 435 O
appropriate NCT03929887 436 447 O
, NCT03929887 448 449 O
informed NCT03929887 450 458 O
assent NCT03929887 459 465 O
( NCT03929887 466 467 O
clinical NCT03929887 468 476 O
data NCT03929887 477 481 O
, NCT03929887 482 483 O
human NCT03929887 484 489 O
derived NCT03929887 490 497 O
materials NCT03929887 498 507 O
including NCT03929887 508 517 O
genomic NCT03929887 518 525 O
data NCT03929887 526 530 O
) NCT03929887 531 532 O

Exclusion NCT03929887 534 543 O
Criteria NCT03929887 544 552 O
: NCT03929887 553 554 O

- NCT03929887 558 559 O
Unwillingness NCT03929887 561 574 O
to NCT03929887 575 577 O
give NCT03929887 578 582 O
informed NCT03929887 583 591 O
consent NCT03929887 592 599 O

- NCT03929887 602 603 O
Not NCT03929887 605 608 B-Negation
enough NCT03929887 609 615 B-Assertion___Assertion-Type-Value:hypothetical|Modifier
kidney NCT03929887 616 622 B-Observation
tissue NCT03929887 623 629 I-Observation
to NCT03929887 630 632 O
confirm NCT03929887 633 640 O
a NCT03929887 641 642 O
diagnosis NCT03929887 643 652 O
( NCT03929887 653 654 O
adequate NCT03929887 655 663 O
tissue NCT03929887 664 670 O
: NCT03929887 671 672 O
more NCT03929887 673 677 B-Eq-Comparison
than NCT03929887 678 682 I-Eq-Comparison
2 NCT03929887 683 684 I-Eq-Comparison
cores NCT03929887 685 690 I-Eq-Comparison
of NCT03929887 691 693 O
kidney NCT03929887 694 700 B-Observation
tissues NCT03929887 701 708 I-Observation
( NCT03929887 709 710 O
10 NCT03929887 711 713 I-Eq-Comparison|Eq-Comparison
x NCT03929887 714 715 I-Eq-Comparison
1.2 NCT03929887 716 719 I-Eq-Comparison
mm NCT03929887 720 722 I-Eq-Comparison
) NCT03929887 723 724 O
including NCT03929887 725 734 O
over NCT03929887 735 739 B-Eq-Comparison
10 NCT03929887 740 742 O
- NCT03929887 743 744 I-Eq-Comparison
15 NCT03929887 745 747 I-Eq-Comparison
glomerulus NCT03929887 748 758 I-Eq-Comparison
each NCT03929887 759 763 O
) NCT03929887 764 765 O

Inclusion NCT03926546 0 9 O
Criteria NCT03926546 10 18 O
: NCT03926546 19 20 O

- NCT03926546 24 25 O
Participants NCT03926546 27 39 O
must NCT03926546 40 44 O
be NCT03926546 45 47 O
adults NCT03926546 48 54 O
18 NCT03926546 55 57 B-Eq-Comparison
years NCT03926546 58 63 I-Eq-Comparison
or NCT03926546 64 66 I-Eq-Comparison
older NCT03926546 67 72 I-Eq-Comparison
. NCT03926546 72 73 O

- NCT03926546 77 78 O
Participants NCT03926546 80 92 O
must NCT03926546 93 97 O
have NCT03926546 98 102 O
the NCT03926546 103 106 O
capacity NCT03926546 107 115 O
and NCT03926546 116 119 O
ability NCT03926546 120 127 O
to NCT03926546 128 130 O
give NCT03926546 131 135 O
informed NCT03926546 136 144 O
consent NCT03926546 145 152 O
. NCT03926546 152 153 O

- NCT03926546 157 158 O
Participants NCT03926546 160 172 O
have NCT03926546 173 177 O
been NCT03926546 178 182 O
given NCT03926546 183 188 B-Eq-Comparison
an NCT03926546 189 191 O
assessment NCT03926546 192 202 B-Procedure
and NCT03926546 203 206 B-And
received NCT03926546 207 215 B-Eq-Comparison
a NCT03926546 216 217 O
diagnosis NCT03926546 218 227 O
of NCT03926546 228 230 O
OCD NCT03926546 231 234 B-Condition
. NCT03926546 234 235 O

- NCT03926546 239 240 O
Participants NCT03926546 242 254 O
must NCT03926546 255 259 O
speak NCT03926546 260 265 O
English NCT03926546 266 273 O
. NCT03926546 273 274 O

- NCT03926546 278 279 O
Participants NCT03926546 281 293 O
must NCT03926546 294 298 O
be NCT03926546 299 301 O
able NCT03926546 302 306 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926546 307 309 I-Assertion___Assertion-Type-Value:hypothetical
physically NCT03926546 310 320 O
attend NCT03926546 321 327 O
treatment NCT03926546 328 337 B-Procedure
. NCT03926546 337 338 O

Exclusion NCT03926546 340 349 O
Criteria NCT03926546 350 358 O
: NCT03926546 359 360 O

- NCT03926546 364 365 O
Prisoners NCT03926546 367 376 B-Observation
or NCT03926546 377 379 B-Or
any NCT03926546 380 383 O
other NCT03926546 384 389 B-Other
high NCT03926546 390 394 O
- NCT03926546 395 396 O
risk NCT03926546 397 401 B-Risk
population NCT03926546 402 412 O
group NCT03926546 413 418 O
. NCT03926546 418 419 O

- NCT03926546 423 424 O
experiencing NCT03926546 426 438 O
active NCT03926546 439 445 B-Eq-Comparison
psychosis NCT03926546 446 455 B-Condition

- NCT03926546 458 459 O
experiencing NCT03926546 461 473 O
active NCT03926546 474 480 B-Eq-Comparison
substance NCT03926546 481 490 B-Condition
abuse NCT03926546 491 496 I-Condition
disorder NCT03926546 497 505 I-Condition

- NCT03926546 508 509 O
experiencing NCT03926546 511 523 O
active NCT03926546 524 530 B-Eq-Comparison
suicidality NCT03926546 531 542 B-Condition

Inclusion NCT03926234 0 9 O
Criteria NCT03926234 10 18 O
: NCT03926234 19 20 O

- NCT03926234 24 25 O
Patients NCT03926234 27 35 O
, NCT03926234 36 37 O
older NCT03926234 38 43 B-Eq-Comparison
than NCT03926234 44 48 I-Eq-Comparison
14 NCT03926234 49 51 I-Eq-Comparison
years NCT03926234 52 57 I-Age|Eq-Comparison
and NCT03926234 58 61 B-And
admitted NCT03926234 62 70 B-Encounter
to NCT03926234 71 73 O
the NCT03926234 74 77 O
ED NCT03926234 78 80 O
, NCT03926234 81 82 O
were NCT03926234 83 87 O
eligible NCT03926234 88 96 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03926234 97 100 I-Assertion___Assertion-Type-Value:hypothetical
this NCT03926234 101 105 O
study NCT03926234 106 111 B-Study
. NCT03926234 111 112 O

Exclusion NCT03926234 114 123 O
Criteria NCT03926234 124 132 O
: NCT03926234 133 134 O

- NCT03926234 138 139 O
Gynecologic NCT03926234 141 152 B-Modifier
and NCT03926234 153 156 B-Or
obstetric NCT03926234 157 166 B-Modifier
emergencies NCT03926234 167 178 B-Condition

- NCT03926234 181 182 O
Patients NCT03926234 184 192 O
, NCT03926234 193 194 O
who NCT03926234 195 198 O
left NCT03926234 199 203 B-Observation
against NCT03926234 204 211 I-Observation
medical NCT03926234 212 219 I-Observation
advice NCT03926234 220 226 I-Observation
or NCT03926234 227 229 O
had NCT03926234 230 233 O
n't NCT03926234 233 236 O
been NCT03926234 237 241 O
aided NCT03926234 242 247 O
by NCT03926234 248 250 O
a NCT03926234 251 252 O
doctor NCT03926234 253 259 O

Inclusion NCT03927664 0 9 O
Criteria NCT03927664 10 18 O

- NCT03927664 21 22 O
Patients NCT03927664 24 32 O
diagnosed NCT03927664 33 42 O
with NCT03927664 43 47 O
peritoneal NCT03927664 48 58 B-Condition
tuberculosis NCT03927664 59 71 I-Condition

- NCT03927664 74 75 O
Patients NCT03927664 77 85 O
who NCT03927664 86 89 O
have NCT03927664 90 94 O
undergone NCT03927664 95 104 B-Eq-Comparison
a NCT03927664 105 106 O
computed NCT03927664 107 115 B-Procedure
tomographic NCT03927664 116 127 I-Procedure
examination NCT03927664 128 139 I-Procedure

Exclusion NCT03927664 140 149 O
Criteria NCT03927664 150 158 O
: NCT03927664 159 160 O

- NCT03927664 164 165 O
Age NCT03927664 167 170 B-Age
< NCT03927664 171 172 B-Eq-Comparison
12 NCT03927664 173 175 I-Eq-Comparison

- NCT03927664 179 180 O
Unclear NCT03927664 182 189 O
diagnosis NCT03927664 190 199 O

- NCT03927664 202 203 O
More NCT03927664 205 209 B-Eq-Comparison
than NCT03927664 210 214 I-Eq-Comparison
one NCT03927664 215 218 I-Eq-Comparison
etiology NCT03927664 219 227 B-Condition
for NCT03927664 228 231 O
ascites NCT03927664 232 239 B-Condition

- NCT03927664 242 243 O
Not NCT03927664 245 248 O
willing NCT03927664 249 256 O
for NCT03927664 257 260 O
consent NCT03927664 261 268 O

Inclusion NCT03926208 0 9 O
Criteria NCT03926208 10 18 O
: NCT03926208 19 20 O

1 NCT03926208 24 25 O
. NCT03926208 25 26 O
≥ NCT03926208 28 29 B-Eq-Comparison
18 NCT03926208 30 32 I-Eq-Comparison
years NCT03926208 33 38 I-Eq-Comparison
of NCT03926208 39 41 O
age NCT03926208 42 45 B-Age

2 NCT03926208 48 49 O
. NCT03926208 49 50 O
Patient NCT03926208 52 59 O
requires NCT03926208 60 68 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03926208 69 70 O
foot NCT03926208 71 75 B-Modifier
or NCT03926208 76 78 B-Or
ankle NCT03926208 79 84 B-Modifier
operative NCT03926208 85 94 B-Procedure
procedure NCT03926208 95 104 I-Procedure

3 NCT03926208 107 108 O
. NCT03926208 108 109 O
Patient NCT03926208 111 118 O
provides NCT03926208 119 127 O
informed NCT03926208 128 136 O
consent NCT03926208 137 144 O

Exclusion NCT03926208 145 154 O
Criteria NCT03926208 155 163 O
: NCT03926208 164 165 O

1 NCT03926208 169 170 O
. NCT03926208 170 171 O
Patient NCT03926208 173 180 O
refuses NCT03926208 181 188 O

2 NCT03926208 191 192 O
. NCT03926208 192 193 O
Patient NCT03926208 195 202 O
is NCT03926208 203 205 O
incarcerated NCT03926208 206 218 B-Observation
, NCT03926208 219 220 O
incapacitated NCT03926208 221 234 B-Condition
, NCT03926208 235 236 O
or NCT03926208 237 239 O
otherwise NCT03926208 240 249 O
unable NCT03926208 250 256 O
to NCT03926208 257 259 O
provide NCT03926208 260 267 O
appropriate NCT03926208 268 279 O
informed NCT03926208 280 288 O
consent NCT03926208 289 296 O

Inclusion NCT03921567 0 9 O
Criteria NCT03921567 10 18 O
: NCT03921567 19 20 O

- NCT03921567 24 25 O
Age NCT03921567 27 30 B-Age
of NCT03921567 31 33 O
both NCT03921567 34 38 O
genders NCT03921567 39 46 O
from NCT03921567 47 51 O
18 NCT03921567 52 54 B-Eq-Comparison
to NCT03921567 55 57 I-Eq-Comparison
75 NCT03921567 58 60 I-Eq-Comparison
years NCT03921567 61 66 I-Eq-Comparison

- NCT03921567 69 70 O
ASA NCT03921567 72 75 B-Condition
physiological NCT03921567 76 89 O
status NCT03921567 90 96 O
I NCT03921567 97 98 B-Eq-Comparison
- NCT03921567 99 100 I-Eq-Comparison
III NCT03921567 101 104 I-Eq-Comparison

- NCT03921567 107 108 O
Participation NCT03921567 110 123 O
in NCT03921567 124 126 O
abdominal NCT03921567 127 136 B-Modifier
, NCT03921567 137 138 O
orthopedic NCT03921567 139 149 B-Modifier
, NCT03921567 150 151 O
laparoscopical NCT03921567 152 166 B-Modifier
, NCT03921567 167 168 O
gynecological NCT03921567 169 182 B-Modifier
and NCT03921567 183 186 B-Or
urological NCT03921567 187 197 B-Modifier
interventions NCT03921567 198 211 B-Study
. NCT03921567 211 212 O

Exclusion NCT03921567 214 223 O
Criteria NCT03921567 224 232 O
: NCT03921567 233 234 O

- NCT03921567 238 239 O
Patient NCT03921567 241 248 O
rejection NCT03921567 249 258 O

- NCT03921567 261 262 O
History NCT03921567 264 271 B-Eq-Comparison
of NCT03921567 272 274 O
chronic NCT03921567 275 282 B-Modifier
opioid NCT03921567 283 289 B-Drug
intake NCT03921567 290 296 O

- NCT03921567 299 300 O
History NCT03921567 302 309 B-Eq-Comparison
of NCT03921567 310 312 O
renal NCT03921567 313 318 B-Modifier
, NCT03921567 319 320 O
hepatic NCT03921567 321 328 B-Modifier
or NCT03921567 329 331 B-Or
psychiatric NCT03921567 332 343 B-Modifier
disorders NCT03921567 344 353 B-Condition

- NCT03921567 356 357 O
Heart NCT03921567 359 364 B-Condition
failure NCT03921567 365 372 I-Condition
, NCT03921567 373 374 O

- NCT03921567 378 379 O
Organ NCT03921567 381 386 B-Procedure
transplant NCT03921567 387 397 I-Procedure
history NCT03921567 398 405 B-Eq-Comparison
, NCT03921567 406 407 O

- NCT03921567 411 412 O
Lidocaine NCT03921567 414 423 B-Drug
allergy NCT03921567 424 431 B-Allergy

- NCT03921567 434 435 O
Family NCT03921567 437 443 B-Family-Member
history NCT03921567 444 451 I-Family-Member
of NCT03921567 452 454 O
malignant NCT03921567 455 464 B-Condition
hyperthermia NCT03921567 465 477 I-Condition

Inclusion NCT03925701 0 9 O
Criteria NCT03925701 10 18 O
: NCT03925701 19 20 O

- NCT03925701 24 25 O
NAFLD NCT03925701 27 32 B-Condition
and NCT03925701 33 36 O
type NCT03925701 37 41 B-Condition
2 NCT03925701 42 43 I-Condition
DM NCT03925701 44 46 I-Condition

Exclusion NCT03925701 47 56 O
Criteria NCT03925701 57 65 O
: NCT03925701 66 67 O

- NCT03925701 71 72 O
Viral NCT03925701 74 79 B-Condition
hepatitis NCT03925701 80 89 I-Condition
. NCT03925701 89 90 O

- NCT03925701 94 95 O
Child NCT03925701 97 102 O
score NCT03925701 103 108 O
more NCT03925701 109 113 B-Eq-Comparison
than NCT03925701 114 118 I-Eq-Comparison
6 NCT03925701 119 120 I-Eq-Comparison
. NCT03925701 120 121 O

- NCT03925701 125 126 O
renal NCT03925701 128 133 B-Modifier
impairment NCT03925701 134 144 B-Condition
. NCT03925701 144 145 O

Inclusion NCT03926585 0 9 O
Criteria NCT03926585 10 18 O
: NCT03926585 19 20 O

- NCT03926585 24 25 O
Patients NCT03926585 27 35 O
admitted NCT03926585 36 44 B-Encounter
to NCT03926585 45 47 O
the NCT03926585 48 51 O
department NCT03926585 52 62 O
of NCT03926585 63 65 O
endocrinology NCT03926585 66 79 B-Provider
with NCT03926585 80 84 B-And
the NCT03926585 85 88 O
diagnose NCT03926585 89 97 O
hypothyroidism NCT03926585 98 112 B-Condition
because NCT03926585 113 120 O
of NCT03926585 121 123 O
persistent NCT03926585 124 134 B-Modifier
hypothyroid NCT03926585 135 146 B-Condition
symptoms NCT03926585 147 155 B-Assertion___Assertion-Type-Value:possible
despite NCT03926585 156 163 B-And
treatment NCT03926585 164 173 B-Procedure
with NCT03926585 174 178 O
L NCT03926585 179 180 B-Drug
- NCT03926585 181 182 I-Drug
thyroxine NCT03926585 183 192 I-Drug
mono NCT03926585 193 197 B-Procedure
- NCT03926585 198 199 I-Procedure
therapy NCT03926585 200 207 I-Procedure
and NCT03926585 208 211 B-And
normal NCT03926585 212 218 O
and NCT03926585 219 222 B-And
stable NCT03926585 223 229 O
TSH NCT03926585 230 233 B-Observation
( NCT03926585 234 235 O
for NCT03926585 236 239 O
at NCT03926585 240 242 B-Eq-Comparison
least NCT03926585 243 248 I-Eq-Comparison
6 NCT03926585 249 250 I-Eq-Comparison
months NCT03926585 251 257 I-Eq-Comparison
) NCT03926585 258 259 O
. NCT03926585 260 261 O

- NCT03926585 265 266 O
Started NCT03926585 268 275 O
in NCT03926585 276 278 O
combination NCT03926585 279 290 B-Procedure
therapy NCT03926585 291 298 I-Procedure
with NCT03926585 299 303 O
L NCT03926585 304 305 B-Drug
- NCT03926585 306 307 I-Drug
thyroxine NCT03926585 308 317 I-Drug
and NCT03926585 318 321 B-And
Liothyronine NCT03926585 322 334 B-Drug
in NCT03926585 335 337 O
an NCT03926585 338 340 O
approximately NCT03926585 341 354 O
17 NCT03926585 355 357 B-Eq-Comparison
/ NCT03926585 358 359 I-Eq-Comparison
1 NCT03926585 360 361 O
ratio NCT03926585 362 367 I-Eq-Comparison

- NCT03926585 370 371 O
Exclusion NCT03926585 373 382 B-Negation
of NCT03926585 383 385 O
an NCT03926585 386 388 O
alternative NCT03926585 389 400 B-Other
explanation NCT03926585 401 412 B-Condition
for NCT03926585 413 416 O
persistent NCT03926585 417 427 B-Modifier
hypothyroid NCT03926585 428 439 B-Condition
symptoms NCT03926585 440 448 B-Assertion___Assertion-Type-Value:possible

Exclusion NCT03926585 449 458 O
Criteria NCT03926585 459 467 O
: NCT03926585 468 469 O

- NCT03926585 473 474 O
Initiation NCT03926585 476 486 B-Eq-Comparison
of NCT03926585 487 489 O
L NCT03926585 490 491 B-Drug
- NCT03926585 492 493 I-Drug
thyroxine NCT03926585 494 503 I-Drug
treatment NCT03926585 504 513 B-Procedure
in NCT03926585 514 516 O
patients NCT03926585 517 525 O
with NCT03926585 526 530 B-And
s NCT03926585 531 532 B-Observation
- NCT03926585 533 534 I-Observation
TSH NCT03926585 535 538 I-Observation
below NCT03926585 539 544 B-Eq-Comparison
upper NCT03926585 545 550 I-Eq-Comparison
normal NCT03926585 551 557 I-Eq-Comparison
limit NCT03926585 558 563 I-Eq-Comparison
( NCT03926585 564 565 O
with NCT03926585 566 570 O
assay NCT03926585 571 576 O
in NCT03926585 577 579 O
current NCT03926585 580 587 O
use NCT03926585 588 591 O
, NCT03926585 592 593 O
that NCT03926585 594 598 O
is NCT03926585 599 601 O
TSH NCT03926585 602 605 B-Observation
< NCT03926585 606 607 B-Eq-Comparison
4 NCT03926585 608 609 I-Eq-Comparison
mU NCT03926585 610 612 I-Eq-Comparison
/ NCT03926585 613 614 I-Eq-Comparison
L NCT03926585 615 616 I-Eq-Comparison
) NCT03926585 617 618 O

- NCT03926585 622 623 O
Ongoing NCT03926585 625 632 B-Eq-Comparison
pregnancy NCT03926585 633 642 B-Condition

- NCT03926585 645 646 O
Age NCT03926585 648 651 B-Age
below NCT03926585 652 657 B-Eq-Comparison
18 NCT03926585 658 660 I-Eq-Comparison
years NCT03926585 661 666 I-Eq-Comparison|Eq-Comparison
or NCT03926585 667 669 B-Or
above NCT03926585 670 675 B-Eq-Comparison
80 NCT03926585 676 678 I-Eq-Comparison
years NCT03926585 679 684 O
. NCT03926585 684 685 O

- NCT03926585 689 690 O
Patients NCT03926585 692 700 O
who NCT03926585 701 704 O
do NCT03926585 705 707 O
not NCT03926585 708 711 O
read NCT03926585 712 716 O
and NCT03926585 717 720 O
understand NCT03926585 721 731 O
information NCT03926585 732 743 O
material NCT03926585 744 752 O
given NCT03926585 753 758 O

- NCT03926585 761 762 O
Patients NCT03926585 764 772 O
who NCT03926585 773 776 O
are NCT03926585 777 780 O
not NCT03926585 781 784 O
competent NCT03926585 785 794 O
to NCT03926585 795 797 O
give NCT03926585 798 802 O
informed NCT03926585 803 811 O
consent NCT03926585 812 819 O


Inclusion NCT03928769 0 9 O
Criteria NCT03928769 10 18 O
: NCT03928769 19 20 O

- NCT03928769 24 25 O
Male NCT03928769 27 31 O
or NCT03928769 32 34 B-Or
female NCT03928769 35 41 O
≥ NCT03928769 42 43 B-Eq-Comparison
18 NCT03928769 44 46 I-Eq-Comparison
years NCT03928769 47 52 I-Age|Eq-Comparison

- NCT03928769 55 56 O
Patient NCT03928769 58 65 O
for NCT03928769 66 69 O
whom NCT03928769 70 74 O
a NCT03928769 75 76 O
vascular NCT03928769 77 85 B-Modifier
surgery NCT03928769 86 93 B-Procedure
is NCT03928769 94 96 O
programmed NCT03928769 97 107 B-Eq-Comparison
, NCT03928769 108 109 O
and NCT03928769 110 113 B-And
whose NCT03928769 114 119 O
nature NCT03928769 120 126 O
allows NCT03928769 127 133 B-Assertion___Assertion-Type-Value:hypothetical
obtaining NCT03928769 134 143 O
of NCT03928769 144 146 O
arterial NCT03928769 147 155 B-Condition
segment NCT03928769 156 163 I-Condition
without NCT03928769 164 171 B-Negation
any NCT03928769 172 175 O
harm NCT03928769 176 180 O
for NCT03928769 181 184 O
the NCT03928769 185 188 O
health NCT03928769 189 195 B-Condition
of NCT03928769 196 198 O
the NCT03928769 199 202 O
patient NCT03928769 203 210 O

- NCT03928769 213 214 O
Patient NCT03928769 216 223 O
for NCT03928769 224 227 O
whom NCT03928769 228 232 O
a NCT03928769 233 234 O
blood NCT03928769 235 240 B-Observation
sample NCT03928769 241 247 I-Observation
is NCT03928769 248 250 O
planned NCT03928769 251 258 B-Eq-Comparison
on NCT03928769 259 261 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928769 262 265 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03928769 266 269 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928769 270 272 O
the NCT03928769 273 276 O
procedure NCT03928769 277 286 B-Procedure

- NCT03928769 289 290 O
Person NCT03928769 292 298 O
who NCT03928769 299 302 O
has NCT03928769 303 306 O
received NCT03928769 307 315 O
complete NCT03928769 316 324 O
information NCT03928769 325 336 O
on NCT03928769 337 339 O
the NCT03928769 340 343 O
organization NCT03928769 344 356 O
of NCT03928769 357 359 O
the NCT03928769 360 363 O
research NCT03928769 364 372 O
and NCT03928769 373 376 O
who NCT03928769 377 380 O
has NCT03928769 381 384 O
not NCT03928769 385 388 O
objected NCT03928769 389 397 O
to NCT03928769 398 400 O
his NCT03928769 401 404 O
participation NCT03928769 405 418 O
and NCT03928769 419 422 O
the NCT03928769 423 426 O
exploitation NCT03928769 427 439 O
of NCT03928769 440 442 O
his NCT03928769 443 446 O
data NCT03928769 447 451 O

- NCT03928769 454 455 O
Compulsory NCT03928769 457 467 O
affiliation NCT03928769 468 479 O
to NCT03928769 480 482 O
social NCT03928769 483 489 O
security NCT03928769 490 498 O

Exclusion NCT03928769 499 508 O
Criteria NCT03928769 509 517 O
: NCT03928769 518 519 O

- NCT03928769 523 524 O
Patient NCT03928769 526 533 O
who NCT03928769 534 537 O
has NCT03928769 538 541 O
previously NCT03928769 542 552 B-Eq-Comparison
undergone NCT03928769 553 562 I-Eq-Comparison
radiotherapy NCT03928769 563 575 B-Procedure
at NCT03928769 576 578 O
the NCT03928769 579 582 O
sampling NCT03928769 583 591 B-Modifier
site NCT03928769 592 596 I-Modifier

- NCT03928769 599 600 O
Patient NCT03928769 602 609 O
with NCT03928769 610 614 O
cancer NCT03928769 615 621 B-Condition
at NCT03928769 622 624 O
the NCT03928769 625 628 O
sampling NCT03928769 629 637 B-Modifier
site NCT03928769 638 642 I-Modifier

Inclusion NCT03925259 0 9 O
Criteria NCT03925259 10 18 O
: NCT03925259 19 20 O

- NCT03925259 24 25 O
Long NCT03925259 27 31 B-Modifier
term NCT03925259 32 36 I-Modifier
physical NCT03925259 37 45 B-Condition
health NCT03925259 46 52 I-Condition
condition NCT03925259 53 62 I-Condition
and NCT03925259 63 66 B-Or
comorbid NCT03925259 67 75 B-Condition
mental NCT03925259 76 82 I-Condition
health NCT03925259 83 89 I-Condition
problem NCT03925259 90 97 I-Condition

- NCT03925259 100 101 O
Age NCT03925259 103 106 B-Age
16 NCT03925259 107 109 B-Eq-Comparison
+ NCT03925259 110 111 O

- NCT03925259 115 116 O
Referred NCT03925259 118 126 B-Encounter
to NCT03925259 127 129 O
a NCT03925259 130 131 O
psychological NCT03925259 132 145 B-Provider
therapies NCT03925259 146 155 I-Provider
service NCT03925259 156 163 I-Provider

Exclusion NCT03925259 164 173 O
Criteria NCT03925259 174 182 O
: NCT03925259 183 184 O

- NCT03925259 188 189 O
Diagnosis NCT03925259 191 200 O
of NCT03925259 201 203 O
' NCT03925259 204 205 O
medically NCT03925259 205 214 B-Condition
unexplained NCT03925259 215 226 I-Condition
symptoms NCT03925259 227 235 I-Condition
' NCT03925259 235 236 O
including NCT03925259 237 246 O
somatoform NCT03925259 247 257 B-Condition
disorders NCT03925259 258 267 I-Condition
( NCT03925259 268 269 O
e. NCT03925259 270 272 O
g. NCT03925259 273 275 O
pain NCT03925259 277 281 B-Condition
disorder NCT03925259 282 290 I-Condition
, NCT03925259 291 292 O
conversion NCT03925259 293 303 B-Condition
disorder NCT03925259 304 312 I-Condition
, NCT03925259 313 314 O
body NCT03925259 315 319 B-Condition
dysmorphic NCT03925259 320 330 I-Condition
disorder NCT03925259 331 339 I-Condition
, NCT03925259 340 341 O
hypochondriasis NCT03925259 342 357 B-Condition
) NCT03925259 358 359 O
and NCT03925259 360 363 O
functional NCT03925259 364 374 B-Condition
somatic NCT03925259 375 382 I-Condition
syndromes NCT03925259 383 392 I-Condition
( NCT03925259 393 394 O
e. NCT03925259 395 397 O
g. NCT03925259 398 400 O
irritable NCT03925259 402 411 B-Condition
bowel NCT03925259 412 417 I-Condition
syndrome NCT03925259 418 426 I-Condition
, NCT03925259 427 428 O
chronic NCT03925259 429 436 B-Condition
fatigue NCT03925259 437 444 I-Condition
syndrome NCT03925259 445 453 I-Condition
, NCT03925259 454 455 O
fibromyalgia NCT03925259 456 468 B-Condition
, NCT03925259 469 470 O
non NCT03925259 471 474 B-Modifier
- NCT03925259 475 476 I-Modifier
cardiac NCT03925259 477 484 I-Modifier
chest NCT03925259 485 490 I-Modifier
pain NCT03925259 491 495 B-Condition
, NCT03925259 496 497 O
non NCT03925259 498 501 B-Condition
- NCT03925259 502 503 I-Condition
epileptic NCT03925259 504 513 I-Condition
seizures NCT03925259 514 522 I-Condition
) NCT03925259 523 524 O

- NCT03925259 528 529 O
Mental NCT03925259 531 537 B-Condition
health NCT03925259 538 544 I-Condition
diagnoses NCT03925259 545 554 O
in NCT03925259 555 557 B-Or
addition NCT03925259 558 566 I-Or
to NCT03925259 567 569 I-Or
anxiety NCT03925259 570 577 B-Condition
or NCT03925259 578 580 B-Or
depression NCT03925259 581 591 B-Condition
( NCT03925259 592 593 O
e. NCT03925259 594 596 O
g. NCT03925259 597 599 O
personality NCT03925259 601 612 B-Condition
disorder NCT03925259 613 621 I-Condition|Condition
, NCT03925259 622 623 O
bipolar NCT03925259 624 631 B-Condition
disorder NCT03925259 632 640 O
or NCT03925259 641 643 B-Or
psychosis NCT03925259 644 653 B-Condition
) NCT03925259 654 655 O

- NCT03925259 659 660 O
Currently NCT03925259 662 671 B-Eq-Comparison
accesses NCT03925259 672 680 B-Encounter
secondary NCT03925259 681 690 O
care NCT03925259 691 695 O
mental NCT03925259 696 702 B-Provider
health NCT03925259 703 709 I-Provider
services NCT03925259 710 718 I-Provider

- NCT03925259 721 722 O
Significant NCT03925259 724 735 O
current NCT03925259 736 743 B-Eq-Comparison
suicidal NCT03925259 744 752 B-Condition
risk NCT03925259 753 757 B-Risk

- NCT03925259 760 761 O
Current NCT03925259 763 770 B-Eq-Comparison
substance NCT03925259 771 780 B-Condition
misuse NCT03925259 781 787 I-Condition

- NCT03925259 790 791 O
Previous NCT03925259 793 801 B-Eq-Comparison
contact NCT03925259 802 809 B-Encounter
with NCT03925259 810 814 O
mental NCT03925259 815 821 B-Provider
health NCT03925259 822 828 I-Provider
services NCT03925259 829 837 I-Provider
( NCT03925259 838 839 O
defined NCT03925259 840 847 O
as NCT03925259 848 850 O
two NCT03925259 851 854 B-Eq-Comparison
or NCT03925259 855 857 I-Eq-Comparison
more NCT03925259 858 862 I-Eq-Comparison
prior NCT03925259 863 868 B-Eq-Comparison
episodes NCT03925259 869 877 O
of NCT03925259 878 880 O
service NCT03925259 881 888 B-Encounter
contact NCT03925259 889 896 I-Encounter
without NCT03925259 897 904 B-Negation
significant NCT03925259 905 916 O
change NCT03925259 917 923 O
) NCT03925259 924 925 O

- NCT03925259 929 930 O
Inpatient NCT03925259 932 941 B-Encounter
admission NCT03925259 942 951 I-Encounter
for NCT03925259 952 955 O
mental NCT03925259 956 962 B-Condition
health NCT03925259 963 969 I-Condition
difficulties NCT03925259 970 982 I-Condition
within NCT03925259 983 989 B-Eq-Comparison
the NCT03925259 990 993 I-Eq-Comparison
last NCT03925259 994 998 I-Eq-Comparison
five NCT03925259 999 1003 I-Eq-Comparison
years NCT03925259 1004 1009 I-Eq-Comparison

- NCT03925259 1012 1013 I-Condition
History NCT03925259 1015 1022 B-Eq-Comparison
of NCT03925259 1023 1025 O
self NCT03925259 1026 1030 B-Condition
- NCT03925259 1031 1032 O
injury NCT03925259 1033 1039 I-Condition

- NCT03925259 1042 1043 O
A NCT03925259 1045 1046 O
stated NCT03925259 1047 1053 O
reluctance NCT03925259 1054 1064 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925259 1065 1067 O
engage NCT03925259 1068 1074 O
in NCT03925259 1075 1077 O
psychotherapy NCT03925259 1078 1091 B-Procedure
. NCT03925259 1091 1092 O

Inclusion NCT03927300 0 9 O
Criteria NCT03927300 10 18 O
: NCT03927300 19 20 O

- NCT03927300 24 25 O
Adult NCT03927300 27 32 O
patients NCT03927300 33 41 O
( NCT03927300 42 43 O
≥ NCT03927300 45 46 B-Eq-Comparison
18 NCT03927300 47 49 I-Eq-Comparison
years NCT03927300 50 55 I-Eq-Comparison
) NCT03927300 56 57 O
with NCT03927300 58 62 O
no NCT03927300 63 65 O
age NCT03927300 66 69 O
limit NCT03927300 70 75 O
; NCT03927300 75 76 O

- NCT03927300 79 80 O
Patients NCT03927300 82 90 O
receiving NCT03927300 91 100 B-Eq-Comparison
peritoneal NCT03927300 101 111 B-Procedure
dialysis NCT03927300 112 120 I-Procedure
on NCT03927300 121 123 O
the NCT03927300 124 127 O
investigation NCT03927300 128 141 O
center NCT03927300 142 148 O
between NCT03927300 149 156 B-Eq-Comparison
2012 NCT03927300 157 161 I-Eq-Comparison
and NCT03927300 162 165 I-Eq-Comparison
2014 NCT03927300 166 170 I-Eq-Comparison
( NCT03927300 171 172 O
Group1 NCT03927300 173 179 O
) NCT03927300 180 181 O
and NCT03927300 182 185 B-And
between NCT03927300 186 193 B-Eq-Comparison
2016 NCT03927300 194 198 I-Eq-Comparison
and NCT03927300 199 202 I-Eq-Comparison
2018 NCT03927300 203 207 I-Eq-Comparison
( NCT03927300 208 209 O
Group NCT03927300 210 215 O
2 NCT03927300 216 217 O
) NCT03927300 218 219 O
; NCT03927300 220 221 O

- NCT03927300 224 225 O
Patient NCT03927300 227 234 O
information NCT03927300 235 246 O
in NCT03927300 247 249 O
this NCT03927300 250 254 O
retrospective NCT03927300 255 268 O
study NCT03927300 269 274 B-Study
; NCT03927300 274 275 O

Exclusion NCT03927300 276 285 O
Criteria NCT03927300 286 294 O
: NCT03927300 295 296 O

- NCT03927300 300 301 O
Patients NCT03927300 303 311 O
who NCT03927300 312 315 O
have NCT03927300 316 320 O
started NCT03927300 321 328 B-Eq-Comparison
a NCT03927300 329 330 O
peritoneal NCT03927300 331 341 B-Procedure
dialysis NCT03927300 342 350 I-Procedure
program NCT03927300 351 358 O
before NCT03927300 359 365 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03927300 366 369 O
periods NCT03927300 370 377 O
of NCT03927300 378 380 O
investigation NCT03927300 381 394 B-Study
; NCT03927300 394 395 O

- NCT03927300 398 399 O
Patients NCT03927300 401 409 O
who NCT03927300 410 413 O
have NCT03927300 414 418 O
been NCT03927300 419 423 O
equipped NCT03927300 424 432 O
with NCT03927300 433 437 O
apTeleCare NCT03927300 438 448 B-Procedure
during NCT03927300 449 455 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927300 456 459 O
dialysis NCT03927300 460 468 B-Procedure
program NCT03927300 469 476 O
; NCT03927300 476 477 O

- NCT03927300 480 481 O
Subject NCT03927300 483 490 O
under NCT03927300 491 496 B-Observation
guardianship NCT03927300 497 509 I-Observation
, NCT03927300 510 511 O
curators NCT03927300 512 520 O
or NCT03927300 521 523 O
safeguard NCT03927300 524 533 O
of NCT03927300 534 536 O
justice NCT03927300 537 544 O
; NCT03927300 544 545 O

- NCT03927300 548 549 O
Patient NCT03927300 551 558 O
not NCT03927300 559 562 O
affiliated NCT03927300 563 573 O
to NCT03927300 574 576 O
a NCT03927300 577 578 O
French NCT03927300 579 585 O
social NCT03927300 586 592 O
protection NCT03927300 593 603 O
; NCT03927300 603 604 O


Inclusion NCT03924609 0 9 O
Criteria NCT03924609 10 18 O
: NCT03924609 19 20 O

A. NCT03924609 22 24 O
Histologically NCT03924609 26 40 B-Procedure
proven NCT03924609 41 47 O
breast NCT03924609 48 54 B-Modifier
cancer NCT03924609 55 61 B-Condition
confirmed NCT03924609 62 71 O
by NCT03924609 72 74 O
biopsy NCT03924609 75 81 B-Procedure
or NCT03924609 82 84 B-Or
pathological NCT03924609 85 97 B-Procedure
examination NCT03924609 98 109 I-Procedure
of NCT03924609 110 112 O
the NCT03924609 113 116 O
resected NCT03924609 117 125 B-Modifier
tumor NCT03924609 126 131 B-Condition
. NCT03924609 131 132 O

B. NCT03924609 134 136 O
Histologically NCT03924609 138 152 B-Procedure
confirmed NCT03924609 153 162 O
breast NCT03924609 163 169 B-Modifier
cancer NCT03924609 170 176 B-Condition
patients NCT03924609 177 185 O
, NCT03924609 186 187 O
fulfilling NCT03924609 188 198 O
any NCT03924609 199 202 O
of NCT03924609 203 205 O
the NCT03924609 206 209 B-Criteria-Count
following NCT03924609 210 219 I-Criteria-Count
: NCT03924609 220 221 O

1 NCT03924609 225 226 O
. NCT03924609 226 227 O
Multiple NCT03924609 229 237 B-Eq-Comparison
bone NCT03924609 238 242 B-Modifier
metastases NCT03924609 243 253 B-Condition
indicated NCT03924609 254 263 O
by NCT03924609 264 266 O
bone NCT03924609 267 271 B-Procedure
scan NCT03924609 272 276 I-Procedure

2 NCT03924609 279 280 O
. NCT03924609 280 281 O
Bone NCT03924609 283 287 B-Procedure
scan NCT03924609 288 292 I-Procedure
positive NCT03924609 293 301 O
, NCT03924609 302 303 O
and NCT03924609 304 307 B-And
proven NCT03924609 308 314 O
by NCT03924609 315 317 O
other NCT03924609 318 323 B-Other
imaging NCT03924609 324 331 B-Procedure
examinations NCT03924609 332 344 I-Procedure
, NCT03924609 345 346 O
including NCT03924609 347 356 O
computed NCT03924609 357 365 B-Procedure
tomography NCT03924609 366 376 I-Procedure
( NCT03924609 377 378 O
CT NCT03924609 379 381 B-Procedure
) NCT03924609 382 383 O
, NCT03924609 385 386 O
magnetic NCT03924609 387 395 B-Procedure
resonance NCT03924609 396 405 I-Procedure
imaging NCT03924609 406 413 I-Procedure
( NCT03924609 414 415 O
MRI NCT03924609 416 419 B-Procedure
) NCT03924609 420 421 O
and NCT03924609 422 425 B-Or
X NCT03924609 426 427 B-Procedure
- NCT03924609 428 429 I-Procedure
ray NCT03924609 430 433 I-Procedure
. NCT03924609 433 434 O

3 NCT03924609 438 439 O
. NCT03924609 439 440 O
Bone NCT03924609 442 446 B-Procedure
scan NCT03924609 447 451 I-Procedure
positive NCT03924609 452 460 O
, NCT03924609 461 462 O
with NCT03924609 463 467 B-And
clinical NCT03924609 468 476 O
symptoms NCT03924609 477 485 B-Condition
, NCT03924609 486 487 O
including NCT03924609 488 497 O
bone NCT03924609 498 502 B-Modifier
pain NCT03924609 503 507 B-Condition
, NCT03924609 508 509 O
pathologic NCT03924609 510 520 B-Condition
fracture NCT03924609 521 529 I-Condition
, NCT03924609 530 531 O
spinal NCT03924609 532 538 B-Condition
cord NCT03924609 539 543 I-Condition
compression NCT03924609 544 555 I-Condition
and NCT03924609 556 559 O
so NCT03924609 560 562 O
on NCT03924609 563 565 O
. NCT03924609 565 566 O

4 NCT03924609 570 571 O
. NCT03924609 571 572 O
Bone NCT03924609 574 578 B-Modifier
metastases NCT03924609 579 589 B-Condition
indicated NCT03924609 590 599 O
by NCT03924609 600 602 O
PET NCT03924609 603 606 B-Procedure
- NCT03924609 607 608 I-Procedure
CT NCT03924609 609 611 I-Procedure

5 NCT03924609 614 615 O
. NCT03924609 615 616 O
Histologically NCT03924609 618 632 B-Procedure
proven NCT03924609 633 639 O
bone NCT03924609 640 644 B-Modifier
metastases NCT03924609 645 655 B-Condition

Exclusion NCT03924609 656 665 O
Criteria NCT03924609 666 674 O
: NCT03924609 675 676 O

A. NCT03924609 678 680 O
No NCT03924609 682 684 B-Negation
bone NCT03924609 685 689 B-Modifier
metastases NCT03924609 690 700 B-Condition
confirmed NCT03924609 701 710 O
by NCT03924609 711 713 O
pathological NCT03924609 714 726 B-Procedure
examination NCT03924609 727 738 I-Procedure

B. NCT03924609 740 742 O
Bone NCT03924609 744 748 B-Modifier
metastases NCT03924609 749 759 B-Condition
secondary NCT03924609 760 769 O
to NCT03924609 770 772 O
other NCT03924609 773 778 B-Exception|Other
malignant NCT03924609 779 788 B-Condition
tumor NCT03924609 789 794 I-Condition
other NCT03924609 795 800 O
than NCT03924609 801 805 I-Exception
breast NCT03924609 806 812 B-Modifier
cancer NCT03924609 813 819 B-Condition

C. NCT03924609 821 823 O
Secondary NCT03924609 825 834 B-Modifier
primary NCT03924609 835 842 I-Modifier
tumor NCT03924609 843 848 B-Condition


Inclusion NCT03926793 0 9 O
Criteria NCT03926793 10 18 O
: NCT03926793 19 20 O

1 NCT03926793 24 25 O
. NCT03926793 25 26 O
Adult NCT03926793 28 33 O
( NCT03926793 34 35 O
males NCT03926793 36 41 O
and NCT03926793 42 45 B-Or
females NCT03926793 46 53 O
) NCT03926793 54 55 O
aged NCT03926793 56 60 B-Age
18 NCT03926793 61 63 B-Eq-Comparison
to NCT03926793 64 66 I-Eq-Comparison
75 NCT03926793 67 69 I-Eq-Comparison
years NCT03926793 70 75 I-Eq-Comparison
( NCT03926793 76 77 O
inclusive NCT03926793 78 87 O
) NCT03926793 88 89 O
with NCT03926793 90 94 B-And
pulmonary NCT03926793 95 104 B-Condition
arterial NCT03926793 105 113 I-Condition
hypertension NCT03926793 114 126 I-Condition
( NCT03926793 127 128 O
PAH NCT03926793 129 132 B-Condition
) NCT03926793 133 134 O

2 NCT03926793 138 139 O
. NCT03926793 139 140 O
A NCT03926793 142 143 O
current NCT03926793 144 151 B-Eq-Comparison
diagnosis NCT03926793 152 161 O
of NCT03926793 162 164 O
symptomatic NCT03926793 165 176 B-Assertion___Assertion-Type-Value:possible
PAH NCT03926793 177 180 B-Condition
classified NCT03926793 181 191 O
by NCT03926793 192 194 O
one NCT03926793 195 198 B-Eq-Comparison
of NCT03926793 199 201 O
the NCT03926793 202 205 B-Criteria-Count
following NCT03926793 206 215 I-Criteria-Count
: NCT03926793 216 217 O

1 NCT03926793 226 227 O
. NCT03926793 227 228 O
Idiopathic NCT03926793 230 240 B-Condition
( NCT03926793 241 242 O
IPAH NCT03926793 243 247 B-Condition
) NCT03926793 248 249 O
or NCT03926793 250 252 B-Or
heritable NCT03926793 253 262 B-Modifier
pulmonary NCT03926793 263 272 B-Condition
arterial NCT03926793 273 281 I-Condition
hypertension NCT03926793 282 294 I-Condition
( NCT03926793 295 296 O
HPAH NCT03926793 297 301 B-Condition
) NCT03926793 302 303 O

2 NCT03926793 312 313 O
. NCT03926793 313 314 O
PAH NCT03926793 316 319 B-Condition
associated NCT03926793 320 330 O
with NCT03926793 331 335 O
one NCT03926793 336 339 B-Eq-Comparison
of NCT03926793 340 342 O
the NCT03926793 343 346 B-Criteria-Count
following NCT03926793 347 356 I-Criteria-Count
connective NCT03926793 357 367 B-Condition
tissue NCT03926793 368 374 I-Condition
diseases NCT03926793 375 383 I-Condition
( NCT03926793 384 385 O
CTDs NCT03926793 386 390 B-Condition
) NCT03926793 391 392 O
: NCT03926793 394 395 O

limited NCT03926793 407 414 B-Condition
scleroderma NCT03926793 415 426 I-Condition
, NCT03926793 427 428 O
mixed NCT03926793 429 434 B-Condition
connective NCT03926793 435 445 I-Condition
tissue NCT03926793 446 452 I-Condition
disease NCT03926793 453 460 I-Condition
or NCT03926793 461 463 B-Or|Or
overlap NCT03926793 464 471 B-Condition
syndrome NCT03926793 472 480 I-Condition
, NCT03926793 481 482 O
or NCT03926793 483 485 O
systemic NCT03926793 486 494 B-Modifier
lupus NCT03926793 495 500 B-Condition
erythematosus NCT03926793 501 514 I-Condition

3 NCT03926793 522 523 O
. NCT03926793 523 524 O
PAH NCT03926793 526 529 B-Condition
associated NCT03926793 530 540 O
with NCT03926793 541 545 O
anorexigen NCT03926793 546 556 B-Drug
or NCT03926793 557 559 B-Or
methamphetamine NCT03926793 560 575 B-Drug
use NCT03926793 576 579 O

3 NCT03926793 582 583 O
. NCT03926793 583 584 O
World NCT03926793 586 591 B-Condition
Health NCT03926793 592 598 I-Condition
Organization NCT03926793 599 611 I-Condition
( NCT03926793 612 613 O
WHO NCT03926793 614 617 B-Condition
) NCT03926793 618 619 O
/ NCT03926793 621 622 B-Or
New NCT03926793 623 626 B-Condition
York NCT03926793 627 631 I-Condition
Heart NCT03926793 632 637 I-Condition
Association NCT03926793 638 649 I-Condition
( NCT03926793 650 651 O
NYHA NCT03926793 652 656 B-Condition
) NCT03926793 657 658 O
functional NCT03926793 659 669 O
class NCT03926793 670 675 B-Eq-Comparison
II NCT03926793 676 678 I-Eq-Comparison
- NCT03926793 679 680 I-Eq-Comparison
IV NCT03926793 681 683 I-Eq-Comparison
symptomatology NCT03926793 684 698 O

Exclusion NCT03926793 699 708 O
Criteria NCT03926793 709 717 O
: NCT03926793 718 719 O

1 NCT03926793 723 724 O
. NCT03926793 724 725 O
Clinically NCT03926793 727 737 O
significant NCT03926793 738 749 O
systemic NCT03926793 750 758 B-Condition
hypertension NCT03926793 759 771 I-Condition
or NCT03926793 772 774 B-Or
hypotension NCT03926793 775 786 B-Condition

2 NCT03926793 789 790 O
. NCT03926793 790 791 O
History NCT03926793 793 800 B-Eq-Comparison
of NCT03926793 801 803 O
left NCT03926793 804 808 B-Modifier
- NCT03926793 809 810 I-Modifier
sided NCT03926793 811 816 I-Modifier
heart NCT03926793 817 822 B-Condition
disease NCT03926793 823 830 I-Condition
and NCT03926793 831 834 B-Or
/ NCT03926793 835 836 I-Or
or NCT03926793 837 839 I-Or
clinically NCT03926793 840 850 O
significant NCT03926793 851 862 O
cardiac NCT03926793 863 870 B-Condition
disease NCT03926793 871 878 I-Condition

3 NCT03926793 881 882 O
. NCT03926793 882 883 O
History NCT03926793 885 892 B-Eq-Comparison
of NCT03926793 893 895 O
decompensated NCT03926793 896 909 B-Modifier
right NCT03926793 910 915 B-Condition
heart NCT03926793 916 921 I-Condition
failure NCT03926793 922 929 I-Condition
within NCT03926793 930 936 B-Eq-Comparison
30 NCT03926793 937 939 I-Eq-Comparison
days NCT03926793 940 944 I-Eq-Comparison
of NCT03926793 945 947 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926793 948 957 B-Study
( NCT03926793 958 959 O
e. NCT03926793 960 962 O
g. NCT03926793 963 965 O
, NCT03926793 966 967 O
hospitalization NCT03926793 968 983 B-Encounter
for NCT03926793 984 987 O
PAH NCT03926793 988 991 B-Condition|Condition
or NCT03926793 992 994 B-Or
the NCT03926793 995 998 O
need NCT03926793 999 1003 O
to NCT03926793 1004 1006 O
add NCT03926793 1007 1010 B-Other
an NCT03926793 1011 1013 O
additional NCT03926793 1014 1024 O
PAH NCT03926793 1025 1028 O
medication NCT03926793 1029 1039 B-Drug
) NCT03926793 1040 1041 O

Inclusion NCT03928782 0 9 O
Criteria NCT03928782 10 18 O
: NCT03928782 19 20 O

- NCT03928782 24 25 O
subjects NCT03928782 27 35 O
who NCT03928782 36 39 O
suffer NCT03928782 40 46 O
from NCT03928782 47 51 O
acute NCT03928782 52 57 O
leukemic NCT03928782 58 66 B-Condition
subjects NCT03928782 67 75 O
who NCT03928782 76 79 O
accept NCT03928782 80 86 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03928782 87 99 B-Procedure
within NCT03928782 100 106 B-Eq-Comparison
one NCT03928782 107 110 I-Eq-Comparison
month NCT03928782 111 116 I-Eq-Comparison
and NCT03928782 117 120 B-And
will NCT03928782 121 125 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03928782 126 128 I-Assertion___Assertion-Type-Value:hypothetical
pretreated NCT03928782 129 139 B-Procedure
by NCT03928782 140 142 O
whole NCT03928782 143 148 B-Procedure
- NCT03928782 149 150 I-Procedure
body NCT03928782 151 155 I-Procedure
irradiation NCT03928782 156 167 I-Procedure
peripheral NCT03928782 168 178 B-Modifier
blood NCT03928782 179 184 I-Modifier
cells NCT03928782 185 190 I-Modifier
of NCT03928782 191 193 O
subjects NCT03928782 194 202 O
are NCT03928782 203 206 O
approximate NCT03928782 207 218 O
to NCT03928782 219 221 O
those NCT03928782 222 227 O
of NCT03928782 228 230 O
healthy NCT03928782 231 238 O
person NCT03928782 239 245 O
aged NCT03928782 246 250 B-Age
between NCT03928782 251 258 B-Eq-Comparison
18 NCT03928782 259 261 I-Eq-Comparison
and NCT03928782 262 265 I-Eq-Comparison
50 NCT03928782 266 268 I-Eq-Comparison
years NCT03928782 269 274 I-Eq-Comparison
old NCT03928782 275 278 O
subjects NCT03928782 279 287 O
who NCT03928782 288 291 O
are NCT03928782 292 295 O
competent NCT03928782 296 305 O
to NCT03928782 306 308 O
give NCT03928782 309 313 O
written NCT03928782 314 321 O
informed NCT03928782 322 330 O
consent NCT03928782 331 338 O
subjects NCT03928782 339 347 O
without NCT03928782 348 355 O
other NCT03928782 356 361 O
systemic NCT03928782 362 370 O
diseases NCT03928782 371 379 O

Exclusion NCT03928782 380 389 O
Criteria NCT03928782 390 398 O
: NCT03928782 399 400 O

- NCT03928782 404 405 O
subjects NCT03928782 407 415 O
who NCT03928782 416 419 O
suffer NCT03928782 420 426 O
from NCT03928782 427 431 O
serious NCT03928782 432 439 O
other NCT03928782 440 445 B-Other
systemic NCT03928782 446 454 B-Modifier
diseases NCT03928782 455 463 B-Condition
subjects NCT03928782 464 472 O
who NCT03928782 473 476 O
are NCT03928782 477 480 O
unwilling NCT03928782 481 490 O
or NCT03928782 491 493 O
unable NCT03928782 494 500 O
to NCT03928782 501 503 O
cooperate NCT03928782 504 513 O
with NCT03928782 514 518 O
this NCT03928782 519 523 O
clinical NCT03928782 524 532 O
study NCT03928782 533 538 B-Study
other NCT03928782 539 544 O
serious NCT03928782 545 552 O
cases NCT03928782 553 558 B-Condition
that NCT03928782 559 563 O
probably NCT03928782 564 572 B-Assertion___Assertion-Type-Value:hypothetical
hinder NCT03928782 573 579 O
this NCT03928782 580 584 O
clinical NCT03928782 585 593 O
study NCT03928782 594 599 B-Study

Inclusion NCT03925675 0 9 O
Criteria NCT03925675 10 18 O
: NCT03925675 19 20 O

1 NCT03925675 24 25 O
. NCT03925675 25 26 O
Patients NCT03925675 28 36 O
evaluated NCT03925675 37 46 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925675 47 50 I-Assertion___Assertion-Type-Value:hypothetical
residual NCT03925675 51 59 B-Modifier
or NCT03925675 60 62 B-Or
recurrent NCT03925675 63 72 B-Modifier
gliomas NCT03925675 73 80 B-Condition
after NCT03925675 81 86 B-Temporal-Connection___Temporal-Connection-Type-Value:after
initial NCT03925675 87 94 B-Eq-Comparison
tumor NCT03925675 95 100 B-Condition
surgery NCT03925675 101 108 B-Procedure
, NCT03925675 109 110 O
external NCT03925675 111 119 B-Procedure
beam NCT03925675 120 124 I-Procedure
radiation NCT03925675 125 134 I-Procedure
and NCT03925675 135 138 B-Or
/ NCT03925675 139 140 I-Or
or NCT03925675 141 143 I-Or
chemotherapy NCT03925675 144 156 B-Procedure
with NCT03925675 157 161 O
temozolamide NCT03925675 162 174 B-Drug
. NCT03925675 174 175 O

2 NCT03925675 179 180 O
. NCT03925675 180 181 O
Male NCT03925675 183 187 O
and NCT03925675 188 191 B-Or
female NCT03925675 192 198 O

3 NCT03925675 201 202 O
. NCT03925675 202 203 O
Ages NCT03925675 205 209 B-Age
18 NCT03925675 210 212 B-Eq-Comparison
to NCT03925675 213 215 I-Eq-Comparison
70 NCT03925675 216 218 I-Eq-Comparison

Exclusion NCT03925675 220 229 O
Criteria NCT03925675 230 238 O
: NCT03925675 239 240 O

1 NCT03925675 244 245 O
. NCT03925675 245 246 O
Patient NCT03925675 248 255 O
diagnosis NCT03925675 256 265 O
with NCT03925675 266 270 O
glioma NCT03925675 271 277 B-Condition
but NCT03925675 278 281 O
before NCT03925675 282 288 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03925675 289 296 B-Procedure
, NCT03925675 297 298 O
external NCT03925675 299 307 B-Procedure
beam NCT03925675 308 312 I-Procedure
radiation NCT03925675 313 322 I-Procedure
and NCT03925675 323 326 B-Or
/ NCT03925675 327 328 I-Or
or NCT03925675 329 331 I-Or
chemotherapy NCT03925675 332 344 B-Procedure
with NCT03925675 345 349 O
temozolamide NCT03925675 350 362 B-Drug
. NCT03925675 362 363 O

2 NCT03925675 367 368 O
. NCT03925675 368 369 O
Women NCT03925675 371 376 O
who NCT03925675 377 380 O
were NCT03925675 381 385 B-Eq-Comparison
pregnant NCT03925675 386 394 B-Condition
, NCT03925675 395 396 O
breast NCT03925675 397 403 B-Condition
feeding NCT03925675 404 411 I-Condition
, NCT03925675 412 413 O
or NCT03925675 414 416 B-Or
possibly NCT03925675 417 425 B-Assertion___Assertion-Type-Value:possible
pregnant NCT03925675 426 434 B-Condition
. NCT03925675 434 435 O

3 NCT03925675 439 440 O
. NCT03925675 440 441 O
Patients NCT03925675 443 451 O
with NCT03925675 452 456 O
hepatic NCT03925675 457 464 B-Modifier
or NCT03925675 465 467 B-Or
renal NCT03925675 468 473 B-Modifier
dysfunction NCT03925675 474 485 B-Condition
. NCT03925675 485 486 O

4 NCT03925675 490 491 O
. NCT03925675 491 492 O
Patients NCT03925675 494 502 O
with NCT03925675 503 507 O
MRI NCT03925675 508 511 B-Procedure
contraindications NCT03925675 512 529 B-Contraindication
( NCT03925675 530 531 O
i. NCT03925675 532 534 O
e. NCT03925675 535 537 O
pacemakers NCT03925675 539 549 B-Procedure
, NCT03925675 550 551 O
non NCT03925675 552 555 B-Procedure
- NCT03925675 556 557 I-Procedure
MR NCT03925675 558 560 I-Procedure
compatible NCT03925675 561 571 I-Procedure
devices NCT03925675 572 579 I-Procedure
) NCT03925675 580 581 O
. NCT03925675 582 583 O

5 NCT03925675 587 588 O
. NCT03925675 588 589 O
Patients NCT03925675 591 599 O
with NCT03925675 600 604 O
a NCT03925675 605 606 O
history NCT03925675 607 614 B-Eq-Comparison
of NCT03925675 615 617 O
drug NCT03925675 618 622 B-Drug
hypersensitivity NCT03925675 623 639 B-Condition
to NCT03925675 640 642 O
18 NCT03925675 643 645 B-Drug
F NCT03925675 646 647 O
- NCT03925675 648 649 I-Drug
Fluciclovine NCT03925675 650 662 I-Drug
. NCT03925675 662 663 O

Inclusion NCT03920917 0 9 O
Criteria NCT03920917 10 18 O
: NCT03920917 19 20 O

- NCT03920917 24 25 O
1 NCT03920917 27 28 O
. NCT03920917 28 29 O
Patient NCT03920917 31 38 O
with NCT03920917 39 43 O
paroxysmal NCT03920917 44 54 B-Condition
atrial NCT03920917 55 61 I-Condition
fibrillation NCT03920917 62 74 I-Condition
who NCT03920917 75 78 B-And
is NCT03920917 79 81 O
scheduled NCT03920917 82 91 B-Eq-Comparison
for NCT03920917 92 95 O
ablation NCT03920917 96 104 B-Procedure
procedure NCT03920917 105 114 I-Procedure
and NCT03920917 115 118 B-And
≥ NCT03920917 119 120 B-Eq-Comparison
20 NCT03920917 121 123 I-Eq-Comparison
and NCT03920917 124 127 B-And
≤ NCT03920917 128 129 B-Eq-Comparison
80 NCT03920917 130 132 I-Eq-Comparison
years NCT03920917 133 138 I-Eq-Comparison
of NCT03920917 139 141 O
age NCT03920917 142 145 B-Age

- NCT03920917 148 149 O
2 NCT03920917 151 152 O
. NCT03920917 152 153 O
Left NCT03920917 155 159 B-Observation
atrium NCT03920917 160 166 I-Observation
size NCT03920917 167 171 I-Observation
< NCT03920917 172 173 B-Eq-Comparison
45 NCT03920917 174 176 I-Eq-Comparison
mm NCT03920917 177 179 O

- NCT03920917 182 183 O
3 NCT03920917 185 186 O
. NCT03920917 186 187 O
paroxysmal NCT03920917 189 199 B-Condition
atrial NCT03920917 200 206 I-Condition
fibrillation NCT03920917 207 219 I-Condition
that NCT03920917 220 224 O
is NCT03920917 225 227 O
recurrence NCT03920917 228 238 O
during NCT03920917 239 245 B-Temporal-Connection___Temporal-Connection-Type-Value:during
antiarrhythmic NCT03920917 246 260 B-Drug
drug NCT03920917 261 265 I-Drug
treatment NCT03920917 266 275 B-Procedure
or NCT03920917 276 278 B-Or
is NCT03920917 279 281 O
not NCT03920917 282 285 B-Negation
able NCT03920917 286 290 O
to NCT03920917 291 293 O
use NCT03920917 294 297 O
an NCT03920917 298 300 B-Drug
antiarrhythmic NCT03920917 301 315 O
drug NCT03920917 316 320 I-Drug
. NCT03920917 320 321 O

- NCT03920917 325 326 O
4 NCT03920917 328 329 O
. NCT03920917 329 330 O
Patient NCT03920917 332 339 O
who NCT03920917 340 343 O
is NCT03920917 344 346 O
indicated NCT03920917 347 356 B-Indication
for NCT03920917 357 360 O
anticoagulation NCT03920917 361 376 B-Procedure
therapy NCT03920917 377 384 I-Procedure
( NCT03920917 385 386 O
for NCT03920917 387 390 O
prevention NCT03920917 391 401 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920917 402 404 O
cerebral NCT03920917 405 413 B-Condition
infarction NCT03920917 414 424 I-Condition
) NCT03920917 425 426 O

Exclusion NCT03920917 428 437 O
Criteria NCT03920917 438 446 O
: NCT03920917 447 448 O

- NCT03920917 452 453 O
1 NCT03920917 455 456 O
. NCT03920917 456 457 O
Patients NCT03920917 459 467 O
with NCT03920917 468 472 O
persistent NCT03920917 473 483 B-Modifier
or NCT03920917 484 486 B-Or
permanent NCT03920917 487 496 B-Modifier
atrial NCT03920917 497 503 B-Condition
fibrillation NCT03920917 504 516 I-Condition

- NCT03920917 519 520 O
2 NCT03920917 522 523 O
. NCT03920917 523 524 O
Atrial NCT03920917 526 532 B-Condition
fibrillation NCT03920917 533 545 I-Condition
associated NCT03920917 546 556 O
with NCT03920917 557 561 O
severe NCT03920917 562 568 O
cardiac NCT03920917 569 576 B-Condition
malformation NCT03920917 577 589 I-Condition
or NCT03920917 590 592 B-Or
a NCT03920917 593 594 O
structural NCT03920917 595 605 B-Modifier
heart NCT03920917 606 611 B-Condition
disease NCT03920917 612 619 I-Condition
that NCT03920917 620 624 O
is NCT03920917 625 627 O
hemodynamically NCT03920917 628 643 B-Modifier
affected NCT03920917 644 652 O

- NCT03920917 655 656 O
3 NCT03920917 658 659 O
. NCT03920917 659 660 O
Patients NCT03920917 662 670 O
with NCT03920917 671 675 O
severe NCT03920917 676 682 O
renal NCT03920917 683 688 B-Condition
impairment NCT03920917 689 699 I-Condition
or NCT03920917 700 702 B-Or
CT NCT03920917 703 705 B-Procedure
imaging NCT03920917 706 713 I-Procedure
difficulty NCT03920917 714 724 O
using NCT03920917 725 730 O
contrast NCT03920917 731 739 B-Procedure
media NCT03920917 740 745 I-Procedure

- NCT03920917 748 749 O
4 NCT03920917 751 752 O
. NCT03920917 752 753 O
Patients NCT03920917 755 763 O
with NCT03920917 764 768 O
a NCT03920917 769 770 O
past NCT03920917 771 775 B-Eq-Comparison
history NCT03920917 776 783 I-Eq-Comparison
of NCT03920917 784 786 O
radiofrequency NCT03920917 787 801 B-Procedure
ablation NCT03920917 802 810 I-Procedure
for NCT03920917 811 814 O
atrial NCT03920917 815 821 B-Condition
fibrillation NCT03920917 822 834 I-Condition
or NCT03920917 835 837 B-Or
other NCT03920917 838 843 B-Other
cardiac NCT03920917 844 851 B-Procedure
surgery NCT03920917 852 859 I-Procedure

- NCT03920917 862 863 O
5 NCT03920917 865 866 O
. NCT03920917 866 867 O
Patients NCT03920917 869 877 O
with NCT03920917 878 882 O
active NCT03920917 883 889 B-Eq-Comparison
internal NCT03920917 890 898 B-Condition
bleeding NCT03920917 899 907 I-Condition

- NCT03920917 910 911 O
6 NCT03920917 913 914 O
. NCT03920917 914 915 O
Patients NCT03920917 917 925 O
with NCT03920917 926 930 O
contraindications NCT03920917 931 948 B-Contraindication
for NCT03920917 949 952 O
anticoagulation NCT03920917 953 968 B-Procedure
therapy NCT03920917 969 976 I-Procedure
( NCT03920917 977 978 O
for NCT03920917 979 982 O
prevention NCT03920917 983 993 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920917 994 996 O
cerebral NCT03920917 997 1005 B-Condition
infarction NCT03920917 1006 1016 I-Condition
) NCT03920917 1017 1018 O
and NCT03920917 1019 1022 B-And
antiarrhythmic NCT03920917 1023 1037 B-Drug
drugs NCT03920917 1038 1043 I-Drug

- NCT03920917 1046 1047 O
7 NCT03920917 1049 1050 O
. NCT03920917 1050 1051 O
Patients NCT03920917 1053 1061 O
with NCT03920917 1062 1066 O
valvular NCT03920917 1067 1075 B-Modifier
atrial NCT03920917 1076 1082 B-Condition
fibrillation NCT03920917 1083 1095 I-Condition
( NCT03920917 1096 1097 O
mitral NCT03920917 1098 1104 B-Condition
stenosis NCT03920917 1105 1113 I-Condition
> NCT03920917 1114 1115 B-Eq-Comparison
grade NCT03920917 1116 1121 I-Eq-Comparison
2 NCT03920917 1122 1123 I-Eq-Comparison
, NCT03920917 1124 1125 O
mechanical NCT03920917 1126 1136 B-Procedure
valve NCT03920917 1137 1142 I-Procedure
, NCT03920917 1143 1144 O
mitral NCT03920917 1145 1151 B-Procedure
valvuloplasty NCT03920917 1152 1165 I-Procedure
) NCT03920917 1166 1167 O

- NCT03920917 1171 1172 O
8 NCT03920917 1174 1175 O
. NCT03920917 1175 1176 O
Patients NCT03920917 1178 1186 O
with NCT03920917 1187 1191 O
a NCT03920917 1192 1193 O
severe NCT03920917 1194 1200 O
comorbid NCT03920917 1201 1209 B-Condition
disease NCT03920917 1210 1217 I-Condition

- NCT03920917 1220 1221 O
9 NCT03920917 1223 1224 O
. NCT03920917 1224 1225 O
Expected NCT03920917 1227 1235 B-Observation
survival NCT03920917 1236 1244 I-Observation
< NCT03920917 1245 1246 B-Eq-Comparison
1 NCT03920917 1247 1248 I-Eq-Comparison
year NCT03920917 1249 1253 I-Eq-Comparison

- NCT03920917 1256 1257 O
10 NCT03920917 1259 1261 O
. NCT03920917 1261 1262 O
Drug NCT03920917 1264 1268 B-Condition
addicts NCT03920917 1269 1276 I-Condition
or NCT03920917 1277 1279 B-Or
alcoholics NCT03920917 1280 1290 B-Condition

- NCT03920917 1293 1294 O
11 NCT03920917 1296 1298 O
. NCT03920917 1298 1299 O
Patients NCT03920917 1301 1309 O
who NCT03920917 1310 1313 O
can NCT03920917 1314 1317 O
not NCT03920917 1317 1320 O
read NCT03920917 1321 1325 O
the NCT03920917 1326 1329 O
consent NCT03920917 1330 1337 O
form NCT03920917 1338 1342 O
( NCT03920917 1343 1344 O
illiterates NCT03920917 1345 1356 B-Condition
, NCT03920917 1357 1358 O
foreigners NCT03920917 1359 1369 O
, NCT03920917 1370 1371 O
etc NCT03920917 1372 1375 O
. NCT03920917 1375 1376 O
) NCT03920917 1377 1378 O

- NCT03920917 1382 1383 O
12 NCT03920917 1385 1387 O
. NCT03920917 1387 1388 O
Other NCT03920917 1390 1395 O
patients NCT03920917 1396 1404 O
who NCT03920917 1405 1408 O
are NCT03920917 1409 1412 O
judged NCT03920917 1413 1419 O
by NCT03920917 1420 1422 O
the NCT03920917 1423 1426 O
principal NCT03920917 1427 1436 O
or NCT03920917 1437 1439 O
sub NCT03920917 1440 1443 O
- NCT03920917 1444 1445 O
investigator NCT03920917 1446 1458 O
to NCT03920917 1459 1461 O
be NCT03920917 1462 1464 O
ineligible NCT03920917 1465 1475 O
for NCT03920917 1476 1479 O
participation NCT03920917 1480 1493 O
in NCT03920917 1494 1496 O
this NCT03920917 1497 1501 O
clinical NCT03920917 1502 1510 O
study NCT03920917 1511 1516 B-Study

Inclusion NCT03923205 0 9 O
Criteria NCT03923205 10 18 O
: NCT03923205 19 20 O

Healthy NCT03923205 22 29 B-Condition
and NCT03923205 30 33 B-And
T2D NCT03923205 34 37 B-Condition
( NCT03923205 38 39 O
controlled NCT03923205 40 50 O
by NCT03923205 51 53 O
diet NCT03923205 54 58 B-Procedure
and NCT03923205 59 62 B-And
lifestyle NCT03923205 63 72 B-Observation
or NCT03923205 73 75 B-Or
metformin NCT03923205 76 85 B-Drug
) NCT03923205 86 87 O
volunteers NCT03923205 88 98 O
; NCT03923205 98 99 O
Age NCT03923205 100 103 B-Age
18 NCT03923205 104 106 B-Eq-Comparison
+ NCT03923205 107 108 O
; NCT03923205 109 110 O
males NCT03923205 111 116 O
and NCT03923205 117 120 B-Or
females NCT03923205 121 128 O
. NCT03923205 128 129 O

Exclusion NCT03923205 132 141 O
Criteria NCT03923205 142 150 O
: NCT03923205 151 152 O

For NCT03923205 154 157 O
the NCT03923205 158 161 O
healthy NCT03923205 162 169 B-Condition
group NCT03923205 170 175 O
: NCT03923205 176 177 O

- NCT03923205 181 182 O
taking NCT03923205 184 190 B-Eq-Comparison
prescribed NCT03923205 191 201 O
medication NCT03923205 202 212 B-Drug

- NCT03923205 215 216 O
HbA1c NCT03923205 218 223 B-Observation
above NCT03923205 224 229 B-Eq-Comparison
48 NCT03923205 230 232 I-Eq-Comparison
mmol NCT03923205 233 237 O
/ NCT03923205 238 239 I-Eq-Comparison
mol NCT03923205 240 243 I-Eq-Comparison
( NCT03923205 244 245 O
or NCT03923205 246 248 B-Or
6.5 NCT03923205 249 252 B-Eq-Comparison
% NCT03923205 253 254 O
) NCT03923205 255 256 O

- NCT03923205 260 261 O
pregnant NCT03923205 263 271 B-Condition
or NCT03923205 272 274 B-Or
breastfeeding NCT03923205 275 288 B-Condition

- NCT03923205 291 292 O
blood NCT03923205 294 299 B-Observation
donation NCT03923205 300 308 I-Observation
in NCT03923205 309 311 O
the NCT03923205 312 315 O
last NCT03923205 316 320 B-Eq-Comparison
three NCT03923205 321 326 I-Eq-Comparison
months NCT03923205 327 333 I-Eq-Comparison

- NCT03923205 336 337 O
unable NCT03923205 339 345 O
to NCT03923205 346 348 O
give NCT03923205 349 353 O
written NCT03923205 354 361 O
informed NCT03923205 362 370 O
consent NCT03923205 371 378 O

- NCT03923205 381 382 O
eating NCT03923205 384 390 B-Condition
disorders NCT03923205 391 400 I-Condition
such NCT03923205 401 405 O
as NCT03923205 406 408 O
anorexia NCT03923205 409 417 B-Condition
, NCT03923205 418 419 O
bulimia NCT03923205 420 427 B-Condition
, NCT03923205 428 429 O
binge NCT03923205 430 435 B-Condition
eating NCT03923205 436 442 I-Condition|Condition
or NCT03923205 443 445 B-Or
night NCT03923205 446 451 B-Condition
eating NCT03923205 452 458 O
syndrome NCT03923205 459 467 I-Condition
. NCT03923205 467 468 O

- NCT03923205 472 473 O
significant NCT03923205 475 486 O
health NCT03923205 487 493 B-Condition
issue NCT03923205 494 499 I-Condition

- NCT03923205 502 503 O
taking NCT03923205 505 511 B-Eq-Comparison
vitamin NCT03923205 512 519 B-Drug
or NCT03923205 520 522 B-Or
mineral NCT03923205 523 530 B-Drug
supplements NCT03923205 531 542 I-Drug
( NCT03923205 543 544 O
unless NCT03923205 545 551 B-Exception
they NCT03923205 552 556 O
agree NCT03923205 557 562 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923205 563 565 I-Assertion___Assertion-Type-Value:hypothetical
discontinue NCT03923205 566 577 B-Negation
supplementation NCT03923205 578 593 B-Drug
2 NCT03923205 594 595 B-Eq-Comparison
weeks NCT03923205 596 601 I-Eq-Comparison
or NCT03923205 602 604 I-Eq-Comparison
more NCT03923205 605 609 I-Eq-Comparison
before NCT03923205 610 616 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923205 617 620 O
start NCT03923205 621 626 O
of NCT03923205 627 629 O
the NCT03923205 630 633 O
study NCT03923205 634 639 B-Study
) NCT03923205 640 641 O

- NCT03923205 645 646 O
Food NCT03923205 648 652 O
allergies NCT03923205 653 662 B-Allergy
/ NCT03923205 663 664 B-Or
intolerances NCT03923205 665 677 B-Condition

For NCT03923205 678 681 O
the NCT03923205 682 685 O
T2D NCT03923205 686 689 B-Condition|Condition
groups NCT03923205 690 696 O
: NCT03923205 697 698 O

- NCT03923205 702 703 O
T2D NCT03923205 705 708 O
controlled NCT03923205 709 719 O
by NCT03923205 720 722 O
medication NCT03923205 723 733 B-Drug
other NCT03923205 734 739 B-Exception
than NCT03923205 740 744 I-Exception
metformin NCT03923205 745 754 B-Drug

- NCT03923205 757 758 O
pregnant NCT03923205 760 768 B-Condition
or NCT03923205 769 771 B-Or
breastfeeding NCT03923205 772 785 B-Condition

- NCT03923205 788 789 O
blood NCT03923205 791 796 B-Observation
donation NCT03923205 797 805 I-Observation
in NCT03923205 806 808 O
the NCT03923205 809 812 O
last NCT03923205 813 817 B-Eq-Comparison
three NCT03923205 818 823 I-Eq-Comparison
months NCT03923205 824 830 I-Eq-Comparison

- NCT03923205 833 834 O
unable NCT03923205 836 842 O
to NCT03923205 843 845 O
give NCT03923205 846 850 O
written NCT03923205 851 858 O
informed NCT03923205 859 867 O
consent NCT03923205 868 875 O

- NCT03923205 878 879 O
eating NCT03923205 881 887 B-Condition
disorders NCT03923205 888 897 I-Condition
such NCT03923205 898 902 O
as NCT03923205 903 905 O
anorexia NCT03923205 906 914 B-Condition
, NCT03923205 915 916 O
bulimia NCT03923205 917 924 B-Condition
, NCT03923205 925 926 O
binge NCT03923205 927 932 B-Condition
eating NCT03923205 933 939 I-Condition|Condition
or NCT03923205 940 942 B-Or
night NCT03923205 943 948 B-Condition
eating NCT03923205 949 955 O
syndrome NCT03923205 956 964 I-Condition
. NCT03923205 964 965 O

- NCT03923205 969 970 O
any NCT03923205 972 975 O
other NCT03923205 976 981 B-Exception
significant NCT03923205 982 993 O
health NCT03923205 994 1000 B-Condition
issue NCT03923205 1001 1006 I-Condition
other NCT03923205 1007 1012 O
than NCT03923205 1013 1017 I-Exception
T2D NCT03923205 1018 1021 B-Condition

- NCT03923205 1024 1025 O
taking NCT03923205 1027 1033 B-Eq-Comparison
vitamin NCT03923205 1034 1041 B-Drug
or NCT03923205 1042 1044 B-Or
mineral NCT03923205 1045 1052 B-Drug
supplements NCT03923205 1053 1064 I-Drug
( NCT03923205 1065 1066 O
unless NCT03923205 1067 1073 B-Exception
they NCT03923205 1074 1078 I-Exception
agree NCT03923205 1079 1084 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923205 1085 1087 I-Assertion___Assertion-Type-Value:hypothetical
discontinue NCT03923205 1088 1099 B-Negation
supplementation NCT03923205 1100 1115 B-Drug
2 NCT03923205 1116 1117 B-Eq-Comparison
weeks NCT03923205 1118 1123 I-Eq-Comparison
before NCT03923205 1124 1130 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923205 1131 1134 O
start NCT03923205 1135 1140 O
of NCT03923205 1141 1143 O
the NCT03923205 1144 1147 O
study NCT03923205 1148 1153 B-Study
) NCT03923205 1154 1155 O

- NCT03923205 1159 1160 O
food NCT03923205 1162 1166 O
allergies NCT03923205 1167 1176 B-Allergy
/ NCT03923205 1177 1178 B-Or
intolerances NCT03923205 1179 1191 B-Condition


Inclusion NCT03924973 0 9 O
Criteria NCT03924973 10 18 O
: NCT03924973 19 20 O

- NCT03924973 24 25 O
Inclusion NCT03924973 27 36 O
in NCT03924973 37 39 O
the NCT03924973 40 43 O
initial NCT03924973 44 51 O
IDEA NCT03924973 52 56 O
trail NCT03924973 57 62 O

- NCT03924973 65 66 O
Requiring NCT03924973 68 77 B-Assertion___Assertion-Type-Value:hypothetical
less NCT03924973 78 82 B-Eq-Comparison
than NCT03924973 83 87 I-Eq-Comparison
40 NCT03924973 88 90 I-Eq-Comparison
minutes NCT03924973 91 98 I-Eq-Comparison
travel NCT03924973 99 105 B-Observation
to NCT03924973 106 108 O
the NCT03924973 109 112 O
assessment NCT03924973 113 123 O
center NCT03924973 124 130 O

Exclusion NCT03924973 131 140 O
Criteria NCT03924973 141 149 O
: NCT03924973 150 151 O

- NCT03924973 155 156 O
Impossibility NCT03924973 158 171 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03924973 172 174 O
coming NCT03924973 175 181 B-Observation
in NCT03924973 182 184 I-Observation
for NCT03924973 185 188 O
assessment NCT03924973 189 199 B-Procedure

- NCT03924973 202 203 O
Exclusion NCT03924973 205 214 O
from NCT03924973 215 219 O
IDEA NCT03924973 220 224 O

